Selegiline B-Chemical 0 0.999998
- O 0 0.23429897
induced O 0 0.0069939494
postural B-Disease 0 0.9997769
hypotension I-Disease 2 0.9999995
in O 0 0.008311353
Parkinson B-Disease 0 0.99977416
' I-Disease 0 0.0012762113
s I-Disease 0 0.000901747
disease I-Disease 0 0.56140333
: O 0 0.00079169753
a O 0 0.00046109923
longitudinal O 0 0.0006326522
study O 0 0.00047735102
on O 0 0.00036487327
the O 0 0.0006172451
effects O 0 0.0011378499
of O 0 0.002337509
drug O 0 0.7791321
withdrawal O 0 0.67152154
. O 0 0.007524659

OBJECTIVES O 0 0.0056443377
: O 0 0.0038583938
The O 0 0.0019756989
United O 0 0.0031206626
Kingdom O 0 0.050483942
Parkinson B-Disease 0 0.99818075
' I-Disease 0 0.0013771959
s I-Disease 0 0.0010318435
Disease I-Disease 0 0.06373689
Research O 0 0.024322424
Group O 0 0.01574716
( O 0 0.00081313093
UKPDRG O 0 0.18492392
) O 0 0.0006111428
trial O 0 0.00031574862
found O 0 0.00019820234
an O 0 0.00025942377
increased O 0 0.00035689696
mortality O 0 0.3139854
in O 0 0.000282449
patients O 0 0.00052218075
with O 0 0.0006971765
Parkinson B-Disease 0 0.9996824
' I-Disease 0 0.00069165684
s I-Disease 0 0.00066643424
disease I-Disease 0 0.9246569
( O 0 0.014183223
PD B-Disease 0 0.99990106
) O 0 0.0006415173
randomized O 0 0.00017865024
to O 0 0.00011592353
receive O 0 0.00011023505
10 O 0 0.00016586724
mg O 0 0.059357125
selegiline B-Chemical 1 0.99998915
per O 0 0.00011930765
day O 0 0.00015450298
and O 0 0.0005107687
L B-Chemical 1 0.99946016
- I-Chemical 1 0.7568177
dopa I-Chemical 1 0.99999154
compared O 0 0.00025798203
with O 0 0.00041694375
those O 0 0.000827467
taking O 0 0.010720573
L B-Chemical 1 0.9988605
- I-Chemical 1 0.80549425
dopa I-Chemical 1 0.9999821
alone O 0 0.0053559677
. O 0 0.007457713

Recently O 0 0.0052437247
, O 0 0.0031808275
we O 0 0.0013301204
found O 0 0.0010295323
that O 0 0.0007430617
therapy O 0 0.0019542344
with O 0 0.0069303303
selegiline B-Chemical 1 0.99999976
and O 0 0.048730787
L B-Chemical 1 0.9999541
- I-Chemical 1 0.954414
dopa I-Chemical 1 0.9999981
was O 0 0.0004087371
associated O 0 0.00029822363
with O 0 0.00034343157
selective O 0 0.008235522
systolic B-Disease 0 0.9989128
orthostatic I-Disease 2 0.99999857
hypotension I-Disease 2 0.9999999
which O 0 0.0011806266
was O 0 0.00048522337
abolished O 0 0.00068415015
by O 0 0.0011444566
withdrawal O 0 0.454001
of O 0 0.02298014
selegiline B-Chemical 1 0.99999464
. O 0 0.008248548

This O 0 0.0062058545
unwanted O 0 0.008689683
effect O 0 0.0022535203
on O 0 0.0014214992
postural O 0 0.6608765
blood O 0 0.047870897
pressure O 0 0.053687997
was O 0 0.0008045891
not O 0 0.0006494432
the O 0 0.0007304135
result O 0 0.0008848677
of O 0 0.0016047438
underlying O 0 0.003909196
autonomic O 0 0.64814574
failure O 0 0.43718323
. O 0 0.0085097775

The O 0 0.0032838692
aims O 0 0.002917178
of O 0 0.0018066473
this O 0 0.0011974232
study O 0 0.0009887828
were O 0 0.00056767097
to O 0 0.00035853384
confirm O 0 0.0002244155
our O 0 0.00026939414
previous O 0 0.00023427047
findings O 0 0.00031720015
in O 0 0.00022003161
a O 0 0.00023837686
separate O 0 0.00013466069
cohort O 0 0.00038829294
of O 0 0.00023327617
patients O 0 0.00029293238
and O 0 0.00017388155
to O 0 0.00011063353
determine O 0 6.625838e-05
the O 0 0.00010475533
time O 0 8.742343e-05
course O 0 0.00011975103
of O 0 0.00018698748
the O 0 0.00023169944
cardiovascular O 0 0.86413807
consequences O 0 0.0007252804
of O 0 0.0008303456
stopping O 0 0.38532907
selegiline B-Chemical 1 0.9999995
in O 0 0.00019656312
the O 0 0.00013723513
expectation O 0 0.00015050596
that O 0 0.0001160067
this O 0 0.00014418366
might O 0 0.00012103613
shed O 0 0.00024334512
light O 0 0.0005628236
on O 0 0.00014515372
the O 0 0.0002050982
mechanisms O 0 0.0002491401
by O 0 0.00038314567
which O 0 0.0006168375
the O 0 0.00083712983
drug O 0 0.66459405
causes O 0 0.12523521
orthostatic B-Disease 2 0.99999535
hypotension I-Disease 2 0.9999975
. O 0 0.010589805

METHODS O 0 0.003955535
: O 0 0.0035855114
The O 0 0.0019489976
cardiovascular O 0 0.26567772
responses O 0 0.0015041385
to O 0 0.0007105366
standing O 0 0.0012500505
and O 0 0.0007337109
head O 0 0.074384145
- O 0 0.0069481903
up O 0 0.00032305435
tilt O 0 0.008035517
were O 0 0.00026866596
studied O 0 0.00025535826
repeatedly O 0 0.00030546365
in O 0 0.00045486563
PD B-Disease 0 0.999706
patients O 0 0.0012312634
receiving O 0 0.0035935035
selegiline B-Chemical 1 0.99999595
and O 0 0.0006509458
as O 0 0.00064331887
the O 0 0.0010204177
drug O 0 0.1103222
was O 0 0.0025217861
withdrawn O 0 0.005703159
. O 0 0.0060772425

RESULTS O 0 0.006532197
: O 0 0.0052756905
Head O 0 0.03435647
- O 0 0.0053523667
up O 0 0.001369555
tilt O 0 0.018326147
caused O 0 0.0018317264
systolic B-Disease 0 0.99950695
orthostatic I-Disease 2 0.99999917
hypotension I-Disease 2 1.0
which O 0 0.0028653543
was O 0 0.00035651997
marked O 0 0.00039860714
in O 0 0.00019758457
six O 0 0.0001438486
of O 0 0.00024430736
20 O 0 0.00037882707
PD B-Disease 0 0.999111
patients O 0 0.00050934195
on O 0 0.0002610932
selegiline B-Chemical 1 0.99999833
, O 0 0.00050984806
one O 0 0.00024295285
of O 0 0.00033895165
whom O 0 0.00071713526
lost O 0 0.0006434034
consciousness O 0 0.49603522
with O 0 0.0013696878
unrecordable O 0 0.26140392
blood O 0 0.011861573
pressures O 0 0.007574918
. O 0 0.0064191157

A O 0 0.062417116
lesser O 0 0.011073038
degree O 0 0.007538877
of O 0 0.021585682
orthostatic B-Disease 2 0.9999888
hypotension I-Disease 2 0.9999976
occurred O 0 0.0075480943
with O 0 0.0067082304
standing O 0 0.013832137
. O 0 0.011974653

Orthostatic B-Disease 0 0.9999429
hypotension I-Disease 2 0.9999969
was O 0 0.0034838165
ameliorated O 0 0.037892982
4 O 0 0.0006835838
days O 0 0.00040464153
after O 0 0.00034757284
withdrawal O 0 0.09426816
of O 0 0.003468885
selegiline B-Chemical 1 0.99999917
and O 0 0.00064188027
totally O 0 0.00060333667
abolished O 0 0.00038430875
7 O 0 0.00032836854
days O 0 0.00033013005
after O 0 0.00048100876
discontinuation O 0 0.056421228
of O 0 0.0016414492
the O 0 0.0026120823
drug O 0 0.37013385
. O 0 0.0072511183

Stopping O 0 0.9520791
selegiline B-Chemical 1 0.9999926
also O 0 0.002465138
significantly O 0 0.0013289049
reduced B-Disease 0 0.00086139544
the I-Disease 0 0.0006461734
supine I-Disease 0 0.0014177446
systolic I-Disease 0 0.19480647
and I-Disease 0 0.0005611556
diastolic I-Disease 0 0.74603516
blood I-Disease 0 0.004261896
pressures I-Disease 0 0.00082892587
consistent O 0 0.00033557494
with O 0 0.00042026842
a O 0 0.0005880533
previously O 0 0.00066882785
undescribed O 0 0.001087184
supine O 0 0.0034953072
pressor O 0 0.5243345
action O 0 0.0046448307
. O 0 0.0064051296

CONCLUSION O 0 0.03315544
: O 0 0.004424734
This O 0 0.0025937064
study O 0 0.0015583809
confirms O 0 0.00086099247
our O 0 0.0006995951
previous O 0 0.0005807207
finding O 0 0.0011468577
that O 0 0.0008904248
selegiline B-Chemical 1 0.99999917
in O 0 0.0005021541
combination O 0 0.00081189343
with O 0 0.0034139503
L B-Chemical 1 0.99987817
- I-Chemical 1 0.9274382
dopa I-Chemical 1 0.9999969
is O 0 0.0008123163
associated O 0 0.0009299209
with O 0 0.0017671115
selective O 0 0.18851581
orthostatic B-Disease 2 0.9999902
hypotension I-Disease 2 0.9999962
. O 0 0.009639769

The O 0 0.0028403264
possibilities O 0 0.0019716846
that O 0 0.0013683112
these O 0 0.0015961668
cardiovascular O 0 0.8922356
findings O 0 0.0013453425
might O 0 0.00041398645
be O 0 0.00038489868
the O 0 0.00029932166
result O 0 0.00025824417
of O 0 0.00045617545
non O 0 0.0035911733
- O 0 0.029948415
selective O 0 0.0011405878
inhibition O 0 0.0012912268
of O 0 0.0048014675
monoamine O 0 0.9999958
oxidase O 0 0.9988675
or O 0 0.0007869056
of O 0 0.012721006
amphetamine B-Chemical 1 0.9999994
and O 0 0.018788122
metamphetamine B-Chemical 0 0.999969
are O 0 0.002283932
discussed O 0 0.0030717289
. O 0 0.005771459

Further O 0 0.0058970028
studies O 0 0.004229376
on O 0 0.0029556856
effects O 0 0.0035734433
of O 0 0.003867421
irrigation O 0 0.009603088
solutions O 0 0.0057246475
on O 0 0.0039781677
rat O 0 0.010301662
bladders O 0 0.12486823
. O 0 0.01256089

Further O 0 0.0038336073
studies O 0 0.0023926767
on O 0 0.0013636434
the O 0 0.0012186744
effects O 0 0.0011163225
of O 0 0.0009433252
certain O 0 0.00096880435
irrigating O 0 0.014951995
fluids O 0 0.0015397496
on O 0 0.0003268917
the O 0 0.0004567269
rat O 0 0.0011255576
bladder O 0 0.034650214
for O 0 0.0007676193
18 O 0 0.0010292429
hours O 0 0.0011549317
are O 0 0.0020776677
reported O 0 0.0041003753
. O 0 0.006779238

The O 0 0.0029954207
results O 0 0.001946748
have O 0 0.0013420511
shown O 0 0.0008963246
that O 0 0.00067302975
the O 0 0.0006421452
degradation O 0 0.0012456854
product O 0 0.0018093273
p B-Chemical 0 0.0030123517
- I-Chemical 0 0.024294093
choloroaniline I-Chemical 0 0.10364917
is O 0 0.00038152043
not O 0 0.00028996286
a O 0 0.00039755862
significant O 0 0.00040958545
factor O 0 0.011897451
in O 0 0.0015712567
chlorhexidine B-Chemical 0 0.9986827
- I-Chemical 0 0.35331503
digluconate I-Chemical 0 0.9851382
associated O 0 0.030962463
erosive O 0 0.999811
cystitis B-Disease 0 0.9999808
. O 0 0.014860598

A O 0 0.024960356
high O 0 0.002970346
percentage O 0 0.0014403351
of O 0 0.002538206
kanamycin B-Chemical 1 0.9994
- O 0 0.6872581
colistin B-Chemical 0 0.99996257
and O 0 0.04639336
povidone B-Chemical 0 0.9999349
- I-Chemical 0 0.6852956
iodine I-Chemical 0 0.99998546
irrigations O 0 0.23347019
were O 0 0.0002892858
associated O 0 0.00028912612
with O 0 0.00056311773
erosive O 0 0.9993561
cystitis B-Disease 0 0.99998724
and O 0 0.00086521637
suggested O 0 0.00036860086
a O 0 0.0005531065
possible O 0 0.00070838106
complication O 0 0.07708875
with O 0 0.0014798597
human O 0 0.0029810537
usage O 0 0.0050263535
. O 0 0.0067397906

Picloxydine B-Chemical 0 0.786987
irrigations O 0 0.03645685
appeared O 0 0.001826727
to O 0 0.0010487995
have O 0 0.000772902
a O 0 0.00081688014
lower O 0 0.00057751266
incidence O 0 0.0017838309
of O 0 0.0017217654
erosive O 0 0.9998652
cystitis B-Disease 0 0.9999969
but O 0 0.0019217243
further O 0 0.00025627753
studies O 0 0.00023356681
would O 0 0.00017438547
have O 0 0.00015651752
to O 0 0.0001601718
be O 0 0.00018592307
performed O 0 0.00017551513
before O 0 0.00016861223
it O 0 0.00026623104
could O 0 0.0002374301
be O 0 0.00033487857
recommended O 0 0.0004356671
for O 0 0.0005420442
use O 0 0.0008826093
in O 0 0.0013379048
urological O 0 0.005065128
procedures O 0 0.0038553472
. O 0 0.006485811

Effects O 0 0.0065637333
of O 0 0.0065679876
tetrandrine B-Chemical 0 0.99998164
and O 0 0.011066085
fangchinoline B-Chemical 0 0.99895656
on O 0 0.001067886
experimental O 0 0.0030662576
thrombosis B-Disease 2 0.99997187
in O 0 0.0011063077
mice O 0 0.00088142685
and O 0 0.0018019808
human O 0 0.0055263103
platelet B-Disease 2 0.9969638
aggregation I-Disease 2 0.9329274
. O 0 0.009873086

Tetrandrine B-Chemical 0 0.9999701
( O 0 0.15415825
TET B-Chemical 1 0.9997117
) O 0 0.010537496
and O 0 0.003369146
fangchinoline B-Chemical 0 0.99972767
( O 0 0.05341789
FAN B-Chemical 1 0.9997452
) O 0 0.0019289918
are O 0 0.0005629792
two O 0 0.00046163163
naturally O 0 0.0010382838
occurring O 0 0.0010326466
analogues O 0 0.023476975
with O 0 0.0015067066
a O 0 0.0029158108
bisbenzylisoquinoline B-Chemical 0 0.9910308
structure O 0 0.008291382
. O 0 0.007671441

The O 0 0.0029949483
present O 0 0.0018702904
study O 0 0.0016611724
was O 0 0.0009833913
undertaken O 0 0.00057674444
to O 0 0.00043906685
investigate O 0 0.00024766815
the O 0 0.00033459807
effects O 0 0.00053918303
of O 0 0.0022228074
TET B-Chemical 1 0.9999422
and O 0 0.008397478
FAN B-Chemical 1 0.9995122
on O 0 0.00016761293
the O 0 0.00021773491
experimental O 0 0.00066945155
thrombosis B-Disease 2 0.9999801
induced O 0 0.00039187007
by O 0 0.00045389216
collagen O 0 0.60871565
plus O 0 0.0014152619
epinephrine B-Chemical 0 0.9999449
( O 0 0.01639461
EP B-Chemical 0 0.99874735
) O 0 0.0013398373
in O 0 0.00023058277
mice O 0 0.00018217736
, O 0 0.0004724122
and O 0 0.00074678153
platelet B-Disease 2 0.9930924
aggregation I-Disease 2 0.80973744
and O 0 0.002229743
blood B-Disease 2 0.7523894
coagulation I-Disease 2 0.9765379
in O 0 0.0021258937
vitro O 0 0.0042177746
. O 0 0.0065093157

In O 0 0.0036046186
the O 0 0.0022308452
in O 0 0.0016820607
vivo O 0 0.0018262671
study O 0 0.0014656499
, O 0 0.0010798682
the O 0 0.0005777048
administration O 0 0.0058651324
( O 0 0.00075174606
50 O 0 0.00046492467
mg O 0 0.020538155
/ O 0 0.0019020241
kg O 0 0.0013023062
, O 0 0.0004926973
i O 0 0.0020217174
. O 0 0.0002367598
p O 0 0.0002695881
. O 0 0.0002346391
) O 0 0.00060047745
of O 0 0.0011075194
TET B-Chemical 1 0.9998938
and O 0 0.005987977
FAN B-Chemical 1 0.99961156
in O 0 0.00021348087
mice O 0 0.00011627505
showed O 0 0.00014913127
the O 0 0.00015850936
inhibition O 0 0.00049348007
of O 0 0.0014958811
thrombosis B-Disease 2 0.99999213
by O 0 0.00031547694
55 O 0 0.00027163303
% O 0 0.00021394975
and O 0 0.00018669566
35 O 0 0.00019025001
% O 0 0.00024915958
, O 0 0.00032683465
respectively O 0 0.002271037
, O 0 0.00082854484
while O 0 0.005537003
acetylsalicylic B-Chemical 0 0.9999999
acid I-Chemical 0 0.9996582
( O 0 0.06067074
ASA B-Chemical 1 0.99944776
, O 0 0.0006058761
50 O 0 0.00031738653
mg O 0 0.012880592
/ O 0 0.0012635913
kg O 0 0.0009383905
, O 0 0.00039413918
i O 0 0.0014787384
. O 0 0.00022282409
p O 0 0.000268553
. O 0 0.00025136073
) O 0 0.0005256459
, O 0 0.00038649942
a O 0 0.00034643552
positive O 0 0.00044435516
control O 0 0.00046432164
, O 0 0.00069692405
showed O 0 0.00062191125
only O 0 0.00093325105
30 O 0 0.001220224
% O 0 0.002447869
inhibition O 0 0.0051467842
. O 0 0.0072667045

In O 0 0.0037454986
the O 0 0.0023954723
vitro O 0 0.0026454546
human O 0 0.0042348555
platelet B-Disease 0 0.9930943
aggregations I-Disease 0 0.10619938
induced O 0 0.0008000302
by O 0 0.00060914725
the O 0 0.00050150906
agonists O 0 0.12596965
used O 0 0.00030538152
in O 0 0.0003329656
tests O 0 0.0010961436
, O 0 0.0022633271
TET B-Chemical 1 0.99974066
and O 0 0.0039319526
FAN B-Chemical 1 0.9992699
showed O 0 0.0008658534
the O 0 0.0011689177
inhibitions O 0 0.4360087
dose O 0 0.08012084
dependently O 0 0.9357661
. O 0 0.008292665

In O 0 0.003612057
addition O 0 0.0019765028
, O 0 0.002778983
neither O 0 0.0023175979
TET B-Chemical 1 0.99971575
nor O 0 0.0072030085
FAN B-Chemical 1 0.99972314
showed O 0 0.0007078585
any O 0 0.00046350466
anticoagulation O 0 0.32675144
activities O 0 0.00027835323
in O 0 0.00018251831
the O 0 0.00015779966
measurement O 0 0.00013175912
of O 0 0.00019094985
the O 0 0.0001744648
activated O 0 0.00023077303
partial O 0 0.00088693487
thromboplastin O 0 0.85906965
time O 0 0.00014509642
( O 0 0.0013047092
APTT O 0 0.9956801
) O 0 0.00081544527
, O 0 0.00056943984
prothrombin O 0 0.91496444
time O 0 0.00015632168
( O 0 0.00046943783
PT O 0 0.057117734
) O 0 0.00047876182
and O 0 0.00034124346
thrombin O 0 0.30504102
time O 0 0.00026206762
( O 0 0.00091691886
TT O 0 0.6676251
) O 0 0.0010440552
using O 0 0.0007138861
human O 0 0.0017652425
- O 0 0.032101784
citrated O 0 0.2086689
plasma O 0 0.025112757
. O 0 0.0067316745

These O 0 0.0035371715
results O 0 0.002119014
suggest O 0 0.001279119
that O 0 0.0013197962
antithrombosis O 0 0.23660506
of O 0 0.006536731
TET B-Chemical 1 0.9999229
and O 0 0.013959976
FAN B-Chemical 1 0.999635
in O 0 0.00049800536
mice O 0 0.0002879809
may O 0 0.000336602
be O 0 0.0003765239
mainly O 0 0.00046359922
related O 0 0.00040971587
to O 0 0.0006183064
the O 0 0.0011759592
antiplatelet O 0 0.95484495
aggregation O 0 0.062781125
activities O 0 0.004769721
. O 0 0.0066536195

Angioedema B-Disease 0 0.9994351
due O 0 0.004503298
to O 0 0.0049806153
ACE B-Chemical 0 0.9995902
inhibitors I-Chemical 0 0.13683876
: O 0 0.0045916596
common O 0 0.0035096284
and O 0 0.004131648
inadequately O 0 0.046102867
diagnosed O 0 0.028669273
. O 0 0.01085308

The O 0 0.0030013006
estimated O 0 0.0021960472
incidence O 0 0.0056056147
of O 0 0.00964245
angioedema B-Disease 2 0.99999654
during O 0 0.0057947743
angiotensin B-Chemical 1 0.9999976
- I-Chemical 0 0.5353276
converting I-Chemical 0 0.096284516
enzyme I-Chemical 0 0.3304177
( I-Chemical 0 0.019669672
ACE I-Chemical 0 0.9995142
) I-Chemical 0 0.0014126867
inhibitor I-Chemical 0 0.0033574048
treatment O 0 0.0003923267
is O 0 0.00029701088
between O 0 0.0002777782
1 O 0 0.00042616745
and O 0 0.00056118454
7 O 0 0.00066423963
per O 0 0.00084750925
thousand O 0 0.0020470677
patients O 0 0.00411703
. O 0 0.0063367058

This O 0 0.005432719
potentially O 0 0.004422143
serious O 0 0.098765455
adverse O 0 0.5735772
effect O 0 0.001446799
is O 0 0.0009761128
often O 0 0.0008441064
preceded O 0 0.00064300414
by O 0 0.00069151283
minor O 0 0.0019547243
manifestations O 0 0.07666655
that O 0 0.0006451848
may O 0 0.00084348733
serve O 0 0.001283934
as O 0 0.0017422066
a O 0 0.0035352225
warning O 0 0.032871522
. O 0 0.007979916

Cocaine B-Chemical 0 0.99998736
- O 0 0.14564952
induced O 0 0.005693161
mood B-Disease 0 0.9991346
disorder I-Disease 0 0.9923437
: O 0 0.0021530145
prevalence O 0 0.0016655863
rates O 0 0.0009204395
and O 0 0.0022033532
psychiatric B-Disease 2 0.99991167
symptoms O 0 0.9377784
in O 0 0.00063799275
an O 0 0.0009079687
outpatient O 0 0.0021260614
cocaine B-Chemical 1 0.9999416
- O 0 0.008564826
dependent O 0 0.0022069782
sample O 0 0.004250613
. O 0 0.006939785

This O 0 0.0053477543
paper O 0 0.0031854939
attempts O 0 0.0016987724
to O 0 0.00097318576
examine O 0 0.00051034114
and O 0 0.00061792164
compare O 0 0.00030995024
prevalence O 0 0.00064376934
rates O 0 0.00047007125
and O 0 0.0005018663
symptom O 0 0.0049358653
patterns O 0 0.00031365294
of O 0 0.0006320127
DSM O 0 0.18016121
substance O 0 0.95732695
- O 0 0.011970039
induced O 0 0.0008640227
and O 0 0.0015355063
other O 0 0.0034801355
mood B-Disease 0 0.9965178
disorders I-Disease 0 0.89114547
. O 0 0.0073897946

243 O 0 0.15762337
cocaine B-Chemical 1 0.99994826
- O 0 0.036181625
dependent O 0 0.0013356787
outpatients O 0 0.0068069124
with O 0 0.0030435333
cocaine B-Chemical 1 0.9999951
- O 0 0.11692423
induced O 0 0.0017835074
mood B-Disease 0 0.9996486
disorder I-Disease 0 0.99797565
( O 0 0.018576594
CIMD B-Disease 0 0.99907804
) O 0 0.0037931039
, O 0 0.00058759114
other O 0 0.00064518914
mood B-Disease 0 0.9960263
disorders I-Disease 0 0.78755844
, O 0 0.0004243596
or O 0 0.0002598124
no O 0 0.00029985124
mood B-Disease 0 0.9947748
disorder I-Disease 0 0.89703906
were O 0 0.00034022116
compared O 0 0.0002906498
on O 0 0.0003998844
measures O 0 0.0007901682
of O 0 0.0028738873
psychiatric B-Disease 2 0.9998456
symptoms O 0 0.97723114
. O 0 0.0076391255

The O 0 0.00495879
prevalence O 0 0.005267149
rate O 0 0.0041270675
for O 0 0.004189813
CIMD B-Disease 0 0.9729652
was O 0 0.0034854312
12 O 0 0.002776373
% O 0 0.003956854
at O 0 0.004357632
baseline O 0 0.0068185306
. O 0 0.010963661

Introduction O 0 0.005910458
of O 0 0.0031917624
the O 0 0.0025873983
DSM O 0 0.11029715
- O 0 0.051318772
IV O 0 0.21398567
diagnosis O 0 0.004983352
of O 0 0.002262993
CIMD B-Disease 0 0.9974342
did O 0 0.00079802575
not O 0 0.00043851833
substantially O 0 0.00048332885
affect O 0 0.00040189514
rates O 0 0.00068443123
of O 0 0.0009896678
the O 0 0.0013511992
other O 0 0.005408741
depressive B-Disease 2 0.9999807
disorders I-Disease 0 0.9509911
. O 0 0.008074169

Patients O 0 0.0052321265
with O 0 0.0037405181
CIMD B-Disease 0 0.96865046
had O 0 0.0018241492
symptom O 0 0.022743475
severity O 0 0.0024863866
levels O 0 0.00055270724
between O 0 0.0004025267
those O 0 0.00055560307
of O 0 0.0005668047
patients O 0 0.0007374187
with O 0 0.00063280837
and O 0 0.00089079316
without O 0 0.0012444829
a O 0 0.0036858558
mood B-Disease 0 0.9963736
disorder I-Disease 0 0.97548306
. O 0 0.007794172

These O 0 0.0034261697
findings O 0 0.0024243917
suggest O 0 0.0011525957
some O 0 0.0010809056
validity O 0 0.0010468294
for O 0 0.0006733554
the O 0 0.00059443485
new O 0 0.00096440146
DSM O 0 0.10838813
- O 0 0.037607238
IV O 0 0.17790173
diagnosis O 0 0.0030158223
of O 0 0.0014822733
CIMD B-Disease 0 0.9987614
, O 0 0.0010932267
but O 0 0.00041353126
also O 0 0.00027489488
suggest O 0 0.00023486873
that O 0 0.0003426036
it O 0 0.0005163409
requires O 0 0.00051132997
further O 0 0.00092525786
specification O 0 0.0055203964
and O 0 0.0029380315
replication O 0 0.08007147
. O 0 0.008253138

Effect O 0 0.0053751827
of O 0 0.004931872
fucoidan B-Chemical 0 0.9928288
treatment O 0 0.0038836093
on O 0 0.0017024186
collagenase O 0 0.90707177
- O 0 0.15049696
induced O 0 0.0105278
intracerebral B-Disease 0 0.99992096
hemorrhage I-Disease 2 0.9999887
in O 0 0.0054020323
rats O 0 0.008243042
. O 0 0.008258126

Inflammatory O 0 0.04286682
cells O 0 0.0036418096
are O 0 0.0020539802
postulated O 0 0.0016055438
to O 0 0.0010084156
mediate O 0 0.00071432715
some O 0 0.000899191
of O 0 0.0011163811
the O 0 0.0014313319
brain B-Disease 2 0.8503735
damage I-Disease 2 0.99768126
following O 0 0.025818484
ischemic B-Disease 2 0.9999981
stroke I-Disease 2 0.9999927
. O 0 0.016688999

Intracerebral B-Disease 0 0.9992906
hemorrhage I-Disease 2 0.9999877
is O 0 0.0045287474
associated O 0 0.0028920248
with O 0 0.0027451043
more O 0 0.004194242
inflammation B-Disease 0 0.9988493
than O 0 0.018384924
ischemic B-Disease 2 0.99999726
stroke I-Disease 2 0.9999913
. O 0 0.019187942

We O 0 0.0036259964
tested O 0 0.0023356848
the O 0 0.0021057685
sulfated O 0 0.67061734
polysaccharide O 0 0.72160214
fucoidan B-Chemical 0 0.9998042
, O 0 0.0083908895
which O 0 0.0011320481
has O 0 0.00039093598
been O 0 0.00031335585
reported O 0 0.00029142396
to O 0 0.00019277594
reduce O 0 0.0001935266
inflammatory O 0 0.82623696
brain B-Disease 2 0.97668046
damage I-Disease 2 0.9984267
, O 0 0.0012916088
in O 0 0.0002358478
a O 0 0.0002852608
rat O 0 0.0004926799
model O 0 0.00026374075
of O 0 0.002191764
intracerebral B-Disease 0 0.99991083
hemorrhage I-Disease 2 0.9999951
induced O 0 0.00047155988
by O 0 0.00034806627
injection O 0 0.0005238863
of O 0 0.00046244572
bacterial O 0 0.006075552
collagenase O 0 0.44794676
into O 0 0.0006575568
the O 0 0.0014903842
caudate O 0 0.64415807
nucleus O 0 0.0043485155
. O 0 0.005953253

Rats O 0 0.0096821785
were O 0 0.0025269515
treated O 0 0.0016976699
with O 0 0.001130023
seven O 0 0.0007436728
day O 0 0.0005981965
intravenous O 0 0.008573707
infusion O 0 0.0013217687
of O 0 0.00084971916
fucoidan B-Chemical 0 0.9980229
( O 0 0.0013456136
30 O 0 0.0004137738
micrograms O 0 0.0030010226
h O 0 0.00084532757
- O 0 0.0032890516
1 O 0 0.0011397591
) O 0 0.0021408335
or O 0 0.0026058482
vehicle O 0 0.019045964
. O 0 0.0077777277

The O 0 0.00716481
hematoma B-Disease 0 0.98995495
was O 0 0.0041837455
assessed O 0 0.0029242851
in O 0 0.003223846
vivo O 0 0.0042729727
by O 0 0.005256941
magnetic O 0 0.04334039
resonance O 0 0.5628602
imaging O 0 0.01596364
. O 0 0.013395937

Motor O 0 0.16636951
behavior O 0 0.005699029
, O 0 0.003205707
passive O 0 0.0033259538
avoidance O 0 0.0066205957
, O 0 0.0016301546
and O 0 0.0011276057
skilled O 0 0.0017471113
forelimb O 0 0.053611852
function O 0 0.0007233587
were O 0 0.0007226035
tested O 0 0.00074216584
repeatedly O 0 0.0011484529
for O 0 0.0014536626
six O 0 0.0019525831
weeks O 0 0.002978913
. O 0 0.0066832146

Fucoidan B-Chemical 0 0.99798137
- O 0 0.04494896
treated O 0 0.0024502745
rats O 0 0.0017891098
exhibited O 0 0.0008564313
evidence O 0 0.00057163544
of O 0 0.00072538893
impaired B-Disease 0 0.0055999053
blood I-Disease 0 0.1250804
clotting I-Disease 0 0.8006732
and O 0 0.00091262494
hemodilution B-Disease 0 0.9976192
, O 0 0.00043070808
had O 0 0.00022405718
larger O 0 0.00033910983
hematomas B-Disease 0 0.99966514
, O 0 0.00040933272
and O 0 0.0002479347
tended O 0 0.00016898112
to O 0 0.00014007057
have O 0 0.00016461074
less O 0 0.00026962798
inflammation B-Disease 0 0.97199696
in O 0 0.00029990324
the O 0 0.00026613384
vicinity O 0 0.00033083392
of O 0 0.00053772546
the O 0 0.00082055037
hematoma B-Disease 0 0.997823
after O 0 0.00088421867
three O 0 0.0012844413
days O 0 0.0024445911
. O 0 0.005558337

They O 0 0.0049356334
showed O 0 0.002376172
significantly O 0 0.0017056016
more O 0 0.0013046172
rapid O 0 0.0013804302
improvement O 0 0.0008023408
of O 0 0.00068588794
motor O 0 0.007824643
function O 0 0.00035777298
in O 0 0.00027950818
the O 0 0.00023114253
first O 0 0.0001860442
week O 0 0.00018730189
following O 0 0.00028377565
hemorrhage B-Disease 2 0.99991345
and O 0 0.00045727513
better O 0 0.00045692746
memory O 0 0.07312783
retention O 0 0.0010817318
in O 0 0.0006634083
the O 0 0.0009456641
passive O 0 0.0026303628
avoidance O 0 0.008046585
test O 0 0.0043139895
. O 0 0.0068852375

Acute O 0 0.7727505
white B-Disease 0 0.460753
matter I-Disease 0 0.33200493
edema I-Disease 0 0.9999809
and O 0 0.002543407
eventual O 0 0.06738217
neuronal B-Disease 0 0.9445741
loss I-Disease 0 0.06587445
in O 0 0.0004593626
the O 0 0.0004117998
striatum O 0 0.21411909
adjacent O 0 0.00039127487
to O 0 0.0002681531
the O 0 0.00046589627
hematoma B-Disease 0 0.99942917
did O 0 0.0005000123
not O 0 0.00041868107
differ O 0 0.000553203
between O 0 0.0006402882
the O 0 0.0011757275
two O 0 0.0017207451
groups O 0 0.0033988291
. O 0 0.0063098664

Investigation O 0 0.007755082
of O 0 0.003242015
more O 0 0.0023007405
specific O 0 0.0016860339
anti O 0 0.27685612
- O 0 0.09686461
inflammatory O 0 0.68159646
agents O 0 0.051578633
and O 0 0.001355849
hemodiluting O 0 0.15373333
agents O 0 0.005167351
are O 0 0.00082555326
warranted O 0 0.0010544885
in O 0 0.002330007
intracerebral B-Disease 0 0.99954
hemorrhage I-Disease 2 0.9999696
. O 0 0.010108897

Recurarization O 0 0.035132006
in O 0 0.01593653
the O 0 0.016124444
recovery O 0 0.021982472
room O 0 0.022958966
. O 0 0.02879496

A O 0 0.03407047
case O 0 0.005320299
of O 0 0.0047555612
recurarization O 0 0.17422181
in O 0 0.0028598555
the O 0 0.0026763817
recovery O 0 0.0038009647
room O 0 0.0037454795
is O 0 0.00463989
reported O 0 0.0073391953
. O 0 0.010684198

Accumulation O 0 0.008470724
of O 0 0.004379847
atracurium B-Chemical 0 0.9966427
in O 0 0.00166151
the O 0 0.0011168108
intravenous O 0 0.037534785
line O 0 0.00088039186
led O 0 0.000540957
to O 0 0.00048940774
recurarization O 0 0.12799644
after O 0 0.0003820886
flushing O 0 0.51034033
the O 0 0.0005580721
line O 0 0.00092266
in O 0 0.0009702945
the O 0 0.0014288381
recovery O 0 0.002945685
room O 0 0.0038473909
. O 0 0.0062234746

A O 0 0.32520676
respiratory B-Disease 0 0.9261254
arrest I-Disease 0 0.95031005
with O 0 0.0090509765
severe O 0 0.731856
desaturation B-Disease 0 0.99935514
and O 0 0.015302689
bradycardia B-Disease 0 0.9990803
occurred O 0 0.009603146
. O 0 0.011899083

Circumstances O 0 0.07638006
leading O 0 0.0035639647
to O 0 0.001731374
this O 0 0.0013034311
event O 0 0.00237989
and O 0 0.00077512546
the O 0 0.00046534525
mechanisms O 0 0.00038790688
enabling O 0 0.0006613239
a O 0 0.0007936909
neuromuscular B-Disease 0 0.8566655
blockade I-Disease 0 0.1805846
to O 0 0.00022370582
occur O 0 0.00023793228
, O 0 0.00031959152
following O 0 0.00017523706
the O 0 0.00021466677
administration O 0 0.00090783293
of O 0 0.00033386418
a O 0 0.0004154775
small O 0 0.00046467103
dose O 0 0.0033458883
of O 0 0.0016412953
relaxant O 0 0.88768923
, O 0 0.0022546218
are O 0 0.0021521489
discussed O 0 0.003172289
. O 0 0.0060805534

The O 0 0.0035030455
haemodynamic O 0 0.11011292
effects O 0 0.002623449
of O 0 0.0029839196
propofol B-Chemical 1 0.9997725
in O 0 0.0009305501
combination O 0 0.0011665074
with O 0 0.0025752955
ephedrine B-Chemical 1 0.99999094
in O 0 0.0006631975
elderly O 0 0.2734504
patients O 0 0.0011944079
( O 0 0.0016936533
ASA O 1 0.9871874
groups O 0 0.0008367626
3 O 0 0.0008846194
and O 0 0.0014666392
4 O 0 0.0021759693
) O 0 0.0049979337
. O 0 0.007234448

The O 0 0.0036962824
marked O 0 0.004502642
vasodilator O 0 0.9017937
and O 0 0.0019492713
negative O 0 0.0021288353
inotropic O 0 0.93920743
effects O 0 0.0017801243
of O 0 0.0019900817
propofol B-Chemical 1 0.9994042
are O 0 0.00078299065
disadvantages O 0 0.0007518298
in O 0 0.0013624621
frail O 0 0.27228996
elderly O 0 0.21682298
patients O 0 0.006235456
. O 0 0.0073735756

We O 0 0.0033004594
investigated O 0 0.0018706643
the O 0 0.0014526409
safety O 0 0.00141319
and O 0 0.00091032404
efficacy O 0 0.0008487821
of O 0 0.00058864494
adding O 0 0.0005063436
different O 0 0.00033280725
doses O 0 0.0031415855
of O 0 0.0028890122
ephedrine B-Chemical 1 0.99999404
to O 0 0.0006551797
propofol B-Chemical 1 0.999121
in O 0 0.00039802294
order O 0 0.0003727942
to O 0 0.00058432843
obtund O 0 0.0036104135
the O 0 0.0016044192
hypotensive B-Disease 0 0.9931251
response O 0 0.0047186045
. O 0 0.0066708643

The O 0 0.0034067752
haemodynamic O 0 0.08084317
effects O 0 0.0019408026
of O 0 0.0012398332
adding O 0 0.0009953144
15 O 0 0.00057181006
, O 0 0.000566459
20 O 0 0.00033776264
or O 0 0.00027061382
25 O 0 0.00034356012
mg O 0 0.010023057
of O 0 0.00076863676
ephedrine B-Chemical 1 0.9999716
to O 0 0.0001961763
200 O 0 0.0003346772
mg O 0 0.0063433647
of O 0 0.0003973383
propofol B-Chemical 1 0.99862015
were O 0 0.00016093912
compared O 0 9.960276e-05
to O 0 0.00011524812
control O 0 0.00015510285
in O 0 0.0001759087
40 O 0 0.00028050444
ASA O 1 0.97522426
3 O 0 0.00018938685
/ O 0 0.0005072296
4 O 0 0.00017458279
patients O 0 0.00020363927
over O 0 0.00015057976
60 O 0 0.00024713765
years O 0 0.00035650027
presenting O 0 0.00071017304
for O 0 0.00072906376
genito O 0 0.0326756
- O 0 0.021854637
urinary O 0 0.42144027
surgery O 0 0.008197318
. O 0 0.00697103

The O 0 0.0028658977
addition O 0 0.001769768
of O 0 0.0038807364
ephedrine B-Chemical 1 0.99998534
to O 0 0.0021591967
propofol B-Chemical 1 0.9998093
appears O 0 0.00054350146
to O 0 0.00031231254
be O 0 0.00030536987
an O 0 0.00031596393
effective O 0 0.0002903676
method O 0 0.00036807606
of O 0 0.0005022539
obtunding O 0 0.5526481
the O 0 0.0004249549
hypotensive B-Disease 0 0.9954241
response O 0 0.00048418975
to O 0 0.00036975468
propofol B-Chemical 1 0.99864584
at O 0 0.0002993525
all O 0 0.00036870505
doses O 0 0.00097471464
used O 0 0.0006997498
in O 0 0.0011464362
this O 0 0.001952597
study O 0 0.0040810076
. O 0 0.0061965594

However O 0 0.0050001875
, O 0 0.0042319573
marked O 0 0.0057862476
tachycardia B-Disease 2 0.9991217
associated O 0 0.0014837676
with O 0 0.000726014
the O 0 0.00045911572
use O 0 0.00043772085
of O 0 0.0014765629
ephedrine B-Chemical 1 0.9999902
in O 0 0.0003155452
combination O 0 0.0004342139
with O 0 0.0006653579
propofol B-Chemical 1 0.9993036
occurred O 0 0.0002478765
in O 0 0.00017503316
the O 0 0.00016508323
majority O 0 0.00018424251
of O 0 0.00028223798
patients O 0 0.00051614834
, O 0 0.00043372117
occasionally O 0 0.0006217358
reaching O 0 0.00060912495
high O 0 0.0007215459
levels O 0 0.0007696805
in O 0 0.0011781589
individual O 0 0.0019400571
patients O 0 0.0047418815
. O 0 0.006174095

Due O 0 0.003410303
to O 0 0.002261155
the O 0 0.0017993888
risk O 0 0.019732447
of O 0 0.0014853134
this O 0 0.0014698256
tachycardia B-Disease 2 0.99980956
inducing O 0 0.1023074
myocardial B-Disease 0 0.99999297
ischemia I-Disease 2 0.99999905
, O 0 0.0030018673
we O 0 0.00017445015
would O 0 0.00017208123
not O 0 0.00015563738
recommend O 0 0.00015134209
the O 0 0.00015977948
use O 0 0.00018961489
in O 0 0.00021900245
elderly O 0 0.05692853
patients O 0 0.00031413682
of O 0 0.00027270708
any O 0 0.00024392514
of O 0 0.00046257733
the O 0 0.0014088576
ephedrine B-Chemical 1 0.9999951
/ O 0 0.24853902
propofol B-Chemical 1 0.9998381
/ O 0 0.02089015
mixtures O 0 0.005696738
studied O 0 0.004429177
. O 0 0.0065651014

Gemcitabine B-Chemical 0 0.99781764
plus O 0 0.0044520595
vinorelbine B-Chemical 0 0.99882823
in O 0 0.004080399
nonsmall B-Disease 0 0.99884903
cell I-Disease 0 0.075470775
lung I-Disease 0 0.91852945
carcinoma I-Disease 2 0.99998474
patients O 0 0.0054837638
age O 0 0.00097020704
70 O 0 0.00038698
years O 0 0.00042048199
or O 0 0.00041973474
older O 0 0.0010675254
or O 0 0.00064814894
patients O 0 0.0012432408
who O 0 0.0018832863
cannot O 0 0.0033663039
receive O 0 0.0028150505
cisplatin B-Chemical 1 0.99798465
. O 0 0.009009634

Oncopaz O 0 0.12635337
Cooperative O 0 0.10573538
Group O 0 0.0902996
. O 0 0.06927159

BACKGROUND O 0 0.016424265
: O 0 0.0034062702
Although O 0 0.0013705165
the O 0 0.0010468493
prevalence O 0 0.0016654528
of O 0 0.0020661387
nonsmall B-Disease 0 0.9991535
cell I-Disease 0 0.10353595
lung I-Disease 0 0.9720453
carcinoma I-Disease 2 0.9999981
( O 0 0.3137707
NSCLC B-Disease 2 0.99994516
) O 0 0.003331
is O 0 0.00030886
high O 0 0.00042482163
among O 0 0.000527999
elderly O 0 0.1470844
patients O 0 0.0004072067
, O 0 0.00025273574
few O 0 0.00012960032
data O 0 0.00016823804
are O 0 0.00014572007
available O 0 0.0001527698
regarding O 0 0.00011407081
the O 0 0.00016688988
efficacy O 0 0.00035361285
and O 0 0.0005009973
toxicity B-Disease 2 0.99429625
of O 0 0.00086370565
chemotherapy O 0 0.04703197
in O 0 0.0005992648
this O 0 0.00081785064
group O 0 0.0014603197
of O 0 0.0024899014
patients O 0 0.005787378
. O 0 0.00641046

Recent O 0 0.0040620007
reports O 0 0.0022618175
indicate O 0 0.0011315105
that O 0 0.00093662814
single O 0 0.00094357063
agent O 0 0.016900545
therapy O 0 0.0025963995
with O 0 0.0018276343
vinorelbine B-Chemical 0 0.99975485
( O 0 0.037312277
VNB B-Chemical 0 0.9990287
) O 0 0.0015612534
or O 0 0.00052197376
gemcitabine B-Chemical 0 0.9992488
( O 0 0.022603333
GEM B-Chemical 0 0.9992254
) O 0 0.0010543956
may O 0 0.00016005654
obtain O 0 0.00010899873
a O 0 0.00017556903
response O 0 0.00018605946
rate O 0 0.00019110485
of O 0 0.00026396665
20 O 0 0.00025019274
- O 0 0.0012564923
30 O 0 0.00014883208
% O 0 0.00020308122
in O 0 0.00019384205
elderly O 0 0.043723427
patients O 0 0.00033413424
, O 0 0.00027542954
with O 0 0.00025101684
acceptable O 0 0.00043456274
toxicity B-Disease 2 0.9838748
and O 0 0.0004377644
improvement O 0 0.0004422117
in O 0 0.00048086824
symptoms O 0 0.017780382
and O 0 0.0008512614
quality O 0 0.0011556008
of O 0 0.0023615123
life O 0 0.004795538
. O 0 0.006802117

In O 0 0.0035018055
the O 0 0.0021540308
current O 0 0.002045181
study O 0 0.0012581282
the O 0 0.0007322971
efficacy O 0 0.0010288684
and O 0 0.0010349124
toxicity B-Disease 2 0.99575436
of O 0 0.0006292144
the O 0 0.00032742537
combination O 0 0.00052894454
of O 0 0.0015593532
GEM B-Chemical 0 0.99950826
and O 0 0.005976524
VNB B-Chemical 0 0.99792755
in O 0 0.00030350563
elderly O 0 0.10758329
patients O 0 0.0003558811
with O 0 0.0003414926
advanced O 0 0.08755601
NSCLC B-Disease 2 0.9994511
or O 0 0.00031108706
those O 0 0.00034562894
with O 0 0.00029057165
some O 0 0.0003157658
contraindication O 0 0.00042869753
to O 0 0.00053455884
receiving O 0 0.0019878082
cisplatin B-Chemical 1 0.9966607
were O 0 0.0022276128
assessed O 0 0.0030874484
. O 0 0.0061830194

METHODS O 0 0.0042768945
: O 0 0.0040567066
Forty O 0 0.0037678634
- O 0 0.0038160488
nine O 0 0.0011845931
patients O 0 0.0010725908
with O 0 0.00091422285
advanced O 0 0.06743523
NSCLC B-Disease 2 0.99892455
were O 0 0.00047310823
included O 0 0.00030857718
, O 0 0.00038137098
38 O 0 0.00034060836
of O 0 0.00027108044
whom O 0 0.0004722886
were O 0 0.0002280744
age O 0 0.00052405713
> O 0 0.0010157417
/ O 0 0.0025436333
= O 0 0.0005172296
70 O 0 0.0002073407
years O 0 0.00021458902
and O 0 0.0002124465
11 O 0 0.00020633372
were O 0 0.00018405674
age O 0 0.00028692847
< O 0 0.00021455708
70 O 0 0.0002606669
years O 0 0.00034549288
but O 0 0.00040369487
who O 0 0.0005323496
had O 0 0.00043839417
some O 0 0.0005874671
contraindication O 0 0.0009010427
to O 0 0.0013288105
receiving O 0 0.005934711
cisplatin B-Chemical 1 0.9987966
. O 0 0.008369413

All O 0 0.0065065627
patients O 0 0.0062317518
were O 0 0.0049094255
evaluable O 0 0.006431003
for O 0 0.004872894
response O 0 0.00735435
and O 0 0.011422801
toxicity B-Disease 2 0.9979673
. O 0 0.018272478

Treatment O 0 0.0073427814
was O 0 0.0026281157
comprised O 0 0.0018321797
of O 0 0.0027212878
VNB B-Chemical 0 0.99573284
, O 0 0.001462472
25 O 0 0.00084946735
mg O 0 0.027067497
/ O 0 0.003006912
m O 0 0.004182732
( O 0 0.0007108786
2 O 0 0.00033904132
) O 0 0.00053857383
, O 0 0.0004238124
plus O 0 0.00039163238
GEM B-Chemical 0 0.9970304
, O 0 0.00068915426
1000 O 0 0.0005455423
mg O 0 0.015309647
/ O 0 0.0018468185
m O 0 0.0028699175
( O 0 0.0004988813
2 O 0 0.00025413485
) O 0 0.00039100045
, O 0 0.00028694872
both O 0 0.00021539134
on O 0 0.00021013178
Days O 0 0.005359703
1 O 0 0.00033718854
, O 0 0.0004628058
8 O 0 0.00042118964
, O 0 0.0006051911
and O 0 0.0006917093
15 O 0 0.00077921123
every O 0 0.0008354548
28 O 0 0.0020168878
days O 0 0.002797799
. O 0 0.0063113794

Patients O 0 0.005605529
received O 0 0.002747873
a O 0 0.0024312735
minimum O 0 0.0014744462
of O 0 0.0016026269
three O 0 0.001046957
courses O 0 0.0013966172
unless O 0 0.0016341856
progressive O 0 0.15365218
disease O 0 0.9116272
was O 0 0.0041336855
detected O 0 0.0049801567
. O 0 0.008981086

RESULTS O 0 0.006687458
: O 0 0.0044864016
One O 0 0.002775386
hundred O 0 0.002022059
sixty O 0 0.0020673827
- O 0 0.0023280196
five O 0 0.0008086286
courses O 0 0.00085079466
were O 0 0.00080339814
administered O 0 0.00081333646
, O 0 0.0010913818
with O 0 0.0010843524
a O 0 0.0015051852
median O 0 0.0015084472
of O 0 0.0030544389
3 O 0 0.004187484
. O 0 0.0073967623

6 O 0 0.02044628
courses O 0 0.021116082
per O 0 0.019527938
patient O 0 0.03009903
. O 0 0.037519388

The O 0 0.0032542215
overall O 0 0.0023875819
response O 0 0.0020324849
rate O 0 0.0015601782
was O 0 0.0012113919
26 O 0 0.001111232
% O 0 0.00092811685
( O 0 0.0008955337
95 O 0 0.0009296798
% O 0 0.0007060297
confidence O 0 0.0011037161
interval O 0 0.0006775789
, O 0 0.0010443421
15 O 0 0.0010752253
- O 0 0.0027802929
41 O 0 0.0029519994
% O 0 0.0039279996
) O 0 0.0070550013
. O 0 0.009281724

Two O 0 0.0039892723
patients O 0 0.0028187314
attained O 0 0.0023072583
a O 0 0.001495681
complete O 0 0.00087296916
response O 0 0.0010538017
( O 0 0.0010609132
4 O 0 0.0004990542
% O 0 0.00057557144
) O 0 0.00065335364
and O 0 0.00046543375
11 O 0 0.00045213973
patients O 0 0.0005367809
( O 0 0.000665742
22 O 0 0.00068016176
% O 0 0.000818903
) O 0 0.001217128
achieved O 0 0.0012970873
a O 0 0.0020224294
partial O 0 0.0031570827
response O 0 0.00520651
. O 0 0.007928545

Eastern O 0 0.10960543
Cooperative O 0 0.02346947
Oncology O 0 0.0060335514
Group O 0 0.004576468
performance O 0 0.0013808063
status O 0 0.0010120614
improved O 0 0.00075049524
in O 0 0.00047156506
35 O 0 0.00042691722
% O 0 0.0003982569
of O 0 0.00034026694
those O 0 0.0003530843
patients O 0 0.0003107485
with O 0 0.00020979624
an O 0 0.0001997457
initial O 0 0.00014981754
value O 0 0.00021285893
> O 0 0.0007854755
0 O 0 0.0002524116
, O 0 0.00025532927
whereas O 0 0.00021114842
relief O 0 0.0004889139
of O 0 0.00018258877
at O 0 0.0001342019
least O 0 0.00012238236
1 O 0 0.00016410688
symptom O 0 0.00094954995
without O 0 0.00017528786
worsening O 0 0.036892865
of O 0 0.00032419222
other O 0 0.00042328757
symptoms O 0 0.088361576
was O 0 0.00026336734
noted O 0 0.00025099574
in O 0 0.0003700395
27 O 0 0.0006780544
patients O 0 0.0008754289
( O 0 0.0012959709
55 O 0 0.0017864369
% O 0 0.002868705
) O 0 0.005462561
. O 0 0.0073791593

The O 0 0.0027467806
median O 0 0.0015518581
time O 0 0.0011424077
to O 0 0.0010794897
progression O 0 0.021339292
was O 0 0.00081185234
16 O 0 0.0005839508
weeks O 0 0.00034219163
and O 0 0.00045384365
the O 0 0.0004754372
1 O 0 0.0005844193
- O 0 0.0014135014
year O 0 0.0007915444
survival O 0 0.0032690868
rate O 0 0.0015015124
was O 0 0.0020602194
33 O 0 0.0035525966
% O 0 0.0050813844
. O 0 0.0077363327

Toxicity B-Disease 0 0.9480373
was O 0 0.05293091
mild O 0 0.59765935
. O 0 0.06015921

Six O 0 0.0049730125
patients O 0 0.003360489
( O 0 0.002589619
12 O 0 0.0012642004
% O 0 0.0012768904
) O 0 0.0011921675
had O 0 0.00066142913
World O 0 0.001114684
Health O 0 0.00069458934
Organization O 0 0.00076551986
Grade O 0 0.106261455
3 O 0 0.00034579835
- O 0 0.0019792337
4 O 0 0.000331605
neutropenia B-Disease 0 0.99537754
, O 0 0.00051885855
2 O 0 0.00023289125
patients O 0 0.00029201916
( O 0 0.00030678752
4 O 0 0.00017596692
% O 0 0.00024085795
) O 0 0.00033950462
had O 0 0.00024332355
Grade O 0 0.14554264
3 O 0 0.00025421943
- O 0 0.003465272
4 O 0 0.00032505847
thrombocytopenia B-Disease 0 0.99976665
, O 0 0.00045823597
and O 0 0.0003314236
2 O 0 0.00027831792
patients O 0 0.00039614126
( O 0 0.0004939246
4 O 0 0.00040309707
% O 0 0.00069498795
) O 0 0.0012113207
had O 0 0.0013865174
Grade O 0 0.3026454
3 O 0 0.0032149004
neurotoxicity B-Disease 2 0.9996797
. O 0 0.008901801

Three O 0 0.005081744
patients O 0 0.0038399308
with O 0 0.0031762375
severe O 0 0.3735694
neutropenia B-Disease 0 0.9997687
( O 0 0.0041153063
6 O 0 0.0015516836
% O 0 0.002283205
) O 0 0.0033963297
died O 0 0.0060034813
of O 0 0.0072801397
sepsis B-Disease 2 0.9995468
. O 0 0.014494694

The O 0 0.002778037
median O 0 0.0016541587
age O 0 0.001873192
of O 0 0.0012252815
those O 0 0.001044403
patients O 0 0.0010368219
developing O 0 0.013770041
Grade O 0 0.5909335
3 O 0 0.00046615175
- O 0 0.005673449
4 O 0 0.00036416313
neutropenia B-Disease 0 0.9960937
was O 0 0.00028739445
significantly O 0 0.00022729159
higher O 0 0.0001710477
than O 0 0.00011322131
that O 0 0.00011844344
of O 0 0.00018794932
the O 0 0.00016608059
remaining O 0 0.00019694734
patients O 0 0.00032624972
( O 0 0.00029553022
75 O 0 0.00022248655
years O 0 0.00021671529
vs O 0 0.0002813093
. O 0 0.0002443996
72 O 0 0.00036830932
years O 0 0.00044265558
; O 0 0.0008628934
P O 0 0.01517856
= O 0 0.0015470822
0 O 0 0.0015097166
. O 0 0.0021212376
047 O 0 0.1382626
) O 0 0.0066198935
. O 0 0.008368262

CONCLUSIONS O 0 0.017930664
: O 0 0.0036559992
The O 0 0.0015955649
combination O 0 0.00166447
of O 0 0.0023998294
GEM B-Chemical 0 0.9988059
and O 0 0.009456948
VNB B-Chemical 0 0.9980755
is O 0 0.0006560038
moderately O 0 0.0053634895
active O 0 0.0006616842
and O 0 0.00036249813
well O 0 0.00029764356
tolerated O 0 0.0011737702
except O 0 0.00024059582
in O 0 0.0003190925
patients O 0 0.0006161099
age O 0 0.0011309506
> O 0 0.0019190984
/ O 0 0.0039337385
= O 0 0.0028732615
75 O 0 0.002914106
years O 0 0.0043180897
. O 0 0.006934884

This O 0 0.008749085
age O 0 0.0068722563
group O 0 0.005035177
had O 0 0.0038612115
an O 0 0.0044312757
increased O 0 0.005458583
risk O 0 0.28929892
of O 0 0.043954507
myelosuppression B-Disease 0 0.99995804
. O 0 0.01925111

Therefore O 0 0.0033408196
the O 0 0.0023215518
prophylactic O 0 0.0029900472
use O 0 0.0014315253
of O 0 0.0020907053
granulocyte O 0 0.98529875
- O 0 0.16256098
colony O 0 0.1938081
stimulating O 0 0.001654888
factor O 0 0.007620932
should O 0 0.00050842034
be O 0 0.000690194
considered O 0 0.00080524076
with O 0 0.0013845677
this O 0 0.0021387038
treatment O 0 0.0041899304
. O 0 0.006956146

New O 0 0.0061658155
chemotherapy O 0 0.008517909
combinations O 0 0.0016417158
with O 0 0.0013068495
higher O 0 0.0009482074
activity O 0 0.00078385434
and O 0 0.0008266183
lower O 0 0.00088409905
toxicity B-Disease 2 0.98942405
are O 0 0.00049113424
needed O 0 0.0003878725
for O 0 0.00060001464
elderly O 0 0.07939317
patients O 0 0.001583015
with O 0 0.002170565
advanced O 0 0.21202603
NSCLC B-Disease 2 0.99905044
. O 0 0.008905874

A O 0 0.30787635
selective O 0 0.23286006
dopamine B-Chemical 1 0.999982
D4 O 0 0.9999286
receptor O 0 0.5938229
antagonist O 0 0.98590535
, O 0 0.01584484
NRA0160 B-Chemical 1 0.9968268
: O 0 0.0030210984
a O 0 0.0023258775
preclinical O 0 0.009297895
neuropharmacological O 0 0.7112158
profile O 0 0.0054498925
. O 0 0.008222236

NRA0160 B-Chemical 1 0.98623693
, O 0 0.005142523
5 B-Chemical 0 0.0024606718
- I-Chemical 0 0.007416088
[ I-Chemical 0 0.003617706
2 I-Chemical 0 0.0011568839
- I-Chemical 0 0.003154131
( I-Chemical 0 0.00097574736
4 I-Chemical 0 0.0005515708
- I-Chemical 0 0.001835769
( I-Chemical 0 0.0006152117
3 I-Chemical 0 0.0003658593
- I-Chemical 0 0.0016392205
fluorobenzylidene I-Chemical 0 0.008637716
) I-Chemical 0 0.0017381037
piperidin I-Chemical 0 0.7119765
- I-Chemical 0 0.04300771
1 I-Chemical 0 0.0005483279
- I-Chemical 0 0.09166701
yl I-Chemical 0 0.9875331
) I-Chemical 0 0.025380166
ethyl I-Chemical 0 0.9997633
] I-Chemical 0 0.020137273
- I-Chemical 0 0.015951432
4 I-Chemical 0 0.00024221852
- I-Chemical 0 0.0022524667
( I-Chemical 0 0.000421979
4 I-Chemical 0 0.0002578075
- I-Chemical 0 0.019866165
fluorophenyl I-Chemical 0 0.990728
) I-Chemical 0 0.010771308
thiazole I-Chemical 0 0.9981329
- I-Chemical 0 0.08570733
2 I-Chemical 0 0.0004057962
- I-Chemical 0 0.030006804
carboxamide I-Chemical 0 0.955993
, O 0 0.00046625637
has O 0 0.00017439728
a O 0 0.00022539978
high O 0 0.00025711404
affinity O 0 0.0005786593
for O 0 0.00023346485
human O 0 0.00096840126
cloned O 0 0.012115756
dopamine B-Chemical 1 0.99999607
D4 O 0 0.99989986
. O 0 0.00025870008
2 O 0 0.00022806828
, O 0 0.00081903173
D4 O 0 0.9985606
. O 0 0.00019756348
4 O 0 0.00016548495
and O 0 0.0004008783
D4 O 0 0.9982652
. O 0 0.0001994916
7 O 0 0.00016227757
receptors O 0 0.0005869586
, O 0 0.0002831295
with O 0 0.00024350156
Ki O 0 0.4425018
values O 0 0.00018275689
of O 0 0.00024532274
0 O 0 0.00024797625
. O 0 0.0001763645
5 O 0 0.00017248321
, O 0 0.00026100263
0 O 0 0.00026020108
. O 0 0.00024180848
9 O 0 0.000284252
and O 0 0.0003835983
2 O 0 0.00047700625
. O 0 0.0006165848
7 O 0 0.00092426763
nM O 0 0.00474768
, O 0 0.0037059374
respectively O 0 0.007944659
. O 0 0.008148078

NRA0160 B-Chemical 1 0.97127885
is O 0 0.0029130979
over O 0 0.0014143868
20 O 0 0.0013228465
, O 0 0.0013088076
000fold O 0 0.0038522275
more O 0 0.0007127475
potent O 0 0.00097286736
at O 0 0.00039035818
the O 0 0.00097591226
dopamine B-Chemical 1 0.9999869
D4 O 0 0.9997757
. O 0 0.0003534408
2 O 0 0.0002919395
receptor O 0 0.0007452619
compared O 0 0.00023507823
with O 0 0.00036394066
the O 0 0.0004854005
human O 0 0.0013652159
cloned O 0 0.0119905565
dopamine B-Chemical 1 0.99997973
D2L O 0 0.9998079
receptor O 0 0.14595506
. O 0 0.00804302

NRA0160 B-Chemical 1 0.9861638
has O 0 0.0028424014
negligible O 0 0.0022055558
affinity O 0 0.002465396
for O 0 0.00096527295
the O 0 0.00075126474
human O 0 0.0014421584
cloned O 0 0.013324471
dopamine B-Chemical 1 0.9999964
D3 O 0 0.99999547
receptor O 0 0.28535923
( O 0 0.0044227834
Ki O 0 0.9442069
= O 0 0.0019080171
39 O 0 0.00057554216
nM O 0 0.0119362995
) O 0 0.0013096193
, O 0 0.0006170436
rat O 0 0.010693596
serotonin B-Chemical 0 0.99962413
( O 0 0.0007769619
5 B-Chemical 0 0.00027489828
- I-Chemical 0 0.069225386
HT I-Chemical 0 0.9995378
) O 0 0.0022958445
2A O 0 0.0007749784
receptors O 0 0.0039305747
( O 0 0.00092506316
Ki O 0 0.84800804
= O 0 0.0009397169
180 O 0 0.00038323022
nM O 0 0.0048510944
) O 0 0.0007548493
and O 0 0.00052549
rat O 0 0.021398783
alpha1 O 0 0.9996793
adrenoceptor O 0 0.99998987
( O 0 0.014333115
Ki O 0 0.957022
= O 0 0.004139665
237 O 0 0.0065409997
nM O 0 0.026541043
) O 0 0.0075506987
. O 0 0.008142898

NRA0160 B-Chemical 1 0.99703133
and O 0 0.056315962
clozapine B-Chemical 0 0.99999857
antagonized O 0 0.9938524
locomotor O 0 0.9999138
hyperactivity B-Disease 2 0.99999785
induced O 0 0.0037787377
by O 0 0.011439684
methamphetamine B-Chemical 1 0.99999917
( O 0 0.02491574
MAP B-Chemical 0 0.97133887
) O 0 0.0036435712
in O 0 0.0027588117
mice O 0 0.0035338923
. O 0 0.007731539

NRA0160 B-Chemical 1 0.99700207
and O 0 0.054417938
clozapine B-Chemical 0 0.99999857
antagonized O 0 0.9894825
MAP B-Chemical 0 0.9993766
- O 0 0.13596319
induced O 0 0.0011498027
stereotyped O 0 0.76406854
behavior O 0 0.0021078417
in O 0 0.00029619594
mice O 0 0.00018750023
, O 0 0.00038502
although O 0 0.0002336969
their O 0 0.00023406529
effects O 0 0.0003225761
did O 0 0.0002400386
not O 0 0.00017632601
exceed O 0 0.00021039
50 O 0 0.0003184203
% O 0 0.00035016375
inhibition O 0 0.0005833969
, O 0 0.00056576537
even O 0 0.0005003011
at O 0 0.00050124974
the O 0 0.0007592845
highest O 0 0.0014126733
dose O 0 0.004078977
given O 0 0.0028166438
. O 0 0.006280441

NRA0160 B-Chemical 1 0.9965957
and O 0 0.031091014
clozapine B-Chemical 0 0.9999964
significantly O 0 0.0064580445
induced O 0 0.02472742
catalepsy B-Disease 2 0.9999995
in O 0 0.0011299626
rats O 0 0.0012759404
, O 0 0.0005873061
although O 0 0.00030546918
their O 0 0.0002860165
effects O 0 0.00037090544
did O 0 0.00027472904
not O 0 0.0002023923
exceed O 0 0.00023665532
50 O 0 0.0003332721
% O 0 0.000352631
induction O 0 0.00033623562
even O 0 0.00047926322
at O 0 0.000502376
the O 0 0.00076753955
highest O 0 0.0014326267
dose O 0 0.00416797
given O 0 0.0028378798
. O 0 0.0063157175

NRA0160 B-Chemical 1 0.9967069
and O 0 0.028743558
clozapine B-Chemical 0 0.99999523
significantly O 0 0.002377013
reversed O 0 0.0012136092
the O 0 0.00065391086
disruption O 0 0.0006234385
of O 0 0.0008632519
prepulse O 0 0.891519
inhibition O 0 0.004965453
( O 0 0.0027411126
PPI O 0 0.24031088
) O 0 0.0011993181
in O 0 0.0008266159
rats O 0 0.0014016096
produced O 0 0.0016079533
by O 0 0.0049285125
apomorphine B-Chemical 1 0.9999795
. O 0 0.009129778

NRA0160 B-Chemical 1 0.995619
and O 0 0.018833993
clozapine B-Chemical 0 0.99999344
significantly O 0 0.002309094
shortened O 0 0.0017079186
the O 0 0.004257448
phencyclidine B-Chemical 0 1.0
( O 0 0.21288356
PCP B-Chemical 0 0.9999765
) O 0 0.022076815
- O 0 0.009897681
induced O 0 0.00042440346
prolonged O 0 0.0009318898
swimming O 0 0.041926242
latency O 0 0.0012645635
in O 0 0.00048716844
rats O 0 0.00076519966
in O 0 0.00072674715
a O 0 0.0013489408
water O 0 0.013933157
maze O 0 0.071289025
task O 0 0.0056308336
. O 0 0.006833896

These O 0 0.0035763378
findings O 0 0.0026259369
suggest O 0 0.0013397052
that O 0 0.0015201604
NRA0160 B-Chemical 1 0.99062294
may O 0 0.000849911
have O 0 0.0005435534
unique O 0 0.0008394711
antipsychotic O 0 0.9975738
activities O 0 0.00040632917
without O 0 0.00029093536
the O 0 0.00033063904
liability O 0 0.040701404
of O 0 0.0006052445
motor O 0 0.029209329
side O 0 0.008981238
effects O 0 0.00082481647
typical O 0 0.0010525055
of O 0 0.002005533
classical O 0 0.016529618
antipsychotics O 0 0.9992317
. O 0 0.0064417273

Warfarin B-Chemical 0 0.9999156
- O 0 0.100297324
induced O 0 0.006346182
artery B-Disease 2 0.99520063
calcification I-Disease 2 0.99996996
is O 0 0.002443705
accelerated O 0 0.0025263638
by O 0 0.002095068
growth O 0 0.014580222
and O 0 0.018096112
vitamin B-Chemical 0 0.9999937
D I-Chemical 0 0.9995943
. O 0 0.015989456

The O 0 0.0027235872
present O 0 0.0015680075
studies O 0 0.0011771097
demonstrate O 0 0.0006155748
that O 0 0.0006462809
growth O 0 0.013971807
and O 0 0.025371393
vitamin B-Chemical 0 0.99999976
D I-Chemical 0 0.99994516
treatment O 0 0.001308415
enhance O 0 0.00015957667
the O 0 0.00018638831
extent O 0 0.00014384875
of O 0 0.0008285472
artery B-Disease 2 0.994392
calcification I-Disease 2 0.99999356
in O 0 0.00027211
rats O 0 0.0002251721
given O 0 9.0784815e-05
sufficient O 0 0.00010557927
doses O 0 0.0011116375
of O 0 0.0016685288
Warfarin B-Chemical 0 0.9999795
to O 0 0.0002079045
inhibit O 0 0.00027085358
gamma O 0 0.99516004
- O 0 0.49921092
carboxylation O 0 0.92884403
of O 0 0.0005689814
matrix O 0 0.04384088
Gla O 0 0.9951721
protein O 0 0.0045172875
, O 0 0.0008321496
a O 0 0.00086102536
calcification B-Disease 2 0.99935335
inhibitor O 0 0.006791109
known O 0 0.0002500692
to O 0 0.00013646456
be O 0 0.0001595511
expressed O 0 0.00014555844
by O 0 0.00024178426
smooth O 0 0.0025685348
muscle O 0 0.0046486966
cells O 0 0.00055875146
and O 0 0.0006262297
macrophages O 0 0.0013210243
in O 0 0.0010153272
the O 0 0.0016521377
artery O 0 0.0920953
wall O 0 0.02792446
. O 0 0.0070838337

The O 0 0.0030056818
first O 0 0.0018249804
series O 0 0.0015943934
of O 0 0.0010858332
experiments O 0 0.0005977348
examined O 0 0.000453222
the O 0 0.00042667636
influence O 0 0.00030590896
of O 0 0.000442896
age O 0 0.00083847577
and O 0 0.00044444218
growth O 0 0.002214171
status O 0 0.00081582455
on O 0 0.00039084058
artery B-Disease 2 0.9896875
calcification I-Disease 2 0.99999344
in O 0 0.009677228
Warfarin B-Chemical 0 0.99998426
- O 0 0.03741337
treated O 0 0.0034840303
rats O 0 0.0052907257
. O 0 0.0064037205

Treatment O 0 0.006889645
for O 0 0.002345974
2 O 0 0.0015854789
weeks O 0 0.00093053415
with O 0 0.0014784144
Warfarin B-Chemical 0 0.99986994
caused O 0 0.0008548374
massive O 0 0.057623208
focal O 0 0.5039816
calcification B-Disease 2 0.99985826
of I-Disease 0 0.0006440452
the I-Disease 0 0.00032963188
artery I-Disease 0 0.044422977
media O 0 0.00088074675
in O 0 0.00022159147
20 O 0 0.00023177743
- O 0 0.0011430486
day O 0 0.00019038953
- O 0 0.0010563617
old O 0 0.00022859777
rats O 0 0.00024647315
and O 0 0.00020615631
less O 0 0.00019899159
extensive O 0 0.00030269797
focal O 0 0.06411434
calcification B-Disease 2 0.99942136
in O 0 0.00056874094
42 O 0 0.00091808726
- O 0 0.0022138918
day O 0 0.0010272862
- O 0 0.0035831209
old O 0 0.0029632542
rats O 0 0.00489386
. O 0 0.0066483016

In O 0 0.0038103904
contrast O 0 0.003035869
, O 0 0.0027923246
no O 0 0.0015997894
artery B-Disease 2 0.9871106
calcification I-Disease 2 0.9999784
could O 0 0.0005746208
be O 0 0.00040569712
detected O 0 0.00030598856
in O 0 0.0003176511
10 O 0 0.00032987713
- O 0 0.0012756803
month O 0 0.00027172238
- O 0 0.0011766254
old O 0 0.00034255016
adult O 0 0.00043147002
rats O 0 0.0004284865
even O 0 0.00037654545
after O 0 0.00033492933
4 O 0 0.0005262829
weeks O 0 0.0006819239
of O 0 0.002197941
Warfarin B-Chemical 0 0.9998677
treatment O 0 0.0064417943
. O 0 0.007318381

To O 0 0.0026539478
directly O 0 0.0017318173
examine O 0 0.0008424632
the O 0 0.0008298849
importance O 0 0.0006305357
of O 0 0.0007957296
growth O 0 0.017853294
to O 0 0.0019561984
Warfarin B-Chemical 0 0.9999963
- O 0 0.13570702
induced O 0 0.0016028952
artery B-Disease 2 0.9972429
calcification I-Disease 2 0.9999937
in O 0 0.00027425273
animals O 0 0.00014730515
of O 0 0.00018490847
the O 0 0.00014743584
same O 0 0.000113637856
age O 0 0.00036461817
, O 0 0.0002949948
20 O 0 0.00021683433
- O 0 0.0014722042
day O 0 0.00018708144
- O 0 0.0015611827
old O 0 0.00022660218
rats O 0 0.00024434392
were O 0 0.00015857874
fed O 0 0.00019051139
for O 0 0.00014861059
2 O 0 0.00014852133
weeks O 0 0.000107398715
either O 0 0.00014591502
an O 0 0.00021688767
ad O 0 0.00040860442
libitum O 0 0.001107452
diet O 0 0.0037525587
or O 0 0.00018736726
a O 0 0.0002681779
6 O 0 0.00018946613
- O 0 0.0011075848
g O 0 0.00056455185
/ O 0 0.00093517994
d O 0 0.00046470758
restricted O 0 0.0003520066
diet O 0 0.0038938296
that O 0 0.00042724516
maintains O 0 0.0007797197
weight O 0 0.0032730692
but O 0 0.0018764802
prevents O 0 0.0027474912
growth O 0 0.029906843
. O 0 0.008350518

Concurrent O 0 0.006211159
treatment O 0 0.0028681403
of O 0 0.0019804328
both O 0 0.0014438814
dietary O 0 0.23022594
groups O 0 0.0010808458
with O 0 0.0020678432
Warfarin B-Chemical 0 0.999959
produced O 0 0.00042906115
massive O 0 0.036859643
focal O 0 0.46342093
calcification B-Disease 2 0.99987376
of I-Disease 0 0.00062686566
the I-Disease 0 0.00032953388
artery I-Disease 0 0.07005617
media O 0 0.0010596593
in O 0 0.0002069607
the O 0 0.00019655468
ad O 0 0.00047943633
libitum O 0 0.0027009014
- O 0 0.0020768824
fed O 0 0.0002573831
rats O 0 0.0002591306
but O 0 0.00019602706
no O 0 0.00014548766
detectable O 0 0.00039881637
artery B-Disease 2 0.9876993
calcification I-Disease 2 0.9999876
in O 0 0.00032376626
the O 0 0.0002796292
restricted O 0 0.0003593356
- O 0 0.010547662
diet O 0 0.043370288
, O 0 0.0013981889
growth O 0 0.016433263
- O 0 0.023564495
inhibited O 0 0.0034305952
group O 0 0.005514169
. O 0 0.0070034107

Although O 0 0.0026953418
the O 0 0.0017048318
explanation O 0 0.0009216501
for O 0 0.00085474417
the O 0 0.00063094875
association O 0 0.00051333325
between O 0 0.00048790267
artery B-Disease 2 0.9894811
calcification I-Disease 2 0.9999912
and O 0 0.00082886184
growth O 0 0.0043577086
status O 0 0.00063749286
cannot O 0 0.0005727698
be O 0 0.00016418638
determined O 0 0.0001274246
from O 0 0.00013093388
the O 0 0.00014222313
present O 0 0.00012490347
study O 0 0.00024355286
, O 0 0.00023464758
there O 0 0.0001106482
was O 0 0.0001409535
a O 0 0.00014179388
relationship O 0 8.762875e-05
between O 0 0.00010667058
higher O 0 0.00021948847
serum O 0 0.46082947
phosphate B-Chemical 0 0.9981982
and O 0 0.000543743
susceptibility O 0 0.0050021615
to O 0 0.00032942643
artery B-Disease 2 0.99408025
calcification I-Disease 2 0.99999535
, O 0 0.000617358
with O 0 0.00018606389
30 O 0 0.00012269554
% O 0 0.0001585246
higher O 0 0.00012116729
levels O 0 0.00013442784
of O 0 0.000307468
serum O 0 0.68442434
phosphate B-Chemical 0 0.9991425
in O 0 0.00047975322
young O 0 0.015736379
, O 0 0.00040984363
ad O 0 0.00059874036
libitum O 0 0.004376436
- O 0 0.0030357765
fed O 0 0.00023352697
rats O 0 0.00019325558
compared O 0 9.358753e-05
with O 0 0.0001404591
either O 0 0.00013192254
of O 0 0.00019530172
the O 0 0.00016212942
groups O 0 0.00017396512
that O 0 0.000119795804
was O 0 0.00017446463
resistant O 0 0.00028217176
to O 0 0.0004560124
Warfarin B-Chemical 0 0.99999547
- O 0 0.085725695
induced O 0 0.0011760157
artery B-Disease 2 0.998097
calcification I-Disease 2 0.99999774
, O 0 0.0017050285
ie O 0 0.0006593089
, O 0 0.000264015
the O 0 0.00016580938
10 O 0 0.00018759035
- O 0 0.0010266198
month O 0 0.00017299101
- O 0 0.0009719821
old O 0 0.00022349009
rats O 0 0.0002483899
and O 0 0.00021453254
the O 0 0.00023005575
restricted O 0 0.00032041126
- O 0 0.012113879
diet O 0 0.05312764
, O 0 0.0013043339
growth O 0 0.021048808
- O 0 0.030753566
inhibited O 0 0.0028754207
young O 0 0.03706556
rats O 0 0.0060854484
. O 0 0.0066659376

This O 0 0.004857272
observation O 0 0.0023615945
suggests O 0 0.001242557
that O 0 0.0010156101
increased O 0 0.0012217968
susceptibility O 0 0.014599225
to O 0 0.0028039333
Warfarin B-Chemical 0 0.99999666
- O 0 0.16728793
induced O 0 0.0021183176
artery B-Disease 2 0.9973506
calcification I-Disease 2 0.99999034
could O 0 0.0003781657
be O 0 0.00036917705
related O 0 0.00033069894
to O 0 0.0005107917
higher O 0 0.0009592231
serum O 0 0.26216844
phosphate B-Chemical 0 0.99240595
levels O 0 0.004985176
. O 0 0.0073144124

The O 0 0.0031344546
second O 0 0.00208998
set O 0 0.0014314142
of O 0 0.0011467279
experiments O 0 0.0006511351
examined O 0 0.00051061745
the O 0 0.0005241495
possible O 0 0.0005611864
synergy O 0 0.0025583422
between O 0 0.0010055748
vitamin B-Chemical 0 0.9999994
D I-Chemical 0 0.99994564
and O 0 0.09115855
Warfarin B-Chemical 0 0.9999882
in O 0 0.0047670216
artery B-Disease 2 0.9920826
calcification I-Disease 2 0.99993014
. O 0 0.008987475

High O 0 0.010349073
doses O 0 0.013315799
of O 0 0.020496244
vitamin B-Chemical 0 0.9999989
D I-Chemical 0 0.99985933
are O 0 0.001277807
known O 0 0.00077058835
to O 0 0.00040344577
cause O 0 0.0009909185
calcification B-Disease 2 0.9991667
of I-Disease 0 0.00058434013
the I-Disease 0 0.00040647562
artery I-Disease 0 0.03721766
media O 0 0.0008437872
in O 0 0.0003362808
as O 0 0.0003518853
little O 0 0.0004232153
as O 0 0.00058571185
3 O 0 0.0007585175
to O 0 0.0010540196
4 O 0 0.0017232028
days O 0 0.0026877078
. O 0 0.006060132

High O 0 0.0092369355
doses O 0 0.006081357
of O 0 0.0027145927
the O 0 0.011475302
vitamin B-Chemical 0 0.99999976
K I-Chemical 1 0.9999999
antagonist O 0 0.99993134
Warfarin B-Chemical 0 0.9999976
are O 0 0.00048212885
also O 0 0.00025536332
known O 0 0.00027874837
to O 0 0.00018305423
cause O 0 0.00058253895
calcification B-Disease 2 0.99929523
of I-Disease 0 0.0004360963
the I-Disease 0 0.0003059463
artery I-Disease 0 0.10341665
media O 0 0.0030275788
, O 0 0.00048562032
but O 0 0.00023860791
at O 0 0.0001440832
treatment O 0 0.00016452318
times O 0 0.00012157051
of O 0 0.00021552855
2 O 0 0.00021575205
weeks O 0 0.00017997496
or O 0 0.00027864825
longer O 0 0.0003168447
yet O 0 0.0006379471
not O 0 0.0007156947
at O 0 0.0011064315
1 O 0 0.0018663327
week O 0 0.0027057233
. O 0 0.0058590746

In O 0 0.0035936434
the O 0 0.0022715298
current O 0 0.002418759
study O 0 0.001619844
, O 0 0.0010868468
we O 0 0.00043780328
investigated O 0 0.0003587009
the O 0 0.00034469395
synergy O 0 0.0007991323
between O 0 0.0002088068
these O 0 0.00028973073
2 O 0 0.00021660952
treatments O 0 0.00023877993
and O 0 0.00021451904
found O 0 0.00016786742
that O 0 0.00016397299
concurrent O 0 0.010096084
Warfarin B-Chemical 0 0.99999285
administration O 0 0.019034836
dramatically O 0 0.00030053552
increased O 0 0.00022988449
the O 0 0.00014282108
extent O 0 0.00011157528
of O 0 0.00048536193
calcification B-Disease 2 0.99937624
in O 0 0.00020468111
the O 0 0.0001866298
media O 0 0.001540531
of O 0 0.009888097
vitamin B-Chemical 0 0.9999999
D I-Chemical 0 0.9999815
- O 0 0.19203074
treated O 0 0.00072941714
rats O 0 0.00060817244
at O 0 0.00046588338
3 O 0 0.00065579626
and O 0 0.0011133967
4 O 0 0.0016347864
days O 0 0.0025814194
. O 0 0.005870774

There O 0 0.004264754
was O 0 0.0025879326
a O 0 0.0017876992
close O 0 0.00103864
parallel O 0 0.00083021785
between O 0 0.00047830297
the O 0 0.00046423453
effect O 0 0.0004995434
of O 0 0.007860722
vitamin B-Chemical 0 0.9999999
D I-Chemical 0 0.9999628
dose O 0 0.072887674
on O 0 0.00027932887
artery B-Disease 2 0.9926212
calcification I-Disease 2 0.99999166
and O 0 0.0003864178
the O 0 0.0001733113
effect O 0 0.00020984486
of O 0 0.0055911024
vitamin B-Chemical 0 0.9999999
D I-Chemical 0 0.9999548
dose O 0 0.018991502
on O 0 0.00011223131
the O 0 0.00017970968
elevation O 0 0.04208008
of O 0 0.0006071143
serum O 0 0.87563175
calcium B-Chemical 0 0.999708
, O 0 0.0014514136
which O 0 0.00030850092
suggests O 0 0.00014202931
that O 0 0.0004175551
vitamin B-Chemical 0 0.99999964
D I-Chemical 0 0.99990237
may O 0 0.00043482654
induce O 0 0.00031797163
artery B-Disease 2 0.9906635
calcification I-Disease 2 0.9999726
through O 0 0.00039629004
its O 0 0.0008816183
effect O 0 0.00078869454
on O 0 0.0011351249
serum O 0 0.541681
calcium B-Chemical 0 0.9979679
. O 0 0.009202663

Because O 0 0.005037848
Warfarin B-Chemical 0 0.99968684
treatment O 0 0.002755347
had O 0 0.0010403205
no O 0 0.00055602053
effect O 0 0.00046866233
on O 0 0.0002829525
the O 0 0.0003676579
elevation O 0 0.06829057
in O 0 0.00041176227
serum O 0 0.60475206
calcium B-Chemical 0 0.99839634
produced O 0 0.0003952934
by O 0 0.0048593795
vitamin B-Chemical 0 0.9999999
D I-Chemical 0 0.9999689
, O 0 0.0022411977
the O 0 0.00022003267
synergy O 0 0.0023720362
between O 0 0.0002934666
Warfarin B-Chemical 0 0.9999939
and O 0 0.029425075
vitamin B-Chemical 0 0.9999999
D I-Chemical 0 0.999959
is O 0 0.00064818136
probably O 0 0.0003927712
best O 0 0.00018584475
explained O 0 0.00013043766
by O 0 0.00015271489
the O 0 0.00015360574
hypothesis O 0 0.00023150558
that O 0 0.0003524243
Warfarin B-Chemical 0 0.9999641
inhibits O 0 0.00021630054
the O 0 0.00024414106
activity O 0 0.00029345034
of O 0 0.0005105569
matrix O 0 0.023943327
Gla O 0 0.9861647
protein O 0 0.0021087553
as O 0 0.0010988456
a O 0 0.0029086452
calcification B-Disease 2 0.9990245
inhibitor O 0 0.11116778
. O 0 0.0072212825

High O 0 0.008219445
levels O 0 0.00258425
of O 0 0.002420056
matrix O 0 0.033050958
Gla O 0 0.9855657
protein O 0 0.002781356
are O 0 0.00058871007
found O 0 0.00036235526
at O 0 0.00027312888
sites O 0 0.00034725986
of O 0 0.0008854964
artery B-Disease 2 0.99309736
calcification I-Disease 2 0.9999925
in O 0 0.00034151538
rats O 0 0.0003406131
treated O 0 0.00028738516
with O 0 0.0026816358
vitamin B-Chemical 0 0.99999976
D I-Chemical 0 0.9999769
plus O 0 0.018705057
Warfarin B-Chemical 0 0.99999666
, O 0 0.00088384806
and O 0 0.00027414894
chemical O 0 0.0014354275
analysis O 0 0.00018965991
showed O 0 0.0001526095
that O 0 0.00014410767
the O 0 0.0001989768
protein O 0 0.0004145482
that O 0 0.00025890168
accumulated O 0 0.0003614591
was O 0 0.000511594
indeed O 0 0.00077643356
not O 0 0.001509073
gamma B-Chemical 0 0.9955676
- I-Chemical 0 0.5915124
carboxylated I-Chemical 0 0.9860366
. O 0 0.009986512

These O 0 0.0032247442
observations O 0 0.002055887
indicate O 0 0.0010965555
that O 0 0.0009661314
although O 0 0.0009964359
the O 0 0.0014540891
gamma B-Chemical 0 0.99929166
- I-Chemical 0 0.53611314
carboxyglutamate I-Chemical 0 0.7841072
residues O 0 0.0488785
of O 0 0.0009782205
matrix O 0 0.05406201
Gla O 0 0.9928884
protein O 0 0.001477214
are O 0 0.00023905603
apparently O 0 0.00037181514
required O 0 0.00011494018
for O 0 0.00015799298
its O 0 0.00027929503
function O 0 0.00018817256
as O 0 0.00020616125
a O 0 0.0006747188
calcification B-Disease 2 0.99953496
inhibitor O 0 0.017526546
, O 0 0.00041963544
they O 0 0.000177339
are O 0 0.00019163109
not O 0 0.00019713615
required O 0 0.0002067654
for O 0 0.0003761117
its O 0 0.0009078433
accumulation O 0 0.0013338774
at O 0 0.0016009781
calcification B-Disease 2 0.99691904
sites O 0 0.0050367946
. O 0 0.0069564064

Test O 0 0.012330872
conditions O 0 0.0036595783
influence O 0 0.0022566468
the O 0 0.002103495
response O 0 0.002349281
to O 0 0.0019865532
a O 0 0.0028671639
drug O 0 0.14139456
challenge O 0 0.0036709255
in O 0 0.004501426
rodents O 0 0.012389688
. O 0 0.009829614

These O 0 0.0034570175
studies O 0 0.0022594412
were O 0 0.0014713288
conducted O 0 0.0009205946
to O 0 0.00065275485
examine O 0 0.0003519863
the O 0 0.00041479015
differential O 0 0.00042595743
response O 0 0.0004668334
to O 0 0.000290575
a O 0 0.0004689944
drug O 0 0.06403211
challenge O 0 0.00025263362
under O 0 0.00015576149
varied O 0 0.00019046635
experimental O 0 0.00020685927
test O 0 0.00018216466
conditions O 0 0.00017920745
routinely O 0 0.00014418986
employed O 0 0.00017275117
to O 0 0.00016916476
study O 0 0.00045227856
drug O 0 0.30823028
- O 0 0.0075465157
induced O 0 0.00045019967
behavioral O 0 0.013131303
and O 0 0.0007302482
neurophysiological O 0 0.0048722285
responses O 0 0.0016314938
in O 0 0.002156751
rodents O 0 0.007162097
. O 0 0.0064338576

Apomorphine B-Chemical 0 0.9999933
, O 0 0.009893957
a O 0 0.0051456955
nonselective O 0 0.96081275
dopamine B-Chemical 1 0.9999838
agonist I-Chemical 0 0.9696667
, O 0 0.0014409648
was O 0 0.00040529863
selected O 0 0.00025396913
due O 0 0.00019083172
to O 0 0.00020385376
its O 0 0.00050200813
biphasic O 0 0.012068165
behavioral O 0 0.040263936
effects O 0 0.00045943685
, O 0 0.0003520529
its O 0 0.00034540283
ability O 0 0.00017678896
to O 0 0.00015965929
induce O 0 0.00020258498
hypothermia B-Disease 2 0.9998952
, O 0 0.0005480758
and O 0 0.00022278544
to O 0 0.00014529705
produce O 0 0.00013791924
distinct O 0 0.00019345984
changes O 0 0.00035484272
to O 0 0.00040386678
dopamine B-Chemical 1 0.9985055
turnover O 0 0.0012983215
in O 0 0.00082995684
the O 0 0.0012994304
rodent O 0 0.0040425253
brain O 0 0.02893149
. O 0 0.0063972804

From O 0 0.003416537
such O 0 0.0019165474
experiments O 0 0.0011871652
there O 0 0.0008849253
is O 0 0.0007864109
evidence O 0 0.0005052478
that O 0 0.0003943175
characterization O 0 0.00041089123
and O 0 0.00050944247
detection O 0 0.0014286496
of O 0 0.018330479
apomorphine B-Chemical 1 0.99999976
- O 0 0.106734954
induced O 0 0.00041830193
activity O 0 0.00044424695
in O 0 0.00035550198
rodents O 0 0.0007702077
critically O 0 0.00046301496
depends O 0 0.00037308305
upon O 0 0.0005106404
the O 0 0.0008543215
test O 0 0.0014050008
conditions O 0 0.0022501913
employed O 0 0.0043827733
. O 0 0.006687524

In O 0 0.0042808927
rats O 0 0.003814115
, O 0 0.002760183
detection O 0 0.0027667037
of O 0 0.01601929
apomorphine B-Chemical 1 0.9999995
- O 0 0.35194242
induced O 0 0.0035992856
hyperactivity B-Disease 2 0.99996936
was O 0 0.00055414205
facilitated O 0 0.0003968227
by O 0 0.00041056552
a O 0 0.00044882204
period O 0 0.00037174777
of O 0 0.0006471946
acclimatization O 0 0.005980114
to O 0 0.00083358807
the O 0 0.001272427
test O 0 0.0022029928
conditions O 0 0.003745319
. O 0 0.006949446

Moreover O 0 0.005212025
, O 0 0.0036430499
test O 0 0.0019810125
conditions O 0 0.0014031255
can O 0 0.00081848714
impact O 0 0.0005872048
upon O 0 0.00047859366
other O 0 0.00055123173
physiological O 0 0.00070377317
responses O 0 0.000995091
to O 0 0.00083388
apomorphine B-Chemical 1 0.9999938
such O 0 0.00074775174
as O 0 0.0010161472
drug O 0 0.618039
- O 0 0.05077462
induced O 0 0.007016658
hypothermia B-Disease 2 0.99983513
. O 0 0.009796014

In O 0 0.003998388
mice O 0 0.0023611877
, O 0 0.0072053927
apomorphine B-Chemical 1 0.9999839
produced O 0 0.0011429796
qualitatively O 0 0.0008403126
different O 0 0.0004364683
responses O 0 0.0005130373
under O 0 0.00028271115
novel O 0 0.00034705835
conditions O 0 0.0003082628
when O 0 0.00020823423
compared O 0 0.00020078963
to O 0 0.00024775387
those O 0 0.00041200354
behaviors O 0 0.0023027326
elicited O 0 0.00048526932
in O 0 0.00065169134
the O 0 0.00093486544
home O 0 0.0016994518
test O 0 0.002450158
cage O 0 0.0064652017
. O 0 0.0065644453

Drug O 0 0.8002311
- O 0 0.017633308
induced O 0 0.0021848257
gross O 0 0.0033419474
activity O 0 0.0011705165
counts O 0 0.00077447086
were O 0 0.0004947539
increased O 0 0.00041621146
in O 0 0.00031910592
the O 0 0.00027247812
novel O 0 0.00033272224
exploratory O 0 0.0010478002
box O 0 0.00087229727
only O 0 0.0003880609
, O 0 0.00043412656
while O 0 0.00030329416
measures O 0 0.00029479997
of O 0 0.0005907624
stereotypic O 0 0.76470006
behavior O 0 0.0015188574
were O 0 0.0008247359
similar O 0 0.0009783262
in O 0 0.001823893
both O 0 0.003317877
. O 0 0.006404887

By O 0 0.005513989
contrast O 0 0.0055971816
, O 0 0.05004296
apomorphine B-Chemical 1 0.99999833
- O 0 0.18646936
induced O 0 0.0019888282
locomotion O 0 0.31187218
was O 0 0.001036971
more O 0 0.00095128664
prominent O 0 0.0017790248
in O 0 0.0009922038
the O 0 0.001268699
novel O 0 0.0021877552
exploratory O 0 0.005667427
box O 0 0.007771599
. O 0 0.008485764

Dopamine B-Chemical 1 0.999509
turnover O 0 0.010341516
ratios O 0 0.005359723
( O 0 0.29610196
DOPAC B-Chemical 1 0.9999999
: O 0 0.17466442
DA B-Chemical 0 0.9999629
and O 0 0.069896184
HVA B-Chemical 0 0.9999999
: O 0 0.053671382
DA B-Chemical 0 0.9998834
) O 0 0.0010158774
were O 0 0.0002652154
found O 0 0.00019759343
to O 0 0.00017784006
be O 0 0.00021196215
lower O 0 0.00021061761
in O 0 0.00019258836
those O 0 0.00022821753
animals O 0 0.00015395679
exposed O 0 0.00021874372
to O 0 0.00017358072
the O 0 0.00021586851
exploratory O 0 0.0006130958
box O 0 0.00051340077
when O 0 0.00027392167
compared O 0 0.00034330672
to O 0 0.0005395393
their O 0 0.0009655815
home O 0 0.0017091369
cage O 0 0.0036233633
counterparts O 0 0.0043302597
. O 0 0.006741119

However O 0 0.007046789
, O 0 0.037506796
apomorphine B-Chemical 1 0.99999714
- O 0 0.12908514
induced O 0 0.001393558
reductions O 0 0.0014985343
in O 0 0.001074664
striatal O 0 0.98292726
dopamine B-Chemical 1 0.99971515
turnover O 0 0.0012138
were O 0 0.0003739066
detected O 0 0.00033012847
in O 0 0.00041503177
both O 0 0.00052523176
novel O 0 0.0008349948
and O 0 0.0012177924
home O 0 0.0019974988
cage O 0 0.0041001975
environments O 0 0.004742219
. O 0 0.0069408794

The O 0 0.0030974876
implications O 0 0.0021848131
of O 0 0.0017725114
these O 0 0.0013221651
findings O 0 0.0012204099
are O 0 0.00073313224
discussed O 0 0.00052061334
with O 0 0.00052104227
particular O 0 0.00044566212
emphasis O 0 0.00069943484
upon O 0 0.0004709761
conducting O 0 0.000786801
psychopharmacological O 0 0.189543
challenge O 0 0.0012986022
tests O 0 0.0023673647
in O 0 0.0025804392
rodents O 0 0.00830857
. O 0 0.0072438037

Hemolysis B-Disease 0 0.99854624
of O 0 0.0045456607
human O 0 0.0041841865
erythrocytes O 0 0.28828713
induced O 0 0.0020725837
by O 0 0.0027978052
tamoxifen B-Chemical 1 0.99916124
is O 0 0.0011690236
related O 0 0.0007147875
to O 0 0.0008796112
disruption O 0 0.0013581236
of O 0 0.0022807776
membrane O 0 0.009411638
structure O 0 0.008356296
. O 0 0.008359762

Tamoxifen B-Chemical 0 0.9998789
( O 0 0.25706315
TAM B-Chemical 1 0.999972
) O 0 0.031588063
, O 0 0.002899603
the O 0 0.001755082
antiestrogenic O 0 0.994231
drug O 0 0.6779642
most O 0 0.0011657415
widely O 0 0.00043856824
prescribed O 0 0.00049503054
in O 0 0.00019802159
the O 0 0.00021880503
chemotherapy O 0 0.024477731
of O 0 0.0028770673
breast B-Disease 0 0.99984634
cancer I-Disease 0 0.9999931
, O 0 0.003842084
induces O 0 0.0003097494
changes O 0 0.0005251494
in O 0 0.0003116466
normal O 0 0.0007501227
discoid O 0 0.79190004
shape O 0 0.0008691011
of O 0 0.0011796885
erythrocytes O 0 0.7050586
and O 0 0.050532877
hemolytic B-Disease 2 0.9999994
anemia I-Disease 2 0.99999845
. O 0 0.021749852

This O 0 0.0051661376
work O 0 0.0027914122
evaluates O 0 0.0016047048
the O 0 0.0011385644
effects O 0 0.0013945842
of O 0 0.0032950942
TAM B-Chemical 1 0.9999502
on O 0 0.0003614875
isolated O 0 0.00031879908
human O 0 0.00095133844
erythrocytes O 0 0.44245058
, O 0 0.0004894585
attempting O 0 0.000340962
to O 0 0.00013929243
identify O 0 0.000119891796
the O 0 0.00013075896
underlying O 0 0.00017742052
mechanisms O 0 0.00017852799
on O 0 0.0002776948
TAM B-Chemical 1 0.9999964
- O 0 0.45349967
induced O 0 0.04073834
hemolytic B-Disease 2 1.0
anemia I-Disease 2 0.9999999
and O 0 0.0022482504
the O 0 0.00032519546
involvement O 0 0.0005675842
of O 0 0.0006909634
biomembranes O 0 0.8645722
in O 0 0.00075698306
its O 0 0.0023995633
cytostatic O 0 0.33624384
action O 0 0.0033784676
mechanisms O 0 0.0035187055
. O 0 0.006704498

TAM B-Chemical 1 0.9996748
induces O 0 0.0107377255
hemolysis B-Disease 0 0.9999342
of O 0 0.0077902717
erythrocytes O 0 0.37877244
as O 0 0.0027108518
a O 0 0.0030644087
function O 0 0.0030816307
of O 0 0.0049182754
concentration O 0 0.010847021
. O 0 0.011302377

The O 0 0.0030136069
extension O 0 0.002813419
of O 0 0.0037753
hemolysis B-Disease 0 0.9999535
is O 0 0.0014050531
variable O 0 0.00085943675
with O 0 0.0007992427
erythrocyte O 0 0.4555699
samples O 0 0.00047485676
, O 0 0.0005231191
but O 0 0.00036162572
12 O 0 0.00021560809
. O 0 0.00023751862
5 O 0 0.00030197852
microM O 0 0.6684169
TAM B-Chemical 1 0.99990916
induces O 0 0.0005950604
total O 0 0.0010048911
hemolysis B-Disease 0 0.9999577
of O 0 0.0016386977
all O 0 0.0013949303
tested O 0 0.0020960555
suspensions O 0 0.009016487
. O 0 0.006991118

Despite O 0 0.0040218593
inducing O 0 0.0037102096
extensive O 0 0.0029999614
erythrocyte O 0 0.6794289
lysis O 0 0.40171307
, O 0 0.05361077
TAM B-Chemical 1 0.9999728
does O 0 0.0012072708
not O 0 0.0007389836
shift O 0 0.0013429589
the O 0 0.0009369146
osmotic O 0 0.024879994
fragility O 0 0.42996597
curves O 0 0.0025239605
of O 0 0.004481989
erythrocytes O 0 0.5259358
. O 0 0.008656244

The O 0 0.004891715
hemolytic B-Disease 0 0.99980277
effect O 0 0.0040294263
of O 0 0.022853853
TAM B-Chemical 1 0.999985
is O 0 0.0013569199
prevented O 0 0.0008775878
by O 0 0.00045633284
low O 0 0.00048945803
concentrations O 0 0.001302728
of O 0 0.0020743862
alpha B-Chemical 0 0.99935824
- I-Chemical 0 0.9743672
tocopherol I-Chemical 0 0.9999999
( O 0 0.12782979
alpha B-Chemical 0 0.9992756
- I-Chemical 0 0.8127825
T I-Chemical 0 0.9992513
) O 0 0.008308759
and O 0 0.0022715405
alpha B-Chemical 0 0.99900013
- I-Chemical 0 0.97751856
tocopherol I-Chemical 0 1.0
acetate I-Chemical 0 0.9999106
( O 0 0.03845951
alpha B-Chemical 0 0.9985318
- I-Chemical 0 0.7234545
TAc I-Chemical 0 0.9956119
) O 0 0.002029196
( O 0 0.00041140016
inactivated O 0 0.00035376067
functional O 0 0.0010293523
hydroxyl B-Chemical 0 0.9999589
) O 0 0.004374247
indicating O 0 0.0002837754
that O 0 0.00057302584
TAM B-Chemical 1 0.9999949
- O 0 0.20435274
induced O 0 0.0031881083
hemolysis B-Disease 0 0.99999285
is O 0 0.00069337414
not O 0 0.00046172162
related O 0 0.0005186712
to O 0 0.0009441003
oxidative O 0 0.8133503
membrane O 0 0.1293492
damage O 0 0.9205095
. O 0 0.008856679

This O 0 0.0049948525
was O 0 0.0024280238
further O 0 0.0015639211
evidenced O 0 0.0016314074
by O 0 0.0009857307
absence O 0 0.0006199515
of O 0 0.0013999256
oxygen B-Chemical 1 0.999332
consumption O 0 0.50310725
and O 0 0.001699706
hemoglobin O 0 0.9929819
oxidation O 0 0.93468153
both O 0 0.0003348773
determined O 0 0.00028038042
in O 0 0.0003860119
parallel O 0 0.00064854627
with O 0 0.0025899457
TAM B-Chemical 1 0.9999658
- O 0 0.15647556
induced O 0 0.011750037
hemolysis B-Disease 0 0.99996793
. O 0 0.0115620615

Furthermore O 0 0.005089964
, O 0 0.0038900326
it O 0 0.0021837906
was O 0 0.0013561982
observed O 0 0.0009250922
that O 0 0.0010885395
TAM B-Chemical 1 0.99994683
inhibits O 0 0.0007883358
the O 0 0.0022315618
peroxidation O 0 0.99999785
of O 0 0.001763861
human O 0 0.002636917
erythrocytes O 0 0.59910643
induced O 0 0.0010891188
by O 0 0.018786084
AAPH B-Chemical 0 1.0
, O 0 0.0029257676
thus O 0 0.0007073122
ruling O 0 0.0065341117
out O 0 0.00062398834
TAM B-Chemical 1 0.99995446
- O 0 0.028513426
induced O 0 0.0015697693
cell O 0 0.032746773
oxidative O 0 0.9830793
stress O 0 0.78541696
. O 0 0.010752414

Hemolysis B-Disease 0 0.99910766
caused O 0 0.004450744
by O 0 0.007000006
TAM B-Chemical 1 0.99992883
was O 0 0.0014312576
not O 0 0.0006523622
preceded O 0 0.00055648363
by O 0 0.00048018532
the O 0 0.00044712485
leakage O 0 0.43869615
of O 0 0.005330086
K B-Chemical 1 0.9999887
( O 0 0.013133348
+ O 0 0.0082943905
) O 0 0.00060955295
from O 0 0.00017541542
the O 0 0.0001890044
cells O 0 0.00028176856
, O 0 0.00031273568
also O 0 0.00018033518
excluding O 0 0.00036885837
a O 0 0.0003817691
colloid O 0 0.41207913
- O 0 0.01729485
osmotic O 0 0.010481333
type O 0 0.00029599998
mechanism O 0 0.00025629072
of O 0 0.0035460903
hemolysis B-Disease 0 0.99999535
, O 0 0.0009575411
according O 0 0.00024729982
to O 0 0.0002737154
the O 0 0.00037959224
effects O 0 0.0006158764
on O 0 0.00071934884
osmotic O 0 0.03420876
fragility O 0 0.6730031
curves O 0 0.00528667
. O 0 0.00722347

However O 0 0.0063358466
, O 0 0.010295995
TAM B-Chemical 1 0.99968934
induces O 0 0.001870092
release O 0 0.0049649747
of O 0 0.0012560207
peripheral O 0 0.0034797746
proteins O 0 0.0007333872
of O 0 0.0007109477
membrane O 0 0.014564336
- O 0 0.012182851
cytoskeleton O 0 0.008864972
and O 0 0.00062599813
cytosol O 0 0.0012771056
proteins O 0 0.0006996485
essentially O 0 0.0007143468
bound O 0 0.00090468593
to O 0 0.0014820097
band O 0 0.0052599567
3 O 0 0.0037687602
. O 0 0.0066339476

Either O 0 0.057204824
alpha B-Chemical 0 0.9933757
- I-Chemical 0 0.5458592
T I-Chemical 0 0.99694604
or O 0 0.007202027
alpha B-Chemical 0 0.9982126
- I-Chemical 0 0.59622383
TAc I-Chemical 0 0.98037475
increases O 0 0.00091797666
membrane O 0 0.0061481735
packing O 0 0.04141161
and O 0 0.0010791308
prevents O 0 0.0017998463
TAM B-Chemical 1 0.9998965
partition O 0 0.0025975013
into O 0 0.0013347389
model O 0 0.0030395659
membranes O 0 0.024050932
. O 0 0.008307879

These O 0 0.0035111762
effects O 0 0.0023910482
suggest O 0 0.0011015104
that O 0 0.00093515683
the O 0 0.0008607071
protection O 0 0.0048518153
from O 0 0.0012265366
hemolysis B-Disease 0 0.99999547
by O 0 0.019953348
tocopherols B-Chemical 0 0.9999995
is O 0 0.0005550854
related O 0 0.00016874944
to O 0 0.00017669561
a O 0 0.00035157133
decreased O 0 0.0021893617
TAM B-Chemical 1 0.9999784
incorporation O 0 0.0075900634
in O 0 0.0002910119
condensed O 0 0.007836021
membranes O 0 0.0024442677
and O 0 0.00026207886
the O 0 0.00022895943
structural O 0 0.0007779504
damage O 0 0.23699124
of O 0 0.00056503434
the O 0 0.00061058765
erythrocyte O 0 0.35705927
membrane O 0 0.004235089
is O 0 0.0015312377
consequently O 0 0.0029596074
avoided O 0 0.0039694197
. O 0 0.0065943743

Therefore O 0 0.0047605564
, O 0 0.022747323
TAM B-Chemical 1 0.99996436
- O 0 0.21393873
induced O 0 0.0052190763
hemolysis B-Disease 0 0.99997795
results O 0 0.0007136902
from O 0 0.000401959
a O 0 0.00042369263
structural O 0 0.00054687297
perturbation O 0 0.00049664226
of O 0 0.0005113895
red O 0 0.041110426
cell O 0 0.0053371517
membrane O 0 0.017933091
, O 0 0.00048462406
leading O 0 0.00035192943
to O 0 0.00015942367
changes O 0 0.0002292163
in O 0 0.00014335319
the O 0 0.00013542688
framework O 0 0.00014535013
of O 0 0.00019996178
the O 0 0.00023265333
erythrocyte O 0 0.31670478
membrane O 0 0.0024646863
and O 0 0.00031738833
its O 0 0.00054716814
cytoskeleton O 0 0.007923565
caused O 0 0.00036828575
by O 0 0.000446679
its O 0 0.0008393759
high O 0 0.00091640546
partition O 0 0.0013661523
in O 0 0.001346164
the O 0 0.0021837822
membrane O 0 0.009297201
. O 0 0.007285549

These O 0 0.00373141
defects O 0 0.0030017856
explain O 0 0.001442967
the O 0 0.0012994844
abnormal O 0 0.007454202
erythrocyte O 0 0.3370639
shape O 0 0.0011073349
and O 0 0.0006511968
decreased O 0 0.0005866062
mechanical O 0 0.00084560236
stability O 0 0.00069194695
promoted O 0 0.0011227899
by O 0 0.0020821877
TAM B-Chemical 1 0.999966
, O 0 0.0023734919
resulting O 0 0.0017898526
in O 0 0.011302377
hemolytic B-Disease 2 0.99999917
anemia I-Disease 2 0.9999982
. O 0 0.023050716

Additionally O 0 0.004510868
, O 0 0.0032876546
since O 0 0.0017014885
membrane O 0 0.007074536
leakage O 0 0.4090142
is O 0 0.0008915598
a O 0 0.00063979055
final O 0 0.00050124567
stage O 0 0.0016906293
of O 0 0.0012454706
cytotoxicity O 0 0.99848586
, O 0 0.0011351043
the O 0 0.00024435905
disruption O 0 0.00023335891
of O 0 0.00024077299
the O 0 0.0001787184
structural O 0 0.00034913688
characteristics O 0 0.0001778143
of O 0 0.00038136353
biomembranes O 0 0.95346653
by O 0 0.001753347
TAM B-Chemical 1 0.9999633
may O 0 0.00026256058
contribute O 0 0.00020618386
to O 0 0.00022581557
the O 0 0.00027878853
multiple O 0 0.0004253922
mechanisms O 0 0.0005150231
of O 0 0.0011196614
its O 0 0.0048841615
anticancer O 0 0.694162
action O 0 0.008140094
. O 0 0.006961405

Changes O 0 0.004267434
of O 0 0.0040606586
sodium B-Chemical 0 0.99891007
and O 0 0.0071724723
ATP B-Chemical 0 0.9979001
affinities O 0 0.007673536
of O 0 0.00092899543
the O 0 0.0006708125
cardiac O 0 0.18136549
( O 0 0.019832471
Na B-Chemical 1 0.99999714
, O 0 0.04053051
K B-Chemical 1 0.99998355
) O 0 0.03269495
- O 0 0.036652148
ATPase O 0 0.024027899
during O 0 0.00038909333
and O 0 0.00066760706
after O 0 0.0007852487
nitric B-Chemical 0 0.99778783
oxide I-Chemical 0 0.9884349
deficient O 0 0.0056816973
hypertension B-Disease 2 0.9999763
. O 0 0.009057173

In O 0 0.0045027398
the O 0 0.0034396707
cardiovascular O 0 0.8604563
system O 0 0.0029093896
, O 0 0.004886546
NO B-Chemical 0 0.99717027
is O 0 0.001050456
involved O 0 0.0006186191
in O 0 0.0006419338
the O 0 0.00063595903
regulation O 0 0.0006392313
of O 0 0.0011268798
a O 0 0.0015675357
variety O 0 0.002161053
of O 0 0.00311659
functions O 0 0.004661931
. O 0 0.008006856

Inhibition O 0 0.0152240675
of O 0 0.013874278
NO B-Chemical 0 0.9963198
synthesis O 0 0.06639778
induces O 0 0.01197441
sustained O 0 0.5348711
hypertension B-Disease 2 0.99998045
. O 0 0.026535623

In O 0 0.0038204126
several O 0 0.0022799778
models O 0 0.0022208916
of O 0 0.004749492
hypertension B-Disease 2 0.99999535
, O 0 0.005010684
elevation O 0 0.10990484
of O 0 0.0010311932
intracellular O 0 0.007126238
sodium B-Chemical 0 0.9993807
level O 0 0.0007504845
was O 0 0.00091111363
documented O 0 0.0014010066
in O 0 0.0017336196
cardiac O 0 0.052489854
tissue O 0 0.016163304
. O 0 0.0075793494

To O 0 0.0027869004
assess O 0 0.001421713
the O 0 0.0013915879
molecular O 0 0.002075335
basis O 0 0.0009664964
of O 0 0.00094155275
disturbances O 0 0.12933642
in O 0 0.00048153865
transmembraneous O 0 0.0028221887
transport O 0 0.0010023543
of O 0 0.0031224345
Na B-Chemical 1 0.999998
+ O 0 0.025793428
, O 0 0.00042344292
we O 0 0.00013321001
studied O 0 0.00017234462
the O 0 0.00014952413
response O 0 0.00023238952
of O 0 0.00038088232
cardiac O 0 0.25664064
( O 0 0.028253935
Na B-Chemical 1 0.9999987
, O 0 0.049394898
K B-Chemical 1 0.9999918
) O 0 0.051796548
- O 0 0.09854968
ATPase O 0 0.1536522
to O 0 0.00042726
NO B-Chemical 0 0.99976104
- O 0 0.10717854
deficient O 0 0.0006510106
hypertension B-Disease 2 0.99999654
induced O 0 0.00040057366
in O 0 0.00024997292
rats O 0 0.0004703086
by O 0 0.00042708617
NO B-Chemical 0 0.99965584
- O 0 0.113755666
synthase O 0 0.28870884
inhibition O 0 0.0006961238
with O 0 0.0002390182
40 O 0 0.00019625729
mg O 0 0.0068017435
/ O 0 0.0008403951
kg O 0 0.0006972855
/ O 0 0.0013599419
day O 0 0.0002706915
N B-Chemical 0 0.99814355
( I-Chemical 0 0.0095042605
G I-Chemical 0 0.99807584
) I-Chemical 0 0.055361006
- I-Chemical 0 0.5793719
nitro I-Chemical 0 0.9999857
- I-Chemical 0 0.7246538
L I-Chemical 0 0.9998568
- I-Chemical 0 0.7614934
arginine I-Chemical 0 0.9985129
methyl I-Chemical 0 0.9997645
ester I-Chemical 0 0.9948053
( O 0 0.049091227
L B-Chemical 1 0.99984145
- I-Chemical 1 0.87047744
NAME I-Chemical 1 0.9999851
) O 0 0.0018653505
for O 0 0.0009063048
4 O 0 0.0011353219
four O 0 0.001490441
weeks O 0 0.0025087376
. O 0 0.0058989045

After O 0 0.0030859667
4 O 0 0.002689127
- O 0 0.003652058
week O 0 0.0012209348
administration O 0 0.003963407
of O 0 0.0045131654
L B-Chemical 1 0.99985194
- I-Chemical 1 0.9419117
NAME I-Chemical 1 0.9999927
, O 0 0.0015295008
the O 0 0.0005799175
systolic O 0 0.614591
blood O 0 0.022217799
pressure O 0 0.060052354
( O 0 0.0012645507
SBP O 0 0.44177747
) O 0 0.0013423054
increased O 0 0.0012868482
by O 0 0.0018715949
36 O 0 0.0028589729
% O 0 0.0047337376
. O 0 0.0073874868

Two O 0 0.004220401
weeks O 0 0.002355081
after O 0 0.0017129014
terminating O 0 0.0030058029
the O 0 0.0015687341
treatment O 0 0.0017447834
, O 0 0.0018420253
the O 0 0.0014625004
SBP O 0 0.19582413
recovered O 0 0.0013985657
to O 0 0.0018145086
control O 0 0.0028527281
value O 0 0.00491337
. O 0 0.008726468

When O 0 0.003105663
activating O 0 0.002549994
the O 0 0.002098233
( O 0 0.0119055705
Na B-Chemical 1 0.99998987
, O 0 0.074363336
K B-Chemical 1 0.99998
) O 0 0.06383584
- O 0 0.07627649
ATPase O 0 0.066651635
with O 0 0.00047657627
its O 0 0.001184879
substrate O 0 0.027648743
ATP B-Chemical 0 0.99934834
, O 0 0.0007961429
no O 0 0.00020233786
changes O 0 0.0003546951
in O 0 0.00027627932
Km O 0 0.055829767
and O 0 0.00040832523
Vmax O 0 0.048072793
values O 0 0.00032462212
were O 0 0.00039386685
observed O 0 0.000500373
in O 0 0.0011523288
NO B-Chemical 0 0.99794406
- O 0 0.020610735
deficient O 0 0.0025939583
rats O 0 0.005618896
. O 0 0.0067143305

During O 0 0.0028986158
activation O 0 0.0032467102
with O 0 0.004866217
Na B-Chemical 1 0.99998546
+ O 0 0.032888953
, O 0 0.0013497131
the O 0 0.00061819376
Vmax O 0 0.16136894
remained O 0 0.0007074009
unchanged O 0 0.00044593413
, O 0 0.000504522
however O 0 0.0004799215
the O 0 0.00067242456
K B-Chemical 1 0.999984
( O 0 0.09276271
Na B-Chemical 1 0.99999774
) O 0 0.003441149
increased O 0 0.00030198743
by O 0 0.00023141618
50 O 0 0.00027558714
% O 0 0.0002657631
, O 0 0.0002585277
indicating O 0 0.00016206695
a O 0 0.00025070203
profound O 0 0.0006175931
decrease O 0 0.00020938917
in O 0 0.0001883555
the O 0 0.0001804974
affinity O 0 0.00057299813
of O 0 0.0004761989
the O 0 0.001363285
Na B-Chemical 1 0.99999774
+ O 0 0.06608605
- O 0 0.017011603
binding O 0 0.0006675269
site O 0 0.0009805537
in O 0 0.0015360834
NO B-Chemical 0 0.9985121
- O 0 0.021355668
deficient O 0 0.0025987616
rats O 0 0.0055587557
. O 0 0.0067103533

After O 0 0.0029150357
recovery O 0 0.0032501875
from O 0 0.0024274993
hypertension B-Disease 2 0.99998367
, O 0 0.0019025729
the O 0 0.0006361621
activity O 0 0.00055633485
of O 0 0.00084552245
( O 0 0.01915062
Na B-Chemical 1 0.99999785
, O 0 0.05961568
K B-Chemical 1 0.9999902
) O 0 0.060882356
- O 0 0.10435984
ATPase O 0 0.1283135
increased O 0 0.0004357859
, O 0 0.00034729633
due O 0 0.00014608473
to O 0 0.00015906348
higher O 0 0.00018174463
affinity O 0 0.00048062648
of O 0 0.0004205305
the O 0 0.00087368523
ATP B-Chemical 0 0.99975795
- O 0 0.059962675
binding O 0 0.00043482071
site O 0 0.00040978967
, O 0 0.00040052383
as O 0 0.00024665767
revealed O 0 0.00028094693
from O 0 0.00031919326
the O 0 0.0004818412
lowered O 0 0.0019242715
Km O 0 0.05936005
value O 0 0.0016937886
for O 0 0.0032560874
ATP B-Chemical 0 0.99334455
. O 0 0.009455635

The O 0 0.0062961546
K B-Chemical 1 0.99943906
( O 0 0.052195515
Na B-Chemical 1 0.99995136
) O 0 0.004952324
value O 0 0.0019158508
for O 0 0.0025099218
Na B-Chemical 1 0.9999542
+ O 0 0.0046505383
returned O 0 0.0019144696
to O 0 0.0019625907
control O 0 0.0029907024
value O 0 0.005067905
. O 0 0.008963614

Inhibition O 0 0.0068364274
of O 0 0.0070955004
NO B-Chemical 0 0.99961805
- O 0 0.21432753
synthase O 0 0.34173948
induced O 0 0.0012990634
a O 0 0.0019979845
reversible O 0 0.70811003
hypertension B-Disease 2 0.999998
accompanied O 0 0.004406482
by O 0 0.0018050891
depressed B-Disease 2 0.9990657
Na B-Chemical 1 0.9999989
+ O 0 0.110164985
- O 0 0.04354156
extrusion O 0 0.04437606
from O 0 0.00020044207
cardiac O 0 0.0059036263
cells O 0 0.0002330083
as O 0 0.00016656175
a O 0 0.00020010331
consequence O 0 0.00013739459
of O 0 0.00045820678
deteriorated O 0 0.61568034
Na B-Chemical 1 0.9999987
+ O 0 0.065587215
- O 0 0.009357336
binding O 0 0.0003072643
properties O 0 0.00026657418
of O 0 0.00039076983
the O 0 0.0005386334
( O 0 0.0071489294
Na B-Chemical 1 0.999992
, O 0 0.02886711
K B-Chemical 1 0.9999223
) O 0 0.03223518
- O 0 0.05553447
ATPase O 0 0.18392283
. O 0 0.008475372

After O 0 0.002848686
recovery O 0 0.0028723574
of O 0 0.0020824298
blood O 0 0.011766088
pressure O 0 0.026665919
to O 0 0.00055901916
control O 0 0.0004628693
values O 0 0.0003728608
, O 0 0.0004566984
the O 0 0.00032108618
extrusion O 0 0.097642206
of O 0 0.004435799
Na B-Chemical 1 0.9999976
+ O 0 0.010810817
from O 0 0.00025251586
cardiac O 0 0.015175075
cells O 0 0.0002886659
was O 0 0.00018386361
normalized O 0 0.00012363803
, O 0 0.00024159116
as O 0 0.00016136597
revealed O 0 0.00017724941
by O 0 0.00020760893
restoration O 0 0.00030383305
of O 0 0.00035399312
the O 0 0.0004686436
( O 0 0.008174824
Na B-Chemical 1 0.99999475
, O 0 0.03010651
K B-Chemical 1 0.9999503
) O 0 0.02708883
- O 0 0.04050987
ATPase O 0 0.1015343
activity O 0 0.0046901824
. O 0 0.0074025057

Effects O 0 0.004899149
of O 0 0.0028656214
long O 0 0.0023965621
- O 0 0.006996645
term O 0 0.0011790679
pretreatment O 0 0.08719099
with O 0 0.004011029
isoproterenol B-Chemical 0 0.99997175
on O 0 0.0016631315
bromocriptine B-Chemical 0 0.9999981
- O 0 0.14096093
induced O 0 0.0028414098
tachycardia B-Disease 2 0.9997073
in O 0 0.0025054142
conscious O 0 0.017656785
rats O 0 0.004822313
. O 0 0.0064350897

It O 0 0.004816781
has O 0 0.0024868762
been O 0 0.0018427304
shown O 0 0.0011631974
that O 0 0.0014765896
bromocriptine B-Chemical 0 0.9999968
- O 0 0.21204735
induced O 0 0.0024949564
tachycardia B-Disease 2 0.9999229
, O 0 0.0015736163
which O 0 0.00041790676
persisted O 0 0.00024810797
after O 0 0.00017191413
adrenalectomy O 0 0.23319514
, O 0 0.00051199674
is O 0 0.00029072328
( O 0 0.00059067516
i O 0 0.002922095
) O 0 0.0004172746
mediated O 0 0.00012850178
by O 0 0.0002722361
central O 0 0.01697778
dopamine B-Chemical 1 0.9999901
D2 O 0 0.9997955
receptor O 0 0.021427222
activation O 0 0.0005856075
and O 0 0.00033587342
( O 0 0.00048799126
ii O 0 0.00095278624
) O 0 0.0005195024
reduced O 0 0.00018280584
by O 0 0.0001948566
5 O 0 0.00017448692
- O 0 0.0027653566
day O 0 0.0002466927
isoproterenol B-Chemical 0 0.9998702
pretreatment O 0 0.20210995
, O 0 0.00043171522
supporting O 0 0.00017463756
therefore O 0 0.000177951
the O 0 0.000149518
hypothesis O 0 0.00017441175
that O 0 0.00015670568
this O 0 0.00021259462
effect O 0 0.00023746946
is O 0 0.00029791385
dependent O 0 0.00029215173
on O 0 0.00038152057
sympathetic O 0 0.029374758
outflow O 0 0.20689677
to O 0 0.0013213191
the O 0 0.002333468
heart O 0 0.10827685
. O 0 0.0065596486

This O 0 0.0052787685
study O 0 0.0028660041
was O 0 0.001592995
conducted O 0 0.00095001963
to O 0 0.00066261686
examine O 0 0.00035132907
whether O 0 0.00031139445
prolonged O 0 0.00080712704
pretreatment O 0 0.104410216
with O 0 0.004121071
isoproterenol B-Chemical 0 0.9999714
could O 0 0.0006825672
abolish O 0 0.008413988
bromocriptine B-Chemical 0 0.99999845
- O 0 0.1458116
induced O 0 0.0025192618
tachycardia B-Disease 2 0.99971145
in O 0 0.0021661154
conscious O 0 0.016077489
rats O 0 0.004366663
. O 0 0.005929458

Isoproterenol B-Chemical 0 0.9999597
pretreatment O 0 0.23319824
for O 0 0.0019501278
15 O 0 0.0011463474
days O 0 0.00077971554
caused O 0 0.0010498257
cardiac B-Disease 0 0.9514876
hypertrophy I-Disease 2 0.99995756
without O 0 0.0010332745
affecting O 0 0.0009884343
baseline O 0 0.0008341982
blood O 0 0.006072127
pressure O 0 0.015378506
and O 0 0.0019214893
heart O 0 0.038945984
rate O 0 0.004547139
. O 0 0.0073199333

In O 0 0.004048391
control O 0 0.0027120628
rats O 0 0.003170304
, O 0 0.0033548416
intravenous O 0 0.7339337
bromocriptine B-Chemical 0 0.9999943
( O 0 0.002255963
150 O 0 0.00079780153
microg O 0 0.00094587856
/ O 0 0.0032030377
kg O 0 0.0023242084
) O 0 0.0013931943
induced O 0 0.0012033404
significant O 0 0.0037045768
hypotension B-Disease 2 0.99998057
and O 0 0.017521553
tachycardia B-Disease 2 0.99963367
. O 0 0.008903688

Bromocriptine B-Chemical 0 0.99997294
- O 0 0.24757466
induced O 0 0.010238493
hypotension B-Disease 2 0.99999034
was O 0 0.0018727196
unaffected O 0 0.0014683343
by O 0 0.0021019222
isoproterenol B-Chemical 0 0.99998236
pretreatment O 0 0.7113077
, O 0 0.0030237813
while O 0 0.0011670842
tachycardia B-Disease 2 0.99955255
was O 0 0.00028209944
reversed O 0 0.00022865116
to O 0 0.00016947392
significant O 0 0.00048490101
bradycardia B-Disease 0 0.9993759
, O 0 0.0005284439
an O 0 0.00024249671
effect O 0 0.00017086952
that O 0 0.00013996869
was O 0 0.00018321017
partly O 0 0.00022798221
reduced O 0 0.00020257822
by O 0 0.00025642954
i O 0 0.0035106558
. O 0 0.0003004324
v O 0 0.054052867
. O 0 0.001042101
domperidone B-Chemical 0 0.99999666
( O 0 0.0009310955
0 O 0 0.00049161504
. O 0 0.00047620165
5 O 0 0.000645489
mg O 0 0.0049229097
/ O 0 0.0032524015
kg O 0 0.005091527
) O 0 0.006127812
. O 0 0.00772832

Neither O 0 0.005816107
cardiac O 0 0.073258884
vagal O 0 0.48280522
nor O 0 0.0029772795
sympathetic O 0 0.15362047
tone O 0 0.13041353
was O 0 0.0022665325
altered O 0 0.0026369719
by O 0 0.004450196
isoproterenol B-Chemical 0 0.9998481
pretreatment O 0 0.6690609
. O 0 0.010898996

In O 0 0.0035966977
isolated O 0 0.0021603464
perfused O 0 0.053932164
heart O 0 0.2138378
preparations O 0 0.0017955534
from O 0 0.0012536377
isoproterenol B-Chemical 0 0.99998736
- O 0 0.25068206
pretreated O 0 0.018258756
rats O 0 0.0011155147
, O 0 0.0006429198
the O 0 0.00071623205
isoproterenol B-Chemical 0 0.9999807
- O 0 0.055042613
induced O 0 0.00024017137
maximal O 0 0.00020038188
increase O 0 0.00015666819
in O 0 0.00019810599
left O 0 0.0012167959
ventricular O 0 0.80458355
systolic O 0 0.8312696
pressure O 0 0.060856022
was O 0 0.0001640185
significantly O 0 0.0001573854
reduced O 0 0.00016337664
, O 0 0.00023019487
compared O 0 0.000107005864
with O 0 0.0002650718
saline O 0 0.06028385
- O 0 0.019149644
pretreated O 0 0.0042700325
rats O 0 0.0004595943
( O 0 0.00034590944
the O 0 0.00020452701
EC50 O 0 0.7138895
of O 0 0.000539536
the O 0 0.0012526356
isoproterenol B-Chemical 0 0.9999863
- O 0 0.06560992
induced O 0 0.00024848987
increase O 0 0.00018787246
in O 0 0.00024341498
left O 0 0.0012459487
ventricular O 0 0.75705564
systolic O 0 0.7021906
pressure O 0 0.017130243
was O 0 0.0003285219
enhanced O 0 0.00040720034
approximately O 0 0.000626438
22 O 0 0.0012978956
- O 0 0.0035514154
fold O 0 0.0036119698
) O 0 0.0068768626
. O 0 0.0075710835

These O 0 0.0033271806
results O 0 0.001996668
show O 0 0.0012881375
that O 0 0.0010108086
15 O 0 0.0009754866
- O 0 0.0050331373
day O 0 0.0008164468
isoproterenol B-Chemical 0 0.9998981
pretreatment O 0 0.24384852
not O 0 0.00037178164
only O 0 0.00038297637
abolished O 0 0.0005562965
but O 0 0.0012648343
reversed O 0 0.018706992
bromocriptine B-Chemical 0 0.99999917
- O 0 0.17977974
induced O 0 0.0011229899
tachycardia B-Disease 2 0.9998734
to O 0 0.00056308764
bradycardia B-Disease 0 0.9994974
, O 0 0.0004536696
an O 0 0.00021455054
effect O 0 0.00015446762
that O 0 0.00012835226
is O 0 0.000174831
mainly O 0 0.00017781954
related O 0 0.00010113669
to O 0 0.000117015705
further O 0 0.00019720964
cardiac O 0 0.30364907
beta O 0 0.9970488
- O 0 0.8646266
adrenoceptor O 0 0.999985
desensitization O 0 0.14906181
rather O 0 0.00022188405
than O 0 0.00017839066
to O 0 0.00025059545
impairment O 0 0.04033911
of O 0 0.0006488671
autonomic O 0 0.05107622
regulation O 0 0.0006603575
of O 0 0.0014833431
the O 0 0.0024395194
heart O 0 0.15512942
. O 0 0.0067644687

They O 0 0.004530141
suggest O 0 0.0018016025
that O 0 0.0015828816
, O 0 0.0018458061
in O 0 0.0010600737
normal O 0 0.0014224815
conscious O 0 0.009486018
rats O 0 0.00077411084
, O 0 0.00051303534
the O 0 0.00031905636
central O 0 0.0012368772
tachycardia B-Disease 2 0.99954814
of O 0 0.0067809373
bromocriptine B-Chemical 0 0.9999943
appears O 0 0.00024682988
to O 0 0.00016922137
predominate O 0 0.0005594365
and O 0 0.00022403282
to O 0 0.00016941043
mask O 0 0.00041088692
the O 0 0.00035618182
bradycardia B-Disease 0 0.9959837
of O 0 0.00046788654
this O 0 0.0004870781
agonist O 0 0.4283342
at O 0 0.0007198005
peripheral O 0 0.1991432
dopamine B-Chemical 1 0.99993646
D2 O 0 0.99831283
receptors O 0 0.027063202
. O 0 0.0068406924

A O 0 0.033352517
developmental O 0 0.0043801046
analysis O 0 0.0023359072
of O 0 0.0037348468
clonidine B-Chemical 0 0.99998057
' O 0 0.0021699457
s O 0 0.0010049465
effects O 0 0.00068889227
on O 0 0.00043888003
cardiac O 0 0.0037761184
rate O 0 0.0006661364
and O 0 0.00083676697
ultrasound O 0 0.0026144474
production O 0 0.0017336864
in O 0 0.0020699818
infant O 0 0.010996175
rats O 0 0.0070566684
. O 0 0.007370198

Under O 0 0.0054017967
controlled O 0 0.0025951625
conditions O 0 0.002262006
, O 0 0.0022610885
infant O 0 0.0043221307
rats O 0 0.0015880489
emit O 0 0.0024657992
ultrasonic O 0 0.007308453
vocalizations O 0 0.0135939475
during O 0 0.00026280724
extreme O 0 0.0010591521
cold O 0 0.016609665
exposure O 0 0.003488075
and O 0 0.00032735826
after O 0 0.00016327621
administration O 0 0.0009027726
of O 0 0.0003214644
the O 0 0.0004303646
alpha O 0 0.76914495
( O 0 0.0038149215
2 O 0 0.0008386744
) O 0 0.013403509
adrenoceptor O 0 0.999974
agonist O 0 0.9882394
, O 0 0.077932075
clonidine B-Chemical 0 0.9999465
. O 0 0.008016967

Previous O 0 0.0035902539
investigations O 0 0.0024555249
have O 0 0.0014184687
determined O 0 0.0010148967
that O 0 0.0008532782
, O 0 0.0010761352
in O 0 0.00060551707
response O 0 0.0008305312
to O 0 0.0008145867
clonidine B-Chemical 0 0.9999895
, O 0 0.0009146803
ultrasound O 0 0.0018939611
production O 0 0.0004457817
increases O 0 0.0002793806
through O 0 0.00024744915
the O 0 0.00036582653
2nd O 0 0.0012779154
- O 0 0.0022071628
week O 0 0.0005585926
postpartum O 0 0.0013796417
and O 0 0.0013972518
decreases O 0 0.0022853033
thereafter O 0 0.0039403806
. O 0 0.006554778

Given O 0 0.0027931011
that O 0 0.0020923119
sympathetic O 0 0.025401196
neural O 0 0.0036597333
dominance O 0 0.0061056996
exhibits O 0 0.0013507599
a O 0 0.0006607814
similar O 0 0.00031425606
developmental O 0 0.00076612114
pattern O 0 0.00031964638
, O 0 0.00040184002
and O 0 0.00026436007
given O 0 0.00015355376
that O 0 0.00028179536
clonidine B-Chemical 0 0.999977
induces O 0 0.00033073302
sympathetic O 0 0.37273973
withdrawal O 0 0.37506622
and O 0 0.0012650694
bradycardia B-Disease 0 0.99927
, O 0 0.00032202856
we O 0 0.00010028448
hypothesized O 0 0.00012652391
that O 0 0.00026628844
clonidine B-Chemical 0 0.99998295
' O 0 0.00054499274
s O 0 0.00029334237
developmental O 0 0.0004194539
effects O 0 0.00022918265
on O 0 0.0001554093
cardiac O 0 0.0030703854
rate O 0 0.00031971492
and O 0 0.0004307531
ultrasound O 0 0.0016152913
production O 0 0.0008895785
would O 0 0.0008927322
mirror O 0 0.0024204932
each O 0 0.0014178589
other O 0 0.0034009616
. O 0 0.0062807593

Therefore O 0 0.0036685695
, O 0 0.0031269793
in O 0 0.0015859924
the O 0 0.001047027
present O 0 0.0006500345
experiment O 0 0.0005196765
, O 0 0.00066744606
the O 0 0.00038306348
effects O 0 0.0005985812
of O 0 0.0029673113
clonidine B-Chemical 0 0.9999963
administration O 0 0.049932484
( O 0 0.00080024265
0 O 0 0.00026864622
. O 0 0.00015993159
5 O 0 0.00014932734
mg O 0 0.0038496873
/ O 0 0.00089850544
kg O 0 0.0006940419
) O 0 0.00031998666
on O 0 0.00012414731
cardiac O 0 0.0016827534
rate O 0 0.00018248313
and O 0 0.00020364238
ultrasound O 0 0.0007233449
production O 0 0.00025346165
were O 0 0.00015608576
examined O 0 0.00011562061
in O 0 0.00018167602
2 O 0 0.00023411843
- O 0 0.0022540188
, O 0 0.0003729401
8 O 0 0.00026764223
- O 0 0.001582193
, O 0 0.00039280084
15 O 0 0.0002999799
- O 0 0.0011960246
, O 0 0.00049817155
and O 0 0.00053790864
20 O 0 0.00066639704
- O 0 0.0019325421
day O 0 0.0011215003
- O 0 0.0037134397
old O 0 0.0031641948
rats O 0 0.0051775603
. O 0 0.006970856

Age O 0 0.40935048
- O 0 0.009568252
related O 0 0.0014972698
changes O 0 0.0013972345
in O 0 0.0008858381
ultrasound O 0 0.0017150277
production O 0 0.00075474504
corresponded O 0 0.00038048349
with O 0 0.00040224817
changes O 0 0.00047699007
in O 0 0.00036907237
cardiovascular O 0 0.80064917
variables O 0 0.0005266158
, O 0 0.0003721096
including O 0 0.00025790927
baseline O 0 0.00034755364
cardiac O 0 0.0052651884
rate O 0 0.0006939026
and O 0 0.0038995042
clonidine B-Chemical 0 0.99998856
- O 0 0.082122944
induced O 0 0.0073515303
bradycardia B-Disease 0 0.9993826
. O 0 0.007988668

This O 0 0.004713747
experiment O 0 0.0020487236
is O 0 0.0015646927
discussed O 0 0.00091746997
with O 0 0.00073289505
regard O 0 0.00046008
to O 0 0.0003618473
the O 0 0.0003115551
hypothesis O 0 0.0002863917
that O 0 0.00022960192
ultrasound O 0 0.002022754
production O 0 0.00051004736
is O 0 0.00027300493
the O 0 0.00022490088
acoustic O 0 0.011428146
by O 0 0.00033944513
- O 0 0.006072374
product O 0 0.00034887035
of O 0 0.00026544812
a O 0 0.00028310038
physiological O 0 0.0004045806
maneuver O 0 0.03025037
that O 0 0.00016682655
compensates O 0 0.00023718708
for O 0 0.00061841303
clonidine B-Chemical 0 0.9999733
' O 0 0.0007587951
s O 0 0.0005981754
detrimental O 0 0.0008002254
effects O 0 0.0010281815
on O 0 0.0011588098
cardiovascular O 0 0.82949644
function O 0 0.004345525
. O 0 0.007077537

Recurrent O 0 0.012960787
use O 0 0.0036689758
of O 0 0.003587734
newer O 0 0.14910364
oral B-Chemical 1 0.9945205
contraceptives I-Chemical 1 0.99997866
and O 0 0.002749627
the O 0 0.0020493038
risk O 0 0.086947374
of O 0 0.007856618
venous B-Disease 0 0.9897836
thromboembolism I-Disease 0 0.99999404
. O 0 0.015819803

The O 0 0.0030285176
epidemiological O 0 0.002854674
studies O 0 0.0014315739
that O 0 0.00088838796
assessed O 0 0.00067290885
the O 0 0.00067061436
risk O 0 0.031477526
of O 0 0.0023569523
venous B-Disease 0 0.9960078
thromboembolism I-Disease 0 0.9999999
( O 0 0.40069848
VTE B-Disease 2 0.99999845
) O 0 0.0037506267
associated O 0 0.0003498451
with O 0 0.00041640693
newer O 0 0.13398178
oral B-Chemical 1 0.9970631
contraceptives I-Chemical 1 0.99999917
( O 0 0.17812419
OC B-Chemical 1 0.9999852
) O 0 0.003354126
did O 0 0.00021989549
not O 0 0.00012497079
distinguish O 0 0.00010371566
between O 0 0.00011336813
patterns O 0 0.00017620064
of O 0 0.00074229215
OC B-Chemical 1 0.99987876
use O 0 0.0004236012
, O 0 0.00044641344
namely O 0 0.00048420572
first O 0 0.00033172074
- O 0 0.0016036503
time O 0 0.00047391848
users O 0 0.0018049678
, O 0 0.0015106042
repeaters O 0 0.02090718
and O 0 0.0030887392
switchers O 0 0.024835395
. O 0 0.0070198076

Data O 0 0.0040479465
from O 0 0.0023026404
a O 0 0.0022839983
Transnational O 0 0.004974825
case O 0 0.0016052794
- O 0 0.004729053
control O 0 0.0006274807
study O 0 0.000537512
were O 0 0.00031177409
used O 0 0.00021826787
to O 0 0.0001829771
assess O 0 0.00012571253
the O 0 0.00021854733
risk O 0 0.038010396
of O 0 0.004622891
VTE B-Disease 2 0.9999956
for O 0 0.0003409191
the O 0 0.00024427567
latter O 0 0.00042224253
patterns O 0 0.00020215237
of O 0 0.00030769204
use O 0 0.00034785148
, O 0 0.00048464118
while O 0 0.00044011362
accounting O 0 0.0009536653
for O 0 0.0007823951
duration O 0 0.0010806693
of O 0 0.002371755
use O 0 0.003898319
. O 0 0.0064009544

Over O 0 0.0043680626
the O 0 0.0024818932
period O 0 0.0018765759
1993 O 0 0.0065002963
- O 0 0.006035344
1996 O 0 0.0030406222
, O 0 0.001343607
551 O 0 0.011704482
cases O 0 0.0009996888
of O 0 0.0018301264
VTE B-Disease 2 0.9999838
were O 0 0.0005612977
identified O 0 0.00041449955
in O 0 0.0005028019
Germany O 0 0.0046119136
and O 0 0.0006240205
the O 0 0.0006950542
UK O 0 0.007405692
along O 0 0.0009827432
with O 0 0.0018457464
2066 O 0 0.025157118
controls O 0 0.0050683687
. O 0 0.007134265

Totals O 0 0.9139298
of O 0 0.0036027506
128 O 0 0.0033955553
cases O 0 0.0018893633
and O 0 0.0013063753
650 O 0 0.002186006
controls O 0 0.00080431724
were O 0 0.00048007522
analysed O 0 0.00037883723
for O 0 0.00035148166
repeat O 0 0.00047033254
use O 0 0.00036671295
and O 0 0.00042736286
135 O 0 0.00069724757
cases O 0 0.0005983775
and O 0 0.00071751885
622 O 0 0.0038404346
controls O 0 0.0012394948
for O 0 0.0014126388
switching O 0 0.0026692613
patterns O 0 0.0037585476
. O 0 0.006902887

The O 0 0.0029420252
adjusted O 0 0.002121314
rate O 0 0.0016800753
ratio O 0 0.0017238582
of O 0 0.0041329004
VTE B-Disease 2 0.9999857
for O 0 0.00079816004
repeat O 0 0.0009631852
users O 0 0.001165933
of O 0 0.0003303032
third O 0 0.00037256576
generation O 0 0.0009763378
OC B-Chemical 1 0.9998337
was O 0 0.00032596866
0 O 0 0.00025130992
. O 0 0.00016866368
6 O 0 0.00014633888
( O 0 0.00023512641
95 O 0 0.0003676053
% O 0 0.0003233625
CI O 0 0.21010455
: O 0 0.00040204308
0 O 0 0.00023410904
. O 0 0.00018160639
3 O 0 0.00018962285
- O 0 0.0008734571
1 O 0 0.00019445401
. O 0 0.00017098065
2 O 0 0.00017414786
) O 0 0.00023617272
relative O 0 0.00013720816
to O 0 0.00014472363
repeat O 0 0.00030872133
users O 0 0.00054754945
of O 0 0.00018453576
second O 0 0.00018101893
generation O 0 0.00048771998
pills O 0 0.5150361
, O 0 0.000406758
whereas O 0 0.00024424307
it O 0 0.00021222663
was O 0 0.00017955332
1 O 0 0.00016042248
. O 0 0.00014395852
3 O 0 0.00014250126
( O 0 0.00022496351
95 O 0 0.00036635145
% O 0 0.00031613448
CI O 0 0.21988454
: O 0 0.00038900247
0 O 0 0.00022466107
. O 0 0.00017504932
7 O 0 0.00018439471
- O 0 0.0008440012
2 O 0 0.00019164644
. O 0 0.00017267474
4 O 0 0.00016844863
) O 0 0.00027398564
for O 0 0.00018810044
switchers O 0 0.0008499791
from O 0 0.00014894268
second O 0 0.00015997034
to O 0 0.00015570656
third O 0 0.00023387079
generation O 0 0.00035293755
pills O 0 0.06050995
relative O 0 0.00022573875
to O 0 0.00028535005
switchers O 0 0.0012078615
from O 0 0.0003793963
third O 0 0.0006078728
to O 0 0.0007341428
second O 0 0.0013017283
generation O 0 0.0031270627
pills O 0 0.45172372
. O 0 0.0066949944

We O 0 0.0032433772
conclude O 0 0.0016943306
that O 0 0.0012585776
second O 0 0.0010296121
and O 0 0.00089131267
third O 0 0.0007011002
generation O 0 0.0006532964
agents O 0 0.00449307
are O 0 0.00033369366
associated O 0 0.00030837805
with O 0 0.0002767599
equivalent O 0 0.00024593255
risks O 0 0.013377125
of O 0 0.006267883
VTE B-Disease 2 0.9999963
when O 0 0.0001866971
the O 0 0.00017835207
same O 0 0.00012489823
agent O 0 0.0032291599
is O 0 0.00018384207
used O 0 0.0001350954
repeatedly O 0 0.00015609915
after O 0 0.00010632327
interruption O 0 0.00024531758
periods O 0 0.00015327304
or O 0 0.00017128207
when O 0 0.00017034473
users O 0 0.00061381195
are O 0 0.00023197621
switched O 0 0.0003138566
between O 0 0.00029680564
the O 0 0.000509262
two O 0 0.0006938771
generations O 0 0.0015417043
of O 0 0.0034919954
pills O 0 0.5654567
. O 0 0.007006173

These O 0 0.003245658
analyses O 0 0.0020332276
suggest O 0 0.001107972
that O 0 0.00096079626
the O 0 0.00087142753
higher O 0 0.0007946513
risk O 0 0.027024707
observed O 0 0.0004274509
for O 0 0.00038440074
the O 0 0.00045306823
newer O 0 0.16777119
OC B-Chemical 1 0.9998816
in O 0 0.00032569095
other O 0 0.00027070803
studies O 0 0.00022520451
may O 0 0.00017227612
be O 0 0.0001775969
the O 0 0.00016575879
result O 0 0.00016002219
of O 0 0.00023829461
inadequate O 0 0.00029279164
comparisons O 0 0.00022467993
of O 0 0.0005173356
pill O 0 0.66114557
users O 0 0.0014316636
with O 0 0.00043719437
different O 0 0.0005043994
patterns O 0 0.00084850786
of O 0 0.0020015514
pill O 0 0.58966374
use O 0 0.0040692408
. O 0 0.006343254

Differential O 0 0.0043634097
effects O 0 0.0027779047
of O 0 0.0020898627
systemically O 0 0.02624768
administered O 0 0.005958837
ketamine B-Chemical 0 0.99999
and O 0 0.007518701
lidocaine B-Chemical 0 0.99985516
on O 0 0.00029959148
dynamic O 0 0.0004840438
and O 0 0.00056663505
static O 0 0.004107941
hyperalgesia B-Disease 2 0.99973685
induced O 0 0.000932948
by O 0 0.0014593592
intradermal O 0 0.59564143
capsaicin B-Chemical 0 0.9997758
in O 0 0.003352972
humans O 0 0.014401227
. O 0 0.007277169

We O 0 0.0032432217
have O 0 0.0018526308
examined O 0 0.0011809219
the O 0 0.0010303701
effect O 0 0.00083943986
of O 0 0.00108412
systemic O 0 0.8363712
administration O 0 0.0690008
of O 0 0.008254776
ketamine B-Chemical 0 0.9999956
and O 0 0.007642666
lidocaine B-Chemical 0 0.99991834
on O 0 0.00018774586
brush O 0 0.026765356
- O 0 0.011656827
evoked O 0 0.0025838441
( O 0 0.00035980577
dynamic O 0 0.00032862215
) O 0 0.001026193
pain B-Disease 0 0.7070676
and O 0 0.000320686
punctate O 0 0.0008635379
- O 0 0.010081679
evoked O 0 0.005572754
( O 0 0.0009959665
static O 0 0.0022904167
) O 0 0.011721439
hyperalgesia B-Disease 2 0.9997578
induced O 0 0.0027484805
by O 0 0.005824986
capsaicin B-Chemical 0 0.9996437
. O 0 0.009556361

In O 0 0.0041246577
a O 0 0.0031175874
randomized O 0 0.00220911
, O 0 0.0019832037
double O 0 0.0016458107
- O 0 0.014476097
blind O 0 0.038707674
, O 0 0.001595496
placebo O 0 0.06337272
- O 0 0.0029300118
controlled O 0 0.0004187733
, O 0 0.0006280587
crossover O 0 0.0017504967
study O 0 0.0005552097
, O 0 0.0005289184
we O 0 0.00035396818
studied O 0 0.0005746317
12 O 0 0.00060527626
volunteers O 0 0.0011053012
in O 0 0.0012026231
three O 0 0.0015000405
experiments O 0 0.0027716008
. O 0 0.006567941

Capsaicin B-Chemical 1 0.99981683
100 O 0 0.0069553363
micrograms O 0 0.02509806
was O 0 0.0012403255
injected O 0 0.0007429683
intradermally O 0 0.0008619265
on O 0 0.0003235123
the O 0 0.00037542716
volar O 0 0.02101585
forearm O 0 0.035034623
followed O 0 0.00022522965
by O 0 0.0002673362
an O 0 0.00034487882
i O 0 0.002955853
. O 0 0.00026915927
v O 0 0.013526668
. O 0 0.0002434043
infusion O 0 0.00072187156
of O 0 0.0007595088
ketamine B-Chemical 0 0.99998176
( O 0 0.0009365647
bolus O 0 0.0021913117
0 O 0 0.0002121093
. O 0 0.0001428873
1 O 0 0.00015263306
mg O 0 0.0019522478
kg O 0 0.00064750004
- O 0 0.0011935334
1 O 0 0.00013374865
over O 0 8.667023e-05
10 O 0 0.00011300958
min O 0 0.00013697718
followed O 0 0.000106828054
by O 0 0.00014427886
infusion O 0 0.00024696926
of O 0 0.00016825921
7 O 0 0.00014148756
micrograms O 0 0.0010709317
kg O 0 0.0009623281
- O 0 0.00248346
1 O 0 0.00018047968
min O 0 0.00029235735
- O 0 0.0014437463
1 O 0 0.00022266398
) O 0 0.0004830154
, O 0 0.0007828943
lidocaine B-Chemical 0 0.99953544
5 O 0 0.00024756003
mg O 0 0.004683947
kg O 0 0.00097173406
- O 0 0.00162257
1 O 0 0.00045270842
or O 0 0.0005632658
saline O 0 0.0020546783
for O 0 0.001215565
50 O 0 0.0022292614
min O 0 0.0037232433
. O 0 0.0062174373

Infusion O 0 0.025640955
started O 0 0.0058537167
15 O 0 0.004395839
min O 0 0.004874685
after O 0 0.004224928
injection O 0 0.007966679
of O 0 0.012219068
capsaicin B-Chemical 0 0.99946135
. O 0 0.019433802

The O 0 0.0030125552
following O 0 0.001875017
were O 0 0.0014456187
measured O 0 0.0010225509
: O 0 0.0015945581
spontaneous O 0 0.01477445
pain B-Disease 0 0.9707245
, O 0 0.001613986
pain B-Disease 0 0.83847183
evoked O 0 0.0018618435
by O 0 0.00028377486
punctate O 0 0.00037638107
and O 0 0.0003149513
brush O 0 0.0027403685
stimuli O 0 0.0006559532
( O 0 0.0010571451
VAS O 0 0.04387066
) O 0 0.0004903801
, O 0 0.00033939656
and O 0 0.00029981206
areas O 0 0.0006140003
of O 0 0.0005069753
brush O 0 0.023422476
- O 0 0.00833857
evoked O 0 0.0026540363
and O 0 0.0009512034
punctate O 0 0.0028240196
- O 0 0.05671219
evoked O 0 0.26886642
hyperalgesia B-Disease 2 0.9997677
. O 0 0.00871688

Ketamine B-Chemical 1 0.99969435
reduced O 0 0.0031751404
both O 0 0.001665785
the O 0 0.0011092932
area O 0 0.0013109248
of O 0 0.0010946878
brush O 0 0.043538414
- O 0 0.011946072
evoked O 0 0.0029576637
and O 0 0.0004970706
punctate O 0 0.001483367
- O 0 0.034141168
evoked O 0 0.08489795
hyperalgesia B-Disease 2 0.9998895
significantly O 0 0.00048403983
and O 0 0.00042346632
it O 0 0.00040724516
tended O 0 0.0003758762
to O 0 0.0004270764
reduce O 0 0.00063420343
brush O 0 0.023286987
- O 0 0.037775025
evoked O 0 0.09652103
pain B-Disease 0 0.94587845
. O 0 0.0073479754

Lidocaine B-Chemical 0 0.9996824
reduced O 0 0.0048434236
the O 0 0.0031688607
area O 0 0.003603817
of O 0 0.0033763587
punctate O 0 0.006379017
- O 0 0.07201078
evoked O 0 0.35122076
hyperalgesia B-Disease 2 0.9998373
significantly O 0 0.009414635
. O 0 0.011352944

It O 0 0.0051553072
tended O 0 0.0026173152
to O 0 0.001755199
reduce O 0 0.0013417507
VAS O 0 0.005762563
scores O 0 0.00089594215
of O 0 0.0010140826
spontaneous O 0 0.012926907
pain B-Disease 0 0.9317023
but O 0 0.0009730522
had O 0 0.00074784696
no O 0 0.0007373526
effect O 0 0.0011868129
on O 0 0.0016693661
evoked O 0 0.08793315
pain B-Disease 0 0.9658802
. O 0 0.008276919

The O 0 0.0029479126
differential O 0 0.002330539
effects O 0 0.0021938696
of O 0 0.004100884
ketamine B-Chemical 0 0.99999034
and O 0 0.01551609
lidocaine B-Chemical 0 0.9999174
on O 0 0.00030017472
static O 0 0.00063630065
and O 0 0.0003883835
dynamic O 0 0.00073663524
hyperalgesia B-Disease 2 0.9993082
suggest O 0 0.00015455278
that O 0 0.00015975525
the O 0 0.00017628902
two O 0 0.00014877733
types O 0 0.00017919739
of O 0 0.00061674253
hyperalgesia B-Disease 2 0.9997025
are O 0 0.00024515387
mediated O 0 0.00018816431
by O 0 0.00028643486
separate O 0 0.00023747829
mechanisms O 0 0.00036934958
and O 0 0.0006463
have O 0 0.0008160652
a O 0 0.0015618795
distinct O 0 0.0022062461
pharmacology O 0 0.01952711
. O 0 0.0063211597

Development O 0 0.027766168
of O 0 0.018838601
apomorphine B-Chemical 1 0.99999774
- O 0 0.22948784
induced O 0 0.0030527753
aggressive B-Disease 2 0.91401047
behavior I-Disease 2 0.1728604
: O 0 0.0015163386
comparison O 0 0.00067379896
of O 0 0.0009465457
adult O 0 0.0015931344
male O 0 0.0037346592
and O 0 0.002016143
female O 0 0.010848643
Wistar O 0 0.035855927
rats O 0 0.005853395
. O 0 0.0073678405

The O 0 0.003253696
development O 0 0.0041310596
of O 0 0.013554017
apomorphine B-Chemical 1 0.9999989
- O 0 0.2071237
induced O 0 0.0012430258
( O 0 0.0015430703
1 O 0 0.00046241155
. O 0 0.00031340544
0 O 0 0.00033582907
mg O 0 0.004159555
/ O 0 0.0007862116
kg O 0 0.00053334783
s O 0 0.0003534197
. O 0 0.00023600551
c O 0 0.0021192716
. O 0 0.00020810003
once O 0 0.00016513754
daily O 0 0.00027110343
) O 0 0.0007358726
aggressive B-Disease 2 0.44646233
behavior I-Disease 2 0.020042004
of O 0 0.00034582854
adult O 0 0.00063772406
male O 0 0.00248519
and O 0 0.00033904955
female O 0 0.0028191227
Wistar O 0 0.0055834563
rats O 0 0.00025644177
obtained O 0 0.00017430335
from O 0 0.00019306659
the O 0 0.00024296189
same O 0 0.00025437484
breeder O 0 0.001209156
was O 0 0.00047529736
studied O 0 0.0006035961
in O 0 0.0007576373
two O 0 0.0009942387
consecutive O 0 0.001707761
sets O 0 0.0029639418
. O 0 0.0060562044

In O 0 0.0041339383
male O 0 0.0048805145
animals O 0 0.0017362846
, O 0 0.0019989507
repeated O 0 0.0013072958
apomorphine B-Chemical 1 0.99999547
treatment O 0 0.0014770663
induced O 0 0.0005748804
a O 0 0.0005661449
gradual O 0 0.00042327546
development O 0 0.0011429295
of O 0 0.0010146652
aggressive B-Disease 2 0.8668715
behavior I-Disease 2 0.050925303
as O 0 0.00020595084
evidenced O 0 0.00041975168
by O 0 0.00019334716
the O 0 0.0001625145
increased O 0 0.00019163036
intensity O 0 0.00019621669
of O 0 0.0005214757
aggressiveness B-Disease 2 0.9897121
and O 0 0.0004170449
shortened O 0 0.00034424616
latency O 0 0.0005474474
before O 0 0.00025259968
the O 0 0.00041521617
first O 0 0.00057672855
attack O 0 0.09007787
toward O 0 0.0017656634
the O 0 0.0027251535
opponent O 0 0.18151118
. O 0 0.007071355

In O 0 0.0056407265
female O 0 0.006825021
rats O 0 0.0042422623
, O 0 0.003067134
only O 0 0.00213013
a O 0 0.0021905277
weak O 0 0.0036795542
tendency O 0 0.0028268157
toward O 0 0.0032119881
aggressiveness B-Disease 2 0.9832375
was O 0 0.004618814
found O 0 0.0054343813
. O 0 0.009348725

In O 0 0.0036100445
conclusion O 0 0.002104903
, O 0 0.0020679997
the O 0 0.0010546795
present O 0 0.0006644637
study O 0 0.0007124079
demonstrates O 0 0.0003747395
gender O 0 0.002088493
differences O 0 0.0002429524
in O 0 0.00024507023
the O 0 0.00022625935
development O 0 0.0005711251
of O 0 0.0005645211
the O 0 0.0034964003
apomorphine B-Chemical 1 0.99999964
- O 0 0.13920781
induced O 0 0.00077920186
aggressive B-Disease 2 0.9284317
behavior I-Disease 2 0.10531286
and O 0 0.00031681306
indicates O 0 0.00015739123
that O 0 0.00014154679
the O 0 0.00020184882
female O 0 0.0010885089
rats O 0 0.00030397793
do O 0 0.00016655143
not O 0 0.00014765785
fill O 0 0.00015249953
the O 0 0.00020296256
validation O 0 0.0003181657
criteria O 0 0.00042066563
for O 0 0.0005203129
use O 0 0.00083499117
in O 0 0.0012186934
this O 0 0.002032932
method O 0 0.004479339
. O 0 0.0066819857

Intracranial B-Disease 0 0.9935731
aneurysms I-Disease 2 0.9998517
and O 0 0.052929483
cocaine B-Disease 0 0.999998
abuse I-Disease 2 0.9998628
: O 0 0.0054904283
analysis O 0 0.003067112
of O 0 0.0038689387
prognostic O 0 0.006822765
indicators O 0 0.006474305
. O 0 0.010775795

OBJECTIVE O 0 0.019689819
: O 0 0.0040944368
The O 0 0.0019232112
outcome O 0 0.0024357536
of O 0 0.003440511
subarachnoid B-Disease 0 0.9999155
hemorrhage I-Disease 2 0.9999914
associated O 0 0.00432407
with O 0 0.024692848
cocaine B-Disease 0 0.9999994
abuse I-Disease 2 0.99993634
is O 0 0.004153302
reportedly O 0 0.041449
poor O 0 0.016179506
. O 0 0.0084489295

However O 0 0.004615674
, O 0 0.003312103
no O 0 0.0015182766
study O 0 0.0014403282
in O 0 0.00086740794
the O 0 0.00066423137
literature O 0 0.0008209922
has O 0 0.0004309459
reported O 0 0.00044076506
the O 0 0.00031257232
use O 0 0.00030657346
of O 0 0.00035124537
a O 0 0.00038066218
statistical O 0 0.0005027947
model O 0 0.00033033532
to O 0 0.00030592646
analyze O 0 0.00029160766
the O 0 0.0004936831
variables O 0 0.00081617053
that O 0 0.0009929531
influence O 0 0.0017174066
outcome O 0 0.0058617806
. O 0 0.00672481

METHODS O 0 0.004460634
: O 0 0.004463149
A O 0 0.007655392
review O 0 0.0024439192
of O 0 0.0015772054
admissions O 0 0.0024794515
during O 0 0.0006866251
a O 0 0.00083781854
6 O 0 0.00052555074
- O 0 0.0010383921
year O 0 0.00042708535
period O 0 0.00034503802
revealed O 0 0.0004146203
14 O 0 0.00049972866
patients O 0 0.0007917193
with O 0 0.0017430816
cocaine B-Chemical 1 0.99997604
- O 0 0.047001056
related O 0 0.0030739945
aneurysms B-Disease 2 0.997755
. O 0 0.007853949

This O 0 0.0055333357
group O 0 0.0030199315
was O 0 0.0016971291
compared O 0 0.0008857783
with O 0 0.00086901046
a O 0 0.0008070213
control O 0 0.0005496175
group O 0 0.0005403985
of O 0 0.000473191
135 O 0 0.0008475657
patients O 0 0.00050025526
with O 0 0.0006846034
ruptured B-Disease 0 0.9958026
aneurysms I-Disease 2 0.9999505
and O 0 0.00075535924
no O 0 0.00061454956
history O 0 0.016596228
of O 0 0.03829385
cocaine B-Disease 0 0.99999905
abuse I-Disease 2 0.9999256
. O 0 0.011101919

Age O 0 0.03520912
at O 0 0.0025759032
presentation O 0 0.0024983804
, O 0 0.0016381402
time O 0 0.00078356644
of O 0 0.0012144789
ictus O 0 0.6810433
after O 0 0.0004880625
intoxication O 0 0.99926335
, O 0 0.001559751
Hunt O 0 0.074235074
and O 0 0.0005443408
Hess O 0 0.3561255
grade O 0 0.077906445
of O 0 0.0042610844
subarachnoid B-Disease 0 0.9999763
hemorrhage I-Disease 2 0.9999962
, O 0 0.0006761398
size O 0 0.00029346682
of O 0 0.00029921727
the O 0 0.00037511945
aneurysm B-Disease 2 0.9982761
, O 0 0.0004289164
location O 0 0.00018805168
of O 0 0.00027090526
the O 0 0.00036127062
aneurysm B-Disease 2 0.9977551
, O 0 0.00053888065
and O 0 0.00031937708
the O 0 0.00032377738
Glasgow O 0 0.009110391
Outcome O 0 0.00056479475
Scale O 0 0.004288359
score O 0 0.00052786875
were O 0 0.0007478915
assessed O 0 0.0010281957
and O 0 0.0020593922
compared O 0 0.0030032173
. O 0 0.0066802907

RESULTS O 0 0.0055102957
: O 0 0.0035157036
The O 0 0.0016385091
patients O 0 0.0014956518
in O 0 0.0009337403
the O 0 0.0007177356
study O 0 0.00073891564
group O 0 0.00058364606
were O 0 0.0003618366
significantly O 0 0.0003377034
younger O 0 0.0018553152
than O 0 0.00018460685
the O 0 0.0002123412
patients O 0 0.0003013561
in O 0 0.00022230166
the O 0 0.00024968132
control O 0 0.00033822437
group O 0 0.0006208491
( O 0 0.001013512
P O 0 0.023625968
< O 0 0.0008920428
0 O 0 0.0014196761
. O 0 0.0020382397
002 O 0 0.04711742
) O 0 0.0063250973
. O 0 0.0081757335

In O 0 0.0043758648
patients O 0 0.0032175072
in O 0 0.00197042
the O 0 0.0015038848
study O 0 0.001543938
group O 0 0.0013740034
, O 0 0.001287189
all O 0 0.0009949009
aneurysms B-Disease 2 0.9870516
were O 0 0.0008602663
located O 0 0.0008817964
in O 0 0.0012060526
the O 0 0.0019271051
anterior O 0 0.020578595
circulation O 0 0.01095582
. O 0 0.007928281

The O 0 0.0030261169
majority O 0 0.0020798272
of O 0 0.0017931372
these O 0 0.001833654
aneurysms B-Disease 2 0.995227
were O 0 0.0007217519
smaller O 0 0.00043164816
than O 0 0.00026876226
those O 0 0.00030291508
of O 0 0.00027242408
the O 0 0.00022483272
control O 0 0.00024187191
group O 0 0.0003483486
( O 0 0.00039860408
8 O 0 0.00022362202
+ O 0 0.0010119717
/ O 0 0.007876812
- O 0 0.0061715213
6 O 0 0.00017360471
. O 0 0.00018640874
08 O 0 0.0017289706
mm O 0 0.00032545815
versus O 0 0.00019125706
11 O 0 0.0002524116
+ O 0 0.00074599264
/ O 0 0.004209481
- O 0 0.0033906775
5 O 0 0.0002476677
. O 0 0.00025961405
4 O 0 0.00029285866
mm O 0 0.00074413104
; O 0 0.0010614061
P O 0 0.016490659
= O 0 0.0017937672
0 O 0 0.0017589863
. O 0 0.002421993
05 O 0 0.0113257505
) O 0 0.006827368
. O 0 0.008862221

The O 0 0.0035234953
differences O 0 0.0023055528
in O 0 0.0022305343
mortality O 0 0.11557411
and O 0 0.0022794737
morbidity O 0 0.24390304
between O 0 0.0009593474
the O 0 0.0010463928
two O 0 0.0010116049
groups O 0 0.0014151738
were O 0 0.0018562372
not O 0 0.0025873722
significant O 0 0.0046075336
. O 0 0.008447676

Hunt O 0 0.031572286
and O 0 0.004476707
Hess O 0 0.32422203
grade O 0 0.1304232
( O 0 0.0035066162
P O 0 0.0761956
< O 0 0.0008369695
0 O 0 0.0007873279
. O 0 0.0005945711
005 O 0 0.011021307
) O 0 0.00068674027
and O 0 0.00042634827
age O 0 0.0008855221
( O 0 0.0008732849
P O 0 0.042345062
< O 0 0.0002910394
0 O 0 0.00033703953
. O 0 0.00028687817
007 O 0 0.012649856
) O 0 0.00042561267
were O 0 0.00021599657
significant O 0 0.00019320063
predictors O 0 0.00018913059
of O 0 0.00026578593
outcome O 0 0.00052171183
for O 0 0.00028376188
the O 0 0.00036863863
patients O 0 0.0009470463
with O 0 0.0025299222
cocaine B-Chemical 1 0.99998426
- O 0 0.05504315
related O 0 0.0027019433
aneurysms B-Disease 2 0.9978542
. O 0 0.007171896

CONCLUSION O 0 0.09410456
: O 0 0.019854821
Cocaine B-Chemical 0 0.99998176
use O 0 0.0053290166
predisposed O 0 0.89900213
aneurysmal B-Disease 0 0.9999989
rupture I-Disease 0 0.9999697
at O 0 0.00085366855
a O 0 0.00076776603
significantly O 0 0.0005611003
earlier O 0 0.00061148044
age O 0 0.0009900098
and O 0 0.000979123
in O 0 0.0012446607
much O 0 0.0017217103
smaller O 0 0.0033669982
aneurysms B-Disease 2 0.9957361
. O 0 0.0080378065

Contrary O 0 0.0034969652
to O 0 0.0023726714
the O 0 0.001843792
published O 0 0.0015991513
literature O 0 0.0017681934
, O 0 0.0015107953
this O 0 0.0010224602
group O 0 0.0011819319
did O 0 0.0010508726
reasonably O 0 0.0012954286
well O 0 0.0013266362
with O 0 0.002282082
aggressive O 0 0.06027225
management O 0 0.0068269284
. O 0 0.007899216

Effect O 0 0.0050520273
of O 0 0.0047208956
intravenous O 0 0.76949894
nimodipine B-Chemical 0 0.9999968
on O 0 0.0014827091
blood O 0 0.018887607
pressure O 0 0.03293547
and O 0 0.0015700497
outcome O 0 0.0029987006
after O 0 0.002375678
acute B-Disease 0 0.9992448
stroke I-Disease 2 0.9999845
. O 0 0.015222752

BACKGROUND O 0 0.009999376
AND O 0 0.0027650043
PURPOSE O 0 0.0025638286
: O 0 0.0021461658
The O 0 0.0013825117
Intravenous O 0 0.8515327
Nimodipine B-Chemical 0 0.99999905
West O 0 0.13416117
European O 0 0.0359972
Stroke B-Disease 0 0.9968556
Trial O 0 0.004003222
( O 0 0.0006907175
INWEST O 0 0.15051542
) O 0 0.00046291566
found O 0 0.0001943128
a O 0 0.00021790939
correlation O 0 0.00017114035
between O 0 0.0003177274
nimodipine B-Chemical 0 0.99999976
- O 0 0.07283987
induced O 0 0.00032976142
reduction B-Disease 0 0.0010103547
in I-Disease 0 0.00032307344
blood I-Disease 0 0.032817625
pressure I-Disease 0 0.13407539
( O 0 0.0015062339
BP O 0 0.9497381
) O 0 0.0006423214
and O 0 0.0004275473
an O 0 0.00057148066
unfavorable O 0 0.020508928
outcome O 0 0.0035105671
in O 0 0.0027565784
acute B-Disease 0 0.9995745
stroke I-Disease 2 0.9999883
. O 0 0.013217217

We O 0 0.003286211
sought O 0 0.002158759
to O 0 0.0012685485
confirm O 0 0.0006742386
this O 0 0.00062418444
correlation O 0 0.00043219537
with O 0 0.00045934092
and O 0 0.00041748682
without O 0 0.00028785627
adjustment O 0 0.00034201992
for O 0 0.00020569454
prognostic O 0 0.0004924043
variables O 0 0.00023508695
and O 0 0.0001939663
to O 0 0.00014723452
investigate O 0 0.00011104934
outcome O 0 0.00036854114
in O 0 0.00024332262
subgroups O 0 0.00045136764
with O 0 0.0004148378
increasing O 0 0.00061655685
levels O 0 0.0010744834
of O 0 0.005741026
BP B-Disease 0 0.99946254
reduction I-Disease 0 0.13218623
. O 0 0.007721193

METHODS O 0 0.004042679
: O 0 0.003602987
Patients O 0 0.0021586942
with O 0 0.0013534892
a O 0 0.0012736358
clinical O 0 0.001943285
diagnosis O 0 0.0045834463
of O 0 0.013936052
ischemic B-Disease 2 0.99999976
stroke I-Disease 2 0.9999995
( O 0 0.003141481
within O 0 0.00018371169
24 O 0 0.00021162105
hours O 0 0.00015471216
) O 0 0.00026519567
were O 0 0.00015345144
consecutively O 0 0.00014963467
allocated O 0 0.000108400236
to O 0 0.00011239603
receive O 0 0.00011937116
placebo O 0 0.0024150421
( O 0 0.00023616618
n O 0 0.00016509251
= O 0 0.00045156816
100 O 0 0.0004186673
) O 0 0.00044217988
, O 0 0.0002903363
1 O 0 0.00018779651
mg O 0 0.007412336
/ O 0 0.0013673262
h O 0 0.0002885352
( O 0 0.00039770716
low O 0 0.0005436386
- O 0 0.012928605
dose O 0 0.010298609
) O 0 0.034801114
nimodipine B-Chemical 0 0.9999994
( O 0 0.00082226255
n O 0 0.00021930168
= O 0 0.00058706466
101 O 0 0.001378724
) O 0 0.0004406556
, O 0 0.0002745819
or O 0 0.0001901856
2 O 0 0.00020559062
mg O 0 0.0076142712
/ O 0 0.0012994224
h O 0 0.00034284586
( O 0 0.00048796454
high O 0 0.0006928163
- O 0 0.011758191
dose O 0 0.013093206
) O 0 0.032483544
nimodipine B-Chemical 0 0.9999982
( O 0 0.0018155365
n O 0 0.0011873704
= O 0 0.0025750333
94 O 0 0.0035596308
) O 0 0.005592155
. O 0 0.007562192

The O 0 0.0027837297
correlation O 0 0.0017174409
between O 0 0.0012643586
average O 0 0.0011051123
BP O 0 0.80499357
change O 0 0.0007857011
during O 0 0.00041374937
the O 0 0.00039903022
first O 0 0.00031498945
2 O 0 0.00032339853
days O 0 0.00025668318
and O 0 0.0003814959
the O 0 0.0004225641
outcome O 0 0.0007469246
at O 0 0.0006278463
day O 0 0.00087383843
21 O 0 0.0015102372
was O 0 0.002096527
analyzed O 0 0.0034978841
. O 0 0.0069378074

RESULTS O 0 0.0058549955
: O 0 0.0036666878
Two O 0 0.0020156913
hundred O 0 0.0016529866
sixty O 0 0.0016666736
- O 0 0.0020126423
five O 0 0.0005631024
patients O 0 0.0005998768
were O 0 0.00039374354
included O 0 0.00028750303
in O 0 0.0002634786
this O 0 0.00023956576
analysis O 0 0.0002709094
( O 0 0.00037464235
n O 0 0.00026058414
= O 0 0.0005832112
92 O 0 0.00056949764
, O 0 0.00037167376
93 O 0 0.00053687964
, O 0 0.00029274225
and O 0 0.00024277571
80 O 0 0.00026063854
for O 0 0.00023482171
placebo O 0 0.006505157
, O 0 0.0003677934
low O 0 0.0004199444
dose O 0 0.0017273567
, O 0 0.00063226704
and O 0 0.00062087865
high O 0 0.0011540471
dose O 0 0.006289968
, O 0 0.002470876
respectively O 0 0.0072025117
) O 0 0.0071151056
. O 0 0.007387438

Nimodipine B-Chemical 0 0.9999895
treatment O 0 0.0049510696
resulted O 0 0.0015472989
in O 0 0.0011258868
a O 0 0.0010025349
statistically O 0 0.0005750189
significant O 0 0.00051791605
reduction B-Disease 0 0.00092535967
in I-Disease 0 0.00061548006
systolic I-Disease 0 0.9632337
BP I-Disease 0 0.994732
( O 0 0.0019099205
SBP O 0 0.7456239
) O 0 0.00067088474
and O 0 0.0004603465
diastolic O 0 0.9817616
BP O 0 0.9929877
( O 0 0.0020761923
DBP O 0 0.9261018
) O 0 0.00043992218
from O 0 0.00019744634
baseline O 0 0.000219576
compared O 0 0.00019957531
with O 0 0.0003623088
placebo O 0 0.0014367905
during O 0 0.00040049196
the O 0 0.0006691243
first O 0 0.0009006483
few O 0 0.0014556741
days O 0 0.002489956
. O 0 0.0056630727

In O 0 0.0034568761
multivariate O 0 0.0044039977
analysis O 0 0.0019217472
, O 0 0.0016807177
a O 0 0.0010189798
significant O 0 0.0006129672
correlation O 0 0.00043571004
between O 0 0.00049677904
DBP B-Disease 0 0.99946886
reduction I-Disease 0 0.045937497
and O 0 0.0006509188
worsening O 0 0.14287513
of O 0 0.00038152022
the O 0 0.00030871076
neurological O 0 0.77922416
score O 0 0.00019069984
was O 0 0.00015082375
found O 0 0.00012693963
for O 0 0.00013599705
the O 0 0.00016868154
high O 0 0.0005005133
- O 0 0.0071550068
dose O 0 0.0016784837
group O 0 0.00051839097
( O 0 0.0011145194
beta O 0 0.9092693
= O 0 0.004049035
0 O 0 0.0004301829
. O 0 0.0003341916
49 O 0 0.00060842634
, O 0 0.0007572973
P O 0 0.021616057
= O 0 0.0016081325
0 O 0 0.0015027827
. O 0 0.0020751334
048 O 0 0.045081932
) O 0 0.0064190915
. O 0 0.008344173

Patients O 0 0.0045495806
with O 0 0.002721337
a O 0 0.004105008
DBP B-Disease 0 0.9983858
reduction I-Disease 0 0.031818807
of O 0 0.0013125445
> O 0 0.0022801743
or O 0 0.0005640121
= O 0 0.00088773563
20 O 0 0.00032002508
% O 0 0.00031040917
in O 0 0.00022202438
the O 0 0.00022953295
high O 0 0.0005789581
- O 0 0.007950798
dose O 0 0.0017440129
group O 0 0.00034993066
had O 0 0.0001843903
a O 0 0.00022281751
significantly O 0 0.00018350124
increased O 0 0.00021217405
adjusted O 0 0.00041736627
OR O 0 0.20579241
for O 0 0.00017782429
the O 0 0.0001972751
compound O 0 0.086678185
outcome O 0 0.00085592427
variable O 0 0.0004937765
death B-Disease 0 0.9975629
or O 0 0.0002795503
dependency O 0 0.0005996579
( O 0 0.00037393015
Barthel O 0 0.0003538939
Index O 0 0.00022170538
< O 0 0.00012905104
60 O 0 0.00015827404
) O 0 0.00026039316
( O 0 0.00025716453
n O 0 0.00022077048
/ O 0 0.010574878
N O 0 0.99829537
= O 0 0.0018187949
25 O 0 0.00036421523
/ O 0 0.001084902
26 O 0 0.00035667568
, O 0 0.00038846178
OR O 0 0.0498
10 O 0 0.00020797507
. O 0 0.00017979043
16 O 0 0.00020799908
, O 0 0.00024313942
95 O 0 0.0004247795
% O 0 0.00036490997
CI O 0 0.22780593
1 O 0 0.00023697597
. O 0 0.00021734039
02 O 0 0.003175276
to O 0 0.0001711459
101 O 0 0.0005666108
. O 0 0.0001830757
74 O 0 0.00030576374
) O 0 0.00037760678
and O 0 0.00039075527
death B-Disease 0 0.99682873
alone O 0 0.0004394963
( O 0 0.0005231714
n O 0 0.00027893978
/ O 0 0.024630519
N O 0 0.9989635
= O 0 0.0024385927
9 O 0 0.00026226407
/ O 0 0.0008727749
26 O 0 0.0003490715
, O 0 0.0003960952
OR O 0 0.058804736
4 O 0 0.00020757627
. O 0 0.00021103631
336 O 0 0.0015500233
, O 0 0.00028610788
95 O 0 0.0004638004
% O 0 0.00036779972
CI O 0 0.19869788
1 O 0 0.00022094272
. O 0 0.00018907434
131 O 0 0.00044106194
16 O 0 0.0002217077
. O 0 0.00020180477
619 O 0 0.005173976
) O 0 0.00030133085
compared O 0 0.00013301948
with O 0 0.00018289928
all O 0 0.00018618547
placebo O 0 0.0025381034
patients O 0 0.00027257946
( O 0 0.00029942018
n O 0 0.00025643932
/ O 0 0.01481175
N O 0 0.99846303
= O 0 0.0022133538
62 O 0 0.00071961735
/ O 0 0.0010276684
92 O 0 0.000645365
and O 0 0.00051616924
14 O 0 0.0006621589
/ O 0 0.0016072845
92 O 0 0.0019351706
, O 0 0.002250077
respectively O 0 0.004751128
) O 0 0.006890656
. O 0 0.008296685

There O 0 0.00690844
was O 0 0.0047527854
no O 0 0.0031480733
correlation O 0 0.003031447
between O 0 0.003548678
SBP O 0 0.3277982
change O 0 0.0052405144
and O 0 0.006631029
outcome O 0 0.01201456
. O 0 0.013075842

CONCLUSIONS O 0 0.075221464
: O 0 0.009519293
DBP O 0 0.9558394
, O 0 0.0033924405
but O 0 0.0018143377
not O 0 0.0011477706
SBP O 0 0.77645165
, O 0 0.0011721132
reduction O 0 0.000999007
was O 0 0.0004246653
associated O 0 0.00039217225
with O 0 0.0005363188
neurological O 0 0.9424517
worsening O 0 0.16180879
after O 0 0.000153696
the O 0 0.00022838164
intravenous O 0 0.014855915
administration O 0 0.0015425012
of O 0 0.00044910843
high O 0 0.0024310849
- O 0 0.1037773
dose O 0 0.3147415
nimodipine B-Chemical 0 0.99999917
after O 0 0.002395201
acute B-Disease 0 0.999754
stroke I-Disease 2 0.99999034
. O 0 0.013097939

For O 0 0.005298795
low O 0 0.0061908835
- O 0 0.037382595
dose O 0 0.3025176
nimodipine B-Chemical 0 0.99999774
, O 0 0.0046158843
the O 0 0.0022460949
results O 0 0.0023772258
were O 0 0.0030836058
not O 0 0.0040919194
conclusive O 0 0.009284267
. O 0 0.010318399

These O 0 0.004834138
results O 0 0.0032345976
do O 0 0.0025607515
not O 0 0.0017226761
confirm O 0 0.0011706015
or O 0 0.0014566365
exclude O 0 0.0013472453
a O 0 0.0024037275
neuroprotective O 0 0.33823407
property O 0 0.010538966
of O 0 0.040783666
nimodipine B-Chemical 0 0.99999535
. O 0 0.013613579

Neonatal O 0 0.46727723
pyridoxine B-Chemical 1 0.9999846
responsive O 0 0.018560352
convulsions B-Disease 0 0.9999616
due O 0 0.0050777425
to O 0 0.0072718216
isoniazid B-Chemical 1 0.99998105
therapy O 0 0.07478921
. O 0 0.013747026

A O 1 0.61040556
17 O 1 0.010961056
- O 0 0.0071404087
day O 0 0.0016100906
- O 0 0.0032620248
old O 0 0.0010022551
infant O 0 0.002020003
on O 0 0.00062345364
isoniazid B-Chemical 1 0.99999654
therapy O 0 0.005822164
13 O 0 0.0005238948
mg O 0 0.020392535
/ O 0 0.0012127253
kg O 0 0.00061644876
daily O 0 0.00024018557
from O 0 0.0001727604
birth O 0 0.00048277536
because O 0 0.00018314744
of O 0 0.00033901754
maternal O 0 0.009952502
tuberculosis B-Disease 2 0.97556543
was O 0 0.0005388401
admitted O 0 0.00079809164
after O 0 0.00033304625
4 O 0 0.0005300948
days O 0 0.0007590027
of O 0 0.0030165205
clonic B-Disease 0 0.99999034
fits I-Disease 0 0.8142523
. O 0 0.008230141

No O 0 0.008943473
underlying O 0 0.006362416
infective O 0 0.06455615
or O 0 0.004121721
biochemical O 0 0.008099264
cause O 0 0.0046902806
could O 0 0.0037316228
be O 0 0.00526593
found O 0 0.006910962
. O 0 0.011807656

The O 0 0.0034801646
fits B-Disease 0 0.004947941
ceased O 0 0.0024531854
within O 0 0.0008802044
4 O 0 0.0007288758
hours O 0 0.0005115231
of O 0 0.0005943323
administering O 0 0.004207185
intramuscular O 0 0.81068355
pyridoxine B-Chemical 1 0.9999995
, O 0 0.0017335246
suggesting O 0 0.00032946476
an O 0 0.00054888293
aetiology O 0 0.12151335
of O 0 0.020729745
pyridoxine B-Chemical 1 0.99999964
deficiency O 0 0.9524282
secondary O 0 0.18189098
to O 0 0.004280084
isoniazid B-Chemical 1 0.9999958
medication O 0 0.53654516
. O 0 0.0064375107

Ketamine B-Chemical 1 0.99982625
sedation O 0 0.33712155
for O 0 0.0020699766
the O 0 0.00147862
reduction O 0 0.0016054744
of O 0 0.0013044981
children O 0 0.0022854144
' O 0 0.0017922028
s O 0 0.0019670152
fractures B-Disease 2 0.9815524
in O 0 0.0017873504
the O 0 0.002391383
emergency O 0 0.009912611
department O 0 0.011492154
. O 0 0.008410464

BACKGROUND O 0 0.016365547
: O 0 0.003967183
There O 0 0.002218963
recently O 0 0.0015918677
has O 0 0.0010792511
been O 0 0.0008942649
a O 0 0.0008505032
resurgence O 0 0.0027103748
in O 0 0.00049642124
the O 0 0.00039282328
utilization O 0 0.0006068285
of O 0 0.0013822101
ketamine B-Chemical 0 0.9999846
, O 0 0.0008006903
a O 0 0.000425912
unique O 0 0.00041770202
anesthetic O 0 0.0390053
, O 0 0.0005105827
for O 0 0.0004557086
emergency O 0 0.0009902172
- O 0 0.0020321133
department O 0 0.001260592
procedures O 0 0.0014603323
requiring O 0 0.0025334791
sedation O 0 0.076079406
. O 0 0.0062759276

The O 0 0.0030406395
purpose O 0 0.0021062293
of O 0 0.001579212
the O 0 0.0010333498
present O 0 0.00066800235
study O 0 0.0007134447
was O 0 0.0004200241
to O 0 0.00026074043
examine O 0 0.00015162895
the O 0 0.0002095943
safety O 0 0.00029003638
and O 0 0.00021899183
efficacy O 0 0.00037385657
of O 0 0.0008556633
ketamine B-Chemical 0 0.9999788
for O 0 0.00038272658
sedation O 0 0.065318115
in O 0 0.0001749911
the O 0 0.00018263965
treatment O 0 0.00024923537
of O 0 0.0003346947
children O 0 0.0009996236
' O 0 0.00082441146
s O 0 0.0010302003
fractures B-Disease 2 0.9820385
in O 0 0.0010611183
the O 0 0.0015900113
emergency O 0 0.008499898
department O 0 0.009531016
. O 0 0.006763495

METHODS O 0 0.0041211294
: O 0 0.0036259964
One O 0 0.00223023
hundred O 0 0.0015168692
and O 0 0.0011902653
fourteen O 0 0.0011158958
children O 0 0.0011154201
( O 0 0.0007550033
average O 0 0.00035031931
age O 0 0.0007643055
, O 0 0.00051081367
5 O 0 0.0002613507
. O 0 0.00022873098
3 O 0 0.00019488002
years O 0 0.00023952693
; O 0 0.00029525647
range O 0 0.00021437243
, O 0 0.0002389601
twelve O 0 0.00015692637
months O 0 0.00011352359
to O 0 0.000112752314
ten O 0 0.00011099228
years O 0 0.00015331719
and O 0 0.00014658915
ten O 0 0.0001166236
months O 0 0.00012082821
) O 0 0.0002446985
who O 0 0.00020844616
underwent O 0 0.00014791207
closed O 0 0.00031715454
reduction O 0 0.00027506717
of O 0 0.00022883416
an O 0 0.00024154833
isolated O 0 0.0001932375
fracture B-Disease 0 0.993747
or O 0 0.00052523124
dislocation B-Disease 0 0.99624807
in O 0 0.000265043
the O 0 0.00024138717
emergency O 0 0.0015475419
department O 0 0.00068908266
at O 0 0.00020445992
a O 0 0.00031693146
level O 0 0.00036391482
- O 0 0.012025436
I O 0 0.023246396
trauma B-Disease 0 0.82005996
center O 0 0.001117164
were O 0 0.001298076
prospectively O 0 0.0020816193
evaluated O 0 0.002940617
. O 0 0.0061590336

Ketamine B-Chemical 1 0.99999225
hydrochloride I-Chemical 0 0.9998964
was O 0 0.002289287
administered O 0 0.0011305985
intravenously O 0 0.0010510018
( O 0 0.00073858094
at O 0 0.00034796377
a O 0 0.00038798456
dose O 0 0.00066215254
of O 0 0.00028786695
two O 0 0.00017116092
milligrams O 0 0.00020229314
per O 0 0.00011290263
kilogram O 0 0.00019712825
of O 0 0.00018317068
body O 0 0.00064117525
weight O 0 0.0017129389
) O 0 0.0006367556
in O 0 0.00021842169
ninety O 0 0.0005300933
- O 0 0.0010549477
nine O 0 0.00015223409
of O 0 0.0001714935
the O 0 0.00016269468
patients O 0 0.0002604632
and O 0 0.00022523435
intramuscularly O 0 0.0008852977
( O 0 0.00028868683
at O 0 0.00014671304
a O 0 0.00020701652
dose O 0 0.00041576577
of O 0 0.00020707912
four O 0 0.0001383836
milligrams O 0 0.00019489042
per O 0 0.00013546471
kilogram O 0 0.00026723277
of O 0 0.00031191087
body O 0 0.0009616443
weight O 0 0.0017861043
) O 0 0.0012501939
in O 0 0.0009432579
the O 0 0.0013494678
other O 0 0.0023328618
fifteen O 0 0.0041059833
. O 0 0.006326949

A O 0 0.08241846
board O 0 0.008708849
- O 0 0.0071579306
certified O 0 0.0020813935
emergency O 0 0.0016577375
physician O 0 0.0016164145
skilled O 0 0.0011800437
in O 0 0.00059971155
airway O 0 0.0041397237
management O 0 0.000719556
supervised O 0 0.00046850022
administration O 0 0.0010936508
of O 0 0.00034261402
the O 0 0.00034462262
anesthetic O 0 0.059424836
, O 0 0.00040743212
and O 0 0.0003325478
the O 0 0.00032978182
patients O 0 0.00050171075
were O 0 0.00046415973
monitored O 0 0.0005334144
by O 0 0.0010534328
a O 0 0.0017975741
registered O 0 0.0029477638
nurse O 0 0.004981419
. O 0 0.006903841

Any O 0 0.007857627
pain B-Disease 0 0.62227
during O 0 0.0014604302
the O 0 0.0011852579
reduction O 0 0.0013140022
was O 0 0.0007075853
rated O 0 0.0006625528
by O 0 0.0004147085
the O 0 0.00034660564
orthopaedic O 0 0.00058640644
surgeon O 0 0.00040889162
treating O 0 0.00034481176
the O 0 0.00021097375
patient O 0 0.00021390793
according O 0 0.00015275653
to O 0 0.00016569716
the O 0 0.00021399444
Children O 0 0.00061941345
' O 0 0.00038458512
s O 0 0.00042215962
Hospital O 0 0.0007803754
of O 0 0.00059021486
Eastern O 0 0.07258811
Ontario O 0 0.036075763
Pain B-Disease 0 0.9545966
Scale O 0 0.21698745
( O 0 0.0031360325
CHEOPS O 0 0.1820034
) O 0 0.0056958525
. O 0 0.00774933

RESULTS O 0 0.005200038
: O 0 0.0031199164
The O 0 0.0013068059
average O 0 0.0007871909
time O 0 0.0006112188
from O 0 0.00058938714
intravenous O 0 0.015864505
administration O 0 0.006910733
of O 0 0.0018192598
ketamine B-Chemical 0 0.9999739
to O 0 0.0002473873
manipulation O 0 0.00022410548
of O 0 0.00027602105
the O 0 0.0003366715
fracture B-Disease 0 0.99442035
or O 0 0.00053774007
dislocation B-Disease 0 0.99610376
was O 0 0.00020683363
one O 0 0.00011926034
minute O 0 0.0001120492
and O 0 0.00014788119
thirty O 0 0.00016168201
- O 0 0.00046836
six O 0 9.6942575e-05
seconds O 0 0.00011849677
( O 0 0.00018547494
range O 0 0.00015645858
, O 0 0.00017410931
twenty O 0 0.00011127894
seconds O 0 0.00010423807
to O 0 9.7883174e-05
five O 0 9.199519e-05
minutes O 0 0.00011766625
) O 0 0.00028028153
, O 0 0.00021780882
and O 0 0.00016481146
the O 0 0.00012203836
average O 0 9.2797236e-05
time O 0 9.641266e-05
from O 0 0.0001287342
intramuscular O 0 0.0050220983
administration O 0 0.0006227039
to O 0 0.000117402305
manipulation O 0 0.00014068844
was O 0 0.00012794729
four O 0 9.341607e-05
minutes O 0 0.000109056426
and O 0 0.00016775493
forty O 0 0.00026350978
- O 0 0.00052917935
two O 0 0.00015267426
seconds O 0 0.00019748833
( O 0 0.0003312979
range O 0 0.0003392484
, O 0 0.0004893872
sixty O 0 0.0005628917
seconds O 0 0.00050675066
to O 0 0.0007209933
fifteen O 0 0.0013195429
minutes O 0 0.0018203884
) O 0 0.004769816
. O 0 0.007006292

The O 0 0.0027735562
average O 0 0.0015532196
score O 0 0.0012846728
according O 0 0.000800302
to O 0 0.0006484409
the O 0 0.00058176
Children O 0 0.0010296372
' O 0 0.00057544676
s O 0 0.0004965918
Hospital O 0 0.0007144075
of O 0 0.00039481945
Eastern O 0 0.07521939
Ontario O 0 0.030113544
Pain B-Disease 0 0.9399821
Scale O 0 0.051429834
was O 0 0.0001996722
6 O 0 0.00014632785
. O 0 0.00015129491
4 O 0 0.00013954288
points O 0 0.00016005883
( O 0 0.00024139295
range O 0 0.00020655537
, O 0 0.0002464574
5 O 0 0.00014868076
to O 0 0.00014144655
10 O 0 0.00016883327
points O 0 0.0002033723
) O 0 0.00041176617
, O 0 0.0003439991
reflecting O 0 0.000321054
minimal O 0 0.00034432512
or O 0 0.00048803946
no O 0 0.0006585094
pain B-Disease 0 0.8507792
during O 0 0.0013731923
fracture B-Disease 0 0.99034894
reduction O 0 0.008787524
. O 0 0.007259959

Adequate O 0 0.00936764
fracture B-Disease 0 0.93108225
reduction O 0 0.0058747493
was O 0 0.003329288
obtained O 0 0.0027228075
in O 0 0.0030405656
111 O 0 0.00521864
of O 0 0.004218363
the O 0 0.0051585096
children O 0 0.010781678
. O 0 0.012222263

Ninety O 0 0.0074171834
- O 0 0.006053128
nine O 0 0.0018155471
percent O 0 0.0012471523
( O 0 0.0015884845
sixty O 0 0.001366644
- O 0 0.0020815597
eight O 0 0.0004857305
) O 0 0.0006625515
of O 0 0.0004418087
the O 0 0.0003748801
sixty O 0 0.0005855388
- O 0 0.0013197095
nine O 0 0.00023146826
parents O 0 0.0003336008
present O 0 0.0001525721
during O 0 0.00014005559
the O 0 0.00018556106
reduction O 0 0.0003467372
were O 0 0.0002244859
pleased O 0 0.0011364017
with O 0 0.00019752054
the O 0 0.0002183203
sedation O 0 0.020801866
and O 0 0.00021629436
would O 0 0.00017943335
allow O 0 0.00018678344
it O 0 0.00025772688
to O 0 0.00024062199
be O 0 0.00033471896
used O 0 0.00040693858
again O 0 0.00063039514
in O 0 0.0008650585
a O 0 0.0015059019
similar O 0 0.0018768571
situation O 0 0.0043424685
. O 0 0.0067142383

Patency O 0 0.009392443
of O 0 0.003436875
the O 0 0.0022873646
airway O 0 0.0048686597
and O 0 0.0015635147
independent O 0 0.0009985038
respiration O 0 0.020052776
were O 0 0.000983484
maintained O 0 0.0009083231
in O 0 0.0010509843
all O 0 0.00127582
of O 0 0.00210147
the O 0 0.0029468052
patients O 0 0.006286115
. O 0 0.0079657985

Blood O 0 0.044144414
pressure O 0 0.030238839
and O 0 0.009797189
heart O 0 0.033397295
rate O 0 0.009662704
remained O 0 0.012356649
stable O 0 0.015705852
. O 0 0.018911269

Minor O 0 0.26040813
side O 0 0.020312587
effects O 0 0.0032299547
included O 0 0.0027561358
nausea B-Disease 2 0.9999918
( O 0 0.0020218086
thirteen O 0 0.0009330502
patients O 0 0.0009800219
) O 0 0.0018094762
, O 0 0.0030019272
emesis B-Disease 0 0.9999714
( O 0 0.00069753005
eight O 0 0.00017628347
of O 0 0.00020389826
the O 0 0.0001775209
thirteen O 0 0.00026209909
patients O 0 0.00032597332
with O 0 0.0011336618
nausea B-Disease 2 0.99999845
) O 0 0.012576347
, O 0 0.005209751
clumsiness B-Disease 0 0.99984753
( O 0 0.0010397211
evident O 0 0.00033680763
as O 0 0.0004466965
ataxic B-Disease 0 0.9999813
movements I-Disease 0 0.057130884
in O 0 0.00020802763
ten O 0 0.00017093013
patients O 0 0.0003451245
) O 0 0.0005832693
, O 0 0.00061660534
and O 0 0.0015099102
dysphoric B-Disease 0 0.99996996
reaction I-Disease 0 0.19479567
( O 0 0.0015255777
one O 0 0.0013586499
patient O 0 0.0024638085
) O 0 0.005107154
. O 0 0.006835035

No O 0 0.005988121
long O 0 0.003525408
- O 0 0.0055681323
term O 0 0.0018342091
sequelae O 0 0.15922716
were O 0 0.0011553372
noted O 0 0.000829375
, O 0 0.0010702397
and O 0 0.0009302
no O 0 0.0008256212
patients O 0 0.0018848556
had O 0 0.002650072
hallucinations B-Disease 2 0.9999882
or O 0 0.0057648546
nightmares O 0 0.98723537
. O 0 0.009102891

CONCLUSIONS O 0 0.08140672
: O 0 0.011860473
Ketamine B-Chemical 1 0.9997795
reliably O 0 0.0029498572
, O 0 0.0017050122
safely O 0 0.001099286
, O 0 0.00080372894
and O 0 0.0005386321
quickly O 0 0.00051832077
provided O 0 0.00030367932
adequate O 0 0.00028847822
sedation O 0 0.0085055875
to O 0 0.00016836546
effectively O 0 0.0001735564
facilitate O 0 0.00013442911
the O 0 0.00018665988
reduction O 0 0.0003227766
of O 0 0.00031020623
children O 0 0.0009761393
' O 0 0.0006350813
s O 0 0.0007229266
fractures B-Disease 2 0.9833493
in O 0 0.00045145286
the O 0 0.000552811
emergency O 0 0.002142723
department O 0 0.0018192676
at O 0 0.0011511002
our O 0 0.0020131883
institution O 0 0.0042782533
. O 0 0.006595337

Ketamine B-Chemical 1 0.99967456
should O 0 0.0022051937
only O 0 0.0016684969
be O 0 0.0010759659
used O 0 0.0007242864
in O 0 0.0006047881
an O 0 0.00057282386
environment O 0 0.00057196565
such O 0 0.00032314428
as O 0 0.0002988874
the O 0 0.0003183693
emergency O 0 0.003757377
department O 0 0.0020433597
, O 0 0.00030775453
where O 0 0.00018611444
proper O 0 0.0001892724
one O 0 0.00022421962
- O 0 0.0018561435
on O 0 0.00015248236
- O 0 0.0021748843
one O 0 0.0001598572
monitoring O 0 0.00019635259
is O 0 0.00016316041
used O 0 0.00015199359
and O 0 0.0002436128
board O 0 0.0008405709
- O 0 0.0016634562
certified O 0 0.00026228582
physicians O 0 0.00029436802
skilled O 0 0.00034621844
in O 0 0.00021308065
airway O 0 0.0019995274
management O 0 0.0004013833
are O 0 0.00023599649
directly O 0 0.00024179765
involved O 0 0.00027760878
in O 0 0.00040417066
the O 0 0.0005528087
care O 0 0.0009294775
of O 0 0.0013908016
the O 0 0.0020873751
patient O 0 0.004071178
. O 0 0.006377815

Cyclosporine B-Chemical 0 0.9998977
and O 0 0.083408535
tacrolimus B-Chemical 0 0.9999881
- O 0 0.6687704
associated O 0 0.24697746
thrombotic B-Disease 2 0.9999943
microangiopathy I-Disease 2 0.99999857
. O 0 0.032339226

The O 0 0.0036009625
development O 0 0.004689891
of O 0 0.024251994
thrombotic B-Disease 2 0.99999917
microangiopathy I-Disease 2 1.0
( O 0 0.41816184
TMA B-Disease 2 0.9998024
) O 0 0.0022383374
associated O 0 0.00052933133
with O 0 0.00043165943
the O 0 0.00040393625
use O 0 0.0005217056
of O 0 0.0013918357
cyclosporine B-Chemical 1 0.99999475
has O 0 0.0013306247
been O 0 0.0015323303
well O 0 0.0021334102
documented O 0 0.0050679864
. O 0 0.006981515

Treatments O 0 0.015079581
have O 0 0.0021670568
included O 0 0.0016157082
discontinuation O 0 0.20994034
or O 0 0.00091149576
reduction O 0 0.0014967124
of O 0 0.0029074466
cyclosporine B-Chemical 1 0.9999989
dose O 0 0.063590005
with O 0 0.0005290676
or O 0 0.00025619738
without O 0 0.00022709361
concurrent O 0 0.00056786556
plasma O 0 0.017893968
exchange O 0 0.0005522752
, O 0 0.0005214871
plasma O 0 0.011974089
infusion O 0 0.0013290889
, O 0 0.00064113794
anticoagulation O 0 0.43046233
, O 0 0.00068290526
and O 0 0.0009335766
intravenous O 0 0.24423371
immunoglobulin O 0 0.99159265
G O 0 0.99616784
infusion O 0 0.071258925
. O 0 0.0067306357

However O 0 0.0045704655
, O 0 0.0032528888
for O 0 0.0017149051
recipients O 0 0.0017124172
of O 0 0.0013529363
organ O 0 0.023809047
transplantation O 0 0.07508867
, O 0 0.0009858283
removing O 0 0.0005628998
the O 0 0.00042226425
inciting O 0 0.13740218
agent O 0 0.046481356
is O 0 0.000367887
not O 0 0.00023490009
without O 0 0.00024632257
the O 0 0.0002782744
attendant O 0 0.0011766376
risk O 0 0.057668615
of O 0 0.0012859305
precipitating O 0 0.90258926
acute O 0 0.96763724
rejection O 0 0.98228985
and O 0 0.0039744703
graft O 0 0.05354682
loss O 0 0.011395115
. O 0 0.0075880126

The O 0 0.0030247131
last O 0 0.0017942522
decade O 0 0.002419758
has O 0 0.0011264839
seen O 0 0.00081405905
the O 0 0.0006197063
emergence O 0 0.0009521708
of O 0 0.0017421634
tacrolimus B-Chemical 0 0.99999404
as O 0 0.00058107724
a O 0 0.0006401107
potent O 0 0.0042399038
immunosuppressive O 0 0.69131863
agent O 0 0.027640248
with O 0 0.00032006385
mechanisms O 0 0.00024520952
of O 0 0.00038973292
action O 0 0.0005596813
virtually O 0 0.0004225276
identical O 0 0.0004366943
to O 0 0.00074161857
those O 0 0.0016710898
of O 0 0.0047306768
cyclosporine B-Chemical 1 0.9999844
. O 0 0.010631475

As O 0 0.003548066
a O 0 0.0028634747
result O 0 0.0017151737
, O 0 0.0018498772
switching O 0 0.001524117
to O 0 0.001209845
tacrolimus B-Chemical 0 0.9999925
has O 0 0.0007120309
been O 0 0.0004378946
reported O 0 0.00037919293
to O 0 0.00024499945
be O 0 0.0002727193
a O 0 0.00031499486
viable O 0 0.00033247302
therapeutic O 0 0.00067135424
option O 0 0.0004196149
in O 0 0.0003187614
the O 0 0.0003832231
setting O 0 0.0006041581
of O 0 0.002984351
cyclosporine B-Chemical 1 0.9999981
- O 0 0.37575004
induced O 0 0.0147958305
TMA B-Disease 2 0.998992
. O 0 0.0091897035

With O 0 0.0040492425
the O 0 0.002394292
more O 0 0.001904797
widespread O 0 0.0019394332
application O 0 0.0013992846
of O 0 0.0019730895
tacrolimus B-Chemical 0 0.99999034
in O 0 0.0009942343
organ O 0 0.031522837
transplantation O 0 0.16072759
, O 0 0.017832713
tacrolimus B-Chemical 0 0.99999833
- O 0 0.23875888
associated O 0 0.0042653433
TMA B-Disease 2 0.99660695
has O 0 0.0011433493
also O 0 0.0015453605
been O 0 0.0025184348
recognized O 0 0.0046153786
. O 0 0.0076076086

However O 0 0.004481534
, O 0 0.0031834715
literature O 0 0.0019652925
regarding O 0 0.00093014806
the O 0 0.0008588176
incidence O 0 0.0015984966
of O 0 0.00077701424
the O 0 0.00067793584
recurrence O 0 0.71422786
of O 0 0.0033105782
TMA B-Disease 2 0.99910456
in O 0 0.0004317008
patients O 0 0.0004829729
exposed O 0 0.00039445303
sequentially O 0 0.00044413412
to O 0 0.00066620053
cyclosporine B-Chemical 1 0.99999416
and O 0 0.013975605
tacrolimus B-Chemical 0 0.99998426
is O 0 0.0034401692
limited O 0 0.0040961225
. O 0 0.006773968

We O 0 0.003939935
report O 0 0.0035306767
a O 0 0.0021752883
case O 0 0.0013992419
of O 0 0.0011267124
a O 0 0.0010238736
living O 0 0.0033431263
donor O 0 0.0012505179
renal O 0 0.83371353
transplant O 0 0.14625958
recipient O 0 0.0014051533
who O 0 0.0009371449
developed O 0 0.0072985166
cyclosporine B-Chemical 1 0.99999964
- O 0 0.36526844
induced O 0 0.0024121543
TMA B-Disease 2 0.9993587
that O 0 0.0001876537
responded O 0 0.000256942
to O 0 0.00014065369
the O 0 0.00020097331
withdrawal O 0 0.08560789
of O 0 0.0012164621
cyclosporine B-Chemical 1 0.99999833
in O 0 0.00037238587
conjunction O 0 0.00035603682
with O 0 0.0003740419
plasmapheresis O 0 0.06410193
and O 0 0.00050568767
fresh O 0 0.0009844174
frozen O 0 0.0018506584
plasma O 0 0.008634748
replacement O 0 0.0046057752
therapy O 0 0.0054504815
. O 0 0.006101505

Introduction O 0 0.006499462
of O 0 0.0047344253
tacrolimus B-Chemical 0 0.9999554
as O 0 0.0019177784
an O 0 0.0013755916
alternative O 0 0.0009002742
immunosuppressive O 0 0.7717082
agent O 0 0.07648162
resulted O 0 0.0004225522
in O 0 0.00037356082
the O 0 0.00039848383
recurrence O 0 0.59597397
of O 0 0.001885122
TMA B-Disease 2 0.99859947
and O 0 0.0005093813
the O 0 0.00039267915
subsequent O 0 0.0005240216
loss O 0 0.0010410928
of O 0 0.0012447815
the O 0 0.001880594
renal O 0 0.8963026
allograft O 0 0.9167677
. O 0 0.008775541

Patients O 0 0.0052015577
who O 0 0.0030951148
are O 0 0.0015634159
switched O 0 0.0013645892
from O 0 0.001114564
cyclosporine B-Chemical 1 0.9999945
to O 0 0.002879065
tacrolimus B-Chemical 0 0.9999976
or O 0 0.0021688496
vice O 0 0.4800278
versa O 0 0.00266392
should O 0 0.00018859954
be O 0 0.00021740136
closely O 0 0.00021809188
monitored O 0 0.00019863727
for O 0 0.0002912631
the O 0 0.00042134928
signs O 0 0.012679327
and O 0 0.0011077282
symptoms O 0 0.17831896
of O 0 0.0033652096
recurrent O 0 0.8298358
TMA B-Disease 2 0.99871504
. O 0 0.008829181

Analgesic O 0 0.988468
effect O 0 0.0030169925
of O 0 0.0031043494
intravenous O 0 0.8104249
ketamine B-Chemical 0 0.9999927
in O 0 0.0028636914
cancer B-Disease 0 0.9975725
patients O 0 0.0023395948
on O 0 0.0003845345
morphine B-Chemical 0 0.9999515
therapy O 0 0.0018749231
: O 0 0.0005559588
a O 0 0.00030327626
randomized O 0 0.00025792574
, O 0 0.00027384775
controlled O 0 0.00021726
, O 0 0.0003797455
double O 0 0.00046195203
- O 0 0.009878148
blind O 0 0.01978846
, O 0 0.0008376054
crossover O 0 0.0025664247
, O 0 0.0011149523
double O 0 0.0014092192
- O 0 0.0074345386
dose O 0 0.0069454093
study O 0 0.0053614248
. O 0 0.0072043804

Pain B-Disease 0 0.6220411
not O 0 0.006203055
responsive O 0 0.005642785
to O 0 0.0065810313
morphine B-Chemical 0 0.9997354
is O 0 0.008005633
often O 0 0.00939456
problematic O 0 0.012280479
. O 0 0.014244284

Animal O 0 0.007353946
and O 0 0.0029379446
clinical O 0 0.0026739289
studies O 0 0.0010963347
have O 0 0.00069695985
suggested O 0 0.00060864445
that O 0 0.0008293647
N B-Chemical 0 0.9998996
- I-Chemical 0 0.84763825
methyl I-Chemical 0 0.99985814
- I-Chemical 0 0.77798027
D I-Chemical 0 0.9997428
- I-Chemical 0 0.9172285
aspartate I-Chemical 1 0.99999845
( O 0 0.47453895
NMDA B-Chemical 1 0.99999976
) O 0 0.03099626
antagonists O 0 0.6332388
, O 0 0.00038649928
such O 0 0.00020510406
as O 0 0.00047973168
ketamine B-Chemical 0 0.9999821
, O 0 0.00058120774
may O 0 0.00017164386
be O 0 0.00017094988
effective O 0 0.00019313766
in O 0 0.00019384075
improving O 0 0.00040876458
opioid O 0 0.99152535
analgesia O 0 0.83978236
in O 0 0.00026277293
difficult O 0 0.00041872004
pain B-Disease 0 0.8755482
syndromes O 0 0.06446151
, O 0 0.0009030904
such O 0 0.001017583
as O 0 0.003024891
neuropathic B-Disease 0 0.9999856
pain I-Disease 0 0.9991386
. O 0 0.007999346

A O 0 0.0390988
slow O 0 0.004690783
bolus O 0 0.0105781015
of O 0 0.0032141048
subhypnotic O 0 0.9988187
doses O 0 0.053815227
of O 0 0.009886939
ketamine B-Chemical 0 0.99999475
( O 0 0.0027487748
0 O 0 0.00042379822
. O 0 0.00022984046
25 O 0 0.00026783932
mg O 0 0.0045925057
/ O 0 0.0007554503
kg O 0 0.0005079306
or O 0 0.0001947275
0 O 0 0.00022666916
. O 0 0.00016346129
50 O 0 0.00022509138
mg O 0 0.0068762773
/ O 0 0.001265146
kg O 0 0.0010120509
) O 0 0.0004122499
was O 0 0.0001627434
given O 0 0.00010894012
to O 0 0.00013860005
10 O 0 0.00021578536
cancer B-Disease 0 0.9648077
patients O 0 0.00073016365
whose O 0 0.0008931238
pain B-Disease 0 0.9079403
was O 0 0.00026869102
unrelieved O 0 0.07210061
by O 0 0.0004552968
morphine B-Chemical 0 0.9998419
in O 0 0.00023119211
a O 0 0.00027213283
randomized O 0 0.00024934494
, O 0 0.0003126528
double O 0 0.000395987
- O 0 0.008317155
blind O 0 0.018104916
, O 0 0.00079147343
crossover O 0 0.002471226
, O 0 0.0010726326
double O 0 0.001364866
- O 0 0.007396094
dose O 0 0.0068351943
study O 0 0.0052688336
. O 0 0.007095683

Pain B-Disease 0 0.4424944
intensity O 0 0.0022602603
on O 0 0.0012995017
a O 0 0.0013488122
0 O 0 0.0009112917
to O 0 0.0005552785
10 O 0 0.0004831372
numerical O 0 0.0008483899
scale O 0 0.0005859662
; O 0 0.0029979865
nausea B-Disease 2 0.99999404
and O 0 0.0054844064
vomiting B-Disease 0 0.9999808
, O 0 0.031936776
drowsiness O 0 0.99999607
, O 0 0.00581874
confusion B-Disease 0 0.90107566
, O 0 0.00076759886
and O 0 0.0006555388
dry B-Disease 2 0.89556634
mouth I-Disease 2 0.83264863
, O 0 0.00038336142
using O 0 0.00015748206
a O 0 0.0001821056
scale O 0 0.00016513439
from O 0 0.0001236424
0 O 0 0.00016005822
to O 0 0.00012602843
3 O 0 0.00014190694
( O 0 0.00020176456
not O 0 0.00013626249
at O 0 0.00014178846
all O 0 0.00016655604
, O 0 0.00029117177
slight O 0 0.000462178
, O 0 0.0003864646
a O 0 0.00031388446
lot O 0 0.00035231718
, O 0 0.00052791147
awful O 0 0.039880708
) O 0 0.0009950353
; O 0 0.0006544717
Mini O 0 0.00095676497
- O 0 0.001834149
Mental O 0 0.0006159108
State O 0 0.0004694645
Examination O 0 0.00020370219
( O 0 0.00038570346
MMSE O 0 0.89011675
) O 0 0.00041891463
( O 0 0.00032792988
0 O 0 0.00027476545
- O 0 0.0010443272
30 O 0 0.0001705695
) O 0 0.00033851308
; O 0 0.00033174604
and O 0 0.0002606863
arterial O 0 0.10659801
pressure O 0 0.011025316
were O 0 0.00013797672
recorded O 0 0.00012285826
before O 0 9.5518415e-05
administration O 0 0.0004098235
of O 0 0.00026589035
drugs O 0 0.25222838
( O 0 0.0012772997
T0 O 0 0.01191935
) O 0 0.00034028623
and O 0 0.00015930801
after O 0 9.574722e-05
30 O 0 0.00011187037
minutes O 0 0.0001247398
( O 0 0.00034503324
T30 O 0 0.15566348
) O 0 0.0004037297
, O 0 0.00023104138
60 O 0 0.0001576108
minutes O 0 0.00014400121
( O 0 0.00033238367
T60 O 0 0.045425843
) O 0 0.00041362055
, O 0 0.0002730466
120 O 0 0.00021878957
minutes O 0 0.00020736798
( O 0 0.0005180294
T120 O 0 0.14845774
) O 0 0.00069524173
, O 0 0.00058334577
and O 0 0.0006173412
180 O 0 0.00091018615
minutes O 0 0.0010011914
( O 0 0.0024915482
T180 O 0 0.03931168
) O 0 0.0061220587
. O 0 0.0077873683

Ketamine B-Chemical 1 0.9998797
, O 0 0.0069209374
but O 0 0.0026252798
not O 0 0.0013648465
saline O 0 0.017404811
solution O 0 0.016252253
, O 0 0.0010137521
significantly O 0 0.0004997308
reduced O 0 0.00041440793
the O 0 0.00044810236
pain B-Disease 0 0.6792017
intensity O 0 0.00030797903
in O 0 0.0003170191
almost O 0 0.00033918422
all O 0 0.00042108545
the O 0 0.0005594989
patients O 0 0.0010106156
at O 0 0.00108224
both O 0 0.0020467697
doses O 0 0.009289202
. O 0 0.006780561

This O 0 0.0064774496
effect O 0 0.003566948
was O 0 0.0027604823
more O 0 0.002135649
relevant O 0 0.0015609516
in O 0 0.0016235404
patients O 0 0.0021143358
treated O 0 0.0021593897
with O 0 0.002770764
higher O 0 0.0039669927
doses O 0 0.016109342
. O 0 0.0094235055

Hallucinations B-Disease 2 0.99741745
occurred O 0 0.0029439349
in O 0 0.0018200098
4 O 0 0.0012349243
patients O 0 0.0011568245
, O 0 0.00096106634
and O 0 0.00070980366
an O 0 0.00080321066
unpleasant O 0 0.38475192
sensation O 0 0.4519598
( O 0 0.0009882437
" O 0 0.0006527269
empty O 0 0.00063409784
head O 0 0.05944134
" O 0 0.0010593402
) O 0 0.00096776336
was O 0 0.00062533445
also O 0 0.0007212311
reported O 0 0.0011770042
by O 0 0.0016362813
2 O 0 0.002378436
patients O 0 0.0046082945
. O 0 0.0068095787

These O 0 0.004896357
episodes O 0 0.00823976
reversed O 0 0.0030495261
after O 0 0.0016355958
the O 0 0.0018280133
administration O 0 0.02074463
of O 0 0.01230001
diazepam B-Chemical 0 0.9999981
1 O 0 0.0035485192
mg O 0 0.077545
intravenously O 0 0.0057641254
. O 0 0.007827616

Significant O 0 0.004504737
increases O 0 0.0026700343
in O 0 0.002897278
drowsiness O 0 0.9999385
were O 0 0.0011205779
reported O 0 0.00075578724
in O 0 0.00045322324
patients O 0 0.00054969714
treated O 0 0.0004788499
with O 0 0.0011736999
ketamine B-Chemical 0 0.99997234
in O 0 0.00027873114
both O 0 0.00022141532
groups O 0 0.00022833963
and O 0 0.00023101452
were O 0 0.00021169957
more O 0 0.00024329293
marked O 0 0.000461285
with O 0 0.0009189852
ketamine B-Chemical 0 0.99994886
0 O 0 0.0006716012
. O 0 0.0006276542
50 O 0 0.0011471076
mg O 0 0.012513647
/ O 0 0.0047930554
kg O 0 0.0074022426
. O 0 0.007094137

A O 0 0.027360354
significant O 0 0.0028655818
difference O 0 0.0016095348
in O 0 0.0017044345
MMSE O 0 0.8713248
was O 0 0.0008358318
observed O 0 0.00054641033
at O 0 0.0005326886
T30 O 0 0.06814801
in O 0 0.00040842567
patients O 0 0.00048558007
who O 0 0.00044937135
received O 0 0.00029195036
0 O 0 0.00041634656
. O 0 0.00043377248
50 O 0 0.00071252
mg O 0 0.009402938
/ O 0 0.0027971484
kg O 0 0.0043223933
of O 0 0.006018528
ketamine B-Chemical 0 0.9998871
. O 0 0.008935641

Ketamine B-Chemical 1 0.99966097
can O 0 0.003514982
improve O 0 0.0026489305
morphine B-Chemical 0 0.99996316
analgesia O 0 0.9813441
in O 0 0.0012061715
difficult O 0 0.0012448722
pain B-Disease 0 0.9277507
syndromes O 0 0.108506024
, O 0 0.0015640842
such O 0 0.0015985562
as O 0 0.004100457
neuropathic B-Disease 0 0.99998415
pain I-Disease 0 0.9992418
. O 0 0.0095780725

However O 0 0.0047014975
, O 0 0.0033568607
the O 0 0.0017524842
occurrence O 0 0.0019611286
of O 0 0.0012349783
central O 0 0.0017725383
adverse O 0 0.24199945
effects O 0 0.00067262136
should O 0 0.00027062983
be O 0 0.0003013297
taken O 0 0.0002534793
into O 0 0.0002469989
account O 0 0.00043242302
, O 0 0.00071055285
especially O 0 0.000853525
when O 0 0.00077445724
using O 0 0.0013610629
higher O 0 0.002358018
doses O 0 0.008948229
. O 0 0.0071096653

This O 0 0.006217126
observation O 0 0.0033888007
should O 0 0.0019286834
be O 0 0.001947314
tested O 0 0.0016243793
in O 0 0.0017259774
studies O 0 0.0019923535
of O 0 0.003119138
prolonged O 0 0.059833657
ketamine B-Chemical 0 0.9999745
administration O 0 0.2926004
. O 0 0.010220118

Paclitaxel B-Chemical 0 0.9994708
, O 0 0.036417134
cisplatin B-Chemical 1 0.9996903
, O 0 0.0049130297
and O 0 0.00255796
gemcitabine B-Chemical 0 0.996564
combination O 0 0.0018257481
chemotherapy O 0 0.02614509
within O 0 0.0003227302
a O 0 0.0004633724
multidisciplinary O 0 0.00057093654
therapeutic O 0 0.0006483778
approach O 0 0.00052271417
in O 0 0.00076989114
metastatic O 0 0.9095839
nonsmall B-Disease 0 0.9993451
cell I-Disease 0 0.16899458
lung I-Disease 0 0.949071
carcinoma I-Disease 2 0.99995947
. O 0 0.020184562

BACKGROUND O 0 0.07269215
: O 0 0.020184603
Cisplatin B-Chemical 0 0.99992085
- O 0 0.04237576
based O 0 0.0013431015
chemotherapy O 0 0.0054090824
combinations O 0 0.00046082222
improve O 0 0.00029713777
quality O 0 0.00029727464
of O 0 0.0003469275
life O 0 0.00044119294
and O 0 0.00040133143
survival O 0 0.009477151
in O 0 0.00047726685
advanced O 0 0.06783035
nonsmall B-Disease 0 0.9990606
cell I-Disease 0 0.091729805
lung I-Disease 0 0.95783806
carcinoma I-Disease 2 0.99999285
( O 0 0.27886575
NSCLC B-Disease 2 0.9997539
) O 0 0.01640134
. O 0 0.008533811

The O 0 0.0033003855
emergence O 0 0.0030367868
of O 0 0.0020937996
new O 0 0.0019030201
active O 0 0.0023379968
drugs O 0 0.11533994
might O 0 0.00048029816
translate O 0 0.00041938972
into O 0 0.0002768581
more O 0 0.00040369085
effective O 0 0.00040749463
regimens O 0 0.0005385459
for O 0 0.00046376282
the O 0 0.0006393492
treatment O 0 0.0010852154
of O 0 0.0019108078
this O 0 0.0030462982
disease O 0 0.8872703
. O 0 0.008295512

METHODS O 0 0.003789851
: O 0 0.0032597575
The O 0 0.0016102195
objective O 0 0.0016447376
of O 0 0.0011523255
this O 0 0.0008137573
study O 0 0.0007332272
was O 0 0.000432662
to O 0 0.00026901017
determine O 0 0.00014644428
the O 0 0.0002093684
feasibility O 0 0.0002035395
, O 0 0.0002928779
response O 0 0.000292179
rate O 0 0.00032750782
, O 0 0.0005422183
and O 0 0.00064853946
toxicity B-Disease 2 0.9967257
of O 0 0.0007766785
a O 0 0.0022247846
paclitaxel B-Chemical 1 0.99937254
, O 0 0.016530951
cisplatin B-Chemical 1 0.9998858
, O 0 0.0015292597
and O 0 0.0010632747
gemcitabine B-Chemical 0 0.9935773
combination O 0 0.0011619107
to O 0 0.0009681614
treat O 0 0.0043039285
metastatic O 0 0.963604
NSCLC B-Disease 2 0.9994449
. O 0 0.008682296

Thirty O 0 0.007000921
- O 0 0.005082163
five O 0 0.0013470042
consecutive O 0 0.0011519991
chemotherapy O 0 0.032521438
- O 0 0.0066013057
naive O 0 0.0011790775
patients O 0 0.0007431743
with O 0 0.0007167171
Stage O 0 0.82278746
IV O 0 0.9003993
NSCLC B-Disease 2 0.9994985
and O 0 0.0005697518
an O 0 0.00057777803
Eastern O 0 0.1356673
Cooperative O 0 0.034963716
Oncology O 0 0.0018915758
Group O 0 0.0012638349
performance O 0 0.00023069778
status O 0 0.00023198617
of O 0 0.00024605592
0 O 0 0.00036251504
- O 0 0.002686346
2 O 0 0.00016154826
were O 0 0.00013427717
treated O 0 0.00015078262
with O 0 0.00016045645
a O 0 0.00019244793
combination O 0 0.00023580552
of O 0 0.0005187837
paclitaxel B-Chemical 1 0.9980756
( O 0 0.0013352525
135 O 0 0.0012560897
mg O 0 0.02250386
/ O 0 0.0025040347
m O 0 0.003797963
( O 0 0.00041202814
2 O 0 0.00017148322
) O 0 0.00021671467
given O 0 9.7249875e-05
intravenously O 0 0.00014907312
in O 0 0.00012637055
3 O 0 0.00011812222
hours O 0 0.000112734255
) O 0 0.00019702113
on O 0 0.0001061381
Day O 0 0.00044516026
1 O 0 0.00019770971
, O 0 0.0005037565
cisplatin B-Chemical 1 0.9990089
( O 0 0.0005816563
120 O 0 0.0002395491
mg O 0 0.009334007
/ O 0 0.0015916639
m O 0 0.00289944
( O 0 0.000399914
2 O 0 0.00017336584
) O 0 0.00021732342
given O 0 9.7525786e-05
intravenously O 0 0.00014622757
in O 0 0.00012301804
6 O 0 0.000107216474
hours O 0 0.000111624984
) O 0 0.00019649003
on O 0 0.0001055693
Day O 0 0.00040744222
1 O 0 0.00016907975
, O 0 0.00023881317
and O 0 0.00036119795
gemcitabine B-Chemical 0 0.9945036
( O 0 0.00080927653
800 O 0 0.00085148844
mg O 0 0.020626754
/ O 0 0.0024825956
m O 0 0.0038341458
( O 0 0.00043800945
2 O 0 0.00018891649
) O 0 0.00023958519
given O 0 0.000112452
intravenously O 0 0.00016288947
in O 0 0.00014036174
30 O 0 0.00013938837
minutes O 0 0.0001517655
) O 0 0.000285693
on O 0 0.00021220822
Days O 0 0.0018980118
1 O 0 0.00037179334
and O 0 0.0005005844
8 O 0 0.0006185404
, O 0 0.0009618267
every O 0 0.0008338284
4 O 0 0.0016972779
weeks O 0 0.002617121
. O 0 0.0061363443

Although O 0 0.0032525084
responding O 0 0.003250595
patients O 0 0.0018421673
were O 0 0.0009365862
scheduled O 0 0.0005043167
to O 0 0.00042015646
receive O 0 0.00033776136
consolidation O 0 0.0061616674
radiotherapy O 0 0.028640946
and O 0 0.00037884625
24 O 0 0.00024826275
patients O 0 0.00021760105
received O 0 0.00014282817
preplanned O 0 0.0009157162
second O 0 0.00022368916
- O 0 0.0049946103
line O 0 0.0004279436
chemotherapy O 0 0.019162873
after O 0 0.00016763964
disease O 0 0.8886627
progression O 0 0.44506195
, O 0 0.0005421374
the O 0 0.00020062199
response O 0 0.00036499277
and O 0 0.0006717607
toxicity B-Disease 2 0.99555343
rates O 0 0.00045552102
reported O 0 0.00040447823
refer O 0 0.00034178427
only O 0 0.00039544774
to O 0 0.00046792443
the O 0 0.000789767
chemotherapy O 0 0.014055775
regimen O 0 0.002420786
given O 0 0.0025602705
. O 0 0.00592895

RESULTS O 0 0.006255222
: O 0 0.0038161287
All O 0 0.0018483837
the O 0 0.0015597112
patients O 0 0.0014457027
were O 0 0.0009997422
examined O 0 0.0007620451
for O 0 0.0011744602
toxicity B-Disease 2 0.99576676
; O 0 0.0023833152
34 O 0 0.0014939485
were O 0 0.0014320421
examinable O 0 0.0026256258
for O 0 0.002573782
response O 0 0.0052653905
. O 0 0.008370101

An O 0 0.004962502
objective O 0 0.0032997425
response O 0 0.0022631472
was O 0 0.0013604511
observed O 0 0.0008506702
in O 0 0.00075114163
73 O 0 0.0010776145
. O 0 0.0004292627
5 O 0 0.00031524152
% O 0 0.00034613837
of O 0 0.0003010638
the O 0 0.00026412026
patients O 0 0.00039098092
( O 0 0.00037281835
95 O 0 0.00043199232
% O 0 0.00026183462
confidence O 0 0.0005968872
interval O 0 0.00027602472
[ O 0 0.0033069612
CI O 0 0.67225635
] O 0 0.00095545466
, O 0 0.00033671723
55 O 0 0.00027021652
. O 0 0.00019386735
6 O 0 0.0001882133
- O 0 0.00077781983
87 O 0 0.0003907141
. O 0 0.0002136668
1 O 0 0.00022710874
% O 0 0.00030582616
) O 0 0.00044730582
, O 0 0.00033331945
including O 0 0.0002511638
4 O 0 0.0002547107
complete O 0 0.00027937125
responses O 0 0.00056304305
( O 0 0.0008070974
11 O 0 0.0007895578
. O 0 0.0009475359
7 O 0 0.0014259713
% O 0 0.0029535296
) O 0 0.0057921405
. O 0 0.007955497

According O 0 0.003579814
to O 0 0.0024932222
intention O 0 0.016015202
- O 0 0.013127879
to O 0 0.0012159987
- O 0 0.007698069
treat O 0 0.0009050097
, O 0 0.0006652909
the O 0 0.00034649647
overall O 0 0.0003227988
response O 0 0.0003651852
rate O 0 0.00034985543
was O 0 0.00031205776
71 O 0 0.00057797885
. O 0 0.00021969934
4 O 0 0.00020252202
% O 0 0.00028557918
( O 0 0.00036829597
95 O 0 0.0005666018
% O 0 0.00050417345
CI O 0 0.23808686
, O 0 0.000522477
53 O 0 0.0005741089
. O 0 0.00041087574
7 O 0 0.0005068574
- O 0 0.0014108313
85 O 0 0.0010864814
. O 0 0.0011324087
4 O 0 0.0016324859
% O 0 0.003294753
) O 0 0.0063241795
. O 0 0.008631625

After O 0 0.0029010656
154 O 0 0.0036871692
courses O 0 0.0016630919
of O 0 0.0013849422
therapy O 0 0.0018219053
, O 0 0.0008756783
the O 0 0.00040247102
median O 0 0.00026268576
dose O 0 0.00059744384
intensity O 0 0.00026013658
was O 0 0.00027592946
131 O 0 0.0009655029
mg O 0 0.015245807
/ O 0 0.0020302741
m O 0 0.00309564
( O 0 0.00045398428
2 O 0 0.00021239668
) O 0 0.00034753527
for O 0 0.00026279746
paclitaxel B-Chemical 1 0.9930634
( O 0 0.0008609166
97 O 0 0.00053591793
. O 0 0.00018037474
3 O 0 0.00016035426
% O 0 0.0002391787
) O 0 0.0003857007
, O 0 0.000305946
117 O 0 0.00072622136
mg O 0 0.013384006
/ O 0 0.0017762205
m O 0 0.0027545358
( O 0 0.0004287517
2 O 0 0.0002059308
) O 0 0.00035692638
for O 0 0.0002988085
cisplatin B-Chemical 1 0.9993668
( O 0 0.00093442114
97 O 0 0.0005540876
. O 0 0.00018701707
3 O 0 0.00016870133
% O 0 0.00025321718
) O 0 0.0004070573
, O 0 0.00032716297
and O 0 0.0003674268
1378 O 0 0.08456344
mg O 0 0.02027806
/ O 0 0.0018244305
m O 0 0.0023682038
( O 0 0.00050267397
2 O 0 0.00029221075
) O 0 0.0004906544
for O 0 0.00045852308
gemcitabine B-Chemical 0 0.9878962
( O 0 0.0012694056
86 O 0 0.0013313293
. O 0 0.0010424043
2 O 0 0.0015643515
% O 0 0.0029983218
) O 0 0.0057642893
. O 0 0.007857386

World O 0 0.007467172
Health O 0 0.0038345524
Organization O 0 0.0030755745
Grade O 0 0.1121787
3 O 0 0.0012869941
- O 0 0.003282496
4 O 0 0.0008636279
neutropenia B-Disease 0 0.9970897
and O 0 0.0024880168
thrombocytopenia B-Disease 0 0.99995625
occurred O 0 0.00052647677
in O 0 0.00034269405
39 O 0 0.00046872263
. O 0 0.00025642806
9 O 0 0.00026004584
% O 0 0.0003251313
and O 0 0.00035096818
11 O 0 0.00039772232
. O 0 0.0004025595
4 O 0 0.0004868848
% O 0 0.00082360697
of O 0 0.0012275353
patients O 0 0.0023714695
, O 0 0.0033665535
respectively O 0 0.0076064095
. O 0 0.008037068

There O 0 0.010609058
was O 0 0.008502362
one O 0 0.0072794086
treatment O 0 0.009160914
- O 0 0.01876515
related O 0 0.010687263
death B-Disease 0 0.9944372
. O 0 0.023643406

Nonhematologic O 0 0.9985511
toxicities B-Disease 2 0.99739504
were O 0 0.034416392
mild O 0 0.67270786
. O 0 0.03925168

After O 0 0.002726359
a O 0 0.0023432272
median O 0 0.0011901774
follow O 0 0.0010057837
- O 0 0.0021074724
up O 0 0.00060857227
of O 0 0.00056434487
22 O 0 0.00050381606
months O 0 0.00026953622
, O 0 0.00031785527
the O 0 0.00021246514
median O 0 0.00018234453
progression O 0 0.008561139
free O 0 0.00036405327
survival O 0 0.007494823
rate O 0 0.00028028313
was O 0 0.00022508108
7 O 0 0.00017404376
months O 0 0.00016245393
, O 0 0.0002673148
and O 0 0.00027329012
the O 0 0.0002881624
median O 0 0.00032970856
survival O 0 0.0013795692
time O 0 0.00064414035
was O 0 0.0011800246
16 O 0 0.0018651712
months O 0 0.002459483
. O 0 0.0055716075

CONCLUSIONS O 0 0.019089755
: O 0 0.0035247863
The O 0 0.0014967574
combination O 0 0.0015206273
of O 0 0.0020259127
paclitaxel B-Chemical 1 0.99934727
, O 0 0.03990133
cisplatin B-Chemical 1 0.9999299
, O 0 0.0031155176
and O 0 0.0013909097
gemcitabine B-Chemical 0 0.99670583
is O 0 0.00046100232
well O 0 0.00035372295
tolerated O 0 0.0013894339
and O 0 0.0003753745
shows O 0 0.00033265914
high O 0 0.0008157297
activity O 0 0.0010568274
in O 0 0.0020096172
metastatic O 0 0.9630303
NSCLC B-Disease 2 0.9994568
. O 0 0.009059146

This O 0 0.00598895
treatment O 0 0.0032803768
merits O 0 0.0023629114
further O 0 0.001898938
comparison O 0 0.0016414828
with O 0 0.002066115
other O 0 0.003951629
cisplatin B-Chemical 1 0.99976903
- O 0 0.05016089
based O 0 0.004872869
regimens O 0 0.007966501
. O 0 0.009241033

Serotonergic B-Chemical 0 0.99330336
antidepressants I-Chemical 0 0.99981624
and O 0 0.025736647
urinary B-Disease 0 0.85252005
incontinence I-Disease 0 0.9931282
. O 0 0.03467707

Many O 0 0.006078219
new O 0 0.0068091727
serotonergic B-Chemical 0 0.9891454
antidepressants I-Chemical 0 0.999962
have O 0 0.0021951746
been O 0 0.0019286704
introduced O 0 0.0017395738
over O 0 0.0017466487
the O 0 0.0028153278
past O 0 0.004967098
decade O 0 0.009890507
. O 0 0.011041116

Although O 0 0.0038637547
urinary B-Disease 0 0.36407414
incontinence I-Disease 0 0.9801467
is O 0 0.0014640474
listed O 0 0.0006146567
as O 0 0.00055802736
one O 0 0.00045371905
side O 0 0.0033637164
effect O 0 0.00034478676
of O 0 0.00039645063
these O 0 0.0004343946
drugs O 0 0.07584862
in O 0 0.0002662364
their O 0 0.00029145062
package O 0 0.0005382308
inserts O 0 0.00051671953
there O 0 0.00025647428
is O 0 0.00040015118
only O 0 0.00051431207
one O 0 0.00060507574
report O 0 0.0012702703
in O 0 0.0012715547
the O 0 0.0020761362
literature O 0 0.004797965
. O 0 0.006754596

This O 0 0.0066127735
concerns O 0 0.004482359
2 O 0 0.0033585473
male O 0 0.004229153
patients O 0 0.0029453852
who O 0 0.0030447892
experienced O 0 0.0032072589
incontinence B-Disease 0 0.97291803
while O 0 0.004744981
taking O 0 0.06703288
venlafaxine B-Chemical 0 0.9999213
. O 0 0.011404251

In O 0 0.003612711
the O 0 0.0022036717
present O 0 0.0014203523
paper O 0 0.0014138892
the O 0 0.0006899402
authors O 0 0.00044704406
describe O 0 0.00044654025
2 O 0 0.00042939256
female O 0 0.0007897806
patients O 0 0.00047610563
who O 0 0.00045791158
developed O 0 0.0006394242
incontinence B-Disease 0 0.97458094
secondary O 0 0.0077953264
to O 0 0.00019747438
the O 0 0.00027437723
selective O 0 0.031383067
serotonin B-Chemical 0 0.99999106
reuptake O 0 0.99800557
inhibitors O 0 0.48432255
paroxetine B-Chemical 0 0.9999995
and O 0 0.00705299
sertraline B-Chemical 0 0.99999845
, O 0 0.00034104098
as O 0 0.00015874348
well O 0 0.00016655684
as O 0 0.00019045726
a O 0 0.0002828675
third O 0 0.0003289839
who O 0 0.0004666523
developed O 0 0.0005099093
this O 0 0.00053231453
side O 0 0.0053988667
effect O 0 0.0013163546
on O 0 0.00219178
venlafaxine B-Chemical 0 0.99994385
. O 0 0.007482532

In O 0 0.003846934
2 O 0 0.002435334
of O 0 0.0017523326
the O 0 0.0011916454
3 O 0 0.0008396335
cases O 0 0.00079015014
the O 0 0.00051108736
patients O 0 0.00056707946
were O 0 0.00033558646
also O 0 0.00032299
taking O 0 0.006933134
lithium B-Chemical 0 0.99998343
carbonate I-Chemical 0 0.9990694
and O 0 0.00495743
beta O 0 0.9964981
- O 0 0.666094
blockers O 0 0.99677867
, O 0 0.0007106778
both O 0 0.00030852505
of O 0 0.00042217085
which O 0 0.00050084386
could O 0 0.00041590986
have O 0 0.00055163563
contributed O 0 0.001104668
to O 0 0.0013051652
the O 0 0.0026375703
incontinence B-Disease 0 0.97087765
. O 0 0.007841007

Animal O 0 0.0064956844
studies O 0 0.0023828843
suggest O 0 0.0012560029
that O 0 0.0013034572
incontinence B-Disease 0 0.9704925
secondary O 0 0.030656764
to O 0 0.0013261662
serotonergic B-Chemical 0 0.9980921
antidepressants I-Chemical 0 0.9999951
could O 0 0.00032836947
be O 0 0.00029774464
mediated O 0 0.00025626578
by O 0 0.00044627045
the O 0 0.0006790607
5HT4 O 0 0.96503353
receptors O 0 0.0022612112
found O 0 0.0008671658
on O 0 0.0011148093
the O 0 0.00238715
bladder O 0 0.16552325
. O 0 0.007724752

Further O 0 0.004116027
research O 0 0.002944597
is O 0 0.0016920923
needed O 0 0.0009169364
to O 0 0.0007150623
delineate O 0 0.00047127678
the O 0 0.00048119313
frequency O 0 0.00050729624
of O 0 0.0005176454
this O 0 0.00048801335
troubling O 0 0.003681565
side O 0 0.0046265945
effect O 0 0.0004946034
and O 0 0.00063896703
how O 0 0.00062299304
best O 0 0.001081368
to O 0 0.0013800687
treat O 0 0.003032922
it O 0 0.0041521583
. O 0 0.006709498

Acute O 0 0.98438317
cocaine B-Chemical 1 0.9999876
- O 0 0.3676893
induced O 0 0.017022992
seizures B-Disease 0 0.9999974
: O 0 0.0056502605
differential O 0 0.0016001498
sensitivity O 0 0.0023387915
of O 0 0.0016759208
six O 0 0.0014711469
inbred O 0 0.0027281279
mouse O 0 0.0034806016
strains O 0 0.0051485132
. O 0 0.008544041

Mature O 0 0.008958697
male O 0 0.0059816088
and O 0 0.0023404954
female O 0 0.0023997563
mice O 0 0.00072965486
from O 0 0.0006100499
six O 0 0.00042386615
inbred O 0 0.0005594866
stains O 0 0.0010133316
were O 0 0.00031172266
tested O 0 0.00024710846
for O 0 0.00027652702
susceptibility O 0 0.0011276219
to O 0 0.00037577032
behavioral O 0 0.3262783
seizures B-Disease 0 0.99999666
induced O 0 0.0006389706
by O 0 0.0006151285
a O 0 0.00079826993
single O 0 0.0009482861
injection O 0 0.0023248098
of O 0 0.005505863
cocaine B-Chemical 1 0.99994636
. O 0 0.008449709

Cocaine B-Chemical 0 0.9999683
was O 0 0.0039615114
injected O 0 0.002171121
ip O 0 0.15473485
over O 0 0.00063914777
a O 0 0.0006782615
range O 0 0.0004923266
of O 0 0.00051013025
doses O 0 0.0040558055
( O 0 0.000908687
50 O 0 0.00063936133
- O 0 0.003654729
100 O 0 0.0005891776
mg O 0 0.016053751
/ O 0 0.0013876079
kg O 0 0.0010299608
) O 0 0.0006435196
and O 0 0.00047792922
behavior O 0 0.0008141071
was O 0 0.00060774654
monitored O 0 0.00065195747
for O 0 0.0011409073
20 O 0 0.0018224872
minutes O 0 0.0027088802
. O 0 0.0058678244

Seizure B-Disease 2 0.9979055
end O 0 0.0021516483
points O 0 0.0015857687
included O 0 0.0010254239
latency O 0 0.0013974652
to O 0 0.0007304163
forelimb O 0 0.21891516
or O 0 0.0008340095
hindlimb O 0 0.57260716
clonus O 0 0.99976355
, O 0 0.001005528
latency O 0 0.0018822433
to O 0 0.0005303491
clonic O 0 0.9999565
running O 0 0.02343454
seizure B-Disease 2 0.99989367
and O 0 0.00082031265
latency O 0 0.0015858444
to O 0 0.0012039348
jumping O 0 0.12264129
bouncing O 0 0.30188072
seizure B-Disease 2 0.99980396
. O 0 0.0081051085

A O 0 0.023627564
range O 0 0.0027984134
of O 0 0.0019884931
strain O 0 0.0012577215
specific O 0 0.0009035105
sensitivities O 0 0.0013558386
was O 0 0.00064874213
documented O 0 0.0006832138
with O 0 0.0006774234
A O 0 0.31007957
/ O 0 0.064763725
J O 0 0.9826386
and O 0 0.0008934907
SJL O 0 0.061300974
mice O 0 0.00027405223
being O 0 0.00054454274
most O 0 0.00054189644
sensitive O 0 0.00063518056
and O 0 0.001122328
C57BL O 0 0.79281807
/ O 0 0.025343757
6J O 0 0.11028377
most O 0 0.0037931902
resistant O 0 0.0052578035
. O 0 0.0076190243

DBA O 0 0.988884
/ O 0 0.19371746
2J O 0 0.92933714
, O 0 0.005531864
BALB O 0 0.15007015
/ O 0 0.008531991
cByJ O 0 0.010155497
and O 0 0.0023016143
NZW O 0 0.44558373
/ O 0 0.0066200322
LacJ O 0 0.0061533684
strains O 0 0.0021255438
exhibited O 0 0.0026723957
intermediate O 0 0.0071271593
sensitivity O 0 0.012386853
. O 0 0.009874889

EEG O 0 0.42507863
recordings O 0 0.003414683
were O 0 0.0018925121
made O 0 0.0013565217
in O 0 0.00135994
SJL O 0 0.15523142
, O 0 0.0022732462
A O 0 0.33665064
/ O 0 0.08283486
J O 0 0.9886662
and O 0 0.0025943825
C57BL O 0 0.92092925
/ O 0 0.021666234
6J O 0 0.02022738
mice O 0 0.00028649383
revealing O 0 0.00049405947
a O 0 0.00042931995
close O 0 0.0004020791
correspondence O 0 0.0006802084
between O 0 0.0006306121
electrical O 0 0.007737043
activity O 0 0.0015729323
and O 0 0.0027517092
behavior O 0 0.007552183
. O 0 0.0072353384

Additionally O 0 0.0044922982
, O 0 0.0032736016
levels O 0 0.0019111007
of O 0 0.0028969818
cocaine B-Chemical 1 0.9999535
determined O 0 0.0008955217
in O 0 0.0008803231
hippocampus O 0 0.3208458
and O 0 0.0007773972
cortex O 0 0.12804626
were O 0 0.00040569733
not O 0 0.00035945486
different O 0 0.00040771085
between O 0 0.0005348835
sensitive O 0 0.001045707
and O 0 0.0015870753
resistant O 0 0.0027558054
strains O 0 0.0042809374
. O 0 0.007274965

Additional O 0 0.002947243
studies O 0 0.0021577177
of O 0 0.0017912075
these O 0 0.0014625534
murine O 0 0.0024122794
strains O 0 0.0010862792
may O 0 0.0006044489
be O 0 0.00048948935
useful O 0 0.00040541377
for O 0 0.00036522004
investigating O 0 0.00037900047
genetic O 0 0.00094401446
influences O 0 0.0006475608
on O 0 0.0009866914
cocaine B-Chemical 1 0.9999889
- O 0 0.20669991
induced O 0 0.025943458
seizures B-Disease 0 0.9999939
. O 0 0.012097262

Hypotension B-Disease 2 0.9991586
following O 0 0.0022654945
the O 0 0.0015076186
initiation O 0 0.0016030478
of O 0 0.0050230827
tizanidine B-Chemical 0 0.99999714
in O 0 0.00081656926
a O 0 0.00064243807
patient O 0 0.00043572378
treated O 0 0.00043042697
with O 0 0.00050636654
an O 0 0.0020400058
angiotensin B-Chemical 1 0.9999801
converting O 0 0.11059735
enzyme O 0 0.12676422
inhibitor O 0 0.043443546
for O 0 0.0025758727
chronic O 0 0.9948967
hypertension B-Disease 2 0.9999938
. O 0 0.010992182

Centrally O 0 0.33108097
acting O 0 0.015398142
alpha O 0 0.9641032
- O 0 0.21879826
2 O 0 0.002166726
adrenergic O 0 0.98443884
agonists O 0 0.36671394
are O 0 0.0004736118
one O 0 0.0002945769
of O 0 0.00029997504
several O 0 0.00022415376
pharmacologic O 0 0.0029108892
agents O 0 0.0015971322
used O 0 0.00018761432
in O 0 0.00019419835
the O 0 0.00020717114
treatment O 0 0.0003512187
of O 0 0.0010106959
spasticity B-Disease 0 0.99992645
related O 0 0.00026683966
to O 0 0.00036323702
disorders B-Disease 0 0.23371673
of I-Disease 0 0.00073922763
the I-Disease 0 0.00091430004
central I-Disease 0 0.002067914
nervous I-Disease 0 0.036209237
system I-Disease 0 0.0040413886
. O 0 0.0063340995

In O 0 0.0036907536
addition O 0 0.0018824125
to O 0 0.0016419283
their O 0 0.0014427998
effects O 0 0.0015076301
on O 0 0.0010476864
spasticity B-Disease 0 0.999933
, O 0 0.0018495885
certain O 0 0.0012868702
adverse O 0 0.37591696
cardiorespiratory O 0 0.14317971
effects O 0 0.0014832541
have O 0 0.001511142
been O 0 0.002606255
reported O 0 0.0047884383
. O 0 0.0073704147

Adults O 0 0.016614504
chronically O 0 0.009296862
treated O 0 0.0026219247
with O 0 0.00541552
angiotensin B-Chemical 1 0.99998343
converting O 0 0.22400698
enzyme O 0 0.10660368
inhibitors O 0 0.0031671382
may O 0 0.0002799074
have O 0 0.00021189303
a O 0 0.00025957418
limited O 0 0.00018507567
ability O 0 0.00019953422
to O 0 0.00018947462
respond O 0 0.00020401046
to O 0 0.00034370148
hypotension B-Disease 2 0.99992085
when O 0 0.00028815801
the O 0 0.00044787113
sympathetic O 0 0.009243203
response O 0 0.00090651354
is O 0 0.0012300824
simultaneously O 0 0.0019031633
blocked O 0 0.0047394047
. O 0 0.006806583

The O 0 0.0027757275
authors O 0 0.0016355383
present O 0 0.0012972897
a O 0 0.0013985704
10 O 0 0.0010359249
- O 0 0.002969722
year O 0 0.00080843834
- O 0 0.003401227
old O 0 0.00053190446
boy O 0 0.0012009289
chronically O 0 0.008308891
treated O 0 0.00071115204
with O 0 0.004701644
lisinopril B-Chemical 0 0.99999917
, O 0 0.004287968
an O 0 0.0063199797
angiotensin B-Chemical 1 0.99999106
converting O 0 0.13435522
enzyme O 0 0.13054782
inhibitor O 0 0.019586368
, O 0 0.00043584034
to O 0 0.00016909942
control O 0 0.0008931962
hypertension B-Disease 2 0.9999976
who O 0 0.0027498927
developed O 0 0.0033785403
hypotension B-Disease 2 0.99995685
following O 0 0.00012745657
the O 0 0.00012414494
addition O 0 0.000108494954
of O 0 0.0025371846
tizanidine B-Chemical 0 0.9999988
, O 0 0.0011685587
an O 0 0.0009886369
alpha O 0 0.9528081
- O 0 0.21878047
2 O 0 0.0005705334
agonist O 0 0.35488698
, O 0 0.00071608636
for O 0 0.0005758571
the O 0 0.0008577184
treatment O 0 0.0018318318
of O 0 0.006545702
spasticity B-Disease 0 0.9999107
. O 0 0.008336787

The O 0 0.002815961
possible O 0 0.002045682
interaction O 0 0.0019530004
of O 0 0.006113424
tizanidine B-Chemical 0 0.9999975
and O 0 0.0023519055
other O 0 0.0014311186
antihypertensive O 0 0.96850824
agents O 0 0.00492716
should O 0 0.00017356285
be O 0 0.0001961284
kept O 0 0.00019918369
in O 0 0.00021459472
mind O 0 0.0005207393
when O 0 0.0001712324
prescribing O 0 0.0010178918
therapy O 0 0.00033434643
to O 0 0.00021551416
treat O 0 0.00050509174
either O 0 0.0009063074
hypertension B-Disease 2 0.99999666
or O 0 0.0035628679
spasticity B-Disease 0 0.99992526
in O 0 0.0013785147
such O 0 0.0019502059
patients O 0 0.0048558367
. O 0 0.006042265

Two O 0 0.0037249262
mouse O 0 0.0029099525
lines O 0 0.002260486
selected O 0 0.0010061249
for O 0 0.00076287275
differential O 0 0.0007026132
sensitivities O 0 0.0014560582
to O 0 0.000921467
beta B-Chemical 0 0.99975437
- I-Chemical 0 0.95991117
carboline I-Chemical 0 0.9999869
- O 0 0.3078244
induced O 0 0.00407565
seizures B-Disease 0 0.99999917
are O 0 0.0003040272
also O 0 0.0001785658
differentially O 0 0.00015102781
sensitive O 0 0.00018621547
to O 0 0.0001491664
various O 0 0.00023903484
pharmacological O 0 0.0037502581
effects O 0 0.00038049818
of O 0 0.00064485404
other O 0 0.008523068
GABA B-Chemical 1 0.9999962
( O 0 0.009415043
A O 0 0.33617893
) O 0 0.004803282
receptor O 0 0.04494071
ligands O 0 0.06606671
. O 0 0.008039578

Two O 0 0.0039084307
mouse O 0 0.0032423106
lines O 0 0.0028874935
were O 0 0.0012499343
selectively O 0 0.0009122047
bred O 0 0.0012150296
according O 0 0.0003923519
to O 0 0.0003202711
their O 0 0.00035671718
sensitivity O 0 0.002752497
( O 0 0.004177957
BS O 0 0.9952245
line O 0 0.0016256053
) O 0 0.0010617737
or O 0 0.00030188294
resistance O 0 0.006782964
( O 0 0.0027907782
BR O 0 0.8616173
line O 0 0.0011800987
) O 0 0.0011073152
to O 0 0.00033118483
seizures B-Disease 0 0.9999962
induced O 0 0.00030496749
by O 0 0.00023972984
a O 0 0.00026092154
single O 0 0.00022632428
i O 0 0.0021905778
. O 0 0.00018284768
p O 0 0.00020436579
. O 0 0.00016635367
injection O 0 0.00033803968
of O 0 0.0009011573
methyl B-Chemical 0 0.99976
beta I-Chemical 0 0.99992406
- I-Chemical 0 0.96731967
carboline I-Chemical 0 0.9999845
- I-Chemical 0 0.18553783
3 I-Chemical 0 0.00030687553
- I-Chemical 0 0.021917352
carboxylate I-Chemical 0 0.9806044
( O 0 0.019509291
beta B-Chemical 0 0.9996755
- I-Chemical 0 0.84914076
CCM I-Chemical 0 0.9981774
) O 0 0.0037228933
, O 0 0.0004581183
an O 0 0.0003119082
inverse O 0 0.00040634215
agonist O 0 0.52494156
of O 0 0.00086755684
the O 0 0.002603688
GABA B-Chemical 1 0.9999962
( O 0 0.007826682
A O 0 0.43221548
) O 0 0.01195266
receptor O 0 0.5190646
benzodiazepine B-Chemical 1 0.9999864
site O 0 0.0066550877
. O 0 0.0075173443

Our O 0 0.0040220045
aim O 0 0.0026570407
was O 0 0.0016609676
to O 0 0.0010058824
characterize O 0 0.00059007504
both O 0 0.0006903019
lines O 0 0.0015550859
' O 0 0.00079463655
sensitivities O 0 0.0007016186
to O 0 0.00029015614
various O 0 0.00032078996
physiological O 0 0.00037226203
effects O 0 0.00033846468
of O 0 0.00035733034
other O 0 0.00041697102
ligands O 0 0.006480897
of O 0 0.0011417429
the O 0 0.003353721
GABA B-Chemical 1 0.9999927
( O 0 0.007902336
A O 0 0.29203618
) O 0 0.0064015123
receptor O 0 0.055910237
. O 0 0.008143744

We O 0 0.0038719391
measured O 0 0.003944438
diazepam B-Chemical 0 0.9999975
- O 0 0.23460619
induced O 0 0.0036133807
anxiolysis O 0 0.999265
with O 0 0.000796558
the O 0 0.00044011133
elevated O 0 0.0038835157
plus O 0 0.00039713414
- O 0 0.03639976
maze O 0 0.107841834
test O 0 0.0005784933
, O 0 0.012302618
diazepam B-Chemical 0 0.99999976
- O 0 0.06034053
induced O 0 0.00034735905
sedation O 0 0.06750979
by O 0 0.00015632198
recording O 0 0.00018844297
the O 0 0.00015298845
vigilance O 0 0.014234966
states O 0 0.0004629046
, O 0 0.00077121577
and O 0 0.010644202
picrotoxin B-Chemical 0 1.0
- O 0 0.60091037
and O 0 0.043851126
pentylenetetrazol B-Chemical 0 1.0
- O 0 0.27679542
induced O 0 0.0037055481
seizures B-Disease 0 0.99999833
after O 0 0.0004746893
i O 0 0.0033984513
. O 0 0.00086865533
p O 0 0.0013944322
. O 0 0.002083521
injections O 0 0.0047752056
. O 0 0.0064568454

Results O 0 0.0035157856
presented O 0 0.002191718
here O 0 0.0015636189
show O 0 0.00088579976
that O 0 0.0006848269
the O 0 0.000603895
differential O 0 0.00061323366
sensitivities O 0 0.0014191753
of O 0 0.001742281
BS O 0 0.9970252
and O 0 0.0016937387
BR O 0 0.8806363
lines O 0 0.004534969
to O 0 0.00056446757
beta B-Chemical 0 0.99949086
- I-Chemical 0 0.74124455
CCM I-Chemical 0 0.9909299
can O 0 0.00019838348
be O 0 0.00018334648
extended O 0 0.00019504064
to O 0 0.0004781407
diazepam B-Chemical 0 0.99999976
, O 0 0.1512094
picrotoxin B-Chemical 0 0.9999999
, O 0 0.016328014
and O 0 0.023504177
pentylenetetrazol B-Chemical 0 0.9999999
, O 0 0.0011627754
suggesting O 0 0.00016285703
a O 0 0.00024180733
genetic O 0 0.0005779064
selection O 0 0.00029986096
of O 0 0.00025198003
a O 0 0.0002700092
general O 0 0.00017925359
sensitivity O 0 0.00059451733
and O 0 0.00027884857
resistance O 0 0.00070792966
to O 0 0.00019269269
several O 0 0.0002188599
ligands O 0 0.0015277686
of O 0 0.0007713312
the O 0 0.002235093
GABA B-Chemical 1 0.9999914
( O 0 0.0069326935
A O 0 0.28213122
) O 0 0.006266915
receptor O 0 0.056303617
. O 0 0.007989884

Propylthiouracil B-Chemical 0 0.999928
- O 0 0.03305434
induced O 0 0.002323639
perinuclear O 0 0.005439938
- O 0 0.010582215
staining O 0 0.0021679366
antineutrophil O 0 0.9727184
cytoplasmic O 0 0.0028846227
autoantibody O 0 0.99638784
- O 0 0.110668294
positive O 0 0.008907991
vasculitis B-Disease 2 0.999982
in O 0 0.0016060782
conjunction O 0 0.0023081969
with O 0 0.004292447
pericarditis B-Disease 0 0.9990231
. O 0 0.009652414

OBJECTIVE O 0 0.015901502
: O 0 0.003935495
To O 0 0.0017872644
describe O 0 0.0015020021
a O 0 0.001635381
case O 0 0.0015388093
of O 0 0.0052015875
propylthiouracil B-Chemical 0 0.99999833
- O 0 0.40516827
induced O 0 0.015685558
vasculitis B-Disease 2 0.99999595
manifesting O 0 0.94712913
with O 0 0.022406172
pericarditis B-Disease 0 0.99967504
. O 0 0.01152828

METHODS O 0 0.0039289095
: O 0 0.0033161242
We O 0 0.001741961
present O 0 0.00109218
the O 0 0.00091070397
first O 0 0.00065064157
case O 0 0.00067709415
report O 0 0.0009501305
of O 0 0.0006046711
a O 0 0.00070701475
woman O 0 0.013824667
with O 0 0.004295085
hyperthyroidism B-Disease 0 0.9999975
treated O 0 0.0051867226
with O 0 0.0051776734
propylthiouracil B-Chemical 0 0.99999714
in O 0 0.00043713703
whom O 0 0.001216161
a O 0 0.0005243669
syndrome O 0 0.28243515
of O 0 0.0015737847
pericarditis B-Disease 0 0.9998945
, O 0 0.04691915
fever B-Disease 0 0.9999548
, O 0 0.0053161527
and O 0 0.0066746855
glomerulonephritis B-Disease 2 0.99999285
developed O 0 0.038824324
. O 0 0.007732275

Serologic O 0 0.3051165
testing O 0 0.0034364362
and O 0 0.0025656777
immunologic O 0 0.009471109
studies O 0 0.0014870315
were O 0 0.0011559449
done O 0 0.0009591769
, O 0 0.001321693
and O 0 0.0012934561
a O 0 0.0017070797
pericardial O 0 0.0098667145
biopsy O 0 0.004215928
was O 0 0.0032164566
performed O 0 0.004489629
. O 0 0.00812202

RESULTS O 0 0.0060846033
: O 0 0.0046415227
A O 0 0.016745172
25 O 0 0.0025912109
- O 0 0.004267875
year O 0 0.0013466028
- O 0 0.002987873
old O 0 0.00083771395
woman O 0 0.0023754633
with O 0 0.001111647
Graves B-Disease 2 0.99024045
' I-Disease 2 0.006835625
disease I-Disease 2 0.9786435
had O 0 0.0006301579
a O 0 0.0017670206
febrile B-Disease 0 0.9998281
illness I-Disease 0 0.9984384
and O 0 0.00065100635
evidence O 0 0.0003410693
of O 0 0.0010580367
pericarditis B-Disease 0 0.99968934
, O 0 0.0019959374
which O 0 0.00097084604
was O 0 0.0009713656
confirmed O 0 0.0013854575
by O 0 0.0025200923
biopsy O 0 0.008109092
. O 0 0.007024762

Serologic O 0 0.22364518
evaluation O 0 0.0023670709
revealed O 0 0.0014427525
the O 0 0.000992344
presence O 0 0.000776391
of O 0 0.0008553674
perinuclear O 0 0.003160776
- O 0 0.009785216
staining O 0 0.0014075568
antineutrophil O 0 0.9674402
cytoplasmic O 0 0.0012441499
autoantibodies O 0 0.8850596
( O 0 0.0052954787
pANCA O 0 0.8863727
) O 0 0.0018621251
against O 0 0.0014456938
myeloperoxidase O 0 0.99853945
( O 0 0.027305005
MPO O 0 0.9980567
) O 0 0.009199899
. O 0 0.0078629535

Propylthiouracil B-Chemical 0 0.99988914
therapy O 0 0.014753296
was O 0 0.0021369744
withdrawn O 0 0.002761743
, O 0 0.0012382563
and O 0 0.0007369143
she O 0 0.00045126054
was O 0 0.000387475
treated O 0 0.00036776287
with O 0 0.0003543542
a O 0 0.00043445404
1 O 0 0.00034077413
- O 0 0.0008351805
month O 0 0.0002462
course O 0 0.00034194218
of O 0 0.00092449307
prednisone B-Chemical 1 0.9996019
, O 0 0.0017275588
which O 0 0.0016230211
alleviated O 0 0.017666653
her O 0 0.003889299
symptoms O 0 0.2809262
. O 0 0.006894566

A O 0 0.022643987
literature O 0 0.0034562834
review O 0 0.0023967172
revealed O 0 0.0011883435
no O 0 0.00073201064
prior O 0 0.00052656914
reports O 0 0.00060514326
of O 0 0.0008670214
pericarditis B-Disease 0 0.9992342
in O 0 0.0012927097
anti O 0 0.7997578
- O 0 0.7355998
MPO O 0 0.99992967
pANCA O 0 0.99161243
- O 0 0.064048484
positive O 0 0.0057209055
vasculitis B-Disease 2 0.9999896
associated O 0 0.0019129679
with O 0 0.002269177
propylthio B-Chemical 0 0.9140679
- I-Chemical 0 0.116387546
uracil I-Chemical 0 0.89527726
therapy O 0 0.011614438
. O 0 0.007051735

CONCLUSION O 0 0.07991275
: O 0 0.00984834
Pericarditis B-Disease 0 0.9975389
may O 0 0.0015486601
be O 0 0.0010052478
the O 0 0.00068867893
initial O 0 0.0005791084
manifestation O 0 0.0120667275
of O 0 0.0012226816
drug O 0 0.80588025
- O 0 0.056233123
induced O 0 0.0018420349
vasculitis B-Disease 2 0.99998915
attributable O 0 0.00089278736
to O 0 0.0011649838
propylthio B-Chemical 0 0.9059243
- I-Chemical 0 0.11625515
uracil I-Chemical 0 0.8996606
therapy O 0 0.012123561
. O 0 0.0072318255

Repeated O 0 0.009528505
transient O 0 0.11505062
anuria B-Disease 2 0.9990915
following O 0 0.005592083
losartan B-Chemical 1 0.99999404
administration O 0 0.07535735
in O 0 0.0011423297
a O 0 0.0012529972
patient O 0 0.0012433389
with O 0 0.001546251
a O 0 0.0026925055
solitary O 0 0.017383946
kidney O 0 0.56383586
. O 0 0.009512412

We O 0 0.0037737407
report O 0 0.0032136359
the O 0 0.0016626345
case O 0 0.0013238031
of O 0 0.0011037372
a O 0 0.0010324395
70 O 0 0.000796777
- O 0 0.0030701174
year O 0 0.0006056314
- O 0 0.00489223
old O 0 0.00075998815
hypertensive B-Disease 2 0.99936503
man O 0 0.025597021
with O 0 0.00030334134
a O 0 0.00034544346
solitary O 0 0.005438976
kidney O 0 0.50015926
and O 0 0.00145399
chronic B-Disease 0 0.9949032
renal I-Disease 0 0.9981439
insufficiency I-Disease 0 0.99991405
who O 0 0.0019936925
developed O 0 0.0004017636
two O 0 0.00021891958
episodes O 0 0.0015542671
of O 0 0.0007320403
transient O 0 0.19635513
anuria B-Disease 2 0.9997111
after O 0 0.0021572823
losartan B-Chemical 1 0.9999908
administration O 0 0.19991171
. O 0 0.0065945927

He O 0 0.008829636
was O 0 0.0033441526
hospitalized O 0 0.010392492
for O 0 0.0017997827
a O 0 0.0040302146
myocardial B-Disease 0 0.99996257
infarction I-Disease 2 0.99999964
with O 0 0.038424004
pulmonary B-Disease 0 0.99726737
edema I-Disease 0 0.99999774
, O 0 0.0029932698
treated O 0 0.0009894039
with O 0 0.0010068978
high O 0 0.0025060854
- O 0 0.045465995
dose O 0 0.13877854
diuretics O 0 0.99972814
. O 0 0.008299047

Due O 0 0.007313769
to O 0 0.0067477953
severe O 0 0.43452182
systolic B-Disease 0 0.99955314
dysfunction I-Disease 0 0.9998853
losartan B-Chemical 1 0.9999943
was O 0 0.013532856
prescribed O 0 0.02920686
. O 0 0.012553204

Surprisingly O 0 0.004563264
, O 0 0.003086589
the O 0 0.0014965108
first O 0 0.0009453749
dose O 0 0.0019979635
of O 0 0.0009027515
50 O 0 0.0009297202
mg O 0 0.06725523
of O 0 0.0020638208
losartan B-Chemical 1 0.9999931
resulted O 0 0.00035465977
in O 0 0.00033073174
a O 0 0.0008388473
sudden O 0 0.9945556
anuria B-Disease 2 0.9996853
, O 0 0.0006541403
which O 0 0.00024407753
lasted O 0 0.00013470012
eight O 0 0.00014253713
hours O 0 0.00016577601
despite O 0 0.00024371523
high O 0 0.00073104334
- O 0 0.02389895
dose O 0 0.1058046
furosemide B-Chemical 1 0.9999945
and O 0 0.012778639
amine B-Chemical 0 0.99948066
infusion O 0 0.036205735
. O 0 0.006285081

One O 0 0.0042765127
week O 0 0.0020834152
later O 0 0.0016511218
, O 0 0.0017408784
by O 0 0.0013048135
mistake O 0 0.026428623
, O 0 0.013585573
losartan B-Chemical 1 0.999995
was O 0 0.00087274535
prescribed O 0 0.0011041989
again O 0 0.000263008
and O 0 0.00022322984
after O 0 0.00013232118
the O 0 0.00015927295
second O 0 0.00016536129
dose O 0 0.0005147709
of O 0 0.00027224547
50 O 0 0.0003756097
mg O 0 0.015070709
, O 0 0.00027030928
the O 0 0.00017914287
patient O 0 0.0002193891
developed O 0 0.00028258478
a O 0 0.00025831535
second O 0 0.00024721285
episode O 0 0.0006299897
of O 0 0.0006495576
transient O 0 0.06753434
anuria B-Disease 2 0.9980679
lasting O 0 0.0015167104
10 O 0 0.001704496
hours O 0 0.0025456278
. O 0 0.005504456

During O 0 0.0031390511
these O 0 0.0026293998
two O 0 0.0018116453
episodes O 0 0.006602247
, O 0 0.001964108
his O 0 0.0016719071
blood O 0 0.00933302
pressure O 0 0.034216836
diminished O 0 0.001132138
but O 0 0.001239376
no O 0 0.0011518219
severe O 0 0.65266573
hypotension B-Disease 2 0.99997485
was O 0 0.0033824102
noted O 0 0.0039939624
. O 0 0.0074151303

Ultimately O 0 0.010377485
, O 0 0.0053296997
an O 0 0.0037406269
arteriography O 0 0.023820475
showed O 0 0.0018742685
a O 0 0.0020176154
70 O 0 0.0019471444
- O 0 0.0037410194
80 O 0 0.002390671
% O 0 0.0036228318
renal B-Disease 0 0.9626226
artery I-Disease 0 0.82640076
stenosis I-Disease 0 0.9995466
. O 0 0.012463843

In O 0 0.0037923434
this O 0 0.002495505
patient O 0 0.0022000389
, O 0 0.0031585295
renal B-Disease 0 0.98935807
artery I-Disease 0 0.89580643
stenosis I-Disease 0 0.99987507
combined O 0 0.0015976933
with O 0 0.0008556793
heart B-Disease 0 0.4089808
failure I-Disease 0 0.5305572
and O 0 0.004136812
diuretic O 0 0.9999505
therapy O 0 0.002559349
certainly O 0 0.00029003527
resulted O 0 0.00016650013
in O 0 0.00019313287
a O 0 0.00025042254
strong O 0 0.0002944177
activation O 0 0.00042631675
of O 0 0.0004779816
the O 0 0.0008052515
renin O 0 0.9920397
- O 0 0.3153
angiotensin B-Chemical 1 0.9999434
system O 0 0.00226818
( O 0 0.0053503974
RAS O 0 0.8633023
) O 0 0.0070802453
. O 0 0.0071751224

Under O 0 0.005369891
such O 0 0.0026709957
conditions O 0 0.0033915956
, O 0 0.05143083
angiotensin B-Chemical 1 0.99999845
II I-Chemical 1 0.9802051
receptor O 0 0.22303332
blockade O 0 0.09354211
by O 0 0.0026968417
losartan B-Chemical 1 0.9999945
probably O 0 0.0012235956
induced O 0 0.0005132342
a O 0 0.00060470443
critical O 0 0.0005248054
fall O 0 0.0014856742
in O 0 0.0011713699
glomerular O 0 0.7176358
filtration O 0 0.018380063
pressure O 0 0.08525666
. O 0 0.0070853564

This O 0 0.0050920844
case O 0 0.0027748249
report O 0 0.0025909694
highlights O 0 0.0012370823
the O 0 0.0007729731
fact O 0 0.0004893606
that O 0 0.0004834705
the O 0 0.0025645408
angiotensin B-Chemical 1 0.9999994
II I-Chemical 1 0.99340713
receptor O 0 0.8161803
antagonist O 0 0.9987429
losartan B-Chemical 1 0.9999988
can O 0 0.0002696642
cause O 0 0.00043189322
serious O 0 0.04148121
unexpected O 0 0.0011409443
complications O 0 0.33650467
in O 0 0.00024723547
patients O 0 0.0006920976
with O 0 0.0022258423
renovascular B-Disease 0 0.9999989
disease I-Disease 0 0.99907327
and O 0 0.0004918579
should O 0 0.00016219853
be O 0 0.00021851108
used O 0 0.00024369315
with O 0 0.00038109423
extreme O 0 0.0008508883
caution O 0 0.000843139
in O 0 0.001147365
this O 0 0.0018355298
setting O 0 0.0033340047
. O 0 0.0062052286

Calcineurin O 0 0.8470247
- O 0 0.028356085
inhibitor O 0 0.008294367
induced O 0 0.0035906944
pain B-Disease 0 0.9962478
syndrome O 0 0.9438655
( O 0 0.026518015
CIPS B-Disease 0 0.99972516
) O 0 0.0033607893
: O 0 0.0013710513
a O 0 0.0011007378
severe O 0 0.10528228
disabling O 0 0.87267774
complication O 0 0.16529499
after O 0 0.0014641547
organ O 0 0.011385382
transplantation O 0 0.05754746
. O 0 0.007823199

Bone O 0 0.013815177
pain B-Disease 0 0.62412775
after O 0 0.002087959
transplantation O 0 0.006262438
is O 0 0.0015530052
a O 0 0.0015597867
frequent O 0 0.0027584052
complication O 0 0.043803845
that O 0 0.0007491458
can O 0 0.0007834414
be O 0 0.0010524709
caused O 0 0.0014016737
by O 0 0.0022874093
several O 0 0.0031860874
diseases O 0 0.71165574
. O 0 0.009517252

Treatment O 0 0.008693766
strategies O 0 0.0043802857
depend O 0 0.002933738
on O 0 0.0021347783
the O 0 0.0023843846
correct O 0 0.002905954
diagnosis O 0 0.005432977
of O 0 0.00456756
the O 0 0.006204523
pain B-Disease 0 0.94858557
. O 0 0.011340411

Nine O 0 0.0065045683
patients O 0 0.0033692422
with O 0 0.0024156142
severe O 0 0.16957384
pain B-Disease 0 0.93713737
in O 0 0.00089240586
their O 0 0.0007838453
feet O 0 0.010586348
, O 0 0.00091696874
which O 0 0.00073317095
was O 0 0.00064794446
registered O 0 0.0007683932
after O 0 0.0006853499
transplantation O 0 0.0040044966
, O 0 0.0021536958
were O 0 0.002486824
investigated O 0 0.0034971565
. O 0 0.007196581

Bone O 0 0.0095057525
scans O 0 0.0060566235
showed O 0 0.0033367295
an O 0 0.0033780602
increased O 0 0.0032363357
tracer O 0 0.008765178
uptake O 0 0.0059596393
of O 0 0.0038156465
the O 0 0.004241827
foot O 0 0.060416937
bones O 0 0.06461374
. O 0 0.011730934

Magnetic O 0 0.21358155
resonance O 0 0.115286626
imaging O 0 0.0056927907
demonstrated O 0 0.0029463684
bone B-Disease 0 0.010651676
marrow I-Disease 0 0.35724467
oedema I-Disease 0 0.99992645
in O 0 0.0040791356
the O 0 0.0047582407
painful O 0 0.85549724
bones O 0 0.08354916
. O 0 0.011825734

Pain B-Disease 0 0.8268035
was O 0 0.0028832883
not O 0 0.001655509
explained O 0 0.0012276728
by O 0 0.0011534634
other O 0 0.0012726573
diseases O 0 0.7880328
causing O 0 0.019279392
foot O 0 0.62444097
pain B-Disease 0 0.9901355
, O 0 0.0007975097
like O 0 0.00037989722
reflex B-Disease 0 0.62287724
sympathetic I-Disease 0 0.4481604
dystrophy I-Disease 0 0.99776864
, O 0 0.007838481
polyneuropathy B-Disease 0 0.99996567
, O 0 0.002557139
Morton B-Disease 0 0.29722202
' I-Disease 0 0.00077043776
s I-Disease 0 0.0021589673
neuralgia I-Disease 0 0.9999919
, O 0 0.012705086
gout B-Disease 0 0.99999845
, O 0 0.048419442
osteoporosis B-Disease 0 0.9999975
, O 0 0.057173368
avascular B-Disease 0 0.9999914
necrosis I-Disease 2 0.9999994
, O 0 0.027629603
intermittent B-Disease 0 0.15863626
claudication I-Disease 0 0.9834115
, O 0 0.0006034919
orthopaedic O 0 0.0010097533
foot B-Disease 0 0.027850298
deformities I-Disease 0 0.81327045
, O 0 0.0025686035
stress B-Disease 0 0.97570723
fractures I-Disease 2 0.999961
, O 0 0.0060424423
and O 0 0.008835704
hyperparathyroidism B-Disease 0 0.99998665
. O 0 0.010175265

The O 0 0.0031149727
reduction O 0 0.003302218
of O 0 0.00481392
cyclosporine B-Chemical 1 0.99999845
- O 0 0.505675
or O 0 0.0037900922
tacrolimus B-Chemical 0 0.99999714
trough O 0 0.55078346
levels O 0 0.0004347428
and O 0 0.00038450866
the O 0 0.00030668516
administration O 0 0.002233389
of O 0 0.0008909619
calcium B-Chemical 0 0.9990946
channel O 0 0.48625025
blockers O 0 0.98628217
led O 0 0.0008937742
to O 0 0.0010070283
relief O 0 0.0048974794
of O 0 0.0039844587
pain B-Disease 0 0.95183086
. O 0 0.0071280063

The O 0 0.004328916
Calcineurin O 0 0.62479883
- O 0 0.016888496
inhibitor O 0 0.012453799
Induced O 0 0.32876638
Pain B-Disease 0 0.99654514
Syndrome O 0 0.8227636
( O 0 0.0054782354
CIPS B-Disease 0 0.9992743
) O 0 0.0016101879
is O 0 0.00040860075
a O 0 0.00044463392
rare O 0 0.001765065
but O 0 0.00046694573
severe O 0 0.039724987
side O 0 0.020074254
effect O 0 0.00028844114
of O 0 0.0026701307
cyclosporine B-Chemical 1 0.99999964
or O 0 0.014951979
tacrolimus B-Chemical 0 0.99999845
and O 0 0.0007389336
is O 0 0.00023734069
accurately O 0 0.0001815465
diagnosed O 0 0.00051868084
by O 0 0.00020497054
its O 0 0.00033675914
typical O 0 0.0003071685
presentation O 0 0.00054731366
, O 0 0.0007085516
magnetic O 0 0.011192646
resonance O 0 0.2880521
imaging O 0 0.0019057473
and O 0 0.001680221
bone O 0 0.0058181915
scans O 0 0.006515832
. O 0 0.0071124183

Incorrect O 0 0.019658366
diagnosis O 0 0.0048737223
of O 0 0.0023240868
the O 0 0.0016634853
syndrome O 0 0.22937208
will O 0 0.00074091397
lead O 0 0.0024609328
to O 0 0.00047953552
a O 0 0.0005495546
significant O 0 0.00043212963
reduction O 0 0.0006048416
of O 0 0.0005492878
life O 0 0.0006964207
quality O 0 0.00060003233
in O 0 0.00087129755
patients O 0 0.0019584107
suffering O 0 0.13407294
from O 0 0.0037983689
CIPS B-Disease 0 0.9984597
. O 0 0.008665648

Brain O 0 0.26501343
natriuretic O 0 0.8537844
peptide O 0 0.006094436
is O 0 0.003037721
a O 0 0.0027009433
predictor O 0 0.00224704
of O 0 0.0046288962
anthracycline B-Chemical 1 0.9999187
- O 0 0.37896806
induced O 0 0.048771847
cardiotoxicity B-Disease 0 0.9999924
. O 0 0.019179758

Anthracyclines B-Chemical 0 0.99754745
are O 0 0.0035677024
effective O 0 0.0031841556
antineoplastic O 0 0.7685997
drugs O 0 0.6575686
, O 0 0.0023397396
but O 0 0.0012433608
they O 0 0.00081497565
frequently O 0 0.0011805338
cause O 0 0.0015439697
dose O 0 0.016844748
- O 0 0.03058905
related O 0 0.0037902475
cardiotoxicity B-Disease 0 0.999972
. O 0 0.01092562

The O 0 0.0044552586
cardiotoxicity B-Disease 0 0.9999349
of O 0 0.0035023848
conventional O 0 0.0028218157
anthracycline B-Chemical 1 0.9996791
therapy O 0 0.0053317426
highlights O 0 0.0006288715
a O 0 0.0004628325
need O 0 0.00025119635
to O 0 0.00021954563
search O 0 0.0002639979
for O 0 0.00021219287
methods O 0 0.00021303722
that O 0 0.0002067869
are O 0 0.00026581637
highly O 0 0.00034908616
sensitive O 0 0.0003954342
and O 0 0.0004880497
capable O 0 0.0006443274
of O 0 0.0011719492
predicting O 0 0.0029311895
cardiac B-Disease 0 0.94587857
dysfunction I-Disease 0 0.9968273
. O 0 0.009060198

We O 0 0.0032479942
measured O 0 0.0019362818
the O 0 0.0015753291
plasma O 0 0.0036654791
level O 0 0.00078981515
of O 0 0.0010358331
brain O 0 0.109013036
natriuretic O 0 0.98220485
peptide O 0 0.0069509437
( O 0 0.008086414
BNP O 0 0.99524915
) O 0 0.0006706234
to O 0 0.00017173668
determine O 0 9.977939e-05
whether O 0 0.00013132849
BNP O 0 0.88684714
might O 0 0.00012959105
serve O 0 0.0001634555
as O 0 0.00014850532
a O 0 0.00019144718
simple O 0 0.00020713302
diagnostic O 0 0.00021737398
indicator O 0 0.00013993478
of O 0 0.0009330848
anthracycline B-Chemical 1 0.99997234
- O 0 0.27861014
induced O 0 0.0044409316
cardiotoxicity B-Disease 0 0.9999994
in O 0 0.0005863227
patients O 0 0.0014088314
with O 0 0.0019872265
acute B-Disease 0 0.99979264
leukemia I-Disease 0 0.99999976
treated O 0 0.009231971
with O 0 0.00089934055
a O 0 0.0025366647
daunorubicin B-Chemical 1 0.9999716
( O 0 0.04028758
DNR B-Chemical 0 0.99976796
) O 0 0.006935229
- O 0 0.006215387
containing O 0 0.0020295628
regimen O 0 0.005205403
. O 0 0.006543566

Thirteen O 0 0.00850083
patients O 0 0.00457104
with O 0 0.004788825
acute B-Disease 0 0.99957746
leukemia I-Disease 0 0.99999845
were O 0 0.0028187928
treated O 0 0.0016951938
with O 0 0.0015941998
a O 0 0.0031858024
DNR B-Chemical 0 0.99913293
- O 0 0.017814575
containing O 0 0.0030368143
regimen O 0 0.0070028827
. O 0 0.008251451

Cardiac O 0 0.021939995
functions O 0 0.0048844228
were O 0 0.0038748886
evaluated O 0 0.003122513
with O 0 0.0039906744
radionuclide O 0 0.01417561
angiography O 0 0.06532337
before O 0 0.005276431
chemotherapies O 0 0.03935595
. O 0 0.013046357

The O 0 0.0033514027
plasma O 0 0.0055075497
levels O 0 0.0017145559
of O 0 0.0019460687
atrial O 0 0.9442891
natriuretic O 0 0.99152136
peptide O 0 0.013502163
( O 0 0.021379579
ANP O 1 0.9999193
) O 0 0.0042734686
and O 0 0.0010342174
BNP O 0 0.956446
were O 0 0.00045456324
measured O 0 0.00038640344
at O 0 0.00048256974
the O 0 0.0006572536
time O 0 0.0008584775
of O 0 0.0020380663
radionuclide O 0 0.026889274
angiography O 0 0.17754163
. O 0 0.0076912898

Three O 0 0.0060767476
patients O 0 0.0052189277
developed O 0 0.007547048
congestive B-Disease 0 0.99974865
heart I-Disease 0 0.7610507
failure I-Disease 0 0.27319852
after O 0 0.0015614259
the O 0 0.0019430704
completion O 0 0.0023583993
of O 0 0.004417579
chemotherapy O 0 0.10379435
. O 0 0.009386708

Five O 0 0.0053788424
patients O 0 0.003388065
were O 0 0.0021309531
diagnosed O 0 0.0026301325
as O 0 0.001365506
having O 0 0.0020025
subclinical O 0 0.8857815
heart B-Disease 0 0.5041676
failure I-Disease 0 0.1690397
after O 0 0.0008442344
the O 0 0.0011879643
completion O 0 0.001576119
of O 0 0.0032548774
chemotherapy O 0 0.089934245
. O 0 0.0077269673

The O 0 0.003325222
plasma O 0 0.006791141
levels O 0 0.0018006475
of O 0 0.002439466
BNP O 0 0.98972917
in O 0 0.000807432
all O 0 0.00045471019
the O 0 0.00035122794
patients O 0 0.00042144168
with O 0 0.00031869242
clinical O 0 0.0015601313
and O 0 0.000517133
subclinical O 0 0.9102866
heart B-Disease 0 0.5466964
failure I-Disease 0 0.29236042
increased O 0 0.00029895038
above O 0 0.00014410313
the O 0 0.00015411836
normal O 0 0.0002918839
limit O 0 0.00028764966
( O 0 0.00034334237
40 O 0 0.0001866006
pg O 0 0.014897459
/ O 0 0.0041457517
ml O 0 0.00080428744
) O 0 0.00039388376
before O 0 0.00013596733
the O 0 0.00018023256
detection O 0 0.00031940755
of O 0 0.00037933124
clinical O 0 0.0018880698
or O 0 0.0006127216
subclinical O 0 0.87946546
heart B-Disease 0 0.41226098
failure I-Disease 0 0.25549498
by O 0 0.0021370891
radionuclide O 0 0.051231053
angiography O 0 0.21106787
. O 0 0.0069772257

On O 0 0.0033696492
the O 0 0.0023786623
other O 0 0.0021378105
hand O 0 0.0031082032
, O 0 0.0047828723
BNP O 0 0.99435246
did O 0 0.00088456075
not O 0 0.00039833173
increase O 0 0.00030809888
in O 0 0.00031107044
the O 0 0.00028088075
patients O 0 0.00041822914
without O 0 0.00032354906
heart B-Disease 0 0.20845701
failure I-Disease 0 0.26303282
given O 0 0.00031765833
DNR B-Chemical 0 0.9994473
, O 0 0.00061042997
even O 0 0.00030326354
at O 0 0.00021359204
more O 0 0.00027311218
than O 0 0.00024210977
700 O 0 0.00075142697
mg O 0 0.008713085
/ O 0 0.002133924
m O 0 0.0034976304
( O 0 0.0023842088
2 O 0 0.0025733635
) O 0 0.0053272336
. O 0 0.0074213548

The O 0 0.0035853193
plasma O 0 0.0069153355
level O 0 0.0018659232
of O 0 0.0037893674
ANP O 1 0.99985373
did O 0 0.0015151175
not O 0 0.0006066001
always O 0 0.00056811736
increase O 0 0.00035885893
in O 0 0.00037907454
all O 0 0.0003378435
the O 0 0.00035877625
patients O 0 0.00054862566
with O 0 0.00058088615
clinical O 0 0.0020475609
and O 0 0.0015973229
subclinical O 0 0.91655576
heart B-Disease 0 0.6396457
failure I-Disease 0 0.6838097
. O 0 0.007953108

These O 0 0.003807269
preliminary O 0 0.0027291854
results O 0 0.0016233162
suggest O 0 0.0010481197
that O 0 0.0012500369
BNP O 0 0.9843962
may O 0 0.00073917024
be O 0 0.0005365221
useful O 0 0.00042900068
as O 0 0.00038129845
an O 0 0.00044534577
early O 0 0.0005744433
and O 0 0.0005044141
sensitive O 0 0.0005195064
indicator O 0 0.00053941
of O 0 0.002368802
anthracycline B-Chemical 1 0.999943
- O 0 0.33228928
induced O 0 0.03453203
cardiotoxicity B-Disease 0 0.9999938
. O 0 0.013670086

Nephrotoxicity B-Disease 2 0.9989274
of O 0 0.012311258
combined O 0 0.034997
cephalothin B-Chemical 1 0.9999231
- O 0 0.69378185
gentamicin B-Chemical 1 0.99969995
regimen O 0 0.09250358
. O 0 0.018042246

Two O 0 0.0039730645
patients O 0 0.003196007
developed O 0 0.0038042448
acute B-Disease 2 0.9925991
tubular I-Disease 2 0.9997774
necrosis I-Disease 2 0.99999964
, O 0 0.031107418
characterized O 0 0.0022330745
clinically O 0 0.03411077
by O 0 0.00068175094
acute O 0 0.97071093
oliguric B-Disease 0 0.99997926
renal I-Disease 0 0.99607384
failure I-Disease 0 0.83309
, O 0 0.001026723
while O 0 0.00027150466
they O 0 0.00016624472
were O 0 0.00018919464
receiving O 0 0.0002310304
a O 0 0.0002638766
combination O 0 0.00044119186
of O 0 0.003824589
cephalothin B-Chemical 1 0.99999857
sodium I-Chemical 0 0.9999938
and O 0 0.083101876
gentamicin B-Chemical 1 0.99999547
sulfate I-Chemical 0 0.9997862
therapy O 0 0.06741613
. O 0 0.0070707924

Patients O 0 0.005488673
who O 0 0.003300235
are O 0 0.0016406408
given O 0 0.0009998516
this O 0 0.0010249678
drug O 0 0.059989937
regimen O 0 0.0010010126
should O 0 0.0003814608
be O 0 0.0004363067
observed O 0 0.0004063939
very O 0 0.00059299305
carefully O 0 0.0004558844
for O 0 0.00073436147
early O 0 0.0018925844
signs O 0 0.18619157
of O 0 0.02112828
nephrotoxicity B-Disease 0 0.9999944
. O 0 0.014100448

High O 0 0.010798484
doses O 0 0.006899913
of O 0 0.0028743495
this O 0 0.0020550068
antibiotic O 0 0.04139198
combination O 0 0.0017631232
should O 0 0.00083953433
be O 0 0.0010687077
avoided O 0 0.0012780944
especially O 0 0.0020685184
in O 0 0.0025523007
elderly O 0 0.245787
patients O 0 0.0072938823
. O 0 0.008224138

Patients O 0 0.006982808
with O 0 0.005199121
renal B-Disease 0 0.92979217
insufficiency I-Disease 0 0.9955087
should O 0 0.0020519285
not O 0 0.0020533567
be O 0 0.002392483
given O 0 0.002388895
this O 0 0.003974769
regimen O 0 0.0076229554
. O 0 0.010104786

In O 0 0.0040010647
vivo O 0 0.0033993218
protection O 0 0.005795203
of O 0 0.0030204367
dna O 0 0.7170301
damage O 0 0.9356724
associated O 0 0.0029419062
apoptotic O 0 0.77399755
and O 0 0.0022320526
necrotic B-Disease 2 0.9870106
cell O 0 0.033225875
deaths O 0 0.9548267
during O 0 0.0013409983
acetaminophen B-Chemical 0 0.9999999
- O 0 0.33213085
induced O 0 0.008809622
nephrotoxicity B-Disease 0 0.9999999
, O 0 0.33339494
amiodarone B-Chemical 1 0.99999964
- O 0 0.27277794
induced O 0 0.001831444
lung B-Disease 0 0.99819726
toxicity I-Disease 2 0.9999969
and O 0 0.031601407
doxorubicin B-Chemical 1 0.9999777
- O 0 0.23843217
induced O 0 0.002782506
cardiotoxicity B-Disease 0 0.9999981
by O 0 0.0007719286
a O 0 0.00093024597
novel O 0 0.0021312614
IH636 B-Chemical 0 0.99688965
grape I-Chemical 0 0.90174466
seed I-Chemical 0 0.03575546
proanthocyanidin I-Chemical 0 0.9994005
extract I-Chemical 0 0.09364044
. O 0 0.007533727

Grape B-Chemical 0 0.97924554
seed I-Chemical 0 0.011044512
extract I-Chemical 0 0.081323765
, O 0 0.0024164417
primarily O 0 0.0013079478
a O 0 0.0011186466
mixture O 0 0.0020096938
of O 0 0.005293866
proanthocyanidins B-Chemical 0 0.99999
, O 0 0.0022914447
has O 0 0.00032819388
been O 0 0.00025189284
shown O 0 0.00015934161
to O 0 0.0001450559
modulate O 0 0.00010959414
a O 0 0.00023998365
wide O 0 0.00046074862
- O 0 0.0017835762
range O 0 0.00021604083
of O 0 0.00025642806
biological O 0 0.00034945557
, O 0 0.00044954312
pharmacological O 0 0.006564942
and O 0 0.0005129678
toxicological O 0 0.1393655
effects O 0 0.00076090766
which O 0 0.0009782616
are O 0 0.0012602751
mainly O 0 0.002806449
cytoprotective O 0 0.59819925
. O 0 0.00759921

This O 0 0.005133602
study O 0 0.0027543786
assessed O 0 0.001453824
the O 0 0.001193936
ability O 0 0.0010787201
of O 0 0.0027289777
IH636 B-Chemical 0 0.9990977
grape I-Chemical 0 0.96325696
seed I-Chemical 0 0.07423972
proanthocyanidin I-Chemical 0 0.99993706
extract I-Chemical 0 0.36644843
( O 0 0.15227543
GSPE B-Chemical 0 0.9999999
) O 0 0.0073788725
to O 0 0.00026024424
prevent O 0 0.00084835873
acetaminophen B-Chemical 0 0.9999999
( O 0 0.09689177
AAP B-Chemical 0 0.99990165
) O 0 0.022559358
- O 0 0.052026127
induced O 0 0.0032262863
nephrotoxicity B-Disease 0 0.9999999
, O 0 0.292809
amiodarone B-Chemical 1 0.99999976
( O 0 0.31227756
AMI B-Chemical 1 0.9999994
) O 0 0.030131508
- O 0 0.035212092
induced O 0 0.000840518
lung B-Disease 0 0.9972978
toxicity I-Disease 2 0.9999957
, O 0 0.0056572626
and O 0 0.0030206132
doxorubicin B-Chemical 1 0.9999436
( O 0 0.09266609
DOX B-Chemical 1 0.99998736
) O 0 0.033737924
- O 0 0.04853738
induced O 0 0.0034253362
cardiotoxicity B-Disease 0 0.99999213
in O 0 0.0028377844
mice O 0 0.0030978175
. O 0 0.006848767

Experimental O 0 0.006181406
design O 0 0.0029280193
consisted O 0 0.0014141412
of O 0 0.0012534979
four O 0 0.0007339896
groups O 0 0.0007902266
: O 0 0.0009805793
control O 0 0.00061750365
( O 0 0.0011096345
vehicle O 0 0.015360704
alone O 0 0.0008807862
) O 0 0.012873173
, O 0 0.040833667
GSPE B-Chemical 0 0.9999999
alone O 0 0.0033497005
, O 0 0.003106856
drug O 0 0.5076027
alone O 0 0.0016610879
and O 0 0.028618103
GSPE B-Chemical 0 0.9999994
+ O 0 0.25118354
drug O 0 0.83497643
. O 0 0.008300119

For O 0 0.0036756822
the O 0 0.0030015989
cytoprotection O 0 0.93691146
study O 0 0.0032781279
, O 0 0.0015434957
animals O 0 0.0006273276
were O 0 0.00052663445
orally O 0 0.0009136999
gavaged O 0 0.008865312
100 O 0 0.00068719225
mg O 0 0.036159728
/ O 0 0.01406216
Kg O 0 0.7729102
GSPE B-Chemical 0 0.99999964
for O 0 0.00039339048
7 O 0 0.00022039843
- O 0 0.0007167882
10 O 0 0.0001379195
days O 0 0.0001002556
followed O 0 0.000119921184
by O 0 0.00018787927
i O 0 0.0013432672
. O 0 0.00019672172
p O 0 0.00021766602
. O 0 0.00016920846
injections O 0 0.0002473783
of O 0 0.0002010776
organ O 0 0.0011626711
specific O 0 0.00015901255
three O 0 0.0001231078
drugs O 0 0.113312155
( O 0 0.0034126604
AAP B-Chemical 0 0.99896944
: O 0 0.0011155403
500 O 0 0.00048266427
mg O 0 0.011862451
/ O 0 0.0013582754
Kg O 0 0.010321789
for O 0 0.00017085372
24 O 0 0.00019335841
h O 0 0.00026306522
; O 0 0.0023560622
AMI B-Chemical 1 0.99998605
: O 0 0.00077662227
50 O 0 0.00030118035
mg O 0 0.010751987
/ O 0 0.0018798662
Kg O 0 0.026720067
/ O 0 0.00067835883
day O 0 0.00014947963
for O 0 0.00014651929
four O 0 0.00013418769
days O 0 0.00016448568
; O 0 0.00094022555
DOX B-Chemical 1 0.99972385
: O 0 0.0009934002
20 O 0 0.00039865216
mg O 0 0.00817515
/ O 0 0.001708932
Kg O 0 0.00946725
for O 0 0.0009889981
48 O 0 0.0016652689
h O 0 0.0024917806
) O 0 0.005391334
. O 0 0.0073676878

Parameters O 0 0.008220767
of O 0 0.00276919
study O 0 0.0018614827
included O 0 0.0009772489
analysis O 0 0.00082731486
of O 0 0.0009507141
serum O 0 0.40930042
chemistry O 0 0.43371862
( O 0 0.02958951
ALT O 0 0.9999856
, O 0 0.056912836
BUN O 0 0.9999995
and O 0 0.018146185
CPK O 0 0.9999858
) O 0 0.0018971402
, O 0 0.00036571722
and O 0 0.0002602445
orderly O 0 0.0009170037
fragmentation O 0 0.006616821
of O 0 0.00032507395
genomic O 0 0.0013156778
DNA O 0 0.20731296
( O 0 0.0006209911
both O 0 0.00028566198
endonuclease O 0 0.41674381
- O 0 0.009159979
dependent O 0 0.00013865253
and O 0 0.0001799427
independent O 0 0.00012157214
) O 0 0.0003020951
in O 0 0.00013536128
addition O 0 9.830954e-05
to O 0 0.00012954965
microscopic O 0 0.00044857827
evaluation O 0 0.00019035542
of O 0 0.00035797255
damage O 0 0.56242394
and O 0 0.00067519833
/ O 0 0.004004755
or O 0 0.00045409164
protection O 0 0.0018459756
in O 0 0.00073649373
corresponding O 0 0.001013474
PAS O 0 0.65597373
stained O 0 0.0049358276
tissues O 0 0.006094875
. O 0 0.0069355597

Results O 0 0.003721408
indicate O 0 0.0020873414
that O 0 0.0030122905
GSPE B-Chemical 0 0.9999989
preexposure O 0 0.556937
prior O 0 0.000870498
to O 0 0.0013182849
AAP B-Chemical 0 0.99985456
, O 0 0.086620644
AMI B-Chemical 1 0.99999845
and O 0 0.022713924
DOX B-Chemical 1 0.9999814
, O 0 0.0009806477
provided O 0 0.00024181472
near O 0 0.00028260902
complete O 0 0.00017448458
protection O 0 0.0006797836
in O 0 0.00018760789
terms O 0 0.00014837738
of O 0 0.0003018818
serum O 0 0.30741987
chemistry O 0 0.12814543
changes O 0 0.0013828791
( O 0 0.009872725
ALT O 0 0.99998283
, O 0 0.034635145
BUN O 0 0.9999994
and O 0 0.012060288
CPK O 0 0.99997365
) O 0 0.0018669475
, O 0 0.0008047559
and O 0 0.0008198989
significantly O 0 0.0010934793
reduced O 0 0.0018751491
DNA O 0 0.14191571
fragmentation O 0 0.14478432
. O 0 0.00835581

Histopathological O 0 0.022280306
examination O 0 0.0028174515
of O 0 0.0026923763
kidney O 0 0.6854363
, O 0 0.0034066946
heart O 0 0.20573343
and O 0 0.0009043429
lung O 0 0.03930372
sections O 0 0.00058096705
revealed O 0 0.00030683458
moderate O 0 0.0033263662
to O 0 0.00024571456
massive O 0 0.044593554
tissue B-Disease 0 0.72189015
damage I-Disease 0 0.9918612
with O 0 0.00044682212
a O 0 0.00026454864
variety O 0 0.00022770413
of O 0 0.0002593377
morphological O 0 0.009692677
aberrations O 0 0.63051605
by O 0 0.0001956359
all O 0 0.00014384203
the O 0 0.00013981767
three O 0 0.00011803913
drugs O 0 0.0075803506
in O 0 0.00018880844
the O 0 0.00021881629
absence O 0 0.00026394878
of O 0 0.008467353
GSPE B-Chemical 0 0.99999976
preexposure O 0 0.41977155
than O 0 0.00078728364
in O 0 0.0012332257
its O 0 0.0029934037
presence O 0 0.0036715285
. O 0 0.0067363568

GSPE B-Chemical 0 0.9999969
+ O 0 0.11445276
drug O 0 0.49464175
exposed O 0 0.0029720848
tissues O 0 0.0024461779
exhibited O 0 0.0013113038
minor O 0 0.0024024618
residual O 0 0.0017436576
damage O 0 0.4953906
or O 0 0.0017703874
near O 0 0.0026279392
total O 0 0.0028522657
recovery O 0 0.0064246166
. O 0 0.007932446

Additionally O 0 0.004926974
, O 0 0.0041100816
histopathological O 0 0.072441
alterations O 0 0.0036529363
mirrored O 0 0.001616139
both O 0 0.0011309206
serum O 0 0.17149472
chemistry O 0 0.046990633
changes O 0 0.001068035
and O 0 0.0009391378
the O 0 0.0009900592
pattern O 0 0.0014083118
of O 0 0.0027245188
DNA O 0 0.22527757
fragmentation O 0 0.18334228
. O 0 0.00943116

Interestingly O 0 0.004390544
, O 0 0.0033186686
all O 0 0.0016156296
the O 0 0.0013054798
drugs O 0 0.12599337
, O 0 0.0011174653
such O 0 0.0005594488
as O 0 0.0006542562
, O 0 0.008369413
AAP B-Chemical 0 0.9998685
, O 0 0.07749744
AMI B-Chemical 1 0.99999845
and O 0 0.015070257
DOX B-Chemical 1 0.9999782
induced O 0 0.0034798041
apoptotic O 0 0.9868564
death O 0 0.99985206
in O 0 0.0003433494
addition O 0 0.00015378513
to O 0 0.00027037962
necrosis B-Disease 2 0.9997385
in O 0 0.00036360064
the O 0 0.00025357958
respective O 0 0.0002794016
organs O 0 0.0013968812
which O 0 0.00051196304
was O 0 0.0005179803
very O 0 0.0008368196
effectively O 0 0.0010623514
blocked O 0 0.0032172548
by O 0 0.008853687
GSPE B-Chemical 0 0.9999957
. O 0 0.012606547

Since O 0 0.005569294
AAP B-Chemical 0 0.9983448
, O 0 0.077713914
AMI B-Chemical 1 0.99998856
and O 0 0.027694866
DOX B-Chemical 1 0.99995613
undergo O 0 0.0015856972
biotransformation O 0 0.9918681
and O 0 0.0006622255
are O 0 0.0003216502
known O 0 0.00029040079
to O 0 0.00018409746
produce O 0 0.00019046472
damaging O 0 0.20233543
radicals O 0 0.99895906
in O 0 0.00044856247
vivo O 0 0.00076442386
, O 0 0.00047247644
the O 0 0.0002435018
protection O 0 0.009692426
by O 0 0.0066071316
GSPE B-Chemical 0 0.9999999
may O 0 0.0003562964
be O 0 0.00021343895
linked O 0 0.00018099391
to O 0 0.00015021564
both O 0 0.00019253329
inhibition O 0 0.00044676126
of O 0 0.000512233
metabolism O 0 0.11146874
and O 0 0.00067082857
/ O 0 0.0045291022
or O 0 0.00095662934
detoxification O 0 0.42281517
of O 0 0.0028906607
cytotoxic O 0 0.7892094
radicals O 0 0.9987
. O 0 0.010161214

In O 0 0.0036985558
addition O 0 0.002043957
, O 0 0.0026797885
its O 0 0.0025872053
' O 0 0.0017760873
presumed O 0 0.0012321279
contribution O 0 0.00049724453
to O 0 0.0004885669
DNA O 0 0.069941975
repair O 0 0.0008949046
may O 0 0.00029888653
be O 0 0.00027756218
another O 0 0.00027945862
important O 0 0.0002217204
attribute O 0 0.0003611188
, O 0 0.00049900584
which O 0 0.0004719817
played O 0 0.0008824054
a O 0 0.0006322694
role O 0 0.00053882133
in O 0 0.0009747605
the O 0 0.0016070206
chemoprevention O 0 0.34227815
process O 0 0.0049593924
. O 0 0.0075189564

Additionally O 0 0.0049539222
, O 0 0.003638425
this O 0 0.0018830711
may O 0 0.0012140087
have O 0 0.0008387538
been O 0 0.00072063546
the O 0 0.0005437736
first O 0 0.00044991565
report O 0 0.0010869426
on O 0 0.0006188169
AMI B-Chemical 1 0.9999963
- O 0 0.081630275
induced O 0 0.0013259875
apoptotic O 0 0.9496798
death O 0 0.9996045
in O 0 0.0017830473
the O 0 0.0020205497
lung O 0 0.20336878
tissue O 0 0.058481615
. O 0 0.008172941

Taken O 0 0.00776712
together O 0 0.0026423237
, O 0 0.0023857676
these O 0 0.0014469739
events O 0 0.004004085
undoubtedly O 0 0.0016592826
establish O 0 0.0010048394
GSPE B-Chemical 0 0.99999976
' O 0 0.003617649
s O 0 0.0008267671
abundant O 0 0.0005398631
bioavailability O 0 0.863144
, O 0 0.00046917278
and O 0 0.00026791313
the O 0 0.00020591941
power O 0 0.001130261
to O 0 0.00017233905
defend O 0 0.00034601713
multiple O 0 0.00023650557
target O 0 0.00019391246
organs O 0 0.0008969051
from O 0 0.00022746327
toxic O 0 0.5146878
assaults O 0 0.4792655
induced O 0 0.0003198924
by O 0 0.00031611216
structurally O 0 0.0005475824
diverse O 0 0.0004459749
and O 0 0.00044816715
functionally O 0 0.0005578852
different O 0 0.0006863859
entities O 0 0.0016795762
in O 0 0.0019922715
vivo O 0 0.0045593698
. O 0 0.0068295416

Antidepressant B-Chemical 0 0.99991333
- O 0 0.07137453
induced O 0 0.006090454
mania B-Disease 0 0.99989235
in O 0 0.0040312787
bipolar B-Disease 2 0.998689
patients O 0 0.002901986
: O 0 0.0023728092
identification O 0 0.0023051032
of O 0 0.003240559
risk O 0 0.110087626
factors O 0 0.019365296
. O 0 0.010855865

BACKGROUND O 0 0.017403023
: O 0 0.004000158
Concerns O 0 0.0026084944
about O 0 0.0011788708
possible O 0 0.001004367
risks O 0 0.002229391
of O 0 0.00078695355
switching O 0 0.0009575999
to O 0 0.0006012614
mania B-Disease 0 0.9999131
associated O 0 0.0006890107
with O 0 0.0012024288
antidepressants B-Chemical 0 0.99993384
continue O 0 0.00021122053
to O 0 0.00015812983
interfere O 0 0.00017191298
with O 0 0.00021293119
the O 0 0.00020233692
establishment O 0 0.00036705288
of O 0 0.00035676375
an O 0 0.0003641607
optimal O 0 0.0003036321
treatment O 0 0.0006728445
paradigm O 0 0.0011374089
for O 0 0.0022801068
bipolar B-Disease 2 0.9997862
depression I-Disease 0 0.99914515
. O 0 0.0072885356

METHOD O 0 0.007698463
: O 0 0.0036710438
The O 0 0.0016097173
response O 0 0.0014959251
of O 0 0.0011913514
44 O 0 0.0011541613
patients O 0 0.0008267766
meeting O 0 0.00081894593
DSM O 0 0.045741316
- O 0 0.013718867
IV O 0 0.048013367
criteria O 0 0.00036147115
for O 0 0.00043937212
bipolar B-Disease 2 0.9996681
disorder I-Disease 0 0.9586861
to O 0 0.00020263676
naturalistic O 0 0.0038383715
treatment O 0 0.00021188009
was O 0 0.00014562561
assessed O 0 0.00010938762
for O 0 0.00012727718
at O 0 0.0001176685
least O 0 0.00010427635
6 O 0 0.00010552845
weeks O 0 9.467336e-05
using O 0 0.0001385361
the O 0 0.00022354547
Montgomery O 0 0.064586535
- O 0 0.03242574
Asberg O 0 0.43016106
Depression O 2 0.9868347
Rating O 0 0.0023473552
Scale O 0 0.0036786539
and O 0 0.00058220484
the O 0 0.0008627171
Bech O 0 0.06345477
- O 0 0.0062073665
Rafaelson O 0 0.06785743
Mania O 2 0.9720356
Rating O 0 0.037867364
Scale O 0 0.051632542
. O 0 0.00827474

Patients O 0 0.0054164315
who O 0 0.0035191954
experienced O 0 0.002387374
a O 0 0.0032033236
manic B-Disease 0 0.999987
or O 0 0.0031546284
hypomanic B-Disease 0 0.9999845
switch O 0 0.00079255196
were O 0 0.00033155413
compared O 0 0.00019289105
with O 0 0.00026160004
those O 0 0.00033712326
who O 0 0.0003639004
did O 0 0.00018915604
not O 0 0.00012778977
on O 0 9.937478e-05
several O 0 0.00011741653
variables O 0 0.0001808847
including O 0 0.00016205985
age O 0 0.00076182437
, O 0 0.00054504693
sex O 0 0.02658658
, O 0 0.0005269591
diagnosis O 0 0.0056057493
( O 0 0.0012934887
DSM B-Disease 0 0.14302826
- I-Disease 0 0.09397132
IV I-Disease 0 0.878566
bipolar I-Disease 2 0.9999918
I I-Disease 0 0.61192524
vs O 0 0.0007879013
. O 0 0.00050026027
bipolar B-Disease 2 0.99998903
II I-Disease 0 0.83079165
) O 0 0.0009175027
, O 0 0.00026386802
number O 0 0.00015695946
of O 0 0.00024020758
previous O 0 0.0005005605
manic B-Disease 0 0.99999475
episodes O 0 0.034296047
, O 0 0.00047763414
type O 0 0.0003249367
of O 0 0.0015509591
antidepressant B-Chemical 1 0.9999541
therapy O 0 0.0008701067
used O 0 0.00018383049
( O 0 0.0010332455
electroconvulsive O 0 0.960972
therapy O 0 0.0005354331
vs O 0 0.00051766116
. O 0 0.00033484533
antidepressant B-Chemical 1 0.9999045
drugs O 0 0.14554444
and O 0 0.00031603654
, O 0 0.00038229793
more O 0 0.00024428355
particularly O 0 0.000667027
, O 0 0.0006784468
selective O 0 0.03135041
serotonin B-Chemical 0 0.9999895
reuptake I-Chemical 0 0.9962658
inhibitors I-Chemical 0 0.14173214
[ O 0 0.17703208
SSRIs B-Chemical 0 0.9999647
] O 0 0.0023421182
) O 0 0.00053184363
, O 0 0.00023799148
use O 0 0.00014793238
and O 0 0.00017134185
type O 0 0.00020922493
of O 0 0.0006006532
mood O 0 0.9978333
stabilizers O 0 0.83945507
( O 0 0.0046137646
lithium B-Chemical 0 0.9999459
vs O 0 0.0017465899
. O 0 0.00039329857
anticonvulsants O 0 0.9994147
) O 0 0.0008045519
, O 0 0.00029659292
and O 0 0.00025850453
temperament O 0 0.11228858
of O 0 0.00022185445
the O 0 0.00017861907
patient O 0 0.00021259564
, O 0 0.00021683
assessed O 0 0.00012619978
during O 0 0.00013348325
a O 0 0.00028845738
normothymic O 0 0.36062834
period O 0 0.00014520036
using O 0 0.00017870308
the O 0 0.00025655498
hyperthymia O 0 0.32225475
component O 0 0.00036069867
of O 0 0.000509937
the O 0 0.00065054855
Semi O 0 0.0072740796
- O 0 0.0025092475
structured O 0 0.0013750494
Affective O 0 0.009481432
Temperament O 0 0.057853453
Interview O 0 0.007463928
. O 0 0.0074070096

RESULTS O 0 0.0059150094
: O 0 0.004276726
Switches O 0 0.0069029876
to O 0 0.0021160236
hypomania B-Disease 0 0.99983025
or O 0 0.0020103545
mania B-Disease 0 0.99980813
occurred O 0 0.0006645518
in O 0 0.0004233856
27 O 0 0.00047618715
% O 0 0.00033189444
of O 0 0.00027815718
all O 0 0.0002330943
patients O 0 0.000462928
( O 0 0.0011603467
N O 0 0.99838746
= O 0 0.0021153712
12 O 0 0.00020302007
) O 0 0.0003797741
( O 0 0.00030583522
and O 0 0.00022350287
in O 0 0.0001935336
24 O 0 0.00018685414
% O 0 0.00018445766
of O 0 0.0001776948
the O 0 0.00016876214
subgroup O 0 0.00065693795
of O 0 0.00022360176
patients O 0 0.00032403335
treated O 0 0.00029728992
with O 0 0.0011498783
SSRIs B-Chemical 0 0.9999232
[ O 0 0.0024110153
8 O 0 0.000187806
/ O 0 0.0007970811
33 O 0 0.000390632
] O 0 0.0005968053
) O 0 0.0004685335
; O 0 0.0003878442
16 O 0 0.00023220656
% O 0 0.00029079616
( O 0 0.00065479276
N O 0 0.99497944
= O 0 0.001093192
7 O 0 0.0002364528
) O 0 0.0004455075
experienced O 0 0.00058817613
manic B-Disease 0 0.9999846
episodes O 0 0.012347329
, O 0 0.0004294622
and O 0 0.00033898233
11 O 0 0.0003406629
% O 0 0.00047813682
( O 0 0.0010110475
N O 0 0.9902352
= O 0 0.0017679906
5 O 0 0.0008520031
) O 0 0.0018577556
experienced O 0 0.0033926326
hypomanic B-Disease 0 0.9999002
episodes O 0 0.07325816
. O 0 0.007924068

Sex O 0 0.46271536
, O 0 0.004986697
age O 0 0.0039497716
, O 0 0.0026022962
diagnosis O 0 0.009315447
( O 0 0.014478004
bipolar B-Disease 2 0.9999815
I I-Disease 0 0.6780432
vs O 0 0.0014558627
. O 0 0.0009143532
bipolar B-Disease 2 0.99998343
II I-Disease 0 0.8357796
) O 0 0.0013929456
, O 0 0.00050064165
and O 0 0.00036685186
additional O 0 0.00027006143
treatment O 0 0.00043501763
did O 0 0.00044654598
not O 0 0.00042711795
affect O 0 0.0005158188
the O 0 0.0009685525
risk O 0 0.024736287
of O 0 0.003239612
switching O 0 0.0062547894
. O 0 0.0072678407

The O 0 0.003507346
incidence O 0 0.0047779283
of O 0 0.0032717446
mood O 0 0.98583233
switches O 0 0.0024425758
seemed O 0 0.00087946124
not O 0 0.0004807727
to O 0 0.00037989105
differ O 0 0.00034959137
between O 0 0.0002679941
patients O 0 0.0005165669
receiving O 0 0.0005429237
an O 0 0.00078172615
anticonvulsant O 0 0.99866056
and O 0 0.00067251176
those O 0 0.0008868733
receiving O 0 0.0012242374
no O 0 0.0014548128
mood O 0 0.98970246
stabilizer O 0 0.3850113
. O 0 0.0071019204

In O 0 0.003928309
contrast O 0 0.0033090415
, O 0 0.0039378842
mood O 0 0.9655624
switches O 0 0.0018738535
were O 0 0.00071696646
less O 0 0.0005142758
frequent O 0 0.0008016973
in O 0 0.000318635
patients O 0 0.00052364165
receiving O 0 0.0012629024
lithium B-Chemical 0 0.99992144
( O 0 0.0006914252
15 O 0 0.00019350299
% O 0 0.00025343313
, O 0 0.00027239157
4 O 0 0.00018011985
/ O 0 0.00063828466
26 O 0 0.0002958251
) O 0 0.00032127355
than O 0 0.00013441169
in O 0 0.00016067983
patients O 0 0.00022929434
not O 0 0.00014712338
treated O 0 0.00027382662
with O 0 0.0008299853
lithium B-Chemical 0 0.9999529
( O 0 0.00090174744
44 O 0 0.00044779092
% O 0 0.000342268
, O 0 0.00038287474
8 O 0 0.00032787767
/ O 0 0.0008247881
18 O 0 0.00055867987
; O 0 0.0008955738
p O 0 0.0010226303
= O 0 0.0021588595
. O 0 0.0024131886
04 O 0 0.05254294
) O 0 0.0068988833
. O 0 0.008662016

The O 0 0.003076651
number O 0 0.0021740308
of O 0 0.0020643214
previous O 0 0.002586158
manic B-Disease 0 0.9999912
episodes O 0 0.14923158
did O 0 0.0007545616
not O 0 0.0003333785
affect O 0 0.00021996595
the O 0 0.00023656442
probability O 0 0.00029474264
of O 0 0.00035164706
switching O 0 0.0006719498
, O 0 0.00045103644
whereas O 0 0.00026005178
a O 0 0.0002494422
high O 0 0.00023406708
score O 0 0.00014659726
on O 0 0.00011004056
the O 0 0.00019736579
hyperthymia O 0 0.4671987
component O 0 0.00018697427
of O 0 0.00019292378
the O 0 0.00016351255
Semistructured O 0 0.0002571648
Affective O 0 0.001136648
Temperament O 0 0.018669441
Interview O 0 0.00038201918
was O 0 0.00017917022
associated O 0 0.00019212453
with O 0 0.00022064526
a O 0 0.00028267803
greater O 0 0.00025086416
risk O 0 0.008607195
of O 0 0.0005329428
switching O 0 0.00093423907
( O 0 0.0010980263
p O 0 0.0010156769
= O 0 0.0021059327
. O 0 0.0020109508
008 O 0 0.010426837
) O 0 0.006139279
. O 0 0.007910015

CONCLUSION O 0 0.01939833
: O 0 0.003727654
The O 0 0.0016052291
frequency O 0 0.0014800323
of O 0 0.0016305635
mood O 0 0.979359
switching O 0 0.0011941384
associated O 0 0.00076617085
with O 0 0.0011968862
acute O 0 0.98669654
antidepressant B-Chemical 1 0.9999882
therapy O 0 0.0026999163
may O 0 0.00052650215
be O 0 0.0006914041
reduced O 0 0.0010666595
by O 0 0.0023020022
lithium B-Chemical 0 0.999757
treatment O 0 0.0070336014
. O 0 0.007239766

Particular O 0 0.0038366348
attention O 0 0.0035051154
should O 0 0.001376712
be O 0 0.0012577364
paid O 0 0.0012227468
to O 0 0.00071892084
patients O 0 0.00084426097
with O 0 0.00066443434
a O 0 0.001537388
hyperthymic O 0 0.99987817
temperament O 0 0.5315326
, O 0 0.0007637987
who O 0 0.000651642
have O 0 0.0004382061
a O 0 0.0007123496
greater O 0 0.000826805
risk O 0 0.03164829
of O 0 0.0040003182
mood O 0 0.9904295
switches O 0 0.008052997
. O 0 0.007688389

Peritubular O 0 0.06266272
capillary O 0 0.05882588
basement O 0 0.048715293
membrane O 0 0.0063358825
reduplication O 0 0.012821884
in O 0 0.001018289
allografts O 0 0.007020293
and O 0 0.0007812674
native O 0 0.0011989503
kidney B-Disease 0 0.8508182
disease I-Disease 0 0.95718145
: O 0 0.0014448384
a O 0 0.0006414467
clinicopathologic O 0 0.00682178
study O 0 0.0008029167
of O 0 0.0010068067
278 O 0 0.006023225
consecutive O 0 0.0016110168
renal O 0 0.2830564
specimens O 0 0.0050683836
. O 0 0.0070508006

BACKGROUND O 0 0.01956188
: O 0 0.0041490993
An O 0 0.0024484815
association O 0 0.0013286605
has O 0 0.00097827
been O 0 0.0007574701
found O 0 0.0005477823
between O 0 0.00051457336
transplant B-Disease 0 0.9870143
glomerulopathy I-Disease 0 0.9999999
( O 0 0.1236828
TG B-Disease 2 0.99953485
) O 0 0.0013875874
and O 0 0.00048545768
reduplication O 0 0.0057794983
of O 0 0.0007365651
peritubular O 0 0.13735214
capillary O 0 0.19460925
basement O 0 0.18519196
membranes O 0 0.040054947
( O 0 0.004675483
PTCR O 0 0.64351636
) O 0 0.0077563045
. O 0 0.008251388

Although O 0 0.0030203264
such O 0 0.0020843884
an O 0 0.0018390958
association O 0 0.0011654961
is O 0 0.0009636144
of O 0 0.0008146457
practical O 0 0.00062463275
and O 0 0.0005338231
theoretical O 0 0.00092551974
importance O 0 0.00040406335
, O 0 0.0005931242
only O 0 0.0004452201
one O 0 0.00040794106
prospective O 0 0.0009209649
study O 0 0.00069144333
has O 0 0.0006938484
tried O 0 0.001210446
to O 0 0.0012429311
confirm O 0 0.001711203
it O 0 0.004098055
. O 0 0.006892464

METHODS O 0 0.0042689457
: O 0 0.0035997268
We O 0 0.0019679854
examined O 0 0.0013237497
278 O 0 0.0028669212
consecutive O 0 0.0009977088
renal O 0 0.18224816
specimens O 0 0.0008338744
( O 0 0.00072293653
from O 0 0.00042293666
135 O 0 0.0006989008
transplants O 0 0.001011592
and O 0 0.00045899782
143 O 0 0.00081233954
native O 0 0.000629239
kidneys O 0 0.0038822887
) O 0 0.001098101
for O 0 0.0008717214
ultrastructural O 0 0.004653342
evidence O 0 0.0017582271
of O 0 0.004232256
PTCR O 0 0.82840616
. O 0 0.008792862

In O 0 0.0032953827
addition O 0 0.0016976375
to O 0 0.0016692015
renal O 0 0.7297555
allografts O 0 0.24729793
with O 0 0.0063925562
TG B-Disease 2 0.9992804
, O 0 0.0008624804
we O 0 0.00023894255
also O 0 0.00023579295
examined O 0 0.00018958992
grafts O 0 0.00049623026
with O 0 0.00036038968
acute O 0 0.78762597
rejection O 0 0.9901259
, O 0 0.011523162
recurrent O 0 0.9251849
glomerulonephritis B-Disease 2 0.99999976
, O 0 0.02880999
chronic B-Disease 0 0.99583095
allograft I-Disease 0 0.9988398
nephropathy I-Disease 2 1.0
and O 0 0.0027396323
stable O 0 0.0010080267
grafts O 0 0.0015149033
( O 0 0.0009244953
" O 0 0.0010364688
protocol O 0 0.0011124554
biopsies O 0 0.0024714547
" O 0 0.0035778692
) O 0 0.005925196
. O 0 0.007720024

Native O 0 0.039564554
kidney O 0 0.20050064
specimens O 0 0.0020282837
included O 0 0.0010761168
a O 0 0.000908571
wide O 0 0.00080505037
range O 0 0.0005839248
of O 0 0.00078749034
glomerulopathies B-Disease 0 0.9997918
as O 0 0.00041569796
well O 0 0.00028768997
as O 0 0.0002612202
cases O 0 0.0008043856
of O 0 0.014323344
thrombotic B-Disease 2 0.9999999
microangiopathy I-Disease 2 1.0
, O 0 0.28561252
malignant B-Disease 0 0.99999
hypertension I-Disease 2 1.0
, O 0 0.03299042
acute O 0 0.9919539
interstitial B-Disease 0 0.9997031
nephritis I-Disease 0 1.0
, O 0 0.02280964
and O 0 0.0050931955
acute B-Disease 2 0.9973284
tubular I-Disease 2 0.9994733
necrosis I-Disease 2 0.9999969
. O 0 0.048820943

RESULTS O 0 0.0058180336
: O 0 0.0037799731
We O 0 0.0020322062
found O 0 0.0016648473
PTCR O 0 0.15507574
in O 0 0.00089248584
14 O 0 0.0006311183
of O 0 0.00051972683
15 O 0 0.0003839854
cases O 0 0.0005078592
of O 0 0.0008783884
TG B-Disease 2 0.9983662
, O 0 0.00068218
in O 0 0.00028662797
7 O 0 0.00022795917
transplant O 0 0.0017523841
biopsy O 0 0.00050803326
specimens O 0 0.00032785424
without O 0 0.00043089007
TG B-Disease 2 0.99604505
, O 0 0.00058291556
and O 0 0.0004000476
in O 0 0.00038639863
13 O 0 0.00049851165
of O 0 0.0006417496
143 O 0 0.0014947888
native O 0 0.0015615628
kidney O 0 0.24597219
biopsy O 0 0.007991025
specimens O 0 0.005300728
. O 0 0.0073160394

These O 0 0.0038247344
13 O 0 0.0027992893
included O 0 0.0016323467
cases O 0 0.0018787741
of O 0 0.0037451626
malignant B-Disease 0 0.9999596
hypertension I-Disease 2 1.0
, O 0 0.666283
thrombotic B-Disease 2 0.99999976
microangiopathy I-Disease 2 1.0
, O 0 0.315012
lupus B-Disease 0 0.9999999
nephritis I-Disease 0 0.9999999
, O 0 0.19403346
Henoch B-Disease 0 0.999974
- I-Disease 0 0.82790285
Schonlein I-Disease 0 0.9999876
nephritis I-Disease 0 0.99999964
, O 0 0.04215531
crescentic O 0 0.99997544
glomerulonephritis B-Disease 2 0.9999999
, O 0 0.024166148
and O 0 0.013487187
cocaine B-Chemical 1 0.9999939
- O 0 0.040107694
related O 0 0.0010332838
acute B-Disease 0 0.85770553
renal I-Disease 0 0.97936195
failure I-Disease 0 0.84529424
. O 0 0.008773235

Mild O 0 0.986834
PTCR O 0 0.64321095
in O 0 0.0024576366
allografts O 0 0.050574828
without O 0 0.0025726391
TG B-Disease 2 0.9982469
did O 0 0.00088968733
not O 0 0.00042119305
predict O 0 0.000370787
renal B-Disease 0 0.7747999
failure I-Disease 0 0.310546
or O 0 0.00046713144
significant O 0 0.001125335
proteinuria B-Disease 0 0.9999968
after O 0 0.00020518951
follow O 0 0.0002060394
- O 0 0.0009729651
up O 0 0.00021348984
periods O 0 0.00022874473
of O 0 0.00032066705
between O 0 0.00032815317
3 O 0 0.0004864988
months O 0 0.0005917442
and O 0 0.0012155216
1 O 0 0.0019242732
year O 0 0.003544529
. O 0 0.006526032

CONCLUSIONS O 0 0.01738524
: O 0 0.0036804476
We O 0 0.0016916308
conclude O 0 0.0009865452
that O 0 0.0008193306
in O 0 0.00081513333
transplants O 0 0.008425238
, O 0 0.00075183157
there O 0 0.00029161572
is O 0 0.00031797952
a O 0 0.00031031863
strong O 0 0.00028567613
association O 0 0.00020287803
between O 0 0.00017008878
well O 0 0.00034156375
- O 0 0.02172349
developed O 0 0.0016043672
PTCR O 0 0.88398254
and O 0 0.0022848826
TG B-Disease 2 0.99917394
, O 0 0.0005243311
while O 0 0.000205361
the O 0 0.00015817056
significance O 0 0.00018615351
of O 0 0.00039494105
mild O 0 0.76055485
PTCR O 0 0.85212326
and O 0 0.00037356923
its O 0 0.0005020564
predictive O 0 0.00075250294
value O 0 0.00029148618
in O 0 0.00034176695
the O 0 0.0004268112
absence O 0 0.00056378444
of O 0 0.0023382483
TG B-Disease 2 0.99701655
is O 0 0.0030706425
unclear O 0 0.0040551084
. O 0 0.0069216006

PTCR O 0 0.30349514
also O 0 0.0028143467
occurs O 0 0.0018097028
in O 0 0.0013533527
certain O 0 0.0012888893
native O 0 0.00202802
kidney B-Disease 0 0.9353353
diseases I-Disease 0 0.97742426
, O 0 0.0019863273
though O 0 0.00054754474
the O 0 0.0003541774
association O 0 0.00035433788
is O 0 0.0004120896
not O 0 0.0003939468
as O 0 0.0004988534
strong O 0 0.0008284966
as O 0 0.0009918072
that O 0 0.0014859415
for O 0 0.0035016974
TG B-Disease 2 0.99479854
. O 0 0.008837413

We O 0 0.0032128277
suggest O 0 0.0015653692
that O 0 0.0013377493
repeated O 0 0.0013330823
endothelial B-Disease 0 0.99925107
injury I-Disease 0 0.9995105
, O 0 0.0032090945
including O 0 0.00092548755
immunologic B-Disease 0 0.98654336
injury I-Disease 0 0.99966514
, O 0 0.0020722738
may O 0 0.00029306728
be O 0 0.00025931495
the O 0 0.00024223239
cause O 0 0.00033300722
of O 0 0.00038601228
this O 0 0.00038406556
lesion O 0 0.01311269
both O 0 0.00050745736
in O 0 0.0007163876
allografts O 0 0.0059952387
and O 0 0.0016557878
native O 0 0.0034189261
kidneys O 0 0.04337027
. O 0 0.007445377

Caffeine B-Chemical 0 0.99997175
- O 0 0.12635079
induced O 0 0.0073691
cardiac B-Disease 0 0.99374086
arrhythmia I-Disease 2 0.99999213
: O 0 0.006805765
an O 0 0.0025524537
unrecognised O 0 0.006177449
danger O 0 0.0051365844
of O 0 0.0041412693
healthfood O 0 0.049264926
products O 0 0.009106061
. O 0 0.009746085

We O 0 0.0034921798
describe O 0 0.0022321367
a O 0 0.0021580444
25 O 0 0.0018740428
- O 0 0.0036159996
year O 0 0.0010702044
- O 0 0.002692006
old O 0 0.0006253839
woman O 0 0.0013353294
with O 0 0.0004682408
pre O 0 0.0014850596
- O 0 0.0019098243
existing O 0 0.00035161836
mitral B-Disease 0 0.21809627
valve I-Disease 0 0.032526333
prolapse I-Disease 0 0.95163184
who O 0 0.00054249103
developed O 0 0.00044201803
intractable O 0 0.42941216
ventricular B-Disease 0 0.95410407
fibrillation I-Disease 0 0.999992
after O 0 0.00017811041
consuming O 0 0.0008212051
a O 0 0.00023166476
" O 0 0.00028708004
natural O 0 0.00058256957
energy O 0 0.0066887373
" O 0 0.0018159793
guarana O 0 0.99108946
health O 0 0.008320995
drink O 0 0.054436363
containing O 0 0.00037261494
a O 0 0.0006630284
high O 0 0.0010540878
concentration O 0 0.0025445288
of O 0 0.007482759
caffeine B-Chemical 0 0.99985826
. O 0 0.008799106

This O 0 0.0059442692
case O 0 0.0032439306
highlights O 0 0.0022170416
the O 0 0.0015631499
need O 0 0.0011852579
for O 0 0.001083704
adequate O 0 0.0010648923
labelling O 0 0.0015438624
and O 0 0.0013784334
regulation O 0 0.0013513241
of O 0 0.0024711604
such O 0 0.003294972
products O 0 0.0075423066
. O 0 0.008803025

Conformationally O 0 0.70332706
restricted O 0 0.0030028336
analogs O 0 0.046529576
of O 0 0.004991516
BD1008 B-Chemical 0 0.99945456
and O 0 0.0015550895
an O 0 0.0010100683
antisense O 0 0.010252327
oligodeoxynucleotide B-Chemical 0 0.65123314
targeting O 0 0.00069895905
sigma1 O 0 0.97280526
receptors O 0 0.02017695
produce O 0 0.0005750826
anti O 0 0.6758068
- O 0 0.63845295
cocaine B-Chemical 1 0.9999784
effects O 0 0.0024559968
in O 0 0.002219072
mice O 0 0.0029313022
. O 0 0.0066729123

Cocaine B-Chemical 0 0.9999633
' O 0 0.005531531
s O 0 0.0024360477
ability O 0 0.0012823952
to O 0 0.00083104736
interact O 0 0.0005615564
with O 0 0.0007124283
sigma O 0 0.01368084
receptors O 0 0.0034170905
suggests O 0 0.000323034
that O 0 0.00031378694
these O 0 0.00040511627
proteins O 0 0.0005145462
mediate O 0 0.000403681
some O 0 0.00071458623
of O 0 0.0011963425
its O 0 0.0031332313
behavioral O 0 0.046333034
effects O 0 0.0048354776
. O 0 0.0068719704

Therefore O 0 0.0034531623
, O 0 0.0027371957
three O 0 0.0011254718
novel O 0 0.0013737935
sigma O 0 0.03961222
receptor O 0 0.075451694
ligands O 0 0.061018713
with O 0 0.0018383012
antagonist O 0 0.7699029
activity O 0 0.00039718606
were O 0 0.00022594762
evaluated O 0 0.00017131685
in O 0 0.00023650084
Swiss O 0 0.0055233575
Webster O 0 0.04722589
mice O 0 0.00016374284
: O 0 0.0013898184
BD1018 B-Chemical 0 0.98404825
( O 0 0.005909287
3S B-Chemical 0 0.93873715
- I-Chemical 0 0.017000807
1 I-Chemical 0 0.00031287406
- I-Chemical 0 0.0040711933
[ I-Chemical 0 0.0014092441
2 I-Chemical 0 0.0002748891
- I-Chemical 0 0.0018798717
( I-Chemical 0 0.0003560645
3 I-Chemical 0 0.00019054499
, I-Chemical 0 0.00029708561
4 I-Chemical 0 0.00025176417
- I-Chemical 0 0.034070343
dichlorophenyl I-Chemical 0 0.9984611
) I-Chemical 0 0.03073065
ethyl I-Chemical 0 0.9997776
] I-Chemical 0 0.018946255
- I-Chemical 0 0.011802977
1 I-Chemical 0 0.00021912152
, I-Chemical 0 0.0002812071
4 I-Chemical 0 0.0002090682
- I-Chemical 0 0.0051169326
diazabicyclo I-Chemical 0 0.45263988
[ I-Chemical 0 0.002406242
4 I-Chemical 0 0.00017395502
. I-Chemical 0 0.00015747907
3 I-Chemical 0 0.00014813211
. I-Chemical 0 0.00016280655
0 I-Chemical 0 0.00027665307
] I-Chemical 0 0.0026675672
nonane I-Chemical 0 0.9988925
) O 0 0.009821446
, O 0 0.00958686
BD1063 B-Chemical 0 0.9999881
( O 0 0.0018458517
1 B-Chemical 0 0.00033840368
- I-Chemical 0 0.0061390493
[ I-Chemical 0 0.0016805656
2 I-Chemical 0 0.00026429302
- I-Chemical 0 0.0020198124
( I-Chemical 0 0.00034641207
3 I-Chemical 0 0.00018336868
, I-Chemical 0 0.00028985727
4 I-Chemical 0 0.0002461559
- I-Chemical 0 0.03533389
dichlorophenyl I-Chemical 0 0.99852055
) I-Chemical 0 0.032749515
ethyl I-Chemical 0 0.9998066
] I-Chemical 0 0.026208915
- I-Chemical 0 0.024124028
4 I-Chemical 0 0.00026347183
- I-Chemical 0 0.01171489
methylpiperazine I-Chemical 0 0.88109374
) O 0 0.0012248241
, O 0 0.00045148339
and O 0 0.0006686112
LR132 B-Chemical 0 0.9935051
( O 0 0.015851876
1R O 0 0.99915695
, O 0 0.0039564557
2S O 0 0.9840443
- O 0 0.027909977
( O 0 0.00069675804
+ O 0 0.0029669756
) O 0 0.002342421
- O 0 0.02955869
cis O 0 0.2289068
- O 0 0.2884492
N O 0 0.9997744
- O 0 0.16952795
[ O 0 0.0075964667
2 O 0 0.00032163056
- O 0 0.0023030995
( O 0 0.00036812047
3 O 0 0.00019964327
, O 0 0.00030843803
4 O 0 0.0002673607
- O 0 0.029121738
dichlorophenyl O 0 0.9981711
) O 0 0.026359843
ethyl O 0 0.99971896
] O 0 0.017638927
- O 0 0.0158555
2 O 0 0.00044343653
- O 0 0.0027095024
( O 0 0.00088665483
1 O 0 0.00083358644
- O 0 0.018330596
pyrrolidinyl O 0 0.9696763
) O 0 0.027756672
cyclohexylamine O 0 0.99972004
) O 0 0.009792962
. O 0 0.007917584

Competition O 0 0.006853582
binding O 0 0.0035008544
assays O 0 0.0025794634
demonstrated O 0 0.0014490768
that O 0 0.0010901776
all O 0 0.0009633555
three O 0 0.00072520156
compounds O 0 0.04719076
have O 0 0.0009067946
high O 0 0.001506284
affinities O 0 0.0042863353
for O 0 0.0027547257
sigma1 O 0 0.9179053
receptors O 0 0.09367777
. O 0 0.009764833

The O 0 0.0030898743
three O 0 0.0018118669
compounds O 0 0.06060661
vary O 0 0.0011835848
in O 0 0.0007934932
their O 0 0.0006244691
affinities O 0 0.0013910725
for O 0 0.000529559
sigma2 O 0 0.09624651
receptors O 0 0.0065700696
and O 0 0.00041202517
exhibit O 0 0.00027792098
negligible O 0 0.00037908956
affinities O 0 0.0040107965
for O 0 0.0010920912
dopamine B-Chemical 1 0.9999411
, O 0 0.0060909707
opioid O 0 0.9974776
, O 0 0.01919464
GABA B-Chemical 1 0.9999944
( O 0 0.0052079577
A O 0 0.2894491
) O 0 0.005123032
and O 0 0.007644966
NMDA B-Chemical 1 0.9999865
receptors O 0 0.10454022
. O 0 0.008200713

In O 0 0.004022329
behavioral O 0 0.007224072
studies O 0 0.0020083082
, O 0 0.0022312626
pre O 0 0.0044757635
- O 0 0.007192181
treatment O 0 0.0007132785
of O 0 0.0005518755
mice O 0 0.00031472347
with O 0 0.0016183226
BD1018 B-Chemical 0 0.998459
, O 0 0.055395253
BD1063 B-Chemical 0 0.9999945
, O 0 0.0026613101
or O 0 0.0007755052
LR132 B-Chemical 0 0.9827504
significantly O 0 0.0008304144
attenuated O 0 0.02726049
cocaine B-Chemical 1 0.9999968
- O 0 0.2141619
induced O 0 0.009501434
convulsions B-Disease 0 0.99999404
and O 0 0.010508702
lethality O 0 0.87055147
. O 0 0.009580556

Moreover O 0 0.00523598
, O 0 0.0040449183
post O 0 0.0026312661
- O 0 0.010634023
treatment O 0 0.0016306962
with O 0 0.0021964388
LR132 B-Chemical 0 0.9952987
prevented O 0 0.064020455
cocaine B-Chemical 1 0.99999845
- O 0 0.14738813
induced O 0 0.0010248305
lethality O 0 0.55828434
in O 0 0.0008559104
a O 0 0.001005892
significant O 0 0.0010105978
proportion O 0 0.0014773443
of O 0 0.0027800708
animals O 0 0.003750215
. O 0 0.0069974307

In O 0 0.0035695052
contrast O 0 0.0024110454
to O 0 0.001447337
the O 0 0.0011241095
protection O 0 0.0024299438
provided O 0 0.00067916646
by O 0 0.00053490995
the O 0 0.00040675417
putative O 0 0.0005442999
antagonists O 0 0.59990776
, O 0 0.00052601733
the O 0 0.00023887513
well O 0 0.00028110898
- O 0 0.006695226
characterized O 0 0.0004853281
sigma O 0 0.11864805
receptor O 0 0.36640826
agonist O 0 0.9699912
di B-Chemical 0 0.49736854
- I-Chemical 0 0.12975815
o I-Chemical 0 0.1487452
- I-Chemical 0 0.0976257
tolylguanidine I-Chemical 0 0.14075264
( O 0 0.012424358
DTG B-Chemical 0 0.9999757
) O 0 0.00087580475
and O 0 0.00020886336
the O 0 0.0001562965
novel O 0 0.00026605622
sigma O 0 0.06255396
receptor O 0 0.37534517
agonist O 0 0.99107766
BD1031 B-Chemical 0 0.9995493
( O 0 0.027683776
3R B-Chemical 0 0.99567044
- I-Chemical 0 0.023766274
1 I-Chemical 0 0.00028145037
- I-Chemical 0 0.004403855
[ I-Chemical 0 0.0014335964
2 I-Chemical 0 0.00025511172
- I-Chemical 0 0.0019178322
( I-Chemical 0 0.00034060772
3 I-Chemical 0 0.00018128009
, I-Chemical 0 0.00028685902
4 I-Chemical 0 0.00024430454
- I-Chemical 0 0.034385893
dichlorophenyl I-Chemical 0 0.9984694
) I-Chemical 0 0.030627802
ethyl I-Chemical 0 0.99977607
] I-Chemical 0 0.018721035
- I-Chemical 0 0.011694221
1 I-Chemical 0 0.00022134124
, I-Chemical 0 0.0002852135
4 I-Chemical 0 0.00021430194
- I-Chemical 0 0.004986124
diazabicyclo I-Chemical 0 0.4441192
[ I-Chemical 0 0.0022956992
4 I-Chemical 0 0.00019065221
. I-Chemical 0 0.0001792266
3 I-Chemical 0 0.00017671514
. I-Chemical 0 0.00020478654
0 I-Chemical 0 0.00035045762
] I-Chemical 0 0.0019329156
nonane I-Chemical 0 0.99535865
) O 0 0.00087896816
each O 0 0.0002996358
worsened O 0 0.005166052
the O 0 0.00071140996
behavioral O 0 0.10816638
toxicity B-Disease 2 0.99781716
of O 0 0.028715082
cocaine B-Chemical 1 0.9999701
. O 0 0.009044032

At O 0 0.0028942325
doses O 0 0.0048500425
where O 0 0.0018320829
alone O 0 0.0014052625
, O 0 0.0012261978
they O 0 0.000518117
produced O 0 0.000406633
no O 0 0.00030924246
significant O 0 0.00035686445
effects O 0 0.00045083137
on O 0 0.000242704
locomotion O 0 0.56946576
, O 0 0.011281475
BD1018 B-Chemical 0 0.998606
, O 0 0.038857754
BD1063 B-Chemical 0 0.9999931
and O 0 0.0037676573
LR132 B-Chemical 0 0.98182595
significantly O 0 0.0004478462
attenuated O 0 0.0006772364
the O 0 0.0005968602
locomotor O 0 0.45386773
stimulatory O 0 0.002284107
effects O 0 0.0029475284
of O 0 0.016866226
cocaine B-Chemical 1 0.99997413
. O 0 0.009246409

To O 0 0.0025857869
further O 0 0.0017928827
validate O 0 0.0010321037
the O 0 0.00087134645
hypothesis O 0 0.0007130807
that O 0 0.00051564496
the O 0 0.0007009025
anti O 0 0.7720104
- O 0 0.8043362
cocaine B-Chemical 1 0.9999943
effects O 0 0.00097433437
of O 0 0.00034593866
the O 0 0.00021597782
novel O 0 0.0002753791
ligands O 0 0.0047829584
involved O 0 0.00018855548
antagonism O 0 0.117290474
of O 0 0.00050907495
sigma O 0 0.10385063
receptors O 0 0.0356686
, O 0 0.0006626996
an O 0 0.00031609708
antisense O 0 0.009534942
oligodeoxynucleotide B-Chemical 0 0.7938913
against O 0 0.0037067
sigma1 O 0 0.9949995
receptors O 0 0.06111062
was O 0 0.00028364503
also O 0 0.00017665164
shown O 0 0.0001370553
to O 0 0.00014757959
significantly O 0 0.00021653289
attenuate O 0 0.00033297768
the O 0 0.000731504
convulsive B-Disease 2 0.9999957
and O 0 0.001573671
locomotor O 0 0.6147367
stimulatory O 0 0.0024002
effects O 0 0.0028541826
of O 0 0.016209524
cocaine B-Chemical 1 0.99997365
. O 0 0.008918233

Together O 0 0.008227277
, O 0 0.0038920098
the O 0 0.0018649404
data O 0 0.0013455143
suggests O 0 0.00066997105
that O 0 0.00058363046
functional O 0 0.0007272204
antagonism O 0 0.1299715
of O 0 0.00088217075
sigma O 0 0.064199306
receptors O 0 0.013027391
is O 0 0.0004117605
capable O 0 0.00033046634
of O 0 0.00043883442
attenuating O 0 0.0017039119
a O 0 0.0006246988
number O 0 0.00059194467
of O 0 0.003564756
cocaine B-Chemical 1 0.9999888
- O 0 0.054978147
induced O 0 0.0034004932
behaviors O 0 0.16684598
. O 0 0.00751912

Ranitidine B-Chemical 0 0.9999846
- O 0 0.089595295
induced O 0 0.0056032604
acute O 0 0.9892595
interstitial B-Disease 0 0.9995927
nephritis I-Disease 0 0.99999976
in O 0 0.004748421
a O 0 0.004064189
cadaveric O 0 0.1327539
renal O 0 0.9089654
allograft O 0 0.91157544
. O 0 0.011399639

Ranitidine B-Chemical 0 0.9999622
frequently O 0 0.0061732326
is O 0 0.0028562231
used O 0 0.0020834832
for O 0 0.002163462
preventing O 0 0.007915256
peptic O 0 0.9999354
ulceration O 0 0.99993694
after O 0 0.0035079725
renal O 0 0.94560623
transplantation O 0 0.23434429
. O 0 0.010197584

This O 0 0.0074986545
drug O 0 0.19188678
occasionally O 0 0.0052544284
has O 0 0.0018462596
been O 0 0.001506102
associated O 0 0.0013939781
with O 0 0.0018820928
acute O 0 0.9803349
interstitial B-Disease 0 0.99943286
nephritis I-Disease 0 0.99999976
in O 0 0.00480245
native O 0 0.0061394335
kidneys O 0 0.07898986
. O 0 0.00879198

There O 0 0.007749272
are O 0 0.0052973623
no O 0 0.0039603245
similar O 0 0.003850786
reports O 0 0.0051823673
with O 0 0.0069656717
renal O 0 0.8995779
transplantation O 0 0.26896888
. O 0 0.015931593

We O 0 0.0038636646
report O 0 0.0035225595
a O 0 0.0022546293
case O 0 0.0018075154
of O 0 0.0068113813
ranitidine B-Chemical 1 0.9999989
- O 0 0.20139018
induced O 0 0.0015589136
acute O 0 0.9933234
interstitial B-Disease 0 0.99983764
nephritis I-Disease 0 1.0
in O 0 0.0010227077
a O 0 0.00039838243
recipient O 0 0.0003671866
of O 0 0.00024693555
a O 0 0.0003186283
cadaveric O 0 0.019804375
renal O 0 0.6922854
allograft O 0 0.6973727
presenting O 0 0.0052345223
with O 0 0.0004698654
acute O 0 0.7908614
allograft O 0 0.9548947
dysfunction O 0 0.86027664
within O 0 0.00023476529
48 O 0 0.00034501136
hours O 0 0.00029409953
of O 0 0.0005585031
exposure O 0 0.00176513
to O 0 0.0012044727
the O 0 0.0022792653
drug O 0 0.2950288
. O 0 0.0066607585

The O 0 0.0034838214
biopsy O 0 0.003359823
specimen O 0 0.0021978198
showed O 0 0.0015054796
pathognomonic O 0 0.0036900716
features O 0 0.0014231326
, O 0 0.0012895247
including O 0 0.0011377252
eosinophilic O 0 0.99646914
infiltration O 0 0.7404104
of O 0 0.0019999994
the O 0 0.0020828517
interstitial O 0 0.13514213
compartment O 0 0.0055228863
. O 0 0.0077822707

Allograft O 0 0.014953005
function O 0 0.0035569426
improved O 0 0.0030395542
rapidly O 0 0.002320886
and O 0 0.001757996
returned O 0 0.0013915673
to O 0 0.0011954415
baseline O 0 0.0013624724
after O 0 0.0013634643
stopping O 0 0.0039913696
the O 0 0.0037165284
drug O 0 0.2960413
. O 0 0.009318953

Liver B-Disease 0 0.99628663
disease I-Disease 0 0.99148655
caused O 0 0.024859993
by O 0 0.035199888
propylthiouracil B-Chemical 0 0.9999294
. O 0 0.04217512

This O 0 0.0051749675
report O 0 0.0036601853
presents O 0 0.002018152
the O 0 0.001301434
clinical O 0 0.0029475172
, O 0 0.0011004987
laboratory O 0 0.0009057826
, O 0 0.0005863964
and O 0 0.00040739714
light O 0 0.00083262555
and O 0 0.000320294
electron O 0 0.005884167
microscopic O 0 0.00073565374
observations O 0 0.00021281955
on O 0 0.00014367781
a O 0 0.00025431806
patient O 0 0.00024454994
with O 0 0.00032467564
chronic B-Disease 0 0.68035036
active I-Disease 0 0.007818374
( I-Disease 0 0.003762903
aggressive I-Disease 0 0.38405943
) I-Disease 0 0.047843847
hepatitis I-Disease 2 0.9999999
caused O 0 0.0052968473
by O 0 0.0011739961
the O 0 0.0011508486
administration O 0 0.035807412
of O 0 0.011101635
propylthiouracil B-Chemical 0 0.99998474
. O 0 0.010801357

This O 0 0.0054897973
is O 0 0.0026583702
an O 0 0.0018583959
addition O 0 0.0008839904
to O 0 0.0007753896
the O 0 0.00062133215
list O 0 0.00047665968
of O 0 0.0005957448
drugs O 0 0.04537706
that O 0 0.0002975982
must O 0 0.00024057954
be O 0 0.00030530294
considered O 0 0.00030005883
in O 0 0.00037793972
the O 0 0.00047572388
evaluation O 0 0.00073870126
of O 0 0.001968506
chronic O 0 0.9973605
liver B-Disease 2 0.9997553
disease I-Disease 2 0.9999058
. O 0 0.016040523

Withdrawal B-Disease 0 0.7811677
- I-Disease 0 0.020034859
emergent I-Disease 0 0.006820937
rabbit I-Disease 0 0.35487804
syndrome I-Disease 0 0.94438636
during O 0 0.0025294863
dose O 0 0.013743601
reduction O 0 0.008178885
of O 0 0.03157437
risperidone B-Chemical 0 0.9999925
. O 0 0.0130285695

Rabbit B-Disease 0 0.80993956
syndrome I-Disease 0 0.9918303
( O 0 0.03250475
RS B-Disease 0 0.99330586
) O 0 0.0038273444
is O 0 0.0012867169
a O 0 0.0014640925
rare O 0 0.05067668
extrapyramidal O 0 0.99999213
side O 0 0.057502374
effect O 0 0.0008374417
caused O 0 0.0010472055
by O 0 0.0018376547
prolonged O 0 0.073016055
neuroleptic O 0 0.999997
medication O 0 0.46234837
. O 0 0.0070549543

Here O 0 0.0046159215
we O 0 0.0020291756
present O 0 0.0014936506
a O 0 0.0015295096
case O 0 0.001192972
of O 0 0.0015539926
withdrawal B-Disease 0 0.80261815
- I-Disease 0 0.083317034
emergent I-Disease 0 0.008490676
RS I-Disease 0 0.99570674
, O 0 0.0009655084
which O 0 0.00053537986
is O 0 0.00039666292
the O 0 0.00037084625
first O 0 0.00037489424
of O 0 0.00065297016
its O 0 0.0012475116
kind O 0 0.0013882238
to O 0 0.0013880486
be O 0 0.0024093208
reported O 0 0.0044983625
. O 0 0.0069694594

The O 0 0.0058036107
patient O 0 0.0053727003
developed O 0 0.0063464222
RS B-Disease 0 0.8801046
during O 0 0.003182007
dose O 0 0.010756482
reduction O 0 0.009129769
of O 0 0.03296111
risperidone B-Chemical 0 0.9999918
. O 0 0.014880604

The O 0 0.005384018
symptom O 0 0.011298536
was O 0 0.0032508362
treated O 0 0.0029826174
successfully O 0 0.003543214
with O 0 0.025562994
trihexyphenidyl B-Chemical 1 0.99999976
anticholinergic O 0 0.9999336
therapy O 0 0.038708244
. O 0 0.010599783

The O 0 0.0028706614
underlying O 0 0.002175618
mechanism O 0 0.0014515227
of O 0 0.0022393034
withdrawal B-Disease 0 0.85695654
- I-Disease 0 0.104786254
emergent I-Disease 0 0.007017615
RS I-Disease 0 0.9894118
in O 0 0.00038516038
the O 0 0.00026510062
present O 0 0.00019104818
case O 0 0.00025887773
may O 0 0.00018105449
have O 0 0.00015313907
been O 0 0.00015852446
related O 0 0.00010914558
to O 0 0.000121165685
the O 0 0.00014822083
pharmacological O 0 0.003740106
profile O 0 0.00025669273
of O 0 0.0038249104
risperidone B-Chemical 0 0.99999976
, O 0 0.0021096636
a O 0 0.0051673213
serotonin B-Chemical 0 0.9999751
- O 0 0.69795454
dopamine B-Chemical 1 0.9999738
antagonist O 0 0.85877097
, O 0 0.00037387208
suggesting O 0 0.00013226048
the O 0 0.00014822224
pathophysiologic O 0 0.0003595762
influence O 0 0.00015069841
of O 0 0.00032431493
the O 0 0.00052392925
serotonin B-Chemical 0 0.99779415
system O 0 0.00051622477
in O 0 0.0005911917
the O 0 0.00089165807
development O 0 0.0026368315
of O 0 0.005172734
RS B-Disease 0 0.98956025
. O 0 0.007972427

Pharmacokinetic O 0 0.3864484
/ O 0 0.009013241
pharmacodynamic O 0 0.0332539
assessment O 0 0.0012251368
of O 0 0.001010169
the O 0 0.0007090041
effects O 0 0.0010723303
of O 0 0.008185715
E4031 B-Chemical 0 0.99999964
, O 0 0.16618903
cisapride B-Chemical 0 0.99999595
, O 0 0.056027215
terfenadine B-Chemical 1 0.9999989
and O 0 0.0037241494
terodiline B-Chemical 0 0.99946004
on O 0 0.00031834323
monophasic O 0 0.018539276
action O 0 0.0007628948
potential O 0 0.0008925845
duration O 0 0.0011901662
in O 0 0.0022790397
dog O 0 0.007628642
. O 0 0.00653771

1 O 0 0.09718908
. O 0 0.11277451

Torsades B-Disease 0 0.9990144
de I-Disease 0 0.32270494
pointes I-Disease 0 0.9999938
( O 0 0.21403082
TDP B-Disease 0 0.9998945
) O 0 0.004189889
is O 0 0.0007783693
a O 0 0.0007322754
potentially O 0 0.0027173592
fatal O 0 0.9978192
ventricular B-Disease 2 0.9999286
tachycardia I-Disease 2 0.99999714
associated O 0 0.0007613984
with O 0 0.0003048748
increases O 0 0.0002343366
in O 0 0.00028601923
QT O 0 0.49217698
interval O 0 0.00022989917
and O 0 0.0003131396
monophasic O 0 0.010363158
action O 0 0.00056493044
potential O 0 0.0006839725
duration O 0 0.00094218994
( O 0 0.0028891785
MAPD O 0 0.6270788
) O 0 0.0071297414
. O 0 0.007145552

TDP B-Disease 0 0.9981571
is O 0 0.0038691352
a O 0 0.00330792
side O 0 0.12781571
- O 0 0.017523969
effect O 0 0.00082084996
that O 0 0.0005098773
has O 0 0.00042906156
led O 0 0.0003956567
to O 0 0.0003415867
withdrawal O 0 0.06765795
of O 0 0.0003495967
several O 0 0.00023083508
drugs O 0 0.0127132125
from O 0 0.00018556869
the O 0 0.00022694423
market O 0 0.0006929265
( O 0 0.00044740134
e O 0 0.0008105329
. O 0 0.00046696377
g O 0 0.0018311571
. O 0 0.0013145761
terfenadine B-Chemical 1 0.9999914
and O 0 0.0083830375
terodiline B-Chemical 0 0.99972874
) O 0 0.008613902
. O 0 0.00741837

2 O 0 0.09703088
. O 0 0.11310669

The O 0 0.0032021545
potential O 0 0.002638022
of O 0 0.0025866758
compounds O 0 0.44295692
to O 0 0.0013928581
cause O 0 0.0059610913
TDP B-Disease 0 0.99971277
was O 0 0.00073568325
evaluated O 0 0.00046609438
by O 0 0.0005585771
monitoring O 0 0.0006543629
their O 0 0.00070904574
effects O 0 0.0010120036
on O 0 0.0011332984
MAPD O 0 0.3450744
in O 0 0.0032397367
dog O 0 0.009833992
. O 0 0.0076640393

Four O 0 0.005343471
compounds O 0 0.15414818
known O 0 0.002299854
to O 0 0.001252394
increase O 0 0.0010619456
QT O 0 0.6472019
interval O 0 0.00065144576
and O 0 0.0006847046
cause O 0 0.0016740487
TDP B-Disease 0 0.9995914
were O 0 0.0004980942
investigated O 0 0.0004520717
: O 0 0.013674395
terfenadine B-Chemical 1 0.9999987
, O 0 0.046057697
terodiline B-Chemical 0 0.9999573
, O 0 0.026147714
cisapride B-Chemical 0 0.9999485
and O 0 0.016463533
E4031 B-Chemical 0 0.9999782
. O 0 0.009282267

On O 0 0.0031119229
the O 0 0.0020462682
basis O 0 0.0015174795
that O 0 0.0009562984
only O 0 0.00095513836
free O 0 0.0010966492
drug O 0 0.21702924
in O 0 0.00049236795
the O 0 0.00042730157
systemic O 0 0.48654333
circulation O 0 0.0050825197
will O 0 0.00016883375
elicit O 0 0.00013128945
a O 0 0.00024274841
pharmacological O 0 0.0033720646
response O 0 0.00026796706
target O 0 0.00020695674
, O 0 0.00034236733
free O 0 0.000286894
concentrations O 0 0.0009164325
in O 0 0.00024616104
plasma O 0 0.0038528258
were O 0 0.00019486868
selected O 0 0.00018694592
to O 0 0.00021739595
mimic O 0 0.0002887388
the O 0 0.00043398092
free O 0 0.0009654257
drug O 0 0.28963754
exposures O 0 0.09304111
in O 0 0.003027215
man O 0 0.2545532
. O 0 0.007388466

Infusion O 0 0.038136974
regimens O 0 0.0030956122
were O 0 0.0014411554
designed O 0 0.00090877496
that O 0 0.0005983721
rapidly O 0 0.00066252286
achieved O 0 0.0004854797
and O 0 0.00041864702
maintained O 0 0.00031857
target O 0 0.00037125938
- O 0 0.0059897513
free O 0 0.00032607996
concentrations O 0 0.00062625296
of O 0 0.0002755086
these O 0 0.00031469436
drugs O 0 0.099028915
in O 0 0.00023284818
plasma O 0 0.00740831
and O 0 0.00020668382
data O 0 0.00014947238
on O 0 9.082898e-05
the O 0 0.00011458145
relationship O 0 9.729041e-05
between O 0 0.00012127157
free O 0 0.00024754257
concentration O 0 0.00053360633
and O 0 0.00037035623
changes O 0 0.00048719792
in O 0 0.00043706494
MAPD O 0 0.15480408
were O 0 0.0005728544
obtained O 0 0.0007115849
for O 0 0.001170714
these O 0 0.00247474
compounds O 0 0.3834857
. O 0 0.007071548

3 O 0 0.0941019
. O 0 0.112802126

These O 0 0.0035517311
data O 0 0.0022975295
indicate O 0 0.0010881138
that O 0 0.00091509795
the O 0 0.00084349065
free O 0 0.0014400238
ED50 O 0 0.99139214
in O 0 0.0007920371
plasma O 0 0.06270239
for O 0 0.0014678037
terfenadine B-Chemical 1 0.9999988
( O 0 0.0024523148
1 O 0 0.00025949848
. O 0 0.00018219279
9 O 0 0.00019256651
nM O 0 0.0041195373
) O 0 0.0016266473
, O 0 0.0020112789
terodiline B-Chemical 0 0.99981993
( O 0 0.000946121
76 O 0 0.0007567674
nM O 0 0.01786693
) O 0 0.0031234142
, O 0 0.0031282878
cisapride B-Chemical 0 0.99994993
( O 0 0.00084099185
11 O 0 0.00025155323
nM O 0 0.006105062
) O 0 0.0012125734
and O 0 0.0016145034
E4031 B-Chemical 0 0.9999982
( O 0 0.0016543563
1 O 0 0.00022119988
. O 0 0.00016769207
9 O 0 0.00018415715
nM O 0 0.0018925031
) O 0 0.0004787614
closely O 0 0.00021197546
correlate O 0 0.00019364992
with O 0 0.00023024555
the O 0 0.0002592695
free O 0 0.00043027438
concentration O 0 0.0009547818
in O 0 0.0008652683
man O 0 0.1322046
causing O 0 0.014981049
QT O 0 0.95318204
effects O 0 0.0050462903
. O 0 0.006611645

For O 0 0.0039181127
compounds O 0 0.10706333
that O 0 0.0015954633
have O 0 0.0012622103
shown O 0 0.0012931338
TDP B-Disease 0 0.99896514
in O 0 0.0006481869
the O 0 0.0004903608
clinic O 0 0.0008024017
( O 0 0.007421154
terfenadine B-Chemical 1 0.9999989
, O 0 0.032216392
terodiline B-Chemical 0 0.9999728
, O 0 0.016422177
cisapride B-Chemical 0 0.99996936
) O 0 0.0008789088
there O 0 0.00012502096
is O 0 0.00016514855
little O 0 0.00015596168
differentiation O 0 0.008601224
between O 0 0.00013224084
the O 0 0.00022383106
dog O 0 0.0066697774
ED50 O 0 0.9826574
and O 0 0.00028518224
the O 0 0.00018027483
efficacious O 0 0.00067562587
free O 0 0.00025322734
plasma O 0 0.007910042
concentrations O 0 0.00070843316
in O 0 0.00024628756
man O 0 0.050199877
( O 0 0.00052538625
< O 0 0.0002472805
10 O 0 0.00030300458
- O 0 0.0012996563
fold O 0 0.00068575767
) O 0 0.00087611313
reflecting O 0 0.0006895977
their O 0 0.0008892903
limited O 0 0.0012935158
safety O 0 0.0028412258
margins O 0 0.012473983
. O 0 0.0066066496

These O 0 0.003696876
data O 0 0.0024445343
underline O 0 0.00147056
the O 0 0.0010599565
need O 0 0.00070164626
to O 0 0.0005066011
maximize O 0 0.00033030479
the O 0 0.00036947528
therapeutic O 0 0.00072068616
ratio O 0 0.0004154533
with O 0 0.0003269282
respect O 0 0.00024722275
to O 0 0.00031974696
TDP B-Disease 0 0.99924386
in O 0 0.00018993606
potential O 0 0.00020736916
development O 0 0.0003390056
candidates O 0 0.00016971244
and O 0 0.00019587015
the O 0 0.00015689393
importance O 0 0.0001564829
of O 0 0.00023767471
using O 0 0.00022973788
free O 0 0.00046042175
drug O 0 0.15717094
concentrations O 0 0.001704875
in O 0 0.00076284364
pharmacokinetic O 0 0.279453
/ O 0 0.0064873444
pharmacodynamic O 0 0.10555657
studies O 0 0.0038090565
. O 0 0.0063303225

Bladder O 0 0.031826485
retention B-Disease 0 0.0078371465
of I-Disease 0 0.0033168618
urine I-Disease 0 0.49822202
as O 0 0.0012259912
a O 0 0.0009962992
result O 0 0.00059933384
of O 0 0.00068265735
continuous O 0 0.0006011428
intravenous O 0 0.02791047
infusion O 0 0.0022308987
of O 0 0.0019927218
fentanyl B-Chemical 1 0.999912
: O 0 0.0023416325
2 O 0 0.0016075646
case O 0 0.0024409753
reports O 0 0.0043643587
. O 0 0.007213308

Sedation O 0 0.02836331
has O 0 0.0024188096
been O 0 0.001688236
commonly O 0 0.0013574508
used O 0 0.00071738235
in O 0 0.00058869435
the O 0 0.0004889693
neonate O 0 0.0019283125
to O 0 0.0003068167
decrease O 0 0.00030471582
the O 0 0.0003078675
stress O 0 0.07961607
and O 0 0.0009764355
pain B-Disease 0 0.84828097
from O 0 0.00016603609
the O 0 0.00019010746
noxious O 0 0.03768888
stimuli O 0 0.00032648246
and O 0 0.00025384518
invasive O 0 0.0005964228
procedures O 0 0.00017086919
in O 0 0.00015898632
the O 0 0.00016861335
neonatal O 0 0.0007652248
intensive O 0 0.00018915693
care O 0 0.00018709216
unit O 0 0.00015984713
, O 0 0.00023670997
as O 0 0.0001762981
well O 0 0.00019453675
as O 0 0.00021277148
to O 0 0.00022561029
facilitate O 0 0.00026244143
synchrony O 0 0.00080154685
between O 0 0.00052022166
ventilator O 0 0.0018836772
and O 0 0.0015533334
spontaneous O 0 0.005904866
breaths O 0 0.007960781
. O 0 0.0063989474

Fentanyl B-Chemical 0 0.9999411
, O 0 0.0076698544
an O 0 0.005746619
opioid O 0 0.99773717
analgesic O 0 0.94732356
, O 0 0.0015796986
is O 0 0.0006754288
frequently O 0 0.0005596438
used O 0 0.00032827305
in O 0 0.00033176187
the O 0 0.0003441758
neonatal O 0 0.0009049373
intensive O 0 0.00039047672
care O 0 0.00042803457
unit O 0 0.00041507927
setting O 0 0.00057356356
for O 0 0.00081707747
these O 0 0.001435798
very O 0 0.0027513953
purposes O 0 0.003923578
. O 0 0.0070238137

Various O 0 0.0054668426
reported O 0 0.0032169765
side O 0 0.01134799
effects O 0 0.0022312072
of O 0 0.0033490143
fentanyl B-Chemical 1 0.99995184
administration O 0 0.017860362
include O 0 0.00057343574
chest B-Disease 0 0.11643
wall I-Disease 0 0.11703158
rigidity I-Disease 2 0.9997869
, O 0 0.028922167
hypotension B-Disease 2 0.9999927
, O 0 0.0048268507
respiratory B-Disease 0 0.63051605
depression I-Disease 0 0.99963415
, O 0 0.0037677756
and O 0 0.0054413183
bradycardia B-Disease 0 0.9982899
. O 0 0.0076843305

Here O 0 0.0054454384
, O 0 0.003593218
2 O 0 0.0019432508
cases O 0 0.001619318
of O 0 0.001478278
urinary B-Disease 0 0.76418316
bladder I-Disease 0 0.37313348
retention I-Disease 0 0.014009659
leading O 0 0.00093511405
to O 0 0.00042244466
renal O 0 0.8004739
pelvocalyceal O 0 0.2681591
dilatation O 0 0.63667196
mimicking O 0 0.00502185
hydronephrosis B-Disease 0 0.99927956
as O 0 0.0003459959
a O 0 0.00033777632
result O 0 0.0002463
of O 0 0.00039172109
continuous O 0 0.0004380896
infusion O 0 0.0015751026
of O 0 0.0019637847
fentanyl B-Chemical 1 0.99979824
are O 0 0.0022607665
reported O 0 0.0041403016
. O 0 0.0062338104

Fatal O 0 0.7900662
myeloencephalopathy B-Disease 0 0.9959139
due O 0 0.0022523114
to O 0 0.001983571
accidental O 0 0.89687765
intrathecal O 0 0.97151023
vincristin B-Chemical 0 0.99992967
administration O 0 0.06841354
: O 0 0.0019258418
a O 0 0.0014173127
report O 0 0.002064237
of O 0 0.0021508224
two O 0 0.00250658
cases O 0 0.0058474736
. O 0 0.007991914

We O 0 0.0036809877
report O 0 0.002990644
on O 0 0.0013132617
two O 0 0.0011825772
fatal O 0 0.7828198
cases O 0 0.0019088872
of O 0 0.0015497775
accidental O 0 0.96224165
intrathecal O 0 0.9679965
vincristine B-Chemical 1 0.99997854
instillation O 0 0.106715
in O 0 0.00031407186
a O 0 0.0003382808
5 O 0 0.00019441177
- O 0 0.000714451
year O 0 0.00018293732
old O 0 0.0002073075
girl O 0 0.0004844707
with O 0 0.00033213024
recurrent O 0 0.4047308
acute B-Disease 0 0.99875534
lymphoblastic I-Disease 0 0.9999994
leucemia I-Disease 0 0.99958414
and O 0 0.0018461101
a O 0 0.0007017566
57 O 0 0.000915343
- O 0 0.0015848262
year O 0 0.0005665276
old O 0 0.0009513834
man O 0 0.07276291
with O 0 0.012246591
lymphoblastic B-Disease 0 0.9999982
lymphoma I-Disease 0 0.9999863
. O 0 0.032788787

The O 0 0.0038575798
girl O 0 0.00451863
died O 0 0.0032783863
seven O 0 0.0013264965
days O 0 0.0009420409
, O 0 0.0011770463
the O 0 0.0008456715
man O 0 0.0056835674
four O 0 0.0005832129
weeks O 0 0.00055891817
after O 0 0.00073915086
intrathecal O 0 0.06685066
injection O 0 0.0029100273
of O 0 0.0055555915
vincristine B-Chemical 1 0.9997453
. O 0 0.009811624

Clinically O 0 0.07320488
, O 0 0.0037087447
the O 0 0.0018263827
onset O 0 0.002153875
was O 0 0.0009962934
characterized O 0 0.00081175065
by O 0 0.00062661566
the O 0 0.0005350359
signs O 0 0.011623413
of O 0 0.0006910477
opistothonus B-Disease 0 0.02970593
, I-Disease 0 0.00084243994
sensory I-Disease 0 0.0015667978
and I-Disease 0 0.0008546391
motor I-Disease 0 0.031835288
dysfunction I-Disease 0 0.55533326
and O 0 0.0028698305
ascending O 0 0.08846998
paralysis B-Disease 2 0.9996786
. O 0 0.009513927

Histological O 0 0.009520088
and O 0 0.0027247942
immunohistochemical O 0 0.0034562517
investigations O 0 0.0021775835
( O 0 0.0056648073
HE O 0 0.9995908
- O 0 0.55545574
LFB O 0 0.9996972
, O 0 0.0058385236
CD O 0 0.99714833
- O 0 0.02547
68 O 0 0.0007571577
, O 0 0.00066949456
Neurofilament O 0 0.9244385
) O 0 0.00085333554
revealed O 0 0.00035358215
degeneration B-Disease 0 0.97000813
of I-Disease 0 0.00041971394
myelin I-Disease 0 0.032221697
and I-Disease 0 0.00025985154
axons I-Disease 0 0.00033825648
as O 0 0.00014568007
well O 0 0.00015308434
as O 0 0.00020552124
pseudocystic B-Disease 0 0.715406
transformation I-Disease 0 0.20885421
in O 0 0.00022758692
areas O 0 0.00053578813
exposed O 0 0.00030318636
to O 0 0.00031314496
vincristine B-Chemical 1 0.9998416
, O 0 0.0006368027
accompanied O 0 0.0005075744
by O 0 0.0004362277
secondary O 0 0.002259485
changes O 0 0.00081147795
with O 0 0.0009213612
numerous O 0 0.001734478
prominent O 0 0.00599043
macrophages O 0 0.0076117776
. O 0 0.0069472645

The O 0 0.0039370204
clinical O 0 0.003926738
course O 0 0.0021563587
and O 0 0.0020187853
histopathological O 0 0.026471995
results O 0 0.0012823964
of O 0 0.0014723733
the O 0 0.0014037122
two O 0 0.0014942011
cases O 0 0.0027313665
are O 0 0.0031970432
presented O 0 0.004745655
. O 0 0.00825496

A O 0 0.026803901
review O 0 0.005437521
of O 0 0.0034107426
all O 0 0.0024092912
reported O 0 0.0023739778
cases O 0 0.0024822033
in O 0 0.002097075
the O 0 0.002360268
literature O 0 0.0037762334
is O 0 0.004263515
given O 0 0.0050340234
. O 0 0.009952512

A O 0 0.018725554
better O 0 0.0034581118
controlled O 0 0.0021631515
regimen O 0 0.0021453877
for O 0 0.001616005
administering O 0 0.013203039
vincristine B-Chemical 1 0.99989784
and O 0 0.0042350204
intrathecal O 0 0.72298366
chemotherapy O 0 0.122330904
is O 0 0.0033995998
recommended O 0 0.0051844963
. O 0 0.0077412315

Palpebral B-Disease 0 0.9792947
twitching I-Disease 0 0.9617176
in O 0 0.006871095
a O 0 0.0080249915
depressed B-Disease 2 0.9122699
adolescent O 0 0.24596073
on O 0 0.008649417
citalopram B-Chemical 1 0.9999738
. O 0 0.017222298

Current O 0 0.007253555
estimates O 0 0.00207492
suggest O 0 0.001071205
that O 0 0.00087829767
between O 0 0.0006946655
0 O 0 0.000798739
. O 0 0.00052102434
4 O 0 0.00039992735
% O 0 0.0004430402
and O 0 0.00039640756
8 O 0 0.0003337077
. O 0 0.0002980184
3 O 0 0.00028210078
% O 0 0.00036133145
of O 0 0.00039092757
children O 0 0.00070141297
and O 0 0.0006090915
adolescents O 0 0.0045522354
are O 0 0.00075536355
affected O 0 0.0010857261
by O 0 0.0019338301
major B-Disease 2 0.04401239
depression I-Disease 2 0.99984634
. O 0 0.008646404

We O 0 0.0037633933
report O 0 0.0033730585
a O 0 0.0021183507
favorable O 0 0.0030140379
response O 0 0.0011586976
to O 0 0.0006017631
treatment O 0 0.0008233912
with O 0 0.0021252807
citalopram B-Chemical 1 0.9999982
by O 0 0.0004007532
a O 0 0.00036059844
15 O 0 0.00023193794
- O 0 0.0010156275
year O 0 0.00028061093
- O 0 0.0012954107
old O 0 0.00025462717
boy O 0 0.0005312089
with O 0 0.00034481322
major B-Disease 2 0.024278492
depression I-Disease 2 0.99996555
who O 0 0.000760246
exhibited O 0 0.00039105673
palpebral B-Disease 0 0.9481985
twitching I-Disease 0 0.97936624
during O 0 0.0003021352
his O 0 0.0005100177
first O 0 0.00042226666
2 O 0 0.00065688096
weeks O 0 0.0007946331
of O 0 0.0019380297
treatment O 0 0.00387545
. O 0 0.0065589277

This O 0 0.0056351903
may O 0 0.002680367
have O 0 0.0017796059
been O 0 0.0015555782
a O 0 0.0014734096
side O 0 0.00999637
effect O 0 0.001066128
of O 0 0.004555499
citalopram B-Chemical 1 0.99999845
as O 0 0.0009944272
it O 0 0.0012449713
remitted O 0 0.698442
with O 0 0.0011837691
redistribution O 0 0.0022836463
of O 0 0.003411785
doses O 0 0.027941871
. O 0 0.007760697

The O 0 0.0072660656
3 O 0 0.0068552895
- O 0 0.011152455
week O 0 0.00729315
sulphasalazine B-Chemical 1 0.9999486
syndrome O 0 0.9136912
strikes O 0 0.4322456
again O 0 0.01291048
. O 0 0.016299466

A O 0 0.06237528
34 O 0 0.004976354
- O 0 0.0065200645
year O 0 0.002110021
- O 0 0.0036478408
old O 0 0.0011686449
lady O 0 0.002059154
developed O 0 0.0009386998
a O 0 0.0008220016
constellation O 0 0.15812019
of O 0 0.0067368094
dermatitis B-Disease 0 0.9999988
, O 0 0.15985148
fever B-Disease 0 0.9999927
, O 0 0.04780565
lymphadenopathy B-Disease 2 0.99987924
and O 0 0.02622014
hepatitis B-Disease 2 1.0
, O 0 0.011012714
beginning O 0 0.00018025593
on O 0 0.000120384175
the O 0 0.00016747123
17th O 0 0.00046306904
day O 0 0.00014939444
of O 0 0.00020753471
a O 0 0.00024824924
course O 0 0.00023433169
of O 0 0.0005957541
oral O 0 0.8260027
sulphasalazine B-Chemical 1 0.9999968
for O 0 0.0012966223
sero O 0 0.90482527
- O 0 0.07137484
negative O 0 0.027376952
rheumatoid B-Disease 0 0.9999665
arthritis I-Disease 0 0.9999869
. O 0 0.014216202

Cervical O 0 0.03408235
and O 0 0.0029787517
inguinal O 0 0.0025200767
lymph O 0 0.0052416627
node O 0 0.001233395
biopsies O 0 0.00082574826
showed O 0 0.00046407187
the O 0 0.0003689134
features O 0 0.00047451945
of O 0 0.0005838898
severe O 0 0.5517546
necrotising O 0 0.99999285
lymphadenitis B-Disease 0 0.9999852
, O 0 0.0030839604
associated O 0 0.0003654879
with O 0 0.0003601999
erythrophagocytosis O 0 0.9095297
and O 0 0.0004522445
prominent O 0 0.029202143
eosinophilic O 0 0.99924636
infiltrates O 0 0.9871617
, O 0 0.0006407576
without O 0 0.0001842961
viral O 0 0.0105001135
inclusion O 0 0.0002587277
bodies O 0 0.0018838044
, O 0 0.00032080038
suggestive O 0 0.00028722192
of O 0 0.0002548793
an O 0 0.0004794247
adverse B-Disease 0 0.888389
drug I-Disease 0 0.5806095
reaction I-Disease 0 0.16480905
. O 0 0.00025187604
A O 0 0.033811573
week O 0 0.00013519115
later O 0 0.00016380734
, O 0 0.0007258599
fulminant O 0 0.9999374
drug B-Disease 0 0.9841679
- I-Disease 0 0.35816798
induced I-Disease 0 0.012512874
hepatitis I-Disease 2 1.0
, O 0 0.06815746
associated O 0 0.00071434415
with O 0 0.00022641775
the O 0 0.00014057232
presence O 0 0.0001521782
of O 0 0.00036371817
anti O 0 0.53392017
- O 0 0.18488266
nuclear O 0 0.07005591
autoantibodies O 0 0.94438636
( O 0 0.0015898492
but O 0 0.0002555548
not O 0 0.00013364373
with O 0 0.00016496632
other O 0 0.00018467096
markers O 0 0.0006116393
of O 0 0.0010168203
autoimmunity B-Disease 0 0.9998815
) O 0 0.015754424
, O 0 0.0005845474
and O 0 0.0003243072
accompanied O 0 0.00045370092
by O 0 0.0004541438
multi B-Disease 0 0.04654579
- I-Disease 0 0.018335955
organ I-Disease 0 0.017523704
failure I-Disease 0 0.41320002
and O 0 0.0048455684
sepsis B-Disease 2 0.99983
, O 0 0.021297086
supervened O 0 0.8017687
. O 0 0.007941539

She O 0 0.0047230697
subsequently O 0 0.0027644339
died O 0 0.0028411217
some O 0 0.0011501061
5 O 0 0.0007082523
weeks O 0 0.00043082717
after O 0 0.00032141354
the O 0 0.00033431206
commencement O 0 0.00034503127
of O 0 0.00035832802
her O 0 0.00044689837
drug O 0 0.14068532
therapy O 0 0.000985196
. O 0 0.00025507453
Post O 0 0.0064076236
- O 0 0.008463799
mortem O 0 0.062287603
examination O 0 0.00018432089
showed O 0 0.0001433919
evidence O 0 0.0001438711
of O 0 0.00058651884
massive B-Disease 0 0.9563766
hepatocellular I-Disease 0 1.0
necrosis I-Disease 2 1.0
, O 0 0.59193283
acute O 0 0.99966645
hypersensitivity O 0 0.99999833
myocarditis B-Disease 2 1.0
, O 0 0.05563685
focal O 0 0.43532985
acute O 0 0.97006804
tubulo O 0 0.95684505
- O 0 0.5180887
interstitial O 0 0.9974267
nephritis B-Disease 0 0.9999999
and O 0 0.00092519185
extensive O 0 0.0004558138
bone B-Disease 0 0.081984304
marrow I-Disease 0 0.30854312
necrosis I-Disease 2 0.9999684
, O 0 0.0015724082
with O 0 0.000761451
no O 0 0.0007614583
evidence O 0 0.0013715924
of O 0 0.004823128
malignancy B-Disease 2 0.99974996
. O 0 0.012056721

It O 0 0.004650179
is O 0 0.0025038442
thought O 0 0.0016339351
that O 0 0.0010098664
the O 0 0.0009894411
clinico O 0 0.21380961
- O 0 0.014016997
pathological O 0 0.026508205
features O 0 0.00060794054
and O 0 0.0003694491
chronology O 0 0.001413295
of O 0 0.00032222815
this O 0 0.00023527732
case O 0 0.00026656632
bore O 0 0.00138577
the O 0 0.0001847331
hallmarks O 0 0.00035613746
of O 0 0.00026407238
the O 0 0.00022673466
so O 0 0.00026877556
- O 0 0.0046465164
called O 0 0.00031684534
" O 0 0.0003822673
3 O 0 0.00020020541
- O 0 0.0017434923
week O 0 0.0002591963
sulphasalazine B-Chemical 1 0.9999943
syndrome O 0 0.82030404
" O 0 0.0008644871
, O 0 0.00045812156
a O 0 0.00041421718
rare O 0 0.0021078105
, O 0 0.000614984
but O 0 0.00057754375
often O 0 0.0010945033
fatal O 0 0.9577352
, O 0 0.0045363465
immunoallergic O 0 0.9965899
reaction O 0 0.1361069
to O 0 0.00412881
sulphasalazine B-Chemical 1 0.9999764
. O 0 0.00912393

Intravenous O 0 0.32639188
administration O 0 0.025177324
of O 0 0.0060631623
prochlorperazine B-Chemical 0 0.99998164
by O 0 0.0011068444
15 O 0 0.0005835087
- O 0 0.0010695598
minute O 0 0.00030029324
infusion O 0 0.00045326
versus O 0 0.00024974157
2 O 0 0.00027348948
- O 0 0.00075625017
minute O 0 0.00020918486
bolus O 0 0.000657439
does O 0 0.00020293528
not O 0 0.00016671205
affect O 0 0.00015048702
the O 0 0.00022245348
incidence O 0 0.0019947202
of O 0 0.003211942
akathisia B-Disease 0 0.9999981
: O 0 0.0011767833
a O 0 0.00060428795
prospective O 0 0.0012509789
, O 0 0.0009457479
randomized O 0 0.0010531573
, O 0 0.0016467118
controlled O 0 0.0020275523
trial O 0 0.0042874445
. O 0 0.006642261

STUDY O 0 0.006575036
OBJECTIVE O 0 0.0098664025
: O 0 0.002666594
We O 0 0.0012938441
sought O 0 0.0009804579
to O 0 0.00063481875
compare O 0 0.0003496497
the O 0 0.00041028886
rate O 0 0.0005068298
of O 0 0.0020185942
akathisia B-Disease 0 0.99999714
after O 0 0.00024317141
administration O 0 0.0027342853
of O 0 0.00063499244
intravenous O 0 0.5740023
prochlorperazine B-Chemical 0 0.999985
as O 0 0.00024799825
a O 0 0.0003459253
2 O 0 0.00027841452
- O 0 0.00075080886
minute O 0 0.0003027805
bolus O 0 0.0007804195
or O 0 0.00052653183
15 O 0 0.00077675993
- O 0 0.0021611922
minute O 0 0.0018207314
infusion O 0 0.004643012
. O 0 0.0060105314

METHODS O 0 0.004308379
: O 0 0.0035666109
We O 0 0.0019367777
conducted O 0 0.0014356478
a O 0 0.0014974402
prospective O 0 0.001905808
, O 0 0.0011560125
randomized O 0 0.0008071813
, O 0 0.000798324
double O 0 0.0007540312
- O 0 0.009228586
blind O 0 0.010721731
study O 0 0.0005032008
in O 0 0.00035233056
the O 0 0.00038684558
emergency O 0 0.0015736426
department O 0 0.0011320853
of O 0 0.0005961242
a O 0 0.0008116184
central O 0 0.0013551202
- O 0 0.0035019855
city O 0 0.0034637477
teaching O 0 0.0033920298
hospital O 0 0.0052152453
. O 0 0.0066994415

Patients O 0 0.0047497805
aged O 0 0.0032963553
18 O 0 0.0018950051
years O 0 0.0014846699
or O 0 0.0010520853
older O 0 0.0018630817
treated O 0 0.00090484845
with O 0 0.0019935132
prochlorperazine B-Chemical 0 0.99999356
for O 0 0.0027101792
headache B-Disease 0 0.999987
, O 0 0.026983062
nausea B-Disease 2 0.9999969
, O 0 0.0016452513
or O 0 0.0011528438
vomiting B-Disease 0 0.9994122
were O 0 0.0010069526
eligible O 0 0.001413698
for O 0 0.0018414959
inclusion O 0 0.0034711587
. O 0 0.006830424

Study O 0 0.006221882
participants O 0 0.002481365
were O 0 0.0016620598
randomized O 0 0.0011594242
to O 0 0.00070398516
receive O 0 0.00049867184
10 O 0 0.0004961892
mg O 0 0.009894906
of O 0 0.0011117968
prochlorperazine B-Chemical 0 0.9999745
administered O 0 0.00027126865
intravenously O 0 0.00021438103
by O 0 0.00015270601
means O 0 0.0001312301
of O 0 0.00021184335
2 O 0 0.0002067936
- O 0 0.0007033823
minute O 0 0.00014629787
push O 0 0.0005203533
( O 0 0.00033112927
bolus O 0 0.00096713885
group O 0 0.000267581
) O 0 0.00033489484
or O 0 0.0001505631
10 O 0 0.00014877407
mg O 0 0.0025900872
diluted O 0 0.00036944167
in O 0 0.00014439337
50 O 0 0.00018937999
mL O 0 0.00034290634
of O 0 0.00017145755
normal O 0 0.00032087805
saline O 0 0.0031785017
solution O 0 0.00087424275
administered O 0 0.00013698319
by O 0 0.00012879042
means O 0 0.00012036833
of O 0 0.00022212409
intravenous O 0 0.011849642
infusion O 0 0.00038777918
during O 0 0.00014724379
a O 0 0.00026943162
15 O 0 0.00024959017
- O 0 0.0006540542
minute O 0 0.00033951338
period O 0 0.00049118506
( O 0 0.0011618818
infusion O 0 0.002203825
group O 0 0.002545312
) O 0 0.0051980554
. O 0 0.0068286033

The O 0 0.003400396
main O 0 0.0027451576
outcome O 0 0.0025241994
was O 0 0.0013306417
the O 0 0.00087038934
number O 0 0.00071101886
of O 0 0.0007769916
study O 0 0.0008205425
participants O 0 0.00073672365
experiencing O 0 0.11067618
akathisia B-Disease 0 0.99998844
within O 0 0.00061158073
60 O 0 0.0009175079
minutes O 0 0.0011020865
of O 0 0.002483298
administration O 0 0.010345918
. O 0 0.0069447057

Akathisia O 0 0.9998609
was O 0 0.0028332472
defined O 0 0.001484576
as O 0 0.001077166
either O 0 0.0008138717
a O 0 0.00084939296
spontaneous O 0 0.0020671487
report O 0 0.0012956705
of O 0 0.0012224336
restlessness O 0 0.9993067
or O 0 0.0006826548
agitation B-Disease 2 0.9931599
or O 0 0.00027752726
a O 0 0.00028794137
change O 0 0.00022021167
of O 0 0.00024257074
2 O 0 0.00017535222
or O 0 0.00015027336
more O 0 0.00017873255
in O 0 0.00014422505
the O 0 0.00016484603
patient O 0 0.00031533407
- O 0 0.013307116
reported O 0 0.001268101
akathisia B-Disease 0 0.99999154
rating O 0 0.0002742023
scale O 0 0.00018176126
and O 0 0.00017827417
a O 0 0.00020142278
change O 0 0.00018342113
of O 0 0.00020220982
at O 0 0.00016347716
least O 0 0.00015867631
1 O 0 0.00021292287
in O 0 0.00024249533
the O 0 0.0003581501
investigator O 0 0.0022805918
- O 0 0.0071059098
observed O 0 0.0015943843
akathisia B-Disease 0 0.9999794
rating O 0 0.0033757878
scale O 0 0.0041630166
. O 0 0.006321681

The O 0 0.003197289
intensity O 0 0.0025219473
of O 0 0.0037306107
headache B-Disease 0 0.9999231
and O 0 0.014730427
nausea B-Disease 2 0.9999932
was O 0 0.0008565444
measured O 0 0.00051490084
with O 0 0.0006320372
a O 0 0.0008357291
100 O 0 0.001225966
- O 0 0.0027730046
mm O 0 0.0027457399
visual O 0 0.022844803
analog O 0 0.004718811
scale O 0 0.0050608143
. O 0 0.007291824

RESULTS O 0 0.0169234
: O 0 0.0133579755
One O 0 0.010867197
hundred O 0 0.01061106
patients O 0 0.0119027225
were O 0 0.013279011
enrolled O 0 0.020102888
. O 0 0.02324397

One O 0 0.009840852
study O 0 0.0069257636
participant O 0 0.005030263
was O 0 0.005271023
excluded O 0 0.0052947607
after O 0 0.0051720273
protocol O 0 0.008400608
violation O 0 0.025017703
. O 0 0.0169714

Seventy O 0 0.0076509477
- O 0 0.005751711
three O 0 0.001370929
percent O 0 0.0011958402
( O 0 0.0015751101
73 O 0 0.0016975243
/ O 0 0.002563013
99 O 0 0.0014321402
) O 0 0.0008041127
of O 0 0.00047470606
the O 0 0.00035869336
study O 0 0.0003741894
participants O 0 0.00025705667
were O 0 0.00024079597
treated O 0 0.00030643324
for O 0 0.0004466118
headache B-Disease 0 0.99976426
and O 0 0.00041761342
70 O 0 0.00038336247
% O 0 0.0004906396
( O 0 0.00064580305
70 O 0 0.00068854174
/ O 0 0.0018237645
99 O 0 0.0022943977
) O 0 0.0028331869
for O 0 0.0041451906
nausea B-Disease 2 0.9999243
. O 0 0.008955222

In O 0 0.0037337402
the O 0 0.0024544671
bolus O 0 0.0050275438
group O 0 0.0018255919
, O 0 0.0013713482
26 O 0 0.0009362155
. O 0 0.0005320895
0 O 0 0.00050481595
% O 0 0.00049983035
( O 0 0.00052502373
13 O 0 0.0003915596
/ O 0 0.0009473924
50 O 0 0.00041132385
) O 0 0.0006174901
had O 0 0.0004607906
akathisia B-Disease 0 0.99998796
compared O 0 0.00016133704
with O 0 0.0002203253
32 O 0 0.0002619794
. O 0 0.000160017
7 O 0 0.00015067714
% O 0 0.00022253535
( O 0 0.00029414333
16 O 0 0.00023754987
/ O 0 0.00071954634
49 O 0 0.00035134316
) O 0 0.0003144137
in O 0 0.00016367558
the O 0 0.00016630246
infusion O 0 0.00043486425
group O 0 0.00028215212
( O 0 0.00051269727
Delta O 0 0.12783761
= O 0 0.0029747456
- O 0 0.0056128087
6 O 0 0.00015957424
. O 0 0.00016027324
7 O 0 0.00015669761
% O 0 0.00022219826
; O 0 0.0002854077
95 O 0 0.00031796133
% O 0 0.0002330583
confidence O 0 0.00050415663
interval O 0 0.00027362985
[ O 0 0.002736605
CI O 0 0.71610737
] O 0 0.0022642035
- O 0 0.0032368584
24 O 0 0.00031335227
. O 0 0.00027694626
6 O 0 0.00028306607
% O 0 0.0004558188
to O 0 0.00048659384
11 O 0 0.0007828795
. O 0 0.0009934898
2 O 0 0.0015981406
% O 0 0.0031189956
) O 0 0.006040879
. O 0 0.00824627

The O 0 0.002730102
difference O 0 0.0015227769
between O 0 0.001085024
the O 0 0.001005026
bolus O 0 0.0025641958
and O 0 0.0007773468
infusion O 0 0.0012895665
groups O 0 0.0003840037
in O 0 0.00025764896
the O 0 0.00020997995
percentage O 0 0.00016236921
of O 0 0.0002460212
participants O 0 0.0002188547
who O 0 0.0003098681
saw O 0 0.00027795677
a O 0 0.00024564148
50 O 0 0.00023197378
% O 0 0.0002181996
reduction O 0 0.00025931647
in O 0 0.00017503915
their O 0 0.00032157757
headache B-Disease 0 0.99931276
intensity O 0 0.00013335096
within O 0 9.171544e-05
30 O 0 0.000103933955
minutes O 0 0.000103658305
was O 0 0.00013711804
11 O 0 0.00015474966
. O 0 0.00014457219
8 O 0 0.00016059114
% O 0 0.00022544235
( O 0 0.00030357394
95 O 0 0.000497433
% O 0 0.00047313416
CI O 0 0.50564027
- O 0 0.0025147744
9 O 0 0.00030309072
. O 0 0.00029266102
6 O 0 0.0003022475
% O 0 0.00049097434
to O 0 0.0005284789
33 O 0 0.0010103605
. O 0 0.0010511235
3 O 0 0.0015543561
% O 0 0.003151484
) O 0 0.0061086253
. O 0 0.008373538

The O 0 0.0029322763
difference O 0 0.0017004691
in O 0 0.001337924
the O 0 0.00090045825
percentage O 0 0.00057366694
of O 0 0.00068254606
patients O 0 0.0006964118
with O 0 0.00043481926
a O 0 0.00043464184
50 O 0 0.00035526903
% O 0 0.0003087917
reduction O 0 0.0003384387
in O 0 0.00024149168
their O 0 0.00056840875
nausea B-Disease 2 0.9999908
was O 0 0.00026038176
12 O 0 0.00015167506
. O 0 0.00015250592
6 O 0 0.0001443595
% O 0 0.00022507596
( O 0 0.0003024816
95 O 0 0.0004954901
% O 0 0.00047414916
CI O 0 0.51154935
- O 0 0.002385915
4 O 0 0.00027499397
. O 0 0.00028957526
6 O 0 0.0002997246
% O 0 0.0004853022
to O 0 0.0005249961
29 O 0 0.0010546439
. O 0 0.0010537745
8 O 0 0.0016268573
% O 0 0.0031401643
) O 0 0.006085374
. O 0 0.0083305845

CONCLUSION O 0 0.03639055
: O 0 0.005345385
A O 0 0.030640423
50 O 0 0.001995719
% O 0 0.0014338788
reduction O 0 0.0011597688
in O 0 0.00062641
the O 0 0.00051140855
incidence O 0 0.003944172
of O 0 0.0069647552
akathisia B-Disease 0 0.9999993
when O 0 0.0009527616
prochlorperazine B-Chemical 0 0.99999106
was O 0 0.00023582195
administered O 0 0.00015567908
by O 0 0.00014298812
means O 0 0.00012422145
of O 0 0.00018695251
15 O 0 0.00016982398
- O 0 0.0005812194
minute O 0 0.0001599656
intravenous O 0 0.0017464468
infusion O 0 0.00030731733
versus O 0 0.00018822208
a O 0 0.00031047163
2 O 0 0.00031480868
- O 0 0.00092437415
minute O 0 0.00043991627
intravenous O 0 0.0045233723
push O 0 0.0014969256
was O 0 0.0012355597
not O 0 0.001782389
detected O 0 0.0032223375
. O 0 0.00666397

The O 0 0.0031259332
efficacy O 0 0.0032987702
of O 0 0.0046543414
prochlorperazine B-Chemical 0 0.9999794
in O 0 0.0010290361
the O 0 0.0006132836
treatment O 0 0.00072784745
of O 0 0.0025657364
headache B-Disease 0 0.9999871
and O 0 0.02055754
nausea B-Disease 2 0.9999988
likewise O 0 0.042543843
did O 0 0.00035472197
not O 0 0.00017965984
appear O 0 0.00017463806
to O 0 0.00014086912
be O 0 0.0001701715
affected O 0 0.00017179074
by O 0 0.00018186441
the O 0 0.00017491102
rate O 0 0.00024226792
of O 0 0.0004012245
administration O 0 0.0077260425
, O 0 0.0005314927
although O 0 0.00036468878
no O 0 0.00036671487
formal O 0 0.0006977009
statistical O 0 0.0012501845
comparisons O 0 0.0011622871
were O 0 0.0019711223
made O 0 0.0033096496
. O 0 0.006437767

Combined O 0 0.012442944
antiretroviral O 0 0.1881162
therapy O 0 0.0062436205
causes O 0 0.006234957
cardiomyopathy B-Disease 0 0.99998915
and O 0 0.006691577
elevates O 0 0.11199437
plasma O 0 0.24412563
lactate B-Chemical 0 0.9261561
in O 0 0.001855624
transgenic O 0 0.00375119
AIDS B-Disease 2 0.9994978
mice O 0 0.0042723627
. O 0 0.008433505

Highly O 0 0.022046734
active O 0 0.0057767397
antiretroviral O 0 0.3481773
therapy O 0 0.012746652
( O 0 0.007234
HAART O 0 0.9812418
) O 0 0.0022236174
is O 0 0.0004833641
implicated O 0 0.00034460638
in O 0 0.0006946384
cardiomyopathy B-Disease 0 0.99999726
( O 0 0.03943141
CM B-Disease 2 0.9935359
) O 0 0.0014053494
and O 0 0.00030276837
in O 0 0.000252167
elevated O 0 0.0049456363
plasma O 0 0.108473696
lactate B-Chemical 0 0.9747593
( O 0 0.005344792
LA B-Chemical 0 0.9991623
) O 0 0.0019939095
in O 0 0.0006482216
AIDS B-Disease 2 0.9993048
through O 0 0.0005664045
mechanisms O 0 0.0009178586
of O 0 0.002779287
mitochondrial B-Disease 0 0.98581576
dysfunction I-Disease 0 0.9985812
. O 0 0.00984154

To O 0 0.0026954338
determine O 0 0.0014264066
mitochondrial O 0 0.028131051
events O 0 0.006021846
from O 0 0.0009912353
HAART O 0 0.8773018
in O 0 0.00059611513
vivo O 0 0.000800007
, O 0 0.00072383904
8 O 0 0.00036598177
- O 0 0.0012537404
week O 0 0.00021907724
- O 0 0.0010210245
old O 0 0.0002990906
hemizygous O 0 0.0050921543
transgenic O 0 0.000796454
AIDS B-Disease 2 0.99988806
mice O 0 0.00021901519
( O 0 0.00314542
NL4 O 0 0.9593731
- O 0 0.053536594
3Delta O 0 0.09092249
gag O 0 0.13590883
/ O 0 0.036379337
pol O 0 0.45295376
; O 0 0.038825892
TG O 2 0.9994093
) O 0 0.0014884959
and O 0 0.00035118574
wild O 0 0.0003440698
- O 0 0.010909831
type O 0 0.00040015002
FVB O 0 0.0251179
/ O 0 0.0010380563
n O 0 0.0001454609
littermates O 0 9.560453e-05
were O 0 0.00014561825
treated O 0 0.00016827334
with O 0 0.00018878287
the O 0 0.00023180198
HAART O 0 0.8895756
combination O 0 0.00045432846
of O 0 0.0012712018
zidovudine B-Chemical 1 0.99947506
, O 0 0.08005245
lamivudine B-Chemical 1 0.99999964
, O 0 0.009402862
and O 0 0.0026163445
indinavir B-Chemical 1 0.9998323
or O 0 0.00042047718
vehicle O 0 0.003743914
control O 0 0.00032650298
for O 0 0.0003573501
10 O 0 0.00045627242
days O 0 0.0005275377
or O 0 0.0009971197
35 O 0 0.0018393305
days O 0 0.0025248206
. O 0 0.005694349

At O 0 0.0029262435
termination O 0 0.0029870023
of O 0 0.0018115798
the O 0 0.0010974867
experiments O 0 0.00069003
, O 0 0.00079304905
mice O 0 0.0003622969
underwent O 0 0.00043230373
echocardiography O 0 0.002501392
, O 0 0.0004670635
quantitation O 0 0.0005623228
of O 0 0.0003075776
abundance O 0 0.00030630353
of O 0 0.00032098577
molecular O 0 0.0028619526
markers O 0 0.0016936644
of O 0 0.0012799643
CM B-Disease 2 0.9925655
( O 0 0.0017450093
ventricular O 0 0.5915883
mRNA O 0 0.00038242384
encoding O 0 0.00029385742
atrial O 0 0.9273146
natriuretic O 0 0.98844016
factor O 0 0.12023178
[ O 0 0.19688801
ANF O 1 0.9999585
] O 0 0.0022309632
and O 0 0.00041322212
sarcoplasmic O 0 0.34951696
calcium B-Chemical 0 0.9988555
ATPase O 0 0.64515686
[ O 0 0.06876821
SERCA2 O 0 0.9677095
] O 0 0.006025449
) O 0 0.0011562412
, O 0 0.0007563773
and O 0 0.0008277801
determination O 0 0.00232096
of O 0 0.0024968642
plasma O 0 0.2750671
LA B-Chemical 0 0.99728227
. O 0 0.008445067

Myocardial O 0 0.12024286
histologic O 0 0.011192872
features O 0 0.0024010604
were O 0 0.0014245291
analyzed O 0 0.0010848277
semiquantitatively O 0 0.0017098497
and O 0 0.0010133471
results O 0 0.00087511865
were O 0 0.0009857251
confirmed O 0 0.0011428968
by O 0 0.0017614596
transmission O 0 0.0046025435
electron O 0 0.028376456
microscopy O 0 0.007801318
. O 0 0.009287048

After O 0 0.0028204205
35 O 0 0.002395665
days O 0 0.001441279
in O 0 0.0013873224
the O 0 0.0015620891
TG O 2 0.9982553
+ O 0 0.041129638
HAART O 0 0.9740888
cohort O 0 0.005893803
, O 0 0.0011318491
left O 0 0.0014699524
ventricular O 0 0.3078828
mass O 0 0.0023527434
increased O 0 0.001192463
160 O 0 0.0020183807
% O 0 0.0021735716
by O 0 0.0031627272
echocardiography O 0 0.011083956
. O 0 0.008046117

Molecularly O 0 0.02332518
, O 0 0.011732685
ANF O 1 0.9996038
mRNA O 0 0.004581615
increased O 0 0.0025895992
250 O 0 0.0022704364
% O 0 0.0020611128
and O 0 0.0022901185
SERCA2 O 0 0.73984236
mRNA O 0 0.0038173976
decreased O 0 0.0043814504
57 O 0 0.006153059
% O 0 0.007278579
. O 0 0.010042835

Biochemically O 0 0.18772535
, O 0 0.008661648
LA B-Chemical 0 0.9959198
was O 0 0.0024377354
elevated O 0 0.0052115084
( O 0 0.0015617582
8 O 0 0.00078797905
. O 0 0.0006458517
5 O 0 0.000632242
+ O 0 0.0014039958
/ O 0 0.0038117478
- O 0 0.0044438927
2 O 0 0.0011804427
. O 0 0.0014356859
0 O 0 0.0025440145
mM O 0 0.022668118
) O 0 0.008121001
. O 0 0.009609788

Pathologically O 0 0.31600186
, O 0 0.0044179778
granular O 0 0.0060002417
cytoplasmic O 0 0.0016887713
changes O 0 0.0014067902
were O 0 0.0008528311
found O 0 0.00066386175
in O 0 0.0007207113
cardiac O 0 0.012770792
myocytes O 0 0.003961004
, O 0 0.0012625253
indicating O 0 0.000995948
enlarged O 0 0.005120529
, O 0 0.0028512878
damaged O 0 0.011278217
mitochondria O 0 0.074495584
. O 0 0.008750569

Findings O 0 0.028293788
were O 0 0.02546097
confirmed O 0 0.029088218
ultrastructurally O 0 0.05268312
. O 0 0.045437854

No O 0 0.011983656
changes O 0 0.008263351
were O 0 0.006684551
found O 0 0.0060997326
in O 0 0.007312429
other O 0 0.009659764
cohorts O 0 0.0149072185
. O 0 0.018399693

After O 0 0.0028727888
10 O 0 0.0023321074
days O 0 0.0015630652
, O 0 0.0020674735
only O 0 0.0024604942
ANF O 1 0.9998273
was O 0 0.001466496
elevated O 0 0.0051494827
, O 0 0.001002597
and O 0 0.00075671397
only O 0 0.00076368224
in O 0 0.0008672807
the O 0 0.0014864596
TG O 2 0.9973418
+ O 0 0.034968946
HAART O 0 0.97316045
cohort O 0 0.021589745
. O 0 0.008877664

Results O 0 0.00393397
show O 0 0.0022861764
that O 0 0.0018483037
cumulative O 0 0.004045062
HAART O 0 0.9639453
caused O 0 0.0025245633
mitochondrial O 0 0.90793955
CM B-Disease 2 0.9954366
with O 0 0.0031649198
elevated O 0 0.1177932
LA B-Chemical 0 0.9992213
in O 0 0.0032627333
AIDS B-Disease 2 0.9997851
transgenic O 0 0.003973909
mice O 0 0.0037242218
. O 0 0.007822518

A O 0 0.05234151
Phase O 0 0.0074702683
II O 0 0.010596687
trial O 0 0.0022070294
of O 0 0.0023364238
cisplatin B-Chemical 1 0.99968743
plus O 0 0.0034208114
WR B-Chemical 0 0.99717206
- I-Chemical 0 0.5552369
2721 I-Chemical 0 0.99894696
( O 0 0.0109395925
amifostine B-Chemical 0 0.999938
) O 0 0.003430957
for O 0 0.0006067629
metastatic O 0 0.98095196
breast B-Disease 2 0.99988186
carcinoma I-Disease 2 0.9999993
: O 0 0.022711853
an O 0 0.0013290169
Eastern O 0 0.18006355
Cooperative O 0 0.048382197
Oncology O 0 0.003601662
Group O 0 0.0043036356
Study O 0 0.003679491
( O 0 0.0031039151
E8188 O 0 0.05444223
) O 0 0.0067424984
. O 0 0.008502752

BACKGROUND O 0 0.06929004
: O 0 0.012942663
Cisplatin B-Chemical 0 0.9997131
has O 0 0.0016229176
minimal O 0 0.001154864
antitumor O 0 0.16773964
activity O 0 0.00065766904
when O 0 0.0003284712
used O 0 0.00030553734
as O 0 0.00030887176
second O 0 0.00038269514
- O 0 0.0030790211
or O 0 0.00038238394
third O 0 0.0006857066
- O 0 0.0047774934
line O 0 0.00086112367
treatment O 0 0.0010816653
of O 0 0.0027311055
metastatic O 0 0.9920483
breast B-Disease 2 0.99978584
carcinoma I-Disease 2 0.9999944
. O 0 0.0335063

Older O 0 0.012555981
reports O 0 0.002499638
suggest O 0 0.00130222
an O 0 0.0014286205
objective O 0 0.001283443
response O 0 0.00087379554
rate O 0 0.0006524324
of O 0 0.00062794914
8 O 0 0.0003884347
% O 0 0.00035736492
when O 0 0.00021634654
60 O 0 0.0002955009
- O 0 0.0008395883
120 O 0 0.00027683855
mg O 0 0.0039110696
/ O 0 0.0010802004
m2 O 0 0.0078011644
of O 0 0.0007792547
cisplatin B-Chemical 1 0.9989004
is O 0 0.00049342104
administered O 0 0.00045572905
every O 0 0.00038770298
3 O 0 0.0008001594
- O 0 0.002221696
4 O 0 0.0018140804
weeks O 0 0.0026576384
. O 0 0.0061293277

Although O 0 0.003224868
a O 0 0.0029793694
dose O 0 0.015813077
- O 0 0.018717244
response O 0 0.0014308958
effect O 0 0.00078971736
has O 0 0.00047709126
been O 0 0.00037728527
observed O 0 0.00029924177
with O 0 0.0010446507
cisplatin B-Chemical 1 0.99983454
, O 0 0.0009272215
the O 0 0.00027099517
dose O 0 0.009020476
- O 0 0.023981692
limiting O 0 0.0012041257
toxicities B-Disease 2 0.99840564
associated O 0 0.00053900346
with O 0 0.0014937159
cisplatin B-Chemical 1 0.99982893
( O 0 0.0009772866
e O 0 0.0018467569
. O 0 0.00023070196
g O 0 0.0009529995
. O 0 0.00025760086
, O 0 0.0025943888
nephrotoxicity B-Disease 0 0.99999964
, O 0 0.08320384
ototoxicity B-Disease 0 0.99999785
, O 0 0.007005623
and O 0 0.00509129
neurotoxicity B-Disease 2 0.9999893
) O 0 0.0014177948
have O 0 0.00020173684
limited O 0 0.00023246862
its O 0 0.0004476714
use O 0 0.00036825193
as O 0 0.00043450377
a O 0 0.0007782517
treatment O 0 0.0013243259
for O 0 0.0027111585
breast B-Disease 2 0.9992525
carcinoma I-Disease 2 0.99999213
. O 0 0.025436327

WR B-Chemical 0 0.9708181
- I-Chemical 0 0.29851106
2721 I-Chemical 0 0.9917892
or O 0 0.004012854
amifostine B-Chemical 0 0.9997862
initially O 0 0.0019528656
was O 0 0.0008865057
developed O 0 0.00079203106
to O 0 0.00051097583
protect O 0 0.00074817694
military O 0 0.007492869
personnel O 0 0.0013581908
in O 0 0.0007351075
the O 0 0.0009405145
event O 0 0.0026633698
of O 0 0.002614523
nuclear O 0 0.021711703
war O 0 0.056353614
. O 0 0.008874006

Amifostine B-Chemical 0 0.9997706
subsequently O 0 0.004240667
was O 0 0.0018974057
shown O 0 0.0009208464
to O 0 0.0006729634
protect O 0 0.0007701926
normal O 0 0.0010167346
tissues O 0 0.0007739449
from O 0 0.0002893142
the O 0 0.00034710678
toxic O 0 0.4412355
effects O 0 0.00066218444
of O 0 0.0010196802
alkylating B-Chemical 0 0.9962745
agents I-Chemical 0 0.07732828
and O 0 0.0027821048
cisplatin B-Chemical 1 0.9997142
without O 0 0.00041416782
decreasing O 0 0.000511803
the O 0 0.00051654427
antitumor O 0 0.12261441
effect O 0 0.00088650314
of O 0 0.001737591
the O 0 0.0025696917
chemotherapy O 0 0.17260888
. O 0 0.006396059

Early O 0 0.007146408
trials O 0 0.0028947857
of O 0 0.0035400768
cisplatin B-Chemical 1 0.99973696
and O 0 0.01572414
amifostine B-Chemical 0 0.9999422
also O 0 0.00074333476
suggested O 0 0.00036513165
that O 0 0.00026311332
the O 0 0.00028484932
incidence O 0 0.00140837
and O 0 0.00040234136
severity O 0 0.00756845
of O 0 0.0030216433
cisplatin B-Chemical 1 0.9999732
- O 0 0.27367806
induced O 0 0.013017916
nephrotoxicity B-Disease 0 0.9999999
, O 0 0.26563743
ototoxicity B-Disease 0 0.99999666
, O 0 0.010113593
and O 0 0.0065279244
neuropathy B-Disease 0 0.99994755
were O 0 0.002598392
reduced O 0 0.0038423976
. O 0 0.0067146136

METHODS O 0 0.0042309687
: O 0 0.0043659164
A O 0 0.0140416
Phase O 0 0.0047571072
II O 0 0.008613854
study O 0 0.0011778353
of O 0 0.0007910701
the O 0 0.0005397093
combination O 0 0.0006997032
of O 0 0.0014614209
cisplatin B-Chemical 1 0.99988914
plus O 0 0.0021740496
amifostine B-Chemical 0 0.9999583
was O 0 0.00032720598
conducted O 0 0.0001698055
in O 0 0.00016988018
patients O 0 0.0002564156
with O 0 0.00025784926
progressive O 0 0.26377493
metastatic O 0 0.9954919
breast B-Disease 2 0.9999516
carcinoma I-Disease 2 0.99999964
who O 0 0.014582002
had O 0 0.0002446682
received O 0 0.00016423744
one O 0 0.00018700225
, O 0 0.00032030832
but O 0 0.0002671828
not O 0 0.00020498579
more O 0 0.0002725228
than O 0 0.00021427087
one O 0 0.00030968676
, O 0 0.0006021785
chemotherapy O 0 0.0095038675
regimen O 0 0.0012982967
for O 0 0.0016311521
metastatic O 0 0.9111513
disease O 0 0.9676225
. O 0 0.0089921905

Patients O 0 0.006292087
received O 0 0.003957963
amifostine B-Chemical 0 0.9995328
, O 0 0.005472678
910 O 0 0.0105734365
mg O 0 0.07963619
/ O 0 0.0044350787
m2 O 0 0.0063285865
intravenously O 0 0.0019040937
over O 0 0.0016350354
15 O 0 0.0026260728
minutes O 0 0.003894567
. O 0 0.0080386195

After O 0 0.0026342422
completion O 0 0.0018916009
of O 0 0.0018130238
the O 0 0.001773709
amifostine B-Chemical 0 0.99986315
infusion O 0 0.06436731
, O 0 0.0048339083
cisplatin B-Chemical 1 0.999613
120 O 0 0.0010273875
mg O 0 0.04008156
/ O 0 0.002364751
m2 O 0 0.00583472
was O 0 0.0007703468
administered O 0 0.00081631483
over O 0 0.00092689815
30 O 0 0.0016960688
minutes O 0 0.002779341
. O 0 0.0060997563

Intravenous O 0 0.34304854
hydration O 0 0.21707192
and O 0 0.0060630683
mannitol B-Chemical 0 0.9980392
was O 0 0.002869159
administered O 0 0.0022072783
before O 0 0.0018606969
and O 0 0.0032789255
after O 0 0.004225119
cisplatin B-Chemical 1 0.99823976
. O 0 0.0120235635

Treatment O 0 0.010324248
was O 0 0.004514205
administered O 0 0.0031403047
every O 0 0.002014396
3 O 0 0.0024842683
weeks O 0 0.0024602145
until O 0 0.0036685579
disease O 0 0.42490056
progression O 0 0.409781
. O 0 0.014627857

RESULTS O 0 0.0063415826
: O 0 0.0044657933
Forty O 0 0.004084858
- O 0 0.0038184351
four O 0 0.0010681861
patients O 0 0.001089973
were O 0 0.0007330714
enrolled O 0 0.0007304152
in O 0 0.00048501336
the O 0 0.00044549606
study O 0 0.00052356033
of O 0 0.0005404062
which O 0 0.0006605101
7 O 0 0.0005772793
( O 0 0.0009524902
16 O 0 0.0010427654
% O 0 0.0015626068
) O 0 0.002629152
were O 0 0.003067503
ineligible O 0 0.00652597
. O 0 0.0077722617

A O 0 0.013639132
median O 0 0.002456031
of O 0 0.002323493
2 O 0 0.0015570095
cycles O 0 0.0010167264
of O 0 0.001269668
therapy O 0 0.0015605978
was O 0 0.0010432424
administered O 0 0.0009640225
to O 0 0.0010193645
the O 0 0.001435153
37 O 0 0.0026087463
eligible O 0 0.0033762949
patients O 0 0.00565382
. O 0 0.007957829

Six O 0 0.0052666594
partial O 0 0.0035704835
responses O 0 0.0029397192
were O 0 0.0017612533
observed O 0 0.0012627201
for O 0 0.0012121408
an O 0 0.0013397939
overall O 0 0.0012830799
response O 0 0.001631541
rate O 0 0.0020242985
of O 0 0.0030382643
16 O 0 0.003939819
% O 0 0.006059799
. O 0 0.008813117

Most O 0 0.0070184255
patients O 0 0.0047395574
( O 0 0.0039533298
57 O 0 0.0032477519
% O 0 0.0026145906
) O 0 0.002702073
stopped O 0 0.0021992936
treatment O 0 0.0020521062
because O 0 0.0021269983
of O 0 0.004235407
disease O 0 0.9504597
progression O 0 0.7884878
. O 0 0.012436757

Neurologic B-Disease 0 0.9980666
toxicity I-Disease 2 0.9997148
was O 0 0.0057852087
reported O 0 0.0044890093
in O 0 0.0038818263
52 O 0 0.0052161063
% O 0 0.00559447
of O 0 0.0072201607
patients O 0 0.011358827
. O 0 0.013565262

Seven O 0 0.0059441538
different O 0 0.002826126
life O 0 0.0035400167
- O 0 0.009000115
threatening O 0 0.03306304
toxicities B-Disease 2 0.9971681
were O 0 0.0012934505
observed O 0 0.0009896023
in O 0 0.0012033272
patients O 0 0.0018728122
while O 0 0.0019591847
receiving O 0 0.00339416
treatment O 0 0.0049964827
. O 0 0.007940759

CONCLUSIONS O 0 0.019135842
: O 0 0.0035510915
The O 0 0.0015129909
combination O 0 0.0015492862
of O 0 0.0021689704
cisplatin B-Chemical 1 0.9998357
and O 0 0.013114628
amifostine B-Chemical 0 0.9999554
in O 0 0.0007156115
this O 0 0.0004354871
study O 0 0.00044977112
resulted O 0 0.000320163
in O 0 0.00038979092
an O 0 0.0004942278
overall O 0 0.00056382397
response O 0 0.00084027776
rate O 0 0.0011798481
of O 0 0.002018424
16 O 0 0.002809322
% O 0 0.004588721
. O 0 0.0070131565

Neither O 0 0.003888813
a O 0 0.0041653696
tumor B-Disease 0 0.92695886
- O 0 0.054276202
protective O 0 0.011144355
effect O 0 0.0009844112
nor O 0 0.0008030656
reduced O 0 0.0012682145
toxicity B-Disease 2 0.9987779
to O 0 0.0003795966
normal O 0 0.000986198
tissues O 0 0.0006919292
was O 0 0.00022216859
observed O 0 0.00017224047
with O 0 0.00021808397
the O 0 0.00020323464
addition O 0 0.00019511298
of O 0 0.0010093497
amifostine B-Chemical 0 0.9999099
to O 0 0.0012079955
cisplatin B-Chemical 1 0.9993333
in O 0 0.0014641867
this O 0 0.0020391091
trial O 0 0.0039387485
. O 0 0.0059052072

Oral B-Chemical 0 0.99795747
contraceptives I-Chemical 0 0.999876
and O 0 0.007815117
the O 0 0.006082236
risk O 0 0.20941496
of O 0 0.03983456
myocardial B-Disease 0 0.9999559
infarction I-Disease 2 0.99999666
. O 0 0.041719455

BACKGROUND O 0 0.016799733
: O 0 0.0037641812
An O 0 0.0021319645
association O 0 0.0010850468
between O 0 0.00073372456
the O 0 0.00068144244
use O 0 0.00065153424
of O 0 0.0016095212
oral B-Chemical 1 0.9965287
contraceptives I-Chemical 1 0.9999956
and O 0 0.0010900721
the O 0 0.0004255727
risk O 0 0.13436703
of O 0 0.008943938
myocardial B-Disease 0 0.9999943
infarction I-Disease 2 0.9999999
has O 0 0.00065004406
been O 0 0.00030973577
found O 0 0.0002711249
in O 0 0.00033224488
some O 0 0.00044193084
, O 0 0.00074035954
but O 0 0.0007955025
not O 0 0.00089656666
all O 0 0.0014014923
, O 0 0.0028092205
studies O 0 0.004072891
. O 0 0.0069790957

We O 0 0.003217232
investigated O 0 0.0018497927
this O 0 0.0014549561
association O 0 0.0010876235
, O 0 0.0010978935
according O 0 0.00047840553
to O 0 0.00037776268
the O 0 0.00035264782
type O 0 0.0004496419
of O 0 0.0020151436
progestagen B-Chemical 0 0.99997854
included O 0 0.00029366976
in O 0 0.0002261722
third O 0 0.00037459825
- O 0 0.0033869462
generation O 0 0.00032464223
( O 0 0.0005729317
i O 0 0.0022303287
. O 0 0.00019370495
e O 0 0.0008873677
. O 0 0.00036628943
, O 0 0.011677864
desogestrel B-Chemical 1 0.99999917
or O 0 0.014450228
gestodene B-Chemical 0 0.9999993
) O 0 0.0012577658
and O 0 0.00025872793
second O 0 0.0002331423
- O 0 0.002902386
generation O 0 0.0002916171
( O 0 0.0005205051
i O 0 0.002014278
. O 0 0.0001810735
e O 0 0.00083016086
. O 0 0.00034838266
, O 0 0.009466083
levonorgestrel B-Chemical 0 0.9999931
) O 0 0.04949241
oral B-Chemical 1 0.99680257
contraceptives I-Chemical 1 0.9999969
, O 0 0.0010300885
the O 0 0.00021206967
dose O 0 0.0045670955
of O 0 0.007270752
estrogen B-Chemical 1 0.99999404
, O 0 0.0014947761
and O 0 0.00026173927
the O 0 0.00015336425
presence O 0 0.00015086905
or O 0 0.0001483078
absence O 0 0.00012449989
of O 0 0.0003993052
prothrombotic O 0 0.92331475
mutations O 0 0.0077311913
METHODS O 0 0.00020801454
: O 0 0.00031319575
In O 0 0.00017102747
a O 0 0.00021217586
nationwide O 0 0.00040890308
, O 0 0.00036585375
population O 0 0.0011304811
- O 0 0.008441802
based O 0 0.00028268527
, O 0 0.00040300662
case O 0 0.00043815604
- O 0 0.0069795656
control O 0 0.00022568148
study O 0 0.0002903144
, O 0 0.00022257991
we O 0 0.00010641984
identified O 0 0.00013628537
and O 0 0.00020227114
enrolled O 0 0.00038192217
248 O 0 0.0060123177
women O 0 0.00094987295
18 O 0 0.00016423447
through O 0 0.000118057025
49 O 0 0.00021690235
years O 0 0.00018005665
of O 0 0.00020321256
age O 0 0.00047049712
who O 0 0.0003186423
had O 0 0.00016355357
had O 0 0.00016214226
a O 0 0.00024095947
first O 0 0.00024795637
myocardial B-Disease 0 0.9999181
infarction I-Disease 2 0.9999994
between O 0 0.00020827571
1990 O 0 0.0018011933
and O 0 0.00024399611
1995 O 0 0.00124977
and O 0 0.00024814703
925 O 0 0.008558173
control O 0 0.00022059835
women O 0 0.0022264186
who O 0 0.000301551
had O 0 0.00015445451
not O 0 0.00014788189
had O 0 0.00020683226
a O 0 0.0010338265
myocardial B-Disease 0 0.999972
infarction I-Disease 2 0.99999976
and O 0 0.0021358298
who O 0 0.00055411056
were O 0 0.00015374523
matched O 0 0.00014497833
for O 0 0.00015600615
age O 0 0.00037690904
, O 0 0.0002662143
calendar O 0 0.00023240322
year O 0 0.00022880708
of O 0 0.00028160334
the O 0 0.00030581944
index O 0 0.0006000397
event O 0 0.0020457339
, O 0 0.0010079833
and O 0 0.0011467236
area O 0 0.0022502688
of O 0 0.0031143203
residence O 0 0.021202577
. O 0 0.0076304628

Subjects O 0 0.005716625
supplied O 0 0.004038016
information O 0 0.0023272042
on O 0 0.0017343996
oral B-Chemical 0 0.8169248
- I-Chemical 0 0.1773456
contraceptive I-Chemical 0 0.9912531
use O 0 0.001616356
and O 0 0.0017232003
major O 0 0.0026971945
cardiovascular O 0 0.9554142
risk O 0 0.3163207
factors O 0 0.030530268
. O 0 0.010201655

An O 0 0.0045782565
analysis O 0 0.0026033462
for O 0 0.0022717696
factor O 1 0.6546445
V O 1 0.9993061
Leiden O 1 0.9999461
and O 0 0.0025782688
the O 0 0.0107576605
G20210A O 0 0.9999987
mutation O 0 0.013436641
in O 0 0.0003357042
the O 0 0.00037688372
prothrombin O 0 0.9612819
gene O 0 0.00034201925
was O 0 0.0001783937
conducted O 0 0.00014886886
in O 0 0.00017730519
217 O 0 0.0010242913
patients O 0 0.00023876538
and O 0 0.00023774178
763 O 0 0.0093217585
controls O 0 0.00030331154
RESULTS O 0 0.0003437831
: O 0 0.00025698906
The O 0 0.00014779929
odds O 0 0.0005550206
ratio O 0 0.00034011403
for O 0 0.0006790454
myocardial B-Disease 0 0.9999784
infarction I-Disease 2 0.9999999
among O 0 0.012227058
women O 0 0.023937933
who O 0 0.0003645732
used O 0 0.00013717546
any O 0 0.00013281632
type O 0 0.00017941622
of O 0 0.00029057165
combined O 0 0.0024005277
oral B-Chemical 0 0.986284
contraceptive I-Chemical 0 0.99952567
, O 0 0.0007816621
as O 0 0.0001616925
compared O 0 0.000121020654
with O 0 0.000323095
nonusers O 0 0.4074156
, O 0 0.00033484216
was O 0 0.00018634708
2 O 0 0.00015826135
. O 0 0.00014737302
0 O 0 0.00018775428
( O 0 0.00022456833
95 O 0 0.00024949358
percent O 0 0.00014976328
confidence O 0 0.00044605698
interval O 0 0.0002347756
, O 0 0.000355084
1 O 0 0.00030721366
. O 0 0.00033079102
5 O 0 0.00039427012
to O 0 0.0005505424
2 O 0 0.00091051316
. O 0 0.0013570936
8 O 0 0.0023293463
) O 0 0.0051211244
. O 0 0.007499212

The O 0 0.0030384273
adjusted O 0 0.002352389
odds O 0 0.003554118
ratio O 0 0.0016290126
was O 0 0.0010479819
2 O 0 0.0006828695
. O 0 0.00047303474
5 O 0 0.000362219
( O 0 0.00042331213
95 O 0 0.00038976266
percent O 0 0.0002064014
confidence O 0 0.00051090156
interval O 0 0.00022837751
, O 0 0.00030138888
1 O 0 0.00020154267
. O 0 0.00016232247
5 O 0 0.00014024884
to O 0 0.00013726509
4 O 0 0.00015365101
. O 0 0.00016112151
1 O 0 0.00018382103
) O 0 0.0003123906
among O 0 0.00029376385
women O 0 0.0014923392
who O 0 0.00027287015
used O 0 0.00014783705
second O 0 0.00020705347
- O 0 0.0055006905
generation O 0 0.0008958094
oral B-Chemical 1 0.9932655
contraceptives I-Chemical 1 0.9999951
and O 0 0.0008214148
1 O 0 0.0002208705
. O 0 0.000151429
3 O 0 0.00013583696
( O 0 0.00018843093
95 O 0 0.00020676007
percent O 0 0.00011505948
confidence O 0 0.0003481345
interval O 0 0.0001577893
, O 0 0.0002257788
0 O 0 0.00019112582
. O 0 0.00014902651
7 O 0 0.00013883629
to O 0 0.00014441594
2 O 0 0.0001837404
. O 0 0.00018410782
5 O 0 0.00019947448
) O 0 0.000370376
among O 0 0.0003613261
those O 0 0.00041062926
who O 0 0.000539212
used O 0 0.00047111462
third O 0 0.000923485
- O 0 0.0059653874
generation O 0 0.0038215742
oral B-Chemical 1 0.99473685
contraceptives I-Chemical 1 0.99996567
. O 0 0.010676359

Among O 0 0.007159893
women O 0 0.009333673
who O 0 0.0031826135
used O 0 0.0019725768
oral B-Chemical 1 0.99226815
contraceptives I-Chemical 1 0.9999932
, O 0 0.0021752538
the O 0 0.000518258
odds O 0 0.0022520209
ratio O 0 0.00052481436
was O 0 0.00035251622
2 O 0 0.00025124475
. O 0 0.00020461359
1 O 0 0.00020132831
( O 0 0.00024017527
95 O 0 0.0002487046
percent O 0 0.00013462218
confidence O 0 0.00040132203
interval O 0 0.0001745064
, O 0 0.00024536153
1 O 0 0.00016637873
. O 0 0.00013737872
5 O 0 0.00012126579
to O 0 0.00012101709
3 O 0 0.00013627548
. O 0 0.00014270688
0 O 0 0.00018842843
) O 0 0.00026114873
for O 0 0.0001526111
those O 0 0.00019907889
without O 0 0.00016326048
a O 0 0.00033668356
prothrombotic O 0 0.87962085
mutation O 0 0.019142669
and O 0 0.00035713537
1 O 0 0.00018961597
. O 0 0.00014367713
9 O 0 0.0001442849
( O 0 0.00018600552
95 O 0 0.0002028993
percent O 0 0.00011047856
confidence O 0 0.00034355882
interval O 0 0.00014944258
, O 0 0.00021430518
0 O 0 0.00017647872
. O 0 0.00013072354
6 O 0 0.00010755531
to O 0 0.00011084156
5 O 0 0.00012536715
. O 0 0.00013358702
5 O 0 0.00013383388
) O 0 0.00023019222
for O 0 0.00014596149
those O 0 0.0001891739
with O 0 0.00018360207
a O 0 0.00027879386
mutation O 0 0.012931259
CONCLUSIONS O 0 0.17027086
: O 0 0.0005312554
The O 0 0.00018730189
risk O 0 0.033664145
of O 0 0.003622346
myocardial B-Disease 0 0.9999907
infarction I-Disease 2 0.9999999
was O 0 0.0009695288
increased O 0 0.00048295813
among O 0 0.0006800764
women O 0 0.0050917394
who O 0 0.00061382924
used O 0 0.00043987896
second O 0 0.00072338764
- O 0 0.006633712
generation O 0 0.0038270568
oral B-Chemical 1 0.9950289
contraceptives I-Chemical 1 0.9999671
. O 0 0.010480053

The O 0 0.002890569
results O 0 0.0018542927
with O 0 0.0013664841
respect O 0 0.00085644843
to O 0 0.0006287852
the O 0 0.0005005472
use O 0 0.00042304836
of O 0 0.00046361293
third O 0 0.0007202969
- O 0 0.01492385
generation O 0 0.0016945524
oral B-Chemical 1 0.9957547
contraceptives I-Chemical 1 0.9999963
were O 0 0.0005385376
inconclusive O 0 0.007811183
but O 0 0.0002404406
suggested O 0 0.00014497971
that O 0 0.00014372493
the O 0 0.00023161486
risk O 0 0.047054436
was O 0 0.0002647533
lower O 0 0.00021462092
than O 0 0.00015491468
the O 0 0.00023272343
risk O 0 0.013917861
associated O 0 0.00046888174
with O 0 0.0005897718
second O 0 0.00079989346
- O 0 0.0130033875
generation O 0 0.0043363255
oral B-Chemical 1 0.99578214
contraceptives I-Chemical 1 0.99996936
. O 0 0.010298366

The O 0 0.003857171
risk O 0 0.039517436
of O 0 0.007610459
myocardial B-Disease 0 0.9999738
infarction I-Disease 2 0.9999995
was O 0 0.0019845264
similar O 0 0.0005212617
among O 0 0.0008072351
women O 0 0.0057479898
who O 0 0.0007716958
used O 0 0.00050884986
oral B-Chemical 1 0.9766674
contraceptives I-Chemical 1 0.99997354
whether O 0 0.00026826357
or O 0 0.00041189202
not O 0 0.00046169935
they O 0 0.0005756184
had O 0 0.0009323037
a O 0 0.0019556717
prothrombotic O 0 0.9057979
mutation O 0 0.066525325
. O 0 0.007805424

End B-Disease 0 0.016119525
- I-Disease 0 0.024675049
stage I-Disease 0 0.027083408
renal I-Disease 0 0.999632
disease I-Disease 0 0.99987245
( O 0 0.24528262
ESRD B-Disease 2 0.99999714
) O 0 0.0034720863
after O 0 0.00038807237
orthotopic O 0 0.88364816
liver O 0 0.91246974
transplantation O 0 0.2101257
( O 0 0.0042431727
OLTX O 0 0.9159265
) O 0 0.0006663834
using O 0 0.00028354497
calcineurin O 0 0.40835252
- O 0 0.008282358
based O 0 0.00043133882
immunotherapy O 0 0.002383586
: O 0 0.0014822269
risk O 0 0.03735366
of O 0 0.0014021092
development O 0 0.0035944767
and O 0 0.0028991587
treatment O 0 0.0050738826
. O 0 0.0069339806

BACKGROUND O 0 0.01605694
: O 0 0.0041784863
The O 0 0.0020201574
calcineurin O 0 0.1697214
inhibitors O 0 0.10302709
cyclosporine B-Chemical 1 0.9999982
and O 0 0.041962508
tacrolimus B-Chemical 0 0.9999944
are O 0 0.0012293801
both O 0 0.001060052
known O 0 0.0015087913
to O 0 0.0017189377
be O 0 0.0036994307
nephrotoxic B-Disease 2 0.9995704
. O 0 0.009365604

Their O 0 0.007589762
use O 0 0.0032526841
in O 0 0.002788694
orthotopic O 0 0.87117267
liver O 0 0.93377125
transplantation O 0 0.3923547
( O 0 0.01196955
OLTX O 0 0.9542505
) O 0 0.0024525553
has O 0 0.001294575
dramatically O 0 0.0018908735
improved O 0 0.0030846498
success O 0 0.0061906804
rates O 0 0.006429081
. O 0 0.009451532

Recently O 0 0.005939833
, O 0 0.0041732537
however O 0 0.0026370287
, O 0 0.0018493509
we O 0 0.0007845792
have O 0 0.0006518339
had O 0 0.0005743892
an O 0 0.00055372965
increase O 0 0.00036984636
of O 0 0.0005330808
patients O 0 0.0007230561
who O 0 0.0004981711
are O 0 0.00024985019
presenting O 0 0.00059352367
after O 0 0.0002267003
OLTX O 0 0.444584
with O 0 0.00034440882
end B-Disease 0 0.00032091478
- I-Disease 0 0.0064867996
stage I-Disease 0 0.015307726
renal I-Disease 0 0.99966
disease I-Disease 0 0.9997917
( O 0 0.19770822
ESRD B-Disease 2 0.99998593
) O 0 0.02331402
. O 0 0.008371138

This O 0 0.005167393
retrospective O 0 0.005950048
study O 0 0.0023037023
examines O 0 0.0015285785
the O 0 0.0009874993
incidence O 0 0.0023688888
and O 0 0.00090683054
treatment O 0 0.0010815071
of O 0 0.005321647
ESRD B-Disease 2 0.99999774
and O 0 0.006109468
chronic B-Disease 2 0.9968323
renal I-Disease 2 0.99766964
failure I-Disease 2 0.99319625
( O 0 0.09373903
CRF B-Disease 0 0.999941
) O 0 0.0041637924
in O 0 0.0022739745
OLTX O 0 0.7490305
patients O 0 0.006256597
. O 0 0.007077085

METHODS O 0 0.004467025
: O 0 0.0040811314
Patients O 0 0.0026009728
receiving O 0 0.0018146711
an O 0 0.0017539355
OLTX O 0 0.46464285
only O 0 0.0008071166
from O 0 0.0005293014
June O 0 0.00062099844
1985 O 0 0.00069651497
through O 0 0.0002888707
December O 0 0.0004243141
of O 0 0.00034462346
1994 O 0 0.0009109053
who O 0 0.00037857998
survived O 0 0.0003052677
6 O 0 0.00021384146
months O 0 0.00021208827
postoperatively O 0 0.0003034142
were O 0 0.00038271816
studied O 0 0.00058081455
( O 0 0.0010350454
n O 0 0.001256058
= O 0 0.0032110782
834 O 0 0.014408004
) O 0 0.00633485
. O 0 0.008139659

Our O 0 0.006816661
prospectively O 0 0.00533148
collected O 0 0.0039605843
database O 0 0.0050456226
was O 0 0.00400981
the O 0 0.003936634
source O 0 0.004905336
of O 0 0.0075341337
information O 0 0.0095019005
. O 0 0.013708021

Patients O 0 0.0043278434
were O 0 0.002191228
divided O 0 0.0012397493
into O 0 0.00073354907
three O 0 0.0005659501
groups O 0 0.0007138848
: O 0 0.001079264
Controls O 0 0.027386671
, O 0 0.00084110285
no O 0 0.00054558343
CRF B-Disease 0 0.9999392
or O 0 0.0036282095
ESRD B-Disease 2 0.9999969
, O 0 0.00090021855
n O 0 0.000325224
= O 0 0.001303019
748 O 0 0.03458192
; O 0 0.0033923874
CRF B-Disease 0 0.9998004
, O 0 0.00050127535
sustained O 0 0.0017770209
serum O 0 0.66976464
creatinine B-Chemical 1 0.9997904
> O 0 0.00327412
2 O 0 0.00020329453
. O 0 0.00015821098
5 O 0 0.00015989029
mg O 0 0.0032658752
/ O 0 0.0013985444
dl O 0 0.028805308
, O 0 0.00041854026
n O 0 0.00031570529
= O 0 0.0006874036
41 O 0 0.00074304396
; O 0 0.00090256357
and O 0 0.0013816825
ESRD B-Disease 2 0.99996436
, O 0 0.0020227067
n O 0 0.0018427155
= O 0 0.003821095
45 O 0 0.004365909
. O 0 0.0071866666

Groups O 0 0.010428628
were O 0 0.002379638
compared O 0 0.001192531
for O 0 0.0010256739
preoperative O 0 0.0012160311
laboratory O 0 0.00087435805
variables O 0 0.00063646113
, O 0 0.000602185
diagnosis O 0 0.0012450699
, O 0 0.0004960241
postoperative O 0 0.000933755
variables O 0 0.0003854693
, O 0 0.00043887625
survival O 0 0.016862202
, O 0 0.0005355109
type O 0 0.0004775622
of O 0 0.003422284
ESRD B-Disease 2 0.9999974
therapy O 0 0.0050031394
, O 0 0.0007266655
and O 0 0.0006466098
survival O 0 0.005142443
from O 0 0.00097293186
onset O 0 0.0031985843
of O 0 0.0071112732
ESRD B-Disease 2 0.99996185
. O 0 0.01011855

RESULTS O 0 0.005493167
: O 0 0.0033976876
At O 0 0.0014568362
13 O 0 0.0014134229
years O 0 0.0011618127
after O 0 0.00077801774
OLTX O 0 0.5023522
, O 0 0.0008350119
the O 0 0.0004525697
incidence O 0 0.0015093797
of O 0 0.0008657379
severe O 0 0.6462668
renal B-Disease 2 0.99982184
dysfunction I-Disease 2 0.9992482
was O 0 0.0005336843
18 O 0 0.0002733688
. O 0 0.00019360043
1 O 0 0.00021282402
% O 0 0.0003312644
( O 0 0.0009189681
CRF B-Disease 0 0.9994867
8 O 0 0.00029183156
. O 0 0.00025466652
6 O 0 0.00025855066
% O 0 0.00045897262
and O 0 0.00085224095
ESRD B-Disease 2 0.9999523
9 O 0 0.0009353146
. O 0 0.0010290145
5 O 0 0.0014451361
% O 0 0.0030439643
) O 0 0.0059109177
. O 0 0.008140109

Compared O 0 0.0031097874
with O 0 0.002156492
control O 0 0.0017279421
patients O 0 0.002705681
, O 0 0.0077693905
CRF B-Disease 0 0.99995077
and O 0 0.016752116
ESRD B-Disease 2 0.99999547
patients O 0 0.0012428226
had O 0 0.0002790768
higher O 0 0.00023360155
preoperative O 0 0.0008122471
serum O 0 0.44557714
creatinine B-Chemical 1 0.99948907
levels O 0 0.00037379775
, O 0 0.00037249635
a O 0 0.00021919257
greater O 0 0.00012673014
percentage O 0 0.00010907057
of O 0 0.0002072407
patients O 0 0.00041905302
with O 0 0.00079779234
hepatorenal B-Disease 0 0.99994516
syndrome I-Disease 0 0.8722184
, O 0 0.0005310593
higher O 0 0.00014157096
percentage O 0 9.441282e-05
requirement O 0 0.000105185354
for O 0 0.00014955462
dialysis O 0 0.00077520113
in O 0 0.00013527444
the O 0 0.00013023731
first O 0 0.000115266594
3 O 0 0.0001242833
months O 0 0.00011840901
postoperatively O 0 0.00017954988
, O 0 0.0002596039
and O 0 0.00030043354
a O 0 0.00042523773
higher O 0 0.00047468726
1 O 0 0.0006600919
- O 0 0.0022286272
year O 0 0.0017451362
serum O 0 0.42943448
creatinine B-Chemical 1 0.9984388
. O 0 0.008189052

Multivariate O 0 0.006436785
stepwise O 0 0.0036985485
logistic O 0 0.0028265575
regression O 0 0.003093241
analysis O 0 0.00087255874
using O 0 0.0005565704
preoperative O 0 0.00069574086
and O 0 0.00041583215
postoperative O 0 0.0007153415
variables O 0 0.0002820228
identified O 0 0.00018318414
that O 0 0.00016091885
an O 0 0.00023182275
increase O 0 0.00016544393
of O 0 0.0004828357
serum O 0 0.7449527
creatinine B-Chemical 1 0.9993697
compared O 0 0.00013055363
with O 0 0.00013676392
average O 0 9.207718e-05
at O 0 0.00011312138
1 O 0 0.00012704631
year O 0 0.00014139329
, O 0 0.00019031331
3 O 0 0.000118049706
months O 0 0.00010200217
, O 0 0.00016107113
and O 0 0.00014932835
4 O 0 0.000112563794
weeks O 0 8.5155545e-05
postoperatively O 0 0.00011383969
were O 0 0.0001050326
independent O 0 9.535661e-05
risk O 0 0.004166068
factors O 0 0.0006895681
for O 0 0.00018781371
the O 0 0.00019674236
development O 0 0.0013990193
of O 0 0.0056237634
CRF B-Disease 0 0.99998724
or O 0 0.0051082303
ESRD B-Disease 2 0.99999714
with O 0 0.00048511956
odds O 0 0.0019156545
ratios O 0 0.00023648843
of O 0 0.0002995401
2 O 0 0.00021042107
. O 0 0.00017539
6 O 0 0.00016563396
, O 0 0.000268984
2 O 0 0.00023826689
. O 0 0.000257564
2 O 0 0.00031912932
, O 0 0.0004707838
and O 0 0.00057173264
1 O 0 0.0006987615
. O 0 0.0008967004
6 O 0 0.0012632932
, O 0 0.0027624562
respectively O 0 0.0059494446
. O 0 0.0077132653

Overall O 0 0.0053529306
survival O 0 0.0062235333
from O 0 0.001439683
the O 0 0.0009925148
time O 0 0.0006473149
of O 0 0.0010283823
OLTX O 0 0.835835
was O 0 0.0004732864
not O 0 0.0002863475
significantly O 0 0.00026801354
different O 0 0.00019517736
among O 0 0.00031605733
groups O 0 0.000285947
, O 0 0.00034814494
but O 0 0.00025374745
by O 0 0.00019222329
year O 0 0.00021856191
13 O 0 0.0002162451
, O 0 0.00021499612
the O 0 0.00016654508
survival O 0 0.003425667
of O 0 0.00025035947
the O 0 0.00021223717
patients O 0 0.00043074467
who O 0 0.0005251952
had O 0 0.0005059174
ESRD B-Disease 2 0.9999937
was O 0 0.00029975091
only O 0 0.00023893981
28 O 0 0.00021961723
. O 0 0.00017115536
2 O 0 0.00017719566
% O 0 0.00021239872
compared O 0 0.00015754679
with O 0 0.00025834513
54 O 0 0.00046071789
. O 0 0.00033060566
6 O 0 0.00036787003
% O 0 0.00065064407
in O 0 0.0007977643
the O 0 0.0012355054
control O 0 0.002161503
group O 0 0.004386983
. O 0 0.006732287

Patients O 0 0.0069313417
developing O 0 0.12300257
ESRD B-Disease 2 0.99996245
had O 0 0.0016885912
a O 0 0.0012945419
6 O 0 0.000659607
- O 0 0.0015508182
year O 0 0.00046608638
survival O 0 0.002616088
after O 0 0.00024150091
onset O 0 0.00076720095
of O 0 0.0014832342
ESRD B-Disease 2 0.999995
of O 0 0.00077592133
27 O 0 0.0005246199
% O 0 0.00025413098
for O 0 0.00016383296
the O 0 0.00016787784
patients O 0 0.0002639878
receiving O 0 0.0002597121
hemodialysis O 0 0.07068294
versus O 0 0.0001972356
71 O 0 0.0005131102
. O 0 0.0001787109
4 O 0 0.00016961958
% O 0 0.00022941481
for O 0 0.00021128214
the O 0 0.00028020833
patients O 0 0.00072538306
developing O 0 0.06464533
ESRD B-Disease 2 0.9999894
who O 0 0.0018862797
subsequently O 0 0.0011535424
received O 0 0.0015208139
kidney O 0 0.34927055
transplants O 0 0.1303761
. O 0 0.007610715

CONCLUSIONS O 0 0.023245605
: O 0 0.0047670845
Patients O 0 0.0027666427
who O 0 0.0018786883
are O 0 0.0010257805
more O 0 0.0008163638
than O 0 0.00047014694
10 O 0 0.00046326482
years O 0 0.0005280232
post O 0 0.00058448163
- O 0 0.0071824226
OLTX O 0 0.74544865
have O 0 0.00085826486
CRF B-Disease 0 0.9998498
and O 0 0.0042952397
ESRD B-Disease 2 0.99997294
at O 0 0.0013470749
a O 0 0.0020665526
high O 0 0.0030838815
rate O 0 0.004732603
. O 0 0.007995177

The O 0 0.0037222782
development O 0 0.0043684943
of O 0 0.006312043
ESRD B-Disease 2 0.9999856
decreases O 0 0.0031308762
survival O 0 0.12919435
, O 0 0.0016309036
particularly O 0 0.0012981211
in O 0 0.00072527595
those O 0 0.0008929843
patients O 0 0.0010602485
treated O 0 0.0011692274
with O 0 0.0017426935
dialysis O 0 0.007974543
only O 0 0.004200902
. O 0 0.00709491

Patients O 0 0.0057638497
who O 0 0.0040209508
develop O 0 0.003476636
ESRD B-Disease 2 0.99994016
have O 0 0.0010235001
a O 0 0.00091912056
higher O 0 0.0005564473
preoperative O 0 0.000781899
and O 0 0.0004945584
1 O 0 0.00041924167
- O 0 0.0012917928
year O 0 0.00042340215
serum O 0 0.23789847
creatinine B-Chemical 1 0.99809474
and O 0 0.0005571367
are O 0 0.0004262607
more O 0 0.00051401876
likely O 0 0.00058743043
to O 0 0.00081487896
have O 0 0.0016473093
hepatorenal B-Disease 0 0.99956733
syndrome I-Disease 0 0.8585189
. O 0 0.008102114

However O 0 0.004800923
, O 0 0.0034470207
an O 0 0.0020438733
increase O 0 0.0011764958
of O 0 0.0015620667
serum O 0 0.65571386
creatinine B-Chemical 1 0.9991437
at O 0 0.00044297724
various O 0 0.00034610293
times O 0 0.00020843722
postoperatively O 0 0.00027739417
is O 0 0.00027103492
more O 0 0.00031881552
predictive O 0 0.0006243304
of O 0 0.00050318375
the O 0 0.0006014529
development O 0 0.0021147644
of O 0 0.0069011054
CRF B-Disease 0 0.99992967
or O 0 0.016018607
ESRD B-Disease 2 0.99997175
. O 0 0.010729002

New O 0 0.0058791954
strategies O 0 0.0030626305
for O 0 0.0021387842
long O 0 0.0020058174
- O 0 0.0043253326
term O 0 0.0014105377
immunosuppression O 0 0.8526117
may O 0 0.0010702239
be O 0 0.000979894
needed O 0 0.0008551376
to O 0 0.001200213
decrease O 0 0.0019713605
this O 0 0.003199827
complication O 0 0.24452634
. O 0 0.008482114

Epileptic B-Disease 0 0.9999964
seizures I-Disease 0 0.9999982
following O 0 0.0028118317
cortical O 0 0.012986152
application O 0 0.0018473523
of O 0 0.0018371381
fibrin O 0 0.6722429
sealants O 0 0.11601858
containing O 0 0.002271773
tranexamic B-Chemical 0 0.9990114
acid I-Chemical 0 0.8447345
in O 0 0.0038981133
rats O 0 0.00678834
. O 0 0.007764598

BACKGROUND O 0 0.021091793
: O 0 0.0069921613
Fibrin O 0 0.4326372
sealants O 0 0.061354473
( O 0 0.0036546965
FS O 0 0.090014786
) O 0 0.0016181499
derived O 0 0.0007534967
from O 0 0.00082696805
human O 0 0.0012227456
plasma O 0 0.006299476
are O 0 0.0011530669
frequently O 0 0.0015574233
used O 0 0.0017342195
in O 0 0.0029582824
neurosurgery O 0 0.009498428
. O 0 0.0076761898

In O 0 0.0039128307
order O 0 0.002177989
to O 0 0.0017909773
increase O 0 0.0015518448
clot O 0 0.11235091
stability O 0 0.0020062032
, O 0 0.0018872917
FS O 0 0.10323476
typically O 0 0.00096898444
contain O 0 0.0007487725
aprotinin O 0 0.8705565
, O 0 0.0017718028
a O 0 0.0018832665
natural O 0 0.013710077
fibrinolysis O 0 0.9954737
inhibitor O 0 0.09759679
. O 0 0.008119912

Recently O 0 0.005984986
, O 0 0.0041910224
synthetic O 0 0.0034425799
fibrinolysis O 0 0.96686125
inhibitors O 0 0.0043942495
such O 0 0.0008939144
as O 0 0.001297356
tranexamic B-Chemical 0 0.9995654
acid I-Chemical 0 0.9839533
( O 0 0.020392306
tAMCA B-Chemical 1 0.99376607
) O 0 0.0012010742
have O 0 0.00045176712
been O 0 0.0005616538
considered O 0 0.0006379806
as O 0 0.0010096529
substitutes O 0 0.002625631
for O 0 0.002916146
aprotinin O 0 0.9298189
. O 0 0.00798948

However O 0 0.008344312
, O 0 0.010245245
tAMCA B-Chemical 1 0.9565653
has O 0 0.0037304247
been O 0 0.0032920213
shown O 0 0.0027239926
to O 0 0.0038521418
cause O 0 0.07065939
epileptic B-Disease 0 0.9999987
seizures I-Disease 0 0.99999905
. O 0 0.024271004

We O 0 0.004242006
wanted O 0 0.0031792736
to O 0 0.0019575667
study O 0 0.0018885873
whether O 0 0.0010959854
tAMCA B-Chemical 1 0.96255386
retains O 0 0.0024494752
its O 0 0.02087556
convulsive B-Disease 2 0.9999914
action O 0 0.002375651
if O 0 0.0009931821
incorporated O 0 0.0013930877
into O 0 0.0015708309
a O 0 0.004150475
FS O 0 0.22088414
. O 0 0.008789974

METHOD O 0 0.009050036
: O 0 0.004907326
FS O 0 0.042214002
containing O 0 0.0017118084
aprotinin O 0 0.8006552
or O 0 0.00079807226
different O 0 0.00045527596
concentrations O 0 0.0010664084
of O 0 0.0011905897
tAMCA B-Chemical 1 0.99468166
( O 0 0.001106205
0 O 0 0.00036375682
. O 0 0.00022548813
5 O 0 0.00021704739
- O 0 0.0009937718
47 O 0 0.00035242666
. O 0 0.00018372115
5 O 0 0.00017557088
mg O 0 0.0033168995
/ O 0 0.0010191149
ml O 0 0.0006015867
) O 0 0.00041644304
were O 0 0.00019870339
applied O 0 0.00017711999
to O 0 0.00019268443
the O 0 0.00027576165
pial O 0 0.40157014
surface O 0 0.00094784336
of O 0 0.00068824267
the O 0 0.0008748811
cortex O 0 0.23596056
of O 0 0.0021855119
anaesthetized O 0 0.047468264
rats O 0 0.0043868124
. O 0 0.00598464

The O 0 0.0031048008
response O 0 0.002603844
of O 0 0.0017762611
the O 0 0.001080447
animals O 0 0.00070226716
was O 0 0.00056108076
evaluated O 0 0.00036613914
using O 0 0.00038781593
electroencephalography O 0 0.036494
and O 0 0.0003314293
by O 0 0.00029669786
monitoring O 0 0.00032585743
the O 0 0.00029657848
clinical O 0 0.00069639785
behaviour O 0 0.00065506675
during O 0 0.00036505263
and O 0 0.00064205244
after O 0 0.0006828174
recovery O 0 0.0016600704
from O 0 0.002121837
anaesthesia O 0 0.020670298
. O 0 0.0061234664

FINDINGS O 0 0.010493912
: O 0 0.0057967114
FS O 0 0.07955099
containing O 0 0.002471534
tAMCA B-Chemical 1 0.97146535
caused O 0 0.0024259465
paroxysmal O 0 0.9997185
brain O 0 0.065610595
activity O 0 0.00085221085
which O 0 0.00082607655
was O 0 0.0007355655
associated O 0 0.00090604246
with O 0 0.0013449327
distinct O 0 0.0025329562
convulsive B-Disease 2 0.9999789
behaviours O 0 0.23342547
. O 0 0.0074876184

The O 0 0.0041117663
degree O 0 0.0037019623
of O 0 0.0032985713
these O 0 0.004975882
seizures B-Disease 0 0.99999166
increased O 0 0.003370302
with O 0 0.002206623
increasing O 0 0.0024387725
concentration O 0 0.0067811357
of O 0 0.010885162
tAMCA B-Chemical 1 0.994735
. O 0 0.011558722

Thus O 0 0.0046562194
, O 0 0.004471052
FS O 0 0.06256907
containing O 0 0.0014149412
47 O 0 0.001747363
. O 0 0.0007307797
5 O 0 0.00053454813
mg O 0 0.008891142
/ O 0 0.0028371797
ml O 0 0.0042529586
tAMCA B-Chemical 1 0.9914948
evoked O 0 0.16989504
generalized B-Disease 0 0.99390393
seizures I-Disease 0 0.9999999
in O 0 0.00038561816
all O 0 0.00017632516
tested O 0 0.00015011441
rats O 0 0.00026453304
( O 0 0.0002575483
n O 0 0.00017170557
= O 0 0.00043309605
6 O 0 0.00014209354
) O 0 0.00027050494
while O 0 0.00015717077
the O 0 0.00013747676
lowest O 0 0.00019327029
concentration O 0 0.00047936165
of O 0 0.0010841871
tAMCA B-Chemical 1 0.99623126
( O 0 0.00090576365
0 O 0 0.0002394397
. O 0 0.00014228592
5 O 0 0.00013634528
mg O 0 0.0033334454
/ O 0 0.0009450925
ml O 0 0.00054128317
) O 0 0.0003997036
only O 0 0.00020807721
evoked O 0 0.00061467465
brief O 0 0.00019118596
episodes O 0 0.0021953636
of O 0 0.0006213218
jerk O 0 0.97670484
- O 0 0.055258423
correlated O 0 0.000612825
convulsive B-Disease 2 0.99998057
potentials O 0 0.012553724
in O 0 0.0006530154
1 O 0 0.00087076175
of O 0 0.0014091288
6 O 0 0.0019034711
rats O 0 0.0040458906
. O 0 0.0060771015

In O 0 0.0052495603
contrast O 0 0.004475485
, O 0 0.004920577
FS O 0 0.12004637
containing O 0 0.002527644
aprotinin O 0 0.9343534
did O 0 0.0020848548
not O 0 0.0016005664
evoke O 0 0.0025366407
any O 0 0.0029643304
paroxysmal O 0 0.9973308
activity O 0 0.0060599456
. O 0 0.008737002

INTERPRETATION O 0 0.07112837
: O 0 0.041831903
Tranexamic B-Chemical 0 0.9997923
acid I-Chemical 0 0.99047697
retains O 0 0.008352168
its O 0 0.0464601
convulsive B-Disease 2 0.9999821
action O 0 0.011104559
within O 0 0.0050690253
FS O 0 0.24138686
. O 0 0.012042257

Thus O 0 0.0043433444
, O 0 0.0034255772
use O 0 0.0019049558
of O 0 0.0018951829
FS O 0 0.22243808
containing O 0 0.001224343
tAMCA B-Chemical 1 0.9758967
for O 0 0.0005757112
surgery O 0 0.00056944386
within O 0 0.00021761164
or O 0 0.0002482919
close O 0 0.00026016636
to O 0 0.00026370556
the O 0 0.0003563776
CNS O 0 0.06237707
may O 0 0.00034454922
pose O 0 0.0005377575
a O 0 0.00066965446
substantial O 0 0.00083805004
risk O 0 0.020955395
to O 0 0.0013854217
the O 0 0.0022576689
patient O 0 0.004266895
. O 0 0.0065338793

Sequential O 0 0.0042276876
observations O 0 0.002557808
of O 0 0.0032108265
exencephaly B-Disease 0 0.99934214
and O 0 0.0014999349
subsequent O 0 0.00078995374
morphological O 0 0.00263809
changes O 0 0.00065399875
by O 0 0.0004165058
mouse O 0 0.0009842105
exo O 0 0.39561555
utero O 0 0.019819701
development O 0 0.0014391339
system O 0 0.00037672208
: O 0 0.00045241913
analysis O 0 0.00025714884
of O 0 0.0003020165
the O 0 0.00029529873
mechanism O 0 0.00035631814
of O 0 0.0007563103
transformation O 0 0.0125397295
from O 0 0.0015184742
exencephaly B-Disease 0 0.9997576
to O 0 0.0040664673
anencephaly B-Disease 2 0.999749
. O 0 0.010341222

Anencephaly B-Disease 0 0.9328611
has O 0 0.0027451147
been O 0 0.0016761099
suggested O 0 0.0009794991
to O 0 0.000755515
develop O 0 0.0007227227
from O 0 0.0007552213
exencephaly B-Disease 0 0.99991596
; O 0 0.004517845
however O 0 0.00066975155
, O 0 0.00041507374
there O 0 0.00017548435
is O 0 0.00021105947
little O 0 0.00016871966
direct O 0 0.00017053843
experimental O 0 0.00022898651
evidence O 0 0.00016962361
to O 0 0.00017855848
support O 0 0.00019642222
this O 0 0.00026974292
, O 0 0.00041126137
and O 0 0.0003827479
the O 0 0.0004040845
mechanism O 0 0.00054772926
of O 0 0.0012070214
transformation O 0 0.012578089
remains O 0 0.0024893617
unclear O 0 0.0038180288
. O 0 0.0067275437

We O 0 0.003306053
examined O 0 0.0018088277
this O 0 0.0015362324
theory O 0 0.0015127265
using O 0 0.00088871724
the O 0 0.00086542586
exo O 0 0.2740126
utero O 0 0.019610645
development O 0 0.0013903002
system O 0 0.00038603417
that O 0 0.00022030622
allows O 0 0.00021653867
direct O 0 0.00020407644
and O 0 0.00025284878
sequential O 0 0.00025553798
observations O 0 0.00027072968
of O 0 0.00040650336
mid O 0 0.0013098764
- O 0 0.0043335487
to O 0 0.00057081983
late O 0 0.0023342182
- O 0 0.007701205
gestation O 0 0.003085411
mouse O 0 0.003406353
embryos O 0 0.007002267
. O 0 0.007354551

We O 0 0.0033971514
observed O 0 0.0022042966
the O 0 0.0021631464
exencephaly B-Disease 0 0.9987669
induced O 0 0.0014535465
by O 0 0.0009901294
5 B-Chemical 0 0.00064145826
- I-Chemical 0 0.014900988
azacytidine I-Chemical 0 0.9464965
at O 0 0.00034454593
embryonic O 0 0.0066295085
day O 0 0.00021986781
13 O 0 0.00023118529
. O 0 0.0001733822
5 O 0 0.00017370391
( O 0 0.00039129393
E13 O 0 0.2761523
. O 0 0.00021959044
5 O 0 0.00018787784
) O 0 0.00038277308
, O 0 0.00032466176
let O 0 0.000480349
the O 0 0.00019940983
embryos O 0 0.00045915556
develop O 0 0.00030203495
exo O 0 0.254089
utero O 0 0.010869729
until O 0 0.00018891378
E18 O 0 0.07024739
. O 0 0.00018651845
5 O 0 0.0001668749
, O 0 0.0002466812
and O 0 0.00029657906
re O 0 0.0054551978
- O 0 0.002151287
observed O 0 0.00030057997
the O 0 0.0003678507
same O 0 0.00039071502
embryos O 0 0.0009965646
at O 0 0.00098268
E18 O 0 0.026145404
. O 0 0.00208757
5 O 0 0.0031473676
. O 0 0.006179709

We O 0 0.0053201877
confirmed O 0 0.0037765987
several O 0 0.0030875176
cases O 0 0.0036881645
of O 0 0.003684282
transformation O 0 0.011354668
from O 0 0.0046578306
exencephaly B-Disease 0 0.99954873
to O 0 0.008350585
anencephaly B-Disease 2 0.9996043
. O 0 0.016013917

However O 0 0.0049098674
, O 0 0.0035406926
in O 0 0.0018381841
many O 0 0.001318205
cases O 0 0.0015832778
, O 0 0.0013098258
the O 0 0.00091612514
exencephalic B-Disease 2 0.9756045
brain O 0 0.0593592
tissue O 0 0.004363051
was O 0 0.00042773515
preserved O 0 0.0004958733
with O 0 0.0004112312
more O 0 0.00047285084
or O 0 0.00049064547
less O 0 0.0006501801
reduction O 0 0.0010960125
during O 0 0.0010912071
this O 0 0.0019551842
period O 0 0.0030949132
. O 0 0.0062756124

To O 0 0.0027661747
analyze O 0 0.0015886432
the O 0 0.0014802113
transformation O 0 0.0027141953
patterns O 0 0.00085943926
, O 0 0.00084826583
we O 0 0.0003813646
classified O 0 0.0005155799
the O 0 0.00053190975
exencephaly B-Disease 0 0.9996351
by O 0 0.00038473925
size O 0 0.0003439739
and O 0 0.00026793996
shape O 0 0.00034940112
of O 0 0.0003031242
the O 0 0.0003255063
exencephalic B-Disease 2 0.9492704
tissue O 0 0.0014108219
into O 0 0.00013650075
several O 0 0.00017231505
types O 0 0.00021348047
at O 0 0.00031723618
E13 O 0 0.13915986
. O 0 0.00049831736
5 O 0 0.0006006889
and O 0 0.0011209314
E18 O 0 0.021997401
. O 0 0.002211674
5 O 0 0.0033115724
. O 0 0.006447846

It O 0 0.004534655
was O 0 0.0024947764
found O 0 0.0014860603
that O 0 0.0009885412
the O 0 0.000904062
transformation O 0 0.0045940424
of O 0 0.0016798667
exencephalic B-Disease 2 0.9928295
tissue O 0 0.018929021
was O 0 0.00034765457
not O 0 0.00021728985
simply O 0 0.00025122944
size O 0 0.00043646185
- O 0 0.0055084564
dependent O 0 0.00019431095
, O 0 0.00032091903
and O 0 0.00022488245
all O 0 0.0001623943
cases O 0 0.000299429
of O 0 0.0005620763
anencephaly B-Disease 2 0.99993265
at O 0 0.0004870507
E18 O 0 0.22040413
. O 0 0.00017845447
5 O 0 0.00013380132
resulted O 0 0.00012794949
from O 0 0.00015247743
embryos O 0 0.0003201807
with O 0 0.00022467478
a O 0 0.0002541259
large O 0 0.00024179603
amount O 0 0.00021741191
of O 0 0.0007057142
exencephalic B-Disease 2 0.97572577
tissue O 0 0.010842059
at O 0 0.0011317434
E13 O 0 0.20951316
. O 0 0.0021352782
5 O 0 0.0031376681
. O 0 0.00610754

Microscopic O 0 0.012356649
observation O 0 0.0025003215
showed O 0 0.001484554
the O 0 0.0010702136
configuration O 0 0.001421411
of O 0 0.0018283277
exencephaly B-Disease 0 0.9998659
at O 0 0.0008879496
E13 O 0 0.6709925
. O 0 0.00033074722
5 O 0 0.0002434528
, O 0 0.0003845554
frequent O 0 0.002930452
hemorrhaging B-Disease 0 0.9986853
and O 0 0.00079268374
detachment O 0 0.98607975
of O 0 0.00043282393
the O 0 0.00022697498
neural O 0 0.00092476344
plate O 0 0.0011464384
from O 0 0.0001481933
surface O 0 0.0016483071
ectoderm O 0 0.8927968
in O 0 0.00023504483
the O 0 0.0002567476
exencephalic B-Disease 2 0.96623826
head O 0 0.06985325
at O 0 0.0002676933
E15 O 0 0.7801981
. O 0 0.00017971054
5 O 0 0.0001473532
, O 0 0.00019760341
and O 0 0.0001805783
multiple O 0 0.000216155
modes O 0 0.00023556172
of O 0 0.00031238285
reduction O 0 0.00057409244
in O 0 0.00036383225
the O 0 0.0005508463
exencephalic B-Disease 2 0.95786124
tissue O 0 0.0068950853
at O 0 0.0010420335
E18 O 0 0.03872064
. O 0 0.002043531
5 O 0 0.003076092
. O 0 0.006056276

From O 0 0.003811382
observations O 0 0.002536537
of O 0 0.00214395
the O 0 0.0016634853
vasculature O 0 0.10972157
, O 0 0.0013802093
altered O 0 0.0007097901
distribution O 0 0.00048065264
patterns O 0 0.00050572766
of O 0 0.00070169853
vessels O 0 0.008454201
were O 0 0.0006954405
identified O 0 0.0007797219
in O 0 0.0012183319
the O 0 0.0021661916
exencephalic B-Disease 2 0.9579839
head O 0 0.25906217
. O 0 0.008268008

These O 0 0.0034439887
findings O 0 0.002453267
suggest O 0 0.0011729622
that O 0 0.0010900742
overgrowth O 0 0.07840568
of O 0 0.001209992
the O 0 0.0009495409
exencephalic B-Disease 2 0.9830261
neural O 0 0.010796972
tissue O 0 0.004614077
causes O 0 0.00036340186
the O 0 0.000214435
altered O 0 0.00018725904
distribution O 0 0.00013665247
patterns O 0 0.0001550168
of O 0 0.00027819324
vessels O 0 0.043584716
, O 0 0.00035370808
subsequent O 0 0.0002661285
peripheral O 0 0.028971627
circulatory B-Disease 0 0.94833595
failure I-Disease 0 0.9557392
and O 0 0.0008481409
/ O 0 0.015398931
or O 0 0.00054447993
hemorrhaging B-Disease 0 0.9993641
in O 0 0.00020647778
various O 0 0.00019504954
parts O 0 0.00016913959
of O 0 0.00020179573
the O 0 0.00027972547
exencephalic B-Disease 2 0.9856493
head O 0 0.15132375
, O 0 0.00042181226
leading O 0 0.00031010484
to O 0 0.00014912587
the O 0 0.00015646916
multiple O 0 0.00021359061
modes O 0 0.0002396663
of O 0 0.00035840893
tissue O 0 0.0033684385
reduction O 0 0.0006893743
during O 0 0.000409
transformation O 0 0.0039732037
from O 0 0.0012590573
exencephaly B-Disease 0 0.9996536
to O 0 0.0036944074
anencephaly B-Disease 2 0.9997303
. O 0 0.010006222

99mTc B-Chemical 0 0.8054116
- I-Chemical 0 0.12320385
glucarate I-Chemical 0 0.96320474
for O 0 0.0022994832
detection O 0 0.0028994705
of O 0 0.0058257426
isoproterenol B-Chemical 0 0.999984
- O 0 0.4045235
induced O 0 0.025986139
myocardial B-Disease 0 0.9999857
infarction I-Disease 2 0.99999905
in O 0 0.009960823
rats O 0 0.010797098
. O 0 0.008490276

Infarct B-Disease 0 0.998847
- O 0 0.027776487
avid O 0 0.0075275903
radiopharmaceuticals O 0 0.0065982053
are O 0 0.0013239374
necessary O 0 0.0008382868
for O 0 0.0009003227
rapid O 0 0.0013401749
and O 0 0.0010652681
timely O 0 0.0014146597
diagnosis O 0 0.007560604
of O 0 0.005400288
acute O 2 0.99960345
myocardial B-Disease 2 0.9999925
infarction I-Disease 2 0.9999995
. O 0 0.050061997

The O 0 0.0032916276
animal O 0 0.0029010149
model O 0 0.0017314292
used O 0 0.0011267681
to O 0 0.0009121135
produce O 0 0.0010881894
infarction B-Disease 2 0.9999982
implies O 0 0.001845085
artery O 0 0.35128808
ligation O 0 0.002783706
but O 0 0.0007672397
chemical O 0 0.003881415
induction O 0 0.0005378323
can O 0 0.00048355423
be O 0 0.0006870617
easily O 0 0.0009632105
obtained O 0 0.0013367293
with O 0 0.0036991742
isoproterenol B-Chemical 0 0.99958867
. O 0 0.008758468

A O 0 0.0793846
new O 0 0.008013733
infarct B-Disease 0 0.9997322
- O 0 0.0961678
avid O 0 0.013858343
radiopharmaceutical O 0 0.033140052
based O 0 0.0010191276
on O 0 0.00069870433
glucaric B-Chemical 0 0.99893314
acid I-Chemical 0 0.8924979
was O 0 0.00064966944
prepared O 0 0.0004888199
in O 0 0.0005395293
the O 0 0.0006460105
hospital O 0 0.001227785
radiopharmacy O 0 0.0014364066
of O 0 0.0018999251
the O 0 0.0030779457
INCMNSZ O 0 0.59090817
. O 0 0.0073858853

99mTc B-Chemical 0 0.8213288
- I-Chemical 0 0.1547495
glucarate I-Chemical 0 0.9739621
was O 0 0.0017791628
easy O 0 0.0013289478
to O 0 0.00066059787
prepare O 0 0.00058402726
, O 0 0.000606603
stable O 0 0.00048118393
for O 0 0.0003479326
96 O 0 0.00069246045
h O 0 0.00029800416
and O 0 0.00026372116
was O 0 0.00021396465
used O 0 0.00017183955
to O 0 0.00017344224
study O 0 0.00027916703
its O 0 0.0004479083
biodistribution O 0 0.017098831
in O 0 0.00030979337
rats O 0 0.0006460268
with O 0 0.0013249011
isoproterenol B-Chemical 0 0.99996996
- O 0 0.15885654
induced O 0 0.007118529
acute O 2 0.9997713
myocardial B-Disease 2 0.9999945
infarction I-Disease 2 0.99999964
. O 0 0.04921083

Histological O 0 0.010842867
studies O 0 0.0028248953
demonstrated O 0 0.0017268048
that O 0 0.0013113242
the O 0 0.0012314809
rats O 0 0.0015052883
developed O 0 0.0014583332
an O 0 0.0017343616
infarct B-Disease 0 0.9995253
18 O 0 0.001448983
h O 0 0.0015211768
after O 0 0.0018393727
isoproterenol B-Chemical 0 0.9996816
administration O 0 0.14701821
. O 0 0.008284261

The O 0 0.004458324
rat O 0 0.005005694
biodistribution O 0 0.008576714
studies O 0 0.0021674333
showed O 0 0.0017190538
a O 0 0.0020065084
rapid O 0 0.0029108906
blood O 0 0.0087193595
clearance O 0 0.010591719
via O 0 0.002501221
the O 0 0.0037654496
kidneys O 0 0.021011358
. O 0 0.009518888

Thirty O 0 0.0045598866
minutes O 0 0.0020655575
after O 0 0.001580961
99mTc B-Chemical 0 0.58758765
- I-Chemical 0 0.100387506
glucarate I-Chemical 0 0.9870754
administration O 0 0.0064985924
the O 0 0.00044402617
standardised O 0 0.00037963095
heart O 0 0.03896276
uptake O 0 0.0028310863
value O 0 0.00057610363
S O 0 0.9931549
( O 0 0.0015098779
h O 0 0.00065304764
) O 0 0.004068132
UV O 0 0.9953237
was O 0 0.0003782598
4 O 0 0.0002009643
. O 0 0.0001788442
7 O 0 0.00016815079
in O 0 0.0002058833
infarcted O 0 0.03510457
rat O 0 0.001494258
heart O 0 0.05108654
which O 0 0.00036961993
is O 0 0.0002878244
six O 0 0.00023970971
times O 0 0.0002750488
more O 0 0.0005391036
than O 0 0.0006222709
in O 0 0.0012481764
normal O 0 0.0029415442
rats O 0 0.0048259143
. O 0 0.006205258

ROIs O 0 0.006408997
drawn O 0 0.003241369
over O 0 0.0019486073
the O 0 0.0022112716
gamma O 0 0.4206742
camera O 0 0.003737946
images O 0 0.0016880791
showed O 0 0.0011928232
a O 0 0.0014318207
ratio O 0 0.0016289676
of O 0 0.0021520047
4 O 0 0.0022709137
. O 0 0.003115155
4 O 0 0.004729238
. O 0 0.008497938

The O 0 0.0030085992
high O 0 0.002376907
image O 0 0.001640939
quality O 0 0.0009621777
suggests O 0 0.0005743175
that O 0 0.00049768557
high O 0 0.0006459616
contrast O 0 0.0005162221
images O 0 0.00049396366
can O 0 0.00022909962
be O 0 0.00021958062
obtained O 0 0.00019836702
in O 0 0.00022553222
humans O 0 0.00059931335
and O 0 0.00024706486
the O 0 0.00021204502
96 O 0 0.00053205533
h O 0 0.00021198274
stability O 0 0.0002639244
makes O 0 0.00025329785
it O 0 0.00022960956
an O 0 0.00023118462
ideal O 0 0.00022575425
agent O 0 0.002520694
to O 0 0.00024603575
detect O 0 0.00028312573
, O 0 0.0005760135
in O 0 0.0005334345
patients O 0 0.0012141451
, O 0 0.0016912395
early O 0 0.013794976
cardiac B-Disease 0 0.99710053
infarction I-Disease 2 0.99999917
. O 0 0.018675221

Bupropion B-Chemical 0 0.9999546
( O 0 0.25319692
Zyban B-Chemical 0 0.9998161
) O 0 0.10556002
toxicity B-Disease 2 0.9970204
. O 0 0.03420356

Bupropion B-Chemical 0 0.9999535
is O 0 0.007939518
a O 0 0.010044973
monocyclic O 0 0.999361
antidepressant B-Chemical 1 0.9999418
structurally O 0 0.00890531
related O 0 0.0036035394
to O 0 0.006453564
amphetamine B-Chemical 1 0.9999825
. O 0 0.013515061

Zyban B-Chemical 0 0.99980897
, O 0 0.005445973
a O 0 0.0028371608
sustained O 0 0.007128536
- O 0 0.023582466
release O 0 0.008396898
formulation O 0 0.12709247
of O 0 0.09241721
bupropion B-Chemical 0 1.0
hydrochloride I-Chemical 0 0.9999902
, O 0 0.001684488
was O 0 0.00036742716
recently O 0 0.0003184291
released O 0 0.00040594433
in O 0 0.0005012418
Ireland O 0 0.06180583
, O 0 0.0008437422
as O 0 0.0008232554
a O 0 0.0018699673
smoking O 1 0.9876159
cessation O 0 0.051073305
aid O 0 0.0064888042
. O 0 0.007458878

In O 0 0.0035074076
the O 0 0.0020411462
initial O 0 0.0013386887
6 O 0 0.0009320355
months O 0 0.0006236938
since O 0 0.00052468287
it O 0 0.0005932002
' O 0 0.0006443869
s O 0 0.00055527635
introduction O 0 0.00044279193
, O 0 0.0006601992
12 O 0 0.00041747035
overdose B-Disease 0 0.9991829
cases O 0 0.0005783089
have O 0 0.00033665035
been O 0 0.00042249335
reported O 0 0.00054708624
to O 0 0.000590117
The O 0 0.00088154105
National O 0 0.0045450456
Poisons O 0 0.68569607
Information O 0 0.0044876817
Centre O 0 0.009445101
. O 0 0.007029034

8 O 0 0.012642533
patients O 0 0.012439368
developed O 0 0.014502352
symptoms O 0 0.2903508
of O 0 0.020849638
toxicity B-Disease 2 0.9982443
. O 0 0.026825925

Common O 0 0.010181611
features O 0 0.005719574
included O 0 0.004810065
tachycardia B-Disease 2 0.9995091
, O 0 0.050358057
drowsiness O 0 0.9999815
, O 0 0.095579915
hallucinations B-Disease 2 0.9999944
and O 0 0.05627369
convulsions B-Disease 0 0.99997103
. O 0 0.014716744

Two O 0 0.004299196
patients O 0 0.003415402
developed O 0 0.0035087212
severe O 0 0.4157272
cardiac B-Disease 2 0.99567974
arrhythmias I-Disease 2 0.9999989
, O 0 0.0028498187
including O 0 0.000641113
one O 0 0.0005256379
patient O 0 0.000613516
who O 0 0.0008338875
was O 0 0.0007115866
resuscitated O 0 0.0024755828
following O 0 0.0010548227
a O 0 0.0025396105
cardiac B-Disease 2 0.82293594
arrest I-Disease 2 0.9566626
. O 0 0.009096304

All O 0 0.014113129
patients O 0 0.015232748
recovered O 0 0.013687006
without O 0 0.017989192
sequelae O 0 0.6107512
. O 0 0.031084523

We O 0 0.0040296214
report O 0 0.0036382177
a O 0 0.0022608077
case O 0 0.0014662015
of O 0 0.0011746817
a O 0 0.0009903465
31 O 0 0.00074858667
year O 0 0.0004900675
old O 0 0.00047973788
female O 0 0.000824087
who O 0 0.00038171653
required O 0 0.00017979316
admission O 0 0.00047929992
to O 0 0.00018549405
the O 0 0.00023985647
Intensive O 0 0.0070961327
Care O 0 0.0013807416
Unit O 0 0.0007259297
for O 0 0.00018049791
ventilation O 0 0.00071683666
and O 0 0.00019917078
full O 0 0.00017381871
supportive O 0 0.00040452025
therapy O 0 0.0005069101
, O 0 0.0004402292
following O 0 0.00036203535
ingestion O 0 0.20822212
of O 0 0.0009462008
13 O 0 0.0011917214
. O 0 0.0015100143
5g O 0 0.092044786
bupropion B-Chemical 0 0.9999654
. O 0 0.007435116

Recurrent O 0 0.5299992
seizures B-Disease 0 0.9999815
were O 0 0.0026181368
treated O 0 0.0020467814
with O 0 0.0038011088
diazepam B-Chemical 0 0.999998
and O 0 0.0013089502
broad O 0 0.0012198183
complex O 0 0.001302194
tachycardia B-Disease 2 0.9989686
was O 0 0.000947725
successfully O 0 0.001106584
treated O 0 0.001750775
with O 0 0.0038192659
adenosine B-Chemical 1 0.9971379
. O 0 0.008145631

Zyban B-Chemical 0 0.9994997
caused O 0 0.006012876
significant O 0 0.0059040817
neurological B-Disease 0 0.9750606
and I-Disease 0 0.024235616
cardiovascular I-Disease 0 0.9999186
toxicity I-Disease 2 0.9999815
in O 0 0.05819138
overdose B-Disease 0 0.9999436
. O 0 0.013938026

The O 0 0.0034020608
potential O 0 0.003254599
toxic O 0 0.4543737
effects O 0 0.0021780937
should O 0 0.00078466267
be O 0 0.00077445386
considered O 0 0.0006229446
when O 0 0.0005904115
prescribing O 0 0.0018845361
it O 0 0.00086714193
as O 0 0.0010021997
a O 0 0.0021220774
smoking O 1 0.9870574
cessation O 0 0.05539812
aid O 0 0.007144845
. O 0 0.008081062

GLEPP1 O 0 0.73299044
receptor O 0 0.22216749
tyrosine B-Chemical 1 0.98266625
phosphatase O 0 0.8830823
( O 0 0.010570229
Ptpro O 0 0.35030925
) O 0 0.0054716645
in O 0 0.004046167
rat O 0 0.08712302
PAN B-Chemical 1 0.9999578
nephrosis B-Disease 2 0.99998844
. O 0 0.029155994

A O 0 0.036444753
marker O 0 0.015233314
of O 0 0.017150287
acute O 0 0.9741864
podocyte O 0 0.99702543
injury O 0 0.9968731
. O 0 0.031753357

Glomerular O 0 0.43141112
epithelial O 0 0.026716733
protein O 0 0.0043884325
1 O 0 0.0017418051
( O 0 0.0023779133
GLEPP1 O 0 0.51456356
) O 0 0.0016191994
is O 0 0.00058295444
a O 0 0.00069379085
podocyte O 0 0.8713441
receptor O 0 0.08950269
membrane O 0 0.026616978
protein O 0 0.009597438
tyrosine B-Chemical 1 0.97930443
phosphatase O 0 0.47348368
located O 0 0.0002205813
on O 0 0.00013063956
the O 0 0.00017951548
apical O 0 0.00037153965
cell O 0 0.00074296194
membrane O 0 0.0016293118
of O 0 0.0005706066
visceral O 0 0.067702346
glomerular O 0 0.85866165
epithelial O 0 0.052212752
cell O 0 0.006141075
and O 0 0.0022739929
foot O 0 0.031884488
processes O 0 0.0053445026
. O 0 0.006987018

This O 0 0.006711287
receptor O 0 0.007462205
plays O 0 0.0021244395
a O 0 0.0018009201
role O 0 0.0009194679
in O 0 0.0008819177
regulating O 0 0.0005766621
the O 0 0.0007285807
structure O 0 0.0010652539
and O 0 0.0009834424
function O 0 0.0011486899
of O 0 0.0021570555
podocyte O 0 0.9261245
foot O 0 0.21819298
process O 0 0.0058901273
. O 0 0.008290311

To O 0 0.002898595
better O 0 0.0020898667
understand O 0 0.0009920393
the O 0 0.000889245
utility O 0 0.0007366601
of O 0 0.00093690475
GLEPP1 O 0 0.3082193
as O 0 0.00046693842
a O 0 0.00047625112
marker O 0 0.0005341109
of O 0 0.0013898854
glomerular B-Disease 0 0.9998392
injury I-Disease 0 0.9994742
, O 0 0.000731375
the O 0 0.00016832743
amount O 0 0.00010341385
and O 0 0.00016138722
distribution O 0 0.00013085973
of O 0 0.00036233486
GLEPP1 O 0 0.63464403
protein O 0 0.001318896
and O 0 0.00035231077
mRNA O 0 0.0002830577
were O 0 0.00014659643
examined O 0 0.00010395487
by O 0 0.00016918007
immunohistochemistry O 0 0.0025992424
, O 0 0.00038629735
Western O 0 0.010498562
blot O 0 0.015034478
and O 0 0.0007648618
RNase O 0 0.9366227
protection O 0 0.030613929
assay O 0 0.0046055745
in O 0 0.00033993894
a O 0 0.0004047731
model O 0 0.0004308383
of O 0 0.0009864782
podocyte O 0 0.97653234
injury O 0 0.9647563
in O 0 0.0018488165
the O 0 0.002529583
rat O 0 0.007321025
. O 0 0.0067374194

Puromycin B-Chemical 0 0.9999763
aminonucleoside I-Chemical 0 0.9999995
nephrosis B-Disease 2 0.99999845
was O 0 0.005573658
induced O 0 0.0011903277
by O 0 0.00077745086
single O 0 0.0006147569
intraperitoneal O 0 0.007107517
injection O 0 0.0009897334
of O 0 0.0011481446
puromycin B-Chemical 0 0.9965906
aminonucleoside I-Chemical 0 0.99999964
( O 0 0.35929292
PAN B-Chemical 1 0.99999034
, O 0 0.0031125927
20 O 0 0.00090642704
mg O 0 0.058031168
/ O 0 0.013824166
100g O 0 0.4741782
BW O 0 0.27748007
) O 0 0.0066955457
. O 0 0.0078468155

Tissues O 0 0.00655073
were O 0 0.0024359191
analyzed O 0 0.0015048805
at O 0 0.0011656077
0 O 0 0.0011144839
, O 0 0.0009776242
5 O 0 0.0005840699
, O 0 0.00065532274
7 O 0 0.0004254899
, O 0 0.000514605
11 O 0 0.00040376594
, O 0 0.00042890458
21 O 0 0.0003502963
, O 0 0.00033903273
45 O 0 0.0002486605
, O 0 0.00028164822
80 O 0 0.00023714434
and O 0 0.00021757967
126 O 0 0.00041965168
days O 0 0.00014035654
after O 0 0.00017195987
PAN B-Chemical 1 0.9998016
injection O 0 0.0008203837
so O 0 0.00017232721
as O 0 0.00013616144
to O 0 0.000121472134
include O 0 0.00013214386
both O 0 0.00015817463
the O 0 0.00019915064
acute O 0 0.44547072
phase O 0 0.0013612728
of O 0 0.004578495
proteinuria B-Disease 0 0.99999905
associated O 0 0.0006622709
with O 0 0.00029290805
foot O 0 0.010042579
process O 0 0.0002334034
effacement O 0 0.1597251
( O 0 0.00028401168
days O 0 0.000114490795
5 O 0 0.00014580751
- O 0 0.0008736623
11 O 0 0.0001883977
) O 0 0.00027560082
and O 0 0.00020660028
the O 0 0.00021781048
chronic O 0 0.35054684
phase O 0 0.0010911219
of O 0 0.0037996538
proteinuria B-Disease 0 0.9999989
associated O 0 0.0019462672
with O 0 0.0038854731
glomerulosclerosis B-Disease 2 0.9999988
( O 0 0.0023162973
days O 0 0.0005900093
45 O 0 0.0010426104
- O 0 0.003326191
126 O 0 0.0045808824
) O 0 0.005130291
. O 0 0.007052957

At O 0 0.0026576563
day O 0 0.0019992837
5 O 0 0.0015684831
, O 0 0.0019130263
GLEPP1 O 0 0.19734289
protein O 0 0.0017626849
and O 0 0.0009371084
mRNA O 0 0.0008051777
were O 0 0.00038979982
reduced O 0 0.00028112106
from O 0 0.00020968667
the O 0 0.00020547146
normal O 0 0.00029935452
range O 0 0.00025591833
( O 0 0.00041219353
265 O 0 0.004908146
. O 0 0.00019575104
2 O 0 0.00020897095
+ O 0 0.0008512208
/ O 0 0.007842969
- O 0 0.008144823
79 O 0 0.00037175132
. O 0 0.00015825835
6 O 0 0.00012671469
x O 0 0.00030723502
10 O 0 0.00017999008
( O 0 0.0002491779
6 O 0 0.00015578467
) O 0 0.00036028321
moles O 0 0.1003163
/ O 0 0.0072017885
glomerulus O 0 0.055543523
and O 0 0.00030286482
100 O 0 0.00038812144
% O 0 0.00024934852
) O 0 0.0002720685
to O 0 0.00013400665
15 O 0 0.00013583308
% O 0 0.00017145394
of O 0 0.00018655312
normal O 0 0.00035486673
( O 0 0.00036018252
41 O 0 0.00035253994
. O 0 0.00016780385
8 O 0 0.00018415364
+ O 0 0.00073352316
/ O 0 0.006962074
- O 0 0.006783757
4 O 0 0.00018201517
. O 0 0.00016192607
8 O 0 0.00015938719
x O 0 0.0003400845
10 O 0 0.00021553226
( O 0 0.0003019618
6 O 0 0.00021425942
) O 0 0.0004819703
moles O 0 0.08173544
/ O 0 0.0072207353
glomerulus O 0 0.07257826
, O 0 0.0008238872
p O 0 0.00069982716
< O 0 0.0008667974
0 O 0 0.0014378421
. O 0 0.0020943328
005 O 0 0.014503307
) O 0 0.0064688227
. O 0 0.008446708

This O 0 0.004643322
occurred O 0 0.0022665067
in O 0 0.0014753148
association O 0 0.0010124673
with O 0 0.00089108845
an O 0 0.00075623963
increase O 0 0.00044223346
in O 0 0.0004960855
urinary O 0 0.21752444
protein O 0 0.0010014155
content O 0 0.0003429539
from O 0 0.00020723812
1 O 0 0.00021131641
. O 0 0.0001789039
8 O 0 0.00019733341
+ O 0 0.000695477
/ O 0 0.0054864306
- O 0 0.0051419865
1 O 0 0.00020123276
to O 0 0.00016108988
99 O 0 0.00038340015
. O 0 0.0001841923
0 O 0 0.0002579956
+ O 0 0.00084324024
/ O 0 0.006058248
- O 0 0.0072882078
61 O 0 0.0005997902
mg O 0 0.008668471
/ O 0 0.0009399699
day O 0 0.0003597565
( O 0 0.0006188844
p O 0 0.0006347352
< O 0 0.00083221775
0 O 0 0.0014018568
. O 0 0.0020681333
001 O 0 0.039400104
) O 0 0.0065700035
. O 0 0.008344501

In O 0 0.0052913786
contrast O 0 0.004439043
, O 0 0.004836758
podocalyxin O 0 0.0738386
did O 0 0.0026306275
not O 0 0.0018498622
change O 0 0.002044451
significantly O 0 0.002047331
at O 0 0.0022925765
this O 0 0.0031694283
time O 0 0.004269217
. O 0 0.008759471

By O 0 0.005169658
day O 0 0.0030994804
11 O 0 0.0028496247
, O 0 0.0030276305
GLEPP1 O 0 0.16114523
protein O 0 0.0026074662
and O 0 0.0017497878
mRNA O 0 0.0017568007
had O 0 0.0013374558
begun O 0 0.0016143704
to O 0 0.0014676554
return O 0 0.002373176
towards O 0 0.0031302748
baseline O 0 0.0047623906
. O 0 0.007769126

By O 0 0.004436597
day O 0 0.0025243293
45 O 0 0.002249312
- O 0 0.0048167356
126 O 0 0.0024274532
, O 0 0.0010639152
at O 0 0.0005532699
a O 0 0.0005031351
time O 0 0.0002860752
when O 0 0.00030538908
glomerular O 0 0.87532985
scarring O 0 0.98848754
was O 0 0.0003975834
present O 0 0.00022176307
, O 0 0.0007243817
GLEPP1 O 0 0.49492308
was O 0 0.00025705274
absent O 0 0.0001869094
from O 0 0.00019279799
glomerulosclerotic O 0 0.7582979
areas O 0 0.0007192196
although O 0 0.0001855892
the O 0 0.00017559047
total O 0 0.00021038037
glomerular O 0 0.52890134
content O 0 0.00045463993
of O 0 0.000768442
GLEPP1 O 0 0.41763332
was O 0 0.00072591205
not O 0 0.0007742558
different O 0 0.0010848423
from O 0 0.001880925
normal O 0 0.0044550938
. O 0 0.0065724947

We O 0 0.0038171404
conclude O 0 0.0022008384
that O 0 0.0020635752
GLEPP1 O 0 0.30836362
expression O 0 0.0019341026
, O 0 0.0017768719
unlike O 0 0.0010238006
podocalyxin O 0 0.11738366
, O 0 0.0016923491
reflects O 0 0.0011398266
podocyte O 0 0.96246374
injury O 0 0.9749742
induced O 0 0.0047682226
by O 0 0.008429578
PAN B-Chemical 1 0.9998419
. O 0 0.01279017

GLEPP1 O 0 0.22993873
expression O 0 0.0053319093
may O 0 0.0035677871
be O 0 0.003199501
a O 0 0.0032492203
useful O 0 0.0029119346
marker O 0 0.00403051
of O 0 0.006247058
podocyte O 0 0.9863427
injury O 0 0.99301577
. O 0 0.016027268

Antithymocyte B-Chemical 0 0.9982134
globulin I-Chemical 0 0.9997533
in O 0 0.0031208112
the O 0 0.001840595
treatment O 0 0.002151796
of O 0 0.0068293535
D B-Chemical 0 0.999913
- I-Chemical 0 0.9727983
penicillamine I-Chemical 1 0.99999976
- O 0 0.7126301
induced O 0 0.08763234
aplastic B-Disease 0 0.99999726
anemia I-Disease 0 0.99999833
. O 0 0.030932842

A O 0 0.035186246
patient O 0 0.0035026579
who O 0 0.0028548802
received O 0 0.0018351839
antithymocyte B-Chemical 0 0.99992025
globulin I-Chemical 0 0.9999889
therapy O 0 0.15504168
for O 0 0.013178093
aplastic B-Disease 0 0.99999905
anemia I-Disease 0 0.99999976
due O 0 0.00075343857
to O 0 0.0012575017
D B-Chemical 0 0.9998585
- I-Chemical 0 0.8807207
penicillamine I-Chemical 1 0.9999993
therapy O 0 0.019398022
is O 0 0.0027886636
described O 0 0.0035707466
. O 0 0.006526561

Bone O 0 0.008181101
marrow O 0 0.0094328495
recovery O 0 0.0026675658
and O 0 0.0016122583
peripheral O 0 0.0040619583
blood O 0 0.0038818372
recovery O 0 0.00066509924
were O 0 0.00033211662
complete O 0 0.00023209036
1 O 0 0.00021186999
month O 0 0.00015436322
and O 0 0.00019289456
3 O 0 0.00015724033
months O 0 0.00013718214
, O 0 0.00025038767
respectively O 0 0.0008061044
, O 0 0.00029395433
after O 0 0.00013042123
treatment O 0 0.0002667746
, O 0 0.00033900462
and O 0 0.00032490323
blood O 0 0.017121397
transfusion O 0 0.014840995
or O 0 0.00016115887
other O 0 0.00019286678
therapies O 0 0.00031058505
were O 0 0.00015807527
not O 0 0.00013422393
necessary O 0 0.00013090354
in O 0 0.00019218573
a O 0 0.0002576313
follow O 0 0.00021627393
- O 0 0.0008560943
up O 0 0.00030485503
period O 0 0.00034748125
of O 0 0.00063227606
more O 0 0.0008874548
than O 0 0.00097545265
2 O 0 0.0018305322
years O 0 0.0036535228
. O 0 0.0062214397

Use O 0 0.008678902
of O 0 0.0059611388
antithymocyte B-Chemical 0 0.99992037
globulin I-Chemical 0 0.9999752
may O 0 0.0019143749
be O 0 0.0008579779
the O 0 0.00054447737
optimal O 0 0.00039258687
treatment O 0 0.00075964385
of O 0 0.0035567144
D B-Chemical 0 0.9999441
- I-Chemical 0 0.97468555
penicillamine I-Chemical 1 0.9999999
- O 0 0.697372
induced O 0 0.07661226
aplastic B-Disease 0 0.9999976
anemia I-Disease 0 0.99999845
. O 0 0.028289251

Metamizol B-Chemical 0 0.99953246
potentiates O 0 0.49498117
morphine B-Chemical 0 0.99999475
antinociception O 0 0.999974
but O 0 0.006270093
not O 0 0.0034620117
constipation B-Disease 2 0.9997435
after O 0 0.002993536
chronic O 0 0.83181703
treatment O 0 0.012028746
. O 0 0.010368118

This O 0 0.005238911
work O 0 0.0028576779
evaluates O 0 0.0017133632
the O 0 0.0014535742
antinociceptive O 0 0.9433481
and O 0 0.0025382915
constipating B-Disease 0 0.9955348
effects O 0 0.00071457354
of O 0 0.00040318412
the O 0 0.0002676476
combination O 0 0.0003462158
of O 0 0.00033088372
3 O 0 0.00019672285
. O 0 0.0001705399
2 O 0 0.00017588722
mg O 0 0.0029731463
/ O 0 0.00061734184
kg O 0 0.00043453355
s O 0 0.00029101997
. O 0 0.00020753374
c O 0 0.008430602
. O 0 0.00042550635
morphine B-Chemical 0 0.9998198
with O 0 0.00037826793
177 O 0 0.0044932663
. O 0 0.00016795947
8 O 0 0.00016078418
mg O 0 0.00215676
/ O 0 0.0005634382
kg O 0 0.0004225828
s O 0 0.00029370308
. O 0 0.00021762533
c O 0 0.013888377
. O 0 0.00073149917
metamizol B-Chemical 0 0.9999987
in O 0 0.00028485776
acutely O 0 0.003751607
and O 0 0.00028860368
chronically O 0 0.0037962403
treated O 0 0.00035330516
( O 0 0.00039331225
once O 0 0.00023671311
a O 0 0.00034344732
day O 0 0.000333651
for O 0 0.00049304636
12 O 0 0.00067747885
days O 0 0.0010217455
) O 0 0.0029235457
rats O 0 0.0046440605
. O 0 0.0064475155

On O 0 0.0032896362
the O 0 0.0023893316
13th O 0 0.0036705972
day O 0 0.00133837
, O 0 0.0018446872
antinociceptive O 0 0.7731752
effects O 0 0.0007782791
were O 0 0.000373711
assessed O 0 0.00023659893
using O 0 0.00023953196
a O 0 0.0002793806
model O 0 0.00025000697
of O 0 0.000513978
inflammatory O 0 0.9155814
nociception O 0 0.9914145
, O 0 0.006970945
pain B-Disease 0 0.9895867
- O 0 0.011501875
induced O 0 0.00023196006
functional O 0 0.00039764008
impairment O 0 0.21086933
model O 0 0.00033202133
, O 0 0.00045915996
and O 0 0.00033665946
the O 0 0.00040198007
charcoal B-Chemical 0 0.9745234
meal O 0 0.005300042
test O 0 0.00034959553
was O 0 0.00033781704
used O 0 0.00036261822
to O 0 0.00046693863
evaluate O 0 0.0005444617
the O 0 0.0013383892
intestinal O 0 0.023649722
transit O 0 0.016971653
. O 0 0.0067635495

Simultaneous O 0 0.014305824
administration O 0 0.027687846
of O 0 0.010870268
morphine B-Chemical 0 0.99998784
with O 0 0.101471886
metamizol B-Chemical 0 0.99999964
resulted O 0 0.00073084206
in O 0 0.00045203717
a O 0 0.0005352063
markedly O 0 0.0036386843
antinociceptive O 0 0.97082597
potentiation O 0 0.60841465
and O 0 0.00039542685
an O 0 0.00025794102
increasing O 0 0.00018870909
of O 0 0.00021402808
the O 0 0.00014837284
duration O 0 0.000115514384
of O 0 0.00017343364
action O 0 0.00023175578
after O 0 0.000102021426
a O 0 0.00018680857
single O 0 0.00019574468
( O 0 0.00051140436
298 O 0 0.31932274
+ O 0 0.003872568
/ O 0 0.01264746
- O 0 0.00563022
7 O 0 0.00015919992
vs O 0 0.00022546254
. O 0 0.00017850295
139 O 0 0.0006175878
+ O 0 0.0012446055
/ O 0 0.0073909466
- O 0 0.0043418007
36 O 0 0.00020247027
units O 0 0.00016288372
area O 0 0.00041180546
( O 0 0.0011921581
ua O 0 0.9656628
) O 0 0.0021449775
; O 0 0.0012724985
P O 0 0.049645662
< O 0 0.00023260829
0 O 0 0.0002809707
. O 0 0.0002397888
001 O 0 0.027704269
) O 0 0.00034711458
and O 0 0.00019000436
repeated O 0 0.00013954409
administration O 0 0.0008246302
( O 0 0.0004547587
280 O 0 0.028056266
+ O 0 0.0031167755
/ O 0 0.013250063
- O 0 0.008194942
17 O 0 0.00029766996
vs O 0 0.0002918282
. O 0 0.00023579746
131 O 0 0.00085527165
+ O 0 0.0012197822
/ O 0 0.007886573
- O 0 0.014811352
22 O 0 0.0010275512
ua O 0 0.83188957
; O 0 0.0016008735
P O 0 0.019351013
< O 0 0.0010763777
0 O 0 0.0016472465
. O 0 0.0023254224
001 O 0 0.03779724
) O 0 0.0070373793
. O 0 0.008897779

Antinociceptive O 0 0.984609
effect O 0 0.00380904
of O 0 0.007982834
morphine B-Chemical 0 0.9999753
was O 0 0.0015319363
reduced O 0 0.00073146715
in O 0 0.0005149291
chronically O 0 0.005590664
treated O 0 0.0004866584
rats O 0 0.0005325107
( O 0 0.00046549874
39 O 0 0.000509058
+ O 0 0.0017011961
/ O 0 0.009343546
- O 0 0.0053486642
10 O 0 0.00019248022
vs O 0 0.0002439219
. O 0 0.00017657768
18 O 0 0.00021933789
+ O 0 0.00081995706
/ O 0 0.0068120337
- O 0 0.0058574644
5 O 0 0.0001789271
au O 0 0.0021546932
) O 0 0.0005745386
while O 0 0.00021673512
the O 0 0.00019545354
combination O 0 0.00065429055
- O 0 0.028052703
induced O 0 0.0011747731
antinociception O 0 0.99980396
was O 0 0.00024302864
remained O 0 0.00023799535
similar O 0 0.00012157539
as O 0 0.00015427716
an O 0 0.00028985782
acute O 0 0.5125779
treatment O 0 0.0011744625
( O 0 0.0019697826
298 O 0 0.5679552
+ O 0 0.005812019
/ O 0 0.012806744
- O 0 0.0047876886
7 O 0 0.00025569517
vs O 0 0.00038575736
. O 0 0.00041099897
280 O 0 0.0063239457
+ O 0 0.0020256669
/ O 0 0.006572376
- O 0 0.0077634077
17 O 0 0.0026464134
au O 0 0.009440097
) O 0 0.0074224714
. O 0 0.008633127

Acute O 0 0.818145
antinociceptive O 0 0.96523863
effects O 0 0.0029996845
of O 0 0.0014655599
the O 0 0.00085468264
combination O 0 0.00086063653
were O 0 0.00048804388
partially O 0 0.00040352735
prevented O 0 0.00051554665
by O 0 0.00044181457
3 O 0 0.00033989942
. O 0 0.0003474993
2 O 0 0.00042683785
mg O 0 0.007781891
/ O 0 0.0028207612
kg O 0 0.014044372
naloxone B-Chemical 1 0.99994624
s O 0 0.0026201322
. O 0 0.002857303
c O 0 0.011483775
. O 0 0.008726856

( O 0 0.008401403
P O 0 0.055712283
< O 0 0.002453176
0 O 0 0.002125156
. O 0 0.0015798248
05 O 0 0.009956169
) O 0 0.0016420307
, O 0 0.0009412101
suggesting O 0 0.00047748434
the O 0 0.0004608861
partial O 0 0.00057932915
involvement O 0 0.0006197004
of O 0 0.00058162137
the O 0 0.0006497109
opioidergic O 0 0.24515992
system O 0 0.00076304347
in O 0 0.00092229043
the O 0 0.0014334508
synergism O 0 0.023807224
observed O 0 0.003950661
. O 0 0.0074498607

In O 0 0.003337487
independent O 0 0.0018755811
groups O 0 0.002130122
, O 0 0.003944676
morphine B-Chemical 0 0.99988294
inhibited O 0 0.0013177369
the O 0 0.0006023834
intestinal O 0 0.017515695
transit O 0 0.0030990972
in O 0 0.0003488037
48 O 0 0.0003823271
+ O 0 0.0011167077
/ O 0 0.0071385093
- O 0 0.005312251
4 O 0 0.00019040877
% O 0 0.00022291378
and O 0 0.00022061665
38 O 0 0.00038141786
+ O 0 0.001544374
/ O 0 0.01324752
- O 0 0.010780142
4 O 0 0.00019408933
% O 0 0.00022865747
after O 0 0.00014911464
acute O 0 0.23415777
and O 0 0.0006743634
chronic O 0 0.82723796
treatment O 0 0.0026230693
, O 0 0.0012191653
respectively O 0 0.0061143204
, O 0 0.00044441698
suggesting O 0 0.00021035869
that O 0 0.00025943565
tolerance O 0 0.02598393
did O 0 0.00043954275
not O 0 0.00038349867
develop O 0 0.0005738414
to O 0 0.0007382305
the O 0 0.0015535319
constipating B-Disease 0 0.9872105
effects O 0 0.00484449
. O 0 0.006382203

The O 0 0.0031220512
combination O 0 0.0026713717
inhibited O 0 0.0021306623
intestinal O 0 0.026869554
transit O 0 0.0036848404
similar O 0 0.00044437294
to O 0 0.000324972
that O 0 0.0002565132
produced O 0 0.0002906609
by O 0 0.00067949045
morphine B-Chemical 0 0.99990094
regardless O 0 0.00017303487
of O 0 0.00024959113
the O 0 0.0001738285
time O 0 0.0001282978
of O 0 0.00024375871
treatment O 0 0.00039112705
, O 0 0.00042182213
suggesting O 0 0.00024640033
that O 0 0.0006195994
metamizol B-Chemical 0 0.9999994
did O 0 0.0006249847
not O 0 0.0005051452
potentiate O 0 0.005576169
morphine B-Chemical 0 0.9999825
- O 0 0.12785776
induced O 0 0.00987262
constipation B-Disease 2 0.9999125
. O 0 0.009749932

These O 0 0.0034270429
findings O 0 0.0025426138
show O 0 0.0013555771
a O 0 0.0012997293
significant O 0 0.00084167416
interaction O 0 0.0008692373
between O 0 0.0007544304
morphine B-Chemical 0 0.9999907
and O 0 0.054179717
metamizol B-Chemical 0 0.99999976
in O 0 0.0005336606
chronically O 0 0.01524842
treated O 0 0.00044936876
rats O 0 0.00045826114
, O 0 0.00028390042
suggesting O 0 0.00014585783
that O 0 0.00015345437
this O 0 0.00019886412
combination O 0 0.0002864223
could O 0 0.00020065221
be O 0 0.00025651537
useful O 0 0.00030320082
for O 0 0.00037517885
the O 0 0.00055592385
treatment O 0 0.0010965196
of O 0 0.0028240304
chronic B-Disease 0 0.98451275
pain I-Disease 0 0.99498487
. O 0 0.008017778

Ifosfamide B-Chemical 1 0.99985266
encephalopathy B-Disease 2 0.999948
presenting O 0 0.49900898
with O 0 0.12717618
asterixis B-Disease 0 0.999966
. O 0 0.03034665

CNS O 0 0.5452027
toxic O 0 0.6286214
effects O 0 0.0025904714
of O 0 0.001476702
the O 0 0.0010868281
antineoplastic O 0 0.83463204
agent O 0 0.73551786
ifosfamide B-Chemical 1 0.9999809
( O 0 0.07845211
IFX B-Chemical 0 0.9999753
) O 0 0.0025660917
are O 0 0.00029859913
frequent O 0 0.0005213455
and O 0 0.00023055969
include O 0 0.00020917488
a O 0 0.00029285112
variety O 0 0.0003955646
of O 0 0.0009434952
neurological O 0 0.99932265
symptoms O 0 0.8860966
that O 0 0.0005834208
can O 0 0.00081131415
limit O 0 0.0020575477
drug O 0 0.24375783
use O 0 0.0042707985
. O 0 0.0066424087

We O 0 0.0039364016
report O 0 0.0035091098
a O 0 0.0021716622
case O 0 0.0014160095
of O 0 0.0011784923
a O 0 0.0011552018
51 O 0 0.0014975863
- O 0 0.004061989
year O 0 0.000622711
- O 0 0.0028663857
old O 0 0.00047848697
man O 0 0.019371482
who O 0 0.0006412819
developed O 0 0.0006445211
severe O 0 0.075687595
, O 0 0.0013988133
disabling O 0 0.90096986
negative O 0 0.01037099
myoclonus B-Disease 2 0.9999962
of O 0 0.00053657923
the O 0 0.000251684
upper O 0 0.00038842027
and O 0 0.00032104237
lower O 0 0.00031517085
extremities O 0 0.020110514
after O 0 0.00022667521
the O 0 0.00039171267
infusion O 0 0.0011126652
of O 0 0.0015090319
ifosfamide B-Chemical 1 0.9987557
for O 0 0.0033333139
plasmacytoma B-Disease 0 0.99736005
. O 0 0.008719376

He O 0 0.008196806
was O 0 0.0031913435
awake O 0 0.0039741434
, O 0 0.0016778732
revealed O 0 0.0009137247
no O 0 0.0006266957
changes O 0 0.0007280431
of O 0 0.0006924876
mental O 0 0.030713085
status O 0 0.0007257236
and O 0 0.00045173138
at O 0 0.00035758302
rest O 0 0.0004497266
there O 0 0.00037803774
were O 0 0.0006155971
no O 0 0.00073687115
further O 0 0.0015442602
motor O 0 0.055709194
symptoms O 0 0.29014593
. O 0 0.007169648

Cranial O 0 0.21107975
magnetic O 0 0.020300701
resonance O 0 0.19081666
imaging O 0 0.002900306
and O 0 0.0013027001
extensive O 0 0.0009601795
laboratory O 0 0.0008988762
studies O 0 0.00055685715
failed O 0 0.0005028527
to O 0 0.000382876
reveal O 0 0.00040295933
structural B-Disease 0 0.0010189732
lesions I-Disease 0 0.10924359
of I-Disease 0 0.00079672725
the I-Disease 0 0.00087643287
brain I-Disease 0 0.014487762
and O 0 0.0024800177
metabolic B-Disease 0 0.8262027
abnormalities I-Disease 0 0.888773
. O 0 0.007597923

An O 0 0.0060322154
electroencephalogram O 0 0.10065505
showed O 0 0.0017972026
continuous O 0 0.0013471144
, O 0 0.0015994239
generalized O 0 0.011052172
irregular O 0 0.0030630555
slowing O 0 0.0043069758
with O 0 0.0008378265
admixed O 0 0.01588494
periodic O 0 0.0068538743
triphasic O 0 0.7639337
waves O 0 0.020514237
indicating O 0 0.0021639573
symptomatic O 0 0.80463856
encephalopathy B-Disease 2 0.9999794
. O 0 0.011477233

The O 0 0.0034782568
administration O 0 0.006006399
of O 0 0.0036363993
ifosfamide B-Chemical 1 0.99932003
was O 0 0.0016263423
discontinued O 0 0.003235828
and O 0 0.0008068806
within O 0 0.00055957783
12 O 0 0.0006858733
h O 0 0.0010639431
the O 0 0.0017608318
asterixis B-Disease 0 0.9999678
resolved O 0 0.0040941797
completely O 0 0.0042512105
. O 0 0.007500667

In O 0 0.0036450203
the O 0 0.0022602847
patient O 0 0.0017454388
described O 0 0.0010867191
, O 0 0.0010446288
the O 0 0.00059190864
presence O 0 0.0005731488
of O 0 0.0022186527
asterixis B-Disease 0 0.9999974
during O 0 0.00027432412
infusion O 0 0.0013357531
of O 0 0.0007300572
ifosfamide B-Chemical 1 0.99962974
, O 0 0.00054397364
normal O 0 0.00036226198
laboratory O 0 0.00026545598
findings O 0 0.000187183
and O 0 0.00017078107
imaging O 0 0.00034696684
studies O 0 0.00013994586
and O 0 0.00015743205
the O 0 0.00014744344
resolution O 0 0.0039434205
of O 0 0.0003562499
symptoms O 0 0.08883017
following O 0 0.00014479154
the O 0 0.00019772725
discontinuation O 0 0.1671144
of O 0 0.0002348047
the O 0 0.00021835716
drug O 0 0.044686913
suggest O 0 0.00012526273
that O 0 0.0001933706
negative O 0 0.005335919
myoclonus B-Disease 2 0.99999666
is O 0 0.00060095324
associated O 0 0.00056483404
with O 0 0.0006419188
the O 0 0.00084958394
use O 0 0.0015248285
of O 0 0.0043848986
IFX B-Chemical 0 0.9996562
. O 0 0.008470861

Antagonism O 0 0.06833238
between O 0 0.0024428987
interleukin O 0 0.57964987
3 O 0 0.0016524083
and O 0 0.0016285968
erythropoietin O 0 0.9366528
in O 0 0.00068048557
mice O 0 0.000400807
with O 0 0.0013837622
azidothymidine B-Chemical 0 0.99995077
- O 0 0.19226095
induced O 0 0.0027212144
anemia B-Disease 0 0.9999831
and O 0 0.0012878648
in O 0 0.00092841586
bone O 0 0.013610505
marrow O 0 0.09018699
endothelial O 0 0.8729788
cells O 0 0.0067985873
. O 0 0.007821316

Azidothymidine B-Chemical 0 0.99957615
( O 0 0.15677385
AZT B-Chemical 1 0.9999478
) O 0 0.113816924
- O 0 0.09352667
induced O 0 0.0038998874
anemia B-Disease 0 0.99998593
in O 0 0.0007185469
mice O 0 0.00026238136
can O 0 0.00023940181
be O 0 0.00024185253
reversed O 0 0.00026474145
by O 0 0.00022919924
the O 0 0.00022523435
administration O 0 0.0039207153
of O 0 0.0022196916
IGF O 0 0.9997179
- O 0 0.5270857
IL O 0 0.9916892
- O 0 0.07197385
3 O 0 0.00020763568
( O 0 0.00026569754
fusion O 0 0.0002476124
protein O 0 0.0005397813
of O 0 0.00085543474
insulin O 0 0.9829441
- O 0 0.022161223
like O 0 0.00027415864
growth O 0 0.0056965873
factor O 0 0.057669457
II O 0 0.23520733
( O 0 0.0057876245
IGF O 0 0.9963322
II O 0 0.106709056
) O 0 0.0016331621
and O 0 0.0014343725
interleukin O 0 0.6821256
3 O 0 0.0030360667
) O 0 0.0061643897
. O 0 0.0076931054

Although O 0 0.003653042
interleukin O 0 0.4548837
3 O 0 0.0024208538
( O 0 0.0037457263
IL O 0 0.942102
- O 0 0.057683088
3 O 0 0.0007517353
) O 0 0.0010808078
and O 0 0.00096697954
erythropoietin O 0 0.9952624
( O 0 0.028581237
EPO O 0 0.99985516
) O 0 0.0021160962
are O 0 0.00025299325
known O 0 0.00023271366
to O 0 0.00014210194
act O 0 0.00016318983
synergistically O 0 0.0002811138
on O 0 0.00015009852
hematopoietic O 0 0.3551848
cell O 0 0.017789485
proliferation O 0 0.8171886
in O 0 0.00028272948
vitro O 0 0.00043792385
, O 0 0.00044932595
injection O 0 0.00066099805
of O 0 0.0017177108
IGF O 0 0.9997067
- O 0 0.55847585
IL O 0 0.9939851
- O 0 0.12581818
3 O 0 0.00022512143
and O 0 0.0005593347
EPO O 0 0.9996977
in O 0 0.0020868082
AZT B-Chemical 1 0.9999851
- O 0 0.07692978
treated O 0 0.00027191805
mice O 0 0.00010430997
resulted O 0 0.0001346313
in O 0 0.00016502877
a O 0 0.00023370449
reduction O 0 0.0003555852
of O 0 0.00036342407
red O 0 0.02610397
cells O 0 0.00033568087
and O 0 0.00028063392
an O 0 0.00023722781
increase O 0 0.00015708776
of O 0 0.000617486
plasma O 0 0.3646447
EPO O 0 0.99951994
levels O 0 0.00023213396
as O 0 0.00015924622
compared O 0 0.00012284606
to O 0 0.00014201929
animals O 0 0.00016486189
treated O 0 0.00034880688
with O 0 0.0012516112
IGF O 0 0.99908507
- O 0 0.38307074
IL O 0 0.98539704
- O 0 0.068380505
3 O 0 0.0010849838
or O 0 0.0018902555
EPO O 0 0.9966516
alone O 0 0.005053641
. O 0 0.007932859

We O 0 0.0033154748
tested O 0 0.001992175
the O 0 0.0014438508
hypothesis O 0 0.0010929051
that O 0 0.00072622724
the O 0 0.000659209
antagonistic O 0 0.0013754921
effect O 0 0.0006132381
of O 0 0.0019394385
IL O 0 0.99490166
- O 0 0.16086535
3 O 0 0.0003726551
and O 0 0.0006148606
EPO O 0 0.99750465
on O 0 0.0003510391
erythroid O 0 0.93154424
cells O 0 0.0009232149
may O 0 0.00057733955
be O 0 0.00070966705
mediated O 0 0.0008612181
by O 0 0.002013698
endothelial O 0 0.8328617
cells O 0 0.0072356407
. O 0 0.0080854315

Bovine O 0 0.22167891
liver O 0 0.90536505
erythroid O 0 0.986093
cells O 0 0.002441248
were O 0 0.00096544443
cultured O 0 0.0006869216
on O 0 0.00036190302
monolayers O 0 0.0012215442
of O 0 0.00051310385
human O 0 0.0007187264
bone O 0 0.022304974
marrow O 0 0.12472467
endothelial O 0 0.90374655
cells O 0 0.0006056617
previously O 0 0.00037532617
treated O 0 0.00050034374
with O 0 0.0012249706
EPO O 0 0.99964654
and O 0 0.0069501936
IGF O 0 0.9990833
- O 0 0.3402066
IL O 0 0.9740485
- O 0 0.05900746
3 O 0 0.00431212
. O 0 0.007200057

There O 0 0.0041810526
was O 0 0.0025901785
a O 0 0.0019383029
significant O 0 0.0012755685
reduction O 0 0.0015703704
of O 0 0.0017119566
thymidine B-Chemical 0 0.9889549
incorporation O 0 0.0063228165
into O 0 0.0002542773
both O 0 0.00043178888
erythroid O 0 0.97151
and O 0 0.0011688871
endothelial O 0 0.90240705
cells O 0 0.00049259583
in O 0 0.0002644725
cultures O 0 0.00035405453
pre O 0 0.0016575481
- O 0 0.0035622178
treated O 0 0.0005112145
with O 0 0.0013877988
IGF O 0 0.99857664
- O 0 0.2912769
IL O 0 0.9767006
- O 0 0.05327757
3 O 0 0.0018456816
and O 0 0.0037582372
EPO O 0 0.9961436
. O 0 0.008855304

Endothelial O 0 0.88824296
cell O 0 0.0056674434
culture O 0 0.0028854911
supernatants O 0 0.0012608712
separated O 0 0.0008385157
by O 0 0.0006752637
ultrafiltration O 0 0.0034224764
and O 0 0.0004388658
ultracentrifugation O 0 0.00062795216
from O 0 0.00025532514
cells O 0 0.00033440642
treated O 0 0.00041121859
with O 0 0.00097325724
EPO O 0 0.9997255
and O 0 0.0024443867
IL O 0 0.99104404
- O 0 0.07998127
3 O 0 0.00018202802
significantly O 0 0.00017646626
reduced O 0 0.00026225083
thymidine B-Chemical 0 0.9535285
incorporation O 0 0.0030013178
into O 0 0.00014618227
erythroid O 0 0.9335203
cells O 0 0.00039182266
as O 0 0.00017117364
compared O 0 0.000117416304
to O 0 0.00012234645
identical O 0 0.00011088364
fractions O 0 0.00014849995
obtained O 0 0.00016303382
from O 0 0.00018276472
the O 0 0.00024577876
media O 0 0.0006577072
of O 0 0.0005625614
cells O 0 0.0008816854
cultured O 0 0.0015218107
with O 0 0.0047338763
EPO O 0 0.9990128
alone O 0 0.0051063113
. O 0 0.007401031

These O 0 0.0033684548
results O 0 0.001991723
suggest O 0 0.0011791886
that O 0 0.001191743
endothelial O 0 0.77092874
cells O 0 0.0012315353
treated O 0 0.0008119773
simultaneously O 0 0.00055393344
with O 0 0.0011425039
EPO O 0 0.99964046
and O 0 0.0020417694
IL O 0 0.9837535
- O 0 0.03452745
3 O 0 0.00030399536
have O 0 0.00027598022
a O 0 0.00042981154
negative O 0 0.0005849582
effect O 0 0.0006912275
on O 0 0.0009280947
erythroid O 0 0.9374065
cell O 0 0.03406612
production O 0 0.010653712
. O 0 0.008714894

The O 0 0.0025281527
relationship O 0 0.0015101719
between O 0 0.0014065264
hippocampal O 0 0.84078324
acetylcholine B-Chemical 1 0.9999207
release O 0 0.06434785
and O 0 0.0035887018
cholinergic O 0 0.9611202
convulsant O 0 0.9998449
sensitivity O 0 0.0072309976
in O 0 0.0006075403
withdrawal O 0 0.8990207
seizure B-Disease 2 0.9999944
- O 0 0.057602987
prone O 0 0.00048653127
and O 0 0.0006989561
withdrawal O 0 0.83336014
seizure B-Disease 2 0.9999832
- O 0 0.021737527
resistant O 0 0.0011084429
selected O 0 0.0013151724
mouse O 0 0.0030217264
lines O 0 0.008820438
. O 0 0.0069898106

BACKGROUND O 0 0.01737138
: O 0 0.0038544661
The O 0 0.0018172606
septo O 0 0.3263454
- O 0 0.056332767
hippocampal O 0 0.600286
cholinergic O 0 0.53604746
pathway O 0 0.00049947796
has O 0 0.0003268549
been O 0 0.00027637518
implicated O 0 0.00023237355
in O 0 0.00039615354
epileptogenesis O 0 0.9986112
, O 0 0.0005708509
and O 0 0.00027708095
genetic O 0 0.00070102606
factors O 0 0.0005501272
influence O 0 0.00012905215
the O 0 0.00015964684
response O 0 0.00026492425
to O 0 0.00020759745
cholinergic O 0 0.44595814
agents O 0 0.006549508
, O 0 0.000403887
but O 0 0.00024214278
limited O 0 0.00017552635
data O 0 0.00021227279
are O 0 0.00019669642
available O 0 0.00024278638
on O 0 0.00023255132
cholinergic O 0 0.11207825
involvement O 0 0.0010035344
in O 0 0.0013275759
alcohol B-Chemical 0 0.9999269
withdrawal O 0 0.7626962
severity O 0 0.061410695
. O 0 0.0064214184

Thus O 0 0.003889188
, O 0 0.0027958385
the O 0 0.0013130521
relationship O 0 0.00076640525
between O 0 0.00068065966
cholinergic O 0 0.22894092
activity O 0 0.00052498205
and O 0 0.00043925043
responsiveness O 0 0.0005227241
and O 0 0.0018062802
alcohol B-Chemical 0 0.9999826
withdrawal O 0 0.5069726
was O 0 0.0002727141
investigated O 0 0.00018547883
in O 0 0.00024057519
a O 0 0.0003531917
genetic O 0 0.00077249476
animal O 0 0.0007252092
model O 0 0.0007358869
of O 0 0.003368445
ethanol B-Chemical 1 0.99985826
withdrawal O 0 0.850566
severity O 0 0.077628985
. O 0 0.006586561

METHODS O 0 0.0042681997
: O 0 0.005195235
Cholinergic O 0 0.6204965
convulsant O 0 0.998645
sensitivity O 0 0.0035945931
was O 0 0.00091131026
examined O 0 0.00056225364
in O 0 0.0011388384
alcohol B-Chemical 0 0.9999888
- O 0 0.8594501
na O 0 0.9999951
ve O 0 0.98838156
Withdrawal O 0 0.9961293
Seizure B-Disease 2 0.9999924
- O 0 0.08059066
Prone O 0 0.41030914
( O 0 0.0019146483
WSP O 0 0.9563632
) O 0 0.0012689256
and O 0 0.0010174154
- O 0 0.012042796
Resistant O 0 0.06481825
( O 0 0.004109886
WSR O 0 0.9596786
) O 0 0.0042457823
mice O 0 0.0037992876
. O 0 0.008125255

Animals O 0 0.0058515025
were O 0 0.0027177588
administered O 0 0.003578959
nicotine B-Chemical 1 0.9999263
, O 0 0.05148679
carbachol B-Chemical 1 0.99996626
, O 0 0.007076781
or O 0 0.0013653432
neostigmine B-Chemical 0 0.999941
via O 0 0.00026637196
timed O 0 0.00036332363
tail O 0 0.00037363387
vein O 0 0.012611856
infusion O 0 0.0009705662
, O 0 0.00029114127
and O 0 0.00020831106
the O 0 0.0001702585
latencies O 0 0.00045723768
to O 0 0.00016091517
onset O 0 0.0005342267
of O 0 0.001131635
tremor B-Disease 0 0.99999225
and O 0 0.0018564651
clonus O 0 0.998058
were O 0 0.0003505198
recorded O 0 0.00037609733
and O 0 0.0005366412
converted O 0 0.0007395035
to O 0 0.0009528687
threshold O 0 0.001719851
dose O 0 0.007704085
. O 0 0.00653696

We O 0 0.0034061763
also O 0 0.0022022089
used O 0 0.0016227553
microdialysis O 0 0.019594455
to O 0 0.0007038778
measure O 0 0.00044147103
basal O 0 0.0010248945
and O 0 0.001569224
potassium B-Chemical 0 0.999984
- O 0 0.118970804
stimulated O 0 0.0010521055
acetylcholine B-Chemical 1 0.9999702
( O 0 0.037665095
ACh B-Chemical 1 0.99995756
) O 0 0.002032012
release O 0 0.0014935284
in O 0 0.00047022343
the O 0 0.00067926483
CA1 O 0 0.8385919
region O 0 0.0011548134
of O 0 0.0017448199
the O 0 0.0027239483
hippocampus O 0 0.38036126
. O 0 0.0069923806

Potassium B-Chemical 0 0.99918324
was O 0 0.004115513
applied O 0 0.002501248
by O 0 0.002341227
reverse O 0 0.004094845
dialysis O 0 0.0043705264
twice O 0 0.0014363657
, O 0 0.0019396887
separated O 0 0.0018949594
by O 0 0.0026823268
75 O 0 0.004099133
min O 0 0.005860252
. O 0 0.009154251

Hippocampal O 0 0.93553925
ACh B-Chemical 1 0.9993881
also O 0 0.0029464609
was O 0 0.0019827706
measured O 0 0.0012928415
during O 0 0.0011026947
testing O 0 0.001445291
for O 0 0.0016488048
handling O 0 0.004303618
- O 0 0.02969123
induced O 0 0.0114704035
convulsions B-Disease 0 0.9999808
. O 0 0.0140315825

RESULTS O 0 0.005713639
: O 0 0.0040161144
Sensitivity O 0 0.00947784
to O 0 0.0015042917
several O 0 0.0014430623
convulsion B-Disease 2 0.99994755
endpoints O 0 0.0053017335
induced O 0 0.0008624738
by O 0 0.002639779
nicotine B-Chemical 1 0.999985
, O 0 0.05233028
carbachol B-Chemical 1 0.9999751
, O 0 0.005090126
and O 0 0.0027873565
neostigmine B-Chemical 0 0.99996316
were O 0 0.00046207293
significantly O 0 0.0004675718
greater O 0 0.00059343065
in O 0 0.0011116585
WSR O 0 0.95155305
versus O 0 0.0022832516
WSP O 0 0.80431134
mice O 0 0.003344782
. O 0 0.007216798

In O 0 0.004378755
microdialysis O 0 0.042713266
experiments O 0 0.0015022762
, O 0 0.0017843778
the O 0 0.0010427466
lines O 0 0.002129739
did O 0 0.00073962123
not O 0 0.0004180552
differ O 0 0.00036842327
in O 0 0.00032513315
basal O 0 0.0007368122
release O 0 0.0021254504
of O 0 0.0018826697
ACh B-Chemical 1 0.9999436
, O 0 0.0006808625
and O 0 0.00035701707
50 O 0 0.00050014415
mM O 0 0.22040325
KCl B-Chemical 0 0.9996927
increased O 0 0.004603964
ACh B-Chemical 1 0.9998375
output O 0 0.0007843258
in O 0 0.0006180071
both O 0 0.00088760705
lines O 0 0.002146135
of O 0 0.0024650511
mice O 0 0.0029843166
. O 0 0.006799496

However O 0 0.004675583
, O 0 0.003252425
the O 0 0.0016208685
increase O 0 0.0011057847
in O 0 0.0010005682
release O 0 0.004519848
of O 0 0.0029233675
ACh B-Chemical 1 0.9998989
produced O 0 0.00043324352
by O 0 0.0003406186
the O 0 0.0002447158
first O 0 0.00019291605
application O 0 0.0003208823
of O 0 0.0005776927
KCl B-Chemical 0 0.9995504
was O 0 0.00057529745
2 O 0 0.00043542587
- O 0 0.0018233446
fold O 0 0.0008810355
higher O 0 0.0008146682
in O 0 0.0012540364
WSP O 0 0.9217962
versus O 0 0.0023341696
WSR O 0 0.89186156
mice O 0 0.0034537497
. O 0 0.0074469307

When O 0 0.003837462
hippocampal O 0 0.7234778
ACh B-Chemical 1 0.9997533
was O 0 0.0013756106
measured O 0 0.0006239872
during O 0 0.00041745102
testing O 0 0.0004568264
for O 0 0.00038467898
handling O 0 0.0016447799
- O 0 0.03202815
induced O 0 0.0022412052
convulsions B-Disease 0 0.9999989
, O 0 0.011294865
extracellular O 0 0.2001222
ACh B-Chemical 1 0.9999745
was O 0 0.00034594408
significantly O 0 0.00027998586
elevated O 0 0.0027745531
( O 0 0.0005671035
192 O 0 0.0043260474
% O 0 0.00035412543
) O 0 0.00056703785
in O 0 0.000340813
WSP O 0 0.88193727
mice O 0 0.00017759249
, O 0 0.0004322444
but O 0 0.00038736124
was O 0 0.00039277162
nonsignificantly O 0 0.15969875
elevated O 0 0.0030958815
( O 0 0.0008612292
59 O 0 0.0010120701
% O 0 0.0010944882
) O 0 0.0019027402
in O 0 0.0021931452
WSR O 0 0.85026616
mice O 0 0.0034608375
. O 0 0.007480503

CONCLUSIONS O 0 0.018775877
: O 0 0.0034505264
These O 0 0.0016714305
results O 0 0.0010541179
suggest O 0 0.0006285312
that O 0 0.0005687263
differences O 0 0.00044740646
in O 0 0.00052519346
cholinergic O 0 0.29160103
activity O 0 0.00040790663
and O 0 0.00047500522
postsynaptic O 0 0.28809413
sensitivity O 0 0.0037837785
to O 0 0.00041972773
cholinergic O 0 0.96981937
convulsants B-Disease 0 0.99999416
may O 0 0.0002255907
be O 0 0.00019033182
associated O 0 0.0002667458
with O 0 0.000807559
ethanol B-Chemical 1 0.9998579
withdrawal O 0 0.46544546
severity O 0 0.003772649
and O 0 0.00035048186
implicate O 0 0.00034901692
cholinergic O 0 0.118507184
mechanisms O 0 0.0007302197
in O 0 0.0018680326
alcohol B-Chemical 0 0.9999106
withdrawal O 0 0.7822757
. O 0 0.0067468937

Specifically O 0 0.006180489
, O 0 0.0068853977
WSP O 0 0.8094465
mice O 0 0.0012089107
may O 0 0.0009689706
have O 0 0.0006715795
lower O 0 0.00063507434
sensitivity O 0 0.0016775042
to O 0 0.0006399073
cholinergic O 0 0.9661297
convulsants B-Disease 0 0.99999213
compared O 0 0.00025867784
with O 0 0.0005614942
WSR O 0 0.9635112
because O 0 0.00019796248
of O 0 0.00040511414
postsynaptic O 0 0.48635966
receptor O 0 0.037754674
desensitization O 0 0.031220367
brought O 0 0.0003914351
on O 0 0.0002538256
by O 0 0.00044294135
higher O 0 0.0005681044
activity O 0 0.0008776228
of O 0 0.0020892553
cholinergic O 0 0.597957
neurons O 0 0.0075106174
. O 0 0.0062696384

Capsaicin B-Chemical 1 0.9999374
- O 0 0.11874019
induced O 0 0.0048559792
muscle B-Disease 0 0.9345
pain I-Disease 0 0.99890304
alters O 0 0.0010370831
the O 0 0.0010272072
excitability O 0 0.12170711
of O 0 0.0010434451
the O 0 0.0010735977
human O 0 0.002365721
jaw O 0 0.67718846
- O 0 0.036816023
stretch O 0 0.018555723
reflex O 0 0.6690236
. O 0 0.008652366

The O 0 0.003426154
pathophysiology O 0 0.009450616
of O 0 0.0036597403
painful O 0 0.99370956
temporomandibular B-Disease 0 0.9999218
disorders I-Disease 0 0.9991541
is O 0 0.00077733415
not O 0 0.00038577555
fully O 0 0.0003563338
understood O 0 0.00074122223
, O 0 0.00045280808
but O 0 0.00032981296
evidence O 0 0.00022295458
suggests O 0 0.00021600831
that O 0 0.0003550652
muscle B-Disease 0 0.7733091
pain I-Disease 0 0.9973654
modulates O 0 0.00043006032
motor O 0 0.005457476
function O 0 0.00089362345
in O 0 0.0013244534
characteristic O 0 0.002666172
ways O 0 0.0037843336
. O 0 0.0063850707

This O 0 0.004906169
study O 0 0.0025814872
tested O 0 0.0013719504
the O 0 0.0010149853
hypothesis O 0 0.0008079115
that O 0 0.00055867934
activation O 0 0.0010016676
of O 0 0.0013428766
nociceptive B-Disease 0 0.9557416
muscle I-Disease 0 0.41512012
afferent O 0 0.0028528608
fibers O 0 0.000803567
would O 0 0.00018864269
be O 0 0.00018282275
linked O 0 0.00017337245
to O 0 0.00014913385
an O 0 0.00022906488
increased O 0 0.00029727604
excitability O 0 0.1517637
of O 0 0.0002580037
the O 0 0.00022347984
human O 0 0.0007861351
jaw O 0 0.7471942
- O 0 0.03461058
stretch O 0 0.0031507532
reflex O 0 0.26065972
and O 0 0.00021160292
whether O 0 0.000106605716
this O 0 0.0001648855
process O 0 0.00020082602
would O 0 0.00019296573
be O 0 0.00022888719
sensitive O 0 0.00026877353
to O 0 0.0002595247
length O 0 0.0003627375
and O 0 0.00063802704
velocity O 0 0.0011701399
of O 0 0.0015928146
the O 0 0.0023197366
stretch O 0 0.0076432507
. O 0 0.007258993

Capsaicin B-Chemical 1 0.9998209
( O 0 0.005887406
10 O 0 0.0021670763
micro O 0 0.0048017865
g O 0 0.0025454403
) O 0 0.0015255815
was O 0 0.0006995255
injected O 0 0.0005010073
into O 0 0.00035016745
the O 0 0.00049897085
masseter O 0 0.007547495
muscle O 0 0.0018809948
to O 0 0.0005195411
induce O 0 0.0006510597
pain B-Disease 0 0.7349126
in O 0 0.0012033844
11 O 0 0.0018657519
healthy O 0 0.004897626
volunteers O 0 0.0057261214
. O 0 0.0068527963

Short O 0 0.007272872
- O 0 0.008053899
latency O 0 0.004196288
reflex O 0 0.15320858
responses O 0 0.001659917
were O 0 0.0007809009
evoked O 0 0.0016365304
in O 0 0.00042800888
the O 0 0.00037351937
masseter O 0 0.0042482624
and O 0 0.00033655856
temporalis O 0 0.0022367558
muscles O 0 0.0006392398
by O 0 0.00023950273
a O 0 0.00027136228
stretch O 0 0.00057715114
device O 0 0.00039924568
with O 0 0.00020476758
different O 0 0.00016037154
velocities O 0 0.00034570144
and O 0 0.0002871406
displacements O 0 0.0036944253
before O 0 0.00026620415
, O 0 0.00049281196
during O 0 0.00040778102
, O 0 0.0008290625
and O 0 0.0009868831
after O 0 0.0011498991
the O 0 0.002688182
pain B-Disease 0 0.8645929
. O 0 0.0070438962

The O 0 0.0029359816
normalized O 0 0.0017606723
reflex O 0 0.13643692
amplitude O 0 0.004477213
increased O 0 0.0010970429
with O 0 0.00077028805
an O 0 0.00062705565
increase O 0 0.00034213177
in O 0 0.00032468274
velocity O 0 0.000459932
at O 0 0.00023240015
a O 0 0.00026959326
given O 0 0.00017291779
displacement O 0 0.001811347
, O 0 0.00048234806
but O 0 0.0003383108
remained O 0 0.00035559112
constant O 0 0.00034727197
with O 0 0.00039974853
different O 0 0.0004262808
displacements O 0 0.002985821
at O 0 0.00082465063
a O 0 0.0014312724
given O 0 0.0016328837
velocity O 0 0.0045503196
. O 0 0.006724371

The O 0 0.0031785816
normalized O 0 0.0019489513
reflex O 0 0.12857614
amplitude O 0 0.0043392205
was O 0 0.0010773153
significantly O 0 0.0007517912
higher O 0 0.0005978403
during O 0 0.00050028984
pain B-Disease 0 0.90623677
, O 0 0.0008051233
but O 0 0.00054816355
only O 0 0.00046227625
at O 0 0.00043422775
faster O 0 0.00056764757
stretches O 0 0.0011876938
in O 0 0.0011766215
the O 0 0.0022106804
painful B-Disease 0 0.9924384
muscle I-Disease 0 0.5378591
. O 0 0.008345039

Increased O 0 0.004757292
sensitivity O 0 0.0040694806
of O 0 0.002219128
the O 0 0.001512944
fusimotor O 0 0.025189927
system O 0 0.00097149104
during O 0 0.0006485249
acute O 0 0.9206925
muscle B-Disease 0 0.97846675
pain I-Disease 0 0.99949825
could O 0 0.00041252113
be O 0 0.000418097
one O 0 0.00039695742
likely O 0 0.00045424618
mechanism O 0 0.00056189584
to O 0 0.000814679
explain O 0 0.0011727365
the O 0 0.0021951569
findings O 0 0.005066217
. O 0 0.007066197

Effects O 0 0.004761918
of O 0 0.0029399332
5 O 0 0.0021185414
- O 0 0.022101898
HT1B O 0 0.5355851
receptor O 0 0.017204003
ligands O 0 0.011312628
microinjected O 0 0.0017458776
into O 0 0.0002849523
the O 0 0.0005018538
accumbal O 0 0.9874858
shell O 0 0.005889728
or O 0 0.00026752744
core O 0 0.0003145009
on O 0 0.0002343252
the O 0 0.000843854
cocaine B-Chemical 1 0.99999404
- O 0 0.13176815
induced O 0 0.005452338
locomotor B-Disease 0 0.9996755
hyperactivity I-Disease 2 0.99999106
in O 0 0.0029631525
rats O 0 0.0053926557
. O 0 0.0062068277

The O 0 0.0029999183
present O 0 0.0018724834
study O 0 0.0016653846
was O 0 0.0009954884
designed O 0 0.0006447453
to O 0 0.00041861626
examine O 0 0.00023365457
the O 0 0.000295395
effect O 0 0.0002792562
of O 0 0.00041519187
5 O 0 0.00034772136
- O 0 0.026763828
HT1B O 0 0.6386155
receptor O 0 0.014164626
ligands O 0 0.008163449
microinjected O 0 0.00069912657
into O 0 0.00010018469
the O 0 0.00013853742
subregions O 0 0.0004912454
of O 0 0.00016736731
the O 0 0.0001802219
nucleus O 0 0.0008474001
accumbens O 0 0.38514507
( O 0 0.0002447559
the O 0 0.00016013332
shell O 0 0.0028770575
and O 0 0.00022706631
the O 0 0.00019145997
core O 0 0.00030062778
) O 0 0.00047729275
on O 0 0.00019645614
the O 0 0.0005628928
locomotor B-Disease 0 0.9983772
hyperactivity I-Disease 2 0.99999416
induced O 0 0.0012925533
by O 0 0.002834813
cocaine B-Chemical 1 0.9999579
in O 0 0.002851699
rats O 0 0.0054869945
. O 0 0.0061940993

Male O 0 0.022333791
Wistar O 0 0.011025508
rats O 0 0.0024197325
were O 0 0.0012354031
implanted O 0 0.0013281677
bilaterally O 0 0.0023984509
with O 0 0.0004908027
cannulae O 0 0.00081804075
into O 0 0.00021250162
the O 0 0.00032223214
accumbens O 0 0.36532557
shell O 0 0.003276369
or O 0 0.00022925825
core O 0 0.00030779061
, O 0 0.00032641183
and O 0 0.00021678781
then O 0 0.00015329877
were O 0 0.00016010768
locally O 0 0.0003582117
injected O 0 0.00020605138
with O 0 0.0018920997
GR B-Chemical 0 0.9998789
55562 I-Chemical 0 0.99899393
( O 0 0.0012080099
an O 0 0.0004540276
antagonist O 0 0.4668934
of O 0 0.00040285217
5 O 0 0.000259074
- O 0 0.020336038
HT1B O 0 0.6084879
receptors O 0 0.011672826
) O 0 0.0027124493
or O 0 0.0016230874
CP B-Chemical 0 0.9999871
93129 I-Chemical 0 0.9999225
( O 0 0.0011392267
an O 0 0.000618086
agonist O 0 0.3176433
of O 0 0.0008705553
5 O 0 0.0008424231
- O 0 0.010033738
HT1B O 0 0.42640042
receptors O 0 0.014584064
) O 0 0.0071675265
. O 0 0.00752069

Given O 0 0.002875604
alone O 0 0.0022847487
to O 0 0.0016301529
any O 0 0.0017599042
accumbal O 0 0.99643445
subregion O 0 0.13968548
, O 0 0.011752428
GR B-Chemical 0 0.99973637
55562 I-Chemical 0 0.99796045
( O 0 0.0010199405
0 O 0 0.00038033203
. O 0 0.0002485446
1 O 0 0.0002570388
- O 0 0.00072332594
10 O 0 0.00018912122
microg O 0 0.00033621895
/ O 0 0.00587532
side O 0 0.052172396
) O 0 0.002723082
or O 0 0.0015149293
CP B-Chemical 0 0.99998665
93129 I-Chemical 0 0.99990726
( O 0 0.00071901135
0 O 0 0.0002596163
. O 0 0.00018474279
1 O 0 0.00021644207
- O 0 0.00068609655
10 O 0 0.00020659654
microg O 0 0.00040069892
/ O 0 0.005298601
side O 0 0.037502483
) O 0 0.0012682466
did O 0 0.00056718756
not O 0 0.00056944333
change O 0 0.0010424604
basal O 0 0.0036736224
locomotor O 0 0.4621647
activity O 0 0.0035896844
. O 0 0.0063334964

Systemic O 0 0.9833244
cocaine B-Chemical 1 0.99996305
( O 0 0.0059354226
10 O 0 0.0018199708
mg O 0 0.03787442
/ O 0 0.003520038
kg O 0 0.0025707565
) O 0 0.0015224549
significantly O 0 0.000874264
increased O 0 0.0010338825
the O 0 0.0012510993
locomotor O 0 0.29562393
activity O 0 0.001986231
of O 0 0.0035736011
rats O 0 0.0066988515
. O 0 0.007542667

GR B-Chemical 0 0.9990429
55562 I-Chemical 0 0.9959396
( O 0 0.004413309
0 O 0 0.0018441675
. O 0 0.0010939925
1 O 0 0.00090495404
- O 0 0.0015808882
10 O 0 0.00047329365
microg O 0 0.0006887695
/ O 0 0.0068318383
side O 0 0.04735236
) O 0 0.0013478204
, O 0 0.0004632593
administered O 0 0.00032118353
intra O 0 0.008554233
- O 0 0.05019439
accumbens O 0 0.5061802
shell O 0 0.0024159313
prior O 0 0.00015501768
to O 0 0.0003003405
cocaine B-Chemical 1 0.9999858
, O 0 0.0015981718
dose O 0 0.03795972
- O 0 0.1297823
dependently O 0 0.83718425
attenuated O 0 0.0028571454
the O 0 0.0015789535
psychostimulant O 0 0.9998136
- O 0 0.0924119
induced O 0 0.009019763
locomotor B-Disease 0 0.99967396
hyperactivity I-Disease 2 0.99998605
. O 0 0.008202188

Such O 0 0.0053351773
attenuation O 0 0.0042575053
was O 0 0.0020649591
not O 0 0.0012827298
found O 0 0.00094762933
in O 0 0.000746667
animals O 0 0.0005627496
which O 0 0.00065435533
had O 0 0.00047396112
been O 0 0.0004558833
injected O 0 0.00052142947
with O 0 0.001762196
GR B-Chemical 0 0.99922645
55562 I-Chemical 0 0.9875152
into O 0 0.00087313965
the O 0 0.0018161813
accumbens O 0 0.28781372
core O 0 0.0041975756
. O 0 0.007012466

When O 0 0.0027277581
injected O 0 0.0018899073
into O 0 0.0010981525
the O 0 0.001289935
accumbens O 0 0.700236
shell O 0 0.032530334
( O 0 0.0011277427
but O 0 0.00053283386
not O 0 0.00029453676
the O 0 0.00027591843
core O 0 0.00040667018
) O 0 0.0009584165
before O 0 0.0003118359
cocaine B-Chemical 1 0.9999937
, O 0 0.038594756
CP B-Chemical 0 0.9999896
93129 I-Chemical 0 0.99991333
( O 0 0.0007242754
0 O 0 0.00024401078
. O 0 0.00016334472
1 O 0 0.00018545263
- O 0 0.00067964464
10 O 0 0.00015078808
microg O 0 0.00030389449
/ O 0 0.008213243
side O 0 0.04616359
) O 0 0.0008948633
enhanced O 0 0.00022335032
the O 0 0.00025209875
locomotor O 0 0.3196884
response O 0 0.0003447671
to O 0 0.0003402259
cocaine B-Chemical 1 0.9999864
; O 0 0.0006043211
the O 0 0.00014597735
maximum O 0 0.00014035212
effect O 0 0.00017518943
being O 0 0.0002852135
observed O 0 0.00017882767
after O 0 0.00018306085
10 O 0 0.0002972542
microg O 0 0.00064844737
/ O 0 0.004594897
side O 0 0.018618282
of O 0 0.00202185
the O 0 0.002998058
agonist O 0 0.8212088
. O 0 0.007675845

The O 0 0.0031237972
later O 0 0.0021780583
enhancement O 0 0.002343953
was O 0 0.0012559935
attenuated O 0 0.0012091963
after O 0 0.0005843068
intra O 0 0.015056893
- O 0 0.07566751
accumbens O 0 0.6759894
shell O 0 0.008712628
treatment O 0 0.0006658743
with O 0 0.0024041976
GR B-Chemical 0 0.9997259
55562 I-Chemical 0 0.997695
( O 0 0.0013541287
1 O 0 0.00083020004
microg O 0 0.001599672
/ O 0 0.0077217813
side O 0 0.053453293
) O 0 0.00799452
. O 0 0.008144761

Our O 0 0.0036449074
findings O 0 0.002516373
indicate O 0 0.0012884161
that O 0 0.0017209287
cocaine B-Chemical 1 0.9999882
induced O 0 0.061995976
hyperlocomotion B-Disease 0 0.9999994
is O 0 0.0008945994
modified O 0 0.00042704542
by O 0 0.00034435972
5 O 0 0.0002937633
- O 0 0.01214221
HT1B O 0 0.50715554
receptor O 0 0.010401421
ligands O 0 0.007529678
microinjected O 0 0.0008316102
into O 0 0.000114522576
the O 0 0.00024616456
accumbens O 0 0.5884614
shell O 0 0.010906998
, O 0 0.00035746882
but O 0 0.0002251865
not O 0 0.00014720911
core O 0 0.00025023447
, O 0 0.00029485254
this O 0 0.00016043548
modification O 0 0.00029366193
consisting O 0 0.00013629108
in O 0 0.00015470774
inhibitory O 0 0.00062020647
and O 0 0.00032765954
facilitatory O 0 0.04251505
effects O 0 0.00025233562
of O 0 0.00023630743
the O 0 0.00022696373
5 O 0 0.00023678082
- O 0 0.04173885
HT1B O 0 0.86864525
receptor O 0 0.24876373
antagonist O 0 0.9833362
( O 0 0.06798607
GR B-Chemical 0 0.99990475
55562 I-Chemical 0 0.99901223
) O 0 0.0028724363
and O 0 0.0010635443
agonist O 0 0.91894454
( O 0 0.047347736
CP B-Chemical 0 0.99997294
93129 I-Chemical 0 0.99986386
) O 0 0.0040863445
, O 0 0.0032790904
respectively O 0 0.006761782
. O 0 0.007156002

In O 0 0.0037742998
other O 0 0.0025769079
words O 0 0.0022630147
, O 0 0.001638417
the O 0 0.0007972095
present O 0 0.0004750082
results O 0 0.00038399638
suggest O 0 0.00025907747
that O 0 0.0002948891
the O 0 0.00053812354
accumbal O 0 0.9946338
shell O 0 0.02852344
5 O 0 0.00032795552
- O 0 0.010594158
HT1B O 0 0.29691872
receptors O 0 0.0009667161
play O 0 0.00024786798
a O 0 0.00031774436
permissive O 0 0.00031576699
role O 0 0.00023458363
in O 0 0.0003548713
the O 0 0.00044838374
behavioural O 0 0.0028852194
response O 0 0.0009608768
to O 0 0.001189185
the O 0 0.002576173
psychostimulant O 0 0.9971782
. O 0 0.0066271354

Cocaine B-Chemical 0 0.9999138
related O 0 0.0045590643
chest B-Disease 0 0.085319236
pain I-Disease 0 0.9060625
: O 0 0.0030294578
are O 0 0.0016482066
we O 0 0.0013411772
seeing O 0 0.0026708723
the O 0 0.001985263
tip O 0 0.0038203695
of O 0 0.0043462384
an O 0 0.0066754287
iceberg O 0 0.03940095
? O 0 0.016418736

The O 0 0.0056396136
recreational O 0 0.016996747
use O 0 0.00455014
of O 0 0.006384224
cocaine B-Chemical 1 0.9999168
is O 0 0.004617175
on O 0 0.003531076
the O 0 0.005147912
increase O 0 0.0071885586
. O 0 0.012622131

The O 0 0.003951712
emergency O 0 0.0035611296
nurse O 0 0.0026095293
ought O 0 0.0018347427
to O 0 0.0010498666
be O 0 0.0009821025
familiar O 0 0.0012303184
with O 0 0.0007223109
some O 0 0.0006595464
of O 0 0.00081455987
the O 0 0.000976096
cardiovascular O 0 0.87962604
consequences O 0 0.00365578
of O 0 0.009171603
cocaine B-Chemical 1 0.99996734
use O 0 0.006126221
. O 0 0.007647618

In O 0 0.003821538
particular O 0 0.0022797696
, O 0 0.0022740285
the O 0 0.0012511504
tendency O 0 0.0015529032
of O 0 0.0020213507
cocaine B-Chemical 1 0.9999634
to O 0 0.00046772225
produce O 0 0.00033888765
chest B-Disease 0 0.039697632
pain I-Disease 0 0.8386973
ought O 0 0.00033126344
to O 0 0.00017097918
be O 0 0.00018926211
in O 0 0.00018151256
the O 0 0.00019350687
mind O 0 0.00044371432
of O 0 0.00023332686
the O 0 0.00020180919
emergency O 0 0.00028538538
nurse O 0 0.00021421001
when O 0 0.00012811089
faced O 0 0.00024742555
with O 0 0.00022632752
a O 0 0.00029799284
young O 0 0.0014492727
victim O 0 0.0015287305
of O 0 0.00054713886
chest B-Disease 0 0.07951229
pain I-Disease 0 0.889534
who O 0 0.00085080886
is O 0 0.00062959414
otherwise O 0 0.0010110257
at O 0 0.0012300477
low O 0 0.002940888
risk O 0 0.10907301
. O 0 0.007727165

The O 0 0.003183626
mechanism O 0 0.0023050704
of O 0 0.0024720163
chest B-Disease 0 0.07014424
pain I-Disease 0 0.88378
related O 0 0.0007450013
to O 0 0.0009217967
cocaine B-Chemical 1 0.99994385
use O 0 0.00082023925
is O 0 0.0006670766
discussed O 0 0.00059970986
and O 0 0.00089072814
treatment O 0 0.0013040673
dilemmas O 0 0.0023035754
are O 0 0.002419576
discussed O 0 0.0036685956
. O 0 0.0069189817

Finally O 0 0.004886894
, O 0 0.003929871
moral O 0 0.004559017
issues O 0 0.0017875553
relating O 0 0.00092422136
to O 0 0.0008512532
the O 0 0.00077716564
testing O 0 0.000810021
of O 0 0.0010257532
potential O 0 0.0033862973
cocaine B-Chemical 1 0.99998
users O 0 0.009894364
will O 0 0.0016514048
be O 0 0.0025693718
addressed O 0 0.0035412228
. O 0 0.0074371425

Crossover O 0 0.013370803
comparison O 0 0.0024005326
of O 0 0.0019739836
efficacy O 0 0.0018086109
and O 0 0.0012466777
preference O 0 0.0012994602
for O 0 0.0015048647
rizatriptan B-Chemical 0 0.9999908
10 O 0 0.0007662811
mg O 0 0.034192864
versus O 0 0.0016264244
ergotamine B-Chemical 1 0.9999981
/ O 0 0.31161082
caffeine B-Chemical 0 0.9999535
in O 0 0.016159352
migraine B-Disease 0 0.99997807
. O 0 0.009398866

Rizatriptan B-Chemical 0 0.999874
is O 0 0.003184902
a O 0 0.002215887
selective O 0 0.0026951453
5 B-Chemical 0 0.0012257918
- I-Chemical 0 0.10332798
HT I-Chemical 0 0.9994229
( O 0 0.0025079707
1B O 0 0.0013173943
/ O 0 0.009851581
1D O 0 0.005180425
) O 0 0.0021538741
receptor O 0 0.048945844
agonist O 0 0.64909774
with O 0 0.00048140602
rapid O 0 0.0019735468
oral O 0 0.27894226
absorption O 0 0.660732
and O 0 0.00037119782
early O 0 0.00051316735
onset O 0 0.0006954843
of O 0 0.00039928997
action O 0 0.0006752164
in O 0 0.00046023048
the O 0 0.0007205084
acute O 0 0.7026609
treatment O 0 0.0058387727
of O 0 0.045103103
migraine B-Disease 0 0.99999046
. O 0 0.009971197

This O 0 0.0048412634
randomized O 0 0.002874475
double O 0 0.0024414859
- O 0 0.008717501
blind O 0 0.013922061
crossover O 0 0.0035251887
outpatient O 0 0.0006718251
study O 0 0.00046550803
assessed O 0 0.0002640462
the O 0 0.0002650963
preference O 0 0.00033882062
for O 0 0.0002919512
1 O 0 0.00050407206
rizatriptan B-Chemical 0 0.999974
10 O 0 0.00022223468
mg O 0 0.010952492
tablet O 0 0.09218598
to O 0 0.00017905203
2 O 0 0.0003856603
ergotamine B-Chemical 1 0.9999926
1 O 0 0.00022964943
mg O 0 0.024997719
/ O 0 0.023061467
caffeine B-Chemical 0 0.99988544
100 O 0 0.0013616903
mg O 0 0.04144823
tablets O 0 0.071236424
in O 0 0.00022115832
439 O 0 0.0010467276
patients O 0 0.00030960262
treating O 0 0.00040642798
a O 0 0.00052498904
single O 0 0.0013636576
migraine B-Disease 0 0.9999945
attack O 0 0.6703972
with O 0 0.001581759
each O 0 0.001463767
therapy O 0 0.004493917
. O 0 0.005875821

Of O 0 0.004695831
patients O 0 0.0027782707
expressing O 0 0.0014052212
a O 0 0.0015751446
preference O 0 0.0013995382
( O 0 0.0013417054
89 O 0 0.001277761
. O 0 0.0005017409
1 O 0 0.00042614693
% O 0 0.000488769
) O 0 0.00066158647
, O 0 0.00043686526
more O 0 0.00027295263
than O 0 0.00015115808
twice O 0 0.00014196867
as O 0 0.00014897011
many O 0 0.00017214903
preferred O 0 0.000400643
rizatriptan B-Chemical 0 0.9999925
to O 0 0.00074180803
ergotamine B-Chemical 1 0.9999995
/ O 0 0.26428634
caffeine B-Chemical 0 0.9999677
( O 0 0.00094842067
69 O 0 0.00034675057
. O 0 0.00015958307
9 O 0 0.00015769484
vs O 0 0.00020832318
. O 0 0.00017158707
30 O 0 0.00017421476
. O 0 0.00020050228
1 O 0 0.00024187374
% O 0 0.0003363853
, O 0 0.00040996048
p O 0 0.0004064997
< O 0 0.0004723812
or O 0 0.0006778554
= O 0 0.0015748746
0 O 0 0.0015528211
. O 0 0.0021515877
001 O 0 0.049946304
) O 0 0.0066422415
. O 0 0.008372001

Faster O 0 0.04590364
relief O 0 0.010669766
of O 0 0.005636304
headache B-Disease 0 0.9998785
was O 0 0.0013027875
the O 0 0.0006879127
most O 0 0.0006026065
important O 0 0.00031444157
reason O 0 0.00027362411
for O 0 0.00029321515
preference O 0 0.00045381382
, O 0 0.00047412087
cited O 0 0.00068600697
by O 0 0.0002692054
67 O 0 0.00044631766
. O 0 0.00019790645
3 O 0 0.0001711671
% O 0 0.00021551088
of O 0 0.00024433483
patients O 0 0.00069374783
preferring O 0 0.28512043
rizatriptan B-Chemical 0 0.99999297
and O 0 0.0003835661
54 O 0 0.00046483008
. O 0 0.00023618105
2 O 0 0.00026343743
% O 0 0.0003625436
of O 0 0.00046877493
patients O 0 0.000905481
who O 0 0.0016152337
preferred O 0 0.003087447
ergotamine B-Chemical 1 0.99999666
/ O 0 0.3234724
caffeine B-Chemical 0 0.99985015
. O 0 0.009044667

The O 0 0.0043750126
co O 0 0.25824258
- O 0 0.009081251
primary O 0 0.0017416981
endpoint O 0 0.0017996782
of O 0 0.0011071011
being O 0 0.0019323666
pain B-Disease 0 0.7534723
free O 0 0.0006426043
at O 0 0.00043275437
2 O 0 0.00046291214
h O 0 0.00054179266
was O 0 0.0005983368
also O 0 0.0007253073
in O 0 0.001103672
favor O 0 0.002356524
of O 0 0.011251386
rizatriptan B-Chemical 0 0.9999783
. O 0 0.008977323

Forty O 0 0.008363693
- O 0 0.0059770206
nine O 0 0.0016688147
percent O 0 0.0010491067
of O 0 0.0010550825
patients O 0 0.001040375
were O 0 0.0006937003
pain B-Disease 0 0.57500666
free O 0 0.00050621474
2 O 0 0.00031663032
h O 0 0.0003287431
after O 0 0.00026811167
rizatriptan B-Chemical 0 0.9999881
, O 0 0.0003719364
compared O 0 0.00013567362
with O 0 0.00020701396
24 O 0 0.00019120784
. O 0 0.0001410951
3 O 0 0.00013148588
% O 0 0.00017855999
treated O 0 0.00023263335
with O 0 0.0016745158
ergotamine B-Chemical 1 0.9999995
/ O 0 0.3108926
caffeine B-Chemical 0 0.99997306
( O 0 0.0009143061
p O 0 0.00023019883
< O 0 0.00017332089
or O 0 0.00020401397
= O 0 0.0005379523
0 O 0 0.0002960384
. O 0 0.00026671452
001 O 0 0.068420924
) O 0 0.0009837628
, O 0 0.0017016805
rizatriptan B-Chemical 0 0.99998367
being O 0 0.0006001959
superior O 0 0.00052658975
within O 0 0.0003820456
1 O 0 0.00072809344
h O 0 0.0011946323
of O 0 0.002240332
treatment O 0 0.0042608418
. O 0 0.006791109

Headache B-Disease 2 0.9617573
relief O 0 0.0065269535
at O 0 0.0016792582
2 O 0 0.001265106
h O 0 0.0010273394
was O 0 0.00073154416
75 O 0 0.0006626608
. O 0 0.00042621535
9 O 0 0.00036847984
% O 0 0.00041613888
for O 0 0.00048787848
rizatriptan B-Chemical 0 0.99997914
and O 0 0.000430252
47 O 0 0.00050348765
. O 0 0.00020166492
3 O 0 0.00017558344
% O 0 0.00025836384
for O 0 0.00045259684
ergotamine B-Chemical 1 0.9999989
/ O 0 0.22232878
caffeine B-Chemical 0 0.9999678
( O 0 0.0009090542
p O 0 0.00023708986
< O 0 0.00017499246
or O 0 0.00020289699
= O 0 0.00056205166
0 O 0 0.00028702177
. O 0 0.0002413439
001 O 0 0.06834775
) O 0 0.0005886904
, O 0 0.00039455417
with O 0 0.00080392737
rizatriptan B-Chemical 0 0.9999924
being O 0 0.00058559043
superior O 0 0.0005730095
to O 0 0.00041529437
ergotamine B-Chemical 1 0.99999857
/ O 0 0.08100414
caffeine B-Chemical 0 0.99959666
within O 0 0.00042404557
30 O 0 0.00063378253
min O 0 0.0011402968
of O 0 0.0020763879
dosing O 0 0.0066580386
. O 0 0.0058470718

Almost O 0 0.0051950305
36 O 0 0.0028752484
% O 0 0.0020979652
of O 0 0.0015198998
patients O 0 0.0018969707
taking O 0 0.01720955
rizatriptan B-Chemical 0 0.9999913
were O 0 0.0007185065
pain B-Disease 0 0.58778614
free O 0 0.00033123407
at O 0 0.0002044418
2 O 0 0.00019498801
h O 0 0.00019629586
and O 0 0.00018866014
had O 0 0.00016040381
no O 0 0.00014373536
recurrence O 0 0.15852132
or O 0 0.00017055226
need O 0 0.00012703711
for O 0 0.00013803753
additional O 0 0.00012483727
medication O 0 0.0016737299
within O 0 9.445388e-05
24 O 0 0.00014643924
h O 0 0.0001588204
, O 0 0.00017528786
compared O 0 0.00010211856
to O 0 0.00012000961
20 O 0 0.00014463121
% O 0 0.00017494638
of O 0 0.00019380951
patients O 0 0.00035048637
on O 0 0.00025971976
ergotamine B-Chemical 1 0.9999993
/ O 0 0.2520508
caffeine B-Chemical 0 0.999962
( O 0 0.0010169371
p O 0 0.0004215612
< O 0 0.0004244286
or O 0 0.0005985344
= O 0 0.0014338153
0 O 0 0.0013920486
. O 0 0.0019510968
001 O 0 0.048048273
) O 0 0.0062205787
. O 0 0.00791131

Rizatriptan B-Chemical 0 0.9998683
was O 0 0.0027909651
also O 0 0.001610056
superior O 0 0.0022332848
to O 0 0.0015939251
ergotamine B-Chemical 1 0.99999905
/ O 0 0.41982916
caffeine B-Chemical 0 0.9999504
in O 0 0.00042142379
the O 0 0.00024514174
proportions O 0 0.00021318227
of O 0 0.0002481338
patients O 0 0.00031483933
with O 0 0.00027155588
no O 0 0.0003998141
nausea B-Disease 2 0.9999995
, O 0 0.037741423
vomiting B-Disease 0 0.9999974
, O 0 0.18446621
phonophobia B-Disease 0 1.0
or O 0 0.0051057637
photophobia B-Disease 0 0.9999968
and O 0 0.0004909582
for O 0 0.00018591368
patients O 0 0.00024779333
with O 0 0.00016618022
normal O 0 0.00024153313
function O 0 0.00016662941
2 O 0 0.00016188441
h O 0 0.00018094233
after O 0 0.00014861724
drug O 0 0.1007688
intake O 0 0.37579685
( O 0 0.00056225015
p O 0 0.00036988588
< O 0 0.00040182506
or O 0 0.0005837303
= O 0 0.0014284885
0 O 0 0.0013776171
. O 0 0.0019327261
001 O 0 0.051044144
) O 0 0.006188009
. O 0 0.007850631

More O 0 0.011066858
patients O 0 0.0034644587
were O 0 0.0019112565
( O 0 0.0017605794
completely O 0 0.0009790662
, O 0 0.0009835131
very O 0 0.0007379153
or O 0 0.00047448982
somewhat O 0 0.0008205135
) O 0 0.0007231265
satisfied O 0 0.00038844012
2 O 0 0.00021912862
h O 0 0.00020657822
after O 0 0.00012946987
treatment O 0 0.0002558947
with O 0 0.0011674778
rizatriptan B-Chemical 0 0.9999964
( O 0 0.00066423265
69 O 0 0.00032427628
. O 0 0.0001532365
8 O 0 0.000147471
% O 0 0.00019699804
) O 0 0.000257968
than O 0 0.0001122342
at O 0 0.00012438181
2 O 0 0.00013868518
h O 0 0.00014996034
after O 0 0.00010289488
treatment O 0 0.00024361628
with O 0 0.0025759107
ergotamine B-Chemical 1 0.99999964
/ O 0 0.34690568
caffeine B-Chemical 0 0.9999747
( O 0 0.0011220596
38 O 0 0.00040211435
. O 0 0.0001993446
6 O 0 0.0001891894
% O 0 0.00030383767
, O 0 0.00037593013
p O 0 0.0003796666
< O 0 0.0004475707
or O 0 0.0006490561
= O 0 0.0015245772
0 O 0 0.0015094989
. O 0 0.0021011662
001 O 0 0.049813382
) O 0 0.006542397
. O 0 0.00826207

Recurrence O 0 0.12096841
rates O 0 0.003216639
were O 0 0.002074398
31 O 0 0.001820793
. O 0 0.0010562823
4 O 0 0.0007832525
% O 0 0.0008775535
with O 0 0.0010985417
rizatriptan B-Chemical 0 0.9999732
and O 0 0.0007198076
15 O 0 0.00049562944
. O 0 0.00052196305
3 O 0 0.0006135812
% O 0 0.0011185836
with O 0 0.0030031076
ergotamine B-Chemical 1 0.9999958
/ O 0 0.30768245
caffeine B-Chemical 0 0.9998355
. O 0 0.009942772

Both O 0 0.011480859
active O 0 0.011825623
treatments O 0 0.01080208
were O 0 0.010209588
well O 0 0.011527562
tolerated O 0 0.029822761
. O 0 0.019917723

The O 0 0.0032173481
most O 0 0.0027317875
common O 0 0.0022642508
adverse O 0 0.2648753
events O 0 0.020491559
( O 0 0.0015206047
incidence O 0 0.005757882
> O 0 0.0018536908
or O 0 0.0004390288
= O 0 0.0007802897
5 O 0 0.00023506994
% O 0 0.00026792745
in O 0 0.00019805536
one O 0 0.00017969939
group O 0 0.00027405276
) O 0 0.00047945054
after O 0 0.00022964067
rizatriptan B-Chemical 0 0.9999963
and O 0 0.011232347
ergotamine B-Chemical 1 0.99999964
/ O 0 0.36176208
caffeine B-Chemical 0 0.9999788
, O 0 0.0012819585
respectively O 0 0.0040774117
, O 0 0.000431199
were O 0 0.00036400743
dizziness B-Disease 2 0.9998766
( O 0 0.00042864546
6 O 0 0.00013076319
. O 0 0.00012917318
7 O 0 0.0001209354
and O 0 0.00015037326
5 O 0 0.00013627237
. O 0 0.00014574008
3 O 0 0.00014784453
% O 0 0.00023759856
) O 0 0.0005857609
, O 0 0.0018640511
nausea B-Disease 2 0.999995
( O 0 0.00077274186
4 O 0 0.00017643027
. O 0 0.00015572317
2 O 0 0.00015304345
and O 0 0.00017344738
8 O 0 0.00016264223
. O 0 0.00015331602
5 O 0 0.00015393946
% O 0 0.00024000792
) O 0 0.00042294918
and O 0 0.0005779841
somnolence B-Disease 2 0.99994886
( O 0 0.0005627689
5 O 0 0.0002528139
. O 0 0.00027988365
5 O 0 0.00031994574
and O 0 0.0005072979
2 O 0 0.000673754
. O 0 0.0009220501
3 O 0 0.0014086564
% O 0 0.002910617
) O 0 0.0057381797
. O 0 0.007922483

Severe O 0 0.59015375
ocular B-Disease 0 0.7478517
and I-Disease 0 0.0042179767
orbital I-Disease 0 0.49631223
toxicity I-Disease 2 0.998137
after O 0 0.0012953114
intracarotid O 0 0.96668977
injection O 0 0.0021437418
of O 0 0.0021229198
carboplatin B-Chemical 1 0.9974542
for O 0 0.0032748233
recurrent O 0 0.8045508
glioblastomas B-Disease 0 0.9994374
. O 0 0.010588197

BACKGROUND O 0 0.047279656
: O 0 0.009908424
Glioblastoma B-Disease 0 0.9823204
is O 0 0.0025261967
a O 0 0.0029953641
malignant B-Disease 0 0.9969228
tumor I-Disease 0 0.99488777
that O 0 0.001088455
occurs O 0 0.0011280542
in O 0 0.0012739943
the O 0 0.0017441621
cerebrum O 0 0.46480113
during O 0 0.0027370227
adulthood O 0 0.19077523
. O 0 0.008614391

With O 0 0.003856212
current O 0 0.0028987594
treatment O 0 0.0017039127
regimens O 0 0.001450257
including O 0 0.00070166204
combined O 0 0.00089135556
surgery O 0 0.0012153167
, O 0 0.00078755897
radiation O 0 0.13436799
and O 0 0.000675329
chemotherapy O 0 0.05065614
, O 0 0.00037277056
the O 0 0.00018452223
average O 0 0.00014581905
life O 0 0.0002520579
expectancy O 0 0.00033677922
of O 0 0.00032646692
the O 0 0.0003220147
patients O 0 0.0005139506
is O 0 0.00042235508
limited O 0 0.0005057809
to O 0 0.00068070187
approximately O 0 0.0011379919
1 O 0 0.0019267842
year O 0 0.0034643975
. O 0 0.0063325544

Therefore O 0 0.003907259
, O 0 0.0035997578
patients O 0 0.0026120772
with O 0 0.0023811825
glioblastoma B-Disease 2 0.9986162
sometimes O 0 0.0040513547
have O 0 0.0008079381
intracarotid O 0 0.9408316
injection O 0 0.0011830792
of O 0 0.00090569205
carcinostatics O 0 0.18370427
added O 0 0.0007777536
to O 0 0.00089828036
the O 0 0.0013642305
treatment O 0 0.002614068
regimen O 0 0.0055207647
. O 0 0.0067561027

Generally O 0 0.0052250884
, O 0 0.005706438
carboplatin B-Chemical 1 0.99033153
is O 0 0.0019791506
said O 0 0.0015837989
to O 0 0.00067868055
have O 0 0.00058089005
milder O 0 0.043905776
side O 0 0.02425107
effects O 0 0.0008071212
than O 0 0.00044514157
cisplatin B-Chemical 1 0.9995123
, O 0 0.0009494921
whose O 0 0.00089963916
ocular B-Disease 0 0.71906155
and I-Disease 0 0.0011364949
orbital I-Disease 0 0.48237693
toxicity I-Disease 2 0.9955325
are O 0 0.0014386359
well O 0 0.0020072307
known O 0 0.0042025708
. O 0 0.0064500705

However O 0 0.0048860344
, O 0 0.0034322385
we O 0 0.0015336353
experienced O 0 0.001493802
a O 0 0.001185396
case O 0 0.00085991475
of O 0 0.0009106988
severe O 0 0.15522659
ocular B-Disease 0 0.914624
and I-Disease 0 0.0014170753
orbital I-Disease 0 0.6299205
toxicity I-Disease 2 0.99848664
after O 0 0.00032420055
intracarotid O 0 0.9456699
injection O 0 0.00075401465
of O 0 0.00090735214
carboplatin B-Chemical 1 0.9980422
, O 0 0.0014391409
which O 0 0.0012800606
is O 0 0.0016173074
infrequently O 0 0.0037902184
reported O 0 0.004206339
. O 0 0.00650451

CASE O 0 0.5647928
: O 0 0.0063023223
A O 0 0.042674582
58 O 0 0.0035812755
- O 0 0.0054149036
year O 0 0.001457124
- O 0 0.0034806577
old O 0 0.000891666
man O 0 0.008659289
received O 0 0.0004359064
an O 0 0.0006822004
intracarotid O 0 0.92593527
injection O 0 0.00076278765
of O 0 0.00069818174
carboplatin B-Chemical 1 0.9968437
for O 0 0.0006689707
recurrent O 0 0.5426004
glioblastomas B-Disease 0 0.9993581
in O 0 0.00094674237
his O 0 0.0015984905
left O 0 0.0030499236
temporal O 0 0.090860866
lobe O 0 0.780087
. O 0 0.007185846

He O 0 0.008709722
complained O 0 0.008636707
of O 0 0.003085773
pain B-Disease 0 0.9007855
and I-Disease 0 0.0022268975
visual I-Disease 0 0.8674053
disturbance I-Disease 0 0.6748576
in I-Disease 0 0.0007320256
the I-Disease 0 0.0006527714
ipsilateral I-Disease 0 0.0032854318
eye I-Disease 0 0.011861042
30 O 0 0.0007287029
h O 0 0.000986253
after O 0 0.00108826
the O 0 0.0021990591
injection O 0 0.0048998557
. O 0 0.0069367127

Various O 0 0.008751658
ocular O 0 0.62737316
symptoms O 0 0.20360243
and O 0 0.002668851
findings O 0 0.002396797
caused O 0 0.0022016827
by O 0 0.003832254
carboplatin B-Chemical 1 0.9997031
toxicity B-Disease 2 0.9993787
were O 0 0.0051051364
seen O 0 0.0057980223
. O 0 0.009299459

RESULTS O 0 0.0063619395
: O 0 0.004647406
He O 0 0.003735055
was O 0 0.0015358771
treated O 0 0.001184466
with O 0 0.0010271154
intravenous O 0 0.047504365
administration O 0 0.007888118
of O 0 0.0014024884
corticosteroids O 1 0.9998553
and O 0 0.0064605596
glycerin B-Chemical 0 0.99968195
for O 0 0.0005975691
6 O 0 0.00050966104
days O 0 0.0005819696
after O 0 0.0008749811
the O 0 0.0019014865
injection O 0 0.0044524274
. O 0 0.0064667305

Although O 0 0.0031809728
the O 0 0.002714039
intraocular O 0 0.98093355
pressure O 0 0.44220832
elevation O 0 0.15023099
caused O 0 0.00081417465
by O 0 0.0007519681
secondary O 0 0.035010003
acute O 0 0.96448994
angle O 0 0.95033026
- O 0 0.4123686
closure O 0 0.56421584
glaucoma B-Disease 2 0.99999917
decreased O 0 0.0021180059
and O 0 0.0017698945
ocular B-Disease 0 0.9996425
pain I-Disease 0 0.99965954
diminished O 0 0.000864543
, O 0 0.0010555313
inexorable O 0 0.22186895
papilledema B-Disease 0 0.999998
and O 0 0.009537352
exudative O 0 0.9999926
retinal B-Disease 0 0.9982913
detachment I-Disease 0 0.99780685
continued O 0 0.0012959888
for O 0 0.0012662356
3 O 0 0.0017437885
weeks O 0 0.0024204024
. O 0 0.00559185

Finally O 0 0.004320641
, O 0 0.0031633887
6 O 0 0.0014708975
weeks O 0 0.00092939194
later O 0 0.0008629941
, O 0 0.0012296312
diffuse O 0 0.26740596
chorioretinal B-Disease 0 0.9999969
atrophy I-Disease 2 0.99999857
with O 0 0.016837098
optic B-Disease 0 0.99959546
atrophy I-Disease 2 0.9999256
occurred O 0 0.0005423718
and O 0 0.00043824414
the O 0 0.00043025304
vision O 0 0.10624127
in O 0 0.0006512446
his O 0 0.0011401066
left O 0 0.0019202837
eye O 0 0.024700742
was O 0 0.0025558756
lost O 0 0.0041131256
. O 0 0.0068566725

CONCLUSION O 0 0.017591892
: O 0 0.003514665
When O 0 0.0015622305
performing O 0 0.0015267637
intracarotid O 0 0.8842455
injection O 0 0.0019858566
of O 0 0.0016325426
carboplatin B-Chemical 1 0.9984169
, O 0 0.0010268228
we O 0 0.00034726833
must O 0 0.00031106453
be O 0 0.00042512116
aware O 0 0.00048596947
of O 0 0.0006809783
its O 0 0.0014685894
potentially O 0 0.0034288068
blinding O 0 0.27181077
ocular B-Disease 0 0.99963784
toxicity I-Disease 2 0.9999434
. O 0 0.011145506

It O 0 0.004808413
is O 0 0.002583471
recommended O 0 0.0015815543
that O 0 0.00096296455
further O 0 0.00081107765
studies O 0 0.0007054735
and O 0 0.0006444725
investigations O 0 0.0005855897
are O 0 0.00039364013
undertaken O 0 0.00032749906
in O 0 0.0003689199
the O 0 0.00038747667
effort O 0 0.0004853887
to O 0 0.0004356075
minimize O 0 0.00047663058
such O 0 0.0010050334
severe O 0 0.09248059
side O 0 0.06358677
effects O 0 0.0059775924
. O 0 0.007256358

Visual B-Disease 0 0.9969247
hallucinations I-Disease 2 0.9999819
associated O 0 0.026357455
with O 0 0.040491063
zonisamide B-Chemical 1 0.9999542
. O 0 0.03269192

Zonisamide B-Chemical 0 0.9997905
is O 0 0.0035397946
a O 0 0.0025498206
broad O 0 0.0026126474
- O 0 0.010860934
spectrum O 0 0.002914784
antiepileptic O 0 0.9989686
drug O 0 0.21492755
used O 0 0.00067295093
to O 0 0.000663444
treat O 0 0.0010200639
various O 0 0.0012370234
types O 0 0.0016837423
of O 0 0.0073691877
seizures B-Disease 0 0.99998856
. O 0 0.010999899

Although O 0 0.004612023
visual B-Disease 0 0.980688
hallucinations I-Disease 2 0.9999982
have O 0 0.0013886555
not O 0 0.0008575855
been O 0 0.00066086266
reported O 0 0.00055841584
as O 0 0.00039460947
an O 0 0.00052867667
adverse O 0 0.17319521
effect O 0 0.000313288
of O 0 0.0004094513
this O 0 0.0003398463
agent O 0 0.019787766
, O 0 0.00035511295
we O 0 0.000119000666
describe O 0 0.00012814582
three O 0 0.00010399404
patients O 0 0.00020530578
who O 0 0.00022644365
experienced O 0 0.00019887587
complex O 0 0.00042165385
visual B-Disease 0 0.9922019
hallucinations I-Disease 2 0.9999999
and O 0 0.0005228848
altered O 0 0.00030931705
mental O 0 0.031152884
status O 0 0.0006264189
after O 0 0.00027535082
zonisamide B-Chemical 1 0.9999939
treatment O 0 0.0006063672
was O 0 0.00045232018
begun O 0 0.00065415027
or O 0 0.0007805415
its O 0 0.0025699977
dosage O 0 0.07384188
increased O 0 0.00485955
. O 0 0.0068789483

All O 0 0.0031789215
three O 0 0.0018467726
had O 0 0.0015848828
been O 0 0.0012824641
diagnosed O 0 0.002333621
earlier O 0 0.0011243396
with O 0 0.0028412393
epilepsy B-Disease 2 0.9999962
, O 0 0.0013788969
and O 0 0.0006401263
their O 0 0.0007118691
electroencephalogram O 0 0.56064713
( O 0 0.0016461851
EEG O 0 0.79340637
) O 0 0.0016990053
findings O 0 0.0019780186
were O 0 0.0026108688
abnormal O 0 0.008597235
. O 0 0.007326679

During O 0 0.003162004
monitoring O 0 0.0032649469
, O 0 0.005077897
visual B-Disease 0 0.9921819
hallucinations I-Disease 2 0.9999995
did O 0 0.0015458644
not O 0 0.0005452735
correlate O 0 0.00044335367
with O 0 0.0005737604
EEG O 0 0.8201547
readings O 0 0.00047246114
, O 0 0.0004190199
nor O 0 0.0003314034
did O 0 0.00037580004
video O 0 0.0006151833
recording O 0 0.00046065616
capture O 0 0.000566588
any O 0 0.0005911413
of O 0 0.0009958209
the O 0 0.0013768589
described O 0 0.0021409162
events O 0 0.008011664
. O 0 0.007007534

None O 0 0.0076840944
of O 0 0.0042557525
the O 0 0.0029979495
patients O 0 0.003026039
had O 0 0.0022724657
experienced O 0 0.003723907
visual B-Disease 0 0.9852498
hallucinations I-Disease 2 0.99999785
before O 0 0.002825094
this O 0 0.0041445605
event O 0 0.011529855
. O 0 0.010150005

The O 0 0.0034234119
only O 0 0.0026288817
recent O 0 0.0019802812
change O 0 0.001492224
in O 0 0.0010297953
their O 0 0.0008997854
treatment O 0 0.00088043464
was O 0 0.00067147607
the O 0 0.0005813861
introduction O 0 0.00069074554
or O 0 0.0008756808
increased O 0 0.0017402057
dosage O 0 0.17403235
of O 0 0.027963242
zonisamide B-Chemical 1 0.99999106
. O 0 0.009799137

With O 0 0.004344939
either O 0 0.0029115442
discontinuation O 0 0.38232434
or O 0 0.0015248727
decreased O 0 0.0015744839
dosage O 0 0.027779689
of O 0 0.0009411425
the O 0 0.00076628913
drug O 0 0.1790036
the O 0 0.00080991874
symptoms O 0 0.099945486
disappeared O 0 0.0011738375
and O 0 0.0014163507
did O 0 0.001961685
not O 0 0.0027114553
recur O 0 0.020757033
. O 0 0.007343838

Further O 0 0.0055957115
observations O 0 0.004176233
and O 0 0.003685709
reports O 0 0.003088636
will O 0 0.0023306003
help O 0 0.002471726
clarify O 0 0.0018779769
this O 0 0.0035966788
adverse O 0 0.20853426
effect O 0 0.0072979024
. O 0 0.011676842

Until O 0 0.0046521747
then O 0 0.0028339035
, O 0 0.0027109676
clinicians O 0 0.0018391851
need O 0 0.0010226509
to O 0 0.0008338398
be O 0 0.0008282966
aware O 0 0.00075092376
of O 0 0.0008168969
this O 0 0.00081067154
possible O 0 0.0011616639
complication O 0 0.16824245
associated O 0 0.0029134774
with O 0 0.013020233
zonisamide B-Chemical 1 0.9999851
. O 0 0.009395692

Anti O 0 0.974258
- O 0 0.57456726
epileptic B-Disease 0 0.99993896
drugs O 0 0.8972546
- O 0 0.02219953
induced O 0 0.0038823644
de O 0 0.0255609
novo O 0 0.043102678
absence B-Disease 0 0.079055175
seizures I-Disease 0 0.9999976
. O 0 0.01929599

The O 0 0.0030269139
authors O 0 0.0017633135
present O 0 0.0012875084
three O 0 0.00083785446
patients O 0 0.00097515865
with O 0 0.0007669898
de O 0 0.0033595467
novo O 0 0.008878034
absence B-Disease 0 0.017876195
epilepsy I-Disease 2 0.99999964
after O 0 0.0006981013
administration O 0 0.033737544
of O 0 0.015284076
carbamazepine B-Chemical 1 0.9999995
and O 0 0.06683647
vigabatrin B-Chemical 0 0.99999046
. O 0 0.008962596

Despite O 0 0.0036970412
the O 0 0.0024433415
underlying O 0 0.0029934223
diseases O 0 0.79888064
, O 0 0.0021738405
the O 0 0.0009258408
prognosis O 0 0.7080004
for O 0 0.00084487424
drug O 0 0.70954645
- O 0 0.018258583
induced O 0 0.00038110878
de O 0 0.010987164
novo O 0 0.012914393
absence B-Disease 0 0.01094968
seizure I-Disease 2 0.99999905
is O 0 0.00044036898
good O 0 0.00033843532
because O 0 0.00017776969
it O 0 0.00024612443
subsides O 0 0.0003802677
rapidly O 0 0.0003103849
after O 0 0.00022314792
discontinuing O 0 0.0099280905
the O 0 0.0003963339
use O 0 0.0005811692
of O 0 0.0009965061
the O 0 0.0016201616
offending O 0 0.58496845
drugs O 0 0.42667717
. O 0 0.006783542

The O 0 0.0051925573
gamma B-Chemical 0 0.9896807
- I-Chemical 0 0.84826005
aminobutyric I-Chemical 0 0.9999715
acid I-Chemical 0 0.9972222
- O 0 0.116420045
transmitted O 0 0.0014173944
thalamocortical O 0 0.068259545
circuitry O 0 0.0012617764
accounts O 0 0.00035465418
for O 0 0.00029084826
a O 0 0.00034599556
major O 0 0.00032470847
part O 0 0.00026753
of O 0 0.00035749664
the O 0 0.00037816534
underlying O 0 0.00068820955
neurophysiology O 0 0.0035296734
of O 0 0.0010948214
the O 0 0.0017049666
absence B-Disease 0 0.017498216
epilepsy I-Disease 2 0.99999774
. O 0 0.0112810945

Because O 0 0.0042054853
drug O 0 0.35303283
- O 0 0.010975584
induced O 0 0.0016422488
de O 0 0.008924508
novo O 0 0.015394644
absence B-Disease 0 0.01889494
seizure I-Disease 2 0.9999988
is O 0 0.0014855977
rare O 0 0.00983304
, O 0 0.0011352646
pro O 0 0.11505765
- O 0 0.012917992
absence O 0 0.00033878267
drugs O 0 0.06522047
can O 0 0.00037551284
only O 0 0.0005205096
be O 0 0.000656314
considered O 0 0.0008587496
a O 0 0.0016422762
promoting O 0 0.0028061487
factor O 0 0.042733096
. O 0 0.009196639

The O 0 0.0030727978
underlying O 0 0.0027720816
epileptogenecity O 0 0.02132817
of O 0 0.0014111061
the O 0 0.00086131913
patients O 0 0.00090289605
or O 0 0.00044777806
the O 0 0.0003570169
synergistic O 0 0.00054811605
effects O 0 0.0005454008
of O 0 0.00044066127
the O 0 0.00035152503
accompanying O 0 0.001212802
drugs O 0 0.088265
is O 0 0.00029605196
required O 0 0.00021846336
to O 0 0.00031491165
trigger O 0 0.00042818356
the O 0 0.0006969994
de O 0 0.004914685
novo O 0 0.010348365
absence B-Disease 0 0.018243078
seizure I-Disease 2 0.9999877
. O 0 0.009956493

The O 0 0.0029636428
possibility O 0 0.001989014
of O 0 0.0025474594
drug O 0 0.8010103
- O 0 0.07796544
induced O 0 0.0015603068
aggravation O 0 0.89718425
should O 0 0.00033751928
be O 0 0.0002996666
considered O 0 0.0002184565
whenever O 0 0.000215901
an O 0 0.0002668753
unexpected O 0 0.0003434861
increase O 0 0.00021656572
in O 0 0.00052738946
seizure B-Disease 2 0.99996173
frequency O 0 0.0005774868
and O 0 0.00041974828
/ O 0 0.0033396294
or O 0 0.00031328952
new O 0 0.0009752384
seizure B-Disease 2 0.99988425
types O 0 0.0003010173
appear O 0 0.00032938563
following O 0 0.00035026757
a O 0 0.0006475324
change O 0 0.0008892281
in O 0 0.0013851869
drug O 0 0.19173785
treatment O 0 0.004660225
. O 0 0.00656507

By O 0 0.004076769
understanding O 0 0.0021066726
the O 0 0.00144852
underlying O 0 0.0012279605
mechanism O 0 0.0008437708
of O 0 0.0017816009
absence B-Disease 0 0.07168396
epilepsy I-Disease 2 0.9999999
, O 0 0.0030381498
we O 0 0.00021733584
can O 0 0.00018158872
avoid O 0 0.00015227197
the O 0 0.00018014631
inappropriate O 0 0.0003559941
use O 0 0.00023453083
of O 0 0.00059154234
anticonvulsants O 0 0.9992636
in O 0 0.00025087516
children O 0 0.0011158526
with O 0 0.0019253487
epilepsy B-Disease 2 0.9999963
and O 0 0.00079147343
prevent O 0 0.0006620472
drug O 0 0.7082241
- O 0 0.037982386
induced O 0 0.0026100108
absence B-Disease 0 0.07597914
seizures I-Disease 0 0.99999905
. O 0 0.0136258975

Prenatal O 0 0.5094454
dexamethasone B-Chemical 0 0.9996762
programs O 0 0.059892245
hypertension B-Disease 2 0.99999416
and O 0 0.036590025
renal B-Disease 2 0.9996419
injury I-Disease 2 0.99884146
in O 0 0.0043421714
the O 0 0.004883524
rat O 0 0.011220157
. O 0 0.010246193

Dexamethasone O 0 0.9997037
is O 0 0.0047647464
frequently O 0 0.0029327339
administered O 0 0.0016999721
to O 0 0.0013112325
the O 0 0.0013845084
developing O 0 0.0046163513
fetus O 0 0.0108013665
to O 0 0.0018095236
accelerate O 0 0.002818313
pulmonary O 0 0.57843715
development O 0 0.014227058
. O 0 0.008982593

The O 0 0.00308756
purpose O 0 0.002150807
of O 0 0.001623341
the O 0 0.0010711056
present O 0 0.0007003022
study O 0 0.0007706937
was O 0 0.00045765802
to O 0 0.00029017578
determine O 0 0.00016662815
if O 0 0.00025416145
prenatal O 0 0.059055053
dexamethasone B-Chemical 0 0.9998839
programmed O 0 0.45799378
a O 0 0.00081543275
progressive O 0 0.031472873
increase B-Disease 0 0.000298696
in I-Disease 0 0.00041670993
blood I-Disease 0 0.014996098
pressure I-Disease 0 0.054900836
and O 0 0.0014494957
renal B-Disease 2 0.99823284
injury I-Disease 2 0.9972812
in O 0 0.0031723708
rats O 0 0.005748145
. O 0 0.0063419202

Pregnant O 0 0.033168286
rats O 0 0.0036142322
were O 0 0.0016334201
given O 0 0.0008694884
either O 0 0.00082441344
vehicle O 0 0.0042209476
or O 0 0.0005562903
2 O 0 0.0003900998
daily O 0 0.00035524822
intraperitoneal O 0 0.0019557648
injections O 0 0.00062584097
of O 0 0.00079722394
dexamethasone B-Chemical 0 0.9998503
( O 0 0.002893268
0 O 0 0.00034691856
. O 0 0.00018137762
2 O 0 0.00018420561
mg O 0 0.0046493467
/ O 0 0.00080111384
kg O 0 0.00054600264
body O 0 0.00060339324
weight O 0 0.00087977963
) O 0 0.00034234286
on O 0 0.00011903561
gestational O 0 0.0011330297
days O 0 0.00012624866
11 O 0 0.00015585018
and O 0 0.00016211318
12 O 0 0.00013959216
, O 0 0.00020104097
13 O 0 0.00018524234
and O 0 0.00018959446
14 O 0 0.00019674856
, O 0 0.00023465251
15 O 0 0.00018249375
and O 0 0.0002391577
16 O 0 0.00029641655
, O 0 0.00036913835
17 O 0 0.00040601753
and O 0 0.00045251162
18 O 0 0.00060145
, O 0 0.00086594676
or O 0 0.0010202754
19 O 0 0.0018903294
and O 0 0.0024366318
20 O 0 0.0038063035
. O 0 0.006582583

Offspring O 0 0.011379537
of O 0 0.0029911732
rats O 0 0.0026586507
administered O 0 0.0019227152
dexamethasone B-Chemical 0 0.99663675
on O 0 0.000474721
days O 0 0.0003512142
15 O 0 0.00029766173
and O 0 0.00030143085
16 O 0 0.00028362471
gestation O 0 0.0003735434
had O 0 0.00020461944
a O 0 0.00024111598
20 O 0 0.00018931572
% O 0 0.00022525757
reduction B-Disease 2 0.00027892494
in I-Disease 2 0.00021420265
glomerular I-Disease 2 0.46204633
number I-Disease 2 0.00015871336
compared O 0 0.000105065956
with O 0 0.0001390313
control O 0 0.00013358334
at O 0 0.000112897775
6 O 0 9.8094446e-05
to O 0 9.8495155e-05
9 O 0 0.00011388823
months O 0 9.271224e-05
of O 0 0.00014795044
age O 0 0.0003533286
( O 0 0.00033613044
22 O 0 0.00028969508
527 O 0 0.0027068944
+ O 0 0.0013360152
/ O 0 0.008258353
- O 0 0.008741289
509 O 0 0.0030921134
versus O 0 0.00017994494
28 O 0 0.00025935206
050 O 0 0.06505955
+ O 0 0.0017416304
/ O 0 0.014622978
- O 0 0.042360943
561 O 0 0.3062785
, O 0 0.00070883223
P O 0 0.051401418
< O 0 0.00023988575
0 O 0 0.000299451
. O 0 0.0002648222
05 O 0 0.007353849
) O 0 0.0005736478
, O 0 0.0003643437
which O 0 0.00028620881
was O 0 0.0001962485
comparable O 0 0.00013453902
to O 0 0.00014895888
the O 0 0.00016653507
percent O 0 0.00017572027
reduction O 0 0.00033737806
in O 0 0.0002958065
glomeruli O 0 0.002917744
measured O 0 0.00036679424
at O 0 0.0004935626
3 O 0 0.0006780476
weeks O 0 0.0008719358
of O 0 0.0021461945
age O 0 0.0054409057
. O 0 0.007034041

Six O 0 0.005719737
- O 0 0.0065244613
to O 0 0.0018514013
9 O 0 0.0016213537
- O 0 0.0024382968
month O 0 0.00065101567
old O 0 0.0006670334
rats O 0 0.00067356625
receiving O 0 0.00061531697
prenatal O 0 0.034502946
dexamethasone B-Chemical 0 0.998823
on O 0 0.0001885616
days O 0 0.00016917297
17 O 0 0.0002246889
and O 0 0.00018379859
18 O 0 0.00017273273
of O 0 0.00018304864
gestation O 0 0.0004194559
had O 0 0.00017713605
a O 0 0.00022988382
17 O 0 0.00022727597
% O 0 0.00020850443
reduction O 0 0.00025406698
in O 0 0.00019523282
glomeruli O 0 0.015177627
( O 0 0.00039917298
23 O 0 0.00034033557
380 O 0 0.0038057019
+ O 0 0.0019240845
/ O 0 0.017665617
- O 0 0.03750183
587 O 0 0.109896615
) O 0 0.0004532747
compared O 0 0.00018037301
with O 0 0.0002659335
control O 0 0.00034184876
rats O 0 0.0006679233
( O 0 0.0009163662
P O 0 0.02081401
< O 0 0.00093217625
0 O 0 0.0015070129
. O 0 0.0021618896
05 O 0 0.011371772
) O 0 0.006356631
. O 0 0.008268644

Male O 0 0.01632343
rats O 0 0.003369588
that O 0 0.0014945633
received O 0 0.0011733209
prenatal O 0 0.05241594
dexamethasone B-Chemical 0 0.99907184
on O 0 0.00038817953
days O 0 0.00028861527
15 O 0 0.00025269482
and O 0 0.00027239445
16 O 0 0.00027673985
, O 0 0.00028917685
17 O 0 0.0002541552
and O 0 0.00022063474
18 O 0 0.00022061414
, O 0 0.0002382301
and O 0 0.00021401013
13 O 0 0.00020054012
and O 0 0.00017841584
14 O 0 0.00016042202
of O 0 0.00018154857
gestation O 0 0.0004866537
had O 0 0.00020506437
elevated B-Disease 0 0.008645069
blood I-Disease 0 0.004341269
pressures I-Disease 0 0.0015027261
at O 0 0.00012595969
6 O 0 0.00011018966
months O 0 0.00010302664
of O 0 0.00017168612
age O 0 0.0004597308
; O 0 0.00040985222
the O 0 0.00023079613
latter O 0 0.0005649641
group O 0 0.00039663006
did O 0 0.00031766953
not O 0 0.00030008145
have O 0 0.000395761
a O 0 0.00074001425
reduction B-Disease 2 0.0012689249
in I-Disease 2 0.0016201001
glomerular I-Disease 2 0.65412176
number I-Disease 2 0.004113352
. O 0 0.006776754

Adult O 0 0.006423095
rats O 0 0.0034213883
given O 0 0.0016898362
dexamethasone B-Chemical 0 0.9913523
on O 0 0.00071952306
days O 0 0.00053698506
15 O 0 0.0004581928
and O 0 0.00045686585
16 O 0 0.0004226146
of O 0 0.0004175177
gestation O 0 0.0007501245
had O 0 0.00042200868
more O 0 0.00056424213
glomeruli O 0 0.02208632
with O 0 0.0018691791
glomerulosclerosis B-Disease 2 0.9999951
than O 0 0.0015481905
control O 0 0.0024610818
rats O 0 0.0050071455
. O 0 0.0061417823

This O 0 0.004959812
study O 0 0.0025893063
shows O 0 0.0011716813
that O 0 0.0011259934
prenatal O 0 0.1318604
dexamethasone B-Chemical 0 0.999845
in O 0 0.0009248596
rats O 0 0.00073270407
results O 0 0.00028468264
in O 0 0.00027506164
a O 0 0.00034397046
reduction B-Disease 2 0.00046275195
in I-Disease 2 0.00031345023
glomerular I-Disease 2 0.778298
number I-Disease 2 0.00040009507
, O 0 0.004263873
glomerulosclerosis B-Disease 2 0.9999994
, O 0 0.007411134
and O 0 0.0031856394
hypertension B-Disease 2 0.99999046
when O 0 0.00030779207
administered O 0 0.00039228963
at O 0 0.0004373411
specific O 0 0.0006738193
points O 0 0.0011315957
during O 0 0.0016439838
gestation O 0 0.0052759163
. O 0 0.006328232

Hypertension B-Disease 0 0.9988341
was O 0 0.0029998969
observed O 0 0.0015244596
in O 0 0.0010771414
animals O 0 0.0006801293
that O 0 0.0005074479
had O 0 0.00047415026
a O 0 0.0005216438
reduction O 0 0.0006123059
in O 0 0.0003298205
glomeruli O 0 0.011968144
as O 0 0.00021214735
well O 0 0.00019087794
as O 0 0.00018422441
in O 0 0.0001958485
a O 0 0.0002540021
group O 0 0.00024182991
that O 0 0.00014140879
did O 0 0.00018663034
not O 0 0.00013026538
have O 0 0.00012928728
a O 0 0.00021987454
reduction B-Disease 2 0.00034865993
in I-Disease 2 0.00023571405
glomerular I-Disease 2 0.7541358
number I-Disease 2 0.00022205529
, O 0 0.00026972953
suggesting O 0 0.00012896124
that O 0 0.00013542481
a O 0 0.00024859034
reduction B-Disease 2 0.0003796847
in I-Disease 2 0.00026051333
glomerular I-Disease 2 0.6571744
number I-Disease 2 0.00024074913
is O 0 0.00023625516
not O 0 0.00021924335
the O 0 0.00029370087
sole O 0 0.0008480699
cause O 0 0.0005672256
for O 0 0.0005791594
the O 0 0.0008789946
development O 0 0.0033317946
of O 0 0.0146848215
hypertension B-Disease 2 0.9999846
. O 0 0.009542276

Kidney O 0 0.015424285
function O 0 0.0025766005
and O 0 0.0019236266
morphology O 0 0.0019799455
after O 0 0.00069233973
short O 0 0.00066812837
- O 0 0.0018943397
term O 0 0.0004401017
combination O 0 0.0005909114
therapy O 0 0.0012268346
with O 0 0.0043863184
cyclosporine B-Chemical 1 0.9999999
A I-Chemical 0 0.9965262
, O 0 0.050105385
tacrolimus B-Chemical 0 0.9999963
and O 0 0.008988049
sirolimus B-Chemical 1 0.99986184
in O 0 0.0018468511
the O 0 0.002569516
rat O 0 0.0069937413
. O 0 0.0067877616

BACKGROUND O 0 0.04684425
: O 0 0.010370687
Sirolimus B-Chemical 1 0.998522
( O 0 0.058454916
SRL B-Chemical 0 0.99997616
) O 0 0.0054658833
may O 0 0.0013178976
supplement O 0 0.0038021456
calcineurin O 0 0.31333476
inhibitors O 0 0.0044892263
in O 0 0.0015654556
clinical O 0 0.004434363
organ O 0 0.0117521845
transplantation O 0 0.04784686
. O 0 0.008058263

These O 0 0.0044144345
are O 0 0.0041282205
nephrotoxic B-Disease 2 0.99983907
, O 0 0.01819643
but O 0 0.020027867
SRL B-Chemical 0 0.99998295
seems O 0 0.000731074
to O 0 0.00037022276
act O 0 0.00033083832
differently O 0 0.00023227275
displaying O 0 0.00037252152
only O 0 0.00040380997
minor O 0 0.009912157
nephrotoxic B-Disease 2 0.99992263
effects O 0 0.001875897
, O 0 0.00078674854
although O 0 0.0004888803
this O 0 0.00057746866
question O 0 0.00082456775
is O 0 0.0012607822
still O 0 0.0020161478
open O 0 0.0043691415
. O 0 0.006529106

In O 0 0.003915601
a O 0 0.0027444656
number O 0 0.0015817409
of O 0 0.0014007296
treatment O 0 0.001141993
protocols O 0 0.0008007849
where O 0 0.001690396
SRL B-Chemical 0 0.99998605
was O 0 0.0006264052
combined O 0 0.0004630026
with O 0 0.00036542412
a O 0 0.0004662837
calcineurin O 0 0.26358095
inhibitor O 0 0.005571827
indications O 0 0.0003474453
of O 0 0.00047621908
a O 0 0.0007477639
synergistic O 0 0.0049021156
nephrotoxic B-Disease 2 0.9999261
effect O 0 0.0021240858
were O 0 0.0023340096
described O 0 0.0030789669
. O 0 0.005898518

The O 0 0.0031241341
aim O 0 0.0023562193
of O 0 0.0017416053
this O 0 0.0011877058
study O 0 0.0010150906
was O 0 0.0005746707
to O 0 0.00034252292
examine O 0 0.00019124646
further O 0 0.0002644375
the O 0 0.00031046246
renal O 0 0.5760713
function O 0 0.00035721363
, O 0 0.0003928121
including O 0 0.00019575552
morphological O 0 0.00086226594
analysis O 0 0.00019396834
of O 0 0.00021011355
the O 0 0.00019996769
kidneys O 0 0.0041113836
of O 0 0.00039858793
male O 0 0.015284428
Sprague O 0 0.27186942
- O 0 0.017032107
Dawley O 0 0.010330482
rats O 0 0.0002420756
treated O 0 0.00018451906
with O 0 0.00022583174
either O 0 0.000829903
cyclosporine B-Chemical 1 0.9999999
A I-Chemical 0 0.9975056
( O 0 0.08829393
CsA B-Chemical 1 0.9999976
) O 0 0.04301371
, O 0 0.015659055
tacrolimus B-Chemical 0 0.99999857
( O 0 0.057170197
FK506 B-Chemical 1 0.99999607
) O 0 0.019119188
or O 0 0.0014127176
SRL B-Chemical 0 0.9999832
as O 0 0.00074277364
monotherapies O 0 0.2022712
or O 0 0.00077889126
in O 0 0.001111881
different O 0 0.0015939099
combinations O 0 0.0029192718
. O 0 0.0061241104

METHODS O 0 0.004049635
: O 0 0.0035536506
For O 0 0.0018377407
a O 0 0.0015779083
period O 0 0.0009390344
of O 0 0.0009397441
2 O 0 0.000675884
weeks O 0 0.0004417525
, O 0 0.0009979983
CsA B-Chemical 1 0.9999182
15 O 0 0.00045333043
mg O 0 0.022473255
/ O 0 0.0016611445
kg O 0 0.0010741747
/ O 0 0.0011839478
day O 0 0.00020324938
( O 0 0.00027919284
given O 0 0.00013973998
orally O 0 0.0005604955
) O 0 0.0007499901
, O 0 0.0011773075
FK506 B-Chemical 1 0.99997604
3 O 0 0.00025470564
. O 0 0.0001722086
0 O 0 0.00021623209
mg O 0 0.0053649372
/ O 0 0.00097500754
kg O 0 0.0008072343
/ O 0 0.0010441662
day O 0 0.00016197043
( O 0 0.00023685265
given O 0 0.00011677337
orally O 0 0.0004466007
) O 0 0.0005155558
or O 0 0.00045455547
SRL B-Chemical 0 0.99999
0 O 0 0.0004299474
. O 0 0.0001655667
4 O 0 0.00014887993
mg O 0 0.003095358
/ O 0 0.0008357032
kg O 0 0.0007801578
/ O 0 0.0011018976
day O 0 0.00016246554
( O 0 0.00024590347
given O 0 0.00011820402
intraperitoneally O 0 0.0005416873
) O 0 0.00041412245
was O 0 0.00015793319
administered O 0 0.0001355942
once O 0 0.000111713365
a O 0 0.00014898217
day O 0 0.0001098353
as O 0 0.000119653785
these O 0 0.00016546271
doses O 0 0.00064359885
have O 0 0.00015170632
earlier O 0 0.00020698988
been O 0 0.0001822291
found O 0 0.00017078269
to O 0 0.00017615224
achieve O 0 0.00019626497
a O 0 0.0003616933
significant O 0 0.00045396615
immunosuppressive O 0 0.4618092
effect O 0 0.0009973116
in O 0 0.001619841
Sprague O 0 0.29946887
- O 0 0.03038469
Dawley O 0 0.045947872
rats O 0 0.0054667774
. O 0 0.0069174385

In O 0 0.0039780135
the O 0 0.0026629546
' O 0 0.0028429662
conscious O 0 0.004451113
catheterized O 0 0.001490803
rat O 0 0.0017347117
' O 0 0.0009720293
model O 0 0.0005609022
, O 0 0.00064658525
the O 0 0.0004330994
glomerular O 0 0.68169326
filtration O 0 0.0028430219
rate O 0 0.00048093815
( O 0 0.0015949096
GFR O 0 0.99659866
) O 0 0.0007572804
was O 0 0.0002907909
measured O 0 0.00024582612
as O 0 0.00031885866
the O 0 0.00045260636
clearance O 0 0.036975518
of O 0 0.016567232
Cr O 0 0.9999981
( O 0 0.044968214
EDTA O 0 0.99405897
) O 0 0.009489106
. O 0 0.008123694

The O 0 0.0030074923
morphological O 0 0.0031112009
analysis O 0 0.0015171567
of O 0 0.0011984137
the O 0 0.0008516119
kidneys O 0 0.003231927
included O 0 0.0004895244
a O 0 0.0005223894
semi O 0 0.0010124838
- O 0 0.00275656
quantitative O 0 0.00032040486
scoring O 0 0.00032772266
system O 0 0.000205213
analysing O 0 0.00017624263
the O 0 0.00016726315
degree O 0 0.00023584982
of O 0 0.00044572604
striped O 0 0.3520156
fibrosis B-Disease 2 0.99985147
, O 0 0.017717626
subcapsular O 0 0.9833557
fibrosis B-Disease 2 0.99944514
and O 0 0.00046791512
the O 0 0.000163265
number O 0 0.00014534208
of O 0 0.00028261036
basophilic O 0 0.85045314
tubules O 0 0.029058827
, O 0 0.00041782967
plus O 0 0.00015664846
an O 0 0.00018351333
additional O 0 0.00011464494
stereological O 0 0.0002703495
analysis O 0 0.0001522621
of O 0 0.00017957606
the O 0 0.00017205236
total O 0 0.00019813735
grade O 0 0.02937813
of O 0 0.0008273515
fibrosis B-Disease 2 0.99874026
in O 0 0.0006680274
the O 0 0.00072844524
cortex O 0 0.2124146
stained O 0 0.0023154016
with O 0 0.003121986
Sirius O 0 0.93846434
Red O 0 0.45590478
. O 0 0.007626571

RESULTS O 0 0.008749531
: O 0 0.009798605
CsA B-Chemical 1 0.999871
, O 0 0.05079095
FK506 B-Chemical 1 0.99997914
and O 0 0.06448601
SRL B-Chemical 0 0.99997246
all O 0 0.0026056077
significantly O 0 0.0025310616
decreased O 0 0.0036763637
the O 0 0.0050243745
GFR O 0 0.9904163
. O 0 0.011282626

A O 0 0.04461307
further O 0 0.0031890022
deterioration O 0 0.076966375
was O 0 0.0015340062
seen O 0 0.0009959547
when O 0 0.00083585683
CsA B-Chemical 1 0.99996924
was O 0 0.00077256473
combined O 0 0.0005577666
with O 0 0.00045207384
either O 0 0.00083903404
FK506 B-Chemical 1 0.9999962
or O 0 0.028308606
SRL B-Chemical 0 0.9999988
, O 0 0.00277178
whereas O 0 0.00037565286
the O 0 0.00034410393
GFR O 0 0.9965403
remained O 0 0.00044059573
unchanged O 0 0.00021692616
in O 0 0.0001647981
the O 0 0.00015923344
group O 0 0.0002393183
treated O 0 0.00027594366
with O 0 0.0009136499
FK506 B-Chemical 1 0.99999285
plus O 0 0.004270016
SRL B-Chemical 0 0.99999416
when O 0 0.00018942478
compared O 0 0.00016056465
with O 0 0.00025497263
treatment O 0 0.00033935157
with O 0 0.00042021074
any O 0 0.00048762214
of O 0 0.0008771589
the O 0 0.0012719035
single O 0 0.0024665664
substances O 0 0.35702318
. O 0 0.0065296004

The O 0 0.007907898
morphological O 0 0.009757431
changes O 0 0.007386221
presented O 0 0.00638596
a O 0 0.007872632
similar O 0 0.007526201
pattern O 0 0.0114920605
. O 0 0.017098952

The O 0 0.0035196901
semi O 0 0.004549282
- O 0 0.005759323
quantitative O 0 0.0015761409
scoring O 0 0.0014438336
was O 0 0.00078516296
significantly O 0 0.000611567
worst O 0 0.001922158
in O 0 0.0003515663
the O 0 0.0002864346
group O 0 0.00035072805
treated O 0 0.00034467274
with O 0 0.0009175819
CsA B-Chemical 1 0.9999926
plus O 0 0.0074389665
SRL B-Chemical 0 0.9999988
( O 0 0.015196382
P O 0 0.21370594
< O 0 0.0002166568
0 O 0 0.00025136408
. O 0 0.00019335361
001 O 0 0.008674075
compared O 0 0.00011293826
with O 0 0.00016918282
controls O 0 0.00032847526
) O 0 0.00036370585
and O 0 0.00017729134
the O 0 0.00013323974
analysis O 0 0.00014735799
of O 0 0.00016276387
the O 0 0.00013898688
total O 0 0.00014775532
grade O 0 0.04738962
of O 0 0.00084787264
fibrosis B-Disease 2 0.9993831
also O 0 0.00032057686
showed O 0 0.00018246764
the O 0 0.00015344647
highest O 0 0.00018266278
proportion O 0 0.00014285567
in O 0 0.00014655867
the O 0 0.0001406777
same O 0 0.000113062386
group O 0 0.0002127453
and O 0 0.00020842868
was O 0 0.00018791258
significantly O 0 0.00017970968
different O 0 0.00016891831
from O 0 0.00022461201
controls O 0 0.00057673926
( O 0 0.0009094544
P O 0 0.020144153
< O 0 0.0008580609
0 O 0 0.0013869479
. O 0 0.002011595
02 O 0 0.018421864
) O 0 0.006047035
. O 0 0.007956701

The O 0 0.0046649077
FK506 B-Chemical 1 0.9998375
plus O 0 0.011355311
SRL B-Chemical 0 0.99998343
combination O 0 0.003482981
showed O 0 0.0007795158
only O 0 0.00063971704
a O 0 0.0005982826
marginally O 0 0.0010470165
higher O 0 0.00032877008
degree O 0 0.00039302182
of O 0 0.0007263068
fibrosis B-Disease 2 0.99814713
as O 0 0.00035727586
compared O 0 0.00022435455
with O 0 0.00036415117
controls O 0 0.0008159827
( O 0 0.0012205137
P O 0 0.05667921
= O 0 0.0018021368
0 O 0 0.0015801229
. O 0 0.002160072
05 O 0 0.011252033
) O 0 0.0062481957
. O 0 0.008155249

CONCLUSION O 0 0.030292662
: O 0 0.004509711
This O 0 0.0028025748
rat O 0 0.0026175005
study O 0 0.0012733483
demonstrated O 0 0.00068359944
a O 0 0.0008409499
synergistic O 0 0.0042056437
nephrotoxic B-Disease 2 0.9999677
effect O 0 0.0019905318
of O 0 0.015762754
CsA B-Chemical 1 0.9999982
plus O 0 0.02577509
SRL B-Chemical 0 0.99999857
, O 0 0.007765156
whereas O 0 0.0036474771
FK506 B-Chemical 1 0.9999888
plus O 0 0.006279717
SRL B-Chemical 0 0.9999795
was O 0 0.0021144957
better O 0 0.0027109624
tolerated O 0 0.010175361
. O 0 0.0060287598

Evaluation O 0 0.0044090813
of O 0 0.0033593422
cardiac O 0 0.31574136
troponin O 0 0.9994055
I O 0 0.15602347
and O 0 0.0017669112
T O 0 0.84758574
levels O 0 0.0005457477
as O 0 0.00039084058
markers O 0 0.0011328608
of O 0 0.0026907502
myocardial B-Disease 0 0.999997
damage I-Disease 0 0.99961436
in O 0 0.005933299
doxorubicin B-Chemical 1 0.9999727
- O 0 0.23319256
induced O 0 0.0027064953
cardiomyopathy B-Disease 0 0.9999981
rats O 0 0.0038434528
, O 0 0.00042163883
and O 0 0.00028585948
their O 0 0.00028236178
relationship O 0 0.00027507817
with O 0 0.0005700703
echocardiographic O 0 0.0035304334
and O 0 0.0014182132
histological O 0 0.054577008
findings O 0 0.0048259674
. O 0 0.0062547475

BACKGROUND O 0 0.016844993
: O 0 0.005770482
Cardiac O 0 0.30626434
troponins O 0 0.9902811
I O 0 0.087389834
( O 0 0.0035496894
cTnI O 0 0.96657425
) O 0 0.0021738696
and O 0 0.0012992554
T O 0 0.9753979
( O 0 0.015130749
cTnT O 0 0.9955492
) O 0 0.0011223108
have O 0 0.0002690089
been O 0 0.00026583587
shown O 0 0.00019248336
to O 0 0.00020169184
be O 0 0.00025155395
highly O 0 0.00031140394
sensitive O 0 0.0003393336
and O 0 0.00039913732
specific O 0 0.00048492322
markers O 0 0.0013926424
of O 0 0.002672894
myocardial B-Disease 0 0.9998832
cell I-Disease 0 0.2381347
injury I-Disease 0 0.9960001
. O 0 0.009672659

We O 0 0.0031697762
investigated O 0 0.001758432
the O 0 0.0013285017
diagnostic O 0 0.0012111772
value O 0 0.0008291775
of O 0 0.001424542
cTnI O 0 0.9875566
and O 0 0.0023943242
cTnT O 0 0.98477006
for O 0 0.000343228
the O 0 0.00027494362
diagnosis O 0 0.0020037033
of O 0 0.0019697007
myocardial B-Disease 0 0.99999607
damage I-Disease 0 0.99853003
in O 0 0.00036244767
a O 0 0.00030255626
rat O 0 0.00044341877
model O 0 0.00020638546
of O 0 0.0012875048
doxorubicin B-Chemical 1 0.99996555
( O 0 0.15656725
DOX B-Chemical 1 0.9999958
) O 0 0.060502797
- O 0 0.06905439
induced O 0 0.0014625095
cardiomyopathy B-Disease 0 0.99999833
, O 0 0.0015772893
and O 0 0.00020691787
we O 0 8.73058e-05
examined O 0 8.268776e-05
the O 0 9.6223645e-05
relationship O 0 7.9587655e-05
between O 0 0.00010069431
serial O 0 0.0005359803
cTnI O 0 0.97922075
and O 0 0.00092638965
cTnT O 0 0.97783136
with O 0 0.00022595795
the O 0 0.00017034505
development O 0 0.00043354637
of O 0 0.0005339905
cardiac B-Disease 0 0.87375355
disorders I-Disease 0 0.97059745
monitored O 0 0.00018975975
by O 0 0.00029010334
echocardiography O 0 0.0012110423
and O 0 0.00046796596
histological O 0 0.00901314
examinations O 0 0.0010042613
in O 0 0.0011211268
this O 0 0.0018210304
model O 0 0.0036170306
. O 0 0.0065981806

METHODS O 0 0.004482023
: O 0 0.004318016
Thirty O 0 0.0038297556
- O 0 0.004059868
five O 0 0.0011455761
Wistar O 0 0.0030214824
rats O 0 0.0009154981
were O 0 0.00051389675
given O 0 0.0003254743
1 O 0 0.00036369232
. O 0 0.00028912033
5 O 0 0.0002600471
mg O 0 0.004766938
/ O 0 0.0021838841
kg O 0 0.014017934
DOX B-Chemical 1 0.9999442
, O 0 0.001559224
i O 0 0.00674844
. O 0 0.0003054651
v O 0 0.014312517
. O 0 0.00026512664
, O 0 0.0002904185
weekly O 0 0.00017788197
for O 0 0.0001494007
up O 0 0.00014656749
to O 0 0.00013874682
8 O 0 0.0001495153
weeks O 0 0.00011463434
for O 0 0.00016118454
a O 0 0.00022771326
total O 0 0.00020810381
cumulative O 0 0.00048536263
dose O 0 0.0013259932
of O 0 0.00073351164
12 O 0 0.00072028104
mg O 0 0.019917062
/ O 0 0.004715674
kg O 0 0.008201094
BW O 0 0.32760304
. O 0 0.0077988016

Ten O 0 0.009807613
rats O 0 0.007539919
received O 0 0.0049228473
saline O 0 0.008871288
as O 0 0.005147504
a O 0 0.006650752
control O 0 0.007237258
group O 0 0.011094353
. O 0 0.014526512

cTnI O 0 0.8194246
was O 0 0.0028300444
measured O 0 0.001570834
with O 0 0.0015594558
Access O 0 0.006312893
( O 0 0.005078711
R O 0 0.99811053
) O 0 0.003526063
( O 0 0.00084796845
ng O 0 0.0010800853
/ O 0 0.0067422944
ml O 0 0.0012866706
) O 0 0.0006286977
and O 0 0.000293644
a O 0 0.00030489394
research O 0 0.00035261756
immunoassay O 0 0.12292594
( O 0 0.0005503682
pg O 0 0.05857742
/ O 0 0.008925461
ml O 0 0.0014410937
) O 0 0.00072556763
, O 0 0.00035121938
and O 0 0.00027411865
compared O 0 0.00023037774
with O 0 0.0006865833
cTnT O 0 0.9937767
, O 0 0.0064483434
CK O 0 0.99938536
- O 0 0.19061081
MB O 0 0.9981495
mass O 0 0.018378109
and O 0 0.005585638
CK O 0 0.99072987
. O 0 0.008798275

By O 0 0.004004781
using O 0 0.002297315
transthoracic O 0 0.0034816437
echocardiography O 0 0.0051467405
, O 0 0.0014999356
anterior O 0 0.003994171
and O 0 0.00072748895
posterior O 0 0.012552548
wall O 0 0.012766926
thickness O 0 0.21174729
, O 0 0.0013523194
LV O 0 0.9964753
diameters O 0 0.0035550285
and O 0 0.000549793
LV O 0 0.99667215
fractional O 0 0.0034772193
shortening O 0 0.007628668
( O 0 0.0012613258
FS O 0 0.2611452
) O 0 0.00049031334
were O 0 0.00016551004
measured O 0 0.00012817736
in O 0 0.00015261926
all O 0 0.0001498011
rats O 0 0.00023877878
before O 0 0.00015791904
DOX B-Chemical 1 0.99967325
or O 0 0.000342023
saline O 0 0.01582858
, O 0 0.00029296166
and O 0 0.00019666941
at O 0 0.00015228504
weeks O 0 0.00013565875
6 O 0 0.0001649712
and O 0 0.00025054006
9 O 0 0.00029224422
after O 0 0.00028663647
treatment O 0 0.00058713043
in O 0 0.0008378713
all O 0 0.0013137659
surviving O 0 0.0041920734
rats O 0 0.0050622816
. O 0 0.0063245036

Histology O 0 0.026864156
was O 0 0.0027100283
performed O 0 0.0017552442
in O 0 0.0023565579
DOX B-Chemical 1 0.99994266
- O 0 0.056665678
rats O 0 0.0010215216
at O 0 0.0004322992
6 O 0 0.00032184253
and O 0 0.00034074008
9 O 0 0.00029233922
weeks O 0 0.00020671221
after O 0 0.00021771912
the O 0 0.00034303564
last O 0 0.00043734527
DOX B-Chemical 1 0.9993888
dose O 0 0.0061932774
and O 0 0.0012094538
in O 0 0.0014303746
all O 0 0.0021152184
controls O 0 0.0047819032
. O 0 0.0068366244

RESULTS O 0 0.0063299146
: O 0 0.0043410505
Eighteen O 0 0.0036976668
of O 0 0.0020756363
the O 0 0.0021566665
DOX B-Chemical 1 0.9998211
rats O 0 0.0033862283
died O 0 0.003997321
prematurely O 0 0.008084357
of O 0 0.0008477733
general O 0 0.0008541767
toxicity B-Disease 2 0.9879019
during O 0 0.0006152895
the O 0 0.0008885251
9 O 0 0.0012136867
- O 0 0.0027590087
week O 0 0.0019516987
period O 0 0.003372015
. O 0 0.0067996765

End O 0 0.017428525
- O 0 0.03782915
diastolic O 0 0.9226685
( O 0 0.00624999
ED O 0 0.22206509
) O 0 0.0017267738
and O 0 0.0007988339
end O 0 0.00053887727
- O 0 0.00963803
systolic O 0 0.64712626
( O 0 0.001819587
ES O 0 0.34867987
) O 0 0.004983901
LV O 0 0.99864393
diameters O 0 0.017869405
/ O 0 0.016777419
BW O 0 0.35469875
significantly O 0 0.00033573626
increased O 0 0.00035454077
, O 0 0.00058912486
whereas O 0 0.0010336618
LV O 0 0.99980694
FS O 0 0.54531914
was O 0 0.0002411337
decreased O 0 0.00021311926
after O 0 0.00012781074
9 O 0 0.00016050876
weeks O 0 0.00012593748
in O 0 0.00019792172
the O 0 0.0003761395
DOX B-Chemical 1 0.9997657
group O 0 0.0009999198
( O 0 0.0008038193
p O 0 0.0006371511
< O 0 0.0007917749
0 O 0 0.001327354
. O 0 0.0019486435
001 O 0 0.043316785
) O 0 0.006288293
. O 0 0.00800067

These O 0 0.010186083
parameters O 0 0.009747927
remained O 0 0.010217895
unchanged O 0 0.010371876
in O 0 0.012394881
controls O 0 0.018942222
. O 0 0.02222531

Histological O 0 0.01054493
evaluation O 0 0.002522847
of O 0 0.0020168677
hearts O 0 0.0022935541
from O 0 0.0008799314
all O 0 0.00069560827
rats O 0 0.0008146014
given O 0 0.0005075947
DOX B-Chemical 1 0.99943084
revealed O 0 0.0005948932
significant O 0 0.0005639567
slight O 0 0.0009799476
degrees O 0 0.0074448865
of O 0 0.0017498403
perivascular O 0 0.51398015
and O 0 0.004641705
interstitial O 0 0.9917876
fibrosis B-Disease 2 0.99995136
. O 0 0.014991021

In O 0 0.004630443
7 O 0 0.0029683895
of O 0 0.0025068782
the O 0 0.0019395734
18 O 0 0.0018933356
rats O 0 0.0021031378
, O 0 0.0025204793
degeneration O 0 0.97451836
and O 0 0.0028163895
myocyte O 0 0.81799895
vacuolisation O 0 0.92439365
were O 0 0.004087763
found O 0 0.0048021236
. O 0 0.008569229

Only O 0 0.0050674267
five O 0 0.0024994963
of O 0 0.0024086817
the O 0 0.0018253783
controls O 0 0.0019320302
exhibited O 0 0.0014618894
evidence O 0 0.0013463385
of O 0 0.002005972
very O 0 0.0033544493
slight O 0 0.008882649
perivascular O 0 0.8835595
fibrosis B-Disease 2 0.99944013
. O 0 0.014585717

A O 0 0.033420578
significant O 0 0.0029755519
rise O 0 0.0026404331
in O 0 0.0022073311
cTnT O 0 0.98361176
was O 0 0.001032112
found O 0 0.00064760464
in O 0 0.000860575
DOX B-Chemical 1 0.99988365
rats O 0 0.0008058502
after O 0 0.00018227377
cumulative O 0 0.00037875472
doses O 0 0.0011981409
of O 0 0.00031507533
7 O 0 0.00018583058
. O 0 0.00016025826
5 O 0 0.00014066965
and O 0 0.00017588034
12 O 0 0.00015607965
mg O 0 0.002355547
/ O 0 0.0006450489
kg O 0 0.00046021005
in O 0 0.0002020932
comparison O 0 0.00019736843
with O 0 0.00027359175
baseline O 0 0.00035459283
( O 0 0.0005788286
p O 0 0.0006088139
< O 0 0.0008179516
0 O 0 0.0014063657
. O 0 0.0020817383
05 O 0 0.010950484
) O 0 0.00623312
. O 0 0.008127522

cTnT O 0 0.9442386
found O 0 0.0028252283
in O 0 0.0017751305
rats O 0 0.0014989703
after O 0 0.00066600175
12 O 0 0.00059913285
mg O 0 0.0075840927
/ O 0 0.0014738896
kg O 0 0.00090022234
were O 0 0.00033862863
significantly O 0 0.00026925138
greater O 0 0.00022625677
than O 0 0.00018516746
that O 0 0.00020903528
found O 0 0.00026464197
after O 0 0.00025465293
7 O 0 0.00037114494
. O 0 0.00049324846
5 O 0 0.0007073821
mg O 0 0.008720003
/ O 0 0.0051644663
kg O 0 0.025040999
DOX B-Chemical 1 0.9993325
. O 0 0.009751407

Maximal O 0 0.026879748
cTnI O 0 0.94393015
( O 0 0.003906788
pg O 0 0.07493025
/ O 0 0.0109715015
ml O 0 0.0028018567
) O 0 0.0018388937
and O 0 0.0011533984
cTnT O 0 0.96904784
levels O 0 0.0004296956
were O 0 0.00031300262
significantly O 0 0.00027837922
increased O 0 0.00035199488
in O 0 0.0005445417
DOX B-Chemical 1 0.9998833
rats O 0 0.0005493367
compared O 0 0.00014866317
with O 0 0.00022386094
controls O 0 0.0004129945
( O 0 0.00044098907
p O 0 0.0003515985
= O 0 0.00065597915
0 O 0 0.00050115684
. O 0 0.00056464947
006 O 0 0.008146053
, O 0 0.0012122694
0 O 0 0.0014879797
. O 0 0.0021051373
007 O 0 0.022982404
) O 0 0.0066954447
. O 0 0.008551803

cTnI O 0 0.9152715
( O 0 0.004655925
ng O 0 0.0042496747
/ O 0 0.008243486
ml O 0 0.003950006
) O 0 0.0037710755
, O 0 0.0045590797
CK O 0 0.9995117
- O 0 0.25929198
MB O 0 0.9988393
mass O 0 0.0063382005
and O 0 0.0012869837
CK O 0 0.9933869
remained O 0 0.0009228324
unchanged O 0 0.00072891713
in O 0 0.0010581567
DOX B-Chemical 1 0.99972385
rats O 0 0.0018103868
compared O 0 0.0010753655
with O 0 0.0022119796
controls O 0 0.005052804
. O 0 0.006900413

All O 0 0.009940106
markers O 0 0.011702948
remained O 0 0.011063121
stable O 0 0.012128863
in O 0 0.012618585
controls O 0 0.019078828
. O 0 0.022808587

Analysis O 0 0.0042756945
of O 0 0.0026421228
data O 0 0.0017680671
revealed O 0 0.0010935778
a O 0 0.00094266183
significant O 0 0.00057099067
correlation O 0 0.00038500346
between O 0 0.00033420374
maximal O 0 0.0005909391
cTnT O 0 0.9897976
and O 0 0.0008698032
ED O 0 0.17578733
and O 0 0.0005304587
ES O 0 0.39442915
LV O 0 0.9987866
diameters O 0 0.0109525705
/ O 0 0.009413878
BW O 0 0.2749467
( O 0 0.00044478953
r O 0 0.00032382
= O 0 0.0004589057
0 O 0 0.00025863052
. O 0 0.00020677132
81 O 0 0.00032602585
and O 0 0.00026499145
0 O 0 0.0003148189
. O 0 0.00030274474
65 O 0 0.00044672907
; O 0 0.00062368484
p O 0 0.0006243625
< O 0 0.00083525624
0 O 0 0.0013969018
. O 0 0.0020205025
0001 O 0 0.009741789
) O 0 0.006657181
. O 0 0.00864386

A O 0 0.025546003
significant O 0 0.0024207006
relationship O 0 0.0012809997
was O 0 0.001109944
observed O 0 0.0006699813
between O 0 0.00050039496
maximal O 0 0.0007673905
cTnT O 0 0.97842854
and O 0 0.0004840864
the O 0 0.00027032656
extent O 0 0.00019980648
of O 0 0.00050578837
myocardial O 0 0.9986456
morphological O 0 0.01352567
changes O 0 0.0006054467
, O 0 0.00042190054
and O 0 0.00035248662
between O 0 0.00036436715
LV O 0 0.99744713
diameters O 0 0.011369253
/ O 0 0.008079792
BW O 0 0.18768166
and O 0 0.0018647859
histological O 0 0.06515076
findings O 0 0.0054283123
. O 0 0.0069016055

CONCLUSIONS O 0 0.019182509
: O 0 0.0039688353
Among O 0 0.0029490648
markers O 0 0.0031097191
of O 0 0.008455635
ischemic B-Disease 0 0.9999988
injury I-Disease 0 0.99989045
after O 0 0.0014035592
DOX B-Chemical 1 0.99997175
in O 0 0.0007250779
rats O 0 0.0013647876
, O 0 0.0013257052
cTnT O 0 0.97224945
showed O 0 0.00024344373
the O 0 0.00019758758
greatest O 0 0.0002757527
ability O 0 0.0002048873
to O 0 0.00020690702
detect O 0 0.0003132871
myocardial B-Disease 0 0.99997365
damage I-Disease 0 0.9841485
assessed O 0 0.00035614768
by O 0 0.0004879906
echocardiographic O 0 0.0027342415
detection O 0 0.0011101316
and O 0 0.001489669
histological O 0 0.07730259
changes O 0 0.004674735
. O 0 0.006379616

Although O 0 0.0029554511
there O 0 0.0018080033
was O 0 0.0015191111
a O 0 0.0011703919
discrepancy O 0 0.00076747447
between O 0 0.0004366425
the O 0 0.00039320657
amount O 0 0.00027028684
of O 0 0.00078959693
cTnI O 0 0.9885938
and O 0 0.0022437754
cTnT O 0 0.9951003
after O 0 0.0003548081
DOX B-Chemical 1 0.99994445
, O 0 0.0007735663
probably O 0 0.000315655
due O 0 0.000127221
to O 0 0.00013782013
heterogeneity O 0 0.00025729428
in O 0 0.0001787293
cross O 0 0.00045095562
- O 0 0.005729317
reactivities O 0 0.047446396
of O 0 0.00027273697
mAbs O 0 0.0011183855
to O 0 0.00017557641
various O 0 0.00057864544
cTnI O 0 0.97976285
and O 0 0.0011338595
cTnT O 0 0.98890275
forms O 0 0.00030569642
, O 0 0.00041252724
it O 0 0.00021466124
is O 0 0.00017743542
likely O 0 0.0001627679
that O 0 0.0001806775
cTnT O 0 0.9743705
in O 0 0.00020627628
rats O 0 0.00031565106
after O 0 0.00015806637
DOX B-Chemical 1 0.9998425
indicates O 0 0.00027851542
cell O 0 0.0069403895
damage O 0 0.5870951
determined O 0 0.00015709916
by O 0 0.00016307688
the O 0 0.0001312141
magnitude O 0 0.0001232202
of O 0 0.00032182565
injury O 0 0.7763642
induced O 0 0.0003050661
and O 0 0.00042447067
that O 0 0.00027606313
cTnT O 0 0.98671365
should O 0 0.00012267646
be O 0 0.00014575677
a O 0 0.00017324026
useful O 0 0.00014874073
marker O 0 0.00021859736
for O 0 0.00016998517
the O 0 0.00017763466
prediction O 0 0.0002611231
of O 0 0.000322395
experimentally O 0 0.0007135828
induced O 0 0.0016040374
cardiotoxicity B-Disease 0 0.99999785
and O 0 0.0015896017
possibly O 0 0.002532525
for O 0 0.001492599
cardioprotective O 0 0.16382253
experiments O 0 0.0027460286
. O 0 0.006142896

Octreotide B-Chemical 0 0.9998404
- O 0 0.09011258
induced O 0 0.00727155
hypoxemia B-Disease 0 0.99968994
and O 0 0.03210785
pulmonary B-Disease 2 0.99982566
hypertension I-Disease 2 0.9999994
in O 0 0.007182048
premature O 0 0.13356507
neonates O 0 0.06569844
. O 0 0.010785004

The O 0 0.0034432474
authors O 0 0.0022629837
report O 0 0.0029026442
2 O 0 0.0016682135
cases O 0 0.0015852924
of O 0 0.0014965328
premature O 0 0.015415183
neonates O 0 0.010270919
who O 0 0.0018609149
had O 0 0.0013486897
enterocutaneous O 0 0.97940457
fistula B-Disease 0 0.9915803
complicating O 0 0.97454494
necrotizing B-Disease 0 0.9999988
enterocolitis I-Disease 0 0.9999901
. O 0 0.03601018

Pulmonary B-Disease 0 0.99242496
hypertension I-Disease 2 0.99999523
developed O 0 0.00429022
after O 0 0.0010463843
administration O 0 0.0032452138
of O 0 0.0010409073
a O 0 0.0016030433
somatostatin O 0 0.9273695
analogue O 0 0.06635599
, O 0 0.0034832617
octreotide B-Chemical 1 0.99833375
, O 0 0.0009326831
to O 0 0.0005567948
enhance O 0 0.0006320197
resolution O 0 0.0044923346
of O 0 0.0022408308
the O 0 0.0033299457
fistula B-Disease 0 0.8423303
. O 0 0.008312295

The O 0 0.0028245286
authors O 0 0.001589147
discuss O 0 0.0011737769
the O 0 0.0009577574
mechanism O 0 0.0007254338
of O 0 0.00077137037
the O 0 0.0005492506
occurrence O 0 0.00089048967
of O 0 0.0005122203
this O 0 0.00040915655
complication O 0 0.05260209
and O 0 0.0003383126
recommend O 0 0.00022660304
caution O 0 0.0002743796
of O 0 0.00035384923
its O 0 0.0006592762
use O 0 0.00044616245
in O 0 0.00054583873
high O 0 0.001518592
- O 0 0.02233552
risk O 0 0.18641198
premature O 0 0.11590722
neonates O 0 0.085187055
. O 0 0.007965638

The O 0 0.00362548
risk O 0 0.018182747
of O 0 0.0041013607
venous B-Disease 0 0.9865413
thromboembolism I-Disease 0 0.99999917
in O 0 0.0045407224
women O 0 0.26475063
prescribed O 0 0.60833603
cyproterone B-Chemical 0 0.9999999
acetate I-Chemical 0 0.9993767
in O 0 0.00042926578
combination O 0 0.00082698185
with O 0 0.011806748
ethinyl B-Chemical 0 0.9999993
estradiol I-Chemical 0 0.9999975
: O 0 0.0024283053
a O 0 0.00045063332
nested O 0 0.000658791
cohort O 0 0.000731504
analysis O 0 0.0005119689
and O 0 0.00077278266
case O 0 0.0012634738
- O 0 0.004948068
control O 0 0.0024519137
study O 0 0.0048541576
. O 0 0.0067368415

BACKGROUND O 0 0.1959097
: O 0 0.18957816
Cyproterone B-Chemical 0 0.99999785
acetate I-Chemical 0 0.99989426
combined O 0 0.011755853
with O 0 0.07934029
ethinyl B-Chemical 0 0.99999964
estradiol I-Chemical 0 0.99999964
( O 0 0.37214458
CPA B-Chemical 1 0.99999416
/ O 0 0.5654628
EE B-Chemical 1 0.99956435
) O 0 0.003128439
is O 0 0.00031492638
licensed O 0 0.0006558082
in O 0 0.00022534929
the O 0 0.0002530104
UK O 0 0.022996936
for O 0 0.00017540272
the O 0 0.00016470163
treatment O 0 0.00022495793
of O 0 0.00034103627
women O 0 0.020519333
with O 0 0.0021643362
acne B-Disease 0 0.99994063
and O 0 0.0109227905
hirsutism B-Disease 0 0.99992716
and O 0 0.0004604187
is O 0 0.00024349807
also O 0 0.00020983626
a O 0 0.00030199636
treatment O 0 0.00034345844
option O 0 0.00056715973
for O 0 0.00073312176
polycystic B-Disease 0 0.9959133
ovary I-Disease 0 0.9293013
syndrome I-Disease 0 0.9685118
( O 0 0.07003174
PCOS B-Disease 0 0.99973327
) O 0 0.011137831
. O 0 0.008074944

Previous O 0 0.003613729
studies O 0 0.0023374155
have O 0 0.0015078656
demonstrated O 0 0.0011196134
an O 0 0.0011583263
increased O 0 0.0010805808
risk O 0 0.09075333
of O 0 0.004520552
venous B-Disease 0 0.9974764
thromboembolism I-Disease 0 0.9999999
( O 0 0.46668714
VTE B-Disease 2 0.9999987
) O 0 0.0068768896
associated O 0 0.0006211767
with O 0 0.0021405432
CPA B-Chemical 1 0.99997365
/ O 0 0.15454218
EE B-Chemical 1 0.9924429
compared O 0 0.0002577453
with O 0 0.000378405
conventional O 0 0.0005585601
combined O 0 0.0138573665
oral B-Chemical 1 0.9975074
contraceptives I-Chemical 1 0.9999982
( O 0 0.07334171
COCs O 0 0.9760635
) O 0 0.009440632
. O 0 0.007690911

We O 0 0.0043012216
believe O 0 0.0027419701
the O 0 0.0019541355
results O 0 0.0015017341
of O 0 0.0015386473
those O 0 0.0013704579
studies O 0 0.0010480238
may O 0 0.00089054904
have O 0 0.0008923056
been O 0 0.0011570244
affected O 0 0.0013935149
by O 0 0.0020294422
residual O 0 0.0032050463
confounding O 0 0.007648302
. O 0 0.009028275

METHODS O 0 0.004257418
: O 0 0.003702768
Using O 0 0.0021819782
the O 0 0.0017399208
General O 0 0.0023860876
Practice O 0 0.0034058334
Research O 0 0.00458354
Database O 0 0.0012956038
we O 0 0.0003256326
conducted O 0 0.0003158019
a O 0 0.00036870365
cohort O 0 0.0005564982
analysis O 0 0.00028765405
and O 0 0.00032838035
case O 0 0.00044588395
- O 0 0.004643465
control O 0 0.00022445446
study O 0 0.00026357383
nested O 0 0.0003230226
within O 0 0.000113119226
a O 0 0.00019984113
population O 0 0.0003295144
of O 0 0.00028197977
women O 0 0.00274583
aged O 0 0.0002672888
between O 0 0.000115445226
15 O 0 0.00013342549
and O 0 0.00015999383
39 O 0 0.00023372943
years O 0 0.00022959623
with O 0 0.0005150526
acne B-Disease 0 0.9998909
, O 0 0.020882048
hirsutism B-Disease 0 0.99995697
or O 0 0.0020254336
PCOS B-Disease 0 0.9996549
to O 0 0.00020997235
estimate O 0 0.00018771812
the O 0 0.0003076337
risk O 0 0.051187243
of O 0 0.0063856705
VTE B-Disease 2 0.99999464
associated O 0 0.004511597
with O 0 0.013021617
CPA B-Chemical 1 0.999933
/ O 0 0.36666209
EE B-Chemical 1 0.9968959
. O 0 0.009295264

RESULTS O 0 0.005402079
: O 0 0.003504251
The O 0 0.0017109513
age O 0 0.002447529
- O 0 0.003555719
adjusted O 0 0.000888371
incidence O 0 0.0015502868
rate O 0 0.0006209716
ratio O 0 0.000818502
for O 0 0.0012562763
CPA B-Chemical 1 0.9999738
/ O 0 0.20061246
EE B-Chemical 1 0.9959643
versus O 0 0.00035391602
conventional O 0 0.0004577361
COCs O 0 0.69774276
was O 0 0.0002488747
2 O 0 0.00019471119
. O 0 0.00017385566
20 O 0 0.00019628818
[ O 0 0.00041711112
95 O 0 0.00034437238
% O 0 0.00025082205
confidence O 0 0.00050922815
interval O 0 0.00026468997
( O 0 0.0005800502
CI O 0 0.33938673
) O 0 0.00073287723
1 O 0 0.0004102372
. O 0 0.00045206305
35 O 0 0.00070010533
- O 0 0.0017648652
3 O 0 0.0011001953
. O 0 0.0016896509
58 O 0 0.0037826386
] O 0 0.006389777
. O 0 0.008301426

Using O 0 0.003596592
as O 0 0.0023073668
the O 0 0.0016092032
reference O 0 0.0013440248
group O 0 0.0013129745
women O 0 0.0036656812
who O 0 0.00083063915
were O 0 0.00039704994
not O 0 0.00030359015
using O 0 0.000382326
oral O 0 0.91828394
contraception O 0 0.9879602
, O 0 0.00057417346
had O 0 0.00020162876
no O 0 0.00014079004
recent O 0 0.00029406394
pregnancy O 0 0.31202003
or O 0 0.002981937
menopausal O 0 0.9999851
symptoms O 0 0.9891123
, O 0 0.00063399825
the O 0 0.00021463135
case O 0 0.0003791282
- O 0 0.0044790497
control O 0 0.0001688143
analysis O 0 0.00018008963
gave O 0 0.00024385401
an O 0 0.00018168711
adjusted O 0 0.00021136114
odds O 0 0.0020365724
ratio O 0 0.0005439483
( O 0 0.002473024
OR O 0 0.53654426
( O 0 0.0016959169
adj O 0 0.23136364
) O 0 0.00086351315
) O 0 0.00043223164
of O 0 0.00024563444
7 O 0 0.00017355042
. O 0 0.00016932013
44 O 0 0.00025840793
( O 0 0.0002706561
95 O 0 0.00042802276
% O 0 0.00035019912
CI O 0 0.18733306
3 O 0 0.00018907867
. O 0 0.00018651132
67 O 0 0.00037333797
- O 0 0.00089205866
15 O 0 0.00019048015
. O 0 0.00022199134
08 O 0 0.016783774
) O 0 0.00055190467
for O 0 0.00049164763
CPA B-Chemical 1 0.99995625
/ O 0 0.15841967
EE B-Chemical 1 0.9958364
use O 0 0.0002365723
compared O 0 0.00013071256
with O 0 0.00021153936
an O 0 0.00038901248
OR O 0 0.38352978
( O 0 0.0013794616
adj O 0 0.16528554
) O 0 0.0005526422
of O 0 0.00028154298
2 O 0 0.00020718182
. O 0 0.00017327313
58 O 0 0.00027206328
( O 0 0.00028366398
95 O 0 0.00043859187
% O 0 0.00036698746
CI O 0 0.16568874
1 O 0 0.00024114634
. O 0 0.00022082459
60 O 0 0.00028635105
- O 0 0.00079583685
4 O 0 0.00029485254
. O 0 0.00035154683
18 O 0 0.0004923314
) O 0 0.0007787877
for O 0 0.00076665037
use O 0 0.0012252011
of O 0 0.0021829552
conventional O 0 0.004049827
COCs O 0 0.8084761
. O 0 0.0083295535

CONCLUSIONS O 0 0.018203065
: O 0 0.0037244412
We O 0 0.0017206748
have O 0 0.0011265535
demonstrated O 0 0.0008787144
an O 0 0.0009867126
increased O 0 0.0011094074
risk O 0 0.26867124
of O 0 0.024836589
VTE B-Disease 2 0.9999976
associated O 0 0.0010815458
with O 0 0.0003857917
the O 0 0.00024875443
use O 0 0.00028177447
of O 0 0.0015942802
CPA B-Chemical 1 0.9999857
/ O 0 0.35525388
EE B-Chemical 1 0.9989047
in O 0 0.0004471506
women O 0 0.017325647
with O 0 0.0020870646
acne B-Disease 0 0.9999579
, O 0 0.034969088
hirsutism B-Disease 0 0.999966
or O 0 0.0030216144
PCOS B-Disease 0 0.9998305
although O 0 0.00037406955
residual O 0 0.00042102148
confounding O 0 0.00069411955
by O 0 0.0007101335
indication O 0 0.0008389648
cannot O 0 0.002490117
be O 0 0.002282979
excluded O 0 0.004195814
. O 0 0.0070480164

The O 0 0.0033503405
effect O 0 0.0023990807
of O 0 0.0020456626
treatment O 0 0.0019545224
with O 0 0.0025156504
gum B-Chemical 0 0.9834094
Arabic I-Chemical 0 0.31450614
on O 0 0.00090957363
gentamicin B-Chemical 1 0.9999821
nephrotoxicity B-Disease 0 0.9999995
in O 0 0.0021226723
rats O 0 0.00231307
: O 0 0.0020188373
a O 0 0.002161715
preliminary O 0 0.0033061944
study O 0 0.005156672
. O 0 0.0074493736

In O 0 0.0035864336
the O 0 0.0021569312
present O 0 0.0013349125
work O 0 0.0011531771
we O 0 0.0005976324
assessed O 0 0.0004924092
the O 0 0.00047075868
effect O 0 0.0004155108
of O 0 0.0004951924
treatment O 0 0.0005376887
of O 0 0.00049225346
rats O 0 0.00080372125
with O 0 0.0008312338
gum B-Chemical 0 0.9684116
Arabic I-Chemical 0 0.11418232
on O 0 0.0002320191
acute B-Disease 0 0.81051517
renal I-Disease 0 0.9749093
failure I-Disease 0 0.58552563
induced O 0 0.0011775016
by O 0 0.0033650638
gentamicin B-Chemical 1 0.99996793
( O 0 0.1536426
GM B-Chemical 0 0.9997607
) O 0 0.2022362
nephrotoxicity B-Disease 0 0.99999154
. O 0 0.010954585

Rats O 0 0.009714604
were O 0 0.002461749
treated O 0 0.0016950356
with O 0 0.0011886264
the O 0 0.0009202952
vehicle O 0 0.010251437
( O 0 0.0011384462
2 O 0 0.00048154138
mL O 0 0.0010189499
/ O 0 0.0009014936
kg O 0 0.00057928095
of O 0 0.0003267387
distilled O 0 0.0012589704
water O 0 0.0023228775
and O 0 0.00025616903
5 O 0 0.00018457166
% O 0 0.00025994072
w O 0 0.0015141664
/ O 0 0.0071286676
v O 0 0.09093586
cellulose O 0 0.6309971
, O 0 0.00041451302
10 O 0 0.00018163999
days O 0 0.00014557052
) O 0 0.0004360884
, O 0 0.0006711361
gum B-Chemical 0 0.9339439
Arabic I-Chemical 0 0.14783658
( O 0 0.00042053428
2 O 0 0.00021580757
mL O 0 0.00055601523
/ O 0 0.0005937036
kg O 0 0.00041777606
of O 0 0.00023399435
a O 0 0.00025361587
10 O 0 0.00018597113
% O 0 0.0002453959
w O 0 0.0015258103
/ O 0 0.0058289664
v O 0 0.054947786
aqueous O 0 0.4298687
suspension O 0 0.004849416
of O 0 0.0014591152
gum B-Chemical 0 0.9900932
Arabic I-Chemical 0 0.5543597
powder O 0 0.2591271
, O 0 0.0003443776
orally O 0 0.0003285733
for O 0 0.0001335417
10 O 0 0.00013247986
days O 0 0.000114703675
) O 0 0.00033665658
, O 0 0.000319353
or O 0 0.00036444134
gum B-Chemical 0 0.96506804
Arabic I-Chemical 0 0.20424864
concomitantly O 0 0.0023065743
with O 0 0.0013492587
GM B-Chemical 0 0.99958116
( O 0 0.0068551307
80mg O 0 0.9799628
/ O 0 0.0027173297
kg O 0 0.0009993664
/ O 0 0.0009805085
day O 0 0.00018722011
intramuscularly O 0 0.0004962629
, O 0 0.000256024
during O 0 0.00015695482
the O 0 0.00020090758
last O 0 0.00017710599
six O 0 0.0002079588
days O 0 0.00026644053
of O 0 0.000540016
the O 0 0.00076593575
treatment O 0 0.0013852174
period O 0 0.001971857
) O 0 0.0052546803
. O 0 0.0067907874

Nephrotoxicity B-Disease 2 0.99927956
was O 0 0.0026051705
assessed O 0 0.00122979
by O 0 0.0010082321
measuring O 0 0.000615093
the O 0 0.0005249663
concentrations O 0 0.0009906758
of O 0 0.0009931311
creatinine B-Chemical 1 0.9995782
and O 0 0.003638771
urea B-Chemical 1 0.999876
in O 0 0.0003220101
the O 0 0.00024160222
plasma O 0 0.006365274
and O 0 0.00038237975
reduced O 0 0.025684271
glutathione B-Chemical 0 0.99999964
( O 0 0.30352542
GSH B-Chemical 1 0.99999976
) O 0 0.0037045274
in O 0 0.00023910186
the O 0 0.00028757044
kidney O 0 0.6431632
cortex O 0 0.60756886
, O 0 0.0004226817
and O 0 0.00033136766
by O 0 0.00038243955
light O 0 0.0008905024
microscopic O 0 0.0012913449
examination O 0 0.0010523549
of O 0 0.0019150767
kidney O 0 0.49845988
sections O 0 0.0070230225
. O 0 0.007137306

The O 0 0.0028566236
results O 0 0.0018151936
indicated O 0 0.0011689849
that O 0 0.00091620453
concomitant O 0 0.0018428303
treatment O 0 0.001231749
with O 0 0.0022411305
gum B-Chemical 0 0.9919453
Arabic I-Chemical 0 0.47571772
and O 0 0.0012387772
GM B-Chemical 0 0.99674654
significantly O 0 0.00038145352
increased O 0 0.0005093973
creatinine B-Chemical 1 0.9987336
and O 0 0.0011048517
urea B-Chemical 1 0.99963677
by O 0 0.00025077903
about O 0 0.0001812134
183 O 0 0.0016103222
and O 0 0.00025199328
239 O 0 0.00461967
% O 0 0.00030683255
, O 0 0.0003186064
respectively O 0 0.0007922575
( O 0 0.00027960492
compared O 0 0.00012688903
to O 0 0.00015574084
432 O 0 0.004112883
and O 0 0.00026582548
346 O 0 0.011013908
% O 0 0.00032549974
, O 0 0.00036769992
respectively O 0 0.0016598016
, O 0 0.00034613194
in O 0 0.00018574111
rats O 0 0.0002555582
treated O 0 0.0002157909
with O 0 0.0003466592
cellulose O 0 0.6735679
and O 0 0.0028234192
GM B-Chemical 0 0.99961156
) O 0 0.0027668143
, O 0 0.0003448897
and O 0 0.00021252493
decreased O 0 0.00019933873
that O 0 0.00013118482
of O 0 0.00039513592
cortical O 0 0.560558
GSH B-Chemical 1 0.99999917
by O 0 0.0003881947
21 O 0 0.00027910396
% O 0 0.00023879633
( O 0 0.00022684885
compared O 0 0.00011423758
to O 0 0.00013490707
27 O 0 0.00023420101
% O 0 0.00019495453
in O 0 0.00015432746
the O 0 0.00019997913
cellulose O 0 0.2730481
plus O 0 0.00038435368
GM B-Chemical 0 0.9985049
group O 0 0.0006966292
) O 0 0.000732564
The O 0 0.00026232036
GM B-Chemical 0 0.99842024
- O 0 0.007405401
induced O 0 0.00021534982
proximal O 0 0.0020233707
tubular B-Disease 0 0.9972671
necrosis I-Disease 2 0.9999987
appeared O 0 0.0008814511
to O 0 0.00016642491
be O 0 0.00018087572
slightly O 0 0.00025338243
less O 0 0.00020450319
severe O 0 0.008233504
in O 0 0.00019729184
rats O 0 0.0003022072
given O 0 0.00017239098
GM B-Chemical 0 0.9812873
together O 0 0.00028404043
with O 0 0.0006831064
gum B-Chemical 0 0.93750423
Arabic I-Chemical 0 0.057151355
than O 0 0.00030465744
in O 0 0.00047206695
those O 0 0.0008292221
given O 0 0.001007886
GM B-Chemical 0 0.97990257
and O 0 0.004118035
cellulose O 0 0.53770703
. O 0 0.0077977316

It O 0 0.004597489
could O 0 0.0021885524
be O 0 0.0016568822
inferred O 0 0.0013294929
that O 0 0.0012569359
gum B-Chemical 0 0.97665477
Arabic I-Chemical 0 0.30463827
treatment O 0 0.000827635
has O 0 0.00040165082
induced O 0 0.00041535514
a O 0 0.00057936675
modest O 0 0.001040718
amelioration O 0 0.13854487
of O 0 0.0004933966
some O 0 0.00030779443
of O 0 0.00035748212
the O 0 0.0003554381
histological O 0 0.024794167
and O 0 0.0006066646
biochemical O 0 0.0021394193
indices O 0 0.0014500471
of O 0 0.0049720206
GM B-Chemical 0 0.99980015
nephrotoxicity B-Disease 0 0.99999547
. O 0 0.012300444

Further O 0 0.004126958
work O 0 0.002871261
is O 0 0.0016605303
warranted O 0 0.00093521865
on O 0 0.0006063389
the O 0 0.00058460253
effect O 0 0.00048442173
of O 0 0.00050711836
the O 0 0.0003588548
treatments O 0 0.00042286387
on O 0 0.00019800704
renal O 0 0.38842723
functional O 0 0.00024522495
aspects O 0 0.00014431888
in O 0 0.00017212096
models O 0 0.00023428812
of O 0 0.0006000672
chronic B-Disease 2 0.9933344
renal I-Disease 2 0.9958156
failure I-Disease 2 0.9630607
, O 0 0.00097313477
and O 0 0.0003775546
on O 0 0.0002659406
the O 0 0.00042369912
mechanism O 0 0.0006217464
( O 0 0.0014316248
s O 0 0.0019255099
) O 0 0.0032965306
involved O 0 0.0035056898
. O 0 0.0067806453

Increased O 0 0.004295324
frequency O 0 0.00283461
of O 0 0.0031793884
venous B-Disease 0 0.976482
thromboembolism I-Disease 0 0.99999845
with O 0 0.001531412
the O 0 0.00052959635
combination O 0 0.0006077117
of O 0 0.00095508114
docetaxel B-Chemical 1 0.9992586
and O 0 0.0028435222
thalidomide B-Chemical 1 0.99993634
in O 0 0.00046635768
patients O 0 0.00073645834
with O 0 0.0008533725
metastatic O 0 0.9780465
androgen O 0 0.99984777
- O 0 0.0835564
independent O 0 0.0019083458
prostate B-Disease 2 0.9991922
cancer I-Disease 2 0.99991024
. O 0 0.0172699

STUDY O 0 0.006117424
OBJECTIVE O 0 0.007911194
: O 0 0.0022917585
To O 0 0.00096979353
evaluate O 0 0.000540817
the O 0 0.00059623865
frequency O 0 0.0006413592
of O 0 0.0011043019
venous B-Disease 0 0.98965514
thromboembolism I-Disease 0 0.9999999
( O 0 0.36285803
VTE B-Disease 2 0.99999833
) O 0 0.003286983
in O 0 0.00025726558
patients O 0 0.0003458071
with O 0 0.00036747268
advanced O 0 0.21854188
androgen O 0 0.99991703
- O 0 0.08442755
independent O 0 0.00033782027
prostate B-Disease 2 0.99977154
cancer I-Disease 2 0.99998903
who O 0 0.006411563
were O 0 0.00026236637
treated O 0 0.00032450884
with O 0 0.0005822609
docetaxel B-Chemical 1 0.9959914
alone O 0 0.00050583493
or O 0 0.0005706558
in O 0 0.0007913717
combination O 0 0.0018335981
with O 0 0.0048394077
thalidomide B-Chemical 1 0.99981695
. O 0 0.0088976985

DESIGN O 0 0.009936868
: O 0 0.007692902
Retrospective O 0 0.011725135
analysis O 0 0.004820975
of O 0 0.005023018
a O 0 0.005457791
randomized O 0 0.005550991
phase O 0 0.007852366
II O 0 0.021941407
trial O 0 0.011662152
. O 0 0.014500008

SETTING O 0 0.013385656
: O 0 0.008997675
National O 0 0.008454725
Institutes O 0 0.009075285
of O 0 0.005570377
Health O 0 0.0067181126
clinical O 0 0.007673982
research O 0 0.007755508
center O 0 0.010225362
. O 0 0.0145013025

PATIENTS O 0 0.004670894
: O 0 0.004065911
Seventy O 0 0.0037070625
men O 0 0.008430829
, O 0 0.0020872978
aged O 0 0.0018233046
50 O 0 0.0013731569
- O 0 0.002142565
80 O 0 0.0008067241
years O 0 0.0007979791
, O 0 0.0008844107
with O 0 0.0009787924
advanced O 0 0.13625777
androgen O 0 0.999663
- O 0 0.060176093
independent O 0 0.0025521696
prostate B-Disease 2 0.99913305
cancer I-Disease 2 0.999897
. O 0 0.019070556

INTERVENTION O 0 0.0049897614
: O 0 0.0031273123
Each O 0 0.0012414271
patient O 0 0.0010362616
received O 0 0.00063810224
either O 0 0.0006493407
intravenous O 0 0.113018714
docetaxel B-Chemical 1 0.9966078
30 O 0 0.00036978608
mg O 0 0.020113427
/ O 0 0.0022134136
m2 O 0 0.014542438
/ O 0 0.0010470973
week O 0 0.00015166569
for O 0 0.00014994731
3 O 0 0.00012967744
consecutive O 0 0.00011794125
weeks O 0 0.00010552764
, O 0 0.00017099208
followed O 0 0.00012944444
by O 0 0.00017199201
1 O 0 0.00015648366
week O 0 0.00011688054
off O 0 0.00016299156
, O 0 0.0002207231
or O 0 0.00015215918
the O 0 0.00015122726
combination O 0 0.00021348984
of O 0 0.000238117
continuous O 0 0.00027474947
oral O 0 0.5098058
thalidomide B-Chemical 1 0.99994373
200 O 0 0.0009900484
mg O 0 0.004224158
every O 0 0.00017086935
evening O 0 0.00047957533
plus O 0 0.00038429504
the O 0 0.0006711476
same O 0 0.0010466739
docetaxel B-Chemical 1 0.9853157
regimen O 0 0.0058650943
. O 0 0.0061834212

This O 0 0.005909861
4 O 0 0.0031355792
- O 0 0.0042219697
week O 0 0.0013132684
cycle O 0 0.0015692232
was O 0 0.00083337113
repeated O 0 0.00050848763
until O 0 0.00043680734
there O 0 0.00040652388
was O 0 0.0005237322
evidence O 0 0.0005214208
of O 0 0.0010422857
excessive O 0 0.090746574
toxicity B-Disease 2 0.9994455
or O 0 0.0051587517
disease O 0 0.98437274
progression O 0 0.8465063
. O 0 0.009842237

MEASUREMENTS O 0 0.009120051
AND O 0 0.0033698573
MAIN O 0 0.007240012
RESULTS O 0 0.0024847458
: O 0 0.001967211
None O 0 0.0017823098
of O 0 0.0011140215
23 O 0 0.0011088391
patients O 0 0.0008077384
who O 0 0.0006932842
received O 0 0.00040731055
docetaxel B-Chemical 1 0.9941397
alone O 0 0.00079431885
developed O 0 0.032474156
VTE B-Disease 2 0.9999976
, O 0 0.0013177095
whereas O 0 0.00032649178
9 O 0 0.00019780926
of O 0 0.00022035954
47 O 0 0.00040076865
patients O 0 0.00031617304
( O 0 0.00035494962
19 O 0 0.0003277036
% O 0 0.00028875974
) O 0 0.0003972898
who O 0 0.0003105649
received O 0 0.000202232
docetaxel B-Chemical 1 0.98676664
plus O 0 0.0005124293
thalidomide B-Chemical 1 0.99997246
developed O 0 0.08985605
VTE B-Disease 2 0.9999964
( O 0 0.0019545187
p O 0 0.00079235865
= O 0 0.0014519196
0 O 0 0.0013254515
. O 0 0.0018326263
025 O 0 0.05294262
) O 0 0.006299901
. O 0 0.007904995

CONCLUSION O 0 0.019623192
: O 0 0.0034335828
The O 0 0.00137882
addition O 0 0.0008776672
of O 0 0.0016399364
thalidomide B-Chemical 1 0.9999225
to O 0 0.0014201582
docetaxel B-Chemical 1 0.99893874
in O 0 0.0005017127
the O 0 0.00037099
treatment O 0 0.00056089036
of O 0 0.002568382
prostate B-Disease 2 0.9998598
cancer I-Disease 2 0.9999802
significantly O 0 0.0017389826
increases O 0 0.00083240063
the O 0 0.0010995008
frequency O 0 0.0022592442
of O 0 0.01066155
VTE B-Disease 2 0.99996305
. O 0 0.010707578

Clinicians O 0 0.0057875374
should O 0 0.0021317422
be O 0 0.0018855751
aware O 0 0.0014392368
of O 0 0.0012500488
this O 0 0.0009619967
potential O 0 0.0011267209
complication O 0 0.08120848
when O 0 0.00081908243
adding O 0 0.0019953013
thalidomide B-Chemical 1 0.9998468
to O 0 0.0023647263
chemotherapeutic O 0 0.5257918
regimens O 0 0.011101552
. O 0 0.0076408605

Ticlopidine B-Chemical 0 0.99985874
- O 0 0.30087712
induced O 0 0.15111838
cholestatic B-Disease 0 0.99999523
hepatitis I-Disease 2 0.99999917
. O 0 0.63798535

OBJECTIVE O 0 0.014840661
: O 0 0.0034381542
To O 0 0.0015646942
report O 0 0.0020067645
2 O 0 0.0010522833
cases O 0 0.0012734721
of O 0 0.0063849837
ticlopidine B-Chemical 1 0.9999995
- O 0 0.3491715
induced O 0 0.023342673
cholestatic B-Disease 0 1.0
hepatitis I-Disease 2 1.0
, O 0 0.1106253
investigate O 0 0.0001622109
its O 0 0.0006014578
mechanism O 0 0.00022316622
, O 0 0.00035549534
and O 0 0.00020918364
compare O 0 0.0001066174
the O 0 0.00016901434
observed O 0 0.00018544415
main O 0 0.00025738752
characteristics O 0 0.0002703268
with O 0 0.00039937394
those O 0 0.00061061064
of O 0 0.00086629874
the O 0 0.0011993856
published O 0 0.0020757536
cases O 0 0.0047048857
. O 0 0.006568389

CASE O 0 0.68553376
SUMMARIES O 0 0.05513887
: O 0 0.003499898
Two O 0 0.0017249053
patients O 0 0.001545258
developed O 0 0.0018409456
prolonged O 0 0.062406525
cholestatic B-Disease 0 0.9999999
hepatitis I-Disease 2 1.0
after O 0 0.014638624
receiving O 0 0.1593993
ticlopidine B-Chemical 1 0.9999987
following O 0 0.00029743026
percutaneous O 0 0.0010709877
coronary O 0 0.19294983
angioplasty O 0 0.40441373
, O 0 0.0003486335
with O 0 0.0002629318
complete O 0 0.00028210992
remission O 0 0.012959743
during O 0 0.00033282946
the O 0 0.0005469775
follow O 0 0.00075958006
- O 0 0.0026466097
up O 0 0.0019321899
period O 0 0.0030547148
. O 0 0.006210747

T O 0 0.9725074
- O 0 0.04213966
cell O 0 0.003956933
stimulation O 0 0.001664841
by O 0 0.0011201297
therapeutic O 0 0.0021671548
concentration O 0 0.0040490483
of O 0 0.011940687
ticlopidine B-Chemical 1 0.9999988
was O 0 0.00046450566
demonstrated O 0 0.00024560612
in O 0 0.00026015594
vitro O 0 0.0003634324
in O 0 0.00030724236
the O 0 0.0003568801
patients O 0 0.0007038229
, O 0 0.0007289744
but O 0 0.0007588147
not O 0 0.00085091504
in O 0 0.0014465455
healthy O 0 0.0069386517
controls O 0 0.0051053036
. O 0 0.0067908126

DISCUSSION O 0 0.006279497
: O 0 0.012068086
Cholestatic B-Disease 0 0.9999901
hepatitis I-Disease 2 0.9999999
is O 0 0.024556555
a O 0 0.0027829544
rare O 0 0.0128628155
complication O 0 0.20340943
of O 0 0.0007739003
the O 0 0.0008303136
antiplatelet O 0 0.99663323
agent O 0 0.7588836
ticlopidine B-Chemical 1 0.9999994
; O 0 0.0009708446
several O 0 0.0001973895
cases O 0 0.00031663757
have O 0 0.00023096165
been O 0 0.00031572123
reported O 0 0.00044526806
but O 0 0.00051530154
few O 0 0.00050618965
in O 0 0.00084444514
the O 0 0.001418936
English O 0 0.0037245953
literature O 0 0.004769925
. O 0 0.0070315837

Our O 0 0.0040046745
patients O 0 0.003253608
developed O 0 0.0038779746
jaundice B-Disease 2 0.99860436
following O 0 0.0010684218
treatment O 0 0.0016973022
with O 0 0.00571904
ticlopidine B-Chemical 1 0.9999981
and O 0 0.00051331904
showed O 0 0.00024312086
the O 0 0.00021797982
clinical O 0 0.0005792464
and O 0 0.00023161684
laboratory O 0 0.00030989706
characteristics O 0 0.0002261942
of O 0 0.0024853887
cholestatic B-Disease 0 0.9999999
hepatitis I-Disease 2 1.0
, O 0 0.17798449
which O 0 0.0016289536
resolved O 0 0.00082776666
after O 0 0.0005036567
discontinuation O 0 0.13578853
of O 0 0.0015810846
the O 0 0.0024804627
drug O 0 0.36100978
. O 0 0.006920636

Hepatitis B-Disease 0 0.9999558
may O 0 0.0035060314
develop O 0 0.0018528538
weeks O 0 0.00092504156
after O 0 0.00066066615
discontinuation O 0 0.11940164
of O 0 0.00064028485
the O 0 0.0005008968
drug O 0 0.12630177
and O 0 0.00040918388
may O 0 0.00023959113
run O 0 0.0002644135
a O 0 0.00027923062
prolonged O 0 0.0003202378
course O 0 0.0002610932
, O 0 0.00040564165
but O 0 0.0003280218
complete O 0 0.000292747
remission O 0 0.064212434
was O 0 0.00041682017
observed O 0 0.0004814097
in O 0 0.00076995924
all O 0 0.001157681
reported O 0 0.0022917087
cases O 0 0.0047227154
. O 0 0.0066367285

An O 0 0.004890606
objective O 0 0.0032085658
causality O 0 0.0024489602
assessment O 0 0.0011497523
revealed O 0 0.0008438902
that O 0 0.00063680054
the O 0 0.0007409334
adverse O 0 0.5006487
drug O 0 0.46827674
event O 0 0.009095255
was O 0 0.0005633593
probably O 0 0.0006212634
related O 0 0.0004197571
to O 0 0.00058143295
the O 0 0.0009156504
use O 0 0.0016639885
of O 0 0.0059399456
ticlopidine B-Chemical 1 0.99998295
. O 0 0.008134767

The O 0 0.00439119
mechanisms O 0 0.00359799
of O 0 0.0042151394
this O 0 0.0075185397
ticlopidine B-Chemical 1 0.99999666
- O 0 0.21574976
induced O 0 0.012640145
cholestasis B-Disease 2 0.9999958
are O 0 0.008980076
unclear O 0 0.0076620956
. O 0 0.010818958

Immune O 0 0.040479556
mechanisms O 0 0.0027611363
may O 0 0.0016957498
be O 0 0.0012045216
involved O 0 0.00075384293
in O 0 0.00069225987
the O 0 0.00063586875
drug O 0 0.19205827
' O 0 0.0013440645
s O 0 0.0041164514
hepatotoxicity B-Disease 2 0.9999993
, O 0 0.00093313504
as O 0 0.00030281112
suggested O 0 0.00028037612
by O 0 0.00039307313
the O 0 0.0005976013
T O 0 0.94848907
- O 0 0.026126878
cell O 0 0.0025095874
stimulation O 0 0.0013877803
study O 0 0.0021589973
reported O 0 0.0029323574
here O 0 0.00375016
. O 0 0.0066530206

CONCLUSIONS O 0 0.11668332
: O 0 0.03739847
Cholestatic B-Disease 0 0.9999943
hepatitis I-Disease 2 0.9999999
is O 0 0.03153989
a O 0 0.0032121714
rare O 0 0.017596548
adverse O 0 0.47320172
effect O 0 0.0009876649
of O 0 0.0052078534
ticlopidine B-Chemical 1 0.99999547
that O 0 0.00091129134
may O 0 0.0011747243
be O 0 0.0017926063
immune O 0 0.019911144
mediated O 0 0.0039513065
. O 0 0.00822611

Patients O 0 0.0049955794
receiving O 0 0.0028294176
the O 0 0.0017933247
drug O 0 0.065283805
should O 0 0.0006651344
be O 0 0.00060567644
monitored O 0 0.00043285295
with O 0 0.0006094937
liver O 0 0.1823766
function O 0 0.0005567619
tests O 0 0.0007317979
along O 0 0.00049879926
with O 0 0.00075668446
complete O 0 0.0010105858
blood O 0 0.0047056223
cell O 0 0.004121858
counts O 0 0.00429616
. O 0 0.0065181283

This O 0 0.006288763
complication O 0 0.04099957
will O 0 0.0015443166
be O 0 0.0011568323
observed O 0 0.00080072164
even O 0 0.0008475964
less O 0 0.0005506623
often O 0 0.00052460184
in O 0 0.0003217996
the O 0 0.0002859437
future O 0 0.0003457181
as O 0 0.0006281324
ticlopidine B-Chemical 1 0.99999607
is O 0 0.00043006506
being O 0 0.00047474724
replaced O 0 0.000360266
by O 0 0.000510309
the O 0 0.0007352585
newer O 0 0.056369133
antiplatelet O 0 0.99209994
agent O 0 0.55106574
clopidogrel B-Chemical 1 0.99990225
. O 0 0.0074732876

Epithelial O 0 0.548596
sodium B-Chemical 0 0.99924123
channel O 0 0.35455042
( O 0 0.0073210835
ENaC O 0 0.89841753
) O 0 0.0054774457
subunit O 0 0.029674284
mRNA O 0 0.0012534513
and O 0 0.00066631037
protein O 0 0.0010024441
expression O 0 0.00055484945
in O 0 0.00042505376
rats O 0 0.0006929212
with O 0 0.00090332975
puromycin B-Chemical 0 0.99164563
aminonucleoside I-Chemical 0 0.99999905
- O 0 0.76553607
induced O 0 0.081006594
nephrotic B-Disease 0 0.9999987
syndrome I-Disease 0 0.9825655
. O 0 0.009691474

In O 0 0.0044577336
experimental O 0 0.006902707
nephrotic B-Disease 0 0.9999933
syndrome I-Disease 0 0.96670514
, O 0 0.011205979
urinary O 0 0.9576088
sodium B-Chemical 0 0.99996614
excretion O 0 0.98969704
is O 0 0.00076494005
decreased O 0 0.0006084173
during O 0 0.0004138819
the O 0 0.00058563676
early O 0 0.0010895163
phase O 0 0.0015359707
of O 0 0.0021713688
the O 0 0.003333075
disease O 0 0.90533304
. O 0 0.008716842

The O 0 0.00366891
molecular O 0 0.0043558506
mechanism O 0 0.0021007515
( O 0 0.0023744092
s O 0 0.0019787946
) O 0 0.0019315484
leading O 0 0.001465364
to O 0 0.0011401577
salt O 0 0.9774768
retention O 0 0.0036257538
has O 0 0.0011380607
not O 0 0.0013055514
been O 0 0.0019199536
completely O 0 0.0027675773
elucidated O 0 0.0059486944
. O 0 0.008075971

The O 0 0.0035365887
rate O 0 0.0032570455
- O 0 0.005475051
limiting O 0 0.0018144394
constituent O 0 0.00230622
of O 0 0.0010649064
collecting O 0 0.0015409251
duct O 0 0.613952
sodium B-Chemical 0 0.9997639
transport O 0 0.0019784537
is O 0 0.0005978814
the O 0 0.0006512217
epithelial O 0 0.15057364
sodium B-Chemical 0 0.99980074
channel O 0 0.35406137
( O 0 0.008288379
ENaC O 0 0.88750297
) O 0 0.010941738
. O 0 0.008289747

We O 0 0.0033053556
examined O 0 0.0018003279
the O 0 0.0015214295
abundance O 0 0.0014736314
of O 0 0.0017202572
ENaC O 0 0.89912146
subunit O 0 0.10825853
mRNAs O 0 0.001885331
and O 0 0.000745313
proteins O 0 0.00083326997
in O 0 0.00084431603
puromycin B-Chemical 0 0.993487
aminonucleoside I-Chemical 0 0.9999994
( O 0 0.41131353
PAN B-Chemical 1 0.99999416
) O 0 0.077236235
- O 0 0.11056192
induced O 0 0.015289029
nephrotic B-Disease 0 0.9999974
syndrome I-Disease 0 0.9719016
. O 0 0.00973308

The O 0 0.0026787831
time O 0 0.0015614533
courses O 0 0.0014168662
of O 0 0.0015453714
urinary O 0 0.8778741
sodium B-Chemical 0 0.99997056
excretion O 0 0.9978655
, O 0 0.009166371
plasma O 0 0.37174517
aldosterone B-Chemical 0 0.9999465
concentration O 0 0.005780803
and O 0 0.0027013186
proteinuria B-Disease 0 0.9999976
were O 0 0.00031880397
studied O 0 0.0002512912
in O 0 0.00023888198
male O 0 0.0035083275
Sprague O 0 0.13060065
- O 0 0.010016067
Dawley O 0 0.008099621
rats O 0 0.0003215567
treated O 0 0.00025966403
with O 0 0.00028272896
a O 0 0.00036801503
single O 0 0.0003896466
dose O 0 0.0013551719
of O 0 0.0010106988
either O 0 0.0020872708
PAN B-Chemical 1 0.9999181
or O 0 0.0047682724
vehicle O 0 0.13287358
. O 0 0.0076484107

The O 0 0.0028904025
relative O 0 0.0018081651
amounts O 0 0.0014360236
of O 0 0.002107279
alphaENaC O 0 0.6686944
, O 0 0.0065832813
betaENaC O 0 0.73334503
and O 0 0.0032453462
gammaENaC O 0 0.9466183
mRNAs O 0 0.0011578404
were O 0 0.00033125302
determined O 0 0.00021084305
in O 0 0.00024312596
kidneys O 0 0.0012357031
from O 0 0.00017057048
these O 0 0.0002029525
rats O 0 0.00025617928
by O 0 0.00019489434
real O 0 0.00024647242
- O 0 0.0008748761
time O 0 0.0001646492
quantitative O 0 0.00034433903
TaqMan O 0 0.030510657
PCR O 0 0.0326454
, O 0 0.00046352387
and O 0 0.0003675659
the O 0 0.00036381872
amounts O 0 0.00044289365
of O 0 0.000840323
proteins O 0 0.0014307873
by O 0 0.0020547807
Western O 0 0.028791966
blot O 0 0.05180658
. O 0 0.008812941

The O 0 0.0031517656
kinetics O 0 0.0027811353
of O 0 0.002701952
urinary O 0 0.8550217
sodium B-Chemical 0 0.9999187
excretion O 0 0.98083514
and O 0 0.00093494746
the O 0 0.0005265554
appearance O 0 0.0012821729
of O 0 0.001751707
proteinuria B-Disease 0 0.999995
were O 0 0.0006835642
comparable O 0 0.0005028297
with O 0 0.0008724232
those O 0 0.0014999748
reported O 0 0.002351099
previously O 0 0.0035020704
. O 0 0.0064534075

Sodium B-Chemical 0 0.99935347
retention O 0 0.0054769306
occurred O 0 0.0021877135
on O 0 0.0012689141
days O 0 0.0011627576
2 O 0 0.001269871
, O 0 0.0014541986
3 O 0 0.001152712
and O 0 0.0014664417
6 O 0 0.0016245842
after O 0 0.0023818668
PAN B-Chemical 1 0.99901044
injection O 0 0.015792001
. O 0 0.010253682

A O 0 0.03441366
significant O 0 0.0030474886
up O 0 0.002162469
- O 0 0.0037456055
regulation O 0 0.0008571861
of O 0 0.001248632
alphaENaC O 0 0.38915005
and O 0 0.0017813566
betaENaC O 0 0.49874237
mRNA O 0 0.0007308048
abundance O 0 0.00040089324
on O 0 0.00021316396
days O 0 0.00021548169
1 O 0 0.00025493762
and O 0 0.00028782195
2 O 0 0.0003043822
preceded O 0 0.00045026833
sodium B-Chemical 0 0.9922585
retention O 0 0.0009969705
on O 0 0.0005020423
days O 0 0.0007300186
2 O 0 0.001249801
and O 0 0.002152747
3 O 0 0.003344782
. O 0 0.006310542

Conversely O 0 0.0053872853
, O 0 0.0037692152
down O 0 0.0024578716
- O 0 0.004844754
regulation O 0 0.00086843193
of O 0 0.0014395033
alphaENaC O 0 0.6437782
, O 0 0.0054094237
betaENaC O 0 0.70935863
and O 0 0.0027790267
gammaENaC O 0 0.9461718
mRNA O 0 0.0008612312
expression O 0 0.000339322
on O 0 0.00015642369
day O 0 0.000170791
3 O 0 0.00014935328
occurred O 0 0.00014555622
in O 0 0.00014341761
the O 0 0.0001436833
presence O 0 0.00016870069
of O 0 0.00037551718
high O 0 0.0070758616
aldosterone B-Chemical 0 0.9999716
concentrations O 0 0.010863323
, O 0 0.0005334152
and O 0 0.00027442485
was O 0 0.00019936323
followed O 0 0.00017390524
by O 0 0.00025024806
a O 0 0.00033007088
return O 0 0.00041518296
of O 0 0.000885232
sodium B-Chemical 0 0.99952865
excretion O 0 0.8916121
to O 0 0.0011809905
control O 0 0.0018883987
values O 0 0.0032916665
. O 0 0.0061103194

The O 0 0.0032481023
amounts O 0 0.0023724863
of O 0 0.003036481
alphaENaC O 0 0.5758151
, O 0 0.0056631803
betaENaC O 0 0.6519221
and O 0 0.0027839507
gammaENaC O 0 0.87652904
proteins O 0 0.0012974042
were O 0 0.0006451753
not O 0 0.00052947365
increased O 0 0.0007853104
during O 0 0.00095440063
PAN B-Chemical 1 0.99995077
- O 0 0.12214019
induced O 0 0.004756178
sodium B-Chemical 0 0.99945754
retention O 0 0.034717124
. O 0 0.008497262

In O 0 0.0037670701
conclusion O 0 0.0023996835
, O 0 0.0037482076
ENaC O 0 0.81649995
mRNA O 0 0.002647919
expression O 0 0.001582919
, O 0 0.0019117346
especially O 0 0.005401764
alphaENaC O 0 0.69982886
, O 0 0.0015638274
is O 0 0.00040132168
increased O 0 0.0003398006
in O 0 0.00023207287
the O 0 0.00020309072
very O 0 0.00029602708
early O 0 0.0003804637
phase O 0 0.00036048895
of O 0 0.00025123014
the O 0 0.00017654942
experimental O 0 0.00022349306
model O 0 0.0002935746
of O 0 0.0068099657
PAN B-Chemical 1 0.999998
- O 0 0.5652983
induced O 0 0.015037063
nephrotic B-Disease 0 0.99999976
syndrome I-Disease 0 0.9560771
in O 0 0.0004188402
rats O 0 0.0006310203
, O 0 0.0003643128
but O 0 0.0002578559
appears O 0 0.00017874702
to O 0 0.00017833064
escape O 0 0.00038870476
from O 0 0.00023533453
the O 0 0.00029763396
regulation O 0 0.00035576627
by O 0 0.0008533103
aldosterone B-Chemical 0 0.99878865
after O 0 0.0010771834
day O 0 0.0018163379
3 O 0 0.0029346251
. O 0 0.0056698225

Sub O 0 0.8138223
- O 0 0.040642716
chronic O 0 0.529038
low O 0 0.0041502505
dose O 0 0.20071946
gamma B-Chemical 0 0.9987324
- I-Chemical 0 0.9000382
vinyl I-Chemical 0 0.99951625
GABA I-Chemical 1 0.9999995
( O 0 0.1771059
vigabatrin B-Chemical 0 0.99999917
) O 0 0.009694651
inhibits O 0 0.0010297603
cocaine B-Chemical 1 0.99999547
- O 0 0.027600355
induced O 0 0.00060207857
increases O 0 0.00074701605
in O 0 0.0011737847
nucleus O 0 0.0073358812
accumbens O 0 0.9484087
dopamine B-Chemical 1 0.99719405
. O 0 0.006704159

RATIONALE O 0 0.013028532
: O 0 0.009507493
gamma B-Chemical 0 0.96936023
- I-Chemical 0 0.5871259
Vinyl I-Chemical 0 0.9973449
GABA I-Chemical 1 0.9999976
( O 0 0.43593663
GVG B-Chemical 0 0.99999905
) O 0 0.039260782
irreversibly O 0 0.54095477
inhibits O 0 0.012193369
GABA B-Chemical 1 0.9999956
- O 0 0.8350485
transaminase O 0 0.99995935
. O 0 0.0116069205

This O 0 0.0065878676
non O 0 0.006742412
- O 0 0.021607429
receptor O 0 0.0064625316
mediated O 0 0.0011405434
inhibition O 0 0.0016840084
requires O 0 0.00072977546
de O 0 0.0035035133
novo O 0 0.002415667
synthesis O 0 0.0029352729
for O 0 0.00086330174
restoration O 0 0.0014384298
of O 0 0.0020618357
functional O 0 0.007823081
GABA B-Chemical 1 0.9999746
catabolism O 0 0.6570416
. O 0 0.008850408

OBJECTIVES O 0 0.004879642
: O 0 0.0030991533
Given O 0 0.0013810324
its O 0 0.0017823525
preclinical O 0 0.0030919109
success O 0 0.0022051728
for O 0 0.0007263411
treating O 0 0.010889142
substance B-Disease 0 0.99982065
abuse I-Disease 0 0.9999448
and O 0 0.00083242555
the O 0 0.0002905221
increased O 0 0.0003657216
risk O 0 0.038165275
of O 0 0.00056617026
visual B-Disease 2 0.56113946
field I-Disease 2 0.0013689094
defects I-Disease 2 0.01743679
( O 0 0.0125646945
VFD B-Disease 0 0.999869
) O 0 0.0009197758
associated O 0 0.0002048451
with O 0 0.00018863425
cumulative O 0 0.00053478335
lifetime O 0 0.05808621
exposure O 0 0.013566117
, O 0 0.00036376063
we O 0 9.5533724e-05
explored O 0 0.00010448398
the O 0 0.0001284747
effects O 0 0.00021472755
of O 0 0.0003741047
sub O 0 0.06753249
- O 0 0.12017734
chronic O 0 0.8299805
low O 0 0.0062874737
dose O 0 0.38058755
GVG B-Chemical 0 0.99999976
on O 0 0.0005117874
cocaine B-Chemical 1 0.9999974
- O 0 0.034806594
induced O 0 0.00024335743
increases O 0 0.00023977576
in O 0 0.00029053068
nucleus O 0 0.0015983634
accumbens O 0 0.64961797
( O 0 0.0010214556
NAcc O 0 0.14546841
) O 0 0.00537592
dopamine B-Chemical 1 0.99971694
( O 0 0.011928514
DA B-Chemical 0 0.9992254
) O 0 0.007814906
. O 0 0.007679795

METHODS O 0 0.0038333933
: O 0 0.0033617986
Using O 0 0.0019416669
in O 0 0.0015399349
vivo O 0 0.0020442235
microdialysis O 0 0.2993844
, O 0 0.0009882485
we O 0 0.0003850099
compared O 0 0.00034994062
acute O 0 0.5011726
exposure O 0 0.03394492
( O 0 0.0021974852
450 O 0 0.011381672
mg O 0 0.037000705
/ O 0 0.0020249216
kg O 0 0.0009533891
) O 0 0.00037403943
to O 0 0.00015499523
an O 0 0.00019284913
identical O 0 0.0001421857
sub O 0 0.007004859
- O 0 0.027436353
chronic O 0 0.6611196
exposure O 0 0.025861418
( O 0 0.00088159606
150 O 0 0.0003265718
mg O 0 0.008752558
/ O 0 0.00058198354
kg O 0 0.00028622546
per O 0 0.000101042795
day O 0 0.00011598059
for O 0 0.00013406377
3 O 0 0.00014038451
days O 0 0.0001386565
) O 0 0.00033031328
, O 0 0.00028807973
followed O 0 0.0002313028
by O 0 0.00036963486
1 O 0 0.0004662639
- O 0 0.001487142
or O 0 0.0006927476
3 O 0 0.0009614817
- O 0 0.002690954
day O 0 0.002016052
washout O 0 0.0047038407
. O 0 0.006370144

Finally O 0 0.0042892136
, O 0 0.002987843
we O 0 0.001268763
examined O 0 0.00087870396
the O 0 0.00080349843
low O 0 0.0008443221
dose O 0 0.0015319553
of O 0 0.0006322158
150 O 0 0.0006699283
mg O 0 0.029700637
/ O 0 0.0019779247
kg O 0 0.0011026936
( O 0 0.0004910624
50 O 0 0.00037059688
mg O 0 0.0047361352
/ O 0 0.0007054395
kg O 0 0.0004901275
per O 0 0.00023960987
day O 0 0.00034437023
) O 0 0.0006575349
using O 0 0.0006111006
a O 0 0.000983654
similar O 0 0.0011360694
washout O 0 0.002607869
period O 0 0.0030963144
. O 0 0.0062008128

RESULTS O 0 0.006693257
: O 0 0.0065661557
Sub O 0 0.84287167
- O 0 0.2709309
chronic O 0 0.9969817
GVG B-Chemical 0 0.9999995
exposure O 0 0.16157219
inhibited O 0 0.0014395494
the O 0 0.00049015466
effect O 0 0.00044609353
of O 0 0.0025602032
cocaine B-Chemical 1 0.99999046
for O 0 0.00034194937
3 O 0 0.00019578163
days O 0 0.00015408867
, O 0 0.0002681462
which O 0 0.00025159042
exceeded O 0 0.00020446927
in O 0 0.00024003905
magnitude O 0 0.00026307174
and O 0 0.0004259816
duration O 0 0.00045726815
the O 0 0.00073376927
identical O 0 0.0010871808
acute O 0 0.675486
dose O 0 0.05766266
. O 0 0.0073438757

CONCLUSIONS O 0 0.04961071
: O 0 0.007935418
Sub O 0 0.82578826
- O 0 0.06413148
chronic O 0 0.7751253
low O 0 0.010116941
dose O 0 0.6161053
GVG B-Chemical 0 0.99999964
potentiates O 0 0.021654028
and O 0 0.0006577618
extends O 0 0.0003221016
the O 0 0.00024597897
inhibition O 0 0.0012260228
of O 0 0.009210832
cocaine B-Chemical 1 0.9999987
- O 0 0.10987752
induced O 0 0.00035915474
increases O 0 0.00040954948
in O 0 0.0010248233
dopamine B-Chemical 1 0.99985886
, O 0 0.0004569767
effectively O 0 0.00025767848
reducing O 0 0.0003246636
cumulative O 0 0.000794574
exposures O 0 0.036967613
and O 0 0.00091245596
the O 0 0.0011139627
risk O 0 0.090504095
for O 0 0.0033511848
VFDS O 0 0.59806246
. O 0 0.0075108083

MR O 2 0.8866335
imaging O 0 0.0050941114
with O 0 0.0020357468
quantitative O 0 0.0017420714
diffusion O 0 0.0028853498
mapping O 0 0.0010926969
of O 0 0.0025499347
tacrolimus B-Chemical 0 0.999997
- O 0 0.2534091
induced O 0 0.005252888
neurotoxicity B-Disease 2 0.99997556
in O 0 0.002322051
organ O 0 0.032274634
transplant O 0 0.21543215
patients O 0 0.008014525
. O 0 0.0076452843

Our O 0 0.0039340933
objective O 0 0.0030384809
was O 0 0.0016304356
to O 0 0.0009903078
investigate O 0 0.0005878578
brain O 0 0.020966502
MR O 2 0.97873515
imaging O 0 0.0012950423
findings O 0 0.00043276593
and O 0 0.0003074709
the O 0 0.0002265808
utility O 0 0.00021652361
of O 0 0.0003194374
diffusion O 0 0.02933441
- O 0 0.009262752
weighted O 0 0.00037172888
( O 0 0.0010724753
DW O 0 0.9225698
) O 0 0.0006480445
imaging O 0 0.00057306414
in O 0 0.00025685187
organ O 0 0.0012147999
transplant O 0 0.016340548
patients O 0 0.00060859276
who O 0 0.00068467396
developed O 0 0.0011466001
neurologic O 0 0.9702842
symptoms O 0 0.31894007
during O 0 0.0015948564
tacrolimus B-Chemical 0 0.9999665
therapy O 0 0.025269305
. O 0 0.0071188062

Brain O 0 0.3718545
MR O 2 0.9322734
studies O 0 0.0026854617
, O 0 0.0023469878
including O 0 0.0015144246
DW O 0 0.8504278
imaging O 0 0.0023517893
, O 0 0.00082111935
were O 0 0.00046385144
prospectively O 0 0.00038565882
performed O 0 0.00029130786
in O 0 0.00032690106
14 O 0 0.00036559172
organ O 0 0.0009888272
transplant O 0 0.01648145
patients O 0 0.0010311385
receiving O 0 0.0025005192
tacrolimus B-Chemical 0 0.99998295
who O 0 0.009171858
developed O 0 0.015078661
neurologic B-Disease 0 0.9996753
complications I-Disease 0 0.98691595
. O 0 0.008111536

In O 0 0.0037128243
each O 0 0.0018053993
patient O 0 0.0017674092
who O 0 0.0015508417
had O 0 0.0008598263
abnormalities O 0 0.0037975642
on O 0 0.00035875643
the O 0 0.00039499544
initial O 0 0.00048858166
MR O 2 0.9875509
study O 0 0.00064529484
, O 0 0.00046937924
a O 0 0.00037245936
follow O 0 0.00029207734
- O 0 0.0017515837
up O 0 0.00050700817
MR O 2 0.9097322
study O 0 0.00072918425
was O 0 0.0006699507
performed O 0 0.0007989815
1 O 0 0.0012118454
month O 0 0.0016833136
later O 0 0.0031537623
. O 0 0.006469577

Apparent O 0 0.008157897
diffusion O 0 0.012280121
coefficient O 0 0.0055662734
( O 0 0.00433034
ADC O 0 0.7162189
) O 0 0.0016257626
values O 0 0.0006232389
on O 0 0.00042112666
the O 0 0.00048327036
initial O 0 0.0005907369
MR O 2 0.9729733
study O 0 0.00070099597
were O 0 0.0004892517
correlated O 0 0.00047036933
with O 0 0.0007934418
reversibility O 0 0.009677873
of O 0 0.0020674479
the O 0 0.003013651
lesions O 0 0.5420109
. O 0 0.0076984735

Of O 0 0.0045812563
the O 0 0.002493355
14 O 0 0.0018515879
patients O 0 0.001572525
, O 0 0.0012615949
5 O 0 0.00069204817
( O 0 0.0007599124
35 O 0 0.0005076588
. O 0 0.00037701524
7 O 0 0.00031175773
% O 0 0.00038650035
) O 0 0.00048442796
had O 0 0.0002992832
white B-Disease 0 0.047197387
matter I-Disease 0 0.011620604
abnormalities I-Disease 0 0.18507242
, O 0 0.00042675488
1 O 0 0.00022549588
( O 0 0.00028682343
7 O 0 0.00017009446
. O 0 0.0001728347
1 O 0 0.00018603924
% O 0 0.0002475095
) O 0 0.00041707038
had O 0 0.0003944361
putaminal B-Disease 0 0.9998683
hemorrhage I-Disease 2 0.9999933
, O 0 0.00065522786
and O 0 0.00030496778
8 O 0 0.00022023162
( O 0 0.00031721406
57 O 0 0.00036532345
. O 0 0.00023723637
1 O 0 0.00027510623
% O 0 0.00039089014
) O 0 0.0005597987
had O 0 0.00043833148
normal O 0 0.0006864739
findings O 0 0.00087555277
on O 0 0.00089032337
initial O 0 0.001982118
MR O 2 0.953243
images O 0 0.0060731107
. O 0 0.0074626207

Among O 0 0.004719093
the O 0 0.0021215451
5 O 0 0.0013778494
patients O 0 0.001165923
with O 0 0.00094701385
white B-Disease 0 0.086171485
matter I-Disease 0 0.01977492
abnormalities I-Disease 0 0.2285159
, O 0 0.0006006394
4 O 0 0.00026593375
patients O 0 0.0003316436
( O 0 0.0003482535
80 O 0 0.0002687966
. O 0 0.00019504491
0 O 0 0.00023161662
% O 0 0.0002664083
) O 0 0.0003467868
showed O 0 0.00018570144
higher O 0 0.00018546221
than O 0 0.00014278419
normal O 0 0.00037658997
ADC O 0 0.28942922
values O 0 0.00016271886
on O 0 0.00012673957
initial O 0 0.00022706631
MR O 2 0.9619125
images O 0 0.00038685
, O 0 0.00033795653
and O 0 0.00026759072
all O 0 0.00023970149
showed O 0 0.00026909405
complete O 0 0.00033123468
resolution O 0 0.00130766
on O 0 0.00053087523
follow O 0 0.0008791968
- O 0 0.00310763
up O 0 0.0022789182
images O 0 0.0046618097
. O 0 0.006868264

The O 0 0.0029615022
remaining O 0 0.002195513
1 O 0 0.0016406516
patient O 0 0.0012196421
( O 0 0.0011730795
20 O 0 0.0006752518
. O 0 0.00051218586
0 O 0 0.00050826964
% O 0 0.0005172823
) O 0 0.00057939166
showed O 0 0.00031122705
lower O 0 0.0002935919
than O 0 0.00021879125
normal O 0 0.0004993625
ADC O 0 0.3313188
value O 0 0.00030555218
and O 0 0.00035958047
showed O 0 0.0003553324
incomplete O 0 0.00065410405
resolution O 0 0.0051100887
with O 0 0.001322152
cortical B-Disease 0 0.22959384
laminar I-Disease 0 0.16168511
necrosis I-Disease 2 0.9998603
. O 0 0.012462773

Diffusion O 0 0.14641695
- O 0 0.008007912
weighted O 0 0.0023162533
imaging O 0 0.00276708
may O 0 0.0010079371
be O 0 0.0007927416
useful O 0 0.0006159214
in O 0 0.000505757
predicting O 0 0.00047801947
the O 0 0.0004130687
outcomes O 0 0.00060872454
of O 0 0.0005160167
the O 0 0.0006015924
lesions O 0 0.41493693
of O 0 0.010271976
tacrolimus B-Chemical 0 0.9999975
- O 0 0.39795947
induced O 0 0.026869869
neurotoxicity B-Disease 2 0.99996877
. O 0 0.011808495

L B-Chemical 0 0.99603075
- I-Chemical 0 0.1963616
arginine I-Chemical 0 0.8889051
transport O 0 0.0050416235
in O 0 0.0024341226
humans O 0 0.005479833
with O 0 0.0045354767
cortisol B-Chemical 1 0.9993625
- O 0 0.15899412
induced O 0 0.024455264
hypertension B-Disease 2 0.999985
. O 0 0.015026797

A O 0 0.104073375
deficient O 0 0.0054405443
L B-Chemical 0 0.998468
- I-Chemical 0 0.54650736
arginine I-Chemical 0 0.99530387
- O 0 0.3365579
nitric B-Chemical 0 0.999102
oxide I-Chemical 0 0.9775399
system O 0 0.0010537565
is O 0 0.0008097776
implicated O 0 0.0007893006
in O 0 0.0015008413
cortisol B-Chemical 1 0.99866307
- O 0 0.09780304
induced O 0 0.01573338
hypertension B-Disease 2 0.99998605
. O 0 0.01198226

We O 0 0.0036827233
investigate O 0 0.0016867948
whether O 0 0.0014800273
abnormalities O 0 0.021018896
in O 0 0.0026328957
L B-Chemical 0 0.998728
- I-Chemical 0 0.32793376
arginine I-Chemical 0 0.9461539
uptake O 0 0.006349208
contribute O 0 0.0015374025
to O 0 0.0020397592
this O 0 0.0033836062
deficiency O 0 0.3930712
. O 0 0.00946151

Eight O 0 0.027009876
healthy O 0 0.0283037
men O 0 0.034692794
were O 0 0.021102905
recruited O 0 0.025005214
. O 0 0.033393256

Hydrocortisone B-Chemical 0 0.99999785
acetate I-Chemical 0 0.9999018
( O 0 0.0076328535
50 O 0 0.002094472
mg O 0 0.0748692
) O 0 0.0012639439
was O 0 0.0004371735
given O 0 0.00023797582
orally O 0 0.0003352683
every O 0 0.0001278044
6 O 0 0.00014273204
hours O 0 0.00013651507
for O 0 0.00015540943
24 O 0 0.00016760496
hours O 0 0.00012847863
after O 0 0.00011825769
a O 0 0.00021133274
5 O 0 0.00018698748
- O 0 0.00062188937
day O 0 0.00020189944
fixed O 0 0.00041239712
- O 0 0.023467928
salt O 0 0.98878
diet O 0 0.14787462
( O 0 0.0012336868
150 O 0 0.0010380945
mmol O 0 0.17018244
/ O 0 0.004415414
d O 0 0.003694952
) O 0 0.006597021
. O 0 0.007758818

Crossover O 0 0.023799
studies O 0 0.009103502
were O 0 0.007964658
performed O 0 0.007394294
2 O 0 0.0085084615
weeks O 0 0.0087481
apart O 0 0.013550569
. O 0 0.02075077

Thirty O 0 0.0053956746
milliliters O 0 0.0026903872
of O 0 0.0022099328
blood O 0 0.0039407625
was O 0 0.001023232
obtained O 0 0.0006963365
for O 0 0.0006099784
isolation O 0 0.00065142557
of O 0 0.0007664528
peripheral O 0 0.008147089
blood O 0 0.014048013
mononuclear O 0 0.020577421
cells O 0 0.0008350369
after O 0 0.0006985645
each O 0 0.00092798594
treatment O 0 0.0020737862
period O 0 0.0032035995
. O 0 0.006442911

L B-Chemical 0 0.99763954
- I-Chemical 0 0.29380625
arginine I-Chemical 0 0.9329628
uptake O 0 0.011780086
was O 0 0.0010629988
assessed O 0 0.00057431584
in O 0 0.00056919624
mononuclear O 0 0.0190422
cells O 0 0.00043735633
incubated O 0 0.00037509904
with O 0 0.0014107857
L B-Chemical 0 0.9995814
- I-Chemical 0 0.42669168
arginine I-Chemical 0 0.96437806
( O 0 0.0006610712
1 O 0 0.0001865035
to O 0 0.00014190127
300 O 0 0.00030856451
micromol O 0 0.1039825
/ O 0 0.027866505
L O 0 0.9735492
) O 0 0.0014996277
, O 0 0.00031946113
incorporating O 0 0.00021399363
100 O 0 0.00052097684
nmol O 0 0.37020084
/ O 0 0.076384254
L O 0 0.9961773
[ B-Chemical 0 0.27849945
3H I-Chemical 0 0.9898375
] I-Chemical 0 0.012694396
- I-Chemical 0 0.032263763
l I-Chemical 0 0.114689566
- I-Chemical 0 0.06555816
arginine I-Chemical 0 0.7239448
for O 0 0.00030992835
a O 0 0.00034280107
period O 0 0.00027037086
of O 0 0.0004191146
5 O 0 0.0004229959
minutes O 0 0.00054055796
at O 0 0.000911335
37 O 0 0.0021938048
degrees O 0 0.010287214
C O 0 0.99209
. O 0 0.010603494

Forearm O 0 0.6722457
[ B-Chemical 0 0.12389688
3H I-Chemical 0 0.97728515
] I-Chemical 0 0.057274915
- I-Chemical 0 0.318996
L I-Chemical 0 0.99912435
- I-Chemical 0 0.34842953
arginine I-Chemical 0 0.93611217
extraction O 0 0.0013859101
was O 0 0.00034950773
calculated O 0 0.00019736314
after O 0 0.0001856377
infusion O 0 0.00055748835
of O 0 0.0005590544
[ B-Chemical 0 0.09783774
3H I-Chemical 0 0.99173003
] I-Chemical 0 0.041694358
- I-Chemical 0 0.2974532
L I-Chemical 0 0.99947304
- I-Chemical 0 0.23701239
arginine I-Chemical 0 0.80200046
into O 0 0.00014801971
the O 0 0.00023412668
brachial O 0 0.45833698
artery O 0 0.011769216
at O 0 0.00018076021
a O 0 0.00023510847
rate O 0 0.00026025766
of O 0 0.00041733627
100 O 0 0.0011341032
nCi O 0 0.16045623
/ O 0 0.002059857
min O 0 0.0010411448
for O 0 0.0011841875
80 O 0 0.0021103946
minutes O 0 0.0027894008
. O 0 0.005976873

Deep O 0 0.048203923
forearm O 0 0.13146307
venous O 0 0.09749639
samples O 0 0.0021651345
were O 0 0.0015741993
collected O 0 0.0011672131
for O 0 0.0013463483
determination O 0 0.00268082
of O 0 0.0036760927
L B-Chemical 0 0.99791974
- I-Chemical 0 0.32624942
arginine I-Chemical 0 0.9553865
extraction O 0 0.017596252
. O 0 0.010330463

Plasma O 0 0.66168684
cortisol B-Chemical 1 0.9952011
concentrations O 0 0.006106915
were O 0 0.0012279253
significantly O 0 0.000750068
raised O 0 0.0006159472
during O 0 0.00033870034
the O 0 0.00035288627
active O 0 0.00060305116
phase O 0 0.000722723
( O 0 0.00096791505
323 O 0 0.0571382
+ O 0 0.0035693368
/ O 0 0.01158144
- O 0 0.0058934875
43 O 0 0.00041222145
to O 0 0.00025555675
1082 O 0 0.23378217
+ O 0 0.0018374396
/ O 0 0.009340474
- O 0 0.014207665
245 O 0 0.017630897
mmol O 0 0.55932593
/ O 0 0.027930437
L O 0 0.9450001
, O 0 0.0017992825
P O 0 0.03605874
< O 0 0.0011174307
0 O 0 0.0017170142
. O 0 0.0024172189
05 O 0 0.011119937
) O 0 0.0068662064
. O 0 0.008915874

Systolic O 0 0.8157842
blood O 0 0.02190695
pressure O 0 0.04246876
was O 0 0.0025874744
elevated O 0 0.002967859
by O 0 0.0017856208
an O 0 0.0017329513
average O 0 0.0014050431
of O 0 0.0024350605
7 O 0 0.0029080107
mm O 0 0.009058337
Hg O 0 0.9492495
. O 0 0.011596607

Neither O 0 0.0066974554
L B-Chemical 0 0.9963108
- I-Chemical 0 0.1905948
arginine I-Chemical 0 0.87776196
transport O 0 0.0020732959
into O 0 0.0005731515
mononuclear O 0 0.040345274
cells O 0 0.0007394172
( O 0 0.0009777112
placebo O 0 0.010326783
vs O 0 0.0004247977
active O 0 0.0005311537
, O 0 0.00038814973
26 O 0 0.00030805892
. O 0 0.00018616415
3 O 0 0.00018552975
+ O 0 0.0007309717
/ O 0 0.006605504
- O 0 0.0065232376
3 O 0 0.00017854024
. O 0 0.00015258738
6 O 0 0.00012808229
vs O 0 0.00018646101
29 O 0 0.00024419394
. O 0 0.00016045063
0 O 0 0.00022877613
+ O 0 0.0009199827
/ O 0 0.0100786425
- O 0 0.011673761
2 O 0 0.00020722962
. O 0 0.00016108205
1 O 0 0.000158745
pmol O 0 0.00042332523
/ O 0 0.00074190914
10 O 0 0.00015441167
000 O 0 0.00015585806
cells O 0 0.00014578151
per O 0 9.731639e-05
5 O 0 0.00011043695
minutes O 0 0.000117082454
, O 0 0.00021305952
respectively O 0 0.0005338462
, O 0 0.00025048797
at O 0 0.00015350763
an O 0 0.00030559415
l B-Chemical 0 0.12960374
- I-Chemical 0 0.11387852
arginine I-Chemical 0 0.8435011
concentration O 0 0.00069209497
of O 0 0.00029934593
300 O 0 0.00062760786
micromol O 0 0.25683895
/ O 0 0.04422476
L O 0 0.9825216
) O 0 0.004278261
nor O 0 0.0011994541
L B-Chemical 0 0.99974185
- I-Chemical 0 0.46694928
arginine I-Chemical 0 0.9462762
extraction O 0 0.0009517206
in O 0 0.00017676351
the O 0 0.00018622488
forearm O 0 0.051370412
( O 0 0.000249252
at O 0 0.00012411087
80 O 0 0.0001494899
minutes O 0 0.00012250146
, O 0 0.00022681229
placebo O 0 0.0013137945
vs O 0 0.00023042454
active O 0 0.00033657075
, O 0 0.00031410117
1 O 0 0.00022222853
868 O 0 0.008889183
904 O 0 0.009964877
+ O 0 0.0012971435
/ O 0 0.00668583
- O 0 0.0072202976
434 O 0 0.0012454102
962 O 0 0.006605454
vs O 0 0.00025364634
2 O 0 0.00020353658
013 O 0 0.0027768721
910 O 0 0.00078293093
+ O 0 0.0010086889
/ O 0 0.0084043015
- O 0 0.017858556
770 O 0 0.018019006
619 O 0 0.005495747
disintegrations O 0 0.00037498376
per O 0 0.00010333874
minute O 0 0.00013983794
) O 0 0.000271051
was O 0 0.0001650003
affected O 0 0.00017096111
by O 0 0.00028848537
cortisol B-Chemical 1 0.99518836
treatment O 0 0.00065136503
; O 0 0.0008260781
ie O 0 0.00062347954
, O 0 0.00041476166
that O 0 0.00034645933
L B-Chemical 0 0.9996333
- I-Chemical 0 0.50552523
arginine I-Chemical 0 0.9724392
uptake O 0 0.0099597
is O 0 0.0003176102
not O 0 0.00025789032
affected O 0 0.00032959043
by O 0 0.0004378026
short O 0 0.0005699701
- O 0 0.0035757192
term O 0 0.0017476243
cortisol B-Chemical 1 0.99300295
treatment O 0 0.0063839187
. O 0 0.0072008343

We O 0 0.0033797682
conclude O 0 0.0019592384
that O 0 0.0020737844
cortisol B-Chemical 1 0.99928504
- O 0 0.06419599
induced O 0 0.0010520903
increases B-Disease 0 0.0007691714
in I-Disease 0 0.00065414276
blood I-Disease 0 0.021374473
pressure I-Disease 0 0.028571885
are O 0 0.0002706427
not O 0 0.00022902929
associated O 0 0.00029633852
with O 0 0.00037096348
abnormalities O 0 0.014726262
in O 0 0.00041251996
the O 0 0.0006093328
l B-Chemical 0 0.054068472
- I-Chemical 0 0.065678366
arginine I-Chemical 0 0.85186917
transport O 0 0.0046405904
system O 0 0.004494529
. O 0 0.006881056

Amount O 0 0.008324575
of O 0 0.005241752
bleeding B-Disease 0 0.9970868
and O 0 0.004451493
hematoma B-Disease 0 0.9994031
size O 0 0.00151314
in O 0 0.0009267984
the O 0 0.0010227346
collagenase O 0 0.8036546
- O 0 0.079699755
induced O 0 0.005935682
intracerebral B-Disease 0 0.99991465
hemorrhage I-Disease 2 0.99999034
rat O 0 0.030998912
model O 0 0.0058326786
. O 0 0.008246863

The O 0 0.0039128014
aggravated O 0 0.07112764
risk O 0 0.113651484
on O 0 0.0019049441
intracerebral B-Disease 0 0.99992466
hemorrhage I-Disease 2 0.99999917
( O 0 0.5348947
ICH B-Disease 2 0.9999995
) O 0 0.0037603732
with O 0 0.00058786094
drugs O 0 0.047696404
used O 0 0.00040001652
for O 0 0.00065531646
stroke B-Disease 2 0.9991416
patients O 0 0.0011253095
should O 0 0.0006231008
be O 0 0.0011188458
estimated O 0 0.0017512619
carefully O 0 0.0027849174
. O 0 0.0060583167

We O 0 0.003683687
therefore O 0 0.0025216807
established O 0 0.0019092752
sensitive O 0 0.0013282849
quantification O 0 0.0009889379
methods O 0 0.00077193044
and O 0 0.0007904198
provided O 0 0.0007210304
a O 0 0.0011700096
rat O 0 0.0455636
ICH B-Disease 2 0.9999957
model O 0 0.0010799288
for O 0 0.0010672621
detection O 0 0.0029488672
of O 0 0.021856962
ICH B-Disease 2 0.99999607
deterioration O 0 0.7520336
. O 0 0.009114821

In O 0 0.010475707
ICH B-Disease 2 0.999985
intrastriatally O 0 0.9108483
induced O 0 0.0016584101
by O 0 0.0011951773
0 O 0 0.0010189543
. O 0 0.0007028969
014 O 0 0.013407778
- O 0 0.0018111677
unit O 0 0.000340982
, O 0 0.00045973412
0 O 0 0.00037274408
. O 0 0.00031078912
070 O 0 0.02381336
- O 0 0.0013266632
unit O 0 0.00021431112
, O 0 0.00028844088
and O 0 0.00025229904
0 O 0 0.00025715717
. O 0 0.00019382764
350 O 0 0.0003565822
- O 0 0.0010957866
unit O 0 0.00021249533
collagenase O 0 0.30833772
, O 0 0.00037737915
the O 0 0.00016528246
amount O 0 0.00012221736
of O 0 0.00056478265
bleeding B-Disease 0 0.9983516
was O 0 0.00018460826
measured O 0 0.00011970879
using O 0 0.00014561812
a O 0 0.00031550098
hemoglobin O 0 0.92001104
assay O 0 0.001108452
developed O 0 0.000313903
in O 0 0.00015579017
the O 0 0.00015260732
present O 0 0.00014065276
study O 0 0.00025057254
and O 0 0.00025345874
was O 0 0.00024264984
compared O 0 0.00021502258
with O 0 0.0003679007
the O 0 0.00050996133
morphologically O 0 0.001285325
determined O 0 0.0014006918
hematoma B-Disease 0 0.99919015
volume O 0 0.0066778916
. O 0 0.0065024304

The O 0 0.0032350745
blood O 0 0.0042038504
amounts O 0 0.001469077
and O 0 0.002022826
hematoma B-Disease 0 0.9991548
volumes O 0 0.0012981211
were O 0 0.00049449457
significantly O 0 0.0003609603
correlated O 0 0.00026826153
, O 0 0.0003687374
and O 0 0.00031484172
the O 0 0.00037246683
hematoma B-Disease 0 0.9992336
induced O 0 0.0003241143
by O 0 0.00033403328
0 O 0 0.00038322803
. O 0 0.00032686553
014 O 0 0.010012634
- O 0 0.0015296451
unit O 0 0.00041003939
collagenase O 0 0.100043006
was O 0 0.0006139904
adequate O 0 0.00067855924
to O 0 0.0009952514
detect O 0 0.0021863866
ICH B-Disease 2 0.99999046
deterioration O 0 0.53977674
. O 0 0.007995291

In O 0 0.0078017986
ICH B-Disease 2 0.99993956
induction O 0 0.002276584
using O 0 0.0013255184
0 O 0 0.0012664045
. O 0 0.00090583006
014 O 0 0.014797902
- O 0 0.002724206
unit O 0 0.00048814836
collagenase O 0 0.5389002
, O 0 0.002029937
heparin B-Chemical 1 0.98494935
enhanced O 0 0.00039368382
the O 0 0.0004684216
hematoma B-Disease 0 0.9997427
volume O 0 0.0010305993
3 O 0 0.00018459825
. O 0 0.00016689673
4 O 0 0.00017264464
- O 0 0.0005932777
fold O 0 0.00024871386
over O 0 0.00012466431
that O 0 0.00014907497
seen O 0 0.00020211286
in O 0 0.00026088968
control O 0 0.0009797188
ICH B-Disease 2 0.99999654
animals O 0 0.00028304613
and O 0 0.0004071665
the O 0 0.00057388726
bleeding B-Disease 0 0.99468565
7 O 0 0.00062673446
. O 0 0.0008560793
6 O 0 0.0012669854
- O 0 0.0040941215
fold O 0 0.0053662905
. O 0 0.007940341

Data O 0 0.0035710267
suggest O 0 0.00156941
that O 0 0.0012989078
this O 0 0.0011598748
sensitive O 0 0.0013629684
hemoglobin O 0 0.9495705
assay O 0 0.003433937
is O 0 0.0005252363
useful O 0 0.0004490504
for O 0 0.0011429187
ICH B-Disease 2 0.9999987
detection O 0 0.0019520675
, O 0 0.000476326
and O 0 0.0002554257
that O 0 0.00016109049
a O 0 0.00023120933
model O 0 0.00019695035
with O 0 0.00025261144
a O 0 0.0003730553
small O 0 0.00197573
ICH B-Disease 2 0.99999905
induced O 0 0.0003293366
with O 0 0.0003648818
a O 0 0.0003903431
low O 0 0.0008919324
- O 0 0.019599466
dose O 0 0.005960781
collagenase O 0 0.51402974
should O 0 0.00016137984
be O 0 0.0001932281
used O 0 0.00019412095
for O 0 0.00023978835
evaluation O 0 0.0003398633
of O 0 0.00061571324
drugs O 0 0.05869868
that O 0 0.0008770173
may O 0 0.0016528048
affect O 0 0.0032250278
ICH B-Disease 2 0.9999833
. O 0 0.0088704955

Estradiol B-Chemical 0 0.99998164
reduces O 0 0.02554941
seizure B-Disease 2 0.99998724
- O 0 0.26887548
induced O 0 0.0046139476
hippocampal B-Disease 0 0.9986677
injury I-Disease 0 0.9994474
in O 0 0.002199707
ovariectomized O 0 0.46825102
female O 0 0.0044174097
but O 0 0.0013004787
not O 0 0.0013088706
in O 0 0.002074863
male O 0 0.0074897246
rats O 0 0.0060940315
. O 0 0.0074994806

Estrogens O 0 0.9868296
protect O 0 0.0068103108
ovariectomized O 0 0.4349173
rats O 0 0.002916396
from O 0 0.0014066362
hippocampal B-Disease 0 0.9912924
injury I-Disease 0 0.99838185
induced O 0 0.0033031725
by O 0 0.024406133
kainic B-Chemical 0 0.99999964
acid I-Chemical 0 0.99597615
- O 0 0.082065165
induced O 0 0.0013361119
status B-Disease 0 0.05169189
epilepticus I-Disease 0 0.9999932
( O 0 0.017058855
SE B-Disease 0 0.8617809
) O 0 0.007869532
. O 0 0.0077588507

We O 0 0.0033246926
compared O 0 0.0017124222
the O 0 0.0015170745
effects O 0 0.0024047764
of O 0 0.099098496
17beta B-Chemical 1 0.99999976
- I-Chemical 1 0.98752975
estradiol I-Chemical 1 0.9999993
in O 0 0.0011622388
adult O 0 0.0013139916
male O 0 0.004408738
and O 0 0.0006234248
ovariectomized O 0 0.1222696
female O 0 0.0011138348
rats O 0 0.00038997823
subjected O 0 0.0002768745
to O 0 0.0006397143
lithium B-Chemical 0 0.9999845
- O 0 0.8098977
pilocarpine B-Chemical 1 0.99999845
- O 0 0.1394849
induced O 0 0.0049409056
SE B-Disease 0 0.9092942
. O 0 0.008375875

Rats O 0 0.008694099
received O 0 0.0023454854
subcutaneous O 0 0.0075019347
injections O 0 0.0060714246
of O 0 0.07877059
17beta B-Chemical 1 0.99999964
- I-Chemical 1 0.9853549
estradiol I-Chemical 1 0.9999995
( O 0 0.007547162
2 O 0 0.00045381725
microg O 0 0.00070889166
/ O 0 0.0061893584
rat O 0 0.0023101487
) O 0 0.001154137
or O 0 0.0005800207
oil O 0 0.8757575
once O 0 0.00044542705
daily O 0 0.00057254
for O 0 0.0006643862
four O 0 0.0008756959
consecutive O 0 0.0015741027
days O 0 0.002538812
. O 0 0.0057614916

SE B-Disease 0 0.38900805
was O 0 0.003251133
induced O 0 0.0021495936
20 O 0 0.001586089
h O 0 0.0012830762
following O 0 0.0008234005
the O 0 0.00080664456
second O 0 0.00083118357
injection O 0 0.0011667318
and O 0 0.0011705423
terminated O 0 0.0016078064
3 O 0 0.00168169
h O 0 0.002733322
later O 0 0.0040191747
. O 0 0.007582708

The O 0 0.0030643025
extent O 0 0.001983862
of O 0 0.002750213
silver B-Chemical 0 0.993486
- O 0 0.073738135
stained O 0 0.011930773
CA3 O 0 0.99565953
and O 0 0.0019451113
CA1 O 0 0.9779081
hippocampal O 0 0.26984185
neurons O 0 0.0014508055
was O 0 0.00069986586
evaluated O 0 0.0007277822
2 O 0 0.0010622179
days O 0 0.0013163766
after O 0 0.0022902437
SE B-Disease 0 0.29196098
. O 0 0.008200008

17beta B-Chemical 1 0.99999547
- I-Chemical 1 0.98626107
Estradiol I-Chemical 1 0.99999833
did O 0 0.0037873606
not O 0 0.001072276
alter O 0 0.0006902052
the O 0 0.0005952039
onset O 0 0.0009551038
of O 0 0.0006687619
first O 0 0.0006180113
clonus O 0 0.99936205
in O 0 0.0008626537
ovariectomized O 0 0.24633689
rats O 0 0.0011011731
but O 0 0.00092806556
accelerated O 0 0.0016259933
it O 0 0.0018112728
in O 0 0.0025319373
males O 0 0.0062922244
. O 0 0.0072509227

17beta B-Chemical 1 0.99999416
- I-Chemical 1 0.96882117
Estradiol I-Chemical 1 0.9999968
reduced O 0 0.0030685298
the O 0 0.001757776
argyrophilic O 0 0.9082752
neurons O 0 0.002430665
in O 0 0.00064145157
the O 0 0.0007964976
CA1 O 0 0.97529185
and O 0 0.0030863378
CA3 O 0 0.9990256
- O 0 0.14825243
C O 0 0.9977202
sectors O 0 0.08208872
of O 0 0.00443745
ovariectomized O 0 0.48938614
rats O 0 0.006938589
. O 0 0.0076176007

In O 0 0.0073422175
males O 0 0.010375429
, O 0 0.0139957145
estradiol B-Chemical 0 0.99989164
increased O 0 0.0061736563
the O 0 0.004582657
total O 0 0.005150292
damage O 0 0.6004958
score O 0 0.009508868
. O 0 0.012726578

These O 0 0.0034552354
findings O 0 0.0024405313
suggest O 0 0.0011326278
that O 0 0.00096380943
the O 0 0.0008751653
effects O 0 0.0015115142
of O 0 0.011377451
estradiol B-Chemical 0 0.99999654
on O 0 0.0007536325
seizure B-Disease 2 0.99997795
threshold O 0 0.00044990322
and O 0 0.0006990867
damage O 0 0.59377784
may O 0 0.00028099082
be O 0 0.0002594742
altered O 0 0.00030433518
by O 0 0.0004021073
sex O 0 0.031021861
- O 0 0.0034093633
related O 0 0.00037018993
differences O 0 0.00047685212
in O 0 0.000831605
the O 0 0.0014355622
hormonal O 0 0.048514135
environment O 0 0.0052733314
. O 0 0.007032306

Pseudoacromegaly B-Disease 0 0.15949394
induced O 0 0.0046173856
by O 0 0.0037423025
the O 0 0.0029289688
long O 0 0.0031088253
- O 0 0.005942861
term O 0 0.0033032119
use O 0 0.004686344
of O 0 0.012062652
minoxidil B-Chemical 0 0.9999825
. O 0 0.01635202

Acromegaly B-Disease 0 0.9969829
is O 0 0.004853713
an O 0 0.0065799113
endocrine B-Disease 0 0.99809664
disorder I-Disease 0 0.999648
caused O 0 0.001588024
by O 0 0.0013624337
chronic O 0 0.8960621
excessive O 0 0.12286677
growth O 0 0.18216375
hormone O 0 0.9218198
secretion O 0 0.0033209722
from O 0 0.000967327
the O 0 0.0014825594
anterior O 0 0.10757787
pituitary O 0 0.7779586
gland O 0 0.23649348
. O 0 0.008777145

Significant O 0 0.0050158068
disfiguring O 0 0.010450154
changes O 0 0.0022452576
occur O 0 0.0011647864
as O 0 0.000846081
a O 0 0.0007542597
result O 0 0.00045296375
of O 0 0.0006230094
bone O 0 0.02130553
, O 0 0.0010880496
cartilage O 0 0.061254334
, O 0 0.00054089323
and O 0 0.00040232835
soft O 0 0.018420808
tissue O 0 0.02969854
hypertrophy B-Disease 2 0.99881727
, O 0 0.0005991131
including O 0 0.00020073718
the O 0 0.00022214824
thickening O 0 0.31070283
of O 0 0.00033204412
the O 0 0.00031451441
skin O 0 0.040087122
, O 0 0.00076028466
coarsening O 0 0.45682612
of O 0 0.00068427855
facial O 0 0.10298997
features O 0 0.0012228505
, O 0 0.0012788835
and O 0 0.0021282479
cutis B-Disease 0 0.9944581
verticis I-Disease 0 0.99876094
gyrata I-Disease 0 0.9963977
. O 0 0.009600245

Pseudoacromegaly B-Disease 0 0.43836686
, O 0 0.0035735639
on O 0 0.0013751333
the O 0 0.0012052418
other O 0 0.0011431919
hand O 0 0.0014688602
, O 0 0.0009974702
is O 0 0.00047550243
the O 0 0.00032413256
presence O 0 0.00029140175
of O 0 0.00037297513
similar O 0 0.00025994793
acromegaloid O 0 0.5588504
features O 0 0.00039280156
in O 0 0.0001770609
the O 0 0.00015807452
absence O 0 0.00014026302
of O 0 0.00036657802
elevated O 0 0.012958804
growth O 0 0.061645184
hormone O 0 0.93596363
or O 0 0.0012222822
insulin O 0 0.98329645
- O 0 0.025735237
like O 0 0.00093022117
growth O 0 0.006030718
factor O 0 0.023024155
levels O 0 0.0045947144
. O 0 0.0072666765

We O 0 0.0035125078
present O 0 0.0020652118
a O 0 0.0019817064
patient O 0 0.0014203489
with O 0 0.0013614154
pseudoacromegaly B-Disease 0 0.8270928
that O 0 0.0004793779
resulted O 0 0.00037689306
from O 0 0.00031270733
the O 0 0.0003116249
long O 0 0.00038200137
- O 0 0.0016446727
term O 0 0.0003333922
use O 0 0.00045585155
of O 0 0.0014895428
minoxidil B-Chemical 0 0.9999939
at O 0 0.0008023393
an O 0 0.0012293326
unusually O 0 0.024041343
high O 0 0.0039631566
dose O 0 0.018012075
. O 0 0.00722359

This O 0 0.0056562033
is O 0 0.0028611938
the O 0 0.0018690455
first O 0 0.0012956853
case O 0 0.0013202431
report O 0 0.0018325686
of O 0 0.0016288543
pseudoacromegaly B-Disease 0 0.915383
as O 0 0.0009753783
a O 0 0.0013046104
side O 0 0.016969195
effect O 0 0.0016815348
of O 0 0.010674876
minoxidil B-Chemical 0 0.9999931
use O 0 0.007522071
. O 0 0.007896514

Combined O 0 0.16501126
androgen O 0 0.9994387
blockade O 0 0.3789457
- O 0 0.13842201
induced O 0 0.007867422
anemia B-Disease 0 0.9999919
in O 0 0.020717708
prostate B-Disease 2 0.9998466
cancer I-Disease 2 0.9999585
patients O 0 0.011678559
without O 0 0.00249165
bone O 0 0.025704337
involvement O 0 0.008203433
. O 0 0.008327197

BACKGROUND O 0 0.012693232
: O 0 0.003223492
To O 0 0.0012582971
determine O 0 0.00063171523
the O 0 0.00072587986
onset O 0 0.00091598195
and O 0 0.0005009916
extent O 0 0.00029607848
of O 0 0.00055732863
combined O 0 0.0065179863
androgen O 0 0.9998673
blockade O 0 0.1947501
( O 0 0.011401262
CAB O 0 0.6452406
) O 0 0.005532805
- O 0 0.021676425
induced O 0 0.0014117399
anemia B-Disease 0 0.99999404
in O 0 0.006585758
prostate B-Disease 2 0.9998253
cancer I-Disease 2 0.99996555
patients O 0 0.008087099
without O 0 0.0016764442
bone O 0 0.022932261
involvement O 0 0.006746312
. O 0 0.0068543027

PATIENTS O 0 0.0052497815
AND O 0 0.0029908728
METHODS O 0 0.0020504596
: O 0 0.0023315372
Forty O 0 0.002385949
- O 0 0.0024993513
two O 0 0.00075339945
patients O 0 0.0007413737
with O 0 0.00057971396
biopsy O 0 0.0022427668
- O 0 0.019213114
proven O 0 0.022745743
prostatic B-Disease 0 0.9999777
adenocarcinoma I-Disease 0 0.9999993
[ O 0 0.07462532
26 O 0 0.00044508945
with O 0 0.00028910657
stage O 0 0.0080023585
C O 0 0.9997193
( O 0 0.030039659
T3N0M0 O 0 0.99953544
) O 0 0.0010868884
and O 0 0.0002749961
16 O 0 0.00022458119
with O 0 0.00024341405
stage O 0 0.0086627165
D1 O 0 0.99966633
( O 0 0.01189024
T3N1M0 O 0 0.999108
) O 0 0.0020946795
] O 0 0.001124851
were O 0 0.0006609688
included O 0 0.0007965997
in O 0 0.0012618136
this O 0 0.0021343883
study O 0 0.0043690996
. O 0 0.0066934787

All O 0 0.0034208861
patients O 0 0.0030042087
received O 0 0.0019550754
CAB O 0 0.47217295
[ O 0 0.33556786
leuprolide B-Chemical 0 0.99998677
acetate I-Chemical 0 0.9999759
( O 0 0.11726057
LHRH B-Chemical 0 0.99987113
- I-Chemical 0 0.45632654
A I-Chemical 0 0.89643353
) O 0 0.0021472743
3 O 0 0.00026200843
. O 0 0.0002138433
75 O 0 0.00027972812
mg O 0 0.004942607
, O 0 0.00030996115
intramuscularly O 0 0.0005250453
, O 0 0.00021356679
every O 0 8.78477e-05
28 O 0 0.00012525197
days O 0 9.204259e-05
plus O 0 0.00012363862
250 O 0 0.00029526802
mg O 0 0.34629208
flutamide B-Chemical 0 0.99999404
, O 0 0.0074226693
tid O 0 0.9882647
, O 0 0.0003288638
per O 0 0.00017505651
Os O 0 0.9988223
] O 0 0.00060384383
and O 0 0.00018516586
were O 0 0.00014160243
evaluated O 0 0.00012509571
for O 0 0.00025307815
anemia B-Disease 0 0.9999275
by O 0 0.00024368525
physical O 0 0.0006743431
examination O 0 0.00019230452
and O 0 0.00018414485
laboratory O 0 0.00024253603
tests O 0 0.00019826285
at O 0 0.000109498345
baseline O 0 0.00012859015
and O 0 0.00014646312
4 O 0 0.00011742459
subsequent O 0 0.00012870817
intervals O 0 0.00013134691
( O 0 0.0002681132
1 O 0 0.00021025163
, O 0 0.00028697008
2 O 0 0.00024616387
, O 0 0.00032702138
3 O 0 0.00027335185
and O 0 0.0003718908
6 O 0 0.00040758768
months O 0 0.0005588577
post O 0 0.0012208755
- O 0 0.006018188
CAB O 0 0.099259965
) O 0 0.0074620345
. O 0 0.00842647

Hb O 0 0.9712601
, O 0 0.01604471
PSA O 0 0.926221
and O 0 0.015221493
Testosterone B-Chemical 1 0.9997819
measurements O 0 0.008047856
were O 0 0.009124284
recorded O 0 0.011302228
. O 0 0.016112737

Patients O 0 0.0044774977
with O 0 0.0029528951
stage O 0 0.063340165
D2 O 0 0.99975246
- O 0 0.07440589
3 O 0 0.0009684496
disease O 0 0.64525133
, O 0 0.0011489026
abnormal O 0 0.019273309
hemoglobin O 0 0.94050777
level O 0 0.0002761724
or O 0 0.0003438462
renal O 0 0.7259899
and O 0 0.0006158254
liver O 0 0.43297976
function O 0 0.00028003153
tests O 0 0.0003858949
that O 0 0.00016558202
were O 0 0.00021195608
higher O 0 0.00020287918
than O 0 0.00017790534
the O 0 0.0002595846
upper O 0 0.00045373553
limits O 0 0.0006838057
were O 0 0.00062048296
excluded O 0 0.00083819305
from O 0 0.0011670414
the O 0 0.0020502117
study O 0 0.0042965985
. O 0 0.0064402837

The O 0 0.0059211594
duration O 0 0.0046109725
of O 0 0.005106927
the O 0 0.004581513
study O 0 0.0053539765
was O 0 0.0050968914
six O 0 0.0049797557
months O 0 0.0067176702
. O 0 0.012400838

RESULTS O 0 0.0051709726
: O 0 0.0031579921
The O 0 0.0014247332
mean O 0 0.0010230517
hemoglobin O 0 0.9013036
( O 0 0.006278375
Hb O 0 0.9947857
) O 0 0.0014653032
levels O 0 0.00042552687
were O 0 0.00033078942
significantly O 0 0.00027932966
declined O 0 0.00033957974
in O 0 0.0002005126
all O 0 0.00016965502
patients O 0 0.00019823051
from O 0 0.00012749448
baseline O 0 0.00014911122
of O 0 0.00018667252
14 O 0 0.00017639225
. O 0 0.00014630094
2 O 0 0.00015362244
g O 0 0.00035332335
/ O 0 0.0011614205
dl O 0 0.013570061
to O 0 0.00015803004
14 O 0 0.00017056397
. O 0 0.00014413969
0 O 0 0.00018126401
g O 0 0.00039626932
/ O 0 0.001995328
dl O 0 0.056167502
, O 0 0.0003959123
13 O 0 0.00022675087
. O 0 0.00015573921
5 O 0 0.0001465056
g O 0 0.00036447222
/ O 0 0.0016169423
dl O 0 0.049865454
, O 0 0.00040814644
13 O 0 0.00024073075
. O 0 0.00016931482
2 O 0 0.00017203564
g O 0 0.00036854163
/ O 0 0.0012051683
dl O 0 0.019639961
and O 0 0.00026561166
12 O 0 0.00015827434
. O 0 0.00015432923
7 O 0 0.00015324936
g O 0 0.00034721618
/ O 0 0.0009935882
dl O 0 0.012200706
at O 0 0.00021276559
1 O 0 0.00023527014
, O 0 0.0002946002
2 O 0 0.00024289775
, O 0 0.00030773133
3 O 0 0.00024508193
and O 0 0.00031556233
6 O 0 0.00032359007
months O 0 0.00041485322
post O 0 0.0008600921
- O 0 0.0048695705
CAB O 0 0.07519566
, O 0 0.003907122
respectively O 0 0.008237749
. O 0 0.008313812

Severe O 0 0.3245598
and O 0 0.0037412609
clinically O 0 0.03493312
evident O 0 0.003999957
anemia B-Disease 0 0.999966
of O 0 0.010915597
Hb O 0 0.9972019
< O 0 0.00049167825
11 O 0 0.00039316065
g O 0 0.0006805598
/ O 0 0.0017032032
dl O 0 0.021338927
with O 0 0.00035886953
clinical O 0 0.0017807116
symptoms O 0 0.030187033
was O 0 0.00022617479
detected O 0 0.00020702778
in O 0 0.00026284184
6 O 0 0.00027213802
patients O 0 0.00048249753
( O 0 0.0006849748
14 O 0 0.00070150854
. O 0 0.0009073686
3 O 0 0.0013791226
% O 0 0.0028567053
) O 0 0.0056443433
. O 0 0.0077991346

This O 0 0.0145610785
CAB O 0 0.3348437
- O 0 0.031584546
induced O 0 0.011866733
anemia B-Disease 0 0.9999503
was O 0 0.013523927
normochromic O 0 0.97554976
and O 0 0.010991598
normocytic O 0 0.97559017
. O 0 0.014090058

At O 0 0.0026220193
six O 0 0.001669924
months O 0 0.0012943575
post O 0 0.0014597282
- O 0 0.015271536
CAB O 0 0.123468935
, O 0 0.0011118747
patients O 0 0.0008395919
with O 0 0.0007302225
severe O 0 0.50447893
anemia B-Disease 0 0.99999
had O 0 0.0005811811
a O 0 0.000635292
Hb O 0 0.89553595
mean O 0 0.00010746263
value O 0 0.00014491197
of O 0 0.0001930861
10 O 0 0.00016797228
. O 0 0.00015444936
2 O 0 0.00017847455
+ O 0 0.00070355664
/ O 0 0.0064928015
- O 0 0.008186358
0 O 0 0.00024855026
. O 0 0.00016643268
1 O 0 0.00017057291
g O 0 0.00038879926
/ O 0 0.0023543995
dl O 0 0.14245659
( O 0 0.0033663197
X O 0 0.97541547
+ O 0 0.027157657
/ O 0 0.08855324
- O 0 0.17177433
SE O 0 0.9426459
) O 0 0.0016064598
, O 0 0.00038016788
whereas O 0 0.00022394037
the O 0 0.00017397889
other O 0 0.00020730236
patients O 0 0.00033307835
had O 0 0.00027309163
mild O 0 0.86911666
anemia B-Disease 0 0.9999927
with O 0 0.002317803
Hb O 0 0.969296
mean O 0 9.372927e-05
value O 0 0.00013415611
of O 0 0.0001940436
13 O 0 0.00020924247
. O 0 0.00016598083
2 O 0 0.00020083215
+ O 0 0.00070542836
/ O 0 0.004891729
- O 0 0.0062607317
0 O 0 0.00038087138
. O 0 0.00033826966
17 O 0 0.00054823986
( O 0 0.0010327031
X O 0 0.81935924
+ O 0 0.009932365
/ O 0 0.03538688
- O 0 0.069958754
SE O 0 0.77998346
) O 0 0.008410684
. O 0 0.008626632

The O 0 0.0032229377
development O 0 0.0032644738
of O 0 0.0027339447
severe O 0 0.5666907
anemia B-Disease 0 0.9999722
at O 0 0.0006794351
6 O 0 0.00034887253
months O 0 0.0002576087
post O 0 0.0003575728
- O 0 0.006934578
CAB O 0 0.051458664
was O 0 0.00028159612
predictable O 0 0.00043725185
by O 0 0.00019724689
the O 0 0.00018492433
reduction O 0 0.00037293797
of O 0 0.00053225015
Hb O 0 0.98550355
baseline O 0 0.00018151221
value O 0 0.00014747676
of O 0 0.00020414824
more O 0 0.00020668106
than O 0 0.00012357402
2 O 0 0.00014766263
. O 0 0.00013660674
5 O 0 0.00013797631
g O 0 0.00034287252
/ O 0 0.0009760514
dl O 0 0.0075033973
after O 0 0.00016206664
3 O 0 0.00019202435
months O 0 0.00018878143
of O 0 0.00037727485
CAB O 0 0.035087142
( O 0 0.00081769674
p O 0 0.0007736329
= O 0 0.0014528434
0 O 0 0.0014689426
. O 0 0.0019958045
01 O 0 0.005873279
) O 0 0.0060587362
. O 0 0.008160172

The O 0 0.0032871622
development O 0 0.0033779605
of O 0 0.0028436345
severe O 0 0.5275031
CAB O 0 0.87383765
- O 0 0.08975042
induced O 0 0.004133046
anemia B-Disease 0 0.99999654
in O 0 0.023673242
prostate B-Disease 2 0.99995124
cancer I-Disease 2 0.9999931
patients O 0 0.013033818
did O 0 0.00034165606
not O 0 0.0001714466
correlate O 0 0.00018138332
with O 0 0.0003128612
T O 0 0.7873775
baseline O 0 0.00023231929
values O 0 0.0002070349
( O 0 0.00071627845
T O 0 0.79227954
< O 0 0.00020142643
3 O 0 0.00015074985
ng O 0 0.00028090217
/ O 0 0.0014213475
ml O 0 0.00056771137
versus O 0 0.00030237838
T O 0 0.91682845
> O 0 0.0017257064
or O 0 0.0002461831
= O 0 0.0005287348
3 O 0 0.0001564729
ng O 0 0.0003219665
/ O 0 0.0034937386
ml O 0 0.0012713899
) O 0 0.00074776355
, O 0 0.0003081735
with O 0 0.00023090883
age O 0 0.00052255567
( O 0 0.0003227871
< O 0 0.00017237487
76 O 0 0.00026421092
yrs O 0 0.00025093855
versus O 0 0.0001700672
> O 0 0.00038724125
or O 0 0.00021439145
= O 0 0.00047435344
76 O 0 0.00038680737
yrs O 0 0.0004326465
) O 0 0.00042391138
, O 0 0.00032459918
and O 0 0.0003169414
clinical O 0 0.0008771882
stage O 0 0.0010361712
( O 0 0.0009278123
stage O 0 0.0052283383
C O 0 0.996811
versus O 0 0.0019482381
stage O 0 0.076418854
D1 O 0 0.9989385
) O 0 0.011226286
. O 0 0.008062545

Severe O 0 0.38652742
and O 0 0.003887541
clinically O 0 0.051377397
evident O 0 0.0047362745
anemia B-Disease 0 0.9999597
was O 0 0.0009344871
easily O 0 0.00048684023
corrected O 0 0.00028962217
by O 0 0.00032091903
subcutaneous O 0 0.0015115285
injections O 0 0.00048577174
( O 0 0.0003229786
3 O 0 0.0001628806
times O 0 0.00012709635
/ O 0 0.0003755338
week O 0 0.00014842775
for O 0 0.00017642186
1 O 0 0.00019906675
month O 0 0.00018965322
) O 0 0.000388444
of O 0 0.00041108986
recombinant O 0 0.001011287
erythropoietin O 0 0.9978532
( O 0 0.02905592
rHuEPO O 0 0.9910319
- O 0 0.09742712
beta O 0 0.8970577
) O 0 0.021678362
. O 0 0.00872728

CONCLUSION O 0 0.018577972
: O 0 0.0039038556
Our O 0 0.0020434298
data O 0 0.001398061
suggest O 0 0.000789166
that O 0 0.0010378477
rHuEPO O 0 0.9906102
- O 0 0.34864867
beta O 0 0.9904608
correctable O 0 0.879989
CAB O 0 0.9195151
- O 0 0.074292
induced O 0 0.0015488244
anemia B-Disease 0 0.99998844
occurs O 0 0.0005185429
in O 0 0.00030265815
14 O 0 0.00024426958
. O 0 0.00019393559
3 O 0 0.00019304521
% O 0 0.00029369723
of O 0 0.00062547904
prostate B-Disease 2 0.9992021
cancer I-Disease 2 0.9999449
patients O 0 0.0019064686
after O 0 0.00048546254
6 O 0 0.0006725429
months O 0 0.0009388573
of O 0 0.0022002042
therapy O 0 0.0051538157
. O 0 0.0067500835

Delirium B-Disease 2 0.9975745
during O 0 0.0059053553
clozapine B-Chemical 0 0.9999882
treatment O 0 0.006146735
: O 0 0.00424702
incidence O 0 0.005593043
and O 0 0.0032912756
associated O 0 0.004378644
risk O 0 0.13194847
factors O 0 0.02328073
. O 0 0.012283211

BACKGROUND O 0 0.019528052
: O 0 0.0052669174
Incidence O 0 0.011333442
and O 0 0.0023610608
risk O 0 0.034427937
factors O 0 0.005641208
for O 0 0.0031703718
delirium B-Disease 2 0.99999106
during O 0 0.0019721405
clozapine B-Chemical 0 0.9999962
treatment O 0 0.0018116091
require O 0 0.0014920115
further O 0 0.0024166773
clarification O 0 0.0045477087
. O 0 0.0076543917

METHODS O 0 0.004169676
: O 0 0.0034976997
We O 0 0.0019135963
used O 0 0.0014427511
computerized O 0 0.002038989
pharmacy O 0 0.002099068
records O 0 0.00077547453
to O 0 0.0004267323
identify O 0 0.00032472177
all O 0 0.00032611814
adult O 0 0.00075589167
psychiatric B-Disease 2 0.97614473
inpatients O 0 0.011890223
treated O 0 0.00041831107
with O 0 0.0020058048
clozapine B-Chemical 0 0.9999994
( O 0 0.0022971116
1995 O 0 0.026620807
- O 0 0.013094789
96 O 0 0.00088485965
) O 0 0.00039424535
, O 0 0.00026340454
reviewed O 0 0.00027496752
their O 0 0.00018866733
medical O 0 0.00039084375
records O 0 0.00019493279
to O 0 0.00012461937
score O 0 0.00015517237
incidence O 0 0.00049606577
and O 0 0.0002757948
severity O 0 0.004958338
of O 0 0.0030444884
delirium B-Disease 2 0.9999957
, O 0 0.0006811944
and O 0 0.00036518247
tested O 0 0.00032897576
associations O 0 0.00049830787
with O 0 0.0007891599
potential O 0 0.0016238093
risk O 0 0.13037531
factors O 0 0.021441381
. O 0 0.008009144

RESULTS O 0 0.0059666797
: O 0 0.004022459
Subjects O 0 0.0026212912
( O 0 0.0019508201
n O 0 0.0012233305
= O 0 0.001630659
139 O 0 0.0016882931
) O 0 0.001049556
were O 0 0.0005459027
72 O 0 0.00058227195
women O 0 0.0008897235
and O 0 0.0003968687
67 O 0 0.000652383
men O 0 0.004237092
, O 0 0.00038044082
aged O 0 0.0003777535
40 O 0 0.00023038105
. O 0 0.00019670899
8 O 0 0.00021307253
+ O 0 0.00069327926
/ O 0 0.005741336
- O 0 0.005949642
12 O 0 0.00017691746
. O 0 0.00016549567
1 O 0 0.00016673685
years O 0 0.0002024033
, O 0 0.00025503465
hospitalized O 0 0.0024676567
for O 0 0.00018616309
24 O 0 0.00019523618
. O 0 0.00015546015
9 O 0 0.00018453789
+ O 0 0.00082961214
/ O 0 0.010301648
- O 0 0.0138123
23 O 0 0.0003495837
. O 0 0.00015947384
3 O 0 0.00013291792
days O 0 0.00011494478
, O 0 0.00021078513
and O 0 0.00022697888
given O 0 0.00023646092
clozapine B-Chemical 0 0.9999987
, O 0 0.0005487773
gradually O 0 0.00034542175
increased O 0 0.00019092216
to O 0 0.00012625853
an O 0 0.00015040152
average O 0 0.00010020952
daily O 0 0.00016841204
dose O 0 0.0004127084
of O 0 0.0002979056
282 O 0 0.062798664
+ O 0 0.0073230937
/ O 0 0.029290626
- O 0 0.028290449
203 O 0 0.009010371
mg O 0 0.016274728
( O 0 0.00030195087
3 O 0 0.00014629925
. O 0 0.00014190261
45 O 0 0.00017404958
+ O 0 0.0006762954
/ O 0 0.00684487
- O 0 0.008763711
2 O 0 0.00021089171
. O 0 0.00016832438
45 O 0 0.0001858995
mg O 0 0.0022483575
/ O 0 0.00069799455
kg O 0 0.0006248775
) O 0 0.0004082655
for O 0 0.00023682056
18 O 0 0.00028400926
. O 0 0.00027826487
9 O 0 0.00037200836
+ O 0 0.0010133731
/ O 0 0.0038105424
- O 0 0.004691449
16 O 0 0.001210079
. O 0 0.0013635708
4 O 0 0.0019952878
days O 0 0.0030610848
. O 0 0.0067321146

Delirium B-Disease 2 0.99574465
was O 0 0.0031051342
diagnosed O 0 0.0033844311
in O 0 0.0013079216
14 O 0 0.0009994069
( O 0 0.000956062
10 O 0 0.0005547728
. O 0 0.00043446483
1 O 0 0.0003836612
% O 0 0.000411289
incidence O 0 0.00089057715
, O 0 0.0004630377
or O 0 0.0002955147
1 O 0 0.0002688999
. O 0 0.00021538681
48 O 0 0.00023589416
cases O 0 0.00031173546
/ O 0 0.0014984023
person O 0 0.00071338215
- O 0 0.0042386595
years O 0 0.00028230768
of O 0 0.0002927093
exposure O 0 0.0057084723
) O 0 0.0016080139
; O 0 0.0007357701
71 O 0 0.0006464484
. O 0 0.00027363273
4 O 0 0.00028413438
% O 0 0.00042140376
of O 0 0.0005387235
cases O 0 0.00094694254
were O 0 0.0010568363
moderate O 0 0.0047677457
or O 0 0.0026773466
severe O 0 0.17732069
. O 0 0.0076326835

Associated O 0 0.00780815
factors O 0 0.0051242034
were O 0 0.002653496
co O 0 0.59268904
- O 0 0.025754951
treatment O 0 0.00097567105
with O 0 0.0006121318
other O 0 0.0005573949
centrally O 0 0.0046240394
antimuscarinic O 0 0.9884594
agents O 0 0.008475717
, O 0 0.0004721055
poor O 0 0.0011073591
clinical O 0 0.0017861716
outcome O 0 0.0008928984
, O 0 0.00040666864
older O 0 0.0015554605
age O 0 0.00049127406
, O 0 0.00026895347
and O 0 0.0001942513
longer O 0 0.00011824247
hospitalization O 0 0.0032861661
( O 0 0.00030856716
by O 0 0.00018356336
17 O 0 0.00021443234
. O 0 0.00012825828
5 O 0 0.000112404065
days O 0 0.000103714076
, O 0 0.00018598567
increasing O 0 0.00017577775
cost O 0 0.00044098316
) O 0 0.0011319967
; O 0 0.000961245
sex O 0 0.01868423
, O 0 0.00040507363
diagnosis O 0 0.0014159488
or O 0 0.00025197834
medical O 0 0.009407265
co O 0 0.8277998
- O 0 0.19026053
morbidity O 0 0.8071531
, O 0 0.0005763804
and O 0 0.00042667965
daily O 0 0.003749852
clozapine B-Chemical 0 0.99999857
dose O 0 0.00797073
, O 0 0.0005851059
which O 0 0.0004823688
fell O 0 0.000751908
with O 0 0.0006685175
age O 0 0.0015885268
, O 0 0.0017739951
were O 0 0.0021651376
unrelated O 0 0.0045058127
. O 0 0.0064013368

CONCLUSIONS O 0 0.06369412
: O 0 0.009543426
Delirium B-Disease 2 0.9954668
was O 0 0.0016404057
found O 0 0.00094401266
in O 0 0.0007356699
10 O 0 0.0005975048
% O 0 0.0006812353
of O 0 0.0017159806
clozapine B-Chemical 0 0.9999994
- O 0 0.0550038
treated O 0 0.00070144073
inpatients O 0 0.015741285
, O 0 0.0005011961
particularly O 0 0.00055356347
in O 0 0.0003757761
older O 0 0.0011744653
patients O 0 0.00059435295
exposed O 0 0.0006647637
to O 0 0.00076202914
other O 0 0.0015208103
central O 0 0.0068202587
anticholinergics O 0 0.9982607
. O 0 0.0067966683

Delirium B-Disease 2 0.9970329
was O 0 0.0032701106
inconsistently O 0 0.0051347762
recognized O 0 0.001742393
clinically O 0 0.011554451
in O 0 0.0008693006
milder O 0 0.047827058
cases O 0 0.00095275935
and O 0 0.00049134373
was O 0 0.00031726007
associated O 0 0.00028120494
with O 0 0.00026484524
increased O 0 0.0002796937
length O 0 0.0002888575
- O 0 0.0067196786
of O 0 0.0004998861
- O 0 0.0035107776
stay O 0 0.00033512161
and O 0 0.00037198263
higher O 0 0.00040395706
costs O 0 0.00085085747
, O 0 0.00088201155
and O 0 0.0011658852
inferior O 0 0.019449633
clinical O 0 0.003964842
outcome O 0 0.0053459066
. O 0 0.0063317353

Neuroprotective O 0 0.9506971
action O 0 0.014667072
of O 0 0.05394091
MPEP B-Chemical 1 0.99999964
, O 0 0.014480275
a O 0 0.0021490892
selective O 0 0.025906468
mGluR5 O 0 0.99454933
antagonist O 0 0.9645805
, O 0 0.0031321472
in O 0 0.0028017382
methamphetamine B-Chemical 1 0.99999976
- O 0 0.16535512
induced O 0 0.0012997412
dopaminergic O 0 0.9853764
neurotoxicity B-Disease 2 0.9999875
is O 0 0.00038844085
associated O 0 0.0002800203
with O 0 0.00025447868
a O 0 0.00029781958
decrease O 0 0.000274034
in O 0 0.0005925701
dopamine B-Chemical 1 0.9997533
outflow O 0 0.5433096
and O 0 0.00073921954
inhibition O 0 0.0017728454
of O 0 0.0029728268
hyperthermia B-Disease 2 0.9994912
in O 0 0.0030482376
rats O 0 0.005915509
. O 0 0.006224321

The O 0 0.003145124
aim O 0 0.0023759424
of O 0 0.0017577693
this O 0 0.0012019564
study O 0 0.0010276308
was O 0 0.0005888773
to O 0 0.00035334512
examine O 0 0.0001990341
the O 0 0.00025813287
role O 0 0.00022693255
of O 0 0.006819141
metabotropic O 0 0.9999974
glutamate B-Chemical 1 0.9999951
receptor O 0 0.25230458
5 O 0 0.0002935161
( O 0 0.0008086066
mGluR5 O 0 0.85154885
) O 0 0.0005735507
in O 0 0.00021643423
the O 0 0.00026850868
toxic O 0 0.30911645
action O 0 0.001083869
of O 0 0.0037786558
methamphetamine B-Chemical 1 0.99999833
on O 0 0.0007085145
dopaminergic O 0 0.5021901
neurones O 0 0.008918453
in O 0 0.0020801905
rats O 0 0.0043158988
. O 0 0.005929737

Methamphetamine B-Chemical 1 0.99997735
( O 0 0.006497356
10 O 0 0.0020981508
mg O 0 0.03604744
/ O 0 0.004133476
kg O 0 0.003585798
sc O 0 0.07230314
) O 0 0.001355525
, O 0 0.00056192157
administered O 0 0.00028367343
five O 0 0.0001745956
times O 0 0.00014903674
, O 0 0.00025697926
reduced O 0 0.00019311778
the O 0 0.00018623054
levels O 0 0.00022906641
of O 0 0.0011832572
dopamine B-Chemical 1 0.99985504
and O 0 0.000444456
its O 0 0.0019291954
metabolites O 0 0.8369051
in O 0 0.00032183423
striatal O 0 0.55405354
tissue O 0 0.00079181604
when O 0 0.00018980606
measured O 0 0.00026296166
72 O 0 0.00047873627
h O 0 0.00049093534
after O 0 0.0005155998
the O 0 0.0009932937
last O 0 0.001446283
injection O 0 0.0037762541
. O 0 0.005853198

A O 0 0.1555825
selective O 0 0.011524874
antagonist O 0 0.819697
of O 0 0.0049105664
mGluR5 O 0 0.98582524
, O 0 0.0029516863
2 B-Chemical 0 0.0010717241
- I-Chemical 0 0.06740551
methyl I-Chemical 0 0.99595934
- I-Chemical 0 0.033178087
6 I-Chemical 0 0.00034493717
- I-Chemical 0 0.0045847497
( I-Chemical 0 0.0008979098
phenylethynyl I-Chemical 0 0.90484244
) I-Chemical 0 0.028105471
pyridine I-Chemical 0 0.9999665
( O 0 0.15751839
MPEP B-Chemical 1 0.9999999
; O 0 0.0022178476
5 O 0 0.00018918615
mg O 0 0.0081894435
/ O 0 0.0015690067
kg O 0 0.0025387455
ip O 0 0.42913577
) O 0 0.00075927464
, O 0 0.0002680309
when O 0 0.00011867135
administered O 0 0.00012636126
five O 0 9.238712e-05
times O 0 8.618644e-05
immediately O 0 0.00012122671
before O 0 0.00010995056
each O 0 0.00016340766
methamphetamine B-Chemical 1 0.99999356
injection O 0 0.000649254
reversed O 0 0.00035567806
the O 0 0.00037866156
above O 0 0.000545876
- O 0 0.011895042
mentioned O 0 0.0015959227
methamphetamine B-Chemical 1 0.9999881
effects O 0 0.0065747458
. O 0 0.0068614827

A O 0 0.2022071
single O 0 0.013099665
MPEP B-Chemical 1 0.99999785
( O 0 0.0054175444
5 O 0 0.0010729735
mg O 0 0.031318795
/ O 0 0.0035893775
kg O 0 0.0036291196
ip O 0 0.50239277
) O 0 0.001054977
injection O 0 0.0005074467
reduced O 0 0.00024011137
the O 0 0.00022922504
basal O 0 0.001269715
extracellular O 0 0.05141721
dopamine B-Chemical 1 0.9997855
level O 0 0.00016492384
in O 0 0.00017195428
the O 0 0.00023165107
striatum O 0 0.44879317
, O 0 0.0002443106
as O 0 0.00013336608
well O 0 0.00015734532
as O 0 0.00030592587
dopamine B-Chemical 1 0.9995427
release O 0 0.0010923326
stimulated O 0 0.0001537602
either O 0 0.00023249633
by O 0 0.0012181463
methamphetamine B-Chemical 1 0.9999994
( O 0 0.0011658208
10 O 0 0.00020674057
mg O 0 0.011722162
/ O 0 0.0014780697
kg O 0 0.0015833768
sc O 0 0.022445552
) O 0 0.00049870554
or O 0 0.0002597438
by O 0 0.00040484837
intrastriatally O 0 0.7262443
administered O 0 0.0013094342
veratridine B-Chemical 0 0.9999101
( O 0 0.0041403174
100 O 0 0.00453515
microM O 0 0.61290354
) O 0 0.0075684753
. O 0 0.007120794

Moreover O 0 0.005080603
, O 0 0.0037279993
it O 0 0.00220171
transiently O 0 0.0031251027
diminished O 0 0.0019040437
the O 0 0.003140991
methamphetamine B-Chemical 1 0.99999905
( O 0 0.0026701523
10 O 0 0.00046404052
mg O 0 0.016686494
/ O 0 0.0018412856
kg O 0 0.0021606477
sc O 0 0.05879029
) O 0 0.0017459133
- O 0 0.0071960567
induced O 0 0.0009884717
hyperthermia B-Disease 2 0.9994424
and O 0 0.0013299609
reduced O 0 0.0013648452
basal O 0 0.0033444483
body O 0 0.0076409727
temperature O 0 0.011736546
. O 0 0.0070998454

MPEP B-Chemical 1 0.99998724
administered O 0 0.0032041643
into O 0 0.0010930373
the O 0 0.0010825497
striatum O 0 0.2648997
at O 0 0.0004953175
high O 0 0.000600761
concentrations O 0 0.0014312433
( O 0 0.0009014824
500 O 0 0.0012219918
microM O 0 0.49469638
) O 0 0.0012940469
increased O 0 0.00047030117
extracellular O 0 0.082623266
dopamine B-Chemical 1 0.99990666
levels O 0 0.0003123787
, O 0 0.0003763443
while O 0 0.00022831696
lower O 0 0.00020786426
concentrations O 0 0.0007921782
( O 0 0.00057699933
50 O 0 0.00050329097
- O 0 0.0050130947
100 O 0 0.00085954485
microM O 0 0.24921669
) O 0 0.00094405626
were O 0 0.0005902891
devoid O 0 0.0006376805
of O 0 0.0013937086
any O 0 0.0019603653
effect O 0 0.0034930476
. O 0 0.0068216086

The O 0 0.003024716
results O 0 0.0020183597
of O 0 0.001773296
this O 0 0.001175996
study O 0 0.0009287573
suggest O 0 0.00042986314
that O 0 0.00042593793
the O 0 0.00047460358
blockade O 0 0.008984205
of O 0 0.0022057362
mGluR5 O 0 0.991998
by O 0 0.0057384274
MPEP B-Chemical 1 0.99999964
may O 0 0.00045254506
protect O 0 0.00076127506
dopaminergic O 0 0.67141753
neurones O 0 0.031077242
against O 0 0.00209
methamphetamine B-Chemical 1 0.9999989
- O 0 0.17391068
induced O 0 0.007357177
toxicity B-Disease 2 0.999169
. O 0 0.009550636

Neuroprotection O 0 0.95899254
rendered O 0 0.006511089
by O 0 0.011473907
MPEP B-Chemical 1 0.9999988
may O 0 0.0014659731
be O 0 0.00074673776
associated O 0 0.00055112224
with O 0 0.00041802152
the O 0 0.00031536145
reduction O 0 0.0005680117
of O 0 0.00055358646
the O 0 0.0034882077
methamphetamine B-Chemical 1 0.9999999
- O 0 0.28649348
induced O 0 0.0034896105
dopamine B-Chemical 1 0.999964
efflux O 0 0.061815117
in O 0 0.00019484824
the O 0 0.00021286806
striatum O 0 0.14053045
due O 0 0.00011049121
to O 0 0.00012755372
the O 0 0.0001694563
blockade O 0 0.002718246
of O 0 0.0020445795
extrastriatal O 0 0.9996811
mGluR5 O 0 0.914374
, O 0 0.00057900406
and O 0 0.0004929937
with O 0 0.0006659006
a O 0 0.0010976661
decrease O 0 0.0015381705
in O 0 0.0033329763
hyperthermia B-Disease 2 0.9989691
. O 0 0.008312955

Protective O 0 0.42318994
efficacy O 0 0.0058669904
of O 0 0.0055637057
neuroactive O 0 0.99331176
steroids B-Chemical 0 0.99987686
against O 0 0.09351168
cocaine B-Chemical 1 0.9999994
kindled O 0 0.999985
- O 0 0.7823973
seizures B-Disease 0 0.9999918
in O 0 0.003793053
mice O 0 0.004045147
. O 0 0.008334746

Neuroactive O 0 0.97247666
steroids B-Chemical 0 0.9951715
demonstrate O 0 0.0015383478
pharmacological O 0 0.012450879
actions O 0 0.0018954787
that O 0 0.00060514786
have O 0 0.00049702276
relevance O 0 0.00043773773
for O 0 0.00054216356
a O 0 0.00076711876
host O 0 0.0016618485
of O 0 0.002120175
neurological B-Disease 0 0.9856527
and I-Disease 0 0.015847266
psychiatric I-Disease 2 0.9999182
disorders I-Disease 0 0.9977367
. O 0 0.008540413

They O 0 0.0050805532
offer O 0 0.003018519
protection O 0 0.0055334438
against O 0 0.0043421653
seizures B-Disease 0 0.99999714
in O 0 0.0013053481
a O 0 0.00078715757
range O 0 0.00047391394
of O 0 0.0004354827
models O 0 0.00040390776
and O 0 0.00040993973
seem O 0 0.000323034
to O 0 0.00023714908
inhibit O 0 0.00023569718
certain O 0 0.0003910059
stages O 0 0.0005561684
of O 0 0.0010344648
drug B-Disease 0 0.9558492
dependence I-Disease 0 0.083448246
in O 0 0.0015376946
preclinical O 0 0.005616967
assessments O 0 0.0035889733
. O 0 0.0059460723

The O 0 0.0029909043
present O 0 0.0018642162
study O 0 0.0016583974
was O 0 0.00098681
designed O 0 0.0006356361
to O 0 0.00040678226
evaluate O 0 0.00021985482
two O 0 0.00023231197
endogenous O 0 0.0002455792
and O 0 0.00031048467
one O 0 0.00022872705
synthetic O 0 0.0005462455
neuroactive O 0 0.9753582
steroid B-Chemical 1 0.99723154
that O 0 0.00017228647
positively O 0 0.00020310195
modulate O 0 0.00010192332
the O 0 0.00047679938
gamma B-Chemical 0 0.99805224
- I-Chemical 0 0.95714474
aminobutyric I-Chemical 0 0.99999523
acid I-Chemical 0 0.999134
( O 0 0.31739226
GABA B-Chemical 1 0.99999917
( O 0 0.012321253
A O 0 0.5435376
) O 0 0.0039157425
) O 0 0.0013539696
receptor O 0 0.005464903
against O 0 0.00019942448
the O 0 0.00018399743
increase O 0 0.00014079285
in O 0 0.00017478266
sensitivity O 0 0.0007470324
to O 0 0.00016529602
the O 0 0.00034530502
convulsant O 0 0.9995161
effects O 0 0.0006918364
of O 0 0.0023954322
cocaine B-Chemical 1 0.9999876
engendered O 0 0.0012250083
by O 0 0.00038336162
repeated O 0 0.0004827149
cocaine B-Chemical 1 0.9999851
administration O 0 0.14545539
( O 0 0.039043423
seizure B-Disease 2 0.99999034
kindling O 0 0.99979156
) O 0 0.011245376
. O 0 0.0068705683

Allopregnanolone B-Chemical 0 0.9999316
( O 0 0.111777715
3alpha B-Chemical 0 0.9991793
- I-Chemical 0 0.8378718
hydroxy I-Chemical 0 0.9999913
- I-Chemical 0 0.85271245
5alpha I-Chemical 0 0.9996019
- I-Chemical 0 0.35603532
pregnan I-Chemical 0 0.8296331
- I-Chemical 0 0.025245333
20 I-Chemical 0 0.00042170592
- I-Chemical 0 0.0018488412
one I-Chemical 0 0.0002696979
) O 0 0.0010855519
, O 0 0.007265738
pregnanolone B-Chemical 0 0.99999905
( O 0 0.058178186
3alpha B-Chemical 0 0.99955577
- I-Chemical 0 0.8375865
hydroxy I-Chemical 0 0.999997
- I-Chemical 0 0.84155184
5beta I-Chemical 0 0.9998204
- I-Chemical 0 0.3249041
pregnan I-Chemical 0 0.7735093
- I-Chemical 0 0.021986602
20 I-Chemical 0 0.00025888512
- I-Chemical 0 0.0015854366
one I-Chemical 0 0.00017621524
) O 0 0.0004962828
and O 0 0.0006744434
ganaxolone B-Chemical 0 0.9997235
( O 0 0.00071543764
a O 0 0.0002716325
synthetic O 0 0.00027840392
derivative O 0 0.041060016
of O 0 0.037699383
allopregnanolone B-Chemical 0 1.0
3alpha B-Chemical 0 0.9999528
- I-Chemical 0 0.9454013
hydroxy I-Chemical 0 0.999998
- I-Chemical 0 0.81427145
3beta I-Chemical 0 0.9973367
- I-Chemical 0 0.5359289
methyl I-Chemical 0 0.99941623
- I-Chemical 0 0.51058
5alpha I-Chemical 0 0.99916494
- I-Chemical 0 0.25895077
pregnan I-Chemical 0 0.76705563
- I-Chemical 0 0.02349841
20 I-Chemical 0 0.00024946837
- I-Chemical 0 0.0015087783
one I-Chemical 0 0.00015719894
) O 0 0.0002819292
were O 0 0.00014021755
tested O 0 0.000117977674
for O 0 0.0001283492
their O 0 0.00013788781
ability O 0 0.00012858231
to O 0 0.000110061235
suppress O 0 9.216195e-05
the O 0 0.00015673348
expression O 0 0.00039404654
( O 0 0.0047773393
anticonvulsant O 0 0.9994438
effect O 0 0.00026757974
) O 0 0.00080710434
and O 0 0.00029374115
development O 0 0.0023981004
( O 0 0.0033495508
antiepileptogenic O 0 0.9880833
effect O 0 0.00035157567
) O 0 0.0024475078
of O 0 0.009278202
cocaine B-Chemical 1 0.99999917
- O 0 0.85348177
kindled O 0 0.9999614
seizures B-Disease 0 0.99999845
in O 0 0.0008378377
male O 0 0.009176258
, O 0 0.0018282771
Swiss O 0 0.035093077
- O 0 0.019917648
Webster O 0 0.10303059
mice O 0 0.0032535782
. O 0 0.007100955

Kindled O 0 0.99973696
seizures B-Disease 0 0.9999865
were O 0 0.0024743169
induced O 0 0.0014371126
by O 0 0.0011493558
daily O 0 0.0010500946
administration O 0 0.002283435
of O 0 0.00071303756
60 O 0 0.0006931742
mg O 0 0.024609087
/ O 0 0.0035515488
kg O 0 0.010994945
cocaine B-Chemical 1 0.9998178
for O 0 0.0016748233
5 O 0 0.0020809306
days O 0 0.0030756856
. O 0 0.0065833726

All O 0 0.0029128804
of O 0 0.0024239474
these O 0 0.0020492305
positive O 0 0.016506149
GABA B-Chemical 1 0.9999957
( O 0 0.025171269
A O 0 0.49651247
) O 0 0.0026881222
modulators O 0 0.0024145711
suppressed O 0 0.00035073154
the O 0 0.00029720206
expression O 0 0.00045384627
of O 0 0.005098074
kindled O 0 0.99998
seizures B-Disease 0 0.99999976
, O 0 0.004625257
whereas O 0 0.0009484989
only O 0 0.007931943
allopregnanolone B-Chemical 0 0.9999994
and O 0 0.008713819
ganaxolone B-Chemical 0 0.9997888
inhibited O 0 0.0011760017
the O 0 0.0010072826
development O 0 0.0036656987
of O 0 0.008491552
kindling O 0 0.999355
. O 0 0.0075620813

Allopregnanolone B-Chemical 0 0.9999219
and O 0 0.11498839
pregnanolone B-Chemical 0 0.9999963
, O 0 0.010886703
but O 0 0.0025783118
not O 0 0.0016878085
ganaxolone B-Chemical 0 0.99978846
, O 0 0.0015866373
also O 0 0.00077711523
reduced O 0 0.00092781056
cumulative O 0 0.0027077752
lethality O 0 0.66842365
associated O 0 0.0052518467
with O 0 0.0133345295
kindling O 0 0.9993773
. O 0 0.0085194195

These O 0 0.0033085146
findings O 0 0.0023242107
demonstrate O 0 0.0010253906
that O 0 0.0009928609
some O 0 0.0015602652
neuroactive O 0 0.98930335
steroids B-Chemical 0 0.99988675
attenuate O 0 0.034028925
convulsant O 0 0.9999598
and O 0 0.0009476429
sensitizing O 0 0.010101805
properties O 0 0.00032348614
of O 0 0.002032098
cocaine B-Chemical 1 0.9999888
and O 0 0.00035236485
add O 0 0.00016977605
to O 0 0.0001367042
a O 0 0.0001848309
growing O 0 0.00016890412
literature O 0 0.00021074737
on O 0 0.00010800763
their O 0 0.00015970148
potential O 0 0.00021139055
use O 0 0.0002157
in O 0 0.00021209718
the O 0 0.00024413294
modulation O 0 0.00033093107
of O 0 0.0005220588
effects O 0 0.0008505345
of O 0 0.0014560595
drugs O 0 0.3620915
of O 0 0.0056675025
abuse O 0 0.9972994
. O 0 0.008656235

Effect O 0 0.0043206
of O 0 0.0034742677
humoral O 0 0.65716976
modulators O 0 0.06952666
of O 0 0.02699522
morphine B-Chemical 0 0.99999523
- O 0 0.11362662
induced O 0 0.0011123313
increase B-Disease 0 0.00094214553
in I-Disease 0 0.0013773475
locomotor I-Disease 0 0.4010383
activity I-Disease 0 0.0017390844
of O 0 0.00283972
mice O 0 0.0033808642
. O 0 0.007479208

The O 0 0.003157425
effect O 0 0.0022865573
of O 0 0.0021655385
humoral O 0 0.62904245
modulators O 0 0.01376024
on O 0 0.0006202677
the O 0 0.001760307
morphine B-Chemical 0 0.99999166
- O 0 0.055972923
induced O 0 0.0005659674
increase B-Disease 0 0.00047125615
in I-Disease 0 0.00069463777
locomotor I-Disease 0 0.33265728
activity I-Disease 0 0.0007161191
of O 0 0.0010517667
mice O 0 0.0011269915
was O 0 0.0023270098
studied O 0 0.004124153
. O 0 0.0067812805

The O 0 0.0033952259
subcutaneous O 0 0.006111469
administration O 0 0.0043711932
of O 0 0.0014141351
10 O 0 0.00093939056
mg O 0 0.026856126
/ O 0 0.0025326044
kg O 0 0.00209874
of O 0 0.0034781909
morphine B-Chemical 0 0.9999958
- O 0 0.6364498
HC1 O 0 0.99994946
produced O 0 0.00054108433
a O 0 0.0006492312
marked O 0 0.00077987387
increase B-Disease 0 0.0005041591
in I-Disease 0 0.0008722138
locomotor I-Disease 0 0.30280888
activity I-Disease 0 0.00132659
in O 0 0.001958308
mice O 0 0.002785083
. O 0 0.0065138713

The O 0 0.006082669
morphine B-Chemical 0 0.99993813
- O 0 0.15219405
induced O 0 0.0061420123
hyperactivity B-Disease 2 0.99996495
was O 0 0.0027084409
potentiated O 0 0.12420532
by O 0 0.0080630705
scopolamine B-Chemical 1 0.99999917
and O 0 0.0036480175
attenuated O 0 0.0107271345
by O 0 0.009661864
physostigmine B-Chemical 0 0.9999877
. O 0 0.010233127

In O 0 0.0039106994
contrast O 0 0.0032504715
, O 0 0.0032106068
both O 0 0.0029559853
methscopolamine B-Chemical 0 0.9999584
and O 0 0.022818685
neostigmine B-Chemical 0 0.9999919
, O 0 0.0016182653
which O 0 0.0005500645
do O 0 0.0002899352
not O 0 0.00022234085
penetrate O 0 0.00037422546
the O 0 0.0002754973
blood O 0 0.022922508
- O 0 0.0097791515
brain O 0 0.008725532
barrier O 0 0.0037728085
, O 0 0.00046666962
had O 0 0.0002602001
no O 0 0.00022164852
effect O 0 0.00031609347
on O 0 0.0003511343
the O 0 0.00088762894
hyperactivity B-Disease 2 0.9997671
produced O 0 0.0016286358
by O 0 0.0046379613
morphine B-Chemical 0 0.9998698
. O 0 0.007986291

Pretreatment O 0 0.12520531
of O 0 0.002661038
mice O 0 0.0013156816
with O 0 0.002560001
alpha B-Chemical 0 0.99703574
- I-Chemical 0 0.62313694
methyltyrosine I-Chemical 0 0.987222
( O 0 0.0014381532
20 O 0 0.00042295616
mg O 0 0.011845455
/ O 0 0.0013276549
kg O 0 0.0010634612
i O 0 0.0017510492
. O 0 0.00025172983
p O 0 0.00027420858
. O 0 0.00022259666
, O 0 0.00028758965
one O 0 0.0001766304
hour O 0 0.00019193337
) O 0 0.00047269036
, O 0 0.0003291207
an O 0 0.00028417152
inhibitor O 0 0.0057028355
of O 0 0.0030447664
tyrosine B-Chemical 1 0.9991009
hydroxylase O 0 0.9997024
, O 0 0.00073051
significantly O 0 0.00028628635
decreased O 0 0.00032997775
the O 0 0.0003233631
activity O 0 0.0005849654
- O 0 0.0044236826
increasing O 0 0.0009333058
effects O 0 0.002231475
of O 0 0.01103844
morphine B-Chemical 0 0.99993885
. O 0 0.008617997

On O 0 0.0032195984
the O 0 0.002221547
other O 0 0.0018729942
hand O 0 0.002044708
, O 0 0.0016089856
pretreatment O 0 0.036539648
with O 0 0.000946327
p B-Chemical 0 0.0027091505
- I-Chemical 0 0.02826061
chlorophenylalamine I-Chemical 0 0.2255717
( O 0 0.0008825605
3 O 0 0.00033932785
X O 0 0.6223527
320 O 0 0.004127654
mg O 0 0.017600184
/ O 0 0.0012992864
kg O 0 0.000941843
i O 0 0.001499163
. O 0 0.0002239944
p O 0 0.00025220812
. O 0 0.00021692201
, O 0 0.00032694463
24 O 0 0.00024560755
hr O 0 0.00043451405
) O 0 0.00061407796
, O 0 0.0005440807
a O 0 0.001596451
serotonin B-Chemical 0 0.99991965
depletor O 0 0.99808466
, O 0 0.00053995725
caused O 0 0.00034959486
no O 0 0.0003690043
significant O 0 0.00062351394
change O 0 0.0010172632
in O 0 0.0014357009
the O 0 0.00306827
hyperactivity B-Disease 2 0.99972016
. O 0 0.007347996

The O 0 0.00309209
study O 0 0.00233069
suggests O 0 0.0010748646
that O 0 0.00085378246
the O 0 0.0008013762
activity O 0 0.0010356739
- O 0 0.00973028
increasing O 0 0.0004928965
effects O 0 0.0008097505
of O 0 0.002725194
morphine B-Chemical 0 0.9999716
are O 0 0.00028366368
mediated O 0 0.00017530975
by O 0 0.00026308652
the O 0 0.0002691554
release O 0 0.0016133869
of O 0 0.00142489
catecholamines B-Chemical 1 0.9994991
from O 0 0.0007145437
adrenergic O 0 0.92359686
neurons O 0 0.0017696988
in O 0 0.0012453318
the O 0 0.0021046975
brain O 0 0.015574527
. O 0 0.0064831357

And O 0 0.007792443
the O 0 0.0022913576
results O 0 0.0014774435
are O 0 0.0010716128
consistent O 0 0.00078373525
with O 0 0.0006366218
the O 0 0.0004750272
hypothesis O 0 0.00050731754
that O 0 0.0005637573
morphine B-Chemical 0 0.99994946
acts O 0 0.0006791098
by O 0 0.0004961927
retarding O 0 0.08980432
the O 0 0.00042903092
release O 0 0.003117035
of O 0 0.0018276352
acetylcholine B-Chemical 1 0.99956983
at O 0 0.0006501615
some O 0 0.0009129412
central O 0 0.0021599939
cholinergic O 0 0.25401497
synapses O 0 0.014750551
. O 0 0.006337486

It O 0 0.004560787
is O 0 0.0024090046
also O 0 0.001482524
suggested O 0 0.0009410286
from O 0 0.00066356506
collected O 0 0.0004466403
evidence O 0 0.0003518102
that O 0 0.00029372965
the O 0 0.00033639188
activity O 0 0.00055551087
- O 0 0.010055682
increasing O 0 0.0003056492
effects O 0 0.00061377423
of O 0 0.0029327183
morphine B-Chemical 0 0.9999758
in O 0 0.00022806351
mice O 0 0.00011301228
are O 0 0.00013457032
mediated O 0 0.00010656281
by O 0 0.00015535079
mechanisms O 0 0.00013953517
different O 0 0.00013093736
from O 0 0.00014004999
those O 0 0.00020626684
which O 0 0.0001818072
mediate O 0 0.00012584889
the O 0 0.0002350677
activity O 0 0.00043571048
- O 0 0.005249481
increasing O 0 0.000507497
effects O 0 0.0011343186
of O 0 0.0047025057
morphine B-Chemical 0 0.9999474
in O 0 0.0028816808
rats O 0 0.00564908
. O 0 0.0061192834

Effects O 0 0.005331039
of O 0 0.0036639539
uninephrectomy O 0 0.7337513
and O 0 0.0019381987
high O 0 0.0016665197
protein O 0 0.0019334633
feeding O 0 0.0028152193
on O 0 0.0007808053
lithium B-Chemical 0 0.9999777
- O 0 0.08054676
induced O 0 0.0020538552
chronic B-Disease 2 0.99709356
renal I-Disease 2 0.9966126
failure I-Disease 2 0.97064006
in O 0 0.0040072394
rats O 0 0.0069944127
. O 0 0.006968568

Rats O 0 0.014935099
with O 0 0.0061612846
lithium B-Chemical 0 0.99995077
- O 0 0.13524938
induced O 0 0.0052098176
nephropathy B-Disease 2 0.99999917
were O 0 0.00072146585
subjected O 0 0.00028025638
to O 0 0.00027082162
high O 0 0.00046107854
protein O 0 0.0013116853
( O 0 0.0028961983
HP O 0 0.74531937
) O 0 0.0018038721
feeding O 0 0.0021080843
, O 0 0.0012889059
uninephrectomy O 0 0.9673883
( O 0 0.01642394
NX O 0 0.99901485
) O 0 0.00092851045
or O 0 0.00020933508
a O 0 0.0002475506
combination O 0 0.00024563703
of O 0 0.00025231155
these O 0 0.00029025078
, O 0 0.00036061977
in O 0 0.00020499753
an O 0 0.00022664409
attempt O 0 0.0002044615
to O 0 0.00018642402
induce O 0 0.00023796402
glomerular O 0 0.9557425
hyperfiltration O 0 0.99977416
and O 0 0.0007907723
further O 0 0.0007044342
progression O 0 0.11236336
of O 0 0.0035337983
renal B-Disease 0 0.96861756
failure I-Disease 0 0.81748104
. O 0 0.0085279215

Newborn O 0 0.012241303
female O 0 0.008313742
Wistar O 0 0.013893733
rats O 0 0.0021802045
were O 0 0.0011250468
fed O 0 0.0011534096
a O 0 0.0018829198
lithium B-Chemical 0 0.9999645
- O 0 0.027059026
containing O 0 0.00041665588
diet O 0 0.044540722
( O 0 0.00066792907
50 O 0 0.00039719947
mmol O 0 0.2760678
/ O 0 0.0025108114
kg O 0 0.0009210115
) O 0 0.0003686613
for O 0 0.00016537406
8 O 0 0.00014587857
weeks O 0 0.00010168732
and O 0 0.00014509242
then O 0 0.00013719586
randomized O 0 0.00016512025
to O 0 0.00014296103
normal O 0 0.0003987985
diet O 0 0.040098224
, O 0 0.0009923696
HP O 0 0.5989459
diet O 0 0.04600715
( O 0 0.00041567223
40 O 0 0.00019600074
vs O 0 0.00025483556
. O 0 0.00020292697
19 O 0 0.00032704728
% O 0 0.00038103753
) O 0 0.0008727309
, O 0 0.0014019662
NX O 0 0.9955519
or O 0 0.00080684596
HP O 0 0.79401183
+ O 0 0.032957166
NX O 0 0.99143475
for O 0 0.00105808
another O 0 0.0015538492
8 O 0 0.0020454621
weeks O 0 0.0027168966
. O 0 0.00621015

Corresponding O 0 0.012927273
non O 0 0.0133667085
- O 0 0.19570512
lithium B-Chemical 0 0.99971646
pretreated O 0 0.033010934
groups O 0 0.00616934
were O 0 0.0065523717
generated O 0 0.0075138803
. O 0 0.013909487

When O 0 0.0027217877
comparing O 0 0.0015994704
all O 0 0.0017903083
lithium B-Chemical 0 0.99951124
treated O 0 0.0012607792
versus O 0 0.00072056666
non O 0 0.0102582695
- O 0 0.5731501
lithium B-Chemical 0 0.99999297
- O 0 0.09223986
treated O 0 0.0006352124
groups O 0 0.0005156558
, O 0 0.0018919106
lithium B-Chemical 0 0.9998933
caused O 0 0.00028878235
a O 0 0.00039097757
reduction O 0 0.00047167
in O 0 0.00024646678
glomerular O 0 0.7481296
filtration O 0 0.002621154
rate O 0 0.00030782112
( O 0 0.0014082143
GFR O 0 0.99708986
) O 0 0.00056144025
without O 0 0.00016419546
significant O 0 0.00017445131
changes O 0 0.00023905603
in O 0 0.0001706554
effective O 0 0.0002992886
renal O 0 0.7487981
plasma O 0 0.0381053
flow O 0 0.0037904312
( O 0 0.0002781577
as O 0 0.00014156407
determined O 0 0.00013367011
by O 0 0.00018406323
a O 0 0.00022462485
marker O 0 0.00025623792
secreted O 0 0.00023078777
into O 0 0.00018935307
the O 0 0.0003148363
proximal O 0 0.0007029926
tubules O 0 0.007059899
) O 0 0.002408347
or O 0 0.002356654
lithium B-Chemical 0 0.999826
clearance O 0 0.3212735
. O 0 0.008059044

Consequently O 0 0.0055104815
, O 0 0.01031282
lithium B-Chemical 0 0.9998733
pretreatment O 0 0.24119213
caused O 0 0.0014853693
a O 0 0.001401252
fall O 0 0.0017919255
in O 0 0.0005808184
filtration O 0 0.0012761372
fraction O 0 0.00049523753
and O 0 0.00068113406
an O 0 0.00080142426
increase O 0 0.00085298915
in O 0 0.0015495465
fractional O 0 0.057203628
Li B-Chemical 1 0.99896276
excretion O 0 0.9772853
. O 0 0.009432773

Lithium B-Chemical 1 0.9998178
also O 0 0.004937997
caused O 0 0.006421975
proteinuria B-Disease 0 0.9999933
and O 0 0.02316859
systolic O 0 0.9963983
hypertension B-Disease 2 0.9999919
in O 0 0.002523675
absence O 0 0.0024780557
of O 0 0.009897587
glomerulosclerosis B-Disease 2 0.9999926
. O 0 0.018288884

HP O 0 0.12254982
failed O 0 0.0029112978
to O 0 0.0018036806
accentuante O 0 0.012091474
progression O 0 0.13034903
of O 0 0.0021708854
renal B-Disease 0 0.96689457
failure I-Disease 0 0.628736
and O 0 0.00078701176
in O 0 0.00032936927
fact O 0 0.0002107803
tended O 0 0.0002189791
to O 0 0.00018910895
increase O 0 0.00027188985
GFR O 0 0.9934495
and O 0 0.00044110004
decrease O 0 0.0004335823
plasma O 0 0.0873484
creatinine B-Chemical 1 0.9982357
levels O 0 0.00092424644
in O 0 0.0017605989
lithium B-Chemical 0 0.99986875
pretreated O 0 0.06507272
rats O 0 0.006050008
. O 0 0.0061747893

NX O 0 0.98550874
caused O 0 0.004230302
an O 0 0.0038405438
additive O 0 0.028897831
deterioration O 0 0.4361663
in O 0 0.002666513
GFR O 0 0.99876934
which O 0 0.0022036417
, O 0 0.0017741319
however O 0 0.0016993005
, O 0 0.002076545
was O 0 0.0021544637
ameliorated O 0 0.041805018
by O 0 0.0049329875
HP O 0 0.5679762
. O 0 0.009645042

NX O 0 0.99749124
+ O 0 0.03249305
HP O 0 0.2674202
caused O 0 0.002184463
a O 0 0.001841879
further O 0 0.0012071363
rise O 0 0.001352881
in O 0 0.0011888982
blood O 0 0.021305261
pressure O 0 0.12802385
in O 0 0.0023413072
Li B-Chemical 1 0.99794656
- O 0 0.049894936
pretreated O 0 0.025095025
rats O 0 0.00730192
. O 0 0.008220627

The O 0 0.0029741388
results O 0 0.0019360358
indicate O 0 0.0012398696
that O 0 0.001601556
Li B-Chemical 1 0.9992249
- O 0 0.14073928
induced O 0 0.01065972
nephropathy B-Disease 2 0.9999999
, O 0 0.0130977295
even O 0 0.00070956425
when O 0 0.00025168544
the O 0 0.00042322598
GFR O 0 0.9966601
is O 0 0.00035831894
only O 0 0.00034370148
modestly O 0 0.007921519
reduced O 0 0.000433904
, O 0 0.0006009938
is O 0 0.00038356756
associated O 0 0.00056128163
with O 0 0.0018481797
proteinuria B-Disease 0 0.99999595
and O 0 0.0054072635
arterial O 0 0.93473715
systolic O 0 0.9899066
hypertension B-Disease 2 0.9999709
. O 0 0.007761572

In O 0 0.0036383437
this O 0 0.0022762518
model O 0 0.0018369368
of O 0 0.0024126882
chronic B-Disease 2 0.993651
renal I-Disease 2 0.9970214
failure I-Disease 2 0.9728387
the O 0 0.0010810441
decline O 0 0.017202206
in O 0 0.000707497
GFR O 0 0.9978788
is O 0 0.00031021275
not O 0 0.0001907184
accompanied O 0 0.0002947761
by O 0 0.00022726903
a O 0 0.00023758454
corresponding O 0 0.00015964212
fall O 0 0.00054527295
in O 0 0.00017759384
effective O 0 0.0003235586
renal O 0 0.7970605
plasma O 0 0.06711702
flow O 0 0.010096333
, O 0 0.00039653268
which O 0 0.00026093842
may O 0 0.00016394205
be O 0 0.0001742668
the O 0 0.00018201934
functional O 0 0.00023644378
expression O 0 0.0003065276
of O 0 0.00043340708
the O 0 0.0004953343
formation O 0 0.0016700894
of O 0 0.001482469
nonfiltrating O 0 0.0685335
atubular O 0 0.3229708
glomeruli O 0 0.11995216
. O 0 0.006970001

The O 0 0.0032254662
fractional O 0 0.004510583
reabsorption O 0 0.34352148
of O 0 0.0018939368
tubular O 0 0.23930776
fluid O 0 0.008104767
by O 0 0.00055439747
the O 0 0.00038475686
proximal O 0 0.0005438477
tubules O 0 0.0029677742
is O 0 0.0003773094
reduced O 0 0.00034615968
, O 0 0.00044236836
leaving O 0 0.00043817985
the O 0 0.0002571101
distal O 0 0.00038090858
delivery O 0 0.00038032877
unchanged O 0 0.00056038937
. O 0 0.00072633143
( O 0 0.0016840589
ABSTRACT O 0 0.006889318
TRUNCATED O 0 0.006566946
AT O 0 0.01208906
250 O 0 0.005610185
WORDS O 0 0.010622018
) O 0 0.01720964

Treatment O 0 0.009275722
of O 0 0.0050594914
Crohn B-Disease 0 0.985427
' I-Disease 0 0.00390013
s I-Disease 0 0.002976995
disease I-Disease 0 0.9141187
with O 0 0.010077715
fusidic B-Chemical 0 0.99997604
acid I-Chemical 0 0.9909044
: O 0 0.003497622
an O 0 0.00085002603
antibiotic O 0 0.04461566
with O 0 0.0009495744
immunosuppressive O 0 0.37655804
properties O 0 0.0011027881
similar O 0 0.0013821021
to O 0 0.002979573
cyclosporin B-Chemical 0 0.9999752
. O 0 0.011228726

Fusidic O 0 0.99993443
acid O 0 0.9956851
is O 0 0.0033657197
an O 0 0.002435568
antibiotic O 0 0.14892964
with O 0 0.0044337586
T O 0 0.9922896
- O 0 0.061982244
cell O 0 0.002303836
specific O 0 0.0006886045
immunosuppressive O 0 0.43478656
effects O 0 0.0009284618
similar O 0 0.0006881415
to O 0 0.0010040711
those O 0 0.0021237521
of O 0 0.005599332
cyclosporin B-Chemical 0 0.9999845
. O 0 0.0132999495

Because O 0 0.0030972182
of O 0 0.0024154696
the O 0 0.0014727918
need O 0 0.00096670684
for O 0 0.00076034485
the O 0 0.000604953
development O 0 0.0008164043
of O 0 0.00055256207
new O 0 0.00054102804
treatments O 0 0.00055358355
for O 0 0.00043403712
Crohn B-Disease 0 0.9926684
' I-Disease 0 0.0013108174
s I-Disease 0 0.00083150674
disease I-Disease 0 0.80190307
, O 0 0.0005256009
a O 0 0.0003040736
pilot O 0 0.00033787763
study O 0 0.00022070165
was O 0 0.00014203528
undertaken O 0 0.00010802195
to O 0 0.00011049121
estimate O 0 0.00010928576
the O 0 0.00017997892
pharmacodynamics O 0 0.09103705
and O 0 0.0002472105
tolerability O 0 0.015379473
of O 0 0.0012979974
fusidic B-Chemical 0 0.99996865
acid I-Chemical 0 0.97854257
treatment O 0 0.0015427294
in O 0 0.00049892504
chronic O 0 0.78358126
active O 0 0.007340411
, O 0 0.001724368
therapy O 0 0.0038879968
- O 0 0.009640707
resistant O 0 0.0029271478
patients O 0 0.005624107
. O 0 0.0063220044

Eight O 0 0.01616015
Crohn B-Disease 0 0.8913795
' I-Disease 0 0.009367743
s I-Disease 0 0.008648527
disease I-Disease 0 0.52188104
patients O 0 0.008986733
were O 0 0.00801927
included O 0 0.009518951
. O 0 0.014786798

Fusidic B-Chemical 0 0.9999542
acid I-Chemical 0 0.9967435
was O 0 0.0026183682
administered O 0 0.0013608333
orally O 0 0.0016691333
in O 0 0.0005416858
a O 0 0.00052274053
dose O 0 0.0009875303
of O 0 0.00045566782
500 O 0 0.0007754131
mg O 0 0.019604148
t O 0 0.0009178708
. O 0 0.00023532289
d O 0 0.00035880657
. O 0 0.00023567743
s O 0 0.00034335876
. O 0 0.000261925
and O 0 0.00030794498
the O 0 0.00031565106
treatment O 0 0.0004333513
was O 0 0.0004727539
planned O 0 0.00060577854
to O 0 0.0006888085
last O 0 0.00093599386
8 O 0 0.0017207388
weeks O 0 0.002448307
. O 0 0.0057857926

The O 0 0.004965128
disease O 0 0.3117884
activity O 0 0.0027226575
was O 0 0.0019202059
primarily O 0 0.0016188063
measured O 0 0.0012913565
by O 0 0.0015942613
a O 0 0.0018751946
modified O 0 0.002037594
individual O 0 0.0023743913
grading O 0 0.006264266
score O 0 0.005331176
. O 0 0.008690582

Five O 0 0.0045684096
of O 0 0.0029384072
8 O 0 0.0020173062
patients O 0 0.0017946586
( O 0 0.001590954
63 O 0 0.001308714
% O 0 0.00099239
) O 0 0.0010517467
improved O 0 0.0007408094
during O 0 0.0005416891
fusidic B-Chemical 0 0.99990165
acid I-Chemical 0 0.9672267
treatment O 0 0.0014251195
: O 0 0.000721905
3 O 0 0.00026570234
at O 0 0.00024362255
two O 0 0.00026869358
weeks O 0 0.0003109121
and O 0 0.0005885257
2 O 0 0.0007684852
after O 0 0.0008856783
four O 0 0.001549242
weeks O 0 0.002596212
. O 0 0.006043935

There O 0 0.004184636
were O 0 0.0025713434
no O 0 0.0016592329
serious O 0 0.019808097
clinical O 0 0.008250382
side O 0 0.046478596
effects O 0 0.0016116205
, O 0 0.001162998
but O 0 0.0007187829
dose O 0 0.0026557166
reduction O 0 0.0008051218
was O 0 0.00041654386
required O 0 0.0003146227
in O 0 0.00050212967
two O 0 0.00059791177
patients O 0 0.0011918173
because O 0 0.0014587826
of O 0 0.006118706
nausea B-Disease 2 0.99996734
. O 0 0.009091587

Biochemically O 0 0.098079585
, O 0 0.003953417
an O 0 0.0021945962
increase O 0 0.0012470721
in O 0 0.0012895714
alkaline O 0 0.60548705
phosphatases O 0 0.26450714
was O 0 0.0004994305
noted O 0 0.00027619186
in O 0 0.0002539832
5 O 0 0.00019869015
of O 0 0.00023178694
8 O 0 0.00020710635
cases O 0 0.00030900666
( O 0 0.0003894466
63 O 0 0.0004062746
% O 0 0.00034216442
) O 0 0.0005034037
, O 0 0.00031172388
and O 0 0.00023402869
the O 0 0.00019480701
greatest O 0 0.000320385
increases O 0 0.00022335928
were O 0 0.00022832351
seen O 0 0.000216296
in O 0 0.0002493994
those O 0 0.0003910586
who O 0 0.00050715654
had O 0 0.00039893386
elevated O 0 0.0011333098
levels O 0 0.00071670016
prior O 0 0.0009385291
to O 0 0.0017090613
treatment O 0 0.0038727303
. O 0 0.0063219382

All O 0 0.0041356334
reversed O 0 0.0038156214
to O 0 0.002805064
pre O 0 0.0050399187
- O 0 0.0060353465
treatment O 0 0.0020520554
levels O 0 0.0018970137
after O 0 0.0018555376
cessation O 0 0.0067927944
of O 0 0.0046230783
treatment O 0 0.007561552
. O 0 0.009879692

The O 0 0.0030677128
results O 0 0.002058061
of O 0 0.0018303755
this O 0 0.0012785442
pilot O 0 0.001376269
study O 0 0.00084109075
suggest O 0 0.00042850955
that O 0 0.0007741123
fusidic B-Chemical 0 0.99996805
acid I-Chemical 0 0.9862823
may O 0 0.00044371898
be O 0 0.0002808893
of O 0 0.00029004607
benefit O 0 0.00025422743
in O 0 0.00020850245
selected O 0 0.0002469405
chronic O 0 0.59423345
active O 0 0.0126171755
Crohn B-Disease 0 0.9979748
' I-Disease 0 0.0016276186
s I-Disease 0 0.00078376394
disease I-Disease 0 0.6026153
patients O 0 0.0006613201
in O 0 0.00044348088
whom O 0 0.00094714103
conventional O 0 0.0008551506
treatment O 0 0.0014213448
is O 0 0.0023884675
ineffective O 0 0.0113366265
. O 0 0.0069702384

Because O 0 0.0030453827
there O 0 0.0018849991
seems O 0 0.001383933
to O 0 0.0009394667
exist O 0 0.0007498572
a O 0 0.00076775544
scientific O 0 0.0009893992
rationale O 0 0.00048431254
for O 0 0.00034477445
the O 0 0.00031009328
use O 0 0.00035185227
of O 0 0.0015551465
fusidic B-Chemical 0 0.9999683
acid I-Chemical 0 0.9636138
at O 0 0.00023686707
the O 0 0.00021588003
cytokine O 0 0.035288356
level O 0 0.0001775488
in O 0 0.00025499694
inflammatory B-Disease 0 0.9022945
bowel I-Disease 0 0.9349172
disease I-Disease 0 0.9977373
, O 0 0.0006492652
we O 0 0.000121654935
suggest O 0 0.00011425565
that O 0 0.00015175015
the O 0 0.00019422019
role O 0 0.00018692367
of O 0 0.00039342328
this O 0 0.0004078256
treatment O 0 0.0005775696
should O 0 0.00054386683
be O 0 0.0010374711
further O 0 0.0016555514
investigated O 0 0.0029674326
. O 0 0.006306689

Changes O 0 0.0061308704
in O 0 0.0053310418
depressive B-Disease 2 0.9997955
status O 0 0.0041084015
associated O 0 0.0028504287
with O 0 0.003928253
topical O 0 0.99186486
beta O 0 0.9954514
- O 0 0.7493104
blockers O 0 0.99792683
. O 0 0.013533116

Depression B-Disease 2 0.9949882
and O 0 0.005971153
sexual B-Disease 0 0.9385203
dysfunction I-Disease 0 0.9878897
have O 0 0.0012981743
been O 0 0.0009644268
related O 0 0.0005997682
to O 0 0.00066962064
side O 0 0.00426255
effects O 0 0.0012161018
of O 0 0.0024504284
topical O 0 0.9948409
beta O 0 0.99651814
- O 0 0.7984849
blockers O 0 0.9979894
. O 0 0.010510414

We O 0 0.0034676308
performed O 0 0.0021537521
a O 0 0.0019624226
preliminary O 0 0.0014362356
study O 0 0.0010528945
in O 0 0.00060404063
order O 0 0.00036452248
to O 0 0.0002949352
determine O 0 0.00015935255
any O 0 0.00020255099
difference O 0 0.00014500707
between O 0 0.00015305937
a O 0 0.00027734105
non O 0 0.00070814346
selective O 0 0.016099755
beta O 0 0.9965262
- O 0 0.7606317
blocker O 0 0.9954495
( O 0 0.08346774
timolol B-Chemical 0 0.99999964
) O 0 0.0030232235
and O 0 0.00031587112
a O 0 0.00038082892
selective O 0 0.0057842294
beta O 0 0.9894169
- O 0 0.61974555
blocker O 0 0.9944759
( O 0 0.09732956
betaxolol B-Chemical 0 0.9999995
) O 0 0.004322356
regarding O 0 0.0009627058
CNS O 0 0.2940072
side O 0 0.030210199
effects O 0 0.004884177
. O 0 0.0067529357

Eight O 0 0.013180983
glaucomatous B-Disease 0 0.9999403
patients O 0 0.0047311815
chronically O 0 0.016138406
treated O 0 0.001437778
with O 0 0.0030626513
timolol B-Chemical 0 0.9999989
0 O 0 0.00092283334
. O 0 0.0003068167
5 O 0 0.000244179
% O 0 0.00037994236
/ O 0 0.0035651876
12h O 0 0.077997066
, O 0 0.00043422633
suffering O 0 0.021421503
from O 0 0.00029231777
depression B-Disease 0 0.996442
diagnosed O 0 0.0045096516
through O 0 0.00036606885
DMS O 0 0.9998115
- O 0 0.19389229
III O 0 0.350673
- O 0 0.08432226
R O 0 0.9916569
criteria O 0 0.0008071735
, O 0 0.0007655101
were O 0 0.0006807447
included O 0 0.00082033343
in O 0 0.0012823183
the O 0 0.002175987
study O 0 0.004522492
. O 0 0.00673762

During O 0 0.0029976687
the O 0 0.00229729
six O 0 0.0015003482
- O 0 0.002412229
month O 0 0.00072861253
follow O 0 0.0005378172
up O 0 0.00059796625
, O 0 0.0010135241
depression B-Disease 0 0.98797685
was O 0 0.00040975004
quantified O 0 0.0003259124
through O 0 0.0003040162
the O 0 0.00045645618
Beck O 0 0.037882533
and O 0 0.00068603177
Zung O 0 0.03399839
- O 0 0.0017773022
Conde O 0 0.013402102
scales O 0 0.00090906717
every O 0 0.0008618987
two O 0 0.001676232
months O 0 0.0028884574
. O 0 0.0064525404

In O 0 0.003833778
a O 0 0.0028667469
double O 0 0.0021120422
blind O 0 0.011779086
cross O 0 0.0020514072
- O 0 0.0033060121
over O 0 0.0004350193
study O 0 0.0005247369
with O 0 0.0003858872
control O 0 0.00036031133
group O 0 0.0004683937
, O 0 0.00037553973
the O 0 0.0002197846
patients O 0 0.0003651897
under O 0 0.0002716346
timolol B-Chemical 0 0.99999833
treatment O 0 0.0005504227
presented O 0 0.00019515821
higher O 0 0.0002471242
depression B-Disease 0 0.98096234
values O 0 0.00013397828
measured O 0 0.00011557068
through O 0 0.00012331034
the O 0 0.00019634284
Beck O 0 0.019456258
and O 0 0.00020946466
the O 0 0.00025780848
Zung O 0 0.040837172
- O 0 0.0012579664
Conde O 0 0.04097723
scales O 0 0.0002880877
( O 0 0.0004122071
p O 0 0.00038931187
< O 0 0.00046056445
0 O 0 0.00069852785
. O 0 0.0008908936
001 O 0 0.010070797
vs O 0 0.0019886475
control O 0 0.002659684
) O 0 0.0061121294
. O 0 0.0078439005

These O 0 0.0036110978
results O 0 0.0022254782
suggest O 0 0.0014421633
that O 0 0.002042658
betaxolol B-Chemical 0 0.99999845
could O 0 0.0010272216
be O 0 0.0006862924
less O 0 0.00052287633
of O 0 0.00067888363
a O 0 0.0019568347
depression B-Disease 0 0.9997714
- O 0 0.06576409
inducer O 0 0.053883035
than O 0 0.0015966562
timolol B-Chemical 0 0.99999523
in O 0 0.0025647262
predisposed O 0 0.21631819
patients O 0 0.00675986
. O 0 0.0067133447

Protection O 0 0.018666234
against O 0 0.013715997
amphetamine B-Chemical 1 0.99999917
- O 0 0.47978392
induced O 0 0.009217462
neurotoxicity B-Disease 2 0.9999918
toward O 0 0.024689099
striatal O 0 0.99791056
dopamine B-Chemical 1 0.9999298
neurons O 0 0.0022807512
in O 0 0.00040400098
rodents O 0 0.001782292
by O 0 0.0010770813
LY274614 B-Chemical 0 0.99991167
, O 0 0.0016402696
an O 0 0.0019326159
excitatory O 0 0.95555663
amino B-Chemical 0 0.9988152
acid I-Chemical 0 0.99940693
antagonist O 0 0.99124205
. O 0 0.009351741

LY274614 B-Chemical 0 0.99982613
, O 0 0.013116604
3SR B-Chemical 0 0.5305231
, I-Chemical 0 0.003832427
4aRS I-Chemical 0 0.011722417
, I-Chemical 0 0.0029399653
6SR I-Chemical 0 0.8443794
, I-Chemical 0 0.0017831619
8aRS I-Chemical 0 0.018596305
- I-Chemical 0 0.008805205
6 I-Chemical 0 0.00049478875
- I-Chemical 0 0.006235347
[ I-Chemical 0 0.0067755915
phosphonomethyl I-Chemical 0 0.9316421
] I-Chemical 0 0.0021750694
decahydr I-Chemical 0 0.021366633
oisoquinoline I-Chemical 0 0.0742473
- I-Chemical 0 0.02497431
3 I-Chemical 0 0.00037345456
- I-Chemical 0 0.062329724
carboxylic I-Chemical 0 0.99935156
acid I-Chemical 0 0.9658313
, O 0 0.00093201856
has O 0 0.00020536079
been O 0 0.00017689586
described O 0 0.00014460747
as O 0 0.00015599797
a O 0 0.0002833731
potent O 0 0.0028644688
antagonist O 0 0.5738551
of O 0 0.0005146825
the O 0 0.0012191887
N B-Chemical 0 0.9999472
- I-Chemical 0 0.8165685
methyl I-Chemical 0 0.9997943
- I-Chemical 0 0.6559123
D I-Chemical 0 0.9995939
- I-Chemical 0 0.867473
aspartate I-Chemical 1 0.999997
( O 0 0.28535986
NMDA B-Chemical 1 0.9999988
) O 0 0.012079347
subtype O 0 0.3749145
of O 0 0.011463267
glutamate B-Chemical 1 0.9998499
receptor O 0 0.33748338
. O 0 0.008237513

Here O 0 0.004852901
its O 0 0.003127412
ability O 0 0.0016859374
to O 0 0.0011097181
antagonize O 0 0.0011225792
the O 0 0.00068392494
prolonged O 0 0.0009570664
depletion O 0 0.0010069328
of O 0 0.0036104938
dopamine B-Chemical 1 0.99989176
in O 0 0.00036547918
the O 0 0.00040209293
striatum O 0 0.7118995
by O 0 0.0014941911
amphetamine B-Chemical 1 0.9999995
in O 0 0.011539806
iprindole B-Chemical 0 0.99999976
- O 0 0.050393503
treated O 0 0.001484704
rats O 0 0.0019422919
is O 0 0.0021498576
reported O 0 0.0041416744
. O 0 0.006402465

A O 0 0.02738539
single O 0 0.0031057796
18 O 0 0.0021315455
. O 0 0.0013291782
4 O 0 0.0009791893
mg O 0 0.0063861543
/ O 0 0.002064519
kg O 0 0.0016924322
( O 0 0.00093930913
i O 0 0.0018462996
. O 0 0.0003674247
p O 0 0.00036566838
. O 0 0.00029188776
) O 0 0.00047899556
dose O 0 0.0008676465
of O 0 0.0004765477
( O 0 0.0017891064
+ O 0 0.018761044
/ O 0 0.12181779
- O 0 0.26263046
) O 0 0.048092384
- O 0 0.8647792
amphetamine B-Chemical 1 0.9999999
hemisulfate O 0 0.99998915
, O 0 0.00091372646
given O 0 0.00012342763
to O 0 0.00013658432
rats O 0 0.00031813234
pretreated O 0 0.0047997837
with O 0 0.0053207683
iprindole B-Chemical 0 0.9999999
, O 0 0.0006207774
resulted O 0 0.00017769955
in O 0 0.0002215363
persistent O 0 0.009089644
depletion O 0 0.0006988841
of O 0 0.0024738088
dopamine B-Chemical 1 0.99972814
in O 0 0.00046514365
the O 0 0.00064841553
striatum O 0 0.14548476
1 O 0 0.0010753762
week O 0 0.0013818508
later O 0 0.0026341283
. O 0 0.005616416

This O 0 0.004786871
prolonged O 0 0.0032166587
depletion O 0 0.002813125
of O 0 0.006302074
dopamine B-Chemical 1 0.999908
in O 0 0.0009608173
the O 0 0.0008074075
striatum O 0 0.7391506
was O 0 0.0005551817
antagonized O 0 0.22148053
by O 0 0.0041798376
dizocilpine B-Chemical 0 0.9999994
( O 0 0.068375915
MK B-Chemical 0 0.9990797
- I-Chemical 0 0.2851283
801 I-Chemical 0 0.64151675
, O 0 0.0004059192
a O 0 0.0003253226
non O 0 0.0013322694
- O 0 0.03879707
competitive O 0 0.04669988
antagonist O 0 0.93348914
of O 0 0.028087242
NMDA B-Chemical 1 0.99999964
receptors O 0 0.08588381
) O 0 0.0019160128
or O 0 0.00033607072
by O 0 0.00089578377
LY274614 B-Chemical 0 0.9999367
( O 0 0.0010704539
a O 0 0.0007205907
competitive O 0 0.03313527
antagonist O 0 0.9211954
of O 0 0.027979804
NMDA B-Chemical 1 0.9999963
receptors O 0 0.15239567
) O 0 0.009221953
. O 0 0.007086289

The O 0 0.0033067463
protective O 0 0.006038022
effect O 0 0.002348567
of O 0 0.009401836
LY274614 B-Chemical 0 0.99997425
was O 0 0.0015080185
dose O 0 0.022105932
- O 0 0.013824105
dependent O 0 0.0003463337
, O 0 0.00048713596
being O 0 0.00036728653
maximum O 0 0.00022460472
at O 0 0.00024222222
10 O 0 0.00031533255
- O 0 0.0012571717
40 O 0 0.00047397966
mgkg O 0 0.44982326
( O 0 0.0010531083
i O 0 0.0020524715
. O 0 0.0011037536
p O 0 0.0017693134
. O 0 0.002661396
) O 0 0.006224099
. O 0 0.008227534

A O 0 0.05125711
10 O 0 0.0031462798
mg O 0 0.03561839
/ O 0 0.004495161
kg O 0 0.0027398772
dose O 0 0.0072962507
of O 0 0.0049424972
LY274614 B-Chemical 0 0.99996066
was O 0 0.0006194031
effective O 0 0.00038496434
in O 0 0.00026374578
antagonizing O 0 0.0010543308
the O 0 0.00024885
depletion O 0 0.0005572291
of O 0 0.0030955104
dopamine B-Chemical 1 0.9998988
in O 0 0.00024365041
the O 0 0.00027991328
striatum O 0 0.4874443
, O 0 0.00023271145
when O 0 0.000100706704
given O 0 9.102729e-05
as O 0 0.00011311048
long O 0 0.00013089794
as O 0 0.00014068549
8 O 0 0.00015369101
hr O 0 0.00023819419
prior O 0 0.00014379842
to O 0 0.00032589282
amphetamine B-Chemical 1 0.9999982
but O 0 0.00039361705
not O 0 0.00022949664
when O 0 0.00023211402
given O 0 0.00029791243
24 O 0 0.0005272326
hr O 0 0.00091578736
prior O 0 0.0010525369
to O 0 0.0026746397
amphetamine B-Chemical 1 0.99998546
. O 0 0.007770163

Depletion O 0 0.008565049
of O 0 0.007157273
dopamine B-Chemical 1 0.9997478
in O 0 0.0016743699
the O 0 0.0012725348
striatum O 0 0.6684841
was O 0 0.00060186576
also O 0 0.0004679024
antagonized O 0 0.19933589
when O 0 0.0006496923
LY274614 B-Chemical 0 0.99994993
was O 0 0.00027762912
given O 0 0.0001228906
after O 0 0.000109746084
the O 0 0.00016374535
injection O 0 0.0006181166
of O 0 0.0070470953
amphetamine B-Chemical 1 0.9999999
; O 0 0.11884003
LY274614 B-Chemical 0 0.9999244
protected O 0 0.00026191672
when O 0 0.000117022624
given O 0 9.977225e-05
up O 0 0.00012213054
to O 0 0.00012577308
4 O 0 0.00014384175
hr O 0 0.00023255353
after O 0 0.000132341
but O 0 0.0002142092
not O 0 0.00017895733
when O 0 0.00018390955
given O 0 0.00022455056
8 O 0 0.00035679064
or O 0 0.0005002777
24 O 0 0.00084870926
hr O 0 0.001737816
after O 0 0.0022521366
amphetamine B-Chemical 1 0.9999808
. O 0 0.007814787

The O 0 0.0029438436
prolonged O 0 0.0027206358
depletion O 0 0.0023902955
of O 0 0.0046807323
dopamine B-Chemical 1 0.9998858
in O 0 0.00083063956
the O 0 0.0006430152
striatum O 0 0.41412148
in O 0 0.00028223504
mice O 0 0.0001753539
, O 0 0.0002908688
given O 0 0.00014128884
multiple O 0 0.00027333933
injections O 0 0.00072052894
of O 0 0.003202733
methamphetamine B-Chemical 1 0.99999964
, O 0 0.0018179092
was O 0 0.00032735328
also O 0 0.00033135602
antagonized O 0 0.19190231
dose O 0 0.058243647
- O 0 0.13472398
dependently O 0 0.8049403
and O 0 0.0014068056
completely O 0 0.0017798285
by O 0 0.0042600813
LY274614 B-Chemical 0 0.99966776
. O 0 0.007732764

The O 0 0.003113349
data O 0 0.002193571
strengthen O 0 0.0014147492
the O 0 0.0010024986
evidence O 0 0.0006839891
that O 0 0.00055469584
the O 0 0.00082449114
neurotoxic B-Disease 0 0.99932396
effect O 0 0.0012183591
of O 0 0.017982394
amphetamine B-Chemical 1 0.99999976
and O 0 0.0009617222
related O 0 0.00019323363
compounds O 0 0.4029412
toward O 0 0.0013474431
nigrostriatal O 0 0.9968311
dopamine B-Chemical 1 0.9998241
neurons O 0 0.00236572
involves O 0 0.00040896545
NMDA B-Chemical 1 0.99999857
receptors O 0 0.01992679
and O 0 0.00046598905
that O 0 0.00039563593
LY274614 B-Chemical 0 0.99996626
is O 0 0.0008283392
an O 0 0.013399549
NMDA B-Chemical 1 0.99999964
receptor O 0 0.42025942
antagonist O 0 0.84289175
with O 0 0.00039630593
long O 0 0.00036738848
- O 0 0.0020000108
lasting O 0 0.00041767556
in O 0 0.00052547216
vivo O 0 0.0010361057
effects O 0 0.0015946173
in O 0 0.002226859
rats O 0 0.0049897977
. O 0 0.0060950886

Ketoconazole B-Chemical 0 0.9999341
- O 0 0.23882717
induced O 0 0.035676684
neurologic B-Disease 0 0.9996081
sequelae I-Disease 0 0.9976082
. O 0 0.034664206

A O 0 0.08745351
77 O 0 0.008477463
- O 0 0.010933444
y O 0 0.012141815
- O 0 0.005357258
old O 0 0.0012184427
patient O 0 0.0009138336
developed O 0 0.0013676273
weakness B-Disease 0 0.98070085
of I-Disease 0 0.0017739917
extremities I-Disease 0 0.949777
, O 0 0.008735345
legs B-Disease 0 0.9946149
paralysis I-Disease 2 0.9999989
, O 0 0.06533496
dysarthria B-Disease 0 0.99999416
and O 0 0.01558361
tremor B-Disease 0 0.99999344
1 O 0 0.00026549416
h O 0 0.00020361872
after O 0 0.00013726468
ingestion O 0 0.05414351
of O 0 0.00033760985
200 O 0 0.0009086794
mg O 0 0.32621643
ketoconazole B-Chemical 1 0.99999785
for O 0 0.00039894163
the O 0 0.00040198985
first O 0 0.00043652518
time O 0 0.00061076606
in O 0 0.0012106386
his O 0 0.002556508
life O 0 0.0041891644
. O 0 0.0064279777

All O 0 0.010245347
complaints O 0 0.018669432
faded O 0 0.012156838
away O 0 0.0078105736
within O 0 0.0070358333
24 O 0 0.010421811
h O 0 0.0139761055
. O 0 0.020106874

Few O 0 0.0043532928
days O 0 0.002097018
later O 0 0.0016597654
, O 0 0.0015551398
the O 0 0.000849363
patient O 0 0.0006814213
used O 0 0.00044486378
another O 0 0.00050815433
200 O 0 0.0008329151
mg O 0 0.5081958
ketoconazole B-Chemical 1 0.99999976
tablet O 0 0.939058
, O 0 0.00057035213
and O 0 0.00023918597
within O 0 0.00013527986
an O 0 0.00019788077
hour O 0 0.00016727686
experienced O 0 0.00021360854
a O 0 0.00022379178
similar O 0 0.00017903018
clinical O 0 0.0005515692
picture O 0 0.00035425663
, O 0 0.00045691393
which O 0 0.00049212604
resolved O 0 0.00069996295
again O 0 0.0008208909
spontaneously O 0 0.0015373828
within O 0 0.0013134804
hours O 0 0.002718475
. O 0 0.0057816524

Laboratory O 0 0.013892015
evaluations O 0 0.0048390287
, O 0 0.0050887885
including O 0 0.0037837531
head O 0 0.03795904
CT O 0 0.2077293
scan O 0 0.007032383
, O 0 0.006046938
were O 0 0.0062133493
normal O 0 0.009536617
. O 0 0.012942653

This O 0 0.0051413206
case O 0 0.0026246784
illustrates O 0 0.0014205924
the O 0 0.0011035631
need O 0 0.00077210285
for O 0 0.0006526861
close O 0 0.0006461011
vigilance O 0 0.026363827
in O 0 0.00075803185
adverse B-Disease 0 0.81935835
drug I-Disease 0 0.49334583
reactions I-Disease 0 0.086925894
, O 0 0.0014190718
particularly O 0 0.0017952825
in O 0 0.0016933929
the O 0 0.0028302206
elderly O 0 0.2802549
. O 0 0.0073348396

Development O 0 0.027451342
of O 0 0.017186975
levodopa B-Chemical 0 0.99999595
- O 0 0.32360122
induced O 0 0.012824872
dyskinesias B-Disease 2 0.9999982
in O 0 0.0064179837
parkinsonian B-Disease 2 0.99998105
monkeys O 0 0.0005647409
may O 0 0.00025444978
depend O 0 0.00021673161
upon O 0 0.00020586485
rate O 0 0.0003250278
of O 0 0.0005079713
symptom O 0 0.019798525
onset O 0 0.0009417273
and O 0 0.0006716493
/ O 0 0.0020061666
or O 0 0.0009295558
duration O 0 0.0012764393
of O 0 0.003199758
symptoms O 0 0.39745232
. O 0 0.0070317867

Levodopa B-Chemical 0 0.99998784
- O 0 0.2378753
induced O 0 0.017303023
dyskinesias B-Disease 2 0.9999975
( O 0 0.12651297
LIDs B-Disease 0 0.9999099
) O 0 0.001464635
present O 0 0.00033492455
a O 0 0.00038747632
major O 0 0.0003387667
problem O 0 0.00040951886
for O 0 0.00022635408
the O 0 0.00022681335
long O 0 0.0002936468
- O 0 0.0013433562
term O 0 0.00026504046
management O 0 0.00049895013
of O 0 0.0010336206
Parkinson B-Disease 0 0.9996915
' I-Disease 0 0.0012726615
s I-Disease 0 0.0013600546
disease I-Disease 0 0.89666915
( O 0 0.014085396
PD B-Disease 0 0.9996132
) O 0 0.0054687555
patients O 0 0.0061511546
. O 0 0.0072288103

Due O 0 0.0032430862
to O 0 0.0020453578
the O 0 0.0014478657
interdependence O 0 0.0013993725
of O 0 0.0012650344
risk O 0 0.06000488
factors O 0 0.0034653693
in O 0 0.0006317083
clinical O 0 0.004015828
populations O 0 0.0010463408
, O 0 0.0005519844
it O 0 0.00030570838
is O 0 0.00022526036
difficult O 0 0.00018547635
to O 0 0.00015777168
independently O 0 0.0001569388
examine O 0 0.00013536631
factors O 0 0.00044459943
that O 0 0.0003112294
may O 0 0.00042267342
influence O 0 0.00050594605
the O 0 0.00093350234
development O 0 0.003478161
of O 0 0.011547095
LIDs B-Disease 0 0.9997317
. O 0 0.0076726787

Using O 0 0.0034283702
macaque O 0 0.0025884295
monkeys O 0 0.0018125216
with O 0 0.0010847317
different O 0 0.00071033445
types O 0 0.0006746137
of O 0 0.015912378
MPTP B-Chemical 0 1.0
- O 0 0.6920129
induced O 0 0.025895229
parkinsonism B-Disease 2 0.99999976
, O 0 0.0013477214
the O 0 0.00023845278
current O 0 0.00035113582
study O 0 0.00020831065
evaluated O 0 0.00012084134
the O 0 0.00013394852
degree O 0 0.00017910564
to O 0 0.0001344304
which O 0 0.00018822245
rate O 0 0.00018188539
of O 0 0.00032917655
symptom O 0 0.06447396
progression O 0 0.26096603
, O 0 0.0010394373
symptom O 0 0.034339868
severity O 0 0.003702921
, O 0 0.00028421998
and O 0 0.00019019248
response O 0 0.00021318714
to O 0 0.00013950991
and O 0 0.00020054511
duration O 0 0.00018180825
of O 0 0.0014300654
levodopa B-Chemical 0 0.99999607
therapy O 0 0.0009210983
may O 0 0.00025540133
be O 0 0.00031187636
involved O 0 0.0003445267
in O 0 0.00055255834
the O 0 0.0008674965
development O 0 0.002827985
of O 0 0.008046258
LIDs B-Disease 0 0.9996604
. O 0 0.007472775

Monkeys O 0 0.027433101
with O 0 0.0035375596
acute O 0 0.67172855
( O 0 0.0028342162
short O 0 0.0010527461
- O 0 0.010454217
term O 0 0.0009077386
) O 0 0.09035192
MPTP B-Chemical 0 0.9999999
exposure O 0 0.10987319
, O 0 0.0010867086
rapid O 0 0.0014845824
symptom O 0 0.017023887
onset O 0 0.00042960327
and O 0 0.00019733285
short O 0 0.00014923625
symptom O 0 0.0011330378
duration O 0 0.00010961629
prior O 0 9.854776e-05
to O 0 0.00012148801
initiation O 0 0.00025529834
of O 0 0.0020631687
levodopa B-Chemical 0 0.9999976
therapy O 0 0.0034470274
developed O 0 0.006264765
dyskinesia B-Disease 0 0.99999857
between O 0 0.00020184516
11 O 0 0.00027221636
and O 0 0.0002944845
24 O 0 0.00033642576
days O 0 0.00035334274
of O 0 0.00090180966
daily O 0 0.006099183
levodopa B-Chemical 0 0.9999784
administration O 0 0.053807702
. O 0 0.006166467

In O 0 0.00363297
contrast O 0 0.002755293
, O 0 0.0021501991
monkeys O 0 0.0013687543
with O 0 0.0009042366
long O 0 0.00095641316
- O 0 0.021402013
term O 0 0.0021657404
MPTP B-Chemical 0 0.9999999
exposure O 0 0.090544015
, O 0 0.00096208695
slow O 0 0.0011629775
symptom O 0 0.037585758
progression O 0 0.09436207
and O 0 0.00041549
/ O 0 0.0024558308
or O 0 0.0001805976
long O 0 0.00019463284
symptom O 0 0.001600075
duration O 0 0.00010271753
prior O 0 9.116609e-05
to O 0 0.000111731046
initiation O 0 0.00023635497
of O 0 0.0019678955
levodopa B-Chemical 0 0.99999714
therapy O 0 0.00096837303
were O 0 0.00016911588
more O 0 0.00016254038
resistant O 0 0.00017985265
to O 0 0.00016578677
developing O 0 0.08669159
LIDs B-Disease 0 0.99990296
( O 0 0.0004794496
e O 0 0.0008797538
. O 0 0.00022689793
g O 0 0.00085539836
. O 0 0.00028285867
, O 0 0.0014822149
dyskinesia B-Disease 0 0.99999833
developed O 0 0.000635458
no O 0 0.00021167414
sooner O 0 0.00046071433
than O 0 0.00021782253
146 O 0 0.00062958035
days O 0 0.00033287072
of O 0 0.0010060203
chronic O 0 0.99266773
levodopa B-Chemical 0 0.99999785
administration O 0 0.18174899
) O 0 0.0074092643
. O 0 0.006776273

All O 0 0.003208837
animals O 0 0.0021888015
were O 0 0.0016634079
similarly O 0 0.0012596222
symptomatic O 0 0.004689183
at O 0 0.00060721755
the O 0 0.00049092574
start O 0 0.00046052973
of O 0 0.0015560546
levodopa B-Chemical 0 0.9999938
treatment O 0 0.0007411798
and O 0 0.0004891903
had O 0 0.0004098106
similar O 0 0.00041642875
therapeutic O 0 0.0009946935
responses O 0 0.0012218184
to O 0 0.0013118971
the O 0 0.0024864408
drug O 0 0.31786668
. O 0 0.007146269

These O 0 0.003577789
data O 0 0.0023207534
suggest O 0 0.0011065755
distinct O 0 0.0009735641
differences O 0 0.00063927943
in O 0 0.0005600672
the O 0 0.00043799964
propensity O 0 0.0007166878
to O 0 0.0003274425
develop O 0 0.00069931254
LIDs B-Disease 0 0.99963176
in O 0 0.00022725863
monkeys O 0 0.00022335524
with O 0 0.00015965522
different O 0 0.000120004
rates O 0 0.00017541109
of O 0 0.00028089547
symptom O 0 0.03511661
progression O 0 0.102076724
or O 0 0.00024387377
symptom O 0 0.0039505335
durations O 0 0.00011752306
prior O 0 0.000109212524
to O 0 0.00022331903
levodopa B-Chemical 0 0.99998283
and O 0 0.00018631562
demonstrate O 0 8.8294575e-05
the O 0 0.00013253218
value O 0 0.00015644857
of O 0 0.00021490226
these O 0 0.0002324737
models O 0 0.00027091923
for O 0 0.00029611713
further O 0 0.0003915973
studying O 0 0.0007058602
the O 0 0.0010152106
pathophysiology O 0 0.049960528
of O 0 0.010287854
LIDs B-Disease 0 0.99971753
. O 0 0.007507845

A O 0 0.121288635
diet O 0 0.064802155
promoting O 0 0.0047802106
sugar B-Disease 0 0.98519355
dependency I-Disease 0 0.058103222
causes O 0 0.0020600108
behavioral B-Disease 0 0.06346725
cross I-Disease 0 0.0019460929
- I-Disease 0 0.010795743
sensitization I-Disease 0 0.020102486
to O 0 0.0007293608
a O 0 0.0011236116
low O 0 0.0016862327
dose O 0 0.015845748
of O 0 0.02714573
amphetamine B-Chemical 1 0.9999958
. O 0 0.010634685

Previous O 0 0.0038644003
research O 0 0.0028914525
in O 0 0.0017930699
this O 0 0.0013084735
laboratory O 0 0.0013741396
has O 0 0.000661716
shown O 0 0.00043693188
that O 0 0.00037425235
a O 0 0.0005647931
diet O 0 0.013488895
of O 0 0.00055733265
intermittent O 0 0.020326046
excessive O 0 0.029743852
sugar O 0 0.8618988
consumption O 0 0.16097938
produces O 0 0.0003001327
a O 0 0.00030330545
state O 0 0.00032121874
with O 0 0.00038305233
neurochemical O 0 0.14203788
and O 0 0.00049448415
behavioral O 0 0.002691792
similarities O 0 0.00078317267
to O 0 0.0013512392
drug B-Disease 0 0.8948858
dependency I-Disease 0 0.060805798
. O 0 0.0069198753

The O 0 0.002936973
present O 0 0.0017945775
study O 0 0.0015303318
examined O 0 0.00078122795
whether O 0 0.00053223944
female O 0 0.0014467161
rats O 0 0.0006470532
on O 0 0.00027348427
various O 0 0.00037610866
regimens O 0 0.00050712854
of O 0 0.00050170196
sugar O 0 0.2845369
access O 0 0.00025026285
would O 0 0.00019551991
show O 0 0.000195236
behavioral B-Disease 0 0.0053134905
cross I-Disease 0 0.000634708
- I-Disease 0 0.0058930903
sensitization I-Disease 0 0.011960817
to O 0 0.00044946087
a O 0 0.0007874172
low O 0 0.0013261812
dose O 0 0.014328636
of O 0 0.02566577
amphetamine B-Chemical 1 0.99999595
. O 0 0.009584199

After O 0 0.0027835167
a O 0 0.0026407507
30 O 0 0.0016469487
- O 0 0.0025114706
min O 0 0.0009769025
baseline O 0 0.00056100055
measure O 0 0.0003172086
of O 0 0.0005050168
locomotor O 0 0.23447478
activity O 0 0.0003644403
( O 0 0.0004060142
day O 0 0.00020964787
0 O 0 0.00028402306
) O 0 0.00041467982
, O 0 0.00027196243
animals O 0 0.00015574142
were O 0 0.00015839934
maintained O 0 0.00014202783
on O 0 0.0001222887
a O 0 0.00026248748
cyclic O 0 0.00980765
diet O 0 0.012025201
of O 0 0.000294039
12 O 0 0.00017097627
- O 0 0.0012006566
h O 0 0.00019574766
deprivation O 0 0.00066033384
followed O 0 0.00013580448
by O 0 0.0001847925
12 O 0 0.00015284412
- O 0 0.00074030337
h O 0 0.0001660714
access O 0 0.00012785557
to O 0 0.00011981786
10 O 0 0.0001457537
% O 0 0.00023211534
sucrose B-Chemical 0 0.48015627
solution O 0 0.0034045256
and O 0 0.00031099867
chow O 0 0.018104246
pellets O 0 0.0014917417
( O 0 0.00026433237
12 O 0 0.000120622724
h O 0 0.0001390789
access O 0 0.00012343269
starting O 0 0.0001227188
4 O 0 0.00014016703
h O 0 0.00017517606
after O 0 0.00014097837
onset O 0 0.0003095274
of O 0 0.0003055015
the O 0 0.00034187725
dark O 0 0.00070066506
period O 0 0.0005317278
) O 0 0.0011765419
for O 0 0.0012241744
21 O 0 0.0021642223
days O 0 0.0026941653
. O 0 0.0059648673

Locomotor O 0 0.20206183
activity O 0 0.0026713144
was O 0 0.0016286403
measured O 0 0.0009791632
again O 0 0.00089740264
for O 0 0.00062000524
30 O 0 0.000475188
min O 0 0.00050599815
at O 0 0.00035093224
the O 0 0.000344066
beginning O 0 0.0003205836
of O 0 0.0004570858
days O 0 0.00043435735
1 O 0 0.0006284359
and O 0 0.00089660526
21 O 0 0.0013883626
of O 0 0.0022199345
sugar O 0 0.17310949
access O 0 0.004583464
. O 0 0.007276956

Beginning O 0 0.008522158
on O 0 0.0030163273
day O 0 0.0027649505
22 O 0 0.002992853
, O 0 0.0026041623
all O 0 0.0018379733
rats O 0 0.0022195324
were O 0 0.0017874839
maintained O 0 0.0019240573
on O 0 0.0022418096
ad O 0 0.0059892144
libitum O 0 0.012822686
chow O 0 0.04472567
. O 0 0.008999434

Nine O 0 0.0051682116
days O 0 0.0020674989
later O 0 0.001738707
locomotor O 0 0.12683842
activity O 0 0.000932249
was O 0 0.00060746184
measured O 0 0.00038430837
in O 0 0.00036307206
response O 0 0.00040288217
to O 0 0.00026544687
a O 0 0.0003289538
single O 0 0.00026199842
low O 0 0.00036725242
dose O 0 0.0027136558
of O 0 0.005471319
amphetamine B-Chemical 1 0.9999995
( O 0 0.0017259645
0 O 0 0.0005339582
. O 0 0.00047831165
5 O 0 0.0006372903
mg O 0 0.0053571668
/ O 0 0.0032379588
kg O 0 0.0050454065
) O 0 0.00602431
. O 0 0.007597506

The O 0 0.0031374637
animals O 0 0.0019873185
that O 0 0.0013992451
had O 0 0.0011911722
experienced O 0 0.0013407288
cyclic O 0 0.10636597
sucrose B-Chemical 0 0.9454225
and O 0 0.0010484584
chow O 0 0.043916203
were O 0 0.00035294262
hyperactive B-Disease 0 0.17782953
in O 0 0.00021873703
response O 0 0.00036210698
to O 0 0.0003934426
amphetamine B-Chemical 1 0.99999833
compared O 0 0.00014888277
with O 0 0.00017622413
four O 0 0.00011219237
control O 0 0.00015467455
groups O 0 0.00020396263
( O 0 0.00027686893
ad O 0 0.00033069073
libitum O 0 0.0005473428
10 O 0 0.00014426124
% O 0 0.00022590843
sucrose B-Chemical 0 0.4009628
and O 0 0.00026981105
chow O 0 0.0077505554
followed O 0 0.00015402389
by O 0 0.000639048
amphetamine B-Chemical 1 0.9999993
injection O 0 0.003851469
, O 0 0.0007128412
cyclic O 0 0.027806647
chow O 0 0.020029113
followed O 0 0.00016488832
by O 0 0.0007536089
amphetamine B-Chemical 1 0.9999993
injection O 0 0.0025014824
, O 0 0.00041095522
ad O 0 0.000540182
libitum O 0 0.0020521309
chow O 0 0.0233617
with O 0 0.0011007792
amphetamine B-Chemical 1 0.99999905
, O 0 0.00059867906
or O 0 0.00026798362
cyclic O 0 0.010042873
10 O 0 0.00024582632
% O 0 0.00039227935
sucrose B-Chemical 0 0.4501489
and O 0 0.00055146456
chow O 0 0.012011119
with O 0 0.0005960441
a O 0 0.0010223818
saline O 0 0.008080631
injection O 0 0.0029927322
) O 0 0.004930936
. O 0 0.006469136

These O 0 0.003479948
results O 0 0.0020579637
suggest O 0 0.0011984993
that O 0 0.0010845813
a O 0 0.0012749861
diet O 0 0.009980362
comprised O 0 0.0005506436
of O 0 0.00052554725
alternating O 0 0.0019119424
deprivation O 0 0.004559757
and O 0 0.0003347426
access O 0 0.00021248641
to O 0 0.00018580417
a O 0 0.00037683992
sugar O 0 0.33222753
solution O 0 0.008413711
and O 0 0.00039401723
chow O 0 0.03682546
produces O 0 0.00042459366
bingeing O 0 0.9979678
on O 0 0.00013195576
sugar O 0 0.16427836
that O 0 0.00012570713
leads O 0 0.0001405033
to O 0 0.0001262713
a O 0 0.00016563808
long O 0 0.00012592356
lasting O 0 0.00013896861
state O 0 0.00017231701
of O 0 0.00021230134
increased O 0 0.0002787226
sensitivity O 0 0.0041646105
to O 0 0.0007528774
amphetamine B-Chemical 1 0.9999995
, O 0 0.0007513743
possibly O 0 0.00045527227
due O 0 0.0001826365
to O 0 0.00022718303
a O 0 0.0003617369
lasting O 0 0.00040789397
alteration O 0 0.0006816686
in O 0 0.00085978647
the O 0 0.0017745998
dopamine B-Chemical 1 0.9981762
system O 0 0.004114157
. O 0 0.006301327

Reversible O 0 0.7196272
dilated B-Disease 2 0.99830556
cardiomyopathy I-Disease 2 0.99999034
related O 0 0.0065482296
to O 0 0.00864008
amphotericin B-Chemical 1 0.99998486
B I-Chemical 1 0.99834025
therapy O 0 0.16325818
. O 0 0.015665691

We O 0 0.0036471447
describe O 0 0.0022957155
a O 0 0.002081039
patient O 0 0.0014663619
who O 0 0.0014736453
developed O 0 0.0021374421
dilated B-Disease 2 0.99910164
cardiomyopathy I-Disease 2 0.99999964
and O 0 0.0057983575
clinical O 0 0.07660802
congestive O 0 0.9999068
heart B-Disease 0 0.5898346
failure I-Disease 0 0.13516217
after O 0 0.00015417626
2 O 0 0.00016967699
months O 0 0.00013163003
of O 0 0.00021503141
therapy O 0 0.0005658778
with O 0 0.0018256127
amphotericin B-Chemical 1 0.9999993
B I-Chemical 1 0.9998653
( O 0 0.23911647
AmB B-Chemical 1 0.9999901
) O 0 0.015787791
for O 0 0.002810832
disseminated O 0 0.9886524
coccidioidomycosis B-Disease 0 0.9999696
. O 0 0.011627095

His O 0 0.009474563
echocardiographic O 0 0.010208871
abnormalities O 0 0.022817958
and O 0 0.0027606096
heart B-Disease 0 0.1608489
failure I-Disease 0 0.20973532
resolved O 0 0.0025879976
after O 0 0.0015273672
posaconazole B-Chemical 0 0.9999938
was O 0 0.002959025
substituted O 0 0.021707805
for O 0 0.0052679735
AmB B-Chemical 1 0.99984634
. O 0 0.011488486

It O 0 0.00555276
is O 0 0.0030666324
important O 0 0.0018415012
to O 0 0.0015102525
recognize O 0 0.0012342874
the O 0 0.0013158157
rare O 0 0.002453629
and O 0 0.0015981436
potentially O 0 0.0034954753
reversible O 0 0.588399
toxicity B-Disease 2 0.9994449
of O 0 0.060166895
AmB B-Chemical 1 0.9999505
. O 0 0.014058972

NO B-Chemical 0 0.9989398
- O 0 0.15202776
induced O 0 0.019334765
migraine B-Disease 0 0.99999774
attack O 0 0.9780716
: O 0 0.003577065
strong O 0 0.0008881247
increase O 0 0.0004011033
in O 0 0.0004670931
plasma O 0 0.07957867
calcitonin B-Chemical 0 0.9538178
gene I-Chemical 0 0.0017942111
- I-Chemical 0 0.0077657006
related I-Chemical 0 0.00018016707
peptide I-Chemical 0 0.0008063425
( O 0 0.0051876158
CGRP B-Chemical 1 0.99893636
) O 0 0.0009436929
concentration O 0 0.00054429105
and O 0 0.00037059726
negative O 0 0.0005000095
correlation O 0 0.0005175659
with O 0 0.0015419172
platelet O 0 0.9608223
serotonin B-Chemical 0 0.99945813
release O 0 0.016438859
. O 0 0.0067638536

The O 0 0.0030763377
aim O 0 0.0022826663
of O 0 0.001615365
the O 0 0.0010488948
present O 0 0.0006730818
study O 0 0.0007161351
was O 0 0.0004178631
to O 0 0.00025980073
investigate O 0 0.0001519019
changes O 0 0.00027605786
in O 0 0.00019803969
the O 0 0.00022685964
plasma O 0 0.036161594
calcitonin B-Chemical 0 0.9214996
gene I-Chemical 0 0.0013773567
- I-Chemical 0 0.007995933
related I-Chemical 0 0.00013448938
peptide I-Chemical 0 0.00072072604
( O 0 0.005665439
CGRP B-Chemical 1 0.99915886
) O 0 0.0010561201
concentration O 0 0.00074930186
and O 0 0.0006547834
platelet O 0 0.95908344
serotonin B-Chemical 0 0.99972314
( O 0 0.00047883074
5 B-Chemical 0 0.00017140852
- I-Chemical 0 0.0016582088
hydroxytriptamine I-Chemical 0 0.0057511213
, O 0 0.0003857053
5 B-Chemical 0 0.00025420947
- I-Chemical 0 0.05691474
HT I-Chemical 0 0.99910295
) O 0 0.0006107384
content O 0 0.00021252716
during O 0 0.00014538699
the O 0 0.00021713908
immediate O 0 0.0016262957
headache B-Disease 0 0.99982494
and O 0 0.0004069535
the O 0 0.00037826938
delayed O 0 0.0026876465
genuine O 0 0.023179933
migraine B-Disease 0 0.999998
attack O 0 0.9628078
provoked O 0 0.264089
by O 0 0.017132547
nitroglycerin B-Chemical 1 0.99998236
. O 0 0.009327847

Fifteen O 0 0.008244503
female O 0 0.026836028
migraineurs B-Disease 0 0.9982967
( I-Disease 0 0.00453458
without I-Disease 0 0.004173305
aura I-Disease 0 0.999995
) I-Disease 0 0.0033792579
and O 0 0.0012981088
eight O 0 0.0010141076
controls O 0 0.0015534209
participated O 0 0.0024077727
in O 0 0.0020632423
the O 0 0.0030617833
study O 0 0.005747567
. O 0 0.008236156

Sublingual O 0 0.9952264
nitroglycerin B-Chemical 1 0.9999802
( O 0 0.007648056
0 O 0 0.003372446
. O 0 0.0025645345
5 O 0 0.002585757
mg O 0 0.011534613
) O 0 0.0053832037
was O 0 0.00536252
administered O 0 0.0071705175
. O 0 0.011043741

Blood O 0 0.019309957
was O 0 0.0024587216
collected O 0 0.0013039557
from O 0 0.0009963339
the O 0 0.00089860527
antecubital O 0 0.00337947
vein O 0 0.0019003159
four O 0 0.00029414694
times O 0 0.00022035261
: O 0 0.00035857043
60 O 0 0.0002276846
min O 0 0.00023712286
before O 0 0.00013789399
and O 0 0.00019146726
after O 0 0.0001418803
the O 0 0.00034138223
nitroglycerin B-Chemical 1 0.999992
application O 0 0.00072459335
, O 0 0.0003132811
and O 0 0.00019435634
60 O 0 0.00015087496
and O 0 0.00014238949
120 O 0 0.00014059657
min O 0 0.00014904357
after O 0 9.3645736e-05
the O 0 0.00012554062
beginning O 0 0.00012635645
of O 0 0.00024777517
the O 0 0.00082050066
migraine B-Disease 0 0.99999833
attack O 0 0.8075236
( O 0 0.0005814966
mean O 0 0.00022659398
344 O 0 0.0013655715
and O 0 0.00043359425
404 O 0 0.0014304385
min O 0 0.0008169078
; O 0 0.0012882713
12 O 0 0.0012527078
subjects O 0 0.0025967958
) O 0 0.0050207498
. O 0 0.007220677

In O 0 0.0043341224
those O 0 0.0031096337
subjects O 0 0.0024599044
who O 0 0.0019453594
had O 0 0.0011696094
no O 0 0.0013436523
migraine B-Disease 0 0.9999969
attack O 0 0.94594496
( O 0 0.0021510834
11 O 0 0.00065297016
subjects O 0 0.00070241507
) O 0 0.00085164513
a O 0 0.00071937015
similar O 0 0.0006288092
time O 0 0.00082103454
schedule O 0 0.0015481107
was O 0 0.0023194498
used O 0 0.0036048756
. O 0 0.006850642

Plasma O 0 0.68856
CGRP B-Chemical 1 0.9971413
concentration O 0 0.0062963786
increased O 0 0.0020921673
significantly O 0 0.0014838369
( O 0 0.0020763762
P O 0 0.08542704
< O 0 0.00053596287
0 O 0 0.00053755916
. O 0 0.00041115162
01 O 0 0.0012706696
) O 0 0.00048505754
during O 0 0.0002486406
the O 0 0.0006669819
migraine B-Disease 0 0.9999969
attack O 0 0.69796157
and O 0 0.00042401996
returned O 0 0.0002667173
to O 0 0.00023302497
baseline O 0 0.00029390672
after O 0 0.0002841306
the O 0 0.00054787786
cessation O 0 0.0027133424
of O 0 0.0018994061
the O 0 0.0050497893
migraine B-Disease 0 0.9999776
. O 0 0.0087096505

In O 0 0.0035092048
addition O 0 0.0018610689
, O 0 0.002182438
both O 0 0.0011866592
change O 0 0.0010128823
and O 0 0.0007859074
peak O 0 0.0007608786
, O 0 0.00061425817
showed O 0 0.00031662974
significant O 0 0.00029082442
positive O 0 0.0004199228
correlations O 0 0.00041258626
with O 0 0.01639764
migraine B-Disease 0 1.0
headache B-Disease 0 0.99999905
intensity O 0 0.00077340525
( O 0 0.0015382995
P O 0 0.03746897
< O 0 0.00090260623
0 O 0 0.0014106501
. O 0 0.0020118179
001 O 0 0.041499026
) O 0 0.006371242
. O 0 0.008119534

However O 0 0.0053131045
, O 0 0.0052557667
plasma O 0 0.1789482
CGRP B-Chemical 1 0.9983948
concentrations O 0 0.0037241175
failed O 0 0.00086710934
to O 0 0.00050415134
change O 0 0.00048777202
during O 0 0.0003488187
immediate O 0 0.0023959395
headache B-Disease 0 0.9998566
and O 0 0.0005455227
in O 0 0.0004320281
the O 0 0.00050197914
subjects O 0 0.00089588575
with O 0 0.0012134324
no O 0 0.0022736422
migraine B-Disease 0 0.9999894
attack O 0 0.9433793
. O 0 0.00982954

Basal O 0 0.35944206
CGRP B-Chemical 1 0.9969958
concentration O 0 0.006406792
was O 0 0.001631047
significantly O 0 0.001014252
higher O 0 0.0007380686
and O 0 0.0008543745
platelet O 0 0.661179
5 B-Chemical 0 0.00061343034
- I-Chemical 0 0.056749947
HT I-Chemical 0 0.9973214
content O 0 0.0004432797
tended O 0 0.0002892731
to O 0 0.00024674827
be O 0 0.0003220712
lower O 0 0.0003697304
in O 0 0.00045123772
subjects O 0 0.00082609616
who O 0 0.001229694
experienced O 0 0.0016349613
a O 0 0.005347657
migraine B-Disease 0 0.9999869
attack O 0 0.9279296
. O 0 0.009860461

Platelet O 0 0.9627954
serotonin B-Chemical 0 0.99834955
content O 0 0.0025144035
decreased O 0 0.0017830465
significantly O 0 0.001222072
( O 0 0.0017412754
P O 0 0.069266416
< O 0 0.0005055194
0 O 0 0.0005124684
. O 0 0.0003921137
01 O 0 0.0015489883
) O 0 0.0005754003
after O 0 0.00028252575
nitroglycerin B-Chemical 1 0.999979
in O 0 0.00027409484
subjects O 0 0.00032823955
with O 0 0.00029148342
no O 0 0.00042235103
migraine B-Disease 0 0.9999988
attack O 0 0.9101449
but O 0 0.0005536899
no O 0 0.00018121013
consistent O 0 0.00029332223
change O 0 0.00033932363
was O 0 0.00032960865
observed O 0 0.00036514623
in O 0 0.00060699106
patients O 0 0.0017821837
with O 0 0.007357285
migraine B-Disease 0 0.9999914
attack O 0 0.9366467
. O 0 0.009138187

In O 0 0.0036898402
conclusion O 0 0.002152015
, O 0 0.0021371697
the O 0 0.0010476965
fact O 0 0.0006594634
that O 0 0.0006415995
plasma O 0 0.20277403
CGRP B-Chemical 1 0.999138
concentration O 0 0.0019693335
correlates O 0 0.0003632748
with O 0 0.0002635638
the O 0 0.00018904857
timing O 0 0.00016861623
and O 0 0.00025812403
severity O 0 0.0020143117
of O 0 0.00073815515
a O 0 0.049184013
migraine B-Disease 0 1.0
headache B-Disease 0 0.9999988
suggests O 0 0.00028029864
a O 0 0.0003871785
direct O 0 0.00035293552
relationship O 0 0.00045734012
between O 0 0.0009875087
CGRP B-Chemical 1 0.9986578
and O 0 0.023478407
migraine B-Disease 0 0.99998105
. O 0 0.009034373

In O 0 0.0039775395
contrast O 0 0.003792524
, O 0 0.006867799
serotonin B-Chemical 0 0.9992799
release O 0 0.012119278
from O 0 0.00089331286
platelets O 0 0.12836611
does O 0 0.000534635
not O 0 0.00040580158
provoke O 0 0.03634208
migraine B-Disease 0 0.9999989
, O 0 0.0016895432
it O 0 0.0003597519
may O 0 0.0002152476
even O 0 0.00025992983
counteract O 0 0.0002806334
the O 0 0.0006218869
headache B-Disease 0 0.99989116
and O 0 0.00047995054
the O 0 0.00046885895
concomitant O 0 0.014764722
CGRP B-Chemical 1 0.9983901
release O 0 0.0045974124
in O 0 0.0014001328
this O 0 0.002006395
model O 0 0.0038098276
. O 0 0.0067402693

Hyperbaric O 0 0.9947607
oxygen B-Chemical 1 0.9942009
therapy O 0 0.0054186215
for O 0 0.0019353237
control O 0 0.0017046225
of O 0 0.0025026202
intractable O 0 0.97755176
cyclophosphamide B-Chemical 0 0.99998355
- O 0 0.39919236
induced O 0 0.046169575
hemorrhagic B-Disease 2 0.9999927
cystitis I-Disease 0 0.9999926
. O 0 0.03796859

We O 0 0.0043304283
report O 0 0.0039472906
a O 0 0.0025686424
case O 0 0.0018774136
of O 0 0.0023458202
intractable O 0 0.9795846
hemorrhagic B-Disease 2 0.9999949
cystitis I-Disease 0 0.9999938
due O 0 0.0007858333
to O 0 0.0009160845
cyclophosphamide B-Chemical 0 0.99981314
therapy O 0 0.003385089
for O 0 0.0013684205
Wegener B-Disease 0 0.9449986
' I-Disease 0 0.0039253714
s I-Disease 0 0.0047293385
granulomatosis I-Disease 0 0.89621544
. O 0 0.008289175

Conservative O 0 0.11971424
treatment O 0 0.0035691569
, O 0 0.0024964644
including O 0 0.0013318247
bladder O 0 0.087730885
irrigation O 0 0.0075467946
with O 0 0.00064129446
physiological O 0 0.0007851252
saline O 0 0.0062638777
and O 0 0.00048808902
instillation O 0 0.035611402
of O 0 0.03219245
prostaglandin B-Chemical 0 1.0
F2 I-Chemical 0 0.99979466
alpha I-Chemical 0 0.9981187
, O 0 0.0029368359
failed O 0 0.0009754281
to O 0 0.0009674052
totally O 0 0.002510644
control O 0 0.0040992186
hemorrhage B-Disease 2 0.99992025
. O 0 0.008574088

We O 0 0.0034413433
then O 0 0.0022384385
used O 0 0.0019469154
hyperbaric O 0 0.7854925
oxygen B-Chemical 1 0.9919465
at O 0 0.0008095869
an O 0 0.0007040707
absolute O 0 0.0005943419
pressure O 0 0.017350331
of O 0 0.0005127664
2 O 0 0.0004383438
atm O 0 0.2420771
, O 0 0.0005046884
5 O 0 0.0003182018
days O 0 0.00030619814
a O 0 0.0005078648
week O 0 0.00049080595
for O 0 0.00077873544
8 O 0 0.0011857749
consecutive O 0 0.0017706208
weeks O 0 0.002693267
. O 0 0.0062106764

The O 0 0.004953842
bleeding B-Disease 0 0.98606443
ceased O 0 0.0035080025
completely O 0 0.00131844
by O 0 0.0009797964
the O 0 0.0006658229
end O 0 0.00046647486
of O 0 0.0005935452
treatment O 0 0.0006068244
and O 0 0.00057464355
the O 0 0.0005302179
patient O 0 0.0006958986
remained O 0 0.0009806145
free O 0 0.0014849853
of O 0 0.0042783287
hematuria B-Disease 0 0.9999436
thereafter O 0 0.005999266
. O 0 0.007386207

No O 0 0.009058464
side O 0 0.014950567
effect O 0 0.0037151214
was O 0 0.002962167
noted O 0 0.0021838548
during O 0 0.0019837448
the O 0 0.0025477728
course O 0 0.0033185142
of O 0 0.0053666467
therapy O 0 0.011128492
. O 0 0.010728262

In O 0 0.003972736
future O 0 0.0028225405
, O 0 0.002511847
this O 0 0.0013358898
form O 0 0.0009785189
of O 0 0.0009959328
therapy O 0 0.0012596066
can O 0 0.0004258468
offer O 0 0.00044283923
a O 0 0.00045890134
safe O 0 0.00048649835
alternative O 0 0.00027700356
in O 0 0.00029479942
the O 0 0.0003335286
treatment O 0 0.0005860262
of O 0 0.0021838893
cyclophosphamide B-Chemical 0 0.99997604
- O 0 0.30875334
induced O 0 0.03439922
hemorrhagic B-Disease 2 0.99999404
cystitis I-Disease 0 0.9999932
. O 0 0.033563912

Acute B-Disease 0 0.9976096
psychosis I-Disease 0 0.9999685
due O 0 0.0026702564
to O 0 0.0021215887
treatment O 0 0.0026730415
with O 0 0.0062490124
phenytoin B-Chemical 1 0.999997
in O 0 0.003358817
a O 0 0.0059366436
nonepileptic O 0 0.9986675
patient O 0 0.006362003
. O 0 0.008435897

The O 0 0.0031703177
development O 0 0.0034282154
of O 0 0.0036667103
psychosis B-Disease 0 0.9998951
related O 0 0.00076994085
to O 0 0.0008321219
antiepileptic O 0 0.999345
drug O 0 0.5418792
treatment O 0 0.0007386238
is O 0 0.00031656635
usually O 0 0.00028291013
attributed O 0 0.00015732537
to O 0 0.00015936546
the O 0 0.0001772129
interaction O 0 0.00023042235
between O 0 0.00021386084
the O 0 0.00056940375
epileptic B-Disease 0 0.9999664
brain O 0 0.033711273
substratum O 0 0.028254757
and O 0 0.0011635554
the O 0 0.0017977606
antiepileptic O 0 0.9983827
drugs O 0 0.31080964
. O 0 0.0062393225

The O 0 0.0035494636
case O 0 0.0027815453
of O 0 0.0024008364
a O 0 0.0032216483
nonepileptic O 0 0.9985806
patient O 0 0.0011662784
who O 0 0.0012066023
developed O 0 0.0023284692
psychosis B-Disease 0 0.9999629
following O 0 0.0015241214
phenytoin B-Chemical 1 0.9999987
treatment O 0 0.0013490629
for O 0 0.0010905006
trigeminal B-Disease 0 0.58535475
neuralgia I-Disease 0 0.9999124
is O 0 0.0024841123
described O 0 0.003354719
. O 0 0.0062735314

This O 0 0.005057594
case O 0 0.002545524
suggests O 0 0.0012826883
that O 0 0.001154225
the O 0 0.003288831
psychotic B-Disease 0 0.99999976
symptoms I-Disease 0 0.9840493
that O 0 0.00038986243
occur O 0 0.00040995207
following O 0 0.0007476716
phenytoin B-Chemical 1 0.9999993
treatment O 0 0.0009744611
in O 0 0.000321891
some O 0 0.0005989285
epileptic B-Disease 0 0.9999614
patients O 0 0.00057055353
may O 0 0.0001853579
be O 0 0.0002005153
the O 0 0.00020839587
direct O 0 0.0002473456
result O 0 0.00033546443
of O 0 0.00079209363
medication O 0 0.05439007
, O 0 0.0013310607
unrelated O 0 0.0027657552
to O 0 0.0031796426
seizures B-Disease 0 0.99998283
. O 0 0.00860065

Risks O 0 0.026358841
of O 0 0.0073936787
the O 0 0.0061647166
consumption O 0 0.062687956
of O 0 0.0088523235
beverages O 0 0.9802986
containing O 0 0.011448476
quinine B-Chemical 1 0.9998344
. O 0 0.016526487

Although O 0 0.0033766606
the O 0 0.0025917261
United O 0 0.0032537084
States O 0 0.004083
Food O 0 0.17637427
and O 0 0.0013528964
Drug O 0 0.7525216
Administration O 0 0.12605117
banned O 0 0.021044075
its O 0 0.0007239714
use O 0 0.00033909964
for O 0 0.00034565676
nocturnal B-Disease 0 0.6658437
leg I-Disease 0 0.88891566
cramps I-Disease 0 0.9999573
due O 0 0.00015595545
to O 0 0.00014087798
lack O 0 0.00013903542
of O 0 0.00020534416
safety O 0 0.00031174975
and O 0 0.0002274403
efficacy O 0 0.00070321147
, O 0 0.002213318
quinine B-Chemical 1 0.9999429
is O 0 0.00036484786
widely O 0 0.00031329307
available O 0 0.00029159235
in O 0 0.00036973602
beverages O 0 0.72716254
including O 0 0.00065590726
tonic O 0 0.100793
water O 0 0.025124043
and O 0 0.0032618463
bitter O 0 0.9010336
lemon O 0 0.99132216
. O 0 0.0076026986

Numerous O 0 0.00430689
anecdotal O 0 0.004199884
reports O 0 0.0016926683
suggest O 0 0.00086720684
that O 0 0.0007898788
products O 0 0.0014494783
containing O 0 0.0009806112
quinine B-Chemical 1 0.9999392
may O 0 0.000459966
produce O 0 0.00037865608
neurological B-Disease 0 0.99962294
complications I-Disease 0 0.9910734
, O 0 0.00086107623
including O 0 0.00039271824
confusion B-Disease 0 0.79016095
, O 0 0.0005049842
altered O 0 0.00032965015
mental O 0 0.059762828
status O 0 0.0022306875
, O 0 0.0080771325
seizures B-Disease 0 0.9999988
, O 0 0.002901866
and O 0 0.0029628032
coma B-Disease 0 0.9999355
, O 0 0.0014022578
particularly O 0 0.0017352424
in O 0 0.0016748952
older O 0 0.008184572
women O 0 0.015219978
. O 0 0.0071836025

Psychologists O 0 0.006882131
need O 0 0.002476512
to O 0 0.0018514707
inquire O 0 0.001954476
about O 0 0.0010898322
consumption O 0 0.047307063
of O 0 0.003704749
quinine B-Chemical 1 0.9999852
- O 0 0.049092256
containing O 0 0.00084043876
beverages O 0 0.8293581
as O 0 0.00072899385
part O 0 0.0008135026
of O 0 0.0012882291
an O 0 0.0018578173
evaluation O 0 0.0025781093
process O 0 0.0045175916
. O 0 0.00749642

Transient O 0 0.47468358
platypnea B-Disease 0 0.9474335
- I-Disease 0 0.35082948
orthodeoxia I-Disease 0 0.9962656
- I-Disease 0 0.03632654
like I-Disease 0 0.00097489374
syndrome I-Disease 0 0.26564547
induced O 0 0.000992156
by O 0 0.00648284
propafenone B-Chemical 0 0.9999999
overdose B-Disease 0 0.999992
in O 0 0.0006137196
a O 0 0.0006699286
young O 0 0.0028408086
woman O 0 0.0023695794
with O 0 0.0011205279
Ebstein B-Disease 0 0.15174234
' I-Disease 0 0.0024842173
s I-Disease 0 0.0034623933
anomaly I-Disease 0 0.18335593
. O 0 0.007819148

In O 0 0.00374625
this O 0 0.002383068
report O 0 0.002071415
we O 0 0.00087883376
describe O 0 0.00071356713
the O 0 0.000600658
case O 0 0.00055766315
of O 0 0.0005456044
a O 0 0.00061757717
37 O 0 0.00093389826
- O 0 0.0032237985
year O 0 0.00038292838
- O 0 0.0021445916
old O 0 0.00030663953
white O 0 0.0023052096
woman O 0 0.00087361486
with O 0 0.00028695146
Ebstein B-Disease 0 0.10400616
' I-Disease 0 0.00037211282
s I-Disease 0 0.0003703426
anomaly I-Disease 0 0.119551435
, O 0 0.00038647806
who O 0 0.00030944002
developed O 0 0.0002626131
a O 0 0.00024768565
rare O 0 0.00173113
syndrome O 0 0.27325556
called O 0 0.0007253613
platypnea B-Disease 0 0.909029
- I-Disease 0 0.11019798
orthodeoxia I-Disease 0 0.9732574
, O 0 0.00033740606
characterized O 0 0.00024508938
by O 0 0.00022318003
massive O 0 0.0078010308
right O 0 0.0041241096
- O 0 0.008700208
to O 0 0.00023253846
- O 0 0.0029724932
left O 0 0.00057833677
interatrial O 0 0.010434407
shunting O 0 0.019045927
with O 0 0.00048789987
transient O 0 0.007862228
profound O 0 0.025845874
hypoxia B-Disease 2 0.9967914
and O 0 0.025654247
cyanosis B-Disease 0 0.999137
. O 0 0.008038413

This O 0 0.0051056277
shunt O 0 0.0051087798
of O 0 0.0020241893
blood O 0 0.0029090564
via O 0 0.00074430235
a O 0 0.0008142289
patent B-Disease 0 0.03935988
foramen I-Disease 0 0.6912591
ovale I-Disease 0 0.996145
occurred O 0 0.00044509664
in O 0 0.0002649816
the O 0 0.00021882005
presence O 0 0.00021723972
of O 0 0.00030664305
a O 0 0.00037556063
normal O 0 0.00076877885
pulmonary O 0 0.64081675
artery O 0 0.32707813
pressure O 0 0.11153334
, O 0 0.000457341
and O 0 0.00037570513
was O 0 0.00039073534
probably O 0 0.0006001505
precipitated O 0 0.0010155293
by O 0 0.0012921547
a O 0 0.011280774
propafenone B-Chemical 0 0.9999987
overdose B-Disease 0 0.9999696
. O 0 0.008822152

This O 0 0.0068723215
drug O 0 0.20349371
caused O 0 0.004094166
biventricular B-Disease 0 0.99406415
dysfunction I-Disease 0 0.9992643
, O 0 0.0021180646
due O 0 0.00044146768
to O 0 0.00037755046
its O 0 0.00067907624
negative O 0 0.00095990463
inotropic O 0 0.94330686
effect O 0 0.0006235086
, O 0 0.0011659252
and O 0 0.002889585
hypotension B-Disease 2 0.9999881
, O 0 0.00079821754
due O 0 0.000401262
to O 0 0.000579914
its O 0 0.0017371558
peripheral O 0 0.024509318
vasodilatory O 0 0.75969607
effect O 0 0.0037188951
. O 0 0.0065990337

These O 0 0.0036883557
effects O 0 0.0028479737
gave O 0 0.002274405
rise O 0 0.0014668424
to O 0 0.000815084
an O 0 0.0007816152
increase O 0 0.00044175354
in O 0 0.00040634177
the O 0 0.0003593647
right O 0 0.0015226678
atrial O 0 0.7120175
pressure O 0 0.059374165
and O 0 0.000266422
a O 0 0.00024890955
decrease O 0 0.0001764074
in O 0 0.0001646828
the O 0 0.0001619102
left O 0 0.0003231098
one O 0 0.00013322766
with O 0 0.00015543865
a O 0 0.00019086976
consequent O 0 0.00031403953
stretching O 0 0.006268551
of O 0 0.00022985182
the O 0 0.00022756132
foramen O 0 0.5467358
ovale O 0 0.9709075
and O 0 0.00026454285
the O 0 0.0002038971
creation O 0 0.0003062302
of O 0 0.00042220633
massive O 0 0.0097117685
right O 0 0.0037183636
- O 0 0.006605995
to O 0 0.0011050919
- O 0 0.006969882
left O 0 0.0048797806
shunting O 0 0.16762997
. O 0 0.006875653

In O 0 0.0042360104
our O 0 0.0028087357
case O 0 0.0021818609
this O 0 0.0016694124
interatrial O 0 0.0070663537
shunt O 0 0.0033596107
was O 0 0.0009898295
very O 0 0.0010296998
accurately O 0 0.00086960517
detected O 0 0.0009770945
at O 0 0.0014038339
bubble O 0 0.010629378
contrast O 0 0.0040772646
echocardiography O 0 0.03961534
. O 0 0.008837175

Noxious O 0 0.90876424
chemical O 0 0.009910068
stimulation O 0 0.002504977
of O 0 0.0020311447
rat O 0 0.006001149
facial O 0 0.33578873
mucosa O 0 0.5511199
increases O 0 0.0009779661
intracranial O 0 0.93226105
blood O 0 0.010614681
flow O 0 0.0008614258
through O 0 0.00019441251
a O 0 0.00039254723
trigemino O 0 0.108606406
- O 0 0.043540806
parasympathetic O 0 0.8726454
reflex O 0 0.83743715
- O 0 0.04433176
- O 0 0.0042457236
an O 0 0.0003414441
experimental O 0 0.0003618211
model O 0 0.00047074474
for O 0 0.00079244707
vascular B-Disease 0 0.9917092
dysfunctions I-Disease 0 0.99587375
in O 0 0.0020886678
cluster B-Disease 0 0.010777961
headache I-Disease 0 0.9997428
. O 0 0.0073032724

Cluster B-Disease 0 0.98807704
headache I-Disease 0 0.9999658
is O 0 0.0028230636
characterized O 0 0.0018855599
by O 0 0.0013706607
typical O 0 0.0013318583
autonomic O 0 0.28847694
dysfunctions O 0 0.37389603
including O 0 0.0009786899
facial O 0 0.08320451
and O 0 0.0024660362
intracranial B-Disease 0 0.9935774
vascular I-Disease 0 0.85274017
disturbances I-Disease 0 0.8971684
. O 0 0.008237578

Both O 0 0.0038829711
the O 0 0.0026785005
trigeminal O 0 0.00738989
and O 0 0.0016382
the O 0 0.001264505
cranial O 0 0.115080655
parasympathetic O 0 0.39457494
systems O 0 0.000900207
may O 0 0.00067476294
be O 0 0.00075857894
involved O 0 0.0007711496
in O 0 0.0011138922
mediating O 0 0.0014652411
these O 0 0.0035137697
dysfunctions O 0 0.72453296
. O 0 0.00844116

An O 0 0.0049465443
experimental O 0 0.0027142507
model O 0 0.0019780092
was O 0 0.0014078015
developed O 0 0.0012450957
in O 0 0.00067656813
the O 0 0.0005268249
rat O 0 0.00075202767
to O 0 0.00027920664
measure O 0 0.00019731911
changes O 0 0.00038824353
in O 0 0.00042174573
lacrimation O 0 0.9985104
and O 0 0.00088640436
intracranial O 0 0.92541605
blood O 0 0.009246235
flow O 0 0.0011125406
following O 0 0.00039766493
noxious O 0 0.058310393
chemical O 0 0.0028737122
stimulation O 0 0.0012501333
of O 0 0.002747955
facial O 0 0.5328503
mucosa O 0 0.7869619
. O 0 0.008594972

Blood O 0 0.03334531
flow O 0 0.006225775
was O 0 0.0020107373
monitored O 0 0.0011523255
in O 0 0.0011456655
arteries O 0 0.035078205
of O 0 0.0007587322
the O 0 0.00053749356
exposed O 0 0.0006667356
cranial O 0 0.1357504
dura O 0 0.16836268
mater O 0 0.07529363
and O 0 0.00053439377
the O 0 0.00066554116
parietal O 0 0.50267607
cortex O 0 0.05638937
using O 0 0.0014427663
laser O 0 0.021620916
Doppler O 0 0.32404605
flowmetry O 0 0.29429162
. O 0 0.008663921

Capsaicin B-Chemical 1 0.9998254
( O 0 0.0066707283
0 O 0 0.0027108195
. O 0 0.001719242
01 O 0 0.004306131
- O 0 0.0025810953
1 O 0 0.00065583293
mm O 0 0.0009829374
) O 0 0.0006919937
applied O 0 0.00035339376
to O 0 0.00032611442
oral O 0 0.019729001
or O 0 0.00034880088
nasal O 0 0.01033969
mucosa O 0 0.28060877
induced O 0 0.00040417662
increases B-Disease 0 0.00035312958
in I-Disease 0 0.00041288114
dural I-Disease 0 0.5981699
and I-Disease 0 0.0005805231
cortical I-Disease 0 0.009839204
blood I-Disease 0 0.0075797876
flow I-Disease 0 0.002915212
and O 0 0.002223869
provoked O 0 0.10024755
lacrimation O 0 0.9991922
. O 0 0.009026958

These O 0 0.0038360495
responses O 0 0.0033498022
were O 0 0.0018770065
blocked O 0 0.0017254304
by O 0 0.0014391779
systemic O 0 0.7240006
pre O 0 0.023479223
- O 0 0.036539346
administration O 0 0.023653356
of O 0 0.027920121
hexamethonium B-Chemical 0 1.0
chloride I-Chemical 0 0.99999857
( O 0 0.0073821037
20 O 0 0.0010783139
mg O 0 0.021760363
/ O 0 0.0038725422
kg O 0 0.0054149884
) O 0 0.006184948
. O 0 0.007766782

The O 0 0.0032258802
evoked O 0 0.0049962983
increases B-Disease 0 0.0016894629
in I-Disease 0 0.0014608941
dural I-Disease 0 0.7537329
blood I-Disease 0 0.018716462
flow I-Disease 0 0.002358624
were O 0 0.00037201334
also O 0 0.00027426478
abolished O 0 0.0003272116
by O 0 0.00040849793
topical O 0 0.8852784
pre O 0 0.016636815
- O 0 0.025559537
administration O 0 0.0054465444
of O 0 0.0017001316
atropine B-Chemical 0 0.9999932
( O 0 0.000916311
1 O 0 0.00018570552
mm O 0 0.0005612065
) O 0 0.00044671353
and O 0 0.00036252025
[ O 0 0.009207882
Lys1 O 0 0.16930936
, O 0 0.0014953854
Pro2 O 0 0.5879533
, O 0 0.0004345899
5 O 0 0.00020379311
, O 0 0.00048539657
Arg3 O 0 0.77562773
, O 0 0.00047921197
4 O 0 0.00022951151
, O 0 0.0005646201
Tyr6 O 0 0.904124
] O 0 0.017020337
- O 0 0.070131384
VIP O 0 0.93626565
( O 0 0.0005618278
0 O 0 0.00025371506
. O 0 0.00017574354
1 O 0 0.00018053973
mm O 0 0.00044214993
) O 0 0.00044579513
, O 0 0.00034192015
a O 0 0.00034447512
vasoactive O 0 0.028587174
intestinal O 0 0.04711068
polypeptide O 0 0.22640118
( O 0 0.029251225
VIP O 0 0.9952583
) O 0 0.014455907
antagonist O 0 0.74510896
, O 0 0.0008541848
onto O 0 0.000620179
the O 0 0.0009986378
exposed O 0 0.0022427165
dura O 0 0.32229826
mater O 0 0.33142224
. O 0 0.006517088

We O 0 0.0036029972
conclude O 0 0.0019621076
that O 0 0.0016586453
noxious O 0 0.10488741
stimulation O 0 0.0013457399
of O 0 0.001376182
facial O 0 0.365532
mucosa O 0 0.6094681
increases O 0 0.001046143
intracranial O 0 0.9499205
blood O 0 0.018686213
flow O 0 0.002511824
and O 0 0.0008311372
lacrimation O 0 0.9941713
via O 0 0.00068948464
a O 0 0.0014507483
trigemino O 0 0.16786982
- O 0 0.06074845
parasympathetic O 0 0.8446612
reflex O 0 0.53995925
. O 0 0.0075962082

The O 0 0.0038506053
blood O 0 0.006347156
flow O 0 0.004556518
responses O 0 0.002074697
seem O 0 0.0011226188
to O 0 0.00067609636
be O 0 0.00060107495
mediated O 0 0.0004413322
by O 0 0.00058272615
the O 0 0.00056088076
release O 0 0.0025366708
of O 0 0.0026041758
acetylcholine B-Chemical 1 0.9998611
and O 0 0.0025465954
VIP O 0 0.85870147
within O 0 0.0013104416
the O 0 0.0026247292
meninges O 0 0.30681533
. O 0 0.0070116464

Similar O 0 0.004439484
mechanisms O 0 0.0034316743
may O 0 0.0026165608
be O 0 0.002255349
involved O 0 0.001733094
in O 0 0.0018927734
the O 0 0.0020481395
pathogenesis O 0 0.0046557817
of O 0 0.004750378
cluster B-Disease 0 0.024317572
headache I-Disease 0 0.9998276
. O 0 0.011347684

Organophosphate B-Chemical 0 0.99996674
- O 0 0.14778851
induced O 0 0.012077645
convulsions B-Disease 0 0.9999734
and O 0 0.0073178057
prevention O 0 0.03364853
of O 0 0.015065127
neuropathological B-Disease 0 0.9993892
damages I-Disease 0 0.99552625
. O 0 0.016631411

Such O 0 0.102426454
organophosphorus B-Chemical 0 0.99999726
( O 0 0.346955
OP B-Chemical 0 0.9999691
) O 0 0.03950616
compounds O 0 0.8488705
as O 0 0.00475201
diisopropylfluorophosphate B-Chemical 0 0.9999981
( O 0 0.45543537
DFP B-Chemical 0 0.9999989
) O 0 0.050996702
, O 0 0.016733425
sarin B-Chemical 0 0.9999963
and O 0 0.012237054
soman B-Chemical 0 0.9999894
are O 0 0.00036536614
potent O 0 0.0009263826
inhibitors O 0 0.0014163454
of O 0 0.0008149936
acetylcholinesterases O 0 0.87141573
( O 0 0.003270198
AChEs O 0 0.6509892
) O 0 0.0014394247
and O 0 0.0012877629
butyrylcholinesterases O 0 0.7888245
( O 0 0.004244017
BChEs O 0 0.42095044
) O 0 0.0068805376
. O 0 0.007218698

The O 0 0.004249519
acute O 0 0.9160252
toxicity B-Disease 2 0.99961495
of O 0 0.032652028
OPs B-Chemical 0 0.9974529
is O 0 0.0009587803
the O 0 0.00047251556
result O 0 0.00033432894
of O 0 0.00042625255
their O 0 0.00040921528
irreversible O 0 0.06971686
binding O 0 0.0006008853
with O 0 0.00068661
AChEs O 0 0.39228985
in O 0 0.00019467295
the O 0 0.00018252752
central O 0 0.0003476574
nervous O 0 0.011519366
system O 0 0.00032776737
( O 0 0.00083946664
CNS O 0 0.34919176
) O 0 0.0011185335
, O 0 0.00066081225
which O 0 0.0009465475
elevates O 0 0.16557756
acetylcholine B-Chemical 1 0.99993956
( O 0 0.04225115
ACh B-Chemical 1 0.999856
) O 0 0.0053069666
levels O 0 0.003984599
. O 0 0.006970278

The O 0 0.0031470098
protective O 0 0.0047678496
action O 0 0.0025680116
of O 0 0.001558755
subcutaneously O 0 0.0017227008
( O 0 0.0027410085
SC O 0 0.3010817
) O 0 0.0013108897
administered O 0 0.0004958898
antidotes O 0 0.3205739
or O 0 0.00024593488
their O 0 0.00023124172
combinations O 0 0.0002474444
in O 0 0.00080196327
DFP B-Chemical 0 0.9999945
( O 0 0.0012404993
2 O 0 0.00021290583
. O 0 0.00016486725
0 O 0 0.00021887243
mg O 0 0.0062636663
/ O 0 0.0014626773
kg O 0 0.0022538987
BW O 0 0.5484101
) O 0 0.004319341
intoxication O 0 0.9983858
was O 0 0.0002593209
studied O 0 0.00022986959
in O 0 0.00021850692
9 O 0 0.0002679103
- O 0 0.0011580378
10 O 0 0.00031684682
- O 0 0.0010483719
weeks O 0 0.00036858645
- O 0 0.0019619723
old O 0 0.0013805564
Han O 0 0.96436524
- O 0 0.017182972
Wistar O 0 0.01979748
male O 0 0.0065880804
rats O 0 0.005809457
. O 0 0.00737932

The O 0 0.0033777072
rats O 0 0.003300916
received O 0 0.0021606302
AChE O 0 0.9923683
reactivator O 0 0.99232215
pralidoxime B-Chemical 0 0.99994195
- I-Chemical 0 0.099340305
2 I-Chemical 0 0.0007245606
- I-Chemical 0 0.08459572
chloride I-Chemical 0 0.9999529
( O 0 0.022981567
2PAM B-Chemical 1 0.9993492
) O 0 0.002053599
( O 0 0.00043384853
30 O 0 0.0001829265
. O 0 0.00017372625
0 O 0 0.00022649807
mg O 0 0.005442209
/ O 0 0.0014634716
kg O 0 0.0023359326
BW O 0 0.5477256
) O 0 0.0031491183
, O 0 0.0055933245
anticonvulsant O 0 0.99998164
diazepam B-Chemical 0 0.99999964
( O 0 0.0013758655
2 O 0 0.000197984
. O 0 0.00015295885
0 O 0 0.00020463858
mg O 0 0.0054016123
/ O 0 0.0012761968
kg O 0 0.0017371541
BW O 0 0.4037892
) O 0 0.0010643451
, O 0 0.0005656745
A O 0 0.1103749
( O 0 0.0006630019
1 O 0 0.00029087823
) O 0 0.0017678821
- O 0 0.1456002
adenosine B-Chemical 1 0.99975115
receptor O 0 0.50688773
agonist O 0 0.9900254
N B-Chemical 0 0.9998554
( I-Chemical 0 0.002387817
6 I-Chemical 0 0.00021470833
) I-Chemical 0 0.0019204351
- I-Chemical 0 0.21423173
cyclopentyl I-Chemical 0 0.99995875
adenosine I-Chemical 1 0.999944
( O 0 0.044436313
CPA B-Chemical 1 0.99997115
) O 0 0.0038201173
( O 0 0.0004996051
2 O 0 0.00018289684
. O 0 0.00015366668
0 O 0 0.00020876301
mg O 0 0.0066257915
/ O 0 0.001814571
kg O 0 0.003447696
BW O 0 0.7031373
) O 0 0.010403135
, O 0 0.046764605
NMDA B-Chemical 1 0.99999976
- O 0 0.72406065
receptor O 0 0.7252449
antagonist O 0 0.99962974
dizocilpine B-Chemical 0 1.0
maleate I-Chemical 0 1.0
( O 0 0.0799875
+ O 0 0.34752426
- O 0 0.9641627
MK801 O 1 1.0
hydrogen O 0 0.9999999
maleate O 0 1.0
) O 0 0.04742602
( O 0 0.0008730082
2 O 0 0.00018180757
. O 0 0.00014447297
0 O 0 0.00019724727
mg O 0 0.0064924946
/ O 0 0.0015724689
kg O 0 0.002135531
BW O 0 0.36088482
) O 0 0.000490757
or O 0 0.00015639147
their O 0 0.0001526479
combinations O 0 0.00015428069
with O 0 0.0006082721
cholinolytic O 0 0.99977654
drug O 0 0.98762274
atropine B-Chemical 0 0.9999999
sulfate I-Chemical 0 0.99989283
( O 0 0.0024526205
50 O 0 0.00029252737
. O 0 0.00014778927
0 O 0 0.00020356434
mg O 0 0.0068140053
/ O 0 0.0013603668
kg O 0 0.0016121936
BW O 0 0.25761947
) O 0 0.00047781694
immediately O 0 0.00019710738
or O 0 0.00019083155
30 O 0 0.00020053286
min O 0 0.00028822315
after O 0 0.00024887256
the O 0 0.00045058652
single O 0 0.0008179297
SC O 0 0.06520592
injection O 0 0.003289929
of O 0 0.007444284
DFP B-Chemical 0 0.9999478
. O 0 0.009387405

The O 0 0.003313241
control O 0 0.0024676954
rats O 0 0.0027477606
received O 0 0.0025408282
atropine B-Chemical 0 0.9999995
sulfate I-Chemical 0 0.99994016
, O 0 0.005855057
but O 0 0.0007820503
also O 0 0.00043845284
saline O 0 0.012152056
and O 0 0.00090726174
olive O 0 0.9427063
oil O 0 0.95318764
instead O 0 0.00041565998
of O 0 0.0006222091
other O 0 0.0011338304
antidotes O 0 0.89517635
and O 0 0.009015831
DFP B-Chemical 0 0.9999808
, O 0 0.005444561
respectively O 0 0.010460602
. O 0 0.0074820938

All O 0 0.0037887788
rats O 0 0.0034336513
were O 0 0.0019639006
terminated O 0 0.0017021104
either O 0 0.0012548866
24 O 0 0.0011325383
h O 0 0.0010235045
or O 0 0.00089280267
3 O 0 0.0008784704
weeks O 0 0.0008395886
after O 0 0.0012050024
the O 0 0.002929059
DFP B-Chemical 0 0.99991274
injection O 0 0.014173644
. O 0 0.008883148

The O 0 0.0036262963
rats O 0 0.0035450156
treated O 0 0.0028168557
with O 0 0.014409534
DFP B-Chemical 0 0.9999974
- O 0 0.83711475
atropine B-Chemical 0 0.9999931
showed O 0 0.0017885137
severe O 0 0.29665
typical O 0 0.015624966
OP B-Chemical 0 0.9999751
- O 0 0.10275468
induced O 0 0.0052559637
toxicity B-Disease 2 0.9995419
signs O 0 0.71767247
. O 0 0.009106246

When O 0 0.0058456855
CPA B-Chemical 1 0.9998072
, O 0 0.1552632
diazepam B-Chemical 0 0.9999988
or O 0 0.016926669
2PAM B-Chemical 1 0.99905103
was O 0 0.00076811766
given O 0 0.00033412722
immediately O 0 0.00039718038
after O 0 0.0004356667
DFP B-Chemical 0 0.999998
- O 0 0.7703547
atropine B-Chemical 0 0.9999958
, O 0 0.00094038685
these O 0 0.000317629
treatments O 0 0.0004357741
prevented O 0 0.0005112457
, O 0 0.00059535715
delayed O 0 0.000834832
or O 0 0.0002957752
shortened O 0 0.00036847367
the O 0 0.0003608827
occurrence O 0 0.00086606597
of O 0 0.0010613116
serious O 0 0.19643155
signs O 0 0.3932781
of O 0 0.025057781
poisoning B-Disease 2 0.9999728
. O 0 0.01043645

Atropine B-Chemical 0 0.9999962
- O 0 0.9719849
MK801 B-Chemical 1 0.99999833
did O 0 0.0040477933
not O 0 0.0017440892
offer O 0 0.0016987328
any O 0 0.0014385093
additional O 0 0.0014643671
protection O 0 0.0076726866
against O 0 0.024179207
DFP B-Chemical 0 0.99999535
toxicity B-Disease 2 0.9998037
. O 0 0.01462284

In O 0 0.0040295604
conclusion O 0 0.0028046574
, O 0 0.0158478
CPA B-Chemical 1 0.9999572
, O 0 0.23537487
diazepam B-Chemical 0 0.9999995
and O 0 0.030582123
2PAM B-Chemical 1 0.9992505
in O 0 0.0005715679
combination O 0 0.0007903302
with O 0 0.0017091132
atropine B-Chemical 0 0.9999889
prevented O 0 0.0008315444
the O 0 0.0002750606
occurrence O 0 0.0006815367
of O 0 0.0004343975
serious O 0 0.12553836
signs O 0 0.21444002
of O 0 0.005487231
poisoning B-Disease 2 0.9999933
and O 0 0.0007127523
thus O 0 0.000552781
reduced O 0 0.000510337
the O 0 0.0009224311
toxicity B-Disease 2 0.99903405
of O 0 0.03316779
DFP B-Chemical 0 0.99998665
in O 0 0.003486327
rat O 0 0.010442306
. O 0 0.006854977

A O 0 0.8467957
pyridoxine B-Chemical 1 0.9999893
- O 0 0.11143221
dependent O 0 0.0052300002
behavioral B-Disease 0 0.9181504
disorder I-Disease 0 0.9993948
unmasked O 0 0.48606086
by O 0 0.012943822
isoniazid B-Chemical 1 0.9999739
. O 0 0.016513271

A O 0 0.069846496
3 O 0 0.00357008
- O 0 0.005626993
year O 0 0.001988431
- O 0 0.0036913054
old O 0 0.0011008809
girl O 0 0.0018530048
had O 0 0.0007787743
behavioral B-Disease 0 0.71568173
deterioration I-Disease 0 0.9139125
, O 0 0.001034388
with O 0 0.0013481259
hyperkinesis B-Disease 0 0.999964
, O 0 0.020621486
irritability B-Disease 2 0.99998474
, O 0 0.0010649891
and O 0 0.00074251136
sleeping B-Disease 0 0.9286747
difficulties I-Disease 0 0.011206765
after O 0 0.0003196363
the O 0 0.0005348585
therapeutic O 0 0.0019038682
administration O 0 0.019738983
of O 0 0.009905445
isoniazid B-Chemical 1 0.9999895
. O 0 0.009960925

The O 0 0.0037075344
administration O 0 0.0057684556
of O 0 0.0024663494
pharmacologic O 0 0.038545955
doses O 0 0.07284911
of O 0 0.09785003
pyridoxine B-Chemical 1 1.0
hydrochloride I-Chemical 0 0.9999732
led O 0 0.0013436332
to O 0 0.0010180199
a O 0 0.0016083086
disappearance O 0 0.0047977255
of O 0 0.0042983303
symptoms O 0 0.48439416
. O 0 0.007692341

After O 0 0.0036373774
discontinuing O 0 0.6903673
isoniazid B-Chemical 1 0.9999906
therapy O 0 0.009849834
a O 0 0.0012536459
similar O 0 0.0005894455
pattern O 0 0.0005778012
of O 0 0.00069176726
behavior O 0 0.0013171472
was O 0 0.0006100615
noted O 0 0.0005498076
that O 0 0.00069594104
was O 0 0.0011643415
controlled O 0 0.0016303066
by O 0 0.0042788684
pyridoxine B-Chemical 1 0.9999747
. O 0 0.009604261

A O 0 0.1287558
placebo O 0 0.038593847
had O 0 0.0024140247
no O 0 0.0016007661
effect O 0 0.0018023428
, O 0 0.0030857555
but O 0 0.007039835
niacinamide B-Chemical 0 0.99998844
was O 0 0.0019640052
as O 0 0.0017339216
effective O 0 0.0028049615
as O 0 0.004973692
pyridoxine B-Chemical 1 0.9999802
. O 0 0.0111355055

Periodic O 0 0.0127806
withdrawal O 0 0.39847115
of O 0 0.01480875
pyridoxine B-Chemical 1 0.9999945
was O 0 0.0028733655
associated O 0 0.002022338
with O 0 0.0019574345
return O 0 0.002544524
of O 0 0.0033034491
the O 0 0.0051823575
hyperkinesis B-Disease 0 0.9994831
. O 0 0.010701217

The O 0 0.0035667398
level O 0 0.002734266
of O 0 0.003989087
pyridoxal B-Chemical 0 0.99990463
in O 0 0.0017857798
the O 0 0.0012535177
blood O 0 0.004780855
was O 0 0.00091219164
normal O 0 0.001001148
during O 0 0.00079662935
the O 0 0.0011920314
periods O 0 0.001774332
of O 0 0.0037734266
relapse O 0 0.9422608
. O 0 0.008754954

Metabolic O 0 0.029046198
studies O 0 0.0035477001
suggested O 0 0.002373747
a O 0 0.0023318566
block O 0 0.0017080291
in O 0 0.0016398168
the O 0 0.0020078283
kynurenine B-Chemical 0 0.9987715
pathway O 0 0.0026111926
of O 0 0.005811881
tryptophan B-Chemical 0 0.9987307
metabolism O 0 0.59504277
. O 0 0.009788155

The O 0 0.003423963
patient O 0 0.002592022
has O 0 0.0015316359
been O 0 0.0011068137
followed O 0 0.0007204541
for O 0 0.0006170748
six O 0 0.00041889233
years O 0 0.0005251327
and O 0 0.00045878478
has O 0 0.00035374687
required O 0 0.0002933032
pharmacologic O 0 0.0039359964
doses O 0 0.006070173
of O 0 0.004217474
pyridoxine B-Chemical 1 0.99999666
to O 0 0.0011624946
control O 0 0.0016741356
her O 0 0.0028711448
behavior O 0 0.0061551007
. O 0 0.006702377

Recurrent O 0 0.03231496
excitation O 0 0.4074046
in O 0 0.002681905
the O 0 0.0023460502
dentate O 0 0.47966152
gyrus O 0 0.8677346
of O 0 0.0014694765
a O 0 0.0014011359
murine O 0 0.0020365473
model O 0 0.0016085813
of O 0 0.0035563498
temporal B-Disease 2 0.9151995
lobe I-Disease 2 0.99819154
epilepsy I-Disease 2 0.99999535
. O 0 0.012929354

Similar O 0 0.0032770152
to O 0 0.0023517155
rats O 0 0.0029103137
, O 0 0.0033718657
systemic O 0 0.9850787
pilocarpine B-Chemical 1 0.9999993
injection O 0 0.01548755
causes O 0 0.0014745451
status B-Disease 0 0.042461623
epilepticus I-Disease 0 0.9999987
( O 0 0.01794896
SE B-Disease 0 0.93935657
) O 0 0.00077616575
and O 0 0.00023681876
the O 0 0.00017849801
eventual O 0 0.0010807923
development O 0 0.0006928113
of O 0 0.0005282236
spontaneous O 0 0.11005933
seizures B-Disease 0 0.9999988
and O 0 0.0009388627
mossy O 0 0.344341
fiber O 0 0.015087571
sprouting O 0 0.6349928
in O 0 0.00038720143
C57BL O 0 0.7397635
/ O 0 0.002801385
6 O 0 0.00015874319
and O 0 0.0002248803
CD1 O 0 0.015778324
mice O 0 0.00014977554
, O 0 0.00034643605
but O 0 0.00024380238
the O 0 0.00017767515
physiological O 0 0.00025992686
correlates O 0 0.00022305748
of O 0 0.0002786097
these O 0 0.00033404538
events O 0 0.0012521704
have O 0 0.0003786879
not O 0 0.000522619
been O 0 0.00079780497
identified O 0 0.001119372
in O 0 0.001910306
mice O 0 0.0027932648
. O 0 0.0065718503

Population O 0 0.0070697437
responses O 0 0.003552209
in O 0 0.0020543789
granule O 0 0.042742874
cells O 0 0.0011684914
of O 0 0.00093306176
the O 0 0.0008292726
dentate O 0 0.5618815
gyrus O 0 0.88540983
were O 0 0.00028264834
examined O 0 0.00017078042
in O 0 0.00020604786
transverse O 0 0.0006527795
slices O 0 0.0006129602
of O 0 0.0002576652
the O 0 0.00026749176
ventral O 0 0.0045870175
hippocampus O 0 0.26564604
from O 0 0.00073220243
pilocarpine B-Chemical 1 0.9999981
- O 0 0.03304974
treated O 0 0.0011571512
and O 0 0.0014047553
untreated O 0 0.0022626573
mice O 0 0.0026849867
. O 0 0.006257502

In O 0 0.0075570587
Mg B-Chemical 0 0.9999676
( O 0 0.005733225
2 O 0 0.0018651107
+ O 0 0.0035648916
) O 0 0.0027171709
- O 0 0.005166843
free O 0 0.0007988986
bathing O 0 0.015009325
medium O 0 0.0067454334
containing O 0 0.0013008525
bicuculline B-Chemical 1 0.9999989
, O 0 0.00087488024
conditions O 0 0.00024876933
designed O 0 0.00017070032
to O 0 0.00013745882
increase O 0 0.00016078449
excitability O 0 0.11235624
in O 0 0.00016288993
the O 0 0.0001660825
slices O 0 0.0016103106
, O 0 0.00033197636
electrical O 0 0.008112759
stimulation O 0 0.00018343056
of O 0 0.00023785855
the O 0 0.00023544674
hilus O 0 0.044493787
resulted O 0 0.00015351584
in O 0 0.00016571107
a O 0 0.00019885087
single O 0 0.00016072042
population O 0 0.00032063096
spike O 0 0.00069711264
in O 0 0.000215456
granule O 0 0.030946733
cells O 0 0.00024424703
from O 0 0.0001524658
control O 0 0.00018407535
mice O 0 0.00016062726
and O 0 0.00242746
pilocarpine B-Chemical 1 0.9999993
- O 0 0.0416282
treated O 0 0.0005080919
mice O 0 0.00035783026
that O 0 0.0006006485
did O 0 0.0010951348
not O 0 0.0014821168
experience O 0 0.0038901984
SE B-Disease 0 0.6717442
. O 0 0.0075107873

In O 0 0.004758636
SE B-Disease 0 0.411498
survivors O 0 0.005158297
, O 0 0.0019442267
similar O 0 0.00078824454
stimulation O 0 0.00074784446
resulted O 0 0.00050742825
in O 0 0.0004654251
a O 0 0.0004885585
population O 0 0.00063171407
spike O 0 0.0008828813
followed O 0 0.00022371607
, O 0 0.0003244711
at O 0 0.00017129496
a O 0 0.0002156344
variable O 0 0.00021613605
latency O 0 0.0006214535
, O 0 0.0002942479
by O 0 0.00020076895
negative O 0 0.0004492523
DC O 0 0.12412322
shifts O 0 0.001689721
and O 0 0.00032118568
repetitive O 0 0.0011101443
afterdischarges O 0 0.9820846
of O 0 0.00030791917
3 O 0 0.0002008011
- O 0 0.0007576448
60 O 0 0.00016729646
s O 0 0.00021382618
duration O 0 0.00018332776
, O 0 0.00032213598
which O 0 0.00034144343
were O 0 0.00036098264
blocked O 0 0.0007468164
by O 0 0.0015835146
ionotropic O 0 0.99850947
glutamate B-Chemical 1 0.99995613
receptor O 0 0.6423856
antagonists O 0 0.9277571
. O 0 0.007103437

Focal O 0 0.53577733
glutamate B-Chemical 1 0.9996532
photostimulation O 0 0.089943916
of O 0 0.0016471572
the O 0 0.0010992949
granule O 0 0.1221877
cell O 0 0.0033210511
layer O 0 0.0045118164
at O 0 0.00028662392
sites O 0 0.00032584593
distant O 0 0.001700895
from O 0 0.0001732766
the O 0 0.00017081382
recording O 0 0.00023966812
pipette O 0 0.002129121
resulted O 0 0.00015931152
in O 0 0.00017018057
population O 0 0.00031524783
responses O 0 0.00030924127
of O 0 0.0003058142
1 O 0 0.00026235788
- O 0 0.00079731544
30 O 0 0.00014977068
s O 0 0.00020661089
duration O 0 0.0001705417
in O 0 0.00023602598
slices O 0 0.0006418998
from O 0 0.0003801822
SE B-Disease 0 0.29162127
survivors O 0 0.0014764629
but O 0 0.0010280121
not O 0 0.0012225744
other O 0 0.002217836
groups O 0 0.0038232482
. O 0 0.006715383

These O 0 0.0037050308
data O 0 0.0024579647
support O 0 0.0013773678
the O 0 0.0011015997
hypothesis O 0 0.0009648302
that O 0 0.00084999047
SE B-Disease 0 0.92919964
- O 0 0.014862392
induced O 0 0.0005996978
mossy O 0 0.33177978
fiber O 0 0.014647899
sprouting O 0 0.47976035
and O 0 0.00039650264
synaptic O 0 0.0022625262
reorganization O 0 0.00091932894
are O 0 0.00016215337
relevant O 0 0.00013527999
characteristics O 0 0.00015171414
of O 0 0.0004479303
seizure B-Disease 2 0.9999567
development O 0 0.00137188
in O 0 0.00020445565
these O 0 0.00023020625
murine O 0 0.0008809696
strains O 0 0.00042680633
, O 0 0.0005153831
resembling O 0 0.00054062874
rat O 0 0.00074397464
models O 0 0.00046488855
of O 0 0.00081910315
human O 0 0.0030327125
temporal B-Disease 2 0.9050897
lobe I-Disease 2 0.9980628
epilepsy I-Disease 2 0.99999607
. O 0 0.010543557

Urinary B-Disease 0 0.9563771
bladder I-Disease 0 0.9893289
cancer I-Disease 0 0.9998807
in O 0 0.004796826
Wegener B-Disease 0 0.9541287
' I-Disease 0 0.0030970825
s I-Disease 0 0.0024879149
granulomatosis I-Disease 0 0.8578039
: O 0 0.002345616
risks O 0 0.0037167014
and O 0 0.0018588738
relation O 0 0.001974256
to O 0 0.00393777
cyclophosphamide B-Chemical 0 0.99937636
. O 0 0.0102742305

OBJECTIVE O 0 0.014899328
: O 0 0.003226135
To O 0 0.0013125583
assess O 0 0.000722152
and O 0 0.0008145626
characterise O 0 0.00050460326
the O 0 0.00052768464
risk O 0 0.026617175
of O 0 0.0020200796
bladder B-Disease 0 0.99836844
cancer I-Disease 0 0.9999895
, O 0 0.003815634
and O 0 0.00046405924
its O 0 0.00047937947
relation O 0 0.00022068144
to O 0 0.00036841255
cyclophosphamide B-Chemical 0 0.9997099
, O 0 0.00079190725
in O 0 0.0004853318
patients O 0 0.0008580429
with O 0 0.0011157927
Wegener B-Disease 0 0.89984995
' I-Disease 0 0.0032666712
s I-Disease 0 0.004247228
granulomatosis I-Disease 0 0.88644236
. O 0 0.007838751

METHODS O 0 0.0042628124
: O 0 0.0037739663
In O 0 0.0020579237
the O 0 0.0015108832
population O 0 0.0016244528
based O 0 0.0011493001
, O 0 0.0011197287
nationwide O 0 0.0012864494
Swedish O 0 0.0014366844
Inpatient O 0 0.0012312575
Register O 0 0.0005455597
a O 0 0.0003999715
cohort O 0 0.00058372586
of O 0 0.0004919962
1065 O 0 0.17408909
patients O 0 0.00044774948
with O 0 0.00043115593
Wegener B-Disease 0 0.83036363
' I-Disease 0 0.00081906456
s I-Disease 0 0.00084733154
granulomatosis I-Disease 0 0.8419346
, O 0 0.0012475995
1969 O 0 0.013765063
- O 0 0.0037643334
95 O 0 0.0018729317
, O 0 0.0020376
was O 0 0.0025262174
identified O 0 0.003845268
. O 0 0.0074160146

Through O 0 0.005057562
linkage O 0 0.0053195497
with O 0 0.002135962
the O 0 0.0017353573
Swedish O 0 0.0045443554
Cancer B-Disease 0 0.6495673
Register O 0 0.00122868
, O 0 0.00079365727
all O 0 0.00047732214
subjects O 0 0.0005415241
in O 0 0.00042785017
this O 0 0.00046313676
cohort O 0 0.0011174638
diagnosed O 0 0.0037617737
with O 0 0.0018326873
bladder B-Disease 0 0.98679465
cancer I-Disease 0 0.99983346
were O 0 0.0037511666
identified O 0 0.0041213064
. O 0 0.0074244393

Nested O 0 0.010893307
within O 0 0.0019447079
the O 0 0.001683304
cohort O 0 0.0026349074
, O 0 0.0014111479
a O 0 0.0009026319
matched O 0 0.0006085821
case O 0 0.0007769036
- O 0 0.0055672396
control O 0 0.00035311663
study O 0 0.00034523476
was O 0 0.00019937655
performed O 0 0.0001420464
to O 0 0.00012848437
estimate O 0 0.000110664034
the O 0 0.0001330512
association O 0 0.00014493588
between O 0 0.00018540066
cyclophosphamide B-Chemical 0 0.9998599
and O 0 0.0032409474
bladder B-Disease 0 0.99602926
cancer I-Disease 0 0.9999573
using O 0 0.00051126984
odds O 0 0.0045602852
ratios O 0 0.0006678043
( O 0 0.0012480315
ORs O 0 0.002920432
) O 0 0.0015521199
as O 0 0.001340545
relative O 0 0.0022115197
risk O 0 0.10127909
. O 0 0.007844256

In O 0 0.0036194026
the O 0 0.0022616982
cohort O 0 0.0025072792
the O 0 0.0011654245
cumulative O 0 0.0016799298
risk O 0 0.079961985
of O 0 0.0028142678
bladder B-Disease 0 0.9971022
cancer I-Disease 0 0.9999716
after O 0 0.00053782255
Wegener B-Disease 0 0.97085136
' I-Disease 0 0.0011160058
s I-Disease 0 0.0007593739
granulomatosis I-Disease 0 0.85761005
, O 0 0.00043524825
and O 0 0.00023041973
the O 0 0.0001608874
relative O 0 0.0001445238
prevalence O 0 0.00042997283
of O 0 0.00026319217
a O 0 0.000317901
history O 0 0.003300577
of O 0 0.0012692398
bladder B-Disease 0 0.9962406
cancer I-Disease 0 0.999959
at O 0 0.00024803137
the O 0 0.00017392384
time O 0 0.00014046552
of O 0 0.00024512655
diagnosis O 0 0.0009090153
of O 0 0.0005900914
Wegener B-Disease 0 0.94406503
' I-Disease 0 0.0012377176
s I-Disease 0 0.0011794067
granulomatosis I-Disease 0 0.7865183
, O 0 0.0013632553
were O 0 0.0013397078
also O 0 0.0019085094
estimated O 0 0.0035103105
. O 0 0.006952728

RESULTS O 0 0.0050570345
: O 0 0.0030239525
The O 0 0.0012915122
median O 0 0.0008421495
cumulative O 0 0.0010562596
doses O 0 0.0025139889
of O 0 0.0015492656
cyclophosphamide B-Chemical 0 0.9999249
among O 0 0.0016209795
cases O 0 0.0009450805
( O 0 0.00053052494
n O 0 0.00026754325
= O 0 0.0005469179
11 O 0 0.0002561031
) O 0 0.0003343229
and O 0 0.000244332
controls O 0 0.00036747847
( O 0 0.00035413218
n O 0 0.00024929908
= O 0 0.0004967812
25 O 0 0.0003583437
) O 0 0.00046701098
were O 0 0.00036529946
113 O 0 0.0007414547
g O 0 0.00072559674
and O 0 0.0007670494
25 O 0 0.0011744078
g O 0 0.0021549256
, O 0 0.0031197933
respectively O 0 0.0064281914
. O 0 0.007840257

The O 0 0.0034309814
risk O 0 0.018788306
of O 0 0.0037784937
bladder B-Disease 0 0.99205774
cancer I-Disease 0 0.99990225
doubled O 0 0.001357716
for O 0 0.00048234372
every O 0 0.0002238522
10 O 0 0.000247022
g O 0 0.00034431872
increment O 0 0.00027211
in O 0 0.00036311394
cyclophosphamide B-Chemical 0 0.9998336
( O 0 0.004361705
OR O 0 0.46872485
= O 0 0.0011031891
2 O 0 0.00022185234
. O 0 0.00018469842
0 O 0 0.00022052981
, O 0 0.00024751303
95 O 0 0.00034246364
% O 0 0.00025052502
confidence O 0 0.0005053166
interval O 0 0.00025809841
( O 0 0.0005531433
CI O 0 0.30315787
) O 0 0.00066035846
0 O 0 0.00041784937
. O 0 0.0003944508
8 O 0 0.00047617464
to O 0 0.0005905655
4 O 0 0.0009024484
. O 0 0.0014304216
9 O 0 0.0025151477
) O 0 0.0053800163
. O 0 0.007827608

Treatment O 0 0.0056171934
duration O 0 0.0018924078
longer O 0 0.0010922482
than O 0 0.00077603635
1 O 0 0.00069736317
year O 0 0.0005745386
was O 0 0.0004654031
associated O 0 0.0004006193
with O 0 0.00037866822
an O 0 0.00042744257
eightfold O 0 0.0013262648
increased O 0 0.00059366715
risk O 0 0.20969546
( O 0 0.0035956677
OR O 0 0.48698533
= O 0 0.001065898
7 O 0 0.00023898175
. O 0 0.00023650467
7 O 0 0.00024777043
, O 0 0.0003768659
95 O 0 0.0006315407
% O 0 0.0006440599
CI O 0 0.09113359
0 O 0 0.00070504524
. O 0 0.00075903017
9 O 0 0.0010671172
to O 0 0.0014939037
69 O 0 0.0034969205
) O 0 0.005799537
. O 0 0.0081038615

The O 0 0.0030174858
absolute O 0 0.0024810915
risk O 0 0.036517657
for O 0 0.0021163395
bladder B-Disease 0 0.99309915
cancer I-Disease 0 0.99993956
in O 0 0.0009276846
the O 0 0.00047259583
cohort O 0 0.00085314363
reached O 0 0.0002977441
10 O 0 0.00024251244
% O 0 0.00025782865
16 O 0 0.00019935545
years O 0 0.00018589152
after O 0 0.00012803737
diagnosis O 0 0.00035981435
of O 0 0.0003295556
Wegener B-Disease 0 0.89996135
' I-Disease 0 0.00069798186
s I-Disease 0 0.00056741544
granulomatosis I-Disease 0 0.813579
, O 0 0.0003802271
and O 0 0.00023420861
a O 0 0.0002534626
history O 0 0.0016008547
of O 0 0.0010125417
bladder B-Disease 0 0.9975827
cancer I-Disease 0 0.99999094
was O 0 0.0015580271
( O 0 0.0013102744
non O 0 0.0026172802
- O 0 0.018451137
significantly O 0 0.00026504704
) O 0 0.00033727483
twice O 0 0.00013728758
as O 0 0.0001490467
common O 0 0.00020205641
as O 0 0.0001617545
expected O 0 0.00015894856
at O 0 0.00018169456
the O 0 0.00021341778
time O 0 0.00022697389
of O 0 0.00045449223
diagnosis O 0 0.0016635497
of O 0 0.0014251628
Wegener B-Disease 0 0.9535401
' I-Disease 0 0.003721539
s I-Disease 0 0.0043969573
granulomatosis I-Disease 0 0.8973299
. O 0 0.007777408

CONCLUSION O 0 0.019937951
: O 0 0.003501646
The O 0 0.0013982973
results O 0 0.000970374
indicate O 0 0.00062523194
a O 0 0.0008626825
dose O 0 0.005668677
- O 0 0.0048952396
response O 0 0.00039296897
relationship O 0 0.0001983464
between O 0 0.0002452633
cyclophosphamide B-Chemical 0 0.99975747
and O 0 0.00046156292
the O 0 0.0002650018
risk O 0 0.06093064
of O 0 0.0021279834
bladder B-Disease 0 0.9985846
cancer I-Disease 0 0.9999931
, O 0 0.0052915043
high O 0 0.0006826509
cumulative O 0 0.0007328437
risks O 0 0.006029332
in O 0 0.00018246
the O 0 0.00015866011
entire O 0 0.00015215295
cohort O 0 0.0008248491
, O 0 0.00029478507
and O 0 0.00020926243
also O 0 0.00016550768
the O 0 0.0001695182
possibility O 0 0.00016862508
of O 0 0.0003520883
risk O 0 0.03252779
factors O 0 0.0014368445
operating O 0 0.00082168024
even O 0 0.0006796232
before O 0 0.00071882195
Wegener B-Disease 0 0.7866058
' I-Disease 0 0.002936085
s I-Disease 0 0.0040253145
granulomatosis I-Disease 0 0.8746569
. O 0 0.0077097514

Differential O 0 0.0043328507
modulation O 0 0.0028719774
by O 0 0.003876094
estrogen B-Chemical 1 0.9999542
of O 0 0.048400857
alpha2 O 0 0.9997904
- O 0 0.6934864
adrenergic O 0 0.9964858
and O 0 0.0059948517
I1 O 0 0.9985013
- O 0 0.4937476
imidazoline B-Chemical 0 0.99997246
receptor O 0 0.2410208
- O 0 0.03805998
mediated O 0 0.0011965043
hypotension B-Disease 2 0.9999647
in O 0 0.0022523103
female O 0 0.011490641
rats O 0 0.0058413753
. O 0 0.0066805813

We O 0 0.003392486
have O 0 0.002035431
recently O 0 0.0016785803
shown O 0 0.0010940192
that O 0 0.0011978933
estrogen B-Chemical 1 0.9999107
negatively O 0 0.00087525207
modulates O 0 0.00033367457
the O 0 0.00058682554
hypotensive B-Disease 0 0.9976762
effect O 0 0.000434812
of O 0 0.0045947996
clonidine B-Chemical 0 0.999997
( O 0 0.0038525825
mixed O 0 0.023577109
alpha2 O 0 0.99956304
- O 0 0.5053077
/ O 0 0.33420497
I1 O 0 0.9992925
- O 0 0.27218142
receptor O 0 0.17748454
agonist O 0 0.88536185
) O 0 0.0014792116
in O 0 0.00024016979
female O 0 0.0009514409
rats O 0 0.0003175306
and O 0 0.0002470592
implicates O 0 0.00029669615
the O 0 0.00042839051
cardiovascular O 0 0.8844442
autonomic O 0 0.1400847
control O 0 0.00074412394
in O 0 0.0010747388
this O 0 0.0017040953
interaction O 0 0.0034705766
. O 0 0.0066319397

The O 0 0.0028746035
present O 0 0.0017494697
study O 0 0.0014872242
investigated O 0 0.0007738692
whether O 0 0.00046301537
this O 0 0.00054255954
effect O 0 0.0005568784
of O 0 0.0029822714
estrogen B-Chemical 1 0.99997306
involves O 0 0.00044292893
interaction O 0 0.00083106005
with O 0 0.0032436347
alpha2 O 0 0.99774975
- O 0 0.05832474
and O 0 0.000997774
/ O 0 0.0071635344
or O 0 0.001905244
I1 O 0 0.9795084
- O 0 0.03728623
receptors O 0 0.018124478
. O 0 0.007836852

Changes O 0 0.0039163055
evoked O 0 0.0050050053
by O 0 0.0018508013
a O 0 0.0014598706
single O 0 0.0010050974
intraperitoneal O 0 0.008806808
injection O 0 0.002060341
of O 0 0.0042045773
rilmenidine B-Chemical 0 0.99999833
( O 0 0.0022173356
600 O 0 0.0008963857
microg O 0 0.00046704343
/ O 0 0.002885997
kg O 0 0.00165408
) O 0 0.0008066846
or O 0 0.0005639207
alpha B-Chemical 1 0.99867505
- I-Chemical 1 0.9716572
methyldopa I-Chemical 1 1.0
( O 0 0.0042074854
100 O 0 0.00083133916
mg O 0 0.022858376
/ O 0 0.0015518412
kg O 0 0.0011046533
) O 0 0.00058348314
, O 0 0.00039279615
selective O 0 0.005113458
I1 O 0 0.9925162
- O 0 0.04859939
and O 0 0.0022291746
alpha2 O 0 0.9991922
- O 0 0.37989774
receptor O 0 0.18542086
agonists O 0 0.70717216
, O 0 0.0010946994
respectively O 0 0.0046221786
, O 0 0.00038865366
in O 0 0.00021439226
blood O 0 0.01209271
pressure O 0 0.0426262
, O 0 0.00035004027
hemodynamic O 0 0.045180965
variability O 0 0.0002508419
, O 0 0.0002634191
and O 0 0.00026471622
locomotor O 0 0.16485563
activity O 0 0.00016301889
were O 0 0.00013475855
assessed O 0 0.000115528484
in O 0 0.00018907164
radiotelemetered O 0 0.031523973
sham O 0 0.0003252649
- O 0 0.004706243
operated O 0 0.00091153395
and O 0 0.0005154447
ovariectomized O 0 0.4181022
( O 0 0.0034614373
Ovx O 0 0.9176443
) O 0 0.0020536585
Sprague O 0 0.13561685
- O 0 0.00982067
Dawley O 0 0.010355325
female O 0 0.00085631345
rats O 0 0.0003883759
with O 0 0.0003096853
or O 0 0.00035782447
without O 0 0.00049922353
12 O 0 0.00065020955
- O 0 0.0028766952
wk O 0 0.0016549558
estrogen B-Chemical 1 0.9996339
replacement O 0 0.052055325
. O 0 0.00828963

Three O 0 0.0034901309
time O 0 0.0017624024
domain O 0 0.0015807789
indexes O 0 0.001317045
of O 0 0.0011410427
hemodynamic O 0 0.07219456
variability O 0 0.00066447636
were O 0 0.0003879278
employed O 0 0.0003517081
: O 0 0.00040793617
the O 0 0.00020531245
standard O 0 0.00016254905
deviation O 0 0.00023642348
of O 0 0.00018421651
mean O 0 0.00013209412
arterial O 0 0.037850376
pressure O 0 0.0058659744
as O 0 0.00014372946
a O 0 0.00016399784
measure O 0 9.524646e-05
of O 0 0.00021212813
blood O 0 0.007866372
pressure O 0 0.015007726
variability O 0 0.00017382951
and O 0 0.00014415673
the O 0 0.000115654584
standard O 0 0.00010476482
deviation O 0 0.0001989176
of O 0 0.00022218045
beat O 0 0.00651319
- O 0 0.008765898
to O 0 0.0001948278
- O 0 0.0028873396
beat O 0 0.0007220209
intervals O 0 0.00014872724
( O 0 0.000468343
SDRR O 0 0.44147062
) O 0 0.00032301646
and O 0 0.00017278924
the O 0 0.00014056334
root O 0 0.00025148684
mean O 0 8.961641e-05
square O 0 0.00016827334
of O 0 0.00015084591
successive O 0 0.00013840644
differences O 0 0.0001406863
in O 0 0.0003328993
R O 0 0.9990546
- O 0 0.09806319
wave O 0 0.1018025
- O 0 0.03377963
to O 0 0.0004226412
- O 0 0.20564686
R O 0 0.9991818
- O 0 0.025264537
wave O 0 0.0021382186
intervals O 0 0.00030813116
as O 0 0.0003897159
measures O 0 0.0005320092
of O 0 0.0011220222
heart O 0 0.03480765
rate O 0 0.0026008366
variability O 0 0.00443339
. O 0 0.006680097

In O 0 0.004606948
sham O 0 0.003818094
- O 0 0.0073145507
operated O 0 0.00307354
rats O 0 0.0026460735
, O 0 0.0068738516
rilmenidine B-Chemical 0 0.99999714
or O 0 0.012001705
alpha B-Chemical 1 0.9996859
- I-Chemical 1 0.97786474
methyldopa I-Chemical 1 1.0
elicited O 0 0.0009942898
similar O 0 0.00041647203
hypotension B-Disease 2 0.99993837
that O 0 0.00013900187
lasted O 0 0.000106801876
at O 0 0.00011050132
least O 0 0.00010409057
5 O 0 0.00012216014
h O 0 0.00017138955
and O 0 0.00019991508
was O 0 0.00019592354
associated O 0 0.00022362202
with O 0 0.00025920375
reductions O 0 0.00030786166
in O 0 0.00027939523
standard O 0 0.00032530926
deviation O 0 0.0006357948
of O 0 0.00084518583
mean O 0 0.0010680677
arterial O 0 0.117331415
pressure O 0 0.038068403
. O 0 0.0062372414

SDRR O 0 0.28629512
was O 0 0.0067858584
reduced O 0 0.0057058022
only O 0 0.0061406586
by O 0 0.008550763
alpha B-Chemical 1 0.9939687
- I-Chemical 1 0.94915694
methyldopa I-Chemical 1 0.9999982
. O 0 0.026874311

Ovx O 0 0.80225694
significantly O 0 0.0029965334
enhanced O 0 0.0019933213
the O 0 0.001684544
hypotensive B-Disease 0 0.99606735
response O 0 0.0017896837
to O 0 0.0012478776
alpha B-Chemical 1 0.99940753
- I-Chemical 1 0.9831701
methyldopa I-Chemical 1 1.0
, O 0 0.0022689076
in O 0 0.00042121578
contrast O 0 0.00048041146
to O 0 0.0004366467
no O 0 0.00052553095
effect O 0 0.0010460924
on O 0 0.0020797334
rilmenidine B-Chemical 0 0.9999975
hypotension B-Disease 2 0.99998474
. O 0 0.009882422

The O 0 0.0036795295
enhanced O 0 0.0052428865
alpha B-Chemical 1 0.99902856
- I-Chemical 1 0.9940428
methyldopa I-Chemical 1 1.0
hypotension B-Disease 2 0.99999964
in O 0 0.016325848
Ovx O 0 0.9684752
rats O 0 0.0008539302
was O 0 0.00032455032
paralleled O 0 0.00029722333
with O 0 0.00032209913
further O 0 0.00032282775
reduction O 0 0.0007543007
in O 0 0.0006110351
SDRR O 0 0.40671948
and O 0 0.0007636925
a B-Disease 0 0.0011292978
reduced I-Disease 0 0.0016867074
locomotor I-Disease 0 0.41538152
activity I-Disease 0 0.00372508
. O 0 0.006512086

Estrogen O 0 0.9999814
replacement O 0 0.4667934
( O 0 0.5860005
17beta B-Chemical 1 0.9999989
- I-Chemical 1 0.97265446
estradiol I-Chemical 1 0.9999989
subcutaneous O 0 0.17264584
pellet O 0 0.0018657943
, O 0 0.00070009136
14 O 0 0.0003313399
. O 0 0.00024300731
2 O 0 0.00022206016
microg O 0 0.00033154117
/ O 0 0.0012151025
day O 0 0.00022551329
, O 0 0.00030790945
12 O 0 0.00016172303
wk O 0 0.00015203127
) O 0 0.00042571165
of O 0 0.00053979206
Ovx O 0 0.81441957
rats O 0 0.0003599682
restored O 0 0.00018555806
the O 0 0.00021371937
hemodynamic O 0 0.046205558
and O 0 0.00036906727
locomotor O 0 0.2762546
effects O 0 0.00039911724
of O 0 0.0015015189
alpha B-Chemical 1 0.9991911
- I-Chemical 1 0.9741698
methyldopa I-Chemical 1 0.9999999
to O 0 0.0010247608
sham O 0 0.0014515504
- O 0 0.005553189
operated O 0 0.0040964866
levels O 0 0.00353512
. O 0 0.0066632945

These O 0 0.0033374398
findings O 0 0.0024383129
suggest O 0 0.0012791173
that O 0 0.0018646136
estrogen B-Chemical 1 0.99997735
downregulates O 0 0.045331117
alpha2 O 0 0.99985576
- O 0 0.35843018
but O 0 0.0010577695
not O 0 0.00067747367
I1 O 0 0.99694663
- O 0 0.14163435
receptor O 0 0.09754848
- O 0 0.026808726
mediated O 0 0.00028507347
hypotension B-Disease 2 0.99997365
and O 0 0.0002747466
highlight O 0 0.00013705896
a O 0 0.0001873401
role O 0 0.00012054212
for O 0 0.00017527583
the O 0 0.00021974396
cardiac O 0 0.017065797
autonomic O 0 0.06708695
control O 0 0.00031696467
in O 0 0.0006265494
alpha B-Chemical 1 0.99747616
- I-Chemical 1 0.9836586
methyldopa I-Chemical 1 1.0
- O 0 0.8821952
estrogen B-Chemical 1 0.9999304
interaction O 0 0.010341755
. O 0 0.008440466

Severe O 0 0.5336943
reversible O 0 0.106748
left B-Disease 0 0.008052845
ventricular I-Disease 0 0.8753512
systolic I-Disease 0 0.89576817
and I-Disease 0 0.002994262
diastolic I-Disease 0 0.9992489
dysfunction I-Disease 0 0.9896226
due O 0 0.0009566475
to O 0 0.0013071322
accidental O 0 0.9347134
iatrogenic O 0 0.99459547
epinephrine B-Chemical 0 0.9999814
overdose B-Disease 0 0.999979
. O 0 0.01097335

Catecholamine B-Chemical 0 0.99959
- O 0 0.06601316
induced O 0 0.0045086155
cardiomyopathy B-Disease 0 0.9999651
due O 0 0.0010093517
to O 0 0.0008091338
chronic O 0 0.6528065
excess O 0 0.0016527436
of O 0 0.00096385035
endogenous O 0 0.0020597659
catecholamines B-Chemical 1 0.99977165
has O 0 0.00042459715
been O 0 0.00039095164
recognized O 0 0.00049787486
for O 0 0.00055913377
decades O 0 0.0012327519
as O 0 0.0010677893
a O 0 0.0020182915
clinical O 0 0.006412687
phenomenon O 0 0.012427021
. O 0 0.0072416514

In O 0 0.00439773
contrast O 0 0.0034692378
, O 0 0.0030822137
reports O 0 0.0021754722
of O 0 0.0047667725
myocardial B-Disease 0 0.9999887
dysfunction I-Disease 0 0.9989423
due O 0 0.0011110657
to O 0 0.0013482221
acute O 0 0.96680874
iatrogenic O 0 0.99403197
overdose B-Disease 0 0.9999858
are O 0 0.004551795
rare O 0 0.021204494
. O 0 0.008040429

A O 0 0.052863527
35 O 0 0.004027467
- O 0 0.0062949266
year O 0 0.0020194126
- O 0 0.003805002
old O 0 0.001116506
woman O 0 0.0031672148
whose O 0 0.0017791922
cervix O 0 0.5941932
uteri O 0 0.10502489
was O 0 0.00038938312
inadvertently O 0 0.00065471156
injected O 0 0.0002198125
with O 0 0.00024220835
8 O 0 0.0002073569
mg O 0 0.0077214376
of O 0 0.00063915603
epinephrine B-Chemical 0 0.9996474
developed O 0 0.0061834883
myocardial B-Disease 0 0.9996991
stunning I-Disease 0 0.88641053
that O 0 0.0001750859
was O 0 0.00018815103
characterized O 0 0.0002282652
by O 0 0.00022396706
severe O 0 0.039179713
hemodynamic O 0 0.12779115
compromise O 0 0.00053652714
, O 0 0.000538664
profound O 0 0.0038180777
, O 0 0.00080371136
albeit O 0 0.006936161
transient O 0 0.018044963
, O 0 0.00059246283
left B-Disease 0 0.0016148115
ventricular I-Disease 0 0.77715856
systolic I-Disease 0 0.7297945
and I-Disease 0 0.0006688247
diastolic I-Disease 0 0.99938154
dysfunction I-Disease 0 0.994251
, O 0 0.0005804045
and O 0 0.00031073135
only O 0 0.00032918
modestly O 0 0.0049174214
elevated O 0 0.00252337
biochemical O 0 0.0033019984
markers O 0 0.002935588
of O 0 0.0127111655
myocardial B-Disease 0 0.99999106
necrosis I-Disease 2 0.9999918
. O 0 0.033327468

Our O 0 0.0039462405
case O 0 0.00256161
illustrates O 0 0.0014744946
the O 0 0.0013247113
serious O 0 0.013605774
consequences O 0 0.001480274
of O 0 0.0010154354
medical O 0 0.0042511034
errors O 0 0.0015193883
that O 0 0.0003194404
can O 0 0.0002934414
be O 0 0.00033324162
avoided O 0 0.00036025362
through O 0 0.00038238557
improved O 0 0.0008025221
medication O 0 0.004872758
labeling O 0 0.0013483879
and O 0 0.0017849366
staff O 0 0.0037176863
supervision O 0 0.007000013
. O 0 0.006939906

Cardioprotective O 0 0.5747829
effect O 0 0.0043120915
of O 0 0.0067771007
tincture B-Chemical 0 0.998816
of I-Chemical 0 0.021549268
Crataegus I-Chemical 0 0.9994886
on O 0 0.0015567177
isoproterenol B-Chemical 0 0.9999807
- O 0 0.298882
induced O 0 0.01733255
myocardial B-Disease 0 0.999985
infarction I-Disease 2 0.99999905
in O 0 0.0087591475
rats O 0 0.009941279
. O 0 0.007970052

Tincture B-Chemical 0 0.9923894
of I-Chemical 0 0.010250013
Crataegus I-Chemical 0 0.9989729
( O 0 0.021247175
TCR B-Chemical 0 0.9940341
) O 0 0.011018521
, O 0 0.0020920557
an O 0 0.0021996116
alcoholic B-Chemical 0 0.999882
extract I-Chemical 0 0.03174572
of I-Chemical 0 0.0007925064
the I-Chemical 0 0.0006573012
berries I-Chemical 0 0.8569453
of I-Chemical 0 0.0018198712
hawthorn I-Chemical 0 0.9948691
( O 0 0.028800065
Crataegus B-Chemical 0 0.9998851
oxycantha I-Chemical 0 0.98232526
) O 0 0.0017725071
, O 0 0.00060396665
is O 0 0.00045340738
used O 0 0.0005050888
in O 0 0.00083888974
herbal O 0 0.64183277
and O 0 0.0024056262
homeopathic O 0 0.21060169
medicine O 0 0.01977893
. O 0 0.0070287473

The O 0 0.003142282
present O 0 0.0019904522
study O 0 0.0018018022
was O 0 0.0011033376
done O 0 0.000679137
to O 0 0.00051325595
investigate O 0 0.00030309302
the O 0 0.00042828967
protective O 0 0.001734004
effect O 0 0.00058667344
of O 0 0.0015258212
TCR B-Chemical 0 0.9880844
on O 0 0.00051299087
experimentally O 0 0.0019643633
induced O 0 0.007459704
myocardial B-Disease 0 0.9999857
infarction I-Disease 2 0.99999917
in O 0 0.007881255
rats O 0 0.009042297
. O 0 0.006998398

Pretreatment O 0 0.34094045
of O 0 0.006514992
TCR B-Chemical 0 0.9832774
, O 0 0.0027051857
at O 0 0.0009438377
a O 0 0.0008572702
dose O 0 0.0013485658
of O 0 0.00061053963
0 O 0 0.0004892409
. O 0 0.0002846265
5 O 0 0.00023969052
mL O 0 0.0006814327
/ O 0 0.00088511227
100 O 0 0.00037540655
g O 0 0.00043374186
bodyweight O 0 0.0038965659
per O 0 0.00011763372
day O 0 0.00013958963
, O 0 0.00021281182
orally O 0 0.00026107577
for O 0 0.00012891844
30 O 0 0.00011909693
days O 0 0.0001060614
, O 0 0.00019953137
prevented O 0 0.00020403342
the O 0 0.00016669855
increase O 0 0.00015284776
in O 0 0.00034414936
lipid O 0 0.9896744
peroxidation O 0 0.99999905
and O 0 0.00049599144
activity O 0 0.00019772479
of O 0 0.00021951801
marker O 0 0.00046729285
enzymes O 0 0.009209152
observed O 0 0.00022497015
in O 0 0.0008008841
isoproterenol B-Chemical 0 0.99998355
- O 0 0.07322009
induced O 0 0.00028079344
rats O 0 0.0005511619
( O 0 0.00033714075
85 O 0 0.00027897145
mg O 0 0.005074959
kg O 0 0.0007174915
( O 0 0.0005009768
- O 0 0.0028563235
1 O 0 0.00019522948
) O 0 0.00028944606
s O 0 0.0002851515
. O 0 0.00022620888
c O 0 0.0017738863
. O 0 0.00024402564
for O 0 0.00023420839
2 O 0 0.0002447718
days O 0 0.00020993233
at O 0 0.00029043542
an O 0 0.00045521412
interval O 0 0.00055469264
of O 0 0.0010167244
24 O 0 0.0014676137
h O 0 0.0023859844
) O 0 0.005279661
. O 0 0.007140104

TCR B-Chemical 0 0.95935017
prevented O 0 0.007340108
the O 0 0.007016359
isoproterenol B-Chemical 0 0.9999833
- O 0 0.21770781
induced O 0 0.0011717236
decrease O 0 0.00092797447
in O 0 0.0010941558
antioxidant O 0 0.99891376
enzymes O 0 0.033544283
in O 0 0.0003181724
the O 0 0.00029629987
heart O 0 0.048528
and O 0 0.0002770176
increased O 0 0.00023739116
the O 0 0.00020272024
rate O 0 0.0003183071
of O 0 0.0019542815
ADP B-Chemical 0 0.99992764
- O 0 0.05138236
stimulated O 0 0.00059640605
oxygen B-Chemical 1 0.99534
uptake O 0 0.008848593
and O 0 0.0013788718
respiratory O 0 0.03076747
coupling O 0 0.004064239
ratio O 0 0.0046601724
. O 0 0.007029806

TCR B-Chemical 0 0.77891296
protected O 0 0.00512023
against O 0 0.0035343943
pathological O 0 0.1067168
changes O 0 0.003328786
induced O 0 0.0026503874
by O 0 0.004291412
isoproterenol B-Chemical 0 0.9998841
in O 0 0.004977849
rat O 0 0.023993235
heart O 0 0.37990862
. O 0 0.010049749

The O 0 0.002992413
results O 0 0.001949674
show O 0 0.0012939168
that O 0 0.0010711561
pretreatment O 0 0.056276537
with O 0 0.0026692292
TCR B-Chemical 0 0.9909339
may O 0 0.0006358681
be O 0 0.00045161467
useful O 0 0.0003818004
in O 0 0.00036476806
preventing O 0 0.00062678324
the O 0 0.00059296057
damage O 0 0.57472557
induced O 0 0.0011925232
by O 0 0.0024113236
isoproterenol B-Chemical 0 0.9998832
in O 0 0.0026365397
rat O 0 0.015404454
heart O 0 0.29488698
. O 0 0.0072388095

Treatment O 0 0.009798558
of O 0 0.0055613555
tinnitus B-Disease 2 0.9994485
by O 0 0.0030757939
intratympanic O 0 0.9950073
instillation O 0 0.19099623
of O 0 0.017747974
lignocaine B-Chemical 0 0.9999918
( O 0 0.05836578
lidocaine B-Chemical 0 0.9999509
) O 0 0.0014273035
2 O 0 0.0006098016
per O 0 0.0005246869
cent O 0 0.00094718847
through O 0 0.0013793093
ventilation O 0 0.004905871
tubes O 0 0.0050228797
. O 0 0.007077457

Idiopathic B-Disease 0 0.91226083
subjective I-Disease 0 0.13253824
tinnitus I-Disease 2 0.9999465
( O 0 0.031221244
IST B-Disease 0 0.98983204
) O 0 0.0025964438
is O 0 0.0012034955
one O 0 0.0009529518
of O 0 0.0011738407
the O 0 0.0013021339
most O 0 0.002236962
obscure O 0 0.008882246
otological O 0 0.3252339
pathologies O 0 0.4639474
. O 0 0.009053556

This O 0 0.006023856
paper O 0 0.0038878785
presents O 0 0.0019214738
the O 0 0.0011485865
results O 0 0.00084596337
of O 0 0.0010130011
treating O 0 0.0059235226
IST B-Disease 0 0.98942834
by O 0 0.000743112
intratympanic O 0 0.9890381
instillation O 0 0.08288657
of O 0 0.0093480665
lignocaine B-Chemical 0 0.9999926
( O 0 0.04241355
lidocaine B-Chemical 0 0.999962
) O 0 0.0008170946
2 O 0 0.00021162246
per O 0 0.00014758353
cent O 0 0.00021830782
through O 0 0.00025260902
a O 0 0.0005446525
grommet O 0 0.070629895
, O 0 0.0009158799
for O 0 0.0008699375
five O 0 0.0011074861
weekly O 0 0.0019964734
courses O 0 0.003400115
. O 0 0.006137319

Fifty O 0 0.009794193
- O 0 0.007226076
two O 0 0.0017892794
patients O 0 0.0018421647
suffering O 0 0.030923417
from O 0 0.00097281684
intractable O 0 0.8510338
tinnitus B-Disease 2 0.9997235
entered O 0 0.0007552008
this O 0 0.00039389855
therapeutic O 0 0.0008620975
trial O 0 0.0006554667
, O 0 0.000655298
but O 0 0.0005928797
only O 0 0.0006199727
nine O 0 0.00075002806
finished O 0 0.0012339978
all O 0 0.001222479
five O 0 0.0017259725
courses O 0 0.003472124
. O 0 0.0063078003

In O 0 0.0038826095
one O 0 0.0023719436
patient O 0 0.00196815
, O 0 0.001975681
the O 0 0.0015437212
tinnitus B-Disease 2 0.99957913
was O 0 0.00070565974
almost O 0 0.00041592095
completely O 0 0.00039476258
abolished O 0 0.0005629685
, O 0 0.0007690969
but O 0 0.00040902902
in O 0 0.00024505012
all O 0 0.0002091982
the O 0 0.00021132852
nine O 0 0.0002412367
patients O 0 0.00038185375
the O 0 0.0004908172
decompensated O 0 0.99966884
tinnitus B-Disease 2 0.999856
changed O 0 0.0009108958
to O 0 0.0008924412
a O 0 0.0016616643
compensated O 0 0.0032047005
one O 0 0.0034822111
. O 0 0.0063219084

We O 0 0.003308801
suggest O 0 0.0016618193
this O 0 0.0015097751
mode O 0 0.0013528558
of O 0 0.0011035863
treatment O 0 0.000967126
for O 0 0.00055482745
patients O 0 0.00061920605
that O 0 0.00028733554
were O 0 0.00031068717
previously O 0 0.0002836526
treated O 0 0.0003432447
by O 0 0.0003882393
drugs O 0 0.11958915
, O 0 0.0007959332
acupuncture O 0 0.002922481
and O 0 0.00071561016
biofeedback O 0 0.004213515
, O 0 0.0012199013
with O 0 0.0015696416
disappointing O 0 0.005084599
results O 0 0.0037328852
. O 0 0.006876866

Patients O 0 0.004583627
should O 0 0.001809129
be O 0 0.0016159859
warned O 0 0.0022743347
about O 0 0.0008238927
the O 0 0.00069907965
side O 0 0.00780648
effects O 0 0.0009246199
of O 0 0.0037603176
vertigo B-Disease 0 0.99999845
and O 0 0.024796627
vomiting B-Disease 0 0.99997926
, O 0 0.0011909396
which O 0 0.00038957063
subsides O 0 0.0004001214
gradually O 0 0.00023761534
with O 0 0.0001567882
every O 0 8.6889355e-05
new O 0 0.00019333592
instillation O 0 0.005175795
, O 0 0.00034426636
and O 0 0.00022741058
that O 0 0.0001585042
the O 0 0.00041420813
tinnitus B-Disease 2 0.9996443
may O 0 0.0002062401
not O 0 0.00017920711
disappear O 0 0.0005347285
but O 0 0.00027209625
will O 0 0.00014513075
be O 0 0.00018925904
alleviated O 0 0.0017935495
, O 0 0.0003288105
enabling O 0 0.00029370503
them O 0 0.00027111248
to O 0 0.00016203483
cope O 0 0.0003118231
more O 0 0.00025058733
easily O 0 0.00023789801
with O 0 0.00025362434
the O 0 0.00036066512
disease O 0 0.52865815
and O 0 0.0007955229
lead O 0 0.008633695
a O 0 0.0012881345
more O 0 0.0015466801
normal O 0 0.0027459424
life O 0 0.0045418194
. O 0 0.006456075

The O 0 0.0043712035
alpha3 O 0 0.98054045
and O 0 0.014566614
beta4 O 0 0.9998272
nicotinic O 0 0.999992
acetylcholine B-Chemical 1 0.9999908
receptor O 0 0.24653977
subunits O 0 0.0063378643
are O 0 0.00041652523
necessary O 0 0.00029184046
for O 0 0.0007181023
nicotine B-Chemical 1 0.99995506
- O 0 0.14802252
induced O 0 0.009434187
seizures B-Disease 0 0.9999993
and O 0 0.04806326
hypolocomotion B-Disease 0 0.99995136
in O 0 0.0023954713
mice O 0 0.0028925033
. O 0 0.006502178

Binding O 0 0.0050420784
of O 0 0.005369585
nicotine B-Chemical 1 0.99980265
to O 0 0.006055125
nicotinic O 0 0.9999697
acetylcholine B-Chemical 1 0.9999858
receptors O 0 0.2473857
( O 0 0.011395921
nAChRs O 0 0.8994152
) O 0 0.00081096444
elicits O 0 0.00031771258
a O 0 0.0002940564
series O 0 0.00026350602
of O 0 0.00028769163
dose O 0 0.006417547
- O 0 0.007198966
dependent O 0 0.00017715174
behaviors O 0 0.0034421426
that O 0 0.00014868104
go O 0 0.00022360326
from O 0 0.00015881132
altered O 0 0.00022546298
exploration O 0 0.000527388
, O 0 0.00076160807
sedation O 0 0.16327886
, O 0 0.00063585053
and O 0 0.0012527066
tremors B-Disease 2 0.9999318
, O 0 0.002118624
to O 0 0.001762873
seizures B-Disease 0 0.99999404
and O 0 0.011588324
death B-Disease 0 0.9989272
. O 0 0.010332768

nAChRs O 0 0.5852898
are O 0 0.004416392
pentameric O 0 0.026910692
ion O 0 0.07832297
channels O 0 0.0036872255
usually O 0 0.0017568048
composed O 0 0.0014817422
of O 0 0.0022074392
alpha O 0 0.4685688
and O 0 0.0060255467
beta O 0 0.9361341
subunits O 0 0.15474412
. O 0 0.014349772

A O 0 0.034222666
gene O 0 0.0038173944
cluster O 0 0.0023574592
comprises O 0 0.001485133
the O 0 0.0015210652
alpha3 O 0 0.99567467
, O 0 0.02047386
alpha5 O 0 0.9998634
and O 0 0.0076618497
beta4 O 0 0.99787784
subunits O 0 0.045539495
, O 0 0.0016582996
which O 0 0.0010595729
coassemble O 0 0.002758443
to O 0 0.0010210985
form O 0 0.0015340749
functional O 0 0.002662752
receptors O 0 0.010832408
. O 0 0.007519989

We O 0 0.0031882809
examined O 0 0.0016888396
the O 0 0.0013083292
role O 0 0.00081747427
of O 0 0.0010075206
the O 0 0.0011136767
beta4 O 0 0.99772173
subunits O 0 0.15144286
in O 0 0.009225412
nicotine B-Chemical 1 0.999992
- O 0 0.27113503
induced O 0 0.005995145
seizures B-Disease 0 0.99999964
and O 0 0.02560437
hypolocomotion B-Disease 0 0.9999882
in O 0 0.0006267856
beta4 O 0 0.99549377
homozygous O 0 0.006877423
null O 0 0.00024204399
( O 0 0.0050404975
beta4 O 0 0.99937063
- O 0 0.43408006
/ O 0 0.07128778
- O 0 0.034387186
) O 0 0.00092090305
and O 0 0.0006920838
alpha3 O 0 0.9904604
heterozygous O 0 0.010840904
( O 0 0.0021443763
+ O 0 0.0065172585
/ O 0 0.01902302
- O 0 0.015219078
) O 0 0.0037121135
mice O 0 0.003293471
. O 0 0.0072929533

beta4 O 0 0.9975157
- O 0 0.28729844
/ O 0 0.04656866
- O 0 0.0065253703
mice O 0 0.00079455506
were O 0 0.0007275624
less O 0 0.0004935255
sensitive O 0 0.00041153745
to O 0 0.0002714482
the O 0 0.00026132682
effects O 0 0.00039701778
of O 0 0.0010998201
nicotine B-Chemical 1 0.99989986
both O 0 0.0003160037
at O 0 0.00017424884
low O 0 0.00029321515
doses O 0 0.0013842336
, O 0 0.0002591321
measured O 0 0.00012806582
as O 0 0.00014838418
decreased O 0 0.000219405
exploration O 0 0.00030486693
in O 0 0.00017447576
an O 0 0.00022944326
open O 0 0.00031113744
field O 0 0.00041345932
, O 0 0.00028327396
and O 0 0.00021224079
at O 0 0.00016746596
high O 0 0.0003063777
doses O 0 0.0010134605
, O 0 0.00034497876
measured O 0 0.00023323501
as O 0 0.0003286538
sensitivity O 0 0.0017383868
to O 0 0.0010816588
nicotine B-Chemical 1 0.9999243
- O 0 0.16442116
induced O 0 0.021482235
seizures B-Disease 0 0.9999938
. O 0 0.011180244

Using O 0 0.0035463853
in O 0 0.0023185648
situ O 0 0.0025095805
hybridization O 0 0.0014233536
probes O 0 0.0009951228
for O 0 0.0006420283
the O 0 0.0007560487
alpha3 O 0 0.9957468
and O 0 0.013570259
alpha5 O 0 0.9999529
subunits O 0 0.07958568
, O 0 0.00072214304
we O 0 0.0001492216
showed O 0 0.00018397724
that O 0 0.0002513974
alpha5 O 0 0.9998419
mRNA O 0 0.0015444548
levels O 0 0.00026810527
are O 0 0.00018879655
unchanged O 0 0.0002715357
, O 0 0.0005376565
whereas O 0 0.00090528995
alpha3 O 0 0.99730265
mRNA O 0 0.0012634745
levels O 0 0.00023080228
are O 0 0.00015514308
selectively O 0 0.00016194416
decreased O 0 0.0001987091
in O 0 0.00014333337
the O 0 0.00016879351
mitral O 0 0.17503521
cell O 0 0.0011099349
layer O 0 0.0023464262
of O 0 0.00022462163
the O 0 0.00023034654
olfactory O 0 0.025752733
bulb O 0 0.39332145
, O 0 0.00029214864
and O 0 0.00020600132
the O 0 0.0001967964
inferior O 0 0.0018825757
and O 0 0.00022695116
the O 0 0.0002526852
superior O 0 0.0006226751
colliculus O 0 0.011081406
of O 0 0.000927765
beta4 O 0 0.99732035
- O 0 0.29381007
/ O 0 0.051328138
- O 0 0.033516247
brains O 0 0.009941288
. O 0 0.007371587

alpha3 O 0 0.99628276
+ O 0 0.07254329
/ O 0 0.0501324
- O 0 0.006482481
mice O 0 0.00078705413
were O 0 0.0007316585
partially O 0 0.0005903029
resistant O 0 0.0006998046
to O 0 0.0007558445
nicotine B-Chemical 1 0.99997044
- O 0 0.13689984
induced O 0 0.002947694
seizures B-Disease 0 0.99999785
when O 0 0.00041753158
compared O 0 0.00040912654
to O 0 0.000597038
wild O 0 0.0010762244
- O 0 0.0038838084
type O 0 0.0021130033
littermates O 0 0.0025921375
. O 0 0.0066501405

mRNA O 0 0.004765144
levels O 0 0.0025053476
for O 0 0.0018482219
the O 0 0.0019279885
alpha5 O 0 0.99906224
and O 0 0.0016419736
the O 0 0.0011439436
beta4 O 0 0.99198747
subunits O 0 0.013302722
were O 0 0.00068604195
unchanged O 0 0.000721264
in O 0 0.0010480199
alpha3 O 0 0.9930333
+ O 0 0.04897659
/ O 0 0.047518954
- O 0 0.031712625
brains O 0 0.010097281
. O 0 0.0077705225

Together O 0 0.0075287195
, O 0 0.0034740516
these O 0 0.0017727036
results O 0 0.0010847554
suggest O 0 0.0006489713
that O 0 0.0006332829
the O 0 0.00082649896
beta4 O 0 0.9896623
and O 0 0.0012275372
the O 0 0.00085293065
alpha3 O 0 0.9939879
subunits O 0 0.011873613
are O 0 0.0004718398
mediators O 0 0.002832966
of O 0 0.0065844175
nicotine B-Chemical 1 0.9999831
- O 0 0.27213615
induced O 0 0.020683333
seizures B-Disease 0 0.9999988
and O 0 0.12357109
hypolocomotion B-Disease 0 0.99995637
. O 0 0.008609586

The O 0 0.0053258887
effects O 0 0.0052903094
of O 0 0.0065527223
sevoflurane B-Chemical 1 0.99980396
on O 0 0.0052610496
lidocaine B-Chemical 0 0.9999639
- O 0 0.23816171
induced O 0 0.03055386
convulsions B-Disease 0 0.99998045
. O 0 0.018018112

The O 0 0.0036277233
influence O 0 0.0024775534
of O 0 0.003547661
sevoflurane B-Chemical 1 0.999788
on O 0 0.002383889
lidocaine B-Chemical 0 0.99998415
- O 0 0.1817808
induced O 0 0.0066859596
convulsions B-Disease 0 0.9999925
was O 0 0.002475193
studied O 0 0.0026038885
in O 0 0.003338082
cats O 0 0.00981042
. O 0 0.008115077

The O 0 0.0044958265
convulsive B-Disease 2 0.9997905
threshold O 0 0.0017851414
( O 0 0.0015741669
mean O 0 0.0006979805
+ O 0 0.003186787
/ O 0 0.01950098
- O 0 0.032672357
SD O 0 0.10235651
) O 0 0.0009576799
was O 0 0.00044775844
41 O 0 0.0005945598
. O 0 0.00039297758
4 O 0 0.00043934342
+ O 0 0.0011255448
/ O 0 0.0034489147
- O 0 0.0038748425
6 O 0 0.0010318181
. O 0 0.0015240089
5 O 0 0.002385973
mg O 0 0.010958114
. O 0 0.0074780714

l O 0 0.013671661
( O 0 0.006107132
- O 0 0.010402403
1 O 0 0.0015911805
) O 0 0.0017117261
with O 0 0.001451428
lidocaine B-Chemical 0 0.99988127
infusion O 0 0.0071964376
( O 0 0.0006860589
6 O 0 0.00026349697
mg O 0 0.0034869085
. O 0 0.00022815575
kg O 0 0.00065598264
( O 0 0.00061393133
- O 0 0.0039356016
1 O 0 0.00024355589
) O 0 0.00037102553
. O 0 0.00019456311
min O 0 0.0003339858
( O 0 0.00053149724
- O 0 0.004530608
1 O 0 0.0002592235
) O 0 0.000521469
) O 0 0.00054806855
, O 0 0.0003229484
increasing O 0 0.00022426106
significantly O 0 0.00022489124
to O 0 0.00019713012
66 O 0 0.00038980113
. O 0 0.00025679357
6 O 0 0.0002882569
+ O 0 0.00094690965
/ O 0 0.0037709286
- O 0 0.004349034
10 O 0 0.001027825
. O 0 0.001383993
9 O 0 0.002387291
mg O 0 0.011293557
. O 0 0.006862627

l O 0 0.013989136
( O 0 0.0065906835
- O 0 0.010417986
1 O 0 0.0018076107
) O 0 0.0016290621
when O 0 0.0007260906
the O 0 0.0006798889
end O 0 0.0005720099
- O 0 0.0025266248
tidal O 0 0.012367081
concentration O 0 0.0015495068
of O 0 0.0019728716
sevoflurane B-Chemical 1 0.99979264
was O 0 0.0011627843
0 O 0 0.0013073675
. O 0 0.0015606943
8 O 0 0.002429552
% O 0 0.0047211936
. O 0 0.007580218

However O 0 0.004425913
, O 0 0.0030612678
the O 0 0.0015354442
threshold O 0 0.0011314102
( O 0 0.0014370675
61 O 0 0.0011371917
. O 0 0.00055327936
6 O 0 0.000420571
+ O 0 0.0010978502
/ O 0 0.006384206
- O 0 0.0071027037
8 O 0 0.00029405474
. O 0 0.00022662723
7 O 0 0.00020592373
mg O 0 0.0022644557
. O 0 0.00022106853
l O 0 0.0012505566
( O 0 0.00087262114
- O 0 0.008147135
1 O 0 0.0002584846
) O 0 0.00043228868
) O 0 0.00036300076
during O 0 0.0001529339
1 O 0 0.00019337243
. O 0 0.00016796908
6 O 0 0.00015898161
% O 0 0.00035397577
sevoflurane B-Chemical 1 0.9980261
was O 0 0.00020812286
not O 0 0.0001523918
significant O 0 0.00016352613
from O 0 0.0001460676
that O 0 0.0001480296
during O 0 0.00016376065
0 O 0 0.0002769811
. O 0 0.00025790583
8 O 0 0.0003327381
% O 0 0.00072842167
sevoflurane B-Chemical 1 0.99855596
, O 0 0.0010787309
indicating O 0 0.00093965814
a O 0 0.0019417927
celling O 0 0.006891289
effect O 0 0.003944796
. O 0 0.0071745417

There O 0 0.0049483026
was O 0 0.0031324986
no O 0 0.0018738002
significant O 0 0.0016990863
difference O 0 0.0011565158
in O 0 0.0013259844
the O 0 0.0017223145
convulsive B-Disease 2 0.9999747
threshold O 0 0.0014788298
between O 0 0.0019588443
sevoflurane B-Chemical 1 0.99983644
and O 0 0.026607223
enflurane B-Chemical 1 0.99995875
. O 0 0.00996292

The O 0 0.0033175505
rise O 0 0.0029070738
in O 0 0.0019319061
blood O 0 0.013960508
pressure O 0 0.08085743
became O 0 0.0014490314
less O 0 0.000511843
marked O 0 0.0005712036
when O 0 0.00024651992
higher O 0 0.00026912717
concentrations O 0 0.0007539572
of O 0 0.0012854622
sevoflurane B-Chemical 1 0.9999653
or O 0 0.0038227579
enflurane B-Chemical 1 0.99999535
were O 0 0.00022064212
administered O 0 0.00015778432
and O 0 0.00017781106
the O 0 0.00017863917
blood O 0 0.009290654
pressure O 0 0.03761785
at O 0 0.00024367806
convulsions B-Disease 0 0.99998415
decreased O 0 0.0004077074
significantly O 0 0.00020658057
in O 0 0.00016469676
1 O 0 0.00016089185
. O 0 0.00014018906
6 O 0 0.00013785822
% O 0 0.0003357828
sevoflurane B-Chemical 1 0.9988066
, O 0 0.0003551536
and O 0 0.00024478955
in O 0 0.00022330604
0 O 0 0.0002778071
. O 0 0.0002467847
8 O 0 0.0002882891
% O 0 0.00042783874
and O 0 0.00054772093
1 O 0 0.000701016
. O 0 0.00094997877
6 O 0 0.0014586018
% O 0 0.0041196286
enflurane B-Chemical 1 0.9997192
. O 0 0.008369005

However O 0 0.004600191
, O 0 0.0032065334
there O 0 0.0014394019
was O 0 0.0012079978
no O 0 0.0007115462
significant O 0 0.0006612917
difference O 0 0.00041777824
in O 0 0.00048270638
the O 0 0.0007043663
lidocaine B-Chemical 0 0.9998105
concentrations O 0 0.0011393423
measured O 0 0.0002899612
when O 0 0.00029296952
the O 0 0.00047826374
systolic O 0 0.42328012
blood O 0 0.01089228
pressure O 0 0.017436208
became O 0 0.0019490024
70 O 0 0.0023344792
mmHg O 0 0.005750538
. O 0 0.006320468

Apamin B-Chemical 0 0.9996774
, O 0 0.00671199
a O 0 0.0029899704
selective O 0 0.004991346
blocker O 0 0.9014704
of O 0 0.0049193166
calcium B-Chemical 0 0.9997497
- O 0 0.14762014
dependent O 0 0.0007531077
potassium B-Chemical 0 0.9999732
channels O 0 0.026732566
, O 0 0.00057490624
was O 0 0.00022672322
administered O 0 0.00023221609
intracerebroventricularly O 0 0.21902812
in O 0 0.00015861352
rats O 0 0.00023106915
anesthetized O 0 0.0004122548
with O 0 0.000162905
0 O 0 0.00020210283
. O 0 0.00016745192
8 O 0 0.0001944088
% O 0 0.00036624636
sevoflurane B-Chemical 1 0.9927147
to O 0 0.00022158575
investigate O 0 0.00017502232
the O 0 0.0003391991
mechanism O 0 0.00049285416
of O 0 0.0011660724
the O 0 0.0023777143
anticonvulsive O 0 0.99963284
effects O 0 0.0060717757
. O 0 0.0067526954

Apamin B-Chemical 0 0.99958867
( O 0 0.00578128
10 O 0 0.0019407321
ng O 0 0.0023579302
) O 0 0.0019946955
had O 0 0.0007656329
a O 0 0.0006982151
tendency O 0 0.00060124474
to O 0 0.00032050844
decrease O 0 0.00035602375
the O 0 0.0005242875
convulsive B-Disease 2 0.9999888
threshold O 0 0.00029362104
( O 0 0.0004922997
21 O 0 0.000248069
. O 0 0.00016760736
6 O 0 0.00015758826
+ O 0 0.0006764985
/ O 0 0.007057026
- O 0 0.00883355
2 O 0 0.00020568198
. O 0 0.00016113903
2 O 0 0.00015030733
to O 0 0.00013516923
19 O 0 0.00022622656
. O 0 0.00016024422
9 O 0 0.00018904911
+ O 0 0.0007337123
/ O 0 0.008011319
- O 0 0.010088628
2 O 0 0.00021181325
. O 0 0.00016812001
5 O 0 0.00016314111
mg O 0 0.0019434921
. O 0 0.00020746666
l O 0 0.001072269
( O 0 0.0008350978
- O 0 0.0066354275
1 O 0 0.00037603747
) O 0 0.0007144442
) O 0 0.00082320214
but O 0 0.0006407995
this O 0 0.0006687453
was O 0 0.00093610084
not O 0 0.0012718338
statistically O 0 0.002089161
significant O 0 0.0038340476
. O 0 0.0073551605

It O 0 0.004785796
is O 0 0.0026195066
suggested O 0 0.0016825269
that O 0 0.0016566016
sevoflurane B-Chemical 1 0.9997807
reduces O 0 0.0011815857
the O 0 0.0017628553
convulsive B-Disease 2 0.99999595
effect O 0 0.0011688832
of O 0 0.014776415
lidocaine B-Chemical 0 0.9999969
toxicity B-Disease 2 0.999824
but O 0 0.0011458555
carries O 0 0.0007496322
some O 0 0.0006225452
risk O 0 0.015738351
due O 0 0.00088380347
to O 0 0.0016710031
circulatory O 0 0.6322792
depression B-Disease 0 0.9987214
. O 0 0.0074346503

Cardiac B-Disease 0 0.9775416
toxicity I-Disease 2 0.9994929
observed O 0 0.0018755213
in O 0 0.0011738375
association O 0 0.000834564
with O 0 0.00088774227
high O 0 0.0016882513
- O 0 0.026070246
dose O 0 0.058361925
cyclophosphamide B-Chemical 0 0.99996996
- O 0 0.05365937
based O 0 0.0009550465
chemotherapy O 0 0.04107587
for O 0 0.0016606884
metastatic O 0 0.98317105
breast B-Disease 0 0.9996195
cancer I-Disease 0 0.99994314
. O 0 0.024466434

INTRODUCTION O 0 0.019887287
: O 0 0.010825826
Cyclophosphamide B-Chemical 0 0.99979085
is O 0 0.0029829848
an O 0 0.002933356
alkylating O 0 0.98981315
agent O 0 0.0884655
given O 0 0.0006276243
frequently O 0 0.00079775177
as O 0 0.0005885153
a O 0 0.00079001166
component O 0 0.0008784144
of O 0 0.0012676379
many O 0 0.0016078891
conditioning O 0 0.0034587393
regimens O 0 0.005068674
. O 0 0.0069181263

In O 0 0.0047643348
high O 0 0.004027911
doses O 0 0.00803979
, O 0 0.0036690438
its O 0 0.013571172
nonhematological O 0 0.99986243
dose O 0 0.16193984
- O 0 0.07702
limiting O 0 0.007971725
toxicity B-Disease 2 0.99939466
is O 0 0.024567021
cardiomyopathy B-Disease 0 0.9999751
. O 0 0.0139416745

STUDY O 0 0.0062120156
DESIGN O 0 0.0033551394
: O 0 0.0025663695
We O 0 0.0014974074
combined O 0 0.0018176674
paclitaxel B-Chemical 1 0.99471694
, O 0 0.009886458
melphalan B-Chemical 1 0.9999312
and O 0 0.0016913773
high O 0 0.0024331487
- O 0 0.02999382
dose O 0 0.038770724
cyclophosphamide B-Chemical 0 0.9999769
, O 0 0.023139674
thiotepa B-Chemical 0 0.99997807
, O 0 0.0013004439
and O 0 0.0007023086
carboplatin B-Chemical 1 0.9940182
in O 0 0.0002346948
a O 0 0.00027256698
triple O 0 0.0005557484
sequential O 0 0.00030162893
high O 0 0.0006532039
- O 0 0.0059439144
dose O 0 0.0011316873
regimen O 0 0.0005187147
for O 0 0.00041835994
patients O 0 0.0010249618
with O 0 0.0017503868
metastatic O 0 0.9832086
breast B-Disease 0 0.9996201
cancer I-Disease 0 0.999946
. O 0 0.02315655

Analysis O 0 0.0043028593
was O 0 0.002301451
performed O 0 0.0013470826
on O 0 0.0009149187
61 O 0 0.0013125213
women O 0 0.0020838124
with O 0 0.000757385
chemotherapy O 0 0.120384954
- O 0 0.01931121
responsive O 0 0.0006072225
metastatic O 0 0.97841734
breast B-Disease 0 0.999856
cancer I-Disease 0 0.99999154
receiving O 0 0.013949524
96 O 0 0.0093033165
- O 0 0.0067225248
h O 0 0.00039684845
infusional O 0 0.68035203
cyclophosphamide B-Chemical 0 0.9992716
as O 0 0.00017460741
part O 0 0.000134909
of O 0 0.00018978564
a O 0 0.000232798
triple O 0 0.0005941412
sequential O 0 0.0002595816
high O 0 0.0006892915
- O 0 0.007919717
dose O 0 0.0007482914
regimen O 0 0.00020089454
to O 0 9.505793e-05
assess O 0 6.224091e-05
association O 0 9.6325726e-05
between O 0 9.509673e-05
presence O 0 0.00015945315
of O 0 0.00044467382
peritransplant O 0 0.68690133
congestive B-Disease 0 0.9999769
heart I-Disease 0 0.93690246
failure I-Disease 0 0.932342
( O 0 0.10461849
CHF B-Disease 2 0.9999962
) O 0 0.0027991668
and O 0 0.00022161598
the O 0 0.0001414707
following O 0 0.00012359617
pretreatment O 0 0.004766139
characteristics O 0 0.00014468555
: O 0 0.00024262739
presence O 0 0.00014546131
of O 0 0.00033512
electrocardiogram O 0 0.51046336
( O 0 0.001200058
EKG O 0 0.5780123
) O 0 0.0006828526
abnormalities O 0 0.033647772
, O 0 0.00038854952
age O 0 0.0015698681
, O 0 0.0040231296
hypertension B-Disease 2 0.99999666
, O 0 0.0005541956
prior O 0 0.00015428055
cardiac O 0 0.029213743
history O 0 0.0154980095
, O 0 0.004129585
smoking O 1 0.99930584
, O 0 0.03597032
diabetes B-Disease 0 0.9999912
mellitus I-Disease 0 0.9999064
, O 0 0.00091015926
prior O 0 0.00017222913
use O 0 0.00025258452
of O 0 0.0006214535
anthracyclines B-Chemical 0 0.9997938
, O 0 0.0010989555
and O 0 0.0008857441
left O 0 0.0033254954
- O 0 0.018542875
sided O 0 0.1728399
chest O 0 0.05304693
irradiation O 0 0.036891356
. O 0 0.007815275

RESULTS O 0 0.0058509675
: O 0 0.0037926391
Six O 0 0.0023314727
of O 0 0.0017135931
61 O 0 0.0020165318
women O 0 0.0037354305
( O 0 0.0011828312
10 O 0 0.0006216615
% O 0 0.0006395439
) O 0 0.000707473
developed O 0 0.00059625314
clinically O 0 0.006864197
reversible O 0 0.07323542
grade O 0 0.21923417
3 O 0 0.00045297405
CHF B-Disease 2 0.9998776
following O 0 0.0003125905
infusional O 0 0.81782293
cyclophosphamide B-Chemical 0 0.9995633
with O 0 0.00031303396
a O 0 0.00025292937
median O 0 0.00017048724
percent O 0 0.00023866477
decline O 0 0.0007125681
in O 0 0.0005047808
ejection O 0 0.040941358
fraction O 0 0.0008843598
of O 0 0.0017413633
31 O 0 0.0029223044
% O 0 0.0043761097
. O 0 0.0067756884

Incidence O 0 0.01646422
of O 0 0.004007403
transient O 0 0.3093825
cyclophosphamide B-Chemical 0 0.99997854
- O 0 0.24742895
related O 0 0.0009925351
cardiac B-Disease 0 0.9788126
toxicity I-Disease 2 0.99997747
( O 0 0.002281689
10 O 0 0.0005087027
% O 0 0.00061441987
) O 0 0.0007689942
is O 0 0.0005803506
comparable O 0 0.00055932824
to O 0 0.0008385093
previous O 0 0.0013723896
recorded O 0 0.002378746
literature O 0 0.004863995
. O 0 0.0071166353

Older O 0 0.04217494
age O 0 0.0040924926
was O 0 0.0018763024
significantly O 0 0.0011658603
correlated O 0 0.0007084713
with O 0 0.0007720922
the O 0 0.0011399124
CHF B-Disease 2 0.99997747
development O 0 0.0068650804
; O 0 0.0007484694
with O 0 0.00022745853
median O 0 0.00014238567
ages O 0 0.00020674076
for O 0 0.00016263325
the O 0 0.00016457165
entire O 0 0.00016269498
group O 0 0.00024625965
and O 0 0.00024505574
for O 0 0.00026555904
patients O 0 0.0008307113
developing O 0 0.07204176
CHF B-Disease 2 0.999951
of O 0 0.0008127661
45 O 0 0.00070523954
and O 0 0.0010006417
59 O 0 0.0020108863
, O 0 0.0027263812
respectively O 0 0.0059735533
. O 0 0.007197671

No O 0 0.008686295
association O 0 0.0051165395
was O 0 0.0048075733
found O 0 0.0039631077
with O 0 0.0045208563
other O 0 0.0058401213
pretreatment O 0 0.07117993
characteristics O 0 0.00874333
. O 0 0.01272221

CONCLUSIONS O 0 0.024361825
: O 0 0.0043803193
As O 0 0.0019083066
a O 0 0.0016955651
result O 0 0.001046958
of O 0 0.0010335994
these O 0 0.00088321464
findings O 0 0.0010363227
, O 0 0.0009286405
oncologists O 0 0.00074092916
should O 0 0.0003593053
carefully O 0 0.00037942
monitor O 0 0.00052651024
fluid O 0 0.0012952003
balance O 0 0.001447561
in O 0 0.0017291558
older O 0 0.005256061
patients O 0 0.005421233
. O 0 0.007189283

Routine O 0 0.0076960768
EKG O 0 0.034383345
monitoring O 0 0.0032461642
during O 0 0.0025699264
infusional O 0 0.84132224
cyclophosphamide B-Chemical 0 0.9997744
did O 0 0.0030620133
not O 0 0.002550682
predict O 0 0.003833585
CHF B-Disease 2 0.9998417
development O 0 0.02509015
. O 0 0.0107203

Tremor B-Disease 0 0.9890099
side O 0 0.029162228
effects O 0 0.004509305
of O 0 0.005389317
salbutamol B-Chemical 0 0.9999163
, O 0 0.0037284933
quantified O 0 0.0021702098
by O 0 0.002569768
a O 0 0.003506283
laser O 0 0.0147017
pointer O 0 0.008305274
technique O 0 0.008316124
. O 0 0.010306446

OBJECTIVE O 0 0.019122316
: O 0 0.0038206214
To O 0 0.001816715
study O 0 0.003382738
tremor B-Disease 0 0.99995446
side O 0 0.078509666
effects O 0 0.0013820719
of O 0 0.002026085
salbutamol B-Chemical 0 0.9999603
an O 0 0.001016066
easily O 0 0.00052632584
applicable O 0 0.00038867292
, O 0 0.00048903
quick O 0 0.0008149551
and O 0 0.0006301071
low O 0 0.0012001937
- O 0 0.008928832
priced O 0 0.033725243
method O 0 0.0021476457
is O 0 0.0025633858
needed O 0 0.003396291
. O 0 0.0068515283

A O 0 0.024337374
new O 0 0.0044467514
method O 0 0.003161275
using O 0 0.0020626974
a O 0 0.002224974
commercially O 0 0.004354426
available O 0 0.0016055515
, O 0 0.0018945743
pen O 0 0.0063174823
- O 0 0.0045083524
shaped O 0 0.0029316132
laser O 0 0.016654385
pointer O 0 0.0053989
was O 0 0.003993519
developed O 0 0.0068593617
. O 0 0.009017706

Aim O 0 0.023346562
of O 0 0.003150834
the O 0 0.0019438964
study O 0 0.0016306139
was O 0 0.00093922147
to O 0 0.0005772468
determine O 0 0.00032110876
sensitivity O 0 0.0010391468
, O 0 0.00070750347
reproducibility O 0 0.0006757829
, O 0 0.0005621173
reference O 0 0.00042251835
values O 0 0.00043312952
and O 0 0.00060757855
the O 0 0.00072059355
agreement O 0 0.001379524
with O 0 0.0016677598
a O 0 0.0029040622
questionnaire O 0 0.0039825346
. O 0 0.00665112

METHODS O 0 0.008600654
: O 0 0.010511649
Tremor B-Disease 0 0.77858347
was O 0 0.0049264105
measured O 0 0.003910932
using O 0 0.0045085596
a O 0 0.0064409426
laser O 0 0.016407693
pointer O 0 0.012797608
technique O 0 0.012792584
. O 0 0.0151014095

To O 0 0.0027186505
determine O 0 0.0013152976
sensitivity O 0 0.0020486426
we O 0 0.00097010395
assessed O 0 0.001059995
tremor B-Disease 0 0.999933
in O 0 0.0007148328
44 O 0 0.00070406735
patients O 0 0.0005293776
with O 0 0.0006031604
obstructive B-Disease 0 0.99821436
lung I-Disease 0 0.8574728
disease I-Disease 0 0.9949603
after O 0 0.000391108
administration O 0 0.003727022
of O 0 0.00084905553
cumulative O 0 0.0024575607
doses O 0 0.031147977
of O 0 0.014011002
salbutamol B-Chemical 0 0.99991786
. O 0 0.010447837

Subjects O 0 0.0049403384
were O 0 0.0024331675
asked O 0 0.0013940936
to O 0 0.0010850809
aim O 0 0.0009499667
at O 0 0.00062117464
the O 0 0.0005252075
centre O 0 0.0005522557
of O 0 0.0005046158
a O 0 0.0004993925
target O 0 0.0004058751
, O 0 0.00060756697
subdivided O 0 0.0006162422
in O 0 0.00045553883
concentric O 0 0.021911457
circles O 0 0.0009756883
, O 0 0.0010109802
from O 0 0.0009377478
5 O 0 0.0013136519
m O 0 0.003439527
distance O 0 0.0042253435
. O 0 0.0075908075

The O 0 0.0039265016
circle O 0 0.0042046392
in O 0 0.0023631947
which O 0 0.0020335335
the O 0 0.0013694916
participant O 0 0.0011387628
succeeded O 0 0.0025157854
to O 0 0.0010349359
aim O 0 0.0012456432
was O 0 0.0012309344
recorded O 0 0.0014538455
in O 0 0.0019571397
millimetres O 0 0.0038703082
radius O 0 0.012431452
. O 0 0.009416467

In O 0 0.0037423507
another O 0 0.0024637338
series O 0 0.0017625474
of O 0 0.0012411682
measurements O 0 0.0007753807
, O 0 0.000883088
reproducibility O 0 0.000677889
and O 0 0.00044894358
reference O 0 0.00033269907
values O 0 0.0002645033
of O 0 0.00036185537
the O 0 0.0005444893
tremor B-Disease 0 0.9999709
was O 0 0.00024315449
assessed O 0 0.00014439502
in O 0 0.00017218711
65 O 0 0.00022789832
healthy O 0 0.0004869911
subjects O 0 0.00019229278
in O 0 0.00012735538
three O 0 9.270083e-05
sessions O 0 0.0001138766
, O 0 0.00017777037
at O 0 0.0001350762
9 O 0 0.00015462146
a O 0 0.0001920897
. O 0 0.00017696705
m O 0 0.0009999978
. O 0 0.00021445606
, O 0 0.00029060687
4 O 0 0.00017443733
p O 0 0.00020479591
. O 0 0.00020405269
m O 0 0.000744701
. O 0 0.00023057024
and O 0 0.00027259218
9 O 0 0.0002583259
a O 0 0.00031927633
. O 0 0.00032308543
m O 0 0.001277588
. O 0 0.00051520043
, O 0 0.00086428365
respectively O 0 0.0017289532
, O 0 0.0014587422
1 O 0 0.001459175
week O 0 0.0017964217
later O 0 0.0032449868
. O 0 0.0066066748

Postural O 0 0.9684147
tremor B-Disease 0 0.9998747
was O 0 0.0019922915
measured O 0 0.0009460768
with O 0 0.0007733024
the O 0 0.00056577724
arm O 0 0.0006872686
horizontally O 0 0.0010313267
outstretched O 0 0.088562906
rest O 0 0.0010999548
tremor B-Disease 0 0.99993706
with O 0 0.0003045947
the O 0 0.00020450125
arm O 0 0.00027399897
supported O 0 0.00023322922
by O 0 0.00022434129
an O 0 0.00033044745
armrest O 0 0.06894951
and O 0 0.00039817946
finally O 0 0.0058299
tremor B-Disease 0 0.99996614
was O 0 0.00023926672
measured O 0 0.00018035324
after O 0 0.00019127839
holding O 0 0.0006886097
a O 0 0.00054647436
2 O 0 0.00058627425
- O 0 0.0016584827
kg O 0 0.0016278296
weight O 0 0.0024274185
until O 0 0.0021450764
exhaustion O 0 0.012217833
. O 0 0.007176834

Inter O 0 0.066063546
- O 0 0.011481102
observer O 0 0.005041523
variability O 0 0.002400992
was O 0 0.0017326924
measured O 0 0.0013006693
in O 0 0.0014173829
a O 0 0.0016788215
series O 0 0.0018631987
of O 0 0.0022514327
10 O 0 0.0027073347
healthy O 0 0.006564062
subjects O 0 0.0066341325
. O 0 0.00873843

Tremor B-Disease 0 0.94987935
was O 0 0.006402811
measured O 0 0.004453882
simultaneously O 0 0.004607682
by O 0 0.0052807922
two O 0 0.0049703135
independent O 0 0.0060449434
observers O 0 0.012593609
. O 0 0.015478262

RESULTS O 0 0.007638768
: O 0 0.009320235
Salbutamol B-Chemical 0 0.99981135
significantly O 0 0.0034064224
increased O 0 0.0054275403
tremor B-Disease 0 0.9999771
severity O 0 0.021149354
in O 0 0.00087494607
patients O 0 0.0010591294
in O 0 0.0008669065
a O 0 0.0013595666
dose O 0 0.005186509
- O 0 0.0057771895
dependent O 0 0.002606431
way O 0 0.004731206
. O 0 0.007850554

Within O 0 0.003195579
healthy O 0 0.004406231
adults O 0 0.002950282
no O 0 0.0010590457
age O 0 0.0026465491
- O 0 0.0071195415
dependency O 0 0.000885699
could O 0 0.00036686624
be O 0 0.0003496387
found O 0 0.00031844524
( O 0 0.00050738745
b O 0 0.00086227164
= O 0 0.0007253367
0 O 0 0.00033721435
. O 0 0.00026935432
262 O 0 0.00088765094
mm O 0 0.0006965602
/ O 0 0.0010472424
year O 0 0.000569985
; O 0 0.0011969283
P O 0 0.024868343
= O 0 0.0015885177
0 O 0 0.001421541
. O 0 0.0018005447
72 O 0 0.0035581174
) O 0 0.0058950325
. O 0 0.008185761

There O 0 0.004221704
was O 0 0.0025286325
no O 0 0.0013886079
agreement O 0 0.0014044946
between O 0 0.000710194
the O 0 0.00064855086
questionnaire O 0 0.0005564712
and O 0 0.00095271575
tremor B-Disease 0 0.9999654
severity O 0 0.010203318
( O 0 0.0006234763
r O 0 0.00046336596
= O 0 0.00067942735
0 O 0 0.00045848964
. O 0 0.00047300273
093 O 0 0.030257259
; O 0 0.0011460443
P O 0 0.018827703
= O 0 0.0016311249
0 O 0 0.0014969974
. O 0 0.001891907
53 O 0 0.00408648
) O 0 0.0062730256
. O 0 0.008573386

Postural O 0 0.95091105
tremor B-Disease 0 0.99981874
showed O 0 0.001868391
no O 0 0.000975291
significant O 0 0.00080194103
difference O 0 0.00047374546
between O 0 0.0003981476
the O 0 0.00041866058
first O 0 0.00034186651
and O 0 0.000440432
third O 0 0.00049188366
session O 0 0.00054970395
( O 0 0.0011056192
P O 0 0.03457622
= O 0 0.0018829027
0 O 0 0.0016957896
. O 0 0.0022504656
07 O 0 0.009634703
) O 0 0.006587587
. O 0 0.008616056

Support O 0 0.007903155
of O 0 0.003657681
the O 0 0.0025671404
arm O 0 0.0032648742
decreased O 0 0.0075205327
tremor B-Disease 0 0.9999826
severity O 0 0.08776942
, O 0 0.0027013288
exhaustion O 0 0.10650076
increased O 0 0.010568135
tremor B-Disease 0 0.9999765
severity O 0 0.077513635
significantly O 0 0.005301115
. O 0 0.007912216

A O 0 0.036496125
good O 0 0.003807137
agreement O 0 0.0028365133
was O 0 0.0014903459
found O 0 0.00088671345
between O 0 0.00058651855
two O 0 0.0004853716
independent O 0 0.0004061586
observers O 0 0.0007225846
( O 0 0.00076762005
interclass O 0 0.0011041503
correlation O 0 0.0006102156
coefficient O 0 0.0014512497
0 O 0 0.0015316476
. O 0 0.0018867006
72 O 0 0.0036638582
) O 0 0.0060344976
. O 0 0.0083227875

DISCUSSION O 0 0.004902437
: O 0 0.0041536177
Quantifying O 0 0.0038189504
tremor B-Disease 0 0.9996618
by O 0 0.0013707958
using O 0 0.00084023265
an O 0 0.00087036396
inexpensive O 0 0.012784216
laser O 0 0.033622816
pointer O 0 0.0028928828
is O 0 0.00045745046
, O 0 0.0004568896
with O 0 0.00028680317
the O 0 0.0002300066
exception O 0 0.00021408954
of O 0 0.00030903556
children O 0 0.0008482714
( O 0 0.00050818635
< O 0 0.00029245266
12 O 0 0.00028240107
years O 0 0.000457081
) O 0 0.0007491165
a O 0 0.0008137085
sensitive O 0 0.0010454741
and O 0 0.0016211029
reproducible O 0 0.0032033129
method O 0 0.0049040066
. O 0 0.0070822844

Safety O 0 0.012109076
and O 0 0.003901511
adverse O 0 0.18688503
effects O 0 0.0025184767
associated O 0 0.0019185212
with O 0 0.004334551
raloxifene B-Chemical 0 0.999925
: O 0 0.0024110316
multiple O 0 0.0015200315
outcomes O 0 0.002602685
of O 0 0.004175037
raloxifene B-Chemical 0 0.9996569
evaluation O 0 0.006258068
. O 0 0.008204966

OBJECTIVE O 0 0.01540397
: O 0 0.0032195617
To O 0 0.0013056005
examine O 0 0.00072413846
the O 0 0.0008165836
effect O 0 0.00078256766
of O 0 0.0021282833
raloxifene B-Chemical 0 0.99988604
on O 0 0.00036579985
major O 0 0.0006592743
adverse O 0 0.27001294
events O 0 0.0032153334
that O 0 0.00029742374
occur O 0 0.0004587688
with O 0 0.002327759
postmenopausal O 0 0.9988249
estrogen B-Chemical 1 0.99997723
therapy O 0 0.04175434
or O 0 0.005325967
tamoxifen B-Chemical 1 0.99911267
. O 0 0.009363968

METHODS O 0 0.0041362406
: O 0 0.003515116
The O 0 0.0018037321
Multiple O 0 0.002249083
Outcomes O 0 0.0018383021
of O 0 0.0020390141
Raloxifene B-Chemical 1 0.9999523
Evaluation O 0 0.0014669639
, O 0 0.00083308737
a O 0 0.0006691846
multicenter O 0 0.014671504
, O 0 0.00056000636
randomized O 0 0.00039041103
, O 0 0.00041832982
double O 0 0.00044376464
- O 0 0.005116054
blind O 0 0.007638595
trial O 0 0.00048436195
, O 0 0.0004760637
enrolled O 0 0.00058003725
7 O 0 0.00045312263
, O 0 0.00089247397
705 O 0 0.05454938
postmenopausal O 0 0.9111766
women O 0 0.025848258
with O 0 0.0060523013
osteoporosis B-Disease 0 0.9999149
. O 0 0.010522848

Women O 0 0.008524975
were O 0 0.00255074
randomly O 0 0.001258133
assigned O 0 0.0011244167
to O 0 0.0012167501
raloxifene B-Chemical 0 0.99951863
60 O 0 0.0009902144
mg O 0 0.018710027
/ O 0 0.0015345708
d O 0 0.00079890696
or O 0 0.00063003117
120 O 0 0.00085363723
mg O 0 0.0073908865
/ O 0 0.0024127169
d O 0 0.0024016968
or O 0 0.0031117748
placebo O 0 0.036314614
. O 0 0.0075185504

Outcomes O 0 0.0059331334
included O 0 0.0038132549
venous B-Disease 0 0.91654116
thromboembolism I-Disease 0 0.999998
, O 0 0.1483784
cataracts B-Disease 2 0.99999344
, O 0 0.041098975
gallbladder B-Disease 2 0.99858
disease I-Disease 2 0.999658
, O 0 0.005261136
and O 0 0.0041837636
endometrial B-Disease 0 0.99803156
hyperplasia I-Disease 0 0.9999156
or I-Disease 0 0.021601714
cancer I-Disease 0 0.99856
. O 0 0.013721086

RESULTS O 0 0.0056266757
: O 0 0.00341449
During O 0 0.0014738952
a O 0 0.0013341549
mean O 0 0.00065975485
follow O 0 0.00064615614
- O 0 0.0016341661
up O 0 0.00044363542
of O 0 0.00046470936
3 O 0 0.00032876822
. O 0 0.00027184343
3 O 0 0.0002342821
years O 0 0.00036066512
, O 0 0.0011460934
raloxifene B-Chemical 0 0.9997937
was O 0 0.00030855037
associated O 0 0.0002464757
with O 0 0.00022815292
an O 0 0.0002514717
increased O 0 0.00030656793
risk O 0 0.065682285
for O 0 0.0005745597
venous B-Disease 0 0.9816428
thromboembolism I-Disease 0 0.99999976
( O 0 0.0022131454
relative O 0 0.000260605
risk O 0 0.29428047
[ O 0 0.059926618
RR O 0 0.9597228
] O 0 0.0022110003
2 O 0 0.00020493304
. O 0 0.00017025703
1 O 0 0.00018129894
; O 0 0.0002590592
95 O 0 0.00031157146
% O 0 0.00023966172
confidence O 0 0.00052878883
interval O 0 0.00029800928
[ O 0 0.0020024697
CI O 0 0.4863508
] O 0 0.0009193202
1 O 0 0.00040156717
. O 0 0.00044505458
2 O 0 0.000629592
- O 0 0.001632929
3 O 0 0.0010238829
. O 0 0.0015369465
8 O 0 0.0025800746
) O 0 0.005558909
. O 0 0.008056411

The O 0 0.0032582146
excess O 0 0.0029902249
event O 0 0.003959638
rate O 0 0.0015114452
was O 0 0.00105806
1 O 0 0.00068795634
. O 0 0.00045283895
8 O 0 0.00033440703
per O 0 0.00022580805
1 O 0 0.00028108593
, O 0 0.0003134407
000 O 0 0.0003237289
woman O 0 0.0013540442
- O 0 0.002279172
years O 0 0.00033962005
( O 0 0.00036718222
95 O 0 0.0005095143
% O 0 0.00042810026
CI O 0 0.5152292
- O 0 0.0033363376
0 O 0 0.0002574879
. O 0 0.00018741445
5 O 0 0.00018850261
- O 0 0.00078803714
4 O 0 0.0001769819
. O 0 0.00018113479
1 O 0 0.00020653586
) O 0 0.0003647745
, O 0 0.00027870986
and O 0 0.00021006766
the O 0 0.0001575531
number O 0 0.00014204992
needed O 0 0.000114632596
to O 0 0.00012831333
treat O 0 0.00018748878
to O 0 0.0001429805
cause O 0 0.00025059353
1 O 0 0.00020477579
event O 0 0.0006175237
was O 0 0.00021914786
170 O 0 0.0004666932
( O 0 0.00034484066
95 O 0 0.00052718783
% O 0 0.00044467594
CI O 0 0.26375532
100 O 0 0.0007911062
- O 0 0.0028362467
582 O 0 0.009829968
) O 0 0.00076021807
over O 0 0.00052738265
3 O 0 0.0008516654
. O 0 0.0012682321
3 O 0 0.0020174792
years O 0 0.0041685714
. O 0 0.0071526086

Risk O 0 0.012691344
in O 0 0.0031793374
the O 0 0.0034511217
raloxifene B-Chemical 0 0.9998368
group O 0 0.0023584801
was O 0 0.00080208626
higher O 0 0.0004979722
than O 0 0.00028403907
in O 0 0.00029259518
the O 0 0.00030256234
placebo O 0 0.0070703467
group O 0 0.00025802513
for O 0 0.00016394361
the O 0 0.00015949331
first O 0 0.00014084346
2 O 0 0.00016642174
years O 0 0.0002238599
, O 0 0.0002808569
but O 0 0.00024369966
decreased O 0 0.00023289614
to O 0 0.00017083304
about O 0 0.0001822611
the O 0 0.0002085549
same O 0 0.00018979976
rate O 0 0.00032707377
as O 0 0.00039607647
in O 0 0.0005743815
the O 0 0.0009078943
placebo O 0 0.009252435
group O 0 0.0022834546
thereafter O 0 0.0034388243
. O 0 0.0059494446

Raloxifene B-Chemical 1 0.99990153
did O 0 0.0037799932
not O 0 0.0016303858
increase O 0 0.0012119643
risk O 0 0.09529477
for O 0 0.0029989474
cataracts B-Disease 2 0.9999962
( O 0 0.030222666
RR O 0 0.92954993
0 O 0 0.0005096056
. O 0 0.00026286588
9 O 0 0.00023943516
; O 0 0.00032014656
95 O 0 0.00040359772
% O 0 0.00034439255
CI O 0 0.13302232
0 O 0 0.00026128997
. O 0 0.00019770896
8 O 0 0.00021744054
- O 0 0.0007809682
1 O 0 0.00020631561
. O 0 0.00018749059
1 O 0 0.00021156721
) O 0 0.00042258968
, O 0 0.0006170477
gallbladder B-Disease 2 0.99263155
disease I-Disease 2 0.9996755
( O 0 0.012099587
RR O 0 0.8925434
1 O 0 0.00023511385
. O 0 0.00016805479
0 O 0 0.00020161203
; O 0 0.00026748306
95 O 0 0.00035538353
% O 0 0.00029913144
CI O 0 0.14639673
0 O 0 0.00023171051
. O 0 0.0001742683
7 O 0 0.00018183337
- O 0 0.0007656184
1 O 0 0.00019127293
. O 0 0.00017122342
3 O 0 0.00017452486
) O 0 0.00041359218
, O 0 0.00086001924
endometrial B-Disease 0 0.9972372
hyperplasia I-Disease 0 0.99997807
( O 0 0.027158557
RR O 0 0.9312681
1 O 0 0.00025318243
. O 0 0.00017157431
3 O 0 0.00015750385
; O 0 0.00025035572
95 O 0 0.00034529544
% O 0 0.00030036454
CI O 0 0.15695044
0 O 0 0.00023691723
. O 0 0.00017616265
4 O 0 0.0001801547
- O 0 0.0006300113
5 O 0 0.00016128337
. O 0 0.0001708156
1 O 0 0.00019348382
) O 0 0.0003582798
, O 0 0.00037023105
or O 0 0.00068596186
endometrial B-Disease 2 0.9999652
cancer I-Disease 2 0.9999937
( O 0 0.036508355
RR O 0 0.93692905
0 O 0 0.00036662133
. O 0 0.00020821158
9 O 0 0.00021546443
; O 0 0.0003267658
95 O 0 0.00045447142
% O 0 0.00043967922
CI O 0 0.103120014
0 O 0 0.00044786217
. O 0 0.00044846925
3 O 0 0.0005901038
- O 0 0.0016070518
2 O 0 0.0011072925
. O 0 0.001559478
7 O 0 0.0025057388
) O 0 0.005678622
. O 0 0.008206883

CONCLUSION O 0 0.15083854
: O 0 0.033941697
Raloxifene B-Chemical 1 0.9999386
was O 0 0.0020019647
associated O 0 0.0011293117
with O 0 0.00080216164
an O 0 0.00072328217
increased O 0 0.00069856714
risk O 0 0.09239132
for O 0 0.0010291664
venous B-Disease 0 0.9909237
thromboembolism I-Disease 0 0.99999976
, O 0 0.00428452
but O 0 0.00037426897
there O 0 0.00015238758
was O 0 0.0001891995
no O 0 0.00014835573
increased O 0 0.00033416323
risk O 0 0.12917739
for O 0 0.0020527118
cataracts B-Disease 2 0.9999982
, O 0 0.039547935
gallbladder B-Disease 2 0.9994259
disease I-Disease 2 0.99991584
, O 0 0.063318476
endometrial B-Disease 0 0.999479
hyperplasia I-Disease 0 0.99996984
, O 0 0.018589681
or O 0 0.007403673
endometrial B-Disease 2 0.9998958
cancer I-Disease 2 0.9999306
. O 0 0.018163772

LEVEL O 0 0.091374226
OF O 0 0.0702554
EVIDENCE O 0 0.094671406
: O 0 0.07323547
I O 0 0.11508829

Optimization O 0 0.035303
of O 0 0.039448228
levodopa B-Chemical 0 0.9998543
therapy O 0 0.10119275
. O 0 0.038787756

While O 0 0.0034611763
there O 0 0.0019101122
is O 0 0.0015375981
no O 0 0.0008848482
single O 0 0.0007599616
correct O 0 0.00059052603
starting O 0 0.00042167318
dose O 0 0.0037334845
for O 0 0.0014313475
levodopa B-Chemical 0 0.99999726
therapy O 0 0.003284172
, O 0 0.00042818845
many O 0 0.00019285794
individuals O 0 0.00034125955
can O 0 0.0001379679
be O 0 0.0001466392
started O 0 0.00013768167
on O 0 9.6458454e-05
either O 0 0.00013098646
the O 0 0.00015287951
25 O 0 0.00023071538
/ O 0 0.0007753863
100 O 0 0.00027408518
or O 0 0.00015096331
controlled O 0 0.00019120019
- O 0 0.0068666814
release O 0 0.0019517981
formula O 0 0.006727047
, O 0 0.00035191703
following O 0 0.00013890621
the O 0 0.00014841415
general O 0 0.00014562173
rule O 0 0.00020267116
not O 0 0.00012403005
to O 0 0.00011770307
attempt O 0 0.00016112367
to O 0 0.00017145884
titrate O 0 0.0065337834
carbidopa B-Chemical 0 0.99999976
- O 0 0.6435632
levodopa B-Chemical 0 0.99999154
to O 0 0.0001601118
the O 0 0.00016204904
point O 0 0.00016782594
of O 0 0.00032493545
" O 0 0.00060455845
normality O 0 0.006778693
, O 0 0.0007945172
" O 0 0.0008317948
which O 0 0.00084126234
can O 0 0.00093300926
lead O 0 0.009520786
to O 0 0.0030578368
toxicity B-Disease 2 0.9969259
. O 0 0.008476693

The O 0 0.003322873
physician O 0 0.0031952718
should O 0 0.0011151583
also O 0 0.0008646024
determine O 0 0.00041443796
the O 0 0.00048434697
proper O 0 0.00042593447
use O 0 0.00039726897
of O 0 0.00042418527
any O 0 0.00033649374
adjunctive O 0 0.007362884
medications O 0 0.03299424
; O 0 0.00044566212
such O 0 0.00023335891
combined O 0 0.0004048055
therapy O 0 0.000600125
has O 0 0.00034172446
become O 0 0.00050203106
the O 0 0.00051192497
standard O 0 0.0006722346
approach O 0 0.0011781893
to O 0 0.0017085163
treatment O 0 0.0037656536
. O 0 0.0063573653

Following O 0 0.003341557
the O 0 0.002016782
initial O 0 0.0012720984
period O 0 0.00093987933
of O 0 0.0010167331
therapy O 0 0.001534728
, O 0 0.00078854617
emerging O 0 0.0005600226
difficulties O 0 0.00067523925
require O 0 0.00023403227
a O 0 0.0003346076
reassessment O 0 0.00059334864
of O 0 0.00029921698
therapeutic O 0 0.0006835183
approaches O 0 0.0003253263
, O 0 0.00035005723
such O 0 0.00021804715
as O 0 0.0002672274
dosage O 0 0.012024298
adjustment O 0 0.0005161338
or O 0 0.000407976
introduction O 0 0.00061139825
of O 0 0.0014240395
a O 0 0.009634257
dopamine B-Chemical 1 0.9998765
agonist O 0 0.90250045
. O 0 0.0074739815

Other O 0 0.0060243816
possible O 0 0.0029723365
adverse O 0 0.36771682
effects O 0 0.007098142
- O 0 0.08426792
- O 0 0.008161493
such O 0 0.00060059986
as O 0 0.0009226332
gastrointestinal B-Disease 0 0.9994691
disorders I-Disease 0 0.99987733
, O 0 0.15059462
orthostatic B-Disease 2 0.9999993
hypotension I-Disease 2 1.0
, O 0 0.24181193
levodopa B-Chemical 0 0.9999995
- O 0 0.10346739
induced O 0 0.0015213521
psychosis B-Disease 0 0.9999925
, O 0 0.0035486084
sleep B-Disease 0 0.88726556
disturbances I-Disease 0 0.9215563
or O 0 0.00046553247
parasomnias B-Disease 0 0.99593484
, O 0 0.00043485433
or O 0 0.00028572435
drug O 0 0.19946
interactions O 0 0.002783229
- O 0 0.03660373
- O 0 0.0023545597
also O 0 0.0003818401
require O 0 0.00039753434
carefully O 0 0.00051787193
monitored O 0 0.000825217
individual O 0 0.0016569013
treatment O 0 0.003586677
. O 0 0.0062908386

Nonpharmacologic O 0 0.00822362
concerns O 0 0.0026928023
can O 0 0.0014309091
help O 0 0.001248833
the O 0 0.0013307736
Parkinson B-Disease 0 0.9989473
' I-Disease 0 0.0013397058
s I-Disease 0 0.0009652343
disease I-Disease 0 0.41390765
patient O 0 0.0003494341
achieve O 0 0.00018590198
and O 0 0.00020775151
maintain O 0 0.00013905542
optimal O 0 0.00014098213
functioning O 0 0.0005562309
, O 0 0.00029243092
including O 0 0.00020849687
daily O 0 0.0003338286
exercise O 0 0.0010992514
, O 0 0.00041598576
physical O 0 0.0012130719
therapy O 0 0.00072635734
, O 0 0.0005845363
and O 0 0.000620958
involvement O 0 0.0010467027
with O 0 0.0012212598
support O 0 0.0017444761
groups O 0 0.0034080225
. O 0 0.0061580734

Long O 0 0.010642505
term O 0 0.005069451
audiological O 0 0.0071275104
evaluation O 0 0.004301866
of O 0 0.00629165
beta B-Disease 0 0.99329317
- I-Disease 0 0.59354544
thalassemic I-Disease 0 0.99969816
patients O 0 0.042218648
. O 0 0.01479996

OBJECTIVE O 0 0.020270873
: O 0 0.0035291552
The O 0 0.0015158643
objective O 0 0.0015297411
of O 0 0.0010395359
this O 0 0.0007264698
study O 0 0.0006735794
was O 0 0.00039643707
to O 0 0.00025892362
identify O 0 0.00020971804
the O 0 0.00022362542
incidence O 0 0.0006389027
and O 0 0.00024267273
to O 0 0.00016137183
monitor O 0 0.00014896016
the O 0 0.00018689407
progression O 0 0.033041365
of O 0 0.0006042891
hearing B-Disease 0 0.9560565
loss I-Disease 0 0.0011059222
in O 0 0.00026496037
children O 0 0.0005879497
and O 0 0.00041986152
young O 0 0.003422634
adults O 0 0.0022461975
with O 0 0.0016637349
beta B-Disease 0 0.99637824
- I-Disease 0 0.82335246
thalassemia I-Disease 0 0.9999968
major O 0 0.016808083
. O 0 0.008548323

METHODS O 0 0.004195826
: O 0 0.0036831186
One O 0 0.0022746744
hundred O 0 0.0015537493
and O 0 0.0012127437
four O 0 0.0007822132
( O 0 0.0009876782
104 O 0 0.0009371646
) O 0 0.00089489477
patients O 0 0.00059695943
aged O 0 0.0006197338
6 O 0 0.00033759605
- O 0 0.00079390424
35 O 0 0.0003145408
years O 0 0.0003385796
( O 0 0.0003710296
mean O 0 0.0002412827
17 O 0 0.00044015056
, O 0 0.0005104394
2 O 0 0.0004930309
years O 0 0.0007476734
) O 0 0.001246299
participated O 0 0.0018135856
in O 0 0.0016302079
the O 0 0.0025502327
study O 0 0.0050157597
. O 0 0.0073620263

All O 0 0.0033979767
patients O 0 0.0027553677
were O 0 0.0015979488
on O 0 0.00093841733
a O 0 0.001135682
regular O 0 0.0011370081
transfusion O 0 0.17023614
- O 0 0.03190282
chelation O 0 0.59002393
program O 0 0.00046975122
maintaining O 0 0.00038509927
a O 0 0.00034950406
mean O 0 0.00023718165
hemoglobin O 0 0.4158106
level O 0 0.00033557173
of O 0 0.0005476635
9 O 0 0.0005985543
. O 0 0.0007204379
5 O 0 0.0010638909
gr O 0 0.0039372114
/ O 0 0.00624254
dl O 0 0.10627049
. O 0 0.008488811

Subjects O 0 0.0049529206
were O 0 0.002746287
receiving O 0 0.006767029
desferrioxamine B-Chemical 1 0.9999956
( O 0 0.37105104
DFO B-Chemical 1 0.99999905
) O 0 0.07094401
chelation O 0 0.9144039
treatment O 0 0.00052872853
with O 0 0.00027779993
a O 0 0.00021891897
mean O 0 0.00011535466
daily O 0 0.00018180982
dose O 0 0.00038173964
of O 0 0.00025057636
50 O 0 0.0003997116
- O 0 0.0022773535
60 O 0 0.00019323695
mg O 0 0.004979623
/ O 0 0.00084156863
kg O 0 0.00064792135
, O 0 0.0002940581
5 O 0 0.00017054885
- O 0 0.00055758556
6 O 0 0.00011924715
days O 0 0.00010427217
a O 0 0.00014915943
week O 0 0.00010347097
during O 0 9.614512e-05
the O 0 0.0001213618
first O 0 0.00010410249
six O 0 9.657544e-05
years O 0 0.00014736952
of O 0 0.00016588923
the O 0 0.00017476933
study O 0 0.00030967966
, O 0 0.00030778942
which O 0 0.00023814992
was O 0 0.00016371207
then O 0 0.00013911219
reduced O 0 0.00016635002
to O 0 0.00016921911
40 O 0 0.000262996
- O 0 0.0013922574
50 O 0 0.00035761573
mg O 0 0.0065536206
/ O 0 0.0009892045
kg O 0 0.000819123
for O 0 0.00054583873
the O 0 0.0007590854
following O 0 0.0010363888
eight O 0 0.0016819607
years O 0 0.0036515067
. O 0 0.0062349536

Patients O 0 0.008714177
were O 0 0.0055313963
followed O 0 0.0044779396
for O 0 0.005163575
8 O 0 0.0061204517
- O 0 0.010539588
14 O 0 0.008312826
years O 0 0.012232141
. O 0 0.0171952

RESULTS O 0 0.0058318605
: O 0 0.0040471316
Overall O 0 0.0029246912
, O 0 0.0019592685
21 O 0 0.0011515509
out O 0 0.0006311713
of O 0 0.00067674706
104 O 0 0.0008099979
patients O 0 0.00069814216
( O 0 0.00060355634
20 O 0 0.0003402348
. O 0 0.00027444918
2 O 0 0.00025751983
% O 0 0.00030063582
) O 0 0.00034336562
presented O 0 0.00019250005
with O 0 0.00022674419
high O 0 0.00041119216
frequency O 0 0.0014398195
sensorineural B-Disease 2 0.9999908
hearing I-Disease 2 0.9988219
loss I-Disease 2 0.34825623
( O 0 0.16020167
SNHL B-Disease 0 0.9999994
) O 0 0.010482536
, O 0 0.0013173411
either O 0 0.0011474611
unilateral O 0 0.13032185
or O 0 0.0027264939
bilateral O 0 0.13521132
. O 0 0.0069819577

No O 0 0.018270185
ototoxic B-Disease 0 0.9993338
factor O 0 0.14337623
, O 0 0.0041901497
other O 0 0.002265627
than O 0 0.0018987437
DFO B-Chemical 1 0.9999926
, O 0 0.0020781513
was O 0 0.00088158133
present O 0 0.0006798214
in O 0 0.00093906926
any O 0 0.0011541245
of O 0 0.0019585271
the O 0 0.0028004078
patients O 0 0.006247665
. O 0 0.0076490333

Patients O 0 0.005831105
with O 0 0.005751138
SNHL B-Disease 0 0.999977
presented O 0 0.0012868103
with O 0 0.00085639826
relatively O 0 0.0008826194
lower O 0 0.0006918029
serum O 0 0.49260536
ferritin O 0 0.99826306
levels O 0 0.00044338155
than O 0 0.00020500239
those O 0 0.00027456984
with O 0 0.0002755761
normal O 0 0.0010377166
hearing O 0 0.94754475
, O 0 0.00075943687
however O 0 0.000552708
, O 0 0.00052270317
no O 0 0.00036700198
statistically O 0 0.00054940145
significant O 0 0.0008271431
difference O 0 0.001053877
was O 0 0.0021269924
observed O 0 0.0033393344
. O 0 0.006867364

Subjects O 0 0.008556555
with O 0 0.008189706
SNHL B-Disease 0 0.9999573
were O 0 0.003125211
submitted O 0 0.0026053998
to O 0 0.0028988805
DFO B-Chemical 1 0.99996316
reduction O 0 0.006556303
or O 0 0.004020419
temporary O 0 0.055871364
withdrawal O 0 0.6164073
. O 0 0.010729968

Following O 0 0.0040449165
intervention O 0 0.0030577483
, O 0 0.0023599346
7 O 0 0.001202836
out O 0 0.0007990535
of O 0 0.0008889824
21 O 0 0.0007981692
affected O 0 0.00057918736
patients O 0 0.00063029176
recovered O 0 0.00044110886
, O 0 0.0006577135
10 O 0 0.00051173667
remained O 0 0.00067677384
stable O 0 0.0008959843
and O 0 0.0011555948
4 O 0 0.0014454933
demonstrated O 0 0.0023779063
aggravation O 0 0.6500495
. O 0 0.008395335

CONCLUSION O 0 0.01829112
: O 0 0.0039047657
The O 0 0.0016894065
findings O 0 0.0015546955
are O 0 0.0010530389
indicative O 0 0.0009501427
of O 0 0.0030421934
DFO B-Chemical 1 0.9999951
' O 0 0.0019232185
s O 0 0.0007826638
contributing O 0 0.000612011
role O 0 0.00044469352
in O 0 0.00064929493
the O 0 0.00083034247
development O 0 0.0019853325
of O 0 0.0035322488
hearing B-Disease 0 0.9887184
impairment I-Disease 0 0.8504717
. O 0 0.008806672

Regular O 0 0.0088280365
audiologic O 0 0.010949595
evaluation O 0 0.001745983
is O 0 0.0012277254
imperative O 0 0.0009973086
in O 0 0.00071204075
all O 0 0.0006808729
thalassemic B-Disease 0 0.9957633
patients O 0 0.0008415738
so O 0 0.00028118567
that O 0 0.00020488809
early O 0 0.00043735508
changes O 0 0.00040692848
may O 0 0.00019287707
be O 0 0.0001956665
recognized O 0 0.00026173476
and O 0 0.0002867283
treatment O 0 0.00029728454
may O 0 0.0001841473
be O 0 0.00019800894
judiciously O 0 0.00027267978
adjusted O 0 0.0002464252
in O 0 0.0002483885
order O 0 0.00024914462
to O 0 0.0003562229
prevent O 0 0.0005528437
or O 0 0.001027637
reverse O 0 0.056027792
hearing B-Disease 0 0.99077356
impairment I-Disease 0 0.85308504
. O 0 0.007921437

Individual O 0 0.0042355014
differences O 0 0.0022433281
in O 0 0.0023521797
renal O 0 0.97311157
ACE O 0 0.9993099
activity O 0 0.0012707381
in O 0 0.0007459867
healthy O 0 0.0024731911
rats O 0 0.00063322706
predict O 0 0.00039538293
susceptibility O 0 0.0017098399
to O 0 0.0010580735
adriamycin B-Chemical 0 0.999959
- O 0 0.18718861
induced O 0 0.008938462
renal B-Disease 0 0.99969184
damage I-Disease 0 0.99884355
. O 0 0.012235615

BACKGROUND O 0 0.021472357
: O 0 0.00446869
In O 0 0.0022076576
man O 0 0.03281843
, O 0 0.001807856
differences O 0 0.00078307494
in O 0 0.0017112656
angiotensin B-Chemical 1 0.99999225
- O 0 0.3861301
converting O 0 0.07909887
enzyme O 0 0.31679082
( O 0 0.019395031
ACE O 0 0.99951696
) O 0 0.0011041487
levels O 0 0.0002659976
, O 0 0.00032540975
related O 0 0.0001662127
to O 0 0.00030036396
ACE O 0 0.99881446
( O 0 0.0017968178
I O 0 0.06312262
/ O 0 0.038426634
D O 0 0.99330693
) O 0 0.00619629
genotype O 0 0.022291826
, O 0 0.00083928555
are O 0 0.00063545915
associated O 0 0.001009046
with O 0 0.0020040933
renal O 0 0.9211971
prognosis O 0 0.92870843
. O 0 0.008028237

This O 0 0.004528916
raises O 0 0.0016876976
the O 0 0.0014469553
hypothesis O 0 0.0010871337
that O 0 0.00071871234
individual O 0 0.0006104821
differences O 0 0.00047518822
in O 0 0.0007056087
renal O 0 0.9829233
ACE O 0 0.999366
activity O 0 0.0005536566
are O 0 0.00039680742
involved O 0 0.00039403545
in O 0 0.0006680723
renal O 0 0.5618799
susceptibility O 0 0.0071177543
to O 0 0.0021494646
inflicted O 0 0.8539533
damage O 0 0.93811023
. O 0 0.009591072

Therefore O 0 0.0036497235
, O 0 0.0029724722
we O 0 0.001285008
studied O 0 0.001144506
the O 0 0.0008034965
predictive O 0 0.0015793211
effect O 0 0.00062937516
of O 0 0.0017186775
renal O 0 0.9968857
ACE O 0 0.9997844
activity O 0 0.0004559
for O 0 0.00023722487
the O 0 0.00023500762
severity O 0 0.0029507957
of O 0 0.0010720688
renal B-Disease 0 0.9994112
damage I-Disease 0 0.9956505
induced O 0 0.00056185265
by O 0 0.00042720707
a O 0 0.0004931869
single O 0 0.0005041072
injection O 0 0.0010671054
of O 0 0.0019084548
adriamycin B-Chemical 0 0.9997619
in O 0 0.0031382276
rats O 0 0.006117679
. O 0 0.0063037463

METHODS O 0 0.0043108854
: O 0 0.004832762
Renal O 0 0.17671381
ACE O 0 0.99233305
activity O 0 0.0020358902
( O 0 0.0027248492
Hip B-Chemical 0 0.3727841
- I-Chemical 0 0.04071659
His I-Chemical 0 0.020813655
- I-Chemical 0 0.07370753
Leu I-Chemical 0 0.9936062
cleavage O 0 0.0032654789
by O 0 0.0005433808
cortical O 0 0.019274222
homogenates O 0 0.008955441
) O 0 0.0007283192
was O 0 0.0002994564
determined O 0 0.00026245596
by O 0 0.00043632853
renal O 0 0.39282727
biopsy O 0 0.0017302023
in O 0 0.0007261462
27 O 0 0.0012766868
adult O 0 0.0018032402
male O 0 0.0060289027
Wistar O 0 0.016974963
rats O 0 0.0051889988
. O 0 0.0068848757

After O 0 0.0028020649
1 O 0 0.0022434082
week O 0 0.001293089
of O 0 0.0012944839
recovery O 0 0.0019067607
, O 0 0.0039848923
proteinuria B-Disease 0 0.99999523
was O 0 0.00073192944
induced O 0 0.0005106194
by O 0 0.0011379827
adriamycin B-Chemical 0 0.9999769
[ O 0 0.045123477
1 O 0 0.00029332444
. O 0 0.00018538865
5 O 0 0.00016404901
mg O 0 0.0023018771
/ O 0 0.0006107352
kg O 0 0.00047006228
intravenously O 0 0.00027756588
( O 0 0.00033750318
i O 0 0.0011361409
. O 0 0.00022397729
v O 0 0.007289871
. O 0 0.00024586124
) O 0 0.0004044073
n O 0 0.00022671068
= O 0 0.00047686213
18 O 0 0.0002623509
; O 0 0.00036140683
controls O 0 0.00040166112
, O 0 0.00047535406
saline O 0 0.004372374
i O 0 0.0012793653
. O 0 0.0004943379
v O 0 0.0029840216
. O 0 0.00082305225
n O 0 0.0011793942
= O 0 0.002644745
9 O 0 0.0028851493
] O 0 0.006038197
. O 0 0.007915787

Proteinuria B-Disease 2 0.99967694
was O 0 0.011140299
measured O 0 0.00815359
every O 0 0.007029899
2 O 0 0.010686192
weeks O 0 0.012227652
. O 0 0.021079743

After O 0 0.004032332
12 O 0 0.0032334358
weeks O 0 0.002444976
, O 0 0.003122152
rats O 0 0.002735291
were O 0 0.0020459022
sacrificed O 0 0.0020227241
and O 0 0.00264568
their O 0 0.0034965149
kidneys O 0 0.008637524
harvested O 0 0.0057484475
. O 0 0.010783717

RESULTS O 0 0.005848463
: O 0 0.0037755352
As O 0 0.0018136346
anticipated O 0 0.0017059776
, O 0 0.0030990646
adriamycin B-Chemical 0 0.9998418
elicited O 0 0.01939121
nephrotic B-Disease 0 0.99999905
range O 0 0.05266007
proteinuria B-Disease 0 0.99999917
, O 0 0.014307094
renal B-Disease 0 0.9945011
interstitial I-Disease 0 0.7973366
damage I-Disease 0 0.9844657
and O 0 0.006128317
mild O 0 0.96668607
focal B-Disease 0 0.9970094
glomerulosclerosis I-Disease 2 0.9999995
. O 0 0.03307716

Baseline O 0 0.009633821
renal O 0 0.9631646
ACE O 0 0.9980848
positively O 0 0.0013791833
correlated O 0 0.00062513904
with O 0 0.00051082514
the O 0 0.00035956677
relative O 0 0.00028381895
rise O 0 0.00041644362
in O 0 0.0005308062
proteinuria B-Disease 0 0.999997
after O 0 0.00034183118
adriamycin B-Chemical 0 0.9999211
( O 0 0.001103055
r O 0 0.00041260413
= O 0 0.00057134504
0 O 0 0.00024390192
. O 0 0.00017831942
62 O 0 0.00032679638
, O 0 0.00033767568
P O 0 0.017119424
< O 0 0.0002071342
0 O 0 0.00025694838
. O 0 0.00022109212
01 O 0 0.0010563345
) O 0 0.00042582914
, O 0 0.00041400263
renal O 0 0.7577418
interstitial O 0 0.60978276
alpha O 0 0.9508801
- O 0 0.07553906
smooth O 0 0.015393703
muscle O 0 0.019994454
actin O 0 0.033912364
( O 0 0.00057878287
r O 0 0.00033454993
= O 0 0.00049396575
0 O 0 0.00023621846
. O 0 0.0001793343
49 O 0 0.00031411796
, O 0 0.0003459444
P O 0 0.019474449
< O 0 0.00021407667
0 O 0 0.00026883298
. O 0 0.0002342325
05 O 0 0.0039835447
) O 0 0.00043818925
, O 0 0.00034831307
interstitial O 0 0.040445603
macrophage O 0 0.05694406
influx O 0 0.16469258
( O 0 0.00061374257
r O 0 0.00034012538
= O 0 0.0005137048
0 O 0 0.00023379494
. O 0 0.00017313818
56 O 0 0.00025949898
, O 0 0.0003362548
P O 0 0.018887272
< O 0 0.00021477771
0 O 0 0.0002701001
. O 0 0.00023690614
05 O 0 0.0036901168
) O 0 0.00044969723
, O 0 0.00039205674
interstitial O 0 0.14637578
collagen O 0 0.7164213
III O 0 0.119459055
( O 0 0.00042292656
r O 0 0.00030978097
= O 0 0.0004895999
0 O 0 0.0002468798
. O 0 0.00018792333
53 O 0 0.0003442191
, O 0 0.0003668965
P O 0 0.020358233
< O 0 0.00022139397
0 O 0 0.0002747733
. O 0 0.00023990612
05 O 0 0.0037322964
) O 0 0.00048410994
, O 0 0.00049144984
glomerular O 0 0.9278742
alpha O 0 0.91737527
- O 0 0.050490644
smooth O 0 0.011524411
muscle O 0 0.016394341
actin O 0 0.029690104
( O 0 0.00057079527
r O 0 0.0003389941
= O 0 0.0004943365
0 O 0 0.0002387235
. O 0 0.0001808235
74 O 0 0.00031927545
, O 0 0.00033984272
P O 0 0.015184762
< O 0 0.00021399971
0 O 0 0.0002576908
. O 0 0.0002207627
01 O 0 0.0006874914
) O 0 0.0003276243
and O 0 0.00029730098
glomerular O 0 0.7759187
desmin O 0 0.631116
( O 0 0.0006740784
r O 0 0.00042538307
= O 0 0.000617083
0 O 0 0.0003759045
. O 0 0.00035529866
48 O 0 0.00050642475
, O 0 0.00073262164
P O 0 0.007320841
< O 0 0.0010209355
0 O 0 0.0016418159
. O 0 0.0023577115
05 O 0 0.011328858
) O 0 0.0067771384
. O 0 0.008778238

Baseline O 0 0.010950814
renal O 0 0.971582
ACE O 0 0.9988519
did O 0 0.001834377
not O 0 0.00087513856
correlate O 0 0.0006978379
with O 0 0.0009623785
focal B-Disease 0 0.9706608
glomerulosclerosis I-Disease 2 0.9999999
( O 0 0.010449218
r O 0 0.0010324199
= O 0 0.0012362911
0 O 0 0.0008878362
. O 0 0.0010103004
22 O 0 0.0018497513
, O 0 0.0031733913
NS O 0 0.7715084
) O 0 0.008138747
. O 0 0.00909865

In O 0 0.0051870397
controls O 0 0.004280986
, O 0 0.0034066022
no O 0 0.0019056214
predictive O 0 0.0029011858
values O 0 0.0019427459
for O 0 0.0022839773
renal O 0 0.47277898
parameters O 0 0.003723063
were O 0 0.003939226
observed O 0 0.0051833214
. O 0 0.0096213315

CONCLUSION O 0 0.019374842
: O 0 0.0037553604
Individual O 0 0.0020849102
differences O 0 0.0011522135
in O 0 0.0013077336
renal O 0 0.9689792
ACE O 0 0.9989209
activity O 0 0.0005732498
predict O 0 0.0002960435
the O 0 0.00031594586
severity O 0 0.0026799822
of O 0 0.0020235921
adriamycin B-Chemical 0 0.9999881
- O 0 0.22813644
induced O 0 0.0030350378
renal B-Disease 0 0.9997516
damage I-Disease 0 0.9972498
in O 0 0.0011310342
this O 0 0.0011957256
outbred O 0 0.0036282698
rat O 0 0.003665885
strain O 0 0.0037428648
. O 0 0.0070378724

This O 0 0.004883306
supports O 0 0.0021328623
the O 0 0.0015267702
assumption O 0 0.0012354671
that O 0 0.00079346186
differences O 0 0.0006390675
in O 0 0.00091539393
renal O 0 0.9872874
ACE O 0 0.99950457
activity O 0 0.0006607175
predispose O 0 0.00084945885
to O 0 0.00039062285
a O 0 0.0005641728
less O 0 0.0005538463
favourable O 0 0.0015568594
course O 0 0.0011083648
of O 0 0.0034389093
renal B-Disease 0 0.99916875
damage I-Disease 0 0.9979843
. O 0 0.0108395945

Recurrent O 0 0.17709292
acute O 0 0.97806853
interstitial B-Disease 0 0.99899477
nephritis I-Disease 0 0.9999988
induced O 0 0.07387733
by O 0 0.027290689
azithromycin B-Chemical 0 0.99982494
. O 0 0.022856878

A O 0 0.06329576
14 O 0 0.0039979974
- O 0 0.0061096014
year O 0 0.0021092482
- O 0 0.003926781
old O 0 0.0012068914
girl O 0 0.0017862481
is O 0 0.0007228436
reported O 0 0.0006813619
with O 0 0.00071050384
recurrent O 0 0.2752456
, O 0 0.013593073
azithromycin B-Chemical 0 0.99998164
- O 0 0.16414897
induced O 0 0.0018374257
, O 0 0.009251967
acute O 0 0.99356705
interstitial B-Disease 0 0.99960285
nephritis I-Disease 0 0.9999995
. O 0 0.03346241

The O 0 0.003082011
second O 0 0.0021968307
episode O 0 0.0030277946
was O 0 0.0012917349
more O 0 0.0010512943
severe O 0 0.013460307
than O 0 0.00034416528
the O 0 0.0003150555
first O 0 0.0002563034
; O 0 0.0004995913
and O 0 0.00030182968
although O 0 0.00023820784
both O 0 0.00021618507
were O 0 0.00021102684
treated O 0 0.00025100916
with O 0 0.00031373007
intensive O 0 0.00050135655
corticosteroid O 0 0.99928576
therapy O 0 0.0042081843
, O 0 0.0015517356
renal O 0 0.6801865
function O 0 0.0015798323
remained O 0 0.0033589366
impaired O 0 0.005635444
. O 0 0.006783935

Although O 0 0.003312756
most O 0 0.0026808798
cases O 0 0.0021204322
of O 0 0.0016669583
antibiotic O 0 0.09998531
induced O 0 0.0022887418
acute O 0 0.9952592
interstitial B-Disease 0 0.9998746
nephritis I-Disease 0 1.0
are O 0 0.0028490624
benign O 0 0.420466
and O 0 0.0005481887
self O 0 0.005409124
- O 0 0.0059761475
limited O 0 0.00026827864
, O 0 0.00038979412
some O 0 0.0002874372
patients O 0 0.00041516693
are O 0 0.00034763038
at O 0 0.00044420184
risk O 0 0.012652066
for O 0 0.00131922
permanent O 0 0.28781697
renal B-Disease 2 0.99949884
injury I-Disease 2 0.9992048
. O 0 0.010274525

Spironolactone B-Chemical 0 0.99996316
- O 0 0.10705877
induced O 0 0.0052586314
renal B-Disease 0 0.99230546
insufficiency I-Disease 0 0.99974257
and O 0 0.046160568
hyperkalemia B-Disease 2 0.99999607
in O 0 0.002210056
patients O 0 0.0030643488
with O 0 0.0031598662
heart B-Disease 0 0.34959194
failure I-Disease 0 0.58400685
. O 0 0.009350805

BACKGROUND O 0 0.022694167
: O 0 0.004785635
A O 0 0.010378435
previous O 0 0.0013025511
randomized O 0 0.0009938433
controlled O 0 0.00060505985
trial O 0 0.0005572312
evaluating O 0 0.0002821976
the O 0 0.00031777797
use O 0 0.00036280995
of O 0 0.0016050984
spironolactone B-Chemical 1 0.9999974
in O 0 0.00085218245
heart B-Disease 0 0.39345646
failure I-Disease 0 0.25644827
patients O 0 0.00059400353
reported O 0 0.00026916177
a O 0 0.00024619765
low O 0 0.00039855315
risk O 0 0.08302312
of O 0 0.0064585675
hyperkalemia B-Disease 2 0.99999917
( O 0 0.003494087
2 O 0 0.00030146155
% O 0 0.00038813328
) O 0 0.00061116903
and O 0 0.0006847881
renal B-Disease 0 0.9404907
insufficiency I-Disease 0 0.99762315
( O 0 0.0025157603
0 O 0 0.0018166187
% O 0 0.002952287
) O 0 0.00546819
. O 0 0.0072971843

Because O 0 0.003273407
treatments O 0 0.0031270387
for O 0 0.002118759
heart B-Disease 0 0.28117743
failure I-Disease 0 0.27143475
have O 0 0.00062585826
changed O 0 0.00051184057
since O 0 0.00029168688
the O 0 0.0002864717
benefits O 0 0.000306736
of O 0 0.001375881
spironolactone B-Chemical 1 0.9999969
were O 0 0.0004322942
reported O 0 0.00036495583
, O 0 0.00031524783
the O 0 0.00021244472
prevalence O 0 0.0005142199
of O 0 0.00036287794
these O 0 0.00047858251
complications O 0 0.12738308
may O 0 0.00046377297
differ O 0 0.00059335935
in O 0 0.00080761214
current O 0 0.0017800183
clinical O 0 0.004032826
practice O 0 0.0039425185
. O 0 0.0059702727

We O 0 0.0034629134
therefore O 0 0.0022546034
sought O 0 0.0015573871
to O 0 0.0009288489
determine O 0 0.00044525875
the O 0 0.00053247623
prevalence O 0 0.0009308995
and O 0 0.000532897
clinical O 0 0.0011248527
associations O 0 0.00039748944
of O 0 0.0015216861
hyperkalemia B-Disease 2 0.99999845
and O 0 0.0066594454
renal B-Disease 0 0.9925228
insufficiency I-Disease 0 0.9993381
in O 0 0.0010713653
heart B-Disease 0 0.40884447
failure I-Disease 0 0.328942
patients O 0 0.0020191022
treated O 0 0.0021108156
with O 0 0.009241204
spironolactone B-Chemical 1 0.99997735
. O 0 0.008579131

METHODS O 0 0.004275843
: O 0 0.0036157947
We O 0 0.0019548908
performed O 0 0.0014044397
a O 0 0.001435474
case O 0 0.0010575309
control O 0 0.0008284749
study O 0 0.00086203666
of O 0 0.00096276775
heart B-Disease 0 0.3855153
failure I-Disease 0 0.3988625
patients O 0 0.0014595774
treated O 0 0.0009374039
with O 0 0.0025175847
spironolactone B-Chemical 1 0.99998724
in O 0 0.0011584244
our O 0 0.0015079783
clinical O 0 0.004008939
practice O 0 0.004037464
. O 0 0.006115024

Cases O 0 0.010726566
were O 0 0.0028633426
patients O 0 0.0023099335
who O 0 0.0021188688
developed O 0 0.006051613
hyperkalemia B-Disease 2 0.999998
( O 0 0.109098956
K B-Chemical 1 0.99998033
( O 0 0.010865136
+ O 0 0.008537054
) O 0 0.00121424
> O 0 0.00071826205
5 O 0 0.00020746783
. O 0 0.00019992977
0 O 0 0.0002906332
mEq O 0 0.31604773
/ O 0 0.010019396
L O 0 0.94689584
) O 0 0.0013828486
or O 0 0.00041495942
renal B-Disease 0 0.9807484
insufficiency I-Disease 0 0.9998343
( O 0 0.18693879
Cr B-Chemical 0 0.99999964
> O 0 0.0052808602
or O 0 0.00027845908
= O 0 0.0006590513
2 O 0 0.00018697303
. O 0 0.00015483097
5 O 0 0.00015497484
mg O 0 0.004143886
/ O 0 0.0023743662
dL O 0 0.03839255
) O 0 0.0006377739
, O 0 0.00033967334
and O 0 0.00025810875
they O 0 0.00019819516
were O 0 0.00022490433
compared O 0 0.00019835094
to O 0 0.0002769782
2 O 0 0.0003589215
randomly O 0 0.00034013382
selected O 0 0.0006566701
controls O 0 0.0013523508
per O 0 0.001549627
case O 0 0.0037012554
. O 0 0.0064778547

Clinical O 0 0.008632952
characteristics O 0 0.0025113416
, O 0 0.0027469923
medications O 0 0.02905927
, O 0 0.0014505037
and O 0 0.0010505033
serum O 0 0.09595373
chemistries O 0 0.040709652
at O 0 0.0004302477
baseline O 0 0.0004143874
and O 0 0.00045367936
follow O 0 0.00043467584
- O 0 0.0012629915
up O 0 0.0006442493
time O 0 0.0007214747
periods O 0 0.0012415407
were O 0 0.001993847
compared O 0 0.002842207
. O 0 0.0065230457

RESULTS O 0 0.0062210714
: O 0 0.0043460946
Sixty O 0 0.004001922
- O 0 0.0036153172
seven O 0 0.0010890301
of O 0 0.0011404342
926 O 0 0.17030402
patients O 0 0.0010843545
( O 0 0.00078643824
7 O 0 0.0003718958
. O 0 0.0003218683
2 O 0 0.00029598616
% O 0 0.00034190321
) O 0 0.0003972875
required O 0 0.00019117101
discontinuation O 0 0.22970363
of O 0 0.0013398138
spironolactone B-Chemical 1 0.99999344
due O 0 0.00022300392
to O 0 0.00040500407
hyperkalemia B-Disease 2 0.9999964
( O 0 0.00084505376
n O 0 0.00027267405
= O 0 0.0006158541
33 O 0 0.00044382512
) O 0 0.00053069973
or O 0 0.00045229454
renal B-Disease 0 0.7606881
failure I-Disease 0 0.28470364
( O 0 0.0014731536
n O 0 0.0011740128
= O 0 0.002630728
34 O 0 0.0032755765
) O 0 0.005545082
. O 0 0.007579551

Patients O 0 0.005491938
who O 0 0.0040123584
developed O 0 0.0056833676
hyperkalemia B-Disease 2 0.9999858
were O 0 0.001484953
older O 0 0.0026601837
and O 0 0.00061992963
more O 0 0.00046126233
likely O 0 0.0002952914
to O 0 0.00024264751
have O 0 0.00034133246
diabetes B-Disease 0 0.99977714
, O 0 0.00089190685
had O 0 0.00022555543
higher O 0 0.00018766872
baseline O 0 0.00024717135
serum O 0 0.48116076
potassium B-Chemical 0 0.999959
levels O 0 0.00028303615
and O 0 0.0002577335
lower O 0 0.00020400425
baseline O 0 0.00038307824
potassium B-Chemical 0 0.99992
supplement O 0 0.010244268
doses O 0 0.005402891
, O 0 0.00034390306
and O 0 0.00022841865
were O 0 0.00017306689
more O 0 0.0001682836
likely O 0 0.00013081182
to O 0 0.00011549168
be O 0 0.00014881746
treated O 0 0.00023618016
with O 0 0.0005598475
beta O 0 0.984297
- O 0 0.39184725
blockers O 0 0.98562384
than O 0 0.00036191387
controls O 0 0.0007852823
( O 0 0.0009669578
n O 0 0.0010414092
= O 0 0.0025243352
134 O 0 0.0047872
) O 0 0.005392815
. O 0 0.0072592986

Patients O 0 0.005302046
who O 0 0.0036877566
developed O 0 0.0038082588
renal B-Disease 0 0.9613374
insufficiency I-Disease 0 0.99855846
had O 0 0.0010168435
lower O 0 0.0005379974
baseline O 0 0.00037236532
body O 0 0.00072049326
weight O 0 0.0009218762
and O 0 0.00032327
higher O 0 0.00022813136
baseline O 0 0.00027007484
serum O 0 0.33926576
creatinine B-Chemical 1 0.99934095
, O 0 0.00037623022
required O 0 0.00011821936
higher O 0 0.00017303554
doses O 0 0.00064680586
of O 0 0.00034202953
loop O 0 0.007507141
diuretics O 0 0.9999478
, O 0 0.0007308703
and O 0 0.0002962784
were O 0 0.00021283964
more O 0 0.00021331993
likely O 0 0.0001861709
to O 0 0.00018670883
be O 0 0.0002768866
treated O 0 0.0005369027
with O 0 0.0029861701
thiazide B-Chemical 0 0.9999982
diuretics O 0 0.99991715
than O 0 0.001809968
controls O 0 0.0047542043
. O 0 0.005953191

CONCLUSIONS O 0 0.12253858
: O 0 0.031875394
Spironolactone B-Chemical 0 0.99998
- O 0 0.14965631
induced O 0 0.005688944
hyperkalemia B-Disease 2 0.9999976
and O 0 0.012482239
renal B-Disease 0 0.99241954
insufficiency I-Disease 0 0.9990489
are O 0 0.0005933908
more O 0 0.00045989538
common O 0 0.00044467274
in O 0 0.0003831827
our O 0 0.00048653822
clinical O 0 0.0010834066
experience O 0 0.0010143329
than O 0 0.0009961056
reported O 0 0.002226087
previously O 0 0.0034447548
. O 0 0.006409112

This O 0 0.005149207
difference O 0 0.0022664042
is O 0 0.0018884114
explained O 0 0.0013483635
by O 0 0.0013112844
patient O 0 0.00130368
comorbidities O 0 0.1435294
and O 0 0.0009761672
more O 0 0.00094520027
frequent O 0 0.0014994801
use O 0 0.0010365029
of O 0 0.0021738857
beta O 0 0.97592807
- O 0 0.61052716
blockers O 0 0.9970577
. O 0 0.010500986

Acute O 0 0.9880546
reserpine B-Chemical 1 0.9999968
and O 0 0.3243209
subchronic O 0 0.99999726
haloperidol B-Chemical 1 0.9999999
treatments O 0 0.01900844
change O 0 0.0023190314
synaptosomal O 0 0.964601
brain O 0 0.35737664
glutamate B-Chemical 1 0.99984
uptake O 0 0.011488654
and O 0 0.0009872334
elicit O 0 0.0011169907
orofacial B-Disease 0 0.99982977
dyskinesia I-Disease 0 0.99999964
in O 0 0.0039223707
rats O 0 0.0061131
. O 0 0.0066177994

Reserpine B-Chemical 1 0.9999883
- O 0 0.48215735
and O 0 0.06247681
haloperidol B-Chemical 1 0.99999976
- O 0 0.42251801
induced O 0 0.010780691
orofacial B-Disease 0 0.9999567
dyskinesia I-Disease 0 1.0
are O 0 0.000585799
putative O 0 0.00033487633
animal O 0 0.00052844285
models O 0 0.00045806263
of O 0 0.021714887
tardive B-Disease 0 1.0
dyskinesia I-Disease 0 1.0
( O 0 0.22231749
TD B-Disease 0 0.9999845
) O 0 0.002517331
whose O 0 0.0005481946
pathophysiology O 0 0.006674935
has O 0 0.00023857922
been O 0 0.0002447312
related O 0 0.00021305363
to O 0 0.00031200782
free O 0 0.00065285165
radical O 0 0.20247027
generation O 0 0.0013529363
and O 0 0.002390754
oxidative O 0 0.9460916
stress O 0 0.6851724
. O 0 0.009764696

In O 0 0.0037799913
the O 0 0.0023459173
present O 0 0.0015450551
study O 0 0.0016220324
, O 0 0.0012687552
the O 0 0.0006974296
authors O 0 0.0005236512
induced O 0 0.0021149435
orofacial B-Disease 0 0.9999614
dyskinesia I-Disease 0 1.0
by O 0 0.015715357
acute O 0 0.9989409
reserpine B-Chemical 1 0.9999999
and O 0 0.2975861
subchronic O 0 0.99999857
haloperidol B-Chemical 1 0.9999999
administration O 0 0.088919245
to O 0 0.002207307
rats O 0 0.00482843
. O 0 0.005922731

Reserpine B-Chemical 1 0.99996054
injection O 0 0.016952595
( O 0 0.002939613
one O 0 0.0010803193
dose O 0 0.0017892988
of O 0 0.0008467149
1 O 0 0.0005857537
mg O 0 0.015306972
/ O 0 0.001294464
kg O 0 0.00072468416
s O 0 0.00044461913
. O 0 0.0002861248
c O 0 0.0035805353
. O 0 0.00026501468
) O 0 0.00033578966
every O 0 0.000110268906
other O 0 0.00015466732
day O 0 0.0001320017
for O 0 0.00014264252
3 O 0 0.00013069935
days O 0 0.000106517706
caused O 0 0.00014534929
a O 0 0.00024011184
significant O 0 0.00020565062
increase O 0 0.00020282075
in O 0 0.0006058442
vacuous O 0 0.9960299
chewing O 0 0.9955627
, O 0 0.0011335722
tongue O 0 0.15493898
protrusion O 0 0.116532296
and O 0 0.00028684313
duration O 0 0.00021765626
of O 0 0.00043823122
facial O 0 0.21259725
twitching O 0 0.7417524
, O 0 0.00084086566
compared O 0 0.00061588903
to O 0 0.0010026189
the O 0 0.0017499593
control O 0 0.0032537067
. O 0 0.0062737213

Haloperidol B-Chemical 1 0.99999714
administration O 0 0.19676754
( O 0 0.003128704
one O 0 0.0010224555
dose O 0 0.001670188
of O 0 0.0007472692
12 O 0 0.0004331035
mg O 0 0.009082767
/ O 0 0.0010447631
kg O 0 0.0005586623
once O 0 0.00019690188
a O 0 0.00021227765
week O 0 0.00014227683
s O 0 0.000253524
. O 0 0.00021675102
c O 0 0.0038114004
. O 0 0.0002594809
) O 0 0.0004155076
for O 0 0.00018838044
4 O 0 0.00015527451
weeks O 0 0.00011420142
caused O 0 0.00015613057
an O 0 0.00025341476
increase O 0 0.00021085954
in O 0 0.0005933851
vacuous O 0 0.99562633
chewing O 0 0.9952194
, O 0 0.001095127
tongue O 0 0.14538556
protrusion O 0 0.1081017
and O 0 0.00028443034
duration O 0 0.0002142288
of O 0 0.00040762243
facial O 0 0.12094304
twitching O 0 0.50500226
observed O 0 0.00054882234
in O 0 0.00075763406
four O 0 0.00092749274
weekly O 0 0.0016713119
evaluations O 0 0.0028120617
. O 0 0.005583199

After O 0 0.0027811672
the O 0 0.002221309
treatments O 0 0.0020723233
and O 0 0.0016075859
behavioral O 0 0.021130713
observation O 0 0.0013172901
, O 0 0.003971551
glutamate B-Chemical 1 0.99979645
uptake O 0 0.008493853
by O 0 0.00071783306
segments O 0 0.0007884068
of O 0 0.0009751353
the O 0 0.0012412564
brain O 0 0.0060954005
was O 0 0.0025313026
analyzed O 0 0.0037610305
. O 0 0.007145099

A O 0 0.21388704
decreased O 0 0.014282416
glutamate B-Chemical 1 0.9998084
uptake O 0 0.04781184
was O 0 0.0011270682
observed O 0 0.00059022196
in O 0 0.0005043287
the O 0 0.00050709513
subcortical O 0 0.78565294
parts O 0 0.0003361944
of O 0 0.00030475445
animals O 0 0.00023931486
treated O 0 0.00049048325
with O 0 0.0033056461
reserpine B-Chemical 1 0.99999917
and O 0 0.052959885
haloperidol B-Chemical 1 0.99999976
, O 0 0.0010784371
compared O 0 0.00063930865
to O 0 0.001014727
the O 0 0.0017525859
control O 0 0.0032408333
. O 0 0.0062458212

Importantly O 0 0.0043125744
, O 0 0.0037025078
a O 0 0.0023738898
decrease O 0 0.0016934484
in O 0 0.002075735
glutamate B-Chemical 1 0.99986136
uptake O 0 0.0216909
correlates O 0 0.0006309872
negatively O 0 0.000473615
with O 0 0.0004881434
an O 0 0.00051525777
increase O 0 0.00043482485
in O 0 0.0006101667
the O 0 0.00083786645
incidence O 0 0.007271054
of O 0 0.008092019
orofacial B-Disease 0 0.9996259
diskinesia I-Disease 0 0.9993825
. O 0 0.0090386

These O 0 0.0034150288
results O 0 0.0020032304
indicate O 0 0.001154418
that O 0 0.0010217923
early O 0 0.0014838524
changes O 0 0.0016158882
in O 0 0.0014041148
glutamate B-Chemical 1 0.9998678
transport O 0 0.0020736628
may O 0 0.00034005046
be O 0 0.00029771455
related O 0 0.00022239958
to O 0 0.00026923238
the O 0 0.00036589633
development O 0 0.0010663404
of O 0 0.0024672656
vacuous O 0 0.99668115
chewing O 0 0.9919727
movements O 0 0.008385986
in O 0 0.002442979
rats O 0 0.0048506474
. O 0 0.0061769877

Ceftriaxone B-Chemical 0 0.99932945
- O 0 0.065608434
associated O 0 0.008628583
biliary B-Disease 0 0.9980677
pseudolithiasis I-Disease 2 0.999938
in O 0 0.0051387697
paediatric O 0 0.0057431054
surgical O 0 0.006984743
patients O 0 0.009111015
. O 0 0.011102594

It O 0 0.0058926833
is O 0 0.0034831543
well O 0 0.0025822055
known O 0 0.0026003702
that O 0 0.0021915908
ceftriaxone B-Chemical 0 0.99977237
leads O 0 0.0022665435
to O 0 0.0023341496
pseudolithiasis B-Disease 2 0.9983304
in O 0 0.002979069
some O 0 0.003754984
patients O 0 0.0069127753
. O 0 0.008517477

Clinical O 0 0.008977314
and O 0 0.0025613946
experimental O 0 0.0016347457
studies O 0 0.0010635114
also O 0 0.0007075489
suggest O 0 0.00041538625
that O 0 0.00041609205
situations O 0 0.0006120034
causing O 0 0.0079350285
gallbladder B-Disease 0 0.99868494
dysfunction I-Disease 0 0.9996086
, O 0 0.0014207845
such O 0 0.00029298125
as O 0 0.0003246639
fasting O 0 0.26015547
, O 0 0.0004231457
may O 0 0.00025143792
have O 0 0.0002632022
a O 0 0.00038844693
role O 0 0.00034115155
for O 0 0.0005944782
the O 0 0.000923115
development O 0 0.0026943753
of O 0 0.0054403865
pseudolithiasis B-Disease 2 0.99936205
. O 0 0.009901677

In O 0 0.0038079114
this O 0 0.002465172
study O 0 0.0020269426
, O 0 0.0014546803
we O 0 0.0006406725
prospectively O 0 0.0006082837
evaluated O 0 0.00038034384
the O 0 0.00036847527
incidence O 0 0.0009526573
and O 0 0.00039746877
clinical O 0 0.0007016711
importance O 0 0.00021467578
of O 0 0.0005311625
pseudolithiasis B-Disease 2 0.99907744
in O 0 0.00030816026
paediatric O 0 0.0003385741
surgical O 0 0.0003228976
patients O 0 0.00038510788
receiving O 0 0.0010220212
ceftriaxone B-Chemical 0 0.9999293
treatment O 0 0.0016099142
, O 0 0.00069675565
who O 0 0.0004969925
often O 0 0.00028877682
had O 0 0.00021963943
to O 0 0.0002479779
fast O 0 0.0005627378
in O 0 0.00043699038
the O 0 0.0006165251
post O 0 0.0010359333
- O 0 0.0032707104
operative O 0 0.0028484804
period O 0 0.0030892217
. O 0 0.006201727

Fifty O 0 0.008615201
children O 0 0.0052849497
who O 0 0.0036440818
were O 0 0.0022433503
given O 0 0.0018336184
ceftriaxone B-Chemical 0 0.99883205
were O 0 0.0018327886
evaluated O 0 0.0015209784
by O 0 0.0022257217
serial O 0 0.0036823414
abdominal O 0 0.03348836
sonograms O 0 0.031635813
. O 0 0.009695456

Of O 0 0.007565901
those O 0 0.005305039
, O 0 0.0048033344
13 O 0 0.0036698803
( O 0 0.003725395
26 O 0 0.0034656709
% O 0 0.0038071536
) O 0 0.0052348943
developed O 0 0.006587752
biliary O 0 0.72499794
pathology O 0 0.41516584
. O 0 0.014117348

Comparison O 0 0.0030346827
of O 0 0.0023161
the O 0 0.0014773604
patients O 0 0.0013257975
with O 0 0.00080584176
or O 0 0.00061821885
without O 0 0.00068177667
pseudolithiasis B-Disease 2 0.99833655
revealed O 0 0.00041559513
no O 0 0.000208644
significant O 0 0.00023710707
difference O 0 0.00015227095
with O 0 0.0002125373
respect O 0 0.0001819553
to O 0 0.00019210839
age O 0 0.0007583332
, O 0 0.0005750497
sex O 0 0.011246025
, O 0 0.00044746106
duration O 0 0.00028858965
of O 0 0.00047263317
the O 0 0.0005595179
treatment O 0 0.00095058186
and O 0 0.0015267804
starvation O 0 0.010288262
variables O 0 0.0054428745
. O 0 0.0065979236

After O 0 0.0036158361
cessation O 0 0.006024807
of O 0 0.0025028703
the O 0 0.0018153276
treatment O 0 0.0021545189
, O 0 0.0030550223
pseudolithiasis B-Disease 2 0.99798226
resolved O 0 0.00238614
spontaneously O 0 0.0021450366
within O 0 0.0011369127
a O 0 0.0021169723
short O 0 0.0024746105
period O 0 0.0039700004
. O 0 0.0076701017

The O 0 0.0059331073
incidence O 0 0.008229075
of O 0 0.0067625726
pseudolithiasis B-Disease 2 0.9979386
is O 0 0.004623381
not O 0 0.003786981
affected O 0 0.0046966355
by O 0 0.006867234
fasting O 0 0.4088918
. O 0 0.012548453

Coronary B-Disease 0 0.7640706
aneurysm I-Disease 2 0.9968515
after O 0 0.0036719088
implantation O 0 0.0049418057
of O 0 0.0041605504
a O 0 0.0059035867
paclitaxel B-Chemical 1 0.9980293
- O 0 0.07907101
eluting O 0 0.0726634
stent O 0 0.10532752
. O 0 0.013080791

Formation O 0 0.012049288
of O 0 0.0044741575
coronary B-Disease 0 0.57975787
aneurysm I-Disease 2 0.99762625
is O 0 0.0016257246
a O 0 0.0012403458
rare O 0 0.0035577237
complication O 0 0.1102404
of O 0 0.0007437989
stenting O 0 0.10979658
with O 0 0.00045177786
bare O 0 0.03619895
metal O 0 0.29478014
stents O 0 0.013744336
, O 0 0.00036414768
but O 0 0.0002243062
based O 0 0.00016912523
on O 0 0.00011142228
experimental O 0 0.0002001926
studies O 0 0.00029449404
drug O 0 0.49302486
- O 0 0.036882784
eluting O 0 0.010930423
stents O 0 0.0053812056
may O 0 0.00015153372
induce O 0 0.00013686085
toxic O 0 0.29613042
effects O 0 0.0002514082
on O 0 0.000104542385
the O 0 0.00016747905
vessel O 0 0.024175562
wall O 0 0.006903969
with O 0 0.00021044255
incomplete O 0 0.0003175987
stent O 0 0.008420826
apposition O 0 0.0055317506
, O 0 0.0008927108
aneurysm B-Disease 2 0.99646556
formation O 0 0.002395476
and O 0 0.00028072813
with O 0 0.000249935
the O 0 0.00025815208
potential O 0 0.00042060105
of O 0 0.0009204096
stent O 0 0.46684727
thrombosis B-Disease 2 0.9999857
or O 0 0.0043862313
vessel B-Disease 0 0.9839011
rupture I-Disease 0 0.9998944
. O 0 0.010106264

We O 0 0.003651569
present O 0 0.0022271906
a O 0 0.0023235914
43 O 0 0.002587184
- O 0 0.004481589
year O 0 0.0012381655
- O 0 0.0036322915
old O 0 0.00082991575
man O 0 0.021663567
who O 0 0.0008155859
developed O 0 0.00060912553
a O 0 0.0005858157
coronary B-Disease 0 0.34297565
aneurysm I-Disease 2 0.9973436
in O 0 0.0002910119
the O 0 0.000247075
right O 0 0.0007329268
coronary O 0 0.06556026
artery O 0 0.013188782
6 O 0 0.0001963376
months O 0 0.00019413426
after O 0 0.00024151472
receiving O 0 0.00057369156
a O 0 0.0011244601
paclitaxel B-Chemical 1 0.99600154
- O 0 0.050392568
eluting O 0 0.052857623
stent O 0 0.090134285
. O 0 0.007433845

The O 0 0.0039322255
patient O 0 0.0031504524
was O 0 0.002396635
asymptomatic O 0 0.011892408
and O 0 0.001720005
the O 0 0.0016028603
aneurysm B-Disease 2 0.99322414
was O 0 0.0013735337
detected O 0 0.0011753925
in O 0 0.0015552709
a O 0 0.002379419
routine O 0 0.0030178693
control O 0 0.004537932
. O 0 0.008207794

Angiography O 0 0.017004324
and O 0 0.0033131908
intracoronary O 0 0.16372441
ultrasound O 0 0.0032918276
demonstrated O 0 0.00077830587
lack O 0 0.00058742595
of O 0 0.0006033107
contact O 0 0.0007671169
between O 0 0.000313824
stent O 0 0.007303749
and O 0 0.0003938961
vessel O 0 0.021290222
wall O 0 0.0055386117
in O 0 0.00024291605
a O 0 0.00026768204
15 O 0 0.00019338937
- O 0 0.0005631129
mm O 0 0.00036084038
long O 0 0.00020111
segment O 0 0.00028466797
with O 0 0.00026774866
maximal O 0 0.00036774622
aneurysm B-Disease 2 0.99000645
diameter O 0 0.0025777782
of O 0 0.0007820205
6 O 0 0.0007572724
. O 0 0.0011575923
0 O 0 0.0021605827
mm O 0 0.0051000454
. O 0 0.006947209

The O 0 0.0058207763
patient O 0 0.005038635
was O 0 0.004046273
successfully O 0 0.0037929544
treated O 0 0.0038204398
with O 0 0.0042850003
a O 0 0.0061995382
graft O 0 0.017583653
stent O 0 0.09399386
. O 0 0.013448397

Causes O 0 0.017264267
of O 0 0.009758601
acute O 0 0.99808097
thrombotic B-Disease 2 0.99999905
microangiopathy I-Disease 2 0.9999999
in O 0 0.0054182997
patients O 0 0.0056933793
receiving O 0 0.005540117
kidney O 0 0.62368816
transplantation O 0 0.23455408
. O 0 0.011069101

OBJECTIVES O 0 0.008115177
: O 0 0.018446436
Thrombotic B-Disease 0 0.99996614
microangiopathy I-Disease 0 0.9999994
is O 0 0.0027550794
a O 0 0.0015914434
well O 0 0.0011064183
- O 0 0.0044321744
known O 0 0.001017215
problem O 0 0.0011846838
in O 0 0.001004269
patients O 0 0.0016399027
following O 0 0.0017841025
renal O 0 0.75433385
transplantation O 0 0.119856775
. O 0 0.008366485

In O 0 0.0057815155
postrenal O 0 0.9327225
transplantation O 0 0.3839746
, O 0 0.13155568
thrombotic B-Disease 2 0.9999987
microangiopathy I-Disease 2 0.9999999
is O 0 0.002634812
often O 0 0.0014733108
a O 0 0.0012826419
reflection O 0 0.002275784
of O 0 0.010900569
hemolytic B-Disease 0 0.99999845
uremic I-Disease 0 0.9999893
syndrome I-Disease 0 0.99646676
. O 0 0.011701972

We O 0 0.0036321692
aimed O 0 0.0024605547
to O 0 0.0014450633
determine O 0 0.0007200197
the O 0 0.000880785
causes O 0 0.0011951659
of O 0 0.018363396
thrombotic B-Disease 2 0.99999964
microangiopathy I-Disease 2 1.0
in O 0 0.00093595544
a O 0 0.0005767244
population O 0 0.0006805167
of O 0 0.0006689741
renal O 0 0.739333
transplantation O 0 0.014880507
recipients O 0 0.0010292875
and O 0 0.00096278935
discuss O 0 0.0011490022
the O 0 0.0020225998
literature O 0 0.00469613
. O 0 0.0067630694

MATERIALS O 0 0.00578282
AND O 0 0.0029890053
METHODS O 0 0.0021087204
: O 0 0.002201361
We O 0 0.0013498609
investigated O 0 0.0009624156
the O 0 0.000921144
causes O 0 0.0011897503
of O 0 0.014230684
thrombotic B-Disease 2 0.9999995
microangiopathy I-Disease 2 1.0
during O 0 0.00048077106
a O 0 0.0006382522
1 O 0 0.0003324451
- O 0 0.0009216773
year O 0 0.0002182458
period O 0 0.00017460642
, O 0 0.00024923394
from O 0 0.00017530941
June O 0 0.00025065138
2003 O 0 0.00027364783
to O 0 0.00016650205
June O 0 0.00026496823
2004 O 0 0.00036799855
, O 0 0.00024777467
at O 0 0.00017764738
the O 0 0.00024201858
King O 0 0.021466287
Fahad O 0 0.019215
National O 0 0.00060341886
Guard O 0 0.00060521124
Hospital O 0 0.0004244654
in O 0 0.0001986587
Riyadh O 0 0.0013929941
, O 0 0.00035715615
Saudi O 0 0.013845328
Arabia O 0 0.0053893835
, O 0 0.00027336774
by O 0 0.00018490989
reviewing O 0 0.0002776654
the O 0 0.00016958415
slides O 0 0.0005828153
of O 0 0.00022412128
all O 0 0.00020261588
transplant O 0 0.0039267982
biopsies O 0 0.0004312891
( O 0 0.00042768792
n O 0 0.00033217363
= O 0 0.00068685773
25 O 0 0.0005800041
) O 0 0.00080733665
performed O 0 0.0007367672
during O 0 0.0009918489
this O 0 0.0018723774
interval O 0 0.0031434037
. O 0 0.0062310137

Pre O 0 0.023411134
- O 0 0.010992447
and O 0 0.005719259
posttransplant O 0 0.034376014
crossmatching O 0 0.006444182
was O 0 0.0039266823
done O 0 0.003925027
when O 0 0.0047595347
possible O 0 0.008433728
. O 0 0.013159144

RESULTS O 0 0.010608648
: O 0 0.007878674
Five O 0 0.0062967073
cases O 0 0.0066824267
of O 0 0.014234363
thrombotic B-Disease 2 0.99999344
microangiopathy I-Disease 2 0.99999905
were O 0 0.009747632
found O 0 0.008530252
. O 0 0.0132201705

Three O 0 0.0038529872
of O 0 0.0025502427
these O 0 0.0018110143
cases O 0 0.0016281814
were O 0 0.0009076837
from O 0 0.00057772466
the O 0 0.0004969906
25 O 0 0.00049204583
transplantations O 0 0.00089237234
performed O 0 0.00028634476
at O 0 0.00032051417
King O 0 0.019967543
Fahad O 0 0.020530328
National O 0 0.00075050135
Guard O 0 0.0007974022
Hospital O 0 0.00055416813
, O 0 0.00025662815
while O 0 0.0001915151
the O 0 0.00017767242
other O 0 0.00021969769
2 O 0 0.00020452544
transplantations O 0 0.00083188084
had O 0 0.00019538854
been O 0 0.00019544833
performed O 0 0.00020309981
abroad O 0 0.00063177856
and O 0 0.0003382982
were O 0 0.0003357007
referred O 0 0.00038616813
to O 0 0.00043128087
us O 0 0.0007846323
for O 0 0.0008887333
follow O 0 0.0013078345
- O 0 0.0047640842
up O 0 0.0037009427
. O 0 0.0067562433

Three O 0 0.004175824
cases O 0 0.0030022184
were O 0 0.0017773304
related O 0 0.0010808797
to O 0 0.0013206764
cyclosporine B-Chemical 1 0.99999344
, O 0 0.002581826
and O 0 0.00094647496
1 O 0 0.00061387924
case O 0 0.00057453505
was O 0 0.0005875119
secondary O 0 0.0014377683
to O 0 0.00083038077
both O 0 0.0020634916
cyclosporine B-Chemical 1 0.99999356
and O 0 0.055131953
tacrolimus B-Chemical 0 0.99997985
. O 0 0.011355653

The O 0 0.003422587
fifth O 0 0.0032634963
case O 0 0.0018751116
had O 0 0.001211535
features O 0 0.0016070625
of O 0 0.010855794
thrombotic B-Disease 2 0.9999993
microangiopathy I-Disease 2 1.0
related O 0 0.00044032998
to O 0 0.0003698961
an O 0 0.0011784014
antiphospholipid B-Disease 0 0.9999833
syndrome I-Disease 0 0.54986095
in O 0 0.0004835429
a O 0 0.0006368264
patient O 0 0.00079870975
with O 0 0.002039285
systemic B-Disease 0 0.99917597
lupus I-Disease 0 0.9999999
erythematosus I-Disease 0 0.9999993
. O 0 0.01822587

CONCLUSIONS O 0 0.021455213
: O 0 0.0039567132
In O 0 0.0018245026
the O 0 0.0012791258
literature O 0 0.0014908683
, O 0 0.0011694413
the O 0 0.00072567724
most O 0 0.0014505817
- O 0 0.020470263
frequent O 0 0.0019370873
cause O 0 0.00072354754
of O 0 0.012380625
hemolytic B-Disease 0 0.99999976
uremic I-Disease 0 0.9999975
syndrome I-Disease 0 0.989141
in O 0 0.00037734045
patients O 0 0.0004396685
following O 0 0.00024924727
renal O 0 0.6307757
transplantation O 0 0.024005633
is O 0 0.00060799246
recurrence O 0 0.5009447
of O 0 0.0015413505
the O 0 0.007381447
hemolytic B-Disease 0 0.9999988
uremic I-Disease 0 0.99999034
syndrome I-Disease 0 0.99608696
. O 0 0.010155489

Other O 0 0.0065033175
causes O 0 0.0030790078
include O 0 0.0021252765
drug O 0 0.5986393
- O 0 0.025208997
related O 0 0.00073168945
( O 0 0.0052198432
cyclosporine B-Chemical 1 0.9999988
, O 0 0.1323683
tacrolimus B-Chemical 0 0.9999993
) O 0 0.16708368
toxicity B-Disease 2 0.99973685
, O 0 0.003928328
procoagulant O 0 0.7111472
status O 0 0.0014060424
, O 0 0.0009326017
and O 0 0.0010619522
antibody O 0 0.047252204
- O 0 0.0152295865
mediated O 0 0.0027027333
rejection O 0 0.94489205
. O 0 0.010148344

We O 0 0.0035940465
found O 0 0.0022252917
that O 0 0.0015282109
the O 0 0.0014234106
most O 0 0.002303632
- O 0 0.021174705
frequent O 0 0.002624989
cause O 0 0.001224438
of O 0 0.022577465
thrombotic B-Disease 2 0.99999976
microangiopathy I-Disease 2 1.0
was O 0 0.0027884538
drug O 0 0.26678592
related O 0 0.0005107406
, O 0 0.0009796475
secondary O 0 0.0029742518
mainly O 0 0.0021795658
to O 0 0.0033165873
cyclosporine B-Chemical 1 0.9999784
. O 0 0.01049417

In O 0 0.0037080983
the O 0 0.0023593204
current O 0 0.0024808932
study O 0 0.001715751
, O 0 0.0012581641
the O 0 0.0007035425
frequency O 0 0.00095478265
of O 0 0.012294427
thrombotic B-Disease 2 0.99999964
microangiopathy I-Disease 2 1.0
was O 0 0.0006783187
similar O 0 0.00020701672
to O 0 0.00019174679
the O 0 0.00020263018
percentage O 0 0.00019569654
reported O 0 0.00032808812
in O 0 0.00033685047
the O 0 0.00045881426
literature O 0 0.0009447365
( O 0 0.0013506942
20 O 0 0.0014887672
% O 0 0.002797211
) O 0 0.0054009533
. O 0 0.007346136

Comparison O 0 0.0030818149
of O 0 0.0026166257
developmental O 0 0.0062063895
toxicity B-Disease 2 0.99578565
of O 0 0.001713557
selective O 0 0.0028832254
and O 0 0.00084381946
non O 0 0.0036898698
- O 0 0.05235123
selective O 0 0.0160416
cyclooxygenase O 0 0.99982065
- O 0 0.055644117
2 O 0 0.00026353868
inhibitors O 0 0.0006244272
in O 0 0.00035079592
CRL O 0 0.83524156
: O 0 0.00331576
( O 0 0.0016305022
WI O 0 0.07290258
) O 0 0.0041892165
WUBR O 0 0.52183056
Wistar O 0 0.03155529
rats O 0 0.0017407242
- O 0 0.053460218
- O 0 0.26476684
DFU B-Chemical 1 0.9999957
and O 0 0.018811317
piroxicam B-Chemical 0 0.999979
study O 0 0.008599767
. O 0 0.00776249

BACKGROUND O 0 0.0401875
: O 0 0.009567212
Cyclooxygenase O 0 0.9993298
( O 0 0.024623277
COX O 0 0.9997874
) O 0 0.0032150948
inhibitors O 0 0.0018173521
are O 0 0.00060964184
one O 0 0.0004773228
of O 0 0.000564843
the O 0 0.0005810191
most O 0 0.00089843356
often O 0 0.0012072427
ingested O 0 0.013168387
drugs O 0 0.08911345
during O 0 0.0021976293
pregnancy O 0 0.25303856
. O 0 0.007817068

Unlike O 0 0.003928839
general O 0 0.0036191742
toxicity B-Disease 2 0.99213225
data O 0 0.0023462465
, O 0 0.0018654783
their O 0 0.0012631413
prenatal O 0 0.030817987
toxic O 0 0.68913347
effects O 0 0.0014269731
were O 0 0.0009923163
not O 0 0.0010527226
extensively O 0 0.0016858218
studied O 0 0.0025665918
before O 0 0.0032314633
. O 0 0.0071206666

The O 0 0.0031511034
aim O 0 0.0023390716
of O 0 0.0016517894
the O 0 0.0010441865
experiment O 0 0.0006678705
was O 0 0.0005552179
to O 0 0.0003377979
evaluate O 0 0.00019259736
the O 0 0.0002723633
developmental O 0 0.002004407
toxicity B-Disease 2 0.9942901
of O 0 0.00045755334
the O 0 0.00030119816
non O 0 0.0027734423
- O 0 0.042879105
selective O 0 0.0047309953
( O 0 0.008877591
piroxicam B-Chemical 0 0.9999974
) O 0 0.0031201863
and O 0 0.000382197
selective O 0 0.0035129685
( O 0 0.010148507
DFU B-Chemical 1 0.9999989
; O 0 0.0010197763
5 B-Chemical 0 0.0001606717
, I-Chemical 0 0.00023864022
5 I-Chemical 0 0.0001974695
- I-Chemical 0 0.021087065
dimethyl I-Chemical 0 0.99981815
- I-Chemical 0 0.07073745
3 I-Chemical 0 0.00025189618
- I-Chemical 0 0.0029366936
( I-Chemical 0 0.0004143339
3 I-Chemical 0 0.00024496255
- I-Chemical 0 0.0179541
fluorophenyl I-Chemical 0 0.98785573
) I-Chemical 0 0.0036221188
- I-Chemical 0 0.011531605
4 I-Chemical 0 0.00023703561
- I-Chemical 0 0.0023292513
( I-Chemical 0 0.0004361537
4 I-Chemical 0 0.00027154965
- I-Chemical 0 0.026836472
methylsulphonyl I-Chemical 0 0.99202394
) I-Chemical 0 0.018714136
phenyl I-Chemical 0 0.999813
- I-Chemical 0 0.055173006
2 I-Chemical 0 0.00035373913
( I-Chemical 0 0.00080941844
5H I-Chemical 0 0.24238402
) I-Chemical 0 0.0012756729
- I-Chemical 0 0.0065144366
furanon I-Chemical 0 0.031148706
) O 0 0.008003986
COX O 0 0.99977
- O 0 0.021955146
2 O 0 0.002535304
inhibitors O 0 0.0060120355
. O 0 0.0070692785

METHODS O 0 0.0044114427
: O 0 0.0045993268
Drugs O 0 0.075140335
were O 0 0.0017055188
separately O 0 0.0010151903
, O 0 0.0011750545
orally O 0 0.0011010279
once O 0 0.0004575071
daily O 0 0.00048871164
dosed O 0 0.0009243107
to O 0 0.0003176565
pregnant O 0 0.002619403
rats O 0 0.00035454382
from O 0 0.0002291385
day O 0 0.0002472199
8 O 0 0.0002900502
to O 0 0.00033668437
21 O 0 0.00060118065
( O 0 0.0010241986
GD1 O 0 0.032588437
= O 0 0.002207943
plug O 0 0.0038575798
day O 0 0.0025154087
) O 0 0.0056476495
. O 0 0.0076449257

Doses O 0 0.011376063
were O 0 0.0024181425
set O 0 0.0015069175
at O 0 0.0011096891
0 O 0 0.0010431384
. O 0 0.0007000113
3 O 0 0.0005354786
, O 0 0.0005834164
3 O 0 0.000363787
. O 0 0.00031261344
0 O 0 0.00031515522
and O 0 0.00028603233
30 O 0 0.00024672403
. O 0 0.00028668373
0mg O 0 0.8156991
/ O 0 0.0017942999
kg O 0 0.0009080124
for O 0 0.00038736736
piroxicam B-Chemical 0 0.9999814
and O 0 0.00040940644
0 O 0 0.00028611114
. O 0 0.00019565882
2 O 0 0.00020666252
, O 0 0.00027443346
2 O 0 0.00022761645
. O 0 0.00023214323
0 O 0 0.0003064978
and O 0 0.00037644422
20 O 0 0.0004835051
. O 0 0.00069914124
0mg O 0 0.85028577
/ O 0 0.00489913
kg O 0 0.0057001184
for O 0 0.004534022
DFU B-Chemical 1 0.9999651
. O 0 0.009699793

Fetuses O 0 0.013232319
were O 0 0.005390457
delivered O 0 0.0039876075
on O 0 0.0041677323
GD O 0 0.8192652
21 O 0 0.005094537
and O 0 0.0050641936
routinely O 0 0.0056456523
examined O 0 0.007205912
. O 0 0.013467579

Comprehensive O 0 0.014874861
clinical O 0 0.01069453
and O 0 0.0079032
developmental O 0 0.009052919
measurements O 0 0.007175227
were O 0 0.009031992
done O 0 0.010960011
. O 0 0.017131543

The O 0 0.0027581654
pooled O 0 0.0016882875
statistical O 0 0.0017176565
analysis O 0 0.0010327996
for O 0 0.00084824517
ventricular B-Disease 0 0.5155776
septal I-Disease 0 0.16737857
( I-Disease 0 0.0026286556
VSD I-Disease 0 0.9458024
) I-Disease 0 0.00087611726
and I-Disease 0 0.0003774272
midline I-Disease 0 0.006799212
( I-Disease 0 0.0018412311
MD I-Disease 0 0.99683017
) I-Disease 0 0.0011090692
defects I-Disease 0 0.0004708911
was O 0 0.00019115751
performed O 0 0.00014348586
for O 0 0.00017181168
rat O 0 0.0004738674
fetuses O 0 0.00086220505
exposed O 0 0.0003316281
to O 0 0.00033436812
piroxicam B-Chemical 0 0.99999547
, O 0 0.0007769642
selective O 0 0.0007148072
and O 0 0.00029770972
non O 0 0.0015553731
- O 0 0.0447925
selective O 0 0.02450073
COX O 0 0.9999609
- O 0 0.03191082
2 O 0 0.00033522674
inhibitor O 0 0.00073440344
based O 0 0.0004607932
on O 0 0.00044145802
present O 0 0.0007337458
and O 0 0.0016355516
historic O 0 0.008962563
data O 0 0.0044741323
. O 0 0.006660771

RESULTS O 0 0.0057800817
: O 0 0.004791993
Maternal O 0 0.1442762
toxicity B-Disease 2 0.99924845
, O 0 0.024605269
intrauterine B-Disease 0 0.99141395
growth I-Disease 0 0.9697697
retardation I-Disease 0 0.9999151
, O 0 0.0019885378
and O 0 0.00045277592
increase B-Disease 0 0.00024041493
of I-Disease 0 0.00033146975
external I-Disease 0 0.0004891232
and I-Disease 0 0.0003455797
skeletal I-Disease 0 0.0014762023
variations I-Disease 0 0.0002707764
were O 0 0.00021414833
found O 0 0.00019722921
in O 0 0.00023570776
rats O 0 0.00036885697
treated O 0 0.00034381027
with O 0 0.00042256527
the O 0 0.000554154
highest O 0 0.0010755295
dose O 0 0.009349489
of O 0 0.012459499
piroxicam B-Chemical 0 0.9999825
. O 0 0.009658939

Decrease O 0 0.010989016
of O 0 0.0032225163
fetal O 0 0.03514701
length O 0 0.001238109
was O 0 0.0009421872
the O 0 0.00063152413
only O 0 0.0006374709
signs O 0 0.01622257
of O 0 0.00069028215
the O 0 0.0015132978
DFU B-Chemical 1 0.99999917
developmental O 0 0.06104592
toxicity B-Disease 2 0.99835277
observed O 0 0.0003439865
in O 0 0.0003310832
pups O 0 0.00047726728
exposed O 0 0.00051242096
to O 0 0.0005095726
the O 0 0.0008180123
highest O 0 0.0017645116
compound O 0 0.25010744
dose O 0 0.030285407
. O 0 0.0068710465

Lack O 0 0.0067498498
of O 0 0.0071246126
teratogenicity O 0 0.9998161
was O 0 0.0030587604
found O 0 0.0020213653
in O 0 0.0030468134
piroxicam B-Chemical 0 0.99999404
and O 0 0.07970125
DFU B-Chemical 1 0.99999785
- O 0 0.08566542
exposed O 0 0.004836104
groups O 0 0.0056935735
. O 0 0.008820484

Prenatal O 0 0.049785335
exposure O 0 0.008518803
to O 0 0.0019007698
non O 0 0.005864921
- O 0 0.07136979
selective O 0 0.027822463
COX O 0 0.9998671
inhibitors O 0 0.01064263
increases O 0 0.00040756926
the O 0 0.00036563288
risk O 0 0.06950834
of O 0 0.0015301679
VSD O 0 0.99295956
and O 0 0.0018824403
MD O 0 0.9930113
when O 0 0.0001684093
compared O 0 0.0001443325
to O 0 0.00017535858
historic O 0 0.0010189983
control O 0 0.00028712003
but O 0 0.00034272054
not O 0 0.00031078228
with O 0 0.0006413543
selective O 0 0.020369448
COX O 0 0.9998778
- O 0 0.03645004
2 O 0 0.0021650873
inhibitors O 0 0.0057600383
. O 0 0.006329414

CONCLUSION O 0 0.021023197
: O 0 0.0037662114
Both O 0 0.0018993366
selective O 0 0.0020580266
and O 0 0.0013253744
non O 0 0.0030332261
- O 0 0.05600292
selective O 0 0.042820513
COX O 0 0.999972
- O 0 0.06779401
2 O 0 0.00036264554
inhibitors O 0 0.00068385096
were O 0 0.0003434373
toxic O 0 0.14458357
for O 0 0.00031475408
rats O 0 0.00048512852
fetuses O 0 0.00073464564
when O 0 0.0003287406
administered O 0 0.0005205123
in O 0 0.00072252745
the O 0 0.0011747552
highest O 0 0.0024455213
dose O 0 0.011378427
. O 0 0.0068204524

Unlike O 0 0.009732965
DFU B-Chemical 1 0.999985
, O 0 0.092873335
piroxicam B-Chemical 0 0.9999826
was O 0 0.0034113047
also O 0 0.0024126652
highly O 0 0.0031731382
toxic O 0 0.33826703
to O 0 0.0033589175
the O 0 0.0048299893
dams O 0 0.02673721
. O 0 0.010737836

Prenatal O 0 0.05019649
exposure O 0 0.009071863
to O 0 0.0020733636
selective O 0 0.05989597
COX O 0 0.999966
- O 0 0.12679471
2 O 0 0.0005886696
inhibitors O 0 0.0009695506
does O 0 0.00032099645
not O 0 0.00021392996
increase O 0 0.00018665899
the O 0 0.00023389618
risk O 0 0.015954157
of O 0 0.00043583012
ventricular B-Disease 0 0.7482605
septal I-Disease 0 0.06870865
and I-Disease 0 0.0003638054
midline I-Disease 0 0.10379095
defects I-Disease 0 0.006120779
in O 0 0.00021445239
rat O 0 0.00035390927
when O 0 0.00014514459
compared O 0 0.00016485673
to O 0 0.0002445558
non O 0 0.0008470409
- O 0 0.0075239213
selective O 0 0.0017832476
drugs O 0 0.060406294
and O 0 0.001613121
historic O 0 0.010107886
control O 0 0.0036899524
. O 0 0.006528098

Lone O 0 0.18672645
atrial B-Disease 0 0.9646377
fibrillation I-Disease 0 0.9999467
associated O 0 0.008911873
with O 0 0.015998205
creatine B-Chemical 1 0.999969
monohydrate O 0 0.999923
supplementation O 0 0.9828971
. O 0 0.014536563

Atrial B-Disease 0 0.9904479
fibrillation I-Disease 0 0.99998474
in O 0 0.0040644286
young O 0 0.0073183915
patients O 0 0.0026213063
without O 0 0.0020146624
structural O 0 0.0053004865
heart B-Disease 0 0.53576803
disease I-Disease 0 0.92770016
is O 0 0.005815169
rare O 0 0.022566702
. O 0 0.01004817

Therefore O 0 0.0038144363
, O 0 0.0032805244
when O 0 0.0016413397
the O 0 0.0018905371
arrhythmia B-Disease 2 0.99944335
is O 0 0.0009959643
present O 0 0.00048620068
in O 0 0.00048977934
this O 0 0.00047613357
population O 0 0.0010089504
, O 0 0.0009414859
reversible O 0 0.018683266
causes O 0 0.0008010444
must O 0 0.000576816
be O 0 0.00093070255
identified O 0 0.0013161846
and O 0 0.0025386126
resolved O 0 0.005021424
. O 0 0.007132847

Thyroid B-Disease 0 0.9953565
disorders I-Disease 0 0.9969309
, O 0 0.017644143
illicit O 0 0.99846053
drug O 0 0.78386515
or O 0 0.0018035012
stimulant O 0 0.9519039
use O 0 0.0008256429
, O 0 0.00096061005
and O 0 0.001383004
acute B-Disease 0 0.99873894
alcohol I-Disease 0 0.99999785
intoxication I-Disease 0 0.99998593
are O 0 0.0015463077
among O 0 0.001964183
these O 0 0.002455671
causes O 0 0.005087712
. O 0 0.0073738485

We O 0 0.003784357
report O 0 0.0032078382
the O 0 0.0016629358
case O 0 0.0013146157
of O 0 0.0010778665
a O 0 0.00097188714
30 O 0 0.0006044956
- O 0 0.0018178332
year O 0 0.000555107
- O 0 0.0024951973
old O 0 0.00058486004
Caucasian O 0 0.26412445
man O 0 0.030953975
who O 0 0.0005661232
came O 0 0.00034174006
to O 0 0.00023354341
the O 0 0.00029737328
emergency O 0 0.0017506783
department O 0 0.0014298494
in O 0 0.00051789527
atrial B-Disease 0 0.8834248
fibrillation I-Disease 0 0.9999652
with O 0 0.001358901
rapid O 0 0.0036328218
ventricular O 0 0.66712594
response O 0 0.0049918666
. O 0 0.0064856145

His O 0 0.010106274
medical O 0 0.0060785366
history O 0 0.0056630303
was O 0 0.001958724
unremarkable O 0 0.01345642
, O 0 0.0014426378
except O 0 0.00079780375
for O 0 0.0008809545
minor O 0 0.0034660313
fractures B-Disease 2 0.9866225
of O 0 0.0016120012
the O 0 0.0016644978
fingers O 0 0.015577848
and O 0 0.0039537465
foot O 0 0.06299137
. O 0 0.008641065

Thyroid O 0 0.86516535
- O 0 0.05710872
stimulating O 0 0.010692739
hormone O 0 0.9734718
, O 0 0.02676933
magnesium B-Chemical 1 0.99994934
, O 0 0.0034544459
and O 0 0.0021095392
potassium B-Chemical 0 0.9999143
levels O 0 0.00042008059
were O 0 0.00025028148
within O 0 0.00015936987
normal O 0 0.00032256686
limits O 0 0.0005492043
, O 0 0.00075611204
urine O 0 0.4024785
drug O 0 0.11481483
screen O 0 0.0003877331
was O 0 0.0003380448
negative O 0 0.00059292605
, O 0 0.0009329857
and O 0 0.0015764146
alcohol B-Chemical 0 0.99972826
use O 0 0.0020527265
was O 0 0.0026970778
denied O 0 0.0084276125
. O 0 0.006946265

However O 0 0.0046702116
, O 0 0.0032264274
when O 0 0.0014480107
the O 0 0.0011822422
patient O 0 0.0009854813
was O 0 0.0006598476
questioned O 0 0.00054050126
about O 0 0.0003786253
use O 0 0.00039645046
of O 0 0.00060333783
herbal O 0 0.8519918
products O 0 0.0012866135
and O 0 0.0006897052
supplements O 0 0.43746403
, O 0 0.0005909075
the O 0 0.0004025591
use O 0 0.0005861525
of O 0 0.001961827
creatine B-Chemical 1 0.99998045
monohydrate O 0 0.9997545
was O 0 0.0027085235
revealed O 0 0.0035478903
. O 0 0.0062210653

The O 0 0.0033500094
patient O 0 0.0025143477
was O 0 0.001652449
admitted O 0 0.0015553004
to O 0 0.00073891104
the O 0 0.00064150005
hospital O 0 0.0011018557
, O 0 0.0007821636
anticoagulated O 0 0.0020414607
with O 0 0.00032936927
unfractionated O 0 0.02036395
heparin B-Chemical 1 0.99056435
, O 0 0.00052060984
and O 0 0.00026720675
given O 0 0.00017672424
intravenous O 0 0.19747241
diltiazem B-Chemical 1 0.9999976
for O 0 0.00021741628
rate O 0 0.00023905878
control O 0 0.0002672865
and O 0 0.0005324904
intravenous O 0 0.33663362
amiodarone B-Chemical 1 0.9999703
for O 0 0.0005966222
rate O 0 0.0009419718
and O 0 0.0016028412
rhythm O 0 0.007337195
control O 0 0.0031812524
. O 0 0.0059970603

When O 0 0.0032670815
discharged O 0 0.0035261365
less O 0 0.0014867766
than O 0 0.00084066455
24 O 0 0.00073614187
hours O 0 0.0004794185
later O 0 0.0004316395
, O 0 0.0005662072
he O 0 0.0004272547
was O 0 0.00041199458
receiving O 0 0.004807336
metoprolol B-Chemical 1 0.99999976
and O 0 0.017715435
aspirin B-Chemical 0 0.9999945
, O 0 0.00068651704
with O 0 0.00025787926
follow O 0 0.00018881871
- O 0 0.00089226896
up O 0 0.00021363868
plans O 0 0.0003299633
for O 0 0.00030441268
echocardiography O 0 0.0011960679
and O 0 0.00059073017
nuclear O 0 0.0015870695
imaging O 0 0.0016917452
to O 0 0.0012213268
assess O 0 0.0016375334
perfusion O 0 0.024850614
. O 0 0.0066945623

Exogenous O 0 0.5199236
creatine B-Chemical 1 0.9994325
is O 0 0.0039535817
used O 0 0.0023854587
by O 0 0.0023831793
athletes O 0 0.004099141
to O 0 0.001941194
theoretically O 0 0.002665751
improve O 0 0.0027318343
exercise O 0 0.007249039
performance O 0 0.007876104
. O 0 0.009770691

Vegetarians O 0 0.25910985
may O 0 0.002904316
also O 0 0.0020325428
take O 0 0.0016301887
creatine B-Chemical 1 0.99837947
to O 0 0.0008312703
replace O 0 0.0006237182
what O 0 0.00056194933
they O 0 0.00034863746
are O 0 0.00034432038
not O 0 0.00034539922
consuming O 0 0.00076104
from O 0 0.00038605716
meat O 0 0.0493554
, O 0 0.0010598677
fish O 0 0.015782604
, O 0 0.0011045387
and O 0 0.001168499
other O 0 0.0016840221
animal O 0 0.0035901791
products O 0 0.006033909
. O 0 0.007025514

Previous O 0 0.005297368
anecdotal O 0 0.005806662
reports O 0 0.003134201
have O 0 0.0024745103
linked O 0 0.0031600164
creatine B-Chemical 1 0.99915695
to O 0 0.0023092083
the O 0 0.0025398883
development O 0 0.005488142
of O 0 0.010249781
arrhythmia B-Disease 2 0.9997272
. O 0 0.012419158

Clinicians O 0 0.005110031
must O 0 0.0019230008
be O 0 0.0016562917
diligent O 0 0.0016435941
when O 0 0.0007901904
interviewing O 0 0.0014095703
patients O 0 0.0006829925
about O 0 0.00038284351
their O 0 0.00043431073
drug O 0 0.065265074
therapy O 0 0.0005933642
histories O 0 0.00051588315
and O 0 0.0002764071
include O 0 0.00021956784
questions O 0 0.00026396816
about O 0 0.0002261306
their O 0 0.0003189289
use O 0 0.0004128977
of O 0 0.00079117453
herbal O 0 0.7695217
products O 0 0.0021385755
and O 0 0.0022663742
dietary O 0 0.58789426
supplements O 0 0.7649148
. O 0 0.0073489947

In O 0 0.0035953822
addition O 0 0.0019602806
, O 0 0.0024517344
it O 0 0.0014119974
is O 0 0.0008420961
important O 0 0.0005120523
to O 0 0.00047030117
report O 0 0.0013676331
adverse O 0 0.24079984
effects O 0 0.0005412537
associated O 0 0.00036534749
with O 0 0.0003695884
frequently O 0 0.000580181
consumed O 0 0.0033907949
supplements O 0 0.23691323
and O 0 0.00047269807
herbal O 0 0.6452376
products O 0 0.0004064543
to O 0 0.00019860793
the O 0 0.00028488738
Food O 0 0.13002823
and O 0 0.0005941868
Drug O 0 0.6560704
Administration O 0 0.029887358
and O 0 0.0010061513
in O 0 0.0012585704
the O 0 0.0019915882
literature O 0 0.004531778
. O 0 0.00650738

Seizures B-Disease 0 0.9996681
induced O 0 0.006094511
by O 0 0.0052512987
the O 0 0.00878693
cocaine B-Chemical 1 0.9999957
metabolite O 0 0.9998801
benzoylecgonine B-Chemical 1 0.99999976
in O 0 0.01125641
rats O 0 0.012660854
. O 0 0.011648656

The O 0 0.003219972
half O 0 0.0021432147
- O 0 0.0043544522
life O 0 0.0018966871
( O 0 0.0018010613
t1 O 0 0.0022785454
/ O 0 0.002422447
2 O 0 0.0005501605
) O 0 0.0007770161
of O 0 0.0010138641
cocaine B-Chemical 1 0.99997854
is O 0 0.00042298943
relatively O 0 0.0003837589
short O 0 0.00021439063
, O 0 0.00037490836
but O 0 0.00025887773
some O 0 0.00017421726
of O 0 0.00020905823
the O 0 0.00018283338
consequences O 0 0.00031832317
of O 0 0.00029892844
its O 0 0.00069553993
use O 0 0.0002733586
, O 0 0.00031690273
such O 0 0.00023578419
as O 0 0.0005865442
seizures B-Disease 0 0.9999987
and O 0 0.006689251
strokes B-Disease 0 0.9996362
, O 0 0.0010731432
can O 0 0.00048146563
occur O 0 0.0007192002
hours O 0 0.0009578824
after O 0 0.0014652329
exposure O 0 0.006984478
. O 0 0.0067352755

This O 0 0.005303289
led O 0 0.0027700395
us O 0 0.002232127
to O 0 0.0012244256
hypothesize O 0 0.0008945512
that O 0 0.0007767506
a O 0 0.0017633673
metabolite O 0 0.9746422
of O 0 0.008034252
cocaine B-Chemical 1 0.99999
may O 0 0.00051811134
be O 0 0.0004250089
responsible O 0 0.00042457387
for O 0 0.0005359207
some O 0 0.00072363997
of O 0 0.0012080387
those O 0 0.0021727507
delayed O 0 0.008100121
sequelae O 0 0.72163856
. O 0 0.008277471

We O 0 0.003301476
evaluated O 0 0.0018835679
the O 0 0.001430703
potential O 0 0.0012111404
of O 0 0.0010707765
the O 0 0.00080594234
major O 0 0.0014198626
metabolite O 0 0.9789154
of O 0 0.020493366
cocaine B-Chemical 1 0.9999988
, O 0 0.32928935
benzoylecgonine B-Chemical 1 1.0
( O 0 0.0869222
BE B-Chemical 0 0.9981889
) O 0 0.0032269934
, O 0 0.0018481867
to O 0 0.0019267595
cause O 0 0.011260013
seizures B-Disease 0 0.99998546
. O 0 0.010657467

Two O 0 0.003453456
separate O 0 0.001959258
equimolar O 0 0.011473901
doses O 0 0.0075244457
( O 0 0.0017484347
0 O 0 0.0008346583
. O 0 0.0004939373
2 O 0 0.00038723776
and O 0 0.00036549
0 O 0 0.00035848792
. O 0 0.0002630587
4 O 0 0.00023906148
mumol O 0 0.005267874
) O 0 0.000550868
of O 0 0.00041551195
either O 0 0.00082661904
cocaine B-Chemical 1 0.99998844
or O 0 0.0010910964
BE B-Chemical 0 0.9911143
were O 0 0.0004882191
injected O 0 0.00052709645
ventricularly O 0 0.006046379
in O 0 0.0010737998
unanesthetized O 0 0.015790397
juvenile O 0 0.059811316
rats O 0 0.0051644524
. O 0 0.0061889794

Treated O 0 0.0470175
rats O 0 0.0033201922
were O 0 0.0015673528
then O 0 0.0009838351
evaluated O 0 0.0007203903
for O 0 0.0006967096
incidence O 0 0.0028188438
, O 0 0.0009998659
latency O 0 0.0030457738
, O 0 0.0009720868
and O 0 0.001307969
seizure B-Disease 2 0.9999472
pattern O 0 0.00045044825
or O 0 0.00040073026
for O 0 0.00050366553
locomotor O 0 0.27517274
activity O 0 0.00063399825
in O 0 0.00083552004
animals O 0 0.0012930791
without O 0 0.0038024052
seizures B-Disease 0 0.9999852
. O 0 0.009058846

BE B-Chemical 0 0.99347275
- O 0 0.14793906
Induced O 0 0.35645726
seizures B-Disease 0 0.99999225
occurred O 0 0.002455936
more O 0 0.001284855
frequently O 0 0.0008508859
and O 0 0.0005242702
had O 0 0.00037000436
significantly O 0 0.00031660494
longer O 0 0.00022035935
latencies O 0 0.00057578797
than O 0 0.00025251514
those O 0 0.00041032388
induced O 0 0.00049672957
by O 0 0.0008296635
equimolar O 0 0.029181264
amounts O 0 0.001561434
of O 0 0.0129849175
cocaine B-Chemical 1 0.99996376
. O 0 0.009121438

Whereas O 0 0.010654606
cocaine B-Chemical 1 0.9999765
- O 0 0.26489508
induced O 0 0.009853177
seizures B-Disease 0 0.9999974
were O 0 0.0010135715
best O 0 0.0005597963
characterized O 0 0.0004624733
as O 0 0.0003062679
brief O 0 0.0003193454
, O 0 0.00062098406
generalized O 0 0.042484257
, O 0 0.00059599377
and O 0 0.0004211792
tonic O 0 0.05692544
and O 0 0.00028296813
resulted O 0 0.00021228171
in O 0 0.0005133102
death B-Disease 0 0.999602
, O 0 0.0014297005
those O 0 0.00034594373
induced O 0 0.00024304763
by O 0 0.00045044592
BE B-Chemical 0 0.99115175
were O 0 0.00025737402
prolonged O 0 0.0003475008
, O 0 0.00028596554
often O 0 0.00022609609
multiple O 0 0.0002220248
and O 0 0.00024519317
mixed O 0 0.0004108415
in O 0 0.0003082875
type O 0 0.0004830111
, O 0 0.0007077631
and O 0 0.000752334
rarely O 0 0.001211209
resulted O 0 0.0013679542
in O 0 0.003064543
death B-Disease 0 0.99737394
. O 0 0.009841308

Electrical O 0 0.14246672
recordings O 0 0.0031289926
from O 0 0.0016596041
the O 0 0.0014365161
hippocampus O 0 0.08149034
showed O 0 0.00079290057
a O 0 0.0008704143
rhythmic O 0 0.0042190007
progression O 0 0.08244887
in O 0 0.0007332461
EEG O 0 0.8096144
frequency O 0 0.00055515365
and O 0 0.00062604406
voltage O 0 0.008445391
with O 0 0.0013165633
clinical O 0 0.027170694
seizure B-Disease 2 0.9997929
expression O 0 0.005217863
. O 0 0.0073789214

BE B-Chemical 0 0.99208814
- O 0 0.051563222
Injected O 0 0.010268588
rats O 0 0.0022725565
that O 0 0.0010233013
did O 0 0.0009739775
not O 0 0.00065011595
have O 0 0.0008103781
seizures B-Disease 0 0.99999666
had O 0 0.00066723814
significantly O 0 0.0005059967
more O 0 0.00054065144
locomotor O 0 0.30741185
activity O 0 0.00046153087
than O 0 0.0005562715
cocaine B-Chemical 1 0.9999808
- O 0 0.014911895
injected O 0 0.0009273995
animals O 0 0.0013218486
without O 0 0.0038780316
seizures B-Disease 0 0.99998534
. O 0 0.009001687

The O 0 0.0032193
finding O 0 0.003265625
that O 0 0.0026450115
cocaine B-Chemical 1 0.9999914
- O 0 0.3283803
and O 0 0.006540392
BE B-Chemical 0 0.9994266
- O 0 0.17906435
induced O 0 0.005317105
seizures B-Disease 0 0.99999917
differ O 0 0.00052764686
in O 0 0.00025423613
several O 0 0.00017865041
respects O 0 0.00029196404
suggests O 0 0.00013202713
more O 0 0.00019100776
than O 0 0.00011469208
one O 0 0.00012452886
mechanism O 0 0.00015183179
for O 0 0.00076771557
cocaine B-Chemical 1 0.99999726
- O 0 0.1721288
induced O 0 0.0032308272
seizures B-Disease 0 0.99999917
and O 0 0.00065746
emphasizes O 0 0.0003750701
the O 0 0.00027076065
importance O 0 0.000338571
of O 0 0.0008524659
a O 0 0.00868875
cocaine B-Chemical 1 0.99999464
metabolite O 0 0.99449337
, O 0 0.015245972
BE B-Chemical 0 0.9928133
. O 0 0.0081534255

The O 0 0.0033508213
selective O 0 0.004110076
5 O 0 0.0023065426
- O 0 0.09634703
HT6 O 0 0.97872776
receptor O 0 0.3223057
antagonist O 0 0.98822135
Ro4368554 B-Chemical 1 0.9890323
restores O 0 0.00064244785
memory O 0 0.30387524
performance O 0 0.00084817485
in O 0 0.0003816286
cholinergic O 0 0.18290117
and O 0 0.00045549904
serotonergic O 0 0.05638145
models O 0 0.00043659442
of O 0 0.0010288312
memory B-Disease 0 0.98523444
deficiency I-Disease 0 0.9826135
in O 0 0.0019673496
the O 0 0.0026542004
rat O 0 0.0076530515
. O 0 0.006886552

Antagonists O 0 0.103366256
at O 0 0.0032380002
serotonin B-Chemical 0 0.99548715
type O 0 0.0016476975
6 O 0 0.0008496803
( O 0 0.0010178293
5 B-Chemical 0 0.0006919624
- I-Chemical 0 0.029348068
HT I-Chemical 0 0.99821883
( O 0 0.0009898226
6 O 0 0.00037207702
) O 0 0.00067360123
) O 0 0.00068961876
receptors O 0 0.0009300968
show O 0 0.000343174
activity O 0 0.00045372188
in O 0 0.0005239946
models O 0 0.000762446
of O 0 0.0013181111
learning O 0 0.0044313073
and O 0 0.0033211017
memory O 0 0.3523684
. O 0 0.008112771

Although O 0 0.0029134934
the O 0 0.0019489288
underlying O 0 0.0015782132
mechanism O 0 0.0010731417
( O 0 0.0013905984
s O 0 0.0011213949
) O 0 0.0010216098
are O 0 0.00040106845
not O 0 0.0003117875
well O 0 0.00032711306
understood O 0 0.00073011185
, O 0 0.00040047057
these O 0 0.00029728454
effects O 0 0.00035382595
may O 0 0.0002433523
involve O 0 0.00024991544
an O 0 0.0004127379
increase O 0 0.0004329817
in O 0 0.0013427979
acetylcholine B-Chemical 1 0.9999229
( O 0 0.03830343
ACh B-Chemical 1 0.9998473
) O 0 0.0052408203
levels O 0 0.0040063374
. O 0 0.0070139603

The O 0 0.0029359735
present O 0 0.0017834828
study O 0 0.0015068974
sought O 0 0.0009924556
to O 0 0.0006144245
characterize O 0 0.0003721398
the O 0 0.0005225109
cognitive O 0 0.78349483
- O 0 0.0053930935
enhancing O 0 0.00030162372
effects O 0 0.00033062487
of O 0 0.00030834164
the O 0 0.00028701164
5 B-Chemical 0 0.00030301182
- I-Chemical 0 0.088532284
HT I-Chemical 0 0.99943954
( O 0 0.0007799891
6 O 0 0.00019472788
) O 0 0.00089286687
antagonist O 0 0.85974634
Ro4368554 B-Chemical 1 0.98582494
( O 0 0.0009237521
3 B-Chemical 0 0.00025695475
- I-Chemical 0 0.024569828
benzenesulfonyl I-Chemical 0 0.9942531
- I-Chemical 0 0.019666405
7 I-Chemical 0 0.00021668822
- I-Chemical 0 0.0025204197
( I-Chemical 0 0.0004134546
4 I-Chemical 0 0.00025247567
- I-Chemical 0 0.030424662
methyl I-Chemical 0 0.9967527
- I-Chemical 0 0.18738542
piperazin I-Chemical 0 0.9820963
- I-Chemical 0 0.06400462
1 I-Chemical 0 0.00045851216
- I-Chemical 0 0.07692109
yl I-Chemical 0 0.9823209
) I-Chemical 0 0.016256498
1H I-Chemical 0 0.9976624
- I-Chemical 0 0.2993447
indole I-Chemical 0 0.9955011
) O 0 0.0010264287
in O 0 0.00021377132
a O 0 0.00026880123
rat O 0 0.00047161788
object O 0 0.00045638203
recognition O 0 0.00034421124
task O 0 0.0003875973
employing O 0 0.00021559183
a O 0 0.0005562026
cholinergic O 0 0.83274513
( O 0 0.028424205
scopolamine B-Chemical 1 0.99999976
pretreatment O 0 0.33495066
) O 0 0.0013955216
and O 0 0.00028702946
a O 0 0.0005166132
serotonergic O 0 0.6574779
- O 0 0.02687798
( O 0 0.0025913934
tryptophan B-Chemical 0 0.9994222
( O 0 0.023997609
TRP B-Chemical 0 0.9998653
) O 0 0.0024393487
depletion O 0 0.0005244924
) O 0 0.0006019902
deficient O 0 0.00015962796
model O 0 0.00024427427
, O 0 0.0003449068
and O 0 0.00022083153
compared O 0 0.00013667134
its O 0 0.00031265963
pattern O 0 0.00020067059
of O 0 0.0002896219
action O 0 0.00043219863
with O 0 0.00032817695
that O 0 0.00033109644
of O 0 0.00081686926
the O 0 0.0018025871
acetylcholinesterase O 0 0.999749
inhibitor O 0 0.7247636
metrifonate B-Chemical 0 0.9999831
. O 0 0.008099372

Initial O 0 0.0044512544
testing O 0 0.002434618
in O 0 0.0016247466
a O 0 0.0013522613
time O 0 0.00077788293
- O 0 0.0024722444
dependent O 0 0.00051654084
forgetting O 0 0.11012081
task O 0 0.0005969037
employing O 0 0.00032075722
a O 0 0.00041888375
24 O 0 0.0003490712
- O 0 0.0013020613
h O 0 0.00023099978
delay O 0 0.00020693344
between O 0 0.0001289877
training O 0 0.00016450325
and O 0 0.00018670385
testing O 0 0.00018708038
showed O 0 0.00017031873
that O 0 0.00024060385
metrifonate B-Chemical 0 0.99998903
improved O 0 0.0005122051
object O 0 0.0007118616
recognition O 0 0.0004888654
( O 0 0.00035237963
at O 0 0.0001394244
10 O 0 0.00013901539
and O 0 0.00015395223
30 O 0 0.00015223786
mg O 0 0.0026578356
/ O 0 0.00078802934
kg O 0 0.000748535
, O 0 0.00040049045
p O 0 0.0003390214
. O 0 0.00034989446
o O 0 0.0051859324
. O 0 0.0006104262
) O 0 0.0014373049
, O 0 0.0014119766
whereas O 0 0.0018974148
Ro4368554 B-Chemical 1 0.9178007
was O 0 0.00319837
inactive O 0 0.007912725
. O 0 0.007642897

Both O 0 0.0047529303
, O 0 0.005787011
Ro4368554 B-Chemical 1 0.8901366
( O 0 0.0025372717
3 O 0 0.0009818551
and O 0 0.00079822325
10 O 0 0.00062133215
mg O 0 0.009683994
/ O 0 0.0017171212
kg O 0 0.0012296078
, O 0 0.00054454745
intraperitoneally O 0 0.0009705294
( O 0 0.0006120918
i O 0 0.0021868953
. O 0 0.00025032062
p O 0 0.0002792538
. O 0 0.00024203799
) O 0 0.0006507309
) O 0 0.0008285353
and O 0 0.0011111336
metrifonate B-Chemical 0 0.99999285
( O 0 0.00082270376
10 O 0 0.00020821395
mg O 0 0.008332759
/ O 0 0.0011257157
kg O 0 0.00088275975
, O 0 0.0003400137
p O 0 0.00024962347
. O 0 0.00021425002
o O 0 0.0108929165
. O 0 0.0002756305
, O 0 0.00049046223
respectively O 0 0.004817144
) O 0 0.001339135
reversed O 0 0.0010166124
memory B-Disease 0 0.9934987
deficits I-Disease 0 0.9948992
induced O 0 0.0005650301
by O 0 0.004149939
scopolamine B-Chemical 1 0.9999999
and O 0 0.010506372
TRP B-Chemical 0 0.9998473
depletion O 0 0.0011639501
( O 0 0.000534228
10 O 0 0.00018390884
mg O 0 0.007838073
/ O 0 0.0010828015
kg O 0 0.00088850857
, O 0 0.00037939596
i O 0 0.0014743077
. O 0 0.00020938736
p O 0 0.00024264173
. O 0 0.00021021071
, O 0 0.0002955494
and O 0 0.00027355782
3 O 0 0.00023331173
mg O 0 0.00535581
/ O 0 0.0010793364
kg O 0 0.000981415
, O 0 0.00057594053
p O 0 0.0005475333
. O 0 0.00064125104
o O 0 0.0042387187
. O 0 0.001320653
, O 0 0.0024840178
respectively O 0 0.00577196
) O 0 0.007370269
. O 0 0.00836901

In O 0 0.0039035343
conclusion O 0 0.0024268723
, O 0 0.003110905
although O 0 0.0023951943
Ro4368554 B-Chemical 1 0.9493862
did O 0 0.00095852424
not O 0 0.00044732887
improve O 0 0.00030069606
a O 0 0.00038271432
time O 0 0.0002493975
- O 0 0.002374086
related O 0 0.00020918324
retention O 0 0.06538611
deficit O 0 0.90723217
, O 0 0.0006987662
it O 0 0.0002692506
reversed O 0 0.00027672824
a O 0 0.00037523356
cholinergic O 0 0.21832821
and O 0 0.0002595836
a O 0 0.00044716126
serotonergic O 0 0.67661524
memory B-Disease 0 0.97787994
deficit I-Disease 0 0.9322393
, O 0 0.00046177555
suggesting O 0 0.00013607084
that O 0 0.00012152508
both O 0 0.00014688271
mechanisms O 0 0.00014955134
may O 0 0.00014461963
be O 0 0.00014428119
involved O 0 0.00011544765
in O 0 0.00013944766
the O 0 0.00014678107
facilitation O 0 0.00068596454
of O 0 0.00023515735
object O 0 0.001591673
memory O 0 0.25643817
by O 0 0.00046094018
Ro4368554 B-Chemical 1 0.9484119
and O 0 0.00040862255
, O 0 0.00043803785
possibly O 0 0.00065290014
, O 0 0.00045404656
other O 0 0.0003868723
5 B-Chemical 0 0.00041441742
- I-Chemical 0 0.03574177
HT I-Chemical 0 0.99813795
( O 0 0.0014086356
6 O 0 0.00092620694
) O 0 0.0023757876
receptor O 0 0.043844394
antagonists O 0 0.76542276
. O 0 0.007679961

Evaluation O 0 0.0050268043
of O 0 0.0033164897
the O 0 0.0024748517
anticocaine O 0 0.01579653
monoclonal O 0 0.032132357
antibody O 0 0.26684245
GNC92H2 B-Chemical 1 0.986847
as O 0 0.0016425092
an O 0 0.0020186757
immunotherapy O 0 0.04211811
for O 0 0.03631162
cocaine B-Disease 1 0.9999994
overdose I-Disease 0 0.999997
. O 0 0.014476886

The O 0 0.004045748
illicit O 0 0.9335812
use O 0 0.002426437
of O 0 0.003584861
cocaine B-Chemical 1 0.999969
continues O 0 0.0013972571
in O 0 0.00076384237
epidemic O 0 0.016006984
proportions O 0 0.0006543959
and O 0 0.0007714337
treatment O 0 0.0014878749
for O 0 0.0074920324
cocaine B-Disease 1 0.99999976
overdose I-Disease 0 0.9999981
remains O 0 0.0047962316
elusive O 0 0.009850344
. O 0 0.0077939844

Current O 0 0.01585155
protein O 0 0.006588561
- O 0 0.008732623
based O 0 0.0016337625
technology O 0 0.0015088473
offers O 0 0.000896738
a O 0 0.00071653444
new O 0 0.00060129183
therapeutic O 0 0.0008135061
venue O 0 0.00080347824
by O 0 0.00034606352
which O 0 0.00036773764
antibodies O 0 0.0011656932
bind O 0 0.00019865755
the O 0 0.0003269157
drug O 0 0.078483954
in O 0 0.00031444183
the O 0 0.0003628005
blood O 0 0.004468972
stream O 0 0.00090399355
, O 0 0.00095036137
inactivating O 0 0.0023655847
its O 0 0.004673781
toxic O 0 0.7422418
effects O 0 0.0065145353
. O 0 0.0072452473

The O 0 0.0032141646
therapeutic O 0 0.003080327
potential O 0 0.0018549628
of O 0 0.0015743633
the O 0 0.0012389269
anticocaine O 0 0.07566609
antibody O 0 0.31717548
GNC92H2 B-Chemical 1 0.99243706
was O 0 0.0008159788
examined O 0 0.00050382037
using O 0 0.0006704182
a O 0 0.0010427507
model O 0 0.0015976552
of O 0 0.055187523
cocaine B-Disease 1 0.9999995
overdose I-Disease 0 0.99999714
. O 0 0.012587219

Swiss O 0 0.01219693
albino O 0 0.0069705583
mice O 0 0.0012978812
prepared O 0 0.0011346126
with O 0 0.0011768782
intrajugular O 0 0.2597842
catheters O 0 0.0016598728
were O 0 0.00037467666
tested O 0 0.00027681902
in O 0 0.0003199848
photocell O 0 0.020812437
cages O 0 0.00050905993
after O 0 0.00014727004
administration O 0 0.0005485791
of O 0 0.00027130177
93 O 0 0.0010764633
mg O 0 0.031480655
/ O 0 0.0030612142
kg O 0 0.0025498136
( O 0 0.0012912723
LD50 O 0 0.9848936
) O 0 0.0016915493
of O 0 0.0016550951
cocaine B-Chemical 1 0.99998975
and O 0 0.001492646
GNC92H2 B-Chemical 1 0.9748216
infusions O 0 0.001238982
ranging O 0 0.0003400892
from O 0 0.0003139575
30 O 0 0.0004004242
to O 0 0.00057286595
190 O 0 0.0021811528
mg O 0 0.013307769
/ O 0 0.0048568714
kg O 0 0.007415018
. O 0 0.007289015

GNC92H2 B-Chemical 1 0.83658105
was O 0 0.0032772115
delivered O 0 0.001756595
30 O 0 0.0013955734
min O 0 0.0013948904
before O 0 0.00085860916
, O 0 0.0012277587
concomitantly O 0 0.0015013638
or O 0 0.0009816961
3 O 0 0.0010066518
min O 0 0.0015588826
after O 0 0.0018896698
cocaine B-Chemical 1 0.99974734
treatment O 0 0.0067817364
. O 0 0.008566329

Significant O 0 0.004883732
blockade O 0 0.016639788
of O 0 0.017809095
cocaine B-Chemical 1 0.9999969
toxicity B-Disease 2 0.9998777
was O 0 0.0011658614
observed O 0 0.0004232399
with O 0 0.00038770775
the O 0 0.0002881874
higher O 0 0.00026794916
dose O 0 0.0012762188
of O 0 0.0009859331
GNC92H2 B-Chemical 1 0.9954045
( O 0 0.0017430782
190 O 0 0.005404426
mg O 0 0.031765975
/ O 0 0.0020110204
kg O 0 0.001285982
) O 0 0.00057265296
, O 0 0.00031314316
where O 0 0.0002590735
premorbid O 0 0.6886272
behaviors O 0 0.0063751615
were O 0 0.0001736996
reduced O 0 0.00015764777
up O 0 0.00015183352
to O 0 0.00015309617
40 O 0 0.00021349677
% O 0 0.00034249268
, O 0 0.00083018147
seizures B-Disease 0 0.9999877
up O 0 0.00030654165
to O 0 0.00030767234
77 O 0 0.0008158692
% O 0 0.0006806415
and O 0 0.0010486571
death B-Disease 0 0.9879423
by O 0 0.0022342454
72 O 0 0.003424059
% O 0 0.004676127
. O 0 0.007070183

Importantly O 0 0.0068314048
, O 0 0.009206826
GNC92H2 B-Chemical 1 0.969848
prevented O 0 0.021189319
death B-Disease 0 0.9992387
even O 0 0.008352824
post O 0 0.006129563
- O 0 0.35596472
cocaine B-Chemical 1 0.99995375
injection O 0 0.031206537
. O 0 0.011990205

The O 0 0.0033052736
results O 0 0.002172269
support O 0 0.0014951983
the O 0 0.0012002718
important O 0 0.000871181
potential O 0 0.0010757579
of O 0 0.001656537
GNC92H2 B-Chemical 1 0.9669737
as O 0 0.0009622021
a O 0 0.0011295754
therapeutic O 0 0.0021829305
tool O 0 0.0020521071
against O 0 0.016302448
cocaine B-Disease 1 0.9999995
overdose I-Disease 0 0.99999714
. O 0 0.013052877

Electrocardiographic O 0 0.21533264
evidence O 0 0.0043125707
of O 0 0.006814292
myocardial B-Disease 0 0.9999702
injury I-Disease 0 0.9995121
in O 0 0.007824747
psychiatrically O 0 0.99754024
hospitalized O 0 0.9581375
cocaine B-Chemical 1 0.99999106
abusers O 0 0.9996884
. O 0 0.012215298

The O 0 0.0038326837
electrocardiograms O 0 0.04991816
( O 0 0.0040484504
ECG O 0 0.6080833
) O 0 0.0019228709
of O 0 0.0012611236
99 O 0 0.020572603
cocaine B-Chemical 1 0.99999
- O 0 0.13292639
abusing O 0 0.85076
patients O 0 0.0006818361
were O 0 0.0003761918
compared O 0 0.00029456816
with O 0 0.000455942
the O 0 0.00060451374
ECGs O 0 0.0040181023
of O 0 0.0012656184
50 O 0 0.002604099
schizophrenic B-Disease 2 0.9992176
controls O 0 0.0057809176
. O 0 0.00705255

Eleven O 0 0.006670994
of O 0 0.00318352
the O 0 0.0036799456
cocaine B-Chemical 1 0.9999907
abusers O 0 0.99962616
and O 0 0.0012440509
none O 0 0.00060950126
of O 0 0.00047078604
the O 0 0.00034790538
controls O 0 0.0005279512
had O 0 0.00034307572
ECG O 0 0.38954479
evidence O 0 0.00018146548
of O 0 0.000321876
significant O 0 0.0010282579
myocardial B-Disease 0 0.99999404
injury I-Disease 0 0.99916124
defined O 0 0.000566414
as O 0 0.0011839292
myocardial B-Disease 0 0.9999889
infarction I-Disease 2 0.9999999
, O 0 0.18028276
ischemia B-Disease 2 0.9999925
, O 0 0.0024273817
and O 0 0.0013809759
bundle B-Disease 0 0.01090688
branch I-Disease 0 0.004056909
block I-Disease 0 0.0045948015
. O 0 0.00666209

Behavioral O 0 0.019231973
effects O 0 0.0058365813
of O 0 0.007266921
urotensin B-Chemical 0 0.9989581
- I-Chemical 0 0.18495311
II I-Chemical 0 0.22625904
centrally O 0 0.005388353
administered O 0 0.0035249267
in O 0 0.0042194733
mice O 0 0.0053210384
. O 0 0.010830232

Urotensin B-Chemical 0 0.98266625
- I-Chemical 0 0.19197287
II I-Chemical 0 0.50549054
( O 0 0.012351366
U B-Chemical 0 0.9948147
- I-Chemical 0 0.2780572
II I-Chemical 0 0.45789808
) O 0 0.0024958588
receptors O 0 0.0024745446
are O 0 0.0007567569
widely O 0 0.000763829
distributed O 0 0.0007208659
in O 0 0.0008947678
the O 0 0.0012559287
central O 0 0.0025196737
nervous O 0 0.027762588
system O 0 0.0051376023
. O 0 0.0077389097

Intracerebroventricular O 0 0.98780537
( O 0 0.006428648
i O 0 0.0069628293
. O 0 0.0017265576
c O 0 0.011103991
. O 0 0.0011355988
v O 0 0.020179939
. O 0 0.00076855114
) O 0 0.0011205055
injection O 0 0.0009771731
of O 0 0.001503849
U B-Chemical 0 0.9984048
- I-Chemical 0 0.45689783
II I-Chemical 0 0.7010668
causes O 0 0.014390578
hypertension B-Disease 2 0.99999845
and O 0 0.0056147175
bradycardia B-Disease 0 0.99915195
and O 0 0.0007692677
stimulates O 0 0.0007509212
prolactin O 0 0.98928493
and O 0 0.004981521
thyrotropin O 0 0.99936503
secretion O 0 0.055254918
. O 0 0.008995294

However O 0 0.005038155
, O 0 0.0037085912
the O 0 0.0020483034
behavioral O 0 0.0051630023
effects O 0 0.0013296244
of O 0 0.0011487133
centrally O 0 0.0026079013
administered O 0 0.0018546731
U B-Chemical 0 0.98998535
- I-Chemical 0 0.10319602
II I-Chemical 0 0.11382835
have O 0 0.001221136
received O 0 0.0015961545
little O 0 0.0025437193
attention O 0 0.0064683147
. O 0 0.008000542

In O 0 0.0035715266
the O 0 0.002182727
present O 0 0.001413027
study O 0 0.0014729858
, O 0 0.0010926193
we O 0 0.00046441614
tested O 0 0.00041559414
the O 0 0.00037743495
effects O 0 0.00045911287
of O 0 0.0005351558
i O 0 0.009581647
. O 0 0.0003692862
c O 0 0.01840191
. O 0 0.00034129468
v O 0 0.014229896
. O 0 0.00028140316
injections O 0 0.000534076
of O 0 0.0007620709
U B-Chemical 0 0.99719524
- I-Chemical 0 0.22297433
II I-Chemical 0 0.19831513
on O 0 0.00024024876
behavioral O 0 0.013983368
, O 0 0.0006606297
metabolic O 0 0.020155665
, O 0 0.00083133555
and O 0 0.00095316663
endocrine O 0 0.19255234
responses O 0 0.0021101497
in O 0 0.0021111057
mice O 0 0.0028653543
. O 0 0.0066297096

Administration O 0 0.013010523
of O 0 0.0029908505
graded O 0 0.003247233
doses O 0 0.009023085
of O 0 0.0043190517
U B-Chemical 0 0.9986381
- I-Chemical 0 0.48028675
II I-Chemical 0 0.63925934
( O 0 0.0014631859
1 O 0 0.00048043826
- O 0 0.0015039794
10 O 0 0.00025078477
, O 0 0.00026708987
000 O 0 0.0002409218
ng O 0 0.00041992604
/ O 0 0.0030056972
mouse O 0 0.0007171688
) O 0 0.0011032126
provoked O 0 0.0063639833
: O 0 0.0011721379
( O 0 0.00056122564
1 O 0 0.00022841129
) O 0 0.00035870672
a O 0 0.00026205313
dose O 0 0.0030978688
- O 0 0.006529848
dependent O 0 0.00015725098
reduction O 0 0.00034864448
in O 0 0.00015878376
the O 0 0.00013723943
number O 0 0.00013510352
of O 0 0.00022880928
head O 0 0.04169131
dips O 0 0.013454255
in O 0 0.00016299293
the O 0 0.00019756104
hole O 0 0.107937954
- O 0 0.010531609
board O 0 0.0005339452
test O 0 0.0002232245
; O 0 0.00041856995
( O 0 0.0003399134
2 O 0 0.00018182192
) O 0 0.00030469868
a O 0 0.00023740248
dose O 0 0.00285037
- O 0 0.0064630033
dependent O 0 0.000150056
reduction O 0 0.00034132204
in O 0 0.00015329906
the O 0 0.00013148664
number O 0 0.00012548892
of O 0 0.00018358543
entries O 0 0.00034193517
in O 0 0.0001359387
the O 0 0.00014978455
white O 0 0.003192304
chamber O 0 0.0011539359
in O 0 0.0001437647
the O 0 0.00017141883
black O 0 0.009256553
- O 0 0.010216556
and O 0 0.00039709028
- O 0 0.016460376
white O 0 0.0067505916
compartment O 0 0.00022513625
test O 0 0.000216952
, O 0 0.00025808168
and O 0 0.0001923896
in O 0 0.0001428603
the O 0 0.00012907492
number O 0 0.00012823775
of O 0 0.00019232025
entries O 0 0.00037249064
in O 0 0.00013869444
the O 0 0.0001308545
central O 0 0.00021458247
platform O 0 0.00023638293
and O 0 0.00017842281
open O 0 0.0002297804
arms O 0 0.0003189827
in O 0 0.0001322567
the O 0 0.00014247668
plus O 0 0.00019151035
- O 0 0.01401207
maze O 0 0.03913715
test O 0 0.00023076269
; O 0 0.00037280525
and O 0 0.00024118058
( O 0 0.00036396706
3 O 0 0.00016195019
) O 0 0.00030498058
a O 0 0.00024363787
dose O 0 0.0028806943
- O 0 0.005194806
dependent O 0 0.00014220279
increase O 0 0.00013986383
in O 0 0.00016248383
the O 0 0.00015324498
duration O 0 0.00014858606
of O 0 0.00034291955
immobility O 0 0.55018765
in O 0 0.00022711915
the O 0 0.00028662174
forced O 0 0.002195463
- O 0 0.010297822
swimming O 0 0.01725592
test O 0 0.00070822454
and O 0 0.0010055451
tail O 0 0.0018759166
suspension O 0 0.004515889
test O 0 0.0042430637
. O 0 0.006680562

Intracerebroventricular O 0 0.98043066
injection O 0 0.008828321
of O 0 0.0070191366
U B-Chemical 0 0.99814343
- I-Chemical 0 0.42097762
II I-Chemical 0 0.35247785
also O 0 0.0006723871
caused O 0 0.0005284877
an O 0 0.0005741494
increase O 0 0.00032443524
in O 0 0.0003873375
: O 0 0.0008991927
food O 0 0.008776325
intake O 0 0.24108219
at O 0 0.00016602578
doses O 0 0.0005576914
of O 0 0.00023400862
100 O 0 0.00037394927
and O 0 0.00021013459
1 O 0 0.00016588226
, O 0 0.0001875501
000 O 0 0.00017719972
ng O 0 0.0003592433
/ O 0 0.004142808
mouse O 0 0.00067145476
, O 0 0.0005598374
water O 0 0.020198759
intake O 0 0.21421893
at O 0 0.00013879316
doses O 0 0.00054722343
of O 0 0.00026320916
100 O 0 0.0009988396
- O 0 0.0036819687
10 O 0 0.00015681882
, O 0 0.0001844879
000 O 0 0.00017561812
ng O 0 0.000342714
/ O 0 0.002999719
mouse O 0 0.00051149627
, O 0 0.00035183417
and O 0 0.0002496735
horizontal O 0 0.0005394059
locomotion O 0 0.027306933
activity O 0 0.00021914451
at O 0 0.00018869578
a O 0 0.00028171024
dose O 0 0.0006069321
of O 0 0.00044313943
10 O 0 0.00048030223
, O 0 0.0007352571
000 O 0 0.0010080141
ng O 0 0.0021254607
/ O 0 0.006512465
mouse O 0 0.0058343904
. O 0 0.0076610954

Whatever O 0 0.015343758
was O 0 0.002721482
the O 0 0.0016947257
dose O 0 0.004212611
, O 0 0.0013831424
the O 0 0.0006506658
central O 0 0.0008782595
administration O 0 0.005245162
of O 0 0.0019205797
U B-Chemical 0 0.9988135
- I-Chemical 0 0.4024815
II I-Chemical 0 0.35540807
had O 0 0.0002555246
no O 0 0.00015274911
effect O 0 0.00017502064
on O 0 0.00013303242
body O 0 0.0018532887
temperature O 0 0.020582763
, O 0 0.0020209786
nociception O 0 0.9677606
, O 0 0.024592651
apomorphine B-Chemical 1 0.9999994
- O 0 0.05878286
induced O 0 0.0005146296
penile B-Disease 0 0.94240874
erection I-Disease 0 0.9525773
and O 0 0.00041322762
climbing O 0 0.007510844
behavior O 0 0.000853246
, O 0 0.0005008725
and O 0 0.00058013765
stress O 0 0.19655801
- O 0 0.03787845
induced O 0 0.0017932635
plasma O 0 0.51775444
corticosterone B-Chemical 1 0.9996581
level O 0 0.004115859
. O 0 0.0072800843

Taken O 0 0.0074887495
together O 0 0.0025365984
, O 0 0.0022927818
the O 0 0.0011230797
present O 0 0.00069301476
study O 0 0.00069778436
demonstrates O 0 0.0003398189
that O 0 0.00028553972
the O 0 0.00029107244
central O 0 0.00047090586
injection O 0 0.0005988542
of O 0 0.001055368
U B-Chemical 0 0.9983956
- I-Chemical 0 0.31007725
II I-Chemical 0 0.23526329
at O 0 0.00018485046
doses O 0 0.00068454864
of O 0 0.00030776652
1 O 0 0.00028322343
- O 0 0.0018105884
10 O 0 0.00017449458
, O 0 0.00020758816
000 O 0 0.00020309807
ng O 0 0.00039676027
/ O 0 0.0033859224
mouse O 0 0.00073965016
induces O 0 0.0007039537
anxiogenic O 0 0.9997507
- O 0 0.11174206
and O 0 0.0022893676
depressant O 0 0.9983442
- O 0 0.013993918
like O 0 0.0008724956
effects O 0 0.0015344553
in O 0 0.0021115157
mouse O 0 0.0049270415
. O 0 0.00679598

These O 0 0.004223725
data O 0 0.0029578083
suggest O 0 0.0016559236
that O 0 0.0021288637
U B-Chemical 0 0.9933647
- I-Chemical 0 0.28294152
II I-Chemical 0 0.27521235
may O 0 0.00089328387
be O 0 0.000776469
involved O 0 0.000647959
in O 0 0.00080504385
some O 0 0.0009829557
aspects O 0 0.0012254815
of O 0 0.0041211126
psychiatric B-Disease 2 0.99987376
disorders I-Disease 0 0.99780816
. O 0 0.00957991

Learning O 0 0.024604792
of O 0 0.007764503
rats O 0 0.008055572
under O 0 0.0065832417
amnesia B-Disease 0 0.99959105
caused O 0 0.010020447
by O 0 0.016880091
pentobarbital B-Chemical 0 0.9998468
. O 0 0.018827166

Dissociated O 0 0.010372635
learning O 0 0.004904521
of O 0 0.0020820433
rats O 0 0.0017561385
in O 0 0.00085250253
the O 0 0.00062645564
normal O 0 0.0006858135
state O 0 0.0005130265
and O 0 0.00038231944
the O 0 0.00027377205
state O 0 0.00038247067
of O 0 0.00080088567
amnesia B-Disease 0 0.9998987
produced O 0 0.000328505
by O 0 0.0007750364
pentobarbital B-Chemical 0 0.9999205
( O 0 0.00073886034
15 O 0 0.00028180613
mg O 0 0.00874171
/ O 0 0.0015973138
kg O 0 0.0019300955
, O 0 0.0013470955
ip O 0 0.3108327
) O 0 0.00183334
was O 0 0.0016651435
carried O 0 0.002121079
out O 0 0.0032251352
. O 0 0.006763797

Rats O 0 0.010934212
were O 0 0.0038115596
trained O 0 0.0029071758
to O 0 0.001997625
approach O 0 0.0020431157
a O 0 0.0022259706
shelf O 0 0.0032769314
where O 0 0.0020416705
they O 0 0.0021101367
received O 0 0.0027638606
food O 0 0.008137215
reinforcement O 0 0.010311175
. O 0 0.009540934

In O 0 0.004793749
Group O 0 0.009148518
1 O 0 0.0019840533
the O 0 0.001250752
rats O 0 0.0012226024
were O 0 0.0006859573
trained O 0 0.00053474866
under O 0 0.00034111613
the O 0 0.00033858264
influence O 0 0.00028478334
of O 0 0.00077797
pentobarbital B-Chemical 0 0.9997224
to O 0 0.00027048713
run O 0 0.00029706923
to O 0 0.00023817287
the O 0 0.00027797587
same O 0 0.0002798335
shelf O 0 0.00085534464
as O 0 0.0005676083
in O 0 0.00083527283
the O 0 0.0012949832
normal O 0 0.0027681408
state O 0 0.0045254
. O 0 0.006722712

In O 0 0.005404136
Group O 0 0.009054301
2 O 0 0.0023782435
the O 0 0.0016237042
rats O 0 0.0016432857
were O 0 0.0010354522
trained O 0 0.00091963203
to O 0 0.0007068639
approach O 0 0.00085735926
different O 0 0.0008839205
shelves O 0 0.0025224222
in O 0 0.0014419956
different O 0 0.0019405716
drug O 0 0.069201216
states O 0 0.006518765
. O 0 0.008366762

It O 0 0.0067235273
was O 0 0.0042078746
shown O 0 0.0028211877
that O 0 0.002853097
memory B-Disease 0 0.7503674
dissociation I-Disease 0 0.2504474
occurred O 0 0.0038973854
in O 0 0.0037240644
both O 0 0.0047228634
groups O 0 0.007046916
. O 0 0.010845466

Differences O 0 0.0034833283
in O 0 0.0023215716
the O 0 0.0015842777
parameters O 0 0.0013576444
of O 0 0.0010605287
training O 0 0.00073089916
under O 0 0.00048743995
the O 0 0.0004760074
influence O 0 0.00040839353
of O 0 0.0010577486
pentobarbital B-Chemical 0 0.9997693
between O 0 0.00053964194
Groups O 0 0.008837134
1 O 0 0.00079297356
and O 0 0.0010754608
2 O 0 0.0014412886
were O 0 0.0021630258
revealed O 0 0.0036244208
. O 0 0.006917799

These O 0 0.0034610727
findings O 0 0.0025264479
show O 0 0.0013327191
that O 0 0.0010183511
the O 0 0.001051678
brain O 0 0.04433733
- O 0 0.006911977
dissociated O 0 0.0005481103
state O 0 0.0005532583
induced O 0 0.0004929167
by O 0 0.00096815906
pentobarbital B-Chemical 0 0.9998995
is O 0 0.0003760115
formed O 0 0.0003403654
with O 0 0.00031693175
the O 0 0.00030532738
participation O 0 0.0004896104
of O 0 0.00052232214
the O 0 0.0005825942
mechanisms O 0 0.00082120276
of O 0 0.0016698765
information O 0 0.002465049
perception O 0 0.0073862835
. O 0 0.006924885

The O 0 0.0030981177
effects O 0 0.002431181
of O 0 0.0018084861
short O 0 0.0013700605
- O 0 0.015463895
term O 0 0.0016387305
raloxifene B-Chemical 0 0.99990714
therapy O 0 0.0025512967
on O 0 0.00043565716
fibrinolysis O 0 0.98895323
markers O 0 0.0072991666
: O 0 0.01761626
TAFI O 0 0.9998116
, O 0 0.0050822403
tPA O 0 0.815824
, O 0 0.0016404461
and O 0 0.00200555
PAI O 0 0.310876
- O 0 0.008921012
1 O 0 0.004626634
. O 0 0.007581455

BACKGROUND O 0 0.02222904
: O 0 0.0052238908
Markers O 0 0.027978003
of O 0 0.0035932781
fibrinolysis O 0 0.9960633
, O 0 0.008849596
thrombin O 0 0.97863364
- O 0 0.17404948
activatable O 0 0.061127484
fibrinolysis O 0 0.99657357
inhibitor O 0 0.08233672
( O 0 0.021079203
TAFI O 0 0.9998313
) O 0 0.00285043
, O 0 0.00070259505
tissue O 0 0.018606914
- O 0 0.02836117
type O 0 0.0010330416
plasminogen O 0 0.98807913
activator O 0 0.015970957
( O 0 0.009968024
tPA O 0 0.9153667
) O 0 0.0012165704
, O 0 0.0004329411
and O 0 0.00054957607
plasminogen O 0 0.96725297
activator O 0 0.004744081
inhibitor O 0 0.045065533
- O 0 0.034114454
1 O 0 0.00025542325
( O 0 0.0005622907
PAI O 0 0.40685076
- O 0 0.00744457
1 O 0 0.00020752939
) O 0 0.00027879118
levels O 0 0.00016430808
were O 0 0.00016076272
studied O 0 0.00016134443
for O 0 0.0001440883
the O 0 0.00014911662
evaluation O 0 0.00016481601
of O 0 0.0002212811
short O 0 0.0002195088
- O 0 0.0019840072
term O 0 0.00028021715
effects O 0 0.00066105736
of O 0 0.0045734188
raloxifene B-Chemical 0 0.9999715
administration O 0 0.10886698
in O 0 0.002367441
postmenopausal O 0 0.97505516
women O 0 0.06663891
. O 0 0.007118368

METHODS O 0 0.00435799
: O 0 0.0041409195
Thirty O 0 0.0037708408
- O 0 0.0050917193
nine O 0 0.0017213696
postmenopausal O 0 0.86340356
women O 0 0.013964335
with O 0 0.002095523
osteopenia B-Disease 0 0.9999769
or O 0 0.0049780826
osteoporosis B-Disease 0 0.9999788
were O 0 0.0005679555
included O 0 0.00038671357
in O 0 0.00043569642
this O 0 0.00056267634
prospective O 0 0.001349499
, O 0 0.0013187402
controlled O 0 0.0014728317
clinical O 0 0.0042188484
study O 0 0.004781122
. O 0 0.0068847067

Twenty O 0 0.007311069
- O 0 0.006678727
five O 0 0.0015696589
women O 0 0.00312718
were O 0 0.0010698182
given O 0 0.0009434238
raloxifene B-Chemical 0 0.9999701
hydrochloride I-Chemical 0 0.9994815
( O 0 0.0013641891
60 O 0 0.0004193887
mg O 0 0.008206254
/ O 0 0.00091698574
day O 0 0.0002845361
) O 0 0.0005528429
plus O 0 0.00044995642
calcium B-Chemical 0 0.9937318
( O 0 0.0016748426
500 O 0 0.0015538543
mg O 0 0.021175845
/ O 0 0.0031115322
day O 0 0.0022607343
) O 0 0.0052734786
. O 0 0.007118503

Age O 0 0.21190298
- O 0 0.00864898
matched O 0 0.0025619743
controls O 0 0.0025224306
( O 0 0.0021948135
n O 0 0.0015298737
= O 0 0.0021847175
14 O 0 0.0015937664
) O 0 0.0021572353
were O 0 0.0019051661
given O 0 0.0020744246
only O 0 0.004461729
calcium B-Chemical 0 0.9829602
. O 0 0.0114518935

Plasma O 0 0.9012176
TAFI O 0 0.9994405
, O 0 0.019490775
tPA O 0 0.8857427
, O 0 0.0022330256
and O 0 0.0016063473
PAI O 0 0.44007543
- O 0 0.0073487195
1 O 0 0.0005124474
antigen O 0 0.0023882429
levels O 0 0.00033766075
were O 0 0.00026616838
measured O 0 0.0001931756
at O 0 0.00019491144
baseline O 0 0.00021129484
and O 0 0.00022851364
after O 0 0.00017449458
3 O 0 0.00022178593
months O 0 0.00022192045
of O 0 0.00040053434
treatment O 0 0.0006434418
by O 0 0.0009776098
commercially O 0 0.007085172
available O 0 0.0027818307
ELISA O 0 0.9194538
kits O 0 0.36826122
. O 0 0.008937785

Variations O 0 0.008824758
of O 0 0.005198544
individuals O 0 0.00471549
were O 0 0.003337075
assessed O 0 0.0028087024
by O 0 0.003782531
Wilcoxon O 0 0.0064139296
' O 0 0.0059561036
s O 0 0.006995572
test O 0 0.009516282
. O 0 0.013582718

Relationship O 0 0.0050859544
between O 0 0.0034471222
those O 0 0.0037175561
markers O 0 0.0039536534
and O 0 0.0034151396
demographic O 0 0.004233949
characteristics O 0 0.0036158622
were O 0 0.0047555566
investigated O 0 0.006034821
. O 0 0.011111723

RESULTS O 0 0.0052575245
: O 0 0.0032847184
Three O 0 0.0017838115
months O 0 0.001139129
of O 0 0.002025258
raloxifene B-Chemical 0 0.9998666
treatment O 0 0.0017836713
was O 0 0.0005537373
associated O 0 0.00041364384
with O 0 0.00034728853
a O 0 0.0003462452
significant O 0 0.00024219611
decrease O 0 0.00022597476
in O 0 0.0002214318
the O 0 0.00029040797
plasma O 0 0.21717873
TAFI O 0 0.9997502
antigen O 0 0.13781518
concentrations O 0 0.005106866
( O 0 0.0005781174
16 O 0 0.00022651619
% O 0 0.00022441508
change O 0 0.00024084325
, O 0 0.00042687857
P O 0 0.037306532
< O 0 0.00020355251
0 O 0 0.0002584407
. O 0 0.00022218595
01 O 0 0.0014152924
) O 0 0.00043510657
, O 0 0.0002947078
and O 0 0.00023437345
a O 0 0.00024361465
significant O 0 0.0001950265
increase O 0 0.00018788625
in O 0 0.00041134504
tPA O 0 0.8414914
antigen O 0 0.070885904
concentrations O 0 0.0038960292
( O 0 0.0006480943
25 O 0 0.0003790726
% O 0 0.00040952998
change O 0 0.0004799073
, O 0 0.00086548034
P O 0 0.019094666
< O 0 0.00096313434
0 O 0 0.0015434583
. O 0 0.0022107877
05 O 0 0.011213863
) O 0 0.006459409
. O 0 0.008399023

A O 0 0.032425035
significant O 0 0.0025186555
correlation O 0 0.0014412187
was O 0 0.0011776612
found O 0 0.0007244086
between O 0 0.000523743
baseline O 0 0.0010396121
TAFI O 0 0.9990397
antigen O 0 0.076756164
concentrations O 0 0.0018266296
and O 0 0.00033727757
the O 0 0.00022009664
duration O 0 0.00020597636
of O 0 0.00082123314
amenorrhea B-Disease 0 0.9997886
( O 0 0.0022888342
P O 0 0.07657313
< O 0 0.0003181469
0 O 0 0.0004028115
. O 0 0.0004085639
05 O 0 0.0024153774
; O 0 0.00072784984
r O 0 0.0007735755
= O 0 0.0013151999
0 O 0 0.0013374002
. O 0 0.0017331681
33 O 0 0.003580054
) O 0 0.005885704
. O 0 0.008186949

CONCLUSION O 0 0.02081341
: O 0 0.003725572
We O 0 0.0016375624
suggest O 0 0.00087888195
that O 0 0.00078879076
the O 0 0.0007348382
increased O 0 0.0008898494
risk O 0 0.09952823
of O 0 0.003910572
venous B-Disease 0 0.9940165
thromboembolism I-Disease 0 0.99999964
due O 0 0.0004124551
to O 0 0.00071192946
raloxifene B-Chemical 0 0.9999349
treatment O 0 0.0006245792
may O 0 0.00021272825
be O 0 0.00020380982
related O 0 0.00016601819
to O 0 0.00023431782
increased O 0 0.0007363562
tPA O 0 0.7485571
levels O 0 0.000661577
, O 0 0.0012100587
but O 0 0.0013958206
not O 0 0.0020392314
TAFI O 0 0.9980609
levels O 0 0.004428912
. O 0 0.0073634414

Valproate B-Chemical 1 0.9999249
- O 0 0.23921151
induced O 0 0.053797215
encephalopathy B-Disease 2 0.9998826
. O 0 0.052680075

Valproate B-Chemical 1 0.9999895
- O 0 0.21706171
induced O 0 0.008540671
encephalopathy B-Disease 2 0.9999883
is O 0 0.0027861744
a O 0 0.0016987621
rare O 0 0.008060749
syndrome O 0 0.24180833
that O 0 0.0005414232
may O 0 0.0005974304
manifest O 0 0.0014590493
in O 0 0.00086656865
otherwise O 0 0.0018929428
normal O 0 0.009596795
epileptic B-Disease 0 0.99989486
individuals O 0 0.01073621
. O 0 0.0072861174

It O 0 0.0050390773
may O 0 0.002689241
even O 0 0.0021289974
present O 0 0.0012588354
in O 0 0.0011772908
patients O 0 0.0013029061
who O 0 0.001112893
have O 0 0.0006850022
tolerated O 0 0.0019908396
this O 0 0.0008195095
medicine O 0 0.0021589017
well O 0 0.0011547495
in O 0 0.0016921292
the O 0 0.0026121817
past O 0 0.0052366136
. O 0 0.00752893

It O 0 0.008295665
is O 0 0.005448024
usually O 0 0.004921957
but O 0 0.0043100873
not O 0 0.0035361499
necessarily O 0 0.004877419
associated O 0 0.005637323
with O 0 0.012383995
hyperammonemia B-Disease 0 0.999951
. O 0 0.017967217

The O 0 0.0048544956
EEG O 0 0.27971527
shows O 0 0.0019172673
characteristic O 0 0.002444061
triphasic O 0 0.4694302
waves O 0 0.009256436
in O 0 0.0015647153
most O 0 0.0018911671
patients O 0 0.0021561782
with O 0 0.002345741
this O 0 0.0035405583
complication O 0 0.22848247
. O 0 0.008917871

A O 0 0.061536517
case O 0 0.0071599977
of O 0 0.013899267
valproate B-Chemical 0 0.9999925
- O 0 0.27236205
induced O 0 0.014734815
encephalopathy B-Disease 2 0.9999808
is O 0 0.010023729
presented O 0 0.008142904
. O 0 0.011530878

The O 0 0.00544814
problems O 0 0.006584617
in O 0 0.003817688
diagnosing O 0 0.004514158
this O 0 0.00329857
condition O 0 0.004233581
are O 0 0.004031633
subsequently O 0 0.0055713565
discussed O 0 0.0069531356
. O 0 0.011356129

Recurrent O 0 0.40010813
dysphonia B-Disease 0 0.99727243
and O 0 0.07334519
acitretin B-Chemical 0 0.9998841
. O 0 0.05271488

We O 0 0.0042276774
report O 0 0.0036498758
the O 0 0.001974072
case O 0 0.0016301685
of O 0 0.0014273267
a O 0 0.0014290116
woman O 0 0.0062850313
complaining O 0 0.014523386
of O 0 0.0015361895
dysphonia B-Disease 0 0.9985959
while O 0 0.0011659974
she O 0 0.0009558493
was O 0 0.0012653122
treated O 0 0.0021986668
by O 0 0.0045150067
acitretin B-Chemical 0 0.99995995
. O 0 0.011093892

Her O 0 0.009326392
symptoms O 0 0.053148013
totally O 0 0.0036631657
regressed O 0 0.004367378
after O 0 0.0012598465
drug O 0 0.28250325
withdrawal O 0 0.25611386
and O 0 0.001680221
reappeared O 0 0.004759426
when O 0 0.0020761134
acitretin B-Chemical 0 0.999969
was O 0 0.004670251
reintroduced O 0 0.0075591155
. O 0 0.008482142

To O 0 0.003495977
our O 0 0.002859223
knowledge O 0 0.0025556753
, O 0 0.002157151
this O 0 0.0012872847
is O 0 0.0010840415
the O 0 0.00090889836
first O 0 0.00083976873
case O 0 0.0013541533
of O 0 0.0058296626
acitretin B-Chemical 0 0.9999964
- O 0 0.37616143
induced O 0 0.01666447
dysphonia B-Disease 0 0.9996284
. O 0 0.012402227

This O 0 0.0058041275
effect O 0 0.0029324077
may O 0 0.0018525037
be O 0 0.0013966025
related O 0 0.00083930464
to O 0 0.0007749327
the O 0 0.00077190023
pharmacological O 0 0.0045461073
effect O 0 0.00077458966
of O 0 0.001093132
this O 0 0.0012656895
drug O 0 0.13551316
on O 0 0.0019171506
mucous O 0 0.68342066
membranes O 0 0.089716285
. O 0 0.008713377

Nitro B-Chemical 0 0.95621854
- I-Chemical 0 0.4731558
L I-Chemical 0 0.9988269
- I-Chemical 0 0.6705715
arginine I-Chemical 0 0.99825686
methyl I-Chemical 0 0.99959403
ester I-Chemical 0 0.9868144
: O 0 0.0028856474
a O 0 0.0015836699
potential O 0 0.0018659516
protector O 0 0.15065144
against O 0 0.010372777
gentamicin B-Chemical 1 0.9999815
ototoxicity B-Disease 0 0.9999901
. O 0 0.022178456

The O 0 0.0044399956
nitric B-Chemical 0 0.9919973
oxide I-Chemical 0 0.9893939
( O 0 0.02884044
NO B-Chemical 0 0.9995072
) O 0 0.02221584
inhibitor O 0 0.44059357
nitro B-Chemical 0 0.9999927
- I-Chemical 0 0.8687194
L I-Chemical 0 0.9998981
- I-Chemical 0 0.8217869
arginine I-Chemical 0 0.99894446
methyl I-Chemical 0 0.99983585
ester I-Chemical 0 0.9967886
( O 0 0.08357468
L B-Chemical 1 0.9999392
- I-Chemical 1 0.9452816
NAME I-Chemical 1 0.9999963
) O 0 0.0021736233
may O 0 0.00017515836
act O 0 0.00017180598
as O 0 0.00016716411
an O 0 0.0002492216
otoprotectant O 0 0.0114902565
against O 0 0.0002372925
high B-Disease 0 0.001595268
- I-Disease 0 0.023234693
frequency I-Disease 0 0.00062786
hearing I-Disease 0 0.9503167
loss I-Disease 0 0.0014234085
caused O 0 0.000301857
by O 0 0.0010752298
gentamicin B-Chemical 1 0.9999496
, O 0 0.0019797855
but O 0 0.0002670527
further O 0 0.00014045347
studies O 0 0.00014181483
are O 0 0.000118205935
needed O 0 9.2507355e-05
to O 0 0.000102662416
confirm O 0 9.096767e-05
this O 0 0.00017374747
. O 0 0.0002827451
Aminoglycoside B-Chemical 0 0.9976361
antibiotics O 0 0.25429764
are O 0 0.00023926602
still O 0 0.00020493499
widely O 0 0.00022067892
used O 0 0.00019504991
by O 0 0.0002723841
virtue O 0 0.0005029507
of O 0 0.00053208036
their O 0 0.00066797115
efficacy O 0 0.0011575923
and O 0 0.0014590984
low O 0 0.002724898
cost O 0 0.004974298
. O 0 0.0067455196

Their O 0 0.07442882
ototoxicity B-Disease 0 0.99989605
is O 0 0.00294926
a O 0 0.002147461
serious O 0 0.049431566
health O 0 0.014421559
problem O 0 0.0012576154
and O 0 0.00062060537
, O 0 0.0005773938
as O 0 0.00031766985
their O 0 0.0005017194
ototoxic B-Disease 0 0.99792445
mechanism O 0 0.00024441825
involves O 0 0.00018386274
the O 0 0.00021508143
production O 0 0.000620608
of O 0 0.0028590697
NO B-Chemical 0 0.99959236
, O 0 0.00049164833
we O 0 0.00011442815
need O 0 0.000116849806
to O 0 0.00011068629
assess O 0 8.0700236e-05
the O 0 0.00013626718
use O 0 0.00017939929
of O 0 0.00044076337
NO B-Chemical 0 0.9973085
inhibitors O 0 0.0027664958
for O 0 0.0002362063
the O 0 0.0002647147
prevention O 0 0.0020904038
of O 0 0.0020227097
aminoglycoside B-Chemical 0 0.99979585
- O 0 0.33956796
induced O 0 0.017084958
sensorineural B-Disease 2 0.99999225
hearing I-Disease 2 0.99848014
loss I-Disease 2 0.21338752
. O 0 0.008631629

In O 0 0.0040364075
this O 0 0.00252812
experimental O 0 0.0019520833
study O 0 0.0014782005
we O 0 0.00074335776
used O 0 0.0007082599
30 O 0 0.0007154973
Sprague O 0 0.02036709
- O 0 0.004521646
Dawley O 0 0.0070446404
rats O 0 0.00067523087
, O 0 0.0005481173
27 O 0 0.0005014863
of O 0 0.0004504633
which O 0 0.00062266557
had O 0 0.0007883203
gentamicin B-Chemical 1 0.99952865
instilled O 0 0.029279767
into O 0 0.0007951913
the O 0 0.0016000941
middle O 0 0.006451436
ear O 0 0.045324937
. O 0 0.008108343

The O 0 0.005413527
otoprotectant O 0 0.5151498
L B-Chemical 1 0.9994005
- I-Chemical 1 0.8680908
NAME I-Chemical 1 0.99996126
was O 0 0.0021972489
administered O 0 0.0017925807
topically O 0 0.27560273
to O 0 0.0014777206
12 O 0 0.0016817788
/ O 0 0.003732752
27 O 0 0.0042190566
animals O 0 0.004589043
. O 0 0.008555612

Its O 0 0.049576055
effect O 0 0.0027353493
was O 0 0.0017062592
determined O 0 0.0009657255
in O 0 0.0007936603
terms O 0 0.00053045416
of O 0 0.00059170945
attenuation O 0 0.001181075
of O 0 0.0012625806
hearing B-Disease 0 0.98251307
loss I-Disease 0 0.003647626
, O 0 0.0006107515
measured O 0 0.0003027938
by O 0 0.00039994638
shifts O 0 0.0007478719
in O 0 0.0004955929
the O 0 0.0006792237
auditory O 0 0.006048044
brainstem O 0 0.036688607
response O 0 0.0022312105
threshold O 0 0.0032056468
. O 0 0.0066684857

L B-Chemical 1 0.9988721
- I-Chemical 1 0.8534266
NAME I-Chemical 1 0.99996257
reduced O 0 0.019343738
gentamicin B-Chemical 1 0.99997115
- O 0 0.24051614
induced O 0 0.0017562337
hearing B-Disease 0 0.9859707
loss I-Disease 0 0.0030373698
in O 0 0.00037442546
the O 0 0.0003155855
high O 0 0.0006996258
- O 0 0.004523368
frequency O 0 0.000321618
range O 0 0.0003311267
, O 0 0.00043681465
but O 0 0.00034825117
gave O 0 0.00041067117
no O 0 0.00026455318
protection O 0 0.001085284
in O 0 0.0005207979
the O 0 0.0006642956
middle O 0 0.0018761471
or O 0 0.0013663864
low O 0 0.0027904427
frequencies O 0 0.004306671
. O 0 0.0068891128

Safety O 0 0.008729182
profile O 0 0.002551701
of O 0 0.0022757764
a O 0 0.0052566514
nicotine B-Chemical 1 0.9999753
lozenge O 0 0.9977005
compared O 0 0.00041391223
with O 0 0.00038705528
that O 0 0.00027265403
of O 0 0.0014330632
nicotine B-Chemical 1 0.99997413
gum O 0 0.7201871
in O 0 0.00029692735
adult O 0 0.0006184815
smokers O 0 0.06872793
with O 0 0.00020432506
underlying O 0 0.00027636415
medical O 0 0.00068806845
conditions O 0 0.00025751395
: O 0 0.00045712962
a O 0 0.0003088035
12 O 0 0.00023094536
- O 0 0.00070515584
week O 0 0.00027251084
, O 0 0.00050074473
randomized O 0 0.0005846095
, O 0 0.0009480195
open O 0 0.001568
- O 0 0.004861213
label O 0 0.0048340135
study O 0 0.0052609374
. O 0 0.007220476

BACKGROUND O 0 0.095348544
: O 0 0.054438494
Nicotine B-Chemical 0 0.9999937
polacrilex O 0 0.9992685
lozenges O 0 0.9348965
deliver O 0 0.00067586283
25 O 0 0.0007036438
% O 0 0.0005714758
to O 0 0.0003884314
27 O 0 0.00055209117
% O 0 0.00052160246
more O 0 0.0006413116
nicotine B-Chemical 1 0.9979068
compared O 0 0.00032455652
with O 0 0.00046575506
equivalent O 0 0.0005519973
doses O 0 0.0060300943
of O 0 0.008018777
nicotine B-Chemical 1 0.9999783
polacrilex O 0 0.99893504
gum O 0 0.789544
. O 0 0.007541953

The O 0 0.0034606024
increased O 0 0.0043872492
nicotine B-Chemical 1 0.99964356
exposure O 0 0.022166269
from O 0 0.0009832671
the O 0 0.0011260364
lozenge O 0 0.97404003
has O 0 0.000437783
raised O 0 0.000452954
questions O 0 0.00038545788
about O 0 0.0003029399
the O 0 0.00035205865
relative O 0 0.00041234228
safety O 0 0.0008069098
of O 0 0.000991232
the O 0 0.0016857119
lozenge O 0 0.9759493
and O 0 0.004629028
gum O 0 0.5172984
. O 0 0.0075904015

OBJECTIVE O 0 0.020105377
: O 0 0.0035213998
The O 0 0.001511697
objective O 0 0.0015220098
of O 0 0.0010337515
this O 0 0.0007214479
study O 0 0.0006669378
was O 0 0.0003863786
to O 0 0.0002432289
compare O 0 0.00014357056
the O 0 0.00018711248
safety O 0 0.00023344102
profiles O 0 0.00014632854
of O 0 0.00019798968
the O 0 0.00020363773
4 O 0 0.00021346989
- O 0 0.009218425
mg O 0 0.36785507
nicotine B-Chemical 1 0.9999765
lozenge O 0 0.9959324
and O 0 0.0004472244
4 O 0 0.00024388447
- O 0 0.008153251
mg O 0 0.2428048
nicotine B-Chemical 1 0.99987185
gum O 0 0.39268687
in O 0 0.0004054049
smokers O 0 0.039918978
with O 0 0.00047908028
selected O 0 0.00066995894
label O 0 0.0026852204
- O 0 0.0066892696
restricted O 0 0.0026092315
diseases O 0 0.70864546
. O 0 0.007990326

METHODS O 0 0.00420305
: O 0 0.0038692586
This O 0 0.0027056357
was O 0 0.001732514
a O 0 0.0016163213
multicenter O 0 0.01476466
, O 0 0.001199934
randomized O 0 0.00077090005
, O 0 0.00076384965
open O 0 0.00086631277
- O 0 0.0050006094
label O 0 0.0010391036
study O 0 0.00040940876
in O 0 0.0002691328
adult O 0 0.00060451694
smokers O 0 0.14410992
with O 0 0.00054168986
heart B-Disease 0 0.5402082
disease I-Disease 0 0.9757498
, O 0 0.0112534445
hypertension B-Disease 2 0.99999297
not O 0 0.00025782717
controlled O 0 0.00024362837
by O 0 0.00036729444
medication O 0 0.010324477
, O 0 0.00065974693
and O 0 0.00087720365
/ O 0 0.006472627
or O 0 0.0032670472
diabetes B-Disease 0 0.9999155
mellitus I-Disease 0 0.99974054
. O 0 0.0112368865

Patients O 0 0.004560157
were O 0 0.0024088842
randomized O 0 0.0017507784
in O 0 0.0012215305
a O 0 0.0011909367
1 O 0 0.0008342575
: O 0 0.0008617682
1 O 0 0.00047637962
ratio O 0 0.00041744567
to O 0 0.0003021919
receive O 0 0.00024099302
the O 0 0.00029004246
4 O 0 0.00033160532
- O 0 0.006730993
mg O 0 0.39343047
nicotine B-Chemical 1 0.999966
lozenge O 0 0.9945991
or O 0 0.0007626365
4 O 0 0.0008544689
- O 0 0.013928839
mg O 0 0.49985582
nicotine B-Chemical 1 0.9997372
gum O 0 0.74088085
. O 0 0.0078054015

Safety O 0 0.0082386695
assessments O 0 0.0023505776
were O 0 0.0014911422
made O 0 0.0009771689
at O 0 0.0007349103
baseline O 0 0.00060765905
and O 0 0.00053635665
at O 0 0.00040604727
2 O 0 0.00039628908
, O 0 0.0004443937
4 O 0 0.0003078816
, O 0 0.0003924157
6 O 0 0.00027227504
, O 0 0.00037753713
and O 0 0.0003574276
12 O 0 0.00029612138
weeks O 0 0.0002740272
after O 0 0.00034419514
the O 0 0.0005978123
start O 0 0.0008963395
of O 0 0.0017257407
product O 0 0.003359315
use O 0 0.00438221
. O 0 0.0070501287

RESULTS O 0 0.0060042418
: O 0 0.0039056006
Nine O 0 0.002879866
hundred O 0 0.0016320492
one O 0 0.0010649485
patients O 0 0.00095619645
were O 0 0.00063672406
randomized O 0 0.00052226044
to O 0 0.00038550826
treatment O 0 0.00054691423
, O 0 0.00074606057
447 O 0 0.013310259
who O 0 0.00047215537
received O 0 0.00024825448
the O 0 0.0004008678
lozenge O 0 0.9613226
and O 0 0.0005234548
454 O 0 0.0015603068
who O 0 0.0005072726
received O 0 0.00035832747
the O 0 0.00058554916
gum O 0 0.09644026
( O 0 0.001483483
safety O 0 0.00207593
population O 0 0.0033202113
) O 0 0.0059208805
. O 0 0.007215278

The O 0 0.005046857
majority O 0 0.0041814046
were O 0 0.003991359
women O 0 0.0071203564
( O 0 0.0045992066
52 O 0 0.004461602
. O 0 0.0037076157
7 O 0 0.004445196
% O 0 0.0074863927
) O 0 0.012324347
. O 0 0.0151880365

Patients O 0 0.0050163497
' O 0 0.0029962242
mean O 0 0.0012305581
age O 0 0.0018086537
was O 0 0.0010608309
53 O 0 0.0011064706
. O 0 0.000576041
9 O 0 0.00046016817
years O 0 0.00045630586
, O 0 0.00041603638
their O 0 0.00027250042
mean O 0 0.00018672092
weight O 0 0.00060890114
was O 0 0.00032564002
193 O 0 0.0027494412
. O 0 0.0002265741
9 O 0 0.00021101799
pounds O 0 0.00031637866
, O 0 0.00028602034
and O 0 0.00025874496
they O 0 0.00023159278
smoked O 0 0.046541326
a O 0 0.00024260726
mean O 0 0.00015936879
of O 0 0.0003008919
25 O 0 0.00038976414
. O 0 0.00036603305
2 O 0 0.0005020818
cigarettes O 0 0.008539304
per O 0 0.00058699725
day O 0 0.0009976357
at O 0 0.001639155
baseline O 0 0.0032063806
. O 0 0.0059439056

Five O 0 0.004642533
hundred O 0 0.0029172015
fifty O 0 0.0025242944
- O 0 0.003044439
three O 0 0.00080996193
patients O 0 0.0010634925
, O 0 0.0009967778
264 O 0 0.0028495584
taking O 0 0.00089489267
the O 0 0.0005190713
lozenge O 0 0.96516013
and O 0 0.0005087058
289 O 0 0.008400873
taking O 0 0.0005468081
the O 0 0.00027129197
gum O 0 0.13456796
, O 0 0.00029685546
used O 0 0.00014986812
the O 0 0.00015563144
study O 0 0.00022111238
product O 0 0.00026956032
for O 0 0.00018852996
> O 0 0.00056209025
or O 0 0.00021626569
= O 0 0.0004152526
4 O 0 0.00014616038
days O 0 0.00011382394
per O 0 0.00011384457
week O 0 0.00013624586
during O 0 0.0001520723
the O 0 0.0002301446
first O 0 0.000266342
2 O 0 0.0003943889
weeks O 0 0.0004406556
( O 0 0.001118378
evaluable O 0 0.0027780898
population O 0 0.0034428644
) O 0 0.006230624
. O 0 0.0073801824

The O 0 0.0051637976
nicotine B-Chemical 1 0.9998944
lozenge O 0 0.9988722
and O 0 0.017980231
nicotine B-Chemical 1 0.99996173
gum O 0 0.7529512
were O 0 0.00067493104
equally O 0 0.0004927269
well O 0 0.00043360027
tolerated O 0 0.0026329232
, O 0 0.0005889351
despite O 0 0.000515058
increased O 0 0.0017541366
nicotine B-Chemical 1 0.9998073
exposure O 0 0.017803825
from O 0 0.0017280853
the O 0 0.0033057525
lozenge O 0 0.97725815
. O 0 0.007273281

The O 0 0.0032413509
incidence O 0 0.004106669
of O 0 0.002398713
adverse O 0 0.43856546
events O 0 0.0147060035
in O 0 0.00068155065
the O 0 0.00048341134
2 O 0 0.00036482885
groups O 0 0.00029414444
was O 0 0.00022671932
similar O 0 0.00015540722
during O 0 0.00013381446
the O 0 0.00015444375
first O 0 0.00013072952
2 O 0 0.00013749996
weeks O 0 9.6498006e-05
of O 0 0.00015747515
product O 0 0.00026440292
use O 0 0.00018611693
( O 0 0.0002560406
evaluation O 0 0.00017548502
population O 0 0.00044087955
: O 0 0.00041124408
55 O 0 0.00024077117
. O 0 0.00016298908
3 O 0 0.0001652467
% O 0 0.00037584594
lozenge O 0 0.94897074
, O 0 0.00039630386
54 O 0 0.0003880399
. O 0 0.00017343397
7 O 0 0.00016762812
% O 0 0.00031310768
gum O 0 0.11731864
) O 0 0.0005775696
, O 0 0.00027270342
as O 0 0.0001578513
well O 0 0.00014893373
as O 0 0.00013906365
during O 0 0.000111962916
the O 0 0.00013815195
entire O 0 0.00013799804
study O 0 0.00022854806
( O 0 0.0002710272
safety O 0 0.0002780973
population O 0 0.00037228223
: O 0 0.00041582025
63 O 0 0.00034248666
. O 0 0.00020944828
8 O 0 0.00022617997
% O 0 0.0003096838
and O 0 0.0003580637
58 O 0 0.0005627647
. O 0 0.00049177697
6 O 0 0.0006044792
% O 0 0.0012200372
, O 0 0.0020686148
respectively O 0 0.0044655725
) O 0 0.0067429068
. O 0 0.008169591

Stratification O 0 0.07335904
of O 0 0.0032198022
patients O 0 0.00267248
by O 0 0.0017605344
sex O 0 0.040247723
, O 0 0.0015624014
age O 0 0.0014816518
, O 0 0.00061984337
extent O 0 0.00026638797
of O 0 0.0004249784
concurrent O 0 0.0024942588
smoking O 1 0.99740124
, O 0 0.0005988654
extent O 0 0.00016089262
of O 0 0.00028594508
product O 0 0.0004513586
use O 0 0.00023350604
, O 0 0.0002850857
and O 0 0.00024156214
severity O 0 0.0011920297
of O 0 0.0003481375
adverse O 0 0.20052978
events O 0 0.0022270426
revealed O 0 0.00023120953
no O 0 0.00020490216
clinically O 0 0.0018546811
significant O 0 0.00033544074
differences O 0 0.00035458017
between O 0 0.00054563925
the O 0 0.0013845486
lozenge O 0 0.9731871
and O 0 0.0042821527
gum O 0 0.515153
. O 0 0.0071148975

The O 0 0.0032951068
most O 0 0.0027682919
common O 0 0.002228522
adverse O 0 0.19239645
events O 0 0.019010102
were O 0 0.0019457707
nausea B-Disease 2 0.9999944
( O 0 0.0015812103
17 O 0 0.00052172603
. O 0 0.0002731841
2 O 0 0.00024083637
% O 0 0.0002662638
and O 0 0.00025139668
16 O 0 0.0002503533
. O 0 0.00019804234
1 O 0 0.00020641282
% O 0 0.00025983172
; O 0 0.0003474352
95 O 0 0.0004722207
% O 0 0.00041981632
CI O 0 0.47174847
, O 0 0.0006221668
- O 0 0.003095437
3 O 0 0.00018407677
. O 0 0.00016044205
7 O 0 0.00013967764
to O 0 0.00013337727
6 O 0 0.00013805293
. O 0 0.00015927083
0 O 0 0.00022728767
) O 0 0.00048104912
, O 0 0.0008209692
hiccups B-Disease 2 0.99898535
( O 0 0.0005747045
10 O 0 0.00018861142
. O 0 0.00015379833
7 O 0 0.00014078655
% O 0 0.00018510426
and O 0 0.00018210716
6 O 0 0.00014209164
. O 0 0.0001527105
6 O 0 0.0001426489
% O 0 0.00021932136
; O 0 0.0003062895
95 O 0 0.00042115257
% O 0 0.00035840244
CI O 0 0.2594161
, O 0 0.00032839164
0 O 0 0.00022065453
. O 0 0.0001548109
5 O 0 0.0001324829
to O 0 0.00012981083
7 O 0 0.00014617601
. O 0 0.00015699118
8 O 0 0.00017426281
) O 0 0.0003296753
, O 0 0.00034394208
and O 0 0.0007621228
headache B-Disease 0 0.99993384
( O 0 0.0006130531
8 O 0 0.00018931842
. O 0 0.00015695991
7 O 0 0.00014781365
% O 0 0.0001973481
and O 0 0.00019997341
9 O 0 0.00018651808
. O 0 0.00017430668
9 O 0 0.00018786853
% O 0 0.00024947646
; O 0 0.00035014804
95 O 0 0.00055686536
% O 0 0.0008100681
Cl O 0 0.99999094
, O 0 0.0017161104
- O 0 0.003831746
5 O 0 0.0003378193
. O 0 0.00038322367
0 O 0 0.0005296801
to O 0 0.00060132943
2 O 0 0.0009509089
. O 0 0.0013713972
6 O 0 0.0021087804
) O 0 0.005185224
. O 0 0.0076379073

Serious O 0 0.2535099
adverse O 0 0.34229833
events O 0 0.009160733
were O 0 0.0017929102
reported O 0 0.0013815822
in O 0 0.0010415814
11 O 0 0.0010040543
and O 0 0.0009724739
13 O 0 0.0010890667
patients O 0 0.001211439
in O 0 0.0012746976
the O 0 0.0017312106
respective O 0 0.0026588165
groups O 0 0.004724998
. O 0 0.0079748705

Fewer O 0 0.007713882
than O 0 0.002095797
6 O 0 0.0014967751
% O 0 0.0013979513
of O 0 0.0010577153
patients O 0 0.0009933913
in O 0 0.0005580407
either O 0 0.0004431126
group O 0 0.00047809465
were O 0 0.00028562438
considered O 0 0.000214695
by O 0 0.00023965487
the O 0 0.00022670766
investigator O 0 0.000523878
to O 0 0.0001876696
have O 0 0.00020132064
a O 0 0.00034187498
worsening O 0 0.02268398
of O 0 0.00040930868
their O 0 0.00045138827
overall O 0 0.0007169549
disease O 0 0.61740196
condition O 0 0.0015991209
during O 0 0.0011131014
the O 0 0.0020775069
study O 0 0.004288094
. O 0 0.0061940057

The O 0 0.0031561377
majority O 0 0.0022332785
of O 0 0.0020164473
patients O 0 0.0021455768
( O 0 0.001811122
> O 0 0.0017270147
60 O 0 0.0007600254
% O 0 0.0007713186
) O 0 0.0008178397
experienced O 0 0.0005711403
no O 0 0.0004195855
change O 0 0.0006057405
in O 0 0.0006761285
their O 0 0.0010520983
disease O 0 0.43451044
status O 0 0.0024771555
from O 0 0.0022430024
baseline O 0 0.003839555
. O 0 0.0064961743

CONCLUSION O 0 0.018079538
: O 0 0.003627715
The O 0 0.0016203482
4 O 0 0.0014163752
- O 0 0.0066962466
mg O 0 0.4321307
nicotine B-Chemical 1 0.99997735
lozenge O 0 0.99813324
and O 0 0.0009289458
4 O 0 0.0004307073
- O 0 0.009270487
mg O 0 0.29077998
nicotine B-Chemical 1 0.99990857
gum O 0 0.33958966
had O 0 0.00021814075
comparable O 0 0.0001463418
safety O 0 0.00022995094
profiles O 0 0.00016893038
in O 0 0.0002075274
these O 0 0.00028768394
patients O 0 0.00046827318
with O 0 0.00055072084
label O 0 0.002208313
- O 0 0.0036785207
restricted O 0 0.0013384924
medical O 0 0.0039080535
conditions O 0 0.0037269527
. O 0 0.0067209257

Pharmacological O 0 0.32351086
modulation O 0 0.0033775466
of O 0 0.004011688
pain B-Disease 0 0.99055266
- O 0 0.018419212
related O 0 0.0006995265
brain O 0 0.0028418053
activity O 0 0.0005813905
during O 0 0.00043660423
normal O 0 0.0007554017
and O 0 0.00075447175
central O 0 0.0012373321
sensitization O 0 0.018306836
states O 0 0.0022810304
in O 0 0.002597311
humans O 0 0.008326327
. O 0 0.007331598

Abnormal O 0 0.0054906984
processing O 0 0.0023095421
of O 0 0.0019955293
somatosensory O 0 0.06533587
inputs O 0 0.0015019644
in O 0 0.00060850196
the O 0 0.00047241562
central O 0 0.00067237683
nervous O 0 0.01691477
system O 0 0.000401669
( O 0 0.0004970796
central O 0 0.000553128
sensitization O 0 0.05638453
) O 0 0.00091408135
is O 0 0.00021100735
the O 0 0.0001572057
mechanism O 0 0.00015166325
accounting O 0 0.0007122264
for O 0 0.00019943017
the O 0 0.00021229566
enhanced O 0 0.00038628685
pain B-Disease 0 0.9215398
sensitivity O 0 0.0011775851
in O 0 0.00025247424
the O 0 0.0003028033
skin O 0 0.02805585
surrounding O 0 0.0019460523
tissue B-Disease 0 0.7659654
injury I-Disease 0 0.99923015
( O 0 0.0331672
secondary B-Disease 2 0.9736607
hyperalgesia I-Disease 2 0.9999931
) O 0 0.027941693
. O 0 0.007912998

Secondary B-Disease 0 0.9321232
hyperalgesia I-Disease 2 0.9999616
shares O 0 0.0078398725
clinical O 0 0.0052487613
characteristics O 0 0.0013631702
with O 0 0.002123154
neurogenic B-Disease 0 0.99839145
hyperalgesia I-Disease 2 0.999995
in O 0 0.001873325
patients O 0 0.0040047285
with O 0 0.012020571
neuropathic B-Disease 0 0.9999881
pain I-Disease 0 0.9993267
. O 0 0.009398595

Abnormal O 0 0.0075126644
brain O 0 0.0062353057
responses O 0 0.0022537317
to O 0 0.0011879768
somatosensory O 0 0.039138477
stimuli O 0 0.0009484017
have O 0 0.0004540142
been O 0 0.0004251895
found O 0 0.00033450426
in O 0 0.00033410557
patients O 0 0.00055258366
with O 0 0.00071353617
hyperalgesia B-Disease 2 0.9996351
as O 0 0.00028992718
well O 0 0.00027133588
as O 0 0.000292135
in O 0 0.00036374506
normal O 0 0.00063197844
subjects O 0 0.00071413105
during O 0 0.00063204893
experimental O 0 0.0013602852
central O 0 0.0031275533
sensitization O 0 0.09874267
. O 0 0.00675268

The O 0 0.0031552345
aim O 0 0.002386108
of O 0 0.0017673081
this O 0 0.0012113295
study O 0 0.0010423324
was O 0 0.00059894304
to O 0 0.0003620455
assess O 0 0.00020492365
the O 0 0.00027098585
effects O 0 0.00042991113
of O 0 0.001858166
gabapentin B-Chemical 0 0.9999912
, O 0 0.0010608238
a O 0 0.00050931936
drug O 0 0.19358581
effective O 0 0.00047986433
in O 0 0.001092485
neuropathic B-Disease 0 0.99999785
pain I-Disease 0 0.9996233
patients O 0 0.000786373
, O 0 0.00027917526
on O 0 0.00013599407
brain O 0 0.0012323709
processing O 0 0.00021348882
of O 0 0.00034703268
nociceptive O 0 0.020461634
information O 0 0.00031472827
in O 0 0.00038750714
normal O 0 0.0007450804
and O 0 0.00094901276
central O 0 0.0019440638
sensitization O 0 0.03713092
states O 0 0.0052997326
. O 0 0.00665169

Using O 0 0.003501363
functional O 0 0.00270909
magnetic O 0 0.012011573
resonance O 0 0.35799408
imaging O 0 0.0032148
( O 0 0.0015561479
fMRI O 0 0.004355513
) O 0 0.0008615932
in O 0 0.00043602902
normal O 0 0.0005421289
volunteers O 0 0.000618319
, O 0 0.00036425653
we O 0 0.00016992423
studied O 0 0.00028395074
the O 0 0.000547829
gabapentin B-Chemical 0 0.99998915
- O 0 0.01777704
induced O 0 0.00022873774
modulation O 0 0.0002630025
of O 0 0.00038167523
brain O 0 0.0153551735
activity O 0 0.00022230293
in O 0 0.00016493737
response O 0 0.00023659893
to O 0 0.0001770901
nociceptive O 0 0.01638322
mechanical O 0 0.00034546456
stimulation O 0 0.0002367858
of O 0 0.00038875092
normal O 0 0.0014137715
skin O 0 0.14368191
and O 0 0.005344822
capsaicin B-Chemical 0 0.9999471
- O 0 0.14892043
induced O 0 0.0055896253
secondary B-Disease 2 0.9865579
hyperalgesia I-Disease 2 0.9999919
. O 0 0.011510189

The O 0 0.0034548612
dose O 0 0.006103347
of O 0 0.0051090247
gabapentin B-Chemical 0 0.99996436
was O 0 0.0016276466
1 O 0 0.0009186774
, O 0 0.00091049314
800 O 0 0.0010442496
mg O 0 0.0028573694
per O 0 0.0005353137
os O 0 0.033937447
, O 0 0.0011603235
in O 0 0.0011934913
a O 0 0.0019831727
single O 0 0.002773213
administration O 0 0.012366318
. O 0 0.0073825764

We O 0 0.0034038092
found O 0 0.0021430328
that O 0 0.0015423951
( O 0 0.002422097
i O 0 0.01711008
) O 0 0.022738097
gabapentin B-Chemical 0 0.9999603
reduced O 0 0.00059911626
the O 0 0.0003744815
activations O 0 0.0049208812
in O 0 0.00022071891
the O 0 0.00022458247
bilateral O 0 0.025783643
operculoinsular O 0 0.041486118
cortex O 0 0.32501525
, O 0 0.00024920117
independently O 0 0.00012139271
of O 0 0.00016746706
the O 0 0.00014333022
presence O 0 0.00015451081
of O 0 0.00025690673
central O 0 0.00093690114
sensitization O 0 0.13061486
; O 0 0.002159104
( O 0 0.0007917265
ii O 0 0.0048848377
) O 0 0.016850268
gabapentin B-Chemical 0 0.9999553
reduced O 0 0.00020137323
the O 0 0.0001563849
activation O 0 0.00026944705
in O 0 0.0001579996
the O 0 0.00019406508
brainstem O 0 0.1261021
, O 0 0.00023857765
only O 0 0.00014939785
during O 0 0.00010428172
central O 0 0.0003673804
sensitization O 0 0.06080862
; O 0 0.0015904048
( O 0 0.0008115078
iii O 0 0.010726269
) O 0 0.016320933
gabapentin B-Chemical 0 0.9999572
suppressed O 0 0.00024921828
stimulus O 0 0.0012886253
- O 0 0.016655361
induced O 0 0.00033373185
deactivations O 0 0.3040807
, O 0 0.00027877098
only O 0 0.00017021435
during O 0 0.000119092154
central O 0 0.00036164932
sensitization O 0 0.028111763
; O 0 0.000507171
this O 0 0.00018962158
effect O 0 0.00020287339
was O 0 0.00023985557
more O 0 0.0002698656
robust O 0 0.00028453072
than O 0 0.0002788454
the O 0 0.0004533795
effect O 0 0.0006918404
on O 0 0.0010072956
brain O 0 0.01520467
activation O 0 0.005524972
. O 0 0.0067708124

The O 0 0.0035345373
observed O 0 0.0028859866
drug O 0 0.47435778
- O 0 0.017111097
induced O 0 0.0013433594
effects O 0 0.0013349188
were O 0 0.0007307004
not O 0 0.0005276529
due O 0 0.00045717316
to O 0 0.00054539257
changes O 0 0.00079218496
in O 0 0.0008153388
the O 0 0.0011025066
baseline O 0 0.0017648652
fMRI O 0 0.0049692714
signal O 0 0.003797276
. O 0 0.007344422

These O 0 0.0033913092
findings O 0 0.002489961
indicate O 0 0.0012442229
that O 0 0.0015270116
gabapentin B-Chemical 0 0.9999597
has O 0 0.0008734575
a O 0 0.0008752662
measurable O 0 0.0015990342
antinociceptive O 0 0.9118097
effect O 0 0.00035668828
and O 0 0.00040152794
a O 0 0.00047402873
stronger O 0 0.0011522312
antihyperalgesic O 0 0.96359557
effect O 0 0.00025600352
most O 0 0.00040537358
evident O 0 0.00020937738
in O 0 0.00015432983
the O 0 0.00017139118
brain O 0 0.0048565282
areas O 0 0.0004909851
undergoing O 0 0.00018839554
deactivation O 0 0.0034191129
, O 0 0.00027680476
thus O 0 0.00020559828
supporting O 0 0.0001517571
the O 0 0.00015105389
concept O 0 0.0002145035
that O 0 0.0002770057
gabapentin B-Chemical 0 0.999967
is O 0 0.0002913281
more O 0 0.00025082252
effective O 0 0.00021569012
in O 0 0.00019978323
modulating O 0 0.00023262782
nociceptive O 0 0.023035362
transmission O 0 0.0010272714
when O 0 0.0004529827
central O 0 0.0012479313
sensitization O 0 0.025575453
is O 0 0.0021141355
present O 0 0.0028089175
. O 0 0.006019073

Investigation O 0 0.008482323
of O 0 0.0039493246
mitochondrial O 0 0.09973127
involvement O 0 0.0026429344
in O 0 0.0013562763
the O 0 0.0010719096
experimental O 0 0.0011743685
model O 0 0.0014447724
of O 0 0.007839114
epilepsy B-Disease 2 0.9999951
induced O 0 0.010053602
by O 0 0.024815775
pilocarpine B-Chemical 1 0.9999908
. O 0 0.01204984

Mitochondrial B-Disease 0 0.9871365
abnormalities I-Disease 0 0.6509599
have O 0 0.0016034929
been O 0 0.0011329958
associated O 0 0.00077675836
with O 0 0.00055275124
several O 0 0.00035246997
aspects O 0 0.0002831862
of O 0 0.0006514091
epileptogenesis O 0 0.9988312
, O 0 0.0005534472
such O 0 0.00021005147
as O 0 0.00020357949
energy O 0 0.0011775626
generation O 0 0.00036945875
, O 0 0.0003743926
control O 0 0.00023963384
of O 0 0.0004369881
cell O 0 0.042206097
death B-Disease 0 0.9998561
, O 0 0.006539451
neurotransmitter O 0 0.46124712
synthesis O 0 0.003108286
, O 0 0.0005589438
and O 0 0.00051538355
free O 0 0.0010073229
radical O 0 0.7361168
( O 0 0.004364294
FR O 0 0.74705714
) O 0 0.0044770814
production O 0 0.0056972676
. O 0 0.007886673

Increased O 0 0.0047015594
production O 0 0.0038311563
of O 0 0.003346661
FRs O 0 0.4525276
may O 0 0.0012065294
cause O 0 0.0018986813
mtDNA O 0 0.44540757
damage O 0 0.8046087
leading O 0 0.0013218165
to O 0 0.00036811258
decreased O 0 0.00043872904
activities O 0 0.00038510788
of O 0 0.0005272316
oxidative O 0 0.8345179
phosphorylation O 0 0.023178466
complexes O 0 0.0011141787
containing O 0 0.0008595253
mtDNA O 0 0.18141215
- O 0 0.010033511
encoded O 0 0.0024493705
subunits O 0 0.009686501
. O 0 0.008583672

In O 0 0.0038189902
this O 0 0.0024979643
study O 0 0.0021054458
, O 0 0.0015083654
we O 0 0.0006345931
investigated O 0 0.00047772063
whether O 0 0.0003043033
increased O 0 0.00044288204
generation O 0 0.00053435686
of O 0 0.0008317445
FR O 0 0.7757709
during O 0 0.00026421165
status B-Disease 0 0.0072857244
epilepticus I-Disease 0 0.999992
would O 0 0.00022077913
be O 0 0.0001612983
sufficient O 0 0.00011481485
to O 0 0.00013073326
provoke O 0 0.00054808526
abnormalities O 0 0.0587606
in O 0 0.00023707018
mtDNA O 0 0.064433426
and O 0 0.00022238624
in O 0 0.0001387054
the O 0 0.00012689678
expression O 0 0.0001643888
and O 0 0.00018148903
activity O 0 0.00019342828
of O 0 0.0006634361
cytochrome O 0 0.9997923
c O 0 0.7965924
oxidase O 0 0.99987507
( O 0 0.032679573
CCO O 0 0.993826
) O 0 0.0011681926
, O 0 0.00033960142
complex O 0 0.0003142887
IV O 0 0.0522647
of O 0 0.00022713646
the O 0 0.0002316736
respiratory O 0 0.041176658
chain O 0 0.009053988
, O 0 0.00051543117
in O 0 0.00022752966
the O 0 0.00026223835
chronic O 0 0.37966338
phase O 0 0.00073557737
of O 0 0.00064002565
the O 0 0.0011624277
pilocarpine B-Chemical 1 0.9999949
model O 0 0.0010222723
of O 0 0.002510716
temporal B-Disease 2 0.9102717
lobe I-Disease 2 0.9980673
epilepsy I-Disease 2 0.9999962
. O 0 0.010392677

DNA O 0 0.021348998
analysis O 0 0.002536001
revealed O 0 0.0015842248
low O 0 0.0013059585
amounts O 0 0.0007560952
of O 0 0.00083389436
a O 0 0.00077218196
4 O 0 0.00039802672
. O 0 0.00031371517
8 O 0 0.00027752988
kb O 0 0.0006205663
mtDNA O 0 0.030271085
deletion O 0 0.0004828366
but O 0 0.00033619328
with O 0 0.00023887969
no O 0 0.00016221647
differences O 0 0.00016245175
in O 0 0.00020998738
frequency O 0 0.0002838652
or O 0 0.00026229583
quantity O 0 0.00027591526
in O 0 0.00040150384
the O 0 0.00052225246
control O 0 0.0007862168
and O 0 0.0013316503
experimental O 0 0.0022192819
groups O 0 0.003569678
. O 0 0.0062725563

We O 0 0.0039390125
did O 0 0.0026548693
not O 0 0.001483514
find O 0 0.0011170028
abnormalities O 0 0.008620633
in O 0 0.0005874996
the O 0 0.0004241216
expression O 0 0.00040355694
and O 0 0.0003356722
distribution O 0 0.00022544793
of O 0 0.00036247808
an O 0 0.0006219894
mtDNA O 0 0.36555177
- O 0 0.016294956
encoded O 0 0.00027502753
subunit O 0 0.024502303
of O 0 0.007975327
CCO O 0 0.99887186
( O 0 0.022532105
CCO O 0 0.99782854
- O 0 0.09636103
I O 0 0.021760464
) O 0 0.00045019778
or O 0 0.00018567806
a O 0 0.00021630384
relative O 0 0.00015694584
decrease O 0 0.00023916182
in O 0 0.0005097164
CCO O 0 0.9956054
- O 0 0.047361955
I O 0 0.0034298985
when O 0 0.00012282711
compared O 0 0.00012299963
with O 0 0.00022443455
nuclear O 0 0.005833981
- O 0 0.0069883415
encoded O 0 0.00030566816
subunits O 0 0.0094632665
( O 0 0.014519454
CCO O 0 0.99648005
- O 0 0.10013764
IV O 0 0.3343578
and O 0 0.002330366
SDH O 0 0.9988287
- O 0 0.109869674
fp O 0 0.8136897
) O 0 0.008339089
. O 0 0.0081699

No O 0 0.011065375
abnormality O 0 0.043824363
in O 0 0.0058805635
CCO O 0 0.83150536
activity O 0 0.0041155173
was O 0 0.003911937
observed O 0 0.0038627782
through O 0 0.00523604
histochemistry O 0 0.012805278
. O 0 0.01230263

Although O 0 0.0028485467
evidences O 0 0.002353347
of O 0 0.002688943
mitochondrial B-Disease 0 0.97231525
abnormalities I-Disease 0 0.88865197
were O 0 0.0007018202
found O 0 0.00039813697
in O 0 0.00032992804
previously O 0 0.0002966673
published O 0 0.00025197788
studies O 0 0.000253153
, O 0 0.00031944894
our O 0 0.0002079711
results O 0 0.00018131918
do O 0 0.00017877498
not O 0 0.00013810888
suggest O 0 0.00011062657
that O 0 0.00014801873
the O 0 0.00026371313
FRs O 0 0.25205177
, O 0 0.00024287736
generated O 0 0.00011241308
during O 0 0.00012545325
the O 0 0.00020689124
acute O 0 0.45105788
phase O 0 0.00086566666
, O 0 0.00031876474
determined O 0 0.00013179316
important O 0 0.00015325316
abnormalities O 0 0.02513465
in O 0 0.00026206413
mtDNA O 0 0.078516655
, O 0 0.00038040167
in O 0 0.0002299996
expression O 0 0.00036683393
of O 0 0.0014475912
CCO O 0 0.99659723
- O 0 0.07864738
I O 0 0.016568337
, O 0 0.0010618293
and O 0 0.0012674893
in O 0 0.002051131
CCO O 0 0.8623707
activity O 0 0.0044433046
. O 0 0.007220277

Adverse O 0 0.018814065
effect O 0 0.0027488738
of O 0 0.0023003358
the O 0 0.002279027
calcium B-Chemical 0 0.99920136
channel O 0 0.8973394
blocker O 0 0.99976426
nitrendipine B-Chemical 1 0.9999999
on O 0 0.0021852208
nephrosclerosis B-Disease 0 0.9999999
in O 0 0.0020435543
rats O 0 0.0045824954
with O 0 0.017168194
renovascular B-Disease 0 0.9999981
hypertension I-Disease 2 0.9999987
. O 0 0.01250637

The O 0 0.0029934847
effect O 0 0.0020975699
of O 0 0.0017839683
a O 0 0.0016338013
6 O 0 0.00085499993
- O 0 0.0019846454
week O 0 0.00036847193
treatment O 0 0.00038138716
with O 0 0.00035791082
the O 0 0.00049523235
calcium B-Chemical 0 0.99936134
channel O 0 0.8542271
blocker O 0 0.9996377
nitrendipine B-Chemical 1 0.9999999
or O 0 0.0012925903
the O 0 0.0023366006
angiotensin B-Chemical 1 0.9999912
converting O 0 0.15573545
enzyme O 0 0.29106116
inhibitor O 0 0.34963793
enalapril B-Chemical 1 0.9999989
on O 0 0.00013571166
blood O 0 0.026070321
pressure O 0 0.1349504
, O 0 0.002877041
albuminuria B-Disease 2 0.99999833
, O 0 0.0042260177
renal O 0 0.9504807
hemodynamics O 0 0.90400344
, O 0 0.00035495588
and O 0 0.00020810954
morphology O 0 0.000590805
of O 0 0.00024302446
the O 0 0.00025304058
nonclipped O 0 0.2555185
kidney O 0 0.41532156
was O 0 0.00025404734
studied O 0 0.00022797633
in O 0 0.00019621894
rats O 0 0.0002946238
with O 0 0.00026663774
two O 0 0.00031409998
- O 0 0.012092368
kidney O 0 0.49204457
, O 0 0.0018744789
one O 0 0.001470462
clip O 0 0.5802914
renovascular B-Disease 0 0.99999785
hypertension I-Disease 2 0.99999845
. O 0 0.01138801

Six O 0 0.0042398893
weeks O 0 0.001967959
after O 0 0.0013737953
clipping O 0 0.0032387667
of O 0 0.0011744456
one O 0 0.00092946907
renal O 0 0.87838966
artery O 0 0.5662599
, O 0 0.005550049
hypertensive B-Disease 2 0.99977845
rats O 0 0.0008346607
( O 0 0.0005790838
178 O 0 0.0044946726
+ O 0 0.002101574
/ O 0 0.008402046
- O 0 0.005048361
4 O 0 0.0001995304
mm O 0 0.0014128118
Hg O 0 0.9824754
) O 0 0.00040516187
were O 0 0.00016369602
randomly O 0 9.7184515e-05
assigned O 0 0.00011307641
to O 0 0.00011266183
three O 0 9.909716e-05
groups O 0 0.0001714399
: O 0 0.00032597364
untreated O 0 0.00055849034
hypertensive B-Disease 2 0.99937963
controls O 0 0.00042538124
( O 0 0.00028136963
n O 0 0.00017093486
= O 0 0.0004425288
8 O 0 0.0002003448
) O 0 0.00068330107
, O 0 0.0039767493
enalapril B-Chemical 1 0.9999993
- O 0 0.029278634
treated O 0 0.00033256554
( O 0 0.00033501268
n O 0 0.00020384636
= O 0 0.00048500558
8 O 0 0.00023182185
) O 0 0.0004794215
, O 0 0.00054103736
or O 0 0.0012381873
nitrendipine B-Chemical 1 0.99999964
- O 0 0.04732124
treated O 0 0.0008712482
( O 0 0.0010534434
n O 0 0.0010308287
= O 0 0.0022852176
10 O 0 0.00241659
) O 0 0.0051419865
. O 0 0.007258296

Sham O 0 0.33255377
- O 0 0.011305132
operated O 0 0.003633811
rats O 0 0.0021035813
served O 0 0.0015467841
as O 0 0.0010781824
normotensive O 0 0.90383124
controls O 0 0.0010639132
( O 0 0.00087387586
128 O 0 0.0013091902
+ O 0 0.0017116299
/ O 0 0.004535253
- O 0 0.0030587253
3 O 0 0.0005182983
mm O 0 0.0017315132
Hg O 0 0.9228559
, O 0 0.0013400962
n O 0 0.0013773377
= O 0 0.002832764
8 O 0 0.0030365444
) O 0 0.0061510536
. O 0 0.008610197

After O 0 0.002699888
6 O 0 0.0019218187
weeks O 0 0.0012245779
of O 0 0.0012841504
treatment O 0 0.0013494064
, O 0 0.0018651923
renal O 0 0.9249092
hemodynamics O 0 0.94934875
( O 0 0.0016143041
glomerular O 0 0.6840428
filtration O 0 0.001531862
rate O 0 0.00036364514
and O 0 0.0004675651
renal O 0 0.69029176
plasma O 0 0.028522937
flow O 0 0.0034325125
) O 0 0.00075757405
were O 0 0.0004961911
measured O 0 0.0005529483
in O 0 0.0009229485
the O 0 0.0015132827
anesthetized O 0 0.0054377792
rats O 0 0.0043775165
. O 0 0.0062116156

Renal O 0 0.07619136
tissue O 0 0.008172807
was O 0 0.0031623682
obtained O 0 0.0022625667
for O 0 0.002150417
determination O 0 0.0032063473
of O 0 0.0030607032
glomerular O 0 0.7443163
size O 0 0.005093858
and O 0 0.0074680834
sclerosis O 0 0.9971733
. O 0 0.011197559

Enalapril B-Chemical 0 0.9999801
but O 0 0.01421901
not O 0 0.009864637
nitrendipine B-Chemical 1 0.9999945
reduced O 0 0.008936283
blood O 0 0.08870977
pressure O 0 0.13094972
significantly O 0 0.009008123
. O 0 0.013047842

After O 0 0.0029333502
6 O 0 0.002133381
weeks O 0 0.0014050424
of O 0 0.0015327841
therapy O 0 0.0020043536
, O 0 0.0018180124
glomerular O 0 0.69883597
filtration O 0 0.003277148
rate O 0 0.00083899207
was O 0 0.000716769
not O 0 0.00064478896
different O 0 0.000750849
among O 0 0.0012993984
the O 0 0.0016060881
studied O 0 0.0028197903
groups O 0 0.0042956807
. O 0 0.007449465

Renal O 0 0.10354011
plasma O 0 0.021319842
flow O 0 0.009031881
increased O 0 0.0022409374
, O 0 0.0022328282
but O 0 0.002239844
albumin O 0 0.9968631
excretion O 0 0.99121124
and O 0 0.010631566
glomerulosclerosis B-Disease 2 0.9999987
did O 0 0.0016795266
not O 0 0.0008219809
change O 0 0.0012880849
after O 0 0.0016458412
enalapril B-Chemical 1 0.99998534
treatment O 0 0.006621352
. O 0 0.007090215

In O 0 0.003850049
contrast O 0 0.0030982003
, O 0 0.0027025004
in O 0 0.0015907261
the O 0 0.0036629322
nitrendipine B-Chemical 1 0.99999976
- O 0 0.18574621
treated O 0 0.0011699537
group O 0 0.0033875322
albuminuria B-Disease 2 0.9999949
increased O 0 0.00046330062
from O 0 0.00020286757
12 O 0 0.00016123033
. O 0 0.00016086976
8 O 0 0.00018204364
+ O 0 0.00064736925
/ O 0 0.0050356067
- O 0 0.0043276725
2 O 0 0.00017736573
progressively O 0 0.00018381576
to O 0 0.00015587709
163 O 0 0.0015207526
+ O 0 0.0016331576
/ O 0 0.008214334
- O 0 0.0038892732
55 O 0 0.00020936182
compared O 0 0.00011739839
with O 0 0.000178937
19 O 0 0.00026368594
. O 0 0.00017618384
2 O 0 0.00021172319
+ O 0 0.0007822292
/ O 0 0.0061156787
- O 0 0.0076204673
9 O 0 0.00034097437
mg O 0 0.007904127
/ O 0 0.0012647362
24 O 0 0.0005385782
hr O 0 0.0008188784
in O 0 0.00094357383
the O 0 0.0018102542
hypertensive B-Disease 2 0.9984712
controls O 0 0.0056752306
. O 0 0.0068716607

Furthermore O 0 0.0058111125
, O 0 0.009793347
glomerulosclerosis B-Disease 2 0.9999906
index O 0 0.010113867
was O 0 0.0011919969
significantly O 0 0.0007074477
increased O 0 0.00061093376
in O 0 0.0005318064
the O 0 0.0024412223
nitrendipine B-Chemical 1 0.9999999
- O 0 0.12447056
treated O 0 0.00044331563
group O 0 0.00027073536
compared O 0 0.00011948801
with O 0 0.0001844246
the O 0 0.00026323478
hypertensive B-Disease 2 0.999275
controls O 0 0.0004519592
( O 0 0.0003307131
0 O 0 0.00020153691
. O 0 0.0001534412
38 O 0 0.00028384302
+ O 0 0.000927028
/ O 0 0.007056902
- O 0 0.007170565
0 O 0 0.00026207586
. O 0 0.00018519817
1 O 0 0.00018526867
versus O 0 0.00019031185
0 O 0 0.00027834153
. O 0 0.00028677942
13 O 0 0.0004390284
+ O 0 0.0010985396
/ O 0 0.0041295732
- O 0 0.006142489
0 O 0 0.0016023123
. O 0 0.002145933
04 O 0 0.034975443
) O 0 0.006370162
. O 0 0.008192574

In O 0 0.0035360109
addition O 0 0.0019639381
, O 0 0.0029417437
glomerular O 0 0.6585757
size O 0 0.0015833292
was O 0 0.0008254313
higher O 0 0.0005536851
in O 0 0.0004892524
the O 0 0.0013274071
nitrendipine B-Chemical 1 0.99999976
- O 0 0.08313843
treated O 0 0.00048716005
group O 0 0.0004200397
( O 0 0.000372063
14 O 0 0.00019324746
. O 0 0.00016203885
9 O 0 0.00018492184
+ O 0 0.00066398707
/ O 0 0.0060670343
- O 0 0.008233449
0 O 0 0.0002565662
. O 0 0.00017072295
17 O 0 0.00020777529
10 O 0 0.0001702455
( O 0 0.000333328
- O 0 0.0017305086
3 O 0 0.00017186446
) O 0 0.00029631003
mm2 O 0 0.0007186739
) O 0 0.00069012336
but O 0 0.0002861499
lower O 0 0.00020382732
in O 0 0.00021017868
the O 0 0.0007070481
enalapril B-Chemical 1 0.9999994
- O 0 0.03941644
treated O 0 0.00033020874
group O 0 0.00032722685
( O 0 0.00032137954
11 O 0 0.0001723979
. O 0 0.0001333938
5 O 0 0.00014019053
+ O 0 0.00062319794
/ O 0 0.006149569
- O 0 0.007932956
0 O 0 0.00022804156
. O 0 0.00014610353
15 O 0 0.00013416633
10 O 0 0.00015347866
( O 0 0.0003054453
- O 0 0.0015845047
3 O 0 0.00016434536
) O 0 0.00027164185
mm2 O 0 0.0004993808
) O 0 0.0003525048
compared O 0 0.00012429254
with O 0 0.00018372988
the O 0 0.00026318766
hypertensive B-Disease 2 0.9991762
controls O 0 0.0004464132
( O 0 0.0003106579
12 O 0 0.00013159902
. O 0 0.0001415286
1 O 0 0.00017554862
+ O 0 0.0006538
/ O 0 0.005901071
- O 0 0.0077153724
0 O 0 0.00026668372
. O 0 0.00018899214
17 O 0 0.00023797492
10 O 0 0.00020918225
( O 0 0.00039132618
- O 0 0.0013098227
3 O 0 0.000281815
) O 0 0.0004955851
mm2 O 0 0.0009799033
) O 0 0.0011654762
. O 0 0.0008597975
( O 0 0.0018039751
ABSTRACT O 0 0.0059401114
TRUNCATED O 0 0.006731484
AT O 0 0.011809753
250 O 0 0.006161673
WORDS O 0 0.011585429
) O 0 0.018509153

Ketoconazole B-Chemical 0 0.99993443
induced O 0 0.015774
torsades B-Disease 0 0.9999087
de I-Disease 0 0.3910082
pointes I-Disease 0 0.99997354
without O 0 0.001675033
concomitant O 0 0.0024799032
use O 0 0.0010471398
of O 0 0.001496342
QT O 0 0.8356354
interval O 0 0.0015637975
- O 0 0.0048307944
prolonging O 0 0.0034903514
drug O 0 0.25014415
. O 0 0.008138161

Ketoconazole B-Chemical 0 0.9999478
is O 0 0.0040204613
not O 0 0.001912208
known O 0 0.0015453972
to O 0 0.0009086905
be O 0 0.000965215
proarrhythmic O 0 0.78584164
without O 0 0.00075514294
concomitant O 0 0.0016702962
use O 0 0.0007522527
of O 0 0.0012181341
QT O 0 0.86239094
interval O 0 0.001303824
- O 0 0.004444785
prolonging O 0 0.003044286
drugs O 0 0.16231935
. O 0 0.0072179423

We O 0 0.0040052775
report O 0 0.003689006
a O 0 0.002420612
woman O 0 0.0044354326
with O 0 0.001723585
coronary B-Disease 0 0.5096405
artery I-Disease 0 0.6156435
disease I-Disease 0 0.93447423
who O 0 0.0013810917
developed O 0 0.0006360014
a O 0 0.00040956904
markedly O 0 0.0006777711
prolonged B-Disease 0 0.0037465969
QT I-Disease 0 0.7112867
interval I-Disease 0 0.0003124725
and O 0 0.00039821723
torsades B-Disease 0 0.9995974
de I-Disease 0 0.08505568
pointes I-Disease 0 0.99999046
( O 0 0.021004513
TdP B-Disease 2 0.9999857
) O 0 0.0011041432
after O 0 0.00025416267
taking O 0 0.008449821
ketoconazole B-Chemical 1 0.9999976
for O 0 0.0007830652
treatment O 0 0.0013630982
of O 0 0.0028891386
fungal B-Disease 0 0.9512163
infection I-Disease 2 0.99957997
. O 0 0.015176087

Her O 0 0.011549436
QT O 0 0.23518455
interval O 0 0.003026816
returned O 0 0.0024720328
to O 0 0.0021402573
normal O 0 0.0027818042
upon O 0 0.0028048758
withdrawal O 0 0.45389202
of O 0 0.02810163
ketoconazole B-Chemical 1 0.99999523
. O 0 0.018509354

Genetic O 0 0.01669018
study O 0 0.0039409245
did O 0 0.0023271802
not O 0 0.0013382623
find O 0 0.001036374
any O 0 0.00090536923
mutation O 0 0.0028832324
in O 0 0.00074297754
her O 0 0.00077746564
genes O 0 0.0007599168
that O 0 0.00065822963
encode O 0 0.00093444384
cardiac O 0 0.123618715
IKr O 0 0.996332
channel O 0 0.07691578
proteins O 0 0.0063697784
. O 0 0.008085114

We O 0 0.0035593363
postulate O 0 0.0025980044
that O 0 0.0015073767
by O 0 0.0013824549
virtue O 0 0.0016546628
of O 0 0.0010641485
its O 0 0.0011780615
direct O 0 0.00050726125
blocking O 0 0.001183569
action O 0 0.0011366268
on O 0 0.0003925727
IKr O 0 0.99961674
, O 0 0.05434713
ketoconazole B-Chemical 1 0.9999995
alone O 0 0.0009220028
may O 0 0.00048614418
prolong O 0 0.00052767305
QT O 0 0.40345195
interval O 0 0.0008586641
and O 0 0.0015619738
induce O 0 0.0026854337
TdP B-Disease 2 0.99984694
. O 0 0.00793668

This O 0 0.0051616495
calls O 0 0.0033651395
for O 0 0.0018494079
attention O 0 0.0028528993
when O 0 0.0014660459
ketoconazole B-Chemical 1 0.99999857
is O 0 0.0011632601
administered O 0 0.00056304736
to O 0 0.00036967368
patients O 0 0.00054829835
with O 0 0.00048747132
risk O 0 0.019073965
factors O 0 0.0015538305
for O 0 0.0008248054
acquired O 0 0.0025891436
long B-Disease 0 0.0046990793
QT I-Disease 0 0.96658796
syndrome I-Disease 0 0.84553546
. O 0 0.007537104

Cerebral B-Disease 0 0.9984384
vasculitis I-Disease 2 0.9999887
following O 0 0.0046780645
oral O 0 0.9310151
methylphenidate B-Chemical 1 0.9999968
intake O 0 0.85840374
in O 0 0.0013177156
an O 0 0.0014622045
adult O 0 0.0020358826
: O 0 0.0025498935
a O 0 0.0026893225
case O 0 0.0037059635
report O 0 0.008480326
. O 0 0.0087459255

Methylphenidate B-Chemical 0 0.9998766
is O 0 0.006823822
structurally O 0 0.006135376
and O 0 0.0046884865
functionally O 0 0.0046450724
similar O 0 0.0048041707
to O 0 0.008491252
amphetamine B-Chemical 1 0.99997973
. O 0 0.016832976

Cerebral B-Disease 0 0.9988085
vasculitis I-Disease 2 0.99999285
associated O 0 0.009059977
with O 0 0.06519766
amphetamine B-Disease 1 1.0
abuse I-Disease 0 0.9999796
is O 0 0.0011631552
well O 0 0.00045952506
documented O 0 0.00067725714
, O 0 0.00046979217
and O 0 0.0003471076
in O 0 0.00032001597
rare O 0 0.00910965
cases O 0 0.08379393
ischaemic B-Disease 0 1.0
stroke I-Disease 2 0.9999994
has O 0 0.0006656103
been O 0 0.0004391891
reported O 0 0.00064983504
after O 0 0.00066913926
methylphenidate B-Chemical 1 0.9999869
intake O 0 0.5893868
in O 0 0.0023325016
children O 0 0.006570122
. O 0 0.0066941474

We O 0 0.003806602
report O 0 0.0032344349
the O 0 0.0016852851
case O 0 0.0013516148
of O 0 0.0011562482
a O 0 0.0011583053
63 O 0 0.0015137158
- O 0 0.004855201
year O 0 0.00065121363
- O 0 0.0035834932
old O 0 0.00047699033
female O 0 0.0014331287
who O 0 0.0005205957
was O 0 0.00026685238
treated O 0 0.0003490582
with O 0 0.00080583943
methylphenidate B-Chemical 1 0.9999852
due O 0 0.00026790827
to O 0 0.00043494234
hyperactivity B-Disease 2 0.99974805
and O 0 0.0007703996
suffered O 0 0.010153227
from O 0 0.0010996107
multiple O 0 0.027665837
ischaemic B-Disease 0 0.9999987
strokes I-Disease 0 0.9999788
. O 0 0.0133294305

We O 0 0.0035580513
consider O 0 0.0022102399
drug O 0 0.43459076
- O 0 0.052192286
induced O 0 0.0052364543
cerebral B-Disease 0 0.9999697
vasculitis I-Disease 2 0.99999964
as O 0 0.00095576147
the O 0 0.00043735656
most O 0 0.00048572218
likely O 0 0.0002595445
cause O 0 0.0003421991
of O 0 0.0010770694
recurrent O 0 0.9804539
ischaemic B-Disease 0 1.0
strokes I-Disease 0 0.9999987
in O 0 0.0004976404
the O 0 0.00021533298
absence O 0 0.0001603
of O 0 0.00030240286
any O 0 0.0002553103
pathological O 0 0.010994541
findings O 0 0.00045121275
during O 0 0.00033648137
the O 0 0.0005745865
diagnostic O 0 0.0012729153
work O 0 0.0017000247
- O 0 0.0051087993
up O 0 0.0035129152
. O 0 0.006451467

We O 0 0.0035046737
conclude O 0 0.0020208142
that O 0 0.0021200287
methylphenidate B-Chemical 1 0.9999783
mediated O 0 0.0019449113
vasculitis B-Disease 2 0.9999902
should O 0 0.00048124307
be O 0 0.00039721254
considered O 0 0.00029622074
in O 0 0.0003101518
patients O 0 0.0005195626
with O 0 0.00074648834
neurological O 0 0.9991271
symptoms O 0 0.91381395
and O 0 0.0006961902
a O 0 0.000920243
history O 0 0.009912687
of O 0 0.008870902
methylphenidate B-Chemical 1 0.9999896
therapy O 0 0.020958045
. O 0 0.006946811

This O 0 0.00476443
potential O 0 0.003275119
side O 0 0.12701383
- O 0 0.026037203
effect O 0 0.0013359438
, O 0 0.001352336
though O 0 0.00082968397
very O 0 0.0009255436
rare O 0 0.0032108342
, O 0 0.00060936186
represents O 0 0.0003404366
one O 0 0.0002850898
more O 0 0.00028707075
reason O 0 0.00022297606
to O 0 0.00025189284
be O 0 0.00033476748
very O 0 0.0005132322
restrictive O 0 0.00071727746
in O 0 0.0006074477
the O 0 0.00086616335
use O 0 0.0015500076
of O 0 0.005043923
methylphenidate B-Chemical 1 0.9999715
. O 0 0.008357256

MDMA B-Chemical 0 0.9999995
polydrug O 0 0.9999871
users O 0 0.025464425
show O 0 0.0012297023
process O 0 0.0012434035
- O 0 0.0030405337
specific O 0 0.0006570657
central O 0 0.0011306638
executive O 0 0.31069595
impairments O 0 0.15143993
coupled O 0 0.0005665319
with O 0 0.00057225063
impaired B-Disease 0 0.0008969025
social I-Disease 0 0.006155789
and I-Disease 0 0.0014800203
emotional I-Disease 0 0.02699736
judgement I-Disease 0 0.0050569
processes I-Disease 0 0.005490852
. O 0 0.007500557

In O 0 0.003637682
recent O 0 0.0026086976
years O 0 0.0024733616
working O 0 0.0066364734
memory B-Disease 0 0.9792636
deficits I-Disease 0 0.98621327
have O 0 0.0006254871
been O 0 0.0005186358
reported O 0 0.0005078725
in O 0 0.00042748102
users O 0 0.0042251265
of O 0 0.007219009
MDMA B-Chemical 0 1.0
( O 0 0.0017848263
3 B-Chemical 0 0.00044800734
, I-Chemical 0 0.00070301513
4 I-Chemical 0 0.0007556958
- I-Chemical 0 0.1070182
methylenedioxymethamphetamine I-Chemical 0 0.999998
, O 0 0.0396118
ecstasy B-Chemical 1 0.9999813
) O 0 0.0107660815
. O 0 0.008486383

The O 0 0.0031326385
current O 0 0.002677474
study O 0 0.0016606972
aimed O 0 0.0010470389
to O 0 0.0006141191
assess O 0 0.0003307106
the O 0 0.0003892332
impact O 0 0.00037029482
of O 0 0.0055042966
MDMA B-Chemical 0 1.0
use O 0 0.0003406569
on O 0 0.00013732216
three O 0 0.000110664776
separate O 0 0.00011030383
central O 0 0.0002348871
executive O 0 0.03386704
processes O 0 0.00027637547
( O 0 0.0002680524
set O 0 0.00015465671
shifting O 0 0.0003618609
, O 0 0.00031678766
inhibition O 0 0.00046470008
and O 0 0.00038257937
memory O 0 0.24193133
updating O 0 0.0017884558
) O 0 0.0005005978
and O 0 0.00023489763
also O 0 0.00020332864
on O 0 0.00020037558
" O 0 0.0006375815
prefrontal O 0 0.33485794
" O 0 0.0004982641
mediated O 0 0.00040795328
social O 0 0.0041314447
and O 0 0.0013372308
emotional O 0 0.027644526
judgement O 0 0.0048383167
processes O 0 0.0052544926
. O 0 0.007208351

Fifteen O 0 0.022877853
polydrug O 0 0.99998057
ecstasy B-Chemical 1 0.9999894
users O 0 0.015500599
and O 0 0.0012341312
15 O 0 0.00092592725
polydrug O 0 0.99995077
non O 0 0.0082217185
- O 0 0.2294465
ecstasy B-Chemical 1 0.9999901
user O 0 0.00050624926
controls O 0 0.00034158997
completed O 0 0.00020160455
a O 0 0.0002302954
general O 0 0.00019949862
drug O 0 0.017846089
use O 0 0.00018962393
questionnaire O 0 0.00016456317
, O 0 0.00024433996
the O 0 0.00021427537
Brixton O 0 0.17944211
Spatial O 0 0.015193716
Anticipation O 0 0.043242678
task O 0 0.00044722567
( O 0 0.0002916972
set O 0 0.0001769119
shifting O 0 0.00045201113
) O 0 0.0007926238
, O 0 0.00060299
Backward O 0 0.43617463
Digit O 0 0.9995084
Span O 0 0.9622296
procedure O 0 0.00027937497
( O 0 0.0005468865
memory O 0 0.13196103
updating O 0 0.0017809047
) O 0 0.0007283467
, O 0 0.0003530614
Inhibition O 0 0.0004909194
of O 0 0.00038777752
Return O 0 0.010161971
( O 0 0.00050202943
inhibition O 0 0.0008840477
) O 0 0.0009626344
, O 0 0.00036809416
an O 0 0.00029731428
emotional O 0 0.028362522
intelligence O 0 0.06808098
scale O 0 0.0003577037
, O 0 0.00035466906
the O 0 0.0003084904
Tromso O 0 0.014586512
Social O 0 0.012644866
Intelligence O 0 0.0058765206
Scale O 0 0.018631155
and O 0 0.000528365
the O 0 0.00076892617
Dysexecutive O 0 0.635735
Questionnaire O 0 0.002931911
( O 0 0.003878422
DEX O 0 0.9920413
) O 0 0.008697904
. O 0 0.008611863

Compared O 0 0.0037806372
with O 0 0.009934683
MDMA B-Chemical 0 0.99999976
- O 0 0.1771071
free O 0 0.007216894
polydrug O 0 0.99999225
controls O 0 0.026431285
, O 0 0.13315058
MDMA B-Chemical 0 1.0
polydrug O 0 0.99999917
users O 0 0.015109149
showed O 0 0.00029347156
impairments O 0 0.08210958
in O 0 0.00018477206
set O 0 0.000173515
shifting O 0 0.0003368921
and O 0 0.0003484534
memory O 0 0.14689904
updating O 0 0.0012719423
, O 0 0.00043815185
and O 0 0.00035826294
also O 0 0.00037171767
in O 0 0.0005162231
social O 0 0.0036872677
and O 0 0.0012562027
emotional O 0 0.02116055
judgement O 0 0.004562991
processes O 0 0.0051281545
. O 0 0.0071181827

The O 0 0.0038789765
latter O 0 0.0039591757
two O 0 0.0021719371
deficits O 0 0.14612073
remained O 0 0.0018028078
significant O 0 0.0012401945
after O 0 0.00094537396
controlling O 0 0.0013624673
for O 0 0.001716975
other O 0 0.0028579468
drug O 0 0.28804806
use O 0 0.0057619726
. O 0 0.008410742

These O 0 0.003948661
data O 0 0.0026696012
lend O 0 0.0019209828
further O 0 0.0012001363
support O 0 0.0008079446
to O 0 0.0006458683
the O 0 0.0005493022
proposal O 0 0.0008788714
that O 0 0.0003885471
cognitive O 0 0.3153788
processes O 0 0.00040458603
mediated O 0 0.00021485474
by O 0 0.00032401606
the O 0 0.00042475094
prefrontal O 0 0.81539327
cortex O 0 0.11717393
may O 0 0.00034957903
be O 0 0.00047730366
impaired O 0 0.0008742968
by O 0 0.001338653
recreational O 0 0.74632746
ecstasy B-Chemical 1 0.99997425
use O 0 0.004884708
. O 0 0.0068439655

Phase O 0 0.009340064
II O 0 0.009991945
study O 0 0.0024055622
of O 0 0.0018115349
the O 0 0.0019856584
amsacrine B-Chemical 0 0.99997425
analogue O 0 0.40975454
CI B-Chemical 0 0.9802889
- I-Chemical 0 0.09472297
921 I-Chemical 0 0.23832706
( O 0 0.00261401
NSC B-Chemical 0 0.9984717
343499 I-Chemical 0 0.80154186
) O 0 0.0010037252
in O 0 0.0005997287
non B-Disease 2 0.0012711295
- I-Disease 2 0.0037340773
small I-Disease 2 0.0016537452
cell I-Disease 2 0.036920764
lung I-Disease 2 0.99359834
cancer I-Disease 2 0.9999212
. O 0 0.019373197

CI B-Chemical 0 0.84831244
- I-Chemical 0 0.050804783
921 I-Chemical 0 0.13898532
( O 0 0.0060638124
NSC B-Chemical 0 0.99734455
343499 I-Chemical 0 0.84288496
; O 0 0.002021557
9 B-Chemical 0 0.00087100663
- I-Chemical 0 0.0047251633
[ I-Chemical 0 0.0029260751
[ I-Chemical 0 0.0030588256
2 I-Chemical 0 0.0005996579
- I-Chemical 0 0.049855813
methoxy I-Chemical 0 0.9995732
- I-Chemical 0 0.04881691
4 I-Chemical 0 0.00036919466
- I-Chemical 0 0.010129417
[ I-Chemical 0 0.005538602
( I-Chemical 0 0.0025850688
methylsulphonyl I-Chemical 0 0.9944841
) I-Chemical 0 0.010888375
amino I-Chemical 0 0.9813447
] I-Chemical 0 0.14490803
phenyl I-Chemical 0 0.9999201
] I-Chemical 0 0.047028743
amino I-Chemical 0 0.9747353
] I-Chemical 0 0.05451646
- I-Chemical 0 0.17991464
N I-Chemical 0 0.9989692
, I-Chemical 0 0.0009632086
5 I-Chemical 0 0.00031099955
- I-Chemical 0 0.046016965
dimethyl I-Chemical 0 0.9998597
- I-Chemical 0 0.07990167
4 I-Chemical 0 0.00030002394
- I-Chemical 0 0.0047881654
acridinecarboxamide I-Chemical 0 0.03643543
) O 0 0.00062760874
is O 0 0.00032970356
a O 0 0.0005777142
topoisomerase O 0 0.89113986
II O 0 0.12837973
poison O 0 0.12028559
with O 0 0.0007282894
high O 0 0.0011928777
experimental O 0 0.0017454952
antitumour O 0 0.6450112
activity O 0 0.00451679
. O 0 0.006847421

It O 0 0.004318633
was O 0 0.0023064723
administered O 0 0.0014295732
by O 0 0.0010745218
15 O 0 0.0006947317
min O 0 0.0006790613
infusion O 0 0.000642698
to O 0 0.0003139569
16 O 0 0.0003209062
evaluable O 0 0.0004587115
patients O 0 0.0002851681
with O 0 0.00024506927
non B-Disease 2 0.0007175961
- I-Disease 2 0.005551117
small I-Disease 2 0.0003283604
cell I-Disease 2 0.034517564
lung I-Disease 2 0.99877614
cancer I-Disease 2 0.9999981
( O 0 0.31928882
NSCLC B-Disease 2 0.99996495
) O 0 0.005352456
( O 0 0.00044334563
7 O 0 0.00014088149
with O 0 0.00014244558
no O 0 0.00011080204
prior O 0 0.00011344556
treatment O 0 0.00023273364
, O 0 0.00028979313
9 O 0 0.00015718666
patients O 0 0.00020004284
in O 0 0.00017592011
relapse O 0 0.67736906
following O 0 0.0001595756
surgery O 0 0.0005291178
/ O 0 0.0043353946
radiotherapy O 0 0.06710609
) O 0 0.00045645793
at O 0 0.00014573702
a O 0 0.0002169367
dose O 0 0.001105249
( O 0 0.0006007971
648 O 0 0.05008022
mg O 0 0.020963231
/ O 0 0.0011456809
m2 O 0 0.0020433576
divided O 0 0.00013845487
over O 0 0.00010973101
3 O 0 0.00013665103
days O 0 0.00012504635
, O 0 0.00020019547
repeated O 0 0.00014667668
every O 0 0.00014082562
3 O 0 0.00022853194
weeks O 0 0.00025612264
) O 0 0.0006095274
determined O 0 0.0006223061
by O 0 0.0012238515
phase O 0 0.0025356815
I O 0 0.011882747
trial O 0 0.004831892
. O 0 0.0069313347

Patients O 0 0.0046491995
had O 0 0.0022621728
a O 0 0.0017138411
median O 0 0.0009181101
performance O 0 0.001150495
status O 0 0.0009424463
of O 0 0.0008157456
1 O 0 0.0006980936
( O 0 0.00095778244
WHO O 0 0.0037303076
) O 0 0.0010795663
, O 0 0.00077391235
and O 0 0.0007027686
median O 0 0.00068749004
age O 0 0.0015096082
of O 0 0.0019756875
61 O 0 0.0037391093
years O 0 0.004815988
. O 0 0.0075018145

The O 0 0.0032509859
histology O 0 0.01732914
comprised O 0 0.0038616152
squamous B-Disease 0 0.9999862
carcinoma I-Disease 2 0.99999785
( O 0 0.018234642
11 O 0 0.0010486711
) O 0 0.0014371983
, O 0 0.0016381191
adenocarcinoma B-Disease 0 0.9998418
( O 0 0.0023097675
1 O 0 0.00039260014
) O 0 0.0005466124
, O 0 0.00037519095
mixed O 0 0.00058727094
histology O 0 0.101615295
( O 0 0.00060252816
2 O 0 0.00024782313
) O 0 0.00045163752
, O 0 0.00042025998
bronchio B-Disease 0 0.019115916
- I-Disease 0 0.02495014
alveolar I-Disease 0 0.1834872
carcinoma I-Disease 2 0.99997723
( O 0 0.0025848476
1 O 0 0.0003327105
) O 0 0.0004505002
and O 0 0.00037114474
large O 0 0.00052985863
cell O 0 0.009067005
undifferentiated B-Disease 0 0.98165524
carcinoma I-Disease 2 0.99999535
( O 0 0.012223823
1 O 0 0.002934649
) O 0 0.005660638
. O 0 0.0074005052

Neutropenia B-Disease 0 0.99955446
grade O 0 0.12811822
greater O 0 0.0017315174
than O 0 0.0008612288
or O 0 0.00067482464
equal O 0 0.00043719477
to O 0 0.00040232454
3 O 0 0.00033694235
was O 0 0.00029155822
seen O 0 0.00024655895
in O 0 0.00023909275
15 O 0 0.00022110225
patients O 0 0.00034601896
, O 0 0.00048199765
infections B-Disease 2 0.93716365
with O 0 0.00048521828
recovery O 0 0.00056310324
in O 0 0.00028774515
3 O 0 0.00027916062
, O 0 0.00042001187
and O 0 0.0005672097
grand O 0 0.05645923
mal O 0 0.99995255
seizures B-Disease 0 0.9999987
in O 0 0.0020877675
1 O 0 0.0023816177
patient O 0 0.0038793173
. O 0 0.0063181533

Grade O 0 0.13392246
less O 0 0.0027224866
than O 0 0.0013328113
or O 0 0.0010207591
equal O 0 0.0006698322
to O 0 0.0006731199
2 O 0 0.0009849352
nausea B-Disease 2 0.9999851
and O 0 0.001954157
vomiting B-Disease 0 0.99976426
occurred O 0 0.00041088831
in O 0 0.00029097864
66 O 0 0.0004195771
% O 0 0.000317444
courses O 0 0.0003003488
and O 0 0.00059472077
phlebitis B-Disease 0 0.999835
in O 0 0.00047676876
the O 0 0.00054042635
infusion O 0 0.001284532
arm O 0 0.0011469703
in O 0 0.0014304182
37 O 0 0.0030449512
% O 0 0.0044663525
. O 0 0.0068990663

1 O 0 0.004681516
patient O 0 0.0031931507
with O 0 0.0032477044
squamous B-Disease 0 0.9993919
cell I-Disease 0 0.15159263
carcinoma I-Disease 2 0.9999573
achieved O 0 0.0023706327
a O 0 0.0016445512
partial O 0 0.0015823174
response O 0 0.0017418624
lasting O 0 0.0019457724
5 O 0 0.002266718
months O 0 0.0033137042
. O 0 0.0070054103

Further O 0 0.0041344096
testing O 0 0.0027703212
in O 0 0.001969098
this O 0 0.0014894833
and O 0 0.0013925397
other O 0 0.0013800411
tumour B-Disease 0 0.7076496
types O 0 0.00085028604
using O 0 0.0008403403
multiple O 0 0.0011751697
daily O 0 0.0014115088
schedules O 0 0.0018852198
is O 0 0.0025846162
warranted O 0 0.003855684
. O 0 0.007214537

Pharmacokinetics O 0 0.9519181
of O 0 0.09152292
desipramine B-Chemical 0 0.9999999
HCl I-Chemical 0 0.99999094
when O 0 0.0034097037
administered O 0 0.004483168
with O 0 0.01835008
cinacalcet B-Chemical 1 0.9999975
HCl I-Chemical 0 0.99998116
. O 0 0.01655428

OBJECTIVE O 0 0.035886828
: O 0 0.004243217
In O 0 0.001987218
vitro O 0 0.0017788833
work O 0 0.0012729166
has O 0 0.00075796555
demonstrated O 0 0.0006064296
that O 0 0.0007781668
cinacalcet B-Chemical 1 0.9999888
is O 0 0.0006759388
a O 0 0.0005379279
strong O 0 0.00058790646
inhibitor O 0 0.010906653
of O 0 0.0074448693
cytochrome O 0 0.9999722
P450 O 0 0.9999956
isoenzyme O 0 0.99984777
( O 0 0.37368375
CYP O 0 0.99999774
) O 0 0.39068645
2D6 O 0 0.99996424
. O 0 0.010777961

The O 0 0.0031031142
purpose O 0 0.0021881587
of O 0 0.0017117627
this O 0 0.0011806609
study O 0 0.0010194528
was O 0 0.00058720086
to O 0 0.00035518693
evaluate O 0 0.00020079536
the O 0 0.0002676096
effect O 0 0.00031021633
of O 0 0.0020712586
cinacalcet B-Chemical 1 0.9999974
on O 0 0.0005965522
CYP2D6 O 0 0.9999863
activity O 0 0.000547727
, O 0 0.00063053844
using O 0 0.0005385315
desipramine B-Chemical 0 0.99999845
as O 0 0.00035416073
a O 0 0.00046371704
probe O 0 0.0005268096
substrate O 0 0.0016701182
, O 0 0.0013999476
in O 0 0.0015717347
healthy O 0 0.007080762
subjects O 0 0.004872663
. O 0 0.006437157

METHODS O 0 0.004421163
: O 0 0.0040553855
Seventeen O 0 0.0040066
subjects O 0 0.0019886447
who O 0 0.0014996469
were O 0 0.00092372566
genotyped O 0 0.0020991196
as O 0 0.00093396986
CYP2D6 O 0 0.9999038
extensive O 0 0.0010159338
metabolizers O 0 0.9958723
were O 0 0.000279642
enrolled O 0 0.00028822426
in O 0 0.0001864619
this O 0 0.00018474633
randomized O 0 0.00022405398
, O 0 0.00029263814
open O 0 0.0004551195
- O 0 0.0063391374
label O 0 0.0013473313
, O 0 0.00044484934
crossover O 0 0.001644877
study O 0 0.00022511672
to O 0 0.00012938755
receive O 0 0.00011375028
a O 0 0.00018970131
single O 0 0.00020505422
oral O 0 0.054674163
dose O 0 0.007161982
of O 0 0.009987757
desipramine B-Chemical 0 0.9999999
( O 0 0.0018418359
50 O 0 0.00033269366
mg O 0 0.009527199
) O 0 0.00022876523
on O 0 8.638836e-05
two O 0 9.5143165e-05
separate O 0 9.069846e-05
occasions O 0 0.0002091914
, O 0 0.00018393218
once O 0 0.00011771383
alone O 0 0.00014153548
and O 0 0.00017624263
once O 0 0.00012241342
after O 0 0.00010326053
multiple O 0 0.00021378907
doses O 0 0.0011817078
of O 0 0.0015570355
cinacalcet B-Chemical 1 0.99999404
( O 0 0.0011842676
90 O 0 0.00048189153
mg O 0 0.0024161409
for O 0 0.0007142577
7 O 0 0.0010623342
days O 0 0.0016089336
) O 0 0.0045237266
. O 0 0.006667921

Blood O 0 0.015806785
samples O 0 0.003647222
were O 0 0.002757567
obtained O 0 0.002369938
predose O 0 0.011929402
and O 0 0.0020267593
up O 0 0.0019025346
to O 0 0.0021607876
72 O 0 0.003622088
h O 0 0.004584199
postdose O 0 0.011612863
. O 0 0.009246759

RESULTS O 0 0.012643627
: O 0 0.009673213
Fourteen O 0 0.009264463
subjects O 0 0.00675355
completed O 0 0.005933459
both O 0 0.0066798725
treatment O 0 0.009629704
arms O 0 0.01676631
. O 0 0.017478961

Relative O 0 0.0044174828
to O 0 0.0038427082
desipramine B-Chemical 0 0.99999726
alone O 0 0.002345982
, O 0 0.0011599687
mean O 0 0.00043621854
AUC O 0 0.015712425
and O 0 0.001199341
C O 0 0.9993455
( O 0 0.006009796
max O 0 0.17946295
) O 0 0.00155664
of O 0 0.0026179957
desipramine B-Chemical 0 0.99999964
increased O 0 0.0005260108
3 O 0 0.00020671674
. O 0 0.00018700922
6 O 0 0.00018440877
- O 0 0.0006799258
and O 0 0.00028262034
1 O 0 0.00028241938
. O 0 0.00029544288
8 O 0 0.00038261476
- O 0 0.0011653078
fold O 0 0.00088326714
when O 0 0.00086316024
coadministered O 0 0.633206
with O 0 0.009286868
cinacalcet B-Chemical 1 0.99995935
. O 0 0.008718486

The O 0 0.0035225865
t O 0 0.0045398534
( O 0 0.0028666682
1 O 0 0.0016336831
/ O 0 0.0026822786
2 O 0 0.0009121135
, O 0 0.0009452956
z O 0 0.008285073
) O 0 0.0021957566
of O 0 0.004684227
desipramine B-Chemical 0 0.99999964
was O 0 0.00047466782
longer O 0 0.00018807428
when O 0 0.0002938801
desipramine B-Chemical 0 0.9999993
was O 0 0.0003982913
coadministered O 0 0.45835292
with O 0 0.0024283584
cinacalcet B-Chemical 1 0.9999943
( O 0 0.0009677647
21 O 0 0.00034052928
. O 0 0.00027249887
0 O 0 0.00037258188
versus O 0 0.00044194728
43 O 0 0.00093843334
. O 0 0.0009752789
3 O 0 0.0016108726
hs O 0 0.103464976
) O 0 0.0065171774
. O 0 0.007880407

The O 0 0.0053315223
t O 0 0.0071652643
( O 0 0.005891649
max O 0 0.029874476
) O 0 0.0046410635
was O 0 0.0029261461
similar O 0 0.0024392598
between O 0 0.002959371
the O 0 0.004752267
regimens O 0 0.008777193
. O 0 0.011072317

Fewer O 0 0.008779689
subjects O 0 0.0033257469
reported O 0 0.002317663
adverse O 0 0.2354074
events O 0 0.010162542
following O 0 0.0005955392
treatment O 0 0.0011181952
with O 0 0.007743429
desipramine B-Chemical 0 0.99999976
alone O 0 0.00057260116
than O 0 0.00017448625
when O 0 0.00015574129
receiving O 0 0.00354184
desipramine B-Chemical 0 0.99999976
with O 0 0.0073912567
cinacalcet B-Chemical 1 0.9999964
( O 0 0.0008365848
33 O 0 0.00025825843
versus O 0 0.00013979341
86 O 0 0.00030395124
% O 0 0.00026179463
) O 0 0.00040086324
, O 0 0.00025313126
the O 0 0.00017045569
most O 0 0.00027342225
frequent O 0 0.00046642107
of O 0 0.00023313519
which O 0 0.00054787373
( O 0 0.0096579585
nausea B-Disease 2 0.9999982
and O 0 0.010031526
headache B-Disease 0 0.99998355
) O 0 0.0011576286
have O 0 0.00017394323
been O 0 0.00019795606
reported O 0 0.00025072307
for O 0 0.00022981042
patients O 0 0.00043027475
treated O 0 0.00047348224
with O 0 0.00079025823
either O 0 0.0031821446
desipramine B-Chemical 0 0.9999993
or O 0 0.0125980275
cinacalcet B-Chemical 1 0.9999709
. O 0 0.008218652

CONCLUSION O 0 0.025545351
: O 0 0.005114615
This O 0 0.0032464587
study O 0 0.002174999
demonstrates O 0 0.0013589115
that O 0 0.0017402223
cinacalcet B-Chemical 1 0.99997234
is O 0 0.0019163406
a O 0 0.0019118312
strong O 0 0.002520726
inhibitor O 0 0.068960205
of O 0 0.03506396
CYP2D6 O 0 0.9998975
. O 0 0.010320512

These O 0 0.0036097362
data O 0 0.0023302631
suggest O 0 0.0011027871
that O 0 0.0009262282
during O 0 0.0006887662
concomitant O 0 0.002019504
treatment O 0 0.001512548
with O 0 0.008611126
cinacalcet B-Chemical 1 0.999998
, O 0 0.0027274834
dose O 0 0.0065145874
adjustment O 0 0.0005329039
may O 0 0.000176473
be O 0 0.0001624206
necessary O 0 0.00012566926
for O 0 0.00018424568
drugs O 0 0.008634416
that O 0 0.00014858408
demonstrate O 0 0.00013510867
a O 0 0.00028576984
narrow O 0 0.00050244544
therapeutic O 0 0.0006446949
index O 0 0.0006557107
and O 0 0.0008166584
are O 0 0.0012483012
metabolized O 0 0.57276976
by O 0 0.0042549972
CYP2D6 O 0 0.9997185
. O 0 0.0074388995

Case O 0 0.024294851
report O 0 0.014390509
: O 0 0.016328024
acute O 0 0.9792884
unintentional O 0 0.99860364
carbachol B-Chemical 1 0.9999852
intoxication O 0 0.9999492
. O 0 0.032116015

INTRODUCTION O 0 0.01642784
: O 0 0.007522889
Intoxications O 0 0.84575504
with O 0 0.0049979007
carbachol B-Chemical 1 0.99988425
, O 0 0.007302588
a O 0 0.0054664374
muscarinic O 0 0.9987387
cholinergic O 0 0.9285778
receptor O 0 0.15751551
agonist O 0 0.8028848
are O 0 0.003870733
rare O 0 0.011048205
. O 0 0.008308156

We O 0 0.004894423
report O 0 0.0042758514
an O 0 0.0027220284
interesting O 0 0.0015448065
case O 0 0.0017886627
investigating O 0 0.0015573293
a O 0 0.0022730369
( O 0 0.002989416
near O 0 0.0041632145
) O 0 0.023108093
fatal O 0 0.998898
poisoning B-Disease 2 0.99997914
. O 0 0.015842268

METHODS O 0 0.0041489773
: O 0 0.0035905303
The O 0 0.001890511
son O 0 0.0028699383
of O 0 0.0015032679
an O 0 0.0013705957
84 O 0 0.0016524412
- O 0 0.003809876
year O 0 0.0007773382
- O 0 0.0021995257
old O 0 0.0004936506
male O 0 0.00079320406
discovered O 0 0.00036285978
a O 0 0.00037601474
newspaper O 0 0.0004941252
report O 0 0.00054936926
stating O 0 0.00063787936
clinical O 0 0.0008753234
success O 0 0.0008550553
with O 0 0.00051551306
plant O 0 0.006743453
extracts O 0 0.0023739054
in O 0 0.0018156483
Alzheimer B-Disease 0 0.99998486
' I-Disease 0 0.004290585
s I-Disease 0 0.004168981
disease I-Disease 0 0.7550247
. O 0 0.008152763

The O 0 0.0032869657
mode O 0 0.0027397193
of O 0 0.0020621468
action O 0 0.0022958291
was O 0 0.0011127345
said O 0 0.0010409976
to O 0 0.00046171874
be O 0 0.0004024996
comparable O 0 0.000257536
to O 0 0.00024881086
that O 0 0.00023216936
of O 0 0.00033864382
the O 0 0.00032192477
synthetic O 0 0.0005717746
compound O 0 0.38629293
' O 0 0.002910873
carbamylcholin B-Chemical 0 0.6214183
' O 0 0.0017879528
; O 0 0.0013788247
that O 0 0.0010176818
is O 0 0.002167169
, O 0 0.0071435696
carbachol B-Chemical 1 0.9995566
. O 0 0.009911792

He O 0 0.008383779
bought O 0 0.0057219993
25 O 0 0.0023784155
g O 0 0.0025442725
of O 0 0.0019932988
carbachol B-Chemical 1 0.9995907
as O 0 0.0010710659
pure O 0 0.004720054
substance O 0 0.8778741
in O 0 0.00052534643
a O 0 0.0006521191
pharmacy O 0 0.006437416
, O 0 0.00049022224
and O 0 0.00038206548
the O 0 0.00038008648
father O 0 0.0014118723
was O 0 0.0005538811
administered O 0 0.00065864064
400 O 0 0.0011594517
to O 0 0.0011853272
500 O 0 0.0029296845
mg O 0 0.021484066
. O 0 0.006300253

Carbachol B-Chemical 0 0.999856
concentrations O 0 0.014584838
in O 0 0.002336803
serum O 0 0.15797833
and O 0 0.0016229637
urine O 0 0.10910122
on O 0 0.00039189422
day O 0 0.00037942347
1 O 0 0.00036309645
and O 0 0.00036406956
2 O 0 0.00033600038
of O 0 0.00038924528
hospital O 0 0.00064800907
admission O 0 0.0008700494
were O 0 0.00048527814
analysed O 0 0.00066601194
by O 0 0.0012799442
HPLC O 0 0.81335515
- O 0 0.0077368664
mass O 0 0.010439321
spectrometry O 0 0.25642762
. O 0 0.009121663

RESULTS O 0 0.0062434715
: O 0 0.00484068
Minutes O 0 0.07346057
after O 0 0.0015812968
oral O 0 0.06094731
administration O 0 0.012533284
, O 0 0.0011505608
the O 0 0.00063449994
patient O 0 0.00080551615
developed O 0 0.008990602
nausea B-Disease 2 0.9999976
, O 0 0.01662851
sweating O 0 0.9999075
and O 0 0.010368616
hypotension B-Disease 2 0.99998283
, O 0 0.0021477533
and O 0 0.0019969388
finally O 0 0.0040233643
collapsed O 0 0.007477523
. O 0 0.007223313

Bradycardia B-Disease 2 0.9990146
, O 0 0.017454991
cholinergic O 0 0.7742181
symptoms O 0 0.4738251
and O 0 0.012351663
asystole B-Disease 0 0.9963929
occurred O 0 0.013957107
. O 0 0.017147295

Initial O 0 0.004838115
cardiopulmonary O 0 0.0031834655
resuscitation O 0 0.0024732323
and O 0 0.0013742789
immediate O 0 0.0014433683
treatment O 0 0.0013351222
with O 0 0.0064795553
adrenaline B-Chemical 1 0.99999654
( O 0 0.077490926
epinephrine B-Chemical 0 0.9999465
) O 0 0.020196488
, O 0 0.012371095
atropine B-Chemical 0 0.99999034
and O 0 0.014555947
furosemide B-Chemical 1 0.99998474
was O 0 0.0033713724
successful O 0 0.0055139107
. O 0 0.0070938147

On O 0 0.003887618
hospital O 0 0.0041052806
admission O 0 0.0057774493
, O 0 0.002246436
blood O 0 0.0059184926
pressure O 0 0.014949108
of O 0 0.00088241417
the O 0 0.00074274675
intubated O 0 0.0023293311
, O 0 0.0010561636
bradyarrhythmic O 0 0.14297001
patient O 0 0.00089402386
was O 0 0.0009752998
100 O 0 0.0016731451
/ O 0 0.0033336482
65 O 0 0.0033279208
mmHg O 0 0.007058606
. O 0 0.0073877247

Further O 0 0.004834321
signs O 0 0.033349928
were O 0 0.003533634
hyperhidrosis B-Disease 0 0.9997862
, O 0 0.03717063
hypersalivation B-Disease 0 0.99999285
, O 0 0.017691331
bronchorrhoea B-Disease 0 0.9557784
, O 0 0.0012262505
and O 0 0.0010090845
severe O 0 0.71315414
miosis B-Disease 0 0.9999975
; O 0 0.002475983
the O 0 0.00051594246
electrocardiographic O 0 0.5877678
finding O 0 0.0008918619
was O 0 0.000867821
atrio B-Disease 0 0.020031838
- I-Disease 0 0.009379906
ventricular I-Disease 0 0.54714924
dissociation I-Disease 0 0.043431863
. O 0 0.0077649658

High O 0 0.01107026
doses O 0 0.011757802
of O 0 0.0074231457
atropine B-Chemical 0 0.9999882
( O 0 0.0028836532
up O 0 0.0006699219
to O 0 0.00046282785
50 O 0 0.000508041
mg O 0 0.0014750563
per O 0 0.0002525951
24 O 0 0.00034470786
hours O 0 0.00034922955
) O 0 0.00095459254
, O 0 0.0022131242
adrenaline B-Chemical 1 0.9999502
and O 0 0.0034318569
dopamine B-Chemical 1 0.998665
were O 0 0.0023659188
necessary O 0 0.003037578
. O 0 0.0065253614

The O 0 0.008672377
patient O 0 0.008220801
was O 0 0.007550788
extubated O 0 0.008137365
1 O 0 0.006946739
week O 0 0.007404594
later O 0 0.010837703
. O 0 0.017756773

However O 0 0.010159871
, O 0 0.010181625
increased O 0 0.010131358
dyspnoea B-Disease 0 0.9927061
and O 0 0.016335607
bronchospasm B-Disease 0 0.9999043
necessitated O 0 0.04846185
reintubation O 0 0.76456064
. O 0 0.01537439

Respiratory B-Disease 0 0.99093926
insufficiency I-Disease 0 0.9994368
was O 0 0.0037634752
further O 0 0.0026100343
worsened O 0 0.027367411
by O 0 0.0028819467
Proteus B-Disease 0 0.9568449
mirabilis I-Disease 0 0.16489223
infection I-Disease 2 0.996163
and O 0 0.02336441
severe O 0 0.9204893
bronchoconstriction O 0 0.9997204
. O 0 0.013505414

One O 0 0.004510075
week O 0 0.0022265709
later O 0 0.0017567805
, O 0 0.001719053
the O 0 0.0010191378
patient O 0 0.0008974933
was O 0 0.0006572169
again O 0 0.00057443784
extubated O 0 0.0005496882
and O 0 0.00042082925
3 O 0 0.00036169693
days O 0 0.0003325589
later O 0 0.00044358955
was O 0 0.00060957385
transferred O 0 0.00080035394
to O 0 0.001089127
a O 0 0.0020941182
peripheral O 0 0.004762874
ward O 0 0.0048654475
. O 0 0.007075875

On O 0 0.0038638168
the O 0 0.0026391903
next O 0 0.0016643917
day O 0 0.0015947106
he O 0 0.0017147198
died O 0 0.002545897
, O 0 0.001663119
probably O 0 0.0015059406
as O 0 0.0012233288
a O 0 0.0016338793
result O 0 0.0017240315
of O 0 0.0036721567
heart B-Disease 0 0.50416166
failure I-Disease 0 0.69772714
. O 0 0.0100694075

Serum O 0 0.19164836
samples O 0 0.0023263465
from O 0 0.0013405476
the O 0 0.000957782
first O 0 0.0006217473
and O 0 0.00058362016
second O 0 0.00040514296
days O 0 0.00027335758
contained O 0 0.00023981852
3 O 0 0.00025795898
. O 0 0.00024830466
6 O 0 0.00022331243
and O 0 0.00030276173
1 O 0 0.000327046
. O 0 0.00034606978
9 O 0 0.00046439006
mg O 0 0.007872736
/ O 0 0.0038950727
l O 0 0.025330322
carbachol B-Chemical 1 0.9997509
, O 0 0.005970332
respectively O 0 0.010785274
. O 0 0.008043366

The O 0 0.0039610737
corresponding O 0 0.0030484435
urine O 0 0.048398335
concentrations O 0 0.0029686973
amounted O 0 0.0024256953
to O 0 0.0017019146
374 O 0 0.0052389237
and O 0 0.0022795429
554 O 0 0.015203071
mg O 0 0.045486134
/ O 0 0.008489898
l O 0 0.010966742
. O 0 0.011212954

CONCLUSION O 0 0.027995566
: O 0 0.004317243
This O 0 0.0024874853
case O 0 0.0014099113
started O 0 0.0009732619
with O 0 0.0007634417
a O 0 0.0007479453
media O 0 0.0013408298
report O 0 0.000996455
in O 0 0.00033982794
a O 0 0.00038916434
popular O 0 0.0007024789
newspaper O 0 0.0004382132
, O 0 0.000274394
initiated O 0 0.0001857404
by O 0 0.00020658018
published O 0 0.00022961285
, O 0 0.00038494385
peer O 0 0.016790187
- O 0 0.0044745356
reviewed O 0 0.0003484135
research O 0 0.0002346767
on O 0 0.00015679775
herbals O 0 0.62000316
, O 0 0.0003638727
and O 0 0.00024105782
involved O 0 0.00017562028
human O 0 0.00043343805
failure O 0 0.09226295
in O 0 0.00029495065
a O 0 0.0003784589
case O 0 0.00041121116
history O 0 0.0031534862
, O 0 0.0007741629
medical O 0 0.001418048
examination O 0 0.00091049046
and O 0 0.0013520863
clinical O 0 0.0040373374
treatment O 0 0.0038375023
. O 0 0.0061917454

For O 0 0.0033596775
the O 0 0.00217279
first O 0 0.0013577692
time O 0 0.0009739157
, O 0 0.0012251192
an O 0 0.0008782503
analytical O 0 0.0017635704
method O 0 0.0006598331
for O 0 0.00041015292
the O 0 0.0003954732
determination O 0 0.0014412228
of O 0 0.00121718
carbachol B-Chemical 1 0.9998499
in O 0 0.00084460777
plasma O 0 0.029376445
and O 0 0.0011971382
urine O 0 0.21998383
has O 0 0.0014887516
been O 0 0.0023875863
developed O 0 0.004838301
. O 0 0.0068446617

The O 0 0.0031769564
analysed O 0 0.002804176
carbachol B-Chemical 1 0.99879044
concentration O 0 0.0040348764
exceeded O 0 0.00083110115
the O 0 0.0006140844
supposed O 0 0.00070283486
serum O 0 0.04069303
level O 0 0.00031296056
resulting O 0 0.00030149176
from O 0 0.0002765178
a O 0 0.0003794262
therapeutic O 0 0.0006852705
dose O 0 0.0011462092
by O 0 0.00051321974
a O 0 0.00073367945
factor O 0 0.0024184277
of O 0 0.0015269063
130 O 0 0.0023913658
to O 0 0.0022814567
260 O 0 0.011063178
. O 0 0.006937974

Especially O 0 0.008157954
in O 0 0.002714309
old O 0 0.0022798467
patients O 0 0.0019973
, O 0 0.0014895883
intensivists O 0 0.0010402738
should O 0 0.0004200529
consider O 0 0.00043863663
intoxications O 0 0.99921596
( O 0 0.0019250674
with O 0 0.0011576804
cholinergics O 0 0.9457752
) O 0 0.0009370941
as O 0 0.00047130513
a O 0 0.0007276099
cause O 0 0.0011090724
of O 0 0.0027717787
acute B-Disease 0 0.9972978
cardiovascular I-Disease 0 0.99847454
failure I-Disease 0 0.9856629
. O 0 0.010600902

Pharmacological O 0 0.20537879
evidence O 0 0.002810713
for O 0 0.0020346716
the O 0 0.0015804179
potential O 0 0.0016796802
of O 0 0.0026685568
Daucus O 0 0.84259313
carota O 0 0.49240112
in O 0 0.0010631755
the O 0 0.0011623173
management O 0 0.001929503
of O 0 0.0031065017
cognitive B-Disease 0 0.88755095
dysfunctions I-Disease 0 0.8424661
. O 0 0.009182859

The O 0 0.0030855527
present O 0 0.0019470954
study O 0 0.001762274
was O 0 0.0010957015
aimed O 0 0.00080410426
at O 0 0.0005050445
investigating O 0 0.0003955993
the O 0 0.0003866006
effects O 0 0.0005197327
of O 0 0.0010818146
Daucus O 0 0.92527074
carota O 0 0.7812642
seeds O 0 0.001017301
on O 0 0.0001668695
cognitive O 0 0.090034805
functions O 0 0.00021984873
, O 0 0.000303479
total O 0 0.00024647196
serum O 0 0.56897414
cholesterol B-Chemical 0 0.99986196
levels O 0 0.0006365017
and O 0 0.0009645628
brain O 0 0.14853908
cholinesterase O 0 0.9990044
activity O 0 0.0012347549
in O 0 0.0017444978
mice O 0 0.0024939233
. O 0 0.0059559396

The O 0 0.0044589015
ethanolic O 0 0.7688392
extract B-Chemical 0 0.010373187
of I-Chemical 0 0.00380508
Daucus I-Chemical 0 0.93415976
carota I-Chemical 0 0.9157453
seeds I-Chemical 0 0.016620154
( O 0 0.0029062042
DCE B-Chemical 0 0.989579
) O 0 0.001078013
was O 0 0.00033046695
administered O 0 0.00025495052
orally O 0 0.00037654865
in O 0 0.00017162159
three O 0 0.00012382242
doses O 0 0.0007230448
( O 0 0.00043459176
100 O 0 0.000479611
, O 0 0.0003220933
200 O 0 0.00032637475
, O 0 0.00028050822
400 O 0 0.00041628352
mg O 0 0.008119011
/ O 0 0.0010455563
kg O 0 0.0007117453
) O 0 0.00035817755
for O 0 0.00017577338
seven O 0 0.00016034878
successive O 0 0.00016709209
days O 0 0.00016635445
to O 0 0.00021587695
different O 0 0.00027904595
groups O 0 0.00044938634
of O 0 0.0007617743
young O 0 0.0033943516
and O 0 0.00164233
aged O 0 0.0031266804
mice O 0 0.002924006
. O 0 0.0067271455

Elevated O 0 0.028774964
plus O 0 0.0027758004
maze O 0 0.018403655
and O 0 0.0017729745
passive O 0 0.0021901755
avoidance O 0 0.0028467712
apparatus O 0 0.0010694513
served O 0 0.000966251
as O 0 0.000650257
the O 0 0.0007900447
exteroceptive O 0 0.28075856
behavioral O 0 0.0049725114
models O 0 0.0011855746
for O 0 0.0016201402
testing O 0 0.003195928
memory O 0 0.252205
. O 0 0.00831158

Diazepam B-Chemical 0 0.99999785
- O 0 0.7009899
, O 0 0.12876666
scopolamine B-Chemical 1 0.9999994
- O 0 0.26744965
and O 0 0.0025291739
ageing O 0 0.52957636
- O 0 0.036829453
induced O 0 0.0019848268
amnesia B-Disease 0 0.9998932
served O 0 0.0016756942
as O 0 0.0009825185
the O 0 0.0013851486
interoceptive O 0 0.09441404
behavioral O 0 0.011105066
models O 0 0.004494747
. O 0 0.0074458565

DCE B-Chemical 0 0.97296673
( O 0 0.0053155194
200 O 0 0.003054305
, O 0 0.0021695804
400 O 0 0.0019702532
mg O 0 0.02173554
/ O 0 0.0026652527
kg O 0 0.0018106824
, O 0 0.0008226069
p O 0 0.0005458694
. O 0 0.00043168498
o O 0 0.005560565
. O 0 0.00041412818
) O 0 0.0005846883
showed O 0 0.00029816787
significant O 0 0.00032271052
improvement O 0 0.0003945943
in O 0 0.00041105732
memory O 0 0.03882792
scores O 0 0.0005998491
of O 0 0.00091347366
young O 0 0.0036962475
and O 0 0.0017956774
aged O 0 0.0033478257
mice O 0 0.0031321354
. O 0 0.007100959

The O 0 0.0028596162
extent O 0 0.0017403456
of O 0 0.0019017624
memory O 0 0.08313182
improvement O 0 0.0013631838
evoked O 0 0.008233637
by O 0 0.0011680506
DCE B-Chemical 0 0.9890794
was O 0 0.00051921676
23 O 0 0.00046355595
% O 0 0.00030699876
at O 0 0.00019271162
the O 0 0.0001900888
dose O 0 0.00047333247
of O 0 0.00029161794
200 O 0 0.00047522943
mg O 0 0.015980186
/ O 0 0.0011308737
kg O 0 0.0005547736
and O 0 0.00021760105
35 O 0 0.00018850945
% O 0 0.00019153299
at O 0 0.00013679755
the O 0 0.00015420977
dose O 0 0.0004283932
of O 0 0.00030315656
400 O 0 0.00076799764
mg O 0 0.017053915
/ O 0 0.0012251345
kg O 0 0.00076911814
in O 0 0.00037453807
young O 0 0.0009795668
mice O 0 0.00043287998
using O 0 0.00082674826
elevated O 0 0.0026168346
plus O 0 0.0022730215
maze O 0 0.12598151
. O 0 0.006711561

Similarly O 0 0.005351042
, O 0 0.0036494113
significant O 0 0.0020095762
improvements O 0 0.0014187369
in O 0 0.0012021934
memory O 0 0.040818896
scores O 0 0.0008088991
were O 0 0.0006507549
observed O 0 0.00055582135
using O 0 0.00067982107
passive O 0 0.001388559
avoidance O 0 0.0027665258
apparatus O 0 0.0017349577
and O 0 0.002104976
aged O 0 0.0037540616
mice O 0 0.0034669868
. O 0 0.0076535083

Furthermore O 0 0.0058670016
, O 0 0.007311318
DCE B-Chemical 0 0.97473836
reversed O 0 0.0025689467
the O 0 0.00186782
amnesia B-Disease 0 0.99987566
induced O 0 0.0016053771
by O 0 0.007491744
scopolamine B-Chemical 1 0.99999976
( O 0 0.0041126646
0 O 0 0.0004397928
. O 0 0.00023471742
4 O 0 0.00020572473
mg O 0 0.0032767756
/ O 0 0.00095165294
kg O 0 0.00089766516
, O 0 0.0004356513
i O 0 0.0015112889
. O 0 0.00023126445
p O 0 0.00026829782
. O 0 0.0002467219
) O 0 0.00071607134
and O 0 0.0016274444
diazepam B-Chemical 0 0.99999905
( O 0 0.001193995
1 O 0 0.00035912855
mg O 0 0.009475782
/ O 0 0.0013096668
kg O 0 0.0012654134
, O 0 0.0008981502
i O 0 0.0018727339
. O 0 0.0011046411
p O 0 0.0017812311
. O 0 0.0026908335
) O 0 0.006273597
. O 0 0.00832992

Daucus B-Chemical 0 0.9741954
carota I-Chemical 0 0.8784234
extract I-Chemical 0 0.0598047
( O 0 0.0025917322
200 O 0 0.0015741941
, O 0 0.0011515717
400 O 0 0.0011508876
mg O 0 0.016083952
/ O 0 0.0020455534
kg O 0 0.0014473688
, O 0 0.0006217806
p O 0 0.00042372697
. O 0 0.00034096654
o O 0 0.010622591
. O 0 0.0003640602
) O 0 0.00062287966
reduced O 0 0.00027056222
significantly O 0 0.00027143885
the O 0 0.0002853277
brain O 0 0.08136264
acetylcholinesterase O 0 0.9980586
activity O 0 0.0004104256
and O 0 0.0007459244
cholesterol B-Chemical 0 0.99940026
levels O 0 0.00061481
in O 0 0.00071025535
young O 0 0.0031597265
and O 0 0.0015100562
aged O 0 0.002896931
mice O 0 0.0027676774
. O 0 0.0064507117

The O 0 0.002763741
extent O 0 0.0016240227
of O 0 0.0016586541
inhibition O 0 0.0021904735
of O 0 0.0019211253
brain O 0 0.33306235
cholinesterase O 0 0.999637
activity O 0 0.0006238784
evoked O 0 0.006987458
by O 0 0.00052183744
DCE B-Chemical 0 0.96689814
at O 0 0.00019802441
the O 0 0.00018419983
dose O 0 0.00050486554
of O 0 0.0003026873
400 O 0 0.0007164925
mg O 0 0.016035397
/ O 0 0.0011775303
kg O 0 0.00067055173
was O 0 0.00026557368
22 O 0 0.00031040417
% O 0 0.00033216222
in O 0 0.00034064087
young O 0 0.0010465019
and O 0 0.00064249197
19 O 0 0.0009801536
% O 0 0.0011940099
in O 0 0.0015096032
aged O 0 0.0031220394
mice O 0 0.0031740959
. O 0 0.0072507267

There O 0 0.0042927708
was O 0 0.0026857913
a O 0 0.0020435124
remarkable O 0 0.001713376
reduction O 0 0.0015194569
in O 0 0.00071985566
total O 0 0.00065379933
cholesterol B-Chemical 0 0.9994685
level O 0 0.00036964015
as O 0 0.00029495035
well O 0 0.00027336486
, O 0 0.00032788987
to O 0 0.00016875056
the O 0 0.00016308825
extent O 0 0.00013269264
of O 0 0.00024517867
23 O 0 0.00032813655
% O 0 0.00024852494
in O 0 0.00020555023
young O 0 0.000885232
and O 0 0.0002857303
21 O 0 0.0003044008
% O 0 0.0003288011
in O 0 0.0003085951
aged O 0 0.00052029383
animals O 0 0.00041762114
with O 0 0.0006927212
this O 0 0.0010687169
dose O 0 0.004196033
of O 0 0.0054332064
DCE B-Chemical 0 0.9906882
. O 0 0.0085601555

Therefore O 0 0.004597764
, O 0 0.006702733
DCE B-Chemical 0 0.95556796
may O 0 0.0015349392
prove O 0 0.0010748458
to O 0 0.00067661196
be O 0 0.0006015907
a O 0 0.0005644267
useful O 0 0.00039940455
remedy O 0 0.0007266308
for O 0 0.0002752846
the O 0 0.00024734347
management O 0 0.0003633115
of O 0 0.0004701192
cognitive B-Disease 0 0.86355424
dysfunctions I-Disease 0 0.43674925
on O 0 0.00012485322
account O 0 0.00016567094
of O 0 0.00023360223
its O 0 0.00059500796
multifarious O 0 0.002293384
beneficial O 0 0.00025761756
effects O 0 0.00023799171
such O 0 0.0001732016
as O 0 0.00021838027
, O 0 0.00052381743
memory O 0 0.12644559
improving O 0 0.0003483297
property O 0 0.001566328
, O 0 0.0031837574
cholesterol B-Chemical 0 0.9998574
lowering O 0 0.07530392
property O 0 0.0034366222
and O 0 0.0036702973
anticholinesterase O 0 0.99945134
activity O 0 0.0041631632
. O 0 0.006304418

Valproic B-Chemical 0 0.9999956
acid I-Chemical 0 0.99894136
induced O 0 0.113237865
encephalopathy B-Disease 2 0.9999989
- O 0 0.81584585
- O 0 0.05713121
19 O 0 0.00087136065
new O 0 0.00054983125
cases O 0 0.00059746945
in O 0 0.00040004664
Germany O 0 0.0029576553
from O 0 0.00023526678
1994 O 0 0.0008349709
to O 0 0.00022401316
2003 O 0 0.0010452967
- O 0 0.012401222
- O 0 0.0040206984
a O 0 0.00036899673
side O 0 0.0053096362
effect O 0 0.0002932129
associated O 0 0.0005411666
to O 0 0.00094475906
VPA B-Chemical 1 0.9999994
- O 0 0.077955544
therapy O 0 0.0010397973
not O 0 0.0005933348
only O 0 0.0009551339
in O 0 0.0014540746
young O 0 0.0074438546
children O 0 0.006545141
. O 0 0.007088255

Valproic B-Chemical 0 0.9999969
acid I-Chemical 0 0.99964154
( O 0 0.35866475
VPA B-Chemical 1 0.99999774
) O 0 0.009842019
is O 0 0.0009975971
a O 0 0.0008571147
broad O 0 0.001072267
- O 0 0.0074110213
spectrum O 0 0.0018204662
antiepileptic O 0 0.9989599
drug O 0 0.24172808
and O 0 0.0008028234
is O 0 0.00084866077
usually O 0 0.0012762989
well O 0 0.0016156775
- O 0 0.013961499
tolerated O 0 0.015710898
. O 0 0.0066748373

Rare O 0 0.23056054
serious O 0 0.12042764
complications O 0 0.37228522
may O 0 0.0013682473
occur O 0 0.0008911484
in O 0 0.0006788561
some O 0 0.0005611829
patients O 0 0.00078037457
, O 0 0.00076316716
including O 0 0.0014546264
haemorrhagic O 0 0.9999987
pancreatitis B-Disease 0 0.9999999
, O 0 0.06390427
bone B-Disease 0 0.75562984
marrow I-Disease 0 0.97282416
suppression I-Disease 0 0.758873
, O 0 0.13858606
VPA B-Chemical 1 0.99999976
- O 0 0.4399896
induced O 0 0.02102158
hepatotoxicity B-Disease 2 0.9999999
and O 0 0.31905627
VPA B-Chemical 1 0.9999995
- O 0 0.46838394
induced O 0 0.02558979
encephalopathy B-Disease 2 0.99998856
. O 0 0.014982686

The O 0 0.003144771
typical O 0 0.0025749
signs O 0 0.08790323
of O 0 0.026163531
VPA B-Chemical 1 0.9999994
- O 0 0.49071968
induced O 0 0.009058139
encephalopathy B-Disease 2 0.9999981
are O 0 0.0022566307
impaired B-Disease 0 0.17488937
consciousness I-Disease 0 0.9983884
, O 0 0.0008453469
sometimes O 0 0.0010874091
marked O 0 0.001181696
EEG O 0 0.90584093
background O 0 0.00033155826
slowing O 0 0.0047379066
, O 0 0.0006828968
increased O 0 0.0014249288
seizure B-Disease 2 0.9999629
frequency O 0 0.0011712796
, O 0 0.0010082158
with O 0 0.0010134379
or O 0 0.001520987
without O 0 0.004430773
hyperammonemia B-Disease 0 0.9999653
. O 0 0.010121808

There O 0 0.004317614
is O 0 0.0025808648
still O 0 0.0016392018
no O 0 0.0009981666
proof O 0 0.0009611323
of O 0 0.0009652678
causative O 0 0.008735531
effect O 0 0.0011412019
of O 0 0.01943201
VPA B-Chemical 1 0.9999995
in O 0 0.00084184535
patients O 0 0.0015655981
with O 0 0.0023578473
encephalopathy B-Disease 2 0.9999975
, O 0 0.0027165376
but O 0 0.00043816294
only O 0 0.00029984696
of O 0 0.0003603012
an O 0 0.00040734102
association O 0 0.00041466282
with O 0 0.00067020353
an O 0 0.0009411564
assumed O 0 0.0012249962
causal O 0 0.002565718
relation O 0 0.0029988405
. O 0 0.0066283527

We O 0 0.0038575176
report O 0 0.0036449127
19 O 0 0.002546122
patients O 0 0.002117888
with O 0 0.005866659
VPA B-Chemical 1 0.9999993
- O 0 0.43918422
associated O 0 0.011535237
encephalopathy B-Disease 2 0.9999968
in O 0 0.0012184759
Germany O 0 0.013052479
from O 0 0.00022693645
the O 0 0.00022614699
years O 0 0.00030825695
1994 O 0 0.00066387316
to O 0 0.00025670425
2003 O 0 0.0005716264
, O 0 0.00045639943
none O 0 0.00043558693
of O 0 0.0006079267
whom O 0 0.0012362743
had O 0 0.0009628201
been O 0 0.0013792305
published O 0 0.0021634435
previously O 0 0.0036621774
. O 0 0.0068020527

Cerebral B-Disease 0 0.99883395
haemorrhage I-Disease 0 0.9999819
induced O 0 0.0051376317
by O 0 0.0064238133
warfarin B-Chemical 1 0.99996567
- O 0 0.022594081
the O 0 0.0011777618
influence O 0 0.0010375828
of O 0 0.0020806328
drug O 0 0.7044053
- O 0 0.06695684
drug O 0 0.40814027
interactions O 0 0.008620192
. O 0 0.009240418

PURPOSE O 0 0.0048799566
: O 0 0.002951615
To O 0 0.001233395
evaluate O 0 0.0006784688
the O 0 0.00074181124
frequency O 0 0.00079542893
, O 0 0.00083206664
severity O 0 0.0031073475
and O 0 0.0008239861
preventability O 0 0.92737216
of O 0 0.010584206
warfarin B-Chemical 1 0.999995
- O 0 0.17241706
induced O 0 0.0033013944
cerebral B-Disease 0 0.9999809
haemorrhages I-Disease 0 0.9999993
due O 0 0.00020043766
to O 0 0.00033740734
warfarin B-Chemical 1 0.99995875
and O 0 0.00600503
warfarin B-Chemical 1 0.9999895
- O 0 0.07423864
drug O 0 0.11566795
interactions O 0 0.000419101
in O 0 0.000237913
patients O 0 0.0003966773
living O 0 0.0012495636
in O 0 0.00033209476
the O 0 0.0004236226
county O 0 0.0014265076
of O 0 0.0011447677
Osterg O 0 0.04005083
tland O 0 0.026262086
, O 0 0.0040804488
Sweden O 0 0.012417597
. O 0 0.0071644504

METHODS O 0 0.004194688
: O 0 0.0034631982
All O 0 0.0017430302
patients O 0 0.0016411165
with O 0 0.0011876199
a O 0 0.0013871816
diagnosed O 0 0.086791046
cerebral B-Disease 2 0.99995065
haemorrhage I-Disease 2 0.9999987
at O 0 0.00046761704
three O 0 0.00027442325
hospitals O 0 0.0004177161
during O 0 0.0002972851
the O 0 0.00043555125
period O 0 0.0005710772
2000 O 0 0.001434551
- O 0 0.002779941
2002 O 0 0.0026928408
were O 0 0.0024291787
identified O 0 0.0037027365
. O 0 0.0072637023

Medical O 0 0.007297501
records O 0 0.0028732505
were O 0 0.0015874591
studied O 0 0.0010755807
retrospectively O 0 0.0007898668
to O 0 0.00049788103
evaluate O 0 0.0002995121
whether O 0 0.00035023218
warfarin B-Chemical 1 0.99987483
and O 0 0.006635773
warfarin B-Chemical 1 0.9999889
- O 0 0.09234565
drug O 0 0.15895057
interactions O 0 0.0007759617
could O 0 0.00047059468
have O 0 0.0006154604
caused O 0 0.0011491189
the O 0 0.0038176551
cerebral B-Disease 2 0.9999169
haemorrhage I-Disease 2 0.9999958
. O 0 0.011035755

The O 0 0.0038059945
proportion O 0 0.0027426977
of O 0 0.0026823247
possibly O 0 0.0032938432
avoidable O 0 0.0144588975
cases O 0 0.002215752
due O 0 0.0012995115
to O 0 0.0016089511
drug O 0 0.11633597
interactions O 0 0.0034110097
was O 0 0.003562822
estimated O 0 0.0049781017
. O 0 0.008849655

RESULTS O 0 0.0059053386
: O 0 0.0041531506
Among O 0 0.0036883433
593 O 0 0.058772217
patients O 0 0.0019528964
with O 0 0.002663346
cerebral B-Disease 2 0.99994683
haemorrhage I-Disease 2 0.9999994
, O 0 0.0027078597
59 O 0 0.0009515841
( O 0 0.0005901128
10 O 0 0.0003804873
% O 0 0.00047927507
) O 0 0.00059180654
were O 0 0.0004340591
assessed O 0 0.0004339408
as O 0 0.0006273994
related O 0 0.00081401906
to O 0 0.0016894402
warfarin B-Chemical 1 0.99959
treatment O 0 0.005713985
. O 0 0.00725142

This O 0 0.0053799064
imply O 0 0.0025032153
an O 0 0.0026775736
incidence O 0 0.003649453
of O 0 0.0019993407
1 O 0 0.001421988
. O 0 0.0011122591
7 O 0 0.0010839619
/ O 0 0.0021812452
100 O 0 0.001886505
, O 0 0.002041829
000 O 0 0.0024842892
treatment O 0 0.0033688163
years O 0 0.0060347603
. O 0 0.008963224

Of O 0 0.004812693
the O 0 0.0026630294
59 O 0 0.0025613434
cases O 0 0.002002728
, O 0 0.0016642759
26 O 0 0.001242474
( O 0 0.0010474509
44 O 0 0.0008448987
% O 0 0.00066241453
) O 0 0.0007213349
had O 0 0.0003796027
a O 0 0.0005657921
fatal O 0 0.8930099
outcome O 0 0.0025606102
, O 0 0.00037718783
compared O 0 0.00015514588
to O 0 0.0001771369
136 O 0 0.00074075337
( O 0 0.00030750493
25 O 0 0.00024205438
% O 0 0.0002598795
) O 0 0.00034538156
among O 0 0.0002619415
the O 0 0.00023716492
non O 0 0.0014655481
- O 0 0.1558954
warfarin B-Chemical 1 0.9999032
patients O 0 0.0010313346
( O 0 0.00070619624
p O 0 0.00061248685
< O 0 0.000773835
0 O 0 0.001292525
. O 0 0.001848843
01 O 0 0.005593775
) O 0 0.0058199763
. O 0 0.007880221

A O 0 0.81129414
warfarin B-Chemical 1 0.99995077
- O 0 0.22605093
drug O 0 0.30665255
interaction O 0 0.0014434183
could O 0 0.00062482804
have O 0 0.0004239613
contributed O 0 0.0005041504
to O 0 0.00032947355
the O 0 0.0005818692
haemorrhage B-Disease 0 0.9999751
in O 0 0.0003832207
24 O 0 0.00029004688
( O 0 0.00031804745
41 O 0 0.00036314686
% O 0 0.0002699554
) O 0 0.00034253928
of O 0 0.00026324356
the O 0 0.0004146379
warfarin B-Chemical 1 0.99984455
patients O 0 0.00042181046
and O 0 0.00020681118
in O 0 0.0001598226
7 O 0 0.00013396169
of O 0 0.00016601013
these O 0 0.00021356066
( O 0 0.00033897345
12 O 0 0.00017788332
% O 0 0.0002797084
) O 0 0.00046740155
the O 0 0.00043610253
bleeding B-Disease 0 0.99818987
complication O 0 0.1288615
was O 0 0.0004731935
considered O 0 0.00050929026
being O 0 0.00094512006
possible O 0 0.0012166289
to O 0 0.001806345
avoid O 0 0.0031139292
. O 0 0.0063399365

CONCLUSIONS O 0 0.10143898
: O 0 0.023780338
Warfarin B-Chemical 0 0.9999379
- O 0 0.08591444
induced O 0 0.0049739275
cerebral B-Disease 0 0.99994135
haemorrhages I-Disease 0 0.999998
are O 0 0.00089603645
a O 0 0.0007122983
major O 0 0.00065924786
clinical O 0 0.0012810009
problem O 0 0.00092580734
with O 0 0.0009138153
a O 0 0.0014986619
high O 0 0.0028065422
fatality O 0 0.9721124
rate O 0 0.006925534
. O 0 0.008805176

Almost O 0 0.0055367
half O 0 0.0024802748
of O 0 0.0023696735
the O 0 0.0017390853
cases O 0 0.0018924959
was O 0 0.001311097
related O 0 0.0009323233
to O 0 0.0012231955
a O 0 0.0032028332
warfarin B-Chemical 1 0.9999336
- O 0 0.076288074
drug O 0 0.34928787
interaction O 0 0.006387571
. O 0 0.009435866

A O 0 0.031220265
significant O 0 0.002808386
proportion O 0 0.0018804247
of O 0 0.004877597
warfarin B-Chemical 1 0.99998343
- O 0 0.18466753
related O 0 0.0009498875
cerebral B-Disease 0 0.9999368
haemorrhages I-Disease 0 0.99999905
might O 0 0.00032003818
have O 0 0.00023565764
been O 0 0.0002410013
prevented O 0 0.0002892411
if O 0 0.00018068854
greater O 0 0.00019003046
caution O 0 0.00024978397
had O 0 0.00021381455
been O 0 0.0002023182
taken O 0 0.0001801621
when O 0 0.00022467993
prescribing O 0 0.0018443932
drugs O 0 0.022164386
known O 0 0.00062928285
to O 0 0.00066064723
interact O 0 0.0010282976
with O 0 0.0043227216
warfarin B-Chemical 1 0.99977
. O 0 0.0073032374

Antipsychotic O 0 0.9986469
- O 0 0.016071409
like O 0 0.0021655927
profile O 0 0.0019329406
of O 0 0.0049065533
thioperamide B-Chemical 0 0.99999607
, O 0 0.0051931017
a O 0 0.0020643254
selective O 0 0.038446076
H3 O 0 0.9929676
- O 0 0.22203965
receptor O 0 0.21641131
antagonist O 0 0.8773742
in O 0 0.0030560626
mice O 0 0.0035664092
. O 0 0.0076272525

Experimental O 0 0.0066184457
and O 0 0.003064987
clinical O 0 0.002825333
evidence O 0 0.0011438259
points O 0 0.00095490454
to O 0 0.0007053538
a O 0 0.0007166413
role O 0 0.0004427653
of O 0 0.00071110734
central O 0 0.0014378957
histaminergic O 0 0.13462289
system O 0 0.0006899283
in O 0 0.0007563982
the O 0 0.0010805174
pathogenesis O 0 0.004611434
of O 0 0.009260643
schizophrenia B-Disease 2 0.99992824
. O 0 0.009137829

The O 0 0.003039768
present O 0 0.0019061827
study O 0 0.0017117001
was O 0 0.0010426694
designed O 0 0.0007055699
to O 0 0.000502776
study O 0 0.0005112811
the O 0 0.00034415888
effect O 0 0.00037724662
of O 0 0.0044404636
histamine B-Chemical 1 0.9999974
H O 0 0.99999964
( O 0 0.02160118
3 O 0 0.00035869936
) O 0 0.0015744099
- O 0 0.015749738
receptor O 0 0.012454585
ligands O 0 0.024845501
on O 0 0.0004096381
neuroleptic O 0 0.99999976
- O 0 0.3254101
induced O 0 0.023425879
catalepsy B-Disease 2 1.0
, O 0 0.18708324
apomorphine B-Chemical 1 0.99999964
- O 0 0.05557122
induced O 0 0.0003457832
climbing O 0 0.03161787
behavior O 0 0.004748133
and O 0 0.008989284
amphetamine B-Chemical 1 0.99999964
- O 0 0.076860815
induced O 0 0.0011908194
locomotor O 0 0.54282224
activities O 0 0.0013513253
in O 0 0.0017730345
mice O 0 0.0025622742
. O 0 0.006086354

Catalepsy B-Disease 0 0.9998217
was O 0 0.003418624
induced O 0 0.0024642048
by O 0 0.0061710123
haloperidol B-Chemical 1 0.99999964
( O 0 0.0047294735
2 O 0 0.00066154514
mg O 0 0.018060459
/ O 0 0.0015605326
kg O 0 0.00096516305
p O 0 0.00037787235
. O 0 0.00029668427
o O 0 0.0074901143
. O 0 0.0003487211
) O 0 0.00093585375
, O 0 0.00068691367
while O 0 0.0020346376
apomorphine B-Chemical 1 0.99999857
( O 0 0.0012301309
1 O 0 0.00021802139
. O 0 0.00015641637
5 O 0 0.00014573925
mg O 0 0.001821847
/ O 0 0.0005408628
kg O 0 0.00040960888
s O 0 0.00028429157
. O 0 0.00020166648
c O 0 0.0040462557
. O 0 0.0002547583
) O 0 0.00076897413
and O 0 0.0016714956
amphetamine B-Chemical 1 0.9999993
( O 0 0.0010491416
2 O 0 0.0002230877
mg O 0 0.005342698
/ O 0 0.0006553737
kg O 0 0.0004424586
s O 0 0.00029964832
. O 0 0.00021948012
c O 0 0.0031741576
. O 0 0.0002634492
) O 0 0.0004069079
were O 0 0.00021532396
used O 0 0.00019326236
for O 0 0.00023309473
studying O 0 0.00037379275
climbing O 0 0.004665103
behavior O 0 0.0011948542
and O 0 0.0010032783
locomotor O 0 0.3668579
activities O 0 0.0015893967
, O 0 0.0027809462
respectively O 0 0.0065253978
. O 0 0.0069748675

( B-Chemical 0 0.016609496
R I-Chemical 0 0.995992
) I-Chemical 0 0.0328616
- I-Chemical 0 0.20538239
alpha I-Chemical 0 0.9784837
- I-Chemical 0 0.73167855
methylhistamine I-Chemical 0 0.99986494
( O 0 0.11795894
RAMH B-Chemical 1 0.99999166
) O 0 0.005924404
( O 0 0.00062840176
5 O 0 0.00024187926
microg O 0 0.00038874557
i O 0 0.0020471758
. O 0 0.00029821284
c O 0 0.01170065
. O 0 0.00033035988
v O 0 0.027047837
. O 0 0.00034589594
) O 0 0.0012764547
and O 0 0.0029307741
thioperamide B-Chemical 0 0.9999988
( O 0 0.074864574
THP B-Chemical 1 0.99999416
) O 0 0.005790946
( O 0 0.00047970287
15 O 0 0.000191347
mg O 0 0.00361751
/ O 0 0.0007875462
kg O 0 0.00076132943
i O 0 0.0012206079
. O 0 0.00027703604
p O 0 0.00035133547
. O 0 0.00036566315
) O 0 0.0007195922
, O 0 0.0006099295
per O 0 0.0004573157
se O 0 0.001201561
did O 0 0.0013109709
not O 0 0.0018460713
cause O 0 0.026682056
catalepsy B-Disease 2 0.99999344
. O 0 0.009330031

Administration O 0 0.05377576
of O 0 0.008332287
THP B-Chemical 1 0.9999366
( O 0 0.005515273
3 O 0 0.0011121766
. O 0 0.00076102844
75 O 0 0.00072531495
, O 0 0.0006156244
7 O 0 0.00036481954
. O 0 0.00030307512
5 O 0 0.0002414926
and O 0 0.00025852647
15 O 0 0.00023020516
mg O 0 0.0026753328
/ O 0 0.0008860007
kg O 0 0.000863467
i O 0 0.0015157395
. O 0 0.00023044056
p O 0 0.00025658653
. O 0 0.00022007148
) O 0 0.00041698414
1 O 0 0.00019835662
h O 0 0.00019900524
prior O 0 0.00014340981
to O 0 0.00030697152
haloperidol B-Chemical 1 0.9999993
resulted O 0 0.00019933873
in O 0 0.00020305181
a O 0 0.00029500382
dose O 0 0.0040082596
- O 0 0.0055775023
dependent O 0 0.0001618486
increase O 0 0.00018137519
in O 0 0.0002909861
the O 0 0.00079982256
catalepsy B-Disease 2 0.9999974
times O 0 0.00029280334
( O 0 0.0008406042
P O 0 0.01716541
< O 0 0.0008760906
0 O 0 0.0014338099
. O 0 0.0020767911
05 O 0 0.010896467
) O 0 0.006192961
. O 0 0.008095327

However O 0 0.005451609
, O 0 0.0047404617
pretreatment O 0 0.13567661
with O 0 0.01177489
RAMH B-Chemical 1 0.99997604
significantly O 0 0.0014491216
reversed O 0 0.0007459156
such O 0 0.00043137092
an O 0 0.0004935438
effect O 0 0.00044339447
of O 0 0.0025389919
THP B-Chemical 1 0.99999034
( O 0 0.002058051
15 O 0 0.00038648894
mg O 0 0.0077441186
/ O 0 0.0013257419
kg O 0 0.0013949608
i O 0 0.0018346666
. O 0 0.0011109055
p O 0 0.0017901361
. O 0 0.0027140896
) O 0 0.0062970775
. O 0 0.008399182

RAMH B-Chemical 1 0.99921966
per O 0 0.0024034337
se O 0 0.0028258867
showed O 0 0.0012349437
significant O 0 0.0010498847
reduction O 0 0.0015200626
in O 0 0.0007414564
locomotor O 0 0.2929999
time O 0 0.00024704554
, O 0 0.00031603774
distance O 0 0.00023680655
traveled O 0 0.00042045032
and O 0 0.00020133716
average O 0 0.00014077245
speed O 0 0.0004208138
but O 0 0.0008504758
THP B-Chemical 1 0.9999629
( O 0 0.000788548
15 O 0 0.00020126766
mg O 0 0.004984038
/ O 0 0.0008683689
kg O 0 0.00079668633
i O 0 0.001285434
. O 0 0.00024654507
p O 0 0.00029198825
. O 0 0.0002740912
) O 0 0.00042683442
per O 0 0.00024446717
se O 0 0.0005280272
had O 0 0.00045237681
no O 0 0.00047903572
effect O 0 0.000782152
on O 0 0.0010264912
these O 0 0.0022456527
parameters O 0 0.004589614
. O 0 0.00699001

On O 0 0.0072294534
amphetamine B-Chemical 1 0.9999958
- O 0 0.2200702
induced O 0 0.0071573313
hyperactivity B-Disease 2 0.99998844
, O 0 0.08250807
THP B-Chemical 1 0.99999046
( O 0 0.0035192808
3 O 0 0.00037216602
. O 0 0.00027223662
75 O 0 0.00028129318
and O 0 0.00023778577
7 O 0 0.00019372361
. O 0 0.00018560444
5 O 0 0.00018052528
mg O 0 0.0026122115
/ O 0 0.00091404916
kg O 0 0.0009547845
i O 0 0.00195448
. O 0 0.00023625584
p O 0 0.0002748105
. O 0 0.00024063139
) O 0 0.00050914416
reduced O 0 0.00030836213
locomotor O 0 0.1431303
time O 0 0.00015113788
, O 0 0.00023442174
distance O 0 0.00021278953
traveled O 0 0.0004216633
and O 0 0.00025439856
average O 0 0.00022720687
speed O 0 0.0006148254
( O 0 0.0009562179
P O 0 0.016848268
< O 0 0.00096404273
0 O 0 0.001543733
. O 0 0.0022143186
05 O 0 0.011047981
) O 0 0.006459972
. O 0 0.008413761

Pretreatment O 0 0.534452
with O 0 0.011481535
RAMH B-Chemical 1 0.9999443
( O 0 0.0032123392
5 O 0 0.00086129655
microg O 0 0.0011052259
i O 0 0.0033195077
. O 0 0.0005917061
c O 0 0.012955178
. O 0 0.00051770976
v O 0 0.025905527
. O 0 0.00041268065
) O 0 0.00059321435
could O 0 0.00020484079
partially O 0 0.0002239645
reverse O 0 0.00094748044
such O 0 0.00020791283
effects O 0 0.00044025315
of O 0 0.00232602
THP B-Chemical 1 0.99999356
( O 0 0.0027189038
3 O 0 0.0002508967
. O 0 0.00023925713
75 O 0 0.0003626402
mg O 0 0.0034489906
/ O 0 0.0011279259
kg O 0 0.0012926186
i O 0 0.0017673367
. O 0 0.0010687425
p O 0 0.0017358514
. O 0 0.0026429067
) O 0 0.0061757513
. O 0 0.008248379

Climbing O 0 0.0604902
behavior O 0 0.005905417
induced O 0 0.003644835
by O 0 0.006348299
apomorphine B-Chemical 1 0.9999951
was O 0 0.0024924492
reduced O 0 0.0017124636
in O 0 0.0016287814
animals O 0 0.0017600147
treated O 0 0.0031501316
with O 0 0.007133603
THP B-Chemical 1 0.9998417
. O 0 0.012323749

Such O 0 0.0068157543
an O 0 0.004588991
effect O 0 0.0031735844
was O 0 0.002803232
, O 0 0.0029758273
however O 0 0.0025816136
, O 0 0.0026280545
reversed O 0 0.0024261232
in O 0 0.0025226574
presence O 0 0.0037064848
of O 0 0.015774194
RAMH B-Chemical 1 0.99990356
. O 0 0.014529064

THP B-Chemical 1 0.99964607
exhibited O 0 0.0051809615
an O 0 0.008160285
antipsychotic O 0 0.9998312
- O 0 0.02709408
like O 0 0.000623372
profile O 0 0.0005781576
by O 0 0.0006718014
potentiating O 0 0.73041314
haloperidol B-Chemical 1 1.0
- O 0 0.60461086
induced O 0 0.029451886
catalepsy B-Disease 2 0.9999999
, O 0 0.008688615
reducing O 0 0.026973408
amphetamine B-Chemical 1 0.9999999
- O 0 0.19574234
induced O 0 0.0017715951
hyperactivity B-Disease 2 0.999982
and O 0 0.0017201229
reducing O 0 0.021950549
apomorphine B-Chemical 1 0.99999905
- O 0 0.05193356
induced O 0 0.0013263829
climbing O 0 0.02484166
in O 0 0.002031077
mice O 0 0.0027428558
. O 0 0.006343509

Such O 0 0.005425852
effects O 0 0.0037996683
of O 0 0.0050118295
THP B-Chemical 1 0.99993455
were O 0 0.0017750348
reversed O 0 0.0015661765
by O 0 0.0016464891
RAMH B-Chemical 1 0.99993694
indicating O 0 0.00057302095
the O 0 0.0004755648
involvement O 0 0.0008970623
of O 0 0.0037954508
histamine B-Chemical 1 0.99999094
H O 0 0.9999974
( O 0 0.011705895
3 O 0 0.0014619476
) O 0 0.003203479
- O 0 0.008691752
receptors O 0 0.011820131
. O 0 0.008443451

Findings O 0 0.0037316636
suggest O 0 0.0018478701
a O 0 0.0019776311
potential O 0 0.0016726466
for O 0 0.0025605685
H O 1 0.99998677
( O 0 0.0062315897
3 O 0 0.00083478907
) O 0 0.0022180914
- O 0 0.018143931
receptor O 0 0.028125523
antagonists O 0 0.4021007
in O 0 0.0005602594
improving O 0 0.00061338564
the O 0 0.0007626713
refractory O 0 0.0061152205
cases O 0 0.0026793082
of O 0 0.007021363
schizophrenia B-Disease 2 0.9999213
. O 0 0.008846766

Cauda B-Disease 0 0.28382152
equina I-Disease 0 0.025458757
syndrome I-Disease 0 0.28185785
after O 0 0.0025194508
epidural O 0 0.5139256
steroid B-Chemical 1 0.99581194
injection O 0 0.0061650877
: O 0 0.004252355
a O 0 0.004060608
case O 0 0.005110091
report O 0 0.010542473
. O 0 0.010741149

OBJECTIVE O 0 0.02369191
: O 0 0.003906358
Conventional O 0 0.0026408976
treatment O 0 0.001260907
methods O 0 0.00087295455
of O 0 0.0010422172
lumbusacral O 0 0.22539867
radiculopathy B-Disease 0 0.9999628
are O 0 0.0005096678
physical O 0 0.0014574649
therapy O 0 0.0010353117
, O 0 0.0011126689
epidural O 0 0.6500869
steroid B-Chemical 1 0.9972892
injections O 0 0.0032157947
, O 0 0.0009410599
oral O 0 0.23451306
medications O 0 0.06895359
, O 0 0.00089705375
and O 0 0.0011164433
spinal O 0 0.0107606035
manipulative O 0 0.0076039797
therapy O 0 0.005051287
. O 0 0.0063268016

Cauda B-Disease 0 0.33089837
equina I-Disease 0 0.033132758
syndrome I-Disease 0 0.29224974
is O 0 0.0037569485
a O 0 0.0038643985
rare O 0 0.006694424
complication O 0 0.17117849
of O 0 0.006716719
epidural O 0 0.67288196
anesthesia O 0 0.087896846
. O 0 0.010818872

The O 0 0.003202762
following O 0 0.0020759248
case O 0 0.0017847735
is O 0 0.0012708899
a O 0 0.0011471267
report O 0 0.0014081172
of O 0 0.0010905017
cauda B-Disease 0 0.10793468
equina I-Disease 0 0.03583827
syndrome I-Disease 0 0.29540697
possibly O 0 0.00069278036
caused O 0 0.0004415826
by O 0 0.0006550439
epidural O 0 0.112270825
injection O 0 0.0012874784
of O 0 0.003396622
triamcinolone B-Chemical 0 0.99999654
and O 0 0.11135676
bupivacaine B-Chemical 1 0.9999659
. O 0 0.008732005

CLINICAL O 0 0.006646047
FEATURES O 0 0.0048003923
: O 0 0.0036396456
A O 0 0.02482196
50 O 0 0.0020886064
- O 0 0.0037326617
year O 0 0.0010811616
- O 0 0.002530974
old O 0 0.0006649107
woman O 0 0.0012865412
with O 0 0.00046656976
low B-Disease 0 0.0005422963
back I-Disease 0 0.0005530967
and I-Disease 0 0.00044179015
right I-Disease 0 0.0011437566
leg I-Disease 0 0.024282502
pain I-Disease 0 0.7098595
was O 0 0.00047821229
scheduled O 0 0.00047816575
for O 0 0.0009131482
epidural O 0 0.34419736
steroid B-Chemical 1 0.98828584
injection O 0 0.008525003
. O 0 0.006916086

INTERVENTION O 0 0.0058732815
AND O 0 0.0029134466
OUTCOME O 0 0.0033348901
: O 0 0.0023171161
An O 0 0.001828405
18 O 0 0.0013801226
- O 0 0.0020062889
gauge O 0 0.00101315
Touhy O 0 0.0015809942
needle O 0 0.0008154033
was O 0 0.00048697996
inserted O 0 0.0003996464
until O 0 0.00031736773
loss O 0 0.00052942126
of O 0 0.0005225487
resistance O 0 0.0012295194
occurred O 0 0.0005512948
at O 0 0.0005619189
the O 0 0.000884946
L4 O 0 0.042949002
- O 0 0.0042524925
5 O 0 0.0020665547
level O 0 0.0033928666
. O 0 0.007139445

Spread O 0 0.008256377
of O 0 0.0033719975
the O 0 0.002251618
contrast O 0 0.003434333
medium O 0 0.01035365
within O 0 0.0008648892
the O 0 0.0010236386
epidural O 0 0.02352148
space O 0 0.0010123468
was O 0 0.0010523408
determined O 0 0.00119712
by O 0 0.0022330831
radiographic O 0 0.008943325
imaging O 0 0.008224235
. O 0 0.007949471

After O 0 0.0032761618
verifying O 0 0.0030145051
the O 0 0.0024644393
epidural O 0 0.043806206
space O 0 0.0023709654
, O 0 0.0053869104
bupivacaine B-Chemical 1 0.99997175
and O 0 0.04318794
triamcinolone B-Chemical 1 0.9999994
diacetate I-Chemical 1 0.99955744
were O 0 0.004831872
injected O 0 0.005140348
. O 0 0.008485515

After O 0 0.0037404005
the O 0 0.003388683
injection O 0 0.0038791993
, O 0 0.00305049
there O 0 0.001813432
was O 0 0.0021949199
a O 0 0.002655996
reduction O 0 0.0037513701
in O 0 0.0045486307
radicular O 0 0.9843938
symptoms O 0 0.5145243
. O 0 0.010441272

Three O 0 0.0049376874
hours O 0 0.0030042143
later O 0 0.0024212685
, O 0 0.0025985986
she O 0 0.0017907472
complained O 0 0.0044375677
of O 0 0.0021187481
perineal O 0 0.24162437
numbness B-Disease 0 0.99504745
and O 0 0.0032067774
lower B-Disease 0 0.005854788
extremity I-Disease 0 0.55783
weakness I-Disease 0 0.9931485
. O 0 0.011283546

The O 0 0.003745933
neurologic O 0 0.41485462
evaluation O 0 0.0016513247
revealed O 0 0.001181852
loss B-Disease 0 0.0021558928
of I-Disease 0 0.0012212885
sensation I-Disease 0 0.63915783
in O 0 0.0006095651
the O 0 0.0005301544
saddle O 0 0.0062441523
area O 0 0.0008106607
and O 0 0.0007202722
medial O 0 0.0052268556
aspect O 0 0.0008893509
of O 0 0.0014035399
her O 0 0.0023197236
right O 0 0.0046748817
leg O 0 0.021676034
. O 0 0.0076597035

There O 0 0.0069592036
was O 0 0.004983617
a O 0 0.0042980574
decrease O 0 0.003281657
in O 0 0.0030281
the O 0 0.0031595868
perception O 0 0.006011629
of O 0 0.006249332
pinprick O 0 0.5107772
test O 0 0.008473616
. O 0 0.01168837

Deep O 0 0.11500748
- O 0 0.017538816
tendon O 0 0.09189059
reflexes O 0 0.5011859
were O 0 0.0030199285
decreased O 0 0.002863744
especially O 0 0.0030032948
in O 0 0.002935853
the O 0 0.0037813522
right O 0 0.007973265
leg O 0 0.031284735
. O 0 0.011278466

She O 0 0.023535365
was O 0 0.017452817
unable O 0 0.01625361
to O 0 0.020886878
urinate O 0 0.0412512
. O 0 0.03240846

The O 0 0.0042709936
patient O 0 0.0035282802
' O 0 0.0032613163
s O 0 0.002796066
symptoms O 0 0.03390456
improved O 0 0.0017671955
slightly O 0 0.0013932906
over O 0 0.0010441625
the O 0 0.0014356251
next O 0 0.0015703643
few O 0 0.0025312218
hours O 0 0.004124067
. O 0 0.008280579

She O 0 0.0059932214
had O 0 0.0031197625
a O 0 0.0026352932
gradual O 0 0.0020111653
return O 0 0.0017448738
of O 0 0.001577939
motor O 0 0.00488458
function O 0 0.0011724208
and O 0 0.0013539896
ability O 0 0.0015895903
of O 0 0.002761526
feeling O 0 0.08164995
Foley O 0 0.032807652
catheter O 0 0.0071986727
. O 0 0.00867578

All O 0 0.003952767
of O 0 0.0035262473
the O 0 0.002670391
symptoms O 0 0.03020964
were O 0 0.001507808
completely O 0 0.0011993181
resolved O 0 0.0013572648
over O 0 0.0009636952
the O 0 0.0013704873
next O 0 0.0015682911
8 O 0 0.0027626478
hours O 0 0.0039639096
. O 0 0.008068744

CONCLUSION O 0 0.025154905
: O 0 0.0069158208
Complications O 0 0.009095797
associated O 0 0.0032078216
with O 0 0.0036774362
epidural O 0 0.6857977
steroid B-Chemical 1 0.99614763
injections O 0 0.008895916
are O 0 0.005266504
rare O 0 0.012824655
. O 0 0.011048956

Clinical O 0 0.0073055956
examination O 0 0.0026358485
and O 0 0.0019856205
continued O 0 0.0015403464
vigilance O 0 0.026606739
for O 0 0.0015472957
neurologic B-Disease 0 0.9995136
deterioration I-Disease 0 0.9323061
after O 0 0.0009388591
epidural O 0 0.6584434
steroid B-Chemical 1 0.9941135
injections O 0 0.0039300667
is O 0 0.0026999419
important O 0 0.003736824
. O 0 0.0074493596

High O 0 0.047680087
- O 0 0.0495849
dose O 0 0.20745316
testosterone B-Chemical 0 0.999946
is O 0 0.0036778802
associated O 0 0.0030469527
with O 0 0.0061130826
atherosclerosis B-Disease 2 0.99997616
in O 0 0.009191444
postmenopausal O 0 0.98839414
women O 0 0.09525807
. O 0 0.010581147

OBJECTIVES O 0 0.0051758885
: O 0 0.0033067318
To O 0 0.001521118
study O 0 0.0014308636
the O 0 0.0009481622
long O 0 0.0009541298
- O 0 0.002416975
term O 0 0.0006112989
effects O 0 0.0009082759
of O 0 0.0023232775
androgen O 0 0.99958557
treatment O 0 0.002300526
on O 0 0.0010895971
atherosclerosis B-Disease 2 0.9999782
in O 0 0.005591046
postmenopausal O 0 0.9860946
women O 0 0.08078739
. O 0 0.008098161

METHODS O 0 0.0041027204
: O 0 0.0037064354
In O 0 0.0020965643
a O 0 0.0019345004
population O 0 0.0024758922
- O 0 0.004787897
based O 0 0.0008101878
study O 0 0.0007149683
in O 0 0.0005128994
513 O 0 0.014104692
naturally O 0 0.0072821802
postmenopausal O 0 0.9537839
women O 0 0.008870165
aged O 0 0.0006830475
54 O 0 0.00074785727
- O 0 0.0017996072
67 O 0 0.00034922242
years O 0 0.00023948334
, O 0 0.00022122203
we O 0 0.000116325944
studied O 0 0.00015238266
the O 0 0.00013195311
association O 0 0.0001367467
between O 0 0.00013783472
self O 0 0.0051087365
- O 0 0.014189697
reported O 0 0.0002682152
intramuscularly O 0 0.00052092056
administered O 0 0.00018104466
high O 0 0.0006445359
- O 0 0.06374301
dose O 0 0.33802128
estrogen B-Chemical 1 0.99999917
- O 0 0.95829076
testosterone B-Chemical 0 0.99999654
therapy O 0 0.07430533
( O 0 0.109759316
estradiol B-Chemical 0 0.9999987
- I-Chemical 0 0.4396794
and I-Chemical 0 0.015298278
testosterone I-Chemical 0 0.99999166
esters I-Chemical 0 0.9917571
) O 0 0.0054454566
and O 0 0.0031245693
aortic O 0 0.85902506
atherosclerosis B-Disease 2 0.99994254
. O 0 0.009449278

Aortic O 0 0.64875615
atherosclerosis B-Disease 2 0.99983263
was O 0 0.0026876784
diagnosed O 0 0.0028968027
by O 0 0.0010335693
radiographic O 0 0.002248871
detection O 0 0.0008101283
of O 0 0.00067856023
calcified O 0 0.19307886
deposits O 0 0.072983384
in O 0 0.0003357964
the O 0 0.0003357473
abdominal O 0 0.0153963575
aorta O 0 0.027050458
, O 0 0.0005104958
which O 0 0.00041779442
have O 0 0.00036640576
been O 0 0.00050405384
shown O 0 0.0005456957
to O 0 0.00090284273
reflect O 0 0.0017577778
intima O 0 0.98930395
atherosclerosis B-Disease 2 0.9999478
. O 0 0.010737619

Hormone O 0 0.90901166
therapy O 0 0.011914219
users O 0 0.00960781
were O 0 0.004792358
compared O 0 0.003840349
with O 0 0.005764465
never O 0 0.009820077
users O 0 0.017511953
. O 0 0.014737737

RESULTS O 0 0.0066229766
: O 0 0.005878142
Intramuscular O 0 0.52800703
hormone O 0 0.70798826
therapy O 0 0.0026751577
use O 0 0.0010421536
for O 0 0.0007850781
1 O 0 0.0006948211
year O 0 0.0006580126
or O 0 0.00063990057
longer O 0 0.00058912236
was O 0 0.00094172417
reported O 0 0.001358393
by O 0 0.0019629211
25 O 0 0.0033617713
women O 0 0.009619737
. O 0 0.007953074

In O 0 0.0034752802
almost O 0 0.0019866556
half O 0 0.0012061599
of O 0 0.0011929896
these O 0 0.001178626
women O 0 0.036700435
severe O 0 0.6324182
atherosclerosis B-Disease 2 0.999992
of O 0 0.0013508365
the O 0 0.00045592416
aorta O 0 0.02920905
was O 0 0.00022205083
present O 0 0.00015122986
( O 0 0.00027581796
n O 0 0.00019592186
= O 0 0.0005188457
11 O 0 0.0002518213
) O 0 0.00043597244
, O 0 0.0003089701
while O 0 0.00022494573
in O 0 0.00022001022
women O 0 0.0046823956
without O 0 0.00036331324
hormone O 0 0.80582374
use O 0 0.00055237755
severe O 0 0.495321
atherosclerosis B-Disease 2 0.9999933
of O 0 0.00082258857
the O 0 0.00029314915
aorta O 0 0.028263597
was O 0 0.00015054616
present O 0 0.000101968624
in O 0 0.00012618882
less O 0 0.00012813826
than O 0 0.00010485707
20 O 0 0.0001414274
% O 0 0.00021767682
( O 0 0.00038915506
OR O 0 0.063631736
3 O 0 0.0001676561
. O 0 0.00015912752
1 O 0 0.0001736691
; O 0 0.00026571954
95 O 0 0.00038905104
% O 0 0.00034538226
CI O 0 0.2781375
, O 0 0.00034618
1 O 0 0.00020612117
. O 0 0.0001839855
1 O 0 0.00021938157
- O 0 0.0009123472
8 O 0 0.00018359016
. O 0 0.0001649833
5 O 0 0.00015576536
, O 0 0.00020815543
adjusted O 0 0.00019813055
for O 0 0.00019751921
age O 0 0.0005191797
, O 0 0.00035344853
years O 0 0.00033789373
since O 0 0.0002861488
menopause O 0 0.79010636
, O 0 0.0018188838
smoking O 1 0.9914664
, O 0 0.0011997501
and O 0 0.0010176634
body O 0 0.002726415
mass O 0 0.004594563
index O 0 0.0040638144
) O 0 0.00648811
. O 0 0.0077125756

The O 0 0.002860258
association O 0 0.0019600603
remained O 0 0.0017493438
after O 0 0.00081812456
additional O 0 0.00064764725
adjustment O 0 0.0009576753
for O 0 0.0011352948
diabetes B-Disease 0 0.9999502
, O 0 0.02773569
cholesterol B-Chemical 0 0.99989045
level O 0 0.0005952414
, O 0 0.0012478372
systolic O 0 0.6817772
blood O 0 0.022563968
pressure O 0 0.036534768
, O 0 0.0014058274
or O 0 0.0019108952
alcohol B-Chemical 0 0.99945635
use O 0 0.0047889585
. O 0 0.0067216964

No O 0 0.0063852705
association O 0 0.003397857
was O 0 0.0028998938
found O 0 0.0022122662
for O 0 0.00235743
hormone O 0 0.4975261
use O 0 0.0023387836
less O 0 0.0022198712
than O 0 0.0021956249
1 O 0 0.0034600527
year O 0 0.00562714
. O 0 0.009437574

CONCLUSION O 0 0.018785978
: O 0 0.0036138303
Our O 0 0.0017835347
results O 0 0.0010569768
suggest O 0 0.0006639491
that O 0 0.0006881954
high O 0 0.0023384388
- O 0 0.09891113
dose O 0 0.26672432
testosterone B-Chemical 0 0.9999925
therapy O 0 0.010934279
may O 0 0.00036852705
adversely O 0 0.0068367966
affect O 0 0.00034691478
atherosclerosis B-Disease 2 0.9999945
in O 0 0.0019361934
postmenopausal O 0 0.9828509
women O 0 0.0074524703
and O 0 0.00024771044
indicate O 0 0.00016302605
that O 0 0.00032750375
androgen O 0 0.9991887
replacement O 0 0.004578573
in O 0 0.00044067012
these O 0 0.0006291686
women O 0 0.0028468568
may O 0 0.0009425167
not O 0 0.001426518
be O 0 0.0026671332
harmless O 0 0.012455669
. O 0 0.00714565

Optimising O 0 0.016638838
stroke B-Disease 2 0.99815553
prevention O 0 0.013065986
in O 0 0.0046131685
non O 0 0.008006667
- O 0 0.05799111
valvular O 0 0.89900446
atrial B-Disease 0 0.99590576
fibrillation I-Disease 0 0.99996245
. O 0 0.015671356

Atrial B-Disease 0 0.99266255
fibrillation I-Disease 0 0.999984
is O 0 0.005164241
associated O 0 0.003570514
with O 0 0.003372058
substantial O 0 0.0044068126
morbidity O 0 0.6457606
and O 0 0.0076826224
mortality O 0 0.6695902
. O 0 0.013893328

Pooled O 0 0.0060426802
data O 0 0.002382057
from O 0 0.0013193024
trials O 0 0.0010738577
comparing O 0 0.00063819916
antithrombotic O 0 0.69766426
treatment O 0 0.00079026807
with O 0 0.00061382924
placebo O 0 0.019431183
have O 0 0.00020512225
shown O 0 0.00018545636
that O 0 0.00025791593
warfarin B-Chemical 1 0.9998466
reduces O 0 0.0002352172
the O 0 0.00027839703
risk O 0 0.0958255
of O 0 0.0031441676
stroke B-Disease 2 0.99992454
by O 0 0.00039765658
62 O 0 0.00062819035
% O 0 0.00032558822
, O 0 0.00032821202
and O 0 0.00032400986
that O 0 0.00039977007
aspirin B-Chemical 0 0.99997234
alone O 0 0.00058448326
reduces O 0 0.0005362025
the O 0 0.00079332007
risk O 0 0.039508298
by O 0 0.0018075024
22 O 0 0.0028918474
% O 0 0.0043421453
. O 0 0.0067015355

Overall O 0 0.0060638096
, O 0 0.0035824515
in O 0 0.0020356616
high O 0 0.0030095263
- O 0 0.03279213
risk O 0 0.13398708
patients O 0 0.0045161336
, O 0 0.00691034
warfarin B-Chemical 1 0.99993885
is O 0 0.000580765
superior O 0 0.0008772627
to O 0 0.00037637536
aspirin B-Chemical 0 0.9999672
in O 0 0.0004335203
preventing O 0 0.005386989
strokes B-Disease 0 0.99974054
, O 0 0.0009214551
with O 0 0.0004228788
a O 0 0.000473205
relative O 0 0.00046831314
risk O 0 0.03121972
reduction O 0 0.0017300022
of O 0 0.0020497795
36 O 0 0.00275504
% O 0 0.0043680198
. O 0 0.006680999

Ximelagatran B-Chemical 0 0.9995419
, O 0 0.006088417
an O 0 0.0032243105
oral O 0 0.17457014
direct O 0 0.0036755167
thrombin O 0 0.9696172
inhibitor O 0 0.52363056
, O 0 0.0017081917
was O 0 0.00039417614
found O 0 0.00023624324
to O 0 0.00018278457
be O 0 0.00018782858
as O 0 0.00017008392
efficient O 0 0.0002061512
as O 0 0.0010850256
vitamin B-Chemical 0 0.9999999
K I-Chemical 1 0.9999999
antagonist O 0 0.9971746
drugs O 0 0.5476091
in O 0 0.0002102017
the O 0 0.00018834166
prevention O 0 0.0018074509
of O 0 0.0014484858
embolic B-Disease 0 0.99973065
events I-Disease 0 0.7779313
, O 0 0.0011077403
but O 0 0.00037755945
has O 0 0.00022226817
been O 0 0.00024508985
recently O 0 0.0002866611
withdrawn O 0 0.0005115962
because O 0 0.0003594439
of O 0 0.0007837374
abnormal B-Disease 0 0.08645062
liver I-Disease 0 0.6127193
function I-Disease 0 0.0044898167
tests O 0 0.0076804487
. O 0 0.006828908

The O 0 0.0048578526
ACTIVE O 0 0.2755065
- O 0 0.084684275
W O 0 0.98206985
( O 0 0.008372481
Atrial B-Disease 2 0.9781456
Fibrillation I-Disease 2 0.824941
Clopidogrel B-Chemical 0 0.9998679
Trial O 0 0.0025796082
with O 0 0.00068015367
Irbesartan B-Chemical 0 0.9990551
for O 0 0.00033064978
Prevention O 0 0.0008872907
of O 0 0.0004923907
Vascular O 0 0.7851163
Events O 0 0.034239728
) O 0 0.00058405456
study O 0 0.00027925248
has O 0 0.00016458327
demonstrated O 0 0.0001624502
that O 0 0.00024540833
warfarin B-Chemical 1 0.99986875
is O 0 0.0002871192
superior O 0 0.00044772733
to O 0 0.00017986586
platelet O 0 0.49131635
therapy O 0 0.002261212
( O 0 0.0045792623
clopidogrel B-Chemical 1 0.99995565
plus O 0 0.0010252899
aspirin B-Chemical 0 0.9999902
) O 0 0.0018035766
in O 0 0.00054571027
the O 0 0.0007948311
prevention O 0 0.019301098
af O 0 0.6916991
embolic B-Disease 0 0.9989015
events I-Disease 0 0.60659206
. O 0 0.00793021

Idraparinux B-Chemical 0 0.9221483
, O 0 0.006228844
a O 0 0.0057217036
Factor O 0 0.9934918
Xa O 0 0.9984363
inhibitor O 0 0.043059614
, O 0 0.0018367707
is O 0 0.0009488147
being O 0 0.00096963916
evaluated O 0 0.0006985898
in O 0 0.0009646813
patients O 0 0.0017411775
with O 0 0.0027600992
atrial B-Disease 0 0.9760356
fibrillation I-Disease 0 0.999959
. O 0 0.00967769

Angiotensin B-Chemical 0 0.9999751
- O 0 0.2404949
converting O 0 0.034241904
enzyme O 0 0.055350892
inhibitors O 0 0.014730677
and O 0 0.016632704
angiotensin B-Chemical 1 0.99999905
II I-Chemical 1 0.9801757
receptor O 0 0.33550027
- O 0 0.039683353
blocking O 0 0.0012735982
drugs O 0 0.06933192
hold O 0 0.0005273437
promise O 0 0.000559492
in O 0 0.00069457805
atrial B-Disease 0 0.9337931
fibrillation I-Disease 0 0.9999697
through O 0 0.0016648148
cardiac B-Disease 0 0.75583154
remodelling I-Disease 0 0.618934
. O 0 0.0074334126

Preliminary O 0 0.005570065
studies O 0 0.0026910368
suggest O 0 0.0015545823
that O 0 0.001806608
statins B-Chemical 1 0.99848217
could O 0 0.0009849023
interfere O 0 0.0007945778
with O 0 0.00082745915
the O 0 0.00082138117
risk O 0 0.02738322
of O 0 0.0017601001
recurrence O 0 0.5836654
after O 0 0.0017698894
electrical O 0 0.11453197
cardioversion O 0 0.22936395
. O 0 0.0072809565

Finally O 0 0.0045954315
, O 0 0.0034024639
percutaneous O 0 0.0021302223
methods O 0 0.0011522581
for O 0 0.0008462491
the O 0 0.0006637935
exclusion O 0 0.0006769084
of O 0 0.0006629264
left O 0 0.0016476762
atrial O 0 0.5487273
appendage O 0 0.004964169
are O 0 0.00037443257
under O 0 0.00035239206
investigation O 0 0.0006635313
in O 0 0.00078326743
high O 0 0.002003909
- O 0 0.018480921
risk O 0 0.13359407
patients O 0 0.00852731
. O 0 0.0075486125

Anti O 0 0.9510844
- O 0 0.1856837
oxidant O 0 0.9946385
effects O 0 0.008888554
of O 0 0.018856714
atorvastatin B-Chemical 0 0.9999975
in O 0 0.01772572
dexamethasone B-Chemical 0 0.9999726
- O 0 0.329305
induced O 0 0.010360405
hypertension B-Disease 2 0.99999356
in O 0 0.0026579113
the O 0 0.003208953
rat O 0 0.00846564
. O 0 0.0076485113

1 O 0 0.09718908
. O 0 0.11277451

Dexamethasone B-Chemical 0 0.99992776
( O 0 0.13580848
Dex B-Chemical 1 0.9998115
) O 0 0.11595057
- O 0 0.120672315
induced O 0 0.0073494157
hypertension B-Disease 2 0.999998
is O 0 0.0011955252
characterized O 0 0.0008471326
by O 0 0.0006281592
endothelial O 0 0.9737935
dysfunction O 0 0.90494555
associated O 0 0.0006331546
with O 0 0.00084483396
nitric B-Chemical 0 0.99954116
oxide I-Chemical 0 0.99734855
( O 0 0.018124102
NO B-Chemical 0 0.9995596
) O 0 0.005214335
deficiency O 0 0.3561731
and O 0 0.00075516803
increased O 0 0.0043285973
superoxide B-Chemical 1 0.9999906
( O 0 0.09090741
O2 B-Chemical 0 0.99997306
- I-Chemical 0 0.10021153
) O 0 0.0045861164
production O 0 0.0057139965
. O 0 0.007835133

Atorvastatin B-Chemical 0 0.9999392
( O 0 0.03903804
Ato B-Chemical 1 0.9953271
) O 0 0.0037200716
possesses O 0 0.0011194183
pleiotropic O 0 0.0012803038
properties O 0 0.0005257036
that O 0 0.00034435498
have O 0 0.00030202977
been O 0 0.00029742514
reported O 0 0.000285796
to O 0 0.00018638119
improve O 0 0.00017102974
endothelial O 0 0.4231987
function O 0 0.0002127595
through O 0 0.00014801549
increased O 0 0.00021862195
availability O 0 0.0002747382
of O 0 0.00062200456
NO B-Chemical 0 0.9983943
and O 0 0.0007328046
reduced O 0 0.0019350088
O2 B-Chemical 0 0.9999882
- I-Chemical 0 0.03690603
production O 0 0.00081968127
in O 0 0.00066977384
various O 0 0.0010308905
forms O 0 0.0016195555
of O 0 0.00912099
hypertension B-Disease 2 0.99998176
. O 0 0.009476237

In O 0 0.003555819
the O 0 0.0021708948
present O 0 0.001401523
study O 0 0.001446237
, O 0 0.0010619536
we O 0 0.0004461837
investigated O 0 0.0003559004
whether O 0 0.00024282667
50 O 0 0.00043990035
mg O 0 0.012350174
/ O 0 0.0009646
kg O 0 0.00045629483
per O 0 0.0001500447
day O 0 0.00017631962
, O 0 0.00028400222
p O 0 0.00025764015
. O 0 0.00023657254
o O 0 0.009992015
. O 0 0.0003313399
, O 0 0.0009667147
Ato B-Chemical 1 0.99471766
could O 0 0.0002284886
prevent O 0 0.0003027323
endothelial O 0 0.9954086
NO B-Chemical 0 0.9999294
synthase O 0 0.9080772
( O 0 0.008089287
eNOS O 0 0.6903183
) O 0 0.0010316785
downregulation O 0 0.00036408711
and O 0 0.00023981211
the O 0 0.00017967458
increase O 0 0.00018744374
in O 0 0.00063653325
O2 B-Chemical 0 0.99998987
- I-Chemical 0 0.06020087
in O 0 0.00043646252
Sprague O 0 0.12189973
- O 0 0.011381586
Dawley O 0 0.01831239
( O 0 0.0007107736
SD O 0 0.033138447
) O 0 0.0008891967
rats O 0 0.0008104847
, O 0 0.0009134219
thereby O 0 0.0012799912
reducing O 0 0.0020897274
blood O 0 0.05019514
pressure O 0 0.10311606
. O 0 0.0071647693

2 O 0 0.09703088
. O 0 0.11310669

Male O 0 0.02737452
SD O 0 0.033126503
rats O 0 0.0029008759
( O 0 0.0018978799
n O 0 0.0010623828
= O 0 0.0013058952
30 O 0 0.00060534745
) O 0 0.0007317056
were O 0 0.00039539422
treated O 0 0.0003893579
with O 0 0.0005814772
Ato B-Chemical 1 0.99630415
( O 0 0.00090502255
50 O 0 0.0004285719
mg O 0 0.009910342
/ O 0 0.0007235214
kg O 0 0.00039044506
per O 0 0.0001498101
day O 0 0.00018614213
in O 0 0.00026897245
drinking O 0 0.42202148
water O 0 0.012399378
) O 0 0.0008540375
or O 0 0.00055938825
tap O 0 0.0026637306
water O 0 0.0025925853
for O 0 0.0012066414
15 O 0 0.0017545619
days O 0 0.002641718
. O 0 0.0059371004

Dexamethasone B-Chemical 0 0.99977785
( O 0 0.0055857063
10 O 0 0.0018821313
microg O 0 0.0019332166
/ O 0 0.0024618611
kg O 0 0.0011834488
per O 0 0.00039749
day O 0 0.00037262592
, O 0 0.00045221954
s O 0 0.0004876423
. O 0 0.0003488551
c O 0 0.005613128
. O 0 0.00034649498
) O 0 0.00057455455
or O 0 0.00027225845
saline O 0 0.0034378308
was O 0 0.00019280938
started O 0 0.00015697036
after O 0 0.00010791508
4 O 0 0.00012572666
days O 0 0.00011631729
in O 0 0.00023827008
Ato B-Chemical 1 0.9972058
- O 0 0.014968224
treated O 0 0.00034906834
and O 0 0.00035268377
non O 0 0.0012612159
- O 0 0.0075013135
treated O 0 0.0003963855
rats O 0 0.00042053132
and O 0 0.0003680492
continued O 0 0.00045830876
for O 0 0.00064129685
11 O 0 0.0010906252
- O 0 0.0027294764
13 O 0 0.0022809189
days O 0 0.0028508583
. O 0 0.006261672

Systolic O 0 0.85734946
blood O 0 0.03929369
pressure O 0 0.17240088
( O 0 0.004248513
SBP O 0 0.651411
) O 0 0.0018232492
was O 0 0.0007998187
measured O 0 0.00052993064
on O 0 0.00044122664
alternate O 0 0.00061382045
days O 0 0.0005021251
using O 0 0.00068447884
the O 0 0.00095798826
tail O 0 0.0019671558
- O 0 0.0062264483
cuff O 0 0.006116688
method O 0 0.0061420696
. O 0 0.008224825

Endothelial O 0 0.7716177
function O 0 0.0030752195
was O 0 0.0020078265
assessed O 0 0.0013210356
by O 0 0.0022814395
acetylcholine B-Chemical 1 0.9999379
- O 0 0.14753884
induced O 0 0.0030244484
vasorelaxation O 0 0.9999665
and O 0 0.06778642
phenylephrine B-Chemical 0 0.99999726
- O 0 0.22287261
induced O 0 0.003112973
vasoconstriction O 0 0.9994252
in O 0 0.002444947
aortic O 0 0.21109508
segments O 0 0.0049340855
. O 0 0.0068229465

Vascular O 0 0.7307126
eNOS O 0 0.35299277
mRNA O 0 0.0037392676
was O 0 0.002042038
assessed O 0 0.0013045103
by O 0 0.001431147
semi O 0 0.0022785824
- O 0 0.0035717327
quantitative O 0 0.0014316945
reverse O 0 0.0038946723
transcription O 0 0.0036618323
- O 0 0.02171642
polymerase O 0 0.11348211
chain O 0 0.02125138
reaction O 0 0.071495764
. O 0 0.009729941

3 O 0 0.0941019
. O 0 0.112802126

In O 0 0.0039877794
rats O 0 0.003362837
treated O 0 0.0022831517
with O 0 0.003175906
Dex B-Chemical 1 0.99957484
alone O 0 0.003836651
, O 0 0.004986375
SBP O 0 0.8265938
was O 0 0.0004183518
increased O 0 0.00032038015
from O 0 0.00024672353
109 O 0 0.00081379217
+ O 0 0.0018475667
/ O 0 0.008977823
- O 0 0.0052485247
2 O 0 0.0002152041
to O 0 0.00018113531
133 O 0 0.00091767544
+ O 0 0.0012903921
/ O 0 0.006809453
- O 0 0.0044203857
2 O 0 0.00021538556
mmHg O 0 0.0003794578
on O 0 0.00015371137
Days O 0 0.0010286586
4 O 0 0.00018679163
and O 0 0.0002404894
Day O 0 0.0005128163
14 O 0 0.00031198995
, O 0 0.0004664557
respectively O 0 0.0013619239
( O 0 0.0011615255
P O 0 0.023740387
< O 0 0.0009790662
0 O 0 0.0015249004
. O 0 0.002168213
001 O 0 0.04189328
) O 0 0.0067146197
. O 0 0.008503523

In O 0 0.0041527776
the O 0 0.0036100103
Ato B-Chemical 1 0.99633515
+ O 0 0.15861043
Dex B-Chemical 1 0.99962986
group O 0 0.007870128
, O 0 0.0027179255
SBP O 0 0.6808681
was O 0 0.00044561835
increased O 0 0.00034790506
from O 0 0.0002768441
113 O 0 0.001535785
+ O 0 0.0017616759
/ O 0 0.008138639
- O 0 0.0046258653
2 O 0 0.0002100817
to O 0 0.00017153342
119 O 0 0.00065693294
+ O 0 0.0012090403
/ O 0 0.006773269
- O 0 0.0045797457
2 O 0 0.00019566239
mmHg O 0 0.00034867073
on O 0 0.00012914951
Days O 0 0.0010705235
4 O 0 0.00014068066
to O 0 0.00013414999
14 O 0 0.00017711341
, O 0 0.0002599276
respectively O 0 0.0012096916
( O 0 0.0007223564
P O 0 0.052477814
< O 0 0.00022535294
0 O 0 0.00028916338
. O 0 0.0002631304
001 O 0 0.1006885
) O 0 0.0008304449
, O 0 0.0004549799
but O 0 0.00032109473
was O 0 0.00022254427
significantly O 0 0.0002198739
lower O 0 0.00020987507
than O 0 0.00017197429
SBP O 0 0.316094
in O 0 0.00017876185
the O 0 0.00018293592
group O 0 0.00027612233
treated O 0 0.00032662504
with O 0 0.00074340985
Dex B-Chemical 1 0.99918693
alone O 0 0.0011892844
( O 0 0.0027920364
P O 0 0.07924883
< O 0 0.00093868456
0 O 0 0.0014663745
. O 0 0.002072144
05 O 0 0.011109879
) O 0 0.0061265985
. O 0 0.0080041755

Endothelial O 0 0.97024214
- O 0 0.014325754
dependent O 0 0.0018008479
relaxation O 0 0.040456045
and O 0 0.0019552435
eNOS O 0 0.47165087
mRNA O 0 0.0010681861
expression O 0 0.00061088096
were O 0 0.0003715917
greater O 0 0.00026043935
in O 0 0.00027051708
the O 0 0.00044145508
Dex B-Chemical 1 0.99970394
+ O 0 0.14532192
Ato B-Chemical 1 0.9990933
group O 0 0.00060360273
than O 0 0.00014837696
in O 0 0.00017704976
the O 0 0.00027978705
Dex B-Chemical 1 0.9978921
only O 0 0.0005022826
group O 0 0.00062265946
( O 0 0.000842379
P O 0 0.05044028
< O 0 0.00025260184
0 O 0 0.0003192337
. O 0 0.00030408634
05 O 0 0.002116804
and O 0 0.00045483373
P O 0 0.012804687
< O 0 0.0005199996
0 O 0 0.0007437592
. O 0 0.0009275542
0001 O 0 0.0053885095
, O 0 0.0023806589
respectively O 0 0.00511461
) O 0 0.007085789
. O 0 0.008395414

Aortic O 0 0.65589136
superoxide B-Chemical 1 0.9998579
production O 0 0.006141401
was O 0 0.0017472582
lower O 0 0.0010051683
in O 0 0.00072345213
the O 0 0.00092872727
Dex B-Chemical 1 0.9997658
+ O 0 0.1970694
Ato B-Chemical 1 0.9991246
group O 0 0.00072555174
compared O 0 0.00018785778
with O 0 0.00023561293
the O 0 0.0002108161
group O 0 0.00030723063
treated O 0 0.00035214625
with O 0 0.0007948262
Dex B-Chemical 1 0.99925715
alone O 0 0.0011948871
( O 0 0.002693968
P O 0 0.073567204
< O 0 0.00086150784
0 O 0 0.0013194286
. O 0 0.0018316855
0001 O 0 0.00998969
) O 0 0.00612604
. O 0 0.008003805

4 O 0 0.09295644
. O 0 0.11234677

Treatment O 0 0.008918947
with O 0 0.004191405
Ato B-Chemical 1 0.9895823
improved O 0 0.0039380323
endothelial O 0 0.8605992
function O 0 0.0012618569
, O 0 0.001441102
reduced O 0 0.0015606679
superoxide B-Chemical 1 0.999977
production O 0 0.0028810974
and O 0 0.0009993898
reduced O 0 0.0010864524
SBP O 0 0.89276505
in O 0 0.0015020896
Dex B-Chemical 1 0.9995571
- O 0 0.07800316
treated O 0 0.0036364393
SD O 0 0.12651245
rats O 0 0.0056679994
. O 0 0.006910452

Severe O 0 0.92130476
citrate B-Chemical 0 0.9935975
toxicity B-Disease 2 0.9990701
complicating O 0 0.4543501
volunteer O 0 0.04302149
apheresis O 0 0.120383315
platelet O 0 0.791028
donation O 0 0.08580375
. O 0 0.013893092

We O 0 0.004641782
report O 0 0.004230927
a O 0 0.002800891
case O 0 0.0020482293
of O 0 0.0022631118
severe O 0 0.51929647
citrate B-Chemical 0 0.99629444
toxicity B-Disease 2 0.9982498
during O 0 0.0011060397
volunteer O 0 0.0027482517
donor O 0 0.0022824078
apheresis O 0 0.024279634
platelet O 0 0.39927483
collection O 0 0.005463276
. O 0 0.0069450084

The O 0 0.003507291
donor O 0 0.0031956974
was O 0 0.0021427087
a O 0 0.0018347708
40 O 0 0.0014425821
- O 0 0.0030616727
year O 0 0.001126227
- O 0 0.0028931608
old O 0 0.0009768802
female O 0 0.0019317865
, O 0 0.0011237891
first O 0 0.0008652061
- O 0 0.0024429054
time O 0 0.0012486884
apheresis O 0 0.0061531025
platelet O 0 0.20105168
donor O 0 0.005619413
. O 0 0.0077930735

Past O 0 0.07238292
medical O 0 0.008821006
history O 0 0.0077214995
was O 0 0.0026274035
remarkable O 0 0.0031289642
for O 0 0.004191917
hypertension B-Disease 2 0.99999666
, O 0 0.1525951
hyperlipidemia B-Disease 0 0.99999666
, O 0 0.012657075
and O 0 0.008631413
depression B-Disease 0 0.9982084
. O 0 0.009940984

Reported O 0 0.011643761
medications O 0 0.08196733
included O 0 0.0060543674
bumetanide B-Chemical 0 0.99998975
, O 0 0.16720563
pravastatin B-Chemical 0 0.99999166
, O 0 0.01995099
and O 0 0.023332765
paroxetine B-Chemical 0 0.9999856
. O 0 0.013719757

Thirty O 0 0.0047223927
minutes O 0 0.002002421
from O 0 0.0014181971
the O 0 0.0010622072
start O 0 0.00080114824
of O 0 0.00078394625
the O 0 0.0005711344
procedure O 0 0.0005037443
, O 0 0.00055584806
the O 0 0.00035942538
donor O 0 0.0005165972
noted O 0 0.00045125815
tingling O 0 0.42813402
around O 0 0.0004697738
the O 0 0.0006012901
mouth O 0 0.033805028
, O 0 0.001439694
hands O 0 0.0024923421
, O 0 0.0022932314
and O 0 0.0032037336
feet O 0 0.035852596
. O 0 0.00782736

She O 0 0.0053132786
then O 0 0.002845836
very O 0 0.0028031867
rapidly O 0 0.0024242061
developed O 0 0.0026379894
acute O 0 0.6079734
onset O 0 0.0058902414
of O 0 0.0024253111
severe O 0 0.3380335
facial O 0 0.501909
and O 0 0.0062648356
extremity O 0 0.88775486
tetany B-Disease 0 0.9998853
. O 0 0.011483202

Empirical O 0 0.0073642815
treatment O 0 0.0027815886
with O 0 0.0022454741
intravenous O 0 0.5381316
calcium B-Chemical 0 0.9997464
gluconate I-Chemical 0 0.99067557
was O 0 0.0006682929
initiated O 0 0.00045271983
, O 0 0.00062971655
and O 0 0.00062579114
muscle B-Disease 0 0.45857555
contractions I-Disease 0 0.9015429
slowly O 0 0.0011276277
subsided O 0 0.000854031
over O 0 0.0002990852
approximately O 0 0.00049091055
10 O 0 0.0007147923
to O 0 0.00095813203
15 O 0 0.0015767877
minutes O 0 0.0025801812
. O 0 0.005754553

The O 0 0.003335025
events O 0 0.0046929275
are O 0 0.0015439697
consistent O 0 0.0010864276
with O 0 0.00093560683
a O 0 0.0010041092
severe O 0 0.030274265
reaction O 0 0.010480048
to O 0 0.0005345693
calcium B-Chemical 0 0.99887186
chelation O 0 0.97665477
by O 0 0.0019589225
sodium B-Chemical 0 0.99999297
citrate I-Chemical 0 0.99977046
anticoagulant O 0 0.98443836
resulting O 0 0.0006940491
in O 0 0.0010833056
symptomatic O 0 0.3338811
systemic O 0 0.978631
hypocalcemia B-Disease 0 0.99997663
. O 0 0.010207036

Upon O 0 0.004622253
additional O 0 0.002336572
retrospective O 0 0.0045722583
analysis O 0 0.0016739721
, O 0 0.001632175
it O 0 0.000994109
was O 0 0.0006896082
noted O 0 0.00052001886
that O 0 0.000675452
bumetanide B-Chemical 0 0.99999416
is O 0 0.0010818967
a O 0 0.0011375032
loop B-Chemical 0 0.062355313
diuretic I-Chemical 0 0.99998283
that O 0 0.0008794587
may O 0 0.00115957
cause O 0 0.0027422255
significant O 0 0.0061709364
hypocalcemia B-Disease 0 0.99997103
. O 0 0.012260456

We O 0 0.0033158215
conclude O 0 0.0017136812
that O 0 0.0012608417
careful O 0 0.0011993255
screening O 0 0.0011518899
for O 0 0.00070389867
medications O 0 0.014536296
and O 0 0.0004330486
underlying O 0 0.0004231185
conditions O 0 0.00042485324
predisposing O 0 0.043427933
to O 0 0.0006918154
hypocalcemia B-Disease 0 0.9999939
is O 0 0.00057482754
recommended O 0 0.0003205955
to O 0 0.00022432952
help O 0 0.00032226718
prevent O 0 0.0003763414
severe O 0 0.029405216
reactions O 0 0.003355055
due O 0 0.0007344713
to O 0 0.0015761437
citrate B-Chemical 0 0.98769534
toxicity B-Disease 2 0.99870026
. O 0 0.008142843

Laboratory O 0 0.009481699
measurement O 0 0.0022253003
of O 0 0.0021600348
pre O 0 0.00376939
- O 0 0.0045682536
procedure O 0 0.0009834985
serum O 0 0.3073251
calcium B-Chemical 0 0.9953353
levels O 0 0.0006472492
in O 0 0.0004664272
selected O 0 0.0004427476
donors O 0 0.0008117921
may O 0 0.00054121675
identify O 0 0.0006357681
cases O 0 0.0013138395
requiring O 0 0.0017406273
heightened O 0 0.015326346
vigilance O 0 0.23472412
. O 0 0.0077194097

The O 0 0.0031786554
case O 0 0.0023162027
also O 0 0.0014609694
illustrates O 0 0.000923302
the O 0 0.0007516866
importance O 0 0.00057375635
of O 0 0.0006290292
maintaining O 0 0.00063251506
preparedness O 0 0.0020317344
for O 0 0.0005022055
managing O 0 0.0025077665
rare O 0 0.0029209338
but O 0 0.0007294765
serious O 0 0.017270846
reactions O 0 0.0037870046
in O 0 0.0008836329
volunteer O 0 0.002836739
apheresis O 0 0.0085362
blood O 0 0.0068085236
donors O 0 0.005538339
. O 0 0.006581605

Sirolimus B-Chemical 1 0.9978059
- O 0 0.099208854
associated O 0 0.018327031
proteinuria B-Disease 0 0.9999802
and O 0 0.06486619
renal B-Disease 2 0.9994842
dysfunction I-Disease 2 0.9990876
. O 0 0.023204315

Sirolimus B-Chemical 1 0.9914671
is O 0 0.003216284
a O 0 0.0021317292
novel O 0 0.0017477575
immunosuppressant O 0 0.93195415
with O 0 0.0014363232
potent O 0 0.012632011
antiproliferative O 0 0.6613022
actions O 0 0.0018106367
through O 0 0.00022579686
its O 0 0.00041541076
ability O 0 0.00022695592
to O 0 0.00019443996
inhibit O 0 0.0001930964
the O 0 0.00033250853
raptor O 0 0.1351329
- O 0 0.007278961
containing O 0 0.00036666243
mammalian O 0 0.0006055396
target O 0 0.0006792791
of O 0 0.0015693181
rapamycin B-Chemical 1 0.9343427
protein O 0 0.04336748
kinase O 0 0.70654434
. O 0 0.008919558

Sirolimus B-Chemical 1 0.9803622
represents O 0 0.0028856872
a O 0 0.0022452832
major O 0 0.0015186223
therapeutic O 0 0.0020435252
advance O 0 0.0010301513
in O 0 0.00061643875
the O 0 0.0005426089
prevention O 0 0.0017513417
of O 0 0.001111116
acute O 0 0.93850946
renal O 0 0.9882682
allograft O 0 0.9831334
rejection O 0 0.99261016
and O 0 0.014938963
chronic O 0 0.99861944
allograft O 0 0.99949837
nephropathy B-Disease 2 0.99999964
. O 0 0.05081804

Its O 0 0.014425036
role O 0 0.0021576437
in O 0 0.0017711222
the O 0 0.0013048284
therapy O 0 0.0019560906
of O 0 0.003601768
glomerulonephritis B-Disease 2 0.9999993
, O 0 0.08262474
autoimmunity B-Disease 0 0.9999225
, O 0 0.014208795
cystic B-Disease 0 0.9435114
renal I-Disease 0 0.9957873
diseases I-Disease 0 0.996349
and O 0 0.01791756
renal B-Disease 0 0.9998233
cancer I-Disease 0 0.999936
is O 0 0.0028208632
under O 0 0.0023083824
investigation O 0 0.005961555
. O 0 0.0074355267

Because O 0 0.0045085195
sirolimus B-Chemical 1 0.9992155
does O 0 0.002344459
not O 0 0.0011185219
share O 0 0.0009855772
the O 0 0.0010649511
vasomotor O 0 0.99764204
renal O 0 0.97175217
adverse O 0 0.63861597
effects O 0 0.00056717324
exhibited O 0 0.0003117072
by O 0 0.00032143868
calcineurin O 0 0.51618314
inhibitors O 0 0.014387007
, O 0 0.0006800227
it O 0 0.0003074627
has O 0 0.00023270611
been O 0 0.0002686229
designated O 0 0.00032678142
a O 0 0.0005746451
' O 0 0.0011147753
non O 0 0.0036666375
- O 0 0.25743616
nephrotoxic B-Disease 2 0.99994385
drug O 0 0.8778318
' O 0 0.010487557
. O 0 0.007590297

However O 0 0.004736598
, O 0 0.0035719054
clinical O 0 0.002918167
reports O 0 0.0012294328
suggest O 0 0.0006502157
that O 0 0.00063586025
, O 0 0.00079507806
under O 0 0.00040577687
some O 0 0.0004373773
circumstances O 0 0.0008115256
, O 0 0.003035762
sirolimus B-Chemical 1 0.9999254
is O 0 0.00070153165
associated O 0 0.0008049407
with O 0 0.0031416547
proteinuria B-Disease 0 0.9999976
and O 0 0.01815487
acute B-Disease 0 0.99907243
renal I-Disease 2 0.9999038
dysfunction I-Disease 2 0.99985254
. O 0 0.0127837295

A O 0 0.08120449
common O 0 0.0050997166
risk O 0 0.07389022
factor O 0 0.012131651
appears O 0 0.0013335743
to O 0 0.0008950722
be O 0 0.00083600305
presence O 0 0.0007939837
of O 0 0.0011685137
pre O 0 0.004964972
- O 0 0.011059601
existing O 0 0.003015534
chronic B-Disease 0 0.99582785
renal I-Disease 0 0.99982774
damage I-Disease 0 0.99970156
. O 0 0.014546348

The O 0 0.0028572036
mechanisms O 0 0.0021616677
of O 0 0.0035978083
sirolimus B-Chemical 1 0.99996495
- O 0 0.31086102
associated O 0 0.009999834
proteinuria B-Disease 0 0.99999833
are O 0 0.0010619983
multifactorial O 0 0.06879803
and O 0 0.00049810647
may O 0 0.00026024127
be O 0 0.00023481008
due O 0 0.00017844189
to O 0 0.00020816433
an O 0 0.0002912273
increase O 0 0.00025231804
in O 0 0.00044050234
glomerular O 0 0.8777639
capillary O 0 0.22758979
pressure O 0 0.04484592
following O 0 0.00082179415
calcineurin O 0 0.5115235
inhibitor O 0 0.160374
withdrawal O 0 0.61955374
. O 0 0.006707913

It O 0 0.0047774934
has O 0 0.0024152752
also O 0 0.0016918957
been O 0 0.0012476613
suggested O 0 0.0008183584
that O 0 0.0008162134
sirolimus B-Chemical 1 0.9997613
directly O 0 0.0005975389
causes O 0 0.0007152106
increased O 0 0.0010338008
glomerular O 0 0.9831814
permeability O 0 0.97584707
/ O 0 0.20360135
injury O 0 0.95612603
, O 0 0.00092946907
but O 0 0.00044469713
evidence O 0 0.00033203812
for O 0 0.00044788313
this O 0 0.0006052589
mechanism O 0 0.0008784997
is O 0 0.0016733874
currently O 0 0.0032532734
inconclusive O 0 0.027485829
. O 0 0.0072923913

The O 0 0.0042533325
acute B-Disease 0 0.9848514
renal I-Disease 2 0.99980956
dysfunction I-Disease 2 0.9998652
associated O 0 0.005719162
with O 0 0.005208609
sirolimus B-Chemical 1 0.9999676
( O 0 0.0013066193
such O 0 0.00028478933
as O 0 0.00024056372
in O 0 0.0002325451
delayed O 0 0.0006046866
graft O 0 0.0032045953
function O 0 0.00033634718
) O 0 0.0007875661
may O 0 0.00018753922
be O 0 0.00017700148
due O 0 0.00013731116
to O 0 0.00016367338
suppression O 0 0.00028291636
of O 0 0.00034456467
compensatory O 0 0.0013123727
renal O 0 0.92142814
cell O 0 0.02526616
proliferation O 0 0.7942529
and O 0 0.0013441335
survival O 0 0.044987336
/ O 0 0.0062720273
repair O 0 0.0038584962
processes O 0 0.004995188
. O 0 0.006752085

Although O 0 0.003036719
these O 0 0.0025797652
adverse O 0 0.16727212
effects O 0 0.0016416312
occur O 0 0.0008190497
in O 0 0.0006261279
some O 0 0.000518557
patients O 0 0.0007193543
, O 0 0.0005009698
their O 0 0.0003112164
occurrence O 0 0.00057541626
could O 0 0.00018157074
be O 0 0.0001813145
minimised O 0 0.00017951427
by O 0 0.00018789808
knowledge O 0 0.0002275956
of O 0 0.00020756005
the O 0 0.00017366465
molecular O 0 0.0013780921
effects O 0 0.00035740683
of O 0 0.00071373914
sirolimus B-Chemical 1 0.99987566
on O 0 0.0001342892
the O 0 0.00027496673
kidney O 0 0.59154963
, O 0 0.00047931643
the O 0 0.00016258858
use O 0 0.00016922911
of O 0 0.00042457628
sirolimus B-Chemical 1 0.999841
in O 0 0.00019429985
appropriate O 0 0.00014012265
patient O 0 0.00018113462
populations O 0 0.00029676207
, O 0 0.00019604352
close O 0 0.00013151449
monitoring O 0 0.00022189315
of O 0 0.00068368274
proteinuria B-Disease 0 0.99999857
and O 0 0.001550083
renal O 0 0.8246133
function O 0 0.00030885055
, O 0 0.00040808844
use O 0 0.00024390235
of O 0 0.00302635
angiotensin B-Chemical 1 0.9999963
- O 0 0.29758346
converting O 0 0.021602023
enzyme O 0 0.04315902
inhibitors O 0 0.008752099
or O 0 0.0034569977
angiotensin B-Chemical 1 0.9999993
II I-Chemical 1 0.9645421
receptor O 0 0.35420638
blockers O 0 0.9973349
if O 0 0.00070656417
proteinuria B-Disease 0 0.9999949
occurs O 0 0.0008805982
and O 0 0.0013409421
withdrawal O 0 0.093577854
if O 0 0.0015724023
needed O 0 0.0026173797
. O 0 0.005589501

Further O 0 0.0038072781
long O 0 0.0028351275
- O 0 0.003998354
term O 0 0.0011652485
analysis O 0 0.00096494565
of O 0 0.0010404116
renal O 0 0.77566606
allograft O 0 0.7590216
studies O 0 0.00057181664
using O 0 0.000437701
sirolimus B-Chemical 1 0.99944943
as O 0 0.0003092203
de O 0 0.0024827914
novo O 0 0.0024684092
immunosuppression O 0 0.82830006
along O 0 0.00023390289
with O 0 0.00028431482
clinical O 0 0.0007031443
and O 0 0.00026374627
laboratory O 0 0.00034483688
studies O 0 0.00027356358
will O 0 0.00029391234
refine O 0 0.00073922693
these O 0 0.0005777676
issues O 0 0.0009568001
in O 0 0.0011889706
the O 0 0.0019501306
future O 0 0.0036856877
. O 0 0.0067613646

Proteinuria B-Disease 2 0.99982977
after O 0 0.0045155333
conversion O 0 0.006655068
to O 0 0.0042678877
sirolimus B-Chemical 1 0.9993968
in O 0 0.0054852692
renal O 0 0.88636005
transplant O 0 0.33172286
recipients O 0 0.013942659
. O 0 0.0125325

Sirolimus B-Chemical 1 0.9983038
( O 0 0.07983422
SRL B-Chemical 0 0.9999447
) O 0 0.008990796
is O 0 0.0031052344
a O 0 0.0030351933
new O 0 0.003330612
, O 0 0.004187172
potent O 0 0.013293054
immunosuppressive O 0 0.9120257
agent O 0 0.42337376
. O 0 0.0126906745

More O 0 0.01301508
recently O 0 0.0039768172
, O 0 0.009147041
proteinuria B-Disease 0 0.9999901
has O 0 0.001545011
been O 0 0.00088567194
reported O 0 0.00067812356
as O 0 0.00045146316
a O 0 0.00047124064
consequence O 0 0.00031191416
of O 0 0.0010383412
sirolimus B-Chemical 1 0.9999578
therapy O 0 0.0067950077
, O 0 0.0008269059
although O 0 0.0005046673
the O 0 0.00058881356
mechanism O 0 0.0008314933
has O 0 0.0013644021
remained O 0 0.0028149115
unclear O 0 0.0038896054
. O 0 0.0069887186

We O 0 0.0034694965
retrospectively O 0 0.0023229206
examined O 0 0.0013301737
the O 0 0.0011628801
records O 0 0.001131461
of O 0 0.000908852
25 O 0 0.0009877656
renal O 0 0.539145
transplant O 0 0.11055975
patients O 0 0.0012395149
, O 0 0.00070371025
who O 0 0.0006523423
developed O 0 0.000551222
or O 0 0.00044514667
displayed O 0 0.0006041209
increased O 0 0.0030098127
proteinuria B-Disease 0 0.99999523
after O 0 0.0027809304
SRL B-Chemical 0 0.99995995
conversion O 0 0.04809093
. O 0 0.0076199016

The O 0 0.003263943
patient O 0 0.0025792816
cohort O 0 0.0033333928
( O 0 0.0020291314
14 O 0 0.0011419076
men O 0 0.008938077
, O 0 0.0010163917
11 O 0 0.0006731443
women O 0 0.0029297627
) O 0 0.00083732844
was O 0 0.0003553222
treated O 0 0.0004182441
with O 0 0.00108031
SRL B-Chemical 0 0.99998736
as O 0 0.00038255498
conversion O 0 0.002673105
therapy O 0 0.000581579
, O 0 0.0002643815
due O 0 0.00013081693
to O 0 0.00018389325
chronic B-Disease 0 0.95968384
allograft I-Disease 0 0.99879706
nephropathy I-Disease 2 1.0
( O 0 0.25243375
CAN B-Disease 0 0.9998671
) O 0 0.003375799
( O 0 0.00036635128
n O 0 0.00017935704
= O 0 0.00036102993
15 O 0 0.00017698713
) O 0 0.0008212289
neoplasia B-Disease 0 0.99986446
( O 0 0.0005595858
n O 0 0.00022000035
= O 0 0.00049097434
8 O 0 0.00021654363
) O 0 0.0004903939
; O 0 0.0010312599
Kaposi B-Disease 0 0.99809057
' I-Disease 0 0.0014132356
s I-Disease 0 0.0012188961
sarcoma I-Disease 0 0.9995772
, O 0 0.0011162801
Four O 0 0.00070724083
skin B-Disease 0 0.9379488
cancers I-Disease 2 0.9999486
, O 0 0.0024650672
One O 0 0.0007005345
intestinal B-Disease 0 0.89399844
tumors I-Disease 0 0.9995055
, O 0 0.001187911
One O 0 0.0005204359
renal B-Disease 0 0.88176763
cell I-Disease 0 0.0074730897
carsinom I-Disease 0 0.2959549
) O 0 0.0014679689
or O 0 0.0007035704
BK O 0 0.99928856
virus O 0 0.9796012
nephropathy B-Disease 2 0.9999999
( O 0 0.009303977
n O 0 0.0013580342
= O 0 0.00275859
2 O 0 0.0025560968
) O 0 0.005320279
. O 0 0.007402649

SRL B-Chemical 0 0.99974865
was O 0 0.003592807
started O 0 0.0019381664
at O 0 0.0011430721
a O 0 0.00094576506
mean O 0 0.00049803127
of O 0 0.0007076794
78 O 0 0.0012875269
+ O 0 0.0025158369
/ O 0 0.010033046
- O 0 0.006293647
42 O 0 0.0006945656
( O 0 0.000633393
15 O 0 0.00046645707
to O 0 0.0005472041
163 O 0 0.0014839112
) O 0 0.0013831293
months O 0 0.0012302375
after O 0 0.0019208173
transplantation O 0 0.008886105
. O 0 0.007662756

Mean O 0 0.0026980683
follow O 0 0.002248964
- O 0 0.0037557276
up O 0 0.0013503347
on O 0 0.0010900841
SRL B-Chemical 0 0.99991024
therapy O 0 0.0027471727
was O 0 0.0006823724
20 O 0 0.0005755284
+ O 0 0.0014134516
/ O 0 0.0049456246
- O 0 0.0037855655
12 O 0 0.00054366986
( O 0 0.00081266544
6 O 0 0.00069138134
to O 0 0.0009951646
43 O 0 0.0022003194
) O 0 0.0032586108
months O 0 0.0035556129
. O 0 0.0072481944

Proteinuria B-Disease 2 0.9999118
increased O 0 0.0032999136
from O 0 0.0016265049
0 O 0 0.001447789
. O 0 0.0009373388
445 O 0 0.0028054013
( O 0 0.00076629274
0 O 0 0.00047081773
to O 0 0.00031741915
1 O 0 0.00031641306
. O 0 0.0002526688
5 O 0 0.00022539077
) O 0 0.0003697001
g O 0 0.0005303038
/ O 0 0.00086366374
d O 0 0.00034439733
before O 0 0.00015825682
conversion O 0 0.00038486236
to O 0 0.00016004051
3 O 0 0.000160175
. O 0 0.00015635582
2 O 0 0.00016621302
g O 0 0.00035672553
/ O 0 0.0014044008
dL O 0 0.017160326
( O 0 0.0003870608
0 O 0 0.00024736088
. O 0 0.0001852109
2 O 0 0.00018103844
to O 0 0.00016898208
12 O 0 0.00019288332
) O 0 0.0003335588
after O 0 0.0002365254
conversion O 0 0.00095590134
( O 0 0.0010586885
P O 0 0.04424065
= O 0 0.0017302114
0 O 0 0.0015373755
. O 0 0.0021041487
001 O 0 0.04663411
) O 0 0.0065023433
. O 0 0.008248119

Before O 0 0.004675501
conversion O 0 0.0049435203
8 O 0 0.0022102366
( O 0 0.0020633454
32 O 0 0.0015422741
% O 0 0.0012874092
) O 0 0.001285707
patients O 0 0.00090105995
had O 0 0.0006525966
no O 0 0.00076371175
proteinuria B-Disease 0 0.99999595
, O 0 0.0021043317
whereas O 0 0.00097183767
afterwards O 0 0.0013975464
all O 0 0.0011061913
patients O 0 0.002368065
had O 0 0.003775607
proteinuria B-Disease 0 0.9999646
. O 0 0.010096971

In O 0 0.0041903104
28 O 0 0.0029885336
% O 0 0.00235741
of O 0 0.0018816207
patients O 0 0.005015826
proteinuria B-Disease 0 0.9999937
remained O 0 0.0040286034
unchanged O 0 0.0011736249
, O 0 0.0010856765
whereas O 0 0.00073820725
it O 0 0.00073356554
increased O 0 0.00082178554
in O 0 0.0009675366
68 O 0 0.0017694614
% O 0 0.0020584164
of O 0 0.0031112086
patients O 0 0.0061049904
. O 0 0.007600415

In O 0 0.0060879607
40 O 0 0.0047132755
% O 0 0.0044464837
it O 0 0.0036197933
increased O 0 0.003296609
by O 0 0.0035025477
more O 0 0.0037846377
than O 0 0.0034525206
100 O 0 0.006542159
% O 0 0.008882536
. O 0 0.012131033

Twenty O 0 0.007957222
- O 0 0.0061903903
eight O 0 0.0018979369
percent O 0 0.0014537415
of O 0 0.0016177248
patients O 0 0.0016820623
showed O 0 0.0013136708
increased O 0 0.0030750334
proteinuria B-Disease 0 0.9999914
to O 0 0.0023152982
the O 0 0.004337208
nephrotic B-Disease 0 0.9999832
range O 0 0.0073982957
. O 0 0.008719468

Biopsies O 0 0.005283451
performed O 0 0.002438395
in O 0 0.0018246738
five O 0 0.0011266131
patients O 0 0.0011382538
revealed O 0 0.0008114645
new O 0 0.00097484357
pathological O 0 0.02010235
changes O 0 0.0012504244
: O 0 0.0018244678
One O 0 0.0031767797
membranoproliferative B-Disease 0 0.9999995
glomerulopathy I-Disease 0 0.99999964
and O 0 0.09686489
interstitial B-Disease 0 0.9990528
nephritis I-Disease 0 0.99999905
. O 0 0.020053629

These O 0 0.009709931
patients O 0 0.009097512
showed O 0 0.0075594983
persistently O 0 0.022011768
good O 0 0.011291326
graft O 0 0.019630874
function O 0 0.013766345
. O 0 0.019294132

Serum O 0 0.8204032
creatinine B-Chemical 1 0.9945045
values O 0 0.002112606
did O 0 0.0013780158
not O 0 0.0007553506
change O 0 0.00070792565
significantly O 0 0.0005745526
: O 0 0.0007525588
1 O 0 0.0003598357
. O 0 0.00029057945
98 O 0 0.00072447077
+ O 0 0.0013426731
/ O 0 0.008874089
- O 0 0.009197309
0 O 0 0.00030128055
. O 0 0.0001952766
8 O 0 0.00019159711
mg O 0 0.003961638
/ O 0 0.0018537501
dL O 0 0.02108424
before O 0 0.00021431256
SRL B-Chemical 0 0.99995303
therapy O 0 0.00068610377
and O 0 0.00026038423
2 O 0 0.00018770629
. O 0 0.00016527616
53 O 0 0.00034203523
+ O 0 0.0011354786
/ O 0 0.010282029
- O 0 0.011003017
1 O 0 0.00022651446
. O 0 0.00018255536
9 O 0 0.00019876327
mg O 0 0.0031539088
/ O 0 0.0010147967
dL O 0 0.002692061
at O 0 0.00019534511
last O 0 0.00017589008
follow O 0 0.00023636445
- O 0 0.0010215855
up O 0 0.0004660233
( O 0 0.0010769392
P O 0 0.033493515
= O 0 0.002081948
. O 0 0.0017939371
14 O 0 0.0028844718
) O 0 0.005692537
. O 0 0.007992712

Five O 0 0.007325895
grafts O 0 0.006202759
were O 0 0.0035906362
lost O 0 0.0031239204
and O 0 0.0030805084
the O 0 0.0028905869
patients O 0 0.0037384667
returned O 0 0.0037880836
to O 0 0.004664789
dialysis O 0 0.014132315
. O 0 0.011104222

Five O 0 0.009366755
patients O 0 0.0071808994
displayed O 0 0.0062088044
CAN B-Disease 0 0.9858305
and O 0 0.01032978
Kaposi B-Disease 0 0.99896896
' I-Disease 0 0.016781012
s I-Disease 0 0.015290415
sarcoma I-Disease 0 0.99878055
. O 0 0.01952702

Mean O 0 0.0029148348
urinary O 0 0.03523507
protein O 0 0.0028924043
of O 0 0.0016615093
patients O 0 0.00148244
who O 0 0.00090831355
returned O 0 0.00044317602
to O 0 0.0003374099
dialysis O 0 0.0013706464
was O 0 0.00030145783
1 O 0 0.00024224391
. O 0 0.00020104251
26 O 0 0.00026136817
( O 0 0.0002840331
0 O 0 0.0002190033
. O 0 0.0001601654
5 O 0 0.00013706498
to O 0 0.0001339033
3 O 0 0.00014664227
. O 0 0.00014733775
5 O 0 0.00014749236
) O 0 0.0002745465
g O 0 0.0004292621
/ O 0 0.0007446446
d O 0 0.00029032468
before O 0 0.00013514476
and O 0 0.00020693899
4 O 0 0.00016344724
. O 0 0.00016040412
7 O 0 0.00015892342
( O 0 0.00023118108
3 O 0 0.00015684261
to O 0 0.00015327742
12 O 0 0.00017192775
) O 0 0.00031783464
g O 0 0.00048527442
/ O 0 0.00081247423
d O 0 0.0004812936
after O 0 0.00033384547
conversion O 0 0.0015025258
( O 0 0.0014975222
P O 0 0.06847949
= O 0 0.0026874342
. O 0 0.002310559
01 O 0 0.007113611
) O 0 0.006374322
. O 0 0.008350316

Mean O 0 0.0027194717
serum O 0 0.12513706
creatinine B-Chemical 1 0.9935522
level O 0 0.0011681954
before O 0 0.00066340325
conversion O 0 0.0014217517
was O 0 0.00052678556
2 O 0 0.00038547482
. O 0 0.00030237983
21 O 0 0.0003400743
mg O 0 0.00654782
/ O 0 0.0018601055
dL O 0 0.010667053
and O 0 0.00031223753
thereafter O 0 0.00030614994
, O 0 0.00035145672
4 O 0 0.00023510265
. O 0 0.00025805784
93 O 0 0.00058106286
mg O 0 0.008716079
/ O 0 0.002699146
dL O 0 0.038688373
( O 0 0.0016919078
P O 0 0.05473329
= O 0 0.0028867673
. O 0 0.0026534356
02 O 0 0.03228578
) O 0 0.0069391252
. O 0 0.008832954

Heavy O 0 0.99578565
proteinuria B-Disease 0 0.999982
was O 0 0.003481318
common O 0 0.001896263
after O 0 0.0008570905
the O 0 0.0008560988
use O 0 0.00089834275
of O 0 0.001717266
SRL B-Chemical 0 0.9999577
as O 0 0.0010347596
rescue O 0 0.0010943073
therapy O 0 0.002054234
for O 0 0.0020152684
renal O 0 0.8476559
transplantation O 0 0.15813063
. O 0 0.008360781

Therefore O 0 0.004211053
, O 0 0.0039285515
conversion O 0 0.0033753274
should O 0 0.0010620791
be O 0 0.0009982802
considered O 0 0.0007591716
for O 0 0.0007491483
patients O 0 0.00097421365
who O 0 0.0008949306
have O 0 0.0005918293
not O 0 0.00077392196
developed O 0 0.0018130194
advanced O 0 0.086337976
CAN B-Disease 0 0.99879897
and O 0 0.027299587
proteinuria B-Disease 0 0.99998593
. O 0 0.011962778

The O 0 0.003333613
possibility O 0 0.0021401534
of O 0 0.0021034612
de O 0 0.004613256
novo O 0 0.008034134
glomerular O 0 0.95061135
pathology O 0 0.1908145
under O 0 0.0011781394
SRL B-Chemical 0 0.9999672
treatment O 0 0.0010114503
requires O 0 0.00058104075
further O 0 0.00083129207
investigation O 0 0.0015345411
by O 0 0.002194548
renal O 0 0.77833116
biopsy O 0 0.027994711
. O 0 0.007980252

Long O 0 0.016422683
- O 0 0.0060914964
term O 0 0.001724706
follow O 0 0.0011892659
- O 0 0.002768233
up O 0 0.000738696
of O 0 0.0014133946
ifosfamide B-Chemical 1 0.99995756
renal B-Disease 0 0.9999466
toxicity I-Disease 2 0.9999918
in O 0 0.00061194366
children O 0 0.0011154313
treated O 0 0.0004725183
for O 0 0.00046954994
malignant B-Disease 0 0.9966635
mesenchymal I-Disease 0 0.99527764
tumors I-Disease 0 0.99986327
: O 0 0.0018325617
an O 0 0.0007403821
International O 0 0.0017380252
Society O 0 0.0014440239
of O 0 0.0013020018
Pediatric O 0 0.0022012028
Oncology O 0 0.0047333515
report O 0 0.005212886
. O 0 0.0067911213

The O 0 0.0035768067
renal O 0 0.18769331
function O 0 0.0017305614
of O 0 0.0013917444
74 O 0 0.0013595981
children O 0 0.0012613096
with O 0 0.0011138741
malignant B-Disease 0 0.99663615
mesenchymal I-Disease 0 0.9945068
tumors I-Disease 0 0.99974996
in O 0 0.00035274363
complete O 0 0.00024274006
remission O 0 0.11190589
and O 0 0.0002625741
who O 0 0.0002734561
have O 0 0.00012108113
received O 0 0.00011181642
the O 0 0.00013260233
same O 0 0.00014392078
ifosfamide B-Chemical 1 0.99719894
chemotherapy O 0 0.017358502
protocol O 0 0.00021264877
( O 0 0.00042612557
International O 0 0.00069601263
Society O 0 0.00036609152
of O 0 0.00019970397
Pediatric O 0 0.00026679895
Oncology O 0 0.001227757
Malignant B-Disease 0 0.28965694
Mesenchymal I-Disease 0 0.105402574
Tumor I-Disease 0 0.9939319
Study O 0 0.0044076345
84 O 0 0.00049732893
[ O 0 0.0010565178
SIOP O 0 0.0017767348
MMT O 0 0.39014158
84 O 0 0.00047558363
] O 0 0.00055806094
) O 0 0.00043587145
were O 0 0.0002903789
studied O 0 0.0003341629
1 O 0 0.00035047668
year O 0 0.00042032893
after O 0 0.0004232962
the O 0 0.0007394034
completion O 0 0.0010877936
of O 0 0.0022642026
treatment O 0 0.0043553314
. O 0 0.006958926

Total O 0 0.0034990716
cumulative O 0 0.0030865476
doses O 0 0.004368623
were O 0 0.0011842415
36 O 0 0.000820828
or O 0 0.00053004624
60 O 0 0.00047422617
g O 0 0.0007226655
/ O 0 0.0012508503
m2 O 0 0.0072709303
of O 0 0.0008805588
ifosfamide B-Chemical 1 0.99909806
( O 0 0.00050412596
six O 0 0.00016289801
or O 0 0.0001678727
10 O 0 0.0001617093
cycles O 0 0.00014371739
of O 0 0.0004047615
ifosfamide B-Chemical 1 0.9994887
, I-Chemical 0 0.0050122007
vincristine I-Chemical 1 0.9999291
, I-Chemical 0 0.001766018
and I-Chemical 0 0.0021452254
dactinomycin I-Chemical 0 0.99781406
[ O 0 0.28217214
IVA B-Chemical 0 0.9999651
] O 0 0.019528879
) O 0 0.0076618562
. O 0 0.0077766865

None O 0 0.013767788
of O 0 0.009469213
them O 0 0.010057874
had O 0 0.008541261
received O 0 0.010282302
cisplatin B-Chemical 1 0.99918705
chemotherapy O 0 0.69830245
. O 0 0.019885335

Ages O 0 0.007388781
ranged O 0 0.002756099
from O 0 0.0019220911
4 O 0 0.0014000208
months O 0 0.00093472924
to O 0 0.0008737239
17 O 0 0.0010468224
years O 0 0.0010392922
; O 0 0.0012751045
58 O 0 0.0012489097
patients O 0 0.0012185234
were O 0 0.0012721942
males O 0 0.0021776624
and O 0 0.0025240688
42 O 0 0.0043617957
females O 0 0.006887912
. O 0 0.00882236

The O 0 0.0045417035
most O 0 0.0040781945
common O 0 0.0033408469
primary O 0 0.0030574924
tumor B-Disease 0 0.5470124
site O 0 0.0028176268
was O 0 0.0024520652
the O 0 0.0025980498
head O 0 0.030336017
and O 0 0.0057944725
neck O 0 0.26931
. O 0 0.011105385

Renal O 0 0.025708258
function O 0 0.0025534513
was O 0 0.0016053886
investigated O 0 0.0008902259
by O 0 0.0008079396
measuring O 0 0.0005840954
plasma O 0 0.0059738364
and O 0 0.0008064433
urinary O 0 0.7630319
electrolytes O 0 0.9974758
, O 0 0.018979123
glucosuria B-Disease 0 0.9999975
, O 0 0.068449266
proteinuria B-Disease 0 0.99999964
, O 0 0.065511934
aminoaciduria B-Disease 0 0.99999917
, O 0 0.007273326
urinary O 0 0.6998437
pH O 0 0.4669925
, O 0 0.0008988111
osmolarity O 0 0.9197787
, O 0 0.0026738758
creatinine B-Chemical 1 0.9991035
clearance O 0 0.1000835
, O 0 0.0016001825
phosphate B-Chemical 0 0.99628496
tubular O 0 0.71814454
reabsorption O 0 0.94706815
, O 0 0.0027780556
beta O 0 0.88954496
2 O 0 0.0013509954
microglobulinuria O 0 0.36930135
, O 0 0.0025254257
and O 0 0.003741604
lysozymuria O 0 0.9404776
. O 0 0.008059217

Fifty O 0 0.009605606
- O 0 0.0070526064
eight O 0 0.0017680342
patients O 0 0.0018195073
( O 0 0.0016050547
78 O 0 0.0014817097
% O 0 0.000977248
) O 0 0.00094859145
had O 0 0.0004943607
normal O 0 0.00080975477
renal O 0 0.61765444
tests O 0 0.0010971011
, O 0 0.0005548648
whereas O 0 0.00041626702
16 O 0 0.00042372636
patients O 0 0.000530702
( O 0 0.0006832893
22 O 0 0.0007401665
% O 0 0.0009886939
) O 0 0.0018091456
had O 0 0.0022410413
renal B-Disease 0 0.9946549
abnormalities I-Disease 0 0.9361868
. O 0 0.008324273

Two O 0 0.0036721185
subsets O 0 0.0023517893
of O 0 0.0018027691
patients O 0 0.001464294
were O 0 0.00078236486
identified O 0 0.00051480246
from O 0 0.00040387103
this O 0 0.0003848528
latter O 0 0.0007136025
group O 0 0.00045500373
: O 0 0.00041159356
the O 0 0.00019109886
first O 0 0.00014563493
included O 0 0.00014410561
four O 0 0.00012119111
patients O 0 0.00023240478
( O 0 0.0002567422
5 O 0 0.00013658355
% O 0 0.00017037349
of O 0 0.00015813511
the O 0 0.00013876113
total O 0 0.00013652325
population O 0 0.00057685334
) O 0 0.00057760236
who O 0 0.00031261463
developed O 0 0.00029184268
major O 0 0.00039525138
toxicity B-Disease 2 0.9939814
resulting O 0 0.00026239187
in O 0 0.00031866418
Fanconi B-Disease 0 0.9288002
' I-Disease 0 0.0006894972
s I-Disease 0 0.00059301645
syndrome I-Disease 0 0.6114184
( O 0 0.0068705315
TDFS B-Disease 0 0.9993068
) O 0 0.0023494163
; O 0 0.00045143903
and O 0 0.00020191466
the O 0 0.00015659528
second O 0 0.00015694734
group O 0 0.00019172959
included O 0 0.00013333684
five O 0 0.000118272124
patients O 0 0.00021098663
with O 0 0.00026593247
elevated O 0 0.0062555126
beta O 0 0.853976
2 O 0 0.0008037757
microglobulinuria O 0 0.24012871
and O 0 0.0011846996
low O 0 0.003301316
phosphate B-Chemical 0 0.99590343
reabsorption O 0 0.9200376
. O 0 0.008135906

The O 0 0.0051968717
remaining O 0 0.0042741867
seven O 0 0.0035325242
patients O 0 0.0038474423
had O 0 0.0033584037
isolated O 0 0.0038185804
beta O 0 0.74179465
2 O 0 0.00824422
microglobulinuria O 0 0.5392217
. O 0 0.014035516

Severe O 0 0.93027234
toxicity B-Disease 2 0.9983997
was O 0 0.0022431405
correlated O 0 0.00089885824
with O 0 0.00072613725
the O 0 0.0005144368
higher O 0 0.00041048604
cumulative O 0 0.0005308912
dose O 0 0.0012094203
of O 0 0.00035985032
60 O 0 0.00027028247
g O 0 0.00053507445
/ O 0 0.0012844047
m2 O 0 0.009697232
of O 0 0.0007253412
ifosfamide B-Chemical 1 0.9993807
, O 0 0.0005404825
a O 0 0.00035759714
younger O 0 0.006205234
age O 0 0.0004799583
( O 0 0.00031374412
less O 0 0.000167619
than O 0 0.00013171088
2 O 0 0.00016557855
1 O 0 0.00017555732
/ O 0 0.00043283214
2 O 0 0.00019426315
years O 0 0.00024124775
old O 0 0.0003041461
) O 0 0.00051409565
, O 0 0.0004652514
and O 0 0.00048556225
a O 0 0.00066109514
predominance O 0 0.0010734311
of O 0 0.0015338843
vesicoprostatic O 0 0.08826741
tumor B-Disease 0 0.86271983
involvement O 0 0.013113073
. O 0 0.007534801

This O 0 0.004803405
low O 0 0.0027069473
percentage O 0 0.0014078108
( O 0 0.0017885513
5 O 0 0.00090995466
% O 0 0.00101036
) O 0 0.0011820034
of O 0 0.0010799684
TDFS O 0 0.9925013
must O 0 0.00028113526
be O 0 0.00027009443
evaluated O 0 0.00019751112
with O 0 0.00021991563
respect O 0 0.00017604714
to O 0 0.00016078066
the O 0 0.00017851606
efficacy O 0 0.000324468
of O 0 0.00053620635
ifosfamide B-Chemical 1 0.9987752
in O 0 0.00032200644
the O 0 0.0003454534
treatment O 0 0.00059211906
of O 0 0.0013560666
mesenchymal B-Disease 0 0.9649062
tumors I-Disease 0 0.9971179
in O 0 0.002676757
children O 0 0.007744389
. O 0 0.0068731154

Progressive O 0 0.14036855
myopathy B-Disease 2 0.9966107
with O 0 0.0029907706
up O 0 0.0019224032
- O 0 0.0030116474
regulation O 0 0.00096485176
of O 0 0.0014705418
MHC O 0 0.08145183
- O 0 0.061697304
I O 0 0.017575301
associated O 0 0.0019479304
with O 0 0.0036439707
statin B-Chemical 1 0.99871135
therapy O 0 0.015448642
. O 0 0.008403587

Statins B-Chemical 0 0.9992631
can O 0 0.0032268555
cause O 0 0.0030831648
a O 0 0.0048718774
necrotizing O 0 0.9999844
myopathy B-Disease 2 0.999984
and O 0 0.031111956
hyperCKaemia B-Disease 0 0.9877489
which O 0 0.0011698339
is O 0 0.0008012891
reversible O 0 0.009912005
on O 0 0.0007382698
cessation O 0 0.0036959208
of O 0 0.002063909
the O 0 0.0030452844
drug O 0 0.41995323
. O 0 0.007810374

What O 0 0.00904075
is O 0 0.0027809076
less O 0 0.0017176233
well O 0 0.0012397735
known O 0 0.001178826
is O 0 0.00080608524
a O 0 0.00086964626
phenomenon O 0 0.005488746
whereby O 0 0.00086424826
statins B-Chemical 1 0.99926144
may O 0 0.00034069718
induce O 0 0.00024807558
a O 0 0.0014154089
myopathy B-Disease 2 0.9998179
, O 0 0.0012448399
which O 0 0.0004911682
persists O 0 0.00042293788
or O 0 0.00040476923
may O 0 0.00045881688
progress O 0 0.0008339984
after O 0 0.0006707224
stopping O 0 0.0028027776
the O 0 0.00237385
drug O 0 0.29220808
. O 0 0.006976294

We O 0 0.0058411704
investigated O 0 0.003977983
the O 0 0.0040781614
muscle O 0 0.010206428
pathology O 0 0.023460811
in O 0 0.003944322
8 O 0 0.004174815
such O 0 0.0050148265
cases O 0 0.010022508
. O 0 0.013040654

All O 0 0.00479417
had O 0 0.004377735
myofibre O 0 0.243647
necrosis B-Disease 2 0.99951303
but O 0 0.0048958994
only O 0 0.0027801013
3 O 0 0.0022986697
had O 0 0.002644725
an O 0 0.004165813
inflammatory O 0 0.63585186
infiltrate O 0 0.9097633
. O 0 0.012850566

In O 0 0.0036882593
all O 0 0.0021638565
cases O 0 0.0018802234
there O 0 0.0009900385
was O 0 0.000977676
diffuse O 0 0.0054151374
or O 0 0.0007424742
multifocal O 0 0.84901166
up O 0 0.000539627
- O 0 0.0015620869
regulation O 0 0.0002781548
of O 0 0.0005183924
MHC O 0 0.07180216
- O 0 0.04506358
I O 0 0.0075844303
expression O 0 0.00059287576
even O 0 0.0007837984
in O 0 0.00095194683
non O 0 0.0030155643
- O 0 0.041520394
necrotic B-Disease 2 0.9684656
fibres O 0 0.09125906
. O 0 0.008258727

Progressive O 0 0.014973274
improvement O 0 0.003118649
occurred O 0 0.0018547677
in O 0 0.0012837852
7 O 0 0.00088499836
cases O 0 0.0008366514
after O 0 0.00045926543
commencement O 0 0.00061840005
of O 0 0.0011017801
prednisolone B-Chemical 1 0.9999752
and O 0 0.010255375
methotrexate B-Chemical 1 0.9999707
, O 0 0.0016267388
and O 0 0.001012263
in O 0 0.0011166964
one O 0 0.0014933044
case O 0 0.0026509152
spontaneously O 0 0.0066247056
. O 0 0.0066994354

These O 0 0.0034456488
observations O 0 0.0022752436
suggest O 0 0.0012946423
that O 0 0.0014391876
statins B-Chemical 1 0.9976507
may O 0 0.0007045362
initiate O 0 0.0004227869
an O 0 0.00075207494
immune O 0 0.2935585
- O 0 0.052804254
mediated O 0 0.00037306367
myopathy B-Disease 2 0.9996829
that O 0 0.0003022867
persists O 0 0.0003974637
after O 0 0.00021182535
withdrawal O 0 0.04346295
of O 0 0.00041329977
the O 0 0.00045020485
drug O 0 0.09812662
and O 0 0.00074288965
responds O 0 0.0010097547
to O 0 0.0012543246
immunosuppressive O 0 0.652878
therapy O 0 0.009944204
. O 0 0.0065594492

The O 0 0.0029060123
mechanism O 0 0.0020352055
of O 0 0.002057351
this O 0 0.002213539
myopathy B-Disease 2 0.99968994
is O 0 0.0015756928
uncertain O 0 0.0014816631
but O 0 0.00057233893
may O 0 0.00025603574
involve O 0 0.00019128952
the O 0 0.00020302762
induction O 0 0.00023049617
by O 0 0.0003410418
statins B-Chemical 1 0.99511
of O 0 0.000306777
an O 0 0.0003386083
endoplasmic O 0 0.026257444
reticulum O 0 0.07319318
stress O 0 0.042059436
response O 0 0.00033732402
with O 0 0.0002285341
associated O 0 0.00022762945
up O 0 0.00019117465
- O 0 0.000769924
regulation O 0 0.000156194
of O 0 0.0003437693
MHC O 0 0.06018356
- O 0 0.034554623
I O 0 0.004863926
expression O 0 0.0004694826
and O 0 0.00067948457
antigen O 0 0.010631123
presentation O 0 0.001931073
by O 0 0.0019851688
muscle O 0 0.022944523
fibres O 0 0.02633314
. O 0 0.007285942

Use O 0 0.0086504575
of O 0 0.0044921255
chromosome O 0 0.019997787
substitution O 0 0.04153363
strains O 0 0.0019133568
to O 0 0.0014378285
identify O 0 0.001647391
seizure B-Disease 2 0.99980956
susceptibility O 0 0.013144427
loci O 0 0.0053574867
in O 0 0.0031284676
mice O 0 0.003958602
. O 0 0.008409518

Seizure B-Disease 2 0.9987282
susceptibility O 0 0.015686154
varies O 0 0.0085445205
among O 0 0.009008071
inbred O 0 0.010621147
mouse O 0 0.010526165
strains O 0 0.012611783
. O 0 0.017637432

Chromosome O 0 0.36038935
substitution O 0 0.09689819
strains O 0 0.003154083
( O 0 0.006921776
CSS O 0 0.9837509
) O 0 0.0031543076
, O 0 0.0010408775
in O 0 0.000530366
which O 0 0.00052274053
a O 0 0.00043333147
single O 0 0.000342666
chromosome O 0 0.0018307301
from O 0 0.00019867574
one O 0 0.00018399024
inbred O 0 0.00024784767
strain O 0 0.0001846065
( O 0 0.00034488822
donor O 0 0.0004072319
) O 0 0.0005923928
has O 0 0.00017336551
been O 0 0.00015607505
transferred O 0 0.00014603417
onto O 0 0.00012918882
a O 0 0.00018518476
second O 0 0.00015068619
strain O 0 0.00017472534
( O 0 0.0003786253
host O 0 0.0009511734
) O 0 0.000523735
by O 0 0.00017728085
repeated O 0 0.0001371973
backcrossing O 0 0.0005713369
, O 0 0.0002788082
may O 0 0.00014866458
be O 0 0.00014723635
used O 0 0.00012913266
to O 0 0.00012527154
identify O 0 0.00013475509
quantitative O 0 0.00025993778
trait O 0 0.007857829
loci O 0 0.001530066
( O 0 0.0007659394
QTLs O 0 0.047027655
) O 0 0.00076477876
that O 0 0.00053585076
contribute O 0 0.0008824558
to O 0 0.0018256857
seizure B-Disease 2 0.99987197
susceptibility O 0 0.061544474
. O 0 0.007740467

QTLs O 0 0.045823604
for O 0 0.0026061856
susceptibility O 0 0.005910368
to O 0 0.003449895
pilocarpine B-Chemical 1 0.9999993
- O 0 0.47566983
induced O 0 0.013129176
seizures B-Disease 0 0.9999994
, O 0 0.0021934665
a O 0 0.00041790094
model O 0 0.00027929715
of O 0 0.00055760954
temporal B-Disease 2 0.84171444
lobe I-Disease 2 0.9990325
epilepsy I-Disease 2 0.99999976
, O 0 0.0011397983
have O 0 0.00017579886
not O 0 0.00017488134
been O 0 0.00020283586
reported O 0 0.0003065349
, O 0 0.00040196418
and O 0 0.0005153067
CSS O 0 0.8977567
have O 0 0.00022583948
not O 0 0.0002471909
previously O 0 0.00030759434
been O 0 0.000330256
used O 0 0.000376377
to O 0 0.00052400114
localize O 0 0.0007700929
seizure B-Disease 2 0.9996908
susceptibility O 0 0.014988756
genes O 0 0.0051665767
. O 0 0.006960957

We O 0 0.003899187
report O 0 0.0037749847
QTLs O 0 0.010535387
identified O 0 0.0011875039
using O 0 0.0009611716
a O 0 0.0012062344
B6 O 0 0.2621103
( O 0 0.0010202185
host O 0 0.0015882839
) O 0 0.0012613499
x O 0 0.008295414
A O 0 0.4563638
/ O 0 0.083363
J O 0 0.98815197
( O 0 0.0009887776
donor O 0 0.000853042
) O 0 0.0028867824
CSS O 0 0.8658847
panel O 0 0.00028630026
to O 0 0.00019996312
localize O 0 0.00015771002
genes O 0 0.00029928633
involved O 0 0.00025093998
in O 0 0.0003880532
susceptibility O 0 0.0031812042
to O 0 0.0018334882
pilocarpine B-Chemical 1 0.99999857
- O 0 0.30728528
induced O 0 0.029366959
seizures B-Disease 0 0.9999944
. O 0 0.011670967

Three O 0 0.0041874144
hundred O 0 0.0029179577
fifty O 0 0.0025579538
- O 0 0.0031236277
five O 0 0.0009410264
adult O 0 0.0012704518
male O 0 0.00659993
CSS O 0 0.8678962
mice O 0 0.00042821883
, O 0 0.0007597531
58 O 0 0.0009586776
B6 O 0 0.1930042
, O 0 0.00055350247
and O 0 0.00042801522
39 O 0 0.0007302962
A O 0 0.09889877
/ O 0 0.020356834
J O 0 0.93249816
were O 0 0.00039549146
tested O 0 0.00032970164
for O 0 0.00044534533
susceptibility O 0 0.004160347
to O 0 0.0020769404
pilocarpine B-Chemical 1 0.99999857
- O 0 0.32150164
induced O 0 0.030379564
seizures B-Disease 0 0.9999943
. O 0 0.011938848

Highest O 0 0.036342517
stage O 0 0.004990228
reached O 0 0.002465201
and O 0 0.002003013
latency O 0 0.0021484196
to O 0 0.0010882673
each O 0 0.0008030626
stage O 0 0.0015710463
were O 0 0.0011984382
recorded O 0 0.0013644269
for O 0 0.0017348916
all O 0 0.0025383485
mice O 0 0.0035500724
. O 0 0.007975075

B6 O 0 0.095604904
mice O 0 0.0024347408
were O 0 0.0021294574
resistant O 0 0.0018643964
to O 0 0.0017136649
seizures B-Disease 0 0.9999901
and O 0 0.0012103767
slower O 0 0.0007140623
to O 0 0.00050612213
reach O 0 0.0005134546
stages O 0 0.00072132936
compared O 0 0.00064368284
to O 0 0.0011063315
A O 0 0.09882502
/ O 0 0.026138399
J O 0 0.870814
mice O 0 0.0044126073
. O 0 0.008763364

The O 0 0.004476524
CSS O 0 0.645493
for O 0 0.0026138818
Chromosomes O 0 0.17413907
10 O 0 0.0011299773
and O 0 0.00089454785
18 O 0 0.0007149054
progressed O 0 0.0007301188
to O 0 0.00041716977
the O 0 0.00043966557
most O 0 0.0006543735
severe O 0 0.014351213
stages O 0 0.000764685
, O 0 0.0008505998
diverging O 0 0.001267976
dramatically O 0 0.00083493826
from O 0 0.0010297692
the O 0 0.0017333184
B6 O 0 0.22927421
phenotype O 0 0.0067973863
. O 0 0.007566423

Latencies O 0 0.030181339
to O 0 0.0036267992
stages O 0 0.0033139277
were O 0 0.0022795047
also O 0 0.0018392919
significantly O 0 0.0017305614
shorter O 0 0.0015848684
for O 0 0.002184992
CSS10 O 0 0.10996302
and O 0 0.0040990785
CSS18 O 0 0.074985735
mice O 0 0.0051902323
. O 0 0.010274807

CSS O 0 0.71622974
mapping O 0 0.004118043
suggests O 0 0.003070964
seizure B-Disease 2 0.99964345
susceptibility O 0 0.009284103
loci O 0 0.003661104
on O 0 0.0014263082
mouse O 0 0.0028554583
Chromosomes O 0 0.3149291
10 O 0 0.0025369567
and O 0 0.0036538544
18 O 0 0.0056428183
. O 0 0.0085810255

This O 0 0.004927678
approach O 0 0.002651813
provides O 0 0.0016666744
a O 0 0.0014660668
framework O 0 0.0009687523
for O 0 0.00072559394
identifying O 0 0.0007209651
potentially O 0 0.00068982906
novel O 0 0.00055284763
homologous O 0 0.00047885906
candidate O 0 0.0005752049
genes O 0 0.00075419864
for O 0 0.00082774856
human O 0 0.0024409555
temporal B-Disease 2 0.8601269
lobe I-Disease 2 0.9976381
epilepsy I-Disease 2 0.99999547
. O 0 0.0112278415

In O 0 0.00411835
vitro O 0 0.0030228728
characterization O 0 0.0019357583
of O 0 0.0021113527
parasympathetic O 0 0.5851621
and O 0 0.0012916144
sympathetic O 0 0.027825972
responses O 0 0.0012604527
in O 0 0.0012097072
cyclophosphamide B-Chemical 0 0.9999548
- O 0 0.1201802
induced O 0 0.0036431092
cystitis B-Disease 0 0.9999751
in O 0 0.0029931872
the O 0 0.0032392747
rat O 0 0.009398351
. O 0 0.0075544696

In O 0 0.005909139
cyclophosphamide B-Chemical 0 0.9998265
- O 0 0.17592473
induced O 0 0.005299753
cystitis B-Disease 0 0.99997985
in O 0 0.00156772
the O 0 0.00075818
rat O 0 0.0031930765
, O 0 0.0011054224
detrusor O 0 0.90045923
function O 0 0.00041500368
is O 0 0.00034089503
impaired O 0 0.00039338108
and O 0 0.0003292946
the O 0 0.00029777837
expression O 0 0.000423815
and O 0 0.0005950528
effects O 0 0.0009954846
of O 0 0.002350794
muscarinic O 0 0.9947009
receptors O 0 0.02829132
altered O 0 0.0047011757
. O 0 0.0066050095

Whether O 0 0.004118606
or O 0 0.0026809345
not O 0 0.0018878327
the O 0 0.001654169
neuronal O 0 0.026979942
transmission O 0 0.0045364285
may O 0 0.00097429816
be O 0 0.0009862713
affected O 0 0.0011326866
by O 0 0.0018915631
cystitis B-Disease 0 0.9999198
was O 0 0.0030659228
presently O 0 0.0050991746
investigated O 0 0.0040613315
. O 0 0.007770258

Responses O 0 0.004939098
of O 0 0.0030872063
urinary O 0 0.084350616
strip O 0 0.0025058172
preparations O 0 0.0010432533
from O 0 0.0005609914
control O 0 0.0005808834
and O 0 0.0014181174
cyclophosphamide B-Chemical 0 0.9999788
- O 0 0.154085
pretreated O 0 0.007024802
rats O 0 0.00041247747
to O 0 0.000181711
electrical O 0 0.010644181
field O 0 0.00035374047
stimulation O 0 0.0002024089
and O 0 0.0002387226
to O 0 0.00018139734
agonists O 0 0.057834238
were O 0 0.00015904743
assessed O 0 0.00011634303
in O 0 0.00014330687
the O 0 0.00014634419
absence O 0 0.0001372847
and O 0 0.00026020332
presence O 0 0.00030949907
of O 0 0.0016757397
muscarinic O 0 0.9980744
, O 0 0.0046809474
adrenergic O 0 0.9687613
and O 0 0.001773784
purinergic O 0 0.46958366
receptor O 0 0.14753121
antagonists O 0 0.82482135
. O 0 0.006788083

Generally O 0 0.0059581567
, O 0 0.009823574
atropine B-Chemical 0 0.99996257
reduced O 0 0.0037994587
contractions O 0 0.7406126
, O 0 0.0023199222
but O 0 0.00079178426
in O 0 0.00039984685
contrast O 0 0.00043103306
to O 0 0.0002738271
controls O 0 0.0006279513
, O 0 0.00041993122
it O 0 0.00023780346
also O 0 0.00017945677
reduced O 0 0.00018906173
responses O 0 0.0002883427
to O 0 0.0001675893
low O 0 0.0003339266
electrical O 0 0.009926338
field O 0 0.00034365265
stimulation O 0 0.00021862486
intensity O 0 0.00026362963
( O 0 0.0005584741
1 O 0 0.0004016183
- O 0 0.0013906049
5 O 0 0.0005299276
Hz O 0 0.008047707
) O 0 0.0015657628
in O 0 0.0016698119
inflamed O 0 0.0063313725
preparations O 0 0.0047050016
. O 0 0.0070647346

In O 0 0.0036047006
both O 0 0.0022872132
types O 0 0.0017393403
, O 0 0.0030015248
purinoceptor O 0 0.9683507
desensitization O 0 0.24681905
with O 0 0.0019543162
alpha B-Chemical 0 0.9364264
, I-Chemical 0 0.022829343
beta I-Chemical 0 0.9978314
- I-Chemical 0 0.81354576
methylene I-Chemical 0 0.9990709
adenosine I-Chemical 1 0.9999523
- I-Chemical 0 0.072978005
5 I-Chemical 0 0.00023283307
' I-Chemical 0 0.00055123644
- I-Chemical 0 0.010254339
triphosphate I-Chemical 0 0.42546886
( O 0 0.0021571037
alpha B-Chemical 0 0.8879349
, I-Chemical 0 0.02118855
beta I-Chemical 0 0.99864095
- I-Chemical 0 0.92731375
meATP I-Chemical 0 0.9998927
) O 0 0.0044906633
caused O 0 0.0002912434
further O 0 0.00027246773
reductions O 0 0.0003352811
at O 0 0.00027312676
low O 0 0.00047951908
frequencies O 0 0.0006223524
( O 0 0.0009960514
< O 0 0.0010562349
10 O 0 0.001717984
Hz O 0 0.01659858
) O 0 0.0061411266
. O 0 0.007890081

The O 0 0.004592004
muscarinic O 0 0.9932079
receptor O 0 0.4244502
antagonists O 0 0.99365646
atropine B-Chemical 0 0.9999964
, O 0 0.004048554
4 B-Chemical 0 0.0006345919
- I-Chemical 0 0.0057407646
diphenylacetoxy I-Chemical 0 0.07081222
- I-Chemical 0 0.17472641
N I-Chemical 0 0.9997305
- I-Chemical 0 0.2827879
methylpiperidine I-Chemical 0 0.95739
( O 0 0.00096177077
4 B-Chemical 0 0.0003127696
- I-Chemical 0 0.011968867
DAMP I-Chemical 0 0.98547167
) O 0 0.002281407
( O 0 0.00084221805
' O 0 0.0013819376
M O 0 0.9748632
( O 0 0.00086065574
1 O 0 0.00028077632
) O 0 0.000653236
/ O 0 0.011413307
M O 0 0.9807947
( O 0 0.0008269815
3 O 0 0.00022960518
) O 0 0.0005861034
/ O 0 0.009910249
M O 0 0.9795687
( O 0 0.0008126423
5 O 0 0.000231011
) O 0 0.00071092066
- O 0 0.0054468075
selective O 0 0.0009958599
' O 0 0.0009015031
) O 0 0.0020165674
, O 0 0.0047789942
methoctramine B-Chemical 0 0.9999981
( O 0 0.006601653
' O 0 0.003844035
M O 0 0.98768604
( O 0 0.0011275831
2 O 0 0.00027178123
) O 0 0.00076635263
- O 0 0.0055277473
selective O 0 0.0008208772
' O 0 0.00065285165
) O 0 0.0010619708
and O 0 0.002934921
pirenzepine B-Chemical 0 0.99999976
( O 0 0.007902374
' O 0 0.004687074
M O 0 0.9904503
( O 0 0.0014085236
1 O 0 0.00030096708
) O 0 0.001073427
- O 0 0.011274533
selective O 0 0.0014241975
' O 0 0.0009536417
) O 0 0.0011595567
antagonized O 0 0.05282767
the O 0 0.0002651911
tonic O 0 0.025468284
component O 0 0.00020921437
of O 0 0.00023158526
the O 0 0.0002171865
electrical O 0 0.01669331
field O 0 0.0004780842
stimulation O 0 0.00036191783
- O 0 0.00809479
evoked O 0 0.004077108
contractile O 0 0.0436959
response O 0 0.0005672679
more O 0 0.0005721069
potently O 0 0.0019000572
than O 0 0.00067511026
the O 0 0.0012847449
phasic O 0 0.014356651
component O 0 0.003554238
. O 0 0.006165044

4 B-Chemical 0 0.005891007
- I-Chemical 0 0.031077895
DAMP I-Chemical 0 0.9251164
inhibited O 0 0.002931405
the O 0 0.0017997058
tonic O 0 0.18687765
contractions O 0 0.24789113
in O 0 0.00088738115
controls O 0 0.001262137
more O 0 0.0010470942
potently O 0 0.0101008555
than O 0 0.0018051338
methoctramine B-Chemical 0 0.9999926
and O 0 0.072937496
pirenzepine B-Chemical 0 0.99999595
. O 0 0.011436018

In O 0 0.004091381
inflamed O 0 0.006397977
preparations O 0 0.0026680983
, O 0 0.0023270042
the O 0 0.0016160974
muscarinic O 0 0.997399
receptor O 0 0.13154407
antagonism O 0 0.2293878
on O 0 0.00024891522
the O 0 0.00029909975
phasic O 0 0.007928724
component O 0 0.00023754194
of O 0 0.00024991544
the O 0 0.00022453367
electrical O 0 0.019473985
field O 0 0.000498643
stimulation O 0 0.0003545487
- O 0 0.01421333
evoked O 0 0.0070184856
contraction O 0 0.12323942
was O 0 0.00023538503
decreased O 0 0.00025225044
and O 0 0.00029006324
the O 0 0.00065517344
pirenzepine B-Chemical 0 0.9999994
and O 0 0.0009697251
4 B-Chemical 0 0.00030458134
- I-Chemical 0 0.028874863
DAMP I-Chemical 0 0.98869264
antagonism O 0 0.12352623
on O 0 0.00016313272
the O 0 0.00025387376
tonic O 0 0.011158762
component O 0 0.0003303016
was O 0 0.0003437557
much O 0 0.00033879947
less O 0 0.00047128758
efficient O 0 0.00068444596
than O 0 0.0009112796
in O 0 0.0018624886
controls O 0 0.004594361
. O 0 0.006515613

In O 0 0.0036462017
contrast O 0 0.002540577
to O 0 0.0016918691
controls O 0 0.0029068855
, O 0 0.009099873
methoctramine B-Chemical 0 0.9999968
increased O 0 0.020651894
- O 0 0.15828799
- O 0 0.008619993
instead O 0 0.00042504785
of O 0 0.00062438217
decreased O 0 0.0016675306
- O 0 0.044182125
- O 0 0.0059347753
the O 0 0.0006859478
tonic O 0 0.012812394
responses O 0 0.0012401367
at O 0 0.0012766989
high O 0 0.002667043
frequencies O 0 0.0042055314
. O 0 0.00690913

While O 0 0.0041045714
contractions O 0 0.12615941
to O 0 0.002821255
carbachol B-Chemical 1 0.9998776
and O 0 0.016720124
ATP B-Chemical 0 0.9990515
were O 0 0.00067407516
the O 0 0.00034780637
same O 0 0.00021791189
in O 0 0.0002552066
inflamed O 0 0.0013805196
and O 0 0.0002793158
in O 0 0.00020049233
control O 0 0.00020209608
strips O 0 0.0003530949
when O 0 0.00012327486
related O 0 0.000116547555
to O 0 0.00014006173
a O 0 0.0002463693
reference O 0 0.00038898265
potassium B-Chemical 0 0.9998698
response O 0 0.0021287864
, O 0 0.013330477
isoprenaline B-Chemical 0 0.99998343
- O 0 0.058357105
induced O 0 0.0008927622
relaxations O 0 0.9840681
were O 0 0.00077326223
smaller O 0 0.00090500707
in O 0 0.0014569181
inflamed O 0 0.007980683
strips O 0 0.0068366155
. O 0 0.0064627146

Thus O 0 0.0056509604
, O 0 0.005249396
in O 0 0.003956683
cystitis B-Disease 0 0.9997626
substantial O 0 0.0029578237
changes O 0 0.0021896567
of O 0 0.001846785
the O 0 0.001797403
efferent O 0 0.0040896214
functional O 0 0.002491399
responses O 0 0.0042812605
occur O 0 0.0055795284
. O 0 0.0090814885

While O 0 0.0057317517
postjunctional O 0 0.99747187
beta O 0 0.9986646
- O 0 0.9194295
adrenoceptor O 0 0.99999106
- O 0 0.1796517
mediated O 0 0.0007881153
relaxations O 0 0.99359834
are O 0 0.0005989119
reduced O 0 0.00049629086
, O 0 0.0006340578
effects O 0 0.00060399284
by O 0 0.0006799637
prejunctional O 0 0.98267853
inhibitory O 0 0.04494636
muscarinic O 0 0.9961515
receptors O 0 0.009733842
may O 0 0.0014233692
be O 0 0.002229189
increased O 0 0.0041105147
. O 0 0.0069354023

Direct O 0 0.0063349106
inhibition O 0 0.004368896
of O 0 0.0032416787
cardiac O 0 0.23380001
hyperpolarization O 0 0.98091793
- O 0 0.05352333
activated O 0 0.0016915542
cyclic B-Chemical 0 0.6792755
nucleotide I-Chemical 0 0.94254446
- O 0 0.016921608
gated O 0 0.0027021128
pacemaker O 0 0.010631456
channels O 0 0.0049828533
by O 0 0.0045090048
clonidine B-Chemical 0 0.9998467
. O 0 0.008859937

BACKGROUND O 0 0.02426636
: O 0 0.004355544
Inhibition O 0 0.0029414378
of O 0 0.0020540555
cardiac O 0 0.09448667
sympathetic O 0 0.17525233
tone O 0 0.078745574
represents O 0 0.00047272487
an O 0 0.00039962222
important O 0 0.00022995094
strategy O 0 0.00028860095
for O 0 0.0002510625
treatment O 0 0.0003779145
of O 0 0.000995525
cardiovascular B-Disease 0 0.9959033
disease I-Disease 0 0.9869953
, O 0 0.0022697668
including O 0 0.0011015261
arrhythmia B-Disease 2 0.99994016
, O 0 0.0030863245
coronary B-Disease 0 0.53389454
heart I-Disease 0 0.5854542
disease I-Disease 0 0.9237729
, O 0 0.0016816141
and O 0 0.001874619
chronic O 0 0.9316806
heart B-Disease 0 0.78476405
failure I-Disease 0 0.76073897
. O 0 0.008123764

Activation O 0 0.0055848015
of O 0 0.0037146201
presynaptic O 0 0.7059252
alpha2 O 0 0.9994823
- O 0 0.68392694
adrenoceptors O 0 0.99956506
is O 0 0.00086213194
the O 0 0.00044979108
most O 0 0.0005014197
widely O 0 0.00032009615
accepted O 0 0.00031689127
mechanism O 0 0.00017749787
of O 0 0.00027553146
action O 0 0.0004481498
of O 0 0.0003400493
the O 0 0.00043088102
antisympathetic O 0 0.8158712
drug O 0 0.971474
clonidine B-Chemical 0 0.9999976
; O 0 0.0027259921
however O 0 0.00042192786
, O 0 0.00028683656
other O 0 0.00017646256
target O 0 0.00016378173
proteins O 0 0.00027323148
have O 0 0.00017349549
been O 0 0.00019745651
postulated O 0 0.000242243
to O 0 0.00019501311
contribute O 0 0.00022260177
to O 0 0.00027980894
the O 0 0.00039188113
in O 0 0.00056867016
vivo O 0 0.0012233689
actions O 0 0.0045965486
of O 0 0.011442938
clonidine B-Chemical 0 0.9999565
. O 0 0.008139686

METHODS O 0 0.004134875
AND O 0 0.0024617454
RESULTS O 0 0.0024856606
: O 0 0.0019117784
To O 0 0.0009886806
test O 0 0.0009999974
whether O 0 0.000651126
clonidine B-Chemical 0 0.9999454
elicits O 0 0.0009419705
pharmacological O 0 0.023320632
effects O 0 0.0004217859
independent O 0 0.0001968955
of O 0 0.0024493013
alpha2 O 0 0.99975806
- O 0 0.80368924
adrenoceptors O 0 0.9996916
, O 0 0.00045216669
we O 0 0.00011454279
have O 0 0.00011116917
generated O 0 9.897004e-05
mice O 0 0.00010329795
with O 0 0.00017242384
a O 0 0.00018856215
targeted O 0 0.00013637141
deletion O 0 0.00023336425
of O 0 0.00027361233
all O 0 0.00025299084
3 O 0 0.0003324299
alpha2 O 0 0.9910273
- O 0 0.32804477
adrenoceptor O 0 0.9999459
subtypes O 0 0.038358096
( O 0 0.0021245922
alpha2ABC O 0 0.033700805
- O 0 0.02013861
/ O 0 0.013435571
- O 0 0.020283796
) O 0 0.0071883616
. O 0 0.008033251

Alpha2ABC O 0 0.15337916
- O 0 0.062759526
/ O 0 0.01868261
- O 0 0.005275788
mice O 0 0.000809433
were O 0 0.0007292322
completely O 0 0.00050947693
unresponsive O 0 0.0005134392
to O 0 0.00030400115
the O 0 0.00036913712
analgesic O 0 0.4640004
and O 0 0.0005739549
hypnotic O 0 0.9877508
effects O 0 0.000673067
of O 0 0.005430228
clonidine B-Chemical 0 0.9999976
; O 0 0.0056968085
however O 0 0.0014166083
, O 0 0.0056719785
clonidine B-Chemical 0 0.99998367
significantly O 0 0.000366872
lowered O 0 0.0017603684
heart O 0 0.023419008
rate O 0 0.0002643374
in O 0 0.00029450023
alpha2ABC O 0 0.018606078
- O 0 0.017944777
/ O 0 0.0055768965
- O 0 0.0018901754
mice O 0 0.00038572075
by O 0 0.00067818107
up O 0 0.0008537275
to O 0 0.0012439241
150 O 0 0.0024583624
bpm O 0 0.0050277556
. O 0 0.006206655

Clonidine B-Chemical 0 0.9999933
- O 0 0.13866025
induced O 0 0.004030944
bradycardia B-Disease 0 0.99918824
in O 0 0.0014219986
conscious O 0 0.032990973
alpha2ABC O 0 0.04828111
- O 0 0.03663149
/ O 0 0.013004745
- O 0 0.00377902
mice O 0 0.00022452316
was O 0 0.00029586372
32 O 0 0.0003320935
. O 0 0.0002124287
3 O 0 0.00018837454
% O 0 0.0002490299
( O 0 0.00027867957
10 O 0 0.00018029132
microg O 0 0.0002932579
/ O 0 0.0014758712
kg O 0 0.0010759768
) O 0 0.00047597836
and O 0 0.0002558088
26 O 0 0.0002795087
. O 0 0.00017347433
6 O 0 0.00015339175
% O 0 0.00023485888
( O 0 0.00029700066
100 O 0 0.00031421048
microg O 0 0.0003981734
/ O 0 0.0021074896
kg O 0 0.0012358621
) O 0 0.00057079527
of O 0 0.00039244004
the O 0 0.00039959655
effect O 0 0.000504254
in O 0 0.00072684896
wild O 0 0.0012318394
- O 0 0.0053781364
type O 0 0.0024457474
mice O 0 0.003038898
. O 0 0.006863651

A O 0 0.08238695
similar O 0 0.0034694949
bradycardic O 0 0.9995072
effect O 0 0.0025275887
of O 0 0.008869176
clonidine B-Chemical 0 0.99999297
was O 0 0.00081639807
observed O 0 0.00037578002
in O 0 0.00031870307
isolated O 0 0.0002492211
spontaneously O 0 0.0006803815
beating O 0 0.0034203548
right O 0 0.00077567477
atria O 0 0.0033184416
from O 0 0.00029625237
alpha2ABC O 0 0.0031363084
- O 0 0.0015824444
knockout O 0 0.0005311301
and O 0 0.0008535193
wild O 0 0.0012493927
- O 0 0.004644715
type O 0 0.002478231
mice O 0 0.003107079
. O 0 0.0069909696

Clonidine B-Chemical 0 0.9999745
inhibited O 0 0.0043384586
the O 0 0.0017521908
native O 0 0.0017649551
pacemaker O 0 0.020035772
current O 0 0.0019236167
( O 0 0.0017556753
I O 0 0.024884434
( O 0 0.0008693956
f O 0 0.0044291937
) O 0 0.0014659851
) O 0 0.00058786344
in O 0 0.00021401074
isolated O 0 0.00016707902
sinoatrial O 0 0.029161885
node O 0 0.00032721346
pacemaker O 0 0.001144614
cells O 0 0.00020903708
and O 0 0.00022241019
the O 0 0.00023978011
I O 0 0.011166384
( O 0 0.00045933874
f O 0 0.003853088
) O 0 0.0021026563
- O 0 0.004505411
generating O 0 0.0002610937
hyperpolarization O 0 0.88968486
- O 0 0.02267722
activated O 0 0.00046444676
cyclic B-Chemical 0 0.64491767
nucleotide I-Chemical 0 0.9682188
- O 0 0.031597488
gated O 0 0.0015940738
( O 0 0.0013177758
HCN O 0 0.8776544
) O 0 0.00078186806
2 O 0 0.00037076423
and O 0 0.00056592264
HCN4 O 0 0.6032683
channels O 0 0.0019075876
in O 0 0.0011133915
transfected O 0 0.0022911953
HEK293 O 0 0.65664023
cells O 0 0.008701714
. O 0 0.009039181

As O 0 0.0033607988
a O 0 0.0026270372
consequence O 0 0.0014251207
of O 0 0.0015727257
blocking O 0 0.007617911
I O 0 0.14451207
( O 0 0.0021209924
f O 0 0.018606732
) O 0 0.010899366
, O 0 0.009733006
clonidine B-Chemical 0 0.9999864
reduced O 0 0.0003855952
the O 0 0.00024356678
slope O 0 0.0009790354
of O 0 0.0002903064
the O 0 0.00026148383
diastolic O 0 0.88528794
depolarization O 0 0.21755174
and O 0 0.0002383019
the O 0 0.00015102753
frequency O 0 0.00018547421
of O 0 0.0002260752
pacemaker O 0 0.0032230667
potentials O 0 0.002181592
in O 0 0.0001835991
sinoatrial O 0 0.02298435
node O 0 0.0002934302
cells O 0 0.00025362216
from O 0 0.00024372524
wild O 0 0.00039177187
- O 0 0.0022550893
type O 0 0.0006121572
and O 0 0.0009742402
alpha2ABC O 0 0.009257127
- O 0 0.0038274967
knockout O 0 0.0021516022
mice O 0 0.0030459068
. O 0 0.0069069215

CONCLUSIONS O 0 0.021277212
: O 0 0.004077408
Direct O 0 0.0030400902
inhibition O 0 0.002387868
of O 0 0.0019323583
cardiac O 0 0.36746794
HCN O 0 0.9767318
pacemaker O 0 0.031381253
channels O 0 0.0011606661
contributes O 0 0.00022620737
to O 0 0.00022464886
the O 0 0.00034283966
bradycardic O 0 0.9995043
effects O 0 0.00065233075
of O 0 0.003467926
clonidine B-Chemical 0 0.9999968
gene O 0 0.0032393793
- O 0 0.007910083
targeted O 0 0.00013519476
mice O 0 0.000109982015
in O 0 0.00017373006
vivo O 0 0.00035452063
, O 0 0.00036773956
and O 0 0.00029648465
thus O 0 0.00070672104
, O 0 0.010005888
clonidine B-Chemical 0 0.9999956
- O 0 0.019139847
like O 0 0.00025224418
drugs O 0 0.009159737
represent O 0 0.00022646264
novel O 0 0.00033674148
structures O 0 0.000526161
for O 0 0.0005610791
future O 0 0.0011019044
HCN O 0 0.84479535
channel O 0 0.0556905
inhibitors O 0 0.021587892
. O 0 0.00671268

Granulomatous B-Disease 0 0.921436
hepatitis I-Disease 2 0.9999962
due O 0 0.003876208
to O 0 0.0028478683
combination B-Chemical 0 0.0037343856
of I-Chemical 0 0.0071687317
amoxicillin I-Chemical 0 0.9999337
and I-Chemical 0 0.09509854
clavulanic I-Chemical 0 0.99997044
acid I-Chemical 0 0.99163204
. O 0 0.014908591

We O 0 0.003889694
report O 0 0.0033434245
the O 0 0.0017375371
case O 0 0.0013935772
of O 0 0.0011595909
a O 0 0.0010566884
patient O 0 0.0008768606
with O 0 0.002560983
amoxicillin B-Chemical 0 0.99999094
- I-Chemical 0 0.92062116
clavulanic I-Chemical 0 0.9999968
acid I-Chemical 0 0.99819714
- O 0 0.29861605
induced O 0 0.00688623
hepatitis B-Disease 2 0.9999999
with O 0 0.04741131
histologic O 0 0.79344714
multiple O 0 0.01019919
granulomas B-Disease 0 0.9854425
. O 0 0.008229386

This O 0 0.0050611165
type O 0 0.0027422402
of O 0 0.0022857438
lesion O 0 0.07130765
broadens O 0 0.0038830268
the O 0 0.0007007091
spectrum O 0 0.0008989045
of O 0 0.0018232161
liver B-Disease 0 0.99901605
injury I-Disease 0 0.9987583
due O 0 0.00028623882
to O 0 0.00025658825
this O 0 0.0003138013
drug O 0 0.087445825
combination O 0 0.0005395951
, O 0 0.0005247116
mainly O 0 0.0004783428
represented O 0 0.0005387317
by O 0 0.0008335384
a O 0 0.0023795743
benign O 0 0.9861291
cholestatic B-Disease 0 0.99999976
syndrome I-Disease 0 0.9997162
. O 0 0.015727151

The O 0 0.004605655
association O 0 0.0037444758
of O 0 0.0045785257
granulomas B-Disease 0 0.9570509
and O 0 0.00873298
eosinophilia B-Disease 0 0.9997553
favor O 0 0.007821168
an O 0 0.007686039
immunoallergic O 0 0.9953055
mechanism O 0 0.008934761
. O 0 0.012206119

As O 0 0.0057671596
penicillin B-Chemical 1 0.99998593
derivatives O 0 0.73211807
and O 0 0.013253561
amoxicillin B-Chemical 0 0.9999081
alone O 0 0.0012860303
are O 0 0.0004988126
known O 0 0.00039383906
to O 0 0.00020760101
induce O 0 0.00015713752
such O 0 0.00018456532
types O 0 0.00018101807
of O 0 0.00040613615
lesions O 0 0.5662564
, O 0 0.0007887426
the O 0 0.00048340397
amoxicillin B-Chemical 0 0.99985063
component O 0 0.0006421397
, O 0 0.0004431889
with O 0 0.00023145569
or O 0 0.00018601013
without O 0 0.00020173415
a O 0 0.00032115472
potentiating O 0 0.0065239426
effect O 0 0.0004665985
of O 0 0.010080422
clavulanic B-Chemical 0 0.99999547
acid I-Chemical 0 0.98979
, O 0 0.0015347413
might O 0 0.00053691544
have O 0 0.0007861636
a O 0 0.0014655915
major O 0 0.0021754347
role O 0 0.0029687155
. O 0 0.0067063784

Dobutamine B-Chemical 0 0.9991534
stress O 0 0.39067572
echocardiography O 0 0.08086956
: O 0 0.002610099
a O 0 0.0011975333
sensitive O 0 0.00074595714
indicator O 0 0.00046513608
of O 0 0.0005849138
diminished O 0 0.0010581929
myocardial O 0 0.9984457
function O 0 0.0005085571
in O 0 0.00046832298
asymptomatic O 0 0.5966466
doxorubicin B-Chemical 1 0.999946
- O 0 0.06663989
treated O 0 0.0005692002
long O 0 0.000488408
- O 0 0.001771715
term O 0 0.00067726005
survivors O 0 0.0023473564
of O 0 0.0030268636
childhood O 0 0.98943746
cancer B-Disease 0 0.9994467
. O 0 0.015972238

Doxorubicin B-Chemical 1 0.9998016
is O 0 0.004666228
an O 0 0.003151905
effective O 0 0.0028985578
anticancer O 0 0.80723643
chemotherapeutic O 0 0.74683625
agent O 0 0.20803934
known O 0 0.0017327128
to O 0 0.0009547081
cause O 0 0.0023875432
acute O 0 0.92045885
and O 0 0.017143976
chronic O 0 0.9977399
cardiomyopathy B-Disease 0 0.9999944
. O 0 0.020021196

To O 0 0.0030684671
develop O 0 0.0023763007
a O 0 0.0019237439
more O 0 0.001234859
sensitive O 0 0.00088965386
echocardiographic O 0 0.003298159
screening O 0 0.0006779846
test O 0 0.0004459447
for O 0 0.00043960774
cardiac B-Disease 0 0.82567614
damage I-Disease 0 0.9807407
due O 0 0.00022350415
to O 0 0.00031180264
doxorubicin B-Chemical 1 0.9996032
, O 0 0.0009612463
a O 0 0.00036702474
cohort O 0 0.00090117194
study O 0 0.0002453075
was O 0 0.00014318216
performed O 0 0.00012064089
using O 0 0.00018667075
dobutamine B-Chemical 1 0.9992669
infusion O 0 0.000581991
to O 0 0.00012229744
differentiate O 0 0.00019835132
asymptomatic O 0 0.014169761
long O 0 0.00022646697
- O 0 0.0014991672
term O 0 0.0001742505
survivors O 0 0.0007505321
of O 0 0.0006689072
childhood O 0 0.9882796
cancer B-Disease 0 0.9995926
treated O 0 0.004435559
with O 0 0.0019630296
doxorubicin B-Chemical 1 0.99890804
from O 0 0.0010028324
healthy O 0 0.0061597987
control O 0 0.002036647
subjects O 0 0.004494465
. O 0 0.0059305574

Echocardiographic O 0 0.012600122
data O 0 0.0026717223
from O 0 0.0014499977
the O 0 0.0010642598
experimental O 0 0.00091568317
group O 0 0.0007750508
of O 0 0.00060321705
21 O 0 0.0004955305
patients O 0 0.00040945975
( O 0 0.00031471328
mean O 0 0.00015441269
age O 0 0.00039206143
16 O 0 0.0002984398
+ O 0 0.0010890673
/ O 0 0.008191055
- O 0 0.005454034
5 O 0 0.00016951594
years O 0 0.00021554253
) O 0 0.0002798975
treated O 0 0.00018661734
from O 0 0.00014749687
1 O 0 0.00016416964
. O 0 0.00013545941
6 O 0 0.000112543064
to O 0 0.000116809126
14 O 0 0.00014755118
. O 0 0.00013122885
3 O 0 0.00012265155
years O 0 0.00015741555
( O 0 0.00018252108
median O 0 0.00011121848
5 O 0 0.00013107904
. O 0 0.00014210492
3 O 0 0.00014213542
) O 0 0.00022441486
before O 0 0.00010946244
this O 0 0.00014003903
study O 0 0.00017836006
with O 0 0.00016630878
27 O 0 0.00022836773
to O 0 0.00016197258
532 O 0 0.4758375
mg O 0 0.028705481
/ O 0 0.0023043733
m2 O 0 0.012437284
of O 0 0.00058066426
doxorubicin B-Chemical 1 0.9992053
( O 0 0.00045630586
mean O 0 0.00013388415
196 O 0 0.001572954
) O 0 0.00030079868
were O 0 0.00015779426
compared O 0 0.00012205908
with O 0 0.00018737405
echocardiographic O 0 0.00081289624
data O 0 0.00023406529
from O 0 0.0002172853
12 O 0 0.00026233937
normal O 0 0.00049027614
age O 0 0.0010107162
- O 0 0.0020964216
matched O 0 0.0013023936
control O 0 0.002139793
subjects O 0 0.0047191256
. O 0 0.0064337784

Graded O 0 0.049154744
dobutamine B-Chemical 1 0.9994875
infusions O 0 0.018496115
of O 0 0.0017270967
0 O 0 0.0011804721
. O 0 0.00069489336
5 O 0 0.00052089867
, O 0 0.00061295344
2 O 0 0.0004225393
. O 0 0.00034953037
5 O 0 0.00031052282
, O 0 0.00039414703
5 O 0 0.00029183432
and O 0 0.00036590692
10 O 0 0.0004070615
micrograms O 0 0.0015431267
/ O 0 0.0012430582
kg O 0 0.0011012417
per O 0 0.0007059473
min O 0 0.0015324295
were O 0 0.0021835724
administered O 0 0.0034899185
. O 0 0.0064120092

Echocardiographic O 0 0.021602636
Doppler O 0 0.025462225
studies O 0 0.002086
were O 0 0.0013632044
performed O 0 0.00089670636
before O 0 0.0006601023
infusion O 0 0.0010134112
and O 0 0.000640295
after O 0 0.00043158603
15 O 0 0.00051016844
min O 0 0.000710008
of O 0 0.00092020805
infusion O 0 0.0014768159
at O 0 0.0012517995
each O 0 0.0015915784
rate O 0 0.0040081344
. O 0 0.0073346775

Dobutamine B-Chemical 0 0.9986254
infusion O 0 0.008493962
at O 0 0.0015945708
10 O 0 0.0011828583
micrograms O 0 0.004414422
/ O 0 0.001766923
kg O 0 0.0008889206
per O 0 0.00031157502
min O 0 0.00045467223
was O 0 0.00033181626
discontinued O 0 0.0005150204
after O 0 0.00017114852
six O 0 0.00017255508
studies O 0 0.00022822927
secondary O 0 0.0006222993
to O 0 0.0002909151
a O 0 0.00044979728
50 O 0 0.00049377105
% O 0 0.00060194434
incidence O 0 0.0012258593
rate O 0 0.0011502551
of O 0 0.002525773
adverse O 0 0.77931434
symptoms O 0 0.5668542
. O 0 0.007497946

The O 0 0.0031029622
most O 0 0.0023027512
important O 0 0.0012116099
findings O 0 0.0012067035
were O 0 0.00071217655
that O 0 0.00043109382
compared O 0 0.00030762458
with O 0 0.00033214386
values O 0 0.00027156467
in O 0 0.00025236738
control O 0 0.00026327596
subjects O 0 0.00039683218
, O 0 0.0003130241
end O 0 0.00016778627
- O 0 0.0038705932
systolic O 0 0.20665891
left O 0 0.00057577423
ventricular O 0 0.34679666
posterior O 0 0.019308202
wall O 0 0.0017221572
dimension O 0 0.00024341173
and O 0 0.00013883217
percent O 0 0.00010433483
of O 0 0.00015265867
left O 0 0.00038995335
ventricular O 0 0.29980016
posterior O 0 0.028373932
wall O 0 0.013296184
thickening O 0 0.7626342
in O 0 0.000517412
doxorubicin B-Chemical 1 0.9998673
- O 0 0.052763455
treated O 0 0.00034001304
patients O 0 0.0002999985
were O 0 0.00014992201
decreased O 0 0.00016645995
at O 0 0.00012925967
baseline O 0 0.00015694463
study O 0 0.00018973098
and O 0 0.00019010111
these O 0 0.00021708859
findings O 0 0.00032284993
were O 0 0.00030721247
more O 0 0.0003859468
clearly O 0 0.00047076226
delineated O 0 0.0010955402
with O 0 0.002056839
dobutamine B-Chemical 1 0.99947745
stimulation O 0 0.0048785694
. O 0 0.00703201

End O 0 0.0133684
- O 0 0.01338786
systolic O 0 0.29264483
left O 0 0.0031981438
ventricular O 0 0.5167312
posterior O 0 0.030241083
wall O 0 0.0030141782
dimension O 0 0.000587239
at O 0 0.00025955588
baseline O 0 0.00022952202
for O 0 0.00020683838
the O 0 0.00032922643
doxorubicin B-Chemical 1 0.99975556
- O 0 0.047278915
treated O 0 0.00039285136
group O 0 0.00032907238
was O 0 0.00020003825
11 O 0 0.00022463
+ O 0 0.0011139648
/ O 0 0.010615942
- O 0 0.009616035
1 O 0 0.00018834454
. O 0 0.00014127794
9 O 0 0.00013320606
mm O 0 0.00023191891
versus O 0 0.00015243585
13 O 0 0.00019195495
. O 0 0.00016314547
1 O 0 0.0001989491
+ O 0 0.0007658212
/ O 0 0.007425571
- O 0 0.0080598565
1 O 0 0.00021736838
. O 0 0.00016772357
5 O 0 0.00015298408
mm O 0 0.00029044983
for O 0 0.00020449617
control O 0 0.0002602058
subjects O 0 0.000419095
( O 0 0.00048642114
p O 0 0.00043961176
less O 0 0.0005022065
than O 0 0.00058582553
0 O 0 0.0011656698
. O 0 0.0017076667
01 O 0 0.0053431746
) O 0 0.005568818
. O 0 0.007572079

End O 0 0.013225883
- O 0 0.012844018
systolic O 0 0.27718657
left O 0 0.003124428
ventricular O 0 0.49247
posterior O 0 0.028092816
wall O 0 0.0030592068
dimension O 0 0.00063150097
at O 0 0.00028607628
the O 0 0.00026741522
5 O 0 0.00025750705
- O 0 0.0013535265
micrograms O 0 0.0029260875
/ O 0 0.00086098793
kg O 0 0.00037581296
per O 0 0.00012428708
min O 0 0.00033266074
dobutamine B-Chemical 1 0.9982609
infusion O 0 0.0005360556
for O 0 0.00015206535
the O 0 0.00027977637
doxorubicin B-Chemical 1 0.99980694
- O 0 0.054626577
treated O 0 0.00036689913
group O 0 0.0002964236
was O 0 0.00016666055
14 O 0 0.00015200375
. O 0 0.00013964326
1 O 0 0.00017350576
+ O 0 0.0008306095
/ O 0 0.009054994
- O 0 0.009322546
2 O 0 0.0001821466
. O 0 0.00013793899
4 O 0 0.00012107928
mm O 0 0.00022774235
versus O 0 0.00015296906
19 O 0 0.00023642078
. O 0 0.00015932185
3 O 0 0.00016867091
+ O 0 0.00067914446
/ O 0 0.0068785935
- O 0 0.008016672
2 O 0 0.0001966319
. O 0 0.00015029228
6 O 0 0.00012412565
mm O 0 0.00024412293
for O 0 0.0001593135
control O 0 0.00019036377
subjects O 0 0.00029793486
( O 0 0.00031324528
p O 0 0.00022473282
less O 0 0.00020380458
than O 0 0.00019038773
0 O 0 0.00032297152
. O 0 0.00036248186
01 O 0 0.0014196842
) O 0 0.00087352376
. O 0 0.0007729694
( O 0 0.0016788786
ABSTRACT O 0 0.0058153626
TRUNCATED O 0 0.006546794
AT O 0 0.011808863
250 O 0 0.005933144
WORDS O 0 0.011188007
) O 0 0.017987449

Influence O 0 0.014639464
of O 0 0.0137380045
smoking B-Chemical 1 0.9427557
on O 0 0.011281848
developing O 0 0.041779418
cochlea O 0 0.16396095
. O 0 0.023707626

Does O 0 0.013710464
smoking B-Chemical 1 0.96001786
during O 0 0.0024566795
pregnancy O 0 0.07919458
affect O 0 0.0011555117
the O 0 0.0010845631
amplitudes O 0 0.0018575132
of O 0 0.0014565088
transient O 0 0.030309742
evoked O 0 0.22211218
otoacoustic O 0 0.99946004
emissions O 0 0.678367
in O 0 0.004523989
newborns O 0 0.02159298
? O 0 0.014741461

OBJECTIVE O 0 0.03473159
: O 0 0.0065819127
Maternal O 0 0.06917569
tobacco O 0 0.7954806
smoking B-Chemical 1 0.99406826
has O 0 0.002282158
negative O 0 0.0025365984
effects O 0 0.0027587214
on O 0 0.0026578598
fetal O 0 0.17416629
growth O 0 0.06624425
. O 0 0.011873278

The O 0 0.0029469118
influence O 0 0.0018486723
of O 0 0.002376173
smoking B-Chemical 1 0.982483
during O 0 0.00087915285
pregnancy O 0 0.11889927
on O 0 0.00037103734
the O 0 0.00043929231
developing O 0 0.010993322
cochlea O 0 0.039310887
has O 0 0.0002646163
not O 0 0.00021023017
been O 0 0.0002124283
estimated O 0 0.00023492743
, O 0 0.00055166514
although O 0 0.00059868995
smoking B-Chemical 1 0.9928647
has O 0 0.00032135655
been O 0 0.0002996729
positively O 0 0.00038803802
associated O 0 0.0005742523
with O 0 0.0010154155
hearing B-Disease 0 0.9054947
loss I-Disease 0 0.0035486356
in O 0 0.0025125518
adults O 0 0.011756416
. O 0 0.0069955527

The O 0 0.003118219
objective O 0 0.0028245489
of O 0 0.001811003
this O 0 0.0012104663
study O 0 0.0010374682
was O 0 0.000592162
to O 0 0.000356164
determine O 0 0.00018813937
the O 0 0.00026605724
effects O 0 0.00033532392
of O 0 0.00043180122
maternal O 0 0.026779097
smoking B-Chemical 1 0.9934242
on O 0 0.00025603132
transient O 0 0.019795788
evoked O 0 0.1401685
otoacoustic O 0 0.99973494
emissions O 0 0.82120055
( O 0 0.002450333
TEOAEs O 0 0.463287
) O 0 0.0017553638
of O 0 0.0020579167
healthy O 0 0.01214622
neonates O 0 0.01164903
. O 0 0.00709265

METHODS O 0 0.0042135334
: O 0 0.0039565344
This O 0 0.002739197
study O 0 0.0017802742
was O 0 0.0011113681
undertaken O 0 0.00069800584
as O 0 0.000614226
part O 0 0.0004981369
of O 0 0.00057272834
neonatal O 0 0.0024943643
screening O 0 0.00086712796
for O 0 0.00058246235
hearing B-Disease 0 0.96684295
impairment I-Disease 0 0.3525727
and O 0 0.00060819555
involved O 0 0.0005053922
both O 0 0.00078986556
ears O 0 0.0054763965
of O 0 0.0020279933
200 O 0 0.003382889
newborns O 0 0.008325976
. O 0 0.00718749

Newborns O 0 0.015833959
whose O 0 0.0032335247
mothers O 0 0.003367872
reported O 0 0.002462659
smoking B-Chemical 1 0.9787627
during O 0 0.000712813
pregnancy O 0 0.23459052
( O 0 0.0008794561
n O 0 0.00038456605
= O 0 0.00071267266
200 O 0 0.00045994934
ears O 0 0.0048452322
) O 0 0.00045901118
were O 0 0.00019159453
compared O 0 0.00013090354
to O 0 0.00014928394
a O 0 0.00020745934
control O 0 0.00018245268
group O 0 0.00023250653
of O 0 0.0002441562
newborns O 0 0.002170519
( O 0 0.0004115684
n O 0 0.00024059492
= O 0 0.00055090216
200 O 0 0.00044295235
ears O 0 0.0047896565
) O 0 0.0007538638
, O 0 0.00059266
whose O 0 0.00070930325
mothers O 0 0.0013706627
were O 0 0.0011590874
non O 0 0.002898073
- O 0 0.030434933
smokers O 0 0.34944704
. O 0 0.0076626977

Exposure O 0 0.017338367
to O 0 0.003018256
tobacco O 0 0.1942745
was O 0 0.0014524823
characterized O 0 0.0010661167
as O 0 0.00068912073
low O 0 0.0008500071
( O 0 0.00071078003
< O 0 0.00034715497
5 O 0 0.0002902425
cigarettes O 0 0.018035885
per O 0 0.00015531405
day O 0 0.00017438896
, O 0 0.0002421031
n O 0 0.00020216916
= O 0 0.00043045715
88 O 0 0.0005078166
ears O 0 0.0099297315
) O 0 0.0007694814
, O 0 0.0004298259
moderate O 0 0.0051104915
( O 0 0.0003797446
5 O 0 0.00015132506
< O 0 0.00015401523
or O 0 0.00019032002
= O 0 0.0006247352
cigarettes O 0 0.08424535
per O 0 0.000112875605
day O 0 0.0001240865
< O 0 0.0001387537
10 O 0 0.00015364398
, O 0 0.00019760756
n O 0 0.00017692083
= O 0 0.00039082157
76 O 0 0.000375024
) O 0 0.00035056422
or O 0 0.00020691096
high O 0 0.00040479627
( O 0 0.00050583447
> O 0 0.0006671173
or O 0 0.00028949327
= O 0 0.0006125607
10 O 0 0.00033152822
cigarettes O 0 0.016909704
per O 0 0.00027624742
day O 0 0.00043077793
, O 0 0.00080852146
n O 0 0.001015256
= O 0 0.0023478288
36 O 0 0.0028610784
) O 0 0.0053465464
. O 0 0.007512536

RESULTS O 0 0.005882898
: O 0 0.003852969
In O 0 0.0019979
exposed O 0 0.0017703578
neonates O 0 0.0047983583
, O 0 0.0015947281
TEOAEs O 0 0.08877318
mean O 0 0.0003411587
response O 0 0.00051029393
( O 0 0.00047913898
across O 0 0.00022190416
frequency O 0 0.00034194966
) O 0 0.00043396352
and O 0 0.00023318543
mean O 0 0.00015403815
amplitude O 0 0.0005413254
at O 0 0.0002704771
4000Hz O 0 0.121589415
was O 0 0.00030196496
significantly O 0 0.00030835456
lower O 0 0.00035047668
than O 0 0.00035550553
in O 0 0.0006382436
non O 0 0.0017989744
- O 0 0.007721847
exposed O 0 0.0033868044
neonates O 0 0.019095005
. O 0 0.0071773375

Comparisons O 0 0.004208552
between O 0 0.0031759285
exposed O 0 0.0036459577
newborns O 0 0.005736036
' O 0 0.003813898
subgroups O 0 0.0030090685
revealed O 0 0.002602248
no O 0 0.0028226369
significant O 0 0.0044858754
differences O 0 0.005942494
. O 0 0.010884125

However O 0 0.0045681605
, O 0 0.0031667617
by O 0 0.001689281
comparing O 0 0.0008347139
each O 0 0.00059185893
subgroup O 0 0.0011734945
to O 0 0.00044374814
control O 0 0.00046257646
group O 0 0.00055274705
, O 0 0.00042129765
we O 0 0.00019417594
found O 0 0.00023189459
statistically O 0 0.00023243116
significant O 0 0.0002666108
decreases B-Disease 0 0.00033693545
of I-Disease 0 0.0006247054
TEOAEs I-Disease 0 0.5315518
amplitudes I-Disease 0 0.0012779946
at O 0 0.00054412044
4000Hz O 0 0.04780639
for O 0 0.0008019575
all O 0 0.0011057463
three O 0 0.0014066349
groups O 0 0.0031970053
. O 0 0.006135937

Mean O 0 0.0032923534
TEOAEs O 0 0.04180998
responses O 0 0.002515764
of O 0 0.0016440684
highly O 0 0.0013030767
exposed O 0 0.0011258766
newborns O 0 0.002565181
were O 0 0.00061808364
also O 0 0.0004964507
significantly O 0 0.00051990955
lower O 0 0.0005158775
in O 0 0.0005447696
comparison O 0 0.00062777265
to O 0 0.00085879094
our O 0 0.0014169214
control O 0 0.0022790548
group O 0 0.004640315
. O 0 0.006995188

CONCLUSION O 0 0.034489654
: O 0 0.0045891698
In O 0 0.0022102133
utero O 0 0.007756535
, O 0 0.0020168263
exposure O 0 0.0046244054
to O 0 0.0010060132
tobacco O 0 0.8605485
smoking B-Chemical 1 0.997022
seems O 0 0.0005548613
to O 0 0.00039287197
have O 0 0.00039457303
a O 0 0.00054863404
small O 0 0.00058786396
impact O 0 0.00068674877
on O 0 0.0009791375
outer O 0 0.031935304
hair O 0 0.5511379
cells O 0 0.0071473997
. O 0 0.008463535

These O 0 0.003994844
effects O 0 0.0030316117
seem O 0 0.0019092807
to O 0 0.0011252353
be O 0 0.00097459066
equally O 0 0.00082510576
true O 0 0.0007638816
for O 0 0.00052657037
all O 0 0.00047215808
exposed O 0 0.0006293997
newborns O 0 0.002469983
, O 0 0.00075307256
regardless O 0 0.00046554577
of O 0 0.0008598844
the O 0 0.0010315233
degree O 0 0.0019028174
of O 0 0.0033407058
exposure O 0 0.039710987
. O 0 0.008401609

Further O 0 0.0038225546
studies O 0 0.0024233402
are O 0 0.0015317942
needed O 0 0.000896762
in O 0 0.0007493929
order O 0 0.00047112678
to O 0 0.00039258407
establish O 0 0.00029157958
a O 0 0.00036424608
potential O 0 0.0003251316
negative O 0 0.00043436835
effect O 0 0.0003264507
of O 0 0.00058207335
maternal O 0 0.039749037
smoking B-Chemical 1 0.9928893
on O 0 0.00038864664
the O 0 0.00063373125
neonate O 0 0.0074852062
' O 0 0.0020411129
s O 0 0.0029359777
hearing O 0 0.9655763
acuity O 0 0.9916181
. O 0 0.008131736

Simvastatin B-Chemical 0 0.9999728
- O 0 0.06122508
induced O 0 0.003699842
bilateral O 0 0.10917058
leg O 0 0.07892547
compartment B-Disease 0 0.051134337
syndrome I-Disease 0 0.9894991
and O 0 0.008967643
myonecrosis B-Disease 0 0.99996614
associated O 0 0.007519743
with O 0 0.01604236
hypothyroidism B-Disease 0 0.9999683
. O 0 0.012510413

A O 0 0.09232855
54 O 0 0.006463569
- O 0 0.008256018
year O 0 0.0022302882
- O 0 0.0065699294
old O 0 0.0016751407
hypothyroid B-Disease 2 0.98833025
male O 0 0.018772928
taking O 0 0.021244852
thyroxine B-Chemical 1 0.99992335
and O 0 0.0032819284
simvastatin B-Chemical 1 0.999977
presented O 0 0.00047851275
with O 0 0.00059017097
bilateral O 0 0.039438926
leg O 0 0.027249416
compartment B-Disease 0 0.020951306
syndrome I-Disease 0 0.9801052
and O 0 0.010064352
myonecrosis B-Disease 0 0.99992585
. O 0 0.009586092

Urgent O 0 0.0091404645
fasciotomies O 0 0.0070891576
were O 0 0.0020010904
performed O 0 0.0012870339
and O 0 0.0012050506
the O 0 0.0008833572
patient O 0 0.00078545784
made O 0 0.000615071
an O 0 0.00069277966
uneventful O 0 0.0006825429
recovery O 0 0.00090311625
with O 0 0.0009011831
the O 0 0.0012999839
withdrawal O 0 0.29351488
of O 0 0.010510939
simvastatin B-Chemical 1 0.999966
. O 0 0.010663749

It O 0 0.004771569
is O 0 0.0026026121
likely O 0 0.0015725672
that O 0 0.0010318191
this O 0 0.0009855969
complication O 0 0.049760755
will O 0 0.00044956862
be O 0 0.0003935032
seen O 0 0.00033438377
more O 0 0.0003336612
often O 0 0.00030183658
with O 0 0.00022842258
the O 0 0.00021491745
increased O 0 0.00031707104
worldwide O 0 0.009550374
use O 0 0.00028003257
of O 0 0.000336685
this O 0 0.00035339594
drug O 0 0.08225779
and O 0 0.0005090852
its O 0 0.0008402506
approval O 0 0.0008932617
for O 0 0.00091953046
all O 0 0.0017489041
arteriopathic B-Disease 0 0.9981681
patients O 0 0.0057991548
. O 0 0.0062496318

Neuroinflammation B-Disease 0 0.96132505
and O 0 0.0051172483
behavioral B-Disease 0 0.6302058
abnormalities I-Disease 0 0.5995394
after O 0 0.0011247268
neonatal O 0 0.07326476
terbutaline B-Chemical 0 0.99998534
treatment O 0 0.0028476706
in O 0 0.0010728438
rats O 0 0.001568991
: O 0 0.0017407865
implications O 0 0.0019343236
for O 0 0.0033289902
autism B-Disease 0 0.9844208
. O 0 0.00886519

Autism B-Disease 0 0.95775026
is O 0 0.003395978
a O 0 0.0039797723
neurodevelopmental B-Disease 0 0.99917966
disorder I-Disease 0 0.9994729
presenting O 0 0.0068619545
before O 0 0.00039034494
3 O 0 0.00033741957
years O 0 0.00035040503
of O 0 0.00034744895
age O 0 0.00059369224
with O 0 0.00047066534
deficits B-Disease 0 0.21054778
in I-Disease 0 0.00039634167
communication I-Disease 0 0.000986199
and I-Disease 0 0.0007071987
social I-Disease 0 0.007867776
skills I-Disease 0 0.002624989
and O 0 0.0020548657
repetitive B-Disease 0 0.038950678
behaviors I-Disease 0 0.5185405
. O 0 0.0074029574

In O 0 0.0033116587
addition O 0 0.0016682498
to O 0 0.00147728
genetic O 0 0.002150987
influences O 0 0.0009140626
, O 0 0.0010058595
recent O 0 0.00059808395
studies O 0 0.00042323244
suggest O 0 0.0002721375
that O 0 0.0003541344
prenatal O 0 0.03075064
drug O 0 0.44240806
or O 0 0.00057589886
chemical O 0 0.015247719
exposures O 0 0.06904225
are O 0 0.00084997504
risk O 0 0.04390127
factors O 0 0.0058238762
for O 0 0.0037029192
autism B-Disease 0 0.9942555
. O 0 0.007876326

Terbutaline B-Chemical 0 0.9998803
, O 0 0.010119277
a O 0 0.0123227155
beta2 O 0 0.99967206
- O 0 0.883149
adrenoceptor O 0 0.99998915
agonist O 0 0.95188475
used O 0 0.0005721587
to O 0 0.00047243948
arrest O 0 0.60807556
preterm B-Disease 0 0.997865
labor I-Disease 0 0.9663477
, O 0 0.0011269266
has O 0 0.00029851205
been O 0 0.00027744018
associated O 0 0.00030936333
with O 0 0.00036393615
increased O 0 0.00048689827
concordance O 0 0.0011495944
for O 0 0.0009832793
autism B-Disease 0 0.9772528
in O 0 0.0020219444
dizygotic O 0 0.17037319
twins O 0 0.089906015
. O 0 0.008426425

We O 0 0.0035475432
studied O 0 0.0024327405
the O 0 0.0016191994
effects O 0 0.0017102958
of O 0 0.0026673968
terbutaline B-Chemical 0 0.9999788
on O 0 0.00061643816
microglial O 0 0.34386382
activation O 0 0.0008922189
in O 0 0.00036461995
different O 0 0.00030877962
brain O 0 0.0017381071
regions O 0 0.0005212906
and O 0 0.0005946879
behavioral O 0 0.004309676
outcomes O 0 0.001380709
in O 0 0.0014642451
developing O 0 0.008858581
rats O 0 0.0056784707
. O 0 0.006451607

Newborn O 0 0.008861751
rats O 0 0.0034923241
were O 0 0.0018345183
given O 0 0.0013552319
terbutaline B-Chemical 0 0.999954
( O 0 0.0026802258
10 O 0 0.0006448522
mg O 0 0.022821814
/ O 0 0.0018590029
kg O 0 0.0010983297
) O 0 0.0005047187
daily O 0 0.00023436543
on O 0 0.00013819267
postnatal O 0 0.00030948015
days O 0 0.0001678442
( O 0 0.00049968716
PN O 0 0.22292097
) O 0 0.00045199238
2 O 0 0.0001637413
to O 0 0.00013016445
5 O 0 0.0001399097
or O 0 0.00017373486
PN O 0 0.038539894
11 O 0 0.00016786053
to O 0 0.0001270612
14 O 0 0.00015202099
and O 0 0.0001645293
examined O 0 0.00015102724
24 O 0 0.00021577447
h O 0 0.00023271344
after O 0 0.00019011581
the O 0 0.00029859287
last O 0 0.00033797283
dose O 0 0.0010587783
and O 0 0.0010368337
at O 0 0.0014690049
PN O 0 0.07107516
30 O 0 0.003182526
. O 0 0.0058249575

Immunohistochemical O 0 0.008195879
studies O 0 0.0023743052
showed O 0 0.0014724671
that O 0 0.0010366017
administration O 0 0.008816167
of O 0 0.0034770838
terbutaline B-Chemical 0 0.99998844
on O 0 0.0005122991
PN O 0 0.43575594
2 O 0 0.00026365303
to O 0 0.0001710343
5 O 0 0.00015345101
produced O 0 0.00014516438
a O 0 0.00020749279
robust O 0 0.00017447195
increase O 0 0.00015268198
in O 0 0.00022310451
microglial O 0 0.15740554
activation O 0 0.00046286007
on O 0 0.0001474821
PN O 0 0.099934705
30 O 0 0.00013963263
in O 0 0.00014658328
the O 0 0.00022015732
cerebral O 0 0.93122995
cortex O 0 0.3391665
, O 0 0.0003113606
as O 0 0.00020975166
well O 0 0.00024636107
as O 0 0.00032244358
in O 0 0.0005186249
cerebellar O 0 0.33934236
and O 0 0.0015274193
cerebrocortical O 0 0.9607158
white O 0 0.097213656
matter O 0 0.024436522
. O 0 0.006233356

None O 0 0.006498113
of O 0 0.0032482818
these O 0 0.0023295924
effects O 0 0.0020122814
occurred O 0 0.001398242
in O 0 0.0011099307
animals O 0 0.00097267324
given O 0 0.0010971517
terbutaline B-Chemical 0 0.999884
on O 0 0.0013904871
PN O 0 0.15412387
11 O 0 0.0021604225
to O 0 0.0025264977
14 O 0 0.00447987
. O 0 0.0073553394

In O 0 0.004123984
behavioral O 0 0.012347213
tests O 0 0.0028854567
, O 0 0.0016264126
animals O 0 0.00076184253
treated O 0 0.00086681475
with O 0 0.0014444557
terbutaline B-Chemical 0 0.9999769
on O 0 0.0003786226
PN O 0 0.3210182
2 O 0 0.00022378816
to O 0 0.00015046277
5 O 0 0.0001392007
showed O 0 0.0001305845
consistent O 0 0.00014849655
patterns O 0 0.00015736301
of O 0 0.0004479143
hyper O 0 0.97898453
- O 0 0.0530142
reactivity O 0 0.006308617
to O 0 0.00018250088
novelty O 0 0.021052279
and O 0 0.0002573151
aversive O 0 0.014421559
stimuli O 0 0.00022010652
when O 0 0.00011313821
assessed O 0 0.00012370854
in O 0 0.00015917017
a O 0 0.00020845828
novel O 0 0.00022539936
open O 0 0.00032379746
field O 0 0.00041207543
, O 0 0.0003195961
as O 0 0.00023269105
well O 0 0.00027167395
as O 0 0.0003363448
in O 0 0.00046307943
the O 0 0.00070786494
acoustic O 0 0.035389286
startle O 0 0.9572721
response O 0 0.0027696295
test O 0 0.0042099715
. O 0 0.0066428394

Our O 0 0.003635498
findings O 0 0.0025168206
indicate O 0 0.001332968
that O 0 0.0017884804
beta2 O 0 0.9996772
- O 0 0.92101043
adrenoceptor O 0 0.9999945
overstimulation O 0 0.99224174
during O 0 0.0003980176
an O 0 0.000422825
early O 0 0.00036438642
critical O 0 0.00017849632
period O 0 0.00015264004
results O 0 0.00016198726
in O 0 0.00020038513
microglial O 0 0.114669226
activation O 0 0.00047332255
associated O 0 0.00025402996
with O 0 0.00026871124
innate O 0 0.017193517
neuroinflammatory O 0 0.98057234
pathways O 0 0.00043590934
and O 0 0.0005547131
behavioral B-Disease 0 0.7095001
abnormalities I-Disease 0 0.67113435
, O 0 0.00048189246
similar O 0 0.0003240513
to O 0 0.00046583277
those O 0 0.0008730632
described O 0 0.0011341587
in O 0 0.002305182
autism B-Disease 0 0.97282505
. O 0 0.0070007285

This O 0 0.0054857978
study O 0 0.0030794162
provides O 0 0.0017027217
a O 0 0.0015310863
useful O 0 0.0009994137
animal O 0 0.0010689319
model O 0 0.0007103857
for O 0 0.0005557444
understanding O 0 0.0005205438
the O 0 0.0006211145
neuropathological O 0 0.46893594
processes O 0 0.001322744
underlying O 0 0.0026772982
autism B-Disease 0 0.99811006
spectrum I-Disease 0 0.01178857
disorders I-Disease 0 0.98094547
. O 0 0.008023592

Upregulation O 0 0.0065284315
of O 0 0.003028598
brain O 0 0.007841318
expression O 0 0.0016267257
of O 0 0.0020306846
P O 0 0.6016174
- O 0 0.054561503
glycoprotein O 0 0.45654
in O 0 0.0030943307
MRP2 O 0 0.99996245
- O 0 0.094691224
deficient O 0 0.000588221
TR O 0 0.98282987
( O 0 0.004264879
- O 0 0.026463626
) O 0 0.0008294892
rats O 0 0.00054577633
resembles O 0 0.00073328626
seizure B-Disease 2 0.9999863
- O 0 0.023919506
induced O 0 0.00029042407
up O 0 0.00028997503
- O 0 0.0017161561
regulation O 0 0.00020053018
of O 0 0.00036735166
this O 0 0.00046599554
drug O 0 0.25823724
efflux O 0 0.068262696
transporter O 0 0.0111070825
in O 0 0.0014214545
normal O 0 0.0031966146
rats O 0 0.0047465423
. O 0 0.005969444

PURPOSE O 0 0.005184627
: O 0 0.0034438397
The O 0 0.0017190865
multidrug O 0 0.029069485
resistance O 0 0.003978091
protein O 0 0.002415852
2 O 0 0.0008969247
( O 0 0.0030849485
MRP2 O 0 0.99977666
) O 0 0.0022342668
is O 0 0.0004156762
a O 0 0.00051214756
drug O 0 0.24532254
efflux O 0 0.047318585
transporter O 0 0.0038661023
that O 0 0.00014316905
is O 0 0.00016482324
expressed O 0 0.00011373997
predominantly O 0 0.00015426715
at O 0 0.000120849174
the O 0 0.00012919202
apical O 0 0.0002794064
domain O 0 0.00022245556
of O 0 0.0003811284
hepatocytes O 0 0.2178234
but O 0 0.00046878902
seems O 0 0.00015870851
also O 0 0.00013291361
to O 0 0.00011483095
be O 0 0.0001267189
expressed O 0 9.910387e-05
at O 0 0.00011104869
the O 0 0.00012552146
apical O 0 0.00027524107
membrane O 0 0.0010217086
of O 0 0.0003332448
brain O 0 0.024031255
capillary O 0 0.15681902
endothelial O 0 0.74975175
cells O 0 0.00034068123
that O 0 0.00020417316
form O 0 0.00027266238
the O 0 0.00040253048
blood O 0 0.021794738
- O 0 0.008451108
brain O 0 0.013885158
barrier O 0 0.01764492
( O 0 0.007960466
BBB O 0 0.9973055
) O 0 0.009660249
. O 0 0.007997506

MRP2 O 0 0.9981115
is O 0 0.0032508033
absent O 0 0.0017372615
in O 0 0.0011858366
the O 0 0.0009008547
transport O 0 0.0017911018
- O 0 0.0070327553
deficient O 0 0.0005240698
( O 0 0.002741639
TR O 0 0.9792884
( O 0 0.0051796637
- O 0 0.03933706
) O 0 0.0013903269
) O 0 0.001029803
Wistar O 0 0.0076847314
rat O 0 0.0006116212
mutant O 0 0.00020282135
, O 0 0.00036358417
so O 0 0.0001869192
that O 0 0.00014675726
this O 0 0.00019771764
rat O 0 0.00051323953
strain O 0 0.00019257679
was O 0 0.00019433946
very O 0 0.00023016369
helpful O 0 0.00018247984
in O 0 0.00012949371
defining O 0 0.00014216578
substrates O 0 0.00028731363
of O 0 0.0008881853
MRP2 O 0 0.9997564
by O 0 0.00021664688
comparing O 0 0.00011414436
tissue O 0 0.0011667174
concentrations O 0 0.0004729865
or O 0 0.00015334143
functional O 0 0.000174853
activities O 0 0.00019551934
of O 0 0.00033233577
compounds O 0 0.6651395
in O 0 0.0013651627
MRP2 O 0 0.9999629
- O 0 0.037955146
deficient O 0 0.0002619372
rats O 0 0.00040977544
with O 0 0.00033088215
those O 0 0.00048711733
in O 0 0.00056674256
transport O 0 0.0014808866
- O 0 0.0039798403
competent O 0 0.0020404214
Wistar O 0 0.019724518
rats O 0 0.0049246997
. O 0 0.006510728

By O 0 0.0041637844
using O 0 0.0021895918
this O 0 0.0015059292
strategy O 0 0.0011570873
to O 0 0.0007702484
study O 0 0.0007393657
the O 0 0.0004601721
involvement O 0 0.0007032064
of O 0 0.0014651316
MRP2 O 0 0.9998468
in O 0 0.0004539356
brain O 0 0.0060757883
access O 0 0.00021516388
of O 0 0.0005272826
antiepileptic O 0 0.999225
drugs O 0 0.47471672
( O 0 0.0041900324
AEDs O 0 0.943798
) O 0 0.0006614519
, O 0 0.0002712909
we O 0 0.00012948185
recently O 0 0.0001913397
reported O 0 0.00031080068
that O 0 0.00038598964
phenytoin B-Chemical 1 0.9999987
is O 0 0.0005086549
a O 0 0.00059615006
substrate O 0 0.002045537
for O 0 0.001292852
MRP2 O 0 0.99909353
in O 0 0.0020407536
the O 0 0.003540654
BBB O 0 0.9949226
. O 0 0.0081700515

However O 0 0.004792772
, O 0 0.0034641607
one O 0 0.0016728418
drawback O 0 0.0013687437
of O 0 0.00095116295
such O 0 0.00063517335
studies O 0 0.0005755641
in O 0 0.0004649114
genetically O 0 0.00073236966
deficient O 0 0.0003176014
rats O 0 0.00048461044
is O 0 0.00025666822
the O 0 0.00020767369
fact O 0 0.00016622664
that O 0 0.00018844333
compensatory O 0 0.00039659374
changes O 0 0.00043166973
with O 0 0.00039910123
upregulation O 0 0.00057725486
of O 0 0.00083146116
other O 0 0.0011384223
transporters O 0 0.003605809
can O 0 0.0017978145
occur O 0 0.0036004405
. O 0 0.0064415345

This O 0 0.0047351937
prompted O 0 0.0024044022
us O 0 0.0020815558
to O 0 0.0011632828
study O 0 0.0010532807
the O 0 0.00068231585
brain O 0 0.00364201
expression O 0 0.00059737836
of O 0 0.0010585871
P O 0 0.63866353
- O 0 0.07431394
glycoprotein O 0 0.64462006
( O 0 0.015388827
Pgp O 0 0.9980453
) O 0 0.0021653038
, O 0 0.00040469057
a O 0 0.00028326694
major O 0 0.0003305612
drug O 0 0.2748964
efflux O 0 0.059366815
transporter O 0 0.006587206
in O 0 0.00017063977
many O 0 0.00016154612
tissues O 0 0.00036046543
, O 0 0.00025429917
including O 0 0.00018501641
the O 0 0.0003507763
BBB O 0 0.998546
, O 0 0.00082075835
in O 0 0.0004599287
TR O 0 0.9750827
( O 0 0.00338026
- O 0 0.019027336
) O 0 0.00059850275
rats O 0 0.00032685182
compared O 0 0.00019397885
with O 0 0.00041294532
nonmutant O 0 0.15187284
( O 0 0.0009648683
wild O 0 0.00083717046
- O 0 0.007279809
type O 0 0.0016681872
) O 0 0.004371444
Wistar O 0 0.028282855
rats O 0 0.0052302033
. O 0 0.006761196

METHODS O 0 0.003658675
: O 0 0.003098888
The O 0 0.0015612177
expression O 0 0.0015100682
of O 0 0.0022149421
MRP2 O 0 0.9997172
and O 0 0.004021741
Pgp O 0 0.9933409
in O 0 0.0005955864
brain O 0 0.007836657
and O 0 0.00045625807
liver O 0 0.26888666
sections O 0 0.000617659
of O 0 0.0010689512
TR O 0 0.99133426
( O 0 0.007561108
- O 0 0.03911919
) O 0 0.0007392653
rats O 0 0.00033410016
and O 0 0.00023920013
normal O 0 0.00043432193
Wistar O 0 0.0044547953
rats O 0 0.00022294288
was O 0 0.00013255379
determined O 0 0.00010945347
with O 0 0.0001870242
immunohistochemistry O 0 0.003280921
, O 0 0.00028486564
by O 0 0.00017369479
using O 0 0.00015548104
a O 0 0.00021146335
novel O 0 0.00023779122
, O 0 0.00030876047
highly O 0 0.00028165415
selective O 0 0.000995578
monoclonal O 0 0.105832666
MRP2 O 0 0.99985087
antibody O 0 0.06795305
and O 0 0.0006152103
the O 0 0.0005699956
monoclonal O 0 0.077550806
Pgp O 0 0.9972583
antibody O 0 0.33632126
C219 O 0 0.751778
, O 0 0.004555681
respectively O 0 0.008498315
. O 0 0.0076835304

RESULTS O 0 0.0048542283
: O 0 0.0033032384
Immunofluorescence O 0 0.004424604
staining O 0 0.002047213
with O 0 0.0011863415
the O 0 0.0013595108
MRP2 O 0 0.99974996
antibody O 0 0.10909937
was O 0 0.00054730114
found O 0 0.0002970879
to O 0 0.00024000289
label O 0 0.00070883567
a O 0 0.00029544823
high O 0 0.00026678925
number O 0 0.00016974109
of O 0 0.0002608578
microvessels O 0 0.044567637
throughout O 0 0.00013858893
the O 0 0.00018283512
brain O 0 0.0028682302
in O 0 0.0001989453
normal O 0 0.00046200337
Wistar O 0 0.0068525956
rats O 0 0.00032186985
, O 0 0.00027309865
whereas O 0 0.00021624242
such O 0 0.00021269622
labeling O 0 0.00049805973
was O 0 0.00034824785
absent O 0 0.00042601227
in O 0 0.00077235344
TR O 0 0.91476965
( O 0 0.0037175526
- O 0 0.016881175
) O 0 0.0046473173
rats O 0 0.005637157
. O 0 0.0069988323

TR O 0 0.9640244
( O 0 0.010692119
- O 0 0.0247187
) O 0 0.0027941507
rats O 0 0.0014775686
exhibited O 0 0.0007959214
a O 0 0.0007231605
significant O 0 0.0005175815
up O 0 0.00046332358
- O 0 0.0017073659
regulation O 0 0.00027040773
of O 0 0.00062449614
Pgp O 0 0.9894804
in O 0 0.0004538766
brain O 0 0.023468286
capillary O 0 0.15729861
endothelial O 0 0.7415602
cells O 0 0.0005748925
compared O 0 0.0003881858
with O 0 0.0006935972
wild O 0 0.0011149585
- O 0 0.005113409
type O 0 0.0025311543
controls O 0 0.0055657667
. O 0 0.006897675

No O 0 0.0064106723
such O 0 0.0033656128
obvious O 0 0.0029213165
upregulation O 0 0.0029868942
of O 0 0.0040222374
Pgp O 0 0.9917631
was O 0 0.0024788454
observed O 0 0.0021993879
in O 0 0.0032482366
liver O 0 0.42538047
sections O 0 0.008541612
. O 0 0.0098907435

A O 0 0.021866173
comparable O 0 0.0021838115
overexpression O 0 0.0020890075
of O 0 0.002772149
Pgp O 0 0.9932894
in O 0 0.001173294
the O 0 0.0011393798
BBB O 0 0.99687886
was O 0 0.00055233785
obtained O 0 0.00041078098
after O 0 0.0005227353
pilocarpine B-Chemical 1 0.99999905
- O 0 0.17137827
induced O 0 0.0045302934
seizures B-Disease 0 0.99999857
in O 0 0.0012179462
wild O 0 0.0014072453
- O 0 0.013123704
type O 0 0.00260171
Wistar O 0 0.0367796
rats O 0 0.005228631
. O 0 0.006676292

Experiments O 0 0.003909186
with O 0 0.0027089897
systemic O 0 0.45163092
administration O 0 0.019403627
of O 0 0.0013414979
the O 0 0.0014109347
Pgp O 0 0.99898785
substrate O 0 0.40688476
phenobarbital B-Chemical 0 0.9999999
and O 0 0.001107339
the O 0 0.00034070434
selective O 0 0.0075770263
Pgp O 0 0.99727887
inhibitor O 0 0.23063412
tariquidar B-Chemical 0 0.9999871
in O 0 0.0010740162
TR O 0 0.98697925
( O 0 0.003816214
- O 0 0.020850973
) O 0 0.0005395493
rats O 0 0.00029553444
substantiated O 0 0.00046828412
that O 0 0.00022746717
Pgp O 0 0.98409814
is O 0 0.00027321844
functional O 0 0.00024189771
and O 0 0.00025066955
compensates O 0 0.00022726473
for O 0 0.000279359
the O 0 0.00035490142
lack O 0 0.0005167654
of O 0 0.0017656266
MRP2 O 0 0.9995035
in O 0 0.0022407381
the O 0 0.0037867234
BBB O 0 0.9957553
. O 0 0.008353922

CONCLUSIONS O 0 0.016041372
: O 0 0.003745885
The O 0 0.001655982
data O 0 0.0014195396
on O 0 0.0010033905
TR O 0 0.92491275
( O 0 0.0044465214
- O 0 0.022761563
) O 0 0.0010460909
rats O 0 0.00050828996
indicate O 0 0.0002365254
that O 0 0.00032312583
Pgp O 0 0.95238274
plays O 0 0.00028759622
an O 0 0.00032730578
important O 0 0.00020699305
role O 0 0.00020190638
in O 0 0.000298481
the O 0 0.00036486107
compensation O 0 0.0011375693
of O 0 0.002708741
MRP2 O 0 0.99991786
deficiency O 0 0.84185
in O 0 0.002370557
the O 0 0.003849173
BBB O 0 0.9960848
. O 0 0.008300339

Because O 0 0.0030939102
such O 0 0.0021700952
a O 0 0.0019181928
compensatory O 0 0.0015669127
mechanism O 0 0.0009215868
most O 0 0.00109393
likely O 0 0.00050342985
occurs O 0 0.00035251168
to O 0 0.00027678
reduce O 0 0.00024135427
injury B-Disease 0 0.5491751
to I-Disease 0 0.00021690773
the I-Disease 0 0.00023345771
brain I-Disease 0 0.0047776294
from O 0 0.00020700647
cytotoxic O 0 0.32918048
compounds O 0 0.7041618
, O 0 0.00042610976
the O 0 0.00017534319
present O 0 0.00013385659
data O 0 0.00016793657
substantiate O 0 0.0001456648
the O 0 0.0001849564
concept O 0 0.00027707356
that O 0 0.00037771495
MRP2 O 0 0.9994486
performs O 0 0.000752247
a O 0 0.0007232663
protective O 0 0.001711766
role O 0 0.0008741219
in O 0 0.0017610623
the O 0 0.00346316
BBB O 0 0.99607486
. O 0 0.008343914

Furthermore O 0 0.0046811495
, O 0 0.0033164679
our O 0 0.0017178055
data O 0 0.0012098582
suggest O 0 0.0006607817
that O 0 0.0008688805
TR O 0 0.9839304
( O 0 0.010917223
- O 0 0.05232014
) O 0 0.0011219431
rats O 0 0.00046990908
are O 0 0.00022411808
an O 0 0.00021339826
interesting O 0 0.00012784911
tool O 0 0.0001986178
to O 0 0.0001539013
study O 0 0.00021661754
consequences O 0 0.00024165612
of O 0 0.00023699582
overexpression O 0 0.0003703864
of O 0 0.0016752586
Pgp O 0 0.9976561
in O 0 0.00030106984
the O 0 0.00033840624
BBB O 0 0.9894338
on O 0 0.00011493842
access O 0 0.0001406034
of O 0 0.00021971986
drugs O 0 0.04444443
in O 0 0.00017368121
the O 0 0.0001998718
brain O 0 0.00848132
, O 0 0.00027006507
without O 0 0.00015146798
the O 0 0.00014802777
need O 0 0.00014361081
of O 0 0.00028905532
inducing O 0 0.009696822
seizures B-Disease 0 0.99999917
or O 0 0.0007850526
other O 0 0.0018650345
Pgp O 0 0.9979087
- O 0 0.0131933
enhancing O 0 0.00073763204
events O 0 0.002688049
for O 0 0.0012939187
this O 0 0.0020843588
purpose O 0 0.0036866055
. O 0 0.006226507

Role O 0 0.0065970053
of O 0 0.013734411
xanthine B-Chemical 0 0.99999845
oxidase O 0 0.99984086
in O 0 0.025938604
dexamethasone B-Chemical 0 0.9999639
- O 0 0.39950073
induced O 0 0.021030685
hypertension B-Disease 2 0.999992
in O 0 0.0059913383
rats O 0 0.008948386
. O 0 0.008737721

1 O 0 0.09718908
. O 0 0.11277451

Glucocorticoid O 0 0.9978126
- O 0 0.11148401
induced O 0 0.014823694
hypertension B-Disease 2 0.99999785
( O 0 0.16810057
GC O 0 0.9953289
- O 0 0.7249897
HT B-Disease 0 0.99976724
) O 0 0.0020054881
in O 0 0.0005083448
the O 0 0.00047506252
rat O 0 0.0010026208
is O 0 0.00052721804
associated O 0 0.0006991153
with O 0 0.0015055591
nitric B-Chemical 0 0.9994116
oxide I-Chemical 0 0.9957294
- O 0 0.10117462
redox O 0 0.4552576
imbalance O 0 0.042044055
. O 0 0.0076905214

2 O 0 0.09703088
. O 0 0.11310669

We O 0 0.0034839672
studied O 0 0.0023168053
the O 0 0.0014741126
role O 0 0.0010398553
of O 0 0.013958603
xanthine B-Chemical 0 0.9999999
oxidase O 0 0.9999888
( O 0 0.7045565
XO O 0 0.99999976
) O 0 0.022078166
, O 0 0.0007564786
which O 0 0.0003772468
is O 0 0.00022644883
implicated O 0 0.0001627769
in O 0 0.0001710627
the O 0 0.00016555865
production O 0 0.00030664215
of O 0 0.0005512273
reactive O 0 0.8545889
oxygen O 1 0.99953437
species O 0 0.0044532516
, O 0 0.0009255745
in O 0 0.00076737977
dexamethasone B-Chemical 0 0.9999169
- O 0 0.22496076
induced O 0 0.013018149
hypertension B-Disease 2 0.9999993
( O 0 0.1991113
dex B-Chemical 1 0.9999474
- O 0 0.77299756
HT B-Disease 0 0.99946505
) O 0 0.011581964
. O 0 0.00803543

3 O 0 0.0941019
. O 0 0.112802126

Thirty O 0 0.0075198133
male O 0 0.008973276
Sprague O 0 0.10633458
- O 0 0.010985176
Dawley O 0 0.0081575215
rats O 0 0.0012450152
were O 0 0.000626167
divided O 0 0.00037449342
randomly O 0 0.00022947302
into O 0 0.0001927912
four O 0 0.00019569746
treatment O 0 0.00027638284
groups O 0 0.00032507582
: O 0 0.0007556453
saline O 0 0.03798096
, O 0 0.0034454714
dexamethasone B-Chemical 0 0.99992037
( O 0 0.0622162
dex B-Chemical 1 0.99994063
) O 0 0.039687123
, O 0 0.014398994
allopurinol B-Chemical 0 0.9999981
plus O 0 0.00067044375
saline O 0 0.0492585
, O 0 0.0012641938
and O 0 0.0032772738
allopurinol B-Chemical 0 0.99999535
plus O 0 0.006776811
dex B-Chemical 1 0.99939084
. O 0 0.009799974

4 O 0 0.09295644
. O 0 0.11234677

Systolic O 0 0.76971513
blood O 0 0.015463422
pressures O 0 0.009654169
( O 0 0.004664582
SBP O 0 0.5457332
) O 0 0.002941418
and O 0 0.001997343
bodyweights O 0 0.012878608
were O 0 0.0015994604
recorded O 0 0.0016538941
each O 0 0.0016306931
alternate O 0 0.003382619
day O 0 0.004612107
. O 0 0.008472706

Thymus O 0 0.11696456
weight O 0 0.005894387
was O 0 0.002079754
used O 0 0.001217554
as O 0 0.0009695362
a O 0 0.00096731033
marker O 0 0.0009818891
of O 0 0.0013278824
glucocorticoid O 0 0.95313543
activity O 0 0.0011116068
, O 0 0.0010212351
and O 0 0.000980905
serum O 0 0.5131261
urate B-Chemical 0 0.99720615
to O 0 0.0012949747
assess O 0 0.0016116038
XO O 0 0.999969
inhibition O 0 0.018093782
. O 0 0.0078827385

5 O 0 0.08913488
. O 0 0.11072463

Dex B-Chemical 1 0.9985049
increased B-Disease 0 0.19835488
SBP I-Disease 0 0.99546754
( O 0 0.0037110257
110 O 0 0.0029782406
+ O 0 0.0032370677
/ O 0 0.010559393
- O 0 0.011048174
2 O 0 0.00061833236
- O 0 0.0024925582
126 O 0 0.0015598345
+ O 0 0.0016204464
/ O 0 0.0073189004
- O 0 0.0057407646
3 O 0 0.00026223084
mmHg O 0 0.0010355366
; O 0 0.00051575113
P O 0 0.011933674
< O 0 0.00023975495
0 O 0 0.00028909056
. O 0 0.00025778243
001 O 0 0.025381569
) O 0 0.00042496138
and O 0 0.00026930348
decreased B-Disease 0 0.0003483576
thymus I-Disease 0 0.0023880827
( I-Disease 0 0.0015196741
P I-Disease 0 0.08264675
< I-Disease 0 0.00027025823
0 I-Disease 0 0.00033017475
. I-Disease 0 0.0003021205
001 I-Disease 0 0.029308932
) I-Disease 0 0.0005723856
and I-Disease 0 0.00047516372
bodyweights I-Disease 0 0.08938774
( O 0 0.0010389577
P O 0 0.030186892
" O 0 0.0009980766
< O 0 0.00093057496
0 O 0 0.001487011
. O 0 0.0020870792
01 O 0 0.0060667824
) O 0 0.006330136
. O 0 0.008476422

Allopurinol B-Chemical 0 0.99997854
decreased O 0 0.009816239
serum O 0 0.6958664
urate B-Chemical 0 0.9978654
from O 0 0.0008957624
76 O 0 0.0015893907
+ O 0 0.0025198776
/ O 0 0.0073463167
- O 0 0.0027230706
5 O 0 0.00023394235
to O 0 0.00019202929
30 O 0 0.0002120709
+ O 0 0.0006361748
/ O 0 0.003648158
- O 0 0.0047398526
3 O 0 0.00022497616
micromol O 0 0.10357122
/ O 0 0.027868737
L O 0 0.9763583
( O 0 0.0023853977
P O 0 0.077950455
< O 0 0.00023575047
0 O 0 0.0002802981
. O 0 0.00024002028
001 O 0 0.03118086
) O 0 0.0003847622
in O 0 0.00019539746
saline O 0 0.0009817891
and O 0 0.00018358702
from O 0 0.0001508951
84 O 0 0.0003302909
+ O 0 0.0010007074
/ O 0 0.005943987
- O 0 0.0037428753
13 O 0 0.00019949883
to O 0 0.00014384423
28 O 0 0.00021883132
+ O 0 0.0007872221
/ O 0 0.0063445047
- O 0 0.008167637
2 O 0 0.0002534776
micromol O 0 0.13465936
/ O 0 0.026335977
L O 0 0.9700955
in O 0 0.0012217218
dex B-Chemical 1 0.9998318
- O 0 0.064187855
treated O 0 0.0008453187
( O 0 0.0011689657
P O 0 0.032799922
< O 0 0.0006674706
0 O 0 0.000983791
. O 0 0.0012763682
01 O 0 0.0036393155
) O 0 0.003494439
groups O 0 0.0043815607
. O 0 0.0075341803

6 O 0 0.0877012
. O 0 0.109906055

Allopurinol B-Chemical 0 0.99994385
did O 0 0.012568617
not O 0 0.009044275
prevent O 0 0.012675048
dex B-Chemical 1 0.99964976
- O 0 0.77391934
HT B-Disease 0 0.9986992
. O 0 0.02383172

This O 0 0.0057395203
, O 0 0.0032462273
together O 0 0.001623196
with O 0 0.0012402915
our O 0 0.00085518736
previous O 0 0.0006153322
findings O 0 0.000866009
that O 0 0.00071586214
allopurinol B-Chemical 0 0.999998
failed O 0 0.000709546
to O 0 0.0002702227
prevent O 0 0.0005154595
adrenocorticotrophic O 0 0.9994516
hormone O 0 0.99083406
induced O 0 0.032389686
hypertension B-Disease 2 0.99999976
, O 0 0.0038455273
suggests O 0 0.00020569454
that O 0 0.00053556915
XO O 0 0.9999988
activity O 0 0.0004171459
is O 0 0.00023777148
not O 0 0.00019540677
a O 0 0.0002752185
major O 0 0.00029947612
determinant O 0 0.00031339703
of O 0 0.0013338277
GC O 0 0.97399545
- O 0 0.35983655
HT B-Disease 0 0.99835616
in O 0 0.0018347673
the O 0 0.002653073
rat O 0 0.0070282486
. O 0 0.0071156113

Side O 0 0.30040976
effects O 0 0.0033427654
of O 0 0.0022135286
postoperative O 0 0.005134654
administration O 0 0.009812948
of O 0 0.0022974866
methylprednisolone B-Chemical 0 0.9999645
and O 0 0.0038826042
gentamicin B-Chemical 1 0.9996338
into O 0 0.00036196513
the O 0 0.00053308706
posterior O 0 0.043520954
sub O 0 0.011710337
- O 0 0.020350074
Tenon O 0 0.28642243
' O 0 0.002600918
s O 0 0.003105874
space O 0 0.0046176305
. O 0 0.0073373266

PURPOSE O 0 0.004938346
: O 0 0.0029990913
To O 0 0.0012648568
assess O 0 0.00070505193
the O 0 0.000761328
incidence O 0 0.0014166447
of O 0 0.0008696222
postoperative O 0 0.02835395
emetic O 0 0.9719101
side O 0 0.03718698
effects O 0 0.00040303505
after O 0 0.00013893137
the O 0 0.00018735582
administration O 0 0.0021718247
of O 0 0.00085722166
methylprednisolone B-Chemical 0 0.9999641
and O 0 0.002306289
gentamicin B-Chemical 1 0.99965334
into O 0 0.000121620615
the O 0 0.00019418687
posterior O 0 0.046438176
sub O 0 0.01404716
- O 0 0.03048704
Tenon O 0 0.36052307
' O 0 0.00044804197
s O 0 0.0003420328
space O 0 0.00031335943
at O 0 0.0002926454
the O 0 0.00038436407
end O 0 0.00047353373
of O 0 0.0010687665
routine O 0 0.00219459
cataract B-Disease 2 0.9991536
surgery O 0 0.009970976
. O 0 0.00681794

SETTING O 0 0.07605909
: O 0 0.06887393
St O 0 0.09688305
. O 0 0.075250834

Luke O 0 0.03285636
' O 0 0.014033925
s O 0 0.012622393
Hospital O 0 0.016823133
, O 0 0.014850313
Gwardamangia O 0 0.038905688
, O 0 0.019133098
Malta O 0 0.058145277
. O 0 0.023018043

METHODS O 0 0.004278052
: O 0 0.0042724777
A O 0 0.008851044
double O 0 0.0024761988
- O 0 0.006317534
blind O 0 0.007555242
double O 0 0.0012472899
- O 0 0.0047623906
armed O 0 0.00575946
prospective O 0 0.001148987
study O 0 0.0004672661
comprised O 0 0.0003280393
40 O 0 0.00028353525
patients O 0 0.00029062625
who O 0 0.0002688171
had O 0 0.00017590249
uneventful O 0 0.00021328553
sutureless O 0 0.005319063
phacoemulsification O 0 0.7539195
under O 0 0.00021619374
sub O 0 0.008670619
- O 0 0.028072855
Tenon O 0 0.3715303
' O 0 0.0005042095
s O 0 0.00041029902
local O 0 0.00058917876
infiltration O 0 0.08855587
of O 0 0.00067978457
3 O 0 0.000682496
mL O 0 0.001743651
of O 0 0.0021621564
plain O 0 0.12228353
lignocaine B-Chemical 0 0.9994779
. O 0 0.0079526

At O 0 0.0027440654
the O 0 0.0019527709
end O 0 0.0012178591
of O 0 0.0011592739
the O 0 0.0008131117
procedure O 0 0.00072634564
, O 0 0.001136263
Group O 0 0.03435649
A O 0 0.08045186
( O 0 0.00063911313
n O 0 0.00032349228
= O 0 0.00054535177
20 O 0 0.00025230672
) O 0 0.0003291706
had O 0 0.00018140755
20 O 0 0.00018901919
mg O 0 0.004620939
/ O 0 0.0009569743
0 O 0 0.00022139461
. O 0 0.00014818198
5 O 0 0.00013565422
mL O 0 0.0003414563
of O 0 0.00029445754
methylprednisolone B-Chemical 0 0.99951756
and O 0 0.0002808668
10 O 0 0.00017861328
mg O 0 0.008052316
/ O 0 0.0010448028
0 O 0 0.0001984637
. O 0 0.00013275353
5 O 0 0.00012533322
mL O 0 0.00033144763
of O 0 0.00027463137
gentamicin B-Chemical 1 0.99810827
injected O 0 0.00017235482
into O 0 9.328423e-05
the O 0 0.00015037369
posterior O 0 0.028423073
sub O 0 0.012317145
- O 0 0.02946765
Tenon O 0 0.35318798
' O 0 0.00032483911
s O 0 0.00022980866
space O 0 0.00020324822
and O 0 0.000277035
Group O 0 0.028745405
B O 0 0.63163406
( O 0 0.00050223956
n O 0 0.0002167688
= O 0 0.00045522954
20 O 0 0.0002029558
) O 0 0.0002926401
had O 0 0.00016032966
the O 0 0.00015149066
same O 0 0.00012678151
combination O 0 0.00020155919
injected O 0 0.00019034924
into O 0 0.00017321201
the O 0 0.00034332817
anterior O 0 0.017680883
sub O 0 0.0075064343
- O 0 0.018748326
Tenon O 0 0.29559192
' O 0 0.0024165304
s O 0 0.0029019252
space O 0 0.0043629208
. O 0 0.0069945385

Postoperatively O 0 0.009388168
, O 0 0.0037370638
all O 0 0.0019053455
patients O 0 0.0016356481
were O 0 0.001052198
assessed O 0 0.0007865368
for O 0 0.000960572
symptoms O 0 0.16439718
of O 0 0.009982067
nausea B-Disease 2 0.9999993
, I-Disease 0 0.083385736
vomiting I-Disease 0 0.9999825
, O 0 0.007876249
and O 0 0.0117636975
headache B-Disease 0 0.9998312
. O 0 0.009372836

A O 0 0.21668467
chi O 0 0.29717436
- O 0 0.015041951
square O 0 0.0030531788
test O 0 0.0019332689
was O 0 0.0013756793
used O 0 0.0009948906
to O 0 0.00087918213
assess O 0 0.0006915887
the O 0 0.0011106969
statistical O 0 0.002054604
significance O 0 0.0021788066
of O 0 0.003713948
results O 0 0.005486386
. O 0 0.009369087

RESULTS O 0 0.0063067605
: O 0 0.004082907
Sixty O 0 0.0029400242
percent O 0 0.0013872016
in O 0 0.0013996982
Group O 0 0.007148107
A O 0 0.02147762
developed O 0 0.0012920559
postoperative B-Disease 0 0.06025849
emetic I-Disease 0 0.9840809
symptoms I-Disease 0 0.9268632
, O 0 0.010419474
headache B-Disease 0 0.9999629
, O 0 0.00072352315
or O 0 0.00034755218
both O 0 0.00039604836
; O 0 0.0007229962
1 O 0 0.0004698645
patient O 0 0.00061313546
in O 0 0.00089223165
Group O 0 0.018807516
B O 0 0.57584894
developed O 0 0.008900967
symptoms O 0 0.41058144
. O 0 0.0074731256

CONCLUSIONS O 0 0.02071717
: O 0 0.0035411704
The O 0 0.0015217273
administration O 0 0.0032654575
of O 0 0.002215351
methylprednisolone B-Chemical 0 0.9999591
and O 0 0.007965838
gentamicin B-Chemical 1 0.9998661
in O 0 0.00048389586
the O 0 0.00033973256
posterior O 0 0.05613053
sub O 0 0.018733576
- O 0 0.0389199
Tenon O 0 0.43501055
' O 0 0.00042625176
s O 0 0.00028422024
space O 0 0.00022043036
was O 0 0.00017133009
related O 0 0.00012141875
to O 0 0.00014470679
a O 0 0.00022192491
high O 0 0.00028716712
incidence O 0 0.00081788684
of O 0 0.00041171795
side O 0 0.024034949
effects O 0 0.0009836616
including O 0 0.004085339
nausea B-Disease 2 0.9999995
, I-Disease 0 0.06679318
vomiting I-Disease 0 0.99998486
, O 0 0.0064062644
and O 0 0.011100558
headache B-Disease 0 0.9998455
. O 0 0.007907172

All O 0 0.009514403
adverse O 0 0.06039604
effects O 0 0.009255456
were O 0 0.008836457
self O 0 0.015309567
- O 0 0.020028371
limiting O 0 0.016155183
. O 0 0.020310214

Assessment O 0 0.0040629
of O 0 0.0028345976
a O 0 0.0022758134
new O 0 0.0019428422
non O 0 0.0027973666
- O 0 0.009992822
invasive O 0 0.0016809527
index O 0 0.000839284
of O 0 0.00072867435
cardiac O 0 0.021138724
performance O 0 0.0007136477
for O 0 0.00043448678
detection O 0 0.0009030225
of O 0 0.0026336082
dobutamine B-Chemical 1 0.99997544
- O 0 0.17351952
induced O 0 0.012502868
myocardial B-Disease 0 0.99995756
ischemia I-Disease 2 0.9999875
. O 0 0.015363495

BACKGROUND O 0 0.024154378
: O 0 0.0058886
Electrocardiography O 0 0.030447798
has O 0 0.0016221097
a O 0 0.0014907192
very O 0 0.0013215571
low O 0 0.0011756618
sensitivity O 0 0.0017136991
in O 0 0.0010303417
detecting O 0 0.002714723
dobutamine B-Chemical 1 0.9999647
- O 0 0.16364318
induced O 0 0.013258432
myocardial B-Disease 0 0.9999554
ischemia I-Disease 2 0.99998736
. O 0 0.016902944

OBJECTIVES O 0 0.0048474907
: O 0 0.0029758855
To O 0 0.0012536411
assess O 0 0.0006917811
the O 0 0.00071144593
added O 0 0.0005942533
diagnostic O 0 0.0006326266
value O 0 0.00040232163
of O 0 0.00044844783
a O 0 0.00045229794
new O 0 0.00045192946
cardiac O 0 0.013905452
performance O 0 0.00047415547
index O 0 0.0004058031
( O 0 0.0005790096
dP O 0 0.019943532
/ O 0 0.0062907785
dtejc O 0 0.017626164
) O 0 0.00046681002
measurement O 0 0.0001572874
, O 0 0.00023436766
based O 0 0.00017499311
on O 0 0.00013331676
brachial O 0 0.48157236
artery O 0 0.05322449
flow O 0 0.0025118026
changes O 0 0.0002951374
, O 0 0.00022774083
as O 0 0.00013003827
compared O 0 0.00010193606
to O 0 0.00011411129
standard O 0 0.00012995908
12 O 0 0.00015307762
- O 0 0.0020528417
lead O 0 0.016831273
ECG O 0 0.8554361
, O 0 0.00027137238
for O 0 0.00016817196
detecting O 0 0.0005808004
dobutamine B-Chemical 1 0.9999682
- O 0 0.0715136
induced O 0 0.0013008917
myocardial B-Disease 0 0.99997914
ischemia I-Disease 2 0.9999982
, O 0 0.0022832982
using O 0 0.00036064023
Tc99m B-Chemical 0 0.99694544
- I-Chemical 0 0.096218295
Sestamibi I-Chemical 0 0.9917217
single O 0 0.00029549023
- O 0 0.0016324533
photon O 0 0.010173777
emission O 0 0.054241326
computed O 0 0.0002613308
tomography O 0 0.0008798287
as O 0 0.0001881417
the O 0 0.00020628316
gold O 0 0.03633977
standard O 0 0.00019140849
of O 0 0.00024239409
comparison O 0 0.00020585151
to O 0 0.00021003342
assess O 0 0.00018333824
the O 0 0.0003497354
presence O 0 0.00053642795
or O 0 0.00085068075
absence O 0 0.0012912976
of O 0 0.010286524
ischemia B-Disease 2 0.9999658
. O 0 0.011645088

METHODS O 0 0.0044860416
: O 0 0.0039215717
The O 0 0.0020371703
study O 0 0.00190441
group O 0 0.0014498442
comprised O 0 0.0010776023
40 O 0 0.00095460395
patients O 0 0.0010419
undergoing O 0 0.0012483723
Sestamibi B-Chemical 0 0.9794998
- O 0 0.05830603
SPECT O 0 0.9677385
/ O 0 0.05560762
dobutamine B-Chemical 1 0.9997782
stress O 0 0.33768925
test O 0 0.007508243
. O 0 0.009445521

Simultaneous O 0 0.006986833
measurements O 0 0.002588565
of O 0 0.0028582013
ECG O 0 0.60466653
and O 0 0.0018920798
brachial O 0 0.69604355
artery O 0 0.15546489
dP O 0 0.022134725
/ O 0 0.0032163602
dtejc O 0 0.0033441447
were O 0 0.0008103873
performed O 0 0.0007934512
at O 0 0.001048751
each O 0 0.0014819142
dobutamine B-Chemical 1 0.99513537
level O 0 0.0043163784
. O 0 0.008059292

In O 0 0.0044673667
19 O 0 0.0035147483
of O 0 0.0022227776
the O 0 0.0015507266
40 O 0 0.0013457726
patients O 0 0.0013764906
perfusion O 0 0.025755467
defects O 0 0.0014744961
compatible O 0 0.0013895702
with O 0 0.0019269914
ischemia B-Disease 2 0.99991643
were O 0 0.0017600732
detected O 0 0.0019233293
on O 0 0.003059659
SPECT O 0 0.87977105
. O 0 0.008925086

The O 0 0.0032041871
increase O 0 0.0021822783
in O 0 0.0019279325
dP O 0 0.023318287
/ O 0 0.006357866
dtejc O 0 0.0065816203
during O 0 0.00050249905
infusion O 0 0.0012606687
of O 0 0.0009411537
dobutamine B-Chemical 1 0.999882
in O 0 0.00042700596
this O 0 0.00030646852
group O 0 0.00037266736
was O 0 0.00027788308
severely O 0 0.00095830223
impaired O 0 0.00038004556
as O 0 0.00028042909
compared O 0 0.0002767161
to O 0 0.00040904558
the O 0 0.00069093244
non O 0 0.0031104055
- O 0 0.15025772
ischemic O 0 0.99982184
group O 0 0.009347421
. O 0 0.0073091164

dP O 0 0.04159589
/ O 0 0.010202523
dtejc O 0 0.012895417
outcome O 0 0.0027781464
was O 0 0.0011028071
combined O 0 0.00087665766
with O 0 0.00066662475
the O 0 0.0006306139
ECG O 0 0.58290577
results O 0 0.0003475245
, O 0 0.00048561709
giving O 0 0.0005934623
an O 0 0.000828255
ECG O 0 0.9380441
- O 0 0.0041014366
enhanced O 0 0.00038549432
value O 0 0.0004886866
, O 0 0.00075553014
and O 0 0.0007616767
compared O 0 0.0008160675
to O 0 0.0015560538
ECG O 0 0.57073843
alone O 0 0.0037353034
. O 0 0.0068386937

RESULTS O 0 0.0055208756
: O 0 0.0035065329
The O 0 0.0016083905
sensitivity O 0 0.001984704
improved O 0 0.0012449548
dramatically O 0 0.0008367478
from O 0 0.00056305324
16 O 0 0.0005340905
% O 0 0.0004386412
to O 0 0.00028491725
79 O 0 0.00045712787
% O 0 0.00033800877
, O 0 0.000306218
positive O 0 0.00029596192
predictive O 0 0.00059560797
value O 0 0.0002135672
increased O 0 0.00022711848
from O 0 0.00016260704
60 O 0 0.0001829422
% O 0 0.00018888155
to O 0 0.0001355239
68 O 0 0.00024698008
% O 0 0.000189531
and O 0 0.00016723268
negative O 0 0.00022080605
predictive O 0 0.00044013964
value O 0 0.00017752344
from O 0 0.00016836096
54 O 0 0.00032084656
% O 0 0.0002327656
to O 0 0.00017998458
78 O 0 0.00039857937
% O 0 0.0003231677
, O 0 0.00035377196
and O 0 0.00034731187
specificity O 0 0.0010602429
decreased O 0 0.0005860427
from O 0 0.00051952223
90 O 0 0.00073093263
% O 0 0.0011335982
to O 0 0.0014112331
67 O 0 0.003301272
% O 0 0.004643699
. O 0 0.0072226184

CONCLUSIONS O 0 0.026867297
: O 0 0.0044178013
If O 0 0.0022622137
ECG O 0 0.44832182
alone O 0 0.001112342
is O 0 0.00074383116
used O 0 0.0004861363
for O 0 0.00044276257
specificity O 0 0.003023964
, O 0 0.00066250167
the O 0 0.00029511523
combination O 0 0.0003916561
with O 0 0.00040834997
dP O 0 0.049896955
/ O 0 0.011046689
dtejc O 0 0.01620383
improved O 0 0.00029037613
the O 0 0.0001675003
sensitivity O 0 0.00046709558
of O 0 0.00023320188
the O 0 0.00018438873
test O 0 0.00020803772
and O 0 0.00021464938
could O 0 0.00013976515
be O 0 0.00016722757
a O 0 0.00023883641
cost O 0 0.00043390878
- O 0 0.003856906
savings O 0 0.00051808916
alternative O 0 0.00015084591
to O 0 0.00015032038
cardiac O 0 0.0064672544
imaging O 0 0.00055474474
or O 0 0.00018246035
perfusion O 0 0.009720798
studies O 0 0.00018048639
to O 0 0.00017980342
detect O 0 0.0002975437
myocardial B-Disease 0 0.99991274
ischemia I-Disease 2 0.99999607
, O 0 0.0021043408
especially O 0 0.0009079773
in O 0 0.0006485583
patients O 0 0.0010581355
unable O 0 0.001091071
to O 0 0.0020381168
exercise O 0 0.0070248153
. O 0 0.006286073

Cocaine B-Chemical 0 0.99998474
- O 0 0.20054351
induced O 0 0.01534004
myocardial B-Disease 0 0.9999689
infarction I-Disease 2 0.99999905
: O 0 0.020659316
clinical O 0 0.0055339755
observations O 0 0.0025399206
and O 0 0.0033027017
pathogenetic O 0 0.009299257
considerations O 0 0.0065525793
. O 0 0.009864363

Clinical O 0 0.008816383
and O 0 0.0027061787
experimental O 0 0.0018131118
data O 0 0.001263359
published O 0 0.00082978443
to O 0 0.00055306795
date O 0 0.00042405186
suggest O 0 0.0002678904
several O 0 0.00028781345
possible O 0 0.00031291667
mechanisms O 0 0.00032159593
by O 0 0.00049454643
which O 0 0.002406194
cocaine B-Chemical 1 0.9999771
may O 0 0.00067055493
result O 0 0.0007935964
in O 0 0.0019716753
acute B-Disease 2 0.99916136
myocardial I-Disease 2 0.9999908
infarction I-Disease 2 0.9999995
. O 0 0.03956586

In O 0 0.0037140483
individuals O 0 0.002896288
with O 0 0.0018287592
preexisting O 0 0.013647639
, O 0 0.0022052934
high O 0 0.0026881988
- O 0 0.0424048
grade O 0 0.19318877
coronary O 0 0.44513333
arterial O 0 0.6377105
narrowing O 0 0.10576319
, O 0 0.004141464
acute B-Disease 2 0.9987551
myocardial I-Disease 2 0.99999785
infarction I-Disease 2 1.0
may O 0 0.0006094774
result O 0 0.00019068166
from O 0 0.0001599833
an O 0 0.00021948492
increase O 0 0.0001606392
in O 0 0.00035537846
myocardial O 0 0.99971527
oxygen B-Chemical 1 0.9990663
demand O 0 0.000999822
associated O 0 0.0005130157
with O 0 0.0034556934
cocaine B-Chemical 1 0.9999956
- O 0 0.028418088
induced O 0 0.00042452404
increase O 0 0.00044028755
in O 0 0.0006887629
rate O 0 0.0013988267
- O 0 0.021079576
pressure O 0 0.074077524
product O 0 0.0052648163
. O 0 0.0068584

In O 0 0.0037595246
other O 0 0.0024901906
individuals O 0 0.0021632677
with O 0 0.0012672177
no O 0 0.00085111207
underlying O 0 0.009312266
atherosclerotic B-Disease 2 0.99999714
obstruction I-Disease 0 0.9994332
, O 0 0.010900415
coronary B-Disease 0 0.51078194
occlusion I-Disease 0 0.44011366
may O 0 0.00033583707
be O 0 0.0003493981
due O 0 0.00034868682
to O 0 0.0006760316
spasm B-Disease 2 0.9999329
, O 0 0.00872538
thrombus B-Disease 0 0.99955803
, O 0 0.0030588242
or O 0 0.0024468994
both O 0 0.003996203
. O 0 0.0071721748

With O 0 0.004096321
regard O 0 0.002292761
to O 0 0.0023067421
spasm B-Disease 2 0.9997428
, O 0 0.0019751056
the O 0 0.00075285125
clinical O 0 0.0012371212
findings O 0 0.0005325835
are O 0 0.00033196752
largely O 0 0.00040233388
circumstantial O 0 0.0009935352
, O 0 0.00053640496
and O 0 0.00038831678
the O 0 0.00035586668
locus O 0 0.00077100476
of O 0 0.0036133581
cocaine B-Chemical 1 0.9999956
- O 0 0.1201774
induced O 0 0.0032480378
vasoconstriction O 0 0.9993661
remains O 0 0.0039468682
speculative O 0 0.020457182
. O 0 0.007594095

Although O 0 0.0030966909
certain O 0 0.002554195
clinical O 0 0.0028417164
and O 0 0.0012043908
experimental O 0 0.0008757843
findings O 0 0.00074182294
support O 0 0.00038762964
the O 0 0.00037184422
hypothesis O 0 0.00041685693
that O 0 0.00043938993
spasm B-Disease 2 0.9998385
involves O 0 0.00028456922
the O 0 0.0003096546
epicardial O 0 0.024873953
, O 0 0.00065516407
medium O 0 0.0038268515
- O 0 0.0067756437
size O 0 0.00062230404
vessels O 0 0.016898103
, O 0 0.0007616168
other O 0 0.0007619362
data O 0 0.0010845766
suggest O 0 0.0013325308
intramural O 0 0.35036838
vasoconstriction O 0 0.99869764
. O 0 0.0083835125

Diffuse O 0 0.3567743
intramural O 0 0.33309498
vasoconstriction O 0 0.9989587
is O 0 0.0021697693
not O 0 0.0012256731
consistent O 0 0.0010626181
with O 0 0.0010679292
reports O 0 0.001229188
of O 0 0.0017172816
segmental O 0 0.02642731
, O 0 0.004366752
discrete O 0 0.010555339
infarction B-Disease 2 0.9999871
. O 0 0.013467192

Whereas O 0 0.003946441
certain O 0 0.0027269698
in O 0 0.0017438967
vivo O 0 0.0015801919
data O 0 0.00089514634
suggest O 0 0.0004306492
that O 0 0.00040423867
these O 0 0.00046618393
effects O 0 0.0006367869
are O 0 0.000599493
alpha O 0 0.8854332
- O 0 0.044820093
mediated O 0 0.00036609534
, O 0 0.00077559723
other O 0 0.0005392699
in O 0 0.0005592105
vitro O 0 0.00084590685
data O 0 0.0009874146
suggest O 0 0.000997294
the O 0 0.0020896539
opposite O 0 0.004825816
. O 0 0.007187041

The O 0 0.003276712
finding O 0 0.0036416834
of O 0 0.0075424425
cocaine B-Chemical 1 0.99999464
- O 0 0.294546
induced O 0 0.002865155
vasoconstriction O 0 0.99960047
in O 0 0.0005499363
segments O 0 0.00047466528
of O 0 0.00043481824
( O 0 0.0008542784
noninnervated O 0 0.02355824
) O 0 0.0008214516
human O 0 0.0005138759
umbilical O 0 0.025463706
artery O 0 0.040079396
suggests O 0 0.00011896254
that O 0 0.0001198342
the O 0 0.00014061038
presence O 0 0.00015374554
or O 0 0.00015363973
absence O 0 0.000119208606
of O 0 0.0002652629
intact O 0 0.0003260013
innervation O 0 0.008003809
is O 0 0.00017535892
not O 0 0.00013030079
sufficient O 0 0.00011323524
to O 0 0.00012575532
explain O 0 0.00012403881
the O 0 0.0001727795
discrepant O 0 0.00048486618
data O 0 0.00022688409
involving O 0 0.00023512215
the O 0 0.0002821766
possibility O 0 0.00037185426
of O 0 0.0011349726
alpha O 0 0.8309497
- O 0 0.0533668
mediated O 0 0.0021141297
effects O 0 0.00594188
. O 0 0.0073326956

Finally O 0 0.004771684
, O 0 0.0035086744
the O 0 0.0018124612
contribution O 0 0.0012414177
of O 0 0.00138131
a O 0 0.0013915938
primary O 0 0.0014432624
, O 0 0.0036499838
thrombotic B-Disease 2 0.9997043
effect O 0 0.0013794398
of O 0 0.007398639
cocaine B-Chemical 1 0.9999846
has O 0 0.0014600569
not O 0 0.0016720719
been O 0 0.0026132776
excluded O 0 0.0044531124
. O 0 0.0074120844

Proteomic O 0 0.011245573
analysis O 0 0.0030779208
of O 0 0.002841476
striatal O 0 0.50758064
proteins O 0 0.0016560623
in O 0 0.0009996935
the O 0 0.0008473961
rat O 0 0.0014362412
model O 0 0.0010141898
of O 0 0.006861532
L B-Chemical 0 0.999882
- I-Chemical 0 0.9789697
DOPA I-Chemical 0 0.99999833
- O 0 0.2421702
induced O 0 0.026692279
dyskinesia B-Disease 0 0.999995
. O 0 0.012486542

L B-Chemical 0 0.999338
- I-Chemical 0 0.9634416
DOPA I-Chemical 0 0.99999654
- O 0 0.33929786
induced O 0 0.030314645
dyskinesia B-Disease 0 0.99999976
( O 0 0.3355307
LID B-Disease 0 0.9999819
) O 0 0.0035003119
is O 0 0.00043674326
among O 0 0.00040877724
the O 0 0.00028705763
motor O 0 0.007517658
complications O 0 0.028747298
that O 0 0.00015514648
arise O 0 0.00016762382
in O 0 0.0004028121
Parkinson B-Disease 0 0.9994438
' I-Disease 0 0.0006995272
s I-Disease 0 0.00070551183
disease I-Disease 0 0.92153764
( O 0 0.015040622
PD B-Disease 0 0.99990547
) O 0 0.00094886625
patients O 0 0.00039187475
after O 0 0.00022634912
a O 0 0.00042999143
prolonged O 0 0.0006783805
treatment O 0 0.0010244669
with O 0 0.0040466683
L B-Chemical 0 0.9994573
- I-Chemical 0 0.9222551
DOPA I-Chemical 0 0.9999838
. O 0 0.008978281

To O 0 0.0029266358
this O 0 0.002168351
day O 0 0.0015122736
, O 0 0.0015153904
transcriptome O 0 0.0010636867
analysis O 0 0.00071327714
has O 0 0.00048330057
been O 0 0.00038896466
performed O 0 0.0002901603
in O 0 0.00030433168
a O 0 0.00037477398
rat O 0 0.0005993907
model O 0 0.00035512412
of O 0 0.0034210128
LID B-Disease 0 0.9999901
[ O 0 0.1219787
Neurobiol O 0 0.96542
. O 0 0.0003714118
Dis O 0 0.5594221
. O 0 0.00025126728
, O 0 0.0003495042
17 O 0 0.00032426516
( O 0 0.0003709217
2004 O 0 0.0007202633
) O 0 0.00063276105
, O 0 0.00054064655
219 O 0 0.0038927696
] O 0 0.0007003406
but O 0 0.00039102303
information O 0 0.00034635776
regarding O 0 0.00034514195
the O 0 0.00060603005
proteome O 0 0.0015179747
is O 0 0.0014453303
still O 0 0.0020388938
lacking O 0 0.0030063146
. O 0 0.0069206627

In O 0 0.0035266224
the O 0 0.0021476694
present O 0 0.0013835285
study O 0 0.001443412
, O 0 0.0010623473
we O 0 0.0004445022
investigated O 0 0.00036679336
the O 0 0.00035085413
changes O 0 0.00041012422
occurring O 0 0.00034945176
at O 0 0.00018835998
the O 0 0.0001895818
protein O 0 0.00039329095
level O 0 0.00018803804
in O 0 0.0002619652
striatal O 0 0.36671945
samples O 0 0.00014900404
obtained O 0 0.00011413066
from O 0 0.00011106268
the O 0 0.00014243866
unilaterally O 0 0.011351334
6 B-Chemical 0 0.00016222404
- I-Chemical 0 0.013285622
hydroxydopamine I-Chemical 0 0.9331077
- O 0 0.021896087
lesion O 0 0.0504164
rat O 0 0.00080614473
model O 0 0.00026837506
of O 0 0.0020431
PD B-Disease 0 0.99991107
treated O 0 0.00045721282
with O 0 0.00036949254
saline O 0 0.062793024
, O 0 0.006426599
L B-Chemical 0 0.99988425
- I-Chemical 0 0.9514451
DOPA I-Chemical 0 0.9999993
or O 0 0.0015295823
bromocriptine B-Chemical 0 0.9999745
using O 0 0.00021201832
two O 0 0.00019222402
- O 0 0.0007374096
dimensional O 0 0.00035035724
difference O 0 0.0002664812
gel O 0 0.0024834236
electrophoresis O 0 0.013374879
and O 0 0.0008899239
mass O 0 0.0036084503
spectrometry O 0 0.27645275
( O 0 0.005147773
MS O 2 0.9941723
) O 0 0.008322785
. O 0 0.008771328

Rats O 0 0.010982881
treated O 0 0.0037662652
with O 0 0.0065134238
L B-Chemical 0 0.99966335
- I-Chemical 0 0.92002255
DOPA I-Chemical 0 0.99999416
were O 0 0.0007986207
allocated O 0 0.00041667934
to O 0 0.00034322307
two O 0 0.00030732556
groups O 0 0.00036329468
based O 0 0.00038799178
on O 0 0.00032606255
the O 0 0.00051489065
presence O 0 0.0007448568
or O 0 0.0011170172
absence O 0 0.0016223228
of O 0 0.013069444
LID B-Disease 0 0.9998565
. O 0 0.0094774095

Among O 0 0.00523195
the O 0 0.002445268
2000 O 0 0.0024267915
spots O 0 0.0017127711
compared O 0 0.0006819706
for O 0 0.0006136032
statistical O 0 0.0008286842
difference O 0 0.00036392335
, O 0 0.0005491203
67 O 0 0.0005508224
spots O 0 0.00055381074
were O 0 0.00024951427
significantly O 0 0.00021327153
changed O 0 0.00019441584
in O 0 0.00016858973
abundance O 0 0.00021182455
and O 0 0.00021119797
identified O 0 0.00016717016
using O 0 0.00019128222
matrix O 0 0.002872846
- O 0 0.008109057
assisted O 0 0.0007700715
laser O 0 0.066878535
desorption O 0 0.8364724
/ O 0 0.011288244
ionization O 0 0.2916881
time O 0 0.00020070063
- O 0 0.0024150305
of O 0 0.00044803065
- O 0 0.02527553
flight O 0 0.019364715
MS O 2 0.9994624
, O 0 0.0009158786
atmospheric O 0 0.6495873
pressure O 0 0.090019986
matrix O 0 0.00459882
- O 0 0.0067323316
assisted O 0 0.0007860265
laser O 0 0.054799635
desorption O 0 0.8306282
/ O 0 0.014250505
ionization O 0 0.49792796
and O 0 0.0006388521
HPLC O 0 0.6010138
coupled O 0 0.0005265328
tandem O 0 0.0012650501
MS O 2 0.997825
( O 0 0.0024627233
LC O 0 0.6954263
/ O 0 0.07966191
MS O 2 0.99945635
/ O 0 0.16390754
MS O 2 0.9983714
) O 0 0.010255472
. O 0 0.009386012

Out O 0 0.0075908075
of O 0 0.0029521189
these O 0 0.0021058826
67 O 0 0.0023967833
proteins O 0 0.0021434696
, O 0 0.0072065564
LID B-Disease 0 0.999853
significantly O 0 0.0006938543
changed O 0 0.00037440154
the O 0 0.0002609061
expression O 0 0.00026094588
level O 0 0.00019015244
of O 0 0.000232802
five O 0 0.00015731096
proteins O 0 0.00033916885
: O 0 0.0012694587
alphabeta O 0 0.73560846
- O 0 0.08304838
crystalin O 0 0.06789346
, O 0 0.0023076225
gamma O 0 0.9889571
- O 0 0.4723801
enolase O 0 0.9830036
, O 0 0.004137973
guanidoacetate O 0 0.9372864
methyltransferase O 0 0.79981005
, O 0 0.0011112097
vinculin O 0 0.4949041
, O 0 0.0013008397
and O 0 0.0011094962
proteasome O 0 0.6751465
alpha O 0 0.93903446
- O 0 0.10258983
2 O 0 0.0029013418
subunit O 0 0.01351374
. O 0 0.008910626

Complementary O 0 0.0044781733
techniques O 0 0.0024776524
such O 0 0.0015016311
as O 0 0.001180792
western O 0 0.0018305915
immunoblotting O 0 0.0010455577
and O 0 0.0006923721
immunohistochemistry O 0 0.0013919936
were O 0 0.00035714085
performed O 0 0.00024876412
to O 0 0.00021962226
investigate O 0 0.00015258738
the O 0 0.0002484889
validity O 0 0.00037644475
of O 0 0.0004133967
the O 0 0.00044274802
data O 0 0.0005626791
obtained O 0 0.0006185908
using O 0 0.0008819384
the O 0 0.0013621157
proteomic O 0 0.003484353
approach O 0 0.004189676
. O 0 0.0069220187

In O 0 0.0042277714
conclusion O 0 0.0026181068
, O 0 0.0027494358
this O 0 0.001589097
study O 0 0.0013792028
provides O 0 0.00086407445
new O 0 0.0009595237
insights O 0 0.0006823016
into O 0 0.0005487687
the O 0 0.0008482723
protein O 0 0.0017346687
changes O 0 0.0022168118
occurring O 0 0.0037603122
in O 0 0.0051490623
LID B-Disease 0 0.999603
. O 0 0.009484132

Cardiac O 0 0.10341843
Angiography O 0 0.012356032
in O 0 0.002589097
Renally O 0 0.047389682
Impaired O 0 0.0039285105
Patients O 0 0.0015867823
( O 0 0.001335383
CARE O 0 0.029373158
) O 0 0.0010292454
study O 0 0.0005673646
: O 0 0.000539822
a O 0 0.00035899098
randomized O 0 0.00030547648
double O 0 0.00034409916
- O 0 0.003157779
blind O 0 0.0047146403
trial O 0 0.0003220556
of O 0 0.00031371156
contrast O 0 0.00076523214
- O 0 0.027596809
induced O 0 0.002311459
nephropathy B-Disease 2 0.99999964
in O 0 0.0012524847
patients O 0 0.0019926575
with O 0 0.0019016992
chronic B-Disease 0 0.9922463
kidney I-Disease 0 0.989115
disease I-Disease 0 0.9987068
. O 0 0.0116047105

BACKGROUND O 0 0.017610684
: O 0 0.0040135877
No O 0 0.0023310725
direct O 0 0.0011504753
comparisons O 0 0.0007876427
exist O 0 0.000609453
of O 0 0.00062337966
the O 0 0.0005480502
renal O 0 0.6493952
tolerability O 0 0.015749538
of O 0 0.0003241403
the O 0 0.00025462912
low O 0 0.0007148062
- O 0 0.028930513
osmolality O 0 0.812601
contrast B-Chemical 0 0.013668819
medium I-Chemical 0 0.39906517
iopamidol B-Chemical 1 0.99783224
with O 0 0.00019723183
that O 0 0.00012848008
of O 0 0.00024576634
the O 0 0.00041585017
iso O 0 0.9933437
- O 0 0.054168537
osmolality O 0 0.7504865
contrast B-Chemical 0 0.0057243705
medium I-Chemical 0 0.19396518
iodixanol B-Chemical 1 0.99032265
in O 0 0.00077370857
high O 0 0.0018708328
- O 0 0.015021885
risk O 0 0.10262889
patients O 0 0.007218643
. O 0 0.006861747

METHODS O 0 0.004291563
AND O 0 0.0025837412
RESULTS O 0 0.002638618
: O 0 0.0020495572
The O 0 0.0010686228
present O 0 0.00080582104
study O 0 0.0008817267
is O 0 0.0006673198
a O 0 0.0007534164
multicenter O 0 0.022540601
, O 0 0.00064210076
randomized O 0 0.00041272468
, O 0 0.0004214895
double O 0 0.00041721232
- O 0 0.006132013
blind O 0 0.0046220534
comparison O 0 0.00019404343
of O 0 0.0004616844
iopamidol B-Chemical 1 0.9955902
and O 0 0.00052521226
iodixanol B-Chemical 1 0.96399266
in O 0 0.00019630407
patients O 0 0.00029618997
with O 0 0.00032692973
chronic B-Disease 0 0.9828272
kidney I-Disease 0 0.987159
disease I-Disease 0 0.99829966
( O 0 0.0015614786
estimated O 0 0.00027442144
glomerular O 0 0.77578485
filtration O 0 0.0016951552
rate O 0 0.00023209324
, O 0 0.00024858656
20 O 0 0.00015571725
to O 0 0.00014138359
59 O 0 0.00028740047
mL O 0 0.00055956846
/ O 0 0.00073440553
min O 0 0.00041937316
) O 0 0.0005269588
who O 0 0.00048452363
underwent O 0 0.0004737651
cardiac O 0 0.00705085
angiography O 0 0.023089018
or O 0 0.0010020136
percutaneous O 0 0.0024733325
coronary O 0 0.04402784
interventions O 0 0.004062371
. O 0 0.0067484463

Serum O 0 0.8736275
creatinine B-Chemical 1 0.99908483
( O 0 0.021706855
SCr O 0 0.99413955
) O 0 0.0019866102
levels O 0 0.00068207784
and O 0 0.0005896585
estimated O 0 0.000509198
glomerular O 0 0.56747043
filtration O 0 0.0014360031
rate O 0 0.0003339435
were O 0 0.0002493711
assessed O 0 0.00018918615
at O 0 0.00021039201
baseline O 0 0.00024968086
and O 0 0.0003112802
2 O 0 0.00031861887
to O 0 0.0003332375
5 O 0 0.00043535302
days O 0 0.0005469004
after O 0 0.00089087675
receiving O 0 0.002452524
medications O 0 0.029941449
. O 0 0.006100409

The O 0 0.0030982047
primary O 0 0.0024179446
outcome O 0 0.0022282773
was O 0 0.001185797
a O 0 0.0011753029
postdose O 0 0.03713512
SCr O 0 0.9397758
increase O 0 0.00038518943
> O 0 0.00082775415
or O 0 0.0003500304
= O 0 0.00069898734
0 O 0 0.00031850746
. O 0 0.00022211985
5 O 0 0.00021259322
mg O 0 0.004087955
/ O 0 0.0018721706
dL O 0 0.02050229
( O 0 0.0005445401
44 O 0 0.00048676555
. O 0 0.0003638061
2 O 0 0.00048391017
micromol O 0 0.048127986
/ O 0 0.009077793
L O 0 0.799758
) O 0 0.0027523453
over O 0 0.001966232
baseline O 0 0.0039193747
. O 0 0.006809911

Secondary O 0 0.009422012
outcomes O 0 0.0031716875
were O 0 0.0016620022
a O 0 0.0015436133
postdose O 0 0.031827603
SCr O 0 0.9403609
increase O 0 0.00050817366
> O 0 0.0010431475
or O 0 0.00042156404
= O 0 0.0007665071
25 O 0 0.00037708157
% O 0 0.00033657576
, O 0 0.00031549679
a O 0 0.0002808403
postdose O 0 0.0009119392
estimated O 0 0.0001815167
glomerular O 0 0.27800235
filtration O 0 0.0007436688
rate O 0 0.00021579894
decrease O 0 0.00019840655
of O 0 0.0003139982
> O 0 0.0009318046
or O 0 0.00029222274
= O 0 0.00072599994
25 O 0 0.00036307052
% O 0 0.0003803259
, O 0 0.0004062881
and O 0 0.000385475
the O 0 0.00040261418
mean O 0 0.0004372156
peak O 0 0.000989805
change O 0 0.0015660543
in O 0 0.0028435597
SCr O 0 0.9651271
. O 0 0.0073527843

In O 0 0.004481874
414 O 0 0.00975804
patients O 0 0.0026276496
, O 0 0.0017975861
contrast O 0 0.0011982784
volume O 0 0.0016533368
, O 0 0.00095804397
presence O 0 0.0006060098
of O 0 0.0034950764
diabetes B-Disease 0 0.9999877
mellitus I-Disease 0 0.99993825
, O 0 0.00258681
use O 0 0.0004196895
of O 0 0.0030630555
N B-Chemical 0 0.9999919
- I-Chemical 0 0.8333484
acetylcysteine I-Chemical 0 0.99998665
, O 0 0.0004076831
mean O 0 0.00012881597
baseline O 0 0.0002716134
SCr O 0 0.9277845
, O 0 0.0002774582
and O 0 0.00022660261
estimated O 0 0.0002617515
glomerular O 0 0.44294038
filtration O 0 0.001060115
rate O 0 0.00039458787
were O 0 0.00041670733
comparable O 0 0.0004248423
in O 0 0.0007480314
the O 0 0.001194052
2 O 0 0.0019420093
groups O 0 0.0033255871
. O 0 0.006277843

SCr O 0 0.9624421
increases O 0 0.0030108055
> O 0 0.00362641
or O 0 0.0014484124
= O 0 0.0018644363
0 O 0 0.00085329893
. O 0 0.0005172715
5 O 0 0.00040387487
mg O 0 0.005346204
/ O 0 0.0018240911
dL O 0 0.008216716
occurred O 0 0.00028415959
in O 0 0.00024184377
4 O 0 0.00020351348
. O 0 0.0001886857
4 O 0 0.00017667706
% O 0 0.00023777375
( O 0 0.0002747141
9 O 0 0.00018019766
of O 0 0.00020934588
204 O 0 0.00090921146
patients O 0 0.00029139203
) O 0 0.00035555058
after O 0 0.00016536334
iopamidol B-Chemical 1 0.9758322
and O 0 0.00021968846
6 O 0 0.00013501671
. O 0 0.00014028575
7 O 0 0.00013884847
% O 0 0.00019919622
( O 0 0.00023366346
14 O 0 0.0001574406
of O 0 0.00017876271
210 O 0 0.0005289526
patients O 0 0.00026228407
) O 0 0.00032675365
after O 0 0.00015541048
iodixanol B-Chemical 1 0.97792405
( O 0 0.0013285385
P O 0 0.14337486
= O 0 0.0006893188
0 O 0 0.00025527034
. O 0 0.00018093042
39 O 0 0.0003102382
) O 0 0.0003833857
, O 0 0.00027194165
whereas O 0 0.0001971243
rates O 0 0.00023140713
of O 0 0.00051217
SCr O 0 0.9930443
increases O 0 0.0002643921
> O 0 0.00085334206
or O 0 0.00022793049
= O 0 0.00052256667
25 O 0 0.00023129706
% O 0 0.00021073974
were O 0 0.00016317287
9 O 0 0.00015628563
. O 0 0.00015140402
8 O 0 0.00015949484
% O 0 0.00020380206
and O 0 0.00020831285
12 O 0 0.00017370722
. O 0 0.00019385644
4 O 0 0.00021229486
% O 0 0.00033243527
, O 0 0.00046624144
respectively O 0 0.0013265173
( O 0 0.0012077258
P O 0 0.048343662
= O 0 0.0016643559
0 O 0 0.0014046517
. O 0 0.0017612006
44 O 0 0.003652228
) O 0 0.00592034
. O 0 0.008214106

In O 0 0.0039098826
patients O 0 0.0032085532
with O 0 0.003393713
diabetes B-Disease 0 0.99981433
, O 0 0.019735282
SCr O 0 0.99657106
increases O 0 0.00073956477
> O 0 0.0014014369
or O 0 0.00041640492
= O 0 0.0008040691
0 O 0 0.00032598112
. O 0 0.00021054209
5 O 0 0.00018818316
mg O 0 0.0033658938
/ O 0 0.0013175047
dL O 0 0.0075822556
were O 0 0.000191085
5 O 0 0.00015354586
. O 0 0.00016094923
1 O 0 0.00017448093
% O 0 0.00022020747
( O 0 0.00025441265
4 O 0 0.00015101703
of O 0 0.00018356004
78 O 0 0.00033393872
patients O 0 0.00027172058
) O 0 0.00037454432
with O 0 0.00036639595
iopamidol B-Chemical 1 0.98901737
and O 0 0.00023445796
13 O 0 0.00019593774
. O 0 0.00014401633
0 O 0 0.00017942308
% O 0 0.00020775072
( O 0 0.00023026027
12 O 0 0.00012555691
of O 0 0.0001608127
92 O 0 0.00030552247
patients O 0 0.0002465521
) O 0 0.00034189475
with O 0 0.00034278817
iodixanol B-Chemical 1 0.98959607
( O 0 0.001649223
P O 0 0.15004848
= O 0 0.00065177394
0 O 0 0.00023881547
. O 0 0.00016783556
11 O 0 0.00019702585
) O 0 0.00033463538
, O 0 0.00030916167
whereas O 0 0.00041193582
SCr O 0 0.98552936
increases O 0 0.00024260241
> O 0 0.0007513074
or O 0 0.00022587481
= O 0 0.00052608957
25 O 0 0.00023378714
% O 0 0.00021137203
were O 0 0.00016093712
10 O 0 0.00015402095
. O 0 0.00015083383
3 O 0 0.00014902324
% O 0 0.00019879076
and O 0 0.00020046844
15 O 0 0.00018389641
. O 0 0.00020109964
2 O 0 0.00023493571
% O 0 0.00034030405
, O 0 0.0004712094
respectively O 0 0.0013336417
( O 0 0.0011969034
P O 0 0.046075497
= O 0 0.0016367908
0 O 0 0.0013904896
. O 0 0.0017440709
37 O 0 0.0036791237
) O 0 0.0059892656
. O 0 0.00821953

Mean O 0 0.0026343013
post O 0 0.00293278
- O 0 0.028367989
SCr O 0 0.95822614
increases O 0 0.0010244342
were O 0 0.00068268983
significantly O 0 0.00049308443
less O 0 0.0003940392
with O 0 0.00064426987
iopamidol B-Chemical 1 0.99590296
( O 0 0.00047235933
all O 0 0.00020266749
patients O 0 0.0002984039
: O 0 0.00035136356
0 O 0 0.00023365612
. O 0 0.00018598285
07 O 0 0.0008601847
versus O 0 0.0001574684
0 O 0 0.0001942013
. O 0 0.00014929275
12 O 0 0.00013663864
mg O 0 0.0023114746
/ O 0 0.0015671327
dL O 0 0.019780785
, O 0 0.0003030534
6 O 0 0.00014307244
. O 0 0.0001416058
2 O 0 0.00013664372
versus O 0 0.00012941656
10 O 0 0.00014658732
. O 0 0.00014158298
6 O 0 0.00014079714
micromol O 0 0.03536883
/ O 0 0.017077792
L O 0 0.972112
, O 0 0.0019470499
P O 0 0.19062907
= O 0 0.0008379087
0 O 0 0.00031553555
. O 0 0.00025051137
03 O 0 0.008574307
; O 0 0.00033282058
patients O 0 0.00029366752
with O 0 0.00044509114
diabetes B-Disease 0 0.99974865
: O 0 0.0015947814
0 O 0 0.0002817734
. O 0 0.0001836511
07 O 0 0.00096167275
versus O 0 0.00015123448
0 O 0 0.00019134754
. O 0 0.00015239295
16 O 0 0.00019182013
mg O 0 0.0044047674
/ O 0 0.0020436437
dL O 0 0.022268757
, O 0 0.00031885653
6 O 0 0.00015508274
. O 0 0.00015884613
2 O 0 0.00016025933
versus O 0 0.00016122617
14 O 0 0.00020175743
. O 0 0.00020871883
1 O 0 0.00027208173
micromol O 0 0.052505754
/ O 0 0.015689218
L O 0 0.9511028
, O 0 0.0021516
P O 0 0.093361706
= O 0 0.0019442304
0 O 0 0.0016164845
. O 0 0.0021147893
01 O 0 0.006058082
) O 0 0.0062709632
. O 0 0.008423797

CONCLUSIONS O 0 0.016874474
: O 0 0.0034914245
The O 0 0.001467616
rate O 0 0.0012647362
of O 0 0.0011953675
contrast O 0 0.0020456258
- O 0 0.050261553
induced O 0 0.0055175517
nephropathy B-Disease 2 0.9999999
, O 0 0.004672712
defined O 0 0.0003082628
by O 0 0.00023776923
multiple O 0 0.00024023297
end O 0 0.00013518523
points O 0 0.00020198281
, O 0 0.00027963772
is O 0 0.00018305177
not O 0 0.00014534818
statistically O 0 0.00013502341
different O 0 0.000111532514
after O 0 9.88907e-05
the O 0 0.00015792823
intraarterial O 0 0.01582491
administration O 0 0.001023943
of O 0 0.0004932767
iopamidol B-Chemical 1 0.99619305
or O 0 0.00030337716
iodixanol B-Chemical 1 0.953887
to O 0 0.00020233556
high O 0 0.00075557554
- O 0 0.017054267
risk O 0 0.055958007
patients O 0 0.0009271782
, O 0 0.00065143895
with O 0 0.0006802431
or O 0 0.0009922865
without O 0 0.002955642
diabetes B-Disease 0 0.99992776
mellitus I-Disease 0 0.99977905
. O 0 0.011117604

Any O 0 0.0053122705
true O 0 0.0029698038
difference O 0 0.0014824253
between O 0 0.00113242
the O 0 0.0011265137
agents O 0 0.0030735822
is O 0 0.00090970326
small O 0 0.00082773995
and O 0 0.00086286664
not O 0 0.0007759757
likely O 0 0.00092044735
to O 0 0.0010905899
be O 0 0.0018587073
clinically O 0 0.0075248303
significant O 0 0.0044133137
. O 0 0.0078920815

A O 0 0.05563101
novel O 0 0.004684779
compound O 0 0.4072728
, O 0 0.0043028025
maltolyl B-Chemical 1 0.27316594
p I-Chemical 1 0.003594224
- I-Chemical 1 0.2676953
coumarate I-Chemical 1 0.99636453
, O 0 0.0026013956
attenuates O 0 0.028207535
cognitive B-Disease 2 0.9995109
deficits I-Disease 2 0.9922609
and O 0 0.0004184295
shows O 0 0.00021496702
neuroprotective O 0 0.07679527
effects O 0 0.00045120975
in O 0 0.00037369994
vitro O 0 0.00063598994
and O 0 0.000817074
in O 0 0.001103231
vivo O 0 0.006324209
dementia B-Disease 0 0.99993813
models O 0 0.0061119846
. O 0 0.0074525513

To O 0 0.0030206032
develop O 0 0.002302484
a O 0 0.0018255136
novel O 0 0.0013333228
and O 0 0.0011055924
effective O 0 0.0010341904
drug O 0 0.15875414
that O 0 0.00035174613
could O 0 0.00026271457
enhance O 0 0.00020394279
cognitive O 0 0.46263912
function O 0 0.00030217375
and O 0 0.00057067757
neuroprotection O 0 0.7745666
, O 0 0.00039001115
we O 0 0.00013669547
newly O 0 0.0002694406
synthesized O 0 0.00038265708
maltolyl B-Chemical 1 0.12129029
p I-Chemical 1 0.0008782537
- I-Chemical 1 0.09379114
coumarate I-Chemical 1 0.9796139
by O 0 0.00038495616
the O 0 0.00044642956
esterification O 0 0.95758575
of O 0 0.006987283
maltol B-Chemical 0 0.999997
and O 0 0.0023669077
p B-Chemical 0 0.002701653
- I-Chemical 0 0.2949383
coumaric I-Chemical 0 0.99989843
acid I-Chemical 0 0.9573487
. O 0 0.009245055

In O 0 0.0035706686
the O 0 0.002181074
present O 0 0.0014086537
study O 0 0.0014568382
, O 0 0.0010749312
we O 0 0.00045656346
investigated O 0 0.00037799575
whether O 0 0.00028228533
maltolyl B-Chemical 1 0.07709946
p I-Chemical 1 0.0012444628
- I-Chemical 1 0.13010131
coumarate I-Chemical 1 0.9829128
could O 0 0.00022826105
improve O 0 0.0001798523
cognitive B-Disease 0 0.6532056
decline I-Disease 0 0.011382054
in O 0 0.002061877
scopolamine B-Chemical 1 0.9999999
- O 0 0.040005915
injected O 0 0.00020994153
rats O 0 0.00026517847
and O 0 0.00022640824
in O 0 0.00033332163
amyloid B-Chemical 0 0.99895334
beta I-Chemical 0 0.97943604
peptide I-Chemical 0 0.012755597
( I-Chemical 0 0.0023316238
1 I-Chemical 0 0.00062727655
- I-Chemical 0 0.002841543
42 I-Chemical 0 0.0011266142
) I-Chemical 0 0.0019728437
- O 0 0.005764995
infused O 0 0.0042502135
rats O 0 0.0051967264
. O 0 0.0068242066

Maltolyl B-Chemical 0 0.21084319
p I-Chemical 0 0.006416993
- I-Chemical 0 0.16485429
coumarate I-Chemical 0 0.9795502
was O 0 0.0013079103
found O 0 0.0006800356
to O 0 0.00050307374
attenuate O 0 0.0014124634
cognitive B-Disease 2 0.99915326
deficits I-Disease 2 0.992413
in O 0 0.00030528603
both O 0 0.00024191155
rat O 0 0.00044999077
models O 0 0.00019282465
using O 0 0.00016197366
passive O 0 0.000547745
avoidance O 0 0.0020879188
test O 0 0.00020572456
and O 0 0.00019392985
to O 0 0.00013400754
reduce O 0 0.00013846702
apoptotic O 0 0.6023531
cell O 0 0.058561906
death O 0 0.9995758
observed O 0 0.00026807105
in O 0 0.00020028945
the O 0 0.00021372325
hippocampus O 0 0.0861489
of O 0 0.00025437342
the O 0 0.00037443597
amyloid B-Chemical 0 0.999283
beta I-Chemical 0 0.9829664
peptide I-Chemical 0 0.014477935
( I-Chemical 0 0.0025095695
1 I-Chemical 0 0.0006196963
- I-Chemical 0 0.0029026
42 I-Chemical 0 0.0011113813
) I-Chemical 0 0.0019531727
- O 0 0.0057584723
infused O 0 0.004214007
rats O 0 0.0051501403
. O 0 0.006770402

We O 0 0.003466771
also O 0 0.0021960116
examined O 0 0.001368937
the O 0 0.0013300813
neuroprotective O 0 0.1283538
effects O 0 0.0013291795
of O 0 0.0013063516
maltolyl B-Chemical 1 0.3199376
p I-Chemical 1 0.0019820628
- I-Chemical 1 0.11485659
coumarate I-Chemical 1 0.9810426
in O 0 0.0008113679
vitro O 0 0.0013185033
using O 0 0.0018207808
SH O 0 0.99977595
- O 0 0.43393257
SY5Y O 0 0.9995235
cells O 0 0.011764024
. O 0 0.009713828

Cells O 0 0.006694997
were O 0 0.0027597933
pretreated O 0 0.0034764886
with O 0 0.0017334505
maltolyl B-Chemical 1 0.15904525
p I-Chemical 1 0.0023699175
- I-Chemical 1 0.14897378
coumarate I-Chemical 1 0.98770136
, O 0 0.00076547754
before O 0 0.000260607
exposed O 0 0.00036416922
to O 0 0.0003692735
amyloid B-Chemical 0 0.99880564
beta I-Chemical 0 0.98048097
peptide I-Chemical 0 0.013037585
( I-Chemical 0 0.002392687
1 I-Chemical 0 0.0005911937
- I-Chemical 0 0.0028378745
42 I-Chemical 0 0.00092313223
) I-Chemical 0 0.0016890069
, O 0 0.0032719218
glutamate B-Chemical 1 0.9996269
or O 0 0.008179922
H2O2 B-Chemical 0 0.9999087
. O 0 0.01219225

We O 0 0.0034969088
found O 0 0.002217358
that O 0 0.001656753
maltolyl B-Chemical 1 0.09458249
p I-Chemical 1 0.002936469
- I-Chemical 1 0.16378237
coumarate I-Chemical 1 0.9883249
significantly O 0 0.0008701933
decreased O 0 0.0009908061
apoptotic O 0 0.72373337
cell O 0 0.06437733
death O 0 0.99958926
and O 0 0.0008678243
reduced O 0 0.00053742895
reactive O 0 0.733686
oxygen O 1 0.9989949
species O 0 0.0035226666
, O 0 0.002111367
cytochrome O 0 0.998538
c O 0 0.09931879
release O 0 0.010128829
, O 0 0.0013410909
and O 0 0.001392085
caspase O 0 0.25947452
3 O 0 0.0023356448
activation O 0 0.004498081
. O 0 0.00695184

Taking O 0 0.004296615
these O 0 0.002343721
in O 0 0.0016550833
vitro O 0 0.0015655602
and O 0 0.0011166426
in O 0 0.00071085565
vivo O 0 0.0007386368
results O 0 0.0003993368
together O 0 0.00040663514
, O 0 0.0005445383
our O 0 0.00029342488
study O 0 0.00030338846
suggests O 0 0.00015303413
that O 0 0.00019965372
maltolyl B-Chemical 1 0.11622401
p I-Chemical 1 0.0010954113
- I-Chemical 1 0.16707462
coumarate I-Chemical 1 0.9904868
is O 0 0.0002916327
a O 0 0.00023644108
potentially O 0 0.00025965637
effective O 0 0.00017328816
candidate O 0 0.00022774322
against O 0 0.0007391385
Alzheimer B-Disease 0 0.9999989
' I-Disease 0 0.0029689427
s I-Disease 0 0.0007113564
disease I-Disease 0 0.54566336
that O 0 0.00016503318
is O 0 0.00020047475
characterized O 0 0.00023559407
by O 0 0.0002145041
wide O 0 0.00047387285
spread O 0 0.0061699282
neuronal B-Disease 0 0.9668109
death I-Disease 0 0.9999691
and O 0 0.0018041502
progressive O 0 0.14557897
decline B-Disease 0 0.008447167
of I-Disease 0 0.0024194724
cognitive I-Disease 0 0.7098743
function I-Disease 0 0.003879839
. O 0 0.0067600524

Attenuation O 0 0.063430555
of O 0 0.029540684
methamphetamine B-Chemical 1 0.9999981
- O 0 0.3368328
induced O 0 0.0063907425
nigrostriatal O 0 0.9983368
dopaminergic O 0 0.98537505
neurotoxicity B-Disease 2 0.9999441
in O 0 0.0014352595
mice O 0 0.0012868844
by O 0 0.0029904495
lipopolysaccharide B-Chemical 0 0.9989913
pretreatment O 0 0.7393113
. O 0 0.010056093

Immunological O 0 0.22523981
activation O 0 0.004379716
has O 0 0.0019708006
been O 0 0.0013987989
proposed O 0 0.0010620074
to O 0 0.0007537488
play O 0 0.0007090833
a O 0 0.0008097536
role O 0 0.0005897963
in O 0 0.0021537172
methamphetamine B-Chemical 1 0.99999905
- O 0 0.09624309
induced O 0 0.002594558
dopaminergic B-Disease 0 0.9366047
terminal I-Disease 0 0.019108068
damage I-Disease 0 0.9646054
. O 0 0.009486018

In O 0 0.0038409596
this O 0 0.0025114368
study O 0 0.002098835
, O 0 0.0015029887
we O 0 0.00064509874
examined O 0 0.00047179725
the O 0 0.00044537947
roles O 0 0.00036657904
of O 0 0.0010500187
lipopolysaccharide B-Chemical 0 0.9997131
, O 0 0.002912369
a O 0 0.0009159052
pro O 0 0.17881538
- O 0 0.053882983
inflammatory O 0 0.44658387
and O 0 0.00079724676
inflammatory O 0 0.73144215
factor O 0 0.09144997
, O 0 0.0009298269
treatment O 0 0.0003629961
in O 0 0.00023591326
modulating O 0 0.00025971333
the O 0 0.0014864964
methamphetamine B-Chemical 1 0.9999994
- O 0 0.15673144
induced O 0 0.0070480197
nigrostriatal O 0 0.99935704
dopamine B-Chemical 1 0.99996185
neurotoxicity B-Disease 2 0.999936
. O 0 0.00827481

Lipopolysaccharide B-Chemical 0 0.99889296
pretreatment O 0 0.37722552
did O 0 0.0026694285
not O 0 0.0011568525
affect O 0 0.00070269423
the O 0 0.0006827286
basal O 0 0.0010738841
body O 0 0.0019749561
temperature O 0 0.012854522
or O 0 0.0021737847
methamphetamine B-Chemical 1 0.99999917
- O 0 0.057233714
elicited O 0 0.0014054987
hyperthermia B-Disease 2 0.9962698
three O 0 0.0010890155
days O 0 0.0016835756
later O 0 0.003092247
. O 0 0.006240975

Such O 0 0.007932415
systemic O 0 0.9319086
lipopolysaccharide B-Chemical 0 0.99971753
treatment O 0 0.05344432
mitigated O 0 0.7381801
methamphetamine B-Chemical 1 0.9999999
- O 0 0.47242713
induced O 0 0.0035516026
striatal O 0 0.99698776
dopamine B-Chemical 1 0.9999044
and O 0 0.00048082907
3 B-Chemical 0 0.00025106515
, I-Chemical 0 0.0004161403
4 I-Chemical 0 0.00039111567
- I-Chemical 0 0.30206594
dihydroxyphenylacetic I-Chemical 0 0.99999917
acid I-Chemical 0 0.86940354
depletions O 0 0.07385837
in O 0 0.0005293543
a O 0 0.00086659554
dose O 0 0.0036751025
- O 0 0.0047333534
dependent O 0 0.001956634
manner O 0 0.0037791221
. O 0 0.0070078117

As O 0 0.0031658136
the O 0 0.0022034894
most O 0 0.0020075056
potent O 0 0.002945965
dose O 0 0.00970865
( O 0 0.0016482185
1 O 0 0.00061613973
mg O 0 0.025853083
/ O 0 0.002464302
kg O 0 0.0016676727
) O 0 0.00081949
of O 0 0.000711551
lipopolysaccharide B-Chemical 0 0.9989686
was O 0 0.00032891807
administered O 0 0.00018179734
two O 0 0.00012230469
weeks O 0 0.0001068688
, O 0 0.00018290748
one O 0 0.00012083915
day O 0 0.000105776184
before O 0 8.8657034e-05
or O 0 0.00012165238
after O 0 0.00010663864
the O 0 0.00039241044
methamphetamine B-Chemical 1 0.9999988
dosing O 0 0.014287976
regimen O 0 0.0015466801
, O 0 0.015545926
methamphetamine B-Chemical 1 0.99999976
- O 0 0.12323318
induced O 0 0.0010359095
striatal O 0 0.9935237
dopamine B-Chemical 1 0.9997929
and O 0 0.00034851616
3 B-Chemical 0 0.00023690998
, I-Chemical 0 0.00044426622
4 I-Chemical 0 0.00048423407
- I-Chemical 0 0.276046
dihydroxyphenylacetic I-Chemical 0 0.99999845
acid I-Chemical 0 0.8565683
depletions O 0 0.12022459
remained O 0 0.0025888311
unaltered O 0 0.0037369537
. O 0 0.0067294077

Moreover O 0 0.0055423607
, O 0 0.0058400324
systemic O 0 0.960821
lipopolysaccharide B-Chemical 0 0.99988556
pretreatment O 0 0.8245084
( O 0 0.00491014
1 O 0 0.0006656291
mg O 0 0.03442816
/ O 0 0.0026088904
kg O 0 0.0015237847
) O 0 0.00067301217
attenuated O 0 0.0006347458
local O 0 0.011078167
methamphetamine B-Chemical 1 0.9999995
infusion O 0 0.040633913
- O 0 0.019309035
produced O 0 0.00035182043
dopamine B-Chemical 1 0.9997173
and O 0 0.0003259292
3 B-Chemical 0 0.00017284146
, I-Chemical 0 0.00032795174
4 I-Chemical 0 0.00029761068
- I-Chemical 0 0.40016544
dihydroxyphenylacetic I-Chemical 0 0.99999964
acid I-Chemical 0 0.9116312
depletions O 0 0.12025451
in O 0 0.00017690295
the O 0 0.00022981918
striatum O 0 0.4900601
, O 0 0.0002589012
indicating O 0 0.00012524934
that O 0 0.00011704294
the O 0 0.00016324538
protective O 0 0.0021660207
effect O 0 0.000344277
of O 0 0.0030417917
lipopolysaccharide B-Chemical 0 0.99987304
is O 0 0.0007401109
less O 0 0.00025060406
likely O 0 0.00018711695
due O 0 0.00015363241
to O 0 0.00020279949
interrupted O 0 0.00040198618
peripheral O 0 0.0008683185
distribution O 0 0.00044292133
or O 0 0.000899332
metabolism O 0 0.16467123
of O 0 0.014466589
methamphetamine B-Chemical 1 0.99999344
. O 0 0.008531437

We O 0 0.0037053584
concluded O 0 0.002443803
a O 0 0.0017700932
critical O 0 0.00092088594
time O 0 0.00062188937
window O 0 0.0007325344
for O 0 0.00073174946
systemic O 0 0.94537836
lipopolysaccharide B-Chemical 0 0.99989593
pretreatment O 0 0.4699712
in O 0 0.00044105633
exerting O 0 0.0037251932
effective O 0 0.000516626
protection O 0 0.009326519
against O 0 0.013630486
methamphetamine B-Chemical 1 0.9999999
- O 0 0.40500888
induced O 0 0.014733272
nigrostriatal O 0 0.9995602
dopamine B-Chemical 1 0.9999672
neurotoxicity B-Disease 2 0.99994123
. O 0 0.008505136

Acute O 0 0.969491
myocarditis B-Disease 2 0.99996185
associated O 0 0.06332091
with O 0 0.12906599
clozapine B-Chemical 0 0.999984
. O 0 0.031124774

OBJECTIVE O 0 0.05067131
: O 0 0.0054570516
A O 0 0.035265476
case O 0 0.0020806158
of O 0 0.0025573093
acute O 0 0.99254066
myocarditis B-Disease 2 0.9999995
associated O 0 0.009419759
with O 0 0.000702639
the O 0 0.00032665246
commencement O 0 0.0004008978
of O 0 0.00185184
clozapine B-Chemical 0 0.9999993
is O 0 0.0003922352
described O 0 0.0002290756
, O 0 0.00030336645
highlighting O 0 0.00026056851
the O 0 0.0003013047
onset O 0 0.00069039635
, O 0 0.0005814939
course O 0 0.00056916394
and O 0 0.0008710796
possible O 0 0.001302101
contributing O 0 0.0025557273
factors O 0 0.008321561
. O 0 0.0073373863

There O 0 0.005005898
is O 0 0.0031530561
an O 0 0.0023952331
urgent O 0 0.0018206293
need O 0 0.0010039768
to O 0 0.00078210694
raise O 0 0.0006918042
awareness O 0 0.0014193401
about O 0 0.0006437105
this O 0 0.0007386259
potentially O 0 0.0021610116
fatal O 0 0.98976874
complication O 0 0.8628032
of O 0 0.040952794
clozapine B-Chemical 0 0.99999666
use O 0 0.0061215474
. O 0 0.0074199773

RESULTS O 0 0.0060830093
: O 0 0.0046185115
A O 0 0.014540143
20 O 0 0.002121839
- O 0 0.0038383116
year O 0 0.0013253518
- O 0 0.0029725328
old O 0 0.0008487404
male O 0 0.001954515
with O 0 0.0011541228
schizophrenia B-Disease 2 0.9999387
developed O 0 0.0012127534
a O 0 0.00088694505
sudden O 0 0.9269854
onset O 0 0.0043819626
of O 0 0.0028848227
myocarditis B-Disease 2 0.9999958
after O 0 0.0010998044
commencement O 0 0.0025611494
of O 0 0.009849088
clozapine B-Chemical 0 0.9999927
. O 0 0.008410401

The O 0 0.0076659294
patient O 0 0.0068033123
recovered O 0 0.0054705455
with O 0 0.0063313153
intensive O 0 0.0072422535
medical O 0 0.011997613
support O 0 0.0102082165
. O 0 0.016062696

The O 0 0.0041673738
symptoms O 0 0.017424056
occurred O 0 0.0019687237
around O 0 0.0015012021
2 O 0 0.0011862788
weeks O 0 0.0007913283
after O 0 0.0007953312
starting O 0 0.0013975258
clozapine B-Chemical 0 0.999987
in O 0 0.0018680833
an O 0 0.0025706722
inpatient O 0 0.004922305
setting O 0 0.0047037113
. O 0 0.007949414

Possible O 0 0.0082318
contributing O 0 0.003891679
factors O 0 0.003982064
may O 0 0.0017747037
have O 0 0.0013287663
been O 0 0.0014752194
concomitant O 0 0.013074218
antidepressant B-Chemical 1 0.9998896
use O 0 0.001627983
and O 0 0.0019246009
unaccustomed O 0 0.005272758
physical O 0 0.0053881877
activity O 0 0.004736441
. O 0 0.007918334

CONCLUSIONS O 0 0.060816254
: O 0 0.009862049
Myocarditis B-Disease 0 0.9988097
is O 0 0.0025065134
an O 0 0.0017894555
increasingly O 0 0.0015940337
recognized O 0 0.0015056803
complication O 0 0.083936304
associated O 0 0.0011840651
with O 0 0.0011905488
the O 0 0.0014043936
use O 0 0.0022717242
of O 0 0.007969938
clozapine B-Chemical 0 0.9999914
. O 0 0.009900419

It O 0 0.0074496665
can O 0 0.004262491
be O 0 0.004348901
fatal O 0 0.66711766
if O 0 0.002684655
not O 0 0.0026292945
recognized O 0 0.0034883302
and O 0 0.004175591
treated O 0 0.0059121475
early O 0 0.010711473
. O 0 0.012311611

Considering O 0 0.0029713926
that O 0 0.0029344074
clozapine B-Chemical 0 0.9999895
remains O 0 0.0015923255
the O 0 0.0009085165
gold O 0 0.22800063
standard O 0 0.00040497782
in O 0 0.0003478543
treatment O 0 0.00037593066
of O 0 0.0004626446
resistant O 0 0.0033114986
psychosis B-Disease 0 0.9999851
, O 0 0.00063658546
there O 0 0.00016306089
is O 0 0.00021255715
an O 0 0.00022101733
urgent O 0 0.00025286063
need O 0 0.00013975144
to O 0 0.00013799212
raise O 0 0.00015830786
awareness O 0 0.00081881724
among O 0 0.00039474884
medical O 0 0.0010100577
and O 0 0.00036214647
paramedical O 0 0.0013853109
staff O 0 0.0004399675
involved O 0 0.0002789252
in O 0 0.00039488476
the O 0 0.00052954233
care O 0 0.00088358024
of O 0 0.0013293581
these O 0 0.0022509948
patients O 0 0.004957388
. O 0 0.006425225

There O 0 0.0047881817
are O 0 0.0028302625
also O 0 0.002006621
implications O 0 0.0016607201
for O 0 0.0013856996
recommendations O 0 0.0014635468
and O 0 0.0012529619
regulations O 0 0.0017391308
regarding O 0 0.0010288253
the O 0 0.0015427823
use O 0 0.0025090657
of O 0 0.008062007
clozapine B-Chemical 0 0.99999094
. O 0 0.010599803

Severe O 0 0.970327
rhabdomyolysis B-Disease 0 0.99998593
and O 0 0.021636937
acute B-Disease 0 0.9863055
renal I-Disease 0 0.995559
failure I-Disease 0 0.85573864
secondary O 0 0.039586104
to O 0 0.0005524489
concomitant O 0 0.0019069042
use O 0 0.00067781046
of O 0 0.004311952
simvastatin B-Chemical 1 0.9999975
, O 0 0.10228755
amiodarone B-Chemical 1 0.99999523
, O 0 0.0053477385
and O 0 0.0048837606
atazanavir B-Chemical 0 0.9983707
. O 0 0.008027858

OBJECTIVE O 0 0.01572709
: O 0 0.0035274674
To O 0 0.0016029327
report O 0 0.0020130407
a O 0 0.001257816
case O 0 0.0008676593
of O 0 0.00078302115
a O 0 0.0008391488
severe O 0 0.031895615
interaction O 0 0.000670851
between O 0 0.0005509776
simvastatin B-Chemical 1 0.99999833
, O 0 0.09374598
amiodarone B-Chemical 1 0.99999845
, O 0 0.002338611
and O 0 0.0010145019
atazanavir B-Chemical 0 0.9972248
resulting O 0 0.0005645435
in O 0 0.0012353156
rhabdomyolysis B-Disease 0 0.99999285
and O 0 0.005645074
acute B-Disease 0 0.9785454
renal I-Disease 0 0.9924776
failure I-Disease 0 0.90443194
. O 0 0.009015029

BACKGROUND O 0 0.022644507
: O 0 0.005535829
A O 0 0.06272801
72 O 0 0.0031342977
- O 0 0.0042512473
year O 0 0.0011956162
- O 0 0.0030580577
old O 0 0.00077163585
white O 0 0.0049075964
man O 0 0.013433771
with O 0 0.00042415594
underlying O 0 0.00071868906
human B-Disease 0 0.028507827
immunodeficiency I-Disease 0 0.99999726
virus I-Disease 0 0.99642533
, O 0 0.10146703
atrial B-Disease 0 0.9983259
fibrillation I-Disease 0 0.99999905
, O 0 0.0057269037
coronary B-Disease 0 0.5296596
artery I-Disease 0 0.511516
disease I-Disease 0 0.93301797
, O 0 0.0010613146
and O 0 0.0015501715
hyperlipidemia B-Disease 0 0.9999968
presented O 0 0.0002419217
with O 0 0.00031866177
generalized O 0 0.15026899
pain B-Disease 0 0.97824085
, O 0 0.0013991718
fatigue B-Disease 2 0.97640663
, O 0 0.00057860604
and O 0 0.0005187871
dark O 0 0.0024709993
orange O 0 0.503819
urine O 0 0.18120031
for O 0 0.0012342329
3 O 0 0.0017407916
days O 0 0.0025761705
. O 0 0.0057728277

The O 0 0.0032227568
patient O 0 0.0024412444
was O 0 0.0016547525
taking O 0 0.0017563633
80 O 0 0.0012022966
mg O 0 0.25210124
simvastatin B-Chemical 1 0.99997413
at O 0 0.0005611433
bedtime O 0 0.17306481
( O 0 0.0003746756
initiated O 0 0.00020848733
27 O 0 0.00026006516
days O 0 0.00013748594
earlier O 0 0.00023745997
) O 0 0.00094323227
; O 0 0.004192211
amiodarone B-Chemical 1 0.99998033
at O 0 0.0001892706
a O 0 0.00021871658
dose O 0 0.0005334213
of O 0 0.00023995944
400 O 0 0.00050478947
mg O 0 0.0048777177
daily O 0 0.00015161883
for O 0 0.00011147171
7 O 0 0.00010274154
days O 0 9.017524e-05
, O 0 0.00015598712
then O 0 0.00012022174
200 O 0 0.00022051529
mg O 0 0.0028163076
daily O 0 0.00018098856
( O 0 0.00019999096
initiated O 0 0.00013468342
19 O 0 0.00019248831
days O 0 0.00010460739
earlier O 0 0.00018371362
) O 0 0.00044165918
; O 0 0.0003769818
and O 0 0.00025903448
400 O 0 0.00065571134
mg O 0 0.06370231
atazanavir B-Chemical 0 0.9936259
daily O 0 0.0003926784
( O 0 0.00036257447
initiated O 0 0.00028118485
at O 0 0.00032338282
least O 0 0.00039683975
2 O 0 0.00069257297
years O 0 0.0012800291
previously O 0 0.0020364744
) O 0 0.0048606982
. O 0 0.006834504

Laboratory O 0 0.009266757
evaluation O 0 0.0024504343
revealed O 0 0.0017400227
66 O 0 0.0020034323
, O 0 0.0018521184
680 O 0 0.1010735
U O 0 0.88297474
/ O 0 0.19026609
L O 0 0.99860793
creatine B-Chemical 1 0.99999154
kinase O 0 0.66892016
, O 0 0.0010290792
93 O 0 0.000966021
mg O 0 0.017308494
/ O 0 0.003720793
dL O 0 0.1406195
blood B-Chemical 1 0.829912
urea I-Chemical 1 0.99999833
nitrogen I-Chemical 1 0.9999964
, O 0 0.00092727976
4 O 0 0.0001877344
. O 0 0.0001578764
6 O 0 0.00014454655
mg O 0 0.0022829326
/ O 0 0.002063129
dL O 0 0.122958295
creatinine B-Chemical 1 0.99871385
, O 0 0.0012671206
1579 O 0 0.28849047
U O 0 0.9052686
/ O 0 0.23246568
L O 0 0.9994615
aspartate B-Chemical 1 0.9999988
aminotransferase O 0 0.999949
, O 0 0.0014796074
and O 0 0.0010155211
738 O 0 0.18646303
U O 0 0.8597529
/ O 0 0.14612018
L O 0 0.99581933
alanine B-Chemical 1 0.9997904
aminotransferase O 0 0.99978215
. O 0 0.009832956

Simvastatin B-Chemical 0 0.9999827
, O 0 0.12965794
amiodarone B-Chemical 1 0.9999889
, O 0 0.003910687
and O 0 0.0011933605
the O 0 0.0006811104
patient O 0 0.0006193455
' O 0 0.0006678903
s O 0 0.0006678193
human B-Disease 0 0.008675181
immunodeficiency I-Disease 0 0.999992
virus I-Disease 0 0.9886513
medications O 0 0.45688784
were O 0 0.00026508013
all O 0 0.00018055558
temporarily O 0 0.0005499405
discontinued O 0 0.0007509707
and O 0 0.0002095887
the O 0 0.00019774365
patient O 0 0.0002495864
was O 0 0.00023885441
given O 0 0.00023161374
forced O 0 0.0012708899
alkaline O 0 0.7020247
diuresis O 0 0.9948139
and O 0 0.001166958
started O 0 0.0014082493
on O 0 0.0017243867
dialysis O 0 0.009837322
. O 0 0.0064378036

Nine O 0 0.0051213284
days O 0 0.0020500117
later O 0 0.0015192443
the O 0 0.001153257
patient O 0 0.001055393
' O 0 0.001196229
s O 0 0.0017623333
creatine B-Chemical 1 0.9998853
kinase O 0 0.17464136
had O 0 0.00043450127
dropped O 0 0.00068341824
to O 0 0.00033912683
1695 O 0 0.10694049
U O 0 0.8144834
/ O 0 0.049566325
L O 0 0.96123207
and O 0 0.0015178222
creatinine B-Chemical 1 0.99825996
was O 0 0.00057281787
3 O 0 0.0005047423
. O 0 0.0006540056
3 O 0 0.0009852374
mg O 0 0.0070103547
/ O 0 0.0057143536
dL O 0 0.036575884
. O 0 0.008001768

The O 0 0.0035875326
patient O 0 0.0027557346
was O 0 0.0019320825
discharged O 0 0.0020498985
and O 0 0.0010805987
continued O 0 0.0008299525
outpatient O 0 0.0007772153
dialysis O 0 0.0013042936
for O 0 0.00053255155
1 O 0 0.000544577
month O 0 0.00050242845
until O 0 0.0006573068
his O 0 0.0015168318
renal O 0 0.1419128
function O 0 0.002661762
recovered O 0 0.004008802
. O 0 0.0074677584

DISCUSSION O 0 0.0046741227
: O 0 0.003615036
The O 0 0.0019276959
risk O 0 0.021141121
of O 0 0.0046082465
rhabdomyolysis B-Disease 0 0.999995
is O 0 0.001914325
increased O 0 0.00089319446
in O 0 0.00051258196
the O 0 0.00042724414
presence O 0 0.0004535513
of O 0 0.0007460571
concomitant O 0 0.0059566908
drugs O 0 0.25583988
that O 0 0.001010987
inhibit O 0 0.0025914942
simvastatin B-Chemical 1 0.99998736
metabolism O 0 0.75262433
. O 0 0.008017562

Simvastatin B-Chemical 0 0.99987173
is O 0 0.03479855
metabolized O 0 0.94866484
by O 0 0.043560274
CYP3A4 O 0 0.99989223
. O 0 0.040251315

Amiodarone B-Chemical 1 0.9999076
and O 0 0.017279979
atazanavir B-Chemical 0 0.99793196
are O 0 0.009301103
recognized O 0 0.029029269
CYP3A4 O 0 0.99996686
inhibitors O 0 0.21337035
. O 0 0.018275853

CONCLUSIONS O 0 0.026832612
: O 0 0.0045826635
Pharmacokinetic O 0 0.07974596
differences O 0 0.001366924
in O 0 0.0014683476
statins B-Chemical 1 0.99571395
are O 0 0.000737819
an O 0 0.00058899936
important O 0 0.00037415678
consideration O 0 0.0003863738
for O 0 0.00039335393
assessing O 0 0.00039415905
the O 0 0.00058942754
risk O 0 0.012227312
of O 0 0.0013989208
potential O 0 0.0026388953
drug O 0 0.47237638
interactions O 0 0.008209686
. O 0 0.00786564

In O 0 0.0038203038
patients O 0 0.0026500921
requiring O 0 0.0014769383
the O 0 0.00097037206
concurrent O 0 0.0010490649
use O 0 0.0007428004
of O 0 0.0020050749
statins B-Chemical 1 0.99992716
and O 0 0.08231707
CYP3A4 O 0 0.9999995
inhibitors O 0 0.24326968
, O 0 0.074192256
pravastatin B-Chemical 0 0.9999994
, O 0 0.10183359
fluvastatin B-Chemical 0 0.9999993
, O 0 0.0041691237
and O 0 0.001856603
rosuvastatin B-Chemical 0 0.99997556
carry O 0 0.00016194477
the O 0 0.00016119838
lowest O 0 0.0002825853
risk O 0 0.027609069
of O 0 0.00052096276
drug O 0 0.4984949
interactions O 0 0.006472578
; O 0 0.036950413
atorvastatin B-Chemical 0 0.9999963
carries O 0 0.0022102504
moderate O 0 0.11208915
risk O 0 0.42926893
, O 0 0.0031007007
whereas O 0 0.0058462596
simvastatin B-Chemical 1 0.99999785
and O 0 0.015554048
lovastatin B-Chemical 1 0.9999949
have O 0 0.00021255309
the O 0 0.00020275949
highest O 0 0.00032504945
risk O 0 0.028765662
and O 0 0.00030437816
should O 0 0.00016257184
be O 0 0.00023527128
avoided O 0 0.0003000062
in O 0 0.00041199883
patients O 0 0.0010641352
taking O 0 0.0037974096
concomitant O 0 0.11862334
CYP3A4 O 0 0.9999918
inhibitors O 0 0.16062525
. O 0 0.007691891

Interaction O 0 0.011279797
between O 0 0.007378576
warfarin B-Chemical 1 0.99962974
and O 0 0.015027955
levofloxacin B-Chemical 1 0.99980074
: O 0 0.012424663
case O 0 0.008832753
series O 0 0.011992997
. O 0 0.014681496

Warfarin B-Chemical 0 0.9997124
is O 0 0.0035756852
the O 0 0.0019327125
most O 0 0.0017195743
widely O 0 0.0012056419
used O 0 0.0008944583
oral O 0 0.1986379
anticoagulant O 0 0.9614113
and O 0 0.0008393675
is O 0 0.00070710166
indicated O 0 0.00065830426
for O 0 0.00097308704
many O 0 0.0014855955
clinical O 0 0.003645545
conditions O 0 0.003995116
. O 0 0.0072588697

Levofloxacin B-Chemical 0 0.9996123
, O 0 0.0073572956
a O 0 0.0062134676
fluoroquinolone B-Chemical 0 0.9998443
, O 0 0.003800683
is O 0 0.00091570534
one O 0 0.0004844164
of O 0 0.0004648356
the O 0 0.00036505697
most O 0 0.0005185345
commonly O 0 0.00060212455
prescribed O 0 0.0010350681
antibiotics O 0 0.038707335
in O 0 0.00023124769
clinical O 0 0.0009200226
practice O 0 0.00021769568
and O 0 0.00019380324
is O 0 0.00018457904
effective O 0 0.00021055716
against O 0 0.00030005598
Gram O 0 0.8841915
- O 0 0.026937088
positive O 0 0.0009619541
, O 0 0.0015194288
Gram O 0 0.82447946
- O 0 0.013681142
negative O 0 0.00118266
, O 0 0.0015367226
and O 0 0.0019229952
atypical O 0 0.054346163
bacteria O 0 0.009745874
. O 0 0.0073764245

While O 0 0.0034097037
small O 0 0.0023626103
prospective O 0 0.0024920306
studies O 0 0.0011318205
have O 0 0.00071579905
not O 0 0.00057160103
revealed O 0 0.00049038266
any O 0 0.00040939433
significant O 0 0.000555092
drug O 0 0.7216943
- O 0 0.087487414
drug O 0 0.213767
interaction O 0 0.00043207445
between O 0 0.00030922328
warfarin B-Chemical 1 0.9999722
and O 0 0.005293703
levofloxacin B-Chemical 1 0.9999753
, O 0 0.0006429903
several O 0 0.00015395149
case O 0 0.00018171188
reports O 0 0.00017242105
have O 0 0.00014130499
indicated O 0 0.00016829275
that O 0 0.00029982635
levofloxacin B-Chemical 1 0.99992573
may O 0 0.00039400565
significantly O 0 0.00041472056
potentiate O 0 0.00052321365
the O 0 0.0007134311
anticoagulation O 0 0.6225291
effect O 0 0.0014162449
of O 0 0.007483757
warfarin B-Chemical 1 0.9999012
. O 0 0.007967187

We O 0 0.0039905743
report O 0 0.0035215889
3 O 0 0.0018025142
cases O 0 0.001669239
of O 0 0.0016672313
serious O 0 0.4429176
bleeding B-Disease 0 0.9998147
complications O 0 0.5926344
that O 0 0.00039865292
appear O 0 0.00035347987
to O 0 0.00026006048
be O 0 0.00028651953
the O 0 0.0002736499
result O 0 0.00028555852
of O 0 0.00043562477
the O 0 0.00046602153
interaction O 0 0.000794596
between O 0 0.0011630312
warfarin B-Chemical 1 0.9999225
and O 0 0.01073611
levofloxacin B-Chemical 1 0.9998708
. O 0 0.009261864

Physicians O 0 0.005781899
should O 0 0.0018944623
be O 0 0.0016315116
aware O 0 0.0011894504
of O 0 0.0009773319
this O 0 0.0006689675
potential O 0 0.00062295626
interaction O 0 0.0006341421
and O 0 0.0005853379
use O 0 0.00045219192
caution O 0 0.00048395674
when O 0 0.0004540224
prescribing O 0 0.0208011
levofloxacin B-Chemical 1 0.99962115
to O 0 0.0011451052
patients O 0 0.0037703256
taking O 0 0.02483237
warfarin B-Chemical 1 0.99971706
. O 0 0.007644329

Mutations O 0 0.010346128
associated O 0 0.0031111506
with O 0 0.0067798966
lamivudine B-Chemical 1 0.9999982
- O 0 0.40260947
resistance O 0 0.013859815
in O 0 0.0008819362
therapy O 0 0.021255186
- O 0 0.69843835
na B-Chemical 0 0.99999785
ve O 0 0.99956447
hepatitis B-Disease 2 1.0
B I-Disease 2 0.9999957
virus I-Disease 0 0.9965307
( I-Disease 0 0.298058
HBV I-Disease 0 0.99999475
) I-Disease 0 0.01609323
infected I-Disease 0 0.00081798976
patients O 0 0.0004364862
with O 0 0.00021817672
and O 0 0.0002615736
without O 0 0.00038621767
HIV B-Disease 0 0.9978167
co I-Disease 0 0.9754592
- I-Disease 0 0.36714727
infection I-Disease 2 0.9761564
: O 0 0.0013959031
implications O 0 0.0002520742
for O 0 0.00024910521
antiretroviral O 0 0.14745748
therapy O 0 0.0008332156
in O 0 0.0005224329
HBV B-Disease 0 0.9999558
and I-Disease 0 0.014479228
HIV I-Disease 0 0.9992285
co I-Disease 0 0.9575749
- I-Disease 0 0.06825377
infected I-Disease 0 0.0029944382
South O 0 0.07784636
African O 0 0.12016593
patients O 0 0.0059354035
. O 0 0.00669171

This O 0 0.0052369386
was O 0 0.0026717403
an O 0 0.002009945
exploratory O 0 0.0021680086
study O 0 0.0010384683
to O 0 0.0006205155
investigate O 0 0.00048437537
lamivudine B-Chemical 1 0.99999905
- O 0 0.7019099
resistant O 0 0.16630068
hepatitis B-Disease 2 1.0
B I-Disease 2 0.9999957
virus O 0 0.9971105
( O 0 0.32268015
HBV O 0 0.99999464
) O 0 0.012651254
strains O 0 0.0003768666
in O 0 0.00025454466
selected O 0 0.00058312115
lamivudine B-Chemical 1 0.99999964
- O 0 0.9594935
na B-Chemical 0 0.99999845
ve O 0 0.993665
HBV O 0 0.99999213
carriers O 0 0.14292078
with O 0 0.00041596356
and O 0 0.00031066645
without O 0 0.00029538036
human B-Disease 0 0.017454557
immunodeficiency I-Disease 0 0.9999968
virus I-Disease 0 0.9965017
( I-Disease 0 0.1391017
HIV I-Disease 0 0.9992912
) I-Disease 0 0.044536564
co I-Disease 0 0.880028
- I-Disease 0 0.115270965
infection I-Disease 2 0.92698973
in O 0 0.001773438
South O 0 0.058553375
African O 0 0.1058463
patients O 0 0.005836584
. O 0 0.006642431

Thirty O 0 0.008469087
- O 0 0.011447457
five O 0 0.0027607752
lamivudine B-Chemical 1 0.9999969
- O 0 0.96850395
na B-Chemical 0 0.9999956
ve O 0 0.9967964
HBV B-Disease 0 0.99999845
infected I-Disease 0 0.27933314
patients O 0 0.0017656524
with O 0 0.00042073522
or O 0 0.00032500486
without O 0 0.0005242937
HIV B-Disease 0 0.99795794
co I-Disease 0 0.97462124
- I-Disease 0 0.29390457
infection I-Disease 2 0.9515744
were O 0 0.0003513036
studied O 0 0.00029665433
: O 0 0.0004608749
15 O 0 0.00024337275
chronic O 0 0.81061655
HBV B-Disease 0 0.99999404
mono I-Disease 0 0.9806018
- I-Disease 0 0.07454834
infected I-Disease 0 0.0007003062
patients O 0 0.0006142705
and O 0 0.00047920516
20 O 0 0.0007042636
HBV B-Disease 0 0.9999379
- I-Disease 0 0.5133961
HIV I-Disease 0 0.99843854
co I-Disease 0 0.93187153
- I-Disease 0 0.053002626
infected I-Disease 0 0.0051462906
patients O 0 0.007625109
. O 0 0.0074381805

The O 0 0.0033885494
latter O 0 0.0035502885
group O 0 0.0019889004
was O 0 0.001191977
further O 0 0.0009176452
sub O 0 0.0040355586
- O 0 0.0025057197
divided O 0 0.00037932582
into O 0 0.00026588477
13 O 0 0.0004760626
occult O 0 0.6390792
HBV O 0 0.99999046
( O 0 0.2634251
HBsAg B-Chemical 1 0.99999964
- O 0 0.30148196
negative O 0 0.0012647073
) O 0 0.00091136113
and O 0 0.00043445092
7 O 0 0.0003993212
overt O 0 0.31547624
HBV O 0 0.999972
( O 0 0.14294693
HBsAg B-Chemical 1 0.99999833
- O 0 0.23121524
positive O 0 0.004059058
) O 0 0.0056867534
patients O 0 0.006708828
. O 0 0.007366401

HBsAg B-Chemical 1 0.9999243
, O 0 0.0149038
anti O 0 0.6907676
- O 0 0.5846198
HBs O 0 0.99996996
, O 0 0.0140625695
anti O 0 0.76344293
- O 0 0.4979433
HBc O 0 0.99936515
, O 0 0.0022632675
and O 0 0.0010222625
anti O 0 0.5995904
- O 0 0.33652824
HIV O 0 0.99388486
1 O 0 0.00048891484
/ O 0 0.0013746553
2 O 0 0.0002102382
were O 0 0.00016455783
determined O 0 0.00013659344
as O 0 0.00016226861
part O 0 0.0001620753
of O 0 0.00022718064
routine O 0 0.00024808265
diagnosis O 0 0.0009269393
using O 0 0.0003547086
Axsym O 0 0.87278944
assays O 0 0.000990691
( O 0 0.003921579
Abbott O 0 0.984615
Laboratories O 0 0.6724291
, O 0 0.0018781681
North O 0 0.004567854
Chicago O 0 0.1248732
, O 0 0.0035265686
IL O 0 0.86254394
) O 0 0.011954567
. O 0 0.0089946985

Serum O 0 0.26895604
samples O 0 0.0027386658
were O 0 0.0018549794
PCR O 0 0.006626284
amplified O 0 0.0010434192
with O 0 0.0016699574
HBV O 0 0.9999467
reverse O 0 0.36269075
transcriptase O 0 0.86215234
( O 0 0.0066665406
RT O 0 0.22160618
) O 0 0.00100371
primers O 0 0.00073680235
, O 0 0.0003269643
followed O 0 0.00016290936
by O 0 0.0001777824
direct O 0 0.00015410145
sequencing O 0 0.00031294263
across O 0 0.00012732319
the O 0 0.00025907427
tyrosine B-Chemical 1 0.9864428
- O 0 0.7411251
methionine B-Chemical 0 0.99999344
- O 0 0.9394189
aspartate B-Chemical 1 0.99999917
- O 0 0.95238286
aspartate B-Chemical 1 0.99999785
( O 0 0.09163315
YMDD O 0 0.999959
) O 0 0.0032694112
motif O 0 0.00061260804
of O 0 0.00027157503
the O 0 0.0002100048
major O 0 0.00030593696
catalytic O 0 0.008003947
region O 0 0.0004233204
in O 0 0.000324559
the O 0 0.00050201174
C O 0 0.9939453
domain O 0 0.001063373
of O 0 0.0014317156
the O 0 0.0022013476
HBV O 0 0.9999379
RT O 0 0.83300686
enzyme O 0 0.3611824
. O 0 0.0086676795

HBV O 0 0.99909997
viral O 0 0.24067727
load O 0 0.015628913
was O 0 0.0017503018
performed O 0 0.0010239625
with O 0 0.0016187525
Amplicor O 0 0.9889949
HBV O 0 0.99998236
Monitor O 0 0.77279407
test O 0 0.0018015845
v2 O 0 0.17279057
. O 0 0.0006159947
0 O 0 0.0008056401
( O 0 0.0014259496
Roche O 0 0.15600412
Diagnostics O 0 0.4496695
, O 0 0.005558255
Penzberg O 0 0.7672344
, O 0 0.005103654
Germany O 0 0.051639814
) O 0 0.0077405465
. O 0 0.008649111

HBV O 0 0.9999547
lamivudine B-Chemical 1 0.99999833
- O 0 0.43951485
resistant O 0 0.0021119176
strains O 0 0.0010645599
were O 0 0.0006200608
detected O 0 0.0004115735
in O 0 0.00037146083
3 O 0 0.00028866314
of O 0 0.000317101
15 O 0 0.0003082302
mono O 0 0.14834416
- O 0 0.016881736
infected O 0 0.0057987203
chronic O 0 0.99987197
hepatitis B-Disease 2 1.0
B I-Disease 2 0.999997
patients O 0 0.024695655
and O 0 0.00049026887
10 O 0 0.0002864567
of O 0 0.00039911416
20 O 0 0.0006674786
HBV B-Disease 0 0.9999292
- I-Disease 0 0.4999346
HIV I-Disease 0 0.99841416
co I-Disease 0 0.93236434
- I-Disease 0 0.05331662
infected I-Disease 0 0.005175832
patients O 0 0.007658993
. O 0 0.007460651

To O 0 0.0028544865
the O 0 0.0020381168
best O 0 0.0016079427
of O 0 0.0012825032
our O 0 0.0009366745
knowledge O 0 0.00095701305
, O 0 0.000738659
this O 0 0.00037196264
constitutes O 0 0.00027342566
the O 0 0.00025563958
first O 0 0.00021576502
report O 0 0.0008086023
of O 0 0.0038809835
HBV O 0 0.99999905
lamivudine B-Chemical 1 1.0
- O 0 0.5948127
resistant O 0 0.0006903592
strains O 0 0.00038448372
in O 0 0.00036697465
therapy O 0 0.0065391967
- O 0 0.45470336
na B-Chemical 0 0.99999404
ve O 0 0.99453163
HBV B-Disease 0 0.99999547
- I-Disease 0 0.83817786
HIV I-Disease 0 0.9991234
co I-Disease 0 0.94194543
- I-Disease 0 0.052855648
infected I-Disease 0 0.0051784106
patients O 0 0.007646117
. O 0 0.007563473

The O 0 0.0049034343
HBV O 0 0.9985331
viral O 0 0.18831746
loads O 0 0.032691766
for O 0 0.0020640946
mono O 0 0.7892376
- O 0 0.031098029
infected O 0 0.0010864934
and O 0 0.0011551644
co O 0 0.74719507
- O 0 0.020367777
infected O 0 0.00049263996
patients O 0 0.00033134717
ranged O 0 0.00017410833
from O 0 0.00015855802
3 O 0 0.00015435397
. O 0 0.00014649455
32 O 0 0.00018732296
x O 0 0.00037097567
10 O 0 0.00019342035
( O 0 0.00027433172
2 O 0 0.00018605485
) O 0 0.00026462058
to O 0 0.00015290533
3 O 0 0.00015580666
. O 0 0.00015061721
82 O 0 0.00024698715
x O 0 0.00040139625
10 O 0 0.00019570213
( O 0 0.00026529378
7 O 0 0.00017093486
) O 0 0.00028213792
and O 0 0.00020636912
< O 0 0.0001853473
200 O 0 0.00023611353
to O 0 0.00015740683
4 O 0 0.0001688426
. O 0 0.00017198709
40 O 0 0.00020128647
x O 0 0.00043143175
10 O 0 0.0003102098
( O 0 0.000463313
3 O 0 0.0003996451
) O 0 0.0007369814
copies O 0 0.0008398103
/ O 0 0.0026946238
ml O 0 0.0029151163
, O 0 0.0035560317
respectively O 0 0.007135245
. O 0 0.007969681

It O 0 0.00438066
remains O 0 0.0022334487
to O 0 0.0014252184
be O 0 0.0011124569
seen O 0 0.0007277143
whether O 0 0.00037911054
such O 0 0.0004732991
pre O 0 0.0021750622
- O 0 0.005408003
existing O 0 0.00046957322
antiviral O 0 0.15234342
mutations O 0 0.0107142385
could O 0 0.0002042047
result O 0 0.00017999795
in O 0 0.00021413036
widespread O 0 0.0005670035
emergence O 0 0.00058410875
of O 0 0.0013047415
HBV O 0 0.99997735
resistant O 0 0.002388076
strains O 0 0.0005619692
when O 0 0.0003881871
lamivudine B-Chemical 1 0.9999994
- O 0 0.08954508
containing O 0 0.00018605946
highly O 0 0.00031186506
active O 0 0.001232344
antiretroviral O 0 0.46591315
( O 0 0.0019025953
ARV O 0 0.7496383
) O 0 0.0013979732
treatment O 0 0.00059843145
( O 0 0.00251803
HAART O 0 0.9714425
) O 0 0.0008998986
regimens O 0 0.00033077967
become O 0 0.00021109609
widely O 0 0.00016871611
applied O 0 0.00013399796
in O 0 0.00018811355
South O 0 0.016223688
Africa O 0 0.02619018
, O 0 0.00029275034
as O 0 0.00015875712
this O 0 0.00016283932
is O 0 0.00016717431
likely O 0 0.00014251092
to O 0 0.000119439246
have O 0 0.00012158558
potential O 0 0.00017706478
implications O 0 0.00020542054
in O 0 0.0002165397
the O 0 0.00025925785
management O 0 0.00055779016
of O 0 0.0018128271
HBV B-Disease 0 0.9999913
- I-Disease 0 0.8400206
HIV I-Disease 0 0.9993837
co I-Disease 0 0.95920825
- I-Disease 0 0.06989303
infected I-Disease 0 0.005224476
patients O 0 0.007587553
. O 0 0.0072495877

Rabbit B-Disease 0 0.808004
syndrome I-Disease 0 0.99064064
, O 0 0.026293235
antidepressant B-Chemical 1 0.9998653
use O 0 0.0029150916
, O 0 0.0028703967
and O 0 0.0029284644
cerebral O 0 0.95128345
perfusion O 0 0.49387422
SPECT O 0 0.8963212
scan O 0 0.0070371395
findings O 0 0.007537336
. O 0 0.010095713

The O 0 0.0047910595
rabbit B-Disease 0 0.29727116
syndrome I-Disease 0 0.97072303
is O 0 0.002932122
an O 0 0.0060498705
extrapyramidal O 0 0.9999924
side O 0 0.12462856
effect O 0 0.0012147173
associated O 0 0.0016717648
with O 0 0.0039558844
chronic O 0 0.99722064
neuroleptic O 0 0.99999857
therapy O 0 0.06513465
. O 0 0.008208401

Its O 0 0.05875588
occurrence O 0 0.0043808594
in O 0 0.0018371029
a O 0 0.001538829
patient O 0 0.0010445755
being O 0 0.001058866
treated O 0 0.0007861718
with O 0 0.003124697
imipramine B-Chemical 0 0.9999993
is O 0 0.00051002397
described O 0 0.0002508814
, O 0 0.00028673047
representing O 0 0.00020188578
the O 0 0.00019920876
first O 0 0.00018123482
reported O 0 0.00028290608
case O 0 0.0002984978
of O 0 0.00042386516
this O 0 0.00053354027
syndrome O 0 0.19888417
in O 0 0.0008680198
conjunction O 0 0.00168529
with O 0 0.0045851
antidepressants B-Chemical 0 0.9998497
. O 0 0.0067423354

Repeated O 0 0.008931014
cerebral O 0 0.7966495
perfusion O 0 0.3120346
SPECT O 0 0.80104315
scans O 0 0.0016440878
revealed O 0 0.0006792438
decreased B-Disease 0 0.0007180893
basal I-Disease 0 0.0014215207
ganglia I-Disease 0 0.08142528
perfusion I-Disease 0 0.042000055
while O 0 0.00030477947
the O 0 0.00025510346
movement B-Disease 0 0.001702652
disorder I-Disease 0 0.93768144
was O 0 0.00026220933
present O 0 0.00017967458
, O 0 0.00031614592
and O 0 0.00027432753
a O 0 0.0002970757
return O 0 0.00028759128
to O 0 0.00025562325
normal O 0 0.00056583364
perfusion O 0 0.018007742
when O 0 0.0005112452
the O 0 0.0010358784
rabbit B-Disease 0 0.2586042
syndrome I-Disease 0 0.97415257
resolved O 0 0.007098773
. O 0 0.0069037853

Estrogen O 0 0.9999671
prevents O 0 0.0400493
cholesteryl B-Chemical 0 0.9999459
ester I-Chemical 0 0.99912566
accumulation O 0 0.005335104
in O 0 0.0012374016
macrophages O 0 0.0019222541
induced O 0 0.0010535708
by O 0 0.0011924845
the O 0 0.001514343
HIV O 0 0.99201256
protease O 0 0.5700171
inhibitor O 0 0.71499664
ritonavir B-Chemical 0 0.99985313
. O 0 0.011334612

Individuals O 0 0.009406776
with O 0 0.003863736
HIV O 0 0.8685966
can O 0 0.0013383329
now O 0 0.00096833194
live O 0 0.00095534226
long O 0 0.00064383744
lives O 0 0.0017669045
with O 0 0.00068803993
drug O 0 0.19147795
therapy O 0 0.00080503616
that O 0 0.00032506618
often O 0 0.00054492377
includes O 0 0.00047327808
protease O 0 0.0076652216
inhibitors O 0 0.0032301764
such O 0 0.0013634454
as O 0 0.0027056974
ritonavir B-Chemical 0 0.9994419
. O 0 0.008735184

Many O 0 0.0047641946
patients O 0 0.003880777
, O 0 0.0029233093
however O 0 0.0019262267
, O 0 0.0015076445
develop O 0 0.0009344808
negative O 0 0.0010260777
long O 0 0.00092237827
- O 0 0.0033339018
term O 0 0.0007787491
side O 0 0.00924364
effects O 0 0.0012775593
such O 0 0.0013740825
as O 0 0.0027606478
premature B-Disease 0 0.9742811
atherosclerosis I-Disease 2 0.99999607
. O 0 0.018308192

We O 0 0.0033803596
have O 0 0.002022982
previously O 0 0.0015778645
demonstrated O 0 0.0010080524
that O 0 0.0009829211
ritonavir B-Chemical 0 0.9995534
treatment O 0 0.0057545556
increases O 0 0.004751108
atherosclerotic B-Disease 2 0.99999774
lesion I-Disease 0 0.9797816
formation O 0 0.008988266
in O 0 0.00033406928
male O 0 0.00071380753
mice O 0 0.00019901396
to O 0 0.0002739927
a O 0 0.00041230847
greater O 0 0.000388228
extent O 0 0.0004644498
than O 0 0.0006910754
in O 0 0.0013205563
female O 0 0.0037403156
mice O 0 0.0028788187
. O 0 0.006593999

Furthermore O 0 0.0052918503
, O 0 0.00439764
peripheral O 0 0.008403953
blood O 0 0.014482719
monocytes O 0 0.010740395
isolated O 0 0.0007505464
from O 0 0.00095643784
ritonavir B-Chemical 0 0.9998305
- O 0 0.04797215
treated O 0 0.0011343419
females O 0 0.001558237
had O 0 0.0011667296
less O 0 0.0023604936
cholesteryl B-Chemical 0 0.9997342
ester I-Chemical 0 0.9968554
accumulation O 0 0.017811647
. O 0 0.008388093

In O 0 0.0036049765
the O 0 0.0022133517
present O 0 0.0014386626
study O 0 0.0014967133
, O 0 0.001112523
we O 0 0.0004753237
have O 0 0.00040029312
investigated O 0 0.0003227837
the O 0 0.00031995765
molecular O 0 0.00088817975
mechanisms O 0 0.00027866176
by O 0 0.0003192867
which O 0 0.00047427276
female O 0 0.007305904
hormones O 0 0.3792665
influence O 0 0.00039158165
cholesterol B-Chemical 0 0.99994123
metabolism O 0 0.31999913
in O 0 0.00028626996
macrophages O 0 0.00061578694
in O 0 0.00028098677
response O 0 0.00041676094
to O 0 0.00040316395
the O 0 0.0007639959
HIV O 0 0.98720413
protease O 0 0.49453667
inhibitor O 0 0.66805136
ritonavir B-Chemical 0 0.9998518
. O 0 0.009766845

We O 0 0.0034806659
have O 0 0.0020378784
utilized O 0 0.0014896619
the O 0 0.0012494094
human O 0 0.0014875734
monocyte O 0 0.17966574
cell O 0 0.013608816
line O 0 0.005843347
, O 0 0.013773577
THP O 1 0.9999893
- O 0 0.045087375
1 O 0 0.00054745714
as O 0 0.0004839319
a O 0 0.00066933536
model O 0 0.00074427074
to O 0 0.0008737518
address O 0 0.001040964
this O 0 0.0021149667
question O 0 0.0038684278
. O 0 0.0068494286

Briefly O 0 0.0038463825
, O 0 0.0032069995
cells O 0 0.0019448376
were O 0 0.0012674792
differentiated O 0 0.0014937674
for O 0 0.00067445135
72 O 0 0.0007230633
h O 0 0.00046849862
with O 0 0.0004164742
100 O 0 0.0010207162
nM O 0 0.06744384
PMA O 0 0.97714955
to O 0 0.00021260537
obtain O 0 0.00013986928
a O 0 0.00030842127
macrophage O 0 0.07273954
- O 0 0.017744675
like O 0 0.00018069423
phenotype O 0 0.0003708381
in O 0 0.00015833713
the O 0 0.00013590722
presence O 0 0.00014183742
or O 0 0.00014130311
absence O 0 0.00011438015
of O 0 0.00041914772
1 O 0 0.0006656757
nM O 0 0.89950895
17beta B-Chemical 1 0.9999999
- I-Chemical 1 0.9934714
estradiol I-Chemical 1 0.9999999
( O 0 0.5548844
E2 B-Chemical 0 0.99999905
) O 0 0.03923572
, O 0 0.0013144849
100 O 0 0.002564903
nM O 0 0.40190783
progesterone B-Chemical 1 0.9999914
or O 0 0.00065687345
vehicle O 0 0.017535063
( O 0 0.00090156955
0 O 0 0.0006635727
. O 0 0.00077051524
01 O 0 0.0029771181
% O 0 0.0024460556
ethanol B-Chemical 1 0.9954091
) O 0 0.008118101
. O 0 0.007737292

Cells O 0 0.0059293993
were O 0 0.0023504603
then O 0 0.0014226746
treated O 0 0.0011401611
with O 0 0.0008016669
30 O 0 0.00055817206
ng O 0 0.0009535462
/ O 0 0.007982662
ml O 0 0.007901226
ritonavir B-Chemical 0 0.99958295
or O 0 0.00060102163
vehicle O 0 0.0048499783
in O 0 0.00032403803
the O 0 0.00031628218
presence O 0 0.00039594626
of O 0 0.0007444942
aggregated O 0 0.0021019091
LDL O 0 0.9996928
for O 0 0.0016873875
24 O 0 0.0023145403
h O 0 0.0035765942
. O 0 0.0063275932

Cell O 0 0.11118319
extracts O 0 0.005513142
were O 0 0.0027823444
harvested O 0 0.0018914883
, O 0 0.0025715453
and O 0 0.0023329763
lipid O 0 0.29521728
or O 0 0.0020955817
total O 0 0.002270152
RNA O 0 0.011624197
was O 0 0.0042975224
isolated O 0 0.005107486
. O 0 0.009286553

E2 B-Chemical 0 0.99984074
decreased O 0 0.0063431817
the O 0 0.0030200707
accumulation O 0 0.004090515
of O 0 0.01104856
cholesteryl B-Chemical 0 0.9999515
esters I-Chemical 0 0.99885523
in O 0 0.0019425285
macrophages O 0 0.004696618
following O 0 0.0027123487
ritonavir B-Chemical 0 0.9994848
treatment O 0 0.010589256
. O 0 0.008753336

Ritonavir B-Chemical 0 0.9992101
increased O 0 0.003508738
the O 0 0.0016901562
expression O 0 0.0013380074
of O 0 0.0012093044
the O 0 0.0012799181
scavenger O 0 0.996811
receptor O 0 0.36468175
, O 0 0.007939432
CD36 O 0 0.88793445
mRNA O 0 0.0013037539
, O 0 0.000830562
responsible O 0 0.0006049806
for O 0 0.0007959221
the O 0 0.0011991691
uptake O 0 0.006454327
of O 0 0.00718992
LDL O 0 0.9997248
. O 0 0.0098814275

Additionally O 0 0.005485353
, O 0 0.0066941893
ritonavir B-Chemical 0 0.9985507
treatment O 0 0.0026361835
selectively O 0 0.0010044287
increased O 0 0.00068846205
the O 0 0.00040652367
relative O 0 0.00030660623
levels O 0 0.000366323
of O 0 0.0010147957
PPARgamma O 0 0.97212076
mRNA O 0 0.001857997
, O 0 0.00071483856
a O 0 0.00040503326
transcription O 0 0.0006109649
factor O 0 0.0028724924
responsible O 0 0.0003401419
for O 0 0.00036048485
the O 0 0.00042793792
regulation O 0 0.0005166161
of O 0 0.001411678
CD36 O 0 0.71856093
mRNA O 0 0.0039093015
expression O 0 0.0050908937
. O 0 0.00762389

Treatment O 0 0.024201034
with O 0 0.020697862
E2 B-Chemical 0 0.9999796
, O 0 0.009313317
however O 0 0.0028518885
, O 0 0.0016395655
failed O 0 0.00096873427
to O 0 0.0006783614
prevent O 0 0.0006686806
these O 0 0.0008352136
increases O 0 0.0009108863
at O 0 0.0010993949
the O 0 0.0016600159
mRNA O 0 0.0031874022
level O 0 0.0042601945
. O 0 0.008218364

E2 B-Chemical 0 0.99993193
did O 0 0.008229763
, O 0 0.00439783
however O 0 0.0027378544
, O 0 0.0020211057
significantly O 0 0.0011271
suppress O 0 0.0008508316
CD36 O 0 0.45136404
protein O 0 0.0016995847
levels O 0 0.00093223806
as O 0 0.0009709649
measured O 0 0.0011604694
by O 0 0.0020293912
fluorescent O 0 0.0056087812
immunocytochemistry O 0 0.0099949725
. O 0 0.008462359

This O 0 0.0052074036
data O 0 0.0027420253
suggests O 0 0.0015013588
that O 0 0.0019615018
E2 B-Chemical 0 0.99997306
modifies O 0 0.0022949034
the O 0 0.0007059826
expression O 0 0.0006982692
of O 0 0.0010238055
CD36 O 0 0.7127868
at O 0 0.00024099072
the O 0 0.00018644056
level O 0 0.00015630783
of O 0 0.00023467578
protein O 0 0.00058103824
expression O 0 0.00037705927
in O 0 0.00032023873
monocyte O 0 0.39311567
- O 0 0.008611056
derived O 0 0.00016092314
macrophages O 0 0.00052114757
resulting O 0 0.00028394425
in O 0 0.00039697674
reduced O 0 0.001518164
cholesteryl B-Chemical 0 0.9999473
ester I-Chemical 0 0.99803156
accumulation O 0 0.0052600736
following O 0 0.0018423366
ritonavir B-Chemical 0 0.99961805
treatment O 0 0.009053985
. O 0 0.006751202

Acute O 0 0.98763716
hepatitis B-Disease 2 0.9999975
attack O 0 0.9907873
after O 0 0.0073585077
exposure O 0 0.049022283
to O 0 0.011172994
telithromycin B-Chemical 1 0.9990182
. O 0 0.019043887

INTRODUCTION O 0 0.023175636
: O 0 0.0146304965
Antibiotic O 0 0.7960599
- O 0 0.06873776
associated O 0 0.022302387
hepatotoxicity B-Disease 2 0.9999932
is O 0 0.018840833
rare O 0 0.06468655
. O 0 0.017700423

With O 0 0.0043241177
widespread O 0 0.0036260244
use O 0 0.0018104868
of O 0 0.001680396
antimicrobial O 0 0.05794161
agents O 0 0.07066973
, O 0 0.0020315354
however O 0 0.0017823746
, O 0 0.004199599
hepatic B-Disease 0 0.9995228
injury I-Disease 0 0.9994313
occurs O 0 0.0007893149
frequently O 0 0.0008305874
, O 0 0.0003889118
and O 0 0.0003346855
among O 0 0.0006734228
adverse B-Disease 0 0.8310866
drug I-Disease 0 0.4822986
reactions I-Disease 0 0.11430877
, O 0 0.001229202
idiosyncratic O 0 0.21715407
reactions O 0 0.0033972436
are O 0 0.00087649724
the O 0 0.0013148267
most O 0 0.0030948515
serious O 0 0.07000896
. O 0 0.007114887

CASE O 0 0.32474223
SUMMARY O 0 0.00559716
: O 0 0.004005207
A O 0 0.02382703
25 O 0 0.0021487612
- O 0 0.003852339
year O 0 0.0011180796
- O 0 0.0029571857
old O 0 0.00069979514
male O 0 0.0014737815
patient O 0 0.00048800456
, O 0 0.00044800265
with O 0 0.0002980272
a O 0 0.00029593823
height O 0 0.0004612641
of O 0 0.00027552358
175 O 0 0.00046237896
cm O 0 0.00032988214
and O 0 0.00022007043
weight O 0 0.00050046324
of O 0 0.0002927121
72 O 0 0.00030834164
kg O 0 0.00035567262
presented O 0 0.00018106522
to O 0 0.00022396322
Marmara O 0 0.44675058
University O 0 0.0006095663
Hospital O 0 0.0005172237
Emergency O 0 0.0006461481
Department O 0 0.00083220867
, O 0 0.00042198543
Istanbul O 0 0.14369418
, O 0 0.00047303835
Turkey O 0 0.041512504
, O 0 0.00027328465
with O 0 0.00019188579
5 O 0 0.0001565887
days O 0 0.00015237641
' O 0 0.00034580842
history O 0 0.001285925
of O 0 0.0013759519
jaundice B-Disease 2 0.9999492
, O 0 0.10863409
malaise O 0 0.99997926
, O 0 0.087583885
nausea B-Disease 2 0.99999547
, O 0 0.0056373337
and O 0 0.008594891
vomiting B-Disease 0 0.9997346
. O 0 0.00854975

He O 0 0.007961516
had O 0 0.002731299
been O 0 0.0021118412
prescribed O 0 0.0066154934
telithromycin B-Chemical 1 0.99815696
400 O 0 0.004012595
mg O 0 0.07695492
/ O 0 0.0041417456
d O 0 0.0014588505
PO O 0 0.8007519
to O 0 0.00039187682
treat O 0 0.00052168034
an O 0 0.00053608866
upper B-Disease 0 0.0008711253
respiratory I-Disease 0 0.04364693
tract I-Disease 0 0.02932505
infection I-Disease 2 0.91641426
7 O 0 0.0015005748
days O 0 0.0017251774
prior O 0 0.002967647
. O 0 0.0065124924

Admission O 0 0.007427996
laboratory O 0 0.0030584056
tests O 0 0.0020204373
were O 0 0.0010888563
as O 0 0.0008027936
follows O 0 0.00091992307
: O 0 0.0036864202
alanine B-Chemical 1 0.9995609
aminotransferase O 0 0.9999106
, O 0 0.0021016162
67 O 0 0.0024463523
U O 0 0.87670594
/ O 0 0.07484998
L O 0 0.9698185
( O 0 0.0006440958
reference O 0 0.00023399368
range O 0 0.00023217646
, O 0 0.00030707076
10 O 0 0.00023419074
- O 0 0.0016172027
37 O 0 0.00060100557
U O 0 0.7718765
/ O 0 0.096131206
L O 0 0.9931676
) O 0 0.02032555
; O 0 0.035340533
aspartate B-Chemical 1 0.9999969
aminotransferase O 0 0.9999329
, O 0 0.0014249687
98 O 0 0.004508778
U O 0 0.84021306
/ O 0 0.060824927
L O 0 0.97481596
( O 0 0.000934755
10 O 0 0.00026918488
- O 0 0.0015602295
40 O 0 0.0002711554
U O 0 0.6070817
/ O 0 0.050612148
L O 0 0.9848125
) O 0 0.0044826483
; O 0 0.0015468746
alkaline O 0 0.64315146
phosphatase O 0 0.72919786
, O 0 0.0014253501
513 O 0 0.09501543
U O 0 0.8746913
/ O 0 0.05977574
L O 0 0.9714821
( O 0 0.0010126734
0 O 0 0.00041512673
- O 0 0.0037797182
270 O 0 0.005460106
U O 0 0.7647502
/ O 0 0.058737524
L O 0 0.98626024
) O 0 0.007919221
; O 0 0.008140841
gamma O 0 0.9940455
- O 0 0.7888063
glutamyltransferase O 0 0.9999813
, O 0 0.0033377032
32 O 0 0.0009987069
U O 0 0.8374721
/ O 0 0.06261846
L O 0 0.97498375
( O 0 0.0010067952
7 O 0 0.0002607867
- O 0 0.0020537495
49 O 0 0.0005765692
U O 0 0.70781535
/ O 0 0.061661724
L O 0 0.9863962
) O 0 0.0055685947
; O 0 0.0020747387
amylase O 0 0.7924088
, O 0 0.0006214002
46 O 0 0.00074416085
U O 0 0.7672716
/ O 0 0.048749536
L O 0 0.9713003
( O 0 0.0010793343
0 O 0 0.00043020918
- O 0 0.0041805166
220 O 0 0.0034549346
U O 0 0.78980386
/ O 0 0.06739371
L O 0 0.98373544
) O 0 0.0024178938
; O 0 0.0005485981
total O 0 0.00029098775
bilirubin B-Chemical 1 0.9999801
, O 0 0.00069026055
20 O 0 0.00019817721
. O 0 0.00015133603
1 O 0 0.00016333649
mg O 0 0.0037520113
/ O 0 0.0016337779
dL O 0 0.019152744
( O 0 0.0003471495
0 O 0 0.0002214922
. O 0 0.00016747043
2 O 0 0.00019271419
- O 0 0.0008378959
1 O 0 0.00016994725
. O 0 0.00014994045
0 O 0 0.0002009394
mg O 0 0.0064058695
/ O 0 0.002875183
dL O 0 0.040058162
) O 0 0.0005892922
; O 0 0.00039312994
direct O 0 0.0002920047
bilirubin B-Chemical 1 0.99998295
, O 0 0.0008711789
14 O 0 0.00021101559
. O 0 0.00014873121
8 O 0 0.0001515619
mg O 0 0.00276862
/ O 0 0.0014079007
dL O 0 0.018899787
( O 0 0.00038335702
0 O 0 0.00028724817
- O 0 0.0012922641
0 O 0 0.00020515434
. O 0 0.00015379892
3 O 0 0.00015138135
mg O 0 0.003399204
/ O 0 0.0020704425
dL O 0 0.035164863
) O 0 0.00062216766
; O 0 0.00043445465
and O 0 0.00037340156
albumin O 0 0.9840267
, O 0 0.00051847193
4 O 0 0.00017249424
. O 0 0.00015600763
7 O 0 0.00015899072
mg O 0 0.003205718
/ O 0 0.0016759249
dL O 0 0.020201182
( O 0 0.0004166154
3 O 0 0.00022106031
. O 0 0.0002351125
5 O 0 0.00027530536
- O 0 0.00082673406
5 O 0 0.00036704293
. O 0 0.00049099047
4 O 0 0.0007045396
mg O 0 0.006276564
/ O 0 0.0044438164
dL O 0 0.038842462
) O 0 0.0068076057
. O 0 0.008174886

No O 0 0.012337326
toxin O 0 0.67894375
, O 0 0.024267424
alcohol B-Chemical 0 0.9998553
, O 0 0.005744936
or O 0 0.0031277614
other O 0 0.0037323318
drugs O 0 0.17017676
were O 0 0.0048488714
reported O 0 0.0071575213
. O 0 0.010228804

The O 0 0.0034923353
patient O 0 0.0026770616
had O 0 0.0017643605
suffered O 0 0.00459769
a O 0 0.0011885958
previous O 0 0.0007128331
episode O 0 0.0019380177
of O 0 0.0013118852
" O 0 0.013976624
acute O 0 0.9999113
hepatitis B-Disease 2 1.0
of O 0 0.122422904
unknown O 0 0.026783373
origin O 0 0.0024755416
, O 0 0.0010426615
" O 0 0.00079861615
that O 0 0.0006003361
occurred O 0 0.0010503638
after O 0 0.0013843132
telithromycin B-Chemical 1 0.9965661
usage O 0 0.0067144227
. O 0 0.0075120456

Both O 0 0.01255862
incidents O 0 0.017723551
occurred O 0 0.010580917
within O 0 0.008996964
a O 0 0.014325943
year O 0 0.017543525
. O 0 0.023838868

DISCUSSION O 0 0.0053175995
: O 0 0.005422169
Telithromycin B-Chemical 0 0.8777662
is O 0 0.0017649309
the O 0 0.0010482126
first O 0 0.0006889622
of O 0 0.0007557901
the O 0 0.0006841211
ketolide O 0 0.2084497
antibacterials O 0 0.8914551
to O 0 0.00045012348
receive O 0 0.0004062039
US O 0 0.020572312
Food O 0 0.24793567
and O 0 0.00085481425
Drug O 0 0.5992723
Administration O 0 0.021300236
approval O 0 0.0013689831
for O 0 0.001409287
clinical O 0 0.003591646
use O 0 0.0037689107
. O 0 0.006414501

It O 0 0.005955082
has O 0 0.0032868045
been O 0 0.0025704326
associated O 0 0.0020416488
with O 0 0.0018488219
infrequent O 0 0.0038782489
and O 0 0.0018893228
usually O 0 0.0027021484
reversible O 0 0.3009343
severe O 0 0.8123851
hepatic B-Disease 0 0.9996111
dysfunction I-Disease 0 0.9993518
. O 0 0.013403501

Based O 0 0.005983868
on O 0 0.0019179618
a O 0 0.0018306848
score O 0 0.0011027576
of O 0 0.00094181474
8 O 0 0.00060866936
on O 0 0.00036519268
the O 0 0.00048809717
Naranjo O 0 0.6657274
adverse B-Disease 0 0.82632226
drug I-Disease 0 0.37567952
reaction I-Disease 0 0.04630458
probability O 0 0.00042965834
scale O 0 0.00054698664
, O 0 0.001222522
telithromycin B-Chemical 1 0.9989446
was O 0 0.00029701597
the O 0 0.00022420827
probable O 0 0.011346282
cause O 0 0.00062031084
of O 0 0.00813284
acute O 0 0.99997234
hepatitis B-Disease 2 1.0
in O 0 0.016348455
this O 0 0.00049183745
patient O 0 0.00035396175
, O 0 0.0003505011
and O 0 0.00030466265
pathological O 0 0.020900758
findings O 0 0.0006011095
suggested O 0 0.0005734478
drug O 0 0.60425067
- O 0 0.08258475
induced O 0 0.016055176
toxic B-Disease 0 0.9998852
hepatitis I-Disease 2 1.0
. O 0 0.33927017

Recurrence O 0 0.5692452
of O 0 0.022847757
hepatitis B-Disease 2 0.99999964
attack O 0 0.99673283
might O 0 0.0012545944
have O 0 0.0006498093
been O 0 0.00050996913
avoided O 0 0.0003732006
if O 0 0.000255861
the O 0 0.00025476268
initial O 0 0.0002665442
incident O 0 0.02657996
had O 0 0.00029029476
been O 0 0.00023916774
communicated O 0 0.0002400766
to O 0 0.00020535103
the O 0 0.0002640477
attending O 0 0.0005260946
physician O 0 0.0009360398
who O 0 0.00096292794
prescribed O 0 0.0036932125
telithromycin B-Chemical 1 0.9851387
the O 0 0.0012973789
second O 0 0.0018381841
time O 0 0.0026625937
. O 0 0.0058783256

CONCLUSION O 0 0.014932307
: O 0 0.00424572
Here O 0 0.0026960822
we O 0 0.0013903362
report O 0 0.0019256219
a O 0 0.0013951947
case O 0 0.0012803014
of O 0 0.00471669
acute O 0 0.9999558
hepatitis B-Disease 2 1.0
probably O 0 0.29152912
associated O 0 0.0024649303
with O 0 0.0011533046
the O 0 0.0011930196
administration O 0 0.014872343
of O 0 0.0050907824
telithromycin B-Chemical 1 0.9993236
. O 0 0.009370701

A O 0 0.03827507
study O 0 0.003301556
on O 0 0.0015147439
the O 0 0.0013223308
effect O 0 0.0010247857
of O 0 0.0009479365
the O 0 0.00068559655
duration O 0 0.0005706004
of O 0 0.00095488725
subcutaneous O 0 0.042246018
heparin B-Chemical 1 0.990607
injection O 0 0.0027190293
on O 0 0.0013031127
bruising B-Disease 0 0.9990074
and O 0 0.0058134
pain B-Disease 0 0.95841306
. O 0 0.00777003

AIM O 0 0.53476393
: O 0 0.0053343982
This O 0 0.0029587576
study O 0 0.0017269488
was O 0 0.0009880473
carried O 0 0.00055355555
out O 0 0.0003975747
to O 0 0.0003235129
determine O 0 0.00017874294
the O 0 0.00025116047
effect O 0 0.00023937307
of O 0 0.00030873631
injection O 0 0.00041720635
duration O 0 0.00018256092
on O 0 0.00020180245
bruising B-Disease 0 0.99940217
and O 0 0.0009264249
pain B-Disease 0 0.86550146
following O 0 0.00021168383
the O 0 0.00026852664
administration O 0 0.0010830526
of O 0 0.0005039098
the O 0 0.0006627391
subcutaneous O 0 0.006130688
injection O 0 0.0020508547
of O 0 0.003541514
heparin B-Chemical 1 0.9949478
. O 0 0.00818856

BACKGROUND O 0 0.018097382
: O 0 0.0035833982
Although O 0 0.0014017667
different O 0 0.00092703686
methods O 0 0.0007483359
to O 0 0.0006076787
prevent O 0 0.00074472406
bruising B-Disease 0 0.99959296
and O 0 0.00163704
pain B-Disease 0 0.9016723
following O 0 0.0002271213
the O 0 0.00024019084
subcutaneous O 0 0.0024495078
injection O 0 0.00042756356
of O 0 0.0004577237
heparin B-Chemical 1 0.9882222
have O 0 0.00018410412
been O 0 0.00017484266
widely O 0 0.00017423155
studied O 0 0.00016473023
and O 0 0.00019215659
described O 0 0.00015674841
, O 0 0.00022620326
the O 0 0.00015313542
effect O 0 0.00016165397
of O 0 0.00023821305
injection O 0 0.00031687735
duration O 0 0.00013904614
on O 0 0.00013468906
the O 0 0.00022106853
occurrence O 0 0.0007230458
of O 0 0.0013492331
bruising B-Disease 0 0.9997745
and O 0 0.0023179434
pain B-Disease 0 0.9308702
is O 0 0.0013810707
little O 0 0.0019376978
documented O 0 0.0048981467
. O 0 0.0065273526

DESIGN O 0 0.0064085713
: O 0 0.004859587
This O 0 0.003433547
study O 0 0.002345606
was O 0 0.0016120571
designed O 0 0.0012504071
as O 0 0.0010874132
within O 0 0.00095748174
- O 0 0.0028012935
subject O 0 0.0012841037
, O 0 0.0021731972
quasi O 0 0.0053012893
- O 0 0.006862266
experimental O 0 0.004168328
research O 0 0.0066712215
. O 0 0.009169289

METHOD O 0 0.007910031
: O 0 0.0038344157
The O 0 0.0016842561
sample O 0 0.001345112
for O 0 0.0009876111
the O 0 0.0007918627
study O 0 0.0007393041
consisted O 0 0.00047238584
of O 0 0.00059420266
50 O 0 0.0006439439
patients O 0 0.0006608715
to O 0 0.00060809945
whom O 0 0.0019116328
subcutaneous O 0 0.022852309
heparin B-Chemical 1 0.9792838
was O 0 0.0028800264
administered O 0 0.004057913
. O 0 0.006548738

Heparin B-Chemical 1 0.9883259
was O 0 0.0028423893
injected O 0 0.001474246
over O 0 0.0007996225
10 O 0 0.0006781775
seconds O 0 0.0004953067
on O 0 0.0003669539
the O 0 0.0004403738
right O 0 0.0007740659
abdominal O 0 0.002248179
site O 0 0.00045166825
and O 0 0.00044617968
30 O 0 0.00037468525
seconds O 0 0.00042140813
on O 0 0.00050641166
the O 0 0.0009811345
left O 0 0.0023486745
abdominal O 0 0.010999011
site O 0 0.004614927
. O 0 0.007545102

Injections O 0 0.02004737
areas O 0 0.0036369283
were O 0 0.0017246938
assessed O 0 0.0010322665
for O 0 0.0008799436
the O 0 0.00072327803
presence O 0 0.00070055213
of O 0 0.0014232587
bruising B-Disease 0 0.99924916
at O 0 0.0005627877
48 O 0 0.0005946992
and O 0 0.0005979309
72 O 0 0.00080959307
hours O 0 0.0006936877
after O 0 0.00091111887
each O 0 0.0014673623
injection O 0 0.0040528793
. O 0 0.006412848

Dimensions O 0 0.007431604
of O 0 0.0035239293
the O 0 0.002902105
bruising B-Disease 0 0.9935069
on O 0 0.0010753829
the O 0 0.001180437
heparin B-Chemical 1 0.9444194
applied O 0 0.00076715206
areas O 0 0.0010820703
were O 0 0.0006457434
measured O 0 0.0006088319
using O 0 0.00089352904
transparent O 0 0.0022334175
millimetric O 0 0.003862237
measuring O 0 0.0025578008
paper O 0 0.005574597
. O 0 0.007451482

The O 0 0.0033136976
visual O 0 0.01446946
analog O 0 0.0035340737
scale O 0 0.0018029483
( O 0 0.002114848
VAS O 0 0.032578528
) O 0 0.0009631266
was O 0 0.00044989766
used O 0 0.00030669218
to O 0 0.00026212935
measure O 0 0.0002238998
pain B-Disease 0 0.32026565
intensity O 0 0.00026449823
and O 0 0.0003546339
a O 0 0.00047125656
stop O 0 0.0031714854
- O 0 0.006912396
watch O 0 0.0006214435
was O 0 0.0003982613
used O 0 0.00040753037
to O 0 0.0005173475
time O 0 0.00071868836
the O 0 0.001507831
pain B-Disease 0 0.53426665
period O 0 0.0032763863
. O 0 0.006432489

Data O 0 0.004434317
were O 0 0.0025626717
analysed O 0 0.0017961543
using O 0 0.0015850142
chi O 0 0.10148174
- O 0 0.011041897
square O 0 0.0016071773
test O 0 0.001252387
, O 0 0.0019890934
Mann O 0 0.22757311
- O 0 0.09392245
Whitney O 0 0.90510917
U O 0 0.8040945
, O 0 0.0017372014
Wilcoxon O 0 0.0022437358
signed O 0 0.0018948879
ranks O 0 0.0026588556
tests O 0 0.0025546642
and O 0 0.0029513694
correlation O 0 0.004236728
. O 0 0.008532507

RESULTS O 0 0.0054076333
: O 0 0.0033350997
The O 0 0.0014865205
percentage O 0 0.00105269
of O 0 0.0018107211
bruising B-Disease 0 0.9992348
occurrence O 0 0.0040518604
was O 0 0.0006174442
64 O 0 0.00057532795
% O 0 0.00037730703
with O 0 0.00026707584
the O 0 0.00023212
injection O 0 0.00030435348
of O 0 0.00023251495
10 O 0 0.00018282642
seconds O 0 0.00016555407
duration O 0 0.000175332
and O 0 0.00027624425
42 O 0 0.0003908978
% O 0 0.0004236989
in O 0 0.000434211
the O 0 0.0005998934
30 O 0 0.000872839
- O 0 0.0024876667
second O 0 0.0021233691
injection O 0 0.0046584075
. O 0 0.006645814

It O 0 0.004796426
was O 0 0.00259913
determined O 0 0.0014971095
that O 0 0.0011243793
the O 0 0.0009631307
size O 0 0.0010203142
of O 0 0.0009895802
the O 0 0.0011374338
bruising B-Disease 0 0.99903786
was O 0 0.00067561225
smaller O 0 0.0005415474
in O 0 0.0006001758
the O 0 0.0007598176
30 O 0 0.0010402898
- O 0 0.0028317673
second O 0 0.002358017
injection O 0 0.0050392016
. O 0 0.007080893

Pain B-Disease 0 0.61615473
intensity O 0 0.0026538947
and O 0 0.0024805036
pain B-Disease 0 0.58935964
period O 0 0.00081923814
were O 0 0.0006523594
statistically O 0 0.00045529398
significantly O 0 0.00039422524
lower O 0 0.0003234624
for O 0 0.00026892475
the O 0 0.00027019385
30 O 0 0.00027208534
- O 0 0.00085437944
second O 0 0.00026751825
injection O 0 0.00038623036
than O 0 0.00025636522
for O 0 0.00038878963
the O 0 0.0005921648
10 O 0 0.0009157682
- O 0 0.0026978552
second O 0 0.0020533754
injection O 0 0.0046295864
. O 0 0.006408149

CONCLUSIONS O 0 0.027294245
: O 0 0.004294069
It O 0 0.0022504828
was O 0 0.0013334157
determined O 0 0.00080738124
that O 0 0.0006529288
injection O 0 0.00084589765
duration O 0 0.00042511267
had O 0 0.00039451825
an O 0 0.00041609147
effect O 0 0.00036211833
on O 0 0.00035468413
bruising B-Disease 0 0.99955326
and O 0 0.0013288491
pain B-Disease 0 0.87086916
following O 0 0.0004430402
the O 0 0.00068535417
subcutaneous O 0 0.006067282
administration O 0 0.0067887097
of O 0 0.0040127453
heparin B-Chemical 1 0.9958187
. O 0 0.0085623525

This O 0 0.00883441
study O 0 0.00566077
should O 0 0.0031606953
be O 0 0.0034502854
repeated O 0 0.0029584342
on O 0 0.0033260423
a O 0 0.00543182
larger O 0 0.006170404
sample O 0 0.009027759
. O 0 0.01336955

RELEVANCE O 0 0.0076726396
TO O 0 0.0100629935
CLINICAL O 0 0.0032932877
PRACTICE O 0 0.0013685985
: O 0 0.0015678267
When O 0 0.00084258453
administering O 0 0.0016063687
subcutaneous O 0 0.028514823
heparin B-Chemical 1 0.9928706
injections O 0 0.0043500164
, O 0 0.0007475811
it O 0 0.00043824708
is O 0 0.00034769464
important O 0 0.00028566306
to O 0 0.00032461435
extend O 0 0.0003647821
the O 0 0.00053213164
duration O 0 0.0007035848
of O 0 0.0014336176
the O 0 0.0021943853
injection O 0 0.005430607
. O 0 0.006595268

Acute B-Disease 0 0.9430408
liver I-Disease 0 0.90785366
failure I-Disease 0 0.8002132
in O 0 0.001704754
two O 0 0.0009110455
patients O 0 0.0009890278
with O 0 0.00079063105
regular O 0 0.0017098824
alcohol B-Chemical 0 0.9999565
consumption O 0 0.8606889
ingesting O 0 0.9773834
paracetamol B-Chemical 0 0.99998903
at O 0 0.0015535746
therapeutic O 0 0.006162611
dosage O 0 0.083649
. O 0 0.0068345075

BACKGROUND O 0 0.015962895
: O 0 0.0034960464
The O 0 0.0014081091
possible O 0 0.0010526198
role O 0 0.00069255877
of O 0 0.001766758
alcohol B-Chemical 0 0.9999299
in O 0 0.0006353587
the O 0 0.00041016153
development O 0 0.0015730822
of O 0 0.006595156
hepatotoxicity B-Disease 2 0.99999976
associated O 0 0.0012583955
with O 0 0.00042487404
therapeutic O 0 0.0017077439
doses O 0 0.009979028
of O 0 0.009961124
paracetamol B-Chemical 0 0.99999917
( O 0 0.17163068
acetaminophen B-Chemical 0 0.9999993
) O 0 0.005730138
is O 0 0.0017429256
currently O 0 0.0029487903
debated O 0 0.006618006
. O 0 0.0065516485

CASE O 0 0.1442856
REPORT O 0 0.0068722246
: O 0 0.003560793
We O 0 0.0017097482
describe O 0 0.0012068793
2 O 0 0.0010336688
patients O 0 0.0009067864
who O 0 0.0007560321
were O 0 0.00044658175
regular O 0 0.0004351124
consumers O 0 0.002482325
of O 0 0.00086696754
alcohol B-Chemical 0 0.99992955
and O 0 0.0006405996
who O 0 0.0006196963
developed O 0 0.00066678587
liver B-Disease 0 0.6121526
failure I-Disease 0 0.20022926
within O 0 0.00014746017
3 O 0 0.00017410301
- O 0 0.0006755869
5 O 0 0.000112410715
days O 0 9.300436e-05
after O 0 9.769359e-05
hospitalization O 0 0.00093304616
and O 0 0.00026264266
stopping O 0 0.03735961
alcohol B-Chemical 0 0.99997246
consumption O 0 0.27975437
while O 0 0.00033906105
being O 0 0.0004281595
treated O 0 0.00035283633
with O 0 0.000459007
4 O 0 0.00057990936
g O 0 0.0038084323
paracetamol B-Chemical 0 0.99994147
/ O 0 0.008392182
day O 0 0.0034300778
. O 0 0.0062377583

A O 0 0.7335224
paracetamol B-Chemical 0 0.9999733
serum O 0 0.4021631
level O 0 0.001426988
obtained O 0 0.0009938637
in O 0 0.0008180474
one O 0 0.00060942926
of O 0 0.0006441625
these O 0 0.000669771
patients O 0 0.00089061435
was O 0 0.00070091215
not O 0 0.0007552865
in O 0 0.0011154116
the O 0 0.0018014661
toxic O 0 0.3703732
range O 0 0.004914748
. O 0 0.0075507346

Possible O 0 0.01113323
risk O 0 0.034749433
factors O 0 0.0038441592
for O 0 0.0013674144
the O 0 0.001016273
development O 0 0.0024732545
of O 0 0.0103916
hepatotoxicity B-Disease 2 0.99999976
in O 0 0.0011132325
patients O 0 0.0009919675
treated O 0 0.0005321098
with O 0 0.0005260279
therapeutic O 0 0.0017718989
doses O 0 0.010964469
of O 0 0.0058435053
paracetamol B-Chemical 0 0.99998415
are O 0 0.0026898945
discussed O 0 0.003400448
. O 0 0.0062457477

CONCLUSION O 0 0.028151032
: O 0 0.0041175503
In O 0 0.0018747109
patients O 0 0.0015618735
with O 0 0.0011420443
risk O 0 0.050600413
factors O 0 0.004892859
, O 0 0.0010219918
e O 0 0.0017061707
. O 0 0.00042700634
g O 0 0.0008386272
. O 0 0.00028129425
regular O 0 0.0003346539
consumption O 0 0.028591381
of O 0 0.0014229495
alcohol B-Chemical 0 0.9999819
, O 0 0.006400263
liver B-Disease 0 0.896965
failure I-Disease 0 0.47104204
is O 0 0.0005084908
possible O 0 0.00048337033
when O 0 0.0004968499
therapeutic O 0 0.0017722768
doses O 0 0.0048774336
are O 0 0.0024262297
ingested O 0 0.04062494
. O 0 0.006644734

We O 0 0.0033007744
propose O 0 0.0019157822
that O 0 0.00153709
the O 0 0.0021777416
paracetamol B-Chemical 0 0.99998486
dose O 0 0.017441347
should O 0 0.00035706098
not O 0 0.0003042168
exceed O 0 0.00028750795
2 O 0 0.00026805393
g O 0 0.00050827663
/ O 0 0.0007542001
day O 0 0.00018250245
in O 0 0.00017492654
such O 0 0.0001683181
patients O 0 0.00026470865
and O 0 0.00019966743
that O 0 0.000156013
their O 0 0.00026865673
liver O 0 0.20528097
function O 0 0.00025714247
should O 0 0.00015850768
be O 0 0.00020938637
monitored O 0 0.000209198
closely O 0 0.00034703253
while O 0 0.00050226325
being O 0 0.000981032
treated O 0 0.0015583067
with O 0 0.005785239
paracetamol B-Chemical 0 0.9999608
. O 0 0.0076383194

Associations O 0 0.004303656
between O 0 0.0018899326
use O 0 0.0017273591
of O 0 0.002567803
benzodiazepines B-Chemical 1 0.9999502
or O 0 0.00086246146
related O 0 0.00041906623
drugs O 0 0.05689012
and O 0 0.0004944305
health O 0 0.0043307287
, O 0 0.00046256298
physical O 0 0.0008800992
abilities O 0 0.002257234
and O 0 0.00037849316
cognitive O 0 0.29892263
function O 0 0.00028900293
: O 0 0.00051042356
a O 0 0.0003891139
non O 0 0.0007339833
- O 0 0.0024118067
randomised O 0 0.00064340525
clinical O 0 0.0010974873
study O 0 0.001039823
in O 0 0.0013338807
the O 0 0.00243704
elderly O 0 0.20862107
. O 0 0.006955408

OBJECTIVE O 0 0.014277491
: O 0 0.0030688217
To O 0 0.0012529799
describe O 0 0.00091228803
associations O 0 0.00073181716
between O 0 0.0004770585
the O 0 0.00046862324
use O 0 0.00046029626
of O 0 0.0010675906
benzodiazepines B-Chemical 1 0.9999702
or O 0 0.00036523258
related O 0 0.000224548
drugs O 0 0.26997378
( O 0 0.010683261
BZDs B-Chemical 0 0.9999788
/ O 0 0.0112769725
RDs O 0 0.015537375
) O 0 0.0004851036
and O 0 0.00029598252
health O 0 0.0013463604
, O 0 0.00036781578
functional O 0 0.00033191976
abilities O 0 0.0016311124
and O 0 0.0006652124
cognitive O 0 0.2528686
function O 0 0.00092028687
in O 0 0.0014066362
the O 0 0.0024737935
elderly O 0 0.23768812
. O 0 0.0068645612

METHODS O 0 0.0043351986
: O 0 0.0043957345
A O 0 0.009931606
non O 0 0.003291294
- O 0 0.0045241774
randomised O 0 0.0012900394
clinical O 0 0.0013649182
study O 0 0.0006805241
of O 0 0.0005608754
patients O 0 0.0006718346
aged O 0 0.00074249477
> O 0 0.0008200985
or O 0 0.00037837974
= O 0 0.0006682732
65 O 0 0.00040081676
years O 0 0.0004056312
admitted O 0 0.0006006944
to O 0 0.0004583522
acute O 0 0.1343972
hospital O 0 0.0014006516
wards O 0 0.0011888236
during O 0 0.0010389873
1 O 0 0.0018740998
month O 0 0.0027882126
. O 0 0.0060215555

164 O 0 0.007429558
patients O 0 0.0030922901
( O 0 0.0020354881
mean O 0 0.0008911544
age O 0 0.0017638977
+ O 0 0.0031408572
/ O 0 0.007740034
- O 0 0.0026516076
standard O 0 0.00037119995
deviation O 0 0.0007407695
[ O 0 0.0025184243
SD O 0 0.051331133
] O 0 0.0007702271
81 O 0 0.00048784804
. O 0 0.00026948558
6 O 0 0.00026435856
+ O 0 0.0007409464
/ O 0 0.0027464177
- O 0 0.0030242442
6 O 0 0.00044368804
. O 0 0.0005551124
8 O 0 0.0007450779
years O 0 0.001276643
) O 0 0.0023597414
were O 0 0.0028918486
admitted O 0 0.0065070004
. O 0 0.007519387

Of O 0 0.0046553263
these O 0 0.0028164806
, O 0 0.0023305255
nearly O 0 0.0013262065
half O 0 0.00081585255
( O 0 0.0010096104
n O 0 0.00064045
= O 0 0.0009838707
78 O 0 0.0008496131
) O 0 0.00067490444
had O 0 0.0003592964
used O 0 0.0004945511
BZDs B-Chemical 0 0.99992645
/ O 0 0.004644354
RDs O 0 0.0034078055
before O 0 0.00017741157
admission O 0 0.0006331546
, O 0 0.00026839992
and O 0 0.00023399545
the O 0 0.00022503904
remainder O 0 0.00033780528
( O 0 0.0004392833
n O 0 0.0003718414
= O 0 0.000795302
86 O 0 0.00093868596
) O 0 0.0011584891
were O 0 0.001180603
non O 0 0.0025495635
- O 0 0.01088354
users O 0 0.010331052
. O 0 0.0073930137

Cognitive O 0 0.18208084
ability O 0 0.0034764295
was O 0 0.0025339492
assessed O 0 0.0016960299
by O 0 0.0018473872
the O 0 0.0017148709
Mini O 0 0.0030811587
- O 0 0.0040276316
Mental O 0 0.0032595866
State O 0 0.0031035566
Examination O 0 0.0023359717
( O 0 0.0039783344
MMSE O 0 0.81249374
) O 0 0.007895285
. O 0 0.00976796

Patients O 0 0.0045591337
scoring O 0 0.003332007
> O 0 0.0031003938
or O 0 0.0014218009
= O 0 0.0017331756
20 O 0 0.00089524104
MMSE O 0 0.28841022
sum O 0 0.00036381767
points O 0 0.00033761808
were O 0 0.00029791528
interviewed O 0 0.00042673456
( O 0 0.00037242388
n O 0 0.00026807105
= O 0 0.00052439194
79 O 0 0.00044680038
) O 0 0.00039120606
and O 0 0.0002511159
questioned O 0 0.00025550215
regarding O 0 0.00019953726
symptoms O 0 0.01640484
and O 0 0.0003176411
functional O 0 0.00034920714
abilities O 0 0.0011185671
during O 0 0.0003556127
the O 0 0.00052835495
week O 0 0.0006233069
prior O 0 0.0009255127
to O 0 0.0018470831
admission O 0 0.0064049046
. O 0 0.0059236963

Data O 0 0.0040663355
on O 0 0.002034972
use O 0 0.0020284518
of O 0 0.0033693414
BZDs B-Chemical 0 0.9999467
/ O 0 0.018464452
RDs O 0 0.0062042875
before O 0 0.00043602733
admission O 0 0.0011587176
, O 0 0.0005266068
current O 0 0.0006297637
medications O 0 0.0052880594
and O 0 0.0004734791
discharge O 0 0.000924848
diagnoses O 0 0.00096931786
were O 0 0.0006595703
collected O 0 0.00078128197
from O 0 0.001339121
medical O 0 0.0036850173
records O 0 0.0049137995
. O 0 0.006574802

Health O 0 0.005583785
, O 0 0.0034260205
physical O 0 0.003091896
abilities O 0 0.004501396
and O 0 0.0013583252
cognitive O 0 0.32549545
function O 0 0.0005489081
were O 0 0.0003873603
compared O 0 0.00025632174
between O 0 0.00037092913
BZD O 0 0.9999553
/ O 0 0.13652077
RD O 0 0.99975747
users O 0 0.009540861
and O 0 0.00040640857
non O 0 0.0013567958
- O 0 0.019271236
users O 0 0.002171283
, O 0 0.00045798728
and O 0 0.0004183366
adjustments O 0 0.0005043273
were O 0 0.0005240681
made O 0 0.00067237107
for O 0 0.0010839408
confounding O 0 0.0025964885
variables O 0 0.0046075205
. O 0 0.0066976394

The O 0 0.0036209545
residual O 0 0.0032110875
serum O 0 0.09441237
concentrations O 0 0.01785522
of O 0 0.0927297
oxazepam B-Chemical 0 1.0
, O 0 0.5338603
temazepam B-Chemical 0 0.99999976
and O 0 0.04489272
zopiclone B-Chemical 0 0.9999931
were O 0 0.0037873893
analysed O 0 0.0048989994
. O 0 0.00820582

RESULTS O 0 0.0053315703
: O 0 0.003274244
The O 0 0.0014946552
mean O 0 0.0010449303
+ O 0 0.002793043
/ O 0 0.009579022
- O 0 0.011307931
SD O 0 0.02068338
duration O 0 0.00046982398
of O 0 0.0017995669
BZD O 0 0.99997044
/ O 0 0.11783925
RD O 0 0.9992279
use O 0 0.00043306078
was O 0 0.00030188294
7 O 0 0.00026264068
+ O 0 0.00083912
/ O 0 0.0035884278
- O 0 0.0027272056
7 O 0 0.00036022067
years O 0 0.00051571627
( O 0 0.0007472378
range O 0 0.0008946539
1 O 0 0.0013196222
- O 0 0.0034960532
31 O 0 0.0035482072
) O 0 0.005959103
. O 0 0.008216696

Two O 0 0.004086755
or O 0 0.00278566
three O 0 0.0020236955
BZDs B-Chemical 0 0.999796
/ O 0 0.009274407
RDs O 0 0.0047496837
were O 0 0.0006586886
concomitantly O 0 0.0007368472
taken O 0 0.0003851138
by O 0 0.0004728161
26 O 0 0.00057293905
% O 0 0.00059413095
of O 0 0.00071134354
users O 0 0.0018533097
( O 0 0.0012043734
n O 0 0.0012709663
= O 0 0.0026768388
20 O 0 0.0028877323
) O 0 0.0058319983
. O 0 0.008083619

Long O 0 0.021277418
- O 0 0.006787061
term O 0 0.0016892906
use O 0 0.0012223031
of O 0 0.0010185218
these O 0 0.0009382903
drugs O 0 0.14828347
was O 0 0.0005132995
associated O 0 0.00041424623
with O 0 0.0004230572
female O 0 0.0053449846
sex O 0 0.019111848
and O 0 0.00031358478
use O 0 0.00021417916
of O 0 0.00024765398
a O 0 0.00027345872
higher O 0 0.00017025362
number O 0 0.00015206593
of O 0 0.0002593872
drugs O 0 0.051451735
with O 0 0.00022719886
effects O 0 0.00024526916
on O 0 0.00014151726
the O 0 0.0003049797
CNS O 0 0.34266672
, O 0 0.0005272457
which O 0 0.0004003381
tended O 0 0.00032159165
to O 0 0.00033916062
be O 0 0.00052606093
related O 0 0.00064270844
to O 0 0.0012877708
diagnosed O 0 0.11771977
dementia B-Disease 0 0.9999223
. O 0 0.00853776

After O 0 0.0025782208
adjustment O 0 0.0021412289
for O 0 0.0012584068
these O 0 0.00097203767
variables O 0 0.00083677616
as O 0 0.00058401644
confounders O 0 0.0015364835
, O 0 0.0007269363
use O 0 0.0004906843
of O 0 0.0024645994
BZDs B-Chemical 0 0.999987
/ O 0 0.019687483
RDs O 0 0.011013368
was O 0 0.0002668142
not O 0 0.0002225971
associated O 0 0.00030536583
with O 0 0.0004106827
cognitive O 0 0.16023666
function O 0 0.00045978313
as O 0 0.00057621265
measured O 0 0.0008013452
by O 0 0.0015374861
the O 0 0.0027366632
MMSE O 0 0.9370555
. O 0 0.0067247725

However O 0 0.00466565
, O 0 0.0035131574
use O 0 0.002145492
of O 0 0.004392668
BZDs B-Chemical 0 0.9999708
/ O 0 0.03957664
RDs O 0 0.016880963
was O 0 0.00049590616
associated O 0 0.00046220995
with O 0 0.00097114214
dizziness B-Disease 2 0.9999552
, O 0 0.00050768687
inability B-Disease 0 0.0002775701
to I-Disease 0 0.0001916298
sleep I-Disease 0 0.03165777
after O 0 0.00013491196
awaking O 0 0.036469277
at O 0 0.00013435313
night O 0 0.00042935723
and O 0 0.00032216398
tiredness B-Disease 0 0.9732055
in O 0 0.0001752628
the O 0 0.00018256545
mornings O 0 0.006463897
during O 0 0.00010181792
the O 0 0.00012293339
week O 0 9.950375e-05
prior O 0 9.337502e-05
to O 0 0.00012136527
admission O 0 0.00042175356
and O 0 0.00017625422
with O 0 0.00027327993
stronger O 0 0.0045698606
depressive B-Disease 2 0.99999964
symptoms I-Disease 0 0.8590136
measured O 0 0.00024724018
at O 0 0.00027745686
the O 0 0.000366728
beginning O 0 0.0004568103
of O 0 0.000890069
the O 0 0.0013052374
hospital O 0 0.0030332466
stay O 0 0.0038195578
. O 0 0.005973681

Use O 0 0.010489323
of O 0 0.007876006
BZDs B-Chemical 0 0.999926
/ O 0 0.037948124
RDs O 0 0.013350071
tended O 0 0.00068168936
to O 0 0.00043593877
be O 0 0.0004149689
associated O 0 0.0003852276
with O 0 0.00035647396
a O 0 0.00035206217
reduced O 0 0.00023930917
ability O 0 0.00021718505
to O 0 0.00019212671
walk O 0 0.00034554934
and O 0 0.00023174121
shorter O 0 0.00019469074
night O 0 0.000629359
- O 0 0.00083984993
time O 0 0.00024556796
sleep O 0 0.0012105284
during O 0 0.00030329532
the O 0 0.00047502425
week O 0 0.00058360683
prior O 0 0.0008885196
to O 0 0.0017968359
admission O 0 0.006233607
. O 0 0.0058520352

A O 0 0.046661828
higher O 0 0.0027353452
residual O 0 0.0021081695
serum O 0 0.11570942
concentration O 0 0.0074118767
of O 0 0.02451686
temazepam B-Chemical 0 0.9999999
correlated O 0 0.0005462036
with O 0 0.00046479574
a O 0 0.00050325587
lower O 0 0.0004772537
MMSE O 0 0.70438313
sum O 0 0.00030357423
score O 0 0.00037798332
after O 0 0.0003825225
adjustment O 0 0.0007985416
for O 0 0.0010989546
confounding O 0 0.002689769
variables O 0 0.004743061
. O 0 0.0067640496

CONCLUSIONS O 0 0.027671598
: O 0 0.004971832
Long O 0 0.008527599
- O 0 0.0040519685
term O 0 0.0010492987
use O 0 0.000839176
and O 0 0.0007331067
concomitant O 0 0.0010139197
use O 0 0.0004445933
of O 0 0.000458993
more O 0 0.00042822046
than O 0 0.0002533918
one O 0 0.0005170987
BZD O 0 0.9999356
/ O 0 0.06804639
RD O 0 0.9991596
were O 0 0.00039062864
common O 0 0.0004066663
in O 0 0.00038221668
elderly O 0 0.07545216
patients O 0 0.00096627953
hospitalised O 0 0.099644125
because O 0 0.00087676453
of O 0 0.0023654634
acute O 0 0.9525259
illnesses O 0 0.97473764
. O 0 0.010606556

Long O 0 0.022478445
- O 0 0.0072044893
term O 0 0.0017618578
use O 0 0.0013132942
was O 0 0.0009266863
associated O 0 0.0006704258
with O 0 0.0005777747
daytime O 0 0.0047510043
and O 0 0.0004892034
night O 0 0.0018407404
- O 0 0.0015954799
time O 0 0.00019471713
symptoms O 0 0.010371445
indicative O 0 0.00019281858
of O 0 0.0002707547
poorer O 0 0.0006150619
health O 0 0.0012674368
and O 0 0.00027814682
potentially O 0 0.00039472143
caused O 0 0.00030699026
by O 0 0.0004153383
the O 0 0.000520034
adverse O 0 0.13740133
effects O 0 0.0010662813
of O 0 0.0016657193
these O 0 0.0030443144
drugs O 0 0.37219068
. O 0 0.0068102917

Acute O 0 0.65680623
vocal B-Disease 0 0.33951315
fold I-Disease 0 0.08122293
palsy I-Disease 0 0.9999864
after O 0 0.009379441
acute O 0 0.99942183
disulfiram B-Chemical 0 0.9999993
intoxication O 0 0.99996316
. O 0 0.024989393

Acute O 0 0.9022324
peripheral B-Disease 2 0.9642886
neuropathy I-Disease 2 0.9999956
caused O 0 0.0024548243
by O 0 0.0019307412
a O 0 0.030067444
disulfiram B-Chemical 0 0.99999976
overdose B-Disease 0 0.99999607
is O 0 0.00079562113
very O 0 0.00059328385
rare O 0 0.001011899
and O 0 0.00030488527
there O 0 0.0002018296
is O 0 0.0002794919
no O 0 0.00025287314
report O 0 0.00067228585
of O 0 0.0005794187
it O 0 0.0006624552
leading O 0 0.001112467
to O 0 0.0012122575
vocal B-Disease 0 0.27583498
fold I-Disease 0 0.053220645
palsy I-Disease 0 0.99999034
. O 0 0.01319304

A O 0 0.078418605
49 O 0 0.0060234424
- O 0 0.007343852
year O 0 0.0021815703
- O 0 0.0041943756
old O 0 0.0011845225
woman O 0 0.002120972
was O 0 0.00059565285
transferred O 0 0.00042985255
to O 0 0.0003221796
our O 0 0.00031952452
department O 0 0.0003830713
because O 0 0.00024820617
of O 0 0.0007486655
quadriparesis B-Disease 0 0.9999727
, O 0 0.014934439
lancinating O 0 0.99366236
pain B-Disease 0 0.97621787
, O 0 0.0009871069
sensory B-Disease 0 0.11259707
loss I-Disease 0 0.022769254
, O 0 0.0010005373
and O 0 0.0012886365
paresthesia B-Disease 0 0.99742717
of O 0 0.001355468
the O 0 0.0016201616
distal O 0 0.003743115
limbs O 0 0.09989378
. O 0 0.006986177

One O 0 0.004360177
month O 0 0.002213937
previously O 0 0.001795267
, O 0 0.0015353821
she O 0 0.0007801856
had O 0 0.0005637814
taken O 0 0.00038979205
a O 0 0.0004523575
single O 0 0.00035150073
high O 0 0.0004526862
dose O 0 0.0029470562
of O 0 0.0056847557
disulfiram B-Chemical 0 0.9999995
( O 0 0.00323881
130 O 0 0.00088228384
tablets O 0 0.05909775
of O 0 0.0004720087
ALCOHOL B-Chemical 0 0.7503177
STOP O 0 0.644637
TAB O 0 0.9669883
, O 0 0.00317468
Shin O 0 0.8978666
- O 0 0.41301146
Poong O 0 0.99966395
Pharm O 0 0.99887186
. O 0 0.00092670694
Co O 0 0.99973017
. O 0 0.00059880805
, O 0 0.0015762773
Ansan O 0 0.97828144
, O 0 0.0011881652
Korea O 0 0.028186077
) O 0 0.001400617
in O 0 0.0013101384
a O 0 0.0025586039
suicide O 0 0.7873191
attempt O 0 0.0050338726
. O 0 0.007584491

She O 0 0.023724845
was O 0 0.018411594
not O 0 0.01926142
an O 0 0.029622115
alcoholic O 0 0.99855644
. O 0 0.03894891

For O 0 0.0032808895
the O 0 0.0020861153
first O 0 0.0012584513
few O 0 0.00086661
days O 0 0.0006837069
after O 0 0.000593049
ingestion O 0 0.22899255
, O 0 0.0008727612
she O 0 0.00038676258
was O 0 0.00036434233
in O 0 0.00033055583
a O 0 0.00044349485
confused O 0 0.0008549511
state O 0 0.0004166523
and O 0 0.00046028834
had O 0 0.00052736833
mild O 0 0.19115178
to O 0 0.0009301898
moderate O 0 0.49199018
ataxia B-Disease 0 0.9999956
and O 0 0.09286626
giddiness B-Disease 0 0.9999691
. O 0 0.009366985

She O 0 0.005557602
noticed O 0 0.0041493224
hoarseness B-Disease 2 0.9605037
and O 0 0.0020623403
distally O 0 0.0030104306
accentuated O 0 0.0058523742
motor O 0 0.013017488
and O 0 0.0008498645
sensory O 0 0.003005909
dysfunction O 0 0.22316517
after O 0 0.00047982542
she O 0 0.00058347866
had O 0 0.0007009318
recovered O 0 0.00085305504
from O 0 0.001328262
this O 0 0.0022153999
state O 0 0.004577474
. O 0 0.0072234767

A O 0 0.05894979
nerve O 0 0.030686915
conduction O 0 0.007904568
study O 0 0.0029231592
was O 0 0.0020527137
consistent O 0 0.0018291501
with O 0 0.0024416742
severe O 0 0.23177132
sensorimotor O 0 0.72775555
axonal O 0 0.52630025
polyneuropathy B-Disease 0 0.9998933
. O 0 0.012083349

Laryngeal O 0 0.10421967
electromyography O 0 0.11804087
( O 0 0.0064682746
thyroarytenoid O 0 0.01292501
muscle O 0 0.009571275
) O 0 0.0051452583
showed O 0 0.003961177
ample O 0 0.0063155494
denervation O 0 0.8180055
potentials O 0 0.10672714
. O 0 0.013332747

Laryngoscopy O 0 0.01948093
revealed O 0 0.0068087825
asymmetric O 0 0.009027316
vocal O 0 0.03250389
fold O 0 0.008887352
movements O 0 0.011530709
during O 0 0.008071637
phonation O 0 0.056392904
. O 0 0.015637234

Her O 0 0.008810906
vocal O 0 0.01659625
change O 0 0.0030555802
and O 0 0.0026758295
weakness O 0 0.7447511
began O 0 0.0014300061
to O 0 0.000912482
improve O 0 0.00078544696
spontaneously O 0 0.0013461142
about O 0 0.0009680368
3 O 0 0.0011841819
weeks O 0 0.0013358319
after O 0 0.0021156631
transfer O 0 0.005094781
. O 0 0.008423216

This O 0 0.0055477307
was O 0 0.002869646
a O 0 0.0022498204
case O 0 0.0016622482
of O 0 0.0022961218
acute O 0 0.99397546
palsy B-Disease 0 0.9999994
of O 0 0.005502759
the O 0 0.0007562145
recurrent O 0 0.23860098
laryngeal O 0 0.500901
nerve O 0 0.09450434
and O 0 0.0003626241
superimposed O 0 0.0044940943
severe O 0 0.24248871
acute O 0 0.9421519
sensorimotor O 0 0.82590044
axonal O 0 0.28584898
polyneuropathy B-Disease 0 0.99992204
caused O 0 0.0005643982
by O 0 0.0006892357
high O 0 0.0027319617
- O 0 0.12664405
dose O 0 0.5848524
disulfiram B-Chemical 0 0.99999917
intoxication O 0 0.9999325
. O 0 0.01083433

Encephalopathy B-Disease 0 0.9983637
induced O 0 0.009752304
by O 0 0.0113113
levetiracetam B-Chemical 1 0.9999552
added O 0 0.009855304
to O 0 0.011870397
valproate B-Chemical 0 0.9999491
. O 0 0.01703499

BACKGROUND O 0 0.015534487
: O 0 0.004298124
We O 0 0.0021186774
report O 0 0.0019373215
on O 0 0.0009293123
the O 0 0.0009837981
manifestation O 0 0.006736523
of O 0 0.0013749629
a O 0 0.0071493625
levetiracetam B-Chemical 1 0.9999976
( O 0 0.09519603
LEV B-Chemical 0 0.9999758
) O 0 0.011533417
- O 0 0.030818291
induced O 0 0.007732665
encephalopathy B-Disease 2 0.9999794
. O 0 0.014305581

FINDINGS O 0 0.009164646
: O 0 0.005256353
A O 0 0.030270651
28 O 0 0.0024128833
- O 0 0.0045116385
year O 0 0.0013371735
- O 0 0.0037176725
old O 0 0.00091309205
man O 0 0.051794324
suffering O 0 0.25563464
from O 0 0.0010831042
idiopathic B-Disease 0 0.99998534
epilepsy I-Disease 2 1.0
with O 0 0.046288
generalized O 0 0.998692
seizures B-Disease 0 1.0
was O 0 0.0006834773
treated O 0 0.0005713873
with O 0 0.002035095
LEV B-Chemical 0 0.9999745
( O 0 0.00093327335
3000 O 0 0.0006139147
mg O 0 0.007834352
) O 0 0.00037102887
added O 0 0.0002576652
to O 0 0.0005072803
valproate B-Chemical 0 0.9999968
( O 0 0.05251265
VPA B-Chemical 1 0.99999857
) O 0 0.007400355
( O 0 0.0021466408
2000 O 0 0.0031062386
mg O 0 0.04617072
) O 0 0.0054667983
. O 0 0.007011085

Frequency O 0 0.006800455
of O 0 0.003930228
generalized O 0 0.250627
tonic B-Disease 0 0.95483863
- I-Disease 0 0.93046016
clonic I-Disease 0 0.99999976
seizures I-Disease 0 0.9999999
increased O 0 0.0014218158
from O 0 0.00044266615
one O 0 0.0003610835
per O 0 0.0002889484
6 O 0 0.00036413586
months O 0 0.00041853247
to O 0 0.00064145186
two O 0 0.00093540095
per O 0 0.001382964
month O 0 0.0028650805
. O 0 0.006213099

Neuropsychological O 0 0.11630182
testing O 0 0.0034782917
showed O 0 0.0025207815
impaired B-Disease 0 0.0029876684
word I-Disease 0 0.00754757
fluency I-Disease 0 0.99497426
, I-Disease 0 0.006234668
psychomotor I-Disease 0 0.9935133
speed I-Disease 0 0.0038195506
and I-Disease 0 0.0037572267
working I-Disease 0 0.00849127
memory I-Disease 0 0.2603765
. O 0 0.011146052

The O 0 0.0037854034
interictal O 0 0.90662545
electroencephalogram O 0 0.6940252
( O 0 0.003351831
EEG O 0 0.89003366
) O 0 0.0012664027
showed O 0 0.0005272256
a O 0 0.00058840343
generalized O 0 0.007285152
slowing O 0 0.0017436922
to O 0 0.00023651437
5 O 0 0.0001931813
per O 0 0.00015483303
second O 0 0.00025660096
theta O 0 0.22579102
rhythms O 0 0.002725423
with O 0 0.0004873166
bilateral O 0 0.030676652
generalized O 0 0.03293641
high O 0 0.0021697257
- O 0 0.017318303
amplitude O 0 0.012002724
discharges O 0 0.27603543
. O 0 0.0071505336

OUTCOME O 0 0.0074308445
: O 0 0.0041149734
Following O 0 0.0024126216
discontinuation O 0 0.32025144
of O 0 0.004849955
LEV B-Chemical 0 0.99996233
, O 0 0.004248152
EEG O 0 0.9006038
and O 0 0.0009994527
neuropsychological O 0 0.14135554
findings O 0 0.0009749621
improved O 0 0.0013063317
and O 0 0.0022286195
seizure B-Disease 2 0.99983144
frequency O 0 0.0043987823
decreased O 0 0.0065488126
. O 0 0.008209324

Norepinephrine B-Chemical 0 0.99964595
signaling O 0 0.0035169618
through O 0 0.0024860427
beta O 0 0.9879901
- O 0 0.5356108
adrenergic O 0 0.9939328
receptors O 0 0.010909051
is O 0 0.000706591
critical O 0 0.0005038362
for O 0 0.0005967336
expression O 0 0.0009516304
of O 0 0.0055469126
cocaine B-Chemical 1 0.99999225
- O 0 0.1440033
induced O 0 0.0070188143
anxiety B-Disease 0 0.9965682
. O 0 0.0082949

BACKGROUND O 0 0.081799164
: O 0 0.025367325
Cocaine B-Chemical 0 0.9999796
is O 0 0.0030190959
a O 0 0.002278784
widely O 0 0.002168407
abused O 0 0.92648804
psychostimulant O 0 0.9969144
that O 0 0.0008400016
has O 0 0.0009217194
both O 0 0.0012038964
rewarding O 0 0.027281133
and O 0 0.0023903751
aversive O 0 0.06956402
properties O 0 0.0045337006
. O 0 0.0076651596

While O 0 0.003350974
the O 0 0.0020069259
mechanisms O 0 0.0015696797
underlying O 0 0.005592022
cocaine B-Chemical 1 0.9999851
' O 0 0.0028481132
s O 0 0.001105228
rewarding O 0 0.026326917
effects O 0 0.00041055726
have O 0 0.00023397872
been O 0 0.00024602847
studied O 0 0.00027812322
extensively O 0 0.0003087046
, O 0 0.0003588172
less O 0 0.00023427875
attention O 0 0.0004199472
has O 0 0.00018177165
been O 0 0.00018979976
paid O 0 0.00025519056
to O 0 0.00017721561
the O 0 0.00025190605
unpleasant O 0 0.10102563
behavioral O 0 0.0039750724
states O 0 0.00044538395
induced O 0 0.00049006776
by O 0 0.0014796933
cocaine B-Chemical 1 0.9999746
, O 0 0.0017150366
such O 0 0.001428126
as O 0 0.002694455
anxiety B-Disease 0 0.9821422
. O 0 0.006696263

METHODS O 0 0.004008469
: O 0 0.0036316277
In O 0 0.0019638855
this O 0 0.0014572454
study O 0 0.0013313903
, O 0 0.0009998236
we O 0 0.00043104292
evaluated O 0 0.0003599435
the O 0 0.00035456562
performance O 0 0.0006307257
of O 0 0.001930022
dopamine B-Chemical 1 0.9999894
beta O 0 0.99890447
- O 0 0.87107617
hydroxylase O 0 0.9987184
knockout O 0 0.00045067418
( O 0 0.0032052977
Dbh O 0 0.4840619
- O 0 0.03673378
/ O 0 0.026389193
- O 0 0.025604192
) O 0 0.00051751535
mice O 0 0.00014000392
, O 0 0.00032214398
which O 0 0.00031660195
lack O 0 0.0004612278
norepinephrine B-Chemical 1 0.9999875
( O 0 0.017307457
NE B-Chemical 0 0.9998293
) O 0 0.0038921963
, O 0 0.00038310804
in O 0 0.00017353155
the O 0 0.00017410566
elevated O 0 0.0010124606
plus O 0 0.00020533045
maze O 0 0.2218788
( O 0 0.0038609055
EPM O 0 0.98738575
) O 0 0.00037868592
to O 0 0.00013498569
examine O 0 9.5160314e-05
the O 0 0.00015961898
contribution O 0 0.00018155186
of O 0 0.00047113397
noradrenergic O 0 0.45740974
signaling O 0 0.00049993163
to O 0 0.0009774409
cocaine B-Chemical 1 0.9999809
- O 0 0.05717628
induced O 0 0.004734187
anxiety B-Disease 0 0.99525416
. O 0 0.0071895868

RESULTS O 0 0.0053529404
: O 0 0.0033520893
We O 0 0.0016936267
found O 0 0.001257782
that O 0 0.001262175
cocaine B-Chemical 1 0.99998116
dose O 0 0.31750655
- O 0 0.3340757
dependently O 0 0.9485841
increased O 0 0.0086107915
anxiety B-Disease 0 0.9994037
- O 0 0.01667546
like O 0 0.00022626323
behavior O 0 0.00058318174
in O 0 0.0002051375
control O 0 0.00027672033
( O 0 0.0012922826
Dbh O 0 0.28157446
+ O 0 0.006049655
/ O 0 0.03292788
- O 0 0.025519833
) O 0 0.0005367233
mice O 0 0.00018037405
, O 0 0.00032763398
as O 0 0.00024595764
measured O 0 0.00027007124
by O 0 0.00041381537
a O 0 0.00058245874
decrease O 0 0.0006553443
in O 0 0.0009455159
open O 0 0.0017909273
arm O 0 0.0027590205
exploration O 0 0.004876966
. O 0 0.0068614082

The O 0 0.0046547186
Dbh O 0 0.38722625
- O 0 0.041994836
/ O 0 0.01629997
- O 0 0.004632844
mice O 0 0.0006187211
had O 0 0.00058918947
normal O 0 0.0006465427
baseline O 0 0.00041187284
performance O 0 0.000505372
in O 0 0.00032583287
the O 0 0.0004822908
EPM O 0 0.97831535
but O 0 0.00042117157
were O 0 0.0002878066
completely O 0 0.00028056814
resistant O 0 0.00039834352
to O 0 0.00040456478
the O 0 0.0008071278
anxiogenic O 0 0.99312496
effects O 0 0.0025446184
of O 0 0.012386053
cocaine B-Chemical 1 0.999969
. O 0 0.009082278

Cocaine B-Chemical 0 0.9999906
- O 0 0.20311186
induced O 0 0.0048903315
anxiety B-Disease 0 0.99534506
was O 0 0.0011881589
also O 0 0.0006874802
attenuated O 0 0.001182705
in O 0 0.0009009355
Dbh O 0 0.5114338
+ O 0 0.011305702
/ O 0 0.027756972
- O 0 0.005430218
mice O 0 0.00016718387
following O 0 0.00020309209
administration O 0 0.0036260963
of O 0 0.0036760806
disulfiram B-Chemical 0 0.9999995
, O 0 0.0051950356
a O 0 0.007853398
dopamine B-Chemical 1 0.9999815
beta O 0 0.9972167
- O 0 0.886798
hydroxylase O 0 0.9995011
( O 0 0.017109511
DBH O 0 0.9848491
) O 0 0.004418955
inhibitor O 0 0.02403822
. O 0 0.00744482

In O 0 0.0033240244
experiments O 0 0.001755978
using O 0 0.0015676918
specific O 0 0.0017271166
adrenergic O 0 0.99502325
antagonists O 0 0.8923134
, O 0 0.0010580856
we O 0 0.00027367208
found O 0 0.00026191998
that O 0 0.00021672789
pretreatment O 0 0.017724175
with O 0 0.0004143732
the O 0 0.00073487667
beta O 0 0.99780196
- O 0 0.91530126
adrenergic O 0 0.9994567
receptor O 0 0.7373557
antagonist O 0 0.9987342
propranolol B-Chemical 1 0.9999999
blocked O 0 0.18549219
cocaine B-Chemical 1 0.9999993
- O 0 0.19414365
induced O 0 0.0013996996
anxiety B-Disease 0 0.99924064
- O 0 0.01318135
like O 0 0.00016630054
behavior O 0 0.00071831344
in O 0 0.0002845331
Dbh O 0 0.21820988
+ O 0 0.0040803836
/ O 0 0.019252073
- O 0 0.012445111
and O 0 0.00030615696
wild O 0 0.0003098403
- O 0 0.008973887
type O 0 0.00037687615
C57BL6 O 0 0.041723248
/ O 0 0.023994554
J O 0 0.9522284
mice O 0 0.00015506262
, O 0 0.00033059367
while O 0 0.00022564665
the O 0 0.00027551307
alpha O 0 0.7622949
( O 0 0.003045661
1 O 0 0.00039486328
) O 0 0.0048406017
antagonist O 0 0.98663133
prazosin B-Chemical 1 0.99999964
and O 0 0.00069042033
the O 0 0.00042913645
alpha O 0 0.7612819
( O 0 0.002843134
2 O 0 0.00059047237
) O 0 0.0059024226
antagonist O 0 0.991642
yohimbine B-Chemical 1 0.99999905
had O 0 0.0017373955
no O 0 0.0017448664
effect O 0 0.0035442712
. O 0 0.006724276

CONCLUSIONS O 0 0.016691659
: O 0 0.0034443815
These O 0 0.001691184
results O 0 0.0010842243
indicate O 0 0.00067785085
that O 0 0.000702391
noradrenergic O 0 0.29364106
signaling O 0 0.00054887094
via O 0 0.00055222434
beta O 0 0.98811775
- O 0 0.5866682
adrenergic O 0 0.99221814
receptors O 0 0.0068214536
is O 0 0.00037983243
required O 0 0.00027257478
for O 0 0.0008532258
cocaine B-Chemical 1 0.99998856
- O 0 0.051653076
induced O 0 0.0020698276
anxiety B-Disease 0 0.9881499
in O 0 0.0021948155
mice O 0 0.0028970027
. O 0 0.006584345

Hypothalamic O 0 0.9342821
prolactin O 0 0.99700934
receptor O 0 0.24465251
messenger O 0 0.2092163
ribonucleic B-Chemical 0 0.9995328
acid I-Chemical 0 0.99946827
levels O 0 0.0041299323
, O 0 0.008992934
prolactin O 0 0.9922564
signaling O 0 0.0006705514
, O 0 0.0009610077
and O 0 0.0010497186
hyperprolactinemic B-Disease 0 0.99856734
inhibition O 0 0.0010472992
of O 0 0.00091556663
pulsatile O 0 0.14545962
luteinizing O 0 0.9947996
hormone O 0 0.93180746
secretion O 0 0.0051048337
are O 0 0.0010962705
dependent O 0 0.0013567944
on O 0 0.0024780084
estradiol B-Chemical 0 0.9999057
. O 0 0.01058549

Hyperprolactinemia B-Disease 0 0.99927753
can O 0 0.01191624
reduce O 0 0.010734358
fertility O 0 0.058974903
and O 0 0.020956643
libido O 0 0.9756708
. O 0 0.02773592

Although O 0 0.0036449668
central O 0 0.005166457
prolactin O 0 0.96806973
actions O 0 0.0038339857
are O 0 0.001099276
thought O 0 0.0008181959
to O 0 0.00056946016
contribute O 0 0.0005068719
to O 0 0.0005423392
this O 0 0.0006307007
, O 0 0.0008593049
the O 0 0.0007765657
mechanisms O 0 0.0010590426
are O 0 0.0016518434
poorly O 0 0.0035698186
understood O 0 0.0054474096
. O 0 0.007335055

We O 0 0.0033213936
first O 0 0.0018857941
tested O 0 0.0014241969
whether O 0 0.0009775845
chronic O 0 0.98492265
hyperprolactinemia B-Disease 2 0.9999989
inhibited O 0 0.0035675159
two O 0 0.00041335844
neuroendocrine O 0 0.057749167
parameters O 0 0.00036559036
necessary O 0 0.0001795735
for O 0 0.0002535588
female O 0 0.002700538
fertility O 0 0.08086776
: O 0 0.0022437389
pulsatile O 0 0.0703622
LH O 0 0.9966221
secretion O 0 0.0030692094
and O 0 0.0010626086
the O 0 0.0025538036
estrogen B-Chemical 1 0.99998283
- O 0 0.28402644
induced O 0 0.013655844
LH O 0 0.9992217
surge O 0 0.67704415
. O 0 0.010026242

Chronic O 0 0.98533547
hyperprolactinemia B-Disease 2 0.999987
induced O 0 0.0041543003
by O 0 0.002355408
the O 0 0.007370161
dopamine B-Chemical 1 0.9999926
antagonist O 0 0.99956685
sulpiride B-Chemical 0 0.9999999
caused O 0 0.0008279063
a O 0 0.0006144898
40 O 0 0.00030445593
% O 0 0.00039888977
reduction O 0 0.0024501183
LH O 0 0.9958033
pulse O 0 0.0016894065
frequency O 0 0.0003690307
in O 0 0.0003124704
ovariectomized O 0 0.13424042
rats O 0 0.00049797434
, O 0 0.0003670739
but O 0 0.00028514606
only O 0 0.00024411037
in O 0 0.0002265417
the O 0 0.00025358394
presence O 0 0.00034304988
of O 0 0.0007807862
chronic O 0 0.74257076
low O 0 0.0025154767
levels O 0 0.0019787701
of O 0 0.019428467
estradiol B-Chemical 0 0.9999658
. O 0 0.012349778

Sulpiride B-Chemical 0 0.9999896
did O 0 0.004240441
not O 0 0.0015564375
affect O 0 0.0008594008
the O 0 0.0007025971
magnitude O 0 0.0005397144
of O 0 0.0008217331
a O 0 0.0041823946
steroid B-Chemical 1 0.99983203
- O 0 0.2616454
induced O 0 0.0061804564
LH O 0 0.9997913
surge O 0 0.29511017
or O 0 0.0003852105
the O 0 0.00030632253
percentage O 0 0.00029162824
of O 0 0.0007663873
GnRH O 0 0.4076716
neurons O 0 0.0014878077
activated O 0 0.00094827026
during O 0 0.001179439
the O 0 0.0024652034
surge O 0 0.10236699
. O 0 0.0077341143

Estradiol B-Chemical 0 0.9999666
is O 0 0.0038527893
known O 0 0.0019787701
to O 0 0.00094133924
influence O 0 0.0005966358
expression O 0 0.00061866856
of O 0 0.0005290499
the O 0 0.00034767296
long O 0 0.0003030936
form O 0 0.00028760056
of O 0 0.0009786084
prolactin O 0 0.9977246
receptors O 0 0.14474341
( O 0 0.09045518
PRL O 0 0.9999969
- O 0 0.7530799
R O 0 0.9993436
) O 0 0.0015360527
and O 0 0.0004374178
components O 0 0.00044546401
of O 0 0.0010831744
prolactin O 0 0.973368
' O 0 0.0016863332
s O 0 0.0016807497
signaling O 0 0.0022611474
pathway O 0 0.003893036
. O 0 0.0069177886

To O 0 0.0027710013
test O 0 0.002110965
the O 0 0.0013780921
hypothesis O 0 0.0012955525
that O 0 0.0017749631
estrogen B-Chemical 1 0.99999285
increases O 0 0.12509191
PRL O 0 0.9999989
- O 0 0.9155228
R O 0 0.9995546
expression O 0 0.0008770419
and O 0 0.00047821182
sensitivity O 0 0.0022937907
to O 0 0.0003886961
prolactin O 0 0.98750824
, O 0 0.00037327677
we O 0 0.0001347298
next O 0 0.00013140393
demonstrated O 0 0.00020009969
that O 0 0.00040358654
estradiol B-Chemical 0 0.99998796
greatly O 0 0.021645403
augments O 0 0.056993697
prolactin O 0 0.9994037
- O 0 0.114844784
induced O 0 0.003142437
STAT5 O 0 0.84936154
activation O 0 0.016578324
. O 0 0.0080369925

Lastly O 0 0.004788041
, O 0 0.0032201954
we O 0 0.001559766
measured O 0 0.0020766766
PRL O 0 0.9999776
- O 0 0.6064598
R O 0 0.9978421
and O 0 0.0011109917
suppressor O 0 0.0036368903
of O 0 0.00065345457
cytokine O 0 0.12711266
signaling O 0 0.00060290605
( O 0 0.0027031563
SOCS O 0 0.49698937
- O 0 0.021606468
1 O 0 0.00025499743
and O 0 0.00032132567
- O 0 0.0037931039
3 O 0 0.00020139743
and O 0 0.00034475475
CIS O 0 0.81036645
, O 0 0.00039403865
which O 0 0.00023453978
reflect O 0 0.00013649996
the O 0 0.00016396862
level O 0 0.00017535423
of O 0 0.0005468404
prolactin O 0 0.9794358
signaling O 0 0.00047935636
) O 0 0.0011792143
mRNAs O 0 0.00059188745
in O 0 0.00050781487
response O 0 0.0011320696
to O 0 0.002251198
sulpiride B-Chemical 0 0.9999993
and O 0 0.0401134
estradiol B-Chemical 0 0.9999565
. O 0 0.010766046

Sulpiride B-Chemical 0 0.9999838
induced O 0 0.004779142
only O 0 0.0041121277
SOCS O 0 0.49947956
- O 0 0.018987842
1 O 0 0.0007009676
in O 0 0.00045466376
the O 0 0.00041784937
medial O 0 0.020503048
preoptic O 0 0.035019234
area O 0 0.00063791213
, O 0 0.00047570447
where O 0 0.00039290646
GnRH O 0 0.3603937
neurons O 0 0.0006923331
are O 0 0.00017149825
regulated O 0 0.0001236049
, O 0 0.00027478064
but O 0 0.00020612372
in O 0 0.00014704316
the O 0 0.00015981542
arcuate O 0 0.0016617038
nucleus O 0 0.0002578687
and O 0 0.00027212503
choroid O 0 0.9439712
plexus O 0 0.40518644
, O 0 0.0118366955
PRL O 0 0.9999944
- O 0 0.7160762
R O 0 0.9996743
, O 0 0.005682161
SOCS O 0 0.57814634
- O 0 0.020142598
3 O 0 0.00033274034
, O 0 0.00049637933
and O 0 0.00069041806
CIS O 0 0.75493836
mRNA O 0 0.0010873372
levels O 0 0.0010834505
were O 0 0.0015170159
also O 0 0.00218894
induced O 0 0.004274538
. O 0 0.007963001

Estradiol B-Chemical 0 0.99990344
enhanced O 0 0.0058740135
these O 0 0.00422444
effects O 0 0.00395963
on O 0 0.0030848065
SOCS O 0 0.19622391
- O 0 0.015963787
3 O 0 0.004858443
and O 0 0.007636613
CIS O 0 0.7561244
. O 0 0.014369479

Interestingly O 0 0.006026615
, O 0 0.01721397
estradiol B-Chemical 0 0.9999578
also O 0 0.003196513
induced O 0 0.03334082
PRL O 0 0.9999969
- O 0 0.9221252
R O 0 0.9997758
, O 0 0.011960997
SOCS O 0 0.6028198
- O 0 0.020285407
3 O 0 0.0007160891
, O 0 0.0010248033
and O 0 0.0013601247
CIS O 0 0.68589735
mRNA O 0 0.0023843697
levels O 0 0.0027842857
independently O 0 0.0041193417
. O 0 0.008038847

These O 0 0.0039253174
data O 0 0.002727355
show O 0 0.0015824633
that O 0 0.0014583069
GnRH O 0 0.4661278
pulse O 0 0.0032533496
frequency O 0 0.0010180954
is O 0 0.0007067658
inhibited O 0 0.00084019126
by O 0 0.001123794
chronic O 0 0.9941239
hyperprolactinemia B-Disease 2 0.99999917
in O 0 0.0017576689
a O 0 0.0044635935
steroid B-Chemical 1 0.9986028
- O 0 0.026409635
dependent O 0 0.0022596237
manner O 0 0.0040714927
. O 0 0.0072734742

They O 0 0.004315401
also O 0 0.0020782065
provide O 0 0.0013392619
evidence O 0 0.0011826612
for O 0 0.0025999732
estradiol B-Chemical 0 0.9999951
- O 0 0.09599675
dependent O 0 0.00048071568
and O 0 0.00060723926
brain O 0 0.014278001
region O 0 0.00071362895
- O 0 0.002502887
specific O 0 0.00025289872
regulation O 0 0.00025060264
of O 0 0.0028555347
PRL O 0 0.9999944
- O 0 0.61091995
R O 0 0.9977811
expression O 0 0.0008859851
and O 0 0.0008695269
signaling O 0 0.0011198225
responses O 0 0.0024710852
by O 0 0.003500207
prolactin O 0 0.9734721
. O 0 0.008123041

Clonidine B-Chemical 0 0.999961
for O 0 0.006202283
attention B-Disease 0 0.011600189
- I-Disease 0 0.033283405
deficit I-Disease 0 0.45663884
/ I-Disease 0 0.28881657
hyperactivity I-Disease 2 0.9999664
disorder I-Disease 0 0.99711084
: O 0 0.016211145
II O 0 0.07035917
. O 0 0.012296541

ECG O 0 0.39362624
changes O 0 0.012599783
and O 0 0.012498507
adverse O 0 0.25267518
events O 0 0.025262555
analysis O 0 0.01717385
. O 0 0.022261854

OBJECTIVE O 0 0.014526661
: O 0 0.0030764283
To O 0 0.0012255085
examine O 0 0.00066224975
the O 0 0.00071177003
safety O 0 0.0008113091
and O 0 0.0005949011
tolerability O 0 0.012370844
of O 0 0.0015003725
clonidine B-Chemical 0 0.99998236
used O 0 0.0002721245
alone O 0 0.0002667738
or O 0 0.00027571068
with O 0 0.0013317366
methylphenidate B-Chemical 1 0.99999404
in O 0 0.00026030603
children O 0 0.000565688
with O 0 0.00035433078
attention B-Disease 0 0.0016647594
- I-Disease 0 0.018562203
deficit I-Disease 0 0.32560828
/ I-Disease 0 0.24856202
hyperactivity I-Disease 2 0.99999166
disorder I-Disease 0 0.99882406
( O 0 0.0715574
ADHD B-Disease 0 0.99995375
) O 0 0.009320931
. O 0 0.007754752

METHOD O 0 0.008105365
: O 0 0.0041314014
In O 0 0.0020795008
a O 0 0.0018259411
16 O 0 0.0014406362
- O 0 0.0021023704
week O 0 0.00063231756
multicenter O 0 0.0068993247
, O 0 0.00075927906
double O 0 0.00065838266
- O 0 0.0081266295
blind O 0 0.011722914
trial O 0 0.00048884045
, O 0 0.0004221409
122 O 0 0.0008269696
children O 0 0.00056744955
with O 0 0.000795083
ADHD B-Disease 0 0.99995565
were O 0 0.0001780997
randomly O 0 9.805077e-05
assigned O 0 0.00012885849
to O 0 0.0002088319
clonidine B-Chemical 0 0.99994445
( O 0 0.0003934424
n O 0 0.00019336284
= O 0 0.0004764155
31 O 0 0.00032641183
) O 0 0.0006257035
, O 0 0.0012751719
methylphenidate B-Chemical 1 0.99999046
( O 0 0.00048151865
n O 0 0.00020647128
= O 0 0.00051008974
29 O 0 0.00048058486
) O 0 0.0007078936
, O 0 0.0016009645
clonidine B-Chemical 0 0.99998486
and O 0 0.002541764
methylphenidate B-Chemical 1 0.99999475
( O 0 0.0005676705
n O 0 0.00025008566
= O 0 0.00054578617
32 O 0 0.0003967822
) O 0 0.0005520567
, O 0 0.00050097966
or O 0 0.00049608934
placebo O 0 0.008531024
( O 0 0.00095777283
n O 0 0.0010135754
= O 0 0.0022070778
30 O 0 0.002279801
) O 0 0.0050822496
. O 0 0.0072838147

Doses O 0 0.011435021
were O 0 0.0024641647
flexibly O 0 0.0018562017
titrated O 0 0.0012711731
up O 0 0.0007396815
to O 0 0.0005443321
0 O 0 0.00055942993
. O 0 0.00037478757
6 O 0 0.00028863287
mg O 0 0.002680204
/ O 0 0.00084311655
day O 0 0.00023826984
for O 0 0.00038397772
clonidine B-Chemical 0 0.999938
and O 0 0.00033050796
60 O 0 0.00025848558
mg O 0 0.0056705875
/ O 0 0.00077490864
day O 0 0.0002385365
for O 0 0.00047209085
methylphenidate B-Chemical 1 0.99998534
( O 0 0.000806248
both O 0 0.0005378277
with O 0 0.00082385575
divided O 0 0.0011352353
dosing O 0 0.004928475
) O 0 0.004904996
. O 0 0.0064690006

Groups O 0 0.01029175
were O 0 0.002493414
compared O 0 0.0012812184
regarding O 0 0.0010287772
adverse O 0 0.09170481
events O 0 0.0041133915
and O 0 0.00074720365
changes O 0 0.0005926664
from O 0 0.00037190432
baseline O 0 0.00037289143
to O 0 0.00034290258
week O 0 0.00037179387
16 O 0 0.0005685791
in O 0 0.00073628186
electrocardiograms O 0 0.010343067
and O 0 0.0017443609
vital O 0 0.004595503
signs O 0 0.06237083
. O 0 0.007188899

RESULTS O 0 0.0054640425
: O 0 0.0035390041
There O 0 0.0021302844
were O 0 0.001504541
more O 0 0.0012299365
incidents O 0 0.006840974
of O 0 0.0017487694
bradycardia B-Disease 0 0.99930716
in O 0 0.00053987704
subjects O 0 0.0005998671
treated O 0 0.0004945141
with O 0 0.0013825682
clonidine B-Chemical 0 0.9999778
compared O 0 0.00015624941
with O 0 0.00020773527
those O 0 0.0002131969
not O 0 0.00013110455
treated O 0 0.00026760425
with O 0 0.001402875
clonidine B-Chemical 0 0.99999094
( O 0 0.0008176052
17 O 0 0.0002557942
. O 0 0.00013344648
5 O 0 0.00011951295
% O 0 0.00015853021
versus O 0 0.00013801358
3 O 0 0.0001404496
. O 0 0.00014483323
4 O 0 0.00014728044
% O 0 0.00022044926
; O 0 0.00032879921
p O 0 0.00026375332
= O 0 0.00061174505
. O 0 0.0003203184
02 O 0 0.07431762
) O 0 0.0006661567
, O 0 0.00039935738
but O 0 0.00028836852
no O 0 0.00017611697
other O 0 0.0002499221
significant O 0 0.00026678215
group O 0 0.0003465789
differences O 0 0.00025145517
regarding O 0 0.00034801106
electrocardiogram O 0 0.042644914
and O 0 0.00090317224
other O 0 0.0015916419
cardiovascular O 0 0.8017352
outcomes O 0 0.007182102
. O 0 0.006436395

There O 0 0.0046867225
were O 0 0.0028416594
no O 0 0.0017071456
suggestions O 0 0.0016542295
of O 0 0.001485544
interactions O 0 0.0019331622
between O 0 0.001509622
clonidine B-Chemical 0 0.9999882
and O 0 0.010512298
methylphenidate B-Chemical 1 0.99998677
regarding O 0 0.0023253486
cardiovascular O 0 0.8839344
outcomes O 0 0.009438166
. O 0 0.008027094

Moderate O 0 0.41362578
or O 0 0.003442753
severe O 0 0.10841156
adverse O 0 0.5878673
events O 0 0.017526465
were O 0 0.00070971093
more O 0 0.0005220255
common O 0 0.00043451614
in O 0 0.00028873663
subjects O 0 0.00039603445
on O 0 0.00026096628
clonidine B-Chemical 0 0.999979
( O 0 0.00079340435
79 O 0 0.00046926673
. O 0 0.00018344368
4 O 0 0.00015714442
% O 0 0.00019492889
versus O 0 0.00016883198
49 O 0 0.00028307392
. O 0 0.0001797762
2 O 0 0.00018793516
% O 0 0.00025436273
; O 0 0.00036892676
p O 0 0.00028777635
= O 0 0.0006315639
. O 0 0.00031079474
0006 O 0 0.009062267
) O 0 0.00059823703
but O 0 0.00033049283
not O 0 0.00025405583
associated O 0 0.00034621631
with O 0 0.00041233873
higher O 0 0.00046689258
rates O 0 0.000707374
of O 0 0.0011641935
early O 0 0.0027866038
study O 0 0.004590291
withdrawal O 0 0.37808666
. O 0 0.0069271675

Drowsiness B-Disease 0 0.99620974
was O 0 0.0036636319
common O 0 0.0027772181
on O 0 0.0018633488
clonidine B-Chemical 0 0.9999653
, O 0 0.0024580725
but O 0 0.0012990839
generally O 0 0.0010920734
resolved O 0 0.0011584515
by O 0 0.001152374
6 O 0 0.0011514028
to O 0 0.0015986215
8 O 0 0.0025430345
weeks O 0 0.003388865
. O 0 0.0074319183

CONCLUSIONS O 0 0.1344899
: O 0 0.033476185
Clonidine B-Chemical 0 0.9999908
, O 0 0.003377768
used O 0 0.0010797272
alone O 0 0.0009095108
or O 0 0.00081306754
with O 0 0.0026268447
methylphenidate B-Chemical 1 0.99999595
, O 0 0.0012247092
appears O 0 0.0004962928
safe O 0 0.0007213314
and O 0 0.0006109687
well O 0 0.00076568656
tolerated O 0 0.00496112
in O 0 0.0020025268
childhood O 0 0.9906222
ADHD B-Disease 0 0.9999697
. O 0 0.009517476

Physicians O 0 0.009790387
prescribing O 0 0.04605242
clonidine B-Chemical 0 0.9998888
should O 0 0.0010756482
monitor O 0 0.00082751364
for O 0 0.00092712557
bradycardia B-Disease 0 0.99552155
and O 0 0.0007802756
advise O 0 0.0015639211
patients O 0 0.000583172
about O 0 0.00041512298
the O 0 0.0005346557
high O 0 0.0008921717
likelihood O 0 0.0014533416
of O 0 0.0021787186
initial O 0 0.0047080573
drowsiness B-Disease 0 0.99990857
. O 0 0.008499674

Renal B-Disease 0 0.87485576
Fanconi I-Disease 2 0.9984485
syndrome I-Disease 2 0.9966556
and O 0 0.006396004
myopathy B-Disease 2 0.99940073
after O 0 0.001259591
liver O 0 0.7492942
transplantation O 0 0.15363568
: O 0 0.0046359254
drug O 0 0.49293083
- O 0 0.0096639255
related O 0 0.0020786934
mitochondrial B-Disease 0 0.2435415
cytopathy I-Disease 0 0.98555005
? O 0 0.03255908

Advances O 0 0.005669652
in O 0 0.0025083334
the O 0 0.0017141552
field O 0 0.00176901
of O 0 0.0011855242
transplantation O 0 0.0034199366
provide O 0 0.00048448666
a O 0 0.0005187914
better O 0 0.0003645537
quality O 0 0.00027745316
of O 0 0.00032608493
life O 0 0.000387869
and O 0 0.00029608412
allow O 0 0.00023249499
more O 0 0.00032292257
favorable O 0 0.0008457296
conditions O 0 0.00038507394
for O 0 0.0004714839
growth O 0 0.0020865013
and O 0 0.0011709543
development O 0 0.0024366085
in O 0 0.0023536114
children O 0 0.006749028
. O 0 0.0068905847

However O 0 0.0052047293
, O 0 0.0037722064
combinations O 0 0.0020293398
of O 0 0.0018557637
different O 0 0.001235503
therapeutic O 0 0.0017950054
regimens O 0 0.0012941671
require O 0 0.0008083081
consideration O 0 0.0010451245
of O 0 0.0016957419
potential O 0 0.003147095
adverse O 0 0.6768396
reactions O 0 0.056227233
. O 0 0.008651831

We O 0 0.003749134
describe O 0 0.0024099606
a O 0 0.0022776523
15 O 0 0.0015817161
- O 0 0.0030998955
yr O 0 0.0015349559
- O 0 0.0023510754
old O 0 0.0008653763
girl O 0 0.0013419284
who O 0 0.0008816233
had O 0 0.0006369368
orthotopic O 0 0.8531755
liver O 0 0.8359674
transplantation O 0 0.04726098
because O 0 0.0007617488
of O 0 0.001613682
Wilson B-Disease 0 0.4351709
' I-Disease 0 0.003554724
s I-Disease 0 0.0045016613
disease I-Disease 0 0.8087917
. O 0 0.008777765

Tacrolimus B-Chemical 1 0.9999393
, O 0 0.10889026
MMF B-Chemical 0 0.99997413
, O 0 0.009189178
and O 0 0.0055001765
steroids B-Chemical 0 0.9973514
were O 0 0.0034095126
given O 0 0.0028335832
as O 0 0.0048073446
immunosuppressant O 0 0.933995
. O 0 0.012090505

Lamivudine B-Chemical 1 0.9998871
was O 0 0.0039831684
added O 0 0.0022027662
because O 0 0.0014646015
of O 0 0.0017545082
de O 0 0.07691289
nova O 0 0.9909204
hepatitis B-Disease 2 1.0
B I-Disease 2 0.99998033
infection I-Disease 0 0.99957365
during O 0 0.0015660475
her O 0 0.0020041955
follow O 0 0.0018160525
- O 0 0.005659849
up O 0 0.004364849
. O 0 0.0076711574

Three O 0 0.003962485
yr O 0 0.002967609
after O 0 0.0015061185
transplantation O 0 0.003475815
she O 0 0.0010228812
developed O 0 0.0023755606
renal B-Disease 0 0.998126
Fanconi I-Disease 2 0.99994195
syndrome I-Disease 2 0.99953866
with O 0 0.0041552554
severe O 0 0.72644436
metabolic B-Disease 2 0.9966108
acidosis I-Disease 2 0.99999905
, O 0 0.18365462
hypophosphatemia B-Disease 0 0.99999857
, O 0 0.1163545
glycosuria B-Disease 2 0.99999285
, O 0 0.009646124
and O 0 0.011538054
aminoaciduria B-Disease 0 0.9999831
. O 0 0.011773094

Although O 0 0.005241792
tacrolimus B-Chemical 0 0.999949
was O 0 0.0027882592
suspected O 0 0.0055075865
to O 0 0.00076408335
be O 0 0.0006103855
the O 0 0.00044965284
cause O 0 0.0004895441
of O 0 0.0004929632
late O 0 0.0016913369
post O 0 0.00057281513
- O 0 0.026406646
transplant O 0 0.28571495
renal O 0 0.98942506
acidosis B-Disease 2 0.99995434
and O 0 0.00076007895
was O 0 0.0002665343
replaced O 0 0.0002566964
by O 0 0.0005583022
sirolimus B-Chemical 1 0.9999473
, O 0 0.008421774
acidosis B-Disease 2 0.99986184
, O 0 0.0015895541
and O 0 0.0012661307
electrolyte O 0 0.65058064
imbalance O 0 0.017755749
got O 0 0.0052609867
worse O 0 0.0063127195
. O 0 0.006468111

Proximal O 0 0.03451097
muscle B-Disease 0 0.07519547
weakness I-Disease 0 0.8920175
has O 0 0.0036742697
developed O 0 0.003713925
during O 0 0.002578985
her O 0 0.0037386636
follow O 0 0.0036218711
- O 0 0.00905273
up O 0 0.0073371255
. O 0 0.011678933

Fanconi B-Disease 2 0.9972631
syndrome I-Disease 2 0.97964215
, O 0 0.0031391662
as O 0 0.00124788
well O 0 0.0009394891
as O 0 0.0010940968
myopathy B-Disease 2 0.99968624
, O 0 0.0015734523
is O 0 0.00043230498
well O 0 0.00030101815
recognized O 0 0.00035663912
in O 0 0.00029369665
patients O 0 0.000496812
with O 0 0.00063695165
mitochondrial B-Disease 0 0.9792515
disorders I-Disease 0 0.995698
and O 0 0.0007039865
caused O 0 0.00069589727
by O 0 0.0010672803
depletion O 0 0.0019109952
of O 0 0.0037829226
mtDNA O 0 0.29774934
. O 0 0.008031756

We O 0 0.0032709218
suggest O 0 0.0016043549
that O 0 0.0013408049
our O 0 0.0011686672
patient O 0 0.0010237619
' O 0 0.0011156948
s O 0 0.0012943278
tubular B-Disease 0 0.98049796
dysfunction I-Disease 0 0.999102
and O 0 0.008774653
myopathy B-Disease 2 0.9998307
may O 0 0.00033869725
have O 0 0.00019728733
resulted O 0 0.0002041934
from O 0 0.00030054298
mitochondrial B-Disease 0 0.9790692
dysfunction I-Disease 0 0.99661356
which O 0 0.00067174976
is O 0 0.00035162005
triggered O 0 0.0004342226
by O 0 0.0010176789
tacrolimus B-Chemical 0 0.99998176
and O 0 0.0017517372
augmented O 0 0.0027803944
by O 0 0.004872686
lamivudine B-Chemical 1 0.9999862
. O 0 0.011974799

Higher O 0 0.00866746
optical O 0 0.0065016113
density O 0 0.0027511846
of O 0 0.0019137294
an O 0 0.0018028315
antigen O 0 0.06529273
assay O 0 0.010082288
predicts O 0 0.0044707037
thrombosis B-Disease 2 0.9999864
in O 0 0.0010444084
patients O 0 0.0015634091
with O 0 0.0018531228
heparin B-Chemical 1 0.99810326
- O 0 0.11601761
induced O 0 0.0122195
thrombocytopenia B-Disease 0 0.99995124
. O 0 0.0106141

OBJECTIVES O 0 0.004986737
: O 0 0.0031240613
To O 0 0.0013874446
correlate O 0 0.0011039848
optical O 0 0.0025151358
density O 0 0.0010238892
and O 0 0.00058013294
percent O 0 0.00036138634
inhibition O 0 0.00056979683
of O 0 0.0004338051
a O 0 0.00043106507
two O 0 0.0002547549
- O 0 0.0037801992
step O 0 0.00040981
heparin B-Chemical 1 0.99822825
- O 0 0.095746316
induced O 0 0.003017331
thrombocytopenia B-Disease 0 0.9999974
( O 0 0.068097994
HIT B-Disease 2 0.999887
) O 0 0.0034199075
antigen O 0 0.088933356
assay O 0 0.007228191
with O 0 0.0031502023
thrombosis B-Disease 2 0.999995
; O 0 0.0012110064
the O 0 0.00023127325
assay O 0 0.0004950711
utilizes O 0 0.00023025126
reaction O 0 0.001151053
inhibition O 0 0.0005042148
characteristics O 0 0.00040310013
of O 0 0.00069105194
a O 0 0.0011812638
high O 0 0.0028877982
heparin B-Chemical 1 0.99124396
concentration O 0 0.0149471965
. O 0 0.0073505086

PATIENTS O 0 0.0051068002
AND O 0 0.0028995448
METHODS O 0 0.001967079
: O 0 0.002130126
Patients O 0 0.0014509914
with O 0 0.0009784152
more O 0 0.00082238123
than O 0 0.00046696825
50 O 0 0.0005340353
% O 0 0.00046726278
decrease O 0 0.00034250497
in O 0 0.0003721758
platelet O 0 0.40884626
count O 0 0.0015101352
or O 0 0.0005505877
thrombocytopenia B-Disease 0 0.99996126
( O 0 0.00057936047
< O 0 0.00017306855
150 O 0 0.00019659649
x O 0 0.00040746067
10 O 0 0.0001837737
( O 0 0.000266145
9 O 0 0.00019524326
) O 0 0.00051001523
/ O 0 0.012488999
L O 0 0.9608979
) O 0 0.00088904257
after O 0 0.00014380363
exposure O 0 0.0013565437
to O 0 0.0002684941
heparin B-Chemical 1 0.99380976
, O 0 0.00062645
who O 0 0.0003356026
had O 0 0.00014125355
a O 0 0.00017283355
positive O 0 0.00023012813
two O 0 0.00015429965
- O 0 0.0017189622
step O 0 0.0001913623
antigen O 0 0.051861316
assay O 0 0.005859966
[ O 0 0.0037303392
optical O 0 0.0056556966
density O 0 0.0007922862
( O 0 0.00094313483
OD O 0 0.7639195
) O 0 0.0010403007
> O 0 0.00070991524
0 O 0 0.00022338185
. O 0 0.00015322964
4 O 0 0.00013808426
and O 0 0.00018032348
> O 0 0.00038282838
50 O 0 0.00022265082
inhibition O 0 0.00026998037
with O 0 0.00023800806
high O 0 0.00035985926
concentration O 0 0.0007567161
of O 0 0.0012287855
heparin B-Chemical 1 0.9977169
] O 0 0.0022857415
were O 0 0.0006232193
included O 0 0.00072490174
in O 0 0.0011350984
the O 0 0.0019578105
study O 0 0.004143061
. O 0 0.00625527

RESULTS O 0 0.006512122
: O 0 0.004374076
Forty O 0 0.0034472176
of O 0 0.00225106
94 O 0 0.003422717
HIT B-Disease 2 0.9937115
patients O 0 0.0018407947
had O 0 0.0011808026
thrombosis B-Disease 2 0.9999411
at O 0 0.00060524966
diagnosis O 0 0.0024656376
; O 0 0.0009261567
54 O 0 0.00082025246
/ O 0 0.0011689088
94 O 0 0.0008173719
had O 0 0.00071747537
isolated O 0 0.0010137989
- O 0 0.049276453
HIT B-Disease 2 0.99830484
without O 0 0.00698639
thrombosis B-Disease 2 0.9999417
. O 0 0.010421298

Eight O 0 0.005016635
of O 0 0.0027862645
the O 0 0.0018461647
isolated O 0 0.0015366934
- O 0 0.13222946
HIT B-Disease 2 0.99850816
patients O 0 0.001906228
developed O 0 0.002941316
thrombosis B-Disease 2 0.9999498
within O 0 0.00023731013
the O 0 0.00021825953
next O 0 0.00015149066
30 O 0 0.00018161886
d O 0 0.00030035537
; O 0 0.0004058027
thus O 0 0.00033637395
, O 0 0.00037081548
a O 0 0.000307211
total O 0 0.0002518021
of O 0 0.00044177708
48 O 0 0.00051766116
patients O 0 0.0007077684
had O 0 0.00093163335
thrombosis B-Disease 2 0.99978775
at O 0 0.0013222747
day O 0 0.0018422899
30 O 0 0.0029667572
. O 0 0.0057437154

At O 0 0.0028776282
diagnosis O 0 0.003079592
there O 0 0.0012865778
was O 0 0.0010929634
no O 0 0.00066644885
significant O 0 0.00064580276
difference O 0 0.00043987244
in O 0 0.0005830472
OD O 0 0.5600145
between O 0 0.0005461843
HIT B-Disease 2 0.9986181
patients O 0 0.001121817
with O 0 0.0011401371
thrombosis B-Disease 2 0.99996805
and O 0 0.00096570986
those O 0 0.0010085895
with O 0 0.0012306231
isolated O 0 0.0019005656
- O 0 0.08920226
HIT B-Disease 2 0.9974023
. O 0 0.008490929

However O 0 0.0054145777
, O 0 0.0051778997
OD O 0 0.54177535
was O 0 0.0016404135
significantly O 0 0.0010082086
higher O 0 0.00066601543
in O 0 0.0004721113
all O 0 0.0003650319
patients O 0 0.0004940569
with O 0 0.0007209682
thrombosis B-Disease 2 0.9999846
( O 0 0.00082991965
n O 0 0.00027478117
= O 0 0.00061044015
48 O 0 0.00027429117
, O 0 0.00026857576
1 O 0 0.00019226453
. O 0 0.00017231127
34 O 0 0.0002640014
+ O 0 0.00086783123
/ O 0 0.007960165
- O 0 0.0104580065
0 O 0 0.0002874383
. O 0 0.0001949263
89 O 0 0.0004197627
) O 0 0.00038991912
, O 0 0.00026860138
including O 0 0.00019136175
isolated O 0 0.0002380126
- O 0 0.113445625
HIT B-Disease 2 0.9987612
patients O 0 0.00046928463
who O 0 0.00028831768
later O 0 0.00014993874
developed O 0 0.00052645174
thrombosis B-Disease 2 0.99989045
within O 0 0.000114798
30 O 0 0.00012427464
d O 0 0.00019976188
( O 0 0.00023811427
n O 0 0.0001718238
= O 0 0.00037977516
8 O 0 0.00017718149
, O 0 0.00023489763
1 O 0 0.00017690362
. O 0 0.00016231473
84 O 0 0.00029979803
+ O 0 0.0009892762
/ O 0 0.00929945
- O 0 0.011673189
0 O 0 0.0002791316
. O 0 0.00018246486
64 O 0 0.00026102204
) O 0 0.00025840968
as O 0 0.0001476266
compared O 0 0.00012355798
to O 0 0.00015109552
isolated O 0 0.0002131522
- O 0 0.104420595
HIT B-Disease 2 0.99897313
patients O 0 0.0005932407
who O 0 0.00036027495
did O 0 0.00018327252
not O 0 0.00015209755
develop O 0 0.00041496853
thrombosis B-Disease 2 0.9999889
( O 0 0.00097584876
0 O 0 0.00026222484
. O 0 0.00017695726
96 O 0 0.000559832
+ O 0 0.000923046
/ O 0 0.006372178
- O 0 0.006931899
0 O 0 0.00026970173
. O 0 0.00019967886
75 O 0 0.00028599333
; O 0 0.00045983578
P O 0 0.016246803
= O 0 0.00060904975
0 O 0 0.0004032864
. O 0 0.00041719622
011 O 0 0.04190399
and O 0 0.00071438635
P O 0 0.024291044
= O 0 0.0016849987
0 O 0 0.0015613128
. O 0 0.0020808228
008 O 0 0.008040224
) O 0 0.0065157018
. O 0 0.008574461

The O 0 0.00427131
Receiver O 0 0.41957814
Operative O 0 0.0069073634
Characteristic O 0 0.011159815
Curve O 0 0.4952794
showed O 0 0.00097071147
that O 0 0.0007183652
OD O 0 0.7485528
> O 0 0.0023178272
1 O 0 0.00045489526
. O 0 0.00032132748
27 O 0 0.00036506308
in O 0 0.00024722627
the O 0 0.00025518885
isolated O 0 0.0003048562
- O 0 0.11094827
HIT B-Disease 2 0.9988298
group O 0 0.0005139228
had O 0 0.00027033276
a O 0 0.00032834974
significantly O 0 0.00029955263
higher O 0 0.0003254594
chance O 0 0.0005751276
of O 0 0.00090081483
developing O 0 0.12841415
thrombosis B-Disease 2 0.9999677
by O 0 0.0018168066
day O 0 0.0019664902
30 O 0 0.0029995418
. O 0 0.005696263

None O 0 0.0076893205
of O 0 0.0042743003
these O 0 0.0032963443
groups O 0 0.0028004555
showed O 0 0.002301853
significant O 0 0.0024151546
difference O 0 0.0022037828
in O 0 0.0031831719
percent O 0 0.004323633
inhibition O 0 0.009876871
. O 0 0.011617889

Multivariate O 0 0.007218199
analysis O 0 0.0030261616
showed O 0 0.0020822543
a O 0 0.002016524
2 O 0 0.0014131063
. O 0 0.0011432894
8 O 0 0.0011282326
- O 0 0.002294141
fold O 0 0.0015636055
increased O 0 0.0017292703
risk O 0 0.12881738
of O 0 0.00913869
thrombosis B-Disease 2 0.9999764
in O 0 0.0050633196
females O 0 0.0099019995
. O 0 0.008919191

Similarly O 0 0.009002151
, O 0 0.011324927
thrombotic B-Disease 2 0.9994412
risk O 0 0.327225
increased O 0 0.0037401717
with O 0 0.0031716244
age O 0 0.0052029444
and O 0 0.0047237105
OD O 0 0.45383835
values O 0 0.007313242
. O 0 0.011174975

CONCLUSION O 0 0.034935884
: O 0 0.005216556
Higher O 0 0.01627166
OD O 0 0.60339653
is O 0 0.001278551
associated O 0 0.00085232785
with O 0 0.00065493066
significant O 0 0.00059831026
risk O 0 0.040750023
of O 0 0.00072342035
subsequent O 0 0.001662003
thrombosis B-Disease 2 0.9999932
in O 0 0.00042312534
patients O 0 0.00044524556
with O 0 0.0002846072
isolated O 0 0.00030386404
- O 0 0.16865858
HIT B-Disease 2 0.9992385
; O 0 0.00066340197
percent O 0 0.0003089298
inhibition O 0 0.0008564379
, O 0 0.00090565527
however O 0 0.0010286126
, O 0 0.0013451678
was O 0 0.0014565658
not O 0 0.0020770202
predictive O 0 0.0073385593
. O 0 0.007178663

Thalidomide B-Chemical 1 0.99962974
has O 0 0.0027726223
limited O 0 0.0017134578
single O 0 0.0017489191
- O 0 0.012100898
agent O 0 0.015309135
activity O 0 0.0007585493
in O 0 0.0005662982
relapsed O 0 0.3909684
or O 0 0.00036779654
refractory O 0 0.01107285
indolent O 0 0.09001965
non B-Disease 0 0.004011192
- I-Disease 0 0.10125761
Hodgkin I-Disease 0 0.99118924
lymphomas I-Disease 0 0.99804556
: O 0 0.0014682811
a O 0 0.00047128444
phase O 0 0.0006533493
II O 0 0.0058911243
trial O 0 0.00053460285
of O 0 0.0006593641
the O 0 0.0010283137
Cancer B-Disease 0 0.9447487
and O 0 0.004634069
Leukemia B-Disease 0 0.9998109
Group O 0 0.48524404
B O 0 0.85039407
. O 0 0.0097765885

Thalidomide B-Chemical 1 0.99978477
is O 0 0.0040386296
an O 0 0.0026533408
immunomodulatory O 0 0.04576634
agent O 0 0.055770535
with O 0 0.0009084507
demonstrated O 0 0.00048688203
activity O 0 0.0004812633
in O 0 0.0004365401
multiple B-Disease 0 0.0010830103
myeloma I-Disease 0 0.9984895
, O 0 0.0022669497
mantle B-Disease 0 0.7922372
cell I-Disease 0 0.047132414
lymphoma I-Disease 0 0.9998715
and O 0 0.0374465
lymphoplasmacytic B-Disease 0 0.99997365
lymphoma I-Disease 0 0.99997115
. O 0 0.020577166

Its O 0 0.05663227
activity O 0 0.0031882748
is O 0 0.0019782502
believed O 0 0.001504915
to O 0 0.0008117588
be O 0 0.0006597174
due O 0 0.00042232586
modulation O 0 0.00046350114
of O 0 0.000505385
the O 0 0.0005132261
tumour B-Disease 0 0.92027366
milieu O 0 0.0013964841
, O 0 0.00076141977
including O 0 0.00045296072
downregulation O 0 0.0009038773
of O 0 0.001468047
angiogenesis O 0 0.96371454
and O 0 0.003089968
inflammatory O 0 0.784063
cytokines O 0 0.5813642
. O 0 0.009500968

Between O 0 0.0061840746
July O 0 0.0040240446
2001 O 0 0.002998427
and O 0 0.0017188018
April O 0 0.0016871787
2004 O 0 0.0016072064
, O 0 0.0009641837
24 O 0 0.00056269276
patients O 0 0.0004986685
with O 0 0.00047547458
relapsed O 0 0.565083
/ O 0 0.010002676
refractory O 0 0.035684217
indolent O 0 0.3711905
lymphomas B-Disease 0 0.99734986
received O 0 0.00051196426
thalidomide B-Chemical 1 0.99994373
200 O 0 0.0014790376
mg O 0 0.015500084
daily O 0 0.00017629103
with O 0 0.00015821701
escalation O 0 0.002794422
by O 0 0.0001562843
100 O 0 0.00030351113
mg O 0 0.0032402142
daily O 0 0.00014510723
every O 0 8.309705e-05
1 O 0 0.00015536309
- O 0 0.0005174209
2 O 0 0.00014874313
weeks O 0 0.000115578056
as O 0 0.00017324321
tolerated O 0 0.0006880092
, O 0 0.000300319
up O 0 0.0002463148
to O 0 0.00027651305
a O 0 0.0004425712
maximum O 0 0.0005040411
of O 0 0.001043818
800 O 0 0.0026427659
mg O 0 0.026338324
daily O 0 0.0037303502
. O 0 0.0058611524

Patients O 0 0.0049738893
had O 0 0.0024205947
received O 0 0.0014738222
a O 0 0.0013298304
median O 0 0.00076708617
of O 0 0.0009464947
2 O 0 0.00078669644
( O 0 0.0008908677
range O 0 0.0007886577
, O 0 0.001110787
1 O 0 0.001021636
- O 0 0.002407229
4 O 0 0.0013070654
) O 0 0.0023868459
prior O 0 0.0024231155
regimens O 0 0.0055363486
. O 0 0.007901649

Of O 0 0.004932784
24 O 0 0.0028163358
evaluable O 0 0.0029069576
patients O 0 0.0017036662
, O 0 0.0011723825
two O 0 0.0005559919
achieved O 0 0.0005428588
a O 0 0.0005047344
complete O 0 0.00034485382
remission O 0 0.05899283
and O 0 0.0003019814
one O 0 0.00019365193
achieved O 0 0.00020749615
a O 0 0.0002485176
partial O 0 0.00037417462
remission O 0 0.09383516
for O 0 0.00016847785
an O 0 0.00018970022
overall O 0 0.0001690804
response O 0 0.00020613904
rate O 0 0.00019818835
of O 0 0.00024988543
12 O 0 0.00014787173
. O 0 0.00014366822
5 O 0 0.00014100915
% O 0 0.00021119574
( O 0 0.00026270578
95 O 0 0.00033234878
% O 0 0.00023920332
confidence O 0 0.0004556906
interval O 0 0.00023285861
: O 0 0.00039393408
2 O 0 0.00029026184
. O 0 0.00033145552
6 O 0 0.00040880643
- O 0 0.0012764472
32 O 0 0.0009646597
. O 0 0.0010384173
4 O 0 0.0015277228
% O 0 0.0031258438
) O 0 0.0060679265
. O 0 0.008321118

Eleven O 0 0.02659654
patients O 0 0.018261338
progressed O 0 0.020148434
during O 0 0.01561857
therapy O 0 0.02661183
. O 0 0.028127937

Grade O 0 0.22706646
3 O 0 0.0036237333
- O 0 0.0052261683
4 O 0 0.0015899772
adverse O 0 0.025479779
effects O 0 0.0012948008
included O 0 0.0012752679
myelosuppression B-Disease 0 0.9999852
, O 0 0.016421724
fatigue B-Disease 2 0.99872667
, O 0 0.031921364
somnolence B-Disease 2 0.9999958
/ O 0 0.48572856
depressed B-Disease 2 0.99993336
mood I-Disease 0 0.99994135
, O 0 0.016463773
neuropathy B-Disease 0 0.9999597
and O 0 0.008671042
dyspnea B-Disease 0 0.99573684
. O 0 0.008242096

Of O 0 0.008490789
concern O 0 0.00691774
was O 0 0.004661199
the O 0 0.0038665063
occurrence O 0 0.005225804
of O 0 0.005340892
four O 0 0.0057674195
thromboembolic B-Disease 2 0.9998896
events O 0 0.20706055
. O 0 0.01442467

Our O 0 0.003718206
results O 0 0.0021169723
failed O 0 0.0016694479
to O 0 0.0009955904
demonstrate O 0 0.00055207836
an O 0 0.0006584379
important O 0 0.00038542558
response O 0 0.00048364617
rate O 0 0.00037336006
to O 0 0.00025455
single O 0 0.00035671037
agent O 0 0.11093312
thalidomide B-Chemical 1 0.99996424
in O 0 0.00069817045
indolent O 0 0.4889033
lymphomas B-Disease 0 0.99735403
and O 0 0.00051082537
contrast O 0 0.00038399437
with O 0 0.00024433786
the O 0 0.00017819057
higher O 0 0.00016971696
activity O 0 0.00017902318
level O 0 0.00016369775
reported O 0 0.00026514055
with O 0 0.0002542158
the O 0 0.00027800284
second O 0 0.00036831407
generation O 0 0.0007563932
immunomodulatory O 0 0.07003996
agent O 0 0.24153416
, O 0 0.023395637
lenalidomide B-Chemical 0 0.99962044
. O 0 0.008726551

Sex O 0 0.40122247
differences O 0 0.0032044032
in O 0 0.007334656
NMDA B-Chemical 1 0.9999975
antagonist O 0 0.98819274
enhancement O 0 0.026038727
of O 0 0.021253217
morphine B-Chemical 0 0.9999963
antihyperalgesia O 0 0.9939545
in O 0 0.00059219886
a O 0 0.0010832023
capsaicin B-Chemical 0 0.99929094
model O 0 0.00041695588
of O 0 0.0006864883
persistent O 0 0.23041227
pain B-Disease 0 0.9764556
: O 0 0.0006294675
comparisons O 0 0.00030176522
to O 0 0.00036247878
two O 0 0.00048802266
models O 0 0.0009512858
of O 0 0.0025501517
acute B-Disease 0 0.9796183
pain I-Disease 0 0.99440825
. O 0 0.008376404

In O 0 0.005016268
acute B-Disease 0 0.80757695
pain I-Disease 0 0.98046255
models O 0 0.003494246
, O 0 0.027140146
N B-Chemical 0 0.9999201
- I-Chemical 0 0.86146116
methyl I-Chemical 0 0.99983644
- I-Chemical 0 0.7785511
D I-Chemical 0 0.9997112
- I-Chemical 0 0.92036766
aspartate I-Chemical 1 0.99999833
( O 0 0.515347
NMDA B-Chemical 1 0.99999976
) O 0 0.021118186
antagonists O 0 0.2923549
enhance O 0 0.00014427789
the O 0 0.0002759513
antinociceptive O 0 0.74367714
effects O 0 0.00043773247
of O 0 0.0013389233
morphine B-Chemical 0 0.99994075
to O 0 0.0003117616
a O 0 0.000425378
greater O 0 0.00036182193
extent O 0 0.000439191
in O 0 0.0008299929
males O 0 0.0018581253
than O 0 0.0017185891
females O 0 0.0048026573
. O 0 0.006375105

The O 0 0.0030658003
purpose O 0 0.002145352
of O 0 0.001657545
this O 0 0.0011260503
investigation O 0 0.0010468988
was O 0 0.0005979189
to O 0 0.00035868396
extend O 0 0.00026216634
these O 0 0.00028808936
findings O 0 0.00033537523
to O 0 0.00022868234
a O 0 0.00041775257
persistent O 0 0.06411028
pain B-Disease 0 0.95280224
model O 0 0.00031503566
which O 0 0.0003374818
could O 0 0.00014859514
be O 0 0.00016287673
distinguished O 0 0.0001974023
from O 0 0.00019248207
acute B-Disease 0 0.7907448
pain I-Disease 0 0.943867
models O 0 0.00019811657
on O 0 0.00010585165
the O 0 0.0001432051
basis O 0 0.00016791014
of O 0 0.00021542193
the O 0 0.00023019618
nociceptive O 0 0.04564258
fibers O 0 0.00064788247
activated O 0 0.0002937515
, O 0 0.00054168346
neurochemical O 0 0.16517785
substrates O 0 0.0004761263
, O 0 0.0004751701
and O 0 0.00044529376
duration O 0 0.0004757225
of O 0 0.0009304136
the O 0 0.0014245048
nociceptive O 0 0.056606524
stimulus O 0 0.004218547
. O 0 0.006464166

To O 0 0.0030347046
this O 0 0.0022411763
end O 0 0.0015134664
, O 0 0.0025451314
persistent O 0 0.33995333
hyperalgesia B-Disease 2 0.99996376
was O 0 0.00095331366
induced O 0 0.0005484296
by O 0 0.0005250513
administration O 0 0.012575147
of O 0 0.0023194687
capsaicin B-Chemical 0 0.99989545
in O 0 0.00034082323
the O 0 0.00022770022
tail O 0 0.00033666426
of O 0 0.0003960114
gonadally O 0 0.004790989
intact O 0 0.00037101156
F344 O 0 0.16476153
rats O 0 0.00034282115
, O 0 0.00024352293
following O 0 0.000140497
which O 0 0.00020950001
the O 0 0.00016381031
tail O 0 0.00026418117
was O 0 0.00019953478
immersed O 0 0.00041589382
in O 0 0.00019960802
a O 0 0.00033709576
mildly O 0 0.11791673
noxious O 0 0.15440626
thermal O 0 0.0063925837
stimulus O 0 0.0007835146
, O 0 0.00068841246
and O 0 0.0006612123
tail O 0 0.001528227
- O 0 0.020435512
withdrawal O 0 0.12485788
latencies O 0 0.0042332755
measured O 0 0.0030809129
. O 0 0.006293581

For O 0 0.003561886
comparison O 0 0.0023356003
, O 0 0.002313906
tests O 0 0.0016646832
were O 0 0.00088819413
conducted O 0 0.0006222204
in O 0 0.00058113626
two O 0 0.00051371084
acute B-Disease 0 0.77516323
pain I-Disease 0 0.9741432
models O 0 0.0006436242
, O 0 0.00071949215
the O 0 0.0005001561
hotplate O 0 0.25521037
and O 0 0.0006520933
warm O 0 0.004357605
water O 0 0.012175778
tail O 0 0.0021712633
- O 0 0.015119591
withdrawal O 0 0.09471
procedures O 0 0.004249501
. O 0 0.006899286

In O 0 0.0041931807
males O 0 0.004304331
, O 0 0.002577793
the O 0 0.001486495
non O 0 0.0059900717
- O 0 0.24456066
competitive O 0 0.80822676
NMDA B-Chemical 1 0.9999999
antagonist O 0 0.99977356
dextromethorphan B-Chemical 0 0.99999976
enhanced O 0 0.00095525215
the O 0 0.00052403065
antihyperalgesic O 0 0.92995715
effect O 0 0.00020403576
of O 0 0.0002695069
low O 0 0.00037990193
to O 0 0.00017650431
moderate O 0 0.009077308
doses O 0 0.006531806
of O 0 0.0026789783
morphine B-Chemical 0 0.9999701
in O 0 0.0003614329
a O 0 0.000501689
dose O 0 0.004722635
- O 0 0.0041725915
and O 0 0.00067496096
time O 0 0.000744158
- O 0 0.002992776
dependent O 0 0.0017760509
manner O 0 0.0035139504
. O 0 0.006686083

Across O 0 0.004709823
the O 0 0.002693973
doses O 0 0.004344766
and O 0 0.0018663893
pretreatment O 0 0.007954165
times O 0 0.0007176269
examined O 0 0.00071333325
, O 0 0.0011888293
enhancement O 0 0.0014483477
was O 0 0.0011623795
not O 0 0.0012628874
observed O 0 0.0017896446
in O 0 0.0031131802
females O 0 0.0071792575
. O 0 0.0083124675

Enhancement O 0 0.011375289
of O 0 0.012264191
morphine B-Chemical 0 0.9999918
antinociception O 0 0.9999838
by O 0 0.03280065
dextromethorphan B-Chemical 0 0.99999905
was O 0 0.0009056462
seen O 0 0.00038338205
in O 0 0.000287062
both O 0 0.00027383052
males O 0 0.0005234261
and O 0 0.00029573482
females O 0 0.00044811092
in O 0 0.00021859235
the O 0 0.0002908411
acute B-Disease 0 0.86442184
pain I-Disease 0 0.9777991
models O 0 0.00038031774
, O 0 0.0003940939
with O 0 0.00024373058
the O 0 0.00020998475
magnitude O 0 0.00021778807
of O 0 0.0003842732
this O 0 0.00042377206
effect O 0 0.00057511806
being O 0 0.0011390331
greater O 0 0.0012145255
in O 0 0.0021804338
males O 0 0.005769944
. O 0 0.006578313

These O 0 0.0034343593
findings O 0 0.002533719
demonstrate O 0 0.0012453485
a O 0 0.0020229456
sexually O 0 0.20009974
- O 0 0.055312105
dimorphic O 0 0.0067629865
interaction O 0 0.0009195016
between O 0 0.0008996067
NMDA B-Chemical 1 0.9999995
antagonists O 0 0.9697362
and O 0 0.005910643
morphine B-Chemical 0 0.9999604
in O 0 0.0003081394
a O 0 0.00041061497
persistent O 0 0.043251365
pain B-Disease 0 0.88991666
model O 0 0.00023842299
that O 0 0.00017721408
can O 0 0.00018211272
be O 0 0.00022698319
distinguished O 0 0.00027983243
from O 0 0.0002887374
those O 0 0.0004937332
observed O 0 0.00056824676
in O 0 0.0011899219
acute B-Disease 0 0.9229277
pain I-Disease 0 0.9797973
models O 0 0.0050060814
. O 0 0.007163541

Development O 0 0.013182732
of O 0 0.005749709
proteinuria B-Disease 0 0.9999676
after O 0 0.0012075544
switch O 0 0.0012792404
to O 0 0.0010671898
sirolimus B-Chemical 1 0.99994075
- O 0 0.035460588
based O 0 0.0007972175
immunosuppression O 0 0.83666855
in O 0 0.00067826506
long O 0 0.0008201228
- O 0 0.002861447
term O 0 0.0012535576
cardiac O 0 0.043816254
transplant O 0 0.1255222
patients O 0 0.006765158
. O 0 0.007047683

Calcineurin O 0 0.8783204
- O 0 0.038630214
inhibitor O 0 0.009524734
therapy O 0 0.0039088894
can O 0 0.0013644657
lead O 0 0.0074980236
to O 0 0.0016720956
renal B-Disease 2 0.998901
dysfunction I-Disease 2 0.9979272
in O 0 0.0028358016
heart O 0 0.26678985
transplantation O 0 0.051789567
patients O 0 0.007507464
. O 0 0.007863534

The O 0 0.0031609447
novel O 0 0.0029752094
immunosuppressive O 0 0.73763955
( O 0 0.008337564
IS O 0 0.7306706
) O 0 0.005708624
drug O 0 0.6519853
sirolmus B-Chemical 0 0.9197281
( O 0 0.013569424
Srl B-Chemical 1 0.997693
) O 0 0.0021424508
lacks O 0 0.0004801027
nephrotoxic B-Disease 2 0.99989307
effects O 0 0.0023234342
; O 0 0.0016918997
however O 0 0.0010200026
, O 0 0.0053610145
proteinuria B-Disease 0 0.99999833
associated O 0 0.001766896
with O 0 0.0019371372
Srl B-Chemical 1 0.99427587
has O 0 0.00049058965
been O 0 0.0005918697
reported O 0 0.00092254835
following O 0 0.0012625878
renal O 0 0.70192456
transplantation O 0 0.10228104
. O 0 0.007131294

In O 0 0.005296817
cardiac O 0 0.030061964
transplantation O 0 0.025345054
, O 0 0.0027082323
the O 0 0.0015598744
incidence O 0 0.0052394755
of O 0 0.0057784407
proteinuria B-Disease 0 0.9999968
associated O 0 0.007252862
with O 0 0.006490305
Srl B-Chemical 1 0.99398416
is O 0 0.004157389
unknown O 0 0.008497665
. O 0 0.008532837

In O 0 0.0039347494
this O 0 0.0025990447
study O 0 0.0022709032
, O 0 0.0018787348
long O 0 0.0013150277
- O 0 0.0031339999
term O 0 0.00079929107
cardiac O 0 0.02533171
transplant O 0 0.043694247
patients O 0 0.00078463793
were O 0 0.00046639438
switched O 0 0.0005916548
from O 0 0.0007395958
cyclosporine B-Chemical 1 0.99999166
to O 0 0.0022153112
Srl B-Chemical 1 0.9972012
- O 0 0.024789765
based O 0 0.003849528
IS O 0 0.22792704
. O 0 0.00784111

Concomitant O 0 0.01434222
IS O 0 0.033812676
consisted O 0 0.0034754982
of O 0 0.00674567
mycophenolate B-Chemical 0 0.999997
mofetil I-Chemical 0 0.9999989
+ O 0 0.47236183
/ O 0 0.29307377
- O 0 0.3415889
steroids B-Chemical 0 0.9988826
. O 0 0.014501535

Proteinuria O 2 0.9999423
increased O 0 0.0036937478
significantly O 0 0.001603541
from O 0 0.00090268406
a O 0 0.000765274
median O 0 0.00040347714
of O 0 0.0004958233
0 O 0 0.00045061784
. O 0 0.00029472017
13 O 0 0.00029113627
g O 0 0.00043137977
/ O 0 0.00063101394
day O 0 0.00019680485
( O 0 0.00027656893
range O 0 0.00023059685
0 O 0 0.00029080617
- O 0 0.0009699109
5 O 0 0.00016581602
. O 0 0.00016558472
7 O 0 0.00016499999
) O 0 0.00032223243
preswitch O 0 0.0031945703
to O 0 0.0001634862
0 O 0 0.00021598545
. O 0 0.00016242759
23 O 0 0.00022110838
g O 0 0.0003219794
/ O 0 0.00055741234
day O 0 0.00017666562
( O 0 0.000335329
0 O 0 0.00030491778
- O 0 0.0012462391
9 O 0 0.00020618818
. O 0 0.00019202472
88 O 0 0.00034554966
) O 0 0.00031730902
at O 0 0.00020175244
24 O 0 0.00023389774
months O 0 0.00021412097
postswitch O 0 0.00070467725
( O 0 0.00060680136
p O 0 0.0006753525
= O 0 0.0013216389
0 O 0 0.0013819007
. O 0 0.0019289824
0024 O 0 0.02879489
) O 0 0.006365344
. O 0 0.0081521915

Before O 0 0.0040250155
the O 0 0.0024536476
switch O 0 0.002157462
, O 0 0.0019295253
11 O 0 0.001104587
. O 0 0.0006852592
5 O 0 0.0004902544
% O 0 0.00050876476
of O 0 0.00042712723
patients O 0 0.00046710047
had O 0 0.00030342521
high O 0 0.0007414811
- O 0 0.044346277
grade O 0 0.7408236
proteinuria B-Disease 0 0.9999995
( O 0 0.007252004
> O 0 0.0019384274
1 O 0 0.00021019869
. O 0 0.00016066956
0 O 0 0.00018931716
g O 0 0.00034832588
/ O 0 0.0007054469
day O 0 0.00019377698
) O 0 0.00045175763
; O 0 0.00034987158
this O 0 0.00018331954
increased O 0 0.00021086073
to O 0 0.000192403
22 O 0 0.00028725367
. O 0 0.0002181942
9 O 0 0.0002532102
% O 0 0.00037147643
postswitch O 0 0.0010908144
( O 0 0.0006879957
p O 0 0.0007186294
= O 0 0.0013767947
0 O 0 0.0014382161
. O 0 0.0020053976
006 O 0 0.017338788
) O 0 0.006512286
. O 0 0.008374817

ACE B-Chemical 0 0.9996623
inhibitor I-Chemical 0 0.5281687
and O 0 0.036970507
angiotensin B-Chemical 1 0.9999901
- I-Chemical 0 0.4278242
releasing I-Chemical 0 0.10544428
blocker I-Chemical 0 0.9978689
( O 0 0.18022427
ARB B-Chemical 0 0.9999931
) O 0 0.006563736
therapy O 0 0.0041660387
reduced O 0 0.0042184694
proteinuria B-Disease 0 0.9999857
development O 0 0.056755953
. O 0 0.009260477

Patients O 0 0.0051224823
without O 0 0.0038892806
proteinuria B-Disease 0 0.99997985
had O 0 0.0017644839
increased O 0 0.0015295895
renal O 0 0.7593759
function O 0 0.00067943416
( O 0 0.0006060012
median O 0 0.00023468207
42 O 0 0.0003285805
. O 0 0.0002043157
5 O 0 0.00017590383
vs O 0 0.00024369037
. O 0 0.00019340635
64 O 0 0.0002727367
. O 0 0.0001844886
1 O 0 0.00019178592
, O 0 0.00024037664
p O 0 0.00023209368
= O 0 0.00043079746
0 O 0 0.0002498025
. O 0 0.00018607703
25 O 0 0.00025394783
) O 0 0.0003940349
, O 0 0.0003036692
whereas O 0 0.00023871895
patients O 0 0.00031760352
who O 0 0.0002983422
developed O 0 0.000327703
high O 0 0.00073365256
- O 0 0.060468305
grade O 0 0.7103769
proteinuria B-Disease 0 0.99999917
showed O 0 0.0006234543
decreased O 0 0.0042021424
renal O 0 0.73611087
function O 0 0.0003610902
at O 0 0.00013133451
the O 0 0.000120344
end O 0 9.5091826e-05
of O 0 0.00015302391
follow O 0 0.00013267936
- O 0 0.0013278534
up O 0 0.0001485382
( O 0 0.0002106907
median O 0 0.00012486869
39 O 0 0.00023171933
. O 0 0.00015782013
6 O 0 0.00014909757
vs O 0 0.00024015442
. O 0 0.0002277202
29 O 0 0.0003842104
. O 0 0.00029054037
2 O 0 0.0003585169
, O 0 0.00053860847
p O 0 0.00065227604
= O 0 0.001255571
0 O 0 0.0013043289
. O 0 0.0017461111
125 O 0 0.004547465
) O 0 0.005879984
. O 0 0.007951111

Thus O 0 0.0052285516
, O 0 0.00888453
proteinuria B-Disease 0 0.9999769
may O 0 0.0016927125
develop O 0 0.0011044702
in O 0 0.00082062883
cardiac O 0 0.039870493
transplant O 0 0.053650822
patients O 0 0.0005471159
after O 0 0.00019874056
switch O 0 0.0003449337
to O 0 0.00035520707
Srl B-Chemical 1 0.99446785
, O 0 0.0005684527
which O 0 0.0003255494
may O 0 0.00021103208
have O 0 0.00021324957
an O 0 0.0003712426
adverse O 0 0.079486564
effect O 0 0.00037008815
on O 0 0.00039549448
renal O 0 0.47017267
function O 0 0.00096944254
in O 0 0.0013197113
these O 0 0.0022930652
patients O 0 0.0050672656
. O 0 0.0063730357

Srl B-Chemical 1 0.9251171
should O 0 0.0021911468
be O 0 0.0017636408
used O 0 0.001311739
with O 0 0.0029650945
ACEi B-Chemical 0 0.9999813
/ O 0 0.66719985
ARB B-Chemical 0 0.99999344
therapy O 0 0.0022645849
and O 0 0.00053046073
patients O 0 0.00053569063
monitored O 0 0.00037277912
for O 0 0.0008551067
proteinuria B-Disease 0 0.9999919
and O 0 0.002607859
increased O 0 0.008072011
renal B-Disease 2 0.99938476
dysfunction I-Disease 2 0.99887913
. O 0 0.010488893

Ginsenoside B-Chemical 0 0.9999889
Rg1 I-Chemical 1 0.99999535
restores O 0 0.0034686446
the O 0 0.002447792
impairment B-Disease 0 0.692652
of I-Disease 0 0.001688261
learning I-Disease 0 0.017327491
induced O 0 0.0012386687
by O 0 0.002172829
chronic O 0 0.9963916
morphine B-Chemical 0 0.9999933
administration O 0 0.16975492
in O 0 0.0031817064
rats O 0 0.0061847493
. O 0 0.0069926055

Rg1 B-Chemical 1 0.9999261
, O 0 0.0064036297
as O 0 0.0030831015
a O 0 0.00518104
ginsenoside B-Chemical 0 0.9999137
extracted O 0 0.0012470649
from O 0 0.0014545626
Panax O 0 0.84750783
ginseng O 0 0.7600252
, O 0 0.0015285369
could O 0 0.0010589493
ameliorate O 0 0.0034587067
spatial O 0 0.029894276
learning B-Disease 0 0.4804668
impairment I-Disease 0 0.9703159
. O 0 0.009208065

Previous O 0 0.00361679
studies O 0 0.0023449948
have O 0 0.00155331
demonstrated O 0 0.0012846322
that O 0 0.0017307441
Rg1 B-Chemical 1 0.99998987
might O 0 0.0006481354
be O 0 0.0005442361
a O 0 0.00052140537
useful O 0 0.00037901383
agent O 0 0.0041390047
for O 0 0.00031982316
the O 0 0.00032105064
prevention O 0 0.0014129087
and O 0 0.00046159924
treatment O 0 0.0005043984
of O 0 0.00062561315
the O 0 0.0007839422
adverse O 0 0.35385394
effects O 0 0.0025177414
of O 0 0.013113486
morphine B-Chemical 0 0.99994254
. O 0 0.008727788

The O 0 0.0031469301
aim O 0 0.002377868
of O 0 0.0017605476
this O 0 0.0012052079
study O 0 0.0010350572
was O 0 0.0005916105
to O 0 0.000356948
investigate O 0 0.000199949
the O 0 0.0002784188
effect O 0 0.00033720216
of O 0 0.0038836645
Rg1 B-Chemical 1 0.9999981
on O 0 0.00030057682
learning B-Disease 0 0.50881207
impairment I-Disease 0 0.9823268
by O 0 0.0009433307
chronic O 0 0.99025774
morphine B-Chemical 0 0.99999344
administration O 0 0.018441718
and O 0 0.00039838374
the O 0 0.0003526804
mechanism O 0 0.00044418275
responsible O 0 0.00070998934
for O 0 0.0011340495
this O 0 0.0018867087
effect O 0 0.0033328466
. O 0 0.006495509

Male O 0 0.0148576265
rats O 0 0.0032339522
were O 0 0.0015271881
subcutaneously O 0 0.0011242412
injected O 0 0.00084542786
with O 0 0.0016351817
morphine B-Chemical 0 0.9999695
( O 0 0.0015885744
10 O 0 0.00038852327
mg O 0 0.015713632
/ O 0 0.0013858501
kg O 0 0.0008154021
) O 0 0.00037222228
twice O 0 0.00015599633
a O 0 0.00017812348
day O 0 0.00012422596
at O 0 0.000118006035
12 O 0 0.00010212188
hour O 0 9.590796e-05
intervals O 0 8.7692366e-05
for O 0 0.000107878244
10 O 0 0.0001185135
days O 0 0.00010703678
, O 0 0.00025747909
and O 0 0.0010945231
Rg1 B-Chemical 1 0.999997
( O 0 0.0010128794
30 O 0 0.00018127388
mg O 0 0.010202744
/ O 0 0.0013862314
kg O 0 0.0010361475
) O 0 0.00042868382
was O 0 0.00016954602
intraperitoneally O 0 0.00028105968
injected O 0 0.00014380705
2 O 0 0.0001363973
hours O 0 0.00011044127
after O 0 9.912153e-05
the O 0 0.0001464627
second O 0 0.00018543673
injection O 0 0.00040826612
of O 0 0.0007567754
morphine B-Chemical 0 0.9998344
once O 0 0.00039730797
a O 0 0.00058264565
day O 0 0.0006090245
for O 0 0.000986371
10 O 0 0.0016421817
days O 0 0.002455574
. O 0 0.0055757943

Spatial O 0 0.013061462
learning O 0 0.0074761533
capacity O 0 0.004805046
was O 0 0.003589985
assessed O 0 0.0028559964
in O 0 0.00340776
the O 0 0.004265149
Morris O 0 0.04980025
water O 0 0.060374394
maze O 0 0.19401857
. O 0 0.012915068

The O 0 0.003011133
results O 0 0.0019827867
showed O 0 0.0013981516
that O 0 0.0009644235
rats O 0 0.001232399
treated O 0 0.00106774
with O 0 0.007925282
Morphine B-Chemical 0 0.9999994
/ O 0 0.81083316
Rg1 B-Chemical 1 0.99999845
decreased O 0 0.0013256106
escape O 0 0.0014843349
latency O 0 0.0014412454
and O 0 0.00035001623
increased O 0 0.00030485183
the O 0 0.00025678574
time O 0 0.00023567496
spent O 0 0.00034533697
in O 0 0.00043754894
platform O 0 0.0008960752
quadrant O 0 0.0016885702
and O 0 0.0014121728
entering O 0 0.0028367548
frequency O 0 0.004168912
. O 0 0.0067679207

By O 0 0.0043527186
implantation O 0 0.0033306929
of O 0 0.0018858666
electrodes O 0 0.0041909316
and O 0 0.0009871305
electrophysiological O 0 0.0028821495
recording O 0 0.00060689915
in O 0 0.00039077672
vivo O 0 0.00052388426
, O 0 0.00043369265
the O 0 0.00022611616
results O 0 0.00019743315
showed O 0 0.00022959274
that O 0 0.00038624107
Rg1 B-Chemical 1 0.9999956
restored O 0 0.00033207322
the O 0 0.00023025367
long O 0 0.0003005808
- O 0 0.0047632544
term O 0 0.0002635437
potentiation O 0 0.74278027
( O 0 0.011638362
LTP O 0 0.9985891
) O 0 0.0015640128
impaired O 0 0.0005976192
by O 0 0.00068878196
morphine B-Chemical 0 0.99985695
in O 0 0.00042531677
both O 0 0.000503042
freely O 0 0.0008314411
moving O 0 0.0014461818
and O 0 0.0018041115
anaesthetised O 0 0.058545172
rats O 0 0.004280149
. O 0 0.005950657

The O 0 0.0028681485
electrophysiological O 0 0.0040043937
recording O 0 0.0016370784
in O 0 0.0009993208
vitro O 0 0.0009695824
showed O 0 0.00068583374
that O 0 0.0009558462
Rg1 B-Chemical 1 0.99999595
restored O 0 0.0009256494
the O 0 0.0009541715
LTP O 0 0.99715483
in O 0 0.00032445035
slices O 0 0.001091751
from O 0 0.00015641787
the O 0 0.00016498503
rats O 0 0.0002566996
treated O 0 0.00027634672
with O 0 0.0014852979
morphine B-Chemical 0 0.9999821
, O 0 0.0010291056
but O 0 0.00030004824
not O 0 0.00017291449
changed O 0 0.00039737162
LTP O 0 0.98787326
in O 0 0.00017232573
the O 0 0.00014577011
slices O 0 0.00046378095
from O 0 0.00012208585
normal O 0 0.00036125598
saline O 0 0.024232674
- O 0 0.013413373
or O 0 0.00068880036
morphine B-Chemical 0 0.99999356
/ O 0 0.8288513
Rg1 B-Chemical 1 0.99999976
- O 0 0.20713966
treated O 0 0.0006057191
rats O 0 0.00048025989
; O 0 0.00034575092
this O 0 0.00015152084
restoration O 0 0.00022971537
could O 0 0.00013551691
be O 0 0.00016782916
inhibited O 0 0.00030420697
by O 0 0.00095265586
N B-Chemical 0 0.9999386
- I-Chemical 0 0.8299975
methyl I-Chemical 0 0.99981385
- I-Chemical 0 0.6823627
D I-Chemical 0 0.9996165
- I-Chemical 0 0.88444734
aspartate I-Chemical 1 0.99999726
( O 0 0.41525662
NMDA B-Chemical 1 0.99999917
) O 0 0.07303039
receptor O 0 0.7145846
antagonist O 0 0.9991241
MK801 B-Chemical 1 0.99999833
. O 0 0.01073574

We O 0 0.003700494
conclude O 0 0.0022665218
that O 0 0.00292267
Rg1 B-Chemical 1 0.999982
may O 0 0.0012642671
significantly O 0 0.0007061852
improve O 0 0.0003612054
the O 0 0.0003678291
spatial O 0 0.0011855598
learning O 0 0.00093412615
capacity O 0 0.00041249444
impaired O 0 0.0005304901
by O 0 0.00052041287
chonic O 0 0.71969646
morphine B-Chemical 0 0.9999782
administration O 0 0.010645406
and O 0 0.00045404397
restore O 0 0.0004118642
the O 0 0.0014558681
morphine B-Chemical 0 0.99997365
- O 0 0.10707344
inhibited O 0 0.015092915
LTP O 0 0.99716175
. O 0 0.008750586

This O 0 0.016061626
effect O 0 0.013029665
is O 0 0.021474028
NMDA B-Chemical 1 0.9999616
receptor O 0 0.32244992
dependent O 0 0.017378546
. O 0 0.02286283

Synthesis O 0 0.016712302
of O 0 0.008171245
N B-Chemical 0 0.9993112
- I-Chemical 0 0.528918
pyrimidinyl I-Chemical 0 0.99387544
- I-Chemical 0 0.07130512
2 I-Chemical 0 0.0018845629
- I-Chemical 0 0.0067010373
phenoxyacetamides I-Chemical 0 0.044043075
as O 0 0.0034100893
adenosine B-Chemical 1 0.99992764
A2A O 0 0.9999405
receptor O 0 0.5041777
antagonists O 0 0.9132039
. O 0 0.009663735

A O 0 0.021351751
series O 0 0.0041559897
of O 0 0.005196517
N B-Chemical 0 0.99945146
- I-Chemical 0 0.52798444
pyrimidinyl I-Chemical 0 0.9948368
- I-Chemical 0 0.085989304
2 I-Chemical 0 0.0012157189
- I-Chemical 0 0.024189098
phenoxyacetamide I-Chemical 0 0.77236944
adenosine B-Chemical 1 0.99971646
A O 0 0.61246735
( O 0 0.0028962505
2A O 0 0.0024588774
) O 0 0.003407967
antagonists O 0 0.38447693
is O 0 0.0031607493
described O 0 0.0041202377
. O 0 0.0074002603

SAR O 0 0.6243397
studies O 0 0.0030362671
led O 0 0.0019945607
to O 0 0.0014186293
compound O 0 0.085419014
14 O 0 0.00072989205
with O 0 0.00051730307
excellent O 0 0.00085657695
potency O 0 0.06880642
( O 0 0.010363705
K O 1 0.9999604
( O 0 0.0036983483
i O 0 0.009422562
) O 0 0.0012369249
= O 0 0.0007374893
0 O 0 0.00027811102
. O 0 0.00018916558
4 O 0 0.00018123342
nM O 0 0.002720579
) O 0 0.0008460714
, O 0 0.00046512944
selectivity O 0 0.014042491
( O 0 0.0011178465
A O 0 0.15101476
( O 0 0.0006461669
1 O 0 0.00025918175
) O 0 0.00063526054
/ O 0 0.008553303
A O 0 0.26617992
( O 0 0.0011938972
2A O 0 0.0009281814
) O 0 0.0008505
> O 0 0.0009141441
100 O 0 0.00052950805
) O 0 0.00048677367
, O 0 0.0002914245
and O 0 0.0002392494
efficacy O 0 0.00050962094
( O 0 0.0009137352
MED O 0 0.59311485
10 O 0 0.00019661596
mg O 0 0.006772872
/ O 0 0.00091756217
kg O 0 0.0006629323
p O 0 0.00025266447
. O 0 0.00021531759
o O 0 0.0066194427
. O 0 0.00027180792
) O 0 0.0004938393
in O 0 0.00023852738
the O 0 0.0003569135
rat O 0 0.10928882
haloperidol B-Chemical 1 0.9999999
- O 0 0.18858306
induced O 0 0.0060209217
catalepsy B-Disease 2 0.99999905
model O 0 0.0010396562
for O 0 0.0015756104
Parkinson B-Disease 0 0.99948776
' I-Disease 0 0.003134006
s I-Disease 0 0.0037217333
disease I-Disease 0 0.7368761
. O 0 0.007831895

Evidence O 0 0.0051741083
for O 0 0.0024587743
an O 0 0.002077135
involvement O 0 0.002045692
of O 0 0.004257115
D1 O 0 0.9998294
and O 0 0.04534261
D2 O 0 0.9999702
dopamine B-Chemical 1 0.9999424
receptors O 0 0.0078044496
in O 0 0.0005335825
mediating O 0 0.0006618753
nicotine B-Chemical 1 0.9999367
- O 0 0.085056506
induced O 0 0.0035830033
hyperactivity B-Disease 2 0.99991524
in O 0 0.0031793038
rats O 0 0.0058817375
. O 0 0.0066332626

Previous O 0 0.0035708244
studies O 0 0.0022747847
have O 0 0.001389919
suggested O 0 0.00096842
that O 0 0.00069114316
repeated O 0 0.0005380387
exposure O 0 0.0018249169
of O 0 0.00064054364
rats O 0 0.0006339173
to O 0 0.0002567182
the O 0 0.00029918845
drug O 0 0.07685992
or O 0 0.00023441056
to O 0 0.00018062239
the O 0 0.00019347866
experimental O 0 0.0002548528
environment O 0 0.0003749327
is O 0 0.0002488099
necessary O 0 0.0002047387
to O 0 0.00031244953
observe O 0 0.0005120599
nicotine B-Chemical 1 0.9998988
- O 0 0.056696963
induced O 0 0.0025635518
locomotor O 0 0.77644503
stimulation O 0 0.0041926564
. O 0 0.00671837

In O 0 0.003545012
the O 0 0.0021341413
present O 0 0.0013271796
study O 0 0.0012059801
the O 0 0.0007052463
role O 0 0.0004594077
of O 0 0.00068663165
habituation O 0 0.021951243
to O 0 0.00030203178
the O 0 0.00027155742
experimental O 0 0.00030475273
environment O 0 0.00038506498
on O 0 0.0002013836
the O 0 0.00036936734
stimulant O 0 0.84585714
effect O 0 0.0005256454
of O 0 0.0026293232
nicotine B-Chemical 1 0.99987507
in O 0 0.0012522293
rats O 0 0.0019589309
was O 0 0.0018958504
examined O 0 0.0027016615
. O 0 0.0061043855

In O 0 0.0034133706
addition O 0 0.0017844371
, O 0 0.001966467
the O 0 0.0009995288
role O 0 0.0006541602
of O 0 0.0025984144
dopamine B-Chemical 1 0.9999248
receptors O 0 0.016669236
in O 0 0.00040245743
mediating O 0 0.0004214182
nicotine B-Chemical 1 0.9999813
- O 0 0.109225035
induced O 0 0.00058273453
locomotor O 0 0.6300764
stimulation O 0 0.00022972345
was O 0 0.00016075138
investigated O 0 0.00010824994
by O 0 0.00012869148
examining O 0 9.583958e-05
the O 0 0.0001365795
effects O 0 0.00022601012
of O 0 0.00040109316
selective O 0 0.053128004
D1 O 0 0.999912
and O 0 0.03416529
D2 O 0 0.99998593
dopamine B-Chemical 1 0.9999703
receptor O 0 0.08909308
antagonists O 0 0.32298523
on O 0 0.00040596855
activity O 0 0.00079209515
induced O 0 0.0014636269
by O 0 0.0039383336
nicotine B-Chemical 1 0.9996376
. O 0 0.008139416

Locomotor O 0 0.19565295
activity O 0 0.0037880228
was O 0 0.0026553012
assessed O 0 0.0018652137
in O 0 0.0020897295
male O 0 0.0063073914
Sprague O 0 0.14283483
- O 0 0.010875699
Dawley O 0 0.010938561
rats O 0 0.002255727
tested O 0 0.002033549
in O 0 0.0033462353
photocell O 0 0.06495198
cages O 0 0.0096317865
. O 0 0.009445225

Nicotine B-Chemical 0 0.9999598
( O 0 0.0066542244
1 O 0 0.002112034
. O 0 0.0012862515
0 O 0 0.0011464139
mg O 0 0.015674097
/ O 0 0.002680496
kg O 0 0.0019306577
) O 0 0.00087001495
caused O 0 0.00037299452
a O 0 0.0004548381
significant O 0 0.00030997535
increase B-Disease 0 0.000243305
in I-Disease 0 0.0003669203
locomotor I-Disease 0 0.4611566
activity I-Disease 0 0.00024807744
in O 0 0.00018138523
rats O 0 0.00022840932
that O 0 0.0001199602
were O 0 0.00014934315
habituated O 0 0.0002157148
to O 0 0.000109137254
the O 0 0.00013258021
test O 0 0.0001848658
environment O 0 0.00040545472
, O 0 0.0004132621
but O 0 0.00025745895
had O 0 0.00017104867
only O 0 0.00020321335
a O 0 0.0002725727
weak O 0 0.0015832238
and O 0 0.0004121562
delayed O 0 0.006565878
stimulant O 0 0.9328335
action O 0 0.0006890774
in O 0 0.0002671505
rats O 0 0.00037476915
that O 0 0.00025841384
were O 0 0.00041702206
unfamiliar O 0 0.0010772429
with O 0 0.0007738711
the O 0 0.0011618342
test O 0 0.0021589294
environment O 0 0.004499922
. O 0 0.0067279264

The O 0 0.0036650875
stimulant O 0 0.7777671
action O 0 0.0050642854
of O 0 0.006032908
nicotine B-Chemical 1 0.9999391
was O 0 0.0011269174
blocked O 0 0.0009054435
by O 0 0.00047639487
the O 0 0.00042897693
central O 0 0.014487857
nicotinic O 0 0.9999652
antagonist O 0 0.9988643
mecamylamine B-Chemical 0 0.99999964
but O 0 0.00070247595
not O 0 0.00017226364
by O 0 0.00019496272
the O 0 0.00025419443
peripheral O 0 0.13313675
nicotinic O 0 0.9999534
blocker O 0 0.99936587
hexamethonium B-Chemical 0 0.99999964
, O 0 0.0011009638
indicating O 0 0.00017894349
that O 0 0.00015927812
the O 0 0.00021323473
response O 0 0.000362695
is O 0 0.00036974874
probably O 0 0.0005549322
mediated O 0 0.0004862517
by O 0 0.0011144048
central O 0 0.0065222206
nicotinic O 0 0.9980938
receptors O 0 0.040197175
. O 0 0.006829179

Nicotine B-Chemical 0 0.9999856
- O 0 0.18687221
induced O 0 0.0057702037
hyperactivity B-Disease 2 0.99992716
was O 0 0.0013588789
blocked O 0 0.0010697223
by O 0 0.0006401833
the O 0 0.0006468829
selective O 0 0.14189416
D1 O 0 0.9999906
antagonist O 0 0.9999169
SCH B-Chemical 0 1.0
23390 I-Chemical 0 0.99999976
, O 0 0.0013651404
the O 0 0.00038886085
selective O 0 0.046248656
D2 O 0 0.99994576
antagonist O 0 0.996498
raclopride B-Chemical 0 0.9999993
and O 0 0.0009708326
the O 0 0.0013396331
D1 O 0 0.99981207
/ O 0 0.6293016
D2 O 0 0.9999484
antagonist O 0 0.9991411
fluphenazine B-Chemical 0 0.9999982
. O 0 0.008960505

Pretreatment O 0 0.3684076
with O 0 0.004012191
the O 0 0.0072165593
D2 O 0 0.9999263
agonist O 0 0.9988939
PHNO B-Chemical 0 0.99999654
enhanced O 0 0.014514938
nicotine B-Chemical 1 0.99998903
- O 0 0.20734611
induced O 0 0.0030262305
hyperactivity B-Disease 2 0.99998903
, O 0 0.0019849697
whereas O 0 0.00080026774
the O 0 0.0029469638
D1 O 0 0.9999826
agonist O 0 0.99988127
SKF B-Chemical 0 1.0
38393 I-Chemical 0 1.0
had O 0 0.0016869691
no O 0 0.0016745874
effect O 0 0.0033619837
. O 0 0.006506668

The O 0 0.0029533342
results O 0 0.0018990492
indicate O 0 0.001171022
that O 0 0.0012942225
acute O 0 0.9769306
nicotine B-Chemical 1 0.99998164
injection O 0 0.010506595
induces O 0 0.00061773293
a O 0 0.0012989757
pronounced O 0 0.016608585
hyperactivity B-Disease 2 0.9999174
in O 0 0.00060221006
rats O 0 0.00082339824
habituated O 0 0.0008791721
to O 0 0.00073979044
the O 0 0.0012377953
test O 0 0.0023001123
environment O 0 0.004719511
. O 0 0.007108412

The O 0 0.003144949
effect O 0 0.0021950724
appears O 0 0.0013206367
to O 0 0.000866052
be O 0 0.00069155364
mediated O 0 0.00045388436
by O 0 0.0006219418
central O 0 0.0055542765
nicotine B-Chemical 1 0.99993384
receptors O 0 0.035809122
, O 0 0.00061277713
possibly O 0 0.00044913578
located O 0 0.00020176744
on O 0 0.00015216602
dopaminergic O 0 0.20063569
neurons O 0 0.0006816656
, O 0 0.00027676203
and O 0 0.0002096115
also O 0 0.0001735021
requires O 0 0.00015365057
the O 0 0.00021850817
activation O 0 0.0003999833
of O 0 0.00054806645
both O 0 0.0013718186
D1 O 0 0.999607
and O 0 0.020227807
D2 O 0 0.99989414
dopamine B-Chemical 1 0.9997602
receptors O 0 0.034024335
. O 0 0.0072098216

Central O 0 0.010949193
retinal B-Disease 0 0.822747
vein I-Disease 0 0.19577488
occlusion I-Disease 0 0.6282103
associated O 0 0.0046967897
with O 0 0.014749109
clomiphene B-Chemical 0 0.9999862
- O 0 0.1928106
induced O 0 0.010409999
ovulation O 0 0.9708011
. O 0 0.01368416

OBJECTIVE O 0 0.016061941
: O 0 0.0037786337
To O 0 0.001756615
report O 0 0.0021496448
a O 0 0.0013811627
case O 0 0.0009694476
of O 0 0.00090762967
central O 0 0.0019107761
retinal B-Disease 0 0.9544621
vein I-Disease 0 0.22119299
occlusion I-Disease 0 0.6137288
associated O 0 0.0013073966
with O 0 0.013786246
clomiphene B-Chemical 0 0.9999993
citrate I-Chemical 0 0.9997174
( O 0 0.03211877
CC B-Chemical 0 0.9939804
) O 0 0.010202961
. O 0 0.008247098

DESIGN O 0 0.049961243
: O 0 0.043990787
Case O 0 0.05856871
study O 0 0.0478802
. O 0 0.05488603

SETTING O 0 0.016835423
: O 0 0.012380473
Ophthalmology O 0 0.019842379
clinic O 0 0.00825526
of O 0 0.00822135
an O 0 0.00986209
academic O 0 0.015832769
hospital O 0 0.018164603
. O 0 0.019088386

PATIENT O 0 0.0073688454
( O 0 0.0068396074
S O 0 0.94780654
) O 0 0.0054435376
: O 0 0.0033592943
A O 0 0.05324913
36 O 0 0.0014696079
- O 0 0.0027957456
year O 0 0.0009466652
- O 0 0.0022077942
old O 0 0.00076916
woman O 0 0.0013661184
referred O 0 0.0006525991
from O 0 0.0006186972
the O 0 0.0009710916
infertility B-Disease 0 0.9783781
clinic O 0 0.0022302438
for O 0 0.0026070904
blurred B-Disease 0 0.96146864
vision I-Disease 0 0.96368235
. O 0 0.009720537

INTERVENTION O 0 0.010209185
( O 0 0.010077782
S O 0 0.915029
) O 0 0.008967032
: O 0 0.007070504
Ophthalmic O 0 0.05620861
examination O 0 0.0051139668
after O 0 0.005050925
CC B-Chemical 0 0.94533426
therapy O 0 0.016511885
. O 0 0.0140377

MAIN O 0 0.035974424
OUTCOME O 0 0.0071159014
MEASURE O 0 0.0077647604
( O 0 0.0049512857
S O 0 0.9360259
) O 0 0.004035371
: O 0 0.002496424
Central O 0 0.002871527
retinal B-Disease 0 0.8442924
vein I-Disease 0 0.1222214
occlusion I-Disease 0 0.40432635
after O 0 0.0012694073
ovulation O 0 0.675195
induction O 0 0.0026670697
with O 0 0.0059515033
CC B-Chemical 0 0.9898941
. O 0 0.010497557

RESULT O 0 0.011024406
( O 0 0.0077083223
S O 0 0.9634572
) O 0 0.005550243
: O 0 0.0032417944
A O 0 0.054785773
36 O 0 0.001334404
- O 0 0.0026107358
year O 0 0.0008251588
- O 0 0.0024792394
old O 0 0.0007150958
Chinese O 0 0.013937205
woman O 0 0.0015880594
developed O 0 0.0007089904
central O 0 0.0010254164
retinal B-Disease 0 0.8751457
vein I-Disease 0 0.07336812
occlusion I-Disease 0 0.12791802
after O 0 0.0006079597
eight O 0 0.00091401907
courses O 0 0.0016115077
of O 0 0.0036602586
CC B-Chemical 0 0.98498106
. O 0 0.009075749

A O 0 0.025583949
search O 0 0.0030570785
of O 0 0.002016381
the O 0 0.0012611145
literature O 0 0.0011840255
on O 0 0.0006026849
the O 0 0.0010405817
thromboembolic B-Disease 2 0.9999888
complications O 0 0.90599555
of O 0 0.008247847
CC B-Chemical 0 0.9987238
does O 0 0.0003806353
not O 0 0.00019547797
include O 0 0.00018742336
this O 0 0.00023251583
severe O 0 0.03629907
ophthalmic O 0 0.37068787
complication O 0 0.32334492
, O 0 0.00062677515
although O 0 0.000438132
mild O 0 0.7022446
visual B-Disease 0 0.95336497
disturbance I-Disease 0 0.87019646
after O 0 0.000610029
CC B-Chemical 0 0.9957216
intake O 0 0.6606876
is O 0 0.0016649439
not O 0 0.002285072
uncommon O 0 0.025037449
. O 0 0.0065701595

CONCLUSION O 0 0.08106934
( O 0 0.009652004
S O 0 0.9814402
) O 0 0.006112063
: O 0 0.0026175077
This O 0 0.0014424426
is O 0 0.0007707433
the O 0 0.00055503246
first O 0 0.0004169869
reported O 0 0.0004976898
case O 0 0.0004418757
of O 0 0.00052672805
central O 0 0.0014285845
retinal B-Disease 0 0.94421405
vein I-Disease 0 0.16820478
occlusion I-Disease 0 0.3312336
after O 0 0.0007872191
treatment O 0 0.0017825756
with O 0 0.0038570159
CC B-Chemical 0 0.987056
. O 0 0.008402308

Extra O 0 0.011180086
caution O 0 0.002765554
is O 0 0.0017843556
warranted O 0 0.001075798
in O 0 0.0009953025
treating O 0 0.0040857587
infertility B-Disease 0 0.9975431
patients O 0 0.0037055481
with O 0 0.0023231006
CC B-Chemical 0 0.99822754
, O 0 0.0009183896
and O 0 0.00040227614
patients O 0 0.00038192963
should O 0 0.00016169065
be O 0 0.00021199285
well O 0 0.00023748352
informed O 0 0.0006303591
of O 0 0.00038140605
this O 0 0.00041049698
side O 0 0.0032516706
effect O 0 0.0005946964
before O 0 0.000665917
commencement O 0 0.0014482533
of O 0 0.0024820757
therapy O 0 0.0062935688
. O 0 0.0066317795

Acute O 0 0.7498787
bronchodilating O 0 0.992184
effects O 0 0.009493225
of O 0 0.059390146
ipratropium B-Chemical 0 0.99999976
bromide I-Chemical 0 0.999998
and O 0 0.094886184
theophylline B-Chemical 1 0.99999404
in O 0 0.003474202
chronic B-Disease 0 0.98264503
obstructive I-Disease 0 0.9993905
pulmonary I-Disease 0 0.99411446
disease I-Disease 0 0.9902327
. O 0 0.009792389

The O 0 0.0035187653
bronchodilator O 0 0.46075574
effects O 0 0.002153537
of O 0 0.0013021339
a O 0 0.0009975034
single O 0 0.0006541727
dose O 0 0.005384488
of O 0 0.0192554
ipratropium B-Chemical 0 0.9999999
bromide I-Chemical 0 0.99999905
aerosol O 0 0.744353
( O 0 0.0013386396
36 O 0 0.0002716538
micrograms O 0 0.0024543619
) O 0 0.00036439928
and O 0 0.00019914268
short O 0 0.00017901653
- O 0 0.008314882
acting O 0 0.0055835675
theophylline B-Chemical 1 0.9999968
tablets O 0 0.8302423
( O 0 0.0005800527
dose O 0 0.000691607
titrated O 0 0.00022535208
to O 0 0.00010551999
produce O 0 0.00010669449
serum O 0 0.03798503
levels O 0 0.0001731151
of O 0 0.00024883647
10 O 0 0.00021023338
- O 0 0.0014974737
20 O 0 0.0001547445
micrograms O 0 0.0021855722
/ O 0 0.0027828563
mL O 0 0.0017108691
) O 0 0.00034073048
were O 0 0.0001436052
compared O 0 0.00010541711
in O 0 0.00014198438
a O 0 0.00020732942
double O 0 0.000294002
- O 0 0.012050974
blind O 0 0.031736664
, O 0 0.00060863775
placebo O 0 0.027497673
- O 0 0.0014900579
controlled O 0 0.00018545883
crossover O 0 0.0007529843
study O 0 0.0002583806
in O 0 0.00021154198
21 O 0 0.00026763076
patients O 0 0.00031646917
with O 0 0.00037105026
stable O 0 0.00077680586
, O 0 0.0016102409
chronic B-Disease 0 0.94880545
obstructive I-Disease 0 0.99916816
pulmonary I-Disease 0 0.9936087
disease I-Disease 0 0.9901063
. O 0 0.008836966

Mean O 0 0.002469627
peak O 0 0.0024939966
forced O 0 0.0030841043
expiratory O 0 0.07589902
volume O 0 0.0015950182
in O 0 0.0007263152
1 O 0 0.0005368789
second O 0 0.00042191806
( O 0 0.00074959244
FEV1 O 0 0.25517637
) O 0 0.00061419705
increases O 0 0.00021501746
over O 0 0.00014293894
baseline O 0 0.0001790517
and O 0 0.00017883466
the O 0 0.00014778152
proportion O 0 0.00014712983
of O 0 0.00021643857
patients O 0 0.0003141728
attaining O 0 0.0017277726
at O 0 0.00013382455
least O 0 0.00011337138
a O 0 0.00016808795
15 O 0 0.00012458516
% O 0 0.00015688779
increase O 0 0.00011617617
in O 0 0.00014987958
the O 0 0.00019631792
FEV1 O 0 0.20315492
( O 0 0.00041203084
responders O 0 0.0010015983
) O 0 0.00037024042
were O 0 0.00017476048
31 O 0 0.0002102815
% O 0 0.00019466293
and O 0 0.0001811087
90 O 0 0.00017696687
% O 0 0.00023683952
, O 0 0.00029710235
respectively O 0 0.00091201824
, O 0 0.00041764407
for O 0 0.00043505
ipratropium B-Chemical 0 0.9999659
and O 0 0.00045773483
17 O 0 0.00035054583
% O 0 0.00032004886
and O 0 0.00034437497
50 O 0 0.00047155042
% O 0 0.0006394811
, O 0 0.0009408201
respectively O 0 0.002214405
, O 0 0.0023547234
for O 0 0.0035745525
theophylline B-Chemical 1 0.99991953
. O 0 0.009440548

The O 0 0.002904352
average O 0 0.0018730575
FEV1 O 0 0.05976141
increases O 0 0.0011172902
during O 0 0.0006705604
the O 0 0.0006452408
6 O 0 0.0004957528
- O 0 0.0010489
hour O 0 0.00031875927
observation O 0 0.00030212483
period O 0 0.00026532667
were O 0 0.00031073493
18 O 0 0.00034379028
% O 0 0.00046200005
for O 0 0.0006217296
ipratropium B-Chemical 0 0.9998766
and O 0 0.001039472
8 O 0 0.001028989
% O 0 0.0018187949
for O 0 0.0030390644
theophylline B-Chemical 1 0.99985003
. O 0 0.00897415

The O 0 0.0026707465
mean O 0 0.0013977388
duration O 0 0.0011911358
of O 0 0.0011803635
action O 0 0.001378717
was O 0 0.0007453741
3 O 0 0.000477379
. O 0 0.00038867086
8 O 0 0.00034397974
hours O 0 0.00031017014
with O 0 0.0005918234
ipratropium B-Chemical 0 0.99993813
and O 0 0.00071926427
2 O 0 0.0005277719
. O 0 0.0005654395
4 O 0 0.0007350165
hours O 0 0.0011202579
with O 0 0.0030454015
theophylline B-Chemical 1 0.9998642
. O 0 0.0085822465

While O 0 0.004216341
side O 0 0.010032894
effects O 0 0.0026184928
were O 0 0.0015694585
rare O 0 0.003226058
, O 0 0.0012698856
those O 0 0.00084594765
experienced O 0 0.0007152481
after O 0 0.0005071155
theophylline B-Chemical 1 0.9999583
use O 0 0.000690325
did O 0 0.0005429144
involve O 0 0.0005021615
the O 0 0.00086099457
cardiovascular B-Disease 0 0.81164795
and I-Disease 0 0.0026813683
gastrointestinal I-Disease 0 0.7708562
systems I-Disease 0 0.005053319
. O 0 0.006948736

These O 0 0.0035639869
results O 0 0.0022531375
show O 0 0.0016199359
that O 0 0.0017623552
ipratropium B-Chemical 0 0.9999726
is O 0 0.001426899
a O 0 0.0009636048
more O 0 0.00070118514
potent O 0 0.0037325942
bronchodilator O 0 0.8473644
than O 0 0.0004931728
oral O 0 0.6783921
theophylline B-Chemical 1 0.999987
in O 0 0.00076079345
patients O 0 0.001315347
with O 0 0.0016084855
chronic B-Disease 0 0.9817054
airflow I-Disease 0 0.9710797
obstruction I-Disease 0 0.9880058
. O 0 0.009074007

Methamphetamine B-Chemical 1 0.99999154
- O 0 0.23429613
induced O 0 0.00772215
neurotoxicity B-Disease 2 0.9999685
and O 0 0.003942355
microglial O 0 0.42493314
activation O 0 0.0015849485
are O 0 0.0007609828
not O 0 0.0006893044
mediated O 0 0.00080479647
by O 0 0.0017421425
fractalkine O 0 0.85614944
receptor O 0 0.10167282
signaling O 0 0.0060423193
. O 0 0.008470292

Methamphetamine B-Chemical 1 0.99999297
( O 0 0.42264566
METH B-Chemical 0 0.99999857
) O 0 0.15481462
damages O 0 0.98907405
dopamine B-Chemical 1 0.9999893
( O 0 0.0962889
DA B-Chemical 0 0.99993145
) O 0 0.0027829118
nerve O 0 0.040373806
endings O 0 0.013845197
by O 0 0.00029624617
a O 0 0.0002918549
process O 0 0.00022543718
that O 0 0.00018033052
has O 0 0.00019362886
been O 0 0.0001887944
linked O 0 0.0001822729
to O 0 0.00017696571
microglial O 0 0.16572908
activation O 0 0.00062925165
but O 0 0.00025703045
the O 0 0.00016233113
signaling O 0 0.00018376336
pathways O 0 0.0002138019
that O 0 0.00016810768
mediate O 0 0.00017944034
this O 0 0.0003097246
response O 0 0.000497502
have O 0 0.00053669664
not O 0 0.0008441564
yet O 0 0.0016693788
been O 0 0.0021806962
delineated O 0 0.004562292
. O 0 0.006588835

Cardona O 0 0.14063989
et O 0 0.06580497
al O 0 0.07653521
. O 0 0.07164278

[ O 0 0.022076495
Nat O 0 0.19971435
. O 0 0.0036969709
Neurosci O 0 0.9615674
. O 0 0.0014318465
9 O 0 0.0010295524
( O 0 0.0010716522
2006 O 0 0.0013270178
) O 0 0.0013284612
, O 0 0.0011318497
917 O 0 0.31608933
] O 0 0.00079586526
recently O 0 0.00028108942
identified O 0 0.0002288898
the O 0 0.0002739846
microglial O 0 0.40256715
- O 0 0.017723303
specific O 0 0.00033896908
fractalkine O 0 0.94911516
receptor O 0 0.30604884
( O 0 0.017498635
CX3CR1 O 0 0.98513633
) O 0 0.0010887386
as O 0 0.00021590368
an O 0 0.00024720104
important O 0 0.0002093271
mediator O 0 0.0008486106
of O 0 0.03499961
MPTP B-Chemical 0 1.0
- O 0 0.366697
induced O 0 0.005132414
neurodegeneration B-Disease 0 0.9999342
of O 0 0.073754966
DA B-Chemical 0 0.99984705
neurons O 0 0.018301027
. O 0 0.007074327

Because O 0 0.003570017
the O 0 0.0035508687
CNS B-Disease 0 0.98067445
damage I-Disease 0 0.9919403
caused O 0 0.0026693055
by O 0 0.023070093
METH B-Chemical 0 0.99999976
and O 0 0.25980675
MPTP B-Chemical 0 0.9999999
is O 0 0.001253332
highly O 0 0.0005205969
selective O 0 0.0007400844
for O 0 0.00024412526
the O 0 0.000518985
DA B-Chemical 0 0.99987733
neuronal O 0 0.045368973
system O 0 0.00022569613
in O 0 0.00016832694
mouse O 0 0.00028164877
models O 0 0.00025844536
of O 0 0.0022723102
neurotoxicity B-Disease 2 0.99999225
, O 0 0.0006983355
we O 0 0.00011225517
hypothesized O 0 0.00012185836
that O 0 0.00014919655
the O 0 0.00030924837
CX3CR1 O 0 0.86647856
plays O 0 0.00023840735
a O 0 0.00033961245
role O 0 0.00022772801
in O 0 0.0019940045
METH B-Chemical 0 0.99999964
- O 0 0.16343571
induced O 0 0.0036994412
neurotoxicity B-Disease 2 0.9999783
and O 0 0.004065523
microglial O 0 0.6513631
activation O 0 0.008605889
. O 0 0.006907654

Mice O 0 0.0032693956
in O 0 0.0024498366
which O 0 0.0022298384
the O 0 0.0018538338
CX3CR1 O 0 0.9366914
gene O 0 0.0018526192
has O 0 0.0005838636
been O 0 0.0004398146
deleted O 0 0.000387092
and O 0 0.00034900027
replaced O 0 0.0002629318
with O 0 0.00027758942
a O 0 0.00028185453
cDNA O 0 0.00024579378
encoding O 0 0.0002137004
enhanced O 0 0.0002892196
green O 0 0.01523265
fluorescent O 0 0.007843589
protein O 0 0.0044262577
( O 0 0.0026093207
eGFP O 0 0.004655068
) O 0 0.00086983637
were O 0 0.00027866467
treated O 0 0.000417373
with O 0 0.0015002777
METH B-Chemical 0 0.99999726
and O 0 0.0007957879
examined O 0 0.0007016105
for O 0 0.0017917542
striatal O 0 0.9812401
neurotoxicity B-Disease 2 0.9999193
. O 0 0.008400909

METH B-Chemical 0 0.99999154
depleted O 0 0.025718695
DA B-Chemical 0 0.999902
, O 0 0.0036518187
caused O 0 0.0014325571
microglial O 0 0.5360484
activation O 0 0.0029173624
, O 0 0.00092777866
and O 0 0.0004727859
increased O 0 0.00040960187
body O 0 0.0021977748
temperature O 0 0.009842636
in O 0 0.00042524017
CX3CR1 O 0 0.8591283
knockout O 0 0.00021999783
mice O 0 0.0001252133
to O 0 0.00013948145
the O 0 0.00014257684
same O 0 0.00010629103
extent O 0 0.00011156176
and O 0 0.00017031922
over O 0 0.000121010744
the O 0 0.0001608075
same O 0 0.00014268987
time O 0 0.00017390608
course O 0 0.00028547522
seen O 0 0.00039927702
in O 0 0.0005977651
wild O 0 0.0010740908
- O 0 0.005323757
type O 0 0.0025095004
controls O 0 0.005577008
. O 0 0.006830919

The O 0 0.0032865282
effects O 0 0.0032745632
of O 0 0.008349495
METH B-Chemical 0 0.99999845
in O 0 0.004872113
CX3CR1 O 0 0.94272
knockout O 0 0.00066650566
mice O 0 0.00035033686
were O 0 0.00038926693
not O 0 0.00035522436
gender O 0 0.00731428
- O 0 0.003698513
dependent O 0 0.0003722794
and O 0 0.0005444771
did O 0 0.00056108454
not O 0 0.00053952803
extend O 0 0.00070368836
beyond O 0 0.0011920824
the O 0 0.002409738
striatum O 0 0.46281677
. O 0 0.0068832324

Striatal O 0 0.973081
microglia O 0 0.018153375
expressing O 0 0.0017440766
eGFP O 0 0.0028265454
constitutively O 0 0.0009673753
show O 0 0.0007821688
morphological O 0 0.002388336
changes O 0 0.0012362865
after O 0 0.0008686006
METH B-Chemical 0 0.99999356
that O 0 0.00094339094
are O 0 0.0012000084
characteristic O 0 0.0019858908
of O 0 0.0031489325
activation O 0 0.00661096
. O 0 0.007970941

This O 0 0.0047593047
response O 0 0.0028676412
was O 0 0.0016112807
restricted O 0 0.0009192463
to O 0 0.00069885375
the O 0 0.0006931475
striatum O 0 0.31656164
and O 0 0.00048429868
contrasted O 0 0.00066266954
sharply O 0 0.00092875335
with O 0 0.00033174353
unresponsive O 0 0.00075486733
eGFP O 0 0.007972631
- O 0 0.025461692
microglia O 0 0.029373877
in O 0 0.00030853096
surrounding O 0 0.0005003244
brain O 0 0.003653287
areas O 0 0.0007423203
that O 0 0.00043425013
are O 0 0.0006729304
not O 0 0.0009963486
damaged O 0 0.008147589
by O 0 0.0063087307
METH B-Chemical 0 0.99998915
. O 0 0.009613683

We O 0 0.0036796767
conclude O 0 0.0019461891
from O 0 0.0014928499
these O 0 0.0013091877
studies O 0 0.0011130689
that O 0 0.0010017352
CX3CR1 O 0 0.8504078
signaling O 0 0.0010740806
does O 0 0.0008149248
not O 0 0.00068414427
modulate O 0 0.00084395485
METH B-Chemical 0 0.99999964
neurotoxicity B-Disease 2 0.99998903
or O 0 0.0036373567
microglial O 0 0.6774423
activation O 0 0.009593971
. O 0 0.007640763

Furthermore O 0 0.0049012457
, O 0 0.0036770834
it O 0 0.0020672036
appears O 0 0.0011856548
that O 0 0.0010144684
striatal O 0 0.93010443
- O 0 0.014786172
resident O 0 0.0007352949
microglia O 0 0.018678766
respond O 0 0.00029735258
to O 0 0.0005237325
METH B-Chemical 0 0.99999857
with O 0 0.00050367444
an O 0 0.00033600422
activation O 0 0.00038715915
cascade O 0 0.00040206933
and O 0 0.0002340278
then O 0 0.00018290294
return O 0 0.00023898107
to O 0 0.00021046061
a O 0 0.00033469533
surveying O 0 0.0006029929
state O 0 0.0005066354
without O 0 0.0005961691
undergoing O 0 0.001191424
apoptosis O 0 0.7211102
or O 0 0.0031136465
migration O 0 0.114050984
. O 0 0.007932424

Nicotine B-Chemical 0 0.99995935
- O 0 0.08443554
induced O 0 0.00946257
nystagmus B-Disease 0 0.99969196
correlates O 0 0.0068124007
with O 0 0.007818323
midpontine O 0 0.58698195
activation O 0 0.0113583775
. O 0 0.013351887

The O 0 0.0046210596
pathomechanism O 0 0.119206734
of O 0 0.008793948
nicotine B-Chemical 1 0.99995816
- O 0 0.22884679
induced O 0 0.009696793
nystagmus B-Disease 0 0.9999857
( O 0 0.11700727
NIN B-Disease 0 0.9979791
) O 0 0.0060399915
is O 0 0.004608065
unknown O 0 0.008931967
. O 0 0.01011942

The O 0 0.0035118836
aim O 0 0.0027288168
of O 0 0.002072923
this O 0 0.0014746729
study O 0 0.0013051194
was O 0 0.0008489632
to O 0 0.0006005272
delineate O 0 0.00050597935
brain O 0 0.0017049002
structures O 0 0.0008278314
that O 0 0.00069439644
are O 0 0.0009852059
involved O 0 0.0012614207
in O 0 0.0025049627
NIN B-Disease 0 0.9594057
generation O 0 0.005945571
. O 0 0.008445587

Eight O 0 0.005341477
healthy O 0 0.0053322283
volunteers O 0 0.0041169985
inhaled O 0 0.9802403
nicotine B-Chemical 1 0.99992704
in O 0 0.0011421067
darkness O 0 0.014112
during O 0 0.00032183883
a O 0 0.00038244028
functional O 0 0.00035222832
magnetic O 0 0.010278386
resonance O 0 0.45155585
imaging O 0 0.001139114
( O 0 0.00055190205
fMRI O 0 0.0018166603
) O 0 0.000451273
experiment O 0 0.0002890787
; O 0 0.0006636926
eye O 0 0.007488345
movements O 0 0.0011193191
were O 0 0.00063429744
registered O 0 0.0008863308
using O 0 0.0011424494
video O 0 0.0035225225
- O 0 0.011215386
oculography O 0 0.19234884
. O 0 0.007652907

NIN B-Disease 0 0.93776995
correlated O 0 0.002350662
with O 0 0.0020109592
blood O 0 0.0347345
oxygen B-Chemical 1 0.99314487
level O 0 0.001000037
- O 0 0.0071005314
dependent O 0 0.00050168275
( O 0 0.0012853397
BOLD O 0 0.32023504
) O 0 0.00066042884
activity O 0 0.0003313863
levels O 0 0.0003181175
in O 0 0.00036129542
a O 0 0.00058002264
midpontine O 0 0.0570215
site O 0 0.0005731133
in O 0 0.00067697896
the O 0 0.0010022637
posterior O 0 0.009984862
basis O 0 0.002860516
pontis O 0 0.008326297
. O 0 0.006700587

NIN B-Disease 0 0.9949056
- O 0 0.022664864
induced O 0 0.002825075
midpontine O 0 0.3372372
activation O 0 0.0015115106
may O 0 0.0005880455
correspond O 0 0.00034638913
to O 0 0.00029808716
activation O 0 0.00036736653
of O 0 0.00030803715
the O 0 0.0002880325
dorsomedial O 0 0.082954556
pontine O 0 0.10846391
nuclei O 0 0.00036332483
and O 0 0.00016301424
the O 0 0.00015250534
nucleus O 0 0.00029995476
reticularis O 0 0.020754794
tegmenti O 0 0.0002997406
pontis O 0 0.00051441015
, O 0 0.00022867862
structures O 0 0.0002439903
known O 0 0.0002208347
to O 0 0.00016126248
participate O 0 0.0001684194
in O 0 0.0002004822
the O 0 0.00021939079
generation O 0 0.000323262
of O 0 0.00047410277
multidirectional O 0 0.021115659
saccades O 0 0.090141006
and O 0 0.0010225732
smooth O 0 0.013094056
pursuit O 0 0.03534607
eye O 0 0.13764259
movements O 0 0.014919021
. O 0 0.006985801

Acute O 0 0.2739574
effects O 0 0.0044886256
of O 0 0.0059969802
N B-Chemical 0 0.99961406
- I-Chemical 0 0.16127531
( I-Chemical 0 0.0021338165
2 I-Chemical 0 0.0008684657
- I-Chemical 0 0.0036223049
propylpentanoyl I-Chemical 0 0.014628697
) I-Chemical 0 0.0029235443
urea I-Chemical 1 0.9993206
on O 0 0.00038750825
hippocampal O 0 0.8647894
amino B-Chemical 0 0.99914825
acid I-Chemical 0 0.9993826
neurotransmitters O 0 0.76893073
in O 0 0.0043369965
pilocarpine B-Chemical 1 0.99999917
- O 0 0.18061098
induced O 0 0.0050761877
seizure B-Disease 2 0.9999597
in O 0 0.003407433
rats O 0 0.0060483045
. O 0 0.006385791

The O 0 0.0028810946
present O 0 0.0017507768
study O 0 0.0015018642
aimed O 0 0.0009920917
to O 0 0.0005965854
investigate O 0 0.00032894127
the O 0 0.0005725166
anticonvulsant O 0 0.9982691
activity O 0 0.00035567704
as O 0 0.0002185494
well O 0 0.0001919879
as O 0 0.00017115472
the O 0 0.00016309292
effects O 0 0.0001926958
on O 0 0.000100482044
the O 0 0.00013823522
level O 0 0.00013935103
of O 0 0.00054408977
hippocampal O 0 0.95688313
amino B-Chemical 0 0.9997172
acid I-Chemical 0 0.9997818
neurotransmitters O 0 0.89649034
( O 0 0.04131549
glutamate B-Chemical 1 0.9999858
, O 0 0.049606588
aspartate B-Chemical 1 0.9999962
, O 0 0.035604816
glycine B-Chemical 1 0.9999323
and O 0 0.022397285
GABA B-Chemical 1 0.999998
) O 0 0.0037891923
of O 0 0.0017384827
N B-Chemical 0 0.9998393
- I-Chemical 0 0.11272299
( I-Chemical 0 0.00068692456
2 I-Chemical 0 0.0002529855
- I-Chemical 0 0.0026856381
propylpentanoyl I-Chemical 0 0.017078778
) I-Chemical 0 0.007201509
urea I-Chemical 1 0.99995375
( O 0 0.0221616
VPU B-Chemical 0 0.9992884
) O 0 0.00111913
in O 0 0.00022771108
comparison O 0 0.00019759813
to O 0 0.0002164685
its O 0 0.00063770456
parent O 0 0.001192153
compound O 0 0.6939165
, O 0 0.045326553
valproic B-Chemical 0 0.9999982
acid I-Chemical 0 0.9938985
( O 0 0.1865578
VPA B-Chemical 1 0.9999944
) O 0 0.02236587
. O 0 0.007848028

VPU B-Chemical 0 0.9873998
was O 0 0.0037706476
more O 0 0.0025509123
potent O 0 0.0060032434
than O 0 0.00182526
VPA B-Chemical 1 0.9999968
, O 0 0.0016685025
exhibiting O 0 0.0006910062
the O 0 0.00027483463
median O 0 0.00018975268
effective O 0 0.0002663631
dose O 0 0.0023115145
( O 0 0.0013698393
ED O 0 0.23870409
( O 0 0.00049904035
50 O 0 0.0003256748
) O 0 0.0004624839
) O 0 0.000400651
of O 0 0.00027568228
49 O 0 0.00052109954
mg O 0 0.021350864
/ O 0 0.001423504
kg O 0 0.0006601825
in O 0 0.00019508954
protecting O 0 0.0009626904
rats O 0 0.0005830395
against O 0 0.0016032417
pilocarpine B-Chemical 1 0.99999976
- O 0 0.3522464
induced O 0 0.0038053114
seizure B-Disease 2 0.99999154
whereas O 0 0.00049574446
the O 0 0.00022312599
corresponding O 0 0.00021220822
value O 0 0.00038283184
for O 0 0.001026588
VPA B-Chemical 1 0.9999957
was O 0 0.0013750892
322 O 0 0.012122791
mg O 0 0.038817067
/ O 0 0.0054510483
kg O 0 0.007704552
. O 0 0.007166587

In O 0 0.003853454
vivo O 0 0.0037551732
microdialysis O 0 0.15204403
demonstrated O 0 0.0010079781
that O 0 0.0007143468
an O 0 0.0009792333
intraperitoneal O 0 0.034611113
administration O 0 0.052911002
of O 0 0.015078681
pilocarpine B-Chemical 1 0.9999994
induced O 0 0.0011654067
a O 0 0.00077211246
pronounced O 0 0.0008275211
increment O 0 0.00029323608
of O 0 0.00079543993
hippocampal O 0 0.9783116
glutamate B-Chemical 1 0.99998426
and O 0 0.012842839
aspartate B-Chemical 1 0.9999857
whereas O 0 0.00048718072
no O 0 0.00014659978
significant O 0 0.00020987327
change O 0 0.00026658716
was O 0 0.00022327752
observed O 0 0.000206996
on O 0 0.00022411572
the O 0 0.00038732955
level O 0 0.000582785
of O 0 0.002477762
glycine B-Chemical 1 0.9997589
and O 0 0.07523649
GABA B-Chemical 1 0.9999665
. O 0 0.009270421

Pretreatment O 0 0.2928808
with O 0 0.0034217152
either O 0 0.0034086376
VPU B-Chemical 0 0.9975752
( O 0 0.0023013756
50 O 0 0.00090238
and O 0 0.000614431
100 O 0 0.0007926169
mg O 0 0.023212748
/ O 0 0.0021454673
kg O 0 0.0017689394
) O 0 0.0011332841
or O 0 0.0008782102
VPA B-Chemical 1 0.99999833
( O 0 0.0011853364
300 O 0 0.00044659112
and O 0 0.0002381479
600 O 0 0.0006002062
mg O 0 0.011116806
/ O 0 0.0013749595
kg O 0 0.0010589352
) O 0 0.0005173149
completely O 0 0.0002818787
abolished O 0 0.0032113558
pilocarpine B-Chemical 1 0.9999995
- O 0 0.10371724
evoked O 0 0.0063985405
increases O 0 0.0004793975
in O 0 0.0007464379
extracellular O 0 0.09046067
glutamate B-Chemical 1 0.9999021
and O 0 0.022466319
aspartate B-Chemical 1 0.9999192
. O 0 0.0096429195

In O 0 0.00353637
addition O 0 0.0018948627
, O 0 0.0023211166
a O 0 0.0015110739
statistically O 0 0.0008723692
significant O 0 0.0007380342
reduction O 0 0.0010430466
was O 0 0.00044341455
also O 0 0.0002959698
observed O 0 0.00022774235
on O 0 0.00016702742
the O 0 0.00021292793
level O 0 0.0002311498
of O 0 0.0034995337
GABA B-Chemical 1 0.9999982
and O 0 0.009580733
glycine B-Chemical 1 0.9998486
but O 0 0.0006628768
less O 0 0.0002495383
than O 0 0.00019048214
a O 0 0.00033284916
drastic O 0 0.0007570343
reduction O 0 0.0012607961
of O 0 0.0037569338
glutamate B-Chemical 1 0.99991906
and O 0 0.0146903
aspartate B-Chemical 1 0.999915
level O 0 0.0042323587
. O 0 0.0068480987

Based O 0 0.006193677
on O 0 0.0018825711
the O 0 0.0016636541
finding O 0 0.0020614709
that O 0 0.0014666873
VPU B-Chemical 0 0.99953103
and O 0 0.04062225
VPA B-Chemical 1 0.9999988
could O 0 0.0004962781
protect O 0 0.00044333993
the O 0 0.00028655177
animals O 0 0.00024199898
against O 0 0.0019926243
pilocarpine B-Chemical 1 0.9999999
- O 0 0.46585914
induced O 0 0.0060649132
seizure B-Disease 2 0.9999957
it O 0 0.00060204015
is O 0 0.0001996109
suggested O 0 0.00012948048
that O 0 0.00011860133
the O 0 0.00016503804
reduction O 0 0.0004155663
of O 0 0.00045310406
inhibitory O 0 0.04656704
amino B-Chemical 0 0.99969447
acid I-Chemical 0 0.99961793
neurotransmitters O 0 0.43338677
was O 0 0.00023059796
comparatively O 0 0.00058933767
minor O 0 0.0005538255
and O 0 0.00025733572
offset O 0 0.00042145676
by O 0 0.0003094908
a O 0 0.00045927375
pronounced O 0 0.00091881625
reduction O 0 0.0012312374
of O 0 0.003907712
glutamate B-Chemical 1 0.9998965
and O 0 0.027263826
aspartate B-Chemical 1 0.99993074
. O 0 0.010003493

Therefore O 0 0.0040718406
, O 0 0.004563771
like O 0 0.0042598303
VPA B-Chemical 1 0.9999956
, O 0 0.004069483
the O 0 0.0009585821
finding O 0 0.0013960508
that O 0 0.00071150414
VPU B-Chemical 0 0.9985663
could O 0 0.00041265826
drastically O 0 0.001639183
reduce O 0 0.0007237066
pilocarpine B-Chemical 1 0.99999976
- O 0 0.15749659
induced O 0 0.00038130514
increases O 0 0.0004140636
in O 0 0.0012715934
glutamate B-Chemical 1 0.9999739
and O 0 0.012695084
aspartate B-Chemical 1 0.9999846
should O 0 0.00015574589
account O 0 0.0001732609
, O 0 0.0002127798
at O 0 0.000114908165
least O 0 0.000104697916
partly O 0 0.00020958751
, O 0 0.00027435238
for O 0 0.00020213793
its O 0 0.0025546702
anticonvulsant O 0 0.9991036
activity O 0 0.00030212913
observed O 0 0.00031301094
in O 0 0.0019888966
pilocarpine B-Chemical 1 0.9999994
- O 0 0.18663222
induced O 0 0.0032962144
seizure B-Disease 2 0.99995744
in O 0 0.00157362
experimental O 0 0.0023438602
animals O 0 0.0031175874
. O 0 0.0060307155

Some O 0 0.005278103
other O 0 0.0031546946
mechanism O 0 0.0022258805
than O 0 0.0015591126
those O 0 0.001775192
being O 0 0.0017661193
reported O 0 0.0014822776
herein O 0 0.0016035702
should O 0 0.0012257121
be O 0 0.002032957
further O 0 0.002871078
investigated O 0 0.0045784735
. O 0 0.008889613

Protective O 0 0.49240813
effect O 0 0.004907145
of O 0 0.007820228
verapamil B-Chemical 0 0.99999
on O 0 0.003542616
gastric B-Disease 0 0.9997571
hemorrhagic I-Disease 2 0.99999964
ulcers B-Disease 0 0.99999654
in O 0 0.012263221
severe O 0 0.87202525
atherosclerotic B-Disease 2 0.9998192
rats O 0 0.01642958
. O 0 0.008354404

Studies O 0 0.00639882
concerning O 0 0.0022155407
with O 0 0.0019865541
pathogenesis O 0 0.0038240259
of O 0 0.0044311937
gastric B-Disease 0 0.99957186
hemorrhage I-Disease 2 0.9999995
and O 0 0.007509401
mucosal O 0 0.9272264
ulceration O 0 0.99992955
produced O 0 0.001308751
in O 0 0.001877715
atherosclerotic B-Disease 2 0.99953556
rats O 0 0.002934978
are O 0 0.002081344
lacking O 0 0.0029400603
. O 0 0.006835625

The O 0 0.0031492754
aim O 0 0.0023805979
of O 0 0.001764725
this O 0 0.0012125467
study O 0 0.0010481987
is O 0 0.0006070298
to O 0 0.00037008637
examine O 0 0.00020500024
the O 0 0.00025417746
role O 0 0.00020089762
of O 0 0.0005078747
gastric O 0 0.78920734
acid O 0 0.9759034
back O 0 0.006815445
- O 0 0.029763065
diffusion O 0 0.025829975
, O 0 0.0010491987
mast O 0 0.78572327
cell O 0 0.116184376
histamine B-Chemical 1 0.99996614
release O 0 0.056667954
, O 0 0.0069883284
lipid O 0 0.9957546
peroxide O 0 0.99999774
( O 0 0.33606398
LPO O 0 1.0
) O 0 0.002578421
generation O 0 0.00029117873
and O 0 0.00031422309
mucosal O 0 0.4747372
microvascular O 0 0.97781897
permeability O 0 0.8496629
in O 0 0.00028409186
modulating O 0 0.00032797366
gastric B-Disease 0 0.99948335
hemorrhage I-Disease 2 0.9999999
and O 0 0.0147246
ulcer B-Disease 2 0.9999697
in O 0 0.0005016202
rats O 0 0.0006870316
with O 0 0.00075805467
atherosclerosis B-Disease 2 0.99997973
induced O 0 0.0006701416
by O 0 0.0008282361
coadministration O 0 0.9817493
of O 0 0.05211885
vitamin B-Chemical 0 0.99999964
D2 I-Chemical 0 0.99998593
and O 0 0.022171684
cholesterol B-Chemical 0 0.99966383
. O 0 0.008939193

Additionally O 0 0.0053004543
, O 0 0.0040203216
the O 0 0.0023287514
protective O 0 0.0051717283
effect O 0 0.0019800514
of O 0 0.0049240203
verapamil B-Chemical 0 0.9999913
on O 0 0.0012128835
this O 0 0.0018958441
ulcer B-Disease 2 0.9995528
model O 0 0.0030697496
was O 0 0.003266915
evaluated O 0 0.0041674175
. O 0 0.007815908

Male O 0 0.034172166
Wistar O 0 0.01731686
rats O 0 0.002746761
were O 0 0.0012778473
challenged O 0 0.0009456393
intragastrically O 0 0.012047768
once O 0 0.00044065708
daily O 0 0.00038681863
for O 0 0.00026290398
9 O 0 0.00022511628
days O 0 0.00015735942
with O 0 0.00021617561
1 O 0 0.00021535948
. O 0 0.000191357
0 O 0 0.00023505425
ml O 0 0.00039442745
/ O 0 0.00086957123
kg O 0 0.00078592426
of O 0 0.00067765714
corn O 0 0.97959626
oil O 0 0.99236065
containing O 0 0.003034755
vitamin B-Chemical 0 0.99999976
D2 I-Chemical 0 0.99998844
and O 0 0.0047198744
cholesterol B-Chemical 0 0.99952996
to O 0 0.0017366327
induce O 0 0.0028426596
atherosclerosis B-Disease 2 0.99993694
. O 0 0.010018233

Control O 0 0.022550365
rats O 0 0.017860636
received O 0 0.015148588
corn O 0 0.96434903
oil O 0 0.983422
only O 0 0.021503942
. O 0 0.025244655

After O 0 0.00352774
gastric O 0 0.061632693
surgery O 0 0.0038197066
, O 0 0.0022170574
rat O 0 0.0025220104
stomachs O 0 0.007790899
were O 0 0.00076304644
irrigated O 0 0.009483271
for O 0 0.0004758663
3 O 0 0.00038881632
h O 0 0.00041662098
with O 0 0.00041743374
either O 0 0.00046412562
simulated O 0 0.0006755099
gastric O 0 0.7368438
juice O 0 0.9958339
or O 0 0.0019699587
normal O 0 0.0052281152
saline O 0 0.049199533
. O 0 0.0066766837

Gastric O 0 0.140902
acid O 0 0.80355525
back O 0 0.0059367
- O 0 0.015470037
diffusion O 0 0.019770881
, O 0 0.0027495488
mucosal O 0 0.96560395
LPO O 0 0.9999999
generation O 0 0.013719169
, O 0 0.0148801
histamine B-Chemical 1 0.9999045
concentration O 0 0.01103089
, O 0 0.0019998613
microvascular O 0 0.95527804
permeability O 0 0.918645
, O 0 0.0021504918
luminal B-Chemical 0 0.6938858
hemoglobin O 0 0.98241514
content O 0 0.00085484027
and O 0 0.001349154
ulcer B-Disease 2 0.9996037
areas O 0 0.0053945184
were O 0 0.0021845242
determined O 0 0.0030901476
. O 0 0.006504994

Elevated O 0 0.42825693
atherosclerotic B-Disease 2 0.99796766
parameters O 0 0.0031593507
, O 0 0.0016395265
such O 0 0.0007795414
as O 0 0.0007810352
serum O 0 0.58421844
calcium B-Chemical 0 0.99920887
, O 0 0.0013890933
total O 0 0.0004968894
cholesterol B-Chemical 0 0.99977773
and O 0 0.0007827139
low O 0 0.0011293837
- O 0 0.010286641
density O 0 0.0018309244
lipoprotein O 0 0.99602544
concentration O 0 0.0012822669
were O 0 0.00069541327
obtained O 0 0.00092161633
in O 0 0.0018789101
atherosclerotic B-Disease 2 0.998703
rats O 0 0.007170314
. O 0 0.006492168

Severe O 0 0.82191974
gastric O 0 0.9171037
ulcers B-Disease 0 0.99994826
accompanied O 0 0.008558508
with O 0 0.0018126994
increased O 0 0.0024715438
ulcerogenic O 0 0.99954957
factors O 0 0.022945631
, O 0 0.0011064622
including O 0 0.0005200747
gastric O 0 0.8118698
acid O 0 0.9749963
back O 0 0.0068225777
- O 0 0.035299785
diffusion O 0 0.045483653
, O 0 0.004655764
histamine B-Chemical 1 0.9999037
release O 0 0.063761435
, O 0 0.030822776
LPO O 0 0.99999976
generation O 0 0.0007730092
and O 0 0.0006325377
luminal B-Chemical 0 0.6845106
hemoglobin O 0 0.9812744
content O 0 0.000476366
were O 0 0.00041184376
also O 0 0.00048583682
observed O 0 0.0007130294
in O 0 0.0012460473
these O 0 0.002325791
rats O 0 0.00470568
. O 0 0.006219995

Moreover O 0 0.0049802517
, O 0 0.0034628687
a O 0 0.0020863456
positive O 0 0.0014903098
correlation O 0 0.0009732252
of O 0 0.0021027185
histamine B-Chemical 1 0.9998692
to O 0 0.0018659427
gastric B-Disease 0 0.99956137
hemorrhage I-Disease 2 0.99999964
and O 0 0.0016316172
to O 0 0.0006959746
ulcer B-Disease 2 0.9998097
was O 0 0.0008449418
found O 0 0.00072879106
in O 0 0.0011241726
those O 0 0.0031866597
atherosclerotic B-Disease 2 0.9990608
rats O 0 0.007950801
. O 0 0.0067126392

This O 0 0.015739614
hemorrhagic B-Disease 2 0.99989164
ulcer B-Disease 0 0.9999101
and O 0 0.0044846702
various O 0 0.0030360492
ulcerogenic O 0 0.9987452
parameters O 0 0.0015715506
were O 0 0.00076373684
dose O 0 0.021128979
- O 0 0.11119291
dependently O 0 0.90838444
ameliorated O 0 0.12725838
by O 0 0.0016903806
daily O 0 0.007587553
intragastric O 0 0.98967034
verapamil B-Chemical 0 0.99998057
. O 0 0.009525995

Atherosclerosis B-Disease 0 0.9890442
could O 0 0.003044358
produce O 0 0.0024337242
gastric B-Disease 0 0.9980812
hemorrhagic I-Disease 2 0.99999917
ulcer B-Disease 0 0.9999889
via O 0 0.0011663634
aggravation O 0 0.89825284
of O 0 0.0027591148
gastric O 0 0.92721075
acid O 0 0.9859358
back O 0 0.0095260115
- O 0 0.04366066
diffusion O 0 0.067861445
, O 0 0.017205527
LPO O 0 0.9999999
generation O 0 0.003081891
, O 0 0.007455053
histamine B-Chemical 1 0.9998696
release O 0 0.012241771
and O 0 0.0008510513
microvascular O 0 0.94272083
permeability O 0 0.7533975
that O 0 0.00032010197
could O 0 0.000343558
be O 0 0.0005550108
ameliorated O 0 0.03594117
by O 0 0.0022027693
verapamil B-Chemical 0 0.99998164
in O 0 0.003088968
rats O 0 0.0057492517
. O 0 0.0061652833

Lamivudine B-Chemical 1 0.9998944
for O 0 0.0033485387
the O 0 0.0020845574
prevention O 0 0.015052579
of O 0 0.07343606
hepatitis B-Disease 2 1.0
B I-Disease 2 0.9999895
virus O 0 0.99353105
reactivation O 0 0.9907907
in O 0 0.049808867
hepatitis B-Chemical 2 1.0
- I-Chemical 0 0.9573507
B I-Chemical 0 0.9824979
surface I-Chemical 0 0.03959907
antigen I-Chemical 0 0.5203934
( O 0 0.028273081
HBSAG B-Chemical 0 0.99989045
) O 0 0.016689187
seropositive O 0 0.865911
cancer B-Disease 0 0.99636227
patients O 0 0.0035913375
undergoing O 0 0.0024237714
cytotoxic O 0 0.34672004
chemotherapy O 0 0.2797461
. O 0 0.00751943

Hepatitis B-Disease 0 0.99999833
B I-Disease 0 0.9995802
virus O 0 0.95955926
( O 0 0.18587355
HBV O 0 0.99996746
) O 0 0.020191822
is O 0 0.0010934763
one O 0 0.0006370479
of O 0 0.0006460385
the O 0 0.00057914644
major O 0 0.00075787667
causes O 0 0.0011183311
of O 0 0.0030640315
chronic O 0 0.99888414
liver B-Disease 2 0.99987125
disease I-Disease 2 0.9999517
worldwide O 0 0.83336276
. O 0 0.010920644

Cancer B-Disease 0 0.67110014
patients O 0 0.0044308635
who O 0 0.0029322305
are O 0 0.0015580606
chronic O 0 0.6233584
carriers O 0 0.07822219
of O 0 0.0049140486
HBV O 0 0.9999635
have O 0 0.0006935072
a O 0 0.0008472311
higher O 0 0.00066170184
hepatic B-Disease 0 0.9971468
complication I-Disease 0 0.9498202
rate O 0 0.00039453537
while O 0 0.00030010322
receiving O 0 0.00045715465
cytotoxic O 0 0.19977099
chemotherapy O 0 0.16349913
( O 0 0.0018558538
CT O 0 0.4060569
) O 0 0.00080463133
and O 0 0.00035403567
this O 0 0.00032058943
has O 0 0.0003627204
mainly O 0 0.00056936196
been O 0 0.0007027723
attributed O 0 0.00092859316
to O 0 0.0019189962
HBV O 0 0.99987125
reactivation O 0 0.9625192
. O 0 0.012569671

In O 0 0.00387485
this O 0 0.0026206544
study O 0 0.0026990434
, O 0 0.0036456732
cancer B-Disease 0 0.99137986
patients O 0 0.0027772393
who O 0 0.0011149346
have O 0 0.00041725507
solid O 0 0.023759736
and O 0 0.0035921822
hematological B-Disease 0 0.99986327
malignancies I-Disease 2 0.9999888
with O 0 0.019789062
chronic O 0 0.99900514
HBV B-Disease 0 0.9999999
infection I-Disease 2 0.9999821
received O 0 0.00076329045
the O 0 0.0004275915
antiviral O 0 0.70256364
agent O 0 0.7663895
lamivudine B-Chemical 1 0.9999993
prior O 0 0.00023304141
and O 0 0.00028119262
during O 0 0.00016703985
CT O 0 0.031870067
compared O 0 0.00015652976
with O 0 0.0002459663
historical O 0 0.0009527009
control O 0 0.00038587337
group O 0 0.0006455588
who O 0 0.0009807275
did O 0 0.0009016942
not O 0 0.0012371672
receive O 0 0.002291362
lamivudine B-Chemical 1 0.99996924
. O 0 0.010605831

The O 0 0.0031440805
objectives O 0 0.0025476166
were O 0 0.0014441615
to O 0 0.0008731704
assess O 0 0.00046714986
the O 0 0.00052820775
efficacy O 0 0.0007974249
of O 0 0.0017680932
lamivudine B-Chemical 1 0.9999981
in O 0 0.00071408687
reducing O 0 0.00049060804
the O 0 0.0003324787
incidence O 0 0.00402554
of O 0 0.0023853367
HBV O 0 0.9999902
reactivation O 0 0.9552263
, O 0 0.0025315904
and O 0 0.0008557213
diminishing O 0 0.0031303065
morbidity O 0 0.6651834
and O 0 0.0017921779
mortality O 0 0.34343293
during O 0 0.0028674502
CT O 0 0.32766122
. O 0 0.007566739

Two O 0 0.009365446
groups O 0 0.0073932232
were O 0 0.006540191
compared O 0 0.0053956565
in O 0 0.007453253
this O 0 0.009409611
study O 0 0.014126862
. O 0 0.017920526

The O 0 0.004199916
prophylactic O 0 0.009349501
lamivudin B-Chemical 0 0.9737675
group O 0 0.002205897
consisted O 0 0.0010710424
of O 0 0.001229507
37 O 0 0.0015022719
patients O 0 0.0013563848
who O 0 0.001570339
received O 0 0.0013832083
prophylactic O 0 0.045683842
lamivudine B-Chemical 1 0.9999896
treatment O 0 0.034975626
. O 0 0.009625394

The O 0 0.003694906
historical O 0 0.0043792026
controls O 0 0.0022623958
consisted O 0 0.0012510051
of O 0 0.0012828043
50 O 0 0.0011443697
consecutive O 0 0.000857613
patients O 0 0.001122637
who O 0 0.0012975155
underwent O 0 0.0013219265
CT O 0 0.038131308
without O 0 0.0023758363
prophylactic O 0 0.11316204
lamivudine B-Chemical 1 0.9999832
. O 0 0.014634676

They O 0 0.0066938405
were O 0 0.003643424
followed O 0 0.0025005247
up O 0 0.0023026331
during O 0 0.0017702372
and O 0 0.0022713146
for O 0 0.002266262
8 O 0 0.0026160383
weeks O 0 0.0027191704
after O 0 0.0042507485
CT O 0 0.05841168
. O 0 0.01207685

The O 0 0.007207744
outcomes O 0 0.0074377125
were O 0 0.0056957635
compared O 0 0.00452625
for O 0 0.00601268
both O 0 0.007934676
groups O 0 0.011297018
. O 0 0.016435282

Of O 0 0.004766748
our O 0 0.002637362
control O 0 0.0018681269
group O 0 0.0016732877
( O 0 0.0014170104
n O 0 0.000870878
= O 0 0.00129641
50 O 0 0.0008549926
) O 0 0.0010056488
, O 0 0.0007678446
21 O 0 0.000645132
patients O 0 0.00072659686
( O 0 0.0008919546
42 O 0 0.0010045895
% O 0 0.0012410453
) O 0 0.0019784742
were O 0 0.0022264905
established O 0 0.0061225174
hepatitis B-Disease 2 0.9999981
. O 0 0.049658872

Twelve O 0 0.009377779
( O 0 0.0054782354
24 O 0 0.0033230186
% O 0 0.0030862454
) O 0 0.0030720064
of O 0 0.0023380928
them O 0 0.002589619
were O 0 0.0021638616
evaluated O 0 0.0023240335
as O 0 0.0039466065
severe O 0 0.7615151
hepatitis B-Disease 2 0.99999905
. O 0 0.12881798

In O 0 0.0037257525
the O 0 0.0026321083
prophylactic O 0 0.06702825
lamivudine B-Chemical 1 0.9999968
group O 0 0.06309866
severe O 0 0.9406632
hepatitis B-Disease 2 1.0
were O 0 0.0029033439
observed O 0 0.00035050645
only O 0 0.00032250935
in O 0 0.00023918282
1 O 0 0.00021595578
patient O 0 0.00022619721
( O 0 0.00032734516
2 O 0 0.00020325734
. O 0 0.00018619752
7 O 0 0.00018945619
% O 0 0.00028118512
) O 0 0.0003860592
of O 0 0.00034452358
37 O 0 0.0005365067
patients O 0 0.00053000817
( O 0 0.00063701876
p O 0 0.00062895066
< O 0 0.00081107765
0 O 0 0.001358747
. O 0 0.0019731168
006 O 0 0.016971128
) O 0 0.0065219523
. O 0 0.00837334

Comparison O 0 0.0030449107
of O 0 0.0022785086
the O 0 0.0014345591
mean O 0 0.0009856095
ALT O 0 0.99880433
values O 0 0.00064540684
revealed O 0 0.00044545575
significantly O 0 0.00036364482
higher O 0 0.00026750242
mean O 0 0.00021269053
alanine B-Chemical 1 0.99943036
aminotransferase O 0 0.99997115
( O 0 0.06477054
ALT O 0 0.9999778
) O 0 0.0011212197
values O 0 0.00017835274
in O 0 0.00015395838
the O 0 0.00014503031
control O 0 0.00016183918
group O 0 0.00020249595
than O 0 0.00011343279
the O 0 0.00017557875
prophylactic O 0 0.020881498
lamivudine B-Chemical 1 0.99999845
group O 0 0.003311733
; O 0 0.0010710974
154 O 0 0.0018596107
: O 0 0.00049800915
64 O 0 0.00047398917
( O 0 0.00052452285
p O 0 0.00054561615
< O 0 0.0007161651
0 O 0 0.0011730364
. O 0 0.0016011746
32 O 0 0.0032273033
) O 0 0.005635577
. O 0 0.00791063

Our O 0 0.0039179637
study O 0 0.0026055537
suggests O 0 0.0012502678
that O 0 0.0011620838
prophylactic O 0 0.108901404
lamivudine B-Chemical 1 0.99999845
significantly O 0 0.002759565
decreases O 0 0.0005931759
the O 0 0.0003873225
incidence O 0 0.0042654728
of O 0 0.002274467
HBV O 0 0.9999889
reactivation O 0 0.9138801
and O 0 0.0012251612
overall O 0 0.000787075
morbidity O 0 0.7452319
in O 0 0.00067667296
cancer B-Disease 0 0.99307126
patients O 0 0.0010594947
during O 0 0.00045977198
and O 0 0.0008670238
after O 0 0.0010296254
immunosuppressive O 0 0.5392131
therapy O 0 0.009137402
. O 0 0.0066469787

Further O 0 0.00369512
studies O 0 0.002309872
are O 0 0.0014315043
needed O 0 0.0008137647
to O 0 0.00062694657
determine O 0 0.00032070742
the O 0 0.00041287462
most O 0 0.00047929466
appropriate O 0 0.00034972903
nucleoside B-Chemical 0 0.87299436
or O 0 0.0005080865
nucleotide B-Chemical 0 0.5022421
analogue O 0 0.010053594
for O 0 0.00026024575
antiviral O 0 0.11248853
prophylaxis O 0 0.011734671
during O 0 0.00020810241
CT O 0 0.121560596
and O 0 0.00026565042
the O 0 0.00020029476
optimal O 0 0.00018209606
duration O 0 0.00027011888
of O 0 0.0005300115
administration O 0 0.001609859
after O 0 0.00067814835
completion O 0 0.0012707737
of O 0 0.0030970252
CT O 0 0.28932956
. O 0 0.0073658186

Recovery O 0 0.010407656
of O 0 0.007651839
tacrolimus B-Chemical 0 0.99999297
- O 0 0.34069878
associated O 0 0.006463374
brachial B-Disease 0 0.99966717
neuritis I-Disease 0 0.9999981
after O 0 0.00040988403
conversion O 0 0.0012624934
to O 0 0.0003218677
everolimus B-Chemical 0 0.9941407
in O 0 0.00027819056
a O 0 0.00031833534
pediatric O 0 0.0005294302
renal O 0 0.5465923
transplant O 0 0.101757385
recipient O 0 0.003519712
- O 0 0.034790546
- O 0 0.004561424
case O 0 0.000509816
report O 0 0.0008966001
and O 0 0.00078166026
review O 0 0.0013285668
of O 0 0.0015307437
the O 0 0.0022088268
literature O 0 0.00502565
. O 0 0.0069111194

TAC B-Chemical 1 0.9982559
has O 0 0.0034635356
been O 0 0.0021455223
shown O 0 0.0011745164
to O 0 0.0009283468
be O 0 0.00090483035
a O 0 0.0010029098
potent O 0 0.0025352114
immunosuppressive O 0 0.6589395
agent O 0 0.05447118
for O 0 0.0010054935
solid O 0 0.032694392
organ O 0 0.026117615
transplantation O 0 0.04121135
in O 0 0.003009432
pediatrics O 0 0.010249255
. O 0 0.007316192

Neurotoxicity B-Disease 0 0.99917895
is O 0 0.010042579
a O 0 0.009185609
potentially O 0 0.010767852
serious O 0 0.32927826
toxic O 0 0.90429866
effect O 0 0.015182858
. O 0 0.018724846

It O 0 0.0058628647
is O 0 0.0035978823
characterized O 0 0.0034618883
by O 0 0.004875522
encephalopathy B-Disease 2 0.9999937
, O 0 0.2904261
headaches B-Disease 0 0.99999535
, O 0 0.15354957
seizures B-Disease 0 0.9999982
, O 0 0.01065146
or O 0 0.005399489
neurological B-Disease 0 0.9996468
deficits I-Disease 0 0.9958683
. O 0 0.009431798

Here O 0 0.0055945474
, O 0 0.0033921248
we O 0 0.001531948
describe O 0 0.0012411948
an O 0 0.0012247115
eight O 0 0.00083359354
- O 0 0.0038450817
and O 0 0.0009783347
- O 0 0.009161052
a O 0 0.0008836261
- O 0 0.0040891864
half O 0 0.00036578483
- O 0 0.0022330617
yr O 0 0.0006957826
- O 0 0.0015329301
old O 0 0.0006107428
male O 0 0.0019307231
renal O 0 0.50833446
transplant O 0 0.057592507
recipient O 0 0.0022704105
with O 0 0.0024788408
right O 0 0.014051889
BN O 0 0.9581438
. O 0 0.00800383

MRI O 0 0.26279083
demonstrated O 0 0.0028522315
hyperintense O 0 0.30936646
T2 O 0 0.0057281116
signals O 0 0.0009857988
in O 0 0.0007168708
the O 0 0.0006410442
cervical O 0 0.10549197
cord O 0 0.043917406
and O 0 0.0004980621
right O 0 0.0011589284
brachial O 0 0.56097996
plexus O 0 0.030582447
roots O 0 0.00088560185
indicative O 0 0.00032885344
of O 0 0.0005391935
both O 0 0.0011282352
myelitis B-Disease 0 0.99999416
and O 0 0.0031016173
right O 0 0.039017264
brachial B-Disease 0 0.99777824
plexitis I-Disease 0 0.99405104
. O 0 0.007139567

Symptoms O 0 0.02009921
persisted O 0 0.0021476948
for O 0 0.0012900248
three O 0 0.0007074622
months O 0 0.00061741105
despite O 0 0.00075634633
TAC B-Chemical 1 0.99927264
dose O 0 0.021610018
reduction O 0 0.002708705
, O 0 0.0010363538
administration O 0 0.00826791
of O 0 0.0013099012
IVIG O 0 0.9967513
and O 0 0.00061719236
four O 0 0.00042874555
doses O 0 0.002345248
of O 0 0.0024615265
methylprednisolone B-Chemical 0 0.99990153
pulse O 0 0.017545719
therapy O 0 0.008338893
. O 0 0.006743003

Improvement O 0 0.006337919
and O 0 0.0028146931
eventually O 0 0.002421654
full O 0 0.0012151981
recovery O 0 0.0013499138
only O 0 0.00085850863
occurred O 0 0.0007015199
after O 0 0.000578453
TAC B-Chemical 1 0.9990451
was O 0 0.0006774905
completely O 0 0.00057397917
discontinued O 0 0.0017061091
and O 0 0.0007822187
successfully O 0 0.0010857955
replaced O 0 0.0015561508
by O 0 0.003198636
everolimus B-Chemical 0 0.9966355
. O 0 0.008142054

Omitting O 0 0.089546494
fentanyl B-Chemical 1 0.9998394
reduces O 0 0.008318784
nausea B-Disease 2 0.9999958
and O 0 0.024453335
vomiting B-Disease 0 0.9999567
, O 0 0.0017963869
without O 0 0.0007473176
increasing O 0 0.0012915307
pain B-Disease 0 0.96204776
, O 0 0.0012972765
after O 0 0.0008938841
sevoflurane B-Chemical 1 0.9979668
for O 0 0.0016753911
day O 0 0.0023533243
surgery O 0 0.0051627397
. O 0 0.006627267

BACKGROUND O 0 0.011002851
AND O 0 0.00305643
OBJECTIVE O 0 0.0065402533
: O 0 0.0019709754
Despite O 0 0.0010418792
advantages O 0 0.0005960839
of O 0 0.00070020545
induction O 0 0.0006084803
and O 0 0.00061552087
maintenance O 0 0.0006430276
of O 0 0.00066647015
anaesthesia O 0 0.027491298
with O 0 0.0009236737
sevoflurane B-Chemical 1 0.99982065
, O 0 0.0018547924
postoperative B-Disease 0 0.13064899
nausea I-Disease 2 0.99999344
and I-Disease 0 0.005610063
vomiting I-Disease 0 0.99979
occurs O 0 0.003149205
frequently O 0 0.0058808285
. O 0 0.0065881046

Fentanyl B-Chemical 0 0.99991024
is O 0 0.003813773
a O 0 0.0024550837
commonly O 0 0.001715854
used O 0 0.00089743506
supplement O 0 0.001538928
that O 0 0.0005007531
may O 0 0.00044200587
contribute O 0 0.00037469025
to O 0 0.00040398707
this O 0 0.00049414515
, O 0 0.0007401451
although O 0 0.00063968415
it O 0 0.0008504831
may O 0 0.0009528605
also O 0 0.0014918268
improve O 0 0.002425357
analgesia O 0 0.8174132
. O 0 0.0069711986

METHODS O 0 0.0039316784
: O 0 0.0036322384
This O 0 0.0026336997
double O 0 0.0020468284
- O 0 0.007071214
blind O 0 0.006998969
study O 0 0.0007971753
examined O 0 0.0003816003
the O 0 0.00038339815
incidence O 0 0.0009214525
and O 0 0.0003863727
severity O 0 0.0013629352
of O 0 0.00048018256
postoperative B-Disease 0 0.105332695
nausea I-Disease 2 0.9999976
and I-Disease 0 0.0041611786
vomiting I-Disease 0 0.99994576
and O 0 0.0013054971
pain B-Disease 0 0.8964692
in O 0 0.00017908959
the O 0 0.0001602685
first O 0 0.00014725263
24 O 0 0.00019365139
h O 0 0.00023183669
after O 0 0.00024402961
sevoflurane B-Chemical 1 0.9991571
anaesthesia O 0 0.011866957
in O 0 0.00048919686
216 O 0 0.0015891804
adult O 0 0.001011404
day O 0 0.0011490142
surgery O 0 0.0025870588
patients O 0 0.004078227
. O 0 0.0060303635

Patients O 0 0.0047085714
were O 0 0.0022917478
randomly O 0 0.0011195515
allocated O 0 0.0008691984
to O 0 0.00068141456
either O 0 0.0005680426
receive O 0 0.0003906618
or O 0 0.00036617983
not O 0 0.00030136417
receive O 0 0.0002437538
1 O 0 0.000318897
1 O 0 0.00041294354
fentanyl B-Chemical 1 0.9994491
, O 0 0.00047156212
while O 0 0.00030658956
a O 0 0.0003530592
third O 0 0.0003707625
group O 0 0.00047672124
received O 0 0.0004823235
dexamethasone B-Chemical 0 0.9956275
in O 0 0.00089250196
addition O 0 0.0010272332
to O 0 0.0028998798
fentanyl B-Chemical 1 0.9997557
. O 0 0.0069827647

RESULTS O 0 0.0058707013
: O 0 0.004329339
Omission O 0 0.010898903
of O 0 0.0042342446
fentanyl B-Chemical 1 0.9999255
did O 0 0.0012857316
not O 0 0.00050562155
reduce O 0 0.0003140473
the O 0 0.00030402432
overall O 0 0.00030334192
incidence O 0 0.0008520964
of O 0 0.0005297526
postoperative B-Disease 0 0.1644545
nausea I-Disease 2 0.99999857
and I-Disease 0 0.011697651
vomiting I-Disease 0 0.9999801
, O 0 0.001972529
but O 0 0.00041150194
did O 0 0.00019779266
reduce O 0 0.000108661545
the O 0 0.00015406634
incidence O 0 0.0016399089
of O 0 0.0014293989
vomiting B-Disease 0 0.9999367
and O 0 0.00078316405
/ O 0 0.0087787025
or O 0 0.0002451352
moderate O 0 0.008448934
to O 0 0.00023227275
severe O 0 0.5567938
nausea B-Disease 2 0.9999949
prior O 0 0.00012114952
to O 0 0.00012340717
discharge O 0 0.00030678953
from O 0 0.00010840241
20 O 0 0.00012798414
% O 0 0.00015798486
and O 0 0.00016068458
17 O 0 0.00018973298
% O 0 0.00019618154
with O 0 0.0003527773
fentanyl B-Chemical 1 0.99989796
and O 0 0.0038396572
fentanyl B-Chemical 1 0.99999297
- O 0 0.43623498
dexamethasone B-Chemical 0 0.99983406
, O 0 0.0015368132
respectively O 0 0.0030346524
, O 0 0.00036475156
to O 0 0.00021918798
5 O 0 0.00025719078
% O 0 0.0004464398
( O 0 0.00078717264
P O 0 0.01917654
= O 0 0.0014750782
0 O 0 0.0013913282
. O 0 0.0019019969
013 O 0 0.012228736
) O 0 0.0061694854
. O 0 0.00816033

Antiemetic O 0 0.3090726
requirements O 0 0.0022848286
were O 0 0.0016728361
reduced O 0 0.0011703762
from O 0 0.00085576926
24 O 0 0.00076425954
% O 0 0.00069170794
and O 0 0.00056999124
31 O 0 0.00059827033
% O 0 0.00051583035
to O 0 0.00040267926
7 O 0 0.0004568022
% O 0 0.0007069652
( O 0 0.0011195387
P O 0 0.01938927
= O 0 0.0019785415
0 O 0 0.0018350852
. O 0 0.002413371
0012 O 0 0.01212672
) O 0 0.007071006
. O 0 0.009225997

Dexamethasone B-Chemical 0 0.9995328
had O 0 0.0031976863
no O 0 0.0016242038
significant O 0 0.0013545718
effect O 0 0.000961965
on O 0 0.00062246236
the O 0 0.00071287283
incidence O 0 0.0018995056
or O 0 0.000785438
severity O 0 0.0038413298
of O 0 0.0018511657
postoperative B-Disease 0 0.27489778
nausea I-Disease 2 0.9999918
and I-Disease 0 0.022121904
vomiting I-Disease 0 0.9998292
. O 0 0.009230409

Combining O 0 0.003650351
the O 0 0.0022609334
two O 0 0.0017916927
fentanyl B-Chemical 1 0.99946743
groups O 0 0.0009618963
revealed O 0 0.0005014426
further O 0 0.0003834502
significant O 0 0.0003351635
benefits O 0 0.0002664715
from O 0 0.0002086126
the O 0 0.00022720946
avoidance O 0 0.0016212945
of O 0 0.00053833984
opioids O 0 0.94872814
, O 0 0.00039271693
reducing O 0 0.0003761268
postoperative B-Disease 0 0.08682923
nausea I-Disease 2 0.9999975
and I-Disease 0 0.004447691
vomiting I-Disease 0 0.999966
and O 0 0.0072560217
nausea B-Disease 2 0.9999949
prior O 0 0.00013065526
to O 0 0.00013165122
discharge O 0 0.00031737925
from O 0 0.0001166255
35 O 0 0.00015004628
% O 0 0.00017590701
and O 0 0.00017481598
33 O 0 0.00022529409
% O 0 0.0001840083
to O 0 0.00013788874
22 O 0 0.00019470208
% O 0 0.00019088303
and O 0 0.00019303159
19 O 0 0.0002674563
% O 0 0.00026850615
( O 0 0.0004471666
P O 0 0.04041262
= O 0 0.0005602311
0 O 0 0.00027790692
. O 0 0.00023087273
049 O 0 0.060773674
and O 0 0.00035803756
P O 0 0.07380914
= O 0 0.0006687998
0 O 0 0.000296561
. O 0 0.00023429528
035 O 0 0.014990466
) O 0 0.0005525948
, O 0 0.00038415453
respectively O 0 0.0016907395
, O 0 0.0005271904
while O 0 0.0009080449
nausea B-Disease 2 0.99999106
in O 0 0.00020704872
the O 0 0.00016478174
first O 0 0.0001388723
24 O 0 0.0001747983
h O 0 0.00018401671
was O 0 0.00017438197
decreased O 0 0.00020369675
from O 0 0.00017479698
42 O 0 0.00027442537
% O 0 0.00026518074
to O 0 0.00023296053
27 O 0 0.00042885388
% O 0 0.0005108183
( O 0 0.0008769095
P O 0 0.022164408
= O 0 0.001644941
0 O 0 0.0015556256
. O 0 0.0021621657
034 O 0 0.069050096
) O 0 0.0064196754
. O 0 0.008295454

Pain B-Disease 0 0.8361654
severity O 0 0.008710434
and O 0 0.0033580842
analgesic O 0 0.20085615
requirements O 0 0.0013898178
were O 0 0.0013280597
unaffected O 0 0.0014223697
by O 0 0.0016439415
the O 0 0.0019496229
omission O 0 0.0061142244
of O 0 0.008439432
fentanyl B-Chemical 1 0.99985576
. O 0 0.010533071

Fentanyl B-Chemical 0 0.9998833
did O 0 0.0034318115
reduce O 0 0.0014068888
minor O 0 0.0022358203
intraoperative O 0 0.0022531569
movement O 0 0.0015884193
but O 0 0.0007246907
had O 0 0.00046149522
no O 0 0.0004973294
sevoflurane B-Chemical 1 0.9999515
- O 0 0.059032064
sparing O 0 0.010567751
effect O 0 0.00038219558
and O 0 0.0005506352
increased O 0 0.0011312908
respiratory B-Disease 0 0.745221
depression I-Disease 0 0.9999311
, O 0 0.044015773
hypotension B-Disease 2 0.9999852
and O 0 0.015277324
bradycardia B-Disease 0 0.9991411
. O 0 0.0073932232

CONCLUSION O 0 0.027702926
: O 0 0.0044340217
As O 0 0.00220611
fentanyl B-Chemical 1 0.9994186
exacerbated O 0 0.023951218
postoperative B-Disease 0 0.401109
nausea I-Disease 2 0.9999982
and I-Disease 0 0.008674263
vomiting I-Disease 0 0.99990237
without O 0 0.00040474936
an O 0 0.00035866429
improvement O 0 0.0002976402
in O 0 0.00027734315
postoperative B-Disease 0 0.3518266
pain I-Disease 0 0.99606776
and O 0 0.00026330512
also O 0 0.00018242102
had O 0 0.00021896866
adverse O 0 0.2086087
cardiorespiratory O 0 0.1924369
effects O 0 0.0005957255
, O 0 0.00046135267
it O 0 0.00023519369
appears O 0 0.00015990216
to O 0 0.00014654944
be O 0 0.00018622843
an O 0 0.00023523672
unnecessary O 0 0.00034400373
and O 0 0.0003100389
possibly O 0 0.0006178195
detrimental O 0 0.00083865196
supplement O 0 0.004519582
to O 0 0.0008609055
sevoflurane B-Chemical 1 0.9990132
in O 0 0.0013390245
day O 0 0.0018695688
surgery O 0 0.004323212
. O 0 0.0056914226

Valvular B-Disease 0 0.5119904
heart I-Disease 0 0.5642543
disease I-Disease 0 0.94434446
in O 0 0.0022520947
patients O 0 0.0024202885
with O 0 0.0025604933
Parkinson B-Disease 0 0.99946576
' I-Disease 0 0.0023546796
s I-Disease 0 0.0022347441
disease I-Disease 0 0.71091056
treated O 0 0.004185266
with O 0 0.013126502
pergolide B-Chemical 0 0.9999702
. O 0 0.009521783

Course O 0 0.030158889
following O 0 0.019504635
treatment O 0 0.025274845
modifications O 0 0.03716619
. O 0 0.03891899

Valvular B-Disease 0 0.43093848
heart I-Disease 0 0.33618647
abnormalities I-Disease 0 0.16845676
have O 0 0.0012312001
been O 0 0.0009774418
reported O 0 0.0008112156
in O 0 0.0005937449
patients O 0 0.00079456187
with O 0 0.0010183923
Parkinson B-Disease 0 0.9995222
' I-Disease 0 0.0011510421
s I-Disease 0 0.0011872584
disease I-Disease 0 0.926232
( O 0 0.017513242
PD B-Disease 0 0.999843
) O 0 0.0030107913
treated O 0 0.0025762683
with O 0 0.008078421
pergolide B-Chemical 0 0.9999654
. O 0 0.008120544

However O 0 0.004645687
, O 0 0.0032974018
the O 0 0.0017272448
incidence O 0 0.003038641
and O 0 0.0012248469
severity O 0 0.0028670277
of O 0 0.00066684623
these O 0 0.0005742983
abnormalities O 0 0.019116478
vary O 0 0.00029500155
from O 0 0.00021749754
study O 0 0.00027157532
to O 0 0.00018351068
study O 0 0.0002586266
and O 0 0.000229071
their O 0 0.00022578634
course O 0 0.0002467193
after O 0 0.0002442123
drug O 0 0.2123426
withdrawal O 0 0.11761496
has O 0 0.0005644955
not O 0 0.00073446427
been O 0 0.0011621133
systematically O 0 0.0016272105
assessed O 0 0.0030000655
. O 0 0.006205696

OBJECTIVES O 0 0.004781728
: O 0 0.0029500462
To O 0 0.001261882
estimate O 0 0.0008520806
the O 0 0.0007659617
frequency O 0 0.0007434676
and O 0 0.0006515656
severity O 0 0.0025189393
of O 0 0.0008133213
valvular B-Disease 0 0.9224861
heart I-Disease 0 0.66444933
abnormality I-Disease 0 0.37309733
and O 0 0.00034638846
its O 0 0.00044044983
possible O 0 0.00028677343
reversibility O 0 0.01610418
after O 0 0.00023575047
drug O 0 0.24650513
withdrawal O 0 0.11609566
in O 0 0.00050330535
a O 0 0.00082249567
case O 0 0.0011662402
- O 0 0.0046297708
control O 0 0.0023019998
study O 0 0.0046059764
. O 0 0.0064604133

METHODS O 0 0.00440838
: O 0 0.0040706038
All O 0 0.002503749
PD B-Disease 0 0.99401975
patients O 0 0.0018610195
in O 0 0.00096545636
the O 0 0.00080274465
Amiens O 0 0.006377304
area O 0 0.00086762704
treated O 0 0.00071327743
with O 0 0.0014271254
pergolide B-Chemical 0 0.9999883
were O 0 0.00040207952
invited O 0 0.00041468596
to O 0 0.00031317395
attend O 0 0.00046511902
a O 0 0.00057143386
cardiologic O 0 0.0011379756
assessment O 0 0.0008201884
including O 0 0.0013173228
transthoracic O 0 0.005325174
echocardiography O 0 0.012092032
. O 0 0.0068476447

Thirty O 0 0.027232671
PD B-Disease 0 0.9947037
patients O 0 0.011589859
participated O 0 0.012015849
in O 0 0.009025464
the O 0 0.010678628
study O 0 0.01573858
. O 0 0.019520769

A O 0 0.022098824
second O 0 0.0029911066
echocardiography O 0 0.0050387834
was O 0 0.0013897511
performed O 0 0.00086923153
( O 0 0.0008911501
median O 0 0.00043345045
interval O 0 0.00043907418
: O 0 0.00056220224
13 O 0 0.00038534202
months O 0 0.0002800614
) O 0 0.000547929
after O 0 0.0004212043
pergolide B-Chemical 0 0.9999912
withdrawal O 0 0.21178535
( O 0 0.00092515827
n O 0 0.0007922439
= O 0 0.0016105322
10 O 0 0.0015705894
patients O 0 0.0029832004
) O 0 0.0054502394
. O 0 0.007486181

Controls O 0 0.013499609
were O 0 0.0031754903
age O 0 0.003928542
- O 0 0.0064452984
and O 0 0.0018145094
sex O 0 0.03834472
- O 0 0.0067337668
matched O 0 0.00094219355
non O 0 0.0031430493
- O 0 0.13686849
PD B-Disease 0 0.9994382
patients O 0 0.0013219038
referred O 0 0.0010328647
to O 0 0.0011312395
the O 0 0.0018145561
cardiology O 0 0.0042521837
department O 0 0.0057412437
. O 0 0.007479657

RESULTS O 0 0.005712751
: O 0 0.003566094
Compared O 0 0.0015937771
to O 0 0.0011783589
controls O 0 0.0014937809
, O 0 0.0019878044
aortic B-Disease 0 0.98064685
regurgitation I-Disease 0 0.9998851
( O 0 0.006463113
OR O 0 0.30387604
: O 0 0.00075735967
3 O 0 0.0002629333
. O 0 0.00023418001
1 O 0 0.00023587995
; O 0 0.0003214708
95 O 0 0.00041957028
% O 0 0.00036048776
IC O 0 0.11110468
: O 0 0.0004471323
1 O 0 0.00021968887
. O 0 0.0001952522
1 O 0 0.00022712346
- O 0 0.0008580364
8 O 0 0.00018335557
. O 0 0.00016566209
8 O 0 0.00017086772
) O 0 0.00028681496
and O 0 0.0003503596
mitral B-Disease 2 0.99164057
regurgitation I-Disease 2 0.99975795
( O 0 0.002365444
OR O 0 0.20064452
: O 0 0.00044309633
10 O 0 0.00017603571
. O 0 0.00015624674
7 O 0 0.00015430569
; O 0 0.00025564083
95 O 0 0.0003646401
% O 0 0.0003272163
IC O 0 0.11620084
: O 0 0.00043677652
2 O 0 0.00021780861
. O 0 0.00020837881
1 O 0 0.00025585978
- O 0 0.0009650357
53 O 0 0.0004077628
) O 0 0.0004127558
were O 0 0.00027746163
more O 0 0.00033883014
frequent O 0 0.0008503792
in O 0 0.0005896017
PD B-Disease 0 0.99938476
patients O 0 0.0014418378
( O 0 0.0017884423
tricuspid O 0 0.5678365
: O 0 0.0060781036
NS O 0 0.8663797
) O 0 0.007149779
. O 0 0.007907539

The O 0 0.002927827
number O 0 0.0019954229
of O 0 0.0017107503
affected O 0 0.0012848042
valves O 0 0.007090034
( O 0 0.0010801418
n O 0 0.0005783695
= O 0 0.0008741973
2 O 0 0.00038696415
. O 0 0.00030270606
4 O 0 0.0002798244
+ O 0 0.00081147143
/ O 0 0.006021806
- O 0 0.008796263
0 O 0 0.00032357406
. O 0 0.00020720708
7 O 0 0.00018255571
) O 0 0.00027754682
and O 0 0.00019139699
the O 0 0.00015930634
sum O 0 0.00015089827
of O 0 0.0003174885
regurgitation O 0 0.958457
grades O 0 0.0067024627
( O 0 0.00036736182
n O 0 0.00019087705
= O 0 0.0004252736
2 O 0 0.00017752072
. O 0 0.00016064612
8 O 0 0.0001819978
+ O 0 0.00068721815
/ O 0 0.006839264
- O 0 0.00995827
1 O 0 0.00024625447
. O 0 0.00022686247
09 O 0 0.015269456
) O 0 0.00036424887
were O 0 0.00019558368
higher O 0 0.0001891757
( O 0 0.00029890134
p O 0 0.00024573284
= O 0 0.00043729207
0 O 0 0.00026027948
. O 0 0.00021337689
008 O 0 0.0008510026
and O 0 0.00024237466
p O 0 0.00028381002
= O 0 0.00051116047
0 O 0 0.00036275687
. O 0 0.00035778663
006 O 0 0.012723529
, O 0 0.0006769026
respectively O 0 0.0015665077
) O 0 0.0013642657
in O 0 0.0011855541
the O 0 0.002531169
pergolide B-Chemical 0 0.99996066
group O 0 0.005598063
. O 0 0.006986833

Severity O 0 0.006609898
of O 0 0.0054502
regurgitation O 0 0.93670696
was O 0 0.0029129188
not O 0 0.002137437
correlated O 0 0.002108351
with O 0 0.0046842867
pergolide B-Chemical 0 0.9999777
cumulative O 0 0.012503264
dose O 0 0.04580394
. O 0 0.010666526

A O 0 0.03053977
restrictive O 0 0.0038016865
pattern O 0 0.0018930058
of O 0 0.0025208655
valvular B-Disease 0 0.9964401
regurgitation I-Disease 0 0.99991965
, O 0 0.0018742273
suggestive O 0 0.00070395606
of O 0 0.00038475852
the O 0 0.00025856541
role O 0 0.00020110232
of O 0 0.0030621516
pergolide B-Chemical 0 0.99999845
, O 0 0.0007354456
was O 0 0.00022050226
observed O 0 0.00016540148
in O 0 0.00019086212
12 O 0 0.00017032766
/ O 0 0.00047363032
30 O 0 0.00019989413
( O 0 0.0003054316
40 O 0 0.00027160457
% O 0 0.0003834191
) O 0 0.0005595384
patients O 0 0.0005418962
including O 0 0.0005451922
two O 0 0.00077033794
with O 0 0.0017042527
heart B-Disease 0 0.1984488
failure I-Disease 0 0.46951035
. O 0 0.0076586744

Pergolide B-Chemical 0 0.9999175
was O 0 0.0036301403
discontinued O 0 0.0050692465
in O 0 0.0010937841
10 O 0 0.000749958
patients O 0 0.0006794183
with O 0 0.00062260986
valvular B-Disease 0 0.8430772
heart I-Disease 0 0.79685324
disease I-Disease 0 0.9907828
, O 0 0.00064861483
resulting O 0 0.00023758273
in O 0 0.00021719892
a O 0 0.00028207924
lower O 0 0.00030328316
regurgitation O 0 0.967424
grade O 0 0.1228983
( O 0 0.0005196121
p O 0 0.00026116916
= O 0 0.0005205349
0 O 0 0.00026126378
. O 0 0.00020504248
01 O 0 0.00084490073
) O 0 0.00026084736
at O 0 0.00013179782
the O 0 0.00013406888
second O 0 0.00014657684
transthoracic O 0 0.0005008063
echocardiography O 0 0.00080468337
and O 0 0.00018991435
the O 0 0.00016413225
two O 0 0.00015669221
patients O 0 0.00027433748
with O 0 0.0003310159
heart B-Disease 0 0.06132726
failure I-Disease 0 0.038462374
returned O 0 0.0004091047
to O 0 0.00043553632
nearly O 0 0.0007632784
normal O 0 0.0016289924
clinical O 0 0.0036024046
examination O 0 0.0037434832
. O 0 0.005922776

This O 0 0.0050371885
study O 0 0.0026805568
supports O 0 0.0013861173
the O 0 0.0010587798
high O 0 0.0010344688
frequency O 0 0.0007274588
of O 0 0.00070304755
restrictive O 0 0.005193138
valve B-Disease 0 0.94202864
regurgitation I-Disease 0 0.9999347
in O 0 0.0027902739
PD B-Disease 0 0.9998778
patients O 0 0.0005605056
treated O 0 0.00034367034
with O 0 0.0010587121
pergolide B-Chemical 0 0.99999344
and O 0 0.00025650047
reveals O 0 0.00018761218
that O 0 0.00013162488
a O 0 0.000221747
significant O 0 0.00018983668
improvement O 0 0.00023628377
is O 0 0.00019665704
usual O 0 0.00019397755
when O 0 0.00013097734
the O 0 0.00018451113
treatment O 0 0.0002830097
is O 0 0.00028882056
converted O 0 0.00035817755
to O 0 0.00042040585
non O 0 0.0057173073
- O 0 0.5939715
ergot O 0 0.9999877
dopamine B-Chemical 1 0.99991226
agonists O 0 0.6757728
. O 0 0.0070402888

Adriamycin B-Chemical 0 0.9998499
- O 0 0.059489075
induced O 0 0.0030270738
autophagic O 0 0.37163267
cardiomyocyte O 0 0.9871438
death B-Disease 0 0.99970394
plays O 0 0.0010751595
a O 0 0.0010075062
pathogenic O 0 0.0011105943
role O 0 0.00047681393
in O 0 0.00067879894
a O 0 0.00097353075
rat O 0 0.001612332
model O 0 0.0014182377
of O 0 0.0031652583
heart B-Disease 0 0.5367506
failure I-Disease 0 0.688742
. O 0 0.00872105

BACKGROUND O 0 0.01669833
: O 0 0.0039783437
The O 0 0.0016718938
mechanisms O 0 0.0013738079
underlying O 0 0.0019056993
heart B-Disease 0 0.27934057
failure I-Disease 0 0.2822044
induced O 0 0.0012124422
by O 0 0.0016959298
adriamycin B-Chemical 0 0.99987435
are O 0 0.0010047279
very O 0 0.0013336577
complicated O 0 0.0026567488
and O 0 0.0018086144
still O 0 0.0024680402
unclear O 0 0.004059517
. O 0 0.007203019

The O 0 0.0031220631
aim O 0 0.0023556778
of O 0 0.0017449751
this O 0 0.0011934731
study O 0 0.0010294954
was O 0 0.00058157236
to O 0 0.00034550574
investigate O 0 0.00018842141
whether O 0 0.00018588992
autophagy O 0 0.027763128
was O 0 0.00028614525
involved O 0 0.00016873317
in O 0 0.0001919235
the O 0 0.00021582858
progression O 0 0.065683454
of O 0 0.00071192405
heart B-Disease 0 0.38695344
failure I-Disease 0 0.24616396
induced O 0 0.0004362876
by O 0 0.0012147091
adriamycin B-Chemical 0 0.99996185
, O 0 0.0009889271
so O 0 0.00021885365
that O 0 0.0001629698
we O 0 0.0001577613
can O 0 0.0001936082
develop O 0 0.00028215535
a O 0 0.0003896254
novel O 0 0.0004795424
treatment O 0 0.0006885687
strategy O 0 0.0010667994
for O 0 0.0017593246
heart B-Disease 0 0.37727565
failure I-Disease 0 0.6112706
. O 0 0.0076689837

METHODS O 0 0.0040748743
: O 0 0.0040292596
3 B-Chemical 0 0.0026395628
- I-Chemical 0 0.012984698
methyladenine I-Chemical 0 0.73553616
( O 0 0.015400718
3MA B-Chemical 0 0.99978024
) O 0 0.014569291
, O 0 0.00120124
a O 0 0.00062750705
specific O 0 0.00037753352
inhibitor O 0 0.001464004
on O 0 0.0002485003
autophagy O 0 0.046403565
was O 0 0.0003469505
used O 0 0.00025474132
in O 0 0.00030577334
a O 0 0.0005512788
heart B-Disease 0 0.09979883
failure I-Disease 0 0.09055618
model O 0 0.00066134694
of O 0 0.0010244182
rats O 0 0.0016578054
induced O 0 0.0017571972
by O 0 0.0045040334
adriamycin B-Chemical 0 0.99976367
. O 0 0.009779881

Neonatal O 0 0.012329165
cardiomyocytes O 0 0.009544156
were O 0 0.0019080733
isolated O 0 0.0010805257
from O 0 0.0010548185
Sprague O 0 0.05829276
- O 0 0.0072492543
Dawley O 0 0.0077993996
rat O 0 0.0008614008
hearts O 0 0.0006645733
and O 0 0.0002884541
randomly O 0 0.00015071966
divided O 0 0.00015903742
into O 0 0.00013248414
controls O 0 0.00035724655
, O 0 0.00048034944
an O 0 0.001217975
adriamycin B-Chemical 0 0.9999796
- O 0 0.10682726
treated O 0 0.00064175605
group O 0 0.00055127114
, O 0 0.00047986067
and O 0 0.0004883665
a O 0 0.0012095972
3MA B-Chemical 0 0.9996923
plus O 0 0.006090134
adriamycin B-Chemical 0 0.9999732
- O 0 0.12153781
treated O 0 0.0038741226
group O 0 0.0049672956
. O 0 0.006599612

We O 0 0.0031090542
then O 0 0.0018623369
examined O 0 0.0011584781
the O 0 0.0010473112
morphology O 0 0.0016862609
, O 0 0.0009338671
expression O 0 0.0006098112
of O 0 0.00076704094
beclin O 0 0.88883257
1 O 0 0.0006035198
gene O 0 0.0006615647
, O 0 0.0007430681
mitochondrial O 0 0.32419962
permeability O 0 0.8677257
transition O 0 0.084288046
( O 0 0.01866172
MPT O 0 0.99998
) O 0 0.0046640597
, O 0 0.00074503466
and O 0 0.001715769
Na O 1 0.9999962
+ O 0 0.13109629
- O 0 0.39288136
K B-Chemical 1 0.9999441
+ O 0 0.034271233
ATPase O 0 0.12678035
activity O 0 0.0017462441
in O 0 0.0024053794
vivo O 0 0.0050932127
. O 0 0.0073541836

We O 0 0.0035293482
also O 0 0.0023380483
assessed O 0 0.0017188885
cell O 0 0.0035893212
viability O 0 0.31016955
, O 0 0.0022990613
mitochondrial O 0 0.13130605
membrane O 0 0.0027732474
potential O 0 0.0006800606
changes O 0 0.0006492101
and O 0 0.000560172
counted O 0 0.00055616256
autophagic O 0 0.0069365883
vacuoles O 0 0.0022255036
in O 0 0.0017624191
cultured O 0 0.0032987813
cardiomyocytes O 0 0.06164795
. O 0 0.00842894

In O 0 0.0035428114
addition O 0 0.0018567356
, O 0 0.0019762856
we O 0 0.00085594144
analyzed O 0 0.0006984436
the O 0 0.0005845154
expression O 0 0.00057238236
of O 0 0.0006394385
autophagy O 0 0.13253374
associated O 0 0.00079778326
gene O 0 0.0008843497
, O 0 0.0008778446
beclin O 0 0.77240694
1 O 0 0.00041667974
using O 0 0.00034429788
RT O 0 0.08931193
- O 0 0.0076733865
PCR O 0 0.024518685
and O 0 0.00067697157
Western O 0 0.008506137
blotting O 0 0.007958124
in O 0 0.0012067582
an O 0 0.0018733562
animal O 0 0.0033781563
model O 0 0.004761631
. O 0 0.0077748327

RESULTS O 0 0.009000107
: O 0 0.008649312
3MA B-Chemical 0 0.9894693
significantly O 0 0.0037904058
improved O 0 0.0036460734
cardiac O 0 0.017190365
function O 0 0.0025316626
and O 0 0.0032481644
reduced O 0 0.005095581
mitochondrial O 0 0.98382276
injury O 0 0.9990119
. O 0 0.014362086

Furthermore O 0 0.005235016
, O 0 0.0063696182
adriamycin B-Chemical 0 0.9994087
induced O 0 0.0020076337
the O 0 0.0010504449
formation O 0 0.002598381
of O 0 0.0008313942
autophagic O 0 0.10884371
vacuoles O 0 0.008614293
, O 0 0.0012119435
and O 0 0.001181602
3MA B-Chemical 0 0.9996294
strongly O 0 0.0012033627
downregulated O 0 0.00026164396
the O 0 0.0001846065
expression O 0 0.00023234167
of O 0 0.00041544865
beclin O 0 0.9082383
1 O 0 0.00048074586
in O 0 0.0005609348
adriamycin B-Chemical 0 0.9999678
- O 0 0.052687656
induced O 0 0.00042817622
failing O 0 0.015711907
heart O 0 0.13616993
and O 0 0.0004793438
inhibited O 0 0.0005506987
the O 0 0.0006195309
formation O 0 0.0020447837
of O 0 0.0018775647
autophagic O 0 0.1145623
vacuoles O 0 0.014402824
. O 0 0.0073704845

CONCLUSION O 0 0.036896385
: O 0 0.006433632
Autophagic O 0 0.5969058
cardiomyocyte O 0 0.94631237
death B-Disease 0 0.99909055
plays O 0 0.0011604322
an O 0 0.0008995556
important O 0 0.00043313717
role O 0 0.00034134614
in O 0 0.00041423854
the O 0 0.0004107894
pathogenesis O 0 0.0014784636
of O 0 0.0011244108
heart B-Disease 0 0.46364644
failure I-Disease 0 0.32759148
in O 0 0.00092777866
rats O 0 0.0015392276
induced O 0 0.0017414261
by O 0 0.0043307077
adriamycin B-Chemical 0 0.99973136
. O 0 0.009840128

Mitochondrial O 0 0.82704026
injury O 0 0.8253166
may O 0 0.002051997
be O 0 0.001297466
involved O 0 0.00078341825
in O 0 0.00072355446
the O 0 0.00066848507
progression O 0 0.069733165
of O 0 0.001345178
heart B-Disease 0 0.44294262
failure I-Disease 0 0.28678754
caused O 0 0.0007999132
by O 0 0.0013536464
adriamycin B-Chemical 0 0.99968064
via O 0 0.0010644535
the O 0 0.0015952049
autophagy O 0 0.083882175
pathway O 0 0.004527673
. O 0 0.0072913654

mToR O 0 0.05127881
inhibitors O 0 0.018890303
- O 0 0.02999105
induced O 0 0.0059590912
proteinuria B-Disease 0 0.9999937
: O 0 0.0051639965
mechanisms O 0 0.0018871623
, O 0 0.0025530194
significance O 0 0.0023778137
, O 0 0.0036431816
and O 0 0.0044870046
management O 0 0.008061969
. O 0 0.009934936

Massive O 0 0.13106832
urinary O 0 0.70218533
protein O 0 0.4894225
excretion O 0 0.99903464
has O 0 0.0012262885
been O 0 0.0006757173
observed O 0 0.0004090444
after O 0 0.00027976095
conversion O 0 0.0007062631
from O 0 0.00024824406
calcineurin O 0 0.17644545
inhibitors O 0 0.0016383311
to O 0 0.0001756521
mammalian O 0 0.00025328528
target O 0 0.0001918759
of O 0 0.00048110666
rapamycin B-Chemical 1 0.9717386
( O 0 0.0120361205
mToR O 0 0.1701608
) O 0 0.0012825392
inhibitors O 0 0.0029841636
, O 0 0.00060321786
especially O 0 0.0027792023
sirolimus B-Chemical 1 0.9999083
, O 0 0.0007797361
in O 0 0.00043086743
renal O 0 0.63403744
transplant O 0 0.060543142
recipients O 0 0.0012882602
with O 0 0.0017440012
chronic B-Disease 0 0.99339926
allograft I-Disease 0 0.999
nephropathy I-Disease 2 0.99999964
. O 0 0.044585764

Because O 0 0.004922616
proteinuria B-Disease 0 0.9999509
is O 0 0.002490349
a O 0 0.0015407702
major O 0 0.0010503293
predictive O 0 0.0019401939
factor O 0 0.0039684363
of O 0 0.00076623034
poor O 0 0.003029632
transplantation O 0 0.019677231
outcome O 0 0.0012102305
, O 0 0.00039986512
many O 0 0.00023019443
studies O 0 0.00024073535
focused O 0 0.0002675517
on O 0 0.00024084785
this O 0 0.0004303414
adverse O 0 0.082489535
event O 0 0.0017170182
during O 0 0.0007343038
the O 0 0.0012926322
past O 0 0.0025712738
years O 0 0.0042071515
. O 0 0.006374678

Whether O 0 0.0072958814
proteinuria B-Disease 0 0.999969
was O 0 0.0022106247
due O 0 0.0009396305
to O 0 0.0009718941
sirolimus B-Chemical 1 0.99976605
or O 0 0.00069880154
only O 0 0.0004756053
a O 0 0.00036306377
consequence O 0 0.00018827198
of O 0 0.00037866677
calcineurin O 0 0.611576
inhibitors O 0 0.023298671
withdrawal O 0 0.24041674
remained O 0 0.00033137368
unsolved O 0 0.00028506533
until O 0 0.00010736604
high O 0 0.00023644559
range O 0 0.00056018727
proteinuria B-Disease 0 0.9999968
has O 0 0.00021844357
been O 0 0.00016264347
observed O 0 0.00014527778
during O 0 0.000179806
sirolimus B-Chemical 1 0.99971634
therapy O 0 0.00081310706
in O 0 0.0002732604
islet O 0 0.19659595
transplantation O 0 0.023267725
and O 0 0.00048260932
in O 0 0.000448565
patients O 0 0.00084715727
who O 0 0.0011196561
received O 0 0.0011425519
sirolimus B-Chemical 1 0.99904853
de O 0 0.036104362
novo O 0 0.01617915
. O 0 0.007626632

Podocyte O 0 0.8326137
injury O 0 0.8631442
and O 0 0.0033800513
focal O 0 0.33731207
segmental O 0 0.5460621
glomerulosclerosis B-Disease 2 0.9999995
have O 0 0.00078394625
been O 0 0.00041770143
related O 0 0.00023275582
to O 0 0.00026560354
mToR O 0 0.010148895
inhibition O 0 0.000645536
in O 0 0.00028745338
some O 0 0.00029281367
patients O 0 0.00050982693
, O 0 0.00045731332
but O 0 0.00037033382
the O 0 0.00033189284
pathways O 0 0.00047716152
underlying O 0 0.00072482775
these O 0 0.0011087788
lesions O 0 0.16252907
remain O 0 0.0025517908
hypothetic O 0 0.017683253
. O 0 0.007289484

We O 0 0.0037126427
discuss O 0 0.0021428147
herein O 0 0.0020703175
the O 0 0.0012810767
possible O 0 0.0010272436
mechanisms O 0 0.0008343453
and O 0 0.00088719686
the O 0 0.00073440204
significance O 0 0.0008490207
of O 0 0.001431616
mToR O 0 0.17201924
blockade O 0 0.11365381
- O 0 0.08029593
induced O 0 0.013968721
proteinuria B-Disease 0 0.9999896
. O 0 0.013858121

Neuropsychiatric O 0 0.45262134
side O 0 0.014317736
effects O 0 0.0051488844
after O 0 0.003436245
the O 0 0.0042933947
use O 0 0.005793107
of O 0 0.010793739
mefloquine B-Chemical 1 0.9998779
. O 0 0.017909333

This O 0 0.00625932
study O 0 0.0041552396
describes O 0 0.0045663174
neuropsychiatric O 0 0.99446505
side O 0 0.053120974
effects O 0 0.0018024371
in O 0 0.0012224137
patients O 0 0.0015398997
after O 0 0.0010941072
treatment O 0 0.0023520857
with O 0 0.006007538
mefloquine B-Chemical 1 0.9999113
. O 0 0.010239663

Reactions O 0 0.006823877
consisted O 0 0.0022271834
mainly O 0 0.0022731554
of O 0 0.0048205745
seizures B-Disease 0 0.99999833
, O 0 0.050218627
acute O 0 0.9978059
psychoses B-Disease 0 0.99999833
, O 0 0.22816956
anxiety B-Disease 0 0.9999938
neurosis I-Disease 0 0.99998415
, O 0 0.0010351511
and O 0 0.0005816261
major O 0 0.0007504198
disturbances B-Disease 0 0.07950596
of I-Disease 0 0.0014247897
sleep I-Disease 0 0.09026402
- I-Disease 0 0.007188429
wake I-Disease 0 0.0039837356
rhythm I-Disease 0 0.010873195
. O 0 0.0067780116

Side O 0 0.3804622
effects O 0 0.0036717656
occurred O 0 0.0019140545
after O 0 0.0010173911
both O 0 0.00095837534
therapeutic O 0 0.001549866
and O 0 0.00094884087
prophylactic O 0 0.0053616175
intake O 0 0.35597125
and O 0 0.0007548767
were O 0 0.000691607
graded O 0 0.0011311339
from O 0 0.0009848733
moderate O 0 0.004489175
to O 0 0.0024577416
severe O 0 0.11189827
. O 0 0.0074133365

In O 0 0.0039658137
a O 0 0.003151421
risk O 0 0.013449333
analysis O 0 0.0014983795
of O 0 0.0019229586
neuropsychiatric O 0 0.998635
side O 0 0.13079101
effects O 0 0.0014259596
in O 0 0.0006544471
Germany O 0 0.04779576
, O 0 0.0005908073
it O 0 0.00029855876
is O 0 0.00022067303
estimated O 0 0.00018965665
that O 0 0.00018223519
one O 0 0.00020726005
of O 0 0.00029509777
8 O 0 0.00030011666
, O 0 0.00046540934
000 O 0 0.00076287566
mefloquine B-Chemical 1 0.9998404
users O 0 0.0032588772
suffers O 0 0.0018480126
from O 0 0.0012788196
such O 0 0.0021227458
reactions O 0 0.010093202
. O 0 0.006788247

The O 0 0.0031309146
incidence O 0 0.0032763768
calculation O 0 0.0013685419
revealed O 0 0.0009742503
that O 0 0.0006640522
one O 0 0.0005575949
of O 0 0.00062496477
215 O 0 0.0065030064
therapeutic O 0 0.0015767816
users O 0 0.0022080305
had O 0 0.00026955214
reactions O 0 0.0025838441
, O 0 0.00030418957
compared O 0 0.00013183491
with O 0 0.00018061379
one O 0 0.00014424074
of O 0 0.00020078006
13 O 0 0.00021592552
, O 0 0.00021007567
000 O 0 0.00018090695
in O 0 0.00014870385
the O 0 0.00016663753
prophylaxis O 0 0.002542245
group O 0 0.00038456623
, O 0 0.00033559767
making O 0 0.00040402653
the O 0 0.00021573353
risk O 0 0.035349093
of O 0 0.00086157804
neuropsychiatric O 0 0.9982572
reactions O 0 0.01435498
after O 0 0.00024112519
mefloquine B-Chemical 1 0.9999156
treatment O 0 0.00045087718
60 O 0 0.0003302037
times O 0 0.0002978545
higher O 0 0.00057046465
than O 0 0.0007560927
after O 0 0.0013633006
prophylaxis O 0 0.009354343
. O 0 0.006152534

Therefore O 0 0.0042168773
, O 0 0.0036546965
certain O 0 0.0022451014
limitations O 0 0.0015999533
for O 0 0.0016433022
malaria B-Disease 0 0.99083567
prophylaxis O 0 0.08063175
and O 0 0.0016414782
treatment O 0 0.0020500782
with O 0 0.004003458
mefloquine B-Chemical 1 0.99994075
are O 0 0.0033643045
recommended O 0 0.0047953147
. O 0 0.0070716627

Prenatal O 0 0.04835665
protein O 0 0.006098056
deprivation O 0 0.048438955
alters O 0 0.002937097
dopamine B-Chemical 1 0.999941
- O 0 0.017541718
mediated O 0 0.00075018744
behaviors O 0 0.025772886
and O 0 0.0014448396
dopaminergic O 0 0.48519284
and O 0 0.0019686448
glutamatergic O 0 0.6272434
receptor O 0 0.021410372
binding O 0 0.005976726
. O 0 0.008241296

Epidemiological O 0 0.010736793
evidence O 0 0.0026158465
indicates O 0 0.0017805692
that O 0 0.001513068
prenatal O 0 0.011637551
nutritional O 0 0.109072596
deprivation O 0 0.02756458
may O 0 0.0011260421
increase O 0 0.0011128442
the O 0 0.0017115877
risk O 0 0.17610423
of O 0 0.020979011
schizophrenia B-Disease 2 0.9999474
. O 0 0.010548249

The O 0 0.0031125837
goal O 0 0.0025435789
of O 0 0.0016207711
these O 0 0.0011645601
studies O 0 0.00087199983
was O 0 0.00063642167
to O 0 0.0004204533
use O 0 0.0004008013
an O 0 0.00038084923
animal O 0 0.00043088227
model O 0 0.00025215285
to O 0 0.00016758688
examine O 0 0.000101985635
the O 0 0.00016127307
effects O 0 0.0002339022
of O 0 0.00029562658
prenatal O 0 0.016013077
protein O 0 0.0015516719
deprivation O 0 0.008968283
on O 0 0.0001947838
behaviors O 0 0.016493233
and O 0 0.0004962464
receptor O 0 0.005927106
binding O 0 0.00072216365
with O 0 0.0008503727
relevance O 0 0.0010667416
to O 0 0.002415182
schizophrenia B-Disease 2 0.99980646
. O 0 0.007067599

We O 0 0.0037255099
report O 0 0.0032901524
that O 0 0.0017845188
prenatally O 0 0.39728045
protein O 0 0.004222857
deprived O 0 0.015759869
( O 0 0.028486744
PD O 0 0.9999392
) O 0 0.0033476413
female O 0 0.0024042786
rats O 0 0.00050407974
showed O 0 0.00025435034
an O 0 0.00032714487
increased O 0 0.00047724048
stereotypic O 0 0.86431926
response O 0 0.0009267526
to O 0 0.00071762205
apomorphine B-Chemical 1 0.99999774
and O 0 0.00057369814
an O 0 0.00048447764
increased O 0 0.00071011693
locomotor O 0 0.45005152
response O 0 0.0010061921
to O 0 0.0015062697
amphetamine B-Chemical 1 0.99999607
in O 0 0.002964452
adulthood O 0 0.37503716
. O 0 0.0070508937

These O 0 0.008895412
differences O 0 0.0064139594
were O 0 0.006708513
not O 0 0.0065974044
observed O 0 0.007576255
during O 0 0.009965065
puberty O 0 0.7958781
. O 0 0.021622343

No O 0 0.006695321
changes O 0 0.0047419085
in O 0 0.0073054675
haloperidol B-Chemical 1 0.99999964
- O 0 0.46830305
induced O 0 0.030389216
catalepsy B-Disease 2 0.99999964
or O 0 0.010621838
MK B-Chemical 0 0.9990934
- I-Chemical 0 0.39109525
801 I-Chemical 0 0.8468203
- O 0 0.0068903714
induced O 0 0.00092126336
locomotion O 0 0.09956855
were O 0 0.0012599989
seen O 0 0.0016942854
following O 0 0.0030254866
PD O 0 0.9987417
. O 0 0.008163797

In O 0 0.0038350332
addition O 0 0.0022877795
, O 0 0.0068746684
PD O 0 0.9995585
female O 0 0.0075087124
rats O 0 0.0011941419
showed O 0 0.00053532724
increased O 0 0.0006091319
( O 0 0.00088017544
3 O 0 0.00044538692
) O 0 0.01392679
H B-Chemical 1 0.99999833
- O 0 0.7860488
MK B-Chemical 0 0.99893504
- I-Chemical 0 0.17329364
801 I-Chemical 0 0.28199482
binding O 0 0.0003385689
in O 0 0.00026533732
the O 0 0.0003256006
striatum O 0 0.33578873
and O 0 0.00059978216
hippocampus O 0 0.2569078
, O 0 0.00079376204
but O 0 0.00075834914
not O 0 0.0008471878
in O 0 0.0014034676
the O 0 0.0025724997
cortex O 0 0.375495
. O 0 0.006860053

PD O 0 0.99876815
female O 0 0.008522786
rats O 0 0.0026073842
also O 0 0.0012226361
showed O 0 0.0009138476
increased O 0 0.0009840601
( O 0 0.0013036632
3 O 0 0.0006698054
) O 0 0.01958911
H B-Chemical 1 0.9999982
- O 0 0.91930956
haloperidol B-Chemical 1 0.99999976
binding O 0 0.001170161
and O 0 0.0009015722
decreased O 0 0.003067831
dopamine B-Chemical 1 0.9997112
transporter O 0 0.010725433
binding O 0 0.0018726232
in O 0 0.0028471628
striatum O 0 0.4847886
. O 0 0.006843913

No O 0 0.0053919144
statistically O 0 0.002390691
significant O 0 0.0017020247
changes O 0 0.001430158
in O 0 0.0008804812
behavior O 0 0.001694158
or O 0 0.0006557357
receptor O 0 0.0113929715
binding O 0 0.0006030279
were O 0 0.00033691057
found O 0 0.00027470678
in O 0 0.0004759412
PD O 0 0.99974877
males O 0 0.00064429326
with O 0 0.00021097818
the O 0 0.00017180156
exception O 0 0.00016783987
of O 0 0.00025437243
increased O 0 0.00037055928
( O 0 0.000675007
3 O 0 0.00036702736
) O 0 0.008756341
H B-Chemical 1 0.99999654
- O 0 0.66696906
MK B-Chemical 0 0.997563
- I-Chemical 0 0.11438769
801 I-Chemical 0 0.3231106
binding O 0 0.002063903
in O 0 0.0031031393
cortex O 0 0.31701395
. O 0 0.0072825453

This O 0 0.00521362
animal O 0 0.0033684322
model O 0 0.001906975
may O 0 0.0011090861
be O 0 0.00079096947
useful O 0 0.000538485
to O 0 0.00035550332
explore O 0 0.00022315835
the O 0 0.00024557355
mechanisms O 0 0.00022991825
by O 0 0.00028752707
which O 0 0.0005136019
prenatal O 0 0.07998501
nutritional B-Disease 0 0.9781291
deficiency I-Disease 0 0.99427986
enhances O 0 0.0003475906
risk O 0 0.4382422
for O 0 0.0022914796
schizophrenia B-Disease 2 0.9999914
in O 0 0.0003094394
humans O 0 0.0012805429
and O 0 0.00022673965
may O 0 0.00013952347
also O 0 0.00013334547
have O 0 0.00012190006
implications O 0 0.00016200037
for O 0 0.00017482365
developmental O 0 0.00044487114
processes O 0 0.000343538
leading O 0 0.00039994885
to O 0 0.00029122314
differential O 0 0.0004913658
sensitivity O 0 0.0013526516
to O 0 0.0008980698
drugs O 0 0.13524948
of O 0 0.0040698554
abuse O 0 0.9956567
. O 0 0.008231683

Adverse O 0 0.025776012
effects O 0 0.006178398
of O 0 0.0066955104
topical O 0 0.99222213
papaverine B-Chemical 1 0.99995935
on O 0 0.0037339956
auditory O 0 0.028755493
nerve O 0 0.04931782
function O 0 0.00777278
. O 0 0.012125572

BACKGROUND O 0 0.09997605
: O 0 0.03426444
Papaverine B-Chemical 0 0.99996674
hydrochloride I-Chemical 0 0.99990916
is O 0 0.0019462756
a O 0 0.0012356456
direct O 0 0.0008640053
- O 0 0.008401624
acting O 0 0.0017485048
vasodilator O 0 0.89298517
used O 0 0.00053199445
to O 0 0.0005858121
manage O 0 0.001755469
vasospasm B-Disease 2 0.99999094
during O 0 0.0009694536
various O 0 0.001752798
neurosurgical O 0 0.0038619947
operations O 0 0.004548404
. O 0 0.006410077

Transient O 0 0.27311435
cranial B-Disease 0 0.71848
nerve I-Disease 0 0.49821186
dysfunction I-Disease 0 0.9518736
has O 0 0.0015994573
been O 0 0.0011844006
described O 0 0.00088803546
in O 0 0.00089747703
a O 0 0.001097723
few O 0 0.0009573286
cases O 0 0.0019790167
with O 0 0.0037716615
topical O 0 0.9949536
papaverine B-Chemical 1 0.9999603
. O 0 0.010932527

This O 0 0.005270188
study O 0 0.0028608958
supports O 0 0.0015111399
previous O 0 0.001136614
reports O 0 0.0010028037
and O 0 0.0008515364
provides O 0 0.0005849863
neurophysiological O 0 0.0021613345
evidence O 0 0.0004541799
of O 0 0.00066966406
an O 0 0.0009117984
adverse O 0 0.17215778
effect O 0 0.00079548394
on O 0 0.00085707667
the O 0 0.0016911605
auditory O 0 0.027250096
nerve O 0 0.08022412
. O 0 0.007245652

METHODS O 0 0.004290717
: O 0 0.0035754303
We O 0 0.0019194239
conducted O 0 0.001401044
a O 0 0.0014092495
retrospective O 0 0.0022722927
review O 0 0.0010504078
of O 0 0.00063770823
70 O 0 0.00049218256
consecutive O 0 0.00039651492
microvascular O 0 0.2993718
decompression O 0 0.010078062
operations O 0 0.00047193785
and O 0 0.00036378563
studied O 0 0.0003940484
those O 0 0.000489012
patients O 0 0.0006780017
who O 0 0.0009146468
received O 0 0.00087687944
topical O 0 0.98790354
papaverine B-Chemical 1 0.99998665
for O 0 0.021268718
vasospasm B-Disease 2 0.9999957
. O 0 0.010503275

Topical O 0 0.99916637
papaverine B-Chemical 1 0.9999604
was O 0 0.002660824
used O 0 0.0012133862
as O 0 0.0009109332
a O 0 0.0008336714
direct O 0 0.0005811656
therapeutic O 0 0.0011534678
action O 0 0.0008800756
to O 0 0.00054946344
manage O 0 0.0022469393
vasospasm B-Disease 2 0.99999714
in O 0 0.00076919916
a O 0 0.0008975762
total O 0 0.00089823577
of O 0 0.001769907
11 O 0 0.0025800916
patients O 0 0.0045662546
. O 0 0.0066294204

The O 0 0.0032545126
timing O 0 0.0023463313
of O 0 0.003261527
papaverine B-Chemical 1 0.9999126
application O 0 0.0020308576
and O 0 0.00090907764
ongoing O 0 0.00069572293
operative O 0 0.00091143575
events O 0 0.001538791
was O 0 0.0005226498
reviewed O 0 0.0006525792
relative O 0 0.0005124948
to O 0 0.0006831344
changes O 0 0.0011646237
in O 0 0.0015186765
neurophysiological O 0 0.0067474083
recordings O 0 0.0044727926
. O 0 0.006388506

Brainstem O 0 0.032143824
auditory O 0 0.007616332
evoked O 0 0.005881149
potentials O 0 0.020414991
( O 0 0.0028422137
BAEPs O 0 0.52170044
) O 0 0.0012292676
were O 0 0.0005964777
routinely O 0 0.0004322073
used O 0 0.00040285295
to O 0 0.00043103367
monitor O 0 0.00054337847
cochlear O 0 0.005765877
nerve O 0 0.003920525
function O 0 0.0010616747
during O 0 0.0013219977
these O 0 0.0026159934
operations O 0 0.005288016
. O 0 0.0073090685

FINDINGS O 0 0.009120111
: O 0 0.0049579474
A O 0 0.018139483
temporal O 0 0.0044241594
relationship O 0 0.0009184688
was O 0 0.0008931175
found O 0 0.0006448185
between O 0 0.0006100307
topical O 0 0.98384804
papaverine B-Chemical 1 0.9999907
and O 0 0.002198986
BAEP O 0 0.9284176
changes O 0 0.0007835415
leading O 0 0.0009610335
to O 0 0.0009473924
complete O 0 0.0014120342
waveform O 0 0.0037962801
loss O 0 0.0051981932
. O 0 0.0070604947

The O 0 0.002879128
average O 0 0.0017673426
temporal O 0 0.003923299
delay O 0 0.0016393204
between O 0 0.0011266415
papaverine B-Chemical 1 0.9999305
and O 0 0.0009888982
the O 0 0.0005868009
onset O 0 0.00090018974
of O 0 0.0007019499
an O 0 0.0010404127
adverse O 0 0.66974306
BAEP O 0 0.9371828
change O 0 0.0012233299
was O 0 0.0014903217
5 O 0 0.0018714187
min O 0 0.003811306
. O 0 0.006500536

In O 0 0.003922779
10 O 0 0.0025069139
of O 0 0.0019817709
11 O 0 0.0015537449
patients O 0 0.0013711517
, O 0 0.0014710698
BAEP O 0 0.8683229
waves O 0 0.01664668
II O 0 0.07019234
/ O 0 0.029098686
III O 0 0.2972593
- O 0 0.06266387
V O 0 0.73192966
completely O 0 0.00041679494
disappeared O 0 0.00045674542
within O 0 0.00032896886
2 O 0 0.0004845227
to O 0 0.00056536193
25 O 0 0.0010281081
min O 0 0.0016464094
after O 0 0.0024149825
papaverine B-Chemical 1 0.99946576
. O 0 0.007897063

Eight O 0 0.0055149565
of O 0 0.003104116
these O 0 0.0022651732
10 O 0 0.0016909312
patients O 0 0.0014659461
had O 0 0.0009955326
complete O 0 0.0008704201
loss O 0 0.0013393539
of O 0 0.0015305643
BAEP O 0 0.80484456
waveforms O 0 0.0019524337
within O 0 0.0013892687
10 O 0 0.0024685618
min O 0 0.0044982308
. O 0 0.0074783787

One O 0 0.0049770297
patient O 0 0.0027946183
showed O 0 0.0017684822
no O 0 0.001221183
recovery O 0 0.0014449978
of O 0 0.001129386
later O 0 0.0008811892
waves O 0 0.0025928852
and O 0 0.0011079651
a O 0 0.0013864065
delayed O 0 0.0047892765
profound O 0 0.1263342
sensorineural B-Disease 2 0.9999852
hearing I-Disease 2 0.99818206
loss I-Disease 2 0.2084035
. O 0 0.009984145

The O 0 0.003169275
average O 0 0.0018689389
recovery O 0 0.0019376514
time O 0 0.0010528314
of O 0 0.0013563191
BAEP O 0 0.7065867
waveforms O 0 0.0013084199
to O 0 0.000722701
pre O 0 0.0029479882
- O 0 0.046877924
papaverine B-Chemical 1 0.9998293
baseline O 0 0.0010685174
values O 0 0.0012019955
was O 0 0.0018075523
39 O 0 0.003215411
min O 0 0.004495575
. O 0 0.0073232464

CONCLUSIONS O 0 0.08735347
: O 0 0.012591112
Topical O 0 0.9990281
papaverine B-Chemical 1 0.99997926
for O 0 0.0014693729
the O 0 0.0008111066
treatment O 0 0.0010923045
of O 0 0.007970082
vasospasm B-Disease 2 0.99999964
was O 0 0.0006714032
associated O 0 0.00033284596
with O 0 0.0002497792
the O 0 0.0002008195
onset O 0 0.0004043111
of O 0 0.0002817097
a O 0 0.00038423805
transient O 0 0.008812193
disturbance O 0 0.050265007
in O 0 0.00027947035
neurophysiological O 0 0.0015703883
function O 0 0.00029832684
of O 0 0.00046405883
the O 0 0.0006018442
ascending O 0 0.0026862603
auditory O 0 0.011998767
brainstem O 0 0.06437796
pathway O 0 0.003324658
. O 0 0.006169185

The O 0 0.0030576116
complete O 0 0.0020541209
disappearance O 0 0.003212254
of O 0 0.0019412884
BAEP O 0 0.88286334
waveforms O 0 0.0013884002
with O 0 0.00055283506
a O 0 0.0005086843
consistent O 0 0.00039920435
temporal O 0 0.0036485256
delay O 0 0.00041815222
suggests O 0 0.0002457647
a O 0 0.00039885953
possible O 0 0.0004410103
adverse B-Disease 0 0.07195952
effect I-Disease 0 0.000471039
on I-Disease 0 0.0004995862
the I-Disease 0 0.00091320643
proximal I-Disease 0 0.0021237724
eighth I-Disease 0 0.01648556
nerve I-Disease 0 0.079819895
. O 0 0.0067867297

Recommendations O 0 0.005049554
to O 0 0.0029766762
avoid O 0 0.0022156294
potential O 0 0.002772808
cranial B-Disease 0 0.54532665
nerve I-Disease 0 0.36653852
deficits I-Disease 0 0.91023505
from O 0 0.0036796804
papaverine B-Chemical 1 0.9998305
are O 0 0.004538733
provided O 0 0.0060282256
. O 0 0.009746743

Simvastatin B-Chemical 0 0.99999547
- I-Chemical 0 0.9313276
ezetimibe I-Chemical 0 0.9999887
- O 0 0.17411326
induced O 0 0.005221485
hepatic B-Disease 0 0.960974
failure I-Disease 0 0.8036805
necessitating O 0 0.016675225
liver O 0 0.87818503
transplantation O 0 0.32373706
. O 0 0.01163142

Abstract O 0 0.36966985
Serum O 0 0.94658995
aminotransferase O 0 0.9990246
elevations O 0 0.2094205
are O 0 0.0009652738
a O 0 0.00082771503
commonly O 0 0.0007567746
known O 0 0.0005487104
adverse O 0 0.079514824
effect O 0 0.0003137899
of O 0 0.0005333826
3 O 0 0.00047501293
- O 0 0.1804279
hydroxy O 0 0.99998295
- O 0 0.109044075
3 O 0 0.00037373308
- O 0 0.02190702
methylglutaryl O 0 0.97787344
coenzyme O 0 0.9999939
A O 0 0.9433288
reductase O 0 0.9993692
inhibitor O 0 0.11618328
( O 0 0.011220643
statin B-Chemical 1 0.99899167
) O 0 0.005939481
therapy O 0 0.006765927
. O 0 0.0066312584

However O 0 0.0061491732
, O 0 0.009114857
hepatotoxic B-Disease 0 0.9999423
events O 0 0.059491146
have O 0 0.00096327014
not O 0 0.00070822693
been O 0 0.0006024738
widely O 0 0.0005375919
published O 0 0.00046695306
with O 0 0.0007686214
ezetimibe B-Chemical 0 0.9998155
or O 0 0.00063264195
the O 0 0.0006946457
combination O 0 0.002983501
agent O 0 0.8631502
simvastatin B-Chemical 1 0.9999993
- I-Chemical 0 0.93312466
ezetimibe I-Chemical 0 0.9999827
. O 0 0.011353613

We O 0 0.0035870164
describe O 0 0.0022837438
a O 0 0.002145155
70 O 0 0.0016911454
- O 0 0.0032679043
year O 0 0.001131579
- O 0 0.0033805908
old O 0 0.00093639083
Hispanic O 0 0.64935094
woman O 0 0.006312423
who O 0 0.0010999365
developed O 0 0.0024591978
fulminant B-Disease 2 0.999984
hepatic I-Disease 2 0.9967349
failure I-Disease 2 0.97122633
necessitating O 0 0.007973106
liver O 0 0.8338715
transplantation O 0 0.03638651
10 O 0 0.00015826015
weeks O 0 9.200871e-05
after O 0 9.636257e-05
conversion O 0 0.0004243297
from O 0 0.00022877417
simvastatin B-Chemical 1 0.9999685
40 O 0 0.00029737497
mg O 0 0.013360182
/ O 0 0.00080049434
day O 0 0.00017778325
to O 0 0.00026877917
simvastatin B-Chemical 1 0.9999628
10 I-Chemical 0 0.00046685743
mg I-Chemical 0 0.110523395
- I-Chemical 0 0.056666795
ezetimibe I-Chemical 0 0.9997539
40 I-Chemical 0 0.001215841
mg I-Chemical 0 0.01730886
/ O 0 0.003943975
day O 0 0.0033194593
. O 0 0.0062416554

The O 0 0.003329821
patient O 0 0.0025999756
' O 0 0.0023008063
s O 0 0.0019635425
lipid O 0 0.3910502
panel O 0 0.0009337892
had O 0 0.0005618835
been O 0 0.00041996746
maintained O 0 0.0003711223
with O 0 0.0008159707
simvastatin B-Chemical 1 0.99997044
for O 0 0.00037651905
18 O 0 0.00030568038
months O 0 0.00021190877
before O 0 0.0002275173
the O 0 0.00039287214
conversion O 0 0.00089994835
without O 0 0.0008564134
evidence O 0 0.0014547567
of O 0 0.0117331445
hepatotoxicity B-Disease 2 0.99999714
. O 0 0.013914

A O 0 0.028175082
routine O 0 0.0033357255
laboratory O 0 0.0029812746
work O 0 0.0021470564
- O 0 0.0030438646
up O 0 0.00092294323
10 O 0 0.00071478856
weeks O 0 0.0004991196
after O 0 0.00050187367
conversion O 0 0.0011031169
revealed O 0 0.0009929655
elevated O 0 0.011528085
serum O 0 0.7687086
aminotransferase O 0 0.99947757
levels O 0 0.0057505434
. O 0 0.00819007

Simvastatinezetimibe B-Chemical 0 0.4764189
and O 0 0.007882238
escitalopram B-Chemical 0 0.9999311
( O 0 0.003058904
which O 0 0.0012140578
she O 0 0.00063571904
was O 0 0.0005577836
taking O 0 0.00083914964
for O 0 0.00057754735
depression B-Disease 0 0.99897504
) O 0 0.0012107914
were O 0 0.00036078892
discontinued O 0 0.0015775552
, O 0 0.0004142101
and O 0 0.00036865252
other O 0 0.00041102796
potential O 0 0.00063099177
causes O 0 0.0013462226
of O 0 0.010424918
hepatotoxicity B-Disease 2 0.99999833
were O 0 0.0034532312
excluded O 0 0.004420926
. O 0 0.0066642994

A O 0 0.045390088
repeat O 0 0.004227949
work O 0 0.0028065809
- O 0 0.003890311
up O 0 0.0008866481
revealed O 0 0.000634275
further O 0 0.0005800441
elevations O 0 0.05792805
in O 0 0.0007527855
aminotransferase O 0 0.99883634
levels O 0 0.0004604858
, O 0 0.0005128026
and O 0 0.0004130516
liver O 0 0.25257638
biopsy O 0 0.0007918005
revealed O 0 0.000236396
evidence O 0 0.00023502824
of O 0 0.0005154467
moderate O 0 0.05365036
- O 0 0.025515357
to O 0 0.0009006565
- O 0 0.07667686
severe O 0 0.70116293
drug B-Disease 0 0.9984273
toxicity I-Disease 2 0.9999336
. O 0 0.010457647

She O 0 0.00835943
underwent O 0 0.005632313
liver O 0 0.14155611
transplantation O 0 0.013124958
with O 0 0.0038656944
an O 0 0.004274641
uneventful O 0 0.004909523
postoperative O 0 0.008266265
course O 0 0.007206174
. O 0 0.011117954

Her O 0 0.013918142
aminotransferase O 0 0.97555655
levels O 0 0.0017333175
returned O 0 0.0010719221
to O 0 0.0006990203
normal O 0 0.0007195189
by O 0 0.00050685083
postoperative O 0 0.0008500059
day O 0 0.00030561717
23 O 0 0.0004119409
, O 0 0.0003583951
and O 0 0.0003293891
her O 0 0.00038300123
2 O 0 0.0003435878
- O 0 0.00083421014
year O 0 0.00037461126
follow O 0 0.0003736043
- O 0 0.0012645375
up O 0 0.00063886645
showed O 0 0.00089438085
no O 0 0.0013446816
adverse O 0 0.24078171
events O 0 0.024330892
. O 0 0.007678551

Ezetimibe B-Chemical 0 0.9992963
undergoes O 0 0.0038837332
extensive O 0 0.0049897786
glucuronidation O 0 0.9998211
by O 0 0.008745512
uridine B-Chemical 0 0.9999175
diphosphate I-Chemical 0 0.9990398
glucoronosyltransferases O 0 0.7889661
( O 0 0.031454373
UGT O 0 0.99978954
) O 0 0.0014945869
in O 0 0.00025283892
the O 0 0.00023044783
intestine O 0 0.0037222567
and O 0 0.00059727475
liver O 0 0.63986623
and O 0 0.0004515408
may O 0 0.00018849544
have O 0 0.00015650499
inhibited O 0 0.000379138
the O 0 0.0009844876
glucuronidation O 0 0.9999659
of O 0 0.1695855
simvastatin B-Chemical 1 1.0
hydroxy I-Chemical 0 0.9999995
acid I-Chemical 0 0.9996158
, O 0 0.0018018931
resulting O 0 0.0003455744
in O 0 0.0004328299
increased O 0 0.0021625215
simvastatin B-Chemical 1 0.9999869
exposure O 0 0.042062875
and O 0 0.0026589164
subsequent O 0 0.010470716
hepatotoxicity B-Disease 2 0.9999968
. O 0 0.011037139

To O 0 0.0030274738
our O 0 0.0023989915
knowledge O 0 0.0021116172
, O 0 0.0016799096
this O 0 0.00088668935
is O 0 0.00065318955
the O 0 0.000461314
first O 0 0.00033980454
case O 0 0.0004412851
report O 0 0.0016427062
of O 0 0.014143469
simvastatin B-Chemical 1 0.9999999
- I-Chemical 0 0.9719758
ezetimibe I-Chemical 0 0.9999993
- O 0 0.19211142
induced O 0 0.0010425657
liver B-Disease 0 0.89611524
failure I-Disease 0 0.41109362
that O 0 0.0006293038
resulted O 0 0.00092647265
in O 0 0.0017571754
liver O 0 0.6950623
transplantation O 0 0.19989161
. O 0 0.007513866

We O 0 0.0034867497
postulate O 0 0.0025001478
that O 0 0.0013815627
the O 0 0.0010509514
mechanism O 0 0.00078697235
of O 0 0.00093654287
the O 0 0.0009410138
simvastatinezetimibe B-Chemical 0 0.92659366
- O 0 0.12869419
induced O 0 0.00693232
hepatotoxicity B-Disease 2 0.9999999
is O 0 0.0015157012
the O 0 0.00056546
increased O 0 0.0042225476
simvastatin B-Chemical 1 0.9999949
exposure O 0 0.08824944
by O 0 0.002690053
ezetimibe B-Chemical 0 0.9999536
inhibition O 0 0.01868116
of O 0 0.015959362
UGT O 0 0.99962866
enzymes O 0 0.1478388
. O 0 0.007696069

Clinicians O 0 0.0051414813
should O 0 0.0017713895
be O 0 0.0014908141
aware O 0 0.0010876205
of O 0 0.00103698
potential O 0 0.0062239524
hepatotoxicity B-Disease 2 0.9999999
with O 0 0.35806856
simvastatin B-Chemical 1 1.0
- I-Chemical 0 0.97078717
ezetimibe I-Chemical 0 0.9999982
especially O 0 0.004182506
in O 0 0.00035379472
elderly O 0 0.11834385
patients O 0 0.00028040688
and O 0 0.00017243174
should O 0 0.000100748584
carefully O 0 0.00010465748
monitor O 0 0.00015355434
serum O 0 0.25553647
aminotransferase O 0 0.9983677
levels O 0 0.00027082983
when O 0 0.00021991563
starting O 0 0.00031323844
therapy O 0 0.0007087565
and O 0 0.00084950385
titrating O 0 0.003973245
the O 0 0.0021262174
dosage O 0 0.074152015
. O 0 0.0063855127

Massive O 0 0.57700366
proteinuria B-Disease 0 0.99998367
and O 0 0.010846498
acute B-Disease 0 0.9764266
renal I-Disease 0 0.9940149
failure I-Disease 0 0.8479932
after O 0 0.000724428
oral O 0 0.8914012
bisphosphonate B-Chemical 0 0.99997854
( O 0 0.065071315
alendronate B-Chemical 0 0.99996006
) O 0 0.0040070643
administration O 0 0.0033652224
in O 0 0.00039676367
a O 0 0.0005546316
patient O 0 0.00065226795
with O 0 0.0010146826
focal B-Disease 0 0.36470562
segmental I-Disease 0 0.6578384
glomerulosclerosis I-Disease 2 0.99999785
. O 0 0.014016701

A O 0 0.07025858
61 O 0 0.006081337
- O 0 0.007057684
year O 0 0.002141245
- O 0 0.0048465733
old O 0 0.0014420645
Japanese O 0 0.053638883
man O 0 0.14241415
with O 0 0.00679405
nephrotic B-Disease 0 0.9999988
syndrome I-Disease 0 0.7407012
due O 0 0.00026933945
to O 0 0.0002828699
focal B-Disease 0 0.15306069
segmental I-Disease 0 0.33947253
glomerulosclerosis I-Disease 2 0.99999964
was O 0 0.0006786925
initially O 0 0.00055059855
responding O 0 0.0008656963
well O 0 0.00079905544
to O 0 0.0014741155
steroid B-Chemical 1 0.9927337
therapy O 0 0.013199311
. O 0 0.006901187

The O 0 0.0029960435
amount O 0 0.0017614218
of O 0 0.0019250326
daily O 0 0.0019513383
urinary O 0 0.1896758
protein O 0 0.0021005645
decreased O 0 0.0009866867
from O 0 0.0005797142
15 O 0 0.00053995213
. O 0 0.0005500703
6 O 0 0.00056533766
to O 0 0.00075428205
2 O 0 0.0011571727
. O 0 0.0016257028
8 O 0 0.002636261
g O 0 0.005679037
. O 0 0.008097126

Within O 0 0.0028225752
14 O 0 0.0019860344
days O 0 0.0011525409
of O 0 0.001177441
the O 0 0.0010824616
oral O 0 0.6713247
bisphosphonate B-Chemical 0 0.9999682
( O 0 0.21106406
alendronate B-Chemical 0 0.9999993
sodium I-Chemical 0 0.9999981
) O 0 0.02395259
administration O 0 0.0129867755
, O 0 0.00032812942
the O 0 0.00015132535
amount O 0 0.00010688052
of O 0 0.0002200612
daily O 0 0.0003484461
urinary O 0 0.11522267
protein O 0 0.0007946433
increased O 0 0.00030842482
rapidly O 0 0.00029689254
up O 0 0.00018681641
to O 0 0.00019210254
12 O 0 0.00021632758
. O 0 0.0002765721
8 O 0 0.00037873865
g O 0 0.00081010326
with O 0 0.0011715947
acute B-Disease 0 0.84517926
renal I-Disease 0 0.9810346
failure I-Disease 0 0.8582539
. O 0 0.00899113

After O 0 0.003150909
discontinuing O 0 0.050710917
the O 0 0.0023090523
oral O 0 0.70494044
alendronate B-Chemical 0 0.99991715
, O 0 0.001652815
the O 0 0.000556595
patient O 0 0.0004552983
underwent O 0 0.00033463567
six O 0 0.0002410923
cycles O 0 0.00025791762
of O 0 0.00047498173
hemodialysis O 0 0.050586466
and O 0 0.0006464047
four O 0 0.0006096999
cycles O 0 0.00091142365
of O 0 0.0027316874
LDL O 0 0.9996132
apheresis O 0 0.12945853
. O 0 0.0075663123

Urinary O 0 0.21337567
volume O 0 0.004137586
and O 0 0.0025662733
serum O 0 0.41127443
creatinine B-Chemical 1 0.9983139
levels O 0 0.00078807626
recovered O 0 0.00042291044
to O 0 0.00034196855
the O 0 0.00032464936
normal O 0 0.0004322794
range O 0 0.0003638293
, O 0 0.0004448148
with O 0 0.00045069715
urinary O 0 0.12744597
protein O 0 0.0015521743
disappearing O 0 0.0029984328
completely O 0 0.0008075944
within O 0 0.0009341888
40 O 0 0.0018715184
days O 0 0.0026056103
. O 0 0.0058547156

This O 0 0.005188147
report O 0 0.0034159527
demonstrates O 0 0.001381727
that O 0 0.0010330034
not O 0 0.00092660775
only O 0 0.0011092911
intravenous O 0 0.11054111
, O 0 0.0011899581
but O 0 0.0007453865
also O 0 0.0006440086
oral O 0 0.7108121
bisphosphonates B-Chemical 0 0.99990726
can O 0 0.00087203755
aggravate O 0 0.7733982
proteinuria B-Disease 0 0.99999857
and O 0 0.015592199
acute B-Disease 0 0.98736924
renal I-Disease 0 0.9942041
failure I-Disease 0 0.9155269
. O 0 0.009408522

Serum O 0 0.81690156
- O 0 0.031689122
and O 0 0.0044524656
glucocorticoid O 0 0.975289
- O 0 0.035309207
inducible O 0 0.0044464245
kinase O 0 0.16456674
1 O 0 0.0013148673
in O 0 0.0015448831
doxorubicin B-Chemical 1 0.99972695
- O 0 0.19202372
induced O 0 0.027605437
nephrotic B-Disease 0 0.9999975
syndrome I-Disease 0 0.9808899
. O 0 0.011446308

Doxorubicin B-Chemical 1 0.99994195
- O 0 0.20498095
induced O 0 0.010486284
nephropathy B-Disease 2 0.9999982
leads O 0 0.0018390863
to O 0 0.0010284176
epithelial O 0 0.38363007
sodium B-Chemical 0 0.99993706
channel O 0 0.4639948
( O 0 0.005961476
ENaC O 0 0.9204263
) O 0 0.004800725
- O 0 0.004424736
dependent O 0 0.00056503917
volume B-Disease 0 0.00895215
retention I-Disease 0 0.029373454
and O 0 0.0029198744
renal O 0 0.97185385
fibrosis B-Disease 2 0.99944896
. O 0 0.011947074

The O 0 0.0047057117
aldosterone B-Chemical 0 0.99984884
- O 0 0.06577644
sensitive O 0 0.0022387423
serum O 0 0.5909231
- O 0 0.07134685
and O 0 0.0021683655
glucocorticoid O 0 0.9914294
- O 0 0.1112499
inducible O 0 0.01579564
kinase O 0 0.8560956
SGK1 O 0 0.98518467
has O 0 0.0003506485
been O 0 0.00023675103
shown O 0 0.00014893444
to O 0 0.00014322872
participate O 0 0.00014355716
in O 0 0.00016499794
the O 0 0.00017084785
stimulation O 0 0.00022722721
of O 0 0.00046619034
ENaC O 0 0.7140122
and O 0 0.00037278375
to O 0 0.00023005862
mediate O 0 0.00026106532
renal O 0 0.9620441
fibrosis B-Disease 2 0.99974805
following O 0 0.003061939
mineralocorticoid O 0 0.9983896
and O 0 0.004385929
salt O 0 0.992061
excess O 0 0.013662681
. O 0 0.007862157

The O 0 0.0031134023
present O 0 0.001964379
study O 0 0.0017603666
was O 0 0.0010678814
performed O 0 0.0006574159
to O 0 0.00048751078
elucidate O 0 0.00027679576
the O 0 0.00035857575
role O 0 0.00029980345
of O 0 0.00081661786
SGK1 O 0 0.87596
in O 0 0.00046872933
the O 0 0.00045376536
volume B-Disease 0 0.012728621
retention I-Disease 0 0.03528581
and O 0 0.0016715998
fibrosis B-Disease 2 0.99918646
during O 0 0.0046091694
nephrotic B-Disease 0 0.99999666
syndrome I-Disease 0 0.9574549
. O 0 0.008938919

To O 0 0.0028299168
this O 0 0.0020643019
end O 0 0.0014198013
, O 0 0.002728638
doxorubicin B-Chemical 1 0.9992493
( O 0 0.0020365133
15 O 0 0.00050704
mug O 0 0.0005915967
/ O 0 0.0026244894
g O 0 0.0009908628
body O 0 0.00096550613
wt O 0 0.00037858755
) O 0 0.00065560325
was O 0 0.00020500415
injected O 0 0.00015960025
intravenously O 0 0.00017915314
into O 0 0.00010747206
gene O 0 0.00034842867
- O 0 0.0016594523
targeted O 0 0.00013484934
mice O 0 0.00011788053
lacking O 0 0.00018798928
SGK1 O 0 0.9240245
( O 0 0.0019568347
sgk1 O 0 0.044782013
( O 0 0.007283097
- O 0 0.09561492
/ O 0 0.047760934
- O 0 0.049205262
) O 0 0.0010709552
) O 0 0.0005390666
and O 0 0.00026236087
their O 0 0.00025247232
wild O 0 0.00030692443
- O 0 0.0023753853
type O 0 0.00026741574
littermates O 0 0.00020166916
( O 0 0.00065664
sgk1 O 0 0.007938133
( O 0 0.0018209404
+ O 0 0.005665772
/ O 0 0.01641506
+ O 0 0.008883128
) O 0 0.0059601767
) O 0 0.007442858
. O 0 0.008091613

Doxorubicin B-Chemical 1 0.999785
treatment O 0 0.004688945
resulted O 0 0.0017949562
in O 0 0.0021046347
heavy O 0 0.9891788
proteinuria B-Disease 0 0.9999994
( O 0 0.018220792
> O 0 0.0034520533
100 O 0 0.00079098594
mg O 0 0.017712839
protein O 0 0.00088304834
/ O 0 0.010112029
mg O 0 0.11585083
crea O 0 0.45037198
) O 0 0.0005248845
in O 0 0.000188328
15 O 0 0.00016980065
/ O 0 0.00044414215
44 O 0 0.0002480411
of O 0 0.00023595958
sgk1 O 0 0.008323453
( O 0 0.0015480401
+ O 0 0.007921623
/ O 0 0.020546483
+ O 0 0.00544907
) O 0 0.0006441173
and O 0 0.0002452399
15 O 0 0.00017497543
/ O 0 0.00050315855
44 O 0 0.00025622916
of O 0 0.00024958397
sgk1 O 0 0.015050162
( O 0 0.004873621
- O 0 0.09159561
/ O 0 0.045526978
- O 0 0.028936638
) O 0 0.0004799473
mice O 0 0.00014195716
leading O 0 0.00036147767
to O 0 0.0002853707
severe O 0 0.67553085
nephrotic B-Disease 0 0.9999995
syndrome I-Disease 0 0.94987506
with O 0 0.005985014
ascites B-Disease 0 0.9998186
, O 0 0.027024053
lipidemia B-Disease 0 0.99995065
, O 0 0.0019129523
and O 0 0.0019405142
hypoalbuminemia B-Disease 0 0.99993956
in O 0 0.0015741416
both O 0 0.002303893
genotypes O 0 0.016793163
. O 0 0.0068911808

Plasma O 0 0.77100027
aldosterone B-Chemical 0 0.99977237
levels O 0 0.0025780285
increased O 0 0.002132976
in O 0 0.0020689457
nephrotic B-Disease 0 0.9999914
mice O 0 0.00039988782
of O 0 0.000545865
both O 0 0.00042186395
genotypes O 0 0.0050013964
and O 0 0.00034905318
was O 0 0.00022219995
followed O 0 0.00017220991
by O 0 0.000245903
increased O 0 0.00048868003
SGK1 O 0 0.8434241
protein O 0 0.0014430927
expression O 0 0.00055727107
in O 0 0.00049726636
sgk1 O 0 0.02093369
( O 0 0.0024463863
+ O 0 0.0073207784
/ O 0 0.01499834
+ O 0 0.0057184678
) O 0 0.0039334917
mice O 0 0.0032757577
. O 0 0.00723074

Urinary O 0 0.8896924
sodium B-Chemical 0 0.9994894
excretion O 0 0.95790285
reached O 0 0.002221845
signficantly O 0 0.04749084
lower O 0 0.0006114286
values O 0 0.00041181606
in O 0 0.00041110575
sgk1 O 0 0.010036527
( O 0 0.0018389191
+ O 0 0.008470284
/ O 0 0.021349987
+ O 0 0.0047976593
) O 0 0.0005689088
mice O 0 0.00014962938
( O 0 0.00034457858
15 O 0 0.00019156934
+ O 0 0.00087072945
/ O 0 0.006619185
- O 0 0.0053871092
5 O 0 0.00017193919
mumol O 0 0.011905499
/ O 0 0.0036094582
mg O 0 0.05250732
crea O 0 0.3149904
) O 0 0.00043637247
than O 0 0.00013144601
in O 0 0.00018087227
sgk1 O 0 0.0073856968
( O 0 0.0029965376
- O 0 0.063456684
/ O 0 0.033375103
- O 0 0.024297232
) O 0 0.00045961095
mice O 0 0.00013283202
( O 0 0.00032847965
35 O 0 0.00024007064
+ O 0 0.0013010973
/ O 0 0.009985051
- O 0 0.007360995
5 O 0 0.0001694479
mumol O 0 0.015490917
/ O 0 0.0050467523
mg O 0 0.08162439
crea O 0 0.47839072
) O 0 0.0006265378
and O 0 0.00024159532
was O 0 0.00018304236
associated O 0 0.00018861769
with O 0 0.00020123314
a O 0 0.00023550063
significantly O 0 0.000190033
higher O 0 0.00016444868
body O 0 0.000528629
weight B-Disease 0 0.00102727
gain I-Disease 0 0.00045817008
in O 0 0.0002331872
sgk1 O 0 0.016960924
( O 0 0.002505481
+ O 0 0.0118442485
/ O 0 0.026450938
+ O 0 0.005711591
) O 0 0.00049415533
compared O 0 0.00012394505
with O 0 0.00022840299
sgk1 O 0 0.013659031
( O 0 0.004044096
- O 0 0.07068302
/ O 0 0.03340434
- O 0 0.024029156
) O 0 0.00045781684
mice O 0 0.00013243363
( O 0 0.0004123621
+ O 0 0.00073916605
6 O 0 0.00014750108
. O 0 0.00015086171
6 O 0 0.00014684713
+ O 0 0.00056521967
/ O 0 0.0046749352
- O 0 0.0063627507
0 O 0 0.0002513823
. O 0 0.00017092704
7 O 0 0.00015858554
vs O 0 0.00023972207
. O 0 0.00021451473
+ O 0 0.0005330556
4 O 0 0.00023015909
. O 0 0.0002543896
1 O 0 0.00033317233
+ O 0 0.00093982933
/ O 0 0.0038485643
- O 0 0.0045547164
0 O 0 0.0009206719
. O 0 0.001033272
8 O 0 0.0015565628
g O 0 0.0033757826
) O 0 0.0058465395
. O 0 0.0079557225

During O 0 0.0027316215
the O 0 0.002071018
course O 0 0.0016729111
of O 0 0.0044626943
nephrotic B-Disease 0 0.99999857
syndrome I-Disease 0 0.983973
, O 0 0.012467835
serum O 0 0.91398257
urea B-Chemical 1 0.9999658
concentrations O 0 0.009511441
increased O 0 0.00040607635
significantly O 0 0.00025370295
faster O 0 0.00018867255
in O 0 0.00020867743
sgk1 O 0 0.0128240865
( O 0 0.0044428753
- O 0 0.08386699
/ O 0 0.04059777
- O 0 0.025169736
) O 0 0.0004092993
mice O 0 0.00011584022
than O 0 0.00012514644
in O 0 0.00018033019
sgk1 O 0 0.008305498
( O 0 0.0019779257
+ O 0 0.012343202
/ O 0 0.032405384
+ O 0 0.007303667
) O 0 0.0005421263
mice O 0 0.00012455191
leading O 0 0.00037899616
to O 0 0.00029545135
uremia B-Disease 0 0.9999697
and O 0 0.00040698375
a O 0 0.00022964855
reduced O 0 0.0001399675
median O 0 0.00011398655
survival O 0 0.0038621891
in O 0 0.00021025163
sgk1 O 0 0.017573096
( O 0 0.0052325116
- O 0 0.09055323
/ O 0 0.04263302
- O 0 0.028977476
) O 0 0.00049234147
mice O 0 0.00014540806
( O 0 0.00034943147
29 O 0 0.00033210363
vs O 0 0.00026266222
. O 0 0.00018342567
40 O 0 0.00018930741
days O 0 0.00016688573
in O 0 0.00027363037
sgk1 O 0 0.0035484268
( O 0 0.0014272783
+ O 0 0.005192234
/ O 0 0.013561013
+ O 0 0.0048876544
) O 0 0.0028467658
mice O 0 0.0021531836
) O 0 0.006199823
. O 0 0.0077799475

In O 0 0.0037385747
conclusion O 0 0.0023128605
, O 0 0.0029052205
gene O 0 0.0028216909
- O 0 0.0044716774
targeted O 0 0.00061831874
mice O 0 0.00042273733
lacking O 0 0.00047035725
SGK1 O 0 0.8471682
showed O 0 0.0005500053
blunted O 0 0.034069814
volume B-Disease 0 0.09953955
retention I-Disease 0 0.13027245
, O 0 0.0007451855
yet O 0 0.00040805695
were O 0 0.00024056098
not O 0 0.00022671693
protected O 0 0.0003749298
against O 0 0.0006597375
renal O 0 0.9823302
fibrosis B-Disease 2 0.99964714
during O 0 0.0013717631
experimental O 0 0.025385499
nephrotic B-Disease 0 0.99999714
syndrome I-Disease 0 0.9632183
. O 0 0.00881675

Severe O 0 0.96761435
thrombocytopenia B-Disease 0 0.9999671
and O 0 0.07791439
haemolytic B-Disease 0 0.9999887
anaemia I-Disease 0 0.99999917
associated O 0 0.013299274
with O 0 0.010181223
ciprofloxacin B-Chemical 1 0.9999876
: O 0 0.0034572738
a O 0 0.0010093201
case O 0 0.0010305351
report O 0 0.0022311737
with O 0 0.002418903
fatal O 0 0.9621275
outcome O 0 0.023149464
. O 0 0.007667416

Haematological O 0 0.9659818
adverse O 0 0.48100138
reactions O 0 0.017235514
associated O 0 0.0019893823
with O 0 0.0018649404
fatal O 0 0.9475314
outcome O 0 0.0039200946
are O 0 0.0010196529
rare O 0 0.00200792
during O 0 0.0010402456
treatment O 0 0.0022504893
with O 0 0.005830774
ciprofloxacin B-Chemical 1 0.9999044
. O 0 0.011057342

A O 0 0.032676026
30 O 0 0.0030363724
- O 0 0.0040453062
year O 0 0.0015333126
old O 0 0.0015354501
Caucasian O 0 0.19037314
man O 0 0.02923795
reported O 0 0.0007175092
with O 0 0.00056713755
abdominal B-Disease 0 0.07856537
pain I-Disease 0 0.9297956
and O 0 0.0006956877
jaundice B-Disease 2 0.9988827
after O 0 0.00022112251
3 O 0 0.0002453489
- O 0 0.0010221711
day O 0 0.00019127675
administration O 0 0.0008476272
of O 0 0.000567103
oral O 0 0.75357515
ciprofloxacin B-Chemical 1 0.99997675
for O 0 0.0006093996
a O 0 0.0007631693
suspect O 0 0.002135514
of O 0 0.0019763159
urinary B-Disease 0 0.74625945
tract I-Disease 0 0.25358203
infection I-Disease 2 0.99189454
. O 0 0.011601379

Clinical O 0 0.008609881
evaluations O 0 0.0031011428
suggested O 0 0.0023084593
an O 0 0.002337738
initial O 0 0.0018276473
diagnosis O 0 0.0045757797
of O 0 0.0038782929
severe O 0 0.89079696
thrombocytopenia B-Disease 0 0.9999856
and O 0 0.0828052
haemolysis B-Disease 0 0.99998283
. O 0 0.015136526

The O 0 0.004216557
patient O 0 0.0034060278
progressively O 0 0.0032085732
developed O 0 0.004793986
petechiae B-Disease 0 0.99809057
and O 0 0.0067052003
purpura B-Disease 0 0.99991906
on O 0 0.0016594619
thorax O 0 0.028671946
and O 0 0.0031035997
lower O 0 0.004268317
limbs O 0 0.07126632
. O 0 0.00916372

Despite O 0 0.0040722447
pharmacological O 0 0.008754073
and O 0 0.0021179705
supportive O 0 0.0020146344
interventions O 0 0.0011630157
, O 0 0.0010712448
laboratory O 0 0.0009028342
parameters O 0 0.0007439931
worsened O 0 0.007962805
and O 0 0.000573656
the O 0 0.000532242
patient O 0 0.00072493654
died O 0 0.0014605102
17 O 0 0.0011222179
hours O 0 0.0011279271
after O 0 0.001761126
admission O 0 0.0062141973
. O 0 0.0063719577

An O 0 0.0073916037
accurate O 0 0.005324732
autopsy O 0 0.010426591
revealed O 0 0.0031456833
most O 0 0.003523028
organs O 0 0.0060277255
with O 0 0.0044904603
diffuse O 0 0.57026356
petechial O 0 0.9990374
haemorrhages B-Disease 0 0.9999509
. O 0 0.014951763

No O 0 0.011291361
signs O 0 0.017201535
of O 0 0.006970809
bone B-Disease 0 0.14549348
marrow I-Disease 0 0.5014657
depression I-Disease 0 0.9993729
were O 0 0.008160802
found O 0 0.008915891
. O 0 0.014322294

No O 0 0.012230417
thrombi B-Disease 2 0.9846735
or O 0 0.004588553
signs O 0 0.10605193
of O 0 0.0063140467
microangiopathies B-Disease 0 0.99991024
were O 0 0.0025748413
observed O 0 0.002327366
in O 0 0.0035716305
arterial O 0 0.37611547
vessels O 0 0.074911945
. O 0 0.009860152

Blood O 0 0.03198528
and O 0 0.005870565
urine O 0 0.07972143
cultures O 0 0.0035945864
did O 0 0.0030201392
not O 0 0.0024316066
show O 0 0.0025248036
any O 0 0.0034736902
bacterial O 0 0.0092997495
growth O 0 0.029252011
. O 0 0.01317521

This O 0 0.004933603
case O 0 0.0026734052
report O 0 0.0024027524
shows O 0 0.00092457363
that O 0 0.0011185921
ciprofloxacin B-Chemical 1 0.9999509
may O 0 0.00087838963
precipitate O 0 0.023745794
life O 0 0.0022750401
- O 0 0.051418733
threatening O 0 0.17052777
thrombocytopenia B-Disease 0 0.99999356
and O 0 0.030567124
haemolytic B-Disease 0 0.99999774
anaemia I-Disease 0 0.9999999
, O 0 0.0061117327
even O 0 0.00039817038
in O 0 0.00020388057
the O 0 0.00020224934
early O 0 0.00035731707
phases O 0 0.00038199296
of O 0 0.00040667522
treatment O 0 0.0005271019
and O 0 0.0006094127
without O 0 0.00074137904
apparent O 0 0.0013123301
previous O 0 0.0023273428
exposures O 0 0.12349628
. O 0 0.0073073455

Alpha B-Chemical 0 0.9631154
- I-Chemical 0 0.70291424
lipoic I-Chemical 0 0.9999789
acid I-Chemical 0 0.9869905
prevents O 0 0.007874865
mitochondrial B-Disease 0 0.9974927
damage I-Disease 0 0.99933296
and O 0 0.028449722
neurotoxicity B-Disease 2 0.9999714
in O 0 0.0022377367
experimental O 0 0.003936445
chemotherapy O 0 0.7508513
neuropathy B-Disease 0 0.99993575
. O 0 0.009984871

The O 0 0.0032257652
study O 0 0.0027068995
investigates O 0 0.0021636803
if O 0 0.0015731173
alpha B-Chemical 1 0.9847312
- I-Chemical 1 0.9294151
lipoic I-Chemical 1 0.99999845
acid I-Chemical 1 0.99656796
is O 0 0.001776273
neuroprotective O 0 0.35369194
against O 0 0.00048308756
chemotherapy O 0 0.26066554
induced O 0 0.005614848
neurotoxicity B-Disease 2 0.99999785
, O 0 0.0063579893
if O 0 0.00034278084
mitochondrial B-Disease 0 0.9885322
damage I-Disease 0 0.9925504
plays O 0 0.00021407117
a O 0 0.00024072731
critical O 0 0.00012808914
role O 0 0.00012500498
in O 0 0.00034410032
toxic B-Disease 0 0.9825782
neurodegenerative I-Disease 0 0.9954122
cascade I-Disease 0 0.0258291
, O 0 0.000565304
and O 0 0.00027053463
if O 0 0.00017722625
neuroprotective O 0 0.07891479
effects O 0 0.0004894319
of O 0 0.0015994604
alpha B-Chemical 1 0.99135053
- I-Chemical 1 0.9264162
lipoic I-Chemical 1 0.99999547
acid I-Chemical 1 0.94477415
depend O 0 0.0010991091
on O 0 0.0012332657
mitochondria O 0 0.02706069
protection O 0 0.02068035
. O 0 0.007907277

We O 0 0.0035105338
used O 0 0.0021986042
an O 0 0.0019085729
in O 0 0.0012053227
vitro O 0 0.0011288277
model O 0 0.0008134573
of O 0 0.0009891858
chemotherapy O 0 0.16890603
induced O 0 0.0025565675
peripheral B-Disease 2 0.9855585
neuropathy I-Disease 2 0.9999995
that O 0 0.00026723556
closely O 0 0.00022786224
mimic O 0 0.00014887638
the O 0 0.00016352112
in O 0 0.00016255697
vivo O 0 0.0002671777
condition O 0 0.0003899037
by O 0 0.00018175397
exposing O 0 0.00052529183
primary O 0 0.00020234752
cultures O 0 0.00018426692
of O 0 0.0002284474
dorsal O 0 0.0018786337
root O 0 0.0042409734
ganglion O 0 0.7246448
( O 0 0.00070889236
DRG O 0 0.0351823
) O 0 0.0004467891
sensory O 0 0.00057588867
neurons O 0 0.00038960832
to O 0 0.00018794053
paclitaxel B-Chemical 1 0.9916653
and O 0 0.001798577
cisplatin B-Chemical 1 0.99974066
, O 0 0.0005944188
two O 0 0.00023407377
widely O 0 0.0003148231
used O 0 0.0003296203
and O 0 0.0005626509
highly O 0 0.00096835924
effective O 0 0.0016725223
chemotherapeutic O 0 0.42510834
drugs O 0 0.5266828
. O 0 0.007125517

This O 0 0.004313453
approach O 0 0.0021474038
allowed O 0 0.0013482595
investigating O 0 0.0008815322
the O 0 0.0007365306
efficacy O 0 0.001069266
of O 0 0.0021197624
alpha B-Chemical 1 0.9951775
- I-Chemical 1 0.955002
lipoic I-Chemical 1 0.9999989
acid I-Chemical 1 0.9926127
in O 0 0.00060436275
preventing O 0 0.0037858083
axonal B-Disease 0 0.96205634
damage I-Disease 0 0.9977841
and O 0 0.0018935502
apoptosis O 0 0.8953182
and O 0 0.00033238172
the O 0 0.00015704343
function O 0 0.00015129276
and O 0 0.00019835132
ultrastructural O 0 0.0050919494
morphology O 0 0.000830017
of O 0 0.00030850712
mitochondria O 0 0.011711521
after O 0 0.00015988617
exposure O 0 0.0011854763
to O 0 0.00033873427
toxic O 0 0.5992001
agents O 0 0.025956273
and O 0 0.0028099474
alpha B-Chemical 1 0.9817135
- I-Chemical 1 0.9178854
lipoic I-Chemical 1 0.9999893
acid I-Chemical 1 0.9905501
. O 0 0.010599057

Our O 0 0.003333347
results O 0 0.0017970479
demonstrate O 0 0.0009700311
that O 0 0.00094065344
both O 0 0.0014136219
cisplatin B-Chemical 1 0.9997918
and O 0 0.0069937776
paclitaxel B-Chemical 1 0.9990773
cause O 0 0.0026521992
early O 0 0.014516904
mitochondrial B-Disease 0 0.99606305
impairment I-Disease 0 0.98757833
with O 0 0.000481372
loss O 0 0.0005507423
of O 0 0.00033663266
membrane O 0 0.0014164817
potential O 0 0.00038015808
and O 0 0.00041941172
induction O 0 0.0004620218
of O 0 0.0008383911
autophagic O 0 0.044012763
vacuoles O 0 0.0039109266
in O 0 0.0025072142
neurons O 0 0.0064929184
. O 0 0.0064276303

Alpha B-Chemical 0 0.97556907
- I-Chemical 0 0.7869923
lipoic I-Chemical 0 0.9999863
acid I-Chemical 0 0.98833966
exerts O 0 0.006485126
neuroprotective O 0 0.64350474
effects O 0 0.0011893802
against O 0 0.00060149067
chemotherapy O 0 0.27470386
induced O 0 0.004454931
neurotoxicity B-Disease 2 0.99999547
in O 0 0.00066256226
sensory O 0 0.00809872
neurons O 0 0.0015517755
: O 0 0.00042220953
it O 0 0.00018816916
rescues O 0 0.00027463766
the O 0 0.00044302497
mitochondrial B-Disease 0 0.99539137
toxicity I-Disease 2 0.9999807
and O 0 0.00044932077
induces O 0 0.00016177671
the O 0 0.00018747376
expression O 0 0.00028096614
of O 0 0.001001418
frataxin O 0 0.9963762
, O 0 0.00089557853
an O 0 0.0003030462
essential O 0 0.00027948155
mitochondrial O 0 0.101024814
protein O 0 0.0012116226
with O 0 0.0008801641
anti O 0 0.4366139
- O 0 0.18118845
oxidant O 0 0.9937534
and O 0 0.0024305542
chaperone O 0 0.0073323934
properties O 0 0.0043944325
. O 0 0.0067486456

In O 0 0.0040035164
conclusion O 0 0.0031365366
mitochondrial B-Disease 0 0.99100155
toxicity I-Disease 2 0.9999633
is O 0 0.0021139255
an O 0 0.0011818104
early O 0 0.0012591189
common O 0 0.0010064639
event O 0 0.0026868212
both O 0 0.0006798782
in O 0 0.0010085808
paclitaxel B-Chemical 1 0.998021
and O 0 0.009282215
cisplatin B-Chemical 1 0.9998869
induced O 0 0.05900809
neurotoxicity B-Disease 2 0.999977
. O 0 0.012715833

Alpha B-Chemical 0 0.96716714
- I-Chemical 0 0.7021411
lipoic I-Chemical 0 0.99997866
acid I-Chemical 0 0.96925116
protects O 0 0.0038056036
sensory O 0 0.011804028
neurons O 0 0.001279851
through O 0 0.00034494343
its O 0 0.000952502
anti O 0 0.36828324
- O 0 0.2026639
oxidant O 0 0.99734664
and O 0 0.0010762541
mitochondrial O 0 0.14702934
regulatory O 0 0.0004831379
functions O 0 0.00039991454
, O 0 0.00058685354
possibly O 0 0.0007914011
inducing O 0 0.00094405224
the O 0 0.0009624083
expression O 0 0.0017774436
of O 0 0.0050618355
frataxin O 0 0.9919613
. O 0 0.010232567

These O 0 0.0034849257
findings O 0 0.0025556944
suggest O 0 0.0013232372
that O 0 0.0016491933
alpha B-Chemical 1 0.98943186
- I-Chemical 1 0.94436234
lipoic I-Chemical 1 0.99999833
acid I-Chemical 1 0.9923423
might O 0 0.00039796412
reduce O 0 0.00023532758
the O 0 0.00029507806
risk O 0 0.027336154
of O 0 0.00055138837
developing O 0 0.036933515
peripheral B-Disease 0 0.23862296
nerve I-Disease 0 0.5574487
toxicity I-Disease 2 0.9994293
in O 0 0.00031206163
patients O 0 0.00040121668
undergoing O 0 0.00032118722
chemotherapy O 0 0.0033277182
and O 0 0.00043567544
encourage O 0 0.00056199596
further O 0 0.00077225704
confirmatory O 0 0.013279879
clinical O 0 0.0041291886
trials O 0 0.0035043892
. O 0 0.0060186503

Toxicity B-Disease 0 0.8386733
in O 0 0.0025760676
rhesus O 0 0.0019195734
monkeys O 0 0.0014157223
following O 0 0.000760246
administration O 0 0.0017895194
of O 0 0.00059412076
the O 0 0.00046290795
8 B-Chemical 0 0.00045130588
- I-Chemical 0 0.009719752
aminoquinoline I-Chemical 0 0.8436903
8 B-Chemical 0 0.0004033752
- I-Chemical 0 0.006445982
[ I-Chemical 0 0.0017590297
( I-Chemical 0 0.00051211263
4 I-Chemical 0 0.0002681669
- I-Chemical 0 0.008415783
amino I-Chemical 0 0.8873732
- I-Chemical 0 0.09331516
l I-Chemical 0 0.03495075
- I-Chemical 0 0.12321466
methylbutyl I-Chemical 0 0.7743286
) I-Chemical 0 0.0051924144
amino I-Chemical 0 0.9458159
] I-Chemical 0 0.017522817
- I-Chemical 0 0.0124655105
5 I-Chemical 0 0.0002374706
- I-Chemical 0 0.0020639726
( I-Chemical 0 0.0004785925
l I-Chemical 0 0.006607406
- I-Chemical 0 0.05310223
hexyloxy I-Chemical 0 0.8058924
) I-Chemical 0 0.0032844637
- I-Chemical 0 0.0125201885
6 I-Chemical 0 0.00036753927
- I-Chemical 0 0.02836366
methoxy I-Chemical 0 0.99909866
- I-Chemical 0 0.026077913
4 I-Chemical 0 0.0007759454
- I-Chemical 0 0.0062905215
methylquinoline I-Chemical 0 0.19938532
( O 0 0.0072467737
WR242511 B-Chemical 1 0.99794215
) O 0 0.008965562
. O 0 0.0083084125

INTRODUCTION O 0 0.01085882
: O 0 0.0042276075
Many O 0 0.0025234926
substances O 0 0.041888475
that O 0 0.0013055165
form O 0 0.0020703294
methemoglobin O 0 0.9999901
( O 0 0.022892516
MHb O 0 0.98547345
) O 0 0.0016603249
effectively O 0 0.0010641535
counter O 0 0.043017697
cyanide O 0 0.9999759
( O 0 0.035224646
CN O 0 0.99514765
) O 0 0.024602834
toxicity B-Disease 2 0.99705553
. O 0 0.009554488

Although O 0 0.0045646746
MHb O 0 0.91060865
formers O 0 0.4916319
are O 0 0.0013433888
generally O 0 0.0009431793
applied O 0 0.0005599877
as O 0 0.00048216924
treatments O 0 0.00079548394
for O 0 0.0011367524
CN O 0 0.99974996
poisoning B-Disease 2 0.99999774
, O 0 0.0028776089
it O 0 0.00037377904
has O 0 0.00020561885
been O 0 0.00018784702
proposed O 0 0.00019229185
that O 0 0.00016665229
a O 0 0.00028015915
stable O 0 0.00035453553
, O 0 0.00037708538
long O 0 0.00033816003
- O 0 0.0048608067
acting O 0 0.001617452
MHb O 0 0.95617527
former O 0 0.00404997
could O 0 0.000457556
serve O 0 0.0007560494
as O 0 0.0010788414
a O 0 0.002836094
CN O 0 0.97914356
pretreatment O 0 0.24890108
. O 0 0.0074669174

Using O 0 0.003518846
this O 0 0.0022520337
rationale O 0 0.0018334439
, O 0 0.001749607
the O 0 0.0010546905
8 B-Chemical 0 0.0010629377
- I-Chemical 0 0.047233574
aminoquinoline I-Chemical 0 0.99175125
WR242511 B-Chemical 1 0.99975103
, O 0 0.0008897434
a O 0 0.00042501118
potent O 0 0.0006727422
long O 0 0.0003067413
- O 0 0.003780052
lasting O 0 0.0004532492
MHb O 0 0.9432277
former O 0 0.005392196
in O 0 0.00020803121
rodents O 0 0.0006081463
and O 0 0.00027332295
beagle O 0 0.0031039477
dogs O 0 0.000608204
, O 0 0.0003113404
was O 0 0.00018344929
studied O 0 0.00018650599
in O 0 0.00016921491
the O 0 0.00018598515
rhesus O 0 0.00028580526
monkey O 0 0.0011660052
for O 0 0.00034760733
advanced O 0 0.0030266435
development O 0 0.00093836273
as O 0 0.0006687654
a O 0 0.0012293303
potential O 0 0.00287544
CN O 0 0.9902693
pretreatment O 0 0.34138808
. O 0 0.0073418254

METHODS O 0 0.0039804373
: O 0 0.0035932816
In O 0 0.0019621984
this O 0 0.0015185456
study O 0 0.0017899531
, O 0 0.0030822868
WR242511 B-Chemical 1 0.9980101
was O 0 0.0006414185
administered O 0 0.00042428353
intravenously O 0 0.0005730879
( O 0 0.0009312157
IV O 0 0.20567557
) O 0 0.0005778435
in O 0 0.00022506586
2 O 0 0.00020266131
female O 0 0.0004221009
and O 0 0.00021160473
4 O 0 0.00015549171
male O 0 0.00031826945
rhesus O 0 0.00017728643
monkeys O 0 0.00019940107
in O 0 0.00015497276
doses O 0 0.0005684527
of O 0 0.0002444229
3 O 0 0.00015775484
. O 0 0.00013750272
5 O 0 0.00012615407
and O 0 0.00017889639
/ O 0 0.00074949354
or O 0 0.00018192807
7 O 0 0.00015345904
. O 0 0.00015265359
0 O 0 0.00020896178
mg O 0 0.005293743
/ O 0 0.0010439741
kg O 0 0.00080848293
; O 0 0.00038005048
a O 0 0.00023205782
single O 0 0.00020423662
male O 0 0.0006312239
also O 0 0.00020832238
received O 0 0.00028649523
WR242511 B-Chemical 1 0.99872977
orally O 0 0.0062870723
( O 0 0.0016609493
PO O 0 0.9254661
) O 0 0.000643006
at O 0 0.00033885165
7 O 0 0.00042189288
. O 0 0.0005990089
0 O 0 0.0011145322
mg O 0 0.007820587
/ O 0 0.004842872
kg O 0 0.0075895465
. O 0 0.007526717

Health O 0 0.0075610937
status O 0 0.005544214
and O 0 0.005213118
MHb O 0 0.71725625
levels O 0 0.003300157
were O 0 0.0032992798
monitored O 0 0.0032001783
following O 0 0.0046042963
exposure O 0 0.013574454
. O 0 0.012770017

RESULTS O 0 0.005429167
: O 0 0.0033420236
The O 0 0.001491258
selected O 0 0.0011815951
doses O 0 0.003721525
of O 0 0.0036774415
WR242511 B-Chemical 1 0.9997509
, O 0 0.0015365141
which O 0 0.00060571014
produced O 0 0.00037843944
significant O 0 0.001539701
methemoglobinemia B-Disease 0 0.9999962
in O 0 0.00051533297
beagle O 0 0.007425023
dogs O 0 0.0004942325
in O 0 0.00017211241
earlier O 0 0.00016965177
studies O 0 0.00015310096
conducted O 0 0.00015424861
elsewhere O 0 0.00027443818
, O 0 0.00021988606
produced O 0 0.00015190915
very O 0 0.00029891048
little O 0 0.00030409097
MHb O 0 0.9283817
( O 0 0.0002865788
mean O 0 0.00014208785
< O 0 0.00022105314
2 O 0 0.0002641915
. O 0 0.00030400892
0 O 0 0.00045245577
% O 0 0.0006712736
) O 0 0.0010477134
in O 0 0.0010589473
the O 0 0.0016331513
rhesus O 0 0.0033458867
monkey O 0 0.0098736435
. O 0 0.007823444

Furthermore O 0 0.005008198
, O 0 0.0048395363
transient O 0 0.14810614
hemoglobinuria B-Disease 0 0.9998754
was O 0 0.0011290455
noted O 0 0.0004425227
approximately O 0 0.00033304276
60 O 0 0.00027094712
minutes O 0 0.00019957342
postinjection O 0 0.0003545734
of O 0 0.00039204684
WR242511 B-Chemical 1 0.997832
( O 0 0.0005683759
3 O 0 0.0001851897
. O 0 0.00015683423
5 O 0 0.000136915
or O 0 0.00014478863
7 O 0 0.00014664899
. O 0 0.00015407514
0 O 0 0.00020979905
mg O 0 0.005116003
/ O 0 0.0011590222
kg O 0 0.0010996441
) O 0 0.00057439215
, O 0 0.0003159127
and O 0 0.0002737034
2 O 0 0.00025753528
lethalities O 0 0.76360494
occurred O 0 0.00028433546
( O 0 0.00044517725
one O 0 0.00024067338
IV O 0 0.05898655
and O 0 0.00027686814
one O 0 0.00028784035
PO O 0 0.85772175
) O 0 0.00045081382
following O 0 0.00020724622
the O 0 0.00026748562
7 O 0 0.00031367622
. O 0 0.00042563965
0 O 0 0.0007531565
mg O 0 0.0076862937
/ O 0 0.0033244588
kg O 0 0.0050740396
dose O 0 0.009055118
. O 0 0.007314433

Myoglobinuria B-Disease 0 0.9964497
was O 0 0.0033715933
also O 0 0.0019853897
observed O 0 0.0014092836
following O 0 0.0011006341
the O 0 0.0010790238
7 O 0 0.0010148474
. O 0 0.001115739
0 O 0 0.001602584
mg O 0 0.011783305
/ O 0 0.005015559
kg O 0 0.006969604
dose O 0 0.011866896
. O 0 0.0095224185

Histopathology O 0 0.030135596
analyses O 0 0.0024494403
in O 0 0.0016625694
the O 0 0.0011653312
2 O 0 0.0008366222
animals O 0 0.0005157193
that O 0 0.0004290845
died O 0 0.0009711489
revealed O 0 0.0005200201
liver B-Disease 0 0.6738062
and I-Disease 0 0.0032811656
kidney I-Disease 0 0.98458993
toxicity I-Disease 2 0.9998797
, O 0 0.0015488062
with O 0 0.00042389
greater O 0 0.0003246342
severity O 0 0.0017465682
in O 0 0.00045042892
the O 0 0.00064402306
orally O 0 0.003600996
- O 0 0.004667466
treated O 0 0.002539515
animal O 0 0.0054966356
. O 0 0.0066556293

CONCLUSIONS O 0 0.015813403
: O 0 0.004210841
These O 0 0.0022873604
data O 0 0.0017375347
demonstrate O 0 0.00091915677
direct O 0 0.0011464139
and O 0 0.001459601
/ O 0 0.0035570052
or O 0 0.0014913375
indirect O 0 0.008703799
drug O 0 0.80533534
- O 0 0.08444694
induced O 0 0.008575556
toxicity B-Disease 2 0.99921155
. O 0 0.012224577

It O 0 0.004885368
is O 0 0.002774126
concluded O 0 0.002038134
that O 0 0.0017291064
WR242511 B-Chemical 1 0.99795806
should O 0 0.0005947398
not O 0 0.00046950296
be O 0 0.0004273973
pursued O 0 0.00081261207
as O 0 0.0003377343
a O 0 0.0004987636
pretreatment O 0 0.06909731
for O 0 0.0012033129
CN O 0 0.9995999
poisoning B-Disease 2 0.9999937
unless O 0 0.00034384176
the O 0 0.00034182842
anti O 0 0.52952194
- O 0 0.30052474
CN O 0 0.9775529
characteristics O 0 0.00020763587
of O 0 0.0002659137
this O 0 0.0002772929
compound O 0 0.04703434
can O 0 0.00021258875
be O 0 0.00026454814
successfully O 0 0.0003335251
dissociated O 0 0.0004219778
from O 0 0.00050348113
those O 0 0.0009444886
producing O 0 0.0016083868
undesirable O 0 0.22862089
toxicity B-Disease 2 0.9985567
. O 0 0.008637347

Repetitive O 0 0.021791376
transcranial O 0 0.1141143
magnetic O 0 0.010252239
stimulation O 0 0.0027040024
for O 0 0.004256553
levodopa B-Chemical 0 0.9999968
- O 0 0.17446102
induced O 0 0.007997318
dyskinesias B-Disease 2 0.9999958
in O 0 0.004823455
Parkinson B-Disease 0 0.99953234
' I-Disease 0 0.0042564394
s I-Disease 0 0.0049439897
disease I-Disease 0 0.71343356
. O 0 0.009670673

In O 0 0.0042468
a O 0 0.0038150738
placebo O 0 0.07679238
- O 0 0.0055196295
controlled O 0 0.0010097903
, O 0 0.0011668941
single O 0 0.0008810095
- O 0 0.005468266
blinded O 0 0.00063175865
, O 0 0.00057538314
crossover O 0 0.001841389
study O 0 0.00040515183
, O 0 0.00030811565
we O 0 0.00014521866
assessed O 0 0.00014965105
the O 0 0.00017862997
effect O 0 0.0001947589
of O 0 0.00031689488
" O 0 0.00039673405
real O 0 0.00023668015
" O 0 0.00032369187
repetitive O 0 0.0005141138
transcranial O 0 0.08679053
magnetic O 0 0.005068222
stimulation O 0 0.00029923292
( O 0 0.0011877136
rTMS O 0 0.4851601
) O 0 0.0005004561
versus O 0 0.00022385348
" O 0 0.0003845657
sham O 0 0.00029846997
" O 0 0.0006871734
rTMS O 0 0.5113417
( O 0 0.0007635425
placebo O 0 0.01694639
) O 0 0.00035098544
on O 0 0.00013737794
peak O 0 0.00036539036
dose O 0 0.036513958
dyskinesias B-Disease 2 0.99999464
in O 0 0.00035199535
patients O 0 0.00058524706
with O 0 0.0008000336
Parkinson B-Disease 0 0.999382
' I-Disease 0 0.00125352
s I-Disease 0 0.0015365719
disease I-Disease 0 0.89231986
( O 0 0.01826828
PD B-Disease 0 0.9995666
) O 0 0.0087326495
. O 0 0.00784886

Ten O 0 0.0046993555
patients O 0 0.003311311
with O 0 0.0032002786
PD B-Disease 0 0.99941254
and O 0 0.002331706
prominent O 0 0.1865221
dyskinesias B-Disease 2 0.99999595
had O 0 0.0013690372
rTMS O 0 0.66105825
( O 0 0.00063614635
1 O 0 0.00028414198
, O 0 0.00030071265
800 O 0 0.00035454534
pulses O 0 0.00032986864
; O 0 0.0003783969
1 O 0 0.00021923313
Hz O 0 0.0060202936
rate O 0 0.0002174312
) O 0 0.00027780814
delivered O 0 0.00011630198
over O 0 0.00010658893
the O 0 0.00016168001
motor O 0 0.008109441
cortex O 0 0.084965505
for O 0 0.00013493138
4 O 0 0.00010817615
consecutive O 0 9.683596e-05
days O 0 8.873595e-05
twice O 0 0.00010607981
, O 0 0.0001582354
once O 0 0.00010595385
real O 0 0.00012699957
stimuli O 0 0.00020313158
and O 0 0.00017987854
once O 0 0.00012849344
sham O 0 0.00014967931
stimulation O 0 0.00014552096
were O 0 0.00014171386
used O 0 0.0001297863
; O 0 0.00022781186
evaluations O 0 0.0001278468
were O 0 0.00012486154
done O 0 0.000106572974
at O 0 0.00011322984
the O 0 0.00013032925
baseline O 0 0.00015295928
and O 0 0.00018327462
1 O 0 0.00016903463
day O 0 0.00014471107
after O 0 0.00014092031
the O 0 0.0002131573
end O 0 0.00022497315
of O 0 0.00040081487
each O 0 0.00037591005
of O 0 0.0008413642
the O 0 0.0012053262
treatment O 0 0.0023255942
series O 0 0.004365554
. O 0 0.0062836288

Direct O 0 0.005228665
comparison O 0 0.0021903773
between O 0 0.0014559743
sham O 0 0.0014048243
and O 0 0.0010944919
real O 0 0.0010598247
rTMS O 0 0.24690272
effects O 0 0.00065927143
showed O 0 0.00043899473
no O 0 0.00035723665
significant O 0 0.00046856256
difference O 0 0.00042910455
in O 0 0.00071527605
clinician O 0 0.0025085541
- O 0 0.0134986
assessed O 0 0.0028690894
dyskinesia B-Disease 0 0.9999945
severity O 0 0.14011045
. O 0 0.0080577675

However O 0 0.0045571434
, O 0 0.003098311
comparison O 0 0.0014070087
with O 0 0.0010750408
the O 0 0.0007504874
baseline O 0 0.0005926644
showed O 0 0.00043470427
small O 0 0.0004577453
but O 0 0.0005196349
significant O 0 0.0004522014
reduction O 0 0.0014974887
in O 0 0.0016715411
dyskinesia B-Disease 0 0.9999993
severity O 0 0.0155939935
following O 0 0.00053217873
real O 0 0.000988272
rTMS O 0 0.30120745
but O 0 0.0016585783
not O 0 0.002331422
placebo O 0 0.028365616
. O 0 0.0066087465

The O 0 0.00818309
major O 0 0.008322675
effect O 0 0.0075094686
was O 0 0.008673705
on O 0 0.00997688
dystonia B-Disease 2 0.99998033
subscore O 0 0.15693064
. O 0 0.017737038

Similarly O 0 0.005197665
, O 0 0.0034764612
in O 0 0.0017992305
patient O 0 0.0014229171
diaries O 0 0.0012365509
, O 0 0.0009599398
although O 0 0.0005140011
both O 0 0.00040296165
treatments O 0 0.0004980315
caused O 0 0.00033851113
reduction O 0 0.0012149065
in O 0 0.00044681618
subjective O 0 0.038566712
dyskinesia B-Disease 0 0.9999989
scores O 0 0.00021961135
during O 0 0.00011246282
the O 0 0.00013029668
days O 0 0.000108809305
of O 0 0.00018710215
intervention O 0 0.00025564007
, O 0 0.00026656504
the O 0 0.00016633717
effect O 0 0.00018215441
was O 0 0.000194755
sustained O 0 0.0004022631
for O 0 0.00018939155
3 O 0 0.00016675181
days O 0 0.00014521022
after O 0 0.00016615124
the O 0 0.0002777819
intervention O 0 0.0004263316
for O 0 0.00052869355
the O 0 0.00087120786
real O 0 0.0017774418
rTMS O 0 0.27562785
only O 0 0.0038474635
. O 0 0.0066687223

Following O 0 0.0051041604
rTMS O 0 0.46963578
, O 0 0.00281413
no O 0 0.0012868108
side O 0 0.008615418
effects O 0 0.0011879813
and O 0 0.0008235285
no O 0 0.0005196456
adverse O 0 0.1438284
effects O 0 0.0006129409
on O 0 0.00037616352
motor O 0 0.0067984327
function O 0 0.00075189257
and O 0 0.002343431
PD B-Disease 0 0.9997876
symptoms O 0 0.253108
were O 0 0.0023332813
noted O 0 0.0033097817
. O 0 0.0066836895

The O 0 0.002879421
results O 0 0.0017986746
suggest O 0 0.0010273189
the O 0 0.00092484895
existence O 0 0.00073623727
of O 0 0.0007290925
residual O 0 0.00068602397
beneficial O 0 0.0007690133
clinical O 0 0.0036689567
aftereffects O 0 0.033134677
of O 0 0.00031606364
consecutive O 0 0.00022920537
daily O 0 0.00025480593
applications O 0 0.00024835934
of O 0 0.00035697792
low O 0 0.000855151
- O 0 0.010656693
frequency O 0 0.00139749
rTMS O 0 0.61125827
on O 0 0.0013864342
dyskinesias B-Disease 2 0.9999856
in O 0 0.0062371697
PD B-Disease 0 0.9993781
. O 0 0.008120329

The O 0 0.0048603867
effects O 0 0.0042162444
may O 0 0.002803172
be O 0 0.0024901573
further O 0 0.0022260724
exploited O 0 0.0028033336
for O 0 0.002712198
potential O 0 0.0040149163
therapeutic O 0 0.008459731
uses O 0 0.007648881
. O 0 0.01102817

Intracavernous O 0 0.9873073
epinephrine B-Chemical 0 0.99945945
: O 0 0.005102664
a O 0 0.0023794498
minimally O 0 0.0020504212
invasive O 0 0.0027357447
treatment O 0 0.0017788935
for O 0 0.0019266244
priapism B-Disease 0 0.9993425
in O 0 0.0020396954
the O 0 0.0026121528
emergency O 0 0.014921264
department O 0 0.013338043
. O 0 0.008515456

Priapism B-Disease 0 0.9911361
is O 0 0.0033972599
the O 0 0.0020695343
prolonged O 0 0.0023710434
erection O 0 0.13271295
of O 0 0.0013041253
the O 0 0.0010370807
penis O 0 0.004585283
in O 0 0.0009801189
the O 0 0.0010524573
absence O 0 0.0012469176
of O 0 0.0030251732
sexual O 0 0.6014542
arousal O 0 0.789965
. O 0 0.008890251

A O 0 0.04057295
45 O 0 0.003671546
- O 0 0.0059916396
year O 0 0.0020756254
- O 0 0.0044350405
old O 0 0.0013234988
man O 0 0.037445065
, O 0 0.0011013293
an O 0 0.0007232202
admitted O 0 0.0026186474
frequent O 0 0.030383844
cocaine B-Chemical 1 0.9999764
user O 0 0.0006303062
, O 0 0.000340579
presented O 0 0.00018452608
to O 0 0.00016804533
the O 0 0.00021274571
Emergency O 0 0.0014614236
Department O 0 0.0019037819
( O 0 0.00053652946
ED O 0 0.040525977
) O 0 0.00029904646
on O 0 0.00012783705
two O 0 0.00014188638
separate O 0 0.00013971014
occasions O 0 0.00026635878
with O 0 0.00027058157
a O 0 0.0004571235
history O 0 0.0031578722
of O 0 0.0025998706
priapism B-Disease 0 0.99986243
after O 0 0.0017825211
cocaine B-Chemical 1 0.9999367
use O 0 0.004720304
. O 0 0.0065845726

The O 0 0.0032833198
management O 0 0.0025917827
options O 0 0.0018753258
in O 0 0.0012224137
the O 0 0.0010819029
ED O 0 0.13211527
, O 0 0.0007818264
as O 0 0.00040477194
exemplified O 0 0.0005131033
by O 0 0.0002983311
four O 0 0.00018308144
individual O 0 0.0001903692
case O 0 0.00024661253
reports O 0 0.00027124587
, O 0 0.00032831467
in O 0 0.00018988845
particular O 0 0.0001581968
the O 0 0.00017515001
use O 0 0.00018834669
of O 0 0.0002388018
a O 0 0.0002855438
minimally O 0 0.00036974307
invasive O 0 0.0008260403
method O 0 0.00047094474
of O 0 0.0007125858
intracorporal O 0 0.1648064
epinephrine B-Chemical 0 0.9995945
instillation O 0 0.07217826
, O 0 0.0022486525
are O 0 0.0021636353
discussed O 0 0.0032055215
. O 0 0.006152802

Prophylactic O 0 0.02973281
use O 0 0.0037975302
of O 0 0.005526292
lamivudine B-Chemical 1 0.99999094
with O 0 0.013578324
chronic O 0 0.98238474
immunosuppressive O 0 0.9870775
therapy O 0 0.050129753
for O 0 0.005724121
rheumatologic B-Disease 0 0.9995734
disorders I-Disease 0 0.9986254
. O 0 0.00997388

The O 0 0.003087754
objective O 0 0.0027742179
of O 0 0.0017680504
this O 0 0.001176282
study O 0 0.0010151361
was O 0 0.0006091359
to O 0 0.00041495624
report O 0 0.00066255336
our O 0 0.00031203282
experience O 0 0.00029974547
concerning O 0 0.00016713941
the O 0 0.00017589846
effectiveness O 0 0.00016301952
of O 0 0.00022042071
the O 0 0.00020990049
prophylactic O 0 0.0024933454
administration O 0 0.010747252
of O 0 0.0060147773
lamivudine B-Chemical 1 0.99999976
in O 0 0.10912592
hepatitis B-Chemical 2 1.0
B I-Chemical 2 0.9999871
virus I-Chemical 0 0.96499836
surface I-Chemical 0 0.11746253
antigen I-Chemical 0 0.6401813
( O 0 0.048533484
HBs B-Chemical 0 0.9999987
Ag I-Chemical 0 0.9968982
) O 0 0.0042143273
positive O 0 0.0013887931
patients O 0 0.0023101864
with O 0 0.003754725
rheumatologic B-Disease 0 0.99903595
disease I-Disease 0 0.99819857
. O 0 0.009119888

From O 0 0.004528821
June O 0 0.0037107698
2004 O 0 0.0027927933
to O 0 0.0014207981
October O 0 0.0015218129
2006 O 0 0.0014242985
, O 0 0.0011162907
11 O 0 0.0011459898
HBs B-Chemical 0 0.99998224
Ag I-Chemical 0 0.98476034
positive O 0 0.002523004
patients O 0 0.0020456421
with O 0 0.0024109178
rheumatologic B-Disease 0 0.9996113
diseases I-Disease 0 0.99904126
, O 0 0.0016251792
who O 0 0.00046432827
were O 0 0.00018277638
on O 0 0.00013500088
both O 0 0.00023211003
immunosuppressive O 0 0.27917233
and O 0 0.0007420506
prophylactic O 0 0.101467475
lamivudine B-Chemical 1 0.9999976
therapies O 0 0.012950963
, O 0 0.0014876568
were O 0 0.0013093175
retrospectively O 0 0.0020921133
assessed O 0 0.0029419202
. O 0 0.006016717

Liver O 0 0.59838206
function O 0 0.0036832811
tests O 0 0.0070848865
, O 0 0.06879175
hepatitis B-Disease 2 1.0
B I-Disease 2 0.99997747
virus O 0 0.9927268
( O 0 0.24375887
HBV O 0 0.9999908
) O 0 0.045349795
serologic O 0 0.91159683
markers O 0 0.008470645
, O 0 0.0010244547
and O 0 0.0013588624
HBV O 0 0.9999765
DNA O 0 0.62716097
levels O 0 0.0003757741
of O 0 0.00033889912
the O 0 0.00024951115
patients O 0 0.0003140928
during O 0 0.0001862247
follow O 0 0.00024358538
- O 0 0.0010238254
up O 0 0.00036743347
were O 0 0.00045205635
obtained O 0 0.00057644636
from O 0 0.0008652931
hospital O 0 0.0018298154
file O 0 0.0015137654
records O 0 0.004166974
. O 0 0.0062459903

Eleven O 0 0.0076981303
patients O 0 0.0034020608
( O 0 0.0023236314
six O 0 0.0010219136
male O 0 0.0020694043
) O 0 0.001069223
with O 0 0.00049334345
median O 0 0.00031790434
age O 0 0.0005376127
47 O 0 0.00046870206
years O 0 0.00032139057
( O 0 0.00033609942
range O 0 0.0002757259
27 O 0 0.00046041343
- O 0 0.0017562738
73 O 0 0.000509225
) O 0 0.00041027437
, O 0 0.00026352308
median O 0 0.00016107559
disease O 0 0.0942825
duration O 0 0.00014034637
50 O 0 0.00017388702
months O 0 0.00011033875
( O 0 0.00018324913
range O 0 0.00017718722
9 O 0 0.00019971769
- O 0 0.0011765531
178 O 0 0.00094176177
) O 0 0.0002813758
and O 0 0.00016245796
median O 0 0.00011544083
follow O 0 0.00013007535
- O 0 0.00054077076
up O 0 0.00013441015
period O 0 0.00012079215
of O 0 0.00018695128
patients O 0 0.0002796372
13 O 0 0.00019572863
. O 0 0.00015021463
8 O 0 0.00014999794
months O 0 0.00013504813
( O 0 0.00023974465
range O 0 0.00025100796
5 O 0 0.00028753697
- O 0 0.0010190003
27 O 0 0.0005961393
) O 0 0.0007643812
were O 0 0.0007304306
enrolled O 0 0.0012233987
in O 0 0.0013874843
this O 0 0.0022825282
study O 0 0.0045787385
. O 0 0.006927994

Lamivudine B-Chemical 1 0.9999244
therapy O 0 0.012171318
was O 0 0.0021846103
started O 0 0.001539227
3 O 0 0.0010955622
- O 0 0.0018282674
7 O 0 0.0006250955
days O 0 0.00048654288
prior O 0 0.0005065992
to O 0 0.00072436826
immunosuppressive O 0 0.22434801
therapy O 0 0.002238049
in O 0 0.0017209819
all O 0 0.002516634
patients O 0 0.005439616
. O 0 0.007148073

Baseline O 0 0.0059974073
, O 0 0.003922768
liver O 0 0.13380837
function O 0 0.0014125643
tests O 0 0.0014674866
were O 0 0.0006859848
elevated O 0 0.0011329617
in O 0 0.00036233055
two O 0 0.00026038176
patients O 0 0.00039951765
( O 0 0.0004118928
fourth O 0 0.00049669074
patient O 0 0.00038900043
: O 0 0.003532855
ALT O 0 0.99991894
: O 0 0.0015044637
122 O 0 0.0051189233
IU O 0 0.43843678
/ O 0 0.008331208
l O 0 0.009327797
, O 0 0.0027498675
AST O 0 0.9996451
: O 0 0.001244554
111 O 0 0.0038408483
IU O 0 0.34204292
/ O 0 0.0038567206
l O 0 0.0017752757
, O 0 0.0003607255
tenth O 0 0.00044378458
patient O 0 0.0003411953
: O 0 0.0028380638
ALT O 0 0.9999088
: O 0 0.0016875297
294 O 0 0.028313065
IU O 0 0.48999345
/ O 0 0.008734742
l O 0 0.009522838
, O 0 0.0029900002
AST O 0 0.9997117
: O 0 0.0019112473
274 O 0 0.051359806
IU O 0 0.5125842
/ O 0 0.00647202
l O 0 0.0025862344
, O 0 0.00040132224
with O 0 0.00026605825
minimal O 0 0.00026218581
changes O 0 0.00040372027
in O 0 0.00036508671
the O 0 0.0005256142
liver O 0 0.24148624
biopsy O 0 0.003062753
in O 0 0.0013955461
both O 0 0.0023327908
) O 0 0.005812843
. O 0 0.007137894

Shortly O 0 0.033510607
after O 0 0.0021640789
treatment O 0 0.0018059458
their O 0 0.0012028866
tests O 0 0.0010518458
normalized O 0 0.000455332
and O 0 0.00053871376
during O 0 0.0003354646
follow O 0 0.00033152252
- O 0 0.0011391042
up O 0 0.00027998962
period O 0 0.00024304252
none O 0 0.00031024707
of O 0 0.00037817
the O 0 0.00042123103
patients O 0 0.0007588706
had O 0 0.0007463351
abnormal B-Disease 0 0.051178556
liver I-Disease 0 0.55271316
function I-Disease 0 0.0045012445
tests O 0 0.007792838
. O 0 0.0070066308

In O 0 0.005000517
four O 0 0.0031740689
patients O 0 0.005353032
HBV O 0 0.9997061
DNA O 0 0.44935608
levels O 0 0.002089171
were O 0 0.0017034684
higher O 0 0.0015368221
than O 0 0.0014177717
normal O 0 0.0025345082
at O 0 0.0028776885
baseline O 0 0.0047780196
. O 0 0.008018045

Two O 0 0.006094898
of O 0 0.0046425113
these O 0 0.0037057346
normalized O 0 0.0026686494
and O 0 0.0037217103
the O 0 0.0038783685
others O 0 0.0066243983
increased O 0 0.006626978
later O 0 0.007920522
. O 0 0.012662941

In O 0 0.0040785274
three O 0 0.002111392
additional O 0 0.0018113012
patients O 0 0.0025688782
, O 0 0.0041043027
HBV O 0 0.9999049
DNA O 0 0.61198366
levels O 0 0.001494362
were O 0 0.0012405277
increased O 0 0.0013131335
during O 0 0.0013016787
follow O 0 0.0019413399
- O 0 0.006020522
up O 0 0.004723088
. O 0 0.008177159

None O 0 0.007857274
of O 0 0.004399075
the O 0 0.0031205944
patients O 0 0.0030994555
had O 0 0.00221926
significant O 0 0.0023417685
clinical O 0 0.0057734023
sings O 0 0.022395615
of O 0 0.0060757357
HBV O 0 0.9998049
activation O 0 0.07116404
. O 0 0.013352095

Lamivudine B-Chemical 1 0.999876
was O 0 0.005168172
well O 0 0.003293422
tolerated O 0 0.00676603
and O 0 0.0024931189
was O 0 0.0022761032
continued O 0 0.002384701
in O 0 0.0029049127
all O 0 0.003922971
patients O 0 0.0073797633
. O 0 0.009686116

Prophylactic O 0 0.07080166
administration O 0 0.031839475
of O 0 0.008493033
lamivudine B-Chemical 1 0.99999535
in O 0 0.0018753848
patients O 0 0.0014506978
who O 0 0.0007228963
required O 0 0.00027214809
immunosuppressive O 0 0.36566442
therapy O 0 0.0010122156
seems O 0 0.0002566345
to O 0 0.00021399035
be O 0 0.00026903942
safe O 0 0.0004756364
, O 0 0.00039452314
well O 0 0.00033009952
tolerated O 0 0.0014259217
and O 0 0.00052617106
effective O 0 0.000748535
in O 0 0.0010715532
preventing O 0 0.0090502165
HBV O 0 0.99995863
reactivation O 0 0.98312736
. O 0 0.014799793

Effect O 0 0.0043892637
of O 0 0.004490686
green B-Chemical 1 0.8874786
tea I-Chemical 1 0.99998534
and O 0 0.20121068
vitamin B-Chemical 1 0.99999976
E I-Chemical 1 0.9999964
combination O 0 0.040207792
in O 0 0.004358829
isoproterenol B-Chemical 0 0.9999746
induced O 0 0.060360298
myocardial B-Disease 0 0.99999046
infarction I-Disease 2 0.9999993
in O 0 0.008028671
rats O 0 0.009095357
. O 0 0.007242302

The O 0 0.0029853813
present O 0 0.0018668107
study O 0 0.0016709038
was O 0 0.0010195771
aimed O 0 0.0007253339
to O 0 0.00043358954
investigate O 0 0.00023213727
the O 0 0.0002929656
combined O 0 0.00035512578
effects O 0 0.0004236246
of O 0 0.0012221442
green B-Chemical 1 0.96892613
tea I-Chemical 1 0.999998
and O 0 0.12125826
vitamin B-Chemical 1 0.9999999
E I-Chemical 1 0.999998
on O 0 0.00031954676
heart O 0 0.30457905
weight O 0 0.0064535486
, O 0 0.00047268227
body O 0 0.0014002462
weight O 0 0.0028666107
, O 0 0.0005607476
serum O 0 0.13644563
marker O 0 0.00090270984
enzymes O 0 0.03301392
, O 0 0.0026177545
lipid O 0 0.99349976
peroxidation O 0 0.9999994
, O 0 0.0017221898
endogenous O 0 0.00053123716
antioxidants O 0 0.9990734
and O 0 0.00043896705
membrane O 0 0.003476968
bound O 0 0.0002618673
ATPases O 0 0.35200867
in O 0 0.00074456795
isoproterenol B-Chemical 0 0.99996865
( O 0 0.023842992
ISO B-Chemical 0 0.99712354
) O 0 0.008489557
- O 0 0.029308787
induced O 0 0.003914896
myocardial B-Disease 0 0.99997735
infarction I-Disease 2 0.9999989
in O 0 0.0060622813
rats O 0 0.00790813
. O 0 0.0067135673

Adult O 0 0.0076059597
male O 0 0.00781964
albino O 0 0.025854269
rats O 0 0.0026976152
, O 0 0.001563901
treated O 0 0.001084309
with O 0 0.0015195176
ISO B-Chemical 0 0.9913918
( O 0 0.001248383
200 O 0 0.0006700784
mg O 0 0.014435187
/ O 0 0.001198447
kg O 0 0.00072863617
, O 0 0.00033203207
s O 0 0.00034224417
. O 0 0.00023943286
c O 0 0.004044088
. O 0 0.00025397495
) O 0 0.00038577113
for O 0 0.00018057865
2 O 0 0.00015731696
days O 0 0.00010937771
at O 0 0.00012341695
an O 0 0.00015435852
interval O 0 0.0001362773
of O 0 0.00019011888
24 O 0 0.00017727714
h O 0 0.00016520037
caused O 0 0.00015269917
a O 0 0.0002716245
significant O 0 0.00027779728
( O 0 0.0011911382
P O 0 0.12366458
< O 0 0.00022432033
0 O 0 0.00028388985
. O 0 0.00023579632
05 O 0 0.008511258
) O 0 0.0005656465
elevation O 0 0.021889228
of O 0 0.00041935797
heart O 0 0.15027982
weight O 0 0.00499325
, O 0 0.00061929243
serum O 0 0.14172165
marker O 0 0.00083100493
enzymes O 0 0.025844295
, O 0 0.0018209873
lipid O 0 0.9906048
peroxidation O 0 0.9999995
and O 0 0.025304
Ca B-Chemical 1 0.99999595
+ O 0 0.02713998
2 O 0 0.00025974456
ATPase O 0 0.010658171
level O 0 0.00013403961
whereas O 0 0.00017029599
there O 0 0.00011189652
was O 0 0.00016023581
a O 0 0.00021548744
significant O 0 0.00023923663
( O 0 0.0009597766
P O 0 0.10556341
< O 0 0.00022289636
0 O 0 0.00028522845
. O 0 0.0002395299
05 O 0 0.006324614
) O 0 0.00039846616
decrease O 0 0.00019999479
in O 0 0.00020056996
body O 0 0.0007595754
weight O 0 0.0016834552
, O 0 0.00047381906
endogenous O 0 0.00059795345
antioxidants O 0 0.9998752
, O 0 0.04585855
Na B-Chemical 1 0.99999857
+ O 0 0.119416304
/ O 0 0.28014773
K B-Chemical 1 0.99998033
+ O 0 0.07068066
ATPase O 0 0.43287838
and O 0 0.007634956
Mg B-Chemical 0 0.999997
+ O 0 0.012460404
2 O 0 0.001779362
ATPase O 0 0.020979485
levels O 0 0.0039274506
. O 0 0.007105428

Administration O 0 0.031765286
of O 0 0.005864535
green B-Chemical 1 0.9203147
tea I-Chemical 1 0.9999777
( O 0 0.005866139
100 O 0 0.0021347774
mg O 0 0.05979842
/ O 0 0.002552983
kg O 0 0.0014239228
/ O 0 0.0014615933
day O 0 0.00029245153
, O 0 0.0004021805
p O 0 0.00031301842
. O 0 0.00026123392
o O 0 0.006081971
. O 0 0.000298774
) O 0 0.0008968222
and O 0 0.0036287368
vitamin B-Chemical 1 0.9999999
E I-Chemical 1 0.9999981
( O 0 0.00929094
100 O 0 0.0011574142
mg O 0 0.026139747
/ O 0 0.0013334391
kg O 0 0.00083113124
/ O 0 0.0010451981
day O 0 0.00017467601
, O 0 0.00028781232
p O 0 0.00023982837
. O 0 0.00021218153
o O 0 0.008960992
. O 0 0.0002472623
) O 0 0.0003711842
together O 0 0.00016027247
for O 0 0.00014420596
30 O 0 0.000117205105
consecutive O 0 0.000104851475
days O 0 9.726981e-05
and O 0 0.00014787696
challenged O 0 0.00017202923
with O 0 0.0004079391
ISO B-Chemical 0 0.90882564
on O 0 0.00011346503
the O 0 0.00013913063
day O 0 0.00013587053
29th O 0 0.0006347128
and O 0 0.0001964934
30th O 0 0.0006825643
, O 0 0.00023078603
showed O 0 0.00015756137
a O 0 0.0002284642
significant O 0 0.0002456804
( O 0 0.0009672504
P O 0 0.10777818
< O 0 0.00022430427
0 O 0 0.0002871242
. O 0 0.00023885511
05 O 0 0.0073627657
) O 0 0.00041845883
decrease O 0 0.00021030233
in O 0 0.00024363486
heart O 0 0.059010837
weight O 0 0.0030019686
, O 0 0.00055639294
serum O 0 0.12695462
marker O 0 0.00083011144
enzymes O 0 0.028336518
, O 0 0.0023415766
lipid O 0 0.9946091
peroxidation O 0 0.99999976
, O 0 0.0790143
Ca B-Chemical 1 0.99999607
+ O 0 0.029321078
2 O 0 0.00028504414
ATPase O 0 0.017550036
and O 0 0.00022151752
a O 0 0.00021252858
significant O 0 0.00015981116
increase O 0 0.00013433801
in O 0 0.00016443378
the O 0 0.00016675785
body O 0 0.00084955717
weight O 0 0.0020600166
, O 0 0.00044938765
endogenous O 0 0.0005799981
antioxidants O 0 0.99989605
, O 0 0.05365525
Na B-Chemical 1 0.99999905
+ O 0 0.15145257
/ O 0 0.36114255
K B-Chemical 1 0.99999046
+ O 0 0.10890654
ATPase O 0 0.5257209
and O 0 0.011839506
Mg B-Chemical 0 0.99999964
+ O 0 0.025020562
2 O 0 0.00028743857
ATPase O 0 0.009416298
when O 0 0.00012503407
compared O 0 0.00012921816
with O 0 0.0003238169
ISO B-Chemical 0 0.9363387
treated O 0 0.0003575077
group O 0 0.0003888471
and O 0 0.00061543577
green B-Chemical 1 0.83314353
tea I-Chemical 1 0.9999924
or O 0 0.02672911
vitamin B-Chemical 1 0.99999964
E I-Chemical 1 0.99999046
alone O 0 0.0046543544
treated O 0 0.0043440275
groups O 0 0.0038837844
. O 0 0.006176442

These O 0 0.003446667
findings O 0 0.002442871
indicate O 0 0.0011493296
the O 0 0.0010489138
synergistic O 0 0.001349471
protective O 0 0.011503843
effect O 0 0.001063374
of O 0 0.0057756165
green B-Chemical 1 0.9850974
tea I-Chemical 1 0.999998
and O 0 0.18130669
vitamin B-Chemical 1 0.9999999
E I-Chemical 1 0.9999976
during O 0 0.002428585
ISO B-Chemical 0 0.9978993
induced O 0 0.017120797
myocardial B-Disease 0 0.9999851
infarction I-Disease 2 0.99999905
in O 0 0.006198745
rats O 0 0.007897616
. O 0 0.006713761

Irreversible O 0 0.4792626
damage O 0 0.35532692
to O 0 0.0025411036
the O 0 0.002119357
medullary O 0 0.27676177
interstitium O 0 0.022201745
in O 0 0.0015515493
experimental O 0 0.0031962774
analgesic O 0 0.99145037
nephropathy B-Disease 2 0.99999857
in O 0 0.008599638
F344 O 0 0.6470717
rats O 0 0.0076365564
. O 0 0.008173383

Renal B-Disease 0 0.8517346
papillary I-Disease 0 0.9990759
necrosis I-Disease 2 0.9999975
( O 0 0.37845358
RPN B-Disease 2 0.9998068
) O 0 0.004153097
and O 0 0.0009079756
a O 0 0.00074821827
decreased O 0 0.0007585924
urinary O 0 0.29665452
concentrating O 0 0.026126193
ability O 0 0.00027758547
developed O 0 0.00031818118
during O 0 0.00014432329
continuous O 0 0.0001681495
long O 0 0.00023821919
- O 0 0.0015952574
term O 0 0.00022564924
treatment O 0 0.0004661963
with O 0 0.0022352324
aspirin B-Chemical 0 0.9999944
and O 0 0.018197162
paracetamol B-Chemical 0 0.9999938
in O 0 0.0013269032
female O 0 0.01649035
Fischer O 0 0.1086896
344 O 0 0.017588068
rats O 0 0.0047495393
. O 0 0.006423129

Renal O 0 0.037175335
structure O 0 0.003818107
and O 0 0.002215564
concentrating O 0 0.007162687
ability O 0 0.000903625
were O 0 0.00061881513
examined O 0 0.0003548236
after O 0 0.00028563393
a O 0 0.00036940307
recovery O 0 0.00034232964
period O 0 0.00018804772
of O 0 0.00022876545
up O 0 0.00017909864
to O 0 0.00015599573
18 O 0 0.00017728694
weeks O 0 0.000117128686
, O 0 0.00019254304
when O 0 0.000133779
no O 0 0.00017142748
analgesics O 0 0.33395228
were O 0 0.00016262969
given O 0 0.00012355033
, O 0 0.00021539174
to O 0 0.00014764108
investigate O 0 0.00011436967
whether O 0 0.00015954532
the O 0 0.0004188344
analgesic O 0 0.6483959
- O 0 0.0034720663
induced O 0 0.0009847259
changes O 0 0.0020576955
were O 0 0.0025043197
reversible O 0 0.06894457
. O 0 0.0067258645

There O 0 0.0041251695
was O 0 0.0024488822
no O 0 0.0013390877
evidence O 0 0.0009850769
of O 0 0.00096949097
repair O 0 0.0010638604
to O 0 0.0004569804
the O 0 0.00040735654
damaged O 0 0.0043749656
medullary O 0 0.5998672
interstitial O 0 0.37977338
matrix O 0 0.01662783
, O 0 0.00069574715
or O 0 0.00032006903
proliferation O 0 0.34532997
of O 0 0.0003197378
remaining O 0 0.00024998694
undamaged O 0 0.001661824
type O 0 0.00028760743
1 O 0 0.00025022135
medullary O 0 0.09668701
interstitial O 0 0.037935633
cells O 0 0.0003884046
after O 0 0.00023875991
the O 0 0.00035949287
recovery O 0 0.0006207009
period O 0 0.00060615165
following O 0 0.0010563226
analgesic O 0 0.35029712
treatment O 0 0.0034927838
. O 0 0.0059248647

The O 0 0.0031767872
recovery O 0 0.0029001378
of O 0 0.0022762811
urinary O 0 0.40235463
concentrating O 0 0.077310905
ability O 0 0.00077913515
was O 0 0.00052263815
related O 0 0.00026576972
to O 0 0.0002365502
the O 0 0.00021878936
length O 0 0.0002096115
of O 0 0.00041988815
analgesic O 0 0.38383418
treatment O 0 0.00028915456
and O 0 0.00025865025
the O 0 0.00021800934
extent O 0 0.00020758518
of O 0 0.00038737085
the O 0 0.00044935633
resulting O 0 0.00073725777
inner O 0 0.09768568
medullary O 0 0.6427912
structural O 0 0.025116418
damage O 0 0.86122173
. O 0 0.008292853

During O 0 0.0028172035
the O 0 0.0021535002
early O 0 0.0020511243
stages O 0 0.0016339134
of O 0 0.0017373578
analgesic O 0 0.80592066
treatment O 0 0.0010198016
, O 0 0.0006241234
the O 0 0.00030548114
changes O 0 0.00039824384
in O 0 0.0002967952
urinary O 0 0.23805836
concentrating O 0 0.026801849
ability O 0 0.0002448201
were O 0 0.00026788068
reversible O 0 0.027063036
, O 0 0.00046025496
but O 0 0.00026068554
after O 0 0.00014492207
prolonged O 0 0.0005482613
analgesic O 0 0.3140409
treatment O 0 0.00033683507
, O 0 0.00042844357
maximum O 0 0.00040809662
urinary O 0 0.21862875
concentrating O 0 0.019069023
ability O 0 0.0009840028
failed O 0 0.0015347397
to O 0 0.0019592356
recover O 0 0.0037432224
. O 0 0.0062389853

This O 0 0.0049621225
study O 0 0.0025756606
shows O 0 0.0011505701
that O 0 0.0010050911
prolonged O 0 0.0023238966
analgesic O 0 0.7539365
treatment O 0 0.0009708164
in O 0 0.0005600293
Fischer O 0 0.08700337
344 O 0 0.014770203
rats O 0 0.0004386703
causes O 0 0.00039677805
progressive O 0 0.05753507
and O 0 0.0007800351
irreversible O 0 0.3485358
damage O 0 0.6716408
to O 0 0.00022477398
the O 0 0.00025394637
interstitial O 0 0.036779534
matrix O 0 0.0015140785
and O 0 0.0004256234
type O 0 0.0005036687
1 O 0 0.000555259
interstitial O 0 0.010493745
cells O 0 0.001361468
leading O 0 0.002972858
to O 0 0.0035172177
RPN B-Disease 2 0.9968803
. O 0 0.008321261

The O 0 0.0033658622
associated O 0 0.002932313
urinary O 0 0.24217767
concentrating O 0 0.075379424
defect O 0 0.0015125782
is O 0 0.0010741277
reversible O 0 0.028872538
only O 0 0.0005716665
during O 0 0.0003308137
the O 0 0.00037712956
early O 0 0.0005577456
stages O 0 0.0005769207
of O 0 0.00068765716
structural O 0 0.0027074632
damage O 0 0.46251118
to O 0 0.0011137001
the O 0 0.0018329421
inner O 0 0.15524423
medulla O 0 0.73408115
. O 0 0.007426952

Testosterone B-Chemical 1 0.99996865
- O 0 0.12787746
dependent O 0 0.0040221247
hypertension B-Disease 2 0.9999801
and O 0 0.0021023212
upregulation O 0 0.0015677409
of O 0 0.001967257
intrarenal O 0 0.9694979
angiotensinogen O 0 0.9975163
in O 0 0.0030988555
Dahl O 0 0.98297197
salt B-Chemical 0 0.995998
- O 0 0.048945956
sensitive O 0 0.0038876054
rats O 0 0.0059430916
. O 0 0.0074154986

Blood O 0 0.111697584
pressure O 0 0.18692306
( O 0 0.007455857
BP O 0 0.9551587
) O 0 0.0032847088
is O 0 0.0015605896
more O 0 0.0016352845
salt B-Chemical 0 0.94404393
sensitive O 0 0.0013856369
in O 0 0.001165077
men O 0 0.008476631
than O 0 0.0012946515
in O 0 0.0024972123
premenopausal O 0 0.6919059
women O 0 0.026016872
. O 0 0.00915878

In O 0 0.0069178706
Dahl O 0 0.9608485
salt B-Chemical 0 0.9969031
- O 0 0.06685895
sensitive O 0 0.0017356325
rats O 0 0.0021358808
( O 0 0.0031305812
DS O 0 0.9826751
) O 0 0.0023974697
, O 0 0.0009827624
high O 0 0.001921451
- O 0 0.12936115
salt B-Chemical 0 0.9981388
( O 0 0.018131027
HS O 0 0.9395569
) O 0 0.0033223263
diet O 0 0.052653074
increases O 0 0.00089119753
BP O 0 0.93230736
more O 0 0.000880991
in O 0 0.0010162721
males O 0 0.002107255
than O 0 0.0019327448
females O 0 0.005175415
. O 0 0.006883168

In O 0 0.0034893234
contrast O 0 0.0023631563
to O 0 0.0014877064
the O 0 0.0014646677
systemic O 0 0.963178
renin O 0 0.99938595
- O 0 0.7763438
angiotensin B-Chemical 1 0.99998593
system O 0 0.0012354678
, O 0 0.00081186474
which O 0 0.00043090116
is O 0 0.00026298297
suppressed O 0 0.00021900787
in O 0 0.00021025805
response O 0 0.0003367646
to O 0 0.0002619819
HS O 0 0.7515529
in O 0 0.000323803
male O 0 0.023667555
DS O 0 0.9846028
, O 0 0.00090785493
intrarenal O 0 0.8233124
angiotensinogen O 0 0.9830171
expression O 0 0.00041993902
is O 0 0.0003016956
increased O 0 0.0003633165
, O 0 0.00047022835
and O 0 0.00045823818
intrarenal O 0 0.31803232
levels O 0 0.00056215667
of O 0 0.0022484858
ANG O 0 0.999482
II O 0 0.08035671
are O 0 0.001409855
not O 0 0.0019802689
suppressed O 0 0.0038065384
. O 0 0.0070790453

In O 0 0.0037247278
this O 0 0.0024290043
study O 0 0.002097079
, O 0 0.001594375
the O 0 0.0008314434
hypothesis O 0 0.0006957836
was O 0 0.00051437895
tested O 0 0.00033166257
that O 0 0.00026187053
there O 0 0.00022138742
is O 0 0.00031022634
a O 0 0.00047792195
sexual O 0 0.21597217
dimorphism O 0 0.02274535
in O 0 0.0006528747
HS O 0 0.94311106
- O 0 0.014112113
induced O 0 0.00023385002
upregulation O 0 0.00039929795
of O 0 0.00068913156
intrarenal O 0 0.93606937
angiotensinogen O 0 0.9874485
mediated O 0 0.00021248337
by O 0 0.0012707477
testosterone B-Chemical 0 0.999954
that O 0 0.00028405394
also O 0 0.0003445876
causes O 0 0.00059129257
increases O 0 0.0006333967
in O 0 0.0012038768
BP O 0 0.97948265
and O 0 0.0037856516
renal B-Disease 2 0.99887675
injury I-Disease 2 0.9986312
. O 0 0.0093738455

On O 0 0.0037964336
a O 0 0.0035777313
low O 0 0.0045938636
- O 0 0.13211586
salt B-Chemical 0 0.99674255
( O 0 0.01334496
LS O 0 0.29202503
) O 0 0.0030686522
diet O 0 0.06699459
, O 0 0.0012499951
male O 0 0.015186802
DS O 0 0.9319398
had O 0 0.00041734776
higher O 0 0.00037726172
levels O 0 0.00043288825
of O 0 0.00091748004
intrarenal O 0 0.9140278
angiotensinogen O 0 0.9900304
mRNA O 0 0.0027011314
than O 0 0.0021910926
females O 0 0.005915178
. O 0 0.006983958

HS O 0 0.634037
diet O 0 0.02912098
for O 0 0.0017906739
4 O 0 0.0010913023
wk O 0 0.00072057283
increased O 0 0.0008732628
renal O 0 0.7742674
cortical O 0 0.28161737
angiotensinogen O 0 0.9926845
mRNA O 0 0.0009169477
and O 0 0.00053612585
protein O 0 0.0009836269
only O 0 0.0005254105
in O 0 0.0005216286
male O 0 0.024237137
DS O 0 0.97566074
, O 0 0.0011206479
which O 0 0.0010216463
was O 0 0.0011937722
prevented O 0 0.0021264348
by O 0 0.0035544168
castration O 0 0.5126255
. O 0 0.008196758

Ovariectomy O 0 0.95693225
of O 0 0.005804766
female O 0 0.04488553
DS O 0 0.9489135
had O 0 0.0015168706
no O 0 0.0009115691
effect O 0 0.0009122225
on O 0 0.00085134484
intrarenal O 0 0.81457216
angiotensinogen O 0 0.9806246
expression O 0 0.0018133121
on O 0 0.0017213556
either O 0 0.0033060152
diet O 0 0.09898685
. O 0 0.008359344

Radiotelemetric O 0 0.26914358
BP O 0 0.83871186
was O 0 0.0031821309
similar O 0 0.0019379836
between O 0 0.0017971718
males O 0 0.0031567796
and O 0 0.0028852567
castrated O 0 0.06910339
rats O 0 0.0038796894
on O 0 0.0032232776
LS O 0 0.07184498
diet O 0 0.07757988
. O 0 0.010946932

HS O 0 0.6685368
diet O 0 0.036985204
for O 0 0.0018850421
4 O 0 0.0011481905
wk O 0 0.0007296055
caused O 0 0.00070198136
a O 0 0.0008773821
progressive O 0 0.02947706
increase O 0 0.0004820236
in O 0 0.00073173584
BP O 0 0.979038
, O 0 0.0005534387
protein O 0 0.0007389818
and O 0 0.00078557385
albumin O 0 0.99771655
excretion O 0 0.97879887
, O 0 0.00084111246
and O 0 0.0009854406
glomerular B-Disease 2 0.99973184
sclerosis I-Disease 2 0.9999851
in O 0 0.0005304408
male O 0 0.018597383
DS O 0 0.9554922
rats O 0 0.0008205112
, O 0 0.0007031745
which O 0 0.0008048049
were O 0 0.001029291
attenuated O 0 0.0020183302
by O 0 0.0032200422
castration O 0 0.4671829
. O 0 0.007913473

Testosterone B-Chemical 1 0.9999559
replacement O 0 0.05906375
in O 0 0.0038558159
castrated O 0 0.6932743
DS O 0 0.98845273
rats O 0 0.0031447979
increased O 0 0.0025492192
BP O 0 0.99433243
, O 0 0.0062799645
renal B-Disease 2 0.9995573
injury I-Disease 2 0.9993774
, O 0 0.0013183935
and O 0 0.0005242387
upregulation O 0 0.00062722305
of O 0 0.001254919
renal O 0 0.9858301
angiotensinogen O 0 0.99507433
associated O 0 0.0025000896
with O 0 0.003857349
HS O 0 0.8937286
diet O 0 0.22184643
. O 0 0.0075299167

Testosterone B-Chemical 1 0.99984086
contributes O 0 0.002388027
to O 0 0.001552467
the O 0 0.0011571425
development O 0 0.00208968
of O 0 0.0063205366
hypertension B-Disease 2 0.99999857
and O 0 0.021958627
renal B-Disease 2 0.9998505
injury I-Disease 2 0.9996271
in O 0 0.0009915247
male O 0 0.053375762
DS O 0 0.9760124
rats O 0 0.00047945735
on O 0 0.00019878603
HS O 0 0.5564816
diet O 0 0.018831225
possibly O 0 0.00046155832
through O 0 0.00020752642
upregulation O 0 0.00036642165
of O 0 0.0005165728
the O 0 0.0007618458
intrarenal O 0 0.94856995
renin O 0 0.9948796
- O 0 0.30807164
angiotensin B-Chemical 1 0.99987054
system O 0 0.005809259
. O 0 0.00706794

Explicit O 0 0.051850952
episodic O 0 0.945084
memory O 0 0.27109733
for O 0 0.0018726678
sensory O 0 0.011634611
- O 0 0.0076408363
discriminative O 0 0.0033373034
components O 0 0.0006791726
of O 0 0.0020523367
capsaicin B-Chemical 0 0.99996257
- O 0 0.11383007
induced O 0 0.0017232748
pain B-Disease 0 0.9758766
: O 0 0.0017817221
immediate O 0 0.0017036994
and O 0 0.0020205653
delayed O 0 0.0051651695
ratings O 0 0.0057124225
. O 0 0.0070940433

Pain B-Disease 0 0.93350714
memory O 0 0.15952325
is O 0 0.0024705657
thought O 0 0.001564149
to O 0 0.0009998317
affect O 0 0.0007270163
future O 0 0.0009942193
pain B-Disease 0 0.79089427
sensitivity O 0 0.0015665636
and O 0 0.00079859863
thus O 0 0.0008581717
contribute O 0 0.0008140692
to O 0 0.0011927582
clinical O 0 0.008335124
pain B-Disease 0 0.8075852
conditions O 0 0.004408554
. O 0 0.0075204405

Systematic O 0 0.005444788
investigations O 0 0.0031357864
of O 0 0.0023646443
the O 0 0.0016703582
human O 0 0.0016040746
capacity O 0 0.0014134053
to O 0 0.0009764546
remember O 0 0.0015912523
sensory O 0 0.001520764
features O 0 0.0010863743
of O 0 0.0012958673
experimental O 0 0.0022464853
pain B-Disease 0 0.8591486
are O 0 0.0028862115
sparse O 0 0.005607882
. O 0 0.0077918833

In O 0 0.0032930279
order O 0 0.0017040401
to O 0 0.0012154989
address O 0 0.0007223082
long O 0 0.00091165205
- O 0 0.002801705
term O 0 0.0007841513
pain B-Disease 0 0.9621239
memory O 0 0.41319606
, O 0 0.00068191806
nine O 0 0.00031921422
healthy O 0 0.0013125463
male O 0 0.0008058678
volunteers O 0 0.0003381404
received O 0 0.00016144186
intradermal O 0 0.005977428
injections O 0 0.00032663252
of O 0 0.00017674683
three O 0 0.00010415482
doses O 0 0.0008507246
of O 0 0.00095157
capsaicin B-Chemical 0 0.9999232
( O 0 0.0024784938
0 O 0 0.00036472682
. O 0 0.00021738953
05 O 0 0.0050287717
, O 0 0.00025067004
1 O 0 0.00015276323
and O 0 0.0001511105
20 O 0 0.00013895947
microg O 0 0.00020992472
, O 0 0.00022632665
separated O 0 0.0001519807
by O 0 0.00015076624
15 O 0 0.00013274896
min O 0 0.00021545334
breaks O 0 0.0036202786
) O 0 0.00049990776
, O 0 0.00024330869
each O 0 0.00010741192
given O 0 0.00010346032
three O 0 9.8895885e-05
times O 0 0.00011144578
in O 0 0.0001757806
a O 0 0.00024927958
balanced O 0 0.00028328018
design O 0 0.0003142435
across O 0 0.00022208811
three O 0 0.00025522508
sessions O 0 0.0003919407
at O 0 0.0006000083
one O 0 0.00094978296
week O 0 0.001387775
intervals O 0 0.0024097767
. O 0 0.0055338293

Pain B-Disease 0 0.616226
rating O 0 0.0031698036
was O 0 0.0016189875
performed O 0 0.000967144
using O 0 0.0007856325
a O 0 0.0008007247
computerized O 0 0.0011530251
visual O 0 0.012620979
analogue O 0 0.0014527782
scale O 0 0.00045668118
( O 0 0.00051241415
0 O 0 0.00040551252
- O 0 0.0014467038
100 O 0 0.00039158424
) O 0 0.00037011865
digitized O 0 0.0005623394
at O 0 0.0001839178
1 O 0 0.00020655162
/ O 0 0.00048492302
s O 0 0.00031596664
, O 0 0.00030470654
either O 0 0.00020753215
immediately O 0 0.00022685123
online O 0 0.00024471883
or O 0 0.00024206752
one O 0 0.0002780681
hour O 0 0.0003367558
or O 0 0.0004902862
one O 0 0.0006745166
day O 0 0.0009362075
after O 0 0.0014217962
injection O 0 0.0040304065
. O 0 0.0060992353

Subjects O 0 0.010348155
also O 0 0.007056064
recalled O 0 0.010185813
their O 0 0.0072605573
pains B-Disease 0 0.5713788
one O 0 0.006113694
week O 0 0.006462642
later O 0 0.0091401795
. O 0 0.014976031

Capsaicin B-Chemical 1 0.99978775
injection O 0 0.0073547396
reliably O 0 0.0021581992
induced O 0 0.0012667646
a O 0 0.0013082318
dose O 0 0.012140575
- O 0 0.016017502
dependent O 0 0.0005800179
flare O 0 0.97488326
( O 0 0.0010803369
p O 0 0.00040347443
< O 0 0.0003188903
0 O 0 0.0003959023
. O 0 0.00037511552
001 O 0 0.023596557
) O 0 0.00059804914
without O 0 0.0003907264
any O 0 0.000421769
difference O 0 0.00042269824
within O 0 0.00059459236
or O 0 0.001121521
across O 0 0.001644769
sessions O 0 0.0030900561
. O 0 0.006209023

The O 0 0.0052485764
strong O 0 0.006266712
burning O 0 0.7719613
pain B-Disease 0 0.94628817
decayed O 0 0.0072520273
exponentially O 0 0.003002628
within O 0 0.0024228594
a O 0 0.003863136
few O 0 0.0038504188
minutes O 0 0.0055992994
. O 0 0.0105816955

Subjects O 0 0.00466231
were O 0 0.002224986
able O 0 0.0012727318
to O 0 0.000974364
reliably O 0 0.0009230351
discriminate O 0 0.00063207117
pain B-Disease 0 0.44680774
magnitude O 0 0.00031778103
and O 0 0.00032520166
duration O 0 0.00022291378
across O 0 0.00023720179
capsaicin B-Chemical 0 0.9992993
doses O 0 0.01126814
( O 0 0.0005332657
both O 0 0.00021070337
p O 0 0.00022066085
< O 0 0.00018680072
0 O 0 0.0002597153
. O 0 0.00023899975
001 O 0 0.071174055
) O 0 0.0005206994
, O 0 0.00025829932
regardless O 0 0.00011938378
of O 0 0.00017928198
whether O 0 0.000106404
first O 0 0.0001598142
- O 0 0.00082395005
time O 0 0.00013118707
ratings O 0 0.00022224653
were O 0 0.00017380064
requested O 0 0.00021819254
immediately O 0 0.00022005364
, O 0 0.00031306976
after O 0 0.00022718456
one O 0 0.00033864964
hour O 0 0.00044257584
or O 0 0.00068865006
after O 0 0.0009118154
one O 0 0.0017401285
day O 0 0.0028720128
. O 0 0.005834684

Pain B-Disease 0 0.7785125
recall O 0 0.0050933505
after O 0 0.0014392834
one O 0 0.0010950905
week O 0 0.0007138745
was O 0 0.0006273234
similarly O 0 0.00048746992
precise O 0 0.00047079142
( O 0 0.0005526101
magnitude O 0 0.00033044117
: O 0 0.00057372893
p O 0 0.0003616695
< O 0 0.0003275899
0 O 0 0.00040813725
. O 0 0.0003831922
01 O 0 0.0010009315
, O 0 0.00048807112
duration O 0 0.00041126588
: O 0 0.0008037282
p O 0 0.00076097477
< O 0 0.000997831
0 O 0 0.0016546131
. O 0 0.0023924343
05 O 0 0.011590346
) O 0 0.0068580783
. O 0 0.008851546

Correlation O 0 0.0030454828
with O 0 0.0021504324
rating O 0 0.0019093317
recall O 0 0.0019565306
after O 0 0.00061089324
one O 0 0.00051338505
week O 0 0.00035214087
was O 0 0.00033803642
best O 0 0.00030417275
when O 0 0.00021174317
first O 0 0.00022601227
- O 0 0.00084050436
time O 0 0.0001495006
ratings O 0 0.00022464179
were O 0 0.00015468457
requested O 0 0.00016543936
as O 0 0.0001458705
late O 0 0.0002980988
as O 0 0.00015109092
one O 0 0.00013089544
day O 0 0.000113703645
after O 0 0.0001063472
injection O 0 0.00044856264
( O 0 0.0018068813
R O 0 0.99830234
( O 0 0.0010921234
2 O 0 0.00024150207
) O 0 0.00044709523
= O 0 0.00047472483
0 O 0 0.0002590372
. O 0 0.0002105887
79 O 0 0.00035708264
) O 0 0.00035853093
indicating O 0 0.00022536088
that O 0 0.00025889947
both O 0 0.0003714286
rating O 0 0.00059459545
retrievals O 0 0.0007306861
utilized O 0 0.00079403515
similar O 0 0.001302664
memory O 0 0.05617987
traces O 0 0.007813175
. O 0 0.0074973735

These O 0 0.0038535858
results O 0 0.0023916797
indicate O 0 0.0015136552
a O 0 0.001832328
reliable O 0 0.0016240737
memory O 0 0.033413403
for O 0 0.0009367406
magnitude O 0 0.0008096965
and O 0 0.0010384648
duration O 0 0.0009921665
of O 0 0.001706178
experimentally O 0 0.003317497
induced O 0 0.005492511
pain B-Disease 0 0.9828873
. O 0 0.009254262

The O 0 0.0031332462
data O 0 0.0022055497
further O 0 0.0013245655
suggest O 0 0.0007623069
that O 0 0.0006948502
the O 0 0.00067912246
consolidation O 0 0.011823239
of O 0 0.00066937786
this O 0 0.0005384083
memory O 0 0.16968021
is O 0 0.00041412696
an O 0 0.00036055734
important O 0 0.00027523216
interim O 0 0.0036773623
stage O 0 0.0013094946
, O 0 0.00063042424
and O 0 0.00051965425
may O 0 0.00048717306
take O 0 0.0005428391
up O 0 0.0008000626
to O 0 0.0011379388
one O 0 0.0018636254
day O 0 0.003009877
. O 0 0.006053171

Severe O 0 0.1934682
and O 0 0.0028235887
long O 0 0.0019042033
lasting O 0 0.0031484389
cholestasis B-Disease 2 0.99999475
after O 0 0.0007653994
high O 0 0.002761399
- O 0 0.035190444
dose O 0 0.038472027
co B-Chemical 0 0.9907335
- I-Chemical 0 0.26813483
trimoxazole I-Chemical 0 0.72462946
treatment O 0 0.00086952857
for O 0 0.0011827821
Pneumocystis B-Disease 0 0.9999938
pneumonia I-Disease 0 0.99999964
in O 0 0.016546292
HIV B-Disease 2 0.9998741
- I-Disease 2 0.14459364
infected I-Disease 2 0.007048504
patients O 0 0.0045530004
- O 0 0.026499938
- O 0 0.0039990996
a O 0 0.000941988
report O 0 0.0014998013
of O 0 0.0016522611
two O 0 0.0020238978
cases O 0 0.0050207213
. O 0 0.007034747

Pneumocystis B-Disease 0 0.9999145
pneumonia I-Disease 0 0.99999666
( O 0 0.4907162
PCP B-Disease 0 0.9999416
) O 0 0.014622978
, O 0 0.0015506513
a O 0 0.00096031587
common O 0 0.0010289499
opportunistic B-Disease 0 0.37513736
infection I-Disease 2 0.9931832
in O 0 0.00798621
HIV B-Disease 2 0.99989057
- I-Disease 2 0.2197546
infected I-Disease 2 0.006743578
individuals O 0 0.0030219203
, O 0 0.00064578553
is O 0 0.000329255
generally O 0 0.0003720105
treated O 0 0.00038001023
with O 0 0.00046224546
high O 0 0.00087619736
doses O 0 0.004690011
of O 0 0.0028492971
co B-Chemical 0 0.98515135
- I-Chemical 0 0.36367008
trimoxazole I-Chemical 0 0.892698
. O 0 0.008907149

However O 0 0.007500713
, O 0 0.0063973255
treatment O 0 0.0044840616
is O 0 0.0037639649
often O 0 0.0037939239
limited O 0 0.0035490484
by O 0 0.0050989953
adverse O 0 0.347424
effects O 0 0.010336969
. O 0 0.01278539

Here O 0 0.0054819416
, O 0 0.0033915348
we O 0 0.0015673924
report O 0 0.0017408106
two O 0 0.00082773477
cases O 0 0.0009754693
of O 0 0.00096613605
severely O 0 0.11936242
immunocompromised O 0 0.99948406
HIV B-Disease 2 0.9999347
- I-Disease 2 0.23849702
infected I-Disease 2 0.0053127743
patients O 0 0.0010406373
who O 0 0.0006094339
developed O 0 0.0008083828
severe O 0 0.43557575
intrahepatic B-Disease 0 0.99995804
cholestasis I-Disease 2 1.0
, O 0 0.034242753
and O 0 0.0005246559
in O 0 0.00020460149
one O 0 0.00015901314
patient O 0 0.00021340924
lesions O 0 0.07166636
mimicking O 0 0.0012480429
liver B-Disease 0 0.8779245
abscess I-Disease 0 0.9748583
formation O 0 0.0020992616
on O 0 0.00017737843
radiologic O 0 0.0031192803
exams O 0 0.0006316985
, O 0 0.00047988357
during O 0 0.00042694123
co B-Chemical 0 0.9227631
- I-Chemical 0 0.11520738
trimoxazole I-Chemical 0 0.71098036
treatment O 0 0.0030834782
for O 0 0.0038867246
PCP B-Disease 0 0.9993862
. O 0 0.008991375

Whereas O 0 0.0038876124
patient O 0 0.0025672845
1 O 0 0.0016518324
showed O 0 0.001107059
lesions O 0 0.02038063
of O 0 0.0007436323
up O 0 0.00045784898
to O 0 0.00033403488
1 O 0 0.00030331992
cm O 0 0.00039209545
readily O 0 0.0002718377
detectable O 0 0.00021099648
on O 0 0.00018660951
magnetic O 0 0.0065396796
resonance O 0 0.31516886
imaging O 0 0.000553253
under O 0 0.00020648331
prolonged O 0 0.0008498463
co B-Chemical 0 0.96436054
- I-Chemical 0 0.18299301
trimoxazole I-Chemical 0 0.72990966
treatment O 0 0.00077747076
, O 0 0.0006272194
therapy O 0 0.00067172793
of O 0 0.00062220136
patient O 0 0.0008407595
2 O 0 0.00090607995
was O 0 0.0013144573
switched O 0 0.002416835
early O 0 0.0047734645
. O 0 0.0070095975

Bradykinin B-Chemical 0 0.99986804
receptors O 0 0.17871544
antagonists O 0 0.8689223
and O 0 0.0042451033
nitric B-Chemical 0 0.9991351
oxide I-Chemical 0 0.9947836
synthase O 0 0.6261807
inhibitors O 0 0.011450533
in O 0 0.0009575567
vincristine B-Chemical 1 0.99994504
and O 0 0.009702061
streptozotocin B-Chemical 0 0.9999976
induced O 0 0.011877402
hyperalgesia B-Disease 2 0.9999751
in O 0 0.00093969324
chemotherapy O 0 0.25442266
and O 0 0.012670949
diabetic B-Disease 2 0.99999845
neuropathy I-Disease 0 0.99999905
rat O 0 0.041699663
model O 0 0.00527749
. O 0 0.0073146652

PURPOSE O 0 0.0053412775
: O 0 0.003380353
The O 0 0.0014563161
influence O 0 0.0009700708
of O 0 0.0011021118
an O 0 0.001192626
irreversible O 0 0.13140674
inhibitor O 0 0.016185854
of O 0 0.0009187738
constitutive O 0 0.00464313
NO B-Chemical 0 0.99984336
synthase O 0 0.92008007
( O 0 0.02255819
L O 0 0.9969332
- O 0 0.25484
NOArg O 0 0.5954007
; O 0 0.0005939125
1 O 0 0.00019415391
. O 0 0.00015881466
0 O 0 0.0002103226
mg O 0 0.005767368
/ O 0 0.0015275707
kg O 0 0.002517284
ip O 0 0.43313277
) O 0 0.0008497118
, O 0 0.00032679015
a O 0 0.00023424882
relatively O 0 0.0002694013
selective O 0 0.00048238895
inhibitor O 0 0.0016017511
of O 0 0.0003456879
inducible O 0 0.018773299
NO B-Chemical 0 0.9998839
synthase O 0 0.9320485
( O 0 0.029687895
L O 0 0.99817824
- O 0 0.44637996
NIL O 0 0.92787266
; O 0 0.0007659945
1 O 0 0.00018477152
. O 0 0.0001482846
0 O 0 0.0001977825
mg O 0 0.0053503565
/ O 0 0.0013540538
kg O 0 0.0019180841
ip O 0 0.29738575
) O 0 0.00048588007
and O 0 0.00021464036
a O 0 0.00020363345
relatively O 0 0.00020951798
specific O 0 0.00015453214
inhibitor O 0 0.0021859715
of O 0 0.00058093993
neuronal O 0 0.5787264
NO B-Chemical 0 0.99978966
synthase O 0 0.7700728
( O 0 0.0014308398
7 O 0 0.0002491249
- O 0 0.017706683
NI O 0 0.80123055
; O 0 0.00059339474
0 O 0 0.00023184906
. O 0 0.00016085502
1 O 0 0.00017779732
mg O 0 0.006009557
/ O 0 0.001768962
kg O 0 0.0031809153
ip O 0 0.48507282
) O 0 0.0009426811
, O 0 0.00032324658
on O 0 0.00014750952
antihyperalgesic O 0 0.8281045
action O 0 0.00037663267
of O 0 0.00033707937
selective O 0 0.0055204323
antagonists O 0 0.66218174
of O 0 0.0031274566
B2 O 0 0.9992731
and O 0 0.0060744756
B1 O 0 0.99988234
receptors O 0 0.113988385
: O 0 0.022358635
D O 0 0.9992094
- O 0 0.70163417
Arg O 0 0.99980956
- O 0 0.5253908
[ O 0 0.09152576
Hyp3 O 0 0.9204963
, O 0 0.0018558139
Thi5 O 0 0.8446896
, O 0 0.0023419822
D O 0 0.99573743
- O 0 0.1319851
Tic7 O 0 0.12852247
, O 0 0.0031405033
Oic8 O 0 0.9992418
] O 0 0.10639791
bradykinin B-Chemical 1 0.99997365
( O 0 0.023860905
HOE B-Chemical 0 0.99996984
140 I-Chemical 0 0.011329701
; O 0 0.0004375387
70 O 0 0.00023678782
nmol O 0 0.09147051
/ O 0 0.0035793127
kg O 0 0.003183505
ip O 0 0.37594467
) O 0 0.0007038543
or O 0 0.00031235695
des B-Chemical 0 0.017705474
Arg10 I-Chemical 0 0.9997185
HOE I-Chemical 0 0.9999925
140 I-Chemical 0 0.022586687
( O 0 0.00040815226
70 O 0 0.00023759902
nmol O 0 0.09648074
/ O 0 0.0036551969
kg O 0 0.0033986967
ip O 0 0.44707975
) O 0 0.0010064001
respectively O 0 0.0018696846
, O 0 0.00031593832
in O 0 0.00017846366
model O 0 0.00023935048
of O 0 0.0013861054
diabetic B-Disease 2 0.9999776
( I-Disease 0 0.111992806
streptozotocin I-Disease 0 0.99999917
- I-Disease 0 0.10973215
induced I-Disease 0 0.0004386918
) I-Disease 0 0.0018650078
and I-Disease 0 0.00077408936
toxic I-Disease 0 0.90076673
( I-Disease 0 0.024004105
vincristine I-Disease 1 0.9999783
- I-Disease 0 0.08090553
induced I-Disease 0 0.0014893429
) I-Disease 0 0.045846954
neuropathy I-Disease 0 0.99995446
was O 0 0.0026553923
investigated O 0 0.0032465004
. O 0 0.0064788894

METHODS O 0 0.0038374146
: O 0 0.0033638314
The O 0 0.001678709
changes O 0 0.001596346
in O 0 0.0012415821
pain B-Disease 0 0.5953537
thresholds O 0 0.000761217
were O 0 0.00042070248
determined O 0 0.0002776805
using O 0 0.00028741526
mechanical O 0 0.00063769304
stimuli O 0 0.0019006877
- O 0 0.06792496
- O 0 0.008172899
the O 0 0.00028329343
modification O 0 0.0005291877
of O 0 0.00041046215
the O 0 0.00044580683
classic O 0 0.12673377
paw O 0 0.9868433
withdrawal O 0 0.15582466
test O 0 0.00068920624
described O 0 0.00079267053
by O 0 0.0015201168
Randall O 0 0.09713231
- O 0 0.08361068
Selitto O 0 0.9711864
. O 0 0.008315567

RESULTS O 0 0.0054358146
: O 0 0.0033946582
The O 0 0.0015119468
results O 0 0.001132808
of O 0 0.001104164
this O 0 0.00081489806
paper O 0 0.00078081124
confirm O 0 0.0002783747
that O 0 0.0003155563
inhibition O 0 0.0011897592
of O 0 0.0045831027
bradykinin B-Chemical 1 0.9999802
receptors O 0 0.052590616
and O 0 0.00079686317
inducible O 0 0.024701057
NO B-Chemical 0 0.9998381
synthase O 0 0.7826561
but O 0 0.0006966186
not O 0 0.00045036792
neuronal O 0 0.38938612
NO B-Chemical 0 0.9995679
synthase O 0 0.72312415
activity O 0 0.002521472
reduces O 0 0.010877627
diabetic B-Disease 2 0.99999714
hyperalgesia I-Disease 0 0.99999475
. O 0 0.012344305

Pretreatment O 0 0.35857275
with O 0 0.0063568475
L O 0 0.988489
- O 0 0.18594061
NOArg O 0 0.66685057
and O 0 0.0035731157
L O 0 0.99501556
- O 0 0.33503103
NIL O 0 0.8700198
but O 0 0.00069691904
not O 0 0.000387672
7 O 0 0.000425942
- O 0 0.02205495
NI O 0 0.84047157
, O 0 0.0007268601
significantly O 0 0.00042128487
increases O 0 0.0005024229
antihyperalgesic O 0 0.949141
activity O 0 0.0006150295
both O 0 0.0011950965
HOE B-Chemical 0 0.99994826
140 I-Chemical 0 0.010582339
and O 0 0.0015744967
des B-Chemical 0 0.036028802
Arg10 I-Chemical 0 0.9992888
HOE I-Chemical 0 0.9999609
140 I-Chemical 0 0.038077686
. O 0 0.0076658092

It O 0 0.00465682
was O 0 0.002541822
also O 0 0.0016015208
shown O 0 0.0009684916
that O 0 0.00069201516
both O 0 0.00064476684
products O 0 0.00088859064
of O 0 0.00067696447
inducible O 0 0.019144854
NO B-Chemical 0 0.99983037
synthase O 0 0.8104988
and O 0 0.0017089483
neuronal O 0 0.582079
NO B-Chemical 0 0.9996444
synthase O 0 0.4351465
activation O 0 0.0005410293
as O 0 0.00023264535
well O 0 0.00026812239
as O 0 0.00045060433
bradykinin B-Chemical 1 0.99958736
are O 0 0.0004473992
involved O 0 0.00044753312
in O 0 0.00097294286
hyperalgesia B-Disease 2 0.99928904
produced O 0 0.0016087757
by O 0 0.003983793
vincristine B-Chemical 1 0.99964595
. O 0 0.008227004

Moreover O 0 0.006063151
, O 0 0.007614624
L O 0 0.97622716
- O 0 0.11989949
NOArg O 0 0.4125658
and O 0 0.0014672609
7 O 0 0.0009651433
- O 0 0.018632732
NI O 0 0.74559087
but O 0 0.00087404245
not O 0 0.00070829404
L O 0 0.99385357
- O 0 0.3415196
NIL O 0 0.8858045
intensify O 0 0.0013389897
antihyperalgesic O 0 0.95096576
activity O 0 0.00044033903
of O 0 0.0012597614
HOE B-Chemical 0 0.999956
140 I-Chemical 0 0.0048432965
or O 0 0.00045263005
des B-Chemical 0 0.0020834308
- I-Chemical 0 0.011240224
Arg10HOE I-Chemical 0 0.015325411
140 I-Chemical 0 0.0016190798
in O 0 0.0021800261
toxic B-Disease 0 0.99795145
neuropathy I-Disease 0 0.99999225
. O 0 0.0104435

CONCLUSIONS O 0 0.016391588
: O 0 0.0036993113
Results O 0 0.0017986096
of O 0 0.0013518891
these O 0 0.0009747081
studies O 0 0.0007256578
suggest O 0 0.00046527293
that O 0 0.0007744735
B1 O 0 0.9997335
and O 0 0.014972333
B2 O 0 0.9988643
receptors O 0 0.011482807
are O 0 0.00032117128
engaged O 0 0.0003625859
in O 0 0.00025318968
transmission O 0 0.0008404011
of O 0 0.00048485948
nociceptive O 0 0.033085536
stimuli O 0 0.00059193344
in O 0 0.0005386783
both O 0 0.0011514457
diabetic B-Disease 2 0.99980825
and I-Disease 0 0.026415475
toxic I-Disease 0 0.9997199
neuropathy I-Disease 0 0.99999654
. O 0 0.011300459

In O 0 0.008685165
streptozotocin B-Chemical 0 0.9999851
- O 0 0.3648559
induced O 0 0.013009979
hyperalgesia B-Disease 2 0.99997747
, O 0 0.0101218745
inducible O 0 0.06343616
NO B-Chemical 0 0.99987185
synthase O 0 0.7316628
participates O 0 0.00046931996
in O 0 0.00039442914
pronociceptive O 0 0.1700709
activity O 0 0.0003684113
of O 0 0.0021044184
bradykinin B-Chemical 1 0.9999752
, O 0 0.002006031
whereas O 0 0.0005308734
in O 0 0.00085983245
vincristine B-Chemical 1 0.99998426
- O 0 0.21219942
induced O 0 0.008162975
hyperalgesia B-Disease 2 0.9999964
bradykinin B-Chemical 1 0.9999763
seemed O 0 0.00076584524
to O 0 0.00041714928
activate O 0 0.0005114777
neuronal O 0 0.3039799
NO B-Chemical 0 0.9989492
synthase O 0 0.57846236
pathway O 0 0.004223145
. O 0 0.006739047

Therefore O 0 0.0037705954
, O 0 0.0036059236
concomitant O 0 0.0037213375
administration O 0 0.009317003
of O 0 0.0011535832
small O 0 0.00089132745
doses O 0 0.025278447
of O 0 0.01559679
bradykinin B-Chemical 1 0.9999949
receptor O 0 0.75374275
antagonists O 0 0.9634103
and O 0 0.005299622
NO B-Chemical 0 0.9996964
synthase O 0 0.60376084
inhibitors O 0 0.0036373655
can O 0 0.00016594272
be O 0 0.0001869946
effective O 0 0.0002264484
in O 0 0.0002553049
alleviation O 0 0.048036058
of O 0 0.011670846
neuropathic B-Disease 0 0.99999845
pain I-Disease 0 0.9996685
, O 0 0.00131424
even O 0 0.0010898442
in O 0 0.0013829053
hospital O 0 0.00307821
care O 0 0.003991463
. O 0 0.0060880356

Confusion B-Disease 0 0.44696394
, O 0 0.004335901
a O 0 0.0025908744
rather O 0 0.0016686128
serious O 0 0.11008933
adverse O 0 0.9643249
drug O 0 0.8471208
reaction O 0 0.47573203
with O 0 0.016284732
valproic B-Chemical 0 0.99999833
acid I-Chemical 0 0.967431
: O 0 0.0015509084
a O 0 0.00073414773
review O 0 0.00094609574
of O 0 0.0010062591
the O 0 0.0014475143
French O 0 0.008609718
Pharmacovigilance O 0 0.16663319
database O 0 0.005287219
. O 0 0.006998978

INTRODUCTION O 0 0.0154756885
: O 0 0.007308238
Confusion B-Disease 0 0.2134009
is O 0 0.002547166
an O 0 0.0026115992
adverse O 0 0.8340207
drug O 0 0.6286895
reaction O 0 0.18394378
frequently O 0 0.002381894
observed O 0 0.0017650014
with O 0 0.009787124
valproic B-Chemical 0 0.9999902
acid I-Chemical 0 0.97125655
. O 0 0.010929093

Some O 0 0.004484877
case O 0 0.0026177182
reports O 0 0.0017733282
are O 0 0.0011965295
published O 0 0.00090941327
in O 0 0.00067642407
the O 0 0.0005549764
literature O 0 0.00070906605
but O 0 0.00050510163
no O 0 0.00030928935
systematic O 0 0.00040208604
study O 0 0.00043716974
from O 0 0.00035711084
a O 0 0.0005120753
sample O 0 0.00056998315
of O 0 0.0008611377
patients O 0 0.0014531588
has O 0 0.0014071815
been O 0 0.002316607
published O 0 0.0038739464
. O 0 0.006943437

We O 0 0.003716378
performed O 0 0.0023131713
this O 0 0.0018457648
study O 0 0.0015133728
in O 0 0.00096587924
order O 0 0.0006374081
to O 0 0.0005785258
describe O 0 0.00053527596
the O 0 0.00054684584
main O 0 0.000632055
characteristics O 0 0.0006365848
of O 0 0.0010358025
this O 0 0.0015178039
adverse O 0 0.8439866
drug O 0 0.61804557
reaction O 0 0.24047333
. O 0 0.008161752

METHODS O 0 0.0041826493
: O 0 0.003663127
Using O 0 0.0022125072
the O 0 0.0018980326
French O 0 0.0063303495
Pharmacovigilance O 0 0.13081342
database O 0 0.0012703683
, O 0 0.00078897044
we O 0 0.0003775593
selected O 0 0.00039102323
the O 0 0.00041449012
cases O 0 0.0006751466
of O 0 0.00088362914
confusion B-Disease 0 0.75096184
reported O 0 0.0010027416
since O 0 0.00077596755
1985 O 0 0.008762295
with O 0 0.0058474154
valproic B-Chemical 0 0.999987
acid I-Chemical 0 0.94597495
. O 0 0.0091685355

RESULTS O 0 0.0064132246
: O 0 0.004594548
272 O 0 0.005728378
cases O 0 0.002384268
of O 0 0.0021253675
confusion B-Disease 0 0.60919833
were O 0 0.0011516134
reported O 0 0.0012403759
with O 0 0.0029233787
valproic B-Chemical 0 0.9999962
acid I-Chemical 0 0.9688802
: O 0 0.0038472519
153 O 0 0.010962895
women O 0 0.004360257
and O 0 0.00252044
119 O 0 0.007084246
men O 0 0.019946646
. O 0 0.008426849

Confusion B-Disease 0 0.25841781
mostly O 0 0.0031777187
occurred O 0 0.0017745921
during O 0 0.0009760895
the O 0 0.00080592924
two O 0 0.000544734
first O 0 0.00043973647
weeks O 0 0.00039521707
following O 0 0.0006512446
valproic B-Chemical 0 0.9999938
acid I-Chemical 0 0.9562722
exposure O 0 0.03716882
( O 0 0.0016995942
39 O 0 0.0012819121
. O 0 0.0010611862
7 O 0 0.0014987555
% O 0 0.0030301576
) O 0 0.0058494834
. O 0 0.008004644

It O 0 0.0051599294
was O 0 0.003214143
" O 0 0.003063446
serious O 0 0.015543457
" O 0 0.001612788
for O 0 0.00073730195
almost O 0 0.0006014993
2 O 0 0.0005423863
/ O 0 0.0010679364
3 O 0 0.000300441
of O 0 0.00029827308
the O 0 0.00026970252
patients O 0 0.00044525153
( O 0 0.0004350998
62 O 0 0.00041128506
. O 0 0.00019831407
5 O 0 0.00017879937
% O 0 0.00025936912
) O 0 0.0003507143
and O 0 0.0002518686
its O 0 0.0004062746
outcome O 0 0.0006111171
favourable O 0 0.0010140506
in O 0 0.00029242926
most O 0 0.0004209366
of O 0 0.00047260977
the O 0 0.0005578216
cases O 0 0.0012920339
( O 0 0.0017671173
82 O 0 0.0028768647
% O 0 0.0031455187
) O 0 0.005750099
. O 0 0.0075432532

The O 0 0.0035492647
occurrence O 0 0.0035391604
of O 0 0.0026032669
this O 0 0.0031945233
ADR O 0 0.9999515
was O 0 0.001527327
more O 0 0.001077171
frequent O 0 0.0013285181
in O 0 0.00061525777
patients O 0 0.00079267274
aged O 0 0.0009143523
between O 0 0.00071826624
61 O 0 0.001559362
and O 0 0.0017613916
80 O 0 0.002900058
years O 0 0.004714682
. O 0 0.0075370753

CONCLUSION O 0 0.03258096
: O 0 0.0044785347
This O 0 0.0025810672
work O 0 0.0014830542
shows O 0 0.0007563564
that O 0 0.00083436765
confusion B-Disease 0 0.86389554
with O 0 0.013964815
valproic B-Chemical 0 0.99999857
acid I-Chemical 0 0.9767229
is O 0 0.0007378971
a O 0 0.0006944097
serious O 0 0.028713567
, O 0 0.00071888836
rather O 0 0.00048654844
frequent O 0 0.0019162591
but O 0 0.0010721617
reversible O 0 0.16074722
adverse O 0 0.94088036
drug O 0 0.66856825
reaction O 0 0.23342803
. O 0 0.00740087

It O 0 0.005107261
occurs O 0 0.002873177
especially O 0 0.002651093
in O 0 0.0017808581
older O 0 0.0029886984
patients O 0 0.0013231162
and O 0 0.0009369789
during O 0 0.0006577486
the O 0 0.00077335583
first O 0 0.0007648275
two O 0 0.00094750215
weeks O 0 0.0012301472
of O 0 0.0027199942
treatment O 0 0.005011364
. O 0 0.008008474

Reversible O 0 0.24003407
inferior B-Disease 0 0.29081663
colliculus I-Disease 0 0.19785589
lesion I-Disease 0 0.2880215
in O 0 0.0026509329
metronidazole B-Chemical 1 0.9999778
- O 0 0.16270727
induced O 0 0.003222662
encephalopathy B-Disease 2 0.999997
: O 0 0.012700029
magnetic O 0 0.08406592
resonance O 0 0.44700125
findings O 0 0.0003989095
on O 0 0.00025001078
diffusion O 0 0.005045388
- O 0 0.0020409652
weighted O 0 0.00051410473
and O 0 0.00069677
fluid O 0 0.0022333676
attenuated O 0 0.0017819537
inversion O 0 0.016344337
recovery O 0 0.0038380234
imaging O 0 0.0072487434
. O 0 0.006740998

OBJECTIVE O 0 0.03176589
: O 0 0.0041593653
This O 0 0.0023760772
is O 0 0.0012344274
to O 0 0.00079945184
present O 0 0.0006129792
reversible O 0 0.030084943
inferior B-Disease 0 0.4109081
colliculus I-Disease 0 0.23448019
lesions I-Disease 0 0.7224893
in O 0 0.0012352255
metronidazole B-Chemical 1 0.99999225
- O 0 0.24602312
induced O 0 0.004051316
encephalopathy B-Disease 2 0.99999833
, O 0 0.0014879033
to O 0 0.00017344159
focus O 0 0.00018355795
on O 0 0.00010948956
the O 0 0.00017473
diffusion O 0 0.008376223
- O 0 0.0025454536
weighted O 0 0.00025426163
imaging O 0 0.001108821
( O 0 0.00086722366
DWI O 0 0.9903295
) O 0 0.0006867903
and O 0 0.00041351002
fluid O 0 0.0014043789
attenuated O 0 0.00085430156
inversion O 0 0.016259763
recovery O 0 0.0017995524
( O 0 0.00314273
FLAIR O 0 0.99515885
) O 0 0.0048081097
imaging O 0 0.0074809417
. O 0 0.0070966235

MATERIALS O 0 0.006335618
AND O 0 0.003264002
METHODS O 0 0.0023138789
: O 0 0.0024208804
From O 0 0.0017052696
November O 0 0.0017213221
2005 O 0 0.0014175538
to O 0 0.00080544484
September O 0 0.0009567091
2007 O 0 0.00095638924
, O 0 0.0006461379
8 O 0 0.00040556447
patients O 0 0.00042965196
( O 0 0.0004405092
5 O 0 0.0002663717
men O 0 0.0013437176
and O 0 0.00030023887
3 O 0 0.00023830483
women O 0 0.0009549473
) O 0 0.00040118623
were O 0 0.00020991571
diagnosed O 0 0.0005470237
as O 0 0.00022684084
having O 0 0.0022716722
metronidazole B-Chemical 1 0.99999094
- O 0 0.20655641
induced O 0 0.003897943
encephalopathy B-Disease 2 0.9999982
( O 0 0.0041851625
age O 0 0.001171861
range O 0 0.00058976305
; O 0 0.00106869
43 O 0 0.0013062079
- O 0 0.0027219274
78 O 0 0.0023889474
years O 0 0.002931319
) O 0 0.005623272
. O 0 0.007704113

They O 0 0.005172818
had O 0 0.0025451751
been O 0 0.0020666718
taking O 0 0.0076629627
metronidazole B-Chemical 1 0.9998934
( O 0 0.0018983977
total O 0 0.00055037084
dosage O 0 0.04247659
, O 0 0.00068802875
45 O 0 0.00036680192
- O 0 0.0011266035
120 O 0 0.00026125557
g O 0 0.0003891495
; O 0 0.000312772
duration O 0 0.0001737584
, O 0 0.00023997795
30 O 0 0.00015738599
days O 0 0.00013358115
to O 0 0.0001658859
2 O 0 0.00020784978
months O 0 0.00019815208
) O 0 0.00039679927
to O 0 0.00032976866
treat O 0 0.00058606314
the O 0 0.00071268156
infection B-Disease 2 0.69217235
in O 0 0.0017693442
various O 0 0.0030885611
organs O 0 0.011526335
. O 0 0.0070514344

Initial O 0 0.0051987655
brain O 0 0.00955549
magnetic O 0 0.031677492
resonance O 0 0.47310337
imaging O 0 0.0040072734
( O 0 0.0021766804
MRI O 0 0.58003163
) O 0 0.0010176111
were O 0 0.00040226008
obtained O 0 0.00028613734
after O 0 0.00021133575
the O 0 0.00026095533
hospitalization O 0 0.003950008
, O 0 0.0004083714
including O 0 0.00038090718
DWI O 0 0.99653023
( O 0 0.0005875307
8 O 0 0.00021855564
/ O 0 0.0007313441
8 O 0 0.00020272758
) O 0 0.0003320932
, O 0 0.00024666332
apparent O 0 0.00020992794
diffusion O 0 0.0059360466
coefficient O 0 0.0018772188
( O 0 0.0012437149
ADC O 0 0.80454767
) O 0 0.0005747944
map O 0 0.00023095394
( O 0 0.00033780417
4 O 0 0.00018529022
/ O 0 0.0005957715
8 O 0 0.00021672975
) O 0 0.00044413455
, O 0 0.00063556334
FLAIR O 0 0.99697196
( O 0 0.00046814754
7 O 0 0.0002118393
/ O 0 0.00062159804
8 O 0 0.00025268327
) O 0 0.00043412452
, O 0 0.00039731667
and O 0 0.00044295914
T2 O 0 0.013841044
- O 0 0.0016734861
weighted O 0 0.00052365515
image O 0 0.0007824178
( O 0 0.001180065
8 O 0 0.0012049243
/ O 0 0.0028963026
8 O 0 0.0027678986
) O 0 0.0057199216
. O 0 0.0080417385

Follow O 0 0.008234136
- O 0 0.0064147078
up O 0 0.0023506572
MRIs O 0 0.0046524154
were O 0 0.0010583007
performed O 0 0.00068468077
on O 0 0.0005063986
5 O 0 0.00050487317
patients O 0 0.00051529054
from O 0 0.00038038212
third O 0 0.0004478364
to O 0 0.00040097098
14th O 0 0.001078973
days O 0 0.00043247212
after O 0 0.00058222096
discontinuation O 0 0.22917446
of O 0 0.0037584763
metronidazole B-Chemical 1 0.9999404
administration O 0 0.28928587
. O 0 0.007777945

Findings O 0 0.0038739261
of O 0 0.0025988852
initial O 0 0.001569913
and O 0 0.0013825365
follow O 0 0.00087461516
- O 0 0.0022397842
up O 0 0.00058159913
MRIs O 0 0.0024585437
were O 0 0.00030372647
retrospectively O 0 0.00025700178
evaluated O 0 0.00019366154
by O 0 0.00024007476
2 O 0 0.00023187071
neuroradiologists O 0 0.0005326282
by O 0 0.00019290062
consensus O 0 0.00020382539
, O 0 0.00025300338
to O 0 0.00014211291
analyze O 0 0.000106413136
the O 0 0.00014201361
presence O 0 0.00015624583
of O 0 0.00023984553
abnormal O 0 0.0014846403
signal O 0 0.00018512121
intensities O 0 0.00019014247
, O 0 0.0002834212
their O 0 0.00021385023
locations O 0 0.00024549352
, O 0 0.00034127015
and O 0 0.00032680322
signal O 0 0.00038084286
changes O 0 0.000565412
on O 0 0.00051034987
follow O 0 0.00086002407
- O 0 0.003033385
up O 0 0.0022464276
images O 0 0.0046067107
. O 0 0.006797773

RESULTS O 0 0.0055455365
: O 0 0.003639426
Initial O 0 0.0026825771
MRIs O 0 0.006535536
showed O 0 0.0010198808
abnormal O 0 0.0015099582
high O 0 0.0006758834
signal O 0 0.0004131999
intensities O 0 0.00034484494
on O 0 0.00030941292
DWI O 0 0.98767054
and O 0 0.0010260269
FLAIR O 0 0.9988042
( O 0 0.0006188258
or O 0 0.0002892538
T2 O 0 0.02089466
- O 0 0.0016862602
weighted O 0 0.0002033719
image O 0 0.00025105965
) O 0 0.00030866452
at O 0 0.0001468981
the O 0 0.00018211741
dentate O 0 0.03847787
nucleus O 0 0.0003462335
( O 0 0.00030292227
8 O 0 0.00017841056
/ O 0 0.00056377286
8 O 0 0.0001854194
) O 0 0.0003284809
, O 0 0.0003198262
inferior O 0 0.01582007
colliculus O 0 0.02156269
( O 0 0.0002730086
6 O 0 0.00014725798
/ O 0 0.0005606349
8 O 0 0.00018816574
) O 0 0.00034484625
, O 0 0.00031002474
corpus O 0 0.0009845505
callosum O 0 0.57710856
( O 0 0.0004669954
2 O 0 0.00020937699
/ O 0 0.00068773516
8 O 0 0.00020419224
) O 0 0.0004316245
, O 0 0.00057137996
pons O 0 0.9417091
( O 0 0.00036503002
2 O 0 0.00019733491
/ O 0 0.0006267701
8 O 0 0.0002035822
) O 0 0.00041639266
, O 0 0.00048415863
medulla O 0 0.4129722
( O 0 0.00042948677
1 O 0 0.0002345418
/ O 0 0.00075035327
8 O 0 0.00023191492
) O 0 0.0003945749
, O 0 0.0003403047
and O 0 0.00038639753
bilateral O 0 0.07036979
cerebral O 0 0.9530194
white O 0 0.030307695
matter O 0 0.005240997
( O 0 0.0010539494
1 O 0 0.0010832539
/ O 0 0.00271896
8 O 0 0.002516414
) O 0 0.0052814744
. O 0 0.007497629

High O 0 0.01729841
- O 0 0.0063131987
signal O 0 0.001756095
intensity O 0 0.0013633253
lesions O 0 0.06940292
on O 0 0.00072403695
DWI O 0 0.98241514
tended O 0 0.0004331163
to O 0 0.00026394124
show O 0 0.00021115245
low O 0 0.00026606384
signal O 0 0.00020482988
intensity O 0 0.00019948056
on O 0 0.00016794441
ADC O 0 0.45958033
map O 0 0.00027430817
( O 0 0.00040212626
3 O 0 0.000192597
/ O 0 0.000787167
4 O 0 0.00019843607
) O 0 0.0004202163
, O 0 0.00033122115
but O 0 0.00025258813
in O 0 0.0001806465
one O 0 0.00016159848
patient O 0 0.00020028754
, O 0 0.00023877039
high O 0 0.00021202804
signal O 0 0.00015868054
intensity O 0 0.00017417342
was O 0 0.0001804998
shown O 0 0.00013852632
at O 0 0.00017642455
bilateral O 0 0.00856196
dentate O 0 0.042689897
nuclei O 0 0.0006077726
on O 0 0.00023815742
not O 0 0.00040409376
only O 0 0.0008845548
DWI O 0 0.9856553
but O 0 0.0015452927
also O 0 0.0019851772
ADC O 0 0.50641817
map O 0 0.004870897
. O 0 0.007438093

All O 0 0.0030917977
the O 0 0.0024964164
lesions O 0 0.038233407
in O 0 0.0016403353
dentate O 0 0.14628999
, O 0 0.001399425
inferior O 0 0.052721664
colliculus O 0 0.119421504
, O 0 0.0011923795
pons O 0 0.9443466
, O 0 0.000485884
and O 0 0.00035383523
medullas O 0 0.0035929948
had O 0 0.00021617809
been O 0 0.00019038282
resolved O 0 0.00022183309
completely O 0 0.00015183628
on O 0 0.000117651325
follow O 0 0.00014759056
- O 0 0.0010540958
up O 0 0.00018552445
MRIs O 0 0.0061977487
in O 0 0.0001669994
5 O 0 0.00016052178
patients O 0 0.00025267072
, O 0 0.00029693384
but O 0 0.00027748916
in O 0 0.00024923205
1 O 0 0.00027345296
patient O 0 0.0003138689
of O 0 0.00045123408
them O 0 0.0008291932
, O 0 0.0011379821
corpus O 0 0.004050524
callosal B-Disease 0 0.5595405
lesion I-Disease 0 0.60722077
persisted O 0 0.0040154066
. O 0 0.0064989016

CONCLUSIONS O 0 0.019757057
: O 0 0.004971002
Reversible O 0 0.21152951
inferior B-Disease 0 0.3799745
colliculus I-Disease 0 0.23803277
lesions I-Disease 0 0.3774808
could O 0 0.0005476278
be O 0 0.00043351058
considered O 0 0.00031080662
as O 0 0.00028308498
the O 0 0.0002695542
characteristic O 0 0.0004905833
for O 0 0.00087012607
metronidazole B-Chemical 1 0.9999907
- O 0 0.20680897
induced O 0 0.00346301
encephalopathy B-Disease 2 0.9999962
, O 0 0.0011024032
next O 0 0.00036193785
to O 0 0.00055050716
the O 0 0.00095564633
dentate O 0 0.057050485
nucleus O 0 0.0027480584
involvement O 0 0.004713649
. O 0 0.006536016

Clinically O 0 0.08284263
significant O 0 0.0065070344
proteinuria B-Disease 0 0.999974
following O 0 0.0019257207
the O 0 0.0015199381
administration O 0 0.007842818
of O 0 0.0026023695
sirolimus B-Chemical 1 0.99982625
to O 0 0.002324132
renal O 0 0.8873569
transplant O 0 0.279266
recipients O 0 0.00919045
. O 0 0.008620314

BACKGROUND O 0 0.04281176
: O 0 0.0075679095
Sirolimus B-Chemical 1 0.98875624
is O 0 0.0017317216
the O 0 0.0010121154
latest O 0 0.0014616087
immunosuppressive O 0 0.532395
agent O 0 0.028119033
used O 0 0.00035226578
to O 0 0.00026899655
prevent O 0 0.00032182134
rejection O 0 0.9369476
, O 0 0.0010288929
and O 0 0.00037991768
may O 0 0.00022006709
have O 0 0.00021359531
less O 0 0.000505229
nephrotoxicity B-Disease 0 0.9999975
than O 0 0.0003917797
calcineurin O 0 0.7100743
inhibitor O 0 0.1525899
( O 0 0.029664114
CNI O 0 0.9999528
) O 0 0.006430853
- O 0 0.007155322
based O 0 0.002551637
regimens O 0 0.004696874
. O 0 0.0063890866

To O 0 0.003138965
date O 0 0.0022143563
there O 0 0.001401631
has O 0 0.0011881703
been O 0 0.0009670643
little O 0 0.00071436045
documentation O 0 0.0008018509
of O 0 0.00077154435
clinically O 0 0.019239208
significant O 0 0.0015811445
proteinuria B-Disease 0 0.9999956
linked O 0 0.00091913017
with O 0 0.00085018645
the O 0 0.0009932342
use O 0 0.0016270323
of O 0 0.0040746685
sirolimus B-Chemical 1 0.9997203
. O 0 0.008942585

We O 0 0.004208794
have O 0 0.0026197499
encountered O 0 0.002285286
several O 0 0.0016219582
patients O 0 0.001817841
who O 0 0.0017203751
developed O 0 0.0016902173
substantial O 0 0.002543642
proteinuria B-Disease 0 0.9999932
associated O 0 0.0042858324
with O 0 0.0058800285
sirolimus B-Chemical 1 0.99978226
use O 0 0.006395807
. O 0 0.008092196

In O 0 0.0034220663
each O 0 0.001628586
patient O 0 0.0015724733
, O 0 0.0012718809
the O 0 0.0006591046
close O 0 0.0005374654
temporal O 0 0.0021565557
association O 0 0.00031801042
between O 0 0.00022888699
the O 0 0.0002478701
commencement O 0 0.00029614396
of O 0 0.0005677568
sirolimus B-Chemical 1 0.9999168
therapy O 0 0.004138804
and O 0 0.0022557334
proteinuria B-Disease 0 0.99999845
implicated O 0 0.000803838
sirolimus B-Chemical 1 0.99984086
as O 0 0.00034381714
the O 0 0.00036107833
most O 0 0.0005891948
likely O 0 0.00060270436
etiology O 0 0.009826924
of O 0 0.001949328
the O 0 0.0043780985
proteinuria B-Disease 0 0.9999826
. O 0 0.00964797

METHODS O 0 0.0039816517
: O 0 0.003337733
We O 0 0.0017647822
analyzed O 0 0.00123779
the O 0 0.0010383847
clinical O 0 0.0014605457
and O 0 0.0007214469
laboratory O 0 0.0007124195
information O 0 0.00037018763
available O 0 0.0003032725
for O 0 0.0002326715
all O 0 0.00022060784
119 O 0 0.00046305382
patients O 0 0.0002705173
transplanted O 0 0.00048692842
at O 0 0.00016608756
the O 0 0.00020279101
Washington O 0 0.0050627813
Hospital O 0 0.00060391024
Center O 0 0.0004131932
between O 0 0.0001428603
1999 O 0 0.00081117544
- O 0 0.0014511626
2003 O 0 0.0004139975
for O 0 0.00025458497
whom O 0 0.0012768194
sirolimus B-Chemical 1 0.9995646
was O 0 0.0004729622
a O 0 0.00054047373
component O 0 0.0006307311
of O 0 0.0010293734
their O 0 0.0017750645
immunosuppressant O 0 0.9313951
regimen O 0 0.008991907
. O 0 0.0066961804

In O 0 0.0036354184
these O 0 0.002552376
patients O 0 0.0023186125
, O 0 0.0015651449
the O 0 0.00079286925
magnitude O 0 0.00061900093
of O 0 0.0016844051
proteinuria B-Disease 0 0.9999969
was O 0 0.0004996639
assessed O 0 0.00021742082
on O 0 0.00018411834
morning O 0 0.0012661439
urine O 0 0.04663672
samples O 0 0.0002023159
by O 0 0.00020151268
turbidometric O 0 0.019679872
measurement O 0 0.00014434256
or O 0 0.00016811298
random O 0 0.0002868984
urine O 0 0.19978417
protein O 0 0.0011300431
: O 0 0.0025700293
creatinine B-Chemical 1 0.9963246
ratios O 0 0.00041024678
, O 0 0.00043833064
an O 0 0.0003432326
estimate O 0 0.00029694094
of O 0 0.00059969584
grams O 0 0.0012046099
of O 0 0.0025941902
proteinuria B-Disease 0 0.99999046
/ O 0 0.041951846
day O 0 0.004017564
. O 0 0.006828895

Laboratory O 0 0.011847085
results O 0 0.0030588708
were O 0 0.002270326
compared O 0 0.0013394551
between O 0 0.0012189107
prior O 0 0.0011962986
, O 0 0.0017383321
during O 0 0.0012864494
and O 0 0.0021198178
following O 0 0.0028062435
sirolimus B-Chemical 1 0.99940884
use O 0 0.0067503164
. O 0 0.009027213

RESULTS O 0 0.0061338725
: O 0 0.0043121483
Twenty O 0 0.0034018233
- O 0 0.003582052
eight O 0 0.0010499505
patients O 0 0.001183243
( O 0 0.0011192663
24 O 0 0.0006716483
% O 0 0.0006708208
) O 0 0.00077969284
developed O 0 0.00071495574
increased O 0 0.0010938789
proteinuria B-Disease 0 0.9999893
from O 0 0.00046280204
baseline O 0 0.00045091525
during O 0 0.00040413573
their O 0 0.00071981753
post O 0 0.0011362318
- O 0 0.0043488517
transplantation O 0 0.009406194
course O 0 0.004227589
. O 0 0.007053214

In O 0 0.0042290245
21 O 0 0.0030626627
patients O 0 0.0021547843
an O 0 0.0015199143
alternative O 0 0.0010107404
cause O 0 0.0012650988
of O 0 0.003823597
proteinuria B-Disease 0 0.9999982
was O 0 0.00091883156
either O 0 0.00046556466
obvious O 0 0.0004524472
or O 0 0.000449032
insufficient O 0 0.0005321816
data O 0 0.00070805073
was O 0 0.0007983642
available O 0 0.0010810117
to O 0 0.0013720335
be O 0 0.0026377898
conclusive O 0 0.0063824574
. O 0 0.0074099055

In O 0 0.0037087004
7 O 0 0.0022218588
of O 0 0.0017219342
the O 0 0.0011776036
28 O 0 0.0009823084
patients O 0 0.00075489725
there O 0 0.00038860567
was O 0 0.00040616596
a O 0 0.00038873835
striking O 0 0.00036740155
temporal O 0 0.0029456513
association O 0 0.0002071439
between O 0 0.00016359927
the O 0 0.00020557885
initiation O 0 0.00030983734
of O 0 0.00073592516
sirolimus B-Chemical 1 0.9998691
and O 0 0.0005362117
the O 0 0.00040714457
development O 0 0.0016546486
of O 0 0.008969054
nephrotic B-Disease 0 0.99999857
- O 0 0.25212657
range O 0 0.009196857
proteinuria B-Disease 0 0.99997604
. O 0 0.009149676

Proteinuria B-Disease 2 0.9999337
correlated O 0 0.002660757
most O 0 0.0021811237
strongly O 0 0.0016447594
with O 0 0.0019134296
sirolimus B-Chemical 1 0.99986506
therapy O 0 0.0019999174
when O 0 0.00044654706
compared O 0 0.0004071508
to O 0 0.0005068927
other O 0 0.00075120793
demographic O 0 0.0014600401
and O 0 0.0016180212
clinical O 0 0.004000683
variables O 0 0.0043176184
. O 0 0.0065852934

In O 0 0.004205943
most O 0 0.0032680286
patients O 0 0.0028829116
, O 0 0.0025881748
discontinuation O 0 0.48933393
of O 0 0.0024778082
sirolimus B-Chemical 1 0.99989855
resulted O 0 0.0007212802
in O 0 0.0006038584
a O 0 0.00069354987
decrease O 0 0.00060540973
, O 0 0.0009154372
but O 0 0.0008146084
not O 0 0.0008462818
resolution O 0 0.014633596
, O 0 0.0030145866
of O 0 0.0086818645
proteinuria B-Disease 0 0.999984
. O 0 0.011703847

CONCLUSIONS O 0 0.045479547
: O 0 0.007134617
Sirolimus B-Chemical 1 0.9823958
induces O 0 0.001861768
or O 0 0.0017486911
aggravates O 0 0.40265086
pre O 0 0.034439895
- O 0 0.030614432
existing O 0 0.0020867714
proteinuria B-Disease 0 0.99999297
in O 0 0.00071807357
an O 0 0.0007307439
unpredictable O 0 0.001496964
subset O 0 0.00089203275
of O 0 0.0016457237
renal O 0 0.8575009
allograft O 0 0.8574307
recipients O 0 0.01282069
. O 0 0.007970816

Proteinuria B-Disease 2 0.999915
may O 0 0.004019291
improve O 0 0.0023073852
, O 0 0.0028578055
but O 0 0.0020713431
does O 0 0.0014206342
not O 0 0.0011375044
resolve O 0 0.0011709927
, O 0 0.0019170446
when O 0 0.0019641577
sirolimus B-Chemical 1 0.99944335
is O 0 0.0049275444
withdrawn O 0 0.010136581
. O 0 0.008565957

Components O 0 0.01179048
of O 0 0.007957255
lemon O 0 0.98906446
essential O 0 0.0058870874
oil O 0 0.993543
attenuate O 0 0.054909766
dementia B-Disease 0 0.99997604
induced O 0 0.012318949
by O 0 0.035175737
scopolamine B-Chemical 1 0.9999962
. O 0 0.015570288

The O 0 0.0038745224
anti O 0 0.26910228
- O 0 0.3905597
dementia B-Disease 0 0.99992216
effects O 0 0.002018233
of O 0 0.0012187515
s B-Chemical 0 0.025761265
- I-Chemical 0 0.33695284
limonene I-Chemical 0 0.99998677
and O 0 0.0008503262
s B-Chemical 0 0.0024506522
- I-Chemical 0 0.4227998
perillyl I-Chemical 0 0.9999933
alcohol I-Chemical 0 0.99999726
were O 0 0.00029228875
observed O 0 0.0001501021
using O 0 0.0001458922
the O 0 0.00015905137
passive O 0 0.0005307647
avoidance O 0 0.003911614
test O 0 0.00043712123
( O 0 0.0021070854
PA O 0 0.9661334
) O 0 0.00091971364
and O 0 0.00033747728
the O 0 0.00031755632
open O 0 0.0005502834
field O 0 0.00090041495
habituation O 0 0.014036896
test O 0 0.0013418894
( O 0 0.0034629065
OFH O 0 0.8966026
) O 0 0.007053538
. O 0 0.007688644

These O 0 0.0057999766
lemon O 0 0.9682653
essential O 0 0.0029313804
oils O 0 0.96692866
showed O 0 0.0009925166
strong O 0 0.0008216348
ability O 0 0.00049422553
to O 0 0.00036130816
improve O 0 0.00031167516
memory B-Disease 0 0.93333817
impaired I-Disease 0 0.06155034
by O 0 0.0056235096
scopolamine B-Chemical 1 0.99999976
; O 0 0.0039627594
however O 0 0.0004790168
, O 0 0.0004164657
s B-Chemical 0 0.0011077753
- I-Chemical 0 0.38592634
perillyl I-Chemical 0 0.9999943
alcohol I-Chemical 0 0.99999857
relieved O 0 0.02183927
the O 0 0.00025490386
deficit B-Disease 0 0.04290583
of I-Disease 0 0.00040653587
associative I-Disease 0 0.15749912
memory I-Disease 0 0.4352901
in O 0 0.0005313139
PA O 0 0.96205246
only O 0 0.00043432484
, O 0 0.00041478558
and O 0 0.00031007704
did O 0 0.00026923648
not O 0 0.00022171681
improve O 0 0.00024863682
non O 0 0.0008688601
- O 0 0.011918133
associative O 0 0.06647648
memory O 0 0.20710681
significantly O 0 0.0020740663
in O 0 0.0032936602
OFH O 0 0.8944688
. O 0 0.007678043

Analysis O 0 0.00419467
of O 0 0.0029848986
neurotransmitter O 0 0.24239166
concentration O 0 0.002599115
in O 0 0.00087693287
some O 0 0.0006543928
brain O 0 0.003708315
regions O 0 0.00043414935
on O 0 0.00019012507
the O 0 0.00021150708
test O 0 0.0002186209
day O 0 0.00016211087
showed O 0 0.00018007074
that O 0 0.0002436927
dopamine B-Chemical 1 0.99961424
concentration O 0 0.0009034837
of O 0 0.00035499988
the O 0 0.00033806838
vehicle O 0 0.1370123
/ O 0 0.61059284
scopolamine B-Chemical 1 0.9999999
group O 0 0.0016511312
was O 0 0.00020299741
significantly O 0 0.00017095378
lower O 0 0.00013740126
than O 0 9.090072e-05
that O 0 0.00010013025
of O 0 0.00020739883
the O 0 0.00023986996
vehicle O 0 0.033085067
/ O 0 0.030856682
vehicle O 0 0.029337177
group O 0 0.0007487336
, O 0 0.00043329474
but O 0 0.00026647685
this O 0 0.00019666829
phenomenon O 0 0.0020498878
was O 0 0.00017441575
reversed O 0 0.00018380051
when O 0 0.00013799
s B-Chemical 0 0.004718266
- I-Chemical 0 0.2013385
limonene I-Chemical 0 0.9999856
or O 0 0.0003675783
s B-Chemical 0 0.0019756933
- I-Chemical 0 0.42100257
perillyl I-Chemical 0 0.9999913
alcohol I-Chemical 0 0.9999956
were O 0 0.00043423148
administered O 0 0.0003475308
before O 0 0.0003367495
the O 0 0.0006845539
injection O 0 0.0021768122
of O 0 0.009603282
scopolamine B-Chemical 1 0.99999654
. O 0 0.009088455

Simultaneously O 0 0.009611281
, O 0 0.0034163827
we O 0 0.0014079798
found O 0 0.0010723359
that O 0 0.0007447962
these O 0 0.0007976191
two O 0 0.00072309194
lemon O 0 0.98776245
essential O 0 0.00088015787
oil O 0 0.96479315
components O 0 0.00043451862
could O 0 0.0003003634
inhibit O 0 0.0003807614
acetylcholinesterase O 0 0.9975303
activity O 0 0.00051739626
in O 0 0.0005079408
vitro O 0 0.0008263544
using O 0 0.0010278221
the O 0 0.0018645684
Ellman O 0 0.8311069
method O 0 0.0052687987
. O 0 0.0069535845

Attentional O 0 0.09483922
modulation O 0 0.0034829509
of O 0 0.002968357
perceived O 0 0.004626893
pain B-Disease 0 0.8910227
intensity O 0 0.0019343604
in O 0 0.0030403272
capsaicin B-Chemical 0 0.9999145
- O 0 0.16673876
induced O 0 0.008672426
secondary O 2 0.987087
hyperalgesia B-Disease 2 0.9999907
. O 0 0.0155449975

Perceived O 0 0.020936923
pain B-Disease 0 0.55130464
intensity O 0 0.0070052207
is O 0 0.007178642
modulated O 0 0.0064582587
by O 0 0.010762862
attention O 0 0.017326178
. O 0 0.019457774

However O 0 0.005264871
, O 0 0.0040261494
it O 0 0.002289982
is O 0 0.001375737
not O 0 0.0008970128
known O 0 0.0007872919
that O 0 0.00046116367
how O 0 0.00044662837
pain B-Disease 0 0.5513055
intensity O 0 0.00034171276
ratings O 0 0.0004417611
are O 0 0.0002951771
affected O 0 0.00033253038
by O 0 0.00044260037
attention O 0 0.0012334395
in O 0 0.0011706426
capsaicin B-Chemical 0 0.9999033
- O 0 0.12690546
induced O 0 0.005914623
secondary O 2 0.98695326
hyperalgesia B-Disease 2 0.999992
. O 0 0.0123651475

Here O 0 0.00452941
we O 0 0.0019248144
show O 0 0.0013369521
that O 0 0.0010938038
perceived O 0 0.0024347606
pain B-Disease 0 0.89429337
intensity O 0 0.00072179484
in O 0 0.00084684964
secondary O 2 0.9260493
hyperalgesia B-Disease 2 0.99999845
is O 0 0.00083701854
decreased O 0 0.00048068428
when O 0 0.00021698054
attention O 0 0.00052368233
is O 0 0.0002725181
distracted O 0 0.001041312
away O 0 0.0002477267
from O 0 0.00025650804
the O 0 0.00039258218
painful O 0 0.6367905
pinprick O 0 0.08286809
stimulus O 0 0.00078373257
with O 0 0.0010312167
a O 0 0.0019088227
visual O 0 0.0373592
task O 0 0.0056895097
. O 0 0.006712702

Furthermore O 0 0.005060337
, O 0 0.0038660434
it O 0 0.002137544
was O 0 0.0012746492
found O 0 0.0007609414
that O 0 0.0005033924
the O 0 0.00043514994
magnitude O 0 0.00034148898
of O 0 0.0005238353
attentional O 0 0.28082854
modulation O 0 0.00048949773
in O 0 0.0005630436
secondary O 2 0.9233793
hyperalgesia B-Disease 2 0.9999981
is O 0 0.0004942325
very O 0 0.00036103994
similar O 0 0.00018558178
to O 0 0.0002109802
that O 0 0.00027368957
of O 0 0.0016146561
capsaicin B-Chemical 0 0.99994516
- O 0 0.07261823
untreated O 0 0.0016642831
, O 0 0.0018975431
control O 0 0.0022076576
condition O 0 0.0053522326
. O 0 0.0068120207

Our O 0 0.0038224256
findings O 0 0.0029264744
, O 0 0.0022629069
showing O 0 0.0012343463
no O 0 0.0007132789
interaction O 0 0.00083410484
between O 0 0.0006410308
capsaicin B-Chemical 0 0.99983823
treatment O 0 0.0014957577
and O 0 0.00061532494
attentional O 0 0.17499991
modulation O 0 0.0002591306
suggest O 0 0.00016155891
that O 0 0.00040037933
capsaicin B-Chemical 0 0.9999733
- O 0 0.20065294
induced O 0 0.0017435928
secondary O 2 0.98239636
hyperalgesia B-Disease 2 0.9999988
and O 0 0.0011636663
attention O 0 0.0008436619
might O 0 0.00028046974
affect O 0 0.0003722226
mechanical O 0 0.0015459462
pain B-Disease 0 0.5211082
through O 0 0.0009568394
independent O 0 0.001478822
mechanisms O 0 0.0031831656
. O 0 0.0065051783

Cardioprotective O 0 0.6792935
effect O 0 0.0056931744
of O 0 0.082033195
salvianolic B-Chemical 1 0.9999999
acid I-Chemical 1 0.99995804
A I-Chemical 1 0.99273795
on O 0 0.0019786013
isoproterenol B-Chemical 0 0.999987
- O 0 0.32522517
induced O 0 0.016944608
myocardial B-Disease 0 0.99998486
infarction I-Disease 2 0.99999905
in O 0 0.008132344
rats O 0 0.009462037
. O 0 0.00771864

The O 0 0.0030946983
present O 0 0.0019507608
study O 0 0.0017684096
was O 0 0.0010691651
designed O 0 0.00070520054
to O 0 0.00046703653
evaluate O 0 0.00026866366
the O 0 0.00037367875
cardioprotective O 0 0.07855974
potential O 0 0.0009672928
of O 0 0.0545588
salvianolic B-Chemical 1 1.0
acid I-Chemical 1 0.9999777
A I-Chemical 1 0.99514884
on O 0 0.00095763785
isoproterenol B-Chemical 0 0.9999887
- O 0 0.2636971
induced O 0 0.011984009
myocardial B-Disease 0 0.9999858
infarction I-Disease 2 0.99999917
in O 0 0.0065416815
rats O 0 0.008067778
. O 0 0.0066056857

Hemodynamic O 0 0.111931235
parameters O 0 0.004862025
and O 0 0.0040051886
lead O 0 0.014027532
II O 0 0.04175325
electrocardiograph O 0 0.07495161
were O 0 0.00199889
monitored O 0 0.0017739107
and O 0 0.0028441628
recorded O 0 0.0038921412
continuously O 0 0.005513764
. O 0 0.009363256

Cardiac O 0 0.054081418
marker O 0 0.0042502154
enzymes O 0 0.0073614377
and O 0 0.0028326402
antioxidative O 0 0.9600587
parameters O 0 0.0019478442
in O 0 0.0013697676
serum O 0 0.13088785
and O 0 0.002186038
heart O 0 0.12668005
tissues O 0 0.0032016814
were O 0 0.0028802701
measured O 0 0.003939491
. O 0 0.0077162297

Assay O 0 0.028886912
for O 0 0.0038618336
mitochondrial O 0 0.109534755
respiratory O 0 0.0458736
function O 0 0.0016048715
and O 0 0.0015042374
histopathological O 0 0.075996116
examination O 0 0.0014297215
of O 0 0.0018443589
heart O 0 0.09295721
tissues O 0 0.0032596646
were O 0 0.0029930635
performed O 0 0.004177921
. O 0 0.0077029984

Isoproterenol B-Chemical 0 0.9999864
- O 0 0.15667078
treated O 0 0.0026298233
rats O 0 0.001902254
showed O 0 0.00077650824
significant O 0 0.0006295228
increases O 0 0.00046652067
in O 0 0.00036873567
the O 0 0.00029459962
levels O 0 0.00031008798
of O 0 0.0013911361
lactate B-Chemical 0 0.99843806
dehydrogenase O 0 0.9992607
, O 0 0.13172369
aspartate B-Chemical 1 0.9999995
transaminase O 0 0.99999964
, O 0 0.06436749
creatine B-Chemical 1 0.9999932
kinase O 0 0.783424
and O 0 0.030096745
malondialdehyde B-Chemical 1 1.0
and O 0 0.00086263113
significant O 0 0.00023054761
decreases O 0 0.00019756498
in O 0 0.0001574681
the O 0 0.00015809758
activities O 0 0.00026071657
of O 0 0.0036616728
superoxide B-Chemical 1 0.9999994
dismutase O 0 0.9999999
, O 0 0.1450273
catalase O 0 0.9999535
and O 0 0.016935574
glutathione B-Chemical 0 0.99999285
peroxidase O 0 0.99460346
in O 0 0.00137531
serum O 0 0.24828206
and O 0 0.0036618013
heart O 0 0.23944652
. O 0 0.0066510662

These O 0 0.0037155417
rats O 0 0.003000643
also O 0 0.0016149207
showed O 0 0.0012039834
declines O 0 0.0019919304
in O 0 0.0007518664
left O 0 0.0017503242
ventricular O 0 0.82288545
systolic O 0 0.87738246
pressure O 0 0.08552718
, O 0 0.00033981484
maximum O 0 0.00017860155
and O 0 0.00018876199
minimum O 0 0.000132173
rate O 0 0.00018385958
of O 0 0.00022875912
developed O 0 0.00040100465
left O 0 0.0010724304
ventricular O 0 0.73773956
pressure O 0 0.122315966
, O 0 0.0003277005
and O 0 0.00027058672
elevation O 0 0.014430114
of O 0 0.00032918065
left O 0 0.0011366403
ventricular O 0 0.40312183
end O 0 0.00030850593
- O 0 0.0066126483
diastolic O 0 0.8328091
pressure O 0 0.06665511
and O 0 0.0017674185
ST O 0 0.84028095
- O 0 0.008637225
segment O 0 0.0051914435
. O 0 0.0069516087

In O 0 0.0034967444
addition O 0 0.0019780092
, O 0 0.0034142663
mitochondrial O 0 0.6188875
respiratory B-Disease 0 0.9831444
dysfunction I-Disease 0 0.9984163
characterized O 0 0.0018661027
by O 0 0.0005800433
decreased O 0 0.00061405916
respiratory O 0 0.020044586
control O 0 0.0003756294
ratio O 0 0.00055919396
and O 0 0.002416743
ADP B-Chemical 0 0.9999403
/ O 0 0.41084185
O O 0 0.99996984
was O 0 0.0007562699
observed O 0 0.0006163506
in O 0 0.0014654881
isoproterenol B-Chemical 0 0.99992156
- O 0 0.058657456
treated O 0 0.0038230359
rats O 0 0.0055973777
. O 0 0.0065051755

Administration O 0 0.15742217
of O 0 0.07252116
salvianolic B-Chemical 1 0.99999976
acid I-Chemical 1 0.99991584
A I-Chemical 1 0.96913445
for O 0 0.00097391667
a O 0 0.0006446967
period O 0 0.00031673783
of O 0 0.00036621105
8 O 0 0.00025450098
days O 0 0.00017738096
significantly O 0 0.00027974174
attenuated O 0 0.0051774285
isoproterenol B-Chemical 0 0.9999901
- O 0 0.20440204
induced O 0 0.0014653136
cardiac B-Disease 0 0.9877864
dysfunction I-Disease 0 0.999204
and O 0 0.018541373
myocardial B-Disease 0 0.99999475
injury I-Disease 0 0.99884415
and O 0 0.0013380169
improved O 0 0.0018120074
mitochondrial O 0 0.18020761
respiratory O 0 0.13118531
function O 0 0.0042828564
. O 0 0.006812689

The O 0 0.0034655307
protective O 0 0.0048131845
role O 0 0.0017960423
of O 0 0.052109364
salvianolic B-Chemical 1 1.0
acid I-Chemical 1 0.9999765
A I-Chemical 1 0.99640083
against O 0 0.029831398
isoproterenol B-Chemical 0 0.99999726
- O 0 0.46908194
induced O 0 0.008613157
myocardial B-Disease 0 0.9999969
damage I-Disease 0 0.9984414
was O 0 0.00074457115
further O 0 0.0006050354
confirmed O 0 0.0009066991
by O 0 0.0015663242
histopathological O 0 0.20508178
examination O 0 0.0047082477
. O 0 0.0065518813

The O 0 0.0030699095
results O 0 0.0020487693
of O 0 0.0017907182
our O 0 0.0012454458
study O 0 0.0010644413
suggest O 0 0.000574234
that O 0 0.0019698895
salvianolic B-Chemical 1 1.0
acid I-Chemical 1 0.99997735
A I-Chemical 1 0.9962568
possessing O 0 0.06509403
antioxidant O 0 0.99920624
activity O 0 0.00055378745
has O 0 0.00024574102
a O 0 0.00031491645
significant O 0 0.00029535108
protective O 0 0.0036381418
effect O 0 0.00069730665
against O 0 0.0051592803
isoproterenol B-Chemical 0 0.9999933
- O 0 0.5231771
induced O 0 0.046739362
myocardial B-Disease 0 0.99998486
infarction I-Disease 2 0.9999987
. O 0 0.027623363

Long O 0 0.029635878
- O 0 0.014609771
term O 0 0.0044905026
glutamate B-Chemical 1 0.99979955
supplementation O 0 0.87298393
failed O 0 0.0016776321
to O 0 0.0010538613
protect O 0 0.0014855447
against O 0 0.0024201665
peripheral B-Disease 0 0.97587603
neurotoxicity I-Disease 2 0.9999976
of O 0 0.07394199
paclitaxel B-Chemical 1 0.99934584
. O 0 0.011190159

Toxic O 0 0.9683838
peripheral B-Disease 2 0.96959376
neuropathy I-Disease 2 0.9999963
is O 0 0.0021004144
still O 0 0.00089239486
a O 0 0.0007373783
significant O 0 0.0004780486
limiting O 0 0.00061016524
factor O 0 0.006873311
for O 0 0.00042353998
chemotherapy O 0 0.07528313
with O 0 0.0014903005
paclitaxel B-Chemical 1 0.99967694
( O 0 0.05550653
PAC B-Chemical 0 0.99963546
) O 0 0.007847817
, O 0 0.00085935404
although O 0 0.00080248463
glutamate B-Chemical 1 0.9997478
and O 0 0.00041271446
its O 0 0.0005196275
closely O 0 0.00027568202
related O 0 0.00026382424
amino B-Chemical 0 0.9957411
acid I-Chemical 0 0.9995426
glutamine B-Chemical 0 0.9999219
were O 0 0.0010444134
claimed O 0 0.0014710164
to O 0 0.0010481027
ameliorate O 0 0.0874788
PAC B-Chemical 0 0.9996389
neurotoxicity B-Disease 2 0.9999696
. O 0 0.009923798

This O 0 0.0050224033
pilot O 0 0.0032278278
trial O 0 0.0018867375
aimed O 0 0.0011560853
to O 0 0.0006712621
evaluate O 0 0.00035007345
the O 0 0.0003883724
role O 0 0.00030283886
of O 0 0.0019475113
glutamate B-Chemical 1 0.9999808
supplementation O 0 0.96784914
for O 0 0.000694694
preventing O 0 0.02471571
PAC B-Chemical 0 0.9998523
- O 0 0.11707007
induced O 0 0.0009500924
peripheral B-Disease 2 0.95738924
neuropathy I-Disease 2 0.9999993
in O 0 0.0002865332
a O 0 0.00028325047
randomized O 0 0.00025330606
, O 0 0.00037520335
placebo O 0 0.016509546
- O 0 0.0014468367
controlled O 0 0.0002137206
, O 0 0.00036812152
double O 0 0.0004135831
- O 0 0.00256575
blinded O 0 0.00055170426
clinical O 0 0.0009939403
and O 0 0.0009324423
electro O 0 0.060505047
- O 0 0.0046349284
diagnostic O 0 0.003187799
study O 0 0.004579634
. O 0 0.006658127

Forty O 0 0.008573528
- O 0 0.009208892
three O 0 0.0019326893
ovarian B-Disease 2 0.9958794
cancer I-Disease 2 0.99988437
patients O 0 0.004229707
were O 0 0.0006201444
available O 0 0.00040747967
for O 0 0.0002699078
analysis O 0 0.00025408977
following O 0 0.00017373255
six O 0 0.00012983868
cycles O 0 0.00012034216
of O 0 0.00018968107
the O 0 0.00019765581
same O 0 0.00020612137
PAC B-Chemical 0 0.9965585
- O 0 0.009961637
containing O 0 0.00018316491
regimen O 0 0.0004399792
: O 0 0.00049096637
23 O 0 0.00027587422
had O 0 0.0001456352
been O 0 0.00015726598
supplemented O 0 0.00065669825
by O 0 0.0005271673
glutamate B-Chemical 1 0.9996644
all O 0 0.00016421816
along O 0 0.00011874935
the O 0 0.0001284344
treatment O 0 0.00016064581
period O 0 0.00011748865
, O 0 0.00020657289
at O 0 0.0001215522
a O 0 0.00017364477
daily O 0 0.00016428255
dose O 0 0.00029491913
of O 0 0.00014257371
three O 0 8.171514e-05
times O 0 8.6505745e-05
500 O 0 0.00023582284
mg O 0 0.0059907762
( O 0 0.00037963022
group O 0 0.0007582971
G O 0 0.98738384
) O 0 0.0020400234
, O 0 0.0004179942
and O 0 0.0002984563
20 O 0 0.000262521
had O 0 0.00026882888
received O 0 0.0003210935
a O 0 0.000666358
placebo O 0 0.01323197
( O 0 0.0015753914
group O 0 0.002409424
P O 0 0.07595645
) O 0 0.006783394
. O 0 0.007713817

Patients O 0 0.004800178
were O 0 0.0025525799
evaluated O 0 0.0016757916
by O 0 0.0018367884
neurological O 0 0.4709752
examinations O 0 0.001438599
, O 0 0.0011073863
questionnaires O 0 0.000806738
and O 0 0.00096054375
sensory O 0 0.0028008244
- O 0 0.005055643
motor O 0 0.01130178
nerve O 0 0.01940295
conduction O 0 0.0058738412
studies O 0 0.0047289412
. O 0 0.007842673

There O 0 0.0041048992
was O 0 0.0024568802
no O 0 0.0013584495
significant O 0 0.001120482
difference O 0 0.00064448785
in O 0 0.0005785805
the O 0 0.00044997962
frequency O 0 0.0004817927
of O 0 0.00053047057
signs O 0 0.05560948
or O 0 0.00038388072
symptoms O 0 0.04949694
between O 0 0.000143167
the O 0 0.00016699286
two O 0 0.00014043432
groups O 0 0.00022795895
although O 0 0.00047508362
neurotoxicity B-Disease 2 0.9999796
symptoms O 0 0.26140934
presented O 0 0.0002091982
mostly O 0 0.00030216627
with O 0 0.00030252832
lower O 0 0.00033372105
scores O 0 0.00041563972
of O 0 0.00072052446
severity O 0 0.004107867
in O 0 0.0016697857
group O 0 0.004366634
G O 0 0.9528917
. O 0 0.008569274

However O 0 0.004687808
, O 0 0.00322659
this O 0 0.0015821554
difference O 0 0.00087408186
reached O 0 0.0007978866
statistical O 0 0.0010065924
significance O 0 0.00055801834
only O 0 0.0004694421
with O 0 0.00038576341
regard O 0 0.00029354886
to O 0 0.00031664723
reported O 0 0.00074637594
pain B-Disease 0 0.930717
sensation O 0 0.42727682
( O 0 0.0015938947
P O 0 0.06921261
= O 0 0.0018593868
0 O 0 0.0015833256
. O 0 0.0021684833
011 O 0 0.096716434
) O 0 0.0065445206
. O 0 0.008403648

Also O 0 0.004307659
the O 0 0.002184066
frequency O 0 0.0017593555
of O 0 0.001583934
abnormal O 0 0.032736883
electro O 0 0.48210508
- O 0 0.009511851
diagnostic O 0 0.0005756848
findings O 0 0.00038177165
showed O 0 0.00022757998
similarity O 0 0.00022489575
between O 0 0.00015681764
the O 0 0.00018136845
two O 0 0.00015901982
groups O 0 0.00025877036
( O 0 0.0008385873
G O 0 0.97742635
: O 0 0.000907637
7 O 0 0.0002158578
/ O 0 0.00074009504
23 O 0 0.00034049343
= O 0 0.00034854395
30 O 0 0.00019081843
. O 0 0.00020397236
4 O 0 0.0002191466
% O 0 0.00035014088
; O 0 0.0006408154
P O 0 0.014397355
: O 0 0.00071545196
6 O 0 0.00046785534
/ O 0 0.0011649905
20 O 0 0.0008907468
= O 0 0.001589455
30 O 0 0.0016206739
% O 0 0.003227346
) O 0 0.0061463853
. O 0 0.008438989

This O 0 0.0055979276
pilot O 0 0.0036671008
study O 0 0.0020967617
leads O 0 0.0011579086
to O 0 0.0008109825
the O 0 0.0006454
conclusion O 0 0.0004946624
that O 0 0.00075254304
glutamate B-Chemical 1 0.9999654
supplementation O 0 0.9053035
at O 0 0.00030813526
the O 0 0.00024833638
chosen O 0 0.00024503237
regimen O 0 0.00037301925
fails O 0 0.00033632712
to O 0 0.0003521637
protect O 0 0.0006921352
against O 0 0.0015653031
peripheral B-Disease 0 0.97332543
neurotoxicity I-Disease 2 0.9999976
of O 0 0.06394807
PAC B-Chemical 0 0.9980525
. O 0 0.009013045

Development O 0 0.0123495385
of O 0 0.0054697497
ocular B-Disease 0 0.99692565
myasthenia I-Disease 0 0.9999037
during O 0 0.003457668
pegylated B-Chemical 0 0.999966
interferon I-Chemical 0 0.99999857
and O 0 0.258401
ribavirin B-Chemical 1 0.99999475
treatment O 0 0.035774834
for O 0 0.0100359395
chronic B-Disease 2 0.99989665
hepatitis I-Disease 2 1.0
C I-Disease 2 0.99999845
. O 0 0.20211208

A O 0 0.06799781
63 O 0 0.0057822666
- O 0 0.0071107284
year O 0 0.0020908278
- O 0 0.0037996522
old O 0 0.0011290837
male O 0 0.0021366796
experienced O 0 0.0012940574
sudden O 0 0.9907409
diplopia B-Disease 0 0.99989927
after O 0 0.00027556875
9 O 0 0.00023986105
weeks O 0 0.00014526476
of O 0 0.00022134547
administration O 0 0.0014787734
of O 0 0.0014024877
pegylated B-Chemical 0 0.999982
interferon I-Chemical 0 0.99999976
( I-Chemical 0 0.722595
IFN I-Chemical 0 0.9999993
) I-Chemical 0 0.34738532
alpha I-Chemical 0 0.98900384
- I-Chemical 0 0.23020495
2b I-Chemical 0 0.0012183766
and O 0 0.0013748248
ribavirin B-Chemical 1 0.999984
for O 0 0.011643513
chronic B-Disease 2 0.99994874
hepatitis I-Disease 2 1.0
C I-Disease 2 0.99999976
( O 0 0.83577514
CHC B-Disease 0 0.9999515
) O 0 0.07551963
. O 0 0.00935263

Ophthalmologic O 0 0.14774308
examinations O 0 0.0031620236
showed O 0 0.00195771
ptosis B-Disease 0 0.6584776
on I-Disease 0 0.00076031155
the I-Disease 0 0.00072657067
right I-Disease 0 0.0011260933
upper I-Disease 0 0.00083589705
lid I-Disease 0 0.017562767
and O 0 0.00050663133
restricted B-Disease 0 0.00040413465
right I-Disease 0 0.00096406986
eye I-Disease 0 0.017255219
movement I-Disease 0 0.0012350054
without O 0 0.0007493725
any O 0 0.0009779586
other O 0 0.0020015896
neurological O 0 0.9512207
signs O 0 0.2811362
. O 0 0.00725576

A O 0 0.05303606
brain O 0 0.011557931
imaging O 0 0.0048642727
study O 0 0.0024338006
and O 0 0.0019265146
repetitive O 0 0.0022399216
nerve O 0 0.01048523
stimulation O 0 0.0017406704
test O 0 0.0020324297
indicated O 0 0.0021557359
no O 0 0.0033055786
abnormality O 0 0.097252816
. O 0 0.009654174

The O 0 0.0049271653
acetylcholine B-Chemical 1 0.99949527
receptor O 0 0.12873358
antibody O 0 0.13459648
titer O 0 0.2318948
and O 0 0.0011092321
response O 0 0.0010269803
to O 0 0.00061290205
acetylcholinesterase O 0 0.9981653
inhibitors O 0 0.0022859853
were O 0 0.0002647417
negative O 0 0.0003673974
, O 0 0.00038853232
and O 0 0.00030936924
the O 0 0.00028706636
results O 0 0.00034449535
of O 0 0.0006855351
thyroid O 0 0.2692737
function O 0 0.0011792823
tests O 0 0.002401268
were O 0 0.002257
normal O 0 0.00451682
. O 0 0.006585446

The O 0 0.0033966268
patient O 0 0.002630603
' O 0 0.0022724085
s O 0 0.0018658388
ophthalmological O 0 0.17119859
symptoms O 0 0.094366655
improved O 0 0.0007707382
rapidly O 0 0.00056028954
3 O 0 0.0003252491
weeks O 0 0.00023350581
after O 0 0.0002622291
discontinuation O 0 0.067125104
of O 0 0.0012182618
pegylated B-Chemical 0 0.9997714
IFN I-Chemical 0 0.99999857
alpha I-Chemical 0 0.99853337
- I-Chemical 0 0.5578707
2b I-Chemical 0 0.005538854
and O 0 0.006452313
ribavirin B-Chemical 1 0.99989927
. O 0 0.012107227

The O 0 0.0042589386
ocular B-Disease 0 0.9914664
myasthenia I-Disease 0 0.9997509
associated O 0 0.002206767
with O 0 0.0009925447
combination O 0 0.0009312646
therapy O 0 0.0014208318
of O 0 0.0024647133
pegylated B-Chemical 0 0.99993074
IFN I-Chemical 0 0.99999976
alpha I-Chemical 0 0.9996742
- I-Chemical 0 0.7104415
2b I-Chemical 0 0.0034155126
and O 0 0.0023195823
ribavirin B-Chemical 1 0.9999912
for O 0 0.0035334136
CHC B-Disease 0 0.99993837
is O 0 0.00062025175
very O 0 0.0005209392
rarely O 0 0.0004282419
reported O 0 0.00031057972
; O 0 0.00039093074
therefore O 0 0.00021476053
, O 0 0.00023591417
we O 0 0.00011308148
present O 0 0.00012408459
this O 0 0.00015892525
case O 0 0.00020189502
with O 0 0.00023267683
a O 0 0.00029559078
review O 0 0.00039398234
of O 0 0.0003291665
the O 0 0.00037121554
various O 0 0.0006945659
eye O 0 0.106656194
complications O 0 0.57169545
of O 0 0.008601785
IFN B-Chemical 0 0.9999572
therapy O 0 0.14970842
. O 0 0.008782287

Learning B-Disease 0 0.038630743
and I-Disease 0 0.00481592
memory I-Disease 0 0.9729806
deficits I-Disease 0 0.9949649
in O 0 0.0044354154
ecstasy B-Chemical 1 0.9999931
users O 0 0.009012572
and O 0 0.00075497595
their O 0 0.0006346254
neural O 0 0.0010302298
correlates O 0 0.0006509759
during O 0 0.0006213283
a O 0 0.0011639461
face O 0 0.002215891
- O 0 0.007889368
learning O 0 0.0062658517
task O 0 0.0066795307
. O 0 0.0077840276

It O 0 0.005265136
has O 0 0.002776104
been O 0 0.0020606
consistently O 0 0.0015201597
shown O 0 0.0010627988
that O 0 0.0012569173
ecstasy B-Chemical 1 0.99998796
users O 0 0.008493221
display O 0 0.0009748014
impairments B-Disease 0 0.13773878
in I-Disease 0 0.0011212176
learning I-Disease 0 0.0026277057
and I-Disease 0 0.002406826
memory I-Disease 0 0.17137016
performance O 0 0.0073396326
. O 0 0.008152924

In O 0 0.0033888842
addition O 0 0.0018302258
, O 0 0.0023882727
working O 0 0.0031204312
memory O 0 0.16776311
processing O 0 0.0010898826
in O 0 0.0018611018
ecstasy B-Chemical 1 0.9999975
users O 0 0.025302542
has O 0 0.00032188857
been O 0 0.00025909924
shown O 0 0.00016715903
to O 0 0.00015592258
be O 0 0.00017526062
associated O 0 0.00019182508
with O 0 0.00020783927
neural O 0 0.0008503262
alterations O 0 0.00078588194
in O 0 0.00020922294
hippocampal O 0 0.18403858
and O 0 0.0003167825
/ O 0 0.0015957337
or O 0 0.00020837643
cortical O 0 0.002011367
regions O 0 0.00025522753
as O 0 0.00019234484
measured O 0 0.00021359204
by O 0 0.00033342463
functional O 0 0.0005186549
magnetic O 0 0.010311575
resonance O 0 0.40446857
imaging O 0 0.0028308977
( O 0 0.0026439803
fMRI O 0 0.0072492827
) O 0 0.0055470127
. O 0 0.007633428

Using O 0 0.003392623
functional O 0 0.0023701591
imaging O 0 0.002712287
and O 0 0.001391446
a O 0 0.0012257928
face O 0 0.0017950039
- O 0 0.011527209
learning O 0 0.0019530163
task O 0 0.0008568668
, O 0 0.00043610964
we O 0 0.00019013413
investigated O 0 0.00018840452
neural O 0 0.0004715585
correlates O 0 0.000215286
of O 0 0.00024034455
encoding O 0 0.0002274919
and O 0 0.00035212425
recalling O 0 0.011008726
face O 0 0.001060216
- O 0 0.006170875
name O 0 0.00021702028
associations O 0 0.00017927772
in O 0 0.00017221451
20 O 0 0.00020259967
recreational O 0 0.0204695
drug O 0 0.096092604
users O 0 0.0011076644
whose O 0 0.00035755354
predominant O 0 0.0005232774
drug O 0 0.13133982
use O 0 0.00062682916
was O 0 0.0011105124
ecstasy B-Chemical 1 0.9999572
and O 0 0.0016209718
20 O 0 0.0020319384
controls O 0 0.0039932188
. O 0 0.006176975

To O 0 0.0025154278
address O 0 0.0013340901
the O 0 0.0011720207
potential O 0 0.0010092497
confounding O 0 0.0011621995
effects O 0 0.00089185167
of O 0 0.0007829959
the O 0 0.0010833107
cannabis B-Chemical 0 0.9999788
use O 0 0.00041466142
of O 0 0.00041323435
the O 0 0.00067984604
ecstasy B-Chemical 1 0.9999939
using O 0 0.00024200429
group O 0 0.00032462983
, O 0 0.00026141206
a O 0 0.00018830036
second O 0 0.00013183289
analysis O 0 0.00014322791
included O 0 0.00012481869
14 O 0 0.00013200799
previously O 0 0.00014338463
tested O 0 0.00023980893
cannabis B-Chemical 0 0.9999769
users O 0 0.012415312
( O 0 0.00078751286
Nestor O 0 0.33312914
, O 0 0.0010322725
L O 0 0.9460465
. O 0 0.00031762655
, O 0 0.00058986625
Roberts O 0 0.14521174
, O 0 0.0020050136
G O 0 0.99184656
. O 0 0.000423408
, O 0 0.001143473
Garavan O 0 0.9704889
, O 0 0.0057651727
H O 1 0.9999956
. O 0 0.0005505859
, O 0 0.0010837395
Hester O 0 0.35655618
, O 0 0.0032939734
R O 0 0.9986362
. O 0 0.0003773326
, O 0 0.00046333633
2008 O 0 0.0010072951
. O 0 0.00022107865
Deficits B-Disease 0 0.0037596659
in I-Disease 0 0.00017641614
learning I-Disease 0 0.00050382037
and I-Disease 0 0.0002947949
memory I-Disease 0 0.29383868
: O 0 0.006077966
parahippocampal O 0 0.9983411
hyperactivity B-Disease 2 0.99995804
and O 0 0.0015567599
frontocortical O 0 0.99292564
hypoactivity O 0 0.99979144
in O 0 0.00071756495
cannabis B-Chemical 0 0.99997854
users O 0 0.007238909
. O 0 0.00048497922
Neuroimage O 0 0.04258864
40 O 0 0.0007769619
, O 0 0.0014432967
1328 O 0 0.015062034
- O 0 0.009729734
1339 O 0 0.22677335
) O 0 0.007208542
. O 0 0.008630141

Ecstasy B-Chemical 0 0.99989414
users O 0 0.008526813
performed O 0 0.0020023058
significantly O 0 0.001602233
worse O 0 0.0016899864
in O 0 0.0009388166
learning O 0 0.001558841
and O 0 0.0009710296
memory O 0 0.030864628
compared O 0 0.0006868341
to O 0 0.0009143057
controls O 0 0.0019633884
and O 0 0.003527224
cannabis B-Chemical 0 0.9999136
users O 0 0.0394895
. O 0 0.008009611

A O 0 0.02962827
conjunction O 0 0.0028945722
analysis O 0 0.001771329
of O 0 0.0013301634
the O 0 0.0008404812
encode O 0 0.0005617584
and O 0 0.0006204137
recall O 0 0.0013135192
phases O 0 0.0005001649
of O 0 0.0003682054
the O 0 0.00027929692
task O 0 0.0006188806
revealed O 0 0.00076689076
ecstasy B-Chemical 1 0.99999845
- O 0 0.041467324
specific O 0 0.00037403926
hyperactivity B-Disease 2 0.9998857
in O 0 0.00027210635
bilateral O 0 0.059311375
frontal O 0 0.49620628
regions O 0 0.0002797401
, O 0 0.0002531339
left O 0 0.00043263723
temporal O 0 0.008586171
, O 0 0.0003760432
right O 0 0.0012329909
parietal O 0 0.7457931
, O 0 0.0004795442
bilateral O 0 0.015432657
temporal O 0 0.010481041
, O 0 0.00069544645
and O 0 0.000891061
bilateral O 0 0.15411475
occipital O 0 0.96933013
brain O 0 0.016609589
regions O 0 0.004287328
. O 0 0.0064233537

Ecstasy B-Chemical 0 0.99997175
- O 0 0.10137224
specific O 0 0.00333141
hypoactivity O 0 0.9991473
was O 0 0.0011688832
evident O 0 0.0006843405
in O 0 0.00046135447
the O 0 0.00038512368
right O 0 0.00070250675
dorsal O 0 0.0017288949
anterior O 0 0.1277408
cingulated O 0 0.9997528
cortex O 0 0.5592361
( O 0 0.0012435373
ACC O 0 0.728041
) O 0 0.0010273885
and O 0 0.00092407735
left O 0 0.002836446
posterior O 0 0.43040788
cingulated O 0 0.9995165
cortex O 0 0.50320876
. O 0 0.006903139

In O 0 0.0039537
both O 0 0.004100046
ecstasy B-Chemical 1 0.9999764
and O 0 0.014429952
cannabis B-Chemical 0 0.99997425
groups O 0 0.0016796394
brain O 0 0.0145748295
activation O 0 0.000777908
was O 0 0.00035476443
decreased O 0 0.0003158844
in O 0 0.00021912152
the O 0 0.00021614674
right O 0 0.00083250896
medial O 0 0.118539765
frontal O 0 0.9087057
gyrus O 0 0.9566539
, O 0 0.0005498441
left O 0 0.0038308364
parahippocampal O 0 0.99493647
gyrus O 0 0.9463944
, O 0 0.0005454177
left O 0 0.0011053486
dorsal O 0 0.013690533
cingulate O 0 0.9991025
gyrus O 0 0.9239372
, O 0 0.0014732552
and O 0 0.0018328966
left O 0 0.0059351213
caudate O 0 0.6999682
. O 0 0.0068163387

These O 0 0.0037866838
results O 0 0.0027954837
elucidated O 0 0.008859238
ecstasy B-Chemical 1 0.9999914
- O 0 0.071844146
related O 0 0.000989034
deficits O 0 0.48389146
, O 0 0.0010017129
only O 0 0.00060627644
some O 0 0.0005059297
of O 0 0.00061146414
which O 0 0.00069866265
might O 0 0.00052509014
be O 0 0.00079209596
attributed O 0 0.0010161598
to O 0 0.0019900326
cannabis B-Chemical 0 0.9998266
use O 0 0.0052772923
. O 0 0.007400015

These O 0 0.008047681
ecstasy B-Chemical 1 0.99997306
- O 0 0.043495316
specific O 0 0.0015059793
effects O 0 0.0013884573
may O 0 0.00067367346
be O 0 0.0005104163
related O 0 0.0003022043
to O 0 0.00028479612
the O 0 0.00030045275
vulnerability O 0 0.009663584
of O 0 0.00074821763
isocortical O 0 0.9768059
and O 0 0.00063107925
allocortical O 0 0.41267815
regions O 0 0.0005315632
to O 0 0.0004359766
the O 0 0.0008185066
neurotoxic B-Disease 0 0.9971438
effects O 0 0.0034093442
of O 0 0.01621334
ecstasy B-Chemical 1 0.9999851
. O 0 0.00929386

Disulfiram B-Chemical 0 0.99998546
- O 0 0.086041234
like O 0 0.002635514
syndrome O 0 0.48953703
after O 0 0.0020245113
hydrogen B-Chemical 0 0.9999987
cyanamide I-Chemical 0 0.99999917
professional O 0 0.027476456
skin O 0 0.18892074
exposure O 0 0.010787588
: O 0 0.0013766491
two O 0 0.000784844
case O 0 0.0012574317
reports O 0 0.0019852126
in O 0 0.0031182545
France O 0 0.03588532
. O 0 0.008059132

Hydrogen B-Chemical 0 0.9999193
cyanamide I-Chemical 0 0.9999888
is O 0 0.004522864
a O 0 0.0027484177
plant O 0 0.012389395
growth O 0 0.0031534801
regulator O 0 0.00069311744
used O 0 0.0006531768
in O 0 0.0007174737
agriculture O 0 0.066470325
to O 0 0.0006874101
induce O 0 0.0007458477
bud O 0 0.018114883
break O 0 0.0024433264
in O 0 0.0022979183
fruit O 0 0.19533022
trees O 0 0.006443668
. O 0 0.008100026

Contact O 0 0.13501865
with O 0 0.0029789442
the O 0 0.00202657
skin O 0 0.018230604
can O 0 0.0008198359
result O 0 0.00059468363
in O 0 0.0005527765
percutaneous O 0 0.0010018473
absorption O 0 0.37533817
of O 0 0.0005185644
the O 0 0.00043723354
substance O 0 0.79689646
that O 0 0.00028539952
inhibits O 0 0.0011440711
aldehyde B-Chemical 0 0.9999987
dehydrogenase O 0 0.99834836
and O 0 0.00083267223
can O 0 0.0002756933
induce O 0 0.00045066193
acetaldehyde B-Chemical 0 0.99999905
syndrome O 0 0.8151529
in O 0 0.0007334799
case O 0 0.001114563
of O 0 0.0028364137
alcohol B-Chemical 0 0.9997849
use O 0 0.0048682354
. O 0 0.006387649

The O 0 0.0031528836
purpose O 0 0.0022261643
of O 0 0.0017431845
this O 0 0.0012363814
report O 0 0.0014758783
is O 0 0.0006800453
to O 0 0.00042476915
describe O 0 0.0003429624
two O 0 0.00027868012
cases O 0 0.00043994104
of O 0 0.0005806443
a O 0 0.008685728
disulfiram B-Chemical 0 0.9999995
- O 0 0.10463927
like O 0 0.00049274525
syndrome O 0 0.24438532
following O 0 0.0004899423
occupational O 0 0.013222511
exposure O 0 0.027981753
to O 0 0.0048496653
hydrogen B-Chemical 0 0.9999964
cyanamide I-Chemical 0 0.9999968
. O 0 0.017123204

The O 0 0.0030808481
first O 0 0.0019282582
case O 0 0.0015681844
involved O 0 0.0009883662
a O 0 0.0011433477
59 O 0 0.0013926312
- O 0 0.0030957519
year O 0 0.00068638887
- O 0 0.0025489475
old O 0 0.000516118
man O 0 0.014825289
who O 0 0.00059718074
used O 0 0.00032405622
Dormex B-Chemical 0 0.7892994
, O 0 0.00056454184
which O 0 0.0005692057
contains O 0 0.0016134591
hydrogen B-Chemical 0 0.99999976
cyanamide I-Chemical 0 0.99999976
, O 0 0.003016952
without O 0 0.00031907824
protection O 0 0.0013370584
after O 0 0.00021104376
consuming O 0 0.00067131367
a O 0 0.00029202417
large O 0 0.00032177992
amount O 0 0.00033491082
of O 0 0.0012338491
alcohol B-Chemical 0 0.99962294
during O 0 0.0014687503
a O 0 0.0032709003
meal O 0 0.015395165
. O 0 0.0063563897

In O 0 0.0037000652
less O 0 0.0022255203
than O 0 0.0012304304
1 O 0 0.0009987322
hour O 0 0.0006414405
after O 0 0.00044013272
the O 0 0.0005272789
ingestion O 0 0.29882964
of O 0 0.0033306929
alcohol B-Chemical 0 0.9999801
, O 0 0.0016525751
he O 0 0.00048894767
developed O 0 0.002047626
malaise O 0 0.9996418
with O 0 0.0008339066
flushing B-Disease 0 0.7990353
of I-Disease 0 0.0005004852
the I-Disease 0 0.00048541487
face I-Disease 0 0.0015355494
, O 0 0.0031082148
tachycardia B-Disease 2 0.99945396
, O 0 0.0033488316
and O 0 0.0045966813
dyspnea B-Disease 0 0.9919125
. O 0 0.007546687

Manifestations O 0 0.026559012
regressed O 0 0.011387855
spontaneously O 0 0.0074405293
under O 0 0.0043009007
surveillance O 0 0.00599396
in O 0 0.005900123
the O 0 0.0072720284
hospital O 0 0.013270814
. O 0 0.014559361

The O 0 0.003388147
second O 0 0.002427557
case O 0 0.001879073
occurred O 0 0.0013494887
in O 0 0.0010711397
a O 0 0.0011325862
55 O 0 0.0011482277
- O 0 0.0026496814
year O 0 0.0009187563
- O 0 0.0025069998
old O 0 0.0010326835
farmer O 0 0.0037853855
following O 0 0.00112535
cutaneous O 0 0.18139479
contact O 0 0.0045087864
with O 0 0.005254678
Dormex B-Chemical 0 0.90625215
. O 0 0.008787807

Five O 0 0.0042301915
hours O 0 0.00210556
after O 0 0.001308157
exposure O 0 0.0032875293
, O 0 0.0016749398
he O 0 0.0011923482
developed O 0 0.02243584
disulfiram B-Chemical 0 0.9999995
- O 0 0.18771604
like O 0 0.00053522777
syndrome O 0 0.532025
with O 0 0.0012939409
flushing B-Disease 0 0.9768198
, O 0 0.0038193094
tachycardia B-Disease 2 0.99971706
, O 0 0.0010421774
and O 0 0.0011461934
arterial B-Disease 0 0.9969825
hypotension I-Disease 2 0.9999968
after O 0 0.00044918203
consuming O 0 0.0011804551
three O 0 0.00065785646
glasses O 0 0.011190155
of O 0 0.0035857095
wine O 0 0.94213456
. O 0 0.007161683

The O 0 0.0040494506
patient O 0 0.00305624
recovered O 0 0.0020214308
spontaneously O 0 0.0026436131
in O 0 0.0014677102
3 O 0 0.0012227783
hours O 0 0.0010600326
under O 0 0.0012277137
surveillance O 0 0.002207057
in O 0 0.0025012456
the O 0 0.0035755832
hospital O 0 0.007734389
. O 0 0.009025187

These O 0 0.0035167278
cases O 0 0.002560843
confirm O 0 0.0010810436
the O 0 0.0009818419
necessity O 0 0.0009112517
of O 0 0.00092236034
avoiding O 0 0.004500646
alcohol B-Chemical 0 0.9999788
consumption O 0 0.40252316
as O 0 0.00034602932
recommended O 0 0.000290043
in O 0 0.00020332962
the O 0 0.0001931303
instructions O 0 0.00022535509
for O 0 0.00020846684
use O 0 0.00025907598
of O 0 0.00046742425
Dormex B-Chemical 0 0.71696717
and O 0 0.00054507086
of O 0 0.00071860553
preventing O 0 0.0018231638
cutaneous O 0 0.44587803
contact O 0 0.003064416
during O 0 0.0018678647
use O 0 0.0037875024
. O 0 0.0062240344

Sulpiride B-Chemical 0 0.99998343
- O 0 0.560342
induced O 0 0.35339665
tardive B-Disease 0 0.9999969
dystonia I-Disease 2 0.9999926
. O 0 0.04956696

Sulpiride B-Chemical 0 0.9999869
is O 0 0.0051070885
a O 0 0.0043465416
selective O 0 0.11138917
D2 O 0 0.9998585
- O 0 0.23137233
receptor O 0 0.21059951
antagonist O 0 0.95551515
with O 0 0.00727708
antipsychotic O 0 0.9997267
and O 0 0.0042808987
antidepressant B-Chemical 1 0.99965286
properties O 0 0.004653681
. O 0 0.0072938194

Although O 0 0.003108017
initially O 0 0.002406866
thought O 0 0.0015558365
to O 0 0.00097132113
be O 0 0.00084127043
free O 0 0.0009562847
of O 0 0.002846904
extrapyramidal O 0 0.99999726
side O 0 0.32970557
effects O 0 0.010755417
, O 0 0.112436056
sulpiride B-Chemical 0 1.0
- O 0 0.5555225
induced O 0 0.052130375
tardive B-Disease 0 1.0
dyskinesia I-Disease 0 0.9999999
and O 0 0.06924784
parkinsonism B-Disease 2 0.99999774
have O 0 0.0009967482
been O 0 0.001444695
reported O 0 0.0025251915
occasionally O 0 0.005469747
. O 0 0.006632882

We O 0 0.0038333153
studied O 0 0.002835672
a O 0 0.0024676637
37 O 0 0.0026384008
- O 0 0.0041867862
year O 0 0.0012731387
- O 0 0.0033260537
old O 0 0.0008685369
man O 0 0.017423388
who O 0 0.0008495152
developed O 0 0.00070950476
persistent O 0 0.027809167
segmental O 0 0.3224285
dystonia B-Disease 2 0.99999833
within O 0 0.00033773913
2 O 0 0.00041840764
months O 0 0.00040981703
after O 0 0.0006121423
starting O 0 0.0017161709
sulpiride B-Chemical 0 0.9999943
therapy O 0 0.01179756
. O 0 0.006989391

We O 0 0.0045174155
could O 0 0.002694064
not O 0 0.0020207826
find O 0 0.001582633
any O 0 0.0013059784
previous O 0 0.0012158557
reports O 0 0.0018265375
of O 0 0.030844074
sulpiride B-Chemical 0 0.9999999
- O 0 0.73881465
induced O 0 0.27476984
tardive B-Disease 0 0.99999976
dystonia I-Disease 2 0.9999987
. O 0 0.017539637

Comparative O 0 0.007069915
cognitive O 0 0.21574612
and O 0 0.002091741
subjective O 0 0.0024601126
side O 0 0.005885754
effects O 0 0.0009407301
of O 0 0.00084603106
immediate O 0 0.0039518396
- O 0 0.07026648
release O 0 0.097794905
oxycodone B-Chemical 1 0.9999943
in O 0 0.0007561294
healthy O 0 0.010606641
middle O 0 0.003598393
- O 0 0.00475857
aged O 0 0.0017254633
and O 0 0.0019115873
older O 0 0.0060044327
adults O 0 0.008346097
. O 0 0.0076566883

This O 0 0.004575337
study O 0 0.002398923
measured O 0 0.0012567537
the O 0 0.000988386
objective O 0 0.0010967986
and O 0 0.00075043377
subjective O 0 0.0016671964
neurocognitive O 0 0.4046458
effects O 0 0.0004033225
of O 0 0.00033589342
a O 0 0.00034102995
single O 0 0.00026005972
10 O 0 0.0002407466
- O 0 0.0022027076
mg O 0 0.006288216
dose O 0 0.0005656877
of O 0 0.0002824027
immediate O 0 0.0023562675
- O 0 0.069232896
release O 0 0.07388348
oxycodone B-Chemical 1 0.9999956
in O 0 0.00034221445
healthy O 0 0.009478575
, O 0 0.00043025674
older O 0 0.0018085487
( O 0 0.00034428787
> O 0 0.0004249832
65 O 0 0.00020710201
years O 0 0.00021450901
) O 0 0.00034572123
, O 0 0.00027235216
and O 0 0.0002799194
middle O 0 0.0039490103
- O 0 0.008695611
aged O 0 0.0004438323
( O 0 0.00029432142
35 O 0 0.00017877243
to O 0 0.00014383324
55 O 0 0.00021532415
years O 0 0.0002495169
) O 0 0.00040135536
adults O 0 0.00068241026
who O 0 0.00041390787
were O 0 0.0002686398
not O 0 0.00029132253
suffering O 0 0.0147936465
from O 0 0.0005016544
chronic O 0 0.37919816
or O 0 0.0010908277
significant O 0 0.0017592583
daily O 0 0.005756086
pain B-Disease 0 0.92493755
. O 0 0.0067709824

Seventy O 0 0.007837327
- O 0 0.0066321786
one O 0 0.0017431263
participants O 0 0.0011747255
completed O 0 0.00084115256
2 O 0 0.0006206946
separate O 0 0.0003743778
study O 0 0.0004240284
days O 0 0.00027671928
and O 0 0.00035182916
were O 0 0.00033217456
blind O 0 0.0017633395
to O 0 0.0002803395
medication O 0 0.006180044
condition O 0 0.0006640703
( O 0 0.0009422985
placebo O 0 0.0176317
, O 0 0.0007815579
10 O 0 0.0007909909
- O 0 0.014609168
mg O 0 0.5952059
oxycodone B-Chemical 1 0.9999641
) O 0 0.00864225
. O 0 0.0075607644

Plasma O 0 0.77519727
oxycodone B-Chemical 1 0.99994004
concentration O 0 0.0063866447
peaked O 0 0.0021611738
between O 0 0.0006291161
60 O 0 0.00054716936
and O 0 0.00041288036
90 O 0 0.0003108564
minutes O 0 0.00025928183
postdose O 0 0.0015885555
( O 0 0.0004502619
P O 0 0.015160208
< O 0 0.0002738086
. O 0 0.00028437722
01 O 0 0.0011648546
) O 0 0.00037955225
and O 0 0.0002552465
pupil O 0 0.005917876
size O 0 0.00038480316
, O 0 0.0003475328
an O 0 0.00021670351
indication O 0 0.00012997592
of O 0 0.00020131144
physiological O 0 0.00030720953
effects O 0 0.00024929526
of O 0 0.00025314046
the O 0 0.00026708603
medication O 0 0.02598907
, O 0 0.00029588206
peaked O 0 0.00031539178
at O 0 0.00013298154
approximately O 0 0.00014244273
90 O 0 0.00015659214
to O 0 0.0001471255
120 O 0 0.00021256364
minutes O 0 0.00023828325
postdose O 0 0.0011194737
( O 0 0.0007323438
P O 0 0.0054338756
< O 0 0.0011905846
. O 0 0.0019562135
01 O 0 0.0061033824
) O 0 0.005995912
. O 0 0.00799427

Significant O 0 0.0046446137
declines B-Disease 0 0.003997602
in I-Disease 0 0.0016698462
simple I-Disease 0 0.0014888821
and I-Disease 0 0.0010385292
sustained I-Disease 0 0.0019298566
attention I-Disease 0 0.0018269062
, I-Disease 0 0.0008165937
working I-Disease 0 0.0023845478
memory I-Disease 0 0.29444468
, I-Disease 0 0.0006172954
and I-Disease 0 0.00042374193
verbal I-Disease 0 0.065344974
memory I-Disease 0 0.08885559
were O 0 0.00019211262
observed O 0 0.00013752763
at O 0 0.0001337744
1 O 0 0.00013638404
hour O 0 0.00012236675
postdose O 0 0.0004066504
compared O 0 8.286947e-05
to O 0 9.8791264e-05
baseline O 0 0.00012365631
for O 0 0.00012161262
both O 0 0.00014786045
age O 0 0.00033153707
groups O 0 0.00019331396
with O 0 0.00020703272
a O 0 0.0002618356
trend O 0 0.00031379052
toward O 0 0.00027596258
return O 0 0.00033767198
to O 0 0.00030683138
baseline O 0 0.00045042654
by O 0 0.0006638991
5 O 0 0.00088965264
hours O 0 0.0015266634
postdose O 0 0.0058087995
. O 0 0.0051795407

For O 0 0.0031082
almost O 0 0.0020271046
all O 0 0.0015763313
cognitive O 0 0.14943503
measures O 0 0.00073304586
, O 0 0.00074433663
there O 0 0.00035088626
were O 0 0.00035502188
no O 0 0.00026139212
medication O 0 0.006693421
by O 0 0.00028703737
age O 0 0.001357987
- O 0 0.006776837
interaction O 0 0.00034265945
effects O 0 0.0005683857
, O 0 0.000460885
which O 0 0.00028925657
indicates O 0 0.00016411752
that O 0 0.000155616
the O 0 0.00020567256
2 O 0 0.00021302422
age O 0 0.0003336908
groups O 0 0.0002695611
exhibited O 0 0.0002983789
similar O 0 0.00033152028
responses O 0 0.0006829704
to O 0 0.0007195395
the O 0 0.0013028254
medication O 0 0.019411024
challenge O 0 0.0036001343
. O 0 0.006152709

This O 0 0.0050481986
study O 0 0.0026577015
suggests O 0 0.0012183249
that O 0 0.000982255
for O 0 0.0009444102
healthy O 0 0.008577128
older O 0 0.0044705104
adults O 0 0.0021548264
who O 0 0.0006365144
are O 0 0.0002730302
not O 0 0.0002403285
suffering O 0 0.024522463
from O 0 0.00028319377
chronic B-Disease 0 0.92655987
pain I-Disease 0 0.99376255
, O 0 0.001235149
neurocognitive O 0 0.6670689
and O 0 0.00024740238
pharmacodynamic O 0 0.01988734
changes O 0 0.00020998497
in O 0 0.00013311465
response O 0 0.00018440385
to O 0 0.00013123211
a O 0 0.00022874124
10 O 0 0.00019080352
- O 0 0.0022055702
mg O 0 0.005959854
dose O 0 0.0005181313
of O 0 0.00027403998
immediate O 0 0.0021514988
- O 0 0.06134867
release O 0 0.05770145
oxycodone B-Chemical 1 0.99999094
are O 0 0.00024403611
similar O 0 0.00017770666
to O 0 0.00021588395
those O 0 0.00034552976
observed O 0 0.00037843434
for O 0 0.00066298834
middle O 0 0.004216665
- O 0 0.011663653
aged O 0 0.004228249
adults O 0 0.008784023
. O 0 0.007129157

PERSPECTIVE O 0 0.01035278
: O 0 0.004233051
Study O 0 0.0031195546
findings O 0 0.0014362481
indicate O 0 0.00068963884
that O 0 0.0006224049
the O 0 0.00068921206
metabolism O 0 0.16506773
, O 0 0.0014401334
neurocognitive O 0 0.7727093
effects O 0 0.0005945207
, O 0 0.00044610244
and O 0 0.0003315636
physical O 0 0.0018780087
side O 0 0.010729385
effects O 0 0.00040984323
of O 0 0.0007763352
oral O 0 0.8869322
oxycodone B-Chemical 1 0.9999945
are O 0 0.0002652508
similar O 0 0.00019675831
for O 0 0.00029174867
healthy O 0 0.0032090766
middle O 0 0.0026341206
- O 0 0.0047806688
aged O 0 0.0015155394
and O 0 0.001690486
older O 0 0.005695096
adults O 0 0.007896716
. O 0 0.007120417

Therefore O 0 0.0038625507
, O 0 0.0033748383
clinicians O 0 0.0021287177
should O 0 0.00086756755
not O 0 0.0007124141
avoid O 0 0.0005606026
prescribing O 0 0.0070224004
oral O 0 0.25451753
opioids O 0 0.9328814
to O 0 0.00028729995
older O 0 0.0012157821
adults O 0 0.00059776136
based O 0 0.00020840103
on O 0 0.00012961503
the O 0 0.00018590127
belief O 0 0.00063492137
that O 0 0.00019567843
older O 0 0.0015604731
adults O 0 0.0007590894
are O 0 0.00022180729
at O 0 0.00021630859
higher O 0 0.00030201537
risk O 0 0.008989073
for O 0 0.00050733256
side O 0 0.010828638
effects O 0 0.0011846055
than O 0 0.0011703456
younger O 0 0.017062536
adults O 0 0.009212285
. O 0 0.006763819

The O 0 0.0046226745
glycine B-Chemical 1 0.9989794
transporter O 0 0.28030717
- O 0 0.04306116
1 O 0 0.0012214227
inhibitor O 0 0.018016664
SSR103800 B-Chemical 0 0.99405503
displays O 0 0.000585929
a O 0 0.0005230792
selective O 0 0.0006790936
and O 0 0.00043113658
specific O 0 0.00055687863
antipsychotic O 0 0.99960834
- O 0 0.003908841
like O 0 0.00037285726
profile O 0 0.0004935596
in O 0 0.00060554536
normal O 0 0.0011254242
and O 0 0.0014215301
transgenic O 0 0.0022464788
mice O 0 0.0028375657
. O 0 0.0065555912

Schizophrenia B-Disease 0 0.95102143
has O 0 0.004076419
been O 0 0.0030829443
initially O 0 0.0027597316
associated O 0 0.002616913
with O 0 0.003247488
dysfunction O 0 0.9090857
in O 0 0.009269901
dopamine B-Chemical 1 0.9998592
neurotransmission O 0 0.8731288
. O 0 0.010853679

However O 0 0.0046266364
, O 0 0.00319922
the O 0 0.0015740546
observation O 0 0.0011981478
that O 0 0.00084761705
antagonists O 0 0.41774094
of O 0 0.0011736652
the O 0 0.0038376495
glutamate B-Chemical 1 0.99999666
N B-Chemical 0 0.9999908
- I-Chemical 0 0.9136427
methyl I-Chemical 0 0.9998542
- I-Chemical 0 0.70215774
D I-Chemical 0 0.99966776
- I-Chemical 0 0.88342065
aspartate I-Chemical 1 0.999998
( O 0 0.33293322
NMDA B-Chemical 1 0.99999964
) O 0 0.009229937
receptor O 0 0.016861964
produce O 0 0.00030983027
schizophrenic B-Disease 2 0.99998677
- O 0 0.022698477
like O 0 0.00023318808
symptoms O 0 0.0910987
in O 0 0.00021143048
humans O 0 0.00077087764
has O 0 0.00015341649
led O 0 0.0001648333
to O 0 0.00014591016
the O 0 0.00016695098
idea O 0 0.00019748589
of O 0 0.00028628332
a O 0 0.00040220833
dysfunctioning O 0 0.02837568
of O 0 0.00041590573
the O 0 0.00048531583
glutamatergic O 0 0.27615723
system O 0 0.00072779786
via O 0 0.0009418076
its O 0 0.024687136
NMDA B-Chemical 1 0.9999907
receptor O 0 0.3044691
. O 0 0.008262555

As O 0 0.0034879858
a O 0 0.0028391639
result O 0 0.0016915575
, O 0 0.0017233323
there O 0 0.00076839793
is O 0 0.00073287095
a O 0 0.0006413708
growing O 0 0.00048545768
interest O 0 0.00038306456
in O 0 0.00028793447
the O 0 0.00025528204
development O 0 0.0005951738
of O 0 0.00043058454
pharmacological O 0 0.034673095
agents O 0 0.0069859526
with O 0 0.00030933387
potential O 0 0.0009718442
antipsychotic O 0 0.99830604
properties O 0 0.00014319253
that O 0 0.000104128594
enhance O 0 9.6930184e-05
the O 0 0.0001538089
activity O 0 0.00019437785
of O 0 0.00027111248
the O 0 0.0003095758
glutamatergic O 0 0.25801933
system O 0 0.0002969279
via O 0 0.00028009267
a O 0 0.0004849362
modulation O 0 0.0006249853
of O 0 0.0013792265
the O 0 0.0043842513
NMDA B-Chemical 1 0.9999918
receptor O 0 0.34445158
. O 0 0.008322383

Among O 0 0.0054953694
them O 0 0.0037188192
are O 0 0.0026544137
glycine B-Chemical 1 0.99955934
transporter O 0 0.34575602
- O 0 0.055300012
1 O 0 0.00077695644
( O 0 0.0015712132
GlyT1 O 0 0.99371403
) O 0 0.00084409246
inhibitors O 0 0.000743385
such O 0 0.00025647331
as O 0 0.00045236954
SSR103800 B-Chemical 0 0.9980233
, O 0 0.0006350429
which O 0 0.0003349967
indirectly O 0 0.0004850573
enhance O 0 0.00031911657
NMDA B-Chemical 1 0.9999993
receptor O 0 0.06269866
function O 0 0.0002499014
by O 0 0.00020272372
increasing O 0 0.00023325058
the O 0 0.00044236053
glycine B-Chemical 1 0.99976856
( O 0 0.0026539504
a O 0 0.0010646699
co O 0 0.87591195
- O 0 0.23359159
agonist O 0 0.71251905
for O 0 0.00047893572
the O 0 0.001834899
NMDA B-Chemical 1 0.99999845
receptor O 0 0.11352007
) O 0 0.0017120618
levels O 0 0.00090356346
in O 0 0.0013202871
the O 0 0.0021763523
synapse O 0 0.015719866
. O 0 0.007166496

This O 0 0.0047420864
study O 0 0.0025145737
aimed O 0 0.0015536324
at O 0 0.0008979693
investigating O 0 0.00064088905
the O 0 0.00059538666
potential O 0 0.0015457438
antipsychotic O 0 0.99985886
- O 0 0.013220058
like O 0 0.000257456
properties O 0 0.0002776458
of O 0 0.0009968214
SSR103800 B-Chemical 0 0.99872273
, O 0 0.0005584752
with O 0 0.0002444681
a O 0 0.00021556839
particular O 0 0.00012641549
focus O 0 0.000151609
on O 0 9.599562e-05
models O 0 0.00018792672
of O 0 0.0009985038
hyperactivity B-Disease 2 0.9999796
, O 0 0.0005515566
involving O 0 0.00021239587
either O 0 0.00020178533
drug O 0 0.1263983
challenge O 0 0.00032641835
( O 0 0.0008862853
ie O 0 0.002483689
, O 0 0.010204603
amphetamine B-Chemical 1 0.99999964
and O 0 0.006918834
MK B-Chemical 0 0.99874854
- I-Chemical 0 0.25631565
801 I-Chemical 0 0.6373681
) O 0 0.000481361
or O 0 0.00017108489
transgenic O 0 0.00020136671
mice O 0 0.00012829475
( O 0 0.00047145516
ie O 0 0.0015913713
, O 0 0.013284923
NMDA B-Chemical 1 0.9999994
Nr1 O 0 0.93426496
( O 0 0.0016492388
neo O 0 0.13506627
- O 0 0.102942936
/ O 0 0.03683547
- O 0 0.034235705
) O 0 0.0013968225
and O 0 0.001370193
DAT O 0 0.9978703
( O 0 0.0021588071
- O 0 0.017510427
/ O 0 0.011976599
- O 0 0.018710842
) O 0 0.0053678486
) O 0 0.0073273727
. O 0 0.008575276

Results O 0 0.0035743094
showed O 0 0.0023420781
that O 0 0.002014626
SSR103800 B-Chemical 0 0.993341
( O 0 0.0024739383
10 O 0 0.0009397383
- O 0 0.0020036395
30 O 0 0.0004435777
mg O 0 0.006080057
/ O 0 0.0012491667
kg O 0 0.000932588
p O 0 0.00038338188
. O 0 0.00030104083
o O 0 0.008319193
. O 0 0.00033235003
) O 0 0.00076519453
blocked O 0 0.0014669304
hyperactivity B-Disease 2 0.9999242
induced O 0 0.00031633797
by O 0 0.00025996403
the O 0 0.00025097086
non O 0 0.004324417
- O 0 0.22302867
competitive O 0 0.68002355
NMDA B-Chemical 1 0.9999999
receptor O 0 0.7668186
antagonist O 0 0.9902772
, O 0 0.02184318
MK B-Chemical 0 0.9986224
- I-Chemical 0 0.18549171
801 I-Chemical 0 0.35628933
and O 0 0.00021781796
partially O 0 0.00019616038
reversed O 0 0.00034489427
spontaneous O 0 0.035204105
hyperactivity B-Disease 2 0.9999795
of O 0 0.034460787
NMDA B-Chemical 1 0.99999964
Nr1 O 0 0.9521335
( O 0 0.0024292492
neo O 0 0.12863654
- O 0 0.080834255
/ O 0 0.025359157
- O 0 0.01699833
) O 0 0.0037794616
mice O 0 0.0033371926
. O 0 0.007358466

In O 0 0.0041237143
contrast O 0 0.0039902125
, O 0 0.006355791
SSR103800 B-Chemical 0 0.9918258
failed O 0 0.0012851114
to O 0 0.0006576361
affect O 0 0.0005389012
hyperactivity B-Disease 2 0.99988234
induced O 0 0.0009101783
by O 0 0.0038912685
amphetamine B-Chemical 1 0.9999995
or O 0 0.00050159893
naturally O 0 0.0025400864
observed O 0 0.00023984643
in O 0 0.00058820134
dopamine B-Chemical 1 0.99990916
transporter O 0 0.06730766
( O 0 0.006344989
DAT O 0 0.9988061
( O 0 0.0019568624
- O 0 0.036695145
/ O 0 0.025033293
- O 0 0.033283573
) O 0 0.0008770795
) O 0 0.00045272373
knockout O 0 0.00019741661
mice O 0 0.00016029633
( O 0 0.00040211435
10 O 0 0.00027656526
- O 0 0.0009550124
30 O 0 0.00028606373
mg O 0 0.0031099396
/ O 0 0.0011097827
kg O 0 0.0011864596
p O 0 0.0009034404
. O 0 0.0012061278
o O 0 0.005412724
. O 0 0.0030578037
) O 0 0.0068241553
. O 0 0.008544783

Importantly O 0 0.0039616153
, O 0 0.0032606528
both O 0 0.0018078819
classical O 0 0.0034526028
( O 0 0.04618573
haloperidol B-Chemical 1 0.99999976
) O 0 0.0075881747
and O 0 0.0008661725
atypical O 0 0.1725711
( O 0 0.025323143
olanzapine B-Chemical 1 0.99999964
, O 0 0.0377641
clozapine B-Chemical 0 0.9999995
and O 0 0.00973866
aripiprazole B-Chemical 0 0.99999785
) O 0 0.014504077
antipsychotics O 0 0.9978568
were O 0 0.00027886187
effective O 0 0.0003011298
in O 0 0.0003546924
all O 0 0.00046638417
these O 0 0.0007817027
models O 0 0.0014682609
of O 0 0.0050863023
hyperactivity B-Disease 2 0.9998565
. O 0 0.008173696

However O 0 0.0048642284
, O 0 0.0034375482
unlike O 0 0.001571024
these O 0 0.0015673498
latter O 0 0.0055773994
, O 0 0.0063851434
SSR103800 B-Chemical 0 0.99791986
did O 0 0.00078638986
not O 0 0.00040801903
produce O 0 0.0005403146
catalepsy B-Disease 2 0.99999917
( O 0 0.00086397736
retention O 0 0.0004778577
on O 0 0.00015044685
the O 0 0.00020516606
bar O 0 0.0012656389
test O 0 0.0003098536
) O 0 0.00043455962
up O 0 0.00025284276
to O 0 0.00027350723
30 O 0 0.00037847206
mg O 0 0.0031142696
/ O 0 0.0015915167
kg O 0 0.001979386
p O 0 0.001800398
. O 0 0.0027120458
o O 0 0.011628153
. O 0 0.008767237

Together O 0 0.0056418846
these O 0 0.0024837684
findings O 0 0.0019059586
show O 0 0.0009785253
that O 0 0.0007908793
the O 0 0.0011974494
GlyT1 O 0 0.99863017
inhibitor O 0 0.120069355
, O 0 0.016461628
SSR103800 B-Chemical 0 0.99933285
, O 0 0.001615316
produces O 0 0.0015807338
antipsychotic O 0 0.99987495
- O 0 0.015395858
like O 0 0.0002071435
effects O 0 0.00040688307
, O 0 0.000399301
which O 0 0.0002723758
differ O 0 0.00015783549
from O 0 0.00012374618
those O 0 0.00018258809
observed O 0 0.00012747892
with O 0 0.00023798013
compounds O 0 0.19185545
primarily O 0 0.0001856639
targeting O 0 0.00011395785
the O 0 0.0002341434
dopaminergic O 0 0.27467862
system O 0 0.00021637522
, O 0 0.00028392128
and O 0 0.00022351544
has O 0 0.0001734515
a O 0 0.00026460216
reduced O 0 0.00030254276
side O 0 0.057282824
- O 0 0.0076857707
effect O 0 0.00026463822
potential O 0 0.00037444956
as O 0 0.00037653017
compared O 0 0.00041510715
with O 0 0.0008037014
these O 0 0.001424768
latter O 0 0.0045390544
drugs O 0 0.25649694
. O 0 0.006545054

Pyrrolidine B-Chemical 0 0.9999409
dithiocarbamate I-Chemical 0 0.99995863
protects O 0 0.010314115
the O 0 0.0036661602
piriform O 0 0.84861493
cortex O 0 0.28059694
in O 0 0.0015482805
the O 0 0.0025346628
pilocarpine B-Chemical 1 0.9999937
status B-Disease 0 0.09966701
epilepticus I-Disease 0 0.9999727
model O 0 0.008179705
. O 0 0.009278011

Pyrrolidine B-Chemical 0 0.99998033
dithiocarbamate I-Chemical 0 0.9999958
( O 0 0.73452306
PDTC B-Chemical 1 0.9999993
) O 0 0.042571243
has O 0 0.0008800135
a O 0 0.0007378995
dual O 0 0.000648993
mechanism O 0 0.00034733998
of O 0 0.00046071963
action O 0 0.0006819161
as O 0 0.00033692567
an O 0 0.00083804526
antioxidant O 0 0.9960723
and O 0 0.0005311549
an O 0 0.0004337344
inhibitor O 0 0.0020268566
of O 0 0.0005028978
the O 0 0.0005149743
transcription O 0 0.0014144705
factor O 0 0.038575333
kappa O 0 0.735474
- O 0 0.31411564
beta O 0 0.947433
. O 0 0.012480576

Both O 0 0.0039937156
, O 0 0.0032192296
production O 0 0.0024601477
of O 0 0.0022619264
reactive O 0 0.81408936
oxygen B-Chemical 1 0.99899715
species O 0 0.0017981319
as O 0 0.00043266156
well O 0 0.0003186873
as O 0 0.00028057562
activation O 0 0.0005047856
of O 0 0.001186145
NF O 0 0.99745816
- O 0 0.112926826
kappaB O 0 0.0777031
have O 0 0.00024493522
been O 0 0.00020360084
implicated O 0 0.00016623615
in O 0 0.00024579707
severe O 0 0.15106556
neuronal B-Disease 0 0.9469094
damage I-Disease 0 0.99031174
in O 0 0.0002665328
different O 0 0.00018574021
sub O 0 0.003924009
- O 0 0.0033924163
regions O 0 0.0002934554
of O 0 0.00028007184
the O 0 0.00031877597
hippocampus O 0 0.0645145
as O 0 0.000312502
well O 0 0.0003865538
as O 0 0.00052944134
in O 0 0.00080191053
the O 0 0.0013016436
surrounding O 0 0.0035397776
cortices O 0 0.8751591
. O 0 0.0065832846

The O 0 0.00322005
effect O 0 0.0025424345
of O 0 0.0043476503
PDTC B-Chemical 1 0.99999535
on O 0 0.001093245
status B-Disease 0 0.05039025
epilepticus I-Disease 0 0.99999845
- O 0 0.13969977
associated O 0 0.0006089699
cell O 0 0.0017468334
loss O 0 0.0007686309
in O 0 0.00025135954
the O 0 0.00027352394
hippocampus O 0 0.17185408
and O 0 0.00047814046
piriform O 0 0.58281136
cortex O 0 0.08401344
was O 0 0.00027540696
evaluated O 0 0.00027650906
in O 0 0.00042909716
the O 0 0.0006710548
rat O 0 0.0026942163
fractionated O 0 0.007208836
pilocarpine B-Chemical 1 0.99998605
model O 0 0.006250289
. O 0 0.0076257954

Treatment O 0 0.006978811
with O 0 0.0026166476
150 O 0 0.0024230713
mg O 0 0.07833949
/ O 0 0.012793
kg O 0 0.04350344
PDTC B-Chemical 1 0.9999969
before O 0 0.0004686525
and O 0 0.00049092853
following O 0 0.00036968177
status B-Disease 0 0.0029468783
epilepticus I-Disease 0 0.9999858
significantly O 0 0.0005840773
increased O 0 0.00052540755
the O 0 0.00057905325
mortality O 0 0.10473964
rate O 0 0.0012216135
to O 0 0.0014639357
100 O 0 0.0031980586
% O 0 0.0044818977
. O 0 0.0067082527

Administration O 0 0.019619083
of O 0 0.003201395
50 O 0 0.0026069118
mg O 0 0.0967858
/ O 0 0.0165489
kg O 0 0.08452639
PDTC B-Chemical 1 0.99999917
( O 0 0.010631545
low O 0 0.0028819114
- O 0 0.024826216
dose O 0 0.0067956783
) O 0 0.0011621033
did O 0 0.00029813717
not O 0 0.00018515105
exert O 0 0.00020590487
major O 0 0.0002633618
effects O 0 0.00026384587
on O 0 0.00014857898
the O 0 0.00021886305
development O 0 0.0004894031
of O 0 0.00045861315
a O 0 0.0006902973
status B-Disease 0 0.00619417
epilepticus I-Disease 0 0.99997926
or O 0 0.0010639714
the O 0 0.0014630731
mortality O 0 0.25551948
rate O 0 0.0048178644
. O 0 0.007149156

In O 0 0.0047495165
vehicle O 0 0.046071984
- O 0 0.01835934
treated O 0 0.0018416097
rats O 0 0.0019412495
, O 0 0.0014309126
status B-Disease 0 0.0064545143
epilepticus I-Disease 0 0.99999034
caused O 0 0.0010584792
pronounced O 0 0.020776695
neuronal B-Disease 0 0.9510669
damage I-Disease 0 0.9901688
in O 0 0.00040960364
the O 0 0.00042379904
piriform O 0 0.42513886
cortex O 0 0.04464319
comprising O 0 0.00045776885
both O 0 0.0006893319
pyramidal O 0 0.27069032
cells O 0 0.0018117382
and O 0 0.0030471105
interneurons O 0 0.06295542
. O 0 0.006588492

Low O 0 0.14410362
- O 0 0.08926057
dose O 0 0.31194562
PDTC B-Chemical 1 0.99999714
treatment O 0 0.005479337
almost O 0 0.0011351608
completely O 0 0.00090911833
protected O 0 0.0010088538
from O 0 0.00097423093
lesions O 0 0.1182619
in O 0 0.0015146075
the O 0 0.002468212
piriform O 0 0.6487458
cortex O 0 0.30158946
. O 0 0.0075665703

A O 0 0.05221181
significant O 0 0.0028660437
decrease O 0 0.0018661292
in O 0 0.0013642437
neuronal O 0 0.016101915
density O 0 0.0012301431
of O 0 0.00068941177
the O 0 0.0005544984
hippocampal O 0 0.5379978
hilar O 0 0.7905326
formation O 0 0.0028059634
was O 0 0.00027997332
identified O 0 0.00022800807
in O 0 0.00031137097
vehicle O 0 0.036897525
- O 0 0.07904869
and O 0 0.008901603
PDTC B-Chemical 1 0.99999964
- O 0 0.16831835
treated O 0 0.001306057
rats O 0 0.0013655663
following O 0 0.0012826656
status B-Disease 0 0.0112198135
epilepticus I-Disease 0 0.9999515
. O 0 0.00824202

In O 0 0.0038895796
conclusion O 0 0.0024015366
, O 0 0.0028491267
the O 0 0.0022151908
NF O 0 0.9915207
- O 0 0.11958179
kappaB O 0 0.18653847
inhibitor O 0 0.08867768
and O 0 0.013279522
antioxidant O 0 0.9999503
PDTC B-Chemical 1 0.99999964
protected O 0 0.0024995934
the O 0 0.00090619177
piriform O 0 0.8934431
cortex O 0 0.42796233
, O 0 0.000548611
whereas O 0 0.00044632427
it O 0 0.00051247986
did O 0 0.00056771515
not O 0 0.0006329465
affect O 0 0.0009689997
hilar O 0 0.84233385
neuronal B-Disease 0 0.8493771
loss I-Disease 0 0.15507498
. O 0 0.00817235

These O 0 0.003719939
data O 0 0.0024690644
might O 0 0.0012149451
indicate O 0 0.00073064637
that O 0 0.0006209112
the O 0 0.0005441754
generation O 0 0.00060720346
of O 0 0.0008025787
reactive O 0 0.8002682
oxygen B-Chemical 1 0.999185
species O 0 0.0014274477
and O 0 0.00038048075
activation O 0 0.0005500876
of O 0 0.0011127796
NF O 0 0.9968168
- O 0 0.083584055
kappaB O 0 0.051276173
plays O 0 0.00026276364
a O 0 0.00035265338
more O 0 0.00021765438
central O 0 0.00022193421
role O 0 0.00013129944
in O 0 0.00048495558
seizure B-Disease 2 0.9999912
- O 0 0.09253246
associated O 0 0.00093784695
neuronal B-Disease 0 0.9196689
damage I-Disease 0 0.98489535
in O 0 0.00028919117
the O 0 0.0002767066
temporal O 0 0.017019842
cortex O 0 0.08387047
as O 0 0.00035141347
compared O 0 0.00040900253
to O 0 0.000707202
the O 0 0.0013989161
hippocampal O 0 0.39860174
hilus O 0 0.18333696
. O 0 0.006724555

However O 0 0.0046690237
, O 0 0.0032908295
future O 0 0.0018153101
investigations O 0 0.0014074482
are O 0 0.0008048157
necessary O 0 0.0004740138
to O 0 0.00041411753
exactly O 0 0.0003133397
analyze O 0 0.00021367962
the O 0 0.00025716235
biochemical O 0 0.0006029805
mechanisms O 0 0.0002656137
by O 0 0.00042154233
which O 0 0.0042172656
PDTC B-Chemical 1 0.9999993
exerted O 0 0.00667681
its O 0 0.0021654188
beneficial O 0 0.00085504394
effects O 0 0.00090784294
in O 0 0.0009989596
the O 0 0.0019077712
piriform O 0 0.7467711
cortex O 0 0.35339838
. O 0 0.0062826695

Anaesthetists O 0 0.06384999
' O 0 0.006052509
nightmare O 0 0.027916564
: O 0 0.006599693
masseter B-Disease 0 0.94995177
spasm I-Disease 2 0.999977
after O 0 0.0009381438
induction O 0 0.0009856062
in O 0 0.00096761493
an O 0 0.0012915486
undiagnosed O 0 0.04944635
case O 0 0.0022130231
of O 0 0.0083319945
myotonia B-Disease 0 0.99991214
congenita I-Disease 0 0.70638686
. O 0 0.009605207

We O 0 0.0038695415
report O 0 0.0035750617
an O 0 0.0023757329
undiagnosed O 0 0.023438722
case O 0 0.0015281113
of O 0 0.0034059954
myotonia B-Disease 0 0.9999528
congenita I-Disease 0 0.33077094
in O 0 0.00047074654
a O 0 0.0005000741
24 O 0 0.0003552186
- O 0 0.0013050571
year O 0 0.00029328757
- O 0 0.0013720876
old O 0 0.00024426728
previously O 0 0.00022917958
healthy O 0 0.002206177
primigravida O 0 0.08247451
, O 0 0.0003806213
who O 0 0.00031840726
developed O 0 0.00027814152
life O 0 0.00036809646
threatening O 0 0.030969275
masseter B-Disease 0 0.97214895
spasm I-Disease 2 0.9999937
following O 0 0.0002342113
a O 0 0.00025881352
standard O 0 0.00018763903
dose O 0 0.00078340893
of O 0 0.00066624745
intravenous O 0 0.3994516
suxamethonium B-Chemical 0 0.99949
for O 0 0.0008309768
induction O 0 0.0013483712
of O 0 0.0033797526
anaesthesia O 0 0.12601367
. O 0 0.0062494474

Neither O 0 0.003600312
the O 0 0.0023569881
patient O 0 0.0018079241
nor O 0 0.0012342011
the O 0 0.00094339764
anaesthetist O 0 0.0012035954
was O 0 0.000608909
aware O 0 0.0004888729
of O 0 0.00051489356
the O 0 0.00048215545
diagnosis O 0 0.0010583563
before O 0 0.00043687315
this O 0 0.000685756
potentially O 0 0.0014431436
lethal O 0 0.025087887
complication O 0 0.4973357
occurred O 0 0.0051404694
. O 0 0.007266935

Twin O 0 0.019498894
preterm O 0 0.18696626
neonates O 0 0.011495935
with O 0 0.0038392376
cardiac B-Disease 0 0.9699959
toxicity I-Disease 2 0.99991953
related O 0 0.0014592987
to O 0 0.002002671
lopinavir B-Chemical 0 0.99978465
/ I-Chemical 0 0.41027305
ritonavir I-Chemical 0 0.99995434
therapy O 0 0.05582422
. O 0 0.0093326755

We O 0 0.0042968327
report O 0 0.0042843693
twin O 0 0.02174459
neonates O 0 0.0068316637
who O 0 0.0018103335
were O 0 0.0008760497
born O 0 0.001105266
prematurely O 0 0.0017460977
at O 0 0.00040614602
32 O 0 0.00043043646
weeks O 0 0.00024628543
of O 0 0.00036410624
gestation O 0 0.0006206562
to O 0 0.0003793963
a O 0 0.00058448274
mother O 0 0.0013953974
with O 0 0.0011973846
human B-Disease 0 0.029479107
immunodeficiency I-Disease 0 0.9999896
virus I-Disease 0 0.998338
infection I-Disease 2 0.99932516
. O 0 0.03360663

One O 0 0.0044746185
of O 0 0.0026611923
the O 0 0.0017734024
twins O 0 0.004783301
developed O 0 0.0013902896
complete O 0 0.0007029661
heart B-Disease 0 0.030246977
block I-Disease 0 0.00046252794
and O 0 0.00085158506
dilated B-Disease 2 0.999281
cardiomyopathy I-Disease 2 0.99999976
related O 0 0.0003021349
to O 0 0.00039656935
lopinavir B-Chemical 0 0.99989486
/ I-Chemical 0 0.41725904
ritonavir I-Chemical 0 0.9999882
therapy O 0 0.008253074
, O 0 0.00049556524
a O 0 0.00029152844
boosted O 0 0.00042332866
protease O 0 0.13313031
- O 0 0.07625977
inhibitor O 0 0.02417775
agent O 0 0.06058367
, O 0 0.0006876882
while O 0 0.00042153307
the O 0 0.00047457326
other O 0 0.0008222895
twin O 0 0.09157538
developed O 0 0.01064024
mild O 0 0.94880176
bradycardia B-Disease 0 0.99932957
. O 0 0.0075749783

We O 0 0.0036924458
recommend O 0 0.002131164
caution O 0 0.001759209
in O 0 0.0013039563
the O 0 0.0010088888
use O 0 0.0009889831
of O 0 0.0021960752
lopinavir B-Chemical 0 0.9999019
/ I-Chemical 0 0.42228267
ritonavir I-Chemical 0 0.9999552
in O 0 0.0012926548
the O 0 0.0012761536
immediate O 0 0.0023493518
neonatal O 0 0.00537474
period O 0 0.0039101224
. O 0 0.0071552545

When O 0 0.0041786986
drugs O 0 0.030487701
disappear O 0 0.0031064423
from O 0 0.0015377342
the O 0 0.0013288966
patient O 0 0.0013620554
: O 0 0.0015887915
elimination O 0 0.001826961
of O 0 0.001967635
intravenous O 0 0.17512302
medication O 0 0.040736783
by O 0 0.0034523897
hemodiafiltration O 0 0.07264356
. O 0 0.007938224

Twenty O 0 0.0065912264
- O 0 0.005112936
three O 0 0.0012165155
hours O 0 0.0009985208
after O 0 0.0007314378
heart O 0 0.04716564
transplantation O 0 0.022377843
, O 0 0.0010050323
life O 0 0.0014019842
- O 0 0.024015186
threatening O 0 0.02543136
acute O 0 0.8915926
right B-Disease 0 0.13113472
heart I-Disease 0 0.6354084
failure I-Disease 0 0.7344288
was O 0 0.000362532
diagnosed O 0 0.0013025587
in O 0 0.0002604299
a O 0 0.0003266649
patient O 0 0.0003170206
requiring O 0 0.00034643422
continuous O 0 0.00046565427
venovenous O 0 0.0019224442
hemodiafiltration O 0 0.028393788
( O 0 0.0031016937
CVVHDF O 0 0.4652302
) O 0 0.0058352007
. O 0 0.0074682957

Increasing O 0 0.0045782775
doses O 0 0.0112062795
of O 0 0.007915623
catecholamines B-Chemical 1 0.9999201
, O 0 0.025029965
sedatives O 0 0.99488443
, O 0 0.0012578862
and O 0 0.00081167603
muscle O 0 0.01716085
relaxants O 0 0.31844416
administered O 0 0.00042896142
through O 0 0.00038605038
a O 0 0.00067997957
central O 0 0.0011203714
venous O 0 0.06334464
catheter O 0 0.0019664892
were O 0 0.002244698
ineffective O 0 0.0055190325
. O 0 0.0066841994

However O 0 0.005282241
, O 0 0.004144008
a O 0 0.0028847433
bolus O 0 0.0065976144
of O 0 0.0029168008
epinephrine B-Chemical 0 0.9989675
injected O 0 0.0010135454
through O 0 0.0007128749
an O 0 0.000951677
alternative O 0 0.00097065326
catheter O 0 0.0019823622
provoked O 0 0.008850216
a O 0 0.005834495
hypertensive B-Disease 2 0.999724
crisis O 0 0.42841566
. O 0 0.009045505

Thus O 0 0.004770679
, O 0 0.0038771366
interference O 0 0.0027700528
with O 0 0.0016902536
the O 0 0.001298954
central O 0 0.0017806854
venous O 0 0.14224674
infusion O 0 0.0016248534
by O 0 0.0009780356
the O 0 0.0011116036
dialysis O 0 0.0034206389
catheter O 0 0.0027044835
was O 0 0.0030645065
suspected O 0 0.013729381
. O 0 0.008159605

The O 0 0.0043890863
catheters O 0 0.0054188035
were O 0 0.0026472616
changed O 0 0.002197662
, O 0 0.00233765
and O 0 0.0021485055
hemodynamics O 0 0.5269601
stabilized O 0 0.0036214446
at O 0 0.00207158
lower O 0 0.0037288547
catecholamine B-Chemical 0 0.9991347
doses O 0 0.049331162
. O 0 0.009545753

When O 0 0.002961571
the O 0 0.0021342398
effects O 0 0.0019553653
of O 0 0.002140618
IV O 0 0.48355004
drugs O 0 0.1977201
are O 0 0.00051500055
inadequate O 0 0.0004940508
in O 0 0.00034563142
patients O 0 0.0005804426
receiving O 0 0.0008262057
CVVHDF O 0 0.51498693
, O 0 0.00033164676
interference O 0 0.0003069139
with O 0 0.00023704919
adjacent O 0 0.0003450472
catheters O 0 0.0005779433
resulting O 0 0.00019207908
in O 0 0.00021981625
elimination O 0 0.00046666389
of O 0 0.0004183306
the O 0 0.00049090746
drug O 0 0.14335477
by O 0 0.0010051391
CVVHDF O 0 0.24692738
should O 0 0.001003351
be O 0 0.0021426617
suspected O 0 0.012797535
. O 0 0.0070179636

Less O 0 0.35311016
frequent O 0 0.059092246
lithium B-Chemical 0 0.9996954
administration O 0 0.07555241
and O 0 0.006207352
lower O 0 0.0066349213
urine O 0 0.2925489
volume O 0 0.012783909
. O 0 0.014107431

OBJECTIVE O 0 0.03453914
: O 0 0.004314854
This O 0 0.0025679988
study O 0 0.0015446153
was O 0 0.00090839365
designed O 0 0.0005910117
to O 0 0.00038122977
determine O 0 0.00019442104
whether O 0 0.0001818887
patients O 0 0.00029251847
maintained O 0 0.00019955971
on O 0 0.00014971987
a O 0 0.00025254596
regimen O 0 0.00035022502
of O 0 0.0007187548
lithium B-Chemical 0 0.99988866
on O 0 0.00014779266
a O 0 0.00027234122
once O 0 0.00017841431
- O 0 0.0011028595
per O 0 0.00013294735
- O 0 0.00068374106
day O 0 0.00013477886
schedule O 0 0.00016026529
have O 0 0.00015624137
lower O 0 0.00024136901
urine O 0 0.044139426
volumes O 0 0.0003382669
than O 0 0.00021305181
do O 0 0.00030089534
patients O 0 0.00046299244
receiving O 0 0.00054638763
multiple O 0 0.0008276311
doses O 0 0.0018574435
per O 0 0.0013877545
day O 0 0.0028131932
. O 0 0.005715102

METHOD O 0 0.008884601
: O 0 0.004585694
This O 0 0.002885196
was O 0 0.0017221989
a O 0 0.0015072068
cross O 0 0.0016425545
- O 0 0.0029529862
sectional O 0 0.0012627791
study O 0 0.0006816815
of O 0 0.00056572683
85 O 0 0.00062364177
patients O 0 0.00051625434
from O 0 0.00041899935
a O 0 0.0009699894
lithium B-Chemical 0 0.99967384
clinic O 0 0.0010039016
who O 0 0.0010385578
received O 0 0.00082265236
different O 0 0.0012277792
dose O 0 0.0038941398
schedules O 0 0.004414766
. O 0 0.006714315

Patients O 0 0.004655528
were O 0 0.0024118528
admitted O 0 0.0020871358
to O 0 0.0010238595
the O 0 0.000794065
hospital O 0 0.0008562746
for O 0 0.0004576783
measurement O 0 0.00036206713
of O 0 0.0008341899
lithium B-Chemical 0 0.9999033
level O 0 0.00045906383
, O 0 0.0017101641
creatinine B-Chemical 1 0.999273
clearance O 0 0.16186765
, O 0 0.001601774
urine O 0 0.21460034
volume O 0 0.0012516958
, O 0 0.0012448208
and O 0 0.0015165956
maximum O 0 0.0024433795
osmolality O 0 0.60998243
. O 0 0.0075181206

RESULTS O 0 0.006545972
: O 0 0.0043514213
Multiple O 0 0.0035848678
daily O 0 0.0022670967
doses O 0 0.0042412262
of O 0 0.0031401364
lithium B-Chemical 0 0.99986947
were O 0 0.0015378409
associated O 0 0.0014748189
with O 0 0.001809763
higher O 0 0.002574301
urine O 0 0.18886067
volumes O 0 0.0064030592
. O 0 0.00832871

The O 0 0.0031155874
dosing O 0 0.0037381453
schedule O 0 0.0016481441
, O 0 0.0013996608
duration O 0 0.00075936446
of O 0 0.0019014901
lithium B-Chemical 0 0.99996674
treatment O 0 0.0022653125
, O 0 0.00078093546
and O 0 0.0004281027
daily O 0 0.00043454472
dose O 0 0.0021754135
of O 0 0.0018264384
lithium B-Chemical 0 0.99996305
did O 0 0.00048053535
not O 0 0.0003068723
affect O 0 0.00032186368
maximum O 0 0.0006095698
osmolality O 0 0.595046
or O 0 0.0020473523
creatinine B-Chemical 1 0.9983113
clearance O 0 0.22722696
. O 0 0.007682099

CONCLUSIONS O 0 0.03084964
: O 0 0.005499053
Urine O 0 0.19497971
volume O 0 0.0022485948
can O 0 0.00092819514
be O 0 0.00076342287
reduced O 0 0.0006377514
by O 0 0.00063201186
giving O 0 0.0021153209
lithium B-Chemical 0 0.99985874
once O 0 0.00037389147
daily O 0 0.00040709457
and O 0 0.00040772874
/ O 0 0.0012862154
or O 0 0.00042151907
by O 0 0.0005554379
lowering O 0 0.0018801712
the O 0 0.000756026
total O 0 0.0011256149
daily O 0 0.002473663
dose O 0 0.007822378
. O 0 0.006407187

Lithium B-Chemical 1 0.9999676
- O 0 0.14430816
induced O 0 0.0054354225
polyuria B-Disease 2 0.9989023
seems O 0 0.0012723202
to O 0 0.00074266415
be O 0 0.00065408356
related O 0 0.00045694964
to O 0 0.00054930826
extrarenal O 0 0.15131854
as O 0 0.0006590601
well O 0 0.000762441
as O 0 0.0010365671
to O 0 0.0016207024
renal O 0 0.7049118
effects O 0 0.0063001034
. O 0 0.00754054

Antibacterial O 0 0.16772686
medication O 0 0.023997903
use O 0 0.001923247
during O 0 0.0012559947
pregnancy O 0 0.058409564
and O 0 0.001462669
risk O 0 0.032004856
of O 0 0.0014174208
birth B-Disease 0 0.0059474315
defects I-Disease 0 0.0027888133
: O 0 0.002725751
National O 0 0.004987781
Birth B-Disease 0 0.066684544
Defects I-Disease 0 0.01715141
Prevention O 0 0.012184224
Study O 0 0.013003349
. O 0 0.009125681

OBJECTIVE O 0 0.016520038
: O 0 0.0039129164
To O 0 0.0017229969
estimate O 0 0.001228234
the O 0 0.0011653122
association O 0 0.0010386192
between O 0 0.0010380916
antibacterial O 0 0.093935765
medications O 0 0.046536885
and O 0 0.0017075983
selected O 0 0.0021570628
birth B-Disease 0 0.0067769852
defects I-Disease 0 0.008620446
. O 0 0.009033149

DESIGN O 0 0.006880551
, O 0 0.0049620382
SETTING O 0 0.004127409
, O 0 0.0024838818
AND O 0 0.0014956539
PARTICIPANTS O 0 0.0017071888
: O 0 0.0015203557
Population O 0 0.0035765364
- O 0 0.0032095236
based O 0 0.0007397305
, O 0 0.00079146435
multisite O 0 0.0019743594
, O 0 0.00078573485
case O 0 0.00064924074
- O 0 0.0053003435
control O 0 0.00030088413
study O 0 0.00034806447
of O 0 0.00037401338
women O 0 0.00826809
who O 0 0.0004692287
had O 0 0.00022867449
pregnancies O 0 0.13059378
affected O 0 0.00021010594
by O 0 0.00019555812
1 O 0 0.00016171146
of O 0 0.00017544419
more O 0 0.00017380629
than O 0 0.00010231273
30 O 0 0.00010762845
eligible O 0 0.00012954124
major O 0 0.0001592614
birth B-Disease 0 0.00053715735
defects I-Disease 0 0.00029936823
identified O 0 0.00014389087
via O 0 0.00013010897
birth B-Disease 0 0.00051173917
defect I-Disease 0 0.00019122935
surveillance O 0 0.00026359796
programs O 0 0.00020742533
in O 0 0.00015627252
10 O 0 0.00014263992
states O 0 0.00020603293
( O 0 0.0002473788
n O 0 0.00017260035
= O 0 0.00037634914
13 O 0 0.00021583783
155 O 0 0.00048341433
) O 0 0.00030791917
and O 0 0.00021284634
control O 0 0.00021323371
women O 0 0.00053292984
randomly O 0 0.0001190875
selected O 0 0.00015957911
from O 0 0.00017563198
the O 0 0.00021303151
same O 0 0.00021082054
geographical O 0 0.0005550986
regions O 0 0.00065604824
( O 0 0.00097001944
n O 0 0.0011375683
= O 0 0.0030737752
4941 O 0 0.0113029955
) O 0 0.0057188957
. O 0 0.0075792708

MAIN O 0 0.050284155
EXPOSURE O 0 0.0085222395
: O 0 0.0033082063
Reported O 0 0.002827123
maternal O 0 0.0024100775
use O 0 0.0009913278
of O 0 0.0012264743
antibacterials O 0 0.9532596
( O 0 0.0012416176
1 O 0 0.0003930518
month O 0 0.0002647036
before O 0 0.00024155708
pregnancy O 0 0.0030277171
through O 0 0.00029167914
the O 0 0.0003661599
end O 0 0.00037412875
of O 0 0.0006867723
the O 0 0.00091012975
first O 0 0.0013372081
trimester O 0 0.18045865
) O 0 0.0074654506
. O 0 0.007573828

MAIN O 0 0.032936927
OUTCOME O 0 0.0060390932
MEASURE O 0 0.0052335337
: O 0 0.0027744845
Odds O 0 0.004734973
ratios O 0 0.0013947496
( O 0 0.0015597555
ORs O 0 0.0022673837
) O 0 0.0008732394
measuring O 0 0.00035517223
the O 0 0.0003241808
association O 0 0.0002897912
between O 0 0.0002685097
antibacterial O 0 0.019187668
use O 0 0.00034025882
and O 0 0.00035156697
selected O 0 0.00035912002
birth B-Disease 0 0.0011522251
defects I-Disease 0 0.0009051286
adjusted O 0 0.00084643386
for O 0 0.0010872864
potential O 0 0.0021828203
confounders O 0 0.0075594266
. O 0 0.006963383

RESULTS O 0 0.005961592
: O 0 0.0038471862
The O 0 0.0018421903
reported O 0 0.0016276909
use O 0 0.0012580024
of O 0 0.0014654294
antibacterials O 0 0.8883718
increased O 0 0.0012182106
during O 0 0.00074615516
pregnancy O 0 0.24296409
, O 0 0.0016336659
peaking O 0 0.010946467
during O 0 0.0009989024
the O 0 0.0015364841
third O 0 0.0025315434
month O 0 0.0033076701
. O 0 0.006611764

Sulfonamides B-Chemical 0 0.99262965
were O 0 0.0027785762
associated O 0 0.0018401246
with O 0 0.0019142393
anencephaly B-Disease 2 0.99957114
( O 0 0.002710424
adjusted O 0 0.0014952836
OR O 0 0.6770016
[ O 0 0.06006788
AOR O 0 0.98891604
] O 0 0.004118845
= O 0 0.000794877
3 O 0 0.00024037524
. O 0 0.00021214128
4 O 0 0.00019538443
; O 0 0.00028169277
95 O 0 0.00032408864
% O 0 0.00024190694
confidence O 0 0.00051163184
interval O 0 0.0002671385
[ O 0 0.002822618
CI O 0 0.66102445
] O 0 0.0010600444
, O 0 0.00036726502
1 O 0 0.00021453152
. O 0 0.00018451395
3 O 0 0.00019106387
- O 0 0.0008051087
8 O 0 0.00018375198
. O 0 0.000172141
8 O 0 0.00018527308
) O 0 0.00033463154
, O 0 0.00032904508
hypoplastic B-Disease 0 0.09295262
left I-Disease 0 0.0016964532
heart I-Disease 0 0.2591181
syndrome I-Disease 0 0.61284983
( O 0 0.0026954468
AOR O 0 0.97451854
= O 0 0.0010512698
3 O 0 0.0001799451
. O 0 0.0001676246
2 O 0 0.00017689924
; O 0 0.00026916817
95 O 0 0.0003894596
% O 0 0.00035002208
CI O 0 0.27165577
, O 0 0.00035262495
1 O 0 0.00020833629
. O 0 0.00018154667
3 O 0 0.00018876523
- O 0 0.0007171244
7 O 0 0.00016979773
. O 0 0.0001725574
6 O 0 0.00016325503
) O 0 0.0003421091
, O 0 0.0003460366
coarctation B-Disease 0 0.23695263
of I-Disease 0 0.0002828538
the I-Disease 0 0.00026151526
aorta I-Disease 0 0.06193592
( O 0 0.0012609672
AOR O 0 0.957723
= O 0 0.00096861523
2 O 0 0.00020531245
. O 0 0.0001687713
7 O 0 0.00016307565
; O 0 0.0002686951
95 O 0 0.0003899292
% O 0 0.00035567637
CI O 0 0.27580112
, O 0 0.0003593197
1 O 0 0.0002108881
. O 0 0.00018238033
3 O 0 0.00018750507
- O 0 0.0006698322
5 O 0 0.00016258517
. O 0 0.00016633241
6 O 0 0.00015657992
) O 0 0.00031943194
, O 0 0.00033609525
choanal B-Disease 0 0.18534832
atresia I-Disease 0 0.93055046
( O 0 0.009387029
AOR O 0 0.9797972
= O 0 0.0010368703
8 O 0 0.00019878603
. O 0 0.00017161522
0 O 0 0.00021179124
; O 0 0.0002882693
95 O 0 0.00040315036
% O 0 0.00035917995
CI O 0 0.2615993
, O 0 0.00035341328
2 O 0 0.00020664599
. O 0 0.00018314779
7 O 0 0.00019306768
- O 0 0.00080706045
23 O 0 0.00027294614
. O 0 0.00017253238
5 O 0 0.00016379001
) O 0 0.0002907335
, O 0 0.00027722525
transverse B-Disease 0 0.010089743
limb I-Disease 0 0.23508862
deficiency I-Disease 0 0.9352555
( O 0 0.0072553
AOR O 0 0.98453474
= O 0 0.0014094205
2 O 0 0.00020697014
. O 0 0.00016415666
5 O 0 0.00015549053
; O 0 0.00025995364
95 O 0 0.00037622932
% O 0 0.00034073554
CI O 0 0.24766245
, O 0 0.0003365929
1 O 0 0.00020063673
. O 0 0.00017789517
0 O 0 0.0002515765
- O 0 0.00083562784
5 O 0 0.00016545024
. O 0 0.00016969284
9 O 0 0.00018483373
) O 0 0.00030855596
, O 0 0.00027397808
and O 0 0.00032860527
diaphragmatic B-Disease 0 0.8553138
hernia I-Disease 0 0.9847661
( O 0 0.005946862
AOR O 0 0.9775173
= O 0 0.0011297485
2 O 0 0.00022793528
. O 0 0.00019417316
4 O 0 0.0001941928
; O 0 0.00032099616
95 O 0 0.00046758942
% O 0 0.00046037434
CI O 0 0.19368103
, O 0 0.0005306795
1 O 0 0.00040883102
. O 0 0.00045521976
1 O 0 0.0006458459
- O 0 0.0016263904
5 O 0 0.0009930212
. O 0 0.001527408
4 O 0 0.0024416475
) O 0 0.005569318
. O 0 0.008071485

Nitrofurantoins B-Chemical 0 0.50410575
were O 0 0.0026792039
associated O 0 0.0018447952
with O 0 0.0021440634
anophthalmia B-Disease 0 0.999634
or O 0 0.00327881
microphthalmos B-Disease 0 0.9999862
( O 0 0.025191963
AOR O 0 0.98661774
= O 0 0.0014758423
3 O 0 0.00026855225
. O 0 0.00022734012
7 O 0 0.00020972264
; O 0 0.0003202903
95 O 0 0.00043576263
% O 0 0.00039512708
CI O 0 0.24936128
, O 0 0.00038566912
1 O 0 0.00023077129
. O 0 0.00020200208
1 O 0 0.00023353432
- O 0 0.00083186815
12 O 0 0.00016540433
. O 0 0.00017432992
2 O 0 0.0001935567
) O 0 0.00034496692
, O 0 0.0003336975
hypoplastic B-Disease 0 0.094142385
left I-Disease 0 0.001702195
heart I-Disease 0 0.2587235
syndrome I-Disease 0 0.6116177
( O 0 0.002671979
AOR O 0 0.9740578
= O 0 0.0010239985
4 O 0 0.00017890561
. O 0 0.00016758754
2 O 0 0.00017717844
; O 0 0.00026980898
95 O 0 0.00039021476
% O 0 0.00034950871
CI O 0 0.2620877
, O 0 0.00034708742
1 O 0 0.00020592294
. O 0 0.0001809223
9 O 0 0.00020886934
- O 0 0.0007846428
9 O 0 0.00018780923
. O 0 0.00017253205
1 O 0 0.0001906275
) O 0 0.0003325719
, O 0 0.00034188706
atrial B-Disease 0 0.68573016
septal I-Disease 0 0.02889066
defects I-Disease 0 0.0041020247
( O 0 0.0013321685
AOR O 0 0.9548522
= O 0 0.00091604353
1 O 0 0.00020337889
. O 0 0.00016704555
9 O 0 0.00017460775
; O 0 0.00026369447
95 O 0 0.00038258152
% O 0 0.00034737377
CI O 0 0.2713026
, O 0 0.00035329373
1 O 0 0.00021089952
. O 0 0.000188108
1 O 0 0.00022493156
- O 0 0.000979241
3 O 0 0.00017802295
. O 0 0.00017703506
4 O 0 0.0001813489
) O 0 0.00036101806
, O 0 0.00031874346
and O 0 0.00032773486
cleft B-Disease 0 0.05280517
lip I-Disease 0 0.13367434
with O 0 0.000405124
cleft B-Disease 0 0.09488439
palate I-Disease 0 0.6143028
( O 0 0.002822991
AOR O 0 0.96098906
= O 0 0.00094900734
2 O 0 0.00023077062
. O 0 0.00020286042
1 O 0 0.00022401231
; O 0 0.00033885695
95 O 0 0.0004873361
% O 0 0.00047191555
CI O 0 0.19691095
, O 0 0.0005416501
1 O 0 0.00041944074
. O 0 0.00046924033
2 O 0 0.00066249154
- O 0 0.0017078657
3 O 0 0.0010689802
. O 0 0.0015956637
9 O 0 0.002718798
) O 0 0.0057017915
. O 0 0.008208159

Other O 0 0.008532455
antibacterial O 0 0.047094285
agents O 0 0.0058872662
that O 0 0.00095528946
showed O 0 0.0007206093
associations O 0 0.00068753626
included O 0 0.00072673196
erythromycins B-Chemical 0 0.99896145
( O 0 0.0014514289
2 O 0 0.00034338588
defects O 0 0.00068368216
) O 0 0.0014059967
, O 0 0.0014491015
penicillins B-Chemical 0 0.9995647
( O 0 0.0012274985
1 O 0 0.00025196298
defect O 0 0.00029671993
) O 0 0.0011408775
, O 0 0.0015505465
cephalosporins B-Chemical 1 0.99987996
( O 0 0.0010959024
1 O 0 0.00031048438
defect O 0 0.0003813646
) O 0 0.00090402935
, O 0 0.0007615624
and O 0 0.0010948173
quinolones B-Chemical 0 0.9967108
( O 0 0.002557672
1 O 0 0.0017024736
defect O 0 0.0028169802
) O 0 0.006156279
. O 0 0.007564765

CONCLUSIONS O 0 0.03185598
: O 0 0.0056630597
Reassuringly O 0 0.025990617
, O 0 0.0060566664
penicillins B-Chemical 0 0.9997198
, O 0 0.035926186
erythromycins B-Chemical 0 0.9997744
, O 0 0.0046494748
and O 0 0.0038876804
cephalosporins B-Chemical 1 0.9999541
, O 0 0.0013934624
although O 0 0.00034983907
used O 0 0.00025626822
commonly O 0 0.00040822773
by O 0 0.00033721727
pregnant O 0 0.019044323
women O 0 0.0047980095
, O 0 0.00053997996
were O 0 0.00040321623
not O 0 0.0004221053
associated O 0 0.0006761946
with O 0 0.0009768606
many O 0 0.0014740074
birth B-Disease 0 0.0049219877
defects I-Disease 0 0.006955131
. O 0 0.007518192

Sulfonamides B-Chemical 0 0.99675494
and O 0 0.0051605413
nitrofurantoins B-Chemical 0 0.5844182
were O 0 0.0016532856
associated O 0 0.0011096557
with O 0 0.0008492286
several O 0 0.0006677836
birth B-Disease 0 0.0017968947
defects I-Disease 0 0.001306549
, O 0 0.0009958935
indicating O 0 0.00068615505
a O 0 0.0010075038
need O 0 0.0009841917
for O 0 0.0014557642
additional O 0 0.0020880916
scrutiny O 0 0.0065237265
. O 0 0.007662727

Differential O 0 0.0042381026
impact O 0 0.0021921832
of O 0 0.002078814
immune O 0 0.056235537
escape O 0 0.017364629
mutations O 0 0.22082552
G145R O 0 0.99200857
and O 0 0.0018018237
P120T O 0 0.16667105
on O 0 0.00023263559
the O 0 0.0002831063
replication O 0 0.021541545
of O 0 0.010281893
lamivudine B-Chemical 1 0.99999976
- O 0 0.7554981
resistant O 0 0.108170256
hepatitis B-Chemical 2 1.0
B I-Chemical 2 0.99997485
virus I-Chemical 0 0.9274574
e I-Chemical 0 0.049721286
antigen I-Chemical 0 0.5475121
- O 0 0.04265705
positive O 0 0.0012797376
and O 0 0.00146626
- O 0 0.005654651
negative O 0 0.002834804
strains O 0 0.004494905
. O 0 0.0073856823

Immune O 0 0.050919604
escape O 0 0.0052270116
variants O 0 0.0031694795
of O 0 0.0025340575
the O 0 0.013503053
hepatitis B-Disease 2 1.0
B I-Disease 2 0.99998903
virus O 0 0.99570036
( O 0 0.28409046
HBV O 0 0.9999901
) O 0 0.0062439158
represent O 0 0.00028810665
an O 0 0.00029802465
emerging O 0 0.00033076355
clinical O 0 0.00085465255
challenge O 0 0.00027566412
, O 0 0.0003261465
because O 0 0.0001575223
they O 0 0.00014826353
can O 0 0.00014256501
be O 0 0.00017613257
associated O 0 0.00021852314
with O 0 0.00026928342
vaccine O 0 0.0025379232
escape O 0 0.008629921
, O 0 0.010570614
HBV O 0 0.999987
reactivation O 0 0.95137376
, O 0 0.003238003
and O 0 0.0013580471
failure O 0 0.1341241
of O 0 0.0020849144
diagnostic O 0 0.004014035
tests O 0 0.0057253614
. O 0 0.0066670957

Recent O 0 0.0049015526
data O 0 0.002862331
suggest O 0 0.0014433586
a O 0 0.0016032335
preferential O 0 0.0011642532
selection O 0 0.0011955315
of O 0 0.0009754443
immune O 0 0.03503424
escape O 0 0.0016375491
mutants O 0 0.00044341478
in O 0 0.0004358704
distinct O 0 0.0004444827
peripheral O 0 0.0017765876
blood O 0 0.00299095
leukocyte O 0 0.012189613
compartments O 0 0.00084648014
of O 0 0.0015860458
infected O 0 0.0033700191
individuals O 0 0.0073882355
. O 0 0.0072040292

We O 0 0.0032870143
therefore O 0 0.002093737
systematically O 0 0.0012304299
analyzed O 0 0.00090762094
the O 0 0.00070501916
functional O 0 0.0005737735
impact O 0 0.00038931964
of O 0 0.000452467
the O 0 0.00037506907
most O 0 0.00058953825
prevalent O 0 0.0031378996
immune O 0 0.03535683
escape O 0 0.0029509328
variants O 0 0.0015789173
, O 0 0.0005654158
the O 0 0.00031376566
sG145R O 0 0.27543914
and O 0 0.00037859476
sP120T O 0 0.0034545083
mutants O 0 0.00016779508
, O 0 0.00024543266
on O 0 0.00010762056
the O 0 0.00015635404
viral O 0 0.011180757
replication O 0 0.05053144
efficacy O 0 0.00095783576
and O 0 0.00038391966
antiviral O 0 0.38185436
drug O 0 0.5537476
susceptibility O 0 0.006657579
of O 0 0.00051888183
common O 0 0.00077006716
treatment O 0 0.0008066599
- O 0 0.010687465
associated O 0 0.00020946724
mutants O 0 0.00014312223
with O 0 0.0002563425
resistance O 0 0.0024552166
to O 0 0.0005346755
lamivudine B-Chemical 1 0.9999993
( O 0 0.071378335
LAM B-Chemical 0 0.9999374
) O 0 0.0033373856
and O 0 0.0011228969
/ O 0 0.008917302
or O 0 0.0038067321
HBeAg B-Chemical 0 0.9999982
negativity O 0 0.9788658
. O 0 0.01062804

Replication O 0 0.034708187
- O 0 0.015348886
competent O 0 0.003162753
HBV O 0 0.9994671
strains O 0 0.0025611192
with O 0 0.0019276628
sG145R O 0 0.43742764
or O 0 0.00077745155
sP120T O 0 0.019025631
and O 0 0.0019513345
LAM B-Chemical 0 0.9999275
resistance O 0 0.07609945
( O 0 0.013004059
rtM204I O 0 0.99762124
or O 0 0.0025627252
rtL180M O 0 0.99987566
/ O 0 0.3805238
rtM204V O 0 0.99429107
) O 0 0.00059836305
were O 0 0.0001556436
generated O 0 0.000108514825
on O 0 0.00013566508
an O 0 0.0014670952
HBeAg B-Chemical 0 0.9999999
- O 0 0.21495806
positive O 0 0.0010620857
and O 0 0.0006968479
an O 0 0.009240504
HBeAg B-Chemical 0 1.0
- O 0 0.24576864
negative O 0 0.0007046224
background O 0 0.00034029383
with O 0 0.0006635632
precore O 0 0.99567324
( O 0 0.01167344
PC O 0 0.80759394
) O 0 0.0009180353
and O 0 0.00043429376
basal O 0 0.00073370006
core O 0 0.00069276284
promoter O 0 0.001213922
( O 0 0.0028894544
BCP O 0 0.62766856
) O 0 0.00418339
mutants O 0 0.0040097735
. O 0 0.007733068

The O 0 0.0039001114
sG145R O 0 0.18266198
mutation O 0 0.015400898
strongly O 0 0.0024149157
reduced O 0 0.0033182271
HBsAg B-Chemical 1 0.99999535
levels O 0 0.0015357484
and O 0 0.0007404523
was O 0 0.0003565759
able O 0 0.00020402954
to O 0 0.00018812521
fully O 0 0.00017457678
restore O 0 0.00013281961
the O 0 0.00017206189
impaired O 0 0.00031278873
replication O 0 0.033603795
of O 0 0.008726081
LAM B-Chemical 0 0.99999225
- O 0 0.29854807
resistant O 0 0.0026449063
HBV O 0 0.9999393
mutants O 0 0.0002633528
to O 0 0.00017359477
the O 0 0.00017042515
levels O 0 0.00018325137
of O 0 0.00030067426
wild O 0 0.00042660744
- O 0 0.035496566
type O 0 0.0015458991
HBV O 0 0.9999788
, O 0 0.005311898
and O 0 0.0013464919
PC O 0 0.6574548
or O 0 0.0006671701
BCP O 0 0.5791278
mutations O 0 0.0024762538
further O 0 0.00093964476
enhanced O 0 0.0016524506
viral O 0 0.10431187
replication O 0 0.40844262
. O 0 0.010009923

Although O 0 0.0034490856
the O 0 0.0027003991
sP120T O 0 0.010534393
substitution O 0 0.07633584
also O 0 0.0013848684
impaired O 0 0.010897335
HBsAg B-Chemical 1 0.99999774
secretion O 0 0.14577414
, O 0 0.0029176637
it O 0 0.0006843496
did O 0 0.00044510726
not O 0 0.00031433336
enhance O 0 0.0002944775
the O 0 0.000517285
replication O 0 0.021988276
of O 0 0.0059186923
LAM B-Chemical 0 0.999915
- O 0 0.06588727
resistant O 0 0.003720475
clones O 0 0.0051354584
. O 0 0.0076862797

However O 0 0.0046344167
, O 0 0.0032773141
the O 0 0.0017181506
concomitant O 0 0.0023893327
occurrence O 0 0.003160898
of O 0 0.014026418
HBeAg B-Chemical 0 0.9999999
negativity O 0 0.9974124
( O 0 0.05210356
PC O 0 0.9573098
/ O 0 0.10637266
BCP O 0 0.935103
) O 0 0.0023382627
, O 0 0.0007257485
sP120T O 0 0.008560289
, O 0 0.00063222303
and O 0 0.0010129077
LAM B-Chemical 0 0.9998411
resistance O 0 0.005217348
resulted O 0 0.0002330885
in O 0 0.00022545546
the O 0 0.00021535189
restoration O 0 0.00032800683
of O 0 0.00036237543
replication O 0 0.007013316
to O 0 0.00038536516
levels O 0 0.0005424763
of O 0 0.0009742702
wild O 0 0.0015561891
- O 0 0.024649723
type O 0 0.0054089716
HBV O 0 0.9998522
. O 0 0.014927158

In O 0 0.0036130322
all O 0 0.0020838035
clones O 0 0.0016707018
with O 0 0.0011981489
combined O 0 0.0012050408
immune O 0 0.057997677
escape O 0 0.009819492
and O 0 0.006972559
LAM B-Chemical 0 0.99995375
resistance O 0 0.05634476
mutations O 0 0.031946328
, O 0 0.00068542437
the O 0 0.00034693858
nucleotide B-Chemical 0 0.6139978
analogues O 0 0.7788212
adefovir B-Chemical 0 0.9999981
and O 0 0.00835656
tenofovir B-Chemical 0 0.99980444
remained O 0 0.0009917524
effective O 0 0.0004113539
in O 0 0.0004005704
suppressing O 0 0.00072090974
viral O 0 0.055186704
replication O 0 0.16103828
in O 0 0.002824925
vitro O 0 0.00562283
. O 0 0.007104308

These O 0 0.0035406258
findings O 0 0.0025494618
reveal O 0 0.0014562245
the O 0 0.0010689053
differential O 0 0.0008867945
impact O 0 0.00056621456
of O 0 0.0006918355
immune O 0 0.05484013
escape O 0 0.0027065312
variants O 0 0.0006961191
on O 0 0.00018084487
the O 0 0.00024199138
replication O 0 0.017098486
and O 0 0.00057408254
drug O 0 0.25119242
susceptibility O 0 0.0033458027
of O 0 0.00052192126
complex O 0 0.0017093589
HBV O 0 0.9999739
mutants O 0 0.00041546105
, O 0 0.00049604353
supporting O 0 0.00017353288
the O 0 0.00014120397
need O 0 0.00011872342
of O 0 0.00015863923
close O 0 0.00015605512
surveillance O 0 0.00027759766
and O 0 0.00024625938
treatment O 0 0.00026656984
adjustment O 0 0.00030286252
in O 0 0.00021005787
response O 0 0.00030641188
to O 0 0.00026973186
the O 0 0.00036885327
selection O 0 0.0006580461
of O 0 0.0008989165
distinct O 0 0.0012188125
mutational O 0 0.0076192883
patterns O 0 0.0035610264
. O 0 0.006338459

Hemolytic B-Disease 0 0.99962187
anemia I-Disease 0 0.999982
associated O 0 0.007334441
with O 0 0.004643177
the O 0 0.004369162
use O 0 0.0055973935
of O 0 0.010865321
omeprazole B-Chemical 1 0.99983966
. O 0 0.01578345

Omeprazole B-Chemical 0 0.99992514
is O 0 0.003263931
the O 0 0.0016404993
first O 0 0.0010618794
drug O 0 0.03596812
designed O 0 0.000614404
to O 0 0.00040516033
block O 0 0.000361354
the O 0 0.00030651706
final O 0 0.00032747563
step O 0 0.00032413998
in O 0 0.00034954073
the O 0 0.00043864604
acid O 0 0.21849746
secretory O 0 0.0008653244
process O 0 0.00069527124
within O 0 0.0007185969
the O 0 0.001585039
parietal O 0 0.5675445
cell O 0 0.007851712
. O 0 0.0071970955

It O 0 0.0049689435
has O 0 0.0025681208
been O 0 0.0018338246
shown O 0 0.0010293587
to O 0 0.000788784
be O 0 0.000726094
extremely O 0 0.0011225849
effective O 0 0.000549782
in O 0 0.0003795754
the O 0 0.00034043938
treatment O 0 0.0005062616
of O 0 0.0021124503
peptic B-Disease 0 0.9999944
ulcer I-Disease 2 0.99999845
disease I-Disease 0 0.99983096
, O 0 0.06485397
reflux B-Disease 0 0.9997558
esophagitis I-Disease 0 0.99996376
, O 0 0.0014498311
and O 0 0.000838797
the O 0 0.001132445
Zollinger B-Disease 0 0.44440082
- I-Disease 0 0.017053021
Ellison I-Disease 0 0.017816052
syndrome I-Disease 0 0.39194897
. O 0 0.007780736

Although O 0 0.003224168
clinical O 0 0.003753589
experience O 0 0.0021398375
with O 0 0.002326483
omeprazole B-Chemical 1 0.99992764
is O 0 0.0008923931
still O 0 0.0004776888
limited O 0 0.00037035867
, O 0 0.00042182373
many O 0 0.00025408104
controlled O 0 0.00022185869
studies O 0 0.00023929114
have O 0 0.00022129566
established O 0 0.0003216192
the O 0 0.0003235956
short O 0 0.00039593983
- O 0 0.001474312
term O 0 0.0006740636
safety O 0 0.0012720841
of O 0 0.0016683469
this O 0 0.002631694
drug O 0 0.27769563
. O 0 0.00737706

We O 0 0.0037894733
report O 0 0.003160751
the O 0 0.0016056785
first O 0 0.0010403908
case O 0 0.0009553354
of O 0 0.00085765834
a O 0 0.00088358275
serious O 0 0.016120706
short O 0 0.00048842625
- O 0 0.003843902
term O 0 0.00042051467
adverse O 0 0.2010332
reaction O 0 0.0036462345
with O 0 0.0004168303
the O 0 0.0004226011
use O 0 0.0006390997
of O 0 0.0029005748
omeprazole B-Chemical 1 0.9999901
: O 0 0.5431261
hemolytic B-Disease 2 0.9999995
anemia I-Disease 2 0.99999857
. O 0 0.025080109

The O 0 0.0036078
patient O 0 0.003028228
developed O 0 0.004091476
weakness O 0 0.9811157
, O 0 0.017654559
lethargy B-Disease 0 0.9999579
, O 0 0.002136268
and O 0 0.0011151886
shortness B-Disease 0 0.88750815
of I-Disease 0 0.00093250227
breath I-Disease 0 0.24479483
2 O 0 0.00046671947
days O 0 0.0003735019
after O 0 0.00044723315
starting O 0 0.0007891257
therapy O 0 0.0020933643
with O 0 0.004288827
omeprazole B-Chemical 1 0.99984205
. O 0 0.008638328

Two O 0 0.0034423082
weeks O 0 0.001789028
after O 0 0.0011501148
the O 0 0.0010135333
initiation O 0 0.0009728567
of O 0 0.0009595494
therapy O 0 0.0021386598
, O 0 0.0009254052
her O 0 0.0006781888
hematocrit O 0 0.67769617
had O 0 0.00027675624
decreased O 0 0.00028602578
from O 0 0.00019425593
44 O 0 0.0003327546
. O 0 0.00018057488
1 O 0 0.0001749629
% O 0 0.00019466052
to O 0 0.00014695582
20 O 0 0.00017554426
. O 0 0.00016375269
4 O 0 0.00016276355
% O 0 0.00023388349
, O 0 0.00025714468
and O 0 0.00022252348
she O 0 0.00016932741
had O 0 0.0001816057
a O 0 0.00024133056
positive O 0 0.0003634802
direct O 0 0.00051239517
Coombs O 0 0.9991774
antiglobulin O 0 0.99847513
test O 0 0.0007965721
and O 0 0.0008314897
an O 0 0.0012318394
elevated O 0 0.011150803
indirect O 0 0.032214373
bilirubin B-Chemical 1 0.9999232
. O 0 0.010859742

After O 0 0.0032082102
she O 0 0.0026805445
discontinued O 0 0.005090822
the O 0 0.0024225207
omeprazole B-Chemical 1 0.9999207
, O 0 0.0025684726
her O 0 0.0016542642
hemoglobin O 0 0.87143195
and O 0 0.0014729837
hematocrit O 0 0.57951224
gradually O 0 0.0016935532
returned O 0 0.0017709392
to O 0 0.002301612
normal O 0 0.0050550145
. O 0 0.007349847

The O 0 0.0030451282
mechanism O 0 0.0021888732
by O 0 0.0021411239
which O 0 0.0037231408
omeprazole B-Chemical 1 0.9998889
caused O 0 0.0010280639
the O 0 0.00066194247
patient O 0 0.00068693864
' O 0 0.001245085
s O 0 0.01794992
hemolytic B-Disease 2 0.9999999
anemia I-Disease 2 0.9999999
is O 0 0.0024832448
uncertain O 0 0.0015835507
, O 0 0.00062705146
but O 0 0.00040385214
physicians O 0 0.00041736744
should O 0 0.00022205657
be O 0 0.00035187506
alerted O 0 0.00072341727
to O 0 0.0005104097
this O 0 0.00079842436
possible O 0 0.0015031762
adverse O 0 0.22754845
effect O 0 0.0038763077
. O 0 0.0070908195

Phenylephrine B-Chemical 0 0.99995375
but O 0 0.0077582416
not O 0 0.0041967425
ephedrine B-Chemical 1 0.9999653
reduces B-Disease 0 0.0024381066
frontal I-Disease 0 0.9291451
lobe I-Disease 0 0.8799497
oxygenation I-Disease 0 0.3328061
following O 0 0.0013675914
anesthesia O 0 0.08978164
- O 0 0.013656052
induced O 0 0.0074180956
hypotension B-Disease 2 0.9999584
. O 0 0.010822083

BACKGROUND O 0 0.03416041
: O 0 0.007693965
Vasopressor O 0 0.21550524
agents O 0 0.005996532
are O 0 0.0018155824
used O 0 0.0014417476
to O 0 0.0014830041
correct O 0 0.002325313
anesthesia O 0 0.10242673
- O 0 0.017139558
induced O 0 0.00937863
hypotension B-Disease 2 0.9999573
. O 0 0.012567149

We O 0 0.003371031
describe O 0 0.0020183816
the O 0 0.0015275388
effect O 0 0.0012828435
of O 0 0.0027079298
phenylephrine B-Chemical 0 0.99999
and O 0 0.020053124
ephedrine B-Chemical 1 0.99998987
on O 0 0.00035228764
frontal O 0 0.86621785
lobe O 0 0.8930926
oxygenation O 0 0.6310003
( O 0 0.0022036068
S O 0 0.9869206
( O 0 0.0013657634
c O 0 0.0648327
) O 0 0.025444707
O O 0 0.99996185
( O 0 0.0018747153
2 O 0 0.00047961602
) O 0 0.0008125664
) O 0 0.00095048815
following O 0 0.00078695285
anesthesia O 0 0.052501533
- O 0 0.0113491295
induced O 0 0.006343359
hypotension B-Disease 2 0.99995875
. O 0 0.0096145

METHODS O 0 0.003780275
: O 0 0.003211083
Following O 0 0.0017338977
induction O 0 0.0013678154
of O 0 0.0014142791
anesthesia O 0 0.04297781
by O 0 0.001400563
fentanyl B-Chemical 1 0.9999374
( O 0 0.0012440858
0 O 0 0.0004163728
. O 0 0.00024156952
15 O 0 0.00020433131
mg O 0 0.0013006903
kg O 0 0.00064393965
( O 0 0.0005660688
- O 0 0.003573255
1 O 0 0.0002393847
) O 0 0.00042960345
) O 0 0.00051531626
and O 0 0.000553716
propofol B-Chemical 1 0.9995826
( O 0 0.00063427264
2 O 0 0.00018592378
. O 0 0.00014772011
0 O 0 0.00018412835
mg O 0 0.0019821725
kg O 0 0.0006398356
( O 0 0.00054709456
- O 0 0.0050777425
1 O 0 0.00023183889
) O 0 0.00047225898
) O 0 0.0005154072
, O 0 0.00031747215
13 O 0 0.00021671777
patients O 0 0.00024210355
received O 0 0.00021938577
phenylephrine B-Chemical 0 0.999954
( O 0 0.00097627967
0 O 0 0.00026355678
. O 0 0.00015762479
1 O 0 0.00016744647
mg O 0 0.004198267
iv O 0 0.0009720052
) O 0 0.00039929262
and O 0 0.00020857897
12 O 0 0.00013662562
patients O 0 0.00021434425
received O 0 0.00022514118
ephedrine B-Chemical 1 0.99997103
( O 0 0.00053314504
10 O 0 0.00022300669
mg O 0 0.008015185
iv O 0 0.000986198
) O 0 0.00043431864
to O 0 0.00024532413
restore O 0 0.0002704696
mean O 0 0.00039274484
arterial O 0 0.08648477
pressure O 0 0.048035536
( O 0 0.003151083
MAP O 0 0.88840395
) O 0 0.0073180273
. O 0 0.007486694

Heart O 0 0.02039785
rate O 0 0.0038701869
( O 0 0.00533683
HR O 0 0.67782354
) O 0 0.005232109
, O 0 0.0034616808
MAP O 0 0.98240626
, O 0 0.010675501
stroke B-Disease 2 0.99984396
volume O 0 0.008261606
( O 0 0.0025652081
SV O 0 0.55038023
) O 0 0.0014814952
, O 0 0.00057218294
cardiac O 0 0.01912962
output O 0 0.0006705016
( O 0 0.002688915
CO O 1 0.9999002
) O 0 0.001663799
, O 0 0.00040705517
and O 0 0.0004111641
frontal O 0 0.80422854
lobe O 0 0.8574733
oxygenation O 0 0.54770637
( O 0 0.001789091
S O 0 0.9826728
( O 0 0.0013767369
c O 0 0.055070523
) O 0 0.021898735
O O 0 0.99992716
( O 0 0.0023640231
2 O 0 0.0010256065
) O 0 0.0018130806
) O 0 0.0025086591
were O 0 0.0027710234
registered O 0 0.004887882
. O 0 0.007228029

RESULTS O 0 0.005724186
: O 0 0.003867136
Induction O 0 0.0027086006
of O 0 0.0020549498
anesthesia O 0 0.019055577
was O 0 0.0008197767
followed O 0 0.0005106243
by O 0 0.0005405907
a B-Disease 0 0.0005649972
decrease I-Disease 0 0.00046212162
in I-Disease 0 0.0006506384
MAP I-Disease 0 0.9891717
, I-Disease 0 0.0054026344
HR I-Disease 0 0.85023195
, I-Disease 0 0.0014449607
SV I-Disease 0 0.5019008
, I-Disease 0 0.0007841547
and I-Disease 0 0.0009797562
CO I-Disease 1 0.99983203
concomitant O 0 0.0021677818
with O 0 0.00037721303
an O 0 0.00045918155
elevation O 0 0.090520605
in O 0 0.0007079209
S O 0 0.9886563
( O 0 0.0024111678
c O 0 0.07682132
) O 0 0.027700882
O O 0 0.9998536
( O 0 0.004829921
2 O 0 0.0030539439
) O 0 0.005895083
. O 0 0.0078664515

After O 0 0.0030227136
administration O 0 0.008017613
of O 0 0.006166394
phenylephrine B-Chemical 0 0.9999889
, O 0 0.027913872
MAP O 0 0.9830428
increased O 0 0.0013017631
( O 0 0.0011263968
51 O 0 0.0009720905
+ O 0 0.002175611
/ O 0 0.007729973
- O 0 0.003155302
12 O 0 0.00020048642
to O 0 0.00018560143
81 O 0 0.00045177617
+ O 0 0.00094730174
/ O 0 0.0052550957
- O 0 0.005212366
13 O 0 0.0003263023
mmHg O 0 0.0010793539
; O 0 0.00053139444
P O 0 0.008081974
< O 0 0.0003121685
0 O 0 0.00040238583
. O 0 0.00042188066
001 O 0 0.00929381
; O 0 0.00069832517
mean O 0 0.000519294
+ O 0 0.0020239411
/ O 0 0.0071908324
- O 0 0.019716278
SD O 0 0.088541046
) O 0 0.007230511
. O 0 0.008545704

However O 0 0.0048463917
, O 0 0.0036664302
a O 0 0.002348079
14 O 0 0.001487096
% O 0 0.0012846941
( O 0 0.0010122716
from O 0 0.0005559734
70 O 0 0.0006136432
+ O 0 0.0013970986
/ O 0 0.0057864618
- O 0 0.004367349
8 O 0 0.00030048282
% O 0 0.00028626996
to O 0 0.00020089955
60 O 0 0.00025613385
+ O 0 0.0007557703
/ O 0 0.004879568
- O 0 0.004995478
7 O 0 0.00020606279
% O 0 0.00027808055
) O 0 0.00040595536
reduction O 0 0.00042171357
in O 0 0.0003866229
S O 0 0.98849225
( O 0 0.0016015877
c O 0 0.09205404
) O 0 0.036338978
O O 0 0.9999795
( O 0 0.002379356
2 O 0 0.0003002434
) O 0 0.00059400353
( O 0 0.0005915793
P O 0 0.036442738
< O 0 0.00022718975
0 O 0 0.0002800721
. O 0 0.00023448166
05 O 0 0.0028719176
) O 0 0.00029982635
followed O 0 0.00014377636
with O 0 0.0001797426
no O 0 0.00013768955
change O 0 0.00026688547
in O 0 0.0004401701
CO O 1 0.99991477
( O 0 0.0008465713
3 O 0 0.00016899433
. O 0 0.00015252017
7 O 0 0.00015969935
+ O 0 0.00064995483
/ O 0 0.006527534
- O 0 0.008548505
1 O 0 0.00021224222
. O 0 0.00016518479
1 O 0 0.0001574292
to O 0 0.00013768062
3 O 0 0.00015424743
. O 0 0.00016494555
4 O 0 0.00018531935
+ O 0 0.00060741586
/ O 0 0.00390958
- O 0 0.005059602
0 O 0 0.00034134937
. O 0 0.0002789042
9 O 0 0.000326926
l O 0 0.0007162986
min O 0 0.0008102754
( O 0 0.0013323297
- O 0 0.0034961528
1 O 0 0.0018693232
) O 0 0.0038158135
) O 0 0.0063697034
. O 0 0.008289488

The O 0 0.0034595088
administration O 0 0.009243186
of O 0 0.0054208925
ephedrine B-Chemical 1 0.999972
led O 0 0.0011089772
to O 0 0.0005892029
a O 0 0.0005765903
similar O 0 0.0003070965
increase O 0 0.0003858642
in O 0 0.0005036331
MAP O 0 0.99342996
( O 0 0.0010707562
53 O 0 0.00077051524
+ O 0 0.0019139041
/ O 0 0.007946128
- O 0 0.0040053427
9 O 0 0.0001939156
to O 0 0.00015872532
79 O 0 0.00036362093
+ O 0 0.00093570305
/ O 0 0.006183998
- O 0 0.006224091
8 O 0 0.00021753198
mmHg O 0 0.0009361433
; O 0 0.00044511547
P O 0 0.012329805
< O 0 0.00021065936
0 O 0 0.00026599964
. O 0 0.00024471694
001 O 0 0.046993375
) O 0 0.0005729191
, O 0 0.00039384956
restored O 0 0.0004762325
CO O 1 0.99990773
( O 0 0.00087344344
3 O 0 0.00018803302
. O 0 0.00017079231
2 O 0 0.00019337096
+ O 0 0.00072212925
/ O 0 0.007070136
- O 0 0.008750557
1 O 0 0.00020824693
. O 0 0.00015715428
2 O 0 0.00014216728
to O 0 0.000121094534
5 O 0 0.00013170888
. O 0 0.00014611482
0 O 0 0.00021439185
+ O 0 0.00079734746
/ O 0 0.0081641525
- O 0 0.0095237
1 O 0 0.00020854497
. O 0 0.00016057598
3 O 0 0.00014856228
l O 0 0.00037070573
min O 0 0.00032962937
( O 0 0.0004952738
- O 0 0.0029230397
1 O 0 0.0002676614
) O 0 0.0004978122
) O 0 0.000557829
, O 0 0.0004234859
and O 0 0.0004395087
preserved O 0 0.0014746757
S O 0 0.97724473
( O 0 0.0019552594
c O 0 0.058031917
) O 0 0.023551797
O O 0 0.99983084
( O 0 0.004913193
2 O 0 0.0032028349
) O 0 0.0061341054
. O 0 0.008152894

CONCLUSIONS O 0 0.021245964
: O 0 0.0038268259
The O 0 0.0016680156
utilization O 0 0.0017354616
of O 0 0.0021713905
phenylephrine B-Chemical 0 0.9999541
to O 0 0.0007971123
correct O 0 0.0015302933
hypotension B-Disease 2 0.99998057
induced O 0 0.00057116157
by O 0 0.0004593633
anesthesia O 0 0.014291839
has O 0 0.00017956442
a O 0 0.00020851573
negative O 0 0.0002231996
impact O 0 0.00016115732
on O 0 0.00018366052
S O 0 0.9906042
( O 0 0.002349785
c O 0 0.13670062
) O 0 0.050089795
O O 0 0.99998343
( O 0 0.002317534
2 O 0 0.0002818572
) O 0 0.00050852256
while O 0 0.0004951669
ephedrine B-Chemical 1 0.9999553
maintains O 0 0.00052998064
frontal O 0 0.87732667
lobe O 0 0.77332497
oxygenation O 0 0.10446704
potentially O 0 0.00047925315
related O 0 0.00034300998
to O 0 0.00052641233
an O 0 0.0009892521
increase O 0 0.001408376
in O 0 0.0036345948
CO O 1 0.99925476
. O 0 0.00908213

Prolonged O 0 0.010378741
elevation O 0 0.09797558
of O 0 0.0032580176
plasma O 0 0.27076343
argatroban B-Chemical 1 0.99878556
in O 0 0.0007853912
a O 0 0.0007563417
cardiac O 0 0.018512268
transplant O 0 0.025185488
patient O 0 0.00038283732
with O 0 0.0003262662
a O 0 0.00039665628
suspected O 0 0.0037344904
history O 0 0.008083084
of O 0 0.002526817
heparin B-Chemical 1 0.9994672
- O 0 0.17444521
induced O 0 0.008219236
thrombocytopenia B-Disease 0 0.9999864
with O 0 0.06994954
thrombosis B-Disease 2 0.9999776
. O 0 0.010060072

BACKGROUND O 0 0.025623256
: O 0 0.005186769
Direct O 0 0.012200867
thrombin O 0 0.7869676
inhibitors O 0 0.14319217
( O 0 0.00347124
DTIs O 0 0.05291163
) O 0 0.0006890692
provide O 0 0.0002777078
an O 0 0.00031667657
alternative O 0 0.00024018901
method O 0 0.00034667092
of O 0 0.00042659056
anticoagulation O 0 0.48512056
for O 0 0.00020230317
patients O 0 0.00027257402
with O 0 0.00019745575
a O 0 0.0002645658
history O 0 0.003022238
of O 0 0.0015414695
heparin B-Chemical 1 0.99956185
- O 0 0.21476416
induced O 0 0.005706659
thrombocytopenia B-Disease 0 0.9999981
( O 0 0.09364651
HIT B-Disease 2 0.9999112
) O 0 0.003974151
or O 0 0.0007343292
HIT B-Disease 2 0.99956566
with O 0 0.004941789
thrombosis B-Disease 2 0.99999726
( O 0 0.04340233
HITT B-Disease 2 0.99991584
) O 0 0.0013098489
undergoing O 0 0.00071133807
cardiopulmonary O 0 0.0010738298
bypass O 0 0.0014198499
( O 0 0.0029554695
CPB O 0 0.13637465
) O 0 0.006208828
. O 0 0.0076774512

In O 0 0.00360203
the O 0 0.002217856
following O 0 0.0015272865
report O 0 0.0022552973
, O 0 0.0014788341
a O 0 0.0010510505
65 O 0 0.0009807617
- O 0 0.0029506355
year O 0 0.0005994864
- O 0 0.002599422
old O 0 0.00044922828
critically B-Disease 0 0.0031091075
ill I-Disease 0 0.480364
patient O 0 0.00028850025
with O 0 0.00024529605
a O 0 0.00030369032
suspected O 0 0.003744812
history O 0 0.010955287
of O 0 0.0047810683
HITT B-Disease 2 0.9999639
was O 0 0.0004554585
administered O 0 0.00059011875
argatroban B-Chemical 1 0.9940612
for O 0 0.0004162932
anticoagulation O 0 0.10375958
on O 0 0.0004324964
bypass O 0 0.00089239527
during O 0 0.001146574
heart O 0 0.06334192
transplantation O 0 0.034503344
. O 0 0.0065898774

The O 0 0.0031031969
patient O 0 0.002160576
required O 0 0.0011964155
massive O 0 0.0044499636
transfusion O 0 0.025933793
support O 0 0.0006022525
( O 0 0.00075354165
55 O 0 0.00045602783
units O 0 0.00030583463
of O 0 0.0004074265
red O 0 0.018172199
blood O 0 0.009369605
cells O 0 0.00037480117
, O 0 0.0003597879
42 O 0 0.00024844197
units O 0 0.00016354048
of O 0 0.0002455347
fresh O 0 0.0010556122
- O 0 0.006958037
frozen O 0 0.0012568132
plasma O 0 0.0052650957
, O 0 0.00025920224
40 O 0 0.00015847215
units O 0 0.00014734027
of O 0 0.000277979
cryoprecipitate O 0 0.35397342
, O 0 0.00027393835
40 O 0 0.00016134567
units O 0 0.00014790811
of O 0 0.00025300725
platelets O 0 0.07356441
, O 0 0.00031013266
and O 0 0.0001946839
three O 0 0.0001213191
doses O 0 0.00037924913
of O 0 0.0002978315
recombinant O 0 0.0009781452
Factor O 0 0.99942505
VIIa O 0 0.9983261
) O 0 0.0018208096
for O 0 0.0005732498
severe O 0 0.015473176
intraoperative B-Disease 0 0.002355819
and I-Disease 0 0.0017720102
postoperative I-Disease 0 0.0328524
bleeding I-Disease 0 0.9968215
. O 0 0.0070039444

STUDY O 0 0.007985513
DESIGN O 0 0.0044163335
AND O 0 0.0023295912
METHODS O 0 0.0017566885
: O 0 0.0022088625
Plasma O 0 0.0048606754
samples O 0 0.0009314936
from O 0 0.0006317899
before O 0 0.00043672865
and O 0 0.0005096673
after O 0 0.00034447448
CPB O 0 0.013881279
were O 0 0.00026083394
analyzed O 0 0.00021029715
postoperatively O 0 0.0002569778
for O 0 0.00028227994
argatroban B-Chemical 1 0.98369294
concentration O 0 0.0004664388
using O 0 0.00027590446
a O 0 0.0003980372
modified O 0 0.0005080299
ecarin O 0 0.01787744
clotting O 0 0.027374884
time O 0 0.00058167626
( O 0 0.0018923294
ECT O 0 0.88560396
) O 0 0.003795642
assay O 0 0.007440452
. O 0 0.007491617

RESULTS O 0 0.0053399317
: O 0 0.0036321918
Unexpectedly O 0 0.0028344132
high O 0 0.0017153673
concentrations O 0 0.002278951
of O 0 0.0018330232
argatroban B-Chemical 1 0.9977362
were O 0 0.00040514738
measured O 0 0.00023270745
in O 0 0.00022217198
these O 0 0.00022483847
samples O 0 0.00022477377
( O 0 0.00029577402
range O 0 0.00023415145
, O 0 0.0003328117
0 O 0 0.0003015303
- O 0 0.0011674766
32 O 0 0.00023626846
microg O 0 0.00034416709
/ O 0 0.0065562776
mL O 0 0.004882815
) O 0 0.0006695894
, O 0 0.00030576083
and O 0 0.00022720319
a O 0 0.00024921543
prolonged O 0 0.0004515146
plasma O 0 0.044353835
argatroban B-Chemical 1 0.991097
half O 0 0.00011196654
life O 0 0.00022420677
( O 0 0.0002990989
t O 0 0.000753691
( O 0 0.00037901636
1 O 0 0.0002021389
/ O 0 0.0008514897
2 O 0 0.00019870285
) O 0 0.00035389594
) O 0 0.00033108666
of O 0 0.0002443481
514 O 0 0.011848731
minutes O 0 0.00013646312
was O 0 0.00014698695
observed O 0 0.0001369602
( O 0 0.00024834822
published O 0 0.00016440872
elimination O 0 0.00042160143
t O 0 0.0014297399
( O 0 0.00047676623
1 O 0 0.00022644365
/ O 0 0.00095217535
2 O 0 0.00021586132
) O 0 0.00035798788
is O 0 0.0002308921
39 O 0 0.00042022872
- O 0 0.00103208
51 O 0 0.00028070112
minutes O 0 0.00018891216
[ O 0 0.00049094704
< O 0 0.00023865547
or O 0 0.0002919434
= O 0 0.00063029653
181 O 0 0.0011000973
minutes O 0 0.00042600435
with O 0 0.0009688183
hepatic B-Disease 0 0.99623835
impairment I-Disease 0 0.99155676
] O 0 0.012025398
) O 0 0.007195457
. O 0 0.007523175

CONCLUSIONS O 0 0.014928408
: O 0 0.0032738862
Correlation O 0 0.0016559449
of O 0 0.00170013
plasma O 0 0.08571274
argatroban B-Chemical 1 0.9970804
concentration O 0 0.0012319755
versus O 0 0.00037560542
the O 0 0.0003004284
patient O 0 0.00031653285
' O 0 0.0003807137
s O 0 0.0003804951
coagulation O 0 0.20996335
variables O 0 0.00024100198
and O 0 0.00019867271
clinical O 0 0.0003674506
course O 0 0.00012736325
suggest O 0 9.213813e-05
that O 0 0.00012168835
prolonged O 0 0.0003534293
elevated O 0 0.0015910623
levels O 0 0.00021318492
of O 0 0.0005724994
plasma O 0 0.27032885
argatroban B-Chemical 1 0.9983193
may O 0 0.0002031864
have O 0 0.0001904273
contributed O 0 0.00032426885
to O 0 0.00028603777
the O 0 0.00041515287
patient O 0 0.0006842195
' O 0 0.0011829591
s O 0 0.0016803977
extended O 0 0.0029144124
coagulopathy B-Disease 2 0.99978954
. O 0 0.007714649

Because O 0 0.0040342477
DTIs O 0 0.009722074
do O 0 0.0017136729
not O 0 0.0010282805
have O 0 0.00076165085
reversal O 0 0.0011536195
agents O 0 0.0051791673
, O 0 0.000727221
surgical O 0 0.00051204086
teams O 0 0.00034949539
and O 0 0.00035506114
transfusion O 0 0.0077933795
services O 0 0.00028853217
should O 0 0.0001321687
remain O 0 0.0001649553
aware O 0 0.0001760013
of O 0 0.00020561532
the O 0 0.00019375703
possibility O 0 0.00019163458
of O 0 0.00040368256
massive O 0 0.017953157
transfusion O 0 0.08155708
events O 0 0.002754587
during O 0 0.0005339422
anticoagulation O 0 0.33408308
with O 0 0.0012459056
these O 0 0.0021887554
agents O 0 0.0133234495
. O 0 0.0063861576

This O 0 0.0051847277
is O 0 0.0025069448
the O 0 0.0015636219
first O 0 0.0010242825
report O 0 0.0012046718
to O 0 0.0005937978
measure O 0 0.00043171953
plasma O 0 0.040766247
argatroban B-Chemical 1 0.9966311
concentration O 0 0.0008785475
in O 0 0.00041231676
the O 0 0.00041872181
context O 0 0.0004435475
of O 0 0.001095548
CPB O 0 0.13800368
and O 0 0.0019112861
extended O 0 0.0035015428
coagulopathy B-Disease 2 0.9998591
. O 0 0.008452606

The O 0 0.002982785
effects O 0 0.0023486116
of O 0 0.0017341617
the O 0 0.0013737456
adjunctive O 0 0.24577563
bupropion B-Chemical 0 0.99999714
on O 0 0.0004442478
male O 0 0.03312205
sexual B-Disease 0 0.98479396
dysfunction I-Disease 0 0.99613035
induced O 0 0.0005725957
by O 0 0.0003831329
a O 0 0.0005711591
selective B-Chemical 0 0.018451959
serotonin I-Chemical 0 0.9998815
reuptake I-Chemical 0 0.98347396
inhibitor I-Chemical 0 0.0022513096
: O 0 0.00044118578
a O 0 0.00029917335
double O 0 0.00040221313
- O 0 0.008244212
blind O 0 0.032874987
placebo O 0 0.017503554
- O 0 0.0016516423
controlled O 0 0.00080407446
and O 0 0.0014415289
randomized O 0 0.0023261441
study O 0 0.0040837293
. O 0 0.0063343365

OBJECTIVE O 0 0.014958322
: O 0 0.0030938543
To O 0 0.0012223299
determine O 0 0.0006073927
the O 0 0.0006729355
safety O 0 0.00072428264
and O 0 0.00048614325
efficacy O 0 0.00056103955
of O 0 0.0006034321
adjunctive O 0 0.2916483
bupropion B-Chemical 0 0.99999917
sustained O 0 0.03670153
- O 0 0.059124034
release O 0 0.0069337054
( O 0 0.0016626905
SR O 0 0.37601262
) O 0 0.0005342038
on O 0 0.00013792833
male O 0 0.010802238
sexual B-Disease 0 0.98523825
dysfunction I-Disease 0 0.99885297
( O 0 0.0061574085
SD B-Disease 0 0.23352541
) O 0 0.00046710137
induced O 0 0.00018298319
by O 0 0.00021776608
a O 0 0.00039585624
selective B-Chemical 0 0.017368412
serotonin I-Chemical 0 0.9999119
reuptake I-Chemical 0 0.9932829
inhibitor I-Chemical 0 0.024775637
( O 0 0.016665835
SSRI B-Chemical 0 0.9999951
) O 0 0.0011133669
, O 0 0.0002912326
as O 0 0.00018032332
SD B-Disease 0 0.025241708
is O 0 0.00018789218
a O 0 0.0002389421
common O 0 0.0003642253
side O 0 0.03540279
- O 0 0.010704084
effect O 0 0.00026066886
of O 0 0.0013945762
SSRIs B-Chemical 0 0.99985707
and O 0 0.00030109647
the O 0 0.00024523665
most O 0 0.00036806712
effective O 0 0.00035270816
treatments O 0 0.0004947744
have O 0 0.0005145594
yet O 0 0.000948992
to O 0 0.0010616047
be O 0 0.0019459012
determined O 0 0.0031127895
. O 0 0.006630928

PATIENTS O 0 0.005557691
AND O 0 0.0031506543
METHODS O 0 0.0021171013
: O 0 0.0021636784
The O 0 0.0012347156
randomized O 0 0.0011259634
sample O 0 0.0008660338
consisted O 0 0.00066644914
of O 0 0.0009155012
234 O 0 0.03558809
euthymic O 0 0.9522673
men O 0 0.01824399
who O 0 0.0010066753
were O 0 0.00072719646
receiving O 0 0.000916384
some O 0 0.001137559
type O 0 0.0020556396
of O 0 0.008417322
SSRI B-Chemical 0 0.9999583
. O 0 0.008875297

The O 0 0.0036798024
men O 0 0.006321812
were O 0 0.0015870158
randomly O 0 0.00078653975
assigned O 0 0.00073283183
to O 0 0.0009485598
bupropion B-Chemical 0 0.99999714
SR O 0 0.7282999
( O 0 0.00085266173
150 O 0 0.0003982224
mg O 0 0.00158032
twice O 0 0.00018650954
daily O 0 0.00024243338
, O 0 0.0003017238
117 O 0 0.0006604688
) O 0 0.0004539114
or O 0 0.00029842212
placebo O 0 0.00756743
( O 0 0.00039545546
twice O 0 0.00027135556
daily O 0 0.00041929437
, O 0 0.0006274532
117 O 0 0.0012382363
) O 0 0.001209205
for O 0 0.0012446832
12 O 0 0.0017515342
weeks O 0 0.002579456
. O 0 0.0059804153

Efficacy O 0 0.006391551
was O 0 0.0024249407
evaluated O 0 0.0013541958
using O 0 0.001092024
the O 0 0.00095047447
Clinical O 0 0.004298114
Global O 0 0.0030814135
Impression O 0 0.012961647
- O 0 0.0018791212
Sexual O 0 0.013615705
Function O 0 0.0029992023
( O 0 0.0015036416
CGI O 0 0.7728501
- O 0 0.016524946
SF O 0 0.048586715
; O 0 0.00043937127
the O 0 0.00020292445
primary O 0 0.00022886034
outcome O 0 0.00033501972
measure O 0 0.00013500151
) O 0 0.0004348673
, O 0 0.00028416392
the O 0 0.000193316
International O 0 0.00043915914
Index O 0 0.00029869628
of O 0 0.00022055797
Erectile O 0 0.0005705843
Function O 0 0.0006454388
( O 0 0.0003722592
IIEF O 0 0.0024639245
) O 0 0.0004020868
, O 0 0.00037510478
Arizona O 0 0.011171087
Sexual O 0 0.031702254
Experience O 0 0.026548017
Scale O 0 0.24080774
( O 0 0.0010545218
ASEX O 0 0.96856153
) O 0 0.00049839215
, O 0 0.00034125856
and O 0 0.00035643723
Erectile B-Disease 0 0.008977683
Dysfunction I-Disease 0 0.005983687
Inventory O 0 0.0010462073
of O 0 0.0002936905
Treatment O 0 0.0012137919
Satisfaction O 0 0.0010584802
( O 0 0.00081763085
EDITS O 0 0.036375992
) O 0 0.00097378856
( O 0 0.0010873491
secondary O 0 0.002336854
outcome O 0 0.0025103765
measures O 0 0.0023437846
) O 0 0.0057671764
. O 0 0.007617727

Participants O 0 0.010268814
were O 0 0.007794294
followed O 0 0.0067084213
biweekly O 0 0.009024509
during O 0 0.0072581097
study O 0 0.010925764
period O 0 0.011758534
. O 0 0.018245272

RESULTS O 0 0.0052775997
: O 0 0.0031967652
After O 0 0.0013303851
12 O 0 0.001028547
weeks O 0 0.0006868008
of O 0 0.0007659639
treatment O 0 0.00075086474
, O 0 0.00064069143
the O 0 0.00032979567
mean O 0 0.0002203316
( O 0 0.00040900585
sd O 0 0.00048635298
) O 0 0.0004370139
scores O 0 0.0002363719
for O 0 0.0003239546
CGI O 0 0.6995942
- O 0 0.012273801
SF O 0 0.02999424
were O 0 0.00022389786
significantly O 0 0.00021284512
lower O 0 0.00022375745
, O 0 0.00035271794
i O 0 0.0014322114
. O 0 0.0001930986
e O 0 0.00054171303
. O 0 0.000212547
better O 0 0.00022750796
, O 0 0.00026870024
in O 0 0.00017760503
patients O 0 0.00030276895
on O 0 0.0002048287
bupropion B-Chemical 0 0.99999845
SR O 0 0.56421345
, O 0 0.00034783987
at O 0 0.00014666982
2 O 0 0.00015261212
. O 0 0.00013714275
4 O 0 0.00013784629
( O 0 0.0002274598
1 O 0 0.0001705669
. O 0 0.00016041941
2 O 0 0.00018015507
) O 0 0.00033466984
, O 0 0.00025671648
than O 0 0.00013142407
in O 0 0.0001610495
the O 0 0.00020149616
placebo O 0 0.007609876
group O 0 0.00026319694
, O 0 0.0002400885
at O 0 0.00014942093
3 O 0 0.00015287193
. O 0 0.00016262782
9 O 0 0.00018893863
( O 0 0.00028727064
1 O 0 0.00024098244
. O 0 0.00025871312
1 O 0 0.00034291597
) O 0 0.0006972057
( O 0 0.0009988985
P O 0 0.03160684
= O 0 0.0017424329
0 O 0 0.0015761055
. O 0 0.0020871935
01 O 0 0.006058549
) O 0 0.0062198592
. O 0 0.008343062

Men O 0 0.07043114
who O 0 0.0045621726
received O 0 0.0027600992
bupropion B-Chemical 0 0.9999877
had O 0 0.0012212693
a O 0 0.0008613584
significant O 0 0.00049926306
increase O 0 0.00033474324
in O 0 0.00031128584
the O 0 0.00025140482
total O 0 0.00022738197
IIEF O 0 0.0028084528
score O 0 0.00021365375
( O 0 0.0003274625
54 O 0 0.00033334742
. O 0 0.00017532546
4 O 0 0.00015709481
% O 0 0.00020259502
vs O 0 0.00023895394
1 O 0 0.00018828815
. O 0 0.0001740884
2 O 0 0.00018870117
% O 0 0.00026979894
; O 0 0.0005102722
P O 0 0.03023449
= O 0 0.00061189407
0 O 0 0.0003412519
. O 0 0.0003076662
003 O 0 0.01790421
) O 0 0.000571179
, O 0 0.00041722527
and O 0 0.00035682705
in O 0 0.00033797201
the O 0 0.00036547534
five O 0 0.00036355073
different O 0 0.00050303194
domains O 0 0.00086024747
of O 0 0.0017362433
the O 0 0.0028011745
IIEF O 0 0.026170896
. O 0 0.006871456

Total O 0 0.0053635533
ASEX O 0 0.88591903
scores O 0 0.0018054628
were O 0 0.0012319015
significantly O 0 0.0009255066
lower O 0 0.00077946525
, O 0 0.0009199546
i O 0 0.0019422218
. O 0 0.00040433675
e O 0 0.0007937892
. O 0 0.00034829017
better O 0 0.00035540966
, O 0 0.00044638515
among O 0 0.0005157888
men O 0 0.017150583
who O 0 0.0005331656
received O 0 0.00032470629
bupropion B-Chemical 0 0.99999595
than O 0 0.00021178435
placebo O 0 0.009218734
, O 0 0.00021935107
at O 0 0.00012611943
15 O 0 0.00012619376
. O 0 0.0001280884
5 O 0 0.0001306043
( O 0 0.00021426985
4 O 0 0.0001466459
. O 0 0.00015169634
3 O 0 0.00015432246
) O 0 0.00026304013
vs O 0 0.0002558688
21 O 0 0.0002242461
. O 0 0.00018132178
5 O 0 0.0001849252
( O 0 0.00029465358
4 O 0 0.0002261668
. O 0 0.00026279347
7 O 0 0.00032369315
) O 0 0.0006994131
( O 0 0.0010217401
P O 0 0.028130101
= O 0 0.001843678
0 O 0 0.0017004982
. O 0 0.0023169464
002 O 0 0.046709646
) O 0 0.006853231
. O 0 0.008791188

The O 0 0.003858148
EDITS O 0 0.009831526
scores O 0 0.0016875386
were O 0 0.0012608803
67 O 0 0.001325199
. O 0 0.0007354726
4 O 0 0.0005550975
( O 0 0.0006315919
10 O 0 0.00040500777
. O 0 0.0003345467
2 O 0 0.00030780231
) O 0 0.00040589366
for O 0 0.00026169908
the O 0 0.0004809606
bupropion B-Chemical 0 0.99999475
and O 0 0.00038643717
36 O 0 0.000255892
. O 0 0.00017653375
3 O 0 0.00016821382
( O 0 0.00025735513
11 O 0 0.00020841039
. O 0 0.00018136273
7 O 0 0.00018690762
) O 0 0.0003095684
for O 0 0.0002303661
the O 0 0.00030829103
placebo O 0 0.0072335848
group O 0 0.0005913256
( O 0 0.0010374445
P O 0 0.046160776
= O 0 0.001686737
0 O 0 0.0014852412
. O 0 0.002038683
001 O 0 0.04777781
) O 0 0.006366499
. O 0 0.008078833

The O 0 0.0047277566
ASEX O 0 0.81063056
score O 0 0.0022534465
and O 0 0.0026050764
CGI O 0 0.61618656
- O 0 0.008637826
SF O 0 0.010646552
score O 0 0.0008491028
were O 0 0.0007704173
correlated O 0 0.0007147285
( O 0 0.0014202704
P O 0 0.024477229
= O 0 0.0023839083
0 O 0 0.0021912532
. O 0 0.002881623
003 O 0 0.019411277
) O 0 0.007677324
. O 0 0.009813486

In O 0 0.0033464292
linear O 0 0.0027026704
regression O 0 0.0037835084
analyses O 0 0.0014178974
the O 0 0.0015094816
CGI O 0 0.8370505
- O 0 0.028777976
SF O 0 0.04285913
score O 0 0.00048640883
was O 0 0.0003721964
not O 0 0.00027659634
affected O 0 0.00028099777
significantly O 0 0.00026417512
by O 0 0.00024892925
the O 0 0.00022674009
duration O 0 0.00022539916
of O 0 0.0004389281
SD B-Disease 0 0.07456843
, O 0 0.0006616429
type O 0 0.00070002
of O 0 0.0023637086
SSRI B-Chemical 0 0.9999597
used O 0 0.0014013302
and O 0 0.0024490547
age O 0 0.0058699283
. O 0 0.006961811

CONCLUSIONS O 0 0.10944254
: O 0 0.022448974
Bupropion B-Chemical 0 0.9999634
is O 0 0.0027018941
an O 0 0.0019484209
effective O 0 0.0014992495
treatment O 0 0.0014394274
for O 0 0.0013943152
male O 0 0.0058148084
SD B-Disease 0 0.047365703
induced O 0 0.002851814
by O 0 0.0058628675
SSRIs B-Chemical 0 0.99953246
. O 0 0.009124843

These O 0 0.0043231486
results O 0 0.0027438381
provide O 0 0.001989707
empirical O 0 0.0021243726
support O 0 0.0014564263
for O 0 0.001434351
conducting O 0 0.001559919
a O 0 0.0018541692
further O 0 0.0019054327
study O 0 0.0034613633
of O 0 0.009648021
bupropion B-Chemical 0 0.9999846
. O 0 0.011265786

Prevention O 0 0.007502482
of O 0 0.006215281
seizures B-Disease 0 0.9999794
and O 0 0.002459986
reorganization O 0 0.004352233
of O 0 0.0011249895
hippocampal O 0 0.14351952
functions O 0 0.00048310866
by O 0 0.00043069848
transplantation O 0 0.0023398853
of O 0 0.00047896267
bone O 0 0.009777244
marrow O 0 0.01945068
cells O 0 0.00057267095
in O 0 0.00048504065
the O 0 0.00063878973
acute O 0 0.42802444
phase O 0 0.0020586338
of O 0 0.0029092955
experimental O 0 0.023205603
epilepsy B-Disease 2 0.99998784
. O 0 0.010257162

In O 0 0.0038182356
this O 0 0.0024936716
study O 0 0.0020940427
, O 0 0.001504005
we O 0 0.00064217334
investigated O 0 0.00049489865
the O 0 0.00043891184
therapeutic O 0 0.0006253136
potential O 0 0.00039656632
of O 0 0.00047602376
bone O 0 0.018012762
marrow O 0 0.09367981
mononuclear O 0 0.1515107
cells O 0 0.00054562907
( O 0 0.00095215
BMCs O 0 0.020702235
) O 0 0.0005889342
in O 0 0.00027096207
a O 0 0.00035717146
model O 0 0.00043230082
of O 0 0.0029588311
epilepsy B-Disease 2 0.99999714
induced O 0 0.002919104
by O 0 0.007993502
pilocarpine B-Chemical 1 0.99999475
in O 0 0.0034236575
rats O 0 0.006087612
. O 0 0.0063172677

BMCs O 0 0.00803554
obtained O 0 0.0021859838
from O 0 0.0016148891
green O 0 0.0041057644
fluorescent O 0 0.0038362334
protein O 0 0.003397915
( O 0 0.003342932
GFP O 0 0.05120728
) O 0 0.0014426857
transgenic O 0 0.0004584313
mice O 0 0.00023582284
or O 0 0.0002962069
rats O 0 0.0003939472
were O 0 0.0002522192
transplanted O 0 0.00057380093
intravenously O 0 0.00029207874
after O 0 0.00021050198
induction O 0 0.00037978025
of O 0 0.0008565313
status B-Disease 0 0.02621873
epilepticus I-Disease 0 0.9999925
( O 0 0.015841303
SE B-Disease 0 0.8675533
) O 0 0.007624027
. O 0 0.0074054953

Spontaneous B-Disease 0 0.085417286
recurrent I-Disease 0 0.8920313
seizures I-Disease 0 0.9999988
( O 0 0.09628371
SRS B-Disease 0 0.979549
) O 0 0.0020665636
were O 0 0.00094474235
monitored O 0 0.00071623106
using O 0 0.0009955752
Racine O 0 0.003695057
' O 0 0.0018615527
s O 0 0.0029725584
seizure B-Disease 2 0.9997385
severity O 0 0.025105376
scale O 0 0.0061321747
. O 0 0.008142511

All O 0 0.0030805436
of O 0 0.0025530597
the O 0 0.0016285388
rats O 0 0.0015841495
in O 0 0.0008557301
the O 0 0.00076364365
saline O 0 0.06358361
- O 0 0.024914011
treated O 0 0.0019901234
epileptic B-Disease 0 0.99996066
control O 0 0.00044312485
group O 0 0.00054516696
developed O 0 0.0019495636
SRS B-Disease 0 0.97916234
, O 0 0.00040579675
whereas O 0 0.00022782445
none O 0 0.00020501745
of O 0 0.0002678355
the O 0 0.00050960877
BMC O 0 0.9951616
- O 0 0.079331934
treated O 0 0.0028182715
epileptic B-Disease 0 0.9999684
animals O 0 0.00023354676
had O 0 0.0004910694
seizures B-Disease 0 0.99999666
in O 0 0.00019852445
the O 0 0.00013889773
short O 0 0.000121255725
term O 0 0.00015871806
( O 0 0.00026670104
15 O 0 0.00015342071
days O 0 0.00014030635
after O 0 0.00017897163
transplantation O 0 0.0026264263
) O 0 0.0008255359
, O 0 0.00065160065
regardless O 0 0.00052131945
of O 0 0.00119289
the O 0 0.0018872335
BMC O 0 0.8087696
source O 0 0.0041669426
. O 0 0.007233801

Over O 0 0.00396116
the O 0 0.00223991
long O 0 0.0019280169
- O 0 0.0038533532
term O 0 0.0010431544
chronic O 0 0.5259744
phase O 0 0.002106046
( O 0 0.0008013346
120 O 0 0.00033265312
days O 0 0.0001873501
after O 0 0.00017480948
transplantation O 0 0.003674544
) O 0 0.0007332558
, O 0 0.00037259824
only O 0 0.00025450677
25 O 0 0.00026880225
% O 0 0.00028093756
of O 0 0.0005546229
BMC O 0 0.99260896
- O 0 0.057729926
treated O 0 0.0023597977
epileptic B-Disease 0 0.99996555
animals O 0 0.00027004836
had O 0 0.0008167155
seizures B-Disease 0 0.99999905
, O 0 0.0015398997
but O 0 0.00032625248
with O 0 0.00024922992
a O 0 0.0002750627
lower O 0 0.0002089305
frequency O 0 0.00024983205
and O 0 0.0002688699
duration O 0 0.00024464578
compared O 0 0.00029772194
to O 0 0.000500025
the O 0 0.0010899865
epileptic B-Disease 0 0.9998066
control O 0 0.0023244768
group O 0 0.0042687166
. O 0 0.0060627405

The O 0 0.0030506079
density O 0 0.0029164653
of O 0 0.002340196
hippocampal O 0 0.25930607
neurons O 0 0.0026694185
in O 0 0.0007875653
the O 0 0.00065362576
brains O 0 0.0010882216
of O 0 0.0006588961
animals O 0 0.0005651432
treated O 0 0.00084853463
with O 0 0.0011422025
BMCs O 0 0.014764778
was O 0 0.00186803
markedly O 0 0.003799152
preserved O 0 0.0060894643
. O 0 0.0073898016

At O 0 0.0032485998
hippocampal O 0 0.14237808
Schaeffer O 0 0.0682421
collateral O 0 0.45020023
- O 0 0.17502142
CA1 O 0 0.97995454
synapses O 0 0.028358513
, O 0 0.0009009616
long O 0 0.00057912164
- O 0 0.0025451027
term O 0 0.0004098276
potentiation O 0 0.2773398
was O 0 0.00044455403
preserved O 0 0.00067199825
in O 0 0.0005872746
BMC O 0 0.9686946
- O 0 0.011480279
transplanted O 0 0.0021468357
rats O 0 0.0009504859
compared O 0 0.0007859359
to O 0 0.0016743228
epileptic B-Disease 0 0.9997873
controls O 0 0.0072306516
. O 0 0.0070059407

The O 0 0.0033762981
donor O 0 0.0035840438
- O 0 0.0051014107
derived O 0 0.0012939957
GFP O 0 0.027059507
( O 0 0.002581928
+ O 0 0.004112864
) O 0 0.0014360907
cells O 0 0.00072057423
were O 0 0.00051395403
rarely O 0 0.00053539354
found O 0 0.00041009564
in O 0 0.00048327036
the O 0 0.0006140583
brains O 0 0.0015970772
of O 0 0.0016838955
transplanted O 0 0.11766621
epileptic B-Disease 0 0.9999379
rats O 0 0.008694313
. O 0 0.0069403662

In O 0 0.0037623274
conclusion O 0 0.0022624324
, O 0 0.0024864834
treatment O 0 0.0016280683
with O 0 0.0012908875
BMCs O 0 0.020161102
can O 0 0.0004288645
prevent O 0 0.00033965765
the O 0 0.00034352439
development O 0 0.001007555
of O 0 0.0018999523
chronic O 0 0.9979231
seizures B-Disease 0 0.9999999
, O 0 0.0056302994
reduce O 0 0.0002785606
neuronal B-Disease 0 0.8915266
loss I-Disease 0 0.07408143
, O 0 0.0005032183
and O 0 0.00028833997
influence O 0 0.00022039675
the O 0 0.00032970702
reorganization O 0 0.0012552314
of O 0 0.00073857314
the O 0 0.0010041886
hippocampal O 0 0.3074549
neuronal O 0 0.052483372
network O 0 0.004156222
. O 0 0.006351398

Normalizing O 0 0.007254315
effects O 0 0.004675989
of O 0 0.005374538
modafinil B-Chemical 1 0.99992824
on O 0 0.0024077774
sleep O 0 0.08208859
in O 0 0.0036219503
chronic O 0 0.9899941
cocaine B-Chemical 1 0.9999862
users O 0 0.15616904
. O 0 0.010563952

OBJECTIVE O 0 0.020679954
: O 0 0.0035546026
The O 0 0.0014962644
purpose O 0 0.0011351077
of O 0 0.0009257248
the O 0 0.0006452774
present O 0 0.00043758983
study O 0 0.000519656
was O 0 0.00031654735
to O 0 0.00020695121
determine O 0 0.0001188614
the O 0 0.00018576412
effect O 0 0.0002004784
of O 0 0.00039864227
morning O 0 0.014413963
- O 0 0.019575302
dosed O 0 0.027252346
modafinil B-Chemical 1 0.9999218
on O 0 0.00020548244
sleep O 0 0.009695378
and O 0 0.00053693744
daytime B-Disease 0 0.5663043
sleepiness I-Disease 0 0.99698263
in O 0 0.0011972733
chronic O 0 0.9721162
cocaine B-Chemical 1 0.999982
users O 0 0.06130997
. O 0 0.006570988

METHOD O 0 0.008670844
: O 0 0.0050035445
Twenty O 0 0.00689612
cocaine B-Chemical 1 0.9999498
- O 0 0.01644448
dependent O 0 0.0007565504
participants O 0 0.0005733204
were O 0 0.0003935874
randomly O 0 0.00021412708
assigned O 0 0.00021845607
to O 0 0.00021673368
receive O 0 0.0002545823
modafinil B-Chemical 1 0.9999535
, O 0 0.0006004236
400 O 0 0.0006537869
mg O 0 0.02452502
( O 0 0.0011049786
N O 0 0.9977424
= O 0 0.0014957022
10 O 0 0.00023078272
) O 0 0.00040033963
, O 0 0.00030385042
or O 0 0.00025956033
placebo O 0 0.04030892
( O 0 0.001540435
N O 0 0.99843746
= O 0 0.0014402145
10 O 0 0.00019489657
) O 0 0.0002363852
every O 0 9.869192e-05
morning O 0 0.0002449679
at O 0 0.00012509013
7 O 0 0.00013925672
: O 0 0.0002155491
30 O 0 0.00014921164
a O 0 0.00020405327
. O 0 0.00019148295
m O 0 0.0006839396
. O 0 0.00020794253
for O 0 0.00020246023
16 O 0 0.00023304632
days O 0 0.00017939707
in O 0 0.0002672552
an O 0 0.00041060342
inpatient O 0 0.00086962135
, O 0 0.0007481355
double O 0 0.0009709153
- O 0 0.0046800785
blind O 0 0.00790191
randomized O 0 0.0025355525
trial O 0 0.0041410928
. O 0 0.006524026

Participants O 0 0.0036371422
underwent O 0 0.0022505021
polysomnographic O 0 0.004038093
sleep O 0 0.0030798484
recordings O 0 0.00082902337
on O 0 0.0004086685
days O 0 0.00035647073
1 O 0 0.0003575515
to O 0 0.00027966997
3 O 0 0.0002745837
, O 0 0.00032075937
7 O 0 0.00021239587
to O 0 0.00019612597
9 O 0 0.00022717415
, O 0 0.0002655352
and O 0 0.00023760422
14 O 0 0.00020968208
to O 0 0.00018264103
16 O 0 0.00025337105
( O 0 0.00030398546
first O 0 0.0002207871
, O 0 0.00037674073
second O 0 0.00033565157
, O 0 0.0005069014
and O 0 0.00053129235
third O 0 0.00070580497
weeks O 0 0.00071585807
of O 0 0.0018500827
abstinence O 0 0.77674526
) O 0 0.006286976
. O 0 0.0071741915

The O 0 0.0036972342
Multiple O 0 0.00428088
Sleep O 0 0.008562356
Latency O 0 0.009326322
Test O 0 0.0040917443
was O 0 0.0007640902
performed O 0 0.000497153
at O 0 0.00043402455
11 O 0 0.00044307165
: O 0 0.00046558862
30 O 0 0.00028157304
a O 0 0.00033274258
. O 0 0.00028308146
m O 0 0.0010062591
. O 0 0.0002945227
, O 0 0.00038880637
2 O 0 0.00027468713
: O 0 0.00048086068
00 O 0 0.0031183967
p O 0 0.00026667712
. O 0 0.00023770913
m O 0 0.00096672395
. O 0 0.00025477094
, O 0 0.00032042438
and O 0 0.0002716574
4 O 0 0.00021080645
: O 0 0.00030026748
30 O 0 0.00019574095
p O 0 0.00024354359
. O 0 0.000258066
m O 0 0.0006999033
. O 0 0.00030060517
on O 0 0.00026607013
days O 0 0.0003649157
2 O 0 0.00057639886
, O 0 0.0009457809
8 O 0 0.0010741133
, O 0 0.001850757
and O 0 0.0026336145
15 O 0 0.003801347
. O 0 0.0068664597

For O 0 0.0032574746
comparison O 0 0.0020139397
of O 0 0.00186872
sleep O 0 0.01588819
architecture O 0 0.0015099001
variables O 0 0.0009193973
, O 0 0.00073063973
12 O 0 0.00035658202
healthy O 0 0.00058860873
comparison O 0 0.00022519656
participants O 0 0.00021793036
underwent O 0 0.00021607772
a O 0 0.0002572538
single O 0 0.00024224022
night O 0 0.0004118928
of O 0 0.00026312287
experimental O 0 0.00029873295
polysomnography O 0 0.00044743821
that O 0 0.0002766507
followed O 0 0.0004039066
1 O 0 0.0006492878
night O 0 0.0012230107
of O 0 0.0016184471
accommodation O 0 0.013011523
polysomnography O 0 0.0070415856
. O 0 0.0064121615

RESULTS O 0 0.006161562
: O 0 0.0046454514
Progressive O 0 0.025589658
abstinence O 0 0.8300802
from O 0 0.0020984167
cocaine B-Chemical 1 0.9999567
was O 0 0.0011538481
associated O 0 0.00080903555
with O 0 0.000781155
worsening O 0 0.04514812
of O 0 0.0007965284
all O 0 0.0007442225
measured O 0 0.0009682637
polysomnographic O 0 0.012052155
sleep O 0 0.009265725
outcomes O 0 0.0046641976
. O 0 0.0063524093

Compared O 0 0.0032688552
with O 0 0.0026942499
placebo O 0 0.11280156
, O 0 0.0048073563
modafinil B-Chemical 1 0.9999652
decreased O 0 0.001508504
nighttime O 0 0.007988668
sleep O 0 0.009072086
latency O 0 0.0006787122
and O 0 0.00036613896
increased O 0 0.00040245053
slow O 0 0.0010741184
- O 0 0.007398779
wave O 0 0.0076884553
sleep O 0 0.011975003
time O 0 0.0004286785
in O 0 0.0010125552
cocaine B-Chemical 1 0.9999386
- O 0 0.0077943895
dependent O 0 0.0020944404
participants O 0 0.003832875
. O 0 0.006440189

The O 0 0.00300516
effect O 0 0.0022998443
of O 0 0.0033738136
modafinil B-Chemical 1 0.99997306
interacted O 0 0.0013959362
with O 0 0.00077992777
the O 0 0.0005814944
abstinence O 0 0.6647399
week O 0 0.00022581236
and O 0 0.0002654565
was O 0 0.00021544348
associated O 0 0.00019936344
with O 0 0.00017719214
longer O 0 0.00011380288
total O 0 0.00014115001
sleep O 0 0.001135766
time O 0 0.00012575844
and O 0 0.00020624837
shorter O 0 0.00021726996
REM O 0 0.8673691
sleep O 0 0.005843541
latency O 0 0.00053325755
in O 0 0.00038147133
the O 0 0.0005112901
third O 0 0.0008387267
week O 0 0.0010060023
of O 0 0.002551104
abstinence O 0 0.7280077
. O 0 0.0064480784

Comparison O 0 0.0032932032
of O 0 0.0027839548
slow O 0 0.0038228347
- O 0 0.011102798
wave O 0 0.013506311
sleep O 0 0.021217732
time O 0 0.00041390985
, O 0 0.00048233478
total O 0 0.00028232142
sleep O 0 0.0032730927
time O 0 0.0001749991
, O 0 0.00028168687
and O 0 0.00025468593
sleep O 0 0.010005854
latency O 0 0.0010110543
in O 0 0.0005223555
cocaine B-Chemical 1 0.9999913
- O 0 0.014954529
dependent O 0 0.00016067293
and O 0 0.00023925077
healthy O 0 0.0009196033
participants O 0 0.00015860943
revealed O 0 0.00016533321
a O 0 0.00022713993
normalizing O 0 0.00029095536
effect O 0 0.00031762142
of O 0 0.002340325
modafinil B-Chemical 1 0.99999404
in O 0 0.0035359685
cocaine B-Chemical 1 0.99998283
- O 0 0.01560434
dependent O 0 0.0019547557
participants O 0 0.0035937221
. O 0 0.006053547

Modafinil B-Chemical 0 0.99991155
was O 0 0.0031835653
associated O 0 0.0016942339
with O 0 0.0011544989
increased O 0 0.0010265446
daytime O 0 0.013904346
sleep O 0 0.025996316
latency O 0 0.0010620125
, O 0 0.00041663763
as O 0 0.0002359724
measured O 0 0.00019789457
by O 0 0.00023349201
the O 0 0.00022518155
Multiple O 0 0.00078447646
Sleep O 0 0.008794317
Latency O 0 0.013774556
Test O 0 0.0093735
, O 0 0.0003580746
and O 0 0.00031544562
a O 0 0.00035625903
nearly O 0 0.00036657625
significant O 0 0.00047588017
decrease O 0 0.00066694483
in O 0 0.0010522141
subjective O 0 0.0063338717
daytime B-Disease 0 0.6714953
sleepiness I-Disease 0 0.9940158
. O 0 0.0066089653

CONCLUSIONS O 0 0.028415436
: O 0 0.005979785
Morning O 0 0.1857933
- O 0 0.015305678
dosed O 0 0.034378912
modafinil B-Chemical 1 0.9999448
promotes O 0 0.00076258846
nocturnal O 0 0.22034498
sleep O 0 0.082723245
, O 0 0.0007224455
normalizes O 0 0.0041587567
sleep O 0 0.01790378
architecture O 0 0.0006948161
, O 0 0.00045883414
and O 0 0.00041443462
decreases O 0 0.00063643744
daytime B-Disease 0 0.68586975
sleepiness I-Disease 0 0.99825937
in O 0 0.0015978592
abstinent O 0 0.9952429
cocaine B-Chemical 1 0.99991846
users O 0 0.017415488
. O 0 0.0064533623

These O 0 0.0048897658
effects O 0 0.0038690325
may O 0 0.0023936736
be O 0 0.0020029063
relevant O 0 0.0015874881
in O 0 0.0016196158
the O 0 0.0017404369
treatment O 0 0.0026471408
of O 0 0.006737422
cocaine B-Chemical 1 0.99996376
dependence O 0 0.06747579
. O 0 0.010670296

Safety O 0 0.010241344
of O 0 0.0046850187
transesophageal O 0 0.0469549
echocardiography O 0 0.008262074
in O 0 0.0024545605
adults O 0 0.0039462163
: O 0 0.0031064232
study O 0 0.0025723407
in O 0 0.002575793
a O 0 0.003813999
multidisciplinary O 0 0.0061315247
hospital O 0 0.008426094
. O 0 0.009861591

BACKGROUND O 0 0.023428408
: O 0 0.0055453633
TEE O 0 0.13563327
is O 0 0.0018268434
a O 0 0.0015159523
semi O 0 0.002145392
- O 0 0.0046910974
invasive O 0 0.0011485295
tool O 0 0.00053772645
broadly O 0 0.0004210052
used O 0 0.000297428
and O 0 0.00035074478
its O 0 0.0005307697
utilization O 0 0.0004631518
associated O 0 0.00038307553
to O 0 0.00039482585
sedatives O 0 0.97365135
drugs O 0 0.032258406
might O 0 0.00035834304
to O 0 0.00050386816
affect O 0 0.0006485237
the O 0 0.001163039
procedure O 0 0.0020132037
safety O 0 0.0043657576
. O 0 0.005906951

OBJECTIVE O 0 0.019417124
: O 0 0.00338543
to O 0 0.0014959908
analyze O 0 0.00083327945
aspects O 0 0.00068814255
of O 0 0.00086516025
TEE O 0 0.19044535
safety O 0 0.00072321465
associated O 0 0.0003587291
to O 0 0.0002428012
the O 0 0.00023505425
use O 0 0.00025420997
of O 0 0.00058188813
Midazolan B-Chemical 0 0.9899922
( O 0 0.008428614
MZ B-Chemical 1 0.99921525
) O 0 0.0151733365
and O 0 0.011098783
Flumazenil B-Chemical 0 0.99999964
( O 0 0.011509907
FL B-Chemical 0 0.9860088
) O 0 0.001015226
and O 0 0.00027018585
the O 0 0.0002076988
influence O 0 0.00018668106
of O 0 0.00031513962
the O 0 0.0003477593
clinical O 0 0.00080991175
variables O 0 0.00060279167
on O 0 0.00060952245
the O 0 0.0012392469
event O 0 0.0042515295
rate O 0 0.004310441
. O 0 0.0071881777

METHOD O 0 0.008502479
: O 0 0.0045464523
prospective O 0 0.0036747674
study O 0 0.0020453169
with O 0 0.0014399334
137 O 0 0.0019223326
patients O 0 0.0010345253
that O 0 0.00068985077
underwent O 0 0.00091594964
TEE O 0 0.16518202
with O 0 0.0014256734
MZ B-Chemical 1 0.9672417
associated O 0 0.0020085531
to O 0 0.0020716232
moderate O 0 0.045984443
sedation O 0 0.3269572
. O 0 0.0074059227

We O 0 0.0034322417
analyzed O 0 0.0021003585
the O 0 0.0015810854
following O 0 0.001153113
events O 0 0.004977445
: O 0 0.0018258855
complications O 0 0.09188196
related O 0 0.000356759
with O 0 0.0004214861
the O 0 0.00047342136
topical O 0 0.89494085
anesthesia O 0 0.0909979
, O 0 0.00070803217
with O 0 0.00079740974
MZ B-Chemical 1 0.9829653
use O 0 0.0008518683
and O 0 0.0010030861
with O 0 0.0014006076
the O 0 0.0020920916
procedure O 0 0.0036761193
. O 0 0.0065270425

Uni O 0 0.9824724
- O 0 0.01383606
and O 0 0.0021098384
multivariate O 0 0.00274723
analyses O 0 0.00096066267
were O 0 0.00065207994
used O 0 0.0004237074
to O 0 0.00033858168
test O 0 0.0003353495
the O 0 0.00024725363
influence O 0 0.00018226978
of O 0 0.00026412754
the O 0 0.00023286017
clinical O 0 0.0008680563
variables O 0 0.00033749707
: O 0 0.00048945245
age O 0 0.00090041745
, O 0 0.0007560127
sex O 0 0.10565469
, O 0 0.010566499
stroke B-Disease 2 0.9999759
, O 0 0.029381095
myocardiopathy B-Disease 0 0.99999785
( O 0 0.076203406
MP B-Disease 0 0.9991353
) O 0 0.0023284603
, O 0 0.0003108872
duration O 0 0.0001520126
of O 0 0.00021510766
the O 0 0.0002103619
test O 0 0.0003248605
, O 0 0.0009638715
mitral B-Disease 2 0.9955519
regurgitation I-Disease 2 0.9998313
( O 0 0.0063022855
MR B-Disease 2 0.98815405
) O 0 0.001491596
and O 0 0.0012645785
the O 0 0.001984385
MZ B-Chemical 1 0.9810879
dose O 0 0.053795904
. O 0 0.008071702

RESULTS O 0 0.005972288
: O 0 0.0036727097
All O 0 0.0018388947
patients O 0 0.0019117111
( O 0 0.001747275
65 O 0 0.0013879417
+ O 0 0.002248687
/ O 0 0.005438991
- O 0 0.0044578034
16 O 0 0.0007883106
yrs O 0 0.00097582163
; O 0 0.0009878813
58 O 0 0.001008775
% O 0 0.0011094074
males O 0 0.0016737673
) O 0 0.0021225368
finished O 0 0.0027419548
the O 0 0.0027934837
examination O 0 0.0052771517
. O 0 0.008198665

The O 0 0.00274542
mean O 0 0.0015463961
doses O 0 0.0031856361
of O 0 0.0023175979
MZ B-Chemical 1 0.99330056
and O 0 0.0033984948
FL B-Chemical 0 0.9650434
were O 0 0.000594489
4 O 0 0.0003399733
. O 0 0.00028964263
3 O 0 0.00027546525
+ O 0 0.00079663843
/ O 0 0.005852468
- O 0 0.0075622173
1 O 0 0.00026706772
. O 0 0.00020537373
9 O 0 0.00020420822
mg O 0 0.000954689
and O 0 0.00023615452
0 O 0 0.00025848928
. O 0 0.00022442579
28 O 0 0.00030873631
+ O 0 0.0008622038
/ O 0 0.0044165263
- O 0 0.005628488
0 O 0 0.0006694225
. O 0 0.00069945975
2 O 0 0.0010497541
mg O 0 0.0072558434
, O 0 0.0030375232
respectively O 0 0.006408823
. O 0 0.0076510385

The O 0 0.0028193172
duration O 0 0.001748846
of O 0 0.0014852895
the O 0 0.0009522031
examination O 0 0.00078203616
and O 0 0.0005876822
the O 0 0.00037117852
mean O 0 0.00025014
ejection O 0 0.03803579
fraction O 0 0.0003116499
( O 0 0.0008547791
EF O 0 0.750289
) O 0 0.0006276548
were O 0 0.00022140982
16 O 0 0.00021314326
. O 0 0.00017385915
4 O 0 0.00018522149
+ O 0 0.0006302287
/ O 0 0.0047017517
- O 0 0.00466747
6 O 0 0.00019054026
. O 0 0.0001892446
1 O 0 0.00018859145
minutes O 0 0.000177717
and O 0 0.00027980786
60 O 0 0.0003766824
+ O 0 0.0009902762
/ O 0 0.003458909
- O 0 0.0046812715
9 O 0 0.0011968464
% O 0 0.0019765075
, O 0 0.0032499647
respectively O 0 0.006577721
. O 0 0.008064817

Mild O 0 0.9961593
hypoxia B-Disease 2 0.99896884
( O 0 0.08243666
SO2 O 0 0.9998771
< O 0 0.0013519279
90 O 0 0.0008686727
% O 0 0.00083832484
) O 0 0.0008242779
was O 0 0.000411938
the O 0 0.00031865353
most O 0 0.00039442573
common O 0 0.00040232146
event O 0 0.0019189334
( O 0 0.000511582
11 O 0 0.0002556513
patients O 0 0.00032422866
) O 0 0.00048239634
; O 0 0.00038824725
3 O 0 0.00016550024
patients O 0 0.00023991824
( O 0 0.0002859339
2 O 0 0.00017716223
% O 0 0.00022341676
) O 0 0.0002992912
presented O 0 0.00018208321
transient O 0 0.007218062
hypoxia B-Disease 2 0.9731502
due O 0 0.00015060918
to O 0 0.00015202128
upper O 0 0.00031882647
airway B-Disease 0 0.013419451
obstruction I-Disease 0 0.28703156
by O 0 0.0001889925
probe O 0 0.00015685128
introduction O 0 0.00016479965
and O 0 0.0002151686
8 O 0 0.00018230069
( O 0 0.0002592944
5 O 0 0.00017561861
. O 0 0.00020202444
8 O 0 0.00023677741
% O 0 0.00035288525
) O 0 0.0004972294
due O 0 0.00036346028
to O 0 0.00061433547
hypoxia B-Disease 2 0.9393639
caused O 0 0.0017019405
by O 0 0.0030023125
MZ B-Chemical 1 0.9921978
use O 0 0.006060951
. O 0 0.00756757

Transient O 0 0.90677696
hypotension B-Disease 2 0.99998546
( O 0 0.059275206
SAP O 0 0.9754625
< O 0 0.0016934581
90mmHg O 0 0.025519827
) O 0 0.0012932234
occurred O 0 0.00070968724
in O 0 0.00064921944
1 O 0 0.0006591062
patient O 0 0.0007337465
( O 0 0.0010607596
0 O 0 0.0010874372
. O 0 0.0012490941
7 O 0 0.0017832036
% O 0 0.003523882
) O 0 0.006665113
. O 0 0.009002871

The O 0 0.0029045497
multivariate O 0 0.0033933194
analysis O 0 0.0016384895
showed O 0 0.0011073465
that O 0 0.0009418053
severe O 0 0.4930097
MR B-Disease 2 0.99951696
, O 0 0.01485877
MP B-Disease 0 0.9983311
( O 0 0.0041196942
EF O 0 0.7547793
< O 0 0.00030819201
45 O 0 0.0002580586
% O 0 0.00030815526
) O 0 0.0003756734
and O 0 0.00025180232
high O 0 0.00032874563
doses O 0 0.0014871632
of O 0 0.0010867044
MZ B-Chemical 1 0.99949384
( O 0 0.011138491
> O 0 0.019332796
5mg O 0 0.90053093
) O 0 0.00051618763
were O 0 0.00022383555
associated O 0 0.000245656
with O 0 0.00032010316
events O 0 0.0020098435
( O 0 0.00070561003
p O 0 0.0006155986
< O 0 0.000781059
0 O 0 0.0013164035
. O 0 0.0019369953
001 O 0 0.043361276
) O 0 0.006264676
. O 0 0.007970575

The O 0 0.0041565043
EF O 0 0.42495796
was O 0 0.0021832432
40 O 0 0.0014921429
% O 0 0.0013453529
, O 0 0.0010538254
in O 0 0.0006039065
the O 0 0.00048463448
group O 0 0.0005803638
with O 0 0.00065477774
MP B-Disease 0 0.9875448
and O 0 0.00056032423
44 O 0 0.00049682806
% O 0 0.00029201136
in O 0 0.00019439028
the O 0 0.00018629893
group O 0 0.00026187155
with O 0 0.00030845363
severe O 0 0.20342879
MR B-Disease 2 0.99624985
and O 0 0.0003830319
it O 0 0.0002449394
can O 0 0.00015824416
be O 0 0.00019995624
a O 0 0.0002904451
factor O 0 0.0016651643
associated O 0 0.00042006376
with O 0 0.00045731984
clinical O 0 0.0014796215
events O 0 0.0016858829
in O 0 0.0007628051
the O 0 0.001112893
last O 0 0.0015132999
group O 0 0.0036276404
. O 0 0.0059377328

CONCLUSION O 0 0.028291177
: O 0 0.0071502253
TEE O 0 0.105112195
with O 0 0.0036365674
sedation O 0 0.074513026
presents O 0 0.002673057
a O 0 0.0027080737
low O 0 0.0030085049
rate O 0 0.003712812
of O 0 0.005904591
events O 0 0.03290141
. O 0 0.011729909

There O 0 0.0047797933
were O 0 0.00305693
no O 0 0.0020568625
severe O 0 0.012562021
events O 0 0.00530591
and O 0 0.0013401863
there O 0 0.0008388978
was O 0 0.0009599485
no O 0 0.00078658917
need O 0 0.0010003685
to O 0 0.0012798803
interrupt O 0 0.0020563547
the O 0 0.0028006234
examinations O 0 0.0058012996
. O 0 0.007834934

Effect O 0 0.004154501
of O 0 0.002873655
direct O 0 0.0022192716
intracoronary O 0 0.59364134
administration O 0 0.04682235
of O 0 0.005375966
methylergonovine B-Chemical 0 0.9999323
in O 0 0.0009943543
patients O 0 0.0011771232
with O 0 0.0010222198
and O 0 0.0015766436
without O 0 0.0028421162
variant B-Disease 2 0.76742715
angina I-Disease 2 0.9999962
. O 0 0.011194545

The O 0 0.0030636408
effects O 0 0.002561948
of O 0 0.002269054
intracoronary O 0 0.67307395
administration O 0 0.04918024
of O 0 0.0053590373
methylergonovine B-Chemical 0 0.9999448
were O 0 0.0004540246
studied O 0 0.0003163226
in O 0 0.00023875263
21 O 0 0.00025592322
patients O 0 0.00028089038
with O 0 0.00039332992
variant B-Disease 2 0.49836043
angina I-Disease 2 0.99999964
and O 0 0.0005298478
22 O 0 0.00026585057
patients O 0 0.00020415428
with O 0 0.00019334993
atypical O 0 0.020551357
chest B-Disease 0 0.032247093
pain I-Disease 0 0.74918264
and O 0 0.00030132453
in O 0 0.00031158808
others O 0 0.0015675455
without O 0 0.0030170013
angina B-Disease 0 0.99999905
pectoris I-Disease 0 0.9999976
( O 0 0.0034752735
control O 0 0.0016919158
group O 0 0.0030827732
) O 0 0.0056537185
. O 0 0.0068223164

Methylergonovine B-Chemical 0 0.8553275
was O 0 0.0029320451
administered O 0 0.0016828297
continuously O 0 0.0011806475
at O 0 0.00083322113
a O 0 0.0008238092
rate O 0 0.00069110235
of O 0 0.00074091076
10 O 0 0.00066580286
micrograms O 0 0.0033053206
/ O 0 0.0017451847
min O 0 0.0010690921
up O 0 0.0010735395
to O 0 0.0014784229
50 O 0 0.0029356102
micrograms O 0 0.009411322
. O 0 0.007450841

In O 0 0.0038127874
all O 0 0.0023257898
patients O 0 0.002305169
with O 0 0.0025034607
variant B-Disease 2 0.84151053
angina I-Disease 2 0.99999976
, O 0 0.096368425
coronary B-Disease 2 0.9991037
spasm I-Disease 2 0.9999987
was O 0 0.0006870027
provoked O 0 0.0016024963
at O 0 0.00020886536
a O 0 0.00020847519
mean O 0 0.0001244498
dose O 0 0.00037260182
of O 0 0.00026752643
28 O 0 0.00033154938
+ O 0 0.0015628523
/ O 0 0.0094229635
- O 0 0.0072341743
13 O 0 0.00040291483
micrograms O 0 0.0013976442
( O 0 0.00056493696
mean O 0 0.0004566107
+ O 0 0.0020363242
/ O 0 0.008568484
- O 0 0.022826353
SD O 0 0.09436798
) O 0 0.006885916
. O 0 0.008131359

In O 0 0.0047854376
the O 0 0.0031947829
control O 0 0.0026524412
group O 0 0.002767088
neither O 0 0.002875572
ischemic O 0 0.99995637
ST O 0 0.98042953
change O 0 0.0022099
nor O 0 0.0021857498
localized O 0 0.003412135
spasm B-Disease 2 0.99968266
occurred O 0 0.0073139
. O 0 0.009279703

The O 0 0.0034899006
basal O 0 0.0038181923
tone O 0 0.023841063
of O 0 0.0016796498
the O 0 0.0011636224
right O 0 0.0028181819
coronary O 0 0.2772761
artery O 0 0.10191947
was O 0 0.0005623606
significantly O 0 0.00045700106
lower O 0 0.00042751853
than O 0 0.0003547502
that O 0 0.0004759956
of O 0 0.00090139353
the O 0 0.0012450592
left O 0 0.0041677677
coronary O 0 0.363918
artery O 0 0.23476236
. O 0 0.0074196476

The O 0 0.003091155
percentage O 0 0.0019386571
of O 0 0.002612522
vasoconstriction O 0 0.9974718
of O 0 0.0016370993
the O 0 0.0009286834
right O 0 0.0031731625
coronary O 0 0.30619338
artery O 0 0.0957599
was O 0 0.00044512967
significantly O 0 0.0003776835
higher O 0 0.0003635727
than O 0 0.000315442
that O 0 0.00043538437
of O 0 0.0008432576
the O 0 0.0011807914
left O 0 0.0040855403
coronary O 0 0.36443752
artery O 0 0.23479949
. O 0 0.0072499514

These O 0 0.0035050954
results O 0 0.0021150885
suggest O 0 0.0013265767
that O 0 0.001686448
spasm B-Disease 2 0.99995077
provocation O 0 0.9338947
tests O 0 0.0045076394
, O 0 0.00092420273
which O 0 0.0005252843
use O 0 0.00034368082
an O 0 0.00041542863
intracoronary O 0 0.21188088
injection O 0 0.00041824888
of O 0 0.00024653776
a O 0 0.000257269
relatively O 0 0.0002956604
low O 0 0.00037082785
dose O 0 0.0045110686
of O 0 0.004654056
methylergonovine B-Chemical 0 0.99997556
, O 0 0.00058525626
have O 0 0.0001487437
a O 0 0.00022776732
high O 0 0.00030641392
sensitivity O 0 0.0017244074
in O 0 0.0004848253
variant B-Disease 2 0.73877525
angina I-Disease 2 0.99999976
and O 0 0.00080244744
the O 0 0.00035399428
vasoreactivity O 0 0.9917116
of O 0 0.00028917904
the O 0 0.0002281927
right O 0 0.0013022071
coronary O 0 0.17420706
artery O 0 0.043054163
may O 0 0.00020368879
be O 0 0.0002272335
greater O 0 0.00023547368
than O 0 0.00024338064
that O 0 0.00035024353
of O 0 0.0007028248
the O 0 0.0009697205
other O 0 0.0019940655
coronary O 0 0.42406008
arteries O 0 0.6019473
. O 0 0.006976568

Oral O 0 0.5759226
manifestations O 0 0.21585916
of O 0 0.0058384356
" O 0 0.015584143
meth B-Disease 2 0.9999645
mouth I-Disease 2 0.95675874
" O 0 0.0052748597
: O 0 0.004623341
a O 0 0.004531104
case O 0 0.005636411
report O 0 0.010980644
. O 0 0.011612765

AIM O 0 0.35518062
: O 0 0.004172782
The O 0 0.0016752508
aim O 0 0.0013401979
of O 0 0.0010301777
the O 0 0.0007242009
documentation O 0 0.00069944386
of O 0 0.0005472119
this O 0 0.00042608415
clinical O 0 0.0012003998
case O 0 0.00035029495
is O 0 0.00025447382
to O 0 0.00018713213
make O 0 0.00019741643
clinicians O 0 0.00030070575
aware O 0 0.00020418367
of O 0 0.0003736766
" O 0 0.0044091227
meth B-Disease 2 0.99999225
mouth I-Disease 2 0.9397592
" O 0 0.00066899584
and O 0 0.00033670507
the O 0 0.00032507055
medical O 0 0.0011489596
risks O 0 0.0022790418
associated O 0 0.00071381
with O 0 0.0009707031
this O 0 0.0014322152
serious O 0 0.041829553
condition O 0 0.0067941267
. O 0 0.0071727415

BACKGROUND O 0 0.08276244
: O 0 0.02687412
Methamphetamine B-Chemical 1 0.99998486
is O 0 0.0023273248
a O 0 0.0016134628
very O 0 0.0022196895
addictive O 0 0.9905495
, O 0 0.0011366213
powerful O 0 0.002405276
stimulant O 0 0.7622394
that O 0 0.00023456439
increases O 0 0.00031331342
wakefulness O 0 0.25731188
and O 0 0.00027698587
physical O 0 0.0008526991
activity O 0 0.0002064457
and O 0 0.00021039683
can O 0 0.00012759544
produce O 0 0.00011817834
other O 0 0.0001837653
effects O 0 0.0002322141
such O 0 0.00020790055
as O 0 0.00045198097
cardiac B-Disease 0 0.99241453
dysrhythmias I-Disease 0 0.9999995
, O 0 0.13213731
hypertension B-Disease 2 0.99999917
, O 0 0.07405474
hallucinations B-Disease 2 0.999998
, O 0 0.002932929
and O 0 0.003313512
violent B-Disease 0 0.9973105
behavior I-Disease 0 0.19677861
. O 0 0.007583501

Dental O 0 0.0123174945
patients O 0 0.006344552
abusing O 0 0.9911011
methamphetamine B-Chemical 1 0.9999951
can O 0 0.0009699192
present O 0 0.0005226478
with O 0 0.0005748317
poor O 0 0.0023615067
oral O 0 0.240401
hygiene O 0 0.07628232
, O 0 0.008067286
xerostomia B-Disease 0 0.9999602
, O 0 0.0045847385
rampant O 0 0.559864
caries B-Disease 0 0.99994695
( O 0 0.010198209
" O 0 0.010975373
meth B-Disease 2 0.99999106
mouth I-Disease 2 0.9564982
" O 0 0.0017516203
) O 0 0.001494554
, O 0 0.0013082125
and O 0 0.0016439587
excessive O 0 0.011001268
tooth B-Disease 0 0.2988688
wear I-Disease 0 0.2619785
. O 0 0.008219468

Oral O 0 0.3986125
rehabilitation O 0 0.008056663
of O 0 0.0048081004
patients O 0 0.005185985
using O 0 0.0049761697
methamphetamine B-Chemical 1 0.99997747
can O 0 0.0046478934
be O 0 0.0059764762
challenging O 0 0.008974964
. O 0 0.01187242

CASE O 0 0.49783707
DESCRIPTION O 0 0.013769264
: O 0 0.004328463
A O 0 0.017821142
30 O 0 0.0015154326
- O 0 0.0028653531
year O 0 0.001074276
- O 0 0.0026341383
old O 0 0.0008527068
Caucasian O 0 0.104427814
woman O 0 0.0014172703
presented O 0 0.00037246826
with O 0 0.00043936144
dental O 0 0.0028587922
pain B-Disease 0 0.93855727
, O 0 0.0011359851
bad B-Disease 0 0.4702416
breath I-Disease 0 0.7962543
, O 0 0.0009146054
and O 0 0.0008992249
self O 0 0.0033941225
- O 0 0.0061586834
reported O 0 0.0024798338
poor O 0 0.0071204207
esthetics O 0 0.26080522
. O 0 0.008180346

A O 0 0.016376419
comprehensive O 0 0.0027022872
examination O 0 0.0017611602
including O 0 0.0011932737
her O 0 0.0011960975
medical O 0 0.0018977075
history O 0 0.0029362636
, O 0 0.00084378564
panoramic O 0 0.011521956
radiograph O 0 0.00315756
, O 0 0.00039835754
and O 0 0.00027583737
intraoral O 0 0.00041066998
examination O 0 0.00023900112
revealed O 0 0.00024428172
19 O 0 0.00060672616
carious B-Disease 0 0.96108353
lesions I-Disease 0 0.9553158
, O 0 0.00062345754
which O 0 0.00041185043
is O 0 0.00035724518
not O 0 0.00036979842
very O 0 0.00066288025
common O 0 0.00083363807
for O 0 0.00097322336
a O 0 0.0019128423
healthy O 0 0.007516911
adult O 0 0.0052684005
. O 0 0.006715383

She O 0 0.0048279506
reported O 0 0.0026356492
her O 0 0.0018806111
use O 0 0.0013449673
of O 0 0.002505575
methamphetamine B-Chemical 1 0.9999957
for O 0 0.0006788161
five O 0 0.0003279105
years O 0 0.00039400303
and O 0 0.00033751174
had O 0 0.00027464915
not O 0 0.0002523036
experienced O 0 0.00034357407
any O 0 0.00029197795
major O 0 0.00057175284
carious B-Disease 0 0.9515765
episodes I-Disease 0 0.13575135
before O 0 0.00039564536
she O 0 0.00055088376
started O 0 0.00083211233
using O 0 0.0012098696
the O 0 0.0022486567
drug O 0 0.20573954
. O 0 0.0070832097

SUMMARY O 0 0.006512582
: O 0 0.0037155063
The O 0 0.001681871
patient O 0 0.0014432677
' O 0 0.001344387
s O 0 0.0010583573
medical O 0 0.0013202317
and O 0 0.0005657034
dental O 0 0.0006625954
histories O 0 0.00047452011
along O 0 0.00021687444
with O 0 0.00024647714
radiographic O 0 0.001451401
and O 0 0.0002573892
clinical O 0 0.0005795242
findings O 0 0.00026295587
lead O 0 0.0014404407
to O 0 0.0001607313
a O 0 0.00024292948
diagnosis O 0 0.0009931655
of O 0 0.0004953853
" O 0 0.009578578
meth B-Disease 2 0.9999958
mouth I-Disease 2 0.9663479
. O 0 0.00028283813
" O 0 0.0002569131
Although O 0 0.00011443404
three O 0 8.828431e-05
different O 0 0.00010965832
dental O 0 0.0002863786
treatment O 0 0.00019289712
modalities O 0 0.00030313575
( O 0 0.0002836028
either O 0 0.00014656734
conventional O 0 0.00018068042
or O 0 0.00019371307
implant O 0 0.0053498237
- O 0 0.011665418
supported O 0 0.00034353996
) O 0 0.0004884615
have O 0 0.00015446747
been O 0 0.00016725948
offered O 0 0.00018224977
to O 0 0.0001425445
the O 0 0.00016802129
patient O 0 0.000203852
since O 0 0.00016923458
August O 0 0.00033877298
2007 O 0 0.00043428797
, O 0 0.00033037819
the O 0 0.00028908587
patient O 0 0.00041058936
has O 0 0.00043312227
yet O 0 0.00067699095
to O 0 0.00067690643
initiate O 0 0.000993784
any O 0 0.0018691639
treatment O 0 0.0038534575
. O 0 0.0065422417

CLINICAL O 0 0.0069019524
SIGNIFICANCE O 0 0.005195822
: O 0 0.0028914497
This O 0 0.0019183962
clinical O 0 0.0018531334
case O 0 0.00089726667
showing O 0 0.0008341852
oral O 0 0.17421077
manifestations O 0 0.51728874
of O 0 0.009809529
meth B-Disease 2 0.999997
mouth I-Disease 2 0.94012904
was O 0 0.0003323209
presented O 0 0.00020324433
to O 0 0.0001872919
help O 0 0.00026402913
dental O 0 0.0004902129
practitioners O 0 0.0003394422
recognize O 0 0.00023388617
and O 0 0.0003886592
manage O 0 0.00053348707
patients O 0 0.0007380093
who O 0 0.0009676846
may O 0 0.0009328706
be O 0 0.0020761942
abusing O 0 0.9948244
methamphetamines B-Chemical 0 0.99999213
. O 0 0.009015787

Dental O 0 0.011452525
practitioners O 0 0.00347058
also O 0 0.0017575802
may O 0 0.0011578877
be O 0 0.0009182128
skeptical O 0 0.0010229279
about O 0 0.0004727276
the O 0 0.0003978052
reliability O 0 0.00041307008
of O 0 0.00039166675
appointment O 0 0.0005940033
keeping O 0 0.00035612614
by O 0 0.00027824577
these O 0 0.00030533847
patients O 0 0.00046051262
, O 0 0.00040445337
as O 0 0.00030449394
they O 0 0.00031891247
frequently O 0 0.0005063726
miss O 0 0.0009050757
their O 0 0.0007360714
appointments O 0 0.001648235
without O 0 0.001211806
reasonable O 0 0.0020171155
justification O 0 0.0042092693
. O 0 0.0068823337

Antituberculosis B-Chemical 0 0.99657816
therapy O 0 0.04294573
- O 0 0.04096431
induced O 0 0.0030802889
acute B-Disease 2 0.9964503
liver I-Disease 2 0.9949356
failure I-Disease 2 0.98714453
: O 0 0.0041572386
magnitude O 0 0.0005315606
, O 0 0.0007990051
profile O 0 0.000665199
, O 0 0.001111277
prognosis O 0 0.46478432
, O 0 0.0011488019
and O 0 0.0011186219
predictors O 0 0.0013709565
of O 0 0.002681103
outcome O 0 0.007224058
. O 0 0.0072428035

Antituberculosis B-Chemical 0 0.99437535
therapy O 0 0.02079605
( O 0 0.009771816
ATT O 0 0.9771663
) O 0 0.012893304
- O 0 0.019299835
associated O 0 0.001375361
acute B-Disease 2 0.98799986
liver I-Disease 2 0.9903087
failure I-Disease 2 0.9926708
( O 0 0.077775165
ATT O 0 0.9986829
- O 0 0.66911227
ALF B-Disease 2 0.99999213
) O 0 0.0038846869
is O 0 0.00044588992
the O 0 0.0004750469
commonest O 0 0.23815262
drug O 0 0.7752887
- O 0 0.056294248
induced O 0 0.0035465253
ALF B-Disease 2 0.9999708
in O 0 0.0037993505
South O 0 0.15933703
Asia O 0 0.28554243
. O 0 0.0081560295

Prospective O 0 0.019870194
studies O 0 0.008359177
on O 0 0.0078111277
ATT O 0 0.9443637
- O 0 0.23675215
ALF B-Disease 2 0.99960905
are O 0 0.011396921
lacking O 0 0.010956719
. O 0 0.018742299

The O 0 0.0031236308
current O 0 0.0026424981
study O 0 0.001668315
prospectively O 0 0.0010753025
evaluated O 0 0.00063468737
the O 0 0.00056005194
magnitude O 0 0.0004844031
, O 0 0.00069871964
clinical O 0 0.0010465413
course O 0 0.0004262361
, O 0 0.00057694816
outcome O 0 0.00079004664
, O 0 0.00057095045
and O 0 0.0005658239
prognostic O 0 0.0014689784
factors O 0 0.0024017547
in O 0 0.002392787
ATT O 0 0.9889213
- O 0 0.34885845
ALF B-Disease 2 0.99987185
. O 0 0.011427094

From O 0 0.0044484427
January O 0 0.0032465176
1986 O 0 0.0037454967
to O 0 0.0014601118
January O 0 0.0013839238
2009 O 0 0.0019327712
, O 0 0.0012629072
1223 O 0 0.015006725
consecutive O 0 0.0007630072
ALF B-Disease 2 0.99987304
patients O 0 0.00089403836
were O 0 0.00033093075
evaluated O 0 0.00027154965
: O 0 0.0010653549
ATT O 0 0.8239391
alone O 0 0.00035800942
was O 0 0.00028837487
the O 0 0.00024972492
cause O 0 0.0003553039
in O 0 0.0003175542
70 O 0 0.000397867
( O 0 0.00055251346
5 O 0 0.00046355682
. O 0 0.00064130634
7 O 0 0.00092408486
% O 0 0.0018476247
) O 0 0.0035401243
patients O 0 0.0054685925
. O 0 0.0075098197

Another O 0 0.005918129
15 O 0 0.003078456
( O 0 0.0030623612
1 O 0 0.0019243035
. O 0 0.0014696423
2 O 0 0.0013064947
% O 0 0.0014747384
) O 0 0.0017834055
had O 0 0.0014293694
ATT O 0 0.63670707
and O 0 0.0023093545
simultaneous O 0 0.046404954
hepatitis B-Disease 2 0.9999999
virus I-Disease 0 0.99886787
infection I-Disease 2 0.9998466
. O 0 0.05733952

In O 0 0.004521
44 O 0 0.003985121
( O 0 0.002997139
62 O 0 0.0022889695
. O 0 0.0012769641
8 O 0 0.0010079892
% O 0 0.0010806684
) O 0 0.001255494
patients O 0 0.0011060423
, O 0 0.0013283631
ATT O 0 0.76679957
was O 0 0.00072324293
prescribed O 0 0.00097174145
empirically O 0 0.0007329743
without O 0 0.00079062243
definitive O 0 0.0013851014
evidence O 0 0.0016612347
of O 0 0.00412825
tuberculosis B-Disease 2 0.9870208
. O 0 0.011273018

ATT O 0 0.98279667
- O 0 0.42427126
ALF B-Disease 2 0.99985445
patients O 0 0.0038296736
were O 0 0.0013183169
younger O 0 0.0075616227
( O 0 0.0010094133
32 O 0 0.00068832526
. O 0 0.0004342743
87 O 0 0.0007949898
[ O 0 0.0018413732
+ O 0 0.0023293786
/ O 0 0.011213267
- O 0 0.0062586013
15 O 0 0.0002584289
. O 0 0.00023630269
8 O 0 0.00024531805
] O 0 0.00042293017
years O 0 0.0003472993
) O 0 0.0005304112
, O 0 0.00042823085
and O 0 0.00040624285
49 O 0 0.00059513445
( O 0 0.0005650121
70 O 0 0.0005345532
% O 0 0.0007678231
) O 0 0.0011699137
of O 0 0.0013807549
them O 0 0.0023413384
were O 0 0.0029457463
women O 0 0.010203976
. O 0 0.007811165

Most O 0 0.0055012014
had O 0 0.0029127847
hyperacute O 0 0.5911771
presentation O 0 0.0031952548
; O 0 0.001655534
the O 0 0.00071463356
median O 0 0.0007457382
icterus B-Disease 0 0.9999862
encephalopathy B-Disease 2 0.9999969
interval O 0 0.0007316225
was O 0 0.00038507083
4 O 0 0.00029924323
. O 0 0.00032951095
5 O 0 0.00038990128
( O 0 0.0007302622
0 O 0 0.00092026405
- O 0 0.0021401828
30 O 0 0.0014603919
) O 0 0.0029822532
days O 0 0.0034157338
. O 0 0.007094252

The O 0 0.0030755363
median O 0 0.0018522877
duration O 0 0.0015975381
of O 0 0.0021182348
ATT O 0 0.8879983
before O 0 0.0013837097
ALF B-Disease 2 0.99989307
was O 0 0.0012194029
30 O 0 0.00088539853
( O 0 0.0012898073
7 O 0 0.0012213477
- O 0 0.0029767586
350 O 0 0.0028538974
) O 0 0.0040652445
days O 0 0.004319761
. O 0 0.0084903315

At O 0 0.0029296651
presentation O 0 0.003465157
, O 0 0.003402289
advanced O 0 0.14858095
encephalopathy B-Disease 2 0.9999931
and O 0 0.030710414
cerebral B-Disease 0 0.9993499
edema I-Disease 0 0.99999213
were O 0 0.0004644166
present O 0 0.00021335026
in O 0 0.0002447781
51 O 0 0.0004147468
( O 0 0.00037278375
76 O 0 0.00042143004
% O 0 0.000334869
) O 0 0.0004347697
and O 0 0.00033404285
29 O 0 0.00053098425
( O 0 0.0004901944
41 O 0 0.00058487954
. O 0 0.00042465763
4 O 0 0.0005116806
% O 0 0.0009154663
) O 0 0.001620896
patients O 0 0.0022496437
, O 0 0.0033220742
respectively O 0 0.007229282
. O 0 0.008089173

Gastrointestinal B-Disease 0 0.75308996
bleed I-Disease 0 0.9725342
, O 0 0.04196147
seizures B-Disease 0 0.9999968
, O 0 0.022732431
infection B-Disease 2 0.98586476
, O 0 0.004248773
and O 0 0.0015988544
acute B-Disease 0 0.95195645
renal I-Disease 0 0.98873657
failure I-Disease 0 0.6194692
were O 0 0.0003282627
documented O 0 0.00031210718
in O 0 0.00017831687
seven O 0 0.00016553212
( O 0 0.00027135503
10 O 0 0.00017505517
% O 0 0.00024984207
) O 0 0.00037739193
, O 0 0.00025013142
five O 0 0.00013901088
( O 0 0.00025871707
7 O 0 0.00015916362
. O 0 0.00016697233
1 O 0 0.00018531972
% O 0 0.00025851218
) O 0 0.00042142865
, O 0 0.0003308027
26 O 0 0.00031497353
( O 0 0.0003279721
37 O 0 0.00034764793
. O 0 0.00021215886
1 O 0 0.00022995268
% O 0 0.0003169118
) O 0 0.00048514653
, O 0 0.00038619465
and O 0 0.00035202675
seven O 0 0.00034564096
( O 0 0.00057567324
10 O 0 0.0005376037
% O 0 0.00089823327
) O 0 0.0015722526
patients O 0 0.0021748492
, O 0 0.0031815988
respectively O 0 0.007050473
. O 0 0.007831467

Compared O 0 0.0041717533
with O 0 0.016959213
hepatitis B-Disease 2 1.0
E I-Disease 0 0.99999905
virus O 0 0.99317145
( O 0 0.14222477
HEV O 0 0.9992878
) O 0 0.00471616
and O 0 0.00067233964
non O 0 0.0021847342
- O 0 0.038757212
A O 0 0.22168736
non O 0 0.010840126
- O 0 0.46195582
E O 0 0.9999647
- O 0 0.2934464
induced O 0 0.0066683847
ALF B-Disease 2 0.99999833
, O 0 0.06270595
ATT O 0 0.9983962
- O 0 0.54001856
ALF B-Disease 2 0.9999826
patients O 0 0.0007754657
had O 0 0.00018724582
nearly O 0 0.00017824852
similar O 0 0.00014903815
presentations O 0 0.00030960262
except O 0 0.00018099649
for O 0 0.00024283776
older O 0 0.0009098541
age O 0 0.0006023633
and O 0 0.0005491637
less O 0 0.00072357105
elevation O 0 0.038336605
of O 0 0.0024795835
liver O 0 0.8242353
enzymes O 0 0.11942005
. O 0 0.0075609577

The O 0 0.0034858866
mortality O 0 0.055556696
rate O 0 0.0020272513
among O 0 0.0016877314
patients O 0 0.0014790059
with O 0 0.0017343153
ATT O 0 0.99570054
- O 0 0.52842915
ALF B-Disease 2 0.99998343
was O 0 0.000674997
high O 0 0.0006663008
( O 0 0.00056394626
67 O 0 0.00049418403
. O 0 0.00022455507
1 O 0 0.00021538722
% O 0 0.0002550081
, O 0 0.0002694784
n O 0 0.0002232852
= O 0 0.00051255047
47 O 0 0.0005104492
) O 0 0.00048317548
, O 0 0.0003290545
and O 0 0.0002754172
only O 0 0.00028981137
23 O 0 0.0003922917
( O 0 0.00037586366
32 O 0 0.00035136254
. O 0 0.00027789953
9 O 0 0.0003294029
% O 0 0.0004859093
) O 0 0.0007294185
patients O 0 0.0007511954
recovered O 0 0.0007608291
with O 0 0.0014465061
medical O 0 0.0045588417
treatment O 0 0.004286912
. O 0 0.0067977505

In O 0 0.0034230358
multivariate O 0 0.0041403533
analysis O 0 0.0017975346
, O 0 0.0013934075
three O 0 0.00055271725
factors O 0 0.0008098852
independently O 0 0.0003916072
predicted O 0 0.0004617174
mortality O 0 0.5130571
: O 0 0.0059668664
serum O 0 0.9144196
bilirubin B-Chemical 1 0.99999774
( O 0 0.007904
> O 0 0.0019796235
or O 0 0.00026088493
= O 0 0.00055649556
10 O 0 0.00017831396
. O 0 0.00015346725
8 O 0 0.00016188904
mg O 0 0.0044716396
/ O 0 0.0028062088
dL O 0 0.057742234
) O 0 0.001018109
, O 0 0.00073231023
prothrombin O 0 0.93958306
time O 0 0.00015532205
( O 0 0.00046067836
PT O 0 0.057233788
) O 0 0.00044385603
prolongation O 0 0.0005802718
( O 0 0.00038078448
> O 0 0.00050097913
or O 0 0.00022141321
= O 0 0.00043573065
26 O 0 0.00025307626
seconds O 0 0.00021147645
) O 0 0.00042711734
, O 0 0.00042860702
and O 0 0.00055476563
grade O 0 0.124975145
III O 0 0.17773016
/ O 0 0.05492996
IV O 0 0.8477268
encephalopathy B-Disease 2 0.99996424
at O 0 0.0026626075
presentation O 0 0.0059753777
. O 0 0.0069460412

CONCLUSION O 0 0.051884953
: O 0 0.008885428
ATT O 0 0.97230726
- O 0 0.34364069
ALF B-Disease 2 0.9999007
constituted O 0 0.0030575306
5 O 0 0.0007828295
. O 0 0.0005996187
7 O 0 0.0004962708
% O 0 0.00063046004
of O 0 0.00090452295
ALF B-Disease 2 0.99986875
at O 0 0.0005179642
our O 0 0.00048535684
center O 0 0.00058860955
and O 0 0.0006943382
had O 0 0.00081548607
a O 0 0.0013049887
high O 0 0.0023114914
mortality O 0 0.2351334
rate O 0 0.0058187563
. O 0 0.00838215

Because O 0 0.0035168303
the O 0 0.0028178936
mortality O 0 0.084688045
rate O 0 0.0019389173
is O 0 0.0013471022
so O 0 0.00097564695
high O 0 0.001061758
, O 0 0.0008613461
determining O 0 0.0005352094
which O 0 0.00074920326
factors O 0 0.0012269211
are O 0 0.0008523526
predictors O 0 0.0010250347
is O 0 0.0016144456
less O 0 0.0023058613
important O 0 0.003542675
. O 0 0.007220694

A O 0 0.0319702
high O 0 0.0037427547
proportion O 0 0.0020108207
of O 0 0.0018615403
patients O 0 0.0017901668
had O 0 0.0011573023
consumed O 0 0.010671575
ATT O 0 0.8285067
empirically O 0 0.0013539197
, O 0 0.0012164789
which O 0 0.001182473
could O 0 0.0011453448
have O 0 0.0016550581
been O 0 0.0028932279
prevented O 0 0.00571624
. O 0 0.008892377

Design O 0 0.032686338
and O 0 0.0028817588
analysis O 0 0.0018298728
of O 0 0.0015389887
the O 0 0.0013345166
HYPREN O 0 0.5972492
- O 0 0.01381794
trial O 0 0.00083414547
: O 0 0.0007362008
safety O 0 0.0006923446
of O 0 0.0018821296
enalapril B-Chemical 1 0.9999994
and O 0 0.023063466
prazosin B-Chemical 1 0.9999995
in O 0 0.0003459586
the O 0 0.00022879968
initial O 0 0.00022191792
treatment O 0 0.00035028596
phase O 0 0.00050802506
of O 0 0.0006612136
patients O 0 0.0015760155
with O 0 0.0030901239
congestive B-Disease 0 0.99988973
heart I-Disease 0 0.80038095
failure I-Disease 0 0.7393663
. O 0 0.007829107

Since O 0 0.0029030072
the O 0 0.0020966
introduction O 0 0.001745566
of O 0 0.005060226
angiotensin B-Chemical 1 0.99998844
converting I-Chemical 0 0.51158094
enzyme I-Chemical 0 0.6487157
( I-Chemical 0 0.043419637
ACE I-Chemical 0 0.9996076
) I-Chemical 0 0.0012237409
inhibitors I-Chemical 0 0.0007011002
into O 0 0.000121564946
the O 0 0.00017230255
adjunctive O 0 0.0014236761
treatment O 0 0.00021603031
of O 0 0.00025660367
patients O 0 0.00055450056
with O 0 0.00093606336
congestive B-Disease 0 0.9999217
heart I-Disease 0 0.7859134
failure I-Disease 0 0.55187434
, O 0 0.0006935291
cases O 0 0.0005658353
of O 0 0.0007973082
severe O 0 0.8151974
hypotension B-Disease 2 0.99999714
, O 0 0.00086688256
especially O 0 0.00031705387
on O 0 0.00012657364
the O 0 0.00017203465
first O 0 0.00016797196
day O 0 0.00020874593
of O 0 0.00036495185
treatment O 0 0.00060726365
, O 0 0.0008338493
have O 0 0.0007830279
occasionally O 0 0.0021125688
been O 0 0.0021222227
reported O 0 0.0040372685
. O 0 0.006430914

To O 0 0.0026979884
assess O 0 0.001365353
the O 0 0.0013290661
safety O 0 0.0013688762
of O 0 0.0011390125
the O 0 0.0019510763
ACE B-Chemical 0 0.99996924
inhibitor I-Chemical 0 0.9444175
enalapril B-Chemical 1 0.9999994
a O 0 0.0015768756
multicenter O 0 0.07586915
, O 0 0.00052514666
randomized O 0 0.0004224849
, O 0 0.0038918823
prazosin B-Chemical 1 0.99999976
- O 0 0.03728118
controlled O 0 0.00019788531
trial O 0 0.00024070781
was O 0 0.00014741474
designed O 0 0.00012737054
that O 0 0.00011135516
compared O 0 0.00011361098
the O 0 0.00015912145
incidence O 0 0.0007422946
and O 0 0.00030670324
severity O 0 0.0030265094
of O 0 0.00069219456
symptomatic O 0 0.54400396
hypotension B-Disease 2 0.99995816
on O 0 0.00030587657
the O 0 0.0004684337
first O 0 0.0005800193
day O 0 0.000931222
of O 0 0.001993277
treatment O 0 0.004027955
. O 0 0.006371592

Trial O 0 0.009752361
medication O 0 0.014649454
was O 0 0.0023592939
2 O 0 0.0016857914
. O 0 0.0013368297
5 O 0 0.0012958111
mg O 0 0.14497048
enalapril B-Chemical 1 0.9999863
or O 0 0.001678169
0 O 0 0.0019943377
. O 0 0.0023737461
5 O 0 0.0040816506
prazosin B-Chemical 1 0.99996436
. O 0 0.010800679

Subjects O 0 0.0062973336
were O 0 0.003967613
1210 O 0 0.07923603
inpatients O 0 0.004520597
with O 0 0.0016487921
New O 0 0.0022684648
York O 0 0.0042144493
Heart O 0 0.005006886
Association O 0 0.0011450016
( O 0 0.001366943
NYHA O 0 0.09229411
) O 0 0.0013821246
functional O 0 0.001348851
class O 0 0.0025796266
II O 0 0.014088403
and O 0 0.004340834
III O 0 0.0608184
. O 0 0.008849162

Patients O 0 0.005899721
who O 0 0.004058495
received O 0 0.0025888383
enalapril B-Chemical 1 0.9999919
experienced O 0 0.0024546562
clinically O 0 0.0145626515
and O 0 0.00060870417
statistically O 0 0.00035862482
significantly O 0 0.00034135478
less O 0 0.00035622562
symptomatic O 0 0.3044264
hypotension B-Disease 2 0.9999912
( O 0 0.0008578459
5 O 0 0.00018393938
. O 0 0.0001754375
2 O 0 0.00018461971
% O 0 0.00024697772
) O 0 0.00032790864
than O 0 0.00016236612
the O 0 0.00021555567
patients O 0 0.00040677487
who O 0 0.00057739276
received O 0 0.0005746032
prazosin B-Chemical 1 0.99999845
( O 0 0.0014574579
12 O 0 0.0006345846
. O 0 0.0008810422
9 O 0 0.0014195091
% O 0 0.0027426432
) O 0 0.0054212254
. O 0 0.00753623

All O 0 0.033859115
patients O 0 0.03997979
recovered O 0 0.03996835
. O 0 0.05350473

It O 0 0.0046106908
was O 0 0.0025311739
concluded O 0 0.0016414742
that O 0 0.0010427693
treatment O 0 0.0015222193
with O 0 0.005687694
enalapril B-Chemical 1 0.9999987
was O 0 0.00063606177
well O 0 0.0003442614
tolerated O 0 0.0025652887
and O 0 0.00031967167
it O 0 0.00030612515
is O 0 0.00028325667
, O 0 0.00040110786
therefore O 0 0.0003139754
, O 0 0.0004228764
unreasonable O 0 0.0009575247
to O 0 0.00018195789
restrict O 0 0.00018657073
the O 0 0.00025149545
initiation O 0 0.0003839292
of O 0 0.00058354647
treatment O 0 0.0011647013
with O 0 0.004896541
enalapril B-Chemical 1 0.99999285
to O 0 0.0023508084
inpatients O 0 0.066350706
. O 0 0.005995122

Central B-Disease 0 0.0068204654
nervous I-Disease 0 0.012121904
system I-Disease 0 0.002712874
complications I-Disease 0 0.048210893
during O 0 0.0009744393
treatment O 0 0.0012734764
of O 0 0.0026697044
acute B-Disease 0 0.99955314
lymphoblastic I-Disease 0 0.9999995
leukemia I-Disease 0 0.9999995
in O 0 0.005043373
a O 0 0.0021609724
single O 0 0.0019446597
pediatric O 0 0.0035581612
institution O 0 0.0051917215
. O 0 0.007222937

Central B-Disease 0 0.006606305
nervous I-Disease 0 0.017702296
system I-Disease 0 0.0026801722
( I-Disease 0 0.0030942897
CNS I-Disease 0 0.3050956
) I-Disease 0 0.002331526
complications I-Disease 0 0.063276105
during O 0 0.00038408005
treatment O 0 0.0005142113
of O 0 0.0008851127
childhood O 0 0.9948072
acute B-Disease 0 0.9999442
lymphoblastic I-Disease 0 0.9999999
leukemia I-Disease 0 1.0
( O 0 0.7373968
ALL B-Disease 0 0.9999646
) O 0 0.0044944254
remain O 0 0.0008921946
a O 0 0.00126477
challenging O 0 0.0017911103
clinical O 0 0.0038532251
problem O 0 0.0052143666
. O 0 0.0068400735

Outcome O 0 0.0045030904
improvement O 0 0.0027084653
with O 0 0.0018184409
more O 0 0.0014935056
intensive O 0 0.0010584673
chemotherapy O 0 0.012149877
has O 0 0.00062633
significantly O 0 0.00059651124
increased O 0 0.0006315823
the O 0 0.00061451294
incidence O 0 0.0023013286
and O 0 0.0011505728
severity O 0 0.0063229804
of O 0 0.0027541588
adverse O 0 0.617637
events O 0 0.044081036
. O 0 0.0078681

This O 0 0.0048248405
study O 0 0.0025772292
analyzed O 0 0.0014518918
the O 0 0.0011651663
incidence O 0 0.0029918598
of O 0 0.002731589
neurological B-Disease 0 0.99979085
complications I-Disease 0 0.99403906
during O 0 0.00061582687
ALL B-Disease 0 0.9996973
treatment O 0 0.0008035482
in O 0 0.00027940562
a O 0 0.00029697578
single O 0 0.00023209811
pediatric O 0 0.00033112103
institution O 0 0.0003267334
, O 0 0.00033416355
focusing O 0 0.00037734784
on O 0 0.00024197709
clinical O 0 0.0010084021
, O 0 0.0007190983
radiological O 0 0.0034864945
, O 0 0.0011878653
and O 0 0.0015359859
electrophysiological O 0 0.010018979
findings O 0 0.0045486367
. O 0 0.00645646

Exclusion O 0 0.05827287
criteria O 0 0.0030031747
included O 0 0.0021147984
CNS O 0 0.6698585
leukemic B-Disease 0 0.99921834
infiltration I-Disease 0 0.82809186
at O 0 0.00062738144
diagnosis O 0 0.004753905
, O 0 0.0008223483
therapy O 0 0.0020248117
- O 0 0.009608032
related O 0 0.00028099402
peripheral B-Disease 2 0.8377406
neuropathy I-Disease 2 0.9999993
, O 0 0.0018784273
late O 0 0.00986033
- O 0 0.06327542
onset O 0 0.023597492
encephalopathy B-Disease 2 0.99999416
, O 0 0.0014031295
or O 0 0.00057094474
long O 0 0.00084392884
- O 0 0.0052303923
term O 0 0.0020028988
neurocognitive B-Disease 0 0.9914922
defects I-Disease 0 0.09111514
. O 0 0.007723334

During O 0 0.0032965841
a O 0 0.003258287
9 O 0 0.0022630836
- O 0 0.0029875266
year O 0 0.001067558
period O 0 0.0007026765
, O 0 0.0007139844
we O 0 0.00034152027
retrospectively O 0 0.00036857577
collected O 0 0.00027054723
27 O 0 0.00045638616
neurological O 0 0.3995658
events O 0 0.003647127
( O 0 0.00051522785
11 O 0 0.000277979
% O 0 0.00030123518
) O 0 0.0003652618
in O 0 0.00020108103
as O 0 0.00019320303
many O 0 0.0002042933
patients O 0 0.0003225967
, O 0 0.0003032563
from O 0 0.00023704783
253 O 0 0.0016103649
children O 0 0.0004991255
enrolled O 0 0.0005286121
in O 0 0.00044908718
the O 0 0.00079058745
ALL B-Disease 0 0.99889153
front O 0 0.007069112
- O 0 0.008758225
line O 0 0.0034746823
protocol O 0 0.0045266505
. O 0 0.0074208346

CNS O 0 0.17848349
complications O 0 0.09290628
included O 0 0.0016506612
posterior O 0 0.044307813
reversible O 0 0.45188257
leukoencephalopathy B-Disease 2 0.99997354
syndrome O 0 0.94448674
( O 0 0.0012707772
n O 0 0.00037243313
= O 0 0.0006750993
10 O 0 0.00028444687
) O 0 0.0006224073
, O 0 0.0009470029
stroke B-Disease 2 0.99955124
( O 0 0.00053554284
n O 0 0.00021211234
= O 0 0.0003938912
5 O 0 0.00016807932
) O 0 0.0003331733
, O 0 0.0003606682
temporal B-Disease 2 0.37403908
lobe I-Disease 2 0.9951395
epilepsy I-Disease 2 0.9999995
( O 0 0.0009917166
n O 0 0.00021752098
= O 0 0.00053492526
2 O 0 0.00019638515
) O 0 0.00037513164
, O 0 0.00030718668
high O 0 0.00052832806
- O 0 0.015730428
dose O 0 0.04020791
methotrexate B-Chemical 1 0.9999932
toxicity B-Disease 2 0.99974626
( O 0 0.0013318196
n O 0 0.00023185261
= O 0 0.0006872169
2 O 0 0.00020350594
) O 0 0.00043006116
, O 0 0.00036184952
syndrome O 0 0.104338095
of O 0 0.00034369118
inappropriate B-Disease 0 0.005600569
antidiuretic I-Disease 0 0.97728115
hormone I-Disease 0 0.9159722
secretion I-Disease 0 0.005863987
( O 0 0.0007097732
n O 0 0.00024755296
= O 0 0.00064342585
1 O 0 0.0002496587
) O 0 0.00043608632
, O 0 0.00034058644
and O 0 0.00031718807
other O 0 0.00039199952
unclassified O 0 0.01013883
events O 0 0.0038945898
( O 0 0.0011037203
n O 0 0.0010668173
= O 0 0.002340825
7 O 0 0.0023510298
) O 0 0.005256211
. O 0 0.007440198

In O 0 0.003995085
conclusion O 0 0.0025528588
, O 0 0.003560717
CNS O 0 0.36937144
complications O 0 0.33901477
are O 0 0.0009299634
frequent O 0 0.0017789189
events O 0 0.0037755948
during O 0 0.0004697868
ALL B-Disease 0 0.99961394
therapy O 0 0.0043807807
, O 0 0.0005732239
and O 0 0.0003412111
require O 0 0.00024125466
rapid O 0 0.0005734048
detection O 0 0.00062125275
and O 0 0.00056809414
prompt O 0 0.0013808312
treatment O 0 0.00096848333
to O 0 0.001034962
limit O 0 0.0027140998
permanent O 0 0.13574117
damage O 0 0.88360274
. O 0 0.008819025

Cocaine B-Chemical 0 0.9999677
causes O 0 0.007483726
memory B-Disease 0 0.4133304
and I-Disease 0 0.0022528514
learning I-Disease 0 0.009933065
impairments I-Disease 0 0.42594695
in O 0 0.00062766223
rats O 0 0.00070495694
: O 0 0.0005676004
involvement O 0 0.00043587145
of O 0 0.00044386534
nuclear O 0 0.0085228365
factor O 0 0.04137689
kappa O 0 0.6774171
B O 0 0.9546358
and O 0 0.0019505029
oxidative O 0 0.9692815
stress O 0 0.5246707
, O 0 0.0019616315
and O 0 0.0014636995
prevention O 0 0.015756102
by O 0 0.0060956636
topiramate B-Chemical 0 0.99998796
. O 0 0.008645093

Different O 0 0.0039196983
mechanisms O 0 0.0021706263
have O 0 0.0014316419
been O 0 0.0011501417
suggested O 0 0.0008360218
for O 0 0.0018160803
cocaine B-Chemical 1 0.999997
toxicity B-Disease 2 0.9997571
including O 0 0.0006512999
an O 0 0.00045492587
increase O 0 0.00023887742
in O 0 0.0003537199
oxidative O 0 0.9511946
stress O 0 0.49483857
but O 0 0.00048104225
the O 0 0.00017093388
association O 0 0.0001527277
between O 0 0.0001524841
oxidative O 0 0.78293425
status O 0 0.0013523154
in O 0 0.00023490927
the O 0 0.0002619959
brain O 0 0.016396273
and O 0 0.001358412
cocaine B-Chemical 1 0.9999763
induced O 0 0.0011661019
- O 0 0.025632866
behaviour O 0 0.003060171
is O 0 0.0015195583
poorly O 0 0.0033229017
understood O 0 0.00473971
. O 0 0.0063050487

Nuclear O 0 0.12818573
factor O 0 0.03341352
kappa O 0 0.6077499
B O 0 0.9590695
( O 0 0.012445895
NFkappaB O 0 0.7069048
) O 0 0.003170295
is O 0 0.00066610216
a O 0 0.000532295
sensor O 0 0.00042357048
of O 0 0.0005146173
oxidative O 0 0.91381544
stress O 0 0.3224016
and O 0 0.00057315646
participates O 0 0.0002868133
in O 0 0.00031330084
memory O 0 0.14261498
formation O 0 0.0013371469
that O 0 0.00021286582
could O 0 0.00021867029
be O 0 0.00027436417
involved O 0 0.00030588944
in O 0 0.0006825919
drug O 0 0.9912403
toxicity B-Disease 2 0.999943
and O 0 0.0053758896
addiction O 0 0.9657385
mechanisms O 0 0.003776825
. O 0 0.0067335884

Therefore O 0 0.004115423
NFkappaB O 0 0.12528037
activity O 0 0.0026438474
, O 0 0.0031666746
oxidative O 0 0.963408
stress O 0 0.7837957
, O 0 0.009974073
neuronal O 0 0.59601885
nitric B-Chemical 0 0.9997526
oxide I-Chemical 0 0.9978326
synthase O 0 0.846351
( O 0 0.00416557
nNOS O 0 0.12432816
) O 0 0.0006446264
activity O 0 0.00024929858
, O 0 0.0003081882
spatial O 0 0.0012227444
learning O 0 0.00095387205
and O 0 0.00027226255
memory O 0 0.065351754
as O 0 0.00015936227
well O 0 0.00014555192
as O 0 0.00013884211
the O 0 0.00015309032
effect O 0 0.00021425799
of O 0 0.0044470364
topiramate B-Chemical 0 0.99999964
, O 0 0.0010921629
a O 0 0.00027461041
previously O 0 0.0001646944
proposed O 0 0.0001859949
therapy O 0 0.00072948384
for O 0 0.0016205537
cocaine B-Disease 1 0.9999999
addiction I-Disease 0 0.9999163
, O 0 0.00056943094
were O 0 0.00018790057
evaluated O 0 0.00015520673
in O 0 0.00020819133
an O 0 0.00028314244
experimental O 0 0.0003651852
model O 0 0.00058152963
of O 0 0.0053383014
cocaine B-Chemical 1 0.99998975
administration O 0 0.06843993
in O 0 0.0023895474
rats O 0 0.005024548
. O 0 0.0059342133

NFkappaB O 0 0.18773428
activity O 0 0.0030728036
was O 0 0.0017784964
decreased O 0 0.0013258669
in O 0 0.00082025485
the O 0 0.0008083567
frontal O 0 0.868128
cortex O 0 0.6558454
of O 0 0.0030069635
cocaine B-Chemical 1 0.9999902
treated O 0 0.0012103936
rats O 0 0.0006234483
, O 0 0.00030521446
as O 0 0.00017034555
well O 0 0.00020592393
as O 0 0.0005789269
GSH B-Chemical 1 0.9999988
concentration O 0 0.012033485
and O 0 0.007755853
glutathione B-Chemical 0 0.99999654
peroxidase O 0 0.99595696
activity O 0 0.0003940287
in O 0 0.00021065895
the O 0 0.00027533137
hippocampus O 0 0.34510922
, O 0 0.00046243958
whereas O 0 0.00042133042
nNOS O 0 0.02219884
activity O 0 0.00045869465
in O 0 0.00058215053
the O 0 0.0009685672
hippocampus O 0 0.1761865
was O 0 0.0021779817
increased O 0 0.0039107013
. O 0 0.006665877

Memory O 0 0.20928887
retrieval O 0 0.0036066365
of O 0 0.0020924225
experiences O 0 0.0022305737
acquired O 0 0.0015248212
prior O 0 0.00064183585
to O 0 0.00089403574
cocaine B-Chemical 1 0.99998474
administration O 0 0.033572223
was O 0 0.00041397597
impaired O 0 0.00041391185
and O 0 0.0003262034
negatively O 0 0.0003048588
correlated O 0 0.00028417204
with O 0 0.0004693954
NFkappaB O 0 0.12900867
activity O 0 0.0007856547
in O 0 0.0009502318
the O 0 0.0017109971
frontal O 0 0.81566095
cortex O 0 0.4167267
. O 0 0.006370814

In O 0 0.0038711538
contrast O 0 0.003068711
, O 0 0.002668591
learning O 0 0.002813842
of O 0 0.0011863292
new O 0 0.0010978939
tasks O 0 0.0013622274
was O 0 0.00047635008
enhanced O 0 0.00038347326
and O 0 0.0003959249
correlated O 0 0.00024003058
with O 0 0.0002665772
the O 0 0.00023448255
increase O 0 0.00022885422
of O 0 0.0005225736
nNOS O 0 0.051227555
activity O 0 0.00044558672
and O 0 0.00054597174
the O 0 0.00064499915
decrease O 0 0.0011115336
of O 0 0.0062012593
glutathione B-Chemical 0 0.99997056
peroxidase O 0 0.99706227
. O 0 0.009633534

These O 0 0.0033894868
results O 0 0.0020148205
provide O 0 0.0013485035
evidence O 0 0.0010439751
for O 0 0.00089141674
a O 0 0.0008398912
possible O 0 0.0005509495
mechanistic O 0 0.00053817127
role O 0 0.0003113143
of O 0 0.0006831578
oxidative O 0 0.9333883
and O 0 0.0035769918
nitrosative O 0 0.9994211
stress O 0 0.7538956
and O 0 0.0023174284
NFkappaB O 0 0.48966467
in O 0 0.0006048947
the O 0 0.000669139
alterations O 0 0.0018963477
induced O 0 0.0017036962
by O 0 0.0048758877
cocaine B-Chemical 1 0.9999422
. O 0 0.008574497

Topiramate B-Chemical 0 0.99997854
prevented O 0 0.006505487
all O 0 0.0025048305
the O 0 0.0019209159
alterations O 0 0.002720998
observed O 0 0.0015102035
, O 0 0.002138785
showing O 0 0.0020540033
novel O 0 0.0032309422
neuroprotective O 0 0.28574577
properties O 0 0.005839078
. O 0 0.008956466

Efficacy O 0 0.006304523
and O 0 0.0027194018
safety O 0 0.0024615757
of O 0 0.0027632706
asenapine B-Chemical 1 0.9999634
in O 0 0.0009645715
a O 0 0.0011157517
placebo O 0 0.11979106
- O 0 0.025291666
and O 0 0.0040948
haloperidol B-Chemical 1 0.99999976
- O 0 0.014041197
controlled O 0 0.0003068846
trial O 0 0.0004053162
in O 0 0.00036391465
patients O 0 0.00066678587
with O 0 0.00093781843
acute O 0 0.8906735
exacerbation O 0 0.98283756
of O 0 0.08084518
schizophrenia B-Disease 2 0.9999696
. O 0 0.009206978

Asenapine B-Chemical 0 0.99922013
is O 0 0.0030611544
approved O 0 0.0020883954
by O 0 0.0014384188
the O 0 0.0010657128
Food O 0 0.19045623
and O 0 0.0011282031
Drugs O 0 0.7068706
Administration O 0 0.04314446
in O 0 0.00037252222
adults O 0 0.001303451
for O 0 0.00032996206
acute O 0 0.5457189
treatment O 0 0.0010743206
of O 0 0.0037680012
schizophrenia B-Disease 2 0.99999046
or O 0 0.0004169742
of O 0 0.0024871363
manic B-Disease 0 0.9999963
or O 0 0.00027180972
mixed O 0 0.00053932617
episodes O 0 0.007311816
associated O 0 0.0004907467
with O 0 0.0050484953
bipolar B-Disease 2 0.9999988
I I-Disease 0 0.9506082
disorder I-Disease 0 0.99380857
with O 0 0.00082426646
or O 0 0.0010064096
without O 0 0.0027243304
psychotic B-Disease 0 0.99997663
features O 0 0.007740448
. O 0 0.0066076443

In O 0 0.0039305487
a O 0 0.0030818076
double O 0 0.0025327872
- O 0 0.009413577
blind O 0 0.013834252
6 O 0 0.00082464045
- O 0 0.0014852447
week O 0 0.00040924788
trial O 0 0.00051648176
, O 0 0.0005431882
458 O 0 0.0036233065
patients O 0 0.00044554658
with O 0 0.0004932995
acute O 0 0.95989394
schizophrenia B-Disease 2 0.9999882
were O 0 0.0002061522
randomly O 0 9.182921e-05
assigned O 0 0.00010612403
to O 0 0.00011634148
fixed O 0 0.00027377284
- O 0 0.006444413
dose O 0 0.0013439275
treatment O 0 0.00035663624
with O 0 0.0010634592
asenapine B-Chemical 1 0.9999727
at O 0 0.0001228195
5 O 0 0.00010780595
mg O 0 0.0006517717
twice O 0 0.00010133749
daily O 0 0.00018242364
( O 0 0.0005482289
BID O 0 0.9941883
) O 0 0.0059365146
, O 0 0.0032347178
asenapine B-Chemical 1 0.999962
at O 0 0.00015283318
10 O 0 0.00017495839
mg O 0 0.031729788
BID O 0 0.9897982
, O 0 0.0011340026
placebo O 0 0.041981947
, O 0 0.0005065132
or O 0 0.0007827258
haloperidol B-Chemical 1 0.9999994
at O 0 0.00024501135
4 O 0 0.00026159207
mg O 0 0.028590417
BID O 0 0.9556905
( O 0 0.0007404506
to O 0 0.0005201942
verify O 0 0.0005759861
assay O 0 0.0023310736
sensitivity O 0 0.0054506054
) O 0 0.006725779
. O 0 0.007341857

With O 0 0.0036718673
last O 0 0.0017394528
observations O 0 0.0014391325
carried O 0 0.0010257682
forward O 0 0.0072511355
( O 0 0.0026982003
LOCF O 0 0.36702242
) O 0 0.0007028047
, O 0 0.00037916348
mean O 0 0.00019944902
Positive O 0 0.0014467136
and O 0 0.00037922908
Negative O 0 0.12213075
Syndrome O 0 0.43867505
Scale O 0 0.030378154
total O 0 0.00014334744
score O 0 0.00015669446
reductions O 0 0.00016084462
from O 0 0.00011988105
baseline O 0 0.00013566222
to O 0 0.00011670703
endpoint O 0 0.00026693175
were O 0 0.00013068267
significantly O 0 0.000132527
greater O 0 0.00012762402
with O 0 0.00038521198
asenapine B-Chemical 1 0.9999355
at O 0 0.0001257678
5 O 0 0.00012987395
mg O 0 0.020803362
BID O 0 0.9879319
( O 0 0.0016740621
- O 0 0.009593998
16 O 0 0.00021533626
. O 0 0.0001480327
2 O 0 0.00016383576
) O 0 0.00040101612
and O 0 0.0014094125
haloperidol B-Chemical 1 0.99999976
( O 0 0.002979525
- O 0 0.0065140016
15 O 0 0.00015059096
. O 0 0.00013972732
4 O 0 0.00013670094
) O 0 0.00024758742
than O 0 0.00014357822
placebo O 0 0.0082036555
( O 0 0.0005004518
- O 0 0.0033842977
10 O 0 0.00017221649
. O 0 0.00015000494
7 O 0 0.0001453457
; O 0 0.00025614267
both O 0 0.00021022836
P O 0 0.028944924
< O 0 0.00020763012
0 O 0 0.00027176674
. O 0 0.00023825916
05 O 0 0.0073361737
) O 0 0.00048176845
; O 0 0.00031990124
using O 0 0.00015772025
mixed O 0 0.00024600406
model O 0 0.00017106562
for O 0 0.0001403991
repeated O 0 0.00011362029
measures O 0 0.00015672317
( O 0 0.0007454312
MMRM O 0 0.77382326
) O 0 0.0005501112
, O 0 0.00026525633
changes O 0 0.00020478986
at O 0 0.00012687621
day O 0 0.00012305372
42 O 0 0.00017561727
were O 0 0.00012651258
significantly O 0 0.00013123236
greater O 0 0.00013098221
with O 0 0.00038175052
asenapine B-Chemical 1 0.9999287
at O 0 0.000120426084
5 O 0 0.00010479041
and O 0 0.00013077018
10 O 0 0.0001472921
mg O 0 0.02372417
BID O 0 0.9894566
( O 0 0.00172018
- O 0 0.008287831
21 O 0 0.00022294353
. O 0 0.00014871947
3 O 0 0.00014112915
and O 0 0.00022144025
- O 0 0.0026448593
19 O 0 0.00029360928
. O 0 0.00016015775
4 O 0 0.00015020161
, O 0 0.00023962057
respectively O 0 0.0011734231
) O 0 0.0011174376
and O 0 0.0036423372
haloperidol B-Chemical 1 0.9999999
( O 0 0.0033378282
- O 0 0.0067178207
20 O 0 0.00017667605
. O 0 0.00015004115
0 O 0 0.00019214908
) O 0 0.0002905265
than O 0 0.00016472017
placebo O 0 0.0077745314
( O 0 0.0005330832
- O 0 0.0027651542
14 O 0 0.0002598827
. O 0 0.0002463794
6 O 0 0.00026322322
; O 0 0.0005024073
all O 0 0.0004893092
P O 0 0.0061124195
< O 0 0.0009470545
0 O 0 0.0015544877
. O 0 0.0022568668
05 O 0 0.011336872
) O 0 0.0065893913
. O 0 0.00854888

On O 0 0.0030893104
the O 0 0.002246405
Positive O 0 0.004841617
and O 0 0.001745865
Negative O 0 0.121603124
Syndrome O 0 0.45984825
Scale O 0 0.09037394
positive O 0 0.00070305326
subscale O 0 0.0009488287
, O 0 0.0004513694
all O 0 0.00024977874
treatments O 0 0.00029865096
were O 0 0.00021191727
superior O 0 0.00030260795
to O 0 0.00016781474
placebo O 0 0.0063673253
with O 0 0.00030968824
LOCF O 0 0.26750013
and O 0 0.00027959558
MMRM O 0 0.7375608
; O 0 0.001409077
asenapine B-Chemical 1 0.9998597
at O 0 0.00013188382
5 O 0 0.00013727712
mg O 0 0.0117467595
BID O 0 0.95038635
was O 0 0.00020285713
superior O 0 0.00027020054
to O 0 0.00012876085
placebo O 0 0.0010345338
on O 0 8.943049e-05
the O 0 0.0001312111
negative O 0 0.00026596308
subscale O 0 0.00060176454
with O 0 0.00031446852
MMRM O 0 0.33271065
and O 0 0.00020903429
on O 0 0.000158062
the O 0 0.00025573027
general O 0 0.00041814405
psychopathology O 0 0.9413084
subscale O 0 0.0015497237
with O 0 0.0012953422
LOCF O 0 0.18369143
and O 0 0.0025763393
MMRM O 0 0.40213335
. O 0 0.0063052573

Treatment O 0 0.016713722
- O 0 0.008564884
related O 0 0.0016517901
adverse O 0 0.2174208
events O 0 0.029622223
( O 0 0.00368121
AEs O 0 0.7077715
) O 0 0.0009907694
occurred O 0 0.00039751444
in O 0 0.00032902908
44 O 0 0.00042859596
% O 0 0.00032362738
and O 0 0.00028584746
52 O 0 0.00037307062
% O 0 0.00032239346
, O 0 0.00033669753
57 O 0 0.00038118468
% O 0 0.00030086693
, O 0 0.0002979343
and O 0 0.0002540205
41 O 0 0.0003679443
% O 0 0.0002429362
of O 0 0.0002480836
the O 0 0.00036581885
asenapine B-Chemical 1 0.99992085
at O 0 0.00015912767
5 O 0 0.0001425347
and O 0 0.00018425936
10 O 0 0.00022259136
mg O 0 0.050628025
BID O 0 0.99698466
, O 0 0.031781923
haloperidol B-Chemical 1 0.99999964
, O 0 0.0012160913
and O 0 0.0009881664
placebo O 0 0.013528393
groups O 0 0.0014058247
, O 0 0.0026882999
respectively O 0 0.0063946503
. O 0 0.0069663743

Extrapyramidal B-Disease 0 0.9998429
symptoms I-Disease 0 0.89840716
reported O 0 0.002256843
as O 0 0.0013598022
AEs O 0 0.21910791
occurred O 0 0.00060482696
in O 0 0.00044102603
15 O 0 0.00033930535
% O 0 0.00037442884
and O 0 0.00032930085
18 O 0 0.0003092268
% O 0 0.00033627453
, O 0 0.00035216787
34 O 0 0.00032271602
% O 0 0.0003050818
, O 0 0.00029921925
and O 0 0.00024362418
10 O 0 0.00019665966
% O 0 0.00022327028
of O 0 0.00023775765
the O 0 0.00035618435
asenapine B-Chemical 1 0.99991953
at O 0 0.00015938749
5 O 0 0.00014281155
and O 0 0.00018466708
10 O 0 0.00022300413
mg O 0 0.051257826
BID O 0 0.99701095
, O 0 0.031935025
haloperidol B-Chemical 1 0.99999964
, O 0 0.0012166342
and O 0 0.0009882409
placebo O 0 0.013533307
groups O 0 0.0014057563
, O 0 0.0026881755
respectively O 0 0.006394431
. O 0 0.006966127

Across O 0 0.004721725
all O 0 0.0025952945
groups O 0 0.0020951778
, O 0 0.0018080962
no O 0 0.0009552444
more O 0 0.0009526023
than O 0 0.00057868636
5 O 0 0.0005706561
% O 0 0.00072037725
of O 0 0.00077193155
patients O 0 0.0010598758
had O 0 0.0009786818
clinically O 0 0.0042336415
significant O 0 0.0018052342
weight O 0 0.006571134
change O 0 0.0055397153
. O 0 0.0081135025

Post O 0 0.007789657
hoc O 0 0.0056263045
analyses O 0 0.0016924298
indicated O 0 0.0010018297
that O 0 0.0007687551
efficacy O 0 0.0010058933
was O 0 0.00056721404
similar O 0 0.00037952437
with O 0 0.0013346062
asenapine B-Chemical 1 0.9999949
and O 0 0.01312993
haloperidol B-Chemical 1 0.99999976
; O 0 0.0010033802
greater O 0 0.00025573344
contrasts O 0 0.00041771412
were O 0 0.0003149093
seen O 0 0.00037227853
in O 0 0.0006256665
AEs O 0 0.54830277
, O 0 0.0019162656
especially O 0 0.048922077
extrapyramidal B-Disease 0 0.99999857
symptoms I-Disease 0 0.9851408
. O 0 0.007679402

Salvage O 0 0.009919246
therapy O 0 0.004099997
with O 0 0.0025080268
nelarabine B-Chemical 0 0.9323044
, O 0 0.009258005
etoposide B-Chemical 1 0.99987364
, O 0 0.0027103028
and O 0 0.0017245582
cyclophosphamide B-Chemical 0 0.99990165
in O 0 0.0009013875
relapsed O 0 0.79526484
/ O 0 0.009498832
refractory O 0 0.022278542
paediatric O 0 0.0021595664
T B-Disease 0 0.974033
- I-Disease 0 0.14785294
cell I-Disease 0 0.2000247
lymphoblastic I-Disease 0 0.9999975
leukaemia I-Disease 0 0.9999976
and I-Disease 0 0.21862984
lymphoma I-Disease 0 0.99969184
. O 0 0.013932711

A O 0 0.027932549
combination O 0 0.0030238503
of O 0 0.0019318508
5 O 0 0.001135428
d O 0 0.0012093645
of O 0 0.0012316012
nelarabine B-Chemical 0 0.9324415
( O 0 0.004740743
AraG B-Chemical 0 0.83868635
) O 0 0.0008636539
with O 0 0.00029654743
5 O 0 0.00019909408
d O 0 0.00030810625
of O 0 0.0006406634
etoposide B-Chemical 1 0.99993527
( O 0 0.019175492
VP B-Chemical 0 0.9972066
) O 0 0.002016166
and O 0 0.00092257914
cyclophosphamide B-Chemical 0 0.9999602
( O 0 0.025660107
CPM B-Chemical 0 0.99953175
) O 0 0.001159348
and O 0 0.00029539104
prophylactic O 0 0.0036781542
intrathecal O 0 0.2143354
chemotherapy O 0 0.016568894
was O 0 0.00015424774
used O 0 0.00012528541
as O 0 0.00014568258
salvage O 0 0.0007068749
therapy O 0 0.00028703408
in O 0 0.0001548165
seven O 0 0.0001501001
children O 0 0.00030779265
with O 0 0.00027363663
refractory O 0 0.0066236705
or O 0 0.00055211986
relapsed O 0 0.94177276
T B-Disease 0 0.98973316
- I-Disease 0 0.2132291
cell I-Disease 0 0.14695555
leukaemia I-Disease 0 0.99998724
or I-Disease 0 0.029649636
lymphoma I-Disease 0 0.99954563
. O 0 0.012496807

The O 0 0.0033273231
most O 0 0.0028178296
common O 0 0.00212842
side O 0 0.0070850677
effects O 0 0.001072831
attributable O 0 0.0005413951
to O 0 0.00045812508
the O 0 0.00051647064
AraG B-Chemical 0 0.38856807
included O 0 0.00043068497
Grade O 0 0.105536096
2 O 0 0.00032079333
and O 0 0.00034578284
3 O 0 0.00034303023
sensory O 0 0.0007894788
and O 0 0.00088653906
motor O 0 0.9089907
neuropathy B-Disease 0 0.99999523
and O 0 0.0046252618
musculoskeletal B-Disease 0 0.6800998
pain I-Disease 0 0.9590965
. O 0 0.007485758

Haematological B-Disease 0 0.9997527
toxicity I-Disease 2 0.99986994
was O 0 0.002414615
greater O 0 0.0010503458
for O 0 0.0007143802
the O 0 0.00055062684
combination O 0 0.00071840524
than O 0 0.00041788942
AraG B-Chemical 0 0.69913405
alone O 0 0.00044704753
, O 0 0.00045405133
although O 0 0.00020334398
median O 0 0.00013718866
time O 0 0.00013488893
to O 0 0.00018068646
neutrophil O 0 0.01204586
and O 0 0.0005306797
platelet O 0 0.45017627
recovery O 0 0.00065924093
was O 0 0.00041062574
consistent O 0 0.0005188962
with O 0 0.0008410091
other O 0 0.0014554273
salvage O 0 0.006284998
therapies O 0 0.005564825
. O 0 0.006256244

All O 0 0.0031982865
patients O 0 0.0026730543
had O 0 0.0014371496
some O 0 0.001003459
response O 0 0.0009211484
to O 0 0.000539412
the O 0 0.0004602348
combined O 0 0.00052880746
therapy O 0 0.0006020826
and O 0 0.00030136816
five O 0 0.00017080078
of O 0 0.00021814721
the O 0 0.00018827216
seven O 0 0.00016914943
went O 0 0.00024974372
into O 0 0.000116565345
complete O 0 0.00017316116
remission O 0 0.014335454
after O 0 0.00015119195
one O 0 0.00020013117
or O 0 0.00023633358
two O 0 0.00027566703
courses O 0 0.00045846254
of O 0 0.0010845538
AraG B-Chemical 0 0.9182643
/ O 0 0.16358177
VP B-Chemical 0 0.99805474
/ O 0 0.24677113
CPM B-Chemical 0 0.9975485
. O 0 0.009146236

Our O 0 0.003972871
experience O 0 0.0027234447
supports O 0 0.0014627838
the O 0 0.0011209361
safety O 0 0.0011814057
of O 0 0.00087114814
giving O 0 0.0018407757
AraG B-Chemical 0 0.6687334
as O 0 0.00043147415
salvage O 0 0.0018389253
therapy O 0 0.0005170869
in O 0 0.00023583206
synchrony O 0 0.001214915
with O 0 0.0006695339
etoposide B-Chemical 1 0.9998387
and O 0 0.004822412
cyclophosphamide B-Chemical 0 0.9999716
, O 0 0.0037618198
although O 0 0.0021977893
neurological B-Disease 0 0.9997856
toxicity I-Disease 2 0.9998791
must O 0 0.00068826554
be O 0 0.0011308204
closely O 0 0.0017404931
monitored O 0 0.0026854821
. O 0 0.005947648

Effect O 0 0.004861928
of O 0 0.0048417184
adriamycin B-Chemical 0 0.9996032
combined O 0 0.0032920844
with O 0 0.0017228876
whole O 0 0.0016006824
body O 0 0.010592074
hyperthermia B-Disease 2 0.9986934
on O 0 0.0011876492
tumor B-Disease 0 0.6750704
and O 0 0.0029130948
normal O 0 0.005063338
tissues O 0 0.007597751
. O 0 0.008201558

Thermal O 0 0.015214875
enhancement O 0 0.0050327075
of O 0 0.0061803744
Adriamycin B-Chemical 0 0.9999752
- O 0 0.08289794
mediated O 0 0.00072232814
antitumor O 0 0.3469615
activity O 0 0.0007310559
and O 0 0.0005922788
normal O 0 0.0011901611
tissue O 0 0.02875754
toxicities B-Disease 2 0.9971175
by O 0 0.00039717223
whole O 0 0.00046698962
body O 0 0.0064342543
hyperthermia B-Disease 2 0.99831784
were O 0 0.0004808206
compared O 0 0.00042726652
using O 0 0.0007526449
a O 0 0.0015741617
F344 O 0 0.109728366
rat O 0 0.003959678
model O 0 0.0043939985
. O 0 0.0074278247

Antitumor O 0 0.23142558
activity O 0 0.0047652144
was O 0 0.0035118556
studied O 0 0.0029494094
using O 0 0.0026465454
a O 0 0.00369597
tumor B-Disease 0 0.6228658
growth O 0 0.022056278
delay O 0 0.0088224765
assay O 0 0.01781096
. O 0 0.012202935

Acute O 0 0.34800568
normal O 0 0.005571201
tissue O 0 0.073446274
toxicities B-Disease 2 0.9993893
( O 0 0.004282651
i O 0 0.0050082593
. O 0 0.0005528582
e O 0 0.0011130001
. O 0 0.00054629415
, O 0 0.0021677115
leukopenia B-Disease 0 0.9999876
and O 0 0.011276521
thrombocytopenia B-Disease 0 0.9999913
) O 0 0.0025112953
and O 0 0.00031866357
late O 0 0.0009087737
normal O 0 0.0010322403
tissue O 0 0.05089664
toxicities B-Disease 2 0.9993587
( O 0 0.0015980485
i O 0 0.0042500705
. O 0 0.00019231916
e O 0 0.00069787184
. O 0 0.000258544
, O 0 0.0007039114
myocardial B-Disease 0 0.99876475
and I-Disease 0 0.0034178572
kidney I-Disease 0 0.9989427
injury I-Disease 0 0.99953425
) O 0 0.0020670737
were O 0 0.00020979946
evaluated O 0 0.00016947488
by O 0 0.00024559838
functional O 0 0.00033638804
/ O 0 0.0010682273
physiological O 0 0.0006234468
assays O 0 0.0007901457
and O 0 0.0010226122
by O 0 0.0015196676
morphological O 0 0.0040958445
techniques O 0 0.004269696
. O 0 0.0064410274

Whole O 0 0.011327982
body O 0 0.012286421
hyperthermia B-Disease 2 0.99853957
( O 0 0.0025457854
120 O 0 0.0010269549
min O 0 0.00080405304
at O 0 0.0004889349
41 O 0 0.0006139182
. O 0 0.00035089607
5 O 0 0.00030635082
degrees O 0 0.004028231
C O 0 0.99795294
) O 0 0.0018764901
enhanced O 0 0.0004916155
both O 0 0.0011683501
Adriamycin B-Chemical 0 0.99998236
- O 0 0.03273533
mediated O 0 0.0004237134
antitumor O 0 0.28291705
activity O 0 0.0011289192
and O 0 0.0020243013
toxic O 0 0.8548992
side O 0 0.13459745
effects O 0 0.006468762
. O 0 0.007156301

The O 0 0.004147646
thermal O 0 0.0061968532
enhancement O 0 0.003164177
ratio O 0 0.0019994036
calculated O 0 0.0012482265
for O 0 0.0015372084
antitumor O 0 0.1760505
activity O 0 0.0019583108
was O 0 0.00204676
1 O 0 0.002276729
. O 0 0.0029415984
6 O 0 0.004238364
. O 0 0.008101908

Thermal O 0 0.012640287
enhancement O 0 0.0035060712
ratios O 0 0.0018891088
estimated O 0 0.0012443282
for O 0 0.0011308275
" O 0 0.0018004443
acute O 0 0.8030685
" O 0 0.0036228176
hematological O 0 0.86728835
changes O 0 0.0006243816
were O 0 0.00028648673
1 O 0 0.00022818378
. O 0 0.00018970638
3 O 0 0.00017465222
, O 0 0.00023405413
whereas O 0 0.00019752751
those O 0 0.0002068561
estimated O 0 0.00016231736
for O 0 0.00020668934
" O 0 0.00039324333
late O 0 0.0013691246
" O 0 0.00095207425
damage O 0 0.5871728
( O 0 0.00053686893
based O 0 0.00019496272
on O 0 0.000120070516
morphological O 0 0.0013511182
cardiac B-Disease 0 0.03700696
and I-Disease 0 0.0007773716
renal I-Disease 0 0.99857557
lesions I-Disease 0 0.98705006
) O 0 0.00079015427
varied O 0 0.00025318534
between O 0 0.00023125605
2 O 0 0.0003523645
. O 0 0.0004090483
4 O 0 0.00052770064
and O 0 0.0008815514
4 O 0 0.0012153849
. O 0 0.001974103
3 O 0 0.003365133
. O 0 0.006471097

Thus O 0 0.0042310073
, O 0 0.00335977
while O 0 0.0018307188
whole O 0 0.0014823031
body O 0 0.009722874
hyperthermia B-Disease 2 0.9996846
enhances O 0 0.001884354
Adriamycin B-Chemical 0 0.99999535
- O 0 0.13039389
mediated O 0 0.0003166415
antitumor O 0 0.5123817
effect O 0 0.0006008395
, O 0 0.0010032882
normal O 0 0.0027371268
tissue O 0 0.09636898
toxicity B-Disease 2 0.9990345
is O 0 0.00034711888
also O 0 0.00022006163
increased O 0 0.00031728036
, O 0 0.00035698863
and O 0 0.00023484591
the O 0 0.00018421405
potential O 0 0.00026586096
therapeutic O 0 0.0006951397
gain O 0 0.00048216645
of O 0 0.00044655686
the O 0 0.00047486468
combined O 0 0.00084581866
modality O 0 0.0018009602
treatment O 0 0.0020108472
is O 0 0.0029451165
eroded O 0 0.046739634
. O 0 0.0071850745

Permeability O 0 0.13764392
, O 0 0.0042412225
ultrastructural O 0 0.0076294118
changes O 0 0.002034451
, O 0 0.0013449142
and O 0 0.00078491727
distribution O 0 0.00048697623
of O 0 0.0005627059
novel O 0 0.0005468492
proteins O 0 0.000596256
in O 0 0.0004677129
the O 0 0.0005609366
glomerular O 0 0.70555884
barrier O 0 0.0073913196
in O 0 0.0010657918
early O 0 0.00705756
puromycin B-Chemical 0 0.99700266
aminonucleoside I-Chemical 0 0.9999987
nephrosis B-Disease 2 0.9999974
. O 0 0.05287787

BACKGROUND O 0 0.034623522
/ O 0 0.013760531
AIMS O 0 0.0520546
: O 0 0.0030532703
It O 0 0.0017483874
is O 0 0.0011952309
still O 0 0.0009598813
unclear O 0 0.0008236108
what O 0 0.00096539484
happens O 0 0.00090737117
in O 0 0.00088188384
the O 0 0.0011517495
glomerulus O 0 0.047957987
when O 0 0.0024454123
proteinuria B-Disease 0 0.99996674
starts O 0 0.010251224
. O 0 0.009005875

Using O 0 0.0052686334
puromycin B-Chemical 0 0.98899966
aminonucleoside I-Chemical 0 0.9999987
nephrosis B-Disease 2 0.99999964
( O 0 0.81742626
PAN O 1 0.9999958
) O 0 0.027748635
rats O 0 0.0012139087
, O 0 0.00047135854
we O 0 0.00019154651
studied O 0 0.00024608875
early O 0 0.00037093888
ultrastructural O 0 0.013127731
and O 0 0.00042762898
permeability O 0 0.51671636
changes O 0 0.00038039932
in O 0 0.0001449811
relation O 0 9.9017234e-05
to O 0 0.00010842576
the O 0 0.00012265013
expression O 0 0.00016164719
of O 0 0.00021159546
the O 0 0.00025451745
podocyte O 0 0.95570993
- O 0 0.03759547
associated O 0 0.00025951306
molecules O 0 0.0005513059
nephrin O 0 0.9775105
, O 0 0.0016170949
a O 0 0.00089340424
- O 0 0.071395874
actinin O 0 0.96698785
, O 0 0.0027657447
dendrin O 0 0.147478
, O 0 0.0005970826
and O 0 0.00038305743
plekhh2 O 0 0.0135493
, O 0 0.0003366054
the O 0 0.00019377792
last O 0 0.00015398291
two O 0 0.00018370153
of O 0 0.00030332367
which O 0 0.00042348064
were O 0 0.0004561702
only O 0 0.00060599425
recently O 0 0.0008969179
discovered O 0 0.0015178664
in O 0 0.0024273056
podocytes O 0 0.23149104
. O 0 0.008063235

METHODS O 0 0.0048418427
: O 0 0.004349015
Using O 0 0.0028352742
immune O 0 0.0067514004
stainings O 0 0.0047525065
, O 0 0.0021391525
semiquantitative O 0 0.0016256821
measurement O 0 0.0010894233
was O 0 0.0012376758
performed O 0 0.0012125433
under O 0 0.0015118107
the O 0 0.0025877885
electron O 0 0.01435187
microscope O 0 0.0090094665
. O 0 0.009873207

Permeability O 0 0.045833804
was O 0 0.005267069
assessed O 0 0.003549494
using O 0 0.0035460333
isolated O 0 0.0037666073
kidney O 0 0.4295118
perfusion O 0 0.31412524
with O 0 0.0075381203
tracers O 0 0.019528031
. O 0 0.012746101

Possible O 0 0.0159479
effects O 0 0.009936343
of O 0 0.012505112
ACE O 0 0.9975897
inhibition O 0 0.01463934
were O 0 0.009564806
tested O 0 0.010844945
. O 0 0.016878447

RESULTS O 0 0.0061072567
: O 0 0.0040152296
By O 0 0.002605028
day O 0 0.0016878583
2 O 0 0.001452326
, O 0 0.001373034
some O 0 0.0009908552
patchy O 0 0.0022899746
foot O 0 0.008350486
process O 0 0.0011357048
effacement O 0 0.22212407
, O 0 0.001579291
but O 0 0.0015503244
no O 0 0.0018093822
proteinuria B-Disease 0 0.99998355
, O 0 0.0065835253
appeared O 0 0.005494569
. O 0 0.008057765

The O 0 0.0036080282
amount O 0 0.0023600582
of O 0 0.0032298923
nephrin O 0 0.83958375
was O 0 0.0022053458
reduced O 0 0.001641336
in O 0 0.0015058244
both O 0 0.0016665205
diseased O 0 0.0049160914
and O 0 0.002827871
normal O 0 0.0047981353
areas O 0 0.009265903
. O 0 0.008954689

The O 0 0.0038169918
other O 0 0.0029819412
proteins O 0 0.002553566
showed O 0 0.0016507258
few O 0 0.0012684955
changes O 0 0.0016069355
, O 0 0.0016884193
which O 0 0.0015199896
were O 0 0.0014577535
limited O 0 0.0016728814
to O 0 0.002329771
diseased O 0 0.008603838
areas O 0 0.009472765
. O 0 0.009112548

By O 0 0.0046530156
day O 0 0.002624963
4 O 0 0.0019555273
, O 0 0.0019128104
foot O 0 0.0038555374
process O 0 0.001162013
effacement O 0 0.06102583
was O 0 0.00062216294
complete O 0 0.00045798143
and O 0 0.00092692336
proteinuria B-Disease 0 0.999992
appeared O 0 0.0005968758
in O 0 0.00041950645
parallel O 0 0.00051642733
with O 0 0.0006884791
signs O 0 0.008795984
of O 0 0.0013864532
size O 0 0.002584261
barrier O 0 0.043842446
damage O 0 0.8682328
. O 0 0.009214522

Nephrin O 0 0.03579754
decreased O 0 0.0035417797
further O 0 0.0021715714
, O 0 0.0022235434
while O 0 0.001466751
dendrin O 0 0.02880651
and O 0 0.0012524978
plekhh2 O 0 0.01105041
also O 0 0.00079084624
decreased O 0 0.0010749917
but O 0 0.0011882691
a O 0 0.0016980221
- O 0 0.023839546
actinin O 0 0.89128894
remained O 0 0.007241178
unchanged O 0 0.0059501217
. O 0 0.0085017225

ACE O 0 0.99115294
inhibition O 0 0.011131273
had O 0 0.006705816
no O 0 0.0056498484
significant O 0 0.007631108
protective O 0 0.022434369
effect O 0 0.013730214
. O 0 0.01840679

CONCLUSIONS O 0 0.058202308
: O 0 0.009251394
PAN O 1 0.99950063
glomeruli O 0 0.08187786
already O 0 0.0012940117
showed O 0 0.00091803796
significant O 0 0.0008753637
pathology O 0 0.008918326
by O 0 0.0007617787
day O 0 0.0006474336
4 O 0 0.000707371
, O 0 0.0010928523
despite O 0 0.0012833617
relatively O 0 0.0040694303
mild O 0 0.9642855
proteinuria B-Disease 0 0.99998903
. O 0 0.012525412

This O 0 0.005576867
was O 0 0.0028787612
preceded O 0 0.0021423663
by O 0 0.0018384203
altered O 0 0.0019080498
nephrin O 0 0.90581846
expression O 0 0.0018815446
, O 0 0.001431064
supporting O 0 0.0008583156
its O 0 0.001273004
pivotal O 0 0.001061228
role O 0 0.0011293268
in O 0 0.0021943457
podocyte O 0 0.85057217
morphology O 0 0.04796285
. O 0 0.008786905

The O 0 0.0030951842
novel O 0 0.0025662659
proteins O 0 0.002338751
dendrin O 0 0.035751186
and O 0 0.0016333471
plekhh2 O 0 0.017258104
were O 0 0.0006626304
both O 0 0.0004902546
reduced O 0 0.00049101206
, O 0 0.0005570724
suggesting O 0 0.000301986
roles O 0 0.00033319774
in O 0 0.0007452963
PAN O 1 0.99993896
, O 0 0.0017104652
whereas O 0 0.00096622895
a O 0 0.0016138878
- O 0 0.029635232
actinin O 0 0.8821706
was O 0 0.0034505448
unchanged O 0 0.0048253583
. O 0 0.0076883854

A O 0 0.025067914
novel O 0 0.0038928068
, O 0 0.0029946934
multiple O 0 0.002112374
symptom O 0 0.0078119338
model O 0 0.0013769101
of O 0 0.0071631814
obsessive B-Disease 0 0.99999213
- I-Disease 0 0.6598841
compulsive I-Disease 0 0.9999789
- I-Disease 0 0.018941617
like I-Disease 0 0.0015450661
behaviors I-Disease 0 0.008967502
in O 0 0.0027246622
animals O 0 0.004014787
. O 0 0.007434193

BACKGROUND O 0 0.016837982
: O 0 0.004275368
Current O 0 0.005045955
animal O 0 0.0019470063
models O 0 0.0013462027
of O 0 0.0071025062
obsessive B-Disease 0 0.9999945
- I-Disease 0 0.8015022
compulsive I-Disease 0 0.9999963
disorder I-Disease 0 0.9994809
( O 0 0.114005305
OCD B-Disease 2 0.99999917
) O 0 0.0009346985
typically O 0 0.00028330504
involve O 0 0.000208208
acute O 0 0.6082328
, O 0 0.0025476592
drug O 0 0.6949765
- O 0 0.023375152
induced O 0 0.00043608798
symptom O 0 0.10329438
provocation O 0 0.2642726
or O 0 0.00032488248
a O 0 0.0004550009
genetic O 0 0.0010588836
association O 0 0.0007358445
with O 0 0.004838854
stereotypies O 0 0.99997985
or O 0 0.00532122
anxiety B-Disease 0 0.99402076
. O 0 0.0067377673

None O 0 0.0072938786
of O 0 0.0039286334
these O 0 0.0029374016
current O 0 0.002782482
models O 0 0.0021430473
demonstrate O 0 0.0016394383
multiple O 0 0.011187416
OCD B-Disease 2 0.9999933
- O 0 0.02231452
like O 0 0.004719292
behaviors O 0 0.045136347
. O 0 0.01035256

METHODS O 0 0.004074526
: O 0 0.0039359983
Neonatal O 0 0.004727705
rats O 0 0.0020264161
were O 0 0.0010053858
treated O 0 0.0007950678
with O 0 0.00070963893
the O 0 0.0012743954
tricyclic O 0 0.9999932
antidepressant B-Chemical 1 0.9999989
clomipramine B-Chemical 0 0.9999999
or O 0 0.00039022104
vehicle O 0 0.001245176
between O 0 0.00014610423
days O 0 0.0001507852
9 O 0 0.00018511646
and O 0 0.00021909186
16 O 0 0.00025228818
twice O 0 0.00023348087
daily O 0 0.00037567073
and O 0 0.0005837106
behaviorally O 0 0.0051023667
tested O 0 0.0011294025
in O 0 0.0022285918
adulthood O 0 0.19724591
. O 0 0.0072816075

RESULTS O 0 0.006630827
: O 0 0.011635588
Clomipramine B-Chemical 0 0.99998534
exposure O 0 0.022998745
in O 0 0.0011680418
immature O 0 0.0015696484
rats O 0 0.0007526811
produced O 0 0.00034501532
significant O 0 0.00039682593
behavioral O 0 0.011063987
and O 0 0.00031699004
biochemical O 0 0.0013485003
changes O 0 0.00025457234
that O 0 0.00013000939
include O 0 0.00017035431
enhanced O 0 0.00042257577
anxiety B-Disease 0 0.9969338
( O 0 0.0008223413
elevated O 0 0.0018999504
plus O 0 0.0001765198
maze O 0 0.0495575
and O 0 0.0003256779
marble O 0 0.039374955
burying O 0 0.5482191
) O 0 0.004770242
, O 0 0.0014653032
behavioral B-Disease 0 0.84033364
inflexibility I-Disease 0 0.97187763
( O 0 0.0033388645
perseveration O 0 0.9863085
in O 0 0.0001734568
the O 0 0.00016212926
spontaneous O 0 0.0010581461
alternation O 0 0.0034602536
task O 0 0.000315045
and O 0 0.00018567221
impaired O 0 0.0002555046
reversal O 0 0.0006366497
learning O 0 0.0032389362
) O 0 0.0008323058
, O 0 0.00045600825
working O 0 0.0066640587
memory B-Disease 2 0.98851204
impairment I-Disease 2 0.98136973
( O 0 0.00063939823
e O 0 0.0009643013
. O 0 0.00024454924
g O 0 0.0006214733
. O 0 0.00024427567
, O 0 0.0003810009
win O 0 0.0011605114
- O 0 0.005176048
shift O 0 0.0008923507
paradigm O 0 0.00066149404
) O 0 0.0018671295
, O 0 0.0022638289
hoarding B-Disease 0 0.99571675
, O 0 0.001817406
and O 0 0.002907899
corticostriatal B-Disease 0 0.991091
dysfunction I-Disease 0 0.99272126
. O 0 0.00857654

Dopamine B-Chemical 1 0.9999635
D2 O 0 0.99925953
receptors O 0 0.0167491
were O 0 0.001480666
elevated O 0 0.0022706222
in O 0 0.0006561827
the O 0 0.00067340996
striatum O 0 0.7368799
, O 0 0.0010903354
whereas O 0 0.0017786981
serotonin B-Chemical 0 0.99983895
2C O 0 0.0021983082
, O 0 0.00052401365
but O 0 0.0003953901
not O 0 0.0004018452
serotonin B-Chemical 0 0.9994904
1A O 0 0.0006437745
, O 0 0.00048195053
receptors O 0 0.0011604218
were O 0 0.0004251238
elevated O 0 0.0008927262
in O 0 0.00061136764
the O 0 0.0010181211
orbital O 0 0.22859518
frontal O 0 0.87573487
cortex O 0 0.4402416
. O 0 0.0064437473

CONCLUSIONS O 0 0.02679313
: O 0 0.00446644
This O 0 0.0026238232
is O 0 0.0013933808
the O 0 0.0009197408
first O 0 0.0006219551
demonstration O 0 0.00063343014
of O 0 0.0006213238
multiple O 0 0.00086489326
symptoms O 0 0.1036587
consistent O 0 0.0005257682
with O 0 0.0007581511
an O 0 0.005705474
OCD B-Disease 2 0.99999833
- O 0 0.009184708
like O 0 0.0010175557
profile O 0 0.0015321041
in O 0 0.0021991953
animals O 0 0.0034738355
. O 0 0.006730776

Moreover O 0 0.0049803318
, O 0 0.0034599986
these O 0 0.002104978
behaviors O 0 0.008093409
are O 0 0.0010084463
accompanied O 0 0.0009895345
by O 0 0.00072369486
biochemical O 0 0.0018872109
changes O 0 0.000679429
in O 0 0.0004866718
brain O 0 0.0025617355
regions O 0 0.00060455414
previously O 0 0.00054489507
identified O 0 0.00065039116
as O 0 0.0009692771
relevant O 0 0.0016244139
to O 0 0.0034574477
OCD B-Disease 2 0.9999629
. O 0 0.0077896006

This O 0 0.004597943
novel O 0 0.002684494
model O 0 0.0021629075
of O 0 0.008277686
OCD B-Disease 2 0.9999958
demonstrates O 0 0.0006579248
that O 0 0.0004865827
drug O 0 0.18576545
exposure O 0 0.0031016627
during O 0 0.0002270568
a O 0 0.00029857128
sensitive O 0 0.00021616076
period O 0 0.00015253792
can O 0 0.00016183966
program O 0 0.00039242825
disease O 0 0.9393867
- O 0 0.025875142
like O 0 0.00020223527
systems O 0 0.00026302406
permanently O 0 0.0012880721
, O 0 0.00033611731
which O 0 0.00023067843
could O 0 0.00012971196
have O 0 0.00012210262
implications O 0 0.00015917198
for O 0 0.00016885645
current O 0 0.00031296472
and O 0 0.00023506457
future O 0 0.00023279512
therapeutic O 0 0.00043262774
strategies O 0 0.00035024656
for O 0 0.00041092667
this O 0 0.000590487
and O 0 0.0011522906
other O 0 0.0041437913
psychiatric B-Disease 2 0.99989414
disorders I-Disease 0 0.9975637
. O 0 0.007864285

Elevation O 0 0.09662527
of O 0 0.005807722
ADAM10 O 0 0.98898417
, O 0 0.02423302
ADAM17 O 0 0.9938672
, O 0 0.027418723
MMP O 0 0.99865603
- O 0 0.06283443
2 O 0 0.0005598761
and O 0 0.00074549805
MMP O 0 0.99216145
- O 0 0.011820042
9 O 0 0.00026616966
expression O 0 0.00024284008
with O 0 0.0002880605
media O 0 0.0036979406
degeneration O 0 0.99505484
features O 0 0.008975846
CaCl2 B-Chemical 0 0.999861
- O 0 0.026786393
induced O 0 0.00056254823
thoracic B-Disease 0 0.11726254
aortic I-Disease 0 0.6808477
aneurysm I-Disease 2 0.9995894
in O 0 0.0012842959
a O 0 0.001953218
rat O 0 0.0036725942
model O 0 0.004158885
. O 0 0.007077022

PURPOSE O 0 0.005681623
: O 0 0.0039697746
This O 0 0.002515904
study O 0 0.001551183
was O 0 0.00092968735
designed O 0 0.00061978167
to O 0 0.00042591017
establish O 0 0.0003180693
a O 0 0.00043714372
rat O 0 0.0005610519
model O 0 0.0002839808
of O 0 0.00041376968
thoracic B-Disease 0 0.085376516
aortic I-Disease 0 0.80518025
aneurysm I-Disease 2 0.9999566
( O 0 0.016256766
TAA B-Disease 0 0.99962103
) O 0 0.0018369508
by O 0 0.0004914777
calcium B-Chemical 0 0.9997576
chloride I-Chemical 0 0.99999297
( O 0 0.050449543
CaCl B-Chemical 0 0.9999132
( I-Chemical 0 0.0018338313
2 I-Chemical 0 0.00024812313
) I-Chemical 0 0.00069510523
) O 0 0.0013091965
- O 0 0.008857024
induced O 0 0.00048517386
arterial B-Disease 0 0.9954283
injury I-Disease 0 0.9956624
and O 0 0.00027653258
to O 0 0.000114959796
explore O 0 8.201461e-05
the O 0 0.00010913455
potential O 0 0.00013415024
role O 0 0.000100617246
of O 0 0.00023246618
a O 0 0.00038834775
disintegrin O 0 0.5824198
and O 0 0.001497178
metalloproteinase O 0 0.9698601
( O 0 0.017469049
ADAM O 0 0.9798086
) O 0 0.003075975
, O 0 0.00053519866
matrix O 0 0.00951776
metalloproteinases O 0 0.9861881
( O 0 0.0061048456
MMPs O 0 0.9148564
) O 0 0.00075554743
and O 0 0.00026971204
their O 0 0.0002531023
endogenous O 0 0.0003135076
inhibitors O 0 0.0038218081
( O 0 0.0020668663
TIMPs O 0 0.9498483
) O 0 0.0029081975
in O 0 0.002277364
TAA B-Disease 0 0.99660194
formation O 0 0.036005724
. O 0 0.007559888

METHODS O 0 0.0047788266
: O 0 0.00479339
Thoracic O 0 0.005368093
aorta O 0 0.0074389596
of O 0 0.0021039518
male O 0 0.0076556886
Sprague O 0 0.18264206
- O 0 0.014504445
Dawley O 0 0.010692608
rats O 0 0.0007445265
was O 0 0.0004110971
exposed O 0 0.00038808607
to O 0 0.00029995217
0 O 0 0.00042979638
. O 0 0.00044302584
5M O 0 0.90021497
CaCl B-Chemical 0 0.99946254
( I-Chemical 0 0.0009774592
2 I-Chemical 0 0.0004308621
) I-Chemical 0 0.00064524723
or O 0 0.0005575723
normal O 0 0.0012963722
saline O 0 0.020125777
( O 0 0.0036906784
NaCl B-Chemical 1 0.99105525
) O 0 0.0093564065
. O 0 0.008173266

After O 0 0.003172728
12weeks O 0 0.0051967925
, O 0 0.0020871097
animals O 0 0.0010154649
were O 0 0.00080052816
euthanized O 0 0.0006854
, O 0 0.00080774643
and O 0 0.0010864153
CaCl B-Chemical 0 0.9996935
( I-Chemical 0 0.0018012868
2 I-Chemical 0 0.00040704527
) I-Chemical 0 0.00092780124
- O 0 0.004024364
treated O 0 0.00048782062
, O 0 0.0018858119
CaCl B-Chemical 0 0.9997538
( I-Chemical 0 0.0014114764
2 I-Chemical 0 0.00028500636
) I-Chemical 0 0.0007138718
- O 0 0.002592604
untreated O 0 0.00027602524
( O 0 0.0003017854
n O 0 0.00018380735
= O 0 0.0003697108
12 O 0 0.00015211118
) O 0 0.0003106034
and O 0 0.00041436672
NaCl B-Chemical 1 0.9990157
- O 0 0.017073248
treated O 0 0.00038371974
aortic O 0 0.040346492
segments O 0 0.00030660504
( O 0 0.00031483333
n O 0 0.00022818182
= O 0 0.00043876772
12 O 0 0.00023792118
) O 0 0.0003964049
were O 0 0.00032903944
collected O 0 0.00034945624
for O 0 0.00056959863
histological O 0 0.0058431393
and O 0 0.0015966265
molecular O 0 0.0050016195
assessments O 0 0.0040941993
. O 0 0.006503459

MMP O 0 0.992765
- O 0 0.20145565
TIMP O 0 0.85582715
and O 0 0.0031857784
ADAM O 0 0.59869653
mRNAs O 0 0.0018135381
were O 0 0.0009738174
semi O 0 0.0013839132
- O 0 0.0017592859
quantitatively O 0 0.0005438114
analyzed O 0 0.0004893225
and O 0 0.00064202
protein O 0 0.0009622868
expressions O 0 0.0009890604
were O 0 0.0011399525
determined O 0 0.0013914091
by O 0 0.0027811087
immunohistochemistry O 0 0.009334211
. O 0 0.0079053175

RESULTS O 0 0.005277234
: O 0 0.0032155472
Despite O 0 0.0016367354
similar O 0 0.0009845824
external O 0 0.0011135866
diameters O 0 0.0023573716
among O 0 0.002472134
CaCl B-Chemical 0 0.99970716
( I-Chemical 0 0.001960508
2 I-Chemical 0 0.0004740639
) I-Chemical 0 0.0009929081
- O 0 0.0032064314
treated O 0 0.00039696065
, O 0 0.0005145624
non O 0 0.0027525886
- O 0 0.2405028
CaCl B-Chemical 0 0.9998541
( I-Chemical 0 0.0017509742
2 I-Chemical 0 0.0002812098
) I-Chemical 0 0.00069612643
- O 0 0.0026253222
treated O 0 0.00029418478
and O 0 0.0006720008
NaCl B-Chemical 1 0.9995765
- O 0 0.024627034
treated O 0 0.00028850272
segments O 0 0.0002866731
, O 0 0.00030947692
aneurymal O 0 0.005350707
alteration O 0 0.0003447743
( O 0 0.0003140931
n O 0 0.00018059708
= O 0 0.00041143995
6 O 0 0.00014516729
, O 0 0.00022354972
50 O 0 0.00022608037
% O 0 0.00026732092
) O 0 0.00046560855
, O 0 0.000365113
media O 0 0.004524914
degeneration O 0 0.9901452
with O 0 0.00029088487
regional O 0 0.00031713062
disruption O 0 0.00022173539
, O 0 0.00031107815
fragmentation O 0 0.0041220984
of O 0 0.00029508144
elastic O 0 0.005829132
fiber O 0 0.006830926
, O 0 0.00038572552
and O 0 0.00025025546
increased O 0 0.00034222897
collagen O 0 0.38026443
deposition O 0 0.042680975
( O 0 0.00046864626
n O 0 0.00020165223
= O 0 0.00042286605
12 O 0 0.00015699254
, O 0 0.00023694162
100 O 0 0.00031053054
% O 0 0.00027963854
) O 0 0.00035455517
were O 0 0.0002271863
demonstrated O 0 0.00023733413
in O 0 0.00049496425
CaCl B-Chemical 0 0.9990245
( I-Chemical 0 0.001503222
2 I-Chemical 0 0.0008294484
) I-Chemical 0 0.0018102352
- O 0 0.004218736
treated O 0 0.0027613568
segments O 0 0.004520234
. O 0 0.0069511873

MMP O 0 0.9881152
- O 0 0.045830976
2 O 0 0.0027890664
, O 0 0.0037226034
MMP O 0 0.9866877
- O 0 0.02648736
9 O 0 0.0009308746
, O 0 0.0012333961
ADAM O 0 0.83568734
- O 0 0.007862362
10 O 0 0.00039213354
and O 0 0.00050663133
ADAM O 0 0.9004311
- O 0 0.015714105
17 O 0 0.00037960324
mRNA O 0 0.00028770097
levels O 0 0.00021444462
were O 0 0.00020326508
increased O 0 0.00025450147
in O 0 0.0004409218
CaCl B-Chemical 0 0.9997634
( I-Chemical 0 0.0016732854
2 I-Chemical 0 0.0002755007
) I-Chemical 0 0.00075064437
- O 0 0.0025502765
treated O 0 0.00023313385
segments O 0 0.00026510668
( O 0 0.00028311386
all O 0 0.00014702506
p O 0 0.00017198348
< O 0 0.0001651662
0 O 0 0.00023203701
. O 0 0.0002105148
01 O 0 0.0013807175
) O 0 0.00039932577
, O 0 0.0002513454
with O 0 0.00018456743
trends O 0 0.00024525466
of O 0 0.00029042875
elevation O 0 0.11081297
in O 0 0.0006559157
CaCl B-Chemical 0 0.99983954
( I-Chemical 0 0.001810735
2 I-Chemical 0 0.00029385654
) I-Chemical 0 0.0007714053
- O 0 0.002350713
untreated O 0 0.0003081873
segments O 0 0.0003403375
, O 0 0.0003661512
as O 0 0.0003027707
compared O 0 0.00035617145
with O 0 0.0010630257
NaCl B-Chemical 1 0.9972626
- O 0 0.026606418
treated O 0 0.0031257428
segments O 0 0.00453991
. O 0 0.006672713

Immunohistochemistry O 0 0.010351871
displayed O 0 0.0020930257
significantly O 0 0.001472038
increased O 0 0.0011398525
expressions O 0 0.0010962762
of O 0 0.0025585114
MMP O 0 0.9990815
- O 0 0.12370537
2 O 0 0.00056592963
, O 0 0.001134471
MMP O 0 0.994414
- O 0 0.026881378
9 O 0 0.0003290504
, O 0 0.0005461484
ADAM O 0 0.85862565
- O 0 0.0071694623
10 O 0 0.0002325012
and O 0 0.0003479757
ADAM O 0 0.905811
- O 0 0.0155419465
17 O 0 0.0003327089
( O 0 0.00027466094
all O 0 0.00016716665
p O 0 0.00019439399
< O 0 0.0001892789
0 O 0 0.00025219514
. O 0 0.0002311443
01 O 0 0.0008790298
) O 0 0.00038145407
in O 0 0.00027991514
intima O 0 0.66354203
and O 0 0.00037268584
media O 0 0.0011137065
for O 0 0.00070905796
CaCl B-Chemical 0 0.99940145
( I-Chemical 0 0.0015879174
2 I-Chemical 0 0.0008319466
) I-Chemical 0 0.0017910736
- O 0 0.0041272324
treated O 0 0.0027520417
segments O 0 0.004515105
. O 0 0.0069537093

TIMP O 0 0.8247205
mRNA O 0 0.005187188
and O 0 0.0031667678
tissue O 0 0.005099637
levels O 0 0.001712149
did O 0 0.0014413272
not O 0 0.0010128563
differ O 0 0.0010699425
obviously O 0 0.0018648631
among O 0 0.0014172049
the O 0 0.0014038025
three O 0 0.0016126358
aortic O 0 0.025021147
segments O 0 0.005272758
. O 0 0.0077480585

CONCLUSION O 0 0.026281537
: O 0 0.004328182
This O 0 0.0025715919
study O 0 0.0016201957
establishes O 0 0.0014250489
a O 0 0.0018314891
TAA B-Disease 0 0.9976036
model O 0 0.00088405854
by O 0 0.0009780582
periarterial O 0 0.96992916
CaCl B-Chemical 0 0.9999306
( I-Chemical 0 0.0025543666
2 I-Chemical 0 0.00031044972
) I-Chemical 0 0.0004894209
exposure O 0 0.0012341534
in O 0 0.00023639869
rats O 0 0.00038083582
, O 0 0.0002718219
and O 0 0.00020188578
demonstrates O 0 0.00013159715
a O 0 0.00021156903
significant O 0 0.0001990246
elevation O 0 0.025431626
of O 0 0.00029086825
expression O 0 0.0004208818
of O 0 0.0029820206
MMP O 0 0.9995716
- O 0 0.1395838
2 O 0 0.0003149576
, O 0 0.0008201516
MMP O 0 0.9955231
- O 0 0.030291997
9 O 0 0.00030581187
, O 0 0.0005685198
ADAM10 O 0 0.9529913
and O 0 0.0012995314
ADAM17 O 0 0.93686545
in O 0 0.00062828977
the O 0 0.00071988796
pathogenesis O 0 0.0023405878
of O 0 0.0024530066
vascular O 0 0.6598212
remodeling O 0 0.09102807
. O 0 0.007809118

Suxamethonium B-Chemical 1 0.975934
induced O 0 0.005166113
prolonged O 0 0.007919286
apnea B-Disease 0 0.98797184
in O 0 0.0027289183
a O 0 0.0028646702
patient O 0 0.0029985511
receiving O 0 0.0054899487
electroconvulsive O 0 0.9810401
therapy O 0 0.00997851
. O 0 0.009404279

Suxamethonium B-Chemical 1 0.9852372
causes O 0 0.004087241
prolonged O 0 0.00562195
apnea B-Disease 0 0.9909116
in O 0 0.0012118465
patients O 0 0.001225579
in O 0 0.0006886438
whom O 0 0.008279764
pseudocholinesterase O 0 0.99939096
enzyme O 0 0.08117659
gets O 0 0.002199978
deactivated O 0 0.043913566
by O 0 0.0038386453
organophosphorus B-Chemical 0 0.9999995
( I-Chemical 0 0.15039842
OP I-Chemical 0 0.99994063
) I-Chemical 0 0.022631237
poisons I-Chemical 0 0.7453305
. O 0 0.00842218

Here O 0 0.005715169
, O 0 0.0035164356
we O 0 0.0015915685
present O 0 0.0011897802
a O 0 0.0012244082
similar O 0 0.00077173364
incident O 0 0.016098924
in O 0 0.00072563475
a O 0 0.0008722785
severely O 0 0.016499795
depressed B-Disease 2 0.9016745
patient O 0 0.0007060125
who O 0 0.00090748054
received O 0 0.0006995831
electroconvulsive O 0 0.96355313
therapy O 0 0.003660175
( O 0 0.0057605137
ECT O 0 0.9764692
) O 0 0.0070489044
. O 0 0.0077168397

Prolonged O 0 0.014140868
apnea B-Disease 0 0.96235466
in O 0 0.0020243332
our O 0 0.0013189221
case O 0 0.001117558
ensued O 0 0.0030565273
because O 0 0.0004940352
the O 0 0.00043636997
information O 0 0.0004079335
about O 0 0.00044525875
suicidal O 0 0.99919564
attempt O 0 0.00064693904
by O 0 0.0017341014
OP B-Chemical 0 0.9999958
compound I-Chemical 0 0.9247924
was O 0 0.00079242734
concealed O 0 0.0012701874
from O 0 0.0008683854
the O 0 0.001348718
treating O 0 0.0028016944
team O 0 0.0041903406
. O 0 0.0065605775

Curcumin B-Chemical 0 0.9999738
ameliorates O 0 0.9536121
cognitive B-Disease 0 0.9892573
dysfunction I-Disease 0 0.9568087
and O 0 0.0044307755
oxidative O 0 0.992722
damage O 0 0.9923591
in O 0 0.03679886
phenobarbitone B-Chemical 0 0.9999995
and O 0 0.123501755
carbamazepine B-Chemical 1 0.9999993
administered O 0 0.0065943394
rats O 0 0.0062739924
. O 0 0.006933692

The O 0 0.0042867875
antiepileptic O 0 0.99806005
drugs O 0 0.874805
, O 0 0.082620956
phenobarbitone B-Chemical 0 0.9999995
and O 0 0.10448963
carbamazepine B-Chemical 1 0.99999976
are O 0 0.00067289197
well O 0 0.00044566172
known O 0 0.00052064325
to O 0 0.00044876456
cause O 0 0.0010601701
cognitive B-Disease 0 0.8173931
impairment I-Disease 0 0.23375623
on O 0 0.0013806379
chronic O 0 0.6643694
use O 0 0.005144729
. O 0 0.0071316278

The O 0 0.0030568226
increase O 0 0.0020242764
in O 0 0.0016496149
free O 0 0.001912856
radical O 0 0.4619859
generation O 0 0.0014011166
has O 0 0.0006074844
been O 0 0.00045460789
implicated O 0 0.00032534526
as O 0 0.00031925226
one O 0 0.00027381696
of O 0 0.0003085551
the O 0 0.00026898168
important O 0 0.00025019085
mechanisms O 0 0.0003528772
of O 0 0.00088053575
cognitive B-Disease 0 0.9178385
impairment I-Disease 0 0.5683357
by O 0 0.0028151374
antiepileptic O 0 0.9991935
drugs O 0 0.42921472
. O 0 0.006652308

Curcumin B-Chemical 0 0.9999361
has O 0 0.0049102544
shown O 0 0.0033583303
antioxidant O 0 0.9966415
, O 0 0.005071219
anti O 0 0.4598957
- O 0 0.108191706
inflammatory O 0 0.6923417
and O 0 0.0039941235
neuro O 0 0.46585575
- O 0 0.017532704
protective O 0 0.009534591
properties O 0 0.0060009216
. O 0 0.009050606

Therefore O 0 0.0036837906
, O 0 0.0031027335
the O 0 0.0016062871
present O 0 0.0010233696
study O 0 0.0010193703
was O 0 0.0005962901
carried O 0 0.00034587123
out O 0 0.00026049797
to O 0 0.00022613427
investigate O 0 0.00014010529
the O 0 0.00020886934
effect O 0 0.00024289219
of O 0 0.0008102738
chronic O 0 0.99311936
curcumin B-Chemical 1 0.99999654
administration O 0 0.27951163
on O 0 0.00062855304
phenobarbitone B-Chemical 0 0.9999999
- O 0 0.5762653
and O 0 0.03221021
carbamazepine B-Chemical 1 0.9999999
- O 0 0.10087622
induced O 0 0.00072654913
cognitive B-Disease 0 0.92288536
impairment I-Disease 0 0.35081124
and O 0 0.0012995802
oxidative O 0 0.92511815
stress O 0 0.40677384
in O 0 0.0031871402
rats O 0 0.0059505785
. O 0 0.006286565

Pharmacokinetic O 0 0.16588087
interactions O 0 0.0055285674
of O 0 0.0063094366
curcumin B-Chemical 1 0.9999291
with O 0 0.13481578
phenobarbitone B-Chemical 0 0.9999995
and O 0 0.16455676
carbamazepine B-Chemical 1 0.99999905
were O 0 0.0032148948
also O 0 0.0033792977
studied O 0 0.005691992
. O 0 0.008640157

Vehicle O 0 0.66057014
/ O 0 0.015883343
drugs O 0 0.10380896
were O 0 0.002389038
administered O 0 0.0018725174
daily O 0 0.001861675
for O 0 0.0018545956
21days O 0 0.053868897
to O 0 0.002457261
male O 0 0.009280369
Wistar O 0 0.026222052
rats O 0 0.007248215
. O 0 0.008972793

Passive O 0 0.024614496
avoidance O 0 0.0073409355
paradigm O 0 0.0028082058
and O 0 0.0021294777
elevated O 0 0.0035552667
plus O 0 0.0011577107
maze O 0 0.03362707
test O 0 0.0009992503
were O 0 0.0008734559
used O 0 0.0008634905
to O 0 0.0010788507
assess O 0 0.0013088261
cognitive O 0 0.13556969
function O 0 0.004512279
. O 0 0.008056963

At O 0 0.0027243071
the O 0 0.0019491664
end O 0 0.0012276366
of O 0 0.0012099872
study O 0 0.0010088317
period O 0 0.0006367975
, O 0 0.0016819903
serum O 0 0.9414546
phenobarbitone B-Chemical 0 0.9999999
and O 0 0.14284971
carbamazepine B-Chemical 1 0.9999999
, O 0 0.0021992736
whole O 0 0.0008690079
brain O 0 0.4252268
malondialdehyde B-Chemical 1 1.0
and O 0 0.0024589063
reduced O 0 0.027375007
glutathione B-Chemical 0 0.99998486
levels O 0 0.0018391868
were O 0 0.002160707
estimated O 0 0.003272032
. O 0 0.0063926443

The O 0 0.003264337
administration O 0 0.011928711
of O 0 0.013793567
phenobarbitone B-Chemical 0 0.9999994
and O 0 0.21516848
carbamazepine B-Chemical 1 0.9999999
for O 0 0.0017640187
21days O 0 0.22611725
caused O 0 0.00036523674
a O 0 0.00046084326
significant O 0 0.00039944152
impairment B-Disease 0 0.5141321
of I-Disease 0 0.0005284356
learning I-Disease 0 0.011910543
and I-Disease 0 0.0005029081
memory I-Disease 0 0.075092405
as O 0 0.0004055537
well O 0 0.0004885254
as O 0 0.00067438616
an O 0 0.0012170172
increased O 0 0.0025611448
oxidative O 0 0.9583248
stress O 0 0.75798917
. O 0 0.010616654

Concomitant O 0 0.22456215
curcumin B-Chemical 1 0.9998535
administration O 0 0.1597933
prevented O 0 0.0034601565
the O 0 0.0016246105
cognitive B-Disease 0 0.94341093
impairment I-Disease 0 0.506268
and O 0 0.0007016667
decreased O 0 0.0005852345
the O 0 0.00042509948
increased O 0 0.0007272689
oxidative O 0 0.92406577
stress O 0 0.32531518
induced O 0 0.0012454712
by O 0 0.0014074215
these O 0 0.0032681748
antiepileptic O 0 0.999323
drugs O 0 0.48007736
. O 0 0.006813328

Curcumin B-Chemical 0 0.9999857
co O 0 0.98350775
- O 0 0.2711729
administration O 0 0.04840412
did O 0 0.0013958219
not O 0 0.00067185867
cause O 0 0.00074636424
any O 0 0.0004362292
significant O 0 0.00041182726
alteration O 0 0.0005804142
in O 0 0.00032519203
the O 0 0.00034550426
serum O 0 0.11298711
concentrations O 0 0.0019833266
of O 0 0.00080693664
both O 0 0.002271186
phenobarbitone B-Chemical 0 0.9999974
as O 0 0.0010556113
well O 0 0.0015177637
as O 0 0.003858632
carbamazepine B-Chemical 1 0.9999957
. O 0 0.008448635

These O 0 0.003385245
results O 0 0.0020824603
show O 0 0.0014421178
that O 0 0.0014862005
curcumin B-Chemical 1 0.9998684
has O 0 0.0010141201
beneficial O 0 0.0009366402
effect O 0 0.0004918503
in O 0 0.0003931215
mitigating O 0 0.0044642375
the O 0 0.00041393773
deterioration B-Disease 0 0.11450856
of I-Disease 0 0.00057428813
cognitive I-Disease 0 0.6295341
functions I-Disease 0 0.00024932143
and O 0 0.0004938953
oxidative O 0 0.97568136
damage O 0 0.9430592
in O 0 0.00038472848
rats O 0 0.00047679164
treated O 0 0.0004048084
with O 0 0.00356637
phenobarbitone B-Chemical 0 0.99999976
and O 0 0.037265334
carbamazepine B-Chemical 1 0.99999976
without O 0 0.0005672029
significantly O 0 0.0005529594
altering O 0 0.0008009647
their O 0 0.0013835211
serum O 0 0.22897717
concentrations O 0 0.014679883
. O 0 0.006629901

The O 0 0.003023544
findings O 0 0.0023715328
suggest O 0 0.0012133216
that O 0 0.0014520785
curcumin B-Chemical 1 0.9998379
can O 0 0.0007603355
be O 0 0.00051287253
considered O 0 0.00033604298
as O 0 0.00029497934
a O 0 0.00032296937
potential O 0 0.0003054852
safe O 0 0.0004572695
and O 0 0.00027611313
effective O 0 0.0003175445
adjuvant O 0 0.012666517
to O 0 0.0007239622
phenobarbitone B-Chemical 0 0.99999976
and O 0 0.05752755
carbamazepine B-Chemical 1 0.9999999
therapy O 0 0.003372898
in O 0 0.00033061413
preventing O 0 0.0015025851
cognitive B-Disease 0 0.9154436
impairment I-Disease 0 0.27928808
associated O 0 0.0009929342
with O 0 0.0013315793
these O 0 0.0024369007
drugs O 0 0.22837003
. O 0 0.006289896

Can O 0 0.041057054
angiogenesis O 0 0.71722835
be O 0 0.0033377649
a O 0 0.0025789116
target O 0 0.0018215872
of O 0 0.0020660923
treatment O 0 0.0027129694
for O 0 0.004116995
ribavirin B-Chemical 1 0.99998844
associated O 0 0.7267442
hemolytic B-Disease 2 0.9999995
anemia I-Disease 2 0.9999989
? O 0 0.41576028

BACKGROUND O 0 0.03653282
/ O 0 0.015819581
AIMS O 0 0.08430608
: O 0 0.0032127502
Recently O 0 0.0037394222
ribavirin B-Chemical 1 0.9999558
has O 0 0.001039422
been O 0 0.00058107893
found O 0 0.0003620678
to O 0 0.0002805981
inhibit O 0 0.00028136882
angiogenesis O 0 0.92905265
and O 0 0.00045476694
a O 0 0.00030157628
number O 0 0.00019028827
of O 0 0.00035703907
angiogenesis O 0 0.9013875
inhibitors O 0 0.001931518
such O 0 0.00021942092
as O 0 0.0003640076
sunitinib B-Chemical 0 0.9997658
and O 0 0.001688163
sorafenib B-Chemical 0 0.9998247
have O 0 0.0003697184
been O 0 0.00045422846
found O 0 0.00055761007
to O 0 0.00089459727
cause O 0 0.004271537
acute O 0 0.9940165
hemolysis B-Disease 0 0.9999871
. O 0 0.015121863

We O 0 0.0033539375
aimed O 0 0.0022276095
to O 0 0.0012566467
investigate O 0 0.0006056291
whether O 0 0.0004606149
there O 0 0.00043366334
is O 0 0.00045838323
a O 0 0.00040869438
relation O 0 0.00022292187
between O 0 0.00025588076
hemoglobin O 0 0.97881967
, O 0 0.002711553
haptoglobin O 0 0.9961909
and O 0 0.0010268923
angiogenesis O 0 0.9503799
soluble O 0 0.00364023
markers O 0 0.0011492693
which O 0 0.00035127075
are O 0 0.00026297566
modifiable O 0 0.008694017
and O 0 0.00038316008
can O 0 0.00030633388
help O 0 0.00047186384
in O 0 0.00061101525
developing O 0 0.0024722752
strategies O 0 0.0017801997
against O 0 0.004729278
anemia B-Disease 0 0.9999621
. O 0 0.011690431

METHODS O 0 0.004487701
: O 0 0.0041651167
Fourteen O 0 0.0036730238
patients O 0 0.0021697455
chronically B-Disease 0 0.004796951
infected I-Disease 0 0.0024424037
with I-Disease 0 0.047182247
hepatitis I-Disease 2 1.0
C I-Disease 0 0.9999993
virus I-Disease 0 0.9702927
were O 0 0.0011633852
treated O 0 0.00094841525
by O 0 0.0012856042
pegylated B-Chemical 0 0.99991107
interferon I-Chemical 0 0.999998
alpha I-Chemical 0 0.9954047
2a I-Chemical 0 0.033850614
and O 0 0.018643556
ribavirin B-Chemical 1 0.99993813
. O 0 0.013340642

Serum O 0 0.8501583
hemoglobin O 0 0.97974235
, O 0 0.0090680495
haptoglobin O 0 0.9919613
and O 0 0.0023264794
angiogenesis O 0 0.93812746
markers O 0 0.0023460435
of O 0 0.0009553841
vascular O 0 0.811174
endothelial O 0 0.9766568
growth O 0 0.03409462
factor O 0 0.031716324
and O 0 0.0011578458
angiopoetin O 0 0.37914
- O 0 0.012342585
2 O 0 0.00037754685
were O 0 0.00038559426
investigated O 0 0.00042274094
before O 0 0.00057760515
and O 0 0.0012374729
after O 0 0.0016507542
therapy O 0 0.004836306
. O 0 0.00648771

RESULTS O 0 0.005851691
: O 0 0.0037267136
We O 0 0.0019220529
observed O 0 0.001363254
a O 0 0.0013618
significant O 0 0.000981414
decrease O 0 0.000895762
in O 0 0.0010206355
haptoglobin O 0 0.985023
levels O 0 0.00068517454
at O 0 0.0005210005
the O 0 0.000559324
end O 0 0.0005803757
of O 0 0.0010635696
the O 0 0.0014125507
treatment O 0 0.0024636688
period O 0 0.003474025
. O 0 0.006752894

Hemoglobin O 0 0.99589914
levels O 0 0.0066097695
also O 0 0.0057303547
decreased O 0 0.0067168907
but O 0 0.0072460882
insignificantly O 0 0.064510606
by O 0 0.008091863
treatment O 0 0.010861479
. O 0 0.01462504

In O 0 0.0034808628
contrast O 0 0.002386502
with O 0 0.0015641534
the O 0 0.0011147924
literature O 0 0.0015273489
, O 0 0.0012642882
serum O 0 0.09481307
levels O 0 0.00058621675
of O 0 0.0009460868
angiogenesis O 0 0.9709269
factors O 0 0.0071173673
did O 0 0.00046986787
not O 0 0.0003019779
change O 0 0.00041353542
significantly O 0 0.00050824834
by O 0 0.0010385114
pegylated B-Chemical 0 0.9998816
interferon I-Chemical 0 0.99999666
and O 0 0.25848544
ribavirin B-Chemical 1 0.99998677
therapy O 0 0.142661
. O 0 0.008448279

We O 0 0.0037769612
found O 0 0.0023397496
no O 0 0.0015035162
correlation O 0 0.0012804552
of O 0 0.0017938234
angiogenesis O 0 0.9144465
soluble O 0 0.006201859
markers O 0 0.0025351124
with O 0 0.0014366597
either O 0 0.0018375708
hemoglobin O 0 0.9622976
or O 0 0.0046680444
haptoglobin O 0 0.99469167
. O 0 0.009800522

CONCLUSION O 0 0.03271729
: O 0 0.004368602
This O 0 0.0024966947
is O 0 0.0012969817
the O 0 0.0008490635
first O 0 0.00056403736
study O 0 0.00058736297
in O 0 0.00036254257
the O 0 0.00028853107
literature O 0 0.000338284
investigating O 0 0.00019811091
a O 0 0.00023565383
link O 0 0.00015898101
between O 0 0.00017777477
angiogenesis O 0 0.91073686
soluble O 0 0.00676043
markers O 0 0.0054578534
and O 0 0.0037098571
ribavirin B-Chemical 1 0.9999945
induced O 0 0.022983622
anemia B-Disease 0 0.9999975
in O 0 0.000804834
patients O 0 0.0032865813
with O 0 0.022580922
hepatitis B-Disease 2 1.0
C I-Disease 0 0.99999905
and O 0 0.0042828545
we O 0 0.0004081585
could O 0 0.000502376
not O 0 0.0007194185
find O 0 0.0010574526
any O 0 0.0016720057
relation O 0 0.0026544023
. O 0 0.0062421057

Future O 0 0.0039493684
research O 0 0.0028412868
with O 0 0.0017603498
larger O 0 0.0012226403
number O 0 0.00087922957
of O 0 0.00087406114
patients O 0 0.0008562155
is O 0 0.000455564
needed O 0 0.00027759233
to O 0 0.00026633232
find O 0 0.00025003986
out O 0 0.00023987248
modifiable O 0 0.0033409325
factors O 0 0.0007269958
that O 0 0.0003147091
will O 0 0.0003328139
improve O 0 0.00035110876
the O 0 0.0005877542
safety O 0 0.0013657386
of O 0 0.0026493939
ribavirin B-Chemical 1 0.9999367
therapy O 0 0.058796067
. O 0 0.008015614

Reduction O 0 0.007456742
in O 0 0.0030843036
injection O 0 0.004646841
pain B-Disease 0 0.8333916
using O 0 0.001620373
buffered O 0 0.62823683
lidocaine B-Chemical 0 0.9996978
as O 0 0.0010385361
a O 0 0.00120562
local O 0 0.0016687582
anesthetic O 0 0.024929482
before O 0 0.0015000377
cardiac O 0 0.017991787
catheterization O 0 0.007544177
. O 0 0.0070089996

Previous O 0 0.0036068747
reports O 0 0.0023937116
have O 0 0.0014745914
suggested O 0 0.0011171344
that O 0 0.0010215251
pain B-Disease 0 0.89693844
associated O 0 0.00074077625
with O 0 0.0005149195
the O 0 0.00039802445
injection O 0 0.0008354297
of O 0 0.0013200305
lidocaine B-Chemical 0 0.99990654
is O 0 0.00040036713
related O 0 0.00026019165
to O 0 0.0003387815
the O 0 0.0005354219
acidic O 0 0.021599587
pH O 0 0.049516056
of O 0 0.0019068895
the O 0 0.0025612763
solution O 0 0.017214939
. O 0 0.007489795

To O 0 0.0026074313
determine O 0 0.0011972904
if O 0 0.0010774082
the O 0 0.0008218862
addition O 0 0.00050941337
of O 0 0.00067249924
a O 0 0.00070261926
buffering O 0 0.008257758
solution O 0 0.0034179382
to O 0 0.00021785579
adjust O 0 0.00017267096
the O 0 0.00022843826
pH O 0 0.062231813
of O 0 0.00084003276
lidocaine B-Chemical 0 0.99974257
into O 0 0.00011652088
the O 0 0.00014837427
physiologic O 0 0.00034283163
range O 0 0.00018920745
would O 0 0.00014925191
reduce O 0 0.00015353868
pain B-Disease 0 0.651566
during O 0 0.00014506295
injection O 0 0.00035157785
, O 0 0.00024592693
we O 0 0.00013973558
performed O 0 0.00018415152
a O 0 0.00028188946
blinded O 0 0.0003342792
randomized O 0 0.00033200707
study O 0 0.00043837493
in O 0 0.0005342563
patients O 0 0.0010235616
undergoing O 0 0.0014786172
cardiac O 0 0.02595383
catheterization O 0 0.006938812
. O 0 0.006076122

Twenty O 0 0.005269898
patients O 0 0.0027125666
were O 0 0.0014719609
asked O 0 0.0008313214
to O 0 0.00063202577
quantify O 0 0.00041201417
the O 0 0.0004548667
severity O 0 0.0016498144
of O 0 0.000768535
pain B-Disease 0 0.87982047
after O 0 0.00018744552
receiving O 0 0.00031355486
standard O 0 0.0002593711
lidocaine B-Chemical 0 0.99952745
in O 0 0.00021341942
one O 0 0.00018330086
femoral O 0 0.0015347486
area O 0 0.00041696103
and O 0 0.00052550744
buffered O 0 0.59730315
lidocaine B-Chemical 0 0.99937797
in O 0 0.00060278707
the O 0 0.0008084664
opposite O 0 0.0017446638
femoral O 0 0.024718981
area O 0 0.0053323144
. O 0 0.0065894313

The O 0 0.0027389927
mean O 0 0.0016424606
pain B-Disease 0 0.3486395
score O 0 0.0010742013
for O 0 0.0010515151
buffered O 0 0.7731409
lidocaine B-Chemical 0 0.9999244
was O 0 0.0005735975
significantly O 0 0.00034546407
lower O 0 0.00023507017
than O 0 0.00013687769
the O 0 0.00013044637
mean O 0 9.553428e-05
score O 0 0.00013284241
for O 0 0.00014142969
standard O 0 0.00021027768
lidocaine B-Chemical 0 0.99974734
( O 0 0.0004801544
2 O 0 0.0001731344
. O 0 0.00014674076
7 O 0 0.00015491809
+ O 0 0.00066838367
/ O 0 0.0068728556
- O 0 0.008722423
1 O 0 0.00020880123
. O 0 0.00016454278
9 O 0 0.00016276666
vs O 0 0.00021342674
. O 0 0.00017355075
3 O 0 0.00016555407
. O 0 0.00017996656
8 O 0 0.00021677997
+ O 0 0.00068873796
/ O 0 0.004992127
- O 0 0.006702073
2 O 0 0.0003524794
. O 0 0.00035377027
2 O 0 0.00045157614
, O 0 0.00078790507
P O 0 0.017256683
= O 0 0.0017863103
0 O 0 0.0017131476
. O 0 0.0023538219
03 O 0 0.013028188
) O 0 0.0064924574
. O 0 0.00863738

The O 0 0.003637058
pH O 0 0.025400816
adjustment O 0 0.0020683138
of O 0 0.0015164288
standard O 0 0.0012096444
lidocaine B-Chemical 0 0.99983037
can O 0 0.00046414335
be O 0 0.0003670312
accomplished O 0 0.00036911457
easily O 0 0.00031169027
in O 0 0.00021153351
the O 0 0.00020191929
catheterization O 0 0.00041024192
laboratory O 0 0.00023544228
before O 0 0.00011713717
injection O 0 0.00021119634
and O 0 0.00017656255
results O 0 0.0001615692
in O 0 0.00019326844
a O 0 0.000276283
reduction O 0 0.00037941764
of O 0 0.0003766201
the O 0 0.0004652315
pain B-Disease 0 0.77524847
occurring O 0 0.00057880214
during O 0 0.00047228616
the O 0 0.0009149811
infiltration O 0 0.22196168
of O 0 0.0031264652
tissues O 0 0.0074696075
. O 0 0.0069297957

Effect O 0 0.0051944563
of O 0 0.0055846744
L B-Chemical 0 0.98756415
- I-Chemical 0 0.4064082
alpha I-Chemical 0 0.982011
- I-Chemical 0 0.6575509
glyceryl I-Chemical 0 0.9996815
- I-Chemical 0 0.10732448
phosphorylcholine I-Chemical 0 0.15469073
on O 0 0.0016598365
amnesia B-Disease 0 0.9998271
caused O 0 0.0040183063
by O 0 0.01478679
scopolamine B-Chemical 1 0.99999595
. O 0 0.012534163

The O 0 0.0031657293
present O 0 0.002004407
study O 0 0.0017955286
was O 0 0.0010708469
carried O 0 0.0006072257
out O 0 0.00044346545
to O 0 0.0003869099
test O 0 0.00038281144
the O 0 0.00030597838
effects O 0 0.00042333835
of O 0 0.0010906496
L B-Chemical 0 0.9974482
- I-Chemical 0 0.53271693
alpha I-Chemical 0 0.98492104
- I-Chemical 0 0.55548114
glycerylphosphorylcholine I-Chemical 0 0.9794072
( O 0 0.009498971
L B-Chemical 0 0.9949037
- I-Chemical 0 0.36396074
alpha I-Chemical 0 0.97701216
- I-Chemical 0 0.62351674
GFC I-Chemical 0 0.99889094
) O 0 0.0013472171
on O 0 0.00037727252
memory B-Disease 2 0.96359545
impairment I-Disease 2 0.96693957
induced O 0 0.0017495913
by O 0 0.0071861017
scopolamine B-Chemical 1 0.99999833
in O 0 0.004412507
man O 0 0.34646118
. O 0 0.008144545

Thirty O 0 0.008799239
- O 0 0.0073700245
two O 0 0.002473244
healthy O 0 0.0039903675
young O 0 0.0036787498
volunteers O 0 0.0019600154
were O 0 0.0011676695
randomly O 0 0.00081526843
allocated O 0 0.0010095664
to O 0 0.0012706852
four O 0 0.0016042541
different O 0 0.002496957
groups O 0 0.0046837805
. O 0 0.008224874

They O 0 0.0049496084
were O 0 0.0023664685
given O 0 0.0012743941
a O 0 0.0012100263
ten O 0 0.00064974616
day O 0 0.0005365857
pretreatment O 0 0.0039829756
with O 0 0.000532715
either O 0 0.00074157125
L B-Chemical 0 0.9955627
- I-Chemical 0 0.5064868
alpha I-Chemical 0 0.9882804
- I-Chemical 0 0.69559604
GFC I-Chemical 0 0.9990404
or O 0 0.0005892863
placebo O 0 0.045571588
, O 0 0.0004171272
p O 0 0.00029382823
. O 0 0.000246058
o O 0 0.008158254
. O 0 0.00027615763
, O 0 0.00032180818
and O 0 0.0002270271
on O 0 0.00015234953
the O 0 0.00021998525
eleventh O 0 0.0011832628
day O 0 0.00028173847
either O 0 0.0007789311
scopolamine B-Chemical 1 0.99999905
or O 0 0.0011675112
placebo O 0 0.060605902
, O 0 0.0015513898
i O 0 0.003630235
. O 0 0.0024180904
m O 0 0.008545054
. O 0 0.007443904

Before O 0 0.0040828795
and O 0 0.0029049485
0 O 0 0.0021172843
. O 0 0.0013147371
5 O 0 0.00094095373
, O 0 0.0010248583
1 O 0 0.0007020985
, O 0 0.0007227919
2 O 0 0.0004893106
, O 0 0.0005238451
3 O 0 0.00033501015
, O 0 0.00038872127
and O 0 0.00032976078
6 O 0 0.00024005439
h O 0 0.00028150485
after O 0 0.00020657269
injection O 0 0.00037399612
the O 0 0.000318502
subjects O 0 0.0004926811
were O 0 0.0004589024
given O 0 0.00049098744
attention O 0 0.0012607751
and O 0 0.0017689931
mnemonic O 0 0.026618447
tests O 0 0.0058987583
. O 0 0.007152741

The O 0 0.003090506
findings O 0 0.0025231338
of O 0 0.0018232153
this O 0 0.0011897365
study O 0 0.00093833235
indicate O 0 0.00044131515
that O 0 0.00043246575
the O 0 0.00052141486
drug O 0 0.14219128
is O 0 0.0003885516
able O 0 0.0002438696
to O 0 0.00026532667
antagonize O 0 0.00054690166
impairment B-Disease 0 0.15287751
of I-Disease 0 0.0006510889
attention I-Disease 0 0.0013046612
and I-Disease 0 0.00093045353
memory I-Disease 0 0.22220363
induced O 0 0.0026322724
by O 0 0.014209447
scopolamine B-Chemical 1 0.9999968
. O 0 0.010139041

Safety O 0 0.030041328
of O 0 0.019451454
capecitabine B-Chemical 1 0.9967378
: O 0 0.022175483
a O 0 0.019579958
review O 0 0.024898864
. O 0 0.0257191

IMPORTANCE O 0 0.009518142
OF O 0 0.005942305
THE O 0 0.004570201
FIELD O 0 0.07538197
: O 0 0.0037712676
Fluoropyrimidines B-Chemical 0 0.9379573
, O 0 0.0013321076
in O 0 0.0006162481
particular O 0 0.00044348722
5 B-Chemical 0 0.00045886653
- I-Chemical 0 0.012644151
fluorouracil I-Chemical 0 0.99855596
( O 0 0.0009061521
5 B-Chemical 0 0.00034222458
- I-Chemical 0 0.015971752
FU I-Chemical 0 0.6314429
) O 0 0.0007839933
, O 0 0.00034556567
have O 0 0.00017534521
been O 0 0.00018122134
the O 0 0.00016703921
mainstay O 0 0.00047289496
of O 0 0.00023727845
treatment O 0 0.00025145852
for O 0 0.0001671262
several O 0 0.00017113677
solid O 0 0.041402128
tumors B-Disease 0 0.95289874
, O 0 0.0006209228
including O 0 0.00039762052
colorectal B-Disease 0 0.9716119
, I-Disease 0 0.003341315
breast I-Disease 0 0.7168428
and I-Disease 0 0.00061333744
head I-Disease 0 0.06362554
and I-Disease 0 0.00089514034
neck I-Disease 0 0.5683175
cancers I-Disease 2 0.9959928
, O 0 0.0016280712
for O 0 0.0010761311
> O 0 0.0024751718
40 O 0 0.0022973258
years O 0 0.00406196
. O 0 0.006631497

AREAS O 0 0.010053801
COVERED O 0 0.010615642
IN O 0 0.022689791
THIS O 0 0.015104615
REVIEW O 0 0.008983429
: O 0 0.0019633193
This O 0 0.0012765817
article O 0 0.00087924674
reviews O 0 0.00080023037
the O 0 0.0005108385
pharmacology O 0 0.0023334348
and O 0 0.00045428515
efficacy O 0 0.00062408805
of O 0 0.00085149094
capecitabine B-Chemical 1 0.99860495
with O 0 0.00068606646
a O 0 0.00074683485
special O 0 0.00078971736
emphasis O 0 0.0012774529
on O 0 0.0011572184
its O 0 0.003354824
safety O 0 0.005769495
. O 0 0.0066969544

WHAT O 0 0.016934978
THE O 0 0.007815601
READER O 0 0.72079384
WILL O 0 0.21396133
GAIN O 0 0.103277504
: O 0 0.0018874146
The O 0 0.0008817947
reader O 0 0.0020090952
will O 0 0.0004939731
gain O 0 0.0005577634
better O 0 0.00036143634
insight O 0 0.00024554384
into O 0 0.00016051366
the O 0 0.00020510836
safety O 0 0.00034093406
of O 0 0.00042972306
capecitabine B-Chemical 1 0.9979886
in O 0 0.00023276916
special O 0 0.00022731499
populations O 0 0.0003095469
such O 0 0.0001849469
as O 0 0.00021200316
patients O 0 0.00037853123
with O 0 0.00037351868
advanced O 0 0.0068122465
age O 0 0.0015889821
, O 0 0.0014834024
renal B-Disease 0 0.79453325
and I-Disease 0 0.00341729
kidney I-Disease 0 0.91969144
disease I-Disease 0 0.98530626
. O 0 0.0096829515

We O 0 0.004918784
also O 0 0.0032789535
explore O 0 0.0021282479
different O 0 0.0022199473
dosing O 0 0.003521897
and O 0 0.0025721986
schedules O 0 0.0032396687
of O 0 0.0056239525
capecitabine B-Chemical 1 0.99954563
administration O 0 0.21591458
. O 0 0.011061878

TAKE O 0 0.068736725
HOME O 0 0.092397496
MESSAGE O 0 0.13755614
: O 0 0.0065934183
Capecitabine B-Chemical 0 0.9986993
is O 0 0.001448941
an O 0 0.0013808076
oral O 0 0.31059405
prodrug O 0 0.6937148
of O 0 0.0007915934
5 B-Chemical 0 0.00043637914
- I-Chemical 0 0.017169803
FU I-Chemical 0 0.36213887
and O 0 0.00030383564
was O 0 0.00022266612
developed O 0 0.0002371561
to O 0 0.00014659166
fulfill O 0 0.00014956348
the O 0 0.0001559431
need O 0 0.00014811261
for O 0 0.00017856545
a O 0 0.0002601604
more O 0 0.00025253536
convenient O 0 0.00029866234
therapy O 0 0.00031965002
and O 0 0.00029004633
provide O 0 0.00028940773
an O 0 0.0005162371
improved O 0 0.00082594744
safety O 0 0.0013808778
/ O 0 0.0028965054
efficacy O 0 0.0028965534
profile O 0 0.0039254255
. O 0 0.006595542

It O 0 0.004501116
has O 0 0.0022543878
shown O 0 0.0013597679
promising O 0 0.0012988212
results O 0 0.00077148766
alone O 0 0.0007186763
or O 0 0.00054937263
in O 0 0.00042570924
combination O 0 0.0005063875
with O 0 0.000383854
other O 0 0.00042184623
chemotherapeutic O 0 0.25139907
agents O 0 0.02019068
in O 0 0.00057538424
colorectal B-Disease 0 0.98399067
, I-Disease 0 0.0072425418
breast I-Disease 0 0.88514763
, I-Disease 0 0.0017229656
pancreaticobiliary I-Disease 0 0.69803303
, I-Disease 0 0.0018617795
gastric I-Disease 0 0.56341255
, I-Disease 0 0.0017718828
renal I-Disease 0 0.77810574
cell I-Disease 0 0.0038190156
and I-Disease 0 0.0012323457
head I-Disease 0 0.07285501
and I-Disease 0 0.002994514
neck I-Disease 0 0.665353
cancers I-Disease 2 0.9945081
. O 0 0.00993563

The O 0 0.0033408166
most O 0 0.0028976237
commonly O 0 0.0024142952
reported O 0 0.0017123895
toxic O 0 0.3752499
effects O 0 0.0013365682
of O 0 0.0019723393
capecitabine B-Chemical 1 0.99983466
are O 0 0.0022910973
diarrhea B-Disease 0 0.9999808
, O 0 0.20968413
nausea B-Disease 2 0.99999976
, O 0 0.05497211
vomiting B-Disease 0 0.99999094
, O 0 0.0063739656
stomatitis B-Disease 2 0.9998851
and O 0 0.0032437241
hand B-Disease 2 0.00494276
- I-Disease 2 0.053828843
foot I-Disease 2 0.2022432
syndrome I-Disease 2 0.65369326
. O 0 0.0077811554

Capecitabine B-Chemical 0 0.99780947
has O 0 0.0029496986
a O 0 0.0023350404
well O 0 0.0015374002
- O 0 0.0044004032
established O 0 0.00085092115
safety O 0 0.0007866451
profile O 0 0.00045352994
and O 0 0.00041684342
can O 0 0.00025750065
be O 0 0.0002572658
given O 0 0.00019029026
safely O 0 0.0002800235
to O 0 0.0002149158
patients O 0 0.00036874306
with O 0 0.00038875316
advanced O 0 0.005760274
age O 0 0.0016481596
, O 0 0.0015333701
hepatic B-Disease 0 0.7947696
and I-Disease 0 0.00395162
renal I-Disease 0 0.9740096
dysfunctions I-Disease 0 0.946752
. O 0 0.0077867047

Levodopa B-Chemical 0 0.99998796
- O 0 0.21140677
induced O 0 0.008996993
dyskinesias B-Disease 2 0.99998903
in O 0 0.0015074916
patients O 0 0.0015029758
with O 0 0.0014296091
Parkinson B-Disease 0 0.9994735
' I-Disease 0 0.0010623473
s I-Disease 0 0.00086702674
disease I-Disease 0 0.51063174
: O 0 0.0009314575
filling O 0 0.0012275606
the O 0 0.0006570463
bench O 0 0.0052975887
- O 0 0.0027680642
to O 0 0.0013585226
- O 0 0.004674482
bedside O 0 0.0043150773
gap O 0 0.005358737
. O 0 0.008113474

Levodopa B-Chemical 0 0.9999484
is O 0 0.003777225
the O 0 0.0020743762
most O 0 0.0019092433
effective O 0 0.00152105
drug O 0 0.09226383
for O 0 0.0009107135
the O 0 0.0008994039
treatment O 0 0.0013190836
of O 0 0.0030087938
Parkinson B-Disease 0 0.9996244
' I-Disease 0 0.0042782105
s I-Disease 0 0.0047967965
disease I-Disease 0 0.76541746
. O 0 0.009225565

However O 0 0.0045671025
, O 0 0.0032607645
the O 0 0.0017148325
long O 0 0.0015387705
- O 0 0.0031792978
term O 0 0.0007213108
use O 0 0.00063323614
of O 0 0.00072948623
this O 0 0.001063294
dopamine B-Chemical 1 0.9997255
precursor O 0 0.0028166613
is O 0 0.0006017481
complicated O 0 0.0014104968
by O 0 0.00070603675
highly O 0 0.001300838
disabling O 0 0.77724516
fluctuations O 0 0.0044761165
and O 0 0.007912583
dyskinesias B-Disease 2 0.99996936
. O 0 0.008476798

Although O 0 0.0031011577
preclinical O 0 0.0041591967
and O 0 0.0017753671
clinical O 0 0.0020373198
findings O 0 0.00086939975
suggest O 0 0.0004268698
pulsatile O 0 0.0023667633
stimulation O 0 0.0005240104
of O 0 0.0010245626
striatal O 0 0.94844157
postsynaptic O 0 0.5003243
receptors O 0 0.0029395209
as O 0 0.00022057416
a O 0 0.00023365079
key O 0 0.00018464893
mechanism O 0 0.00022910575
underlying O 0 0.011478785
levodopa B-Chemical 0 0.9999993
- O 0 0.16007686
induced O 0 0.004948561
dyskinesias B-Disease 2 0.99999785
, O 0 0.0012784548
their O 0 0.000742063
pathogenesis O 0 0.0023884382
is O 0 0.0014612963
still O 0 0.0020592452
unclear O 0 0.0035518527
. O 0 0.0064966576

In O 0 0.0037334722
recent O 0 0.0026296698
years O 0 0.0022194954
, O 0 0.0016659888
evidence O 0 0.0008146717
from O 0 0.00062921376
animal O 0 0.0008143515
models O 0 0.00060782704
of O 0 0.0018264332
Parkinson B-Disease 0 0.9998586
' I-Disease 0 0.0013631132
s I-Disease 0 0.00080629333
disease I-Disease 0 0.6091265
has O 0 0.00021489285
provided O 0 0.00017129039
important O 0 0.00013781566
information O 0 0.00014711988
to O 0 0.00011560341
understand O 0 9.0541966e-05
the O 0 0.0001322611
effect O 0 0.00014563758
of O 0 0.00022740843
specific O 0 0.00023661111
receptor O 0 0.014158607
and O 0 0.00042112666
post O 0 0.0003935647
- O 0 0.011376941
receptor O 0 0.0042265113
molecular O 0 0.0013248306
mechanisms O 0 0.00034082582
underlying O 0 0.00060635613
the O 0 0.0006715449
development O 0 0.0031807306
of O 0 0.020538308
dyskinetic B-Disease 0 0.99999726
movements I-Disease 0 0.6684976
. O 0 0.007383544

Recent O 0 0.0046208845
preclinical O 0 0.0051182383
and O 0 0.0021612854
clinical O 0 0.0024369145
data O 0 0.0008823124
from O 0 0.00053021865
promising O 0 0.00065187307
lines O 0 0.0008525569
of O 0 0.00045293974
research O 0 0.00039429098
focus O 0 0.0002618511
on O 0 0.0001438401
the O 0 0.0001717547
differential O 0 0.00018770236
role O 0 0.00012352137
of O 0 0.00027013174
presynaptic O 0 0.01920816
versus O 0 0.00021747555
postsynaptic O 0 0.12347909
mechanisms O 0 0.00027530408
, O 0 0.0071583036
dopamine B-Chemical 1 0.9999465
receptor O 0 0.103749484
subtypes O 0 0.05357454
, O 0 0.004527327
ionotropic O 0 0.9905206
and O 0 0.02109973
metabotropic O 0 0.9999962
glutamate B-Chemical 1 0.99998796
receptors O 0 0.047297753
, O 0 0.0004910573
and O 0 0.00028888506
non O 0 0.0016448778
- O 0 0.05520523
dopaminergic O 0 0.5017015
neurotransmitter O 0 0.059664413
systems O 0 0.0002377894
in O 0 0.00024154993
the O 0 0.00034233584
pathophysiology O 0 0.018638104
of O 0 0.010604465
levodopa B-Chemical 0 0.99999785
- O 0 0.16807109
induced O 0 0.019318111
dyskinesias B-Disease 2 0.9999863
. O 0 0.009088631

Effects O 0 0.0057523325
of O 0 0.005039723
pallidal O 0 0.99428964
neurotensin B-Chemical 0 0.9995215
on O 0 0.0035694898
haloperidol B-Chemical 1 0.9999999
- O 0 0.6218696
induced O 0 0.14118856
parkinsonian B-Disease 2 1.0
catalepsy I-Disease 0 1.0
: O 0 0.0059550474
behavioral O 0 0.011463581
and O 0 0.0018172719
electrophysiological O 0 0.0074270293
studies O 0 0.0039654444
. O 0 0.0067549967

OBJECTIVE O 0 0.019532828
: O 0 0.0055770315
The O 0 0.003505718
globus O 0 0.9296215
pallidus O 0 0.98976153
plays O 0 0.0019783624
a O 0 0.002017726
critical O 0 0.0015804343
role O 0 0.001749502
in O 0 0.002778802
movement O 0 0.005473244
regulation O 0 0.005137778
. O 0 0.009749773

Previous O 0 0.0034779264
studies O 0 0.0021788753
have O 0 0.0013299735
indicated O 0 0.0008927776
that O 0 0.0007481891
the O 0 0.0009800195
globus O 0 0.98376346
pallidus O 0 0.99776196
receives O 0 0.0005245536
neurotensinergic O 0 0.0018635464
innervation O 0 0.0012340235
from O 0 0.00020793105
the O 0 0.00028338554
striatum O 0 0.38029245
, O 0 0.0004092923
and O 0 0.00037540979
systemic O 0 0.39510986
administration O 0 0.0048067337
of O 0 0.00054861436
a O 0 0.0013653876
neurotensin B-Chemical 0 0.9975382
analog O 0 0.0036141358
could O 0 0.000710884
produce O 0 0.0011718877
antiparkinsonian O 0 0.9866354
effects O 0 0.0039462466
. O 0 0.0060469233

The O 0 0.0031067492
present O 0 0.001927195
study O 0 0.0016763047
aimed O 0 0.0011259849
to O 0 0.0006938761
investigate O 0 0.0003867108
the O 0 0.0004983546
effects O 0 0.00066700607
of O 0 0.0015036372
pallidal O 0 0.99797624
neurotensin B-Chemical 0 0.9996247
on O 0 0.0017432161
haloperidol B-Chemical 1 0.9999999
- O 0 0.28697
induced O 0 0.040549513
parkinsonian B-Disease 2 0.9999988
symptoms I-Disease 0 0.98878163
. O 0 0.007886126

METHODS O 0 0.0051798504
: O 0 0.0048322706
Behavioral O 0 0.005200593
experiments O 0 0.0017594418
and O 0 0.0019025274
electrophysiological O 0 0.0027879872
recordings O 0 0.0016374906
were O 0 0.0012842432
performed O 0 0.0012522741
in O 0 0.0016643957
the O 0 0.0022606624
present O 0 0.003012578
study O 0 0.0062483074
. O 0 0.00900671

RESULTS O 0 0.005694764
: O 0 0.004067653
Bilateral O 0 0.006787681
infusions O 0 0.0034171557
of O 0 0.0016494422
neurotensin B-Chemical 0 0.9858753
into O 0 0.00057294697
the O 0 0.00096621463
globus O 0 0.9963899
pallidus O 0 0.9998783
reversed O 0 0.08644368
haloperidol B-Chemical 1 0.9999999
- O 0 0.44824985
induced O 0 0.11537758
parkinsonian B-Disease 2 0.9999999
catalepsy I-Disease 0 0.9999999
in O 0 0.0036999087
rats O 0 0.006057984
. O 0 0.006661752

Electrophysiological O 0 0.011912777
recordings O 0 0.002731785
showed O 0 0.0014510972
that O 0 0.0010512568
microinjection O 0 0.006363746
of O 0 0.001627253
neurotensin B-Chemical 0 0.99804497
induced O 0 0.0014118326
excitation O 0 0.9167059
of O 0 0.003236288
pallidal O 0 0.9835189
neurons O 0 0.001261992
in O 0 0.00036126992
the O 0 0.0004130538
presence O 0 0.0006270135
of O 0 0.002703089
systemic O 0 0.99765575
haloperidol B-Chemical 1 0.9999995
administration O 0 0.25585806
. O 0 0.0068447078

The O 0 0.0042814803
neurotensin B-Chemical 0 0.9944991
type I-Chemical 0 0.0059132096
- I-Chemical 0 0.08689951
1 I-Chemical 0 0.0017468478
receptor I-Chemical 0 0.24257642
antagonist I-Chemical 0 0.9979005
SR48692 B-Chemical 0 0.99999785
blocked O 0 0.00254522
both O 0 0.00046271365
the O 0 0.00038305836
behavioral O 0 0.0037002533
and O 0 0.00041980512
the O 0 0.00045042438
electrophysiological O 0 0.0031666893
effects O 0 0.0009865701
induced O 0 0.001578746
by O 0 0.003885936
neurotensin B-Chemical 0 0.9972932
. O 0 0.008690199

CONCLUSION O 0 0.022381129
: O 0 0.004612183
Activation O 0 0.0037508316
of O 0 0.0032798606
pallidal O 0 0.99427176
neurotensin B-Chemical 0 0.9991586
receptors O 0 0.017181678
may O 0 0.00073775224
be O 0 0.000643054
involved O 0 0.00059061416
in O 0 0.001096058
neurotensin B-Chemical 0 0.99893504
- O 0 0.0697528
induced O 0 0.004027964
antiparkinsonian O 0 0.997692
effects O 0 0.005853803
. O 0 0.007438061

Carmofur B-Chemical 0 0.9828174
- O 0 0.037723262
induced O 0 0.017256016
organic B-Disease 0 0.9951025
mental I-Disease 0 0.8429319
disorders I-Disease 0 0.98994386
. O 0 0.025708996

Organic B-Disease 0 0.98846954
mental I-Disease 0 0.47491276
disorder I-Disease 0 0.9889882
was O 0 0.0014823596
observed O 0 0.00079957175
in O 0 0.0006823881
a O 0 0.00077640585
29 O 0 0.001197234
- O 0 0.0032801644
year O 0 0.0005142059
- O 0 0.0024059264
old O 0 0.0003673385
female O 0 0.0006605164
in O 0 0.00023591303
the O 0 0.00022234234
prognostic O 0 0.00040460107
period O 0 0.0001984902
after O 0 0.0001997899
the O 0 0.0003299048
onset O 0 0.0009760453
of O 0 0.0020434046
carmofur B-Chemical 0 0.99951196
- O 0 0.0777458
induced O 0 0.00665413
leukoencephalopathy B-Disease 2 0.99994624
. O 0 0.014717657

Symptoms O 0 0.019845322
such O 0 0.0024557565
as O 0 0.002451697
euphoria O 0 0.99906605
, O 0 0.0024917072
emotional O 0 0.11412509
lability O 0 0.36043668
and O 0 0.00084429403
puerile O 0 0.01622898
attitude O 0 0.005666041
noted O 0 0.00025912517
in O 0 0.00023391069
the O 0 0.00020809726
patient O 0 0.00022613535
were O 0 0.0001873308
diagnosed O 0 0.00076562783
as O 0 0.0003201276
organic B-Disease 0 0.9970567
personality I-Disease 0 0.9950978
syndrome I-Disease 0 0.6089906
according O 0 0.00016163777
to O 0 0.00015441696
the O 0 0.00018078848
criteria O 0 0.00025309648
defined O 0 0.00026778824
in O 0 0.00040012217
the O 0 0.0006855658
DSM O 0 0.07102832
- O 0 0.036954083
III O 0 0.20278905
- O 0 0.08367998
R O 0 0.9912718
. O 0 0.009886509

It O 0 0.008473423
is O 0 0.005431387
referred O 0 0.0044696657
to O 0 0.003780282
as O 0 0.004351128
a O 0 0.006987534
frontal B-Disease 0 0.9728769
lobe I-Disease 0 0.95049983
syndrome I-Disease 0 0.9295443
. O 0 0.015251493

Brain O 0 0.100899644
CT O 0 0.038632832
revealed O 0 0.0019340366
a O 0 0.0018475412
periventricular O 0 0.05963608
low O 0 0.0008977597
density O 0 0.0008254805
area O 0 0.0007015908
in O 0 0.00036881544
the O 0 0.00037976398
frontal O 0 0.6408062
white O 0 0.012009556
matter O 0 0.0021379609
and O 0 0.0002899474
moderate O 0 0.0035150626
dilatation O 0 0.11337789
of O 0 0.00032785643
the O 0 0.00028819044
lateral O 0 0.0033161114
ventricles O 0 0.004433256
especially O 0 0.0005155917
at O 0 0.0005232594
the O 0 0.00093751866
bilateral O 0 0.038536407
anterior O 0 0.082106054
horns O 0 0.206222
. O 0 0.0067755952

Consequently O 0 0.0051772413
, O 0 0.00835268
carmofur B-Chemical 0 0.9991603
- O 0 0.09535417
induced O 0 0.0035039096
leukoencephalopathy B-Disease 2 0.9999465
may O 0 0.0019261607
uncommonly O 0 0.23495482
result O 0 0.0005756469
in O 0 0.0009183611
organic B-Disease 0 0.99728835
personality I-Disease 0 0.99600405
syndrome I-Disease 0 0.7705985
in O 0 0.0011159324
the O 0 0.0014428281
residual O 0 0.0025480941
state O 0 0.0049442914
. O 0 0.0071504326

It O 0 0.0060933298
may O 0 0.0032670344
be O 0 0.002547537
attributed O 0 0.0017927752
to O 0 0.0016296068
the O 0 0.0016457174
structural B-Disease 0 0.0030544752
damage I-Disease 0 0.35897
to I-Disease 0 0.0022817259
the I-Disease 0 0.0034738206
frontal I-Disease 0 0.8595366
lobe I-Disease 0 0.7769153
. O 0 0.009545792

Butyrylcholinesterase O 0 0.29389408
gene O 0 0.0041110595
mutations O 0 0.004264732
in O 0 0.0015937338
patients O 0 0.0015303458
with O 0 0.0011754888
prolonged O 0 0.0025365003
apnea B-Disease 0 0.99036694
after O 0 0.0013079741
succinylcholine B-Chemical 1 0.9995778
for O 0 0.002935416
electroconvulsive O 0 0.9891371
therapy O 0 0.00786436
. O 0 0.007359908

BACKGROUND O 0 0.020846857
: O 0 0.00437987
patients O 0 0.0026213834
undergoing O 0 0.0020428833
electroconvulsive O 0 0.9805188
therapy O 0 0.0073864767
( O 0 0.0051292204
ECT O 0 0.9841441
) O 0 0.0014301157
often O 0 0.00074965146
receive O 0 0.00053104485
succinylcholine B-Chemical 1 0.9936015
as O 0 0.0006440179
part O 0 0.00073109707
of O 0 0.0011874948
the O 0 0.0016923782
anesthetic O 0 0.041672222
procedure O 0 0.0037962545
. O 0 0.006649933

The O 0 0.0028992072
duration O 0 0.0018526202
of O 0 0.0017057233
action O 0 0.0018885506
may O 0 0.0007755913
be O 0 0.0006132924
prolonged O 0 0.00070257636
in O 0 0.00037477844
patients O 0 0.00044612456
with O 0 0.00029695878
genetic O 0 0.0009949651
variants O 0 0.00051253085
of O 0 0.00039103362
the O 0 0.0005161264
butyrylcholinesterase O 0 0.99344254
enzyme O 0 0.29632747
( O 0 0.010868971
BChE O 0 0.9986786
) O 0 0.0011383139
, O 0 0.00030694017
the O 0 0.00019025888
most O 0 0.0002832448
common O 0 0.00031627854
being O 0 0.0004497403
the O 0 0.0005472244
K O 1 0.9999025
- O 0 0.032315396
and O 0 0.0010066264
the O 0 0.0013192508
A O 0 0.14965525
- O 0 0.014991917
variants O 0 0.0062279347
. O 0 0.00780689

The O 0 0.0031447054
aim O 0 0.002362208
of O 0 0.0017227401
the O 0 0.0011673432
study O 0 0.0010402636
was O 0 0.0005843379
to O 0 0.00034968375
assess O 0 0.00019574059
the O 0 0.00025311534
clinical O 0 0.00048077956
significance O 0 0.00021203775
of O 0 0.00027114636
genetic O 0 0.0014081878
variants O 0 0.0008574831
in O 0 0.00043517232
butyrylcholinesterase O 0 0.9848476
gene O 0 0.0019091652
( O 0 0.011282747
BCHE O 0 0.999629
) O 0 0.0010027239
in O 0 0.00021237198
patients O 0 0.00029048693
with O 0 0.00022713862
a O 0 0.00029478842
suspected O 0 0.0012836086
prolonged O 0 0.00039351953
duration O 0 0.00027926153
of O 0 0.00054746546
action O 0 0.0014202143
of O 0 0.0032372307
succinylcholine B-Chemical 1 0.9997384
after O 0 0.002579369
ECT O 0 0.97100663
. O 0 0.0065363348

METHODS O 0 0.004243668
: O 0 0.0036984186
a O 0 0.0023489115
total O 0 0.0014042512
of O 0 0.0014466915
13 O 0 0.0011898045
patients O 0 0.00092663994
were O 0 0.0006140358
referred O 0 0.00053215073
to O 0 0.00046376168
the O 0 0.0006099098
Danish O 0 0.00682051
Cholinesterase O 0 0.99467117
Research O 0 0.015230881
Unit O 0 0.002180525
after O 0 0.00074979936
ECT O 0 0.420548
during O 0 0.0012360704
38 O 0 0.0027707324
months O 0 0.0029892297
. O 0 0.006416327

We O 0 0.00335003
determined O 0 0.0020863574
the O 0 0.0021245505
BChE O 0 0.9755052
activity O 0 0.0011560682
and O 0 0.00092543254
the O 0 0.0010941644
BCHE O 0 0.9991673
genotype O 0 0.01169221
using O 0 0.00027944183
molecular O 0 0.0012619914
genetic O 0 0.0007981103
methods O 0 0.00022744636
, O 0 0.0002688571
the O 0 0.00017118311
duration O 0 0.00016199282
of O 0 0.0003625849
apnea B-Disease 0 0.98147696
, O 0 0.0003649811
time O 0 0.0001475385
to O 0 0.00016793353
sufficient O 0 0.00018733225
spontaneous O 0 0.0007798694
ventilation O 0 0.0013241796
and O 0 0.00042484593
whether O 0 0.00039353807
neuromuscular O 0 0.012774957
monitoring O 0 0.0014679562
was O 0 0.0019402463
used O 0 0.0030290845
. O 0 0.005901295

The O 0 0.0037551925
duration O 0 0.0027264382
of O 0 0.0031426344
apnea B-Disease 0 0.9618233
was O 0 0.0017545142
compared O 0 0.0010343505
with O 0 0.0012752637
published O 0 0.0014429118
data O 0 0.001748334
on O 0 0.0017940336
normal O 0 0.0040956303
subjects O 0 0.006746395
. O 0 0.00862479

RESULTS O 0 0.005605893
: O 0 0.0036384314
in O 0 0.002014973
11 O 0 0.0016434493
patients O 0 0.001399415
, O 0 0.0012160757
mutations O 0 0.001924384
were O 0 0.0005493268
found O 0 0.00040225202
in O 0 0.0004069535
the O 0 0.00063580327
BCHE O 0 0.99848586
gene O 0 0.0009262847
, O 0 0.0008021008
the O 0 0.00090108265
K O 1 0.9999387
- O 0 0.054574285
variant O 0 0.0018357271
being O 0 0.0015480976
the O 0 0.001523943
most O 0 0.003221143
frequent O 0 0.007392083
. O 0 0.0066690347

The O 0 0.002942089
duration O 0 0.0019857
of O 0 0.0021976011
apnea B-Disease 0 0.9758506
was O 0 0.0012207895
5 O 0 0.0006889011
- O 0 0.0012849468
15 O 0 0.000360946
min O 0 0.00038332064
compared O 0 0.0002518412
with O 0 0.00036267875
3 O 0 0.00039008755
- O 0 0.0010540633
5 O 0 0.00042155257
. O 0 0.0005108307
3 O 0 0.0006205548
min O 0 0.0010044575
from O 0 0.0013034106
the O 0 0.0022337842
literature O 0 0.0049690097
. O 0 0.007392199

Severe O 0 0.75220984
distress O 0 0.43673044
was O 0 0.003239438
noted O 0 0.0020580443
in O 0 0.0019198641
the O 0 0.0018290273
recovery O 0 0.0025223335
phase O 0 0.0027429394
in O 0 0.002764221
two O 0 0.0034032871
patients O 0 0.006902942
. O 0 0.009222693

Neuromuscular O 0 0.018427232
monitoring O 0 0.008372359
was O 0 0.007072393
used O 0 0.006311652
in O 0 0.007292481
two O 0 0.008355177
patients O 0 0.014093888
. O 0 0.017597523

CONCLUSION O 0 0.01875744
: O 0 0.0036883852
eleven O 0 0.001960987
of O 0 0.0015106552
13 O 0 0.0011603882
patients O 0 0.0008568709
with O 0 0.00056732184
a O 0 0.0005248584
prolonged O 0 0.00043382103
duration O 0 0.00023339606
of O 0 0.00032228898
action O 0 0.0006830895
of O 0 0.001318215
succinylcholine B-Chemical 1 0.9998307
had O 0 0.0004322736
mutations O 0 0.021322498
in O 0 0.0013364949
BCHE O 0 0.9997031
, O 0 0.00050213444
indicating O 0 0.00017048643
that O 0 0.00015524268
this O 0 0.00019854962
is O 0 0.00021593066
the O 0 0.00022251753
possible O 0 0.00028911428
reason O 0 0.00030702626
for O 0 0.0004512502
a O 0 0.00075643935
prolonged O 0 0.0011032021
period O 0 0.0012486848
of O 0 0.0034461431
apnea B-Disease 0 0.9858161
. O 0 0.007906319

We O 0 0.006366282
recommend O 0 0.0043725073
objective O 0 0.0053374553
neuromuscular O 0 0.014938944
monitoring O 0 0.0037181987
during O 0 0.002985611
the O 0 0.0042326488
first O 0 0.0058395755
ECT O 0 0.92422813
. O 0 0.012142146

Perhexiline B-Chemical 0 0.99996996
maleate I-Chemical 0 0.9999968
and O 0 0.17324536
peripheral B-Disease 2 0.98852843
neuropathy I-Disease 2 0.9999765
. O 0 0.03345218

Peripheral B-Disease 2 0.99058574
neuropathy I-Disease 2 0.9999864
has O 0 0.0021135902
been O 0 0.0012040902
noted O 0 0.0007219369
as O 0 0.00063131686
a O 0 0.0007697619
complication O 0 0.068116836
of O 0 0.00070505333
therapy O 0 0.0066789486
with O 0 0.053305537
perhexiline B-Chemical 0 1.0
maleate I-Chemical 0 1.0
, O 0 0.013988945
a O 0 0.00085363886
drug O 0 0.18985324
widely O 0 0.00022212346
used O 0 0.0001408522
in O 0 0.00019735223
France O 0 0.01483064
( O 0 0.00030943233
and O 0 0.00020107777
in O 0 0.00017116776
clinical O 0 0.00041790574
trials O 0 0.00017247071
in O 0 0.00017238013
the O 0 0.00022377045
United O 0 0.0007288984
States O 0 0.0017458134
) O 0 0.0006063337
for O 0 0.00036219019
the O 0 0.0005006667
prophylactic O 0 0.002660195
treatment O 0 0.0022579902
of O 0 0.0613251
angina B-Disease 0 0.9999982
pectoris I-Disease 0 0.99999416
. O 0 0.012561542

In O 0 0.003851324
24 O 0 0.002486241
patients O 0 0.001744795
with O 0 0.001168974
this O 0 0.0010064178
complication O 0 0.11847999
, O 0 0.0009174792
the O 0 0.0004399683
marked O 0 0.0007175611
slowing O 0 0.0032006404
of O 0 0.00050577946
motor O 0 0.02193489
nerve O 0 0.015019232
conduction O 0 0.000902616
velocity O 0 0.00036502164
and O 0 0.00030164444
the O 0 0.00031837265
electromyographic O 0 0.0040795966
changes O 0 0.0004914005
imply O 0 0.00049745553
mainly O 0 0.0012893269
a O 0 0.003869176
demyelinating B-Disease 0 0.9998609
disorder I-Disease 0 0.9997172
. O 0 0.009363312

Improvement O 0 0.012794397
was O 0 0.0071072755
noted O 0 0.005776967
with O 0 0.0069535016
cessation O 0 0.015593401
of O 0 0.01109022
therapy O 0 0.019971315
. O 0 0.017066102

In O 0 0.0040391055
a O 0 0.0028245836
few O 0 0.0014846149
cases O 0 0.0015371443
the O 0 0.0009622992
presence O 0 0.00082174083
of O 0 0.0010161647
active O 0 0.0041119815
denervation O 0 0.9229351
signified O 0 0.018634267
a O 0 0.0009901549
poor O 0 0.004703171
prognosis O 0 0.6947322
, O 0 0.0013355076
with O 0 0.0012311911
only O 0 0.0017662209
slight O 0 0.0036589424
improvement O 0 0.0047555114
. O 0 0.0070648887

The O 0 0.0030008412
underlying O 0 0.0023129706
mechanism O 0 0.0015339166
causing O 0 0.0032021804
the O 0 0.0025196872
neuropathy B-Disease 0 0.9999852
is O 0 0.00089096115
not O 0 0.00043951767
yet O 0 0.00052691967
fully O 0 0.00028577854
known O 0 0.00036758216
, O 0 0.00038104772
although O 0 0.00024509683
some O 0 0.0002300827
evidence O 0 0.00021526526
indicates O 0 0.00025387932
that O 0 0.000312519
it O 0 0.00049413455
may O 0 0.00050170644
be O 0 0.00075558777
a O 0 0.0014040713
lipid O 0 0.4458847
storage O 0 0.0041208244
process O 0 0.004272705
. O 0 0.0068564224

A O 0 0.039164275
phase O 0 0.008164531
I O 0 0.011159378
study O 0 0.0037415826
of O 0 0.0033122774
4 B-Chemical 0 0.0029753011
' I-Chemical 0 0.0045551364
- I-Chemical 0 0.008182258
0 I-Chemical 0 0.0054951324
- I-Chemical 0 0.013635693
tetrahydropyranyladriamycin I-Chemical 0 0.2104518
. O 0 0.013593749

Clinical O 0 0.04310477
pharmacology O 0 0.048455223
and O 0 0.03052434
pharmacokinetics O 0 0.8229314
. O 0 0.03935484

A O 0 0.05634667
Phase O 0 0.008000042
I O 0 0.007836824
study O 0 0.0018118446
of O 0 0.0014952607
intravenous O 0 0.10849985
( O 0 0.0027987224
IV O 0 0.273086
) O 0 0.0011325658
bolus O 0 0.0019990765
4 B-Chemical 0 0.00030264945
' I-Chemical 0 0.00054533844
- I-Chemical 0 0.003551935
0 I-Chemical 0 0.00043759125
- I-Chemical 0 0.007652335
tetrahydropyranyladriamycin I-Chemical 0 0.28632045
( O 0 0.0038331044
Pirarubicin B-Chemical 0 0.9948192
) O 0 0.00088998885
was O 0 0.00024090298
done O 0 0.00018904009
in O 0 0.00022340698
55 O 0 0.00030216054
patients O 0 0.00032699615
in O 0 0.00031762596
good O 0 0.00053551217
performance O 0 0.00081464613
status O 0 0.0012210407
with O 0 0.0017988245
refractory O 0 0.12131057
tumors B-Disease 0 0.91827476
. O 0 0.0074685887

Twenty O 0 0.007124548
- O 0 0.005879009
six O 0 0.0013981368
had O 0 0.0010417595
minimal O 0 0.0007541483
prior O 0 0.0005218775
therapy O 0 0.0010470414
( O 0 0.0008124008
good O 0 0.00081572076
risk O 0 0.1398291
) O 0 0.0023051484
, O 0 0.00058114727
23 O 0 0.00037212542
had O 0 0.0001856862
extensive O 0 0.00019658261
prior O 0 0.00014695695
therapy O 0 0.00042478353
( O 0 0.00045511432
poor O 0 0.0023917444
risk O 0 0.15469432
) O 0 0.0018530594
, O 0 0.00047525435
and O 0 0.0003269846
six O 0 0.00024638858
had O 0 0.00038357417
renal B-Disease 0 0.43460605
and I-Disease 0 0.0011067246
/ I-Disease 0 0.011813226
or I-Disease 0 0.0029058936
hepatic I-Disease 0 0.99914
dysfunction I-Disease 0 0.9989196
. O 0 0.010309498

A O 0 0.015087203
total O 0 0.0026324678
of O 0 0.0023624776
167 O 0 0.0024138384
courses O 0 0.0011661256
at O 0 0.00081646105
doses O 0 0.0013722368
of O 0 0.0007838007
15 O 0 0.0006001579
to O 0 0.00059363456
70 O 0 0.000902147
mg O 0 0.006960354
/ O 0 0.002979875
m2 O 0 0.0080110235
were O 0 0.0033841948
evaluable O 0 0.008096821
. O 0 0.007840072

Maximum O 0 0.00610523
tolerated O 0 0.007746823
dose O 0 0.0047644256
in O 0 0.0013845881
good O 0 0.0021336288
- O 0 0.025957309
risk O 0 0.061679363
patients O 0 0.0009706431
was O 0 0.00040262225
70 O 0 0.00036915668
mg O 0 0.013549945
/ O 0 0.0020711026
m2 O 0 0.013131796
, O 0 0.00045415034
and O 0 0.00033201688
in O 0 0.00032704195
poor O 0 0.0019720034
- O 0 0.012387635
risk O 0 0.046797052
patients O 0 0.001263161
, O 0 0.0011080143
60 O 0 0.0011770463
mg O 0 0.019120634
/ O 0 0.0056326683
m2 O 0 0.03979904
. O 0 0.007822729

The O 0 0.005056334
dose O 0 0.011788953
- O 0 0.014080993
limiting O 0 0.004737288
toxic O 0 0.69513184
effect O 0 0.003366467
was O 0 0.003985125
transient O 0 0.32886046
noncumulative O 0 0.99128073
granulocytopenia B-Disease 0 0.9999614
. O 0 0.014657138

Granulocyte O 0 0.5362349
nadir O 0 0.005084179
was O 0 0.0023543793
on O 0 0.0013840818
day O 0 0.0013768675
14 O 0 0.0014326933
( O 0 0.0017199509
range O 0 0.001668014
, O 0 0.002426601
4 O 0 0.0023677668
- O 0 0.0055945544
22 O 0 0.0053515034
) O 0 0.008357861
. O 0 0.010951631

Less O 0 0.21237928
frequent O 0 0.0098337745
toxic O 0 0.50084764
effects O 0 0.0032308532
included O 0 0.0027501513
thrombocytopenia B-Disease 0 0.99998975
, O 0 0.083019085
anemia B-Disease 0 0.9999975
, O 0 0.21129824
nausea B-Disease 2 0.99999905
, O 0 0.021227745
mild O 0 0.9908592
alopecia B-Disease 0 0.99999785
, O 0 0.107852966
phlebitis B-Disease 0 0.9999814
, O 0 0.008602476
and O 0 0.012906506
mucositis B-Disease 2 0.9999689
. O 0 0.011179127

Myelosuppression B-Disease 0 0.99980694
was O 0 0.0066881897
more O 0 0.0049830596
in O 0 0.004268086
patients O 0 0.005792275
with O 0 0.0076586744
hepatic B-Disease 0 0.9986185
dysfunction I-Disease 0 0.99898165
. O 0 0.018313643

Pharmacokinetic O 0 0.056700353
analyses O 0 0.0024169958
in O 0 0.0016566315
21 O 0 0.0013180401
patients O 0 0.0010233987
revealed O 0 0.00088320236
Pirarubicin B-Chemical 0 0.9923366
plasma O 0 0.18478037
T O 0 0.9454329
1 O 0 0.0005265519
/ O 0 0.0019614934
2 O 0 0.00037840483
alpha O 0 0.42547178
( O 0 0.0018771171
+ O 0 0.010116091
/ O 0 0.047476154
- O 0 0.08314448
SE O 0 0.82548463
) O 0 0.00057994574
of O 0 0.0002725649
2 O 0 0.0002004713
. O 0 0.00016381296
5 O 0 0.00016524292
+ O 0 0.00062179775
/ O 0 0.0049188863
- O 0 0.005949602
0 O 0 0.00023740293
. O 0 0.00015645336
85 O 0 0.00019121366
minutes O 0 0.00015006833
, O 0 0.00039041197
T O 0 0.9272312
beta O 0 0.9440775
1 O 0 0.00042846156
/ O 0 0.0013788339
2 O 0 0.00018370924
of O 0 0.00019171204
25 O 0 0.00022208875
. O 0 0.00015826497
6 O 0 0.00015083783
+ O 0 0.00062949816
/ O 0 0.005680159
- O 0 0.005401435
6 O 0 0.00015291364
. O 0 0.00014179388
5 O 0 0.0001248225
minutes O 0 0.00013188142
, O 0 0.0002286566
and O 0 0.00030763337
T O 0 0.74472785
1 O 0 0.00030776305
/ O 0 0.0012438833
2 O 0 0.00030871225
gamma O 0 0.32607597
of O 0 0.00047769697
23 O 0 0.0005142037
. O 0 0.00029214393
6 O 0 0.00031266292
+ O 0 0.0009672743
/ O 0 0.003349245
- O 0 0.0035517798
7 O 0 0.0009404553
. O 0 0.0012792178
6 O 0 0.0018161633
hours O 0 0.0031240378
. O 0 0.006712483

The O 0 0.003075107
area O 0 0.0026339327
under O 0 0.0013924564
the O 0 0.0010982141
curve O 0 0.0012489872
was O 0 0.0011046833
537 O 0 0.14590776
+ O 0 0.006177684
/ O 0 0.020891901
- O 0 0.012360001
149 O 0 0.0013786467
ng O 0 0.0006042119
/ O 0 0.0018723255
ml O 0 0.00056603155
x O 0 0.00089498697
hours O 0 0.00021188796
, O 0 0.0002523967
volume O 0 0.0002708329
of O 0 0.00020903708
distribution O 0 0.00018272777
( O 0 0.00059317076
Vd O 0 0.2180824
) O 0 0.002124941
3504 O 0 0.43719244
+ O 0 0.003189606
/ O 0 0.016169364
- O 0 0.023866855
644 O 0 0.05230096
l O 0 0.0022512581
/ O 0 0.0034825702
m2 O 0 0.013429227
, O 0 0.00032161557
and O 0 0.00021112911
total O 0 0.00018067441
clearance O 0 0.024925599
( O 0 0.0015770715
ClT O 0 0.8760726
) O 0 0.0008197875
was O 0 0.000316417
204 O 0 0.0015460888
+ O 0 0.0007367746
39 O 0 0.0005160359
. O 0 0.00039603122
3 O 0 0.0004900622
l O 0 0.0012256467
/ O 0 0.0023068795
hour O 0 0.0016613399
/ O 0 0.005689181
m2 O 0 0.036715157
. O 0 0.008414871

Adriamycinol B-Chemical 0 0.9414412
, O 0 0.012543728
doxorubicin B-Chemical 1 0.9996598
, O 0 0.018422456
adriamycinone B-Chemical 0 0.946974
, O 0 0.0019302104
and O 0 0.00097370055
tetrahydropyranyladriamycinol B-Chemical 0 0.3351169
were O 0 0.0004077935
the O 0 0.00034155248
metabolites O 0 0.49385574
detected O 0 0.00022710874
in O 0 0.00024499945
plasma O 0 0.0040183007
and O 0 0.00021082535
the O 0 0.00015023956
amount O 0 0.000118505806
of O 0 0.00047659263
doxorubicin B-Chemical 1 0.9994855
was O 0 0.0003264174
less O 0 0.0002023317
than O 0 0.00014867976
or O 0 0.00018880233
equal O 0 0.0001953561
to O 0 0.00028082775
10 O 0 0.00039204967
% O 0 0.000604165
of O 0 0.00084555155
the O 0 0.0012176665
total O 0 0.0021702833
metabolites O 0 0.7496401
. O 0 0.006831877

Urinary O 0 0.66914064
excretion O 0 0.8771938
of O 0 0.0050925845
Pirarubicin B-Chemical 0 0.98796195
in O 0 0.0011292828
the O 0 0.0007306325
first O 0 0.0005229503
24 O 0 0.0005156872
hours O 0 0.00039003813
was O 0 0.00045170897
less O 0 0.0004521068
than O 0 0.00043261496
or O 0 0.00064522016
equal O 0 0.0008098624
to O 0 0.0013930777
10 O 0 0.0022919462
% O 0 0.004432685
. O 0 0.007031161

Activity O 0 0.0075316597
was O 0 0.0036211023
noted O 0 0.0025739805
in O 0 0.0028132908
mesothelioma B-Disease 0 0.933691
, O 0 0.0069031585
leiomyosarcoma B-Disease 0 0.9972976
, O 0 0.0037230863
and O 0 0.003334957
basal B-Disease 0 0.018264074
cell I-Disease 0 0.09149076
carcinoma I-Disease 2 0.9999255
. O 0 0.017439397

The O 0 0.003129894
recommended O 0 0.002054641
starting O 0 0.0013162061
dose O 0 0.0020882753
for O 0 0.0009663923
Phase O 0 0.0022257238
II O 0 0.0048732343
trials O 0 0.0005489369
is O 0 0.00048188368
60 O 0 0.0005177988
mg O 0 0.008660526
/ O 0 0.002263725
m2 O 0 0.030771686
IV O 0 0.07505152
bolus O 0 0.0018317159
every O 0 0.00091153395
3 O 0 0.0018090671
weeks O 0 0.0027201106
. O 0 0.0063264393

Ocular B-Disease 0 0.52828085
and I-Disease 0 0.006764863
auditory I-Disease 0 0.100152105
toxicity I-Disease 2 0.9967595
in O 0 0.006285722
hemodialyzed O 0 0.99857247
patients O 0 0.015342157
receiving O 0 0.0327855
desferrioxamine B-Chemical 1 0.9999529
. O 0 0.015304852

During O 0 0.003183505
an O 0 0.0030768935
18 O 0 0.0022612025
- O 0 0.0026994336
month O 0 0.00078253594
period O 0 0.0005853592
of O 0 0.0006497062
study O 0 0.0007387196
41 O 0 0.0013346862
hemodialyzed O 0 0.992157
patients O 0 0.0010011885
receiving O 0 0.0027769317
desferrioxamine B-Chemical 1 0.9999964
( O 0 0.0020843372
10 O 0 0.00029834762
- O 0 0.00168913
40 O 0 0.00021606557
mg O 0 0.0067945803
/ O 0 0.0012976157
kg O 0 0.0014182269
BW O 0 0.24589413
/ O 0 0.0011130902
3 O 0 0.000156326
times O 0 0.00011408474
weekly O 0 0.00016955473
) O 0 0.00026400923
for O 0 0.00017849836
the O 0 0.0001905357
first O 0 0.00017594997
time O 0 0.00018933375
were O 0 0.00027603918
monitored O 0 0.00029610837
for O 0 0.00052546815
detection O 0 0.00126346
of O 0 0.0026659237
audiovisual B-Disease 0 0.6647165
toxicity I-Disease 2 0.9998728
. O 0 0.009875276

6 O 0 0.0049093245
patients O 0 0.004024947
presented O 0 0.0029441658
clinical O 0 0.004414552
symptoms O 0 0.039494544
of O 0 0.0032057334
visual B-Disease 0 0.071378924
or I-Disease 0 0.004348121
auditory I-Disease 0 0.20028828
toxicity I-Disease 2 0.99729806
. O 0 0.012663465

Moreover O 0 0.005362668
, O 0 0.0038435368
detailed O 0 0.00199889
ophthalmologic O 0 0.007790342
and O 0 0.0015512413
audiologic O 0 0.0067158947
studies O 0 0.0010290312
disclosed O 0 0.0015626507
abnormalities O 0 0.010181593
in O 0 0.0011938346
7 O 0 0.001411682
more O 0 0.0022524076
asymptomatic O 0 0.034141812
patients O 0 0.0067256647
. O 0 0.008045096

Visual B-Disease 0 0.9960829
toxicity I-Disease 2 0.99974257
was O 0 0.002693604
of O 0 0.0021186913
retinal O 0 0.882221
origin O 0 0.0016183393
and O 0 0.0007511202
was O 0 0.00045419185
characterized O 0 0.0004354923
by O 0 0.00039835926
a O 0 0.0010949486
tritan O 0 0.99969876
- O 0 0.09128174
type O 0 0.00083295366
dyschromatopsy B-Disease 0 0.83023894
, O 0 0.00058864267
sometimes O 0 0.00055470085
associated O 0 0.00025881847
with O 0 0.00027043562
a B-Disease 0 0.0003431928
loss I-Disease 0 0.0005236784
of I-Disease 0 0.0006483448
visual I-Disease 0 0.2613795
acuity I-Disease 0 0.99240017
and O 0 0.003857316
pigmentary B-Disease 0 0.99987996
retinal I-Disease 0 0.9940049
deposits I-Disease 0 0.94799966
. O 0 0.008094707

Auditory B-Disease 0 0.9783337
toxicity I-Disease 2 0.9995561
was O 0 0.0023680844
characterized O 0 0.0015277338
by O 0 0.0010545629
a O 0 0.0009730703
mid O 0 0.0015913644
- O 0 0.0040420378
to O 0 0.0004233511
high O 0 0.000888788
- O 0 0.008855973
frequency O 0 0.0010810487
neurosensorial B-Disease 0 0.9992619
hearing I-Disease 0 0.9906701
loss I-Disease 0 0.01114012
and O 0 0.0005680064
the O 0 0.0005057971
lesion O 0 0.019750262
was O 0 0.0007286442
of O 0 0.001088444
the O 0 0.001593136
cochlear O 0 0.03452961
type O 0 0.0042770267
. O 0 0.00710195

Desferrioxamine B-Chemical 0 0.99991846
withdrawal O 0 0.65176266
resulted O 0 0.0017164961
in O 0 0.0011201442
a O 0 0.00087924587
complete O 0 0.0004765749
recovery O 0 0.00056889164
of O 0 0.00045368425
visual O 0 0.022918452
function O 0 0.0002824668
in O 0 0.00024350273
1 O 0 0.00020527252
patient O 0 0.00018278578
and O 0 0.00019172375
partial O 0 0.00025865517
recovery O 0 0.00030233138
in O 0 0.00018225813
3 O 0 0.00016130353
, O 0 0.00021377539
and O 0 0.00019654924
a O 0 0.00020892153
complete O 0 0.00015563842
reversal O 0 0.00034132611
of O 0 0.00041425411
hearing B-Disease 0 0.9273536
loss I-Disease 0 0.0010646525
in O 0 0.0003356972
3 O 0 0.00032175297
patients O 0 0.0004791627
and O 0 0.0006059914
partial O 0 0.0010447615
recovery O 0 0.00168334
in O 0 0.001990207
3 O 0 0.0031153979
. O 0 0.00583918

This O 0 0.008774969
toxicity B-Disease 2 0.990333
appeared O 0 0.0023795043
in O 0 0.0012799228
patients O 0 0.0012480736
receiving O 0 0.0007804556
the O 0 0.0004469742
higher O 0 0.0004123297
doses O 0 0.0032727772
of O 0 0.0030647847
desferrioxamine B-Chemical 1 0.99999785
or O 0 0.000598144
coincided O 0 0.0008108037
with O 0 0.00033029626
the O 0 0.00028188972
normalization O 0 0.0003819537
of O 0 0.0008809369
ferritin O 0 0.9975751
or O 0 0.0027234396
aluminium B-Chemical 0 0.9995167
serum O 0 0.6019038
levels O 0 0.0047258474
. O 0 0.0070795077

The O 0 0.0033418203
data O 0 0.002399948
indicate O 0 0.0012463962
that O 0 0.0013362893
audiovisual B-Disease 0 0.3560443
toxicity I-Disease 2 0.999913
is O 0 0.0012277804
not O 0 0.00069868536
an O 0 0.0008935393
infrequent O 0 0.0063171536
complication O 0 0.20171428
in O 0 0.0014626121
hemodialyzed O 0 0.99815446
patients O 0 0.006098918
receiving O 0 0.015564069
desferrioxamine B-Chemical 1 0.99996114
. O 0 0.00976855

Periodical O 0 0.0059837718
audiovisual O 0 0.0041525173
monitoring O 0 0.0019178103
should O 0 0.00090139615
be O 0 0.00080476666
performed O 0 0.00059302326
on O 0 0.0005153728
hemodialyzed O 0 0.9887995
patients O 0 0.00088202994
receiving O 0 0.0004886915
the O 0 0.00033014832
drug O 0 0.042548254
in O 0 0.00026853045
order O 0 0.00021604908
to O 0 0.00026393193
detect O 0 0.000341067
adverse O 0 0.056821108
effects O 0 0.0007497468
as O 0 0.0008425921
early O 0 0.0018279708
as O 0 0.002094917
possible O 0 0.0039910236
. O 0 0.0068076667

Serial O 0 0.054809287
epilepsy B-Disease 2 0.9999231
caused O 0 0.0046581025
by O 0 0.028253978
levodopa B-Chemical 0 0.99999964
/ I-Chemical 0 0.9550452
carbidopa I-Chemical 0 0.99999976
administration O 0 0.047463544
in O 0 0.0011663785
two O 0 0.001173792
patients O 0 0.0020719366
on O 0 0.0023790267
hemodialysis O 0 0.30083653
. O 0 0.008117173

Two O 0 0.003655952
patients O 0 0.0024728016
with O 0 0.001443184
similar O 0 0.0008899205
clinical O 0 0.0013286428
features O 0 0.0007124395
are O 0 0.00040890346
presented O 0 0.00033880287
: O 0 0.0004935062
both O 0 0.0002890239
patients O 0 0.00046402327
had O 0 0.00035112567
chronic B-Disease 2 0.97702575
renal I-Disease 2 0.99218494
failure I-Disease 2 0.9512083
, O 0 0.00074389356
on O 0 0.00014393697
hemodialysis O 0 0.1263215
for O 0 0.0001605821
many O 0 0.00014612205
years O 0 0.0002040562
but O 0 0.00017667371
recently O 0 0.00014726161
begun O 0 0.00016667471
on O 0 0.00011209325
a O 0 0.00023749846
high O 0 0.00052847585
- O 0 0.010874684
flux O 0 0.006659051
dialyzer O 0 0.13700536
; O 0 0.00054092525
both O 0 0.00018143696
had O 0 0.00016768214
been O 0 0.00017494004
receiving O 0 0.00045149418
a O 0 0.009458718
carbidopa B-Chemical 0 1.0
/ I-Chemical 0 0.78909516
levodopa I-Chemical 0 0.99999964
preparation O 0 0.0006390175
; O 0 0.0004701407
and O 0 0.00019208109
both O 0 0.00015458315
had O 0 0.0001466915
the O 0 0.00016176622
onset O 0 0.0006354216
of O 0 0.0021763295
hallucinosis B-Disease 0 0.9999994
and O 0 0.0048144725
recurrent O 0 0.93899566
seizures B-Disease 0 0.9999994
, O 0 0.0022780427
which O 0 0.0009081847
were O 0 0.0009136277
refractory O 0 0.0093295155
to O 0 0.0022357127
anticonvulsants O 0 0.9984622
. O 0 0.006184866

The O 0 0.003125526
first O 0 0.0019875832
patient O 0 0.0017024963
died O 0 0.0020559437
without O 0 0.00088883797
a O 0 0.0009538543
diagnosis O 0 0.0028604441
; O 0 0.0007971145
the O 0 0.00034356207
second O 0 0.00031085432
patient O 0 0.00033285137
had O 0 0.0002827513
a O 0 0.00036350466
dramatic O 0 0.00045116464
recovery O 0 0.0005782976
following O 0 0.0004095765
the O 0 0.00066433736
administration O 0 0.011380122
of O 0 0.009492078
vitamin B-Chemical 0 0.99999535
B6 I-Chemical 0 0.99569666
. O 0 0.009867581

Neither O 0 0.0039353305
patient O 0 0.0027599286
was O 0 0.0017482059
considered O 0 0.001081637
to O 0 0.0008682002
have O 0 0.0007609552
a O 0 0.0010319317
renal O 0 0.3381925
state O 0 0.0010190741
sufficiently O 0 0.0010882216
severe O 0 0.009606485
enough O 0 0.0008560573
to O 0 0.00091548334
explain O 0 0.0012559838
their O 0 0.0024862778
presentation O 0 0.005342721
. O 0 0.0072364416

Randomized O 0 0.009072292
, O 0 0.0057621473
double O 0 0.004455015
- O 0 0.009380059
blind O 0 0.011523342
trial O 0 0.00383574
of O 0 0.0069643958
mazindol B-Chemical 0 0.9999926
in O 0 0.014409561
Duchenne B-Disease 0 0.99972826
dystrophy I-Disease 0 0.9997094
. O 0 0.014826376

There O 0 0.0043837223
is O 0 0.002669863
evidence O 0 0.0016719355
that O 0 0.0014200046
growth O 0 0.05144061
hormone O 0 0.91973394
may O 0 0.00087592873
be O 0 0.0006349966
related O 0 0.0004186795
to O 0 0.0004707252
the O 0 0.0006291905
progression O 0 0.078496456
of O 0 0.0028877624
weakness B-Disease 0 0.9932093
in O 0 0.007436178
Duchenne B-Disease 0 0.99981886
dystrophy I-Disease 0 0.9997799
. O 0 0.010741756

We O 0 0.0034810782
conducted O 0 0.0022609013
a O 0 0.0021227559
12 O 0 0.0012700744
- O 0 0.0018609334
month O 0 0.00058785867
controlled O 0 0.0005036218
trial O 0 0.00066337135
of O 0 0.0015161753
mazindol B-Chemical 0 0.9999975
, O 0 0.0010150472
a O 0 0.00044780306
putative O 0 0.00039632202
growth O 0 0.02980679
hormone O 0 0.8930975
secretion O 0 0.0075883716
inhibitor O 0 0.033541415
, O 0 0.0009513248
in O 0 0.00060322887
83 O 0 0.0014900031
boys O 0 0.0092641795
with O 0 0.0036254663
Duchenne B-Disease 0 0.99961025
dystrophy I-Disease 0 0.9996687
. O 0 0.009696574

Muscle O 0 0.086056806
strength O 0 0.005805267
, O 0 0.0053060013
contractures O 0 0.99761367
, O 0 0.0019473241
functional O 0 0.00076989917
ability O 0 0.0005283323
and O 0 0.0005671065
pulmonary O 0 0.12957105
function O 0 0.00032524476
were O 0 0.00022796784
tested O 0 0.0001659443
at O 0 0.00015905198
baseline O 0 0.00018761326
, O 0 0.00022944699
and O 0 0.00019185578
6 O 0 0.00012955384
and O 0 0.00015220839
12 O 0 0.00011702117
months O 0 0.000102451544
after O 0 0.00010599427
treatment O 0 0.00023289568
with O 0 0.0009610344
mazindol B-Chemical 0 0.999997
( O 0 0.00090390234
3 O 0 0.00036621874
mg O 0 0.007430525
/ O 0 0.001635532
d O 0 0.0014381928
) O 0 0.0024863547
or O 0 0.002618555
placebo O 0 0.037570037
. O 0 0.006655444

The O 0 0.0033535457
study O 0 0.0026338652
was O 0 0.0015512346
designed O 0 0.0010111209
to O 0 0.00069125486
have O 0 0.00054144365
a O 0 0.00061891746
power O 0 0.0018047651
of O 0 0.00047294592
greater O 0 0.00031056133
than O 0 0.00021722521
0 O 0 0.00026757593
. O 0 0.0001830598
90 O 0 0.00016473809
to O 0 0.00013570492
detect O 0 0.00014136566
a O 0 0.00022377237
slowing O 0 0.00068297813
to O 0 0.00016028914
25 O 0 0.00022108074
% O 0 0.00020317806
of O 0 0.00018902043
the O 0 0.00016729884
expected O 0 0.00014929005
rate O 0 0.00022669943
of O 0 0.00037632507
progression O 0 0.1468754
of O 0 0.0013190178
weakness B-Disease 0 0.96879476
at O 0 0.00054506224
P O 0 0.027095674
less O 0 0.00073885964
than O 0 0.00086930476
0 O 0 0.0017792865
. O 0 0.0027893318
05 O 0 0.0132269785
. O 0 0.007215384

Mazindol B-Chemical 0 0.999509
did O 0 0.0050782682
not O 0 0.002724367
benefit O 0 0.0024422084
strength O 0 0.0026223587
at O 0 0.0018200608
any O 0 0.0018139005
point O 0 0.001992652
in O 0 0.002824847
the O 0 0.0040397886
study O 0 0.007204305
. O 0 0.009852227

Side O 0 0.41212457
effects O 0 0.0035634572
attributable O 0 0.0017067449
to O 0 0.0019634098
mazindol B-Chemical 0 0.9999938
included O 0 0.0012810657
decreased B-Disease 0 0.058310695
appetite I-Disease 0 0.99881077
( O 0 0.0014139565
36 O 0 0.0004128638
% O 0 0.00042239393
) O 0 0.0007300592
, O 0 0.00072598475
dry B-Disease 2 0.8154446
mouth I-Disease 2 0.8415042
( O 0 0.00070194533
10 O 0 0.00022543932
% O 0 0.00029379243
) O 0 0.00045061592
, O 0 0.0003408497
behavioral O 0 0.0046974286
change O 0 0.0002653449
( O 0 0.00035901216
22 O 0 0.0002604175
% O 0 0.00026838685
) O 0 0.0004302344
, O 0 0.00035161152
and O 0 0.0005497847
gastrointestinal B-Disease 0 0.9974159
symptoms I-Disease 0 0.9776595
( O 0 0.0008236199
18 O 0 0.0002783551
% O 0 0.00037103664
) O 0 0.0011435241
; O 0 0.00801944
mazindol B-Chemical 0 0.9999964
dosage O 0 0.048962586
was O 0 0.00045876837
reduced O 0 0.0005222776
in O 0 0.00070904574
43 O 0 0.0013737894
% O 0 0.0016696141
of O 0 0.002659216
patients O 0 0.0054969583
. O 0 0.00687518

The O 0 0.0031937566
effect O 0 0.0025629213
of O 0 0.0054975348
mazindol B-Chemical 0 0.9999956
on O 0 0.0013141594
GH O 0 0.99400145
secretion O 0 0.006046533
was O 0 0.00047638075
estimated O 0 0.00029123566
indirectly O 0 0.00037189454
by O 0 0.0002459513
comparing O 0 0.00015909823
the O 0 0.00029481653
postabsorptive O 0 0.7588402
IGF O 0 0.99932134
- O 0 0.13649182
I O 0 0.00750803
levels O 0 0.00016597766
obtained O 0 0.00015010354
following O 0 0.00014937393
3 O 0 0.00015529849
, O 0 0.0002225604
6 O 0 0.00014563215
, O 0 0.0002272894
9 O 0 0.00017894282
, O 0 0.00021819044
and O 0 0.0001967388
12 O 0 0.00014606967
months O 0 0.00013590876
in O 0 0.00019925435
the O 0 0.0004028468
mazindol B-Chemical 0 0.99998605
treated O 0 0.00050291687
to O 0 0.00037804135
those O 0 0.00063123286
in O 0 0.00074796885
the O 0 0.0012597998
placebo O 0 0.01024454
groups O 0 0.0032672565
. O 0 0.0058876565

Although O 0 0.0072981506
mazindol B-Chemical 0 0.9999912
- O 0 0.08532835
treated O 0 0.001719121
patients O 0 0.0012598953
gained O 0 0.0008162156
less O 0 0.0004668946
weight O 0 0.0010086366
and O 0 0.00042778495
height O 0 0.0011459161
than O 0 0.00029405864
placebo O 0 0.034197778
- O 0 0.002992745
treated O 0 0.00032758302
patients O 0 0.00040713916
, O 0 0.00032108097
no O 0 0.00019759663
significant O 0 0.00030323173
effect O 0 0.0004132972
on O 0 0.00053120276
IGF O 0 0.99833703
- O 0 0.15941888
I O 0 0.017661117
levels O 0 0.001508769
was O 0 0.0023556028
observed O 0 0.0035086328
. O 0 0.007086315

Mazindol B-Chemical 0 0.9994435
doses O 0 0.014478594
not O 0 0.0029068042
slow O 0 0.003234255
the O 0 0.0022634484
progression O 0 0.13088025
of O 0 0.0055715153
weakness B-Disease 0 0.99444026
in O 0 0.011434832
Duchenne B-Disease 0 0.9997907
dystrophy I-Disease 0 0.9997662
. O 0 0.013650188

Facilitation O 0 0.010847112
of O 0 0.0032905687
memory O 0 0.077315524
retrieval O 0 0.0021880132
by O 0 0.0012244233
pre O 0 0.004082779
- O 0 0.017134087
test O 0 0.0013453965
morphine B-Chemical 0 0.9999175
and O 0 0.0006047581
its O 0 0.00062690326
state O 0 0.00040493018
dependency O 0 0.00044934024
in O 0 0.00023308383
the O 0 0.00022953625
step O 0 0.0002943461
- O 0 0.0013143064
through O 0 0.00025126486
type O 0 0.00043174197
passive O 0 0.0011219378
avoidance O 0 0.0036408075
learning O 0 0.0021263612
test O 0 0.0014068681
in O 0 0.0019525805
mice O 0 0.0027874624
. O 0 0.006502141

Amnesia B-Disease 0 0.9684059
produced O 0 0.0032401306
by O 0 0.006095597
scopolamine B-Chemical 1 0.9999988
and O 0 0.01874936
cycloheximide B-Chemical 1 0.9995989
were O 0 0.0009935976
reversed O 0 0.00078486267
by O 0 0.0007732795
morphine B-Chemical 0 0.9998325
given O 0 0.00016542562
30 O 0 0.00014944829
min O 0 0.0001753743
before O 0 0.000101120684
the O 0 0.00012863394
test O 0 0.00016542878
trial O 0 0.0002446514
( O 0 0.0003496839
pre O 0 0.0014592243
- O 0 0.005631088
test O 0 0.00027634174
) O 0 0.0006250005
, O 0 0.00033722725
and O 0 0.0003088441
pre O 0 0.003479854
- O 0 0.016436515
test O 0 0.0006382667
morphine B-Chemical 0 0.9998154
also O 0 0.00019223978
facilitated O 0 0.000193309
the O 0 0.00022444419
memory O 0 0.08082326
retrieval O 0 0.00044588055
in O 0 0.00023309093
the O 0 0.00025909848
animals O 0 0.0003205399
administered O 0 0.00092033914
naloxone B-Chemical 1 0.9999082
during O 0 0.00070784905
the O 0 0.0011971747
training O 0 0.0020027747
trial O 0 0.0038149885
. O 0 0.0059051486

Similarly O 0 0.0055946023
, O 0 0.0045711333
pre O 0 0.010339222
- O 0 0.056134287
test O 0 0.0053850887
scopolamine B-Chemical 1 0.9999989
partially O 0 0.0017324977
reversed O 0 0.0020449813
the O 0 0.0062028235
scopolamine B-Chemical 1 0.9999999
- O 0 0.33823353
induced O 0 0.004495042
amnesia B-Disease 0 0.99999154
, O 0 0.0017606799
but O 0 0.00036778234
not O 0 0.00019494671
significantly O 0 0.0002625781
; O 0 0.0004339749
and O 0 0.00031161896
pre O 0 0.0022524516
- O 0 0.007586455
test O 0 0.00046493707
cycloheximide B-Chemical 1 0.99449944
failed O 0 0.0005435212
to O 0 0.0003734147
reverse O 0 0.0059059323
the O 0 0.0012439347
cycloheximide B-Chemical 1 0.9996699
- O 0 0.31101623
induced O 0 0.018622227
amnesia B-Disease 0 0.9999286
. O 0 0.009118302

These O 0 0.0033515636
results O 0 0.0019466378
suggest O 0 0.0011020246
that O 0 0.000943701
the O 0 0.00084272336
facilitation O 0 0.0028183104
of O 0 0.0008439593
memory O 0 0.2295003
retrieval O 0 0.0009224351
by O 0 0.0004318198
pre O 0 0.0037656354
- O 0 0.020030739
test O 0 0.0009399796
morphine B-Chemical 0 0.9998884
might O 0 0.00019139607
be O 0 0.00020283934
the O 0 0.00018761164
direct O 0 0.00020954756
action O 0 0.0005307687
of O 0 0.0012417542
morphine B-Chemical 0 0.9999162
rather O 0 0.00046613617
than O 0 0.00047147536
a O 0 0.0008792212
state O 0 0.00132698
dependent O 0 0.0017075032
effect O 0 0.0033391123
. O 0 0.006477041

Naloxone B-Chemical 0 0.99997056
reverses O 0 0.08395644
the O 0 0.008625679
antihypertensive O 0 0.9834536
effect O 0 0.008289309
of O 0 0.026592283
clonidine B-Chemical 0 0.9999547
. O 0 0.018375872

In O 0 0.0045389356
unanesthetized O 0 0.020773849
, O 0 0.0037275334
spontaneously O 0 0.028625064
hypertensive B-Disease 2 0.9996251
rats O 0 0.0014114797
the O 0 0.00048147092
decrease O 0 0.00042138423
in O 0 0.0004020987
blood O 0 0.011642795
pressure O 0 0.032836873
and O 0 0.0003490046
heart O 0 0.017008318
rate O 0 0.00021165193
produced O 0 0.00017251728
by O 0 0.00032511703
intravenous O 0 0.45747823
clonidine B-Chemical 0 0.99998856
, O 0 0.00039873956
5 O 0 0.00012798756
to O 0 0.00011522065
20 O 0 0.00015183339
micrograms O 0 0.0016972269
/ O 0 0.001695871
kg O 0 0.0012898761
, O 0 0.0003550517
was O 0 0.00020513556
inhibited O 0 0.00023718165
or O 0 0.00022174616
reversed O 0 0.0003307992
by O 0 0.00038180003
nalozone B-Chemical 0 0.681386
, O 0 0.0006305174
0 O 0 0.00040466432
. O 0 0.00035864906
2 O 0 0.00044409683
to O 0 0.0005651693
2 O 0 0.0010070677
mg O 0 0.007173967
/ O 0 0.0047162045
kg O 0 0.0074935104
. O 0 0.0074346648

The O 0 0.0042239693
hypotensive B-Disease 0 0.9835276
effect O 0 0.0019014339
of O 0 0.001599816
100 O 0 0.0021563156
mg O 0 0.10104283
/ O 0 0.009769851
kg O 0 0.033038266
alpha B-Chemical 1 0.99820065
- I-Chemical 1 0.9429669
methyldopa I-Chemical 1 0.9999999
was O 0 0.0010418413
also O 0 0.00080826995
partially O 0 0.0011784844
reversed O 0 0.002420002
by O 0 0.005160017
naloxone B-Chemical 1 0.999964
. O 0 0.00941584

Naloxone B-Chemical 0 0.99997866
alone O 0 0.007025374
did O 0 0.0034622026
not O 0 0.002011005
affect O 0 0.0015463048
either O 0 0.0019245598
blood O 0 0.01699673
pressure O 0 0.05363032
or O 0 0.0032180364
heart O 0 0.080058835
rate O 0 0.0066794865
. O 0 0.009887565

In O 0 0.004428855
brain O 0 0.009016627
membranes O 0 0.005828223
from O 0 0.00142913
spontaneously O 0 0.02145217
hypertensive B-Disease 2 0.999851
rats O 0 0.021068294
clonidine B-Chemical 0 0.99998856
, O 0 0.00096989196
10 O 0 0.00035274096
( O 0 0.0005877989
- O 0 0.0025716557
8 O 0 0.00022923248
) O 0 0.00030125215
to O 0 0.00017491936
10 O 0 0.0002128626
( O 0 0.00041242855
- O 0 0.002726127
5 O 0 0.00022061751
) O 0 0.00096043205
M O 0 0.96559125
, O 0 0.0006193632
did O 0 0.0002526083
not O 0 0.00015909065
influence O 0 0.0001533546
stereoselective O 0 0.29697987
binding O 0 0.00039444605
of O 0 0.0014816984
[ B-Chemical 0 0.24443072
3H I-Chemical 0 0.9955929
] I-Chemical 0 0.062460057
- I-Chemical 0 0.41720498
naloxone I-Chemical 1 0.99999547
( O 0 0.001243436
8 O 0 0.00022482136
nM O 0 0.0071652844
) O 0 0.0011197563
, O 0 0.0005344462
and O 0 0.0014517972
naloxone B-Chemical 1 0.9999943
, O 0 0.0007446134
10 O 0 0.00022537423
( O 0 0.00043774417
- O 0 0.002671783
8 O 0 0.00017161522
) O 0 0.00024408243
to O 0 0.0001443182
10 O 0 0.00018536762
( O 0 0.00039283003
- O 0 0.0037229464
4 O 0 0.00021583948
) O 0 0.0009394134
M O 0 0.9656245
, O 0 0.0006158236
did O 0 0.00026302558
not O 0 0.0001879185
influence O 0 0.00030503437
clonidine B-Chemical 0 0.99999464
- O 0 0.06208968
suppressible O 0 0.019129671
binding O 0 0.00054605893
of O 0 0.0017734676
[ B-Chemical 0 0.19213966
3H I-Chemical 0 0.9897384
] I-Chemical 0 0.025328709
- I-Chemical 0 0.112264305
dihydroergocryptine I-Chemical 0 0.9970795
( O 0 0.0019035399
1 O 0 0.0016399847
nM O 0 0.01091099
) O 0 0.006881623
. O 0 0.007854551

These O 0 0.0035930427
findings O 0 0.0025921848
indicate O 0 0.00123698
that O 0 0.0010905401
in O 0 0.0011525458
spontaneously O 0 0.0212269
hypertensive B-Disease 2 0.99967635
rats O 0 0.0007856588
the O 0 0.00031944588
effects O 0 0.0003714922
of O 0 0.00044883494
central O 0 0.0038644022
alpha O 0 0.96487135
- O 0 0.5694025
adrenoceptor O 0 0.9999031
stimulation O 0 0.00074426364
involve O 0 0.0006327149
activation O 0 0.001649326
of O 0 0.0045168884
opiate O 0 0.99963915
receptors O 0 0.053051624
. O 0 0.007292208

As O 0 0.0059747826
naloxone B-Chemical 1 0.9999707
and O 0 0.04110095
clonidine B-Chemical 0 0.9999871
do O 0 0.0012183463
not O 0 0.0005702478
appear O 0 0.00041772527
to O 0 0.00027218732
interact O 0 0.00020391052
with O 0 0.00027193362
the O 0 0.00021929917
same O 0 0.0001630192
receptor O 0 0.004670657
site O 0 0.00034694056
, O 0 0.0003396945
the O 0 0.00016515014
observed O 0 0.00015373203
functional O 0 0.00026892938
antagonism O 0 0.073806256
suggests O 0 0.00011875173
the O 0 0.000159624
release O 0 0.0006881908
of O 0 0.00025879385
an O 0 0.000313795
endogenous O 0 0.0006870342
opiate O 0 0.99975985
by O 0 0.0016587221
clonidine B-Chemical 0 0.9999938
or O 0 0.0023477897
alpha B-Chemical 1 0.99956626
- I-Chemical 1 0.97985053
methyldopa I-Chemical 1 1.0
and O 0 0.0005160878
the O 0 0.00017099844
possible O 0 0.00016124263
role O 0 0.0001288628
of O 0 0.00031067565
the O 0 0.00048203184
opiate O 0 0.9977889
in O 0 0.00033877298
the O 0 0.00039779345
central O 0 0.0007126788
control O 0 0.00086167455
of O 0 0.0019051842
sympathetic O 0 0.13712211
tone O 0 0.09573073
. O 0 0.0066802907

Neurotoxicity B-Disease 0 0.9996978
of O 0 0.018762348
halogenated B-Chemical 0 0.99983525
hydroxyquinolines I-Chemical 0 0.99874663
: O 0 0.0044416734
clinical O 0 0.0030034373
analysis O 0 0.0016516234
of O 0 0.00199181
cases O 0 0.0029919199
reported O 0 0.0035338271
outside O 0 0.004402802
Japan O 0 0.12912169
. O 0 0.009904327

An O 0 0.005102901
analysis O 0 0.0027577928
is O 0 0.001900218
presented O 0 0.0012779373
of O 0 0.0012540844
220 O 0 0.00220957
cases O 0 0.0009842832
of O 0 0.0008311115
possible O 0 0.0012414248
neurotoxic B-Disease 0 0.99932003
reactions O 0 0.05814332
to O 0 0.0011986884
halogenated B-Chemical 0 0.999861
hydroxyquinolines I-Chemical 0 0.9963523
reported O 0 0.0016984829
from O 0 0.0015579899
outside O 0 0.002687907
Japan O 0 0.08818234
. O 0 0.007113803

In O 0 0.003761068
80 O 0 0.0027049102
cases O 0 0.0019693973
insufficient O 0 0.001204709
information O 0 0.0009190273
was O 0 0.00067505066
available O 0 0.00051185524
for O 0 0.00036924114
adequate O 0 0.00034767957
comment O 0 0.000793952
and O 0 0.00034543822
in O 0 0.00029506878
29 O 0 0.00040934148
a O 0 0.000272462
relationship O 0 0.00019219742
to O 0 0.00026929317
the O 0 0.00039241198
administration O 0 0.0049354155
of O 0 0.0024894965
clioquinol B-Chemical 0 0.9999844
could O 0 0.001424034
be O 0 0.0022342212
excluded O 0 0.0039232224
. O 0 0.006527658

Of O 0 0.0048869825
the O 0 0.0026921674
remainder O 0 0.002365495
, O 0 0.0018830146
a O 0 0.0011833401
relationship O 0 0.00067186914
to O 0 0.0009952119
clioquinol B-Chemical 0 0.9999856
was O 0 0.0007197926
considered O 0 0.00048083888
probable O 0 0.0032262912
in O 0 0.00056546973
42 O 0 0.0007786846
and O 0 0.0008007182
possible O 0 0.0011163898
in O 0 0.0016463684
69 O 0 0.0033736224
cases O 0 0.005151223
. O 0 0.0074287904

In O 0 0.003515769
six O 0 0.0018010237
of O 0 0.0016442124
the O 0 0.0012066874
probable O 0 0.009560095
cases O 0 0.0016079511
the O 0 0.0010554586
neurological B-Disease 0 0.9991067
disturbance I-Disease 0 0.7823496
consisted O 0 0.00026836692
of O 0 0.0003767844
an O 0 0.0006877322
acute O 0 0.94384557
reversible O 0 0.92727417
encephalopathy B-Disease 2 0.9999988
usually O 0 0.0013181764
related O 0 0.00013599898
to O 0 0.00014606633
the O 0 0.00021006167
ingestion O 0 0.114753574
of O 0 0.00033729477
a O 0 0.000387815
high O 0 0.0005251237
dose O 0 0.0032040789
of O 0 0.0021191058
clioquinol B-Chemical 0 0.99997866
over O 0 0.0007377765
a O 0 0.0013888982
short O 0 0.0016506942
period O 0 0.0028283936
. O 0 0.0058376663

The O 0 0.0036330838
most O 0 0.0031588778
common O 0 0.0025689683
manifestation O 0 0.016862785
, O 0 0.0016252494
observed O 0 0.0008294256
in O 0 0.000764759
15 O 0 0.0006528186
further O 0 0.0007068679
cases O 0 0.001257229
, O 0 0.0015733084
was O 0 0.0016674519
isolated O 0 0.0024068078
optic B-Disease 0 0.99672467
atrophy I-Disease 2 0.9998134
. O 0 0.011334018

This O 0 0.005494387
was O 0 0.0028626295
most O 0 0.0022277695
frequently O 0 0.001566035
found O 0 0.0008639807
in O 0 0.0007381931
children O 0 0.0012311764
, O 0 0.0007710423
many O 0 0.00043506702
of O 0 0.0005288341
whom O 0 0.00095953746
had O 0 0.0004983644
received O 0 0.00066053367
clioquinol B-Chemical 0 0.99997616
as O 0 0.00088430627
treatment O 0 0.0018044664
for O 0 0.0029317192
acrodermatitis B-Disease 0 0.99899846
enteropathica I-Disease 0 0.99992895
. O 0 0.010757782

In O 0 0.003668859
the O 0 0.0022424434
remaining O 0 0.0017225164
cases O 0 0.0018991748
, O 0 0.001450668
a O 0 0.00097005145
combination O 0 0.0009809377
of O 0 0.0032941925
myelopathy B-Disease 0 0.9999987
, O 0 0.010322631
visual B-Disease 0 0.96507674
disturbance I-Disease 0 0.9095203
, O 0 0.0011028328
and O 0 0.0010754833
peripheral B-Disease 2 0.8687858
neuropathy I-Disease 2 0.99999714
was O 0 0.0009074537
the O 0 0.0009472102
most O 0 0.0018215289
common O 0 0.0030205315
manifestation O 0 0.06021526
. O 0 0.0069318474

Isolated O 0 0.01697177
myelopathy B-Disease 0 0.99995506
or O 0 0.006169711
peripheral B-Disease 2 0.96397024
neuropathy I-Disease 2 0.9999982
, O 0 0.0027091738
or O 0 0.0009842644
these O 0 0.0010725325
manifestations O 0 0.09298466
occurring O 0 0.0014826752
together O 0 0.0014748768
, O 0 0.0026904717
were O 0 0.0031524114
infrequent O 0 0.009046891
. O 0 0.007747233

The O 0 0.0033147593
onset O 0 0.003170833
of O 0 0.0019520302
all O 0 0.0013926504
manifestations O 0 0.24097013
( O 0 0.0018887112
except O 0 0.0009942916
toxic O 0 0.9873002
encephalopathy B-Disease 2 0.9999988
) O 0 0.027295548
was O 0 0.0007992
usually O 0 0.0014743711
subacute O 0 0.98869705
, O 0 0.0012137422
with O 0 0.0010603647
subsequent O 0 0.0015757612
partial O 0 0.0030643912
recovery O 0 0.005523675
. O 0 0.006725123

Older O 0 0.023477029
subjects O 0 0.0077135945
tended O 0 0.0050571156
to O 0 0.0045299996
display O 0 0.0052886084
more O 0 0.0069427798
side O 0 0.020347878
effects O 0 0.012260617
. O 0 0.01548934

The O 0 0.0031582387
full O 0 0.0023188496
syndrome O 0 0.09993231
of O 0 0.0028505493
subacute O 0 0.99930143
myelo B-Disease 0 0.9634096
- I-Disease 0 0.7793067
optic I-Disease 0 0.9999908
neuropathy I-Disease 0 0.99999976
was O 0 0.0008468642
more O 0 0.00046666389
frequent O 0 0.00084836886
in O 0 0.0002789861
women O 0 0.004081916
, O 0 0.00045644207
but O 0 0.00032725747
they O 0 0.00021721609
tended O 0 0.00023407287
to O 0 0.00022933084
have O 0 0.00028053496
taken O 0 0.00034986244
greater O 0 0.00053577445
quantities O 0 0.000882344
of O 0 0.001644541
the O 0 0.0026496954
drug O 0 0.35298538
. O 0 0.00737357

Prazosin B-Chemical 0 0.9999784
- O 0 0.18471856
induced O 0 0.029095726
stress B-Disease 2 0.98996395
incontinence I-Disease 2 0.9995276
. O 0 0.043094143

A O 0 0.02902923
case O 0 0.0034001102
of O 0 0.0026291406
genuine O 0 0.0041144188
stress B-Disease 2 0.9751693
incontinence I-Disease 2 0.9998246
due O 0 0.0011057904
to O 0 0.0019626562
prazosin B-Chemical 1 0.9999994
, O 0 0.0025925892
a O 0 0.001163725
common O 0 0.0018916605
antihypertensive O 0 0.97556937
drug O 0 0.288067
, O 0 0.0024468552
is O 0 0.0027096532
presented O 0 0.003845235
. O 0 0.0067647384

Prazosin B-Chemical 0 0.99999154
exerts O 0 0.010772563
its O 0 0.018256499
antihypertensive O 0 0.98579097
effects O 0 0.001792393
through O 0 0.00072226796
vasodilatation O 0 0.99859196
caused O 0 0.0005987655
by O 0 0.0005478643
selective O 0 0.0011619625
blockade O 0 0.0038052388
of O 0 0.0011097298
postsynaptic O 0 0.8557879
alpha O 0 0.9433691
- O 0 0.17553613
1 O 0 0.0024571256
adrenergic O 0 0.89660233
receptors O 0 0.015892655
. O 0 0.007492702

As O 0 0.00391519
an O 0 0.0049695866
alpha O 0 0.95363325
- O 0 0.4328218
blocker O 0 0.98272806
, O 0 0.0026378476
it O 0 0.0008575839
also O 0 0.00054721505
exerts O 0 0.0005894259
a O 0 0.0006999859
significant O 0 0.0006694184
relaxant O 0 0.58729213
effect O 0 0.00051847094
on O 0 0.00048165227
the O 0 0.0008998158
bladder O 0 0.18337484
neck O 0 0.20743443
and O 0 0.0033816227
urethra O 0 0.032587666
. O 0 0.007436467

The O 0 0.0032542031
patient O 0 0.002498947
' O 0 0.0020982616
s O 0 0.0015292946
clinical O 0 0.0016353001
course O 0 0.000653329
is O 0 0.0005098301
described O 0 0.00034214856
and O 0 0.00033203876
correlated O 0 0.00021937613
with O 0 0.00023064589
initial O 0 0.00021230357
urodynamic O 0 0.001594353
studies O 0 0.00025834658
while O 0 0.00031899882
on O 0 0.0003636192
prazosin B-Chemical 1 0.99999774
and O 0 0.00071541645
subsequent O 0 0.00067838695
studies O 0 0.0009790484
while O 0 0.0017022792
taking O 0 0.034742508
verapamil B-Chemical 0 0.9999635
. O 0 0.008830637

Her O 0 0.0151253985
incontinence B-Disease 0 0.7567626
resolved O 0 0.006633548
with O 0 0.004831881
the O 0 0.0048532654
change O 0 0.005977389
of O 0 0.00881118
medication O 0 0.16150297
. O 0 0.013546453

The O 0 0.0032497873
restoration O 0 0.0028837372
of O 0 0.002159959
continence O 0 0.0060331477
was O 0 0.0010187629
accompanied O 0 0.00091881753
by O 0 0.0006505517
a O 0 0.00058601
substantial O 0 0.00042681384
rise O 0 0.0004080052
in O 0 0.0002757133
maximum O 0 0.00027074025
urethral O 0 0.005836177
pressure O 0 0.026955368
, O 0 0.00036594775
maximum O 0 0.0002845315
urethral O 0 0.002995022
closure O 0 0.009072514
pressure O 0 0.026356313
, O 0 0.00083401665
and O 0 0.00093283947
functional O 0 0.0013787813
urethral O 0 0.004844467
length O 0 0.0032911717
. O 0 0.0066018845

Patients O 0 0.0046870788
who O 0 0.00276163
present O 0 0.0013245555
with O 0 0.0015922892
stress B-Disease 2 0.9747004
incontinence I-Disease 2 0.9999502
while O 0 0.0091092335
taking O 0 0.14097641
prazosin B-Chemical 1 0.9999995
should O 0 0.00027425433
change O 0 0.0003338531
their O 0 0.00034965703
antihypertensive O 0 0.9230431
medication O 0 0.0045131696
before O 0 0.00010261738
considering O 0 0.00014784848
surgery O 0 0.00030872104
, O 0 0.00023007418
because O 0 0.00015732102
their O 0 0.00028346092
incontinence B-Disease 0 0.91684437
may O 0 0.00024873827
resolve O 0 0.00023877861
spontaneously O 0 0.00057311874
with O 0 0.00043579214
a O 0 0.0006901283
change O 0 0.00092748046
in O 0 0.0014501329
drug O 0 0.24085099
therapy O 0 0.006843356
. O 0 0.006469972

Myocardial B-Disease 0 0.99852127
infarction I-Disease 2 0.9999956
following O 0 0.010896287
sublingual O 0 0.98380417
administration O 0 0.48602822
of O 0 0.37848684
isosorbide B-Chemical 0 0.9999999
dinitrate I-Chemical 0 0.99999905
. O 0 0.025542926

A O 0 0.08237379
78 O 0 0.007060909
- O 0 0.008131252
year O 0 0.002121312
- O 0 0.0034552221
old O 0 0.0009616242
with O 0 0.0007079455
healed O 0 0.012828555
septal O 0 0.2325587
necrosis B-Disease 2 0.999905
suffered O 0 0.2384582
a O 0 0.0022069404
recurrent O 0 0.8378034
myocardial B-Disease 0 0.99999046
infarction I-Disease 2 0.99999976
of O 0 0.0018359353
the O 0 0.00037322927
anterior O 0 0.028636217
wall O 0 0.0037123815
following O 0 0.00022579772
the O 0 0.00032035477
administration O 0 0.012110752
of O 0 0.04047665
isosorbide B-Chemical 0 1.0
dinitrate I-Chemical 0 0.9999999
5 O 0 0.0021815007
mg O 0 0.25822884
sublingually O 0 0.83711123
. O 0 0.0060928618

After O 0 0.0026781133
detailing O 0 0.0024284893
the O 0 0.0014920834
course O 0 0.0011277562
of O 0 0.0011596828
events O 0 0.009486475
, O 0 0.0007907189
we O 0 0.0002812634
discuss O 0 0.00023565383
the O 0 0.00023567294
role O 0 0.00018625132
of O 0 0.00048040276
paradoxical O 0 0.35084206
coronary O 2 0.99920493
spasm B-Disease 2 0.99999964
and O 0 0.056562077
hypotension B-Disease 2 0.9999988
- O 0 0.09792246
mediated O 0 0.00030378788
myocardial B-Disease 0 0.9999621
ischemia I-Disease 2 0.99999607
occurring O 0 0.0010496667
downstream O 0 0.00017439527
to O 0 0.00016254984
significant O 0 0.00029749493
coronary B-Disease 0 0.72903585
arterial I-Disease 0 0.84399414
stenosis I-Disease 0 0.9995498
in O 0 0.00039399418
the O 0 0.00045798798
pathophysiology O 0 0.009783433
of O 0 0.001978403
acute B-Disease 0 0.9946091
coronary I-Disease 0 0.9751397
insufficiency I-Disease 0 0.99975985
. O 0 0.010113437

Comparison O 0 0.0032650074
of O 0 0.0025853834
the O 0 0.0018165645
respiratory O 0 0.023082279
effects O 0 0.0015979565
of O 0 0.0012937455
i O 0 0.012369144
. O 0 0.00066185853
v O 0 0.018632028
. O 0 0.0005311141
infusions O 0 0.001857485
of O 0 0.0010343273
morphine B-Chemical 0 0.9998976
and O 0 0.0009897014
regional O 0 0.0021319026
analgesia O 0 0.7462764
by O 0 0.0017262395
extradural O 0 0.34970796
block O 0 0.0035842767
. O 0 0.0064549674

The O 0 0.003101809
incidence O 0 0.0034940506
of O 0 0.0020613854
postoperative O 0 0.010185422
respiratory O 0 0.31218755
apnoea B-Disease 0 0.99735403
was O 0 0.0005372416
compared O 0 0.00022347344
between O 0 0.00018297919
five O 0 0.00016442388
patients O 0 0.00024389749
receiving O 0 0.00021458656
a O 0 0.00020368588
continuous O 0 0.00017400378
i O 0 0.0018479922
. O 0 0.00022268308
v O 0 0.014020538
. O 0 0.00022549178
infusion O 0 0.0007659007
of O 0 0.00075165654
morphine B-Chemical 0 0.99994373
( O 0 0.00036579653
mean O 0 0.000108191205
73 O 0 0.0003068261
. O 0 0.00013590358
6 O 0 0.0001232671
mg O 0 0.002136276
) O 0 0.0002728353
and O 0 0.00016214505
five O 0 0.000106505715
patients O 0 0.00016780673
receiving O 0 0.00014966734
a O 0 0.00014624989
continuous O 0 0.00013449862
extradural O 0 0.14939235
infusion O 0 0.00026758993
of O 0 0.00016958157
0 O 0 0.00019718861
. O 0 0.0001414034
25 O 0 0.00021782088
% O 0 0.00045203068
bupivacaine B-Chemical 1 0.9998029
( O 0 0.00025989735
mean O 0 0.000120207296
192 O 0 0.000997054
mg O 0 0.004996677
) O 0 0.00034830012
in O 0 0.00021245664
the O 0 0.0002611674
24 O 0 0.0003562696
- O 0 0.00088767
h O 0 0.00047001836
period O 0 0.00050985324
following O 0 0.00077565847
upper O 0 0.0019104014
abdominal O 0 0.022632102
surgery O 0 0.005245971
. O 0 0.0061925584

Monitoring O 0 0.0047167568
consisted O 0 0.00205491
of O 0 0.0020088188
airflow O 0 0.2012046
detection O 0 0.001706235
by O 0 0.0009659551
a O 0 0.001389708
carbon B-Chemical 0 0.99626946
dioxide I-Chemical 0 0.99961215
analyser O 0 0.16204794
, O 0 0.00061431737
chest O 0 0.002090229
wall O 0 0.0012192833
movement O 0 0.00044711572
detected O 0 0.00021659546
by O 0 0.0002804967
pneumatic O 0 0.00248809
capsules O 0 0.0021125297
, O 0 0.00037042366
and O 0 0.00031990613
continuous O 0 0.00033497784
electrocardiograph O 0 0.013983144
recorded O 0 0.00047305282
with O 0 0.00069946976
a O 0 0.0013557496
Holter O 0 0.18237641
ambulatory O 0 0.0023095277
monitor O 0 0.0027702209
. O 0 0.005660665

Both O 0 0.005190257
obstructive B-Disease 0 0.963428
( I-Disease 0 0.0068671624
P I-Disease 0 0.10016908
less I-Disease 0 0.0009835694
than I-Disease 0 0.0005612396
0 I-Disease 0 0.00063335325
. I-Disease 0 0.00049466547
05 I-Disease 0 0.0030868642
) I-Disease 0 0.00057176186
and I-Disease 0 0.0003710174
central I-Disease 0 0.000805735
apnoea I-Disease 0 0.9905129
( O 0 0.001318136
P O 0 0.046776637
less O 0 0.00023260473
than O 0 0.00017523757
0 O 0 0.00027174002
. O 0 0.0002595435
05 O 0 0.0028939792
) O 0 0.00043839525
occurred O 0 0.00028641248
more O 0 0.00033827176
frequently O 0 0.0003885807
in O 0 0.00036136346
patients O 0 0.0006713805
who O 0 0.0009322806
had O 0 0.0009671813
a O 0 0.0028845896
morphine B-Chemical 0 0.9998746
infusion O 0 0.019162765
. O 0 0.0065188636

There O 0 0.004417508
was O 0 0.0027195592
also O 0 0.0017918489
a O 0 0.0016234956
higher O 0 0.0010544835
incidence O 0 0.00288996
of O 0 0.0028563791
tachyarrhythmias B-Disease 0 0.9999932
( O 0 0.018437406
P O 0 0.19234686
less O 0 0.0003105495
than O 0 0.00019927582
0 O 0 0.00028316083
. O 0 0.0002464621
05 O 0 0.0031658467
) O 0 0.0004025762
and O 0 0.00031685893
ventricular B-Disease 0 0.7908557
ectopic I-Disease 0 0.0056980136
beats I-Disease 0 0.7054541
( O 0 0.0010491272
P O 0 0.036132768
less O 0 0.00023677676
than O 0 0.00020014205
0 O 0 0.00033266513
. O 0 0.00036868363
05 O 0 0.003265032
) O 0 0.00078052364
in O 0 0.0006959265
the O 0 0.0013673843
morphine B-Chemical 0 0.99984264
infusion O 0 0.007883707
group O 0 0.0043334477
. O 0 0.006413066

Effects O 0 0.0067175403
of O 0 0.0058069187
aminophylline B-Chemical 0 0.99994135
on O 0 0.0013329776
the O 0 0.00110954
threshold O 0 0.00091322477
for O 0 0.0010385421
initiating O 0 0.002591971
ventricular B-Disease 0 0.98111653
fibrillation I-Disease 0 0.9999831
during O 0 0.0024521088
respiratory B-Disease 0 0.22747518
failure I-Disease 0 0.6735731
. O 0 0.009077738

Cardiac B-Disease 0 0.98338866
arrhythmias I-Disease 2 0.99995744
have O 0 0.0032250278
frequently O 0 0.002780186
been O 0 0.0018353097
reported O 0 0.0017693603
in O 0 0.0016832959
association O 0 0.0020640779
with O 0 0.003694541
respiratory B-Disease 0 0.27835205
failure I-Disease 0 0.78614473
. O 0 0.011539109

The O 0 0.0030053586
possible O 0 0.0022394583
additive O 0 0.002971254
role O 0 0.0008866079
of O 0 0.001223151
pharmacologic O 0 0.047436375
agents O 0 0.030608647
in O 0 0.0007966696
precipitating O 0 0.91841793
cardiac B-Disease 0 0.9791236
disturbances I-Disease 0 0.9724364
in O 0 0.00038519147
patients O 0 0.00052477216
with O 0 0.00047141564
respiratory B-Disease 0 0.060563833
failure I-Disease 0 0.24025504
has O 0 0.00070863025
only O 0 0.0009994269
recently O 0 0.0014291327
been O 0 0.0021585042
emphasized O 0 0.003552433
. O 0 0.0067304126

The O 0 0.0031659447
effects O 0 0.002871744
of O 0 0.003502303
aminophylline B-Chemical 0 0.99997437
on O 0 0.00072296895
the O 0 0.000867149
ventricular B-Disease 0 0.9655748
fibrillation I-Disease 0 0.999992
threshold O 0 0.00037334298
during O 0 0.00023467893
normal O 0 0.0014598471
acid O 0 0.9007981
- O 0 0.013662553
base O 0 0.0006228025
conditions O 0 0.00028839352
and O 0 0.00030181732
during O 0 0.00023037271
respiratory B-Disease 0 0.028776497
failure I-Disease 0 0.118847676
were O 0 0.00041477944
studied O 0 0.0004904262
in O 0 0.00064043136
anesthetized O 0 0.0022126737
open O 0 0.0017531099
chest O 0 0.007672846
dogs O 0 0.0053480477
. O 0 0.006234865

The O 0 0.003971751
ventricular B-Disease 0 0.8479077
fibrillation I-Disease 0 0.9999491
threshold O 0 0.0013223572
was O 0 0.00079624914
measured O 0 0.00045854977
by O 0 0.00045096764
passing O 0 0.0005419584
a O 0 0.0003953586
gated O 0 0.00046608638
train O 0 0.00030618324
of O 0 0.0002582279
12 O 0 0.00017048302
constant O 0 0.00019355283
current O 0 0.000257483
pulses O 0 0.00026495455
through O 0 0.00016585365
the O 0 0.00025361055
ventricular O 0 0.41482213
myocardium O 0 0.09950268
during O 0 0.00023203836
the O 0 0.0003268923
vulnerable O 0 0.00073193636
period O 0 0.00047494503
of O 0 0.0009245282
the O 0 0.0014224483
cardiac O 0 0.034151677
cycle O 0 0.0065780575
. O 0 0.00679227

During O 0 0.0027703238
the O 0 0.0022294575
infusion O 0 0.004130516
of O 0 0.0039188717
aminophylline B-Chemical 0 0.9999944
, O 0 0.003185385
the O 0 0.00088264665
ventricular B-Disease 0 0.9755289
fibrillation I-Disease 0 0.9999944
threshold O 0 0.00036903052
was O 0 0.00025585416
reduced O 0 0.00019925777
by O 0 0.00018479461
30 O 0 0.00013784274
to O 0 0.00011815445
40 O 0 0.00012936645
percent O 0 0.00010701881
of O 0 0.00015357003
the O 0 0.00014196434
control O 0 0.0001565041
when O 0 0.0001350847
pH O 0 0.016528929
and O 0 0.00020418174
partial O 0 0.0002532201
pressures O 0 0.00084389583
of O 0 0.00043628865
oxygen B-Chemical 1 0.99870026
( O 0 0.009834572
PO2 B-Chemical 0 0.9999759
) O 0 0.0012408721
and O 0 0.0005688423
carbon B-Chemical 0 0.9937564
dioxide I-Chemical 0 0.9993364
( O 0 0.0030235718
CO2 B-Chemical 0 0.9854966
) O 0 0.0010139332
were O 0 0.00062155456
kept O 0 0.000748886
within O 0 0.00097163854
normal O 0 0.0025623878
limits O 0 0.0053376937
. O 0 0.0071404222

When O 0 0.0038919838
respiratory B-Disease 0 0.052154005
failure I-Disease 0 0.19632381
was O 0 0.0013536502
produced O 0 0.00082784164
by O 0 0.0010501243
hypoventilation B-Disease 0 0.9987159
( O 0 0.003120194
pH O 0 0.14162935
7 O 0 0.000351354
. O 0 0.00031651685
05 O 0 0.001259176
to O 0 0.00021432215
7 O 0 0.00021053008
. O 0 0.00020831861
25 O 0 0.00027422578
; O 0 0.00042474427
PC02 O 0 0.04480005
70 O 0 0.00018687376
to O 0 0.00014252451
100 O 0 0.00026463723
mm O 0 0.0015297192
Hg O 0 0.9899871
: O 0 0.0008246671
P02 O 0 0.09300454
20 O 0 0.00015474479
to O 0 0.00012051028
40 O 0 0.00015576118
mm O 0 0.0009107178
Hg O 0 0.9881661
) O 0 0.0007063386
, O 0 0.00037156674
infusion O 0 0.0007985705
of O 0 0.00081113435
aminophylline B-Chemical 0 0.99999
resulted O 0 0.00024719493
in O 0 0.00022252835
an O 0 0.00025161274
even O 0 0.00024137682
greater O 0 0.00016967538
decrease O 0 0.00021132204
in O 0 0.00032085605
ventricular B-Disease 0 0.9369938
fibrillation I-Disease 0 0.99998176
threshold O 0 0.00026947606
to O 0 0.00026925575
60 O 0 0.00034800757
percent O 0 0.00039085996
of O 0 0.00073909445
the O 0 0.0010569637
control O 0 0.001816158
level O 0 0.00308587
. O 0 0.0064623724

These O 0 0.0031792584
experiments O 0 0.001674735
suggest O 0 0.0010792043
that O 0 0.0009531339
although O 0 0.000828914
many O 0 0.0006141643
factors O 0 0.0012636507
may O 0 0.00036863095
contribute O 0 0.00025978216
to O 0 0.00023212576
the O 0 0.00023713778
increased O 0 0.00030945448
incidence O 0 0.003449131
of O 0 0.0025492436
ventricular B-Disease 0 0.999887
arrhythmias I-Disease 2 0.99999964
in O 0 0.0009448311
respiratory B-Disease 0 0.25015342
failure I-Disease 0 0.5860957
, O 0 0.0010842605
pharmacologic O 0 0.02628605
agents O 0 0.016863182
, O 0 0.0012799747
particularly O 0 0.028721746
aminophylline B-Chemical 0 0.9999949
, O 0 0.0012798833
may O 0 0.0006312744
play O 0 0.0008830365
a O 0 0.0015482022
significant O 0 0.001984167
role O 0 0.003054273
. O 0 0.0068977857

Pentoxifylline B-Chemical 0 0.99995863
( O 0 0.11501486
Trental B-Chemical 0 0.9996069
) O 0 0.007085833
does O 0 0.001145336
not O 0 0.0007052127
inhibit O 0 0.0007907242
dipyridamole B-Chemical 0 0.99999166
- O 0 0.08700397
induced O 0 0.0009445998
coronary O 0 0.835434
hyperemia B-Disease 2 0.99993837
: O 0 0.0010523304
implications O 0 0.00044905272
for O 0 0.00085058797
dipyridamole B-Chemical 0 0.9999908
- O 0 0.46184167
thallium B-Chemical 0 0.9999056
- O 0 0.088993765
201 O 0 0.04489826
myocardial O 0 0.9944291
imaging O 0 0.010874955
. O 0 0.007311425

Dipyridamole B-Chemical 0 0.9999511
- O 0 0.55937755
thallium B-Chemical 0 0.9997646
- O 0 0.053700622
201 O 0 0.004486651
imaging O 0 0.001810204
is O 0 0.00074740377
often O 0 0.00062969525
performed O 0 0.00043526798
in O 0 0.00045050145
patients O 0 0.0005090631
unable O 0 0.00037533336
to O 0 0.0004948857
exercise O 0 0.0011619483
because O 0 0.0007082556
of O 0 0.0015018214
peripheral B-Disease 0 0.14568335
vascular I-Disease 0 0.8839026
disease I-Disease 0 0.993226
. O 0 0.009588943

Many O 0 0.003938668
of O 0 0.002688857
these O 0 0.0019385306
patients O 0 0.0018474461
are O 0 0.0011892997
taking O 0 0.01695257
pentoxifylline B-Chemical 1 0.9999926
( O 0 0.07576405
Trental B-Chemical 0 0.9998461
) O 0 0.007186092
, O 0 0.0013941805
a O 0 0.0024429127
methylxanthine B-Chemical 0 0.99997497
derivative O 0 0.06725944
which O 0 0.0010535779
may O 0 0.00096242805
improve O 0 0.0013541571
intermittent B-Disease 0 0.038724463
claudication I-Disease 0 0.95023036
. O 0 0.006979383

Whether O 0 0.007117327
pentoxifylline B-Chemical 1 0.9999373
inhibits O 0 0.010263088
dipyridamole B-Chemical 0 0.9999962
- O 0 0.3044211
induced O 0 0.0019884866
coronary O 0 0.8943504
hyperemia B-Disease 2 0.9999528
like O 0 0.0005715327
other O 0 0.001344866
methylxanthines B-Chemical 0 0.9999596
such O 0 0.00034151992
as O 0 0.00053717545
theophylline B-Chemical 1 0.9999857
and O 0 0.00043202357
should O 0 0.00014080723
be O 0 0.00017656593
stopped O 0 0.00023109294
prior O 0 0.00018066837
to O 0 0.0003882454
dipyridamole B-Chemical 0 0.9999877
- O 0 0.36132106
thallium B-Chemical 0 0.99988925
- O 0 0.035160296
201 O 0 0.0048593427
imaging O 0 0.002624667
is O 0 0.0024711206
unknown O 0 0.005460173
. O 0 0.0072306097

Therefore O 0 0.0037549
, O 0 0.0030835352
we O 0 0.0013613026
studied O 0 0.0012447792
the O 0 0.00096564036
hyperemic O 0 0.85243315
response O 0 0.0011096791
to O 0 0.00065324036
dipyridamole B-Chemical 0 0.99994826
in O 0 0.00036126166
seven O 0 0.00023721017
open O 0 0.00043404623
- O 0 0.0043101227
chest O 0 0.0027988805
anesthetized O 0 0.00069403986
dogs O 0 0.0002581127
after O 0 0.00010632063
pretreatment O 0 0.006006786
with O 0 0.00024967967
either O 0 0.00048572448
pentoxifylline B-Chemical 1 0.9999902
( O 0 0.0018326907
0 O 0 0.00028814015
, O 0 0.00024688072
7 O 0 0.00013662131
. O 0 0.00013483159
5 O 0 0.0001300281
, O 0 0.00018180427
or O 0 0.00014844164
15 O 0 0.0001553582
mg O 0 0.0039124032
/ O 0 0.00088638527
kg O 0 0.0008398231
i O 0 0.0016206106
. O 0 0.00023980436
v O 0 0.00969542
. O 0 0.00029142175
) O 0 0.00071124046
or O 0 0.0005713995
theophylline B-Chemical 1 0.99998784
( O 0 0.0013307463
3 O 0 0.00033827353
mg O 0 0.0075253746
/ O 0 0.0013304118
kg O 0 0.0014532729
i O 0 0.0020427706
. O 0 0.0012337804
v O 0 0.007322907
. O 0 0.0029921192
) O 0 0.0066267834
. O 0 0.008333264

Baseline O 0 0.00812215
circumflex O 0 0.09889908
coronary O 0 0.11957459
blood O 0 0.011648383
flows O 0 0.005640547
did O 0 0.0018859988
not O 0 0.0014437105
differ O 0 0.0016153359
significantly O 0 0.0018169933
among O 0 0.002797683
treatment O 0 0.0037433712
groups O 0 0.005448156
. O 0 0.008790244

Dipyridamole B-Chemical 0 0.99978524
significantly O 0 0.0036062803
increased O 0 0.0025105798
coronary O 0 0.21749252
blood O 0 0.016746374
flow O 0 0.0021068386
before O 0 0.0003311627
and O 0 0.00036239534
after O 0 0.0002225816
7 O 0 0.00023348622
. O 0 0.00020876262
5 O 0 0.0001760891
or O 0 0.0001733009
15 O 0 0.00017721948
mm O 0 0.00042623546
/ O 0 0.0007864206
kg O 0 0.00082197617
i O 0 0.0013934412
. O 0 0.0003231726
v O 0 0.016028952
. O 0 0.000688527
pentoxifylline B-Chemical 1 0.99995565
( O 0 0.0010356649
p O 0 0.00055246626
less O 0 0.0005631129
than O 0 0.00063516543
0 O 0 0.0012546218
. O 0 0.0018827361
002 O 0 0.043122426
) O 0 0.006118926
. O 0 0.007956359

Neither O 0 0.0036083728
dose O 0 0.009185211
of O 0 0.0067277234
pentoxifylline B-Chemical 1 0.9999831
significantly O 0 0.002517655
decreased O 0 0.0014929522
the O 0 0.0015475567
dipyridamole B-Chemical 0 0.99999523
- O 0 0.17156802
induced O 0 0.0020778074
hyperemia B-Disease 2 0.9999728
, O 0 0.0012194046
while O 0 0.0003086457
peak O 0 0.0004210873
coronary O 0 0.11344863
blood O 0 0.010877305
flow O 0 0.0013770256
was O 0 0.00020302142
significantly O 0 0.0002024388
lower O 0 0.00022149875
after O 0 0.0002353435
theophylline B-Chemical 1 0.9999633
( O 0 0.00090163876
p O 0 0.00045717446
less O 0 0.00047358515
than O 0 0.00054373627
0 O 0 0.0010888064
. O 0 0.0016037165
01 O 0 0.0051236656
) O 0 0.0053327642
. O 0 0.007296413

We O 0 0.003875575
conclude O 0 0.0022034245
that O 0 0.0019918508
pentoxyifylline B-Chemical 0 0.29273668
does O 0 0.0014938433
not O 0 0.0009831379
inhibit O 0 0.0011612235
dipyridamole B-Chemical 0 0.9999908
- O 0 0.091406256
induced O 0 0.001644595
coronary O 0 0.84410435
hyperemia B-Disease 2 0.99984694
even O 0 0.0016875319
at O 0 0.0015407784
high O 0 0.0032850837
doses O 0 0.01133459
. O 0 0.0074627134

Cause O 0 0.02459234
of O 0 0.0055761198
death B-Disease 0 0.9960329
among O 0 0.0035034434
patients O 0 0.002369601
with O 0 0.0021614013
Parkinson B-Disease 0 0.9995209
' I-Disease 0 0.0014479595
s I-Disease 0 0.0011746013
disease I-Disease 0 0.665563
: O 0 0.0013067934
a O 0 0.00088889134
rare O 0 0.0027707627
mortality O 0 0.15066557
due O 0 0.0012864923
to O 0 0.002883671
cerebral B-Disease 2 0.9998752
haemorrhage I-Disease 2 0.99999464
. O 0 0.011257248

Causes O 0 0.014407469
of O 0 0.0062038465
death B-Disease 0 0.9982633
, O 0 0.0033764967
with O 0 0.0011724196
special O 0 0.00080616353
reference O 0 0.00065320206
to O 0 0.00072448596
cerebral B-Disease 2 0.99995494
haemorrhage I-Disease 2 0.99999964
, O 0 0.0018871499
among O 0 0.00047240546
240 O 0 0.0004390039
patients O 0 0.0002275826
with O 0 0.00019834375
pathologically O 0 0.08900705
verified O 0 0.0003679901
Parkinson B-Disease 0 0.99950635
' I-Disease 0 0.0005712795
s I-Disease 0 0.00043355176
disease I-Disease 0 0.3102522
were O 0 0.00018801691
investigated O 0 0.00013887098
using O 0 0.00017070064
the O 0 0.00021960383
Annuals O 0 0.003345043
of O 0 0.00028286295
the O 0 0.00033753412
Pathological O 0 0.327937
Autopsy O 0 0.35897842
Cases O 0 0.0154106915
in O 0 0.00074569526
Japan O 0 0.014686111
from O 0 0.001140538
1981 O 0 0.0032550846
to O 0 0.002469734
1985 O 0 0.008036825
. O 0 0.00720122

The O 0 0.0033161084
leading O 0 0.00302942
causes O 0 0.0023257623
of O 0 0.0032071522
death B-Disease 0 0.9995017
were O 0 0.005592401
pneumonia B-Disease 0 0.99998033
and O 0 0.06794895
bronchitis B-Disease 0 0.999997
( O 0 0.0189175
44 O 0 0.000924881
. O 0 0.00025027647
1 O 0 0.00022690832
% O 0 0.0002931609
) O 0 0.00050881907
, O 0 0.0005555792
malignant O 0 0.92932016
neoplasms B-Disease 0 0.996163
( O 0 0.0014098315
11 O 0 0.0002602497
. O 0 0.0001697835
6 O 0 0.00014879365
% O 0 0.0002519488
) O 0 0.00048545652
, O 0 0.0005300357
heart B-Disease 0 0.2567729
diseases I-Disease 0 0.8395564
( O 0 0.00092186214
4 O 0 0.0001862595
. O 0 0.00016970806
1 O 0 0.0001836026
% O 0 0.0002708562
) O 0 0.00061391963
, O 0 0.0012047131
cerebral B-Disease 0 0.99838877
infarction I-Disease 2 0.9999995
( O 0 0.0028138408
3 O 0 0.00022599804
. O 0 0.00020468698
7 O 0 0.00021379761
% O 0 0.00034571034
) O 0 0.00062837696
and O 0 0.0008338697
septicaemia B-Disease 0 0.9997577
( O 0 0.0019228782
3 O 0 0.000763077
. O 0 0.0009855593
3 O 0 0.0014401403
% O 0 0.0029348817
) O 0 0.0057415892
. O 0 0.00792692

Cerebral B-Disease 0 0.99909925
haemorrhage I-Disease 0 0.99998474
was O 0 0.0024509903
the O 0 0.0013089833
11th O 0 0.0037654424
most O 0 0.0010927073
frequent O 0 0.0014641336
cause O 0 0.00065939745
of O 0 0.0015878191
death B-Disease 0 0.9997067
, O 0 0.0017515135
accounting O 0 0.00151842
for O 0 0.00024621852
only O 0 0.0002665493
0 O 0 0.00024366296
. O 0 0.00016354842
8 O 0 0.00015599559
% O 0 0.00019625785
of O 0 0.0002539815
deaths B-Disease 0 0.54584616
among O 0 0.00050848525
the O 0 0.00023016063
patients O 0 0.0005161254
, O 0 0.00036423604
whereas O 0 0.00025755027
it O 0 0.00021884571
was O 0 0.00017151184
the O 0 0.00016541805
5th O 0 0.00039038298
most O 0 0.0002933113
common O 0 0.00030734783
cause O 0 0.00036636036
of O 0 0.00090649835
death B-Disease 0 0.9990683
among O 0 0.001438768
the O 0 0.00066998514
Japanese O 0 0.019375676
general O 0 0.0009703291
population O 0 0.0020684947
in O 0 0.002508654
1985 O 0 0.009521173
. O 0 0.006700558

The O 0 0.0032138024
low O 0 0.0028594418
incidence O 0 0.0054384833
of O 0 0.008467105
cerebral B-Disease 2 0.99996805
haemorrhage I-Disease 2 0.9999994
as O 0 0.0009961152
a O 0 0.00070348027
cause O 0 0.0006156778
of O 0 0.0014653585
death B-Disease 0 0.99951994
in O 0 0.0005189056
patients O 0 0.0008095411
with O 0 0.0009067903
Parkinson B-Disease 0 0.99973613
' I-Disease 0 0.00073640223
s I-Disease 0 0.00053854333
disease I-Disease 0 0.5309399
may O 0 0.00017603437
reflect O 0 0.00013547491
the O 0 0.00025437924
hypotensive B-Disease 0 0.9947745
effect O 0 0.00030067368
of O 0 0.0050071
levodopa B-Chemical 0 0.99999833
and O 0 0.0006528666
a O 0 0.000742838
hypotensive B-Disease 0 0.98801416
mechanism O 0 0.00018086488
due O 0 0.00017765482
to O 0 0.00026512006
reduced O 0 0.0009760226
noradrenaline B-Chemical 1 0.9999018
levels O 0 0.0006816871
in O 0 0.0009841796
the O 0 0.0023401869
parkinsonian B-Disease 2 0.99995506
brain O 0 0.05637854
. O 0 0.006308981

Possible O 0 0.043204434
intramuscular O 0 0.86561006
midazolam B-Chemical 0 0.9999893
- O 0 0.21792524
associated O 0 0.008614309
cardiorespiratory B-Disease 0 0.988574
arrest I-Disease 0 0.9824492
and O 0 0.01542563
death B-Disease 0 0.998409
. O 0 0.017363971

Midazolam B-Chemical 0 0.99999547
hydrochloride I-Chemical 0 0.9998454
is O 0 0.0047835778
commonly O 0 0.0034662026
used O 0 0.002249909
for O 0 0.0024166177
dental O 0 0.004063149
or O 0 0.0035262303
endoscopic O 0 0.0066192574
procedures O 0 0.006745223
. O 0 0.010376536

Although O 0 0.0031675913
generally O 0 0.0023449154
consisted O 0 0.0012689147
safe O 0 0.0013159248
when O 0 0.00061841484
given O 0 0.0004970929
intramuscularly O 0 0.0018782698
, O 0 0.0010224857
intravenous O 0 0.05393984
administration O 0 0.0050631827
is O 0 0.0004807699
known O 0 0.000564516
to O 0 0.00051070756
cause O 0 0.0012208127
respiratory B-Disease 0 0.1795853
and I-Disease 0 0.01470666
cardiovascular I-Disease 0 0.99988353
depression I-Disease 0 0.9999565
. O 0 0.009064785

This O 0 0.005526465
report O 0 0.0039566117
describes O 0 0.002304725
the O 0 0.0011855598
first O 0 0.00077167264
published O 0 0.0007267409
case O 0 0.0006946354
of O 0 0.0010683343
cardiorespiratory B-Disease 0 0.98872644
arrest I-Disease 0 0.9834345
and O 0 0.0040921546
death B-Disease 0 0.99919397
associated O 0 0.0014618272
with O 0 0.0013746984
intramuscular O 0 0.15700017
administration O 0 0.041774184
of O 0 0.013690921
midazolam B-Chemical 0 0.99997425
. O 0 0.008799069

Information O 0 0.0068738023
regarding O 0 0.0035781611
midazolam B-Chemical 0 0.99986327
use O 0 0.0024308374
is O 0 0.0016974856
reviewed O 0 0.0017640691
to O 0 0.0012059858
provide O 0 0.0012741915
recommendation O 0 0.0025910493
for O 0 0.0024289072
safe O 0 0.0057621147
administration O 0 0.024976365
. O 0 0.008633425

Myasthenia B-Disease 0 0.97383094
gravis I-Disease 0 0.9993333
presenting O 0 0.03310371
as O 0 0.006478183
weakness O 0 0.95929927
after O 0 0.0061072963
magnesium B-Chemical 1 0.9996681
administration O 0 0.27892163
. O 0 0.014191926

We O 0 0.0036945657
studied O 0 0.0026270195
a O 0 0.002016459
patient O 0 0.0012765444
with O 0 0.00086910935
no O 0 0.0005383394
prior O 0 0.00043818154
history O 0 0.002661734
of O 0 0.0014334371
neuromuscular B-Disease 0 0.990204
disease I-Disease 0 0.99915457
who O 0 0.0024339072
became O 0 0.00086991425
virtually O 0 0.0006319243
quadriplegic B-Disease 0 0.99480337
after O 0 0.00044777044
parenteral O 0 0.58685786
magnesium B-Chemical 1 0.99991906
administration O 0 0.15400954
for O 0 0.0052729635
preeclampsia B-Disease 0 0.99998045
. O 0 0.010227767

The O 0 0.0038296077
serum O 0 0.37321025
magnesium B-Chemical 1 0.99965155
concentration O 0 0.0066695726
was O 0 0.0011898295
3 O 0 0.0007024066
. O 0 0.00061385817
0 O 0 0.0007917103
mEq O 0 0.3886499
/ O 0 0.0099022845
L O 0 0.8810413
, O 0 0.0014968672
which O 0 0.001246375
is O 0 0.00137648
usually O 0 0.0020347473
well O 0 0.0026219946
tolerated O 0 0.011292561
. O 0 0.0071546957

The O 0 0.006090073
magnesium B-Chemical 1 0.99678016
was O 0 0.0034423033
stopped O 0 0.002837822
and O 0 0.0021659238
she O 0 0.0016530007
recovered O 0 0.0015383178
over O 0 0.0016356473
a O 0 0.0028812261
few O 0 0.0031149744
days O 0 0.004622821
. O 0 0.009231046

While O 0 0.003784742
she O 0 0.0023639707
was O 0 0.0019059168
weak O 0 0.003685842
, O 0 0.0018740088
2 O 0 0.0010585054
- O 0 0.0055120857
Hz O 0 0.042444304
repetitive O 0 0.00065889047
stimulation O 0 0.0003696444
revealed O 0 0.00030767382
a O 0 0.00036484248
decrement O 0 0.0008958452
without O 0 0.00023865046
significant O 0 0.00026617548
facilitation O 0 0.0013873661
at O 0 0.00020964027
rapid O 0 0.0004162912
rates O 0 0.0003266456
or O 0 0.00030248106
after O 0 0.00029464965
exercise O 0 0.0016579694
, O 0 0.00089597324
suggesting O 0 0.0009634992
postsynaptic B-Disease 0 0.92984164
neuromuscular I-Disease 0 0.9754851
blockade I-Disease 0 0.9039619
. O 0 0.007712295

After O 0 0.0029657627
her O 0 0.0027012222
strength O 0 0.0023244096
returned O 0 0.0014581366
, O 0 0.0014218077
repetitive O 0 0.0011950834
stimulation O 0 0.0008026047
was O 0 0.00067920826
normal O 0 0.00090771314
, O 0 0.0007726582
but O 0 0.0005881868
single O 0 0.0005711638
fiber O 0 0.00637451
EMG O 0 0.3826983
revealed O 0 0.0007731764
increased O 0 0.0012338896
jitter O 0 0.0057563563
and O 0 0.0027422926
blocking O 0 0.006523905
. O 0 0.007899037

Her O 0 0.034974825
acetylcholine B-Chemical 1 0.99915636
receptor O 0 0.09929723
antibody O 0 0.04559704
level O 0 0.0053792153
was O 0 0.006453423
markedly O 0 0.0108478395
elevated O 0 0.034879237
. O 0 0.014614556

Although O 0 0.0046108477
paralysis B-Disease 2 0.99898595
after O 0 0.0024523837
magnesium B-Chemical 1 0.9999161
administration O 0 0.0931642
has O 0 0.0006288949
been O 0 0.00042903255
described O 0 0.00028693065
in O 0 0.0002598213
patients O 0 0.00033040173
with O 0 0.00027278505
known O 0 0.00058589055
myasthenia B-Disease 0 0.9987293
gravis I-Disease 0 0.9998275
, O 0 0.0055421274
it O 0 0.000371455
has O 0 0.0001904302
not O 0 0.00017832605
previously O 0 0.00021406055
been O 0 0.00019105365
reported O 0 0.00022137564
to O 0 0.00017594478
be O 0 0.00022002972
the O 0 0.00023581092
initial O 0 0.00028714034
or O 0 0.00043528437
only O 0 0.00072608126
manifestation O 0 0.012275813
of O 0 0.0018869541
the O 0 0.002971702
disease O 0 0.9062247
. O 0 0.008000519

Patients O 0 0.0051739467
who O 0 0.0031498277
are O 0 0.0016419773
unusually O 0 0.004210581
sensitive O 0 0.0009955193
to O 0 0.00057913107
the O 0 0.0005235683
neuromuscular O 0 0.030062856
effects O 0 0.0006707352
of O 0 0.0012403558
magnesium B-Chemical 1 0.99988556
should O 0 0.0002339167
be O 0 0.0002797284
suspected O 0 0.0012222927
of O 0 0.00043687734
having O 0 0.0005780452
an O 0 0.0006267533
underlying O 0 0.0015261939
disorder B-Disease 0 0.948155
of I-Disease 0 0.0025230977
neuromuscular I-Disease 0 0.2894909
transmission I-Disease 0 0.02660286
. O 0 0.0071341204

No O 0 0.0066952663
enhancement O 0 0.0061065853
by O 0 0.0062332586
phenobarbital B-Chemical 0 0.99999905
of O 0 0.0047678873
the O 0 0.002639818
hepatocarcinogenicity O 0 0.99989307
of O 0 0.003447434
a O 0 0.010533925
choline B-Chemical 1 0.99995077
- O 0 0.03215741
devoid O 0 0.00093199825
diet O 0 0.012058163
in O 0 0.0017340396
the O 0 0.002686615
rat O 0 0.007276009
. O 0 0.0073615173

An O 0 0.0048276456
experiment O 0 0.0021446182
was O 0 0.00159291
performed O 0 0.00095098774
to O 0 0.0007149761
test O 0 0.0006013096
whether O 0 0.00030985745
inclusion O 0 0.00045572428
of O 0 0.0037405791
phenobarbital B-Chemical 0 0.9999999
in O 0 0.0011757447
a O 0 0.0062840274
choline B-Chemical 1 0.9999702
- O 0 0.035971727
devoid O 0 0.0003090915
diet O 0 0.011883637
would O 0 0.0003823134
increase O 0 0.0004852155
the O 0 0.0011156114
hepatocarcinogenicity O 0 0.99955803
of O 0 0.0029349907
the O 0 0.003176657
diet O 0 0.12225205
. O 0 0.007115039

Groups O 0 0.0110551305
of O 0 0.0032392687
5 O 0 0.0020837667
- O 0 0.0030088397
week O 0 0.000887011
old O 0 0.0010054638
male O 0 0.003201996
Fischer O 0 0.12191709
- O 0 0.014958
344 O 0 0.005729793
rats O 0 0.0004959116
were O 0 0.00029016167
fed O 0 0.0002963781
for O 0 0.00022382573
7 O 0 0.00022135285
- O 0 0.00067179976
25 O 0 0.00022264507
months O 0 0.00017455914
semipurified O 0 0.02143127
choline B-Chemical 1 0.99989974
- O 0 0.013465729
devoid O 0 0.00018020574
or O 0 0.00058982626
choline B-Chemical 1 0.99996245
- O 0 0.065181434
supplemented O 0 0.0024132219
diets O 0 0.03466604
, O 0 0.00041787006
containing O 0 0.00027144793
or O 0 0.00036830775
not O 0 0.00047974128
0 O 0 0.0008402633
. O 0 0.0011739782
06 O 0 0.07077314
% O 0 0.0063647856
phenobarbital B-Chemical 0 0.99999356
. O 0 0.009317973

No O 0 0.009352422
hepatic O 0 0.9252248
preneoplastic O 0 0.9972601
nodules O 0 0.95424646
or O 0 0.030231386
hepatocellular B-Disease 0 0.99999976
carcinomas I-Disease 0 0.99996173
developed O 0 0.0106214145
in O 0 0.00048642716
rats O 0 0.0005084237
fed O 0 0.0003380086
the O 0 0.00027831792
plain O 0 0.07056816
choline B-Chemical 1 0.9999615
- O 0 0.07074075
supplemented O 0 0.0037613325
diet O 0 0.09437878
, O 0 0.00046014797
while O 0 0.00024349993
one O 0 0.00022645184
preneoplastic O 0 0.97770727
nodule O 0 0.73026776
and O 0 0.0008066111
one O 0 0.0011877312
hepatocellular B-Disease 0 0.9999999
carcinoma I-Disease 2 0.99999964
developed O 0 0.01105021
in O 0 0.0003528674
two O 0 0.00027234643
rats O 0 0.00046269468
fed O 0 0.00048888737
the O 0 0.00048535218
same O 0 0.0006619935
diet O 0 0.0272317
containing O 0 0.0038250214
phenobarbital B-Chemical 0 0.99999774
. O 0 0.009611549

The O 0 0.0032970228
incidence O 0 0.004414229
of O 0 0.002951675
preneoplastic O 0 0.9882606
nodules O 0 0.7450107
and O 0 0.001702028
of O 0 0.011176493
hepatocellular B-Disease 0 0.9999999
carcinomas I-Disease 0 0.9999616
was O 0 0.0008844385
10 O 0 0.0002914223
% O 0 0.00029256198
and O 0 0.00026019264
37 O 0 0.00038989465
% O 0 0.00033152377
, O 0 0.000392305
respectively O 0 0.0013992231
, O 0 0.00037257906
in O 0 0.00021029936
rats O 0 0.00027571697
fed O 0 0.00022880273
the O 0 0.00021029473
plain O 0 0.04737618
choline B-Chemical 1 0.99993694
- O 0 0.02058431
devoid O 0 0.0001681572
diet O 0 0.019978475
, O 0 0.00035154397
and O 0 0.0002553349
17 O 0 0.0002572418
% O 0 0.00021980537
and O 0 0.00020326333
30 O 0 0.00017784142
% O 0 0.000264799
, O 0 0.00029692112
in O 0 0.00024000632
rats O 0 0.00038171327
fed O 0 0.0004521068
the O 0 0.0009703166
phenobarbital B-Chemical 0 0.9999999
- O 0 0.10454018
containing O 0 0.0015109774
choline B-Chemical 1 0.99987566
- O 0 0.037166517
devoid O 0 0.0023290564
diet O 0 0.05382317
. O 0 0.006944979

The O 0 0.0033540206
results O 0 0.0024532087
evinced O 0 0.006434279
no O 0 0.0012940709
enhancement O 0 0.0018318535
of O 0 0.001363198
the O 0 0.0015778947
hepatocarcinogenicity O 0 0.9998567
of O 0 0.002497584
the O 0 0.0028242157
choline B-Chemical 1 0.9999454
- O 0 0.043069296
devoid O 0 0.0012663791
diet O 0 0.10764982
by O 0 0.0074670515
phenobarbital B-Chemical 0 0.9999974
. O 0 0.010623142

Sporadic O 0 0.66996354
neoplastic O 0 0.72836983
lesions O 0 0.36704224
were O 0 0.0013599659
observed O 0 0.00078584306
in O 0 0.00068363134
organs O 0 0.0016518497
other O 0 0.0004903517
than O 0 0.00028668236
the O 0 0.00035734512
liver O 0 0.21968845
of O 0 0.00049552973
some O 0 0.0003461301
of O 0 0.00041183628
the O 0 0.0003866387
animals O 0 0.00041993684
, O 0 0.0007021125
irrespective O 0 0.0006057266
of O 0 0.0013157554
the O 0 0.0019619428
diet O 0 0.056887485
fed O 0 0.0060271
. O 0 0.0065914514

On O 0 0.0033072943
two O 0 0.0022693716
paradoxical O 0 0.021037787
side O 0 0.16895732
- O 0 0.025895674
effects O 0 0.0014822276
of O 0 0.0026614342
prednisolone B-Chemical 1 0.9999809
in O 0 0.0008960228
rats O 0 0.0012184243
, O 0 0.00084021053
ribosomal O 0 0.02790483
RNA O 0 0.14381808
biosyntheses O 0 0.52064294
, O 0 0.001164571
and O 0 0.0009472142
a O 0 0.0012346685
mechanism O 0 0.0014460993
of O 0 0.003106741
action O 0 0.007190308
. O 0 0.0076154745

Liver B-Disease 0 0.99618596
enlargement I-Disease 0 0.84869885
and O 0 0.0052401917
muscle B-Disease 0 0.69052243
wastage I-Disease 0 0.77951664
occurred O 0 0.0015199115
in O 0 0.0011141881
Wistar O 0 0.005906184
rats O 0 0.0009623928
following O 0 0.0006654911
the O 0 0.0009752208
subcutaneous O 0 0.006958663
administration O 0 0.01335261
of O 0 0.0071853944
prednisolone B-Chemical 1 0.9999167
. O 0 0.010771134

In O 0 0.0037653458
the O 0 0.0026403589
liver O 0 0.23176454
both O 0 0.0012834569
the O 0 0.0008128312
content O 0 0.0007241612
of O 0 0.0007324478
RNA O 0 0.02068345
and O 0 0.0005670743
the O 0 0.00035180565
biosynthesis O 0 0.0049132532
of O 0 0.00046668918
ribosomal O 0 0.059083946
RNA O 0 0.09607302
increased O 0 0.00057042926
while O 0 0.00029538543
both O 0 0.00021656016
the O 0 0.00022150316
RNA O 0 0.005524812
content O 0 0.0003425386
and O 0 0.0004141854
ribosomal O 0 0.023073824
RNA O 0 0.077275485
biosynthesis O 0 0.016780311
were O 0 0.0005290996
reduced O 0 0.0006289979
in O 0 0.00091087364
the O 0 0.0015289343
gastrocnemius O 0 0.012833761
muscle O 0 0.019287854
. O 0 0.006840559

It O 0 0.0046528527
is O 0 0.0024711508
suggested O 0 0.0014490264
that O 0 0.0010606768
the O 0 0.0010301945
drug O 0 0.19177285
acted O 0 0.004044549
in O 0 0.0005221173
a O 0 0.00053764676
selective O 0 0.0008526544
and O 0 0.00048198612
tissue O 0 0.0119026
- O 0 0.0048809294
specific O 0 0.00019783662
manner O 0 0.00019431318
to O 0 0.00016342184
enhance O 0 0.0001550783
ribosomal O 0 0.016510453
RNA O 0 0.06332712
synthesis O 0 0.0098880725
in O 0 0.0003441817
the O 0 0.00039627796
liver O 0 0.43620127
and O 0 0.0007550681
depress O 0 0.0037888866
such O 0 0.0006259415
synthesis O 0 0.0025467686
in O 0 0.0014080455
the O 0 0.0023086583
muscle O 0 0.02334334
. O 0 0.0068780286

This O 0 0.005050728
view O 0 0.0030594321
supports O 0 0.0017044831
the O 0 0.0013346493
contention O 0 0.0013760941
that O 0 0.00078519253
the O 0 0.0008911454
liver O 0 0.3537939
and O 0 0.0010867371
muscle O 0 0.0053508794
are O 0 0.00066918234
independent O 0 0.00063841237
sites O 0 0.0013792331
of O 0 0.0037696
prednisolone B-Chemical 1 0.9999232
action O 0 0.024476707
. O 0 0.008433672

Differential O 0 0.005175041
effects O 0 0.0041024648
of O 0 0.008296564
gamma B-Chemical 0 0.9998135
- I-Chemical 0 0.9918344
hexachlorocyclohexane I-Chemical 0 0.9999999
( O 0 0.7079753
lindane B-Chemical 1 0.99999905
) O 0 0.02101629
on O 0 0.0014331806
pharmacologically O 0 0.88197696
- O 0 0.060358692
induced O 0 0.013456851
seizures B-Disease 0 0.99999106
. O 0 0.013024326

Gamma B-Chemical 0 0.9964484
- I-Chemical 0 0.91251165
hexachlorocyclohexane I-Chemical 0 0.99999833
( O 0 0.4060811
gamma B-Chemical 1 0.99989533
- I-Chemical 1 0.975221
HCH I-Chemical 1 0.99999535
) O 0 0.030539002
, O 0 0.0011858918
the O 0 0.00049108785
active O 0 0.0016898875
ingredient O 0 0.43665218
of O 0 0.0007105562
the O 0 0.0022175647
insecticide O 0 0.99993515
lindane B-Chemical 1 0.9999999
, O 0 0.010873237
has O 0 0.0002596549
been O 0 0.00019120346
shown O 0 0.00012616657
to O 0 0.0001404327
decrease O 0 0.00033316595
seizure B-Disease 2 0.9999186
threshold O 0 0.00021887431
to O 0 0.0002899178
pentylenetrazol O 0 0.9944271
( O 0 0.1532324
PTZ B-Chemical 0 1.0
) O 0 0.006549656
3 O 0 0.00015515136
h O 0 0.00015399966
after O 0 0.000100421705
exposure O 0 0.0011544949
to O 0 0.00043905975
gamma B-Chemical 1 0.9998325
- I-Chemical 1 0.95875
HCH I-Chemical 1 0.99999726
and O 0 0.0022400995
conversely O 0 0.027364062
increase O 0 0.00016778371
threshold O 0 0.00023400216
to O 0 0.0015426339
PTZ B-Chemical 0 1.0
- O 0 0.38039407
induced O 0 0.0048360215
seizures B-Disease 0 0.9999995
24 O 0 0.00038839364
h O 0 0.00019600464
after O 0 0.00012989562
exposure O 0 0.0011609442
to O 0 0.0005213497
gamma B-Chemical 1 0.9996575
- I-Chemical 1 0.9427955
HCH I-Chemical 1 0.99999535
( O 0 0.013523908
Vohland O 0 0.17058602
et O 0 0.0016236996
al O 0 0.0022472176
. O 0 0.0018794503
1981 O 0 0.0059632957
) O 0 0.006227853
. O 0 0.008108302

In O 0 0.0037840302
this O 0 0.0024699126
study O 0 0.0021217545
, O 0 0.0016214009
the O 0 0.00088333286
severity O 0 0.0018416754
of O 0 0.00061821326
response O 0 0.0006528641
to O 0 0.00038945887
other O 0 0.0028638437
seizure B-Disease 2 0.9999957
- O 0 0.120337985
inducing O 0 0.0012426742
agents O 0 0.011632753
was O 0 0.00022170517
tested O 0 0.00015104597
in O 0 0.00014982068
mice O 0 0.0001123477
1 O 0 0.00016106684
and O 0 0.00018578536
24 O 0 0.00018144387
h O 0 0.00018633323
after O 0 0.00014788444
intraperitoneal O 0 0.0013247138
administration O 0 0.0011236389
of O 0 0.00042720546
80 O 0 0.0006861933
mg O 0 0.03696163
/ O 0 0.0063586817
kg O 0 0.03251338
gamma B-Chemical 1 0.9972857
- I-Chemical 1 0.80256635
HCH I-Chemical 1 0.9999162
. O 0 0.013086184

One O 0 0.0039399723
hour O 0 0.0019407441
after O 0 0.0011412122
the O 0 0.0010692496
administration O 0 0.0059926817
of O 0 0.006966793
gamma B-Chemical 1 0.99990463
- I-Chemical 1 0.9764765
HCH I-Chemical 1 0.99999666
, O 0 0.0025224392
the O 0 0.0003634192
activity O 0 0.00040246453
of O 0 0.00275656
seizure B-Disease 2 0.9999964
- O 0 0.12875226
inducing O 0 0.0014000956
agents O 0 0.018878622
was O 0 0.00028950488
increased O 0 0.00030454595
, O 0 0.00029888796
regardless O 0 0.000116719944
of O 0 0.00019895953
their O 0 0.00018572128
mechanism O 0 0.00017902505
, O 0 0.0003719816
while O 0 0.0002613971
24 O 0 0.0002362011
h O 0 0.00027287845
after O 0 0.00030075852
gamma B-Chemical 1 0.9981817
- I-Chemical 1 0.78619856
HCH I-Chemical 1 0.9999776
a O 0 0.001496253
differential O 0 0.0012671272
response O 0 0.0018504884
was O 0 0.0023538107
observed O 0 0.003431772
. O 0 0.006886291

Seizure B-Disease 2 0.9993637
activity O 0 0.0032450533
due O 0 0.0016922542
to O 0 0.004046917
PTZ B-Chemical 0 1.0
and O 0 0.4456824
picrotoxin B-Chemical 0 1.0
( O 0 0.3788496
PTX B-Chemical 0 0.9999789
) O 0 0.010950767
was O 0 0.00037798332
significantly O 0 0.00030680856
decreased O 0 0.00043294544
; O 0 0.00079024734
however O 0 0.0006758719
, O 0 0.0023503106
seizure B-Disease 2 0.99995244
activity O 0 0.00028443008
due O 0 0.0001284583
to O 0 0.00016905268
3 B-Chemical 0 0.00025831582
- I-Chemical 0 0.081788845
mercaptopropionic I-Chemical 0 0.999204
acid I-Chemical 0 0.9892814
( O 0 0.13163227
MPA B-Chemical 0 0.99999905
) O 0 0.05300654
, O 0 0.035705566
bicuculline B-Chemical 1 0.99999964
( O 0 0.13338229
BCC B-Chemical 0 0.9999974
) O 0 0.023860643
, O 0 0.0023575781
methyl B-Chemical 0 0.98223704
6 I-Chemical 0 0.00016719026
, I-Chemical 0 0.00025855607
7 I-Chemical 0 0.0002069597
- I-Chemical 0 0.02302367
dimethoxy I-Chemical 0 0.9989594
- I-Chemical 0 0.051521104
4 I-Chemical 0 0.00032822174
- I-Chemical 0 0.085649416
ethyl I-Chemical 0 0.9997739
- I-Chemical 0 0.37068552
B I-Chemical 0 0.99188775
- I-Chemical 0 0.6968373
carboline I-Chemical 0 0.9996494
- I-Chemical 0 0.1011957
3 I-Chemical 0 0.00035108364
- I-Chemical 0 0.04381403
carboxylate I-Chemical 0 0.994764
( O 0 0.18175651
DMCM B-Chemical 0 0.9999999
) O 0 0.009472438
, O 0 0.0010140922
or O 0 0.0016696269
strychnine B-Chemical 0 0.9999993
( O 0 0.03966181
STR B-Chemical 0 0.9990621
) O 0 0.0012495498
was O 0 0.0006673154
not O 0 0.00075106655
different O 0 0.0010583462
from O 0 0.0018016814
control O 0 0.0034330836
. O 0 0.006660742

In O 0 0.0043158266
vitro O 0 0.005007259
, O 0 0.024776237
gamma B-Chemical 1 0.9997609
- I-Chemical 1 0.98247266
HCH I-Chemical 1 0.99999785
, O 0 0.6592954
pentylenetetrazol B-Chemical 0 1.0
and O 0 0.250226
picrotoxin B-Chemical 0 0.9999999
were O 0 0.0005651241
shown O 0 0.00019706399
to O 0 0.00019527083
inhibit O 0 0.00035562232
3H B-Chemical 1 0.99957496
- I-Chemical 1 0.5653331
TBOB I-Chemical 1 0.99970347
binding O 0 0.00050009415
in O 0 0.00023157995
mouse O 0 0.00037195004
whole O 0 0.00030699876
brain O 0 0.008385029
, O 0 0.00031882647
with O 0 0.000265437
IC50 O 0 0.385997
values O 0 0.00019653913
of O 0 0.00026302107
4 O 0 0.00019393522
. O 0 0.00019641792
6 O 0 0.0001998823
, O 0 0.00034174547
404 O 0 0.00096427463
and O 0 0.0004263265
9 O 0 0.00049199694
. O 0 0.0006229446
4 O 0 0.0009599978
microM O 0 0.09840617
, O 0 0.0035816329
respectively O 0 0.007600746
. O 0 0.007879394

MPA B-Chemical 0 0.9999701
, O 0 0.28404182
BCC B-Chemical 0 0.99997926
, O 0 0.5650641
DMCM B-Chemical 0 0.99999976
, O 0 0.009001535
and O 0 0.0023859388
STR B-Chemical 0 0.9936063
showed O 0 0.00045164055
no O 0 0.00029544742
inhibition O 0 0.0011470846
of O 0 0.01024041
3H B-Chemical 1 0.99984777
- I-Chemical 1 0.78223604
TBOB I-Chemical 1 0.99993825
( O 0 0.004780735
t B-Chemical 0 0.04092462
- I-Chemical 0 0.49409536
butyl I-Chemical 0 0.9999541
bicyclo I-Chemical 0 0.99911565
- I-Chemical 0 0.13875686
orthobenzoate I-Chemical 0 0.35933736
) O 0 0.0008283032
binding O 0 0.00058509863
at O 0 0.00060309144
concentrations O 0 0.0012954983
of O 0 0.0017676095
100 O 0 0.0034215394
micron O 0 0.010467955
. O 0 0.0070639285

The O 0 0.0032948547
pharmacological O 0 0.0059868353
challenge O 0 0.0018235806
data O 0 0.0011206656
suggest O 0 0.0005433751
that O 0 0.0005710805
tolerance O 0 0.042443752
may O 0 0.00042579064
occur O 0 0.00037035072
to O 0 0.00044096023
seizure B-Disease 2 0.9999614
activity O 0 0.0005248722
induced O 0 0.000556074
by O 0 0.012443979
PTZ B-Chemical 0 1.0
and O 0 0.02430866
PTX B-Chemical 0 0.9999299
24 O 0 0.00038022475
h O 0 0.00025457112
after O 0 0.00021654075
gamma B-Chemical 1 0.9994842
- I-Chemical 1 0.93035734
HCH I-Chemical 1 0.9999963
, O 0 0.0011907585
since O 0 0.00017870036
the O 0 0.00018746483
response O 0 0.0002468367
to O 0 0.00019218097
only O 0 0.00025930186
these O 0 0.0003466033
two O 0 0.0005004697
seizure B-Disease 2 0.9999629
- O 0 0.037304997
inducing O 0 0.0023344383
agents O 0 0.028097373
is O 0 0.0028786983
decreased O 0 0.005571502
. O 0 0.007236206

The O 0 0.0031577507
in O 0 0.0022675842
vitro O 0 0.0018963666
data O 0 0.0011545846
suggest O 0 0.0005490881
that O 0 0.0004948494
the O 0 0.00044677188
site O 0 0.00043247725
responsible O 0 0.00030393127
for O 0 0.00027501784
the O 0 0.00025010877
decrease O 0 0.00028249697
in O 0 0.00047320072
seizure B-Disease 2 0.9999486
activity O 0 0.00039273527
24 O 0 0.00022542647
h O 0 0.00022520601
after O 0 0.00021847023
gamma B-Chemical 1 0.9992071
- I-Chemical 1 0.88527226
HCH I-Chemical 1 0.9999924
may O 0 0.0004400329
be O 0 0.00040280478
the O 0 0.0011569116
GABA B-Chemical 1 0.9999969
- O 0 0.18891445
A O 0 0.40054414
receptor O 0 0.123894036
- O 0 0.04401392
linked O 0 0.0029453195
chloride O 0 0.999658
channel O 0 0.25746942
. O 0 0.007952592

Tolerance O 0 0.0636234
and O 0 0.004483462
antiviral O 0 0.110311374
effect O 0 0.002971394
of O 0 0.00633633
ribavirin B-Chemical 1 0.9999769
in O 0 0.003053527
patients O 0 0.004396484
with O 0 0.004657572
Argentine B-Disease 0 0.9640417
hemorrhagic I-Disease 2 0.9999856
fever I-Disease 0 0.9999833
. O 0 0.01733109

Tolerance O 0 0.07292653
and O 0 0.003460834
antiviral O 0 0.13413866
effect O 0 0.0020728055
of O 0 0.0073753223
ribavirin B-Chemical 1 0.9999907
was O 0 0.0013267385
studied O 0 0.000566816
in O 0 0.00033787906
6 O 0 0.00023700214
patients O 0 0.00032357252
with O 0 0.00043844097
Argentine B-Disease 0 0.84195566
hemorrhagic I-Disease 2 0.9999976
fever I-Disease 0 0.9999993
( O 0 0.3280886
AHF B-Disease 0 0.999998
) O 0 0.002300837
of O 0 0.0005748922
more O 0 0.00055072055
than O 0 0.00046263775
8 O 0 0.00071418006
days O 0 0.00091643597
of O 0 0.002165627
evolution O 0 0.0047863848
. O 0 0.0068773217

Administration O 0 0.0675561
of O 0 0.008264833
ribavirin B-Chemical 1 0.99992573
resulted O 0 0.002236033
in O 0 0.0014294691
a O 0 0.0014126631
neutralization O 0 0.12280263
of O 0 0.002964697
viremia B-Disease 0 0.9996056
and O 0 0.0015250418
a O 0 0.001198875
drop O 0 0.0018518011
of O 0 0.0016458844
endogenous O 0 0.0033124462
interferon O 0 0.9998838
titers O 0 0.908483
. O 0 0.012759694

The O 0 0.0072300048
average O 0 0.0054904562
time O 0 0.005926662
of O 0 0.009916568
death B-Disease 0 0.9938425
was O 0 0.013937965
delayed O 0 0.026510691
. O 0 0.019316277

A O 0 0.23659001
reversible O 0 0.6218361
anemia B-Disease 0 0.9998914
was O 0 0.0048275106
the O 0 0.0034954704
only O 0 0.0041528484
adverse O 0 0.2596461
effect O 0 0.0052426946
observed O 0 0.0070752595
. O 0 0.012044912

From O 0 0.003666397
these O 0 0.0024645
results O 0 0.0016967438
, O 0 0.0016420542
we O 0 0.0007411738
conclude O 0 0.0006054184
that O 0 0.0008689367
ribavirin B-Chemical 1 0.999984
has O 0 0.0008401121
an O 0 0.00081314764
antiviral O 0 0.26463306
effect O 0 0.00049512094
in O 0 0.0003723552
advanced O 0 0.016734311
cases O 0 0.0016391573
of O 0 0.009514169
AHF B-Disease 0 0.99999857
, O 0 0.0015480423
and O 0 0.00046015368
that O 0 0.0004111022
anemia B-Disease 0 0.99998605
, O 0 0.0008721568
the O 0 0.00028135485
only O 0 0.0003428717
secondary O 0 0.0029184085
reaction O 0 0.006367579
observed O 0 0.0005289894
, O 0 0.00096063473
can O 0 0.0008208936
be O 0 0.0014168607
easily O 0 0.0023416022
managed O 0 0.004246375
. O 0 0.0063339854

The O 0 0.00338898
possible O 0 0.0025333285
beneficial O 0 0.0021629792
effect O 0 0.0016639219
of O 0 0.0033339204
ribavirin B-Chemical 1 0.9999633
during O 0 0.00091342063
the O 0 0.0008219299
initial O 0 0.0008124572
days O 0 0.0009922424
of O 0 0.0031414842
AHF B-Disease 0 0.999959
is O 0 0.0040414776
discussed O 0 0.004438809
. O 0 0.007687204

Is O 0 0.02201904
the O 0 0.013589671
treatment O 0 0.015960626
of O 0 0.022783704
scabies B-Disease 0 0.99723524
hazardous O 0 0.91968954
? O 0 0.048339557

Treatment O 0 0.010900461
for O 0 0.0039373683
scabies B-Disease 0 0.9826157
is O 0 0.0018714723
usually O 0 0.0011801661
initiated O 0 0.00069169543
by O 0 0.000622863
general O 0 0.00051285984
practitioners O 0 0.0007267464
; O 0 0.00072490936
most O 0 0.0005688061
consider O 0 0.00051636825
lindane B-Chemical 1 0.9999993
( O 0 0.40969887
gamma B-Chemical 0 0.9999901
benzene I-Chemical 0 1.0
hexachloride I-Chemical 0 1.0
) O 0 0.060218867
the O 0 0.0012149799
treatment O 0 0.0017076407
of O 0 0.00273055
choice O 0 0.0045674685
. O 0 0.006759118

Lindane B-Chemical 0 0.9999746
is O 0 0.0040467647
also O 0 0.0019394414
widely O 0 0.001402218
used O 0 0.0007896421
as O 0 0.0006807969
an O 0 0.00085907447
agricultural O 0 0.294023
and O 0 0.0016137018
industrial O 0 0.6766498
pesticide O 0 0.99639577
, O 0 0.0009173568
and O 0 0.0003769114
as O 0 0.00026443772
a O 0 0.00031412274
result O 0 0.00024023322
the O 0 0.00034334877
toxic O 0 0.24440892
profile O 0 0.00048440744
of O 0 0.00072589645
this O 0 0.0010237688
insecticide O 0 0.9675688
is O 0 0.0016448464
well O 0 0.002183422
understood O 0 0.0052625923
. O 0 0.006528586

Evidence O 0 0.005968357
is O 0 0.0028360954
accumulating O 0 0.0025469868
that O 0 0.0023743978
lindane B-Chemical 1 0.99999535
can O 0 0.0011412709
be O 0 0.00090444245
toxic B-Disease 0 0.35058725
to I-Disease 0 0.0004091035
the I-Disease 0 0.0003875997
central I-Disease 0 0.00062428106
nervous I-Disease 0 0.009791589
system I-Disease 0 0.00044187676
and O 0 0.00048685347
may O 0 0.00048129793
be O 0 0.0006979469
associated O 0 0.0013696025
with O 0 0.008903314
aplastic B-Disease 0 0.9999939
anaemia I-Disease 0 0.9999964
. O 0 0.019097105

Preparations O 0 0.0134384595
containing O 0 0.005089749
lindane B-Chemical 1 0.99996936
continue O 0 0.001863135
to O 0 0.0009873159
be O 0 0.00083792506
sold O 0 0.0013507219
over O 0 0.00037804496
the O 0 0.00044543788
counter O 0 0.0008723347
and O 0 0.00050527416
may O 0 0.00042631492
represent O 0 0.00048153245
a O 0 0.00078095857
hazard O 0 0.008573747
to O 0 0.0011001324
poorly O 0 0.002461319
informed O 0 0.0056412257
patients O 0 0.0051751644
. O 0 0.0067671645

This O 0 0.004895644
literature O 0 0.003106224
review O 0 0.0023137522
suggests O 0 0.0009439519
that O 0 0.00078429334
general O 0 0.00074203924
practitioners O 0 0.000860603
should O 0 0.0003359296
prescribe O 0 0.00091871776
scabicides O 0 0.4641077
with O 0 0.00030927904
increased O 0 0.000274946
caution O 0 0.00025902095
for O 0 0.00020888406
certain O 0 0.0002923395
at O 0 0.0002652139
- O 0 0.0104664
risk O 0 0.03274972
groups O 0 0.00042023993
, O 0 0.00045550667
and O 0 0.00039689423
give O 0 0.00041475275
adequate O 0 0.0005575229
warnings O 0 0.0032335802
regarding O 0 0.0010666645
potential O 0 0.0034791664
toxicity B-Disease 2 0.9975291
. O 0 0.0086668935

Mouse O 0 0.014368573
strain O 0 0.0040555242
- O 0 0.0068651917
dependent O 0 0.0017631995
effect O 0 0.0017189024
of O 0 0.0032054589
amantadine B-Chemical 1 0.99995637
on O 0 0.0013932138
motility O 0 0.27924976
and O 0 0.003808773
brain O 0 0.3861049
biogenic O 0 0.99750876
amines B-Chemical 0 0.9991391
. O 0 0.010383894

The O 0 0.00310416
effect O 0 0.002586377
of O 0 0.010602552
amantadine B-Chemical 1 0.9999993
hydrochloride I-Chemical 0 0.99999154
, O 0 0.005287327
injected O 0 0.0006821696
i O 0 0.005569426
. O 0 0.00034189195
p O 0 0.00031778132
. O 0 0.00021975464
in O 0 0.00018946848
6 O 0 0.00014266129
increments O 0 0.00017595149
of O 0 0.00021569856
100 O 0 0.00045481615
mg O 0 0.014503335
/ O 0 0.0008204683
kg O 0 0.00032979157
each O 0 9.129981e-05
over O 0 8.986707e-05
30 O 0 0.00012066115
hr O 0 0.00021383514
, O 0 0.00018463908
on O 0 0.0001134142
mouse O 0 0.0003458402
motility O 0 0.07237428
and O 0 0.00029531927
whole O 0 0.00026014552
brain O 0 0.0020225479
content O 0 0.00018786799
of O 0 0.00023066856
selected O 0 0.0003285498
biogenic O 0 0.99560887
amines B-Chemical 0 0.99928814
and O 0 0.0005230164
major O 0 0.00068882265
metabolites O 0 0.74531186
was O 0 0.00038403738
studied O 0 0.00045388503
in O 0 0.00054442266
4 O 0 0.0007055326
strains O 0 0.0011620158
of O 0 0.0021800885
mice O 0 0.0028562895
. O 0 0.006639034

These O 0 0.0043150666
were O 0 0.003008675
the O 0 0.0023600804
albino O 0 0.01741983
Sprague O 0 0.1366757
- O 0 0.01712294
Dawley O 0 0.031719424
ICR O 0 0.05598413
and O 0 0.0010998779
BALB O 0 0.29709166
/ O 0 0.06396412
C O 0 0.9990452
, O 0 0.0013537689
the O 0 0.0005592515
black O 0 0.019279087
C57BL O 0 0.6874176
/ O 0 0.0020941452
6 O 0 0.00035241595
and O 0 0.0004716718
the O 0 0.00063115475
brown O 0 0.021382935
CDF O 0 0.48091123
- O 0 0.025351861
I O 0 0.009552485
mouse O 0 0.0033724173
strains O 0 0.004795902
. O 0 0.00788435

Amantadine B-Chemical 0 0.9996954
treatment O 0 0.0065926504
produced O 0 0.003966118
a O 0 0.0042809593
biphasic O 0 0.0085101845
effect O 0 0.0035315123
on O 0 0.0035435117
mouse O 0 0.007837633
motility O 0 0.45698413
. O 0 0.012682983

The O 0 0.0028283936
initial O 0 0.0019149946
dose O 0 0.0069132405
of O 0 0.010496839
amantadine B-Chemical 1 0.9999968
depressed B-Disease 2 0.9992213
locomotor O 0 0.8787011
activity O 0 0.00046008307
in O 0 0.0002772226
all O 0 0.00022917413
mouse O 0 0.00031467815
strains O 0 0.00026209085
studied O 0 0.00027669867
with O 0 0.00030935157
the O 0 0.0004139649
BALB O 0 0.21462597
/ O 0 0.024310693
C O 0 0.99410003
mice O 0 0.00064425304
being O 0 0.0013150783
the O 0 0.0013714227
most O 0 0.0027310215
sensitive O 0 0.0040787053
. O 0 0.0065858955

Subsequent O 0 0.0064825914
amantadine B-Chemical 1 0.9996897
treatments O 0 0.0035623768
produced O 0 0.0012145558
enhancement O 0 0.0018401117
of O 0 0.0010756842
motility O 0 0.10350785
from O 0 0.00034878938
corresponding O 0 0.0002588555
control O 0 0.0002690194
in O 0 0.00022803787
all O 0 0.00020766715
mouse O 0 0.0002977554
strains O 0 0.0002632127
with O 0 0.00031033283
the O 0 0.00040658782
BALB O 0 0.20795064
/ O 0 0.022647504
C O 0 0.99331564
mice O 0 0.00060229906
being O 0 0.001163392
the O 0 0.0011982687
least O 0 0.0016492388
sensitive O 0 0.0037298365
. O 0 0.006354763

The O 0 0.003678783
locomotor O 0 0.24313873
activity O 0 0.0018258317
was O 0 0.0011217262
decreased O 0 0.0008244416
from O 0 0.000462323
corresponding O 0 0.00036320277
controls O 0 0.0005043287
in O 0 0.00028041622
all O 0 0.00022533961
strains O 0 0.00026030876
studied O 0 0.0003003906
, O 0 0.0003361835
except O 0 0.00017985763
for O 0 0.00019308297
the O 0 0.00023786377
ICR O 0 0.022657089
mice O 0 0.00014468057
, O 0 0.00026944268
during O 0 0.00015720224
an O 0 0.0002760326
overnight O 0 0.00042657874
drug O 0 0.16255963
- O 0 0.002264054
free O 0 0.00037632813
period O 0 0.00032681847
following O 0 0.00043851938
the O 0 0.00079102255
fourth O 0 0.005095765
amantadine B-Chemical 1 0.99989617
treatment O 0 0.0067671607
. O 0 0.00673399

Readministration O 0 0.49416783
of O 0 0.008146788
amantadine B-Chemical 1 0.99995685
, O 0 0.0034070134
after O 0 0.00075619936
a O 0 0.0012044035
drug O 0 0.48887646
- O 0 0.010793458
free O 0 0.00046813232
overnight O 0 0.00033859414
period O 0 0.00020170935
, O 0 0.0003289375
increased O 0 0.00029013344
motility O 0 0.033676278
from O 0 0.00016391657
respective O 0 0.00017519311
saline O 0 0.0025144923
control O 0 0.00016827174
in O 0 0.00014756565
all O 0 0.00013509746
strains O 0 0.00016296172
with O 0 0.0001816154
exception O 0 0.00017096715
of O 0 0.0002740371
the O 0 0.0003767939
BALB O 0 0.26942548
/ O 0 0.029444804
C O 0 0.9951277
mice O 0 0.00045588677
where O 0 0.0007689841
suppression B-Disease 0 0.0021447877
of I-Disease 0 0.00258058
motility I-Disease 0 0.6986688
occurred O 0 0.0055052205
. O 0 0.0072546545

Treatment O 0 0.016032202
with O 0 0.006937639
amantadine B-Chemical 1 0.9999567
did O 0 0.0022078287
not O 0 0.00072820025
alter O 0 0.0005075696
whole O 0 0.0007741182
brain O 0 0.18277736
dopamine B-Chemical 1 0.99978095
levels O 0 0.00036603323
but O 0 0.0003307469
decreased O 0 0.0002581169
the O 0 0.00017294382
amounts O 0 0.00015842247
of O 0 0.00030628222
3 B-Chemical 0 0.00021983219
, I-Chemical 0 0.00043432755
4 I-Chemical 0 0.0003747543
- I-Chemical 0 0.37985516
dihydroxyphenylacetic I-Chemical 0 0.9999993
acid I-Chemical 0 0.6357135
in O 0 0.0003250631
the O 0 0.0003958172
BALB O 0 0.14813873
/ O 0 0.015639096
C O 0 0.99009365
mice O 0 0.0005441728
compared O 0 0.0007128331
to O 0 0.0012189721
saline O 0 0.0060320245
control O 0 0.00347527
. O 0 0.006469295

Conversely O 0 0.006445674
, O 0 0.0065603694
brain O 0 0.5355006
normetanephrine B-Chemical 0 0.99999595
concentration O 0 0.014794405
was O 0 0.0010057637
increased O 0 0.00069091073
from O 0 0.000498003
saline O 0 0.0032960468
control O 0 0.000538405
by O 0 0.0008345461
amantadine B-Chemical 1 0.9999019
in O 0 0.0009096486
the O 0 0.0012460125
BALB O 0 0.19168669
/ O 0 0.02693044
C O 0 0.9917282
mice O 0 0.0043195845
. O 0 0.00850971

The O 0 0.002978123
results O 0 0.0019222082
suggest O 0 0.0011825091
a O 0 0.0014703058
strain O 0 0.001122538
- O 0 0.0058760582
dependent O 0 0.0004867954
effect O 0 0.00052301766
of O 0 0.0017209599
amantadine B-Chemical 1 0.9999782
on O 0 0.0002693361
motility O 0 0.10540707
and O 0 0.00030346544
indicate O 0 0.00015671943
a O 0 0.00025045552
differential O 0 0.000249798
response O 0 0.00032344632
to O 0 0.00026148485
the O 0 0.0003963949
acute O 0 0.3251959
and O 0 0.00079987897
multiple O 0 0.0011961528
dose O 0 0.0039615096
regimens O 0 0.0028003624
used O 0 0.003080084
. O 0 0.0059938375

The O 0 0.004312697
BALB O 0 0.19347513
/ O 0 0.06783849
C O 0 0.9965203
mouse O 0 0.0034027612
was O 0 0.0010159459
the O 0 0.0006216538
most O 0 0.0006350075
sensitive O 0 0.00042724088
strain O 0 0.00031858037
and O 0 0.00034353486
could O 0 0.00021654653
serve O 0 0.00024662525
as O 0 0.00021733873
the O 0 0.00021797877
strain O 0 0.00023049045
of O 0 0.00031216763
choice O 0 0.0003191622
for O 0 0.00029414834
evaluating O 0 0.0003149591
the O 0 0.00059406506
side O 0 0.009933079
effects O 0 0.002239408
of O 0 0.0089421375
amantadine B-Chemical 1 0.99995923
. O 0 0.009919686

The O 0 0.0031250983
biochemical O 0 0.003324298
results O 0 0.001550785
of O 0 0.0018806618
brain O 0 0.27722177
biogenic O 0 0.9989681
amines B-Chemical 0 0.9998085
of O 0 0.00550079
BALB O 0 0.79711586
/ O 0 0.15914959
C O 0 0.9993624
mouse O 0 0.0011682777
strain O 0 0.00025387813
suggest O 0 0.00015461013
a O 0 0.0003131892
probable O 0 0.006822439
decrease O 0 0.00025522363
of O 0 0.0012366399
catecholamine B-Chemical 0 0.99982494
turnover O 0 0.0020262194
rate O 0 0.0002654651
and O 0 0.00034237356
/ O 0 0.0047707893
or O 0 0.00026250698
metabolism O 0 0.12939906
by O 0 0.0007580416
monoamine O 0 0.9999895
oxidase O 0 0.99689555
and O 0 0.00028744433
a O 0 0.00019581878
resulting O 0 0.00014136486
increase O 0 0.00016109279
in O 0 0.00075105723
O O 0 0.99999416
- O 0 0.35736108
methylation O 0 0.38572824
of O 0 0.0039390335
norepinephrine B-Chemical 1 0.999967
which O 0 0.00031768653
may O 0 0.00015006345
account O 0 0.0001604335
for O 0 0.00018848019
a O 0 0.000534753
behavioral B-Disease 0 0.90800875
depression I-Disease 0 0.9999515
caused O 0 0.0004501999
by O 0 0.0010083589
amantadine B-Chemical 1 0.99995244
in O 0 0.0007459038
the O 0 0.0010500907
BALB O 0 0.2059361
/ O 0 0.027044516
C O 0 0.99219745
mice O 0 0.0038772027
. O 0 0.007819432

Chloroacetaldehyde B-Chemical 0 0.996525
and O 0 0.0043052626
its O 0 0.0032799635
contribution O 0 0.0017163213
to O 0 0.0019077219
urotoxicity O 0 0.99951696
during O 0 0.0012217758
treatment O 0 0.001981171
with O 0 0.0036236926
cyclophosphamide B-Chemical 0 0.9998888
or O 0 0.01095002
ifosfamide B-Chemical 1 0.99957997
. O 0 0.009548953

An O 0 0.016448686
experimental O 0 0.012631721
study O 0 0.013789028
/ O 0 0.018457785
short O 0 0.014022984
communication O 0 0.024807187
. O 0 0.02506885

Based O 0 0.006142105
on O 0 0.0020075897
clinical O 0 0.0031073391
data O 0 0.0014202812
, O 0 0.0012320199
indicating O 0 0.00066525076
that O 0 0.0008625765
chloroacetaldehyde B-Chemical 0 0.99999726
( O 0 0.13514777
CAA B-Chemical 0 0.9999583
) O 0 0.0055167926
is O 0 0.00034074511
an O 0 0.00030629185
important O 0 0.0002408097
metabolite O 0 0.90132457
of O 0 0.0018122153
oxazaphosphorine O 0 0.99876827
cytostatics O 0 0.99488527
, O 0 0.0011148836
an O 0 0.00030419682
experimental O 0 0.0002703835
study O 0 0.0002691851
was O 0 0.00015372632
carried O 0 0.00011421111
out O 0 0.00010911749
in O 0 0.00013112879
order O 0 0.000112879265
to O 0 0.00012272128
elucidate O 0 9.460279e-05
the O 0 0.0001722827
role O 0 0.00019026977
of O 0 0.0007834097
CAA B-Chemical 0 0.9994254
in O 0 0.0006083426
the O 0 0.0006922566
development O 0 0.0024728253
of O 0 0.01352067
hemorrhagic B-Disease 2 0.99998915
cystitis I-Disease 0 0.99999046
. O 0 0.024616629

The O 0 0.0033586018
data O 0 0.00243618
demonstrate O 0 0.0012331741
that O 0 0.0015200055
CAA B-Chemical 0 0.9977811
after O 0 0.0009375459
i O 0 0.005509459
. O 0 0.00086904975
v O 0 0.019863537
. O 0 0.00084324146
administration O 0 0.0032883016
does O 0 0.0008124897
not O 0 0.00083356694
contribute O 0 0.0011763803
to O 0 0.0021835286
bladder B-Disease 0 0.9652057
damage I-Disease 0 0.9959466
. O 0 0.011157884

When O 0 0.0031761276
instilled O 0 0.004725074
directly O 0 0.0014152174
into O 0 0.0008270185
the O 0 0.0009146529
bladder O 0 0.22491007
, O 0 0.009158205
CAA B-Chemical 0 0.9998578
exerts O 0 0.010492923
urotoxic O 0 0.9995307
effects O 0 0.0040060747
, O 0 0.0011150027
it O 0 0.0005134502
is O 0 0.0004558481
, O 0 0.00066541333
however O 0 0.0006951178
, O 0 0.0008089746
susceptible O 0 0.0010889408
to O 0 0.0010254991
detoxification O 0 0.5852301
with O 0 0.0069280206
mesna B-Chemical 1 0.9996735
. O 0 0.007618898

Source O 0 0.02594013
of O 0 0.0055963695
pain B-Disease 0 0.8589129
and O 0 0.003523415
primitive O 0 0.018714592
dysfunction O 0 0.93163246
in O 0 0.0081444075
migraine B-Disease 0 0.9999896
: O 0 0.0050870166
an O 0 0.0034222645
identical O 0 0.0033801396
site O 0 0.0074825673
? O 0 0.015073774

Twenty O 0 0.007270755
common O 0 0.00876178
migraine B-Disease 0 0.9999672
patients O 0 0.0022478923
received O 0 0.0007352743
a O 0 0.00075991027
one O 0 0.00053247495
sided O 0 0.25768864
frontotemporal O 0 0.9992785
application O 0 0.000932636
of O 0 0.001995948
nitroglycerin B-Chemical 1 0.9999975
( O 0 0.0010607789
10 O 0 0.00022914178
patients O 0 0.00030817583
) O 0 0.00042799948
or O 0 0.00030893984
placebo O 0 0.10214553
ointment O 0 0.98997515
( O 0 0.00064833614
10 O 0 0.0003312979
patients O 0 0.00050484913
) O 0 0.0007317686
in O 0 0.0006966119
a O 0 0.0011896527
double O 0 0.0017953065
blind O 0 0.0142220585
study O 0 0.004788039
. O 0 0.0067452635

Early O 0 0.021738878
onset O 0 0.21139924
migraine B-Disease 0 0.9999958
attacks O 0 0.98843247
were O 0 0.0012491161
induced O 0 0.0009426056
by O 0 0.0016541381
nitroglycerin B-Chemical 1 0.9999925
in O 0 0.0004481184
seven O 0 0.0002646417
out O 0 0.00020261046
of O 0 0.00028928634
10 O 0 0.00027742566
patients O 0 0.00033413773
versus O 0 0.0003150489
no O 0 0.00036864987
patient O 0 0.00067508966
in O 0 0.00086462876
the O 0 0.0014482478
placebo O 0 0.015088265
group O 0 0.004134357
. O 0 0.0063067577

Subsequently O 0 0.0053027496
20 O 0 0.0048674634
migraine B-Disease 0 0.99996257
patients O 0 0.0037081016
, O 0 0.0016491069
who O 0 0.0011180468
developed O 0 0.0007661131
an O 0 0.0005500095
early O 0 0.00080884824
onset O 0 0.005165398
attack O 0 0.8595728
with O 0 0.022093285
frontotemporal O 0 0.9999933
nitroglycerin B-Chemical 1 0.99999905
, O 0 0.00071388547
received O 0 0.00018685308
the O 0 0.00023104822
drug O 0 0.048756026
in O 0 0.00026838353
a O 0 0.0003489281
second O 0 0.0003197738
induction O 0 0.00042937257
test O 0 0.0006502535
at O 0 0.00078765687
other O 0 0.0014642361
body O 0 0.005042636
areas O 0 0.007691373
. O 0 0.0068940204

No O 0 0.016824897
early O 0 0.016627464
onset O 0 0.1605294
migraine B-Disease 0 0.9999442
was O 0 0.015624364
observed O 0 0.014786172
. O 0 0.021638203

Thus O 0 0.004596902
the O 0 0.0062931427
migraine B-Disease 0 0.9999949
- O 0 0.1268285
inducing O 0 0.0027901465
effect O 0 0.0013110659
of O 0 0.010161195
nitroglycerin B-Chemical 1 0.9999982
seems O 0 0.00044942144
to O 0 0.00021488691
depend O 0 0.00017086869
on O 0 0.00012445716
direct O 0 0.00015655186
stimulation O 0 0.00021087844
of O 0 0.00027775462
the O 0 0.00024806426
habitual O 0 0.060858265
site O 0 0.0002933379
of O 0 0.00083472027
pain B-Disease 0 0.9707935
, O 0 0.0003566784
suggesting O 0 0.00013649007
that O 0 0.00014270865
the O 0 0.00031721013
frontotemporal O 0 0.9988387
region O 0 0.00033274508
is O 0 0.00021414016
of O 0 0.00022925717
crucial O 0 0.00020152189
importance O 0 0.00025682247
in O 0 0.0003456166
the O 0 0.0004644866
development O 0 0.0011907727
of O 0 0.0018528918
a O 0 0.0131538445
migraine B-Disease 0 0.99998915
crisis O 0 0.7017385
. O 0 0.008579262

This O 0 0.006889586
is O 0 0.0037776201
not O 0 0.0026794714
consistent O 0 0.0023580738
with O 0 0.0024940835
a O 0 0.003259734
CNS O 0 0.25744867
origin O 0 0.005412901
of O 0 0.024472298
migraine B-Disease 0 0.9999918
attack O 0 0.97183347
. O 0 0.014289939

Hypersensitivity B-Disease 0 0.9628765
to O 0 0.005696263
carbamazepine B-Chemical 1 0.9999969
presenting O 0 0.017200842
with O 0 0.0014368143
a O 0 0.0015085909
leukemoid B-Disease 0 0.6777569
reaction I-Disease 0 0.10101467
, O 0 0.009302762
eosinophilia B-Disease 0 0.99995637
, O 0 0.03433343
erythroderma B-Disease 0 0.99953544
, O 0 0.0030330573
and O 0 0.003087048
renal B-Disease 0 0.92779976
failure I-Disease 0 0.7213834
. O 0 0.009014587

We O 0 0.00393577
report O 0 0.003583965
a O 0 0.0022072187
patient O 0 0.0014451884
in O 0 0.0010307973
whom O 0 0.0031907689
hypersensitivity B-Disease 0 0.9651188
to O 0 0.0014965878
carbamazepine B-Chemical 1 0.9999995
presented O 0 0.00043200873
with O 0 0.00051256263
generalized O 0 0.27103037
erythroderma B-Disease 0 0.9995042
, O 0 0.0010047638
a O 0 0.00058638636
severe O 0 0.10681298
leukemoid B-Disease 0 0.8304269
reaction I-Disease 0 0.100344405
, O 0 0.009000055
eosinophilia B-Disease 0 0.9999659
, O 0 0.04582384
hyponatremia B-Disease 2 0.99998283
, O 0 0.0031417846
and O 0 0.0028894392
renal B-Disease 0 0.9366877
failure I-Disease 0 0.73328876
. O 0 0.0083197085

This O 0 0.00637757
is O 0 0.0034025786
the O 0 0.0023428607
first O 0 0.0017462665
report O 0 0.0022691924
of O 0 0.0017358614
such O 0 0.0015469171
an O 0 0.002121732
unusual O 0 0.0055271103
reaction O 0 0.047691934
to O 0 0.0058727944
carbamazepine B-Chemical 1 0.99999547
. O 0 0.011268857

Fluoxetine B-Chemical 1 0.9999893
- O 0 0.21878381
induced O 0 0.017750753
akathisia B-Disease 0 0.9999918
: O 0 0.008661578
clinical O 0 0.0067168106
and O 0 0.0048702774
theoretical O 0 0.008731139
implications O 0 0.008886933
. O 0 0.013010205

Five O 0 0.004910252
patients O 0 0.0037558351
receiving O 0 0.00670304
fluoxetine B-Chemical 1 0.999992
for O 0 0.0011371853
the O 0 0.00077186496
treatment O 0 0.001081876
of O 0 0.010716594
obsessive B-Disease 0 0.9999989
compulsive I-Disease 0 0.9999964
disorder I-Disease 0 0.99901474
or O 0 0.0017229961
major B-Disease 2 0.15216717
depression I-Disease 2 0.9999769
developed O 0 0.18130821
akathisia B-Disease 0 0.99998724
. O 0 0.008516621

The O 0 0.0034177126
typical O 0 0.005748085
fluoxetine B-Chemical 1 0.999997
- O 0 0.08860389
induced O 0 0.0014925159
symptoms O 0 0.44385153
of O 0 0.0029879073
restlessness O 0 0.99946445
, O 0 0.0007431322
constant O 0 0.0004985021
pacing O 0 0.10493145
, O 0 0.0009851857
purposeless O 0 0.9153511
movements O 0 0.00094686274
of O 0 0.00023865707
the O 0 0.00019329406
feet O 0 0.004937758
and O 0 0.0003193704
legs O 0 0.030361414
, O 0 0.00032723873
and O 0 0.00029598476
marked O 0 0.0009621291
anxiety B-Disease 0 0.93956023
were O 0 0.00021211315
indistinguishable O 0 0.00016949122
from O 0 0.0002842387
those O 0 0.0006133868
of O 0 0.0031523309
neuroleptic O 0 0.9999988
- O 0 0.19745885
induced O 0 0.024910538
akathisia B-Disease 0 0.99999166
. O 0 0.008892465

Three O 0 0.0042602494
patients O 0 0.0031446444
who O 0 0.002416028
had O 0 0.0013904818
experienced O 0 0.005606106
neuroleptic O 0 0.9999993
- O 0 0.30660993
induced O 0 0.0066336324
akathisia B-Disease 0 0.9999987
in O 0 0.00041593498
the O 0 0.00026397017
past O 0 0.00030060922
reported O 0 0.00023019618
that O 0 0.00015634001
the O 0 0.00024839985
symptoms O 0 0.20090814
of O 0 0.008497416
fluoxetine B-Chemical 1 0.99999976
- O 0 0.17765889
induced O 0 0.0039134924
akathisia B-Disease 0 0.9999975
were O 0 0.0005498491
identical O 0 0.0004836132
, O 0 0.0011259121
although O 0 0.0014040973
somewhat O 0 0.003916583
milder O 0 0.10444331
. O 0 0.006960733

Akathisia B-Disease 0 0.9998567
appeared O 0 0.0028039704
to O 0 0.0014626202
be O 0 0.0011790572
a O 0 0.0010870866
common O 0 0.0009718572
side O 0 0.012769896
effect O 0 0.0006276383
of O 0 0.0054137763
fluoxetine B-Chemical 1 0.9999993
and O 0 0.00067033514
generally O 0 0.00035717725
responded O 0 0.00024088689
well O 0 0.00015359167
to O 0 0.0001391459
treatment O 0 0.00021227583
with O 0 0.00025354963
the O 0 0.0004931498
beta O 0 0.99624974
- O 0 0.9140206
adrenergic O 0 0.99973935
antagonist O 0 0.9987721
propranolol B-Chemical 1 0.9999995
, O 0 0.0032976854
dose O 0 0.009899343
reduction O 0 0.0018933105
, O 0 0.0018474391
or O 0 0.0020151588
both O 0 0.003543049
. O 0 0.0065366505

The O 0 0.002742124
authors O 0 0.0015746084
suggest O 0 0.0011766881
that O 0 0.0020204894
fluoxetine B-Chemical 1 0.9999994
- O 0 0.48307982
induced O 0 0.016841479
akathisia B-Disease 0 0.99999917
may O 0 0.000497245
be O 0 0.0002935732
caused O 0 0.00024305272
by O 0 0.00030353747
serotonergically O 0 0.029517477
mediated O 0 0.00014548739
inhibition O 0 0.0009910562
of O 0 0.0011842991
dopaminergic O 0 0.8655359
neurotransmission O 0 0.38557065
and O 0 0.00018648678
that O 0 0.000116844676
the O 0 0.00016953146
pathophysiology O 0 0.020322885
of O 0 0.009406141
fluoxetine B-Chemical 1 0.9999999
- O 0 0.22050777
induced O 0 0.00588321
akathisia B-Disease 0 0.99999964
and O 0 0.020700514
tricyclic O 0 0.99999547
antidepressant B-Chemical 1 0.99999094
- O 0 0.03124175
induced O 0 0.00078464055
" O 0 0.0057825022
jitteriness O 0 0.999559
" O 0 0.0016273747
may O 0 0.0012652266
be O 0 0.0019930447
identical O 0 0.0027646797
. O 0 0.006334451

Effect O 0 0.004575769
of O 0 0.003598224
converting O 0 0.013454495
enzyme O 0 0.024143107
inhibition O 0 0.0019102577
on O 0 0.0008061804
the O 0 0.00092932023
course O 0 0.0011550445
of O 0 0.0034617765
adriamycin B-Chemical 0 0.99996364
- O 0 0.33846155
induced O 0 0.042579465
nephropathy B-Disease 2 0.999998
. O 0 0.025655728

The O 0 0.0030857334
effect O 0 0.0021728964
of O 0 0.0018322452
the O 0 0.0014242593
converting O 0 0.029384196
enzyme O 0 0.16958722
inhibitor O 0 0.12844053
( O 0 0.042398095
CEI O 0 0.9996387
) O 0 0.05035993
enalapril B-Chemical 1 0.9999975
was O 0 0.00039771115
assessed O 0 0.0002841008
in O 0 0.00048212835
Munich O 0 0.087796636
- O 0 0.011535688
Wistar O 0 0.0072694365
rats O 0 0.00090628595
with O 0 0.0011076154
established O 0 0.0058784396
adriamycin B-Chemical 0 0.9999639
nephrosis B-Disease 2 0.99999225
. O 0 0.025491266

Rats O 0 0.008774509
were O 0 0.002376075
given O 0 0.001256873
a O 0 0.0012540389
single O 0 0.00086595875
dose O 0 0.0020155348
of O 0 0.0015673618
adriamycin B-Chemical 0 0.99991214
and O 0 0.0007488509
one O 0 0.00025664773
month O 0 0.00017439146
later O 0 0.00015262782
divided O 0 0.00013621703
into O 0 0.000107044434
four O 0 0.00012642404
groups O 0 0.00017615828
matched O 0 0.00021330568
for O 0 0.00045843484
albuminuria B-Disease 2 0.99999654
, O 0 0.0019329839
blood O 0 0.028253615
pressure O 0 0.036108084
, O 0 0.0008168603
and O 0 0.0010642356
plasma O 0 0.044592418
albumin O 0 0.97544265
concentration O 0 0.010880056
. O 0 0.007140774

Groups O 0 0.012834027
1 O 0 0.0033884111
and O 0 0.0024499903
3 O 0 0.0017021154
remained O 0 0.0015922611
untreated O 0 0.0013880465
while O 0 0.0012339901
groups O 0 0.0012834192
2 O 0 0.0013108747
and O 0 0.0017495311
4 O 0 0.002267459
received O 0 0.0039693355
enalapril B-Chemical 1 0.9999534
. O 0 0.00987736

Groups O 0 0.01430292
1 O 0 0.0049510435
and O 0 0.003898765
2 O 0 0.0031460316
underwent O 0 0.00280476
micropuncture O 0 0.0041746013
studies O 0 0.0031568694
after O 0 0.0031119846
10 O 0 0.0048225857
days O 0 0.0062093292
. O 0 0.011736058

These O 0 0.003547823
short O 0 0.002469715
- O 0 0.004154349
term O 0 0.001176083
studies O 0 0.00094926317
showed O 0 0.0007414196
that O 0 0.0008644178
enalapril B-Chemical 1 0.99999774
reduced O 0 0.0010773932
arterial O 0 0.5688664
blood O 0 0.025838293
pressure O 0 0.045969237
( O 0 0.00045436184
101 O 0 0.0016267583
+ O 0 0.0015243514
/ O 0 0.007656703
- O 0 0.0053847
2 O 0 0.00019664223
vs O 0 0.00023960005
. O 0 0.00018373759
124 O 0 0.0005574697
+ O 0 0.0010566994
/ O 0 0.00565803
- O 0 0.0041664117
3 O 0 0.00018268004
mm O 0 0.0012643543
Hg O 0 0.98071116
, O 0 0.00034156046
group O 0 0.0002595054
2 O 0 0.00017255904
vs O 0 0.00022782641
. O 0 0.0001798799
1 O 0 0.00019823712
, O 0 0.00031872676
P O 0 0.01721807
less O 0 0.00018797729
than O 0 0.00014354894
0 O 0 0.00022534843
. O 0 0.000202478
05 O 0 0.0028133204
) O 0 0.00035454467
and O 0 0.00029121173
glomerular O 0 0.782923
capillary O 0 0.19513303
pressure O 0 0.07888015
( O 0 0.00040245435
54 O 0 0.0004700856
+ O 0 0.0012177407
/ O 0 0.007387948
- O 0 0.006021475
1 O 0 0.00019290557
vs O 0 0.00023649092
. O 0 0.00017519429
61 O 0 0.00035195766
+ O 0 0.0009178463
/ O 0 0.005419975
- O 0 0.0049134726
2 O 0 0.00020968128
mm O 0 0.0019147961
Hg O 0 0.9915324
, O 0 0.00058256096
P O 0 0.026673915
less O 0 0.00019134938
than O 0 0.00014402361
0 O 0 0.0002225362
. O 0 0.00020162531
05 O 0 0.0027179874
) O 0 0.00032906674
without O 0 0.00020035781
reducing O 0 0.0009668021
albuminuria B-Disease 2 0.99999845
( O 0 0.0060501136
617 O 0 0.14246
+ O 0 0.005063641
/ O 0 0.013741132
- O 0 0.006519135
50 O 0 0.00023876881
vs O 0 0.0002588718
. O 0 0.00020727981
570 O 0 0.0763696
+ O 0 0.002829673
/ O 0 0.015879
- O 0 0.013419445
47 O 0 0.00055338116
mg O 0 0.011050414
/ O 0 0.000859158
day O 0 0.00017424152
) O 0 0.00039197528
or O 0 0.00029657906
GFR O 0 0.99629265
( O 0 0.0005699418
1 O 0 0.00022820012
. O 0 0.00022226477
03 O 0 0.013613559
+ O 0 0.0010679751
/ O 0 0.007139834
- O 0 0.008252364
0 O 0 0.00030730123
. O 0 0.00023967773
04 O 0 0.01172776
vs O 0 0.0003029087
. O 0 0.00021685666
1 O 0 0.0002376339
. O 0 0.0002734452
04 O 0 0.03780118
+ O 0 0.0014266496
/ O 0 0.0062477454
- O 0 0.0051638195
0 O 0 0.00054203486
. O 0 0.0005221136
11 O 0 0.0007499637
ml O 0 0.0013847419
/ O 0 0.0029972726
min O 0 0.0032376754
) O 0 0.005932452
. O 0 0.007804128

Groups O 0 0.011571848
3 O 0 0.0025342482
and O 0 0.0018584295
4 O 0 0.001176627
were O 0 0.0008494961
studied O 0 0.00065627525
at O 0 0.00044458182
four O 0 0.00031260928
and O 0 0.0003329831
at O 0 0.00023625675
six O 0 0.00017218596
months O 0 0.00014904585
to O 0 0.00014695471
assess O 0 0.00011261262
the O 0 0.00018769412
effect O 0 0.00025607427
of O 0 0.0015114574
enalapril B-Chemical 1 0.99999785
on O 0 0.00029938336
progression O 0 0.20488173
of O 0 0.0046651163
renal B-Disease 2 0.99977404
injury I-Disease 2 0.9997271
in O 0 0.022979915
adriamycin B-Chemical 0 0.9999833
nephrosis B-Disease 2 0.9999937
. O 0 0.025093278

Chronic O 0 0.9870746
enalapril B-Chemical 1 0.9999932
treatment O 0 0.0071787713
reduced O 0 0.0024085692
blood O 0 0.023868067
pressure O 0 0.048986617
without O 0 0.0013793467
reducing O 0 0.0035146615
albuminuria B-Disease 2 0.9999857
in O 0 0.0028985867
group O 0 0.0038920706
4 O 0 0.0041996264
. O 0 0.0072918865

Untreated O 0 0.12150681
group O 0 0.003459387
3 O 0 0.0016468358
rats O 0 0.0013904221
exhibited O 0 0.0008488116
a O 0 0.00088341907
progressive O 0 0.025098432
reduction O 0 0.0016126465
in O 0 0.0007271754
GFR O 0 0.99822706
( O 0 0.00078832003
0 O 0 0.00031461008
. O 0 0.00020686715
35 O 0 0.00024209802
+ O 0 0.0007507756
/ O 0 0.0055168187
- O 0 0.0075540836
0 O 0 0.0003026925
. O 0 0.00022584616
08 O 0 0.0060756793
ml O 0 0.00037664737
/ O 0 0.00057731173
min O 0 0.00022413023
at O 0 0.00013949022
4 O 0 0.0001330545
months O 0 0.00012074678
, O 0 0.0002026615
0 O 0 0.000206051
. O 0 0.00018755351
27 O 0 0.00032673587
+ O 0 0.00088526483
/ O 0 0.0062022917
- O 0 0.007284566
0 O 0 0.00039701606
. O 0 0.00034764828
07 O 0 0.0016478096
ml O 0 0.0006552927
/ O 0 0.0010550724
min O 0 0.0007602785
at O 0 0.00077912287
6 O 0 0.0010851729
months O 0 0.0017214466
) O 0 0.0046928166
. O 0 0.007154275

Enalapril B-Chemical 0 0.99999
treatment O 0 0.016204916
blunted O 0 0.15267472
but O 0 0.0025550604
did O 0 0.000995479
not O 0 0.0005155005
prevent O 0 0.00043166726
reduction O 0 0.0010332234
in O 0 0.00059800694
GFR O 0 0.99640024
in O 0 0.00030734195
group O 0 0.00032391108
4 O 0 0.00018075849
( O 0 0.00025835153
0 O 0 0.00021039382
. O 0 0.00017084656
86 O 0 0.00034117303
+ O 0 0.0010225995
/ O 0 0.008122987
- O 0 0.008193399
0 O 0 0.00024175843
. O 0 0.00015325316
15 O 0 0.00013674279
ml O 0 0.00024295587
/ O 0 0.00042216806
min O 0 0.00019950567
at O 0 0.00012719673
4 O 0 0.00012181071
months O 0 0.00010965319
, O 0 0.0001833774
0 O 0 0.00018269467
. O 0 0.00015813859
69 O 0 0.00028439675
+ O 0 0.0008927325
/ O 0 0.007356136
- O 0 0.008147332
0 O 0 0.00025225838
. O 0 0.00016732933
13 O 0 0.00018330364
ml O 0 0.00027637518
/ O 0 0.00048240827
min O 0 0.00021797109
at O 0 0.0001419313
6 O 0 0.00013183616
months O 0 0.00013220198
, O 0 0.00022774062
both O 0 0.00024188017
P O 0 0.013988267
less O 0 0.00027258726
than O 0 0.00024881418
0 O 0 0.00042068327
. O 0 0.00048818282
05 O 0 0.0023903183
vs O 0 0.00091593934
. O 0 0.0010103567
group O 0 0.0017638911
3 O 0 0.0022734571
) O 0 0.005105231
. O 0 0.007346678

Reduction O 0 0.009482774
in O 0 0.003825539
GFR O 0 0.99220556
was O 0 0.0016418198
associated O 0 0.00097082614
with O 0 0.00067588274
the O 0 0.0004964385
development O 0 0.0009666322
of O 0 0.0019198915
glomerular B-Disease 2 0.999905
sclerosis I-Disease 2 0.99998903
in O 0 0.00038580972
both O 0 0.00028525456
treated O 0 0.00036471622
and O 0 0.00038973254
untreated O 0 0.0005676583
rats O 0 0.0007981619
. O 0 0.0006604439
( O 0 0.0015470956
ABSTRACT O 0 0.0061173546
TRUNCATED O 0 0.0064093336
AT O 0 0.012026768
250 O 0 0.0056159263
WORDS O 0 0.010625498
) O 0 0.017230403

Clotiazepam B-Chemical 0 0.980616
- O 0 0.096589595
induced O 0 0.044506032
acute O 0 0.99973804
hepatitis B-Disease 2 0.9999993
. O 0 0.5515273

We O 0 0.0038274494
report O 0 0.0032977106
the O 0 0.001711493
case O 0 0.0013831082
of O 0 0.0011667768
a O 0 0.0010598566
patient O 0 0.0008120296
who O 0 0.0012112377
developed O 0 0.0061111823
acute O 0 0.99990046
hepatitis B-Disease 2 1.0
with O 0 0.26271668
extensive B-Disease 0 0.61287403
hepatocellular I-Disease 0 1.0
necrosis I-Disease 2 1.0
, O 0 0.01784288
7 O 0 0.00020572357
months O 0 0.00013241002
after O 0 0.00012075404
the O 0 0.00018638154
onset O 0 0.0004070955
of O 0 0.00045994404
administration O 0 0.01612128
of O 0 0.008217062
clotiazepam B-Chemical 0 0.99999595
, O 0 0.0047309077
a O 0 0.0048686834
thienodiazepine B-Chemical 0 0.99822396
derivative O 0 0.15237312
. O 0 0.007528366

Clotiazepam B-Chemical 0 0.95395315
withdrawal O 0 0.27125332
was O 0 0.008473502
followed O 0 0.0069971955
by O 0 0.009590054
prompt O 0 0.0163966
recovery O 0 0.01862968
. O 0 0.019317737

The O 0 0.0032535335
administration O 0 0.005047849
of O 0 0.0021626325
several O 0 0.0019673365
benzodiazepines B-Chemical 1 0.9999709
, O 0 0.0018815696
chemically O 0 0.0058752117
related O 0 0.0003778626
to O 0 0.00063974323
clotiazepam B-Chemical 0 0.9999945
, O 0 0.0010949053
did O 0 0.00035028227
not O 0 0.0002180796
interfere O 0 0.00023629503
with O 0 0.00031419648
recovery O 0 0.000496741
and O 0 0.00042663998
did O 0 0.0004384366
not O 0 0.0004283695
induce O 0 0.0005683118
any O 0 0.0012213693
relapse O 0 0.9606049
of O 0 0.034663714
hepatitis B-Disease 2 0.9999995
. O 0 0.13965079

This O 0 0.004865626
observation O 0 0.0024477178
shows O 0 0.0013744456
that O 0 0.0017418367
clotiazepam B-Chemical 0 0.9999876
can O 0 0.00096568366
induce O 0 0.0008819165
acute O 0 0.9999503
hepatitis B-Disease 2 1.0
and O 0 0.056038138
suggests O 0 0.00031407364
that O 0 0.00023558305
there O 0 0.00020929436
is O 0 0.00030600256
no O 0 0.0002952942
cross O 0 0.004708312
hepatotoxicity B-Disease 2 0.9999994
between O 0 0.0015824505
clotiazepam B-Chemical 0 0.9999908
and O 0 0.0024403378
several O 0 0.002899713
benzodiazepines B-Chemical 1 0.999788
. O 0 0.0069437097

5 B-Chemical 0 0.006257783
- I-Chemical 0 0.027609454
azacytidine I-Chemical 0 0.96118647
potentiates O 0 0.006607501
initiation B-Disease 0 0.0032597652
induced I-Disease 0 0.002940751
by I-Disease 0 0.0039995504
carcinogens I-Disease 0 0.99529415
in O 0 0.0047900835
rat O 0 0.02724881
liver O 0 0.8356873
. O 0 0.01190983

To O 0 0.0027136842
test O 0 0.0020410758
the O 0 0.001288234
validity O 0 0.0012015816
of O 0 0.0008635172
the O 0 0.0005832418
hypothesis O 0 0.0005438933
that O 0 0.0004800125
hypomethylation O 0 0.883732
of O 0 0.001071797
DNA O 0 0.17918324
plays O 0 0.00025897895
an O 0 0.00028388062
important O 0 0.00014775389
role O 0 0.00012569706
in O 0 0.00017085698
the O 0 0.00016541127
initiation B-Disease 0 0.00026453153
of I-Disease 0 0.00086121354
carcinogenic I-Disease 0 0.99968505
process I-Disease 0 0.0005210146
, O 0 0.00066586095
5 B-Chemical 0 0.00022251542
- I-Chemical 0 0.018678047
azacytidine I-Chemical 0 0.9819349
( O 0 0.0011885093
5 B-Chemical 0 0.0002577952
- I-Chemical 0 0.02611865
AzC I-Chemical 0 0.78999114
) O 0 0.0010081807
( O 0 0.0003897848
10 O 0 0.00019173144
mg O 0 0.008808877
/ O 0 0.0014901522
kg O 0 0.001453181
) O 0 0.00065956305
, O 0 0.00032520384
an O 0 0.00025616123
inhibitor O 0 0.0028513095
of O 0 0.0007056725
DNA O 0 0.61788523
methylation O 0 0.49884167
, O 0 0.0005443832
was O 0 0.00017678559
given O 0 0.00010369924
to O 0 0.00012035271
rats O 0 0.00018119854
during O 0 9.6721524e-05
the O 0 0.00013272921
phase O 0 0.00022218765
of O 0 0.00022584682
repair O 0 0.00051711156
synthesis O 0 0.0012845797
induced O 0 0.0001988996
by O 0 0.00019466461
the O 0 0.00016943674
three O 0 0.00014830977
carcinogens O 0 0.9959979
, O 0 0.02486113
benzo B-Chemical 0 0.9999881
[ I-Chemical 0 0.052307382
a I-Chemical 0 0.0011092531
] I-Chemical 0 0.012148302
- I-Chemical 0 0.09489475
pyrene I-Chemical 0 0.99510974
( O 0 0.0007108109
200 O 0 0.00038625355
mg O 0 0.008611224
/ O 0 0.0010922774
kg O 0 0.0011646365
) O 0 0.0010396468
, O 0 0.002025557
N B-Chemical 0 0.99984205
- I-Chemical 0 0.6694063
methyl I-Chemical 0 0.999678
- I-Chemical 0 0.6289069
N I-Chemical 0 0.9999231
- I-Chemical 0 0.46689773
nitrosourea I-Chemical 0 0.99835455
( O 0 0.00065379933
60 O 0 0.00022749884
mg O 0 0.005835231
/ O 0 0.00081405824
kg O 0 0.0006450667
) O 0 0.0003820633
and O 0 0.00023618917
1 B-Chemical 0 0.00020812903
, I-Chemical 0 0.0002999184
2 I-Chemical 0 0.00027900285
- I-Chemical 0 0.015604932
dimethylhydrazine I-Chemical 0 0.9961597
( O 0 0.00076283526
1 B-Chemical 0 0.00028436474
, I-Chemical 0 0.0004123061
2 I-Chemical 0 0.0004011671
- I-Chemical 0 0.023854753
DMH I-Chemical 0 0.9872054
) O 0 0.0013735599
( O 0 0.0010623697
100 O 0 0.0014397481
mg O 0 0.025716973
/ O 0 0.0041793697
kg O 0 0.0056904107
) O 0 0.006328688
. O 0 0.007854929

The O 0 0.0030820814
initiated O 0 0.0024209241
hepatocytes O 0 0.03082458
in O 0 0.0013105015
the O 0 0.0009953437
liver O 0 0.2883947
were O 0 0.00048629942
assayed O 0 0.00030259148
as O 0 0.00029259827
the O 0 0.00048232876
gamma O 0 0.99350774
- O 0 0.8639284
glutamyltransferase O 0 0.9999943
( O 0 0.11992124
gamma O 0 0.99846363
- O 0 0.7006265
GT O 0 0.9954751
) O 0 0.0008121298
positive O 0 0.00029050742
foci O 0 0.00030618586
formed O 0 0.0002225901
following O 0 0.00015551483
a O 0 0.00025762198
2 O 0 0.00019782285
- O 0 0.0006308459
week O 0 0.000114046445
selection O 0 0.00017808322
regimen O 0 0.00018043716
consisting O 0 0.00013311478
of O 0 0.0002585413
dietary O 0 0.16376403
0 O 0 0.0003583611
. O 0 0.00025977174
02 O 0 0.028231908
% O 0 0.00040259265
2 B-Chemical 0 0.00037580435
- I-Chemical 0 0.010684126
acetylaminofluorene I-Chemical 0 0.9884567
coupled O 0 0.00061573385
with O 0 0.0007264231
a O 0 0.0016111026
necrogenic O 0 0.9888726
dose O 0 0.077427834
of O 0 0.048799578
CCl4 B-Chemical 0 0.9999962
. O 0 0.015474192

The O 0 0.0028588031
results O 0 0.0017852613
obtained O 0 0.001221689
indicate O 0 0.0007130678
that O 0 0.0006067053
with O 0 0.0006096785
all O 0 0.0004304922
three O 0 0.0003074102
carcinogens O 0 0.9854264
, O 0 0.0009259335
administration O 0 0.0044865953
of O 0 0.00044922615
5 B-Chemical 0 0.00030928728
- I-Chemical 0 0.019447464
AzC I-Chemical 0 0.39586407
during O 0 0.00014447173
repair O 0 0.0003718472
synthesis O 0 0.0009395548
increased O 0 0.00021916728
the O 0 0.00017247302
incidence O 0 0.0008299378
of O 0 0.0002533087
initiated O 0 0.00026416103
hepatocytes O 0 0.18963836
, O 0 0.0005787345
for O 0 0.0001796384
example O 0 0.00017839423
10 O 0 0.00019799874
- O 0 0.00097557815
20 O 0 0.00014187097
foci O 0 0.00023815266
/ O 0 0.00092783483
cm2 O 0 0.0008074228
in O 0 0.00021527716
5 B-Chemical 0 0.00021362789
- I-Chemical 0 0.013820505
AzC I-Chemical 0 0.7647967
and O 0 0.0020393217
carcinogen O 0 0.99972385
- O 0 0.054224186
treated O 0 0.00033081058
rats O 0 0.00024512163
compared O 0 0.00011537116
with O 0 0.00019903049
3 O 0 0.00019248427
- O 0 0.0007930207
5 O 0 0.000187346
foci O 0 0.00036646656
/ O 0 0.0012849713
cm2 O 0 0.0011992794
in O 0 0.00053052494
rats O 0 0.00087650726
treated O 0 0.001065675
with O 0 0.0023322816
carcinogen O 0 0.9964551
only O 0 0.0051955604
. O 0 0.007178934

Administration O 0 0.038920686
of O 0 0.0060171993
[ B-Chemical 0 0.17841907
3H I-Chemical 0 0.9866932
] I-Chemical 0 0.025042834
- I-Chemical 0 0.016632684
5 I-Chemical 0 0.0007791849
- I-Chemical 0 0.00362518
azadeoxycytidine I-Chemical 0 0.016325235
during O 0 0.00027424333
the O 0 0.00027689055
repair O 0 0.0004443424
synthesis O 0 0.0008343378
induced O 0 0.00026783015
by O 0 0.00030296014
1 B-Chemical 0 0.00026006668
, I-Chemical 0 0.00038043142
2 I-Chemical 0 0.00030699524
- I-Chemical 0 0.017460072
DMH I-Chemical 0 0.935335
further O 0 0.00016914378
showed O 0 0.00015518659
that O 0 0.00014549904
0 O 0 0.00025493227
. O 0 0.00020922234
019 O 0 0.020138053
mol O 0 0.1946849
% O 0 0.00045768268
of O 0 0.00071461033
cytosine B-Chemical 0 0.9989543
residues O 0 0.079708315
in O 0 0.00039209973
DNA O 0 0.106775254
were O 0 0.00023515332
substituted O 0 0.00077415514
by O 0 0.00018739158
the O 0 0.00019842775
analogue O 0 0.001968685
, O 0 0.0003011203
indicating O 0 0.0001775339
that O 0 0.0002030882
incorporation O 0 0.00089826493
of O 0 0.00054264383
5 B-Chemical 0 0.0005217397
- I-Chemical 0 0.010453459
AzC I-Chemical 0 0.32800007
occurs O 0 0.0010064653
during O 0 0.0012616604
repair O 0 0.0036730987
synthesis O 0 0.009452671
. O 0 0.0072048404

In O 0 0.0035403713
the O 0 0.0020916376
absence O 0 0.0013325809
of O 0 0.0015810694
the O 0 0.0018720751
carcinogen O 0 0.9994553
, O 0 0.0039625093
5 B-Chemical 0 0.00066647894
- I-Chemical 0 0.01858082
AzC I-Chemical 0 0.30539387
given O 0 0.00020070387
after O 0 0.00016315794
a O 0 0.00022606656
two O 0 0.00015390909
thirds O 0 0.00026094835
partial O 0 0.00047148077
hepatectomy O 0 0.9658481
, O 0 0.000485117
when O 0 0.00016241812
its O 0 0.00048140256
incorporation O 0 0.000877332
should O 0 0.00014224566
be O 0 0.00018554833
maximum O 0 0.00020826004
, O 0 0.00033754756
failed O 0 0.0002951014
to O 0 0.00027941092
induce O 0 0.00035498297
any O 0 0.00081004796
gamma O 0 0.9604056
- O 0 0.32450396
GT O 0 0.9820322
positive O 0 0.0045149247
foci O 0 0.008290445
. O 0 0.007985434

The O 0 0.0032496096
results O 0 0.0021394764
suggest O 0 0.0013607951
that O 0 0.001505874
hypomethylation O 0 0.63608795
of O 0 0.0018427297
DNA O 0 0.07685291
per O 0 0.0007004584
se O 0 0.0012170201
may O 0 0.00080476736
not O 0 0.00087754935
be O 0 0.0011908063
sufficient O 0 0.0013936888
for O 0 0.0024926101
initiation O 0 0.0052360967
. O 0 0.008294006

Perhaps O 0 0.0052970634
two O 0 0.0022716552
events O 0 0.0036598288
might O 0 0.0009567888
be O 0 0.0007911349
necessary O 0 0.0004897423
for O 0 0.000512761
initiation O 0 0.00063204655
, O 0 0.00061134674
the O 0 0.00032661474
first O 0 0.0002478713
caused O 0 0.00029526828
by O 0 0.00039796563
the O 0 0.0005708127
carcinogen O 0 0.9959416
and O 0 0.00071196235
a O 0 0.00067679485
second O 0 0.0006680204
involving O 0 0.0012082062
hypomethylation O 0 0.61152726
of O 0 0.004001561
DNA O 0 0.31313667
. O 0 0.008105879

Antihypertensive O 0 0.9937396
drugs O 0 0.49980313
and O 0 0.013480072
depression B-Disease 0 0.9974964
: O 0 0.013666236
a O 0 0.013061474
reappraisal O 0 0.1304592
. O 0 0.018802201

Eighty O 0 0.008091277
- O 0 0.0067684622
nine O 0 0.0020097557
new O 0 0.0018771922
referral O 0 0.0028505016
hypertensive B-Disease 2 0.9982609
out O 0 0.00063191674
- O 0 0.0024097173
patients O 0 0.00054337847
and O 0 0.00039064244
46 O 0 0.00042127725
new O 0 0.0003396419
referral O 0 0.0005756201
non O 0 0.0012190673
- O 0 0.07568694
hypertensive B-Disease 2 0.99959534
chronically O 0 0.009380844
physically O 0 0.0006563228
ill O 0 0.014854966
out O 0 0.0001725255
- O 0 0.00093370245
patients O 0 0.000259695
completed O 0 0.00020354473
a O 0 0.0003427274
mood O 0 0.7564246
rating O 0 0.00035651354
scale O 0 0.00035166767
at O 0 0.00034648288
regular O 0 0.00053450605
intervals O 0 0.0005748226
for O 0 0.001024365
one O 0 0.0017279142
year O 0 0.0034667135
. O 0 0.0063337726

The O 0 0.0030083302
results O 0 0.0020226268
showed O 0 0.001511281
a O 0 0.0013967508
high O 0 0.0012139376
prevalence O 0 0.002112271
of O 0 0.0021888213
depression B-Disease 0 0.999315
in O 0 0.000448033
both O 0 0.0003349673
groups O 0 0.00033378403
of O 0 0.0003856226
patients O 0 0.00062808115
, O 0 0.0004874204
with O 0 0.00043363933
no O 0 0.000432347
preponderance O 0 0.002292124
in O 0 0.0011152645
the O 0 0.0022110718
hypertensive B-Disease 2 0.9993986
group O 0 0.0049869097
. O 0 0.006525877

Hypertensive B-Disease 0 0.9986656
patients O 0 0.004516884
with O 0 0.00280336
psychiatric B-Disease 2 0.9502519
histories O 0 0.0022482795
had O 0 0.0008944046
a O 0 0.00087881205
higher O 0 0.000688545
prevalence O 0 0.0014908164
of O 0 0.0017576773
depression B-Disease 0 0.9974185
than O 0 0.0009454776
the O 0 0.0014288375
comparison O 0 0.0021785714
patients O 0 0.005034525
. O 0 0.006803151

This O 0 0.0051803463
was O 0 0.002555454
accounted O 0 0.0017244976
for O 0 0.0012319566
by O 0 0.0010568954
a O 0 0.000911161
significant O 0 0.00060363027
number O 0 0.0005170521
of O 0 0.0010070341
depressions B-Disease 0 0.99882597
occurring O 0 0.0038339603
in O 0 0.0028280106
methyl B-Chemical 0 0.9999738
dopa I-Chemical 0 0.9999968
treated O 0 0.0016184873
patients O 0 0.0017011258
with O 0 0.002056531
psychiatric B-Disease 2 0.97757417
histories O 0 0.009012465
. O 0 0.006829573

Chronic B-Disease 0 0.9534777
active I-Disease 0 0.20884883
hepatitis I-Disease 2 0.9999993
associated O 0 0.19136615
with O 0 0.38735592
diclofenac B-Chemical 1 0.99999976
sodium I-Chemical 0 0.9999776
therapy O 0 0.1572066
. O 0 0.013087845

Diclofenac B-Chemical 0 0.9999963
sodium I-Chemical 0 0.9999838
( O 0 0.28696513
Voltarol B-Chemical 0 0.9999647
, O 0 0.07186707
Geigy O 0 0.9996917
Pharmaceuticals O 0 0.9298646
) O 0 0.0016534051
is O 0 0.0005426841
a O 0 0.000620797
non O 0 0.0019677777
- O 0 0.10116713
steroidal O 0 0.99066824
anti O 0 0.73487353
- O 0 0.2542366
inflammatory O 0 0.8898146
derivative O 0 0.3931235
of O 0 0.06098547
phenylacetic B-Chemical 1 0.9999865
acid I-Chemical 1 0.997884
. O 0 0.011021396

Although O 0 0.0031513283
generally O 0 0.0026404622
well O 0 0.0019649523
- O 0 0.012253431
tolerated O 0 0.011210755
, O 0 0.0013778112
asymptomatic O 0 0.092340834
abnormalities B-Disease 0 0.07664051
of I-Disease 0 0.0007487593
liver I-Disease 0 0.4662718
function I-Disease 0 0.0003633269
have O 0 0.00023122078
been O 0 0.00024056052
recorded O 0 0.00025353464
and O 0 0.0003485845
, O 0 0.0004999288
less O 0 0.000404078
commonly O 0 0.00091630494
, O 0 0.0013681417
severe O 0 0.6688257
hepatitis B-Disease 2 0.9999999
induced O 0 0.13850397
by O 0 0.10327002
diclofenac B-Chemical 1 0.99999607
. O 0 0.011096972

The O 0 0.003217623
patient O 0 0.0024032223
described O 0 0.0015683547
developed O 0 0.002263468
chronic B-Disease 0 0.97777224
active I-Disease 0 0.2715544
hepatitis I-Disease 2 1.0
after O 0 0.00059175567
six O 0 0.00023780664
months O 0 0.0001836026
therapy O 0 0.00044940578
with O 0 0.0031753983
diclofenac B-Chemical 1 1.0
sodium I-Chemical 0 0.99999475
which O 0 0.0010776792
progressed O 0 0.0009077175
despite O 0 0.00018938107
the O 0 0.0002277228
withdrawal O 0 0.03765065
of O 0 0.0003418185
the O 0 0.00040255298
drug O 0 0.23475708
, O 0 0.00081169413
a O 0 0.00075619755
finding O 0 0.0010579601
not O 0 0.0011329063
previously O 0 0.0020040504
reported O 0 0.004053855
. O 0 0.006256369

Arterial O 0 0.93453974
hypertension B-Disease 2 0.99987984
as O 0 0.0049268147
a O 0 0.0048669507
complication O 0 0.11390537
of O 0 0.005463817
prolonged O 0 0.10164362
ketoconazole B-Chemical 1 0.9999963
treatment O 0 0.050777663
. O 0 0.012825016

Two O 0 0.0038264424
of O 0 0.0027609104
14 O 0 0.001889278
patients O 0 0.0015934411
with O 0 0.0014607259
Cushing B-Disease 0 0.98826075
' I-Disease 0 0.0015645332
s I-Disease 0 0.0010676958
syndrome I-Disease 0 0.1303323
treated O 0 0.00045539511
on O 0 0.00024779525
a O 0 0.00038951103
long O 0 0.00038716654
- O 0 0.001390295
term O 0 0.00040739306
basis O 0 0.000651321
with O 0 0.0029709337
ketoconazole B-Chemical 1 0.9999987
developed O 0 0.04032984
sustained O 0 0.3011649
hypertension B-Disease 2 0.9999876
. O 0 0.009777189

In O 0 0.0034354203
both O 0 0.0021202809
cases O 0 0.002122035
normal O 0 0.0019162438
plasma O 0 0.013564816
and O 0 0.0009895826
urinary O 0 0.386021
free O 0 0.0037766995
cortisol B-Chemical 1 0.99861145
levels O 0 0.00043417126
had O 0 0.00026266722
been O 0 0.00020465144
achieved O 0 0.00025457572
following O 0 0.00051296
ketoconazole B-Chemical 1 0.99999976
therapy O 0 0.014323902
, O 0 0.00067988207
yet O 0 0.00029995502
continuous O 0 0.00015347428
blood O 0 0.0030836966
pressure O 0 0.008456607
monitoring O 0 0.00022740127
demonstrated O 0 0.00027255708
hypertension B-Disease 2 0.99998975
31 O 0 0.00045851257
( O 0 0.00029629222
patient O 0 0.00022454884
1 O 0 0.0002050548
) O 0 0.00031845918
and O 0 0.0002698823
52 O 0 0.000372267
weeks O 0 0.00025742405
( O 0 0.0005600463
patient O 0 0.0006690338
2 O 0 0.0008453787
) O 0 0.0015974904
after O 0 0.0016056455
treatment O 0 0.003872432
. O 0 0.0067344047

In O 0 0.0043759746
patient O 0 0.0031800203
1 O 0 0.0023167788
, O 0 0.002204557
plasma O 0 0.004740127
levels O 0 0.0013855234
of O 0 0.0045952876
deoxycorticosterone B-Chemical 0 0.99999714
and O 0 0.0031139792
11 B-Chemical 0 0.0022176472
- I-Chemical 0 0.031522285
deoxycortisol I-Chemical 0 0.9691841
were O 0 0.0037441093
elevated O 0 0.009718779
. O 0 0.008315389

In O 0 0.0038708285
patient O 0 0.0027215339
2 O 0 0.0017973173
, O 0 0.0014525618
in O 0 0.0007816081
addition O 0 0.0004528476
to O 0 0.0004454581
an O 0 0.00048480192
increase O 0 0.0003184437
in O 0 0.0004201376
both O 0 0.0019573066
deoxycorticosterone B-Chemical 0 0.99999905
and O 0 0.0016089046
11 B-Chemical 0 0.00080063497
- I-Chemical 0 0.07114696
deoxycortisol I-Chemical 0 0.9880448
levels O 0 0.00038002076
, O 0 0.00097166636
plasma O 0 0.17104128
aldosterone B-Chemical 0 0.99982136
values O 0 0.000258524
were O 0 0.00023119609
raised O 0 0.00030800136
, O 0 0.00039553182
with O 0 0.00038988196
a O 0 0.0005718142
concomitant O 0 0.0013049664
suppression O 0 0.001508338
of O 0 0.0032557994
renin O 0 0.9593018
levels O 0 0.0041246014
. O 0 0.006936624

Our O 0 0.00360255
findings O 0 0.0024649384
show O 0 0.0013060732
that O 0 0.0009964852
long O 0 0.0011715987
- O 0 0.0049180496
term O 0 0.0005361095
treatment O 0 0.0005794885
with O 0 0.00046580815
high O 0 0.0006857919
doses O 0 0.010039925
of O 0 0.009447395
ketoconazole B-Chemical 1 0.99999976
may O 0 0.0005086654
induce O 0 0.00029184294
enzyme O 0 0.09629128
blockade O 0 0.015789445
leading O 0 0.0019180011
to O 0 0.0012507341
mineralocorticoid O 0 0.9989391
- O 0 0.07712006
related O 0 0.002728067
hypertension B-Disease 2 0.99995303
. O 0 0.007758202

Effects O 0 0.004991824
of O 0 0.0028637962
an O 0 0.0024327266
inhibitor O 0 0.01902723
of O 0 0.018469982
angiotensin B-Chemical 1 0.9999939
converting O 0 0.49481717
enzyme O 0 0.6091262
( O 0 0.05360784
Captopril B-Chemical 0 0.9999976
) O 0 0.0013329085
on O 0 0.0002193316
pulmonary B-Disease 0 0.2457188
and I-Disease 0 0.00083740783
renal I-Disease 0 0.9562021
insufficiency I-Disease 0 0.99504787
due O 0 0.0004002786
to O 0 0.0006713146
intravascular B-Disease 0 0.99092746
coagulation I-Disease 0 0.98502386
in O 0 0.0013959084
the O 0 0.002171165
rat O 0 0.005894641
. O 0 0.0064019007

Induction O 0 0.005759225
of O 0 0.005316644
intravascular B-Disease 0 0.99565107
coagulation I-Disease 0 0.9956086
and O 0 0.0015315971
inhibition O 0 0.0020960395
of O 0 0.0017389511
fibrinolysis O 0 0.99275655
by O 0 0.00046178343
injection O 0 0.00072186225
of O 0 0.00065059855
thrombin O 0 0.9459302
and O 0 0.008578401
tranexamic B-Chemical 0 0.99980086
acid I-Chemical 0 0.99011505
( O 0 0.057771027
AMCA B-Chemical 0 0.9999552
) O 0 0.002811928
in O 0 0.00020651123
the O 0 0.00018816807
rat O 0 0.00043865084
gives O 0 0.0001867528
rise O 0 0.0002081834
to O 0 0.00017375525
pulmonary B-Disease 0 0.2678602
and I-Disease 0 0.00076506473
renal I-Disease 0 0.96572024
insufficiency I-Disease 0 0.9970477
resembling O 0 0.0007577351
that O 0 0.00024733355
occurring O 0 0.00054333196
after O 0 0.00042806193
trauma B-Disease 0 0.958101
or O 0 0.0019072462
sepsis B-Disease 2 0.9996512
in O 0 0.0043208054
man O 0 0.42255855
. O 0 0.007857598

Injection O 0 0.16007604
of O 0 0.012874313
Captopril B-Chemical 0 0.99999213
( O 0 0.006773846
1 O 0 0.0012013218
mg O 0 0.046537858
/ O 0 0.0039463514
kg O 0 0.0026963851
) O 0 0.0011883287
, O 0 0.0005738802
an O 0 0.00044092326
inhibitor O 0 0.008022604
of O 0 0.0073668784
angiotensin B-Chemical 1 0.9999945
converting O 0 0.27225092
enzyme O 0 0.4614403
( O 0 0.02878589
ACE O 0 0.99968624
) O 0 0.0017540507
, O 0 0.0003931303
reduced O 0 0.0002573127
both O 0 0.00032498903
pulmonary B-Disease 0 0.33279496
and I-Disease 0 0.0011230937
renal I-Disease 0 0.96989185
insufficiency I-Disease 0 0.99687696
in O 0 0.0011287013
this O 0 0.0014485891
rat O 0 0.0035431194
model O 0 0.003987113
. O 0 0.006831336

The O 0 0.0038022068
lung O 0 0.010138217
weights O 0 0.0021639438
were O 0 0.0014765202
lower O 0 0.0010850556
and O 0 0.0012316686
PaO2 O 0 0.9182215
was O 0 0.0006760303
improved O 0 0.00066115434
in O 0 0.00051470805
rats O 0 0.00067215547
given O 0 0.00047497946
this O 0 0.00086960144
enzyme O 0 0.055799298
- O 0 0.021001209
blocking O 0 0.0073472
agent O 0 0.18923742
. O 0 0.008697716

The O 0 0.0032893957
contents O 0 0.0035958518
of O 0 0.0025913059
albumin O 0 0.96741617
in O 0 0.0011325867
the O 0 0.00073683664
lungs O 0 0.0015182472
were O 0 0.00045276343
not O 0 0.00033730554
changed O 0 0.00040270074
, O 0 0.00050683995
indicating O 0 0.00034954672
that O 0 0.00059480895
Captopril B-Chemical 0 0.9999931
did O 0 0.00057672604
not O 0 0.00042273186
influence O 0 0.0005068869
the O 0 0.0009699349
extravasation O 0 0.2990191
of O 0 0.0029885962
protein O 0 0.008554523
. O 0 0.008090772

Renal B-Disease 0 0.9117153
damage I-Disease 0 0.948701
as O 0 0.0023633589
reflected O 0 0.0014333786
by O 0 0.0011653957
an O 0 0.000972611
increase O 0 0.000638288
in O 0 0.0008260781
serum O 0 0.7181075
urea B-Chemical 1 0.99992156
and O 0 0.0013459988
in O 0 0.0008808739
kidney O 0 0.4819864
weight O 0 0.009589931
was O 0 0.0015236108
prevented O 0 0.0032435823
by O 0 0.0073541347
Captopril B-Chemical 0 0.99997735
. O 0 0.00930952

The O 0 0.0029938691
amount O 0 0.0017880524
of O 0 0.0021801342
fibrin O 0 0.2314042
in O 0 0.0010671371
the O 0 0.00079325045
kidneys O 0 0.0063850647
was O 0 0.0005263338
also O 0 0.00039280084
considerably O 0 0.00048096175
lower O 0 0.00036060344
than O 0 0.0002689117
in O 0 0.00035014874
animals O 0 0.0003957185
which O 0 0.0006866126
received O 0 0.0008376684
thrombin O 0 0.8093267
and O 0 0.006148465
AMCA B-Chemical 0 0.99954
alone O 0 0.0064606583
. O 0 0.008213997

It O 0 0.0045839446
is O 0 0.002413618
suggested O 0 0.0013904022
that O 0 0.000984127
the O 0 0.00086315774
effects O 0 0.0012420303
of O 0 0.0044487156
Captopril B-Chemical 0 0.99999595
on O 0 0.0002780689
the O 0 0.00031525656
lungs O 0 0.0013396246
may O 0 0.00020736085
be O 0 0.00018566778
attributable O 0 0.0001492956
to O 0 0.00016512212
a O 0 0.00035537832
vasodilatory O 0 0.48506907
effect O 0 0.00016411784
due O 0 0.00011143716
to O 0 0.00013369344
a O 0 0.00023151108
reduction O 0 0.0003183884
in O 0 0.00015383601
the O 0 0.00015430422
circulating O 0 0.001120277
level O 0 0.00016175327
of O 0 0.00075367844
Angiotension B-Chemical 0 0.979539
II I-Chemical 0 0.4301075
and O 0 0.0003109844
an O 0 0.00028909664
increase O 0 0.00024098704
in O 0 0.001078565
prostacyclin B-Chemical 0 0.9999982
( O 0 0.0023550985
secondary O 0 0.0044443817
to O 0 0.00047616102
an O 0 0.00077979366
increase O 0 0.0009559208
in O 0 0.002695171
bradykinin B-Chemical 1 0.99979943
) O 0 0.015294623
. O 0 0.007664409

Captopril B-Chemical 0 0.99995995
may O 0 0.0036033224
, O 0 0.0025720128
by O 0 0.0012684386
the O 0 0.0007883166
same O 0 0.0004642407
mechanism O 0 0.00046460726
, O 0 0.0005939206
reduce O 0 0.00025184458
the O 0 0.00026366863
increase O 0 0.00022046
in O 0 0.00031290174
glomerular O 0 0.79672086
filtration O 0 0.0028213097
that O 0 0.00017218923
is O 0 0.00021058467
known O 0 0.00021655293
to O 0 0.00013193085
occur O 0 0.00014375262
after O 0 0.00011255187
an O 0 0.00021344464
injection O 0 0.00039601326
of O 0 0.00044949
thrombin O 0 0.8846848
, O 0 0.0005050932
thereby O 0 0.00033375094
diminishing O 0 0.00054378394
the O 0 0.00020237436
aggregation O 0 0.014832519
of O 0 0.0005609284
fibrin O 0 0.6427663
monomers O 0 0.0034969603
in O 0 0.00020466297
the O 0 0.00020257049
glomeruli O 0 0.03277898
, O 0 0.00029042238
with O 0 0.00017752546
the O 0 0.00014420183
result O 0 0.0001355624
that O 0 0.00015092749
less O 0 0.00024882366
fibrin O 0 0.16620995
will O 0 0.00018436165
be O 0 0.0002244733
deposited O 0 0.000616844
and O 0 0.00035065063
thus O 0 0.0005685472
less O 0 0.0008336806
kidney B-Disease 0 0.98552173
damage I-Disease 0 0.9886891
will O 0 0.0014711117
be O 0 0.0021863417
produced O 0 0.0033995416
. O 0 0.006807525

Stroke B-Disease 0 0.957824
associated O 0 0.017464628
with O 0 0.021310367
cocaine B-Chemical 1 0.99975055
use O 0 0.026702836
. O 0 0.029059462

We O 0 0.0035759432
describe O 0 0.0021602714
eight O 0 0.0014662642
patients O 0 0.0014753416
in O 0 0.0010866051
whom O 0 0.0072527453
cocaine B-Chemical 1 0.9999697
use O 0 0.00078221166
was O 0 0.00048930803
related O 0 0.00033633082
to O 0 0.00048632632
stroke B-Disease 2 0.99818367
and O 0 0.00073656574
review O 0 0.0010003925
39 O 0 0.00096886634
cases O 0 0.0011302104
from O 0 0.0013040967
the O 0 0.002203824
literature O 0 0.004960089
. O 0 0.0071411994

Among O 0 0.0048848614
these O 0 0.0025782418
47 O 0 0.002370238
patients O 0 0.0012849603
the O 0 0.000723741
mean O 0 0.00047990866
( O 0 0.0010435834
+ O 0 0.0036818082
/ O 0 0.02715841
- O 0 0.04327814
SD O 0 0.12678593
) O 0 0.00075001124
age O 0 0.00052516715
was O 0 0.0002655162
32 O 0 0.00029205394
. O 0 0.00020087657
5 O 0 0.00020377776
+ O 0 0.00070416235
/ O 0 0.004929691
- O 0 0.0048631374
12 O 0 0.00021180112
. O 0 0.0002129921
1 O 0 0.00023339652
years O 0 0.00031076983
; O 0 0.0004641606
76 O 0 0.0005487736
% O 0 0.00054458814
( O 0 0.0007376095
34 O 0 0.0008703802
/ O 0 0.0016305193
45 O 0 0.0013497421
) O 0 0.0024987543
were O 0 0.00314866
men O 0 0.013238809
. O 0 0.008204765

Stroke B-Disease 0 0.9725902
followed O 0 0.004378546
cocaine B-Chemical 1 0.99986243
use O 0 0.002437486
by O 0 0.0019643118
inhalation O 0 0.49720722
, O 0 0.0026306154
intranasal O 0 0.050460793
, O 0 0.0033310824
intravenous O 0 0.13981068
, O 0 0.0023710863
and O 0 0.0028201242
intramuscular O 0 0.06322527
routes O 0 0.008467298
. O 0 0.008337414

Intracranial B-Disease 0 0.9879339
aneurysms I-Disease 2 0.9995726
or O 0 0.0027151918
arteriovenous B-Disease 0 0.5891421
malformations I-Disease 0 0.99468696
were O 0 0.00071502564
present O 0 0.00038307422
in O 0 0.00037983997
17 O 0 0.00039604798
of O 0 0.0003336383
32 O 0 0.00037900644
patients O 0 0.00034427652
studied O 0 0.00034288428
angiographically O 0 0.8308639
or O 0 0.00027671555
at O 0 0.0002834639
autopsy O 0 0.09027337
; O 0 0.0080935005
cerebral B-Disease 0 0.99986565
vasculitis I-Disease 2 0.99999845
was O 0 0.0008486401
present O 0 0.0006963922
in O 0 0.0011689272
two O 0 0.0017400318
patients O 0 0.0042211683
. O 0 0.0061969617

Cerebral B-Disease 0 0.9992993
infarction I-Disease 2 0.999997
occurred O 0 0.0031325524
in O 0 0.0013906605
10 O 0 0.00093019736
patients O 0 0.0009121586
( O 0 0.0008341844
22 O 0 0.000612512
% O 0 0.00059048785
) O 0 0.001028111
, O 0 0.0016437629
intracerebral B-Disease 0 0.9996131
hemorrhage I-Disease 2 0.9999919
in O 0 0.00043971548
22 O 0 0.00041445202
( O 0 0.0003901441
49 O 0 0.0004060949
% O 0 0.00037114066
) O 0 0.0005640185
, O 0 0.0005309112
and O 0 0.0010460684
subarachnoid B-Disease 0 0.9997968
hemorrhage I-Disease 2 0.999969
in O 0 0.0007561222
13 O 0 0.00096786156
( O 0 0.0014545143
29 O 0 0.0022896137
% O 0 0.0031475767
) O 0 0.005906238
. O 0 0.0079330625

These O 0 0.003535169
data O 0 0.0023227646
indicate O 0 0.0011456967
that O 0 0.0010614459
( O 0 0.0015407666
1 O 0 0.00080320676
) O 0 0.00083101646
the O 0 0.00040112375
apparent O 0 0.00041695827
incidence O 0 0.003981069
of O 0 0.002485294
stroke B-Disease 2 0.9998957
related O 0 0.00023006585
to O 0 0.00033653143
cocaine B-Chemical 1 0.99997544
use O 0 0.0002788438
is O 0 0.0002052236
increasing O 0 0.00025440732
; O 0 0.00080015487
( O 0 0.0005375817
2 O 0 0.00026141605
) O 0 0.0063951644
cocaine B-Chemical 1 0.9999945
- O 0 0.090198666
associated O 0 0.0015047486
stroke B-Disease 2 0.99967873
occurs O 0 0.00022469749
primarily O 0 0.00024650112
in O 0 0.00020275195
young O 0 0.005284666
adults O 0 0.0033373386
; O 0 0.000793235
( O 0 0.00047553598
3 O 0 0.00020356453
) O 0 0.0013858625
stroke B-Disease 2 0.99897444
may O 0 0.00015672181
follow O 0 0.00010748436
any O 0 0.00012441278
route O 0 0.00023656261
of O 0 0.0015152589
cocaine B-Chemical 1 0.99999535
administration O 0 0.06025873
; O 0 0.0017736861
( O 0 0.0005657301
4 O 0 0.00019316841
) O 0 0.0022010817
stroke B-Disease 2 0.9997607
after O 0 0.00025333939
cocaine B-Chemical 1 0.999979
use O 0 0.00026278145
is O 0 0.00019900163
frequently O 0 0.00024426915
associated O 0 0.00018969734
with O 0 0.0005274397
intracranial B-Disease 0 0.99970335
aneurysms I-Disease 2 0.9999813
and O 0 0.00063584204
arteriovenous B-Disease 0 0.7698471
malformations I-Disease 0 0.99936503
; O 0 0.00079571933
and O 0 0.00024290888
( O 0 0.00031669342
5 O 0 0.00015485592
) O 0 0.00040392776
in O 0 0.000473869
cocaine B-Chemical 1 0.99999464
- O 0 0.11975184
associated O 0 0.003140932
stroke B-Disease 2 0.9998834
, O 0 0.0005783381
the O 0 0.00023962994
frequency O 0 0.00038855674
of O 0 0.0015009263
intracranial B-Disease 0 0.9999157
hemorrhage I-Disease 2 0.9999981
exceeds O 0 0.0006823403
that O 0 0.0009496553
of O 0 0.006617288
cerebral B-Disease 0 0.99936765
infarction I-Disease 2 0.99999607
. O 0 0.014212153

A O 0 0.022887172
randomized O 0 0.004958169
comparison O 0 0.003560957
of O 0 0.009024509
labetalol B-Chemical 1 0.9999993
and O 0 0.13355404
nitroprusside B-Chemical 1 0.9999982
for O 0 0.006193131
induced O 0 0.023586402
hypotension B-Disease 2 0.9999672
. O 0 0.013821558

In O 0 0.003964576
a O 0 0.0029969052
randomized O 0 0.002196263
study O 0 0.002613949
, O 0 0.029245008
labetalol B-Chemical 1 0.9999999
- O 0 0.40364853
induced O 0 0.008750163
hypotension B-Disease 2 0.99999857
and O 0 0.13124819
nitroprusside B-Chemical 1 0.9999999
- O 0 0.31542134
induced O 0 0.0023302643
hypotension B-Disease 2 0.99999094
were O 0 0.00023748806
compared O 0 0.00012503003
in O 0 0.00015824822
20 O 0 0.00017199594
patients O 0 0.00024100451
( O 0 0.00027962308
10 O 0 0.00019713143
in O 0 0.00020350497
each O 0 0.00019219762
group O 0 0.0004012668
) O 0 0.00060139986
scheduled O 0 0.000475434
for O 0 0.0007639494
major O 0 0.0015177716
orthopedic O 0 0.003606794
procedures O 0 0.0036224804
. O 0 0.006286827

Each O 0 0.0028746154
patient O 0 0.0022203992
was O 0 0.0013850359
subjected O 0 0.0007764314
to O 0 0.00068543776
an O 0 0.0006592284
identical O 0 0.00038314878
anesthetic O 0 0.01010239
protocol O 0 0.00030172296
and O 0 0.00033571813
similar O 0 0.0002581831
drug O 0 0.4134766
- O 0 0.011382322
induced O 0 0.00026492274
reductions B-Disease 0 0.00029577262
in I-Disease 0 0.0001741975
mean I-Disease 0 0.00014810357
arterial I-Disease 0 0.08777555
blood I-Disease 0 0.009424237
pressure I-Disease 0 0.052549656
( O 0 0.0011488168
BP O 0 0.9345541
) O 0 0.0009038136
( O 0 0.000756074
50 O 0 0.00075254234
to O 0 0.00083221064
55 O 0 0.0017384241
mmHg O 0 0.004074102
) O 0 0.0051637273
. O 0 0.0072403103

Nitroprusside O 0 0.9999083
infusion O 0 0.021739813
was O 0 0.0017961295
associated O 0 0.0011125247
with O 0 0.000829726
a O 0 0.0007802408
significant O 0 0.0005638022
( O 0 0.00069820904
p O 0 0.00038294628
less O 0 0.0002724311
than O 0 0.00019969598
0 O 0 0.00030033846
. O 0 0.00026038126
05 O 0 0.0056065368
) O 0 0.00040626354
increase B-Disease 0 0.00018271469
in I-Disease 0 0.0002445194
heart I-Disease 0 0.021823334
rate I-Disease 0 0.00025256595
and I-Disease 0 0.0003133842
cardiac I-Disease 0 0.024115104
output I-Disease 0 0.00054712506
; O 0 0.0015759728
rebound O 0 0.67510027
hypertension B-Disease 2 0.9999968
was O 0 0.00034753064
observed O 0 0.00023471563
in O 0 0.0002818357
three O 0 0.00026764686
patients O 0 0.000613488
after O 0 0.00065927085
discontinuation O 0 0.48526663
of O 0 0.01166649
nitroprusside B-Chemical 1 0.99999356
. O 0 0.008831203

Labetalol B-Chemical 0 0.9999738
administration O 0 0.10247104
was O 0 0.0034290806
not O 0 0.0023327875
associated O 0 0.002349746
with O 0 0.0023413028
any O 0 0.0023844787
of O 0 0.0034081358
these O 0 0.0046573593
findings O 0 0.008363811
. O 0 0.010639834

Arterial O 0 0.8870434
PO2 B-Chemical 0 0.99879944
decreased O 0 0.014390374
in O 0 0.011719317
both O 0 0.012977909
groups O 0 0.016886564
. O 0 0.023065107

It O 0 0.008340754
was O 0 0.005654238
concluded O 0 0.0051200455
that O 0 0.0057461127
labetalol B-Chemical 1 0.9999957
offers O 0 0.005792846
advantages O 0 0.0038829711
over O 0 0.005912479
nitroprusside B-Chemical 1 0.9999695
. O 0 0.014812898

Sodium B-Chemical 0 0.9992945
status O 0 0.008545075
influences O 0 0.0061427946
chronic O 0 0.99672264
amphotericin B-Chemical 1 0.99999905
B I-Chemical 1 0.99995995
nephrotoxicity B-Disease 0 0.9999993
in O 0 0.0211343
rats O 0 0.016498469
. O 0 0.011375139

The O 0 0.0039292662
nephrotoxic B-Disease 2 0.9978561
potential O 0 0.0034441883
of O 0 0.018687254
amphotericin B-Chemical 1 0.99999917
B I-Chemical 1 0.99985397
( O 0 0.011113379
5 O 0 0.00045855
mg O 0 0.016179478
/ O 0 0.00090056815
kg O 0 0.0004161847
per O 0 0.00013775074
day O 0 0.00014638047
intraperitoneally O 0 0.00024342566
for O 0 0.00015169113
3 O 0 0.00014062085
weeks O 0 0.00011726636
) O 0 0.0002709094
has O 0 0.00015882222
been O 0 0.0001685648
investigated O 0 0.0001618906
in O 0 0.00034907684
salt O 0 0.99746835
- O 0 0.05428329
depleted O 0 0.00031211015
, O 0 0.00075423886
normal O 0 0.0026594286
- O 0 0.08413022
salt O 0 0.99203557
, O 0 0.0020105399
and O 0 0.001981944
salt O 0 0.9940042
- O 0 0.03665818
loaded O 0 0.003037334
rats O 0 0.0055147787
. O 0 0.0067052757

In O 0 0.005980285
salt O 0 0.98935306
- O 0 0.035420764
depleted O 0 0.0015481396
rats O 0 0.00346531
, O 0 0.012670633
amphotericin B-Chemical 1 0.9999987
B I-Chemical 1 0.99975675
decreased O 0 0.037186768
creatinine B-Chemical 1 0.99979144
clearance O 0 0.08392062
linearly O 0 0.00043048032
with O 0 0.0002940073
time O 0 0.00021757884
, O 0 0.00037953124
with O 0 0.0003601594
an O 0 0.00048214445
85 O 0 0.00070474064
% O 0 0.00081364217
reduction O 0 0.0011557927
by O 0 0.0014666908
week O 0 0.0018477662
3 O 0 0.0031860706
. O 0 0.0061369026

In O 0 0.0038372215
contrast O 0 0.003068378
, O 0 0.00262445
in O 0 0.0015061736
normal O 0 0.0040530027
- O 0 0.108869635
salt O 0 0.99371755
rats O 0 0.012062435
creatinine B-Chemical 1 0.9995085
clearance O 0 0.12207471
was O 0 0.00041037353
decreased O 0 0.00037779583
but O 0 0.00028355228
to O 0 0.00017545056
a O 0 0.00025492307
lesser O 0 0.00033457187
extent O 0 0.00011581957
at O 0 0.00012463055
week O 0 0.000111207235
2 O 0 0.00013104592
and O 0 0.00015588335
3 O 0 0.00014284207
, O 0 0.00020514202
and O 0 0.00022514205
in O 0 0.0003141905
salt O 0 0.99557316
- O 0 0.023942726
loaded O 0 0.00024990662
rats O 0 0.0007990535
creatinine B-Chemical 1 0.9977064
clearance O 0 0.037831735
did O 0 0.00024866645
not O 0 0.00015264921
change O 0 0.00019479959
for O 0 0.00017571358
2 O 0 0.00018306993
weeks O 0 0.00014727369
and O 0 0.0002605968
was O 0 0.0003222023
decreased O 0 0.00045591328
by O 0 0.0005643896
43 O 0 0.0009615408
% O 0 0.0010460119
at O 0 0.0011559989
week O 0 0.001719648
3 O 0 0.0030716907
. O 0 0.0060272887

All O 0 0.0031556454
rats O 0 0.0029101383
in O 0 0.0017215392
the O 0 0.0018059638
sodium B-Chemical 0 0.99966645
- O 0 0.031884473
depleted O 0 0.00050569995
group O 0 0.0005364988
had O 0 0.00030174624
histopathological O 0 0.01943629
evidence O 0 0.00018331167
of O 0 0.00027364524
patchy O 0 0.006494924
tubular O 0 0.3339871
cytoplasmic O 0 0.004272005
degeneration O 0 0.998064
in O 0 0.0003155897
tubules O 0 0.0021501838
that O 0 0.00016468186
was O 0 0.00018923485
not O 0 0.00016225035
observed O 0 0.00018353206
in O 0 0.00024377357
any O 0 0.00029045204
normal O 0 0.001255195
- O 0 0.05448851
salt O 0 0.9910267
or O 0 0.0023522635
salt O 0 0.99715185
- O 0 0.060296334
loaded O 0 0.0031472712
rat O 0 0.00809875
. O 0 0.00707485

Concentrations O 0 0.28778958
of O 0 0.012430783
amphotericin B-Chemical 1 0.9999951
B I-Chemical 1 0.99929106
in O 0 0.0026948932
plasma O 0 0.03775423
were O 0 0.0005867391
not O 0 0.00037707656
significantly O 0 0.0003432352
different O 0 0.00026996416
among O 0 0.00035655175
the O 0 0.00028434847
three O 0 0.00023470937
groups O 0 0.00036434527
at O 0 0.00039450455
any O 0 0.000506221
time O 0 0.00062312814
during O 0 0.0010127617
the O 0 0.0020386514
study O 0 0.004316343
. O 0 0.006477619

However O 0 0.004611916
, O 0 0.0031648036
at O 0 0.0014992679
the O 0 0.0010296921
end O 0 0.0006553683
of O 0 0.0007043029
3 O 0 0.00048529363
weeks O 0 0.00036352072
, O 0 0.0014275318
amphotericin B-Chemical 1 0.99999785
B I-Chemical 1 0.99909043
levels O 0 0.0006809887
in O 0 0.0002885074
the O 0 0.00024840602
kidneys O 0 0.0069484687
and O 0 0.00044688518
liver O 0 0.48094288
were O 0 0.00023767607
significantly O 0 0.00020195066
higher O 0 0.00019111123
in O 0 0.0002892061
salt O 0 0.99728906
- O 0 0.04228995
depleted O 0 0.00018392182
and O 0 0.00037931153
normal O 0 0.0035293447
- O 0 0.11280404
salt O 0 0.9897483
rats O 0 0.0005924129
than O 0 0.00012392756
those O 0 0.00022767876
in O 0 0.0002646362
salt O 0 0.99595463
- O 0 0.029459454
loaded O 0 0.00022406956
rats O 0 0.00035060334
, O 0 0.0002579924
with O 0 0.00025220236
plasma O 0 0.024865817
/ O 0 0.009052073
kidney O 0 0.30339092
ratios O 0 0.00028342145
of O 0 0.00031557257
21 O 0 0.0002784411
, O 0 0.00025370973
14 O 0 0.00017454117
, O 0 0.00020826639
and O 0 0.00020160225
8 O 0 0.00018099633
in O 0 0.00024686448
salt O 0 0.9926611
- O 0 0.028996991
depleted O 0 0.00026025317
, O 0 0.0006318433
normal O 0 0.0024271782
- O 0 0.08750111
salt O 0 0.99310255
, O 0 0.0015401872
and O 0 0.0013776623
salt O 0 0.9957462
- O 0 0.029146003
loaded O 0 0.0012915591
rats O 0 0.0023041999
, O 0 0.0029509051
respectively O 0 0.0066752895
. O 0 0.007340727

In O 0 0.0036164047
conclusion O 0 0.0021283864
, O 0 0.0022449787
reductions O 0 0.0015027368
in O 0 0.0011805157
creatinine B-Chemical 1 0.9980215
clearance O 0 0.14169143
and O 0 0.0027634401
renal O 0 0.9968892
amphotericin B-Chemical 1 0.99999976
B I-Chemical 1 0.9998129
accumulation O 0 0.011904881
after O 0 0.00034712747
chronic O 0 0.9950552
amphotericin B-Chemical 1 0.9999999
B I-Chemical 1 0.9999262
administration O 0 0.14072788
were O 0 0.00027885285
enhanced O 0 0.0002462822
by O 0 0.0004009494
salt O 0 0.9851482
depletion O 0 0.0010020636
and O 0 0.00060170685
attenuated O 0 0.0011505812
by O 0 0.0011369891
sodium B-Chemical 0 0.9982052
loading O 0 0.0024322404
in O 0 0.0024326292
rats O 0 0.004938447
. O 0 0.0059971428

Flestolol B-Chemical 1 0.96853626
: O 0 0.0063765217
an O 0 0.0039588106
ultra O 0 0.19620465
- O 0 0.007826387
short O 0 0.0017774097
- O 0 0.007028894
acting O 0 0.005877454
beta O 0 0.986362
- O 0 0.57623667
adrenergic O 0 0.9918276
blocking O 0 0.021413095
agent O 0 0.2613942
. O 0 0.010833513

Flestolol B-Chemical 1 0.9929073
( O 0 0.02177602
ACC B-Chemical 0 0.9797483
- I-Chemical 0 0.10296344
9089 I-Chemical 0 0.09253405
) O 0 0.0019645279
is O 0 0.0008123872
a O 0 0.0008347815
nonselective O 0 0.13802794
, O 0 0.0008103008
competitive O 0 0.0062013627
, O 0 0.0008706274
ultra O 0 0.2966783
- O 0 0.0072566676
short O 0 0.00027386314
- O 0 0.006068504
acting O 0 0.0030225024
beta O 0 0.9936121
- O 0 0.66073984
adrenergic O 0 0.9900175
blocking O 0 0.004092423
agent O 0 0.06423123
, O 0 0.00093355344
without O 0 0.00064947124
any O 0 0.0008370436
intrinsic O 0 0.0020441087
sympathomimetic O 0 0.99115515
activity O 0 0.004009448
. O 0 0.0065147607

Flestolol B-Chemical 1 0.9862076
is O 0 0.0054078847
metabolized O 0 0.65719354
by O 0 0.0022065297
plasma O 0 0.12654622
esterases O 0 0.8625525
and O 0 0.0008984156
has O 0 0.000490585
an O 0 0.00050960004
elimination O 0 0.0008458795
half O 0 0.0003754543
- O 0 0.0014509879
life O 0 0.00055052846
of O 0 0.0005751216
approximately O 0 0.0006515662
6 O 0 0.0007804452
. O 0 0.0011600892
5 O 0 0.0017146505
minutes O 0 0.0028829512
. O 0 0.006290739

This O 0 0.006067426
agent O 0 0.014240775
was O 0 0.002073643
well O 0 0.0013607647
tolerated O 0 0.0038111254
in O 0 0.0007637659
healthy O 0 0.0020634846
volunteers O 0 0.0007387991
at O 0 0.0003734665
doses O 0 0.00075208995
up O 0 0.00039629193
to O 0 0.00044835874
100 O 0 0.00094169134
micrograms O 0 0.00489172
/ O 0 0.0031804736
kg O 0 0.0038179564
/ O 0 0.0056025716
min O 0 0.005170188
. O 0 0.007527451

In O 0 0.0035700935
long O 0 0.0026517601
- O 0 0.0042931153
term O 0 0.0011805427
infusion O 0 0.0020269686
studies O 0 0.0008542145
, O 0 0.0014804206
flestolol B-Chemical 1 0.97619003
was O 0 0.00042202038
well O 0 0.00028028927
tolerated O 0 0.0008188243
at O 0 0.00016221631
the O 0 0.00019136723
effective O 0 0.0005014542
beta O 0 0.97504175
- O 0 0.10721869
blocking O 0 0.0017060206
dose O 0 0.007853628
( O 0 0.000548377
5 O 0 0.00019893999
micrograms O 0 0.0021333904
/ O 0 0.0012106812
kg O 0 0.0009691714
/ O 0 0.0012698123
min O 0 0.0005699157
) O 0 0.00069611846
for O 0 0.00058254565
up O 0 0.0007946342
to O 0 0.0010970294
seven O 0 0.0018062785
days O 0 0.002731234
. O 0 0.0060893632

Flestolol B-Chemical 1 0.9884929
blood O 0 0.03447627
concentrations O 0 0.0038458304
increased O 0 0.0013275486
linearly O 0 0.00093095494
with O 0 0.00063571695
increasing O 0 0.00050621474
dose O 0 0.0018231996
and O 0 0.00038777545
good O 0 0.00033569976
correlation O 0 0.00019276052
exists O 0 0.00020318039
between O 0 0.00020735928
blood O 0 0.003099345
concentrations O 0 0.0007695471
of O 0 0.00087724876
flestolol B-Chemical 1 0.99112505
and O 0 0.0026431645
beta O 0 0.9878001
- O 0 0.6761665
adrenergic O 0 0.9922123
blockade O 0 0.09485904
. O 0 0.007564587

Flestolol B-Chemical 1 0.9107439
produced O 0 0.0037184781
a O 0 0.003571763
dose O 0 0.015055888
- O 0 0.008959058
dependent O 0 0.0014899706
attenuation O 0 0.0040100347
of O 0 0.012819138
isoproterenol B-Chemical 0 0.99998
- O 0 0.35268477
induced O 0 0.016268758
tachycardia B-Disease 2 0.99976474
. O 0 0.011579093

Electrophysiologic O 0 0.22062941
and O 0 0.0035408775
hemodynamic O 0 0.048057858
effects O 0 0.0021170892
of O 0 0.002027119
flestolol B-Chemical 1 0.98026854
are O 0 0.00089428446
similar O 0 0.0006457612
to O 0 0.00073808763
those O 0 0.0011031537
of O 0 0.0015836249
other O 0 0.0031188
beta O 0 0.9770811
blockers O 0 0.99901366
. O 0 0.012183592

In O 0 0.0034388518
contrast O 0 0.0024517367
with O 0 0.0018617273
other O 0 0.0030933307
beta O 0 0.9961649
blockers O 0 0.99984276
, O 0 0.071269706
flestolol B-Chemical 1 0.9994942
- O 0 0.04374666
induced O 0 0.00038083346
effects O 0 0.00060299924
reverse O 0 0.0061539747
rapidly O 0 0.000529428
( O 0 0.0003192389
within O 0 0.000121632205
30 O 0 0.00014037995
minutes O 0 0.00015026348
) O 0 0.00030674305
following O 0 0.00023051839
discontinuation O 0 0.03707004
because O 0 0.00029204309
of O 0 0.0005161156
its O 0 0.00096000935
short O 0 0.00084470754
half O 0 0.0012215886
- O 0 0.0047724475
life O 0 0.004722137
. O 0 0.0068672695

Flestolol B-Chemical 1 0.94025224
effectively O 0 0.0050015273
reduced O 0 0.0038851409
heart O 0 0.060785867
rate O 0 0.0027550613
in O 0 0.0025558914
patients O 0 0.0041308054
with O 0 0.007366327
supraventricular B-Disease 0 0.9999466
tachyarrhythmia I-Disease 0 0.9999814
. O 0 0.013754203

In O 0 0.00406334
patients O 0 0.0034207918
with O 0 0.0037009371
unstable B-Disease 0 0.9951409
angina I-Disease 0 0.99999976
, O 0 0.03564469
flestolol B-Chemical 1 0.996635
infusion O 0 0.0049965964
was O 0 0.0004235551
found O 0 0.00031615797
to O 0 0.00030440255
be O 0 0.00039201486
safe O 0 0.0006098848
and O 0 0.00056377397
effective O 0 0.0007254546
in O 0 0.00096671697
controlling O 0 0.0019966613
chest B-Disease 0 0.15244707
pain I-Disease 0 0.9132089
. O 0 0.0071283504

It O 0 0.0047118054
is O 0 0.002615283
concluded O 0 0.0018412444
that O 0 0.0014078156
flestolol B-Chemical 1 0.9809138
is O 0 0.0010774389
a O 0 0.00092473446
potent O 0 0.0023668073
, O 0 0.0007649
well O 0 0.0005123204
- O 0 0.014941254
tolerated O 0 0.00611131
, O 0 0.0006801746
ultra O 0 0.24701108
- O 0 0.0062010363
short O 0 0.00041113535
- O 0 0.0051074596
acting O 0 0.0029854919
beta O 0 0.98343325
- O 0 0.5880221
adrenergic O 0 0.98868203
blocking O 0 0.014232678
agent O 0 0.19965772
. O 0 0.008238942

Use O 0 0.00925919
of O 0 0.0050619575
flestolol B-Chemical 1 0.94225883
in O 0 0.0022836048
the O 0 0.001616393
critical O 0 0.0013502538
care O 0 0.0016546122
setting O 0 0.0015416478
is O 0 0.0019318875
currently O 0 0.0027143783
undergoing O 0 0.0037128662
investigation O 0 0.0064096157
. O 0 0.009151751

Immunohistochemical O 0 0.010602394
, O 0 0.0038780721
electron O 0 0.00704444
microscopic O 0 0.0026760495
and O 0 0.0012481689
morphometric O 0 0.0018865418
studies O 0 0.0009683679
of O 0 0.0038120972
estrogen B-Chemical 1 0.9999901
- O 0 0.17458412
induced O 0 0.0021818993
rat O 0 0.13055874
prolactinomas B-Disease 0 0.99995375
after O 0 0.0031067363
bromocriptine B-Chemical 0 0.99997556
treatment O 0 0.008973212
. O 0 0.007986933

To O 0 0.0025678237
clarify O 0 0.0012738311
the O 0 0.0013156559
effects O 0 0.0014954479
of O 0 0.0037831492
bromocriptine B-Chemical 0 0.999995
on O 0 0.00079515035
prolactinoma B-Disease 2 0.9999745
cells O 0 0.0011151162
in O 0 0.0003734626
vivo O 0 0.0005532762
, O 0 0.0004610922
immunohistochemical O 0 0.0035672954
, O 0 0.00035942075
ultrastructural O 0 0.0040615373
and O 0 0.00020746369
morphometrical O 0 0.0009484269
analyses O 0 0.00014013106
were O 0 0.00012975313
applied O 0 0.00013692533
to O 0 0.00030265554
estrogen B-Chemical 1 0.99998987
- O 0 0.08305822
induced O 0 0.00046632055
rat O 0 0.045036875
prolactinoma B-Disease 2 0.9999813
cells O 0 0.00075711217
1 O 0 0.00020849111
h O 0 0.0001820103
and O 0 0.00017420032
6 O 0 0.00012440245
h O 0 0.00015861276
after O 0 0.000120969424
injection O 0 0.00034874768
of O 0 0.0011383822
bromocriptine B-Chemical 0 0.99999404
( O 0 0.0012387872
3 O 0 0.00036748723
mg O 0 0.007983466
/ O 0 0.0013768367
kg O 0 0.0014072143
of O 0 0.0013084512
body O 0 0.0040215515
weight O 0 0.0076070176
) O 0 0.007417731
. O 0 0.007928281

One O 0 0.0063084466
h O 0 0.004203056
after O 0 0.0025159782
treatment O 0 0.003272175
, O 0 0.0047445395
serum O 0 0.7103289
prolactin O 0 0.9953259
levels O 0 0.0046485616
decreased O 0 0.007006442
markedly O 0 0.0133047
. O 0 0.0118357465

Electron O 0 0.009579651
microscopy O 0 0.0036892863
disclosed O 0 0.0025407074
many O 0 0.0014226305
secretory O 0 0.0016565038
granules O 0 0.001907948
, O 0 0.00094208715
slightly O 0 0.0006384453
distorted O 0 0.0010903064
rough O 0 0.00073924137
endoplasmic O 0 0.010347061
reticulum O 0 0.024092762
, O 0 0.0005691113
and O 0 0.00041667774
partially O 0 0.00046349294
dilated O 0 0.19678007
Golgi O 0 0.0017238525
cisternae O 0 0.0022478406
in O 0 0.0010674237
the O 0 0.0019667728
prolactinoma B-Disease 2 0.99957937
cells O 0 0.0070524593
. O 0 0.008166933

Morphometric O 0 0.01162823
analysis O 0 0.002521549
revealed O 0 0.0015297061
that O 0 0.0009887866
the O 0 0.0008152172
volume O 0 0.00093776215
density O 0 0.00086617825
of O 0 0.00063894567
secretory O 0 0.0010651991
granules O 0 0.0022455596
increased O 0 0.0006324532
, O 0 0.0006308637
while O 0 0.0004096866
the O 0 0.00040034554
volume O 0 0.0006859829
density O 0 0.00093729945
of O 0 0.0011554599
cytoplasmic O 0 0.001961625
microtubules O 0 0.11647463
decreased O 0 0.006542583
. O 0 0.0075083855

These O 0 0.0033405928
findings O 0 0.0023555623
suggest O 0 0.0011178012
that O 0 0.0010663271
lowered O 0 0.015923277
serum O 0 0.88283026
prolactin O 0 0.9982132
levels O 0 0.0006445076
in O 0 0.00035803756
the O 0 0.00028668455
early O 0 0.0005781248
phase O 0 0.0010481396
of O 0 0.0065905554
bromocriptine B-Chemical 0 0.999997
treatment O 0 0.0008644512
may O 0 0.00018938397
result O 0 0.00015526547
from O 0 0.0001641515
an O 0 0.00024823457
impaired O 0 0.00037643022
secretion O 0 0.001641239
of O 0 0.0014981676
prolactin O 0 0.977394
due O 0 0.00030427543
to O 0 0.0003801276
decreasing O 0 0.00059610547
numbers O 0 0.00077886565
of O 0 0.0014256366
cytoplasmic O 0 0.00274489
microtubules O 0 0.19070227
. O 0 0.0076672747

At O 0 0.0028403087
6 O 0 0.0020433324
h O 0 0.0017543939
after O 0 0.0010176277
injection O 0 0.0017024922
, O 0 0.001842099
serum O 0 0.6141274
prolactin O 0 0.9929832
levels O 0 0.0007901111
were O 0 0.0006518382
still O 0 0.0006399854
considerably O 0 0.0008998575
lower O 0 0.0010325694
than O 0 0.0011680158
in O 0 0.0022542998
controls O 0 0.005222585
. O 0 0.00732635

The O 0 0.004691302
prolactinoma B-Disease 2 0.99884087
cells O 0 0.0025093968
at O 0 0.0011654245
this O 0 0.00079289643
time O 0 0.0004992604
were O 0 0.00049942505
well O 0 0.00043931117
granulated O 0 0.0016199179
, O 0 0.00051478605
with O 0 0.00043729207
vesiculated O 0 0.0030733047
rough O 0 0.00075040763
endoplasmic O 0 0.0055903755
reticulum O 0 0.01148972
and O 0 0.0010848917
markedly O 0 0.0022482013
dilated O 0 0.5287562
Golgi O 0 0.0069425753
cisternae O 0 0.011133257
. O 0 0.0068762507

Electron O 0 0.009697654
microscopical O 0 0.0052083274
immunohistochemistry O 0 0.0034125517
revealed O 0 0.0011854871
positive O 0 0.001178017
reaction O 0 0.0031809756
products O 0 0.00082551385
noted O 0 0.00033593507
on O 0 0.00023920058
the O 0 0.00028589356
secretory O 0 0.00048338875
granules O 0 0.00085483084
, O 0 0.00045860393
Golgi O 0 0.00079629314
cisternae O 0 0.0012288633
, O 0 0.00039730323
and O 0 0.00040236206
endoplasmic O 0 0.004766949
reticulum O 0 0.00971219
of O 0 0.00069664576
the O 0 0.0007681286
untreated O 0 0.001685529
rat O 0 0.017120956
prolactinoma B-Disease 2 0.9998386
cells O 0 0.008161333
. O 0 0.00808332

However O 0 0.0044740555
, O 0 0.0032854069
only O 0 0.0019041587
secretory O 0 0.0019352527
granules O 0 0.0018837041
showed O 0 0.00062259735
the O 0 0.0004697069
positive O 0 0.00062405417
reaction O 0 0.0052209776
products O 0 0.00091621414
for O 0 0.0005089333
prolactin O 0 0.97190195
6 O 0 0.00029979632
h O 0 0.00041072752
after O 0 0.0004249087
bromocriptine B-Chemical 0 0.99993944
treatment O 0 0.0010300925
of O 0 0.0014229916
the O 0 0.0023923614
adenoma B-Disease 0 0.9997559
cells O 0 0.014977438
. O 0 0.008980216

An O 0 0.004820371
increase O 0 0.0021999027
in O 0 0.0015841722
the O 0 0.0010712448
volume O 0 0.0011456367
density O 0 0.0009812724
of O 0 0.0006642614
secretory O 0 0.0009818878
granules O 0 0.001566683
and O 0 0.0004276008
a O 0 0.00035411646
decrease O 0 0.00022699877
in O 0 0.00018819087
the O 0 0.00016099773
volume O 0 0.00023098545
densities O 0 0.0002162222
of O 0 0.00018885433
rough O 0 0.00033608466
endoplasmic O 0 0.011801525
reticulum O 0 0.025078606
and O 0 0.00027884645
microtubules O 0 0.009374967
was O 0 0.00015857753
determined O 0 0.00010868631
by O 0 0.00014259208
morphometric O 0 0.00062789564
analysis O 0 0.00019963279
, O 0 0.0002563611
suggesting O 0 0.00015476265
that O 0 0.00028140075
bromocriptine B-Chemical 0 0.9999844
inhibits O 0 0.00022691156
protein O 0 0.0012119376
synthesis O 0 0.0028797358
as O 0 0.00020850205
well O 0 0.00020434355
as O 0 0.00022582871
bringing O 0 0.0005008063
about O 0 0.00032311535
a O 0 0.00059381797
disturbance O 0 0.01282818
of O 0 0.0012536258
the O 0 0.0020690125
prolactin O 0 0.9819936
secretion O 0 0.023855949
. O 0 0.008238396

Sulfasalazine B-Chemical 0 0.99975973
- O 0 0.31117374
induced O 0 0.20204337
lupus B-Disease 0 0.99999666
erythematosus I-Disease 0 0.99999046
. O 0 0.053827833

Pneumonitis B-Disease 0 0.99803525
, O 0 0.006182785
bilateral O 0 0.065527655
pleural B-Disease 0 0.23672345
effusions I-Disease 0 0.7599189
, O 0 0.0012622073
echocardiographic O 0 0.002309407
evidence O 0 0.00036206262
of O 0 0.0004988327
cardiac B-Disease 0 0.11035293
tamponade I-Disease 0 0.8578132
, O 0 0.00047447486
and O 0 0.00027328802
positive O 0 0.0004741659
autoantibodies O 0 0.48584387
developed O 0 0.00055623625
in O 0 0.0002178863
a O 0 0.00030815823
43 O 0 0.00056714675
- O 0 0.002755884
year O 0 0.0003080219
- O 0 0.0029830853
old O 0 0.00033971266
man O 0 0.030117856
, O 0 0.00051049236
who O 0 0.0004276039
was O 0 0.000226153
receiving O 0 0.000286404
long O 0 0.00031777014
- O 0 0.00496628
term O 0 0.0009217093
sulfasalazine B-Chemical 1 0.99999726
therapy O 0 0.015664723
for O 0 0.0029027518
chronic O 0 0.99908686
ulcerative B-Disease 0 0.9999999
colitis I-Disease 0 0.9999994
. O 0 0.102921054

After O 0 0.0029678477
cessation O 0 0.005634193
of O 0 0.0021243847
the O 0 0.0022580032
sulfasalazine B-Chemical 1 0.99999344
and O 0 0.0010837938
completion O 0 0.00042352045
of O 0 0.00044812568
a O 0 0.00042564268
six O 0 0.00023810746
- O 0 0.00083601417
week O 0 0.00017148926
course O 0 0.0002057475
of O 0 0.0004729376
corticosteroids O 1 0.9994128
, O 0 0.0006123175
these O 0 0.00029870225
problems O 0 0.0007262597
resolved O 0 0.0003109717
over O 0 0.00020744845
a O 0 0.00035854548
period O 0 0.00034241047
of O 0 0.00057965325
four O 0 0.0006099315
to O 0 0.0009480141
six O 0 0.0014297835
months O 0 0.002429886
. O 0 0.0055338764

It O 0 0.0046390835
is O 0 0.0024504052
suggested O 0 0.0014255897
that O 0 0.0010187092
the O 0 0.0009005776
patient O 0 0.0010314746
had O 0 0.0018561241
sulfasalazine B-Chemical 1 0.9999994
- O 0 0.36865133
induced O 0 0.008767887
lupus B-Disease 0 0.99999964
, O 0 0.0046971394
which O 0 0.0006510889
manifested O 0 0.0076951003
with O 0 0.0017086139
serositis B-Disease 0 0.9999913
and O 0 0.0012204882
pulmonary O 0 0.7702916
parenchymal O 0 0.68557376
involvement O 0 0.00083489256
in O 0 0.000407727
the O 0 0.0005103902
absence O 0 0.00068606314
of O 0 0.0020221486
joint O 0 0.24793552
symptoms O 0 0.53550917
. O 0 0.0068271738

Physicians O 0 0.007067197
who O 0 0.00403465
use O 0 0.0032855677
sulfasalazine B-Chemical 1 0.9999819
to O 0 0.0011458714
treat O 0 0.001063136
patients O 0 0.00082160026
with O 0 0.0006206074
inflammatory B-Disease 0 0.89488757
bowel I-Disease 0 0.89752644
disease I-Disease 0 0.9926755
should O 0 0.0002290747
be O 0 0.00024903583
aware O 0 0.00024645455
of O 0 0.00031579766
the O 0 0.00039619033
signs O 0 0.07343528
of O 0 0.011352126
sulfasalazine B-Chemical 1 0.9999994
- O 0 0.55772007
induced O 0 0.08442182
lupus B-Disease 0 0.99999976
syndrome I-Disease 0 0.9992704
. O 0 0.011587255

Chronic O 0 0.9910454
carbamazepine B-Chemical 1 0.9999982
treatment O 0 0.0058917548
in O 0 0.0012772237
the O 0 0.0008952564
rat O 0 0.0020124128
: O 0 0.0011578994
efficacy O 0 0.0013026233
, O 0 0.0019943404
toxicity B-Disease 2 0.99839824
, O 0 0.00095345994
and O 0 0.0004844187
effect O 0 0.0004008074
on O 0 0.00039398365
plasma O 0 0.010003809
and O 0 0.0013895411
tissue O 0 0.07716236
folate B-Chemical 0 0.9997795
concentrations O 0 0.028779833
. O 0 0.007286125

Folate B-Chemical 1 0.99997044
depletion O 0 0.0066801957
has O 0 0.0021871012
often O 0 0.0018484736
been O 0 0.0011420508
a O 0 0.0010733778
problem O 0 0.0012523832
in O 0 0.0010400475
chronic O 0 0.9709103
antiepileptic O 0 0.9999269
drug O 0 0.9104738
( O 0 0.019298283
AED O 0 0.9912827
) O 0 0.005684155
therapy O 0 0.0071716714
. O 0 0.007521583

Carbamazepine B-Chemical 0 0.99999833
( O 0 0.63870245
CBZ B-Chemical 0 0.99999964
) O 0 0.020262472
, O 0 0.0020784086
a O 0 0.0012896329
commonly O 0 0.0012496022
used O 0 0.0008545886
AED O 0 0.96876144
, O 0 0.0010348719
has O 0 0.0006498552
been O 0 0.0007276266
implicated O 0 0.0008017076
in O 0 0.0011943242
some O 0 0.0017873342
clinical O 0 0.0041659796
studies O 0 0.004456712
. O 0 0.0074427733

A O 0 0.073677815
rat O 0 0.0055264756
model O 0 0.002222916
was O 0 0.0014517391
developed O 0 0.0011097172
to O 0 0.00056152744
examine O 0 0.00031080362
the O 0 0.0004170624
effects O 0 0.0006257086
of O 0 0.0018645427
chronic O 0 0.9991272
CBZ B-Chemical 0 1.0
treatment O 0 0.0032220662
on O 0 0.00057460816
folate B-Chemical 0 0.9997737
concentrations O 0 0.0042015836
in O 0 0.0014836291
the O 0 0.0023273118
rat O 0 0.0067455196
. O 0 0.006606787

In O 0 0.0034979072
the O 0 0.0020996612
course O 0 0.0015178068
of O 0 0.0014609373
developing O 0 0.0070639625
this O 0 0.0007309926
model O 0 0.00070723414
, O 0 0.000981718
a O 0 0.0006963435
common O 0 0.0009902687
vehicle O 0 0.071506165
, O 0 0.01728074
propylene B-Chemical 0 0.9999242
glycol I-Chemical 0 0.9832365
, O 0 0.0005998608
by O 0 0.00022972171
itself O 0 0.00027073588
in O 0 0.0002013579
high O 0 0.00039162976
doses O 0 0.0035838492
, O 0 0.00042508068
was O 0 0.00021067604
found O 0 0.00016826724
to O 0 0.00016186712
exhibit O 0 0.00021578597
protective O 0 0.00093543314
properties O 0 0.0003394692
against O 0 0.0005138306
induced O 0 0.007645248
seizures B-Disease 0 0.9999988
and O 0 0.0031068851
inhibited O 0 0.0031765911
weight B-Disease 0 0.022376396
gain I-Disease 0 0.007968454
. O 0 0.0072894646

Seizures B-Disease 0 0.9997905
induced O 0 0.0047117793
by O 0 0.00631645
hexafluorodiethyl B-Chemical 0 0.99981874
ether I-Chemical 0 0.9999647
( O 0 0.0476571
HFDE B-Chemical 0 0.9915159
) O 0 0.0017168751
were O 0 0.000405282
also O 0 0.0002921166
found O 0 0.00024950027
to O 0 0.00021379578
be O 0 0.00024047108
a O 0 0.00028113797
more O 0 0.00022854173
sensitive O 0 0.00019282392
measure O 0 0.00012662903
of O 0 0.0002790736
protection O 0 0.010677717
by O 0 0.010848648
CBZ B-Chemical 0 1.0
than O 0 0.0010985724
seizures B-Disease 0 0.9999968
induced O 0 0.00077882124
by O 0 0.0008972231
maximal O 0 0.0031734428
electroshock O 0 0.999995
( O 0 0.058995783
MES O 0 0.99922884
) O 0 0.0105703585
. O 0 0.0075772484

Oral O 0 0.7040999
administration O 0 0.07532392
of O 0 0.028017825
CBZ B-Chemical 0 0.9999994
as O 0 0.0014189077
an O 0 0.0011983657
aqueous O 0 0.21302691
suspension O 0 0.0013594985
every O 0 0.00019414205
8 O 0 0.00022312897
h O 0 0.000221264
at O 0 0.00017386413
a O 0 0.00022602262
dose O 0 0.00046623545
of O 0 0.00027605155
250 O 0 0.00033441468
mg O 0 0.015173756
/ O 0 0.0011485558
kg O 0 0.00050427916
was O 0 0.00016185787
continuously O 0 0.00015445614
protective O 0 0.0006990107
against O 0 0.0005407935
HFDE B-Chemical 0 0.99826485
- O 0 0.13916697
induced O 0 0.0033214015
seizures B-Disease 0 0.9999994
and O 0 0.0008665097
was O 0 0.00027123606
minimally O 0 0.00046010723
toxic O 0 0.18409435
as O 0 0.00021264877
measured O 0 0.00020734878
by O 0 0.00029767762
weight B-Disease 0 0.0007778547
gain I-Disease 0 0.00058499223
over O 0 0.00041495747
8 O 0 0.00068948534
weeks O 0 0.0008293426
of O 0 0.00200648
treatment O 0 0.003983502
. O 0 0.0067102867

The O 0 0.0059170346
CBZ B-Chemical 0 0.9999938
levels O 0 0.002044842
measured O 0 0.0010870424
in O 0 0.00096584606
plasma O 0 0.0074258386
and O 0 0.0007619895
brain O 0 0.004049562
of O 0 0.00048198982
these O 0 0.00042003932
animals O 0 0.00035328057
, O 0 0.0006008922
however O 0 0.0006016409
, O 0 0.00063425745
were O 0 0.0005106007
below O 0 0.00051475817
those O 0 0.00094340893
normally O 0 0.0012038471
considered O 0 0.0020797628
protective O 0 0.008727504
. O 0 0.007963622

This O 0 0.005326775
treatment O 0 0.003710689
with O 0 0.011918514
CBZ B-Chemical 0 0.9999994
had O 0 0.0011429922
no O 0 0.0004713065
apparent O 0 0.00059846
adverse O 0 0.3277314
effect O 0 0.00040372048
on O 0 0.00027065276
folate B-Chemical 0 0.99991643
concentrations O 0 0.0051986272
in O 0 0.0002354629
the O 0 0.00022242802
rat O 0 0.0012098323
, O 0 0.0003935448
and O 0 0.00029455218
, O 0 0.00034985962
indeed O 0 0.00023697439
, O 0 0.00040336425
the O 0 0.00036300477
folate B-Chemical 0 0.9998241
concentration O 0 0.001782785
increased O 0 0.00031979874
in O 0 0.0002420119
liver O 0 0.23883395
after O 0 0.00012285708
6 O 0 0.00012030109
weeks O 0 0.00010410427
of O 0 0.00018320649
treatment O 0 0.0002626016
and O 0 0.0003209001
in O 0 0.00035235425
plasma O 0 0.0024029124
at O 0 0.0004603441
8 O 0 0.0006429416
weeks O 0 0.0007762811
of O 0 0.0018991034
treatment O 0 0.0038035938
. O 0 0.006499554

Dipyridamole B-Chemical 0 0.99982053
- O 0 0.16537449
induced O 0 0.039371036
myocardial B-Disease 0 0.99981767
ischemia I-Disease 2 0.9999579
. O 0 0.048945345

Angina B-Disease 0 0.9956512
and O 0 0.007414744
ischemic O 0 0.99982786
electrocardiographic O 0 0.9269373
changes O 0 0.00148415
occurred O 0 0.0006489843
after O 0 0.00038191816
administration O 0 0.0020998998
of O 0 0.0009007375
oral O 0 0.76502824
dipyridamole B-Chemical 0 0.999974
in O 0 0.00048375982
four O 0 0.0003757562
patients O 0 0.00073154696
awaiting O 0 0.0021926006
urgent O 0 0.0025878893
myocardial O 0 0.9973912
revascularization O 0 0.30628335
procedures O 0 0.0042307135
. O 0 0.006645118

To O 0 0.0030169638
our O 0 0.002406361
knowledge O 0 0.002182003
, O 0 0.0017451888
this O 0 0.00090663746
has O 0 0.000616588
not O 0 0.00048439778
previously O 0 0.00045948723
been O 0 0.00033881818
reported O 0 0.00032991925
as O 0 0.00024284287
a O 0 0.000344632
side O 0 0.005158747
effect O 0 0.00021888284
of O 0 0.00037789904
preoperative O 0 0.024843968
dipyridamole B-Chemical 0 0.9999887
therapy O 0 0.007299377
, O 0 0.0009779829
although O 0 0.0015621635
dipyridamole B-Chemical 0 0.99999523
- O 0 0.14259033
induced O 0 0.0025033464
myocardial B-Disease 0 0.9999877
ischemia I-Disease 2 0.99999845
has O 0 0.0003956499
been O 0 0.00020404393
demonstrated O 0 0.0001562214
to O 0 0.00017052966
occur O 0 0.00021985146
in O 0 0.00025708022
animals O 0 0.00029105524
and O 0 0.0005183588
humans O 0 0.0015010434
with O 0 0.0014170178
coronary B-Disease 0 0.48071265
artery I-Disease 0 0.5743408
disease I-Disease 0 0.92688
. O 0 0.007805579

Epicardial O 0 0.008529333
coronary O 0 0.052701727
collateral O 0 0.0728061
vessels O 0 0.018422179
were O 0 0.0009447419
demonstrated O 0 0.00056288484
in O 0 0.00048259206
all O 0 0.00036969042
four O 0 0.0002793795
patients O 0 0.0004519364
; O 0 0.0005540483
a O 0 0.00046156204
coronary O 0 0.09391843
" O 0 0.00071396166
steal O 0 0.0647645
" O 0 0.00065532455
phenomenon O 0 0.001709923
may O 0 0.00023627745
be O 0 0.00024229636
the O 0 0.00024165542
mechanism O 0 0.00028523064
of O 0 0.00062770175
the O 0 0.0015427736
dipyridamole B-Chemical 0 0.99999034
- O 0 0.13641143
induced O 0 0.0061060116
ischemia B-Disease 2 0.9999697
observed O 0 0.005894971
. O 0 0.0078917565

Inhibition O 0 0.007848875
of O 0 0.0053504785
sympathoadrenal O 0 0.178264
activity O 0 0.003350299
by O 0 0.0036600311
atrial O 0 0.9068079
natriuretic O 0 0.97900546
factor O 0 0.023159884
in O 0 0.0057089627
dogs O 0 0.011733812
. O 0 0.010477804

In O 0 0.0038870992
six O 0 0.0022077796
conscious O 0 0.0052120695
, O 0 0.001771827
trained O 0 0.0011477235
dogs O 0 0.0012009541
, O 0 0.00071897294
maintained O 0 0.00040027173
on O 0 0.0002654848
a O 0 0.00043026698
normal O 0 0.0013226508
sodium B-Chemical 0 0.99950635
intake O 0 0.5373443
of O 0 0.00034167286
2 O 0 0.00018856663
to O 0 0.0001463153
4 O 0 0.00018081401
mEq O 0 0.14299299
/ O 0 0.0010210994
kg O 0 0.0008949759
/ O 0 0.0012985996
day O 0 0.00018240714
, O 0 0.00030535535
sympathetic O 0 0.0061238436
activity O 0 0.00017328553
was O 0 0.0001427047
assessed O 0 0.000108953725
as O 0 0.00013093835
the O 0 0.00014916071
release O 0 0.00055177166
rate O 0 0.00026710232
of O 0 0.001957062
norepinephrine B-Chemical 1 0.9999789
and O 0 0.0012647496
epinephrine B-Chemical 0 0.99816304
during O 0 0.00013368692
15 O 0 0.000158092
- O 0 0.00053422037
minute O 0 0.00016220302
i O 0 0.0006699595
. O 0 0.00023159102
v O 0 0.0038840082
. O 0 0.00030124237
infusions O 0 0.0007184257
of O 0 0.00046795345
human O 0 0.0015939691
alpha O 0 0.9220701
- O 0 0.4050143
atrial O 0 0.97667116
natriuretic O 0 0.98420644
factor O 0 0.047316536
. O 0 0.007901354

Mean O 0 0.0029160632
arterial O 0 0.09221219
pressure O 0 0.05122839
( O 0 0.0017617749
as O 0 0.00084219035
a O 0 0.0006877797
percentage O 0 0.0003737338
of O 0 0.0004935297
control O 0 0.00054557924
+ O 0 0.005755098
/ O 0 0.0196681
- O 0 0.009047454
SEM O 0 0.0006801342
) O 0 0.00034457873
during O 0 0.00014693424
randomized O 0 0.00019105893
infusions O 0 0.00028742346
of O 0 0.0001944989
0 O 0 0.0002521711
. O 0 0.00021863237
03 O 0 0.008959675
, O 0 0.00026705395
0 O 0 0.00021823125
. O 0 0.00016661416
1 O 0 0.00017431563
, O 0 0.00022749993
0 O 0 0.00020891993
. O 0 0.00016309292
3 O 0 0.00015313835
, O 0 0.0002078054
or O 0 0.00017391851
1 O 0 0.00018291934
. O 0 0.00016083864
0 O 0 0.00021472284
microgram O 0 0.008309969
/ O 0 0.0014623242
kg O 0 0.0009218077
/ O 0 0.001183042
min O 0 0.00030598041
was O 0 0.00020551361
99 O 0 0.000509784
+ O 0 0.0009288702
/ O 0 0.0063042957
- O 0 0.006825114
1 O 0 0.00021897869
, O 0 0.00026252776
95 O 0 0.0005417249
+ O 0 0.0012894167
/ O 0 0.009713103
- O 0 0.009843646
1 O 0 0.0002281218
( O 0 0.0002658217
p O 0 0.00019101614
less O 0 0.00016096092
than O 0 0.00013659032
0 O 0 0.00021931152
. O 0 0.00020952278
05 O 0 0.0042176163
) O 0 0.00046570756
, O 0 0.00035209235
93 O 0 0.00076826185
+ O 0 0.0018014756
/ O 0 0.012348701
- O 0 0.011334699
1 O 0 0.0002284374
( O 0 0.0002641049
p O 0 0.00018761613
less O 0 0.00015705061
than O 0 0.00013219366
0 O 0 0.00020898489
. O 0 0.00019455401
01 O 0 0.0010029046
) O 0 0.00038060662
, O 0 0.0002756071
or O 0 0.00020168244
79 O 0 0.000520333
+ O 0 0.0018995472
/ O 0 0.012055618
- O 0 0.008480502
6 O 0 0.0001689679
% O 0 0.00023385517
( O 0 0.00025993428
p O 0 0.00018467342
less O 0 0.000155317
than O 0 0.00013093586
0 O 0 0.00021502319
. O 0 0.00020980765
001 O 0 0.06981042
) O 0 0.000661955
, O 0 0.00042450827
respectively O 0 0.0022847478
, O 0 0.00042484878
but O 0 0.00029082055
no O 0 0.00018751848
tachycardia B-Disease 2 0.99791366
and O 0 0.000262811
no O 0 0.00012431412
augmentation O 0 0.00042076252
of O 0 0.00026628564
the O 0 0.00050647126
norepinephrine B-Chemical 1 0.9999187
release O 0 0.0010685286
rate O 0 0.00022401082
( O 0 0.00026415873
up O 0 0.00012545791
to O 0 0.00012071707
0 O 0 0.00017819091
. O 0 0.00013862806
3 O 0 0.00014026703
microgram O 0 0.0047894316
/ O 0 0.0012824025
kg O 0 0.0009791646
/ O 0 0.0015999791
min O 0 0.00035702984
) O 0 0.00035912648
were O 0 0.00017922318
observed O 0 0.00017134445
, O 0 0.00032060497
which O 0 0.0002879828
is O 0 0.00023024401
in O 0 0.00021535147
contrast O 0 0.0003107278
to O 0 0.00028174947
comparable O 0 0.00044229202
hypotension B-Disease 2 0.99995756
induced O 0 0.0013872517
by O 0 0.010128891
hydralazine B-Chemical 0 0.99999917
or O 0 0.04540488
nitroglycerin B-Chemical 1 0.9999876
. O 0 0.008989732

The O 0 0.003188231
release O 0 0.0040548192
rate O 0 0.0021329913
of O 0 0.0035213365
epinephrine B-Chemical 0 0.99981076
( O 0 0.0023504882
control O 0 0.0006880131
, O 0 0.0006561927
6 O 0 0.00028130793
. O 0 0.00025586004
7 O 0 0.00024345212
+ O 0 0.00078293687
/ O 0 0.0064339195
- O 0 0.00868081
0 O 0 0.00029313014
. O 0 0.00018255849
6 O 0 0.00014459976
ng O 0 0.00028147746
/ O 0 0.0014558918
kg O 0 0.0012433501
/ O 0 0.0021624104
min O 0 0.00040605795
) O 0 0.00038642334
declined O 0 0.00023953241
immediately O 0 0.00013755597
during O 0 0.00010750403
infusions O 0 0.00033877976
of O 0 0.00024046053
atrial O 0 0.817904
natriuretic O 0 0.9405929
factor O 0 0.0028439697
to O 0 0.00013697379
a O 0 0.00015910051
minimum O 0 0.000103866594
of O 0 0.00020475489
49 O 0 0.0004967675
+ O 0 0.0024398128
/ O 0 0.014049101
- O 0 0.0075621745
5 O 0 0.0001527979
% O 0 0.00018433158
of O 0 0.00018160709
control O 0 0.00019888005
( O 0 0.00030044187
p O 0 0.00018362464
less O 0 0.00014826395
than O 0 0.00012243584
0 O 0 0.00019969846
. O 0 0.00018595021
001 O 0 0.02466577
) O 0 0.00029730098
during O 0 0.00012773517
0 O 0 0.0001975424
. O 0 0.00015433467
1 O 0 0.0001721912
microgram O 0 0.005564072
/ O 0 0.0011881351
kg O 0 0.0007787391
/ O 0 0.00086760643
min O 0 0.00024047817
and O 0 0.00017362823
to O 0 0.00014599782
63 O 0 0.0003308752
+ O 0 0.0010122181
/ O 0 0.006988755
- O 0 0.005408562
5 O 0 0.00017017846
% O 0 0.00023241123
( O 0 0.00027893978
0 O 0 0.00020726558
. O 0 0.00015680194
1 O 0 0.00015055304
greater O 0 0.00012674731
than O 0 0.00011331754
p O 0 0.00015246187
greater O 0 0.00013706145
than O 0 0.00012982839
0 O 0 0.00021168606
. O 0 0.00019393816
05 O 0 0.002734353
) O 0 0.00032556118
or O 0 0.00018697284
95 O 0 0.00070769386
+ O 0 0.0018962123
/ O 0 0.012893257
- O 0 0.01034978
13 O 0 0.00026172976
% O 0 0.00025079362
( O 0 0.00025824737
not O 0 0.00016391532
significant O 0 0.00021113554
) O 0 0.000371057
during O 0 0.00016334411
0 O 0 0.00025097467
. O 0 0.00020283353
3 O 0 0.0002049764
or O 0 0.000246542
1 O 0 0.0003261788
. O 0 0.0003839898
0 O 0 0.00063812226
microgram O 0 0.011558362
/ O 0 0.0032723278
kg O 0 0.0038861579
/ O 0 0.005681684
min O 0 0.005146545
. O 0 0.0074825743

Steady O 0 0.06861742
state O 0 0.0040445765
arterial O 0 0.3126665
plasma O 0 0.013166732
concentrations O 0 0.0019345648
of O 0 0.0011508486
atrial O 0 0.92689055
natriuretic O 0 0.97980416
factor O 0 0.0112877125
were O 0 0.00035350077
39 O 0 0.00049504585
+ O 0 0.0013712092
/ O 0 0.007344108
- O 0 0.0047571277
10 O 0 0.00020578319
pg O 0 0.0076704607
/ O 0 0.0019078464
ml O 0 0.00056070974
( O 0 0.00031244478
n O 0 0.0001854194
= O 0 0.00036555546
6 O 0 0.00014474915
) O 0 0.00022484535
during O 0 0.000118287346
infusions O 0 0.00031252587
of O 0 0.00018229656
saline O 0 0.0029252057
and O 0 0.00025144222
284 O 0 0.0050354158
+ O 0 0.002284588
/ O 0 0.012104238
- O 0 0.009337354
24 O 0 0.00020692319
pg O 0 0.006317716
/ O 0 0.0015542347
ml O 0 0.00048099132
( O 0 0.00028035077
n O 0 0.00017296396
= O 0 0.00033223126
6 O 0 0.00014648939
) O 0 0.00027900632
and O 0 0.0002791883
1520 O 0 0.04243817
+ O 0 0.0017990207
/ O 0 0.009277102
- O 0 0.0071170065
300 O 0 0.00040090087
pg O 0 0.011682764
/ O 0 0.0021000027
ml O 0 0.0005457082
( O 0 0.00030654573
n O 0 0.0001871648
= O 0 0.00037085157
9 O 0 0.00018163114
) O 0 0.0002465949
during O 0 0.00013564037
0 O 0 0.00022179227
. O 0 0.0001984357
03 O 0 0.002528096
and O 0 0.00020487206
0 O 0 0.00022614506
. O 0 0.00018076332
1 O 0 0.0002041685
microgram O 0 0.0066928477
/ O 0 0.0013896795
kg O 0 0.00094343757
/ O 0 0.0011070537
min O 0 0.00036766613
infusions O 0 0.00050133665
of O 0 0.00031528808
the O 0 0.0003902365
factor O 0 0.0037590854
. O 0 0.00085352256
( O 0 0.0019445282
ABSTRACT O 0 0.008370561
TRUNCATED O 0 0.006902733
AT O 0 0.012610431
250 O 0 0.0056341984
WORDS O 0 0.010643895
) O 0 0.017235586

Inhibition O 0 0.005045878
of O 0 0.0034570207
immunoreactive O 0 0.031750683
corticotropin O 0 0.99998
- O 0 0.16229694
releasing O 0 0.0074243373
factor O 0 0.01675778
secretion O 0 0.002602366
into O 0 0.00044008053
the O 0 0.00074503047
hypophysial O 0 0.58984995
- O 0 0.010526339
portal O 0 0.038602628
circulation O 0 0.003176085
by O 0 0.0013797757
delayed O 0 0.0072887535
glucocorticoid O 0 0.9104724
feedback O 0 0.00794868
. O 0 0.007979097

Nitroprusside B-Chemical 0 0.9999709
- O 0 0.1805319
induced O 0 0.00960317
hypotension B-Disease 2 0.99999547
evokes O 0 0.78117526
ACTH O 0 0.99999654
secretion O 0 0.072629385
which O 0 0.0013718049
is O 0 0.00040167876
primarily O 0 0.00029591928
mediated O 0 0.000178053
by O 0 0.00024533068
enhanced O 0 0.00024131237
secretion O 0 0.0009839048
of O 0 0.00070020877
immunoreactive O 0 0.056535594
corticotropin O 0 0.9999951
- O 0 0.17861171
releasing O 0 0.007384145
factor O 0 0.08298814
( O 0 0.008725086
irCRF O 0 0.5749103
) O 0 0.0008168876
into O 0 0.0003903943
the O 0 0.0008742552
hypophysial O 0 0.35208282
- O 0 0.009637074
portal O 0 0.08592382
circulation O 0 0.01347758
. O 0 0.0069808047

Portal O 0 0.36157528
plasma O 0 0.01516253
concentrations O 0 0.0037547643
of O 0 0.001980843
neither O 0 0.0018076366
arginine B-Chemical 0 0.9674984
vasopressin I-Chemical 1 0.99987376
nor O 0 0.0038666169
oxytocin B-Chemical 0 0.9971533
are O 0 0.00091220293
significantly O 0 0.0009312242
altered O 0 0.0012111502
in O 0 0.0016053314
this O 0 0.002441679
paradigm O 0 0.0047005247
. O 0 0.007398726

Application O 0 0.0055668885
of O 0 0.0029196078
a O 0 0.0022637912
delayed O 0 0.0023851548
feedback O 0 0.0014623668
signal O 0 0.00082593015
, O 0 0.00084518496
in O 0 0.0004161641
the O 0 0.00031589586
form O 0 0.0002702119
of O 0 0.00035290798
a O 0 0.0004499766
2 O 0 0.00031273568
- O 0 0.004058669
h O 0 0.0004750546
systemic O 0 0.91724175
corticosterone B-Chemical 1 0.9999578
infusion O 0 0.013467965
in O 0 0.0004732697
urethane B-Chemical 0 0.9910286
- O 0 0.027160803
anesthetized O 0 0.0018132362
rats O 0 0.00022286085
with O 0 0.00017489902
pharmacological O 0 0.010259954
blockade O 0 0.007813693
of O 0 0.0014954446
glucocorticoid O 0 0.9863282
synthesis O 0 0.049195163
, O 0 0.00088608044
is O 0 0.00020433111
without O 0 0.00015379496
effect O 0 0.00014091078
on O 0 9.8572564e-05
the O 0 0.00014886801
resting O 0 0.000327913
secretion O 0 0.0010023649
of O 0 0.0014994736
arginine B-Chemical 0 0.9778902
vasopressin I-Chemical 1 0.9998222
and O 0 0.0030345109
oxytocin B-Chemical 0 0.9938811
at O 0 0.00046481303
any O 0 0.0007765697
corticosterone B-Chemical 1 0.9991812
feedback O 0 0.0024357892
dose O 0 0.007614624
tested O 0 0.003433116
. O 0 0.00649631

Resting O 0 0.055762876
irCRF O 0 0.3923756
levels O 0 0.0019353926
are O 0 0.0012157433
suppressed O 0 0.00089078845
only O 0 0.000726149
at O 0 0.0004477815
the O 0 0.00043861594
highest O 0 0.001258447
corticosterone B-Chemical 1 0.99987173
infusion O 0 0.0050239544
rate O 0 0.00041260096
, O 0 0.0005067065
which O 0 0.00035048535
resulted O 0 0.00025669372
in O 0 0.0004521458
systemic O 0 0.9403376
corticosterone B-Chemical 1 0.9998605
levels O 0 0.0006671192
of O 0 0.0009736819
40 O 0 0.0011867054
micrograms O 0 0.015981423
/ O 0 0.010621308
dl O 0 0.1831347
. O 0 0.0077340994

Suppression O 0 0.006729431
of O 0 0.004892075
irCRF O 0 0.6619197
secretion O 0 0.005181856
in O 0 0.0011665496
response O 0 0.0016095204
to O 0 0.0022438865
nitroprusside B-Chemical 1 0.9999999
- O 0 0.33232504
induced O 0 0.0038967768
hypotension B-Disease 2 0.99999523
is O 0 0.00045507096
observed O 0 0.00021615581
and O 0 0.00026178165
occurs O 0 0.0002021543
at O 0 0.00019311113
a O 0 0.0003896475
plasma O 0 0.06657912
corticosterone B-Chemical 1 0.99904925
level O 0 0.00028070086
between O 0 0.00031374654
8 O 0 0.00053375185
- O 0 0.0017900859
12 O 0 0.0008698057
micrograms O 0 0.00451943
/ O 0 0.006588273
dl O 0 0.124065354
. O 0 0.0078942105

These O 0 0.0033457708
studies O 0 0.0020993312
provide O 0 0.0012646659
further O 0 0.0010346704
evidence O 0 0.0007602836
for O 0 0.00067188806
a O 0 0.00069900433
strong O 0 0.00062895304
central O 0 0.0006263369
component O 0 0.00039724205
of O 0 0.00038797606
the O 0 0.00031232805
delayed O 0 0.0007087586
feedback O 0 0.00045949357
process O 0 0.0003532484
which O 0 0.00044989167
is O 0 0.00040862412
mediated O 0 0.00040260417
by O 0 0.00078076613
modulation O 0 0.0012101567
of O 0 0.003187308
irCRF O 0 0.74664414
release O 0 0.02339057
. O 0 0.008019873

Noradrenergic O 0 0.2268699
involvement O 0 0.0064153997
in O 0 0.0063181473
catalepsy B-Disease 2 0.9999888
induced O 0 0.0040176134
by O 0 0.0041394625
delta B-Chemical 0 0.45499498
9 I-Chemical 0 0.006261912
- I-Chemical 0 0.2086934
tetrahydrocannabinol I-Chemical 0 0.9999497
. O 0 0.014167903

In O 0 0.0033167764
order O 0 0.0017070278
to O 0 0.0011851077
elucidate O 0 0.00059671083
the O 0 0.00062297436
role O 0 0.00041442728
of O 0 0.0005816058
the O 0 0.0004989229
catecholaminergic O 0 0.086853445
system O 0 0.0003039585
in O 0 0.00024352083
the O 0 0.00032746218
cataleptogenic O 0 0.9989152
effect O 0 0.0002489525
of O 0 0.0006130134
delta B-Chemical 0 0.74767464
9 I-Chemical 0 0.0013917078
- I-Chemical 0 0.5182101
tetrahydrocannabinol I-Chemical 0 0.9999995
( O 0 0.2509256
THC B-Chemical 0 0.9999999
) O 0 0.009384909
, O 0 0.0003693235
the O 0 0.00015589998
effect O 0 0.00015036152
of O 0 0.00024351201
pretreatment O 0 0.031778466
with O 0 0.00031411138
6 B-Chemical 0 0.00018011076
- I-Chemical 0 0.01612896
hydroxydopamine I-Chemical 0 0.85483354
( O 0 0.00057719456
6 B-Chemical 0 0.0001985837
- I-Chemical 0 0.029979141
OHDA I-Chemical 0 0.9881241
) O 0 0.00076832774
or O 0 0.00022995597
with O 0 0.001687312
desipramine B-Chemical 0 0.99999964
and O 0 0.0005048908
6 B-Chemical 0 0.00023122386
- I-Chemical 0 0.014094516
OHDA I-Chemical 0 0.94682765
and O 0 0.0003593022
lesions O 0 0.05409033
of O 0 0.0003800722
the O 0 0.0004129685
locus O 0 0.0010538269
coeruleus O 0 0.16143404
were O 0 0.00075286196
investigated O 0 0.001026063
in O 0 0.002099633
rats O 0 0.004571125
. O 0 0.006299315

The O 0 0.0045337183
cataleptogenic O 0 0.9991239
effect O 0 0.004010623
of O 0 0.04961542
THC B-Chemical 0 0.99999964
was O 0 0.0019304923
significantly O 0 0.0006647314
reduced O 0 0.00040738453
in O 0 0.00030953446
rats O 0 0.00037519637
treated O 0 0.0002733722
with O 0 0.0003042917
6 B-Chemical 0 0.00023942624
- I-Chemical 0 0.031995032
OHDA I-Chemical 0 0.97839695
and O 0 0.0002813868
in O 0 0.00018172384
rats O 0 0.00024044198
with O 0 0.00019513644
lesions O 0 0.06380222
of O 0 0.00023973166
the O 0 0.00023112426
locus O 0 0.0016226207
coeruleus O 0 0.64703304
but O 0 0.00019460873
not O 0 0.00013538387
in O 0 0.0001578981
rats O 0 0.0002556247
treated O 0 0.00027690508
with O 0 0.0015683889
desipramine B-Chemical 0 0.99999964
and O 0 0.00060946756
6 B-Chemical 0 0.000321039
- I-Chemical 0 0.024796523
OHDA I-Chemical 0 0.9689726
, O 0 0.00065377564
as O 0 0.0005168382
compared O 0 0.0006192485
with O 0 0.0012541392
control O 0 0.0021876406
rats O 0 0.0047687385
. O 0 0.006109109

On O 0 0.0032487325
the O 0 0.0023202621
contrary O 0 0.0024842054
, O 0 0.0023454612
the O 0 0.0017509726
cataleptogenic O 0 0.9998528
effect O 0 0.0020594306
of O 0 0.040272053
haloperidol B-Chemical 1 0.9999999
was O 0 0.000738671
significantly O 0 0.0003209711
reduced O 0 0.0002259347
in O 0 0.00019700367
rats O 0 0.00029880196
treated O 0 0.00029719868
with O 0 0.001994893
desipramine B-Chemical 0 0.99999976
and O 0 0.00067127746
6 B-Chemical 0 0.00023967019
- I-Chemical 0 0.04722429
OHDA I-Chemical 0 0.9865079
but O 0 0.00028351144
not O 0 0.00015168013
in O 0 0.00016380126
rats O 0 0.00023644468
treated O 0 0.00020442756
with O 0 0.00025811812
6 B-Chemical 0 0.00023153448
- I-Chemical 0 0.023688866
OHDA I-Chemical 0 0.966764
or O 0 0.0002964064
in O 0 0.00031350701
rats O 0 0.00049015955
with O 0 0.00051381206
lesions O 0 0.061391387
of O 0 0.0011238107
the O 0 0.0015818961
locus O 0 0.004288654
coeruleus O 0 0.40529886
. O 0 0.0060495203

These O 0 0.0032501037
results O 0 0.0019136389
indicate O 0 0.0011326494
that O 0 0.0011488107
noradrenergic O 0 0.6325563
neurons O 0 0.0014707622
have O 0 0.000412121
an O 0 0.00040879866
important O 0 0.00024621736
role O 0 0.00020378378
in O 0 0.00026606987
the O 0 0.00028744267
manifestation O 0 0.044057854
of O 0 0.013295726
catalepsy B-Disease 2 0.99999964
induced O 0 0.0016129168
by O 0 0.01509663
THC B-Chemical 0 0.9999999
, O 0 0.0036132983
whereas O 0 0.0007126303
dopaminergic O 0 0.36988407
neurons O 0 0.0006519637
are O 0 0.00029735797
important O 0 0.00038769763
in O 0 0.0013506447
catalepsy B-Disease 2 0.9999968
induced O 0 0.0027472235
by O 0 0.014811896
haloperidol B-Chemical 1 0.9999975
. O 0 0.0084511675

Reversibility O 0 0.17967853
of O 0 0.017394204
captopril B-Chemical 1 0.99999344
- O 0 0.23067547
induced O 0 0.003113991
renal B-Disease 0 0.99254954
insufficiency I-Disease 0 0.99900395
after O 0 0.000516643
prolonged O 0 0.00083692523
use O 0 0.00050814654
in O 0 0.00051872944
an O 0 0.0007578492
unusual O 0 0.002276546
case O 0 0.0018707161
of O 0 0.03310925
renovascular B-Disease 0 0.9999988
hypertension I-Disease 2 0.99999905
. O 0 0.014646778

We O 0 0.003957399
report O 0 0.0036512148
a O 0 0.0022813124
case O 0 0.0016282395
of O 0 0.0019855185
severe O 0 0.80432063
hypertension B-Disease 2 0.99999785
with O 0 0.0012796876
an O 0 0.0006563116
occluded O 0 0.008107772
renal O 0 0.8186246
artery O 0 0.06768779
to O 0 0.00020372163
a O 0 0.0003279921
solitary O 0 0.0061176447
kidney O 0 0.53531176
, O 0 0.00081287
who O 0 0.00068239064
developed O 0 0.0009821268
sudden B-Disease 0 0.9660632
deterioration I-Disease 0 0.21395876
of I-Disease 0 0.00087710255
renal I-Disease 0 0.749713
function I-Disease 0 0.00064328325
following O 0 0.0006916044
treatment O 0 0.0017875195
with O 0 0.0074758315
captopril B-Chemical 1 0.99995816
. O 0 0.0076239766

His O 0 0.011895289
renal O 0 0.35373464
function O 0 0.0020642725
remained O 0 0.001905391
impaired O 0 0.001441143
but O 0 0.0009100725
stable O 0 0.0006375748
during O 0 0.00030513678
2 O 0 0.00031763353
years O 0 0.00035558673
' O 0 0.00042926453
treatment O 0 0.0003576052
with O 0 0.00096408185
captopril B-Chemical 1 0.99998784
but O 0 0.00037099
returned O 0 0.00020153612
to O 0 0.00018936842
pre O 0 0.0009884457
- O 0 0.0021309105
treatment O 0 0.00032545693
levels O 0 0.00033965748
soon O 0 0.00046720068
after O 0 0.00046749736
cessation O 0 0.0023080134
of O 0 0.0016231493
the O 0 0.0025716545
drug O 0 0.3997215
. O 0 0.0070219957

This O 0 0.0049639805
indicates O 0 0.002310006
reversibility O 0 0.07701827
in O 0 0.0049268757
captopril B-Chemical 1 0.99999654
- O 0 0.18536574
induced O 0 0.0015221796
renal B-Disease 0 0.97841954
failure I-Disease 0 0.67834234
even O 0 0.0006599381
after O 0 0.00018021744
its O 0 0.00045562003
prolonged O 0 0.00038445112
use O 0 0.00020505578
and O 0 0.00020810697
suggests O 0 0.00013490037
that O 0 0.00017274673
no O 0 0.00025646988
organic O 0 0.9659425
damage O 0 0.654076
occurs O 0 0.00042454916
to O 0 0.00045944058
glomerular O 0 0.93051505
arterioles O 0 0.6078074
following O 0 0.0011649528
chronic O 0 0.9788665
ACE O 0 0.9996043
inhibition O 0 0.028107364
. O 0 0.007553884

HMG O 0 0.9923475
CoA O 1 0.99927133
reductase O 0 0.99611974
inhibitors O 0 0.18310732
. O 0 0.04266079

Current O 0 0.062936254
clinical O 0 0.051967397
experience O 0 0.051846813
. O 0 0.055245783

Lovastatin B-Chemical 1 0.9999639
and O 0 0.03031166
simvastatin B-Chemical 1 0.9999677
are O 0 0.001623803
the O 0 0.00089412177
2 O 0 0.00066543586
best O 0 0.00065538584
- O 0 0.002280426
known O 0 0.00046057213
members O 0 0.0003582764
of O 0 0.0003645949
the O 0 0.00033460284
class O 0 0.00069231197
of O 0 0.0013633585
hypolipidaemic O 0 0.99914503
agents O 0 0.02703395
known O 0 0.0012881095
as O 0 0.0016106487
HMG O 0 0.9988393
CoA O 1 0.99996364
reductase O 0 0.9990645
inhibitors O 0 0.07294792
. O 0 0.007159418

Clinical O 0 0.010501579
experience O 0 0.0032456054
with O 0 0.0030559665
lovastatin B-Chemical 1 0.99994004
includes O 0 0.00091192045
over O 0 0.00045125277
5000 O 0 0.0008046454
patients O 0 0.0005189998
, O 0 0.00045489136
700 O 0 0.00054346584
of O 0 0.00029483117
whom O 0 0.000454765
have O 0 0.00017732226
been O 0 0.00018404183
treated O 0 0.00021119918
for O 0 0.0001763391
2 O 0 0.00016628976
years O 0 0.00019089287
or O 0 0.00016779492
more O 0 0.00023023061
, O 0 0.00026715454
and O 0 0.00022766856
experience O 0 0.00033349014
with O 0 0.0006808726
simvastatin B-Chemical 1 0.9999763
includes O 0 0.00020006075
over O 0 0.00012585585
3500 O 0 0.0004141181
patients O 0 0.00022932602
, O 0 0.0002344396
of O 0 0.00024738398
whom O 0 0.0004804694
350 O 0 0.00033899056
have O 0 0.00022408774
been O 0 0.00030782464
treated O 0 0.00043091492
for O 0 0.0005350574
18 O 0 0.0008171709
months O 0 0.00092359405
or O 0 0.0018409456
more O 0 0.0038190682
. O 0 0.006490218

Lovastatin B-Chemical 1 0.99992394
has O 0 0.004816404
been O 0 0.0034309665
marketed O 0 0.04018437
in O 0 0.0019210558
the O 0 0.0017149999
United O 0 0.0025469551
States O 0 0.002853584
for O 0 0.00165817
over O 0 0.0017370201
6 O 0 0.0026066094
months O 0 0.0038519225
. O 0 0.00800399

Both O 0 0.0036127574
agents O 0 0.004518962
show O 0 0.0013271631
substantial O 0 0.0012477874
clinical O 0 0.0026261278
efficacy O 0 0.0012700615
, O 0 0.00073198794
with O 0 0.00042243398
reductions O 0 0.00039596454
in O 0 0.00025505092
total O 0 0.00028630107
cholesterol B-Chemical 0 0.9990375
of O 0 0.00032660135
over O 0 0.000143808
30 O 0 0.0001678618
% O 0 0.00023467267
and O 0 0.00028325993
in O 0 0.00055865216
LDL O 0 0.9999716
- O 0 0.24245258
cholesterol B-Chemical 0 0.9993938
of O 0 0.00090340036
40 O 0 0.0007567011
% O 0 0.0010547338
in O 0 0.0013291604
clinical O 0 0.0032881203
studies O 0 0.0037776183
. O 0 0.006560509

Modest O 0 0.35385677
increases O 0 0.0043259617
in O 0 0.0055461917
HDL O 0 0.9999542
- O 0 0.4317053
cholesterol B-Chemical 0 0.99942017
levels O 0 0.0013269393
of O 0 0.0012174766
about O 0 0.0010244698
10 O 0 0.0011741404
% O 0 0.0016570472
are O 0 0.0018726422
also O 0 0.0028296195
reported O 0 0.005464525
. O 0 0.008402015

Clinical O 0 0.010380537
tolerability O 0 0.0076556276
of O 0 0.0019298245
both O 0 0.001282775
agents O 0 0.006015371
has O 0 0.00069238985
been O 0 0.00056149263
good O 0 0.0006270602
, O 0 0.00053612737
with O 0 0.00035248848
fewer O 0 0.00026678623
than O 0 0.00019645333
3 O 0 0.00021346255
% O 0 0.00027550597
of O 0 0.00029599605
patients O 0 0.0004103968
withdrawn O 0 0.00046582037
from O 0 0.00029983438
treatment O 0 0.00045792642
because O 0 0.0005239592
of O 0 0.001119383
clinical O 0 0.0075964457
adverse O 0 0.35221648
experiences O 0 0.009408771
. O 0 0.0070549077

Ophthalmological O 0 0.026160195
examinations O 0 0.0026578405
in O 0 0.0014844544
over O 0 0.00088708784
1100 O 0 0.0017059197
patients O 0 0.00076563505
treated O 0 0.0005296547
with O 0 0.00041944752
one O 0 0.0002894422
or O 0 0.0002483174
the O 0 0.0002318926
other O 0 0.00027404024
agent O 0 0.0029984172
have O 0 0.0001620268
revealed O 0 0.00017057422
no O 0 0.00013298968
evidence O 0 0.00014761873
of O 0 0.00023119432
significant O 0 0.00021335593
short O 0 0.00018946578
term O 0 0.00025956528
( O 0 0.00045174084
up O 0 0.00031655698
to O 0 0.00037590682
2 O 0 0.0005630313
years O 0 0.0010193333
) O 0 0.0023090949
cataractogenic O 0 0.7530638
potential O 0 0.005070064
. O 0 0.007474604

One O 0 0.0044575585
to O 0 0.002394839
2 O 0 0.0018513332
% O 0 0.0015074793
of O 0 0.0010903339
patients O 0 0.00097117026
have O 0 0.00055473944
elevations O 0 0.022940265
of O 0 0.00094550103
serum O 0 0.79989946
transaminases O 0 0.9998425
to O 0 0.0003622126
greater O 0 0.00030396317
than O 0 0.00025083785
3 O 0 0.0002899966
times O 0 0.0002878261
the O 0 0.00053654076
upper O 0 0.0010452275
limit O 0 0.0017114442
of O 0 0.0029100194
normal O 0 0.006267915
. O 0 0.0073410887

These O 0 0.0057817507
episodes O 0 0.008709458
are O 0 0.0036550227
asymptomatic O 0 0.02634614
and O 0 0.0032841952
reversible O 0 0.035976093
when O 0 0.0025960985
therapy O 0 0.0053202133
is O 0 0.0052340897
discontinued O 0 0.032913383
. O 0 0.0100104045

Minor O 0 0.31916583
elevations O 0 0.10551813
of O 0 0.0063592694
creatine B-Chemical 1 0.99990904
kinase O 0 0.3234134
levels O 0 0.0012567826
are O 0 0.0009123793
reported O 0 0.00092312734
in O 0 0.0008497911
about O 0 0.00096713245
5 O 0 0.0012354008
% O 0 0.0021939904
of O 0 0.0034046145
patients O 0 0.0065152207
. O 0 0.008291206

Myopathy B-Disease 0 0.9965996
, O 0 0.0045368033
associated O 0 0.0019091398
in O 0 0.0011478853
some O 0 0.00084319414
cases O 0 0.0011781416
with O 0 0.0026147275
myoglobinuria B-Disease 0 0.9999976
, O 0 0.0018801214
and O 0 0.00045177998
in O 0 0.00027055887
2 O 0 0.00021116252
cases O 0 0.00026744354
with O 0 0.00029249955
transient O 0 0.046075232
renal B-Disease 0 0.9812129
failure I-Disease 0 0.82596844
, O 0 0.0016860435
has O 0 0.0002111734
been O 0 0.000194318
rarely O 0 0.00031070053
reported O 0 0.00034076863
with O 0 0.0013827656
lovastatin B-Chemical 1 0.9999964
, O 0 0.0021896253
especially O 0 0.0006725935
in O 0 0.00024899928
patients O 0 0.0004387512
concomitantly O 0 0.0010441352
treated O 0 0.0006893182
with O 0 0.003803726
cyclosporin B-Chemical 0 0.99999905
, O 0 0.34451008
gemfibrozil B-Chemical 0 0.9999987
or O 0 0.059865296
niacin B-Chemical 0 0.99999297
. O 0 0.0107521955

Lovastatin B-Chemical 1 0.9999659
and O 0 0.033888493
simvastatin B-Chemical 1 0.9999715
are O 0 0.0016297478
both O 0 0.0008784796
effective O 0 0.0007320786
and O 0 0.0006453955
well O 0 0.0006052728
- O 0 0.0118570635
tolerated O 0 0.00365303
agents O 0 0.0021165875
for O 0 0.00046737574
lowering O 0 0.010762324
elevated O 0 0.0025556022
levels O 0 0.0009734575
of O 0 0.0026394022
serum O 0 0.877093
cholesterol B-Chemical 0 0.99982125
. O 0 0.010706391

As O 0 0.003357617
wider O 0 0.0028873421
use O 0 0.0017198798
confirms O 0 0.0010945314
their O 0 0.0009117546
safety O 0 0.00096165115
profile O 0 0.00062362035
, O 0 0.00062489894
they O 0 0.00032595903
will O 0 0.00027662457
gain O 0 0.00038346136
increasing O 0 0.00027555195
importance O 0 0.00026473188
in O 0 0.0003008787
the O 0 0.00032558542
therapeutic O 0 0.000746191
approach O 0 0.00061721
to O 0 0.0009373918
hypercholesterolaemia B-Disease 0 0.99998534
and O 0 0.0022230654
its O 0 0.004190677
consequences O 0 0.0062107174
. O 0 0.00699049

Hepatic O 0 0.2825411
reactions O 0 0.015405678
associated O 0 0.005213419
with O 0 0.008477191
ketoconazole B-Chemical 1 0.99999464
in O 0 0.005372667
the O 0 0.005225294
United O 0 0.010295363
Kingdom O 0 0.030675065
. O 0 0.012593579

Ketoconazole B-Chemical 0 0.99988186
was O 0 0.0067739873
introduced O 0 0.0045075584
in O 0 0.0042542014
the O 0 0.004434586
United O 0 0.0072626057
Kingdom O 0 0.013434459
in O 0 0.0074434667
1981 O 0 0.018711079
. O 0 0.014238593

By O 0 0.0054064565
November O 0 0.004258633
1984 O 0 0.0041888007
the O 0 0.0015509002
Committee O 0 0.0019752306
on O 0 0.0007104702
Safety O 0 0.0025446317
of O 0 0.0008196742
Medicines O 0 0.030328233
had O 0 0.00039398103
received O 0 0.00027243185
82 O 0 0.00043747574
reports O 0 0.00027573275
of O 0 0.00038933265
possible O 0 0.0015207597
hepatotoxicity B-Disease 2 0.9999995
associated O 0 0.0011113283
with O 0 0.0006232728
the O 0 0.0006413977
drug O 0 0.1821527
, O 0 0.0012658637
including O 0 0.0012956829
five O 0 0.0019461466
deaths B-Disease 0 0.496273
. O 0 0.007590233

An O 0 0.00477062
analysis O 0 0.0025207154
of O 0 0.0019401552
the O 0 0.0012864862
75 O 0 0.0011479958
cases O 0 0.00087405776
that O 0 0.0004736918
had O 0 0.00043351762
been O 0 0.0003425208
adequately O 0 0.00027087994
followed O 0 0.00019245307
up O 0 0.00019318332
suggested O 0 0.00017337823
that O 0 0.00018062032
16 O 0 0.0002615751
, O 0 0.0002568477
including O 0 0.00019380452
three O 0 0.00017570285
deaths B-Disease 0 0.39572185
, O 0 0.00056141
were O 0 0.00031993352
probably O 0 0.00040628013
related O 0 0.00030685827
to O 0 0.00045289056
treatment O 0 0.0008278449
with O 0 0.0013487194
the O 0 0.002324842
drug O 0 0.32717627
. O 0 0.0068257255

Of O 0 0.004783648
the O 0 0.002668435
remainder O 0 0.0024444421
, O 0 0.002082279
48 O 0 0.0012001263
were O 0 0.0007267922
possibly O 0 0.00074143556
related O 0 0.00036463715
to O 0 0.00035926775
treatment O 0 0.0004756001
, O 0 0.0004669954
five O 0 0.00024464392
were O 0 0.00028520075
unlikely O 0 0.00029802977
to O 0 0.0003178462
be O 0 0.0004531758
so O 0 0.0005772334
, O 0 0.00091529667
and O 0 0.0010904704
six O 0 0.0012706914
were O 0 0.002425175
unclassifiable O 0 0.1375401
. O 0 0.007293467

The O 0 0.0027785033
mean O 0 0.001532806
age O 0 0.0019711128
of O 0 0.0013169253
patients O 0 0.0011652857
in O 0 0.0006378882
the O 0 0.0005186254
16 O 0 0.0005234116
probable O 0 0.0022665227
cases O 0 0.0006455828
was O 0 0.0003885762
57 O 0 0.00053510093
. O 0 0.00030899607
9 O 0 0.00033870325
, O 0 0.00050652097
with O 0 0.0010934048
hepatotoxicity B-Disease 2 0.99999857
being O 0 0.0027363512
more O 0 0.0012281938
common O 0 0.001799059
in O 0 0.0024531283
women O 0 0.015794817
. O 0 0.007220592

The O 0 0.0031874536
average O 0 0.0018761774
duration O 0 0.0015671282
of O 0 0.0015895799
treatment O 0 0.0013250571
before O 0 0.0008122927
the O 0 0.0009842564
onset O 0 0.0019073125
of O 0 0.0023671745
jaundice B-Disease 2 0.9992849
was O 0 0.0028851386
61 O 0 0.0041113133
days O 0 0.0036528874
. O 0 0.007349096

None O 0 0.005936675
of O 0 0.0029295846
these O 0 0.0020037794
well O 0 0.0014310776
validated O 0 0.0012205092
cases O 0 0.0012388392
occurred O 0 0.0008481006
within O 0 0.0005926732
the O 0 0.00074798014
first O 0 0.0007634472
10 O 0 0.0010208786
days O 0 0.0011669114
after O 0 0.0018176334
treatment O 0 0.0042945268
. O 0 0.00750332

The O 0 0.0029622852
results O 0 0.0020376125
of O 0 0.002143292
serum O 0 0.29769206
liver O 0 0.72227347
function O 0 0.001113112
tests O 0 0.002212727
suggested O 0 0.001440106
hepatocellular B-Disease 0 0.99999976
injury I-Disease 0 0.99985754
in O 0 0.00071496225
10 O 0 0.00035228746
( O 0 0.000445246
63 O 0 0.00048355997
% O 0 0.00047000713
) O 0 0.00069196505
; O 0 0.0006683516
the O 0 0.0005340758
rest O 0 0.0007921054
showed O 0 0.0009465325
a O 0 0.0017100445
mixed O 0 0.003039979
pattern O 0 0.0041114227
. O 0 0.0072096377

In O 0 0.004153904
contrast O 0 0.0031687794
, O 0 0.002491412
the O 0 0.0012654858
results O 0 0.0009189901
of O 0 0.000985802
histological O 0 0.016698308
examination O 0 0.0007657289
of O 0 0.0007590432
the O 0 0.0007936781
liver O 0 0.34438857
often O 0 0.0013695199
showed O 0 0.0011790651
evidence O 0 0.0018204926
of O 0 0.008810406
cholestasis B-Disease 2 0.9999944
. O 0 0.03225732

The O 0 0.0036802362
characteristics O 0 0.0025234781
of O 0 0.0023889225
the O 0 0.0018626606
48 O 0 0.0017721046
patients O 0 0.0015455966
in O 0 0.0012736649
the O 0 0.0013887588
possible O 0 0.001853555
cases O 0 0.00301631
were O 0 0.0033512132
similar O 0 0.0043752044
. O 0 0.008568739

Allergic O 0 0.90987813
manifestations O 0 0.18232822
such O 0 0.004725222
as O 0 0.0056531234
rash B-Disease 0 0.9997862
and O 0 0.013424061
eosinophilia B-Disease 0 0.9997322
were O 0 0.007825934
rare O 0 0.018900448
. O 0 0.011930716

Hepatitis B-Disease 0 0.99997485
was O 0 0.00554023
usually O 0 0.003261848
reversible O 0 0.041171987
when O 0 0.0007650342
treatment O 0 0.0008837276
was O 0 0.0005420837
stopped O 0 0.0006252513
, O 0 0.0004761656
with O 0 0.00028522708
the O 0 0.00021593994
results O 0 0.00019927924
of O 0 0.00035760895
liver O 0 0.3991632
function O 0 0.00031863165
tests O 0 0.0005138096
returning O 0 0.0004314764
to O 0 0.00019811848
normal O 0 0.0003174059
after O 0 0.0001955104
an O 0 0.00031763656
average O 0 0.0003127476
of O 0 0.0006581854
3 O 0 0.0007654805
. O 0 0.0010988431
1 O 0 0.0017971316
months O 0 0.002611003
. O 0 0.0058522983

In O 0 0.0034665682
two O 0 0.0018870098
of O 0 0.0015960041
the O 0 0.0010407439
three O 0 0.000635743
deaths B-Disease 0 0.42329907
probably O 0 0.0014243346
associated O 0 0.0009080721
with O 0 0.005892733
ketoconazole B-Chemical 1 0.99999976
treatment O 0 0.0035288653
the O 0 0.00044664054
drug O 0 0.23307472
had O 0 0.0002365076
been O 0 0.00018425936
continued O 0 0.00017879749
after O 0 0.00014466401
the O 0 0.0002256944
onset O 0 0.00058722665
of O 0 0.0007964317
jaundice B-Disease 2 0.9993882
and O 0 0.0016179142
other O 0 0.0020058833
symptoms O 0 0.5676059
of O 0 0.021598447
hepatitis B-Disease 2 0.9999995
. O 0 0.1146429

Clinical O 0 0.008559735
and O 0 0.0026370059
biochemical O 0 0.0027347226
monitoring O 0 0.0012210812
at O 0 0.00069219683
regular O 0 0.00055611983
intervals O 0 0.00032373692
for O 0 0.00032190976
evidence O 0 0.0003225315
of O 0 0.0020511348
hepatitis B-Disease 2 1.0
is O 0 0.00924616
advised O 0 0.0020772873
during O 0 0.00016265744
long O 0 0.00019439211
term O 0 0.00021215624
treatment O 0 0.00043823099
with O 0 0.0019149164
ketoconazole B-Chemical 1 0.9999988
to O 0 0.0005225489
prevent O 0 0.00064965955
possible O 0 0.0016090362
serious O 0 0.59145683
hepatic B-Disease 0 0.9995809
injury I-Disease 0 0.99950135
. O 0 0.010748235

Glyburide B-Chemical 0 0.9996178
- O 0 0.23985195
induced O 0 0.07466434
hepatitis B-Disease 2 0.9999863
. O 0 0.20029241

Drug O 0 0.87214446
- O 0 0.09953678
induced O 0 0.0151719535
hepatotoxicity B-Disease 2 0.99999917
, O 0 0.01633193
although O 0 0.0016966227
common O 0 0.001608926
, O 0 0.0012202011
has O 0 0.00076565484
been O 0 0.00085563515
reported O 0 0.0011339448
only O 0 0.0014404558
infrequently O 0 0.0035118067
with O 0 0.0046213535
sulfonylureas B-Chemical 0 0.9995409
. O 0 0.009301041

For O 0 0.005953081
glyburide B-Chemical 0 0.99980396
, O 0 0.004372295
a O 0 0.0022629404
second O 0 0.0016082888
- O 0 0.013465855
generation O 0 0.00357664
sulfonylurea B-Chemical 0 0.99997365
, O 0 0.0016805592
only O 0 0.00078862836
two O 0 0.0006335352
brief O 0 0.0008488427
reports O 0 0.0014561093
of O 0 0.0044920617
hepatotoxicity B-Disease 2 0.99999595
exist O 0 0.0069677965
. O 0 0.008808686

Two O 0 0.004097662
patients O 0 0.002966823
with O 0 0.0020699797
type B-Disease 0 0.0025108638
II I-Disease 0 0.4025627
diabetes I-Disease 0 0.9999629
mellitus I-Disease 0 0.9998987
developed O 0 0.021792138
an O 0 0.01611644
acute B-Disease 0 0.99997616
hepatitis I-Disease 2 1.0
- I-Disease 0 0.9567036
like I-Disease 0 0.0013433793
syndrome I-Disease 0 0.5032962
soon O 0 0.00061390584
after O 0 0.0004843751
initiation O 0 0.0011479618
of O 0 0.0035162817
glyburide B-Chemical 0 0.99993443
therapy O 0 0.021332482
. O 0 0.007239841

There O 0 0.0042806487
was O 0 0.0026484532
no O 0 0.0016290473
serologic O 0 0.114115044
evidence O 0 0.0010168087
of O 0 0.0016966275
viral B-Disease 0 0.97524536
infection I-Disease 2 0.99991703
, O 0 0.007955776
and O 0 0.00073642464
a O 0 0.0006340973
liver O 0 0.3221244
biopsy O 0 0.0009481089
sample O 0 0.00026560278
showed O 0 0.00023159895
a O 0 0.0003227062
histologic O 0 0.015380649
pattern O 0 0.00035323433
consistent O 0 0.0005299685
with O 0 0.0010567599
drug B-Disease 0 0.62635624
- I-Disease 0 0.07909604
induced I-Disease 0 0.017700903
hepatitis I-Disease 2 0.9999995
. O 0 0.14962019

Both O 0 0.003663155
patients O 0 0.0025209098
recovered O 0 0.0013329915
quickly O 0 0.0013847564
after O 0 0.00069056445
stopping O 0 0.02496475
glyburide B-Chemical 0 0.9999635
therapy O 0 0.001845135
and O 0 0.00042649158
have O 0 0.000268371
remained O 0 0.00037632312
well O 0 0.00028308065
for O 0 0.00031621076
a O 0 0.00043166048
follow O 0 0.00037694158
- O 0 0.0012954884
up O 0 0.0006133567
period O 0 0.0007813226
of O 0 0.0015247704
1 O 0 0.0021579578
year O 0 0.0037935886
. O 0 0.0067902184

Glyburide B-Chemical 0 0.9993894
can O 0 0.003741645
produce O 0 0.0026894838
an O 0 0.0066972077
acute B-Disease 0 0.9999213
hepatitis I-Disease 2 1.0
- I-Disease 0 0.9414208
like I-Disease 0 0.0038756302
illness I-Disease 0 0.92658794
in O 0 0.002933734
some O 0 0.0037589227
persons O 0 0.010731491
. O 0 0.009133151

Intracranial O 0 0.27177536
pressure O 0 0.043881316
increases O 0 0.0059219897
during O 0 0.006300542
alfentanil B-Chemical 0 0.9999316
- O 0 0.1040607
induced O 0 0.012959408
rigidity B-Disease 2 0.99681705
. O 0 0.01854397

Intracranial O 0 0.4667164
pressure O 0 0.25597227
( O 0 0.008237524
ICP O 0 0.9945193
) O 0 0.0028854017
was O 0 0.0013280115
measured O 0 0.0010495681
during O 0 0.0013395303
alfentanil B-Chemical 0 0.999964
- O 0 0.044929862
induced O 0 0.0031013135
rigidity B-Disease 2 0.99489635
in O 0 0.004417378
rats O 0 0.0076308013
. O 0 0.008252746

Ten O 0 0.00532122
rats O 0 0.0037452693
had O 0 0.0022094157
arterial O 0 0.12907057
, O 0 0.0018054218
central O 0 0.0019390924
venous O 0 0.4628519
( O 0 0.0028876157
CVP O 0 0.9931005
) O 0 0.001393809
, O 0 0.00094290706
and O 0 0.0010783862
subdural O 0 0.9934402
cannulae O 0 0.0024069909
inserted O 0 0.0012271198
under O 0 0.002027835
halothane B-Chemical 0 0.9997484
anesthesia O 0 0.2654495
. O 0 0.008134632

The O 0 0.0032857393
animals O 0 0.0021758096
were O 0 0.0017611544
mechanically O 0 0.0024545207
ventilated O 0 0.0020369824
to O 0 0.0005544939
achieve O 0 0.00045583115
normocarbia O 0 0.029049555
( O 0 0.0011185762
PCO2 O 0 0.9856625
= O 0 0.0010590118
42 O 0 0.0005938739
+ O 0 0.0013918836
/ O 0 0.005779369
- O 0 0.004806784
1 O 0 0.00044926727
mmHg O 0 0.0009314358
, O 0 0.000607362
mean O 0 0.00053370325
+ O 0 0.0021237775
/ O 0 0.009192474
- O 0 0.036654748
SE O 0 0.7183751
) O 0 0.008423486
. O 0 0.0088677

Following O 0 0.0041528605
instrumentation O 0 0.011556139
, O 0 0.0056621144
halothane B-Chemical 0 0.9997824
was O 0 0.0016468734
discontinued O 0 0.010894879
and O 0 0.0017337729
alfentanil B-Chemical 0 0.9999689
( O 0 0.0016736359
125 O 0 0.003091777
mu O 0 0.18498807
/ O 0 0.0055172215
kg O 0 0.001825373
) O 0 0.000812211
administered O 0 0.0004954689
iv O 0 0.0010447043
during O 0 0.00060740893
emergence O 0 0.0016061792
from O 0 0.0021225985
halothane B-Chemical 0 0.99984336
anesthesia O 0 0.27450472
. O 0 0.0070563373

In O 0 0.0037397523
the O 0 0.0021976973
five O 0 0.0012873532
rats O 0 0.0013436895
that O 0 0.0007737248
developed O 0 0.0020293756
somatic B-Disease 0 0.48180804
rigidity I-Disease 2 0.99996805
, O 0 0.034037095
ICP O 0 0.99952245
and O 0 0.0014961916
CVP O 0 0.99403584
increased O 0 0.00030564514
significantly O 0 0.00020583991
above O 0 0.00015321489
baseline O 0 0.00021059149
( O 0 0.00055432797
delta O 0 0.55270654
ICP O 0 0.99869895
7 O 0 0.00018405358
. O 0 0.00015878194
5 O 0 0.00016254363
+ O 0 0.0006405312
/ O 0 0.0058143446
- O 0 0.007344516
1 O 0 0.00021621498
. O 0 0.00017663329
0 O 0 0.00022252304
mmHg O 0 0.0007223161
, O 0 0.0004227645
delta O 0 0.2850283
CVP O 0 0.9937856
5 O 0 0.0002528341
. O 0 0.0002594938
9 O 0 0.00032703823
+ O 0 0.00087243697
/ O 0 0.0035161346
- O 0 0.0046641
1 O 0 0.0008523445
. O 0 0.0010345506
3 O 0 0.001540628
mmHg O 0 0.0041671386
) O 0 0.0056868265
. O 0 0.007934202

These O 0 0.004546567
variables O 0 0.0034415366
returned O 0 0.002395737
to O 0 0.0018482624
baseline O 0 0.0018238081
when O 0 0.0017314069
rigidity B-Disease 2 0.9653947
was O 0 0.0026964853
abolished O 0 0.0037289136
with O 0 0.009021925
metocurine B-Chemical 0 0.99980706
. O 0 0.011550221

In O 0 0.004300676
five O 0 0.0023225218
rats O 0 0.0023611663
that O 0 0.0013495428
did O 0 0.0013036111
not O 0 0.00087627384
become O 0 0.0010787257
rigid O 0 0.003472812
, O 0 0.003044662
ICP O 0 0.9977781
and O 0 0.001852479
CVP O 0 0.98828155
did O 0 0.0010962627
not O 0 0.0011066466
change O 0 0.0018971765
following O 0 0.0031447082
alfentanil B-Chemical 0 0.9997584
. O 0 0.0086396225

These O 0 0.003431066
observations O 0 0.0022453154
suggest O 0 0.0012439401
that O 0 0.0012964061
rigidity B-Disease 2 0.97959864
should O 0 0.0005832818
be O 0 0.0005364586
prevented O 0 0.000688992
when O 0 0.00055556494
alfentanil B-Chemical 0 0.99998176
, O 0 0.0011528351
and O 0 0.00048512022
, O 0 0.0005321169
presumably O 0 0.0007613084
, O 0 0.00065225054
other O 0 0.0007724573
opiates O 0 0.99881786
, O 0 0.00043016794
are O 0 0.00020494337
used O 0 0.0001912866
in O 0 0.00023343947
the O 0 0.00030996563
anesthetic O 0 0.012162227
management O 0 0.0005632256
of O 0 0.00074968854
patients O 0 0.0016625125
with O 0 0.002686992
ICP O 0 0.9962624
problems O 0 0.014719137
. O 0 0.006711624

Verapamil B-Chemical 0 0.9999769
withdrawal O 0 0.6621492
as O 0 0.0021637967
a O 0 0.001638662
possible O 0 0.001075881
cause O 0 0.0012945338
of O 0 0.005427509
myocardial B-Disease 0 0.9999889
infarction I-Disease 2 0.99999976
in O 0 0.0025004523
a O 0 0.0039511863
hypertensive B-Disease 2 0.9997894
woman O 0 0.006595671
with O 0 0.0010047916
a O 0 0.001523201
normal O 0 0.0031157637
coronary O 0 0.33046368
angiogram O 0 0.5360802
. O 0 0.007326325

Verapamil B-Chemical 0 0.9999256
is O 0 0.0057103103
an O 0 0.004036536
effective O 0 0.0030700674
and O 0 0.0030266016
relatively O 0 0.0043147127
- O 0 0.02255852
safe O 0 0.0108695505
antihypertensive O 0 0.9855466
drug O 0 0.5552193
. O 0 0.01089394

Serious O 0 0.3114174
adverse O 0 0.3705762
effects O 0 0.0030397272
are O 0 0.0013969144
uncommon O 0 0.0046885
and O 0 0.00077087985
mainly O 0 0.00059161754
have O 0 0.00033535316
been O 0 0.00029627103
related O 0 0.00018672663
to O 0 0.00020397898
the O 0 0.00032415142
depression B-Disease 0 0.9961054
of O 0 0.00047554343
cardiac O 0 0.099389255
contractility O 0 0.6468749
and O 0 0.0004001235
conduction O 0 0.0056648618
, O 0 0.00031974755
especially O 0 0.00027560157
when O 0 0.00015949454
the O 0 0.00025186426
drug O 0 0.061641738
is O 0 0.00039211352
combined O 0 0.0006654257
with O 0 0.001332473
beta O 0 0.9608986
- O 0 0.1696458
blocking O 0 0.012925837
agents O 0 0.08932572
. O 0 0.007479073

We O 0 0.003907931
report O 0 0.00364822
a O 0 0.002258206
case O 0 0.0015574598
in O 0 0.0011995285
which O 0 0.0052707335
myocardial B-Disease 0 0.99997973
infarction I-Disease 2 0.99999976
coincided O 0 0.023742646
with O 0 0.0006078757
the O 0 0.00027957215
introduction O 0 0.00028720326
of O 0 0.00131647
captopril B-Chemical 1 0.9999914
and O 0 0.00049652276
the O 0 0.00030401154
withdrawal O 0 0.16674778
of O 0 0.0015521861
verapamil B-Chemical 0 0.99999416
in O 0 0.00042284108
a O 0 0.0004982245
previously O 0 0.0005156993
asymptomatic O 0 0.059271835
woman O 0 0.013571619
with O 0 0.0031458654
severe O 0 0.8463633
hypertension B-Disease 2 0.99998593
. O 0 0.009085926

Possible O 0 0.006021589
mechanisms O 0 0.0022398399
that O 0 0.0014433956
involve O 0 0.0012259048
a O 0 0.004705618
verapamil B-Chemical 0 0.9999975
- O 0 0.079611115
related O 0 0.0003500381
increase O 0 0.0003141641
in O 0 0.00039648204
platelet O 0 0.39421198
and O 0 0.00047307851
/ O 0 0.0029751372
or O 0 0.00041954147
vascular O 0 0.77930725
alpha O 0 0.9303654
2 O 0 0.0013954882
- O 0 0.14775704
adrenoreceptor O 0 0.99988973
affinity O 0 0.009315689
for O 0 0.0019568643
catecholamines B-Chemical 1 0.9980148
are O 0 0.002390359
discussed O 0 0.0033507897
. O 0 0.0062933965

Haemolytic B-Disease 0 0.8532187
- I-Disease 0 0.1788721
uraemic I-Disease 0 0.9973889
syndrome I-Disease 0 0.49374717
after O 0 0.003682228
treatment O 0 0.0059503727
with O 0 0.010701377
metronidazole B-Chemical 1 0.99978584
. O 0 0.016373562

This O 0 0.0061055543
paper O 0 0.004051759
describes O 0 0.0023055892
the O 0 0.0013085975
clinical O 0 0.0017178962
features O 0 0.0008870536
of O 0 0.00063926267
six O 0 0.00038032496
children O 0 0.00068172376
who O 0 0.00061110355
developed O 0 0.0005841007
the O 0 0.0005960151
haemolytic B-Disease 0 0.9986846
- I-Disease 0 0.43235135
uraemic I-Disease 0 0.9993499
syndrome I-Disease 0 0.46684778
after O 0 0.0006828272
treatment O 0 0.0017163866
with O 0 0.004634542
metronidazole B-Chemical 1 0.9998312
. O 0 0.008778407

These O 0 0.0039327266
children O 0 0.0035743027
were O 0 0.0020100789
older O 0 0.0025991376
and O 0 0.0011324793
were O 0 0.0007836296
more O 0 0.00061309256
likely O 0 0.00041219647
to O 0 0.00031545467
have O 0 0.00028293795
undergone O 0 0.0003148309
recent O 0 0.00042086456
bowel O 0 0.06382645
surgery O 0 0.0007524058
than O 0 0.0002998747
are O 0 0.00041305594
other O 0 0.0005953347
children O 0 0.001275011
with O 0 0.0014043247
this O 0 0.002115494
condition O 0 0.0050652795
. O 0 0.0069511407

While O 0 0.0033829596
the O 0 0.002149478
involvement O 0 0.0022221028
of O 0 0.003105908
metronidazole B-Chemical 1 0.999931
in O 0 0.0009412488
the O 0 0.00056106976
aetiology O 0 0.02465009
of O 0 0.00063559937
the O 0 0.00082566176
haemolytic B-Disease 0 0.99956447
- I-Disease 0 0.64842004
uraemic I-Disease 0 0.99968874
syndrome I-Disease 0 0.6890826
is O 0 0.0002490088
not O 0 0.00015504504
established O 0 0.00024089975
firmly O 0 0.00034897472
, O 0 0.00026524978
the O 0 0.00015207898
action O 0 0.00025584342
of O 0 0.0002367711
this O 0 0.00024121325
drug O 0 0.15257116
in O 0 0.00022039948
sensitizing O 0 0.009047176
tissues O 0 0.0009510113
to O 0 0.00022827194
oxidation O 0 0.98169464
injury O 0 0.8858855
and O 0 0.00029306926
the O 0 0.0001569418
reported O 0 0.00018357248
evidence O 0 0.00012319411
of O 0 0.00035358538
oxidation O 0 0.94369674
changes O 0 0.00045669795
in O 0 0.00019045017
the O 0 0.00033875843
haemolytic B-Disease 0 0.9990195
- I-Disease 0 0.46762633
uraemic I-Disease 0 0.9992107
syndrome I-Disease 0 0.29506764
suggest O 0 0.000109762725
a O 0 0.0001824934
possible O 0 0.00014346697
link O 0 0.00013296925
between O 0 0.00020323155
metronidazole B-Chemical 1 0.99992204
treatment O 0 0.00060204015
and O 0 0.00034307785
some O 0 0.00028742678
cases O 0 0.00050547323
of O 0 0.00065168296
the O 0 0.0012229298
haemolytic B-Disease 0 0.99892175
- I-Disease 0 0.552182
uraemic I-Disease 0 0.9994985
syndrome I-Disease 0 0.84856343
. O 0 0.0075891265

Adverse O 0 0.038139615
cardiac O 0 0.017052494
effects O 0 0.0021764352
during O 0 0.0010587289
induction O 0 0.0011411922
chemotherapy O 0 0.037372645
treatment O 0 0.001127899
with O 0 0.0013771947
cis B-Chemical 0 0.8179604
- I-Chemical 0 0.23442079
platin I-Chemical 0 0.9890105
and O 0 0.0018648683
5 B-Chemical 0 0.0020251262
- I-Chemical 0 0.022965308
fluorouracil I-Chemical 0 0.99645954
. O 0 0.008203414

Survival O 0 0.0128406845
for O 0 0.0025798155
patients O 0 0.0020729348
with O 0 0.0013553674
advanced O 0 0.0069574607
head B-Disease 0 0.03952088
and I-Disease 0 0.001345387
neck I-Disease 0 0.64636534
carcinoma I-Disease 2 0.9999635
and O 0 0.012437366
esophageal B-Disease 0 0.99958736
carcinoma I-Disease 2 0.99999833
is O 0 0.0012420327
poor O 0 0.00207387
with O 0 0.0008628827
radiotherapy O 0 0.04809321
and O 0 0.0014048304
/ O 0 0.0046686423
or O 0 0.0027923167
surgery O 0 0.0065660872
. O 0 0.006981945

Obviously O 0 0.010041175
, O 0 0.0066906195
there O 0 0.0038612871
is O 0 0.0040989676
a O 0 0.004249705
need O 0 0.003650722
for O 0 0.004620073
effective O 0 0.0072121364
chemotherapy O 0 0.12524442
. O 0 0.013230059

In O 0 0.0035421671
the O 0 0.0021575822
present O 0 0.0014248223
study O 0 0.0016853516
, O 0 0.0022132797
cis B-Chemical 0 0.7639638
- I-Chemical 0 0.29262653
platin I-Chemical 0 0.9940177
( O 0 0.0013109846
80 O 0 0.0005958297
- O 0 0.001549273
120 O 0 0.00030337457
mg O 0 0.0049581453
/ O 0 0.0012538853
m2BSA O 0 0.0024440077
) O 0 0.00044716895
and O 0 0.0002755488
5 B-Chemical 0 0.00023733391
- I-Chemical 0 0.007035174
FU I-Chemical 0 0.36414665
( O 0 0.00039317453
1000 O 0 0.0003661662
mg O 0 0.007314579
/ O 0 0.0010849888
m2BSA O 0 0.0010960142
daily O 0 0.00018864954
as O 0 0.00014151658
a O 0 0.0001767207
continuous O 0 0.0001381148
infusion O 0 0.00024647807
during O 0 0.00011426372
5 O 0 0.00013916206
days O 0 0.0001405289
) O 0 0.00030435086
were O 0 0.00021992612
given O 0 0.00019262548
to O 0 0.00029496415
76 O 0 0.000631827
patients O 0 0.00067747204
before O 0 0.0006980347
radiotherapy O 0 0.007894569
and O 0 0.0024667552
surgery O 0 0.005505706
. O 0 0.0064246715

The O 0 0.0032801009
aim O 0 0.0024952271
of O 0 0.0018455673
the O 0 0.0012750856
study O 0 0.0011539343
was O 0 0.00067290437
to O 0 0.00041548265
clarify O 0 0.00024232986
the O 0 0.0003548108
incidence O 0 0.0010145183
and O 0 0.00052589574
severity O 0 0.0028276609
of O 0 0.0008581668
adverse O 0 0.49397486
cardiac O 0 0.0405304
effects O 0 0.001126415
to O 0 0.0011413133
this O 0 0.0019189506
treatment O 0 0.0039019145
. O 0 0.0064248233

Before O 0 0.004473493
treatment O 0 0.0029610628
all O 0 0.0017972112
patients O 0 0.0016625773
had O 0 0.0010159158
a O 0 0.0010613995
cardiac O 0 0.0063769873
evaluation O 0 0.00062800903
and O 0 0.0006263192
during O 0 0.0005039237
treatment O 0 0.00082318723
serial O 0 0.0014448361
ECG O 0 0.31784746
recordings O 0 0.0018651222
were O 0 0.0022134106
performed O 0 0.003382619
. O 0 0.0066426005

In O 0 0.0038854433
the O 0 0.0026644364
pre O 0 0.004568347
- O 0 0.005428145
treatment O 0 0.0011984018
evaluation O 0 0.0008730319
, O 0 0.00109131
signs O 0 0.031258233
of O 0 0.0013888618
cardiovascular B-Disease 0 0.9903233
disease I-Disease 0 0.92817736
were O 0 0.0005026356
found O 0 0.0003948463
in O 0 0.00049710664
33 O 0 0.00085853273
patients O 0 0.0010700077
( O 0 0.001579091
43 O 0 0.0024486564
% O 0 0.0032952556
) O 0 0.0060701934
. O 0 0.008011804

During O 0 0.0034145454
treatment O 0 0.0034288494
, O 0 0.0034929914
adverse O 0 0.35324353
cardiac O 0 0.047797944
effects O 0 0.0012462895
were O 0 0.0007433379
observed O 0 0.00060452934
in O 0 0.00072253746
14 O 0 0.0008644385
patients O 0 0.0012400857
( O 0 0.0017879249
18 O 0 0.002106969
% O 0 0.0035183611
) O 0 0.006520306
. O 0 0.008691181

The O 0 0.002923369
mean O 0 0.0016279502
age O 0 0.0020530692
of O 0 0.0013615463
these O 0 0.0011068782
patients O 0 0.0011119356
was O 0 0.0006445531
the O 0 0.00047709787
same O 0 0.00035962826
as O 0 0.0004339176
for O 0 0.0004922551
the O 0 0.0006068604
entire O 0 0.00077005243
group O 0 0.0013862348
, O 0 0.0020976062
64 O 0 0.0031908914
years O 0 0.004519338
. O 0 0.007174137

The O 0 0.0033683507
incidence O 0 0.0052701533
of O 0 0.005062219
cardiotoxicity B-Disease 0 0.9999945
was O 0 0.0017638784
not O 0 0.0006886101
higher O 0 0.0005171921
in O 0 0.00038418476
patients O 0 0.00047099654
with O 0 0.00037684402
signs O 0 0.031280905
of O 0 0.0010439547
cardiovascular B-Disease 0 0.9917955
disease I-Disease 0 0.9404569
than O 0 0.00024194893
in O 0 0.0002557427
those O 0 0.0003354374
without O 0 0.0003123218
in O 0 0.00042768425
the O 0 0.0006307891
pre O 0 0.002193384
- O 0 0.0039317305
treatment O 0 0.0022744993
evaluation O 0 0.0037011164
. O 0 0.006285254

The O 0 0.0035245186
most O 0 0.0029740965
common O 0 0.0023647498
signs O 0 0.023682939
of O 0 0.002871942
cardiotoxicity B-Disease 0 0.9999956
were O 0 0.0015952778
chest B-Disease 0 0.15079743
pain I-Disease 0 0.9751085
, O 0 0.0028979888
ST O 0 0.96711236
- O 0 0.045342874
T O 0 0.82253534
wave O 0 0.02750077
changes O 0 0.0021846094
and O 0 0.003291909
atrial B-Disease 0 0.97747815
fibrillation I-Disease 0 0.9999552
. O 0 0.0094725415

This O 0 0.005545229
was O 0 0.0028969792
followed O 0 0.0019137829
by O 0 0.0023063396
ventricular B-Disease 0 0.9435229
fibrillation I-Disease 0 0.99998593
in O 0 0.0013347022
one O 0 0.00093137595
patient O 0 0.0011911443
and O 0 0.0024966316
sudden B-Disease 0 0.9997905
death I-Disease 0 0.9999548
in O 0 0.005059204
another O 0 0.0059543364
. O 0 0.008205766

It O 0 0.004638272
is O 0 0.002514918
concluded O 0 0.0016458615
that O 0 0.0010309904
patients O 0 0.0010721311
on O 0 0.0005198923
5 B-Chemical 0 0.00062064495
- I-Chemical 0 0.014566567
FU I-Chemical 0 0.38715523
treatment O 0 0.0004048827
should O 0 0.00017750615
be O 0 0.00019022115
under O 0 0.00015571191
close O 0 0.0002007035
supervision O 0 0.0005790976
and O 0 0.00023072661
that O 0 0.00016073314
the O 0 0.0001958582
treatment O 0 0.00025025115
should O 0 0.00015369877
be O 0 0.00023682778
discontinued O 0 0.00092194387
if O 0 0.00031917894
chest B-Disease 0 0.025082503
pain I-Disease 0 0.8518843
or O 0 0.0013423631
tachyarrhythmia B-Disease 0 0.99951124
is O 0 0.002754207
observed O 0 0.0034832438
. O 0 0.0067603793

Death B-Disease 0 0.55390906
from O 0 0.009063379
chemotherapy O 0 0.032494016
in O 0 0.00936456
gestational B-Disease 0 0.25319573
trophoblastic I-Disease 0 0.99627703
disease I-Disease 0 0.98825574
. O 0 0.02190677

Multiple O 0 0.008586691
cytotoxic O 0 0.41362643
drug O 0 0.6232574
administration O 0 0.044759795
is O 0 0.0011031812
the O 0 0.0006656284
generally O 0 0.0006897262
accepted O 0 0.0007311507
treatment O 0 0.00044796063
of O 0 0.00047065972
patients O 0 0.0006149163
with O 0 0.00048046577
a O 0 0.00069509866
high O 0 0.0013446625
- O 0 0.01567209
risk O 0 0.09151898
stage O 0 0.012077436
of O 0 0.014640634
choriocarcinoma B-Disease 0 0.999895
. O 0 0.012716479

Based O 0 0.005807478
on O 0 0.0018707251
this O 0 0.0015672782
principle O 0 0.0013265527
a O 0 0.001295127
27 O 0 0.001373843
- O 0 0.0021411616
year O 0 0.0005196208
old O 0 0.0005089217
woman O 0 0.0016226905
, O 0 0.0004937626
classified O 0 0.00033087994
as O 0 0.00022609674
being O 0 0.00033864574
in O 0 0.00019150486
the O 0 0.00021476136
high O 0 0.00074236246
- O 0 0.025514279
risk O 0 0.07909405
group O 0 0.0007614111
( O 0 0.00085839495
Goldstein O 0 0.16300307
and O 0 0.00041800074
Berkowitz O 0 0.1783661
score O 0 0.00027215356
: O 0 0.00048559444
11 O 0 0.00033906556
) O 0 0.0005813385
, O 0 0.0005390707
was O 0 0.00048145
treated O 0 0.0006514551
with O 0 0.0009424679
multiple O 0 0.002125579
cytotoxic O 0 0.36390382
drugs O 0 0.5333262
. O 0 0.0073290896

The O 0 0.0031198557
multiple O 0 0.0027447306
drug O 0 0.062020015
schema O 0 0.002314307
consisted O 0 0.0007441612
of O 0 0.0010111255
: O 0 0.007487867
Etoposide B-Chemical 0 0.99997413
16 O 0 0.0009034412
. O 0 0.0004419363
213 O 0 0.0068188827
, O 0 0.0015234083
Methotrexate B-Chemical 0 0.99989927
, O 0 0.010725373
Cyclophosphamide B-Chemical 0 0.99998367
, O 0 0.011655301
Actomycin B-Chemical 0 0.98801595
- I-Chemical 0 0.2749573
D I-Chemical 0 0.99822265
, O 0 0.0065884483
and O 0 0.008453793
Cisplatin B-Chemical 0 0.99983454
. O 0 0.00980195

On O 0 0.0032142298
the O 0 0.0021073965
first O 0 0.0013112294
day O 0 0.0009769985
of O 0 0.00089881883
the O 0 0.0006499623
schedule O 0 0.00065818505
, O 0 0.0008089742
moderate O 0 0.004773854
high O 0 0.0007362233
doses O 0 0.005341576
of O 0 0.0040525324
Methotrexate B-Chemical 0 0.9999833
, O 0 0.043058783
Etoposide B-Chemical 0 0.9999901
and O 0 0.014231098
Cyclophosphamide B-Chemical 0 0.9999299
were O 0 0.0025890206
administered O 0 0.0035717764
. O 0 0.0059227087

Within O 0 0.002892184
8 O 0 0.002080524
hours O 0 0.0012432956
after O 0 0.0007742602
initiation O 0 0.00085246353
of O 0 0.0007970261
therapy O 0 0.0009998498
the O 0 0.0004127308
patient O 0 0.00041390612
died O 0 0.00074837444
with O 0 0.00029646713
a O 0 0.00031706924
clinical O 0 0.0006126574
picture O 0 0.00026220584
resembling O 0 0.00042540478
massive O 0 0.024887836
pulmonary B-Disease 0 0.98866266
obstruction I-Disease 0 0.9557478
due O 0 0.0002014662
to O 0 0.00023959912
choriocarcinomic O 0 0.0066346857
tissue O 0 0.0019852973
plugs O 0 0.0014146604
, O 0 0.00069793523
probably O 0 0.000795714
originating O 0 0.00087543635
from O 0 0.001297288
the O 0 0.0023576454
uterus O 0 0.021839982
. O 0 0.007068526

Formation O 0 0.00960722
of O 0 0.002984392
these O 0 0.0021045145
plugs O 0 0.0031802047
was O 0 0.001090217
probably O 0 0.0008527438
due O 0 0.0004069855
to O 0 0.00037600705
extensive O 0 0.0006513011
tumor B-Disease 0 0.9740965
necrosis B-Disease 2 0.99992824
at O 0 0.00035637012
the O 0 0.00021979364
level O 0 0.00016528089
of O 0 0.00023152564
the O 0 0.00021105986
walls O 0 0.011369006
of O 0 0.0002440582
the O 0 0.00019504789
major O 0 0.0003814599
uterine O 0 0.24527392
veins O 0 0.30170387
, O 0 0.00040058015
which O 0 0.00023638744
resulted O 0 0.00014773518
in O 0 0.0001694143
an O 0 0.0002077234
open O 0 0.00023858105
exchange O 0 0.00024305134
of O 0 0.0002890812
tumor B-Disease 0 0.7830618
plugs O 0 0.0014601195
to O 0 0.00013950939
the O 0 0.00018270861
vascular O 0 0.19395173
spaces O 0 0.0015635742
; O 0 0.00043496667
decrease O 0 0.00018541145
in O 0 0.00023500448
tumor B-Disease 0 0.7913673
tissue O 0 0.010387093
coherence O 0 0.03890303
secondary O 0 0.0042665144
to O 0 0.00023399791
chemotherapy O 0 0.010483618
may O 0 0.00020007067
have O 0 0.00020002796
further O 0 0.00025515648
contributed O 0 0.00043795185
to O 0 0.00040017138
the O 0 0.00061577454
formation O 0 0.002270878
of O 0 0.0028075392
tumor B-Disease 0 0.977808
emboli O 0 0.99436414
. O 0 0.008426872

In O 0 0.0034791946
view O 0 0.0025412703
of O 0 0.0016795298
the O 0 0.0009882776
close O 0 0.00067307474
time O 0 0.00041307107
association O 0 0.00036519373
between O 0 0.00026980875
the O 0 0.00027321532
start O 0 0.0002330552
of O 0 0.00035246782
chemotherapy O 0 0.022523409
and O 0 0.00031805714
the O 0 0.0002789119
acute O 0 0.54456633
onset O 0 0.0031447741
of O 0 0.0009174634
massive O 0 0.40436363
embolism B-Disease 0 0.9999908
other O 0 0.00038258813
explanations O 0 0.0001586754
, O 0 0.00031135528
such O 0 0.0002289662
as O 0 0.00032763928
spontaneous O 0 0.028467482
necrosis B-Disease 2 0.9998622
, O 0 0.0015366033
must O 0 0.00052096474
be O 0 0.00084782264
considered O 0 0.0011593148
less O 0 0.0020390362
likely O 0 0.0035244178
. O 0 0.006311996

Patients O 0 0.0041991267
with O 0 0.0023437098
large O 0 0.0022708005
pelvic B-Disease 0 0.7316651
tumor I-Disease 0 0.9958762
loads O 0 0.016964376
are O 0 0.00071277947
, O 0 0.0005950485
according O 0 0.00027403788
to O 0 0.00024116308
existing O 0 0.00030533204
classifications O 0 0.00033617695
, O 0 0.00036471742
at O 0 0.00026808816
high O 0 0.0004947949
risk O 0 0.00939247
to O 0 0.00044397198
die O 0 0.0009025287
and O 0 0.0008313689
to O 0 0.0009594786
develop O 0 0.0018969533
drug O 0 0.31135875
resistance O 0 0.018117687
. O 0 0.007406946

Notwithstanding O 0 0.0043720384
these O 0 0.0024798205
facts O 0 0.002687235
our O 0 0.0011862568
findings O 0 0.00095919333
suggest O 0 0.00045433082
that O 0 0.0004274197
these O 0 0.00048859423
patients O 0 0.00054396945
might O 0 0.00022179143
benefit O 0 0.0002509601
from O 0 0.00019691353
relatively O 0 0.00042826275
mild O 0 0.15366094
initial O 0 0.00023456618
treatment O 0 0.00044074442
, O 0 0.00042786976
especially O 0 0.00041419922
true O 0 0.000352524
for O 0 0.00027862377
patients O 0 0.00046320015
not O 0 0.00036942016
previously O 0 0.00055434514
exposed O 0 0.0009147392
to O 0 0.0011730426
this O 0 0.002237885
drug O 0 0.21673028
. O 0 0.0067267125

Close O 0 0.008152546
observation O 0 0.0024934832
of O 0 0.0017815686
the O 0 0.0011091063
response O 0 0.0011271627
status O 0 0.0010929592
both O 0 0.0005651394
clinically O 0 0.0076873926
and O 0 0.000515717
with O 0 0.0014690323
beta O 0 0.9973809
- O 0 0.83276415
hCG O 0 0.994819
values O 0 0.00031658928
may O 0 0.00017339543
indicate O 0 0.00011312311
whether O 0 9.8286284e-05
and O 0 0.0001892872
when O 0 0.00014517075
more O 0 0.00027132346
agressive O 0 0.044929087
combination O 0 0.00046202753
chemotherapy O 0 0.013662591
should O 0 0.00019893468
be O 0 0.0003221885
started O 0 0.0004708585
. O 0 0.0006337917
( O 0 0.0015610007
ABSTRACT O 0 0.006893655
TRUNCATED O 0 0.0064918334
AT O 0 0.01242003
250 O 0 0.0054501123
WORDS O 0 0.010329535
) O 0 0.016819095

Pulmonary O 0 0.036010083
shunt O 0 0.009459929
and O 0 0.0036170029
cardiovascular O 0 0.701609
responses O 0 0.0031803618
to O 0 0.0021507854
CPAP O 0 0.98477423
during O 0 0.0030972695
nitroprusside B-Chemical 1 0.99999857
- O 0 0.20366243
induced O 0 0.01625663
hypotension B-Disease 2 0.99996316
. O 0 0.011875421

The O 0 0.0029336321
effects O 0 0.0021903215
of O 0 0.0015058984
continuous O 0 0.0009673471
positive O 0 0.0011927856
airway O 0 0.07582923
pressure O 0 0.6279025
( O 0 0.006909188
CPAP O 0 0.9823715
) O 0 0.00076540455
on O 0 0.00022854217
cardiovascular O 0 0.4948795
dynamics O 0 0.0003906137
and O 0 0.0003665109
pulmonary O 0 0.3661421
shunt O 0 0.026816253
( O 0 0.0010505089
QS O 0 0.19784297
/ O 0 0.013744259
QT O 0 0.8684091
) O 0 0.00041267514
were O 0 0.00015301457
investigated O 0 0.000117232594
in O 0 0.00014416498
12 O 0 0.000121857775
dogs O 0 0.00017812382
before O 0 0.000100336125
and O 0 0.00018959753
during O 0 0.0002621893
sodium B-Chemical 1 0.9999969
nitroprusside I-Chemical 1 1.0
infusion O 0 0.0038224475
that O 0 0.00015522685
decreased O 0 0.00022902733
mean O 0 0.00018200857
arterial O 0 0.0722101
blood O 0 0.0049738376
pressure O 0 0.009422557
40 O 0 0.0006617283
- O 0 0.0015856881
50 O 0 0.0012575004
per O 0 0.0013931717
cent O 0 0.0032885328
. O 0 0.006072763

Before O 0 0.008434146
nitroprusside B-Chemical 1 0.9999914
infusion O 0 0.034671403
, O 0 0.0018664588
5 O 0 0.00084195
cm O 0 0.0022533478
H2O B-Chemical 1 0.9993062
CPAP O 0 0.9838991
significantly O 0 0.0007831865
, O 0 0.0009105348
P O 0 0.055221297
less O 0 0.0003484941
than O 0 0.00024594614
. O 0 0.0003182837
05 O 0 0.007915937
, O 0 0.00040433233
decreased O 0 0.0004606327
arterial O 0 0.3447017
blood O 0 0.030765949
pressure O 0 0.08634465
, O 0 0.0004690697
but O 0 0.00032306914
did O 0 0.00022625829
not O 0 0.00016316914
significantly O 0 0.00021071482
alter O 0 0.00019384094
heart O 0 0.039151926
rate O 0 0.00033479236
, O 0 0.00053536554
cardiac O 0 0.022036416
output O 0 0.0005374254
, O 0 0.0007072951
systemic O 0 0.6472914
vascular O 0 0.662809
resistance O 0 0.013537013
, O 0 0.0016199598
or O 0 0.001591954
QS O 0 0.26154843
/ O 0 0.04685522
QT O 0 0.91065633
. O 0 0.0075225257

Ten O 0 0.004814345
cm O 0 0.008449334
H2O B-Chemical 1 0.99900085
CPAP O 0 0.98757124
before O 0 0.0018123896
nitroprusside B-Chemical 1 0.9999969
infusion O 0 0.005495765
produced O 0 0.00044482682
a O 0 0.00046787315
further O 0 0.00030451687
decrease B-Disease 0 0.00031516934
in I-Disease 0 0.00035741672
arterial I-Disease 0 0.3517073
blood I-Disease 0 0.017367817
pressure I-Disease 0 0.022150574
and O 0 0.00026631152
significantly O 0 0.00025065665
increased O 0 0.00033738418
heart O 0 0.02889074
rate O 0 0.00036920153
and O 0 0.00048606427
decreased B-Disease 0 0.0013333458
cardiac I-Disease 0 0.034780152
output I-Disease 0 0.001803515
and O 0 0.0017095528
QS O 0 0.20262326
/ O 0 0.038049083
QT O 0 0.9046361
. O 0 0.0074752555

Nitroprusside B-Chemical 0 0.9998573
caused O 0 0.0034246282
significant O 0 0.0021214373
decreases B-Disease 0 0.0014339178
in I-Disease 0 0.0011081912
arterial I-Disease 0 0.45659018
blood I-Disease 0 0.02864454
pressure I-Disease 0 0.054038662
and O 0 0.00055201835
systemic O 0 0.6619333
vascular O 0 0.65346634
resistance O 0 0.005751302
and O 0 0.00036721877
increases O 0 0.0002567542
in O 0 0.0002999344
heart O 0 0.06372255
rate O 0 0.0004016577
, O 0 0.0005696736
but O 0 0.00041214618
did O 0 0.0003333201
not O 0 0.00030825872
change O 0 0.00053062005
cardiac O 0 0.013921839
output O 0 0.0010803754
or O 0 0.0013659755
QS O 0 0.18669854
/ O 0 0.039354265
QT O 0 0.9073566
. O 0 0.0075441487

Five O 0 0.005398434
cm O 0 0.009012014
H2O B-Chemical 1 0.9988423
CPAP O 0 0.98685557
during O 0 0.0026302678
nitroprusside B-Chemical 1 0.9999975
did O 0 0.0013409511
not O 0 0.00062594446
further O 0 0.0005622287
alter O 0 0.00052292715
any O 0 0.00054860447
of O 0 0.00074617757
the O 0 0.0008514609
above O 0 0.001110636
- O 0 0.0040791007
mentioned O 0 0.0020724693
variables O 0 0.0044725477
. O 0 0.0072462903

However O 0 0.0047643753
, O 0 0.0035670006
10 O 0 0.0021210276
cm O 0 0.004369863
H2O B-Chemical 1 0.99893934
CPAP O 0 0.9810524
decreased O 0 0.0020291738
arterial O 0 0.32053846
blood O 0 0.01758488
pressure O 0 0.04221028
, O 0 0.00113758
cardiac O 0 0.011876023
output O 0 0.0012661391
, O 0 0.0016071353
and O 0 0.0021508518
QS O 0 0.15285714
/ O 0 0.03149083
QT O 0 0.88939357
. O 0 0.008861616

These O 0 0.0036905715
data O 0 0.0024881174
indicate O 0 0.0013138183
that O 0 0.0017397054
nitroprusside B-Chemical 1 0.999998
infusion O 0 0.012356765
rates O 0 0.0005925809
that O 0 0.00030967582
decrease O 0 0.00029032276
mean O 0 0.00021056778
arterial O 0 0.11193239
blood O 0 0.006192292
pressure O 0 0.009606735
by O 0 0.0002359009
40 O 0 0.00026327145
- O 0 0.0007018677
50 O 0 0.00023086127
per O 0 0.00015343317
cent O 0 0.00022650907
do O 0 0.00026328326
not O 0 0.00029659152
change O 0 0.0005031696
cardiac O 0 0.0073408876
output O 0 0.0010788367
or O 0 0.0014037573
QS O 0 0.16777755
/ O 0 0.036790445
QT O 0 0.90354234
. O 0 0.007735791

During O 0 0.0045817737
nitroprusside B-Chemical 1 0.9999895
infusion O 0 0.024419427
low O 0 0.0017681943
levels O 0 0.0009467234
of O 0 0.0015627082
CPAP O 0 0.98150945
do O 0 0.00047559108
not O 0 0.00030211214
markedly O 0 0.00057456625
alter O 0 0.0003172343
cardiovascular O 0 0.8917877
dynamics O 0 0.00081997627
, O 0 0.0005920443
but O 0 0.00029683733
high O 0 0.00029066755
levels O 0 0.00020754046
of O 0 0.0006007699
CPAP O 0 0.98146534
( O 0 0.00039452335
10 O 0 0.00017306952
cm O 0 0.00073100114
H2O B-Chemical 1 0.9979539
) O 0 0.000924297
, O 0 0.00035392324
while O 0 0.0002522346
decreasing O 0 0.00043887337
QS O 0 0.28399378
/ O 0 0.023806874
QT O 0 0.88362217
, O 0 0.00036313751
produce O 0 0.00019849892
marked O 0 0.00044880813
decreases B-Disease 0 0.00037273607
in I-Disease 0 0.0004781051
arterial I-Disease 0 0.21851005
blood I-Disease 0 0.01056504
pressure I-Disease 0 0.014848443
and I-Disease 0 0.0015714323
cardiac I-Disease 0 0.020933747
output I-Disease 0 0.0042745713
. O 0 0.006339204

Systolic O 0 0.8000859
pressure O 0 0.0763577
variation O 0 0.0025675392
is O 0 0.0014775052
greater O 0 0.0010522557
during O 0 0.0009367071
hemorrhage B-Disease 2 0.9999131
than O 0 0.0006194772
during O 0 0.00089520874
sodium B-Chemical 1 0.9999974
nitroprusside I-Chemical 1 1.0
- O 0 0.36478528
induced O 0 0.0058592465
hypotension B-Disease 2 0.99998033
in O 0 0.002487895
ventilated O 0 0.040835872
dogs O 0 0.007007169
. O 0 0.0066830656

The O 0 0.0037280507
systolic O 0 0.35046193
pressure O 0 0.1390693
variation O 0 0.0026391475
( O 0 0.0035804145
SPV O 0 0.95781314
) O 0 0.0027082206
, O 0 0.0008863912
which O 0 0.00055384974
is O 0 0.0003323209
the O 0 0.00023414899
difference O 0 0.00015310972
between O 0 0.00014358603
the O 0 0.00016985992
maximal O 0 0.00016743275
and O 0 0.00020351891
minimal O 0 0.00015905805
values O 0 0.00016224897
of O 0 0.0002197337
the O 0 0.00023897241
systolic O 0 0.6480357
blood O 0 0.027084416
pressure O 0 0.077556334
( O 0 0.0007128684
SBP O 0 0.55213016
) O 0 0.00031787076
after O 0 0.00011674923
one O 0 0.00015220752
positive O 0 0.00038589802
- O 0 0.013459162
pressure O 0 0.10210232
breath O 0 0.0725457
, O 0 0.00046616435
was O 0 0.00033502578
studied O 0 0.00040596098
in O 0 0.0005084509
ventilated O 0 0.002253973
dogs O 0 0.0011741057
subjected O 0 0.0011210275
to O 0 0.0026053654
hypotension B-Disease 2 0.99986315
. O 0 0.007502624

Mean O 0 0.0028994984
arterial O 0 0.09974297
pressure O 0 0.04123504
was O 0 0.0012577076
decreased O 0 0.0008733278
to O 0 0.0005274407
50 O 0 0.0005637626
mm O 0 0.0017075058
Hg O 0 0.9389626
for O 0 0.0002744125
30 O 0 0.00019333998
minutes O 0 0.00016304175
either O 0 0.00019904567
by O 0 0.00044553005
hemorrhage B-Disease 2 0.9999926
( O 0 0.03856263
HEM B-Disease 0 0.99998605
, O 0 0.00058874115
n O 0 0.00023612118
= O 0 0.00046194854
7 O 0 0.00018200997
) O 0 0.00028311386
or O 0 0.00017339311
by O 0 0.00019103834
continuous O 0 0.00018884912
infusion O 0 0.0006437598
of O 0 0.0018106004
sodium B-Chemical 1 0.99999845
nitroprusside I-Chemical 1 1.0
( O 0 0.044400882
SNP B-Chemical 1 0.993079
, O 0 0.0012530067
n O 0 0.0010942166
= O 0 0.0023316217
7 O 0 0.0023325647
) O 0 0.0052185166
. O 0 0.007424493

During O 0 0.0057235616
HEM B-Disease 0 0.99991655
- O 0 0.11459874
induced O 0 0.0053480477
hypotension B-Disease 2 0.99998546
the O 0 0.0014895293
cardiac O 0 0.08689889
output O 0 0.00083305326
was O 0 0.0003818823
significantly O 0 0.0003133155
lower O 0 0.00028362664
and O 0 0.00040217457
systemic O 0 0.63110703
vascular O 0 0.63592273
resistance O 0 0.005114637
higher O 0 0.000323002
compared O 0 0.0002503724
with O 0 0.00041295294
that O 0 0.0005082072
in O 0 0.0009396055
the O 0 0.0018236361
SNP B-Chemical 1 0.9705344
group O 0 0.0056709507
. O 0 0.006904914

The O 0 0.004015128
systemic O 0 0.31509903
, O 0 0.0032951413
central O 0 0.0029884297
venous O 0 0.3984125
, O 0 0.0016760022
pulmonary O 0 0.41364717
capillary O 0 0.21506228
wedge O 0 0.42862868
pressures O 0 0.0049164323
, O 0 0.00064974
and O 0 0.0005471348
heart O 0 0.024734046
rates O 0 0.0005695346
, O 0 0.00064928347
were O 0 0.00052655215
similar O 0 0.00053624343
in O 0 0.0008499917
the O 0 0.0012483281
two O 0 0.0018054114
groups O 0 0.003531173
. O 0 0.00653138

Analysis O 0 0.0047646877
of O 0 0.003096301
the O 0 0.0022001853
respiratory O 0 0.030080352
changes O 0 0.0016883003
in O 0 0.0008957248
the O 0 0.00081079983
arterial O 0 0.14243118
pressure O 0 0.020959327
waveform O 0 0.0011383595
enabled O 0 0.0007816137
differentiation O 0 0.0025019348
between O 0 0.0008850746
the O 0 0.001420844
two O 0 0.0019526752
groups O 0 0.0037037618
. O 0 0.0067206044

The O 0 0.004483789
SPV O 0 0.6125523
during O 0 0.0024564902
hypotension B-Disease 2 0.99992824
was O 0 0.0011979687
15 O 0 0.00061499537
. O 0 0.0004805766
7 O 0 0.00041707218
+ O 0 0.0010421367
/ O 0 0.0055442406
- O 0 0.0049514314
6 O 0 0.0002418396
. O 0 0.00021386104
7 O 0 0.00019719872
mm O 0 0.0007642173
Hg O 0 0.95691425
in O 0 0.00029209015
the O 0 0.00052767905
HEM B-Disease 0 0.9999565
group O 0 0.00053269725
, O 0 0.00027069304
compared O 0 0.00012411276
with O 0 0.00018133664
9 O 0 0.00016794569
. O 0 0.00015638415
1 O 0 0.00019128989
+ O 0 0.0008392611
/ O 0 0.008363649
- O 0 0.008382181
2 O 0 0.0002007831
. O 0 0.00016428255
0 O 0 0.00020362878
mm O 0 0.0008116667
Hg O 0 0.9446092
in O 0 0.0002678061
the O 0 0.00038206292
SNP B-Chemical 1 0.97482103
group O 0 0.00072196714
( O 0 0.0008967564
P O 0 0.0186413
less O 0 0.00058914674
than O 0 0.0006471869
0 O 0 0.0012744962
. O 0 0.0019098133
02 O 0 0.017580211
) O 0 0.0059256065
. O 0 0.007822526

The O 0 0.0037845257
delta O 0 0.08985552
down O 0 0.0024686228
, O 0 0.0022290281
which O 0 0.0013302534
is O 0 0.0007338962
the O 0 0.00046990011
measure O 0 0.00027716972
of O 0 0.00040887
decrease O 0 0.00036968672
of O 0 0.0006226446
SBP O 0 0.604207
after O 0 0.00017046626
a O 0 0.00026960432
mechanical O 0 0.00067234214
breath O 0 0.07568737
, O 0 0.00034801156
was O 0 0.00018869145
20 O 0 0.00016321162
. O 0 0.00014965277
3 O 0 0.00015881997
+ O 0 0.00066005444
/ O 0 0.0068525793
- O 0 0.008164253
8 O 0 0.00018681354
. O 0 0.00015010238
4 O 0 0.00013385071
and O 0 0.0001594346
10 O 0 0.00015822862
. O 0 0.00015873258
1 O 0 0.00019461615
+ O 0 0.0008278881
/ O 0 0.0086582005
- O 0 0.008220455
3 O 0 0.00017762027
. O 0 0.00015545139
8 O 0 0.0001592927
mm O 0 0.0006659955
Hg O 0 0.952043
in O 0 0.00024819103
the O 0 0.0004817927
HEM B-Disease 0 0.999969
and O 0 0.0017171924
SNP B-Chemical 1 0.99340993
groups O 0 0.00042068507
, O 0 0.00046293152
respectively O 0 0.0016748498
, O 0 0.0005077075
during O 0 0.00037491464
hypotension B-Disease 2 0.9999826
( O 0 0.0018877498
P O 0 0.045349814
less O 0 0.0005594432
than O 0 0.00060877437
0 O 0 0.0012100597
. O 0 0.0018213202
02 O 0 0.017969321
) O 0 0.0057429313
. O 0 0.007609159

It O 0 0.0047840346
is O 0 0.0026249106
concluded O 0 0.0017455964
that O 0 0.0011016468
increases O 0 0.0009544143
in O 0 0.0007986207
the O 0 0.00080726744
SPV O 0 0.8572035
and O 0 0.0005682094
the O 0 0.00040925757
delta O 0 0.06402014
down O 0 0.00037133464
are O 0 0.00026724167
characteristic O 0 0.00034906482
of O 0 0.0004228919
a O 0 0.0007506833
hypotensive B-Disease 0 0.9890766
state O 0 0.00044039672
due O 0 0.00031210182
to O 0 0.000438751
a O 0 0.00078144955
predominant O 0 0.0011731432
decrease O 0 0.0015867422
in O 0 0.0028634665
preload O 0 0.780181
. O 0 0.0073505086

They O 0 0.0061963536
are O 0 0.0032626293
thus O 0 0.0028459243
more O 0 0.002072211
important O 0 0.001379103
during O 0 0.0013100266
absolute O 0 0.0023927917
hypovolemia B-Disease 0 0.99965954
than O 0 0.0017226811
during O 0 0.002372632
deliberate O 0 0.37402976
hypotension B-Disease 2 0.9999417
. O 0 0.010403286

Ventricular B-Disease 0 0.9929381
tachyarrhythmias I-Disease 0 0.9999629
during O 0 0.0022988317
cesarean O 0 0.0031571307
section O 0 0.0013524881
after O 0 0.0013283936
ritodrine B-Chemical 0 0.9998037
therapy O 0 0.004444194
: O 0 0.0026580212
interaction O 0 0.0026505901
with O 0 0.005704203
anesthetics O 0 0.9634073
. O 0 0.008737496

This O 0 0.0048126476
case O 0 0.0023827155
illustrates O 0 0.0012628669
that O 0 0.0009671223
patients O 0 0.0016044788
receiving O 0 0.0058053276
ritodrine B-Chemical 0 0.9999722
for O 0 0.001644635
preterm B-Disease 0 0.99651057
labor I-Disease 0 0.93601704
may O 0 0.00039274918
risk O 0 0.030823987
interactions O 0 0.0004199296
between O 0 0.00014840114
the O 0 0.00020246794
residual O 0 0.0004509651
betamimetic O 0 0.5888589
effects O 0 0.00057691574
of O 0 0.0020936052
ritodrine B-Chemical 0 0.9999652
and O 0 0.0004944375
the O 0 0.0003465756
effects O 0 0.00057516707
of O 0 0.0010163322
anesthetics O 0 0.84036875
during O 0 0.0009839818
cesarean O 0 0.0038037968
section O 0 0.0029734513
. O 0 0.00585084

Such O 0 0.0052614408
interactions O 0 0.0035454268
may O 0 0.0019086538
result O 0 0.0013949821
in O 0 0.0014628897
serious O 0 0.37692034
cardiovascular B-Disease 0 0.9998288
complications I-Disease 0 0.9918052
even O 0 0.001088836
after O 0 0.00051857234
cessation O 0 0.0029301695
of O 0 0.0010638934
an O 0 0.0015731653
infusion O 0 0.006355167
of O 0 0.0066829193
ritodrine B-Chemical 0 0.9998783
. O 0 0.009080342

Preoperative O 0 0.0067623034
assessment O 0 0.0030608883
should O 0 0.0018693588
focus O 0 0.0020371228
on O 0 0.0016110382
cardiovascular O 0 0.6619729
status O 0 0.003451166
and O 0 0.0035381904
serum O 0 0.7868498
potassium B-Chemical 0 0.9998499
level O 0 0.0065086684
. O 0 0.010007314

Delaying O 0 0.009387077
induction O 0 0.00529029
of O 0 0.005234515
anesthesia O 0 0.017218359
should O 0 0.0025204818
be O 0 0.0032085427
considered O 0 0.0034460188
whenever O 0 0.0050418866
possible O 0 0.007918855
. O 0 0.012315081

Careful O 0 0.0052920436
fluid O 0 0.0064480864
administration O 0 0.0054359385
and O 0 0.0020076118
cautious O 0 0.002118516
use O 0 0.0012103583
of O 0 0.0013267706
titrated O 0 0.0021125688
doses O 0 0.014583572
of O 0 0.0076297224
ephedrine B-Chemical 1 0.99996984
are O 0 0.004033753
advised O 0 0.008983072
. O 0 0.007987745

After O 0 0.0026730467
delivery O 0 0.0022776632
of O 0 0.0017818399
the O 0 0.0012781722
infant O 0 0.0043368707
, O 0 0.0011169912
there O 0 0.00040445873
should O 0 0.0002753098
be O 0 0.00029167888
no O 0 0.00021045217
contraindication O 0 0.00024513612
to O 0 0.00018031093
the O 0 0.00019110322
use O 0 0.00020375192
of O 0 0.0003091782
an O 0 0.0010061911
alpha O 0 0.9812806
- O 0 0.757106
adrenergic O 0 0.9974801
vasopressor O 0 0.850698
such O 0 0.00031583622
as O 0 0.00057095423
phenylephrine B-Chemical 0 0.99993515
to O 0 0.0005610245
treat O 0 0.0028495505
hypotensive B-Disease 0 0.9972173
patients O 0 0.0027053514
with O 0 0.003944792
tachycardia B-Disease 2 0.99917775
. O 0 0.006802739

Verapamil B-Chemical 0 0.9999658
- O 0 0.51510173
induced O 0 0.25675204
carbamazepine B-Chemical 1 0.99999833
neurotoxicity B-Disease 2 0.9999726
. O 0 0.044460718

A O 0 0.043366887
report O 0 0.022996295
of O 0 0.019531604
two O 0 0.01825229
cases O 0 0.028398536
. O 0 0.032842528

Two O 0 0.0036701579
patients O 0 0.002666632
with O 0 0.001891077
signs O 0 0.150883
of O 0 0.04849805
carbamazepine B-Chemical 1 1.0
neurotoxicity B-Disease 2 0.9999974
after O 0 0.0004056399
combined O 0 0.0005882964
treatment O 0 0.000540389
with O 0 0.0011407508
verapamil B-Chemical 0 0.99999154
showed O 0 0.0003024908
complete O 0 0.00022184727
recovery O 0 0.00037625982
after O 0 0.0002473451
discontinuation O 0 0.0733784
of O 0 0.0006937601
the O 0 0.0011740933
calcium B-Chemical 0 0.99598557
entry O 0 0.03728649
blocker O 0 0.967229
. O 0 0.0075476984

Use O 0 0.009858738
of O 0 0.006112576
verapamil B-Chemical 0 0.99998
in O 0 0.0021388717
combination O 0 0.0028060968
with O 0 0.010897238
carbamazepine B-Chemical 1 0.99999976
should O 0 0.0003227373
either O 0 0.0002651992
be O 0 0.0002348562
avoided O 0 0.00021904403
or O 0 0.0002223648
prescribed O 0 0.00072673574
only O 0 0.00018134339
with O 0 0.00017072343
appropriate O 0 0.00013616092
adjustment O 0 0.00025573222
of O 0 0.00031295608
the O 0 0.0013820225
carbamazepine B-Chemical 1 0.99999976
dose O 0 0.022893285
( O 0 0.0006788309
usually O 0 0.00033286092
reduction O 0 0.0004168168
of O 0 0.00048015392
the O 0 0.0013691945
carbamazepine B-Chemical 1 0.9999994
dose O 0 0.0075821197
by O 0 0.0009344634
one O 0 0.001129755
half O 0 0.001612268
) O 0 0.004447797
. O 0 0.0062815268

Paracetamol B-Chemical 0 0.9999875
- O 0 0.24289136
associated O 0 0.013537457
coma B-Disease 0 0.9999504
, O 0 0.023220077
metabolic B-Disease 2 0.991435
acidosis I-Disease 2 0.9999945
, O 0 0.02068772
renal B-Disease 0 0.9444518
and I-Disease 0 0.0057930597
hepatic I-Disease 0 0.96014124
failure I-Disease 0 0.8466893
. O 0 0.010970529

A O 0 0.06522033
case O 0 0.003912545
of O 0 0.004365772
metabolic B-Disease 2 0.9903746
acidosis I-Disease 2 0.99999726
, O 0 0.04881613
acute B-Disease 0 0.9856668
renal I-Disease 0 0.9947015
failure I-Disease 0 0.84294164
and I-Disease 0 0.003117386
hepatic I-Disease 0 0.9711666
failure I-Disease 0 0.8258243
following O 0 0.004077855
paracetamol B-Chemical 0 0.99999535
ingestion O 0 0.8632317
is O 0 0.0028281128
presented O 0 0.00358075
. O 0 0.0061970702

The O 0 0.0076412447
diagnostic O 0 0.007923753
difficulty O 0 0.008442578
at O 0 0.0060658962
presentation O 0 0.008591957
is O 0 0.009187025
highlighted O 0 0.011878777
. O 0 0.017886225

Continuous O 0 0.0068729855
arteriovenous O 0 0.123322524
haemofiltration O 0 0.56272084
proved O 0 0.0030575374
a O 0 0.0018068592
valuable O 0 0.0012930922
means O 0 0.0011052954
of O 0 0.0014221367
maintaining O 0 0.0018647192
fluid O 0 0.004869686
and O 0 0.0032332803
electrolyte O 0 0.49250108
balance O 0 0.009025865
. O 0 0.009503162

The O 0 0.032234047
patient O 0 0.036180492
recovered O 0 0.03779655
. O 0 0.050888125

Sexual B-Disease 0 0.7846667
dysfunction I-Disease 0 0.97638696
among O 0 0.014526376
patients O 0 0.015322087
with O 0 0.018215233
arthritis B-Disease 0 0.9993337
. O 0 0.027172823

The O 0 0.002758535
relationship O 0 0.0017674832
of O 0 0.0029140688
arthritis B-Disease 0 0.9998073
and O 0 0.014549554
sexual B-Disease 0 0.99513984
dysfunction I-Disease 0 0.9983981
was O 0 0.00063718634
investigated O 0 0.00027822133
among O 0 0.00040716983
169 O 0 0.0011281237
patients O 0 0.0003783052
with O 0 0.0008661403
rheumatoid B-Disease 0 0.9999862
arthritis I-Disease 0 0.99999905
, O 0 0.03611633
osteoarthritis B-Disease 0 0.99946505
and O 0 0.0022633378
spondyloarthropathy B-Disease 0 0.99989533
, O 0 0.00064438715
130 O 0 0.00044404858
of O 0 0.0003459357
whom O 0 0.0006225037
were O 0 0.00047769744
pair O 0 0.0007770767
- O 0 0.0021363613
matched O 0 0.0013142426
to O 0 0.0019384089
controls O 0 0.004647887
. O 0 0.006755319

Assessments O 0 0.004140876
of O 0 0.0030051684
marital O 0 0.13272458
happiness O 0 0.4552324
and O 0 0.0060418323
depressed B-Disease 2 0.9997726
mood I-Disease 0 0.9997551
were O 0 0.00052193145
also O 0 0.00033043863
made O 0 0.0002969039
using O 0 0.00031918444
the O 0 0.00047410277
CES O 0 0.882258
- O 0 0.0277579
D O 0 0.88097095
and O 0 0.0006841896
the O 0 0.0007143139
Azrin O 0 0.08205582
Marital O 0 0.77000356
Happiness O 0 0.50526077
Scale O 0 0.39380553
( O 0 0.0037517354
AMHS O 0 0.28596243
) O 0 0.006629411
. O 0 0.008301886

Sexual B-Disease 0 0.77772063
dysfunctions I-Disease 0 0.96059716
were O 0 0.0020009675
found O 0 0.0010922753
to O 0 0.00074418104
be O 0 0.0006736571
common O 0 0.0006728368
among O 0 0.0005872813
patients O 0 0.00054857705
and O 0 0.00041119353
controls O 0 0.0005770653
, O 0 0.0004169953
the O 0 0.00026198992
majority O 0 0.00027619948
in O 0 0.00029761778
both O 0 0.0003555964
groups O 0 0.000493213
reporting O 0 0.0008585062
one O 0 0.0008192675
or O 0 0.0013649066
more O 0 0.003035811
dysfunctions O 0 0.6540317
. O 0 0.0071021323

Impotence B-Disease 2 0.93909353
was O 0 0.0029936312
more O 0 0.0019580808
common O 0 0.0014617285
among O 0 0.0011524068
male O 0 0.002109435
patients O 0 0.0007436312
than O 0 0.00030388348
controls O 0 0.00046622942
and O 0 0.000354298
was O 0 0.00027602236
found O 0 0.00021542316
to O 0 0.00019741266
be O 0 0.00024131099
associated O 0 0.00031871645
with O 0 0.0005559156
co O 0 0.69992006
- O 0 0.080208145
morbidity O 0 0.5076916
and O 0 0.00085406716
the O 0 0.0009749547
taking O 0 0.0027390316
of O 0 0.0045501054
methotrexate B-Chemical 1 0.9998165
. O 0 0.008647959

Depressed B-Disease 0 0.9997198
mood I-Disease 0 0.9993111
was O 0 0.002479618
more O 0 0.0015408597
common O 0 0.0011721782
among O 0 0.00093118596
patients O 0 0.0008234708
and O 0 0.0005783378
was O 0 0.0004543432
associated O 0 0.00042953462
with O 0 0.00046048625
certain O 0 0.00066504785
sexual O 0 0.13614196
difficulties O 0 0.0031387915
, O 0 0.0012694437
but O 0 0.0012804533
not O 0 0.0015356204
with O 0 0.003672612
impotence B-Disease 0 0.9665096
. O 0 0.008187685

Marital O 0 0.7885104
unhappiness O 0 0.92275137
, O 0 0.0032972875
as O 0 0.0014750817
indicated O 0 0.00095502834
by O 0 0.0011751982
AMHS O 0 0.25311893
scores O 0 0.00059354067
, O 0 0.0005982467
was O 0 0.00036186902
not O 0 0.00027795968
associated O 0 0.00039096526
with O 0 0.0010303132
arthritis B-Disease 0 0.9999176
but O 0 0.0010266664
was O 0 0.0003263947
associated O 0 0.00037527975
with O 0 0.00076464313
sexual B-Disease 0 0.9839623
dysfunction I-Disease 0 0.9981797
, O 0 0.003178142
sexual O 0 0.30122364
dissatisfaction O 0 0.10843189
and O 0 0.0019071919
being O 0 0.003440619
female O 0 0.0084009925
. O 0 0.0068910993

Does O 0 0.049334683
paracetamol B-Chemical 0 0.99995005
cause O 0 0.070888564
urothelial B-Disease 0 0.9998306
cancer I-Disease 0 0.99994814
or O 0 0.053230025
renal B-Disease 2 0.9995877
papillary I-Disease 2 0.9998461
necrosis I-Disease 2 0.99999416
? O 0 0.4702576

The O 0 0.0034175063
risk O 0 0.013193084
of O 0 0.0025510844
developing O 0 0.116796374
renal B-Disease 2 0.9992918
papillary I-Disease 2 0.999943
necrosis I-Disease 2 0.99999976
or O 0 0.046500973
cancer B-Disease 0 0.9992526
of I-Disease 0 0.0012871504
the I-Disease 0 0.000514007
renal I-Disease 0 0.8754771
pelvis I-Disease 0 0.23182867
, I-Disease 0 0.00045727467
ureter I-Disease 0 0.0034372655
or I-Disease 0 0.00023697597
bladder I-Disease 0 0.065702945
associated O 0 0.0003157357
with O 0 0.00030322192
consumption O 0 0.054350846
of O 0 0.0004465479
either O 0 0.0031079769
phenacetin B-Chemical 1 0.9999999
or O 0 0.009134933
paracetamol B-Chemical 0 0.99999523
was O 0 0.00021339094
calculated O 0 0.00013154531
from O 0 0.0001677063
data O 0 0.00021902208
acquired O 0 0.00033155287
by O 0 0.00030619727
questionnaire O 0 0.0003437287
from O 0 0.0004516082
381 O 0 0.0016914875
cases O 0 0.0012971613
and O 0 0.0020251365
808 O 0 0.14774491
controls O 0 0.005592423
. O 0 0.0073037706

The O 0 0.0034313041
risk O 0 0.017819252
of O 0 0.0035539102
renal B-Disease 2 0.9983065
papillary I-Disease 2 0.99989176
necrosis I-Disease 2 0.9999994
was O 0 0.0028107907
increased O 0 0.00067547837
nearly O 0 0.00045243383
20 O 0 0.0003805765
- O 0 0.0017529073
fold O 0 0.0004476095
by O 0 0.00032065358
consumption O 0 0.13322322
of O 0 0.009977606
phenacetin B-Chemical 1 0.9999999
, O 0 0.0022338256
which O 0 0.00035407513
also O 0 0.00018081073
increased O 0 0.00022936321
the O 0 0.00023104512
risk O 0 0.057293896
for O 0 0.00045789298
cancer B-Disease 0 0.99420327
of I-Disease 0 0.00063118566
the I-Disease 0 0.00042514128
renal I-Disease 0 0.79950875
pelvis I-Disease 0 0.121310815
and I-Disease 0 0.0006287486
bladder I-Disease 0 0.08011234
but O 0 0.00089665223
not O 0 0.0009425612
for O 0 0.0018553645
ureteric B-Disease 0 0.9557367
cancer I-Disease 0 0.99989533
. O 0 0.016285481

By O 0 0.00479445
contrast O 0 0.003273373
, O 0 0.0023990888
we O 0 0.0009844989
were O 0 0.0007797134
unable O 0 0.00047270686
to O 0 0.00041449274
substantiate O 0 0.00036390268
an O 0 0.00046301584
increased O 0 0.0005577413
risk O 0 0.12636538
from O 0 0.0007535553
paracetamol B-Chemical 0 0.9999975
consumption O 0 0.38532567
for O 0 0.00054460193
renal B-Disease 2 0.9980579
papillary I-Disease 2 0.99990475
necrosis I-Disease 2 0.99999976
or O 0 0.0018162299
any O 0 0.00022505749
of O 0 0.00028986172
these O 0 0.0005845229
cancers B-Disease 2 0.99517244
although O 0 0.00033136102
there O 0 0.00015707563
was O 0 0.00022517254
a O 0 0.0002949574
suggestion O 0 0.0005829945
of O 0 0.0004070039
an O 0 0.00047740765
association O 0 0.0005337074
with O 0 0.0014324165
cancer B-Disease 0 0.9899941
of I-Disease 0 0.0029224784
the I-Disease 0 0.003003826
ureter I-Disease 0 0.04910106
. O 0 0.007292052

Dapsone B-Chemical 0 0.9999448
- O 0 0.14801061
associated O 0 0.005854047
Heinz O 0 0.9689419
body O 0 0.63326985
hemolytic B-Disease 2 0.99999976
anemia I-Disease 2 0.99999964
in O 0 0.0022372727
a O 0 0.0016854183
Cambodian O 0 0.16504173
woman O 0 0.010741236
with O 0 0.002987377
hemoglobin O 0 0.9946679
E O 0 0.99959606
trait O 0 0.49197608
. O 0 0.0090308385

A O 0 0.0977753
Cambodian O 0 0.073743515
woman O 0 0.008719452
with O 0 0.0031715715
hemoglobin O 0 0.9981493
E O 0 0.9999385
trait O 0 0.69308066
( O 0 0.009411211
AE O 0 0.98659116
) O 0 0.0017801428
and O 0 0.00072284846
leprosy B-Disease 0 0.9989814
developed O 0 0.0015695939
a O 0 0.0010458496
Heinz O 0 0.96217775
body O 0 0.4954016
hemolytic B-Disease 2 1.0
anemia I-Disease 2 0.9999999
while O 0 0.003753853
taking O 0 0.0016654355
a O 0 0.00026277293
dose O 0 0.0017810363
of O 0 0.001934403
dapsone B-Chemical 0 0.9999962
( O 0 0.0022370908
50 O 0 0.00044926468
mg O 0 0.016619839
/ O 0 0.0010097635
day O 0 0.00026483941
) O 0 0.0005104375
not O 0 0.0003782836
usually O 0 0.0006513396
associated O 0 0.00090072036
with O 0 0.0017275235
clinical O 0 0.068069786
hemolysis B-Disease 0 0.9999161
. O 0 0.008621138

Her O 0 0.008809939
red O 0 0.014140118
blood O 0 0.011248134
cells O 0 0.0021796362
( O 0 0.0027023733
RBCs O 0 0.09384319
) O 0 0.0013527798
had O 0 0.00048527258
increased O 0 0.00047041415
incubated O 0 0.0005629438
Heinz O 0 0.77214694
body O 0 0.0035907729
formation O 0 0.0044769086
, O 0 0.0006875228
decreased O 0 0.0007931995
reduced O 0 0.042085648
glutathione B-Chemical 0 0.9999994
( O 0 0.3869354
GSH B-Chemical 1 0.9999994
) O 0 0.014164667
, O 0 0.0015900976
and O 0 0.0017297429
decreased O 0 0.00972645
GSH B-Chemical 1 0.9999776
stability O 0 0.010935192
. O 0 0.008369706

The O 0 0.004595334
pentose B-Chemical 0 0.87024707
phosphate I-Chemical 0 0.99830616
shunt O 0 0.018313946
activity O 0 0.0011553603
of O 0 0.0010649083
the O 0 0.001672043
dapsone B-Chemical 0 0.9999963
- O 0 0.17899176
exposed O 0 0.0031731245
AE O 0 0.99016577
RBCs O 0 0.10454919
was O 0 0.00067005923
increased O 0 0.00077168917
compared O 0 0.00083237013
to O 0 0.0014672957
normal O 0 0.0037028699
RBCs O 0 0.073801756
. O 0 0.006926279

Although O 0 0.003594622
the O 0 0.0032092365
AE O 0 0.9408654
RBCs O 0 0.047638986
from O 0 0.0008177146
an O 0 0.0007135552
individual O 0 0.0004528489
not O 0 0.00045679027
taking O 0 0.0072127413
dapsone B-Chemical 0 0.99998045
had O 0 0.00041813529
increased O 0 0.00037890978
incubated O 0 0.0004930045
Heinz O 0 0.8148037
body O 0 0.0038049894
formation O 0 0.0048776227
, O 0 0.0008491853
the O 0 0.0010085759
GSH B-Chemical 1 0.9999962
content O 0 0.001420748
and O 0 0.0038045053
GSH B-Chemical 1 0.9999888
stability O 0 0.0029845184
were O 0 0.0025849037
normal O 0 0.004731132
. O 0 0.0067297556

The O 0 0.0044961786
pentose B-Chemical 0 0.8704898
phosphate I-Chemical 0 0.9982736
shunt O 0 0.01572036
activity O 0 0.0010162373
of O 0 0.0007895837
the O 0 0.00064268085
non O 0 0.005192505
- O 0 0.48110768
dapsone B-Chemical 0 0.9999976
- O 0 0.192761
exposed O 0 0.0030846274
AE O 0 0.9900186
RBCs O 0 0.10274407
was O 0 0.00063011405
decreased O 0 0.0007684024
compared O 0 0.0007813594
to O 0 0.0013949396
normal O 0 0.00355179
RBCs O 0 0.07012635
. O 0 0.006788317

Thus O 0 0.0052381903
, O 0 0.0068763127
AE O 0 0.9691654
RBCs O 0 0.10456866
appear O 0 0.0009820008
to O 0 0.0005677555
have O 0 0.00043746573
an O 0 0.0004898289
increased O 0 0.00042983776
sensitivity O 0 0.0012208453
to O 0 0.00038303228
oxidant O 0 0.99799025
stress O 0 0.4075028
both O 0 0.00040250132
in O 0 0.00023616935
vitro O 0 0.00032488897
and O 0 0.00028463136
in O 0 0.00022403625
vivo O 0 0.00052072003
, O 0 0.000639514
since O 0 0.00036089864
dapsone B-Chemical 0 0.9999913
does O 0 0.0004625985
not O 0 0.0003437693
cause O 0 0.0268946
hemolytic B-Disease 2 1.0
anemia I-Disease 2 0.99999976
at O 0 0.0005538268
this O 0 0.00046958265
dose O 0 0.0016547763
in O 0 0.0009587141
hematologically O 0 0.54029375
normal O 0 0.0031138714
individuals O 0 0.005587307
. O 0 0.006272954

Given O 0 0.0028107676
the O 0 0.0023025428
influx O 0 0.023393653
of O 0 0.0022337055
Southeast O 0 0.30425695
Asians O 0 0.7692156
into O 0 0.00040219567
the O 0 0.00046898052
United O 0 0.0014063912
States O 0 0.005620377
, O 0 0.0013451773
oxidant O 0 0.99789387
medications O 0 0.12309105
should O 0 0.00012832423
be O 0 0.00014368467
used O 0 0.00012818299
with O 0 0.00016983967
caution O 0 0.00022691698
, O 0 0.00031742308
especially O 0 0.0003178592
if O 0 0.00015019259
an O 0 0.00034149876
infection B-Disease 2 0.91106427
is O 0 0.00038716893
present O 0 0.00017696638
, O 0 0.0003153969
in O 0 0.00019105183
individuals O 0 0.00038832327
of O 0 0.00034164335
ethnic O 0 0.015552101
backgrounds O 0 0.0004103925
that O 0 0.00024745197
have O 0 0.0003175121
an O 0 0.000533218
increased O 0 0.0007981726
prevalence O 0 0.0044044405
of O 0 0.0061698924
hemoglobin O 0 0.9980971
E O 0 0.9996439
. O 0 0.0119536165

Severe O 0 0.6177274
complications O 0 0.4603501
of O 0 0.004934252
antianginal O 0 0.9989392
drug O 0 0.74179196
therapy O 0 0.0026444811
in O 0 0.00049179705
a O 0 0.0004528001
patient O 0 0.00031257202
identified O 0 0.0002318002
as O 0 0.00024220835
a O 0 0.00038413217
poor O 0 0.0072815805
metabolizer O 0 0.99948716
of O 0 0.013658588
metoprolol B-Chemical 1 0.9999999
, O 0 0.15577653
propafenone B-Chemical 0 0.99999964
, O 0 0.08155528
diltiazem B-Chemical 1 0.99999857
, O 0 0.004671156
and O 0 0.005709872
sparteine B-Chemical 0 0.99979573
. O 0 0.007685916

A O 0 0.089643426
47 O 0 0.007112182
- O 0 0.008100214
year O 0 0.0023207222
- O 0 0.00423603
old O 0 0.0012344208
patient O 0 0.0009613893
suffering O 0 0.0204598
from O 0 0.00061558804
coronary B-Disease 0 0.23721121
artery I-Disease 0 0.33324626
disease I-Disease 0 0.79574054
was O 0 0.00053226383
admitted O 0 0.0008024961
to O 0 0.00044646533
the O 0 0.0007007562
CCU O 0 0.10022348
in O 0 0.0014074971
shock B-Disease 0 0.98951846
with O 0 0.0060891295
III O 0 0.1640456
. O 0 0.0075572515

AV B-Disease 0 0.89447886
block I-Disease 0 0.0112898145
, O 0 0.008154081
severe O 0 0.70612824
hypotension B-Disease 2 0.99998534
, O 0 0.0051600095
and O 0 0.0032018714
impairment B-Disease 0 0.25154996
of I-Disease 0 0.004545236
ventricular I-Disease 0 0.77988976
function I-Disease 0 0.0066956407
. O 0 0.009851772

One O 0 0.004103457
week O 0 0.0018774084
prior O 0 0.001188379
to O 0 0.0010405554
admission O 0 0.0020247782
a O 0 0.0007674324
therapy O 0 0.0007001528
with O 0 0.0003661606
standard O 0 0.00025979083
doses O 0 0.0037345453
of O 0 0.0066100485
metoprolol B-Chemical 1 0.9999999
( O 0 0.003675808
100 O 0 0.00081357476
mg O 0 0.020876613
t O 0 0.00094285177
. O 0 0.00020565394
i O 0 0.000901345
. O 0 0.0001868898
d O 0 0.00030418407
. O 0 0.00017979454
and O 0 0.00019357183
then O 0 0.00017389498
100 O 0 0.00035828492
mg O 0 0.005711876
b O 0 0.0006350408
. O 0 0.00032077773
i O 0 0.0010460848
. O 0 0.00043613915
d O 0 0.00082082604
. O 0 0.00083042757
) O 0 0.0016317522
had O 0 0.0016082757
been O 0 0.0024332935
initiated O 0 0.0040930016
. O 0 0.007405421

Two O 0 0.0034792987
days O 0 0.0019628988
before O 0 0.0015031791
admission O 0 0.021007959
diltiazem B-Chemical 1 0.9999958
( O 0 0.0018787625
60 O 0 0.0006667576
mg O 0 0.008141753
b O 0 0.00097472337
. O 0 0.00047635532
i O 0 0.0012113295
. O 0 0.00048959896
d O 0 0.0008274694
. O 0 0.00074524095
) O 0 0.0013942702
was O 0 0.0012328201
prescribed O 0 0.002309738
in O 0 0.0020275572
addition O 0 0.0028596187
. O 0 0.007158656

Analyses O 0 0.0038249358
of O 0 0.0027836065
a O 0 0.002243975
blood O 0 0.0033336177
sample O 0 0.0008484441
revealed O 0 0.00061858544
unusually O 0 0.010459092
high O 0 0.0010932528
plasma O 0 0.021548737
concentrations O 0 0.0038897847
of O 0 0.009088747
metoprolol B-Chemical 1 0.9999999
( O 0 0.0016070144
greater O 0 0.00021007768
than O 0 0.00015580532
3000 O 0 0.0002946488
ng O 0 0.0003311059
/ O 0 0.0017738972
ml O 0 0.00094614044
) O 0 0.0009871846
and O 0 0.0013936689
diltiazem B-Chemical 1 0.9999982
( O 0 0.002022726
526 O 0 0.03058656
ng O 0 0.0018862518
/ O 0 0.0064438973
ml O 0 0.0049386956
) O 0 0.006409598
. O 0 0.0075544203

The O 0 0.004017073
patient O 0 0.0029647874
recovered O 0 0.0018655848
within O 0 0.0014010066
1 O 0 0.0015330921
week O 0 0.0012487618
following O 0 0.0015594243
discontinuation O 0 0.22041395
of O 0 0.004447138
antianginal O 0 0.99657553
therapy O 0 0.014704305
. O 0 0.0091615515

Three O 0 0.0034874321
months O 0 0.0018339447
later O 0 0.001340563
the O 0 0.0010263601
patient O 0 0.00089000317
was O 0 0.0006215136
exposed O 0 0.000527917
to O 0 0.00034290634
a O 0 0.00040211205
single O 0 0.00031905877
dose O 0 0.0032987108
of O 0 0.012277182
metoprolol B-Chemical 1 1.0
, O 0 0.22620335
diltiazem B-Chemical 1 0.9999999
, O 0 0.10038795
propafenone B-Chemical 0 0.99999964
( O 0 0.0010358549
since O 0 0.0001433469
he O 0 0.00016476384
had O 0 0.00012667468
received O 0 0.00011119472
this O 0 0.0001533625
drug O 0 0.03979819
in O 0 0.00015814476
the O 0 0.00016705543
past O 0 0.00033733205
) O 0 0.00070129905
, O 0 0.00043573728
and O 0 0.0009916145
sparteine B-Chemical 0 0.99996614
( O 0 0.00046912942
as O 0 0.0001640762
a O 0 0.00019273165
probe O 0 0.0001717095
for O 0 0.00021931717
the O 0 0.0008455781
debrisoquine B-Chemical 0 0.9999994
/ O 0 0.22667114
sparteine B-Chemical 0 0.9999641
type O 0 0.000882391
polymorphism O 0 0.11471135
of O 0 0.0015320115
oxidative O 0 0.980293
drug O 0 0.9365545
metabolism O 0 0.5279703
) O 0 0.008033266
. O 0 0.0068685412

It O 0 0.004727052
was O 0 0.0026354988
found O 0 0.0016131327
that O 0 0.0011158601
he O 0 0.001086955
was O 0 0.00076405023
a O 0 0.000791813
poor O 0 0.0048256903
metabolizer O 0 0.99695206
of O 0 0.00044345274
all O 0 0.00027615472
four O 0 0.00021764732
drugs O 0 0.029648324
, O 0 0.00038003072
indicating O 0 0.00022000665
that O 0 0.00023343234
their O 0 0.00039978852
metabolism O 0 0.022922838
is O 0 0.00046088852
under O 0 0.0004717323
the O 0 0.0007450744
same O 0 0.000950773
genetic O 0 0.0029597539
control O 0 0.0035977266
. O 0 0.0066091283

Therefore O 0 0.0036648014
, O 0 0.0030762968
patients O 0 0.0017461551
belonging O 0 0.0009131739
to O 0 0.0006738786
the O 0 0.0006206733
poor O 0 0.0036860767
- O 0 0.0958389
metabolizer O 0 0.9983285
phenotype O 0 0.0010482955
of O 0 0.0039018327
sparteine B-Chemical 0 0.9999968
/ O 0 0.8064975
debrisoquine B-Chemical 0 0.99999976
polymorphism O 0 0.55159837
in O 0 0.00035583612
drug O 0 0.3823507
metabolism O 0 0.13125522
, O 0 0.00033126248
which O 0 0.00020572885
constitutes O 0 0.00014384244
6 O 0 0.00012627298
. O 0 0.0001320853
4 O 0 0.00012673388
% O 0 0.0001672022
of O 0 0.00017875178
the O 0 0.000196057
German O 0 0.00058531115
population O 0 0.0004916567
, O 0 0.0003357807
may O 0 0.00018518265
experience O 0 0.0005003177
adverse B-Disease 0 0.8239081
drug I-Disease 0 0.39839286
reactions I-Disease 0 0.032838766
when O 0 0.00014673852
treated O 0 0.00024626576
with O 0 0.0002279422
standard O 0 0.00021290318
doses O 0 0.0007334019
of O 0 0.0004566631
one O 0 0.0004855736
of O 0 0.0008602143
these O 0 0.0015388504
drugs O 0 0.17084783
alone O 0 0.0037817082
. O 0 0.006811208

Moreover O 0 0.005162409
, O 0 0.0037055167
the O 0 0.002043208
coadministration O 0 0.7713315
of O 0 0.0013445005
these O 0 0.00093015254
frequently O 0 0.00082487817
used O 0 0.00043758337
drugs O 0 0.04048002
is O 0 0.00037809683
expected O 0 0.0002726899
to O 0 0.00029056778
be O 0 0.00038245486
especially O 0 0.00071011117
harmful O 0 0.018460529
in O 0 0.0007190514
this O 0 0.0009707679
subgroup O 0 0.0028502797
of O 0 0.0027895602
patients O 0 0.006230804
. O 0 0.0067540337

Clinical O 0 0.011196302
experiences O 0 0.005609996
in O 0 0.0032264662
an O 0 0.0030594321
open O 0 0.0029249692
and O 0 0.0027483383
a O 0 0.0032189388
double O 0 0.003827613
- O 0 0.011433097
blind O 0 0.023198633
trial O 0 0.00861301
. O 0 0.011114369

A O 0 0.016343411
total O 0 0.002337262
of O 0 0.0020420933
sixty O 0 0.0017501526
patients O 0 0.001234174
were O 0 0.0007803054
trated O 0 0.039542492
with O 0 0.0021125006
bromperidol B-Chemical 0 0.99999833
first O 0 0.0002718325
in O 0 0.000235659
open O 0 0.00028579708
conditions O 0 0.00024766367
( O 0 0.0003611143
20 O 0 0.00019980456
patients O 0 0.00028447865
) O 0 0.00037924407
, O 0 0.0002380085
then O 0 0.00014512188
on O 0 0.00012325594
a O 0 0.00021272033
double O 0 0.00023955981
blind O 0 0.005009908
basis O 0 0.000263827
( O 0 0.00038463422
40 O 0 0.00027086417
patients O 0 0.00043933626
) O 0 0.00083533017
with O 0 0.0017563525
haloperidol B-Chemical 1 0.9999982
as O 0 0.00091237284
the O 0 0.0013323253
reference O 0 0.0025903066
substance O 0 0.7849948
. O 0 0.007055923

The O 0 0.0032444673
open O 0 0.0026678662
study O 0 0.0016799257
lasted O 0 0.000877278
for O 0 0.00073297264
four O 0 0.00050781993
weeks O 0 0.00042530912
; O 0 0.00069802644
the O 0 0.0004931507
drug O 0 0.08041394
was O 0 0.0005075512
administrated O 0 0.0012294692
in O 0 0.00045093225
the O 0 0.0005203357
form O 0 0.0007042196
of O 0 0.0013076962
1 O 0 0.0018360217
mg O 0 0.091944955
tablets O 0 0.3078336
. O 0 0.006973965

The O 0 0.0030033404
daily O 0 0.002410434
dose O 0 0.003930676
( O 0 0.0015862688
initial O 0 0.00073440274
dose O 0 0.0048790625
: O 0 0.0013440645
1 O 0 0.00045238415
mg O 0 0.008084603
; O 0 0.00035670085
mean O 0 0.00014434283
dose O 0 0.00037238552
at O 0 0.00015474657
the O 0 0.00014844276
end O 0 0.0001197249
of O 0 0.00018349738
the O 0 0.00018523457
trial O 0 0.00030948964
: O 0 0.00038361712
4 O 0 0.0001859793
. O 0 0.00020464716
47 O 0 0.00044649257
mg O 0 0.009295314
) O 0 0.0005869611
was O 0 0.00038651543
always O 0 0.00047517507
administered O 0 0.00054500566
in O 0 0.00077329617
one O 0 0.0011618779
single O 0 0.0020919533
dose O 0 0.0072701215
. O 0 0.0066646333

Nineteen O 0 0.007871481
patients O 0 0.0031507276
finished O 0 0.002415889
the O 0 0.0013207971
trial O 0 0.0013360559
, O 0 0.0010724202
and O 0 0.00073805876
in O 0 0.0005685296
18 O 0 0.00052148534
cases O 0 0.0005324394
the O 0 0.00043037097
therapeutic O 0 0.0007745086
result O 0 0.00050643727
was O 0 0.0006548667
considered O 0 0.00071416755
very O 0 0.0013390864
good O 0 0.001952466
to O 0 0.0023438737
good O 0 0.0052409065
. O 0 0.007512984

These O 0 0.009246898
results O 0 0.00734535
were O 0 0.007304853
confirmed O 0 0.007346104
by O 0 0.009538356
statistical O 0 0.013965417
analysis O 0 0.014888686
. O 0 0.020433888

Nine O 0 0.0063178
patients O 0 0.003238234
exhibited O 0 0.002096605
mild O 0 0.15791553
to O 0 0.0012716333
moderate O 0 0.3640199
extrapyramidal B-Disease 0 0.9999988
concomitant I-Disease 0 0.0759593
symptoms I-Disease 0 0.89421237
; O 0 0.0012958063
no O 0 0.0005203633
other O 0 0.00090455404
side O 0 0.010077312
effects O 0 0.0018799388
were O 0 0.0022819606
observed O 0 0.0034086797
. O 0 0.006935617

The O 0 0.0030852095
results O 0 0.0020250382
of O 0 0.00169301
detailed O 0 0.0010070048
laboratory O 0 0.0010896138
tests O 0 0.00083976274
and O 0 0.00052135467
evaluations O 0 0.0003688545
of O 0 0.00037971817
various O 0 0.0003641192
quantitative O 0 0.00036730897
and O 0 0.00034043615
qualitative O 0 0.00052393053
tolerability O 0 0.0016738541
parameters O 0 0.00041327218
were O 0 0.00042386053
not O 0 0.0005050039
indicative O 0 0.0008400536
of O 0 0.0020126747
toxic O 0 0.71396494
effects O 0 0.006714658
. O 0 0.007321153

In O 0 0.0035252618
the O 0 0.0022088785
double O 0 0.0019720364
blind O 0 0.018118272
study O 0 0.0017596118
with O 0 0.0057243407
haloperidol B-Chemical 1 0.99999976
, O 0 0.0019260084
both O 0 0.00051786425
substances O 0 0.2156797
were O 0 0.00026085036
found O 0 0.00018476378
to O 0 0.00016187207
be O 0 0.00018873607
highly O 0 0.00022863201
effective O 0 0.00021301405
in O 0 0.00018324074
the O 0 0.00020402293
treatment O 0 0.0003745756
of O 0 0.0020062164
psychotic B-Disease 0 0.99999785
syndromes I-Disease 0 0.11642833
belonging I-Disease 0 0.00040679387
predominantly I-Disease 0 0.0006018061
to I-Disease 0 0.00079219893
the I-Disease 0 0.0018127346
schizophrenia I-Disease 2 0.9998288
group I-Disease 0 0.0051971236
. O 0 0.0064124526

Certain O 0 0.007245999
clues O 0 0.0028688356
, O 0 0.0025918912
including O 0 0.0013538514
the O 0 0.0010848525
onset O 0 0.0014989667
of O 0 0.00096381176
action O 0 0.0015732531
, O 0 0.00091990636
seem O 0 0.00053933257
to O 0 0.0004071056
be O 0 0.0004912489
indicative O 0 0.00055221934
of O 0 0.00087869726
the O 0 0.0011419599
superiority O 0 0.0025574819
of O 0 0.009558058
bromperidol B-Chemical 0 0.9999939
. O 0 0.009210493

No O 0 0.006033537
differences O 0 0.0026685477
were O 0 0.002173528
observed O 0 0.0015225868
with O 0 0.0014169686
respect O 0 0.0011934163
to O 0 0.0012681783
side O 0 0.0062687467
effects O 0 0.002033161
and O 0 0.0024920297
general O 0 0.003421068
tolerability O 0 0.06060851
. O 0 0.007922336

Prolonged O 0 0.24624358
cholestasis B-Disease 2 0.99998987
after O 0 0.028356176
troleandomycin B-Chemical 0 0.99999917
- O 0 0.7798619
induced O 0 0.12139417
acute O 0 0.99994195
hepatitis B-Disease 2 0.9999999
. O 0 0.54313076

We O 0 0.003951036
report O 0 0.0034078653
the O 0 0.0017885658
case O 0 0.0014495193
of O 0 0.0012156073
a O 0 0.0010909484
patient O 0 0.0008138348
in O 0 0.0007267139
whom O 0 0.052140873
troleandomycin B-Chemical 0 0.9999999
- O 0 0.49645266
induced O 0 0.0120091215
hepatitis B-Disease 2 0.9999999
was O 0 0.0038019975
followed O 0 0.0009867854
by O 0 0.0017216955
prolonged O 0 0.031460367
anicteric O 0 0.9999707
cholestasis B-Disease 2 0.99999857
. O 0 0.06722147

Jaundice B-Disease 0 0.99122685
occurred O 0 0.003044468
after O 0 0.001574302
administration O 0 0.00905407
of O 0 0.005224552
troleandomycin B-Chemical 0 0.9999987
for O 0 0.0012059209
7 O 0 0.0007154656
days O 0 0.0006058491
and O 0 0.000977525
was O 0 0.0012840347
associated O 0 0.0020533197
with O 0 0.0051039862
hypereosinophilia B-Disease 0 0.9998388
. O 0 0.010254393

Jaundice B-Disease 0 0.9897098
disappeared O 0 0.0031319892
within O 0 0.0012354079
3 O 0 0.0009936515
months O 0 0.00066442863
but O 0 0.00068533845
was O 0 0.00047997275
followed O 0 0.00036417943
by O 0 0.00047223823
prolonged O 0 0.0042923023
anicteric O 0 0.99999
cholestasis B-Disease 2 0.9999999
marked O 0 0.12841582
by O 0 0.004186961
pruritus B-Disease 2 0.99997926
and O 0 0.00056292827
high O 0 0.0005177428
levels O 0 0.0003967883
of O 0 0.0008783515
alkaline O 0 0.78131264
phosphatase O 0 0.8368764
and O 0 0.0036204155
gammaglutamyltransferase O 0 0.7005721
activities O 0 0.004679435
. O 0 0.006325288

Finally O 0 0.0052282386
, O 0 0.0070077027
pruritus B-Disease 2 0.99970156
disappeared O 0 0.0019999938
within O 0 0.0007030185
19 O 0 0.00084147404
months O 0 0.00044357727
, O 0 0.00058200455
and O 0 0.00055655604
liver O 0 0.202607
tests O 0 0.0006687641
returned O 0 0.00032176584
to O 0 0.00028470924
normal O 0 0.00045663616
27 O 0 0.00048376492
months O 0 0.00034299315
after O 0 0.0004360192
the O 0 0.0008956592
onset O 0 0.002757402
of O 0 0.008216607
hepatitis B-Disease 2 0.9999993
. O 0 0.104601204

This O 0 0.0055770422
observation O 0 0.0029951688
demonstrates O 0 0.0018503624
that O 0 0.0017438277
prolonged O 0 0.015738744
cholestasis B-Disease 2 0.9999981
can O 0 0.0021822574
follow O 0 0.0024779069
troleandomycin B-Chemical 0 0.99999964
- O 0 0.5741942
induced O 0 0.04906081
acute O 0 0.99995124
hepatitis B-Disease 2 1.0
. O 0 0.46591035

Serial O 0 0.007639986
studies O 0 0.0041210596
of O 0 0.0047674216
auditory B-Disease 0 0.9223076
neurotoxicity I-Disease 2 0.99999106
in O 0 0.0040285806
patients O 0 0.006495681
receiving O 0 0.016771095
deferoxamine B-Chemical 0 0.9999647
therapy O 0 0.04410698
. O 0 0.010650486

Visual B-Disease 0 0.42292917
and I-Disease 0 0.0051666377
auditory I-Disease 0 0.93971646
neurotoxicity I-Disease 2 0.9999945
was O 0 0.0016701118
previously O 0 0.0007949663
documented O 0 0.0006673822
in O 0 0.00039524422
42 O 0 0.0004176652
of O 0 0.0003340906
89 O 0 0.0005393339
patients O 0 0.00034335564
with O 0 0.00034794796
transfusion O 0 0.097050875
- O 0 0.009998097
dependent O 0 0.000403252
anemia B-Disease 0 0.9999758
who O 0 0.001537838
were O 0 0.0003222023
receiving O 0 0.0010365227
iron B-Chemical 0 0.99985373
chelation O 0 0.9497861
therapy O 0 0.0014318002
with O 0 0.00097113615
daily O 0 0.0024121166
subcutaneous O 0 0.12945972
deferoxamine B-Chemical 0 0.99994195
. O 0 0.0075202617

Twenty O 0 0.0071832077
- O 0 0.006620693
two O 0 0.0015524367
patients O 0 0.0014439732
in O 0 0.0008457622
the O 0 0.00063038495
affected O 0 0.0005246481
group O 0 0.00053552014
had O 0 0.00033227814
abnormal B-Disease 0 0.0047864434
audiograms I-Disease 0 0.31238922
with I-Disease 0 0.00040720167
deficits I-Disease 0 0.33745816
mostly I-Disease 0 0.000285049
in I-Disease 0 0.00015775212
the I-Disease 0 0.00014718567
high I-Disease 0 0.00020769525
frequency I-Disease 0 0.00017645283
range I-Disease 0 0.00016835344
of I-Disease 0 0.0002056651
4 I-Disease 0 0.00015290256
, I-Disease 0 0.00018809686
000 I-Disease 0 0.00017099762
to I-Disease 0 0.00013724442
8 I-Disease 0 0.0001604641
, I-Disease 0 0.00020758083
000 I-Disease 0 0.00024129052
Hz I-Disease 0 0.006783935
and O 0 0.00026232336
in O 0 0.0002484396
the O 0 0.00030970862
hearing O 0 0.44821408
threshold O 0 0.0003578417
levels O 0 0.000487723
of O 0 0.0007631221
30 O 0 0.0008575242
to O 0 0.0012462983
100 O 0 0.003045215
decibels O 0 0.008384849
. O 0 0.006654038

When O 0 0.0046784375
deferoxamine B-Chemical 0 0.999915
therapy O 0 0.009960442
was O 0 0.0013439558
discontinued O 0 0.00234014
and O 0 0.0005631929
serial O 0 0.00047683396
studies O 0 0.00033078753
were O 0 0.00026583587
performed O 0 0.00022587698
, O 0 0.00041492417
audiograms O 0 0.0713586
in O 0 0.00020409843
seven O 0 0.00016688112
cases O 0 0.0002572033
reverted O 0 0.00039741155
to O 0 0.00015252133
normal O 0 0.00028148285
or O 0 0.00016432829
near O 0 0.00023545597
normal O 0 0.00022736809
within O 0 0.000103167906
two O 0 0.00011052303
to O 0 0.000114879025
three O 0 0.000106219195
weeks O 0 0.00012687912
, O 0 0.0002383214
and O 0 0.00025135474
nine O 0 0.00027101688
of O 0 0.00038708423
13 O 0 0.0005162496
patients O 0 0.00073764334
with O 0 0.0010936913
symptoms O 0 0.15913887
became O 0 0.0048394855
asymptomatic O 0 0.21864149
. O 0 0.0069923433

Audiograms O 0 0.014283692
from O 0 0.0024388058
15 O 0 0.0017560339
patients O 0 0.001526694
remained O 0 0.0013073878
abnormal O 0 0.0019095707
and O 0 0.0008397559
four O 0 0.00055482273
patients O 0 0.00074341946
required O 0 0.00058746175
hearing O 0 0.5749878
aids O 0 0.0017247003
because O 0 0.0013250804
of O 0 0.0031140118
permanent B-Disease 0 0.852195
disability I-Disease 0 0.9915303
. O 0 0.009547849

Since O 0 0.0031679224
18 O 0 0.002477827
of O 0 0.0017373114
the O 0 0.001201252
22 O 0 0.0011153468
patients O 0 0.0007999128
were O 0 0.0004850196
initially O 0 0.00051867566
receiving O 0 0.0016502102
deferoxamine B-Chemical 0 0.99999
doses O 0 0.018312318
in O 0 0.00027631168
excess O 0 0.00037976925
of O 0 0.00029096092
the O 0 0.00021809457
commonly O 0 0.00035115192
recommended O 0 0.00018241824
50 O 0 0.00021902501
mg O 0 0.008073065
/ O 0 0.0007796461
kg O 0 0.0003744367
per O 0 0.00010844696
dose O 0 0.00063660543
, O 0 0.00031370437
therapy O 0 0.00039177598
was O 0 0.00018608216
restarted O 0 0.0005387995
with O 0 0.00018706986
lower O 0 0.00018865116
doses O 0 0.0015223142
, O 0 0.00032282466
usually O 0 0.0002653244
50 O 0 0.0002519457
mg O 0 0.010385363
/ O 0 0.00080097426
kg O 0 0.00034944175
per O 0 0.0001012716
dose O 0 0.00034946608
or O 0 0.00014800094
less O 0 0.00014379402
depending O 0 0.0001551141
on O 0 9.257778e-05
the O 0 0.00012714714
degree O 0 0.0002058919
of O 0 0.00050780235
auditory B-Disease 0 0.8284802
abnormality I-Disease 0 0.8594224
, O 0 0.0004575553
and O 0 0.000234369
with O 0 0.00020595556
the O 0 0.00018103032
exception O 0 0.0001874852
of O 0 0.00026523662
two O 0 0.00024795972
cases O 0 0.00049474725
no O 0 0.00044753187
further O 0 0.0010305597
toxicity B-Disease 2 0.9945427
was O 0 0.0024348265
demonstrated O 0 0.003176132
. O 0 0.0063572153

Auditory O 0 0.16005163
deterioration O 0 0.05363585
and O 0 0.0021444918
improvement O 0 0.0015196218
, O 0 0.0011332755
demonstrated O 0 0.00053818716
serially O 0 0.00051308156
in O 0 0.00034337284
individual O 0 0.0002801431
patients O 0 0.00039062527
receiving O 0 0.00029932996
and O 0 0.00025002123
not O 0 0.00022357404
receiving O 0 0.0027245572
deferoxamine B-Chemical 0 0.9999962
, O 0 0.0019908038
respectively O 0 0.004184175
, O 0 0.00030270693
provided O 0 0.00016556718
convincing O 0 0.00027030698
evidence O 0 0.0001427492
for O 0 0.00019368759
a O 0 0.0003480283
cause O 0 0.00074397284
- O 0 0.03035559
and O 0 0.00062890927
- O 0 0.005647202
effect O 0 0.00031080036
relation O 0 0.0003315026
between O 0 0.00067656976
deferoxamine B-Chemical 0 0.99999213
administration O 0 0.23311919
and O 0 0.012866823
ototoxicity B-Disease 0 0.9999398
. O 0 0.009312595

Based O 0 0.006159965
on O 0 0.0020589316
these O 0 0.0019890668
data O 0 0.0017024332
, O 0 0.0015214724
a O 0 0.0010521258
plan O 0 0.0008842823
of O 0 0.0007568279
management O 0 0.0008193713
was O 0 0.00048563516
developed O 0 0.0005177142
that O 0 0.00034977356
allows O 0 0.0004649717
effective O 0 0.000680495
yet O 0 0.0010347773
safe O 0 0.0017710861
administration O 0 0.012588255
of O 0 0.0077802273
deferoxamine B-Chemical 0 0.9999784
. O 0 0.010277766

A O 0 0.040010422
dose O 0 0.007191589
of O 0 0.0030144465
50 O 0 0.002647297
mg O 0 0.06865404
/ O 0 0.004073183
kg O 0 0.002375799
is O 0 0.0011254568
recommended O 0 0.0010584011
in O 0 0.0011425148
those O 0 0.0017154587
without O 0 0.0024037366
audiogram O 0 0.73294085
abnormalities O 0 0.2486892
. O 0 0.008381603

With O 0 0.005990716
mild O 0 0.8286809
toxicity B-Disease 2 0.9992429
, O 0 0.0036211193
a O 0 0.0013337351
reduction O 0 0.0010224715
to O 0 0.00041149373
30 O 0 0.00031703993
or O 0 0.00027442773
40 O 0 0.0002987871
mg O 0 0.00655981
/ O 0 0.0008469792
kg O 0 0.00044902277
per O 0 0.00014634391
dose O 0 0.00038936824
should O 0 0.00013081805
result O 0 0.00015847018
in O 0 0.00019900125
a O 0 0.00026461578
reversal O 0 0.00036154402
of O 0 0.0002963326
the O 0 0.00028863095
abnormal O 0 0.001052177
results O 0 0.0003602533
to O 0 0.00045427654
normal O 0 0.00084190274
within O 0 0.00079689134
four O 0 0.0013688144
weeks O 0 0.0022750238
. O 0 0.0053904494

Moderate O 0 0.50284785
abnormalities O 0 0.019359488
require O 0 0.0015452986
a O 0 0.0016429743
reduction O 0 0.0018446379
of O 0 0.0024487693
deferoxamine B-Chemical 0 0.99998784
to O 0 0.0007342005
25 O 0 0.000826301
mg O 0 0.016892156
/ O 0 0.0013392956
kg O 0 0.000981156
per O 0 0.0005503086
dose O 0 0.0014214761
with O 0 0.0014476975
careful O 0 0.0026322333
monitoring O 0 0.0044658906
. O 0 0.0068822876

In O 0 0.003748263
those O 0 0.0026033993
with O 0 0.0019038655
symptoms O 0 0.12965141
of O 0 0.001981732
hearing B-Disease 0 0.98386616
loss I-Disease 0 0.008851311
, O 0 0.0010610117
the O 0 0.00044738062
drug O 0 0.10728459
should O 0 0.00017042743
be O 0 0.0001875074
stopped O 0 0.00022224146
for O 0 0.00015009551
four O 0 0.000118797696
weeks O 0 0.00011015373
, O 0 0.00019637353
and O 0 0.00017452105
when O 0 0.00012508321
the O 0 0.00020077737
audiogram O 0 0.4302742
is O 0 0.00023251362
stable O 0 0.0002983692
or O 0 0.00020903829
improved O 0 0.00038163445
, O 0 0.00035461222
therapy O 0 0.00035330094
should O 0 0.00013168626
be O 0 0.00019228323
restarted O 0 0.00041098386
at O 0 0.00019245197
10 O 0 0.00023606804
to O 0 0.00027210815
25 O 0 0.00052468514
mg O 0 0.004297749
/ O 0 0.0017414007
kg O 0 0.0020872066
per O 0 0.0016690498
dose O 0 0.005875582
. O 0 0.0066362573

Serial O 0 0.0074200695
audiograms O 0 0.030857824
should O 0 0.0012434319
be O 0 0.0009729188
performed O 0 0.0006216419
every O 0 0.00035350345
six O 0 0.00030853067
months O 0 0.00026085283
in O 0 0.00026954905
those O 0 0.00029998735
without O 0 0.00024252446
problems O 0 0.00092809566
and O 0 0.00031319875
more O 0 0.00029737497
frequently O 0 0.00028277663
in O 0 0.0001833872
young O 0 0.0010856506
patients O 0 0.00026598264
with O 0 0.00022699012
normal O 0 0.0006623665
serum O 0 0.44289473
ferritin O 0 0.9963057
values O 0 0.00040277408
and O 0 0.0004863203
in O 0 0.0005412143
those O 0 0.00096646236
with O 0 0.0017586238
auditory B-Disease 0 0.63161695
dysfunction I-Disease 0 0.9880377
. O 0 0.0077483556

Lidocaine B-Chemical 0 0.99983513
- O 0 0.10748006
induced O 0 0.027959334
cardiac B-Disease 0 0.99024093
asystole I-Disease 0 0.9998294
. O 0 0.034920093

Intravenous O 0 0.24628633
administration O 0 0.00770757
of O 0 0.0018636492
a O 0 0.0013902129
single O 0 0.00091241585
50 O 0 0.0009912574
- O 0 0.0043651024
mg O 0 0.019639995
bolus O 0 0.0023463448
of O 0 0.0009054362
lidocaine B-Chemical 0 0.99986064
in O 0 0.00030398782
a O 0 0.00036505924
67 O 0 0.0007149836
- O 0 0.0028071164
year O 0 0.00031344846
- O 0 0.0027465548
old O 0 0.0002909423
man O 0 0.008154559
resulted O 0 0.00019645295
in O 0 0.00026057995
profound O 0 0.009731324
depression B-Disease 0 0.9984668
of O 0 0.00035905567
the O 0 0.00025802216
activity O 0 0.0002938916
of O 0 0.00040196473
the O 0 0.00047416944
sinoatrial O 0 0.06969351
and O 0 0.001085086
atrioventricular O 0 0.18502079
nodal O 0 0.031179417
pacemakers O 0 0.02460249
. O 0 0.005631843

The O 0 0.0031450882
patient O 0 0.0022702161
had O 0 0.0013534151
no O 0 0.0008310125
apparent O 0 0.00079604884
associated O 0 0.0007088788
conditions O 0 0.0006199432
which O 0 0.00057706283
might O 0 0.00026401703
have O 0 0.00027639288
predisposed O 0 0.02980705
him O 0 0.00075865194
to O 0 0.00018016483
the O 0 0.00019654738
development O 0 0.00059773773
of O 0 0.0012023366
bradyarrhythmias B-Disease 0 0.99986064
; O 0 0.0013796089
and O 0 0.0003455265
, O 0 0.0003974186
thus O 0 0.00036588218
, O 0 0.00039962583
this O 0 0.00028773883
probably O 0 0.00045350267
represented O 0 0.0004707656
a O 0 0.0007800913
true O 0 0.0015569095
idiosyncrasy O 0 0.5632537
to O 0 0.00319091
lidocaine B-Chemical 0 0.9996902
. O 0 0.0073731644

Flurbiprofen B-Chemical 0 0.9996222
in O 0 0.0063656
the O 0 0.004908877
treatment O 0 0.0054572946
of O 0 0.0085578365
juvenile B-Disease 0 0.9876444
rheumatoid I-Disease 0 0.9999716
arthritis I-Disease 0 0.9999927
. O 0 0.033443384

Thirty O 0 0.0075219064
- O 0 0.006027675
four O 0 0.0014575204
patients O 0 0.0014920428
with O 0 0.0015383186
juvenile B-Disease 0 0.97054714
rheumatoid I-Disease 0 0.9999962
arthritis I-Disease 0 0.99999976
, O 0 0.015239717
who O 0 0.0010795878
were O 0 0.00026315427
treated O 0 0.00030788858
with O 0 0.0007692468
flurbiprofen B-Chemical 0 0.9999937
at O 0 0.00017706798
a O 0 0.00018446398
maximum O 0 0.00013491942
dose O 0 0.00047776414
of O 0 0.00024390235
4 O 0 0.00017806812
mg O 0 0.010425922
/ O 0 0.001385251
kg O 0 0.0010324188
/ O 0 0.0013244584
day O 0 0.00017670738
, O 0 0.00025500523
had O 0 0.00016545245
statistically O 0 0.0001540703
significant O 0 0.00017145394
decreases O 0 0.00018781621
from O 0 0.00016962913
baseline O 0 0.00021592512
in O 0 0.00023909297
6 O 0 0.0002904174
arthritis B-Disease 0 0.98786455
indices O 0 0.00053098734
after O 0 0.0004064801
12 O 0 0.00059805193
weeks O 0 0.00079444
of O 0 0.0019517824
treatment O 0 0.0038919211
. O 0 0.006657928

Improvements O 0 0.0038811625
were O 0 0.0022934636
seen O 0 0.0014943263
in O 0 0.0010528493
the O 0 0.0007412893
number O 0 0.00059802807
of O 0 0.00081272586
tender B-Disease 0 0.31819555
joints I-Disease 0 0.5138166
, O 0 0.00056930014
the O 0 0.00028328694
severity O 0 0.001410767
of O 0 0.0005843639
swelling B-Disease 0 0.9918424
and O 0 0.0023885306
tenderness B-Disease 0 0.98920596
, O 0 0.00037945565
the O 0 0.00016015623
time O 0 0.00011946955
of O 0 0.0001884047
walk O 0 0.00033368604
50 O 0 0.00023427875
feet O 0 0.0016585285
, O 0 0.000247443
the O 0 0.00016949396
duration O 0 0.00016983124
of O 0 0.00036912144
morning B-Disease 0 0.09507022
stiffness I-Disease 0 0.7780936
and O 0 0.000489187
the O 0 0.0004897355
circumference O 0 0.0040899864
of O 0 0.0011007036
the O 0 0.0015118596
left O 0 0.004227507
knee O 0 0.11250184
. O 0 0.006585652

The O 0 0.0032281566
most O 0 0.0027025586
frequently O 0 0.0018725039
observed O 0 0.0010508107
side O 0 0.009533871
effect O 0 0.00080860505
was O 0 0.0007483769
fecal B-Disease 0 0.4281485
occult I-Disease 0 0.84326696
blood I-Disease 0 0.32663676
( O 0 0.0006482089
25 O 0 0.00030024172
% O 0 0.0002518165
of O 0 0.00025559717
patients O 0 0.00051045837
) O 0 0.00075079384
; O 0 0.00052751665
however O 0 0.00032878324
, O 0 0.00028762803
there O 0 0.00014542775
was O 0 0.00018661948
no O 0 0.0001486765
other O 0 0.00022005827
evidence O 0 0.0002327354
of O 0 0.0006696299
gastrointestinal B-Disease 0 0.9463441
( I-Disease 0 0.012536109
GI I-Disease 0 0.94711906
) I-Disease 0 0.012878785
bleeding I-Disease 0 0.99690443
in O 0 0.0014577964
these O 0 0.002369502
patients O 0 0.0049831183
. O 0 0.0065097013

One O 0 0.005399489
patient O 0 0.0032159688
was O 0 0.0023538417
prematurely O 0 0.0046967203
discontinued O 0 0.0028770948
from O 0 0.00089488586
the O 0 0.0008608982
study O 0 0.001082079
for O 0 0.0011808263
severe O 0 0.48197842
headache B-Disease 0 0.999925
and O 0 0.004301428
abdominal B-Disease 0 0.40045986
pain I-Disease 0 0.9466408
. O 0 0.008114823

Most O 0 0.007906087
side O 0 0.011766217
effects O 0 0.004018312
were O 0 0.003082235
mild O 0 0.09643139
and O 0 0.0023965277
related O 0 0.0018491747
to O 0 0.0024989783
the O 0 0.003975839
GI O 0 0.6282711
tract O 0 0.057062466
. O 0 0.011770192

Hyperkalemia B-Disease 0 0.99945265
associated O 0 0.019027473
with O 0 0.03313809
sulindac B-Chemical 1 0.9999826
therapy O 0 0.21611838
. O 0 0.025763875

Hyperkalemia B-Disease 0 0.9996227
has O 0 0.0029801626
recently O 0 0.0018831107
been O 0 0.0012588318
recognized O 0 0.0010503008
as O 0 0.0007759361
a O 0 0.0009849126
complication O 0 0.19363426
of O 0 0.0060084523
nonsteroidal O 0 0.99999726
antiinflammatory O 0 0.9980835
agents O 0 0.38004914
( O 0 0.103317454
NSAID O 0 0.9999994
) O 0 0.0077668545
such O 0 0.0018102938
as O 0 0.003707716
indomethacin B-Chemical 1 0.99995947
. O 0 0.009546812

Several O 0 0.0036731511
recent O 0 0.0025486497
studies O 0 0.0016825468
have O 0 0.0011205908
stressed O 0 0.0012043627
the O 0 0.0009176933
renal O 0 0.77286124
sparing O 0 0.039849993
features O 0 0.0015735555
of O 0 0.0069390587
sulindac B-Chemical 1 0.99999964
, O 0 0.0015654803
owing O 0 0.0003843031
to O 0 0.00027809935
its O 0 0.00049537397
lack O 0 0.00036428866
of O 0 0.00062517
interference O 0 0.001474906
with O 0 0.0036306945
renal O 0 0.9977049
prostacyclin B-Chemical 0 0.9999963
synthesis O 0 0.31416178
. O 0 0.009044634

We O 0 0.00345626
describe O 0 0.0021493575
4 O 0 0.0015901619
patients O 0 0.0013520892
in O 0 0.0009752436
whom O 0 0.0032079571
hyperkalemia B-Disease 2 0.99998283
ranging O 0 0.00084636325
from O 0 0.00032451752
6 O 0 0.00023999785
. O 0 0.00022051824
1 O 0 0.00020326354
to O 0 0.0001711601
6 O 0 0.0001723752
. O 0 0.00019686171
9 O 0 0.0002457968
mEq O 0 0.09143129
/ O 0 0.00092424033
l O 0 0.00074349693
developed O 0 0.00036775935
within O 0 0.00021665494
3 O 0 0.00028459445
to O 0 0.00033185768
8 O 0 0.0004965795
days O 0 0.0006554946
of O 0 0.0025438005
sulindac B-Chemical 1 0.9999958
administration O 0 0.2991896
. O 0 0.0076125846

In O 0 0.0037415635
all O 0 0.002196493
of O 0 0.0018713635
them O 0 0.0019561853
normal O 0 0.002268427
serum O 0 0.6601497
potassium B-Chemical 0 0.9999224
levels O 0 0.0006584722
reached O 0 0.00046463544
within O 0 0.0003397948
2 O 0 0.0004357119
to O 0 0.00043820572
4 O 0 0.00057006354
days O 0 0.0007228384
of O 0 0.001860612
stopping O 0 0.17369662
sulindac B-Chemical 1 0.99999225
. O 0 0.01115821

As O 0 0.0031336616
no O 0 0.0019195973
other O 0 0.0018073356
medications O 0 0.02613386
known O 0 0.0009166141
to O 0 0.00050292216
effect O 0 0.00070167077
serum O 0 0.858791
potassium B-Chemical 0 0.9999877
had O 0 0.0005165009
been O 0 0.00023246244
given O 0 0.00014343961
concomitantly O 0 0.0007495436
, O 0 0.00029727942
this O 0 0.00015860247
course O 0 0.0001568429
of O 0 0.00024360722
events O 0 0.0036152143
is O 0 0.00022755894
suggestive O 0 0.00034630776
of O 0 0.00030561164
a O 0 0.00042850856
cause O 0 0.0007974056
- O 0 0.025114877
and O 0 0.00061349466
- O 0 0.0042128665
effect O 0 0.00038112656
relationship O 0 0.00045622716
between O 0 0.0011140571
sulindac B-Chemical 1 0.9999982
and O 0 0.08261578
hyperkalemia B-Disease 2 0.9999907
. O 0 0.0099983085

These O 0 0.0033460476
observations O 0 0.0021319187
indicate O 0 0.0011134715
that O 0 0.00092005933
initial O 0 0.00083270326
hopes O 0 0.0070713614
that O 0 0.0012674333
sulindac B-Chemical 1 0.99999917
may O 0 0.00059746945
not O 0 0.00030451544
be O 0 0.00027103446
associated O 0 0.00027936327
with O 0 0.0002837045
the O 0 0.00031366636
adverse O 0 0.374772
renal O 0 0.72242147
effects O 0 0.00071761623
of O 0 0.0009085477
other O 0 0.0075586
NSAID O 0 0.9999987
are O 0 0.001342352
probably O 0 0.0020263714
not O 0 0.0021862292
justified O 0 0.006298312
. O 0 0.00670399

Drug O 0 0.7783257
- O 0 0.03196472
induced O 0 0.010666143
arterial O 0 0.96501213
spasm B-Disease 2 0.9999187
relieved O 0 0.28209817
by O 0 0.015675077
lidocaine B-Chemical 0 0.9997284
. O 0 0.018067742

Case O 0 0.10432168
report O 0 0.0857515
. O 0 0.08370406

Following O 0 0.0037414033
major O 0 0.0033175112
intracranial O 0 0.63886404
surgery O 0 0.0020464933
in O 0 0.0008652815
a O 0 0.0008359266
35 O 0 0.00070310285
- O 0 0.0018823993
year O 0 0.0005728769
- O 0 0.0022603031
old O 0 0.0005721647
man O 0 0.08606881
, O 0 0.00914646
sodium B-Chemical 0 0.9999926
pentothal I-Chemical 0 0.9997416
was O 0 0.00053895084
intravenously O 0 0.0006115542
infused O 0 0.0008198356
to O 0 0.0008119139
minimize O 0 0.0014451905
cerebral B-Disease 0 0.99980575
ischaemia I-Disease 0 0.9999969
. O 0 0.012212641

Intense O 0 0.27376014
vasospasm B-Disease 2 0.99998486
with O 0 0.0057841525
threatened O 0 0.1293337
gangrene B-Disease 0 0.9995485
arose O 0 0.001514224
in O 0 0.001218971
the O 0 0.0011297701
arm O 0 0.0014713822
used O 0 0.0013419387
for O 0 0.0018551261
the O 0 0.0030151885
infusion O 0 0.007915151
. O 0 0.00791781

Since O 0 0.003022616
the O 0 0.002358067
cranial O 0 0.025906708
condition O 0 0.0018167209
precluded O 0 0.001039108
use O 0 0.00069373596
of O 0 0.00064693694
more O 0 0.0005302331
usual O 0 0.00038395135
methods O 0 0.00032896007
, O 0 0.0013445766
lidocaine B-Chemical 0 0.99980253
was O 0 0.00027348768
given O 0 0.00016914314
intra O 0 0.0024671885
- O 0 0.004516655
arterially O 0 0.0008635671
, O 0 0.0003131235
with O 0 0.00028545508
careful O 0 0.0005102147
cardiovascular O 0 0.75472516
monitoring O 0 0.00079265697
, O 0 0.0008576697
to O 0 0.0008320595
counteract O 0 0.0016994759
the O 0 0.004930374
vasospasm B-Disease 2 0.99999344
. O 0 0.009632304

The O 0 0.013923725
treatment O 0 0.014721612
was O 0 0.015846848
rapidly O 0 0.018992385
successful O 0 0.024784708
. O 0 0.028235205

Regional O 0 0.0045393948
localization O 0 0.002437019
of O 0 0.0022025388
the O 0 0.0017877689
antagonism O 0 0.5069486
of O 0 0.043445192
amphetamine B-Chemical 1 0.99999976
- O 0 0.27759334
induced O 0 0.003923297
hyperactivity B-Disease 2 0.9999678
by O 0 0.003622477
intracerebral O 0 0.99913627
calcitonin B-Chemical 0 0.9736849
injections O 0 0.01230715
. O 0 0.0071416725

Calcitonin B-Chemical 0 0.77909106
receptors O 0 0.009127164
are O 0 0.0018211753
found O 0 0.0011387033
in O 0 0.0008879052
the O 0 0.000783116
brain O 0 0.010026408
, O 0 0.0009780324
and O 0 0.0009950196
intracerebral O 0 0.99272126
infusions O 0 0.0049297987
of O 0 0.00090656267
calcitonin B-Chemical 0 0.69775623
can O 0 0.00088002277
produce O 0 0.0012306125
behavioral O 0 0.015780088
effects O 0 0.0043685795
. O 0 0.006663162

Among O 0 0.005206055
these O 0 0.002801196
behavioral O 0 0.009346061
effects O 0 0.0016577037
are O 0 0.00091834005
decreases O 0 0.0007745886
in O 0 0.00070232863
food O 0 0.011855395
intake O 0 0.4687222
and O 0 0.0007527332
decreases O 0 0.00092368736
in O 0 0.0033144746
amphetamine B-Chemical 1 0.9999994
- O 0 0.10134155
induced O 0 0.0028743302
locomotor O 0 0.7783681
activity O 0 0.0042617153
. O 0 0.006828422

In O 0 0.0035315321
previous O 0 0.0019407969
experiments O 0 0.0011604584
we O 0 0.0008382158
found O 0 0.0007150123
that O 0 0.00053284277
decreases O 0 0.00059311825
in O 0 0.0005391807
food O 0 0.014946355
intake O 0 0.40890452
were O 0 0.00026409933
induced O 0 0.00021934394
by O 0 0.0002378835
local O 0 0.00039158424
administration O 0 0.0016021187
of O 0 0.00037406443
calcitonin B-Chemical 0 0.5711233
into O 0 0.00015964684
several O 0 0.00023408806
hypothalamic O 0 0.002178048
sites O 0 0.00041677186
and O 0 0.000555368
into O 0 0.000567273
the O 0 0.001296703
nucleus O 0 0.0040803757
accumbens O 0 0.44324604
. O 0 0.006053358

In O 0 0.0033704368
the O 0 0.001984434
present O 0 0.0012373416
experiment O 0 0.001078699
calcitonin B-Chemical 0 0.84165543
decreased O 0 0.0021697413
locomotor O 0 0.51196676
activity O 0 0.00044565852
when O 0 0.00026308428
locally O 0 0.00057586207
injected O 0 0.00026778108
into O 0 0.00019803365
the O 0 0.00028945573
same O 0 0.0002860517
sites O 0 0.0005395427
where O 0 0.0007358466
it O 0 0.0011617806
decreases O 0 0.001856412
food O 0 0.028350482
intake O 0 0.62305796
. O 0 0.007231251

The O 0 0.0030062376
areas O 0 0.0034022778
where O 0 0.002177277
calcitonin B-Chemical 0 0.8642543
is O 0 0.0012536632
most O 0 0.00097065925
effective O 0 0.0005718566
in O 0 0.0003820995
decreasing O 0 0.0005970655
locomotor O 0 0.39866415
activity O 0 0.00023775401
are O 0 0.0001544355
located O 0 0.00014204951
in O 0 0.00013838163
the O 0 0.0001651196
hypothalamus O 0 0.008896332
and O 0 0.00022963322
nucleus O 0 0.00095231604
accumbens O 0 0.4203509
, O 0 0.00020863824
suggesting O 0 0.00011160167
that O 0 0.000113060116
these O 0 0.00017169902
areas O 0 0.00040671614
are O 0 0.00014861512
the O 0 0.00014311363
major O 0 0.00018597538
sites O 0 0.00020790749
of O 0 0.00026185808
action O 0 0.0004989376
of O 0 0.00064479513
calcitonin B-Chemical 0 0.93690294
in O 0 0.0006455594
inhibiting O 0 0.019440088
amphetamine B-Chemical 1 0.99999964
- O 0 0.14424938
induced O 0 0.0027132405
locomotor O 0 0.7881685
activity O 0 0.0038349507
. O 0 0.006235826

The O 0 0.0037802355
hematologic O 0 0.41145465
effects O 0 0.0026313497
of O 0 0.0029915867
cefonicid B-Chemical 0 0.99879694
and O 0 0.009099326
cefazedone B-Chemical 1 0.9997856
in O 0 0.00066607766
the O 0 0.0005030756
dog O 0 0.0014730666
: O 0 0.0006794833
a O 0 0.000458956
potential O 0 0.000514327
model O 0 0.0008129381
of O 0 0.008609433
cephalosporin B-Chemical 0 0.9999949
hematotoxicity B-Disease 0 0.9999982
in O 0 0.008251435
man O 0 0.5722272
. O 0 0.008433664

Cephalosporin B-Chemical 0 0.9940818
antibiotics O 0 0.38289988
cause O 0 0.0032764
a O 0 0.0018512452
variety O 0 0.0015161356
of O 0 0.0023120134
hematologic B-Disease 0 0.99954873
disturbances I-Disease 0 0.9858417
in O 0 0.0007395553
man O 0 0.08607903
, O 0 0.0006518985
the O 0 0.0003742618
pathogeneses O 0 0.0024314425
and O 0 0.00057737017
hematopathology O 0 0.0010133991
of O 0 0.0007703754
which O 0 0.0010764946
remain O 0 0.0014297727
poorly O 0 0.0030780185
characterized O 0 0.0045329505
. O 0 0.006970024

There O 0 0.0045635113
is O 0 0.0028059178
a O 0 0.0020724514
need O 0 0.0011734539
for O 0 0.0009787491
a O 0 0.0010076751
well O 0 0.00077585597
- O 0 0.0027710327
defined O 0 0.0004556837
animal O 0 0.0006450707
model O 0 0.00047527268
in O 0 0.000467275
which O 0 0.00067699514
these O 0 0.0010751167
blood B-Disease 0 0.8204353
dyscrasias I-Disease 0 0.99952173
can O 0 0.0013627711
be O 0 0.0023418507
studied O 0 0.0042026453
. O 0 0.006955593

In O 0 0.0038948134
four O 0 0.002572042
subacute O 0 0.9955089
toxicity B-Disease 2 0.9991418
studies O 0 0.0016281202
, O 0 0.001168631
the O 0 0.0005653517
intravenous O 0 0.034126163
administration O 0 0.0055611073
of O 0 0.0011333951
cefonicid B-Chemical 0 0.99873835
or O 0 0.0016788449
cefazedone B-Chemical 1 0.9997557
to O 0 0.0002708087
beagle O 0 0.0050217533
dogs O 0 0.00041936277
caused O 0 0.00018829138
a O 0 0.0003434578
dose O 0 0.006016916
- O 0 0.0077405577
dependent O 0 0.00017001403
incidence O 0 0.0035506173
of O 0 0.004224912
anemia B-Disease 0 0.99999785
, O 0 0.05002909
neutropenia B-Disease 0 0.9999337
, O 0 0.0023952993
and O 0 0.002051867
thrombocytopenia B-Disease 0 0.9999455
after O 0 0.00030649194
1 O 0 0.000498372
- O 0 0.0013742769
3 O 0 0.0006549104
months O 0 0.0008555733
of O 0 0.0019677193
treatment O 0 0.0038559772
. O 0 0.006629398

A O 0 0.3917363
nonregenerative O 0 0.9085858
anemia B-Disease 0 0.99995863
was O 0 0.0020023554
the O 0 0.0008991978
most O 0 0.0008227873
compromising O 0 0.0009673868
of O 0 0.00062268635
the O 0 0.0007577596
cytopenias B-Disease 0 0.99995303
and O 0 0.00049528043
occurred O 0 0.00024832026
in O 0 0.0001794643
approximately O 0 0.00017847047
50 O 0 0.00022641731
% O 0 0.0002040128
of O 0 0.00020383354
dogs O 0 0.00039144018
receiving O 0 0.00032216182
400 O 0 0.00059646496
- O 0 0.0021609787
500 O 0 0.00040234483
mg O 0 0.007441925
/ O 0 0.001147389
kg O 0 0.0018816764
cefonicid B-Chemical 0 0.96714437
or O 0 0.0005476262
540 O 0 0.12548321
- O 0 0.009845621
840 O 0 0.018222474
mg O 0 0.041977853
/ O 0 0.006331765
kg O 0 0.021382913
cefazedone B-Chemical 1 0.9977457
. O 0 0.008758684

All O 0 0.0031468947
three O 0 0.0021862313
cytopenias B-Disease 0 0.99906737
were O 0 0.0012379816
completely O 0 0.0008309682
reversible O 0 0.016444365
following O 0 0.0004572017
cessation O 0 0.0075681815
of O 0 0.00046727635
treatment O 0 0.00056853716
; O 0 0.00046053503
the O 0 0.00015558545
time O 0 0.000106057756
required O 0 9.443605e-05
for O 0 0.00013415355
recovery O 0 0.00022210926
of O 0 0.00020767626
the O 0 0.00024083545
erythron O 0 0.7488006
( O 0 0.00033124257
approximately O 0 0.00015069166
1 O 0 0.00014352854
month O 0 0.000121340505
) O 0 0.00026925522
was O 0 0.00015082318
considerably O 0 0.00016309167
longer O 0 9.5686344e-05
than O 0 0.00010042056
that O 0 0.00011909318
of O 0 0.00021863091
the O 0 0.00026569652
granulocytes O 0 0.1772624
and O 0 0.0005342761
platelets O 0 0.10376527
( O 0 0.0005689209
hours O 0 0.0003610339
to O 0 0.00048377874
a O 0 0.00085339404
few O 0 0.0009707281
days O 0 0.0016181776
) O 0 0.0045496603
. O 0 0.00664154

Upon O 0 0.0051606707
rechallenge O 0 0.16717973
with O 0 0.0027905686
either O 0 0.0035349273
cephalosporin B-Chemical 0 0.9999614
, O 0 0.0101436945
the O 0 0.0023172067
hematologic B-Disease 0 0.99980944
syndrome I-Disease 0 0.99516195
was O 0 0.00045312286
reproduced O 0 0.00036681365
in O 0 0.00021656964
most O 0 0.00028565078
dogs O 0 0.0003825535
tested O 0 0.00021634408
; O 0 0.0029978186
cefonicid B-Chemical 0 0.9967116
( O 0 0.0011743138
but O 0 0.00042627958
not O 0 0.0004260078
cefazedone B-Chemical 1 0.9999136
) O 0 0.017476285
- O 0 0.018856935
treated O 0 0.00029721056
dogs O 0 0.00039175487
showed O 0 0.00015209087
a O 0 0.00018634423
substantially O 0 0.00016370491
reduced O 0 0.00014776236
induction O 0 0.00015074323
period O 0 0.00013405368
( O 0 0.0003022677
15 O 0 0.00015814447
+ O 0 0.0010013893
/ O 0 0.008382633
- O 0 0.0049539357
5 O 0 0.00013538309
days O 0 0.00011178731
) O 0 0.00021754236
compared O 0 0.000104166924
to O 0 0.000114897644
that O 0 0.00011747251
of O 0 0.00018346557
the O 0 0.00015968656
first O 0 0.00013756292
exposure O 0 0.0005915369
to O 0 0.00018110492
the O 0 0.0002742237
drug O 0 0.16067997
( O 0 0.00075868744
61 O 0 0.0009448882
+ O 0 0.0019278391
/ O 0 0.006632464
- O 0 0.0055651176
24 O 0 0.00147311
days O 0 0.001784652
) O 0 0.004756408
. O 0 0.0068796873

This O 0 0.0050567943
observation O 0 0.002623026
, O 0 0.0020840059
along O 0 0.0010000317
with O 0 0.00084279646
the O 0 0.0005931162
rapid O 0 0.0007925493
rate O 0 0.00048292754
of O 0 0.00056567346
decline O 0 0.0054493137
in O 0 0.0003989837
red O 0 0.015237449
cell O 0 0.0011180441
mass O 0 0.0015145137
parameters O 0 0.0003510015
of O 0 0.00029800416
affected O 0 0.00026535496
dogs O 0 0.00068975944
, O 0 0.00029538572
suggests O 0 0.00012477324
that O 0 0.00016302512
a O 0 0.00088705483
hemolytic B-Disease 0 0.99997735
component O 0 0.0006428558
complicated O 0 0.0031294194
the O 0 0.0002584491
red O 0 0.015519377
cell O 0 0.0013168223
production O 0 0.0005599628
problem O 0 0.00052318687
and O 0 0.00027325834
that O 0 0.00022409843
multiple O 0 0.0004541477
toxicologic O 0 0.0053450204
mechanisms O 0 0.0005437347
contributed O 0 0.0011266544
to O 0 0.0012930223
the O 0 0.0031039594
cytopenia B-Disease 0 0.99992275
. O 0 0.008496166

We O 0 0.0032984442
conclude O 0 0.0017320177
that O 0 0.0012888955
the O 0 0.0010989269
administration O 0 0.003360428
of O 0 0.0008461661
high O 0 0.00095713977
doses O 0 0.006757441
of O 0 0.0021507088
cefonicid B-Chemical 0 0.99927574
or O 0 0.0025962389
cefazedone B-Chemical 1 0.9997813
to O 0 0.0002610193
dogs O 0 0.00063867716
can O 0 0.00015473254
induce O 0 0.000203536
hematotoxicity B-Disease 0 0.99999356
similar O 0 0.00015842036
to O 0 0.00015535034
the O 0 0.0004532077
cephalosporin B-Chemical 0 0.9999846
- O 0 0.20183568
induced O 0 0.0017307864
blood B-Disease 0 0.9812711
dyscrasias I-Disease 0 0.9999145
described O 0 0.0001708775
in O 0 0.0001748625
man O 0 0.009510574
and O 0 0.00023973075
thus O 0 0.00024849462
provides O 0 0.00017675255
a O 0 0.00023648165
useful O 0 0.00021320199
model O 0 0.00026720064
for O 0 0.00030965728
studying O 0 0.00046221766
the O 0 0.00053160416
mechanisms O 0 0.0007777776
of O 0 0.0016851174
these O 0 0.0034074245
disorders O 0 0.87442297
. O 0 0.007252073

Cerebral O 0 0.53799194
blood O 0 0.011398811
flow O 0 0.005679467
and O 0 0.0019383223
metabolism O 0 0.06390427
during O 0 0.0011032657
isoflurane B-Chemical 1 0.99981886
- O 0 0.08591408
induced O 0 0.0023386446
hypotension B-Disease 2 0.9999869
in O 0 0.00061720976
patients O 0 0.00062606076
subjected O 0 0.00043968527
to O 0 0.00068364595
surgery O 0 0.0016708495
for O 0 0.0022273806
cerebral B-Disease 0 0.9995546
aneurysms I-Disease 2 0.9999281
. O 0 0.008660824

Cerebral O 0 0.5628442
blood O 0 0.012558513
flow O 0 0.00602321
and O 0 0.0019408854
cerebral O 0 0.79680586
metabolic O 0 0.020261323
rate O 0 0.0006521986
for O 0 0.00056384865
oxygen B-Chemical 1 0.9860934
were O 0 0.0003213446
measured O 0 0.00021793929
during O 0 0.00026891555
isoflurane B-Chemical 1 0.9996573
- O 0 0.054906845
induced O 0 0.0012762164
hypotension B-Disease 2 0.99998915
in O 0 0.0002944629
10 O 0 0.0002059249
patients O 0 0.00021416773
subjected O 0 0.0001684644
to O 0 0.00025971234
craniotomy O 0 0.016477492
for O 0 0.00047413696
clipping O 0 0.004642842
of O 0 0.0013953062
a O 0 0.00455745
cerebral B-Disease 0 0.99969745
aneurysm I-Disease 2 0.9999236
. O 0 0.009540951

Flow O 0 0.19667329
and O 0 0.0034551679
metabolism O 0 0.019459533
were O 0 0.0012374582
measured O 0 0.00077477284
5 O 0 0.000683849
- O 0 0.0013423591
13 O 0 0.00042933572
days O 0 0.0002483023
after O 0 0.00023116499
the O 0 0.000610158
subarachnoid B-Disease 0 0.9999944
haemorrhage I-Disease 0 0.9999993
by O 0 0.000415176
a O 0 0.0003340441
modification O 0 0.0004219323
of O 0 0.00027653415
the O 0 0.00023872897
classical O 0 0.0010181997
Kety O 0 0.54909307
- O 0 0.009827926
Schmidt O 0 0.008971925
technique O 0 0.00024055823
using O 0 0.0002230713
xenon B-Chemical 0 0.9937143
- O 0 0.024593899
133 O 0 0.0023255157
i O 0 0.0019127431
. O 0 0.00024329178
v O 0 0.016574258
. O 0 0.0003113689
Anaesthesia O 0 0.09051505
was O 0 0.00017442189
maintained O 0 0.00014572786
with O 0 0.00018240504
an O 0 0.00024579003
inspired O 0 0.0055019427
isoflurane B-Chemical 1 0.9983053
concentration O 0 0.0009057282
of O 0 0.00033891317
0 O 0 0.00027707938
. O 0 0.00015717436
75 O 0 0.00020802605
% O 0 0.00020948242
( O 0 0.00023416529
plus O 0 0.00015185989
67 O 0 0.00038014958
% O 0 0.00040193312
nitrous B-Chemical 0 0.99537814
oxide I-Chemical 0 0.94427407
in O 0 0.00044401642
oxygen B-Chemical 1 0.9983498
) O 0 0.0016802665
, O 0 0.00030843331
during O 0 0.0001420071
which O 0 0.00043561563
CBF O 0 0.9674745
and O 0 0.0006211018
CMRO2 O 0 0.99880767
were O 0 0.00019556521
34 O 0 0.0002040741
. O 0 0.00014620386
3 O 0 0.00015611509
+ O 0 0.000643282
/ O 0 0.006930344
- O 0 0.009035884
2 O 0 0.00019870492
. O 0 0.00015823587
1 O 0 0.00015951825
ml O 0 0.0002780031
/ O 0 0.00058211386
100 O 0 0.00026848871
g O 0 0.00033722192
min O 0 0.00031973506
- O 0 0.00096253114
1 O 0 0.00016610273
and O 0 0.00017591022
2 O 0 0.00016694558
. O 0 0.00015808492
32 O 0 0.00025273574
+ O 0 0.00082861976
/ O 0 0.007300107
- O 0 0.008520869
0 O 0 0.00025104312
. O 0 0.0001644518
16 O 0 0.00017763823
ml O 0 0.0002824738
/ O 0 0.00059131655
100 O 0 0.0002726548
g O 0 0.00033761194
min O 0 0.00031428182
- O 0 0.00081609364
1 O 0 0.00016504058
at O 0 0.000160729
PaCO2 O 0 0.6829201
4 O 0 0.00016545829
. O 0 0.00016971826
1 O 0 0.00020838398
+ O 0 0.0006428681
/ O 0 0.004100488
- O 0 0.0051632617
0 O 0 0.00033438503
. O 0 0.000273324
1 O 0 0.0003307046
kPa O 0 0.0021014053
( O 0 0.0006223444
mean O 0 0.00050571194
+ O 0 0.0019269491
/ O 0 0.005106282
- O 0 0.007495937
SEM O 0 0.005156506
) O 0 0.006466556
. O 0 0.008290411

Controlled O 0 0.0058079096
hypotension B-Disease 2 0.99960476
to O 0 0.00191163
an O 0 0.0014960128
average O 0 0.0008605472
MAP O 0 0.7760339
of O 0 0.000958905
50 O 0 0.00089170766
- O 0 0.0020908813
55 O 0 0.00041163672
mm O 0 0.0020685086
Hg B-Chemical 0 0.9791381
was O 0 0.00027830122
induced O 0 0.00022438899
by O 0 0.00022601377
increasing O 0 0.00021326868
the O 0 0.00020549772
dose O 0 0.0020642737
of O 0 0.0013840772
isoflurane B-Chemical 1 0.999726
, O 0 0.0005955663
and O 0 0.00023095064
maintained O 0 0.000161625
at O 0 0.00014323679
an O 0 0.000191136
inspired O 0 0.0004556939
concentration O 0 0.0004017205
of O 0 0.00033501908
2 O 0 0.00026617292
. O 0 0.00026110094
2 O 0 0.00034476936
+ O 0 0.0010518703
/ O 0 0.004379225
- O 0 0.0052256756
0 O 0 0.0012218521
. O 0 0.0014621856
2 O 0 0.0023197236
% O 0 0.0045395284
. O 0 0.007275248

This O 0 0.004934182
resulted O 0 0.0022854079
in O 0 0.0017360994
a O 0 0.0014908178
significant O 0 0.0009935625
decrease O 0 0.00087546225
in O 0 0.0011334858
CMRO2 O 0 0.9997266
( O 0 0.00089893315
to O 0 0.00029710206
1 O 0 0.00028693886
. O 0 0.00023792639
73 O 0 0.00049088197
+ O 0 0.0010738474
/ O 0 0.007246002
- O 0 0.007472849
0 O 0 0.00029173837
. O 0 0.00019955913
16 O 0 0.00021798897
ml O 0 0.00033823034
/ O 0 0.0006746742
100 O 0 0.0003671624
g O 0 0.00048383058
min O 0 0.00052350666
- O 0 0.0017812167
1 O 0 0.00049799395
) O 0 0.00091967155
, O 0 0.0011120246
while O 0 0.001526111
CBF O 0 0.89431846
was O 0 0.0026400047
unchanged O 0 0.00415608
. O 0 0.007427308

After O 0 0.0029635571
the O 0 0.002514386
clipping O 0 0.005081418
of O 0 0.0016769207
the O 0 0.0014958212
aneurysm B-Disease 2 0.99707854
the O 0 0.00167766
isoflurane B-Chemical 1 0.99909055
concentration O 0 0.0022415987
was O 0 0.00072356174
reduced O 0 0.0007141191
to O 0 0.0008192893
0 O 0 0.0012903197
. O 0 0.0016036999
75 O 0 0.0029799417
% O 0 0.004797409
. O 0 0.0075402544

There O 0 0.0045770435
was O 0 0.0029061062
a O 0 0.0022169591
significant O 0 0.0014458797
increase O 0 0.0010718472
in O 0 0.0015005441
CBF O 0 0.9939427
, O 0 0.0020897144
although O 0 0.0014619804
CMRO2 O 0 0.9994972
was O 0 0.00058287475
unchanged O 0 0.00054920797
, O 0 0.00066315284
compared O 0 0.00047470335
with O 0 0.0009386091
pre O 0 0.005361208
- O 0 0.053219736
hypotensive B-Disease 0 0.9944425
values O 0 0.0040951623
. O 0 0.0070220884

These O 0 0.0046249703
changes O 0 0.00349418
might O 0 0.0018837326
offer O 0 0.0019019907
protection O 0 0.0031565742
to O 0 0.001459189
brain O 0 0.0140772015
tissue O 0 0.0029557995
during O 0 0.0010985469
periods O 0 0.0015609124
of O 0 0.002795966
induced O 0 0.009572003
hypotension B-Disease 2 0.999967
. O 0 0.011633323

Triazolam B-Chemical 0 0.9999819
- O 0 0.028479574
induced O 0 0.0031135457
brief O 0 0.0024262238
episodes O 0 0.009581334
of O 0 0.0027097599
secondary O 0 0.17306064
mania B-Disease 0 0.9999372
in O 0 0.0028254648
a O 0 0.0044884463
depressed B-Disease 2 0.85789686
patient O 0 0.0063235504
. O 0 0.0086108735

Large O 0 0.0072327843
doses O 0 0.011439732
of O 0 0.012470412
triazolam B-Chemical 0 0.9999987
repeatedly O 0 0.0020381273
induced O 0 0.001137385
brief O 0 0.0009991117
episodes O 0 0.013277047
of O 0 0.0028117301
mania B-Disease 0 0.9999155
in O 0 0.0015355789
a O 0 0.002949138
depressed B-Disease 2 0.95811814
elderly O 0 0.50059694
woman O 0 0.03572013
. O 0 0.008529373

Features O 0 0.012466542
of O 0 0.00646943
organic B-Disease 0 0.99096406
mental I-Disease 0 0.78317356
disorder I-Disease 0 0.9992668
( O 0 0.06577771
delirium B-Disease 2 0.99997675
) O 0 0.0052596275
were O 0 0.0030917872
not O 0 0.0035762764
present O 0 0.004925038
. O 0 0.009584172

Manic B-Disease 0 0.9953636
excitement O 0 0.06715366
was O 0 0.0033964685
coincident O 0 0.0028529651
with O 0 0.0020448705
the O 0 0.0017716492
duration O 0 0.0017041228
of O 0 0.0027350725
action O 0 0.0067722006
of O 0 0.045025658
triazolam B-Chemical 0 0.9999976
. O 0 0.014009303

The O 0 0.0033214788
possible O 0 0.0023493862
contribution O 0 0.0015771112
of O 0 0.0017744486
the O 0 0.0018214985
triazolo B-Chemical 0 0.99544096
group O 0 0.0012725668
to O 0 0.0007869341
changes O 0 0.001098605
in O 0 0.0012275003
affective O 0 0.595316
status O 0 0.0026120213
is O 0 0.0029459118
discussed O 0 0.004106619
. O 0 0.0074164327

The O 0 0.0030462025
correlation O 0 0.0020984067
between O 0 0.0020367787
neurotoxic B-Disease 0 0.999551
esterase O 0 0.97332394
inhibition O 0 0.028403752
and O 0 0.026943455
mipafox B-Chemical 0 0.99999416
- O 0 0.30801257
induced O 0 0.01740591
neuropathic B-Disease 0 0.9999951
damage I-Disease 0 0.9976052
in O 0 0.004532673
rats O 0 0.007244298
. O 0 0.0074864286

The O 0 0.0027389158
correlation O 0 0.0018844034
between O 0 0.0019637714
neuropathic B-Disease 0 0.99998534
damage I-Disease 0 0.9978866
and O 0 0.002043457
inhibition O 0 0.004783655
of O 0 0.006699017
neurotoxic B-Disease 0 0.9999633
esterase O 0 0.99276334
or O 0 0.0042176303
neuropathy B-Disease 0 0.9999937
target O 0 0.000738866
enzyme O 0 0.40709886
( O 0 0.023970937
NTE O 0 0.99909306
) O 0 0.0011232563
was O 0 0.00018147482
examined O 0 0.00012121687
in O 0 0.00016729343
rats O 0 0.0002748577
acutely O 0 0.0011165299
exposed O 0 0.000298524
to O 0 0.00035598085
Mipafox B-Chemical 0 0.99997675
( O 0 0.015104359
N B-Chemical 0 0.9996568
, I-Chemical 0 0.011204931
N I-Chemical 0 0.9994729
' I-Chemical 0 0.0068707434
- I-Chemical 0 0.02737245
diisopropylphosphorodiamidofluoridate I-Chemical 0 0.041351143
) O 0 0.0021960314
, O 0 0.0022125493
a O 0 0.00655831
neurotoxic B-Disease 0 0.9999293
organophosphate B-Chemical 0 0.9999974
. O 0 0.013301145

Brain O 0 0.08224411
and O 0 0.0037108653
spinal O 0 0.031419907
cord O 0 0.4078391
NTE O 0 0.9841854
activities O 0 0.000821663
were O 0 0.00046733185
measured O 0 0.0003277055
in O 0 0.00039285925
Long O 0 0.008869013
- O 0 0.016346524
Evans O 0 0.45602426
male O 0 0.0017729382
rats O 0 0.00038041075
1 O 0 0.00020658078
hr O 0 0.00031737986
post O 0 0.00025309456
- O 0 0.0026616948
exposure O 0 0.0008159143
to O 0 0.00017487167
various O 0 0.00029594073
dosages O 0 0.023434842
of O 0 0.0029028968
Mipafox B-Chemical 0 0.9999893
( O 0 0.008865902
ip O 0 0.64786357
, O 0 0.0007458701
1 O 0 0.000499878
- O 0 0.0016243531
15 O 0 0.0006973738
mg O 0 0.005973044
/ O 0 0.0032975432
kg O 0 0.005087149
) O 0 0.006109346
. O 0 0.007713294

These O 0 0.003700306
data O 0 0.0024983385
were O 0 0.0014974929
correlated O 0 0.00085952197
with O 0 0.0007962658
histologically O 0 0.013701832
scored O 0 0.0015958947
cervical O 0 0.643022
cord B-Disease 0 0.97255105
damage I-Disease 0 0.9853703
in O 0 0.00038448704
a O 0 0.00031342098
separate O 0 0.00016500487
group O 0 0.00024425937
of O 0 0.0002513406
similarly O 0 0.000267726
dosed O 0 0.0009962153
rats O 0 0.0003415377
sampled O 0 0.00026703154
14 O 0 0.00039176384
- O 0 0.0010478522
21 O 0 0.00064383313
days O 0 0.00068488927
post O 0 0.0014883957
- O 0 0.005610441
exposure O 0 0.01044799
. O 0 0.007900487

Those O 0 0.007374997
dosages O 0 0.03172688
( O 0 0.0026792635
greater O 0 0.0010950012
than O 0 0.0006121974
or O 0 0.0005014254
equal O 0 0.00033269366
to O 0 0.00031799046
10 O 0 0.000329014
mg O 0 0.0142077245
/ O 0 0.0019124572
kg O 0 0.0012348532
) O 0 0.00045336477
that O 0 0.0001628806
inhibited O 0 0.00024322241
mean O 0 0.0001729986
NTE O 0 0.9864737
activity O 0 0.00022497078
in O 0 0.0001595225
the O 0 0.00017267211
spinal O 0 0.0036989087
cord O 0 0.010385305
greater O 0 0.00012273577
than O 0 9.823102e-05
or O 0 0.00011473178
equal O 0 0.00010269099
to O 0 0.00012920522
73 O 0 0.0003357553
% O 0 0.00020009931
and O 0 0.00019685758
brain O 0 0.0017592466
greater O 0 0.00013318512
than O 0 0.0001042837
or O 0 0.000119913755
equal O 0 0.00010607577
to O 0 0.00013165952
67 O 0 0.0002954198
% O 0 0.00018576908
of O 0 0.00016586788
control O 0 0.00015284425
values O 0 0.0001446658
produced O 0 0.00016838698
severe O 0 0.036506794
( O 0 0.00043331663
greater O 0 0.00014947123
than O 0 0.00011317285
or O 0 0.00013032676
equal O 0 0.00011714655
to O 0 0.00015201751
3 O 0 0.00018786066
) O 0 0.0005063349
cervical O 0 0.11892539
cord O 0 0.072859995
pathology O 0 0.010794475
in O 0 0.00051744067
85 O 0 0.0008686106
% O 0 0.0010687434
of O 0 0.0015721507
the O 0 0.0023777853
rats O 0 0.0049618683
. O 0 0.00654854

In O 0 0.003845827
contrast O 0 0.0030938645
, O 0 0.0028983373
dosages O 0 0.070087954
of O 0 0.008506234
Mipafox B-Chemical 0 0.99997866
( O 0 0.0027734914
less O 0 0.00043404129
than O 0 0.00022198012
or O 0 0.00020636522
equal O 0 0.0001556831
to O 0 0.00016840914
5 O 0 0.00017743085
mg O 0 0.0077367285
/ O 0 0.0014932973
kg O 0 0.0012363514
) O 0 0.0005045456
which O 0 0.00023848918
inhibited O 0 0.00021459676
mean O 0 0.00015252424
NTE O 0 0.984689
activity O 0 0.00022647713
in O 0 0.00018901016
spinal O 0 0.004739447
cord O 0 0.01385816
less O 0 0.0001306904
than O 0 9.409743e-05
or O 0 0.00010995349
equal O 0 9.858404e-05
to O 0 0.00012332987
61 O 0 0.00027459892
% O 0 0.00019542502
and O 0 0.00019933628
brain O 0 0.002368527
less O 0 0.00014732764
than O 0 0.00010310782
or O 0 0.00011922157
equal O 0 0.00010516148
to O 0 0.00012688516
60 O 0 0.00016052867
% O 0 0.00017296296
produced O 0 0.00013488815
this O 0 0.00016578882
degree O 0 0.00027010808
of O 0 0.0008126992
cord B-Disease 0 0.9607337
damage I-Disease 0 0.9747292
in O 0 0.00048658362
only O 0 0.00055131456
9 O 0 0.00062123616
% O 0 0.0009699202
of O 0 0.0014233278
the O 0 0.0020716724
animals O 0 0.0033417533
. O 0 0.0065620947

These O 0 0.0036598344
data O 0 0.0023958962
indicate O 0 0.0011467738
that O 0 0.0009657707
a O 0 0.0009409591
critical O 0 0.0005348815
percentage O 0 0.00043372263
of O 0 0.0013361407
NTE O 0 0.9974189
inhibition O 0 0.0020075848
in O 0 0.00037522693
brain O 0 0.010756929
and O 0 0.00038098783
spinal O 0 0.0061012185
cord O 0 0.011095209
sampled O 0 0.00017488401
shortly O 0 0.00034896555
after O 0 0.00021514256
Mipafox B-Chemical 0 0.9998661
exposure O 0 0.009205195
can O 0 0.00030686823
predict O 0 0.00058253674
neuropathic B-Disease 0 0.99999154
damage I-Disease 0 0.98919964
in O 0 0.00080511713
rats O 0 0.0010520398
several O 0 0.000963557
weeks O 0 0.0013721688
later O 0 0.0027659326
. O 0 0.005853356

Allergic B-Disease 0 0.993721
reaction I-Disease 0 0.22998482
to O 0 0.0077842805
5 B-Chemical 0 0.008177878
- I-Chemical 0 0.028617308
fluorouracil I-Chemical 0 0.997437
infusion O 0 0.036614645
. O 0 0.018166699

An O 0 0.014880086
allergic B-Disease 2 0.9999268
reaction I-Disease 2 0.7848608
consisting O 0 0.0021020554
of O 0 0.05742061
angioneurotic B-Disease 0 0.9999995
edema I-Disease 0 0.99999976
secondary O 0 0.104319245
to O 0 0.00030710705
continuous O 0 0.00024176997
infusion O 0 0.0006591524
5 B-Chemical 0 0.00021203046
- I-Chemical 0 0.0092087705
fluorouracil I-Chemical 0 0.9959009
occurred O 0 0.00021624283
in O 0 0.00017594529
a O 0 0.00022021608
patient O 0 0.00019925302
with O 0 0.00028385062
recurrent O 0 0.36374703
carcinoma B-Disease 2 0.999956
of I-Disease 0 0.0012809925
the I-Disease 0 0.00048786204
oral I-Disease 0 0.3237227
cavity I-Disease 0 0.020472063
, O 0 0.01789474
cirrhosis B-Disease 0 0.99999976
, O 0 0.017694935
and O 0 0.0077657197
cisplatin B-Chemical 1 0.99992526
- O 0 0.047642194
induced O 0 0.0013909995
impaired B-Disease 0 0.020296272
renal I-Disease 0 0.9037273
function I-Disease 0 0.0078917565
. O 0 0.00765458

This O 0 0.006754676
reaction O 0 0.0062720682
occurred O 0 0.0025066398
during O 0 0.0015780426
the O 0 0.0016217977
sixth O 0 0.002787896
and O 0 0.0017480396
seventh O 0 0.0028488706
courses O 0 0.00213779
of O 0 0.0036077916
infusional O 0 0.7787575
chemotherapy O 0 0.123584285
. O 0 0.008570052

Oral O 0 0.989603
diphenhydramine B-Chemical 0 0.99999774
and O 0 0.020701746
prednisone B-Chemical 1 0.9997218
were O 0 0.0016066908
ineffective O 0 0.0025469298
in O 0 0.00089148636
preventing O 0 0.0012437765
the O 0 0.0011776054
recurrence O 0 0.48841432
of O 0 0.0027729068
the O 0 0.005109005
allergic B-Disease 2 0.9999777
reaction I-Disease 2 0.9468101
. O 0 0.0103403935

Discontinuance O 0 0.06962896
of O 0 0.0033460187
effective O 0 0.0025001979
chemotherapy O 0 0.025486458
in O 0 0.0010762617
this O 0 0.00079579395
patient O 0 0.000713963
during O 0 0.0005182481
partial O 0 0.0010398355
remission O 0 0.15004613
resulted O 0 0.00095615134
in O 0 0.0018498711
fatal O 0 0.99411005
disease O 0 0.9915986
progression O 0 0.87500226
. O 0 0.010150969

Myasthenia B-Disease 0 0.97553855
gravis I-Disease 0 0.99946064
caused O 0 0.0053725834
by O 0 0.007899581
penicillamine B-Chemical 1 0.9999956
and O 0 0.023153152
chloroquine B-Chemical 1 0.9998783
therapy O 0 0.049176298
for O 0 0.007729534
rheumatoid B-Disease 0 0.99995315
arthritis I-Disease 0 0.9999838
. O 0 0.017976038

We O 0 0.0036646384
have O 0 0.002217298
described O 0 0.0016622931
a O 0 0.0014869445
unique O 0 0.0010928301
patient O 0 0.00089488627
who O 0 0.000880183
had O 0 0.00048233522
reversible O 0 0.015060493
and O 0 0.0005749013
dose O 0 0.008853491
- O 0 0.008604794
related O 0 0.00029835242
myasthenia B-Disease 0 0.99627185
gravis I-Disease 0 0.99951565
after O 0 0.0009855011
penicillamine B-Chemical 1 0.99999857
and O 0 0.0077519934
chloroquine B-Chemical 1 0.9998647
therapy O 0 0.015467642
for O 0 0.0039225738
rheumatoid B-Disease 0 0.9999583
arthritis I-Disease 0 0.9999856
. O 0 0.013335954

Although O 0 0.0053673345
acetylcholine B-Chemical 1 0.99938583
receptor O 0 0.06563329
antibodies O 0 0.017544206
were O 0 0.0010774976
not O 0 0.0007059388
detectable O 0 0.0006486362
, O 0 0.00069780956
the O 0 0.00044213136
time O 0 0.00036489742
course O 0 0.0004960097
was O 0 0.0006016105
consistent O 0 0.00075837434
with O 0 0.001243718
an O 0 0.0023921337
autoimmune O 0 0.9599887
process O 0 0.0068693478
. O 0 0.008436153

On O 0 0.0033190218
the O 0 0.0021786792
mechanisms O 0 0.001583397
of O 0 0.0014714382
the O 0 0.0010440118
development O 0 0.0015835766
of O 0 0.0010997133
tolerance O 0 0.044159003
to O 0 0.0005316287
the O 0 0.00066210964
muscular B-Disease 0 0.5609223
rigidity I-Disease 2 0.98944306
produced O 0 0.0010487131
by O 0 0.0023437568
morphine B-Chemical 0 0.999864
in O 0 0.0030333067
rats O 0 0.005790729
. O 0 0.0067418213

The O 0 0.003624374
development O 0 0.0035670178
of O 0 0.0025162054
tolerance O 0 0.025966207
to O 0 0.0011170496
the O 0 0.001113163
muscular B-Disease 0 0.5734065
rigidity I-Disease 2 0.99037373
produced O 0 0.0010025855
by O 0 0.001933256
morphine B-Chemical 0 0.99991286
was O 0 0.0015989458
studied O 0 0.002000663
in O 0 0.002767643
rats O 0 0.005538547
. O 0 0.0071094995

Saline O 0 0.99597967
- O 0 0.035802357
pretreated O 0 0.004850189
controls O 0 0.0016108312
given O 0 0.0006359257
a O 0 0.00070117536
test O 0 0.0005376422
dose O 0 0.0024678516
of O 0 0.0030217352
morphine B-Chemical 0 0.9999852
( O 0 0.001367781
20 O 0 0.00029603162
mg O 0 0.011530334
/ O 0 0.0012226291
kg O 0 0.0009771241
i O 0 0.0015976052
. O 0 0.00023081923
p O 0 0.00026586803
. O 0 0.00023794587
) O 0 0.0004209504
showed O 0 0.000253366
a O 0 0.00039883444
pronounced O 0 0.0011106129
rigidity B-Disease 2 0.9493653
recorded O 0 0.00047373323
as O 0 0.0005062956
tonic O 0 0.013917645
activity O 0 0.00090001605
in O 0 0.0013354949
the O 0 0.0023878182
electromyogram O 0 0.20705654
. O 0 0.0065094763

Rats O 0 0.0085979225
treated O 0 0.0024772354
for O 0 0.0014791705
11 O 0 0.0010926131
days O 0 0.00062722573
with O 0 0.00094914425
morphine B-Chemical 0 0.99984884
and O 0 0.00066465
withdrawn O 0 0.0007794589
for O 0 0.00027594392
36 O 0 0.00032912917
- O 0 0.0009262357
40 O 0 0.00019272558
h O 0 0.00019031638
showed O 0 0.00014821957
differences O 0 0.00012194402
in O 0 0.00014776997
the O 0 0.00015835464
development O 0 0.00042237737
of O 0 0.00040430628
tolerance O 0 0.08866695
: O 0 0.000574139
about O 0 0.00013724586
half O 0 0.000107357744
of O 0 0.0001649037
the O 0 0.0001426749
animals O 0 0.00012731978
showed O 0 0.00016545466
a O 0 0.00035389443
rigidity B-Disease 2 0.97193176
after O 0 0.00011392015
the O 0 0.00014516978
test O 0 0.00018754152
dose O 0 0.0017205331
of O 0 0.0018569079
morphine B-Chemical 0 0.9999629
that O 0 0.00018664387
was O 0 0.0001991856
not O 0 0.00014899894
significantly O 0 0.00018565805
less O 0 0.00016129106
than O 0 0.0001325548
in O 0 0.0001782288
the O 0 0.00021859276
controls O 0 0.00041623093
and O 0 0.00047486016
were O 0 0.00074172247
akinetic B-Disease 2 0.99709225
( O 0 0.0022555562
A O 0 0.07650299
group O 0 0.0034167282
) O 0 0.0060221176
. O 0 0.007203977

The O 0 0.0031466433
other O 0 0.002354087
rats O 0 0.002022801
showed O 0 0.0010373811
a O 0 0.000974813
strong O 0 0.0008683557
decrease O 0 0.0005849971
in O 0 0.0004660719
the O 0 0.00048391134
rigidity B-Disease 2 0.98480713
and O 0 0.00042431997
the O 0 0.00024589364
occurrence O 0 0.00059831934
of O 0 0.0005889828
stereotyped O 0 0.8985257
( O 0 0.010588986
S O 0 0.9979656
) O 0 0.011832824
licking O 0 0.8735965
and O 0 0.00043850677
/ O 0 0.0064274697
or O 0 0.00038325487
gnawing O 0 0.90248746
in O 0 0.00015743882
presence O 0 0.00017142911
of O 0 0.00054409914
akinetic B-Disease 2 0.99967146
or O 0 0.001399445
hyperkinetic B-Disease 0 0.99997556
( O 0 0.0314913
K O 1 0.9999788
) O 0 0.0073014535
behaviour O 0 0.008414498
( O 0 0.002258642
AS O 0 0.86574584
/ O 0 0.078420974
KS O 0 0.9975193
group O 0 0.0012787621
) O 0 0.0010940112
, O 0 0.00070746295
suggesting O 0 0.0006080222
signs O 0 0.02702863
of O 0 0.0023104688
dopaminergic O 0 0.50539255
activation O 0 0.0054483623
. O 0 0.0068757134

The O 0 0.004757069
rigidity B-Disease 2 0.9110923
was O 0 0.0027464516
considerably O 0 0.0020374546
decreased O 0 0.0016116734
in O 0 0.0011468595
both O 0 0.0010308174
groups O 0 0.0010686289
after O 0 0.0008901046
20 O 0 0.0013496482
days O 0 0.0016077505
' O 0 0.00377673
treatment O 0 0.005071989
. O 0 0.008388855

In O 0 0.0038117387
a O 0 0.0026434888
further O 0 0.0015497176
series O 0 0.0013523475
of O 0 0.0010113429
experiments O 0 0.0006884158
, O 0 0.0120546995
haloperidol B-Chemical 1 0.99999976
( O 0 0.0022150076
0 O 0 0.00044794462
. O 0 0.00025888416
2 O 0 0.00024442197
mg O 0 0.0038379214
/ O 0 0.0009872087
kg O 0 0.00096079364
i O 0 0.0019045586
. O 0 0.00023320277
p O 0 0.00026619982
. O 0 0.00022536154
) O 0 0.000406538
was O 0 0.00018590943
used O 0 0.00014164766
in O 0 0.00013814127
order O 0 0.00010809552
to O 0 0.00011679365
block O 0 0.00014297098
the O 0 0.00018937746
dopaminergic O 0 0.14098664
activation O 0 0.00024409733
and O 0 0.0001750078
to O 0 0.00012083638
estimate O 0 0.0001111962
the O 0 0.00014617572
real O 0 0.00017063326
degree O 0 0.0002323421
of O 0 0.00030187747
the O 0 0.00030375025
tolerance O 0 0.01374506
to O 0 0.00033485715
the O 0 0.0005582274
rigidity B-Disease 2 0.9748644
without O 0 0.0010380732
any O 0 0.0014685133
dopaminergic O 0 0.27538353
interference O 0 0.0049553043
. O 0 0.006673503

Haloperidol B-Chemical 1 0.9999883
enhanced O 0 0.008990424
the O 0 0.006950808
rigidity B-Disease 2 0.97198987
in O 0 0.006369915
the O 0 0.0070258733
A O 0 0.08089692
group O 0 0.01253819
. O 0 0.015185385

However O 0 0.0048495457
, O 0 0.003450133
the O 0 0.0017808962
level O 0 0.0012739828
in O 0 0.0011547299
the O 0 0.0012491953
AS O 0 0.85520077
/ O 0 0.10036165
KS O 0 0.9956993
group O 0 0.001138841
remained O 0 0.0008020526
considerably O 0 0.00068026804
lower O 0 0.0006320622
than O 0 0.0006182445
in O 0 0.0010696072
the O 0 0.0017971487
A O 0 0.05078042
group O 0 0.005591372
. O 0 0.0075843586

The O 0 0.0029687618
results O 0 0.0019017797
suggest O 0 0.0011663463
that O 0 0.0012987951
rigidity B-Disease 2 0.9944511
, O 0 0.002644554
which O 0 0.0010202749
is O 0 0.00050420733
assumed O 0 0.0003439904
to O 0 0.00024912824
be O 0 0.0002376289
due O 0 0.00016412567
to O 0 0.00017783718
an O 0 0.00026079168
action O 0 0.0005164694
of O 0 0.0018504919
morphine B-Chemical 0 0.99997663
in O 0 0.00032518274
the O 0 0.00038452313
striatum O 0 0.7061991
, O 0 0.00038242858
can O 0 0.00015577515
be O 0 0.00021267717
antagonized O 0 0.017442027
by O 0 0.0002566844
another O 0 0.00027830704
process O 0 0.00027849202
leading O 0 0.000535525
to O 0 0.000446004
dopaminergic O 0 0.16596845
activation O 0 0.0010007523
in O 0 0.0011944881
the O 0 0.002205482
striatum O 0 0.45319885
. O 0 0.0062138294

Nevertheless O 0 0.006128254
, O 0 0.005165018
there O 0 0.0027986558
occurs O 0 0.0027308865
some O 0 0.0027088053
real O 0 0.003021656
tolerance O 0 0.014147032
to O 0 0.0033947437
this O 0 0.004521986
effect O 0 0.006548748
. O 0 0.011054046

The O 0 0.0032119728
rapid O 0 0.0034250764
alternations O 0 0.0056378706
of O 0 0.0022384375
rigidity B-Disease 2 0.98923934
and O 0 0.0011638242
the O 0 0.0006186502
signs O 0 0.035300028
of O 0 0.000787514
dopaminergic O 0 0.4721377
activation O 0 0.00045479948
observed O 0 0.000201743
in O 0 0.00019018125
the O 0 0.00016912654
animals O 0 0.00015057401
of O 0 0.00026324633
the O 0 0.0004152835
AS O 0 0.9238147
/ O 0 0.1527905
KS O 0 0.9982028
group O 0 0.000588898
might O 0 0.00014853069
be O 0 0.00016853123
due O 0 0.00013730788
to O 0 0.0001724467
rapid O 0 0.0004510459
shifts O 0 0.00062324904
in O 0 0.00026239036
the O 0 0.0002991072
predominance O 0 0.00064488116
of O 0 0.00084510853
various O 0 0.0048321467
DA O 0 0.9998211
- O 0 0.028115695
innervated O 0 0.0055051423
structures O 0 0.004582426
. O 0 0.006808331

A O 0 0.033520244
case O 0 0.0074930214
of O 0 0.007973468
massive O 0 0.5059937
rhabdomyolysis B-Disease 0 0.9999943
following O 0 0.17704044
molindone B-Chemical 0 0.9999994
administration O 0 0.6445819
. O 0 0.014909395

Rhabdomyolysis B-Disease 0 0.99960214
is O 0 0.004118859
a O 0 0.0028674668
potentially O 0 0.0028797074
lethal O 0 0.040742822
syndrome O 0 0.7092907
that O 0 0.0016429314
psychiatric B-Disease 2 0.9920631
patients O 0 0.0026221143
seem O 0 0.001972932
predisposed O 0 0.023373105
to O 0 0.0027893372
develop O 0 0.0050537703
. O 0 0.0077677225

The O 0 0.0036506113
clinical O 0 0.004723229
signs O 0 0.025233202
and O 0 0.0021963646
symptoms O 0 0.19596219
, O 0 0.0012770188
typical O 0 0.00077237113
laboratory O 0 0.0008919762
features O 0 0.0008185948
, O 0 0.00087676203
and O 0 0.0010019724
complications O 0 0.25163373
of O 0 0.004499008
rhabdomyolysis B-Disease 0 0.99998593
are O 0 0.0033845745
presented O 0 0.004108846
. O 0 0.006903341

The O 0 0.0033164725
case O 0 0.002574703
of O 0 0.0022371877
a O 0 0.0034734192
schizophrenic B-Disease 2 0.9998642
patient O 0 0.0011182736
is O 0 0.0005786595
reported O 0 0.00045132675
to O 0 0.00029964233
illustrate O 0 0.0002829077
massive O 0 0.06311946
rhabdomyolysis B-Disease 0 0.9999956
and O 0 0.0011924977
subsequent O 0 0.0010202205
acute B-Disease 0 0.9690067
renal I-Disease 0 0.9950223
failure I-Disease 0 0.949355
following O 0 0.026874473
molindone B-Chemical 0 0.99999964
administration O 0 0.23947266
. O 0 0.006969001

Physicians O 0 0.01189725
who O 0 0.008837371
prescribe O 0 0.036253277
molindone B-Chemical 0 0.9999968
should O 0 0.0025828248
be O 0 0.0028549589
aware O 0 0.0031024932
of O 0 0.0041183895
this O 0 0.0052088266
reaction O 0 0.017205551
. O 0 0.011595597

Compression B-Disease 0 0.49422938
neuropathy I-Disease 0 0.9996136
of I-Disease 0 0.0031286594
the I-Disease 0 0.0019265339
radial I-Disease 0 0.004523351
nerve I-Disease 0 0.022683078
due O 0 0.0012748421
to O 0 0.0023833853
pentazocine B-Chemical 1 0.9999987
- O 0 0.11193115
induced O 0 0.00667966
fibrous B-Disease 0 0.9967355
myopathy I-Disease 2 0.9999689
. O 0 0.014486074

Fibrous B-Disease 0 0.86400455
myopathy I-Disease 2 0.9998673
is O 0 0.0031955817
a O 0 0.002175524
common O 0 0.0016886637
, O 0 0.0014212162
well O 0 0.0010221252
- O 0 0.0059063747
known O 0 0.0010989823
side O 0 0.0066696987
effect O 0 0.0010164581
of O 0 0.001828205
repeated O 0 0.002889878
pentazocine B-Chemical 1 0.99999607
injection O 0 0.018502636
. O 0 0.007850747

However O 0 0.0056167226
, O 0 0.006736887
compression B-Disease 0 0.9287923
neuropathy I-Disease 0 0.999992
due O 0 0.0010028196
to O 0 0.00083235896
fibrotic O 0 0.54857683
muscle O 0 0.05603367
affected O 0 0.00086336915
by O 0 0.0034509627
pentazocine B-Chemical 1 0.99999976
- O 0 0.14536618
induced O 0 0.0018981156
myopathy B-Disease 2 0.9998099
has O 0 0.00094844506
not O 0 0.00096834946
previously O 0 0.0014604337
been O 0 0.002271787
reported O 0 0.0042563127
. O 0 0.0067742183

In O 0 0.0040615685
a O 0 0.0033158814
37 O 0 0.003372988
- O 0 0.004996568
year O 0 0.0014572873
- O 0 0.0032748668
old O 0 0.00079302036
woman O 0 0.0019137592
with O 0 0.0007533496
documented O 0 0.029440703
pentazocine B-Chemical 1 0.99999976
- O 0 0.12857711
induced O 0 0.0011527187
fibrous B-Disease 0 0.99619895
myopathy I-Disease 2 0.99999225
of O 0 0.0017665741
triceps O 0 0.8895897
and O 0 0.00032788175
deltoid O 0 0.2627997
muscles O 0 0.0008039396
bilaterally O 0 0.002258624
and O 0 0.00016089338
a O 0 0.00017026287
three O 0 0.000106233274
- O 0 0.00063754653
week O 0 0.000115082745
history O 0 0.0004029248
of O 0 0.00024130318
right O 0 0.0013957607
wrist O 0 0.13928778
drop O 0 0.0008286498
, O 0 0.0002753298
electrodiagnostic O 0 0.005452085
examination O 0 0.00016589888
showed O 0 0.00014852657
a O 0 0.00024917978
severe O 0 0.018802177
but O 0 0.0002628556
partial O 0 0.00036164914
lesion O 0 0.023244776
of O 0 0.00021772702
the O 0 0.00016911539
right O 0 0.00046183428
radial O 0 0.0018995382
nerve O 0 0.008128929
distal O 0 0.00020305296
to O 0 0.00013188219
the O 0 0.00015389045
branches O 0 0.00026693736
to O 0 0.00017760367
the O 0 0.0002772263
triceps O 0 0.52241343
, O 0 0.00046814102
in O 0 0.00037924477
addition O 0 0.00040280845
to O 0 0.0008042653
the O 0 0.0017815128
fibrous B-Disease 0 0.97989094
myopathy I-Disease 2 0.9999497
. O 0 0.010003375

Surgery O 0 0.0068816068
revealed O 0 0.0023620678
the O 0 0.0017161415
right O 0 0.0021023485
radial O 0 0.0032086554
nerve O 0 0.012424632
to O 0 0.0005933368
be O 0 0.000562299
severely O 0 0.0012214088
compressed O 0 0.00069924153
by O 0 0.00045912756
the O 0 0.00046450013
densely O 0 0.0009106833
fibrotic O 0 0.16722468
lateral O 0 0.0091821905
head O 0 0.01247994
of O 0 0.0021083392
the O 0 0.0031039268
triceps O 0 0.7704537
. O 0 0.007527448

Decompression O 0 0.01935546
and O 0 0.0048439107
neurolysis O 0 0.017588207
were O 0 0.0023319144
performed O 0 0.0017458318
with O 0 0.0018914624
good O 0 0.0024305843
subsequent O 0 0.0025453314
recovery O 0 0.0039540716
of O 0 0.0048193005
function O 0 0.006672745
. O 0 0.010793427

Recurrent O 0 0.09407798
reversible O 0 0.34816545
acute B-Disease 0 0.9745619
renal I-Disease 0 0.9931457
failure I-Disease 0 0.9291664
from O 0 0.016569758
amphotericin B-Chemical 0 0.9998988
. O 0 0.026620612

A O 0 0.06301116
patient O 0 0.0039851665
with O 0 0.0063340995
cryptogenic O 0 0.999995
cirrhosis B-Disease 0 0.9999999
and O 0 0.16363028
disseminated O 0 0.99791306
sporotrichosis B-Disease 0 0.99997604
developed O 0 0.03791771
acute B-Disease 0 0.979459
renal I-Disease 0 0.99087465
failure I-Disease 0 0.58913124
immediately O 0 0.00030642972
following O 0 0.00020110156
the O 0 0.00027196112
administration O 0 0.003256931
of O 0 0.002279813
amphotericin B-Chemical 1 0.99999774
B I-Chemical 1 0.99488825
on O 0 0.0008572828
four O 0 0.0010614026
separate O 0 0.0015105789
occasions O 0 0.0037349781
. O 0 0.0056693596

The O 0 0.003507421
abruptness O 0 0.008785975
of O 0 0.002194872
the O 0 0.0017080212
renal B-Disease 0 0.8882492
failure I-Disease 0 0.48645374
and O 0 0.001021928
its O 0 0.0011128602
reversibility O 0 0.014679005
within O 0 0.00020911722
days O 0 0.00018492449
suggests O 0 0.00016637349
that O 0 0.00020108181
there O 0 0.00021572447
was O 0 0.00032139427
a O 0 0.0004107093
functional O 0 0.00045615868
component O 0 0.00064725784
to O 0 0.00085008726
the O 0 0.0019022458
renal B-Disease 2 0.99811447
dysfunction I-Disease 2 0.9979393
. O 0 0.009408643

We O 0 0.0034986122
propose O 0 0.002191417
that O 0 0.002215777
amphotericin B-Chemical 0 0.99991643
, O 0 0.0055628694
in O 0 0.00085584883
the O 0 0.00053624593
setting O 0 0.00042196852
of O 0 0.0004381978
reduced O 0 0.00038710542
effective O 0 0.0004956488
arterial O 0 0.18916595
volume O 0 0.0007741884
, O 0 0.00038830127
may O 0 0.0002081826
activate O 0 0.0001767266
tubuloglomerular O 0 0.023033483
feedback O 0 0.00061613624
, O 0 0.0005729434
thereby O 0 0.0006579668
contributing O 0 0.0009596147
to O 0 0.0011516837
acute B-Disease 0 0.92457044
renal I-Disease 0 0.98803073
failure I-Disease 0 0.8878699
. O 0 0.009066447

Cerebral B-Disease 0 0.9991892
infarction I-Disease 2 0.9999949
with O 0 0.006756522
a O 0 0.005025726
single O 0 0.004363333
oral O 0 0.3037596
dose O 0 0.084255
of O 0 0.076596096
phenylpropanolamine B-Chemical 0 0.9999975
. O 0 0.015962934

Phenylpropanolamine B-Chemical 0 0.9999628
( O 0 0.12815914
PPA B-Chemical 1 0.9998919
) O 0 0.009144261
, O 0 0.001968213
a O 0 0.0011734118
synthetic O 0 0.0011489135
sympathomimetic O 0 0.9879358
that O 0 0.0003645011
is O 0 0.00036107886
structurally O 0 0.000545536
similar O 0 0.00021871575
to O 0 0.00044563832
amphetamine B-Chemical 1 0.99999917
, O 0 0.00076483
is O 0 0.00024969538
available O 0 0.00019968153
over O 0 0.00013141995
the O 0 0.00020494513
counter O 0 0.00072600506
in O 0 0.00039354217
anorectics O 0 0.8127158
, O 0 0.0006811951
nasal O 0 0.006186777
congestants O 0 0.018885558
, O 0 0.0014168357
and O 0 0.0017951764
cold O 0 0.013487891
preparations O 0 0.0048379726
. O 0 0.006937264

Its O 0 0.0474751
prolonged O 0 0.003930142
use O 0 0.0020816845
or O 0 0.0017477674
overuse O 0 0.6487406
has O 0 0.00081901066
been O 0 0.000626352
associated O 0 0.00069184176
with O 0 0.0040541105
seizures B-Disease 0 0.9999995
, O 0 0.09167906
intracerebral B-Disease 0 0.99997294
hemorrhage I-Disease 2 0.99999905
, O 0 0.06907978
neuropsychiatric B-Disease 0 0.9999889
symptoms I-Disease 0 0.98547345
, O 0 0.0021348442
and O 0 0.0054454356
nonhemorrhagic O 0 0.99996233
cerebral B-Disease 0 0.9996605
infarction I-Disease 2 0.9999958
. O 0 0.013292637

We O 0 0.0039682477
report O 0 0.003404102
the O 0 0.0017897554
case O 0 0.0014502819
of O 0 0.0012482556
a O 0 0.0012647936
young O 0 0.008714507
woman O 0 0.007781221
who O 0 0.0013893393
suffered O 0 0.026065016
a O 0 0.0026974033
cerebral B-Disease 0 0.99877673
infarction I-Disease 2 0.9999989
after O 0 0.0004468468
taking O 0 0.0012425852
a O 0 0.0007280784
single O 0 0.0009243539
oral O 0 0.1598105
dose O 0 0.01757257
of O 0 0.0106616905
PPA B-Chemical 1 0.999772
. O 0 0.009176683

Remission O 0 0.4835633
induction O 0 0.00415178
of O 0 0.006528382
meningeal B-Disease 0 0.99990416
leukemia I-Disease 0 0.999998
with O 0 0.014435244
high O 0 0.009306025
- O 0 0.05804877
dose O 0 0.088559896
intravenous O 0 0.86147237
methotrexate B-Chemical 1 0.99984
. O 0 0.011075976

Twenty O 0 0.005252853
children O 0 0.0038999154
with O 0 0.0035023817
acute B-Disease 0 0.9987613
lymphoblastic I-Disease 0 0.9999993
leukemia I-Disease 0 0.99999976
who O 0 0.26850566
developed O 0 0.057812206
meningeal B-Disease 0 0.99994576
disease I-Disease 0 0.9992855
were O 0 0.00035573763
treated O 0 0.00026243768
with O 0 0.00022506093
a O 0 0.00028390205
high O 0 0.0006244045
- O 0 0.014168195
dose O 0 0.007172714
intravenous O 0 0.35875914
methotrexate B-Chemical 1 0.9999292
regimen O 0 0.00057952694
that O 0 0.00012630162
was O 0 0.00013888662
designed O 0 0.0001110287
to O 0 9.2487244e-05
achieve O 0 8.8713874e-05
and O 0 0.00013905783
maintain O 0 0.00013512206
CSF O 0 0.9249425
methotrexate B-Chemical 1 0.99984837
concentrations O 0 0.0011352798
of O 0 0.00028669278
10 O 0 0.00022000035
( O 0 0.00045584328
- O 0 0.0028561591
5 O 0 0.00019342145
) O 0 0.00047711446
mol O 0 0.35776228
/ O 0 0.032690875
L O 0 0.8677792
without O 0 0.0004035654
the O 0 0.00040530693
need O 0 0.00047498557
for O 0 0.00076711545
concomitant O 0 0.004721205
intrathecal O 0 0.55437243
dosing O 0 0.017607871
. O 0 0.0060985396

The O 0 0.004198233
methotrexate B-Chemical 1 0.99925524
was O 0 0.0019102679
administered O 0 0.0010382166
as O 0 0.0006805119
a O 0 0.0006207709
loading O 0 0.0005584121
dose O 0 0.0012606521
of O 0 0.0004379556
6 O 0 0.00023702385
, O 0 0.0002999044
000 O 0 0.0002868374
mg O 0 0.009784652
/ O 0 0.0012457591
m2 O 0 0.0037713645
for O 0 0.00018914466
a O 0 0.00019683281
period O 0 0.00012911174
of O 0 0.00017713133
one O 0 0.00013634723
hour O 0 0.00012299142
followed O 0 0.0001230393
by O 0 0.00016996652
an O 0 0.00021592903
infusion O 0 0.00041922167
of O 0 0.00025928873
1 O 0 0.00024305389
, O 0 0.00033020656
200 O 0 0.00042661087
mg O 0 0.009762915
/ O 0 0.0017490458
m2 O 0 0.014300218
/ O 0 0.0021723972
h O 0 0.0010674135
for O 0 0.0013473327
23 O 0 0.0026025563
hours O 0 0.002993186
. O 0 0.006278729

Leucovorin B-Chemical 0 0.99832577
rescue O 0 0.002945458
was O 0 0.0016850758
initiated O 0 0.001040835
12 O 0 0.0006371627
hours O 0 0.0004218402
after O 0 0.00027579165
the O 0 0.00027535213
end O 0 0.00019903827
of O 0 0.00026570738
the O 0 0.0002288012
infusion O 0 0.0004955917
with O 0 0.00019850457
a O 0 0.00021215584
loading O 0 0.00023271433
dose O 0 0.0008313855
of O 0 0.00028003045
200 O 0 0.0004864965
mg O 0 0.019735118
/ O 0 0.0015202977
m2 O 0 0.003230281
followed O 0 0.00012675601
by O 0 0.00015477664
12 O 0 0.00012587482
mg O 0 0.0024594176
/ O 0 0.0006585562
m2 O 0 0.0013181443
every O 0 7.721366e-05
three O 0 7.597921e-05
hours O 0 9.206401e-05
for O 0 0.00010158401
six O 0 8.921789e-05
doses O 0 0.00024666567
and O 0 0.00013603893
then O 0 0.00010222262
every O 0 6.622369e-05
six O 0 7.552995e-05
hours O 0 8.3053645e-05
until O 0 8.21588e-05
the O 0 0.00013437991
plasma O 0 0.023991356
methotrexate B-Chemical 1 0.99968517
level O 0 0.00016880142
decreased O 0 0.00023358375
to O 0 0.00015374144
less O 0 0.00018537081
than O 0 0.00017002197
1 O 0 0.0002919056
X O 0 0.40007588
10 O 0 0.00039433682
( O 0 0.00074236206
- O 0 0.002257569
7 O 0 0.0008032718
) O 0 0.0019115463
mol O 0 0.35149595
/ O 0 0.062066834
L O 0 0.93007576
. O 0 0.01017506

The O 0 0.0026188802
mean O 0 0.001441914
steady O 0 0.0017509068
- O 0 0.004321158
state O 0 0.0012164238
plasma O 0 0.01721498
and O 0 0.0013004971
CSF O 0 0.9673534
methotrexate B-Chemical 1 0.99991965
concentrations O 0 0.0019797601
achieved O 0 0.00032317816
were O 0 0.00024081569
1 O 0 0.00020760241
. O 0 0.00019089195
1 O 0 0.00024443178
X O 0 0.41073123
10 O 0 0.00024356424
( O 0 0.0004535293
- O 0 0.0024714214
3 O 0 0.00020265512
) O 0 0.0004289172
mol O 0 0.32929197
/ O 0 0.037451256
L O 0 0.9339418
and O 0 0.00042850222
3 O 0 0.0002217373
. O 0 0.00021439041
6 O 0 0.00022980517
X O 0 0.20394434
10 O 0 0.0003369703
( O 0 0.00059184147
- O 0 0.0017690941
5 O 0 0.0004852552
) O 0 0.0011224402
mol O 0 0.33740032
/ O 0 0.051248904
L O 0 0.9385096
, O 0 0.0055086417
respectively O 0 0.009884521
. O 0 0.008566772

All O 0 0.0031911721
20 O 0 0.0024377427
patients O 0 0.001790517
responded O 0 0.001267272
to O 0 0.00074906595
this O 0 0.000641072
regimen O 0 0.00083130953
, O 0 0.0007537481
16 O 0 0.0005029131
/ O 0 0.001064452
20 O 0 0.00032281113
( O 0 0.00038428587
80 O 0 0.00031560598
% O 0 0.00033128145
) O 0 0.0003897558
achieved O 0 0.00027606392
a O 0 0.00032140498
complete O 0 0.00028966996
remission O 0 0.07612391
, O 0 0.00050417014
and O 0 0.0004766222
20 O 0 0.00051676045
% O 0 0.00074208865
obtained O 0 0.0009148477
a O 0 0.0017245936
partial O 0 0.003186987
remission O 0 0.27080643
. O 0 0.0069503845

The O 0 0.0034155988
most O 0 0.0030633002
common O 0 0.0030593853
toxicities B-Disease 2 0.9929309
encountered O 0 0.0013220751
were O 0 0.0008554204
transient O 0 0.036553353
serum O 0 0.94433564
transaminase O 0 0.99999714
and O 0 0.021671927
bilirubin B-Chemical 1 0.9999962
elevations O 0 0.86427355
, O 0 0.0140552
neutropenia B-Disease 0 0.9997429
, O 0 0.006106729
and O 0 0.0124032665
mucositis B-Disease 2 0.9999714
. O 0 0.010897295

One O 0 0.006361732
patient O 0 0.004048033
had O 0 0.0032825116
focal O 0 0.31355143
seizures B-Disease 0 0.9999969
and O 0 0.033536207
transient B-Disease 0 0.9905759
hemiparesis I-Disease 0 0.99999666
but O 0 0.0048652883
recovered O 0 0.0035084079
completely O 0 0.005308991
. O 0 0.009003411

High O 0 0.03183056
- O 0 0.016693164
dose O 0 0.020687478
intravenous O 0 0.73499805
methotrexate B-Chemical 1 0.99997187
is O 0 0.0013255716
an O 0 0.00073415646
effective O 0 0.0004860825
treatment O 0 0.0003948563
for O 0 0.00026266623
the O 0 0.00024761996
induction O 0 0.0002769814
of O 0 0.00048927544
remission O 0 0.24600157
after O 0 0.00036443005
meningeal O 0 0.9813996
relapse O 0 0.988361
in O 0 0.0030616361
acute B-Disease 0 0.99933165
lymphoblastic I-Disease 0 0.99999845
leukemia I-Disease 0 0.99999845
. O 0 0.12886111

Interaction O 0 0.016191376
of O 0 0.01864417
cyclosporin B-Chemical 1 0.9999951
A I-Chemical 1 0.98418635
with O 0 0.020376975
antineoplastic O 0 0.94652945
agents O 0 0.28025952
. O 0 0.018552639

A O 0 0.036106925
synergistic O 0 0.0038013835
effect O 0 0.0021832834
of O 0 0.003655551
etoposide B-Chemical 1 0.99993825
and O 0 0.09333533
cyclosporin B-Chemical 1 0.9999999
A I-Chemical 1 0.9945898
was O 0 0.0006930398
observed O 0 0.00033099574
in O 0 0.00032919855
a O 0 0.0004017542
patient O 0 0.00040982937
with O 0 0.00070476317
acute B-Disease 0 0.9627912
T I-Disease 0 0.99837565
- I-Disease 0 0.77317864
lymphocytic I-Disease 0 0.9999759
leukemia I-Disease 0 0.9999957
in O 0 0.037283853
relapse O 0 0.9933362
. O 0 0.00913771

The O 0 0.003195937
concomitant O 0 0.0036959383
administration O 0 0.009454502
of O 0 0.0036618253
etoposide B-Chemical 1 0.9999391
and O 0 0.080813915
cyclosporin B-Chemical 1 0.9999999
A I-Chemical 1 0.9914785
resulted O 0 0.00066134974
in O 0 0.00053994876
eradication O 0 0.04221724
of O 0 0.0009796446
hitherto O 0 0.024683475
refractory O 0 0.16001995
leukemic B-Disease 0 0.9991357
infiltration I-Disease 0 0.8097151
of O 0 0.0029185545
bone O 0 0.06258034
marrow O 0 0.12681511
. O 0 0.007539198

Severe O 0 0.60275847
side O 0 0.04781271
effects O 0 0.0023948913
in O 0 0.0010890139
terms O 0 0.0006706802
of O 0 0.000867699
mental O 0 0.25410426
confusion B-Disease 0 0.8636364
and O 0 0.0014224381
progressive O 0 0.82385844
hyperbilirubinemia B-Disease 0 0.99999905
, O 0 0.0071674217
however O 0 0.000831018
, O 0 0.0003484082
point O 0 0.00016034326
to O 0 0.00015749634
an O 0 0.00022736483
enhancement O 0 0.0003655607
not O 0 0.00018960041
only O 0 0.00025600375
of O 0 0.00042710896
antineoplastic O 0 0.4983648
effects O 0 0.000691971
but O 0 0.0005021244
also O 0 0.00047964297
of O 0 0.0014777725
toxicity B-Disease 2 0.9976682
in O 0 0.0017225384
normal O 0 0.0040582404
tissues O 0 0.006163998
. O 0 0.006485755

This O 0 0.0050103604
report O 0 0.0033436061
demonstrates O 0 0.0013241469
for O 0 0.0010121535
the O 0 0.0007044177
first O 0 0.00042885018
time O 0 0.0002934173
that O 0 0.0002642517
the O 0 0.00028088127
pharmacodynamic O 0 0.008570582
properties O 0 0.0002958488
of O 0 0.0022292668
cyclosporin B-Chemical 1 0.9999999
A I-Chemical 1 0.9885423
may O 0 0.0003281857
not O 0 0.0002091577
be O 0 0.00020982008
confined O 0 0.00020114296
strictly O 0 0.00023626936
to O 0 0.0002719266
suppression O 0 0.00052210107
of O 0 0.0008781327
normal O 0 0.0058065276
T O 0 0.9577857
- O 0 0.03886655
cell O 0 0.006608675
functions O 0 0.00451866
. O 0 0.0073972913

Incidence O 0 0.02235878
of O 0 0.004889276
neoplasms B-Disease 0 0.91053915
in O 0 0.0021722398
patients O 0 0.0025712152
with O 0 0.0040069926
rheumatoid B-Disease 0 0.99997115
arthritis I-Disease 0 0.9999924
exposed O 0 0.0028548166
to O 0 0.0013074932
different O 0 0.001566219
treatment O 0 0.002842027
regimens O 0 0.0056959414
. O 0 0.007297149

Immunosuppressive O 0 0.9415134
drugs O 0 0.27479264
have O 0 0.0016308733
been O 0 0.0011410931
used O 0 0.00070030085
during O 0 0.00047048723
the O 0 0.00044525575
last O 0 0.00030912456
30 O 0 0.00031599164
years O 0 0.00039076348
in O 0 0.00037345313
treatment O 0 0.00048245315
of O 0 0.00068689475
patients O 0 0.0013137106
with O 0 0.0019667991
severe O 0 0.8473554
rheumatoid B-Disease 0 0.99997616
arthritis I-Disease 0 0.9999894
. O 0 0.016850049

The O 0 0.0033018119
drugs O 0 0.04229358
commonly O 0 0.0020761392
used O 0 0.0009795979
are O 0 0.0010687801
cyclophosphamide B-Chemical 0 0.99987006
and O 0 0.020685239
chlorambucil B-Chemical 0 0.9999976
( O 0 0.04202201
alkylating B-Chemical 0 0.9973943
agents I-Chemical 0 0.12842146
) O 0 0.0086244065
, O 0 0.006936864
azathioprine B-Chemical 0 0.9999976
( O 0 0.022121899
purine B-Chemical 0 0.9996424
analogue O 0 0.08461313
) O 0 0.0018710116
, O 0 0.00077263254
and O 0 0.0017172873
methotrexate B-Chemical 1 0.9999809
( O 0 0.091274984
folic B-Chemical 0 0.999992
acid I-Chemical 0 0.98455435
analogue O 0 0.15874133
) O 0 0.0075978115
. O 0 0.006884184

There O 0 0.004214115
is O 0 0.0024813903
evidence O 0 0.0014379614
that O 0 0.0010107885
all O 0 0.00081242545
four O 0 0.00057834777
immunosuppressive O 0 0.50057703
drugs O 0 0.27006766
can O 0 0.00037113362
reduce O 0 0.00039068077
synovitis B-Disease 0 0.9999089
, O 0 0.0031318688
but O 0 0.0010046604
disease O 0 0.72611713
activity O 0 0.00046353918
almost O 0 0.00041507412
always O 0 0.00067877007
recurs O 0 0.003870639
after O 0 0.00070691097
therapy O 0 0.0020023251
is O 0 0.0023787913
stopped O 0 0.0049894475
. O 0 0.0066200066

Since O 0 0.003659262
adverse O 0 0.1364932
reactions O 0 0.011421499
are O 0 0.0014581027
frequent O 0 0.002621199
, O 0 0.00095226977
less O 0 0.00047948296
than O 0 0.00029304938
50 O 0 0.00031537708
percent O 0 0.00021771
of O 0 0.00029097864
patients O 0 0.00033834853
are O 0 0.00021133233
able O 0 0.00017790451
to O 0 0.0002039389
continue O 0 0.00025715766
a O 0 0.0003531375
particular O 0 0.00034397555
drug O 0 0.034541074
for O 0 0.0006053945
more O 0 0.0008998942
than O 0 0.00095269724
one O 0 0.001699603
year O 0 0.0033958054
. O 0 0.006192961

Since O 0 0.0032518252
it O 0 0.0024891482
takes O 0 0.0012657074
three O 0 0.00073899655
to O 0 0.0006478664
12 O 0 0.0004652315
months O 0 0.00031751906
to O 0 0.00027502177
achieve O 0 0.00023535921
maximal O 0 0.00027236954
effects O 0 0.00043595728
, O 0 0.0004779816
those O 0 0.0003949794
patients O 0 0.00039968337
who O 0 0.0003357679
are O 0 0.0001949196
unable O 0 0.00017710395
to O 0 0.00022628436
continue O 0 0.0003057789
the O 0 0.0004095413
drug O 0 0.021888098
receive O 0 0.00053568353
little O 0 0.0008310172
benefit O 0 0.001507234
from O 0 0.0020556943
it O 0 0.003984194
. O 0 0.0065906867

Patients O 0 0.0046827337
treated O 0 0.002705196
with O 0 0.0023631745
alkylating B-Chemical 0 0.9832896
agents I-Chemical 0 0.04016736
have O 0 0.0006226336
an O 0 0.00071037887
increased O 0 0.00071831135
risk O 0 0.06985223
of O 0 0.00065184943
development O 0 0.0036417106
of O 0 0.004426194
acute B-Disease 0 0.9994215
nonlymphocytic I-Disease 0 0.99999845
leukemia I-Disease 0 0.9999999
, O 0 0.046863485
and O 0 0.0009317713
both O 0 0.00047869183
alkylating B-Chemical 0 0.9857583
agents I-Chemical 0 0.026813908
and O 0 0.0020397748
azathioprine B-Chemical 0 0.99999285
are O 0 0.0002753744
associated O 0 0.0002502984
with O 0 0.0002381597
the O 0 0.0002420569
development O 0 0.00055022497
of O 0 0.00063226005
non B-Disease 0 0.0027172987
- I-Disease 0 0.04250099
Hodgkin I-Disease 0 0.9396919
' I-Disease 0 0.0037339742
s I-Disease 0 0.00466513
lymphoma I-Disease 0 0.99603015
. O 0 0.009291173

Cyclophosphamide B-Chemical 0 0.9995803
therapy O 0 0.009862188
increases O 0 0.00342477
the O 0 0.003044729
risk O 0 0.083266005
of O 0 0.006753214
carcinoma B-Disease 2 0.99979264
of I-Disease 0 0.007882529
the I-Disease 0 0.0063779117
bladder I-Disease 0 0.47617504
. O 0 0.012403208

There O 0 0.003973547
have O 0 0.0021824287
been O 0 0.0016152766
several O 0 0.0010153983
long O 0 0.0010051131
- O 0 0.0021524418
term O 0 0.00049489207
studies O 0 0.00043059973
of O 0 0.0004709416
patients O 0 0.0008278858
with O 0 0.0023597165
rheumatoid B-Disease 0 0.99998975
arthritis I-Disease 0 0.9999982
treated O 0 0.003809156
with O 0 0.002468705
azathioprine B-Chemical 0 0.9999957
and O 0 0.0037427102
cyclophosphamide B-Chemical 0 0.99989986
and O 0 0.00039783705
the O 0 0.0002253942
incidence O 0 0.0009543634
of O 0 0.0003497597
most O 0 0.00044587842
of O 0 0.00045382115
the O 0 0.00055125274
common O 0 0.0018027269
cancers B-Disease 2 0.9869616
is O 0 0.0018746547
not O 0 0.002197297
increased O 0 0.004594359
. O 0 0.007156884

Data O 0 0.003698257
on O 0 0.0017300226
the O 0 0.0014399579
possible O 0 0.0011826314
increased O 0 0.0012166093
risk O 0 0.08882448
of O 0 0.004183302
malignancy B-Disease 2 0.9999565
in O 0 0.02343693
rheumatoid B-Disease 0 0.99999607
arthritis I-Disease 0 0.9999987
are O 0 0.00053535635
still O 0 0.00023716628
being O 0 0.00027508996
collected O 0 0.00013387279
, O 0 0.00020626328
and O 0 0.00015835857
until O 0 0.00010490788
further O 0 0.00013072604
information O 0 0.00015403565
is O 0 0.00016953339
available O 0 0.00020168857
, O 0 0.00021851671
the O 0 0.00014380882
use O 0 0.0001624008
of O 0 0.00030882057
immunosuppressive O 0 0.8753874
drugs O 0 0.6558505
, O 0 0.0017043498
particularly O 0 0.008119538
alkylating B-Chemical 0 0.9954268
agents I-Chemical 0 0.04963041
, O 0 0.0005174865
in O 0 0.00017006249
the O 0 0.0001615341
treatment O 0 0.00029719496
of O 0 0.0027896673
rheumatoid B-Disease 0 0.99999404
arthritis I-Disease 0 0.9999982
should O 0 0.00018919302
be O 0 0.00018294081
reserved O 0 0.00024816504
for O 0 0.00017782107
patients O 0 0.0003144221
with O 0 0.00034041615
severe O 0 0.059004284
progressive O 0 0.21040456
disease O 0 0.8960791
or O 0 0.00092314015
life O 0 0.0022407968
- O 0 0.022294518
threatening O 0 0.039822016
complications O 0 0.5289561
. O 0 0.007269568

Warfarin B-Chemical 0 0.999861
- O 0 0.046422537
induced O 0 0.005848638
iliopsoas O 0 0.83307326
hemorrhage B-Disease 2 0.9999292
with O 0 0.0037281874
subsequent O 0 0.004102915
femoral B-Disease 0 0.6865182
nerve I-Disease 0 0.88314915
palsy I-Disease 0 0.9999893
. O 0 0.017561559

We O 0 0.0033889262
present O 0 0.0019108105
the O 0 0.0015039622
case O 0 0.0012409418
of O 0 0.0010709061
a O 0 0.0010547594
28 O 0 0.00085150474
- O 0 0.003053907
year O 0 0.0005821261
- O 0 0.0026725482
old O 0 0.00043992803
man O 0 0.01195662
on O 0 0.00025961653
chronic O 0 0.96447533
warfarin B-Chemical 1 0.9999862
therapy O 0 0.0028989438
who O 0 0.0004919094
sustained O 0 0.00054905197
a O 0 0.00032724685
minor O 0 0.002952033
muscle B-Disease 0 0.68200475
tear I-Disease 0 0.9893148
and O 0 0.00045369333
developed O 0 0.00049675896
increasing O 0 0.00043490672
pain B-Disease 0 0.8110572
and O 0 0.00047592257
a O 0 0.00077791733
flexure O 0 0.8235912
contracture B-Disease 0 0.99928963
of O 0 0.0015932848
the O 0 0.0017572757
right O 0 0.0070099495
hip O 0 0.6469254
. O 0 0.007210508

Surgical O 0 0.004856099
exploration O 0 0.002700913
revealed O 0 0.0016449866
an O 0 0.0017672324
iliopsoas O 0 0.36711296
hematoma B-Disease 0 0.9996501
and O 0 0.0012067645
femoral O 0 0.092036486
nerve B-Disease 0 0.8662498
entrapment I-Disease 0 0.8438763
, O 0 0.0005799845
resulting O 0 0.00030104656
in O 0 0.00030857572
a O 0 0.0004605025
femoral B-Disease 0 0.1551066
nerve I-Disease 0 0.4922446
palsy I-Disease 0 0.99999785
and O 0 0.0011067025
partial B-Disease 0 0.0012517757
loss I-Disease 0 0.0018349444
of I-Disease 0 0.0023466707
quadriceps I-Disease 0 0.32612285
functions I-Disease 0 0.0041341484
. O 0 0.0069801067

Anticoagulant O 0 0.8306432
- O 0 0.012239909
induced O 0 0.0022393644
femoral B-Disease 0 0.41235065
nerve I-Disease 0 0.8729784
palsy I-Disease 0 0.99999845
represents O 0 0.0010377147
the O 0 0.0005051798
most O 0 0.00052096974
common O 0 0.00038838404
form O 0 0.00027196735
of O 0 0.0022895443
warfarin B-Chemical 1 0.99999154
- O 0 0.10678786
induced O 0 0.0012862962
peripheral B-Disease 2 0.9850767
neuropathy I-Disease 2 0.99999976
; O 0 0.0045038797
it O 0 0.00024786443
is O 0 0.00017619172
characterized O 0 0.00023311473
by O 0 0.0002496497
severe O 0 0.12829532
pain B-Disease 0 0.9033524
in O 0 0.00016158122
the O 0 0.00014884798
inguinal O 0 0.0002723181
region O 0 0.00022305705
, O 0 0.00023063445
varying O 0 0.00017887898
degrees O 0 0.0018284651
of O 0 0.00038009608
motor B-Disease 0 0.012966218
and I-Disease 0 0.0003577858
sensory I-Disease 0 0.0032100482
impairment I-Disease 0 0.15533096
, O 0 0.00063784316
and O 0 0.00075322756
flexure O 0 0.8563601
contracture B-Disease 0 0.99928635
of O 0 0.0014925473
the O 0 0.0015287437
involved O 0 0.0022924764
extremity O 0 0.1043618
. O 0 0.0068865973

Pneumonitis O 0 0.99094945
with O 0 0.004089394
pleural B-Disease 0 0.033916485
and I-Disease 0 0.0027899477
pericardial I-Disease 0 0.09909052
effusion I-Disease 0 0.7921054
and O 0 0.007949635
neuropathy B-Disease 0 0.9999716
during O 0 0.004357508
amiodarone B-Chemical 1 0.99997723
therapy O 0 0.0336536
. O 0 0.009491862

A O 0 0.04328643
patient O 0 0.0028677487
with O 0 0.0021909082
sinuatrial B-Disease 0 0.75382507
disease I-Disease 0 0.99161196
and O 0 0.0011656408
implanted O 0 0.0015796445
pacemaker O 0 0.00850461
was O 0 0.00032334335
treated O 0 0.00036612767
with O 0 0.001050599
amiodarone B-Chemical 1 0.9999937
( O 0 0.0007107384
maximum O 0 0.00018644803
dose O 0 0.0014411268
1000 O 0 0.000471151
mg O 0 0.011597012
, O 0 0.0002469723
maintenance O 0 0.00022651814
dose O 0 0.0007922817
800 O 0 0.0005261081
mg O 0 0.0061844257
daily O 0 0.0002383446
) O 0 0.00031004482
for O 0 0.0001967433
10 O 0 0.00022872681
months O 0 0.00023057002
, O 0 0.00044259868
for O 0 0.00051916135
control O 0 0.0009679327
of O 0 0.0048125065
supraventricular B-Disease 0 0.99997044
tachyarrhythmias I-Disease 0 0.99999475
. O 0 0.00980917

He O 0 0.010178675
developed O 0 0.00812565
pneumonitis B-Disease 0 0.99993145
, O 0 0.0057294616
pleural B-Disease 0 0.1184389
and I-Disease 0 0.0016993451
pericardial I-Disease 0 0.11914091
effusions I-Disease 0 0.7701189
, O 0 0.0013728681
and O 0 0.0010319473
a O 0 0.0012737347
predominantly O 0 0.0016647388
proximal B-Disease 0 0.018872935
motor I-Disease 0 0.9792143
neuropathy I-Disease 0 0.9999943
. O 0 0.01081303

Immediate O 0 0.010101466
but O 0 0.0037848752
gradual O 0 0.0025345695
improvement O 0 0.0019686355
followed O 0 0.0014717227
withdrawal O 0 0.25349712
of O 0 0.005624648
amiodarone B-Chemical 1 0.9999913
and O 0 0.0033161049
treatment O 0 0.0040813014
with O 0 0.009560456
prednisolone B-Chemical 1 0.99990463
. O 0 0.010731203

Review O 0 0.0055870847
of O 0 0.0027791853
this O 0 0.0017090377
and O 0 0.0013710473
previously O 0 0.0009458537
reported O 0 0.00075284945
cases O 0 0.0006854874
indicates O 0 0.00031963998
the O 0 0.00026989673
need O 0 0.0002083204
for O 0 0.00021317169
early O 0 0.00042949847
diagnosis O 0 0.0065561193
of O 0 0.010023649
amiodarone B-Chemical 1 0.99999976
pneumonitis B-Disease 0 0.9999994
, O 0 0.01988215
immediate O 0 0.007493334
withdrawal O 0 0.5045026
of O 0 0.0055116
amiodarone B-Chemical 1 0.9999976
, O 0 0.0010176566
and O 0 0.00037652673
prompt O 0 0.0013130296
but O 0 0.00053558906
continued O 0 0.00067917386
steroid B-Chemical 1 0.9883476
therapy O 0 0.001074706
to O 0 0.00067784573
ensure O 0 0.000778465
full O 0 0.0017391152
recovery O 0 0.004244817
. O 0 0.0061024395

Amiodarone B-Chemical 1 0.99989414
- O 0 0.06776584
induced O 0 0.020712387
sinoatrial B-Disease 0 0.5348463
block I-Disease 0 0.022704018
. O 0 0.027583767

We O 0 0.0034307335
observed O 0 0.0021699674
sinoatrial B-Disease 0 0.034149114
block I-Disease 0 0.0010903977
due O 0 0.0006515184
to O 0 0.00070857827
chronic O 0 0.9783124
amiodarone B-Chemical 1 0.9999987
administration O 0 0.06576799
in O 0 0.00033276857
a O 0 0.00036009258
5 O 0 0.00022549824
- O 0 0.0012421102
year O 0 0.00028681112
- O 0 0.001387939
old O 0 0.00025925462
boy O 0 0.0005462715
with O 0 0.00037796295
primary B-Disease 0 0.06410467
cardiomyopathy I-Disease 0 0.99999976
, O 0 0.040595952
Wolff B-Disease 0 0.9826372
- I-Disease 0 0.45590064
Parkinson I-Disease 0 0.9999223
- I-Disease 0 0.07156813
White I-Disease 0 0.2558672
syndrome I-Disease 0 0.5131933
and O 0 0.005842394
supraventricular B-Disease 0 0.9999434
tachycardia I-Disease 2 0.9999535
. O 0 0.0082847355

Reduction O 0 0.007200421
in O 0 0.002470567
the O 0 0.0017951131
dosage O 0 0.063080035
of O 0 0.006396153
amiodarone B-Chemical 1 0.99999416
resulted O 0 0.000732258
in O 0 0.0004547169
the O 0 0.0003452647
disappearance O 0 0.0012234504
of O 0 0.0003847589
the O 0 0.00031678585
sinoatrial B-Disease 0 0.042490646
block I-Disease 0 0.00030276607
and O 0 0.0003854168
the O 0 0.00044187022
persistence O 0 0.0012078224
of O 0 0.002001898
asymptomatic O 0 0.8091798
sinus B-Disease 0 0.98262805
bradycardia I-Disease 0 0.99990666
. O 0 0.0075378846

Desipramine B-Chemical 0 0.9999918
- O 0 0.19457522
induced O 0 0.008764365
delirium B-Disease 2 0.9999745
at O 0 0.0022654168
" O 0 0.0036981092
subtherapeutic O 0 0.978276
" O 0 0.0023389738
concentrations O 0 0.003006738
: O 0 0.003007996
a O 0 0.003078266
case O 0 0.004106527
report O 0 0.00913139
. O 0 0.009327141

An O 0 0.006422036
elderly O 0 0.06662955
patient O 0 0.0019705747
treated O 0 0.0013347764
with O 0 0.000999107
low O 0 0.0015907465
dose O 0 0.2210353
Desipramine B-Chemical 0 0.9999994
developed O 0 0.007200793
a O 0 0.004838774
delirium B-Disease 2 0.9999919
while O 0 0.00049634237
her O 0 0.000436758
plasma O 0 0.0028603135
level O 0 0.00030667198
was O 0 0.00041814146
in O 0 0.0005064817
the O 0 0.00078962254
" O 0 0.0021080985
subtherapeutic O 0 0.95030236
" O 0 0.0033088964
range O 0 0.004060348
. O 0 0.006890029

Delirium B-Disease 2 0.9986534
, O 0 0.005246506
which O 0 0.0025615112
may O 0 0.0012600829
be O 0 0.0009811807
induced O 0 0.0009069653
by O 0 0.0015739301
tricyclic O 0 0.99993455
drug O 0 0.6283637
therapy O 0 0.0015368668
in O 0 0.0003436348
the O 0 0.00038977308
elderly O 0 0.23059404
, O 0 0.0004970064
can O 0 0.00023970743
be O 0 0.00029803716
caused O 0 0.0003828483
by O 0 0.00085709465
tricyclics O 0 0.9981627
with O 0 0.001159685
low O 0 0.005441793
anticholinergic O 0 0.999613
potency O 0 0.21044749
. O 0 0.0072272806

Therapeutic O 0 0.010240402
ranges O 0 0.0026545362
for O 0 0.002475141
antidepressants B-Chemical 0 0.9997404
that O 0 0.000826369
have O 0 0.000576147
been O 0 0.00047094002
derived O 0 0.00031211166
from O 0 0.00033556327
general O 0 0.00035374096
adult O 0 0.00049099495
population O 0 0.0005863788
studies O 0 0.0004092412
may O 0 0.00038945107
not O 0 0.00045625438
be O 0 0.0006421011
appropriate O 0 0.00082373846
for O 0 0.0013893128
the O 0 0.0026089943
elderly O 0 0.27563193
. O 0 0.007188947

Further O 0 0.003890688
studies O 0 0.002573579
of O 0 0.0021275177
specifically O 0 0.0015184894
elderly O 0 0.09678539
patients O 0 0.0011474894
are O 0 0.0005526611
now O 0 0.00044029555
required O 0 0.00027779277
to O 0 0.000320793
establish O 0 0.00031473098
safer O 0 0.00069386483
and O 0 0.0004911279
more O 0 0.00055771606
appropriate O 0 0.0005860933
guidelines O 0 0.0009898255
for O 0 0.0014968051
drug O 0 0.18930794
therapy O 0 0.007163283
. O 0 0.006944512

Indomethacin B-Chemical 0 0.9999827
- O 0 0.1359208
induced O 0 0.00849844
renal B-Disease 0 0.99169075
insufficiency I-Disease 0 0.99949
: O 0 0.018250592
recurrence O 0 0.6741432
on O 0 0.0057354188
rechallenge O 0 0.49492377
. O 0 0.013982758

We O 0 0.003630651
have O 0 0.002255097
reported O 0 0.0019918934
a O 0 0.0016137704
case O 0 0.0012262517
of O 0 0.0016464493
acute O 0 0.98679525
oliguric O 0 0.99998736
renal B-Disease 0 0.99805605
failure I-Disease 0 0.92028546
with O 0 0.018791683
hyperkalemia B-Disease 2 0.9999987
in O 0 0.00045327665
a O 0 0.00041258882
patient O 0 0.00038001456
with O 0 0.0018042893
cirrhosis B-Disease 0 0.99999976
, O 0 0.06922228
ascites B-Disease 0 0.9998202
, O 0 0.0061768866
and O 0 0.013678574
cor B-Disease 0 0.99999464
pulmonale I-Disease 0 0.9999999
after O 0 0.0051717893
indomethacin B-Chemical 1 0.99998665
therapy O 0 0.033527248
. O 0 0.00682764

Prompt O 0 0.01883707
restoration O 0 0.0036723453
of O 0 0.0026070692
renal O 0 0.5975856
function O 0 0.0011486287
followed O 0 0.0007859965
drug O 0 0.65051484
withdrawal O 0 0.6070596
, O 0 0.00096489367
while O 0 0.0005277643
re O 0 0.03008027
- O 0 0.0121566085
exposure O 0 0.0014621238
to O 0 0.00023468072
a O 0 0.000322308
single O 0 0.000285083
dose O 0 0.0016587789
of O 0 0.0017041578
indomethacin B-Chemical 1 0.9999926
caused O 0 0.0017268313
recurrence O 0 0.9218053
of O 0 0.0072038476
acute O 0 0.992569
reversible O 0 0.97984904
oliguria B-Disease 0 0.99996793
. O 0 0.009679606

Our O 0 0.0038511136
case O 0 0.0024468037
supports O 0 0.0013777438
the O 0 0.0010304217
hypothesis O 0 0.00082706416
that O 0 0.00058745506
endogenous O 0 0.0011348807
renal O 0 0.99250984
prostaglandins B-Chemical 1 0.9999666
play O 0 0.0004752881
a O 0 0.0004058072
role O 0 0.00017677192
in O 0 0.00022397304
the O 0 0.00021433238
maintenance O 0 0.0003147052
of O 0 0.00044541876
renal O 0 0.8123961
blood O 0 0.020279912
flow O 0 0.0013879217
when O 0 0.0003569975
circulating O 0 0.002541041
plasma O 0 0.00909187
volume O 0 0.0020188622
is O 0 0.0022826795
diminished O 0 0.004258318
. O 0 0.0068189413

Since O 0 0.004588237
nonsteroidal O 0 0.99994767
anti O 0 0.88381547
- O 0 0.32969543
inflammatory O 0 0.81614417
agents O 0 0.048740517
interfere O 0 0.00054952945
with O 0 0.00047217068
this O 0 0.00029608776
compensatory O 0 0.00037654163
mechanism O 0 0.00025035805
and O 0 0.0004019921
may O 0 0.0002842124
cause O 0 0.000945085
acute B-Disease 0 0.962907
renal I-Disease 0 0.994253
failure I-Disease 0 0.8232763
, O 0 0.0008752053
they O 0 0.00021818753
should O 0 0.0001824647
be O 0 0.0002721403
used O 0 0.00032501385
with O 0 0.00051006436
caution O 0 0.0008269455
in O 0 0.0011649567
such O 0 0.0019344987
patients O 0 0.005017419
. O 0 0.006378111

Patterns O 0 0.014080946
of O 0 0.012671396
hepatic B-Disease 0 0.9976926
injury I-Disease 0 0.99875796
induced O 0 0.026733572
by O 0 0.062716536
methyldopa B-Chemical 0 0.9999943
. O 0 0.024705293

Twelve O 0 0.0076202834
patients O 0 0.004003646
with O 0 0.003674663
liver B-Disease 2 0.9962496
disease I-Disease 2 0.99827254
related O 0 0.0012422996
to O 0 0.0017795237
methyldopa B-Chemical 0 0.999998
were O 0 0.0011513009
seen O 0 0.0010624734
between O 0 0.0012954879
1967 O 0 0.0045787077
and O 0 0.003741407
1977 O 0 0.014595438
. O 0 0.008385511

Illness O 0 0.013332992
occurred O 0 0.002422628
within O 0 0.001409863
1 O 0 0.0016032082
- O 0 0.0063991207
- O 0 0.0027222796
9 O 0 0.000557631
weeks O 0 0.00031792192
of O 0 0.00036948215
commencement O 0 0.0003522008
of O 0 0.00035461428
therapy O 0 0.0005578727
in O 0 0.00025075942
9 O 0 0.00022145925
patients O 0 0.00027289666
, O 0 0.00023980754
the O 0 0.00015878542
remaining O 0 0.00017797679
3 O 0 0.0001446436
patients O 0 0.00018405779
having O 0 0.00017054983
received O 0 0.00012667554
the O 0 0.00017091498
drug O 0 0.028723381
for O 0 0.00018858354
13 O 0 0.00020956575
months O 0 0.00015196766
, O 0 0.00024211232
15 O 0 0.00020697922
months O 0 0.00022003161
and O 0 0.00038357126
7 O 0 0.00048595262
years O 0 0.0008649081
before O 0 0.0010986117
experiencing O 0 0.009508675
symptoms O 0 0.2113561
. O 0 0.007067783

Jaundice B-Disease 0 0.99218714
with O 0 0.0040987167
tender O 0 0.11794335
hepatomegaly B-Disease 2 0.99970716
, O 0 0.002292713
usually O 0 0.00092274963
preceded O 0 0.0006091813
by O 0 0.00061311
symptoms O 0 0.13582373
of O 0 0.0019544426
malaise O 0 0.99994516
, O 0 0.014048771
anorexia B-Disease 0 0.9999815
, O 0 0.06208202
nausea B-Disease 2 0.9999989
and O 0 0.009334132
vomiting B-Disease 0 0.99996006
, O 0 0.0006679144
and O 0 0.00027643974
associated O 0 0.00024620938
with O 0 0.000256452
upper O 0 0.0006331785
abdominal B-Disease 0 0.116572514
pain I-Disease 0 0.9171393
, O 0 0.0005377047
was O 0 0.0004050298
an O 0 0.00059759535
invariable O 0 0.035855975
finding O 0 0.0014550227
in O 0 0.0013729399
all O 0 0.0020874073
patients O 0 0.0047111325
. O 0 0.0063784067

Biochemical O 0 0.15693308
liver O 0 0.39455995
function O 0 0.0021420931
tests O 0 0.0029702077
indicated O 0 0.0020645908
hepatocellular O 0 0.99999976
necrosis B-Disease 2 0.9999994
and O 0 0.0074323076
correlated O 0 0.00034149876
with O 0 0.0003325897
histopathological O 0 0.09344076
evidence O 0 0.00021581436
of O 0 0.0010330421
hepatic B-Disease 0 0.99977356
injury I-Disease 0 0.99973625
, O 0 0.0012710448
the O 0 0.00020753553
spectrum O 0 0.00028545916
of O 0 0.00026057
which O 0 0.00026237738
ranged O 0 0.00021118809
from O 0 0.00030501085
fatty B-Disease 0 0.99973804
change I-Disease 0 0.008822572
and O 0 0.00093264756
focal O 0 0.77225584
hepatocellular O 0 0.9999999
necrosis B-Disease 2 0.9999987
to O 0 0.004827504
massive B-Disease 0 0.4709245
hepatic I-Disease 0 0.9945785
necrosis I-Disease 2 0.99992085
. O 0 0.018630028

Most O 0 0.005582043
patients O 0 0.0032959995
showed O 0 0.0019792297
moderate O 0 0.0066614463
to O 0 0.0015321407
severe O 0 0.82562596
acute B-Disease 0 0.9999747
hepatitis I-Disease 2 1.0
or O 0 0.42914286
chronic B-Disease 0 0.99980146
active I-Disease 0 0.8182325
hepatitis I-Disease 2 1.0
with O 0 0.41331828
associated O 0 0.31155944
cholestasis B-Disease 2 0.999997
. O 0 0.039206948

The O 0 0.0038496726
drug O 0 0.04958001
was O 0 0.0019454723
withdrawn O 0 0.0016222601
on O 0 0.00066626654
presentation O 0 0.0008432207
to O 0 0.0005327506
hospital O 0 0.0007751575
in O 0 0.00046971967
11 O 0 0.0004882133
patients O 0 0.0005598163
, O 0 0.00061459607
with O 0 0.00063424837
rapid O 0 0.0013492884
clinical O 0 0.0023017896
improvement O 0 0.001617121
in O 0 0.0022341073
9 O 0 0.0037198598
. O 0 0.006406692

One O 0 0.004873533
patient O 0 0.002886833
died O 0 0.0037507534
, O 0 0.0017983846
having O 0 0.0010878495
presented O 0 0.0006729458
in O 0 0.00069428526
hepatic B-Disease 0 0.8853949
failure I-Disease 0 0.6972739
, O 0 0.0014025912
and O 0 0.0005429216
another O 0 0.00051714724
, O 0 0.0005005632
who O 0 0.00044581425
had O 0 0.00021496312
been O 0 0.0002623569
taking O 0 0.010960005
methyldopa B-Chemical 0 0.99999905
for O 0 0.00022880557
7 O 0 0.00015767498
years O 0 0.00020734721
, O 0 0.00022582528
showed O 0 0.00017144138
slower O 0 0.00021398484
clinical O 0 0.0004521393
and O 0 0.00025853634
biochemical O 0 0.0007120862
resolution O 0 0.0013350053
over O 0 0.00031339886
a O 0 0.00057587604
period O 0 0.0006220263
of O 0 0.0011895406
several O 0 0.0016444728
months O 0 0.0026020368
. O 0 0.005676363

The O 0 0.003061754
remaining O 0 0.0021890337
patient O 0 0.0016177902
in O 0 0.0010594679
the O 0 0.0008110595
series O 0 0.0011066366
developed O 0 0.017502537
fulminant B-Disease 0 0.99999964
hepatitis I-Disease 2 1.0
when O 0 0.0053270105
the O 0 0.0009904908
drug O 0 0.4162535
was O 0 0.00036502702
accidentally O 0 0.0031332907
recommenced O 0 0.0054373797
1 O 0 0.00022541484
year O 0 0.00022301327
after O 0 0.00018418174
a O 0 0.00032180236
prior O 0 0.0002969633
episode O 0 0.0018139629
of O 0 0.012555403
methyldopa B-Chemical 0 0.99999964
- O 0 0.34981486
induced O 0 0.035625026
hepatitis B-Disease 2 0.99999964
. O 0 0.15987124

In O 0 0.0037220272
this O 0 0.0024402216
latter O 0 0.0028607424
patient O 0 0.0015456612
, O 0 0.0013363524
and O 0 0.00083347165
in O 0 0.0005904718
2 O 0 0.0004721851
others O 0 0.0007258992
, O 0 0.00039245354
the O 0 0.00022207921
causal O 0 0.0003084201
relationship O 0 0.00017224441
between O 0 0.00036163552
methyldopa B-Chemical 0 0.99999976
and O 0 0.008769562
hepatic B-Disease 0 0.99977154
dysfunction I-Disease 0 0.99907553
was O 0 0.00039249033
proved O 0 0.00038321398
with O 0 0.00018269362
the O 0 0.00021003404
recurrence O 0 0.4852794
of O 0 0.0027337305
hepatitis B-Disease 2 1.0
within O 0 0.0003888008
2 O 0 0.00028940497
weeks O 0 0.00020552223
of O 0 0.0004371098
re O 0 0.009173848
- O 0 0.005588226
exposure O 0 0.0025054214
to O 0 0.0013839318
the O 0 0.0025048722
drug O 0 0.2845674
. O 0 0.0070434595

Suxamethonium B-Chemical 1 0.98126304
infusion O 0 0.017096652
rate O 0 0.010626721
and O 0 0.012399739
observed O 0 0.015936516
fasciculations B-Disease 0 0.9997285
. O 0 0.024877684

A O 0 0.081139974
dose O 0 0.04415562
- O 0 0.03447962
response O 0 0.02499021
study O 0 0.029200971
. O 0 0.032029845

Suxamethonium B-Chemical 1 0.99994886
chloride I-Chemical 0 0.99999416
( O 0 0.4258955
Sch B-Chemical 0 0.99999857
) O 0 0.027826294
was O 0 0.00090122945
administered O 0 0.0006595502
i O 0 0.0027892948
. O 0 0.00042072596
v O 0 0.008696306
. O 0 0.0002995878
to O 0 0.0002221887
36 O 0 0.00024846333
adult O 0 0.0002688863
males O 0 0.00030046105
at O 0 0.00015156638
six O 0 0.00012713707
rates O 0 0.00019989564
: O 0 0.00034873706
0 O 0 0.00023819738
. O 0 0.00019238079
25 O 0 0.00025518858
mg O 0 0.001669428
s O 0 0.0004417527
- O 0 0.0011666474
1 O 0 0.00037162908
to O 0 0.00040013687
20 O 0 0.0006566697
mg O 0 0.0028724035
s O 0 0.0019335219
- O 0 0.0051566646
1 O 0 0.0039956165
. O 0 0.006864808

The O 0 0.0032254907
infusion O 0 0.0044121463
was O 0 0.0017299594
discontinued O 0 0.002786058
either O 0 0.0006786036
when O 0 0.0004235075
there O 0 0.00032726745
was O 0 0.00036078066
no O 0 0.00026876485
muscular O 0 0.08217263
response O 0 0.00047697715
to O 0 0.00032070617
tetanic B-Disease 0 0.9926885
stimulation O 0 0.00031649272
of O 0 0.00032497945
the O 0 0.00029933683
ulnar O 0 0.15216483
nerve O 0 0.022154078
or O 0 0.00043979197
when O 0 0.00063933886
Sch B-Chemical 0 0.9999949
120 O 0 0.0019158917
mg O 0 0.023054648
was O 0 0.0021021243
exceeded O 0 0.0031814948
. O 0 0.006276861

Six O 0 0.00502601
additional O 0 0.002452518
patients O 0 0.002223681
received O 0 0.0013489762
a O 0 0.0014887097
30 O 0 0.001183786
- O 0 0.0040956303
mg O 0 0.031805977
i O 0 0.0031483427
. O 0 0.0015337879
v O 0 0.008150534
. O 0 0.00280995
bolus O 0 0.009946528
dose O 0 0.012389711
. O 0 0.009222886

Fasciculations B-Disease 0 0.579174
in O 0 0.0026334766
six O 0 0.001428124
areas O 0 0.0016630793
of O 0 0.0010773579
the O 0 0.0007661898
body O 0 0.0011814013
were O 0 0.00049766374
scored O 0 0.0004961248
from O 0 0.0003343764
0 O 0 0.0003837611
to O 0 0.00031196827
3 O 0 0.0003487163
and O 0 0.000453054
summated O 0 0.00063775835
as O 0 0.00068123016
a O 0 0.0011739883
total O 0 0.0015646005
fasciculation B-Disease 0 0.8228364
score O 0 0.0043564527
. O 0 0.0068268026

The O 0 0.002937068
times O 0 0.0016703638
to O 0 0.0014843201
first O 0 0.0012525014
fasciculation B-Disease 0 0.81802016
, O 0 0.0021944395
twitch B-Disease 0 0.9114248
suppression O 0 0.001525893
and O 0 0.001320984
tetanus B-Disease 0 0.997486
suppression O 0 0.0019441729
were O 0 0.00052583095
inversely O 0 0.00042808824
related O 0 0.00048018643
to O 0 0.00073394383
the O 0 0.0012602721
infusion O 0 0.0030597576
rates O 0 0.0039949887
. O 0 0.006740553

Fasciculations B-Disease 0 0.6188854
in O 0 0.0025947872
the O 0 0.001578885
six O 0 0.0009504877
areas O 0 0.0012206871
and O 0 0.0007700465
the O 0 0.00055831816
total O 0 0.00050890155
fasciculation B-Disease 0 0.6952446
score O 0 0.00047554754
were O 0 0.0003970941
related O 0 0.00031321545
directly O 0 0.00042934105
to O 0 0.00056052324
the O 0 0.00084106764
rate O 0 0.0015139276
of O 0 0.002993758
infusion O 0 0.009412438
. O 0 0.006868424

Total O 0 0.004090027
fasciculation B-Disease 0 0.45282108
scores O 0 0.0016087627
in O 0 0.0010244825
the O 0 0.00075032894
30 O 0 0.0006287636
- O 0 0.0023042525
mg O 0 0.011667551
bolus O 0 0.0013223542
group O 0 0.00034308797
and O 0 0.00025267483
the O 0 0.0002121874
5 O 0 0.00020603469
- O 0 0.0012781875
mg O 0 0.005150951
s O 0 0.00039255622
- O 0 0.0016030227
1 O 0 0.00019473606
and O 0 0.00020804547
20 O 0 0.00023613963
- O 0 0.0011561938
mg O 0 0.0047576106
s O 0 0.0004984409
- O 0 0.0018096596
1 O 0 0.00039833476
infusion O 0 0.00061323284
groups O 0 0.0005776523
were O 0 0.00078670983
not O 0 0.0010985855
significantly O 0 0.0019248264
different O 0 0.003092907
. O 0 0.0063651777

Treatment O 0 0.029463818
of O 0 0.025076
psoriasis B-Disease 2 0.99961615
with O 0 0.1182847
azathioprine B-Chemical 0 0.9999343
. O 0 0.03669275

Azathioprine B-Chemical 0 0.99988544
treatment O 0 0.006401655
benefited O 0 0.0069505027
19 O 0 0.0025627739
( O 0 0.0017512351
66 O 0 0.0014512608
% O 0 0.0011513496
) O 0 0.0011375264
out O 0 0.00068340066
of O 0 0.0009877061
29 O 0 0.0014955079
patients O 0 0.0016623606
suffering O 0 0.05446768
from O 0 0.0025691802
severe O 0 0.63173777
psoriasis B-Disease 2 0.9998859
. O 0 0.011575017

Haematological O 0 0.94866574
complications O 0 0.18267766
were O 0 0.002209899
not O 0 0.001527104
troublesome O 0 0.009733765
and O 0 0.0010455098
results O 0 0.00080170645
of O 0 0.0010440089
biochemical O 0 0.0055113253
liver O 0 0.39669403
function O 0 0.0016874535
tests O 0 0.0031231376
remained O 0 0.0035727266
normal O 0 0.0062680393
. O 0 0.007897602

Minimal O 0 0.067188084
cholestasis B-Disease 2 0.99998415
was O 0 0.003394184
seen O 0 0.0014980393
in O 0 0.0010095513
two O 0 0.0007049066
cases O 0 0.00097279093
and O 0 0.0010373723
portal O 0 0.23963884
fibrosis B-Disease 2 0.9978421
of O 0 0.001934273
a O 0 0.0017586369
reversible O 0 0.030241325
degree O 0 0.0023175748
in O 0 0.0026841315
eight O 0 0.0037349747
. O 0 0.006790665

Liver O 0 0.5085936
biopsies O 0 0.0033797286
should O 0 0.0013163056
be O 0 0.0010631147
undertaken O 0 0.0006807888
at O 0 0.0005435059
regular O 0 0.00048319504
intervals O 0 0.0003135414
if O 0 0.00036513875
azathioprine B-Chemical 0 0.99996674
therapy O 0 0.0018253626
is O 0 0.00029718422
continued O 0 0.00024632912
so O 0 0.00020546833
that O 0 0.00018921393
structural O 0 0.005403844
liver B-Disease 2 0.99839264
damage I-Disease 2 0.99669266
may O 0 0.00037915172
be O 0 0.00032495774
detected O 0 0.00033442394
at O 0 0.00043018025
an O 0 0.0007233556
early O 0 0.0013626348
and O 0 0.0020222398
reversible O 0 0.10166995
stage O 0 0.014260697
. O 0 0.007428689

Angiosarcoma B-Disease 0 0.27463126
of I-Disease 0 0.008931836
the I-Disease 0 0.008015762
liver I-Disease 0 0.6163858
associated O 0 0.012774693
with O 0 0.039970364
diethylstilbestrol B-Chemical 0 0.9999598
. O 0 0.02529595

Angiosarcoma B-Disease 0 0.24162601
of I-Disease 0 0.00313176
the I-Disease 0 0.0021082757
liver I-Disease 0 0.30103704
occurred O 0 0.0011453213
in O 0 0.000740874
a O 0 0.0007963796
76 O 0 0.0012477428
- O 0 0.003331236
year O 0 0.0005141542
- O 0 0.0031818815
old O 0 0.00044405067
man O 0 0.023381293
who O 0 0.0005358436
had O 0 0.00021587881
been O 0 0.00018873034
treated O 0 0.00021786119
for O 0 0.0001924208
a O 0 0.00028357527
well O 0 0.00030037342
- O 0 0.01641958
differentiated O 0 0.0087858625
adenocarcinoma B-Disease 0 0.99977964
of I-Disease 0 0.00093732716
the I-Disease 0 0.0007088653
liver I-Disease 0 0.82939893
with O 0 0.0118577955
diethylstilbestrol B-Chemical 0 0.9999882
for O 0 0.0018208147
13 O 0 0.002511072
years O 0 0.0038816878
. O 0 0.006210953

Angiosarcoma B-Disease 0 0.30019206
was O 0 0.005079907
also O 0 0.0036483298
present O 0 0.002934226
within O 0 0.0030238705
pulmonary O 0 0.24352297
and O 0 0.0072415345
renal O 0 0.9660167
arteries O 0 0.8633211
. O 0 0.013459852

The O 0 0.0034135622
possibility O 0 0.0022213273
that O 0 0.0018223381
the O 0 0.0020497171
intraarterial B-Disease 0 0.8929572
lesions I-Disease 0 0.81919616
might O 0 0.0008380876
represent O 0 0.0008452986
independent O 0 0.00091254414
primary O 0 0.0019483893
tumors B-Disease 0 0.72871286
is O 0 0.0034062644
considered O 0 0.0044230227
. O 0 0.00809721

Galanthamine B-Chemical 0 0.99996746
hydrobromide I-Chemical 0 0.9999838
, O 0 0.005559405
a O 0 0.0016862986
longer O 0 0.000718774
acting O 0 0.0046561197
anticholinesterase O 0 0.99989283
drug O 0 0.76847833
, O 0 0.00090959785
in O 0 0.0003321296
the O 0 0.00028157947
treatment O 0 0.00032570589
of O 0 0.00035411934
the O 0 0.00033861623
central O 0 0.00068711047
effects O 0 0.0010195064
of O 0 0.015078526
scopolamine B-Chemical 1 0.99999964
( O 0 0.1304747
Hyoscine B-Chemical 0 0.9997764
) O 0 0.011094403
. O 0 0.007614732

Galanthamine B-Chemical 0 0.99997103
hydrobromide I-Chemical 0 0.9999883
, O 0 0.015580626
an O 0 0.0060221804
anticholinesterase O 0 0.9997515
drug O 0 0.41447482
capable O 0 0.00061005366
of O 0 0.00077177444
penetrating O 0 0.87169963
the O 0 0.0006205811
blood O 0 0.099418715
- O 0 0.022926407
brain O 0 0.015058229
barrier O 0 0.00602321
, O 0 0.00046142132
was O 0 0.00021283863
used O 0 0.00016693937
in O 0 0.00018551137
a O 0 0.00023998687
patient O 0 0.00022092987
demonstrating O 0 0.00020525862
central O 0 0.00046033532
effects O 0 0.0007264581
of O 0 0.016355742
scopolamine B-Chemical 1 0.9999999
( O 0 0.45431092
hyoscine B-Chemical 0 0.9999994
) O 0 0.36397287
overdosage B-Disease 0 0.99996877
. O 0 0.008870366

It O 0 0.004648718
is O 0 0.0024506242
longer O 0 0.0013130277
acting O 0 0.0020836724
than O 0 0.0013380361
physostigmine B-Chemical 0 0.9999937
and O 0 0.0010929878
is O 0 0.0005348381
used O 0 0.00037517239
in O 0 0.00040394627
anaesthesia O 0 0.002447309
to O 0 0.00034866322
reverse O 0 0.0012961581
the O 0 0.00059168466
non O 0 0.001816253
- O 0 0.017174158
depolarizing O 0 0.18887848
neuromuscular O 0 0.1398279
block O 0 0.0039494787
. O 0 0.006486681

However O 0 0.0051597673
, O 0 0.003755665
studies O 0 0.00210167
into O 0 0.0012507818
the O 0 0.0012867023
dose O 0 0.0021633862
necessary O 0 0.00094627345
to O 0 0.0013347218
combating O 0 0.3531348
scopolamine B-Chemical 1 0.99999976
intoxication O 0 0.99993277
are O 0 0.003915216
indicated O 0 0.0041352287
. O 0 0.007770258

Comparison O 0 0.0029626032
of O 0 0.002240215
the O 0 0.0014648484
subjective O 0 0.0018660876
effects O 0 0.0010585176
and O 0 0.0008599061
plasma O 0 0.0117977
concentrations O 0 0.0012829485
following O 0 0.0003812367
oral O 0 0.07738362
and O 0 0.0005691129
i O 0 0.00358395
. O 0 0.00042720058
m O 0 0.0023696043
. O 0 0.00061141286
administration O 0 0.005874396
of O 0 0.0048553017
flunitrazepam B-Chemical 0 0.99999726
in O 0 0.0032670377
volunteers O 0 0.0077186753
. O 0 0.0068978965

Flunitrazepam B-Chemical 0 0.9999287
0 O 0 0.0038221225
. O 0 0.0017487286
5 O 0 0.0011357296
, O 0 0.0011498914
1 O 0 0.0007206134
. O 0 0.00051817455
0 O 0 0.00047491194
or O 0 0.0003606361
2 O 0 0.00033205966
. O 0 0.00027074307
0 O 0 0.00030907532
mg O 0 0.002197256
was O 0 0.00020389806
given O 0 0.00013721641
by O 0 0.000194833
the O 0 0.00022456063
oral O 0 0.045065925
or O 0 0.00029846482
i O 0 0.004107922
. O 0 0.0002689463
m O 0 0.0013609272
. O 0 0.00024649664
routes O 0 0.00036917953
to O 0 0.0002566932
groups O 0 0.0003577566
of O 0 0.00051046174
volunteers O 0 0.0010048031
and O 0 0.00092647533
its O 0 0.0018809116
effects O 0 0.0023644767
compared O 0 0.0028848585
. O 0 0.0063731684

Plasma O 0 0.08945347
concentrations O 0 0.004280866
of O 0 0.0021470594
the O 0 0.0014486421
drug O 0 0.07308467
were O 0 0.00074541953
estimated O 0 0.0005563943
by O 0 0.0007085874
gas O 0 0.34464076
- O 0 0.01430087
liquid O 0 0.0035312253
chromatography O 0 0.003936959
, O 0 0.00066312164
in O 0 0.00054058246
a O 0 0.00071969576
smaller O 0 0.00073295616
number O 0 0.0010039333
of O 0 0.0017564511
the O 0 0.0025802287
subjects O 0 0.0055277995
. O 0 0.007314163

The O 0 0.0031563444
most O 0 0.0025383807
striking O 0 0.001806687
effect O 0 0.0012942472
was O 0 0.0011346509
sedation O 0 0.13320704
which O 0 0.00061386346
increased O 0 0.00042689848
with O 0 0.0003607083
the O 0 0.0002997612
dose O 0 0.0024548604
, O 0 0.0005072451
2 O 0 0.00025915922
mg O 0 0.0028045678
producing O 0 0.00030124007
deep O 0 0.0020675128
sleep O 0 0.006942437
although O 0 0.00034497713
the O 0 0.00044240544
subjects O 0 0.00077993405
could O 0 0.0007768762
still O 0 0.0013898038
be O 0 0.0025506308
aroused O 0 0.009667043
. O 0 0.0070761843

The O 0 0.0031981647
effects O 0 0.0026519934
of O 0 0.0022451272
i O 0 0.006901263
. O 0 0.0011714408
m O 0 0.0047286362
. O 0 0.0007043143
administration O 0 0.0015435509
were O 0 0.00041052164
apparent O 0 0.00036959135
earlier O 0 0.0003863786
and O 0 0.00040028014
sometimes O 0 0.00052267173
lasted O 0 0.00028297518
longer O 0 0.00030184377
than O 0 0.00042840114
those O 0 0.00088345516
following O 0 0.0012330243
oral O 0 0.25325277
administration O 0 0.04592799
. O 0 0.006656749

Dizziness B-Disease 0 0.9976736
was O 0 0.003905037
less O 0 0.0025167144
marked O 0 0.0026291658
than O 0 0.0015993607
sedation O 0 0.11865056
, O 0 0.0020081117
but O 0 0.001788158
increased O 0 0.0019717389
with O 0 0.002562367
the O 0 0.003605848
dose O 0 0.016708104
. O 0 0.009237695

There O 0 0.0048935
was O 0 0.0036394722
pain B-Disease 0 0.6023451
on O 0 0.0012440092
i O 0 0.0033338696
. O 0 0.0009765807
m O 0 0.0031276916
. O 0 0.00069937453
injection O 0 0.0011590619
of O 0 0.003376059
flunitrazepam B-Chemical 0 0.9999994
significantly O 0 0.00091756566
more O 0 0.00068359164
often O 0 0.0007610886
than O 0 0.0006697419
with O 0 0.0014742923
isotonic O 0 0.11800163
saline O 0 0.04441607
. O 0 0.006688452

Plasma O 0 0.0958837
concentrations O 0 0.0043630735
varied O 0 0.0019824007
with O 0 0.0014838566
dose O 0 0.0028281128
and O 0 0.0010644301
route O 0 0.0010427516
and O 0 0.00080066745
corresponded O 0 0.0006426221
qualitatively O 0 0.0008974702
with O 0 0.0011007887
the O 0 0.001558277
subjective O 0 0.0036259275
effects O 0 0.0044294
. O 0 0.007186899

The O 0 0.0038300846
drug O 0 0.06111708
was O 0 0.001916907
still O 0 0.0011794931
present O 0 0.00074447464
in O 0 0.0006991109
measurable O 0 0.00074608723
quantities O 0 0.00055999035
after O 0 0.00041575683
24 O 0 0.0005552219
h O 0 0.0006301573
even O 0 0.0007844866
with O 0 0.0010312088
the O 0 0.0014613408
smallest O 0 0.002687474
dose O 0 0.011712361
. O 0 0.007432519

Possible O 0 0.21269754
teratogenicity O 0 0.9994572
of O 0 0.1609739
sulphasalazine B-Chemical 1 0.99993205
. O 0 0.053977262

Three O 0 0.004340038
infants O 0 0.0040808287
, O 0 0.0025038419
born O 0 0.0019834945
of O 0 0.0010969593
two O 0 0.00063960545
mothers O 0 0.0010994977
with O 0 0.0007675257
inflammatory B-Disease 0 0.93015075
bowel I-Disease 0 0.9429035
disease I-Disease 0 0.9976151
who O 0 0.0016120987
received O 0 0.00019692387
treatment O 0 0.00033935334
with O 0 0.0011306722
sulphasalazine B-Chemical 1 0.99999547
throughout O 0 0.0003013768
pregnancy O 0 0.19026
, O 0 0.00051406474
were O 0 0.00032764085
found O 0 0.00034366574
to O 0 0.00046737574
have O 0 0.00074909796
major O 0 0.0018830146
congenital B-Disease 0 0.88861805
anomalies I-Disease 0 0.97616583
. O 0 0.007883107

In O 0 0.0038675573
the O 0 0.0026187953
singleton O 0 0.0070829755
pregnancy O 0 0.23820168
, O 0 0.0019208768
the O 0 0.00093379896
mother O 0 0.0071491324
had O 0 0.006844069
ulcerative B-Disease 0 0.9999999
colitis I-Disease 0 0.9999999
, O 0 0.02390223
and O 0 0.0005966358
the O 0 0.0003191805
infant O 0 0.0038431624
, O 0 0.00058296614
a O 0 0.00042693288
male O 0 0.0021332533
, O 0 0.0004422343
had O 0 0.00031945563
coarctation B-Disease 0 0.31212145
of I-Disease 0 0.00045435014
the I-Disease 0 0.00046691304
aorta I-Disease 0 0.011164567
and O 0 0.0008030292
a O 0 0.0013633993
ventricular B-Disease 0 0.81495285
septal I-Disease 0 0.061835557
defect I-Disease 0 0.0055470676
. O 0 0.006753768

In O 0 0.0053337654
the O 0 0.0040734964
twin O 0 0.040621474
pregnancy O 0 0.26505077
, O 0 0.0036847321
the O 0 0.00238089
mother O 0 0.0048933774
had O 0 0.0033810104
Crohn B-Disease 0 0.9877457
' I-Disease 0 0.006289193
s I-Disease 0 0.006829094
disease I-Disease 0 0.80538356
. O 0 0.01170911

The O 0 0.0033986645
first O 0 0.0024163474
twin O 0 0.017394619
, O 0 0.002493635
a O 0 0.0017048222
female O 0 0.003295854
, O 0 0.0011302382
had O 0 0.0006062709
a O 0 0.0006676974
left O 0 0.0012923218
Potter B-Disease 0 0.044822417
- I-Disease 0 0.008108792
type I-Disease 0 0.0010488809
IIa I-Disease 0 0.8837068
polycystic I-Disease 0 0.9916146
kidney I-Disease 0 0.7947427
and O 0 0.0013253153
a O 0 0.0014351896
rudimentary B-Disease 0 0.0043068044
left I-Disease 0 0.004925013
uterine I-Disease 0 0.33775792
cornu I-Disease 0 0.63062173
. O 0 0.007907785

The O 0 0.0033481533
second O 0 0.0026399624
twin O 0 0.024674477
, O 0 0.002481581
a O 0 0.0016518232
male O 0 0.0038155126
, O 0 0.0010199501
had O 0 0.0004863402
some O 0 0.00037882457
features O 0 0.00045986252
of O 0 0.00048265344
Potter B-Disease 0 0.022645509
' I-Disease 0 0.0005994345
s I-Disease 0 0.0005802427
facies I-Disease 0 0.55739254
, O 0 0.0012424178
hypoplastic B-Disease 0 0.94648314
lungs I-Disease 0 0.100438304
, O 0 0.0005798717
absent B-Disease 0 0.00038352006
kidneys I-Disease 0 0.0026340818
and I-Disease 0 0.00075485616
ureters I-Disease 0 0.047107145
, O 0 0.0019340531
and O 0 0.0035722482
talipes B-Disease 0 0.99968207
equinovarus I-Disease 0 0.9999057
. O 0 0.011266072

Despite O 0 0.0040841987
reports O 0 0.00282239
to O 0 0.0019338193
the O 0 0.001632475
contrary O 0 0.0018860778
, O 0 0.001856762
it O 0 0.0012637448
is O 0 0.0010559603
suggested O 0 0.0010447183
that O 0 0.0016837959
sulphasalazine B-Chemical 1 0.9999887
may O 0 0.0032676184
be O 0 0.0058080107
teratogenic O 0 0.999587
. O 0 0.010808614

Thrombotic B-Disease 0 0.9999553
microangiopathy I-Disease 0 0.99999833
and O 0 0.020304315
renal B-Disease 0 0.97529477
failure I-Disease 0 0.69870675
associated O 0 0.005129362
with O 0 0.005937516
antineoplastic O 0 0.8997931
chemotherapy O 0 0.4653734
. O 0 0.011231537

Five O 0 0.0046645296
patients O 0 0.0032434005
with O 0 0.0034186481
carcinoma B-Disease 2 0.99990904
developed O 0 0.4811871
thrombotic B-Disease 2 0.99999976
microangiopathy I-Disease 2 1.0
( O 0 0.013153071
characterized O 0 0.000948643
by O 0 0.00070046645
renal B-Disease 0 0.98482126
insufficiency I-Disease 0 0.999826
, O 0 0.10385067
microangiopathic B-Disease 0 0.9999969
hemolytic I-Disease 2 1.0
anemia I-Disease 2 1.0
, O 0 0.026990227
and O 0 0.0011866947
usually O 0 0.0065215323
thrombocytopenia B-Disease 0 0.9999813
) O 0 0.001075339
after O 0 0.00014249922
treatment O 0 0.0003283347
with O 0 0.0009940966
cisplatin B-Chemical 1 0.999874
, O 0 0.010782482
bleomycin B-Chemical 0 0.9993399
, O 0 0.0021568842
and O 0 0.0016667981
a O 0 0.004068372
vinca B-Chemical 0 0.9992155
alkaloid I-Chemical 0 0.99901974
. O 0 0.0077798115

One O 0 0.0052831704
patient O 0 0.0034755804
had O 0 0.0038967025
thrombotic B-Disease 2 0.9999856
thrombocytopenic I-Disease 0 0.9999987
purpura I-Disease 0 0.9999993
, O 0 0.004634326
three O 0 0.0003621795
the O 0 0.000960314
hemolytic B-Disease 0 0.9999975
- I-Disease 0 0.80802053
uremic I-Disease 0 0.9999821
syndrome I-Disease 0 0.90024006
, O 0 0.0007125017
and O 0 0.00034041307
one O 0 0.00024864107
an O 0 0.00031329726
apparent O 0 0.00043691378
forme O 0 0.3885709
fruste O 0 0.92392683
of O 0 0.0010075456
one O 0 0.0009145417
of O 0 0.0016055506
these O 0 0.0030133373
disorders O 0 0.78170735
. O 0 0.0071714814

Histologic O 0 0.011916043
examination O 0 0.0026166728
of O 0 0.00195137
the O 0 0.00146257
renal O 0 0.6815945
tissue O 0 0.005893739
showed O 0 0.0005506993
evidence O 0 0.00042265328
of O 0 0.0012791953
intravascular B-Disease 0 0.99856734
coagulation I-Disease 0 0.9982431
, O 0 0.0006542999
primarily O 0 0.0003658602
affecting O 0 0.0004044316
the O 0 0.0003718665
small O 0 0.00062915444
arteries O 0 0.34840637
, O 0 0.0015836866
arterioles O 0 0.24340053
, O 0 0.0021143681
and O 0 0.002899323
glomeruli O 0 0.05793633
. O 0 0.0073716147

Because O 0 0.0028993324
each O 0 0.001611985
patient O 0 0.0016386042
was O 0 0.0014625215
tumor B-Disease 0 0.8602917
- O 0 0.017742956
free O 0 0.00076360797
or O 0 0.00044178043
had O 0 0.00033740592
only O 0 0.00031760414
a O 0 0.0003223704
small O 0 0.0003291389
tumor B-Disease 0 0.63791716
at O 0 0.00020249576
the O 0 0.00019311778
onset O 0 0.00039067338
of O 0 0.00029489305
this O 0 0.00034595365
syndrome O 0 0.49855545
, O 0 0.0012635309
the O 0 0.0029791938
thrombotic B-Disease 2 0.9999994
microangiopathy I-Disease 2 0.9999999
may O 0 0.00070029387
have O 0 0.0005764123
been O 0 0.00086254196
induced O 0 0.0013624673
by O 0 0.0027641
chemotherapy O 0 0.11858406
. O 0 0.006756522

Diagnosis O 0 0.010595783
of O 0 0.0028996358
this O 0 0.0019165814
potentially O 0 0.0040476704
fatal O 0 0.9898657
complication O 0 0.7061248
may O 0 0.0006159284
be O 0 0.00043543734
delayed O 0 0.00079909567
or O 0 0.0002997332
missed O 0 0.00042086333
if O 0 0.00022787659
renal O 0 0.7184425
tissue O 0 0.007426879
or O 0 0.00022706414
the O 0 0.00021720928
peripheral O 0 0.005210848
blood O 0 0.011395288
smear O 0 0.004839465
is O 0 0.00017007596
not O 0 0.00013636466
examined O 0 0.00013106804
, O 0 0.0003181681
because O 0 0.00020168071
renal B-Disease 0 0.840898
failure I-Disease 0 0.31968328
may O 0 0.00019658073
be O 0 0.00016678807
ascribed O 0 0.00018055196
to O 0 0.00029591253
cisplatin B-Chemical 1 0.99997425
nephrotoxicity B-Disease 0 0.99999976
and O 0 0.0026179934
the O 0 0.0013280191
anemia B-Disease 0 0.9999932
and O 0 0.012309323
thrombocytopenia B-Disease 0 0.999984
to O 0 0.0005578048
drug O 0 0.59294134
- O 0 0.014898928
induced O 0 0.0012320399
bone B-Disease 0 0.34613276
marrow I-Disease 0 0.8630035
suppression I-Disease 0 0.3420664
. O 0 0.008110949

International O 0 0.020337272
mexiletine B-Chemical 0 0.9999169
and O 0 0.008061622
placebo O 0 0.28847718
antiarrhythmic O 0 0.9678463
coronary O 0 0.28360695
trial O 0 0.006335282
: O 0 0.009019159
I O 0 0.019424252
. O 0 0.0122738825

Report O 0 0.020868639
on O 0 0.011751875
arrhythmia B-Disease 2 0.9954417
and O 0 0.013839099
other O 0 0.01462148
findings O 0 0.020596873
. O 0 0.023467168

Impact O 0 0.05846044
Research O 0 0.082705416
Group O 0 0.08072965
. O 0 0.06297297

The O 0 0.0035454133
antiarrhythmic O 0 0.6042605
effects O 0 0.0019427006
of O 0 0.0011860648
the O 0 0.00076025975
sustained O 0 0.0016219072
release O 0 0.0029086082
form O 0 0.00049153937
of O 0 0.003831357
mexiletine B-Chemical 0 0.9999989
( O 0 0.034532283
Mexitil B-Chemical 0 0.9884636
- I-Chemical 0 0.12248268
Perlongets I-Chemical 0 0.40495896
) O 0 0.00047654813
were O 0 0.0001683807
evaluated O 0 0.00013324457
in O 0 0.00016784693
a O 0 0.00024338992
double O 0 0.00033260172
- O 0 0.010317761
blind O 0 0.023784911
placebo O 0 0.0062965727
trial O 0 0.0003217953
in O 0 0.00030502828
630 O 0 0.010863697
patients O 0 0.0005695744
with O 0 0.0006324635
recent O 0 0.0012477017
documented O 0 0.01480167
myocardial B-Disease 0 0.99993324
infarction I-Disease 2 0.9999975
. O 0 0.019529816

The O 0 0.0030186193
primary O 0 0.002284973
response O 0 0.0018233869
variable O 0 0.0012507335
was O 0 0.0007885397
based O 0 0.00055014476
on O 0 0.00030663193
central O 0 0.00053562375
reading O 0 0.0012789011
of O 0 0.00032817258
24 O 0 0.00022800395
hour O 0 0.00016292659
ambulatory O 0 0.00023367727
electrocardiographic O 0 0.023532242
recordings O 0 0.00018539395
and O 0 0.00015485489
was O 0 0.00013474663
defined O 0 0.00011681982
as O 0 0.00012467001
the O 0 0.00013865028
occurrence O 0 0.00029668314
of O 0 0.00019465512
30 O 0 0.0001323536
or O 0 0.00013355532
more O 0 0.00017335196
single O 0 0.0001806968
premature O 0 0.0071048024
ventricular O 0 0.5201008
complexes O 0 0.00032063678
in O 0 0.00014433361
any O 0 0.0001071017
two O 0 8.4460684e-05
consecutive O 0 8.655451e-05
30 O 0 8.441036e-05
minute O 0 8.70144e-05
blocks O 0 9.974314e-05
or O 0 0.00012348098
one O 0 0.00012641995
or O 0 0.00013684388
more O 0 0.00016021213
runs O 0 0.00018370083
of O 0 0.0001883607
two O 0 0.00014200293
or O 0 0.00018253777
more O 0 0.00028263865
premature O 0 0.006714302
ventricular O 0 0.46223992
complexes O 0 0.00043068887
in O 0 0.0002917111
the O 0 0.00033554583
entire O 0 0.00043197046
24 O 0 0.0006758029
hour O 0 0.0009781301
electrocardiographic O 0 0.10862536
recording O 0 0.0034208926
. O 0 0.005375749

Large O 0 0.0056601116
differences O 0 0.002211092
, O 0 0.0021695017
regarded O 0 0.0015021675
as O 0 0.00090818503
statistically O 0 0.0006763725
significant O 0 0.000582405
, O 0 0.000595717
between O 0 0.0002952151
the O 0 0.0006548432
mexiletine B-Chemical 0 0.99999416
and O 0 0.00094891095
placebo O 0 0.020934206
groups O 0 0.00020470179
were O 0 0.00014933404
noted O 0 0.000121049845
in O 0 0.00013263052
that O 0 0.00011229886
end O 0 0.000101258556
point O 0 0.00011247697
at O 0 0.00012120335
months O 0 0.000120769815
1 O 0 0.0001552458
and O 0 0.00019772632
4 O 0 0.00020540449
, O 0 0.00031607784
but O 0 0.0003344902
only O 0 0.00036003563
trends O 0 0.0005365003
were O 0 0.00055257604
observed O 0 0.0006676128
at O 0 0.0010319066
month O 0 0.0016199927
12 O 0 0.0027597984
. O 0 0.0055265725

These O 0 0.0033082832
differences O 0 0.0018432161
were O 0 0.0014386558
observed O 0 0.00096480263
even O 0 0.00096458074
though O 0 0.00076020975
the O 0 0.000672373
serum O 0 0.80195415
mexiletine B-Chemical 0 0.9999964
levels O 0 0.0004082978
obtained O 0 0.00022908192
in O 0 0.00021235092
this O 0 0.00019096259
study O 0 0.00023630494
were O 0 0.000169514
generally O 0 0.00019975654
lower O 0 0.0001589513
than O 0 0.00012046732
those O 0 0.00018473892
observed O 0 0.00015058018
in O 0 0.00017957024
studies O 0 0.00019914458
that O 0 0.00018922276
have O 0 0.0002385997
used O 0 0.0003074724
the O 0 0.00041936117
regular O 0 0.0006668281
form O 0 0.0008378201
of O 0 0.001632904
the O 0 0.002585857
drug O 0 0.36634043
. O 0 0.0071255364

There O 0 0.004249213
were O 0 0.0026943677
more O 0 0.002208561
deaths B-Disease 0 0.32408878
in O 0 0.001246553
the O 0 0.0014558544
mexiletine B-Chemical 0 0.9999927
group O 0 0.0017334733
( O 0 0.0007170506
7 O 0 0.00026534745
. O 0 0.00022793398
6 O 0 0.00018858533
% O 0 0.0002674068
) O 0 0.0003418688
than O 0 0.0001537951
in O 0 0.00018306993
the O 0 0.00022003392
placebo O 0 0.006711879
group O 0 0.00031186448
( O 0 0.00035227014
4 O 0 0.00018929441
. O 0 0.00020123218
8 O 0 0.000233169
% O 0 0.00036183107
) O 0 0.0005941503
; O 0 0.0005926374
the O 0 0.00046139536
difference O 0 0.0005024287
was O 0 0.0008949716
not O 0 0.001240449
statistically O 0 0.002054646
significant O 0 0.0037869413
. O 0 0.0072853933

The O 0 0.0050365813
incidence O 0 0.0062540364
of O 0 0.0043808394
coronary O 0 0.1365574
events O 0 0.008587117
was O 0 0.0026081097
similar O 0 0.0021949867
in O 0 0.0030098725
both O 0 0.0041441275
groups O 0 0.0064907754
. O 0 0.010287684

Previously O 0 0.004993691
recognized O 0 0.0032744945
side O 0 0.025298743
effects O 0 0.002767085
, O 0 0.002397869
particularly O 0 0.019185226
tremor B-Disease 0 0.99999166
and O 0 0.004975297
gastrointestinal B-Disease 0 0.99787736
problems I-Disease 0 0.40186238
, O 0 0.0006454878
were O 0 0.0002945519
more O 0 0.0003054858
frequent O 0 0.00054898864
in O 0 0.00027269303
the O 0 0.0004977142
mexiletine B-Chemical 0 0.9999778
group O 0 0.00068680313
than O 0 0.0004426543
in O 0 0.0007550882
the O 0 0.001307847
placebo O 0 0.0126602445
group O 0 0.00390489
. O 0 0.006034875

Changes O 0 0.004763661
in O 0 0.0031982588
heart O 0 0.01788198
size O 0 0.0019177893
during O 0 0.001105642
long O 0 0.0014228914
- O 0 0.007651541
term O 0 0.0022704494
timolol B-Chemical 0 0.99999654
treatment O 0 0.00665673
after O 0 0.0029557843
myocardial B-Disease 0 0.99993086
infarction I-Disease 2 0.999997
. O 0 0.019584015

The O 0 0.0029459929
effect O 0 0.002051009
of O 0 0.0017459948
long O 0 0.0017509618
- O 0 0.023700558
term O 0 0.0017548917
timolol B-Chemical 0 0.99999833
treatment O 0 0.0013223535
on O 0 0.0002729305
heart O 0 0.047907602
size O 0 0.00043540137
after O 0 0.00027738913
myocardial B-Disease 0 0.9999479
infarction I-Disease 2 0.99999964
was O 0 0.0004480992
evaluated O 0 0.0002027964
by O 0 0.0004836651
X O 0 0.9854827
- O 0 0.08055877
ray O 0 0.26612362
in O 0 0.00025012213
a O 0 0.00030388523
double O 0 0.00035621188
- O 0 0.006788042
blind O 0 0.0062850164
study O 0 0.0003010546
including O 0 0.0002527695
241 O 0 0.0012655695
patients O 0 0.0005347566
( O 0 0.00082268374
placebo O 0 0.019010419
126 O 0 0.004000652
, O 0 0.0033587976
timolol B-Chemical 0 0.9999907
115 O 0 0.015094673
) O 0 0.0060559805
. O 0 0.0071551627

The O 0 0.006719214
follow O 0 0.0055527226
- O 0 0.008763902
up O 0 0.0049211844
period O 0 0.004703693
was O 0 0.0058584665
12 O 0 0.006106145
months O 0 0.0077705667
. O 0 0.014208179

The O 0 0.005971747
timolol B-Chemical 0 0.9999939
- O 0 0.09475297
treated O 0 0.0016896654
patients O 0 0.0011933282
showed O 0 0.0005629698
a O 0 0.0005554807
small O 0 0.00043887124
but O 0 0.00044495708
significant O 0 0.00030503699
increase O 0 0.00024607586
in O 0 0.00033021535
heart O 0 0.033645872
size O 0 0.0002994884
from O 0 0.00018730084
baseline O 0 0.00021309937
in O 0 0.00021503755
contrast O 0 0.00030574913
to O 0 0.0003151943
a O 0 0.0005236579
decrease O 0 0.0005860821
in O 0 0.0008578627
the O 0 0.0014275665
placebo O 0 0.018471083
group O 0 0.00403994
. O 0 0.0061321263

These O 0 0.0038381873
differences O 0 0.0021943373
may O 0 0.0016363435
be O 0 0.0013568294
caused O 0 0.0012802295
by O 0 0.004712047
timolol B-Chemical 0 0.99999964
- O 0 0.31446278
induced O 0 0.0023491168
bradycardia B-Disease 0 0.99961275
and O 0 0.00073538255
a O 0 0.00058292336
compensatory O 0 0.00065086555
increase O 0 0.00052438094
in O 0 0.0007675765
end O 0 0.00097154605
- O 0 0.009766216
diastolic O 0 0.79823875
volume O 0 0.0064828894
. O 0 0.0071683447

The O 0 0.006195468
timolol B-Chemical 0 0.99999356
- O 0 0.06018434
related O 0 0.0010133001
increase O 0 0.000804358
in O 0 0.00081364956
heart O 0 0.05244989
size O 0 0.00069031474
was O 0 0.00042854002
observed O 0 0.00032786303
only O 0 0.00039280983
in O 0 0.00037845565
patients O 0 0.00055975065
with O 0 0.0005528887
normal O 0 0.0010511662
and O 0 0.001390125
borderline O 0 0.24826898
heart O 0 0.11916298
size O 0 0.005089486
. O 0 0.00700167

In O 0 0.0042934925
patients O 0 0.003524696
with O 0 0.003271101
cardiomegaly B-Disease 0 0.99950945
, O 0 0.0024172785
the O 0 0.0009481709
increase O 0 0.0007518449
in O 0 0.0009046054
heart O 0 0.043738395
size O 0 0.0010813479
was O 0 0.00095236406
similar O 0 0.00095240906
in O 0 0.0015276173
both O 0 0.002410442
groups O 0 0.0042476067
. O 0 0.0073417355

After O 0 0.0037828686
re O 0 0.0552057
- O 0 0.49090365
infarction B-Disease 2 0.9999957
, O 0 0.011976493
heart O 0 0.2456309
size O 0 0.0011261024
increased O 0 0.00072091015
in O 0 0.000497835
the O 0 0.00048496533
placebo O 0 0.009205359
group O 0 0.0004814376
and O 0 0.00046549184
remained O 0 0.00068266003
unchanged O 0 0.0007733849
in O 0 0.0011094513
the O 0 0.002636913
timolol B-Chemical 0 0.99999034
group O 0 0.007451835
. O 0 0.0070039206

Vitamin B-Chemical 0 0.99999535
D3 I-Chemical 0 0.9999814
toxicity B-Disease 2 0.9995584
in O 0 0.024310421
dairy O 0 0.44776604
cows O 0 0.06055185
. O 0 0.02570103

Large O 0 0.0068761893
parenteral O 0 0.05396759
doses O 0 0.025636347
of O 0 0.042975426
vitamin B-Chemical 0 0.99999976
D3 I-Chemical 0 0.9999993
( O 0 0.0044520306
15 O 0 0.00036327427
to O 0 0.00025836952
17 O 0 0.0003054252
. O 0 0.00019633834
5 O 0 0.0001667895
x O 0 0.00036338842
10 O 0 0.000209521
( O 0 0.00028470327
6 O 0 0.00018186875
) O 0 0.0009554624
IU O 0 0.9841319
vitamin B-Chemical 0 0.9999999
D3 I-Chemical 0 0.99999976
) O 0 0.01013352
were O 0 0.00022378047
associated O 0 0.00020306573
with O 0 0.0002654972
prolonged O 0 0.008490604
hypercalcemia B-Disease 2 0.9999988
, O 0 0.11349479
hyperphosphatemia B-Disease 0 0.99999976
, O 0 0.0025106068
and O 0 0.0002741398
large O 0 0.00021135267
increases O 0 0.0002267299
of O 0 0.010656898
vitamin B-Chemical 0 1.0
D3 I-Chemical 0 0.99999964
and O 0 0.0030842845
its O 0 0.0062315012
metabolites O 0 0.83167845
in O 0 0.0002565127
the O 0 0.00029041438
blood O 0 0.0051239827
plasma O 0 0.0034349568
of O 0 0.0007614376
nonlactating O 0 0.030454738
nonpregnant O 0 0.018063039
and O 0 0.0016533565
pregnant O 0 0.028163798
Jersey O 0 0.0135653
cows O 0 0.008538913
. O 0 0.0071125296

Calcium B-Chemical 0 0.9974154
concentrations O 0 0.00623934
1 O 0 0.0018246642
day O 0 0.0010919237
postpartum O 0 0.001594744
were O 0 0.0006343183
higher O 0 0.00047436185
in O 0 0.00040491973
cows O 0 0.0010558803
treated O 0 0.000501652
with O 0 0.0049993284
vitamin B-Chemical 0 0.9999999
D3 I-Chemical 0 0.9999988
about O 0 0.0002987472
32 O 0 0.00027546083
days O 0 0.00013650426
prepartum O 0 0.0016432834
( O 0 0.00031499003
8 O 0 0.00016353391
. O 0 0.00014708901
8 O 0 0.00015846161
mg O 0 0.0027768116
/ O 0 0.0008313439
100 O 0 0.00034883546
ml O 0 0.00042788117
) O 0 0.00035933012
than O 0 0.00014499271
in O 0 0.00018737405
control O 0 0.00025295443
cows O 0 0.0009823486
( O 0 0.0004310063
5 O 0 0.00026730026
. O 0 0.00032689763
5 O 0 0.00043093687
mg O 0 0.00374769
/ O 0 0.0021023143
100 O 0 0.002110214
ml O 0 0.0034528112
) O 0 0.005661374
. O 0 0.007299954

None O 0 0.0064130602
of O 0 0.0029902733
the O 0 0.0019322792
cows O 0 0.0035934434
treated O 0 0.0015449316
with O 0 0.0125682615
vitamin B-Chemical 0 0.99999976
D3 I-Chemical 0 0.9999993
showed O 0 0.0016529313
signs O 0 0.20540488
of O 0 0.0037689856
milk B-Disease 2 0.9950749
fever I-Disease 2 0.9999975
during O 0 0.0002488773
the O 0 0.00027019487
peripartal O 0 0.010727204
period O 0 0.00016908652
; O 0 0.0004203115
however O 0 0.00030525462
, O 0 0.0003255438
22 O 0 0.00025277722
% O 0 0.00022501628
of O 0 0.00022094883
the O 0 0.0002156264
control O 0 0.00027517547
cows O 0 0.0009099265
developed O 0 0.0004985939
clinical O 0 0.0017900161
signs O 0 0.035034254
of O 0 0.001964541
milk B-Disease 2 0.9856962
fever I-Disease 2 0.99998796
during O 0 0.0014289606
this O 0 0.002139857
period O 0 0.0031298406
. O 0 0.006215033

Signs O 0 0.75387335
of O 0 0.056408543
vitamin B-Chemical 0 0.9999994
D3 I-Chemical 0 0.9999994
toxicity B-Disease 2 0.9999093
were O 0 0.0011756512
not O 0 0.0005066543
observed O 0 0.0004152447
in O 0 0.00050968624
nonlactating O 0 0.041332956
nonpregnant O 0 0.042028796
cows O 0 0.0021071155
; O 0 0.0006203215
however O 0 0.00046400508
, O 0 0.00057872356
pregnant O 0 0.015640933
cows O 0 0.0013519793
commonly O 0 0.0004002763
developed O 0 0.00042176942
severe O 0 0.03562247
signs O 0 0.1373574
of O 0 0.028575337
vitamin B-Chemical 0 1.0
D3 I-Chemical 0 0.99999976
toxicity B-Disease 2 0.9998497
and O 0 0.0012332358
10 O 0 0.0008178042
of O 0 0.001281411
17 O 0 0.0021926903
cows O 0 0.0050110975
died O 0 0.007567007
. O 0 0.0071075973

There O 0 0.006918339
was O 0 0.0053818584
widespread O 0 0.007868609
metastatic O 0 0.8696901
calcification O 2 0.9991357
in O 0 0.0041292184
the O 0 0.0040173465
cows O 0 0.007816141
that O 0 0.0051570926
died O 0 0.015018507
. O 0 0.012392489

Because O 0 0.0030478335
of O 0 0.0024809511
the O 0 0.0017562989
extreme O 0 0.010630341
toxicity B-Disease 2 0.9994217
of O 0 0.17928377
vitamin B-Chemical 0 0.9999999
D3 I-Chemical 0 0.99999964
in O 0 0.0021266383
pregnant O 0 0.10929642
Jersey O 0 0.008857396
cows O 0 0.00070060935
and O 0 0.00020735413
the O 0 0.00016381734
low O 0 0.00023886468
margin O 0 0.0022062925
of O 0 0.0002089813
safety O 0 0.00023775175
between O 0 0.00011431189
doses O 0 0.0026255306
of O 0 0.013832716
vitamin B-Chemical 0 1.0
D3 I-Chemical 0 0.99999964
that O 0 0.000420822
prevent O 0 0.00087810593
milk B-Disease 2 0.9974554
fever I-Disease 2 0.99999905
and O 0 0.0017035583
doses O 0 0.005060572
that O 0 0.00017155241
induce O 0 0.0002638932
milk B-Disease 2 0.99710125
fever I-Disease 2 0.99999917
, O 0 0.0018633077
we O 0 0.00013240385
concluded O 0 0.00024455533
that O 0 0.00060951785
vitamin B-Chemical 0 0.9999999
D3 I-Chemical 0 0.9999994
cannot O 0 0.011801452
be O 0 0.00024999434
used O 0 0.00020610231
practically O 0 0.0003832854
to O 0 0.0002646998
prevent O 0 0.0005111585
milk B-Disease 2 0.97986126
fever I-Disease 2 0.99999225
when O 0 0.0006178776
injected O 0 0.0008292952
several O 0 0.0011085648
weeks O 0 0.0016677283
prepartum O 0 0.007306647
. O 0 0.0065134987

Diseases B-Disease 0 0.010584007
of I-Disease 0 0.005817251
peripheral I-Disease 0 0.00783431
nerves I-Disease 0 0.009643223
as O 0 0.0031755765
seen O 0 0.003179434
in O 0 0.003720961
the O 0 0.005060291
Nigerian O 0 0.08881508
African O 0 0.1188209
. O 0 0.012719389

The O 0 0.0028769304
anatomical O 0 0.0025581392
and O 0 0.0017714166
aetiological O 0 0.020808337
diagnoses O 0 0.0036487489
of O 0 0.0011006934
peripheral B-Disease 0 0.13313603
nerve I-Disease 0 0.43724802
disease I-Disease 0 0.970666
excluding O 0 0.0011857362
its O 0 0.0007367609
primary O 0 0.0005341891
benign O 0 0.26745728
and O 0 0.00090303976
malignant O 0 0.96687615
disorders O 0 0.9224477
, O 0 0.0006704131
as O 0 0.00043120232
seen O 0 0.00056908384
in O 0 0.0008648125
358 O 0 0.008246844
Nigerians O 0 0.03903797
are O 0 0.0022092117
presented O 0 0.0034698085
. O 0 0.006405903

There O 0 0.0051062214
is O 0 0.0033681472
a O 0 0.0028723925
male O 0 0.004150822
preponderance O 0 0.003567811
and O 0 0.0014055882
the O 0 0.0010617808
peak O 0 0.0013200708
incidence O 0 0.0029537836
is O 0 0.0013633071
in O 0 0.0014903756
the O 0 0.0020191483
fourth O 0 0.004135119
decade O 0 0.007965646
. O 0 0.008589963

Sensori B-Disease 0 0.09355672
- I-Disease 0 0.11193816
motor I-Disease 0 0.94396347
neuropathy I-Disease 0 0.99999
was O 0 0.0026032594
the O 0 0.001875423
commonest O 0 0.031791136
presentation O 0 0.0031710623
( O 0 0.0031580522
50 O 0 0.003299631
% O 0 0.004763541
) O 0 0.008042179
. O 0 0.010154261

Guillain B-Disease 0 0.9983493
- I-Disease 0 0.22411323
Barr I-Disease 0 0.9536309
syndrome I-Disease 0 0.6345191
was O 0 0.0013738371
the O 0 0.00089915725
commonest O 0 0.06911052
identifiable O 0 0.01398383
cause O 0 0.00079965335
( O 0 0.0007097779
15 O 0 0.00027117608
. O 0 0.00023935527
6 O 0 0.00021111341
% O 0 0.00032860934
) O 0 0.00050117593
, O 0 0.00039587397
accounting O 0 0.0005511256
for O 0 0.00032400986
half O 0 0.00029922437
of O 0 0.0005096475
the O 0 0.0006436099
cases O 0 0.0015993539
with O 0 0.0033759929
motor B-Disease 0 0.9766644
neuropathy I-Disease 0 0.9999895
. O 0 0.0092756525

Peripheral B-Disease 2 0.9838573
neuropathy I-Disease 2 0.9999738
due O 0 0.0016025001
to O 0 0.0013415995
nutritional B-Disease 0 0.8767935
deficiency I-Disease 0 0.99337703
of O 0 0.03241319
thiamine B-Chemical 0 0.99999785
and O 0 0.029526852
riboflavin B-Chemical 0 0.9999981
was O 0 0.00059501565
common O 0 0.00047872873
( O 0 0.00039770355
10 O 0 0.00020310603
. O 0 0.00018542116
1 O 0 0.00020169337
% O 0 0.00026514256
) O 0 0.00034928822
and O 0 0.00025889947
presented O 0 0.0002408421
mainly O 0 0.00033102668
as O 0 0.00038994517
sensory O 0 0.0012998965
and O 0 0.0010525314
sensori B-Disease 0 0.118068635
- I-Disease 0 0.15912764
motor I-Disease 0 0.97429717
neuropathy I-Disease 0 0.99998724
. O 0 0.009304513

Diabetes B-Disease 0 0.9995061
mellitus I-Disease 0 0.9996861
was O 0 0.0059794225
the O 0 0.0040958137
major O 0 0.0045820647
cause O 0 0.0060156332
of O 0 0.013249127
autonomic B-Disease 0 0.99914956
neuropathy I-Disease 0 0.9999887
. O 0 0.01704675

Isoniazid B-Chemical 0 0.99990666
was O 0 0.004779022
the O 0 0.0029309343
most O 0 0.0030906294
frequent O 0 0.004520749
agent O 0 0.028801633
in O 0 0.0027752894
drug O 0 0.7489023
- O 0 0.07764449
induced O 0 0.01421035
neuropathy B-Disease 0 0.99995327
. O 0 0.013194127

Migraine B-Disease 0 0.9998443
( O 0 0.005171669
20 O 0 0.002112063
% O 0 0.0018746279
) O 0 0.0017050672
was O 0 0.00082030095
not O 0 0.000570872
an O 0 0.0006619803
uncommon O 0 0.0027487352
cause O 0 0.00056854426
of O 0 0.001728663
cranial B-Disease 0 0.9993825
neuropathy I-Disease 0 0.99999976
although O 0 0.0018428942
malignancies B-Disease 2 0.99290764
arising O 0 0.00021459024
from O 0 0.00016562575
the O 0 0.0002083371
reticuloendothelial O 0 0.054751962
system O 0 0.00019359766
or O 0 0.00015055506
related O 0 0.00011651599
structures O 0 0.00021261066
of O 0 0.00022199239
the O 0 0.00023122452
head O 0 0.0130981915
and O 0 0.00044947802
neck O 0 0.034893844
were O 0 0.00043436873
more O 0 0.00058334076
frequent O 0 0.0013496913
( O 0 0.0013252054
26 O 0 0.0018388595
% O 0 0.0028493132
) O 0 0.005447329
. O 0 0.007359308

In O 0 0.004360318
26 O 0 0.0034672932
. O 0 0.002006264
5 O 0 0.0013813864
% O 0 0.00133227
of O 0 0.0010309604
all O 0 0.0007562469
the O 0 0.0006921511
cases O 0 0.0010058375
, O 0 0.000945788
the O 0 0.000748977
aetiology O 0 0.023066808
of O 0 0.0016729557
the O 0 0.0029147018
neuropathy B-Disease 0 0.99995756
was O 0 0.004027521
undetermined O 0 0.13735044
. O 0 0.007890088

Heredofamilial O 0 0.38015962
and O 0 0.01103868
connective B-Disease 0 0.34391284
tissue I-Disease 0 0.04889565
disorders I-Disease 0 0.93308246
were O 0 0.011801855
rare O 0 0.020726338
. O 0 0.01809659

Some O 0 0.004496945
of O 0 0.0027981396
the O 0 0.0017910082
factors O 0 0.0019419083
related O 0 0.00076505233
to O 0 0.0006493704
the O 0 0.0005974652
clinical O 0 0.0010476845
presentation O 0 0.0007339368
and O 0 0.00061819854
pathogenesis O 0 0.0015187741
of O 0 0.0010861359
the O 0 0.0015184184
neuropathies B-Disease 0 0.9997249
are O 0 0.001785824
briefly O 0 0.0027177082
discussed O 0 0.003448243
. O 0 0.006541049

Reduction O 0 0.022039859
in O 0 0.01615179
caffeine B-Chemical 0 0.9998921
toxicity B-Disease 2 0.99967575
by O 0 0.116623245
acetaminophen B-Chemical 0 0.9999883
. O 0 0.03009197

A O 0 0.043689366
patient O 0 0.0034763191
who O 0 0.00290163
allegedly O 0 0.008234089
consumed O 0 0.0049996576
100 O 0 0.001456237
tablets O 0 0.053408094
of O 0 0.0005205622
an O 0 0.0004381888
over O 0 0.0002498521
- O 0 0.0035751723
the O 0 0.00033510305
- O 0 0.009876824
counter O 0 0.00391451
analgesic O 0 0.52293664
containing O 0 0.00069869834
sodium B-Chemical 0 0.99999905
acetylsalicylate I-Chemical 0 1.0
, O 0 0.07662268
caffeine B-Chemical 0 0.9999883
, O 0 0.0027502612
and O 0 0.0035150922
acetaminophen B-Chemical 0 0.99999917
displayed O 0 0.00020983124
no O 0 0.0001359194
significant O 0 0.00026114125
CNS O 0 0.20268464
stimulation O 0 0.00021560871
despite O 0 0.0001687467
the O 0 0.0001678141
presence O 0 0.00019608877
of O 0 0.00034453903
175 O 0 0.0011675017
micrograms O 0 0.005188231
of O 0 0.0009717686
caffeine B-Chemical 0 0.999482
per O 0 0.00070500496
mL O 0 0.0025085958
of O 0 0.002661572
serum O 0 0.21597256
. O 0 0.0073625343

Because O 0 0.0048726494
salicylates O 0 0.9998204
have O 0 0.0018718035
been O 0 0.0012656912
reported O 0 0.0008779797
to O 0 0.00048699154
augment O 0 0.00036370152
the O 0 0.00036188643
stimulatory O 0 0.0011086061
effects O 0 0.0009097188
of O 0 0.0026929432
caffeine B-Chemical 0 0.99996233
on O 0 0.0001913229
the O 0 0.0003751096
CNS O 0 0.49933934
, O 0 0.0004885347
attention O 0 0.00043469618
was O 0 0.00015313397
focused O 0 0.00013794858
on O 0 9.511468e-05
the O 0 0.00012585284
possibility O 0 0.00011080689
that O 0 0.00011863222
the O 0 0.00015649365
presence O 0 0.00023229247
of O 0 0.0052300943
acetaminophen B-Chemical 0 0.99999976
( O 0 0.0023472325
52 O 0 0.00058133795
micrograms O 0 0.007811246
/ O 0 0.004005386
mL O 0 0.0022999048
) O 0 0.00075261627
reduced O 0 0.00055410236
the O 0 0.0009105561
CNS O 0 0.7513981
toxicity B-Disease 2 0.9986084
of O 0 0.025456002
caffeine B-Chemical 0 0.9999021
. O 0 0.009430868

Studies O 0 0.010977444
in O 0 0.0045259846
DBA O 0 0.9910357
/ O 0 0.12853645
2J O 0 0.76453865
mice O 0 0.0006155334
showed O 0 0.00054709404
that O 0 0.0004285694
: O 0 0.0009222048
1 O 0 0.00041392032
) O 0 0.0007280892
pretreatment O 0 0.040930115
with O 0 0.004710004
acetaminophen B-Chemical 0 0.99999976
( O 0 0.003078911
100 O 0 0.0009473865
mg O 0 0.03612206
/ O 0 0.0024166878
kg O 0 0.0013058484
) O 0 0.00043744448
increased O 0 0.00018044439
the O 0 0.00013303763
interval O 0 0.00011618493
between O 0 9.482434e-05
the O 0 0.0001435462
administration O 0 0.0017513967
of O 0 0.0010248768
caffeine B-Chemical 0 0.9999652
( O 0 0.0009858768
300 O 0 0.0003235688
to O 0 0.00012831333
450 O 0 0.001436906
mg O 0 0.01140697
/ O 0 0.0017048742
kg O 0 0.0018359945
IP O 0 0.038707867
) O 0 0.00042386615
and O 0 0.00019440436
the O 0 0.00016496664
onset O 0 0.0005081456
of O 0 0.0007902955
fatal O 0 0.9986992
convulsions B-Disease 0 0.9999988
by O 0 0.00043282163
a O 0 0.00034437844
factor O 0 0.0033437565
of O 0 0.00026334298
about O 0 0.00015038374
two O 0 0.00013494078
; O 0 0.00032843676
and O 0 0.00022000454
2 O 0 0.00018167499
) O 0 0.00041252034
pretreatment O 0 0.029991554
with O 0 0.003479581
acetaminophen B-Chemical 0 0.99999964
( O 0 0.0019092706
75 O 0 0.0003802909
mg O 0 0.016306939
/ O 0 0.0015884746
kg O 0 0.0010680249
) O 0 0.00041080738
reduced O 0 0.00017719921
the O 0 0.00018699798
incidence O 0 0.0041021905
of O 0 0.009530035
audiogenic O 0 0.99999917
seizures B-Disease 0 0.9999995
produced O 0 0.00024505807
in O 0 0.00017949306
the O 0 0.00015695406
presence O 0 0.00020349759
of O 0 0.0014496634
caffeine B-Chemical 0 0.9999691
( O 0 0.0010451771
12 O 0 0.00019747458
. O 0 0.00020747061
5 O 0 0.00022649659
to O 0 0.0002981858
75 O 0 0.00062066066
mg O 0 0.0065913643
/ O 0 0.0027374367
kg O 0 0.0046710577
IP O 0 0.050480355
) O 0 0.006419937
. O 0 0.007708293

The O 0 0.003061568
frequency O 0 0.0024518392
of O 0 0.0021362302
sound O 0 0.026548145
- O 0 0.044481557
induced O 0 0.0035268436
seizures B-Disease 0 0.999998
after O 0 0.00043761253
12 O 0 0.0003019526
. O 0 0.00024341731
5 O 0 0.00020037539
or O 0 0.00020804805
25 O 0 0.0003073273
mg O 0 0.010781408
/ O 0 0.0024534725
kg O 0 0.008445479
caffeine B-Chemical 0 0.99973077
was O 0 0.0003594574
reduced O 0 0.00031721345
from O 0 0.00033302084
50 O 0 0.00049670634
to O 0 0.0005145224
5 O 0 0.00078608084
% O 0 0.0017136598
by O 0 0.0034461706
acetaminophen B-Chemical 0 0.9999788
. O 0 0.0087118335

In O 0 0.003502911
the O 0 0.002103547
absence O 0 0.0014439056
of O 0 0.003919568
caffeine B-Chemical 0 0.9999876
, O 0 0.20671779
acetaminophen B-Chemical 0 0.99999964
( O 0 0.002211318
up O 0 0.00031316408
to O 0 0.00023834551
300 O 0 0.00048435017
mg O 0 0.0133082
/ O 0 0.0019218058
kg O 0 0.0015992862
) O 0 0.0006517286
did O 0 0.00023959912
not O 0 0.00016342963
modify O 0 0.00017118311
the O 0 0.00047744566
seizures B-Disease 0 0.99999785
induced O 0 0.0004755378
by O 0 0.0003800794
maximal O 0 0.0011027608
electroshock O 0 0.9999956
and O 0 0.0008796095
did O 0 0.00025851265
not O 0 0.0001440589
alter O 0 0.00014333459
the O 0 0.00029567958
convulsant O 0 0.9992685
dose O 0 0.0028863456
of O 0 0.00043329207
pentylenetetrezol B-Chemical 0 0.47428662
in O 0 0.00020288944
mice O 0 0.00014401262
( O 0 0.00032929078
tests O 0 0.00031685014
performed O 0 0.00023160779
by O 0 0.00036874236
the O 0 0.00067128194
Anticonvulsant O 0 0.999556
Screening O 0 0.0056989375
Project O 0 0.04400949
of O 0 0.0030835136
NINCDS O 0 0.87172085
) O 0 0.0068653086
. O 0 0.007349648

Acetaminophen B-Chemical 0 0.99999094
( O 0 0.0045649414
up O 0 0.0016056807
to O 0 0.0010582756
150 O 0 0.0011058821
micrograms O 0 0.008976397
/ O 0 0.0073649785
mL O 0 0.0046937075
) O 0 0.0010949319
did O 0 0.00044275244
not O 0 0.00031004185
retard O 0 0.0051867836
the O 0 0.00033115922
incorporation O 0 0.0011871272
of O 0 0.0005745414
radioactive O 0 0.056400042
adenosine B-Chemical 1 0.99868804
into O 0 0.0003717003
ATP B-Chemical 0 0.9928076
in O 0 0.00069568807
slices O 0 0.0024011116
of O 0 0.0014744757
rat O 0 0.014265456
cerebral O 0 0.98311687
cortex O 0 0.66052514
. O 0 0.0067586824

Thus O 0 0.003753985
the O 0 0.0022667407
mechanism O 0 0.0016934838
by O 0 0.0018646013
which O 0 0.008870483
acetaminophen B-Chemical 0 0.9999987
antagonizes O 0 0.0056529297
the O 0 0.00077876623
actions O 0 0.0023218784
of O 0 0.0021861203
caffeine B-Chemical 0 0.9999198
in O 0 0.0011407867
the O 0 0.0013891805
CNS O 0 0.21214753
remains O 0 0.002710286
unknown O 0 0.006663737
. O 0 0.0074125715

A O 0 0.056928035
double O 0 0.0045467853
- O 0 0.014157638
blind O 0 0.009918262
study O 0 0.0013268346
of O 0 0.0008717235
the O 0 0.000590704
efficacy O 0 0.00070047076
and O 0 0.00053809024
safety O 0 0.0011289213
of O 0 0.019240022
dothiepin B-Chemical 0 1.0
hydrochloride I-Chemical 0 0.9999386
in O 0 0.00052844366
the O 0 0.0004991607
treatment O 0 0.000765114
of O 0 0.0014165612
major O 0 0.008708864
depressive B-Disease 2 0.9999882
disorder I-Disease 0 0.992415
. O 0 0.007968622

In O 0 0.003937877
a O 0 0.0030482046
6 O 0 0.0018037036
- O 0 0.0026671696
week O 0 0.00084464805
double O 0 0.0010013116
- O 0 0.005085735
blind O 0 0.0063616475
parallel O 0 0.00050844316
treatment O 0 0.0005363991
study O 0 0.0010081073
, O 0 0.017189238
dothiepin B-Chemical 0 1.0
and O 0 0.014440719
amitriptyline B-Chemical 0 0.9999995
were O 0 0.00026198942
compared O 0 0.00016796363
to O 0 0.00022817506
placebo O 0 0.0018821043
in O 0 0.00030559563
the O 0 0.0004050607
treatment O 0 0.00068801513
of O 0 0.0012604971
33 O 0 0.0031453453
depressed B-Disease 2 0.8510355
outpatients O 0 0.017120507
. O 0 0.0062285136

Dothiepin B-Chemical 0 0.99983644
and O 0 0.037031677
amitriptyline B-Chemical 0 0.999998
were O 0 0.0016172634
equally O 0 0.0009120421
effective O 0 0.00065917755
in O 0 0.000493833
alleviating O 0 0.0033828474
the O 0 0.00048244672
symptoms O 0 0.29600677
of O 0 0.012543839
depressive B-Disease 2 0.9999999
illness I-Disease 0 0.99949443
, O 0 0.0012677853
and O 0 0.0005243444
both O 0 0.0004872439
were O 0 0.0006239414
significantly O 0 0.000844774
superior O 0 0.0016818582
to O 0 0.0019140188
placebo O 0 0.015607093
. O 0 0.0060828496

The O 0 0.0030113983
overall O 0 0.0022547322
incidence O 0 0.0032189465
of O 0 0.0016417688
side O 0 0.03175986
effects O 0 0.0010736969
and O 0 0.00058194745
the O 0 0.00035489464
frequency O 0 0.00038310164
and O 0 0.00036019337
severity O 0 0.002853808
of O 0 0.0011110441
blurred B-Disease 0 0.9967416
vision I-Disease 0 0.9966683
, O 0 0.008372096
dry B-Disease 2 0.95808643
mouth I-Disease 2 0.9311143
, O 0 0.00106144
and O 0 0.0011225664
drowsiness O 0 0.9999535
were O 0 0.00032073524
significantly O 0 0.00032446923
less O 0 0.00041558605
with O 0 0.0024956285
dothiepin B-Chemical 0 0.99999964
than O 0 0.0011576953
with O 0 0.0071941623
amitriptyline B-Chemical 0 0.99999475
. O 0 0.0071353535

Dothiepin B-Chemical 0 0.9985758
also O 0 0.006752453
produced O 0 0.0055987504
fewer O 0 0.0058905324
CNS O 0 0.22434452
and O 0 0.008249945
cardiovascular O 0 0.93697166
effects O 0 0.014750573
. O 0 0.014996959

There O 0 0.0069693243
were O 0 0.004861829
no O 0 0.0035765278
clinically O 0 0.0063264817
important O 0 0.003139851
changes O 0 0.0041381987
in O 0 0.0043683965
laboratory O 0 0.0070362557
parameters O 0 0.008644168
. O 0 0.011940063

Dothiepin B-Chemical 0 0.999537
thus O 0 0.0042838003
was O 0 0.0018860039
found O 0 0.0010604631
to O 0 0.0007293865
be O 0 0.0006734
an O 0 0.0007570307
effective O 0 0.0018491353
antidepressant B-Chemical 1 0.99996686
drug O 0 0.47595066
associated O 0 0.00044986917
with O 0 0.0003234451
fewer O 0 0.00026057297
side O 0 0.0070352834
effects O 0 0.0006168713
than O 0 0.00052564894
amitriptyline B-Chemical 0 0.9999988
in O 0 0.00046843948
the O 0 0.0005581909
treatment O 0 0.0010235625
of O 0 0.0023473597
depressed B-Disease 2 0.9585263
outpatients O 0 0.036499072
. O 0 0.006096565

Behavioral O 0 0.028898051
effects O 0 0.004886715
of O 0 0.010208293
diazepam B-Chemical 0 0.99999857
and O 0 0.056189366
propranolol B-Chemical 1 0.9999982
in O 0 0.0018537139
patients O 0 0.0028455358
with O 0 0.00585026
panic B-Disease 0 0.9999875
disorder I-Disease 0 0.99764663
and O 0 0.057248045
agoraphobia B-Disease 0 0.9999968
. O 0 0.011465193

The O 0 0.0030449384
effects O 0 0.0025683236
of O 0 0.0022028836
oral O 0 0.20952879
doses O 0 0.058150634
of O 0 0.030199362
diazepam B-Chemical 0 0.99999976
( O 0 0.0031822643
single O 0 0.0003734021
dose O 0 0.00091423467
of O 0 0.0003039788
10 O 0 0.00021401503
mg O 0 0.0038046336
and O 0 0.00017863848
a O 0 0.00016270972
median O 0 0.00010266133
dose O 0 0.00029009394
of O 0 0.00017921429
30 O 0 0.00014362013
mg O 0 0.0047189514
/ O 0 0.00056516094
day O 0 0.00011844333
for O 0 0.00012596186
2 O 0 0.0001299929
weeks O 0 0.0001004443
) O 0 0.00034768519
and O 0 0.00081666384
propranolol B-Chemical 1 0.9999987
( O 0 0.0009692398
single O 0 0.00019499286
dose O 0 0.00056655356
of O 0 0.0002114692
80 O 0 0.00024159993
mg O 0 0.0045820433
and O 0 0.00015424537
a O 0 0.00014287802
median O 0 9.249757e-05
dose O 0 0.0002810002
of O 0 0.00019365878
240 O 0 0.0005532172
mg O 0 0.010571511
/ O 0 0.0006807262
day O 0 0.00011973321
for O 0 0.00012688166
2 O 0 0.00012855044
weeks O 0 9.448342e-05
) O 0 0.00019019938
on O 0 0.000101345795
psychological O 0 0.0008337155
performance O 0 0.0002648525
of O 0 0.00022116803
patients O 0 0.00048087921
with O 0 0.0013757998
panic B-Disease 0 0.99999404
disorders I-Disease 0 0.9641952
and O 0 0.007846602
agoraphobia B-Disease 0 0.99999964
were O 0 0.00024074981
investigated O 0 0.00016848976
in O 0 0.00022947566
a O 0 0.0003530653
double O 0 0.00050053647
- O 0 0.0061712638
blind O 0 0.009354365
, O 0 0.0010021271
randomized O 0 0.0010907936
and O 0 0.001657807
crossover O 0 0.0046040113
design O 0 0.0051867203
. O 0 0.006862452

Both O 0 0.004476444
drugs O 0 0.03751877
impaired B-Disease 0 0.002593714
immediate I-Disease 0 0.0021894649
free I-Disease 0 0.0016863791
recall I-Disease 0 0.0049121445
but O 0 0.0010431608
the O 0 0.00070312695
decrease O 0 0.0007496557
was O 0 0.0008419223
greater O 0 0.0009743497
for O 0 0.002631759
diazepam B-Chemical 0 0.9999976
than O 0 0.005450722
propranolol B-Chemical 1 0.99998677
. O 0 0.010012757

Delayed B-Disease 0 0.014421734
free I-Disease 0 0.00464679
recall I-Disease 0 0.0058275023
was I-Disease 0 0.0021567435
also I-Disease 0 0.00162312
impaired I-Disease 0 0.0019160467
but O 0 0.0015987108
the O 0 0.0013121475
two O 0 0.0014283967
drugs O 0 0.057920117
did O 0 0.0026173647
not O 0 0.0031194051
differ O 0 0.005242951
. O 0 0.0085078515

Patients O 0 0.0053798356
tapped O 0 0.0048826407
faster O 0 0.0021992265
after O 0 0.0016933371
propranolol B-Chemical 1 0.99999535
than O 0 0.003006293
diazepam B-Chemical 0 0.99999774
and O 0 0.0010433488
they O 0 0.00055434013
were O 0 0.00062423164
more O 0 0.0008196575
sedated O 0 0.019281613
after O 0 0.001134
diazepam B-Chemical 0 0.99999404
than O 0 0.003971221
propranolol B-Chemical 1 0.9999821
. O 0 0.009406668

After O 0 0.0027194638
2 O 0 0.002147837
weeks O 0 0.0012021381
of O 0 0.0012101717
treatment O 0 0.0011315154
, O 0 0.0010131005
patients O 0 0.0007281725
tested O 0 0.00040281686
5 O 0 0.00037407168
- O 0 0.0015601818
8 O 0 0.00026541218
h O 0 0.00025503148
after O 0 0.00016253155
the O 0 0.00020225572
last O 0 0.0001756655
dose O 0 0.0005704698
of O 0 0.00047699534
medication O 0 0.022086866
did O 0 0.00040180245
not O 0 0.00038970824
show O 0 0.00050482166
any O 0 0.0008218579
decrement O 0 0.0025142794
of O 0 0.0026739428
performance O 0 0.005804172
. O 0 0.0067404867

These O 0 0.004796449
results O 0 0.0032098836
are O 0 0.0025209684
similar O 0 0.0018037956
to O 0 0.0017746825
those O 0 0.002064459
previously O 0 0.0019331917
found O 0 0.0021091257
in O 0 0.0030880356
healthy O 0 0.00963326
subjects O 0 0.007686211
. O 0 0.009454055

Accumulation O 0 0.010035803
of O 0 0.0054829447
drugs O 0 0.13967478
was O 0 0.0030575027
not O 0 0.0023099377
reflected O 0 0.0024129797
in O 0 0.0030062173
prolonged O 0 0.0074766236
behavioral B-Disease 0 0.870692
impairment I-Disease 0 0.9761888
. O 0 0.01167672

Comparison O 0 0.003361089
of O 0 0.002980606
i O 0 0.005987199
. O 0 0.0017371981
v O 0 0.07956338
. O 0 0.0027782852
glycopyrrolate B-Chemical 0 0.99999774
and O 0 0.02013538
atropine B-Chemical 0 0.999992
in O 0 0.0005339742
the O 0 0.00036513823
prevention O 0 0.00245793
of O 0 0.0016188741
bradycardia B-Disease 0 0.9997458
and O 0 0.002247042
arrhythmias B-Disease 2 0.9999193
following O 0 0.0003397198
repeated O 0 0.00035167742
doses O 0 0.0021311734
of O 0 0.0021343608
suxamethonium B-Chemical 0 0.9996978
in O 0 0.0025390862
children O 0 0.007856298
. O 0 0.0068426887

The O 0 0.0028202261
effectiveness O 0 0.0019027158
of O 0 0.0017846243
administration O 0 0.013031401
of O 0 0.0050526964
glycopyrrolate B-Chemical 0 0.99999714
5 O 0 0.0005100727
and O 0 0.0003786112
10 O 0 0.00027853987
micrograms O 0 0.0014148186
kg O 0 0.0012837163
- O 0 0.0035286003
1 O 0 0.0002420973
and O 0 0.00038158792
atropine B-Chemical 0 0.9999076
10 O 0 0.00019080135
and O 0 0.0001704778
20 O 0 0.00015725293
micrograms O 0 0.00087980065
kg O 0 0.0009854457
- O 0 0.0037549394
1 O 0 0.00020822826
i O 0 0.000804481
. O 0 0.00021248622
v O 0 0.0075076246
. O 0 0.00019672133
immediately O 0 0.00015111598
before O 0 0.00010381431
the O 0 0.00013463886
induction O 0 0.00016898144
of O 0 0.00035599596
anaesthesia O 0 0.030111864
, O 0 0.0003134891
to O 0 0.00017312121
prevent O 0 0.00032910565
arrhythmia B-Disease 2 0.99989974
and O 0 0.0019957763
bradycardia B-Disease 0 0.99731594
following O 0 0.0001683385
repeated O 0 0.00016755523
doses O 0 0.0010364348
of O 0 0.0010426414
suxamethonium B-Chemical 0 0.9997733
in O 0 0.0008039243
children O 0 0.0024681555
, O 0 0.0019949973
was O 0 0.0022725512
studied O 0 0.0039152084
. O 0 0.0064056264

A O 0 0.046823286
control O 0 0.003122479
group O 0 0.0022990773
was O 0 0.0013245302
included O 0 0.0008227367
for O 0 0.0006535178
comparison O 0 0.00052339415
with O 0 0.0005548886
the O 0 0.000524123
lower O 0 0.0005836555
dose O 0 0.0016505559
range O 0 0.0011133766
of O 0 0.006059041
glycopyrrolate B-Chemical 0 0.999997
and O 0 0.043663714
atropine B-Chemical 0 0.9999695
. O 0 0.009689328

A O 0 0.03801019
frequency O 0 0.0034790868
of O 0 0.00333195
bradycardia B-Disease 0 0.998195
of O 0 0.0017770089
50 O 0 0.0011180753
% O 0 0.0007166967
was O 0 0.0004229427
noted O 0 0.00028685847
in O 0 0.00028039914
the O 0 0.0002601403
control O 0 0.00030051204
group O 0 0.0004867938
, O 0 0.00047088927
but O 0 0.000330375
this O 0 0.00022663675
was O 0 0.0002194611
not O 0 0.00019450967
significantly O 0 0.00022648944
different O 0 0.00020763786
from O 0 0.0002557881
the O 0 0.00035814702
frequency O 0 0.0005837137
with O 0 0.0008449478
the O 0 0.0013114485
active O 0 0.004654611
drugs O 0 0.3092897
. O 0 0.0066608777

Bradycardia B-Disease 2 0.99877304
( O 0 0.004208123
defined O 0 0.0017016148
as O 0 0.001265892
a O 0 0.0011596655
decrease O 0 0.00078170496
in O 0 0.0006724409
heart O 0 0.03282825
rate O 0 0.000418478
to O 0 0.0002587257
less O 0 0.00023204964
than O 0 0.0001603344
50 O 0 0.00022209783
beat O 0 0.00062519376
min O 0 0.0004989246
- O 0 0.0037348575
1 O 0 0.00024103552
) O 0 0.00037110303
was O 0 0.00021640245
prevented O 0 0.00024726562
when O 0 0.00018001924
the O 0 0.00023510309
larger O 0 0.0002819948
dose O 0 0.0007805117
of O 0 0.00057243905
either O 0 0.00072140706
active O 0 0.0031166482
drug O 0 0.28752914
was O 0 0.0023309938
used O 0 0.0032927273
. O 0 0.0061500333

It O 0 0.004652406
is O 0 0.002507899
recommended O 0 0.001586793
that O 0 0.0010489692
either O 0 0.0016411087
glycopyrrolate B-Chemical 0 0.9999945
10 O 0 0.0007098679
micrograms O 0 0.00875131
kg O 0 0.0028600947
- O 0 0.00509128
1 O 0 0.0002930089
or O 0 0.00033843468
atropine B-Chemical 0 0.9999192
20 O 0 0.00026141654
micrograms O 0 0.0024150766
kg O 0 0.0014394122
- O 0 0.0042879903
1 O 0 0.00022465871
i O 0 0.0007946902
. O 0 0.00022352206
v O 0 0.0063809734
. O 0 0.00020619744
should O 0 0.00012663605
immediately O 0 0.00014991328
precede O 0 0.00024091032
induction O 0 0.00020236663
of O 0 0.00041007457
anaesthesia O 0 0.036743026
, O 0 0.0003795841
in O 0 0.00023899291
children O 0 0.000706097
, O 0 0.00039881788
if O 0 0.00022071911
the O 0 0.0002863813
repeated O 0 0.00034196302
administration O 0 0.0025733246
of O 0 0.0021086622
suxamethonium B-Chemical 0 0.99969316
is O 0 0.0027619677
anticipated O 0 0.0038895817
. O 0 0.0065695066

Veno B-Disease 0 0.49245185
- I-Disease 0 0.19391908
occlusive I-Disease 0 0.99890184
liver I-Disease 2 0.9986167
disease I-Disease 2 0.99879944
after O 0 0.001983454
dacarbazine B-Chemical 0 0.9996113
therapy O 0 0.03973059
( O 0 0.029501665
DTIC B-Chemical 0 0.99996936
) O 0 0.008789064
for O 0 0.0050897687
melanoma B-Disease 0 0.99857426
. O 0 0.011380057

A O 0 0.040373605
case O 0 0.003418993
of O 0 0.0030121831
veno B-Disease 0 0.14925501
- I-Disease 0 0.24896538
occlusive I-Disease 0 0.9989453
disease I-Disease 0 0.9033203
of I-Disease 0 0.00096314715
the I-Disease 0 0.00061655213
liver I-Disease 0 0.61705905
with O 0 0.0010706082
fatal O 0 0.9634238
outcome O 0 0.0037742674
after O 0 0.00031318382
dacarbazine B-Chemical 0 0.9996941
( O 0 0.030411124
DTIC B-Chemical 0 0.9999893
) O 0 0.0029900288
therapy O 0 0.0017662193
for O 0 0.0013257178
melanoma B-Disease 0 0.9986339
is O 0 0.0033756546
reported O 0 0.0054164417
. O 0 0.0068866694

There O 0 0.0061987685
was O 0 0.004544194
a O 0 0.00471744
fulminant O 0 0.99831223
clinical O 0 0.010219746
course O 0 0.0016323613
from O 0 0.0013074701
start O 0 0.001465306
of O 0 0.0024534306
symptoms O 0 0.212401
until O 0 0.0034776125
death B-Disease 0 0.9932695
. O 0 0.011134649

At O 0 0.003802189
autopsy O 0 0.009475236
the O 0 0.0027378139
liver O 0 0.25815374
was O 0 0.0019092879
enlarged O 0 0.0035071077
and O 0 0.0016393625
firm O 0 0.006068576
with O 0 0.002105496
signs O 0 0.10042523
of O 0 0.006305234
venous B-Disease 0 0.99636334
congestion I-Disease 0 0.9982558
. O 0 0.010692487

Small O 0 0.0143904565
- O 0 0.011284211
and O 0 0.003923802
medium O 0 0.0073337634
- O 0 0.0076543344
sized O 0 0.0029280304
hepatic O 0 0.7390836
veins O 0 0.21970533
were O 0 0.0027477578
blocked O 0 0.0042130826
by O 0 0.007029696
thrombosis B-Disease 2 0.999897
. O 0 0.013005271

Eosinophilic O 0 0.40362406
infiltrations O 0 0.21792479
were O 0 0.006776706
found O 0 0.005879067
around O 0 0.0073875077
the O 0 0.009869711
vessels O 0 0.049320504
. O 0 0.018327957

Published O 0 0.014091793
cases O 0 0.004647776
from O 0 0.0027588105
the O 0 0.002348205
literature O 0 0.0025997532
are O 0 0.0020267286
reviewed O 0 0.002676482
and O 0 0.0025912623
pertinent O 0 0.0029534115
features O 0 0.0047793486
discussed O 0 0.0057957773
. O 0 0.009948547

Maternal O 0 0.25684538
lithium B-Chemical 0 0.9996214
and O 0 0.0034776125
neonatal O 0 0.010967002
Ebstein B-Disease 0 0.26362592
' I-Disease 0 0.0017576219
s I-Disease 0 0.001468233
anomaly I-Disease 0 0.068271376
: O 0 0.0014024631
evaluation O 0 0.0009959385
with O 0 0.0013196447
cross O 0 0.0024955461
- O 0 0.0060694595
sectional O 0 0.0069109453
echocardiography O 0 0.014318889
. O 0 0.008997542

Cross O 0 0.015411768
- O 0 0.007489624
sectional O 0 0.0041238335
echocardiography O 0 0.0048684753
was O 0 0.0015084429
used O 0 0.00095156144
to O 0 0.00072960375
evaluate O 0 0.0004750825
two O 0 0.0006109361
neonates O 0 0.0014287069
whose O 0 0.0011705545
mothers O 0 0.003581405
ingested O 0 0.28097937
lithium B-Chemical 0 0.9998373
during O 0 0.0029652878
pregnancy O 0 0.3889995
. O 0 0.008580259

In O 0 0.0046890965
one O 0 0.003138272
infant O 0 0.0050309217
, O 0 0.0032195523
Ebstein B-Disease 0 0.10750545
' I-Disease 0 0.0020223344
s I-Disease 0 0.0017076487
anomaly I-Disease 0 0.027876193
of O 0 0.0014488479
the O 0 0.0015563241
tricuspid O 0 0.24951145
valve O 0 0.008829259
was O 0 0.003234667
identified O 0 0.004363588
. O 0 0.007974283

In O 0 0.0038861723
the O 0 0.0024547253
other O 0 0.002026038
infant O 0 0.003776154
cross O 0 0.0022484183
- O 0 0.0042004324
sectional O 0 0.0015429894
echocardiography O 0 0.0023708583
provided O 0 0.0005625249
reassurance O 0 0.0009083585
that O 0 0.0004026808
the O 0 0.00050078676
infant O 0 0.0016526026
did O 0 0.0006854992
not O 0 0.0006379897
have O 0 0.0009129525
Ebstein B-Disease 0 0.07866439
' I-Disease 0 0.002661768
s I-Disease 0 0.0037547662
anomaly I-Disease 0 0.19786386
. O 0 0.008318807

Cross O 0 0.014099872
- O 0 0.006371502
sectional O 0 0.0031731152
echocardiographic O 0 0.004209764
screening O 0 0.0014018106
of O 0 0.0009881918
newborns O 0 0.0023109075
exposed O 0 0.0008371354
to O 0 0.0006010684
lithium B-Chemical 0 0.99977213
during O 0 0.00025478017
gestation O 0 0.0005825312
can O 0 0.00016832277
provide O 0 0.00014858946
highly O 0 0.00022098908
accurate O 0 0.0002985741
, O 0 0.0002815784
noninvasive O 0 0.00054823986
assessment O 0 0.00017732548
of O 0 0.00021916561
the O 0 0.00020164378
presence O 0 0.00023530493
or O 0 0.0002852654
absence O 0 0.0003237431
of O 0 0.0049023484
lithium B-Chemical 0 0.9999862
- O 0 0.14932711
induced O 0 0.0054010563
cardiac B-Disease 0 0.9928901
malformations I-Disease 0 0.9999516
. O 0 0.009779793

Effects O 0 0.0056673847
of O 0 0.0032860613
training O 0 0.0021430107
on O 0 0.0012446197
the O 0 0.0011963471
extent O 0 0.0009685101
of O 0 0.0015836852
experimental O 0 0.007135505
myocardial B-Disease 0 0.9999758
infarction I-Disease 2 0.99999917
in O 0 0.0089140115
aging O 0 0.45508018
rats O 0 0.009695621
. O 0 0.008195636

The O 0 0.0031289598
effects O 0 0.0024906925
of O 0 0.0018558104
exercise O 0 0.0026758346
on O 0 0.0005873538
the O 0 0.0006121385
severity O 0 0.0070354464
of O 0 0.004964473
isoproterenol B-Chemical 0 0.99999356
- O 0 0.34678566
induced O 0 0.007118708
myocardial B-Disease 0 0.9999943
infarction I-Disease 2 0.9999999
were O 0 0.00066126516
studied O 0 0.00029399723
in O 0 0.00022933522
female O 0 0.0017648258
albino O 0 0.005623843
rats O 0 0.00028457897
of O 0 0.00025385973
20 O 0 0.00025619444
, O 0 0.00033931862
40 O 0 0.00031756962
, O 0 0.00043164857
60 O 0 0.00044405618
and O 0 0.00060151273
80 O 0 0.00091715483
weeks O 0 0.0009765462
of O 0 0.002323284
age O 0 0.0057943733
. O 0 0.0073417523

The O 0 0.0038985948
rats O 0 0.0034384842
were O 0 0.0019764944
trained O 0 0.0015871691
to O 0 0.0011607568
swim O 0 0.005033424
for O 0 0.0008948612
a O 0 0.000926953
specific O 0 0.0007270824
duration O 0 0.00073707895
and O 0 0.0010910773
for O 0 0.0012943903
a O 0 0.0020547407
particular O 0 0.0023283914
period O 0 0.0038830892
. O 0 0.0074323853

The O 0 0.005797346
occurrence O 0 0.006686957
of O 0 0.0068517583
infarcts B-Disease 0 0.9996964
were O 0 0.0038200424
confirmed O 0 0.0034897
by O 0 0.0047369823
histological O 0 0.03711938
methods O 0 0.007862428
. O 0 0.011913146

Elevations O 0 0.123254
in O 0 0.0027201609
the O 0 0.0023156728
serum O 0 0.8823225
GOT O 0 0.99998844
and O 0 0.0152761405
GPT O 0 0.99956614
were O 0 0.000472154
maximum O 0 0.00031074556
in O 0 0.00031189958
the O 0 0.00034625753
sedentary O 0 0.0068016984
- O 0 0.0048730792
isoproterenols B-Chemical 0 0.07951091
and O 0 0.00046134918
minimum O 0 0.0004200271
in O 0 0.0006759778
the O 0 0.0010591228
exercise O 0 0.0044439724
- O 0 0.00739643
controls O 0 0.005541223
. O 0 0.007210194

These O 0 0.003717208
changes O 0 0.0027845504
in O 0 0.0017386616
the O 0 0.0015463753
serum O 0 0.66094583
transaminases O 0 0.9998548
were O 0 0.0008474923
associated O 0 0.0005718809
with O 0 0.00048742248
corresponding O 0 0.00046292142
depletions O 0 0.026573155
in O 0 0.00066137366
the O 0 0.0010815636
cardiac O 0 0.5984137
GOT O 0 0.9999659
and O 0 0.0122121
GPT O 0 0.9992416
. O 0 0.008343665

However O 0 0.0051887156
, O 0 0.0040035513
age O 0 0.0031740149
was O 0 0.0015622185
seen O 0 0.0010078705
to O 0 0.00070927653
interfere O 0 0.00062331674
with O 0 0.0006052601
the O 0 0.0005245946
responses O 0 0.00073739304
exhibited O 0 0.00060438644
by O 0 0.0007190882
the O 0 0.00088200945
young O 0 0.00334421
and O 0 0.001933453
old O 0 0.0032224322
rats O 0 0.0052126553
. O 0 0.0068791136

Studies O 0 0.008959819
dealing O 0 0.0049880436
with O 0 0.0059920475
myocardial B-Disease 0 0.99993193
infarction I-Disease 2 0.99999845
are O 0 0.0025461838
more O 0 0.0016976707
informative O 0 0.00184554
when O 0 0.0013599033
dealt O 0 0.0030471785
with O 0 0.0033318964
age O 0 0.0076306276
. O 0 0.008950427

Effect O 0 0.006949278
of O 0 0.0076733516
polyethylene B-Chemical 0 0.99511397
glycol I-Chemical 0 0.9974631
400 I-Chemical 0 0.028615376
on O 0 0.0033138287
adriamycin B-Chemical 0 0.99990785
toxicity B-Disease 2 0.9992569
in O 0 0.005595732
mice O 0 0.005638357
. O 0 0.010801674

The O 0 0.0032013054
effect O 0 0.0022718888
of O 0 0.0019082949
a O 0 0.0016557241
widely O 0 0.0011574148
used O 0 0.0008285685
organic O 0 0.96489
solvent O 0 0.9613882
, O 0 0.01902982
polyethylene B-Chemical 0 0.999255
glycol I-Chemical 0 0.9993117
400 I-Chemical 0 0.050080657
( O 0 0.0012465102
PEG B-Chemical 0 0.7872368
400 I-Chemical 0 0.001154301
) O 0 0.0005043405
, O 0 0.00027122055
on O 0 0.00013494425
the O 0 0.00022891905
toxic O 0 0.32314315
action O 0 0.0005753612
of O 0 0.00040452468
an O 0 0.00068976503
acute O 0 0.7968563
or O 0 0.0007289852
chronic O 0 0.86677796
treatment O 0 0.002677591
with O 0 0.0065254695
adriamycin B-Chemical 0 0.99998987
( O 0 0.12774467
ADR B-Chemical 0 0.99999046
) O 0 0.002721415
was O 0 0.0009017634
evaluated O 0 0.0010547959
in O 0 0.0018196183
mice O 0 0.0026648208
. O 0 0.006327072

PEG B-Chemical 0 0.62550914
400 I-Chemical 0 0.0059018517
impressively O 0 0.012067095
decreased O 0 0.0020015656
both O 0 0.0014081864
acute O 0 0.7743667
high O 0 0.007290582
- O 0 0.030068334
dose O 0 0.0049415827
and O 0 0.0009316715
chronic O 0 0.843459
low O 0 0.00913329
- O 0 0.12125147
dose O 0 0.13751608
- O 0 0.6265841
ADR B-Chemical 0 0.9999865
- O 0 0.113324836
associated O 0 0.0050525353
lethality O 0 0.70873374
. O 0 0.009604771

Light O 0 0.022316659
microscopic O 0 0.0047204164
analysis O 0 0.0023013123
showed O 0 0.0016274484
a O 0 0.0016110811
significant O 0 0.0013186774
protection O 0 0.0074871085
against O 0 0.00966467
ADR B-Chemical 0 0.9999956
- O 0 0.17912854
induced O 0 0.002942057
cardiac B-Disease 0 0.6137121
morphological I-Disease 0 0.045147542
alterations I-Disease 0 0.073324494
. O 0 0.008177926

Such O 0 0.006009207
treatment O 0 0.003596766
did O 0 0.0022269208
not O 0 0.0012785576
diminish O 0 0.0011746259
the O 0 0.001851105
ADR B-Chemical 0 0.9999844
antitumor O 0 0.80979973
activity O 0 0.0022798425
in O 0 0.004176953
L1210 B-Disease 0 0.9999925
leukemia I-Disease 0 0.9999993
and O 0 0.011859127
in O 0 0.0033272028
Ehrlich B-Disease 0 0.9963904
ascites I-Disease 0 0.99972767
tumor I-Disease 0 0.99599993
. O 0 0.011956703

Sublingual O 0 0.8779266
absorption O 0 0.3779349
of O 0 0.003875608
the O 0 0.0034835134
quaternary B-Chemical 0 0.98650044
ammonium I-Chemical 0 0.99998236
antiarrhythmic O 0 0.998928
agent O 0 0.5617529
, O 0 0.018330213
UM B-Chemical 0 0.9887094
- I-Chemical 0 0.056343112
272 I-Chemical 0 0.040643226
. O 0 0.010079466

UM B-Chemical 0 0.97271687
- I-Chemical 0 0.052804124
272 I-Chemical 0 0.037281796
( O 0 0.0066355434
N B-Chemical 0 0.998054
, I-Chemical 0 0.020989167
N I-Chemical 0 0.9996848
- I-Chemical 0 0.20862268
dimethylpropranolol I-Chemical 0 0.3142641
) O 0 0.0022521452
, O 0 0.00081694045
a O 0 0.0007258982
quaternary O 0 0.40399125
antiarrhythmic O 0 0.97677135
agent O 0 0.076379016
, O 0 0.0007597495
was O 0 0.0003207753
administered O 0 0.00038494825
sublingually O 0 0.51696813
to O 0 0.0002794426
dogs O 0 0.0009758077
with O 0 0.0018940484
ouabain B-Chemical 1 0.9999896
- O 0 0.16498989
induced O 0 0.005268691
ventricular B-Disease 0 0.9993005
tachycardias I-Disease 0 0.9992175
. O 0 0.007828378

Both O 0 0.005952434
anti O 0 0.24489708
- O 0 0.18965238
arrhythmic O 0 0.9989675
efficacy O 0 0.0048039746
and O 0 0.0025035797
bioavailability O 0 0.88179827
were O 0 0.0016777423
compared O 0 0.0014666554
to O 0 0.0024840909
oral O 0 0.31483138
drug O 0 0.5186228
. O 0 0.009336972

Sublingual O 0 0.9904218
UM B-Chemical 0 0.98764384
- I-Chemical 0 0.038240515
272 I-Chemical 0 0.011727909
converted O 0 0.002696625
ventricular B-Disease 2 0.9948384
tachycardia I-Disease 2 0.99994683
to O 0 0.0013172964
sinus O 0 0.007479859
rhythm O 0 0.0028992142
in O 0 0.0013640182
all O 0 0.0018204898
5 O 0 0.00264591
dogs O 0 0.0058723046
. O 0 0.007729135

The O 0 0.0029529203
area O 0 0.0025623087
under O 0 0.0013509124
the O 0 0.0011252477
plasma O 0 0.0038922997
concentration O 0 0.0008625609
time O 0 0.00030873573
curve O 0 0.000379804
at O 0 0.00024233956
90 O 0 0.0002223557
min O 0 0.00026110717
was O 0 0.00021279807
4 O 0 0.00019228361
- O 0 0.00047973398
12 O 0 0.0001242352
times O 0 9.582405e-05
greater O 0 0.00012384274
than O 0 0.00011705298
for O 0 0.00018574996
oral O 0 0.14842345
drug O 0 0.36831516
, O 0 0.00038113096
suggesting O 0 0.00013016818
the O 0 0.00013409216
existence O 0 0.00014291849
of O 0 0.0002479578
an O 0 0.0005171916
absorption O 0 0.9083285
- O 0 0.022928232
limiting O 0 0.00029747142
process O 0 0.00020689637
in O 0 0.00018987432
the O 0 0.00021247164
intestine O 0 0.0043141395
, O 0 0.0004368836
and O 0 0.00029012715
providing O 0 0.00029570554
an O 0 0.00033848616
alternate O 0 0.00040417604
form O 0 0.00043990224
of O 0 0.00086158246
administration O 0 0.008795763
for O 0 0.0015964935
quaternary O 0 0.43289596
drugs O 0 0.5162605
. O 0 0.0069364435

Early O 0 0.02524973
adjuvant O 0 0.23798987
adriamycin B-Chemical 0 0.99960154
in O 0 0.014230577
superficial O 0 0.5242776
bladder B-Disease 0 0.9376014
carcinoma I-Disease 2 0.9997918
. O 0 0.029389963

A O 0 0.08090245
multicenter O 0 0.027059833
study O 0 0.0028282446
was O 0 0.0015970583
performed O 0 0.0010412113
in O 0 0.0009589622
110 O 0 0.0011969021
patients O 0 0.0008409403
with O 0 0.0008018302
superficial O 0 0.015217171
transitional O 0 0.054880604
cell O 0 0.042041715
carcinoma B-Disease 2 0.99986017
of I-Disease 0 0.0045351433
the I-Disease 0 0.0040338417
bladder I-Disease 0 0.38514033
. O 0 0.009298708

Adriamycin B-Chemical 0 0.99967766
( O 0 0.006105905
50 O 0 0.002606462
mg O 0 0.054063585
/ O 0 0.003651669
50 O 0 0.00090754405
ml O 0 0.0010801968
) O 0 0.00076681474
was O 0 0.00033131428
administered O 0 0.00024978063
intravesically O 0 0.00060071785
within O 0 0.00015778885
24 O 0 0.00019536784
h O 0 0.0001821671
after O 0 0.00013384357
transurethral O 0 0.00037104145
resection O 0 0.0031626746
of O 0 0.0008487963
TA O 0 0.9845085
- O 0 0.09889621
T1 O 0 0.28452647
( O 0 0.011362481
O O 0 0.99996245
- O 0 0.22262305
A O 0 0.39983055
) O 0 0.013816145
bladder B-Disease 0 0.97942364
tumors I-Disease 0 0.9979767
. O 0 0.010306465

Instillation O 0 0.25478584
was O 0 0.0024772142
repeated O 0 0.0012393538
twice O 0 0.00087459467
during O 0 0.00058191916
the O 0 0.0005229234
first O 0 0.0003808854
week O 0 0.0003217824
, O 0 0.00040409013
then O 0 0.00026939952
weekly O 0 0.00026163348
during O 0 0.00019534455
the O 0 0.00024522963
first O 0 0.00023930141
month O 0 0.00029332726
and O 0 0.00048349888
afterwards O 0 0.00083426194
monthly O 0 0.00082697754
for O 0 0.0011956322
1 O 0 0.001987707
year O 0 0.00358591
. O 0 0.006534908

The O 0 0.0037479212
tolerance O 0 0.009929338
was O 0 0.0018104349
evaluated O 0 0.0010322394
in O 0 0.0008751928
these O 0 0.0008038756
110 O 0 0.0011270742
patients O 0 0.0007546249
, O 0 0.0006622516
and O 0 0.0005613311
29 O 0 0.0007144334
patients O 0 0.00057966757
presented O 0 0.00051447557
with O 0 0.0007881844
local O 0 0.0018503447
side O 0 0.052094847
- O 0 0.018848754
effects O 0 0.0055590626
. O 0 0.0076439963

In O 0 0.004104028
24 O 0 0.0026323223
of O 0 0.0018859663
these O 0 0.0015368251
patients O 0 0.0020079014
chemical O 0 0.093490645
cystitis B-Disease 0 0.99998
was O 0 0.0016296037
severe O 0 0.034639772
enough O 0 0.0005267949
for O 0 0.00045499895
them O 0 0.0006564704
to O 0 0.0005732936
drop O 0 0.0011073358
out O 0 0.00086379296
of O 0 0.0016474803
the O 0 0.0024388048
study O 0 0.0048775766
. O 0 0.0070018023

No O 0 0.015865808
systemic O 0 0.7327874
side O 0 0.2590283
- O 0 0.022833651
effects O 0 0.009296956
were O 0 0.009449149
observed O 0 0.010821848
. O 0 0.017392281

Recurrence O 0 0.20281321
was O 0 0.0028140815
studied O 0 0.0018057707
in O 0 0.0012285198
82 O 0 0.0013954778
evaluable O 0 0.0013301634
patients O 0 0.00064036885
after O 0 0.00030452415
1 O 0 0.0003171412
year O 0 0.000275439
of O 0 0.00028382734
follow O 0 0.00022415526
- O 0 0.0012988199
up O 0 0.00020556434
and O 0 0.00023693891
in O 0 0.00021841316
72 O 0 0.00027767385
patients O 0 0.00021453112
followed O 0 0.00017163943
for O 0 0.00024735995
2 O 0 0.00032567946
- O 0 0.0010055628
3 O 0 0.00034829398
years O 0 0.00052319537
( O 0 0.0007536936
mean O 0 0.0006838978
32 O 0 0.0015699905
months O 0 0.0018153241
) O 0 0.0048294165
. O 0 0.0072356737

Of O 0 0.0051734704
the O 0 0.0029279164
82 O 0 0.0030427896
patients O 0 0.0018214025
studied O 0 0.0012249128
after O 0 0.0007578152
1 O 0 0.00083698385
year O 0 0.00084295153
, O 0 0.0010458287
23 O 0 0.0010472195
had O 0 0.00085343886
primary O 0 0.0012124964
and O 0 0.0017748914
59 O 0 0.0037695193
recurrent O 0 0.21255788
disease O 0 0.91632056
. O 0 0.009981294

Of O 0 0.0047593676
the O 0 0.0026522018
82 O 0 0.0028111045
evaluable O 0 0.0028039974
patients O 0 0.0016124593
, O 0 0.0011663386
50 O 0 0.00075268716
did O 0 0.00047759
not O 0 0.00030540075
show O 0 0.00025222375
any O 0 0.00028437993
recurrence O 0 0.120629676
after O 0 0.00017730451
1 O 0 0.00021243742
year O 0 0.00022885794
( O 0 0.00036422236
61 O 0 0.00041641583
% O 0 0.00033668274
) O 0 0.0004947294
, O 0 0.00033445389
while O 0 0.0002459541
32 O 0 0.00027112232
presented O 0 0.00019655882
with O 0 0.0002571437
one O 0 0.00028646897
or O 0 0.00038498806
more O 0 0.0006868849
recurrences O 0 0.05495868
( O 0 0.0016752173
39 O 0 0.0023067454
% O 0 0.0030971796
) O 0 0.005754476
. O 0 0.007595561

Of O 0 0.0051397625
these O 0 0.003482901
recurrences O 0 0.055976547
, O 0 0.0026644468
27 O 0 0.0019434044
were O 0 0.0013043557
T1 O 0 0.027217146
tumors B-Disease 0 0.48434156
while O 0 0.0008871952
five O 0 0.00065643416
progressed O 0 0.0011596804
to O 0 0.0009353502
more O 0 0.0014777016
highly O 0 0.0023002154
invasive O 0 0.008802331
lesions O 0 0.56084746
. O 0 0.008497612

In O 0 0.0037725037
patients O 0 0.0025406552
that O 0 0.0013457116
were O 0 0.0010947015
free O 0 0.0009770199
of O 0 0.0009519577
recurrence O 0 0.3213315
during O 0 0.000333079
the O 0 0.00030409676
first O 0 0.00022301583
year O 0 0.0002887636
, O 0 0.00033821343
80 O 0 0.00027093006
% O 0 0.0002800475
remained O 0 0.00048386105
tumor B-Disease 0 0.85811704
- O 0 0.008213985
free O 0 0.00028354308
during O 0 0.00017074069
the O 0 0.00024298737
2 O 0 0.00029416912
- O 0 0.00090419425
to O 0 0.00031382224
3 O 0 0.00041790694
- O 0 0.0011012554
year O 0 0.00073056074
follow O 0 0.0008951716
- O 0 0.0028191558
up O 0 0.0021603412
period O 0 0.0033568272
. O 0 0.0067058355

Of O 0 0.004624403
the O 0 0.0025165072
patients O 0 0.0023493518
developing O 0 0.0038363938
one O 0 0.00082842004
or O 0 0.00063424296
more O 0 0.0006303014
recurrences O 0 0.015894514
during O 0 0.00023806117
the O 0 0.00024348949
first O 0 0.00019594748
year O 0 0.00027187506
, O 0 0.00034156517
only O 0 0.00026244693
50 O 0 0.00027664227
% O 0 0.00025855558
presented O 0 0.00020417453
with O 0 0.0002674091
further O 0 0.00036306202
recurrence O 0 0.098661765
once O 0 0.0005448008
the O 0 0.00082743
instillations O 0 0.003702666
were O 0 0.0021804203
stopped O 0 0.0042699454
. O 0 0.006201407

The O 0 0.0030033274
beneficial O 0 0.0023921337
effect O 0 0.0016811626
of O 0 0.0033292815
Adriamycin B-Chemical 0 0.9999647
appears O 0 0.001004205
obvious O 0 0.0006018084
and O 0 0.00048960344
might O 0 0.00023431917
be O 0 0.00023870892
related O 0 0.00016398955
to O 0 0.00018239408
the O 0 0.00025108454
drug O 0 0.11664902
itself O 0 0.00045731332
, O 0 0.00040119694
the O 0 0.00024217718
early O 0 0.00038046858
and O 0 0.00033315836
repeated O 0 0.00029896264
instillations O 0 0.0016771986
after O 0 0.0006035972
TUR O 0 0.34093517
, O 0 0.0019711459
or O 0 0.0021954423
both O 0 0.0038284184
. O 0 0.007024033

D B-Chemical 0 0.99851686
- I-Chemical 0 0.89960337
penicillamine I-Chemical 1 0.99999714
- O 0 0.54994434
induced O 0 0.057226427
angiopathy B-Disease 0 0.99999416
in O 0 0.012848886
rats O 0 0.016469358
. O 0 0.015322986

The O 0 0.003035456
effect O 0 0.0021386712
of O 0 0.0018805867
high O 0 0.002627938
dose O 0 0.30181906
D B-Chemical 0 0.99995756
- I-Chemical 0 0.9559862
penicillamine I-Chemical 1 0.99999976
treatment O 0 0.0019545858
on O 0 0.00030350417
aortic O 0 0.14045587
permeability O 0 0.45429432
to O 0 0.00043419775
albumin O 0 0.94202316
and O 0 0.0005087956
on O 0 0.0003910737
the O 0 0.0006671358
ultrastructure O 0 0.002765767
of O 0 0.0017339044
the O 0 0.0025381155
vessel O 0 0.07512142
. O 0 0.00742028

Male O 0 0.0498396
Sprague O 0 0.15756327
- O 0 0.016264167
Dawley O 0 0.012848105
rats O 0 0.0017765834
were O 0 0.0008979885
treated O 0 0.000841444
with O 0 0.001857012
D B-Chemical 0 0.9998733
- I-Chemical 0 0.9464435
penicillamine I-Chemical 1 0.9999999
( O 0 0.23405062
D B-Chemical 1 0.99993527
- I-Chemical 1 0.36675814
pen I-Chemical 1 0.17502989
) O 0 0.0010496476
500 O 0 0.0006220331
mg O 0 0.00878355
/ O 0 0.001073808
kg O 0 0.00092015014
/ O 0 0.0010159343
day O 0 0.00047639123
for O 0 0.00063972466
10 O 0 0.0009132073
or O 0 0.0013147527
42 O 0 0.0026422283
days O 0 0.003020454
. O 0 0.006529019

Pair O 0 0.056248948
fed O 0 0.017931774
rats O 0 0.01529017
served O 0 0.014793098
as O 0 0.013792334
controls O 0 0.02080714
. O 0 0.024980593

Changes O 0 0.00410983
in O 0 0.0026912712
aortic O 0 0.01365383
morphology O 0 0.002246841
were O 0 0.0009873704
examined O 0 0.0006165801
by O 0 0.00080107845
light O 0 0.0026487266
- O 0 0.0035264667
and O 0 0.0009014334
transmission O 0 0.0041188095
- O 0 0.006660026
electron O 0 0.013450598
microscopy O 0 0.00265733
( O 0 0.0036114806
TEM O 0 0.038512584
) O 0 0.008069088
. O 0 0.009236582

In O 0 0.0034579209
addition O 0 0.0018403464
, O 0 0.0022808479
the O 0 0.0014423981
endothelial O 0 0.90166557
permeability O 0 0.79581046
and O 0 0.0008102391
the O 0 0.0004108673
penetration O 0 0.00317866
through O 0 0.0002010542
the O 0 0.00023383288
aortic O 0 0.027324094
wall O 0 0.0042342427
of O 0 0.0004401835
albumin O 0 0.971693
were O 0 0.00019284232
studied O 0 0.00015474332
10 O 0 0.00012110239
minutes O 0 0.00011136355
, O 0 0.0001823953
24 O 0 0.0001438552
and O 0 0.0001489306
48 O 0 0.00015874152
hours O 0 0.00011425152
after O 0 0.00011184788
i O 0 0.00068745855
. O 0 0.00020888426
v O 0 0.0068115303
. O 0 0.00022911624
injection O 0 0.0003270781
of O 0 0.00031794677
human O 0 0.0010358957
serum O 0 0.86420983
131I O 0 0.9992995
- O 0 0.29113403
albumin O 0 0.99767786
( O 0 0.02094269
131I O 0 0.9965557
- O 0 0.12664181
HSA O 0 0.97832334
) O 0 0.009845021
. O 0 0.008392553

TEM O 0 0.013190756
revealed O 0 0.0025948985
extensive O 0 0.002174309
elastolysis O 0 0.4867619
in O 0 0.0010596325
the O 0 0.00077468046
arterial O 0 0.16687933
wall O 0 0.01929322
of O 0 0.0039950004
D B-Chemical 1 0.99990106
- I-Chemical 1 0.54777604
pen I-Chemical 1 0.5301828
- O 0 0.022382904
treated O 0 0.0005101218
rats O 0 0.0005392169
, O 0 0.00040927122
consistent O 0 0.0003349488
with O 0 0.00041942872
an O 0 0.00057209434
inhibitory O 0 0.0011992073
effect O 0 0.000902147
on O 0 0.0011505415
crosslink O 0 0.017489094
formation O 0 0.03980776
. O 0 0.0075939037

In O 0 0.00355336
experimental O 0 0.002300978
animals O 0 0.0013866811
excess O 0 0.0016174737
deposition O 0 0.015402294
of O 0 0.0016096659
collagen O 0 0.66807306
and O 0 0.0014170753
glycoaminoglycans O 0 0.20711775
was O 0 0.00033520244
observed O 0 0.00019471899
in O 0 0.00018613326
the O 0 0.00018696429
subendothelial O 0 0.013332189
and O 0 0.00031284153
medial O 0 0.021037871
layer O 0 0.001296444
of O 0 0.00022439497
the O 0 0.00021671591
aortic O 0 0.07298536
wall O 0 0.008337338
, O 0 0.00030747033
together O 0 0.00018610984
with O 0 0.00026289473
prominent O 0 0.0015728313
basal O 0 0.00085146166
membrane O 0 0.0062134704
substance O 0 0.71300524
around O 0 0.00094493007
aortic O 0 0.11810113
smooth O 0 0.018033236
muscle O 0 0.017241985
cells O 0 0.0051176758
. O 0 0.007171951

The O 0 0.003623148
aorta O 0 0.052043263
/ O 0 0.017881393
serum O 0 0.42172158
- O 0 0.014291416
ratio O 0 0.000980857
and O 0 0.00068402855
the O 0 0.00047346935
radioactive O 0 0.001899041
build O 0 0.00064362516
- O 0 0.0023899546
up O 0 0.00023099073
24 O 0 0.00020789618
and O 0 0.00019311336
48 O 0 0.00018613682
hours O 0 0.000123762
after O 0 0.000109093766
injection O 0 0.00026402104
of O 0 0.00060234574
131I O 0 0.99870694
- O 0 0.30945015
HSA O 0 0.99278075
was O 0 0.00028803357
reduced O 0 0.00018994838
in O 0 0.00015726328
animals O 0 0.00013270744
treated O 0 0.0002694776
with O 0 0.0012350855
D B-Chemical 1 0.99986005
- I-Chemical 1 0.27276456
pen I-Chemical 1 0.06826718
for O 0 0.00019394595
42 O 0 0.00022331413
days O 0 0.0001227744
, O 0 0.00020977305
indicating O 0 0.00014782127
an O 0 0.00020538706
impeded O 0 0.00028037882
transmural O 0 0.22277556
transport O 0 0.00056891015
of O 0 0.0003291276
tracer O 0 0.006856854
which O 0 0.00031229467
may O 0 0.00019515505
be O 0 0.00021944498
caused O 0 0.00025029076
by O 0 0.00036145892
a O 0 0.0005256372
steric O 0 0.031202963
exclusion O 0 0.0009014064
effect O 0 0.0009678809
of O 0 0.002275521
abundant O 0 0.005738664
hyaluronate B-Chemical 0 0.9997546
. O 0 0.009984291

The O 0 0.0036004211
endothelial O 0 0.4690505
ultrastructure O 0 0.01397671
was O 0 0.0013229419
unaffected O 0 0.0012098155
by O 0 0.0017795127
D B-Chemical 1 0.9996995
- I-Chemical 1 0.3146801
pen I-Chemical 1 0.16476089
, O 0 0.0006111174
and O 0 0.00031670218
no O 0 0.00018023067
differences O 0 0.00016839404
in O 0 0.00026033857
aortic O 0 0.5332741
131I O 0 0.99799323
- O 0 0.16209061
HSA O 0 0.9902828
radioactivity O 0 0.0770142
or O 0 0.00029592324
aorta O 0 0.09660602
/ O 0 0.016721567
serum O 0 0.5057403
- O 0 0.013546815
ratio O 0 0.00023721243
were O 0 0.00014517586
recorded O 0 0.000117205665
between O 0 9.2598435e-05
experimental O 0 0.00015113602
and O 0 0.00016359927
control O 0 0.00014299767
groups O 0 0.00014005546
10 O 0 0.00010184337
minutes O 0 8.74391e-05
after O 0 8.728274e-05
tracer O 0 0.0009041598
injection O 0 0.00032903976
, O 0 0.00023043246
indicating O 0 0.00013003877
that O 0 0.00012649896
the O 0 0.00019422204
permeability O 0 0.27976108
of O 0 0.00035352653
the O 0 0.00030260533
endothelial O 0 0.8123197
barrier O 0 0.006349015
to O 0 0.0003431397
albumin O 0 0.9758625
remained O 0 0.00088704977
unaffected O 0 0.0009019184
by O 0 0.0015136495
D B-Chemical 1 0.99909735
- I-Chemical 1 0.20814718
pen I-Chemical 1 0.19867706
treatment O 0 0.005369855
. O 0 0.0070199533

These O 0 0.003259255
observations O 0 0.0021170336
support O 0 0.0012880763
the O 0 0.001005686
hypothesis O 0 0.00080516544
that O 0 0.0005293279
treatment O 0 0.00065121485
with O 0 0.000505764
high O 0 0.000712467
doses O 0 0.0100104995
of O 0 0.0075046755
D B-Chemical 1 0.9999609
- I-Chemical 1 0.5511203
pen I-Chemical 1 0.15040916
may O 0 0.00020821893
induce O 0 0.00014863198
a O 0 0.00035809405
fibroproliferative O 0 0.39798662
response O 0 0.00048137593
in O 0 0.00025352256
rat O 0 0.0019563483
aorta O 0 0.06259272
, O 0 0.00035938647
possibly O 0 0.0003982702
by O 0 0.00021394098
an O 0 0.0002462775
inhibitory O 0 0.00049462373
effect O 0 0.00022875672
on O 0 0.00019127475
the O 0 0.0003217898
cross O 0 0.00073034986
- O 0 0.0020393548
linking O 0 0.00073469884
of O 0 0.0015391287
collagen O 0 0.36077967
and O 0 0.0044361907
elastin O 0 0.53020877
. O 0 0.00796184

Effect O 0 0.004375472
of O 0 0.0048356475
aspirin B-Chemical 0 0.99993813
on O 0 0.0019071709
N B-Chemical 0 0.99966776
- I-Chemical 0 0.21967703
[ I-Chemical 0 0.009363442
4 I-Chemical 0 0.0005908453
- I-Chemical 0 0.0025521817
( I-Chemical 0 0.00064226455
5 I-Chemical 0 0.0004067607
- I-Chemical 0 0.042828098
nitro I-Chemical 0 0.9998727
- I-Chemical 0 0.06474525
2 I-Chemical 0 0.0004972666
- I-Chemical 0 0.040020183
furyl I-Chemical 0 0.9951508
) I-Chemical 0 0.0059723733
- I-Chemical 0 0.029649401
2 I-Chemical 0 0.00046404384
- I-Chemical 0 0.11584062
thiazolyl I-Chemical 0 0.9996841
] I-Chemical 0 0.041594543
- I-Chemical 0 0.11912403
formamide I-Chemical 0 0.98590356
- O 0 0.026478948
induced O 0 0.0004107189
epithelial O 0 0.16654605
proliferation O 0 0.8233138
in O 0 0.00041044943
the O 0 0.0004393497
urinary O 0 0.32616982
bladder O 0 0.2987747
and O 0 0.0019843811
forestomach O 0 0.98166627
of O 0 0.0027388467
the O 0 0.0028784394
rat O 0 0.009182287
. O 0 0.0070891078

The O 0 0.0041659023
co O 0 0.3853867
- O 0 0.028549148
administration O 0 0.016193876
of O 0 0.005213494
aspirin B-Chemical 0 0.99999225
with O 0 0.025769714
N B-Chemical 0 0.99991226
- I-Chemical 0 0.28429303
[ I-Chemical 0 0.009314593
4 I-Chemical 0 0.0003571066
- I-Chemical 0 0.0021321173
( I-Chemical 0 0.000468947
5 I-Chemical 0 0.00030276607
- I-Chemical 0 0.042733196
nitro I-Chemical 0 0.99987817
- I-Chemical 0 0.064126045
2 I-Chemical 0 0.00044239953
- I-Chemical 0 0.041410822
furyl I-Chemical 0 0.99540305
) I-Chemical 0 0.006201386
- I-Chemical 0 0.032272894
2 I-Chemical 0 0.0004503544
- I-Chemical 0 0.1279696
thiazolyl I-Chemical 0 0.9997203
] I-Chemical 0 0.04858056
- I-Chemical 0 0.15605742
formamide I-Chemical 0 0.9929213
( O 0 0.047523744
FANFT B-Chemical 1 0.9999869
) O 0 0.002277284
to O 0 0.00018675049
rats O 0 0.0002723446
resulted O 0 0.00014959458
in O 0 0.00018291776
a O 0 0.00024770878
reduced O 0 0.00023294498
incidence O 0 0.005869199
of O 0 0.008591441
FANFT B-Chemical 1 0.99999607
- O 0 0.1766837
induced O 0 0.0013165766
bladder B-Disease 0 0.99665487
carcinomas I-Disease 0 0.99984014
but O 0 0.0015350066
a O 0 0.00086072105
concomitant O 0 0.0020938485
induction O 0 0.0015331929
of O 0 0.015240024
forestomach B-Disease 0 0.99994814
tumors I-Disease 0 0.99972445
. O 0 0.011938409

An O 0 0.0054866825
autoradiographic O 0 0.0052986066
study O 0 0.0021961443
was O 0 0.0012731387
performed O 0 0.0008122207
on O 0 0.0006499648
male O 0 0.014564364
F O 0 0.9466117
- O 0 0.08662628
344 O 0 0.018977376
rats O 0 0.00059773686
fed O 0 0.00047167
diet O 0 0.013051084
containing O 0 0.0004658057
FANFT B-Chemical 1 0.9999069
at O 0 0.0002190012
a O 0 0.00022169712
level O 0 0.00014342622
of O 0 0.00023540275
0 O 0 0.0002554257
. O 0 0.00016644031
2 O 0 0.00016243332
% O 0 0.00020420353
and O 0 0.00024174419
/ O 0 0.0031916716
or O 0 0.0005214553
aspirin B-Chemical 0 0.99996376
at O 0 0.00017449657
a O 0 0.0001867902
level O 0 0.00012321444
of O 0 0.0002115801
0 O 0 0.00022789139
. O 0 0.00014207186
5 O 0 0.00012306229
% O 0 0.00015254809
to O 0 0.00010469283
evaluate O 0 7.637059e-05
the O 0 0.00012973225
effect O 0 0.0001774124
of O 0 0.00097564695
aspirin B-Chemical 0 0.9999815
on O 0 0.00014739056
the O 0 0.00022226095
increased O 0 0.00038141932
cell O 0 0.009799578
proliferation O 0 0.8309036
induced O 0 0.0010534583
by O 0 0.0026566808
FANFT B-Chemical 1 0.9999474
in O 0 0.001069923
the O 0 0.0014798597
forestomach O 0 0.98122334
and O 0 0.0046606483
bladder O 0 0.49277636
. O 0 0.008091587

FANFT B-Chemical 1 0.9999167
- O 0 0.09309045
induced O 0 0.0029807594
cell O 0 0.01798557
proliferation O 0 0.7842831
in O 0 0.0010068029
the O 0 0.0007094651
bladder O 0 0.1067882
was O 0 0.0004953487
significantly O 0 0.00036598087
suppressed O 0 0.00037076333
by O 0 0.0012351573
aspirin B-Chemical 0 0.9999974
co O 0 0.97352266
- O 0 0.11354157
administration O 0 0.0028117355
after O 0 0.00022870196
4 O 0 0.00029599207
weeks O 0 0.0003010494
but O 0 0.00056739163
not O 0 0.00069963053
after O 0 0.0009311471
12 O 0 0.0016285456
weeks O 0 0.0024776713
. O 0 0.0058401353

In O 0 0.004279243
the O 0 0.0034428057
forestomach O 0 0.9725365
, O 0 0.0029407064
and O 0 0.0012820251
also O 0 0.000772634
in O 0 0.0006546652
the O 0 0.00073937984
liver O 0 0.9080286
, O 0 0.035685178
aspirin B-Chemical 0 0.9999939
did O 0 0.00067233486
not O 0 0.00030985687
affect O 0 0.00029406202
the O 0 0.001001146
FANFT B-Chemical 1 0.9999777
- O 0 0.0362031
induced O 0 0.00084483356
increase O 0 0.0009677712
in O 0 0.0015715582
labeling O 0 0.0034418947
index O 0 0.005544309
. O 0 0.0071194195

The O 0 0.0028241752
present O 0 0.0016623486
results O 0 0.0012436203
are O 0 0.0009472882
consistent O 0 0.00074246427
with O 0 0.0006969944
the O 0 0.0007577105
carcinogenicity O 0 0.99800557
experiment O 0 0.00029151954
suggesting O 0 0.00020861418
that O 0 0.00016763083
different O 0 0.00014907368
mechanisms O 0 0.00016031238
are O 0 0.00017305122
involved O 0 0.00016546855
in O 0 0.00063273875
FANFT B-Chemical 1 0.9999924
carcinogenesis B-Disease 0 0.9998287
in O 0 0.00038370673
the O 0 0.00026752515
bladder O 0 0.19564798
and O 0 0.0015396463
forestomach O 0 0.9962547
, O 0 0.0012628332
and O 0 0.00040007586
that O 0 0.00035117636
aspirin B-Chemical 0 0.9999887
' O 0 0.00089828036
s O 0 0.0003292701
effect O 0 0.00021307702
on O 0 0.0002100931
FANFT B-Chemical 1 0.9999492
in O 0 0.00037007543
the O 0 0.0004359483
forestomach O 0 0.9874171
is O 0 0.0003442583
not O 0 0.00019591495
due O 0 0.00017417576
to O 0 0.00024244958
an O 0 0.0006627059
irritant O 0 0.9888453
effect O 0 0.0006090988
associated O 0 0.00087579596
with O 0 0.001162307
increased O 0 0.0021282826
cell O 0 0.034296114
proliferation O 0 0.90848106
. O 0 0.008913507

Also O 0 0.005976
, O 0 0.0037004678
there O 0 0.0016935903
appears O 0 0.0012985255
to O 0 0.0009527375
be O 0 0.0008833004
an O 0 0.00083941035
adaptation O 0 0.00093238446
by O 0 0.0006721481
the O 0 0.0006010586
rats O 0 0.0008038243
to O 0 0.00062411267
the O 0 0.0010372932
chronic O 0 0.8801651
ingestion O 0 0.95126075
of O 0 0.05464249
aspirin B-Chemical 0 0.9999764
. O 0 0.01054212

A O 0 0.08318647
case O 0 0.010970157
of O 0 0.05888359
tardive B-Disease 0 0.9999989
dyskinesia I-Disease 0 0.99999833
caused O 0 0.026492113
by O 0 0.027665792
metoclopramide B-Chemical 1 0.9999651
. O 0 0.017867096

Abnormal B-Disease 0 0.08000017
involuntary I-Disease 0 0.9499766
movements I-Disease 0 0.2314319
appeared O 0 0.0014422559
in O 0 0.00085103017
the O 0 0.00070112286
mouth O 0 0.046371985
, O 0 0.0010739344
tongue O 0 0.111971326
, O 0 0.0007716185
neck O 0 0.025268123
and O 0 0.00037533802
abdomen O 0 0.004548006
of O 0 0.00030680126
a O 0 0.0003555257
64 O 0 0.00050786237
- O 0 0.0020408838
year O 0 0.0002965364
- O 0 0.0018078862
old O 0 0.0002432665
male O 0 0.00053145696
patient O 0 0.00017825734
after O 0 0.00011492636
he O 0 0.00018508379
took O 0 0.0002866015
metoclopramide B-Chemical 1 0.99998224
for O 0 0.0005926627
gastrointestinal B-Disease 0 0.9992273
disorder I-Disease 0 0.9997433
in O 0 0.00025057254
a O 0 0.0002403748
regimen O 0 0.00023154904
of O 0 0.00020332535
30 O 0 0.00016588543
mg O 0 0.0006707147
per O 0 0.00013890144
day O 0 0.00019413001
for O 0 0.00027014076
a O 0 0.00043095145
total O 0 0.00046892336
of O 0 0.0009235515
about O 0 0.0012946218
260 O 0 0.0062934053
days O 0 0.0029664524
. O 0 0.006188918

The O 0 0.0064319866
symptoms O 0 0.04283754
exacerbated O 0 0.0062705595
to O 0 0.0034423657
a O 0 0.003791382
maximum O 0 0.0033502134
in O 0 0.0042097773
a O 0 0.0060666665
month O 0 0.0066335164
. O 0 0.011561587

When O 0 0.0036428007
the O 0 0.0042636828
metoclopramide B-Chemical 1 0.99997985
administration O 0 0.09772059
was O 0 0.0014235271
discontinued O 0 0.008405873
, O 0 0.0009620503
the O 0 0.0006605248
abnormal B-Disease 0 0.10950787
movements I-Disease 0 0.02679159
gradually O 0 0.00097258424
improved O 0 0.0009850563
to O 0 0.000979106
a O 0 0.001706399
considerable O 0 0.002211506
extent O 0 0.0033313434
. O 0 0.0070864493

Attention O 0 0.011326963
to O 0 0.0022993444
the O 0 0.0016258075
possible O 0 0.0012837608
induction O 0 0.0010906787
of O 0 0.0014976664
specific O 0 0.008460982
tardive B-Disease 0 0.9999999
dyskinesia I-Disease 0 0.9999999
is O 0 0.0012156478
called O 0 0.0006508884
for O 0 0.0004832768
in O 0 0.00056001166
the O 0 0.00069455366
use O 0 0.0010222932
of O 0 0.0017586823
this O 0 0.0027654276
drug O 0 0.29698476
. O 0 0.007638771

Intra O 0 0.29113597
- O 0 0.05996238
arterial O 0 0.8786431
BCNU B-Chemical 0 0.9999497
chemotherapy O 0 0.12312037
for O 0 0.0010927874
treatment O 0 0.0012177137
of O 0 0.0023286706
malignant B-Disease 0 0.99971324
gliomas I-Disease 0 0.9999707
of O 0 0.0020407876
the O 0 0.0015303224
central O 0 0.0030103922
nervous O 0 0.050937016
system O 0 0.0049846433
. O 0 0.007452424

Because O 0 0.0031354541
of O 0 0.00251284
the O 0 0.0016742303
rapid O 0 0.0026529243
systemic O 0 0.6826091
clearance O 0 0.24713802
of O 0 0.017924897
BCNU B-Chemical 0 0.9999944
( O 0 0.0024806312
1 B-Chemical 0 0.00040545547
, I-Chemical 0 0.0004662997
3 I-Chemical 0 0.0003272578
- I-Chemical 0 0.017271632
bis I-Chemical 0 0.8935911
- I-Chemical 0 0.03181449
( I-Chemical 0 0.0007670716
2 I-Chemical 0 0.00038243554
- I-Chemical 0 0.03444514
chloroethyl I-Chemical 0 0.99638593
) I-Chemical 0 0.0069322735
- I-Chemical 0 0.028236093
1 I-Chemical 0 0.00037171875
- I-Chemical 0 0.03168787
nitrosourea I-Chemical 0 0.9966666
) O 0 0.0024309603
, O 0 0.0006112279
intra O 0 0.0118317325
- O 0 0.020512795
arterial O 0 0.12322154
administration O 0 0.0007088525
should O 0 0.000101895814
provide O 0 0.000113811344
a O 0 0.00017592532
substantial O 0 0.00016613206
advantage O 0 0.00014500611
over O 0 0.00015376107
intravenous O 0 0.0058816536
administration O 0 0.0009138523
for O 0 0.000351577
the O 0 0.00052980054
treatment O 0 0.0011564068
of O 0 0.004424711
malignant B-Disease 0 0.9997669
gliomas I-Disease 0 0.9999685
. O 0 0.010592809

Thirty O 0 0.008003951
- O 0 0.0065800836
six O 0 0.0014469409
patients O 0 0.0013559852
were O 0 0.0008268917
treated O 0 0.0007553246
with O 0 0.0011230134
BCNU B-Chemical 0 0.99989116
every O 0 0.00020993291
6 O 0 0.00019118596
to O 0 0.00017025866
8 O 0 0.00017790706
weeks O 0 0.00013224322
, O 0 0.00021384227
either O 0 0.00016391219
by O 0 0.00019506871
transfemoral O 0 0.0003465257
catheterization O 0 0.00028123014
of O 0 0.00015121543
the O 0 0.00013934253
internal O 0 0.00024984972
carotid O 0 0.29135916
or O 0 0.00020770695
vertebral O 0 0.18731013
artery O 0 0.018921113
or O 0 0.000140592
through O 0 0.000114278424
a O 0 0.0001852865
fully O 0 0.00017030492
implantable O 0 0.027076198
intracarotid O 0 0.89776516
drug O 0 0.044951677
delivery O 0 0.00018842069
system O 0 0.00020345568
, O 0 0.00024677976
beginning O 0 0.00013605139
with O 0 0.00018999222
a O 0 0.0002530999
dose O 0 0.0006360051
of O 0 0.00039508677
200 O 0 0.00070105813
mg O 0 0.01454384
/ O 0 0.0016963531
sq O 0 0.0028470135
m O 0 0.002858023
body O 0 0.00327539
surface O 0 0.0045586573
area O 0 0.006562689
. O 0 0.0076460363

Twelve O 0 0.0062322044
patients O 0 0.0030954161
with O 0 0.0023973442
Grade O 0 0.5098611
III O 0 0.08840399
or O 0 0.001581869
IV O 0 0.8302902
astrocytomas B-Disease 0 0.9998318
were O 0 0.00052377745
treated O 0 0.0003946149
after O 0 0.00024910542
partial O 0 0.0004560609
resection O 0 0.0023256948
of O 0 0.00054643274
the O 0 0.0006385475
tumor B-Disease 0 0.5565159
without O 0 0.0011130575
prior O 0 0.0014129356
radiation O 0 0.19387296
therapy O 0 0.010112033
. O 0 0.0073590227

After O 0 0.0026032238
two O 0 0.0017695575
to O 0 0.0012522062
seven O 0 0.00085212645
cycles O 0 0.0006007259
of O 0 0.0007834854
chemotherapy O 0 0.029024413
, O 0 0.0007229755
nine O 0 0.00036697063
patients O 0 0.0003997588
showed O 0 0.00025439836
a O 0 0.00031579589
decrease O 0 0.0002600949
in O 0 0.00030678164
tumor B-Disease 0 0.6054825
size O 0 0.0004837407
and O 0 0.00047011452
surrounding O 0 0.0017549902
edema B-Disease 0 0.9999362
on O 0 0.00041328243
contrast O 0 0.0009673536
- O 0 0.004376401
enhanced O 0 0.0014059546
computerized O 0 0.004170955
tomography O 0 0.0088485675
scans O 0 0.006748958
. O 0 0.0075055845

In O 0 0.0036274923
the O 0 0.0021987339
nine O 0 0.0016093042
responders O 0 0.002162574
, O 0 0.00097219885
median O 0 0.00044019317
duration O 0 0.00037746207
of O 0 0.00046994086
chemotherapy O 0 0.008569504
response O 0 0.0003766853
from O 0 0.00020804208
the O 0 0.00018736423
time O 0 0.0001431404
of O 0 0.00022214846
operation O 0 0.00023980688
was O 0 0.00019627601
25 O 0 0.0002138496
weeks O 0 0.00015265998
( O 0 0.00028637284
range O 0 0.0002832853
12 O 0 0.000280312
to O 0 0.00035681648
more O 0 0.0006013308
than O 0 0.00068607955
91 O 0 0.0018576751
weeks O 0 0.0017011515
) O 0 0.0047256253
. O 0 0.0069745895

The O 0 0.0025856306
median O 0 0.0014603267
duration O 0 0.001130989
of O 0 0.0011629331
survival O 0 0.010005439
in O 0 0.0006266357
the O 0 0.000448527
12 O 0 0.00030402897
patients O 0 0.00034169905
was O 0 0.00024803774
54 O 0 0.0003049527
weeks O 0 0.00014880387
( O 0 0.00024010542
range O 0 0.00019610672
21 O 0 0.00019805574
to O 0 0.00014840283
more O 0 0.00018771812
than O 0 0.00013760779
156 O 0 0.00037582047
weeks O 0 0.0001475613
) O 0 0.00035613764
, O 0 0.00030861274
with O 0 0.0002845215
an O 0 0.000375701
18 O 0 0.0004195629
- O 0 0.0010561163
month O 0 0.00044325477
survival O 0 0.0018290092
rate O 0 0.001139985
of O 0 0.001955734
42 O 0 0.0033441237
% O 0 0.0047696056
. O 0 0.0071811504

Twenty O 0 0.0069021573
- O 0 0.0056479704
four O 0 0.001491199
patients O 0 0.0013983818
with O 0 0.0011033971
recurrent O 0 0.16608572
Grade O 0 0.79655045
I O 0 0.037862055
to O 0 0.00057329057
IV O 0 0.8100489
astrocytomas B-Disease 0 0.99991477
, O 0 0.00069217914
whose O 0 0.00043336413
resection O 0 0.005182269
and O 0 0.00034685453
irradiation O 0 0.014552734
therapy O 0 0.00079752563
had O 0 0.0002368522
failed O 0 0.000277064
, O 0 0.00030560463
received O 0 0.00016606743
two O 0 0.00016151406
to O 0 0.00018715301
eight O 0 0.00021772723
courses O 0 0.000318897
of O 0 0.0006028089
intra O 0 0.01865264
- O 0 0.08519402
arterial O 0 0.9186425
BCNU B-Chemical 0 0.99989617
therapy O 0 0.010426384
. O 0 0.006873741

Seventeen O 0 0.0074462933
of O 0 0.0027627463
these O 0 0.0018628911
had O 0 0.0012453663
a O 0 0.0010763545
response O 0 0.00089835137
or O 0 0.0005680849
were O 0 0.00043698106
stable O 0 0.00040753622
for O 0 0.00027188778
a O 0 0.00027645478
median O 0 0.0001726178
of O 0 0.00024223512
20 O 0 0.00022064822
weeks O 0 0.0001711255
( O 0 0.0003100853
range O 0 0.00030100523
6 O 0 0.00029417445
to O 0 0.00037800116
more O 0 0.00062055653
than O 0 0.0006894781
66 O 0 0.0016544847
weeks O 0 0.0017012795
) O 0 0.0047239373
. O 0 0.0069976593

The O 0 0.003697196
catheterization O 0 0.0038451473
procedure O 0 0.0019876636
is O 0 0.0016272777
safe O 0 0.0017455652
, O 0 0.0012686104
with O 0 0.00088087097
no O 0 0.00072298036
immediate O 0 0.0015229014
complication O 0 0.11441862
in O 0 0.0013865505
111 O 0 0.005070673
infusions O 0 0.006135048
of O 0 0.005915584
BCNU B-Chemical 0 0.99980813
. O 0 0.009582208

A O 0 0.06334784
delayed O 0 0.007689932
complication O 0 0.11884173
in O 0 0.0016430581
nine O 0 0.0011367508
patients O 0 0.0011138933
has O 0 0.000680174
been O 0 0.0007263732
unilateral O 0 0.037294414
loss B-Disease 0 0.0025184804
of I-Disease 0 0.0012186483
vision I-Disease 0 0.77515584
secondary O 0 0.012675746
to O 0 0.0014673286
a O 0 0.0039520324
retinal B-Disease 0 0.9947818
vasculitis I-Disease 2 0.99998033
. O 0 0.01215461

The O 0 0.0032409593
frequency O 0 0.002698163
of O 0 0.0026506507
visual B-Disease 2 0.84800285
loss I-Disease 2 0.039550498
decreased O 0 0.0012398572
after O 0 0.0005526962
the O 0 0.0006172498
concentration O 0 0.001087334
of O 0 0.0011474367
the O 0 0.0017482325
ethanol B-Chemical 1 0.99965477
diluent O 0 0.5712667
was O 0 0.0034927088
lowered O 0 0.009438322
. O 0 0.0072092446

Provocation O 0 0.49135172
of O 0 0.011297418
postural O 0 0.99938214
hypotension B-Disease 2 0.99999833
by O 0 0.050190825
nitroglycerin B-Chemical 1 0.99999547
in O 0 0.029041048
diabetic B-Disease 2 0.99998343
autonomic I-Disease 0 0.99979335
neuropathy I-Disease 0 0.9999962
? O 0 0.066180706

The O 0 0.003278397
effect O 0 0.0025997183
of O 0 0.004228318
nitroglycerin B-Chemical 1 0.99998784
on O 0 0.00091135764
heart O 0 0.103494756
rate O 0 0.0006765204
and O 0 0.00072311546
systolic O 0 0.7240741
blood O 0 0.02348865
pressure O 0 0.021192709
was O 0 0.00020024244
compared O 0 0.00013066485
in O 0 0.00015835073
5 O 0 0.00014699982
normal O 0 0.00022318895
subjects O 0 0.0002794437
, O 0 0.00029755506
12 O 0 0.00020651933
diabetic B-Disease 2 0.99418193
subjects O 0 0.0004820158
without O 0 0.0004920341
autonomic B-Disease 0 0.9973763
neuropathy I-Disease 0 0.9999988
, O 0 0.00082616624
and O 0 0.00053111743
5 O 0 0.0005442358
diabetic B-Disease 2 0.99648476
subjects O 0 0.0018599179
with O 0 0.0032925678
autonomic B-Disease 0 0.9965565
neuropathy I-Disease 0 0.9999856
. O 0 0.008270659

The O 0 0.002786507
magnitude O 0 0.0017913268
and O 0 0.0014433387
time O 0 0.00077961007
course O 0 0.00068889285
of O 0 0.00065257854
the O 0 0.00045859782
increase O 0 0.0003523477
in O 0 0.00042291204
heart O 0 0.06043017
rate O 0 0.00033861157
and O 0 0.0002988253
the O 0 0.00020678296
decrease O 0 0.00021146477
in O 0 0.00025364198
systolic O 0 0.6272694
blood O 0 0.019088872
pressure O 0 0.036371067
after O 0 0.00017661408
nitroglycerin B-Chemical 1 0.99997985
were O 0 0.00016714324
similar O 0 0.00010474155
in O 0 0.00012375799
the O 0 0.00013590747
normal O 0 0.0003049303
and O 0 0.0004405252
diabetic B-Disease 2 0.99952245
subjects O 0 0.00079895154
without O 0 0.00058105285
autonomic B-Disease 0 0.9987702
neuropathy I-Disease 0 0.9999995
, O 0 0.0010012734
whereas O 0 0.0002799405
a O 0 0.00029137533
lesser O 0 0.0005783885
increase O 0 0.00015915968
in O 0 0.00022486359
heart O 0 0.032956224
rate O 0 0.00022759193
and O 0 0.0002435763
a O 0 0.00024168748
greater O 0 0.00016356855
decrease O 0 0.0001963052
in O 0 0.00026032762
systolic O 0 0.5226632
blood O 0 0.009053312
pressure O 0 0.008574663
occurred O 0 0.00027917526
in O 0 0.0003374168
the O 0 0.00058232225
diabetic B-Disease 2 0.99898106
subjects O 0 0.002358489
with O 0 0.003963851
autonomic B-Disease 0 0.99718565
neuropathy I-Disease 0 0.99998665
. O 0 0.00815238

It O 0 0.0048264414
is O 0 0.0026169093
therefore O 0 0.0017575909
suggested O 0 0.0010621328
that O 0 0.0007748252
caution O 0 0.00078572554
should O 0 0.00041663804
be O 0 0.00046788607
exercised O 0 0.00093421637
when O 0 0.00032177687
prescribing O 0 0.008182762
vasodilator O 0 0.9570745
drugs O 0 0.24126294
in O 0 0.0006641643
diabetic B-Disease 2 0.9997557
patients O 0 0.0018314038
, O 0 0.00079745566
particularly O 0 0.0011567214
those O 0 0.0013314525
with O 0 0.003237274
autonomic B-Disease 0 0.99686986
neuropathy I-Disease 0 0.9999865
. O 0 0.008344241

Blood O 0 0.03844646
pressure O 0 0.019504437
response O 0 0.00280085
to O 0 0.001837014
chronic O 0 0.6892148
low O 0 0.0072445516
- O 0 0.056739513
dose O 0 0.060442165
intrarenal O 0 0.9909462
noradrenaline B-Chemical 1 0.9999782
infusion O 0 0.008934166
in O 0 0.0021164226
conscious O 0 0.009810082
rats O 0 0.0051178066
. O 0 0.0068955915

Sodium B-Chemical 0 0.99999094
chloride I-Chemical 0 0.9999832
solution O 0 0.24978733
( O 0 0.0029729796
0 O 0 0.0010732148
. O 0 0.00061237806
9 O 0 0.0004977185
% O 0 0.0005555967
) O 0 0.00080116274
or O 0 0.0006667696
noradrenaline B-Chemical 1 0.9998894
in O 0 0.00030669564
doses O 0 0.0009786927
of O 0 0.00030911807
4 O 0 0.00019496477
, O 0 0.00022924996
12 O 0 0.00013082828
and O 0 0.0001557223
36 O 0 0.00017535943
micrograms O 0 0.0009586383
h O 0 0.00030817703
- O 0 0.0024477364
1 O 0 0.00018900837
kg O 0 0.0006233075
- O 0 0.0020429825
1 O 0 0.00017442339
was O 0 0.00014986785
infused O 0 0.00020156265
for O 0 0.00011938504
five O 0 9.4842784e-05
consecutive O 0 0.000106540356
days O 0 0.000106203704
, O 0 0.00020615279
either O 0 0.0001965365
intrarenally O 0 0.2002126
( O 0 0.00037353573
by O 0 0.0002030423
a O 0 0.00023833755
new O 0 0.0002627895
technique O 0 0.00034370477
) O 0 0.00045123254
or O 0 0.0002620174
intravenously O 0 0.00035177162
into O 0 0.00027160742
rats O 0 0.0006400153
with O 0 0.000802815
one O 0 0.0012768194
kidney O 0 0.1380764
removed O 0 0.00355349
. O 0 0.0066130236

Intrarenal O 0 0.76312995
infusion O 0 0.018259704
of O 0 0.0100800935
noradrenaline B-Chemical 1 0.9999747
caused O 0 0.015529258
hypertension B-Disease 2 0.9999968
at O 0 0.00094493816
doses O 0 0.00536428
which O 0 0.0008470353
did O 0 0.0006638782
not O 0 0.00058007403
do O 0 0.00073419214
so O 0 0.000867296
when O 0 0.001106078
infused O 0 0.0029796695
intravenously O 0 0.0040656864
. O 0 0.006218822

Intrarenal O 0 0.43524197
compared O 0 0.0017539179
with O 0 0.0016459367
intravenous O 0 0.0551633
infusion O 0 0.007865037
of O 0 0.0041440018
noradrenaline B-Chemical 1 0.9999764
caused O 0 0.0007483421
higher O 0 0.0009838323
plasma O 0 0.4544523
noradrenaline B-Chemical 1 0.9999757
concentrations O 0 0.0022832854
and O 0 0.0003101947
a O 0 0.00029721737
shift O 0 0.00052500656
of O 0 0.00029108822
the O 0 0.00035102942
plasma O 0 0.375232
noradrenaline B-Chemical 1 0.9999777
concentration O 0 0.00790006
- O 0 0.037415333
blood O 0 0.011659993
pressure O 0 0.010437814
effect O 0 0.00026557062
curve O 0 0.0005135633
towards O 0 0.0007098591
lower O 0 0.001190986
plasma O 0 0.2693183
noradrenaline B-Chemical 1 0.9997851
levels O 0 0.00368434
. O 0 0.0063639325

These O 0 0.0034309144
results O 0 0.002066689
suggest O 0 0.0012885339
that O 0 0.0016877296
hypertension B-Disease 2 0.9999901
after O 0 0.0008721087
chronic O 0 0.9778942
intrarenal O 0 0.9983901
noradrenaline B-Chemical 1 0.9999958
infusion O 0 0.0061142244
is O 0 0.00022919859
produced O 0 0.00016538179
by O 0 0.00019614991
relatively O 0 0.00028279173
higher O 0 0.00018990222
levels O 0 0.00019527045
of O 0 0.0004461667
circulating O 0 0.18887599
noradrenaline B-Chemical 1 0.9999633
and O 0 0.00040364682
by O 0 0.0003242837
triggering O 0 0.00046708263
of O 0 0.000641465
an O 0 0.00085626036
additional O 0 0.00094113976
intrarenal O 0 0.7562985
pressor O 0 0.8337381
mechanism O 0 0.0035791185
. O 0 0.0068656476

Characterization O 0 0.0055300775
of O 0 0.010847165
estrogen B-Chemical 1 0.9999652
- O 0 0.24084374
induced O 0 0.0075522033
adenohypophyseal B-Disease 0 0.9978429
tumors I-Disease 0 0.998747
in O 0 0.003010173
the O 0 0.0033086827
Fischer O 0 0.09975718
344 O 0 0.026220372
rat O 0 0.0096675595
. O 0 0.010192734

Pituitary B-Disease 0 0.9826575
tumors I-Disease 0 0.99081963
were O 0 0.002422569
induced O 0 0.0017159143
in O 0 0.0015478898
F344 O 0 0.38215977
female O 0 0.004643322
rats O 0 0.0009847945
by O 0 0.0005450215
chronic O 0 0.67451835
treatment O 0 0.0036322933
with O 0 0.024128575
diethylstilbestrol B-Chemical 0 0.9999995
( O 0 0.16686586
DES B-Chemical 0 0.9999517
, O 0 0.0011438967
8 O 0 0.00035615498
- O 0 0.0012516379
10 O 0 0.00034434858
mg O 0 0.003194098
) O 0 0.00076611893
implanted O 0 0.0009499006
subcutaneously O 0 0.0009768793
in O 0 0.0015213449
silastic O 0 0.019367913
capsules O 0 0.012060833
. O 0 0.0068988833

Over O 0 0.004164923
a O 0 0.0026662278
range O 0 0.0017115786
of O 0 0.001533477
1 O 0 0.0012023505
- O 0 0.0021605932
150 O 0 0.00063991523
days O 0 0.0003775447
of O 0 0.0008967359
DES B-Chemical 0 0.99963176
treatment O 0 0.0008334543
, O 0 0.000458136
pairs O 0 0.0002642789
of O 0 0.00031042608
control O 0 0.00039114626
and O 0 0.003479778
DES B-Chemical 0 0.99996173
- O 0 0.037477795
treated O 0 0.0003620286
rats O 0 0.00029491718
were O 0 0.00017106383
sacrificed O 0 0.00017267046
, O 0 0.00026399485
and O 0 0.00025207014
their O 0 0.0002960816
pituitaries O 0 0.0024279025
dissociated O 0 0.0004765259
enzymatically O 0 0.0020722896
into O 0 0.0004719808
single O 0 0.0010701438
- O 0 0.0047782054
cell O 0 0.0048720804
preparations O 0 0.0051236106
. O 0 0.0069394335

The O 0 0.0031893842
cell O 0 0.0033179873
populations O 0 0.0019415645
were O 0 0.00093639037
examined O 0 0.0004941026
regarding O 0 0.00037088443
total O 0 0.00036259438
cell O 0 0.0009868535
recovery O 0 0.00060117256
correlated O 0 0.00021950461
with O 0 0.0002857355
gland O 0 0.018331466
weight O 0 0.0054143416
, O 0 0.00083742576
intracellular O 0 0.017648587
prolactin O 0 0.9994592
( O 0 0.069866724
PRL O 0 0.9999893
) O 0 0.0030819937
content O 0 0.0002534317
and O 0 0.00020644943
subsequent O 0 0.00018485945
release O 0 0.00075269013
in O 0 0.00017512732
primary O 0 0.0002432426
culture O 0 0.0008388577
, O 0 0.00051493867
immunocytochemical O 0 0.051875804
PRL O 0 0.99996984
staining O 0 0.0064007486
, O 0 0.00041018266
density O 0 0.0005537431
and O 0 0.00031865019
/ O 0 0.0018231068
or O 0 0.00017154455
size O 0 0.00022978918
alterations O 0 0.00037022875
via O 0 0.00011925624
separation O 0 0.00022867405
on O 0 0.0001337878
Ficoll O 0 0.1421969
- O 0 0.048274804
Hypaque O 0 0.94076926
and O 0 0.00024231807
by O 0 0.00017867853
unit O 0 0.0001669736
gravity O 0 0.005517091
sedimentation O 0 0.008959268
, O 0 0.00035910157
and O 0 0.0002746591
cell O 0 0.00076170533
cycle O 0 0.0006203561
analysis O 0 0.00032302414
, O 0 0.00044302669
after O 0 0.00032701204
acriflavine B-Chemical 0 0.99975365
DNA O 0 0.3139078
staining O 0 0.0020020735
, O 0 0.0011970263
by O 0 0.0013608813
laser O 0 0.010270651
flow O 0 0.005921332
cytometry O 0 0.0057639335
. O 0 0.0075550666

Total O 0 0.0039380193
cell O 0 0.0041412655
yields O 0 0.0031195176
from O 0 0.0022437088
DES B-Chemical 0 0.999887
- O 0 0.048488785
treated O 0 0.0010490038
pituitaries O 0 0.0182036
increased O 0 0.00048977166
from O 0 0.00030132858
1 O 0 0.00028205232
. O 0 0.00020300961
3 O 0 0.0001579356
times O 0 0.00011478464
control O 0 0.00015740894
yields O 0 0.00022965731
at O 0 0.00015374641
8 O 0 0.00015114105
days O 0 0.00012128891
of O 0 0.00019504437
treatment O 0 0.0002453959
to O 0 0.00021242708
58 O 0 0.00039867358
. O 0 0.0002605146
9 O 0 0.000283261
times O 0 0.00026225732
control O 0 0.00048484097
values O 0 0.0007613577
by O 0 0.0013173793
day O 0 0.001906757
150 O 0 0.0037881522
. O 0 0.006081314

Intracellular O 0 0.054027785
PRL O 0 0.9994618
content O 0 0.0022890696
ranged O 0 0.0011473922
from O 0 0.0008174232
1 O 0 0.00067522476
. O 0 0.00046318077
9 O 0 0.00036812414
to O 0 0.00028319756
9 O 0 0.00028788313
. O 0 0.00022546943
4 O 0 0.0001758428
times O 0 0.00012799195
control O 0 0.00018160431
levels O 0 0.00022262002
, O 0 0.00048466443
and O 0 0.0018759988
PRL O 0 0.9999776
release O 0 0.016391696
in O 0 0.00029555644
vitro O 0 0.00038685993
was O 0 0.00021666817
significantly O 0 0.00018812683
and O 0 0.0002049977
consistently O 0 0.00020484882
higher O 0 0.00017722828
than O 0 0.00014716672
controls O 0 0.00032690915
, O 0 0.00030590402
after O 0 0.00018667856
at O 0 0.00025873238
least O 0 0.00030483466
8 O 0 0.00049666426
days O 0 0.0006761691
of O 0 0.0021484012
DES B-Chemical 0 0.99896526
exposure O 0 0.059280917
. O 0 0.008237087

Beyond O 0 0.0055221613
8 O 0 0.0024975024
days O 0 0.0015458453
of O 0 0.002446429
DES B-Chemical 0 0.9994072
exposure O 0 0.024564574
, O 0 0.0014901053
the O 0 0.0009294474
immunochemically O 0 0.9703602
PRL O 0 0.99999285
- O 0 0.05404042
positive O 0 0.0005067313
proportion O 0 0.00028622657
of O 0 0.00036662936
cells O 0 0.00041410982
increased O 0 0.00036134815
to O 0 0.00028460505
over O 0 0.000282231
50 O 0 0.00051781314
% O 0 0.0006764907
of O 0 0.00090350315
the O 0 0.0012194547
total O 0 0.0019009165
population O 0 0.0053495015
. O 0 0.006926961

Increased O 0 0.0042419476
density O 0 0.0034209671
and O 0 0.0023383708
/ O 0 0.004020984
or O 0 0.0009940304
size O 0 0.0011790212
and O 0 0.002535232
PRL O 0 0.99992347
content O 0 0.0007246061
were O 0 0.0003259892
indicated O 0 0.00020575576
for O 0 0.00021281061
the O 0 0.00020839926
majority O 0 0.00022615581
of O 0 0.00035923164
the O 0 0.00071612315
PRL O 0 0.99993277
cell O 0 0.0072791334
population O 0 0.0012692936
in O 0 0.00050426717
both O 0 0.0005977998
types O 0 0.0007779437
of O 0 0.0015280333
separation O 0 0.003050647
protocols O 0 0.003678848
. O 0 0.0066120243

All O 0 0.00390958
these O 0 0.0034285055
effects O 0 0.003311179
of O 0 0.0044507915
DES B-Chemical 0 0.9993405
were O 0 0.0021856783
more O 0 0.0019799364
pronounced O 0 0.0025983688
among O 0 0.002620743
previously O 0 0.0031367394
ovariectomized O 0 0.12151994
animals O 0 0.0051513473
. O 0 0.008922164

The O 0 0.0031513462
data O 0 0.0021972386
extend O 0 0.0012265216
the O 0 0.001020724
findings O 0 0.0009852401
of O 0 0.0007886111
other O 0 0.0006334365
investigators O 0 0.00048090398
, O 0 0.0005007639
further O 0 0.0002987341
establishing O 0 0.0005363718
the O 0 0.0011552899
DES B-Chemical 0 0.99994624
- O 0 0.037991468
induced O 0 0.0005009868
tumor B-Disease 0 0.8311814
as O 0 0.0003432008
a O 0 0.0003868535
model O 0 0.00035581982
for O 0 0.0004163478
study O 0 0.00079827145
of O 0 0.0018539309
PRL O 0 0.99980634
cellular O 0 0.0073217424
control O 0 0.0026133484
mechanisms O 0 0.00387582
. O 0 0.007030542

Age O 0 0.07997764
and O 0 0.015762072
renal O 0 0.82040834
clearance O 0 0.43309972
of O 0 0.09360224
cimetidine B-Chemical 1 0.99998343
. O 0 0.03481972

In O 0 0.0038371412
35 O 0 0.00269567
patients O 0 0.0020932844
( O 0 0.0015935017
ages O 0 0.0010409198
20 O 0 0.00065412465
to O 0 0.0004524243
86 O 0 0.0006295537
yr O 0 0.00058891065
) O 0 0.00085931265
receiving O 0 0.0018251662
cimetidine B-Chemical 1 0.99999833
therapeutically O 0 0.030402403
two O 0 0.0002215885
serum O 0 0.05762447
samples O 0 0.00023147621
and O 0 0.00022657841
all O 0 0.00019252945
urine O 0 0.05056791
formed O 0 0.00020127073
in O 0 0.00015466097
the O 0 0.0001542536
interim O 0 0.0007804794
were O 0 0.0001437459
collected O 0 0.00011321234
for O 0 0.00014055756
analysis O 0 0.00021146375
of O 0 0.0007282888
cimetidine B-Chemical 1 0.9999981
by O 0 0.00058091665
high O 0 0.0013566586
- O 0 0.017835746
pressure O 0 0.050620493
liquid O 0 0.0028237605
chromatography O 0 0.00322544
and O 0 0.0014608782
for O 0 0.0024914306
creatinine B-Chemical 1 0.99190825
. O 0 0.0075584077

Cimetidine B-Chemical 0 0.9998155
clearance O 0 0.2980774
decreased O 0 0.019091193
with O 0 0.017314611
age O 0 0.02732709
. O 0 0.027129548

The O 0 0.0029136862
extrapolated O 0 0.0021284586
6 O 0 0.0015635996
- O 0 0.0036422056
hr O 0 0.001789815
serum O 0 0.07613195
concentration O 0 0.0030693016
of O 0 0.004415688
cimetidine B-Chemical 1 0.9999981
per O 0 0.00027716655
unit O 0 0.00026667406
dose O 0 0.0011511523
, O 0 0.00045583068
after O 0 0.00025636452
intravenous O 0 0.5219255
cimetidine B-Chemical 1 0.99999905
, O 0 0.0014603531
increased O 0 0.0006459564
with O 0 0.0007390209
age O 0 0.0014481071
of O 0 0.0015580761
the O 0 0.0022117263
patients O 0 0.0052776323
. O 0 0.0063746995

The O 0 0.0031099145
ratio O 0 0.0028265289
of O 0 0.0039763716
cimetidine B-Chemical 1 0.9999958
clearance O 0 0.31924373
to O 0 0.001181668
creatinine B-Chemical 1 0.9994293
clearance O 0 0.29136488
( O 0 0.007845279
Rc O 0 0.9556373
) O 0 0.00051794475
averaged O 0 0.00018671095
4 O 0 0.00019361409
. O 0 0.00019541274
8 O 0 0.00022531877
+ O 0 0.0006761578
/ O 0 0.0049222633
- O 0 0.006750615
2 O 0 0.00031475048
. O 0 0.00029375544
0 O 0 0.0003808765
, O 0 0.00047986273
indicating O 0 0.00045256017
net O 0 0.001000268
tubular O 0 0.2145372
secretion O 0 0.024954148
for O 0 0.009843096
cimetidine B-Chemical 1 0.9999927
. O 0 0.011335696

Rc O 0 0.9164163
seemed O 0 0.0031033398
to O 0 0.0015064131
be O 0 0.0010892039
independent O 0 0.0006443494
of O 0 0.0007764645
age O 0 0.0012265239
and O 0 0.0005784925
decreased O 0 0.00050642516
with O 0 0.00037997653
increasing O 0 0.00041589915
serum O 0 0.23552455
concentration O 0 0.0060665975
of O 0 0.014847647
cimetidine B-Chemical 1 0.99999964
, O 0 0.0015236137
suggesting O 0 0.00026404543
that O 0 0.00029732875
secretion O 0 0.00251499
of O 0 0.009637397
cimetidine B-Chemical 1 0.99999845
is O 0 0.0020592727
a O 0 0.0024311256
saturable O 0 0.099120855
process O 0 0.0049093617
. O 0 0.007220031

There O 0 0.0042798137
was O 0 0.002672434
only O 0 0.0018379163
one O 0 0.0011486564
case O 0 0.0010798265
of O 0 0.0022346317
dementia B-Disease 0 0.9999795
possibly O 0 0.0028202932
due O 0 0.00032561523
to O 0 0.0006054346
cimetidine B-Chemical 1 0.99999917
( O 0 0.0017602493
with O 0 0.0003374921
a O 0 0.0003535847
drug O 0 0.048803695
level O 0 0.00015331719
of O 0 0.00025874987
1 O 0 0.00019694847
. O 0 0.00015014474
9 O 0 0.00015914725
microgram O 0 0.0065418826
/ O 0 0.0013124851
ml O 0 0.00042676262
6 O 0 0.00013330861
hr O 0 0.00020384442
after O 0 0.000105674044
a O 0 0.00019787304
dose O 0 0.0009602691
) O 0 0.0005069746
in O 0 0.00018441299
a O 0 0.00023032482
group O 0 0.00022012812
of O 0 0.0002090313
13 O 0 0.00020206258
patients O 0 0.00021437305
without O 0 0.00020078769
liver B-Disease 0 0.47934097
or I-Disease 0 0.00062787614
kidney I-Disease 0 0.93486696
disease I-Disease 0 0.98546463
who O 0 0.004762047
had O 0 0.00086414616
cimetidine B-Chemical 1 0.9999976
levels O 0 0.00041769206
above O 0 0.00034153802
1 O 0 0.00045271355
. O 0 0.00057011674
25 O 0 0.0010712296
microgram O 0 0.02113426
/ O 0 0.006046413
ml O 0 0.0064746547
. O 0 0.0072203763

Thus O 0 0.00602668
, O 0 0.006270969
high O 0 0.010664458
cimetidine B-Chemical 1 0.9999925
levels O 0 0.0033095411
alone O 0 0.0025180038
do O 0 0.0022390173
not O 0 0.002197693
always O 0 0.0033565816
induce O 0 0.004559218
dementia B-Disease 0 0.9998876
. O 0 0.0125412885

Further O 0 0.005033324
observations O 0 0.0035020355
on O 0 0.0023339076
the O 0 0.002513031
electrophysiologic O 0 0.023805978
effects O 0 0.0032801754
of O 0 0.0052670166
oral O 0 0.9688467
amiodarone B-Chemical 1 0.9999902
therapy O 0 0.079313055
. O 0 0.010662698

A O 0 0.054914173
case O 0 0.003163169
is O 0 0.0018053278
presented O 0 0.0011325199
of O 0 0.0010723487
a O 0 0.0011445611
reversible O 0 0.08453304
intra B-Disease 0 0.035667643
- I-Disease 0 0.026512912
Hisian I-Disease 0 0.03749335
block I-Disease 0 0.00026818734
occurring O 0 0.00037156392
under O 0 0.000306489
amiodarone B-Chemical 1 0.9999896
treatment O 0 0.0009673389
for O 0 0.00064728904
atrial B-Disease 0 0.9991295
tachycardia I-Disease 2 0.9999809
in O 0 0.0003450469
a O 0 0.0003877039
patient O 0 0.0004054464
without O 0 0.00050477317
clear O 0 0.00092733064
intraventricular B-Disease 0 0.9247472
conduction I-Disease 0 0.027954787
abnormalities I-Disease 0 0.2693921
. O 0 0.006086261

His O 0 0.007158466
bundle O 0 0.0040076505
recordings O 0 0.0023012715
showed O 0 0.001383643
an O 0 0.0020661573
atrial B-Disease 0 0.9986928
tachycardia I-Disease 2 0.99998605
with O 0 0.0009840375
intermittent O 0 0.0035646774
exit O 0 0.0005793618
block O 0 0.00026237586
and O 0 0.00029832768
greatly O 0 0.00066986895
prolonged O 0 0.0011305361
BH O 0 0.5325075
and O 0 0.00046014268
HV O 0 0.05273643
intervals O 0 0.00022432693
( O 0 0.0003828065
40 O 0 0.00035161152
and O 0 0.00048183178
100 O 0 0.000884979
msec O 0 0.0024221968
, O 0 0.0019820228
respectively O 0 0.0042531043
) O 0 0.00620621
. O 0 0.007580484

Thirty O 0 0.004920811
days O 0 0.0021739595
after O 0 0.001918243
amiodarone B-Chemical 1 0.99997973
discontinuation O 0 0.9010713
, O 0 0.001517356
His O 0 0.0015073487
bundle O 0 0.0009417721
electrograms O 0 0.0065647154
showed O 0 0.00041801253
atrial B-Disease 0 0.50471485
flutter I-Disease 0 0.8491175
without O 0 0.00040400174
intra O 0 0.003822431
- O 0 0.0060293176
Hisian O 0 0.03842482
or O 0 0.0009544407
infra O 0 0.015176386
- O 0 0.01140625
Hisian O 0 0.09399053
delay O 0 0.005161611
. O 0 0.007297923

Amiodarone B-Chemical 1 0.99990666
should O 0 0.0020813132
be O 0 0.0014674305
used O 0 0.00089559134
with O 0 0.0007082097
caution O 0 0.0005750953
during O 0 0.0003667379
long O 0 0.00050979055
- O 0 0.0031404481
term O 0 0.00039805615
oral O 0 0.08465435
therapy O 0 0.0007972517
in O 0 0.00031203995
patients O 0 0.00045518944
with O 0 0.00037597565
or O 0 0.0004402989
without O 0 0.0006361172
clear O 0 0.0010926473
intraventricular O 0 0.72328746
conduction O 0 0.009727098
defects O 0 0.0054310285
. O 0 0.0064770714

Development O 0 0.010715729
of O 0 0.0044763824
clear B-Disease 0 0.0042728814
cell I-Disease 0 0.03509605
adenocarcinoma I-Disease 0 0.99995935
in O 0 0.0266796
DES B-Chemical 0 0.99992037
- O 0 0.044699617
exposed O 0 0.0031483306
offspring O 0 0.0060195797
under O 0 0.0035460198
observation O 0 0.0063389093
. O 0 0.009945299

Two O 0 0.0038125953
cases O 0 0.0029258637
of O 0 0.0021629333
clear B-Disease 0 0.0021151016
cell I-Disease 0 0.017090196
adenocarcinoma I-Disease 0 0.99992144
of I-Disease 0 0.0015726328
the I-Disease 0 0.00067450124
vagina I-Disease 0 0.012846212
detected O 0 0.00030984977
at O 0 0.0002522211
follow O 0 0.00023100154
- O 0 0.001151755
up O 0 0.00024995644
in O 0 0.00029262784
young O 0 0.0024649573
women O 0 0.0022673274
exposed O 0 0.0005800801
in O 0 0.00061476656
utero O 0 0.017273515
to O 0 0.001905177
diethylstilbestrol B-Chemical 0 0.9999809
are O 0 0.0030711317
reported O 0 0.0049351538
. O 0 0.006708936

One O 0 0.0050074896
patient O 0 0.0030057386
, O 0 0.0025745044
aged O 0 0.002195279
23 O 0 0.0016141129
, O 0 0.0010776946
had O 0 0.0005773327
been O 0 0.0004281852
followed O 0 0.0003050518
for O 0 0.00030928198
2 O 0 0.00027274218
years O 0 0.00029446205
before O 0 0.00022416595
carcinoma B-Disease 2 0.9995345
was O 0 0.00041006497
diagnosed O 0 0.004129832
; O 0 0.00046766983
the O 0 0.00018627495
second O 0 0.00018990003
patient O 0 0.0002439633
, O 0 0.00030865867
aged O 0 0.00039663288
22 O 0 0.00028317218
, O 0 0.00026387558
had O 0 0.00019427836
been O 0 0.00019609251
seen O 0 0.00019062514
on O 0 0.00017251694
a O 0 0.0003009163
regular O 0 0.00031549044
basis O 0 0.00034617254
for O 0 0.000406614
5 O 0 0.0005207403
years O 0 0.0009449224
, O 0 0.0015310658
8 O 0 0.0018632681
months O 0 0.0026736225
. O 0 0.0059762946

In O 0 0.0036100277
both O 0 0.0021870285
instances O 0 0.0014483057
, O 0 0.0018107091
suspicion O 0 0.008879644
of O 0 0.0010290978
the O 0 0.0006204355
presence O 0 0.000588286
of O 0 0.0020937717
carcinoma B-Disease 2 0.9999614
was O 0 0.00081870094
aroused O 0 0.002103404
by O 0 0.00032732956
the O 0 0.00032385672
palpation O 0 0.0049142954
of O 0 0.00045983007
a O 0 0.0005603654
small O 0 0.0006759623
nodule O 0 0.16826889
in O 0 0.001130821
the O 0 0.0017123838
vaginal O 0 0.037200898
fornix O 0 0.43550998
. O 0 0.006948015

Hysterosalpingography O 0 0.0076964875
was O 0 0.0022613765
performed O 0 0.0012732652
on O 0 0.0008239477
both O 0 0.00081229996
patients O 0 0.0009547745
and O 0 0.00071862875
, O 0 0.00071905483
in O 0 0.00040386562
1 O 0 0.00033014704
instance O 0 0.00028180156
, O 0 0.00040099278
an O 0 0.00034438795
abnormal O 0 0.005838333
x O 0 0.021860458
- O 0 0.07588558
ray O 0 0.36242613
film O 0 0.003413507
was O 0 0.00023463102
reflected O 0 0.00018089091
by O 0 0.00019582457
the O 0 0.00019101065
gross O 0 0.00049913407
appearance O 0 0.0005738764
of O 0 0.00036893325
the O 0 0.00038767603
uterine O 0 0.033485916
cavity O 0 0.0011255828
found O 0 0.000585651
in O 0 0.0008382704
the O 0 0.0012732864
surgical O 0 0.0027158686
specimen O 0 0.004367146
. O 0 0.006495198

Neurologic O 0 0.4375273
effects O 0 0.0036087807
of O 0 0.0034388115
subarachnoid O 0 0.9978021
administration O 0 0.016607696
of O 0 0.001194717
2 B-Chemical 0 0.0010448069
- I-Chemical 0 0.21070375
chloroprocaine I-Chemical 0 0.9999542
- I-Chemical 0 0.3614069
CE I-Chemical 0 0.99968696
, O 0 0.014823917
bupivacaine B-Chemical 1 0.99997497
, O 0 0.00079953147
and O 0 0.00059217383
low O 0 0.00096837763
pH O 0 0.052963138
normal O 0 0.0019478888
saline O 0 0.007832401
in O 0 0.0025452091
dogs O 0 0.006031524
. O 0 0.006749339

The O 0 0.0031086288
purpose O 0 0.0021922472
of O 0 0.0017141675
this O 0 0.0011806053
study O 0 0.0010146231
was O 0 0.0005869243
to O 0 0.0003586874
evaluate O 0 0.00020938517
the O 0 0.00031973474
neurologic O 0 0.74618816
consequences O 0 0.0005266505
of O 0 0.0005101896
deliberate O 0 0.17745547
subarachnoid O 0 0.99823654
injection O 0 0.00038579278
of O 0 0.00021691664
large O 0 0.0002243244
volumes O 0 0.0003279271
of O 0 0.0004149525
2 B-Chemical 0 0.00057516043
- I-Chemical 0 0.12402946
chloroprocaine I-Chemical 0 0.99986005
- I-Chemical 0 0.08820557
CE I-Chemical 0 0.99158996
in O 0 0.0016816972
experimental O 0 0.0025477163
animals O 0 0.0035139536
. O 0 0.0067070867

The O 0 0.0030152088
possible O 0 0.0020475434
role O 0 0.0012317805
of O 0 0.0013894704
low O 0 0.0016306746
pH O 0 0.054538094
as O 0 0.00058088504
well O 0 0.00043051108
as O 0 0.000353137
total O 0 0.00029968403
volume O 0 0.000496861
as O 0 0.00033595716
potential O 0 0.00048441454
factors O 0 0.0015588991
in O 0 0.0009944869
causing O 0 0.030276313
neurotoxicity B-Disease 2 0.9999608
was O 0 0.0030649146
evaluated O 0 0.0035405012
. O 0 0.0066586705

The O 0 0.0032485132
65 O 0 0.002687552
dogs O 0 0.0021694389
in O 0 0.0011301048
the O 0 0.0008048548
study O 0 0.0007166174
received O 0 0.00039232784
injections O 0 0.0005602001
in O 0 0.00030007
the O 0 0.00036024128
subarachnoid O 0 0.9848562
space O 0 0.00023902755
as O 0 0.00016805062
follows O 0 0.00021318044
: O 0 0.00027031987
6 O 0 0.000118077616
to O 0 0.00011489195
8 O 0 0.00013485434
ml O 0 0.0002545932
of O 0 0.0005392102
bupivacaine B-Chemical 1 0.99998474
( O 0 0.0049852394
N O 0 0.9988299
= O 0 0.0014828728
15 O 0 0.00019146106
) O 0 0.00036382306
, O 0 0.00033726808
2 B-Chemical 0 0.00030474516
- I-Chemical 0 0.073443994
chloroprocaine I-Chemical 0 0.9999001
- I-Chemical 0 0.21272387
CE I-Chemical 0 0.9995504
( O 0 0.007128
N O 0 0.9988549
= O 0 0.0016325465
20 O 0 0.00024121553
) O 0 0.00036699724
, O 0 0.0002767066
low O 0 0.00032731768
pH O 0 0.039506204
normal O 0 0.0004891729
saline O 0 0.007663778
( O 0 0.0004489971
pH O 0 0.027502581
3 O 0 0.00017762858
. O 0 0.00017272531
0 O 0 0.00023946895
) O 0 0.00048616758
( O 0 0.00090536324
N O 0 0.9969215
= O 0 0.0015083222
20 O 0 0.00033132377
) O 0 0.0005251117
, O 0 0.00043000805
or O 0 0.00038196315
normal O 0 0.0009264505
saline O 0 0.020725701
( O 0 0.0021779723
N O 0 0.9899177
= O 0 0.004085688
10 O 0 0.0027863306
) O 0 0.0055722836
. O 0 0.0076119443

Of O 0 0.0045722187
the O 0 0.0023614822
20 O 0 0.0015644468
animals O 0 0.00094193907
that O 0 0.00072538963
received O 0 0.0007490859
subarachnoid O 0 0.9920277
injection O 0 0.0009484893
of O 0 0.00060863746
2 B-Chemical 0 0.00066550635
- I-Chemical 0 0.17257877
chloroprocaine I-Chemical 0 0.99993396
- I-Chemical 0 0.14829127
CE I-Chemical 0 0.99620384
seven O 0 0.00040013265
( O 0 0.0005398909
35 O 0 0.00047067276
% O 0 0.00067257066
) O 0 0.0011476984
developed O 0 0.0019089563
hind O 0 0.5823382
- O 0 0.06892067
limb O 0 0.71920395
paralysis B-Disease 2 0.9997906
. O 0 0.01062427

None O 0 0.0060101217
of O 0 0.002730881
the O 0 0.0015758827
animals O 0 0.0010042087
that O 0 0.0007804504
received O 0 0.001032992
bupivacaine B-Chemical 1 0.9999814
, O 0 0.0014862799
normal O 0 0.0011729723
saline O 0 0.015766645
, O 0 0.00040702426
or O 0 0.0002354555
normal O 0 0.00039115094
saline O 0 0.0015610089
titrated O 0 0.00028564347
to O 0 0.0002023286
a O 0 0.0003709615
pH O 0 0.019242069
3 O 0 0.00033882968
. O 0 0.00040451292
0 O 0 0.00065463857
developed O 0 0.0013432071
hind O 0 0.45192188
- O 0 0.057778113
limb O 0 0.71204615
paralysis B-Disease 2 0.9997999
. O 0 0.010286631

Of O 0 0.004326767
the O 0 0.0023059084
15 O 0 0.0016291613
spinal O 0 0.002542586
cords O 0 0.002416758
of O 0 0.00076927285
the O 0 0.00048477048
animals O 0 0.00033479717
that O 0 0.00027545268
received O 0 0.00028925214
2 B-Chemical 0 0.00045986558
- I-Chemical 0 0.15739456
chloroprocaine I-Chemical 0 0.9999522
- I-Chemical 0 0.27248073
CE I-Chemical 0 0.99898916
, O 0 0.00061596744
13 O 0 0.00030643324
showed O 0 0.00033202165
subpial B-Disease 0 0.9945485
necrosis I-Disease 2 0.99999
; O 0 0.0023349072
the O 0 0.000429998
nerve O 0 0.032041546
roots O 0 0.0028691671
and O 0 0.0012587492
subarachnoid O 0 0.99564785
vessels O 0 0.018134575
were O 0 0.0022331679
normal O 0 0.0042520384
. O 0 0.0064610434

The O 0 0.003315642
spinal O 0 0.005194299
cords O 0 0.0042883568
of O 0 0.0012928735
the O 0 0.0007646063
animals O 0 0.0005077973
that O 0 0.00041891722
received O 0 0.00057369104
bupivacaine B-Chemical 1 0.9999671
, O 0 0.0007787596
low O 0 0.00063982315
pH O 0 0.09229424
normal O 0 0.00066464714
saline O 0 0.010872355
( O 0 0.0005368323
pH O 0 0.035340015
3 O 0 0.00021228657
. O 0 0.0002106686
0 O 0 0.00028830775
) O 0 0.00046798133
, O 0 0.00041283589
or O 0 0.0003575711
normal O 0 0.00078231003
saline O 0 0.0052907206
did O 0 0.0006824319
not O 0 0.00076753594
show O 0 0.001166682
abnormal O 0 0.006158421
findings O 0 0.0051986645
. O 0 0.0068117855

Procainamide B-Chemical 0 0.9997918
- O 0 0.066448346
induced O 0 0.017647827
polymorphous O 0 0.99737203
ventricular B-Disease 2 0.9997582
tachycardia I-Disease 2 0.9999659
. O 0 0.02823704

Seven O 0 0.0076842327
cases O 0 0.005366321
of O 0 0.007931455
procainamide B-Chemical 1 0.9999901
- O 0 0.11718531
induced O 0 0.0046692207
polymorphous O 0 0.99854445
ventricular B-Disease 2 0.9998597
tachycardia I-Disease 2 0.9999808
are O 0 0.0046244715
presented O 0 0.0052450504
. O 0 0.008416527

In O 0 0.003544049
four O 0 0.0019339169
patients O 0 0.002092731
, O 0 0.0023403408
polymorphous O 0 0.98801905
ventricular B-Disease 2 0.9998223
tachycardia I-Disease 2 0.9999949
appeared O 0 0.0007338773
after O 0 0.00023409164
intravenous O 0 0.009421459
administration O 0 0.000985659
of O 0 0.00026197542
200 O 0 0.00029313043
to O 0 0.00016038086
400 O 0 0.00040754458
mg O 0 0.007328181
of O 0 0.000677597
procainamide B-Chemical 1 0.9999759
for O 0 0.00036355073
the O 0 0.00041416485
treatment O 0 0.00069382257
of O 0 0.0013494336
sustained O 0 0.061391093
ventricular B-Disease 2 0.9996493
tachycardia I-Disease 2 0.9999763
. O 0 0.008318409

In O 0 0.00347809
the O 0 0.0020457658
remaining O 0 0.0014403076
three O 0 0.0008444766
patients O 0 0.0015964312
, O 0 0.004157963
procainamide B-Chemical 1 0.99998987
was O 0 0.00065861514
administered O 0 0.00041180116
orally O 0 0.0006688766
for O 0 0.000280343
treatment O 0 0.0004188909
of O 0 0.0007352193
chronic O 0 0.92775154
premature B-Disease 0 0.7425082
ventricular I-Disease 0 0.98401076
contractions I-Disease 0 0.91344124
or O 0 0.0024224056
atrial B-Disease 0 0.944212
flutter I-Disease 0 0.96479404
. O 0 0.0061354167

These O 0 0.0046316762
patients O 0 0.0041779983
had O 0 0.0034185038
Q B-Disease 0 0.98021543
- I-Disease 0 0.16036549
T I-Disease 0 0.91684276
prolongation I-Disease 0 0.009485642
and O 0 0.002153955
recurrent O 0 0.75531477
syncope B-Disease 0 0.9999887
due O 0 0.0012004033
to O 0 0.0018363554
polymorphous O 0 0.9966781
ventricular B-Disease 2 0.9997744
tachycardia I-Disease 2 0.99997604
. O 0 0.009920585

In O 0 0.0038175462
four O 0 0.0021317096
patients O 0 0.0023104171
, O 0 0.0019914878
the O 0 0.001503955
arrhythmia B-Disease 2 0.9995889
was O 0 0.0008244691
rapidly O 0 0.00071301986
diagnosed O 0 0.0017837859
and O 0 0.00045190964
treated O 0 0.00044292997
with O 0 0.0004298812
disappearance O 0 0.0013188004
of O 0 0.00064932555
further O 0 0.0007291224
episodes O 0 0.0066979877
of O 0 0.0021760988
the O 0 0.0041485573
arrhythmia B-Disease 2 0.9996284
. O 0 0.008685259

In O 0 0.004127074
two O 0 0.002479909
patients O 0 0.0025652375
, O 0 0.0022121556
the O 0 0.001701039
arrhythmia B-Disease 2 0.99948716
degenerated O 0 0.012842795
into O 0 0.0006845995
irreversible O 0 0.21197209
ventricular B-Disease 0 0.98752326
fibrillation I-Disease 0 0.99998724
and O 0 0.0019853294
both O 0 0.0019693794
patients O 0 0.0040886695
died O 0 0.008906862
. O 0 0.007486882

In O 0 0.003732091
the O 0 0.0024335564
seventh O 0 0.0034524864
patient O 0 0.001588967
, O 0 0.0013663046
a O 0 0.001010439
permanent O 0 0.009647834
ventricular O 0 0.6967176
pacemaker O 0 0.016791284
was O 0 0.00031061584
inserted O 0 0.00025255897
and O 0 0.0003042975
, O 0 0.00036528063
despite O 0 0.00025778954
continuation O 0 0.0025430915
of O 0 0.0018542557
procainamide B-Chemical 1 0.9999958
therapy O 0 0.0074772993
, O 0 0.0023138523
polymorphous O 0 0.9975725
ventricular B-Disease 2 0.99983346
tachycardia I-Disease 2 0.99998844
did O 0 0.0020693494
not O 0 0.0021713122
reoccur O 0 0.0061903875
. O 0 0.005879262

These O 0 0.0036034933
seven O 0 0.0021589943
cases O 0 0.001855481
demonstrate O 0 0.0009037102
that O 0 0.0012068
procainamide B-Chemical 1 0.99997187
can O 0 0.0005906614
produce O 0 0.0004058921
an O 0 0.0005354247
acquired O 0 0.0011895807
prolonged B-Disease 0 0.008564009
Q I-Disease 0 0.9952207
- I-Disease 0 0.27380022
T I-Disease 0 0.9804258
syndrome I-Disease 0 0.79379386
with O 0 0.004139732
polymorphous O 0 0.99842393
ventricular B-Disease 2 0.9998086
tachycardia I-Disease 2 0.99997663
. O 0 0.00911564

Phenobarbitone B-Chemical 0 0.9999925
- O 0 0.08829962
induced O 0 0.0026631393
enlargement B-Disease 0 0.0951664
of I-Disease 0 0.0015498851
the I-Disease 0 0.0010663454
liver I-Disease 0 0.5391963
in O 0 0.0006303038
the O 0 0.00051127764
rat O 0 0.0012263323
: O 0 0.00070022617
its O 0 0.00059310126
relationship O 0 0.00041408336
to O 0 0.00093527173
carbon B-Chemical 0 0.9995517
tetrachloride I-Chemical 0 0.99999976
- O 0 0.5660191
induced O 0 0.036936335
cirrhosis B-Disease 0 0.9999975
. O 0 0.031915013

The O 0 0.003345348
yield O 0 0.0031527125
of O 0 0.0030685603
severe O 0 0.72609204
cirrhosis B-Disease 0 0.9999989
of I-Disease 0 0.009709917
the I-Disease 0 0.0013732087
liver I-Disease 0 0.81062204
( O 0 0.00087598787
defined O 0 0.0002475303
as O 0 0.00021329694
a O 0 0.00028584557
shrunken O 0 0.012853779
finely O 0 0.0012201361
nodular O 0 0.96418774
liver O 0 0.7448206
with O 0 0.0018755345
micronodular O 0 0.99980766
histology O 0 0.75573605
, O 0 0.0030385284
ascites B-Disease 0 0.9961385
greater O 0 0.00017597682
than O 0 0.00010830826
30 O 0 0.000115752
ml O 0 0.00026048254
, O 0 0.00027830148
plasma O 0 0.012978936
albumin O 0 0.9618728
less O 0 0.00019386588
than O 0 0.00011932963
2 O 0 0.00013968216
. O 0 0.00012982245
2 O 0 0.0001422756
g O 0 0.00036207933
/ O 0 0.002636191
dl O 0 0.1505693
, O 0 0.0022863115
splenomegaly B-Disease 0 0.99979144
2 O 0 0.00035514918
- O 0 0.0014345694
3 O 0 0.000121223464
times O 0 9.202995e-05
normal O 0 0.00020757905
, O 0 0.0002548589
and O 0 0.00036852565
testicular O 0 0.91166174
atrophy B-Disease 2 0.99983144
approximately O 0 0.00023532377
half O 0 0.00012149658
normal O 0 0.00026557496
weight O 0 0.0011800902
) O 0 0.00041227345
after O 0 0.000106867476
12 O 0 0.00011596488
doses O 0 0.00039616768
of O 0 0.0007553019
carbon B-Chemical 0 0.9998217
tetrachloride I-Chemical 0 1.0
given O 0 0.0002466304
intragastrically O 0 0.06465599
in O 0 0.00022771237
the O 0 0.0009191276
phenobarbitone B-Chemical 0 0.99999976
- O 0 0.055641055
primed O 0 0.0002669328
rat O 0 0.0012136416
was O 0 0.0001908756
increased O 0 0.00017739618
from O 0 0.0001364798
25 O 0 0.00019441344
% O 0 0.00017779802
to O 0 0.00012558515
56 O 0 0.00019819857
% O 0 0.00018167948
by O 0 0.00015233907
giving O 0 0.00021182475
the O 0 0.00014647988
initial O 0 0.00016029342
" O 0 0.00028458494
calibrating O 0 0.00028861169
" O 0 0.00030133052
dose O 0 0.0009651732
of O 0 0.0014223853
carbon B-Chemical 0 0.9998363
tetrachloride I-Chemical 0 0.9999999
at O 0 0.0002887801
the O 0 0.00021172622
peak O 0 0.00029170664
of O 0 0.0004281503
the O 0 0.0015630197
phenobarbitone B-Chemical 0 0.9999995
- O 0 0.067683354
induced O 0 0.0010595659
enlargement B-Disease 0 0.15445384
of I-Disease 0 0.0021935105
the I-Disease 0 0.0028778443
liver I-Disease 0 0.7186899
. O 0 0.008060863

At O 0 0.0029289632
this O 0 0.0021913887
point O 0 0.0014760449
it O 0 0.0013578881
was O 0 0.00090864464
assumed O 0 0.0006598249
that O 0 0.0005566096
the O 0 0.0011935914
cytochrome O 0 0.99995637
P450 O 0 0.99999666
/ O 0 0.92494375
CCl4 B-Chemical 0 0.9999999
toxic O 0 0.96701694
state O 0 0.0013982513
was O 0 0.0008023883
both O 0 0.00089294265
maximal O 0 0.0013137583
and O 0 0.0025166662
stable O 0 0.0048044585
. O 0 0.0069442787

The O 0 0.0028946754
optimal O 0 0.0016967923
rat O 0 0.0023122162
size O 0 0.0012978349
to O 0 0.00083047466
begin O 0 0.0014711805
phenobarbitone B-Chemical 0 0.99999785
was O 0 0.00056285155
determined O 0 0.00026235386
as O 0 0.00026735102
100 O 0 0.00045992102
g O 0 0.0006092294
, O 0 0.00031361703
and O 0 0.0002256987
this O 0 0.00017390308
size O 0 0.0002240807
as O 0 0.0001832561
a O 0 0.00025309264
group O 0 0.00024156123
had O 0 0.00014931454
a O 0 0.00015202041
mean O 0 9.119288e-05
maximum O 0 0.00013062735
relative O 0 0.0001740217
liver O 0 0.26314515
weight O 0 0.0025400245
increase O 0 0.0002324416
47 O 0 0.00054783607
% O 0 0.00030607323
greater O 0 0.00023229158
than O 0 0.0002375356
normal O 0 0.00048389702
rats O 0 0.00058754516
of O 0 0.00066384603
the O 0 0.0008573311
same O 0 0.0011165938
body O 0 0.0041257064
weight O 0 0.008872654
. O 0 0.0074064904

The O 0 0.002916113
optimal O 0 0.001581342
time O 0 0.0011724024
for O 0 0.0010189306
the O 0 0.0007890997
initial O 0 0.00066456915
dose O 0 0.0030399468
of O 0 0.003308266
carbon B-Chemical 0 0.9998481
tetrachloride I-Chemical 0 0.9999999
was O 0 0.0012245862
after O 0 0.00065849937
14 O 0 0.0010187887
days O 0 0.0012161487
on O 0 0.0025055285
phenobarbitone B-Chemical 0 0.99997437
. O 0 0.009461899

Triamterene B-Chemical 0 0.99922335
nephrolithiasis B-Disease 2 0.9999225
complicating O 0 0.91773516
dyazide B-Chemical 0 0.97204506
therapy O 0 0.076999664
. O 0 0.02818075

A O 0 0.07229722
case O 0 0.004544653
of O 0 0.033024468
triamterene B-Chemical 0 1.0
nephrolithiasis B-Disease 2 0.9999987
is O 0 0.0038437925
reported O 0 0.0009837301
in O 0 0.00047113083
a O 0 0.0005435477
man O 0 0.008725792
after O 0 0.00024295099
4 O 0 0.00028037265
years O 0 0.0004532749
of O 0 0.0031605137
hydrochlorothiazide B-Chemical 0 1.0
- I-Chemical 0 0.9598877
triamterene I-Chemical 0 1.0
therapy O 0 0.087174244
for O 0 0.006670419
hypertension B-Disease 2 0.9999788
. O 0 0.008978324

The O 0 0.0039171916
stone O 0 0.020067465
passed O 0 0.002359399
spontaneously O 0 0.003003489
and O 0 0.001246064
was O 0 0.0008456385
found O 0 0.0005774951
to O 0 0.000495306
contain O 0 0.00050023024
a O 0 0.0060852836
triamterene B-Chemical 0 1.0
metabolite O 0 0.99846727
admixed O 0 0.392117
with O 0 0.03159422
uric B-Chemical 0 0.9999964
acid I-Chemical 0 0.99603623
salts I-Chemical 0 0.9986482
. O 0 0.009782712

Factors O 0 0.1373636
affecting O 0 0.08419314
triamterene B-Chemical 0 0.9999999
nephrolithiasis B-Disease 2 0.99999475
are O 0 0.0020211807
discussed O 0 0.0010084262
and O 0 0.0010987064
2 O 0 0.0010356215
previously O 0 0.0011324805
reported O 0 0.0016330937
cases O 0 0.0025706845
are O 0 0.00310772
reviewed O 0 0.0065184613
. O 0 0.008515316

Busulfan B-Chemical 0 0.99928325
- O 0 0.1736282
induced O 0 0.060208656
hemorrhagic B-Disease 2 0.9999467
cystitis I-Disease 0 0.99997187
. O 0 0.0744383

A O 0 0.03185743
case O 0 0.0047141328
of O 0 0.004231756
a O 0 0.00781964
busulfan B-Chemical 0 0.99997365
- O 0 0.3731869
induced O 0 0.04857525
hemorrhage B-Disease 2 0.9999976
cystitis I-Disease 0 0.9999931
is O 0 0.0153613165
reported O 0 0.010302993
. O 0 0.01009204

Spontaneous O 0 0.01211941
resolution O 0 0.011453486
occurred O 0 0.0054815905
following O 0 0.0046233153
cessation O 0 0.01008639
of O 0 0.0068837446
the O 0 0.008091318
drug O 0 0.5314699
. O 0 0.015190761

The O 0 0.0027742232
similarity O 0 0.0019752383
between O 0 0.0011466056
the O 0 0.0010105901
histologic O 0 0.010428825
appearances O 0 0.0047568027
of O 0 0.0042918986
busulfan B-Chemical 0 0.99999654
cystitis B-Disease 0 0.9999964
and O 0 0.0025939334
both O 0 0.0005508927
radiation O 0 0.34821936
and O 0 0.003689919
cyclophosphamide B-Chemical 0 0.99998605
- O 0 0.17442887
induced O 0 0.0021092624
cystitis B-Disease 0 0.9999877
is O 0 0.00087573123
discussed O 0 0.0004543499
and O 0 0.0006723537
the O 0 0.0009095854
world O 0 0.003230253
literature O 0 0.0031526333
reviewed O 0 0.005423745
. O 0 0.0069099898

In O 0 0.0035979114
view O 0 0.0026788304
of O 0 0.0018735325
the O 0 0.0012392598
known O 0 0.0011481992
tendency O 0 0.0011238166
of O 0 0.0013589101
busulfan B-Chemical 0 0.99991083
to O 0 0.00035727347
induce O 0 0.000237032
cellular O 0 0.005035598
atypia O 0 0.9836506
and O 0 0.006746379
carcinoma B-Disease 2 0.99996495
in O 0 0.0004085723
other O 0 0.0002954975
sites O 0 0.00031129445
, O 0 0.0004094332
periodic O 0 0.0019166085
urinary O 0 0.28293
cytology O 0 0.0048264186
is O 0 0.00028171507
suggested O 0 0.0002569001
in O 0 0.00033704567
patients O 0 0.00052416703
on O 0 0.00043536152
long O 0 0.00092077017
- O 0 0.0034456057
term O 0 0.002310272
therapy O 0 0.0060378676
. O 0 0.0069309934

Variant O 0 0.7217178
ventricular B-Disease 2 0.9989889
tachycardia I-Disease 2 0.99997616
in O 0 0.20013201
desipramine B-Chemical 0 0.9999982
toxicity B-Disease 2 0.99960977
. O 0 0.025471753

We O 0 0.004910974
report O 0 0.004532281
a O 0 0.0030573125
case O 0 0.0022616026
of O 0 0.0023677454
variant O 0 0.016404178
ventricular B-Disease 2 0.9997291
tachycardia I-Disease 2 0.9999931
induced O 0 0.009434551
by O 0 0.03707914
desipramine B-Chemical 0 0.9999995
toxicity B-Disease 2 0.9996332
. O 0 0.011360425

Unusual O 0 0.009861709
features O 0 0.0031261472
of O 0 0.0022333933
the O 0 0.0020299156
arrhythmia B-Disease 2 0.99959534
are O 0 0.00085708033
repetitive O 0 0.0009737131
group O 0 0.00061766285
beating O 0 0.0107126
, O 0 0.0006388917
progressive O 0 0.01902819
shortening O 0 0.0036635867
of O 0 0.00056307827
the O 0 0.0014155391
R O 0 0.99990237
- O 0 0.62684953
R O 0 0.99867463
interval O 0 0.00034043984
, O 0 0.00035038698
progressive O 0 0.007584021
widening O 0 0.00084172346
of O 0 0.00024427823
the O 0 0.00023577968
QRS O 0 0.4641532
complex O 0 0.00020315078
with O 0 0.00020475118
eventual O 0 0.0029077677
failure O 0 0.13108386
of O 0 0.00064758427
intraventricular O 0 0.85434335
conduction O 0 0.005832253
, O 0 0.00037466415
and O 0 0.00033028558
changes O 0 0.00043610422
in O 0 0.00045502343
direction O 0 0.00091093575
of O 0 0.0012157833
the O 0 0.0018384309
QRS O 0 0.6278145
axis O 0 0.0068292567
. O 0 0.006742083

Recognition O 0 0.009371871
of O 0 0.0040546195
variant O 0 0.014050344
ventricular B-Disease 2 0.99949694
tachycardia I-Disease 2 0.9999906
is O 0 0.001398605
important O 0 0.00060778874
because O 0 0.0005438876
therapy O 0 0.00077147584
differs O 0 0.0004962253
from O 0 0.0005918485
that O 0 0.00078193774
of O 0 0.001953764
classic O 0 0.39881736
ventricular B-Disease 2 0.99966884
tachycardia I-Disease 2 0.9999753
. O 0 0.009551745

Rebound O 0 0.9550139
hypertensive B-Disease 2 0.99954504
after O 0 0.006265658
sodium B-Chemical 1 0.99998784
nitroprusside I-Chemical 1 0.99999976
prevented O 0 0.06663485
by O 0 0.0108930925
saralasin B-Chemical 1 0.9999393
in O 0 0.0056237313
rats O 0 0.0089420155
. O 0 0.009791954

The O 0 0.0028857999
role O 0 0.0017190856
of O 0 0.0018789833
the O 0 0.0020698064
renin O 0 0.99618965
- O 0 0.4884918
- O 0 0.43978405
angiotensin B-Chemical 1 0.99996114
system O 0 0.000668832
in O 0 0.00031971646
the O 0 0.0002492482
maintenance O 0 0.00031491317
of O 0 0.00034271972
blood O 0 0.010492832
pressure O 0 0.021815285
during O 0 0.00022061581
halothane B-Chemical 0 0.9998882
anesthesia O 0 0.11623338
and O 0 0.003354614
sodium B-Chemical 1 0.99999857
nitroprusside I-Chemical 1 1.0
( O 0 0.08770042
SNP B-Chemical 1 0.9990288
) O 0 0.011525264
- O 0 0.030889472
induced O 0 0.0030394008
hypotension B-Disease 2 0.9999653
was O 0 0.0026377584
evaluated O 0 0.0033202244
. O 0 0.006449719

Control O 0 0.006941945
rats O 0 0.00371626
received O 0 0.0022228074
halothane B-Chemical 0 0.9999101
anesthesia O 0 0.36742893
( O 0 0.0018971917
1 O 0 0.00075996306
MAC O 0 0.67940813
) O 0 0.0008035954
for O 0 0.0002867146
one O 0 0.00022407727
hour O 0 0.00020092522
, O 0 0.0002612242
followed O 0 0.00018397075
by O 0 0.0003853826
SNP B-Chemical 1 0.99209577
infusion O 0 0.0027728027
, O 0 0.00035402787
40 O 0 0.00022571743
microgram O 0 0.01563556
/ O 0 0.0020199942
kg O 0 0.0011479466
/ O 0 0.0015058891
min O 0 0.00034722593
, O 0 0.00026561823
for O 0 0.0001843474
30 O 0 0.000185348
min O 0 0.00027386053
, O 0 0.00031461517
followed O 0 0.00027055215
by O 0 0.0004250866
a O 0 0.00061537337
30 O 0 0.0006779807
- O 0 0.0018579017
min O 0 0.0016342921
recovery O 0 0.0026590482
period O 0 0.0033195885
. O 0 0.0065415916

A O 0 0.04869598
second O 0 0.0029264272
group O 0 0.0022524153
of O 0 0.0015702299
rats O 0 0.0015444903
was O 0 0.0007048169
treated O 0 0.0005538442
identically O 0 0.0003824543
and O 0 0.0004485748
, O 0 0.00047175234
in O 0 0.00025468838
addition O 0 0.00017935311
, O 0 0.0003563873
received O 0 0.00018203896
an O 0 0.0002861125
infusion O 0 0.0013588337
of O 0 0.0015687995
saralasin B-Chemical 1 0.9999814
( O 0 0.0009181814
a O 0 0.00038929033
competitive O 0 0.0035873146
inhibitor O 0 0.012832771
of O 0 0.0098346565
angiotensin B-Chemical 1 0.99999857
II I-Chemical 1 0.81427544
) O 0 0.0013189135
throughout O 0 0.00064934004
the O 0 0.0010921858
experimental O 0 0.0019422891
period O 0 0.0029391127
. O 0 0.0059659923

In O 0 0.003632587
each O 0 0.0018093805
group O 0 0.0024581768
, O 0 0.0038895372
SNP B-Chemical 1 0.990789
infusion O 0 0.0045676637
resulted O 0 0.00052693166
in O 0 0.00044715533
an O 0 0.00041485752
initial O 0 0.00028432783
decrease O 0 0.0003183502
in O 0 0.00032087896
blood O 0 0.0052607176
pressure O 0 0.00513123
from O 0 0.00019823486
86 O 0 0.00037937748
torr O 0 0.0061091264
and O 0 0.0003418237
83 O 0 0.0006695128
torr O 0 0.023192104
, O 0 0.0008160255
respectively O 0 0.0014956224
, O 0 0.0014021111
to O 0 0.0015285239
48 O 0 0.0029260665
torr O 0 0.022919282
. O 0 0.0070719575

During O 0 0.003060155
the O 0 0.0031112954
SNP B-Chemical 1 0.96693
infusion O 0 0.0039003429
the O 0 0.0008127228
control O 0 0.0005818756
animals O 0 0.00038315024
demonstrated O 0 0.00032863097
a O 0 0.00046278397
progressive O 0 0.017820342
increase B-Disease 0 0.00027343555
in I-Disease 0 0.00032006108
blood I-Disease 0 0.008728103
pressure I-Disease 0 0.010481773
to O 0 0.0001793367
61 O 0 0.00040938632
torr O 0 0.032767583
, O 0 0.00039210453
whereas O 0 0.00036777058
the O 0 0.0007175226
saralasin B-Chemical 1 0.999972
- O 0 0.009765151
treated O 0 0.0007159847
animals O 0 0.00071694196
showed O 0 0.001114186
no O 0 0.001642087
change O 0 0.0038599113
. O 0 0.0066512083

Following O 0 0.004349034
discontinuation O 0 0.4936022
of O 0 0.0069720037
SNP B-Chemical 1 0.99768686
, O 0 0.0036315515
blood O 0 0.033078626
pressure O 0 0.043893978
in O 0 0.0004205279
the O 0 0.00031878328
control O 0 0.0002920612
animals O 0 0.0002475629
rebounded O 0 0.0019503923
to O 0 0.00020490568
94 O 0 0.0003800738
torr O 0 0.023644129
, O 0 0.00031062914
as O 0 0.00020076895
compared O 0 0.00017767787
with O 0 0.00028083284
78 O 0 0.00060995657
torr O 0 0.020268688
in O 0 0.0005557805
the O 0 0.001212179
saralasin B-Chemical 1 0.99994564
- O 0 0.018870225
treated O 0 0.0033324251
rats O 0 0.005313591
. O 0 0.0064531052

This O 0 0.004995975
study O 0 0.0026220821
indicates O 0 0.0012861362
that O 0 0.00093077496
with O 0 0.00104797
stable O 0 0.004273728
halothane B-Chemical 0 0.99998176
anesthesia O 0 0.32413733
, O 0 0.0006098953
the O 0 0.00026254304
partial O 0 0.0003551062
recovery O 0 0.00038000877
of O 0 0.0003351807
blood O 0 0.016222982
pressure O 0 0.033182167
during O 0 0.00018974328
SNP B-Chemical 1 0.9813487
infusion O 0 0.0007191631
and O 0 0.00019990213
the O 0 0.00018812234
post O 0 0.00033959042
- O 0 0.07880084
SNP B-Chemical 1 0.99548125
rebound O 0 0.16493367
of O 0 0.0007221874
blood O 0 0.03597401
pressure O 0 0.026454339
can O 0 0.0003722139
be O 0 0.00056684646
completely O 0 0.0008258876
blocked O 0 0.0021544255
by O 0 0.004404284
saralasin B-Chemical 1 0.9998559
. O 0 0.0076630306

This O 0 0.0046659443
demonstrates O 0 0.0019329543
the O 0 0.0015016098
participation O 0 0.0015048898
of O 0 0.0012408774
the O 0 0.0015126446
renin O 0 0.99683833
- O 0 0.44650653
- O 0 0.4066916
angiotensin B-Chemical 1 0.9999608
system O 0 0.00064954715
in O 0 0.0003885253
antagonizing O 0 0.0013953747
the O 0 0.00044649767
combined O 0 0.001426391
hypotensive B-Disease 0 0.99784696
effects O 0 0.0015509098
of O 0 0.00493263
halothane B-Chemical 0 0.9999572
and O 0 0.01920165
SNP B-Chemical 1 0.9945644
. O 0 0.008586516

Clinical O 0 0.21654947
nephrotoxicity B-Disease 0 0.99996173
of O 0 0.059134804
tobramycin B-Chemical 0 0.99983346
and O 0 0.1141828
gentamicin B-Chemical 1 0.9996922
. O 0 0.030096168

A O 0 0.0835003
prospective O 0 0.06242126
study O 0 0.058512736
. O 0 0.063587055

Nearly O 0 0.0064026476
3 O 0 0.0033375684
. O 0 0.002420118
2 O 0 0.0019047019
million O 0 0.001978754
people O 0 0.0020387839
in O 0 0.001446761
this O 0 0.0014637663
country O 0 0.0028144752
receive O 0 0.0021711378
aminoglycoside B-Chemical 0 0.99594504
antibiotics O 0 0.7900592
annually O 0 0.021798166
. O 0 0.009729587

Gentamicin B-Chemical 0 0.99998105
sulfate I-Chemical 0 0.99963
and O 0 0.06678066
tobramycin B-Chemical 0 0.999995
sulfate I-Chemical 0 0.99961936
continue O 0 0.0010014075
to O 0 0.00056606234
demonstrate O 0 0.0004799489
ototoxicity B-Disease 0 0.9999813
and O 0 0.013492708
nephrotoxicity B-Disease 0 0.9999988
in O 0 0.0009248802
both O 0 0.00082967494
animal O 0 0.0015241243
and O 0 0.0017132473
clinical O 0 0.004468565
studies O 0 0.0039134813
. O 0 0.006568585

In O 0 0.0037688566
this O 0 0.0024690728
study O 0 0.0021790764
, O 0 0.0017478638
62 O 0 0.0013425957
patients O 0 0.00077302783
with O 0 0.0004524504
confirmed O 0 0.0003423104
initial O 0 0.0003038247
normal O 0 0.0008124316
renal O 0 0.5953511
function O 0 0.00028221807
and O 0 0.00027161287
treated O 0 0.00025001363
with O 0 0.00020652129
2 O 0 0.000146287
to O 0 0.000116633935
5 O 0 0.00013360282
mg O 0 0.0029210749
/ O 0 0.00070797215
kg O 0 0.0005994293
/ O 0 0.00074208376
day O 0 0.00015965792
of O 0 0.0007540103
gentamicin B-Chemical 1 0.9999976
sulfate I-Chemical 0 0.9999298
or O 0 0.0158062
tobramycin B-Chemical 0 0.9999993
sulfate I-Chemical 0 0.9997764
for O 0 0.0002623126
a O 0 0.00018741908
minimum O 0 9.8915036e-05
of O 0 0.00014384669
seven O 0 0.00010764128
days O 0 8.500009e-05
were O 0 0.000100807
followed O 0 9.094104e-05
up O 0 0.0001061635
prospectively O 0 0.00012336446
for O 0 0.000107759595
the O 0 0.00012578531
development O 0 0.00039548698
of O 0 0.00096443825
aminoglycoside B-Chemical 0 0.99975425
- O 0 0.12448238
related O 0 0.00021050719
renal B-Disease 0 0.8487091
failure I-Disease 0 0.30684268
, O 0 0.00037888525
defined O 0 0.00016327715
as O 0 0.00016041925
at O 0 0.00016274929
least O 0 0.00017084362
a O 0 0.00031280334
one O 0 0.00033857327
- O 0 0.0016367285
third O 0 0.0006906569
reduction O 0 0.0012082079
in O 0 0.0015008277
renal O 0 0.6227503
function O 0 0.0041675307
. O 0 0.006963963

In O 0 0.004201488
these O 0 0.0030582398
62 O 0 0.0031682088
patients O 0 0.00227907
, O 0 0.0018016597
no O 0 0.0009946399
other O 0 0.0011584903
causes O 0 0.0014266865
for O 0 0.001535404
renal B-Disease 0 0.9186419
failure I-Disease 0 0.4368844
could O 0 0.0019376645
be O 0 0.0028894325
identified O 0 0.0042809276
. O 0 0.007949584

Five O 0 0.004623258
of O 0 0.0030216547
33 O 0 0.002712488
( O 0 0.00190665
15 O 0 0.0010005031
% O 0 0.0010233253
) O 0 0.0010001708
of O 0 0.0006955028
the O 0 0.0009222909
tobramycin B-Chemical 0 0.99995744
- O 0 0.0773795
treated O 0 0.00052692916
patients O 0 0.00042358096
and O 0 0.0002690248
16 O 0 0.00022960431
of O 0 0.00023463462
29 O 0 0.00041821218
( O 0 0.0003255385
55 O 0 0.00027140242
. O 0 0.00020204486
2 O 0 0.00021406564
% O 0 0.00029031112
) O 0 0.00041063514
of O 0 0.0003928392
the O 0 0.00072366785
gentamicin B-Chemical 1 0.9999201
- O 0 0.06519531
treated O 0 0.0012696014
patients O 0 0.0018100713
had O 0 0.001840511
renal B-Disease 0 0.87925214
failure I-Disease 0 0.6976831
. O 0 0.008239395

Thus O 0 0.0052793627
, O 0 0.008138847
gentamicin B-Chemical 1 0.9993938
was O 0 0.0022463226
associated O 0 0.0013973601
with O 0 0.0013965314
renal B-Disease 0 0.9165859
failure I-Disease 0 0.42074904
more O 0 0.0006747146
than O 0 0.0003265889
three O 0 0.00028877653
times O 0 0.00035247338
as O 0 0.00062416145
often O 0 0.0011424321
as O 0 0.0015466692
was O 0 0.0033676827
tobramycin B-Chemical 0 0.9992244
. O 0 0.009540686

Metabolic O 0 0.08110122
involvement O 0 0.022073204
in O 0 0.026146192
adriamycin B-Chemical 0 0.999877
cardiotoxicity B-Disease 0 0.99998355
. O 0 0.056720864

The O 0 0.0041260645
cardiotoxic B-Disease 2 0.9931318
effects O 0 0.0035588664
of O 0 0.0036917445
adriamycin B-Chemical 0 0.9999114
were O 0 0.0010826905
studied O 0 0.00073198444
in O 0 0.0005912855
mammalian O 0 0.0011435252
myocardial O 0 0.9974527
cells O 0 0.0010148353
in O 0 0.00074613234
culture O 0 0.0012945936
as O 0 0.0011230914
a O 0 0.0018673331
model O 0 0.0026559124
system O 0 0.00469059
. O 0 0.0073394557

Adriamycin B-Chemical 0 0.9996107
inhibited O 0 0.0071896473
cell O 0 0.008599093
growth O 0 0.010657773
and O 0 0.001701733
the O 0 0.0011756367
rhythmic O 0 0.004775322
contractions O 0 0.07898428
characteristic O 0 0.0014217062
of O 0 0.002084083
myocardial O 0 0.99799216
cells O 0 0.0031587246
in O 0 0.003100683
culture O 0 0.007354235
. O 0 0.008071515

A O 0 0.028997017
possible O 0 0.0027053833
involvement O 0 0.0021970302
of O 0 0.0016769087
energy O 0 0.019909004
metabolism O 0 0.23619998
was O 0 0.0006502077
suggested O 0 0.00039261757
previously O 0 0.00042933653
, O 0 0.00046464332
and O 0 0.00033016782
in O 0 0.00024752415
this O 0 0.00022916078
study O 0 0.00029858036
the O 0 0.0002525826
adenylate O 0 0.22106752
energy O 0 0.0056660464
charge O 0 0.02808132
and O 0 0.0007344503
phosphorylcreatine B-Chemical 0 0.9527034
mole O 0 0.10210425
fraction O 0 0.00024003653
were O 0 0.0002624269
determined O 0 0.00026334325
in O 0 0.00044969955
the O 0 0.0009424697
adriamycin B-Chemical 0 0.99984
- O 0 0.04169043
treated O 0 0.0033418552
cells O 0 0.0052239653
. O 0 0.0074043483

The O 0 0.004448278
adenylate O 0 0.20593573
energy O 0 0.014923192
charge O 0 0.032782443
was O 0 0.00129968
found O 0 0.0007558989
to O 0 0.0005641231
be O 0 0.00057155645
significantly O 0 0.00055094215
decreased O 0 0.0006908245
, O 0 0.00075074885
while O 0 0.00060905825
the O 0 0.00074575597
phophorylcreatine B-Chemical 0 0.2995809
mole O 0 0.10444848
fraction O 0 0.0015114493
was O 0 0.0024703285
unchanged O 0 0.0039762794
. O 0 0.007146784

Such O 0 0.009178638
disparity O 0 0.007002837
suggests O 0 0.004666688
an O 0 0.006355342
inhibition O 0 0.009674437
of O 0 0.0244059
creatine B-Chemical 1 0.9999702
phosphokinase O 0 0.9999776
. O 0 0.021861264

The O 0 0.0027609183
addition O 0 0.00159435
of O 0 0.0018695501
1 O 0 0.0016949502
mM O 0 0.4040911
adenosine B-Chemical 1 0.99766773
to O 0 0.000652652
the O 0 0.00071005535
myocardial O 0 0.9986212
cell O 0 0.005478942
cultures O 0 0.00047623276
markedly O 0 0.00067002
increases O 0 0.00028723286
the O 0 0.0004248649
ATP B-Chemical 0 0.9957224
concentration O 0 0.00092358654
through O 0 0.00022519294
a O 0 0.00034261012
pathway O 0 0.00033710783
reportedly O 0 0.0015684651
leading O 0 0.0007810173
to O 0 0.0007024897
a O 0 0.001357954
compartmentalized O 0 0.002750536
ATP B-Chemical 0 0.9699706
pool O 0 0.004559184
. O 0 0.007256811

In O 0 0.0038643144
the O 0 0.0036843363
adriamycin B-Chemical 0 0.99991274
- O 0 0.14564285
treated O 0 0.0018024095
cells O 0 0.0012254431
, O 0 0.0008794083
the O 0 0.0003714515
addition O 0 0.00024330961
of O 0 0.0012036809
adenosine B-Chemical 1 0.99948597
increased O 0 0.0008644294
the O 0 0.00046171367
adenylate O 0 0.6715182
charge O 0 0.06981941
and O 0 0.0004833779
, O 0 0.00041528468
concomitant O 0 0.00059526437
with O 0 0.00023177301
this O 0 0.00020283199
inrcease O 0 0.008896799
, O 0 0.00028798197
the O 0 0.00017373587
cells O 0 0.0002728379
' O 0 0.00037755372
functional O 0 0.00021276802
integrity O 0 0.00035185815
, O 0 0.00028856026
in O 0 0.00016472803
terms O 0 0.00013897273
of O 0 0.00018908066
percentage O 0 0.00016254115
of O 0 0.0003110007
beating O 0 0.005289278
cells O 0 0.00048120937
and O 0 0.0004919694
rate O 0 0.0006316762
of O 0 0.0012026081
contractions O 0 0.2939924
, O 0 0.0022921185
was O 0 0.0023737517
maintained O 0 0.0035387955
. O 0 0.00659235

Age O 0 0.31914967
- O 0 0.010412013
dependent O 0 0.0024859442
sensitivity O 0 0.003271665
of O 0 0.00217017
the O 0 0.0017938782
rat O 0 0.0035446046
to O 0 0.002025044
neurotoxic B-Disease 0 0.99863607
effects O 0 0.0065580453
of O 0 0.019967986
streptomycin B-Chemical 1 0.99998736
. O 0 0.020433402

Streptomycin B-Chemical 0 0.99979216
sulfate O 0 0.9934854
( O 0 0.0048370017
300 O 0 0.0025298933
mg O 0 0.027348367
/ O 0 0.0019860184
kg O 0 0.0011116755
s O 0 0.00071898906
. O 0 0.00045850233
c O 0 0.004645577
. O 0 0.00041778744
) O 0 0.0006083246
was O 0 0.00027817202
injected O 0 0.00022234065
for O 0 0.00020843663
various O 0 0.0002393619
periods O 0 0.0002179636
into O 0 0.00019819762
preweanling O 0 0.03778474
rats O 0 0.0004255102
and O 0 0.00039041252
for O 0 0.0004558985
3 O 0 0.0005758346
weeks O 0 0.00067158276
into O 0 0.0011305161
weanling O 0 0.010070098
rats O 0 0.0051869215
. O 0 0.006644715

Beginning O 0 0.0070967907
at O 0 0.0023726656
8 O 0 0.0016644875
days O 0 0.0010037759
of O 0 0.0010779266
age O 0 0.0014329979
, O 0 0.0009844754
body O 0 0.0013990939
movement O 0 0.0012017344
and O 0 0.0006854155
hearing O 0 0.722689
were O 0 0.000334599
examined O 0 0.00022658662
for O 0 0.0002909312
6 O 0 0.00028545945
and O 0 0.00039410405
up O 0 0.00045592245
to O 0 0.00058910064
17 O 0 0.0010596814
weeks O 0 0.0010790587
, O 0 0.002685485
respectively O 0 0.0059260493
. O 0 0.0076052747

Abnormal B-Disease 0 0.10919338
movements I-Disease 0 0.08101662
and O 0 0.0053425464
deafness B-Disease 0 0.9998301
occurred O 0 0.0015325755
only O 0 0.00088542217
in O 0 0.000527791
rats O 0 0.00056820124
treated O 0 0.0003434974
during O 0 0.0001976102
the O 0 0.00024435393
preweaning O 0 0.011983208
period O 0 0.00017236698
; O 0 0.00028277986
within O 0 0.00010748559
this O 0 0.00012572535
period O 0 0.00010617433
the O 0 0.0001266335
greatest O 0 0.00020769367
sensitivities O 0 0.00038324195
for O 0 0.00015016794
these O 0 0.00019444237
abnormalities O 0 0.008906484
occurred O 0 0.00014753823
from O 0 0.000119455304
2 O 0 0.00012952951
to O 0 0.00011855576
11 O 0 0.00019326365
- O 0 0.0007998652
17 O 0 0.00017618097
and O 0 0.00014297396
5 O 0 0.000112894115
to O 0 0.00010663071
11 O 0 0.00012827663
days O 0 9.382844e-05
of O 0 0.00017008926
age O 0 0.00064933696
, O 0 0.00045994273
respectively O 0 0.0028770263
, O 0 0.00032449368
indicating O 0 0.00014415124
that O 0 0.00012919387
the O 0 0.00019012832
cochlea O 0 0.012473478
is O 0 0.00021598031
more O 0 0.00020288111
sensitive O 0 0.00020992472
to O 0 0.0002455759
streptomycin B-Chemical 1 0.99999607
than O 0 0.00019711189
the O 0 0.00019468484
site O 0 0.00032488
( O 0 0.0006949575
vestibular O 0 0.2574454
or O 0 0.00036919714
central O 0 0.00072176044
) O 0 0.0009133265
responsible O 0 0.0008520415
for O 0 0.001501386
the O 0 0.0037935544
dyskinesias B-Disease 2 0.9999597
. O 0 0.007936135

Late O 0 0.087920345
, O 0 0.028000109
late O 0 0.105035014
doxorubicin B-Chemical 1 0.99978226
cardiotoxicity B-Disease 0 0.99998033
. O 0 0.064028926

Cardiac B-Disease 0 0.9817603
toxicity I-Disease 2 0.99964297
is O 0 0.002957825
a O 0 0.0019974008
major O 0 0.0016062739
complication O 0 0.095116995
which O 0 0.0010083079
limits O 0 0.0009715238
the O 0 0.0006335724
use O 0 0.0007368957
of O 0 0.0014577861
adriamycin B-Chemical 0 0.99976
as O 0 0.0016920277
a O 0 0.003134417
chemotherapeutic O 0 0.57470226
agent O 0 0.24261941
. O 0 0.00883949

Cardiomyopathy B-Disease 0 0.9835993
is O 0 0.003281345
frequent O 0 0.0026808581
when O 0 0.0007950341
the O 0 0.0006147745
total O 0 0.00043726707
dose O 0 0.0009919688
exceeds O 0 0.00035011652
600 O 0 0.001302328
mg O 0 0.027710255
/ O 0 0.002110037
m2 O 0 0.0058051297
and O 0 0.00030757205
occurs O 0 0.00023515802
within O 0 0.00019287414
one O 0 0.00024102636
to O 0 0.0002555319
six O 0 0.00028992858
months O 0 0.00038204598
after O 0 0.0005827739
cessation O 0 0.0023712958
of O 0 0.0025611387
therapy O 0 0.0066327373
. O 0 0.0067791035

A O 0 0.053559642
patient O 0 0.0033462988
is O 0 0.0020158954
reported O 0 0.0015412471
who O 0 0.0013786303
developed O 0 0.0013098065
progressive O 0 0.29405546
cardiomyopathy B-Disease 0 0.99999154
two O 0 0.00041748563
and O 0 0.00042845705
one O 0 0.00030173187
- O 0 0.001166389
half O 0 0.00015363855
years O 0 0.00021469337
after O 0 0.00014670326
receiving O 0 0.00030383278
580 O 0 0.011411521
mg O 0 0.019335372
/ O 0 0.0017828904
m2 O 0 0.007400719
which O 0 0.00056868786
apparently O 0 0.0010258484
represents O 0 0.00079557113
late O 0 0.0027352297
, O 0 0.0033097898
late O 0 0.07248842
cardiotoxicity B-Disease 0 0.99998677
. O 0 0.011103751

Attenuation O 0 0.014533435
of O 0 0.004072837
the O 0 0.0044743423
lithium B-Chemical 0 0.99996936
- O 0 0.1880706
induced O 0 0.008712513
diabetes B-Disease 0 0.999987
- I-Disease 0 0.83192724
insipidus I-Disease 0 0.9998336
- I-Disease 0 0.0580045
like I-Disease 0 0.0010834355
syndrome I-Disease 0 0.49276796
by O 0 0.002692075
amiloride B-Chemical 1 0.99995387
in O 0 0.003916773
rats O 0 0.006699974
. O 0 0.007210034

The O 0 0.0030782204
effect O 0 0.002381232
of O 0 0.003749264
amiloride B-Chemical 1 0.9999857
on O 0 0.0021539426
lithium B-Chemical 0 0.9999945
- O 0 0.33336434
induced O 0 0.008606853
polydipsia B-Disease 2 0.99999845
and O 0 0.010575657
polyuria B-Disease 2 0.9992017
and O 0 0.000346799
on O 0 0.00013923016
the O 0 0.00034126377
lithium B-Chemical 0 0.99989104
concentration O 0 0.0012596353
in O 0 0.00020041548
the O 0 0.0002084406
plasma O 0 0.017076261
, O 0 0.00047349624
brain O 0 0.020218855
, O 0 0.0007749279
kidney O 0 0.69475013
, O 0 0.0022120955
thyroid O 0 0.6113432
and O 0 0.00079030904
red O 0 0.050558627
blood O 0 0.01150625
cells O 0 0.00032134278
was O 0 0.0002576829
investigated O 0 0.00022972476
in O 0 0.00035646427
rats O 0 0.0007304326
, O 0 0.0008411662
chronically O 0 0.007889307
treated O 0 0.0018310325
with O 0 0.004164108
LiCl B-Chemical 0 0.9987318
. O 0 0.008447472

Amiloride B-Chemical 0 0.9999299
reduced O 0 0.0037772774
the O 0 0.0022863115
drinking O 0 0.78729475
and O 0 0.0017525343
urine O 0 0.27940077
volume O 0 0.0010372458
of O 0 0.00054791494
rats O 0 0.00056847703
in O 0 0.0003123754
an O 0 0.00046597884
acute O 0 0.6009316
( O 0 0.0008078415
6 O 0 0.0001950929
or O 0 0.00019946687
12 O 0 0.00019326695
h O 0 0.00028233594
) O 0 0.0004916544
and O 0 0.00045722807
a O 0 0.00085635745
subacute O 0 0.9846852
( O 0 0.0012680232
3 O 0 0.00085229124
days O 0 0.0010799484
) O 0 0.0027152577
experiment O 0 0.0031616723
. O 0 0.006756096

6 O 0 0.003271247
h O 0 0.002464597
after O 0 0.001210126
the O 0 0.0011146473
administration O 0 0.0059736012
of O 0 0.004176568
amiloride B-Chemical 1 0.9999962
, O 0 0.004970146
a O 0 0.00077246316
reduction O 0 0.0007722645
was O 0 0.00028339148
observed O 0 0.00020408441
in O 0 0.000240345
the O 0 0.00038309395
lithium B-Chemical 0 0.99979955
content O 0 0.00030931176
of O 0 0.0003235759
the O 0 0.000387144
renal O 0 0.9271797
medulla O 0 0.7365124
but O 0 0.0004766388
not O 0 0.00039606832
in O 0 0.0005581535
the O 0 0.0008154394
other O 0 0.0014627234
organs O 0 0.004977081
studied O 0 0.0043353117
. O 0 0.0066803307

At O 0 0.0032814883
12 O 0 0.002470574
h O 0 0.0023161396
, O 0 0.0019956222
all O 0 0.0011878569
the O 0 0.0010625862
tissues O 0 0.0013936156
showed O 0 0.00094349694
a O 0 0.001228398
slight O 0 0.0016976083
increase O 0 0.0015093108
in O 0 0.003226733
lithium B-Chemical 0 0.9997782
levels O 0 0.0060648476
. O 0 0.008939162

After O 0 0.0026724238
3 O 0 0.0019892545
days O 0 0.0012165293
of O 0 0.0012273472
combined O 0 0.001174495
treatment O 0 0.0011372517
, O 0 0.001027477
a O 0 0.0007106267
marked O 0 0.0011578818
elevation O 0 0.09782417
in O 0 0.00042637772
plasma O 0 0.01551141
and O 0 0.0005915519
tissue O 0 0.051611252
lithium B-Chemical 0 0.99989545
levels O 0 0.0005295564
accompanied O 0 0.0008966147
a O 0 0.0010057837
reduction O 0 0.0016138571
in O 0 0.0017004941
water O 0 0.06520266
intake O 0 0.6328165
. O 0 0.0070305183

In O 0 0.0036510297
all O 0 0.0020611058
the O 0 0.0013872887
experiments O 0 0.00089474913
, O 0 0.001078395
the O 0 0.0006076015
attenuation O 0 0.0009778683
of O 0 0.0008087364
the O 0 0.0017069887
lithium B-Chemical 0 0.9999925
- O 0 0.19341752
induced O 0 0.005712937
diabetes B-Disease 0 0.99999535
- I-Disease 0 0.87330884
insipidus I-Disease 0 0.9998815
- I-Disease 0 0.07482877
like I-Disease 0 0.000296312
syndrome I-Disease 0 0.50832087
by O 0 0.0008459501
amiloride B-Chemical 1 0.9999907
was O 0 0.0003264308
accompanied O 0 0.0003332632
by O 0 0.00021343751
a O 0 0.00025126847
reduction O 0 0.00031199175
of O 0 0.00020739704
the O 0 0.00015117004
ratio O 0 0.00019166069
between O 0 0.000118224656
the O 0 0.0003452321
lithium B-Chemical 0 0.999902
concentration O 0 0.001135773
in O 0 0.00018619362
the O 0 0.00023248013
renal O 0 0.8942068
medulla O 0 0.6884229
and O 0 0.0002441099
its O 0 0.0003565715
levels O 0 0.00019372269
in O 0 0.00019197399
the O 0 0.00022511886
blood O 0 0.0024603454
and O 0 0.0003176493
an O 0 0.00044305436
elevation O 0 0.024558233
in O 0 0.0005845953
the O 0 0.000958694
plasma O 0 0.11989055
potassium B-Chemical 0 0.999577
level O 0 0.0036849172
. O 0 0.0066973125

It O 0 0.004670455
is O 0 0.0025889259
concluded O 0 0.0018323262
that O 0 0.0014742349
acute O 0 0.98868704
amiloride B-Chemical 1 0.99999857
administration O 0 0.5135731
to O 0 0.0027199397
lithium B-Chemical 0 0.99999464
- O 0 0.08792616
treated O 0 0.00057187356
patients O 0 0.0007247318
suffering O 0 0.1287584
from O 0 0.00054074166
polydipsia B-Disease 2 0.99999654
and O 0 0.0038697752
polyuria B-Disease 2 0.99866736
might O 0 0.00015390043
relieve O 0 0.00033026357
these O 0 0.00020673485
patients O 0 0.00039915807
but O 0 0.000340527
prolonged O 0 0.005620249
amiloride B-Chemical 1 0.99999714
supplementation O 0 0.9471802
would O 0 0.00025890415
result O 0 0.00022416744
in O 0 0.00037117623
elevated O 0 0.041336987
lithium B-Chemical 0 0.99986243
levels O 0 0.0007155682
and O 0 0.0010211674
might O 0 0.0011298332
be O 0 0.002427728
hazardous O 0 0.14122866
. O 0 0.0067106267

Cardiovascular B-Disease 0 0.9945088
complications I-Disease 0 0.92498374
associated O 0 0.0054686265
with O 0 0.0069298553
terbutaline B-Chemical 0 0.9999584
treatment O 0 0.010948644
for O 0 0.0062212953
preterm B-Disease 0 0.9891761
labor I-Disease 0 0.9468344
. O 0 0.014329303

Severe O 0 0.9364232
cardiovascular B-Disease 0 0.9994222
complications I-Disease 0 0.9762655
occurred O 0 0.0018015947
in O 0 0.0009943334
eight O 0 0.0006461854
of O 0 0.00074610254
160 O 0 0.0011562434
patients O 0 0.0008388035
treated O 0 0.00094462535
with O 0 0.0021908144
terbutaline B-Chemical 0 0.9999621
for O 0 0.0042998837
preterm B-Disease 0 0.9916319
labor I-Disease 0 0.9405354
. O 0 0.009647812

Associated O 0 0.0277898
corticosteroid O 0 0.99865025
therapy O 0 0.009129951
and O 0 0.0035531942
twin O 0 0.075835615
gestations O 0 0.04489282
appear O 0 0.002271106
to O 0 0.0021842988
be O 0 0.0032173744
predisposing O 0 0.014614385
factors O 0 0.013497147
. O 0 0.011452661

Potential O 0 0.010528962
mechanisms O 0 0.0058152103
of O 0 0.005994207
the O 0 0.0054298597
pathophysiology O 0 0.017033458
are O 0 0.005921973
briefly O 0 0.0076830876
discussed O 0 0.00850436
. O 0 0.013524653

Toxic B-Disease 0 0.999627
hepatitis I-Disease 2 0.99999976
induced O 0 0.041777827
by O 0 0.010083339
antithyroid O 0 0.9994862
drugs O 0 0.70455265
: O 0 0.0012056172
four O 0 0.00032241832
cases O 0 0.00043262338
including O 0 0.000310886
one O 0 0.00030438715
with O 0 0.00039487818
cross O 0 0.0008304897
- O 0 0.0045682318
reactivity O 0 0.0044553303
between O 0 0.0011424625
carbimazole B-Chemical 0 0.99986255
and O 0 0.0065006316
benzylthiouracil B-Chemical 0 0.99135345
. O 0 0.008204492

OBJECTIVE O 0 0.03195918
: O 0 0.0044611315
This O 0 0.002700507
study O 0 0.0016520991
was O 0 0.0010006798
conducted O 0 0.0006544523
to O 0 0.00050224527
assess O 0 0.00030944298
the O 0 0.00042313343
occurrence O 0 0.0007782855
of O 0 0.00091609807
hepatic B-Disease 0 0.9894739
adverse I-Disease 0 0.7837846
effects I-Disease 0 0.0035581612
encountered O 0 0.001487023
with O 0 0.0036765623
antithyroid O 0 0.9989525
drugs O 0 0.6310655
. O 0 0.007105667

METHODS O 0 0.004307766
: O 0 0.0040504117
Retrospective O 0 0.0082112085
review O 0 0.002448732
of O 0 0.0015809459
medical O 0 0.0019618177
records O 0 0.00095276575
of O 0 0.00073619274
236 O 0 0.0017805607
patients O 0 0.0006774111
with O 0 0.0008911886
hyperthyroidism B-Disease 0 0.99998975
admitted O 0 0.0034750635
in O 0 0.00026325363
our O 0 0.00024836053
department O 0 0.0003943686
( O 0 0.00042935292
in O 0 0.00031992682
- O 0 0.0018352763
or O 0 0.0003273183
out O 0 0.00035953245
- O 0 0.0021964002
patients O 0 0.00090605364
) O 0 0.0011879032
from O 0 0.0011391633
1986 O 0 0.0040966384
to O 0 0.0025170795
1992 O 0 0.008270655
. O 0 0.00725131

RESULTS O 0 0.0057260757
: O 0 0.003755885
Four O 0 0.0023163757
patients O 0 0.0019086112
( O 0 0.0016921494
1 O 0 0.00093282183
. O 0 0.0006559132
7 O 0 0.0005141427
% O 0 0.0005961697
) O 0 0.00063754566
were O 0 0.00035771477
identified O 0 0.00032585123
with O 0 0.0010629512
toxic B-Disease 0 0.9998123
hepatitis I-Disease 2 1.0
which O 0 0.044727236
could O 0 0.00036914222
reasonably O 0 0.00050805794
be O 0 0.00030488352
attributed O 0 0.00028876113
to O 0 0.0003782946
the O 0 0.0005632205
use O 0 0.00094063056
of O 0 0.0024371117
antithyroid O 0 0.99814105
agent O 0 0.22505647
. O 0 0.007770103

Two O 0 0.005300949
patients O 0 0.0042823483
had O 0 0.0031322874
a O 0 0.0090027815
cholestatic B-Disease 0 0.9999994
hepatitis I-Disease 2 1.0
induced O 0 0.27706185
by O 0 0.06832814
carbimazole B-Chemical 0 0.99998987
( O 0 0.10835691
N B-Chemical 0 0.9998357
omercazole I-Chemical 0 0.85412705
) O 0 0.011695313
. O 0 0.009686792

Two O 0 0.0052045444
others O 0 0.004990013
had O 0 0.0026117158
a O 0 0.002564879
mixed O 0 0.0035549977
( O 0 0.009506272
cholestatic B-Disease 0 0.99999607
and O 0 0.021047315
cytolytic O 0 0.95178646
) O 0 0.32769436
hepatitis B-Disease 2 0.99999976
following O 0 0.19122304
carbimazole B-Chemical 0 0.9999629
. O 0 0.013260242

One O 0 0.004560452
of O 0 0.0027065664
the O 0 0.0017524159
latter O 0 0.0018690795
two O 0 0.00079698354
patients O 0 0.0007966274
further O 0 0.0005288301
experienced O 0 0.0006485249
a O 0 0.00091271155
cytolytic O 0 0.89990324
hepatitis B-Disease 2 1.0
which O 0 0.024314832
appeared O 0 0.0007391844
after O 0 0.00038086108
Benzylthiouracil B-Chemical 0 0.64767826
( O 0 0.002334163
Basd B-Chemical 0 0.76702327
ne I-Chemical 0 0.9234162
) O 0 0.0028865614
had O 0 0.001881618
replaced O 0 0.0036240742
carbimazole B-Chemical 0 0.9997142
. O 0 0.0087774405

Biological O 0 0.02933349
features O 0 0.003987931
of O 0 0.0062815445
hepatitis B-Disease 2 0.9999995
disappeared O 0 0.033280548
in O 0 0.00092492474
all O 0 0.00048507628
cases O 0 0.00054854195
after O 0 0.00025357405
cessation O 0 0.001803393
of O 0 0.00035400796
the O 0 0.0003551942
incriminated O 0 0.0735376
drug O 0 0.4320718
, O 0 0.0007570119
while O 0 0.0005212836
biliary O 0 0.6653881
, O 0 0.0009900181
viral O 0 0.019007182
and O 0 0.0010355435
immunological O 0 0.011216244
searches O 0 0.0015263536
were O 0 0.0020096719
negative O 0 0.003941964
. O 0 0.0068835714

Only O 0 0.0054390472
2 O 0 0.0032651967
patients O 0 0.0024591181
of O 0 0.0019379936
our O 0 0.0016091396
retrospective O 0 0.003976863
study O 0 0.0017362349
experienced O 0 0.0017626574
a O 0 0.0022158637
mild O 0 0.38720265
or O 0 0.0037250961
severe O 0 0.797346
neutropenia B-Disease 0 0.9997284
. O 0 0.012061799

CONCLUSION O 0 0.1086615
: O 0 0.020431258
Toxic B-Disease 0 0.9997278
hepatitis I-Disease 2 0.9999999
is O 0 0.012492217
a O 0 0.0015470859
potential O 0 0.001113785
adverse O 0 0.40776044
effect O 0 0.0005274347
of O 0 0.001753262
antithyroid O 0 0.9993349
drugs O 0 0.4878466
which O 0 0.00051164237
warrants O 0 0.0005321861
, O 0 0.000392118
as O 0 0.00019219358
for O 0 0.0002766264
haematological O 0 0.94227386
disturbances O 0 0.35437933
, O 0 0.00043356142
a O 0 0.00032313136
pre O 0 0.0015236745
- O 0 0.0035815616
therapeutic O 0 0.00053883647
determination O 0 0.0006562115
and O 0 0.00027316922
a O 0 0.00029068807
careful O 0 0.0003108176
follow O 0 0.00030436655
- O 0 0.0011492595
up O 0 0.00052004517
of O 0 0.0008288503
relevant O 0 0.0010994598
biological O 0 0.0021038472
markers O 0 0.00512022
. O 0 0.0067321723

Moreover O 0 0.007928485
, O 0 0.015541254
hepatotoxicity B-Disease 2 0.9999939
may O 0 0.002467714
not O 0 0.0014292961
be O 0 0.001221457
restricted O 0 0.0010045671
to O 0 0.0010518307
one O 0 0.0012491422
class O 0 0.002271924
of O 0 0.0040757125
antithyroid O 0 0.99830437
agents O 0 0.12637922
. O 0 0.009231979

Interactive O 0 0.01722505
effects O 0 0.0031423955
of O 0 0.002202455
variations O 0 0.0016593136
in O 0 0.0016432342
[ O 0 0.1074664
Na B-Chemical 1 0.99999034
] O 0 0.013996963
o O 0 0.030861244
and O 0 0.001799226
[ O 0 0.11155441
Ca B-Chemical 1 0.99997556
] O 0 0.0061637405
o O 0 0.0063164113
on O 0 0.0009049338
rat O 0 0.0035962604
atrial O 0 0.63179314
spontaneous O 0 0.0087632835
frequency O 0 0.0047045285
. O 0 0.0072573097

The O 0 0.0029687989
effects O 0 0.0022624636
of O 0 0.0015516778
varying O 0 0.0010765244
the O 0 0.00075805245
extracellular O 0 0.0021608511
concentrations O 0 0.0032774499
of O 0 0.004055833
Na B-Chemical 1 0.9999969
and O 0 0.025055636
Ca B-Chemical 1 0.999995
( O 0 0.024825422
[ O 0 0.22493047
Na B-Chemical 1 0.9999969
] O 0 0.009526178
o O 0 0.027425403
and O 0 0.0011691649
[ O 0 0.1624757
Ca B-Chemical 1 0.99999356
] O 0 0.018332126
o O 0 0.04170882
) O 0 0.00071584346
on O 0 0.00014025072
both O 0 0.00021154562
, O 0 0.00029836124
the O 0 0.00019275464
spontaneous O 0 0.001218032
beating O 0 0.0057108793
and O 0 0.00023963657
the O 0 0.00017986106
negative O 0 0.0004881311
chronotropic O 0 0.8430914
action O 0 0.0008070259
of O 0 0.002323147
verapamil B-Chemical 0 0.99999714
, O 0 0.0010396438
were O 0 0.00038016064
studied O 0 0.0004473216
in O 0 0.0005512659
the O 0 0.0008103147
isolated O 0 0.0012583007
rat O 0 0.004473536
atria O 0 0.038287632
. O 0 0.0061904234

Basal O 0 0.0249872
frequency O 0 0.0037648648
( O 0 0.0039000562
BF O 0 0.30612096
) O 0 0.0016939468
evaluated O 0 0.0006467905
by O 0 0.00063073356
surface O 0 0.0011352429
electrogram O 0 0.14580707
was O 0 0.00050386746
223 O 0 0.0075146095
+ O 0 0.002008729
/ O 0 0.008151675
- O 0 0.0049357438
4 O 0 0.0002316237
beats O 0 0.012119484
/ O 0 0.0009444089
min O 0 0.0003209402
. O 0 0.00019694302
in O 0 0.00019967392
control O 0 0.00029661244
Krebs O 0 0.5173454
- O 0 0.009886496
Ringer O 0 0.07522374
containing O 0 0.0002470486
137 O 0 0.0018256927
mM O 0 0.37744814
Na B-Chemical 1 0.9999763
and O 0 0.00064962544
1 O 0 0.0004593381
. O 0 0.00050132454
35 O 0 0.00089138275
mM O 0 0.20751004
Ca B-Chemical 1 0.99992204
( O 0 0.018855669
N O 0 0.9963942
) O 0 0.013171614
. O 0 0.009379134

It O 0 0.00454218
decreased O 0 0.0028805644
by O 0 0.0021292078
16 O 0 0.001871108
+ O 0 0.0034208468
/ O 0 0.012095935
- O 0 0.0071078003
3 O 0 0.0005181434
% O 0 0.000521423
by O 0 0.0004662617
lowering O 0 0.023673419
[ O 0 0.08700347
Na B-Chemical 1 0.99999535
] O 0 0.0063696424
o O 0 0.006618025
to O 0 0.0002555918
78 O 0 0.0007845295
mM O 0 0.07618777
( O 0 0.0011957746
LNa O 0 0.4839832
) O 0 0.00070327806
, O 0 0.00039239062
23 O 0 0.0004393011
+ O 0 0.0014564159
/ O 0 0.010834657
- O 0 0.008760654
2 O 0 0.00020650572
% O 0 0.00021546794
by O 0 0.00018846778
lowering O 0 0.0012517095
simultaneously O 0 0.00034196462
[ O 0 0.060650166
Na B-Chemical 1 0.9999958
] O 0 0.0045247446
o O 0 0.0050355066
to O 0 0.00019302222
78 O 0 0.0005494787
mM O 0 0.032599494
and O 0 0.0005950769
[ O 0 0.07116992
Ca B-Chemical 1 0.9999863
] O 0 0.0044411924
o O 0 0.0049172672
to O 0 0.00018328335
0 O 0 0.0002364713
. O 0 0.00019016929
675 O 0 0.0045189536
mM O 0 0.045654457
( O 0 0.001077959
LNa O 0 0.66498816
+ O 0 0.016241295
LCa O 0 0.99499595
) O 0 0.00074848934
and O 0 0.00027827814
31 O 0 0.00037937963
+ O 0 0.0014037418
/ O 0 0.0086495
- O 0 0.0052037146
5 O 0 0.00017002552
% O 0 0.00021692221
by O 0 0.00022183986
lowering O 0 0.017100058
[ O 0 0.073329024
Na B-Chemical 1 0.99999654
] O 0 0.00589442
o O 0 0.0063180844
to O 0 0.00020031579
78 O 0 0.00051276863
mM O 0 0.010910516
plus O 0 0.000208608
increasing O 0 0.00049260457
[ O 0 0.111571446
Ca B-Chemical 1 0.99999
] O 0 0.0068096723
o O 0 0.0066825375
to O 0 0.00027926048
3 O 0 0.00028945904
. O 0 0.00033831404
6 O 0 0.00043907252
mM O 0 0.013253616
( O 0 0.0022736262
LNa O 0 0.58659434
+ O 0 0.017253755
HCa O 0 0.9744245
) O 0 0.007926924
. O 0 0.008059719

At O 0 0.0032604625
normal O 0 0.0048051514
[ O 0 0.10945274
Na B-Chemical 1 0.9999778
] O 0 0.0224107
o O 0 0.03723394
, O 0 0.0012576622
decrease O 0 0.00064030476
( O 0 0.0008114057
0 O 0 0.0004651922
. O 0 0.0003357239
675 O 0 0.007432375
mM O 0 0.04802215
) O 0 0.0006431741
or O 0 0.0002403913
increase O 0 0.00021198214
( O 0 0.00043241394
3 O 0 0.0001870299
. O 0 0.00017461508
6 O 0 0.00017116335
mM O 0 0.010122984
) O 0 0.000605128
of O 0 0.00070370786
[ O 0 0.19316941
Ca B-Chemical 1 0.99999464
] O 0 0.020490116
o O 0 0.037304036
did O 0 0.00031688914
not O 0 0.00018359208
modify O 0 0.0002129393
BF O 0 0.53272825
; O 0 0.0005395105
a O 0 0.00024845288
reduction O 0 0.00025455485
of O 0 0.00017791349
ten O 0 0.0001129247
times O 0 9.95493e-05
( O 0 0.00021582795
0 O 0 0.00018384295
. O 0 0.00015756137
135 O 0 0.00035709722
mM O 0 0.0060210186
of O 0 0.0003243758
normal O 0 0.0026915441
[ O 0 0.14010264
Ca B-Chemical 1 0.99999225
] O 0 0.011909808
o O 0 0.017016435
was O 0 0.00029502405
effective O 0 0.000255527
to O 0 0.00022357788
reduce O 0 0.00026515647
BF O 0 0.1327324
by O 0 0.000508559
40 O 0 0.00066906156
+ O 0 0.0018809681
/ O 0 0.0060533863
- O 0 0.0076298593
13 O 0 0.0030645963
% O 0 0.0048711
. O 0 0.0074676136

All O 0 0.0064227963
negative O 0 0.007643169
chronotropic O 0 0.81421703
effects O 0 0.007538324
were O 0 0.0070665013
BF O 0 0.41437623
- O 0 0.016608482
dependent O 0 0.009818844
. O 0 0.015596211

Dose O 0 0.110113956
- O 0 0.01816188
dependent O 0 0.0029334968
bradycardia B-Disease 0 0.9982672
induced O 0 0.0024626974
by O 0 0.0040940205
verapamil B-Chemical 0 0.9999958
was O 0 0.0019615674
potentiated O 0 0.033996668
by O 0 0.0017030647
LNa O 0 0.7781139
, O 0 0.004358968
LCa O 0 0.9911549
, O 0 0.0038574587
and O 0 0.005318914
HCa O 0 0.9618303
. O 0 0.008725256

Independent O 0 0.012086894
but O 0 0.003279948
not O 0 0.0017449909
additive O 0 0.0044191056
effects O 0 0.0020792217
of O 0 0.009872086
Na B-Chemical 1 0.9999975
and O 0 0.041972496
Ca B-Chemical 1 0.99998796
are O 0 0.00047913965
shown O 0 0.00021150749
by O 0 0.00021871575
decreases O 0 0.00020853661
in O 0 0.00017798257
the O 0 0.00016185909
values O 0 0.0001822993
of O 0 0.00055422314
[ O 0 0.16879745
verapamil B-Chemical 0 0.99999857
] O 0 0.0102817
o O 0 0.0065754345
needed O 0 0.00013290043
to O 0 0.00013269529
reduce O 0 0.00013658263
BF O 0 0.16833971
by O 0 0.00018748915
30 O 0 0.0001585529
% O 0 0.0003021899
( O 0 0.0015781028
IC30 O 0 0.99993646
) O 0 0.0011115157
with O 0 0.00020341804
the O 0 0.00014194295
following O 0 0.00011369117
order O 0 0.00010620633
of O 0 0.00020078197
inhibitory O 0 0.0015109731
potency O 0 0.10029166
: O 0 0.0058558397
LNa O 0 0.8269601
> O 0 0.017028773
LCa O 0 0.9982327
> O 0 0.025886357
HCa O 0 0.99338865
> O 0 0.013294163
N O 0 0.9974589
, O 0 0.0010348917
resulting O 0 0.0008245206
LNa O 0 0.6726595
+ O 0 0.008606015
HCa O 0 0.8955464
similar O 0 0.0015468893
to O 0 0.0027441368
LNa O 0 0.23848176
. O 0 0.0070687165

The O 0 0.0045378283
[ O 0 0.09087998
verapamil B-Chemical 0 0.99998784
] O 0 0.027969873
o O 0 0.0174987
that O 0 0.0007569113
arrested O 0 0.039791614
atrial O 0 0.9119692
beating O 0 0.20354894
( O 0 0.00927301
AC O 0 0.9577882
) O 0 0.0012142591
was O 0 0.00027673194
also O 0 0.00022777276
potentiated O 0 0.0012612237
with O 0 0.0002451097
the O 0 0.00020378028
order O 0 0.00020984505
LNa O 0 0.3948903
= O 0 0.0018171889
LNa O 0 0.60172874
+ O 0 0.015494517
LCa O 0 0.99672854
= O 0 0.0070795957
LNa O 0 0.71485966
+ O 0 0.016043723
HCa O 0 0.98817295
= O 0 0.011708371
LCa O 0 0.99555403
> O 0 0.020596
HCa O 0 0.9818542
= O 0 0.011601199
N O 0 0.9887756
. O 0 0.010400577

The O 0 0.002887016
results O 0 0.001816076
indicate O 0 0.0010711174
that O 0 0.0010118816
rat O 0 0.0030725189
atrial O 0 0.74391
spontaneous O 0 0.008672115
beating O 0 0.014241296
is O 0 0.0003971478
more O 0 0.0002953621
dependent O 0 0.0001973383
on O 0 0.00021269904
[ O 0 0.064364225
Na B-Chemical 1 0.99999654
] O 0 0.007218814
o O 0 0.008519637
than O 0 0.00017873441
on O 0 0.0001868246
[ O 0 0.043288123
Ca B-Chemical 1 0.9999877
] O 0 0.00724234
o O 0 0.008640778
in O 0 0.00024150919
a O 0 0.0002578581
range O 0 0.00024487005
of O 0 0.00039905062
+ O 0 0.0045695873
/ O 0 0.01656035
- O 0 0.009122439
50 O 0 0.0006372191
% O 0 0.000729964
of O 0 0.0009370481
their O 0 0.0013839514
normal O 0 0.0027610234
concentration O 0 0.005491097
. O 0 0.0070963777

Also O 0 0.004622428
the O 0 0.00243116
enhancement O 0 0.0031660907
of O 0 0.0037222141
verapamil B-Chemical 0 0.9999913
effects O 0 0.0022952994
on O 0 0.00047004662
atrial O 0 0.6444796
beating O 0 0.02230372
was O 0 0.00039712715
more O 0 0.0003525742
pronounced O 0 0.0004788182
at O 0 0.0002973438
LNa O 0 0.057687353
than O 0 0.00028108247
at O 0 0.0004687861
LCa O 0 0.95058775
. O 0 0.0008004782
( O 0 0.0017405046
ABSTRACT O 0 0.0063645896
TRUNCATED O 0 0.0064995447
AT O 0 0.011735936
250 O 0 0.0057682423
WORDS O 0 0.010925701
) O 0 0.017630024

Pseudo O 0 0.72868496
- O 0 0.3516745
allergic B-Disease 0 0.9999386
reactions I-Disease 0 0.8251314
to O 0 0.004562771
corticosteroids B-Chemical 1 0.9996917
: O 0 0.007597887
diagnosis O 0 0.009255496
and O 0 0.0050558057
alternatives O 0 0.0069696843
. O 0 0.010216042

Two O 0 0.00411145
patients O 0 0.0029387495
treated O 0 0.0020254615
with O 0 0.0019412634
parenteral O 0 0.82169086
paramethasone B-Chemical 1 0.99998546
( O 0 0.006675798
Triniol O 0 0.08717502
) O 0 0.0018700084
and O 0 0.0016019883
dexamethasone B-Chemical 0 0.9995167
( O 0 0.004144765
Sedionbel O 0 0.049441267
) O 0 0.0028822068
are O 0 0.0026636424
described O 0 0.0038887395
. O 0 0.0072499993

A O 0 0.013880673
few O 0 0.0019920073
minutes O 0 0.0013773502
after O 0 0.00092517026
administration O 0 0.0017679131
of O 0 0.0008167895
the O 0 0.00065372774
drugs O 0 0.123654455
, O 0 0.0006314218
they O 0 0.00030460747
presented O 0 0.000534871
urticaria B-Disease 0 0.9999901
( O 0 0.0013436484
patients O 0 0.00055754144
1 O 0 0.00027480026
and O 0 0.00032318127
2 O 0 0.00037056932
) O 0 0.0007546487
and O 0 0.0011479084
conjunctivitis B-Disease 0 0.9999324
( O 0 0.004503172
patient O 0 0.002221972
1 O 0 0.0024721457
) O 0 0.0051157577
. O 0 0.0070558633

The O 0 0.003115949
purpose O 0 0.0021960272
of O 0 0.0017160843
our O 0 0.001221278
study O 0 0.0010571651
was O 0 0.00061409984
to O 0 0.0003723043
determine O 0 0.0001965275
the O 0 0.00027895338
cause O 0 0.00034247065
of O 0 0.00035932468
the O 0 0.0002993445
patients O 0 0.0006431784
' O 0 0.0006073177
reactions O 0 0.004462737
, O 0 0.00031766164
the O 0 0.00017517441
immunological O 0 0.002007395
mechanisms O 0 0.00015944935
involved O 0 0.00014073124
and O 0 0.00019202674
whether O 0 0.00011387997
these O 0 0.00022736918
patients O 0 0.00034878406
would O 0 0.00023190652
be O 0 0.00028880523
able O 0 0.0002985781
to O 0 0.00043253414
tolerate O 0 0.0008075106
any O 0 0.0008734716
kind O 0 0.0019056739
of O 0 0.0045300466
corticoid O 0 0.99629563
. O 0 0.008447472

Clinical O 0 0.008289293
examinations O 0 0.0032302008
and O 0 0.0025290884
skin O 0 0.038075574
, O 0 0.0025781144
oral O 0 0.09497812
and O 0 0.0011452597
parenteral O 0 0.044487566
challenges O 0 0.00065284356
with O 0 0.00059524877
different O 0 0.00066076
corticosteroids B-Chemical 1 0.9991141
and O 0 0.002594723
ELISA O 0 0.94664377
tests O 0 0.0032324584
were O 0 0.0025606733
performed O 0 0.0036555836
. O 0 0.0068762773

In O 0 0.0036291126
the O 0 0.002193255
two O 0 0.0014550878
patients O 0 0.0016948349
, O 0 0.0015930617
skin O 0 0.041626908
and O 0 0.001522779
ELISA O 0 0.95659256
tests O 0 0.001996783
with O 0 0.0014174477
paramethasone B-Chemical 1 0.99994314
were O 0 0.00039377259
negative O 0 0.00048859516
, O 0 0.00045746114
as O 0 0.00029246355
was O 0 0.0003386903
the O 0 0.00039681102
prick O 0 0.031174649
test O 0 0.00050855073
with O 0 0.00062646077
each O 0 0.00067504647
of O 0 0.0017344854
its O 0 0.0058517214
excipients O 0 0.8486281
. O 0 0.0077266456

A O 0 0.067142695
single O 0 0.004279511
- O 0 0.015010002
blind O 0 0.017356263
parenteral O 0 0.041483793
challenge O 0 0.00089907064
with O 0 0.00074396585
Triniol O 0 0.018075578
was O 0 0.0003551729
positive O 0 0.00038896725
in O 0 0.00025585268
both O 0 0.0002359841
patients O 0 0.000291078
after O 0 0.00012972334
the O 0 0.00017748788
administration O 0 0.0007037264
of O 0 0.00025864877
1 O 0 0.00021672768
ml O 0 0.00033860753
of O 0 0.00029950525
the O 0 0.0003604333
drug O 0 0.11399774
, O 0 0.0006973193
and O 0 0.0006902914
negative O 0 0.0011926232
with O 0 0.0018740079
its O 0 0.0073784995
excipients O 0 0.8765878
. O 0 0.0075063426

We O 0 0.003873723
also O 0 0.002420885
carried O 0 0.0015616443
out O 0 0.0012476947
oral O 0 0.017797587
and O 0 0.0011730761
parenteral O 0 0.04085396
challenges O 0 0.00067631836
with O 0 0.0005902185
other O 0 0.0009086741
corticosteroids B-Chemical 1 0.99938285
and O 0 0.0010983491
found O 0 0.000847053
intolerance O 0 0.30373135
to O 0 0.0009613356
some O 0 0.00148581
of O 0 0.0027241367
them O 0 0.0052837366
. O 0 0.0070527503

These O 0 0.0047061094
results O 0 0.003134651
suggest O 0 0.0022401677
that O 0 0.0031006564
paramethasone B-Chemical 1 0.9999012
caused O 0 0.006926216
pseudoallergic O 0 0.9959061
reactions O 0 0.06363395
in O 0 0.0029924316
our O 0 0.0039471723
patients O 0 0.007302041
. O 0 0.008978375

Corticosteroids O 0 0.7778998
different O 0 0.0024586353
from O 0 0.0021661073
paramethasone B-Chemical 1 0.99977165
also O 0 0.0011926673
produced O 0 0.0009853495
hypersensitivity B-Disease 0 0.9485208
reactions O 0 0.016193502
in O 0 0.0004055958
these O 0 0.0004293893
patients O 0 0.00071958604
; O 0 0.00075983343
however O 0 0.000588212
, O 0 0.00065957784
a O 0 0.0006491737
few O 0 0.00059269776
of O 0 0.0011222514
them O 0 0.0020103364
were O 0 0.0025577082
tolerated O 0 0.007943628
. O 0 0.00647095

The O 0 0.00449857
basic O 0 0.00374565
mechanisms O 0 0.0026577397
of O 0 0.0027711722
those O 0 0.0026732627
reactions O 0 0.004677327
are O 0 0.00195393
not O 0 0.0021392931
yet O 0 0.0033807307
fully O 0 0.003864118
understood O 0 0.0070521897
. O 0 0.009680081

To O 0 0.0032593606
our O 0 0.0026177207
knowledge O 0 0.0022948266
, O 0 0.001867047
this O 0 0.001054226
is O 0 0.00082624226
the O 0 0.00063648773
first O 0 0.00052523124
report O 0 0.000928238
of O 0 0.0008196224
a O 0 0.0012510313
pseudo O 0 0.10478766
- O 0 0.22007886
allergy B-Disease 0 0.9991835
caused O 0 0.0040904325
by O 0 0.009305175
paramethasone B-Chemical 1 0.99988747
. O 0 0.010603043

Study O 0 0.006459823
of O 0 0.0028315277
the O 0 0.001734729
role O 0 0.001210087
of O 0 0.012921026
vitamin B-Chemical 0 0.9999999
B12 I-Chemical 0 1.0
and O 0 0.36891618
folinic B-Chemical 0 0.99999976
acid I-Chemical 0 0.99965525
supplementation O 0 0.9747908
in O 0 0.0011774567
preventing O 0 0.03512325
hematologic O 0 0.99993384
toxicity B-Disease 2 0.9999788
of O 0 0.038411506
zidovudine B-Chemical 1 0.9987851
. O 0 0.010091043

A O 0 0.042954296
prospective O 0 0.006123365
, O 0 0.0028905165
randomized O 0 0.001647416
study O 0 0.0011587341
was O 0 0.00067543425
conducted O 0 0.00043451096
to O 0 0.00032235042
evaluate O 0 0.00018458645
the O 0 0.00023058629
role O 0 0.00020600074
of O 0 0.0079205185
vitamin B-Chemical 0 1.0
B12 I-Chemical 0 1.0
and O 0 0.23691233
folinic B-Chemical 0 0.9999999
acid I-Chemical 0 0.9995382
supplementation O 0 0.9593444
in O 0 0.00044251126
preventing O 0 0.007717716
zidovudine B-Chemical 1 0.99964356
( O 0 0.14689393
ZDV B-Chemical 0 0.99999666
) O 0 0.01535715
- O 0 0.012391247
induced O 0 0.0012587544
bone B-Disease 0 0.2837378
marrow I-Disease 0 0.8318432
suppression I-Disease 0 0.30659503
. O 0 0.008266987

Seventy O 0 0.0076686675
- O 0 0.0071381703
five O 0 0.0017857194
human B-Disease 0 0.006681423
immunodeficiency I-Disease 0 0.9999684
virus I-Disease 0 0.99241525
( I-Disease 0 0.16652453
HIV I-Disease 0 0.9992404
) I-Disease 0 0.04080796
- I-Disease 0 0.016486622
infected I-Disease 0 0.000604209
patients O 0 0.0005859279
with O 0 0.00047462372
CD4 O 0 0.74164426
+ O 0 0.006731062
cell O 0 0.0018041441
counts O 0 0.00028755533
< O 0 0.00018152536
500 O 0 0.00029383835
/ O 0 0.0004972668
mm3 O 0 0.00036151384
were O 0 0.00015918199
randomized O 0 0.00014312236
to O 0 0.00011271565
receive O 0 0.0001182313
either O 0 0.00032744845
ZDV B-Chemical 0 0.9999852
( O 0 0.0012786844
500 O 0 0.0005972574
mg O 0 0.011787458
daily O 0 0.00024459543
) O 0 0.00034985426
alone O 0 0.00020921696
( O 0 0.00045830724
group O 0 0.00049670256
I O 0 0.009499463
, O 0 0.00026932298
n O 0 0.00018668712
= O 0 0.0005017641
38 O 0 0.0003452504
) O 0 0.0003558782
or O 0 0.00016581586
in O 0 0.00017199562
combination O 0 0.00038633164
with O 0 0.00440001
folinic B-Chemical 0 0.99999964
acid I-Chemical 0 0.99833775
( O 0 0.0013662713
15 O 0 0.00015052836
mg O 0 0.0031696232
daily O 0 0.00018752493
) O 0 0.00031643055
and O 0 0.00039955808
intramascular O 0 0.9499591
vitamin B-Chemical 0 0.9999999
B12 I-Chemical 0 1.0
( O 0 0.0025813028
1000 O 0 0.00043358514
micrograms O 0 0.0012205418
monthly O 0 0.00025988842
) O 0 0.00052895106
( O 0 0.0005573462
group O 0 0.00067989726
II O 0 0.005470971
, O 0 0.000965055
n O 0 0.0010960047
= O 0 0.002540589
37 O 0 0.0036321539
) O 0 0.005760924
. O 0 0.007705361

Finally O 0 0.0043990854
, O 0 0.003281679
15 O 0 0.0016610617
patients O 0 0.0013366374
were O 0 0.0007960564
excluded O 0 0.000562829
from O 0 0.00042025716
the O 0 0.00039875592
study O 0 0.0005390122
( O 0 0.0007564908
noncompliance O 0 0.43324265
14 O 0 0.00037556258
, O 0 0.0007420336
death B-Disease 0 0.9983341
1 O 0 0.00044137388
) O 0 0.00066225603
; O 0 0.00044315527
thus O 0 0.00030450991
, O 0 0.00032007147
60 O 0 0.00021497173
patients O 0 0.0002672241
( O 0 0.00029964806
31 O 0 0.00026528366
in O 0 0.00021155691
group O 0 0.00037620688
I O 0 0.001905603
and O 0 0.00031215628
29 O 0 0.00046024864
in O 0 0.00034723833
group O 0 0.0006568196
II O 0 0.0059266766
) O 0 0.0010642965
were O 0 0.00093138573
eligible O 0 0.0014311512
for O 0 0.0019580147
analysis O 0 0.003941807
. O 0 0.006936476

No O 0 0.00793325
significant O 0 0.0045006764
differences O 0 0.0030192798
between O 0 0.002749146
groups O 0 0.003320606
were O 0 0.0034469771
found O 0 0.0036669858
at O 0 0.0049987235
enrollment O 0 0.010766696
. O 0 0.011958101

During O 0 0.0027639433
the O 0 0.0022465545
study O 0 0.0026829368
, O 0 0.025464473
vitamin B-Chemical 0 0.99999964
B12 I-Chemical 0 0.9999999
and O 0 0.051052622
folate B-Chemical 0 0.99994504
levels O 0 0.0005082813
were O 0 0.0002810661
significantly O 0 0.00022796221
higher O 0 0.0001951368
in O 0 0.00019367393
group O 0 0.00040782883
II O 0 0.017208528
patients O 0 0.00047998072
; O 0 0.00046056753
however O 0 0.00029368713
, O 0 0.0002542841
no O 0 0.00011990827
differences O 0 0.00012754678
in O 0 0.0002451955
hemoglobin O 0 0.9738149
, O 0 0.0010607414
hematocrit O 0 0.7914897
, O 0 0.00023837414
mean O 0 0.00011930675
corpuscular O 0 0.9960102
volume O 0 0.0007026427
, O 0 0.00031825824
and O 0 0.0003157483
white O 0 0.04380148
- O 0 0.013104671
cell O 0 0.001976805
, O 0 0.00055481587
neutrophil O 0 0.051628586
and O 0 0.0005063219
platelet O 0 0.3913179
counts O 0 0.00020562962
were O 0 0.00013755755
observed O 0 0.00012315408
between O 0 0.00013283215
groups O 0 0.00021308879
at O 0 0.00021052363
3 O 0 0.0002624274
, O 0 0.00041554627
6 O 0 0.00038357417
, O 0 0.0006946622
9 O 0 0.00078765873
and O 0 0.0012102466
12 O 0 0.0016529337
months O 0 0.0025947639
. O 0 0.005894267

Severe O 0 0.97311157
hematologic O 0 0.9998323
toxicity B-Disease 2 0.9999809
( O 0 0.013483553
neutrophil O 0 0.14780517
count O 0 0.0018996393
< O 0 0.0004528217
1000 O 0 0.00054620253
/ O 0 0.0008034686
mm3 O 0 0.00063816726
and O 0 0.0003707174
/ O 0 0.0015186832
or O 0 0.00034426682
hemoglobin O 0 0.88774866
< O 0 0.00023529776
8 O 0 0.00020255618
g O 0 0.0004767567
/ O 0 0.0022445002
dl O 0 0.058821883
) O 0 0.0005691973
occurred O 0 0.00023505918
in O 0 0.00021478962
4 O 0 0.00019443697
patients O 0 0.0002381597
assigned O 0 0.00020080667
to O 0 0.00025558277
group O 0 0.0005238823
I O 0 0.0018889155
and O 0 0.0005467007
7 O 0 0.00058981526
assigned O 0 0.00079596316
to O 0 0.0013499799
group O 0 0.0031365857
II O 0 0.021530628
. O 0 0.007013054

There O 0 0.0043726214
was O 0 0.0026219958
no O 0 0.0014874961
correlation O 0 0.0012899443
between O 0 0.0018163562
vitamin B-Chemical 0 0.9999995
B12 I-Chemical 0 0.9999999
or O 0 0.013131451
folate B-Chemical 0 0.9998821
levels O 0 0.0012905292
and O 0 0.0016209579
development O 0 0.004226977
of O 0 0.011055877
myelosuppression B-Disease 0 0.9999443
. O 0 0.010277417

Vitamin B-Chemical 0 0.9999994
B12 I-Chemical 0 0.9999995
and O 0 0.36793175
folinic B-Chemical 0 0.9999994
acid I-Chemical 0 0.9998301
supplementation O 0 0.99452424
of O 0 0.06483233
ZDV B-Chemical 0 0.99999666
therapy O 0 0.010624494
does O 0 0.00032975638
not O 0 0.00019356611
seem O 0 0.00019673524
useful O 0 0.000163694
in O 0 0.00016490182
preventing O 0 0.0003607774
or O 0 0.0003615078
reducing O 0 0.01355456
ZDV B-Chemical 0 0.99999905
- O 0 0.37823656
induced O 0 0.0051005343
myelotoxicity B-Disease 0 0.99999833
in O 0 0.00029814686
the O 0 0.00018033208
overall O 0 0.00020181689
treated O 0 0.0002831063
population O 0 0.00090857316
, O 0 0.0004078856
although O 0 0.00021762618
a O 0 0.0002588318
beneficial O 0 0.0002675101
effect O 0 0.00023992693
in O 0 0.0002918366
certain O 0 0.00044514923
subgroups O 0 0.000705495
of O 0 0.0007986889
patients O 0 0.0015913183
cannot O 0 0.002533056
be O 0 0.0021697683
excluded O 0 0.0040050475
. O 0 0.006769036

Safety O 0 0.019902393
and O 0 0.010050423
side O 0 0.056691222
- O 0 0.02111331
effects O 0 0.0122637935
of O 0 0.038517665
alprazolam B-Chemical 1 0.9999919
. O 0 0.024555124

Controlled O 0 0.011101952
study O 0 0.011085048
in O 0 0.01369879
agoraphobia B-Disease 0 0.9999908
with O 0 0.14050476
panic B-Disease 0 0.9999591
disorder I-Disease 0 0.9966364
. O 0 0.022731064

BACKGROUND O 0 0.016524939
: O 0 0.0041319686
The O 0 0.0018555057
widespread O 0 0.0022288573
use O 0 0.001399983
of O 0 0.0024821442
benzodiazepines B-Chemical 1 0.999962
has O 0 0.0008231566
led O 0 0.0007166577
to O 0 0.0006248001
increasing O 0 0.00078034634
recognition O 0 0.0014020676
of O 0 0.0016658177
their O 0 0.0022477908
unwanted O 0 0.03908453
effects O 0 0.0062804287
. O 0 0.007908144

The O 0 0.0030406178
efficacy O 0 0.0032476997
of O 0 0.006336879
alprazolam B-Chemical 1 0.9999989
and O 0 0.004306389
placebo O 0 0.20328754
in O 0 0.001720334
panic B-Disease 0 0.9999938
disorder I-Disease 0 0.99734783
with O 0 0.025951033
agoraphobia B-Disease 0 0.9999999
, O 0 0.0011090914
and O 0 0.00035293636
the O 0 0.0002925539
side O 0 0.04778478
- O 0 0.009033392
effect O 0 0.00026119204
and O 0 0.00040389795
adverse O 0 0.12975383
effect O 0 0.00028815225
profiles O 0 0.0003149081
of O 0 0.00054910587
both O 0 0.00075630454
drug O 0 0.12410007
groups O 0 0.001348935
were O 0 0.0018954473
measured O 0 0.0028518818
. O 0 0.0060068774

METHOD O 0 0.008857701
: O 0 0.004685213
In O 0 0.0025912046
London O 0 0.009537906
and O 0 0.0017890111
Toronto O 0 0.033380184
154 O 0 0.0021009743
patients O 0 0.0008275042
who O 0 0.00072601304
met O 0 0.0006959663
DSM O 0 0.03765526
- O 0 0.009606031
III O 0 0.008864222
criteria O 0 0.00045851216
for O 0 0.00074541
panic B-Disease 0 0.9999896
disorder I-Disease 0 0.99331325
with O 0 0.008335893
agoraphobia B-Disease 0 0.9999994
were O 0 0.00065635523
randomised O 0 0.0008506026
to O 0 0.0011765352
alprazolam B-Chemical 1 0.99999475
or O 0 0.0030351153
placebo O 0 0.062050786
. O 0 0.0064885765

Subjects O 0 0.006180864
in O 0 0.0034017412
each O 0 0.0021370242
drug O 0 0.04295865
group O 0 0.0023131424
also O 0 0.0016881798
received O 0 0.0016049071
either O 0 0.0020525302
exposure O 0 0.0073073385
or O 0 0.004751374
relaxation O 0 0.22524017
. O 0 0.010185861

Treatment O 0 0.0074477876
was O 0 0.002666413
from O 0 0.0015504322
weeks O 0 0.0010485557
0 O 0 0.0010420235
to O 0 0.0007457436
8 O 0 0.0007152795
and O 0 0.00070773065
was O 0 0.00066399586
then O 0 0.0006273237
tapered O 0 0.0010323096
from O 0 0.00079610874
weeks O 0 0.0009340989
8 O 0 0.0015569258
to O 0 0.002330172
16 O 0 0.004579647
. O 0 0.0073274006

RESULTS O 0 0.009111608
: O 0 0.006798098
Mean O 0 0.0045028897
alprazolam B-Chemical 1 0.99998
dose O 0 0.018297732
was O 0 0.004420432
5 O 0 0.0042594033
mg O 0 0.019716764
daily O 0 0.008509169
. O 0 0.01173274

Compared O 0 0.0031876236
with O 0 0.0024458799
placebo O 0 0.03535505
subjects O 0 0.0027682593
, O 0 0.010157665
alprazolam B-Chemical 1 0.99999905
patients O 0 0.001681883
developed O 0 0.0007656246
more O 0 0.00048548888
adverse O 0 0.16617554
reactions O 0 0.006701898
( O 0 0.00050826935
21 O 0 0.00027101117
% O 0 0.0002801268
v O 0 0.004077112
. O 0 0.00021357942
0 O 0 0.00023141905
% O 0 0.00026170557
) O 0 0.00040408337
of O 0 0.0005689958
depression B-Disease 0 0.9995968
, O 0 0.0029265913
enuresis B-Disease 0 0.99824286
, O 0 0.0012922456
disinhibition O 0 0.9482471
and O 0 0.0011545357
aggression B-Disease 0 0.99977416
; O 0 0.001050687
and O 0 0.0003082005
more O 0 0.0003517029
side O 0 0.041553028
- O 0 0.01215658
effects O 0 0.00041133995
, O 0 0.000475519
particularly O 0 0.001803024
sedation O 0 0.41832724
, O 0 0.002186036
irritability B-Disease 2 0.999967
, O 0 0.0014408345
impaired B-Disease 0 0.040659532
memory I-Disease 0 0.9549438
, O 0 0.0016075493
weight B-Disease 0 0.00575601
loss I-Disease 0 0.0070102424
and O 0 0.013061351
ataxia B-Disease 0 0.9999759
. O 0 0.01043679

Side O 0 0.86616814
- O 0 0.01869622
effects O 0 0.0030770837
tended O 0 0.0016043305
to O 0 0.0010779513
diminish O 0 0.00095917325
during O 0 0.0007440119
treatment O 0 0.0010493496
but O 0 0.0010975914
remained O 0 0.0012544176
significant O 0 0.0012689872
at O 0 0.0015996655
week O 0 0.0022129565
8 O 0 0.0038434386
. O 0 0.006842429

Despite O 0 0.00607667
this O 0 0.004648795
, O 0 0.004721624
the O 0 0.003496349
drop O 0 0.005807163
- O 0 0.006213031
out O 0 0.0029762066
rate O 0 0.0044012642
was O 0 0.0059177275
low O 0 0.009063774
. O 0 0.012496906

CONCLUSIONS O 0 0.124295734
: O 0 0.037354656
Alprazolam B-Chemical 0 0.9999938
caused O 0 0.0031008627
side O 0 0.33108273
- O 0 0.031303313
effects O 0 0.0011030571
and O 0 0.0008577262
adverse O 0 0.24433616
effects O 0 0.000579925
during O 0 0.0002981116
treatment O 0 0.0005168545
but O 0 0.00049751054
many O 0 0.00043725286
patients O 0 0.00069632457
were O 0 0.0007011083
willing O 0 0.001131309
to O 0 0.0012010256
accept O 0 0.0024458517
these O 0 0.003797864
. O 0 0.0067699114

Crescentic O 0 0.9898691
fibrillary O 0 0.9706692
glomerulonephritis B-Disease 2 0.9999893
associated O 0 0.004705323
with O 0 0.0033155975
intermittent O 0 0.40142968
rifampin B-Chemical 1 0.99999475
therapy O 0 0.036096945
for O 0 0.0043003554
pulmonary B-Disease 0 0.9970182
tuberculosis I-Disease 2 0.9996107
. O 0 0.014010297

This O 0 0.0051498394
case O 0 0.0027431883
study O 0 0.0019934012
reveals O 0 0.0013165277
an O 0 0.0011362394
unusual O 0 0.0015364973
finding O 0 0.0008290795
of O 0 0.0005800061
rapidly O 0 0.0010375645
proliferative O 0 0.8283759
crescentic O 0 0.9999807
glomerulonephritis B-Disease 2 0.9999999
in O 0 0.0010746312
a O 0 0.00044578855
patient O 0 0.00026476337
treated O 0 0.0003346427
with O 0 0.0011123398
rifampin B-Chemical 1 0.999997
who O 0 0.0012072156
had O 0 0.00024138534
no O 0 0.00020698457
other O 0 0.00039067722
identifiable O 0 0.0031811811
causes O 0 0.00083163515
for O 0 0.00097374513
developing O 0 0.013577289
this O 0 0.0029058312
disease O 0 0.8826075
. O 0 0.0077963374

This O 0 0.00475109
patient O 0 0.0024144356
underwent O 0 0.0015424085
a O 0 0.0013994316
10 O 0 0.0009469936
- O 0 0.0016542879
month O 0 0.00041675026
regimen O 0 0.00058193057
of O 0 0.0016203993
rifampin B-Chemical 1 0.9999989
and O 0 0.04972351
isoniazid B-Chemical 1 0.9999995
for O 0 0.0020171653
pulmonary B-Disease 0 0.99836534
tuberculosis I-Disease 2 0.999814
and O 0 0.00078478496
was O 0 0.00021381374
discovered O 0 0.00018068182
to O 0 0.00013935953
have O 0 0.00015175248
developed O 0 0.0003453954
signs O 0 0.01260631
of O 0 0.0005187661
severe O 0 0.24100055
renal B-Disease 0 0.925854
failure I-Disease 0 0.16598313
five O 0 0.00032808812
weeks O 0 0.00034856136
after O 0 0.00049609994
completion O 0 0.000958743
of O 0 0.0021625876
therapy O 0 0.0054115537
. O 0 0.006472857

Renal O 0 0.02195971
biopsy O 0 0.0043857144
revealed O 0 0.0024139623
severe O 0 0.23530298
glomerulonephritis B-Disease 2 0.99999404
with O 0 0.0040425463
crescents O 0 0.9835825
, O 0 0.0013353118
electron O 0 0.013581568
dense O 0 0.0011377166
fibrillar O 0 0.12627655
deposits O 0 0.1119057
and O 0 0.0013572999
moderate O 0 0.065271
lymphocytic O 0 0.9996847
interstitial O 0 0.923527
infiltrate O 0 0.959237
. O 0 0.0098311

Other O 0 0.007055957
possible O 0 0.00347826
causes O 0 0.002881204
of O 0 0.002551386
rapidly O 0 0.0034519352
progressive O 0 0.63551635
glomerulonephritis B-Disease 2 0.9999962
were O 0 0.0023863544
investigated O 0 0.0017704606
and O 0 0.0028250539
ruled O 0 0.005105616
out O 0 0.00459789
. O 0 0.008614806

This O 0 0.0052135605
report O 0 0.0036695597
documents O 0 0.0023821
the O 0 0.0012794074
unusual O 0 0.0016882826
occurrence O 0 0.0012614098
of O 0 0.0007554153
rapidly O 0 0.001156803
progressive O 0 0.4690705
glomerulonephritis B-Disease 2 0.9999989
with O 0 0.003311028
crescents O 0 0.9894037
and O 0 0.0016495913
fibrillar O 0 0.9015179
glomerulonephritis B-Disease 2 0.99999857
in O 0 0.00081161066
a O 0 0.0008517628
patient O 0 0.0009648812
treated O 0 0.0016788241
with O 0 0.0051445556
rifampin B-Chemical 1 0.99997354
. O 0 0.009557314

Acute O 0 0.69069976
confusion B-Disease 0 0.5812046
induced O 0 0.002472697
by O 0 0.0018451879
a O 0 0.0017256619
high O 0 0.002094517
- O 0 0.009209566
dose O 0 0.002989757
infusion O 0 0.0018183974
of O 0 0.0009130411
5 B-Chemical 0 0.0009491054
- I-Chemical 0 0.0360397
fluorouracil I-Chemical 0 0.9995016
and O 0 0.025798846
folinic B-Chemical 0 0.99999464
acid I-Chemical 0 0.9954223
. O 0 0.0107304845

A O 0 0.08668222
61 O 0 0.0062989155
- O 0 0.00818307
year O 0 0.0021347608
- O 0 0.0055163326
old O 0 0.0012314399
man O 0 0.028489947
was O 0 0.0005801
treated O 0 0.00043604148
with O 0 0.00033481853
combination O 0 0.00042405364
chemotherapy O 0 0.026239958
incorporating O 0 0.0007126171
cisplatinum B-Chemical 0 0.9999677
, O 0 0.017581875
etoposide B-Chemical 1 0.9999517
, O 0 0.0020991815
high O 0 0.0013177083
- O 0 0.010739123
dose O 0 0.0017063696
5 B-Chemical 0 0.00022439989
- I-Chemical 0 0.025447948
fluorouracil I-Chemical 0 0.9988859
( O 0 0.0005405585
2 O 0 0.00019491496
, O 0 0.00023727257
250 O 0 0.00024452593
mg O 0 0.005901035
/ O 0 0.0014352251
m2 O 0 0.015133792
/ O 0 0.0019411332
24 O 0 0.00026562257
hours O 0 0.00023048077
) O 0 0.0006218209
and O 0 0.0014499532
folinic B-Chemical 0 0.99999726
acid I-Chemical 0 0.9845206
for O 0 0.0011258456
an O 0 0.0024398374
inoperable O 0 0.94902545
gastric B-Disease 0 0.99916506
adenocarcinoma I-Disease 0 0.9999887
. O 0 0.021155436

He O 0 0.008575952
developed O 0 0.0048880423
acute O 0 0.89340955
neurologic O 0 0.99682295
symptoms O 0 0.6611473
of O 0 0.0017022362
mental O 0 0.5332059
confusion B-Disease 0 0.95392394
, O 0 0.0062473845
disorientation B-Disease 0 0.9999206
and O 0 0.0047921436
irritability B-Disease 2 0.99997795
, O 0 0.0005219352
and O 0 0.00024496161
then O 0 0.00017811431
lapsed O 0 0.00093756657
into O 0 0.00011506354
a O 0 0.0002834828
deep O 0 0.024755023
coma B-Disease 0 0.9999026
, O 0 0.00035047083
lasting O 0 0.00016999376
for O 0 0.00012443248
approximately O 0 0.00012922393
40 O 0 0.000135674
hours O 0 0.00010323483
during O 0 9.247322e-05
the O 0 0.00012337517
first O 0 0.00012167141
dose O 0 0.0005264587
( O 0 0.00030642972
day O 0 0.00017462173
2 O 0 0.00021038759
) O 0 0.00035811216
of O 0 0.00037097107
5 B-Chemical 0 0.0004430271
- I-Chemical 0 0.02453356
fluorouracil I-Chemical 0 0.99942696
and O 0 0.015484555
folinic B-Chemical 0 0.999997
acid I-Chemical 0 0.99627256
infusion O 0 0.06524304
. O 0 0.0065891813

This O 0 0.0060049337
complication O 0 0.036423
reappeared O 0 0.0031390362
on O 0 0.00088836503
day O 0 0.00072881125
25 O 0 0.0006371025
during O 0 0.00033595558
the O 0 0.00033098974
second O 0 0.0002963442
dose O 0 0.0006967467
of O 0 0.00039815443
5 B-Chemical 0 0.00033583725
- I-Chemical 0 0.03477686
fluorouracil I-Chemical 0 0.99962723
and O 0 0.012406957
folinic B-Chemical 0 0.9999995
acid I-Chemical 0 0.99773526
, O 0 0.0011260739
which O 0 0.0004854616
were O 0 0.0004081431
then O 0 0.0004561724
the O 0 0.0007408508
only O 0 0.0013719974
drugs O 0 0.045365598
given O 0 0.0027363733
. O 0 0.00613806

Because O 0 0.0067503327
folinic B-Chemical 0 0.99999297
acid I-Chemical 0 0.99789834
was O 0 0.0019780772
unlikely O 0 0.00089021615
to O 0 0.00051671115
be O 0 0.00045600676
associated O 0 0.0004078409
with O 0 0.00036680765
this O 0 0.0003188544
condition O 0 0.0012248124
, O 0 0.0027316073
neurotoxicity B-Disease 2 0.99994075
due O 0 0.00022501458
to O 0 0.0002541271
high O 0 0.00074393605
- O 0 0.0076555656
dose O 0 0.002553249
5 B-Chemical 0 0.0005991911
- I-Chemical 0 0.019206712
fluorouracil I-Chemical 0 0.99687165
was O 0 0.0015980966
highly O 0 0.0027006483
suspected O 0 0.027443673
. O 0 0.0070671476

The O 0 0.0031569926
pathogenesis O 0 0.0035013964
of O 0 0.002084218
5 B-Chemical 0 0.0015855536
- I-Chemical 0 0.14017732
fluorouracil I-Chemical 0 0.99994946
neurotoxicity B-Disease 2 0.99999046
may O 0 0.0006280263
be O 0 0.00035618636
due O 0 0.00022364485
to O 0 0.00024566258
a O 0 0.0004784448
Krebs O 0 0.3933539
cycle O 0 0.0011574626
blockade O 0 0.010156141
by O 0 0.0011613437
fluoroacetate B-Chemical 0 0.9999963
and O 0 0.027976874
fluorocitrate B-Chemical 0 0.9999988
, O 0 0.09497058
thiamine B-Chemical 0 0.99999774
deficiency O 0 0.9297154
, O 0 0.0036040996
or O 0 0.0030446216
dihydrouracil B-Chemical 0 0.9999181
dehydrogenase O 0 0.9984219
deficiency O 0 0.9399084
. O 0 0.008767076

High O 0 0.024597948
- O 0 0.010192651
dose O 0 0.0055470285
5 B-Chemical 0 0.0017942557
- I-Chemical 0 0.065295525
fluorouracil I-Chemical 0 0.99982774
/ O 0 0.6708095
folinic B-Chemical 0 0.9999994
acid I-Chemical 0 0.9988901
infusion O 0 0.018337373
therapy O 0 0.00092894316
has O 0 0.00034525746
recently O 0 0.00039476505
become O 0 0.0005356664
a O 0 0.0006732014
popular O 0 0.001310101
regimen O 0 0.0011973748
for O 0 0.0014399824
various O 0 0.0038424656
cancers B-Disease 2 0.991787
. O 0 0.009641285

It O 0 0.0052645314
is O 0 0.0028123562
necessary O 0 0.0015927267
that O 0 0.0013552835
both O 0 0.0013113937
oncologists O 0 0.0015619777
and O 0 0.0011515196
neurologists O 0 0.0014629512
be O 0 0.0008557094
fully O 0 0.0008811111
aware O 0 0.0010654235
of O 0 0.0015627176
this O 0 0.0021510054
unusual O 0 0.008085768
complication O 0 0.39361045
. O 0 0.008794807

Effect O 0 0.0046084607
of O 0 0.0038066092
switching O 0 0.024283951
carbamazepine B-Chemical 1 0.99999917
to O 0 0.0077541578
oxcarbazepine B-Chemical 0 0.9999987
on O 0 0.0010258133
the O 0 0.0013009264
plasma O 0 0.008303378
levels O 0 0.0023158155
of O 0 0.0065827267
neuroleptics O 0 0.9996062
. O 0 0.008565811

A O 0 0.0827464
case O 0 0.049663235
report O 0 0.06332076
. O 0 0.06175323

Carbamazepine B-Chemical 0 0.99999106
was O 0 0.0033013097
switched O 0 0.0018729557
to O 0 0.0010008361
its O 0 0.0015529762
10 O 0 0.0010236786
- O 0 0.12647116
keto O 0 0.99996257
analogue O 0 0.69406134
oxcarbazepine B-Chemical 0 0.99999976
among O 0 0.000620509
six O 0 0.00016987757
difficult O 0 0.00021710056
- O 0 0.0015421318
to O 0 0.00022465229
- O 0 0.008241786
treat O 0 0.0014079497
schizophrenic B-Disease 2 0.9999714
or O 0 0.0021954337
organic B-Disease 0 0.99995816
psychotic I-Disease 0 0.9999999
patients O 0 0.0015715851
using O 0 0.00045218156
concomitantly O 0 0.18801929
haloperidol B-Chemical 1 0.9999999
, O 0 0.060803913
chlorpromazine B-Chemical 1 0.9999975
or O 0 0.025238832
clozapine B-Chemical 0 0.9999944
. O 0 0.008013378

This O 0 0.004850549
change O 0 0.0024222475
resulted O 0 0.0013727065
within O 0 0.000911745
2 O 0 0.0009781705
- O 0 0.001878819
4 O 0 0.0004213085
weeks O 0 0.00026839608
in O 0 0.00029012936
the O 0 0.0002949633
50 O 0 0.00045372295
- O 0 0.002070212
200 O 0 0.0003578021
% O 0 0.00026305366
increase O 0 0.0001733926
in O 0 0.00020557846
the O 0 0.00022360944
plasma O 0 0.0026574575
levels O 0 0.00023086215
of O 0 0.00035273322
these O 0 0.000698476
neuroleptics O 0 0.9989881
and O 0 0.00049631495
the O 0 0.00058493414
appearance O 0 0.003227811
of O 0 0.02294253
extrapyramidal B-Disease 0 0.99999905
symptoms I-Disease 0 0.98829854
. O 0 0.007445366

None O 0 0.006320944
of O 0 0.0031524613
the O 0 0.0020188987
patients O 0 0.0018220997
showed O 0 0.0010813037
any O 0 0.000895497
clinical O 0 0.0018663023
deteriotation O 0 0.00692102
during O 0 0.00055343524
the O 0 0.00069922116
following O 0 0.0008025221
3 O 0 0.0011479438
- O 0 0.0028171157
6 O 0 0.0020207528
months O 0 0.00312293
. O 0 0.006777319

The O 0 0.0029476362
results O 0 0.0019505381
of O 0 0.0017037643
this O 0 0.0011591845
case O 0 0.0009752706
report O 0 0.0011293945
support O 0 0.00040426716
the O 0 0.00035495183
idea O 0 0.00032259486
that O 0 0.00022940934
in O 0 0.00028147132
contrast O 0 0.0010625812
with O 0 0.050604593
carbamazepine B-Chemical 1 1.0
oxcarbazepine B-Chemical 0 1.0
does O 0 0.00039132748
not O 0 0.00015899254
induce O 0 0.00013811243
the O 0 0.00031148887
hepatic O 0 0.95847964
microsomal O 0 0.9933744
enzyme O 0 0.05461722
systems O 0 0.00034588063
regulating O 0 0.00024986733
the O 0 0.0004897299
inactivation O 0 0.0013086743
of O 0 0.004022012
antipsychotic O 0 0.99974996
drugs O 0 0.41215983
. O 0 0.006307797

Time O 0 0.008025675
course O 0 0.0039832555
of O 0 0.004731604
lipid O 0 0.98654675
peroxidation O 0 0.9999963
in O 0 0.012524558
puromycin B-Chemical 0 0.9984835
aminonucleoside I-Chemical 0 0.9999982
- O 0 0.76407546
induced O 0 0.08870129
nephropathy B-Disease 2 0.99999785
. O 0 0.027058728

Reactive O 0 0.9906094
oxygen B-Chemical 1 0.9961414
species O 0 0.0046412377
have O 0 0.0013507933
been O 0 0.000995949
implicated O 0 0.00062616525
in O 0 0.00054441666
the O 0 0.00044679953
pathogenesis O 0 0.0014745705
of O 0 0.0012014048
acute O 0 0.9881507
puromycin B-Chemical 0 0.999645
aminonucleoside I-Chemical 0 0.9999999
( O 0 0.6616382
PAN B-Chemical 1 0.99999833
) O 0 0.097740546
- O 0 0.09868692
induced O 0 0.004419977
nephropathy B-Disease 2 0.9999999
, O 0 0.009364442
with O 0 0.002621718
antioxidants O 0 0.99907184
significantly O 0 0.0012587928
reducing O 0 0.001792253
the O 0 0.004041204
proteinuria B-Disease 0 0.99998224
. O 0 0.00948006

The O 0 0.0031273658
temporal O 0 0.0038227295
relationship O 0 0.0013056551
between O 0 0.0013145743
lipid O 0 0.96727383
peroxidation O 0 0.99999666
in O 0 0.001131461
the O 0 0.0008732886
kidney O 0 0.665234
and O 0 0.0056403894
proteinuria B-Disease 0 0.99999535
was O 0 0.0010710373
examined O 0 0.00087565114
in O 0 0.0014941315
this O 0 0.0023508877
study O 0 0.004640555
. O 0 0.0068985503

Rats O 0 0.009548759
were O 0 0.002466069
treated O 0 0.0016918144
with O 0 0.0012013664
a O 0 0.0011129911
single O 0 0.0009229185
IV O 0 0.11895358
injection O 0 0.00087384414
of O 0 0.00097147847
puromycin B-Chemical 0 0.9953799
aminonucleoside I-Chemical 0 0.9999995
, O 0 0.077432744
( O 0 0.05406852
PAN B-Chemical 1 0.99998844
, O 0 0.0014027889
7 O 0 0.00019489173
. O 0 0.00016118423
5 O 0 0.00015062066
mg O 0 0.0026454383
/ O 0 0.00077649084
kg O 0 0.00069427834
) O 0 0.00038475817
and O 0 0.00021481092
24 O 0 0.00017392582
hour O 0 0.00015222901
urine O 0 0.015041993
samples O 0 0.00015394151
were O 0 0.00013006643
obtained O 0 0.00011371145
prior O 0 0.00010084759
to O 0 0.00011603613
sacrifice O 0 0.00020421346
on O 0 9.685367e-05
days O 0 0.00011374366
3 O 0 0.00013877038
, O 0 0.00020182652
5 O 0 0.00015250634
, O 0 0.00022724607
7 O 0 0.00017046691
, O 0 0.00024839037
10 O 0 0.00020652701
, O 0 0.00028821873
17 O 0 0.00029690049
, O 0 0.0003188629
27 O 0 0.00037501846
, O 0 0.00039069811
41 O 0 0.0006426138
( O 0 0.00094611605
N O 0 0.9927086
= O 0 0.0016405719
5 O 0 0.000645076
- O 0 0.0015745178
10 O 0 0.00093960634
per O 0 0.0011089473
group O 0 0.0027130186
) O 0 0.0055264523
. O 0 0.0076080253

The O 0 0.004879755
kidneys O 0 0.0069436636
were O 0 0.0029192425
removed O 0 0.0022528782
, O 0 0.002877995
flushed O 0 0.0029447898
with O 0 0.0028087986
ice O 0 0.030909318
cold O 0 0.117982075
TRIS O 0 0.99622357
buffer O 0 0.039579086
. O 0 0.013177995

Kidney O 0 0.06201001
cortices O 0 0.26292503
from O 0 0.0033534023
each O 0 0.0022569634
animal O 0 0.0032395334
were O 0 0.0027643628
used O 0 0.0027611507
to O 0 0.003476347
prepare O 0 0.0053754915
homogenates O 0 0.0133548025
. O 0 0.011456197

Tissue O 0 0.23391022
lipid O 0 0.97868013
peroxidation O 0 0.9999902
was O 0 0.0019044979
measured O 0 0.0008024754
in O 0 0.00067121483
whole O 0 0.0006280683
homogenates O 0 0.0012366505
as O 0 0.00034658337
well O 0 0.00031067655
as O 0 0.00031994513
in O 0 0.00040985958
lipid O 0 0.49226907
extracts O 0 0.0011644425
from O 0 0.0005032099
homogenates O 0 0.011135873
as O 0 0.002360523
thiobarbituric B-Chemical 0 0.99999845
acid I-Chemical 0 0.99820244
reactive O 0 0.9488594
substances O 0 0.8810298
. O 0 0.007829923

Proteinuria B-Disease 2 0.9999273
was O 0 0.0035360658
evident O 0 0.001950952
at O 0 0.0012080526
day O 0 0.00093460456
5 O 0 0.00079436204
, O 0 0.0009390819
peaked O 0 0.0009866003
at O 0 0.00060521706
day O 0 0.00060639955
7 O 0 0.00067660224
and O 0 0.00093494746
persisted O 0 0.0011912624
to O 0 0.0016494013
day O 0 0.0025979078
27 O 0 0.0053676143
. O 0 0.0073325834

Lipid O 0 0.9990472
peroxidation O 0 0.9999852
in O 0 0.0034951565
homogenates O 0 0.007718403
was O 0 0.0009875039
maximal O 0 0.00061310566
at O 0 0.0004726118
day O 0 0.00040024502
3 O 0 0.00036788912
and O 0 0.00042088042
declined O 0 0.0005521362
rapidly O 0 0.0005499068
to O 0 0.0005028695
control O 0 0.0007141031
levels O 0 0.0010137892
by O 0 0.0016517633
day O 0 0.0022568263
17 O 0 0.0043852334
. O 0 0.006559842

This O 0 0.005578923
study O 0 0.003071869
supports O 0 0.0016390503
the O 0 0.0012436652
role O 0 0.0008748069
of O 0 0.0019105677
lipid O 0 0.99391514
peroxidation O 0 0.9999982
in O 0 0.000976619
mediating O 0 0.0006765253
the O 0 0.0030182176
proteinuric B-Disease 0 0.9999994
injury I-Disease 0 0.9998435
in O 0 0.04171402
PAN B-Chemical 1 0.99998903
nephropathy B-Disease 2 0.99999905
. O 0 0.029077815

Composition O 0 0.009127591
of O 0 0.004427714
gall B-Disease 0 0.601651
bladder I-Disease 0 0.5462128
stones I-Disease 0 0.97421175
associated O 0 0.0029214388
with O 0 0.0032728752
octreotide B-Chemical 1 0.9993094
: O 0 0.003104163
response O 0 0.0020986493
to O 0 0.0023246328
oral O 0 0.9405003
ursodeoxycholic B-Chemical 0 0.9999721
acid I-Chemical 0 0.98684305
. O 0 0.011605022

Octreotide B-Chemical 0 0.9997032
, O 0 0.0058206744
an O 0 0.0026353972
effective O 0 0.0017118646
treatment O 0 0.0015477381
for O 0 0.0014127856
acromegaly B-Disease 0 0.99857664
, O 0 0.0013118826
induces O 0 0.00066744734
gall B-Disease 0 0.8888673
bladder I-Disease 0 0.76768345
stones I-Disease 0 0.98340225
in O 0 0.0009665678
13 O 0 0.0010232842
- O 0 0.0022175086
60 O 0 0.0011815998
% O 0 0.0018785731
of O 0 0.0029703698
patients O 0 0.0058003254
. O 0 0.0076248427

Because O 0 0.0032089576
knowledge O 0 0.0026211652
of O 0 0.0020854538
stone O 0 0.16556998
composition O 0 0.0024653536
is O 0 0.00073080865
essential O 0 0.00045253
for O 0 0.00035018075
studies O 0 0.0003083598
of O 0 0.0003407084
their O 0 0.000341426
pathogenesis O 0 0.0038721599
, O 0 0.00076634565
treatment O 0 0.0005706315
, O 0 0.0005109841
and O 0 0.0003719871
prevention O 0 0.0049760025
, O 0 0.0004659715
this O 0 0.00018589488
was O 0 0.00015672705
investigated O 0 0.000119853044
by O 0 0.00015365583
direct O 0 0.00015078003
and O 0 0.0002300406
indirect O 0 0.00047167405
methods O 0 0.00022702085
in O 0 0.0002899164
14 O 0 0.0004849968
octreotide B-Chemical 1 0.99311113
treated O 0 0.0025690834
acromegalic B-Disease 0 0.9985758
patients O 0 0.0022706243
with O 0 0.0026642415
gall B-Disease 0 0.9799745
stones I-Disease 0 0.9979861
. O 0 0.010987197

Chemical O 0 0.4591122
analysis O 0 0.0032927808
of O 0 0.0033456946
gall B-Disease 0 0.9491683
stones I-Disease 0 0.9817355
retrieved O 0 0.000857557
at O 0 0.00063333154
cholecystectomy O 0 0.0039916714
from O 0 0.00033739448
two O 0 0.00028314083
patients O 0 0.00041122115
, O 0 0.00036894312
showed O 0 0.00024766012
that O 0 0.00022234318
they O 0 0.0002372952
contained O 0 0.00024919168
71 O 0 0.0006385487
% O 0 0.00054699107
and O 0 0.0006667302
87 O 0 0.0014359868
% O 0 0.0017979632
cholesterol B-Chemical 0 0.993664
by O 0 0.0032691453
weight O 0 0.009768878
. O 0 0.008090729

In O 0 0.0035034367
the O 0 0.002096674
remaining O 0 0.0015302335
12 O 0 0.0009920847
patients O 0 0.0009179216
, O 0 0.00074316084
localised O 0 0.0005600543
computed O 0 0.0004542821
tomography O 0 0.001191453
of O 0 0.00037036327
the O 0 0.00034550705
gall O 0 0.15385783
bladder O 0 0.13845061
showed O 0 0.00027206095
that O 0 0.00016897112
eight O 0 0.00015695991
had O 0 0.00018661271
stones O 0 0.19516033
with O 0 0.00022914853
maximum O 0 0.00016151623
attenuation O 0 0.00040167186
scores O 0 0.00018127006
of O 0 0.00020925145
< O 0 0.00017999555
100 O 0 0.00032065695
Hounsfield O 0 0.0007152106
units O 0 0.00018501676
( O 0 0.0002672129
values O 0 0.00019826811
of O 0 0.00029267778
< O 0 0.0003135067
100 O 0 0.00077496737
HU O 0 0.5315655
predict O 0 0.0006047941
cholesterol B-Chemical 0 0.99926454
rich O 0 0.005026122
, O 0 0.002777391
dissolvable O 0 0.7641218
stones O 0 0.8808384
) O 0 0.010536162
. O 0 0.008043739

Gall O 0 0.13212505
bladder O 0 0.2513979
bile O 0 0.78267735
was O 0 0.0022449049
obtained O 0 0.0013556706
by O 0 0.0012993984
ultrasound O 0 0.0019106851
guided O 0 0.0010103567
, O 0 0.0014176137
fine O 0 0.0019345399
needle O 0 0.0019741773
puncture O 0 0.002496571
from O 0 0.0019394505
six O 0 0.002587585
patients O 0 0.005437039
. O 0 0.008155114

All O 0 0.0032043394
six O 0 0.0020436824
patients O 0 0.0019753547
had O 0 0.0014715713
supersaturated O 0 0.80534554
bile O 0 0.88360626
( O 0 0.0011128284
mean O 0 0.00031761656
( O 0 0.0005618187
SEM O 0 0.0009237001
) O 0 0.0013764735
cholesterol B-Chemical 0 0.9987431
saturation O 0 0.005822449
index O 0 0.0003563039
of O 0 0.00028867798
1 O 0 0.0002188019
. O 0 0.00017723927
19 O 0 0.0002542773
( O 0 0.00027154037
0 O 0 0.00023746044
. O 0 0.00021650438
08 O 0 0.016107725
) O 0 0.00039903462
( O 0 0.00028614388
range O 0 0.00022151436
1 O 0 0.00020986327
. O 0 0.00021434751
01 O 0 0.0019733694
- O 0 0.0019649775
1 O 0 0.00020914673
. O 0 0.00018138366
53 O 0 0.00033518262
) O 0 0.00041637121
) O 0 0.00037748207
and O 0 0.00020916828
all O 0 0.00015424126
had O 0 0.00015328093
abnormally O 0 0.0016258693
rapid O 0 0.006173586
cholesterol B-Chemical 0 0.9999403
microcrystal O 0 0.96574736
nucleation O 0 0.09563082
times O 0 0.0001225115
( O 0 0.00022553008
< O 0 0.00013107878
4 O 0 0.00011483675
days O 0 0.00010115983
( O 0 0.00018971217
range O 0 0.0001882921
1 O 0 0.0002148322
- O 0 0.0013016099
4 O 0 0.00019005562
) O 0 0.00044484995
) O 0 0.0005599353
, O 0 0.000379663
whilst O 0 0.00043083297
in O 0 0.00023901228
four O 0 0.00021017887
, O 0 0.00037282103
the O 0 0.00038282672
bile O 0 0.5259208
contained O 0 0.0006760138
cholesterol B-Chemical 0 0.9997584
microcrystals O 0 0.7342758
immediately O 0 0.0013610938
after O 0 0.0015145858
sampling O 0 0.0033001
. O 0 0.0059555504

Of O 0 0.0045474498
the O 0 0.0023937707
12 O 0 0.0014885162
patients O 0 0.001277028
considered O 0 0.0008115175
for O 0 0.0009705501
oral O 0 0.8425659
ursodeoxycholic B-Chemical 0 0.99999714
acid I-Chemical 0 0.99925596
( O 0 0.4202742
UDCA B-Chemical 0 0.9999999
) O 0 0.029643105
treatment O 0 0.0007696233
, O 0 0.0003844951
two O 0 0.00015863817
had O 0 0.00017055975
a O 0 0.00022709771
blocked O 0 0.00036228844
cystic O 0 0.14227697
duct O 0 0.34276652
and O 0 0.00048802316
were O 0 0.00023492743
not O 0 0.00019799193
started O 0 0.0002862394
on O 0 0.00033689998
UDCA B-Chemical 0 0.9999988
while O 0 0.0007978585
one O 0 0.0005029006
was O 0 0.0006160047
lost O 0 0.0008488568
to O 0 0.0011038376
follow O 0 0.0016667321
up O 0 0.0031648749
. O 0 0.0060664713

After O 0 0.0027162882
one O 0 0.0020212142
year O 0 0.0015891835
of O 0 0.0013404174
treatment O 0 0.0012262341
, O 0 0.00089138106
five O 0 0.00034874305
of O 0 0.00037367304
the O 0 0.00027755398
remaining O 0 0.0002504505
nine O 0 0.00021057503
patients O 0 0.00023741742
showed O 0 0.00015893145
either O 0 0.00016391954
partial O 0 0.0003188818
( O 0 0.0003377786
n O 0 0.00019610129
= O 0 0.0004449935
3 O 0 0.00016655271
) O 0 0.00026308626
or O 0 0.00015919657
complete O 0 0.00015902452
( O 0 0.00027790322
n O 0 0.00020306108
= O 0 0.000481133
2 O 0 0.00026327345
) O 0 0.00080732355
gall B-Disease 0 0.94662935
stone I-Disease 0 0.9935074
dissolution O 0 0.87851584
, O 0 0.0006996178
suggesting O 0 0.00034780806
that O 0 0.00045422433
their O 0 0.0008936265
stones O 0 0.58321655
were O 0 0.0026730238
cholesterol B-Chemical 0 0.99901104
rich O 0 0.013575704
. O 0 0.0073249037

This O 0 0.004976963
corresponds O 0 0.0022547268
, O 0 0.0023078716
by O 0 0.0015625561
actuarial O 0 0.18360068
( O 0 0.0015641885
life O 0 0.0009987949
table O 0 0.00050674076
) O 0 0.00070519716
analysis O 0 0.00040464153
, O 0 0.00043181377
to O 0 0.00026122818
a O 0 0.00037843076
combined O 0 0.00066708203
gall B-Disease 0 0.97161275
stone I-Disease 0 0.9926367
dissolution O 0 0.7240399
rate O 0 0.0004147923
of O 0 0.00044100964
58 O 0 0.0005981107
. O 0 0.00035157532
3 O 0 0.00039437253
( O 0 0.0006597193
15 O 0 0.00065090053
. O 0 0.000948389
9 O 0 0.0015559301
% O 0 0.0029983958
) O 0 0.00587478
. O 0 0.008118532

In O 0 0.0038534994
conclusion O 0 0.0024886653
, O 0 0.004502165
octreotide B-Chemical 1 0.9984352
induced O 0 0.006418246
gall B-Disease 0 0.9972893
stones I-Disease 0 0.9989293
are O 0 0.0008035314
generally O 0 0.0005381185
small O 0 0.00035799097
, O 0 0.00043248385
multiple O 0 0.0004053141
, O 0 0.0004955898
and O 0 0.00076918816
cholesterol B-Chemical 0 0.99987257
rich O 0 0.0055122483
although O 0 0.00028736214
, O 0 0.00029836237
in O 0 0.00016916654
common O 0 0.00023497579
with O 0 0.00024776784
spontaneous O 0 0.023349032
gall B-Disease 0 0.99898416
stone I-Disease 0 0.9994466
disease I-Disease 0 0.99872786
, O 0 0.00084657775
at O 0 0.00016223024
presentation O 0 0.00027150568
some O 0 0.00017146637
patients O 0 0.00023794452
will O 0 0.00014843668
have O 0 0.0001689125
a O 0 0.00028117708
blocked O 0 0.00047429962
cystic O 0 0.12827641
duct O 0 0.3467696
and O 0 0.0011757957
some O 0 0.0012486362
gall B-Disease 0 0.96321595
stones I-Disease 0 0.9963218
containing O 0 0.004534637
calcium B-Chemical 0 0.99759597
. O 0 0.009349673

Erythema B-Disease 0 0.9998752
multiforme I-Disease 0 0.99987364
and O 0 0.09091303
hypersensitivity B-Disease 0 0.99991465
myocarditis I-Disease 2 0.9999993
caused O 0 0.06401624
by O 0 0.025464397
ampicillin B-Chemical 1 0.9997403
. O 0 0.019586515

OBJECTIVE O 0 0.016189143
: O 0 0.0040732236
To O 0 0.0019562754
report O 0 0.0024262858
a O 0 0.0017023215
case O 0 0.0014784271
of O 0 0.0037818626
erythema B-Disease 0 0.99998593
multiforme I-Disease 0 0.999877
and O 0 0.047013495
hypersensitivity B-Disease 0 0.9999678
myocarditis I-Disease 2 0.99999976
caused O 0 0.029384503
by O 0 0.01488987
ampicillin B-Chemical 1 0.9997876
. O 0 0.012407987

CASE O 0 0.31051895
SUMMARY O 0 0.0058967876
: O 0 0.0042778617
A O 0 0.025189389
13 O 0 0.0022276307
- O 0 0.0037801007
year O 0 0.001276711
- O 0 0.0028786515
old O 0 0.00086017005
boy O 0 0.0013084064
was O 0 0.0005775974
treated O 0 0.00064338377
with O 0 0.0012075043
ampicillin B-Chemical 1 0.9998516
and O 0 0.006775445
gentamicin B-Chemical 1 0.99977916
because O 0 0.0013984392
of O 0 0.0032837072
suspected O 0 0.4784654
septicemia B-Disease 0 0.9998969
. O 0 0.014759446

Medications O 0 0.22063562
were O 0 0.0031881293
discontinued O 0 0.0053875996
when O 0 0.0020289905
erythema B-Disease 0 0.9999286
multiforme I-Disease 0 0.9995177
and O 0 0.010273929
congestive B-Disease 0 0.9999429
heart I-Disease 0 0.81152844
failure I-Disease 0 0.5043073
caused O 0 0.0024246536
by O 0 0.0050270115
myocarditis B-Disease 2 0.99999106
occurred O 0 0.017880615
. O 0 0.009216839

The O 0 0.0051688785
patient O 0 0.0044029816
was O 0 0.0035113164
treated O 0 0.0034747217
with O 0 0.004635257
methylprednisolone B-Chemical 0 0.99974185
and O 0 0.0054240073
gradually O 0 0.0072738435
improved O 0 0.009336963
. O 0 0.011269315

Macrophage O 0 0.7516559
- O 0 0.043789126
migration O 0 0.0227959
inhibition O 0 0.010081092
( O 0 0.009866422
MIF O 0 0.98968947
) O 0 0.00484386
test O 0 0.0023086006
with O 0 0.003449603
ampicillin B-Chemical 1 0.99935263
was O 0 0.0046656914
positive O 0 0.0072319973
. O 0 0.009794044

DISCUSSION O 0 0.004584523
: O 0 0.0034211038
After O 0 0.0016286451
most O 0 0.002324259
infections B-Disease 2 0.9768851
causing O 0 0.21981847
erythema B-Disease 0 0.9999945
multiforme I-Disease 0 0.99988353
and O 0 0.013746593
myocarditis B-Disease 2 0.99999833
were O 0 0.0007180893
ruled O 0 0.00066191156
out O 0 0.00028598896
, O 0 0.0005607183
a O 0 0.00076081674
drug B-Disease 0 0.5188303
- I-Disease 0 0.046350144
induced I-Disease 0 0.004614345
allergic I-Disease 2 0.9999931
reaction I-Disease 2 0.9323187
was O 0 0.003983159
suspected O 0 0.07899651
. O 0 0.0073908865

Positive O 0 0.08567937
MIF O 0 0.9306863
test O 0 0.0030838607
for O 0 0.0025922759
ampicillin B-Chemical 1 0.9995401
showed O 0 0.0015190613
sensitization O 0 0.05444135
of O 0 0.0010762187
the O 0 0.00083798944
patient O 0 0.0010443929
' O 0 0.0014809478
s O 0 0.0018598258
lymphocytes O 0 0.11794428
to O 0 0.0036421884
ampicillin B-Chemical 1 0.9992016
. O 0 0.0104593

CONCLUSIONS O 0 0.07993937
: O 0 0.018652556
Hypersensitivity B-Disease 0 0.9998223
myocarditis I-Disease 2 0.99999905
is O 0 0.004081899
a O 0 0.0020478333
rare O 0 0.0032192804
and O 0 0.0015059485
dangerous O 0 0.04556172
manifestation O 0 0.05745812
of O 0 0.004791139
allergy B-Disease 0 0.9995146
to O 0 0.006268551
penicillins B-Chemical 0 0.99952996
. O 0 0.011925827

Clomipramine B-Chemical 0 0.99999094
- O 0 0.09472872
induced O 0 0.004446163
sleep B-Disease 0 0.9363704
disturbance I-Disease 0 0.8720333
does O 0 0.001522882
not O 0 0.001075714
impair O 0 0.0011975385
its O 0 0.0076101646
prolactin O 0 0.9965527
- O 0 0.049043357
releasing O 0 0.010548022
action O 0 0.010174998
. O 0 0.00947784

The O 0 0.0029865906
present O 0 0.001864871
study O 0 0.001651864
was O 0 0.000979452
undertaken O 0 0.00057322695
to O 0 0.00043115573
examine O 0 0.00024157873
the O 0 0.00028952362
role O 0 0.00022396557
of O 0 0.00062466913
sleep B-Disease 0 0.9333182
disturbance I-Disease 0 0.90941375
, O 0 0.00071753556
induced O 0 0.0004002679
by O 0 0.0034232503
clomipramine B-Chemical 0 0.9999999
administration O 0 0.016563037
, O 0 0.00027057977
on O 0 0.00010560475
the O 0 0.00014440712
secretory O 0 0.00027813064
rate O 0 0.00026906095
of O 0 0.0015117985
prolactin O 0 0.99900573
( O 0 0.047565248
PRL O 0 0.9999794
) O 0 0.001936186
in O 0 0.00034931453
addition O 0 0.00029933994
to O 0 0.00049452216
the O 0 0.000771277
direct O 0 0.001352825
drug O 0 0.20992091
effect O 0 0.0039655026
. O 0 0.006956587

Two O 0 0.0036959152
groups O 0 0.0023784856
of O 0 0.0017631573
supine O 0 0.001963609
subjects O 0 0.0010125109
were O 0 0.0005806321
studied O 0 0.0004701434
under O 0 0.0003846432
placebo O 0 0.03689649
- O 0 0.0024037834
controlled O 0 0.00022952992
conditions O 0 0.0002835844
, O 0 0.00033637777
one O 0 0.00016350053
during O 0 0.00012243129
the O 0 0.0001700771
night O 0 0.00055972615
, O 0 0.00024931383
when O 0 0.00014379677
sleeping O 0 0.09516689
( O 0 0.00031843275
n O 0 0.00018542717
= O 0 0.00041949112
7 O 0 0.00017244375
) O 0 0.0002991343
and O 0 0.00021159645
the O 0 0.00019061423
other O 0 0.00022493993
at O 0 0.0002245964
daytime O 0 0.0013751462
, O 0 0.0003940638
when O 0 0.00033045627
awake O 0 0.0010280513
( O 0 0.00077086163
n O 0 0.0009149396
= O 0 0.0020758456
6 O 0 0.0020962846
) O 0 0.005063105
. O 0 0.007319441

Each O 0 0.0027982073
subject O 0 0.0019590436
received O 0 0.0013603305
a O 0 0.0013203474
single O 0 0.000947136
50 O 0 0.00092535483
mg O 0 0.014436097
dose O 0 0.0035662875
of O 0 0.0034221346
clomipramine B-Chemical 0 0.99999905
given O 0 0.00045399685
orally O 0 0.0010418255
2 O 0 0.00061845133
hours O 0 0.00071822037
before O 0 0.0010751114
blood O 0 0.0039041892
collection O 0 0.0040475777
. O 0 0.006116963

Plasma O 0 0.85270596
PRL O 0 0.9997389
concentrations O 0 0.0061847256
were O 0 0.0013627975
analysed O 0 0.0008422173
at O 0 0.0006029658
10 O 0 0.0004973104
min O 0 0.00049180764
intervals O 0 0.00032717106
and O 0 0.00042666437
underlying O 0 0.0005224108
secretory O 0 0.00073455536
rates O 0 0.00070728734
calculated O 0 0.0007036659
by O 0 0.0013039724
a O 0 0.0020321936
deconvolution O 0 0.0040471433
procedure O 0 0.004290927
. O 0 0.0072955675

For O 0 0.0032325168
both O 0 0.002043954
experiments O 0 0.0012715213
the O 0 0.0013093738
drug O 0 0.33056948
intake O 0 0.50393784
led O 0 0.0005641991
to O 0 0.00035217594
significant O 0 0.00038494237
increases O 0 0.00041496695
in O 0 0.0013908896
PRL O 0 0.9999839
secretion O 0 0.02548095
, O 0 0.0007887893
acting O 0 0.00048762767
preferentially O 0 0.00016394828
on O 0 0.00014537729
tonic O 0 0.022165501
secretion O 0 0.0006153472
as O 0 0.00020565864
pulse O 0 0.00072317565
amplitude O 0 0.00093795557
and O 0 0.000306684
frequency O 0 0.00037470454
did O 0 0.00033305548
not O 0 0.00029820032
differ O 0 0.0003934784
significantly O 0 0.00048032214
from O 0 0.00061051466
corresponding O 0 0.0009197382
control O 0 0.0017827621
values O 0 0.0032959746
. O 0 0.0062327352

During O 0 0.0028187474
the O 0 0.0025788082
night O 0 0.07091228
clomipramine B-Chemical 0 0.9999989
ingestion O 0 0.84702194
altered O 0 0.00080097694
the O 0 0.00042164963
complete O 0 0.00032600967
sleep O 0 0.007909099
architecture O 0 0.00047213316
in O 0 0.00022536884
that O 0 0.00019851138
it O 0 0.00029367983
suppressed O 0 0.00040201817
REM O 0 0.9841792
sleep O 0 0.020298671
and O 0 0.00032930338
the O 0 0.00033613495
sleep O 0 0.0016455513
cycles O 0 0.00039858013
and O 0 0.0007982928
induced O 0 0.001375682
increased O 0 0.0038292918
wakefulness O 0 0.5208228
. O 0 0.006699083

As O 0 0.0030677523
the O 0 0.0020054765
relative O 0 0.001332249
increase O 0 0.0011429589
in O 0 0.0018951423
PRL O 0 0.999925
secretion O 0 0.006882375
expressed O 0 0.00038194912
as O 0 0.00034151506
a O 0 0.0003294905
percentage O 0 0.00017772852
of O 0 0.00024862995
the O 0 0.00018248992
mean O 0 0.00012875297
did O 0 0.00019582233
not O 0 0.00014289953
significantly O 0 0.0001615652
differ O 0 0.00013117869
between O 0 0.000102853875
the O 0 0.00014223413
night O 0 0.0003131336
and O 0 0.0001442208
day O 0 0.00010498985
time O 0 9.3305316e-05
studies O 0 0.00014700992
( O 0 0.00027762167
46 O 0 0.00036697273
+ O 0 0.0015821991
/ O 0 0.010853899
- O 0 0.00845289
19 O 0 0.00029980976
% O 0 0.00021577117
vs O 0 0.0002459098
34 O 0 0.0002802046
+ O 0 0.0010080717
/ O 0 0.008580365
- O 0 0.009005369
10 O 0 0.0002262667
% O 0 0.00031463077
) O 0 0.0005180274
, O 0 0.0003390777
it O 0 0.00022594632
can O 0 0.00014680414
be O 0 0.00016415729
concluded O 0 0.00016794393
that O 0 0.00014630429
the O 0 0.00019994918
observed O 0 0.00028964845
sleep B-Disease 0 0.83739007
disturbance I-Disease 0 0.7670109
did O 0 0.00035460378
not O 0 0.00024173681
interfere O 0 0.00031315928
with O 0 0.00048218164
the O 0 0.00065876206
drug O 0 0.073835805
action O 0 0.0016850597
per O 0 0.0015927802
se O 0 0.004757105
. O 0 0.006575531

The O 0 0.0031124318
presence O 0 0.002416683
of O 0 0.0029864814
REM O 0 0.9937588
sleep O 0 0.17239039
was O 0 0.0007321125
shown O 0 0.00035683453
not O 0 0.00028929792
to O 0 0.0002458125
be O 0 0.00025847694
a O 0 0.00027767706
determining O 0 0.0001898153
factor O 0 0.0020991985
either O 0 0.00022356723
for O 0 0.00019731572
secretory O 0 0.00038800156
pulse O 0 0.00077187223
amplitude O 0 0.0008741578
and O 0 0.00023607998
frequency O 0 0.00028275428
, O 0 0.00030815467
as O 0 0.00018718229
, O 0 0.00029310587
for O 0 0.00017700621
both O 0 0.00019301873
, O 0 0.00023657524
mean O 0 0.00013407707
nocturnal O 0 0.0023600627
values O 0 0.00018686093
were O 0 0.00021269702
similar O 0 0.00020783888
with O 0 0.00035149706
and O 0 0.0005583403
without O 0 0.00084794214
prior O 0 0.0017708803
clomipramine B-Chemical 0 0.9999981
ingestion O 0 0.8739606
. O 0 0.0068816366

Survey O 0 0.008632409
of O 0 0.0067958836
complications O 0 0.07070551
of O 0 0.008311654
indocyanine B-Chemical 0 0.99965227
green I-Chemical 0 0.21749675
angiography O 0 0.46375608
in O 0 0.009041624
Japan O 0 0.1546933
. O 0 0.015238112

PURPOSE O 0 0.00628602
: O 0 0.0040548234
We O 0 0.002086556
evaluated O 0 0.0014251635
the O 0 0.0013433965
safety O 0 0.0016657066
of O 0 0.001998034
indocyanine B-Chemical 0 0.9996244
green I-Chemical 0 0.019471742
for O 0 0.0016466099
use O 0 0.0021040346
in O 0 0.0029843706
fundus O 0 0.6674406
angiography O 0 0.32554182
. O 0 0.00934314

METHODS O 0 0.0042233015
: O 0 0.0035774934
We O 0 0.0019217072
sent O 0 0.0014899472
a O 0 0.0011569181
questionnaire O 0 0.0006944193
concerning O 0 0.00052935764
complications O 0 0.031876687
of O 0 0.0012598274
indocyanine B-Chemical 0 0.9999107
green I-Chemical 0 0.032696214
to O 0 0.0002987341
32 O 0 0.00038794847
institutions O 0 0.0005645832
in O 0 0.00031332058
Japan O 0 0.12679178
, O 0 0.00037607367
which O 0 0.00024543385
were O 0 0.00016055562
selected O 0 0.00013095186
on O 0 0.00011047056
the O 0 0.00015139896
basis O 0 0.00017978185
of O 0 0.00021896907
the O 0 0.00019817211
client O 0 0.0003129904
list O 0 0.00017729268
from O 0 0.00019833694
the O 0 0.0003344083
Topcon O 0 0.40051654
Company O 0 0.4304245
, O 0 0.00063803705
which O 0 0.0006281592
manufactures O 0 0.0030774523
the O 0 0.0012603664
indocyanine B-Chemical 0 0.9995609
green I-Chemical 0 0.107577406
fundus O 0 0.8220341
camera O 0 0.027190622
. O 0 0.007943996

RESULTS O 0 0.0061252303
: O 0 0.00440184
Ophthalmologists O 0 0.0050829393
at O 0 0.0012883107
15 O 0 0.0009647359
institutions O 0 0.0011423875
responded O 0 0.0008226465
, O 0 0.00069741206
reporting O 0 0.00060957094
a O 0 0.0003916376
total O 0 0.00025267506
of O 0 0.000353104
3 O 0 0.0002790688
, O 0 0.00043506574
774 O 0 0.02145708
indocyanine B-Chemical 0 0.9994874
green I-Chemical 0 0.011411306
angiograms O 0 0.019639712
performed O 0 0.0002237041
on O 0 0.00020892134
2 O 0 0.00032451938
, O 0 0.00047642962
820 O 0 0.0011957228
patients O 0 0.0005721246
between O 0 0.0005533234
June O 0 0.0011916306
1984 O 0 0.0023740411
and O 0 0.0020568196
September O 0 0.00364851
1992 O 0 0.007428858
. O 0 0.007483212

Before O 0 0.0053243707
angiography O 0 0.05043204
, O 0 0.0030369977
intradermal O 0 0.012893124
or O 0 0.0015590867
intravenous O 0 0.46482313
indocyanine B-Chemical 0 0.99992895
green I-Chemical 0 0.073387094
testing O 0 0.00083534414
, O 0 0.0007268292
or O 0 0.00046677334
both O 0 0.00047786316
was O 0 0.00052172376
performed O 0 0.00052893977
at O 0 0.0006839457
13 O 0 0.0011088955
of O 0 0.0016030701
15 O 0 0.0022633765
institutions O 0 0.0053473525
. O 0 0.0071904175

For O 0 0.0035368977
three O 0 0.0019661859
patients O 0 0.0022547322
, O 0 0.0017788614
the O 0 0.0010235348
decision O 0 0.0012333832
was O 0 0.00068709435
made O 0 0.0005142579
not O 0 0.0004753171
to O 0 0.0004677093
proceed O 0 0.0006869242
with O 0 0.00079729006
angiography O 0 0.014223743
after O 0 0.0008097513
positive O 0 0.0019265385
preangiographic O 0 0.0153182745
testing O 0 0.004575445
. O 0 0.007240194

The O 0 0.0033796367
dosage O 0 0.0103064515
of O 0 0.003669771
indocyanine B-Chemical 0 0.9997714
green I-Chemical 0 0.032793596
used O 0 0.00079158734
for O 0 0.0006921998
angiography O 0 0.018289236
varied O 0 0.0004315967
from O 0 0.00035036996
25 O 0 0.00042445082
to O 0 0.00036625317
75 O 0 0.0006244215
mg O 0 0.003349352
, O 0 0.00094207283
depending O 0 0.001050604
upon O 0 0.0013253756
the O 0 0.0023995156
institution O 0 0.005331307
. O 0 0.007350821

There O 0 0.004219802
were O 0 0.0025822204
13 O 0 0.0019243155
cases O 0 0.0015099376
of O 0 0.0013170695
adverse O 0 0.3357741
reactions O 0 0.022647612
( O 0 0.0011437284
0 O 0 0.000516795
. O 0 0.0003238678
34 O 0 0.00038574098
% O 0 0.00039025903
) O 0 0.0005081141
, O 0 0.0003166418
ten O 0 0.0001744648
of O 0 0.00023299562
which O 0 0.00029146034
were O 0 0.00024712706
mild O 0 0.06092679
reactions O 0 0.0016704624
such O 0 0.00022641904
as O 0 0.0007379684
nausea B-Disease 2 0.99999857
, O 0 0.015651507
exanthema B-Disease 0 0.9999455
, O 0 0.016607765
urtication B-Disease 0 0.9978193
, O 0 0.008174082
itchiness B-Disease 0 0.9988263
, O 0 0.0005651036
and O 0 0.0003889383
urgency O 0 0.006474725
to O 0 0.00036569193
defecate O 0 0.0041273152
, O 0 0.0006541253
and O 0 0.0007422241
did O 0 0.00096324814
not O 0 0.0011418114
require O 0 0.0017361523
treatment O 0 0.0039578653
. O 0 0.0068165776

Also O 0 0.0045645684
recorded O 0 0.002498783
were O 0 0.0017202277
one O 0 0.0011262767
case O 0 0.0009898475
of O 0 0.0011589135
pain B-Disease 0 0.86001337
of O 0 0.0007566665
the O 0 0.0005988457
vein O 0 0.025507487
, O 0 0.0006458598
which O 0 0.0004391761
required O 0 0.00029397928
treatment O 0 0.0005553187
, O 0 0.0007484123
and O 0 0.00079016294
two O 0 0.00089449115
cases O 0 0.0023284568
of O 0 0.0070032543
hypotension B-Disease 2 0.99995184
. O 0 0.009119517

The O 0 0.0063734977
two O 0 0.005607996
hypotensive B-Disease 0 0.97726417
patients O 0 0.005024052
required O 0 0.0032523908
treatment O 0 0.0054389397
for O 0 0.0076095746
shock B-Disease 0 0.99630296
. O 0 0.018218668

CONCLUSIONS O 0 0.03126229
: O 0 0.0048581553
A O 0 0.01142081
comparison O 0 0.0012410985
of O 0 0.001071501
frequency O 0 0.00088403246
of O 0 0.0008384127
adverse O 0 0.28421474
reactions O 0 0.010464517
to O 0 0.0005253354
indocyanine B-Chemical 0 0.99993265
green I-Chemical 0 0.04898968
with O 0 0.00032515364
the O 0 0.0002031583
previously O 0 0.00019280166
reported O 0 0.00018974039
frequency O 0 0.00017360503
of O 0 0.00017921532
such O 0 0.00016118238
reactions O 0 0.0018310141
to O 0 0.00023968593
fluorescein B-Chemical 0 0.99990606
sodium I-Chemical 0 0.99996734
indicated O 0 0.00022573293
that O 0 0.0002794421
indocyanine B-Chemical 0 0.99987483
green I-Chemical 0 0.031232035
is O 0 0.0003861238
a O 0 0.00044036435
safe O 0 0.00061716896
as O 0 0.0005264166
fluorescein B-Chemical 0 0.92949545
for O 0 0.0010415143
use O 0 0.0015724458
in O 0 0.0025410976
angiography O 0 0.106106654
. O 0 0.0068515567

Angioedema B-Disease 0 0.9993017
following O 0 0.006581754
the O 0 0.0065360405
intravenous O 0 0.23052116
administration O 0 0.14535959
of O 0 0.05367443
metoprolol B-Chemical 1 0.99999523
. O 0 0.022021448

A O 0 0.111164026
72 O 0 0.0058920407
- O 0 0.0070313443
year O 0 0.002147976
- O 0 0.0042268205
old O 0 0.0011955701
woman O 0 0.0022496232
was O 0 0.0006389255
admitted O 0 0.0007108685
to O 0 0.0003190025
the O 0 0.00030878314
hospital O 0 0.0004817765
with O 0 0.00035918906
" O 0 0.00057451834
flash O 0 0.017851597
" O 0 0.0010900851
pulmonary B-Disease 0 0.9264121
edema I-Disease 0 0.99999094
, O 0 0.0011733231
preceded O 0 0.0006488832
by O 0 0.0009137975
chest B-Disease 0 0.072938986
pain I-Disease 0 0.85588956
, O 0 0.0023136837
requiring O 0 0.0029502106
intubation O 0 0.010915711
. O 0 0.006688123

Her O 0 0.0077568917
medical O 0 0.0054042237
history O 0 0.005026558
included O 0 0.0016743212
coronary B-Disease 0 0.27840933
artery I-Disease 0 0.41699043
disease I-Disease 0 0.84314734
with O 0 0.0010716816
previous O 0 0.0015928539
myocardial B-Disease 0 0.99995303
infarctions I-Disease 0 0.99998057
, O 0 0.11343327
hypertension B-Disease 2 0.999997
, O 0 0.005924354
and O 0 0.006986148
diabetes B-Disease 0 0.9999132
mellitus I-Disease 0 0.99972004
. O 0 0.011682335

A O 0 0.0881238
history O 0 0.020247739
of O 0 0.013106281
angioedema B-Disease 2 0.99998534
secondary O 0 0.21410285
to O 0 0.0063082585
lisinopril B-Chemical 0 0.9999938
therapy O 0 0.013811955
was O 0 0.004427136
elicited O 0 0.0059497547
. O 0 0.009726961

Current O 0 0.022219982
medications O 0 0.056448713
did O 0 0.0022689216
not O 0 0.0014201534
include O 0 0.0019979523
angiotensin B-Chemical 1 0.9999839
- O 0 0.21991226
converting O 0 0.029083356
enzyme O 0 0.05153977
inhibitors O 0 0.008345753
or O 0 0.0021780708
beta O 0 0.9790739
- O 0 0.6051154
blockers O 0 0.99681026
. O 0 0.010106951

She O 0 0.0074678184
had O 0 0.0042961254
no O 0 0.0033452143
previous O 0 0.0043581277
beta O 0 0.9507864
- O 0 0.14187872
blocking O 0 0.025395034
drug O 0 0.84420544
exposure O 0 0.12758799
. O 0 0.014235803

During O 0 0.002811598
the O 0 0.0020464582
first O 0 0.001292578
day O 0 0.0010045804
of O 0 0.0010758403
hospitalization O 0 0.019454017
( O 0 0.0011984251
while O 0 0.0006611739
intubated O 0 0.0034237546
) O 0 0.00132478
, O 0 0.0014184252
intravenous O 0 0.6991209
metoprolol B-Chemical 1 0.9999994
was O 0 0.00062606914
given O 0 0.00043032793
, O 0 0.0008522312
resulting O 0 0.0010263348
in O 0 0.002141656
severe O 0 0.8015307
angioedema B-Disease 2 0.9999815
. O 0 0.0096820835

The O 0 0.0062055043
angioedema B-Disease 2 0.99984145
resolved O 0 0.0035920918
after O 0 0.0014112055
therapy O 0 0.002320484
with O 0 0.0021253333
intravenous O 0 0.72146344
steroids B-Chemical 0 0.99986756
and O 0 0.26137134
diphenhydramine B-Chemical 0 0.99999964
hydrochloride O 0 0.99972826
. O 0 0.010710634

Effect O 0 0.009297997
of O 0 0.00913701
coniine B-Chemical 1 0.9775949
on O 0 0.005301392
the O 0 0.0065847477
developing O 0 0.028239055
chick O 0 0.19440454
embryo O 0 0.100261375
. O 0 0.01677707

Coniine B-Chemical 0 0.9843492
, O 0 0.006729048
an O 0 0.004913249
alkaloid O 0 0.99133205
from O 0 0.004213711
Conium O 0 0.99997604
maculatum O 0 0.97409374
( O 0 0.008147982
poison O 0 0.7932706
hemlock O 0 0.9939533
) O 0 0.0028080612
, O 0 0.000898621
has O 0 0.0005412022
been O 0 0.0005900782
shown O 0 0.0005549245
to O 0 0.00082272687
be O 0 0.0017195515
teratogenic O 0 0.99911994
in O 0 0.0040490176
livestock O 0 0.56808656
. O 0 0.009134761

The O 0 0.004171312
major O 0 0.0049974853
teratogenic O 0 0.9994479
outcome O 0 0.01852156
is O 0 0.0031831854
arthrogryposis B-Disease 0 0.99723595
, O 0 0.0023503408
presumably O 0 0.0017364481
due O 0 0.0011895247
to O 0 0.002005158
nicotinic O 0 0.99890983
receptor O 0 0.15612052
blockade O 0 0.09980378
. O 0 0.008555805

However O 0 0.0065451995
, O 0 0.008148214
coniine B-Chemical 1 0.9930735
has O 0 0.0016558919
failed O 0 0.0011790651
to O 0 0.0007338438
produce O 0 0.00064240134
arthrogryposis B-Disease 0 0.9904304
in O 0 0.000609922
rats O 0 0.00061776803
or O 0 0.000346861
mice O 0 0.00029407375
and O 0 0.00054519373
is O 0 0.0006751994
only O 0 0.0010423462
weakly O 0 0.0068781297
teratogenic O 0 0.9995946
in O 0 0.003487157
rabbits O 0 0.008109161
. O 0 0.006928319

The O 0 0.00317673
purpose O 0 0.0022543964
of O 0 0.0017717301
this O 0 0.0012319478
study O 0 0.0010668616
was O 0 0.0006347867
to O 0 0.00039542856
evaluate O 0 0.00023127085
and O 0 0.000328505
compare O 0 0.00018645443
the O 0 0.00028680428
effects O 0 0.00046852656
of O 0 0.0011818863
coniine B-Chemical 1 0.99917716
and O 0 0.005229504
nicotine B-Chemical 1 0.99978775
in O 0 0.0012455467
the O 0 0.0017121278
developing O 0 0.021087222
chick O 0 0.11685103
. O 0 0.0076038325

Concentrations O 0 0.21578941
of O 0 0.0058533503
coniine B-Chemical 1 0.998197
and O 0 0.0155109055
nicotine B-Chemical 1 0.9999703
sulfate O 0 0.99472815
were O 0 0.00081892795
0 O 0 0.00058550935
. O 0 0.0004251741
015 O 0 0.04854897
% O 0 0.00041006517
, O 0 0.0003966741
0 O 0 0.00032775925
. O 0 0.0002852532
03 O 0 0.0042866156
% O 0 0.0003194651
, O 0 0.00034109093
0 O 0 0.00028956338
. O 0 0.0002516096
075 O 0 0.01430912
% O 0 0.00031946998
, O 0 0.00031449553
0 O 0 0.00023814471
. O 0 0.00017540573
15 O 0 0.0001645828
% O 0 0.00022762902
, O 0 0.0002647147
0 O 0 0.00022880797
. O 0 0.000181884
75 O 0 0.00023516902
% O 0 0.00025134682
, O 0 0.00028399055
1 O 0 0.00019981277
. O 0 0.00017293278
5 O 0 0.00016570315
% O 0 0.00024160776
, O 0 0.0002741756
3 O 0 0.00018546486
% O 0 0.00024845975
, O 0 0.00026463068
and O 0 0.00023354185
6 O 0 0.00017852218
% O 0 0.00024929908
and O 0 0.00026197342
1 O 0 0.00026576113
% O 0 0.00035112983
, O 0 0.0004108585
5 O 0 0.00033525997
% O 0 0.00053603644
, O 0 0.0007058434
and O 0 0.00084182445
10 O 0 0.0010848808
% O 0 0.0019208146
, O 0 0.0032091343
respectively O 0 0.006595446
. O 0 0.008040746

Both O 0 0.0056679705
compounds O 0 0.1938335
caused O 0 0.0034550088
deformations B-Disease 0 0.67915475
and O 0 0.0034918694
lethality O 0 0.49402475
in O 0 0.0021191463
a O 0 0.002550158
dose O 0 0.013309483
- O 0 0.008748952
dependent O 0 0.0032254267
manner O 0 0.0055290395
. O 0 0.009358064

All O 0 0.0030060287
concentrations O 0 0.0041904757
of O 0 0.005236822
nicotine B-Chemical 1 0.9999651
sulfate O 0 0.9967231
caused O 0 0.0015030045
some O 0 0.0011585121
lethality O 0 0.655028
but O 0 0.00095831096
a O 0 0.00048609733
no O 0 0.00024407219
effect O 0 0.00030302367
level O 0 0.00033198588
for O 0 0.0007946993
coniine B-Chemical 1 0.99909055
lethality O 0 0.7425711
was O 0 0.0011023312
0 O 0 0.0011678092
. O 0 0.0013910988
75 O 0 0.0026227403
% O 0 0.0042725187
. O 0 0.006821163

The O 0 0.003733357
deformations B-Disease 0 0.121140786
caused O 0 0.002130186
by O 0 0.0017982757
both O 0 0.002049725
coniine B-Chemical 1 0.9990675
and O 0 0.014002822
nicotine B-Chemical 1 0.9999814
sulfate O 0 0.99285924
were O 0 0.00064697536
excessive B-Disease 0 0.0028424542
flexion I-Disease 0 0.2523769
or I-Disease 0 0.00046193707
extension I-Disease 0 0.00064648106
of I-Disease 0 0.0008439528
one I-Disease 0 0.0009732048
or I-Disease 0 0.0015022962
more I-Disease 0 0.002986957
toes I-Disease 0 0.076112956
. O 0 0.007149677

No O 0 0.0061805127
histopathological O 0 0.06395993
alterations O 0 0.0034169345
or O 0 0.0010436419
differences O 0 0.0005981122
in O 0 0.00057030533
bone O 0 0.0033399689
formation O 0 0.0017007927
were O 0 0.0003445499
seen O 0 0.00025061984
in O 0 0.00022755744
the O 0 0.00023631622
limbs O 0 0.01095969
or O 0 0.000245435
toes O 0 0.016833104
of O 0 0.00030006084
any O 0 0.0002134923
chicks O 0 0.0007408299
from O 0 0.000161592
any O 0 0.00017506219
group O 0 0.00030031268
; O 0 0.0004160631
however O 0 0.0003077193
, O 0 0.0003612059
extensive O 0 0.0005950791
cranial B-Disease 0 0.9954875
hemorrhage I-Disease 2 0.9999989
occurred O 0 0.00055605307
in O 0 0.00046150578
all O 0 0.00093111687
nicotine B-Chemical 1 0.999928
sulfate O 0 0.99447674
- O 0 0.05736548
treated O 0 0.004161159
chicks O 0 0.014372923
. O 0 0.006918916

There O 0 0.004419807
was O 0 0.0027858114
a O 0 0.0021254912
statistically O 0 0.0013129277
significant O 0 0.0012030659
( O 0 0.00191645
P O 0 0.07334874
< O 0 0.0005689204
or O 0 0.0005117306
= O 0 0.0010233204
0 O 0 0.0004958681
. O 0 0.00036862408
01 O 0 0.0015138332
) O 0 0.00048668476
decrease O 0 0.00026931477
in O 0 0.0002728319
movement O 0 0.00091261935
in O 0 0.0005405036
coniine B-Chemical 1 0.99807537
and O 0 0.004878412
nicotine B-Chemical 1 0.999969
sulfate O 0 0.9847541
treated O 0 0.001181013
chicks O 0 0.0019329286
as O 0 0.0008009013
determined O 0 0.0011543813
by O 0 0.0024096828
ultrasound O 0 0.009893485
. O 0 0.0070264116

Control O 0 0.007800599
chicks O 0 0.0059821014
were O 0 0.0018477882
in O 0 0.0012521388
motion O 0 0.0021486457
an O 0 0.00079547067
average O 0 0.00043143524
of O 0 0.0005956766
33 O 0 0.00069957244
. O 0 0.000349081
67 O 0 0.00045663616
% O 0 0.00031374383
of O 0 0.00025844737
the O 0 0.00020921596
time O 0 0.00017242944
, O 0 0.00043677233
while O 0 0.00076594605
coniine B-Chemical 1 0.9992901
- O 0 0.030318698
treated O 0 0.0003729963
chicks O 0 0.0011973224
were O 0 0.00017076608
only O 0 0.00016727063
moving O 0 0.0003604536
8 O 0 0.0001582253
. O 0 0.00014203202
95 O 0 0.0002624329
% O 0 0.0001913198
of O 0 0.00019384963
a O 0 0.0002445278
5 O 0 0.00017891516
- O 0 0.00068718416
min O 0 0.00022923313
interval O 0 0.00018049017
, O 0 0.0002488747
and O 0 0.00023470802
no O 0 0.00019985142
movement O 0 0.0005849802
was O 0 0.00038468375
observed O 0 0.00046291878
for O 0 0.0012206208
nicotine B-Chemical 1 0.99991703
sulfate O 0 0.988922
treated O 0 0.0072719045
chicks O 0 0.02439187
. O 0 0.0068558115

In O 0 0.0037028717
summary O 0 0.0019149664
, O 0 0.0024692523
the O 0 0.0016246137
chick O 0 0.032544415
embryo O 0 0.007286683
provides O 0 0.00064800226
a O 0 0.0006505464
reliable O 0 0.0005328346
and O 0 0.0004606691
simple O 0 0.00053664844
experimental O 0 0.0004959116
animal O 0 0.00081017887
model O 0 0.00085590803
of O 0 0.0045206724
coniine B-Chemical 1 0.99963033
- O 0 0.13621528
induced O 0 0.0065293843
arthrogryposis B-Disease 0 0.9993345
. O 0 0.010337924

Data O 0 0.004219613
from O 0 0.0022975816
this O 0 0.0017126071
model O 0 0.001337445
support O 0 0.00093714666
a O 0 0.0010150645
mechanism O 0 0.0007690317
involving O 0 0.0019200314
nicotinic O 0 0.9997415
receptor O 0 0.09370519
blockade O 0 0.013400495
with O 0 0.0009973476
subsequent O 0 0.0012767365
decreased O 0 0.0025374442
fetal O 0 0.20487686
movement O 0 0.021086825
. O 0 0.00771105

Immediate O 0 0.16602059
allergic B-Disease 0 0.99975616
reactions I-Disease 0 0.87876886
to O 0 0.025217587
amoxicillin B-Chemical 0 0.9993456
. O 0 0.03244528

A O 0 0.024947675
large O 0 0.003432767
group O 0 0.0024912164
of O 0 0.0018154848
patients O 0 0.0017805785
with O 0 0.0014158047
suspected O 0 0.20518178
allergic B-Disease 0 0.9999949
reactions I-Disease 0 0.9282397
to O 0 0.0019818044
beta B-Chemical 0 0.9993507
- I-Chemical 0 0.8097258
lactam I-Chemical 0 0.99979097
antibiotics O 0 0.8081234
was O 0 0.003191565
evaluated O 0 0.0038229034
. O 0 0.007117134

A O 0 0.022342063
detailed O 0 0.002511423
clinical O 0 0.003843599
history O 0 0.005329477
, O 0 0.0013790426
together O 0 0.0006912842
with O 0 0.00076951773
skin O 0 0.066797614
tests O 0 0.0032374556
, O 0 0.004668053
RAST O 0 0.9995913
( O 0 0.0019084794
radioallergosorbent O 0 0.23325251
test O 0 0.00048243866
) O 0 0.0007710191
, O 0 0.0003253868
and O 0 0.00021750086
controlled O 0 0.00015894478
challenge O 0 0.00021807814
tests O 0 0.00046624188
, O 0 0.00029366303
was O 0 0.0001627434
used O 0 0.00012286153
to O 0 0.00011006512
establish O 0 9.902083e-05
whether O 0 9.686236e-05
patients O 0 0.0006087059
allergic B-Disease 0 0.99961144
to O 0 0.001519818
beta B-Chemical 0 0.99986804
- I-Chemical 0 0.9252838
lactam I-Chemical 0 0.9999291
antibiotics O 0 0.76770806
had O 0 0.0003210023
selective O 0 0.001057961
immediate O 0 0.001714196
allergic B-Disease 0 0.99959964
responses O 0 0.0035368104
to O 0 0.0005484657
amoxicillin B-Chemical 0 0.9999777
( O 0 0.034323424
AX B-Chemical 0 0.9995372
) O 0 0.0011779312
or O 0 0.00028934784
were O 0 0.00032907896
cross O 0 0.00064029894
- O 0 0.004016862
reacting O 0 0.01962667
with O 0 0.0014035224
other O 0 0.0050842655
penicillin B-Chemical 1 0.9999945
derivatives O 0 0.79602796
. O 0 0.0082656

Skin O 0 0.048197437
tests O 0 0.0034519618
were O 0 0.001713898
performed O 0 0.0011311624
with O 0 0.0013766695
benzylpenicilloyl B-Chemical 0 0.9561283
- I-Chemical 0 0.1978076
poly I-Chemical 0 0.45317587
- I-Chemical 0 0.46992368
L I-Chemical 0 0.9969881
- I-Chemical 0 0.36560684
lysine I-Chemical 0 0.92001235
( O 0 0.11362095
BPO B-Chemical 0 0.9999994
- I-Chemical 0 0.75293654
PLL I-Chemical 0 0.99797446
) O 0 0.010618562
, O 0 0.0028344172
benzylpenicilloate B-Chemical 0 0.9973997
, O 0 0.008095013
benzylpenicillin B-Chemical 0 0.99961287
( O 0 0.046161953
PG B-Chemical 0 0.999962
) O 0 0.01823839
, O 0 0.008994893
ampicillin B-Chemical 1 0.9999566
( O 0 0.09187826
AMP B-Chemical 1 0.99992526
) O 0 0.008212935
, O 0 0.0035600518
and O 0 0.005239903
AX B-Chemical 0 0.9926318
. O 0 0.009396548

RAST O 0 0.9960995
for O 0 0.015960148
BPO B-Chemical 0 0.99997485
- I-Chemical 0 0.54461396
PLL I-Chemical 0 0.99050677
and O 0 0.015047802
AX B-Chemical 0 0.9991565
- O 0 0.14297056
PLL O 0 0.653335
was O 0 0.006866825
done O 0 0.007863801
. O 0 0.012555935

When O 0 0.0030781636
both O 0 0.0024367196
skin O 0 0.012860326
test O 0 0.0016794332
and O 0 0.0023263553
RAST O 0 0.9989543
for O 0 0.0018078147
BPO B-Chemical 0 0.9999467
were O 0 0.000557236
negative O 0 0.0005954559
, O 0 0.0005724139
single O 0 0.00047656332
- O 0 0.01435927
blind O 0 0.038796257
, O 0 0.0007716347
placebo O 0 0.033901453
- O 0 0.001395357
controlled O 0 0.00018500845
challenge O 0 0.00023389174
tests O 0 0.0003359719
were O 0 0.00021234079
done O 0 0.00019059914
to O 0 0.00021717718
ensure O 0 0.00022480593
tolerance O 0 0.008977009
of O 0 0.0019005446
PG B-Chemical 0 0.999665
or O 0 0.0016298178
sensitivity O 0 0.008146287
to O 0 0.0036739907
AX B-Chemical 0 0.9943241
. O 0 0.008538278

A O 0 0.015620096
total O 0 0.0031718474
of O 0 0.0031032248
177 O 0 0.0052042925
patients O 0 0.0020174417
were O 0 0.001405199
diagnosed O 0 0.0026371162
as O 0 0.0016568177
allergic B-Disease 0 0.9995421
to O 0 0.003654589
beta B-Chemical 0 0.99911326
- I-Chemical 0 0.8446728
lactam I-Chemical 0 0.9997749
antibiotics O 0 0.9478395
. O 0 0.011529345

We O 0 0.0035707653
selected O 0 0.0022479421
the O 0 0.0018243671
54 O 0 0.0020327934
( O 0 0.0014631259
30 O 0 0.0007891735
. O 0 0.0006583438
5 O 0 0.0005466317
% O 0 0.00068642845
) O 0 0.0008041767
cases O 0 0.00071483006
of O 0 0.0008374338
immediate O 0 0.008386986
AX B-Chemical 0 0.9997285
allergy B-Disease 0 0.99959236
with O 0 0.0022032778
good O 0 0.0028951422
tolerance O 0 0.13886888
of O 0 0.013072833
PG B-Chemical 0 0.99963486
. O 0 0.011360895

Anaphylaxis B-Disease 0 0.98275775
was O 0 0.002976215
seen O 0 0.0017073383
in O 0 0.0012527879
37 O 0 0.0013715586
patients O 0 0.001041977
( O 0 0.0009227585
69 O 0 0.0007733629
% O 0 0.0006465987
) O 0 0.00076318206
, O 0 0.00049071846
the O 0 0.00032518336
other O 0 0.00037426202
17 O 0 0.00044874445
( O 0 0.00047951227
31 O 0 0.0004885002
% O 0 0.0005587135
) O 0 0.0010066273
having O 0 0.0020418493
urticaria B-Disease 0 0.9999821
and O 0 0.00319517
/ O 0 0.049096152
or O 0 0.0089528775
angioedema B-Disease 2 0.99997616
. O 0 0.009938791

All O 0 0.0030938056
the O 0 0.002286456
patients O 0 0.0019218359
were O 0 0.0012235979
skin O 0 0.0044334964
test O 0 0.00076539227
negative O 0 0.0008711618
to O 0 0.000832083
BPO B-Chemical 0 0.99997175
; O 0 0.0019085675
49 O 0 0.0005432493
of O 0 0.00034544858
51 O 0 0.0005306416
( O 0 0.0004623146
96 O 0 0.00063720153
% O 0 0.0003140042
) O 0 0.00035738418
were O 0 0.0001968133
also O 0 0.00018486615
negative O 0 0.00032051725
to O 0 0.0003047893
MDM B-Disease 0 0.88464713
, O 0 0.0006058517
and O 0 0.00039291658
44 O 0 0.00047420515
of O 0 0.00045245365
46 O 0 0.00077022053
( O 0 0.0009490715
96 O 0 0.0015298896
% O 0 0.0015676514
) O 0 0.0028470121
to O 0 0.0035918204
PG B-Chemical 0 0.9977849
. O 0 0.009628054

Skin O 0 0.08322442
tests O 0 0.00548019
with O 0 0.0039183716
AX B-Chemical 0 0.9722553
were O 0 0.0019929628
positive O 0 0.0018492515
in O 0 0.0016604877
34 O 0 0.002123427
( O 0 0.0024464047
63 O 0 0.0030622722
% O 0 0.003669912
) O 0 0.005877768
patients O 0 0.008020495
. O 0 0.010381483

RAST O 0 0.98981994
was O 0 0.0032612293
positive O 0 0.0026119405
for O 0 0.002137921
AX B-Chemical 0 0.9922994
in O 0 0.0010760609
22 O 0 0.0009295815
patients O 0 0.00077939394
( O 0 0.0007433461
41 O 0 0.0007365299
% O 0 0.00056529837
) O 0 0.00067134434
and O 0 0.0005163198
to O 0 0.0006015285
BPO B-Chemical 0 0.99975413
in O 0 0.0006899362
just O 0 0.0007139688
5 O 0 0.0007834661
( O 0 0.0014620041
9 O 0 0.0017406357
% O 0 0.0032146182
) O 0 0.006137409
. O 0 0.008360264

None O 0 0.007088879
of O 0 0.003759101
the O 0 0.0026368403
sera O 0 0.006403821
with O 0 0.0021820986
negative O 0 0.005754804
RAST O 0 0.9988619
for O 0 0.0027647675
AX B-Chemical 0 0.9911809
were O 0 0.0024780508
positive O 0 0.003700638
to O 0 0.005575557
BPO B-Chemical 0 0.99946195
. O 0 0.012697193

Challenge O 0 0.009039873
tests O 0 0.004119838
with O 0 0.002934804
AX B-Chemical 0 0.97942126
were O 0 0.0010539923
performed O 0 0.0006265986
in O 0 0.000565852
23 O 0 0.0006400305
subjects O 0 0.000545352
( O 0 0.0005587464
43 O 0 0.00052177405
% O 0 0.00038472112
) O 0 0.0003780453
to O 0 0.0001779488
establish O 0 0.0001445912
the O 0 0.00018125176
diagnosis O 0 0.00058564264
of O 0 0.00036294092
immediate O 0 0.011841241
allergic B-Disease 2 0.99999726
reaction I-Disease 2 0.93536735
to O 0 0.0007914154
AX B-Chemical 0 0.9995029
, O 0 0.00053389685
and O 0 0.00023622297
in O 0 0.00017160164
15 O 0 0.00015266072
cases O 0 0.00024792427
( O 0 0.000319378
28 O 0 0.00024965347
% O 0 0.00031112056
) O 0 0.0004414014
both O 0 0.0003325605
skin O 0 0.009223408
test O 0 0.00064739207
and O 0 0.0013694225
RAST O 0 0.9977888
for O 0 0.001771258
AX B-Chemical 0 0.9888571
were O 0 0.0026093505
negative O 0 0.0045703924
. O 0 0.007467989

PG B-Chemical 0 0.9962674
was O 0 0.008100949
well O 0 0.0060744523
tolerated O 0 0.009667596
by O 0 0.005750658
all O 0 0.0058945995
54 O 0 0.0097098155
patients O 0 0.011631497
. O 0 0.014532901

We O 0 0.003829574
describe O 0 0.0023782593
the O 0 0.0018757132
largest O 0 0.0018941072
group O 0 0.0017632749
of O 0 0.0031358057
AX B-Chemical 0 0.99978155
- O 0 0.39545262
allergic B-Disease 0 0.99980193
patients O 0 0.004490055
who O 0 0.0014551848
have O 0 0.00086160883
tolerated O 0 0.043703776
PG B-Chemical 0 0.9989549
reported O 0 0.0029247066
so O 0 0.0028162044
far O 0 0.00445824
. O 0 0.0071520945

Diagnosis O 0 0.010650189
of O 0 0.0031820557
these O 0 0.0022456772
patients O 0 0.0019552556
can O 0 0.00097255554
be O 0 0.00088508776
achieved O 0 0.0008721834
only O 0 0.00084206957
if O 0 0.0007270333
specific O 0 0.0012390552
AX B-Chemical 0 0.99818283
- O 0 0.012888196
related O 0 0.0014180107
reagents O 0 0.0058920854
are O 0 0.0029911206
employed O 0 0.0050625145
. O 0 0.007822041

Further O 0 0.0038601423
studies O 0 0.002446839
are O 0 0.0015365852
necessary O 0 0.00088496506
to O 0 0.0007131456
determine O 0 0.00036385708
the O 0 0.00044279255
exact O 0 0.00045072805
extent O 0 0.0003026036
of O 0 0.00044990986
this O 0 0.00038484237
problem O 0 0.00055786764
and O 0 0.00042155458
to O 0 0.00036552362
improve O 0 0.0003860658
the O 0 0.00059669325
efficacy O 0 0.0010842923
of O 0 0.0015417968
diagnostic O 0 0.0029802162
methods O 0 0.0036673553
. O 0 0.00665715

Reversal O 0 0.024466634
by O 0 0.0056551336
phenylephrine B-Chemical 0 0.99990046
of O 0 0.0025437046
the O 0 0.0011469399
beneficial O 0 0.0010834108
effects O 0 0.0010664978
of O 0 0.0016785318
intravenous O 0 0.8641022
nitroglycerin B-Chemical 1 0.99999714
in O 0 0.0009454408
patients O 0 0.0018228508
with O 0 0.002830954
acute B-Disease 2 0.99914765
myocardial I-Disease 2 0.99999046
infarction I-Disease 2 0.9999995
. O 0 0.038617905

Nitroglycerin B-Chemical 0 0.9999629
has O 0 0.0033550824
been O 0 0.0019293884
shown O 0 0.0010203692
to O 0 0.0008174856
reduce O 0 0.00073744147
ST O 0 0.95920354
- O 0 0.019835576
segment O 0 0.0010300394
elevation O 0 0.08602571
during O 0 0.00038641947
acute B-Disease 2 0.99880564
myocardial I-Disease 2 0.99999857
infarction I-Disease 2 1.0
, O 0 0.022645943
an O 0 0.00068685244
effect O 0 0.00035991982
potentiated O 0 0.010601013
in O 0 0.00026706772
the O 0 0.0002669343
dog O 0 0.00089328643
by O 0 0.00032829022
agents O 0 0.0026232954
that O 0 0.00052334805
reverse O 0 0.42650494
nitroglycerin B-Chemical 1 0.99999857
- O 0 0.30421358
induced O 0 0.022238782
hypotension B-Disease 2 0.9999751
. O 0 0.009091672

Our O 0 0.0047196727
study O 0 0.003329968
was O 0 0.0020559859
designed O 0 0.0013933495
to O 0 0.0009577537
determine O 0 0.00054845074
the O 0 0.00078093476
effects O 0 0.0010111083
of O 0 0.0014741338
combined O 0 0.020003822
nitroglycerin B-Chemical 1 0.99999666
and O 0 0.041048005
phenylephrine B-Chemical 0 0.99996674
therapy O 0 0.038560145
. O 0 0.008158069

Ten O 0 0.0046922956
patients O 0 0.003039427
with O 0 0.0022234612
acute O 0 0.86730504
transmural O 0 0.9924434
myocardial B-Disease 0 0.9999869
infarctions I-Disease 0 0.9999672
received O 0 0.0012864359
intravenous O 0 0.8265254
nitroglycerin B-Chemical 1 0.99999845
, O 0 0.00069589197
sufficient O 0 0.00015245154
to O 0 0.00013623234
reduce O 0 0.000108308894
mean O 0 0.000111305686
arterial O 0 0.027129738
pressure O 0 0.0039148796
from O 0 0.00013246192
107 O 0 0.00030065133
+ O 0 0.0012271771
/ O 0 0.006359896
- O 0 0.0032647033
6 O 0 0.00013826185
to O 0 0.00013592199
85 O 0 0.00027332947
+ O 0 0.00073844823
/ O 0 0.0036268907
- O 0 0.002780384
6 O 0 0.00017697616
mm O 0 0.0011835237
Hg O 0 0.98488414
( O 0 0.00065869774
P O 0 0.013881887
less O 0 0.0002713364
than O 0 0.00024362953
0 O 0 0.00041110828
. O 0 0.0004941626
001 O 0 0.026499964
) O 0 0.0012063743
, O 0 0.0012494142
for O 0 0.0013367522
60 O 0 0.0021001175
minutes O 0 0.0029388473
. O 0 0.006236363

Left O 0 0.028814549
ventricular O 0 0.38435236
filling O 0 0.008612529
pressure O 0 0.04428329
decreased O 0 0.0011458979
from O 0 0.00067735167
19 O 0 0.0009605272
+ O 0 0.001757376
/ O 0 0.006754302
- O 0 0.00401233
2 O 0 0.00031587566
to O 0 0.00024600993
11 O 0 0.00032551185
+ O 0 0.0007932373
/ O 0 0.0033293413
- O 0 0.0034006645
2 O 0 0.00033588478
mm O 0 0.0017414147
Hg O 0 0.9829595
( O 0 0.0009773535
P O 0 0.010473621
less O 0 0.0006432147
than O 0 0.00069222035
0 O 0 0.0013340559
. O 0 0.001982512
001 O 0 0.03524872
) O 0 0.0064349864
. O 0 0.008228697

SigmaST O 0 0.10192749
, O 0 0.0036050344
the O 0 0.0017384479
sum O 0 0.0012456374
of O 0 0.0020211826
ST O 0 0.97369236
- O 0 0.020115634
segment O 0 0.0010853435
elevations O 0 0.030887818
in O 0 0.000391276
16 O 0 0.00045839066
precordial O 0 0.4121001
leads O 0 0.00028290987
, O 0 0.00048406146
decreased O 0 0.00048929616
( O 0 0.00084548065
P O 0 0.035199624
less O 0 0.0003128126
than O 0 0.0002778836
0 O 0 0.0004796951
. O 0 0.00059363403
02 O 0 0.016200373
) O 0 0.001599516
with O 0 0.002370177
intravenous O 0 0.73580146
nitroglycerin B-Chemical 1 0.9999646
. O 0 0.008375645

Subsequent O 0 0.0038195017
addition O 0 0.0020764235
of O 0 0.0040055593
phenylephrine B-Chemical 0 0.9999752
infusion O 0 0.047198072
, O 0 0.0011153186
sufficient O 0 0.00040337004
to O 0 0.00040068213
re O 0 0.011493566
- O 0 0.004350033
elevate O 0 0.0003943823
mean O 0 0.0001640437
arterial O 0 0.031854108
pressure O 0 0.004295362
to O 0 0.00014870598
106 O 0 0.00022577406
+ O 0 0.0010989134
/ O 0 0.005415528
- O 0 0.0037369821
4 O 0 0.00017549557
mm O 0 0.0013456182
Hg O 0 0.98929745
( O 0 0.0006402965
P O 0 0.021887895
less O 0 0.00018219609
than O 0 0.00013790687
0 O 0 0.0002157718
. O 0 0.00020013747
001 O 0 0.02608747
) O 0 0.0003089563
for O 0 0.0001444983
30 O 0 0.00012356529
minutes O 0 0.0001193566
, O 0 0.00018408867
increased O 0 0.00017417409
left O 0 0.00041116105
ventricular O 0 0.2369134
filling O 0 0.0016563376
pressure O 0 0.009759588
to O 0 0.00013661807
17 O 0 0.00024848606
+ O 0 0.0007816621
/ O 0 0.004933374
- O 0 0.0046123955
2 O 0 0.00019110175
mm O 0 0.0017848859
Hg O 0 0.99141437
( O 0 0.0006725598
P O 0 0.02486862
less O 0 0.00019154797
than O 0 0.00014911605
0 O 0 0.00023848691
. O 0 0.00022625677
05 O 0 0.0038521548
) O 0 0.00039214382
and O 0 0.00024998313
also O 0 0.00022792528
significantly O 0 0.00030595827
increased O 0 0.00056756794
sigmaST O 0 0.24410538
( O 0 0.0011053401
P O 0 0.03225219
less O 0 0.00059912313
than O 0 0.00065497996
0 O 0 0.0012897397
. O 0 0.0019194913
05 O 0 0.010350992
) O 0 0.005927146
. O 0 0.0077886167

Our O 0 0.003646704
results O 0 0.0019963547
suggest O 0 0.0011401881
that O 0 0.0009731024
addition O 0 0.0007364751
of O 0 0.0039691823
phenylephrine B-Chemical 0 0.99999475
to O 0 0.006572475
nitroglycerin B-Chemical 1 0.99999857
is O 0 0.00062744063
not O 0 0.00028733554
beneficial O 0 0.00035279093
in O 0 0.0002734502
the O 0 0.00029271294
treatment O 0 0.0004270017
of O 0 0.0006288931
patients O 0 0.0016291488
with O 0 0.0032418068
acute B-Disease 2 0.9993643
myocardial I-Disease 2 0.99999213
infarction I-Disease 2 0.9999995
. O 0 0.04160883

Acetazolamide B-Chemical 0 0.99998164
- O 0 0.1660633
induced O 0 0.008351521
nephrolithiasis B-Disease 2 0.99997437
: O 0 0.0053978814
implications O 0 0.0019585504
for O 0 0.0018911138
treatment O 0 0.0027868235
of O 0 0.0054651103
neuromuscular B-Disease 0 0.98911613
disorders I-Disease 0 0.99781466
. O 0 0.010608277

Carbonic O 0 0.9930056
anhydrase O 0 0.99727553
inhibitors O 0 0.04559588
can O 0 0.012473748
cause O 0 0.027571904
nephrolithiasis B-Disease 2 0.99988747
. O 0 0.030342048

We O 0 0.003775159
studied O 0 0.0026610175
20 O 0 0.0018115261
patients O 0 0.0014947988
receiving O 0 0.001116664
long O 0 0.0009416505
- O 0 0.0041423175
term O 0 0.0010914115
carbonic O 0 0.9994419
anhydrase O 0 0.99993265
inhibitor O 0 0.13390677
treatment O 0 0.0016190277
for O 0 0.001104394
periodic O 0 0.053557884
paralysis B-Disease 2 0.9999188
and O 0 0.035529926
myotonia B-Disease 0 0.9998443
. O 0 0.009037179

Three O 0 0.0057091815
patients O 0 0.0044760695
on O 0 0.0033222935
acetazolamide B-Chemical 0 0.99992585
( O 0 0.0044505065
15 O 0 0.002354579
% O 0 0.003170863
) O 0 0.004703689
developed O 0 0.0075728074
renal B-Disease 0 0.99696416
calculi I-Disease 0 0.99910223
. O 0 0.016619794

Extracorporeal O 0 0.005416563
lithotripsy O 0 0.004721886
successfully O 0 0.0018798475
removed O 0 0.0012224581
a O 0 0.0020720568
renal B-Disease 0 0.99851567
calculus I-Disease 0 0.99911624
in O 0 0.0007287323
one O 0 0.0003985391
patient O 0 0.0003653536
and O 0 0.00035334847
surgery O 0 0.00042374476
removed O 0 0.0002804157
a O 0 0.00053743005
staghorn O 0 0.87605697
calculus B-Disease 0 0.96481633
in O 0 0.00081903173
another O 0 0.00096692145
, O 0 0.0013063231
permitting O 0 0.001986781
continued O 0 0.0023703678
treatment O 0 0.0043162247
. O 0 0.0069210916

Renal O 0 0.028527092
function O 0 0.0078896
remained O 0 0.0080823265
normal O 0 0.007949214
in O 0 0.0073795607
all O 0 0.0086445045
patients O 0 0.013808748
. O 0 0.016725471

Nephrolithiasis B-Disease 0 0.99658597
is O 0 0.0046359543
a O 0 0.0040073954
complication O 0 0.19673288
of O 0 0.008134341
acetazolamide B-Chemical 0 0.99999034
but O 0 0.0034830768
does O 0 0.0018592965
not O 0 0.0018035038
preclude O 0 0.0029460099
its O 0 0.0052799415
use O 0 0.006137484
. O 0 0.0091831535

Effects O 0 0.007035747
of O 0 0.0057885395
calcium B-Chemical 0 0.9968657
channel O 0 0.6480651
blockers O 0 0.9986713
on O 0 0.0037484306
bupivacaine B-Chemical 1 0.99998605
- O 0 0.11679519
induced O 0 0.009274609
toxicity B-Disease 2 0.99904853
. O 0 0.013235109

The O 0 0.0031648052
purpose O 0 0.0022455098
of O 0 0.0017666807
this O 0 0.001228811
study O 0 0.0010661219
was O 0 0.00062659115
to O 0 0.00038523256
investigate O 0 0.00021885845
the O 0 0.00028914076
influence O 0 0.00025234043
of O 0 0.00071284664
calcium B-Chemical 0 0.99917597
channel O 0 0.64278305
blockers O 0 0.998248
on O 0 0.0009894953
bupivacaine B-Chemical 1 0.99999225
- O 0 0.071978666
induced O 0 0.0038415673
acute O 0 0.993856
toxicity B-Disease 2 0.9997458
. O 0 0.011499909

For O 0 0.003017522
each O 0 0.0014933348
of O 0 0.0014232538
the O 0 0.000897971
three O 0 0.00052072253
tested O 0 0.00068377727
calcium B-Chemical 0 0.9984004
channel O 0 0.7543736
blockers O 0 0.9996729
( O 0 0.1382077
diltiazem B-Chemical 1 0.9999999
, O 0 0.045913775
verapamil B-Chemical 0 0.99999857
and O 0 0.013254427
bepridil B-Chemical 1 0.99999774
) O 0 0.0023794477
6 O 0 0.00012946517
groups O 0 0.00013105055
of O 0 0.00013935594
mice O 0 9.630166e-05
were O 0 0.00013517335
treated O 0 0.00015461144
by O 0 0.0001357831
two O 0 0.00010545692
different O 0 0.00011479603
doses O 0 0.0008925037
, O 0 0.00037970138
i O 0 0.0020659135
. O 0 0.00016996183
e O 0 0.00047497445
. O 0 0.00018446997
2 O 0 0.00015442682
and O 0 0.00016362438
10 O 0 0.00016150698
mg O 0 0.0039319186
/ O 0 0.00095530227
kg O 0 0.0011334156
/ O 0 0.0039073965
i O 0 0.0032981886
. O 0 0.00022059014
p O 0 0.00024674283
. O 0 0.00019834962
, O 0 0.00026563928
or O 0 0.00017238161
an O 0 0.00018670279
equal O 0 0.00011970949
volume O 0 0.00029944757
of O 0 0.00024183361
saline O 0 0.0033965416
for O 0 0.00013718226
the O 0 0.00013458933
control O 0 0.00015916333
group O 0 0.00023692175
( O 0 0.00025268857
n O 0 0.00016103982
= O 0 0.00038315973
20 O 0 0.00017655852
) O 0 0.00030882115
; O 0 0.00024003585
15 O 0 0.00011504533
minutes O 0 0.00010694741
later O 0 0.0001235342
, O 0 0.00018203809
all O 0 0.00012717902
the O 0 0.000127287
animals O 0 0.000119747594
were O 0 0.00013399552
injected O 0 0.00012879742
with O 0 0.00016442922
a O 0 0.00020424208
single O 0 0.00019013358
50 O 0 0.00026972336
mg O 0 0.008154659
/ O 0 0.0011976903
kg O 0 0.0012221949
/ O 0 0.002441499
i O 0 0.0018301525
. O 0 0.0005125722
p O 0 0.00072580384
. O 0 0.0009713063
dose O 0 0.0041130437
of O 0 0.007492603
bupivacaine B-Chemical 1 0.99992883
. O 0 0.008655176

The O 0 0.004428775
convulsant O 0 0.9986547
activity O 0 0.0026771876
, O 0 0.0016521692
the O 0 0.0007513858
time O 0 0.00046810112
of O 0 0.00056670903
latency O 0 0.0010518669
to O 0 0.00046292754
convulse O 0 0.20683523
and O 0 0.00043719393
the O 0 0.00043025592
mortality O 0 0.053436965
rate O 0 0.00066185347
were O 0 0.0006860387
assessed O 0 0.00075565465
in O 0 0.0012253714
each O 0 0.0015374802
group O 0 0.0039376733
. O 0 0.006422571

The O 0 0.0034813273
local O 0 0.0041342136
anesthetic O 0 0.40004474
- O 0 0.019022029
induced O 0 0.0016555215
mortality O 0 0.6360501
was O 0 0.001038028
significantly O 0 0.00067356817
increased O 0 0.0006177627
by O 0 0.00058062415
the O 0 0.00055397645
three O 0 0.0005283716
different O 0 0.0009963902
calcium B-Chemical 0 0.99007964
channel O 0 0.4745908
blockers O 0 0.9950873
. O 0 0.008598804

The O 0 0.0040254625
convulsant O 0 0.99832565
activity O 0 0.00294715
of O 0 0.00749194
bupivacaine B-Chemical 1 0.99998546
was O 0 0.00086239236
not O 0 0.00039373303
significantly O 0 0.0003626305
modified O 0 0.00039167757
but O 0 0.00093164004
calcium B-Chemical 0 0.99898607
channel O 0 0.5648198
blockers O 0 0.9948714
decreased O 0 0.00038372047
the O 0 0.00014828403
time O 0 0.00010267427
of O 0 0.00016547013
latency O 0 0.00038008086
to O 0 0.00014608528
obtain O 0 0.0001895097
bupivacaine B-Chemical 1 0.9999883
- O 0 0.055088427
induced O 0 0.0020936918
convulsions B-Disease 0 0.999998
; O 0 0.0025900146
this O 0 0.0003564928
effect O 0 0.00041548206
was O 0 0.00059476186
less O 0 0.00083807885
pronounced O 0 0.0024957734
with O 0 0.005038455
bepridil B-Chemical 1 0.99995995
. O 0 0.008325599

Epidural O 0 0.4372625
blood O 0 0.017150695
flow O 0 0.014618026
during O 0 0.005816647
prostaglandin B-Chemical 1 0.9999995
E1 I-Chemical 1 0.9999763
or O 0 0.20992228
trimethaphan B-Chemical 0 0.9999914
induced O 0 0.15856189
hypotension B-Disease 2 0.9999801
. O 0 0.01525551

To O 0 0.0026529157
evaluate O 0 0.0013438399
the O 0 0.0013938136
effect O 0 0.0014912997
of O 0 0.07001337
prostaglandin B-Chemical 1 1.0
E1 I-Chemical 1 0.9999993
( O 0 0.9461108
PGE1 B-Chemical 1 1.0
) O 0 0.15344548
or O 0 0.009154377
trimethaphan B-Chemical 0 0.99999726
( O 0 0.0709798
TMP B-Chemical 0 0.9999963
) O 0 0.008146153
induced O 0 0.0011379377
hypotension B-Disease 2 0.9999869
on O 0 0.00018018545
epidural O 0 0.18718043
blood O 0 0.008505836
flow O 0 0.0035543055
( O 0 0.00072572636
EBF O 0 0.419694
) O 0 0.0005240795
during O 0 0.00014853833
spinal O 0 0.0027801406
surgery O 0 0.00047064378
, O 0 0.00040984483
EBF O 0 0.18652046
was O 0 0.00018446398
measured O 0 0.00013064928
using O 0 0.00014744484
the O 0 0.00017506903
heat O 0 0.0025721376
clearance O 0 0.018200321
method O 0 0.0003523773
in O 0 0.0001946828
30 O 0 0.00017316561
patients O 0 0.00022740994
who O 0 0.00026585208
underwent O 0 0.00026318838
postero O 0 0.035184983
- O 0 0.002230024
lateral O 0 0.0036803568
interbody O 0 0.39630076
fusion O 0 0.0012084565
under O 0 0.0016824283
isoflurane B-Chemical 1 0.9984326
anaesthesia O 0 0.14240149
. O 0 0.006899253

An O 0 0.004372681
initial O 0 0.0020793928
dose O 0 0.003351997
of O 0 0.0016112331
0 O 0 0.0012043306
. O 0 0.0006852839
1 O 0 0.00056648464
microgram O 0 0.011607959
. O 0 0.00041088124
kg O 0 0.0013611456
- O 0 0.003674457
1 O 0 0.00028889472
. O 0 0.00023163823
min O 0 0.00039978206
- O 0 0.001966041
1 O 0 0.00027664093
of O 0 0.001194239
PGE1 B-Chemical 1 0.99999964
( O 0 0.001414207
15 O 0 0.00019916623
patients O 0 0.0002938969
) O 0 0.00041030257
, O 0 0.00026699743
or O 0 0.00017295538
10 O 0 0.00017287755
micrograms O 0 0.0014623096
. O 0 0.00017234101
kg O 0 0.0008083285
- O 0 0.0029057774
1 O 0 0.00018013876
. O 0 0.00015456251
min O 0 0.00029405416
- O 0 0.0014307246
1 O 0 0.00019958556
of O 0 0.0004939928
TMP B-Chemical 0 0.9999856
( O 0 0.0010609365
15 O 0 0.00017538233
patients O 0 0.00025643344
) O 0 0.00031407244
was O 0 0.00014418588
administered O 0 0.00012225464
intravenously O 0 0.00013423877
after O 0 8.3490304e-05
the O 0 0.00014575204
dural O 0 0.4826624
opening O 0 0.0037542135
and O 0 0.00020461554
the O 0 0.00015672272
dose O 0 0.00059386744
was O 0 0.00015270484
adjusted O 0 0.00015451918
to O 0 0.000118078526
maintain O 0 0.00010971083
the O 0 0.00013923283
mean O 0 0.00013962916
arterial O 0 0.056937467
blood O 0 0.007102966
pressure O 0 0.034516815
( O 0 0.0009883209
MAP O 0 0.81258214
) O 0 0.0010856559
at O 0 0.000762446
about O 0 0.0011466797
60 O 0 0.0021569056
mmHg O 0 0.0053958744
. O 0 0.006317202

The O 0 0.00561546
hypotensive B-Disease 0 0.9971154
drug O 0 0.5163179
was O 0 0.0023841315
discontinued O 0 0.0034000373
at O 0 0.0011289525
the O 0 0.001110268
completion O 0 0.0011532195
of O 0 0.0017632481
the O 0 0.0022081323
operative O 0 0.004097341
procedure O 0 0.0048285485
. O 0 0.008122903

After O 0 0.0032892986
starting O 0 0.0054180203
PGE1 B-Chemical 1 0.99999845
or O 0 0.06483282
TMP B-Chemical 0 0.9999958
, O 0 0.03440905
MAP O 0 0.975218
and O 0 0.0007631948
rate O 0 0.0005886303
pressure O 0 0.094040535
product O 0 0.0012679917
( O 0 0.0024463604
RPP O 0 0.9808168
) O 0 0.0009540906
decreased O 0 0.00030093954
significantly O 0 0.00019389416
compared O 0 0.000120319906
with O 0 0.00020251177
preinfusion O 0 0.010217509
values O 0 0.00017159263
( O 0 0.00045671494
P O 0 0.033674337
< O 0 0.0001969629
0 O 0 0.00025557773
. O 0 0.00022323558
01 O 0 0.0015734296
) O 0 0.0004555323
, O 0 0.0003000477
and O 0 0.00022857335
the O 0 0.00019100338
degree O 0 0.00031775134
of O 0 0.0014400936
hypotension B-Disease 2 0.9999862
due O 0 0.00024964896
to O 0 0.0006792021
PGE1 B-Chemical 1 0.9999994
remained O 0 0.00075953815
constant O 0 0.00037680005
until O 0 0.00030024687
60 O 0 0.00047477774
min O 0 0.00073605037
after O 0 0.0008961914
its O 0 0.0030680452
discontinuation O 0 0.43946916
. O 0 0.0065253237

Heart O 0 0.021059947
rate O 0 0.0056592408
( O 0 0.006898243
HR O 0 0.4072289
) O 0 0.0048394855
did O 0 0.0028169507
not O 0 0.0022973544
change O 0 0.002799425
in O 0 0.0032564094
either O 0 0.0044336515
group O 0 0.007775812
. O 0 0.010665957

EBFF O 0 0.2942155
did O 0 0.0035569374
not O 0 0.0018544747
change O 0 0.0018420412
during O 0 0.0016650875
PGE1 B-Chemical 1 0.9999994
infusion O 0 0.04985788
whereas O 0 0.00076084357
in O 0 0.0004587907
the O 0 0.00090769795
TMP B-Chemical 0 0.99999213
group O 0 0.0045747855
, O 0 0.0017772313
EBF O 0 0.58648914
decreased O 0 0.0004040171
significantly O 0 0.00020741465
at O 0 0.00013114755
30 O 0 0.00011862361
and O 0 0.00013421854
60 O 0 0.00013015662
min O 0 0.00014732103
after O 0 9.044272e-05
the O 0 0.000120466844
start O 0 0.00014290963
of O 0 0.00073361263
TMP B-Chemical 0 0.9999933
( O 0 0.004536937
preinfusion O 0 0.077685416
: O 0 0.00030209482
45 O 0 0.00015351803
. O 0 0.00014466222
9 O 0 0.00017166138
+ O 0 0.0006134169
/ O 0 0.005528452
- O 0 0.0066734017
13 O 0 0.00023847645
. O 0 0.00016474201
9 O 0 0.00016914266
ml O 0 0.0003559199
/ O 0 0.0028072975
100g O 0 0.15976183
/ O 0 0.0008131124
min O 0 0.0002593649
. O 0 0.00015052033
30 O 0 0.00013344546
min O 0 0.0001956124
: O 0 0.00025712606
32 O 0 0.00022142039
. O 0 0.00016698761
3 O 0 0.0001763428
+ O 0 0.00064757036
/ O 0 0.005778145
- O 0 0.006842491
9 O 0 0.00020700665
. O 0 0.00016474248
9 O 0 0.0001644788
ml O 0 0.00029026988
/ O 0 0.0006415157
100 O 0 0.00031046305
g O 0 0.00044295026
/ O 0 0.00093521026
min O 0 0.00038327373
( O 0 0.00047631806
P O 0 0.019835686
< O 0 0.00021215806
0 O 0 0.00026474652
. O 0 0.00023443492
05 O 0 0.0034120278
) O 0 0.00038312943
. O 0 0.00017662602
60 O 0 0.00016886466
min O 0 0.00021056698
: O 0 0.0002547758
30 O 0 0.00017445214
+ O 0 0.00060599105
/ O 0 0.0043458464
- O 0 0.0045130136
7 O 0 0.00018961886
. O 0 0.00017448408
5 O 0 0.00016650934
ml O 0 0.00032524165
/ O 0 0.00068836496
100 O 0 0.00039011266
g O 0 0.0005512686
/ O 0 0.0010291958
min O 0 0.000589674
( O 0 0.0008006537
P O 0 0.010604725
< O 0 0.00074973464
0 O 0 0.0011560263
. O 0 0.0015904215
05 O 0 0.008537797
) O 0 0.0045369887
) O 0 0.00704442
. O 0 0.008896202

These O 0 0.0038129631
results O 0 0.002403286
suggest O 0 0.0016122566
that O 0 0.0028364342
PGE1 B-Chemical 1 0.9999989
may O 0 0.0013590564
be O 0 0.0007541599
preferable O 0 0.0005630165
to O 0 0.0006851987
TMP B-Chemical 0 0.9999752
for O 0 0.0015328719
hypotensive B-Disease 0 0.9993237
anaesthesia O 0 0.03385149
in O 0 0.0005275805
spinal O 0 0.0035340048
surgery O 0 0.0014234944
because O 0 0.0014152612
TMP B-Chemical 0 0.9998809
decreased O 0 0.0121923415
EBF O 0 0.7593362
. O 0 0.009296177

Dup B-Chemical 0 0.99891114
753 I-Chemical 0 0.7993735
prevents O 0 0.0036545263
the O 0 0.0027554412
development O 0 0.0038488442
of O 0 0.005213672
puromycin B-Chemical 0 0.99758875
aminonucleoside I-Chemical 0 0.9999981
- O 0 0.7812404
induced O 0 0.063224845
nephrosis B-Disease 2 0.99998593
. O 0 0.026315851

The O 0 0.0032633105
appearance O 0 0.0043403227
of O 0 0.0061536883
nephrotic B-Disease 0 0.9999958
syndromes I-Disease 0 0.636707
such O 0 0.0009194981
as O 0 0.001920844
proteinuria B-Disease 0 0.9999994
, O 0 0.12565574
hypoalbuminemia B-Disease 0 0.9999987
, O 0 0.12083175
hypercholesterolemia B-Disease 0 0.9999995
and O 0 0.0007402756
increase O 0 0.00019836986
in O 0 0.00034641274
blood B-Chemical 0 0.7861484
nitrogen I-Chemical 0 0.9999572
urea I-Chemical 1 0.9999963
, O 0 0.0011816623
induced O 0 0.00024090344
in O 0 0.0001991814
rats O 0 0.00025976085
by O 0 0.00015793259
injection O 0 0.0003243746
of O 0 0.00054692826
puromycin B-Chemical 0 0.9936899
aminonucleoside I-Chemical 0 0.9999993
was O 0 0.0015749376
markedly O 0 0.0018847765
inhibited O 0 0.00044743525
by O 0 0.00032580647
oral O 0 0.19733275
administration O 0 0.015877813
of O 0 0.007191326
Dup B-Chemical 0 0.9999883
753 I-Chemical 0 0.99688655
( O 0 0.023254994
losartan B-Chemical 1 0.99999726
) O 0 0.0031396751
, O 0 0.00037079075
a O 0 0.00032282682
novel O 0 0.0030330543
angiotensin B-Chemical 1 0.9999993
II I-Chemical 1 0.9740094
receptor O 0 0.37721562
antagonist O 0 0.92692065
, O 0 0.0004805656
at O 0 0.00016757523
a O 0 0.0002324325
dose O 0 0.0005079306
of O 0 0.00031677887
1 O 0 0.00030059632
or O 0 0.00034126572
2 O 0 0.00049888954
mg O 0 0.005624009
/ O 0 0.0017673535
kg O 0 0.0019980378
per O 0 0.0015575391
day O 0 0.0030571553
. O 0 0.0060663023

The O 0 0.0029638205
results O 0 0.0018892257
suggest O 0 0.0011288439
a O 0 0.0012779009
possible O 0 0.0008594429
involvement O 0 0.00094103266
of O 0 0.0008112279
the O 0 0.0011219345
renin O 0 0.9963858
- O 0 0.4457618
angiotensin B-Chemical 1 0.999954
system O 0 0.00051995495
in O 0 0.0003288732
the O 0 0.00034146494
development O 0 0.0008857614
of O 0 0.0017857898
puromycin B-Chemical 0 0.9961863
aminonucleoside I-Chemical 0 0.9999988
- O 0 0.7315465
induced O 0 0.04401434
nephrosis B-Disease 2 0.9999894
. O 0 0.020903872

Neuroplasticity O 0 0.031622984
of O 0 0.004253355
the O 0 0.0029573515
adult O 0 0.0031605903
primate O 0 0.003407078
auditory O 0 0.01693781
cortex O 0 0.16295642
following O 0 0.0027357657
cochlear O 0 0.14146297
hearing B-Disease 0 0.92063826
loss I-Disease 0 0.014093783
. O 0 0.011329425

Tonotopic O 0 0.057511825
organization O 0 0.003573664
is O 0 0.0020913172
an O 0 0.0015879627
essential O 0 0.0009982394
feature O 0 0.000954381
of O 0 0.0007768565
the O 0 0.00060777745
primary O 0 0.0007495368
auditory O 0 0.00881437
area O 0 0.001733991
( O 0 0.0025294456
A1 O 0 0.76419115
) O 0 0.0024211246
of O 0 0.0025598353
primate O 0 0.006611383
cortex O 0 0.5036106
. O 0 0.007869328

In O 0 0.0053890715
A1 O 0 0.28412
of O 0 0.0024222669
macaque O 0 0.0019640466
monkeys O 0 0.001634405
, O 0 0.0012876862
low O 0 0.0009171091
frequencies O 0 0.0007067756
are O 0 0.0005430308
represented O 0 0.0005837473
rostrolaterally O 0 0.003340812
and O 0 0.00078963384
high O 0 0.0010811053
frequencies O 0 0.0012938849
are O 0 0.0016716461
represented O 0 0.0027602487
caudomedially O 0 0.026900928
. O 0 0.0074674576

The O 0 0.003267749
purpose O 0 0.0023410064
of O 0 0.0018586171
this O 0 0.0013105968
study O 0 0.0011482359
was O 0 0.0007029172
to O 0 0.00044785746
determine O 0 0.0002528466
if O 0 0.0003254948
changes O 0 0.00043238985
occur O 0 0.0003750687
in O 0 0.00041899193
this O 0 0.00050699874
tonotopic O 0 0.0072043184
organization O 0 0.0010081255
following O 0 0.0011102094
cochlear O 0 0.10330693
hearing B-Disease 0 0.89501655
loss I-Disease 0 0.00991069
. O 0 0.007976477

Under O 0 0.0073868087
anesthesia O 0 0.036081534
, O 0 0.0023828626
the O 0 0.0012153618
superior O 0 0.0016930496
temporal O 0 0.032206435
gyrus O 0 0.8468449
of O 0 0.0006060491
adult O 0 0.00060363597
macaque O 0 0.00042648992
monkeys O 0 0.00040358925
was O 0 0.00027936164
exposed O 0 0.00034678084
, O 0 0.00037338
and O 0 0.00027748122
the O 0 0.0002556457
tonotopic O 0 0.0151609285
organization O 0 0.0004651401
of O 0 0.0006794532
A1 O 0 0.70411986
was O 0 0.00043704893
mapped O 0 0.0004340355
using O 0 0.0005686531
conventional O 0 0.0009265494
microelectrode O 0 0.002368624
recording O 0 0.0022650643
techniques O 0 0.0038232938
. O 0 0.00629586

Following O 0 0.004276399
recovery O 0 0.0038865104
, O 0 0.0026476418
the O 0 0.001429405
monkeys O 0 0.0014075688
were O 0 0.00095493323
selectively O 0 0.0009153861
deafened O 0 0.015892075
for O 0 0.00076216424
high O 0 0.0010431817
frequencies O 0 0.0011693581
using O 0 0.001603418
kanamycin B-Chemical 1 0.9909719
and O 0 0.027033806
furosemide B-Chemical 1 0.99997985
. O 0 0.011015051

The O 0 0.003239888
actual O 0 0.0022526914
frequencies O 0 0.0021608688
deafened O 0 0.01570586
were O 0 0.0010190606
determined O 0 0.0006558232
by O 0 0.00070657453
the O 0 0.0006216253
loss O 0 0.000995799
of O 0 0.0010542143
tone O 0 0.26415953
- O 0 0.009518304
burst O 0 0.0018734524
elicited O 0 0.0015442006
auditory O 0 0.034269884
brainstem O 0 0.1716511
responses O 0 0.005513338
. O 0 0.007288843

Three O 0 0.0083904695
months O 0 0.0058287256
after O 0 0.0058735213
deafening O 0 0.10836461
, O 0 0.012266301
A1 O 0 0.63348126
was O 0 0.011674179
remapped O 0 0.014821236
. O 0 0.017374018

Postmortem O 0 0.15687072
cytoarchitectural O 0 0.019949362
features O 0 0.003700183
identifying O 0 0.0036741423
A1 O 0 0.48464
were O 0 0.0019507478
correlated O 0 0.0015494329
with O 0 0.0021032188
the O 0 0.0028537877
electrophysiologic O 0 0.040308245
data O 0 0.0062739714
. O 0 0.008935438

The O 0 0.0030248798
results O 0 0.00191151
indicate O 0 0.0011091537
that O 0 0.00096139783
the O 0 0.000885205
deprived O 0 0.0013159987
area O 0 0.0011978945
of O 0 0.0012417985
A1 O 0 0.7834167
undergoes O 0 0.00053439377
extensive O 0 0.00056290947
reorganization O 0 0.0016002404
and O 0 0.0006127672
becomes O 0 0.00075850304
responsive O 0 0.00070050376
to O 0 0.00093333557
intact O 0 0.0018344318
cochlear O 0 0.02518659
frequencies O 0 0.0043780217
. O 0 0.007048073

The O 0 0.0031352292
region O 0 0.0026939374
of O 0 0.0023295349
cortex O 0 0.1360808
that O 0 0.0008369034
represents O 0 0.0006975925
the O 0 0.0005973316
low O 0 0.00071336655
frequencies O 0 0.00059792114
was O 0 0.00048824746
not O 0 0.00045367976
obviously O 0 0.0010935225
affected O 0 0.00068210193
by O 0 0.0009276527
the O 0 0.0013691082
cochlear O 0 0.1611899
hearing B-Disease 0 0.9265785
loss I-Disease 0 0.011603896
. O 0 0.008305859

Sodium B-Chemical 0 0.99998844
bicarbonate I-Chemical 0 0.99996555
alleviates O 0 0.7108793
penile B-Disease 0 0.99536926
pain I-Disease 0 0.9993376
induced O 0 0.0022439118
by O 0 0.002376806
intracavernous O 0 0.97340876
injections O 0 0.004035934
for O 0 0.0031902152
erectile B-Disease 0 0.99597186
dysfunction I-Disease 0 0.92067075
. O 0 0.010301505

In O 0 0.0037629425
an O 0 0.002567465
attempt O 0 0.0015427059
to O 0 0.0009016692
determine O 0 0.00043682693
whether O 0 0.0004421744
penile B-Disease 0 0.88105494
pain I-Disease 0 0.99830854
associated O 0 0.0004923478
with O 0 0.00033254275
intracorporeal O 0 0.0005250471
injections O 0 0.0004972223
could O 0 0.0001528463
be O 0 0.0001577171
due O 0 0.00012111417
to O 0 0.00014194808
the O 0 0.00020805758
acidity O 0 0.8405702
of O 0 0.00038452732
the O 0 0.0002851455
medication O 0 0.016923916
, O 0 0.00020410522
we O 0 9.3544084e-05
performed O 0 0.00011226545
a O 0 0.00016563886
randomized O 0 0.00014884245
study O 0 0.00013771857
comparing O 0 8.398834e-05
the O 0 0.0001284425
incidence O 0 0.0007378991
of O 0 0.0005673316
penile B-Disease 0 0.9726653
pain I-Disease 0 0.9977602
following O 0 0.00015087581
intracorporeal O 0 0.00031445175
injections O 0 0.0002997329
with O 0 0.00016609197
or O 0 0.00015799011
without O 0 0.00016697487
the O 0 0.00018367333
addition O 0 0.00018308547
of O 0 0.0009728483
sodium B-Chemical 0 0.9998598
bicarbonate I-Chemical 0 0.99921954
to O 0 0.00085180247
the O 0 0.0012405689
intracorporeal O 0 0.0033477433
medications O 0 0.061369576
. O 0 0.005660225

A O 0 0.015265742
total O 0 0.002341078
of O 0 0.0019935302
38 O 0 0.0016094943
consecutive O 0 0.00082605256
patients O 0 0.0008385061
who O 0 0.00063049403
presented O 0 0.0003343143
to O 0 0.00027147203
our O 0 0.0002804029
clinic O 0 0.00030732204
with O 0 0.00032676646
impotence B-Disease 0 0.7983074
received O 0 0.00018697945
0 O 0 0.0002345013
. O 0 0.00016491409
2 O 0 0.00016354343
ml O 0 0.00028012923
. O 0 0.00015464242
of O 0 0.00018669353
a O 0 0.0002162451
combination O 0 0.00022328009
of O 0 0.00024958304
3 O 0 0.00018372953
drugs O 0 0.030779153
: O 0 0.00043215312
6 O 0 0.00014988682
mg O 0 0.01918439
. O 0 0.00033970244
papaverine B-Chemical 1 0.99995565
, O 0 0.0005856064
100 O 0 0.00063340995
micrograms O 0 0.017104698
. O 0 0.00040721954
phentolamine B-Chemical 0 0.9999939
and O 0 0.0003360281
10 O 0 0.00020126344
micrograms O 0 0.018290605
. O 0 0.0013099125
prostaglandin B-Chemical 1 1.0
E1 I-Chemical 1 0.9999833
with O 0 0.0033461144
( O 0 0.0021497183
pH O 0 0.14329189
7 O 0 0.00020237223
. O 0 0.00020939395
05 O 0 0.0031092227
) O 0 0.0003298935
or O 0 0.00017767277
without O 0 0.00021233958
( O 0 0.0005775831
pH O 0 0.06968553
4 O 0 0.00019776175
. O 0 0.00018362796
17 O 0 0.00023604711
) O 0 0.00026385998
the O 0 0.00017130916
addition O 0 0.00015858341
of O 0 0.0007195666
sodium B-Chemical 0 0.9999237
bicarbonate I-Chemical 0 0.9998754
( O 0 0.0019138596
0 O 0 0.00080600916
. O 0 0.0009134189
03 O 0 0.029666994
mEq O 0 0.2150523
. O 0 0.0024727052
) O 0 0.0056395787
. O 0 0.007660613

Of O 0 0.004484515
the O 0 0.0024329696
19 O 0 0.002176429
patients O 0 0.001518099
without O 0 0.0013745648
sodium B-Chemical 0 0.9998216
bicarbonate I-Chemical 0 0.9997172
added O 0 0.00056285586
to O 0 0.00029996017
the O 0 0.00030645018
medication O 0 0.0076804264
11 O 0 0.00024319922
( O 0 0.0002901946
58 O 0 0.00031134815
% O 0 0.00028165066
) O 0 0.00042063312
complained O 0 0.0023302354
of O 0 0.00042869998
penile B-Disease 0 0.94978267
pain I-Disease 0 0.9966102
due O 0 0.00013948703
to O 0 0.0001439382
the O 0 0.00019680278
medication O 0 0.010982921
, O 0 0.0002522769
while O 0 0.0001803326
only O 0 0.00018394359
1 O 0 0.00015079298
of O 0 0.00016978834
the O 0 0.0001878911
19 O 0 0.00037597117
men O 0 0.0041712252
( O 0 0.00036709014
5 O 0 0.00022051846
% O 0 0.00034503604
) O 0 0.00053044513
who O 0 0.00056642556
received O 0 0.0005435321
sodium B-Chemical 0 0.9994885
bicarbonate I-Chemical 0 0.9997135
complained O 0 0.20109819
of O 0 0.0041703093
penile B-Disease 0 0.98748684
pain I-Disease 0 0.9987379
. O 0 0.008109794

From O 0 0.003702047
these O 0 0.002472515
data O 0 0.0017220948
we O 0 0.0008938091
conclude O 0 0.0006467905
that O 0 0.0005781678
the O 0 0.0007411417
penile B-Disease 0 0.93086684
pain I-Disease 0 0.99744046
following O 0 0.00029324056
intracorporeal O 0 0.00054226123
injections O 0 0.00059644534
is O 0 0.00024320201
most O 0 0.00028516373
likely O 0 0.00016408403
due O 0 0.00011955855
to O 0 0.0001415109
the O 0 0.00020940034
acidity O 0 0.8345228
of O 0 0.0004112535
the O 0 0.00033356613
medication O 0 0.03692729
, O 0 0.00034475984
which O 0 0.00026133432
can O 0 0.00016328882
be O 0 0.00019061369
overcome O 0 0.00017237882
by O 0 0.00033418683
elevating O 0 0.0066266013
the O 0 0.0005789964
pH O 0 0.024535717
to O 0 0.00089681154
a O 0 0.0016624253
neutral O 0 0.0039723134
level O 0 0.0033916102
. O 0 0.0068885805

The O 0 0.003042875
use O 0 0.0023598257
and O 0 0.0025757265
toxicity B-Disease 2 0.9969157
of O 0 0.016202895
didanosine B-Chemical 1 0.9999913
( O 0 0.18089329
ddI B-Chemical 0 0.9998437
) O 0 0.0052029393
in O 0 0.00069980713
HIV B-Disease 0 0.98521775
antibody I-Disease 0 0.24237832
- I-Disease 0 0.024447877
positive I-Disease 0 0.00090290466
individuals O 0 0.0015079416
intolerant O 0 0.0027544117
to O 0 0.0012271273
zidovudine B-Chemical 1 0.99572045
( O 0 0.046627015
AZT B-Chemical 1 0.99982977
) O 0 0.08699644

One O 0 0.00442259
hundred O 0 0.0026536123
and O 0 0.0020509397
fifty O 0 0.001953598
- O 0 0.0034415836
one O 0 0.0007464002
patients O 0 0.00077160157
intolerant O 0 0.0009721265
to O 0 0.00044979923
zidovudine B-Chemical 1 0.99684566
( O 0 0.0353059
AZT B-Chemical 1 0.99997044
) O 0 0.0074435733
received O 0 0.00044715617
didanosine B-Chemical 1 0.99997425
( O 0 0.040929753
ddI B-Chemical 0 0.99955255
) O 0 0.00088095653
to O 0 0.00017729236
a O 0 0.0002189033
maximum O 0 0.00018269067
dose O 0 0.0005445759
of O 0 0.0003395778
12 O 0 0.00027225688
. O 0 0.00033841096
5 O 0 0.00045731678
mg O 0 0.003988414
/ O 0 0.0022444949
kg O 0 0.0031513327
/ O 0 0.004736322
day O 0 0.0038475355
. O 0 0.006996589

Patient O 0 0.004776809
response O 0 0.0027543248
was O 0 0.0015987069
assessed O 0 0.00092033163
using O 0 0.0007922817
changes O 0 0.0008532306
in O 0 0.00070656446
CD4 O 0 0.6187434
+ O 0 0.011856119
lymphocyte O 0 0.60507876
subset O 0 0.00058705604
count O 0 0.0016957831
, O 0 0.0010194004
HIV O 0 0.99156624
p24 O 0 0.9715016
antigen O 0 0.29543203
, O 0 0.0014844998
weight O 0 0.0027647177
, O 0 0.0011391676
and O 0 0.0011303859
quality O 0 0.001433769
of O 0 0.0027419936
life O 0 0.005311101
. O 0 0.007495511

Seventy O 0 0.005953219
patients O 0 0.0032965937
developed O 0 0.0025280467
major O 0 0.0022231562
opportunistic B-Disease 0 0.5093706
infections I-Disease 2 0.99665403
whilst O 0 0.0071053975
on O 0 0.00048078736
therapy O 0 0.001480573
; O 0 0.00091669185
this O 0 0.00047141628
was O 0 0.0005245404
the O 0 0.0006162993
first O 0 0.0009112244
AIDS B-Disease 2 0.9996619
diagnosis O 0 0.023416946
in O 0 0.0028004025
17 O 0 0.00483545
. O 0 0.0066890507

Only O 0 0.0044518993
minor O 0 0.004097066
changes O 0 0.00224098
in O 0 0.0015737624
CD4 O 0 0.6537576
+ O 0 0.01532619
lymphocyte O 0 0.5938454
subset O 0 0.0006254883
count O 0 0.00079164695
were O 0 0.0002790087
observed O 0 0.00024708794
in O 0 0.00047961692
AIDS B-Disease 2 0.9999436
patients O 0 0.002446043
, O 0 0.00049584307
although O 0 0.00025464952
a O 0 0.00029166357
more O 0 0.0002524475
significant O 0 0.00023769418
rise O 0 0.00032477474
occurred O 0 0.00032517407
in O 0 0.00035415517
those O 0 0.000530253
with O 0 0.00063439715
earlier O 0 0.0009564469
stages O 0 0.0017834988
of O 0 0.0039137825
disease O 0 0.9372842
. O 0 0.008635621

Of O 0 0.0043418747
those O 0 0.0025574856
positive O 0 0.0019707012
for O 0 0.0014978119
p24 O 0 0.7184996
antigen O 0 0.06408344
at O 0 0.0005475182
the O 0 0.00038656688
commencement O 0 0.00035118574
of O 0 0.0003132683
the O 0 0.0002548725
study O 0 0.00032929867
67 O 0 0.0003673364
% O 0 0.00023327128
showed O 0 0.00016370771
a O 0 0.00020581498
positive O 0 0.000273422
response O 0 0.00039226742
, O 0 0.0004153579
and O 0 0.0002715867
this O 0 0.00020217513
was O 0 0.00019568365
most O 0 0.00024722677
likely O 0 0.00017430268
in O 0 0.00017848102
those O 0 0.00027116702
with O 0 0.00037104991
CD4 O 0 0.5566227
+ O 0 0.007813556
lymphocyte O 0 0.43584785
subset O 0 0.0007204187
counts O 0 0.0008425797
above O 0 0.0010309264
100 O 0 0.0024058577
mm3 O 0 0.004763489
. O 0 0.006263649

A O 0 0.025836779
positive O 0 0.004782239
weight O 0 0.005495429
response O 0 0.0035039794
was O 0 0.0025506066
seen O 0 0.0021247044
in O 0 0.00226795
16 O 0 0.0027952816
% O 0 0.0036610465
of O 0 0.0051073553
patients O 0 0.00875014
. O 0 0.010734443

Most O 0 0.0055661416
patients O 0 0.0031822703
showed O 0 0.001785364
improvement O 0 0.0014545406
in O 0 0.0010012987
individual O 0 0.0008010028
parameters O 0 0.0009285759
and O 0 0.0009143685
global O 0 0.0011134
score O 0 0.0009962238
of O 0 0.0014098637
quality O 0 0.0017745493
of O 0 0.0032924362
life O 0 0.0061776424
. O 0 0.008389377

Adverse O 0 0.026924793
reactions O 0 0.010888827
possibly O 0 0.006487492
attributable O 0 0.004528918
to O 0 0.005684651
didanosine B-Chemical 1 0.99956053
were O 0 0.008311635
common O 0 0.010465287
. O 0 0.0129573895

The O 0 0.0034627519
most O 0 0.0030760656
common O 0 0.0027724458
side O 0 0.094782405
- O 0 0.02258139
effect O 0 0.0012140938
was O 0 0.00170624
diarrhoea B-Disease 0 0.99989665
, O 0 0.0022450513
which O 0 0.0007328336
resulted O 0 0.000464973
in O 0 0.00059490936
cessation O 0 0.0034705058
of O 0 0.0010160379
therapy O 0 0.0018474356
in O 0 0.0016150706
19 O 0 0.0031246673
individuals O 0 0.005155175
. O 0 0.0069505945

Peripheral B-Disease 2 0.9727171
neuropathy I-Disease 2 0.9999535
occurred O 0 0.004131285
in O 0 0.0028889875
12 O 0 0.0023846568
patients O 0 0.0032436256
and O 0 0.004640017
pancreatitis B-Disease 0 0.9999713
in O 0 0.0062146694
six O 0 0.006137781
. O 0 0.010268588

Thirteen O 0 0.009460278
patients O 0 0.005105737
developed O 0 0.0042046113
a O 0 0.0035932167
raised O 0 0.004009855
serum O 0 0.37043232
amylase O 0 0.93132025
without O 0 0.006326604
abdominal B-Disease 0 0.5230055
pain I-Disease 0 0.9661171
. O 0 0.011034615

Seven O 0 0.0063853255
patients O 0 0.0036732368
developed O 0 0.0042394474
glucose B-Disease 1 0.99487287
tolerance I-Disease 0 0.07441797
curves I-Disease 0 0.0012142052
characteristic O 0 0.0011821104
of O 0 0.0028505626
diabetes B-Disease 0 0.9999269
but O 0 0.0010461205
these O 0 0.0004320895
were O 0 0.00040371146
mild O 0 0.28012934
, O 0 0.000583229
did O 0 0.00029477692
not O 0 0.00020553613
require O 0 0.0001984145
treatment O 0 0.00032760866
and O 0 0.00039409372
returned O 0 0.00043735153
to O 0 0.0005157664
normal O 0 0.0011113776
on O 0 0.0012417536
ceasing O 0 0.12090852
didanosine B-Chemical 1 0.999683
. O 0 0.008231563

Immunohistochemical O 0 0.007434183
studies O 0 0.002549354
with O 0 0.001866137
antibodies O 0 0.0034553702
to O 0 0.0012001329
neurofilament O 0 0.591021
proteins O 0 0.0014178905
on O 0 0.00070344465
axonal B-Disease 0 0.7948269
damage I-Disease 0 0.98651296
in O 0 0.0010203117
experimental O 0 0.0013324522
focal O 0 0.07991971
lesions O 0 0.5663824
in O 0 0.0031475064
rat O 0 0.008611232
. O 0 0.0074896566

Immunohistochemistry O 0 0.007863797
with O 0 0.002293506
monoclonal O 0 0.0041476637
antibodies O 0 0.0050857016
against O 0 0.001475343
neurofilament O 0 0.98276097
( O 0 0.030837493
NF O 0 0.9925525
) O 0 0.0018209005
proteins O 0 0.00050373055
of O 0 0.0004267207
middle O 0 0.0011867179
and O 0 0.0003177268
high O 0 0.00034471034
molecular O 0 0.0011317584
weight O 0 0.0021060049
class O 0 0.0015850668
, O 0 0.0034239304
NF O 0 0.9977254
- O 0 0.3480608
M O 0 0.99390805
and O 0 0.0047850604
NF O 0 0.9992429
- O 0 0.8303323
H O 1 0.99999785
, O 0 0.0014811904
was O 0 0.00025793805
used O 0 0.0001809696
to O 0 0.00018907146
study O 0 0.00044461552
axonal B-Disease 0 0.6418739
injury I-Disease 0 0.99214584
in O 0 0.00047261294
the O 0 0.00061792665
borderzone O 0 0.9794536
of O 0 0.0009914302
focal O 0 0.08223776
lesions O 0 0.5369255
in O 0 0.0025779034
rats O 0 0.0051319515
. O 0 0.0062308754

Focal O 0 0.216803
injury B-Disease 0 0.7642996
in I-Disease 0 0.00222878
the I-Disease 0 0.001602886
cortex I-Disease 0 0.20939514
was O 0 0.00070259575
produced O 0 0.00046507295
by O 0 0.0005056785
infusion O 0 0.0011072092
of O 0 0.00074285147
lactate B-Chemical 0 0.9021642
at O 0 0.00048266104
acid O 0 0.7041848
pH O 0 0.10538666
or O 0 0.0005750175
by O 0 0.0008037818
stab O 0 0.11697404
caused O 0 0.0011190632
by O 0 0.0018099955
needle O 0 0.003631341
insertion O 0 0.004529161
. O 0 0.0072659

Infarcts B-Disease 0 0.7941546
in I-Disease 0 0.004566736
substantia I-Disease 0 0.97291934
nigra I-Disease 0 0.98944384
pars I-Disease 0 0.6234878
reticulata I-Disease 0 0.9289809
were O 0 0.0013218912
evoked O 0 0.00264215
by O 0 0.0013616722
prolonged O 0 0.020843323
pilocarpine B-Chemical 1 0.99999785
- O 0 0.09043771
induced O 0 0.0035312972
status B-Disease 0 0.084119916
epilepticus I-Disease 0 0.99997354
. O 0 0.010907006

Immunohistochemical O 0 0.009141095
staining O 0 0.0039000805
for O 0 0.0022026761
NFs O 0 0.0043016663
showed O 0 0.0011768271
characteristic O 0 0.0011814007
terminal O 0 0.0016451885
clubs O 0 0.001983942
of O 0 0.0010596667
axons O 0 0.0016354868
in O 0 0.0012039304
the O 0 0.0018829117
borderzone O 0 0.9789594
of O 0 0.004454305
lesions O 0 0.5594745
. O 0 0.008612934

Differences O 0 0.0033426494
in O 0 0.0022312996
the O 0 0.0015375717
labelling O 0 0.001651169
pattern O 0 0.0008508494
occurred O 0 0.0006580401
with O 0 0.0005295227
different O 0 0.00039726746
antibodies O 0 0.0021303634
which O 0 0.00055709126
apparently O 0 0.0008279576
depended O 0 0.00038622465
on O 0 0.00028710306
molecular O 0 0.0011338422
weight O 0 0.0014665895
class O 0 0.0010796443
of O 0 0.0011895495
NFs O 0 0.010298259
and O 0 0.0019911977
phosphorylation O 0 0.013145801
state O 0 0.006143773
. O 0 0.0075224303

These O 0 0.0036594379
immunohistochemical O 0 0.0039558522
changes O 0 0.0021686708
of O 0 0.0016512728
NFs O 0 0.004470733
can O 0 0.0006387295
serve O 0 0.00058880047
as O 0 0.00047215223
a O 0 0.0005326434
marker O 0 0.00058629387
for O 0 0.0005454435
axonal B-Disease 0 0.77890366
damage I-Disease 0 0.98600894
in O 0 0.00062747597
various O 0 0.00080755824
experimental O 0 0.0017979515
traumatic B-Disease 0 0.9996604
or O 0 0.018440869
ischemic O 0 0.9999956
lesions O 0 0.9986395
. O 0 0.010151817

Pharmacokinetic O 0 0.13501516
and O 0 0.0039151697
clinical O 0 0.0036735786
studies O 0 0.0019112226
in O 0 0.0016584218
patients O 0 0.0023562664
with O 0 0.0054146573
cimetidine B-Chemical 1 0.99999857
- O 0 0.18276332
associated O 0 0.005157112
mental O 0 0.46940342
confusion B-Disease 0 0.87056845
. O 0 0.00976323

15 O 0 0.004869677
cases O 0 0.0048713777
of O 0 0.007702947
cimetidine B-Chemical 1 0.9999974
- O 0 0.18740876
associated O 0 0.003763774
mental O 0 0.27465338
confusion B-Disease 0 0.6389455
have O 0 0.0028478438
been O 0 0.0041497266
reported O 0 0.0066599976
. O 0 0.009846504

In O 0 0.0033589446
order O 0 0.0017818807
that O 0 0.0013554054
this O 0 0.0012952792
syndrome O 0 0.14287515
might O 0 0.000488537
be O 0 0.0004237496
investigated O 0 0.00028956504
changes O 0 0.00039943485
in O 0 0.00029130673
mental O 0 0.037415724
status O 0 0.00148552
( O 0 0.0044864784
M O 0 0.9970976
. O 0 0.0011456099
S O 0 0.9959883
. O 0 0.00034323503
) O 0 0.0004977562
were O 0 0.00016547076
correlated O 0 0.00012106163
with O 0 0.0001869782
serum O 0 0.06697418
concentrations O 0 0.0015071428
and O 0 0.00042962964
renal O 0 0.7483223
and O 0 0.00047877323
hepatic O 0 0.6186764
function O 0 0.0002248683
in O 0 0.00018131053
36 O 0 0.00018385555
patients O 0 0.00020464968
, O 0 0.00019255439
30 O 0 0.00012781414
patients O 0 0.00017741157
had O 0 0.00015664204
no O 0 0.0002015792
M O 0 0.9903978
. O 0 0.00073441816
S O 0 0.98840684
. O 0 0.0003067916
change O 0 0.0003290385
on O 0 0.0003011924
cimetidine B-Chemical 1 0.99999535
and O 0 0.00065155624
6 O 0 0.000408204
had O 0 0.00057099556
moderate O 0 0.0023300857
to O 0 0.0013233123
severe O 0 0.06405145
changes O 0 0.005051567
. O 0 0.0066277254

These O 0 0.0035903563
6 O 0 0.0021776585
patients O 0 0.0017711906
had O 0 0.0010795915
both O 0 0.0009915163
renal B-Disease 0 0.8052529
and I-Disease 0 0.004590149
liver I-Disease 0 0.9994024
dysfunction I-Disease 0 0.9997658
( O 0 0.018867824
P O 0 0.20203798
less O 0 0.00027314946
than O 0 0.0001786075
0 O 0 0.0002664817
. O 0 0.0002357181
05 O 0 0.005049368
) O 0 0.00042466208
, O 0 0.00025774233
as O 0 0.00016149465
well O 0 0.00018400128
as O 0 0.00042439214
cimetidine B-Chemical 1 0.9999994
trough O 0 0.8039685
- O 0 0.01762193
concentrations O 0 0.00056980056
of O 0 0.00025638993
more O 0 0.00023267907
than O 0 0.00013323694
1 O 0 0.00016641285
. O 0 0.00016191638
25 O 0 0.00024291789
microgram O 0 0.009419589
/ O 0 0.0020693196
ml O 0 0.0010778183
( O 0 0.00089114753
P O 0 0.017262828
less O 0 0.00058512547
than O 0 0.0006513812
0 O 0 0.0012947231
. O 0 0.0019406471
05 O 0 0.010126817
) O 0 0.0060002757
. O 0 0.007894362

The O 0 0.0035256355
severity O 0 0.005596704
of O 0 0.0039534145
M O 0 0.99432254
. O 0 0.0030060685
S O 0 0.98745686
. O 0 0.0008481906
changes O 0 0.00071544136
increased O 0 0.000530954
as O 0 0.00049482624
trough O 0 0.21767834
- O 0 0.008635757
concentrations O 0 0.0015408208
rose O 0 0.005453013
, O 0 0.0008574336
5 O 0 0.00067551126
patients O 0 0.0011782993
had O 0 0.0016027549
lumbar O 0 0.31361657
puncture O 0 0.007697395
. O 0 0.006749221

The O 0 0.0036149034
cerebrospinal O 0 0.6194944
fluid O 0 0.009093408
: O 0 0.0023808244
serum O 0 0.05426518
ratio O 0 0.001259104
of O 0 0.0044694985
cimetidine B-Chemical 1 0.99999917
concentrations O 0 0.021127509
was O 0 0.0004242587
0 O 0 0.00032402287
. O 0 0.0002084241
24 O 0 0.00020926163
: O 0 0.00026989542
1 O 0 0.0001696778
and O 0 0.00017436217
indicates O 0 0.00015936258
that O 0 0.00025081207
cimetidine B-Chemical 1 0.9999974
passes O 0 0.0014767514
the O 0 0.0003507501
blood O 0 0.07034188
- O 0 0.019187441
brain O 0 0.014055392
barrier O 0 0.006558558
; O 0 0.0006181043
it O 0 0.00018449423
also O 0 0.00013047522
raises O 0 9.202933e-05
the O 0 0.00013084638
possibility O 0 0.00013443989
that O 0 0.00023935003
M O 0 0.9961702
. O 0 0.0010502067
S O 0 0.9939851
. O 0 0.00028084728
changes O 0 0.00028147668
are O 0 0.00016635002
due O 0 0.00013523627
to O 0 0.00017943249
blockade O 0 0.0036723488
of O 0 0.0056651835
histamine B-Chemical 1 0.9999943
H2 O 0 0.9999337
- O 0 0.1498455
receptors O 0 0.004579504
in O 0 0.0007058877
the O 0 0.0009258748
central O 0 0.0019775566
nervous O 0 0.025452536
system O 0 0.004064787
. O 0 0.0064131278

Patients O 0 0.004355772
likely O 0 0.0020122633
to O 0 0.0012479632
have O 0 0.0008698866
both O 0 0.00075715914
raised O 0 0.0010328714
trough O 0 0.31104863
- O 0 0.012580634
concentrations O 0 0.0013134232
and O 0 0.0006382603
mental O 0 0.17457746
confusion B-Disease 0 0.6192278
are O 0 0.00033194316
those O 0 0.00037497003
with O 0 0.0003973076
both O 0 0.0005792718
severe O 0 0.14294955
renal B-Disease 0 0.93297666
and I-Disease 0 0.008113661
hepatic I-Disease 0 0.99940836
dysfunction I-Disease 0 0.9990502
. O 0 0.010208506

They O 0 0.005602184
should O 0 0.0022501966
be O 0 0.002025577
closely O 0 0.0015827985
observed O 0 0.0012407339
and O 0 0.0013166136
should O 0 0.00084482104
be O 0 0.0010801371
given O 0 0.0010203419
reduced O 0 0.0018323035
doses O 0 0.01802631
of O 0 0.023724401
cimetidine B-Chemical 1 0.9999943
. O 0 0.0151619185

Prospective O 0 0.014774077
study O 0 0.0030197117
of O 0 0.0019181016
the O 0 0.0012459833
long O 0 0.0011583422
- O 0 0.0028125767
term O 0 0.0005478512
effects O 0 0.0006750256
of O 0 0.0009982298
somatostatin O 0 0.94366837
analog O 0 0.02158461
( O 0 0.003991046
octreotide B-Chemical 1 0.99842876
) O 0 0.000801742
on O 0 0.00023856238
gallbladder O 0 0.060853247
function O 0 0.0005106024
and O 0 0.0012149788
gallstone B-Disease 0 0.99995506
formation O 0 0.057131935
in O 0 0.0021215111
Chinese O 0 0.49892902
acromegalic B-Disease 0 0.99840635
patients O 0 0.007104523
. O 0 0.0066531966

This O 0 0.0049789427
article O 0 0.0027836263
reports O 0 0.0016084167
the O 0 0.001113795
changes O 0 0.0010170611
in O 0 0.0006658552
gallbladder O 0 0.04545249
function O 0 0.00040938554
examined O 0 0.00023689326
by O 0 0.0003056795
ultrasonography O 0 0.0097473385
in O 0 0.00024948167
20 O 0 0.00025621985
Chinese O 0 0.010285281
patients O 0 0.00029050742
with O 0 0.00026613995
active O 0 0.004043668
acromegaly B-Disease 0 0.99827826
treated O 0 0.00054988003
with O 0 0.00037033396
sc O 0 0.030716058
injection O 0 0.00033385688
of O 0 0.00022060866
the O 0 0.00029535024
somatostatin O 0 0.87581414
analog O 0 0.021241631
octreotide B-Chemical 1 0.9977144
in O 0 0.00021119071
dosages O 0 0.00741128
of O 0 0.0002802206
300 O 0 0.0009949763
- O 0 0.0038963177
1500 O 0 0.00033313362
micrograms O 0 0.0013141275
/ O 0 0.00057140394
day O 0 0.00013655984
for O 0 0.00014113264
a O 0 0.00016723873
mean O 0 0.00011625009
of O 0 0.00023204676
24 O 0 0.00025231467
. O 0 0.0002460754
2 O 0 0.00033686525
+ O 0 0.0009944211
/ O 0 0.003848195
- O 0 0.0043051788
13 O 0 0.00115022
. O 0 0.001290563
9 O 0 0.0020343077
months O 0 0.0028638805
. O 0 0.0063527194

During O 0 0.0029436857
treatment O 0 0.002771067
with O 0 0.0029524432
octreotide B-Chemical 1 0.99910766
, O 0 0.0026900251
17 O 0 0.0010987028
patients O 0 0.0008217777
developed O 0 0.000885472
sludge O 0 0.08379234
, O 0 0.0006948615
10 O 0 0.00040956042
had O 0 0.00052089
gallstones B-Disease 0 0.9999137
, O 0 0.001225411
and O 0 0.00075424137
1 O 0 0.00075078814
developed O 0 0.0025040396
acute B-Disease 0 0.9989629
cholecystitis I-Disease 0 0.9999987
requiring O 0 0.012778157
surgery O 0 0.009758308
. O 0 0.0069359643

In O 0 0.0037335132
all O 0 0.0021977182
of O 0 0.0018342303
7 O 0 0.001186784
patients O 0 0.0010243302
examined O 0 0.0006081393
acutely O 0 0.0056744344
, O 0 0.0012311812
gallbladder O 0 0.55288166
contractility O 0 0.9046695
was O 0 0.0005969407
inhibited O 0 0.00050428184
after O 0 0.00035207762
a O 0 0.00063957373
single O 0 0.0007683179
100 O 0 0.0017357077
- O 0 0.0067113196
micrograms O 0 0.022997878
injection O 0 0.0056803296
. O 0 0.0067272824

In O 0 0.0042859036
8 O 0 0.0028163695
patients O 0 0.0020787013
followed O 0 0.0013117096
for O 0 0.0012238619
24 O 0 0.0010976462
weeks O 0 0.00079500047
, O 0 0.0014069189
gallbladder O 0 0.23424795
contractility O 0 0.88602805
remained O 0 0.007583655
depressed B-Disease 2 0.8809813
throughout O 0 0.0024800224
therapy O 0 0.0061067734
. O 0 0.007538577

After O 0 0.0030725172
withdrawal O 0 0.07822096
of O 0 0.0033355083
octreotide B-Chemical 1 0.99775237
in O 0 0.0011513416
10 O 0 0.0006880721
patients O 0 0.00071387994
without O 0 0.00070202386
gallstones B-Disease 0 0.9999646
, O 0 0.0012710346
8 O 0 0.00031915065
patients O 0 0.00030761695
assessed O 0 0.00022030808
had O 0 0.00027233682
return O 0 0.00036123808
of O 0 0.00047107114
normal O 0 0.0010624719
gallbladder O 0 0.38041806
contractility O 0 0.6264284
within O 0 0.0010387044
1 O 0 0.0018257258
month O 0 0.0026441752
. O 0 0.005726537

In O 0 0.003748744
8 O 0 0.0023385198
of O 0 0.0016870099
the O 0 0.001118702
remaining O 0 0.000895928
10 O 0 0.0006870983
patients O 0 0.0007067803
who O 0 0.0007405702
developed O 0 0.0013163339
gallstones B-Disease 0 0.9999263
during O 0 0.00029695197
treatment O 0 0.0005774248
, O 0 0.0006228598
gallbladder O 0 0.34589583
contractility O 0 0.5767159
normalized O 0 0.00013050993
in O 0 0.0001709158
5 O 0 0.00013701661
patients O 0 0.00021181931
( O 0 0.0002377513
3 O 0 0.00013176928
of O 0 0.00016961941
whom O 0 0.00034371755
has O 0 0.0001502314
disappearance O 0 0.00064637786
of O 0 0.00023622926
their O 0 0.00024159256
stones O 0 0.25582084
within O 0 0.00012498138
3 O 0 0.00013346453
weeks O 0 0.00010875112
) O 0 0.00028864417
, O 0 0.00025096367
and O 0 0.00024118011
remained O 0 0.0006152499
depressed B-Disease 2 0.794698
in O 0 0.00021996217
3 O 0 0.00019428131
( O 0 0.00029056336
2 O 0 0.00021974731
of O 0 0.00028139027
whom O 0 0.00054710737
had O 0 0.0004056339
stones O 0 0.1162202
present O 0 0.0005096426
at O 0 0.00071846653
6 O 0 0.0010037057
months O 0 0.0016016542
) O 0 0.004425385
. O 0 0.006725948

Our O 0 0.0035877728
results O 0 0.0019669703
suggest O 0 0.0011309555
that O 0 0.0009746021
the O 0 0.00086162897
suppression O 0 0.0010827009
of O 0 0.0012214663
gallbladder O 0 0.83982265
contractility O 0 0.96742916
is O 0 0.00061776565
the O 0 0.00029116456
cause O 0 0.00031895598
of O 0 0.00028033523
the O 0 0.00019816228
successive O 0 0.00019601475
formation O 0 0.0011479203
of O 0 0.0007324618
bile O 0 0.97332066
sludge O 0 0.8713572
, O 0 0.013315734
gallstones B-Disease 0 0.99998915
, O 0 0.002968072
and O 0 0.0015925855
cholecystitis B-Disease 0 0.99998975
during O 0 0.0008246887
octreotide B-Chemical 1 0.9988625
therapy O 0 0.0032488282
in O 0 0.0014921152
Chinese O 0 0.40144616
acromegalic B-Disease 0 0.99833953
patients O 0 0.007087379
. O 0 0.006547993

It O 0 0.0048462283
is O 0 0.00265757
therefore O 0 0.0018312548
very O 0 0.001437151
important O 0 0.0007281995
to O 0 0.0005583067
follow O 0 0.00039497606
the O 0 0.00039649566
changes O 0 0.00044595916
of O 0 0.0004560063
gallbladder O 0 0.09899334
function O 0 0.00037434552
during O 0 0.00026800178
long O 0 0.0004525783
- O 0 0.0030857802
term O 0 0.00078932836
octreotide B-Chemical 1 0.9970822
therapy O 0 0.003880976
of O 0 0.003927628
acromegalic B-Disease 0 0.9991641
patients O 0 0.009114223
. O 0 0.006829509

Increase O 0 0.016350616
of O 0 0.01707756
Parkinson B-Disease 0 0.99993455
disability I-Disease 0 0.9951131
after O 0 0.010475509
fluoxetine B-Chemical 1 0.99998784
medication O 0 0.57479024
. O 0 0.01626728

Depression B-Disease 2 0.9827755
is O 0 0.004620897
a O 0 0.0037190488
major O 0 0.0030906524
clinical O 0 0.004000356
feature O 0 0.00311346
of O 0 0.0048781824
Parkinson B-Disease 0 0.9993181
' I-Disease 0 0.006361663
s I-Disease 0 0.0070686797
disease I-Disease 0 0.7722013
. O 0 0.012203068

We O 0 0.0036677907
report O 0 0.0031002525
the O 0 0.0015451867
increased O 0 0.001179547
amount O 0 0.0006606285
of O 0 0.0013419553
motor B-Disease 2 0.8960685
disability I-Disease 2 0.97685254
in O 0 0.00040186418
four O 0 0.00023284818
patients O 0 0.00036553288
with O 0 0.00047394962
idiopathic B-Disease 0 0.9939452
Parkinson I-Disease 0 0.9998852
' I-Disease 0 0.00091887324
s I-Disease 0 0.0006429719
disease I-Disease 0 0.33373222
after O 0 0.00033740702
exposure O 0 0.0015655498
to O 0 0.0008379191
the O 0 0.0028549156
antidepressant B-Chemical 1 0.99998534
fluoxetine B-Chemical 0 0.9999925
. O 0 0.0076737464

The O 0 0.0029327925
possibility O 0 0.0018548401
of O 0 0.001788815
a O 0 0.0017226621
clinically O 0 0.02200958
relevant O 0 0.0018028684
dopamine B-Chemical 1 0.99993885
- O 0 0.02648011
antagonistic O 0 0.0010677502
capacity O 0 0.0007772693
of O 0 0.005475965
fluoxetine B-Chemical 1 0.9999993
in O 0 0.0014998306
Parkinson B-Disease 0 0.99962807
' I-Disease 0 0.0010040125
s I-Disease 0 0.00094626803
disease I-Disease 0 0.33284888
patients O 0 0.0012942521
must O 0 0.0010428757
be O 0 0.002052127
considered O 0 0.0032899666
. O 0 0.0067223934

Sinus B-Disease 0 0.51636606
arrest I-Disease 0 0.54171205
associated O 0 0.005956098
with O 0 0.005220527
continuous O 0 0.0058026146
- O 0 0.045213655
infusion O 0 0.2405461
cimetidine B-Chemical 1 0.9999819
. O 0 0.019727407

The O 0 0.003331298
administration O 0 0.0048843483
of O 0 0.0021980363
intermittent O 0 0.021024102
intravenous O 0 0.1458421
infusions O 0 0.018512813
of O 0 0.004469059
cimetidine B-Chemical 1 0.99999917
is O 0 0.001380797
infrequently O 0 0.001532053
associated O 0 0.0006584429
with O 0 0.0007751111
the O 0 0.0010290273
development O 0 0.0030703244
of O 0 0.0069336165
bradyarrhythmias B-Disease 0 0.9995888
. O 0 0.008077417

A O 0 0.052634787
40 O 0 0.0037691665
- O 0 0.0059758862
year O 0 0.001955265
- O 0 0.0040115216
old O 0 0.0011685052
man O 0 0.039555606
with O 0 0.0018258387
leukemia B-Disease 0 0.9999728
and O 0 0.0011062087
no O 0 0.00030134345
history O 0 0.0037254198
of O 0 0.00073900254
cardiac B-Disease 0 0.34679896
disease I-Disease 0 0.94207585
developed O 0 0.0022645602
recurrent O 0 0.11415276
, O 0 0.00036421226
brief O 0 0.0001753574
episodes O 0 0.0015211985
of O 0 0.00025349957
apparent O 0 0.0004331506
sinus B-Disease 0 0.7794297
arrest I-Disease 0 0.8869893
while O 0 0.00032998342
receiving O 0 0.000347846
continuous O 0 0.00030027895
- O 0 0.015567875
infusion O 0 0.027376024
cimetidine B-Chemical 1 0.99999654
50 O 0 0.0020731338
mg O 0 0.05223503
/ O 0 0.0044160695
hour O 0 0.0031251903
. O 0 0.0060642287

The O 0 0.0045726444
arrhythmias B-Disease 2 0.9990938
were O 0 0.0019522859
temporally O 0 0.0019312726
related O 0 0.00070421165
to O 0 0.0009980539
cimetidine B-Chemical 1 0.99999857
administration O 0 0.120917864
, O 0 0.0010097466
disappeared O 0 0.0006512806
after O 0 0.00035710403
dechallenge O 0 0.992916
, O 0 0.0007470986
and O 0 0.0005939764
did O 0 0.0006270479
not O 0 0.00069754524
recur O 0 0.0076235514
during O 0 0.0016486023
ranitidine B-Chemical 1 0.999977
treatment O 0 0.007346049
. O 0 0.0072518117

This O 0 0.0054375753
is O 0 0.0026952315
the O 0 0.001728973
first O 0 0.0011693632
reported O 0 0.0011765519
case O 0 0.0009866769
of O 0 0.0012817075
sinus B-Disease 0 0.70982164
arrest I-Disease 0 0.8630657
associated O 0 0.0010707644
with O 0 0.0010580835
continuous O 0 0.0013873165
- O 0 0.032512985
infusion O 0 0.112199344
cimetidine B-Chemical 1 0.9999856
. O 0 0.01027468

Phase O 0 0.010633707
II O 0 0.011023117
trial O 0 0.0041462397
of O 0 0.004182701
vinorelbine B-Chemical 0 0.9964772
in O 0 0.004325947
metastatic O 0 0.96260947
squamous B-Disease 0 0.9998253
cell I-Disease 0 0.6228776
esophageal I-Disease 0 0.99972457
carcinoma I-Disease 2 0.99998903
. O 0 0.028287511

European O 0 0.008669704
Organization O 0 0.0051932074
for O 0 0.0035216776
Research O 0 0.007280591
and O 0 0.002894366
Treatment O 0 0.005505769
of O 0 0.0040754117
Cancer B-Disease 0 0.9730748
Gastrointestinal O 0 0.38274345
Treat O 0 0.7849163
Cancer B-Disease 0 0.9296628
Cooperative O 0 0.11377378
Group O 0 0.021914724
. O 0 0.010629935

PURPOSE O 0 0.00489017
: O 0 0.0029534032
To O 0 0.0012317747
evaluate O 0 0.0006680404
the O 0 0.00070253987
response O 0 0.00072159705
rate O 0 0.0006349536
and O 0 0.00077692984
toxic O 0 0.5612758
effects O 0 0.0009273751
of O 0 0.0024638495
vinorelbine B-Chemical 0 0.99986064
( O 0 0.041899785
VNB B-Chemical 0 0.99860615
) O 0 0.00068698503
administered O 0 0.000244727
as O 0 0.00023054321
a O 0 0.00033830418
single O 0 0.00037504456
agent O 0 0.006328832
in O 0 0.0008567157
metastatic O 0 0.9451101
squamous B-Disease 0 0.9999037
cell I-Disease 0 0.5633865
esophageal I-Disease 0 0.9997917
carcinoma I-Disease 2 0.9999933
. O 0 0.023767827

PATIENTS O 0 0.005589718
AND O 0 0.0032114156
METHODS O 0 0.0022251538
: O 0 0.0025607357
Forty O 0 0.002628042
- O 0 0.002605204
six O 0 0.0007977529
eligible O 0 0.0007882715
patients O 0 0.0007204026
with O 0 0.00056662236
measurable O 0 0.0007991224
lesions O 0 0.09357388
were O 0 0.0004465713
included O 0 0.00037362872
and O 0 0.00047849288
were O 0 0.00052785315
stratified O 0 0.0007160204
according O 0 0.0007429966
to O 0 0.0011874925
previous O 0 0.0023406858
chemotherapy O 0 0.048062276
. O 0 0.0067734616

Thirty O 0 0.0056331404
patients O 0 0.0027730903
without O 0 0.0015053964
prior O 0 0.00096385775
chemotherapy O 0 0.013814918
and O 0 0.00087200856
16 O 0 0.0006505815
pretreated O 0 0.0017247078
with O 0 0.0012154751
cisplatin B-Chemical 1 0.99986744
- O 0 0.027473371
based O 0 0.0005652218
chemotherapy O 0 0.00879391
were O 0 0.0005542516
assessable O 0 0.0017333876
for O 0 0.0011210633
toxicity B-Disease 2 0.989005
and O 0 0.0030794337
response O 0 0.005419474
. O 0 0.0074523827

VNB B-Chemical 0 0.9730195
was O 0 0.003014396
administered O 0 0.001730483
weekly O 0 0.0011963715
as O 0 0.00087021355
a O 0 0.00092259323
25 O 0 0.0009437456
- O 0 0.0041939914
mg O 0 0.026378911
/ O 0 0.0019197516
m2 O 0 0.004379084
short O 0 0.00044552897
intravenous O 0 0.0137680145
( O 0 0.000882764
i O 0 0.0019230766
. O 0 0.0009339774
v O 0 0.008419935
. O 0 0.0019591292
) O 0 0.0045069074
infusion O 0 0.008063898
. O 0 0.007497008

RESULTS O 0 0.0057671596
: O 0 0.0037016019
Six O 0 0.0022085297
of O 0 0.0015033401
30 O 0 0.0010179407
patients O 0 0.0010333792
( O 0 0.00092366367
20 O 0 0.0005428145
% O 0 0.0005593331
) O 0 0.00056606776
without O 0 0.00028351173
prior O 0 0.00021487522
chemotherapy O 0 0.002645814
achieved O 0 0.0002487824
a O 0 0.00027316975
partial O 0 0.0003471624
response O 0 0.0005924942
( O 0 0.0037698704
PR O 0 0.9705129
) O 0 0.0013065034
( O 0 0.00043660816
95 O 0 0.00044911975
% O 0 0.0002777766
confidence O 0 0.0006176947
interval O 0 0.0003389723
[ O 0 0.0023693733
CI O 0 0.5340718
] O 0 0.001152099
, O 0 0.00069383415
8 O 0 0.0006006056
% O 0 0.0008985171
to O 0 0.0010556516
39 O 0 0.0022541357
% O 0 0.0032868045
) O 0 0.00616389
. O 0 0.00832123

The O 0 0.0030345533
median O 0 0.0017918275
duration O 0 0.0014372543
of O 0 0.001446073
response O 0 0.0014258327
was O 0 0.0010272666
21 O 0 0.0008850582
weeks O 0 0.0005941463
( O 0 0.0010059649
range O 0 0.0010333336
, O 0 0.0015353705
17 O 0 0.0017651014
to O 0 0.0019022957
28 O 0 0.0035036432
) O 0 0.006384224
. O 0 0.00879381

One O 0 0.004400616
of O 0 0.002753877
16 O 0 0.0020411208
patients O 0 0.0016446688
( O 0 0.0013784898
6 O 0 0.0006533212
% O 0 0.00072878203
) O 0 0.00072205113
with O 0 0.00039337695
prior O 0 0.0002702585
chemotherapy O 0 0.0042097513
had O 0 0.00024220975
a O 0 0.00026118857
complete O 0 0.00018686877
response O 0 0.00039628096
( O 0 0.0010156865
CR O 0 0.2509791
) O 0 0.0005225047
of O 0 0.00026167484
31 O 0 0.00026951308
weeks O 0 0.00014526835
' O 0 0.00026457035
duration O 0 0.00019656443
( O 0 0.0004081731
95 O 0 0.0006888024
% O 0 0.00059706724
CI O 0 0.21458606
, O 0 0.0006629434
0 O 0 0.0006276913
% O 0 0.00083150517
to O 0 0.0009146686
30 O 0 0.0014286214
% O 0 0.0029079707
) O 0 0.0056710583
. O 0 0.007907804

The O 0 0.0030425915
overall O 0 0.0021871116
response O 0 0.0018368283
rate O 0 0.0014489361
( O 0 0.0015925575
World O 0 0.0022452222
Health O 0 0.001088476
Organization O 0 0.0011463402
[ O 0 0.0030841273
WHO O 0 0.0048085316
] O 0 0.0007890314
criteria O 0 0.00038021547
) O 0 0.0005280824
was O 0 0.00025579907
15 O 0 0.00021129182
% O 0 0.0003043909
( O 0 0.00047482416
CR O 0 0.06563723
, O 0 0.0004122059
2 O 0 0.0002547758
% O 0 0.00035398838
; O 0 0.000717041
PR O 0 0.5762142
13 O 0 0.0003566745
% O 0 0.0003727414
; O 0 0.00048826582
95 O 0 0.0006403038
% O 0 0.00062025944
CI O 0 0.12596966
, O 0 0.00071332307
6 O 0 0.0005561069
% O 0 0.0009379596
to O 0 0.0011172196
29 O 0 0.0024292066
% O 0 0.0034052571
) O 0 0.0063453037
. O 0 0.008525302

The O 0 0.0030930971
median O 0 0.0020423683
dose O 0 0.0054395897
- O 0 0.0071501783
intensity O 0 0.0014498595
( O 0 0.0029804741
DI O 0 0.89515245
) O 0 0.0020880764
was O 0 0.0010323058
20 O 0 0.001075881
mg O 0 0.010734635
/ O 0 0.0037616058
m2 O 0 0.016705768
/ O 0 0.0066879587
wk O 0 0.004748581
. O 0 0.008884979

VNB B-Chemical 0 0.975416
was O 0 0.003635401
well O 0 0.0022778779
tolerated O 0 0.0036264274
and O 0 0.0012800223
zero O 0 0.00085319165
instances O 0 0.0007497518
of O 0 0.0012695367
WHO O 0 0.0131299365
grade O 0 0.14674222
4 O 0 0.0023133447
nonhematologic O 0 0.9992663
toxicity B-Disease 2 0.9973815
occurred O 0 0.0071031917
. O 0 0.008737721

At O 0 0.0028713194
least O 0 0.0019148744
one O 0 0.0014820242
episode O 0 0.0017795839
of O 0 0.001281737
grade O 0 0.03914567
3 O 0 0.00067561714
or O 0 0.00063600234
4 O 0 0.0007611815
granulocytopenia B-Disease 0 0.99962044
was O 0 0.0007197761
seen O 0 0.0006922074
in O 0 0.0008965727
59 O 0 0.001635012
% O 0 0.001982044
of O 0 0.0030455363
patients O 0 0.005976493
. O 0 0.0076112696

A O 0 0.07529471
grade O 0 0.035476383
2 O 0 0.0024103092
or O 0 0.0016029801
3 O 0 0.001286388
infection B-Disease 2 0.2807789
occurred O 0 0.0009416327
in O 0 0.000697907
16 O 0 0.0006622434
% O 0 0.0006464512
of O 0 0.00067729584
patients O 0 0.0010453828
, O 0 0.0010945424
but O 0 0.0011972443
no O 0 0.0013023217
toxic O 0 0.7676713
deaths B-Disease 0 0.91149443
occurred O 0 0.0075139403
. O 0 0.008622714

Other O 0 0.007978391
side O 0 0.012807376
effects O 0 0.0026744097
were O 0 0.0015850978
rare O 0 0.0033486085
, O 0 0.001530187
and O 0 0.0016774293
peripheral B-Disease 0 0.9149294
neurotoxicity I-Disease 2 0.99999833
has O 0 0.00077389175
been O 0 0.0006395293
minor O 0 0.0014769074
( O 0 0.0011726655
26 O 0 0.0012219622
% O 0 0.0016499462
grade O 0 0.014051545
1 O 0 0.0028915955
) O 0 0.0058815284
. O 0 0.008035024

CONCLUSION O 0 0.017966175
: O 0 0.0039970744
These O 0 0.0021154347
data O 0 0.0016146608
indicate O 0 0.00093825103
that O 0 0.0012156698
VNB B-Chemical 0 0.98956513
is O 0 0.0010354833
an O 0 0.0009962186
active O 0 0.0016213205
agent O 0 0.02701954
in O 0 0.0014099308
metastatic O 0 0.92473
esophageal B-Disease 0 0.9853349
squamous I-Disease 0 0.99997413
cell I-Disease 0 0.74134904
carcinoma I-Disease 2 0.99997926
. O 0 0.020120429

Given O 0 0.0031515798
its O 0 0.003374944
excellent O 0 0.0029213224
tolerance O 0 0.017414387
profile O 0 0.0012000506
and O 0 0.0011083985
low O 0 0.0024654707
toxicity B-Disease 2 0.99822575
, O 0 0.0009848109
further O 0 0.0004448756
evaluation O 0 0.00052273675
of O 0 0.0012285882
VNB B-Chemical 0 0.99070716
in O 0 0.0008021952
combination O 0 0.0013696587
therapy O 0 0.0023728046
is O 0 0.0023985463
warranted O 0 0.0035284362
. O 0 0.006573989

Evaluation O 0 0.007525306
of O 0 0.006089556
adverse O 0 0.21111517
reactions O 0 0.016213525
of O 0 0.006714652
aponidine B-Chemical 0 0.93345374
hydrochloride I-Chemical 0 0.9998903
ophthalmic O 0 0.86920834
solution O 0 0.08606412
. O 0 0.012381185

We O 0 0.0033495731
prospectively O 0 0.0022595827
evaluated O 0 0.0013667998
the O 0 0.0012338662
adverse O 0 0.14958605
reactions O 0 0.015347012
of O 0 0.0033854335
apraclonidine B-Chemical 0 0.9999981
in O 0 0.00055621855
20 O 0 0.0003029272
normal O 0 0.00031240252
volunteers O 0 0.00035284538
by O 0 0.00025144604
instilling O 0 0.0014377532
a O 0 0.00030892508
single O 0 0.00028094987
drop O 0 0.0005467828
of O 0 0.0004474472
1 O 0 0.0005016365
% O 0 0.0011972317
apraclonidine B-Chemical 0 0.99997556
in O 0 0.0011881618
their O 0 0.0018162109
right O 0 0.0050159334
eyes O 0 0.33819836
. O 0 0.007375503

Examinations O 0 0.007591932
, O 0 0.003630898
including O 0 0.001976502
blood O 0 0.012295446
pressure O 0 0.06531485
, O 0 0.001162143
pulse O 0 0.0012368632
rate O 0 0.00062901835
, O 0 0.00095254293
conjunctiva O 0 0.7255696
and O 0 0.0008019854
cornea O 0 0.7805186
, O 0 0.0026509645
intraocular O 0 0.99648213
pressure O 0 0.45379564
( O 0 0.0050315284
IOP O 0 0.9996954
) O 0 0.0008788832
, O 0 0.0003091729
pupil O 0 0.00696515
diameter O 0 0.0036627552
, O 0 0.00038671837
basal O 0 0.0007654761
tear O 0 0.38860017
secretion O 0 0.0010450542
and O 0 0.00032411865
margin O 0 0.021316478
reflex O 0 0.08003111
distance O 0 0.0001713732
of O 0 0.00020607596
both O 0 0.00017845482
upper O 0 0.0002839659
and O 0 0.0002490489
lower O 0 0.0002567461
eyelids O 0 0.38741755
, O 0 0.00028559173
were O 0 0.00014396085
performed O 0 0.00011457096
prior O 0 0.00010672939
to O 0 0.00013506925
entry O 0 0.00029967603
and O 0 0.00021833529
at O 0 0.00018756709
1 O 0 0.00023029278
, O 0 0.00031069756
3 O 0 0.00025861475
, O 0 0.00038364856
5 O 0 0.00035013905
and O 0 0.0005409652
7 O 0 0.0006849284
hours O 0 0.0009655691
after O 0 0.001607955
instillation O 0 0.011226592
. O 0 0.0070987404

The O 0 0.0045710774
ocular B-Disease 0 0.99686414
hypotensive I-Disease 0 0.9999449
effects O 0 0.0032236977
were O 0 0.0007601084
statistically O 0 0.00047972368
significant O 0 0.00047895536
for O 0 0.0011439709
apraclonidine B-Chemical 0 0.9999995
- O 0 0.18005809
treated O 0 0.00084321183
eyes O 0 0.27885956
throughout O 0 0.00014693901
the O 0 0.00016231473
study O 0 0.00020845293
and O 0 0.00017710749
also O 0 0.00015009809
statistically O 0 0.00014752781
significant O 0 0.00016753493
for O 0 0.00020105092
contralateral O 0 0.0059956163
eyes O 0 0.11823958
from O 0 0.00016586424
three O 0 0.0001356294
hours O 0 0.00018824256
after O 0 0.00023403046
topical O 0 0.4631841
administration O 0 0.0045266505
of O 0 0.0011866671
1 O 0 0.0015762113
% O 0 0.0048860083
apraclonidine B-Chemical 0 0.9999628
. O 0 0.0084879035

Decreases B-Disease 0 0.008399149
in I-Disease 0 0.0039972607
systolic I-Disease 0 0.49712834
blood I-Disease 0 0.024274543
pressure I-Disease 0 0.039158195
were O 0 0.0015115177
statistically O 0 0.0012847853
, O 0 0.0017437373
but O 0 0.001774931
not O 0 0.0019204288
clinically O 0 0.010600743
, O 0 0.004618972
significant O 0 0.0056467787
. O 0 0.009554903

No O 0 0.0060562617
significant O 0 0.0031115352
changes O 0 0.0025268672
in O 0 0.0018509094
diastolic O 0 0.9202697
blood O 0 0.051096685
pressure O 0 0.06269819
, O 0 0.0009972217
pulse O 0 0.0010665344
rate O 0 0.0007646516
and O 0 0.000972153
basal O 0 0.002152864
tear O 0 0.42655116
secretion O 0 0.004484483
were O 0 0.0028972598
noted O 0 0.0038399107
. O 0 0.0073916973

Conjunctival B-Disease 0 0.99118793
blanching I-Disease 0 0.9976299
and O 0 0.018351711
mydriasis B-Disease 0 0.9999174
were O 0 0.009024662
commonly O 0 0.010139668
found O 0 0.010067875
. O 0 0.015942207

Upper O 0 0.038154762
lid O 0 0.05434511
retraction O 0 0.060894467
was O 0 0.014834332
frequently O 0 0.015996074
noted O 0 0.01613116
. O 0 0.024141546

While O 0 0.0035145963
the O 0 0.002323599
elevations O 0 0.012676147
of O 0 0.0013167509
the O 0 0.0008436494
upper O 0 0.0010809582
lid O 0 0.05891404
margin O 0 0.012696345
in O 0 0.00038738604
most O 0 0.0004019818
subjects O 0 0.0003350063
were O 0 0.00020122355
not O 0 0.00016535088
more O 0 0.00019162177
than O 0 0.00012618654
2 O 0 0.00014862916
mm O 0 0.0003369125
and O 0 0.00022283853
did O 0 0.00020304095
not O 0 0.00015233863
cause O 0 0.00026345425
noticeable O 0 0.0009044234
change O 0 0.00028050365
in O 0 0.00020243975
appearance O 0 0.0010343593
, O 0 0.00033476079
one O 0 0.0001505888
subject O 0 0.0001383947
suffered O 0 0.0006844195
from O 0 0.00016938797
mechanical O 0 0.0018031131
entropion B-Disease 0 0.9998449
and O 0 0.00073749706
marked O 0 0.0066630016
corneal B-Disease 0 0.9997229
abrasion I-Disease 0 0.9983469
3 O 0 0.000376525
hours O 0 0.00032467284
after O 0 0.00039518153
instillation O 0 0.0021488585
of O 0 0.0015336141
the O 0 0.0023793867
medication O 0 0.0734852
. O 0 0.0060424623

This O 0 0.006978203
may O 0 0.0036422384
well O 0 0.0028167162
be O 0 0.0026502688
a O 0 0.0027699722
particularly O 0 0.003124685
notable O 0 0.004898604
finding O 0 0.0041722828
in O 0 0.004347543
Asian O 0 0.37904727
people O 0 0.013003153
. O 0 0.011222231

Thiopentone B-Chemical 0 0.99951684
pretreatment O 0 0.23688155
for O 0 0.006459409
propofol B-Chemical 1 0.9997315
injection O 0 0.03806286
pain B-Disease 0 0.9336501
in O 0 0.0041384147
ambulatory O 0 0.0062102466
patients O 0 0.0077464716
. O 0 0.010204247

This O 0 0.0062384885
study O 0 0.0040935543
investigated O 0 0.0031447918
propofol B-Chemical 1 0.9994104
injection O 0 0.022075724
pain B-Disease 0 0.9242281
in O 0 0.0020146584
patients O 0 0.0026788954
undergoing O 0 0.002981608
ambulatory O 0 0.0051250514
anaesthesia O 0 0.014355485
. O 0 0.008469203

In O 0 0.0040575126
a O 0 0.003057929
randomized O 0 0.0021591552
, O 0 0.0019210872
double O 0 0.0015555145
- O 0 0.009875239
blind O 0 0.014678447
trial O 0 0.0008994443
, O 0 0.00066036655
90 O 0 0.0004178599
women O 0 0.00081771886
were O 0 0.0002786663
allocated O 0 0.00020188057
to O 0 0.00019009315
receive O 0 0.0001717298
one O 0 0.00018963801
of O 0 0.0002347371
three O 0 0.0001710242
treatments O 0 0.0002844762
prior O 0 0.00023340943
to O 0 0.00034094675
induction O 0 0.000567253
of O 0 0.0013411198
anaesthesia O 0 0.09263057
with O 0 0.00428233
propofol B-Chemical 1 0.9992766
. O 0 0.0072352085

Patients O 0 0.005206462
in O 0 0.003279103
Group O 0 0.050320767
C O 0 0.9778882
received O 0 0.0010453888
2 O 0 0.00075401715
ml O 0 0.00088343554
normal O 0 0.00077149575
saline O 0 0.009430889
, O 0 0.0008585537
Group O 0 0.07071251
L O 0 0.91830724
, O 0 0.00061572384
2 O 0 0.000263003
ml O 0 0.00057303737
, O 0 0.000913223
lidocaine B-Chemical 0 0.99970764
2 O 0 0.0002406665
% O 0 0.00025798994
( O 0 0.00027708412
40 O 0 0.00020232669
mg O 0 0.003428602
) O 0 0.0004087519
and O 0 0.00037535
Group O 0 0.06956109
T O 0 0.8987165
, O 0 0.0006328747
2 O 0 0.0003188489
ml O 0 0.0019080334
thiopentone B-Chemical 0 0.99998045
2 O 0 0.0003974231
. O 0 0.0003734642
5 O 0 0.00044540857
% O 0 0.0008221947
( O 0 0.0013668037
50 O 0 0.0019397351
mg O 0 0.01884577
) O 0 0.0057073142
. O 0 0.007489352

Venous O 0 0.025262766
discomfort O 0 0.0155556705
was O 0 0.0016723617
assessed O 0 0.00093374075
with O 0 0.0008463878
a O 0 0.0008885047
visual O 0 0.028085018
analogue O 0 0.00253977
scale O 0 0.00055998046
( O 0 0.00079080404
VAS O 0 0.022179108
) O 0 0.00047372354
5 O 0 0.00022783138
- O 0 0.00056323095
15 O 0 0.00015537327
sec O 0 0.00017862521
after O 0 0.00013408819
commencing O 0 0.0004973121
propofol B-Chemical 1 0.9971424
administration O 0 0.0015150979
using O 0 0.0001644167
an O 0 0.00023860107
infusion O 0 0.00080507377
pump O 0 0.0019053719
( O 0 0.00031887266
rate O 0 0.00024239732
1000 O 0 0.0003938742
micrograms O 0 0.0018412926
. O 0 0.0002835136
kg O 0 0.00094606006
- O 0 0.0019823867
1 O 0 0.00052930816
. O 0 0.0006547718
min O 0 0.0013262205
- O 0 0.0035392258
1 O 0 0.0026150479
) O 0 0.0054292344
. O 0 0.0076528452

Loss B-Disease 0 0.013821012
of I-Disease 0 0.007512032
consciousness I-Disease 0 0.744311
occurred O 0 0.0047762333
in O 0 0.004336531
60 O 0 0.0049475604
- O 0 0.008391354
90 O 0 0.0064131944
sec O 0 0.009394295
. O 0 0.014233936

Visual O 0 0.3372321
analogue O 0 0.006532583
scores O 0 0.0017840754
( O 0 0.001507956
mean O 0 0.0007221933
+ O 0 0.0028517137
/ O 0 0.019059926
- O 0 0.031344417
SD O 0 0.08157352
) O 0 0.00064614596
during O 0 0.00022828282
induction O 0 0.0002588382
were O 0 0.00023997588
lower O 0 0.00021612718
in O 0 0.0002527064
Groups O 0 0.062120385
L O 0 0.94023097
( O 0 0.0006834043
3 O 0 0.00018846417
. O 0 0.0001707537
3 O 0 0.00017499778
+ O 0 0.0006553546
/ O 0 0.0061466936
- O 0 0.00793656
2 O 0 0.00020521614
. O 0 0.00016351427
5 O 0 0.00015682555
) O 0 0.00031190465
and O 0 0.00035627876
T O 0 0.88185996
( O 0 0.0006536722
4 O 0 0.00019017364
. O 0 0.000177407
1 O 0 0.00020680958
+ O 0 0.0008312604
/ O 0 0.008730346
- O 0 0.010646371
2 O 0 0.00021638842
. O 0 0.00017073206
7 O 0 0.00015885857
) O 0 0.00025616513
than O 0 0.00014091788
in O 0 0.00023195475
Group O 0 0.07577815
C O 0 0.998505
( O 0 0.0008276378
5 O 0 0.00019289105
. O 0 0.00018395692
6 O 0 0.0001819319
+ O 0 0.0006324285
/ O 0 0.0042857956
- O 0 0.0059561934
2 O 0 0.00032968467
. O 0 0.0003268923
3 O 0 0.0003920182
) O 0 0.0008407498
; O 0 0.0013435481
P O 0 0.023602018
= O 0 0.002305833
0 O 0 0.00228748
. O 0 0.0032098636
0031 O 0 0.017521454
. O 0 0.0083414875

The O 0 0.0033787827
incidence O 0 0.004154375
of O 0 0.002666371
venous O 0 0.5950438
discomfort O 0 0.11525081
was O 0 0.0007777898
lower O 0 0.0005486225
in O 0 0.00054194184
Group O 0 0.07178964
L O 0 0.934413
( O 0 0.00091013144
76 O 0 0.0005776217
. O 0 0.00023962514
6 O 0 0.00019657325
% O 0 0.00030168414
; O 0 0.0005142846
P O 0 0.014235387
< O 0 0.0002514602
0 O 0 0.00030558396
. O 0 0.00026735154
05 O 0 0.0028110056
) O 0 0.0003936645
than O 0 0.00017760112
in O 0 0.00028160683
Group O 0 0.08994001
C O 0 0.9988532
( O 0 0.0014673866
100 O 0 0.0006926275
% O 0 0.00041725527
) O 0 0.0005123988
but O 0 0.00033101876
not O 0 0.00028142676
different O 0 0.0003310273
from O 0 0.0005166907
Group O 0 0.025149763
T O 0 0.7478944
( O 0 0.0021604348
90 O 0 0.0018758301
% O 0 0.003238514
) O 0 0.005996187
. O 0 0.008056281

The O 0 0.003617797
VAS O 0 0.007857531
scores O 0 0.001511356
for O 0 0.001134256
recall O 0 0.0021087101
of O 0 0.0012922074
pain B-Disease 0 0.8932208
in O 0 0.00047954306
the O 0 0.0003507016
recovery O 0 0.0004686825
room O 0 0.00028363988
were O 0 0.00018183856
correlated O 0 0.00013896145
with O 0 0.00017403896
the O 0 0.00019829422
VAS O 0 0.0022837785
scores O 0 0.00014550626
during O 0 0.00012393677
induction O 0 0.00019369498
( O 0 0.00036917054
r O 0 0.0003623281
= O 0 0.00060975755
0 O 0 0.00038254767
. O 0 0.00038259142
7045 O 0 0.013465753
; O 0 0.0010190568
P O 0 0.009156323
< O 0 0.0009194968
0 O 0 0.0014410896
. O 0 0.002036706
0001 O 0 0.009548454
) O 0 0.006645685
. O 0 0.008662535

Recovery O 0 0.007475205
room O 0 0.0028870446
discharge O 0 0.0021000067
times O 0 0.00083592016
were O 0 0.00079120125
similar O 0 0.0006036524
: O 0 0.0015592722
C O 0 0.99589074
( O 0 0.0013647452
75 O 0 0.0005577424
. O 0 0.0003094023
9 O 0 0.00030539607
+ O 0 0.0008378648
/ O 0 0.0055935737
- O 0 0.0071144733
19 O 0 0.0003815968
. O 0 0.00019438154
4 O 0 0.0001696563
min O 0 0.0002580866
) O 0 0.0004546404
; O 0 0.00067928975
L O 0 0.7640216
73 O 0 0.0006581631
. O 0 0.0001988137
6 O 0 0.00017546378
+ O 0 0.0006351673
/ O 0 0.004699659
- O 0 0.0053266417
21 O 0 0.0002509223
. O 0 0.00016869232
6 O 0 0.0001469264
min O 0 0.0002521199
) O 0 0.0004836556
; O 0 0.00082004967
T O 0 0.8209366
( O 0 0.0007988425
77 O 0 0.000848901
. O 0 0.00030921501
1 O 0 0.0003741439
+ O 0 0.0010284343
/ O 0 0.003964704
- O 0 0.0042290967
18 O 0 0.00088772585
. O 0 0.0009912867
9 O 0 0.0015079862
min O 0 0.0027405743
) O 0 0.0055833077
. O 0 0.0078110215

Assessing O 0 0.0045909905
their O 0 0.0029446266
overall O 0 0.0024326893
satisfaction O 0 0.0040471544
, O 0 0.0020585437
89 O 0 0.0020546487
. O 0 0.0011665853
7 O 0 0.0010623493
% O 0 0.0014180945
would O 0 0.0013927903
choose O 0 0.0023237993
propofol B-Chemical 1 0.9988887
anaesthesia O 0 0.063975915
again O 0 0.005452718
. O 0 0.00846576

We O 0 0.0034217413
conclude O 0 0.0019816274
that O 0 0.0020446836
lidocaine B-Chemical 0 0.9997793
reduces O 0 0.0009977667
the O 0 0.0006938365
incidence O 0 0.0025918223
and O 0 0.00062301673
severity O 0 0.0067974925
of O 0 0.0016307615
propofol B-Chemical 1 0.999889
injection O 0 0.007638059
pain B-Disease 0 0.87577057
in O 0 0.00030110308
ambulatory O 0 0.00048828305
patients O 0 0.0005592942
whereas O 0 0.001065115
thiopentone B-Chemical 0 0.99998415
only O 0 0.0011687976
reduces O 0 0.0014035413
its O 0 0.004590648
severity O 0 0.040647827
. O 0 0.006972473

Persistent O 0 0.6276449
paralysis B-Disease 2 0.99879277
after O 0 0.0023017544
prolonged O 0 0.0026196663
use O 0 0.0016990863
of O 0 0.0022345814
atracurium B-Chemical 0 0.99780625
in O 0 0.0015230842
the O 0 0.0015844106
absence O 0 0.0019710842
of O 0 0.006364327
corticosteroids O 1 0.99960035
. O 0 0.011902644

Neuromuscular O 0 0.012310425
blocking O 0 0.0048103486
agents O 0 0.030679606
( O 0 0.0053563383
NMBAs O 0 0.92306733
) O 0 0.002023292
are O 0 0.0008031957
often O 0 0.0007964396
used O 0 0.0006330925
for O 0 0.00075569795
patients O 0 0.0011890946
requiring O 0 0.0013155112
prolonged O 0 0.002353523
mechanical O 0 0.005065645
ventilation O 0 0.021220466
. O 0 0.0075720935

Reports O 0 0.007181164
of O 0 0.0038675056
persistent O 0 0.23399715
paralysis B-Disease 2 0.99976856
after O 0 0.0008531615
the O 0 0.0008113423
discontinuance O 0 0.19028756
of O 0 0.00049172895
these O 0 0.00044322055
drugs O 0 0.0609099
have O 0 0.00021378844
most O 0 0.00033462164
often O 0 0.0002896603
involved O 0 0.00019141396
aminosteroid O 0 0.69244677
- O 0 0.012456703
based O 0 0.00033148364
NMBAs O 0 0.4329409
such O 0 0.00019765581
as O 0 0.00035061289
vecuronium B-Chemical 0 0.99448156
bromide I-Chemical 0 0.99990606
, O 0 0.0010004888
especially O 0 0.00052920653
when O 0 0.00031615346
used O 0 0.00047086185
in O 0 0.0007215634
conjunction O 0 0.0014408056
with O 0 0.003378908
corticosteroids O 1 0.99911207
. O 0 0.008415902

Atracurium B-Chemical 0 0.999866
besylate I-Chemical 0 0.99999714
, O 0 0.00533959
a O 0 0.0016211955
short O 0 0.00095136836
- O 0 0.016690072
acting O 0 0.013020992
benzylisoquinolinium B-Chemical 0 0.9998091
NMBA O 0 0.9992643
that O 0 0.0003072576
is O 0 0.00026487952
eliminated O 0 0.0001925311
independently O 0 0.00016773398
of O 0 0.00035186773
renal O 0 0.811055
or O 0 0.00046594604
hepatic O 0 0.8682746
function O 0 0.00050674437
, O 0 0.00056322635
has O 0 0.00018298233
also O 0 0.00018264748
been O 0 0.00019304708
associated O 0 0.00025422595
with O 0 0.00044843336
persistent O 0 0.30071753
paralysis B-Disease 2 0.99997246
, O 0 0.0023717787
but O 0 0.0006434283
only O 0 0.00056579284
when O 0 0.00060689455
used O 0 0.0011297034
with O 0 0.0029872938
corticosteroids O 1 0.99897885
. O 0 0.008326529

We O 0 0.0038885637
report O 0 0.0035330025
a O 0 0.002229847
case O 0 0.0016364699
of O 0 0.0023649863
atracurium B-Chemical 0 0.99981815
- O 0 0.09530473
related O 0 0.00052987156
paralysis B-Disease 2 0.99960524
persisting O 0 0.0055640936
for O 0 0.0002679011
approximately O 0 0.00024294014
50 O 0 0.00028954266
hours O 0 0.00020384172
in O 0 0.0002539982
a O 0 0.00037448487
patient O 0 0.00043676133
who O 0 0.0006443386
was O 0 0.00054797815
not O 0 0.00070928293
treated O 0 0.0015375688
with O 0 0.0038203057
corticosteroids O 1 0.99929583
. O 0 0.008734626

A O 0 0.065702476
phase O 0 0.0072106714
I O 0 0.0504088
/ O 0 0.011937161
II O 0 0.018676257
study O 0 0.0012224738
of O 0 0.0012213733
paclitaxel B-Chemical 1 0.99671656
plus O 0 0.0012747627
cisplatin B-Chemical 1 0.999721
as O 0 0.00046823322
first O 0 0.00033916062
- O 0 0.005890186
line O 0 0.00050822005
therapy O 0 0.0005861494
for O 0 0.0003914857
head B-Disease 0 0.025938291
and I-Disease 0 0.0011936062
neck I-Disease 0 0.5077511
cancers I-Disease 2 0.9925088
: O 0 0.0038449026
preliminary O 0 0.003213346
results O 0 0.0040522898
. O 0 0.00733816

Improved O 0 0.006331381
outcomes O 0 0.0035323713
among O 0 0.0021387658
patients O 0 0.0015713082
with O 0 0.0010780189
head B-Disease 0 0.01693781
and I-Disease 0 0.00113447
neck I-Disease 0 0.14995201
carcinomas I-Disease 0 0.700599
require O 0 0.000487872
investigations O 0 0.0006816529
of O 0 0.0007974975
new O 0 0.0012436227
drugs O 0 0.06968041
for O 0 0.0015333222
induction O 0 0.002689186
therapy O 0 0.007884584
. O 0 0.007446801

Preliminary O 0 0.005473981
results O 0 0.0025781991
of O 0 0.0024201225
an O 0 0.002492338
Eastern O 0 0.13574065
Cooperative O 0 0.042553168
Oncology O 0 0.0037491252
Group O 0 0.0027387657
study O 0 0.00046384125
of O 0 0.00040797426
single O 0 0.00049831806
- O 0 0.020080699
agent O 0 0.15212342
paclitaxel B-Chemical 1 0.9997223
( O 0 0.079516836
Taxol B-Chemical 1 0.9999962
; O 0 0.030720653
Bristol O 0 0.6263818
- O 0 0.07246311
Myers O 0 0.4602292
Squibb O 0 0.9813323
Company O 0 0.8181234
, O 0 0.0012920038
Princeton O 0 0.437493
, O 0 0.0010279425
NJ O 0 0.7084399
) O 0 0.00068858906
reported O 0 0.00025984982
a O 0 0.00023172375
37 O 0 0.0002755304
% O 0 0.00019597066
response O 0 0.0001891259
rate O 0 0.00018614072
in O 0 0.00016391439
patients O 0 0.00023447718
with O 0 0.00019753524
head B-Disease 0 0.026822029
and I-Disease 0 0.0005836135
neck I-Disease 0 0.63657486
cancer I-Disease 0 0.9990194
, O 0 0.0012395532
and O 0 0.00035346422
the O 0 0.00039942458
paclitaxel B-Chemical 1 0.9993025
/ O 0 0.36404487
cisplatin B-Chemical 1 0.99990845
combination O 0 0.0013091242
has O 0 0.0001935351
been O 0 0.00016393923
used O 0 0.0001419665
successfully O 0 0.00019445183
and O 0 0.0002175859
has O 0 0.00018343162
significantly O 0 0.00021310811
improved O 0 0.0002659469
median O 0 0.00022096526
response O 0 0.00043491894
duration O 0 0.0005465604
in O 0 0.0014102799
ovarian B-Disease 2 0.9980882
cancer I-Disease 2 0.99992037
patients O 0 0.08062841
. O 0 0.008076388

We O 0 0.0037304705
initiated O 0 0.0026045672
a O 0 0.0024499728
phase O 0 0.0030509455
I O 0 0.04027622
/ O 0 0.009847768
II O 0 0.01349839
trial O 0 0.00057200337
to O 0 0.00026547036
determine O 0 0.00013888237
the O 0 0.00020257666
response O 0 0.00032696058
and O 0 0.0006035158
toxicity B-Disease 2 0.99765116
of O 0 0.0015214345
escalating O 0 0.6259149
paclitaxel B-Chemical 1 0.9988306
doses O 0 0.01457351
combined O 0 0.00036040874
with O 0 0.00024710916
fixed O 0 0.0004940995
- O 0 0.02746883
dose O 0 0.023827866
cisplatin B-Chemical 1 0.99981934
with O 0 0.002823469
granulocyte O 0 0.9904421
colony O 0 0.8445024
- O 0 0.096896484
stimulating O 0 0.00058810215
factor O 0 0.0057392134
support O 0 0.00018997211
in O 0 0.00021637193
patients O 0 0.00033050164
with O 0 0.0002661798
untreated O 0 0.00043858308
locally O 0 0.0018437358
advanced O 0 0.023233928
inoperable O 0 0.5477124
head B-Disease 0 0.14320658
and I-Disease 0 0.003673626
neck I-Disease 0 0.84956104
carcinoma I-Disease 2 0.99986637
. O 0 0.012162343

To O 0 0.0032856723
date O 0 0.0025202997
, O 0 0.0025134687
23 O 0 0.0020171402
men O 0 0.0039999266
with O 0 0.0008220772
a O 0 0.00068590627
median O 0 0.00038498567
age O 0 0.0005880707
of O 0 0.00045238805
50 O 0 0.00044697165
years O 0 0.00042281064
and O 0 0.000431526
good O 0 0.00056865124
performance O 0 0.0007447017
status O 0 0.0009151341
have O 0 0.0009170077
entered O 0 0.0016924281
the O 0 0.0022106708
trial O 0 0.0044699437
. O 0 0.0067566154

Primary O 0 0.008183307
tumor B-Disease 0 0.36774123
sites O 0 0.002501561
were O 0 0.0017320267
oropharynx O 0 0.35173938
, O 0 0.0012694672
10 O 0 0.00060968596
patients O 0 0.0006741365
; O 0 0.00089548714
hypopharynx O 0 0.49604923
, O 0 0.00054780365
four O 0 0.00024152551
; O 0 0.0005642456
larynx O 0 0.10222375
, O 0 0.00043631255
two O 0 0.00020973464
; O 0 0.00056609855
oral O 0 0.046138298
cavity O 0 0.0013265281
, O 0 0.00034365084
three O 0 0.00014000712
; O 0 0.00033563192
unknown O 0 0.0003569635
primary O 0 0.0003064201
, O 0 0.0003472357
two O 0 0.00020635617
; O 0 0.00040327103
and O 0 0.00034690817
nasal O 0 0.0020731369
cavity O 0 0.0012017768
and O 0 0.0008339413
parotid O 0 0.04777707
gland O 0 0.038371474
, O 0 0.0021648235
one O 0 0.002010102
each O 0 0.0025382757
. O 0 0.0062368154

Of O 0 0.0048852023
20 O 0 0.0027823548
patients O 0 0.0021793824
evaluable O 0 0.00279133
for O 0 0.0015768973
toxicity B-Disease 2 0.99534947
, O 0 0.001372297
four O 0 0.00056218746
had O 0 0.000621277
stage O 0 0.0017174646
III O 0 0.013866635
and O 0 0.0009074204
16 O 0 0.0010871757
had O 0 0.0013450754
stage O 0 0.0058395895
IV O 0 0.5767613
disease O 0 0.9145593
. O 0 0.009320465

Treatment O 0 0.008971605
, O 0 0.003044264
given O 0 0.0011718543
every O 0 0.00069141726
21 O 0 0.0007380711
days O 0 0.00042199247
for O 0 0.00040426967
a O 0 0.0004007339
maximum O 0 0.00027041728
of O 0 0.00027927326
three O 0 0.00014918915
cycles O 0 0.0001461151
, O 0 0.00022095472
consisted O 0 0.00014576665
of O 0 0.00031994542
paclitaxel B-Chemical 1 0.99279916
by O 0 0.0003346488
3 O 0 0.00021200516
- O 0 0.0011012832
hour O 0 0.00014268987
infusion O 0 0.00022138197
followed O 0 0.00010870135
the O 0 0.00012237046
next O 0 9.8234676e-05
day O 0 0.00012366679
by O 0 0.00016107944
a O 0 0.00020836451
fixed O 0 0.00024268826
dose O 0 0.0012174004
of O 0 0.0011946958
cisplatin B-Chemical 1 0.9998012
( O 0 0.002130866
75 O 0 0.001200381
mg O 0 0.028860465
/ O 0 0.0043451926
m2 O 0 0.037257146
) O 0 0.006405778
. O 0 0.0073692324

The O 0 0.0029327981
dose O 0 0.00354147
levels O 0 0.0014781541
incorporate O 0 0.0009851392
escalating O 0 0.28842053
paclitaxel B-Chemical 1 0.9988489
doses O 0 0.06388292
, O 0 0.0011066577
and O 0 0.0006089401
intrapatient O 0 0.073158085
escalations O 0 0.077761225
within O 0 0.00021300797
a O 0 0.00032773297
given O 0 0.00024446347
dose O 0 0.00071739027
level O 0 0.00045961668
are O 0 0.00069828425
permitted O 0 0.0012964907
if O 0 0.0015416633
toxicity B-Disease 2 0.98819333
permits O 0 0.0054619443
. O 0 0.007331057

At O 0 0.0026667234
the O 0 0.001883307
time O 0 0.0011471506
of O 0 0.0011809783
this O 0 0.0008958008
writing O 0 0.004024611
, O 0 0.0008355463
dose O 0 0.0012681161
level O 0 0.0003376432
4 O 0 0.0003048207
( O 0 0.0004602186
260 O 0 0.0045939283
, O 0 0.00044888924
270 O 0 0.0013491978
, O 0 0.0003271062
and O 0 0.0003016266
280 O 0 0.012924803
mg O 0 0.025541004
/ O 0 0.0028368316
m2 O 0 0.020559594
) O 0 0.0006206175
is O 0 0.00026482122
being O 0 0.0003288917
evaluated O 0 0.00023282507
; O 0 0.00041985317
three O 0 0.00024560964
patients O 0 0.0004653417
from O 0 0.0004894681
this O 0 0.00076323195
level O 0 0.0011723712
are O 0 0.00225601
evaluable O 0 0.008151914
. O 0 0.0066626673

With O 0 0.005468585
paclitaxel B-Chemical 1 0.9770777
doses O 0 0.01676695
of O 0 0.0018512082
200 O 0 0.0018097726
mg O 0 0.06261333
/ O 0 0.0036469812
m2 O 0 0.011155643
and O 0 0.0005099475
higher O 0 0.00040069033
, O 0 0.0007915724
granulocyte O 0 0.93244624
colony O 0 0.6371002
- O 0 0.041622866
stimulating O 0 0.0005413424
factor O 0 0.0058619166
5 O 0 0.00023751658
micrograms O 0 0.0037722709
/ O 0 0.001543193
kg O 0 0.0010555015
/ O 0 0.0012413705
d O 0 0.00047702942
is O 0 0.00035249454
given O 0 0.00030558894
( O 0 0.00060100126
days O 0 0.0004986645
4 O 0 0.00074008194
through O 0 0.001067381
12 O 0 0.0019554677
) O 0 0.004679641
. O 0 0.0070438166

Of O 0 0.004840115
18 O 0 0.0028293794
patients O 0 0.001966845
evaluable O 0 0.002036034
for O 0 0.00094782497
response O 0 0.0010908808
, O 0 0.000967361
seven O 0 0.00049928593
( O 0 0.00066675345
39 O 0 0.0005781904
% O 0 0.00045207425
) O 0 0.0004826507
achieved O 0 0.00030644753
a O 0 0.0003119855
complete O 0 0.00022807656
response O 0 0.00032546808
and O 0 0.00033649663
six O 0 0.00027054932
( O 0 0.00052814954
33 O 0 0.0006263151
% O 0 0.00070895994
) O 0 0.0010693794
achieved O 0 0.0011489799
a O 0 0.0018265533
partial O 0 0.002910055
response O 0 0.0048885755
. O 0 0.00751844

Three O 0 0.006059259
patients O 0 0.0045204917
had O 0 0.0030110807
no O 0 0.0023624012
change O 0 0.002900604
and O 0 0.003690734
disease O 0 0.7637889
progressed O 0 0.008427123
in O 0 0.0045971354
two O 0 0.0056832926
. O 0 0.009981836

The O 0 0.0077057257
overall O 0 0.0071505266
response O 0 0.007762792
rate O 0 0.008340002
is O 0 0.009585801
72 O 0 0.012472802
% O 0 0.01492765
. O 0 0.018841783

Eleven O 0 0.009212098
responding O 0 0.0055202316
patients O 0 0.0036606153
had O 0 0.002374965
subsequent O 0 0.0024044309
surgery O 0 0.0036678812
/ O 0 0.0062398636
radiotherapy O 0 0.06414048
or O 0 0.004250026
radical O 0 0.7984202
radiotherapy O 0 0.44824606
. O 0 0.01154098

Two O 0 0.004345907
pathologic O 0 0.006808512
complete O 0 0.001932386
responses O 0 0.0019715156
were O 0 0.0012280797
observed O 0 0.0009237128
in O 0 0.0009808177
patients O 0 0.0012865523
who O 0 0.0013196435
had O 0 0.0010383215
achieved O 0 0.0014659482
clinical O 0 0.0029661278
complete O 0 0.0026182537
responses O 0 0.005554137
. O 0 0.0077472483

Alopecia B-Disease 0 0.99762625
, O 0 0.016417425
paresthesias B-Disease 0 0.9992182
, O 0 0.0037315234
and O 0 0.0035363112
arthralgias B-Disease 0 0.9998902
/ O 0 0.3956004
myalgias B-Disease 0 0.999974
have O 0 0.00043432068
occurred O 0 0.0004602866
frequently O 0 0.0006102607
, O 0 0.00042972472
but O 0 0.0002995632
with O 0 0.00024175202
one O 0 0.00019086486
exception O 0 0.00019863519
( O 0 0.0003629319
a O 0 0.00037420332
grade O 0 0.05415577
3 O 0 0.0005027683
myalgia B-Disease 2 0.9999051
) O 0 0.000812973
they O 0 0.00034594163
have O 0 0.00043834487
been O 0 0.0007421779
grade O 0 0.010320947
1 O 0 0.0014277194
or O 0 0.00210652
2 O 0 0.0036334326
. O 0 0.0064792014

No O 0 0.01000702
dose O 0 0.02654517
- O 0 0.043362573
limiting O 0 0.016860124
hematologic O 0 0.99978477
toxicity B-Disease 2 0.99994886
has O 0 0.005808487
been O 0 0.0061659343
seen O 0 0.007697107
. O 0 0.0121434685

Paclitaxel B-Chemical 0 0.99958163
/ O 0 0.34439287
cisplatin B-Chemical 1 0.99958676
is O 0 0.0021804806
an O 0 0.0013053038
effective O 0 0.00087805913
first O 0 0.0005492404
- O 0 0.0049920445
line O 0 0.0005690885
regimen O 0 0.0005266194
for O 0 0.00036162176
locoregionally O 0 0.5876441
advanced O 0 0.013788567
head B-Disease 0 0.05926099
and I-Disease 0 0.0009547199
neck I-Disease 0 0.49781427
cancer I-Disease 0 0.99383706
and O 0 0.001234348
continued O 0 0.0011796969
study O 0 0.0017927241
is O 0 0.002249224
warranted O 0 0.003342202
. O 0 0.0063532046

Results O 0 0.0037515515
thus O 0 0.0028641364
far O 0 0.0017563257
suggest O 0 0.0009212678
no O 0 0.0008887605
dose O 0 0.010199837
- O 0 0.01405736
response O 0 0.00091358065
effect O 0 0.0006594694
for O 0 0.00081612426
paclitaxel B-Chemical 1 0.99674183
doses O 0 0.013080809
above O 0 0.00080048246
200 O 0 0.001743621
mg O 0 0.038256194
/ O 0 0.006498861
m2 O 0 0.050799575
. O 0 0.007818863

Improvement O 0 0.011108475
of O 0 0.011463132
levodopa B-Chemical 0 0.9999932
- O 0 0.2440921
induced O 0 0.016882323
dyskinesia B-Disease 0 0.9999993
by O 0 0.027863082
propranolol B-Chemical 1 0.99999857
in O 0 0.007115781
Parkinson B-Disease 0 0.99960977
' I-Disease 0 0.0045218244
s I-Disease 0 0.0051356214
disease I-Disease 0 0.71548414
. O 0 0.009848921

Seven O 0 0.006391832
patients O 0 0.003667916
suffering O 0 0.046488058
from O 0 0.0019473148
Parkinson B-Disease 0 0.9989907
' I-Disease 0 0.0018371503
s I-Disease 0 0.0016565393
disease I-Disease 0 0.9461715
( O 0 0.024920572
PD B-Disease 0 0.99991465
) O 0 0.0014396488
with O 0 0.00046732134
severely O 0 0.052919034
disabling O 0 0.9951734
dyskinesia B-Disease 0 0.99999964
received O 0 0.00033513087
low O 0 0.0013345368
- O 0 0.049146153
dose O 0 0.079835296
propranolol B-Chemical 1 0.9999981
as O 0 0.0003784367
an O 0 0.00037928746
adjunct O 0 0.00035816574
to O 0 0.00035866513
the O 0 0.00052160694
currently O 0 0.0008825192
used O 0 0.0011439131
medical O 0 0.0035748444
treatment O 0 0.0038223695
. O 0 0.006305718

There O 0 0.004727799
was O 0 0.0030178593
a O 0 0.0023143906
significant O 0 0.0015200617
40 O 0 0.0012094157
% O 0 0.0011193362
improvement O 0 0.0008517173
in O 0 0.00072783115
the O 0 0.0010795853
dyskinesia B-Disease 0 0.9999962
score O 0 0.0007512461
without O 0 0.00070376176
increase O 0 0.0009321705
of O 0 0.007319202
parkinsonian B-Disease 2 0.9999925
motor B-Disease 0 0.9521339
disability I-Disease 0 0.97977453
. O 0 0.0082981875

Ballistic O 0 0.05487301
and O 0 0.013740556
choreic O 0 0.9999523
dyskinesia B-Disease 0 0.9999982
were O 0 0.0031238208
markedly O 0 0.004747522
ameliorated O 0 0.19060488
, O 0 0.004970078
whereas O 0 0.010479846
dystonia B-Disease 2 0.99999535
was O 0 0.0047265626
not O 0 0.0052038506
. O 0 0.00884565

This O 0 0.0051162797
study O 0 0.002676528
suggests O 0 0.0012143569
that O 0 0.0009865062
administration O 0 0.0031916047
of O 0 0.0008859724
low O 0 0.0010181173
doses O 0 0.010514144
of O 0 0.004525103
beta O 0 0.9985587
- O 0 0.79218143
blockers O 0 0.9975836
may O 0 0.00051227526
improve O 0 0.0005101235
levodopa B-Chemical 0 0.9999969
- O 0 0.01630004
induced O 0 0.0006985655
ballistic O 0 0.13788545
and O 0 0.017178819
choreic O 0 0.9999913
dyskinesia B-Disease 0 0.9999993
in O 0 0.012827759
PD B-Disease 0 0.99950194
. O 0 0.007925515

Habitual O 0 0.07994025
use O 0 0.0032250094
of O 0 0.0047697257
acetaminophen B-Chemical 0 0.99999547
as O 0 0.0016470968
a O 0 0.0015708138
risk O 0 0.093754664
factor O 0 0.025836227
for O 0 0.0013092852
chronic B-Disease 2 0.99466926
renal I-Disease 2 0.9961494
failure I-Disease 2 0.9708807
: O 0 0.0036033667
a O 0 0.0014014402
comparison O 0 0.001527397
with O 0 0.007446808
phenacetin B-Chemical 1 0.9999945
. O 0 0.009668645

Six O 0 0.004339218
epidemiologic O 0 0.0036017147
studies O 0 0.0017684661
in O 0 0.0012749005
the O 0 0.001033244
United O 0 0.001902473
States O 0 0.0026264624
and O 0 0.00069224107
Europe O 0 0.0038410348
indicate O 0 0.00020193662
that O 0 0.00021843982
habitual O 0 0.039911762
use O 0 0.0003060017
of O 0 0.0034004224
phenacetin B-Chemical 1 0.9999999
is O 0 0.0005035035
associated O 0 0.00027896746
with O 0 0.00020633648
the O 0 0.00016514241
development O 0 0.00053527876
of O 0 0.00066098996
chronic B-Disease 2 0.9913762
renal I-Disease 2 0.9917076
failure I-Disease 2 0.9101269
and O 0 0.00049916835
end B-Disease 0 0.00016889897
- I-Disease 0 0.017063031
stage I-Disease 0 0.020168277
renal I-Disease 0 0.99982506
disease I-Disease 0 0.9999305
( O 0 0.23851745
ESRD B-Disease 2 0.9999993
) O 0 0.008408588
, O 0 0.0004398182
with O 0 0.00026316557
a O 0 0.00028623393
relative O 0 0.00024263548
risk O 0 0.010903978
in O 0 0.00036490092
the O 0 0.00042683442
range O 0 0.000639086
of O 0 0.0010170306
4 O 0 0.0012442659
to O 0 0.001929785
19 O 0 0.0043706386
. O 0 0.00622386

As O 0 0.0035292627
a O 0 0.002747456
result O 0 0.0015521551
of O 0 0.0013632051
these O 0 0.0010432523
and O 0 0.00090330356
other O 0 0.0007592305
studies O 0 0.0008728469
, O 0 0.008947316
phenacetin B-Chemical 1 0.9999994
has O 0 0.0005611307
now O 0 0.00046577925
been O 0 0.00042624993
withdrawn O 0 0.0006168713
from O 0 0.00046630748
the O 0 0.0006904947
market O 0 0.0016645873
in O 0 0.0015204527
most O 0 0.0030708879
countries O 0 0.010295654
. O 0 0.007731078

However O 0 0.0044657975
, O 0 0.0030131168
three O 0 0.0012035914
case O 0 0.0011594981
control O 0 0.00083327986
studies O 0 0.0007005185
, O 0 0.00071681215
one O 0 0.00035357557
each O 0 0.00021760956
in O 0 0.00030307076
North O 0 0.00097496255
Carolina O 0 0.023365596
, O 0 0.00046230157
northern O 0 0.005113329
Maryland O 0 0.01183143
, O 0 0.0004251518
and O 0 0.00039908718
West O 0 0.028449077
Berlin O 0 0.02784783
, O 0 0.0008173216
Germany O 0 0.021359934
, O 0 0.00031521023
showed O 0 0.00016055959
that O 0 0.00014614394
habitual O 0 0.040067874
use O 0 0.00024018512
of O 0 0.0022911874
acetaminophen B-Chemical 0 0.99999964
is O 0 0.00039422314
also O 0 0.00019247198
associated O 0 0.00026670942
with O 0 0.00047639487
chronic B-Disease 2 0.9875038
renal I-Disease 2 0.9944326
failure I-Disease 2 0.9843275
and O 0 0.04202032
ESRD B-Disease 2 0.99999905
, O 0 0.0010242634
with O 0 0.000298015
a O 0 0.00028599444
relative O 0 0.00023126401
risk O 0 0.011755465
in O 0 0.0003431586
the O 0 0.00040101842
range O 0 0.000603531
of O 0 0.00097139506
2 O 0 0.0012474331
to O 0 0.0017573417
4 O 0 0.0030548626
. O 0 0.0058746156

These O 0 0.0033019483
studies O 0 0.0020802608
suggest O 0 0.0011293214
that O 0 0.001115935
both O 0 0.003591532
phenacetin B-Chemical 1 0.99999976
and O 0 0.11416776
acetaminophen B-Chemical 0 0.99999964
may O 0 0.00046269773
contribute O 0 0.00022798785
to O 0 0.00019846066
the O 0 0.00021978692
burden O 0 0.0010734388
of O 0 0.005982088
ESRD B-Disease 2 0.9999988
, O 0 0.0011816781
with O 0 0.00030539202
the O 0 0.00024288082
risk O 0 0.017446995
of O 0 0.000334959
the O 0 0.00028184243
latter O 0 0.00074747996
being O 0 0.00049692014
somewhat O 0 0.0004980355
less O 0 0.00039390213
than O 0 0.00042840219
that O 0 0.00070933026
of O 0 0.0016053926
the O 0 0.00255921
former O 0 0.043871302
. O 0 0.007071311

This O 0 0.004876209
apparent O 0 0.0026212342
difference O 0 0.0015734643
in O 0 0.001535649
risk O 0 0.037925728
may O 0 0.0008370436
not O 0 0.00058839
be O 0 0.0005098189
due O 0 0.0003606471
to O 0 0.00038378447
differences O 0 0.00038515747
in O 0 0.00065804826
nephrotoxic B-Disease 2 0.9991716
potential O 0 0.0011709593
of O 0 0.0015686062
the O 0 0.001953415
drugs O 0 0.22924268
themselves O 0 0.005650749
. O 0 0.0069231996

A O 0 0.063461274
lower O 0 0.0029377285
relative O 0 0.0017652704
risk O 0 0.035043634
would O 0 0.00090584304
be O 0 0.00068913325
expected O 0 0.0004996829
for O 0 0.0010631755
acetaminophen B-Chemical 0 0.9999989
if O 0 0.00032964605
the O 0 0.00031744855
risk O 0 0.031154724
of O 0 0.0004029486
both O 0 0.00035464118
drugs O 0 0.10068615
in O 0 0.0002015342
combination O 0 0.00028490392
with O 0 0.0002769856
other O 0 0.00048012327
analgesics O 0 0.68269795
was O 0 0.00022683825
higher O 0 0.00022836468
than O 0 0.0002178537
the O 0 0.00037614553
risk O 0 0.014684939
of O 0 0.0011640198
either O 0 0.0015780448
agent O 0 0.08313172
alone O 0 0.004733176
. O 0 0.0073661357

Thus O 0 0.005607653
, O 0 0.02073448
acetaminophen B-Chemical 0 0.9999957
has O 0 0.0017645998
been O 0 0.00092217705
used O 0 0.00054468523
both O 0 0.00045035416
as O 0 0.00038498602
a O 0 0.00044027288
single O 0 0.0003581958
agent O 0 0.006603962
and O 0 0.00036218693
in O 0 0.00024226053
combination O 0 0.0003247072
with O 0 0.00032348183
other O 0 0.00064195297
analgesics O 0 0.89183766
, O 0 0.00081605895
whereas O 0 0.0029477093
phenacetin B-Chemical 1 0.9999993
was O 0 0.00084662857
available O 0 0.0008898494
only O 0 0.0011525836
in O 0 0.0017796844
combinations O 0 0.0030674709
. O 0 0.0063245874

The O 0 0.0028673604
possibility O 0 0.0017838536
that O 0 0.0014182667
habitual O 0 0.050016426
use O 0 0.0011215648
of O 0 0.0047002835
acetaminophen B-Chemical 0 0.9999994
alone O 0 0.0012094468
increases O 0 0.00049376476
the O 0 0.00047785137
risk O 0 0.18500923
of O 0 0.0110625
ESRD B-Disease 2 0.99999785
has O 0 0.0004452214
not O 0 0.00033396803
been O 0 0.00037646774
clearly O 0 0.0004196685
demonstrated O 0 0.0005847602
, O 0 0.0012369001
but O 0 0.0015974568
cannot O 0 0.0034778374
be O 0 0.0031961955
dismissed O 0 0.01806242
. O 0 0.008208692

Acetaminophen B-Chemical 0 0.9999745
- O 0 0.29809734
induced O 0 0.062396172
hypotension B-Disease 2 0.9998665
. O 0 0.04657124

Through O 0 0.0042871265
30 O 0 0.002300951
years O 0 0.0019802218
of O 0 0.0015851455
widespread O 0 0.00216
use O 0 0.0013796206
, O 0 0.010194109
acetaminophen B-Chemical 0 0.99999905
has O 0 0.00073559734
been O 0 0.00047380195
shown O 0 0.00030986278
to O 0 0.00032200766
be O 0 0.00041550543
a O 0 0.0005772251
remarkably O 0 0.0016052786
safe O 0 0.0016191901
medication O 0 0.011744727
in O 0 0.0013541069
therapeutic O 0 0.004717975
dosages O 0 0.08098148
. O 0 0.006863108

The O 0 0.0039657266
potential O 0 0.0036984715
for O 0 0.004257905
acetaminophen B-Chemical 0 0.9999912
to O 0 0.0024639494
produce O 0 0.0025502427
cardiovascular B-Disease 0 0.9998247
toxicities I-Disease 2 0.9999647
is O 0 0.004270223
very O 0 0.0055196583
low O 0 0.007302018
. O 0 0.009431709

However O 0 0.006681157
, O 0 0.018122293
acetaminophen B-Chemical 0 0.99999475
has O 0 0.0018863954
been O 0 0.001051925
demonstrated O 0 0.0006212338
to O 0 0.0005259121
produce O 0 0.00049800676
symptoms O 0 0.1472204
of O 0 0.0025053974
anaphylaxis B-Disease 2 0.99997723
, O 0 0.0049854903
including O 0 0.0027189313
hypotension B-Disease 2 0.9999846
, O 0 0.0020008849
in O 0 0.0015647508
sensitive O 0 0.0026274247
individuals O 0 0.0054909796
. O 0 0.006895787

This O 0 0.0058561703
article O 0 0.003536615
describes O 0 0.002402444
two O 0 0.0013292212
critically B-Disease 0 0.005117003
ill I-Disease 0 0.67328626
patients O 0 0.001092114
in O 0 0.0005437031
whom O 0 0.0009895222
transient O 0 0.006532401
episodes O 0 0.028735064
of O 0 0.0036139472
hypotension B-Disease 2 0.99999034
reproducibly O 0 0.005041277
developed O 0 0.0010901598
after O 0 0.0007339032
administration O 0 0.013846995
of O 0 0.01180744
acetaminophen B-Chemical 0 0.9999949
. O 0 0.009991627

Other O 0 0.014896956
symptoms O 0 0.23623893
of O 0 0.011151299
allergic B-Disease 0 0.99995863
reactions I-Disease 0 0.79665315
were O 0 0.004219894
not O 0 0.0041064257
clinically O 0 0.015834896
detectable O 0 0.0072933193
. O 0 0.011707808

The O 0 0.0064769005
hypotensive B-Disease 0 0.987033
episodes O 0 0.02939746
were O 0 0.0031261696
severe O 0 0.011278722
enough O 0 0.0023457354
to O 0 0.002270754
require O 0 0.003019874
vasopressor O 0 0.8791861
administration O 0 0.055707242
. O 0 0.010007985

The O 0 0.0030481857
reports O 0 0.002122433
illustrate O 0 0.0011661408
the O 0 0.0010568933
need O 0 0.0007759794
for O 0 0.0006809575
clinicians O 0 0.00077496696
to O 0 0.00050608855
consider O 0 0.00060005055
acetaminophen B-Chemical 0 0.99999785
in O 0 0.00081262056
patients O 0 0.0014224483
with O 0 0.0019578834
hypotension B-Disease 2 0.9999422
of O 0 0.0025371246
unknown O 0 0.006006114
origin O 0 0.0066969157
. O 0 0.007426362

Reduction O 0 0.0076189856
of O 0 0.00520026
heparan B-Chemical 0 0.99856853
sulphate I-Chemical 0 0.99994206
- O 0 0.17662403
associated O 0 0.0013965945
anionic O 0 0.118556954
sites O 0 0.0005821314
in O 0 0.0004084111
the O 0 0.00042989268
glomerular O 0 0.7384943
basement O 0 0.1265241
membrane O 0 0.0048102797
of O 0 0.0007058151
rats O 0 0.0012026367
with O 0 0.0023672779
streptozotocin B-Chemical 0 0.99999535
- O 0 0.25708926
induced O 0 0.0486955
diabetic B-Disease 2 0.99999845
nephropathy I-Disease 0 0.9999999
. O 0 0.061046228

Heparan B-Chemical 0 0.9749416
sulphate I-Chemical 0 0.99960417
- O 0 0.064418875
associated O 0 0.0018638436
anionic O 0 0.087422654
sites O 0 0.00078894716
in O 0 0.0005086101
the O 0 0.00047246204
glomerular O 0 0.76109743
basement O 0 0.15206009
membrane O 0 0.005268983
were O 0 0.00027262126
studied O 0 0.00022708125
in O 0 0.0001844682
rats O 0 0.0002331761
8 O 0 0.00013610718
months O 0 0.00010228542
after O 0 9.7988705e-05
induction O 0 0.00016854376
of O 0 0.0007432367
diabetes B-Disease 0 0.99994624
by O 0 0.0045941253
streptozotocin B-Chemical 0 0.9999968
and O 0 0.0006310714
in O 0 0.00028100554
age O 0 0.0029719847
- O 0 0.038609985
adn O 0 0.45276478
sex O 0 0.09859531
- O 0 0.006828901
matched O 0 0.00027612865
control O 0 0.0003045761
rats O 0 0.0004608209
, O 0 0.00046451163
employing O 0 0.0005003919
the O 0 0.0007456689
cationic O 0 0.007253848
dye O 0 0.27653039
cuprolinic B-Chemical 0 0.9557645
blue I-Chemical 0 0.5350688
. O 0 0.007943238

Morphometric O 0 0.012706631
analysis O 0 0.0033667674
at O 0 0.0022102706
the O 0 0.0018571025
ultrastructural O 0 0.003398831
level O 0 0.0013911732
was O 0 0.0014240878
performed O 0 0.0012979766
using O 0 0.0016095709
a O 0 0.0025051176
computerized O 0 0.0044920896
image O 0 0.004896657
processor O 0 0.010268355
. O 0 0.010089862

The O 0 0.0041276556
heparan B-Chemical 0 0.9812878
sulphate I-Chemical 0 0.99853194
specificity O 0 0.007949515
of O 0 0.0012620864
the O 0 0.0009064283
cuprolinic B-Chemical 0 0.90363723
blue I-Chemical 0 0.36174846
staining O 0 0.0012525169
was O 0 0.00029480841
demonstrated O 0 0.00021431419
by O 0 0.00042455646
glycosaminoglycan B-Chemical 0 0.9993144
- O 0 0.16778381
degrading O 0 0.009941919
enzymes O 0 0.023005636
, O 0 0.00039913622
showing O 0 0.0002205256
that O 0 0.00014810824
pretreatment O 0 0.011998342
of O 0 0.0002478609
the O 0 0.00018655436
sections O 0 0.00036983684
with O 0 0.0004128182
heparitinase O 0 0.92117023
abolished O 0 0.00045068277
all O 0 0.000295842
staining O 0 0.0011377194
, O 0 0.00077182666
whereas O 0 0.0008997065
chondroitinase O 0 0.89311326
ABC O 0 0.09741058
had O 0 0.0013380572
no O 0 0.0016730911
effect O 0 0.003545371
. O 0 0.0068703205

The O 0 0.0031696216
majority O 0 0.002265113
of O 0 0.0021745872
anionic O 0 0.13955516
sites O 0 0.0015078302
( O 0 0.0014652857
74 O 0 0.0010537514
% O 0 0.00071328157
in O 0 0.0006094576
diabetic B-Disease 2 0.9985726
and O 0 0.00060664176
81 O 0 0.00072846893
% O 0 0.00034040175
in O 0 0.00023299298
control O 0 0.0002469551
rats O 0 0.00035997626
) O 0 0.00037036592
were O 0 0.00021071623
found O 0 0.00018967547
within O 0 0.0001836854
the O 0 0.0003278699
lamina O 0 0.0027720716
rara O 0 0.6563199
externa O 0 0.94708526
of O 0 0.0012654229
the O 0 0.001469065
glomerular O 0 0.8411778
basement O 0 0.291241
membrane O 0 0.033749927
. O 0 0.0084220525

A O 0 0.0441252
minority O 0 0.0058110794
of O 0 0.0027714756
anionic O 0 0.0969549
sites O 0 0.0012024185
were O 0 0.0007250005
scattered O 0 0.00068723387
throughout O 0 0.00033609747
the O 0 0.00035633106
lamina O 0 0.00093592075
densa O 0 0.004251239
and O 0 0.000445697
lamina O 0 0.00847429
rara O 0 0.86695784
interna O 0 0.8879872
, O 0 0.00056694454
and O 0 0.00028235235
were O 0 0.00019363292
significantly O 0 0.00016650031
smaller O 0 0.000146352
than O 0 0.00011605748
those O 0 0.0001629597
in O 0 0.00014265638
the O 0 0.00017907817
lamina O 0 0.0034665158
rara O 0 0.7053299
externa O 0 0.9441861
of O 0 0.0003355407
the O 0 0.00026776223
glomerular O 0 0.8318034
basement O 0 0.2004841
membrane O 0 0.011446809
( O 0 0.0004839655
p O 0 0.00022243227
< O 0 0.00018910463
0 O 0 0.00024184515
. O 0 0.0002212465
001 O 0 0.008405725
and O 0 0.0002389077
p O 0 0.0002433356
< O 0 0.00023510488
0 O 0 0.00031455074
. O 0 0.00031126564
01 O 0 0.0009834897
for O 0 0.00045835573
diabetic B-Disease 2 0.9977793
and O 0 0.0007922235
control O 0 0.0008568509
rats O 0 0.0016255976
, O 0 0.0020046635
respectively O 0 0.0050611985
) O 0 0.006592988
. O 0 0.007516246

Diabetic B-Disease 0 0.999551
rats O 0 0.004857758
progressively O 0 0.0028165074
developed O 0 0.0055808774
albuminuria B-Disease 2 0.9999875
reaching O 0 0.0038953277
40 O 0 0.00066888967
. O 0 0.000400693
3 O 0 0.00031402457
( O 0 0.0004035648
32 O 0 0.00035912512
. O 0 0.00025358857
2 O 0 0.00027108507
- O 0 0.0009240866
62 O 0 0.00034257956
. O 0 0.00019409467
0 O 0 0.00023720291
) O 0 0.00039510222
mg O 0 0.013447606
/ O 0 0.0013883422
24 O 0 0.00019576837
h O 0 0.00016090857
after O 0 0.00010127663
8 O 0 0.00012077454
months O 0 9.428443e-05
in O 0 0.00011297144
contrast O 0 0.00015390849
to O 0 0.00011953484
the O 0 0.00013278934
control O 0 0.00014711762
animals O 0 0.00013446552
( O 0 0.00027987885
0 O 0 0.000190334
. O 0 0.00014026891
8 O 0 0.00014343113
( O 0 0.00021530139
0 O 0 0.00019248354
. O 0 0.00016461655
2 O 0 0.0001962485
- O 0 0.0008207896
0 O 0 0.00022349051
. O 0 0.00018474244
9 O 0 0.00020931612
) O 0 0.00041212887
mg O 0 0.01064274
/ O 0 0.0013187213
24 O 0 0.00036709083
h O 0 0.0004223458
, O 0 0.0005898823
p O 0 0.0006452389
< O 0 0.0008505527
0 O 0 0.0014347127
. O 0 0.0021154054
002 O 0 0.042982455
) O 0 0.006578577
. O 0 0.008485524

At O 0 0.0026961982
the O 0 0.0019028119
same O 0 0.00108932
time O 0 0.0008079215
, O 0 0.0009189585
the O 0 0.00052411476
number O 0 0.00045705773
of O 0 0.0009213428
heparan B-Chemical 0 0.9989761
sulphate I-Chemical 0 0.9999243
anionic O 0 0.5991353
sites O 0 0.00036245803
and O 0 0.00025454658
the O 0 0.00017425865
total O 0 0.00016958966
anionic O 0 0.07153188
site O 0 0.00027492215
surface O 0 0.0014481698
( O 0 0.0003689945
number O 0 0.00016469252
of O 0 0.00025007947
anionic O 0 0.05191166
sites O 0 0.0002067733
x O 0 0.00050354196
mean O 0 0.00012462673
anionic O 0 0.028548978
site O 0 0.00023425327
surface O 0 0.00097639073
) O 0 0.00045026554
in O 0 0.00016843932
the O 0 0.0001933066
lamina O 0 0.0036505281
rara O 0 0.7019372
externa O 0 0.94644374
of O 0 0.00034849794
the O 0 0.00027737964
glomerular O 0 0.8563241
basement O 0 0.18779986
membrane O 0 0.006312911
was O 0 0.00021644331
reduced O 0 0.00017737724
by O 0 0.00019682982
19 O 0 0.00028586577
% O 0 0.00024734324
( O 0 0.00028043173
p O 0 0.00020123237
< O 0 0.00019014228
0 O 0 0.00025805712
. O 0 0.00024769982
021 O 0 0.051392775
) O 0 0.0004081515
and O 0 0.00026237787
by O 0 0.0002678424
26 O 0 0.00035541705
% O 0 0.00037261526
( O 0 0.00045759964
p O 0 0.00041781054
< O 0 0.0004942189
0 O 0 0.00077381806
. O 0 0.0010322592
02 O 0 0.015726263
) O 0 0.0027431103
, O 0 0.003700775
respectively O 0 0.0074750492
. O 0 0.008490493

Number O 0 0.005036314
and O 0 0.0026035144
total O 0 0.0016117125
anionic O 0 0.06399999
site O 0 0.0011595555
surface O 0 0.0015874509
in O 0 0.0005547868
the O 0 0.0003910126
remaining O 0 0.00032662752
part O 0 0.00025437947
of O 0 0.00029589052
the O 0 0.00031321333
glomerular O 0 0.6939326
basement O 0 0.10496786
membrane O 0 0.0050593624
( O 0 0.0006253011
lamina O 0 0.0011182746
densa O 0 0.003737538
and O 0 0.0005048477
lamina O 0 0.004551834
rara O 0 0.74315757
interna O 0 0.80850595
) O 0 0.0016305859
were O 0 0.0010478613
not O 0 0.0013217359
significantly O 0 0.0022635877
changed O 0 0.004067332
. O 0 0.007064102

We O 0 0.003466092
conclude O 0 0.0019092597
that O 0 0.001661979
in O 0 0.0032901147
streptozotocin B-Chemical 0 0.9999981
- O 0 0.8461985
diabetic B-Disease 2 0.9999081
rats O 0 0.0017972538
with O 0 0.00042138706
an O 0 0.00039528645
increased O 0 0.00052530866
urinary O 0 0.81355906
albumin O 0 0.9995497
excretion O 0 0.98998004
, O 0 0.00071337173
a O 0 0.00033981595
reduced O 0 0.0004387173
heparan B-Chemical 0 0.9982791
sulphate I-Chemical 0 0.99983156
charge O 0 0.1425194
barrier O 0 0.016804734
/ O 0 0.004528187
density O 0 0.0005422462
is O 0 0.00023473574
found O 0 0.00019606652
at O 0 0.00020866192
the O 0 0.0003057474
lamina O 0 0.0024597957
rara O 0 0.61789304
externa O 0 0.9395715
of O 0 0.0012080017
the O 0 0.0014213895
glomerular O 0 0.8353457
basement O 0 0.28533342
membrane O 0 0.033207938
. O 0 0.008326214

Mediation O 0 0.10974087
of O 0 0.0042729303
enhanced O 0 0.0036035876
reflex O 0 0.8358314
vagal O 0 0.96745616
bradycardia B-Disease 0 0.9998462
by O 0 0.005661057
L B-Chemical 1 0.9997242
- I-Chemical 1 0.8178712
dopa I-Chemical 1 0.9999889
via O 0 0.0009632399
central O 0 0.0034122374
dopamine B-Chemical 1 0.99844176
formation O 0 0.004235238
in O 0 0.0029891615
dogs O 0 0.006747402
. O 0 0.007259592

L B-Chemical 0 0.9987386
- I-Chemical 0 0.82130516
Dopa I-Chemical 0 0.9999101
( O 0 0.0032854255
5 O 0 0.0011387141
mg O 0 0.015292468
/ O 0 0.0023022506
kg O 0 0.001794809
i O 0 0.002801553
. O 0 0.00048758934
v O 0 0.01613097
. O 0 0.00044196265
) O 0 0.000805844
decreased O 0 0.0005064404
blood O 0 0.013363387
pressure O 0 0.034550916
and O 0 0.0003395202
heart O 0 0.03126206
rate O 0 0.00025700888
after O 0 0.00018161332
extracerebral O 0 0.95716363
decarboxylase O 0 0.87302434
inhibition O 0 0.0021343192
with O 0 0.0024144491
MK B-Chemical 0 0.99840814
- I-Chemical 0 0.23080736
486 I-Chemical 0 0.40660143
( O 0 0.00043223123
25 O 0 0.00027919177
mg O 0 0.0070269313
/ O 0 0.00096188806
kg O 0 0.0008636876
i O 0 0.0014232777
. O 0 0.00032266896
v O 0 0.007406652
. O 0 0.0004761304
) O 0 0.00104239
in O 0 0.00095288875
anesthetize O 0 0.32345992
MAO B-Chemical 0 0.9999993
- O 0 0.049322918
inhibited O 0 0.0041836305
dogs O 0 0.009718273
. O 0 0.0074024117

In O 0 0.0037084576
addition O 0 0.0021175274
, O 0 0.004020049
reflex O 0 0.85436594
bradycardia B-Disease 0 0.9993729
caused O 0 0.0010013675
by O 0 0.0008123159
injected O 0 0.0012751033
norepinephrine B-Chemical 1 0.9999478
was O 0 0.00036332433
significantly O 0 0.00026452393
enhanced O 0 0.00029149512
by O 0 0.0010027833
L B-Chemical 1 0.9998865
- I-Chemical 1 0.9600493
dopa I-Chemical 1 0.9999993
, O 0 0.016630832
DL B-Chemical 0 0.9833483
- I-Chemical 0 0.116200216
Threo I-Chemical 0 0.29044682
- I-Chemical 0 0.038787257
dihydroxyphenylserine I-Chemical 0 0.22865172
had O 0 0.00020375426
no O 0 0.00014913698
effect O 0 0.00019367282
on O 0 0.00018377756
blood O 0 0.014804842
pressure O 0 0.062303536
, O 0 0.00066643103
heart O 0 0.022674581
rate O 0 0.00059282494
or O 0 0.0008043342
reflex O 0 0.20342378
responses O 0 0.0023123238
to O 0 0.0029051916
norepinephrine B-Chemical 1 0.9996897
. O 0 0.00694641

FLA B-Chemical 0 0.98249304
- I-Chemical 0 0.024699628
63 I-Chemical 0 0.0035510205
, O 0 0.0026877166
a O 0 0.0040224204
dopamine B-Chemical 1 0.99995327
- O 0 0.50572425
beta O 0 0.99701154
- O 0 0.7945107
oxidase O 0 0.9995128
inhibitor O 0 0.12602025
, O 0 0.0012810217
did O 0 0.00033728158
not O 0 0.00018952342
have O 0 0.00016849137
any O 0 0.00016988942
effect O 0 0.00017326965
on O 0 0.00015682765
the O 0 0.00061986933
hypotension B-Disease 2 0.9999945
, O 0 0.008294704
bradycardia B-Disease 0 0.99944454
or O 0 0.00060476904
reflex O 0 0.64689076
- O 0 0.005335886
enhancing O 0 0.0005983493
effect O 0 0.0009230223
of O 0 0.005947051
L B-Chemical 1 0.9996455
- I-Chemical 1 0.9166556
dopa I-Chemical 1 0.99997973
. O 0 0.009393034

Pimozide B-Chemical 0 0.99997497
did O 0 0.004271397
not O 0 0.0016122819
affect O 0 0.0009158331
the O 0 0.0008292905
actions O 0 0.002123616
of O 0 0.0056677763
L B-Chemical 1 0.9999043
- I-Chemical 1 0.92440975
dopa I-Chemical 1 0.99999535
on O 0 0.00031504137
blood O 0 0.010206336
pressure O 0 0.021424545
and O 0 0.00043737981
heart O 0 0.02432831
rate O 0 0.00044838822
but O 0 0.0005080299
completely O 0 0.00049119577
blocked O 0 0.0008830854
the O 0 0.0010523202
enhancement O 0 0.0027517092
of O 0 0.004676679
reflexes O 0 0.90155995
. O 0 0.007437646

Removal O 0 0.006427302
of O 0 0.0030020871
the O 0 0.002203762
carotid O 0 0.6256753
sinuses O 0 0.14666809
caused O 0 0.000983046
an O 0 0.0012173553
elevation O 0 0.22074789
blood O 0 0.047956295
pressure O 0 0.07218704
and O 0 0.00054433045
heart O 0 0.03294963
rate O 0 0.00038075654
and O 0 0.0003907929
abolished O 0 0.00043771043
the O 0 0.00048570416
negative O 0 0.0014150558
chronotropic O 0 0.91108054
effect O 0 0.0017512301
of O 0 0.010837753
norepinephrine B-Chemical 1 0.9998965
. O 0 0.007530248

However O 0 0.006478754
, O 0 0.01691439
L B-Chemical 1 0.99941635
- I-Chemical 1 0.89551127
dopa I-Chemical 1 0.99999
restored O 0 0.0016558721
the O 0 0.0013092502
bradycardia B-Disease 0 0.9987728
caused O 0 0.00073164667
by O 0 0.001365896
norepinephrine B-Chemical 1 0.9999051
in O 0 0.0003446693
addition O 0 0.00024646937
to O 0 0.00036331944
decreasing O 0 0.0006806714
blood O 0 0.013122617
pressure O 0 0.027769618
and O 0 0.0017892008
heart O 0 0.049636602
rate O 0 0.0042563626
. O 0 0.006907213

5 B-Chemical 0 0.005061679
- I-Chemical 0 0.0142038055
HTP I-Chemical 0 0.10755908
( O 0 0.0024040157
5 O 0 0.0011942192
mg O 0 0.011045845
/ O 0 0.0023693903
kg O 0 0.0018996829
i O 0 0.0027733145
. O 0 0.00054874644
v O 0 0.013791064
. O 0 0.0004964875
) O 0 0.00084099546
decreased O 0 0.00055758987
blood O 0 0.009714351
pressure O 0 0.023781307
and O 0 0.00044814832
heart O 0 0.020243866
rate O 0 0.00042766056
and O 0 0.000531758
decreased O 0 0.00077650824
the O 0 0.0010309623
reflex O 0 0.8604335
bradycardia B-Disease 0 0.99919707
to O 0 0.0033557776
norepinephrine B-Chemical 1 0.9997223
. O 0 0.0069015427

It O 0 0.0051817526
is O 0 0.003027026
concluded O 0 0.0023699482
that O 0 0.0024352286
L B-Chemical 1 0.9995586
- I-Chemical 1 0.8922241
dopa I-Chemical 1 0.99999285
enhances O 0 0.0012191695
reflex O 0 0.8932612
bradycardia B-Disease 0 0.9984669
through O 0 0.0007171589
central O 0 0.0021662682
alpha O 0 0.70574766
- O 0 0.075232014
receptor O 0 0.048397984
stimulation O 0 0.005811242
. O 0 0.008266886

Furthermore O 0 0.004797136
, O 0 0.0033735167
the O 0 0.0016999566
effects O 0 0.0014182925
are O 0 0.0008154954
mediated O 0 0.00056096364
through O 0 0.0007060721
dopamine B-Chemical 1 0.99950576
rather O 0 0.0005440755
than O 0 0.0005308998
norepinephrine B-Chemical 1 0.9996107
and O 0 0.0005542342
do O 0 0.00048573007
not O 0 0.00048609922
require O 0 0.00062684796
the O 0 0.0012610315
carotid O 0 0.59552616
sinus O 0 0.06254927
baroreceptors O 0 0.038408212
. O 0 0.00650828

Microangiopathic B-Disease 0 0.9990796
hemolytic I-Disease 2 0.99999905
anemia I-Disease 2 0.99999976
complicating O 0 0.9974794
FK506 B-Chemical 1 0.9999975
( O 0 0.5461399
tacrolimus B-Chemical 0 0.999992
) O 0 0.04228381
therapy O 0 0.016615946
. O 0 0.011218697

We O 0 0.00370887
describe O 0 0.0023441913
3 O 0 0.0018222826
episodes O 0 0.0043041795
of O 0 0.0044293264
microangiopathic B-Disease 0 0.9999914
hemolytic I-Disease 2 1.0
anemia I-Disease 2 1.0
( O 0 0.8021418
MAHA B-Disease 2 0.9999956
) O 0 0.0040216492
in O 0 0.0003688626
2 O 0 0.00032798212
solid O 0 0.0012214966
organ O 0 0.0015397216
recipients O 0 0.00078388234
under O 0 0.0007493893
FK506 B-Chemical 1 0.9999871
( O 0 0.12825102
tacrolimus B-Chemical 0 0.9999924
) O 0 0.022297846
therapy O 0 0.0105391545
. O 0 0.0072438177

In O 0 0.0036680594
both O 0 0.0023741212
cases O 0 0.002789743
, O 0 0.0027159888
discontinuation O 0 0.6013308
of O 0 0.0037083675
FK506 B-Chemical 1 0.99998903
and O 0 0.0018909476
treatment O 0 0.0007526335
with O 0 0.0004955813
plasma O 0 0.015155426
exchange O 0 0.0004914103
, O 0 0.00039199507
fresh O 0 0.00051387417
frozen O 0 0.0010621541
plasma O 0 0.010237396
replacement O 0 0.0038134283
, O 0 0.0021623261
corticosteroids B-Chemical 1 0.9999033
, O 0 0.04207441
aspirin B-Chemical 0 0.99999547
, O 0 0.0023043226
and O 0 0.0016303367
dipyridamole B-Chemical 0 0.99988914
led O 0 0.0009195532
to O 0 0.0010702275
resolution O 0 0.03547824
of O 0 0.009715208
MAHA B-Disease 2 0.99985445
. O 0 0.009438099

In O 0 0.0049517886
one O 0 0.0032510895
patient O 0 0.002828384
, O 0 0.0028456524
reintroduction O 0 0.0041945865
of O 0 0.0036648156
FK506 B-Chemical 1 0.99994063
led O 0 0.002364129
to O 0 0.0019077866
rapid O 0 0.0061598103
recurrence O 0 0.859908
of O 0 0.027047094
MAHA B-Disease 2 0.9998921
. O 0 0.012840039

FK506 B-Chemical 1 0.99994075
- O 0 0.38424015
associated O 0 0.016492946
MAHA B-Disease 2 0.99990666
is O 0 0.0022225385
probably O 0 0.0020520897
rare O 0 0.0034979375
but O 0 0.0010184189
physicians O 0 0.0009033711
must O 0 0.00051901344
be O 0 0.00075075735
aware O 0 0.00094456103
of O 0 0.0014443203
this O 0 0.0021337657
severe O 0 0.15663551
complication O 0 0.55256736
. O 0 0.008550372

In O 0 0.0037118979
our O 0 0.002370416
experience O 0 0.0018783968
and O 0 0.0012263509
according O 0 0.0006622785
to O 0 0.00052804686
the O 0 0.0004940123
literature O 0 0.0010258055
, O 0 0.0021300307
FK506 B-Chemical 1 0.99997985
does O 0 0.0005747062
not O 0 0.00025228123
seem O 0 0.00024124728
to O 0 0.00018522785
cross O 0 0.00048491513
- O 0 0.004489051
react O 0 0.0008082157
with O 0 0.0020245411
cyclosporin B-Chemical 1 0.9999999
A I-Chemical 1 0.9973456
( O 0 0.06596259
CyA B-Chemical 0 0.99999344
) O 0 0.0064378707
, O 0 0.0006500738
an O 0 0.0006028616
immuno O 0 0.74194074
- O 0 0.024297182
suppressive O 0 0.0023857928
drug O 0 0.21802247
already O 0 0.0007670377
known O 0 0.0012516748
to O 0 0.0014978916
induce O 0 0.0029172306
MAHA B-Disease 2 0.99979955
. O 0 0.009285446

Effect O 0 0.0050130878
of O 0 0.0037637183
some O 0 0.0031249288
anticancer O 0 0.5356141
drugs O 0 0.29680517
and O 0 0.0023470102
combined O 0 0.0027639314
chemotherapy O 0 0.111162834
on O 0 0.003007847
renal B-Disease 0 0.9995433
toxicity I-Disease 2 0.9999484
. O 0 0.015164823

The O 0 0.0041450392
nephrotoxic B-Disease 2 0.9990232
action O 0 0.0061805737
of O 0 0.002585418
anticancer O 0 0.8407203
drugs O 0 0.37066624
such O 0 0.0005825851
as O 0 0.00078463985
nitrogranulogen B-Chemical 0 0.99939895
( O 0 0.032980047
NG B-Chemical 0 0.9977563
) O 0 0.005611271
, O 0 0.0033416918
methotrexate B-Chemical 1 0.9999808
( O 0 0.04571316
MTX B-Chemical 1 0.99999726
) O 0 0.0038627123
, O 0 0.0004494347
5 B-Chemical 0 0.00021713908
- I-Chemical 0 0.013112178
fluorouracil I-Chemical 0 0.9982498
( O 0 0.00054801983
5 B-Chemical 0 0.00021482586
- I-Chemical 0 0.00837925
FU I-Chemical 0 0.44566482
) O 0 0.0006033774
and O 0 0.0006578969
cyclophosphamide B-Chemical 0 0.9999647
( O 0 0.053981777
CY B-Chemical 1 0.9999906
) O 0 0.0024636607
administered O 0 0.00021006087
alone O 0 0.00017150889
or O 0 0.00016857752
in O 0 0.00019012507
combination O 0 0.0009629353
[ O 0 0.14108157
MTX B-Chemical 1 0.999997
+ O 0 0.017485816
5 B-Chemical 0 0.00030764364
- I-Chemical 0 0.027816053
FU I-Chemical 0 0.84687734
+ O 0 0.05633515
CY B-Chemical 1 0.9999852
( O 0 0.01368546
CMF O 0 0.95065236
) O 0 0.0015468686
] O 0 0.00092561764
was O 0 0.0004525878
evaluated O 0 0.00046293222
in O 0 0.0006882518
experiments O 0 0.000857897
on O 0 0.0015105976
Wistar O 0 0.010938313
rats O 0 0.0051196762
. O 0 0.0068675065

After O 0 0.0029940726
drug O 0 0.16206545
administration O 0 0.04892728
, O 0 0.0051413737
creatinine B-Chemical 1 0.99879104
concentrations O 0 0.0048811515
in O 0 0.0005194462
the O 0 0.0004123482
plasma O 0 0.0058285105
and O 0 0.00034912655
in O 0 0.0002644266
the O 0 0.00029454264
urine O 0 0.087469265
of O 0 0.00031869454
the O 0 0.00026890144
rats O 0 0.00037112104
were O 0 0.0002747851
determined O 0 0.00029760753
, O 0 0.00056530104
as O 0 0.0005596056
well O 0 0.000850731
as O 0 0.0016278806
creatinine B-Chemical 1 0.99692386
clearance O 0 0.18778092
. O 0 0.007808328

Histopathologic O 0 0.045142114
evaluation O 0 0.0063129524
of O 0 0.006144037
the O 0 0.0056565446
kidneys O 0 0.012239367
was O 0 0.0066172476
also O 0 0.0072345342
performed O 0 0.0096002985
. O 0 0.015005821

After O 0 0.0039752196
MTX B-Chemical 1 0.99988425
administration O 0 0.036064044
a O 0 0.0016440502
significant O 0 0.0008820619
increase O 0 0.0006164182
( O 0 0.0010174385
p O 0 0.00059938215
= O 0 0.00095659733
0 O 0 0.00043418634
. O 0 0.00029917763
0228 O 0 0.0013917238
) O 0 0.00042195144
in O 0 0.00020536962
the O 0 0.00022018797
plasma O 0 0.02250812
creatinine B-Chemical 1 0.99601716
concentration O 0 0.0006341686
and O 0 0.0002517766
a O 0 0.00024173311
significant O 0 0.00021079177
( O 0 0.0003858686
p O 0 0.00027145311
= O 0 0.00054554566
0 O 0 0.00029395492
. O 0 0.00024745433
0001 O 0 0.0053230603
) O 0 0.00045952506
decrease O 0 0.00029630918
in O 0 0.0004507326
creatinine B-Chemical 1 0.99676883
clearance O 0 0.02583162
was O 0 0.00065261836
noted O 0 0.00067543203
compared O 0 0.00093887787
to O 0 0.0017788775
controls O 0 0.0045133927
. O 0 0.006526217

After O 0 0.0027396907
the O 0 0.0022926095
administration O 0 0.0063382965
of O 0 0.0034272512
NG B-Chemical 0 0.9932468
, O 0 0.002168551
5 B-Chemical 0 0.00076139695
- I-Chemical 0 0.020158578
FU I-Chemical 0 0.64055705
and O 0 0.0014366172
CY B-Chemical 1 0.9999182
neither O 0 0.00036587764
a O 0 0.00036601513
statistically O 0 0.00019873107
significant O 0 0.00018917119
increase O 0 0.00016865823
in O 0 0.00031492216
creatinine B-Chemical 1 0.99812263
concentration O 0 0.0010403937
nor O 0 0.0002228734
an O 0 0.00023380254
increase O 0 0.00016516038
in O 0 0.00033463442
creatinine B-Chemical 1 0.99871075
clearance O 0 0.039093856
was O 0 0.00026904608
observed O 0 0.0002114692
compared O 0 0.00022282833
to O 0 0.0003187553
the O 0 0.00049629115
group O 0 0.000952926
receiving O 0 0.001528574
no O 0 0.0019326544
cytostatics O 0 0.9569846
. O 0 0.007926043

Following O 0 0.0046367594
polytherapy O 0 0.9831892
according O 0 0.0013036198
to O 0 0.00095899013
the O 0 0.0010797416
CMF O 0 0.9811586
regimen O 0 0.009951084
, O 0 0.0007298801
a O 0 0.00043249558
statistically O 0 0.00025453008
significant O 0 0.00025333554
decrease O 0 0.0002839621
( O 0 0.00054660614
p O 0 0.000325385
= O 0 0.00063471886
0 O 0 0.00029043818
. O 0 0.00021607052
0343 O 0 0.0019443284
) O 0 0.00039972094
in O 0 0.00027586738
creatinine B-Chemical 1 0.9970483
clearance O 0 0.03580558
was O 0 0.00027482884
found O 0 0.00023083948
, O 0 0.00044039715
but O 0 0.00060687686
creatinine B-Chemical 1 0.9974481
concentration O 0 0.0013342655
did O 0 0.00041733286
not O 0 0.0003525332
increase O 0 0.00045383003
significantly O 0 0.0007322961
compared O 0 0.0009168858
to O 0 0.001734932
controls O 0 0.0045289006
. O 0 0.0063824

CY B-Chemical 1 0.99978954
caused O 0 0.034751415
hemorrhagic B-Disease 2 0.99998844
cystitis I-Disease 0 0.9999943
in O 0 0.0027349785
40 O 0 0.0009186241
% O 0 0.0007115157
of O 0 0.0005836817
rats O 0 0.00085600134
, O 0 0.00066335115
but O 0 0.0004923996
it O 0 0.00037575117
did O 0 0.00030871635
not O 0 0.00022961416
cause O 0 0.0003463462
this O 0 0.000319886
complication O 0 0.028243069
when O 0 0.00025964226
combined O 0 0.0004944988
with O 0 0.0006508323
5 B-Chemical 0 0.00081752066
- I-Chemical 0 0.010537744
FU I-Chemical 0 0.54381114
and O 0 0.0054316656
MTX B-Chemical 1 0.99990594
. O 0 0.008895934

Histologic O 0 0.02166958
changes O 0 0.0029700238
were O 0 0.0015871888
found O 0 0.0010331341
in O 0 0.00085411395
rat O 0 0.0015402708
kidneys O 0 0.0058379984
after O 0 0.00032534462
administration O 0 0.006358944
of O 0 0.0061856047
MTX B-Chemical 1 0.99999905
, O 0 0.08977748
CY B-Chemical 1 0.9999944
and O 0 0.012527625
NG B-Chemical 0 0.99704105
, O 0 0.0005727396
while O 0 0.00021580531
no O 0 0.00012656229
such O 0 0.00015182802
change O 0 0.00021278669
was O 0 0.0001608495
observed O 0 0.00013039673
after O 0 0.000118511234
5 B-Chemical 0 0.0001822884
- I-Chemical 0 0.0058135455
FU I-Chemical 0 0.2512648
and O 0 0.00026916226
joint O 0 0.01206767
administration O 0 0.003999328
of O 0 0.001892469
MTX B-Chemical 1 0.99999654
+ O 0 0.018236367
5 B-Chemical 0 0.000501543
- I-Chemical 0 0.02513298
FU I-Chemical 0 0.757833
+ O 0 0.01616249
CY B-Chemical 1 0.99956757
compared O 0 0.0012688102
to O 0 0.0020517178
controls O 0 0.0048899767
. O 0 0.006815332

Our O 0 0.003630599
studies O 0 0.0021941066
indicate O 0 0.0012884247
that O 0 0.0016359417
nephrotoxicity B-Disease 0 0.99999774
of O 0 0.13171895
MTX B-Chemical 1 0.9999989
+ O 0 0.09114868
5 B-Chemical 0 0.0007439432
- I-Chemical 0 0.041731086
FU I-Chemical 0 0.8463489
+ O 0 0.028765172
CY B-Chemical 1 0.99990225
administered O 0 0.00079277396
jointly O 0 0.0028772834
is O 0 0.00076455466
lower O 0 0.0009073339
than O 0 0.0010500237
in O 0 0.0022247266
monotherapy O 0 0.22895181
. O 0 0.0066761686

The O 0 0.0042583016
interpeduncular O 0 0.07405582
nucleus O 0 0.0030475045
regulates O 0 0.0013238025
nicotine B-Chemical 1 0.9986951
' O 0 0.0022808348
s O 0 0.0015983126
effects O 0 0.0013758563
on O 0 0.0011649688
free O 0 0.0024277952
- O 0 0.0077083223
field O 0 0.004888708
activity O 0 0.0054533
. O 0 0.0089494

Partial O 0 0.006919561
lesions O 0 0.078470424
were O 0 0.0019737592
made O 0 0.0014357284
with O 0 0.004497637
kainic B-Chemical 0 0.99999845
acid I-Chemical 0 0.941731
in O 0 0.00065286784
the O 0 0.00054000027
interpeduncular O 0 0.13724087
nucleus O 0 0.00051373115
of O 0 0.0004856481
the O 0 0.000604004
ventral O 0 0.0032200252
midbrain O 0 0.13960965
of O 0 0.0017935486
the O 0 0.0025705306
rat O 0 0.0070946747
. O 0 0.007157508

Compared O 0 0.003292297
with O 0 0.0024528038
sham O 0 0.0022922668
- O 0 0.0050508576
operated O 0 0.0019167525
controls O 0 0.0013056588
, O 0 0.0011003871
lesions O 0 0.20013286
significantly O 0 0.0005447662
( O 0 0.0005515287
p O 0 0.00030592032
< O 0 0.00024194249
0 O 0 0.0002772353
. O 0 0.00020727981
25 O 0 0.00026455318
) O 0 0.00037897396
blunted O 0 0.0013167596
the O 0 0.000208689
early O 0 0.00045620516
( O 0 0.00038736532
< O 0 0.00016040257
60 O 0 0.00016143217
min O 0 0.00022528184
) O 0 0.0003428202
free O 0 0.0003829158
- O 0 0.020337531
field O 0 0.0055779624
locomotor B-Disease 0 0.9984989
hypoactivity I-Disease 0 0.999984
caused O 0 0.0002723433
by O 0 0.0007271421
nicotine B-Chemical 1 0.99990964
( O 0 0.0009838295
0 O 0 0.0002324961
. O 0 0.00013445424
5 O 0 0.00012431554
mg O 0 0.0012615
kg O 0 0.00053726515
( O 0 0.0004943553
- O 0 0.0043755136
1 O 0 0.00021854336
) O 0 0.00041939953
, O 0 0.00035961662
i O 0 0.001853084
. O 0 0.00023166476
m O 0 0.0028402708
. O 0 0.00025041107
) O 0 0.0005330888
, O 0 0.00029407963
enhanced O 0 0.00018786959
the O 0 0.00018169924
later O 0 0.00016735677
( O 0 0.00030447711
60 O 0 0.00021867822
- O 0 0.0007199318
120 O 0 0.00019098828
min O 0 0.0003048556
) O 0 0.001706035
nicotine B-Chemical 1 0.9998723
- O 0 0.03525993
induced O 0 0.0011880605
hyperactivity B-Disease 2 0.9999616
, O 0 0.0010474564
and O 0 0.00080028415
raised O 0 0.0012997257
spontaneous O 0 0.008928422
nocturnal O 0 0.09634955
activity O 0 0.0036693683
. O 0 0.006368665

Lesions O 0 0.08018138
reduced O 0 0.0023276128
the O 0 0.0013099961
extent O 0 0.0007454085
of O 0 0.00080773764
immunohistological O 0 0.013082434
staining O 0 0.0019546538
for O 0 0.0010991462
choline B-Chemical 1 0.9999738
acetyltransferase O 0 0.9925315
in O 0 0.00031619417
the O 0 0.00028402603
interpeduncular O 0 0.27184772
nucleus O 0 0.000315587
( O 0 0.0002708417
p O 0 0.00019424017
< O 0 0.00018753957
0 O 0 0.00026038423
. O 0 0.0002507659
025 O 0 0.059379615
) O 0 0.00072118087
, O 0 0.000418096
but O 0 0.00030779236
not O 0 0.00024496042
for O 0 0.0004543731
tyrosine B-Chemical 1 0.9885146
hydroxylase O 0 0.99628437
in O 0 0.0005379033
the O 0 0.0006751077
surrounding O 0 0.0017197077
catecholaminergic O 0 0.3450325
A10 O 0 0.4453143
region O 0 0.0043569035
. O 0 0.006861382

We O 0 0.003198636
conclude O 0 0.0016737514
that O 0 0.0012868751
the O 0 0.0012576322
interpeduncular O 0 0.25848904
nucleus O 0 0.0011458357
mediates O 0 0.00059506774
nicotinic O 0 0.99987185
depression B-Disease 0 0.9996693
of O 0 0.0011144537
locomotor O 0 0.5130593
activity O 0 0.00033700757
and O 0 0.0003924468
dampens O 0 0.00097625324
nicotinic O 0 0.9991485
arousal O 0 0.23412398
mechanisms O 0 0.0004086407
located O 0 0.00059550017
elsewhere O 0 0.0009834461
in O 0 0.0012027834
the O 0 0.0021130554
brain O 0 0.016104845
. O 0 0.0065915077

Lithium B-Chemical 1 0.99996233
- O 0 0.07897499
associated O 0 0.0028471125
cognitive B-Disease 0 0.50892186
and I-Disease 0 0.0012619728
functional I-Disease 0 0.0010328932
deficits I-Disease 0 0.24085009
reduced O 0 0.0005680545
by O 0 0.0005310066
a O 0 0.0005800613
switch O 0 0.0006837639
to O 0 0.0009789547
divalproex B-Chemical 0 0.9999871
sodium I-Chemical 0 0.9993943
: O 0 0.002597904
a O 0 0.0020044625
case O 0 0.0026613732
series O 0 0.0046880012
. O 0 0.0068273945

BACKGROUND O 0 0.05955735
: O 0 0.013772108
Lithium B-Chemical 1 0.9998802
remains O 0 0.0019037494
a O 0 0.0014590971
first O 0 0.00083378225
- O 0 0.0051452075
line O 0 0.0008507618
treatment O 0 0.0006359869
for O 0 0.00048097965
the O 0 0.0005626997
acute O 0 0.40177998
and O 0 0.000935061
maintenance O 0 0.0012497588
treatment O 0 0.001692615
of O 0 0.0056938003
bipolar B-Disease 2 0.999819
disorder I-Disease 0 0.9927908
. O 0 0.008074562

Although O 0 0.0033434725
much O 0 0.0021676393
has O 0 0.0014843661
been O 0 0.0011355404
written O 0 0.0009413528
about O 0 0.00055259897
the O 0 0.00047001522
management O 0 0.0005097832
of O 0 0.00040787336
the O 0 0.00031955252
more O 0 0.00035872412
common O 0 0.0004638693
adverse O 0 0.16819777
effects O 0 0.0005424375
of O 0 0.0027942145
lithium B-Chemical 0 0.9999856
, O 0 0.00074259803
such O 0 0.00022138236
as O 0 0.00036681973
polyuria B-Disease 2 0.99917823
and O 0 0.005104688
tremor B-Disease 0 0.99999475
, O 0 0.00082953507
more O 0 0.00033290466
subtle O 0 0.004827206
lithium B-Chemical 0 0.99994314
side O 0 0.027794603
effects O 0 0.00028323315
such O 0 0.00018361642
as O 0 0.00035226007
cognitive B-Disease 2 0.99861217
deficits I-Disease 2 0.99217856
, O 0 0.0005958544
loss B-Disease 0 0.0017934726
of I-Disease 0 0.0007158448
creativity I-Disease 0 0.77929336
, O 0 0.00088947127
and O 0 0.00088618643
functional B-Disease 0 0.0049827094
impairments I-Disease 0 0.9235044
remain O 0 0.0025905098
understudied O 0 0.01563807
. O 0 0.0067224475

This O 0 0.005122801
report O 0 0.0033548847
summarizes O 0 0.0015826178
our O 0 0.0011510497
experience O 0 0.0010465423
in O 0 0.0007324331
switching O 0 0.0016576989
bipolar B-Disease 2 0.99850357
patients O 0 0.00091252715
from O 0 0.0004609112
lithium B-Chemical 0 0.999918
to O 0 0.00092064205
divalproex B-Chemical 0 0.99999285
sodium I-Chemical 0 0.99899644
to O 0 0.00037011833
alleviate O 0 0.0005420912
such O 0 0.000628787
cognitive B-Disease 0 0.45772704
and I-Disease 0 0.001693463
functional I-Disease 0 0.011534715
impairments I-Disease 0 0.96736443
. O 0 0.006996269

METHOD O 0 0.023427261
: O 0 0.016804805
Open O 0 0.017398475
, O 0 0.014056045
case O 0 0.012982578
series O 0 0.016498951
design O 0 0.021438198
. O 0 0.024315549

RESULTS O 0 0.0056115366
: O 0 0.003568377
We O 0 0.0018715737
report O 0 0.0018161382
seven O 0 0.00093044905
cases O 0 0.0010817673
where O 0 0.0008335877
substitution O 0 0.19344707
of O 0 0.008143413
lithium B-Chemical 0 0.9999883
, O 0 0.0013139434
either O 0 0.00028414305
fully O 0 0.0002125225
or O 0 0.00018787067
partially O 0 0.0002429999
, O 0 0.0005261483
with O 0 0.002500976
divalproex B-Chemical 0 0.9999968
sodium I-Chemical 0 0.99979347
was O 0 0.00026985377
extremely O 0 0.0006118591
helpful O 0 0.00020182478
in O 0 0.00014617182
reducing O 0 0.00019885371
the O 0 0.00024286879
cognitive B-Disease 0 0.7257251
, I-Disease 0 0.0005262882
motivational I-Disease 0 0.02701374
, I-Disease 0 0.00038136277
or I-Disease 0 0.00028716025
creative I-Disease 0 0.018244
deficits I-Disease 0 0.26547593
attributed O 0 0.00033008098
to O 0 0.00057042064
lithium B-Chemical 0 0.9996258
in O 0 0.0010933402
our O 0 0.001976883
bipolar B-Disease 2 0.99633265
patients O 0 0.006212931
. O 0 0.0063693533

CONCLUSION O 0 0.022164894
: O 0 0.003914039
In O 0 0.0017886653
this O 0 0.001231593
preliminary O 0 0.0012404444
report O 0 0.003275653
, O 0 0.014309321
divalproex B-Chemical 0 0.9999958
sodium I-Chemical 0 0.9998561
was O 0 0.00049911364
a O 0 0.00035058593
superior O 0 0.00034645287
alternative O 0 0.000183989
to O 0 0.0002545874
lithium B-Chemical 0 0.9998807
in O 0 0.0005595987
bipolar B-Disease 2 0.9992599
patients O 0 0.0011029394
experiencing O 0 0.09521089
cognitive B-Disease 2 0.998818
deficits I-Disease 2 0.99144125
, O 0 0.00072257733
loss B-Disease 0 0.0020003344
of I-Disease 0 0.001055005
creativity I-Disease 0 0.77823734
, O 0 0.0016480215
and O 0 0.0019430529
functional B-Disease 0 0.01380247
impairments I-Disease 0 0.9694801
. O 0 0.007389375

Effect O 0 0.005627324
of O 0 0.0064847665
nifedipine B-Chemical 1 0.99998236
on O 0 0.0020651293
renal O 0 0.65595055
function O 0 0.0017358614
in O 0 0.0017586105
liver O 0 0.57643574
transplant O 0 0.26012754
recipients O 0 0.007970297
receiving O 0 0.026110645
tacrolimus B-Chemical 0 0.99995124
. O 0 0.012063231

The O 0 0.0032657462
effect O 0 0.0025760366
of O 0 0.0040854053
nifedipine B-Chemical 1 0.99999356
on O 0 0.00096557004
renal O 0 0.725111
function O 0 0.0007238014
in O 0 0.000619229
liver O 0 0.5715366
transplant O 0 0.12598693
recipients O 0 0.0010000508
who O 0 0.0006074656
were O 0 0.00032708186
receiving O 0 0.00084247615
tacrolimus B-Chemical 0 0.99995804
was O 0 0.00043443745
evaluated O 0 0.0003761124
between O 0 0.0004786309
January O 0 0.0008812232
1992 O 0 0.001845431
and O 0 0.0017308571
January O 0 0.002820147
1996 O 0 0.006519237
. O 0 0.007017402

Two O 0 0.0036675713
groups O 0 0.0023913078
of O 0 0.0018305122
patients O 0 0.0019736483
receiving O 0 0.0035493134
tacrolimus B-Chemical 0 0.9999846
were O 0 0.0005718539
compared O 0 0.00024258808
over O 0 0.00018637425
a O 0 0.00024609978
period O 0 0.00017143613
of O 0 0.00025033398
1 O 0 0.00021351589
year O 0 0.00021858442
, O 0 0.00027995702
one O 0 0.0001729798
group O 0 0.00025403115
comprising O 0 0.00036443752
hypertensive B-Disease 2 0.9994709
patients O 0 0.00045485736
who O 0 0.00034461851
were O 0 0.00021831907
receiving O 0 0.0012701758
nifedipine B-Chemical 1 0.9999974
, O 0 0.0006100208
and O 0 0.0003053635
the O 0 0.00026344546
other O 0 0.00037590915
comprising O 0 0.0007213908
nonhypertensive O 0 0.9979716
patients O 0 0.0013699848
not O 0 0.0013134743
receiving O 0 0.011274841
nifedipine B-Chemical 1 0.99997973
. O 0 0.008240325

The O 0 0.004003726
time O 0 0.0025985728
from O 0 0.0024089518
transplant O 0 0.006085281
to O 0 0.0017774928
baseline O 0 0.0017632346
was O 0 0.0017676076
similar O 0 0.001697226
in O 0 0.0025160713
all O 0 0.0035559353
patients O 0 0.0068544457
. O 0 0.009179355

Nifedipine B-Chemical 0 0.9999572
significantly O 0 0.0039833062
improved O 0 0.0031171385
kidney O 0 0.27470598
function O 0 0.0009525515
as O 0 0.0005945615
indicated O 0 0.00039373248
by O 0 0.00042169908
a O 0 0.00044539693
significant O 0 0.00037463274
lowering O 0 0.0039121914
of O 0 0.0006294388
serum O 0 0.65156
creatinine B-Chemical 1 0.99898213
levels O 0 0.0005540647
at O 0 0.00053804973
6 O 0 0.0006433664
and O 0 0.0011142473
12 O 0 0.0015342005
months O 0 0.002433546
. O 0 0.00559464

The O 0 0.0028248762
observed O 0 0.0018353368
positive O 0 0.0016715339
impact O 0 0.0010707704
of O 0 0.0030226703
nifedipine B-Chemical 1 0.99999726
on O 0 0.00043177322
reducing O 0 0.00071691326
the O 0 0.0011154392
nephrotoxicity B-Disease 0 0.9999993
associated O 0 0.002699041
with O 0 0.0045426926
tacrolimus B-Chemical 0 0.9999974
in O 0 0.00075218035
liver O 0 0.79931456
transplant O 0 0.13988982
recipients O 0 0.00052642816
should O 0 0.00012230211
be O 0 0.00016170189
an O 0 0.00019723448
important O 0 0.00016840351
factor O 0 0.0021280737
in O 0 0.0002641895
selecting O 0 0.00027962972
an O 0 0.00042824232
agent O 0 0.008732852
to O 0 0.0005211808
treat O 0 0.005134279
hypertension B-Disease 2 0.9999813
in O 0 0.0014519313
this O 0 0.002000403
population O 0 0.0049196435
. O 0 0.00643505

Alpha O 0 0.4657285
and O 0 0.009081672
beta O 0 0.9934882
coma B-Disease 0 0.9999609
in O 0 0.0061524934
drug O 0 0.9636687
intoxication O 0 0.9999331
uncomplicated O 0 0.94456613
by O 0 0.013764738
cerebral B-Disease 0 0.9998097
hypoxia I-Disease 2 0.9997396
. O 0 0.013755874

Four O 0 0.0050391965
patients O 0 0.0034459138
who O 0 0.002518399
were O 0 0.0014434961
rendered O 0 0.0017558325
comatose B-Disease 0 0.9712941
or O 0 0.0012902741
stuporous B-Disease 0 0.99851507
by O 0 0.0009711814
drug O 0 0.84895873
intoxication O 0 0.9998778
, O 0 0.001980909
but O 0 0.00076154637
who O 0 0.00082955434
were O 0 0.0006039669
not O 0 0.00081113016
hypoxic O 0 0.75506383
, O 0 0.0025913022
are O 0 0.0024230666
described O 0 0.0035177956
. O 0 0.006641701

Three O 0 0.0039798105
patients O 0 0.0025954486
received O 0 0.0013474989
high O 0 0.0014745507
doses O 0 0.008078498
of O 0 0.012758466
chlormethiazole B-Chemical 0 0.99999976
for O 0 0.02328942
alcohol B-Chemical 0 0.9999974
withdrawal B-Disease 0 0.99917585
symptoms I-Disease 0 0.98547757
, O 0 0.0007025094
and O 0 0.00042849508
one O 0 0.0003845308
took O 0 0.0005391617
a O 0 0.0018633067
suicidal O 0 0.99996865
overdose B-Disease 0 0.9999858
of O 0 0.1917943
nitrazepam B-Chemical 0 0.99999964
. O 0 0.01097024

The O 0 0.0031498414
patient O 0 0.0029438008
with O 0 0.025043247
nitrazepam B-Chemical 0 1.0
overdose B-Disease 0 0.99999213
and O 0 0.0012925521
two O 0 0.0003706921
of O 0 0.00043711602
those O 0 0.0006418056
with O 0 0.004438596
chlormethiazole B-Chemical 0 0.9999999
intoxication O 0 0.9998709
conformed O 0 0.0005876203
to O 0 0.00014077606
the O 0 0.0001402074
criteria O 0 0.00019169122
of O 0 0.0003111888
' O 0 0.0038347507
alpha O 0 0.9872666
coma B-Disease 0 0.9999957
' O 0 0.0033106944
, O 0 0.0004241527
showing O 0 0.00030714014
non O 0 0.0012652882
- O 0 0.025704887
reactive O 0 0.29468232
generalized O 0 0.039780263
or O 0 0.00049178046
frontally O 0 0.50559145
predominant O 0 0.0009962745
alpha O 0 0.39080176
activity O 0 0.0013874433
in O 0 0.001605151
the O 0 0.0029130923
EEG O 0 0.8891427
. O 0 0.006662686

The O 0 0.0033479147
fourth O 0 0.0032265764
patient O 0 0.0019557022
who O 0 0.0017393221
was O 0 0.0009962228
unconscious O 0 0.02048707
after O 0 0.0007424204
chlormethiazole B-Chemical 0 0.9999994
administration O 0 0.14178623
exhibite O 0 0.49701217
generalized O 0 0.1093044
non O 0 0.00456593
- O 0 0.032779492
reactive O 0 0.16380994
activity O 0 0.00064300443
in O 0 0.0006877453
the O 0 0.0009821296
slow O 0 0.002734093
beta O 0 0.65322864
range O 0 0.0059553077
. O 0 0.007581047

All O 0 0.0032494152
four O 0 0.0020123252
recovered O 0 0.0015004777
completely O 0 0.0014388366
without O 0 0.0017091304
neurological B-Disease 0 0.9988877
sequelae I-Disease 0 0.9826341
following O 0 0.0008675076
the O 0 0.0009766406
withdrawal O 0 0.086204894
of O 0 0.0016765178
the O 0 0.002221321
offending O 0 0.5178628
agents O 0 0.052807916
. O 0 0.007989274

The O 0 0.002844726
similarities O 0 0.0019136246
between O 0 0.001238858
the O 0 0.0010646392
effects O 0 0.0009903262
of O 0 0.00085013104
structural O 0 0.0027041053
lesions O 0 0.40398583
and O 0 0.0008810015
pharmacological O 0 0.13926
depression B-Disease 0 0.99768543
of O 0 0.0005662982
the O 0 0.00053599145
brain O 0 0.01172378
stem O 0 0.020221874
reticular O 0 0.14344439
formation O 0 0.0035140035
are O 0 0.0021666514
discussed O 0 0.003217073
. O 0 0.0061616413

It O 0 0.004685213
is O 0 0.0024790484
suggested O 0 0.0014457679
that O 0 0.0010284764
in O 0 0.0008636403
both O 0 0.0006767923
situations O 0 0.0007289637
disturbed O 0 0.0071303016
reticulo O 0 0.34326044
- O 0 0.033436418
thalamic O 0 0.10257853
interactions O 0 0.0005129192
are O 0 0.00035593382
important O 0 0.00035138617
in O 0 0.00051896094
the O 0 0.0007397459
pathogenesis O 0 0.0029155586
of O 0 0.0044752965
alpha O 0 0.9843465
coma B-Disease 0 0.9999622
. O 0 0.011167548

It O 0 0.004550296
is O 0 0.0024252613
concluded O 0 0.001537093
that O 0 0.00091213465
when O 0 0.0006550705
this O 0 0.00068075384
electroencephalographic O 0 0.52261585
and O 0 0.0005029035
behavioural O 0 0.006088713
picture O 0 0.00035532765
is O 0 0.0002583656
seen O 0 0.00024185368
in O 0 0.0003308235
drug O 0 0.79796237
intoxication O 0 0.9998518
, O 0 0.00080590387
in O 0 0.00020685767
the O 0 0.00017690126
absence O 0 0.00016071292
of O 0 0.0003868013
significant O 0 0.0008749373
hypoxaemia B-Disease 0 0.9998016
, O 0 0.0010672138
a O 0 0.0007295818
favourable O 0 0.002081249
outcome O 0 0.0014388586
may O 0 0.0012343246
be O 0 0.0021037194
anticipated O 0 0.0036162352
. O 0 0.0065729865

Magnetic O 0 0.3260883
resonance O 0 0.28577462
volumetry O 0 0.011115715
of O 0 0.0027459173
the O 0 0.0023003027
cerebellum O 0 0.087215774
in O 0 0.0026871688
epileptic B-Disease 0 0.99988794
patients O 0 0.005941165
after O 0 0.003423306
phenytoin B-Chemical 1 0.9999969
overdosages B-Disease 0 0.99784005
. O 0 0.010730119

The O 0 0.003164556
aim O 0 0.0023929088
of O 0 0.0017737006
this O 0 0.001212823
study O 0 0.0010343994
was O 0 0.0005887527
to O 0 0.0003493485
evaluate O 0 0.00019118871
the O 0 0.00023234828
relationship O 0 0.00019512973
between O 0 0.00034256536
phenytoin B-Chemical 1 0.9999994
medication O 0 0.19727924
and O 0 0.0014266878
cerebellar B-Disease 0 0.999132
atrophy I-Disease 2 0.99999034
in O 0 0.00058396545
patients O 0 0.00085897587
who O 0 0.0009166743
had O 0 0.00084448344
experienced O 0 0.0017457104
clinical O 0 0.025687777
intoxication O 0 0.99891484
. O 0 0.007836523

Five O 0 0.0046735774
females O 0 0.0034289798
and O 0 0.0020108437
6 O 0 0.0012476209
males O 0 0.0015894845
, O 0 0.0011987551
21 O 0 0.00092246494
- O 0 0.0017315848
59 O 0 0.00057845796
years O 0 0.00041593204
of O 0 0.00038114312
age O 0 0.00063715206
, O 0 0.00038753136
were O 0 0.00022281073
examined O 0 0.00015702653
with O 0 0.00022852063
a O 0 0.00029530772
1 O 0 0.00023151372
. O 0 0.00021860236
5 O 0 0.00026108025
- O 0 0.004106139
T O 0 0.72632843
whole O 0 0.00071952376
- O 0 0.00274884
body O 0 0.00090725865
system O 0 0.0005668738
using O 0 0.00063017436
a O 0 0.0010492587
circular O 0 0.0026654555
polarized O 0 0.004800333
head O 0 0.1576633
coil O 0 0.034223333
. O 0 0.008469508

Conventional O 0 0.008416464
spin O 0 0.00959398
echo O 0 0.0056390683
images O 0 0.0028665017
were O 0 0.0020172717
acquired O 0 0.0022640172
in O 0 0.0017854177
the O 0 0.0019643307
sagittal O 0 0.00596474
and O 0 0.003268591
transverse O 0 0.007075809
orientation O 0 0.0077703274
. O 0 0.010454311

In O 0 0.0037634932
addition O 0 0.0020033696
, O 0 0.0021419139
we O 0 0.0009782858
performed O 0 0.00084028614
a O 0 0.00096603564
high O 0 0.0011450415
- O 0 0.0042705936
resolution O 0 0.006017769
3D O 0 0.0018057638
gradient O 0 0.0007011215
echo O 0 0.0036052864
, O 0 0.0007446766
T1 O 0 0.03113169
- O 0 0.0013824378
weighted O 0 0.00039105973
sequences O 0 0.00042129125
at O 0 0.0004403757
a O 0 0.0007194935
1 O 0 0.0008538699
- O 0 0.0023016734
mm O 0 0.002980147
slice O 0 0.008411462
thickness O 0 0.08776985
. O 0 0.00840629

The O 0 0.00405459
images O 0 0.0036490231
were O 0 0.0024038486
subsequently O 0 0.0019641912
processed O 0 0.0014684035
to O 0 0.0013009618
obtain O 0 0.0011801954
volumetric O 0 0.002614078
data O 0 0.002194784
for O 0 0.0024878075
the O 0 0.0040263925
cerebellum O 0 0.08544248
. O 0 0.009564371

Cerebellar O 0 0.37193078
volume O 0 0.0035555486
for O 0 0.0016585301
the O 0 0.0011423841
patient O 0 0.0008991191
group O 0 0.0006562659
ranged O 0 0.00041548227
between O 0 0.00033721855
67 O 0 0.0005852493
. O 0 0.00033321077
66 O 0 0.0004382663
and O 0 0.0003810626
131 O 0 0.00087619247
. O 0 0.00040080625
08 O 0 0.0040262314
ml O 0 0.0006208414
( O 0 0.0005887493
mean O 0 0.0004281058
108 O 0 0.0010060209
. O 0 0.0010205352
9 O 0 0.0016016398
ml O 0 0.0033441174
) O 0 0.006040077
. O 0 0.008135698

In O 0 0.0036471041
addition O 0 0.0019775424
3D O 0 0.0034686658
gradient O 0 0.0019388259
echo O 0 0.0026390534
data O 0 0.0007696673
sets O 0 0.00047709854
from O 0 0.00038462324
10 O 0 0.0003801066
healthy O 0 0.0007840636
male O 0 0.000718206
and O 0 0.00032454412
10 O 0 0.0002781203
healthy O 0 0.00092061574
female O 0 0.0010090397
age O 0 0.00085347204
- O 0 0.0015007907
matched O 0 0.00034665028
volunteers O 0 0.0005328861
were O 0 0.0004204433
used O 0 0.00048390857
to O 0 0.0006858814
compare O 0 0.0009231828
cerebellar O 0 0.106436044
volumes O 0 0.0043630013
. O 0 0.006390398

Using O 0 0.0032603305
linear O 0 0.002715006
regression O 0 0.0035085976
we O 0 0.0009256305
found O 0 0.00070833386
that O 0 0.00048171423
no O 0 0.00036078668
correlation O 0 0.00032779045
exists O 0 0.0003415056
between O 0 0.0003831318
seizure B-Disease 2 0.9999428
duration O 0 0.00041670576
, O 0 0.0008459674
elevation O 0 0.16787583
of O 0 0.009796689
phenytoin B-Chemical 1 0.9999995
serum O 0 0.5124253
levels O 0 0.0011995466
and O 0 0.0021000516
cerebellar O 0 0.56226623
volume O 0 0.005654254
. O 0 0.006354405

However O 0 0.0042473692
, O 0 0.002910354
multiple O 0 0.0017464934
regression O 0 0.0035481907
for O 0 0.00085011194
the O 0 0.00063907536
daily O 0 0.0007765224
dosage O 0 0.020536458
, O 0 0.0005328435
duration O 0 0.000290359
of O 0 0.0019434819
phenytoin B-Chemical 1 0.9999993
treatment O 0 0.0008140753
and O 0 0.0005383355
cerebellar O 0 0.2577035
volume O 0 0.00055248785
revealed O 0 0.00040799257
a O 0 0.0005857651
correlation O 0 0.0006536881
of O 0 0.0013837129
these O 0 0.0022309897
parameters O 0 0.004430948
. O 0 0.00674621

We O 0 0.0035601198
conclude O 0 0.0022063386
that O 0 0.0038751734
phenytoin B-Chemical 1 0.99999976
overdosage B-Disease 0 0.99999774
does O 0 0.0016093166
not O 0 0.00048237844
necessarily O 0 0.0005455105
result O 0 0.00029977408
in O 0 0.00065700995
cerebellar B-Disease 0 0.99942505
atrophy I-Disease 2 0.99999654
and O 0 0.0009024707
it O 0 0.00030417624
is O 0 0.00021987264
unlikely O 0 0.0002458144
that O 0 0.00040472622
phenytoin B-Chemical 1 0.99999964
medication O 0 0.07822325
was O 0 0.00020694334
the O 0 0.00019099301
only O 0 0.00026075737
cause O 0 0.00044371432
of O 0 0.001928686
cerebellar B-Disease 0 0.99948263
atrophy I-Disease 2 0.99998665
in O 0 0.0010454372
the O 0 0.0012108797
remaining O 0 0.0020245211
patients O 0 0.0045740227
. O 0 0.0060702334

Quantitative O 0 0.005187879
morphometric O 0 0.0039986996
studies O 0 0.0020836391
of O 0 0.001753393
the O 0 0.0013706587
cerebellum O 0 0.006875629
provide O 0 0.00070843013
valuable O 0 0.0007396786
insights O 0 0.00066650595
into O 0 0.0005923228
the O 0 0.0010213037
pathogenesis O 0 0.0039585754
of O 0 0.0072896644
cerebellar B-Disease 0 0.99886703
disorders I-Disease 0 0.9978999
. O 0 0.009327983

Late O 0 0.020565376
recovery O 0 0.0046442263
of O 0 0.0033148793
renal O 0 0.54149437
function O 0 0.0018042268
in O 0 0.0014310748
a O 0 0.0016458875
woman O 0 0.0052525396
with O 0 0.002106955
the O 0 0.005012017
hemolytic B-Disease 0 0.9999976
uremic I-Disease 0 0.9999865
syndrome I-Disease 0 0.99583083
. O 0 0.011780094

A O 0 0.06669469
case O 0 0.0037177114
is O 0 0.0022919006
reported O 0 0.0017838174
of O 0 0.0016809113
the O 0 0.003951586
hemolytic B-Disease 0 0.9999994
uremic I-Disease 0 0.999998
syndrome I-Disease 0 0.9995049
( O 0 0.29931322
HUS B-Disease 0 0.9999993
) O 0 0.006584348
in O 0 0.00086469296
a O 0 0.0013285188
woman O 0 0.016923131
taking O 0 0.032433417
oral B-Chemical 1 0.9926605
contraceptives I-Chemical 1 0.9999596
. O 0 0.010891853

She O 0 0.0049406923
was O 0 0.002507514
treated O 0 0.0019068659
with O 0 0.0020877875
heparin B-Chemical 1 0.9973665
, O 0 0.016950982
dipyridamole B-Chemical 0 0.99998045
and O 0 0.0017635351
hemodialysis O 0 0.66313285
; O 0 0.0007106693
and O 0 0.0002670272
after O 0 0.00014474297
more O 0 0.00018214225
than O 0 0.00010823033
three O 0 9.255183e-05
months O 0 0.00011097767
, O 0 0.00018998624
her O 0 0.00020710654
urinary O 0 0.04067237
output O 0 0.00031376418
rose O 0 0.0011123217
above O 0 0.00014593173
500 O 0 0.00027212297
ml O 0 0.00034094902
; O 0 0.00028075062
and O 0 0.00017095997
six O 0 0.00011998214
months O 0 0.00011940963
after O 0 0.0001248106
the O 0 0.00020950081
onset O 0 0.00053006725
of O 0 0.00086886965
anuria B-Disease 2 0.9986424
, O 0 0.0016922262
dialysis O 0 0.0074004214
treatment O 0 0.0016531723
was O 0 0.0022837308
stopped O 0 0.0044390284
. O 0 0.0062546236

This O 0 0.005272581
case O 0 0.0027681827
emphasizes O 0 0.0019268465
the O 0 0.0011986055
possibility O 0 0.00089135556
that O 0 0.0014478505
HUS B-Disease 0 0.99999845
in O 0 0.0012454434
adults O 0 0.0076605156
is O 0 0.00043411207
not O 0 0.0003087917
invariably O 0 0.005462302
irreversible O 0 0.08136784
and O 0 0.00037834817
that O 0 0.00021393037
, O 0 0.000404214
despite O 0 0.00029800672
prolonged O 0 0.0050242674
oliguria B-Disease 0 0.99995875
, O 0 0.00079535967
recovery O 0 0.0007132034
of O 0 0.0007703479
renal O 0 0.5671147
function O 0 0.0010258568
can O 0 0.0011883774
be O 0 0.0020721122
obtained O 0 0.0035494857
. O 0 0.006699524

Therefore O 0 0.0038629158
, O 0 0.0034236214
in O 0 0.0018935851
adult O 0 0.0019153968
patients O 0 0.0016120725
affected O 0 0.0010429394
by O 0 0.0027588748
HUS B-Disease 0 0.9999989
, O 0 0.0039104116
dialysis O 0 0.006756596
should O 0 0.00018852348
not O 0 0.0001902694
be O 0 0.00022932887
discontinued O 0 0.0027811723
prematurely O 0 0.009189924
; O 0 0.00079070614
moreover O 0 0.008723586
, O 0 0.0006589615
bilateral O 0 0.08872282
nephrectomy O 0 0.6033836
, O 0 0.00038711354
for O 0 0.00019195971
treatment O 0 0.00029365072
of O 0 0.0006645163
severe O 0 0.83205146
hypertension B-Disease 2 0.9999994
and O 0 0.058806665
microangiopathic B-Disease 0 0.99999726
hemolytic I-Disease 2 1.0
anemia I-Disease 2 1.0
, O 0 0.0077916393
should O 0 0.0004631169
be O 0 0.0007047867
performed O 0 0.00095711916
with O 0 0.0018013761
caution O 0 0.00374449
. O 0 0.0062946905

Morphological O 0 0.010013722
features O 0 0.0041016215
of O 0 0.0048229583
encephalopathy B-Disease 2 0.9999709
after O 0 0.0014326621
chronic O 0 0.88155353
administration O 0 0.055634394
of O 0 0.0015236324
the O 0 0.0022232926
antiepileptic O 0 0.99987817
drug O 0 0.9761169
valproate B-Chemical 0 0.9999863
to O 0 0.0027615197
rats O 0 0.0056285756
. O 0 0.006369673

A O 0 0.021687431
transmission O 0 0.0076330407
electron O 0 0.013009195
microscopic O 0 0.0050060814
study O 0 0.002802599
of O 0 0.0026335143
capillaries O 0 0.010809462
in O 0 0.0027995978
the O 0 0.003849945
cerebellar O 0 0.7443784
cortex O 0 0.5245246
. O 0 0.010230025

Long O 0 0.021324012
- O 0 0.007935126
term O 0 0.0020856506
intragastric O 0 0.40243775
application O 0 0.0014153126
of O 0 0.000936762
the O 0 0.0010229435
antiepileptic O 0 0.99972576
drug O 0 0.9751383
sodium B-Chemical 0 0.9999937
valproate I-Chemical 0 0.9999993
( O 0 0.010457113
Vupral O 0 0.8999851
" O 0 0.0032522362
Polfa O 0 0.9802603
" O 0 0.000597842
) O 0 0.0004498623
at O 0 0.00021118023
the O 0 0.00024175755
effective O 0 0.0003286447
dose O 0 0.0008785943
of O 0 0.0007091342
200 O 0 0.0013602374
mg O 0 0.026198976
/ O 0 0.0037201603
kg O 0 0.004815606
b O 0 0.0065465174
. O 0 0.007540732

w O 0 0.010034277
. O 0 0.0027591542
once O 0 0.0015673299
daily O 0 0.0012094249
to O 0 0.00075446384
rats O 0 0.00082812563
for O 0 0.00051632005
1 O 0 0.00046723583
, O 0 0.00049100764
3 O 0 0.00030241528
, O 0 0.0003599011
6 O 0 0.00022202924
, O 0 0.00028558928
9 O 0 0.0002042713
and O 0 0.0001986439
12 O 0 0.00015369189
months O 0 0.00014478878
revealed O 0 0.000261899
neurological B-Disease 0 0.99837315
disorders I-Disease 0 0.9972736
indicating O 0 0.0009111649
cerebellum B-Disease 0 0.98857915
damage I-Disease 0 0.9965513
( O 0 0.013868401
" O 0 0.041136824
valproate B-Chemical 0 0.999998
encephalopathy B-Disease 2 0.99999475
" O 0 0.014851156
) O 0 0.008265858
. O 0 0.007514101

The O 0 0.002874539
first O 0 0.0018353777
ultrastructural O 0 0.003697721
changes O 0 0.0013138395
in O 0 0.00073611236
structural O 0 0.0009762885
elements O 0 0.0007936804
of O 0 0.0005081277
the O 0 0.0004678527
blood O 0 0.06417005
- O 0 0.030345421
brain O 0 0.057097215
- O 0 0.021586021
barrier O 0 0.01446935
( O 0 0.0056464607
BBB O 0 0.9987664
) O 0 0.00089888996
in O 0 0.00023718392
the O 0 0.00027708887
cerebellar O 0 0.41045642
cortex O 0 0.11629361
were O 0 0.00027714885
detectable O 0 0.0002866015
after O 0 0.00030043127
3 O 0 0.00046628728
months O 0 0.0005778039
of O 0 0.0012231487
the O 0 0.0019060739
experiment O 0 0.003002852
. O 0 0.0065197865

They O 0 0.005583991
became O 0 0.0039756694
more O 0 0.002292812
severe O 0 0.012181492
in O 0 0.0008590554
the O 0 0.00056496385
later O 0 0.00039012326
months O 0 0.0002715683
of O 0 0.0003032936
the O 0 0.0002526794
experiment O 0 0.00021307253
, O 0 0.00035920853
and O 0 0.000282291
were O 0 0.00023033141
most O 0 0.00029919986
severe O 0 0.0033652931
after O 0 0.00013018578
12 O 0 0.0001380449
months O 0 0.00013105017
, O 0 0.00021391608
located O 0 0.00020093711
mainly O 0 0.0002741934
in O 0 0.000295864
the O 0 0.0003785455
molecular O 0 0.0016024099
layer O 0 0.0029055923
of O 0 0.0012929578
the O 0 0.0019715456
cerebellar O 0 0.821339
cortex O 0 0.55583274
. O 0 0.0067397486

Lesions O 0 0.044191092
of O 0 0.0061761844
the O 0 0.004962353
capillary O 0 0.035519637
included O 0 0.0052305385
necrosis B-Disease 2 0.9984629
of O 0 0.0137246875
endothelial O 0 0.9669157
cells O 0 0.016492823
. O 0 0.015229808

Organelles O 0 0.0081646275
of O 0 0.0027748884
these O 0 0.0019771059
cells O 0 0.001754703
, O 0 0.001436527
in O 0 0.0007036619
particular O 0 0.00047553141
the O 0 0.0004976973
mitochondria O 0 0.03234437
( O 0 0.0006958642
increased O 0 0.00031959973
number O 0 0.00023403135
and O 0 0.00026655156
size O 0 0.00032972428
, O 0 0.0003666262
distinct O 0 0.0002822544
degeneration O 0 0.94604087
of O 0 0.00034297188
their O 0 0.0003021369
matrix O 0 0.0009533531
and O 0 0.0005679414
cristae O 0 0.2985812
) O 0 0.0011297754
and O 0 0.0008753922
Golgi O 0 0.0019684706
apparatus O 0 0.0018117339
were O 0 0.0022146727
altered O 0 0.0037263436
. O 0 0.0065623033

Reduced O 0 0.005127279
size O 0 0.0030810854
of O 0 0.0024184955
capillary O 0 0.045998912
lumen O 0 0.0026951479
and O 0 0.0013373354
occlusion O 0 0.1923723
were O 0 0.00054671534
caused O 0 0.00042949253
by O 0 0.00050590246
swollen O 0 0.002290783
endothelial O 0 0.67926997
cells O 0 0.0007685166
which O 0 0.00073178846
had O 0 0.0007252313
luminal B-Chemical 0 0.1154766
protrusions O 0 0.059448797
and O 0 0.0023752993
swollen O 0 0.007325396
microvilli O 0 0.097705305
. O 0 0.0077752816

Pressure O 0 0.02671858
on O 0 0.0029555678
the O 0 0.0027994264
vessel O 0 0.010756452
wall O 0 0.006497196
was O 0 0.001928361
produced O 0 0.0016186107
by O 0 0.0022156653
enlarged O 0 0.008758199
perivascular O 0 0.35356262
astrocytic O 0 0.6237258
processes O 0 0.00880508
. O 0 0.009667038

Fragments O 0 0.008783956
of O 0 0.0044318624
necrotic B-Disease 2 0.953117
endothelial O 0 0.93567157
cells O 0 0.0017997152
were O 0 0.00079158205
in O 0 0.0005294977
the O 0 0.0004748099
vascular O 0 0.114371836
lumens O 0 0.004418678
and O 0 0.00040488114
in O 0 0.00029486098
these O 0 0.00031825854
there O 0 0.00027835162
was O 0 0.00046859845
loosening O 0 0.029569542
and O 0 0.00079406094
breaking O 0 0.0026404043
of O 0 0.001331817
tight O 0 0.002452237
cellular O 0 0.005009757
junctions O 0 0.0059778136
. O 0 0.007309459

Damage O 0 0.02139178
to O 0 0.005664504
the O 0 0.005317731
vascular O 0 0.18076791
basement O 0 0.14038052
lamina O 0 0.011080131
was O 0 0.005511453
also O 0 0.006076995
observed O 0 0.008196453
. O 0 0.013829815

Damage O 0 0.024168726
to O 0 0.0029041583
the O 0 0.0022163738
capillary O 0 0.02703134
was O 0 0.0012801437
accompanied O 0 0.0011501526
by O 0 0.0008761198
marked O 0 0.0015842499
damage O 0 0.515003
to O 0 0.00065834756
neuroglial O 0 0.57714796
cells O 0 0.0008421791
, O 0 0.0008124572
mainly O 0 0.00072090054
to O 0 0.00077160564
perivascular O 0 0.036681563
processes O 0 0.00210188
of O 0 0.0033290344
astrocytes O 0 0.19132069
. O 0 0.0078462055

The O 0 0.003848508
proliferation O 0 0.13058093
of O 0 0.0031653473
astrocytes O 0 0.2485513
( O 0 0.0039354744
Bergmann O 0 0.31231964
' O 0 0.0011577648
s O 0 0.00080526376
in O 0 0.00057080784
particular O 0 0.0005330045
) O 0 0.00097078504
and O 0 0.00083075673
occasionally O 0 0.0014860202
of O 0 0.0016259089
oligodendrocytes O 0 0.19197552
was O 0 0.0029607534
found O 0 0.003907573
. O 0 0.007313706

Alterations O 0 0.0046617338
in O 0 0.002185649
the O 0 0.001464082
structural O 0 0.0017009823
elements O 0 0.0013944934
of O 0 0.00094899104
the O 0 0.000983108
BBB O 0 0.99780554
coexisted O 0 0.00969109
with O 0 0.00047545627
marked O 0 0.0008054248
lesions O 0 0.11013995
of O 0 0.0004170877
neurons O 0 0.0007639843
of O 0 0.0003811146
the O 0 0.00045879855
cerebellum O 0 0.10609632
( O 0 0.0011822117
Purkinje O 0 0.075533256
cells O 0 0.0011819224
are O 0 0.0014980849
earliest O 0 0.003077604
) O 0 0.006068548
. O 0 0.0073749376

In O 0 0.0036886802
electron O 0 0.004841886
micrographs O 0 0.001708757
both O 0 0.0014633253
luminal B-Chemical 0 0.08329812
and O 0 0.0013069664
antiluminal O 0 0.0075572343
sides O 0 0.0020656176
of O 0 0.0007592233
the O 0 0.0007958903
BBB O 0 0.9905716
of O 0 0.0009388864
the O 0 0.0009668446
cerebellar O 0 0.6637877
cortex O 0 0.2300644
had O 0 0.0016144995
similar O 0 0.002302277
lesions O 0 0.2737374
. O 0 0.007467002

The O 0 0.0030640287
possible O 0 0.002124695
influence O 0 0.0012921896
of O 0 0.0014657234
the O 0 0.0016931421
hepatic B-Disease 2 0.99956614
damage I-Disease 2 0.9995901
, O 0 0.012240716
mainly O 0 0.0108343
hyperammonemia B-Disease 0 0.99999547
, O 0 0.0012854149
upon O 0 0.00035753738
the O 0 0.000494153
development O 0 0.0026259942
of O 0 0.025957169
valproate B-Chemical 0 0.99999905
encephalopathy B-Disease 2 0.99999523
is O 0 0.0047906525
discussed O 0 0.0037221492
. O 0 0.006404661

Fatal O 0 0.94625723
intracranial B-Disease 0 0.9997024
bleeding I-Disease 0 0.9999076
associated O 0 0.0049337232
with O 0 0.0037723745
prehospital O 0 0.007434391
use O 0 0.004356698
of O 0 0.008145282
epinephrine B-Chemical 0 0.9991252
. O 0 0.013360603

We O 0 0.0035904213
present O 0 0.002114021
a O 0 0.0020106472
case O 0 0.001399857
of O 0 0.0012643496
paramedic O 0 0.0027367647
misjudgment O 0 0.072814055
in O 0 0.0004969436
the O 0 0.00038141132
execution O 0 0.0011711697
of O 0 0.00037682767
a O 0 0.00033746715
protocol O 0 0.00023215896
for O 0 0.00021326035
the O 0 0.00022614484
treatment O 0 0.00039901977
of O 0 0.00204104
allergic B-Disease 2 0.9999964
reaction I-Disease 2 0.8476505
in O 0 0.00046533346
a O 0 0.00053889607
case O 0 0.0006016208
of O 0 0.0014634737
pulmonary B-Disease 0 0.98234427
edema I-Disease 0 0.9999913
with O 0 0.05262518
wheezing B-Disease 0 0.9996865
. O 0 0.009911733

The O 0 0.003974476
sudden O 0 0.72581816
onset O 0 0.0058500487
of O 0 0.0034637295
respiratory B-Disease 0 0.9889753
distress I-Disease 0 0.99920195
, O 0 0.05524642
rash B-Disease 0 0.9999691
, O 0 0.0014949852
and O 0 0.00049698015
a O 0 0.00044112085
history O 0 0.0013193595
of O 0 0.0003934426
a O 0 0.00042310718
new O 0 0.00044986123
medicine O 0 0.0013369598
led O 0 0.00025852746
the O 0 0.000246704
two O 0 0.0002270282
paramedics O 0 0.00031816692
on O 0 0.0002456696
the O 0 0.00043004227
scene O 0 0.0011874698
to O 0 0.0008687372
administer O 0 0.0019587611
subcutaneous O 0 0.055653084
epinephrine B-Chemical 0 0.9972785
. O 0 0.007127584

Subsequently O 0 0.008255306
, O 0 0.008784688
acute O 0 0.92942303
cardiac B-Disease 2 0.9875048
arrest I-Disease 2 0.9917537
and O 0 0.027542373
fatal O 0 0.9996494
subarachnoid B-Disease 0 0.999972
hemorrhage I-Disease 2 0.99997544
occurred O 0 0.011210322
. O 0 0.010958109

Epinephrine B-Chemical 1 0.99963295
has O 0 0.0031695806
a O 0 0.0023116746
proven O 0 0.001820429
role O 0 0.0007363015
in O 0 0.0010492797
cardiac B-Disease 2 0.9000341
arrest I-Disease 2 0.9500365
in O 0 0.00061143417
prehospital O 0 0.0023262491
care O 0 0.00037755445
; O 0 0.00046075278
however O 0 0.0003287412
, O 0 0.00031894806
use O 0 0.00020775232
by O 0 0.00020716857
paramedics O 0 0.00023335268
in O 0 0.00018255431
patients O 0 0.0002968999
with O 0 0.00033656208
suspected O 0 0.14499477
allergic B-Disease 2 0.99999726
reaction I-Disease 2 0.93230677
and O 0 0.003677148
severe O 0 0.7870065
hypertension B-Disease 2 0.99999464
should O 0 0.00046782612
be O 0 0.00073050853
viewed O 0 0.0011757711
with O 0 0.0018918909
caution O 0 0.003879295
. O 0 0.0063399253

Role O 0 0.004311281
of O 0 0.0030489636
activation O 0 0.0033172714
of O 0 0.011161104
bradykinin B-Chemical 1 0.99999344
B2 O 0 0.99970347
receptors O 0 0.023668917
in O 0 0.0006036095
disruption O 0 0.00052364066
of O 0 0.00058791885
the O 0 0.0006134257
blood O 0 0.030894894
- O 0 0.008558716
brain O 0 0.008615239
barrier O 0 0.0058281785
during O 0 0.0018887817
acute O 0 0.98981756
hypertension B-Disease 2 0.99999106
. O 0 0.011566989

Cellular O 0 0.010094069
mechanisms O 0 0.0026542093
which O 0 0.0021917904
account O 0 0.0012621298
for O 0 0.00092425616
disruption O 0 0.00089430023
the O 0 0.00085460494
blood O 0 0.044377808
- O 0 0.012539605
brain O 0 0.009026027
barrier O 0 0.004024427
during O 0 0.000868378
acute O 0 0.9790247
hypertension B-Disease 2 0.99999416
are O 0 0.002117063
not O 0 0.0024199765
clear O 0 0.0040509407
. O 0 0.0069958237

The O 0 0.0031332863
goal O 0 0.0026416956
of O 0 0.001772135
this O 0 0.0011763569
study O 0 0.0010038815
was O 0 0.0005708065
to O 0 0.00034164303
determine O 0 0.00017716934
the O 0 0.00023192733
role O 0 0.00018075056
of O 0 0.0003724047
synthesis O 0 0.012291866
/ O 0 0.022827249
release O 0 0.008708643
of O 0 0.0031605964
bradykinin B-Chemical 1 0.9999188
to O 0 0.00024799848
activate O 0 0.0001843121
B2 O 0 0.9950553
receptors O 0 0.003608553
in O 0 0.00021546526
disruption O 0 0.00024089149
of O 0 0.00033385216
the O 0 0.00039985165
blood O 0 0.029031726
- O 0 0.00807832
brain O 0 0.007981857
barrier O 0 0.0052802796
during O 0 0.0016310518
acute O 0 0.9891543
hypertension B-Disease 2 0.9999913
. O 0 0.010825099

Permeability O 0 0.05528651
of O 0 0.0030822367
the O 0 0.002128028
blood O 0 0.042089533
- O 0 0.014679943
brain O 0 0.007931725
barrier O 0 0.0024441842
was O 0 0.0004804227
quantitated O 0 0.0004912002
by O 0 0.00034363594
clearance O 0 0.0062660263
of O 0 0.0004923114
fluorescent O 0 0.016259916
- O 0 0.017501915
labeled O 0 0.0004165411
dextran B-Chemical 1 0.9753601
before O 0 0.00016391516
and O 0 0.00028933765
during O 0 0.0002925296
phenylephrine B-Chemical 0 0.9999944
- O 0 0.15368089
induced O 0 0.0016965937
acute O 0 0.99769336
hypertension B-Disease 2 0.99999964
in O 0 0.0005611149
rats O 0 0.00044578427
treated O 0 0.00024606247
with O 0 0.00028138142
vehicle O 0 0.011452633
and O 0 0.0020777402
Hoe B-Chemical 0 0.999962
- I-Chemical 0 0.03547261
140 I-Chemical 0 0.0006792936
( O 0 0.000658086
0 O 0 0.0007000006
. O 0 0.0008795082
1 O 0 0.0015346389
microM O 0 0.16273046
) O 0 0.0067225746
. O 0 0.0077013443

Phenylephrine B-Chemical 0 0.99995446
infusion O 0 0.047945574
increased O 0 0.0034691356
arterial O 0 0.60129666
pressure O 0 0.24168673
, O 0 0.0017206485
arteriolar O 0 0.96614975
diameter O 0 0.004333888
and O 0 0.0005418396
clearance O 0 0.005761096
of O 0 0.0005676572
fluorescent O 0 0.0066067083
dextran B-Chemical 1 0.9780889
by O 0 0.00060264784
a O 0 0.00060790667
similar O 0 0.00049619254
magnitude O 0 0.00071404333
in O 0 0.0012359716
both O 0 0.002046277
groups O 0 0.0037271015
. O 0 0.006566193

These O 0 0.003407632
findings O 0 0.0023939346
suggest O 0 0.0011216119
that O 0 0.0009527462
disruption O 0 0.00092953723
of O 0 0.00092674943
the O 0 0.00081106374
blood O 0 0.09758242
- O 0 0.02562771
brain O 0 0.013807281
barrier O 0 0.0046134177
during O 0 0.00035485896
acute O 0 0.98744816
hypertension B-Disease 2 0.9999993
is O 0 0.00048092028
not O 0 0.0001907173
related O 0 0.00014160674
to O 0 0.00016649887
the O 0 0.00023172973
synthesis O 0 0.0023347805
/ O 0 0.0067216456
release O 0 0.0046432833
of O 0 0.0026245771
bradykinin B-Chemical 1 0.9998123
to O 0 0.0011022981
activate O 0 0.001367165
B2 O 0 0.9856793
receptors O 0 0.04766594
. O 0 0.0073385453

Risk O 0 0.015573869
factors O 0 0.009725545
of O 0 0.011154213
sensorineural B-Disease 2 0.9999305
hearing I-Disease 2 0.99683505
loss I-Disease 2 0.099838324
in O 0 0.0078119845
preterm O 0 0.97483397
infants O 0 0.3747626
. O 0 0.015754765

Among O 0 0.008102513
547 O 0 0.09997249
preterm O 0 0.8883144
infants O 0 0.03402168
of O 0 0.0015069346
< O 0 0.0008722848
or O 0 0.0006962031
= O 0 0.0009389432
34 O 0 0.00046979217
weeks O 0 0.00024148615
gestation O 0 0.00040712848
born O 0 0.0003720298
between O 0 0.00020857083
1987 O 0 0.0011546507
and O 0 0.0002894629
1991 O 0 0.0004704415
, O 0 0.00031845737
8 O 0 0.00020804169
children O 0 0.00036563916
( O 0 0.0003973309
1 O 0 0.00024722202
. O 0 0.00022763011
46 O 0 0.00035219343
% O 0 0.00037360378
) O 0 0.0005534231
developed O 0 0.0006334154
severe O 0 0.024575625
progressive O 0 0.067677915
and O 0 0.0022240556
bilateral O 0 0.7487205
sensorineural B-Disease 2 0.9999819
hearing I-Disease 2 0.9965204
loss I-Disease 2 0.1367071
. O 0 0.008576917

Perinatal O 0 0.10487154
risk O 0 0.04858702
factors O 0 0.0039963094
of O 0 0.0017583257
infants O 0 0.0032846618
with O 0 0.0015895504
hearing B-Disease 0 0.97440183
loss I-Disease 0 0.002345057
were O 0 0.00034759523
compared O 0 0.00018873751
with O 0 0.0002369127
those O 0 0.00024948575
of O 0 0.00022029928
two O 0 0.00015689529
control O 0 0.00018366527
groups O 0 0.00019734999
matched O 0 0.0001948397
for O 0 0.00022592778
gestation O 0 0.00054790365
and O 0 0.00042067884
birth O 0 0.0013560607
weight O 0 0.0016538501
and O 0 0.0011255055
for O 0 0.0016038434
perinatal O 0 0.59589475
complications O 0 0.7328217
. O 0 0.0075598275

Our O 0 0.0039407415
observations O 0 0.0025656973
demonstrated O 0 0.0017224728
an O 0 0.0016582316
association O 0 0.0011925225
of O 0 0.0018554121
hearing B-Disease 0 0.9676325
loss I-Disease 0 0.0030647055
with O 0 0.0010679037
a O 0 0.0011386079
higher O 0 0.0010609339
incidence O 0 0.0032540672
of O 0 0.002996355
perinatal O 0 0.8089023
complications O 0 0.8534735
. O 0 0.009018004

Ototoxicity B-Disease 0 0.9991603
appeared O 0 0.0028862979
closely O 0 0.0015003762
related O 0 0.00079627417
to O 0 0.0006786873
a O 0 0.0007391611
prolonged O 0 0.0007972946
administration O 0 0.0027335496
and O 0 0.0004327012
higher O 0 0.00029766513
total O 0 0.00025788098
dose O 0 0.0026371588
of O 0 0.002445973
ototoxic B-Disease 0 0.9999404
drugs O 0 0.8350985
, O 0 0.0026286528
particularly O 0 0.015252317
aminoglycosides B-Chemical 1 0.9988381
and O 0 0.05703635
furosemide B-Chemical 1 0.99998665
. O 0 0.009969535

Finally O 0 0.004424959
, O 0 0.0031229863
we O 0 0.0013578117
strongly O 0 0.0012638614
recommend O 0 0.00075546536
to O 0 0.0005571208
prospectively O 0 0.00051723304
and O 0 0.00038989465
regularly O 0 0.00029763905
perform O 0 0.00021123786
audiologic O 0 0.0013793854
assessment O 0 0.00020420217
in O 0 0.00021399076
sick O 0 0.0007301421
preterm O 0 0.10109464
children O 0 0.0008030438
as O 0 0.00033326383
hearing B-Disease 0 0.937224
loss I-Disease 0 0.0013771167
is O 0 0.00029497204
of O 0 0.0003508618
delayed O 0 0.0010113847
onset O 0 0.00081612344
and O 0 0.00044384119
in O 0 0.00047066534
most O 0 0.00085564656
cases O 0 0.0016197545
bilateral O 0 0.044846863
and O 0 0.0029284023
severe O 0 0.16403879
. O 0 0.007106205

Seizure B-Disease 2 0.9968098
resulting O 0 0.01096483
from O 0 0.0110959625
a O 0 0.023967095
venlafaxine B-Chemical 0 0.9999776
overdose B-Disease 0 0.9999256
. O 0 0.027532302

OBJECTIVE O 0 0.020869268
: O 0 0.0069006253
To O 0 0.003949451
report O 0 0.005394009
a O 0 0.0048664706
case O 0 0.005419171
of O 0 0.023072662
venlafaxine B-Chemical 0 0.99999356
overdose B-Disease 0 0.9999639
. O 0 0.017734297

CASE O 0 0.33299154
SUMMARY O 0 0.0057141967
: O 0 0.0040663276
A O 0 0.019727154
40 O 0 0.0018211413
- O 0 0.0034625034
year O 0 0.0011184332
- O 0 0.0024780722
old O 0 0.0007009312
woman O 0 0.0015450205
with O 0 0.00065963005
major B-Disease 2 0.025211519
depression I-Disease 2 0.99995136
took O 0 0.00054594566
an O 0 0.0012132868
overdose B-Disease 0 0.99995804
of O 0 0.0065004737
venlafaxine B-Chemical 0 0.99998486
in O 0 0.00091499975
an O 0 0.001322802
apparent O 0 0.0022378967
suicide O 0 0.9208533
attempt O 0 0.004945455
. O 0 0.0071818777

After O 0 0.0028991562
the O 0 0.002536905
ingestion O 0 0.12213735
of O 0 0.002070215
26 O 0 0.0050981874
venlafaxine B-Chemical 0 0.99998164
50 O 0 0.001964525
- O 0 0.012515804
mg O 0 0.083690435
tablets O 0 0.19320498
, O 0 0.0007270724
the O 0 0.0005490211
patient O 0 0.0007438566
experienced O 0 0.0010169782
a O 0 0.0015291906
witnessed O 0 0.028380051
generalized O 0 0.6847534
seizure B-Disease 2 0.99992824
. O 0 0.009882063

She O 0 0.005305331
was O 0 0.0027601412
admitted O 0 0.002362936
to O 0 0.0011676725
the O 0 0.00095576834
medical O 0 0.0014339983
intensive O 0 0.00056429976
care O 0 0.00049695355
unit O 0 0.00042528554
, O 0 0.001494781
venlafaxine B-Chemical 0 0.99997604
was O 0 0.0005489327
discontinued O 0 0.002236295
, O 0 0.0005648658
and O 0 0.00055576983
no O 0 0.0005579878
further O 0 0.001020152
sequelae O 0 0.22594337
were O 0 0.0025047304
seen O 0 0.0036730117
. O 0 0.006737537

DISCUSSION O 0 0.004322297
: O 0 0.0031689585
To O 0 0.0015351459
our O 0 0.0013863061
knowledge O 0 0.0013623578
, O 0 0.0011677425
this O 0 0.0006439237
is O 0 0.0005085692
the O 0 0.00038547427
first O 0 0.00030300228
reported O 0 0.00043204537
case O 0 0.0005086419
of O 0 0.005405874
venlafaxine B-Chemical 0 0.9999989
overdose B-Disease 0 0.9999758
that O 0 0.00054016523
resulted O 0 0.000711066
in O 0 0.0011484037
a O 0 0.0026085465
generalized O 0 0.55898976
seizure B-Disease 2 0.99991906
. O 0 0.008928313

Based O 0 0.0061759218
on O 0 0.002158655
nonoverdose O 0 0.07153505
pharmacokinetics O 0 0.6765789
and O 0 0.0017127041
pharmacodynamics O 0 0.5492459
of O 0 0.0026876465
venlafaxine B-Chemical 0 0.9999871
and O 0 0.0005247444
the O 0 0.00029692112
potential O 0 0.00036949394
risks O 0 0.0020094975
of O 0 0.00047645727
available O 0 0.00045689152
interventions O 0 0.0004816596
, O 0 0.0006807664
no O 0 0.00059101306
emergent O 0 0.0015842286
therapy O 0 0.0023608531
was O 0 0.0025314195
instituted O 0 0.005800807
. O 0 0.0068815188

CONCLUSIONS O 0 0.027231334
: O 0 0.00474788
The O 0 0.0028350856
venlafaxine B-Chemical 0 0.9999914
overdose B-Disease 0 0.99996924
in O 0 0.0010825328
our O 0 0.00062209443
patient O 0 0.00049507915
resulted O 0 0.00034324994
in O 0 0.00035319317
a O 0 0.0003977832
single O 0 0.00033867915
episode O 0 0.0008454379
of O 0 0.000766821
generalized O 0 0.52227706
seizure B-Disease 2 0.9999758
but O 0 0.0011027671
elicited O 0 0.0009072725
no O 0 0.0011332695
further O 0 0.0023861828
sequelae O 0 0.6761587
. O 0 0.008002869

Combined O 0 0.008285108
effects O 0 0.0037669183
of O 0 0.0037400282
prolonged O 0 0.4406186
prostaglandin B-Chemical 1 1.0
E1 I-Chemical 1 0.9999975
- O 0 0.7987486
induced O 0 0.022655813
hypotension B-Disease 2 0.9999964
and O 0 0.0063132937
haemodilution B-Disease 2 0.9893472
on O 0 0.0010231672
human O 0 0.0027794074
hepatic O 0 0.80935466
function O 0 0.005374164
. O 0 0.007930728

Combined O 0 0.007917255
effects O 0 0.003432428
of O 0 0.0034318436
prolonged O 0 0.4674096
prostaglandin B-Chemical 1 1.0
E1 I-Chemical 1 0.99999905
( O 0 0.95015144
PGE1 B-Chemical 1 1.0
) O 0 0.27837503
- O 0 0.12761328
induced O 0 0.0025585406
hypotension B-Disease 2 0.9999957
and O 0 0.0027513772
haemodilution B-Disease 2 0.98807764
on O 0 0.00020635262
hepatic O 0 0.39948696
function O 0 0.0003254197
were O 0 0.0003115067
studied O 0 0.000356484
in O 0 0.0004175983
30 O 0 0.00054136623
patients O 0 0.0009850526
undergoing O 0 0.0016054125
hip O 0 0.254398
surgery O 0 0.005799985
. O 0 0.006461546

The O 0 0.0033320861
patients O 0 0.0025651618
were O 0 0.0013987068
randomly O 0 0.0006880695
allocated O 0 0.00055326114
to O 0 0.00045216214
one O 0 0.0003713877
of O 0 0.0003578876
three O 0 0.00021186554
groups O 0 0.00030381657
; O 0 0.00042491517
those O 0 0.0002809951
in O 0 0.0002149285
group O 0 0.00039662418
A O 0 0.055947572
( O 0 0.00040445122
n O 0 0.00021216554
= O 0 0.000446705
10 O 0 0.00018714926
) O 0 0.00025363232
were O 0 0.00013698933
subjected O 0 0.000104796505
to O 0 0.00013430983
controlled O 0 0.00024864203
hypotension B-Disease 2 0.99996424
alone O 0 0.00036054052
, O 0 0.00044021205
those O 0 0.00027088795
in O 0 0.00018143229
group O 0 0.00045913475
B O 0 0.7108745
( O 0 0.00054217177
n O 0 0.00020208182
= O 0 0.00046902813
10 O 0 0.00017974927
) O 0 0.00031672695
to O 0 0.00019082935
haemodilution B-Disease 2 0.95809656
alone O 0 0.00021791604
and O 0 0.0002504087
those O 0 0.00026541218
in O 0 0.0002052136
group O 0 0.00072655675
C O 0 0.9980044
( O 0 0.00078095257
n O 0 0.0002837218
= O 0 0.00054861675
10 O 0 0.00030162343
) O 0 0.00046618862
to O 0 0.00037911197
both O 0 0.00061642996
controlled O 0 0.0011985508
hypotension B-Disease 2 0.9999312
and O 0 0.0054338165
haemodilution B-Disease 2 0.9927492
. O 0 0.007295587

Haemodilution B-Disease 0 0.9786945
in O 0 0.003035586
groups O 0 0.0027255253
B O 0 0.6979885
and O 0 0.0041485634
C O 0 0.99832886
was O 0 0.0008115465
produced O 0 0.000422315
by O 0 0.0004291671
withdrawing O 0 0.0049080364
approximately O 0 0.0002749253
1000 O 0 0.0004240593
mL O 0 0.0005946658
of O 0 0.00027829537
blood O 0 0.0033712124
and O 0 0.00023593326
replacing O 0 0.00035571982
it O 0 0.00019583615
with O 0 0.00016698474
the O 0 0.00013572551
same O 0 0.00010139973
amount O 0 0.00010639213
of O 0 0.00033976595
dextran B-Chemical 1 0.9928311
solution O 0 0.05452096
, O 0 0.00053602393
and O 0 0.0003234892
final O 0 0.00043713974
haematocrit O 0 0.6165211
values O 0 0.00044634743
were O 0 0.0006250496
21 O 0 0.0009326986
or O 0 0.0012712381
22 O 0 0.002596723
% O 0 0.0042342586
. O 0 0.006825344

Controlled O 0 0.005874089
hypotension B-Disease 2 0.9997726
in O 0 0.0024013403
groups O 0 0.0020328755
A O 0 0.14279896
and O 0 0.0029081863
C O 0 0.99892956
was O 0 0.0010497415
induced O 0 0.0008985466
with O 0 0.01215808
PGE1 B-Chemical 1 0.9999994
to O 0 0.00033213655
maintain O 0 0.00021769194
mean O 0 0.00021792311
arterial O 0 0.043727256
blood O 0 0.0023188407
pressure O 0 0.0025861752
at O 0 0.00040440034
55 O 0 0.00069432735
mmHg O 0 0.001279076
for O 0 0.001186519
180 O 0 0.0024121213
min O 0 0.0038048483
. O 0 0.0064543677

Measurements O 0 0.003996421
included O 0 0.00289226
arterial O 0 0.50352854
ketone O 0 0.9988317
body O 0 0.008753536
ratio O 0 0.0020577055
( O 0 0.00848266
AKBR O 0 0.9992575
, O 0 0.00902903
aceto B-Chemical 0 0.9994777
- I-Chemical 0 0.5898633
acetate I-Chemical 0 0.999723
/ O 0 0.033801418
3 B-Chemical 0 0.0006164511
- I-Chemical 0 0.06499235
hydroxybutyrate I-Chemical 0 0.99982953
) O 0 0.0016604158
and O 0 0.00095996
clinical O 0 0.0034775562
hepatic O 0 0.3911668
function O 0 0.0024741504
parameters O 0 0.004901004
. O 0 0.006873321

AKBR O 0 0.984072
and O 0 0.0032729714
biological O 0 0.0023812298
hepatic O 0 0.36238512
function O 0 0.0011369853
tests O 0 0.0011448986
showed O 0 0.0005349587
no O 0 0.00038702186
change O 0 0.00044686726
throughout O 0 0.00031338268
the O 0 0.0003642449
time O 0 0.00035471976
course O 0 0.00055697205
in O 0 0.0008042798
groups O 0 0.0013956066
A O 0 0.045825936
and O 0 0.0041388157
B O 0 0.7641958
. O 0 0.009742271

In O 0 0.0046434584
group O 0 0.0064727687
C O 0 0.9977794
, O 0 0.01728624
AKBR O 0 0.9964645
showed O 0 0.0008812038
a O 0 0.00070736185
significant O 0 0.0004295531
decrease O 0 0.00033377387
at O 0 0.00025438648
120 O 0 0.00027047322
min O 0 0.00034079267
( O 0 0.00047365762
- O 0 0.0014985785
40 O 0 0.00022009372
% O 0 0.00025364393
) O 0 0.0002988697
and O 0 0.00018494725
at O 0 0.00014570619
180 O 0 0.00020677625
min O 0 0.00026642074
( O 0 0.00043029283
- O 0 0.0026427447
49 O 0 0.00035705895
% O 0 0.0002717387
) O 0 0.00029936765
after O 0 0.00011776155
the O 0 0.000143891
start O 0 0.00015328941
of O 0 0.0005022281
hypotension B-Disease 2 0.999969
and O 0 0.00026097274
at O 0 0.00013358626
60 O 0 0.00015124312
min O 0 0.0002291385
( O 0 0.00038182223
- O 0 0.0022831745
32 O 0 0.00026742596
% O 0 0.00024793515
) O 0 0.0002917687
after O 0 0.00012698249
recovery O 0 0.00027844694
of O 0 0.00042743786
normotension O 0 0.98484796
, O 0 0.0006877033
and O 0 0.0052465135
SGOT O 0 0.9999995
, O 0 0.16582896
SGPT O 0 1.0
, O 0 0.06008994
LDH O 0 0.99995637
and O 0 0.00053524005
total O 0 0.00048270109
bilirubin B-Chemical 1 0.9999229
showed O 0 0.0006980893
significant O 0 0.0008350385
increases O 0 0.0011969368
after O 0 0.001614524
operation O 0 0.0037900638
. O 0 0.0059985784

The O 0 0.0029396256
results O 0 0.0018473178
suggest O 0 0.0010731125
that O 0 0.0009584018
a O 0 0.0010428781
prolonged O 0 0.0009610705
combination O 0 0.0007024733
of O 0 0.0005515613
more O 0 0.00041413604
than O 0 0.00019721003
120 O 0 0.00024332771
min O 0 0.00035993717
of O 0 0.0027568368
PGE1 B-Chemical 1 0.9999999
- O 0 0.24683121
induced O 0 0.0030226675
hypotension B-Disease 2 0.99999547
and O 0 0.0018433129
moderate O 0 0.193821
haemodilution B-Disease 2 0.99504316
would O 0 0.0005268345
cause O 0 0.0012676319
impairment B-Disease 0 0.3256705
of I-Disease 0 0.002606079
hepatic I-Disease 0 0.8689331
function I-Disease 0 0.0048762555
. O 0 0.007106407

Cardiovascular B-Disease 0 0.98872954
alterations I-Disease 0 0.051156215
in O 0 0.0037872486
rat O 0 0.004739884
fetuses O 0 0.004677902
exposed O 0 0.0030862656
to O 0 0.0032525237
calcium B-Chemical 0 0.99673754
channel O 0 0.64239407
blockers O 0 0.99663264
. O 0 0.012136195

Preclinical O 0 0.102075286
toxicologic O 0 0.029477306
investigation O 0 0.0020813537
suggested O 0 0.0010126092
that O 0 0.00074772077
a O 0 0.0009447644
new O 0 0.0015403874
calcium B-Chemical 0 0.9991665
channel O 0 0.68476266
blocker O 0 0.99159324
, O 0 0.0051685595
Ro B-Chemical 0 0.9814647
40 I-Chemical 0 0.00063586637
- I-Chemical 0 0.008528567
5967 I-Chemical 0 0.001190474
, O 0 0.00036676152
induced O 0 0.000505083
cardiovascular B-Disease 0 0.9993088
alterations I-Disease 0 0.17496009
in O 0 0.0003848048
rat O 0 0.000946047
fetuses O 0 0.001166338
exposed O 0 0.0005568165
to O 0 0.0005451576
this O 0 0.0008766042
agent O 0 0.0063052396
during O 0 0.00201103
organogenesis O 0 0.2027192
. O 0 0.00732841

The O 0 0.0030252885
present O 0 0.0018944714
study O 0 0.0017010107
was O 0 0.0010168386
designed O 0 0.0006617671
to O 0 0.00043059912
investigate O 0 0.00023550919
the O 0 0.00030542724
hypothesis O 0 0.00034005838
that O 0 0.00038876486
calcium B-Chemical 0 0.99925023
channel O 0 0.6275169
blockers O 0 0.9951466
in O 0 0.0003511472
general O 0 0.00030714893
induce O 0 0.00037249134
cardiovascular B-Disease 0 0.9998543
malformations I-Disease 0 0.9999796
indicating O 0 0.0008395743
a O 0 0.0012502152
pharmacologic O 0 0.008633861
class O 0 0.0030292803
effect O 0 0.0035632793
. O 0 0.0066326847

We O 0 0.0034560203
studied O 0 0.002423581
three O 0 0.0014989553
calcium B-Chemical 0 0.99162674
channel O 0 0.37619796
blockers O 0 0.99157
of O 0 0.000849276
different O 0 0.00039931358
structure O 0 0.0021036493
, O 0 0.013221752
nifedipine B-Chemical 1 0.9999995
, O 0 0.090983935
diltiazem B-Chemical 1 0.99999964
, O 0 0.0031329347
and O 0 0.0024735217
verapamil B-Chemical 0 0.99999225
, O 0 0.00097637373
along O 0 0.0005940254
with O 0 0.00093666377
the O 0 0.0013872379
new O 0 0.0029759293
agent O 0 0.038773943
. O 0 0.00723838

Pregnant O 0 0.028566564
rats O 0 0.003535691
were O 0 0.0016608749
administered O 0 0.0010750787
one O 0 0.00070512324
of O 0 0.0006776897
these O 0 0.0009952575
calcium B-Chemical 0 0.99892104
channel O 0 0.52581835
blockers O 0 0.98851544
during O 0 0.00019692518
the O 0 0.00018515211
period O 0 0.00015169634
of O 0 0.00026601614
cardiac O 0 0.018510448
morphogenesis O 0 0.0018178306
and O 0 0.00028100878
the O 0 0.00020237666
offspring O 0 0.00053936004
examined O 0 0.0001692312
on O 0 0.00018404429
day O 0 0.00026266222
20 O 0 0.00036643492
of O 0 0.0006160881
gestation O 0 0.0019902182
for O 0 0.002272817
cardiovascular B-Disease 0 0.9996263
malformations I-Disease 0 0.9999492
. O 0 0.009916689

A O 0 0.051824935
low O 0 0.0038526617
incidence O 0 0.008128157
of O 0 0.009614292
cardiovascular B-Disease 0 0.9999496
malformations I-Disease 0 0.9999901
was O 0 0.0009573687
observed O 0 0.0003327156
after O 0 0.0002083355
exposure O 0 0.00071152253
to O 0 0.00017573367
each O 0 0.00011833597
of O 0 0.0001841965
the O 0 0.00017422457
four O 0 0.00018226873
calcium B-Chemical 0 0.99694
channel O 0 0.52872765
blockers O 0 0.9979144
, O 0 0.0010498586
but O 0 0.0003271062
this O 0 0.00021931007
incidence O 0 0.0009435864
was O 0 0.00028440836
statistically O 0 0.00028174865
significant O 0 0.00041052594
only O 0 0.0007370126
for O 0 0.0017777246
verapamil B-Chemical 0 0.9999924
and O 0 0.06150498
nifedipine B-Chemical 1 0.9999926
. O 0 0.009453724

All O 0 0.003037737
four O 0 0.0019461691
agents O 0 0.003062753
were O 0 0.0011633438
associated O 0 0.00086625415
with O 0 0.00082073535
aortic O 0 0.19268061
arch O 0 0.450373
branching O 0 0.013390599
variants O 0 0.0010749891
, O 0 0.0005728195
although O 0 0.00032157448
significantly O 0 0.0003179516
increased O 0 0.0003769157
only O 0 0.00045187282
for O 0 0.00059374154
Ro B-Chemical 0 0.9433768
40 I-Chemical 0 0.0011726147
- I-Chemical 0 0.0054463116
5967 I-Chemical 0 0.0041870563
and O 0 0.0037671437
verapamil B-Chemical 0 0.9999293
. O 0 0.00869677

The O 0 0.006157735
site O 0 0.005966033
of O 0 0.0058870823
common O 0 0.0063939383
side O 0 0.03202052
effects O 0 0.009420302
of O 0 0.033548534
sumatriptan B-Chemical 0 0.99998295
. O 0 0.01816698

Atypical B-Disease 0 0.76679444
sensations I-Disease 0 0.6956354
following O 0 0.0017116397
the O 0 0.0012526123
use O 0 0.0010777654
of O 0 0.0013861358
subcutaneous O 0 0.2118685
sumatriptan B-Chemical 0 0.9999943
are O 0 0.0010069434
common O 0 0.0012041716
, O 0 0.0013836405
but O 0 0.0015133122
of O 0 0.00219512
uncertain O 0 0.004337466
origin O 0 0.006466617
. O 0 0.008206304

They O 0 0.005171507
are O 0 0.0025287515
almost O 0 0.0018454915
always O 0 0.0021483216
benign O 0 0.20588632
, O 0 0.0018208632
but O 0 0.0010189664
can O 0 0.0005411893
be O 0 0.00057848886
mistaken O 0 0.0014836284
for O 0 0.0006159648
a O 0 0.0009528052
serious O 0 0.04469304
adverse O 0 0.35493508
event O 0 0.0042766514
by O 0 0.0019123406
the O 0 0.0025497407
patient O 0 0.0046700113
. O 0 0.0070262193

Two O 0 0.0041708425
patients O 0 0.0028819083
are O 0 0.0016585095
presented O 0 0.001232917
with O 0 0.0013582981
tingling B-Disease 0 0.70513725
or I-Disease 0 0.001044372
burning I-Disease 0 0.54165304
sensations I-Disease 0 0.08525484
limited O 0 0.0005936198
to O 0 0.0006075965
areas O 0 0.001310957
of O 0 0.001330856
heat O 0 0.02011555
exposure O 0 0.05411634
or O 0 0.009420319
sunburn B-Disease 0 0.99993753
. O 0 0.014591682

In O 0 0.004230784
these O 0 0.0031280913
individuals O 0 0.00342876
, O 0 0.0028121155
side O 0 0.012310377
effects O 0 0.0016575638
are O 0 0.0010788491
most O 0 0.0011339367
likely O 0 0.0009187441
generated O 0 0.0009324849
superficially O 0 0.0023334248
in O 0 0.0020030378
the O 0 0.0032231493
skin O 0 0.047901813
. O 0 0.008760749

Macula O 0 0.9183516
toxicity B-Disease 2 0.9948397
after O 0 0.020496918
intravitreal O 0 0.99954385
amikacin B-Chemical 0 0.99991274
. O 0 0.046066172

BACKGROUND O 0 0.023156052
: O 0 0.00444428
Although O 0 0.0023154127
intravitreal O 0 0.9987425
aminoglycosides B-Chemical 1 0.9983627
have O 0 0.0008877516
substantially O 0 0.0008015105
improved O 0 0.0010007628
visual O 0 0.14988145
prognosis O 0 0.7726406
in O 0 0.0017231994
endophthalmitis B-Disease 0 0.99999714
, O 0 0.49351722
macular O 0 1.0
infarction B-Disease 2 0.99999964
may O 0 0.0013139371
impair O 0 0.0010347872
full O 0 0.0015477306
visual O 0 0.040491845
recovery O 0 0.0055961413
. O 0 0.0067885425

METHODS O 0 0.004026293
: O 0 0.0034321733
We O 0 0.0018423331
present O 0 0.0012108479
a O 0 0.0012439602
case O 0 0.0009360879
of O 0 0.0010502428
presumed O 0 0.07101022
amikacin B-Chemical 0 0.99999833
retinal B-Disease 0 0.9999924
toxicity I-Disease 2 0.99999464
following O 0 0.00048358092
treatment O 0 0.00063257077
with O 0 0.0012674495
amikacin B-Chemical 0 0.9999753
and O 0 0.0045057014
vancomycin B-Chemical 1 0.9997371
for O 0 0.0017697713
alpha O 0 0.9706516
- O 0 0.75329036
haemolytic O 0 0.99986136
streptococcal B-Disease 0 0.99998486
endophthalmitis I-Disease 0 0.99999905
. O 0 0.04924035

RESULTS O 0 0.006550507
: O 0 0.0060450695
Endophthalmitis B-Disease 0 0.9933021
resolved O 0 0.0023310469
with O 0 0.0012387448
improvement O 0 0.0010322734
in O 0 0.00084706553
visual O 0 0.05368973
acuity O 0 0.9303951
to O 0 0.0006914937
6 O 0 0.00069056184
/ O 0 0.0014775067
24 O 0 0.0010828364
at O 0 0.0011936744
three O 0 0.0015813962
months O 0 0.002933219
. O 0 0.006484797

Fundus O 0 0.8153814
fluorescein B-Chemical 0 0.9764395
angiography O 0 0.3507464
confirmed O 0 0.009288079
macular O 0 0.9999814
capillary O 0 0.6812757
closure O 0 0.13606286
and O 0 0.014809626
telangiectasis B-Disease 0 0.9996512
. O 0 0.01756303

CONCLUSIONS O 0 0.021502385
: O 0 0.0049171555
Currently O 0 0.0033835352
accepted O 0 0.0051151677
intravitreal O 0 0.99802965
antibiotic O 0 0.42417783
regimens O 0 0.005367253
may O 0 0.0012791977
cause O 0 0.00877525
retinal B-Disease 0 0.9999349
toxicity I-Disease 2 0.9999933
and O 0 0.38119608
macular O 0 0.9999994
ischaemia B-Disease 0 0.9999958
. O 0 0.019895237

Treatment O 0 0.009275254
strategies O 0 0.0050592707
aimed O 0 0.004301282
at O 0 0.0035856462
avoiding O 0 0.007277087
retinal B-Disease 0 0.99949
toxicity I-Disease 2 0.9999224
are O 0 0.00722752
discussed O 0 0.007401311
. O 0 0.011444447

The O 0 0.0043212874
role O 0 0.0031136626
of O 0 0.0049933754
nicotine B-Chemical 1 0.9997801
in O 0 0.0066863582
smoking O 1 0.9987418
- O 0 0.082300395
related O 0 0.0040444955
cardiovascular B-Disease 0 0.9756232
disease I-Disease 0 0.96527594
. O 0 0.012676474

Nicotine B-Chemical 0 0.99985874
activates O 0 0.0030089915
the O 0 0.0024308525
sympathetic O 0 0.04806237
nervous O 0 0.02537204
system O 0 0.0011196822
and O 0 0.00090433215
in O 0 0.0007397985
this O 0 0.00071098097
way O 0 0.00081945444
could O 0 0.0008274009
contribute O 0 0.001184772
to O 0 0.0021533535
cardiovascular B-Disease 0 0.9751561
disease I-Disease 0 0.9681023
. O 0 0.009828065

Animal O 0 0.006667285
studies O 0 0.002452599
and O 0 0.0017332259
mechanistic O 0 0.0013672325
studies O 0 0.0008517157
indicate O 0 0.0005031513
that O 0 0.00068508706
nicotine B-Chemical 1 0.9998049
could O 0 0.0003796572
play O 0 0.00029234815
a O 0 0.00032656963
role O 0 0.00017852015
in O 0 0.00029608438
accelerating O 0 0.016901676
atherosclerosis B-Disease 2 0.9999963
, O 0 0.002152102
but O 0 0.0003567697
evidence O 0 0.00019800176
among O 0 0.0003947167
humans O 0 0.0008943471
is O 0 0.00026911896
too O 0 0.00028398595
inadequate O 0 0.00032763928
to O 0 0.00029618546
be O 0 0.00042873557
definitive O 0 0.00065825775
about O 0 0.0007587763
such O 0 0.0012422313
an O 0 0.002471102
effect O 0 0.0038250925
. O 0 0.0071657468

Almost O 0 0.0058564753
certainly O 0 0.00420057
, O 0 0.005120245
nicotine B-Chemical 1 0.99936396
via O 0 0.0010666522
its O 0 0.00177205
hemodynamic O 0 0.117410935
effects O 0 0.00062794436
contributes O 0 0.0002742776
to O 0 0.0003542363
acute O 0 0.9335097
cardiovascular O 0 0.9960439
events O 0 0.11327307
, O 0 0.0006827146
although O 0 0.00021047326
current O 0 0.00029411132
evidence O 0 0.00011919543
suggests O 0 9.819467e-05
that O 0 0.000112423586
the O 0 0.00015354014
effects O 0 0.00031319156
of O 0 0.0012612123
nicotine B-Chemical 1 0.99991405
are O 0 0.00023316499
much O 0 0.00013057032
less O 0 0.0001214777
important O 0 0.00010730412
than O 0 0.00010792393
are O 0 0.00013584681
the O 0 0.00017637778
prothrombotic O 0 0.5833495
effects O 0 0.0003930739
of O 0 0.00089315494
cigarette O 0 0.99729913
smoking O 1 0.9982822
or O 0 0.000611148
the O 0 0.00062507164
effects O 0 0.0012641075
of O 0 0.0037024212
carbon B-Chemical 0 0.99848586
monoxide I-Chemical 0 0.9999591
. O 0 0.010088058

Nicotine B-Chemical 0 0.9998846
does O 0 0.00679758
not O 0 0.004194499
appear O 0 0.0036948307
to O 0 0.0034495294
enhance O 0 0.0042459094
thrombosis B-Disease 2 0.99988735
among O 0 0.012335339
humans O 0 0.022399656
. O 0 0.013589032

Clinical O 0 0.0075678593
studies O 0 0.0024707376
of O 0 0.0023335344
pipe O 0 0.21365403
smokers O 0 0.30933577
and O 0 0.0010078374
people O 0 0.0013163459
using O 0 0.0006947642
transdermal O 0 0.992489
nicotine B-Chemical 1 0.99976
support O 0 0.00026307348
the O 0 0.00022750643
idea O 0 0.00022701976
that O 0 0.00020196664
toxins O 0 0.12905116
other O 0 0.000494373
than O 0 0.00033893646
nicotine B-Chemical 1 0.99956316
are O 0 0.0002911668
the O 0 0.00027716628
most O 0 0.00041498864
important O 0 0.00036935555
causes O 0 0.0008367989
of O 0 0.0021067797
acute O 0 0.9753331
cardiovascular O 0 0.9942075
events O 0 0.19770911
. O 0 0.007820846

Finally O 0 0.004274269
, O 0 0.0031157653
the O 0 0.0015999571
dose O 0 0.0027738921
response O 0 0.0014363452
for O 0 0.0010334187
cardiovascular O 0 0.9674587
events O 0 0.058763698
of O 0 0.005197865
nicotine B-Chemical 1 0.99994886
appears O 0 0.0003312802
to O 0 0.00019047689
be O 0 0.00022403582
flat O 0 0.002908376
, O 0 0.0003084636
suggesting O 0 0.00014437464
that O 0 0.00015356064
if O 0 0.00023826098
nicotine B-Chemical 1 0.9997106
is O 0 0.00028455837
involved O 0 0.0001782351
, O 0 0.0004731574
adverse O 0 0.1373229
effects O 0 0.00029614283
might O 0 0.00015313893
be O 0 0.00020856167
seen O 0 0.00023106298
with O 0 0.0003316983
relatively O 0 0.0006706234
low O 0 0.0012151876
- O 0 0.008887394
level O 0 0.0015448624
cigarette O 0 0.9730512
exposures O 0 0.4434855
. O 0 0.008065371

Iatrogenically O 0 0.5028166
induced O 0 0.0038233607
intractable O 0 0.69161326
atrioventricular B-Disease 0 0.9640866
reentrant I-Disease 0 0.98598516
tachycardia I-Disease 2 0.99993384
after O 0 0.00062393036
verapamil B-Chemical 0 0.99998045
and O 0 0.00049279473
catheter O 0 0.00045393582
ablation O 0 0.00031456805
in O 0 0.00021599348
a O 0 0.0002686562
patient O 0 0.000277904
with O 0 0.0004966297
Wolff B-Disease 0 0.8890166
- I-Disease 0 0.28577194
Parkinson I-Disease 0 0.9999112
- I-Disease 0 0.0616371
White I-Disease 0 0.19218874
syndrome I-Disease 0 0.36542958
and O 0 0.0027371931
idiopathic B-Disease 0 0.9995376
dilated I-Disease 2 0.99986553
cardiomyopathy I-Disease 2 0.99999917
. O 0 0.015711023

In O 0 0.004044661
a O 0 0.0031068146
patient O 0 0.002325279
with O 0 0.0053340495
WPW B-Disease 0 0.9999968
syndrome I-Disease 0 0.996367
and O 0 0.005841112
idiopathic B-Disease 0 0.9996166
dilated I-Disease 2 0.9999578
cardiomyopathy I-Disease 2 1.0
, O 0 0.020150166
intractable O 0 0.831933
atrioventricular B-Disease 0 0.95593417
reentrant I-Disease 0 0.9787611
tachycardia I-Disease 2 0.99994314
( O 0 0.005801096
AVRT B-Disease 0 0.99919516
) O 0 0.0022388871
was O 0 0.001778124
iatrogenically O 0 0.13416347
induced O 0 0.0043003596
. O 0 0.0076694777

QRS O 0 0.5699673
without O 0 0.0039895223
preexcitation O 0 0.98260754
, O 0 0.0020918786
caused O 0 0.00092609884
by O 0 0.00078752
junctional O 0 0.0019398773
escape O 0 0.00148697
beats O 0 0.1565735
after O 0 0.00037080873
verapamil B-Chemical 0 0.9999733
or O 0 0.00032225766
unidirectional O 0 0.00047844983
antegrade O 0 0.0005790637
block O 0 0.00018730956
of O 0 0.00023151217
accessory O 0 0.00027199482
pathway O 0 0.0002432934
after O 0 0.00022937282
catheter O 0 0.00053390115
ablation O 0 0.0006766826
, O 0 0.00095494365
established O 0 0.0016160267
frequent O 0 0.027399313
AVRT B-Disease 0 0.9991805
attack O 0 0.7766203
. O 0 0.008271485

Epidemic O 0 0.14256597
of O 0 0.008974539
liver B-Disease 2 0.99831414
disease I-Disease 2 0.9988533
caused O 0 0.0027986013
by O 0 0.0025151097
hydrochlorofluorocarbons B-Chemical 0 0.98091424
used O 0 0.0010232389
as O 0 0.0013862653
ozone B-Chemical 0 0.9995939
- O 0 0.08830595
sparing O 0 0.040691707
substitutes O 0 0.005370986
of O 0 0.00556726
chlorofluorocarbons B-Chemical 0 0.9842694
. O 0 0.009605442

BACKGROUND O 0 0.036706667
: O 0 0.0078082606
Hydrochlorofluorocarbons B-Chemical 0 0.86779076
( O 0 0.0093806805
HCFCs B-Chemical 0 0.9818657
) O 0 0.0021951862
are O 0 0.0007570415
used O 0 0.00054517994
increasingly O 0 0.0006284581
in O 0 0.00048087118
industry O 0 0.0022799291
as O 0 0.000441466
substitutes O 0 0.0010818358
for O 0 0.0007984773
ozone B-Chemical 0 0.99963856
- O 0 0.12088826
depleting O 0 0.03023902
chlorofluorocarbons B-Chemical 0 0.9964927
( O 0 0.010497503
CFCs B-Chemical 0 0.8575555
) O 0 0.008559342
. O 0 0.008500871

Limited O 0 0.016808486
studies O 0 0.003457987
in O 0 0.002385971
animals O 0 0.0016608507
indicate O 0 0.0012870865
potential O 0 0.0034583204
hepatotoxicity B-Disease 2 0.9999976
of O 0 0.0036302991
some O 0 0.002261839
of O 0 0.0031103478
these O 0 0.0047774906
compounds O 0 0.6615353
. O 0 0.009896298

We O 0 0.003562817
investigated O 0 0.0021602982
an O 0 0.0022379688
epidemic O 0 0.05093843
of O 0 0.0076760957
liver B-Disease 2 0.9995937
disease I-Disease 2 0.9996624
in O 0 0.0009175306
nine O 0 0.0005177036
industrial O 0 0.05206893
workers O 0 0.00090247724
who O 0 0.00044066756
had O 0 0.00018688462
had O 0 0.00015829291
repeated O 0 0.00014293552
accidental O 0 0.18607335
exposure O 0 0.0021241938
to O 0 0.0001661468
a O 0 0.00023577835
mixture O 0 0.00037118953
of O 0 0.0002753736
1 B-Chemical 0 0.00021441148
, I-Chemical 0 0.00031491136
1 I-Chemical 0 0.00028415362
- I-Chemical 0 0.0324814
dichloro I-Chemical 0 0.9848269
- I-Chemical 0 0.017614428
2 I-Chemical 0 0.00020980426
, I-Chemical 0 0.00026005923
2 I-Chemical 0 0.00018643985
, I-Chemical 0 0.00026817358
2 I-Chemical 0 0.00023590203
- I-Chemical 0 0.0041013774
trifluoroethane I-Chemical 0 0.11108139
( O 0 0.0096306
HCFC B-Chemical 0 0.9999715
123 I-Chemical 0 0.2163089
) O 0 0.0005447395
and O 0 0.00031532056
1 B-Chemical 0 0.0003489399
- I-Chemical 0 0.035883583
chloro I-Chemical 0 0.99947995
- I-Chemical 0 0.025558833
1 I-Chemical 0 0.0002914901
, I-Chemical 0 0.00034970633
2 I-Chemical 0 0.00027909383
, I-Chemical 0 0.0003849376
2 I-Chemical 0 0.00035979785
, I-Chemical 0 0.00056642713
2 I-Chemical 0 0.0006517652
- I-Chemical 0 0.009832404
tetrafluoroethane I-Chemical 0 0.92567474
( O 0 0.016825583
HCFC B-Chemical 0 0.9997917
124 I-Chemical 0 0.06814681
) O 0 0.0067872824
. O 0 0.008027911

All O 0 0.0058478923
nine O 0 0.0049973736
exposed O 0 0.0048489613
workers O 0 0.0054016993
were O 0 0.003997769
affected O 0 0.003980411
to O 0 0.0044387775
various O 0 0.006821951
degrees O 0 0.021788731
. O 0 0.0150465015

Both O 0 0.0046997527
compounds O 0 0.38712823
are O 0 0.0027708996
metabolised O 0 0.54951173
in O 0 0.0008902115
the O 0 0.00056076207
same O 0 0.0003383984
way O 0 0.00036754066
as O 0 0.0003586262
1 B-Chemical 0 0.00049130677
- I-Chemical 0 0.056504853
bromo I-Chemical 0 0.9996387
- I-Chemical 0 0.07984371
1 I-Chemical 0 0.0005493111
- I-Chemical 0 0.07063045
chloro I-Chemical 0 0.9996686
- I-Chemical 0 0.034964394
2 I-Chemical 0 0.00025664334
, I-Chemical 0 0.00029929288
2 I-Chemical 0 0.00020899423
, I-Chemical 0 0.00029614678
2 I-Chemical 0 0.0002566986
- I-Chemical 0 0.0045862645
trifluoroethane I-Chemical 0 0.09540044
( O 0 0.0036954854
halothane B-Chemical 0 0.9999397
) O 0 0.0011240162
to O 0 0.00019603717
form O 0 0.0002950716
reactive O 0 0.74096686
trifluoroacetyl B-Chemical 0 0.99959403
halide O 0 0.97422534
intermediates O 0 0.039925877
, O 0 0.0005291576
which O 0 0.0003356252
have O 0 0.0002532049
been O 0 0.00033412848
implicated O 0 0.0004029267
in O 0 0.00070815836
the O 0 0.0019347976
hepatotoxicity B-Disease 2 0.9999982
of O 0 0.076960765
halothane B-Chemical 0 0.99994004
. O 0 0.01010739

We O 0 0.0041415663
aimed O 0 0.002947024
to O 0 0.00194856
test O 0 0.0017494261
whether O 0 0.0011618823
HCFCs B-Chemical 0 0.92734313
123 I-Chemical 0 0.0045935973
and I-Chemical 0 0.0011735791
124 I-Chemical 0 0.0016271005
can O 0 0.00085930125
result O 0 0.0011269668
in O 0 0.001920142
serious O 0 0.3628045
liver B-Disease 2 0.99851495
disease I-Disease 2 0.9994085
. O 0 0.013773791

METHODS O 0 0.004052809
: O 0 0.0036144194
For O 0 0.0018850563
one O 0 0.0014415927
severely O 0 0.0023296345
affected O 0 0.0010249453
worker O 0 0.0021667436
liver O 0 0.43578094
biopsy O 0 0.001639731
and O 0 0.00048279105
immunohistochemical O 0 0.0014567544
stainings O 0 0.0015081384
for O 0 0.0003621159
the O 0 0.0003865213
presence O 0 0.00051488425
of O 0 0.0013660416
trifluoroacetyl B-Chemical 0 0.9963097
protein O 0 0.011799035
adducts O 0 0.92866194
were O 0 0.0027394472
done O 0 0.003549101
. O 0 0.006602395

The O 0 0.0034961826
serum O 0 0.021937031
of O 0 0.001926498
six O 0 0.00093774823
affected O 0 0.0008066369
workers O 0 0.00097540015
and O 0 0.0005306716
five O 0 0.00028432597
controls O 0 0.00040725383
was O 0 0.00025656403
tested O 0 0.00020392393
for O 0 0.00024956925
autoantibodies O 0 0.2783557
that O 0 0.00020180707
react O 0 0.00072149845
with O 0 0.00031864352
human O 0 0.001757581
liver O 0 0.9910874
cytochrome O 0 0.99999034
- O 0 0.9866471
P450 O 0 0.99999905
2E1 O 0 0.99999976
( O 0 0.4872591
P450 O 0 0.9999975
2E1 O 0 0.9999989
) O 0 0.006591763
and O 0 0.0008068741
P58 O 0 0.26408288
protein O 0 0.004131364
disulphide O 0 0.9977368
isomerase O 0 0.9813176
isoform O 0 0.0061499393
( O 0 0.0071725613
P58 O 0 0.44999295
) O 0 0.007632437
. O 0 0.0078078834

FINDINGS O 0 0.007900109
: O 0 0.003823281
The O 0 0.0018185828
liver O 0 0.10751462
biopsy O 0 0.0021563568
sample O 0 0.00096987846
showed O 0 0.0019024261
hepatocellular O 0 0.99999976
necrosis B-Disease 2 0.9999995
which O 0 0.014773916
was O 0 0.0005141951
prominent O 0 0.0032615704
in O 0 0.00034228887
perivenular O 0 0.9727207
zone O 0 0.0022227955
three O 0 0.000119187695
and O 0 0.00016812932
extended O 0 0.00016419764
focally O 0 0.010409826
from O 0 0.00018694256
portal O 0 0.0045621037
tracts O 0 0.00029985383
to O 0 0.00021774779
portal O 0 0.0060965046
tracts O 0 0.0005205183
and O 0 0.00068020646
centrilobular O 0 0.99169266
areas O 0 0.009764201
( O 0 0.0024077878
bridging O 0 0.06260291
necrosis B-Disease 2 0.9997911
) O 0 0.0442476
. O 0 0.008697937

Trifluoroacetyl B-Chemical 0 0.93334997
- O 0 0.021387853
adducted O 0 0.020853188
proteins O 0 0.0052729435
were O 0 0.004151134
detected O 0 0.0039259735
in O 0 0.0052670473
surviving O 0 0.011746448
hepatocytes O 0 0.2530602
. O 0 0.015631458

Autoantibodies O 0 0.13080709
against O 0 0.01840688
P450 O 0 0.9999894
2E1 O 0 0.99999845
or O 0 0.018653478
P58 O 0 0.8260406
, O 0 0.0014012454
previously O 0 0.0006088649
associated O 0 0.00059982075
with O 0 0.0026654762
halothane B-Disease 0 0.99999785
hepatitis I-Disease 2 1.0
, O 0 0.04281544
were O 0 0.0004819751
detected O 0 0.00032422369
in O 0 0.000402491
the O 0 0.0005419936
serum O 0 0.02903877
of O 0 0.0012229467
five O 0 0.0012300794
affected O 0 0.0023341752
workers O 0 0.0059194025
. O 0 0.0069361213

INTERPRETATION O 0 0.01358994
: O 0 0.004105273
Repeated O 0 0.0031218273
exposure O 0 0.0029934708
of O 0 0.001411563
human O 0 0.0015725408
beings O 0 0.023014555
to O 0 0.00086845673
HCFCs B-Chemical 0 0.9842135
123 I-Chemical 0 0.0055257706
and I-Chemical 0 0.00041265885
124 I-Chemical 0 0.0006014408
can O 0 0.00020735353
result O 0 0.00021999446
in O 0 0.00032683995
serious O 0 0.17423217
liver B-Disease 0 0.9985831
injury I-Disease 0 0.9986106
in O 0 0.000509175
a O 0 0.00049598486
large O 0 0.00047454497
proportion O 0 0.0005654692
of O 0 0.0009775385
the O 0 0.00132793
exposed O 0 0.0026797352
population O 0 0.006200026
. O 0 0.007015694

Although O 0 0.0030444118
the O 0 0.0020165502
exact O 0 0.0016661491
mechanism O 0 0.0012680232
of O 0 0.006635415
hepatotoxicity B-Disease 2 0.9999995
of O 0 0.0034310773
these O 0 0.00095427694
agents O 0 0.014755707
is O 0 0.00041795848
not O 0 0.00029193563
known O 0 0.00042827212
, O 0 0.0003688647
the O 0 0.00022345982
results O 0 0.00021683476
suggest O 0 0.00020910746
that O 0 0.0004168641
trifluoroacetyl B-Chemical 0 0.99792284
- O 0 0.03493977
altered O 0 0.0011370124
liver O 0 0.3603911
proteins O 0 0.0022510695
are O 0 0.0022991651
involved O 0 0.0032466396
. O 0 0.0064404453

In O 0 0.0036752913
view O 0 0.0027504533
of O 0 0.0019182238
the O 0 0.0012614712
potentially O 0 0.0014906653
widespread O 0 0.0014547012
use O 0 0.0006187455
of O 0 0.0006009257
these O 0 0.00071360765
compounds O 0 0.47560295
, O 0 0.00074217154
there O 0 0.00035565707
is O 0 0.000498098
an O 0 0.00059652666
urgent O 0 0.00079624983
need O 0 0.00070822926
to O 0 0.0009784081
develop O 0 0.001783414
safer O 0 0.003839595
alternatives O 0 0.003912476
. O 0 0.0066355183

Bile B-Disease 0 0.9630106
duct I-Disease 0 0.56762993
hamartoma I-Disease 0 0.97939277
occurring O 0 0.0030805056
in O 0 0.0012977361
association O 0 0.0010014895
with O 0 0.0010969809
long O 0 0.0012342046
- O 0 0.0035206222
term O 0 0.0015219194
treatment O 0 0.0028135784
with O 0 0.007929159
danazol B-Chemical 0 0.9998068
. O 0 0.010319218

We O 0 0.0041627674
report O 0 0.0037649595
a O 0 0.0024057121
case O 0 0.0016997415
of O 0 0.0018811398
bile B-Disease 0 0.9627656
duct I-Disease 0 0.93030316
hamartoma I-Disease 0 0.9989304
which O 0 0.0016525342
developed O 0 0.0007852326
in O 0 0.0003728372
a O 0 0.00043685274
patient O 0 0.00040120268
who O 0 0.0004856356
had O 0 0.00031416529
been O 0 0.00034862832
on O 0 0.0003508561
long O 0 0.00074740377
- O 0 0.0054762037
term O 0 0.002398795
danazol B-Chemical 0 0.99978346
treatment O 0 0.008107416
. O 0 0.0076686325

Such O 0 0.005570377
patients O 0 0.0031866098
should O 0 0.0013379952
be O 0 0.0011388931
under O 0 0.0007724429
close O 0 0.00074662885
follow O 0 0.0006369793
- O 0 0.0024256571
up O 0 0.00057155424
, O 0 0.00070763764
preferably O 0 0.0006702681
with O 0 0.0005897709
periodic O 0 0.0012503874
ultrasound O 0 0.0018340668
examination O 0 0.0012621032
of O 0 0.0019248337
the O 0 0.0029646521
liver O 0 0.5970889
. O 0 0.008755563

If O 0 0.0035137949
the O 0 0.0023315395
patient O 0 0.001931303
develops O 0 0.0031757
a O 0 0.0024198454
liver B-Disease 0 0.9905595
mass I-Disease 0 0.39648348
, O 0 0.0010380851
because O 0 0.00032884534
of O 0 0.00044816628
non O 0 0.0013668095
- O 0 0.0049045724
specific O 0 0.00023530809
clinical O 0 0.0005561604
features O 0 0.00027253994
and O 0 0.0002357734
imaging O 0 0.00051995646
appearances O 0 0.0011416357
, O 0 0.00040153807
biopsy O 0 0.0005957845
may O 0 0.00023485888
be O 0 0.00026771065
the O 0 0.00029793486
only O 0 0.00039020786
way O 0 0.0004723582
to O 0 0.00055193674
achieve O 0 0.00076657033
a O 0 0.0015689154
definitive O 0 0.0027711934
diagnosis O 0 0.013471076
. O 0 0.0069620614

Endocrine O 0 0.34323853
screening O 0 0.00386387
in O 0 0.0022984804
1 O 0 0.0018857275
, O 0 0.0022492274
022 O 0 0.44282076
men O 0 0.017268267
with O 0 0.0013054251
erectile B-Disease 0 0.9943119
dysfunction I-Disease 0 0.8194518
: O 0 0.0013963763
clinical O 0 0.0012239739
significance O 0 0.00069180684
and O 0 0.0010049199
cost O 0 0.0018827753
- O 0 0.0051067523
effective O 0 0.0029181128
strategy O 0 0.00496971
. O 0 0.008007421

PURPOSE O 0 0.005361544
: O 0 0.0034284566
We O 0 0.0016676837
reviewed O 0 0.0014907576
the O 0 0.00084188546
results O 0 0.0006544115
of O 0 0.0010780529
serum O 0 0.93601954
testosterone B-Chemical 0 0.99999523
and O 0 0.019917717
prolactin O 0 0.9979157
determination O 0 0.006873809
in O 0 0.00032357188
1 O 0 0.00029058137
, O 0 0.00048075136
022 O 0 0.2732362
patients O 0 0.00028501288
referred O 0 0.00017201185
because O 0 0.00014170061
of O 0 0.00038260655
erectile B-Disease 0 0.9950807
dysfunction I-Disease 0 0.7235889
and O 0 0.00027519566
compared O 0 0.000117135154
the O 0 0.00013967669
data O 0 0.00015867267
with O 0 0.00018895054
history O 0 0.002366329
, O 0 0.0002776633
results O 0 0.00013531058
of O 0 0.00021132386
physical O 0 0.0011523503
examination O 0 0.00027746957
, O 0 0.00029444293
other O 0 0.00020398907
etiological O 0 0.027947927
investigations O 0 0.00032907928
and O 0 0.00021881756
effects O 0 0.00028729666
of O 0 0.0004310891
endocrine O 0 0.58145505
therapy O 0 0.0006746295
to O 0 0.00014761816
refine O 0 0.0007626445
the O 0 0.00014060782
rules O 0 0.00018544079
of O 0 0.00025135212
cost O 0 0.00076497986
- O 0 0.011071116
effective O 0 0.0003879936
endocrine O 0 0.22205803
screening O 0 0.00048433285
and O 0 0.00032599413
to O 0 0.0002929832
pinpoint O 0 0.00049077976
actual O 0 0.0005097385
responsibility O 0 0.0014502998
for O 0 0.0014081965
hormonal O 0 0.14819664
abnormalities O 0 0.15333626
. O 0 0.0065243323

MATERIALS O 0 0.009133683
AND O 0 0.0050896015
METHODS O 0 0.0043912414
: O 0 0.007295909
Testosterone B-Chemical 1 0.9993482
and O 0 0.0070907525
prolactin O 0 0.9331769
were O 0 0.00513191
determined O 0 0.0050656307
by O 0 0.008828166
radioimmunoassay O 0 0.7395135
. O 0 0.016204627

Every O 0 0.003698747
patient O 0 0.00238693
was O 0 0.0015954913
screened O 0 0.0013860123
for O 0 0.0015800664
testosterone B-Chemical 0 0.9999255
and O 0 0.0014761603
451 O 0 0.01653582
were O 0 0.00035625903
screened O 0 0.0003622943
for O 0 0.00036902577
prolactin O 0 0.88555205
on O 0 0.00016349618
the O 0 0.00018829282
basis O 0 0.00020852151
of O 0 0.00029221686
low B-Disease 0 0.002694993
sexual I-Disease 0 0.41439626
desire I-Disease 0 0.16604222
, O 0 0.006098221
gynecomastia B-Disease 0 0.99981517
or O 0 0.0034216386
testosterone B-Chemical 0 0.99996567
less O 0 0.00050825125
than O 0 0.00036217828
4 O 0 0.00050837034
ng O 0 0.0011040568
. O 0 0.0014778852
/ O 0 0.005139675
ml O 0 0.006375769
. O 0 0.007323936

Determination O 0 0.009040314
was O 0 0.0046996363
repeated O 0 0.0031937868
in O 0 0.003465486
case O 0 0.0037011043
of O 0 0.0044240747
abnormal O 0 0.008735444
first O 0 0.0049089403
results O 0 0.00754004
. O 0 0.012096178

Prolactin O 0 0.9931532
results O 0 0.002612527
were O 0 0.0016592708
compared O 0 0.0008548753
with O 0 0.00080820994
those O 0 0.0007198845
of O 0 0.0005846251
a O 0 0.0005414885
previous O 0 0.0003796597
personal O 0 0.0020510773
cohort O 0 0.0011374236
of O 0 0.00048545236
1 O 0 0.00037997434
, O 0 0.00050641794
340 O 0 0.007787416
patients O 0 0.00053525815
with O 0 0.00069093145
erectile B-Disease 0 0.9895907
dysfunction I-Disease 0 0.60643744
and O 0 0.0014237061
systematic O 0 0.0024973196
prolactin O 0 0.9655141
determination O 0 0.018054424
. O 0 0.007421158

Main O 0 0.012068199
clinical O 0 0.003854395
criteria O 0 0.0017703156
tested O 0 0.0010589674
regarding O 0 0.0007173444
efficiency O 0 0.0009593685
in O 0 0.0009961067
hormone O 0 0.73600465
determination O 0 0.0029838516
were O 0 0.0006189479
low B-Disease 0 0.0013471427
sexual I-Disease 0 0.13375905
desire I-Disease 0 0.025657805
, O 0 0.0013984431
small O 0 0.0015220345
testes O 0 0.0076734633
and O 0 0.00541748
gynecomastia B-Disease 0 0.9990428
. O 0 0.00966966

Endocrine O 0 0.300733
therapy O 0 0.003980287
consisted O 0 0.0016924549
of O 0 0.0057078125
testosterone B-Chemical 0 0.9999969
heptylate I-Chemical 0 0.9655789
or O 0 0.0016296423
human O 0 0.02387689
chorionic O 0 0.9999255
gonadotropin O 0 0.9999684
for O 0 0.016955718
hypogonadism B-Disease 0 0.9999887
and O 0 0.049736474
bromocriptine B-Chemical 0 0.9999924
for O 0 0.013550933
hyperprolactinemia B-Disease 2 0.9999838
. O 0 0.009943495

RESULTS O 0 0.006944193
: O 0 0.010015858
Testosterone B-Chemical 1 0.9998791
was O 0 0.0020228396
less O 0 0.0010692159
than O 0 0.0005942298
3 O 0 0.0005095498
ng O 0 0.00073796744
. O 0 0.00052454707
/ O 0 0.0017320688
ml O 0 0.000920304
. O 0 0.00035968298
in O 0 0.00032777796
107 O 0 0.00047705352
patients O 0 0.00048554537
but O 0 0.00046019888
normal O 0 0.000595828
in O 0 0.00055798376
40 O 0 0.0007394489
% O 0 0.0010951562
at O 0 0.0012981377
repeat O 0 0.0029301948
determination O 0 0.0067027924
. O 0 0.0072405464

The O 0 0.0029776986
prevalence O 0 0.0029264856
of O 0 0.0017722143
repeatedly O 0 0.0016496739
low O 0 0.008902431
testosterone B-Chemical 0 0.9999664
increased O 0 0.0013971174
with O 0 0.0007571259
age O 0 0.0017269421
( O 0 0.0006502672
4 O 0 0.00024977681
% O 0 0.0002721396
before O 0 0.00016843354
age O 0 0.0003332829
50 O 0 0.00028358767
years O 0 0.0003072734
and O 0 0.00035290446
9 O 0 0.00039651868
% O 0 0.0005718673
50 O 0 0.0007267011
years O 0 0.0010758784
or O 0 0.0015671626
older O 0 0.0052090297
) O 0 0.005987417
. O 0 0.0077819796

Two O 0 0.010827082
pituitary B-Disease 0 0.9853365
tumors I-Disease 0 0.9843999
were O 0 0.0061274604
discovered O 0 0.006343558
after O 0 0.0064184982
testosterone B-Chemical 0 0.9996251
determination O 0 0.081695266
. O 0 0.017080104

Most O 0 0.0046886895
of O 0 0.0025516816
the O 0 0.0016182716
other O 0 0.0016270656
low O 0 0.009874139
testosterone B-Chemical 0 0.9999672
levels O 0 0.0010038596
seemed O 0 0.00056016084
to O 0 0.00026349898
result O 0 0.00023865797
from O 0 0.0003103417
nonorganic O 0 0.9975303
hypothalamic B-Disease 0 0.9786879
dysfunction I-Disease 0 0.99019974
because O 0 0.00017818072
of O 0 0.00030353194
normal O 0 0.002861945
serum O 0 0.9160919
luteinizing O 0 0.999153
hormone O 0 0.9856491
and O 0 0.004903984
prolactin O 0 0.99111533
and O 0 0.0002619312
to O 0 0.00012982618
have O 0 0.00012116337
only O 0 0.00015690111
a O 0 0.00016449651
small O 0 0.00013676235
role O 0 0.00011214798
in O 0 0.0002943947
erectile B-Disease 0 0.99529856
dysfunction I-Disease 0 0.85802567
( O 0 0.0009111041
definite O 0 0.0045220884
improvement O 0 0.00021032902
in O 0 0.00014522945
only O 0 0.00017163911
16 O 0 0.00016656144
of O 0 0.00018855314
44 O 0 0.0003831785
[ O 0 0.00079468754
36 O 0 0.00021288959
% O 0 0.00026611658
] O 0 0.0005174335
after O 0 0.00018582243
androgen O 0 0.9981811
therapy O 0 0.0013154487
, O 0 0.0003814755
normal O 0 0.00044544938
morning O 0 0.0008631656
or O 0 0.00021606393
nocturnal O 0 0.07590214
erections O 0 0.681873
in O 0 0.00020415876
30 O 0 0.00020200112
% O 0 0.00030420726
and O 0 0.00038670417
definite O 0 0.0063650575
vasculogenic O 0 0.8598036
contributions O 0 0.0013187816
in O 0 0.0011532997
42 O 0 0.0020890196
% O 0 0.0029938053
) O 0 0.0055878083
. O 0 0.0074032876

Determining O 0 0.007989476
testosterone B-Chemical 0 0.9997558
only O 0 0.0026208826
in O 0 0.0012537177
cases O 0 0.0012485952
of O 0 0.0009555262
low B-Disease 0 0.004126464
sexual I-Disease 0 0.32909787
desire I-Disease 0 0.035327252
or O 0 0.00039806846
abnormal O 0 0.00329279
physical O 0 0.00090491696
examination O 0 0.0002476646
would O 0 0.00015426906
have O 0 0.00013732977
missed O 0 0.00023008973
40 O 0 0.00017406236
% O 0 0.00018988954
of O 0 0.00017830938
the O 0 0.00016278046
cases O 0 0.00030931027
with O 0 0.0003333957
low O 0 0.0063871895
testosterone B-Chemical 0 0.99997914
, O 0 0.0008148918
including O 0 0.00028995785
37 O 0 0.0004629055
% O 0 0.00035532934
of O 0 0.00038990186
those O 0 0.00052467536
subsequently O 0 0.0006825276
improved O 0 0.0012067104
by O 0 0.0019811464
androgen O 0 0.9969662
therapy O 0 0.015170749
. O 0 0.0073419437

Prolactin O 0 0.9913003
exceeded O 0 0.0026417647
20 O 0 0.0018146434
ng O 0 0.002138706
. O 0 0.0012398602
/ O 0 0.0026415673
ml O 0 0.0014441767
. O 0 0.0005968618
in O 0 0.0005045792
5 O 0 0.0004656805
men O 0 0.0016246105
and O 0 0.00057700014
was O 0 0.0006019575
normal O 0 0.000810524
in O 0 0.00080981414
2 O 0 0.0010254625
at O 0 0.0013208021
repeat O 0 0.0029919995
determination O 0 0.006821951
. O 0 0.007401213

Only O 0 0.022130113
1 O 0 0.022296015
prolactinoma B-Disease 2 0.9970561
was O 0 0.024143739
discovered O 0 0.027662696
. O 0 0.0325456

These O 0 0.003882588
data O 0 0.002724227
are O 0 0.0016740749
lower O 0 0.0011756786
than O 0 0.0006430075
those O 0 0.00061985105
we O 0 0.00032331128
found O 0 0.0003012872
during O 0 0.00021415832
the O 0 0.00022582957
last O 0 0.00016559829
2 O 0 0.00019782003
decades O 0 0.00036229086
( O 0 0.00035350345
overall O 0 0.0003680703
prolactin O 0 0.9388682
greater O 0 0.00017604108
than O 0 0.00012272641
20 O 0 0.00014248281
ng O 0 0.00027201013
. O 0 0.00020918205
/ O 0 0.0015991835
ml O 0 0.00063283846
. O 0 0.00018508766
in O 0 0.00018013772
1 O 0 0.000185251
. O 0 0.00016543067
86 O 0 0.0002653709
% O 0 0.00022994567
of O 0 0.00025133532
1 O 0 0.00025415374
, O 0 0.0003754742
821 O 0 0.004118317
patients O 0 0.00050649367
, O 0 0.0008980758
prolactinomas B-Disease 0 0.99952245
in O 0 0.0004717103
7 O 0 0.00044219883
, O 0 0.0007012609
0 O 0 0.00083343877
. O 0 0.0010471562
38 O 0 0.0021258653
% O 0 0.0031967575
) O 0 0.0060478398
. O 0 0.008134117

Bromocriptine B-Chemical 0 0.9998561
was O 0 0.0041919188
definitely O 0 0.0059407484
effective O 0 0.0015716001
in O 0 0.0010630946
cases O 0 0.0013400599
with O 0 0.0014090086
prolactin O 0 0.97204787
greater O 0 0.0007557854
than O 0 0.00062772416
35 O 0 0.0009463997
ng O 0 0.0016684533
. O 0 0.0020223218
/ O 0 0.0061674165
ml O 0 0.0074760793
. O 0 0.0085985325

( O 0 0.0054859356
8 O 0 0.002585285
of O 0 0.0018200168
12 O 0 0.0010428722
compared O 0 0.0006274903
to O 0 0.0005745085
only O 0 0.0005675028
9 O 0 0.00043102482
of O 0 0.00040902238
22 O 0 0.00042652388
cases O 0 0.0004414519
with O 0 0.00050904904
prolactin O 0 0.904811
between O 0 0.0002493286
20 O 0 0.00030099202
and O 0 0.0003418102
35 O 0 0.00041345874
ng O 0 0.0007376854
. O 0 0.00082165
/ O 0 0.0028642616
ml O 0 0.0028524785
. O 0 0.002705317
) O 0 0.0060031065
. O 0 0.007869555

Testosterone B-Chemical 1 0.99990916
was O 0 0.0038204198
low O 0 0.00245624
in O 0 0.0013039124
less O 0 0.00089995685
than O 0 0.0005414452
50 O 0 0.00060565275
% O 0 0.00053035736
of O 0 0.00047028056
cases O 0 0.0006970499
with O 0 0.00082181796
prolactin O 0 0.9603319
greater O 0 0.00049058825
than O 0 0.00044832946
35 O 0 0.00072621065
ng O 0 0.001356731
. O 0 0.0017108925
/ O 0 0.005644809
ml O 0 0.0068740766
. O 0 0.007876487

CONCLUSIONS O 0 0.025732234
: O 0 0.004740043
Low O 0 0.006646947
prevalences O 0 0.005037356
and O 0 0.001311302
effects O 0 0.0010956132
of O 0 0.0010697495
low O 0 0.012100591
testosterone B-Chemical 0 0.9999788
and O 0 0.0018768955
high O 0 0.0061456976
prolactin O 0 0.99320716
in O 0 0.0010456288
erectile B-Disease 0 0.994974
dysfunction I-Disease 0 0.6889069
cannot O 0 0.00213767
justify O 0 0.001146877
their O 0 0.0015455429
routine O 0 0.0024674267
determination O 0 0.006377096
. O 0 0.006942352

However O 0 0.004964313
, O 0 0.0039915503
cost O 0 0.0034414935
- O 0 0.0076452666
effective O 0 0.0011322739
screening O 0 0.00091474876
strategies O 0 0.0006331091
recommended O 0 0.00051199086
so O 0 0.0003592796
far O 0 0.00030579235
missed O 0 0.00032403832
40 O 0 0.00024362301
to O 0 0.00020052063
50 O 0 0.0002788611
% O 0 0.0002823198
of O 0 0.00028973405
cases O 0 0.0004632511
improved O 0 0.00047447396
with O 0 0.00056778005
endocrine O 0 0.33382004
therapy O 0 0.0017233707
and O 0 0.0013269559
the O 0 0.002465049
pituitary B-Disease 0 0.9975228
tumors I-Disease 0 0.9988802
. O 0 0.009469097

We O 0 0.0034158227
now O 0 0.0023316883
advocate O 0 0.0018886676
that O 0 0.0009835383
before O 0 0.00065639656
age O 0 0.001075719
50 O 0 0.0007377114
years O 0 0.0011515575
testosterone B-Chemical 0 0.99974734
be O 0 0.00036783755
determined O 0 0.00023082274
only O 0 0.00027296698
in O 0 0.00021620406
cases O 0 0.0003316923
of O 0 0.0003219404
low B-Disease 0 0.0025797186
sexual I-Disease 0 0.25383654
desire I-Disease 0 0.024736738
and O 0 0.00033652195
abnormal O 0 0.0032058507
physical O 0 0.0009145422
examination O 0 0.00026027948
but O 0 0.0002295369
that O 0 0.00016159663
it O 0 0.0002228819
be O 0 0.00021655437
measured O 0 0.0002284668
in O 0 0.00033527438
all O 0 0.0004620621
men O 0 0.0056825276
older O 0 0.0016711074
than O 0 0.0010170353
50 O 0 0.0021471588
years O 0 0.0037780993
. O 0 0.006326052

Prolactin O 0 0.9941229
should O 0 0.0020578427
be O 0 0.0015607822
determined O 0 0.0009858449
only O 0 0.0009121982
in O 0 0.0006473263
cases O 0 0.0007452956
of O 0 0.0006495777
low B-Disease 0 0.003693695
sexual I-Disease 0 0.45762375
desire I-Disease 0 0.17575558
, O 0 0.00489521
gynecomastia B-Disease 0 0.99955446
and O 0 0.0011039138
/ O 0 0.018696401
or O 0 0.0011475901
testosterone B-Chemical 0 0.9999385
less O 0 0.0005238032
than O 0 0.0003895981
4 O 0 0.0005433992
ng O 0 0.001159704
. O 0 0.0015496934
/ O 0 0.005234924
ml O 0 0.006524622
. O 0 0.0075346148

Extrapyramidal O 0 0.9971112
side O 0 0.05137634
effects O 0 0.0037521042
with O 0 0.008184487
risperidone B-Chemical 0 0.99999905
and O 0 0.039674178
haloperidol B-Chemical 1 0.9999994
at O 0 0.0010891198
comparable O 0 0.0011654272
D2 O 0 0.995023
receptor O 0 0.019575082
occupancy O 0 0.006725671
levels O 0 0.004811794
. O 0 0.008134349

Risperidone B-Chemical 1 0.99998844
is O 0 0.005261446
an O 0 0.0054263254
antipsychotic O 0 0.9995838
drug O 0 0.45030147
with O 0 0.0009560752
high O 0 0.0009237851
affinity O 0 0.0022328682
at O 0 0.0011818468
dopamine B-Chemical 1 0.99997616
D2 O 0 0.99949574
and O 0 0.0021541968
serotonin B-Chemical 0 0.99908745
5 I-Chemical 0 0.0014256496
- I-Chemical 0 0.01381712
HT2 I-Chemical 0 0.9559497
receptors O 0 0.02230732
. O 0 0.008222975

Previous O 0 0.0037976329
clinical O 0 0.0034419864
studies O 0 0.0015783559
have O 0 0.0010117891
proposed O 0 0.0010525595
that O 0 0.0011844909
risperidone B-Chemical 0 0.9999987
' O 0 0.0015346447
s O 0 0.00063462026
pharmacologic O 0 0.0029428548
profile O 0 0.0002752222
may O 0 0.00017451156
produce O 0 0.00013608435
improved O 0 0.00022554942
efficacy O 0 0.00027618583
for O 0 0.00021856982
negative O 0 0.01792536
psychotic B-Disease 0 1.0
symptoms I-Disease 0 0.98373747
and O 0 0.00038620035
decreased O 0 0.00029774266
propensity O 0 0.0013910474
for O 0 0.0006936567
extrapyramidal O 0 0.99999547
side O 0 0.04520036
effects O 0 0.0004504699
; O 0 0.00044112653
features O 0 0.00033197922
shared O 0 0.0003831783
by O 0 0.00036987104
so O 0 0.0004917059
- O 0 0.0034171718
called O 0 0.0010373895
' O 0 0.0021596856
atypical O 0 0.14174886
' O 0 0.015323238
neuroleptics O 0 0.9993975
. O 0 0.0069346707

To O 0 0.0025479042
determine O 0 0.0012139492
if O 0 0.0012747293
routine O 0 0.0020525057
risperidone B-Chemical 0 0.99999654
treatment O 0 0.0015702237
is O 0 0.00053845503
associated O 0 0.00040972562
with O 0 0.0003343296
a O 0 0.0003145213
unique O 0 0.00024473164
degree O 0 0.00035601138
of O 0 0.0032254143
D2 O 0 0.99981314
receptor O 0 0.033897802
occupancy O 0 0.0021800327
and O 0 0.00023834982
pattern O 0 0.00016687809
of O 0 0.0002443861
clinical O 0 0.0013806957
effects O 0 0.00027804077
, O 0 0.00024389214
we O 0 0.00011216402
used O 0 0.00020636951
[ O 0 0.031874303
123I O 0 0.9991026
] O 0 0.06282974
IBZM O 0 0.9999565
SPECT O 0 0.81907415
to O 0 0.00015168982
determine O 0 0.00011155028
D2 O 0 0.9872371
occupancy O 0 0.00066521903
in O 0 0.00017374448
subjects O 0 0.00022089662
treated O 0 0.00017553255
with O 0 0.00016865597
routine O 0 0.00016892281
clinical O 0 0.0004970332
doses O 0 0.0011362269
of O 0 0.0016203552
risperidone B-Chemical 0 0.99999917
( O 0 0.00052172854
n O 0 0.00023138178
= O 0 0.00048145463
12 O 0 0.0002333322
) O 0 0.0005679528
or O 0 0.00084840815
haloperidol B-Chemical 1 0.9999987
( O 0 0.0012880856
n O 0 0.0010546724
= O 0 0.0022563813
7 O 0 0.0022887492
) O 0 0.005126292
. O 0 0.007316275

Both O 0 0.008898482
risperidone B-Chemical 0 0.9999944
and O 0 0.07753031
haloperidol B-Chemical 1 0.9999995
produced O 0 0.0054491637
D2 O 0 0.999092
occupancy O 0 0.0019952224
levels O 0 0.00043684297
between O 0 0.00030945154
approximately O 0 0.00037042823
60 O 0 0.000419119
and O 0 0.0004694817
90 O 0 0.00054169603
% O 0 0.0007555784
at O 0 0.00081325264
standard O 0 0.0012793574
clinical O 0 0.0036902819
doses O 0 0.0074317413
. O 0 0.00697422

There O 0 0.004661654
was O 0 0.002880037
no O 0 0.001666391
significant O 0 0.001425995
difference O 0 0.00089352904
between O 0 0.0008112036
occupancy O 0 0.0017694194
levels O 0 0.0010771096
obtained O 0 0.0013477517
with O 0 0.012361777
haloperidol B-Chemical 1 0.9999993
or O 0 0.029320635
risperidone B-Chemical 0 0.9999925
. O 0 0.00945317

Drug B-Disease 0 0.8979066
- I-Disease 0 0.120252706
induced I-Disease 0 0.013236641
parkinsonism I-Disease 2 0.9999969
was O 0 0.0015049981
observed O 0 0.0006103968
in O 0 0.00048382115
subjects O 0 0.00056665996
treated O 0 0.000533033
with O 0 0.002578909
risperidone B-Chemical 0 0.9999993
( O 0 0.0009085018
42 O 0 0.00038313397
% O 0 0.00034311236
) O 0 0.0006672534
and O 0 0.0014842496
haloperidol B-Chemical 1 0.99999964
( O 0 0.000896448
29 O 0 0.00051238365
% O 0 0.0003349488
) O 0 0.00043009006
and O 0 0.00029749493
was O 0 0.0002877624
observed O 0 0.00028348414
at O 0 0.00036934536
occupancy O 0 0.00095750415
levels O 0 0.0008482117
above O 0 0.001184351
60 O 0 0.002169422
% O 0 0.0040982845
. O 0 0.0065746806

Based O 0 0.005710803
on O 0 0.0017683936
these O 0 0.0016262013
observations O 0 0.0014109295
, O 0 0.0015456805
it O 0 0.0008956822
is O 0 0.00058339135
concluded O 0 0.00045264687
that O 0 0.0003405712
5 O 0 0.00043961237
- O 0 0.0537322
HT2 O 0 0.98246807
blockade O 0 0.005062851
obtained O 0 0.00026298998
with O 0 0.0020911063
risperidone B-Chemical 0 0.9999993
at O 0 0.00040797796
D2 O 0 0.99628437
occupancy O 0 0.00065121363
rates O 0 0.00022044801
of O 0 0.00023169944
60 O 0 0.0002052545
% O 0 0.00021679484
and O 0 0.00019685777
above O 0 0.00016758642
does O 0 0.00019453267
not O 0 0.00017644947
appear O 0 0.00019951862
to O 0 0.00019010746
protect O 0 0.0003028579
against O 0 0.000364895
the O 0 0.00058156875
risk O 0 0.16650286
for O 0 0.0031216717
extrapyramidal O 0 0.9999906
side O 0 0.1444081
effects O 0 0.005845971
. O 0 0.006757933

Treatment O 0 0.007003566
of O 0 0.002738632
previously O 0 0.0018280804
treated O 0 0.0023812628
metastatic O 0 0.9815569
breast B-Disease 0 0.9998233
cancer I-Disease 0 0.99998605
by O 0 0.008056726
mitoxantrone B-Chemical 1 0.99988186
and O 0 0.0013142031
48 O 0 0.000509919
- O 0 0.0008784796
hour O 0 0.000149013
continuous O 0 0.0001382893
infusion O 0 0.00027536074
of O 0 0.00021291699
high O 0 0.0006179503
- O 0 0.009016623
dose O 0 0.0018536204
5 B-Chemical 0 0.00022499653
- I-Chemical 0 0.009648281
FU I-Chemical 0 0.4423658
and O 0 0.00072192145
leucovorin B-Chemical 0 0.99994135
( O 0 0.0034277316
MFL B-Chemical 0 0.98973584
) O 0 0.001005256
: O 0 0.00048765255
low O 0 0.00034553173
palliative O 0 0.0003111992
benefit O 0 0.00035117622
and O 0 0.0005032823
high O 0 0.00096880255
treatment O 0 0.0016110122
- O 0 0.015214969
related O 0 0.0024193928
toxicity B-Disease 2 0.9949286
. O 0 0.007977245

For O 0 0.0037567392
previously O 0 0.0027845085
treated O 0 0.0028921515
advanced O 0 0.2865521
breast B-Disease 0 0.99961424
cancer I-Disease 0 0.9999707
, O 0 0.003733442
there O 0 0.00072297966
is O 0 0.00080881745
no O 0 0.00066095905
standard O 0 0.0008932966
second O 0 0.0014126847
- O 0 0.005716836
line O 0 0.004007026
therapy O 0 0.007606057
. O 0 0.00798994

Combination O 0 0.05410459
chemotherapy O 0 0.065801956
with O 0 0.0037290708
mitoxantrone B-Chemical 1 0.99970585
, O 0 0.0039579556
high O 0 0.0024758088
- O 0 0.011827652
dose O 0 0.002834204
5 B-Chemical 0 0.00042468027
- I-Chemical 0 0.023796277
fluorouracil I-Chemical 0 0.99886537
( O 0 0.00074908015
5 B-Chemical 0 0.000276307
- I-Chemical 0 0.00727914
FU I-Chemical 0 0.3869623
) O 0 0.00061987055
and O 0 0.0006949115
leucovorin B-Chemical 0 0.9999484
( O 0 0.006483178
MFL B-Chemical 0 0.9993963
regimen I-Chemical 0 0.013945358
) O 0 0.00077797554
had O 0 0.00026182362
been O 0 0.00025915675
reported O 0 0.00032380671
as O 0 0.0003220927
an O 0 0.0004893505
effective O 0 0.0006193538
and O 0 0.000917012
well O 0 0.0013357213
tolerated O 0 0.008487867
regimen O 0 0.0046241777
. O 0 0.0061670453

From O 0 0.004414401
October O 0 0.0036626107
1993 O 0 0.003578068
to O 0 0.0014737597
November O 0 0.0017012367
1995 O 0 0.0022755794
, O 0 0.0008783332
we O 0 0.00039919844
treated O 0 0.0004716718
13 O 0 0.00039391976
patients O 0 0.00034375556
with O 0 0.0002763104
previously O 0 0.00033296784
chemotherapy O 0 0.06719675
- O 0 0.015298968
treated O 0 0.0011667024
metastatic O 0 0.9862213
breast B-Disease 0 0.9998828
cancer I-Disease 0 0.99999404
by O 0 0.009492211
mitoxantrone B-Chemical 1 0.99991846
, O 0 0.0011659341
12 O 0 0.00017067559
mg O 0 0.008786488
/ O 0 0.0014199856
m2 O 0 0.0073924614
, O 0 0.00022065894
on O 0 0.00010115983
day O 0 0.00011894291
1 O 0 0.00012615336
and O 0 0.00013014769
continuous O 0 0.000121874626
infusion O 0 0.00026568968
of O 0 0.0002061632
5 B-Chemical 0 0.00021288937
- I-Chemical 0 0.016245224
FU I-Chemical 0 0.557394
, O 0 0.00039523272
3000 O 0 0.000492501
mg O 0 0.0091324095
/ O 0 0.0014753765
m2 O 0 0.008910596
, O 0 0.00027524316
together O 0 0.00018207227
with O 0 0.0005220185
leucovorin B-Chemical 0 0.99987817
, O 0 0.0005192341
300 O 0 0.000545247
mg O 0 0.014375063
/ O 0 0.0016776035
m2 O 0 0.0096590575
, O 0 0.00042434284
for O 0 0.00031641306
48 O 0 0.00040946383
h O 0 0.00044730218
from O 0 0.00052010297
day O 0 0.00074747467
1 O 0 0.0011839444
to O 0 0.0017817979
2 O 0 0.0033553038
. O 0 0.006168445

Each O 0 0.004533148
course O 0 0.004016732
of O 0 0.0042377845
chemotherapy O 0 0.018057795
was O 0 0.0031287458
given O 0 0.0023567192
every O 0 0.0023978963
4 O 0 0.003999762
weeks O 0 0.0053103813
. O 0 0.010653752

Most O 0 0.005265261
of O 0 0.0030001423
these O 0 0.002164797
patients O 0 0.0019096304
had O 0 0.0011057614
more O 0 0.00092894497
than O 0 0.0005700291
two O 0 0.0006200171
metastatic O 0 0.111473605
sites O 0 0.0011414923
, O 0 0.0015786032
with O 0 0.0021162897
lung O 0 0.64821535
metastasis O 0 0.9999062
predominant O 0 0.026807744
. O 0 0.009567024

Seven O 0 0.013022978
patients O 0 0.008522746
had O 0 0.0064525823
been O 0 0.006691437
treated O 0 0.008184503
with O 0 0.012699178
anthracycline B-Chemical 1 0.9994265
. O 0 0.022186505

Seven O 0 0.0074200337
patients O 0 0.0040388186
had O 0 0.0024475101
previously O 0 0.0019286851
received O 0 0.001528368
radiotherapy O 0 0.013015687
and O 0 0.0016598412
seven O 0 0.0015297921
had O 0 0.0018969362
received O 0 0.0026470136
hormone O 0 0.6518968
therapy O 0 0.013906328
. O 0 0.009771327

Median O 0 0.0026489394
number O 0 0.0019245689
of O 0 0.0016476936
courses O 0 0.0013029582
of O 0 0.0018911419
MFL B-Chemical 0 0.9987795
regimen I-Chemical 0 0.008925748
given O 0 0.00033240774
was O 0 0.00031504288
six O 0 0.00019007428
and O 0 0.000221144
the O 0 0.00018252667
median O 0 0.00015734759
cumulative O 0 0.00032114983
dose O 0 0.0012086002
of O 0 0.000943528
mitoxantrone B-Chemical 1 0.9996125
was O 0 0.0006298576
68 O 0 0.00086960767
. O 0 0.00062536605
35 O 0 0.0010478082
mg O 0 0.010409026
/ O 0 0.0050858487
m2 O 0 0.034639306
. O 0 0.007729037

One O 0 0.004711274
patient O 0 0.0025749847
had O 0 0.0015508905
complete O 0 0.0010755018
response O 0 0.0012078201
, O 0 0.0010323968
seven O 0 0.00054085406
had O 0 0.000489063
stable O 0 0.0009181568
disease O 0 0.823743
, O 0 0.0008126681
none O 0 0.00044270226
had O 0 0.00037052433
partial O 0 0.0005372932
response O 0 0.0006536778
and O 0 0.0007870406
five O 0 0.0008302298
had O 0 0.0015812139
progressive O 0 0.16002214
disease O 0 0.949972
. O 0 0.008791592

The O 0 0.0046306388
overall O 0 0.003798737
objective O 0 0.0038274317
response O 0 0.0031769718
rate O 0 0.003033839
was O 0 0.002987718
7 O 0 0.0027921558
. O 0 0.0033847447
6 O 0 0.0042877397
% O 0 0.008209865
. O 0 0.012107501

The O 0 0.0050387615
median O 0 0.0035512194
follow O 0 0.0035105455
- O 0 0.0060534775
up O 0 0.0034074734
period O 0 0.0033921136
was O 0 0.0044497866
14 O 0 0.0054176836
months O 0 0.0063793133
. O 0 0.011950019

Median O 0 0.013207625
survival O 0 0.02147781
was O 0 0.01511482
16 O 0 0.016217982
months O 0 0.016184831
. O 0 0.026039023

Median O 0 0.006559375
progression O 0 0.05978823
- O 0 0.01159347
free O 0 0.0062388373
survival O 0 0.013790695
was O 0 0.005856251
5 O 0 0.0056557558
months O 0 0.0070793275
. O 0 0.012841944

A O 0 0.01772488
complete O 0 0.003927888
responder O 0 0.016806727
had O 0 0.003045991
relapse O 0 0.9538661
- O 0 0.010500847
free O 0 0.002202241
survival O 0 0.0064096674
up O 0 0.0019100349
to O 0 0.0021857347
17 O 0 0.0036478667
months O 0 0.0039736573
. O 0 0.008033599

Major O 0 0.037631735
toxicities B-Disease 2 0.99634784
were O 0 0.021026919
cardiotoxicity B-Disease 0 0.999969
and O 0 0.12746243
leukopenia B-Disease 0 0.99990845
. O 0 0.028978238

Eight O 0 0.005450818
patients O 0 0.0030368501
were O 0 0.0018240529
dead O 0 0.0020572846
in O 0 0.0009581927
the O 0 0.00068482594
last O 0 0.00044932935
follow O 0 0.00043772394
- O 0 0.0015088005
up O 0 0.0004247884
; O 0 0.0005572684
two O 0 0.0003259323
of O 0 0.00047371472
them O 0 0.000720622
died O 0 0.0013084449
of O 0 0.001067891
treatment O 0 0.002296124
- O 0 0.020977387
related O 0 0.0026631649
toxicity B-Disease 2 0.9953608
. O 0 0.008414346

The O 0 0.0050498014
MFL B-Chemical 0 0.9805073
regimen I-Chemical 0 0.0072818045
achieves O 0 0.001840568
little O 0 0.0010812238
palliative O 0 0.000942854
benefit O 0 0.0007678864
and O 0 0.00077532267
induces O 0 0.0008083674
severe O 0 0.47478116
toxicity B-Disease 2 0.9984049
at O 0 0.0009895826
a O 0 0.0014537063
fairly O 0 0.0026476583
high O 0 0.0031300902
rate O 0 0.0046654483
. O 0 0.007777103

Administration O 0 0.017751409
of O 0 0.0029156017
this O 0 0.0017612558
regimen O 0 0.0021384954
to O 0 0.0017325247
breast B-Disease 0 0.9994722
cancer I-Disease 0 0.9999802
patients O 0 0.01489669
who O 0 0.0010497236
have O 0 0.00027548836
been O 0 0.00027352918
treated O 0 0.00031224528
by O 0 0.00031764203
chemotherapy O 0 0.0110884
and O 0 0.00036904335
those O 0 0.00042787203
with O 0 0.00045846144
impaired B-Disease 0 0.0016441426
heart I-Disease 0 0.040701378
function I-Disease 0 0.001032264
requires O 0 0.0010842171
careful O 0 0.002546511
attention O 0 0.005288841
. O 0 0.0065547563

Ticlopidine B-Chemical 0 0.9999573
- O 0 0.19169287
induced O 0 0.017022481
aplastic B-Disease 0 0.99999654
anemia I-Disease 0 0.99999964
: O 0 0.018370764
report O 0 0.001885522
of O 0 0.00078558957
three O 0 0.00051343895
Chinese O 0 0.006853511
patients O 0 0.0008891586
and O 0 0.00095059635
review O 0 0.0015617023
of O 0 0.0017994711
the O 0 0.0025340817
literature O 0 0.0055559627
. O 0 0.007591616

In O 0 0.0037924803
this O 0 0.0024696833
study O 0 0.002113848
, O 0 0.0016371453
three O 0 0.0007508454
Chinese O 0 0.030670298
patients O 0 0.0012380063
with O 0 0.0046480494
ticlopidine B-Chemical 1 0.9999995
- O 0 0.1900871
induced O 0 0.0063410425
aplastic B-Disease 0 0.9999994
anemia I-Disease 0 0.9999999
were O 0 0.0007142406
reported O 0 0.0003556652
and O 0 0.000286163
another O 0 0.00031082204
13 O 0 0.00032450946
patients O 0 0.0003869326
in O 0 0.00041397894
the O 0 0.0006250306
English O 0 0.0014949604
literature O 0 0.0016825419
were O 0 0.0022545895
reviewed O 0 0.0048141303
. O 0 0.006829923

We O 0 0.0036030982
attempted O 0 0.002531351
to O 0 0.0015346244
find O 0 0.0010885829
underlying O 0 0.0009949878
similarities O 0 0.0007215384
, O 0 0.00072572945
evaluate O 0 0.00028682727
the O 0 0.00042059642
risk O 0 0.02105593
factors O 0 0.0022587725
, O 0 0.00072497776
and O 0 0.00048723858
identify O 0 0.00040127803
appropriate O 0 0.00052706903
treatment O 0 0.00089461985
for O 0 0.0012939366
this O 0 0.0023823266
complication O 0 0.2230997
. O 0 0.0070069367

All O 0 0.003439135
but O 0 0.0029400103
one O 0 0.0015756943
of O 0 0.0012935792
the O 0 0.00089711876
patients O 0 0.000844504
were O 0 0.00046365117
over O 0 0.0002777062
60 O 0 0.00032645135
years O 0 0.00034873356
old O 0 0.0003692559
, O 0 0.00041520712
and O 0 0.00036878625
the O 0 0.00036012213
6 O 0 0.0003604969
who O 0 0.0005911004
died O 0 0.00090835075
were O 0 0.0007053353
all O 0 0.0009110373
older O 0 0.0022802807
than O 0 0.0018177745
65 O 0 0.004175561
. O 0 0.0064860997

Therefore O 0 0.0045294277
, O 0 0.004148276
old O 0 0.002861409
age O 0 0.0027355887
may O 0 0.0015010878
be O 0 0.0014506493
a O 0 0.0017445226
risk O 0 0.034117375
factor O 0 0.009481898
for O 0 0.0022668594
developing O 0 0.014312933
this O 0 0.0041728173
complication O 0 0.36877334
. O 0 0.009166399

Agranulocytosis B-Disease 0 0.99988735
occurred O 0 0.003941537
3 O 0 0.0019605341
- O 0 0.002976119
20 O 0 0.00077722856
weeks O 0 0.00044543511
after O 0 0.0003555511
initiation O 0 0.00055078557
of O 0 0.0020337203
ticlopidine B-Chemical 1 0.9999981
, O 0 0.0008425869
so O 0 0.0003245769
frequent O 0 0.0005093198
examination O 0 0.0002999882
of O 0 0.00044204036
white O 0 0.008625414
cell O 0 0.0015067545
count O 0 0.0010898089
during O 0 0.0006489098
treatment O 0 0.0013750232
is O 0 0.0021808303
recommended O 0 0.0038284098
. O 0 0.0061843675

There O 0 0.0043820306
seemed O 0 0.0027241493
to O 0 0.0014914192
be O 0 0.001141849
no O 0 0.00066314713
direct O 0 0.00055494567
correlation O 0 0.0004266792
between O 0 0.00035078923
the O 0 0.00038584173
dose O 0 0.000983678
or O 0 0.00032104913
duration O 0 0.00026981748
used O 0 0.00030167727
and O 0 0.00041965587
the O 0 0.000489919
severity O 0 0.0018802448
of O 0 0.00139341
bone B-Disease 0 0.23577979
marrow I-Disease 0 0.82530004
suppression I-Disease 0 0.32179424
. O 0 0.008519089

Treatment O 0 0.017446782
for O 0 0.008504087
ticlopidine B-Chemical 1 0.999997
- O 0 0.29748482
induced O 0 0.01578831
aplastic B-Disease 0 0.9999988
anemia I-Disease 0 0.9999999
with O 0 0.027510632
colony O 0 0.74010634
- O 0 0.035069074
stimulating O 0 0.0008542882
factors O 0 0.001486485
seemed O 0 0.00086507044
to O 0 0.0008171258
have O 0 0.001185124
little O 0 0.0020170894
effect O 0 0.0037896226
. O 0 0.007170419

The O 0 0.0029011955
fact O 0 0.0017266003
that O 0 0.0012687976
5 O 0 0.0009836054
of O 0 0.00086142047
the O 0 0.00063780183
6 O 0 0.0004469561
patients O 0 0.0004951952
who O 0 0.00043022944
received O 0 0.0002362144
concurrent O 0 0.00086752867
calcium B-Chemical 0 0.9991462
channel O 0 0.6589767
blockers O 0 0.9978811
died O 0 0.011742276
, O 0 0.0004572368
should O 0 0.00015085567
alert O 0 0.0003300457
clinicians O 0 0.00025266156
to O 0 0.00017336203
be O 0 0.00023341055
more O 0 0.0002934033
cautious O 0 0.00044221658
when O 0 0.00029006597
using O 0 0.00045610082
these O 0 0.00074355403
two O 0 0.0010611144
drugs O 0 0.025444554
simultaneously O 0 0.0032592057
. O 0 0.006217379

Upregulation O 0 0.0064276736
of O 0 0.0026705817
the O 0 0.0016471652
expression O 0 0.0014945633
of O 0 0.0022520605
vasopressin B-Chemical 1 0.999273
gene O 0 0.0011581355
in O 0 0.00045626154
the O 0 0.00042905056
paraventricular O 0 0.011335942
and O 0 0.00038747833
supraoptic O 0 0.0031027528
nuclei O 0 0.00070223026
of O 0 0.0005093245
the O 0 0.0009790672
lithium B-Chemical 0 0.9999659
- O 0 0.0848261
induced O 0 0.0058681862
diabetes B-Disease 0 0.9999703
insipidus I-Disease 0 0.99981207
rat O 0 0.06286358
. O 0 0.007942005

The O 0 0.0030320743
expression O 0 0.0025494446
of O 0 0.0031702889
arginine B-Chemical 0 0.98332906
vasopressin I-Chemical 1 0.9999651
( O 0 0.15390001
AVP B-Chemical 1 0.9999757
) O 0 0.0029396596
gene O 0 0.00058652466
in O 0 0.00030355685
the O 0 0.00033290498
paraventricular O 0 0.0506379
( O 0 0.0005860436
PVN O 0 0.07546099
) O 0 0.00038164173
and O 0 0.0002813347
supraoptic O 0 0.009636167
nuclei O 0 0.0015575421
( O 0 0.00085113646
SON O 0 0.1220475
) O 0 0.00043666206
was O 0 0.00018288256
investigated O 0 0.00013821282
in O 0 0.00017870223
rats O 0 0.0003569584
with O 0 0.0008600946
lithium B-Chemical 0 0.99998665
( O 0 0.03258136
Li B-Chemical 1 0.9997428
) O 0 0.0123760365
- O 0 0.020835422
induced O 0 0.0007805099
polyuria B-Disease 2 0.9987262
, O 0 0.0005977454
using O 0 0.00036201012
in O 0 0.0004631341
situ O 0 0.0011428611
hybridization O 0 0.001311323
histochemistry O 0 0.0033501242
and O 0 0.0029683132
radioimmunoassay O 0 0.74299943
. O 0 0.007424071

The O 0 0.0040852693
male O 0 0.006455172
Wistar O 0 0.012375243
rats O 0 0.0024461555
consuming O 0 0.0024728314
a O 0 0.0009518787
diet O 0 0.0045404634
that O 0 0.00039517778
contained O 0 0.00041710975
LiCl B-Chemical 0 0.99874264
( O 0 0.0010559432
60 O 0 0.00043749512
mmol O 0 0.18555026
/ O 0 0.0018822146
kg O 0 0.0011081875
) O 0 0.00072411424
for O 0 0.00052577624
4 O 0 0.0006352914
weeks O 0 0.00076668354
developed O 0 0.002021367
marked O 0 0.005715427
polyuria B-Disease 2 0.99644476
. O 0 0.008343524

The O 0 0.0060104774
Li B-Chemical 1 0.99570245
- O 0 0.019190975
treated O 0 0.0020343564
rats O 0 0.0015541414
produced O 0 0.00083553675
a O 0 0.0008772392
large O 0 0.0007058225
volume O 0 0.00097379374
of O 0 0.0009949009
hypotonic O 0 0.404571
urine O 0 0.4694891
with O 0 0.001473773
low O 0 0.0025706699
ionic O 0 0.34760267
concentrations O 0 0.015706245
. O 0 0.008225845

Plasma O 0 0.5972416
sodium B-Chemical 0 0.9982016
concentrations O 0 0.006976789
were O 0 0.0012341487
found O 0 0.00072184845
to O 0 0.0005216846
be O 0 0.00050191884
slightly O 0 0.000538948
increased O 0 0.00049604377
in O 0 0.00047272872
the O 0 0.0009038894
Li B-Chemical 1 0.99936837
- O 0 0.026604023
treated O 0 0.0006850478
rats O 0 0.00067065016
compared O 0 0.00046369777
with O 0 0.00086299074
those O 0 0.0014825622
in O 0 0.0020717976
controls O 0 0.0049226484
. O 0 0.006844085

Plasma O 0 0.109168455
concentration O 0 0.0055639273
of O 0 0.0056535196
AVP B-Chemical 1 0.9998416
and O 0 0.0017107689
transcripts O 0 0.0012373392
of O 0 0.003679542
AVP B-Chemical 1 0.9999517
gene O 0 0.0012020059
in O 0 0.00039785262
the O 0 0.0004260058
PVN O 0 0.17820062
and O 0 0.00047177865
SON O 0 0.051479474
were O 0 0.00024338503
significantly O 0 0.00024093557
increased O 0 0.00030654983
in O 0 0.00035826294
the O 0 0.0007704679
Li B-Chemical 1 0.9991252
- O 0 0.023572795
treated O 0 0.00093501515
rats O 0 0.0010628838
compared O 0 0.00091597193
with O 0 0.0020021335
controls O 0 0.0047537377
. O 0 0.0066146962

These O 0 0.0033841627
results O 0 0.0020147555
suggest O 0 0.0012225668
that O 0 0.0013417923
dehydration B-Disease 2 0.99562705
and O 0 0.0023200747
/ O 0 0.011722572
or O 0 0.00049751473
the O 0 0.00035951188
activation O 0 0.00049511343
of O 0 0.00043284288
visceral O 0 0.031066313
afferent O 0 0.0014004135
inputs O 0 0.00048691104
may O 0 0.00014694476
contribute O 0 0.0001262891
to O 0 0.0001327444
the O 0 0.00017948826
elevation O 0 0.043855112
of O 0 0.00078890956
plasma O 0 0.5055358
AVP B-Chemical 1 0.9999275
and O 0 0.00029078507
the O 0 0.00017361861
upregulation O 0 0.0003383966
of O 0 0.0021486916
AVP B-Chemical 1 0.9999466
gene O 0 0.00056754577
expression O 0 0.00028221754
in O 0 0.00021329307
the O 0 0.00026588884
PVN O 0 0.06541701
and O 0 0.00025705155
the O 0 0.00030948193
SON O 0 0.0313786
of O 0 0.0004913379
the O 0 0.0009353048
Li B-Chemical 1 0.9989592
- O 0 0.06518403
induced O 0 0.005019664
diabetes B-Disease 0 0.99996567
insipidus I-Disease 0 0.99979013
rat O 0 0.058508247
. O 0 0.007956521

Antinociceptive O 0 0.98678815
and O 0 0.0058260267
antiamnesic O 0 0.82595116
properties O 0 0.0021891939
of O 0 0.0020771164
the O 0 0.001980713
presynaptic O 0 0.18671279
cholinergic O 0 0.85351217
amplifier O 0 0.20724823
PG B-Chemical 0 0.9997311
- I-Chemical 0 0.053410873
9 I-Chemical 0 0.0063183093
. O 0 0.009249078

The O 0 0.0035958125
antinociceptive O 0 0.60968244
effect O 0 0.0016784127
of O 0 0.0014982783
3 B-Chemical 0 0.0010998767
alpha I-Chemical 0 0.8312342
- I-Chemical 0 0.120841175
tropyl I-Chemical 0 0.5595476
2 I-Chemical 0 0.0006264649
- I-Chemical 0 0.0048184176
( I-Chemical 0 0.0006197985
p I-Chemical 0 0.00052894454
- I-Chemical 0 0.04180229
bromophenyl I-Chemical 0 0.9923815
) I-Chemical 0 0.04475407
propionate I-Chemical 0 0.9998971
[ O 0 0.039519407
( O 0 0.0013354993
+ O 0 0.0073667536
/ O 0 0.04297893
- O 0 0.09382709
) O 0 0.011257441
- O 0 0.35453445
PG B-Chemical 0 0.9999664
- I-Chemical 0 0.07729794
9 I-Chemical 0 0.00029786673
] O 0 0.00055915775
( O 0 0.0003377932
10 O 0 0.00021202439
- O 0 0.00072152115
40 O 0 0.00018173666
mg O 0 0.0017506366
kg O 0 0.00061098963
- O 0 0.0011946112
1 O 0 0.00016871691
s O 0 0.00022795612
. O 0 0.00019477878
c O 0 0.0024878182
. O 0 0.00023170696
; O 0 0.0003618026
30 O 0 0.0001851304
- O 0 0.000636126
60 O 0 0.00018181605
mg O 0 0.0016956354
kg O 0 0.0006794804
- O 0 0.0018313392
1 O 0 0.00018850478
p O 0 0.00019641379
. O 0 0.00019604221
o O 0 0.0038730353
. O 0 0.00025025065
; O 0 0.00043038515
10 O 0 0.00021664605
- O 0 0.0007088971
30 O 0 0.0001560996
mg O 0 0.0016121247
kg O 0 0.00068701815
- O 0 0.00210652
1 O 0 0.00020542835
i O 0 0.00063536287
. O 0 0.00021200861
v O 0 0.007560629
. O 0 0.0002491988
; O 0 0.0004191501
10 O 0 0.00021003323
- O 0 0.0007036561
30 O 0 0.00015253588
micrograms O 0 0.0011567748
/ O 0 0.0012190987
mouse O 0 0.00048778224
i O 0 0.0041048187
. O 0 0.0002455717
c O 0 0.0141931055
. O 0 0.00029023446
v O 0 0.0281915
. O 0 0.00028301805
) O 0 0.00048616875
was O 0 0.00018231252
examined O 0 0.00012549237
in O 0 0.00015974657
mice O 0 0.00012933166
, O 0 0.00030270664
rats O 0 0.00029526209
and O 0 0.00024068373
guinea O 0 0.0010015372
pigs O 0 0.00024247706
by O 0 0.00016905494
use O 0 0.0001572865
of O 0 0.00019800138
the O 0 0.0002253001
hot O 0 0.0052742395
- O 0 0.015523916
plate O 0 0.0073188865
, O 0 0.0007146557
abdominal O 0 0.08249708
- O 0 0.033064257
constriction O 0 0.81737
, O 0 0.00090055825
tail O 0 0.0012941201
- O 0 0.034681156
flick O 0 0.31327018
and O 0 0.0017331665
paw O 0 0.9740017
- O 0 0.028895527
pressure O 0 0.07838392
tests O 0 0.0060791695
. O 0 0.00721619

( O 0 0.008066164
+ O 0 0.010249599
/ O 0 0.04067017
- O 0 0.08358212
) O 0 0.018711772
- O 0 0.39574483
PG B-Chemical 0 0.9999379
- I-Chemical 0 0.14115742
9 I-Chemical 0 0.0011970152
antinociception O 0 0.99756193
peaked O 0 0.0009917289
15 O 0 0.00042466473
min O 0 0.0005250096
after O 0 0.00042713905
injection O 0 0.0008328485
and O 0 0.0010433058
then O 0 0.001409906
slowly O 0 0.0031471432
diminished O 0 0.0046269856
. O 0 0.007447026

The O 0 0.004195845
antinociception O 0 0.9955374
produced O 0 0.0018140613
by O 0 0.0016454047
( O 0 0.002511081
+ O 0 0.0116763795
/ O 0 0.07842351
- O 0 0.15971641
) O 0 0.025639465
- O 0 0.5252099
PG B-Chemical 0 0.99997544
- I-Chemical 0 0.097739704
9 I-Chemical 0 0.00032433748
was O 0 0.00023214502
prevented O 0 0.00027035616
by O 0 0.00026104317
the O 0 0.00035744245
unselective O 0 0.84613734
muscarinic O 0 0.9996966
antagonist O 0 0.997171
atropine B-Chemical 0 0.99999845
, O 0 0.0037432788
the O 0 0.00097102916
M1 O 0 0.99425215
- O 0 0.18241876
selective O 0 0.026518151
antagonists O 0 0.99094754
pirenzepine B-Chemical 0 0.9999999
and O 0 0.036885727
dicyclomine B-Chemical 0 0.9999989
and O 0 0.00078332605
the O 0 0.0011513699
acetylcholine B-Chemical 1 0.9999908
depletor O 0 0.9999672
hemicholinium B-Chemical 0 0.99999523
- I-Chemical 0 0.11584519
3 I-Chemical 0 0.00017146784
, O 0 0.00022974797
but O 0 0.00018043493
not O 0 0.00012899077
by O 0 0.00018477275
the O 0 0.00041895837
opioid O 0 0.99879104
antagonist O 0 0.9962095
naloxone B-Chemical 1 0.9999988
, O 0 0.0031222692
the O 0 0.0013890616
gamma B-Chemical 0 0.9992273
- I-Chemical 0 0.98435044
aminobutyric I-Chemical 0 0.99999833
acidB I-Chemical 0 0.99919444
antagonist O 0 0.9709689
3 B-Chemical 0 0.0003538133
- I-Chemical 0 0.025572648
aminopropyl I-Chemical 0 0.8928501
- I-Chemical 0 0.47901365
diethoxy I-Chemical 0 0.99982315
- I-Chemical 0 0.71228004
methyl I-Chemical 0 0.99964345
- I-Chemical 0 0.43389362
phosphinic I-Chemical 0 0.9975775
acid I-Chemical 0 0.9444759
, O 0 0.0010413412
the O 0 0.0007200615
H3 O 0 0.9978715
agonist O 0 0.99729365
R B-Chemical 0 0.99996424
- I-Chemical 0 0.37725314
( I-Chemical 0 0.005581751
alpha I-Chemical 0 0.947949
) I-Chemical 0 0.072224356
- I-Chemical 0 0.4632986
methylhistamine I-Chemical 0 0.9994036
, O 0 0.0023498824
the O 0 0.0022064047
D2 O 0 0.99996483
antagonist O 0 0.996994
quinpirole B-Chemical 0 0.9999988
, O 0 0.0005416713
the O 0 0.0001773363
5 B-Chemical 0 0.00016368291
- I-Chemical 0 0.0029144858
hydroxytryptamine4 I-Chemical 0 0.028749904
antagonist O 0 0.75982136
2 B-Chemical 0 0.0004490029
- I-Chemical 0 0.09557453
methoxy I-Chemical 0 0.9997284
- I-Chemical 0 0.06133073
4 I-Chemical 0 0.0002607519
- I-Chemical 0 0.015490328
amino I-Chemical 0 0.90864784
- I-Chemical 0 0.067483574
5 I-Chemical 0 0.00029050407
- I-Chemical 0 0.029611561
chlorobenzoic I-Chemical 0 0.9387509
acid I-Chemical 0 0.9432428
2 I-Chemical 0 0.0005790375
- I-Chemical 0 0.030377997
( I-Chemical 0 0.003827024
diethylamino I-Chemical 0 0.9980616
) I-Chemical 0 0.08651223
ethyl I-Chemical 0 0.99993885
ester I-Chemical 0 0.997493
hydrochloride O 0 0.999461
, O 0 0.00046875482
the O 0 0.00017096699
5 B-Chemical 0 0.00016023277
- I-Chemical 0 0.0024501907
hydroxytryptamin1A I-Chemical 0 0.007731766
antagonist O 0 0.5533995
1 B-Chemical 0 0.00028943032
- I-Chemical 0 0.0043913205
( I-Chemical 0 0.0004489513
2 I-Chemical 0 0.00029466732
- I-Chemical 0 0.035807744
methoxyphenyl I-Chemical 0 0.98846775
) I-Chemical 0 0.002628227
- I-Chemical 0 0.009748791
4 I-Chemical 0 0.00023388528
- I-Chemical 0 0.0035832364
[ I-Chemical 0 0.0012981954
4 I-Chemical 0 0.00024136415
- I-Chemical 0 0.0024697175
( I-Chemical 0 0.00052938535
2 I-Chemical 0 0.0003926737
- I-Chemical 0 0.04858118
phthalimido I-Chemical 0 0.996599
) I-Chemical 0 0.07342169
butyl I-Chemical 0 0.99996006
] I-Chemical 0 0.45739457
piperazine I-Chemical 0 0.9999987
hydrobromide O 0 0.9999635
and O 0 0.001502005
the O 0 0.0019025648
polyamines O 0 0.9987502
depletor O 0 0.9999434
reserpine B-Chemical 1 0.9999925
. O 0 0.00934873

Based O 0 0.0060175243
on O 0 0.0019232797
these O 0 0.001859578
data O 0 0.0015834136
, O 0 0.0014557116
it O 0 0.00086065696
can O 0 0.0004602576
be O 0 0.00041082856
postulated O 0 0.00043820046
that O 0 0.00031850746
( O 0 0.0011260761
+ O 0 0.011122931
/ O 0 0.081548005
- O 0 0.17099741
) O 0 0.021708453
- O 0 0.48781097
PG B-Chemical 0 0.99997175
- I-Chemical 0 0.063316844
9 I-Chemical 0 0.0002824385
exerted O 0 0.00037440937
an O 0 0.00050957117
antinociceptive O 0 0.72173107
effect O 0 0.00026494675
mediated O 0 0.00024445553
by O 0 0.00044381118
a O 0 0.00064690114
central O 0 0.0012390362
potentiation O 0 0.31398237
of O 0 0.0027373766
cholinergic O 0 0.65404356
transmission O 0 0.017735185
. O 0 0.006967476

( O 0 0.007716292
+ O 0 0.009554687
/ O 0 0.03651644
- O 0 0.07396187
) O 0 0.016005807
- O 0 0.34608504
PG B-Chemical 0 0.9999249
- I-Chemical 0 0.06201896
9 I-Chemical 0 0.0006027811
( O 0 0.0006118623
10 O 0 0.00038467825
- O 0 0.0009471221
40 O 0 0.00028352335
mg O 0 0.0027651477
kg O 0 0.0009923144
- O 0 0.0029219002
1 O 0 0.00026011674
i O 0 0.00076569273
. O 0 0.00023044628
p O 0 0.00027377336
. O 0 0.00023778826
) O 0 0.00040890466
was O 0 0.00019362626
able O 0 0.0001372779
to O 0 0.00015495607
prevent O 0 0.00026466773
amnesia B-Disease 0 0.9999186
induced O 0 0.0006053255
by O 0 0.005063005
scopolamine B-Chemical 1 0.99999976
( O 0 0.0019896298
1 O 0 0.0002201653
mg O 0 0.006486465
kg O 0 0.0010283353
- O 0 0.0031464456
1 O 0 0.00019110668
i O 0 0.0006163676
. O 0 0.00017715311
p O 0 0.00021594939
. O 0 0.00020247124
) O 0 0.0006092178
and O 0 0.0012609168
dicyclomine B-Chemical 0 0.9999975
( O 0 0.0008257656
2 O 0 0.00021170158
mg O 0 0.0041803694
kg O 0 0.0008695149
- O 0 0.0024042008
1 O 0 0.00022943452
i O 0 0.0006395607
. O 0 0.00024146405
p O 0 0.00030592852
. O 0 0.00031274164
) O 0 0.00056029775
in O 0 0.00041360583
the O 0 0.00054129475
mouse O 0 0.0011126482
passive O 0 0.003586438
- O 0 0.016138187
avoidance O 0 0.010710301
test O 0 0.0046375208
. O 0 0.0072361133

Affinity O 0 0.008035867
profiles O 0 0.0024869628
of O 0 0.0023651235
( O 0 0.0030874838
+ O 0 0.00896136
/ O 0 0.058710113
- O 0 0.11854574
) O 0 0.019265343
- O 0 0.41497177
PG B-Chemical 0 0.99995923
- I-Chemical 0 0.066579714
9 I-Chemical 0 0.00037234987
for O 0 0.00036758374
muscarinic O 0 0.98405933
receptor O 0 0.028151775
subtypes O 0 0.0065156305
, O 0 0.00030334826
determined O 0 0.00013812851
by O 0 0.00016518761
functional O 0 0.00017342437
studies O 0 0.00019371678
( O 0 0.00039146462
rabbit O 0 0.009516605
vas O 0 0.900656
deferens O 0 0.21925999
for O 0 0.00030111716
M1 O 0 0.845398
, O 0 0.00047417375
guinea O 0 0.0019851525
pig O 0 0.0007838395
atrium O 0 0.08498584
for O 0 0.00033379992
M2 O 0 0.85520625
, O 0 0.0005591974
guinea O 0 0.002774164
pig O 0 0.00094513356
ileum O 0 0.5151373
for O 0 0.00068504974
M3 O 0 0.99845517
and O 0 0.00034730477
immature O 0 0.00079683424
guinea O 0 0.0031435578
pig O 0 0.0007744912
uterus O 0 0.02102847
for O 0 0.00022929434
putative O 0 0.0010795327
M4 O 0 0.999851
) O 0 0.0024452424
, O 0 0.00032618194
have O 0 0.00015055506
shown O 0 0.00016712493
an O 0 0.0008804775
M4 O 0 0.9998734
/ O 0 0.16343822
M1 O 0 0.95910484
selectivity O 0 0.0126389135
ratio O 0 0.00029418312
of O 0 0.00028303426
10 O 0 0.00018683456
. O 0 0.00014551928
2 O 0 0.00013248465
that O 0 0.00010776669
might O 0 0.00010625679
be O 0 0.00013318386
responsible O 0 0.0001351548
for O 0 0.00017581212
the O 0 0.00033228635
antinociception O 0 0.99890184
and O 0 0.0002708193
the O 0 0.00026400268
anti O 0 0.64177513
- O 0 0.67372346
amnesic B-Disease 0 0.99999344
effect O 0 0.00024464625
induced O 0 0.00024172159
by O 0 0.0003382748
( O 0 0.0013580723
+ O 0 0.013844587
/ O 0 0.0779672
- O 0 0.14849694
) O 0 0.015157249
- O 0 0.36297008
PG B-Chemical 0 0.99994254
- I-Chemical 0 0.021065235
9 I-Chemical 0 0.00032229142
through O 0 0.00028130767
an O 0 0.00049459166
increase O 0 0.000596457
in O 0 0.0013752537
acetylcholine B-Chemical 1 0.9993333
extracellular O 0 0.02107952
levels O 0 0.004444825
. O 0 0.007124376

In O 0 0.0038269698
the O 0 0.0027258184
antinociceptive O 0 0.896684
and O 0 0.0024377191
antiamnesic O 0 0.94367266
dose O 0 0.00885147
range O 0 0.0008241609
, O 0 0.00094220974
( O 0 0.0011794367
+ O 0 0.008174886
/ O 0 0.059264172
- O 0 0.13418469
) O 0 0.018382652
- O 0 0.46473712
PG B-Chemical 0 0.9999722
- I-Chemical 0 0.069294795
9 I-Chemical 0 0.0002897429
did O 0 0.00022760908
not O 0 0.00017233905
impair O 0 0.00017704943
mouse O 0 0.00032802837
performance O 0 0.0003525582
evaluated O 0 0.00022711047
by O 0 0.00034756787
the O 0 0.0004959026
rota O 0 0.21578991
- O 0 0.012607508
rod O 0 0.016362308
test O 0 0.0015409711
and O 0 0.0024035769
Animex O 0 0.031874936
apparatus O 0 0.0051841084
. O 0 0.007345082

The O 0 0.0038418244
effect O 0 0.0028192326
of O 0 0.0024373177
different O 0 0.0017652401
anaesthetic O 0 0.019078381
agents O 0 0.006142774
in O 0 0.0017222038
hearing B-Disease 0 0.8990363
loss I-Disease 0 0.0038714828
following O 0 0.0023765098
spinal O 0 0.04387001
anaesthesia O 0 0.047828753
. O 0 0.007881387

The O 0 0.0050361757
cause O 0 0.004842086
of O 0 0.0046047485
hearing B-Disease 0 0.883818
loss I-Disease 0 0.0050504315
after O 0 0.002445612
spinal O 0 0.019034768
anaesthesia O 0 0.0318897
is O 0 0.0049249358
unknown O 0 0.009431228
. O 0 0.010999598

Up O 0 0.01222197
until O 0 0.002254597
now O 0 0.00198228
, O 0 0.0017113602
the O 0 0.0009793472
only O 0 0.0009516349
factor O 0 0.00677624
studied O 0 0.0007963845
has O 0 0.0004083445
been O 0 0.00032907803
the O 0 0.00025795258
effect O 0 0.00023782974
of O 0 0.000284914
the O 0 0.00023827644
diameter O 0 0.0010501501
of O 0 0.00031456357
the O 0 0.00028016343
spinal O 0 0.0011140364
needle O 0 0.00044035888
on O 0 0.00030522494
post O 0 0.00063512346
- O 0 0.0049796933
operative O 0 0.0058979816
sensorineural B-Disease 2 0.99993813
hearing I-Disease 2 0.99225324
loss I-Disease 2 0.09842235
. O 0 0.008611314

The O 0 0.0032239305
aim O 0 0.0024497733
of O 0 0.0018175823
this O 0 0.0012507108
study O 0 0.0010690541
was O 0 0.0006418784
to O 0 0.00041954985
describe O 0 0.00037537684
this O 0 0.00044919146
hearing B-Disease 0 0.8297453
loss I-Disease 0 0.00096009206
and O 0 0.00035808553
to O 0 0.00023244803
investigate O 0 0.00016537233
other O 0 0.0003226296
factors O 0 0.0006639631
influencing O 0 0.00045114785
the O 0 0.0006633097
degree O 0 0.0013117709
of O 0 0.0029231342
hearing B-Disease 0 0.9692973
loss I-Disease 0 0.01882841
. O 0 0.008053153

Two O 0 0.003794991
groups O 0 0.0024679396
of O 0 0.0018528573
22 O 0 0.0014574835
similar O 0 0.0007460898
patients O 0 0.00081021746
were O 0 0.00051864894
studied O 0 0.0004799922
: O 0 0.00056592096
one O 0 0.00026828606
group O 0 0.00027832537
received O 0 0.00018413345
6 O 0 0.00020063999
mL O 0 0.005757808
prilocaine B-Chemical 0 0.99997985
2 O 0 0.00026352156
% O 0 0.0002938661
; O 0 0.00033224394
and O 0 0.00023489763
the O 0 0.00021578024
other O 0 0.00025716575
received O 0 0.0002573831
3 O 0 0.00036456695
mL O 0 0.0039901626
bupivacaine B-Chemical 1 0.99973637
0 O 0 0.0010813103
. O 0 0.0012697842
5 O 0 0.0019117075
% O 0 0.0041796635
. O 0 0.006868196

Patients O 0 0.005099748
given O 0 0.0029022577
prilocaine B-Chemical 0 0.9999405
were O 0 0.0014777697
more O 0 0.0009060678
likely O 0 0.0005301908
to O 0 0.00039053668
develop O 0 0.0005056009
hearing B-Disease 0 0.9099714
loss I-Disease 0 0.0018230937
( O 0 0.00051251147
10 O 0 0.00020042887
out O 0 0.00014044745
of O 0 0.00021540445
22 O 0 0.0002771562
) O 0 0.00031186952
than O 0 0.00013872367
those O 0 0.00022575037
given O 0 0.00020560983
bupivacaine B-Chemical 1 0.9998956
( O 0 0.00039837978
4 O 0 0.00017927651
out O 0 0.00016204688
of O 0 0.00029039246
22 O 0 0.00046106297
) O 0 0.0007773649
( O 0 0.0010100866
P O 0 0.019589247
< O 0 0.0010063531
0 O 0 0.0015945345
. O 0 0.0022705854
05 O 0 0.011227163
) O 0 0.006566025
. O 0 0.008530599

The O 0 0.0030752923
average O 0 0.0020694416
hearing B-Disease 0 0.66026986
loss I-Disease 0 0.0026387398
for O 0 0.0011395128
speech O 0 0.03431107
frequencies O 0 0.00079911854
was O 0 0.00052459084
about O 0 0.00040623025
10 O 0 0.00044389602
dB O 0 0.0008789459
after O 0 0.0005566611
prilocaine B-Chemical 0 0.9998995
and O 0 0.0009650753
15 O 0 0.0010310733
dB O 0 0.0024124794
after O 0 0.0024626974
bupivacaine B-Chemical 1 0.99949753
. O 0 0.008170642

None O 0 0.009748958
of O 0 0.0059524258
the O 0 0.0046878927
patients O 0 0.005526041
complained O 0 0.0124158
of O 0 0.0053332397
subjective O 0 0.01356259
hearing B-Disease 0 0.92292464
loss I-Disease 0 0.018205896
. O 0 0.014559996

Long O 0 0.016482959
- O 0 0.007463546
term O 0 0.0027937335
follow O 0 0.0021723618
- O 0 0.0040438813
up O 0 0.001745466
of O 0 0.0019196357
the O 0 0.0019130835
patients O 0 0.0027408754
was O 0 0.0027332637
not O 0 0.0034207217
possible O 0 0.00588362
. O 0 0.009664214

A O 0 0.22368544
transient O 0 0.28074074
neurological B-Disease 0 0.9993824
deficit I-Disease 0 0.9469664
following O 0 0.0012895523
intrathecal O 0 0.3006264
injection O 0 0.0012030252
of O 0 0.0007361278
1 O 0 0.0006479896
% O 0 0.0011982055
hyperbaric O 0 0.94323695
bupivacaine B-Chemical 1 0.9999466
for O 0 0.0014413662
unilateral O 0 0.25613692
spinal O 0 0.048816316
anaesthesia O 0 0.036931675
. O 0 0.006500376

We O 0 0.0034436872
describe O 0 0.0021448303
a O 0 0.0019445523
case O 0 0.001371855
of O 0 0.0014977811
transient O 0 0.30179912
neurological B-Disease 0 0.9998492
deficit I-Disease 0 0.9512275
that O 0 0.00030864895
occurred O 0 0.00029313937
after O 0 0.00017964304
unilateral O 0 0.070260026
spinal O 0 0.007651618
anaesthesia O 0 0.00389259
with O 0 0.00017331213
8 O 0 0.0001517192
mg O 0 0.0012745041
of O 0 0.00019989145
1 O 0 0.00019973941
% O 0 0.00038913335
hyperbaric O 0 0.8688194
bupivacaine B-Chemical 1 0.99993396
slowly O 0 0.0003969018
injected O 0 0.00017460443
through O 0 0.0001727706
a O 0 0.00032378014
25 O 0 0.00044135912
- O 0 0.0014254886
gauge O 0 0.0008047413
pencil O 0 0.012985436
- O 0 0.0029853499
point O 0 0.0014464634
spinal O 0 0.0059877215
needle O 0 0.00525551
. O 0 0.0069722123

The O 0 0.0033393214
surgery O 0 0.0030436083
and O 0 0.0019496675
anaesthesia O 0 0.0041242703
were O 0 0.00082176784
uneventful O 0 0.0006847512
, O 0 0.0007332538
but O 0 0.0004900528
3 O 0 0.00027513978
days O 0 0.0001918225
after O 0 0.00017769549
surgery O 0 0.0003724855
, O 0 0.00029006266
the O 0 0.00019740005
patient O 0 0.0002306914
reported O 0 0.00022997722
an O 0 0.00020709193
area O 0 0.00034585936
of O 0 0.0003881941
hypoaesthesia O 0 0.93218696
over O 0 0.00017821504
L3 O 0 0.30928937
- O 0 0.04723892
L4 O 0 0.11742993
dermatomes O 0 0.028877137
of O 0 0.00021503467
the O 0 0.00020216781
leg O 0 0.0031620145
which O 0 0.00026228282
had O 0 0.00017781106
been O 0 0.00017167088
operated O 0 0.00033252535
on O 0 0.0001462916
( O 0 0.0003573574
loss B-Disease 0 0.00046677512
of I-Disease 0 0.00059367303
pinprick I-Disease 0 0.5714651
sensation I-Disease 0 0.23055673
) O 0 0.0009217366
without O 0 0.0006528351
reduction O 0 0.0014034864
in O 0 0.0016247698
muscular O 0 0.25308305
strength O 0 0.0064759
. O 0 0.00704816

Sensation O 0 0.086748384
in O 0 0.0035957305
this O 0 0.002498025
area O 0 0.0024804047
returned O 0 0.0016909955
to O 0 0.0013724508
normal O 0 0.0015958127
over O 0 0.0011434096
the O 0 0.0016171328
following O 0 0.0019823858
2 O 0 0.0030341882
weeks O 0 0.0038691333
. O 0 0.008156006

Prospective O 0 0.020591471
multicentre O 0 0.010678186
studies O 0 0.0019163649
with O 0 0.0013556784
a O 0 0.0011536108
large O 0 0.00081095594
population O 0 0.00093072525
and O 0 0.00055389147
a O 0 0.00044777448
long O 0 0.00030621942
follow O 0 0.00024703584
- O 0 0.0012300552
up O 0 0.00021256969
should O 0 0.00014499685
be O 0 0.00017639982
performed O 0 0.00016461483
in O 0 0.00018246158
order O 0 0.00015869462
to O 0 0.00018168746
evaluate O 0 0.00015616363
the O 0 0.00030359335
incidence O 0 0.0009403053
of O 0 0.0007845721
this O 0 0.0010062013
unusual O 0 0.004403519
side O 0 0.03611446
effect O 0 0.0040855333
. O 0 0.007128519

However O 0 0.004624728
, O 0 0.0030662084
we O 0 0.0012524447
suggest O 0 0.0007928296
that O 0 0.00073573756
a O 0 0.0008908622
low O 0 0.00091088057
solution O 0 0.007618552
concentration O 0 0.0011185457
should O 0 0.0001964436
be O 0 0.00020636008
preferred O 0 0.00020030545
for O 0 0.0002124052
unilateral O 0 0.061817154
spinal O 0 0.0069548283
anaesthesia O 0 0.004031503
with O 0 0.00018483408
a O 0 0.00031360477
hyperbaric O 0 0.55942196
anaesthetic O 0 0.02166866
solution O 0 0.0038288387
( O 0 0.0003796796
if O 0 0.00015492548
pencil O 0 0.025484517
- O 0 0.002363415
point O 0 0.0001315418
needle O 0 0.0002661689
and O 0 0.00018427307
slow O 0 0.00028446235
injection O 0 0.00023802939
rate O 0 0.00016857557
are O 0 0.00015590043
employed O 0 0.00022876436
) O 0 0.0005613809
, O 0 0.00026879634
in O 0 0.0001426681
order O 0 0.00010520902
to O 0 0.000107223925
minimize O 0 8.791064e-05
the O 0 0.00015568621
risk O 0 0.008819983
of O 0 0.00025591906
a O 0 0.00024647478
localized O 0 0.00015203694
high O 0 0.00029127952
peak O 0 0.0003444246
anaesthetic O 0 0.012813273
concentration O 0 0.00062996364
, O 0 0.00048109566
which O 0 0.000397486
might O 0 0.00029790588
lead O 0 0.002472778
to O 0 0.0006210515
a O 0 0.0014840121
transient O 0 0.17303705
neurological B-Disease 0 0.99963355
deficit I-Disease 0 0.9683151
. O 0 0.007885945

Transient B-Disease 0 0.77885026
neurologic I-Disease 0 0.9875947
symptoms I-Disease 0 0.7619141
after O 0 0.0011491538
spinal O 0 0.01106126
anesthesia O 0 0.028040938
: O 0 0.00097011466
a O 0 0.0006042565
lower O 0 0.00048164834
incidence O 0 0.0026349954
with O 0 0.0037297283
prilocaine B-Chemical 0 0.99999607
and O 0 0.0081065195
bupivacaine B-Chemical 1 0.9999651
than O 0 0.0012894229
with O 0 0.0042308103
lidocaine B-Chemical 0 0.9995975
. O 0 0.007202661

BACKGROUND O 0 0.014986362
: O 0 0.003797669
Recent O 0 0.002224044
evidence O 0 0.0012310897
suggests O 0 0.0008102074
that O 0 0.0008322075
transient B-Disease 0 0.3331422
neurologic I-Disease 0 0.9988218
symptoms I-Disease 0 0.98002404
( O 0 0.009729174
TNSs B-Disease 0 0.94934016
) O 0 0.0009316325
frequently O 0 0.00041451518
follow O 0 0.00030251508
lidocaine B-Chemical 0 0.99963164
spinal O 0 0.010883519
anesthesia O 0 0.008188096
but O 0 0.0006361994
are O 0 0.00079891604
infrequent O 0 0.0045051025
with O 0 0.004823382
bupivacaine B-Chemical 1 0.99988973
. O 0 0.0074044713

However O 0 0.004622793
, O 0 0.0033284805
identification O 0 0.0020762747
of O 0 0.0015260588
a O 0 0.0012402381
short O 0 0.0007863045
- O 0 0.0031957866
acting O 0 0.00080910296
local O 0 0.00080807053
anesthetic O 0 0.020315945
to O 0 0.00024903013
substitute O 0 0.00028000693
for O 0 0.00046010458
lidocaine B-Chemical 0 0.9992841
for O 0 0.00034720756
brief O 0 0.00037575726
surgical O 0 0.00057896815
procedures O 0 0.0006061343
remains O 0 0.0008651339
an O 0 0.0014522922
important O 0 0.001994665
goal O 0 0.005168319
. O 0 0.0069344533

Prilocaine B-Chemical 0 0.9960438
is O 0 0.0041272365
an O 0 0.003675644
amide O 0 0.78594923
local O 0 0.0028008418
anesthetic O 0 0.09593021
with O 0 0.00077313324
a O 0 0.00067263574
duration O 0 0.00045207253
of O 0 0.00062512176
action O 0 0.0008286953
similar O 0 0.00063794624
to O 0 0.00090884726
that O 0 0.0014433509
of O 0 0.005925842
lidocaine B-Chemical 0 0.9998066
. O 0 0.008565879

Accordingly O 0 0.003892008
, O 0 0.0029793354
the O 0 0.0015431554
present O 0 0.0010212454
, O 0 0.0012356838
prospective O 0 0.0018168481
double O 0 0.0009845712
- O 0 0.01602662
blind O 0 0.020601878
study O 0 0.0006710984
compares O 0 0.0008204303
prilocaine B-Chemical 0 0.99999285
with O 0 0.0032312297
lidocaine B-Chemical 0 0.9999721
and O 0 0.004292885
bupivacaine B-Chemical 1 0.9999682
with O 0 0.0002679716
respect O 0 0.00018081401
to O 0 0.00017969648
duration O 0 0.00020612706
of O 0 0.00036328722
action O 0 0.0006232828
and O 0 0.0006951943
relative O 0 0.0009637209
risk O 0 0.0942523
of O 0 0.006557716
TNSs B-Disease 0 0.96747476
. O 0 0.007485702

METHODS O 0 0.0043823863
: O 0 0.0038595481
Ninety O 0 0.0029176027
patients O 0 0.0018316776
classified O 0 0.0013221871
as O 0 0.0009950594
American O 0 0.0022343316
Society O 0 0.0010297569
of O 0 0.0005517211
Anesthesiologists O 0 0.0006330355
physical O 0 0.00072726194
status O 0 0.00079244096
I O 0 0.00858559
or O 0 0.00034152906
II O 0 0.010505465
who O 0 0.00032646378
were O 0 0.00015762012
scheduled O 0 0.00010991314
for O 0 0.00012467716
short O 0 0.00013097347
gynecologic O 0 0.00032751937
procedures O 0 0.00014329799
under O 0 0.00014098913
spinal O 0 0.0020264736
anesthesia O 0 0.001679371
were O 0 0.00012429776
randomly O 0 7.969952e-05
allocated O 0 9.4969306e-05
to O 0 0.000101752594
receive O 0 0.000102813174
2 O 0 0.00013216946
. O 0 0.00012094301
5 O 0 0.00011613775
ml O 0 0.0002312005
2 O 0 0.0001663389
% O 0 0.00033455945
lidocaine B-Chemical 0 0.9986046
in O 0 0.00017860562
7 O 0 0.00014344645
. O 0 0.00014023655
5 O 0 0.00014180523
% O 0 0.00027792124
glucose B-Chemical 1 0.9061352
, O 0 0.00040762516
2 O 0 0.00022964987
% O 0 0.00060446654
prilocaine B-Chemical 0 0.9999677
in O 0 0.00020370219
7 O 0 0.00015526917
. O 0 0.00015082894
5 O 0 0.00015352096
% O 0 0.000292979
glucose B-Chemical 1 0.87145793
, O 0 0.00035487232
or O 0 0.00022359517
0 O 0 0.000269783
. O 0 0.00022200913
5 O 0 0.0002523664
% O 0 0.0006163571
bupivacaine B-Chemical 1 0.99953115
in O 0 0.00052162335
7 O 0 0.0006080977
. O 0 0.0008574941
5 O 0 0.0013225373
% O 0 0.0032023673
glucose B-Chemical 1 0.8109854
. O 0 0.008064883

All O 0 0.004817503
solutions O 0 0.005140323
were O 0 0.003102747
provided O 0 0.0024798948
in O 0 0.0023573057
blinded O 0 0.0027555355
vials O 0 0.0033372587
by O 0 0.002823641
the O 0 0.0034379712
hospital O 0 0.0069225696
pharmacy O 0 0.01630032
. O 0 0.010602593

Details O 0 0.003489287
of O 0 0.0027959424
spinal O 0 0.005179118
puncture O 0 0.0030784353
, O 0 0.001178869
extension O 0 0.00079034746
and O 0 0.00062923
regression O 0 0.0021214362
of O 0 0.0006322032
spinal O 0 0.0032300933
block O 0 0.00037889354
, O 0 0.0004726852
and O 0 0.00035696497
the O 0 0.00030898486
times O 0 0.00026679487
to O 0 0.00038760912
reach O 0 0.0005613215
discharge O 0 0.0012740076
criteria O 0 0.0013941315
were O 0 0.0020434086
noted O 0 0.0031675324
. O 0 0.0065932376

In O 0 0.0035439457
the O 0 0.0022467002
evening O 0 0.0026977856
of O 0 0.001314357
postoperative O 0 0.0020130333
day O 0 0.00061235146
1 O 0 0.00052140537
, O 0 0.0005008128
patients O 0 0.0004065221
were O 0 0.00025914516
evaluated O 0 0.00020986228
for O 0 0.00030516236
TNSs B-Disease 0 0.59338844
by O 0 0.0002705617
a O 0 0.000310937
physician O 0 0.0004813174
unaware O 0 0.00031468386
of O 0 0.0002837976
the O 0 0.00029688064
drug O 0 0.06957936
administered O 0 0.00032773422
and O 0 0.0003678549
the O 0 0.00039163703
details O 0 0.00040138175
of O 0 0.00086994044
the O 0 0.0013908301
anesthetic O 0 0.03894381
procedure O 0 0.0034280168
. O 0 0.006175427

RESULTS O 0 0.0057304446
: O 0 0.0037462267
Nine O 0 0.0027553898
of O 0 0.0015437691
30 O 0 0.0010106724
patients O 0 0.0010888058
receiving O 0 0.0017506684
lidocaine B-Chemical 0 0.99987876
experienced O 0 0.002024
TNSs B-Disease 0 0.91462195
, O 0 0.00052437244
1 O 0 0.0002331083
of O 0 0.00021345483
30 O 0 0.00017522219
patients O 0 0.0002843859
receiving O 0 0.0011725008
prilocaine B-Chemical 0 0.99999416
( O 0 0.0021614744
P O 0 0.18539327
= O 0 0.0008405881
0 O 0 0.00032253182
. O 0 0.0002650205
03 O 0 0.0099915145
) O 0 0.0003872948
had O 0 0.00022534218
them O 0 0.00036148372
, O 0 0.0003532484
and O 0 0.00031008382
none O 0 0.0003238206
of O 0 0.0004115053
30 O 0 0.00044679505
patients O 0 0.00094618223
receiving O 0 0.003060756
bupivacaine B-Chemical 1 0.99988854
had O 0 0.0037573092
TNSs B-Disease 0 0.87858987
. O 0 0.006932635

Times O 0 0.0063435873
to O 0 0.0025617944
ambulate O 0 0.0027602122
and O 0 0.0012889807
to O 0 0.0008052138
void O 0 0.00093090575
were O 0 0.00051760837
similar O 0 0.00034587042
after O 0 0.00035057572
lidocaine B-Chemical 0 0.99984765
and O 0 0.004875804
prilocaine B-Chemical 0 0.9999956
( O 0 0.0006476629
150 O 0 0.00026297994
vs O 0 0.00023461807
. O 0 0.00015843849
165 O 0 0.0002866723
min O 0 0.00020159688
and O 0 0.00018913475
238 O 0 0.00054209173
vs O 0 0.00024484834
. O 0 0.00017302894
253 O 0 0.001028844
min O 0 0.0002667913
, O 0 0.00029626992
respectively O 0 0.001057698
) O 0 0.0005226259
but O 0 0.00025023782
prolonged O 0 0.00032252565
after O 0 0.00020370491
bupivacaine B-Chemical 1 0.9999497
( O 0 0.00048690895
200 O 0 0.00029511692
and O 0 0.00023896922
299 O 0 0.0027674406
min O 0 0.0003572353
, O 0 0.0004487898
respectively O 0 0.0012691583
; O 0 0.0011934827
P O 0 0.016784899
< O 0 0.0009507276
0 O 0 0.0015280494
. O 0 0.0022004773
05 O 0 0.010990176
) O 0 0.0064547225
. O 0 0.008411871

CONCLUSIONS O 0 0.08064581
: O 0 0.009979038
Prilocaine B-Chemical 0 0.9914442
may O 0 0.001435187
be O 0 0.0009736745
preferable O 0 0.0006994065
to O 0 0.00069641747
lidocaine B-Chemical 0 0.999318
for O 0 0.0003714633
short O 0 0.00026066814
surgical O 0 0.00033419573
procedures O 0 0.00023248301
because O 0 0.00020092829
it O 0 0.00025474373
has O 0 0.00021500106
a O 0 0.00026431118
similar O 0 0.0001912217
duration O 0 0.0002241777
of O 0 0.0003943874
action O 0 0.0007805099
but O 0 0.00071303116
a O 0 0.00091870903
lower O 0 0.0011276811
incidence O 0 0.00524856
of O 0 0.0051985336
TNSs B-Disease 0 0.9537658
. O 0 0.0076134168

Suxamethonium B-Chemical 1 0.99818534
- O 0 0.05068955
induced O 0 0.004720735
cardiac B-Disease 2 0.9614167
arrest I-Disease 2 0.97998214
and O 0 0.005338435
death B-Disease 0 0.9965904
following O 0 0.0016909963
5 O 0 0.0016149731
days O 0 0.0018574109
of O 0 0.0038423866
immobilization O 0 0.01113874
. O 0 0.009333471

The O 0 0.0030556777
present O 0 0.0020062497
report O 0 0.002512817
describes O 0 0.0017659274
a O 0 0.0011901276
case O 0 0.0008973026
of O 0 0.0013854402
cardiac B-Disease 2 0.962023
arrest I-Disease 2 0.97356397
and O 0 0.00088410743
subsequent O 0 0.0007420428
death B-Disease 0 0.99878544
as O 0 0.00036177968
a O 0 0.00034365852
result O 0 0.00020599227
of O 0 0.0008042376
hyperkalaemia B-Disease 0 0.99991524
following O 0 0.00020448565
the O 0 0.00019554021
use O 0 0.00022884028
of O 0 0.00057795044
suxamethonium B-Chemical 0 0.9996476
in O 0 0.00036439634
a O 0 0.00052941067
23 O 0 0.0007616855
- O 0 0.001881765
year O 0 0.0009828156
- O 0 0.0034400104
old O 0 0.0023222654
Malawian O 0 0.035699442
woman O 0 0.014966335
. O 0 0.007869604

Five O 0 0.0041062576
days O 0 0.001927816
after O 0 0.0012405313
the O 0 0.0011197467
onset O 0 0.0013221494
of O 0 0.0008919349
the O 0 0.0007727459
symptoms O 0 0.21644466
of O 0 0.0021504036
meningitis B-Disease 0 0.99991035
, O 0 0.0013943298
the O 0 0.00044784363
patient O 0 0.000522228
aspirated O 0 0.00070796744
stomach O 0 0.011639234
contents O 0 0.0013244444
and O 0 0.0011177858
needed O 0 0.0013783338
endotracheal O 0 0.003961397
intubation O 0 0.008668082
. O 0 0.006414549

Forty O 0 0.0059901485
seconds O 0 0.002868346
after O 0 0.0020036697
injection O 0 0.0029533906
of O 0 0.0039259177
suxamethonium B-Chemical 0 0.99993753
, O 0 0.02584967
bradycardia B-Disease 0 0.9996537
and O 0 0.0051421523
cardiac B-Disease 2 0.9244928
arrest I-Disease 2 0.9536314
occurred O 0 0.0077038626
. O 0 0.009514155

Attempts O 0 0.010779176
to O 0 0.007194319
resuscitate O 0 0.010527899
the O 0 0.005363751
patient O 0 0.0058461265
were O 0 0.0060062427
not O 0 0.007052476
successful O 0 0.012171782
. O 0 0.01563548

The O 0 0.0037013607
serum O 0 0.018864146
level O 0 0.0019752653
of O 0 0.0031611207
potassium B-Chemical 0 0.99987006
was O 0 0.0011768703
observed O 0 0.0006542095
to O 0 0.00058177667
be O 0 0.00066846336
8 O 0 0.00069471844
. O 0 0.00080751674
4 O 0 0.0011823232
mequiv O 0 0.65019584
L O 0 0.88310695
- O 0 0.018824197
1 O 0 0.005416709
. O 0 0.008472383

Apart O 0 0.004240248
from O 0 0.0021741064
the O 0 0.0016017106
reduction O 0 0.0016449592
in O 0 0.00083899446
the O 0 0.0006175107
patient O 0 0.0005738094
' O 0 0.00055830885
s O 0 0.0004093251
level O 0 0.00025930555
of O 0 0.00045810363
consciousness O 0 0.69793946
, O 0 0.0003714994
there O 0 0.00015111107
were O 0 0.00017922898
no O 0 0.00014734294
signs O 0 0.008285241
of O 0 0.0004185933
motor O 0 0.07905162
neurone O 0 0.19294389
damage O 0 0.5294647
or O 0 0.00023822146
of O 0 0.00027491376
any O 0 0.00017184185
of O 0 0.00021769339
the O 0 0.00018916704
other O 0 0.0002331512
known O 0 0.00031350256
predisposing O 0 0.006993423
conditions O 0 0.00044053863
for O 0 0.00069277274
hyperkalaemia B-Disease 0 0.9998665
following O 0 0.00054451084
the O 0 0.00085495313
administration O 0 0.017509738
of O 0 0.006343121
suxamethonium B-Chemical 0 0.99979454
. O 0 0.007576603

It O 0 0.0047802874
is O 0 0.0026454795
postulated O 0 0.0020366963
that O 0 0.001292205
her O 0 0.0024044355
death B-Disease 0 0.9982766
was O 0 0.001042462
caused O 0 0.000670072
by O 0 0.0009480791
hypersensitivity B-Disease 0 0.9706012
to O 0 0.0009417869
suxamethonium B-Chemical 0 0.99992156
, O 0 0.00093998725
associated O 0 0.0005584232
with O 0 0.0006211521
her O 0 0.0008652922
5 O 0 0.00091977185
- O 0 0.002665666
day O 0 0.0021429637
immobilization O 0 0.006527721
. O 0 0.006883845

Acute O 0 0.99051523
hepatitis B-Disease 2 0.9999994
, O 0 0.79464483
autoimmune B-Disease 2 0.9999939
hemolytic I-Disease 2 1.0
anemia I-Disease 2 1.0
, O 0 0.058593273
and O 0 0.0033762737
erythroblastocytopenia B-Disease 0 0.5285782
induced O 0 0.0032504464
by O 0 0.006384763
ceftriaxone B-Chemical 0 0.99984956
. O 0 0.0124786245

An O 0 0.00634347
80 O 0 0.004569498
- O 0 0.0066779046
yr O 0 0.0032379911
- O 0 0.0048098373
old O 0 0.0020376854
man O 0 0.08652039
developed O 0 0.021683183
acute O 0 0.99991107
hepatitis B-Disease 2 1.0
shortly O 0 0.46644124
after O 0 0.0024195104
ingesting O 0 0.94481534
oral O 0 0.9660818
ceftriaxone B-Chemical 0 0.9999362
. O 0 0.012029193

Although O 0 0.0032527372
the O 0 0.0029199964
transaminases O 0 0.9977443
gradually O 0 0.0019336351
returned O 0 0.0007196526
to O 0 0.00043787752
baseline O 0 0.00036733606
after O 0 0.00023229823
withholding O 0 0.00077105477
the O 0 0.0006655145
beta B-Chemical 0 0.9997154
lactam I-Chemical 0 0.9999856
antibiotic O 0 0.8658148
, O 0 0.0014878671
there O 0 0.00016227187
was O 0 0.00019216503
a O 0 0.00020162684
gradual O 0 0.00018440772
increase O 0 0.0001469198
in O 0 0.00026579454
serum O 0 0.784925
bilirubin B-Chemical 1 0.9999949
and O 0 0.00089964434
a O 0 0.0003710006
decrease O 0 0.0002326975
in O 0 0.0003053693
hemoglobin O 0 0.91478705
concentration O 0 0.00081203
caused O 0 0.00037995068
by O 0 0.0006191579
an O 0 0.0043388084
autoimmune B-Disease 2 0.9999802
hemolytic I-Disease 2 1.0
anemia I-Disease 2 0.9999999
and O 0 0.10300541
erythroblastocytopenia B-Disease 0 0.93437076
. O 0 0.0077646654

These O 0 0.009402817
responded O 0 0.009109328
to O 0 0.008141888
systemic O 0 0.89930683
steroids B-Chemical 0 0.99929726
and O 0 0.020916034
immunoglobulins O 0 0.9712379
. O 0 0.020404521

Despite O 0 0.003685376
the O 0 0.002389477
widespread O 0 0.0024863156
use O 0 0.0012015175
of O 0 0.00096906757
these O 0 0.0008104777
agents O 0 0.0060151136
this O 0 0.00055735285
triad O 0 0.011615441
of O 0 0.00074019725
side O 0 0.042408157
effects O 0 0.00061970425
has O 0 0.00027015622
not O 0 0.0002602254
previously O 0 0.00031858886
been O 0 0.00031862984
reported O 0 0.00041972913
in O 0 0.00046383485
connection O 0 0.00082374393
with O 0 0.0023326976
beta B-Chemical 0 0.99841404
lactam I-Chemical 0 0.99992394
antibiotics O 0 0.9683051
. O 0 0.010362922

Thyroxine B-Chemical 0 0.99960357
abuse O 0 0.9931666
: O 0 0.008015292
an O 0 0.0043668523
unusual O 0 0.0052876826
case O 0 0.0038785697
of O 0 0.006721894
thyrotoxicosis B-Disease 0 0.9998826
in O 0 0.008385615
pregnancy O 0 0.64843684
. O 0 0.013094082

Eating B-Disease 0 0.73463553
disorders I-Disease 0 0.9360834
and O 0 0.0024711697
the O 0 0.0014746779
associated O 0 0.0013654277
behavioural O 0 0.011134691
problems O 0 0.0037906182
and O 0 0.0018033122
drug B-Disease 0 0.9904384
abuse I-Disease 0 0.9998093
are O 0 0.0021950577
uncommon O 0 0.015965158
in O 0 0.0032164154
pregnancy O 0 0.25510287
. O 0 0.008808336

When O 0 0.0034552603
they O 0 0.0023263819
do O 0 0.001698162
occur O 0 0.001101841
they O 0 0.0007661219
are O 0 0.00063076953
often O 0 0.00060425047
unrecognized O 0 0.00057375326
because O 0 0.0003125401
of O 0 0.00048244948
denial O 0 0.050267573
but O 0 0.00041936955
when O 0 0.00020908295
significant O 0 0.00026753332
may O 0 0.0002444891
pose O 0 0.00039382442
a O 0 0.00051490945
risk O 0 0.01673647
to O 0 0.00038022254
both O 0 0.00050585245
the O 0 0.00069245975
mother O 0 0.002208416
and O 0 0.0019273886
her O 0 0.0032264045
fetus O 0 0.026784653
. O 0 0.007657913

This O 0 0.0049914336
case O 0 0.0025657876
illustrates O 0 0.0014135715
a O 0 0.001319039
number O 0 0.00080237683
of O 0 0.00081955007
problems O 0 0.0016988339
that O 0 0.00036672957
may O 0 0.0003186198
be O 0 0.00029139925
encountered O 0 0.00030836332
in O 0 0.00029021507
women O 0 0.005757551
with O 0 0.00084469793
eating B-Disease 0 0.99572253
disorders I-Disease 0 0.9961461
in O 0 0.00039440338
pregnancy O 0 0.20396315
, O 0 0.0004414437
including O 0 0.00025597593
prolonged O 0 0.000512182
and O 0 0.0005776706
recurrent O 0 0.32861108
metabolic O 0 0.9456668
disturbances O 0 0.98739237
and O 0 0.011337578
diuretic O 0 0.99995327
abuse O 0 0.99873453
. O 0 0.008634107

In O 0 0.003510741
particular O 0 0.0019983763
it O 0 0.0016460848
illustrates O 0 0.0009006397
the O 0 0.00085351354
derangements O 0 0.34910306
of O 0 0.0011472391
thyroid O 0 0.50386345
function O 0 0.0004929918
seen O 0 0.00036058348
in O 0 0.00034494014
pregnant O 0 0.037668154
women O 0 0.008952129
with O 0 0.0008412199
eating B-Disease 0 0.99511945
disorders I-Disease 0 0.99461454
and O 0 0.00040607245
reminds O 0 0.0008138713
us O 0 0.00020898489
that O 0 0.00012894599
when O 0 0.00013123135
a O 0 0.00023336826
cause O 0 0.00030626616
for O 0 0.00045461877
thyrotoxicosis B-Disease 0 0.9999262
remains O 0 0.0006076984
obscure O 0 0.012996729
, O 0 0.0076818294
thyroxine B-Chemical 1 0.99997056
abuse O 0 0.99305046
should O 0 0.00048858725
be O 0 0.00076312356
considered O 0 0.0010332076
and O 0 0.0020375699
explored O 0 0.003208474
. O 0 0.0064837034

Repeated O 0 0.08581347
trimipramine B-Chemical 0 0.9999964
induces O 0 0.026805159
dopamine B-Chemical 1 0.9999924
D2 O 0 0.9999511
/ O 0 0.5808039
D3 O 0 0.99996865
and O 0 0.01377346
alpha1 O 0 0.9993498
- O 0 0.3833935
adrenergic O 0 0.96878594
up O 0 0.0024913964
- O 0 0.0063087097
regulation O 0 0.004199158
. O 0 0.008383188

Trimipramine B-Chemical 0 0.9998435
( O 0 0.052106198
TRI B-Chemical 1 0.99807394
) O 0 0.0063316454
, O 0 0.0016763461
which O 0 0.00091882015
shows O 0 0.00042564122
a O 0 0.00071963074
clinical O 0 0.02014513
antidepressant B-Chemical 1 0.99992335
activity O 0 0.00058237993
, O 0 0.0005322922
is O 0 0.00028007905
chemically O 0 0.0025539654
related O 0 0.00016601472
to O 0 0.00041158314
imipramine B-Chemical 0 0.9999994
but O 0 0.00058925233
does O 0 0.00019003535
not O 0 0.00012690308
inhibit O 0 0.00011621928
the O 0 0.00024614274
reuptake O 0 0.97566426
of O 0 0.000796133
noradrenaline B-Chemical 1 0.999928
and O 0 0.00032867576
5 B-Chemical 0 0.00022459918
- I-Chemical 0 0.0123987235
hydroxytryptamine I-Chemical 0 0.8340608
, O 0 0.00041035473
nor O 0 0.00027248956
does O 0 0.00030199002
it O 0 0.00035297155
induce O 0 0.00040320316
beta O 0 0.98107636
- O 0 0.55410165
adrenergic O 0 0.98363054
down O 0 0.0022379328
- O 0 0.0078321025
regulation O 0 0.003388089
. O 0 0.0070256

The O 0 0.0047895066
mechanism O 0 0.0039267642
of O 0 0.0045203757
its O 0 0.01417158
antidepressant B-Chemical 1 0.99987423
activity O 0 0.0047599794
is O 0 0.004554172
still O 0 0.0054253167
unknown O 0 0.010945806
. O 0 0.0120383045

The O 0 0.003135359
aim O 0 0.002340973
of O 0 0.0016719118
the O 0 0.0010989493
present O 0 0.0007180496
study O 0 0.00080048206
was O 0 0.0004802121
to O 0 0.0003153873
find O 0 0.00025865372
out O 0 0.00020625404
whether O 0 0.00018630445
TRI B-Chemical 1 0.9785669
given O 0 0.0001690912
repeatedly O 0 0.0002156052
was O 0 0.00016753878
able O 0 0.00011923714
to O 0 0.00012221259
induce O 0 0.00011409344
adaptive O 0 0.00030552945
changes O 0 0.00027671002
in O 0 0.00017319764
the O 0 0.00022611399
dopaminergic O 0 0.42911375
and O 0 0.0010638539
alpha1 O 0 0.9993806
- O 0 0.43539897
adrenergic O 0 0.9663852
systems O 0 0.00037081388
, O 0 0.0003919123
demonstrated O 0 0.0002939011
by O 0 0.00045001862
us O 0 0.0006988841
previously O 0 0.00080777524
for O 0 0.001250895
various O 0 0.004010857
antidepressants B-Chemical 0 0.99981433
. O 0 0.00684987

TRI B-Chemical 1 0.9789272
was O 0 0.0035918446
given O 0 0.001757801
to O 0 0.0015627615
male O 0 0.0037605192
Wistar O 0 0.009400132
rats O 0 0.0012164853
and O 0 0.00091138406
male O 0 0.00393659
Albino O 0 0.160085
Swiss O 0 0.0025057232
mice O 0 0.0005029476
perorally O 0 0.006921652
twice O 0 0.0006678279
daily O 0 0.0009818332
for O 0 0.0012984445
14 O 0 0.0021691716
days O 0 0.0029685702
. O 0 0.0065275407

In O 0 0.00401005
the O 0 0.0028348416
acute O 0 0.55465627
experiment O 0 0.0022662964
TRI B-Chemical 1 0.9984397
( O 0 0.0018590186
given O 0 0.00047721228
i O 0 0.0032432831
. O 0 0.00044170697
p O 0 0.00046925913
. O 0 0.00036892344
) O 0 0.00073062413
does O 0 0.0002911271
not O 0 0.00021994437
antagonize O 0 0.0005163961
the O 0 0.0023626238
reserpine B-Chemical 1 0.99999976
hypothermia B-Disease 2 0.99997723
in O 0 0.0002907917
mice O 0 0.00014148418
and O 0 0.0002770717
does O 0 0.00022259497
not O 0 0.00018954692
potentiate O 0 0.00027725013
the O 0 0.00033259537
5 B-Chemical 0 0.00043536795
- I-Chemical 0 0.02653092
hydroxytryptophan I-Chemical 0 0.97722834
head O 0 0.9317706
twitches O 0 0.9885055
in O 0 0.0026941511
rats O 0 0.0051407306
. O 0 0.00621274

TRI B-Chemical 1 0.96708506
given O 0 0.0022074257
repeatedly O 0 0.001779792
to O 0 0.0010937111
rats O 0 0.001206638
increases O 0 0.000694064
the O 0 0.0009612715
locomotor O 0 0.99881196
hyperactivity B-Disease 2 0.99999666
induced O 0 0.0005852314
by O 0 0.0005803677
d B-Chemical 0 0.11671282
- I-Chemical 0 0.9077637
amphetamine I-Chemical 1 1.0
, O 0 0.09676056
quinpirole B-Chemical 0 0.99999833
and O 0 0.0007810877
( O 0 0.0010543439
+ O 0 0.005017152
) O 0 0.0026043095
- O 0 0.015751608
7 O 0 0.00032756024
- O 0 0.06348628
hydroxy O 0 0.9999614
- O 0 0.101798765
dipropyloaminotetralin O 0 0.14122897
( O 0 0.020336788
dopamine B-Chemical 1 0.99997675
D2 O 0 0.9994747
and O 0 0.003943114
D3 O 0 0.99977154
effects O 0 0.005029688
) O 0 0.007230271
. O 0 0.0075432877

The O 0 0.0053971
stereotypies O 0 0.99952626
induced O 0 0.0029733868
by O 0 0.0026261352
d B-Chemical 0 0.1160443
- I-Chemical 0 0.8773979
amphetamine I-Chemical 1 0.9999999
or O 0 0.049784474
apomorphine B-Chemical 1 0.9999976
are O 0 0.0017279191
not O 0 0.0017709318
potentiated O 0 0.031298466
by O 0 0.0055377875
TRI B-Chemical 1 0.9957124
. O 0 0.010094326

It O 0 0.004287636
increases O 0 0.0022185717
the O 0 0.0015538521
behaviour O 0 0.0021945457
stimulation O 0 0.0011539244
evoked O 0 0.024162017
by O 0 0.0022729812
phenylephrine B-Chemical 0 0.9999908
( O 0 0.002367716
given O 0 0.00025861373
intraventricularly O 0 0.1761964
) O 0 0.00067445845
in O 0 0.00021996009
rats O 0 0.0003297114
, O 0 0.0002410569
evaluated O 0 0.00013422368
in O 0 0.00015364955
the O 0 0.00015785597
open O 0 0.00024147396
field O 0 0.00026127673
test O 0 0.00015737682
as O 0 0.00012885344
well O 0 0.00013401023
as O 0 0.00014476586
the O 0 0.00022895681
aggressiveness B-Disease 2 0.9875339
evoked O 0 0.030556705
by O 0 0.0010369365
clonidine B-Chemical 0 0.99998033
in O 0 0.00019991395
mice O 0 0.00012458659
, O 0 0.0002572803
both O 0 0.0001700017
these O 0 0.00020976785
effects O 0 0.00029325398
being O 0 0.00035453332
mediated O 0 0.0002651633
by O 0 0.0006124431
an O 0 0.0023131138
alpha1 O 0 0.99922776
- O 0 0.6909676
adrenergic O 0 0.99333763
receptor O 0 0.15131493
. O 0 0.007848192

It O 0 0.0047707353
may O 0 0.0023909572
be O 0 0.0017635317
concluded O 0 0.001292296
that O 0 0.00087862107
, O 0 0.0011918747
like O 0 0.00067310355
other O 0 0.0029423395
tricyclic O 0 0.9999875
antidepressants B-Chemical 0 0.99999034
studied O 0 0.0006338203
previously O 0 0.00045023314
, O 0 0.0011822748
TRI B-Chemical 1 0.99164176
given O 0 0.00013676341
repeatedly O 0 0.00017521752
increases O 0 0.00013776755
the O 0 0.00014249569
responsiveness O 0 0.00021673038
of O 0 0.0006692602
brain O 0 0.7713747
dopamine B-Chemical 1 0.9999962
D2 O 0 0.9999279
and O 0 0.010886475
D3 O 0 0.9999889
( O 0 0.0053818636
locomotor O 0 0.50133884
activity O 0 0.00025761928
but O 0 0.00029639082
not O 0 0.00029705194
stereotypy O 0 0.99963605
) O 0 0.0005369809
as O 0 0.00019869015
well O 0 0.0002550208
as O 0 0.0005371422
alpha1 O 0 0.9989538
- O 0 0.4693174
adrenergic O 0 0.97916573
receptors O 0 0.0053887237
to O 0 0.0013032461
their O 0 0.0025735511
agonists O 0 0.28132683
. O 0 0.0067602578

A O 0 0.035471585
question O 0 0.0024936907
arises O 0 0.0014345729
whether O 0 0.00078178465
the O 0 0.0010234202
reuptake O 0 0.9724849
inhibition O 0 0.001383821
is O 0 0.00047045003
of O 0 0.00040832657
any O 0 0.00024195931
importance O 0 0.00019172922
to O 0 0.00017827757
the O 0 0.00018922295
adaptive O 0 0.00033232346
changes O 0 0.00029047974
induced O 0 0.00022344617
by O 0 0.0002637805
repeated O 0 0.00028437938
antidepressants B-Chemical 0 0.9999478
, O 0 0.00040501068
suggested O 0 0.00022827194
to O 0 0.00025807062
be O 0 0.00035705947
responsible O 0 0.0004686445
for O 0 0.00077433913
the O 0 0.0016490851
antidepressant B-Chemical 1 0.9996754
activity O 0 0.0039970325
. O 0 0.0064070593

Pethidine B-Chemical 0 0.99993753
- O 0 0.10628779
associated O 0 0.0056705098
seizure B-Disease 2 0.99986255
in O 0 0.0016342603
a O 0 0.0015095923
healthy O 0 0.008439679
adolescent O 0 0.13601445
receiving O 0 0.009095005
pethidine B-Chemical 1 0.9999851
for O 0 0.0018848339
postoperative B-Disease 0 0.50623673
pain I-Disease 0 0.99486625
control O 0 0.004633785
. O 0 0.0075759934

A O 0 0.0795999
healthy O 0 0.011162178
17 O 0 0.003423553
- O 0 0.00519028
year O 0 0.0014952659
- O 0 0.003418479
old O 0 0.00080978376
male O 0 0.0010710143
received O 0 0.00031932717
standard O 0 0.00026795274
intermittent O 0 0.0012366422
doses O 0 0.002418332
of O 0 0.0018884274
pethidine B-Chemical 1 0.99999285
via O 0 0.00021995923
a O 0 0.00032195024
patient O 0 0.00034211678
- O 0 0.0031850003
controlled O 0 0.0003164517
analgesia O 0 0.8906664
( O 0 0.0010522607
PCA O 0 0.698732
) O 0 0.0008458473
pump O 0 0.0012094664
for O 0 0.00044874166
management O 0 0.00084549113
of O 0 0.0014323905
postoperative B-Disease 0 0.5031609
pain I-Disease 0 0.9949956
control O 0 0.0040069195
. O 0 0.0067410804

Twenty O 0 0.0077514206
- O 0 0.006145214
three O 0 0.0018963603
h O 0 0.0021497898
postoperatively O 0 0.0017611143
he O 0 0.0016270315
developed O 0 0.0016914852
a O 0 0.0017328465
brief O 0 0.0018186555
self O 0 0.005392359
- O 0 0.014182049
limited O 0 0.0059678648
seizure B-Disease 2 0.9997917
. O 0 0.011595547

Both O 0 0.00484273
plasma O 0 0.34652415
pethidine B-Chemical 1 0.9999907
and O 0 0.01172455
norpethidine B-Chemical 0 0.9997626
were O 0 0.0009164446
elevated O 0 0.0013900951
in O 0 0.0003831402
the O 0 0.00031915033
range O 0 0.00034686565
associated O 0 0.00037246593
with O 0 0.0004403218
clinical O 0 0.0015553671
manifestations O 0 0.041718565
of O 0 0.0009018789
central O 0 0.0017437323
nervous O 0 0.038089614
system O 0 0.0031227847
excitation O 0 0.52946305
. O 0 0.0075466307

No O 0 0.008899306
other O 0 0.005837832
risk O 0 0.033796977
factors O 0 0.008595057
for O 0 0.0055320864
CNS O 0 0.86824733
toxicity B-Disease 2 0.9980045
were O 0 0.006449792
identified O 0 0.007272424
. O 0 0.011823628

This O 0 0.004845692
method O 0 0.0029187372
allowed O 0 0.0018719247
frequent O 0 0.0030368601
self O 0 0.006024404
- O 0 0.01599693
dosing O 0 0.0062649283
of O 0 0.0020853458
pethidine B-Chemical 1 0.9999864
at O 0 0.00031270884
short O 0 0.00023375396
time O 0 0.00020318039
intervals O 0 0.00022714795
and O 0 0.0003699952
rapid O 0 0.0007805772
accumulation O 0 0.0013025029
of O 0 0.009539987
pethidine B-Chemical 1 0.99999464
and O 0 0.013075012
norpethidine B-Chemical 0 0.9996401
. O 0 0.007814595

The O 0 0.0033770357
routine O 0 0.002460177
use O 0 0.0020078744
of O 0 0.0032106724
pethidine B-Chemical 1 0.9999858
via O 0 0.0012882997
PCA O 0 0.57964194
even O 0 0.0008413935
for O 0 0.00064691564
a O 0 0.00080629566
brief O 0 0.00082841335
postoperative O 0 0.0046321447
analgesia O 0 0.56160766
should O 0 0.0012290734
be O 0 0.0024547519
reconsidered O 0 0.004382624
. O 0 0.0072766286

An O 0 0.007615179
unusual O 0 0.0076672677
toxic O 0 0.4856605
reaction O 0 0.012123447
to O 0 0.0020983904
axillary O 0 0.023033967
block O 0 0.0022436548
by O 0 0.0041133286
mepivacaine B-Chemical 0 0.9999517
with O 0 0.020175874
adrenaline B-Chemical 1 0.99988675
. O 0 0.010980995

An O 0 0.005119268
increase B-Disease 0 0.002462794
in I-Disease 0 0.0020822512
blood I-Disease 0 0.016383428
pressure I-Disease 0 0.090927415
, O 0 0.0011679973
accompanied O 0 0.00092973665
by O 0 0.0009324721
atrial B-Disease 0 0.9887531
fibrillation I-Disease 0 0.9999987
, O 0 0.018342203
agitation B-Disease 2 0.99857545
, O 0 0.0012341647
incomprehensible B-Disease 0 0.032054823
shouts I-Disease 0 0.07775316
and O 0 0.00030035968
loss B-Disease 0 0.0017111656
of I-Disease 0 0.0006926683
consciousness I-Disease 0 0.9797335
, O 0 0.00050017925
was O 0 0.00019911019
observed O 0 0.00015660799
in O 0 0.00019870927
an O 0 0.00040558694
elderly O 0 0.4575582
, O 0 0.0021111236
ASA O 1 0.99644035
classification O 0 0.00044519932
group O 0 0.0005597214
II O 0 0.03522006
, O 0 0.0007816737
cardiovascularly O 0 0.7108508
medicated O 0 0.56104934
male O 0 0.0015804191
, O 0 0.00023576575
12 O 0 0.00010682357
min O 0 0.00013708758
after O 0 8.760937e-05
performance O 0 0.00017306887
of O 0 0.00017437217
axillary O 0 0.0076418943
block O 0 0.00017388667
with O 0 0.0006675046
mepivacaine B-Chemical 0 0.9999639
850 O 0 0.002726552
mg O 0 0.009488537
containing O 0 0.00028303478
adrenaline B-Chemical 1 0.9999517
0 O 0 0.00031587537
. O 0 0.00021416917
225 O 0 0.0008210603
mg O 0 0.0050213593
, O 0 0.0004274405
for O 0 0.00042202583
correction O 0 0.0020430088
of O 0 0.001741534
Dupuytren B-Disease 0 0.9965373
' I-Disease 0 0.0042128987
s I-Disease 0 0.0052970387
contracture I-Disease 0 0.9985764
. O 0 0.008394854

After O 0 0.003041341
intravenous O 0 0.036559615
administration O 0 0.045164824
of O 0 0.050754916
labetalol B-Chemical 1 1.0
, O 0 0.48887098
metoprolol B-Chemical 1 0.9999999
and O 0 0.040951096
midazolam B-Chemical 0 0.99999344
the O 0 0.00042105195
patient O 0 0.00036526148
' O 0 0.00040673808
s O 0 0.00036403956
condition O 0 0.00047757768
improved O 0 0.0004755743
, O 0 0.000498582
and O 0 0.00048377918
15 O 0 0.0005011781
min O 0 0.00080119836
later O 0 0.0010000106
he O 0 0.0018028307
woke O 0 0.0030650382
up O 0 0.0034857888
. O 0 0.0067205126

The O 0 0.0036823659
block O 0 0.0027948497
was O 0 0.0021768007
successful O 0 0.0019033425
and O 0 0.0015256004
surgery O 0 0.001491743
was O 0 0.00088826986
conducted O 0 0.0007461687
as O 0 0.000806603
scheduled O 0 0.000854815
despite O 0 0.0013587807
persisting O 0 0.014875078
atrial B-Disease 0 0.9813339
fibrillation I-Disease 0 0.99996424
. O 0 0.010351338

Postoperatively O 0 0.0107552735
, O 0 0.0052568014
the O 0 0.0032019946
patient O 0 0.0031291577
refused O 0 0.0048945732
DC O 0 0.06426125
cardioversion O 0 0.13170555
and O 0 0.0031926453
was O 0 0.0037200367
treated O 0 0.0058380556
medically O 0 0.39964655
. O 0 0.010702417

Both O 0 0.0032137064
the O 0 0.00203379
temporal O 0 0.002969293
relationship O 0 0.00080201105
of O 0 0.0009559841
events O 0 0.0043532043
and O 0 0.0005906102
the O 0 0.0003557054
response O 0 0.0004015107
to O 0 0.0002207606
treatment O 0 0.00024126247
suggest O 0 0.00012756916
that O 0 0.00015313602
a O 0 0.00027540326
rapid O 0 0.0010395374
systemic O 0 0.7709199
absorption O 0 0.9033667
of O 0 0.012774849
mepivacaine B-Chemical 0 0.99999666
with O 0 0.008683134
adrenaline B-Chemical 1 0.99999094
and O 0 0.00057858985
/ O 0 0.004623741
or O 0 0.00017048237
interaction O 0 0.00020617795
of O 0 0.00023962012
these O 0 0.0002653813
drugs O 0 0.041461647
with O 0 0.00020655399
the O 0 0.0001824506
patient O 0 0.0002509704
' O 0 0.00038197948
s O 0 0.0005056529
cardiovascular O 0 0.81812286
medications O 0 0.011423944
were O 0 0.00035536726
responsible O 0 0.00044226166
for O 0 0.0007239069
the O 0 0.0013180616
perioperative O 0 0.05045538
complications O 0 0.32265458
. O 0 0.006629439

Drug O 0 0.8266538
- O 0 0.044288434
associated O 0 0.004043322
acute O 0 0.9132353
- O 0 0.06959707
onset O 0 0.0058596446
vanishing B-Disease 0 0.25957042
bile I-Disease 0 0.969441
duct I-Disease 0 0.93234354
and O 0 0.0049883244
Stevens B-Disease 0 0.5898435
- I-Disease 0 0.087227896
Johnson I-Disease 0 0.36822584
syndromes I-Disease 0 0.06865524
in O 0 0.002021475
a O 0 0.0034050795
child O 0 0.0063555883
. O 0 0.0082214745

Acute O 0 0.6011532
vanishing B-Disease 0 0.3411776
bile I-Disease 0 0.9816914
duct I-Disease 0 0.9714745
syndrome O 0 0.9302108
is O 0 0.0014201215
a O 0 0.0010626273
rare O 0 0.0030239625
but O 0 0.00053672487
established O 0 0.00042946712
cause O 0 0.00046035697
of O 0 0.0009149257
progressive O 0 0.85698223
cholestasis B-Disease 2 0.9999999
in O 0 0.003097427
adults O 0 0.028841536
, O 0 0.0006833903
is O 0 0.00028580285
most O 0 0.0003863495
often O 0 0.00043939383
drug O 0 0.07953529
or O 0 0.00038493043
toxin O 0 0.32051635
related O 0 0.00035604226
, O 0 0.00068866846
and O 0 0.0007298805
is O 0 0.00096963457
of O 0 0.0017244729
unknown O 0 0.0052048056
pathogenesis O 0 0.023643598
. O 0 0.0076891463

It O 0 0.009208122
has O 0 0.005818944
not O 0 0.0051727216
been O 0 0.0054654884
reported O 0 0.0058693155
previously O 0 0.006124241
in O 0 0.0077895895
children O 0 0.014639326
. O 0 0.016336143

Stevens B-Disease 0 0.24088438
- I-Disease 0 0.06622716
Johnson I-Disease 0 0.29804906
syndrome I-Disease 0 0.28171113
is O 0 0.0012440627
a O 0 0.000985519
well O 0 0.0006884948
- O 0 0.0029190746
recognized O 0 0.0005896518
immune O 0 0.073314376
complex O 0 0.0013527818
- O 0 0.022252817
mediated O 0 0.0002749515
hypersensitivity B-Disease 0 0.9664403
reaction O 0 0.017488962
that O 0 0.00015564954
affects O 0 0.00011916644
all O 0 0.00016406027
age O 0 0.00043826713
groups O 0 0.00025206484
, O 0 0.0003451268
is O 0 0.00028579083
drug O 0 0.19104369
or O 0 0.00039000632
infection B-Disease 2 0.95477194
induced O 0 0.0009951518
, O 0 0.0010717885
and O 0 0.00045666745
has O 0 0.00034636617
classic O 0 0.025492532
systemic O 0 0.6896097
, O 0 0.0014616998
mucosal O 0 0.42194092
, O 0 0.0022631718
and O 0 0.002402446
dermatologic O 0 0.5204559
manifestations O 0 0.60581845
. O 0 0.0068007

A O 0 0.046326693
previously O 0 0.003331855
healthy O 0 0.0047359015
child O 0 0.0022929367
who O 0 0.0018887583
developed O 0 0.0019317311
acute O 0 0.84907854
, O 0 0.0035299887
severe O 0 0.16370091
, O 0 0.0008873237
rapidly O 0 0.00069348287
progressive O 0 0.10220061
vanishing B-Disease 0 0.4414664
bile I-Disease 0 0.98683506
duct I-Disease 0 0.98439646
syndrome I-Disease 0 0.9305448
shortly O 0 0.0013136362
after O 0 0.00020386658
Stevens B-Disease 0 0.2010915
- I-Disease 0 0.06370549
Johnson I-Disease 0 0.44088486
syndrome I-Disease 0 0.35072884
is O 0 0.00033203937
described O 0 0.00026551975
; O 0 0.00046336153
this O 0 0.00032552952
was O 0 0.00043115055
temporally O 0 0.0009458326
associated O 0 0.001075403
with O 0 0.0030812426
ibuprofen B-Chemical 0 0.99996126
use O 0 0.0048181047
. O 0 0.0065016416

Despite O 0 0.0041253595
therapy O 0 0.0052723885
with O 0 0.0055086003
ursodeoxycholic B-Chemical 0 0.99998665
acid I-Chemical 0 0.9970084
, O 0 0.04456378
prednisone B-Chemical 1 0.9999113
, O 0 0.0013755916
and O 0 0.00054567074
then O 0 0.0005627737
tacrolimus B-Chemical 0 0.99999547
, O 0 0.005475521
her O 0 0.015901182
cholestatic B-Disease 0 1.0
disease I-Disease 0 0.9999641
was O 0 0.0026961416
unrelenting O 0 0.34361455
, O 0 0.0009113411
with O 0 0.0015749421
cirrhosis B-Disease 0 0.9999989
shown O 0 0.00043463605
by O 0 0.00048367778
biopsy O 0 0.0009829103
6 O 0 0.00060648454
months O 0 0.00082066964
after O 0 0.0013761235
presentation O 0 0.0039392146
. O 0 0.006271766

This O 0 0.0052112765
case O 0 0.0030319314
documents O 0 0.0039320774
acute O 0 0.9071167
drug O 0 0.9355968
- O 0 0.054193255
related O 0 0.0005329357
vanishing B-Disease 0 0.15823731
bile I-Disease 0 0.9807581
duct I-Disease 0 0.97968024
syndrome I-Disease 0 0.9045742
in O 0 0.0003512485
the O 0 0.00023559586
pediatric O 0 0.00038296267
age O 0 0.00042158837
group O 0 0.00024350411
and O 0 0.00019136888
suggests O 0 0.00012592236
shared O 0 0.0002921002
immune O 0 0.012211326
mechanisms O 0 0.00020940235
in O 0 0.00020405483
the O 0 0.00020263056
pathogenesis O 0 0.0006997177
of O 0 0.00038909964
both O 0 0.0005090861
Stevens B-Disease 0 0.32114115
- I-Disease 0 0.06355285
Johnson I-Disease 0 0.3879597
syndrome I-Disease 0 0.29652864
and O 0 0.0013717833
vanishing B-Disease 0 0.2409414
bile I-Disease 0 0.9698601
duct I-Disease 0 0.9892814
syndrome I-Disease 0 0.9731713
. O 0 0.009799906

High O 0 0.01130096
incidence O 0 0.006664336
of O 0 0.0038626054
primary B-Disease 0 0.020688608
pulmonary I-Disease 2 0.99981135
hypertension I-Disease 2 0.9999999
associated O 0 0.014094498
with O 0 0.010226753
appetite B-Chemical 1 0.99943966
suppressants I-Chemical 1 0.9995826
in O 0 0.0051523563
Belgium O 0 0.0840823
. O 0 0.009018763

Primary B-Disease 0 0.10393136
pulmonary I-Disease 2 0.99946636
hypertension I-Disease 2 0.99999964
is O 0 0.0037310962
a O 0 0.0017984469
rare O 0 0.005203517
, O 0 0.0011831394
progressive O 0 0.052619163
and O 0 0.0011065592
incurable O 0 0.32618186
disease O 0 0.9788078
, O 0 0.0017010155
which O 0 0.0005674571
has O 0 0.0002947581
been O 0 0.00030112633
associated O 0 0.00036005658
with O 0 0.00045401137
the O 0 0.0006298102
intake O 0 0.49420413
of O 0 0.0049441555
appetite B-Chemical 0 0.99939823
suppressant I-Chemical 0 0.9984811
drugs O 0 0.77245826
. O 0 0.0073676035

The O 0 0.0028436964
importance O 0 0.0018593797
of O 0 0.0016221496
this O 0 0.0010706813
association O 0 0.00078391563
was O 0 0.00066810515
evaluated O 0 0.00045303628
in O 0 0.0005292527
Belgium O 0 0.012961616
while O 0 0.0004011425
this O 0 0.00030543335
country O 0 0.0006567363
still O 0 0.00030117805
had O 0 0.00029198072
no O 0 0.00027121615
restriction O 0 0.0009610124
on O 0 0.00042626253
the O 0 0.0007840561
prescription O 0 0.0064044734
of O 0 0.0039907424
appetite B-Chemical 1 0.9989542
suppressants I-Chemical 1 0.99939275
. O 0 0.008359675

Thirty O 0 0.007954933
- O 0 0.006341947
five O 0 0.001462199
patients O 0 0.0014078598
with O 0 0.001074707
primary B-Disease 0 0.005619594
pulmonary I-Disease 2 0.99972695
hypertension I-Disease 2 1.0
and O 0 0.0012454914
85 O 0 0.0004917725
matched O 0 0.00025230768
controls O 0 0.0003010652
were O 0 0.00021922811
recruited O 0 0.00020432156
over O 0 0.0001904658
32 O 0 0.00035098326
months O 0 0.00030821285
( O 0 0.00068727584
1992 O 0 0.0022313157
- O 0 0.003512932
1994 O 0 0.0039335736
) O 0 0.0030204742
in O 0 0.0034911623
Belgium O 0 0.02182757
. O 0 0.008486767

Exposure O 0 0.022294937
to O 0 0.0045057074
appetite B-Chemical 0 0.9979861
- I-Chemical 0 0.3424871
suppressants I-Chemical 0 0.9978035
was O 0 0.001114477
assessed O 0 0.0006268456
on O 0 0.0005043066
the O 0 0.0006118988
basis O 0 0.00073601067
of O 0 0.00094281585
hospital O 0 0.0015089075
records O 0 0.001539333
and O 0 0.001697055
standardized O 0 0.002329588
interview O 0 0.003960887
. O 0 0.00667912

Twenty O 0 0.006878212
- O 0 0.0054372298
three O 0 0.0012602949
of O 0 0.0012618772
the O 0 0.0008844053
patients O 0 0.0008962648
had O 0 0.0004868929
previously O 0 0.00042814578
taken O 0 0.00039045233
appetite B-Chemical 1 0.99825805
suppressants I-Chemical 1 0.99978
, O 0 0.0015575992
mainly O 0 0.0018946806
fenfluramines B-Chemical 0 0.99635506
, O 0 0.00040853533
as O 0 0.00015655663
compared O 0 0.000114160255
with O 0 0.00016469315
only O 0 0.00016819603
5 O 0 0.00012675118
of O 0 0.00016072456
the O 0 0.00017015431
controls O 0 0.0003356684
( O 0 0.0003318713
66 O 0 0.00030354757
versus O 0 0.00021425901
6 O 0 0.0002367876
% O 0 0.00040228348
, O 0 0.0005319615
p O 0 0.0005914715
< O 0 0.00078723335
0 O 0 0.0013206864
. O 0 0.0019176167
0001 O 0 0.009662082
) O 0 0.0064160633
. O 0 0.008361599

Five O 0 0.005682913
patients O 0 0.0036900083
died O 0 0.0033202684
before O 0 0.001293971
the O 0 0.0012071558
interview O 0 0.0011629028
, O 0 0.0013095569
all O 0 0.0009654294
of O 0 0.0012722348
them O 0 0.0017826817
had O 0 0.0018186952
taken O 0 0.0027036988
appetite B-Chemical 1 0.995826
suppressants I-Chemical 1 0.99901545
. O 0 0.0097488975

In O 0 0.003943934
8 O 0 0.0025376626
patients O 0 0.0018734391
the O 0 0.0011904723
diagnosis O 0 0.0018348012
of O 0 0.0011512373
primary B-Disease 0 0.014977418
pulmonary I-Disease 2 0.9998814
hypertension I-Disease 2 1.0
was O 0 0.0012870927
uncertain O 0 0.0009348228
, O 0 0.00062239124
5 O 0 0.0004273875
of O 0 0.0006339324
them O 0 0.0010311863
had O 0 0.0011744245
taken O 0 0.001923083
appetite B-Chemical 1 0.9947154
suppressants I-Chemical 1 0.9988319
. O 0 0.008296547

The O 0 0.00362382
patients O 0 0.0032382803
who O 0 0.0023776554
had O 0 0.0011640398
been O 0 0.0008657788
exposed O 0 0.0008468533
to O 0 0.0007876228
appetite B-Chemical 1 0.999181
suppressants I-Chemical 1 0.9996643
tended O 0 0.0003563796
to O 0 0.00018642635
be O 0 0.00017963002
on O 0 0.00012284981
average O 0 0.00013892143
more O 0 0.000244818
severely O 0 0.0024861633
ill O 0 0.07048616
, O 0 0.0003119647
and O 0 0.0002144908
to O 0 0.00016255758
have O 0 0.00016647758
a O 0 0.00022016487
shorter O 0 0.00015959401
median O 0 0.00017367126
delay O 0 0.0003085598
between O 0 0.00032097535
onset O 0 0.0009214472
of O 0 0.0012570609
symptoms O 0 0.17733742
and O 0 0.002598695
diagnosis O 0 0.02169825
. O 0 0.0066373292

A O 0 0.03354251
policy O 0 0.0051470036
of O 0 0.0025677704
unrestricted O 0 0.0025312568
prescription O 0 0.0077684643
of O 0 0.0025951355
appetite B-Chemical 1 0.9995559
suppressants I-Chemical 1 0.999782
may O 0 0.000651069
lead O 0 0.005359307
to O 0 0.0003996104
a O 0 0.000537532
high O 0 0.00064205896
incidence O 0 0.0016082533
of O 0 0.0010066993
associated O 0 0.0019468406
primary B-Disease 0 0.04275272
pulmonary I-Disease 2 0.9997856
hypertension I-Disease 2 0.9999995
. O 0 0.014526826

Intake O 0 0.57000357
of O 0 0.008763703
appetite B-Chemical 1 0.99873406
suppressants I-Chemical 1 0.9993711
may O 0 0.0023413817
accelerate O 0 0.0020020716
the O 0 0.002148841
progression O 0 0.07623295
of O 0 0.00413347
the O 0 0.0051821065
disease O 0 0.9164107
. O 0 0.011159798

Inappropriate O 0 0.008617605
use O 0 0.004517378
of O 0 0.00899909
carbamazepine B-Chemical 1 0.9999989
and O 0 0.060632046
vigabatrin B-Chemical 0 0.99999475
in O 0 0.0035429257
typical O 0 0.0046885135
absence B-Disease 0 0.024282683
seizures I-Disease 0 0.9999974
. O 0 0.014909902

Carbamazepine B-Chemical 0 0.99999404
and O 0 0.052885722
vigabatrin B-Chemical 0 0.9999887
are O 0 0.0046664802
contraindicated O 0 0.025247281
in O 0 0.0031053175
typical O 0 0.0045563644
absence B-Disease 0 0.020674044
seizures I-Disease 0 0.999997
. O 0 0.01665744

Of O 0 0.0046598935
18 O 0 0.002599763
consecutive O 0 0.0014901927
referrals O 0 0.0016598237
of O 0 0.0010519851
children O 0 0.0012621587
with O 0 0.00066876697
resistant O 0 0.000651614
typical O 0 0.0006925608
absences O 0 0.5514582
only O 0 0.00043809548
, O 0 0.000375061
eight O 0 0.0001712837
were O 0 0.00018939137
erroneously O 0 0.0007127984
treated O 0 0.00035915629
with O 0 0.0016848071
carbamazepine B-Chemical 1 0.9999995
either O 0 0.0003621487
as O 0 0.0003710303
monotherapy O 0 0.092114635
or O 0 0.00046755662
as O 0 0.0006372225
an O 0 0.0011044544
add O 0 0.0015986917
- O 0 0.005862359
on O 0 0.0031302718
. O 0 0.0068720747

Vigabatrin B-Chemical 1 0.999928
was O 0 0.0048153233
also O 0 0.0029316882
used O 0 0.0023124348
in O 0 0.0022148832
the O 0 0.0022327069
treatment O 0 0.0027661775
of O 0 0.0036739646
two O 0 0.004010825
children O 0 0.0092423735
. O 0 0.010765366

Frequency O 0 0.006412061
of O 0 0.003465796
absences O 0 0.3403516
increased O 0 0.0016500502
in O 0 0.0008646276
four O 0 0.0004882877
children O 0 0.00088332064
treated O 0 0.0007582451
with O 0 0.0035835563
carbamazepine B-Chemical 1 0.99999964
and O 0 0.00048736585
two O 0 0.00019372639
of O 0 0.00026820527
these O 0 0.00041506346
developed O 0 0.020791942
myoclonic B-Disease 2 0.9999999
jerks I-Disease 2 0.9999938
, O 0 0.0013609811
which O 0 0.0005905106
resolved O 0 0.00073293655
on O 0 0.0006877237
withdrawal O 0 0.25014067
of O 0 0.016305225
carbamazepine B-Chemical 1 0.9999976
. O 0 0.009320015

Absences O 0 0.19172099
were O 0 0.0036537398
aggravated O 0 0.028130814
in O 0 0.0017481735
both O 0 0.0013403433
cases O 0 0.0020352202
where O 0 0.0023317158
vigabatrin B-Chemical 0 0.9999925
was O 0 0.0011458665
added O 0 0.00094090623
on O 0 0.00092637073
to O 0 0.0014972192
concurrent O 0 0.003209998
treatment O 0 0.005187729
. O 0 0.007855451

Optimal O 0 0.004559536
control O 0 0.0024285282
of O 0 0.0019151479
the O 0 0.0014410492
absences O 0 0.3705186
was O 0 0.0007586051
achieved O 0 0.0006725935
with O 0 0.0023645395
sodium B-Chemical 0 0.9999895
valproate I-Chemical 0 0.99999964
, O 0 0.13551378
lamotrigine B-Chemical 0 0.9999995
, O 0 0.0039804205
or O 0 0.0026183284
ethosuximide B-Chemical 0 0.9999988
alone O 0 0.0012153763
or O 0 0.0013773442
in O 0 0.002103447
combination O 0 0.004504453
. O 0 0.0065240692

Choreoathetoid B-Disease 0 0.723103
movements I-Disease 0 0.029006878
associated O 0 0.0054005287
with O 0 0.004779834
rapid O 0 0.00704384
adjustment O 0 0.007197599
to O 0 0.008093206
methadone B-Chemical 1 0.9993668
. O 0 0.015680162

Choreatiform B-Disease 0 0.3190672
hyperkinesias I-Disease 0 0.9962669
are O 0 0.002145311
known O 0 0.0014766417
to O 0 0.0008508932
be O 0 0.00083916995
occasional O 0 0.004641352
movement B-Disease 0 0.091631964
abnormalities I-Disease 0 0.7983151
during O 0 0.000742849
intoxications O 0 0.99967015
with O 0 0.0111684315
cocaine B-Chemical 1 0.9999831
but O 0 0.0031053235
not O 0 0.0033748285
opiates O 0 0.99833626
. O 0 0.007599264

This O 0 0.0053098397
is O 0 0.002692398
a O 0 0.002090229
case O 0 0.0014613449
report O 0 0.002083644
of O 0 0.0025334237
euphoria O 0 0.9999162
and O 0 0.023501176
choreoathetoid B-Disease 0 0.99999905
movements I-Disease 0 0.24947007
both O 0 0.00033123785
transiently O 0 0.000811736
induced O 0 0.00026282706
by O 0 0.0002521348
rapid O 0 0.0005317922
adjustment O 0 0.00028118675
to O 0 0.00013082454
the O 0 0.00017417077
selective O 0 0.002545129
mu O 0 0.862758
- O 0 0.5987315
opioid O 0 0.9987721
receptor O 0 0.41450137
agonist O 0 0.98419476
methadone B-Chemical 1 0.9998511
in O 0 0.0003837523
an O 0 0.0004642259
inpatient O 0 0.0010370921
previously O 0 0.0008064071
abusing O 0 0.885252
heroine B-Chemical 0 0.34340626
and O 0 0.005883062
cocaine B-Chemical 1 0.9999218
. O 0 0.008088813

In O 0 0.009475553
addition O 0 0.006875446
, O 0 0.01129901
minor O 0 0.020310178
EEG O 0 0.9504346
abnormalities O 0 0.11813097
occurred O 0 0.01407589
. O 0 0.018400824

Possible O 0 0.017666794
underlying O 0 0.01194314
neurobiological O 0 0.022613207
phenomena O 0 0.016382763
are O 0 0.0124320835
discussed O 0 0.01467373
. O 0 0.021511128

Adverse O 0 0.029437974
effects O 0 0.011187648
of O 0 0.011267253
the O 0 0.012179605
atypical O 0 0.5788831
antipsychotics O 0 0.99924445
. O 0 0.020927815

Collaborative O 0 0.02920074
Working O 0 0.028547749
Group O 0 0.019702248
on O 0 0.0104903085
Clinical O 0 0.021590091
Trial O 0 0.021369394
Evaluations O 0 0.019503435
. O 0 0.022130474

Adverse O 0 0.03262199
effects O 0 0.008067813
of O 0 0.009150385
antipsychotics O 0 0.99902606
often O 0 0.0074196444
lead O 0 0.014588864
to O 0 0.0077379686
noncompliance O 0 0.72882205
. O 0 0.01488754

Thus O 0 0.004335621
, O 0 0.0034115545
clinicians O 0 0.0020801716
should O 0 0.0008322185
address O 0 0.0005491295
patients O 0 0.0007917568
' O 0 0.0007219428
concerns O 0 0.00047793792
about O 0 0.00035555603
adverse O 0 0.100983724
effects O 0 0.00041036747
and O 0 0.00028708606
attempt O 0 0.00022555629
to O 0 0.00016516793
choose O 0 0.00019637484
medications O 0 0.0029684063
that O 0 0.00013498221
will O 0 0.00013791161
improve O 0 0.00012744417
their O 0 0.00020113797
patients O 0 0.00031829192
' O 0 0.0003318887
quality O 0 0.0002443283
of O 0 0.00037878106
life O 0 0.0005633553
as O 0 0.0005396959
well O 0 0.00075930584
as O 0 0.0011815362
overall O 0 0.0022756334
health O 0 0.00959894
. O 0 0.006614242

The O 0 0.0035065245
side O 0 0.006749847
effect O 0 0.0017089628
profiles O 0 0.0011015943
of O 0 0.001109825
the O 0 0.0009794864
atypical O 0 0.26019505
antipsychotics O 0 0.99925
are O 0 0.00048273403
more O 0 0.0004530773
advantageous O 0 0.00042812535
than O 0 0.00039909876
those O 0 0.0007049472
of O 0 0.0010531143
the O 0 0.0015552753
conventional O 0 0.0036465651
neuroleptics O 0 0.99880147
. O 0 0.0067168595

Conventional O 0 0.0061796694
agents O 0 0.0057991715
are O 0 0.00163824
associated O 0 0.0011841434
with O 0 0.00095882243
unwanted O 0 0.012939144
central O 0 0.0012038712
nervous O 0 0.02860888
system O 0 0.00042191762
effects O 0 0.000531001
, O 0 0.000680587
including O 0 0.002547314
extrapyramidal B-Disease 0 0.9999999
symptoms I-Disease 0 0.99812645
( O 0 0.050511107
EPS B-Disease 0 0.9999199
) O 0 0.030609712
, O 0 0.0594289
tardive B-Disease 0 1.0
dyskinesia I-Disease 0 1.0
, O 0 0.008739789
sedation O 0 0.23547316
, O 0 0.00027387674
and O 0 0.00019819138
possible O 0 0.00023075829
impairment O 0 0.088189125
of O 0 0.00027265848
some O 0 0.0002438675
cognitive O 0 0.3055958
measures O 0 0.00014494639
, O 0 0.00021829907
as O 0 0.00013923694
well O 0 0.00015159426
as O 0 0.00018573119
cardiac O 0 0.034120947
effects O 0 0.0014828485
, O 0 0.024006216
orthostatic B-Disease 2 0.9999987
hypotension I-Disease 2 0.9999999
, O 0 0.007468204
hepatic O 0 0.92986345
changes O 0 0.003058051
, O 0 0.0038771655
anticholinergic O 0 0.9997193
side O 0 0.05278072
effects O 0 0.001185304
, O 0 0.002793797
sexual B-Disease 0 0.9884799
dysfunction I-Disease 0 0.9976827
, O 0 0.002410334
and O 0 0.0019115437
weight B-Disease 0 0.0067408155
gain I-Disease 0 0.00628955
. O 0 0.007222403

The O 0 0.0033641479
newer O 0 0.0064436747
atypical O 0 0.011762568
agents O 0 0.0056282524
have O 0 0.0008260151
a O 0 0.0009565673
lower O 0 0.000751903
risk O 0 0.13234268
of O 0 0.009256776
EPS B-Disease 0 0.9999217
, O 0 0.0021074393
but O 0 0.00043866612
are O 0 0.00021032178
associated O 0 0.00020599936
in O 0 0.00015757924
varying O 0 0.00017983602
degrees O 0 0.003833275
with O 0 0.0005119845
sedation O 0 0.2788976
, O 0 0.0007034956
cardiovascular O 0 0.93521297
effects O 0 0.0019108979
, O 0 0.0044762585
anticholinergic O 0 0.99969447
effects O 0 0.0007784561
, O 0 0.00047837177
weight B-Disease 0 0.0045373715
gain I-Disease 0 0.0024554036
, O 0 0.0041367607
sexual B-Disease 0 0.9945437
dysfunction I-Disease 0 0.99940133
, O 0 0.006762361
hepatic O 0 0.91739225
effects O 0 0.0019291854
, O 0 0.001143978
lowered O 0 0.033895522
seizure B-Disease 2 0.99996006
threshold O 0 0.00028887184
( O 0 0.00090714026
primarily O 0 0.0035140873
clozapine B-Chemical 0 0.9999994
) O 0 0.0042656064
, O 0 0.0010941623
and O 0 0.004266526
agranulocytosis B-Disease 0 0.9999988
( O 0 0.18200849
clozapine B-Chemical 0 0.99999774
only O 0 0.0034996718
) O 0 0.006636936
. O 0 0.006899795

Since O 0 0.0029682892
the O 0 0.002201266
incidence O 0 0.0032656158
and O 0 0.0015004884
severity O 0 0.0034273684
of O 0 0.0008515887
specific O 0 0.00062024407
adverse O 0 0.3637535
effects O 0 0.00069195515
differ O 0 0.00030240518
among O 0 0.00035433145
the O 0 0.00022924079
various O 0 0.00055991556
atypicals O 0 0.93774205
, O 0 0.00028543547
the O 0 0.00015216121
clinician O 0 0.00023798332
should O 0 8.5694235e-05
carefully O 0 8.1539925e-05
consider O 0 8.84687e-05
which O 0 0.00020091124
side O 0 0.0055409134
effects O 0 0.00029025215
are O 0 0.0001757
most O 0 0.0002511614
likely O 0 0.00015098722
to O 0 0.0001281082
lead O 0 0.0013137807
to O 0 0.00013273908
the O 0 0.00014064605
individual O 0 0.00015117855
' O 0 0.00028614473
s O 0 0.000301857
dissatisfaction O 0 0.012020618
and O 0 0.00035187625
noncompliance O 0 0.141756
before O 0 0.00021323311
choosing O 0 0.00039885
an O 0 0.00078621984
antipsychotic O 0 0.9950482
for O 0 0.0008306638
a O 0 0.0014298884
particular O 0 0.0017762578
patient O 0 0.0038307582
. O 0 0.006106993

A O 0 0.037103772
randomized O 0 0.003899821
, O 0 0.0036863727
placebo O 0 0.08223095
- O 0 0.004894989
controlled O 0 0.00079582963
dose O 0 0.005312077
- O 0 0.0052891406
comparison O 0 0.0003861236
trial O 0 0.0005868479
of O 0 0.0019944601
haloperidol B-Chemical 1 0.99999976
for O 0 0.0014653179
psychosis B-Disease 0 0.99996805
and O 0 0.0011635743
disruptive B-Disease 0 0.81934005
behaviors I-Disease 0 0.6925841
in O 0 0.0019974445
Alzheimer B-Disease 0 0.99998546
' I-Disease 0 0.0041077165
s I-Disease 0 0.0039682463
disease I-Disease 0 0.7427022
. O 0 0.007880911

OBJECTIVE O 0 0.022811111
: O 0 0.0035881754
The O 0 0.0015245735
goal O 0 0.0014377026
of O 0 0.0010322685
this O 0 0.0007132768
study O 0 0.0006599513
was O 0 0.0003757945
to O 0 0.00023566395
compare O 0 0.00013958788
the O 0 0.00018873281
efficacy O 0 0.00030332484
and O 0 0.00027694943
side O 0 0.007742037
effects O 0 0.00029153595
of O 0 0.00024494407
two O 0 0.00015466097
doses O 0 0.0039973534
of O 0 0.0077979607
haloperidol B-Chemical 1 0.9999999
and O 0 0.0011425725
placebo O 0 0.02070616
in O 0 0.00014417131
the O 0 0.00014563715
treatment O 0 0.00023959708
of O 0 0.0008222214
psychosis B-Disease 0 0.9999769
and O 0 0.00095445564
disruptive B-Disease 0 0.8034683
behaviors I-Disease 0 0.42014658
in O 0 0.00042002587
patients O 0 0.000908095
with O 0 0.0017583702
Alzheimer B-Disease 0 0.9999862
' I-Disease 0 0.0039390908
s I-Disease 0 0.0038086316
disease I-Disease 0 0.7628891
. O 0 0.0075623067

METHOD O 0 0.008057493
: O 0 0.0040830616
In O 0 0.0020306944
a O 0 0.0017527854
6 O 0 0.0010855473
- O 0 0.0018376346
week O 0 0.0005574015
random O 0 0.00073022844
- O 0 0.0033744453
assignment O 0 0.0009195129
, O 0 0.0005984993
double O 0 0.00057529745
- O 0 0.017262489
blind O 0 0.03802965
, O 0 0.0007273742
placebo O 0 0.029484686
- O 0 0.0013580639
controlled O 0 0.00017044984
trial O 0 0.00026412276
( O 0 0.00033325175
phase O 0 0.00058995816
A O 0 0.3287075
) O 0 0.008477609
, O 0 0.019572807
haloperidol B-Chemical 1 0.9999999
, O 0 0.0012279078
2 O 0 0.0002714068
- O 0 0.0017530199
3 O 0 0.00015705168
mg O 0 0.0034009586
/ O 0 0.0006541162
day O 0 0.00014553526
( O 0 0.00022077806
standard O 0 0.00013204802
dose O 0 0.0012062024
) O 0 0.00092866796
, O 0 0.0005845095
and O 0 0.0035060633
haloperidol B-Chemical 1 0.99999976
, O 0 0.00065776997
0 O 0 0.00024173586
. O 0 0.00015481962
50 O 0 0.00024369083
- O 0 0.001202355
0 O 0 0.00019763246
. O 0 0.0001496522
75 O 0 0.00020844874
mg O 0 0.0031133015
/ O 0 0.0006608306
day O 0 0.00016652331
( O 0 0.0003035062
low O 0 0.0003216625
dose O 0 0.0026673793
) O 0 0.0009542179
, O 0 0.00038939092
were O 0 0.00023420191
compared O 0 0.00019639637
in O 0 0.00030846923
71 O 0 0.00078293245
outpatients O 0 0.0016625694
with O 0 0.001405233
Alzheimer B-Disease 0 0.99997723
' I-Disease 0 0.0036985064
s I-Disease 0 0.0039156643
disease I-Disease 0 0.7419781
. O 0 0.007937672

For O 0 0.0032486198
the O 0 0.0021409735
subsequent O 0 0.0017227107
6 O 0 0.0012361017
- O 0 0.0020058134
week O 0 0.0005993304
double O 0 0.00073753437
- O 0 0.0040873378
blind O 0 0.009165486
crossover O 0 0.0024351
phase O 0 0.00064148236
( O 0 0.00068936835
phase O 0 0.001254389
B O 0 0.91614586
) O 0 0.004004713
, O 0 0.0005392367
patients O 0 0.00042654824
taking O 0 0.00043902462
standard O 0 0.00017715902
- O 0 0.0035727746
or O 0 0.00021481747
low O 0 0.000996498
- O 0 0.06098834
dose O 0 0.13375734
haloperidol B-Chemical 1 0.99999976
were O 0 0.00021923354
switched O 0 0.00020798319
to O 0 0.0001514411
placebo O 0 0.007900692
, O 0 0.00024547198
and O 0 0.00022095325
patients O 0 0.0003629734
taking O 0 0.0005959657
placebo O 0 0.0018244624
were O 0 0.00014471867
randomly O 0 0.00010407598
assigned O 0 0.0001489944
to O 0 0.00019385791
standard O 0 0.0002964321
- O 0 0.0019995912
or O 0 0.00062839035
low O 0 0.002068037
- O 0 0.0925418
dose O 0 0.46674085
haloperidol B-Chemical 1 0.9999976
. O 0 0.008494669

RESULTS O 0 0.005585744
: O 0 0.0035419615
For O 0 0.0016869917
the O 0 0.0012703957
60 O 0 0.0010426934
patients O 0 0.00089281803
who O 0 0.00072354375
completed O 0 0.00044250285
phase O 0 0.000768553
A O 0 0.08793254
, O 0 0.0006531827
standard O 0 0.0003475328
- O 0 0.034179717
dose O 0 0.137497
haloperidol B-Chemical 1 0.9999999
was O 0 0.00036731368
efficacious O 0 0.00072432694
and O 0 0.00019098428
superior O 0 0.000256086
to O 0 0.00011343095
both O 0 0.00016842871
low O 0 0.0007051562
- O 0 0.0535162
dose O 0 0.1573523
haloperidol B-Chemical 1 0.9999999
and O 0 0.00069057697
placebo O 0 0.008374638
for O 0 0.00014152454
scores O 0 0.000146797
on O 0 0.00012498972
the O 0 0.00022150906
Brief O 0 0.002250697
Psychiatric O 0 0.024530938
Rating O 0 0.00601506
Scale O 0 0.13160846
psychosis B-Disease 0 0.9989975
factor O 0 0.0027651438
and O 0 0.0013195717
on O 0 0.0016267883
psychomotor B-Disease 0 0.99836093
agitation I-Disease 2 0.991966
. O 0 0.0076852543

Response O 0 0.007129856
rates O 0 0.0025149097
according O 0 0.0012750953
to O 0 0.0008742573
three O 0 0.0004958296
sets O 0 0.0004597893
of O 0 0.00046221857
criteria O 0 0.00044133724
were O 0 0.0003078311
greater O 0 0.00022210417
with O 0 0.00022545137
the O 0 0.00018404727
standard O 0 0.00016354873
dose O 0 0.0008631553
( O 0 0.00040247236
55 O 0 0.00029475978
% O 0 0.00033771238
- O 0 0.0015548747
60 O 0 0.00019336984
% O 0 0.00022608791
) O 0 0.0002769943
than O 0 0.00012059856
the O 0 0.00014648715
low O 0 0.000246957
dose O 0 0.0011201142
( O 0 0.00045405264
25 O 0 0.00030876783
% O 0 0.00035943463
- O 0 0.0014236369
35 O 0 0.00024414525
% O 0 0.00031223008
) O 0 0.00046864335
and O 0 0.00042969108
placebo O 0 0.0077979537
( O 0 0.0006577395
25 O 0 0.0006841221
% O 0 0.0010030451
- O 0 0.0024424384
30 O 0 0.001487686
% O 0 0.0029482404
) O 0 0.0056630867
. O 0 0.007812133

The O 0 0.0034979624
advantage O 0 0.002257043
of O 0 0.002016166
standard O 0 0.0013375888
dose O 0 0.0021721118
over O 0 0.00087728346
low O 0 0.001362152
dose O 0 0.002773353
was O 0 0.0013878437
replicated O 0 0.0015384764
in O 0 0.0023748768
phase O 0 0.0053736386
B O 0 0.7303262
. O 0 0.01093629

In O 0 0.004297645
phase O 0 0.005600657
A O 0 0.40149707
, O 0 0.058892705
extrapyramidal B-Disease 0 0.9999994
signs I-Disease 0 0.96726394
tended O 0 0.0006488063
to O 0 0.00031767468
be O 0 0.00029350797
greater O 0 0.00022464414
with O 0 0.0002266884
the O 0 0.00017997617
standard O 0 0.00015193969
dose O 0 0.0005476043
than O 0 0.00012529915
in O 0 0.00014272906
the O 0 0.00014335182
other O 0 0.00015948268
two O 0 0.00012212753
conditions O 0 0.00018607685
, O 0 0.00026423082
primarily O 0 0.00020248533
because O 0 0.00014873888
of O 0 0.00024931144
a O 0 0.00034523147
subgroup O 0 0.0019909437
( O 0 0.00045957722
20 O 0 0.0002866485
% O 0 0.00041504562
) O 0 0.00065648917
who O 0 0.00072962075
developed O 0 0.0009127402
moderate O 0 0.0036380999
to O 0 0.0015113781
severe O 0 0.18404149
signs O 0 0.26915306
. O 0 0.0072345445

Low O 0 0.14158799
- O 0 0.09994872
dose O 0 0.43722165
haloperidol B-Chemical 1 0.9999994
did O 0 0.00231183
not O 0 0.00079845445
differ O 0 0.00063511886
from O 0 0.00051411823
placebo O 0 0.0019848696
on O 0 0.00033109015
any O 0 0.00040157387
measure O 0 0.0003775701
of O 0 0.0007953361
efficacy O 0 0.0014611174
or O 0 0.0016624158
side O 0 0.032272726
effects O 0 0.0058372286
. O 0 0.007490767

CONCLUSIONS O 0 0.018261267
: O 0 0.0035563698
The O 0 0.001455248
results O 0 0.0010317699
indicated O 0 0.0007393992
a O 0 0.00084721245
favorable O 0 0.0024259998
therapeutic O 0 0.0013829145
profile O 0 0.0005983137
for O 0 0.0013093738
haloperidol B-Chemical 1 0.99999964
in O 0 0.0003253707
doses O 0 0.0015348032
of O 0 0.00037513088
2 O 0 0.00030699756
- O 0 0.0025134091
3 O 0 0.0001899415
mg O 0 0.004624478
/ O 0 0.00079165306
day O 0 0.00021044735
, O 0 0.00032669076
although O 0 0.00026568968
a O 0 0.00037892495
subgroup O 0 0.0011760062
developed O 0 0.0007904469
moderate O 0 0.008652117
to O 0 0.0012034143
severe O 0 0.9243794
extrapyramidal B-Disease 0 0.99999917
signs I-Disease 0 0.9733907
. O 0 0.007907685

A O 0 0.020531863
starting O 0 0.0026180793
dose O 0 0.0040722913
of O 0 0.0018910806
1 O 0 0.0013351298
mg O 0 0.026431656
/ O 0 0.002053609
day O 0 0.0005918071
with O 0 0.00064834266
gradual O 0 0.0008494496
, O 0 0.0012451671
upward O 0 0.014122685
dose O 0 0.006555998
titration O 0 0.005069828
is O 0 0.0029790027
recommended O 0 0.0046716635
. O 0 0.0071178623

The O 0 0.002933985
narrow O 0 0.0028391017
therapeutic O 0 0.0023301647
window O 0 0.0013565412
observed O 0 0.000965182
with O 0 0.0056291036
haloperidol B-Chemical 1 0.99999964
may O 0 0.0004972746
also O 0 0.00029303602
apply O 0 0.00021427986
to O 0 0.000222086
other O 0 0.00051032216
neuroleptics O 0 0.99888474
used O 0 0.00023975564
in O 0 0.00048069112
Alzheimer B-Disease 0 0.99999297
' I-Disease 0 0.0010140447
s I-Disease 0 0.00071902026
disease I-Disease 0 0.5724477
patients O 0 0.0011141034
with O 0 0.0015251277
psychosis B-Disease 0 0.9999119
and O 0 0.0029947914
disruptive B-Disease 0 0.8518638
behaviors I-Disease 0 0.71587163
. O 0 0.0073310845

Effects O 0 0.008499943
of O 0 0.024640141
acetylsalicylic B-Chemical 0 0.9999993
acid I-Chemical 0 0.99979824
, O 0 0.11650973
dipyridamole B-Chemical 0 0.99999154
, O 0 0.0048634
and O 0 0.0028177933
hydrocortisone B-Chemical 1 0.9999615
on O 0 0.0010015907
epinephrine B-Chemical 0 0.9999453
- O 0 0.12763716
induced O 0 0.006689346
myocardial B-Disease 0 0.99999213
injury I-Disease 0 0.9994041
in O 0 0.004264724
dogs O 0 0.010750369
. O 0 0.007098734

A O 0 0.027034698
reproducible O 0 0.0032173907
model O 0 0.0017258247
for O 0 0.0011680473
producing O 0 0.0014767852
diffuse O 0 0.6991693
myocardial B-Disease 0 0.99999845
injury I-Disease 0 0.99996734
( O 0 0.19352119
epinephrine B-Chemical 0 0.99995077
infusion O 0 0.022855269
) O 0 0.000992118
has O 0 0.000201683
been O 0 0.00018778935
developed O 0 0.00024751612
to O 0 0.00014959986
study O 0 0.00024289382
the O 0 0.00018795865
cardioprotective O 0 0.076294795
effects O 0 0.00029678812
of O 0 0.0003097169
agents O 0 0.005906279
or O 0 0.00026730512
maneuvers O 0 0.0011389474
which O 0 0.00033253516
might O 0 0.0002056659
alter O 0 0.0002683045
the O 0 0.00040349984
evolution O 0 0.0010324868
of O 0 0.003065987
acute O 2 0.9995011
myocardial B-Disease 2 0.9999927
infarction I-Disease 2 0.9999995
. O 0 0.042487677

Infusions O 0 0.4235006
of O 0 0.00645735
epinephrine B-Chemical 0 0.999617
( O 0 0.0028665427
4 O 0 0.0007534544
mug O 0 0.0005875959
per O 0 0.00030684483
kilogram O 0 0.00033241854
per O 0 0.00016342076
minute O 0 0.00017548336
for O 0 0.00017479397
6 O 0 0.0001503879
hours O 0 0.00015452641
) O 0 0.00033402978
increased O 0 0.00035850346
radiocalcium B-Chemical 0 0.9937709
uptakes O 0 0.041546345
into O 0 0.00011083099
intact O 0 0.00021540282
myocardium O 0 0.08149655
and O 0 0.00018329594
each O 0 8.785391e-05
of O 0 0.0001448012
its O 0 0.00021138813
subcellular O 0 0.00011625575
components O 0 0.0001336362
with O 0 0.00015855108
the O 0 0.00015611807
mitochondrial O 0 0.04018967
fraction O 0 0.00013326059
showing O 0 0.00018218427
the O 0 0.00014032751
most O 0 0.0002003278
consistent O 0 0.00014948592
changes O 0 0.00016764458
when O 0 8.667949e-05
compared O 0 8.938607e-05
to O 0 0.00012493801
saline O 0 0.013393983
- O 0 0.003967827
infused O 0 0.0003054185
control O 0 0.00014927541
animals O 0 0.00014150848
( O 0 0.00030844862
4 O 0 0.00016435006
, O 0 0.00028696514
957 O 0 0.013551015
vs O 0 0.00031635302
. O 0 0.00021084625
827 O 0 0.0012528265
counts O 0 0.00017083596
per O 0 0.00012720778
minute O 0 0.00017433292
per O 0 0.00019611233
gram O 0 0.00068741373
of O 0 0.00057285005
dried O 0 0.0023135694
tissue O 0 0.0019541504
or O 0 0.0013608153
fraction O 0 0.0021650086
) O 0 0.005970236
. O 0 0.0072451276

Myocardial O 0 0.18681654
concentrations O 0 0.0047497917
of O 0 0.0030380057
calcium B-Chemical 0 0.99349904
also O 0 0.0011205049
increased O 0 0.00093579054
significantly O 0 0.0006768406
( O 0 0.0006776164
12 O 0 0.00026153272
. O 0 0.00023078492
0 O 0 0.00024774938
vs O 0 0.0002757414
. O 0 0.00020094687
5 O 0 0.00017729656
. O 0 0.00018752867
0 O 0 0.00024326534
mg O 0 0.0013332505
. O 0 0.00020215353
per O 0 0.00018499294
100 O 0 0.00055724074
Gm O 0 0.5702966
. O 0 0.00043614666
of O 0 0.00088004675
fat O 0 0.977958
- O 0 0.021189943
free O 0 0.0019929819
dry O 0 0.07986782
weight O 0 0.013684212
) O 0 0.0082819825
. O 0 0.008115307

Infusions O 0 0.31632793
of O 0 0.005804829
calcium B-Chemical 0 0.9994081
chloride I-Chemical 0 0.9998884
sufficient O 0 0.0007666064
to O 0 0.00050137134
raise O 0 0.0004413711
serum O 0 0.4081127
calcium B-Chemical 0 0.99856263
concentrations O 0 0.010830763
2 O 0 0.00042697403
mEq O 0 0.20496608
. O 0 0.00019996273
per O 0 0.00015653962
liter O 0 0.000405361
failed O 0 0.00025331814
to O 0 0.0002530012
increase O 0 0.000390691
calcium B-Chemical 0 0.98712236
influx O 0 0.06005979
into O 0 0.00072319875
the O 0 0.0017579049
myocardial O 0 0.9974274
cell O 0 0.03962113
. O 0 0.007856673

Mitochondrial O 0 0.9097565
radiocalcium B-Chemical 0 0.9973355
uptakes O 0 0.34580156
were O 0 0.0015112665
significantly O 0 0.00093609863
decreased O 0 0.0008080385
in O 0 0.0004918405
animals O 0 0.00038286776
pretreated O 0 0.012630293
with O 0 0.015808327
acetylsalicylic B-Chemical 0 0.9999999
acid I-Chemical 0 0.9995358
or O 0 0.0064378404
dipyridamole B-Chemical 0 0.9999908
or O 0 0.00045613127
when O 0 0.00027276663
hydrocortisone B-Chemical 1 0.9999193
was O 0 0.00024138213
added O 0 0.00015529286
to O 0 0.00013875662
the O 0 0.000301199
epinephrine B-Chemical 0 0.9991955
infusion O 0 0.0023322883
( O 0 0.00037735142
2 O 0 0.0001903329
, O 0 0.00029859343
682 O 0 0.005864154
, O 0 0.00030717437
2 O 0 0.00020814133
, O 0 0.0003407627
803 O 0 0.024076723
, O 0 0.0003150531
and O 0 0.00026543625
3 O 0 0.00020707991
, O 0 0.00028658673
424 O 0 0.0006330539
counts O 0 0.00018347992
per O 0 0.00013709765
minute O 0 0.00018594471
per O 0 0.0002073466
gram O 0 0.0006994305
of O 0 0.0005782326
dried O 0 0.0017371549
fraction O 0 0.0009199402
, O 0 0.0020637794
respectively O 0 0.004774121
) O 0 0.0064265197
. O 0 0.007565252

Myocardial O 0 0.71066236
calcium B-Chemical 0 0.9881201
concentrations O 0 0.0048743607
also O 0 0.001212574
were O 0 0.00087661424
decreased O 0 0.0008630723
( O 0 0.0008934107
11 O 0 0.000483698
. O 0 0.00033344718
2 O 0 0.00030308723
, O 0 0.00035270432
8 O 0 0.00024554736
. O 0 0.00021448589
3 O 0 0.00019587782
, O 0 0.0002526601
and O 0 0.0002394685
8 O 0 0.0001978938
. O 0 0.00017365503
9 O 0 0.00018121739
mg O 0 0.0011638929
. O 0 0.00015042303
per O 0 0.00012496387
100 O 0 0.00042136398
Gm O 0 0.73008186
. O 0 0.0002116148
of O 0 0.00044741985
fat O 0 0.9928606
- O 0 0.03739269
free O 0 0.00049401965
dry O 0 0.07162889
weight O 0 0.007177827
, O 0 0.00081002986
respectively O 0 0.0045162584
) O 0 0.0005765469
in O 0 0.00017497993
the O 0 0.00015388824
three O 0 0.000114096496
treatment O 0 0.00020916828
groups O 0 0.00026041476
, O 0 0.00037878627
being O 0 0.0004442914
significantly O 0 0.00034021
decreased O 0 0.0005018914
only O 0 0.00058634393
in O 0 0.000749279
the O 0 0.0010898021
last O 0 0.0014333252
two O 0 0.0026566272
. O 0 0.0056768395

Evidence O 0 0.0059719905
of O 0 0.0036293126
microscopic O 0 0.0064789685
damage O 0 0.45776045
was O 0 0.0017077243
graded O 0 0.001881054
as O 0 0.0009822232
less O 0 0.0009918319
severe O 0 0.0088279825
in O 0 0.0009892685
the O 0 0.0011108933
three O 0 0.0011780255
treatment O 0 0.0024658907
groups O 0 0.00411129
. O 0 0.0072009875

Acetylsalicylic B-Chemical 0 0.99999475
acid I-Chemical 0 0.9992812
, O 0 0.07964733
dipyridamole B-Chemical 0 0.9999831
, O 0 0.0068349796
and O 0 0.0033091824
hydrocortisone B-Chemical 1 0.99991846
all O 0 0.00062008505
appear O 0 0.00040441324
to O 0 0.00031417308
have O 0 0.00035218452
cardioprotective O 0 0.046411105
effects O 0 0.0006025803
when O 0 0.00049780466
tested O 0 0.0008021787
in O 0 0.0013038737
this O 0 0.0020686798
model O 0 0.004019274
. O 0 0.0070723216

Clinical O 0 0.0079938155
and O 0 0.0027440297
histopathologic O 0 0.010199114
examination O 0 0.0014086196
of O 0 0.0013444114
renal O 0 0.75938934
allografts O 0 0.08910677
treated O 0 0.0011562291
with O 0 0.0031238804
tacrolimus B-Chemical 0 0.99999785
( O 0 0.059144866
FK506 B-Chemical 1 0.9999901
) O 0 0.0031737671
for O 0 0.00072339387
at O 0 0.0008151411
least O 0 0.0010188741
one O 0 0.0018090671
year O 0 0.003590851
. O 0 0.0065296344

BACKGROUND O 0 0.0167835
: O 0 0.003882842
We O 0 0.001851053
clinically O 0 0.002981421
and O 0 0.0011396257
pathologically O 0 0.040080935
analyzed O 0 0.00065399654
renal O 0 0.49683163
allografts O 0 0.017359184
from O 0 0.00031557286
1 O 0 0.00030093754
9 O 0 0.00027265534
renal O 0 0.15956153
transplant O 0 0.024201375
patients O 0 0.00042917323
treated O 0 0.00037575798
with O 0 0.0013740662
tacrolimus B-Chemical 0 0.9999976
( O 0 0.042492323
FK506 B-Chemical 1 0.99999094
) O 0 0.0037656336
for O 0 0.0006738369
more O 0 0.0009282203
than O 0 0.0009776728
1 O 0 0.0018020157
year O 0 0.0033415551
. O 0 0.006207078

METHODS O 0 0.004438693
: O 0 0.0042236545
Twenty O 0 0.003406037
- O 0 0.0035067978
six O 0 0.0011695639
renal O 0 0.18365547
allograft O 0 0.37914997
biopsy O 0 0.0016097089
specimens O 0 0.0005429672
from O 0 0.00036103424
1 O 0 0.0003707259
9 O 0 0.0003612937
renal O 0 0.10126523
transplant O 0 0.016372703
patients O 0 0.0005677671
who O 0 0.0004798753
underwent O 0 0.0003770706
transplantations O 0 0.0011097139
between O 0 0.0004720085
1991 O 0 0.0011479246
and O 0 0.0012091023
1993 O 0 0.0033231352
were O 0 0.0022784027
evaluated O 0 0.003364757
. O 0 0.006829101

Thirteen O 0 0.0059280344
biopsies O 0 0.002786752
were O 0 0.0015588886
performed O 0 0.0009550361
from O 0 0.00074735744
stable O 0 0.00082755805
functioning O 0 0.0016500924
renal O 0 0.6054612
allografts O 0 0.038009916
with O 0 0.0005130994
informed O 0 0.0019579998
consent O 0 0.0012051206
( O 0 0.00041265175
nonepisode O 0 0.002158956
biopsy O 0 0.00078263483
) O 0 0.00042514165
and O 0 0.00021696567
the O 0 0.00017293179
other O 0 0.00019563851
13 O 0 0.00018657217
were O 0 0.00014347312
from O 0 0.00014114584
dysfunctional O 0 0.00063466746
renal O 0 0.39639318
allografts O 0 0.012887522
with O 0 0.00028734433
a O 0 0.00033155858
clinical O 0 0.0005737019
indication O 0 0.00026165493
for O 0 0.00042969233
biopsy O 0 0.0015058094
( O 0 0.0014133474
episode O 0 0.0031991259
biopsy O 0 0.006253571
) O 0 0.006048339
. O 0 0.0071871164

RESULTS O 0 0.00527908
: O 0 0.0032943243
The O 0 0.0015293725
main O 0 0.0014149459
pathologic O 0 0.027371705
diagnoses O 0 0.004294785
( O 0 0.00090749987
some O 0 0.00042040524
overlap O 0 0.0003709824
) O 0 0.000667214
were O 0 0.00037706163
acute O 0 0.66948533
rejection O 0 0.9920243
( O 0 0.030940635
AR O 0 0.96559775
; O 0 0.00096337893
n O 0 0.0002427056
= O 0 0.00051916257
4 O 0 0.00019551524
) O 0 0.00039346924
, O 0 0.00040711314
chronic O 0 0.6629022
rejection O 0 0.9847239
( O 0 0.00754433
CR O 0 0.4141826
; O 0 0.00046800205
n O 0 0.0001917446
= O 0 0.00039832146
5 O 0 0.000179057
) O 0 0.0004793859
, O 0 0.0007310256
AR O 0 0.9086838
+ O 0 0.012838298
CR O 0 0.2700372
( O 0 0.00038563547
n O 0 0.0001995947
= O 0 0.00040129467
4 O 0 0.00017566935
) O 0 0.00034301012
, O 0 0.00040856175
recurrent O 0 0.5391376
IgA B-Disease 0 0.99999845
nephropathy I-Disease 2 1.0
( O 0 0.013509704
n O 0 0.0002952787
= O 0 0.00057839847
5 O 0 0.00016496948
) O 0 0.0003140868
, O 0 0.00023731648
normal O 0 0.00025334905
findings O 0 0.00025282038
( O 0 0.00027535993
n O 0 0.00018487673
= O 0 0.00046839032
2 O 0 0.00020363345
) O 0 0.00037014834
, O 0 0.00028754986
minimal O 0 0.00026165045
- O 0 0.008747174
type O 0 0.0005747111
chronic O 0 0.98895943
FK506 B-Chemical 1 0.99999976
nephropathy B-Disease 2 1.0
( O 0 0.012993555
n O 0 0.00031499576
= O 0 0.00067241053
9 O 0 0.00022230273
) O 0 0.0003891913
, O 0 0.00034113025
and O 0 0.00042233232
mild O 0 0.5190522
- O 0 0.031368293
type O 0 0.0031505588
FK506 B-Chemical 1 0.9999982
nephropathy B-Disease 2 0.9999999
( O 0 0.009047617
n O 0 0.0013153101
= O 0 0.0027125769
11 O 0 0.0026938783
) O 0 0.0051667336
. O 0 0.007245718

Of O 0 0.0047554886
the O 0 0.0026860863
nonepisode O 0 0.0046526715
biopsies O 0 0.0018901072
, O 0 0.0013736724
7 O 0 0.00069209037
and O 0 0.00059502525
4 O 0 0.00041875738
biopsies O 0 0.00045474313
showed O 0 0.0003527374
minimal O 0 0.00042728774
- O 0 0.0037820493
type O 0 0.0005141939
and O 0 0.0008096845
mild O 0 0.7271433
- O 0 0.03831201
type O 0 0.0020910585
chronic O 0 0.99701583
FK506 B-Chemical 1 0.9999993
nephropathy B-Disease 2 0.9999999
, O 0 0.08914328
respectively O 0 0.0444408
. O 0 0.007871075

Chronic O 0 0.97040737
FK506 B-Chemical 1 0.99998844
nephropathy B-Disease 2 0.9999987
consisted O 0 0.0014842912
of O 0 0.001027776
rough O 0 0.0010148362
and O 0 0.0007172655
foamy O 0 0.12559785
tubular O 0 0.6194351
vacuolization O 0 0.791126
( O 0 0.00090763613
5 O 0 0.00021306543
biopsies O 0 0.00034920897
) O 0 0.0006035759
, O 0 0.00058828347
arteriolopathy O 0 0.96217483
( O 0 0.0006207751
angiodegeneration O 0 0.0039874082
of O 0 0.00024307867
the O 0 0.0002585235
arteriolar O 0 0.9794024
wall O 0 0.024620347
; O 0 0.0004532574
20 O 0 0.00015692337
biopsies O 0 0.00024117136
) O 0 0.00038715306
, O 0 0.00032228592
focal B-Disease 0 0.11796717
segmental I-Disease 0 0.37714005
glomerulosclerosis I-Disease 2 0.9999999
( O 0 0.002737447
4 O 0 0.00017672255
biopsies O 0 0.00027245056
) O 0 0.00035223723
and O 0 0.00024460568
the O 0 0.00025545227
striped O 0 0.0046890094
form O 0 0.00035739152
of O 0 0.0010265899
interstitial B-Disease 0 0.9890766
fibrosis I-Disease 2 0.9999752
( O 0 0.005138444
11 O 0 0.0017917175
biopsies O 0 0.00320771
) O 0 0.0053713736
. O 0 0.0071419096

The O 0 0.0034606927
serum O 0 0.19695939
creatinine B-Chemical 1 0.9964713
levels O 0 0.0014541633
of O 0 0.0011064986
patients O 0 0.0010009076
in O 0 0.0004933007
the O 0 0.0005137458
mild O 0 0.6609967
- O 0 0.039807696
type O 0 0.0010951436
chronic O 0 0.99504787
FK506 B-Chemical 1 0.9999999
nephropathy B-Disease 2 1.0
group O 0 0.0323332
, O 0 0.0006784539
which O 0 0.00024034132
included O 0 0.00013904402
7 O 0 0.00012053672
episode O 0 0.00024707287
biopsies O 0 0.0002778084
, O 0 0.00026733827
were O 0 0.00016388217
statistically O 0 0.00013936326
higher O 0 0.00014413406
than O 0 0.00010965685
those O 0 0.00016623727
in O 0 0.0001336524
the O 0 0.00014050811
minimum O 0 0.00015488428
- O 0 0.004253145
type O 0 0.000538081
chronic O 0 0.9874834
FK506 B-Chemical 1 0.9999995
- O 0 0.960582
nephropathy B-Disease 2 0.9999999
group O 0 0.0126403775
( O 0 0.0022541196
P O 0 0.046106134
< O 0 0.00084386766
0 O 0 0.0013331617
. O 0 0.0019164862
001 O 0 0.041176885
) O 0 0.0061813383
. O 0 0.007907366

CONCLUSIONS O 0 0.024680018
: O 0 0.0041941046
This O 0 0.0024569924
study O 0 0.0014731858
demonstrates O 0 0.0007778614
that O 0 0.0008009662
chronic O 0 0.9883823
FK506 B-Chemical 1 0.99999964
nephropathy B-Disease 2 1.0
consists O 0 0.000942194
primarily O 0 0.0004987969
of O 0 0.00070255157
arteriolopathy O 0 0.99182844
manifesting O 0 0.22802953
as O 0 0.00024272341
insudative O 0 0.17756622
hyalinosis O 0 0.6091572
of O 0 0.00030322192
the O 0 0.00027296256
arteriolar O 0 0.987693
wall O 0 0.038703326
, O 0 0.00038662218
and O 0 0.00019939423
suggests O 0 0.00011689849
that O 0 0.00017456945
mild O 0 0.6166832
- O 0 0.042401195
type O 0 0.0010512407
chronic O 0 0.9952226
FK506 B-Chemical 1 0.9999999
nephropathy B-Disease 2 1.0
is O 0 0.004081666
a O 0 0.000614127
condition O 0 0.0007116666
which O 0 0.00040759507
may O 0 0.0003050431
lead O 0 0.0025802243
to O 0 0.00049335003
deterioration O 0 0.037782747
of O 0 0.0015819354
renal O 0 0.8896225
allograft O 0 0.83152556
function O 0 0.0050425115
. O 0 0.0072873044

Different O 0 0.0057165646
lobular O 0 0.6616183
distributions O 0 0.0021134624
of O 0 0.0019419221
altered O 0 0.001670013
hepatocyte O 0 0.60386235
tight O 0 0.0017432575
junctions O 0 0.0011864533
in O 0 0.00076517556
rat O 0 0.0011739782
models O 0 0.0008940655
of O 0 0.0015037403
intrahepatic B-Disease 0 0.8939127
and I-Disease 0 0.03471064
extrahepatic I-Disease 0 0.9999658
cholestasis I-Disease 2 0.99999976
. O 0 0.122592255

Hepatocyte O 0 0.5086486
tight O 0 0.0042253174
junctions O 0 0.0030261313
( O 0 0.002680018
TJs O 0 0.048107784
) O 0 0.0020576094
, O 0 0.00090752717
the O 0 0.00049327296
only O 0 0.00046267477
intercellular O 0 0.0012016147
barrier O 0 0.00141002
between O 0 0.00024226146
the O 0 0.00028496777
sinusoidal O 0 0.0037857664
and O 0 0.00037232842
the O 0 0.00034962036
canalicular O 0 0.27304888
spaces O 0 0.0013065321
, O 0 0.0005473277
play O 0 0.00045342467
a O 0 0.00065669167
key O 0 0.00072473596
role O 0 0.0008940779
in O 0 0.001926597
bile O 0 0.734121
formation O 0 0.06754991
. O 0 0.008543522

Although O 0 0.0040376037
hepatocyte O 0 0.5583104
TJs O 0 0.09456436
are O 0 0.0015998482
impaired O 0 0.0018154571
in O 0 0.0018970302
cholestasis B-Disease 2 0.99999857
, O 0 0.002409676
attempts O 0 0.00050323625
to O 0 0.00022916711
localize O 0 0.00014690551
the O 0 0.00019161994
precise O 0 0.00021124633
site O 0 0.00027334248
of O 0 0.0005409463
hepatocyte O 0 0.98267037
TJ O 0 0.9996321
damage O 0 0.9159298
by O 0 0.0006154977
freeze O 0 0.010166894
- O 0 0.015607379
fracture O 0 0.9563229
electron O 0 0.009420982
microscopy O 0 0.0009506036
have O 0 0.00081567717
produced O 0 0.0012572459
limited O 0 0.0022412755
information O 0 0.0037683446
. O 0 0.006667525

Recently O 0 0.0058121732
, O 0 0.0042064344
several O 0 0.0026833683
TJ O 0 0.9848877
- O 0 0.017098175
associated O 0 0.0013068944
proteins O 0 0.001335778
like O 0 0.0012504078
ZO O 0 0.9978771
- O 0 0.024444329
1 O 0 0.0007636338
and O 0 0.0008876404
7H6 O 0 0.20672938
have O 0 0.0009304442
been O 0 0.0012475675
identified O 0 0.001635884
and O 0 0.0030120658
characterized O 0 0.005681062
. O 0 0.008400091

Immunolocalization O 0 0.007844375
of O 0 0.006220334
7H6 O 0 0.43145818
appears O 0 0.00314755
to O 0 0.0025584688
closely O 0 0.0026757123
correlate O 0 0.0029017336
with O 0 0.0043024896
paracellular O 0 0.4188458
permeability O 0 0.9080333
. O 0 0.013685654

We O 0 0.0036537135
used O 0 0.002355325
rat O 0 0.0026405435
models O 0 0.001520088
of O 0 0.0028881936
intrahepatic B-Disease 0 0.9999269
cholestasis I-Disease 2 1.0
by O 0 0.8399038
ethinyl B-Chemical 0 0.9999999
estradiol I-Chemical 0 0.99999976
( O 0 0.17204848
EE B-Chemical 1 0.99955386
) O 0 0.0028886497
treatment O 0 0.0005691585
and O 0 0.0014850079
extrahepatic B-Disease 0 0.9999722
cholestasis I-Disease 2 1.0
by O 0 0.018304395
bile O 0 0.9905099
duct O 0 0.87969786
ligation O 0 0.053087607
( O 0 0.026818022
BDL O 0 0.9995597
) O 0 0.0011081885
to O 0 0.00030804158
precisely O 0 0.0003458414
determine O 0 0.00027422214
the O 0 0.0006436445
site O 0 0.0013148473
of O 0 0.0034094579
TJ O 0 0.9974273
damage O 0 0.9604721
. O 0 0.010085582

Alterations O 0 0.005050683
in O 0 0.00288579
hepatocyte O 0 0.40698588
TJs O 0 0.033401836
were O 0 0.00097016874
assessed O 0 0.00056437287
by O 0 0.0006018199
double O 0 0.0006683481
- O 0 0.0031134998
immunolabeling O 0 0.0015640447
for O 0 0.00056603696
7H6 O 0 0.78212035
and O 0 0.0016450915
ZO O 0 0.997317
- O 0 0.009487192
1 O 0 0.0006207474
using O 0 0.000641957
a O 0 0.0010334128
confocal O 0 0.0018984807
laser O 0 0.009123464
scanning O 0 0.003924037
microscope O 0 0.006921017
. O 0 0.008359727

In O 0 0.0039407993
control O 0 0.002546684
rats O 0 0.002404672
, O 0 0.0017383784
immunostaining O 0 0.0015034983
for O 0 0.0010472119
7H6 O 0 0.8040571
and O 0 0.0023457578
ZO O 0 0.9980197
- O 0 0.012339612
1 O 0 0.00046136283
colocalized O 0 0.00034615787
to O 0 0.0004492197
outline O 0 0.0007540772
bile O 0 0.44326386
canaliculi O 0 0.09363289
in O 0 0.0012831513
a O 0 0.001861526
continuous O 0 0.0021938654
fashion O 0 0.0051056934
. O 0 0.0072253514

In O 0 0.004259883
contrast O 0 0.003547019
, O 0 0.004125077
7H6 O 0 0.7883227
and O 0 0.004247587
ZO O 0 0.9980566
- O 0 0.026127083
1 O 0 0.00077889016
immunostaining O 0 0.000810536
was O 0 0.0006182427
more O 0 0.0006142257
discontinuous O 0 0.0008402234
, O 0 0.0009452195
outlining O 0 0.00124375
the O 0 0.0013875292
bile O 0 0.70531094
canaliculi O 0 0.42312363
after O 0 0.0038380967
BDL O 0 0.9980584
. O 0 0.010132057

Immunostaining O 0 0.007269966
for O 0 0.0034086506
7H6 O 0 0.66314983
, O 0 0.0029479715
not O 0 0.0018040052
ZO O 0 0.9976579
- O 0 0.047883067
1 O 0 0.0007075981
, O 0 0.00062303816
decreased O 0 0.00046531885
and O 0 0.0003884462
predominantly O 0 0.00033121926
appeared O 0 0.00027409854
as O 0 0.0002245131
discrete O 0 0.00025517304
signals O 0 0.00025083928
in O 0 0.00027983135
the O 0 0.0003531134
submembranous O 0 0.019192185
cytoplasm O 0 0.0007272197
of O 0 0.0014584311
periportal O 0 0.9488504
hepatocytes O 0 0.4154938
after O 0 0.0033078098
BDL O 0 0.99833906
. O 0 0.009284254

After O 0 0.0036890758
EE B-Chemical 1 0.9610977
treatment O 0 0.002910885
, O 0 0.0018545026
changes O 0 0.0010646755
in O 0 0.0006276871
immunostaining O 0 0.00084884436
for O 0 0.0005738214
7H6 O 0 0.85384655
and O 0 0.0023684618
ZO O 0 0.9991485
- O 0 0.034739044
1 O 0 0.0002719015
were O 0 0.00019158926
similar O 0 0.00014585549
to O 0 0.00015943035
those O 0 0.00023412779
seen O 0 0.00020644274
in O 0 0.0002923604
periportal O 0 0.9060235
hepatocytes O 0 0.28156367
after O 0 0.00041814803
BDL O 0 0.9991691
, O 0 0.00091221335
but O 0 0.00049595087
distributed O 0 0.00045164654
more O 0 0.00062257104
diffusely O 0 0.0010796685
throughout O 0 0.001177562
the O 0 0.0028087948
lobule O 0 0.9875701
. O 0 0.0071579614

This O 0 0.0052813115
study O 0 0.0028919268
is O 0 0.0016144036
the O 0 0.000996264
first O 0 0.0006121805
to O 0 0.00045647664
demonstrate O 0 0.0002779962
that O 0 0.00034320293
impairment O 0 0.12118394
of O 0 0.0007398164
hepatocyte O 0 0.9428
TJs O 0 0.26786342
occurs O 0 0.0003379517
heterogenously O 0 0.0016613826
in O 0 0.00021358492
the O 0 0.00029633203
liver O 0 0.9408505
lobule O 0 0.9996953
after O 0 0.00028141687
BDL O 0 0.9986785
and O 0 0.00043722437
suggests O 0 0.00018016312
that O 0 0.0003255407
BDL O 0 0.9994894
and O 0 0.0030899975
EE B-Chemical 1 0.9954444
treatments O 0 0.00046672614
produce O 0 0.00024480678
different O 0 0.0003563508
lobular O 0 0.8952095
distributions O 0 0.0007155306
of O 0 0.0013422646
increased O 0 0.0026239844
paracellular O 0 0.66342676
permeability O 0 0.942362
. O 0 0.009296766

Memory O 0 0.38398978
facilitation O 0 0.007715386
and O 0 0.0021760468
stimulation O 0 0.001483541
of O 0 0.0012261682
endogenous O 0 0.0010849667
nerve O 0 0.12657669
growth O 0 0.011954439
factor O 0 0.023615729
synthesis O 0 0.012400364
by O 0 0.0010937826
the O 0 0.002315732
acetylcholine B-Chemical 1 0.99997556
releaser O 0 0.99901986
PG B-Chemical 0 0.9998938
- I-Chemical 0 0.071954556
9 I-Chemical 0 0.0045420565
. O 0 0.00694895

The O 0 0.003281423
effects O 0 0.00309275
of O 0 0.00515676
PG B-Chemical 0 0.999925
- I-Chemical 0 0.15925318
9 I-Chemical 0 0.0011789235
( O 0 0.0027358828
3alpha B-Chemical 0 0.9929254
- I-Chemical 0 0.089364454
tropyl I-Chemical 0 0.4469515
2 I-Chemical 0 0.00050506956
- I-Chemical 0 0.0044795726
( I-Chemical 0 0.0005889469
p I-Chemical 0 0.0005344355
- I-Chemical 0 0.0657967
bromophenyl I-Chemical 0 0.9954678
) I-Chemical 0 0.06747015
propionate I-Chemical 0 0.99990594
) O 0 0.008306063
, O 0 0.00076376734
the O 0 0.0006599142
acetylcholine B-Chemical 1 0.9999453
releaser O 0 0.93152404
, O 0 0.00032240117
on O 0 0.00013879607
memory O 0 0.027905447
processes O 0 0.0003532299
and O 0 0.00035601325
nerve O 0 0.04203518
growth O 0 0.00707396
factor O 0 0.07034875
( O 0 0.022025412
NGF O 1 0.999838
) O 0 0.004898163
synthesis O 0 0.0051060254
were O 0 0.0023253174
evaluated O 0 0.0032176175
. O 0 0.0064552617

In O 0 0.0035713012
the O 0 0.002312225
mouse O 0 0.0023935337
passive O 0 0.0057091652
- O 0 0.023896437
avoidance O 0 0.008577802
test O 0 0.0012397422
, O 0 0.007510837
PG B-Chemical 0 0.9999603
- I-Chemical 0 0.078312024
9 I-Chemical 0 0.00038255623
( O 0 0.00042492713
10 O 0 0.00027151708
- O 0 0.0007947103
30 O 0 0.00019717411
mg O 0 0.003164121
/ O 0 0.0009039514
kg O 0 0.00086361927
, O 0 0.00042815928
i O 0 0.0017547106
. O 0 0.00022458419
p O 0 0.0002582444
. O 0 0.00022168973
) O 0 0.00046482254
, O 0 0.00027054982
administered O 0 0.00016220193
20 O 0 0.00013996614
min O 0 0.000162871
before O 0 9.512057e-05
the O 0 0.00012272185
training O 0 0.00014041223
session O 0 0.00017052624
, O 0 0.00032022165
prevented O 0 0.0012410536
amnesia B-Disease 0 0.99994063
induced O 0 0.0003016787
by O 0 0.00022496653
both O 0 0.0001814155
the O 0 0.00017871227
non O 0 0.000864387
selective O 0 0.016642455
antimuscarinic O 0 0.99929833
drug O 0 0.9757814
scopolamine B-Chemical 1 0.99999976
and O 0 0.0009153486
the O 0 0.0006697202
M1 O 0 0.98831314
- O 0 0.1003965
selective O 0 0.016882483
antagonist O 0 0.98593336
S B-Chemical 0 0.9992655
- I-Chemical 0 0.19296779
( I-Chemical 0 0.0031470591
- I-Chemical 0 0.035829086
) I-Chemical 0 0.004513652
- I-Chemical 0 0.06082478
ET I-Chemical 0 0.8880213
- I-Chemical 0 0.014035826
126 I-Chemical 0 0.009439446
. O 0 0.007454036

In O 0 0.0036090808
the O 0 0.002086995
same O 0 0.0012033026
experimental O 0 0.0011933094
conditions O 0 0.00138546
, O 0 0.010835608
PG B-Chemical 0 0.9999616
- I-Chemical 0 0.10751647
9 I-Chemical 0 0.00048159025
( O 0 0.0005013269
5 O 0 0.00027447433
- O 0 0.00070733886
20 O 0 0.0001923885
microg O 0 0.00022240682
per O 0 0.00014769897
mouse O 0 0.00035167002
, O 0 0.00044172743
i O 0 0.002820128
. O 0 0.00026498287
c O 0 0.01504508
. O 0 0.00032141508
v O 0 0.031242752
. O 0 0.0003151195
) O 0 0.0005269337
was O 0 0.00020267944
also O 0 0.00016308778
able O 0 0.0001395179
to O 0 0.00015922586
prevent O 0 0.00022581794
antimuscarine O 0 0.31103444
- O 0 0.029833594
induced O 0 0.0011195324
amnesia B-Disease 0 0.9999672
, O 0 0.0007024425
demonstrating O 0 0.0003484052
a O 0 0.0005148413
central O 0 0.00066274666
localization O 0 0.00069942715
of O 0 0.0013808208
the O 0 0.0019622787
activity O 0 0.0036121293
. O 0 0.006515347

At O 0 0.0027577023
the O 0 0.0020968346
highest O 0 0.0017273121
effective O 0 0.0014835423
doses O 0 0.032878567
, O 0 0.029212242
PG B-Chemical 0 0.99997747
- I-Chemical 0 0.13562252
9 I-Chemical 0 0.00046293397
did O 0 0.0003122718
not O 0 0.00020264796
produce O 0 0.0001741912
any O 0 0.0002167343
collateral O 0 0.042703807
symptoms O 0 0.039297868
as O 0 0.00016665483
revealed O 0 0.00017130475
by O 0 0.0001927129
the O 0 0.00023696355
Irwin O 0 0.12331704
test O 0 0.00030933297
, O 0 0.0003688531
and O 0 0.00028986778
it O 0 0.00025643784
did O 0 0.00020575633
not O 0 0.00014885295
modify O 0 0.00015902134
spontaneous O 0 0.0019056757
motility O 0 0.06278337
and O 0 0.00029252266
inspection O 0 0.00040720013
activity O 0 0.00028505744
, O 0 0.000354863
as O 0 0.0002779806
revealed O 0 0.00036558285
by O 0 0.00054331095
the O 0 0.00081088167
hole O 0 0.0717401
- O 0 0.010951351
board O 0 0.0045864014
test O 0 0.004118309
. O 0 0.0067224097

PG B-Chemical 0 0.99967575
- I-Chemical 0 0.063461356
9 I-Chemical 0 0.0023305402
was O 0 0.001379455
also O 0 0.00087803573
able O 0 0.0005818334
to O 0 0.00047688693
increase O 0 0.00038060662
the O 0 0.00035193414
amount O 0 0.00025900413
of O 0 0.0010326717
NGF O 1 0.99978274
secreted O 0 0.0005047931
in O 0 0.00037892532
vitro O 0 0.0004950827
by O 0 0.00047362674
astrocytes O 0 0.031436052
in O 0 0.00058212026
a O 0 0.0009403389
dose O 0 0.004722424
- O 0 0.00521569
dependent O 0 0.001967463
manner O 0 0.0037885767
. O 0 0.0070166704

The O 0 0.003535525
maximal O 0 0.0035009375
NGF O 1 0.9985127
contents O 0 0.0039348206
obtained O 0 0.001212895
by O 0 0.0019906948
PG B-Chemical 0 0.9998863
- I-Chemical 0 0.030872274
9 I-Chemical 0 0.00058013434
were O 0 0.00047148325
17 O 0 0.00053458684
. O 0 0.00046270614
6 O 0 0.0005078609
- O 0 0.0013279698
fold O 0 0.0011173494
of O 0 0.0013468241
the O 0 0.0016074198
control O 0 0.0024449448
value O 0 0.0043218634
. O 0 0.0077960305

During O 0 0.0034486316
culture O 0 0.0040470622
, O 0 0.002614926
no O 0 0.0012876004
morphological O 0 0.0022771896
changes O 0 0.0011698963
were O 0 0.0007646813
found O 0 0.0006201624
at O 0 0.00064058986
effective O 0 0.0009093288
concentrations O 0 0.0024606066
of O 0 0.005135697
PG B-Chemical 0 0.99984276
- I-Chemical 0 0.09268533
9 I-Chemical 0 0.005214787
. O 0 0.007801843

The O 0 0.003218734
current O 0 0.0028853223
work O 0 0.0017483566
indicates O 0 0.0009323827
the O 0 0.0007681374
ability O 0 0.0007371117
of O 0 0.00418311
PG B-Chemical 0 0.9999782
- I-Chemical 0 0.095584355
9 I-Chemical 0 0.00034306475
to O 0 0.00021018146
induce O 0 0.0001769296
beneficial O 0 0.0002894999
effects O 0 0.00029788178
on O 0 0.00017918475
cognitive O 0 0.3597176
processes O 0 0.00038022725
and O 0 0.00028709977
stimulate O 0 0.00021143409
activity O 0 0.0004972531
of O 0 0.0017517743
NGF O 1 0.9998211
synthesis O 0 0.040877685
in O 0 0.002268562
astroglial O 0 0.8610494
cells O 0 0.006292161
. O 0 0.0073873536

Therefore O 0 0.004833938
, O 0 0.011005928
PG B-Chemical 0 0.99975044
- I-Chemical 0 0.045327347
9 I-Chemical 0 0.0012571531
could O 0 0.0006780024
represent O 0 0.0005300296
a O 0 0.0005729948
potential O 0 0.00050115946
useful O 0 0.00048965093
drug O 0 0.018354228
able O 0 0.00032067162
to O 0 0.00033051174
improve O 0 0.00033094877
the O 0 0.00048358136
function O 0 0.0007049781
of O 0 0.0013153083
impaired O 0 0.0033362538
cognitive O 0 0.681553
processes O 0 0.0058267782
. O 0 0.0072322697

Mechanisms O 0 0.015860107
of O 0 0.019856215
FK B-Chemical 1 0.9999651
506 I-Chemical 1 0.99921167
- O 0 0.16427039
induced O 0 0.011642191
hypertension B-Disease 2 0.99998415
in O 0 0.005604682
the O 0 0.0060324674
rat O 0 0.013131933
. O 0 0.011619219

- O 0 0.44609106
Tacrolimus B-Chemical 1 0.9999715
( O 0 0.27760866
FK B-Chemical 1 0.9999807
506 I-Chemical 1 0.9979243
) O 0 0.004849412
is O 0 0.0018752926
a O 0 0.0019966862
powerful O 0 0.0027782815
, O 0 0.0026173634
widely O 0 0.002889173
used O 0 0.0037112068
immunosuppressant O 0 0.86555654
. O 0 0.010106455

The O 0 0.0039416645
clinical O 0 0.004113063
utility O 0 0.002543336
of O 0 0.005356486
FK B-Chemical 1 0.9999739
506 I-Chemical 1 0.99533844
is O 0 0.0019242164
complicated O 0 0.0034682024
by O 0 0.0018742345
substantial O 0 0.005337162
hypertension B-Disease 2 0.9999933
and O 0 0.08017299
nephrotoxicity B-Disease 0 0.99999404
. O 0 0.014683476

To O 0 0.0026817021
clarify O 0 0.0013340559
the O 0 0.0013400861
mechanisms O 0 0.0012370517
of O 0 0.010598633
FK B-Chemical 1 0.9999968
506 I-Chemical 1 0.9998344
- O 0 0.27583915
induced O 0 0.009123718
hypertension B-Disease 2 0.99999905
, O 0 0.0014458987
we O 0 0.00018281194
studied O 0 0.00025279482
the O 0 0.00023882456
chronic O 0 0.5078546
effects O 0 0.0019957554
of O 0 0.015949486
FK B-Chemical 1 0.99999785
506 I-Chemical 1 0.9921904
on O 0 0.00012771534
the O 0 0.00017344224
synthesis O 0 0.0018118463
of O 0 0.0015448198
endothelin O 0 0.9998455
- O 0 0.12813902
1 O 0 0.00029899483
( O 0 0.00094147207
ET O 0 0.921106
- O 0 0.01186798
1 O 0 0.0002091958
) O 0 0.00033690463
, O 0 0.00022124419
the O 0 0.00014705211
expression O 0 0.0001969736
of O 0 0.00029011496
mRNA O 0 0.00054645096
of O 0 0.001705729
ET O 0 0.98677725
- O 0 0.029823223
1 O 0 0.00021701613
and O 0 0.00042224093
endothelin O 0 0.9993467
- O 0 0.10064218
converting O 0 0.021527182
enzyme O 0 0.15614097
- O 0 0.029671703
1 O 0 0.00024686754
( O 0 0.00079428486
ECE O 0 0.973251
- O 0 0.037091475
1 O 0 0.0002510336
) O 0 0.00044620087
, O 0 0.0002879512
the O 0 0.00024624413
endothelial O 0 0.9622304
nitric B-Chemical 0 0.9996718
oxide I-Chemical 0 0.99705744
synthase O 0 0.83264405
( O 0 0.006047834
eNOS O 0 0.6608781
) O 0 0.0009893432
activity O 0 0.00024563164
, O 0 0.00026722002
and O 0 0.00018279364
the O 0 0.0001459814
expression O 0 0.00019573703
of O 0 0.00027766434
mRNA O 0 0.0004424261
of O 0 0.0007965868
eNOS O 0 0.7736861
and O 0 0.003589572
C O 0 0.99985886
- O 0 0.13904977
type O 0 0.0010583743
natriuretic O 0 0.9639778
peptide O 0 0.002378042
( O 0 0.002743311
CNP O 0 0.7181844
) O 0 0.0018381078
in O 0 0.0012737275
rat O 0 0.0038102274
blood O 0 0.025659248
vessels O 0 0.041461475
. O 0 0.0068487967

In O 0 0.0035426365
addition O 0 0.0018798035
, O 0 0.0021507384
the O 0 0.0011232072
effect O 0 0.0008338533
of O 0 0.00078024884
the O 0 0.0005738775
specific O 0 0.0006910767
endothelin O 0 0.9992805
type O 0 0.004886894
A O 0 0.8462849
receptor O 0 0.6651718
antagonist O 0 0.9983954
FR B-Chemical 0 0.99989545
139317 I-Chemical 0 0.99999297
on O 0 0.00081712735
FK B-Chemical 1 0.99999547
506 I-Chemical 1 0.9990688
- O 0 0.06291212
induced O 0 0.0029555426
hypertension B-Disease 2 0.99999464
in O 0 0.0014949867
rats O 0 0.0022288805
was O 0 0.0021751896
studied O 0 0.0038319558
. O 0 0.006439542

FK B-Chemical 1 0.9995159
506 I-Chemical 1 0.98596406
, O 0 0.027888047
5 O 0 0.021978697
mg O 0 0.08030445
. O 0 0.034840826

kg O 0 0.059930965
- O 0 0.06658059
1 O 0 0.051832728
. O 0 0.063659094

d O 0 0.0072012837
- O 0 0.008321049
1 O 0 0.0018410209
given O 0 0.0009308002
for O 0 0.00082819356
4 O 0 0.0006223785
weeks O 0 0.00042554148
, O 0 0.00062712346
elevated O 0 0.001495555
blood O 0 0.0055210087
pressure O 0 0.009421681
from O 0 0.00023713417
102 O 0 0.0008410203
+ O 0 0.0014701881
/ O 0 0.006810966
- O 0 0.0038324052
13 O 0 0.00022838819
to O 0 0.00016562513
152 O 0 0.0006034338
+ O 0 0.0011012228
/ O 0 0.0050790994
- O 0 0.0027975792
15 O 0 0.00016846406
mm O 0 0.000857182
Hg O 0 0.95301235
and O 0 0.00023322279
increased O 0 0.0002057532
the O 0 0.0001855186
synthesis O 0 0.0016257353
of O 0 0.0011191149
ET O 0 0.9805971
- O 0 0.016439592
1 O 0 0.00017665213
and O 0 0.0001610561
the O 0 0.00014690316
levels O 0 0.0001860277
of O 0 0.00060287025
ET O 0 0.9723414
- O 0 0.018450864
1 O 0 0.00021798087
mRNA O 0 0.00024326115
in O 0 0.00020109888
the O 0 0.00024915364
mesenteric O 0 0.052310627
artery O 0 0.034137856
( O 0 0.0005378462
240 O 0 0.0005962554
% O 0 0.0004994543
and O 0 0.0006223188
230 O 0 0.001716997
% O 0 0.001358498
, O 0 0.0021084377
respectively O 0 0.004492934
) O 0 0.006602354
. O 0 0.008004354

Little O 0 0.02158197
change O 0 0.003307046
was O 0 0.002015092
observed O 0 0.0012610801
in O 0 0.0010600621
the O 0 0.0008930332
expression O 0 0.0010322292
of O 0 0.0019009816
ECE O 0 0.9860881
- O 0 0.033691324
1 O 0 0.0013353678
mRNA O 0 0.0019912112
and O 0 0.003245197
CNP O 0 0.7185372
mRNA O 0 0.008064841
. O 0 0.009897391

FK B-Chemical 1 0.99992406
506 I-Chemical 1 0.99570674
decreased O 0 0.008495893
eNOS O 0 0.44303063
activity O 0 0.0012622457
and O 0 0.0008290127
the O 0 0.0005152573
levels O 0 0.0004640785
of O 0 0.00080468954
eNOS O 0 0.5503227
mRNA O 0 0.0007205337
in O 0 0.00036676746
the O 0 0.00038618376
aorta O 0 0.028510138
( O 0 0.0006423781
48 O 0 0.00044603233
% O 0 0.000506655
and O 0 0.00060206116
55 O 0 0.0009232827
% O 0 0.0013442169
, O 0 0.0021569734
respectively O 0 0.004572097
) O 0 0.0067892633
. O 0 0.008223876

The O 0 0.0035467513
administration O 0 0.010183327
of O 0 0.0073041846
FR B-Chemical 0 0.99945885
139317 I-Chemical 0 0.99998593
( O 0 0.003302824
10 O 0 0.0006644302
mg O 0 0.0092996955
. O 0 0.00038871498
kg O 0 0.0010228872
- O 0 0.0021693502
1 O 0 0.00032539797
. O 0 0.00028693423
d O 0 0.0005687257
- O 0 0.0043033296
1 O 0 0.00045070273
) O 0 0.0010166856
prevented O 0 0.0092306435
FK B-Chemical 1 0.9999956
506 I-Chemical 1 0.9993795
- O 0 0.103364415
induced O 0 0.006403315
hypertension B-Disease 2 0.9999914
in O 0 0.0039628292
rats O 0 0.006631688
. O 0 0.0068785404

These O 0 0.0035184897
results O 0 0.002172665
indicate O 0 0.0014251528
that O 0 0.0021457288
FK B-Chemical 1 0.9999831
506 I-Chemical 1 0.9969439
may O 0 0.00078968046
increase O 0 0.00051872805
blood O 0 0.015597757
pressure O 0 0.025403874
not O 0 0.00025179703
only O 0 0.00027628802
by O 0 0.00027941543
increasing O 0 0.00057410094
ET O 0 0.96340954
- O 0 0.014399061
1 O 0 0.00026784188
production O 0 0.00036948937
but O 0 0.00037485902
also O 0 0.00032909118
by O 0 0.0004863618
decreasing O 0 0.0012540562
NO B-Chemical 0 0.99769765
synthesis O 0 0.010612217
in O 0 0.0016136181
the O 0 0.0025379586
vasculature O 0 0.15602134
. O 0 0.00710599

